<SEC-DOCUMENT>0000950170-25-034787.txt : 20250306
<SEC-HEADER>0000950170-25-034787.hdr.sgml : 20250306
<ACCEPTANCE-DATETIME>20250306163912
ACCESSION NUMBER:		0000950170-25-034787
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		94
CONFORMED PERIOD OF REPORT:	20241231
FILED AS OF DATE:		20250306
DATE AS OF CHANGE:		20250306

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Arcturus Therapeutics Holdings Inc.
		CENTRAL INDEX KEY:			0001768224
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38942
		FILM NUMBER:		25715856

	BUSINESS ADDRESS:	
		STREET 1:		10628 SCIENCE CENTER DRIVE
		STREET 2:		SUITE 250
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		8589002660

	MAIL ADDRESS:	
		STREET 1:		10628 SCIENCE CENTER DRIVE
		STREET 2:		SUITE 250
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>arct-20241231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-03-06T16:06:55.3542+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:arct="http://arcturusrx.com/20241231" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16">
 <head>
  <title>10-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_87144c4a-992c-429f-9bb4-5fe503136d46" name="dei:EntityCentralIndexKey" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716">0001768224</ix:nonNumeric><ix:nonNumeric id="F_9a775996-6ca2-4999-b2af-1ccbddaf3364" name="dei:AmendmentFlag" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716">false</ix:nonNumeric><ix:nonNumeric id="F_2abdfeb6-700e-492c-b255-9f95c11e5731" name="dei:DocumentFiscalPeriodFocus" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716">FY</ix:nonNumeric><ix:nonNumeric id="F_28c68eba-ea54-404a-a9d6-fb19a33b35b4" name="ecd:TrdArrDuration" contextRef="C_2a5b949d-4097-4151-8f74-d5142e6df00e" format="ixt-sec:durday">162</ix:nonNumeric><ix:nonNumeric id="F_a09c2b80-d521-40d4-b228-c34c98f0be33" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_1431fd58-6694-4958-a082-b782f01ec3b3" format="ixt-sec:duryear">3</ix:nonNumeric><ix:nonNumeric id="F_7bcaf8a7-146c-4002-845d-af462601018d" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212">http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric id="F_9747f896-2497-4837-848b-f002a89071bd" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc">http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric id="F_806a8df4-c83d-4622-a6aa-7b9d8f050c33" name="us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716">http://fasb.org/srt/2024#ChiefExecutiveOfficerMember</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="arct-20241231.xsd"/></ix:references><ix:resources><xbrli:context id="C_801e363e-339f-4807-9e7b-89e95be99722"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arct:UnderlyingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:CysticFibrosisFoundationTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arct:LUNARCFMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-02</xbrli:startDate><xbrli:endDate>2023-09-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_820e29f3-5ff7-4037-b94b-5b58fd071bfb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">arct:FebruaryTwoThousandAndTwentyLeaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_85b74df8-3891-4246-9852-23bd86a40945"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arct:Early-StageProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_860c0a20-b573-41e1-a9a0-9d26576ca073"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:PropertyLeaseGuaranteeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_86445ba3-f6f4-4676-90ed-50251dd3995d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arct:WellsFargoCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_86d66d5d-4c97-45bb-a084-bf8bbda66671"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arct:Covid19VaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arct:ResearchCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:SeqirusIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_88537db2-a4c2-4868-aaa9-8f88cee3858f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arct:DiscoveryTechnologiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8a585c58-b141-436d-8855-b3bbdf1ff8a2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8a8ee8e1-d0f5-45c7-a284-959089bf94e1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8bae3d05-d6e8-46f3-863e-be5c603f6fd1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">arct:DirectorsOrOfficersExceptChiefScientificOfficerCooSvpCcAndPaoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8d83dff5-ceee-4639-a422-5542c54a34d5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8da6d6ac-b3ff-404b-afdf-8fd51a86a7c7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arct:VinbiocareAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8dcffe65-b98b-4723-af16-5b3daa5d33c2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8dd3cd07-367a-4d33-a06e-49f7bc62341e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arct:LUNAR-OTCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8e8fb1ef-45cd-4aa8-9a33-0ec3e20793f1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arct:Early-StageProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8fd663c7-d616-4fa1-9c31-9db23c56c689"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arct:ManufacturingAndSupplyOfArct154DrugProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arct:ResearchCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:SeqirusIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_92f6052b-f423-4970-890f-aaeea914fcef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arct:BARDAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9316938d-e4f7-4709-b45f-2d7d8cc44812"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_94fdde70-e99e-4e78-9fbc-8f8f22d0ba4d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_958a90b7-6a27-4c61-95d4-5f89fe769df8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">arct:OctoberTwoThousandAndSeventeenLeaseAmendmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_967a80b1-1866-4f20-95dd-a83f22149812"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arct:VinbiocareAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_988a9efb-2454-43a7-a157-c666550071c2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:CSLMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_98a6fdf5-4340-4e1b-9ce6-86901cc3549e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arct:LoanAndSecurityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:WesternAllianceBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-14</xbrli:startDate><xbrli:endDate>2023-03-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9b6438ac-a4af-4cb1-a7e8-04fc1dc8917f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9f520c76-36f9-4e10-88ee-34a1bddaa46e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9f995e84-394b-4f80-b22b-985e9d097bfd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a3464474-dfd3-43d9-b123-3d9c2d59b71e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:SG</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a35204b8-793a-4f51-b6a2-2dad74d8547e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arct:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a45712ae-2c2b-44d4-ae48-9d59250b85b6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arct:LUNAR-COVIDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a64be24b-e012-4869-ab48-edbde5729fa1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:WesternAllianceBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a772c31f-b8d4-430f-b45d-52b674305e78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">arct:OrphanDrugCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a80d4900-cff3-43ef-a5a2-5effe03ec8b3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a8f29617-6dbc-47c2-bf34-7e091c3128a3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arct:VinbiocareAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-01</xbrli:startDate><xbrli:endDate>2023-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ac4a66d0-a617-4eb3-97a5-5efc86181fd2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ac8997ea-dc9f-4fed-83e0-b13eb0d07432"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arct:CslCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arct:PhaseIClinicalStudyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_adf77a8d-9580-41d9-9c8e-9064454e7c28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">arct:FebruaryTwoThousandAndTwentyLeaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b5b1f0d6-262c-46b3-85ce-a3305beaaa39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b6a637cc-890d-47eb-bf8f-c3b46e805e7d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b73afaae-41c1-46b6-8616-4cdb808c1c4a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arct:PayrollAndBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b82657d6-82b1-4bfc-88e6-4814252b20d1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">arct:OctoberTwoThousandAndSeventeenLeaseAmendmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-01</xbrli:startDate><xbrli:endDate>2017-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bc749b60-01c7-407d-a66f-0ad31c3e3223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:SG</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bf73fc87-a7ef-43a8-bf1b-0ee33d958d5f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c0934e56-cff8-4842-acec-a05ccd4099a4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arct:DiscoveryTechnologiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c12666e5-df97-469d-b1e4-3c9a57cc9650"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c25d021b-7bf8-40de-b1c3-f954fd411acc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arct:CollaborationRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:JanssenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c45ae1f6-f871-404f-8826-2b495a729716"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c6809d71-13e7-4b1a-924f-d8abae76045c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arct:Covid19VaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:SeqirusIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c8889a7c-69b1-4f25-be7c-2c7d95316544"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:CSLMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c9c5c093-9b6a-4d10-823e-777266370955"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cab06b3d-053b-4c81-b42c-b2445cd0c158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">arct:OrphanDrugCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cb30b8bf-d65b-4a7e-8e21-e4aa8d48e2f3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:CslSeqirusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arct:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cbbb84bd-f6c0-4979-a42e-6dd1dc94cd5c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:CslSeqirusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arct:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cdc3b296-383c-4f2b-8a23-fed8e5efc389"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arct:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d0748bb0-90f5-4425-beb5-86fdc83461e7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arct:UnderlyingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:CysticFibrosisFoundationTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-02</xbrli:startDate><xbrli:endDate>2023-09-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d22dc742-0007-4f3e-97ad-b0aa9112af8c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arct:TwentyTwentyOneInducementEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d2b6f456-3e1e-41e4-bd44-0e037c42e4ca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d4667b25-9ebe-441c-8ace-a7cddce91af6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arct:CslCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d4c6eb14-ee87-46e1-8ff9-0f1eee8139e1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">arct:SeptemberTwoThousandAndTwentyOneLeaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d50d4b6b-e748-48a2-99dc-da00925623e4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d6e35e55-99c4-447c-93d6-7979a6be6791"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d82ff122-590c-489b-87d2-a9001b2499a6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d88f1ae2-2110-4172-a005-770d3804d551"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">arct:ForeignCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_db600b02-dfe3-4388-80ba-2f5ad5b53df0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dbce4aac-da09-4a9a-bdad-eed2250c6e8b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">arct:LanceKurataMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dbe29eec-3da1-447f-afbd-bdbab15adc3a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:SG</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dd07c4b0-0b2b-46df-8180-9141d3a4695f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:PropertyLeaseGuaranteeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dd47aa1c-68e9-4b16-9e78-294207b60f30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_de7040c9-0664-4d4f-9974-fddd45db823c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arct:ManufacturingAndSupplyOfArct154DrugProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arct:ResearchCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:SeqirusIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_de7f4b0b-b0a5-4403-a0c8-005d40a0ea9f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_deb1657c-7399-402c-8536-0419c46c6233"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dfad2efd-655c-4712-ad55-9208245cce2b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:WesternAllianceBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e0b98ca8-b4bb-4d0b-9631-02538172e7f5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">arct:SeptemberTwoThousandAndTwentyOneLeaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e0eeb777-c5ee-445e-89d3-2c8ed430397e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e1270539-8c54-4b3f-a7ca-d75b1c8c8913"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">arct:SeptemberTwoThousandAndTwentyOneLeaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e22ed845-7d56-4d58-bbda-cdb707f0cae4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arct:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e2d495bd-d213-4380-9448-1294459b3c51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arct:LUNAR-CFNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e340decb-8e23-4aec-a50a-9afef8ee8eaf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arct:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e343b8cf-c999-46dc-82b2-5e281a84df00"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e3934ce5-c321-4a31-b7d0-60e3e1ef8264"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">arct:ForeignCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e3cf53cd-b1a1-435f-8cee-4794f5764eb6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arct:TwentyTwentyOneInducementEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e555c3b5-c6bf-47e7-838e-8773ebae68d0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:WesternAllianceBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e570fa19-3556-454e-8682-69a04831b6bc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e6a54d12-2d06-43c8-a611-842ff0eff99d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">arct:ForeignCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e6b834ef-7cbd-42d2-9ba5-f1ffd18aff0f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arct:DiscoveryTechnologiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e7cfc84d-4c9d-4d01-afc8-236747b0ea78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:CSLMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e809b54d-dd94-4594-8f54-a7a9ebc5e794"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arct:Early-StageProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_eacfa335-f40d-41a3-a10a-eb5d58e4252c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:SG</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ed799f3d-249f-4d51-ae92-deaa84f57abd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arct:FacilitiesAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_eeccc958-3920-483a-bc18-4d732d1e801f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arct:CollaborationRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:IsraelMinistryOfHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_eefa9a8b-a137-4b9b-a9bd-84d6397dcbae"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:VinbiocareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arct:StudySupportAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerDurationAxis">us-gaap:ShortTermContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ef9e3212-0c72-453d-8e04-d4b0bc08213a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f0949914-ab4f-42d5-bcb0-e24ecd07e8cf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arct:CslCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f0e7f0b2-1598-4953-9f90-cc64a32fbc98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">arct:EmployeesAndOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f6556892-c686-4b0f-ad35-b323cfa6c9df"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arct:LUNAR-CFNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f82651ae-69da-4140-af2f-5b915dc1aca7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arct:TwoThousandNineteenOmnibusIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f92977ac-e76b-4cb7-8d5a-5b699cbdb902"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f94c3743-e85f-4283-b541-3b2a49e36750"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fdc06d4c-b98b-4078-96e6-528aa846af54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:SG</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fe6dc61d-d3ca-490d-9689-8dcf10e0d322"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arct:FacilitiesAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ff6d8148-36b1-4ba9-847e-b95829a0383f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ff7ed278-8619-4daa-85d7-a6142360937e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_06d432cd-fe67-4805-a95e-d98b0424bbc3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arct:LUNAR-COVIDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_07a158d3-db39-46b0-b8a8-d157b269ad9e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arct:PayrollAndBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_07fceadb-01ec-4fd6-aff8-7976cff4540e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arct:ResearchCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:SeqirusIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_08938b4b-8f37-4a42-96af-9374a057c857"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arct:LUNAR-CFNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_08b6efae-4fda-4db6-b9c0-371c0ef137a3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0a0009ee-75b0-4d6c-8c54-a3de804d67ed"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arct:CollaborationRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:JanssenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0c35a6e2-43f6-4708-bba5-5173dbc3de2f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arct:LUNAR-OTCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0c651e95-fd64-4c52-a5f0-0d5b8015a505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0fe3841a-f105-4a0f-a913-03e14cbebbf8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arct:Covid19VaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:SeqirusIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_10ba438f-86e7-4bea-afe6-6381fb76f525"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_11fe4360-7e34-49ee-baa1-bb4e286f6f12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arct:LUNAR-OTCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_12470630-daf9-4fdf-a875-a3affca4b6e8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1431fd58-6694-4958-a082-b782f01ec3b3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_152910ca-c407-48c4-8614-914f708479a3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_170f1f48-3dbe-4cac-bfe3-571918df82a6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">arct:DrPadmanabhChivukulaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_18e8b3d8-b758-4fc5-9f07-48c66ed98d2a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:SG</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1a296724-396e-481f-8c86-b3b311ff76f9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arct:BARDAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1a91ccd4-4bd8-43c2-8051-45a814608dfc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arct:TwoThousandNineteenOmnibusIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1b0157b0-3108-4ff6-bf3d-93b8178679dc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arct:UnderlyingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:CysticFibrosisFoundationTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1e0106b2-7efd-48ca-85e2-4b61ddf65637"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_200946b9-b524-4e78-9424-4e601b6b9f68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arct:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2177e6fb-ec81-4ef2-b37d-c5ed17225037"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_21bee724-74a7-4507-ac63-b66c0326eeb4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arct:LoanAndSecurityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:WesternAllianceBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-14</xbrli:startDate><xbrli:endDate>2023-03-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_21d1b797-41f5-49d8-a548-8998a1e9873d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_22f5e6fe-f31d-416e-a210-33674b90d66e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arct:Covid19VaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arct:ResearchCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:SeqirusIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_26a8b21d-1c26-4459-a1ee-d89f9f331468"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_28c7b4d4-46b4-403b-a81e-106c6eae4759"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_29eee7a6-fd75-4779-badf-175826fe2dfd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:CSLMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2a5b949d-4097-4151-8f74-d5142e6df00e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">arct:DrPadmanabhChivukulaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2acf2ac7-01e2-4268-a321-5c97d29be022"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">arct:KeithCKummerfeldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2b4a205f-e9c7-4a9b-9f7d-e2d74d8a8790"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:VinbiocareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2b4e1b2e-3490-4f8f-9601-99e9e60ed774"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2b79e174-202f-44db-a40f-0080c01394ba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2bb094b7-f6bc-4639-b097-78aa4e69c032"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2cc45ff1-3360-475a-b5da-15ae2c8d66aa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arct:TwentyTwentyOneInducementEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2d41c197-8a7f-4abe-8802-3f3779ba2106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:SG</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2d657502-e913-475b-9a66-3a5a4dec9710"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arct:CollaborationRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:VinbiocareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_35939c21-6356-4b16-b155-5ff282b4b400"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arct:UnderlyingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:CysticFibrosisFoundationTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arct:LUNARCFMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-31</xbrli:startDate><xbrli:endDate>2019-08-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_37d3f9a9-91a0-4432-bb97-b21a720960db"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_382d54f3-b7c1-44dc-b7ac-45940950e7db"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_384780c2-a461-484e-90b6-4ba525f2b0cb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arct:PayrollAndBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3b5bfb69-0e34-4596-883d-6933762b5f1a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">arct:LanceKurataMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3ca1293d-fd04-40b8-a46a-57af6a5ac7d7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arct:CslCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arct:PhaseIClinicalStudyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3dcdc036-b6bb-44cc-9e78-55386dfe3195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3e3c5d0e-9c24-4b1b-b7e1-d57a6036bc5a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arct:WellsFargoCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_415079ce-5509-40be-96cd-1470dad8f0d8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_41912f33-1403-4518-9ac5-80cc445c3148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arct:WellsFargoCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-21</xbrli:startDate><xbrli:endDate>2023-04-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_42551c33-9281-450d-a0e8-7a28c2252c4a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:CSLMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_42b09082-30d1-4349-88f2-ae97e705f43e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_44b8ebcf-fb2f-4241-9026-e24a66edc6b0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_45eb8bb7-286d-4047-9f32-b23ce157716c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_46790da3-ab07-41f8-bb66-6d90294211d5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arct:Covid19VaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arct:ResearchCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:SeqirusIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_486087ba-60a6-4677-9a46-887bc39af237"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_48e6c1d3-4d22-4c10-8a2a-1bdd49245c23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arct:CollaborationRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:UltragenyxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4903df66-6bad-45f9-8151-6f6455ee1212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4a52e6bd-de03-4707-910b-3abb83ab2003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arct:CslCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arct:PhaseIClinicalStudyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4c016b15-4aaa-4d51-bf03-ece9dddf38ac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arct:WellsFargoCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-26</xbrli:startDate><xbrli:endDate>2024-06-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4e71c9fa-246b-4174-807f-580b538d6c44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:VinbiocareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arct:VinbiocareAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4e721db5-40e6-4075-95cb-a09086f8814b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arct:LoanAndSecurityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:WesternAllianceBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4e7cbee9-3838-4850-806d-710b2e45882f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4fc38bda-72e0-4e2e-bcde-f14d64558664"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_517ad6a3-e9ae-471c-a53f-67c77e50ab6f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_554b9050-1f94-4300-aff9-82c1bde3198b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_55f99ccf-69c7-4793-a958-d0a9d4e65d04"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">arct:EmployeesAndOfficersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_57101dc7-2fbf-4d4c-8577-c3989e4bc34a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arct:BARDAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_59320853-4bcf-4a90-99e2-d4b7e72b628d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_596cb559-9f30-4570-b72b-2e4bf88511d2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:CslSeqirusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arct:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_59dc916f-940a-4c84-98d4-897fc187a986"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">arct:SeptemberTwoThousandAndTwentyOneLeaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5a02c86b-64a7-48c8-9d61-fbfa2c4dde8a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5f293e8e-a39e-4833-9e79-510818455bc1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:VinbiocareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_602adcc3-a068-4d86-ad11-fd96cb49a486"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_652488b3-7499-4d63-b634-9c1ddc35880c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_654bde4e-918b-4b9c-901a-10010de70313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_67ddf72c-3213-4f12-be1f-701d0566198c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:SG</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6853a270-d4df-4f01-ae68-1bd1f016abe4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arct:ManufacturingAndSupplyOfArct154DrugProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arct:ResearchCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:SeqirusIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_69de4a86-a3b0-473a-bcf9-e08244abbdd7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arct:LoanAndSecurityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:WesternAllianceBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-14</xbrli:startDate><xbrli:endDate>2023-03-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_69ed5d25-10c1-4aac-96a2-03a2b894d649"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-03-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6aef7a2d-0065-4f49-a030-b4de642f444a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arct:CollaborationRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:UltragenyxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6ba7dcb1-88d1-40cc-9caa-9904c066fd42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6dcaeb74-849b-4892-8d45-1cf1c0c414a7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arct:UnderlyingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:CysticFibrosisFoundationTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6e132eb5-a5af-499f-bd75-b24d62c5092f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">arct:FebruaryTwoThousandAndTwentyLeaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6e573c31-64c3-4efd-b469-ce13ad81a767"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6f2bd238-0b95-4b22-8c5a-121d7509ed58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arct:CslCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arct:PhaseIClinicalStudyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7265865c-204c-46d5-a156-36e79a71f210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_74cdb34c-62d2-473d-9ee0-84ce4b40931f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:SeqirusIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7882f9eb-6eb4-4f9e-bdb7-9be9e4dde643"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arct:ResearchCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:SeqirusIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_794d8e75-547e-4d8c-b200-6302eefbd65b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arct:UnderlyingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:CysticFibrosisFoundationTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_79990b5c-27fd-44ab-a481-a933f3b6649e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arct:LUNAR-COVIDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_79b86a89-0a00-45b1-8004-7d4dc0cdea25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arct:TwoThousandNineteenOmnibusIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7b5e8cb5-a2d5-4fd1-a235-2bb6e7524e95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202307Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7bb37bf1-61a9-4d5a-8bd6-2abfca1a4ec5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arct:CslCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7c8f1ee8-0d0f-434d-9eb4-6868c4d8c3c9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-01</xbrli:startDate><xbrli:endDate>2023-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7f5b7d69-0f16-49c9-8312-5fabb8348a71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768224</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arct:FacilitiesAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_SGD"><xbrli:measure>iso4217:SGD</xbrli:measure></xbrli:unit><xbrli:unit id="U_Segment"><xbrli:measure>arct:Segment</xbrli:measure></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_e7673c3f-e0a4-4c88-8556-e697212050ab" fromRefs="F_30349b9e-a90b-4868-8b5f-f9f68e52ad16 F_41de01e3-de04-4166-aef7-c6b8d1aed994 F_9edd83ab-be78-4163-82d9-62024f18eaed"/></ix:resources></ix:header></div>
  <div style="z-index:-3;min-height:1in;position:relative;"></div>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double #000000;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reportp</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UNITED STATES</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Washington, D.C. 20549</span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FORM </span><span style="font-size:11pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a093a6c6-cb2f-4497-862b-f08463b0c970" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10-K</span></ix:nonNumeric></span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Mark One)</span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:'Wingdings',serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4%;box-sizing:content-box;"/>
    <td style="width:96%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_ad56bfae-7991-4b50-ae68-d42b602c0d5c" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the fiscal year ended </span><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fa2aacf3-60f2-45e5-b4b7-771eac3bde67" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3d124613-de1c-4243-9e8b-4f7cf094e512" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d2ac132e-a364-4c4f-89f1-61d079d9178b" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="dei:DocumentFiscalYearFocus"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024</span></ix:nonNumeric></span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4%;box-sizing:content-box;"/>
    <td style="width:96%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_bea4fcb0-3f28-49f5-b049-c8fd41f2cfc5" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Transition Period From                     To</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">                     </span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commission File Number </span><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d041caae-afbc-405f-974a-23707a15ebe4" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">001-38942</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img267189834_0.jpg" alt="img267189834_0.jpg" style="width:288px;height:94px;"/></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_69f7a15e-f55f-4512-9224-c2cc26ea2db9" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARCTURUS THERAPEUTICS HOLDINGS INC.</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Exact name of Registrant as specified in its Charter)</span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50%;box-sizing:content-box;"/>
    <td style="width:50%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:7.5pt;"><ix:nonNumeric id="F_8bd44b60-848b-4960-a029-c2d9810975ed" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:7.5pt;"><ix:nonNumeric id="F_121825f5-7fca-4c4a-87d4-323c0da8fd67" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">32-0595345</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(State or other jurisdiction of</span></p><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">incorporation or organization)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(I.R.S. Employer</span></p><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Identification No.)</span></p></td>
   </tr>
   <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:7.5pt;"><ix:nonNumeric id="F_ad3ac702-8474-430f-ba0e-f5a2f61d7063" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">10628 Science Center Drive</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:7.5pt;"><ix:nonNumeric id="F_cc77f51a-e8bc-4f38-97d7-ef0af0e1937e" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Suite 250</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:7.5pt;"><ix:nonNumeric id="F_477f3949-f445-43b7-9b3a-3d3f2900458a" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">San Diego</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:7.5pt;"><ix:nonNumeric id="F_bc96fa4a-da88-48be-b814-6df5316699bc" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">California</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:7.5pt;"><ix:nonNumeric id="F_2502826b-7941-404c-ba19-f7076562b526" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">92121</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Address of principal executive offices)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_03012218-5443-43e6-ad49-943d0b54c6a3" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">858</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) </span><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_dad14bc4-4bd5-4d5c-8089-c87045f5635d" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">900-2660</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Registrant&#8217;s telephone number, including area code)</span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:40%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:18%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:40%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Title of each class</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Trading</span></p><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Symbol(s)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_447952d0-db78-4136-a060-7314312418ec" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common Stock, par value $0.001 per share</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_cef0945e-e447-43dc-99c4-6a785d407e2c" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ARCT</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_38105c46-0f1f-4e17-882f-91567a427a12" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">The Nasdaq Stock Market LLC</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(g) of the Act: </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744; </span><span style="font-size:7pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5f1e1fa2-b12d-4911-9f0b-1b8ca82d9e87" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="dei:EntityWellKnownSeasonedIssuer"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:7pt;font-family:Times New Roman;"><ix:nonNumeric id="F_65bc931c-8a1f-42e2-9756-69766d900566" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="dei:EntityVoluntaryFilers"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. </span><span style="font-size:7pt;font-family:Times New Roman;"><ix:nonNumeric id="F_158d064e-0a83-4969-8785-ad7173cc2a01" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="dei:EntityCurrentReportingStatus"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files). </span><span style="font-size:7pt;font-family:Times New Roman;"><ix:nonNumeric id="F_18287b7f-fbae-4b49-a616-9f1002737656" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="dei:EntityInteractiveDataCurrent"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:27.025%;box-sizing:content-box;"/>
    <td style="width:2.701%;box-sizing:content-box;"/>
    <td style="width:40.548%;box-sizing:content-box;"/>
    <td style="width:27.025%;box-sizing:content-box;"/>
    <td style="width:2.701%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Large accelerated filer</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:7pt;"><ix:nonNumeric id="F_9c410ee0-b31c-4a76-aeec-340a7b800e03" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accelerated filer</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span></p></td>
   </tr>
   <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-accelerated filer</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Smaller reporting company</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:7pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_4da16c82-69dd-4e05-919a-3ea419616dfb" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Emerging growth company</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:7pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_fc4ffd2a-4e07-4279-accb-1abdf2b03288" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the Registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:7pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_237ba54b-4325-414d-b3ad-76816c04a89f" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><span style="font-size:7pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_5f34858b-07c6-4179-bf98-bd778a6c1218" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). </span><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:7pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_88a54649-c515-432c-a02a-3edc970a4ff0" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="dei:EntityShellCompany" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The aggregate market value of the common equity held by non-affiliates of the Registrant, based on the closing price of the common stock on The Nasdaq Stock Market on June 30, 2024 was</span><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> $</span><span style="font-size:7pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_db8373d6-a35f-4f5e-a31f-d8a881f238be" contextRef="C_4e7cbee9-3838-4850-806d-710b2e45882f" name="dei:EntityPublicFloat" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">602.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of March 4, 2025, the registrant ha</span><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">d </span><span style="font-size:7pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_542b021b-128f-4f25-a8dd-14ef9ff3cd11" contextRef="C_69ed5d25-10c1-4aac-96a2-03a2b894d649" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">27,119,823</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> s</span><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">hares of voting common stock outstanding.</span></p>
  <div><ix:nonNumeric id="F_5efe96e2-1e42-43b6-8d54-5ef7a476e268" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="dei:DocumentsIncorporatedByReferenceTextBlock" escape="true"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain portions of the registrant&#8217;s definitive Proxy Statement for its 2025 Annual Meeting of Stockholders are incorporated by reference into Items 10, 11, 12, 13 and 14 of Part III of this Annual Report on Form 10-K.</span></p></ix:nonNumeric></div>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:10.1%;box-sizing:content-box;"/>
    <td style="width:82.82%;box-sizing:content-box;"/>
    <td style="width:7.08%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Page</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_i"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">PART I</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1_business"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Business</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1A.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1a_risk_factors"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Risk Factors</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1B.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1b_unresolved_staff_comments"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Unresolved Staff Comments</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">66</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1C.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1c_cybersecurity"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Cybersecurity</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">66</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 2.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_2_properties"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Properties</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">67</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 3.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_3_legal_proceedings"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Legal Proceedings</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">68</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 4.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_4_mine_safety_disclosures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Mine Safety Disclosures</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">68</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_ii"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">PART II</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 5.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_5_market_for_registrants_common_equ"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">68</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 6.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_6_selected_financial_data"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Reserved</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">69</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 7.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_7_managements_discussion_analysis_f"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">70</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 7A.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_7a_quantitative_qualitative_disclos"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">78</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 8.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_8_financial_statements_supplementar"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Financial Statements and Supplementary Data</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">79</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 9.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9_changes_in_disagreements_with_acc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">79</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 9A.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9a_controls_procedures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Controls and Procedures</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">79</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 9B.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9b_or_information"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Other Information</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">83</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 9C.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9c_disclosure_regarding_foreign"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">83</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_iii"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">PART III</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 10.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_10_directors_executive_ficers_corpo"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 11.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_11_executive_compensation"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Executive Compensation</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 12.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_12_security_ownership_certain_benef"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 13.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_13_certain_relationships_related_tr"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 14.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_14_principal_accounting_fees_servic"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Principal Accounting Fees and Services</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_iv"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">PART IV</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 15.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_15_exhibits_financial_statement_sch"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Exhibits, Financial Statement Schedules</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 16</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_16_form_10k_summary"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form 10-K Summary</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">i</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Special Note Regarding Forward-Looking Statements</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Annual Report on Form 10-K, or this Annual Report, and the documents incorporated by reference herein may contain &#8220;forward-looking statements&#8221; within the meaning of the federal securities laws made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth below under Part I, Item 1.A, &#8220;Risk Factors&#8221; in this Annual Report. Except as required by law, we assume no obligation to update these forward-looking statements, whether as a result of new information, future events or otherwise. These statements, which represent our current expectations or beliefs concerning various future events, may contain words such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;estimate&#8221; or other words indicating future results, though not all forward-looking statements necessarily contain these identifying words. Such statements may include, but are not limited to, statements concerning the following:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our compliance, and ability to remain in compliance, with the requirements of our collaboration agreements, including our collaboration with Seqirus Inc. (&#8220;CSL Seqirus&#8221;);</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the anticipated benefits and success of our collaboration agreement with CSL Seqirus related to the licensure of our STARR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> mRNA technology and LUNAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> lipid-mediated delivery, including our timely receipt of upfront and potential royalty and other payments thereunder; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the continued development activities of the LUNAR-COV19 and LUNAR-FLU programs under our collaboration with CSL Seqirus;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the status, success and benefits of our arrangements with private and governmental entities, some of which are subject to termination for convenience by our counterparties; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our compliance, and ability to remain in compliance, with the stringent requirements of our current and potential government contracts, including our arrangements with the Biomedical Advanced Research and Development Authority, a division of the Office of the Assistant Secretary for Preparedness and Response within the U.S. Department of Health and Human Services and the Department of Defense;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our plans to conduct and advance any of our research and discovery programs;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the initiation, design, cost, timing, progress, enrollment and results of, and our expected ability to undertake certain activities and accomplish certain goals with respect to, our research and development activities, preclinical studies and clinical trials, including those related to our therapeutics pipeline candidates ARCT-810 and ARCT-032;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the potential safety, immunogenicity, efficacy or regulatory approval of any of our product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the potential effects, efficacy and benefits of our technologies and product candidates on their own and in comparison to technologies, drugs or courses of treatment currently available or that may be developed by competitors;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the likelihood that preclinical or clinical data will be predictive of future clinical results or efficacy or safety of a product candidate; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the anticipated timing of enrollment, duration, milestones and announcements of results of clinical trials, and the submission of applications to conduct clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the likelihood that clinical data will be sufficient for regulatory approval or completed in time to submit an application for regulatory approval within a particular timeframe; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the likelihood or timing of any regulatory approval, and the likelihood that the marketing approval of ARCT-154 in Japan will be predictive of any future marketing approvals in other countries or for other versions of our LUNAR-COV19 or other product candidates or of any commercial sales;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the potential administration regimen or dosage, or ability to administer multiple doses of, any of our product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the likelihood of optimizing KOSTAIVE&#8217;s product presentation and formulation; </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to obtain and maintain regulatory approval of our product candidates, and any related restrictions, limitations, and/or warnings in the label of an approved product candidate; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our plans to develop and commercialize our product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability, and the ability of our partners, to successfully commercialize, and our expectations regarding future therapeutic and commercial potential with respect to, our product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the rate and degree of market acceptance of our product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the success of competing therapies that are or may become available; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the size and growth potential of the markets for our product candidates, and our ability to serve those markets and address unmet medical needs; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to obtain and maintain intellectual property protection for our product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">interactions with regulatory authorities in the United States and foreign countries; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to attract and retain experienced and seasoned scientific and management professionals;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the performance of our third-party suppliers and manufacturers, including the ability to implement and scale-up manufacturing levels as necessary; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the receipt of relevant approvals related to the manufacture and distribution of our product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our strategic alliance partners&#8217; election to pursue development and commercialization of any programs or product candidates that are subject to our collaboration and license agreements with such partners; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to attract collaborators with relevant development, regulatory and commercialization expertise; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">future activities to be undertaken by our strategic alliance partners, collaborators and other third parties;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to develop sales and marketing capabilities, whether alone or with potential future collaborators; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to avoid, settle or be victorious at costly litigation with shareholders, former executives or others, should these situations arise; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to obtain and deploy funding for our operations and to efficiently use our financial and other resources;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to continue as a going concern; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the accuracy of our estimates regarding future expenses, future revenues, cash flows, capital requirements need for additional financing, and possible sources of revenue.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These and other forward-looking statements are only current predictions and are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry&#8217;s actual results, levels of activity, performance or achievements to be materially different from those anticipated by the forward-looking statements. In addition, historic results of scientific research, preclinical and clinical trials do not guarantee that future research or trials will suggest the same conclusions, nor that historic results referred to herein will be interpreted the same in light of additional research, preclinical and clinical trial results. The forward-looking statements contained in this Annual Report are subject to risks and uncertainties, including those discussed in our other filings with the United States Securities and Exchange Commission (the &#8220;SEC&#8221;). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Although we currently believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">References to Arcturus</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In this Annual Report on Form 10-K, unless otherwise stated or the context otherwise indicates, references to the &#8220;Company,&#8221; &#8220;Arcturus,&#8221; &#8220;we,&#8221; &#8220;our&#8221; and &#8220;us&#8221; mean Arcturus Therapeutics Holdings Inc. and its consolidated subsidiaries from and after the effective time of the Redomiciliation (as defined below in Part I, Item 1. "Business" - "Available Information") and, prior to that time, to our predecessor, Arcturus Therapeutics Ltd.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Trademarks and Tradenames</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Arcturus logo and other trademarks of Arcturus appearing in this Annual Report on Form 10-K are the property of Arcturus. All other trademarks, service marks and trade names in this Annual Report on Form 10-K are the property of their respective owners. Solely for convenience, trademarks and trade names referred to in this report may appear without the &#174; or &#153; symbols.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Market Data, Forecasts, and Other Information</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unless otherwise indicated, information in this Annual Report on Form 10-K concerning economic conditions, our industry, and our markets, including our general expectations and competitive position, market opportunity and market size, is based on a variety of sources, including information from independent industry analysts and publications, as well as our own estimates and research. In addition, certain information included references to third-party publications regarding our business, results of operations, products, and product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our estimates are derived from industry and general publications, studies and surveys conducted by third-parties, as well as data from our own internal research. These publications, studies and surveys generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information, and we have not independently verified industry data from such third-party sources. While we believe our internal research is reliable and that our internal estimates are reasonable, such research has not been verified by any independent source and our internal estimates are based on our good faith beliefs as of the respective dates of such estimates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_i"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART I</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1_business"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1. Business</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Overview</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. We developed the world&#8217;s first approved self-amplifying messenger RNA (sa-mRNA) vaccine, KOSTAIVE</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(&#8220;KOSTAIVE&#8221;). KOSTAIVE achieved approval in Japan in 2023 as a vaccine against COVID-19. Sales of KOSTAIVE began in Japan in October 2024, marking our transition to a commercial stage company.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have several key platform technologies that we leverage to develop and advance a pipeline of mRNA-based vaccines and therapeutics for infectious diseases and for rare genetic disorders with significant unmet medical needs. Current mRNA medicines have two critical components: the messenger RNA (&#8220;mRNA&#8221;) constructs and the lipid nanoparticles (&#8220;LNP&#8221;) which help deliver the mRNA to disease-relevant target tissues. We believe we are among the world leaders in both areas. We have extensive expertise in the design and optimization of mRNA constructs, including with respect to a type of mRNA technology known as self-amplifying mRNA (sa-mRNA). Our proprietary self-amplifying mRNA technology platform, or STARR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(&#8220;STARR&#8221;), has been demonstrated to induce a longer-lasting and broader humoral immune response at lower dose levels than conventional</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">mRNA-based vaccines. Our proprietary LNP delivery system, LUNAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (&#8220;LUNAR&#8221;), is intended to address the major hurdle in RNA drug development, namely the effective and safe delivery of RNA therapeutics to disease-relevant target tissues. LUNAR may enable multiple nucleic acid medicines. The approval of KOSTAIVE in Japan was a significant milestone which validates our LUNAR and STARR platforms, as well as sa-mRNA more generally as a meaningful modality. Finally, we have significant expertise and valuable know-how in the development and scalability of complex and robust manufacturing processes required to deliver the next generation of nucleic acid medicines.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our internal pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF), both rare diseases. In our vaccine program, we have partnered with Seqirus, Inc. (&#8220;CSL Seqirus&#8221;), a part of CSL Limited and one of the world&#8217;s leading influenza vaccine providers, on the development and commercialization of mRNA vaccines for COVID-19, influenza and certain other infectious diseases.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We made significant progress in 2024. Commercial sales of KOSTAIVE began in October 2024 in Japan by Meiji Seika Pharma (&#8220;Meiji&#8221;), CSL Seqirus&#8217; exclusive partner in Japan, marking the first commercial sales of an Arcturus-developed product. In February 2025, we received approval of KOSTAIVE from the European Commission (EC), which provided further validation of our platform by another significant regulatory authority.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">KOSTAIVE is the brand name approved in Japan and Europe for ARCT-154, which is the version of the sa-mRNA COVID vaccine encoding the ancestral strain of SARS-CoV-2, and also for updated variant-specific versions of this vaccine. We may use KOSTAIVE or the specific internally generated name, such as ARCT-154, ARCT-2301 and ARCT-2303, to identify a version of the vaccine.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We initiated dosing in a Phase 1 clinical trial of a novel seasonal influenza sa-mRNA vaccine candidate under our collaboration with CSL Seqirus in January 2024. In December 2024, we initiated dosing of an sa-mRNA vaccine candidate against pandemic avian influenza (bird flu) in a Phase 1 trial funded by the Biomedical Advanced Research and Development Authority (&#8220;BARDA&#8221;).</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In our OTC program, we completed dosing of eight subjects in August 2024 in a Phase 2 double-blind multiple-dose study of ARCT-810. In the second quarter of 2024, we expanded the Phase 2 clinical program of ARCT-810 with an open-label, multiple-dose study which initiated dosing in December 2024. ARCT-810 has received Orphan Drug Designation from the FDA and Orphan Medicinal Product Designation from the European Medicines Agency (the &#8220;EMA&#8221;) for treatment of OTC deficiency, as well as Fast Track Designation and Rare Pediatric Disease Designation from the FDA.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In our CF program, we initiated dosing in December 2024 in a Phase 2 multiple ascending dose study of ARCT-032 designed to identify a safe and effective dose in people with Class I (null) CFTR mutations and other CF patients who do not benefit from CFTR modulators. In July 2024, we completed dosing and follow-up visits for seven participants in a safety and tolerability Phase 1b clinical study in New Zealand of ARCT-032 in adults with CF. ARCT-032 has received Orphan Drug Designation by the FDA and Orphan Medicinal Product Designation by the EMA for the treatment of CF, and Rare Pediatric Disease Designation from the FDA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also improved our platform technologies and advanced our early-stage research activities and manufacturing process development and operations. We conducted exploratory platform development activities, including the evaluation of genome editing, and new targeting approaches, where our LUNAR and STARR platforms could potentially be useful for identification and development of additional products for our portfolio. Also, with our sourcing partners, we manufactured cGMP (current good manufacturing practices) batches yielding significant quantities of clinical trial materials for global studies of our candidates, and with our collaborator, CSL Seqirus, we have established commercial production processes for the COVID-19 vaccine program.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nucleic Acid Medicines and an Introduction to Arcturus&#8217; Platform Technologies</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Nucleic Acid Medicines</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nucleic acid medicines have the potential to treat diseases caused by genetic mutations, including diseases that cannot be treated by conventional drugs, such as small molecules and biologics. Some of these medicines function by providing the means for producing a deficient yet vital protein in vivo. Within a cell, DNA carries the blueprint, in the form of genes, from which all proteins necessary for life are encoded. Each gene&#8217;s code is transcribed into a nucleic acid molecule called mRNA, which informs the cell&#8217;s own machinery how to organize amino acid building blocks to make one or more proteins needed for normal biological function.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nucleic acid therapeutics represent a significant advancement in targeted medicines and several of these therapeutics are being developed by public and private companies. The general objectives of these therapies include:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to introduce a gene product (e.g., mRNA or DNA) that encodes for a functional protein to replace an absent or defective protein;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to restore a functional protein by genomic DNA editing of the corresponding gene resulting in the correction of the mRNA sequence;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to reduce the amount of a target protein in a patient by binding to and destroying the associated target mRNA (antisense DNA or small interfering RNA (&#8220;siRNA&#8221;)); and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to express proteins from viruses or unique proteins only found in cancer and not in non-cancerous cells resulting in the induction of protective immunity against specific viral pathogens or immune mediated elimination of cancer cells.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Brief Introduction to our LUNAR and STARR Technology Platforms</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">LUNAR</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A key challenge for nucleic acid medicines is the safe and effective delivery of the nucleic acid molecule into cells. In addition to enabling uptake of the medicine into cells, the nucleic acids delivery vehicle seeks to protect the nucleic acid from degradation prior to cell entry and to release the nucleic acid payload inside the cell. Arcturus has developed a novel lipid-mediated delivery system called LUNAR. LUNAR is comprised of a mixture of biodegradable synthetic lipids and naturally occurring lipids. Lipids are molecules that contain hydrocarbons and make up the building blocks of the structure and function of living cells. Examples of lipids include fats, oils, waxes and phospholipids. LUNAR is designed to address technical challenges facing the delivery of nucleic acid medicines into cells. We continue to expand our library of proprietary synthetic lipids, termed ATX, with over 300 to date. Our preclinical studies have shown that formulations can be customized for the indication and target cell type of interest, and we have also demonstrated that our proprietary formulation process is scalable and reproducible. Our LUNAR platform is described in more detail below.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">STARR</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our STARR technology is our proprietary self-amplifying mRNA (or sa-mRNA) technology platform. When combined with a delivery system, such as our lipid-mediated delivery system LUNAR, the STARR technology has the potential to generate a protective immune response or drive therapeutic protein expression to prevent against or treat a variety of diseases. Self-amplifying RNA-based prophylactic vaccines developed with STARR trigger rapid and prolonged antigen expression within host cells which may provide protective immunity against infectious pathogens. We have clinically shown that the combination of LUNAR and STARR technology can result in lower dose requirements with superior immune response and sustained protein expression compared to conventional RNA-based vaccines, which may enable production of greater volumes of vaccine doses more quickly.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Pipeline</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Therapeutics</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img267189834_1.jpg" alt="img267189834_1.jpg" style="width:616px;height:83px;"/></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Vaccines</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img267189834_2.jpg" alt="img267189834_2.jpg" style="width:624px;height:136px;"/></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i) Commercialized in Japan</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Vaccine Programs</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">According to the National Foundation for Infectious Diseases, over 50,000 people die each year due to vaccine-preventable diseases and related complications in the United States alone. Influenza and pneumonia cases approach this number of deaths each year and more than one million individuals in the United States have died of COVID since the beginning of the COVID-19 pandemic (Centers for Disease Control and Prevention). The Department of Health and Human Services estimated that 330,000 lives were saved in the United States due to COVID-19 vaccination in 2021 alone. Outbreaks of new infectious diseases, and the rise of variants to existing viruses, create demand for new and novel approaches to producing vaccines in a more cost effective and quicker manner.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The COVID-19 pandemic has highlighted the efficacy, safety, and rapidity in which nucleic acid medicines can be used to vaccinate vulnerable populations, and our vaccine program has continued to progress. In 2020, we initiated the development of our first self-amplifying mRNA vaccine candidate to protect against COVID-19. In December 2022 we entered into a Collaboration and License Agreement (&#8220;CSL Collaboration Agreement&#8221;) with CSL Seqirus, a part of CSL Limited and one of the world&#8217;s leading influenza vaccine providers, for the global exclusive rights to research, develop, manufacture and commercialize self-amplifying mRNA vaccines against COVID-19, influenza and three other infectious diseases and global non-exclusive rights to pandemic pathogens. The CSL Collaboration Agreement combines CSL Seqirus&#8217; established global vaccine commercial and manufacturing infrastructure with Arcturus&#8217; manufacturing expertise and innovative STARR self-amplifying mRNA vaccine and LUNAR delivery platform technologies. For a more comprehensive discussion of the CSL Collaboration Agreement, please see Item 1 &#8220;Business&#8221; &#8211; &#8220;Revenue and Collaboration Arrangements and Other Material Agreements&#8221; &#8211; &#8220;CSL Seqirus.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2023, ARCT-154 became the world&#8217;s first approved self-amplifying RNA vaccine following Japan&#8217;s approval of ARCT-154 for primary immunization and as a booster dose against COVID-19. In September 2024, Japan&#8217;s Ministry of Health, Labor and Welfare (MHLW) granted approval and authorization for an updated version of KOSTAIVE, targeted to protect against the JN.1 lineage of Omicron subvariants for adults 18 years of age and older. CSL Seqirus&#8217; exclusive partner in Japan, Meiji, began distributing the updated vaccine in Japan in October 2024, marking the world&#8217;s first commercially available sa-mRNA COVID-19 vaccine for adults 18 and older. The approval was based on manufacturing data demonstrating the quality and consistency of the vaccine product, non-clinical immunogenicity data against JN.1 lineage of Omicron subvariants of KOSTAIVE (JN.1), and clinical evidence supporting the safety and immunogenicity of KOSTAIVE (bivalent, BA.4/5 and ancestral strain).</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In our influenza vaccine franchise, a Phase 1 clinical trial of our seasonal influenza candidate was initiated in January 2024 under our collaboration with CSL Seqirus, and a BARDA-funded Phase 1 clinical trial of our H5N1 pandemic flu candidate was initiated in December 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.173%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">KOSTAIVE</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and COVID-19 Vaccine Program</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Coronaviruses are a family of viruses that can lead to respiratory illness. Three viruses in this family have emerged in the past twenty years: Severe Acute Respiratory Syndrome (SARS-CoV), Middle East Respiratory Syndrome (MERS-CoV), and Severe Acute Respiratory Syndrome 2 (SARS-CoV-2), the virus responsible for the COVID-19 pandemic. Throughout the pandemic, there have been surges of infections as protective health measures have waxed and waned. Uncontrolled viral spread has led to billions of cases worldwide and the selection of viral variants that are more contagious, pathogenic, or both. Since late 2021, infections have been dominated by subvariants of the Omicron strain, which continue to displace previous circulating strains by evading immunity and spreading more efficiently, resulting in an increased risk of breakthrough infection among the vaccinated. Vaccines that induce robust and durable immunity against current and emerging variants of concern (&#8220;VOCs&#8221;) can help to reduce the infection and disease burden for both the public and the health care systems globally.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our COVID-19 vaccine candidate, KOSTAIVE, is based on our STARR (self-amplifying mRNA) technology platform and our LUNAR platform. It was designed to promote immune responses to the spike protein of the SARS-CoV-2 virus, the critical part of the virus that allows infection to occur.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">KOSTAIVE is the brand name approved in Japan and Europe for ARCT-154, which is the version of the sa-mRNA COVID-19 vaccine encoding the ancestral strain of SARS-CoV-2, and also for updated variant-specific versions of this vaccine. We may use KOSTAIVE or the specific internally generated name, such as ARCT-154, ARCT-2301 and ARCT-2303, to identify the vaccine.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The approval of KOSTAIVE in Japan in 2023, followed by the approval of an updated version of KOSTAIVE (JN.1 Omicron subvariant) and initiation of commercial sales in Japan in 2024, all as further described below, are significant milestones in the advancement of our vaccines franchise. The recent approval of KOSTAIVE (ARCT-154 version) by the EMA in January 2025 provides further validation of our platform by another significant regulatory authority, in addition to expanding the potential commercialization of KOSTAIVE.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During 2024, several important publications were released relating to our studies, which are summarized below.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2024, Nature Communications published results from the 19,000 subject study performed in Vietnam, with results demonstrating that two 5&#181;g doses of ARCT-154 were well-tolerated, immunogenic and provided significant protection against multiple strains of COVID-19. This publication relates to the study described below &#8211; &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Pivotal Phase 1/2/3 Study in Vietnam&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, npj Vaccines, a Nature Portfolio journal, published the results of Phase 3c of the pivotal Phase 1/2/3 study in Vietnam, demonstrating higher immune response and protective efficacy of ARCT-154 compared to an approved adenovirus-vector COVID-19 vaccine (DOI: 10.1038/s41541-024-01017-5). </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2024, Lancet Infectious Diseases published the follow-up article &#8216;12-month persistence of immune responses to self-amplifying mRNA COVID-19 vaccines: ARCT-154 versus BNT162b2 vaccine&#8217; (https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(24)00615-7/fulltext), which confirmed a better neutralizing immune response against a panel of SARS-CoV-2 strains in pre-immunized Japanese adults boosted with ARCT-154 compared with the conventional mRNA vaccine, BNT162b2, which persisted up to 12 months post-vaccination, including in those age 50 years and older. This publication relates to the study described below &#8211; &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Phase 3 Study of Bivalent Version of KOSTAIVE (COVID-19 Vaccine) Candidate in Japan</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221;.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Approval of KOSTAIVE in Japan</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">KOSTAIVE (ARCT-154 version) received marketing authorization approval in November 2023 from the Japanese Ministry of Health, Labour and Welfare for use as a primary immunization and booster in Japan for adults 18 years and older. The approval was based on positive clinical data from several ARCT-154 studies, including a 19,000-participant efficacy, safety and immunogenicity study performed in Vietnam, as well as a Phase 3 booster study in Japan.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2024, Japan&#8217;s Ministry of Health, Labor and Welfare (MHLW) granted approval and authorization for an updated version of KOSTAIVE, targeted to protect against the JN.1 lineage of Omicron subvariants for adults 18 years of age and older. CSL Seqirus&#8217; exclusive partner in Japan, Meiji, began distributing the updated vaccine in Japan in October 2024, marking the world&#8217;s first commercially available sa-mRNA COVID-19 vaccine. The approval was based on manufacturing data demonstrating the quality and consistency of the vaccine product, non-clinical immunogenicity data against JN.1 lineage of Omicron subvariants of KOSTAIVE, and clinical evidence supporting the safety and immunogenicity of KOSTAIVE (bivalent, BA.4/5 and ancestral strain).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In January 2025, CSL Seqirus&#8217; partner Meiji announced that it received approval for a partial amendment to the manufacturing and marketing approval of KOSTAIVE to include manufacturing sites in Japan. With this approval, Meiji and ARCALIS, Inc., Arcturus&#8217; manufacturing joint venture in Japan, have been added as manufacturing sites. As a result, KOSTAIVE, with active pharmaceutical ingredients manufactured at such sites, may be shipped for commercial use in Japan.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Approval of KOSTAIVE (ARCT-154) in Europe</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In February 2025, the European Commission granted marketing authorization for KOSTAIVE (ARCT-154) for individuals 18 years of age and older. The European Commission approval follows a positive opinion adopted by the Committee for Medicinal Products for Human Use (CHMP) of the EMA on December 12, 2024. The centralized marketing authorization of KOSTAIVE provided by the EC is valid in all 27 European Union (EU) member states and 3 additional European Economic Area (EEA) countries summarized here: Austria, Belgium, Bulgaria, Croatia, Republic of Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Liechtenstein, Lithuania, Luxembourg, Malta, The Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain and Sweden.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Clinical Studies of KOSTAIVE (COVID-19 vaccine)</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the development of KOSTAIVE, we have conducted or are conducting the studies described below.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Pivotal Phase 1/2/3 Study in Vietnam</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During 2021, we entered into a collaboration with Vinbiocare Biotechnology Joint Stock Company (&#8220;Vinbiocare&#8221;), a member company of the Vingroup Joint Stock Company (Vingroup) group of companies. As part of a collaboration with Vinbiocare, ARCT-154, our next-generation, self-amplifying mRNA-based vaccine for COVID-19, was advanced into a Phase 1/2/3 study in Vietnam, funded and sponsored by Vinbiocare (the &#8220;Vinbiocare Study&#8221;). The trial was randomized, observer-blinded, placebo and active-controlled, and intended to assess the safety, immunogenicity, and efficacy of ARCT-154. The Phase 3 arm of the Phase 1/2/3 study was initiated in September 2021. The study enrolled over 19,000 adult subjects in Vietnam, including individuals with medical conditions, putting them at higher risk of severe complications of COVID-19. The Phase 3b placebo-controlled efficacy portion of the study enrolled over 16,000 participants. The study demonstrated that a 2-dose vaccination series with ARCT-154 induced protection in the seronegative population against heterologous SARS-CoV-2 variants (mainly Delta) with vaccine efficacy of 56.6% (48.7&#8211;63.3) for COVID-19 of any severity and 95.3% (80.5&#8211;98.9) for severe COVID-19. The vaccine was immunogenic against ancestral SARS-CoV-2 strain and induced a cross-neutralizing immune response against new emergent variants. The vaccine was well tolerated, and safety analysis did not identify specific safety concerns. The study results were used as a basis for vaccine licensure in Japan and the European Union.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In August 2023, we submitted the primary manuscript with efficacy, immunogenicity and safety results of the pivotal Phase 1/2/3 clinical study of ARCT-154 in Vietnam (</span><span><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">https://www.nature.com/articles/s41467-024-47905-1</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">). Later, we published the results of Phase 3c part of the study, comparing the immunogenicity and efficacy of ARCT-154 and licensed adenoviral vector vaccine ChAdOx-1S, demonstrating higher immunogenicity and relative vaccine efficacy (19.8% (95% CI: 4.0&#8211;33.0)) of ARCT-154 compared to ChAdOx-1S (</span><span><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">https://pmc.ncbi.nlm.nih.gov/articles/PMC11585660/</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">).</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Pivotal Phase 3 Non-Inferiority Study of KOSTAIVE (ARCT-154) in Japan</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Meiji sponsored a randomized, multicenter, Phase 3, observer-blind, active-controlled comparative study to evaluate the safety and immunogenicity of a booster dose of ARCT-154 and to evaluate the non-inferiority of ARCT-154 over COMIRNATY&#174; (Monovalent, Original strain). The study completed enrollment in February 2023 with 828 participants, with half in the ARCT-154 group and half in a comparator group.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The study met all primary and secondary immunogenicity endpoints, including a secondary pre-defined superiority assessment over COMIRNATY (Omicron BA.4/5 strain). Overall, the safety and immunogenicity results of the study support the favorable benefit/risk profile of the ARCT-154 vaccine when administered as a booster dose in adult individuals who previously received other mRNA COVID-19 vaccines.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2024, Lancet Infectious Diseases published the follow-up article &#8216;12-month persistence of immune responses to self-amplifying mRNA COVID-19 vaccines: ARCT-154 versus BNT162b2 vaccine&#8217;, which confirmed a better neutralizing immune response against a panel of SARS-CoV-2 strains in pre-immunized Japanese adults boosted with ARCT-154 compared with the conventional mRNA vaccine, BNT162b2, which persisted up to 12 months post-vaccination, including in those age 50 years and older.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Phase 3 Study of Bivalent Version of KOSTAIVE (COVID-19 Vaccine) Candidate in Japan</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2023, Meiji initiated a Phase 3 clinical study with ARCT-2301, a bivalent version of KOSTAIVE (ancestral strain and Omicron BA.4/5) to further support immunogenicity and safety data for our self-amplifying mRNA platform, which may facilitate the timely release of future seasonal updates of our COVID-19 vaccine against evolving variants of concern. The study enrolled 930 healthy adults and individuals with comorbidities, who previously received three to five doses of mRNA COVID-19 vaccines, including the last booster at least three months prior to recruitment, and compared the investigational vaccine (ARCT-2301) and COMIRNATY (ancestral strain and BA.4/5) to evaluate safety and immunogenicity between observer-blind groups.  The bivalent vaccine met the primary study endpoint (non-inferiority).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Both the geometric mean titer (GMT) ratio and seroresponse rate (SRR) difference of neutralizing antibodies against SARS-CoV-2 (Omicron BA.4/5 and Wuhan strains) met pre-specified non-inferiority and superiority criteria versus COMIRNATY. There were no causally-associated severe or serious adverse events with ARCT-2301.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As with the monovalent vaccine, the bivalent sa-mRNA formulation demonstrated superior immunogenicity over the conventional bivalent mRNA vaccine COMIRNATY, a higher immune response persisting up to six months after a booster dose, and improved breadth, supporting the robustness of the sa-mRNA vaccine platform for future vaccine strain updates. The study results were presented at OPTIONS XII for the Control of Influenza conference in Brisbane, Australia, in September 2024.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Phase 3 Co-administration Study of KOSTAIVE (Monovalent XBB1.5) and Seasonal Influenza Vaccines</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2024, Arcturus and CSL Seqirus initiated a Phase 3 pivotal study with the ARCT-2303 candidate vaccine containing the XBB1.5 Omicron variant. The study aimed to generate additional immunogenicity and safety data in multiple ethnicities to support regulatory filings in the U.S. and globally. In addition, the study assessed the co-administration of the ARCT-2303 vaccine with the age-appropriate seasonal influenza vaccines. Overall, 1,499 adults, including older adults, were recruited in the study in Australia, Costa Rica, Honduras and the Philippines.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The study results showed that all four primary study objectives and key secondary study objectives were met. ARCT-2303 demonstrated a superior immune response compared to ARCT-154 as measured by neutralizing antibodies against Omicron XBB.1.5 in terms of GMT ratio and SRR difference. Co-administration of ARCT-2303 and quadrivalent influenza vaccine (QIV; Flucelvax, CSL) in adults 18-64 years old showed a noninferior immune response compared to standalone QIV. Co-administration of ARCT-2303 and QIV also showed a noninferior immune response compared to standalone ARCT-2303. Co-administration of ARCT-2303 and adjuvanted QIV (Fluad, CSL) in adults 65 years of age and above showed similar results for co-administered and separately administered groups. The safety and reactogenicity of co-administered vaccines were comparable with standalone administration. No safety concerns were raised based on the study results.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">COVID-19 Vaccine Product Format</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The product format of KOSTAIVE that began commercialization in Japan in October 2024 is a lyophilized product presentation. The stability and cold chain characteristics of KOSTAIVE in a lyophilized format compares favorably to frozen liquid format, and our ongoing development of proprietary manufacturing technology has led to significant increases in refrigerated and ambient temperature shelf-lives for both lyophilized and liquid drug products. In conjunction with our collaborator, CSL Seqirus, we are working to optimize KOSTAIVE&#8217;s formulation to better meet the needs of healthcare professionals and their patients.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:5%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Seasonal Flu Collaboration Program</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:5%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">LUNAR-FLU (Seasonal Influenza)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Influenza is estimated to cause one billion infections globally every year and hundreds of thousands of deaths, especially in the elderly and individuals with underlying medical conditions. In many regions, influenza is seasonal, with infections peaking during November through April in the Northern Hemisphere and May through September in the Southern Hemisphere. Year-round surveillance by the World Health Organization (&#8220;WHO&#8221;) in collaboration with various national health agencies informs WHO recommendations on the strains of influenza most likely to spread during the upcoming influenza season. National health agencies (such as the U.S. Food and Drug Administration (&#8220;FDA&#8221;)) then make the final decision of which strains should be covered by vaccines licensed in their country.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our LUNAR-FLU (seasonal) program, now exclusively licensed to CSL Seqirus, has the objective of producing a safe and effective seasonal influenza vaccine candidate with significant advantages over the traditional egg-based inactivated quadrivalent vaccine. Inaccurate predictions of circulating influenza strains as well as mutations due to adaptation in egg-grown vaccines can substantially reduce efficacy on a year-to-year basis. We believe the ability of mRNA platforms to nimbly adapt to new viral strains should help improve efficacy. In addition, we do not expect mRNA vaccines to face the challenge from mutations common to egg-grown vaccines.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LUNAR-FLU has been designed to take advantage of our expertise in both LUNAR lipid delivery systems and our STARR self-amplifying mRNA technology. This platform has been shown to deliver effective protection against COVID-19 and has been optimized to elicit robust immunogenicity with acceptable reactogenicity at a lower dose than conventional mRNA vaccines with the objective of creating a highly effective influenza vaccine for use in general and high-risk populations. Working with CSL Seqirus, we generated a comprehensive non-clinical data package to support the initiation of the Phase 1 clinical trial with a novel influenza sa-mRNA vaccine candidate. A Phase 1 dose-finding safety and immunogenicity study was initiated in January 2024 in Australia and is ongoing.</span></p>
  <p style="text-indent:4.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pandemic Avian Influenza Program (H5N1 Influenza)</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our LUNAR-H5N1 program, which is part of the CSL Collaboration Agreement, continues to progress under the award from BARDA that we obtained in 2022 to advance through Phase 1 a vaccine to protect against disease caused by H5N1 highly-pathogenic avian influenza. H5N1 influenza is a significant concern in animal health. To date, H5N1 flu has affected over 10,000 wild birds, nearly a thousand dairy cows, and over 130 million poultry. Elevated H5N1 infections in animals have led to increasing numbers of human infections including two confirmed severe cases in the United States and one death. Most of the confirmed human infections are due to exposure of U.S. dairy and poultry workers to infected dairy cows and poultry. We are working diligently with our partners, BARDA and CSL Seqirus, to clinically validate our low-dose STARR mRNA technology for H5N1 to assist towards pandemic preparedness.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Phase 1 study of ARCT-2304, a self-amplifying mRNA (sa-mRNA) vaccine candidate, also known as LUNAR-H5N1, initiated dosing in December 2024. The randomized placebo-controlled Phase 1 trial (NCT06602531) is being conducted at multiple sites in the U.S. and designed to enroll approximately 200 healthy adults (120 participants 18-59 years old; 80 participants 60-80 years old). The primary objective of this initial clinical trial is to evaluate safety and immune responses of three different dose levels and two different vaccination schedules of ARCT-2304 vaccine. Immune responses are measured by hemagglutination inhibition (HAI), virus microneutralization (MN) and neuraminidase enzyme-linked lectin assays (ELLA). The clinical study is fully funded by Biomedical Advanced Research and Development Authority (BARDA). For a more comprehensive discussion of the funding award, please see Item 1 &#8220;Business&#8221; &#8211; &#8220;Revenue and Collaboration Arrangements and Other Material Agreements&#8221; &#8211; &#8220;BARDA.&#8221;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Preclinical Ferret Studies of ARCT-2304 (LUNAR-H5N1)</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Several ferret challenge studies have been conducted to establish the efficacy of ARCT-2304, our clinical candidate for the LUNAR-pandFLU program. ARCT-2304 vaccinated ferrets were challenged with the same influenza strain, H5N1 A/Indonesia/5/2005, encoded by the vaccine and protected all ferrets from lethal challenge. Robust HAI and NI titers were observed after two doses of the vaccine and nasal titers in the days following challenge were lower than in either the unvaccinated ferrets (PBS) or ferrets vaccinated with an adjuvanted recombinant trimeric hemagglutinin (rHA). Further, fewer signs of lung damage were observed in ARCT-2304 ferrets compared to either unvaccinated or rHA vaccinated ferrets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In a separate experiment, ARCT-2304 vaccinated ferrets were challenged with an antigenically drifted strain from a different clade of H5N1, A/Vietnam/1203/2004. ARCT-2304 vaccinated ferrets were compared to unvaccinated ferrets and to ferrets receiving an adjuvanted trimeric rHA vaccine encoding either the same strain as encoded by ARCT-2304 (A/Indonesia) or the challenge strain (A/Vietnam). ARCT-2304 vaccinated ferrets were protected from death from this antigenically drifted strain. While HAI and NI titers were lower against A/Vietnam than against A/Indonesia, ARCT-2304 vaccinated ferrets had the lowest nasal wash titers of any group and showed no signs of lung damage in contrast to unvaccinated ferrets and ferrets vaccinated with adjuvanted trimeric rHA protein.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img267189834_3.jpg" alt="img267189834_3.jpg" style="width:617px;height:133px;"/></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img267189834_4.jpg" alt="img267189834_4.jpg" style="width:609px;height:130px;"/></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">    </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Figure 1: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A) Ferrets were vaccinated twice (day 0 &amp; 28) with either ARCT-2304 (5&#181;g) or an adjuvated (Addavax) recombinant trimeric HA protein (15&#181;g) and challenged 3 weeks (day 49 post-vaccination) after the last vaccination with a lethal dose of the homologous H5N1 A/Indonesia/5/2005 strain. All vaccinated ferrets survived infection while all unvaccinated (PBS) ferrets succumbed to the infection by day 7 post-infection. ARCT-2304 ferrets had the highest HAI and NI titers among vaccinated groups both prior to and after challenge.  In addition, nasal wash titers were lowest in the ARCT-2138 vaccinated ferrets.  B) Ferrets were vaccinated twice (day 0 &amp; 28) with either ARCT-2304 (5&#181;g) or an adjuvated (Addavax) recombinant trimeric HA protein (15&#181;g) encoding the same strain at ARCT-2304 (A/Indonesia) or the challenge strain (A/Vietnam) and challenged 4 weeks (day 56 post-vaccination) after the last vaccination with a lethal dose of H5N1 A/Vietnam/1203/2004 strain. While lower HAI and NI titers were observed against the heterologous A/Vietnam strain, all vaccines elicited protection from lethal infection. Similar to the heterologous challenge, however, the lowest nasal wash titers were observed in the ARCT-2304 vaccinated group.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rare Disease Program</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Orphan Drug Act of 1983 (the &#8220;Orphan Drug Act&#8221;) defines a rare disease as a disease affecting fewer than 200,000 individuals in the United States. According to the National Institutes of Health (&#8220;NIH&#8221;), there are approximately 10,000 such diseases that, together, affect nearly 30 million people in the United States. The European Union (the &#8220;EU&#8221;) defines a rare disease as having a prevalence of fewer than five in 10,000 people. Collectively, these disorders affect between 6% and 7% of the population in the developed world.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There is a pressing need for new medicines for rare diseases as few of the 10,000 known rare diseases have approved treatments. Biopharmaceutical industry researchers are making great progress in the fight against some rare diseases as innovative science has opened new opportunities. More than 770 medicines have been approved by the FDA since the enactment of the Orphan Drug Act and more than 800 medicines are currently in clinical development. Despite recent progress, there is more work to be done to overcome the scientific, operational and financial challenges that arise.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe our technology should provide an excellent platform to address genetically inherited rare diseases. Specifically, we are focusing on developing medicines to treat people with rare respiratory and liver diseases who currently have limited or no treatment options.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rare Disease Program &#8211; ARCT-810 (LUNAR-OTC)</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The LUNAR-OTC development program addresses ornithine transcarbamylase (OTC) deficiency, a rare, life-threatening, genetic disease caused by mutations in the OTC gene that lead to dysfunctional or deficient OTC.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">OTC deficiency is the most common of the urea cycle disorders, a group of inherited metabolic disorders that are associated with reduced ability to eliminate ammonia from the body. There are over 5,000 people with OTC deficiency in the United States and the prevalence is approximately one in 14,000 to one in 77,000 people worldwide. Ammonia is a toxic waste product produced from the breakdown of protein. OTC is a critical enzyme in the urea cycle, which takes place in liver cells and converts ammonia to harmless urea which is eliminated by the kidneys. In patients with OTC deficiency, ammonia accumulates in the blood and is toxic to the brain and liver. Symptoms of high ammonia levels include vomiting, headaches, coma and death. OTC deficiency can cause developmental problems, seizures and death in newborn babies. As an X-linked disorder, OTC deficiency tends to be more severe in males, though female carriers are often affected. Patients with less severe symptoms may present later in life, as adults. Currently no cure exists for OTC deficiency apart from liver transplant; however, this treatment comes with significant risks and complications such as organ rejection, and transplant recipients must take immunosuppressant drugs for the rest of their lives. Current standard of care for OTC deficiency is a low-protein diet, dietary supplements, and nitrogenscavengers to try to prevent accumulation of ammonia. Life-threatening episodes of high ammonia levels can still occur, requiring treatment with dialysis or hemofiltration. These treatments do not address the underlying cause of disease and there remains a high unmet need for an effective treatment.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our LUNAR-OTC development candidate, ARCT-810, uses our LUNAR platform to deliver normal OTC mRNA into liver cells which then produce normal functioning OTC with possible disease-modifying effects. Our LUNAR-OTC approach has the potential to treat the underlying defect that causes the debilitating symptoms of OTC deficiency, rather than mitigating symptoms by sequestering ammonia. We have retained worldwide development and commercialization rights to ARCT-810.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LUNAR-OTC has received Orphan Drug Designation from the FDA and Orphan Medicinal Product Designation from the EMA for treatment of OTC deficiency. ARCT-810 was also granted Fast Track Designation in and Rare Pediatric Disease Designation (RPDD). Fast Track Designation is designated to facilitate development and expedite review of new therapeutics intended to treat serious or life-threatening conditions that demonstrate the potential to address important unmet medical needs. Rare Pediatric Disease Designation is designed to recognize rare pediatric diseases in which the serious or life-threatening manifestations primarily affect patients from birth to 18 years of age. Due to such designation, if ARCT-810 achieves approval for a pediatric indication in the original rare pediatric disease product application in the United States, Arcturus (or the sponsor of ARCT-810) is eligible to receive a voucher for priority review of a subsequent marketing application for a different product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Preclinical data in OTC-deficient murine models have demonstrated that dosing of LUNAR-OTC results in robust OTC protein expression and activity, thereby improving ureagenesis, reducing plasma ammonia, and increasing survival.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A Phase 1 double-blind, placebo-controlled, dose-escalation study of ARCT-810 in healthy volunteers, completed in November 2020, and demonstrated favorable safety, tolerability and PK profiles.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A single ascending dose, placebo-controlled study Phase 1b study in 16 stable mild OTC-deficient adults was completed in the United States in September 2023. The trial assessed safety, tolerability and pharmacokinetics of a single dose of ARCT-810, and exploratory biomarkers of drug activity. ARCT-810 was generally safe and well tolerated at doses ranging from 0.1- 0.5mg/kg and no serious or severe adverse events were observed. Sporadic infusion-related reactions (IRRs) were managed with symptomatic treatment and appeared to be less frequent with slower infusion rates. In plasma, ARCT-810 mRNA could be detected up to four weeks, while ionizable lipid was no longer measurable after 48 hours, indicating rapid degradation of the lipid nanoparticle that was utilized to deliver ARCT-810 mRNA. Study results were presented at the Society for Inherited Metabolic Disorders meeting in Charlotte, North Carolina in April 2024 and at the annual symposium for the Society for the Study of Inborn Errors of Metabolism in Porto, Portugal in August 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A Phase 2 double-blind study of ARCT-810 in stable OTC-deficient adolescents and adults in the European Union and the United Kingdom completed dosing of eight subjects in August 2024 at the 0.3 mg/kg dose level. The participants in this group were randomized 3:1 to receive six doses of ARCT-810 or placebo administered every 14 days. Patient follow-up is completed, and data management and analysis are ongoing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the second quarter of 2024, we expanded the Phase 2 clinical program of ARCT-810 to the U.S. with an open-label, multiple-dose study to evaluate pharmacodynamics and safety in adult and adolescent patients requiring clinical management for OTC-deficiency. The first OTC deficient participant receiving 0.5 mg/kg ARCT-810 initiated dosing in December 2024 in the United States. Each participant is expected to receive five intravenous infusions administered over two months.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rare Disease Program - LUNAR-CF (Cystic Fibrosis)</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The LUNAR-CF program addresses cystic fibrosis (CF) lung disease, a progressive disorder caused by mutations in the CF transmembrane conductance regulator (CFTR) gene. ARCT-032, our lead development candidate for the treatment of CF, uses our LUNAR platform to deliver a codon-optimized CFTR mRNA into airway epithelial cells. This allows airway cells to produce functional human CFTR protein using native translational machinery and protein trafficking pathways which could result in the treatment of the underlying defect that causes CF lung disease, regardless of the specific mutation. The Cystic Fibrosis Foundation (the &#8220;CFF&#8221;) has partnered with us to support development of this therapy. ARCT-032 represents the first LUNAR-based mRNA therapeutic delivered by the inhaled route, offering direct delivery to the affected airways to restore functional CFTR.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are close to 40,000 children and adults living with CF in the United States (and an estimated 105,000 people have been diagnosed with CF across 94 countries), and CF can affect people of every racial and ethnic group. Approximately 800 people are newly diagnosed with CF each year in the United States. CF is caused by one of more than 2,000 known mutations in the CFTR gene. These mutations have been grouped into several different classes based on the mechanism by which they cause reduction in the production and/or function of the CFTR protein. When CFTR is absent or defective, the airway surfaces become dehydrated and coated with a layer of thick mucus that clogs the airways, causing difficulty breathing and often resulting in chronic infections, exaggerated inflammation, structural airway damage, and other serious complications in the lungs. CF is a multi-system disease that may also affect the pancreas, intestines, liver, sinuses, reproductive tract and sweat glands. The median predicted survival of CF patients born between 2018-2022 in the United States is approximately 56 years, and the cause of most of the mortality and morbidity is due to the lung disease.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Current non-curative therapies for CF lung disease are directed towards disease severity and to prevent the progression of the disease. These treatments include aerosolized mucolytics, antibiotics, and airway clearance techniques that are time-consuming and represent a significant treatment burden for people with CF. Many CF patients ultimately suffer from a critical decline in lung function and require lung transplants.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA has approved several CFTR modulator therapies (Kalydeco&#174;, Orkambi&#174;, Symdeko&#174;, and Trikafta&#174;) that assist certain classes of abnormal CFTR protein to reach the cell membrane and/or increase functional ion channel activity. The CFTR modulators, while effective in many patients, are mutation-specific and therefore are not effective in all persons with CF. Other treatments are required to target Class I mutations (no CFTR produced; approximately 10% of CF cases worldwide), and people who are intolerant or have poor response to CFTR modulator therapies. We are initially focusing ARCT-032 on these groups of patients, as they currently have the highest unmet need for CF therapies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In 2023, we initiated and successfully completed a safety and tolerability Phase 1 single ascending dose study of ARCT-032 (LUNAR-CF), our mRNA therapeutic candidate for CF. Thirty-two healthy participants (eight subjects in each of four dose cohorts) received a single inhaled dose of ARCT-032. A subsequent protocol amendment to transition to a safety and tolerability Phase 1b clinical study of ARCT-032 in adults with CF received regulatory approval in August 2023 and completed dosing and follow-up visits for seven CF participants in August 2024, with each CF participant having received two administrations of ARCT-032 separated by two days.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the Phase 1/1b clinical study, ARCT-032 was generally safe and well tolerated in both the healthy volunteers and the participants with CF. Of the seven total CF participants in the Phase 1b study, six were being treated with CFTR modulators while one subject had Class I mutations that do not benefit from modulator therapy. No serious or severe adverse events (SAEs) were observed, and the safety profile was similar between healthy volunteers and CF participants.  Mild, transient events of elevated temperature or feeling hot accompanied by other</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">nonspecific symptoms were observed at dose levels that are higher than those planned for the Phase 2 study. In the CF subjects, lung function measured over eight days did not demonstrate a discernable pattern or safety concern after two doses of ARCT-032. Preliminary findings from the study were presented at the European CF Society Conference in June 2024 in Glasgow, Scotland, and at the North American CF Conference in September 2024 in Boston, MA.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2024, we initiated dosing in our ARCT-032 Phase 2 multiple ascending dose study designed to identify a safe and effective dose in Class I (null) and other CF participants who do not benefit from CFTR modulators. This study is supported by safety and tolerability data collected in healthy volunteers (N = 32) and the two-administration Phase 1b study in CF adults. Each participant in the Phase 2 CF study (NCT06747858) is expected to receive daily treatments of ARCT-032 over a period of 28 days.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARCT-032 has received Orphan Drug Designation by the FDA and Orphan Medicinal Product Designation by the EMA. The FDA also granted Rare Pediatric Disease Designation for ARCT-032. The Rare Pediatric Disease Designation is designed to recognize rare pediatric diseases in which the serious or life-threatening manifestations primarily affect patients from birth to 18 years of age. With this designation, if ARCT-032 achieves approval for a pediatric indication in the original rare pediatric disease product application in the United States, Arcturus (or the sponsor of ARCT-032) is eligible to receive a voucher for priority review of a subsequent marketing application for a different product.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An extensive portfolio of nonclinical studies supported the advancement of ARCT-032 to the clinic. Our comprehensive data set showcasing the potential for ARCT-032 as a disease-modifying treatment has been presented at the major CF conferences in North America and Europe. For example, we presented data at the North American Cystic Fibrosis Conference in November 2023 that demonstrated that a single dose of ARCT-032, administered in the airways of CF ferrets by microsprayer, effectively doubled the mucociliary transport rate in vivo.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Platform Technologies and R&amp;D Programs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have four key proprietary platform technologies:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">lipid-mediated delivery (LUNAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">)</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">mRNA and protein design </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">self-amplifying mRNA (STARR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">)</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">manufacturing and formulation for mRNA medicines</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LUNAR (Lipid-Mediated Delivery) Platform</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our LUNAR lipid-mediated delivery technology includes a diverse, growing library of over 300 proprietary lipids that we are rationally designing to be versatile, while maximizing efficacy and improving tolerability of a diverse selection of nucleic acids, refining the LNPs to target specific cell types, and determining the most favorable routes of administration. A key feature of our LUNAR lipids is their biodegradability, decreasing the undesired effects caused by lipid accumulation that are associated with tolerability issues present in other lipid-mediated RNA medicine delivery platforms. Our team continues to advance our LUNAR lipid formulated nucleic acid platform in a scalable and highly reproducible manner, reducing the costs of goods for the therapies in our pipeline.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to our LUNAR lipid-mediated delivery technology, we believe we have created innovative, proprietary advancements in producing mRNA medicines, including improvements that increase purity, scalability, efficiency in production times, and adaptability to different mRNA modification strategies. We strive to use these proprietary innovations to benefit each mRNA medicine in our pipeline.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We continue to invest in and improve our LUNAR lipid-mediated delivery of mRNA with continuous improvements in our mRNA and sa-mRNA platforms in conjunction with improvements in our next generation proprietary lipids to improve targeting, efficacy and safety profiles for both our vaccine and therapeutic protein platforms.  This investment has led to key innovations ensuring that our LUNAR formulated drug product candidates have optimal characteristics for therapeutic use, which we believe sets us apart from other nucleic acid therapeutics and lipid-mediated delivery platforms. As such, we consider ourselves a leader in the research and development of mRNA therapeutics for multiple indications.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We continue to conduct exploratory platform development activities, including the evaluation of genome editing, and new targeting approaches, where our LUNAR and STARR platforms could potentially be useful for identification and development of additional products for our portfolio.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Key Attributes of Our LUNAR Lipid-Mediated Delivery Technology</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have designed our LUNAR lipid-mediated delivery platform to address major challenges with nucleic acid medicine delivery, including transfection efficiency, adverse immune reactions and liver damage.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LUNAR is a multi-component, lipid-mediated drug delivery system that utilizes our proprietary lipids, called ATX lipids. Each of our ATX lipids contain an ionizable head group and a biodegradable lipid backbone. The head group is a key chemical component of the ATX lipid, making it pH-sensitive and providing it distinct advantages as a component of our LUNAR lipid formulation. At acidic pH, ATX lipids are positively charged, facilitating interaction with the negatively charged nucleic acid, thereby enabling LUNAR particle formation. At physiological pH (e.g., pH 7.4), the ATX lipids within the LUNAR formulations are neutrally charged, reducing the toxicity often seen with permanently positively charged lipid-mediated delivery technology. Upon uptake into a cell by endocytosis (a process that forms a cellular structure called an endosome around the LUNAR formulated nucleic acid therapeutic), the head group again becomes positively charged, disrupting the endosome and the LUNAR particle, resulting in release of the nucleic acid therapeutic into the cell where is it translated to produce a therapeutic protein.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The disruption of the LUNAR particle also releases the components of the formulation into the cell, where the ATX lipid is degraded by enzymes in the cell allowing for the lipids to be cleared from the cell. We designed the ATX lipid to be rapidly biodegradable by engineering chemical structural components, called esters, into the ATX backbone that are sensitive to cellular enzymes, called esterases. This degradation prevents ATX lipids from accumulating inside the cell and causing toxicity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Biodegradable, highly optimized for each cell type</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img267189834_5.jpg" alt="img267189834_5.jpg" style="width:624px;height:202px;"/></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">LUNAR-platform development</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The development of our LUNAR platform is focused on continuous innovation and advancement in the following areas:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Design, manufacture and incorporate novel ATX lipids into formulations to enrich our library of proprietary ATX lipids for target cell/tissue specificity, improved tolerability and translatability to larger species;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Develop, optimize and innovate manufacturing processes for LUNAR formulations to ensure RNA encapsulation across compositions and scales;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Develop stabilization strategies (e.g. lyophilized presentation) for LUNAR formulations to mitigate the need for frozen storage and to extend shelf-life; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Continually optimize and innovate LUNAR screening paradigm to enable rigorous selection of ATX lipids for various therapeutic programs and routes of administration.</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Through the above efforts, our versatile LUNAR platform continues to drive internal and partner programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ATX Lipid Design and In Vivo Screening Process</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As mentioned above, we have generated a growing library of more than 300 proprietary ATX lipids. ATX lipids are rationally designed to fit their respective applications and vary depending on the target cell type and route of administration. We perform extensive formulation screening for each nucleic acid therapeutic candidate to determine the optimal ATX lipid  to be used and the appropriate excipient composition (LUNAR composition) for the nucleic acid therapeutic candidate, the desired route of administration, and target cell type.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The design of ATX lipids is an iterative process based on in vivo protein expression and tolerability results from previous ATX lipid candidates. New ATX lipids are chemically synthesized and used to package mRNAs expressing a secreted protein. The ATX lipid formulated RNAs must meet specific chemical and biophysical acceptance criteria before being tested for biological activity. RNA formulations meeting all acceptance criteria are first screened for protein expression in mice. Active candidates are then tested for tolerability and preliminary tissue clearance rates following administration. Active candidates are further verified by evaluating protein expression in non-human primates. Active ATX lipid candidates demonstrating high levels of protein expression and equivalent or improved tissue clearance rates are then assigned to a specific disease target for development of therapeutic applications. The following results are from an in vivo mRNA expression study which identified three new highly active LUNAR lipids with regard to protein expression in non-human primates compared to the positive control.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Expression of Human EPO in Mice 6 hours After IV Administration (Figure 2)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img267189834_6.jpg" alt="img267189834_6.jpg" style="width:624px;height:237px;"/></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Mouse Liver Clearance of LUNAR Lipids 48 hours After IV Administration (Figure 3)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img267189834_7.jpg" alt="img267189834_7.jpg" style="width:565px;height:455px;"/></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">17</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Expression of Human EPO in Non-Human Primates 6 Hours After IV Administration (Figure 4)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img267189834_8.jpg" alt="img267189834_8.jpg" style="width:620px;height:373px;"/></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Figure 2:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> mice were injected intravenously with 4 different LUNAR lipid formulations containing mRNA expressing human erythropoietin (EPO). The LUNAR lipids that were screened were C9G, C9H, C9I and B2G at 0.1 mg/kg and 0.3 mg/kg RNA doses. LUNAR lipid B2G formulation is a positive control to which expressions from the other formulations are compared. Mice were bled 6 hours after injection and assayed for EPO, a secreted protein.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Figure 3:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shows the clearance of the LUNAR lipids from the mouse liver 48 hours after administration of 0.1mg/kg and 0.3 mg/kg RNA doses. C9G, C9H and C9I yielded much higher expression levels of EPO than B2G, the positive control for both doses tested. It also shows that the residual amount of C9G and C9I were below the limit of detection and the residual amount of C9H was at least 10-fold less than the remaining amount of B2G at the 0.1 mg/kg RNA dose and at least two-fold less than the residual amount of B2G at the higher RNA dose.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Figure 4:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> C9G and C9I formulations were tested for EPO expression in non-human primates at a single dose and assayed for secreted hEPO in the blood six hours after IV administration. Both C9G and C9I yielded significantly higher expression levels than the positive control, B2G further confirming the superior performance of the new LUNAR formulations. Hence, this lipid screen identified three LUNAR lipids that yielded greater RNA expression in mice and two LUNAR lipids in NHPs and were rapidly cleared from the liver within 48 hours after administration.  This demonstrated the ability to design and execute LUNAR formulations using our advanced generation lipids with many-fold higher protein expression and ready biodegradability.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Lung Targeting</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Aerosol capabilities have been developed for the CF program using our proprietary lipid nanoparticle delivery platform, LUNAR. Characterization and optimization of the aerosolized LUNAR formulations in targeting airway epithelium have been achieved in rodent (mice, rat) and nonrodent models (ferret, NHP) as depicted in the image using a reporter mRNA encapsulated in LUNAR. We expect that the validation attained for the inhaled LUNAR platform in the CF program will serve as a translatable approach to support other respiratory approaches where targeting airway epithelium is needed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img267189834_9.jpg" alt="img267189834_9.jpg" style="width:621px;height:289px;"/></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">LUNAR delivery to airways epithelium demonstrated in vivo across species (rodents, ferrets, NHPs)</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Alternate Liver Targeting</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As proof of concept for augmenting LUNAR liver-targeting capabilities, we have developed data on LUNAR formulations containing a propriety hepatocyte targeting agent. Traditional lipid nanoparticle-mediated delivery to hepatocytes occurs via uptake by the low-density lipoprotein receptor (LDLR). LUNAR&#8217;s advanced generation lipids have excellent liver targeting capabilities on their own. But diseases mediated by LDLR deficiency such as familiar hypercholesterolemia require alternate liver targeting and LUNAR delivery approaches. Therefore, we evaluated this targeting agent in an LDLR-deficient mouse model and found that only the LUNAR formulations with this targeting agent were able to deliver mRNA to the hepatocytes compared to LUNAR formulations that did not contain the targeting agent. Based on this promising data, we are expanding these platform development efforts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img267189834_10.jpg" alt="img267189834_10.jpg" style="width:624px;height:281px;"/></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">LUNAR Safety and Tolerability (i.v. administration)</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As part of the screening method for our proprietary lipids, we conduct an initial lipid tolerability screen in Balb/C and C57Bl/6 mice strains to ascertain the initial maximum tolerated dose in rodent species(s). LUNAR formulations encapsulating hEPO mRNA with different ATX lipids are intravenously administered to these mouse</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">19</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">strains at three and five mg/kg doses and monitored for clinical signs. Blood was drawn at six and 48 hours after LUNAR administration and assayed for both liver functions and cytokine elevations. Liver function changes are determined by measuring for any increase in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) enzymes in the blood. A significant increase in these enzymes (i.e., above five times the normal range) indicates a negative effect on liver function. The results show that many of the LUNAR formulations that were tested are tolerable up to three mg/kg in both strains of mice for LUNAR formulations containing DSPC. Moreover, there is an even greater improvement in tolerability of up to five mg/kg when the helper lipid is PCA57. Thus, with these innovations we believe that we have substantially improved both the potency and tolerability of our LUNAR platform.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Proprietary mRNA and Protein Design Technology</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The mRNA programs in our pipeline benefit from our in-house expertise in protein and mRNA design, which helps us address many of the known challenges that face the viability of mRNA therapeutics today. We have identified several design elements of mRNA compounds that provide improved translation (the process of making protein based on the instructions/codes in the mRNA) of our mRNA therapeutics, including untranslated regions derived from species that have not previously been combined with human mRNA sequences. This platform technology is applicable to many different human mRNA sequences that we are currently investigating in our discovery efforts. We are able to engineer human protein sequences to increase the half-life of the proteins produced by our mRNA therapies and can more efficiently direct specific types of proteins to certain cellular structures of interest. These innovations are broadly applicable to several programs that are part of our mRNA discovery efforts.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to these platform technologies, we have developed a proprietary tool to aid our team in the efficient design and development of new mRNA drug candidates. Our mRNA Design Suite is a cloud-based software suite with a collection of proprietary bioinformatic algorithms aimed at achieving highly improved potency of a drug substance through optimization of mRNA sequences. The algorithms were developed in house through the integration of experimentally validated optimization processes. Through multi-layered in silico quality control pipelines, mRNA Design Suite promptly generates high-quality and error-free sequences accompanied by various statistics. Additionally, mRNA Design Suite seamlessly interacts with our plasmid/mRNA production database to accelerate the process from mRNA design to gene synthesis, cloning, and mRNA production.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our STARR mRNA Technology</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our distinct and proprietary self-amplifying mRNA (sa-mRNA) platform (STARR) includes proprietary algorithms that inform the design and optimization of sa-mRNA to enhance expression of the applicable antigen while minimizing structures that might inhibit expression. The replicase, an RNA-dependent RNA polymerase, is encoded upstream of the antigen of interest and functions to increase the duration of antigen expression compared to conventional (conventional) mRNA. The enhanced expression leads to higher immunogenicity at lower doses than conventional mRNA vaccines in preclinical studies (Figure 6 below).</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img267189834_11.jpg" alt="img267189834_11.jpg" style="width:547px;height:195px;"/></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Figure 2:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The luciferase expression from an optimized sa-mRNA, STARR Technology (Green), a non-optimized sa-mRNA (Blue) and the conventional RNA (Purple). The STARR Technology was shown to yield at least a 30-fold greater expression level than conventional RNA. The STARR Technology also demonstrated a longer duration of expression compared to the conventional RNA and also the non-optimized self-amplifying RNA.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">20</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Vaccine candidates with STARR technology have been demonstrated to induce a longer-lasting and broader humoral immune response at lower dose levels than conventional mRNA-based vaccines.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Proprietary Manufacturing Technology</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We continue to innovate and improve our capabilities to manufacture nucleic acid medicines with high standards of quality, efficiency, and in compliance with Good Manufacturing Practices and its analogous regulations outside the U.S. Our technologies work to improve every aspect of the drug product manufacturing process from design to filling and packaging. Nucleic acid manufacturing relies on the confluence of complex technologies in the chemical and biological sciences that require extreme precision in their execution. Consequently, the nucleic acid medicines industry has faced many challenges across all steps of the manufacturing process, most notably the ability to scale processes to produce batches of adequate size while continuing to meet product specifications. Notable capabilities include:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">mRNA Drug Substance Manufacturing &#8211; We have developed the ability to manufacture mRNA drug substance with high product yield and exceptional product purity. In addition, we have developed reliable and efficient testing methodologies for characterizing mRNA drug substance. We continue to innovate in this area to further improve the cost, yield, purity and stability of mRNA drug substance.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Drug Product Formulation &#8211; The formulation of mRNA drug substance with our LUNAR delivery platform is essential to achieving effective in vivo delivery and translation of the mRNA. We have developed advanced processes and know-how that enable us to manufacture lipid-encapsulated compounds at large volumes to help ensure that lipid-encapsulated compounds that meet key product specifications, including purity, particle size, concentration, stability, and percent encapsulation, in both liquid and lyophilized product formats. The continued advancement of these capabilities is an important focus of our platform development. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In our efforts to improve these and other capabilities, we use qualified scale down models to optimize operating conditions for each manufacturing step for both drug substance and drug product. Optimized conditions identified by these small-scale models are applied to the cGMP manufacturing processes. This manufacturing development process is also utilized for evaluating potential additives that improve drug substance and drug product quality and efficacy, improve manufacturing efficiency and reduce manufacturing costs. Some of the major accomplishments that have been achieved using this manufacturing development process are increased drug substance yield, reduction in drug substance impurities, increased manufacturing efficiency, and extended refrigerated and ambient temperature shelf life.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Discovery Programs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The versatile nature of our platform technologies may allow for a broad spectrum of nucleic acid medicines. We have conducted, and will continue to conduct, efforts to explore potential new drugs through our discovery and enabling technologies programs, though we are prioritizing our later stage programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Discovery Programs &#8211; Vaccine Programs (Lyme Disease and Gonorrhea)</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on the clinical and regulatory validation of LUNAR and STARR technologies provided by the approval of KOSTAIVE, a self-amplifying messenger RNA (sa-mRNA) vaccine for COVID-19, we initiated vaccine discovery programs for Lyme disease and gonorrhea. The discovery programs rely on the evidence of superior immunogenicity, durability, and breadth of immune response compared to conventional mRNA vaccines, as observed in the COVID-19 program.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lyme disease is a bacterial infection and is the most common vector-borne disease in the United States. Infection can spread to joints, the heart and the nervous system. Gonorrhea is a sexually transmitted disease (STD) that can infect the mucous membranes of the reproductive tract. It is the second most commonly reported bacterial sexually transmitted infection in the United States. We selected these diseases based on high unmet medical needs, good understanding of the path forward in vaccine target selection, and demonstration of proof of concept, as well as platform advantages that may be translated in a favorable vaccine product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Discovery Programs &#8211; HPV</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Arcturus is advancing the development of a post-exposure HPV therapeutic vaccine candidate. Although prophylactic HPV vaccinations have substantially lowered the incidence of cervical cancer in developed countries,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">21</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">cervical cancer is still the fourth leading cause of cancer in women globally with the vast majority (approximately 90%) of cases in countries that have not yet widely adopted prophylactic HPV vaccinations and other cervical cancer prevention strategies, including screening and treatment. Cervical cancer typically develops years after initial HPV exposure due to a failure to clear the virus and the integration of viral oncogenes.  A therapeutic vaccine which induces T-cell responses targeting the integrated HPV genes in precancerous cells could help prevent precancer and cancer in those already exposed to HPV. The Gates Foundation awarded Arcturus a grant of $3.9 million in November 2024 to support the development of such a therapeutic HPV vaccine through clinical candidate nomination stage.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Enabling Technologies</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Enabling Technologies &#8211; Cancer vaccines</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our LUNAR Cancer vaccine discovery efforts are aimed at developing an immunotherapy against a tumor via activated T-cells. We contemplate that the vaccine would encode an antigen(s) that would be specifically presented by (or associated with) a tumor, such that the vaccination would elicit T cell responses that recognize and attack the tumor. We have applied our learnings from our more-advanced LUNAR-COVID-19 vaccine program to establish both STARR (self-amplifying) and conventional mRNA platforms for immuno-oncology therapy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In a preclinical study, our proof of concept (POC) vaccine encoding AH1 antigen of gp70 protein which is highly expressed on the surface of mouse colorectal carcinoma cell line CT26 has demonstrated clear effectiveness in a syngeneic mouse model of a colorectal CT26 cell line. With intramuscular administration of the STARR vaccine (two doses of 10 ug), treated with a checkpoint inhibitor (CPI), anti-PD1/PDL1 antibody, led to a substantial reduction of tumor growth in comparison to the CPI treatment by itself (Panel A). Moreover, the same level of efficacy was achieved with a single administration of a 0.2 ug dose of the STARR vaccine.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With various LUNAR formulations, conventional mRNA vaccine expressing the AH1 antigen also demonstrated a robust T cell response (Panel B) and reduction of tumor growth with anti-PD1/PDL1 treatment in the syngeneic mouse model. We believe that these POC results from the two platforms might lead to applicability to various types of cancer with flexibility in dosing regimens.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our efforts to date have focused on the selection of neoantigens, and other common tumor-specific antigens encoded in the cancer vaccines. Common tumor antigens can be shared among patients, and therefore target broader patient populations, whereas a neoantigen vaccine would be a personalized vaccine specific for an individual patient. Additional advancements of the LUNAR Cancer Vaccine program include the improvement of antigen cassette designs, STARR RNA elements, and immune modulator molecules, all of which can significantly enhance T cell responses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img267189834_12.jpg" alt="img267189834_12.jpg" style="width:623px;height:233px;"/></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Figure 11: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Antitumor activity and T cell response by Arcturus cancer vaccines. A. STARR vaccine expressing a tumor antigen led to a significant reduction of the tumor growth rate of a colorectal cancer cell line, CT26. B. T responses elicited by conventional mRNA cancer vaccine by various LUNAR formulations.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">22</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Enabling Technologies &#8211; Immuno-oncology</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cell-based therapies for hematologic malignancies using chimeric antigen receptor (CAR) T cells have made significant advances in the past decade. The success of CAR-T cells in immuno-oncology has led to a growing number of therapies utilizing other immune cell types engineered to express a variety of immunomodulatory molecules. Yet, despite their promise, extensive challenges still exist with this therapeutic approach. Some of the issues include toxicity, potential for insertional mutagenesis of the CAR construct, T cell malignancies, and an ex vivo manufacturing process that is complex, time consuming and costly. We believe that our LUNAR-I/O approach has the potential to ameliorate some of these issues. For example:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RNA-driven CAR expression in lymphocytes or immune cell types would be transient and therefore expected to have a lower side effect profile;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There is no integration into the germline DNA allowing for co-delivery of multiple therapeutic molecules without the risk of insertional mutagenesis; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Generation of CAR-expressing cells by a process that is quicker and cheaper, particularly when targeting specific immune cell subtypes in vivo.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The goal of the LUNAR-I/O program is to leverage the inherent advantages of both RNA and LUNAR technology to maximize clinical effectiveness of CAR-expressing cells. Initial experiments demonstrated that our proprietary LUNAR lipid nanoparticles can transfect &gt; 90% of both primary human CD8+ and CD4+ T lymphocytes in vitro. Our efforts to date have focused on targeting T lymphocytes in vivo with either CAR-mRNA or CAR-STARR (self-amplifying RNA) constructs in combination with other immunostimulatory molecules.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Supply and Manufacturing</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our supply and manufacturing strategies are focused on supporting the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">multiple pre-clinical and clinical pipeline candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">late-stage clinical and commercial scale COVID vaccine products; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regional and global product demand. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have built a global manufacturing footprint with our partners, including Aldevron, Catalent, Recipharm, Polymun and ARCALIS. With such collaborations, we have established an Integrated Global Supply Chain Network with our primary and secondary sourcing contract development &amp; manufacturing organizations (CDMOs) based in the United States, EU and Asia for producing critical raw materials, drug substance, and packaged finished product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have manufactured and supplied gram quantities of drug substance, and have scaled-up and validated our finished drug products (COVID Vaccine) through our CDMOs for clinical studies, and commercial readiness. We continue to dedicate, resources to advance our sophisticated manufacturing know-how, including formulation of lipid nanoparticles, which improves manufacturing efficiency and capacity. In furtherance of optimizing commercial efforts, we continue, with our collaborator CSL Seqirus, to evaluate and advance manufacturing process and capabilities and technology transfers, including the pursuit of different product presentations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe we have established sufficient manufacturing capacity through our CDMOs to meet our current internal research, development, and potential commercial needs, as well as our obligations under existing agreements with our partners. Additionally, we continue to evaluate relationships with additional suppliers to increase overall capacity and diversify our supply chain.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue and Collaboration Arrangements and Other Material Agreements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to our internal programs, we have collaborated or partnered with other parties on discovery, development, manufacturing or other efforts based on our proprietary platform technologies. Among other collaboration arrangements,</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we have a collaboration with CSL Seqirus for vaccines against SARS-CoV-2 (COVID-19), influenza and three other infectious diseases;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we have received funding from the CFF to support our LUNAR-CF development program; and</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">23</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we have a contract with BARDA to support the development of a low-dose pandemic influenza candidate based on our proprietary self-amplifying messenger RNA-based vaccine platform.</span></div></div>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CSL Seqirus</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2022, we entered into the CSL Collaboration Agreement with CSL Seqirus for the global exclusive rights to research, develop, manufacture and commercialize self-amplifying mRNA vaccines. The CSL Collaboration Agreement became effective on December 8, 2022, following clearance under the Hart-Scott-Rodino Antitrust Improvements Act.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the CSL Collaboration Agreement, CSL Seqirus receives global exclusive rights to our technology for vaccines against SARS-CoV-2 (COVID-19), influenza and three other infectious diseases. Specifically, the collaboration agreement grants CSL Seqirus a license to our STARR mRNA technology and LUNAR lipid-mediated delivery, as well as mRNA drug substance and drug product manufacturing expertise. CSL has also been granted global non-exclusive rights in the field of pandemic preparedness (i.e., pathogens identified as priority diseases by the WHO), with the right to convert to an exclusive license.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The CSL Collaboration Agreement sets forth how the parties will collaborate to research and develop vaccine candidates. In the COVID-19 field, we undertake activities for certain regulatory filings for our leading self-amplifying mRNA vaccine candidate in COVID-19, ARCT-154, in the United States and Europe and for research and development activities of a next-generation COVID vaccine candidate. CSL Seqirus leads and is responsible for all other research and development in COVID-19, influenza and the other fields.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We received an up-front payment of $200.0 million, with the potential to receive development milestones totaling more than $1.3 billion if all products are registered in the licensed fields. We also are entitled to potentially receive up to $3.0 billion in commercial milestones based on &#8220;net sales&#8221; of vaccines in the various fields. In addition, we are entitled to receive a 40% share of net profits from COVID-19 vaccine sales and up to low double-digit royalties of annual net sales for vaccines against influenza, pandemic preparedness and three additional infectious diseases. Entitlement to all such payments is subject to the strict conditions, requirements, royalty reduction provisions and other limitations set forth in the CSL Collaboration Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Either party may terminate the CSL Collaboration Agreement on a field-by-field basis for material breach by the other party, following notice and opportunity to cure. CSL Seqirus may also terminate the collaboration agreement in its entirety or on a field-by-field basis for any reason or no reason whatsoever, with certain limitations. The CSL Collaboration Agreement may also be terminated by CSL Seqirus for safety reasons, clinical data nonviability, commercial nonviability and other specified reasons.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2024, we entered into Amendment Number Two to Collaboration and License Agreement between CSL and the Company to reflect updates to the development program and other adjustments consistent with our prior disclosures regarding the Collaboration and License Agreement (&#8220;Amendment Number Two&#8221;). Amendment Number Two, among other things, adjusts (i) the development plans for certain product candidates, (ii) various development milestones related to such product candidates, (iii) provisions of the CSL Collaboration Agreement related to specific royalty payments, (iii) provisions of the CSL Collaboration Agreement related to distributors, and (iv) proprietary payment calculations related to the foregoing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The CSL Collaboration Agreement allows us to fulfill our obligations under the award from the Biomedical Advanced Research and Development Authority (BARDA) relating to rapid pandemic influenza response, announced by Arcturus in August 2022.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cystic Fibrosis Foundation Agreement</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On May 16, 2017, pursuant to a Development Program Letter Agreement (as amended, the &#8220;CFF Agreement&#8221;) with the CFF, CFF agreed to award us funding for a development program to identify lead CFTR mRNA sequences and LUNAR formulations, demonstrate tolerability of LUNAR CFTR mRNA, and demonstrate translatability of aerosolized LUNAR. The award includes a grant of rights to CFF know-how to assist us to research, develop, commercialize, make or otherwise exploit a product. If the award results in a successful commercialized product, we will pay CFF (i) royalties on sales of the product up to a maximum of a single-digit multiple of the total award amount actually paid to us by CFF, and (ii) thereafter, a single-digit percentage of annual net sales. Further, in the event of a license, sale or other transfer of the product or our development program technology (including a change of control transaction), we will pay CFF a percentage of such license, sale or transfer payments actually received by us or our shareholders (subject to a royalty cap). On August 1, 2019, we entered into an amendment to the CFF</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">24</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Agreement. Pursuant to the amendment, (i) CFF will increase the amount it will award to advance LUNAR-CF, (ii) we will provide a certain amount of matching funds for remaining budgeted costs, and (iii) the related disbursement schedule from CFF to us was modified such that (a) a disbursement was made upon execution of the amendment, (b) an agreed upon amount will be disbursed to us within thirty days of the first day of each of January, April, July and October 2020, and (c) the last payment will be disbursed upon us invoicing CFF to meet good manufacturing practices and submitting an IND application. In January 2022, the parties signed an additional amendment for CFF to fund the development of a CF ferret model for application in the development of ARCT-032, our LUNAR-CF candidate.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On September 25, 2023, we entered into an additional amendment (the &#8220;Fourth Amendment&#8221;) to the CFF Agreement, pursuant to which we and CFF agreed to: (a) increase the Amount of Award (as defined in the CFF Agreement and applicable amendment) from CFF to advance LUNAR-CF by up to $9 million (for a total to date of up to approximately $25 million), and required Arcturus to provide $15 million in matching funds for remaining budgeted costs; (b) modify the existing rates and caps on royalties due to CFF under the CFF Agreement, including the addition of an option for Arcturus to reduce the royalty rate through a one-time payment; (c) modify the calculation of payments from Arcturus to CFF in the event of certain dispositions or licensing of cystic fibrosis or other pulmonary assets or of a change of control of Arcturus; and (d) make corresponding changes to exhibits, definitions and other provisions of the CFF Agreement.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">BARDA</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In August 2022, we entered into a cost reimbursement contract with the Biomedical Advanced Research and Development Authority (&#8220;BARDA&#8221;) of the U.S. Department of Health and Human Services to support the development of a low-dose pandemic influenza candidate based on our proprietary self-amplifying messenger RNA-based vaccine platform.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The contract is to support our non-clinical and pre-clinical development, early-stage clinical development through Phase 1, and associated drug product manufacturing, regulatory and quality-assurance activities over a period of three years. The contract provides for reimbursement by BARDA of Arcturus&#8217; permitted costs incorporated into the contract, up to $63.2 million. The contract does not include the purchase of any pandemic influenza vaccine that eventually may be developed. The contract is terminable by BARDA at any time under specified circumstances, including for convenience.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This contract is part of BARDA&#8217;s ongoing efforts to bolster pandemic preparedness and response capabilities by investing in innovative medical counter-measures that can help prevent the medical consequences that result from outbreaks caused by pandemic influenza and emerging infectious diseases. In December 2024, we initiated a Phase 1 clinical trial for our H5N1 pandemic flu candidate that is supported by funding from BARDA.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARCALIS Joint Venture</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On August 14, 2023, we announced that ARCALIS Inc. (ARCALIS), our manufacturing joint venture in Japan to support the production of mRNA vaccines and therapeutics, had been awarded up to $115 million in two separate grants from the Japanese government. The grants were used to fund the construction of a factory and the purchase of capital equipment to support current Good Manufacturing Practice (cGMP) production of mRNA drug substance and mRNA drug product operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On October 4, 2023, we announced that ARCALIS was selected by the Japanese Ministry of Economy, Trade and Industry to receive additional financial support to construct a DNA template manufacturing facility along with new state-of-the-art equipment. DNA plasmid generated at this facility would be used as key starting material in the manufacture of mRNA drug substance at ARCALIS&#8217; neighboring mRNA drug substance facility, which was completed in July 2023. To date, approximately $165 million has been awarded to ARCALIS by the Japanese government, subject to certain terms and conditions, to build mRNA Drug Substance, mRNA Drug Product manufacturing capabilities and to construct a DNA template manufacturing facility.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On November 14, 2024, Meiji Seika Pharma announced its investment in ARCALIS. This investment will further strengthen the collaborative relationship between the two companies. The combination of ARCALIS' advanced technology and operations in mRNA pharmaceuticals and vaccines with Meiji Seika Pharma's expertise in manufacturing, post-marketing safety management and stable product supply is expected to significantly improve the supply of mRNA vaccines in Japan.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">25</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In January 2025, Meiji Seika Pharma, along with our manufacturing joint venture ARCALIS, received Ministry of Health, Labour and Welfare (MHLW) approval for adding commercial manufacturing sites in Japan for KOSTAIVE. Domestically produced products with active pharmaceutical ingredients manufactured at ARCALIS&#8217;s Minami-soma facilities, and formulated at Meiji Seika Pharmatech, are now able to be shipped for commercial use in Japan.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Legacy Arrangements</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During our formative period, we entered into various collaboration, development and license agreements with larger parties in our industry, providing for the designation of targets for collaborative development using our platform technologies.  Although, as we have previously reported, parties to these agreements, including Ultragenyx, continue to have exclusive rights to certain of these targets, other than as reported above, there has been no significant development activities under the programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intellectual Property</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our business success depends in part on our ability to obtain and maintain intellectual property protection for our proprietary technologies, inventions and know-how, and on our ability to operate without infringing on the proprietary rights of others. We strive to protect our intellectual property through a combination of patents, trademarks, trade secrets, licensing agreements, invention assignment agreements and confidentiality agreements with employees, advisors, consultants and contractors.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We rely on continuing technological innovation to strengthen our proprietary position in the field of nucleic acid medicines. Therefore, we plan to continue to file patent applications in jurisdictions around the world as we discover and develop novel nucleic acid technology platforms and novel nucleic acid therapeutic candidates. We cannot guarantee that future applications will be issued.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Patent Portfolio</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of January 31, 2025, we own over 500 patents and pending patent applications. The claims of these patents and pending applications include compositions of matter, methods of use, manufacturing process and drug product formulations. These claims cover the use of our core platform technologies including the use of LUNAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and lipid components to deliver nucleic acids, specific nucleic acid modalities for treating disease, as well as our proprietary technology regarding the design, manufacture, and purification of nucleic acids for use in therapy. Claims also cover the composition of matter, formulation, and use of our therapeutic candidates to prevent and/or treat target diseases including OTC deficiency, CF, COVID-19 and Influenza. If issued, our patents are expected to expire between 2028 and 2045, without taking into account any possible patent term extensions.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our patent portfolio is built upon a strategy of robust protection for our LUNAR and STARR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> platforms as described below:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LUNAR &#8211; Our patent holdings continue to grow in scope and territory for our LUNAR platform with patents and patent applications directed to composition of matter including chemical structures for our growing library of proprietary lipids, manufacture of lipid nanoparticles (including lyophilization), and use of our LUNAR technology for nucleic acid delivery and drug delivery in more than 50 countries around the world.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">STARR &#8211; In 2019, we began to develop our STARR platform which combines our proprietary LUNAR delivery systems with technologies that enable self-transcribing and self-amplifying RNA. As noted above, our robust LUNAR portfolio provides protection for delivery vehicles that can enable specific and effective delivery of STARR-based drug substances. As with our LUNAR portfolio, our patent holdings directed to our STARR platform have a broad geographical footprint. This portfolio is generally directed to specially designed RNA constructs, specific nucleotide and amino acid sequences, and lipid formulations comprising the same under the STARR technology. We anticipate that further patents will be filed as we continue to innovate with respect to our STARR platform and that current applications covering these developments in our STARR platform, if granted, will last until 2044, not including any patent term extensions. </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">26</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Patent Terms</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The term of individual patents depends on the countries in which they are obtained. The patent term is 20 years from the earliest effective date of filing a non-provisional patent application in most of the countries in which we file.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Drug Price Competition and Patent Term Restoration Act (also known as the Hatch-Waxman Act), U.S. patent holders can apply for a patent term extension to compensate for the patent term lost during the FDA regulatory review process. Patent extension is only available for patents covering FDA-approved drugs. The extension can be up to five years beyond the original expiration date of the patent and cannot extend a patent term for longer than 14 years from the date of product approval. Only one patent extension is granted per approved drug. Similar provisions may be available in foreign jurisdictions, including Europe. We intend to apply for patent term extensions where possible.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Trade Secrets</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have developed valuable trade secrets to protect our product candidates and proprietary processes, including trade secrets related to the design and optimization of nucleic acids, the design and optimization of lipid compositions for delivery of nucleic acids, manufacturing and formulation processes, and analytical techniques.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain Risks to Intellectual Property</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our commercial success also depends in part on our non-infringement of the patents or proprietary rights of third parties. For a more comprehensive discussion of the risks related to our intellectual property, please see Item 1A &#8220;Risk Factors&#8221; &#8211; &#8220;Risks Related to Our Intellectual Property.&#8221;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The laws of some foreign countries do not protect intellectual property rights to the same extent as the laws of the United States. Many companies have encountered significant problems in protecting and defending intellectual property rights in certain foreign jurisdictions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our success depends in part on our ability to:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">preserve trade secrets;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">prevent third parties from infringing upon our proprietary rights; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">operate our business without infringing the patents and proprietary rights of third parties, both in the United States and internationally.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We seek to protect our proprietary technology and processes, in part, by confidentiality and invention assignment agreements with our employees, consultants, scientific advisors and other contractors. These agreements may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. To the extent that our employees, consultants, scientific advisors or other contractors use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Product Approval and Government Regulation</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Government authorities in the United States, at the federal, state and local level, and other countries extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of products such as those we are developing. Any product candidate that we develop must be authorized or approved by the FDA before it may be legally marketed in the United States and by the appropriate foreign regulatory agency before it may be legally marketed in foreign countries.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">U.S. Drug Development Process</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the United States, the development, manufacturing, and marketing of human drugs and vaccines are subject to extensive regulation. The FDA regulates drugs under the Federal Food, Drug and Cosmetic Act (&#8220;FDCA&#8221;) and implementing regulations, and biological products, including vaccines, under provisions of the FDCA and the Public Health Service Act (&#8220;PHSA&#8221;). Drugs and vaccines are also subject to other federal, state and local statutes and regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">27</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may subject an applicant to administrative or judicial civil or criminal sanctions. FDA sanctions could include refusal to approve pending applications, withdrawal of an approval, clinical hold, warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, debarment, restitution, disgorgement or civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us. The process required by the FDA before a drug or biological product may be marketed in the United States generally involves the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">completion of nonclinical laboratory tests, animal studies and formulation and stability studies according to good laboratory practices (&#8220;GLP&#8221;) or other applicable regulations; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">submission to the FDA of an application for an IND, which must become effective before human clinical trials may begin; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">performance of adequate and well-controlled human clinical trials according to the FDA&#8217;s regulations commonly referred to as current good clinical practices (&#8220;GCPs&#8221;) to establish the safety and efficacy of the proposed drug for its intended use; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">submission to the FDA of a new drug application (&#8220;NDA&#8221;) or biologics license application (&#8220;BLA&#8221;) for a new drug or biologics; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">satisfactory completion of FDA inspections of the manufacturing facility or facilities where the drug is produced to ensure compliance with the FDA&#8217;s current good manufacturing practice standards (&#8220;cGMP&#8221;), to assure that the facilities, methods and controls are adequate to preserve the drug&#8217;s identity, strength, quality and purity; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">potential FDA audit of the nonclinical and clinical trial sites that generated the data in support of the NDA or BLA; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FDA review and approval of the NDA or BLA.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The lengthy process of seeking required approvals and the continuing need for compliance with applicable statutes and regulations require the expenditure of substantial resources and approvals are inherently uncertain.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Before testing any compounds with potential therapeutic value in humans, the drug candidate enters the preclinical study stage. Preclinical tests, also referred to as nonclinical studies, include discovery and target identification, in vitro testing to assess biological activity, mechanism of action, and potential toxicity, as well as animal studies to assess the potential safety, pharmacokinetics, and pharmacological activity of the drug candidate. The conduct of the animal studies must comply with federal regulations and requirements including GLP. The sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol, to the FDA as part of the IND. The IND automatically becomes effective thirty days after receipt by the FDA, unless the FDA imposes a clinical hold within that 30-day time period. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. The FDA may also impose clinical holds on a drug candidate at any time before or during clinical trials due to safety concerns or non-compliance. Accordingly, we cannot be sure that submission of an IND will result in the FDA allowing clinical trials to begin, or that, once begun, issues will not arise that suspend or terminate such trial.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clinical trials involve the administration of the drug candidate to healthy volunteers or patients under the supervision of qualified investigators, generally physicians not employed by or under the trial sponsor&#8217;s direct control. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria, and the parameters to be used to monitor subject safety. Each protocol must be submitted to the FDA as part of the IND. Clinical trials must be conducted in accordance with the FDA&#8217;s regulations comprising the good clinical practices requirements. Further, each clinical trial must be reviewed and approved by an independent institutional review board (&#8220;IRB&#8221;) at or servicing each institution at which the clinical trial will be conducted. An IRB is charged with protecting the welfare and rights of trial participants and considers such items as whether the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the form and content of the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">28</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">informed consent that must be signed by each clinical trial subject or his or her legal representative and provides oversight for the clinical trial until completed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Human clinical trials are typically conducted in three sequential phases that may overlap or be combined:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Phase 1. The drug is initially introduced into healthy human subjects and tested for safety, dosage tolerance, absorption, metabolism, distribution and excretion. In the case of some products for severe or life-threatening diseases, especially when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing may be conducted in patients;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Phase 2. The drug is evaluated in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance, optimal dosage and dosing schedule; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Phase 3. Clinical trials are undertaken to further evaluate dosage, clinical efficacy and safety in an expanded patient population at geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the product and provide an adequate basis for product labeling. Generally, a well-controlled Phase 3 clinical trial is required by the FDA for approval of an NDA or BLA.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Post-approval clinical trials, sometimes referred to as Phase 4 clinical trials, may be conducted after initial marketing approval. These clinical trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Annual progress reports detailing the results of the clinical trials must be submitted to the FDA and written IND safety reports must be promptly submitted to the FDA and the investigators for serious and unexpected adverse events or any finding from tests in laboratory animals that suggests a significant risk for human subjects. Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, if at all. The FDA or the sponsor or its data safety monitoring board may suspend a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the drug has been associated with unexpected serious harm to patients.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Concurrently with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the drug as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the drug candidate and, among other things, must develop methods for testing the identity, strength, quality and purity of the final drug. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the drug candidate does not undergo unacceptable deterioration over its shelf life.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">U.S. review and approval processes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The results of product development, nonclinical studies and clinical trials, along with descriptions of the manufacturing process, analytical tests conducted on the chemistry of the drug, proposed labeling and other relevant information are submitted to the FDA as part of an NDA or BLA requesting approval to market the product. The submission of an NDA or BLA is subject to the payment of substantial user fees; a waiver of such fees may be obtained under certain limited circumstances.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, under the Pediatric Research Equity Act (&#8220;PREA&#8221;), an NDA or BLA or supplement to an NDA or BLA must contain data to assess the safety and effectiveness of the drug for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may grant deferrals for submission of data or full or partial waivers. Unless otherwise required by regulation, PREA does not apply to any drug for an indication for which orphan designation has been granted.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA reviews all NDAs or BLAs submitted to determine if they are substantially complete before it accepts them for filing. If the FDA determines that an NDA or BLA is incomplete or is found to be non-navigable, the filing may be refused and must be re-submitted for consideration. Once the submission is accepted for filing, the FDA begins an in-depth review of the NDA or BLA. Under the goals and policies agreed to by the FDA under the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">29</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prescription Drug User Fee Act (&#8220;PDUFA&#8221;), the FDA has 10 months from acceptance of filing in which to complete its initial review of a standard NDA or BLA and respond to the applicant, and six months from acceptance of filing for a priority NDA or BLA. The FDA does not always meet its PDUFA goal dates. The review process and the PDUFA goal date may be extended by three months or longer if the FDA requests or the NDA or BLA sponsor otherwise provides additional information or clarification regarding information already provided in the submission before the PDUFA goal date.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">After the NDA or BLA submission is accepted for filing, the FDA reviews the NDA or BLA to determine, among other things, whether the proposed product is safe and effective for its intended use, and whether the product is being manufactured in accordance with cGMP to assure and preserve the product&#8217;s identity, strength, quality and purity. The FDA may refer applications for novel drug or biological products or drug or biological products which present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. During the drug approval process, the FDA also will determine whether a risk evaluation and mitigation strategy (&#8220;REMS&#8221;) is necessary to assure the safe use of the drug. If the FDA concludes a REMS is needed, the sponsor of the NDA or BLA must submit a proposed REMS; the FDA will not approve the NDA or BLA without a REMS, if required.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Before approving an NDA or BLA, the FDA will inspect the facilities at which the product is manufactured. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. The FDA requires vaccine manufacturers to submit data supporting the demonstration of consistency between manufacturing batches, or lots. The FDA works together with vaccine manufacturers to develop a lot release protocol, the tests conducted on each lot of vaccine post-approval. Additionally, before approving an NDA or BLA, the FDA will typically inspect the sponsor and one or more clinical sites to assure that the clinical trials were conducted in compliance with IND study requirements. If the FDA determines that the application, manufacturing process or manufacturing facilities are not acceptable it will outline the deficiencies in the submission and often will request additional testing or information.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The NDA or BLA review and approval process is lengthy and difficult, and the FDA may refuse to approve an NDA or BLA if the applicable regulatory criteria are not satisfied or may require additional clinical data or other data and information. Even if such data and information are submitted, the FDA may ultimately decide that the NDA or BLA does not satisfy the criteria for approval. Data obtained from clinical trials are not always conclusive and the FDA may interpret data differently than we interpret the same data. The FDA will issue a complete response letter if the agency decides not to approve the NDA or BLA. The complete response letter usually describes all of the specific deficiencies in the NDA or BLA identified by the FDA. The deficiencies identified may be minor, for example, requiring labeling changes, or major, for example, requiring additional clinical trials. Additionally, the complete response letter may include recommended actions that the applicant might take to place the application in a condition for approval. If a complete response letter is issued, the applicant may either submit new information, addressing all of the deficiencies identified in the letter, or withdraw the application.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If a product receives regulatory approval, the approval may be significantly limited to specific diseases and dosages or the indications for use may otherwise be limited, which could restrict the commercial value of the product. Further, the FDA may require that certain contraindications, warnings or precautions be included in the product labeling. In addition, the FDA may require post marketing clinical trials, sometimes referred to as Phase 4 clinical trials, which are designed to further assess a product&#8217;s safety and effectiveness and may require testing and surveillance programs to monitor the safety of approved products that have been commercialized.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Post-approval requirements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any drug or biological products for which we or our strategic alliance partners receive FDA approvals are subject to continuing regulation by the FDA, including, among other things, record-keeping requirements, reporting of adverse experiences with the product, providing the FDA with updated safety and efficacy information, product sampling and distribution requirements, complying with certain electronic records and signature requirements and complying with FDA promotion and advertising requirements, which include, among others, standards for direct-to-consumer advertising, promoting drugs for uses or in patient populations that are not described in the drug&#8217;s approved labeling (known as &#8220;off-label use&#8221;), industry-sponsored scientific and educational activities, and promotional activities involving the internet. Failure to comply with FDA requirements can have negative</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">30</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">consequences, including adverse publicity, enforcement letters from the FDA, mandated corrective advertising or communications with doctors, and civil or criminal penalties. Although physicians may prescribe legally available drugs for off-label uses, manufacturers may not market or promote such off-label uses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Following approval, the FDA continues to monitor vaccine quality through real-time monitoring of lots by requiring manufacturers to submit certain information for each vaccine lot. Vaccine manufacturers may only distribute a lot following release by the FDA. Drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP and other laws. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance. Discovery of problems with a product after approval may result in restrictions on a product, manufacturer, or holder of an approved NDA or BLA, including withdrawal of the product from the market. In addition, changes to the manufacturing process require notice to or prior approval from the FDA before being implemented and other types of changes to the approved product, such as adding new indications and additional labeling claims, are also subject to further FDA review and approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Regulation in Europe and Other Regions</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to regulations in the United States, we and our strategic alliance partners are subject to a variety of regulations in other jurisdictions governing, among other things, clinical trials and any commercial sales and distribution of our products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Whether or not we or our collaborators obtain FDA approval for a product, we must obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical trials or marketing of the product in those countries. Certain countries outside of the United States have a similar process that requires the submission of a clinical trial application much like the IND prior to the commencement of human clinical trials. Once the Clinical Trial Application (&#8220;CTA&#8221;) is approved in accordance with a country&#8217;s requirements, clinical trial development may proceed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To obtain regulatory approval of an investigational drug or biological product under EU regulatory systems, we or our strategic alliance partners must submit a marketing authorization application. The application in the EU is similar to that required in the United States, with the exception of, among other things, region/country-specific document requirements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For other countries outside of the EU, such as countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. In all cases, again, the clinical trials are conducted in accordance with GCPs and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki. The regulatory approval of marketing authorization application of an investigational drug or biological product is similar to that required in the United States, with the exception of, among other things, country-specific document requirements.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Competition</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Business in General</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The RNA pipeline across the biopharma industry is expansive, with mostly early-stage assets. Published market reports indicate that there are 1,000+ RNA assets in development with approximately 90% in pre-clinical and Phase I.  Assets in development are across a broad therapeutic range making for a diffused therapeutic focus across the field.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Competition is intensifying in this space as both biotech and larger pharma companies invest more in RNA technology and RNA pipelines mature in three key areas: RNA platform development (targeted on build of RNA platform components and delivery), platform discovery (unlocking broader therapeutic applicability) and in technology-aided platform accelerators (accelerate RNA design, development, and production - to further leverage advantage of RNA versus traditional technologies).  Pharmaceutical and biotechnology companies are heavily pursuing opportunities to build foundational platforms and to expand and accelerate RNA applications. As a result,  we face competition at the technology platform and therapeutic indication levels from both large and small biopharmaceutical companies, academic institutions, governmental agencies and public and private research institutions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">31</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many of our competitors, including those with strategic partners, have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Mergers and acquisitions, recently and into the future, may result in resource concentration among a potentially consolidated number of competitors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our success will be based in part upon our ability to identify, develop and manage a portfolio of product candidates that are safer and more effective than competing products in the treatment of our targeted patients. The commercial opportunity could be reduced or eliminated if competitors develop and commercialize products that are safer, more effective, are more convenient or are less expensive than any products we may develop in our respective areas. Our collaboration with CSL Seqirus may allow us to compete commercially on the world stage within the COVID and influenza markets.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are aware of several other companies that are working to develop nucleic acid medicines, including gene therapy, gene editing, mRNA (including sa-mRNA), siRNA, and antisense therapeutics. Many of these companies, such as Genevant Sciences and Acuitas Therapeutics, are also developing nucleic acid delivery platforms which compete with LUNAR technology.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Below we have included what we believe to be the competitive landscape for certain of the medicines that we currently have in development.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LUNAR-COVID-19 Vaccine (KOSTAIVE</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">)</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our vaccine franchise is based on our self-amplifying and self-replicating STARR technology platform and our lipid nanoparticle delivery platform called LUNAR. This franchise has advanced into the market with the approval of KOSTAIVE</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in Japan and geographic expansion is underway to other markets through our collaboration with CSL Seqirus. We consider the following companies with approved or late-stage clinical development vaccines as some of our competitors or future competitors to our partnered COVID-19 vaccine franchise: Pfizer/BioNTech, Moderna, Janssen, AstraZeneca, Novavax, and HDT Bio. Dozens of other companies are continuing to develop COVID-19 vaccines. However, the majority of these companies use conventional mRNA (not self-amplifying) and egg-based vaccine technology as the basis for their COVID-19 vaccines.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LUNAR-FLU Vaccine</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have partnered our influenza vaccine franchise with CSL Seqirus. We consider the following companies as some of the competitors or future competitors to our partnered LUNAR-Flu vaccine franchise: Pfizer, BioNTech, Moderna, Novavax, and Sanofi. The flu industry is rapidly shifting to utilizing mRNA-based platforms in addition to other non-egg based technologies and traditional (egg-based) technologies.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Liver Franchise ARCT-810 (LUNAR-OTC)</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our liver franchise has advanced into mid-stage clinical development with ARCT-810 in Phase 2 clinical development. Potential competitors include, but are not limited to, Ultragenyx which is advancing a gene therapy program for OTC in clinical development, and Moderna which has a therapeutic candidate in pre-clinical development.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lung Franchise ARCT-032 (LUNAR-CF)</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The lead candidate of our lung franchise is ARCT-032, an mRNA therapeutic candidate for cystic fibrosis based on our proprietary drug substance mRNA technology platform and our LUNAR lipid nanoparticle delivery platform has advanced into Phase 2 clinical development.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are aware of product candidates of the following companies that we consider as competitors or future competitors to ARCT-032: Moderna/Vertex, Eloxx Pharmaceuticals, Recode, 4DMT, Spirovant, SalioGen and Splisense.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">32</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Multiple Areas</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Of the competitors noted above, the following compete with us across multiple areas of our portfolio and/or aspects of our platform technologies:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While we are the first and only company with an approved sa-mRNA vaccine in a major market, there are two other manufacturers with approved conventional mRNA-based vaccines</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">BioNTech, in collaboration with Pfizer, has a marketed COVID-19 conventional mRNA vaccine, COMIRNATY&#174; available in multiple geographies, and is developing mRNA flu vaccine and COVID-19/flu combination vaccine, as well as latent virus and other vaccines of global public health interest in early development. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moderna manufactures the only other approved conventional mRNA based COVID-19 vaccine, Spikevax&#174;, which is available in multiple geographies. Moderna&#8217;s pipeline includes both infectious disease and rare disease assets. From an infectious disease perspective, beyond Spikevax, Moderna is developing respiratory (e.g., seasonal flu, pandemic flu, COVID-19/flu combo, RSV, etc.), enteric (Norovius), bacterial (Lyme), latent (e.g., CMV, EBV, HSV, etc.), and other virus vaccine candidates which are in the clinical stage of development; ranging from Phase I to Phase III stages of development. Moderna&#8217;s rare disease pipeline includes intercellular therapeutics and inhaled therapeutics. Through the Moderna-Vertex collaboration, the mRNA-3692 / VX-522 asset for CF is in Phase I. Moderna&#8217;s mRNA-3139 asset is in preclinical development for OTC.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The mRNA portfolio resulting from the GSK-CureVac collaboration focuses on vaccines in the prevention of influenza and COVID-19 viruses. Neither entity nor the collaboration has achieved health authority approval for flu and/or COVID-19 mRNA vaccine products. Both the flu and COVID-19 assets are in Phase II clinical development; COVID-19/flu combo is in Phase I. However, CureVac developed the RNA Printer</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, an automated end-to-end system&#8203; for manufacturing of GMP-grade mRNA vaccines and therapeutics&#8203; which also has application in small-scale GMP manufacturing. In collaboration with Elon Musk and Tesla, CureVac plans to optimize and enhance their mRNA microscale manufacturing technology.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Human Capital</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, we had approximately 176 employees, of which 174 were full-time and 2 were part-time. Additionally, we are supported by contractors and scientific consultants in most areas of the business. None of our employees are represented by a labor union or covered by a collective bargaining agreement. We consider relations with our employees to be good.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Available Information</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company was founded in 2013 as Arcturus Therapeutics, Inc., and we have maintained our principal executive offices in San Diego, California since that time. In November 2017, Alcobra Ltd., an Israeli limited company, merged with our company, changed its name to Arcturus Therapeutics Ltd. (&#8220;Arcturus Israel&#8221;), and commenced trading on Nasdaq under the symbol &#8220;ARCT.&#8221; On June 17, 2019, we redomiciled to the United States (the &#8220;Redomiciliation&#8221;) and changed our name to Arcturus Therapeutics Holdings Inc.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Internet address is www.arcturusrx.com. Our Annual Reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and proxy statements, and all amendments thereto, are available free of charge on our Internet website. These reports are posted on our website as soon as reasonably practicable after they are electronically filed with the SEC. The public may read and copy any materials that we file with the SEC electronically through the SEC website (www.sec.gov). The information contained on the SEC&#8217;s website is not incorporated by reference into this Annual Report on Form 10-K and should not be considered to be part thereof.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">33</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1a_risk_factors"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1A. Ris</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">k Factors</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In conducting our business, we face many risks that may interfere with our business objectives. Some of these risks could materially and adversely affect our business, financial condition and results of operations. In particular, we are subject to various risks resulting from inherent unknowns and uncertainties in the drug development and commercialization process, as well as changing economic, political, industry, regulatory, business and financial conditions. The risks and uncertainties described below are not the only ones we face.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You should carefully consider the following factors and other information in this Annual Report before you decide to invest in our common stock. If any of the negative events referred to below occur, our business, financial condition and results of operations could suffer. In any such case, the trading price of our common stock could decline, and you may lose all or part of your investment.</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risk Factor Summary</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following is a summary of certain important factors that may make an investment in our company speculative or risky. You should carefully consider the fuller risk factor disclosure set forth in this Annual Report, in addition to the other information herein, including the section of this report titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and our financial statements and related notes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have a limited operating history, have incurred significant losses since our inception (with the exception of fiscal year 2022) and anticipate that we will continue to incur significant losses for the foreseeable future.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have not generated any revenue from product sales, have generated only limited collaboration and grant revenue since inception, and may never be profitable in the long term.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We expect that we will need to raise additional capital in the future, which may not be available on acceptable terms, or at all.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are dependent upon relationships with our collaboration partners, and the failure of these relationships could negatively affect our business and results of operations.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are exposed to interest rate risk, including under our loan agreements.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our debt contains customary default clauses, a breach of which may result in acceleration of the repayment of some or all of this debt.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are highly dependent upon our relationship with CSL Seqirus to further research, manufacture and commercialize self-amplifying mRNA vaccines against COVID-19, influenza and three other infectious diseases.  </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">KOSTAIVE might not have a profitable commercial market.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">KOSTAIVE only has marketing approval in Japan and Europe and may never achieve marketing approval in any other countries. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Regulatory authorities may change views and recommendations, which could lead to more challenging regulatory paths to approvals and to more expensive clinical and commercial efforts.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Even with the commercialization of KOSTAIVE in Japan, there might not be meaningful sales in Japan. Despite the approval of KOSTAIVE in  Europe, KOSTAIVE has not, and might never, achieve commercialization in Europe.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">There is significant competition in the development of a vaccine against COVID-19, some competitors&#8217; vaccines are already widely accepted in the market, and many of our competitors have substantially greater financial, scientific and other resources than we have.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are unable to generate successful results from preclinical and clinical studies of our product candidates, or experience significant delays in doing so, our business may be materially harmed.</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">34</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our platform focuses on nucleic acid technology, and mRNA drug products in particular, which are relatively new and any adverse results from nucleic acid or mRNA technologies in the industry could significantly impact our ability to develop and commercialize marketable products.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changes to our drug product format could significantly impact our timeline to commercialize our products.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not be successful in our efforts to identify or discover potential product candidates.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may find it difficult to identify and enroll patients in our clinical studies, and the limited number of patients who have the diseases for which certain of our product candidates are being studied could delay or prevent clinical studies of certain of our product candidates.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If any of our product candidates cause undesirable side effects or have other properties impacting safety, their regulatory approval could be prevented, delayed or limited.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Even if we obtain regulatory approval for a product candidate, we will still face extensive regulatory requirements and our products may face future development and regulatory difficulties.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Manufacturing issues may arise that could increase product and regulatory approval costs or delay or hinder commercialization.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The commercial success of our product candidates will depend in part upon the acceptance of our product candidates by the medical community, including physicians, patients and healthcare payors.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If our strategic alliances are unsuccessful or are terminated, we may be unable to commercialize certain product candidates and generate revenues.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If the contract manufacturers we rely on to produce the supply of our preclinical and clinical product candidates, including materials for the manufacture of our product candidates, do not timely deliver adequate quantities of quality materials, development and commercialization of our product candidates would be hindered.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Any disruption in the supply chain of raw materials for, or in the manufacturing capacity and timing for the manufacture of drug substance or drug product for, our product candidates may cause a delay in developing and commercializing these product candidates and limit the revenues that we could generate.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If the contract research organizations and clinical trial sites we rely on to conduct, supervise and monitor our clinical trials perform in an unsatisfactory manner, it may harm our business.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are unable to obtain or protect intellectual property rights related to our products and product candidates, we may not be able to compete effectively in our markets.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Claims that we infringe the intellectual property rights of others, especially in the crowded and competitive field of mRNA patents, may prevent or delay our development and commercialization efforts.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we fail to obtain licenses to necessary intellectual property or do not comply with our obligations in license agreements, we could lose important rights.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may be involved in lawsuits to protect or enforce our patents or to defend against third party intellectual property claims, which could be expensive, time consuming and unsuccessful.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">U.S. Government agencies have special contracting authority that gives them the ability to terminate and/or modify their contracts with us.</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">35</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our business is subject to audit by the U.S. Government, and a negative audit could adversely affect our business.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have identified a material weakness in our internal control over financial reporting, and determined that our disclosure controls and procedures were not effective. If our remediations of this material weakness is not effective, or if we experience additional material weaknesses or otherwise fail to maintain an effective system of internal control over financial reporting or adequate disclosure controls and procedures, we may not be able to accurately and timely report our financial results, in which case our business may be harmed, investors may lose confidence in the accuracy and completeness of our financial reports, and the price of our common stock may decline.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RISKS RELATED TO OUR FINANCIAL CONDITION AND NEED FOR ADDITIONAL CAPITAL</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have a limited operating history, have incurred significant losses since our inception (with the exception of fiscal year 2022) and anticipate that we will continue to incur significant losses for the foreseeable future.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a global messenger RNA medicines company with a limited operating history. Since inception, our operations have been primarily limited to acquiring and licensing intellectual property rights, developing our product platform, undertaking research, partnering assets and running clinical product development programs. We only have one product that, through our partners CSL Seqirus and Meiji, is being commercialized, and it is currently only commercialized in Japan. Consequently, any predictions about our future success or viability, or any evaluation of our business and prospects, is difficult and may not be accurate. In 2024 we recognized a significant portion of our revenue from non-recurring milestone payments and license revenue under our collaboration agreement with CSL Seqirus. Our future payments from CSL Seqirus are dependent on our ability to execute by meeting key product development and other milestones within the contract. We have not recognized any revenue from product sales since our inception.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, we had an accumulated deficit of $448.8 million.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have devoted most of our financial resources to research and development, including our preclinical and clinical development activities. To date, we have funded our operations primarily through upfront payments, research funding and milestone payments from strategic alliances and collaborations, and through the sale of equity and convertible securities. We expect to continue to incur substantial and increased expenses, losses and negative cash flows as we expand our development activities and advance our programs. If our product candidates are not successfully developed or commercialized, including because of a lack of capital, or if we do not generate enough revenue following marketing approval, we will not achieve profitability and our business may fail. Even if we or our strategic alliance partners successfully obtain regulatory approval to market a product candidate, our revenues will also depend upon the size of any markets in which our product candidates have received market approval and our ability to achieve sufficient market acceptance and adequate market share for our products.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future. The net losses we incur may fluctuate significantly from quarter to quarter. We anticipate that our expenses will increase substantially if and as we:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">continue our research and development of our product candidates, both independently and under our strategic alliance agreements; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">seek to identify additional targets and product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">acquire or in-license other products and technologies; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">advance product candidates into and through clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">seek marketing approvals for any product candidates that successfully complete clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establish a sales, marketing and distribution infrastructure to commercialize any products for which we may obtain marketing approval; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">maintain, expand and protect our intellectual property portfolio; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">hire additional clinical, regulatory, research, executive and administrative personnel; and </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">36</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">create additional infrastructure to support our operations and our product development and planned future commercialization efforts.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have not generated any revenue from product sales, have generated only limited collaboration and grant revenue since inception, and may never be profitable in the long term.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our ability to generate revenue and achieve profitability depends on our ability, alone or with strategic alliance partners, to successfully complete the development of, obtain the necessary regulatory approvals for and commercialize our product candidates. Our ability to generate revenues from product sales depends heavily on our success in:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the commercialization efforts of our collaboration partner, CSL Seqirus;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">completing our research and development of product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">initiating and completing clinical trials for product candidates with favorable results; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">seeking, obtaining, and maintaining marketing approvals for product candidates that successfully complete clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establishing and maintaining supply and manufacturing relationships with capable parties; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">launching and commercializing product candidates for which we may obtain marketing approval, with an alliance partner or, if launched independently, successfully establishing a sales force, marketing and distribution infrastructure; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">maintaining, protecting and expanding our intellectual property portfolio; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">attracting, hiring and retaining qualified personnel. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to predict reliably the timing or amount of increased expenses and when we will be able to achieve and maintain profitability, if ever. In addition, our expenses could increase beyond expectations if we are required by the FDA, or other foreign regulatory agencies to perform studies and trials in addition to those that we currently anticipate.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if our internal product candidates are approved for commercial sale, or KOSTAIVE continues to achieve approvals in more countries, we anticipate incurring significant costs associated with commercializing any approved product. Even if we generate revenues from the sale of any approved products, we may not become profitable and may need to obtain additional funding to continue operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We expect that we will need to raise additional capital in the future, which may not be available on acceptable terms, or at all.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Developing pharmaceutical products, including conducting studies and clinical trials, is extremely expensive. We expect our research and development expenses to substantially increase in connection with our ongoing activities, particularly as we advance our product candidates towards and through clinical trials. We expect that we will need to raise additional capital to support our operations and such funding may not be available to us on acceptable terms, or at all. As of December 31, 2024, we had unrestricted cash and cash equivalents of $237.0 million, which we expect should be sufficient to fund currently planned operations for the near future. But if our plans change or we face unexpected circumstances, our capital resources may be depleted more rapidly than we currently anticipate. For example, our clinical trials may encounter technical, regulatory or other difficulties. Any of these events would increase our development costs more than we expect. In order to support our long-term plans, we will need to raise additional capital or otherwise obtain funding through additional strategic alliances if we choose to initiate preclinical or clinical trials for product candidates that are not currently subject to a collaboration. In any event, we will require additional capital to obtain regulatory approval for, and to commercialize, future product candidates. Even if the results of clinical studies of our product candidates are positive, the stock market might not react favorably, which would weaken our ability to raise additional capital.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A portion of our current cash balance is expected to be utilized during 2024 to fund our continued preclinical and clinical development activities for our pipeline, including manufacturing activities to support such development activities.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">37</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any additional fundraising efforts may divert our management from our day-to-day activities, which may delay and hinder our ability to develop and commercialize future product candidates. We may be unable to raise sufficient amounts of additional capital when needed and on acceptable terms, which could require us to:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">significantly delay, scale back or discontinue the development or commercialization of any current or future product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">seek strategic alliances for research and development programs or clinical trials at an earlier stage than otherwise would be desirable or on terms that are less favorable than might otherwise be available; or </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">relinquish or license on unfavorable terms, our rights to technologies or any future or current product candidates that we otherwise would seek to develop or commercialize ourselves. </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are dependent upon relationships with our collaboration partners, and the failure of these relationships could negatively affect our business and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to a number of risks associated with our dependence on our relationships with our collaboration partners, including:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our collaboration partners may terminate their collaboration agreements with us for reasons specified in the collaboration agreements, including our breach;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the need for us to identify and secure on commercially reasonable terms the services of third parties to perform key activities, including development and commercialization activities, currently performed by our collaboration partners in the event that a collaboration partner was to terminate its collaboration with us;
</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">disagreements with our collaboration partners regarding the satisfaction of milestones; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adverse decisions by a collaboration partner regarding the amount and timing of resource expenditures for the commercialization, distribution, and sale of our drug products;
</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure by a collaboration partner to perform its duties under its collaboration agreement with us (e.g., its failure to comply with regulatory requirements);
</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure by a collaboration partner to timely deliver accurate and complete financial information to us or to maintain adequate and effective internal control over its financial reporting may negatively affect our ability to meet our financial reporting obligations as required by the SEC;
</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaboration partners&#8217; and their affiliates&#8217; development and commercialization of products that compete directly or indirectly with our products or products candidates;
</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">decisions by a collaboration partner to prioritize other of its current or future products more highly than our drug products or our product candidates;
</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">possible disagreements with a collaboration partner as to the timing, nature and extent of our development plans or distribution and sales and marketing plans; and
</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the financial returns to us, if any, under our collaboration agreements depend in large part on the achievement of milestones and generation of product sales, and if our partners fail to perform or satisfy their obligations under the collaboration agreement, the development and commercialization of our drug products could be delayed, hindered or may not occur and our business and prospects could be materially and adversely affected.</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">38</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Due to these factors and other possible disagreements with our collaboration partners, we may be delayed or prevented from further developing, manufacturing or commercializing our drug products or our product candidates or we may become involved in litigation or arbitration, which would be time consuming and expensive.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If any collaboration partner were to terminate our collaborative relationship unilaterally, we would need to undertake development, commercialization or distribution or sale activities for our drug products and product candidates solely at our own expense, and/or seek one or more other partners for some or all of these activities worldwide. If we pursued these activities on our own, it would significantly increase our capital and infrastructure requirements, might limit the indications we are able to pursue for our drug products and our product candidates, and could prevent us from effectively developing and commercializing our drug products and our product candidates. If we sought to find one or more other pharmaceutical company partners for some or all of these activities, we may not be successful in such efforts, or they may result in collaborations that have us expending greater funds and efforts than our relationships with our current collaboration partners.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are exposed to interest rate risk, including under our loan agreements.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are exposed to market risk from changes in interest rates. Exposure to interest rate risk results from our debt obligations, including the credit agreement entered into on April 21, 2023 and amended on June 26, 2024 by our wholly-owned subsidiary, Arcturus Therapeutics, Inc., and Wells Fargo Bank, National Association (as amended, the &#8220;Credit Agreement&#8221;), providing for a revolving credit line evidenced by a revolving line of credit note (the &#8220;Note&#8221;). Borrowings under the Credit Agreement will bear interest at a rate of 1.00% above either the Daily Simple SOFR or Term SOFR (as such terms are defined in the Note), with &#8220;SOFR&#8221; being the rate per annum equal to the secured overnight financing rate as administered by the Federal Reserve Bank of New York. All Loans shall bear interest during an Event of Default (as defined in the Credit Agreement) at a rate equal to 2.00% above the interest rate applicable immediately prior to the occurrence of the Event of Default (as defined in the Credit Agreement). As of December 31, 2024, we had no outstanding balance under the Credit Agreement.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our indebtedness could materially and adversely affect our business, financial condition and results of operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Agreements with our lenders, including with Wells Fargo Bank, National Association, create several limitations on us, including but not limited to:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">limiting our flexibility in planning for, or reacting to, changes in our business and our industry;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">placing us at a competitive disadvantage compared to our competitors who may have less debt or comparable debt at more favorable interest rates or less strict covenants and other limitations or requirements;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">limiting our ability to incur specified types of additional indebtedness which may be desired for working capital, capital expenditures, research and development efforts, acquisitions, debt service requirements, execution of our business strategy or other purposes; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">resulting in an acceleration of our obligations upon the occurrence of an event of default.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our ability to comply with these covenants in future periods will depend on our financial and operating performance, which in turn will be subject to economic conditions and to financial, market and competitive factors, many of which are beyond our control. Any of these factors or others described in the Credit Agreement could materially and adversely affect our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our debt contains customary default clauses, a breach of which may result in acceleration of the repayment of some or all of this debt.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Credit Agreement contains customary default clauses. In the event we were to default on our obligations under our debt and were unable to cure or obtain a waiver of such default, the repayment of our debt may be accelerated. If such acceleration were to occur, we would be required to promptly secure alternative sources of equity or debt financing to be able to repay the debt. Alternative financing may not be available on terms satisfactory to us, or at all. New debt financing may require the cooperation and agreement of our existing lenders. If acceptable alternative financing were unavailable, we would have to consider alternatives to fund the repayment of the debt, which could materially and adversely affect our business, financial condition and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">39</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Tax Cuts and Jobs Act, as modified by the Coronavirus Aid, Relief, and Economic Security Act, or CARES Act, U.S. federal net operating losses (&#8220;NOLs&#8221;) incurred in 2018 and in future years may be carried forward indefinitely, but the deductibility of such federal NOLs is limited. It is uncertain if and to what extent various states will conform to the Tax Cuts and Jobs Act. To the extent that we continue to generate taxable losses for United States federal income tax purposes, unused NOLs will carry forward to offset future taxable income (subject to any applicable limitations), if any. Under Sections 382 and 383 of the Internal Revenue Code, as amended, if a corporation undergoes an &#8220;ownership change,&#8221; generally defined as a greater than 50% change (by value) in its equity ownership over a three-year period, the corporation&#8217;s ability to use its pre-change NOLs and other pre-change tax attributes (such as research tax credits) to offset its post-change income may be significantly limited. We believe we may have triggered an &#8220;ownership change&#8221; limitation; however, we have not completed a study in accordance with Sections 382 and 383 of the Code to determine whether this ownership change has occurred or what the possible effects of an ownership change would be on our ability to use NOLs. We may also experience ownership changes in the future as a result of subsequent shifts in our share ownership. As a result, if we earn net taxable income, our ability to use our pre-change NOL carryforwards to offset U.S. federal taxable income may be subject to limitations, which could potentially result in increased future tax liability to us. Similar provisions of U.S. state tax law may also apply to limit our use of accumulated state tax attributes, including our state NOLs. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. As a result, even if we attain profitability, we may be unable to use a material portion of our NOLs and other tax attributes, which could negatively impact our future cash flows.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RISKS RELATED TO THE DEVELOPMENT AND COMMERCIALIZATION OF PRODUCT CANDIDATES</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are highly dependent upon our relationship with CSL Seqirus to further research, manufacture and commercialize self-amplifying mRNA vaccines against COVID-19, influenza and three other infectious diseases.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#d13438;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2022, we entered into the CSL Collaboration Agreement with CSL Seqirus, for the research, manufacture and global commercialization of self-amplifying mRNA vaccines against COVID-19, influenza and three other infectious diseases. If such relationship is unsuccessful, or if CSL Seqirus terminates its collaboration agreement with us, it would negatively impact our ability to conduct our business and generate net product revenue. Failure by CSL Seqirus to perform its duties under its collaboration agreement with us may negatively affect us. The potential financial returns to us under our collaboration agreements with CSL Seqirus depends in large part on the achievement of milestones and generation of product sales. If CSL Seqirus fails to perform or satisfy its obligations under the collaboration agreement or if we otherwise encounter disagreement with CSL Seqirus regarding the satisfaction of milestones, the development and commercialization of the licensed programs could be delayed, hindered or may not occur and our business and prospects could be materially and adversely affected. The fulfillment of our obligations under the CSL Collaboration Agreement may require significant deployment of our resources, which could disrupt or delay our ability to pursue other programs, including our platform development and development of other product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">KOSTAIVE might not have a profitable commercial market.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the prevalence of COVID-19 and public concern about the virus continues to decline, the potential market opportunity will shrink for KOSTAIVE under our collaboration with CSL Seqirus. As further COVID-19 vaccines are approved, production of existing COVID-19 vaccines improves and the COVID-19 impact transitions from pandemic to endemic stage, there may be downward pressure on prices. Therefore, even if we and CSL Seqirus can get through the extremely costly, long and risky process of developing and obtaining regulatory approval to market a vaccine globally, it may not be commercially successful. This failure could be due to reduced demand for COVID-19 vaccines, lower prices, distribution problems, competitors&#8217; products or many other reasons. Our manufacturing process for KOSTAIVE includes a step for lyophilization to enhance the stability of the vaccine product. The additional step of lyophilization adds time and costs to the overall production output, which could adversely impact the production volumes and profitability of our COVID-19 vaccines if approval to market a vaccine is achieved.</span><span style="color:#d13438;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any changes to our manufacturing processes or our product format could take a long time, be expensive and be unsuccessful. It is also still unclear if the vaccines will enable adequate long-term protection, as (i) many vaccinated individuals have become ill due to &#8220;breakthrough infections&#8221; and have transmitted the virus to many others, (ii) there are millions of individuals who refuse to be vaccinated or who cannot be vaccinated due to pre-existing</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">40</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">conditions, (iii) it is unclear how long the vaccine protection will last, and (iv) genetic mutations or variants of the virus already have had, and are expected to continue to have, an adverse impact on the efficacy of available vaccines. If we cannot, with and through our partner, develop and commercialize a vaccine that adequately addresses some of these shortcomings of vaccines currently on the market, we cannot expect to have commercial success.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">KOSTAIVE only has marketing approval in Japan and Europe and may never achieve marketing approval in any other countries.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although we have marketing approval for KOSTAIVE in Japan and Europe, we do not have approval for KOSTAIVE in any other countries and may never achieve marketing approval in any other countries. Our continued development efforts for KOSTAIVE, and the ongoing efforts to retain approval of updated versions, is dependent on the efforts of our partner, CSL Seqirus. KOSTAIVE could face increased research and development costs, including for clinical trials, non-clinical studies and CMC, when updating COVID-19 vaccines containing new variants of concern based on WHO and FDA recommendations. If key regulatory authorities, such as the FDA, determine that our data is inadequate or unacceptable, or make the path to regulatory approval more difficult, we may not be able to achieve regulatory approval and any additional study may prove too costly for us to conduct without a strategic partner. The U.S. is the largest market for vaccines, and if we do not receive approvals to market KOSTAIVE in the U.S., the overall commercial market for KOSTAIVE could be substantially lower than the overall market of our competitors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Even with the commercialization of KOSTAIVE in Japan, there might not be meaningful sales in Japan. Despite the approval of KOSTAIVE in Europe, KOSTAIVE has not, and might never, achieve commercialization in Europe.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are relying on our partner, CSL Seqirus, and CSL Seqirus&#8217; partner, Meiji Seika Pharma (Meiji), to conduct further development and commercialization of KOSTAIVE in Japan. Even if KOSTAIVE continues to be commercialized in Japan, there might not be meaningful sales, due to competition, pricing, product profile or other factors. Japanese regulatory agencies and purchasers might require involvement of Japanese companies in the domestic production of our COVID-19 vaccine, and our Japanese partners and contract manufacturers might not be able to scale up to commercial quantities. If any such Japanese companies do not participate or fail in such activities, then our and our partners&#8217; ability to commercialize our COVID-19 vaccine will be materially harmed. Although KOSTAIVE has received approval in Europe, KOSTAIVE has not, and might never, achieve commercialization in Europe, due to a numbers of factors, such as the competitiveness of different product presentations and formats and the wide market penetration of existing COVID-19 vaccine makers.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">There is significant competition in the COVID-19 vaccine market, some competitors&#8217; vaccines are already widely accepted in the market, and many of our competitors have substantially greater financial, scientific and other resources than we have.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pfizer, Moderna and Novavax have received full approvals or emergency use authorization from the FDA and many other health regulatory authorities throughout the world, and other biopharmaceutical companies have received approvals or authorizations from many health regulatory authorities other than the FDA, for their COVID-19 vaccines and have already commercialized them on a large scale and have vaccinated billions of people around the world.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even with the partnering of our COVID-19 program and initial commercialization in Japan, we are already at a significant competitive disadvantage to those companies with vaccines on the market, as well as many other competitors pursuing vaccine candidates. Many other competitors have significantly greater product candidate development, manufacturing and marketing resources than we do. Larger pharmaceutical and biotechnology companies have extensive experience in clinical testing and obtaining regulatory approval for their products, and may have the resources to heavily invest to accelerate discovery and development of their vaccine candidates. Our business could be further materially and adversely affected by our competitors&#8217; commercialization of their vaccines before our vaccine candidate is approved in various countries. If the COVID-19 vaccines of our competitors are shown to be are safer, more effective against multiple variants, have fewer or less severe side effects, have broader market acceptance, are more convenient or are less expensive than any vaccine candidate than KOSTAIVE, then KOSTAIVE may not achieve any commercial success even where approved. Furthermore, if any competitors are successful in producing a more efficacious vaccine or other treatment for COVID-19, or if any competitors are able</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">41</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to manufacture and distribute any such vaccines or treatments with greater efficiency, there may be a diversion of potential governmental and other funding away from us and toward such other parties.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We face significant competition from other biotechnology and pharmaceutical companies and our operating results will suffer if we fail to compete effectively.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The biotechnology and pharmaceutical industries are intensely competitive. We have competitors both in the United States and internationally, including major multinational pharmaceutical companies, biotechnology companies and universities and other research institutions. Many of our competitors have substantially greater financial, technical and other resources, such as larger research and development staff and experienced marketing, regulatory and manufacturing organizations. Additional mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated in our competitors. Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in these industries. Our competitors may succeed in developing, acquiring or licensing on an exclusive basis, drug products that are more effective, safer or less costly than any product candidate that we may develop. Our existing competitors and new market entrants may respond more quickly to or integrate new or emerging technologies such as artificial intelligence and machine learning, undertake more extensive marketing campaigns, have greater access to clinical information to support ongoing product position in the market, have greater financial, marketing and other resources or be more successful in attracting potential customers, employees and strategic partners. There can be no assurance that any products now in development, or that we may seek to develop in the future, will achieve technological feasibility, obtain regulatory approval or gain market acceptance. If we are unable to develop and launch new products, our ability to maintain or expand our market position in the markets in which we participate may be negatively impacted. Our competitors may achieve patent protection, regulatory approval, or product commercialization that would limit our ability to compete with them. These and other competitive pressures could have a material adverse effect our business.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are unable to generate successful results from preclinical and clinical studies of our product candidates, or experience significant delays in doing so, our business may be materially harmed.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other than the approval of KOSTAIVE in Japan and Europe, we have no products approved for commercial marketing and all of our product candidates are in preclinical or clinical development. Before obtaining regulatory approval for the commercial distribution of our product candidates, we or an existing or future collaborator must conduct extensive preclinical studies and clinical trials to demonstrate the safety and efficacy of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The success of our product candidates will depend on several factors, including the following:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">successfully designing preclinical studies which may be predictive of clinical outcomes; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">successful enrollment in clinical trials and completion of preclinical and clinical studies with favorable results; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">receipt of marketing approvals from applicable regulatory authorities; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtaining and maintaining patent and trade secret protection for future product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establishing and maintaining manufacturing relationships with third parties or establishing our own manufacturing capability; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">successfully commercializing our products, if approved, including successfully establishing a sales force, marketing and distribution infrastructure, whether alone or in collaboration with others. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully complete the development or commercialization of our product candidates, which would materially harm our business.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">42</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our platform focuses on nucleic acid technology, and mRNA drug products in particular, which are relatively new and any adverse results from nucleic acid or mRNA technologies in the industry could significantly impact our ability to develop and commercialize marketable products.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have concentrated our therapeutic product research and development efforts on nucleic acid technology, and mRNA in particular, and our future success depends on the successful development and acceptance of this technology for drug products. The development and commercialization of drug products based on nucleic acid technologies, including mRNA, are relatively new. The scientific evidence to support the feasibility of developing product candidates based on these discoveries is both preliminary and limited. If nucleic acid or mRNA approaches to drug products encounter setbacks based on the safety, efficacy, distribution, costs or other factors, it will significantly hurt our prospects and the value of our common stock.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our focus on nucleic acid technology for developing drugs as opposed to more proven technologies for drug development increases the risks associated with our business. If we are not successful in developing any product candidates using nucleic acid technology, we may be required to change the scope and direction of our product development activities. In that case, we may not be able to identify and successfully implement an alternative product development strategy.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changes to our drug product presentation could significantly impact our timeline to commercialize our products.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each of our products, including KOSTAIVE, has a certain drug product presentation. We evaluate and implement the product presentation attributes based on our considerations of regulatory and commercial potential, along with scientific feasibility. There can be no assurance that the product presentation or characteristics of any of our products will be sufficient to achieve regulatory approval or commercialization per planned timelines. For example, the stability of our products and the vial presentations could impact the commercial attractiveness of a product, and different markets may favor different characteristics. Any changes to drug product formats will likely add additional cost and may delay approvals.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not be successful in our efforts to identify or discover potential product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The success of our business depends primarily upon our ability to identify, develop and commercialize messenger RNA medicines. Our research programs may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development for a number of reasons, including:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our research methodology or that of our strategic alliance partners may be unsuccessful in identifying potential product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">potential product candidates may be shown to have harmful side effects or may have other characteristics that may make the products unmarketable or unlikely to receive marketing approval; or </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our strategic alliance partners may change their development profiles for potential product candidates or abandon a therapeutic area.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If any of these events occur, we may be forced to abandon our development efforts for a program or programs, which would have a material adverse effect on our business and could potentially cause us to cease operations. Research programs to identify new product candidates require substantial technical, financial and human resources. We may focus our efforts and resources on potential programs or product candidates that ultimately prove to be unsuccessful.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If clinical trials of our product candidates fail to demonstrate safety and efficacy to the satisfaction of regulatory authorities or do not otherwise produce positive results, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Before obtaining marketing approval from regulatory authorities for the sale of product candidates, we or our strategic alliance partners must conduct extensive clinical trials to demonstrate the safety and efficacy of the product candidates in humans. Clinical trials are expensive, difficult to design and implement, can take many years to complete and are uncertain as to the outcome. A failure of one or more clinical trials can occur at any stage of testing. The outcome of preclinical studies and early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">43</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval for their products. Furthermore, even if prior animal studies have demonstrated the potential safety and efficacy of our product candidates, there can be no guarantee that such results will be reproducible in preclinical studies and clinical trials involving human subjects.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Events which may result in a delay or unsuccessful completion of clinical development include:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in reaching an agreement with the FDA or other regulatory authorities on final trial design;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in submitting or acceptance of, an application for authorization to administer an investigational new drug product to humans through the submission or acceptance of an IND application to the FDA, or foreign regulatory authority; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">imposition of a clinical hold of our clinical trial operations or trial sites by the FDA or other regulatory authorities; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in reaching agreement on acceptable terms with prospective contract research organizations (&#8220;CROs&#8221;) and clinical trial sites; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our inability to adhere to clinical trial requirements directly or with third parties such as CROs;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clinical trial site or CRO non-compliance with GCPs, GLPs, or other regulatory requirements;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">inability or failure of clinical trial sites to adhere to the clinical trial protocol; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in obtaining required IRB approval at each clinical trial site, or an IRB suspending or terminating a trial; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in recruiting suitable patients to participate in a trial; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in the testing, validation, manufacturing and delivery of the product candidates to the clinical sites; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in having patients complete participation in a trial or return for post-treatment follow-up; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays caused by patients dropping out of a trial due to protocol procedures or requirements, product side effects or disease progression; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clinical sites dropping out of a trial to the detriment of enrollment; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">time required to add new clinical sites; or </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays by our contract manufacturers to produce and deliver sufficient supply of clinical trial materials. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we or our strategic alliance partners are required to conduct additional clinical trials or other testing of any product candidates beyond those that are currently contemplated, are unable to successfully complete clinical trials of any such product candidates or other testing, or if the results of these trials or tests are not positive, are only modestly positive or if there are safety concerns, we or our strategic alliance partners may:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">be delayed in obtaining marketing approval for our future product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">not obtain marketing approval at all; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtain approval for indications or patient populations that are not as broad as originally intended or desired; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">be subject to additional post-marketing testing requirements; or </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">have the product removed from the market after obtaining marketing approval. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our product development costs will also increase if we experience delays in testing or marketing approvals. We face risks that clinical trials may not begin as planned, may need to be restructured or may not be completed on schedule, or at all. Significant clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates or could allow our competitors to bring products to market</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">44</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">before we do, which would impair our ability to successfully commercialize our product candidates. Any inability to timely and successfully complete preclinical and clinical development, whether independently or with our strategic alliance partners, could result in additional costs to us or impair our ability to generate revenues from product sales, regulatory and commercialization milestones and royalties.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may find it difficult to identify and enroll patients in our clinical studies, and the limited number of patients who have the diseases for which certain of our product candidates are being studied could delay or prevent clinical studies of certain of our product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Identifying and qualifying patients to participate in clinical studies of our product candidates is critical to our success. The timing of our clinical studies depends in part on the speed at which we can recruit patients to participate in testing our product candidates, and we may experience delays in our clinical studies if we encounter difficulties in enrollment.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, certain conditions for which we plan to evaluate our current product candidates are rare genetic diseases, and have limited patient pools from which to draw for clinical studies. For example, we estimate that approximately 8,000 patients in the developed world suffer from late-onset OTC deficiency, for which LUNAR-OTC is being studied. In addition to the rarity of these diseases, the eligibility criteria of our clinical studies will further limit the pool of available study participants as we will require patients to have specific characteristics that we can measure or to assure their disease is either severe enough or not too advanced to include them in a study. The process of finding and diagnosing patients may prove costly, especially since the rare diseases we are studying are commonly underdiagnosed. We also may not be able to identify, recruit, and enroll a sufficient number of appropriate patients to complete our clinical studies because of demographic criteria for prospective patients, the perceived risks and benefits of the product candidate under study, the proximity and availability of clinical study sites for prospective patients, and the patient referral practices of physicians. The availability and efficacy of competing therapies and clinical studies can also adversely impact enrollment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to promptly enroll an adequate number of patients in our studies for the foregoing or other reasons, the timeline for conducting studies and obtaining regulatory approval of potential products will be delayed, the commercial prospects of our product candidates will be harmed, and our ability to generate product revenue from any of these product candidates could be delayed or prevented. Furthermore, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical studies may also ultimately lead to the denial of regulatory approval of our product candidates. Delays in achieving approval to conduct and in completing our clinical studies will increase our costs, slow down our product candidate development and approval process, and jeopardize our ability to commence product sales and generate revenue. Any of these occurrences may harm our business, financial condition, and prospects significantly.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If any of our product candidates cause undesirable side effects or have other properties impacting safety, their regulatory approval could be prevented, delayed or limited.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Undesirable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other regulatory authorities. It is likely that there will be side effects associated with use of our product candidates. If results of our trials reveal a high and unacceptable severity and prevalence of side effects, our trials could be suspended or terminated and the FDA or comparable foreign regulatory authorities could order us to cease further development of, or deny approval of, our product candidates for any or all targeted indications. Such side effects could also affect patient recruitment, the ability of enrolled patients to complete the trial or result in potential product liability claims. Any of these occurrences may materially and adversely affect our reputation and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, clinical trials by their nature test product candidates in only samples of the potential patient populations. With a limited number of patients and limited duration of exposure in such trials, rare and severe side effects of our product candidates may not be uncovered until a significantly larger number of patients are exposed to the product candidate.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">45</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If any of our product candidates receives marketing approval, and causes serious, unexpected, or undesired side effects, a number of potentially significant negative consequences could result after we begin commercialization, including:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory authorities may withdraw, suspend, or limit their approval of the product or impose restrictions on its distribution in the form of a modified risk evaluation and mitigation strategy; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory authorities may require the addition of labeling statements, such as warnings or contraindications; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may be required to change the way the product is administered or conduct additional clinical trials or post-marketing surveillance; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we could be sued and held liable for harm caused to patients; or </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our reputation may suffer. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any of these events could prevent us or our partners from achieving or maintaining market acceptance of the affected product and could substantially increase the costs of commercializing our future products and impair our ability to generate revenues from the commercialization of these products either by us or by our strategic alliance partners.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Even if we complete the necessary preclinical studies and clinical trials, we are required to obtain regulatory approval to commercialize a product candidate and we cannot, therefore, predict the timing of any revenue from a future product.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The extent and timing of any product revenue is highly unpredictable because regulatory authorities may not complete their review processes in a timely manner, or we may not be able to obtain regulatory approval for many reasons including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory authorities disagreeing with the design or implementation of our clinical trials;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">such authorities may disagree with our interpretation of data from preclinical studies or clinical trials;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">such authorities may not accept clinical data from trials which are conducted at clinical facilities or in countries where the standard of care is potentially different from that of the United States, such as our phase 1/2/3 clinical trial of ARCT-154 conducted in Vietnam;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">unfavorable or unclear results from our clinical trials or results that may not meet the level of statistical significance required by the FDA or foreign regulatory agencies for approval;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">serious and unexpected drug-related side effects experienced by participants in our clinical trials or by individuals using drugs similar to our product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the population studied in the clinical trial may not be sufficiently broad or representative to assure safety in the full population for which we seek approval;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">such authorities may not agree that the data collected from clinical trials of our product candidates are acceptable or sufficient to support the submission of an NDA or other submission or to obtain regulatory approval in the United States or elsewhere, and such authorities may impose requirements for additional preclinical studies or clinical trials;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">such authorities may disagree regarding the formulation, labeling and/or the specifications of our product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">such authorities may find deficiencies in the manufacturing processes or facilities of manufacturers with which we contract for clinical and commercial supplies; or</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulations or interpretations of such authorities may significantly change in a manner rendering our or any of our potential future collaborators&#8217; clinical data insufficient for approval. </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">46</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additional delays may result if an FDA advisory committee recommends restrictions on approval or recommends non-approval. In addition, we or our strategic alliance partners may experience delays or rejections based upon additional government regulation from future legislation or administrative action, or changes in regulatory agency policy during the period of product development, clinical trials and the review process.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the new 2025 U.S. presidential administration has implemented or threatened reductions in force and work stoppages across several U.S. federal agencies. Any such reductions or stoppages at the FDA or other federal agencies could delay the approval or review processes for any of our products and product candidates, which could negatively impact our business and results of operations. In addition, the new presidential administration may institute policies, communications or programs that could negatively impact the biotechnology industry, vaccine products and our ability to raise additional financing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Even if we obtain regulatory approval for a product candidate, we will still face extensive regulatory requirements and our products may face future development and regulatory difficulties.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we obtain regulatory approval in the United States, the FDA may still impose significant restrictions on the indicated uses or marketing of our product candidates, or impose ongoing requirements for potentially costly post-approval studies or post-market surveillance. The FDA may also require a risk evaluation and mitigation strategy as a condition of approval of our product candidates, which could include requirements for a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. Additionally, the manufacturing processes, packaging, distribution, adverse event reporting, labeling, advertising, promotion, and recordkeeping for the product will be subject to extensive and ongoing FDA regulatory requirements, in addition to other potentially applicable federal and state laws. These requirements include monitoring and reporting of adverse events and other post-marketing information and reports, registration, as well as continued compliance with current good manufacturing practice, or cGMP, regulations. The holder of an approved NDA must also submit new or supplemental applications and obtain FDA approval for certain changes to the approved product, product labeling or manufacturing process. If we or a regulatory agency discovers previously unknown problems with a product such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, a regulatory agency may impose restrictions relative to that product or the manufacturing facility, including requiring recall or withdrawal of the product from the market or suspension of manufacturing.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we or our strategic partners fail to comply with applicable regulatory requirements following approval of any of our product candidates, a regulatory agency may:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">issue a warning letter asserting that we are in violation of the law; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">seek an injunction or impose civil or criminal penalties or monetary fines; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">suspend or withdraw regulatory approval; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">suspend any ongoing clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">refuse to approve a pending NDA or supplements to an NDA submitted by us; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">seize product or require a product recall; or </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">refuse to allow us to enter into supply contracts, including government contracts. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. The occurrence of any event or penalty described above may inhibit our ability to commercialize our future products, if approved, and generate revenues.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may use our financial and human resources to pursue a particular research program or product candidate and fail to capitalize on programs or product candidates that may be more profitable or for which there is a greater likelihood of success.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a result of our limited financial and human resources, we will have to make strategic decisions as to which targets and product candidates to pursue and may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">47</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">relinquish valuable rights to that product candidate through strategic alliance, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate, or we may allocate internal resources to a product candidate in a therapeutic area in which it would have been more advantageous to enter into a partnering arrangement.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed applicable insurance coverage we may have as well as our financial resources. We also could incur significant costs associated with civil or criminal fines and penalties.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials or other work-related injuries, this insurance may not provide adequate coverage against potential liabilities. In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Manufacturing issues may arise that could increase product and regulatory approval costs or delay or hinder commercialization.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As we scale-up manufacturing of product candidates and conduct required stability testing, product, packaging, equipment and process-related issues may require refinement or resolution in order to proceed with any clinical trials and obtain regulatory approval for commercial marketing. We may identify significant impurities, which could result in increased scrutiny by the regulatory agencies, delays in clinical programs and regulatory approval, increases in our operating expenses, or failure to obtain or maintain approval for product candidates or any approved products. The robustness of our manufacturing supply chain to support commercial distribution has not been meaningfully tested. Furthermore, we are required by our contract manufacturers to make financial commitments in advance of the receipt of clinical data or feedback from regulatory authorities, which could result in significant financial obligations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The commercial success of our product candidates will depend in part upon the acceptance of our product candidates by the medical community, including physicians, patients and healthcare payors.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The degree of market acceptance of any product candidates will depend on a number of factors, including:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">demonstration of clinical safety and efficacy compared to other products; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the relative convenience, ease of administration and acceptance by physicians, patients and healthcare payors; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the prevalence and severity of any adverse events; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">limitations or warnings contained in the FDA-approved label for such products; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">availability of alternative treatments; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">pricing and cost-effectiveness; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the commercial packaging and product presentation preferences;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the effectiveness of our, or any of our collaborators&#8217;, sales and marketing strategies; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to obtain hospital or payor formulary approval; </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">48</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to obtain and maintain sufficient coverage from healthcare payors and adequate reimbursement; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the willingness of patients to pay out-of-pocket in the absence or inadequacy of coverage by healthcare payors.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unless other formulations are developed in the future, we expect our compounds to be formulated in an injectable or inhalable form. Injectable medications may be disfavored by patients or their physicians in the event drugs which are easy to administer, such as oral medications, are available. If any of our products is approved, but does not achieve an adequate level of acceptance by physicians, patients and healthcare payors, we may not generate sufficient revenues from such product and we may not become or remain profitable. Such increased competition may decrease any future potential revenue for future product candidates due to increasing pressure for lower pricing and higher discounts in the commercialization of our product.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are unable to establish cost-effective sales and marketing capabilities or enter into agreements with third parties to market and sell our product candidates, we may be unable to generate any revenues from product sales.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In order to market any products that may be approved, we must build our sales, marketing, managerial and other non-technical capabilities or make arrangements with outside parties to perform these services. With respect to certain of our current programs as well as future programs, we may rely completely on a strategic alliance partner for sales and marketing. In addition, we intend to enter into strategic alliances with other parties to commercialize other product candidates, if approved, including in markets outside of the United States or for other large markets that are beyond our resources. Although we might establish a sales organization if we are able to obtain approval to market any product candidates for niche markets in the United States, we will also consider the option to enter into strategic alliances for future product candidates in the United States if commercialization requirements exceed our available resources. This will reduce the potential profit generated from the sales of these products.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our current and any future strategic alliance partners may not dedicate sufficient resources to the commercialization of our product candidates, if approved, or may otherwise fail in their commercialization due to factors beyond our control. If we are unable to establish effective alliances to enable the sale of our product candidates, if approved, to healthcare professionals and in geographical regions, including the United States, that will not be covered by our own marketing and sales force, or if our potential future strategic alliance partners do not successfully commercialize the product candidates that may be approved, our ability to generate revenues from product sales will be adversely affected.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to establish adequate sales, marketing and distribution capabilities, whether independently or with third parties, we may not be able to generate sufficient product revenue and may not become profitable. We will be competing with many companies that currently have extensive and well-funded marketing and sales operations. Without an internal team or the support of a third party to perform marketing and sales functions, we may be unable to compete successfully against these more established companies.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">KOSTAIVE has received marketing approval in Japan and Europe, and might in the future receive approvals in other countries outside of the United States. A variety of risks associated with international operations could materially adversely affect our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">KOSTAIVE has received marketing approval in Japan and Europe, and we intend to make efforts to expand into other countries outside of the United States for such product and for future potential products. As a result, we are and expect that we will be subject to additional risks related to entering into international business relationships, including:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">different regulatory requirements for drug approvals in foreign countries; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">differing payor reimbursement regimes, governmental payors or patient self-pay systems and price controls;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reduced protection for intellectual property rights; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">unexpected changes in tariffs, trade barriers and regulatory requirements; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">economic weakness, including inflation, or political instability in particular foreign economies and markets; </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">49</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">foreign taxes, including withholding of payroll taxes; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations incident to doing business in another country;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">workforce uncertainty in countries where labor unrest is more common than in the United States; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">business interruptions resulting from geopolitical actions, including war and terrorism, or natural disasters including earthquakes, typhoons, floods and fires.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Tariffs could adversely affect our business and financial results.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We purchase components of our product candidates, including raw materials, from U.S. domestic sources, as well as various global sources including but not limited to those located in the People&#8217;s Republic of China (&#8220;PRC&#8221;), Japan, Austria, Germany, and the United Kingdom. The current U.S. presidential administration has proposed the implementation of a number of tariffs, including tariffs on products and materials from PRC, which could increase our production costs. If tariffs make purchases of materials from certain jurisdictions untenable, we may also need to obtain materials from other sources, when possible, which could also increase our costs and delay our planned clinical trials and manufacture of our products and product candidates. Any of these factors may adversely affect our financial condition or results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If coverage and adequate reimbursement is not available for any of our future products, it would be difficult for us to sell that product profitably.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Market acceptance and sales of any product candidates that we develop will depend on coverage and reimbursement policies and may be affected by future healthcare reform measures. Government authorities and third-party payors, such as private health insurers, government payors and health maintenance organizations, decide which drugs they will pay for and establish reimbursement levels. We cannot be sure that coverage and adequate reimbursement will be available for any future product candidates. In the United States, the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;), an agency within the U.S. Department of Health and Human Services, decides whether and to what extent a new drug will be covered and reimbursed under Medicare. Private payors tend to follow the coverage reimbursement policies established by CMS to a substantial degree. It is difficult to predict what CMS will decide with respect to reimbursement for novel product candidates. Inadequate reimbursement amounts could substantially reduce the demand for, or the price of, our future products. Further, one payor&#8217;s determination to provide coverage for a product does not assure that other payors will also provide coverage for the product. If reimbursement is not available, or is available only at limited levels, we may not be able to successfully commercialize product candidates that we develop and that may be approved. Thus, even if we succeed in bringing a product to market, it may not be considered medically necessary or cost-effective, and the amount reimbursed for any products may be insufficient to allow us to sell our products on a competitive basis.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">50</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we cannot be certain if and when we will obtain formulary approval to allow us to sell any products into our target markets. Obtaining formulary approval from hospitals and from pharmacy benefits payors can be an expensive and time-consuming process. Failure to obtain timely formulary approval will limit our commercial success.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There have been a number of legislative and regulatory proposals to change the healthcare system in the United States and in some foreign jurisdictions that could affect our ability to sell products profitably. These legislative and/or regulatory changes may negatively impact the reimbursement for drug products, following approval. The availability of numerous generic treatments may also substantially reduce the likelihood of reimbursement for our future products. We expect to experience pricing pressures in connection with the sale of any products that we develop, due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, and prescription drugs in particular, has and is expected to continue to increase in the future. For instance, government and private payors who reimburse patients or healthcare providers are increasingly seeking greater upfront discounts, additional rebates and other concessions to reduce prices for pharmaceutical products. If we fail to successfully secure and maintain sufficient reimbursement coverage for our future products or are significantly delayed in doing so, we will have difficulty achieving market acceptance of our future products and our business will be harmed.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, in some non-U.S. jurisdictions, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing vary widely from country to country. For example, the EU provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product, or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. If any country that has price controls or reimbursement limitations for pharmaceutical products does not allow favorable reimbursement and pricing arrangements for any of our products, our sales and profits from that product could be severely limited. Historically, products launched in the EU do not follow price structures of the U.S. and generally tend to be priced significantly lower.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RISKS RELATED TO OUR RELIANCE ON OUTSIDE PARTIES</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If our strategic alliances are unsuccessful or are terminated, we may be unable to commercialize certain product candidates and generate revenues.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We depend on alliance partners for financial and scientific resources for the clinical development, manufacture and commercialization of certain of our product candidates. Under these alliances we are likely to have limited influence and control over their approaches to development and commercialization. If strategic alliance partners do not perform in the manner that we expect or fail to fulfill their responsibilities in a timely manner, or at all, the clinical development, regulatory approval and commercialization efforts related to product candidates we have licensed to such strategic alliance partners could be delayed or terminated. These alliances will likely provide us with limited control over the course of development of a product candidate, especially once a candidate has reached the stage of clinical development. Our ability to ultimately recognize revenue from our strategic relationships will depend upon the ability and willingness of our alliance partners to successfully meet their respective responsibilities under our agreements with them.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our ability to recognize revenues from strategic alliances may be impaired by several factors, including:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">an alliance partner may shift its priorities and resources away from our programs due to a change in its business strategies whether or not permitted under agreement with them, or a merger, acquisition, sale or downsizing of its company or business unit; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">an alliance partner may cease development in therapeutic areas which are the subject of our strategic alliances; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">an alliance partner may change the success criteria for a particular program or potential product candidate thereby delaying or ceasing development of such program or candidate;</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">51</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a significant delay in initiation of certain development activities by an alliance partner will also delay payment to us of milestones tied to such activities, thereby impacting our ability to fund our own activities; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">an alliance partner with commercialization obligations may not commit sufficient financial or human resources to the marketing, distribution or sale of a product; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">an alliance partner with manufacturing responsibilities may encounter regulatory, resource or quality issues and be unable to meet demand requirements; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">an alliance partner may exercise its rights under the agreement to terminate a strategic alliance; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a dispute may arise between us and an alliance partner concerning the research, development or commercialization of a program or product candidate resulting in a delay in payments of milestones or royalties, or the termination of a program, and possibly resulting in costly litigation or arbitration which may divert management attention and resources; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">an alliance partner may use our proprietary information or intellectual property in such a way as to invite litigation from a third party or fail to maintain or prosecute intellectual property rights such that our rights in such property are jeopardized. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If any of our alliance partners do not elect to pursue the development and commercialization of our development candidates or if they terminate the strategic alliance, then, depending on the event:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">development of product candidates subject to our alliances may be terminated or significantly delayed; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our cash expenditures could increase significantly if it is necessary for us to hire additional employees and allocate limited resources to the development and commercialization of product candidates that were previously funded, or expected to be funded, by our alliance partners; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we could bear the risks and costs related to the further development and commercialization of product candidates that were previously the subject of our strategic alliance, including the reimbursement of third parties; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in order to fund further development and commercialization, we may need to seek out and establish alternative strategic alliances with other parties; this may not be possible, or we may not be able to do so on terms which are acceptable to us, in which case it may be necessary for us to limit the size or scope of one or more of our programs, increase our expenditures, or seek additional funding by other means. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any of these events would have a material adverse effect on our results of operations and financial condition.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If the outside contractors we rely on to conduct some aspects of our compound formulation, research and studies do not perform satisfactorily and meet deadlines, development of our product candidates could be delayed or precluded.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not independently conduct all aspects of our drug discovery activities, compound formulation research or preclinical and clinical studies of product candidates. We currently rely and expect to continue to rely on outside contractors to conduct some aspects of our preclinical and clinical studies and formulation development, but we remain responsible for ensuring that each of our IND-enabling studies and clinical trials are conducted in accordance with the study plan and protocols for the trial.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If these outside parties terminate their engagements with us or do not successfully carry out their contractual duties, meet expected deadlines or conduct our studies in accordance with regulatory requirements or our stated study plans and protocols, we will not be able to complete, or may be delayed in completing, the necessary preclinical studies to enable us or our strategic alliance partners to select viable product candidates for IND submissions and will not be able to, or may be delayed in our efforts to, successfully develop and commercialize such product candidates.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If the contract manufacturers we rely on to produce the supply of our preclinical and clinical product candidates, including materials for the manufacture of our product candidates do not timely deliver adequate quantities of quality materials, development and commercialization of our product candidates would be hindered.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">52</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We rely on outside contractors to produce the supply of our preclinical and clinical product candidates, and we intend to rely on outside contractors to produce future clinical supplies of product candidates and commercial supplies of any approved product candidates. Reliance on outside suppliers and manufacturers entails risks, some of which we would not be subject to if we manufactured the product candidates ourselves, including:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the inability to meet any product specifications and quality requirements consistently; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a delay or inability to procure or expand sufficient manufacturing capacity; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">manufacturing and product quality issues related to scale-up of manufacturing; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">costs and validation of new equipment and facilities required for scale-up; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a failure to comply with cGMP and similar foreign standards; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the inability to negotiate manufacturing or supply agreements with outside parties on commercially reasonable terms; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">termination or nonrenewal of manufacturing agreements with outside parties in a manner or at a time that is costly or damaging to us; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the reliance on a limited number of sources, and in some cases, single sources for raw materials, such that if we are unable to secure a sufficient supply of these product components, we will be unable to manufacture and sell future product candidates in a timely fashion, in sufficient quantities or under acceptable terms; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the lack of qualified backup suppliers for any raw materials that are currently purchased from a single source supplier; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">operations of our contract manufacturers or suppliers could be disrupted by conditions unrelated to our business or operations, including the bankruptcy of the manufacturer or supplier; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">carrier disruptions or increased costs that are beyond our control; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the failure to deliver products under specified storage conditions and in a timely manner. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any of these events could lead to clinical study delays or failure to obtain regulatory approval, or impact our ability to successfully commercialize future products, if approved. Some of these events could be the basis for detrimental FDA action, including injunction, product recall or seizure, or total or partial suspension of production.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Any disruption in the supply chain of raw materials for, or in the manufacturing capacity and timing for the manufacture of drug substance or drug product for, our product candidates may cause a delay in developing and commercializing these product candidates and limit the revenues that we could generate.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have established manufacturing relationships with a limited number of suppliers to supply raw materials used to create our product candidates and with a limited number of contract manufacturers to manufacture drug substance and drug product. The availability of continued supply and manufacturing capacity from our current vendors, and the availability of additional suppliers and manufacturers, is limited. We have and may continue to experience some supplier shortages and delivery delays. If our vendors fail to supply materials or to manufacture substances or products in the required quantities on a timely basis and at commercially reasonable prices, and we are unable to secure one or more replacement vendors in a timely manner at a substantially equivalent cost, our clinical trials may be delayed, and our commercialization prospects could be materially diminished.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prior to marketing approval for any of our product candidates, a manufacturer and its processes are required to be qualified by the FDA. If supply from the approved manufacturer is interrupted, there could be a significant disruption in our sales of any product. An alternative vendor would need to be qualified through an NDA supplement which could result in further delay. The FDA or other regulatory agencies outside of the United States may also require additional studies if a new supplier is relied upon for commercial production. Switching vendors may involve substantial costs and is likely to result in a delay in our desired clinical and commercial timelines.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, if our alliance partners elect to control manufacturing for certain programs, we may lose control over the manufacturing activities for the product candidate, which would reduce our level of manufacturing process</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">53</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">development and would make the success of such programs dependent on our partners&#8217; ability to manufacture timely and properly.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If the contract research organizations and clinical trial sites we rely on to conduct, supervise and monitor our clinical trials perform in an unsatisfactory manner, it may harm our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We and our strategic alliance partners rely on CROs and clinical trial sites to ensure the proper and timely conduct of our clinical trials. We and our strategic alliance partners have limited control or influence over their actual performance, but remain responsible for ensuring that clinical trials are conducted in accordance with the applicable protocol, legal, regulatory and scientific standards.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we or our CROs fail to comply with applicable good clinical practices, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or applicable non-U.S. regulatory agency may require us to perform additional clinical trials before approving any marketing applications. In addition, our future clinical trials will require a sufficiently large number of test subjects to adequately evaluate the safety and effectiveness of a potential drug product. Accordingly, if our CROs fail to comply with these regulations or fail to recruit a sufficient number of patients, we may be required to repeat such clinical trials, which would delay the regulatory approval process and increase our costs.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our CROs are not our employees, and we are not able to control whether or not they devote sufficient time and resources to our clinical and nonclinical programs. These CROs may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other drug development activities, which could possibly harm our competitive position. If our future CROs do not successfully carry out their contractual duties or obligations, fail to meet expected deadlines, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements, or for any other reasons, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for, or successfully commercialize our product candidates. As a result, the commercial prospects for such products and any product candidates that we develop would be harmed, our costs could increase, and our ability to generate revenues could be delayed.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We rely on other outside parties to store and distribute drug products for clinical trials. Any performance failure or delays by our distributors could delay clinical development, marketing approval or commercialization of our product candidates, resulting in additional losses and depriving us of potential product revenue.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RISKS RELATED TO OUR INTELLECTUAL PROPERTY</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are unable to obtain or protect intellectual property rights related to our products and product candidates, we may not be able to compete effectively in our markets.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our success depends in part on our ability to obtain and maintain patents and other forms of intellectual property rights, including in-licenses of intellectual property rights of others, for our product candidates, methods used to develop and manufacture our product candidates and methods for treating patients using our product candidates, as well as our ability to preserve our trade secrets, to prevent third parties from infringing upon our proprietary rights and to operate without infringing upon the proprietary rights of others. The strength of patents in the biotechnology and pharmaceutical field involves complex legal and scientific questions and can be highly uncertain. The patent applications that we own or in-license may fail to result in patents with claims that cover our products or methods in the United States or in other countries.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our patents could be prevented from issuing or be invalidated after issuance for many reasons, including:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">relevant prior art relating to our patents and patent applications; or</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">third party challenges to their validity, enforceability or scope, which may result in patents being narrowed or invalidated. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the patent applications we hold or have in-licensed with respect to our programs or product candidates fail to issue or are invalidated or if their breadth or strength of protection is threatened, it could dissuade companies from collaborating with us to develop product candidates, and threaten our ability to commercialize, future products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we do not prevail in any challenge to our intellectual property rights, we could be required to cease using the related technology or to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license at all, or on commercially reasonable terms. Our defense of a patent or</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">54</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">patent application in such a proceeding may not be successful and, even if successful, may result in substantial costs and distract our management and other employees. Even if our patents are issued and are not challenged or invalidated, our patents and patent applications may not adequately protect our intellectual property or products, or prevent others from designing around our claims. In addition, patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20 years after it is filed. Various extensions may be available; however, the life of a patent, and the protection it affords is limited. Once the patent life has expired for a product, we may be open to competition from generic medications. Further, if we encounter delays in regulatory approvals, the period during which we could market a product candidate under patent protection could be reduced.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect certain proprietary know-how, including processes for which patents are difficult to enforce, elements of our drug discovery and development processes and elements of our proprietary manufacturing processes. Although each of our employees agrees to assign their inventions to us through an employee inventions agreement, and all of our employees, consultants, advisors and any third parties who have access to our proprietary know-how, information or technology are required to enter into confidentiality agreements, such agreements may not be effective in preventing our trade secrets and other confidential proprietary information from being disclosed or accessed by competitors. In addition, competitors and others may independently discover our trade secrets and proprietary information or independently develop substantially equivalent information and techniques, and regulatory agencies may require additional disclosures of proprietary know-how.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the United States. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the United States and abroad. If we are unable to prevent material disclosure of the non-patented intellectual property related to our technologies to third parties, and there is no guarantee that we will have any such enforceable trade secret protection, we may not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Claims that we infringe the intellectual property rights of others, especially in the crowded and competitive field of mRNA and delivery technology patents, may prevent or delay our development and commercialization efforts.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As the biotechnology and pharmaceutical industries expand and more patents are issued and as our activities expand and mature, the risk increases that our product candidates and activities may be subject to claims of infringement of the patent rights of others. This risk is significantly heightened because of the many patents and other intellectual property rights related to messenger RNA and its delivery.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prior to and since the outbreak of the COVID-19 pandemic, many companies have devoted substantial effort to developing vaccines and therapeutics that use mRNA technology and have developed their own intellectual property rights, applied for patents, and licensed rights to patents held by other companies or research institutions. Some of these patents may have broad claims that cover our current or expected activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are aware of patent challenging and enforcement activities in connection with technologies used in mRNA-based COVID-19 vaccines. The outcomes of such activities and the advancement of our programs could give rise to third party claims of infringement against us and our partners.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our and our partners&#8217; ability to further develop and commercialize products based on our platform. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee and financial resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, pay significant royalties, or try to redesign our infringing products, which may be impossible or require substantial time and monetary expenditure, further delaying and commercialization and substantially reducing potential market revenue. In order to continue development, manufacture or sale of a product, we may need to obtain a license from the owner of intellectual property, which may not be available on commercially reasonable terms or at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we fail to obtain licenses to necessary intellectual property or do not comply with our obligations in license agreements, we could lose important rights.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may need to obtain licenses from owners of intellectual property to advance our research or allow commercialization of our product candidates, and we have done so from time to time. If we fail to obtain any of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">55</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">these licenses at a reasonable cost and on reasonable terms, we would be unable to further develop and commercialize one or more of our product candidates, which could harm our business significantly.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may be involved in lawsuits to protect or enforce our patents or the patents of our licensees, which could be expensive, time consuming and unsuccessful.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Competitors may infringe our patents or the patents of our licensees. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that a patent of ours or of our licensees is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated or interpreted narrowly and could put our patent applications at risk of not issuing.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our defense in a lawsuit may fail and, even if successful, may result in substantial costs and distract our management and other employees. We may not be able to prevent, alone or with our licensees, misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United States.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during the course of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties, we could incur substantial expenses.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We employ individuals who were previously employed at other biotechnology or pharmaceutical companies. We may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed confidential information of our employees&#8217; former employers or other third parties. We may also be subject to claims that former employers or other parties have an ownership interest in our patents. Litigation may be necessary to defend against these claims. We may not be successful in defending these claims, and if we are successful, litigation could result in substantial cost and be a distraction to our management and other employees.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Certain of our patents are, and our future owned and in-licensed patents may be, discovered through government funded programs and thus may subject to federal regulations such as &#8220;march-in&#8221; rights, certain reporting requirements and a preference for U.S.-based companies, and the exercise of such &#8220;march-in&#8221; rights by the U.S. government could harm our business, financial conditions, results of operations and prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Certain of our patents have been, and our future owned and in-licensed patents may be, discovered through government funded programs. As a result, the U.S. government may have certain rights to intellectual property embodied in our current or future products pursuant to the Bayh-Dole Act of 1980 (the &#8220;Bayh-Dole Act&#8221;), and implementing regulations, which are amended from time to time. On December 7, 2023, the Biden administration announced an initiative to control the price of prescription drugs through the use of march-in rights under the Bayh-Dole Act. These U.S. government rights in certain inventions developed under a government-funded program include a non-exclusive, non-transferable, irrevocable worldwide license to use inventions for any governmental purpose. In addition, the U.S. government has the right to require us or our licensors to grant exclusive, partially exclusive, or non-exclusive licenses to any of these inventions to a third party if it determines that: (i) adequate steps have not been taken to commercialize the invention; (ii) government action is necessary to meet public health or safety needs; or (iii) government action is necessary to meet requirements for public use under federal regulations, which are also referred to as &#8220;march-in rights.&#8221; The U.S. government also has the right to take title to these inventions if we, or the applicable licensor, fail to disclose the invention to the government and fail to file an application to register the intellectual property within specified time limits. If the U.S. government decides to exercise these rights, it is not required to engage us as its contractor in connection with doing so. To the extent any of our current or future intellectual property is generated through the use of U.S. government funding, the provisions of the Bayh-Dole Act may similarly apply. Any exercise by the government of any of the foregoing rights could harm our business, financial condition, results of operations and prospects.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">56</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RISKS RELATED TO OUR BUSINESS OPERATIONS AND INDUSTRY</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may need to expand our organization and may experience difficulties in managing this growth, which could disrupt our operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, we had approximately 176 employees. In the future we may expand our employee base to increase our managerial, scientific, operational, commercial, financial and other resources and we may hire more consultants and contractors. Future growth would impose significant additional responsibilities on our management, including the need to identify, recruit, maintain, motivate and integrate additional employees, consultants and contractors. Also, our management may need to divert a disproportionate amount of its attention away from our day-to-day activities and devote a substantial amount of time to managing these growth activities. We may not be able to effectively manage the expansion of our operations, which may result in weaknesses in our infrastructure or give rise to operational mistakes, loss of business opportunities, loss of employees or reduced productivity among remaining employees. Our expected growth could require significant capital expenditures and may divert financial resources from other projects, such as the development of additional product candidates. Moreover, if our management is unable to effectively manage our growth, our expenses may increase more than expected, our ability to generate and/or grow revenues could be reduced, and we may not be able to implement our business strategy. Our future financial performance and our ability to commercialize product candidates and compete effectively will depend, in part, on our ability to effectively manage any future growth.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we cannot continue to attract, retain and motivate key executives and qualified scientists and other personnel, we will not be able to effectively operate our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are highly dependent on principal members of our executive team, and any reduction or loss of their services may adversely impact the achievement of our objectives. While we have entered into employment agreements with each of our executive officers, any of them could leave our employment at any time, as all of our employees are &#8220;at will&#8221; employees. Recruiting and retaining other qualified employees for our business, including scientific and technical personnel, will also be critical to our success. We have in the past experienced a high number of resignations, which could recur. Competition for skilled personnel is intense and the turnover rate can be high, as we have recently seen. We may not be able to attract and retain personnel on acceptable terms given the competition among numerous pharmaceutical companies for individuals with similar skill sets. In addition, failure to succeed in preclinical studies and clinical trials may make it more challenging to recruit and retain qualified personnel. The inability to recruit any executive or key employee or the loss of the services of any executive or key employee might impede the progress of our research, development and commercialization objectives.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are exposed to the risk of employee fraud or other misconduct. Employee misconduct could have significant negative impacts on our business. Misconduct by employees could include intentional or nonintentional failures to comply with the regulations of the FDA and other regulators, to provide accurate information to the FDA and other regulators, to comply with healthcare fraud and abuse laws and regulations in the United States and abroad, to report financial information or data accurately or to disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and cause serious harm to our reputation. Although we have adopted a code of conduct and procedures, we may not always be effective in identifying and deterring employee misconduct, controlling unknown or unmanaged risks or losses, or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we do not fully comply with applicable healthcare fraud and abuse laws, false claims laws and health information privacy and security laws, we could face criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we obtain FDA approval for any of our product candidates and begin commercializing those products in the United States, our operations may be directly, or indirectly through our customers, further subject to various federal and state fraud and abuse laws, including, without limitation, the federal Anti-Kickback Statute and the federal False Claims Act (the &#8220;FCA&#8221;). These laws may impact, among other things, our proposed sales, marketing and education</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">57</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">programs. In addition, we may be subject to patient privacy regulation by the federal government and by the U.S. states and foreign jurisdictions in which we conduct our business. The healthcare laws and regulations that may affect our ability to operate include:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The federal Anti-Kickback Statute, which prohibits, among other things, persons and entities from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, to induce, or in return for, either the referral of an individual, or the purchase or recommendation of an item or service for which payment may be made under a federal healthcare program, such as the Medicare and Medicaid programs. Remuneration has been interpreted broadly to include anything of value. Although there are a number of statutory exemptions and regulatory safe harbors protecting certain common activities from prosecution, the exemptions and safe harbors are drawn narrowly, and those activities may be subject to scrutiny or penalty if they do not qualify for an exemption or safe harbor. A conviction for violation of the Anti-Kickback Statute requires mandatory exclusion from participation in federal healthcare programs. This statute has been applied to arrangements between pharmaceutical manufacturers and those in a position to purchase products or refer others, including prescribers, patients, purchasers and formulary managers. In addition, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (the &#8220;ACA&#8221;), amended the Social Security Act to provide that the United States government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil FCA penalties for which are described below.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Federal civil and criminal false claims laws and civil monetary penalty laws, including the FCA, which imposes criminal or civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for, among other things, knowingly presenting, or causing to be presented, claims for payment to the federal government, including Medicare or Medicaid, that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. FCA liability is potentially significant in the healthcare industry because the statute provides for treble damages and mandatory penalties.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The civil monetary penalties statute, which imposes penalties against any person or entity who, among other things, is determined to have presented or caused to be presented a claim to a federal healthcare program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The federal Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), which imposes civil and criminal penalties for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations or promises, any money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private), knowingly and willfully embezzling or stealing from a health care benefit program, willfully obstructing a criminal investigation of a healthcare offense and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (&#8220;HITECH&#8221;), and its implementing regulations, which imposes certain requirements on certain types of individuals and entities, such as healthcare providers, health plans and healthcare clearing houses, known as &#8220;covered entities,&#8221; as well as their &#8220;business associates,&#8221; independent contractors or agents of covered entities that receive or obtain individually identifiable health information in connection with providing a service on behalf of a covered entity, relating to the privacy, security and transmission of individually identifiable health information. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The federal Physician Payments Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to report annually to CMS, information related to payments or other transfers of value made to physicians, and further requires applicable manufacturers and applicable group purchasing organizations to report annually to CMS ownership and </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">58</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">investment interests held by physicians and their immediate family members. The support for Patients and Communities Act expanded the scope of reporting, such that beginning January 1, 2021 companies must also report payments and transfers of value provided to other types of healthcare professionals. Failure to submit timely, accurately and completely the required information for all covered payments, transfers of value and ownership or investment interests may result in civil monetary penalties.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many state and foreign law equivalents of each of the above federal laws, such as: anti-kickback and false claims laws which may apply to items or services reimbursed by any third party payor, including commercial insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government; state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; state and local laws that require the registration of pharmaceutical sales representatives; and state and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the EU has established its own data security and privacy legal framework, including but not limited to Directive 95/46/EC (the &#8220;Data Protection Directive&#8221;). The European General Data Protection Regulation (&#8220;GDPR&#8221;) took effect on May 25, 2018, which contains new provisions specifically directed at the processing of health information, higher sanctions and extra-territoriality measures intended to bring non-E companies under the regulation. We anticipate that over time we may expand our business operations to include additional operations in the EU, including potentially conducting preclinical and clinical trials. With such expansion, we would be subject to increased governmental regulation in the EU countries in which we might operate, including regulation due to the GDPR.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If our operations are found to be in violation of any of the laws described above or any other governmental regulations or laws that apply to us, we may be subject to substantial penalties, including, without limitation, civil, criminal and administrative penalties, damages, fines, possible exclusion from Medicare, Medicaid and other government healthcare programs, additional reporting requirements and/or oversight, particularly if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance, disgorgement, imprisonment, contractual damages, reputational harm, diminished profits and future earnings, and curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recent and future healthcare legislation may further impact our business operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The United States and some foreign jurisdictions are considering or have enacted a number of legislative and regulatory proposals to change the healthcare system in ways that could affect our ability to sell our products profitably. Among policymakers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives. For example, in March 2010, the ACA was enacted, which made a number of substantial changes in the way healthcare is financed by both governmental and private insurers. The ACA included a number of provisions that may reduce the profitability of drug products, including revising the rebate methodology for covered outpatient drugs under the Medicaid Drug Rebate Program, extending Medicaid rebates to individuals enrolled in Medicaid managed care plans, and requiring drug manufacturers to pay an annual fee based on their market share of prior year total sales of branded programs to certain federal health care programs.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We face potential product liability, and, if successful claims are brought against us, we may incur substantial liability and costs.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The use of our product candidates in clinical trials and the sale of any products for which we obtain marketing approval exposes us to the risk of product liability claims. Product liability claims might be brought against us by consumers, healthcare providers, pharmaceutical companies or others selling or otherwise coming into contact with our product candidates or products. For example, unanticipated adverse effects could result from the use of our future products or product candidates which may result in a potential product liability claim. If we cannot</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">59</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">successfully defend against product liability claims, we could incur substantial liability and costs. In addition, regardless of merit or eventual outcome, product liability claims may result in:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">impairment of our business reputation; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">withdrawal of clinical trial participants; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">costs due to related litigation; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">distraction of management&#8217;s attention from our primary business; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">substantial monetary awards to patients or other claimants; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the inability to commercialize our product candidates; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">decreased demand for our products approved for commercial sale. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have a limited amount of product liability insurance relating to the use of our therapeutics in clinical trials. However, such insurance coverage may not be sufficient to reimburse us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive and in the future we may not be able to obtain or maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. If and when we obtain marketing approval for product candidates, we intend to expand our insurance coverage to include the sale of commercial products; however, we may be unable to obtain product liability insurance on commercially reasonable terms or in adequate amounts. On occasion, large judgments have been awarded in class action lawsuits based on drugs that had unanticipated adverse effects. A successful product liability claim or series of claims brought against us could cause our share price to decline and, if judgments exceed our insurance coverage, could adversely affect our results of operations and business.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cyber security risks and the failure to maintain the confidentiality, integrity, and availability of our computer hardware, software, and Internet applications and related tools and functions could result in damage to our reputation and/or subject us to costs, fines or lawsuits.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our business requires manipulating, analyzing and storing large amounts of data. In addition, we rely on a global enterprise software system to operate and manage our business. We also maintain personally identifiable information about our employees and participants in our clinical trials. Our business therefore depends on the continuous, effective, reliable, and secure operation of our computer hardware, software, networks, Internet servers, and related infrastructure. To the extent that our hardware or software malfunctions or access to our data by internal research personnel is interrupted, our business could suffer. The integrity and protection of our employee and company data is critical to our business and our employees and participants in our clinical trials have a high expectation that we will adequately protect their personal information. The regulatory environment governing information, security and privacy laws is increasingly demanding and continues to evolve. Maintaining compliance with applicable security and privacy regulations may increase our operating costs. Although our computer and communications hardware is protected through physical and software safeguards, it is still vulnerable to fire, storm, flood, power loss, earthquakes, telecommunications failures, physical or software break-ins, software viruses, and similar events. These events could lead to the unauthorized access, disclosure and use of non-public information. The techniques used by cyber criminals are sophisticated, change frequently, may originate from less regulated and more remote areas of the world, may not be recognized until launched and can originate from a wide variety of sources, including insider threats and outside groups such as external service providers, organized crime affiliates, terrorist organizations or hostile foreign governments or agencies, or generated using artificial intelligence. As a result, we may not be able to address these techniques proactively or implement adequate preventative measures. If our computer systems are compromised, we could be subject to fines, damages, litigation and enforcement actions, and we could lose trade secrets, the occurrence of which could harm our business. In addition, any sustained disruption in internet access provided by other companies could harm our business.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">60</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Business interruptions could delay us in the process of developing our future products.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our headquarters is located in San Diego, California. We are vulnerable to natural disasters such as earthquakes, mudslides, floods and wildfires, as well as other events that could disrupt our operations. We do not carry insurance for earthquakes or other natural disasters, and we may not carry sufficient business interruption insurance to compensate us for losses that may occur. Any losses or damages we incur could have a material adverse effect on our business operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">U.S. Government agencies have special contracting authority that gives them the ability to terminate and/or modify their contracts with us.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On August 31, 2022, we entered into a cost reimbursement contract with BARDA to support the development of a low-dose pandemic influenza candidate based on our proprietary self-amplifying messenger RNA-based vaccine platform.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The contract with BARDA, as with most U.S. Government contracts, is subject to audit, and contains termination provisions allowing the government to terminate all or part of the contract at its sole discretion, which will subject us to additional risks. These risks include the ability of the U.S. Government unilaterally to:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">preclude us, either temporarily or for a set period of time, from receiving new contracts or extending our existing or future contracts based on violations or suspected violations of laws or regulations;
</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">terminate our contract, either for the convenience of the government (at the government&#8217;s sole discretion, for example, if funds become unavailable or the government no longer wants the work) or for default (for failing to perform in accordance with the contract schedule and terms);
</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">revise the scope and value of our contract and/or revise the timing for work to be performed;
</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">audit and object to our contract-related costs and fees, including allocated indirect costs;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">control and potentially prohibit the export of our products, if and when developed;
</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">claim rights to intellectual property, including products, that may be developed under the contract; and
</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">add or remove the terms and conditions in our contract.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Termination-for-convenience provisions generally enable us to recover only our costs incurred or committed, settlement expenses, and profit on the work completed prior to termination. A contractor&#8217;s rights under a termination for convenience are limited to an adjustment of profit and, with the contracting officer&#8217;s concurrence, a reduction in the estimated cost. Under the general termination for convenience procedures, a partial termination is treated as a full termination when (i) the terminated portion is clearly severable from the balance of the contract or (ii) when contract performance is virtually complete or performance of the continued portion of the contract is only on subsidiary items or is otherwise not substantial. Termination-for-default provisions do not permit these recoveries and could make us liable for excess costs incurred by the U.S. Government in procuring undelivered items from another source.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the new 2025 U.S. presidential administration has implemented or threatened reductions in force and work stoppages across several U.S. federal agencies. Any such reductions or stoppages at BARDA or other federal agencies could negatively impact our contractual relationships with these entities, which could negatively impact our business and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our business is subject to audit by the U.S. Government, and a negative audit could adversely affect our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Several U.S. Government agencies, such as the Defense Contract Audit Agency (the &#8220;DCAA&#8221;), routinely audit and investigate government contractors. These agencies review, among other things, a contractor&#8217;s performance under its contracts, incurred costs, cost structure and compliance with applicable laws, regulations and standards.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">61</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The DCAA also reviews the adequacy of, and a contractor&#8217;s compliance with, its internal control systems and policies, including the contractor&#8217;s purchasing, property, estimating, compensation and management information systems. Any costs found to be improperly allocated to a specific contract will not be reimbursed, while such costs already reimbursed must be refunded. If an audit uncovers improper or illegal activities, we may be subject to civil and criminal penalties and administrative sanctions, including:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">termination of contracts;
</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">forfeiture of profits;
</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">suspension of payments;
</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">fines; and
</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">suspension or prohibition from conducting business with the U.S. Government. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we could suffer serious reputational harm if allegations of impropriety were made against us.
</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have identified a material weakness in our internal control over financial reporting, and determined that our disclosure controls were not effective as of December 31, 2023 and December 31, 2024. If our remediations of this material weakness are not effective, or if we experience additional material weaknesses or otherwise fail to maintain an effective system of internal control over financial reporting or adequate disclosure controls and procedures, we may not be able to accurately and timely report our financial results, in which case our business may be harmed, investors may lose confidence in the accuracy and completeness of our financial reports, and the price of our common stock may decline.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting and for evaluating and reporting on the effectiveness of our system of internal control. Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external reporting purposes in accordance with generally accepted accounting principles (&#8220;GAAP&#8221;). We are required to furnish annually a report by management of its assessment of the effectiveness of our internal control over financial reporting as of the end of our most recent fiscal year. In addition, our independent registered public accounting firm is required to provide a related attestation report on our internal control over financial reporting.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As previously reported, as part of our assessment of the effectiveness of our internal control over financial reporting as of December 31, 2023, management identified a material weakness related to information technology general controls (&#8220;ITGCs&#8221;) for information systems and applications that are relevant to the preparation of the consolidated financial statements. Specifically, it was determined we did not design and maintain: (i) sufficient user access controls to ensure appropriate segregation of duties and adequately restrict user and privileged access to financial applications, programs and data to the appropriate personnel; (ii) program change management controls to ensure that information technology (&#8220;IT&#8221;) program and data changes affecting financial IT applications and underlying accounting records are identified, tested, authorized and implemented appropriately; and (iii) computer operations controls to ensure that critical batch and interfaced jobs are monitored, privileges are appropriately granted, and data backups are authorized and monitored. Business process controls (automated and manual) that are dependent on the ineffective ITGCs, or that rely on data produced from systems impacted by the ineffective ITGCs, are also deemed ineffective. Management also identified a material weakness related to revenue recognition. Certain control activities within the area of revenue did not operate effectively, specifically controls over the review of costs incurred in satisfaction of our performance obligations under collaboration arrangements. Although we remediated the material weakness related to revenue recognition, management does not believe the corrective measures adopted in response to the ITGC-related material weakness have been fully implemented or operating for a sufficient period of time to enable management to conclude these internal controls over financial reporting are operating effectively and sufficiently to remediate this material weakness. As such, we concluded that our disclosure controls and procedures were not effective as of December 31, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">62</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to successfully remediate our existing material weakness or any future material weakness or other deficiencies in our internal control over financial reporting: the accuracy and timing of our financial reporting may be adversely affected; our liquidity, our access to capital markets and the perceptions of our creditworthiness; we may be unable to maintain compliance with applicable securities laws, Nasdaq listing requirements, and the covenants under our debt instruments regarding the timely filing of periodic reports; we may be subject to regulatory investigations and penalties; and investors may lose confidence in our financial reporting. If any such event or circumstance were to occur, our stock price could decline and our business, financial condition and results of operations could be materially adversely affected.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notwithstanding the identified material weakness, management does not believe that the deficiencies had an adverse effect on our reported operating results or financial condition, and management has determined that the financial statements and other information included in this report and other periodic filings present fairly in all material respects our financial condition and results of operations at and for the periods presented. The effectiveness of our internal control over financial reporting as of December 31, 2024 has been audited by Deloitte &amp; Touche LLP, an independent registered public accounting firm, as stated in their report which is included elsewhere herein. For further discussion of the material weakness identified and our remedial efforts, see Item 9A. Controls and Procedures.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RISKS RELATED TO OUR COMMON STOCK</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We do not intend to pay dividends on our common stock so any returns to investors will be limited to the value of our shares.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have never declared or paid any cash dividends on our common stock. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The market price of our common stock has been, and is expected to continue to be, highly volatile and investors may not be able to resell shares at or above the price at which they purchased the shares.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The trading price of our common stock has been and is likely to continue to be volatile. Our share price could be subject to wide fluctuations in response to a variety of factors, including but not limited to the following factors:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adverse results or delays in preclinical studies or clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">inability to obtain additional funding; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any delay in filing an application for authorization to commence a clinical trial of, or for authorization or approval to market, any of our product candidates and any adverse development or perceived adverse development with respect to the FDA&#8217;s review of that IND or BLA; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure to maintain our existing strategic alliances or enter into new alliances; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure of our strategic alliance partners to elect to develop and commercialize product candidates under our alliance agreements or the termination of any programs under our alliance agreements; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure by us or our licensors and strategic alliance partners to prosecute, maintain or enforce our intellectual property rights; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure to successfully and timely develop and commercialize our product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure to successfully and timely develop and validate manufacturing processes and product presentations; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in laws or regulations applicable to our preclinical and clinical development activities, product candidates or future products; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">inability to obtain adequate product supply for our product candidates or the inability to do so at acceptable prices; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adverse regulatory decisions; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">introduction of new products, services or technologies by our competitors; </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">63</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure to meet or exceed financial projections we may provide to the public; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure to meet or exceed the estimates and projections of the investment community; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">disappointing commercial sales, or profit share or royalty revenue amounts; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the perception of the pharmaceutical industry by the public, legislatures, regulators and the investment community; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us, our strategic alliance partners or our competitors; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">additions or departures of key scientific or management personnel; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">significant lawsuits, including patent or licensing matters; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in the market valuations of similar companies; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sales of our common stock by us or our shareholders in the future; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">trading volume of our common stock. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, companies trading in the stock market in general, and Nasdaq in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies, particularly companies in our industry. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The requirements of being a publicly traded company may strain our resources and divert management&#8217;s attention.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a publicly traded company, we have incurred, and will continue to incur, significant legal, accounting and other expenses that we did not incur as a private company. In addition, the Sarbanes-Oxley Act of 2002 (the "Sarbanes-Oxley Act"), as well as rules subsequently implemented by the SEC and Nasdaq have imposed various requirements on public companies. In July 2010, the Dodd-Frank Wall Street Reform and Consumer Protection Act (the &#8220;Dodd-Frank Act&#8221;) was enacted. There are significant corporate governance and executive compensation related provisions in the Dodd-Frank Act that require the SEC to adopt additional rules and regulations in these areas such as &#8220;say on pay&#8221; and proxy access. Shareholder activism, the current political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate. Our management and other personnel will need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations will increase our legal and financial compliance costs and will make some activities more time-consuming and costly. For example, we expect these rules and regulations to make it more difficult and more expensive for us to obtain director and officer liability insurance and we may be required to incur substantial costs to maintain our current levels of such coverage.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Failure to comply with these requirements could subject us to enforcement actions by the SEC, divert management&#8217;s attention, damage our reputation, and adversely affect our business, results of operations, or financial condition. In particular, if our independent registered public accounting firm is not able to render the required unqualified attestation, it could result in a loss of investor confidence in the accuracy, reliability, and completeness of our financial reports.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are subject to securities class action litigation, we would incur substantial costs and diversion of management&#8217;s attention.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may be at risk of securities class action litigation. This risk is especially relevant for us due to our dependence on positive clinical trial outcomes and regulatory approvals of each of our product candidates. In the past, medicines, biotechnology and pharmaceutical companies have experienced significant stock price volatility, particularly when associated with binary events such as clinical trials results and product approvals. If we face such litigation, it could result in substantial costs, divert management&#8217;s attention and resources, and have a very material adverse effect on our business, operating results and prospects.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">64</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Sales of a substantial number of shares of our common stock in the public market by our existing shareholders could cause our share price to fall.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If our existing shareholders sell, or indicate an intention to sell, substantial amounts of our common stock in the public market, the trading price of our common stock could decline significantly. In particular, the former shareholders, warrant holders and noteholders of Arcturus Therapeutics, Inc. received an aggregate of 6,631,712 of our common stock pursuant to the merger with Alcobra Ltd. in an unregistered transaction, which shares may be sold pursuant to Rule 144 under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). Those shareholders are eligible to sell those shares in the public market without restriction, except for shareholders who are deemed our &#8220;affiliates&#8221; under Rule 144 under the Securities Act. In addition, common stock that is either subject to outstanding options or reserved for future issuance under our employee benefit plans, may become eligible for sale in the public market to the extent permitted by vesting schedules and Rule 144 under the Securities Act. If common stock is sold, or if it is perceived that it will be sold, in the public market, that could cause the trading price to decline.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plans, could result in additional dilution of the percentage ownership of our shareholders and could cause our share price to fall.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect that significant additional capital will be needed in the future to continue our planned operations. To the extent we raise additional capital by issuing equity securities (including but not limited to securities issued in connection with the Sales Agreement, as defined below), our shareholders may experience substantial dilution.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to our 2019 Omnibus Equity Incentive Plan, as amended, our management is authorized to grant options and other equity-based awards to our employees, directors and consultants. We may issue and sell additional shares of common stock, convertible securities or other equity securities in one or more capital-raising or other transactions at prices and in a manner we determine from time to time, any of which may result in material dilution to investors and/or our existing shareholders. New investors could also be issued securities with rights superior to those of our existing shareholders.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 23, 2022, we entered into a Controlled Equity Offering&#8480; Sales Agreement (as amended, the &#8220;Sales Agreement&#8221;) with Cantor Fitzgerald &amp; Co. (&#8220;Cantor&#8221;) and Wells Fargo Securities, LLC (&#8220;Wells Fargo&#8221;), relating to shares of our common stock. On August 7, 2023, we entered into Amendment No. 1 to the Sales Agreement with Cantor, Wells Fargo and William Blair &amp; Company (&#8220;William Blair&#8221;). In accordance with the terms of the Sales Agreement, we may offer and sell shares of our common stock having an aggregate offering price of up to $200,000,000 from time to time through Cantor, Wells Fargo, or William Blair, each acting as our sales agent. As of the date hereof, we have not offered or sold any shares of common stock pursuant to the Sales Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may be unable to comply with the applicable continued listing requirements of Nasdaq.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our common stock is currently listed on Nasdaq. In order to maintain this listing, we must satisfy minimum financial and other continued listing requirements and standards, including a minimum closing bid price requirement for our common stock of $1.00 per share. There can be no assurance that we will be able to comply with the applicable listing standards. For example, if we were to fail to meet the minimum bid price requirement for 30 consecutive business days, we could become subject to delisting. Although Nasdaq may provide us with a compliance period in which to regain compliance with the minimum bid price requirement, we may not be able to regain compliance within the period provided by Nasdaq. In order to regain compliance with such requirement, the closing bid price of our common stock would need to meet or exceed $1.00 per share for at least 10 consecutive business days during the compliance period. If we were not able to regain compliance within the allotted compliance period for this requirement or any other applicable listing standard, including any extensions that may be granted by Nasdaq, our common stock would be subject to delisting. In the event that our common stock is delisted from Nasdaq, liquidity will be reduced, and the trading price of our common stock can be expected to decline immediately. If our common stock is not eligible for quotation or listing on another market or exchange, trading of our common stock could be conducted only in the over-the-counter market or on an electronic bulletin board established for unlisted securities such as the Pink Sheets or the OTC Bulletin Board. In such event, it could become more difficult to dispose of, or obtain accurate price quotations for our common stock and there would likely also be a reduction in our coverage by securities analysts and the news media, which could cause the price of our common stock to decline further.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">65</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1b_unresolved_staff_comments"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1B. Unresolve</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">d Staff Comments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div><ix:nonNumeric id="F_23ad3ef7-8c39-4d4b-84fc-e7afeadb1226" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" escape="true" continuedAt="F_23ad3ef7-8c39-4d4b-84fc-e7afeadb1226_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_3c_cybersecurity"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1C. Cyber</span><span id="item_1c_cybersecurity"></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">security</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risk management and strategy</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We recognize the critical importance of developing, implementing, and maintaining robust cybersecurity measures to safeguard our information systems and protect the confidentiality, integrity, and availability of our data.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e813b58c-9d98-4aad-b97e-bd5b3c96215b" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Managing Material Risks &amp; Integrated Overall Risk Management</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have implemented tools and strategies to promote a company-wide culture of cybersecurity risk management. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_088e7c36-a9a3-4e98-9747-41317dbc866d" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This ensures that cybersecurity considerations are an integral part of our decision-making process.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Our IT Department works closely with our leadership and key operating personnel to evaluate and address cybersecurity risks in alignment with our business objectives and operational needs.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our information security function and our Vice President of Information Technology help identify, assess and manage the Company&#8217;s cybersecurity threats and risks. This group works to identify and assess risks from cybersecurity threats by monitoring and evaluating our threat environment and the Company&#8217;s risk profile using various methods in certain contexts, including, for example, manual tools, subscribing to reports and services that identify cybersecurity threats, analyzing reports of threat actors, conducting scans of certain environments, evaluating certain threats reported to us, conducting threat and vulnerability assessments, using external intelligence feeds, and using third parties to conduct tabletop incident response exercises and other tests.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depending on the environment, we implement and maintain various technical, physical, and organizational measures, processes, standards and policies designed to manage and mitigate material risks from cybersecurity threats to our information systems and data, including, for example: incident detection and response, disaster recovery/business continuity policies, encryption of certain data, network security controls and data segmentation for certain systems, access controls, physical security, asset management and tracking, systems monitoring, annual mandated employee training, penetration testing, cybersecurity insurance, and dedicated cybersecurity staff.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Engage Third-parties on Risk Management</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Due to the complexity and evolving nature of cybersecurity threats, we </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_da68f034-dc2e-4043-9476-634013fbf0c6" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">engage</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> with a range of external experts, including but not limited to cybersecurity assessors, consultants, and auditors to evaluate and test our risk management systems. These partnerships enable us to leverage specialized knowledge and insights, to help ensure our cybersecurity strategies and processes remain at the forefront of industry best practices. Our collaborations with these third-parties includes regular audits, threat assessments, 24-hour monitoring, and consultation on security enhancements.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span><ix:nonNumeric id="F_369a6c22-5600-4cab-b1bf-29fe9398370f" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" continuedAt="F_369a6c22-5600-4cab-b1bf-29fe9398370f_1" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Oversee Third-party Risk</span></ix:nonNumeric></span></p><div><ix:continuation id="F_369a6c22-5600-4cab-b1bf-29fe9398370f_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because we are aware of the risks associated with third-party service providers, we conduct thorough security assessments of all determined high-risk third-party providers as deemed necessary, before engagement to ensure compliance with industry cybersecurity standards and frameworks. This includes assessments performed by our Vice President of IT, who oversees the Company's cybersecurity function.</span></p></ix:continuation></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risks from Cybersecurity Threats</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_41957a5a-1f49-4952-88df-f5e560886b88" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have not encountered cybersecurity challenges that have materially affected or are reasonably likely to materially affect our operations or financial standing.</span></ix:nonNumeric></span></p><div><ix:nonNumeric id="F_0c7cb0d8-3f9b-4553-ac50-aff2ce79aac2" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock" escape="true" continuedAt="F_0c7cb0d8-3f9b-4553-ac50-aff2ce79aac2_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Governance</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have implemented standard operating procedures to define the channels by which cybersecurity threats are communicated to the Company's Board of Directors (the &#8220;Board&#8221;). This ensures that The Board has oversight and effective governance in managing risks associated with cybersecurity threats.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Board of Directors Oversight</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_42e51b47-8e8c-439b-bb61-75092cac258c" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" escape="true" continuedAt="F_42e51b47-8e8c-439b-bb61-75092cac258c_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Audit Committee of the Board (the &#8220;Audit Committee&#8221;) is central to the Board&#8217;s oversight of cybersecurity risks and bears the primary responsibility for this domain. The Audit Committee is composed of board</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:nonNumeric></div></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">66</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_23ad3ef7-8c39-4d4b-84fc-e7afeadb1226_1"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_0c7cb0d8-3f9b-4553-ac50-aff2ce79aac2_1" continuedAt="F_0c7cb0d8-3f9b-4553-ac50-aff2ce79aac2_2"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_42e51b47-8e8c-439b-bb61-75092cac258c_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">members </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">with diverse expertise including, risk management, and finance, equipping them to oversee cybersecurity risks effectively.</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Audit Committee receives briefings on cybersecurity risks from the Vice President of IT or the Chief Legal Officer as described below in &#8220;Management&#8217;s Role Managing Risk.&#8221;</span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4d334d2e-ebd4-4928-a6e5-51c4e01c511a" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="cyd:CybersecurityRiskRoleOfManagementTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Management&#8217;s Role Managing Risk</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_be53ea81-47a8-484a-b4ba-a6a224cb4b13" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Vice President of IT, Chief Legal Officer (&#8220;CLO&#8221;) and the Director of IT Infrastructure and Security, play a pivotal role in informing the Audit Committee on cybersecurity risks. They provide briefings to the Audit Committee on a regular basis, with a minimum frequency of once per year. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2c730627-f654-472e-9b5a-f19df90cab31" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The current Vice President of IT, who is responsible for assessment and management of cybersecurity risks, has over 20 years of experience in information and technology security, including senior roles at several companies in the pharmaceutical industry, and possesses the requisite education, skills, experience, and industry certifications expected of an individual assigned to these duties</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. These briefings encompass a broad range of topics, including:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Current cybersecurity landscape and emerging threats;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Status of ongoing cybersecurity initiatives and strategies;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Incident reports and learnings from any cybersecurity events; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compliance with regulatory requirements and industry standards.</span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risk Management Personnel</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_220d208e-01bc-45b8-9324-a02c857c0e66" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Primary responsibility for assessing, monitoring and managing our cybersecurity risks rests with the Vice President of IT and the Director of IT Infrastructure and Security. Our IT Leadership team oversees our governance programs, tests our compliance with standards, remediates known risks, stays informed of significant developments in the cybersecurity domain, and leads our employee training program.</span></ix:nonNumeric></span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Monitor Cybersecurity Incidents</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_01f74851-11f0-4b6e-be0d-ecfd9392033c" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Vice President of IT is continually informed about the latest developments in cybersecurity, including potential threats and innovative risk management techniques. This ongoing knowledge acquisition is crucial for the effective prevention, detection, mitigation, and remediation of cybersecurity incidents.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> In cooperation with the Vice President of IT, the Director of IT Infrastructure and Security implements and oversees processes for the regular monitoring of our information systems. This includes the deployment of advanced security measures and regular system audits to identify potential vulnerabilities. In the event of a cybersecurity incident, the Vice President of IT is equipped with a well-defined incident response plan. This plan includes immediate actions to mitigate the impact and long-term strategies for remediation and prevention of future incidents.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_0c7cb0d8-3f9b-4553-ac50-aff2ce79aac2_2"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Reporting to Board of Directors</span></p><div><ix:nonNumeric id="F_a44210b4-1803-422a-9508-fea3f0efdfcc" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_493808ae-5381-4422-bb40-4aadb60ea71d" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Vice President of IT and the Director of IT Infrastructure and Security, in their respective capacity, inform the Chief Financial Officer (CFO) and Chief Legal Officer (CLO) of cybersecurity risks and incidents.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Furthermore, significant cybersecurity matters, and strategic risk management decisions are required to be escalated to the Board, ensuring that they have comprehensive oversight and can provide guidance on critical cybersecurity issues.</span><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"></span></p></ix:nonNumeric></div></ix:continuation></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">See Item 1A &#8220;Risk Factors&#8221; &#8211; &#8220;Risks Related to Business Operations and Industry.&#8221;</span></p></ix:nonNumeric></div></ix:continuation></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_2_properties"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 2. Pro</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">perties</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have two properties located in San Diego, California. Our principal place of business is located at 10628 Science Center Drive, Suite 250, and consists of approximately 24,700 square feet of office space and laboratory space leased through March 2027.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On September 29, 2021, we entered into a lease agreement for office, research and development, engineering and laboratory space located at 10285 Science Center Drive, San Diego, California. The additional space of approximately 43,234 square feet is leased for a term of 10 years and 8 months.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe that our properties are suitable for the conduct of our business.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">67</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_3_legal_proceedings"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 3. Legal </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Proceedings</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, we may be involved in various legal proceedings and subject to claims that arise in the ordinary course of business, and the results of litigation and claims are inherently unpredictable and uncertain. We are not currently a party to any material legal proceedings.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_4_mine_safety_disclosures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 4. Mine Saf</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ety Disclosures</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_ii"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART II</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_5_market_for_registrants_common_equ"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 5. Market for Registrant&#8217;s Common Equity, Related Stock</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">holder Matters and Issuer Purchases of Equity Securities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Market for our Common Stock</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our common stock is listed on the Nasdaq under the symbol &#8220;ARCT&#8221;.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Holders of Common Stock</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of March 3, 2025, there were nine registered holders of record of our common stock. Because many of our outstanding shares are held in accounts with brokers and other institutions, the number of beneficial owners is significantly greater than the number of record holders. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dividends</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have never declared or paid any cash dividends on our common stock. We currently intend to retain all available funds and any future earnings to support our operations and finance the growth and development of our business. Any future determination related to our dividend policy will be made at the discretion of the Board and will depend upon, among other factors, our results of operations, financial condition, capital requirements, contractual restrictions, business prospects and other factors the Board may deem relevant.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock Performance Graph</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following graph compares the Company&#8217;s cumulative stockholder return since December 31, 2019 with the Nasdaq Composite Index, and the Nasdaq Biotechnology Index. The graph is based on the assumption that $100 had been invested in Company common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img267189834_13.jpg" alt="img267189834_13.jpg" style="width:545px;height:322px;"/></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">68</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities Authorized for Issuance under Equity Compensation Plans</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Information about our equity compensation plans is incorporated herein by reference to Item 12 of Part III of this Annual Report.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recent Sales of Unregistered Securities</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Purchases of Equity Securities by the Issuer and Affiliated Purchasers</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_6_selected_financial_data"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 6. </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reserved</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">69</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_7_managements_discussion_analysis_f"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 7. Management&#8217;s Discussion and Analysis of </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial Condition and Results of Operations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">You should read the following discussion and analysis together with the consolidated financial statements and related notes included elsewhere herein.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">This report includes forward-looking statements which, although based on assumptions that we consider reasonable, are subject to risks and uncertainties which could cause actual events or conditions to differ materially from those currently anticipated and expressed or implied by such forward-looking statements.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Discussions of 2022 items and year-to-year comparisons between 2023 and 2022 that are not included in this Form 10-K can be found within Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the year ended December 31, 2023.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Overview</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. We developed the world&#8217;s first approved self-amplifying messenger RNA (sa-mRNA) vaccine, KOSTAIVE&#174; (&#8220;KOSTAIVE&#8221;). KOSTAIVE achieved approval in Japan in 2023 as a vaccine against COVID-19. Sales of KOSTAIVE began in Japan in October 2024, marking our transition to a commercial stage company.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have several key platform technologies that we leverage to develop and advance a pipeline of mRNA-based vaccines and therapeutics for infectious diseases and for rare genetic disorders with significant unmet medical needs. Current mRNA medicines have two critical components: the messenger RNA (&#8220;mRNA&#8221;) constructs and the lipid nanoparticles (&#8220;LNP&#8221;) which help deliver the mRNA to disease-relevant target tissues. We believe we are among the world leaders in both areas. We have extensive expertise in the design and optimization of mRNA constructs, including with respect to a type of mRNA technology known as self-amplifying mRNA (sa-mRNA). Our proprietary self-amplifying mRNA technology platform, or STARR&#174; (&#8220;STARR&#8221;), has been demonstrated to induce a longer-lasting and broader humoral immune response at lower dose levels than conventional mRNA-based vaccines. Our proprietary LNP delivery system, LUNAR&#174; (&#8220;LUNAR&#8221;), is intended to address the major hurdle in RNA drug development, namely the effective and safe delivery of RNA therapeutics to disease-relevant target tissues. LUNAR may enable multiple nucleic acid medicines. The approval of KOSTAIVE in Japan was a significant milestone which validates our LUNAR and STARR platforms, as well as sa-mRNA more generally as a meaningful modality. Finally, we have significant expertise and valuable know-how in the development and scalability of complex and robust manufacturing processes required to deliver the next generation of nucleic acid medicines.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our internal pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF), both rare diseases. In our vaccine program, we have partnered with Seqirus, Inc. (&#8220;CSL Seqirus&#8221;), a part of CSL Limited and one of the world&#8217;s leading influenza vaccine providers, on the development and commercialization of mRNA vaccines for COVID-19, influenza and certain other infectious diseases.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> We made significant progress in 2024. Commercial sales of KOSTAIVE began in October 2024 in Japan by Meiji Seika Pharma (&#8220;Meiji&#8221;), CSL Seqirus&#8217; exclusive partner in Japan, marking the first commercial sales of an Arcturus-developed product. In February 2025, we received approval of KOSTAIVE from the European Commission (EC), which provided further validation of our platform by another significant regulatory authority.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">KOSTAIVE is the brand name approved in Japan and Europe for ARCT-154, which is the version of the sa-mRNA COVID vaccine encoding the ancestral strain of SARS-CoV-2, and also for updated variant-specific versions of this vaccine. We may use KOSTAIVE or the specific internally generated name, such as ARCT-154, ARCT-2301 and ARCT-2303, to identify a version of the vaccine.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> We initiated dosing in a Phase 1 clinical trial of a novel seasonal influenza sa-mRNA vaccine candidate under our collaboration with CSL Seqirus in January 2024. In December 2024, we initiated dosing of an sa-mRNA vaccine candidate against pandemic avian influenza (bird flu) in a Phase 1 trial funded by the Biomedical Advanced Research and Development Authority (&#8220;BARDA&#8221;).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In our OTC program, we completed dosing of eight subjects in August 2024 in a Phase 2 double-blind multiple-dose study of ARCT-810. In the second quarter of 2024, we expanded the Phase 2 clinical program of ARCT-810 with an open-label, multiple-dose study which initiated dosing in December 2024. ARCT-810 has</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">70</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">received Orphan Drug Designation from the FDA and Orphan Medicinal Product Designation from the European Medicines Agency (the &#8220;EMA&#8221;) for treatment of OTC deficiency, as well as Fast Track Designation and Rare Pediatric Disease Designation from the FDA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In our CF program, we initiated dosing in December 2024 in a Phase 2 multiple ascending dose study of ARCT-032 designed to identify a safe and effective dose in people with Class I (null) CFTR mutations and other CF patients who do not benefit from CFTR modulators. In July 2024, we completed dosing and follow-up visits for seven participants in a safety and tolerability Phase 1b clinical study in New Zealand of ARCT-032 in adults with CF.   ARCT-032 has received Orphan Drug Designation by the FDA and Orphan Medicinal Product Designation by the EMA for the treatment of CF, and Rare Pediatric Disease Designation from the FDA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also improved our platform technologies and advanced our early-stage research activities and manufacturing process development and operations. We conducted exploratory platform development activities, including the evaluation of genome editing, and new targeting approaches, where our LUNAR and STARR platforms could potentially be useful for identification and development of additional products for our portfolio. Also, with our sourcing partners, we manufactured cGMP (current good manufacturing practices) batches yielding significant quantities of clinical trial materials for global studies of our candidates, and with our collaborator, CSL Seqirus, we have established commercial production processes for the COVID-19 vaccine program.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our activities since inception have consisted principally of performing research and development activities, clinical research activities, general and administrative activities and raising capital to fund those efforts. Our activities are subject to significant risks and uncertainties, including failing to secure additional funding before we achieve sustainable revenues and profit from operations. As of December 31, 2024, we had an accumulated deficit of $448.8 million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Liquidity and Capital Resources</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From the Company&#8217;s inception through the year ended December 31, 2024, the Company has funded its operations principally with the proceeds from revenues earned through collaboration agreements and government contracts, the sale of capital stock and long-term debt. During fiscal year 2024, we received milestone payments totaling $96.0 million from CSL Seqirus. We expect to receive future payments from CSL Seqirus primarily by meeting future milestones related to the CSL Collaboration Agreement. At December 31, 2024, the Company&#8217;s balance of cash and cash equivalents, including restricted cash, was $293.9 million.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">CSL Seqirus, Inc. Collaboration and License Agreement</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In 2022, we entered into the CSL Collaboration Agreement with CSL Seqirus, a part of CSL Limited, one of the world&#8217;s leading influenza vaccine providers, for the global exclusive rights to research, develop, manufacture and commercialize mRNA vaccines.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CSL Seqirus received exclusive global rights to our technology for vaccines against SARS-CoV-2 (COVID-19), influenza and three other infectious diseases with non-exclusive rights to pandemic pathogens. We received an up-front payment of $200.0 million during the fourth quarter of 2022. We will be eligible to receive development milestones totaling more than $1.3 billion if all products are registered in the licensed fields. We will also be entitled to receive up to $3.0 billion in commercial milestones based on &#8220;net sales&#8221; of vaccines in the various fields.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we are entitled to receive a 40% share of net profits from COVID-19 vaccine sales and up to low double-digit royalties of annual net sales for vaccines against influenza and the other three specified infectious disease pathogens, as well as royalties on revenues from vaccines that may be developed for pandemic preparedness.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The CSL Collaboration Agreement sets forth how CSL Seqirus and we shall collaborate to research and develop vaccine candidates. In the COVID-19 field, we will lead activities for certain regulatory filings for ARCT-154 in the US and Europe and for research and development activities of a next-generation COVID vaccine candidate. CSL Seqirus will lead and be responsible for all other research and development in COVID-19, influenza and the other fields.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Wells Fargo Credit Agreement</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 21, 2023, the Company&#8217;s wholly-owned subsidiary, Arcturus Therapeutics, Inc. entered into a credit agreement with Wells Fargo Bank, National Association (&#8220;Wells Fargo&#8221;) whereby Wells Fargo agreed to make a $50.0 million revolving credit line available to the Company (as amended, the &#8220;Wells Fargo Loan&#8221;) with each Wells Fargo Loan evidenced by a revolving line of credit note (each, a &#8220;Note&#8221;). On June 26, 2024, the parties entered into</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">71</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amendment No. 1 to the Wells Fargo Loan, whereby the term was extended by one year to April 2026. As of December 31, 2024, no borrowings were made against the Wells Fargo Loan.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Borrowings under the agreement will bear interest at a rate of 1.00% above either the Daily Simple SOFR or Term SOFR (as such terms are defined in the Wells Fargo Loan), with &#8220;SOFR&#8221; being the rate per annum equal to the secured overnight financing rate as administered by the Federal Reserve Bank of New York. If an Event of Default (as defined in the credit agreement) occurs, then all Wells Fargo Loans shall bear interest at a rate equal to 2.00% above the interest rate applicable immediately prior to the occurrence of the Event of Default.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The original term of the agreement is two years, with an option for one-year renewals subject to Wells Fargo approval and the Company furnishing to Wells Fargo a non-refundable commitment fee equal to 0.25% of the Wells Fargo Loan amount for each such renewal. There is no penalty for terminating the agreement. There is no penalty for terminating the facility prior to the maturity date of the Wells Fargo Loan. As collateral, the Company has agreed to pledge $55.0 million in cash to be held at the Company&#8217;s securities accounts with Wells Fargo Securities, LLC, an affiliate of Wells Fargo, pursuant to a security agreement.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Grant from the Biomedical Advanced Research and Development Authority</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On August 31, 2022, we entered into a cost reimbursement contract (the &#8220;BARDA Contract&#8221;) with the Biomedical Advanced Research and Development Authority (&#8220;BARDA&#8221;), a division of the Office of the Assistant Secretary for Preparedness and Response (&#8220;ASPR&#8221;) within the U.S. Department of Health and Human Services (&#8220;HHS&#8221;) to support the development of a low-dose pandemic influenza candidate based on our proprietary self-amplifying messenger RNA-based vaccine platform. The BARDA Contract is to support our non-clinical and pre-clinical development, early-stage clinical development through Phase 1, and associated drug product manufacturing, regulatory and quality-assurance activities over a period of three years. It provides for reimbursement by BARDA of our permitted costs up to $63.2 million. As of December 31, 2024, the remaining available funding net of revenue earned was $40.0 million.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Vinbiocare Agreement</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During 2021, we entered into a technology license and technical support agreement and the framework drug substance supply agreement with Vinbiocare, a member of Vingroup Joint Stock Company (collectively, the &#8220;Vinbiocare License &amp; Supply Agreements&#8221;), whereby we would provide technical expertise and support services to Vinbiocare to assist in the build out of an mRNA drug product manufacturing facility in Vietnam. We received an upfront payment in aggregate of $40.0 million as part of the Vinbiocare License and Supply Agreements. In October 2022, in association with the termination of the Vinbiocare License and Supply Agreements, we signed the Vinbiocare Support Agreement with Vinbiocare which continues Vinbiocare&#8217;s clinical obligations and reserved a portion of the original $40.0 million upfront payment received from the License and Supply Agreements to be paid over the future periods.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Vinbiocare Support Agreement requires us to pay to Vinbiocare certain limited payments, including upon the occurrence of specified events through the first quarter of 2025. Vinbiocare is also eligible to receive a single digit percentage of amounts received by Arcturus on net sales, if any, of ARCT-154 (or next-generation COVID vaccine) up to a capped amount.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">General Financial Resources</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A portion of our current cash balance is expected to be utilized during fiscal year 2025 to fund (i) the continued Phase 2 trial of ARCT-810, our LUNAR-OTC candidate, (ii) advances to our LUNAR-CF program in clinical trials, (iii) expenses incurred prior to customer payments under the CSL Collaboration Agreement and BARDA agreement and (iv) continued exploratory activities related to our platform and other general administrative activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our future capital requirements are difficult to forecast and will depend on many factors that are out of our control. If we are unable to maintain sufficient financial resources, our business, financial condition and results of operations will be materially and adversely affected. There can be no assurance that we will be able to obtain additional needed financing on acceptable terms or at all. Additionally, equity or debt financings may have a dilutive effect on the holdings of our existing shareholders.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">72</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect to continue to incur additional losses in the long term, and we will need to execute on milestones within the CSL Collaboration Agreement, raise additional debt or equity financing or enter into additional partnerships to fund development. Our ability to transition to profitability is dependent on regulatory approvals and subsequent sales of KOSTAIVE, executing on milestones within the CSL Collaboration Agreement and identifying and developing other successful mRNA drug and vaccine candidates. If we are not able to achieve planned milestones or incur costs in excess of our forecasts, we will need to reduce discretionary spending, discontinue the development of some or all of our programs, which will delay part of our development programs, all of which will have a material adverse effect on our ability to achieve our intended business objectives.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Funding Requirements</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We anticipate that we will continue to generate losses for the foreseeable future, and we expect the losses to increase as we continue the development of, and seek regulatory approvals for, our product candidates, and begin commercialization of our products. As a result, we will require additional capital to fund our operations in order to support our long-term plans. We believe that our current cash position will be sufficient to meet our anticipated cash requirements through at least the next twelve months, assuming, among other things, no significant unforeseen expenses and continued funding from partners at anticipated levels. We intend to seek additional capital through equity and/or debt financings, collaborative or other funding arrangements with partners or through other sources of financing when and as needed. Should we seek additional financing from outside sources, we may not be able to raise such financing on terms acceptable to us or at all. If we are unable to raise additional capital when required or on acceptable terms, we may be required to scale back or discontinue the advancement of product candidates, reduce headcount, liquidate our assets, file for bankruptcy, reorganize, merge with another entity, or cease operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our future funding requirements are difficult to forecast and will depend on many factors, including but not limited to the following:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the development of our LUNAR-COV19 and LUNAR-FLU vaccine candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the achievement of milestones under our strategic alliance agreements;  </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">maintaining and/or expanding our manufacturing network and capabilities;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the terms and timing of any other strategic alliance, licensing and other arrangements that we may establish, including those with CSL Seqirus and CSL Seqirus&#8217; arrangement with Meiji, and any related payments thereunder; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the initiation, progress, timing and completion of preclinical studies and clinical trials for our product candidates;  </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the number and characteristics of product candidates that we pursue;  </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the outcome, timing and cost of regulatory approvals;  </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays that may be caused by changing regulatory requirements;  </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost and timing of hiring new employees to support our continued growth;  </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs involved in filing and prosecuting patent applications and enforcing and defending patent claims;  </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs and timing of procuring clinical and commercial supplies of our product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs and timing of establishing sales, marketing and distribution capabilities;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs associated with legal proceedings;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs associated with potential litigation related to collaboration agreements; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the extent to which we acquire or invest in businesses, products or technologies.</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">73</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table shows a summary of our cash flows for the years ended December 31, 2024 and 2023:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:67.313%;box-sizing:content-box;"/>
    <td style="width:1.5%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.843%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.5%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.843%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash provided by (used in):</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating activities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(59,747</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(18,099</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Investing activities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(648</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(2,901</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Financing activities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,418</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(24,087</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net decrease in cash and restricted cash</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(54,977</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(45,087</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Operating Activities</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net cash used in operating activities was $59.7 million for the year ended December 31, 2024, compared to $18.1 million for the year ended December 31, 2023. The $41.6 million increase in cash used was primarily driven by a $93.8 million year-over-year impact from deferred revenue, as 2023 benefited from a $38.6 million deferred revenue inflow, while 2024 saw a $55.2 million outflow due to revenue recognition exceeding new milestone payments under the CSL collaboration agreement. Additionally, the increase in cash outflows was due to a higher net loss and the absence of a $34.0 million debt extinguishment gain recognized in 2023. These impacts were partially offset by a $57.4 million improvement in accounts receivable, as payments from CSL and BARDA were received in 2024 and a $6.5 million increase in accrued liabilities, primarily due to the timing of bonus accruals.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Investing Activities</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net cash used in investing activities of $0.6 million in 2024 and $2.9 million in 2023 reflected the acquisition of property and equipment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Financing Activities</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net cash provided by financing activities was $5.4 million for the year ended December 31, 2024, compared to a net cash outflow of $24.1 million in 2023 ,representing a $29.5 million increase. The primary drivers of this increase were the repayments of the Singapore Loan and the Loan and Security Agreement with Western Alliance Bank during 2023, with no similar debt repayments occurring in 2024.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Results of Operations</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the consolidated financial statements included in this Annual Report. Our historical results of operations and the year-to-year comparisons of our results of operations that follow are not necessarily indicative of future results.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenues</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We enter into arrangements with pharmaceutical and biotechnology partners and government agencies that may contain upfront payments, license fees for research and development arrangements, research and development funding, milestone payments, option exercise and exclusivity fees and royalties on future sales. The following table summarizes our total revenues for the periods indicated:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.75%;box-sizing:content-box;"/>
    <td style="width:1.121%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:9.187%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.121%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:9.187%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.121%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:8.847%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:9.667%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="8" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended December 31,</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change 2024 vs 2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">%</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Collaboration revenue</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">138,389</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">157,748</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(19,359</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-12</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Grant revenue</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,921</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,051</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,870</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">54</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">152,310</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">166,799</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(14,489</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-9</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue decreased by $14.5 million during the year ended December 31, 2024 as compared to the year ended December 31, 2023. The decrease during 2024 primarily relates to a $15.9 million decrease in revenue related to the CSL collaboration agreement, primarily due to an $82.0 million decrease in milestone achievements during 2024 as compared to 2023, offset by a $23.4 million increase in revenue related to CSL commercial supply agreements and increased revenue recognition from amortization due to the progress of the CSL development programs during 2024. The remaining decrease is primarily due to a decrease of $1.8 million related to the completion of the amortization of the upfront payment during 2023 from the 2015 Research Collaboration and License Agreement with Ultragenyx</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">74</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pharmaceuticals, Inc., as well as $0.7 million less revenue in 2024 due the termination of the 2017 Research Collaboration and License Agreement with Janssen Pharmaceuticals, Inc. The decrease was primarily offset by an increase in the revenue of $4.8 million related to the increase in reimbursable research and development expenses for the grant agreement with BARDA.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating Expenses</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our operating expenses consist of research and development and general and administrative expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.75%;box-sizing:content-box;"/>
    <td style="width:1.121%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:9.187%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.121%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:9.187%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.121%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:8.847%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:9.667%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended December 31,</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change 2024 vs 2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">%</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development, net</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">195,156</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">192,133</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,023</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">52,823</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">52,871</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(48</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">247,979</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">245,004</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,975</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents our total research and development expenses by category:</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Expenses, net</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.75%;box-sizing:content-box;"/>
    <td style="width:1.121%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:9.187%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.121%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:9.187%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.121%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:8.847%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:9.667%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change 2024 vs 2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">%</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">LUNAR-COVID</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">70,464</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">81,262</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(10,798</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-13</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">LUNAR-OTC</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,509</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,315</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">194</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">BARDA</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,807</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,465</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,342</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">LUNAR-CF, net</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,227</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,666</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,561</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Early-stage programs</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,096</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,460</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,636</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Discovery technologies</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,278</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,405</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(127</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-2</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Payroll and benefits</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57,474</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50,924</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,550</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Facilities and equipment</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,301</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,636</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(1,335</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-11</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total research and development expenses, net</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">195,156</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">192,133</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,023</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our research and development expenses consist primarily of external manufacturing costs, in-vivo research studies and clinical trials performed by contract research organizations, clinical and regulatory consultants, personnel related expenses, facility related expenses and laboratory supplies related to conducting research and development activities. Research and development expenses were $195.2 million for the year ended December 31, 2024, compared with $192.1 million for the year ended December 31, 2023, primarily reflecting increased payroll and benefits costs due to share-based compensation expense, progress within our BARDA, LUNAR-CF, and LUNAR-FLU programs, and clinical trial costs for the LUNAR-COVID program. The overall increase was offset by decreased manufacturing-related expenses due to lower costs associated with drug product supply agreements related to the LUNAR-COVID program during the year ended December 31, 2024. We expect that our research and development efforts and associated costs will continue to be substantial over the next several years as our pipeline progresses.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Early-stage programs represent programs that are in the pre-clinical or Phase 1 clinical stage and may be partnered or unpartnered, and primarily includes the LUNAR-FLU program which is partnered with CSL Seqirus. Discovery technologies represent our efforts to expand our product pipeline and are primarily related to pre-partnered studies and new capabilities assessment. A few of our programs are part of our collaborative relationships. The related expenses may be partially offset with funds that have been reimbursed or awarded to the Company and consist of external manufacturing costs, lab supplies, equipment, and consulting and professional fees. Expenses for both early-stage programs and discovery technologies are expected to decrease as we shift our focus to later-stage programs.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Payroll and benefits primarily consists of employee salaries and benefits, share-based compensation and consultant costs. Although such expenses increased during 2024 as compared to 2023, we expect that they will not increase over the next twelve months due to reduced share-based compensation.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">75</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Facilities and equipment expenses include rent, common area maintenance (&#8220;CAM&#8221;) costs, depreciation, shipping costs and various other costs related to the operation of our two office and laboratory locations. These costs decreased during 2024 as compared to 2023 as we downsized from three to two facilities. Facilities and equipment expenses are not expected to increase during the next twelve months.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">General and Administrative Expenses</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General and administrative expenses consist primarily of salaries and related benefits for our executive, administrative and accounting functions and professional service fees for legal and accounting services as well as other general and administrative expenses.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General and administrative expenses were $52.8 million and $52.9 million for the years ended December 31, 2024 and 2023, respectively. We expect that general and administrative expenses will decrease slightly during the next twelve months due to reduced share-based compensation from fully vested stock options.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Finance income (expense), net</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.75%;box-sizing:content-box;"/>
    <td style="width:1.121%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:9.187%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.121%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:9.187%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.121%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:8.847%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:9.667%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended December 31,</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change 2024 vs 2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">%</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest income</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,195</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,359</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(2,164</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-12</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest expense</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(768</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">768</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-100</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,195</span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,591</span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(1,396</span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-8</span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interest income is generated on cash and cash equivalents. The decrease in interest income from 2023 to 2024 was the result of lower interest rates during the year ended 2024 and a decrease in cash and cash equivalents.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interest expense decreased during the year ended 2024 as compared to the year ended 2023 as no interest expense has been incurred since to the first quarter of 2023. This was a result of the extinguishment of the Loan and Security Agreement dated October 12, 2018 with Western Alliance Bank, and forgiveness of the term loan from Economic Development Board of the Republic of Singapore pursuant to the Manufacturing Support Agreement dated November 7, 2020.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Critical Accounting Policies and Estimates</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our significant accounting policies are summarized in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#8220;Note 2 Summary of Significant Accounting Policies,&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> included in our consolidated financial statements included elsewhere in this annual report on Form 10-K.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The preparation of our consolidated financial statements in conformity with &#8220;GAAP&#8221; requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the reporting period. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, assumptions related to revenue recognition, accrual of research and development expenses, determination of incremental borrowing rates, and the valuations of stock options. We based our estimates on historical experience, known trends and other market-specific or other relevant factors that we believe to be reasonable under the circumstances. On an ongoing basis, management evaluates these estimates when there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue Recognition</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We recognize revenue when control of the products and services is transferred to our customers in an amount that reflects the consideration we expect to receive from our customers in exchange for those products and services. This process involves identifying the contract with a customer, determining the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct performance obligations in the contract, and recognizing revenue when the performance obligations have been satisfied.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our collaboration agreements typically contain promised goods and services, including technology licenses or options to obtain technology licenses, research and development and regulatory services. Upon entering into a collaboration agreement, we are required to make the following judgments:</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">76</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Identifying the performance obligations and measuring progress</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our assessment of what constitutes a separate performance obligation requires us to apply judgment. Specifically, we are required to identify which goods and services we are required to provide under the contract are distinct, if any. For performance obligations that are satisfied over time, we typically use the percentage-of-completion method which requires us to estimate the total forecasted costs required to complete the performance obligation. Adjustments to these estimates could materially impact the timing and amount of recognized revenue. If actual costs exceed initial estimates, revenue recognized to date may need to be adjusted downward, negatively impacting current period results. Conversely, favorable cost variances could accelerate revenue recognition.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Determining the transaction price, including any variable consideration</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To determine the transaction price, we review the amount of consideration we are eligible to earn under the agreement. We apply a constraint to any payments we may receive in the future to avoid significant reversals since the payments are typically not probable because they are contingent upon certain future events.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are required to reassess the total transaction price at each reporting period to determine if we should include additional payments that have become probable in the transaction price.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Allocating the transaction price to each of our performance obligations</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">When we allocate the transaction price to more than one performance obligation, we make estimates of the relative stand-alone selling price of each performance obligation because we do not typically sell our goods or services on a stand-alone basis. The estimate of the relative stand-alone selling price requires us in some cases to make significant judgments. In cases where we deliver a license at the start of an agreement, we use valuation methodologies, such as costs to recreate plus margin, to value the license. Additionally, when we estimate the selling price for research and development and regulatory services, we make estimates, including: the number of internal hours we will spend on the services, the cost of work we and third parties will perform and the cost of clinical trial material we will use.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The revenue we recognize each period is comprised of several types of revenue, including license fees, amortization from upfront payments, milestone payments, research and development and other services. Each of these types of revenue require us to make various judgments and estimates.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Amortization from Upfront Payments</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For certain agreements, we recognize revenue from the amortization of upfront payments as we perform research and development, technology transfer and consulting services. We use an input method to estimate the amount of revenue to recognize each period. This method requires us to make estimates of the total costs we expect to incur in order to complete our promised research and development services or the total length of time it will take us to complete our promised research and development services. If we change our estimates, we may have to adjust our revenue.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Milestone Payments</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">When recognizing revenue related to milestone payments, we typically judge and estimate whether the milestone payment is probable (discussed in detail above under &#8220;Determining the transaction price, including any variable consideration&#8221;).</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">License Fees</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In some cases, we deliver a license upon execution of an agreement. If we determine that our partner has full use of the license and we do not have any additional material performance obligations related to the license after delivery, then we consider the license to be a separate performance obligation. We generally recognize as license revenue the total amount of the transaction price we determine to be allocated to the performance obligation based upon the relative stand-alone selling price of a license when we deliver the license to our partner. We discuss the estimates we make related to the relative stand-alone selling price of a license in detail above under &#8220;Allocating the transaction price to our performance obligations.&#8221;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">77</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Expenses, Including Clinical Trial Accruals/Expenses</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development costs consist of salaries and benefits, including share-based compensation, laboratory supplies and facility costs, as well as fees paid to other entities that conduct certain research and development activities on our behalf, such as clinical research organizations, or CROs, and contract manufacturing organizations, or CDMOs. Research and development costs are expensed as incurred.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clinical trial expenses are a significant component of research and development expenses, and we outsource a significant portion of these clinical trial activities to third parties. Third-party clinical trial expenses include investigator fees, site and patient costs, CRO costs, and costs for central laboratory testing and data management. The accrual for site and patient costs includes inputs such as estimates of patient enrollment, patient cycles incurred, clinical site activations, and other pass-through costs. These inputs are required to be estimated due to a lag in receiving the actual clinical information from third parties. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected on the balance sheets as prepaid assets or accrued expenses. These third-party agreements are generally cancelable, and related costs are recorded as research and development expenses as incurred. Non-refundable advance clinical payments for goods or services that will be used or rendered for future research and development activities are recorded as a prepaid asset and recognized as expense as the related goods are delivered or the related services are performed. When evaluating the adequacy of the accrued expenses, we analyze progress of the studies, including the phase or completion of events, invoices received and contracted costs. We make estimates of our accrued balances as of each balance sheet date based on facts and circumstances known to our internal personnel at that time. We periodically confirm the accuracy of our estimates with the service providers and make adjustments if necessary. Judgments and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ from the estimates made. Our historical clinical trial accrual estimates have not been materially different from our actual costs.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot readily determine the interest rate implicit in the lease, therefore, we use our incremental borrowing rate to measure lease liabilities. The incremental borrowing rate is the rate of interest that we would have to pay to borrow over a similar term, and with a similar security, the funds necessary to obtain an asset of a similar value to the right-of-use, or ROU, asset in a similar economic environment. The incremental borrowing rate therefore reflects what we &#8216;would have to pay&#8217;, which requires estimation when no observable rates are available or when they need to be adjusted to reflect the terms and conditions of the lease. We estimate the incremental borrowing rate using observable inputs (such as market interest rates) when available and are required to make certain entity and asset-specific estimates. The incremental borrowing rate used in the calculation of the present value of lease payments in calculating lease liabilities and the corresponding ROU requires the use of significant judgment by management.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Share-Based Compensation</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We recognize compensation expense related to stock options granted to employees and nonemployees based on the estimated grant date fair value and recognize forfeitures as they occur. We estimate the grant date fair value, and the resulting share-based compensation expense, using the Black-Scholes option-pricing model for service-based and performance-based awards. The grant date fair value of the share-based awards is recognized on a straight-line basis over the requisite service period, which is typically the vesting period of the respective awards. The Black-Scholes option-pricing model requires the use of highly subjective assumptions to determine the fair value of share-based awards. Such assumptions involve inherent uncertainties and the application of significant judgment. As a result, if factors or expected outcomes change and we use significantly different assumptions or estimates, our share-based compensation could be materially different.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_7a_quantitative_qualitative_disclos"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 7A. Quantitative and Qualitat</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ive Disclosures About Market Risk</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our primary exposure to market risk is interest income and expense sensitivity, which is affected by changes in the general level of United States interest rates. Due to the nature of our investments, we believe that we are not subject to any material market risk exposure. We do not hold a material balance in foreign currencies or engage in derivative financial instruments that could materially impact our financial position.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">78</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_8_financial_statements_supplementar"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 8. Financial Statement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s and Supplementary Data</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The consolidated financial statements and related financial statement schedules required to be filed are listed in the Index to Consolidated Financial Statements and are incorporated herein and in Item 15 of Part IV of this Annual Report on Form 10-K.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9_changes_in_disagreements_with_acc"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9. Changes in and Disagreements with Accou</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ntants on Accounting and Financial Disclosure</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9a_controls_procedures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9A. Controls</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and Procedures</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Evaluation of Disclosure Controls and Procedures</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our disclosure controls and procedures (as defined in Rules 13a-15(e) or 15d-15(e) under the Exchange Act are designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC&#8217;s rules and forms and to ensure that information required to be disclosed is accumulated and communicated to management, including our principal executive and financial officers, to allow timely decisions regarding disclosure. Our Chief Executive Officer and Chief Financial Officer, with assistance from other members of management, have reviewed the effectiveness of our disclosure controls and procedures as of December 31, 2024, and, based on their evaluation, have concluded that the disclosure controls and procedures were not effective as of such date due to the material weakness in internal control over financial reporting, described below.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Management&#8217;s Report on Internal Control Over Financial Reporting</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management is responsible for establishing and maintaining an adequate system of internal control over financial reporting and for the assessment of the effectiveness of internal control over financial reporting as defined in Rule 13a-15(f) under the Exchange Act. Our internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with &#8220;U.S. GAAP&#8221; and includes those policies and procedures that: (1) pertain to the maintenance of records that accurately and fairly reflect our transactions and the dispositions of our assets; (2) provide reasonable assurance that our transactions are recorded as necessary to permit preparation of financial statements in accordance with &#8220;GAAP&#8221; and that our receipts and expenditures are being made only in accordance with appropriate authorizations; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on our financial statements.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management, under the supervision of and with the participation of the Chief Executive Officer and Chief Financial Officer, assessed the effectiveness of our internal control over financial reporting as of December 31, 2024. In making this assessment, management used the criteria established in Internal Control&#8212;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (&#8220;the COSO criteria&#8221;).</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on our assessment under the COSO criteria, management concluded that our system of internal control over financial reporting was not effective due to the material weakness described below. However, after giving full consideration to the material weakness, and the additional analyses and other procedures we performed to ensure that our consolidated financial statements included in this Annual Report on Form 10-K were prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;), our management has concluded that our consolidated financial statements present fairly, in all material respects, our financial position, results of operations and cash flows for the periods disclosed in conformity with &#8220;GAAP&#8221;.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company&#8217;s annual or interim financial statements will not be prevented or detected on a timely basis.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Previously Reported Material Weaknesses and Remediation Plans</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As reported in Part II, Item 9A. &#8220;Controls and Procedures&#8221; of our Annual Reports on Form 10-K for the fiscal year ended December 31, 2023, we identified a material weakness related to information technology general controls (&#8220;ITGCs&#8221;) that support the financial reporting process. Specifically, the material weakness relates to ineffective controls over (i) user access to ensure appropriate segregation of duties and adequate restriction of user</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">79</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and privileged access to financial applications, programs and data, to the appropriate personnel; (ii) program change management for financial applications to ensure that information technology (&#8220;IT&#8221;) program and data changes affecting financial IT applications and underlying accounting records are identified, tested, authorized and implemented appropriately; and (iii) IT operations controls to ensure that critical interface jobs are monitored.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Management has made significant enhancements to the Company&#8217;s process related to access provisioning and de-provisioning, program change management, as well as IT operations. Management has implemented or is in the process of implementing new or enhanced internal control procedures intended to both address the material weakness identified and strengthen our overall financial control environment, including:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">updated and enhanced the IT policies and relevant internal controls to consider and address ITGCs including access security and change management.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">limited elevated access profiles in financially relevant IT systems and software to appropriate personnel;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">developing and enhancing access administration controls over provisioning, deprovisioning, and authentication; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">developing and enhancing user access reviews for financially relevant IT systems;  </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">designing and refining controls over change management and IT operations controls to monitor critical interface jobs;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">hired an internal audit manager with an appropriate level of knowledge and experience; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">engaged an accounting advisory firm to assist with the documentation, evaluation, remediation, and testing of our internal control over financial reporting; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided training to control owners and relevant personnel to improve documentation that supports effective control activities, including evidence over the completeness and accuracy of information used in controls.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While significant progress has been made to remediate this material weakness, management does not believe that these corrective measures have been either fully implemented or operating for a sufficient period of time to enable management to conclude that these internal controls over financial reporting are operating effectively and are fully implemented to remediate this material weakness. When fully implemented and operational, we believe the measures described above will remediate the material weakness. We are committed to making the necessary changes and improvements to our system of controls to address the material weakness in internal control over financial reporting described above.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, as previously reported in Part II, Item 9A. &#8220;Controls and Procedures&#8221; of our Annual Reports on Form 10-K for the fiscal year ended December 31, 2023, we identified a material weakness related to revenue recognition. Specifically, control activities related to the review of costs incurred in satisfaction of performance obligations under collaboration agreements did not operate effectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have completed the execution of our remediation plan for this material weakness and, as of December 31, 2024, successfully remediated the material weakness by implementing the following measures:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">designed and implemented enhanced control activities over the identification of and accounting assessment of key terms and conditions of all revenue collaboration agreements; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">designed and implemented new control activities around the technical review of quarterly and annual revenue recognition; specifically, (i) verifying the completeness of revenue arrangements and collaboration agreements subject to quarterly measurement of progress toward the satisfaction of the relevant performance obligations and (ii) validating that the measurement of progress, including the measurement of costs incurred for satisfaction of performance obligations, are consistent with the technical conclusions reached within the corresponding technical memo;</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">80</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">engaged a technical accounting consultant to review our revenue accounting and financial disclosures for collaboration arrangements, as needed; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided training to control owners and relevant personnel to improve documentation that supports effective control activities, including evidence over the completeness and accuracy of information used in controls.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These steps are subject to ongoing senior management review, as well as oversight by the Audit Committee of our Board of Directors.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our independent registered public accounting firm, Deloitte &amp; Touche LLP, has issued a report on the effectiveness of our internal control over financial reporting as of December 31, 2024, which is included in Item 8 of this Annual Report on Form 10-K.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Changes in Internal Control over Financing Reporting</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other than the changes associated with the material weaknesses and remediation actions noted above, there have been no changes to our internal control over financial reporting that occurred during the year ended December 31, 2024.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Inherent Limitations on Effectiveness of Disclosure Controls and Procedures, and Internal Controls Over Financial Reporting</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management, including our principal executive officer and principal financial officer, does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of the controls. The design of any system of controls is also based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Due to inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Report of Independent Registered Public Accounting Firm</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the Stockholders and the Board of Directors of Arcturus Therapeutics Holdings Inc.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Opinion on Internal Control Over Financial Reporting</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have audited the internal control over financial reporting of Arcturus Therapeutics Holdings, Inc. and subsidiaries (the &#8220;Company&#8221;) as of December 31, 2024, based on criteria established in Internal Control &#8212; Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). In our opinion, because of the effect of the material weakness identified below on the achievement of the objectives of the control criteria, the Company has not maintained effective internal control over financial reporting as of December 31, 2024, based on criteria established in Internal Control &#8212; Integrated Framework (2013) issued by COSO.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated financial statements as of and for the year ended December 31, 2024, of the Company and our report dated March 6, 2025, expressed an unqualified opinion on those financial statements.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basis for Opinion</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management's Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">81</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Definition and Limitations of Internal Control Over Financial Reporting</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Material Weakness</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the company&#8217;s annual or interim financial statements will not be prevented or detected on a timely basis. The following material weakness has been identified and included in management's assessment:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company identified a material weakness related to information technology general controls (&#8220;ITGCs&#8221;) that support the financial reporting process. Specifically, the material weakness relates to ineffective controls over (i) user access to ensure appropriate segregation of duties and adequate restriction of user and privileged access to financial applications, programs and data to the appropriate personnel; (ii) program change management for financial applications to ensure that information technology (&#8220;IT&#8221;) program and data changes affecting financial IT applications and underlying accounting records are identified, tested, authorized and implemented appropriately; and (iii) IT operations controls to ensure that critical interface jobs are monitored.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This material weakness was considered in determining the nature, timing, and extent of audit tests applied in our audit of the consolidated financial statements as of and for the year ended December 31, 2024, of the Company, and this report does not affect our report on such financial statements.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/s/ Deloitte &amp; Touche LLP</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">San Diego, California</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 6, 2025</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">82</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9b_or_information"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9B. Other</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Information</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c59422c1-e81f-49bf-a009-6f369b761bb5" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="ecd:MtrlTermsOfTrdArrTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Rule 10b5-1 Trading Plans</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the year ended December 31, 2024, none of our directors or officers </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_40eb3675-6317-408d-8bc4-74a689942da3" contextRef="C_8bae3d05-d6e8-46f3-863e-be5c603f6fd1" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adopted </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f0c4a041-0522-4d0c-ad94-968c8a3958b8" contextRef="C_8bae3d05-d6e8-46f3-863e-be5c603f6fd1" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">terminated</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> a "Rule 10b5-1 trading arrangement" (as defined in Item 408 of Regulation S-K of the Exchange Act) intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act, other than as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8d40cb2c-8044-440e-9800-fac26b172807" contextRef="C_2acf2ac7-01e2-4268-a321-5c97d29be022" name="ecd:TrdArrIndName"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Keith C. Kummerfeld&#8217;s</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Rule 10b5-1 trading arrangement </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_042a8158-7df6-4da1-b54f-2a93126a8518" contextRef="C_2acf2ac7-01e2-4268-a321-5c97d29be022" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">terminated</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_701f6d36-b791-41d2-a6b2-7b063a5270de" contextRef="C_2acf2ac7-01e2-4268-a321-5c97d29be022" name="ecd:TrdArrTerminationDate"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 18, 2024</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> upon the effective date of his resignation. </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3b2149d1-072f-47d4-aed4-8c1ba48f8f2a" contextRef="C_3b5bfb69-0e34-4596-883d-6933762b5f1a" name="ecd:TrdArrIndName"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lance Kurata</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, our </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e6400d9d-12e7-43ef-872f-26fba874861d" contextRef="C_3b5bfb69-0e34-4596-883d-6933762b5f1a" name="ecd:TrdArrIndTitle"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chief Legal Officer</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3d487b55-57c6-49f0-98a3-0699b3c6546c" contextRef="C_3b5bfb69-0e34-4596-883d-6933762b5f1a" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adopted</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> a Rule 10b5-1 trading arrangement as of</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ad54e05f-807b-4e10-af88-00a470503d90" contextRef="C_3b5bfb69-0e34-4596-883d-6933762b5f1a" name="ecd:TrdArrAdoptionDate"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> June 12, 2024</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Mr. Kurata's trading arrangement provides for the exercise options to purchase up to an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ea9943e1-86a8-4fc2-b393-dff44888514c" contextRef="C_dbce4aac-da09-4a9a-bdad-eed2250c6e8b" name="ecd:TrdArrSecuritiesAggAvailAmt" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">35,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock and subsequent sale of such underlying shares of common stock, until </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4c8099ba-3f8e-4221-9044-5883af7359b6" contextRef="C_3b5bfb69-0e34-4596-883d-6933762b5f1a" name="ecd:TrdArrExpirationDate"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 12, 2025</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0ad909d2-8532-4c9c-a54e-27d72f88e315" contextRef="C_2a5b949d-4097-4151-8f74-d5142e6df00e" name="ecd:TrdArrIndName"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dr. Padmanabh Chivukula</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bc85d9f6-834c-431e-bcf3-cc1c89032f2e" contextRef="C_2a5b949d-4097-4151-8f74-d5142e6df00e" name="ecd:TrdArrIndTitle"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chief Scientific Officer and Chief Operating Officer</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, cancelled an existing Rule 10b5-1trading arrangement on November 11, 2024. Dr. Chivukula's trading arrangement provided for the sale of up to an aggregate of 152,000 shares of common stock. Subsequent to this, Dr. Chivukula </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a2b518a6-962c-4479-9d35-9c46fff780b4" contextRef="C_2a5b949d-4097-4151-8f74-d5142e6df00e" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">entered</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> into a new Rule 10b5-1 trading arrangement on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_61044f6e-99ad-48c8-8dde-458854000594" contextRef="C_2a5b949d-4097-4151-8f74-d5142e6df00e" name="ecd:TrdArrAdoptionDate"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">November 20, 2024</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The new trading arrangement provides for the sale of up to an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2efa1a6d-a3d1-4611-a0d3-46b7c07644a2" contextRef="C_170f1f48-3dbe-4cac-bfe3-571918df82a6" name="ecd:TrdArrSecuritiesAggAvailAmt" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">120,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_28c68eba-ea54-404a-a9d6-fb19a33b35b4;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">beginning on June 2, 2025 until </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_394bcec6-ac12-468f-a475-d861283cd18d" contextRef="C_2a5b949d-4097-4151-8f74-d5142e6df00e" name="ecd:TrdArrExpirationDate"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">November 10, 2025</span></ix:nonNumeric></span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There were no "non-Rule 10b5-1 trading arrangements" (as defined in Item 408 of Regulation S-K of the Exchange Act) </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_35eceb3d-99da-4dfe-ae09-c69feac4ba48" contextRef="C_8bae3d05-d6e8-46f3-863e-be5c603f6fd1" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adopted</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8a9483b2-1533-4a4a-832c-bb2f68fab83c" contextRef="C_8bae3d05-d6e8-46f3-863e-be5c603f6fd1" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">terminated</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> during the year ended December 31, 2024 by our directors and officers.</span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9c_disclosure_regarding_foreign"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9C. Disc</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">losure Regarding Foreign Jurisdictions that Prevent Inspections</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not Applicable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">83</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_iii"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART III</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_10_directors_executive_ficers_corpo"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 10. Directors, Executive Off</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">icers and Corporate Governance</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Information required </span><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">by this item will be contained in our Definitive Proxy Statement for our 2025 Annual Meeting of Stockholders, to be filed pursuant to Regulation 14A with the Securities and Exchange Commission within 120 days of December 31, 2024. Such information is incorporated herein by reference.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_11_executive_compensation"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 11. Executiv</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">e Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Information required by this item will be contained in our Definitive Proxy Statement for our 2025 Annual Meeting of Stockholders, to be filed pursuant to Regulation 14A with the Securities and Exchange Commission within 120 days of December 31, 2024. Such information is incorporated herein by reference.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_12_security_ownership_certain_benef"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 12. Security Ownership of Certain Beneficial Own</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ers and Management and Related Stockholder Matters</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Information required by this item will be contained in our Definitive Proxy Statement for our 2025 Annual Meeting of Stockholders, to be filed pursuant to Regulation 14A with the Securities and Exchange Commission within 120 days of December 31, 2024. Such information is incorporated herein by reference.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_13_certain_relationships_related_tr"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 13. Certain Relationships and Related</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Transactions, and Director Independence</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Information required by this item will be contained in our Definitive Proxy Statement for our 2025 Annual Meeting of Stockholders, to be filed pursuant to Regulation 14A with the Securities and Exchange Commission within 120 days of December 31, 2024. Such information is incorporated herein by reference.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_14_principal_accounting_fees_servic"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 14. Principal Accoun</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ting Fees and Services</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Information required by this item will be contained in our Definitive Proxy Statement for our 2025 Annual Meeting of Stockholders, to be filed pursuant to Regulation 14A with the Securities and Exchange Commission within 120 days of December 31, 2024. Such information is incorporated herein by reference.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">84</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_iv"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART IV</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_15_exhibits_financial_statement_sch"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 15. Exhibits, Financ</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ial Statement Schedules</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	 </span></p>
  <p style="margin-left:9.08%;text-indent:-5.248%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1)	The information required by this item is included in Item 8 of Part II of this Annual Report.;</span></p>
  <p style="margin-left:9.08%;text-indent:-5.248%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(2)	Financial statement schedules not listed above have been omitted because information required to be set forth therein is not applicable, not required, or the information required by such schedules is shown in the consolidated financial statements or the notes thereto.</span></p>
  <p style="margin-left:9.08%;text-indent:-5.248%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(3)	See the exhibit index preceding the signature pages to this Annual Report, which is incorporated by reference herein.</span></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	See the exhibit index preceding the signature pages to this Annual Report, which is incorporated by reference herein.</span></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	Not applicable.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_16_form_10k_summary"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 16. Form</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> 10-K Summary</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">85</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit Index</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:11.52%;box-sizing:content-box;"/>
    <td style="width:3%;box-sizing:content-box;"/>
    <td style="width:85.48%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:1pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #000000;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Description</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.1</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001768224/000119380520001508/e620125_ex1-1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Controlled Equity Offering&#8480; Sales Agreement, dated as of December 23, 2022 by and between Cantor Fitzgerald &amp; Co, Wells Fargo Securities, LLC and Arcturus Therapeutics Holdings Inc. Incorporated by reference to Exhibit 1.2 to Registration Statement on Form S-3 filed on December 23, 2022 (File No. 333269003).</span></a></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.2</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1768224/000119380523001112/e618839_ex1-1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment No. 1 to Controlled Equity Offering&#8480; Sales Agreement by and between Cantor Fitzgerald &amp; Co, Wells Fargo Securities, LLC, William Blair &amp; Company, L.L.C., and Arcturus Therapeutics Holdings Inc. Incorporated by reference to Exhibit 1.1 to Form 8-K filed on August 7, 2023</span></a><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">.</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.1</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001566049/000119312519077140/d721306ds4.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certificate of Incorporation. Incorporated by reference to Annex B to the proxy statement/prospectus which forms part of the Registration Statement on Form S-4 filed on March 18, 2019 (File No. 333-230353).</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">    </span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.2</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001768224/000119380520001470/e620104_ex3-1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certificate of Amendment, dated November 25, 2020. Incorporated by reference to Exhibit 3.1 to Form 8-K filed on November 25, 2020 (File No. 001-38942).</span></a></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.3</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001768224/000119380520000569/e619613_ex3-2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Bylaws of Arcturus Therapeutics Holdings Inc. Incorporated by reference to Exhibit 3.2 to the Company&#8217;s Registration Statement on Form S-3, filed with the SEC on May 8, 2020 (File No. 333-238139).</span></a></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1*</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="arct-ex4_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Description of Registrant&#8217;s Securities.</span></a></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1&#134;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001768224/000156459020011037/arct-ex101_364.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Indemnification Agreement. Incorporated by reference to Exhibit 10.1 to the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2019 filed on March 16, 2020 (File No. 001-38942).</span></a></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2&#134;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001768224/000119312519259220/d781986ddef14a.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated 2019 Omnibus Equity Incentive Plan. Incorporated by reference Exhibit 4.3 to the Registration Statement on Form S-8 filed on August 5, 2020 (File No. 001-38942).</span></a></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.3&#134;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001566049/000119380518001024/e618195_ex99-2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Arcturus Therapeutics Ltd. Amended and Restated Compensation Policy for Company Office Holders. Incorporated by reference to Exhibit 99.2 to the Company&#8217;s Report of Foreign Private Issuer on Form 6-K filed on July 27, 2018 (File No. 001-35932).</span></a></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.4**</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001566049/000156459018024268/arct-ex101_7.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Loan and Security Agreement, dated October 12, 2018, by and between Western Alliance Bank and Arcturus Therapeutics, Inc. Incorporated by reference to Exhibit 10.1 to the Company&#8217;s Report of Foreign Private Issuer on Form 6-K filed on October 15, 2018 (File No. 001-35932).</span></a></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.5**</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001566049/000156459018013460/arct-ex48_879.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Research and Exclusive License Agreement, by and between Arcturus Therapeutics, Inc. and Synthetic Genomics, Inc., effective October 24, 2017. Incorporated by reference to Exhibit 4.8 to Form 20-F filed on May 14, 2018 (File No. 001-35932).</span></a><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.6**</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001566049/000156459018013460/arct-ex411_878.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Letter Agreement, by and between Arcturus Therapeutics, Inc. and the Cystic Fibrosis Foundation, dated May 16, 2017.  Incorporated by reference to Exhibit 4.11 to Form 20-F filed on May 14, 2018 (File No. 001-35932).</span></a></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:4.0200000000000005pt;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.7**</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001768224/000156459019032166/arct-ex1016_165.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment No. 2 to Letter Agreement, by and between Arcturus Therapeutics, Inc. and the Cystic Fibrosis Foundation, dated August 1, 2019. Incorporated by reference to Exhibit 10.16 to Form 10-Q filed on August 14, 2019.</span></a></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">86</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:11.52%;box-sizing:content-box;"/>
    <td style="width:3%;box-sizing:content-box;"/>
    <td style="width:85.48%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:1pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #000000;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Description</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.8**</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001566049/000156459018016705/arct-ex414_7.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">License Agreement, by and between Arcturus Therapeutics, Inc., as successor-in-interest to Marina Biotech, Inc., and Protiva Biotherapeutics Inc., dated as of November 28, 2012. Incorporated by reference to Exhibit 4.14 to Form 20-F/A filed on July 10, 2018 (File No. 001-35932).</span></a></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.9**</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001566049/000156459019008092/arct-ex1014_583.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated Joint Venture, Research Collaboration and License Agreement, dated as of July 14, 2018 by and between Arcturus Therapeutics, Inc. and Providence Therapeutics, Inc. Incorporated by reference to Exhibit 10.14 to the Company&#8217;s Amendment No. 1 to Annual Report on Form 10-K for the year ended December 31, 2018 filed on April 10, 2019 (File No. 001-35932).</span></a></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.10</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001566049/000156459018013460/arct-ex46_882.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Lease Agreement, by and between Arcturus Therapeutics, Inc. and ARE-SD Region No. 44, LLC, dated October 4, 2017. Incorporated by reference to Exhibit 4.6 to Form 20-F filed on May 14, 2018 (File No. 001-35932).</span></a></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.11</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001768224/000156459020011037/arct-ex1023_426.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">First Amendment to Lease Agreement, by and between Arcturus Therapeutics Holdings Inc. and ARE-SD Region No. 44, LLC dated February 1, 2020. Incorporated by reference to Exhibit 10.23 to the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2019 filed on March 16, 2020 (File No. 001-38942).</span></a></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.12**</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001768224/000156459020011037/arct-ex1024_365.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Acceptance Letter, dated March 4, 2020, by and between Arcturus Therapeutics Holdings Inc. and the Economic Development Board of Singapore. Incorporated by reference to Exhibit 10.24 to the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2019 filed on March 16, 2020 (File No. 001-38942).</span></a></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.13**</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001768224/000156459020052527/arct-ex1033_98.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Manufacturing Support Agreement, dated November 7, 2020, by and between Arcturus Therapeutics Holdings Inc. and the Economic Development Board of Singapore. Incorporated by reference to Exhibit 10.33 to Quarterly Report on Form 10-Q filed on November 9, 2020 (File No. 001-38942).</span></a></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.14</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001768224/000119380520001498/e620119_ex10-1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Fourth Amendment to Loan and Security Agreement, dated December 1, 2020, by and between Arcturus Therapeutics, Inc. and Western Alliance Bank. Incorporated by reference to Exhibit 10.1 to Form 8-K filed on December 7, 2020 (File No. 001-38942).</span></a></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.15&#134;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001768224/000119380520000940/e619825_ex4-3.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">2020 Employee Stock Purchase Plan. Incorporated by reference to Exhibit 4.3 to Form S-8 filed on August 5, 2020 (File No. 001-38942).</span></a></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.16</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1768224/000156459021009872/arct-ex1029_392.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Second Amendment to Lease, by and between Arcturus Therapeutics, Inc. and ARE-SD Region No. 44, LLC, dated November 13, 2020. Incorporated by reference to Exhibit 10.29 to the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020 filed on March 1, 2020 (File No. 001-38942).</span></a></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.17</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1768224/000156459021009872/arct-ex1030_393.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Third Amendment to Lease, by and between Arcturus Therapeutics, Inc. and ARE-SD Region No. 44, LLC, dated February 25, 2021. Incorporated by reference to Exhibit 10.30 to the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020 filed on March 1, 2021 (File No. 001-38942).</span></a></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.18&#134;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1768224/000119380521000538/e620514_ex10-1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Arcturus Therapeutics Holdings Inc. Severance Policy for Executives. Incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed on April 26, 2021 (File No. 001-38942).</span></a></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.19&#134;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001768224/000119312519173808/d826633dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Employment Agreement, dated as of June 13, 2019, between the Company and Joseph Payne. Incorporated by reference to Exhibit 10.1 to Form 8-K12B filed on June 14, 2019 (File No. 001-38942)</span></a></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">87</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:11.52%;box-sizing:content-box;"/>
    <td style="width:3%;box-sizing:content-box;"/>
    <td style="width:85.48%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:1pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #000000;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Description</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.20&#134;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001768224/000119312519173808/d826633dex102.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Employment Agreement, dated as of June 13, 2019, between the Company and Andy Sassine. Incorporated by reference to Exhibit 10.2 to Form 8-K12B filed on June 14, 2019 (File No. 001-38942)</span></a></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.21&#134;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001768224/000119312519173808/d826633dex103.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Employment Agreement, dated as of June 13, 2019, between the Company and Dr. Padmanabh Chivukula. Incorporated by reference to Exhibit 10.3 to Form 8-K12B filed on June 14, 2019 (File No. 001-38942)</span></a></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.22&#134;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1768224/000119380521001468/e621018_ex4-1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">2021 Inducement Equity Incentive Plan. Incorporated by reference to Exhibit 4.1 to Form S-8 filed on October 20, 2021 (File No. 333-260391).</span></a></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.23</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001768224/000156459021055372/arct-ex1034_76.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Fifth Amendment to Loan and Security Agreement, dated October 27, 2021, by and between Arcturus Therapeutics, Inc. and Western Alliance Bank. Incorporated by reference to Exhibit 10.34 to Form 10-Q filed on November 9, 2021 (File No. 001-38942).</span></a></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.24</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001768224/000156459021055372/arct-ex1035_75.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Lease, by and between Arcturus Therapeutics, Inc. and TPSC IX, LLC, dated September 29, 2021. Incorporated by reference to Exhibit 10.35 to Form 10-Q filed on November 9, 2021 (File No. 001-38942).</span></a></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.25</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001768224/000156459021042750/arct-ex1032_47.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Technology License and Technical Support Agreement, signed July 29, 2021 and effective July 30, 2021, by and between Arcturus Therapeutics, Inc. and Vinbiotech Research and Manufacture Joint Stock Company. Incorporated by reference to Exhibit 10.32 to Quarterly Report on Form 10-Q filed on August 10, 2021 (File No. 001-38942).</span></a></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.26</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001768224/000156459021042750/arct-ex1033_46.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Framework Drug Substance Supply Agreement, signed July 29, 2021 and effective July 30, 2021, by and between Arcturus Therapeutics, Inc. and Vinbiotech Research and Manufacture Joint Stock Company. Incorporated by reference to Exhibit 10.33 to Quarterly Report on Form 10-Q filed on August 10, 2021 (File No. 001-38942).</span></a></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.27</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1768224/000095017022008524/arct-ex10_36.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Sixth Amendment to Loan and Security Agreement, dated April 19, 2022, by and between Arcturus Therapeutics, Inc. and Western Alliance Bank. Incorporated by reference to Exhibit 10.36 to Quarterly Report on Form 10-Q filed on May 9, 2022 (File No. 001-38942).</span></a></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.28&#134;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1768224/000119380522001014/e621778_ex10-1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended. Incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed on June 14, 2024 (File No. 001-38942).</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.29**</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1768224/000119380522001480/e617791_ex10-1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Study Support Agreement effective October 31, 2022 by and between Arcturus Therapeutics, Inc. and Vinbiocare Biotechnology Joint Stock Company. Incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed on November 4, 2022 (File No. 001-38942).</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.30**</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1768224/000095017022023969/arct-ex10_36.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Cost Reimbursement Contract dated August 31, 2022, by and between Arcturus Therapeutics Holdings Inc. and Biomedical Advanced Research and Development Authority of the U.S. Department of Health and Human Services. Incorporated by reference to Exhibit 10.36 to Quarterly Report on Form 10-Q filed on November 9, 2022 (File No. 001-38942).</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.31**</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1768224/000095017022023969/arct-ex10_38.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Collaboration and License Agreement, dated November 1, 2022, by and between Arcturus Therapeutics Holdings Inc. and CSL Limited. Incorporated by reference to Exhibit 10.38 to Quarterly Report on Form 10-Q filed on November 9, 2022 (File No. 001-38942).</span></a></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0200000000000005pt;font-kerning:none;min-width:fit-content;"><span style="text-decoration:underline solid;"></span>&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.32**</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1768224/000095017023010380/arct-ex10_41.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Manufacturing Support Agreement Termination Letter, dated March 23, 2023, by and between Arcturus Therapeutics, Inc. and the Economic Development of Singapore. Incorporated by reference to Exhibit 10.41 to Annual Report on Form 10-K filed on March 29, 2023 (File No. 001-38942).</span></a></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">88</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:11.52%;box-sizing:content-box;"/>
    <td style="width:3%;box-sizing:content-box;"/>
    <td style="width:85.48%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:1pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #000000;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Description</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.33**</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1768224/000095017023019773/arct-ex10_28.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Credit Agreement dated April 21, 2023, by and between Arcturus Therapeutics, Inc. and Wells Fargo Bank, National Association. Incorporated by reference to Exhibit 10.28 to Quarterly Report on Form 10-Q filed on May 9, 2023 (File No. 001-38942)</span></a><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">.</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.34**</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1768224/000095017023019773/arct-ex10_29.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Security Agreement dated April 21, 2023, by and between Arcturus Therapeutics, Inc. and Wells Fargo Bank, National Association. Incorporated by reference to Exhibit 10.29 to Quarterly Report on Form 10-Q filed on May 9, 2023 (File No. 001-38942)</span></a><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">.</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.35**</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1768224/000095017023019773/arct-ex10_30.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Revolving Line of Credit Note dated April 21, 2023, by and between Arcturus Therapeutics, Inc. and Wells Fargo Bank, National Association. Incorporated by reference to Exhibit 10.30 to Quarterly Report on Form 10-Q filed on May 9, 2023 (File No. 001-38942)</span></a><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">.</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.36**</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1768224/000095017023063778/arct-ex10_31.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment Number One to Collaboration and License Agreement, dated August 3, 2023, by and between Arcturus Therapeutics, Inc. and Seqirus Inc. Incorporated by reference to Exhibit 10.31 to Quarterly Report on Form 10-Q filed on November 14, 2023 (File No. 001-38942)</span></a><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">.</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.37**</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1768224/000095017023063778/arct-ex10_32.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment No. 4 to Letter Agreement, dated September 25, 2023, by and between Arcturus Therapeutics, Inc. and the Cystic Fibrosis Foundation. Incorporated by reference to Exhibit 10.32 to Quarterly Report on Form 10-Q filed on November 14, 2023 (File No. 001-38942)</span></a></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.38**</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1768224/000095017024090905/arct-ex10_35.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">First Amendment to Credit Agreement and First Amendment to Revolving Line of Credit, dated June 26, 2024, by and between Arcturus Therapeutics, Inc. and Wells Fargo Bank, National Association. Incorporated by reference to Exhibit 10.35 to Quarterly Report on Form 10-Q filed on August 5, 2024 (File No. 001-38942).</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.39</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1768224/000095017024123469/arct-ex10_36.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Fifth Amendment to Lease, by and between Arcturus Therapeutics, Inc. and ARE-SD Region No. 44, LLC, dated July 12, 2024. Incorporated by reference to Exhibit 10.36 to Quarterly Report on Form 10-Q filed on November 7, 2024 (File No. 001-38942).</span></a></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19.1*</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="arct-ex19_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Arcturus Therapeutics Holdings, Inc. Insider Trading Policy</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.1*</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="arct-ex21_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">List of subsidiaries of Arcturus Therapeutics Holdings, Inc.</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23.1*</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="arct-ex23_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consent of Independent Registered Public Accounting Firm</span></a></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23.2*</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="arct-ex23_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consent of Independent Registered Public Accounting Firm</span></a></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24.1*</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#signatures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Power of Attorney (included on the signature page of this Annual Report).</span></a></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.1*</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="arct-ex31_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification by Principal Executive Officer pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as amended.</span></a></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.2*</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="arct-ex31_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification by Principal Financial and Accounting Officer pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as amended.</span></a></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32.1*</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="arct-ex32_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">89</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:11.52%;box-sizing:content-box;"/>
    <td style="width:3%;box-sizing:content-box;"/>
    <td style="width:85.48%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:1pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #000000;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Description</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32.2*</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="arct-ex32_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Principal Financial and Accounting Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">97.1*</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="arct-ex97_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Arcturus Therapeutics Holdings, Inc. Clawback Policy</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101*</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">The following financial statements and footnotes from the Registrant&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2024 formatted in Inline Extensible Business Reporting Language (Inline XBRL):</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.INS Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.SCH Inline XBRL Taxonomy Extension Schema</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:right;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Filed herewith.</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">**</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Certain confidential portions of this exhibit have been redacted from the publicly filed document because such portions are (i) not material and (ii) would be competitively harmful if publicly disclosed.</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#134;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Management compensatory plan, contract or arrangement.</span></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">90</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="signatures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SIGNAT</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">URES</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:52.58%;box-sizing:content-box;"/>
    <td style="width:2.3%;box-sizing:content-box;"/>
    <td style="width:5.54%;box-sizing:content-box;"/>
    <td style="width:39.58%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ARCTURUS THERAPEUTICS HOLDINGS INC.</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: March 6, 2025</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;/s/ Joseph E. Payne</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Name: Joseph E. Payne</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Title: President, Chief Executive Officer and Director</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The undersigned officers and directors of Arcturus Therapeutics Holdings Inc., hereby severally constitute and appoint Joseph E. Payne and Dr. Padmanabh Chivukula, and each of them individually, with full power of substitution and resubstitution, as their true and lawful attorneys and agents, to do any and all acts and things in their name and behalf in their capacities as directors and officers and to execute any and all instruments for them and in their names in the capacities indicated below, which said attorneys and agents, may deem necessary or advisable to enable said corporation to comply with the Securities Exchange Act of 1934, as amended, and any rules, regulations and requirements of the Securities and Exchange Commission, in connection with this Annual Report on Form 10-K, including specifically but without limitation, power and authority to sign for them or any of them in their names in the capacities indicated below, any and all amendments hereto, and they do hereby ratify and confirm all that said attorneys and agents, or either of them, may lawfully do or cause to be done by virtue hereof.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Annual Report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:32.98%;box-sizing:content-box;"/>
    <td style="width:1.04%;box-sizing:content-box;"/>
    <td style="width:43.3%;box-sizing:content-box;"/>
    <td style="width:1.04%;box-sizing:content-box;"/>
    <td style="width:21.64%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Title</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Date</span></p></td>
   </tr>
   <tr style="height:4pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Joseph E. Payne</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">President, Chief Executive Officer and Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 6, 2025</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Joseph E. Payne</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">(principal executive officer)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:4pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Dr. Moncef Slaoui</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chairman of the Board</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 6, 2025</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Dr. Moncef Slaoui</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:4pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Andrew Sassine</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director and Chief Financial Officer</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 6, 2025</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Andrew Sassine</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">(principal financial and accounting officer)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Dr. Magda Marquet</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 6, 2025</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Dr. Magda Marquet</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:4pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ James Barlow</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 6, 2025</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">James Barlow</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:4pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Edward Holmes</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 6, 2025</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Edward Holmes</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Dr. Peter Farrell</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 6, 2025</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Dr. Peter Farrell</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Dr. John Markels</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 6, 2025</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Dr. John Markels</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Jing Marantz</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 6, 2025</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Jing Marantz</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="z-index:-3;min-height:1in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:90.96%;box-sizing:content-box;"/>
    <td style="width:9.04%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#report_independent_registered_public_acc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Report of Independent Registered Public Accounting Firm (PCAOB ID: </span><span><ix:nonNumeric id="F_de4d6e8a-abcf-429a-b5e5-c5a3ed321d32" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="dei:AuditorFirmId"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">34</span></ix:nonNumeric></span><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">)</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#ey_audit_report"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Report of Independent Registered Public Accounting Firm (PCAOB ID: 42)</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_balance_sheet"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Balance Sheets as of December 31, 2024 and 2023</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_operations"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statements of Operations and Comprehensive (Loss) Income for the Years ended December 31, 2024, 2023</span></a><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">&#160;and 2022</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_stockholders_equ"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statements of Changes in Stockholders&#8217; Equity for the Years ended December 31, 2024, 2023</span></a><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">&#160;and 2022</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_cash_flows"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statements of Cash Flows for the Years ended December 31, 2024, 2023</span></a><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">&#160;and 2022</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#notes_to_consolidated_financial_stat"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Notes to Consolidated Financial Statements</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="z-index:-3;min-height:1in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="report_independent_registered_public_acc"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Report of Independent Regist</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ered Public Accounting Firm</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the shareholders and the Board of Directors of Arcturus Therapeutics Holdings, Inc.</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1071075c-353a-4497-8cca-2b415f700f01" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="dei:AuditorOpinionTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Opinion on the Financial Statements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have audited the accompanying consolidated balance sheets of Arcturus Therapeutics Holdings, Inc. and subsidiaries (the &#8220;Company&#8221;) as of December 31, 2024, the related consolidated statements of operations, comprehensive loss, stockholder&#8217;s equity, and cash flows, for the year ended December 31, 2024, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024, and the results of its operations and its cash flows for the year ended December 31, 2024, in conformity with accounting principles generally accepted in the United States of America.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company&#8217;s internal control over financial reporting as of December 31, 2024, based on criteria established in Internal Control &#8212; Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated March 6, 2025, expressed an adverse opinion on the Company&#8217;s internal control over financial reporting because of a material weakness.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basis for Opinion</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Critical Audit Matter</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Collaboration</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue &#8212; Refer to Note 2 and Note 3 to the financial statements</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Critical Audit Matter Description</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has entered into a license and collaborative research and development arrangement with Seqirus, Inc. There are five distinct performance obligations under this arrangement. The Company recognizes revenue over time for all performance obligations except for the vaccine license. The vaccine license is recognized at the point in time it is transferred. The accounting for revenue recognized over time measures the progress using an input method which is based on costs incurred toward the satisfaction of the performance obligation. As of December 31, 2024, Collaboration revenue was $138.4 million, of which $138.4 million relates to the agreement with Seqirus, Inc.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="z-index:-3;min-height:1in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Given the judgments necessary to estimate total costs to be incurred to satisfy the performance obligations, as well as the high volume of expense data used in the revenue calculation, auditing such estimates required extensive audit effort and a high degree of auditor judgment when performing audit procedures and evaluating the results of those procedures.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">How the Critical Audit Matter Was Addressed in the Audit</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our audit procedures related to the recognition of revenue for the Seqirus, Inc. arrangement included the following, among others:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We tested the operating effectiveness of controls over collaboration revenue, including those related to the determination of the timing and amount of revenue recognized.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We evaluated the total costs incurred related to each performance obligation by inspecting, on a sample basis, underlying source documents to determine costs were recorded to the correct performance obligation.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We evaluated the assumptions used in the estimates of total costs and the estimated measure of progress for recognizing revenue by:</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Analyzing period-over-period changes in the total cost assumption, identifying any significant fluctuations.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Inspecting third-party evidence of the agreed-upon total costs to be incurred and comparing that to the total cost to be incurred used by the Company in the calculation.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/s/ </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9ac256b8-35f9-4bc8-b1d1-9cb7bc6575b0" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="dei:AuditorName"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deloitte &amp; Touche LLP</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f7a63ff1-5572-4075-b5eb-dfb839954996" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="dei:AuditorLocation"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">San Diego, California</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 6, 2025</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have served as the Company&#8217;s auditor since 2024.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="z-index:-3;min-height:1in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="ey_audit_report"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Report of Independent Registered Public Accounting Firm</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the Stockholders and the Board of Directors of Arcturus Therapeutics Holdings Inc.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Opinion on the Financial Statements</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have audited the accompanying consolidated balance sheet of Arcturus Therapeutics Holdings Inc. and its subsidiaries (the Company) as of December 31, 2023, the related consolidated statements of operations and comprehensive income (loss), changes in stockholders&#8217; equity and cash flows for each of the two years in the period ended December 31, 2023, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2023, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2023, in conformity with U.S. generally accepted accounting principles.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basis for Opinion</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/s/ Ernst &amp; Young LLP</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We served as the Company's auditor from 2018 to 2024.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">San Diego, California</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 14, 2024</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">except for Note 12, as to which the date is</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 6, 2025</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="z-index:-3;min-height:1in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARCTURUS THERAPEUTICS HOLDINGS INC. AND ITS SUBSIDIARIES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_balance_sheet"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CONSOLIDATED</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> BALANCE SHEETS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:68.733%;box-sizing:content-box;"/>
    <td style="width:1.439%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.195%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.439%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.195%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31,</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(in thousands, except per share data)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Assets</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;text-indent:5pt;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;text-indent:5pt;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current assets:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;text-indent:5pt;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;text-indent:5pt;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d5ceaae2-0787-44bd-b2cf-a5b8576ce5b8" contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">237,028</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2edf19a4-e7de-4770-99ea-4d88e41d3214" contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">292,005</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted cash</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8938d8ed-d97e-41b2-8791-acf015eb2759" contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212" name="us-gaap:RestrictedCash" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">55,000</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d2acd42e-2c7d-447c-9246-a2c552f27f33" contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc" name="us-gaap:RestrictedCash" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">55,000</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts receivable</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_df1b6b11-6a81-4183-bee5-b5ba80a76a45" contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212" name="us-gaap:AccountsReceivableNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,974</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_774c042e-5a9e-42f2-bce5-f67a73180eeb" contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc" name="us-gaap:AccountsReceivableNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,064</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e18959a6-cb31-4aeb-9161-6f3350755e3b" contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212" name="arct:PrepaidExpensesAndOtherReceivables" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,977</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3896b253-f2c2-4cd1-98d6-6c4e504d34a2" contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc" name="arct:PrepaidExpensesAndOtherReceivables" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,521</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total current assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9f16ffc1-5a60-4ac2-9d8e-95b710e7c1e9" contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">305,979</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_29b38493-1db2-48c2-ad59-3de3ce8620d8" contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">386,590</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment, net</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d77030f6-65f2-44ae-8e31-a50c230945d3" contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,531</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_98c11001-363d-4a03-8558-05f9a1ff2a3f" contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,427</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease right-of-use asset</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_415aca41-5445-43e9-b836-9f1d5598e268" contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,674</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_91889c42-a970-47d2-8cad-5fe2ff73166a" contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,500</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-current restricted cash</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fa242944-7cd3-469f-81bc-8319e5ce806e" contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,885</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_02ae9101-b866-49b4-a5c8-e0411ea6dafe" contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,885</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_77ba1028-8f24-407a-9ab0-1da5ad2a0ac1" contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">344,069</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9765dd49-17ae-48a0-918e-07150c692885" contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">429,402</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Liabilities and Stockholders&#8217; Equity</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current liabilities:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9bcfc7c2-8bd3-4d14-af6b-f33399fa419f" contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,194</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_64302058-7e00-4390-a67f-d983301c9a75" contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,279</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dd1ab045-294b-4131-bd57-ebbdacdded54" contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">38,781</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3b177764-df34-4ecf-9b94-b0f25ae7bf11" contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,881</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred revenue</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_84e8c78a-611a-4990-9250-6ede04c225ff" contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212" name="us-gaap:DeferredRevenueCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,514</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6a2b0158-cdb6-4169-967f-b927edf8ea96" contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc" name="us-gaap:DeferredRevenueCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">44,829</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total current liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aed003fb-aea5-49c6-83af-d9b684903d0a" contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">65,489</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4c1a9613-e452-443e-93ac-e7119440fc89" contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">81,989</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred revenue, net of current portion</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e8678f38-a54b-4c9d-84b2-901b9c8b1b37" contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212" name="us-gaap:DeferredRevenueNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,604</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7930a13d-d7c7-4955-b821-6917165385bf" contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc" name="us-gaap:DeferredRevenueNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42,496</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liability, net of current portion</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4ac8e9eb-fe59-4768-89f7-c84cb87a3ca3" contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,998</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5a2231ef-3734-4a5e-9646-32397e9465f8" contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,907</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other non-current liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_de6dbbdb-a8ae-4265-9625-9829b8434e0b" contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">497</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8f8dc7a6-a8dc-41c3-ba4c-7f6828dfc074" contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">103,091</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_01fbabe6-f20a-496e-a070-4335c0fbaefb" contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">150,889</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stockholders&#8217; equity:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock: $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5c09a45e-0e04-4336-b263-bb44b15f833a" contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_e2e2fe7f-5079-4f5e-850b-f511bf704ef8" contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;par value; </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5651927a-821c-40fc-9975-8eb5e92b44ac" contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_50ec6de5-3285-4b83-8659-817d8dc5f18e" contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal">60,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares authorized; issued and outstanding shares were </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1917148c-01b8-47e1-baa8-d7fb380292de" contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal"><ix:nonFraction id="F_6f5a3b25-6a3d-4375-a535-abce8e9bae5c" contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;at December 31, 2024 and </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_544ece10-c0c0-4cf5-96fa-4a7400dbeedf" contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal"><ix:nonFraction id="F_4626543d-5ded-4367-aea3-fd19388c71f4" contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,828</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;at December 31, 2023</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_29363627-f5eb-4a47-8985-0a8d50231053" contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b652617f-8e3c-4883-b8f8-45f8b652dc79" contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additional paid-in capital</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_26387e51-c41b-4d40-bafe-6e5e5a77d59e" contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">689,758</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a9a55618-df11-4123-b57d-388bd9f2fe5e" contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">646,352</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accumulated deficit</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3af42f6b-2c80-4461-a185-1ab1f25ddb3c" contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">448,807</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9e9ab74a-d8bd-4058-b05b-baeb3a5f7a9e" contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">367,866</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total stockholders&#8217; equity</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b1c7cae5-2cb8-40a0-811b-8010f5900650" contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">240,978</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dd3f32c1-f1a4-4f2e-99e0-e813c1039d94" contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">278,513</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total liabilities and stockholders&#8217; equity</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0da254b3-ff85-475e-ad49-e6ee98de7180" contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">344,069</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bceefc30-f2aa-44a9-b677-9d68e05a50e6" contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">429,402</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="z-index:-3;min-height:1in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARCTURUS THERAPEUTICS HOLDINGS INC. AND ITS SUBSIDIARIES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_statements_operations"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">C</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:57.863%;box-sizing:content-box;"/>
    <td style="width:1.281%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.764000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.281%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.764000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.281%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.764000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(in thousands, except per share data)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Collaboration revenue</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_57608586-407f-4a90-9e99-c8106feb1046" contextRef="C_200946b9-b524-4e78-9424-4e601b6b9f68" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">138,389</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_91d1f09c-8c43-4231-adee-fa00653207f3" contextRef="C_e22ed845-7d56-4d58-bbda-cdb707f0cae4" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">157,748</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1c796c73-1d7a-456c-8533-e46a8f751993" contextRef="C_e340decb-8e23-4aec-a50a-9afef8ee8eaf" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">205,755</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Grant revenue</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d8d22e59-4d3a-483e-a17c-edb57cc87de3" contextRef="C_517ad6a3-e9ae-471c-a53f-67c77e50ab6f" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,921</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bd699231-6606-4206-bfa2-3c45203cd7fc" contextRef="C_3dcdc036-b6bb-44cc-9e78-55386dfe3195" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,051</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aee5e084-df0b-4ee1-86eb-383160382873" contextRef="C_45eb8bb7-286d-4047-9f32-b23ce157716c" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">244</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total revenue</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7595175b-12d7-4ea9-a330-e4e37762c32b" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">152,310</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_218b6747-ed69-4497-bd4e-e95806b450cb" contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">166,799</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3e3654dc-8191-42e5-850a-542a3ccb4bd5" contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">205,999</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development, net</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9ea2cd9c-61b3-4319-8567-00b40eac0ac2" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">195,156</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_507e257f-51cb-4f43-aa2d-bdff79fcd2a2" contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">192,133</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_21683dd0-e669-4915-9963-bb676e5f8da3" contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">147,751</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d4d26522-a147-4d20-81b1-187eebb33521" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">52,823</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_81f31a27-ea49-4f01-a7cb-ef8094bfa429" contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">52,871</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ea68ad94-8618-40c7-beb7-fc4110a05ee7" contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">46,071</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d41ff43e-4bf8-4726-8140-67a419b27857" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">247,979</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3493b3c6-a61c-42a5-93ae-799a79404b8c" contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">245,004</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_efd799b2-0520-49a3-92a1-f23d52b1666a" contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">193,822</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Loss) income from operations</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_170b19d5-c44f-448c-87f5-fc3141001f9c" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">95,669</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_268d8201-478b-4e5e-afa5-b62a81f6628d" contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">78,205</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ece59b9d-d9c0-4701-a8eb-6ef3c2eb865f" contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,177</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from equity-method investment</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b30a26d0-b10e-4fd3-b7af-3987fc2435f0" contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812" name="us-gaap:IncomeLossFromEquityMethodInvestments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">515</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from foreign currency</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ede3e677-cc3b-4ffe-8b06-2226c4d98326" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">471</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4c50c61d-b48e-414e-be63-43c928977efb" contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">229</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_692117be-773c-4771-8409-0ae9a07886b0" contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">598</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Finance income (expense), net</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_295b0b12-03d0-4625-85e4-439236770b6e" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,195</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c61d9697-5a33-4ad9-a4bf-c7fc8e77db51" contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,591</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cb5f8f94-8cb6-4133-aaf6-76a3e6f2658a" contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">420</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Gain on debt extinguishment</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f5955b00-0c8c-48af-b4fd-1a33ee39a13d" contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,953</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net (loss) income before income taxes</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d32e70e5-ca35-46ef-9990-9df9a43eb53a" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">80,945</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b3c19a5b-73d1-4ed1-90de-e5cddfa9d5c3" contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">27,890</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1bd74819-9ffd-44a9-bea4-26d404061894" contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,644</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Benefit) provision for income taxes</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e0387b91-776e-4d7a-a38e-c0fc5c90661b" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a36554c7-ca6c-4615-adfa-354f8470e158" contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,835</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_88802aa8-6bbf-40d2-b6d0-a56f80502f97" contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,295</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net (loss) income</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_19f7700e-5f72-4426-bab9-93828dbd4b12" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">80,941</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9d7b2706-37e1-4c36-bbe1-886b73281b4f" contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">29,725</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7ab76c1c-c81b-44e9-89ec-959f1699c22a" contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,349</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Comprehensive (loss) income</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a5475d06-9a92-4bdc-8f99-915362e67ad9" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">80,941</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b11829d0-3a5c-45f7-adfb-85977fe23de2" contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">29,725</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1fccbd61-2bc0-4417-835c-1efb7b95ff3c" contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,349</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Loss) earnings per share:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Basic</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_69b4f5fb-c113-4c9f-a9bf-74f4b5d0a1f6" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-">3.00</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_79f8db12-2f48-4515-80b9-3bc3647f388c" contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.12</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_099d2c2a-64d8-4ee4-b975-8b7dfeae5cf9" contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.35</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Diluted</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_def89b71-8cfc-4384-b0f3-c19bc32147e8" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-">3.00</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_745f340a-3fa5-407f-9f56-1030af2bfea3" contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.12</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5daca0ed-93d0-40e0-aca6-41f0fad82d56" contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.35</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average shares used in calculation of (loss) earnings per share:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Basic</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f0ca73b3-96d1-4a4a-9468-3308a4826440" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,000</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7feae395-df34-4bb8-bc50-b3c2ac56fc09" contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,628</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6de4baa0-2271-4d52-95b9-c95928f524b9" contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,445</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Diluted</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_82924e05-76bf-4c13-87f1-3ba4efb79607" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,000</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a9ea23e3-aad9-4544-b260-cd2c75589e99" contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,628</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c593ae48-445f-49c2-92e5-ee3f68a002b8" contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,093</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="stockholders_equity"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARCTURUS THERAPEUTICS HOLDINGS INC. AND ITS SUBSIDIARIES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_statements_stockholders_equ"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:39.98%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:7.52%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.18%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:7.08%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.18%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:8.78%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.18%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.46%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.18%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.46%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Additional</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Common Stock</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Paid-In</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Stockholders&#8217;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Capital</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Deficit</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Equity</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balance at December 31, 2021</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2585dcf4-2e12-4bbf-a361-6092a71178cc" contextRef="C_8d83dff5-ceee-4639-a422-5542c54a34d5" name="us-gaap:SharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,372</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_38d37368-bfb4-4a29-8cd8-6b1ad0571244" contextRef="C_8d83dff5-ceee-4639-a422-5542c54a34d5" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_64d6e0e8-7ec0-4f33-9e89-0302b9227722" contextRef="C_59320853-4bcf-4a90-99e2-d4b7e72b628d" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">575,675</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c0b4ebad-b0a9-44c7-8492-853560734ec4" contextRef="C_9f520c76-36f9-4e10-88ee-34a1bddaa46e" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">347,490</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dc8428ba-0d82-48c4-8193-aae552c757f1" contextRef="C_12470630-daf9-4fdf-a875-a3affca4b6e8" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">228,211</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Share-based compensation</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4e3d72b7-36c5-4369-a895-60ada7ceee6b" contextRef="C_b5b1f0d6-262c-46b3-85ce-a3305beaaa39" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,611</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8d4ce848-e488-401c-b38a-55d3455274af" contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,611</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock upon exercise of stock options</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e7c483bb-34c3-4e12-ad09-9a57e553ee83" contextRef="C_6ba7dcb1-88d1-40cc-9caa-9904c066fd42" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">161</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_98409805-e474-4de2-9989-48bc4720df14" contextRef="C_6ba7dcb1-88d1-40cc-9caa-9904c066fd42" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_679c9c0f-70d2-41b7-8897-9cb542e1c3e6" contextRef="C_b5b1f0d6-262c-46b3-85ce-a3305beaaa39" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,729</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b7ad6988-1a05-4561-9f7d-f6914926c582" contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,730</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock under equity plans</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_42d56774-76e3-482b-b54a-79423b4eced8" contextRef="C_6ba7dcb1-88d1-40cc-9caa-9904c066fd42" name="arct:StockIssuedDuringPeriodSharesUnderEquityPlan" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">22</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d7fb308d-cf8e-43e1-9701-7d655d79747b" contextRef="C_b5b1f0d6-262c-46b3-85ce-a3305beaaa39" name="arct:StockIssuedDuringPeriodValueUnderEquityPlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">411</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d3c2c498-ff45-4f1a-832e-c1ca0a6fdcba" contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812" name="arct:StockIssuedDuringPeriodValueUnderEquityPlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">411</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net income</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c3c75f4f-2144-457c-9a21-b090066ec4e6" contextRef="C_dd47aa1c-68e9-4b16-9e78-294207b60f30" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,349</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b458da51-5e04-4a5b-90f0-042b009bec13" contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,349</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5ccdc5ab-3104-4a8c-aa15-2c12f3979be0" contextRef="C_382d54f3-b7c1-44dc-b7ac-45940950e7db" name="us-gaap:SharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,555</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_370d0016-1615-4858-9016-f7702191fa5a" contextRef="C_382d54f3-b7c1-44dc-b7ac-45940950e7db" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1f0e4e30-7641-4e4c-aa46-8158b31c8907" contextRef="C_554b9050-1f94-4300-aff9-82c1bde3198b" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">608,426</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_81b517df-bc9c-4c54-b8af-45eb7369a295" contextRef="C_1e0106b2-7efd-48ca-85e2-4b61ddf65637" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">338,141</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a0846df3-7d74-4cb1-8636-e07a35e31700" contextRef="C_9b6438ac-a4af-4cb1-a7e8-04fc1dc8917f" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">270,312</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Share-based compensation</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d3250862-69d0-46e7-8a46-cd2e7a43eacc" contextRef="C_2177e6fb-ec81-4ef2-b37d-c5ed17225037" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">34,649</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_06d4d032-762e-4f02-b0f5-b0bc1b3c9f28" contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">34,649</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock upon exercise of stock options</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_88663f76-43f6-4044-8687-5c2d903559f3" contextRef="C_deb1657c-7399-402c-8536-0419c46c6233" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">238</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6663b01c-eef1-4afd-a086-ee6b4358d4b6" contextRef="C_2177e6fb-ec81-4ef2-b37d-c5ed17225037" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,668</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c29d6c5f-cb7c-4b7b-a41f-827500743b11" contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,668</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock under equity plans</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b090b58c-e214-4cea-9878-683d3c668540" contextRef="C_deb1657c-7399-402c-8536-0419c46c6233" name="arct:StockIssuedDuringPeriodSharesUnderEquityPlan" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">35</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_393e2080-8239-4045-b810-70b2755f2e06" contextRef="C_2177e6fb-ec81-4ef2-b37d-c5ed17225037" name="arct:StockIssuedDuringPeriodValueUnderEquityPlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">609</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_031a31e5-eeea-4491-9fa1-bb05a2394ba2" contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c" name="arct:StockIssuedDuringPeriodValueUnderEquityPlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">609</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_390b3f44-9d56-4dc4-95e8-7ce6381e8c24" contextRef="C_94fdde70-e99e-4e78-9fbc-8f8f22d0ba4d" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">29,725</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9e29d760-8d9f-49cf-86ad-0f522ad4470f" contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">29,725</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balance at December 31, 2023</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a01c97ea-c069-422d-ae07-b994851e429b" contextRef="C_4fc38bda-72e0-4e2e-bcde-f14d64558664" name="us-gaap:SharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,828</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7db6d82a-09f4-417e-bb27-f8d518d9901f" contextRef="C_4fc38bda-72e0-4e2e-bcde-f14d64558664" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_13210c8d-617e-408a-b5a3-c28c715ad9a2" contextRef="C_d2b6f456-3e1e-41e4-bd44-0e037c42e4ca" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">646,352</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1c15ec0d-8481-4012-9799-b754e345da2f" contextRef="C_d82ff122-590c-489b-87d2-a9001b2499a6" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">367,866</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2ca9a7ee-0606-4164-8e3a-5fbcb4625783" contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">278,513</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Share-based compensation</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d8e4c51d-489e-4ec5-9254-e78c62999320" contextRef="C_d6e35e55-99c4-447c-93d6-7979a6be6791" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">37,988</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b211af64-4976-47f8-a8ec-b633721802c5" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">37,988</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock upon exercise of stock options</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ccd0dffe-ef9b-4063-a5fd-0b0849df1d52" contextRef="C_b6a637cc-890d-47eb-bf8f-c3b46e805e7d" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">228</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_af69755e-11b6-4cb1-a294-32118fd65328" contextRef="C_d6e35e55-99c4-447c-93d6-7979a6be6791" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,736</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ba24c6ca-d3cc-47bd-a51e-826db64b7b23" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,736</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock under equity plans</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6590dd78-ea58-45b1-8727-cc05b8fa00bc" contextRef="C_b6a637cc-890d-47eb-bf8f-c3b46e805e7d" name="arct:StockIssuedDuringPeriodSharesUnderEquityPlan" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">40</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_11f41e48-c774-4176-95ae-2e43263edc63" contextRef="C_d6e35e55-99c4-447c-93d6-7979a6be6791" name="arct:StockIssuedDuringPeriodValueUnderEquityPlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">682</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e9eaf6e9-73dd-45a9-bf34-f77e3038e475" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="arct:StockIssuedDuringPeriodValueUnderEquityPlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">682</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_16bc58cb-682c-46c6-b052-ef964f06fa7c" contextRef="C_08b6efae-4fda-4db6-b9c0-371c0ef137a3" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">80,941</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dda347e6-7e21-4308-bd4e-82ce7f4a9034" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">80,941</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balance at December 31, 2024</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1745df12-f686-40b0-9700-f5ae785f0806" contextRef="C_e0eeb777-c5ee-445e-89d3-2c8ed430397e" name="us-gaap:SharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,096</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b80dd2f6-c9dc-4ab5-9b29-ec9c20354ccc" contextRef="C_e0eeb777-c5ee-445e-89d3-2c8ed430397e" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_54ff5477-63b6-4172-a453-e57792816223" contextRef="C_c12666e5-df97-469d-b1e4-3c9a57cc9650" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">689,758</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bee4456b-150d-4928-a3b6-13fe4b710c0d" contextRef="C_ff6d8148-36b1-4ba9-847e-b95829a0383f" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">448,807</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5319abec-3e2a-4c43-9640-a1842d01a34a" contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">240,978</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="cash_flows"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARCTURUS THERAPEUTICS HOLDINGS INC. AND ITS SUBSIDIARIES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_statements_cash_flows"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CONSOLIDATED STATEM</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ENTS OF CASH FLOWS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:57.563%;box-sizing:content-box;"/>
    <td style="width:1.501%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.644%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.501%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.644%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.501%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.644%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Operating activities</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net (loss) income</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_241421a1-1c37-4ca4-bd54-6491534c893b" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">80,941</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0824b906-9376-4869-b517-af7c58599c36" contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">29,725</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7834c771-43e0-41f7-9ccb-d96208f9842b" contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,349</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation and amortization</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_12b00260-549b-479b-b26e-ac5467f725bb" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,544</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_522a4bb3-c8bb-42ff-93c8-4a0c44fc56cd" contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,957</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c44e27eb-1e51-421f-88d2-fb94c2b48af3" contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,527</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Share-based compensation expense</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8d74ed85-b42a-46e9-a014-7a91dd6e29a8" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">37,988</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dc63f865-2369-4bdc-8e95-a250a084505b" contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">34,649</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_71b08048-18a3-4927-9a87-0a0f7af119fa" contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,611</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from equity-method investment</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_52edc4d1-873c-4172-90ec-1d62a3160e70" contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812" name="us-gaap:IncomeLossFromEquityMethodInvestments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">515</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Gain on debt extinguishment</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cb586f44-5b02-453e-9ed0-4a331e3e38be" contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,953</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign currency transaction loss</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6a5a17c3-f377-4cc2-b895-00279872ea19" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:ForeignCurrencyTransactionGainLossRealized" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">471</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_77cabcc0-d89f-4920-83f4-b5d07d3c8553" contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c" name="us-gaap:ForeignCurrencyTransactionGainLossRealized" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">90</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ace2002c-dc47-4340-8e9e-53bb70559724" contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812" name="us-gaap:ForeignCurrencyTransactionGainLossRealized" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">375</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other non-cash expenses</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c803f222-c4a1-460b-a2fd-4bab8dd1670c" contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c" name="us-gaap:OtherNoncashIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">502</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5b697845-df41-4030-a250-c65ea66ceedb" contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812" name="us-gaap:OtherNoncashIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,173</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Changes in assets and liabilities:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts receivable</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e34315f0-4bc4-4376-9bd5-36296c25152c" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:IncreaseDecreaseInAccountsReceivable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">28,090</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d9581d62-dff2-4c43-9e26-9a94c0978704" contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c" name="us-gaap:IncreaseDecreaseInAccountsReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,300</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b69df02f-2522-40f8-a34d-59e9a6f105a9" contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812" name="us-gaap:IncreaseDecreaseInAccountsReceivable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">603</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aa7f62db-112e-482d-85f8-b3ae82681779" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,456</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7d51b7ad-bb05-4cdb-82c6-b6bed45281db" contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,165</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_72cff4e8-91dc-47cf-8496-83fd970b2b50" contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,584</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Right-of-use assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d653fd1c-b475-4a6c-8afd-ccb192799c55" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="arct:IncreaseDecreaseOperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4,562</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_42535b7b-2d35-44e1-b5dd-4b14b1ce96a4" contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c" name="arct:IncreaseDecreaseOperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4,045</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ee0ad45d-ece3-4d9a-a700-ecac9c5ad009" contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812" name="arct:IncreaseDecreaseOperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,264</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bbb7f197-a3d5-4b2a-b6ba-e0d4a5bdc46f" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,915</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c29627cd-d25d-4a29-a9f3-32c119aa85f2" contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,238</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_82b46d9b-827a-43be-b18a-65d963e19711" contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,112</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_039739d5-33f8-4f1f-b75a-d4745d1729db" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,932</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c19a5d7d-24e4-4916-8dfd-416d02253dc9" contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">588</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_19e31acd-a835-4066-a36c-81c206429cee" contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,443</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred revenue</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a8820c9b-d343-4217-8c63-7ea82f287c6b" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">55,207</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_89be997f-cacd-46d9-a49b-0de58deabfe8" contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">38,606</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_19842f41-eb02-4197-a805-b2ded0bff008" contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">14,694</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d6d871c9-dc8a-4585-bc7d-ec7fe70a4990" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,645</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d24c7ec5-091d-40e1-a34c-70ee501ed031" contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4,309</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0b459e2d-1509-463f-8ffa-fd97bab08cd6" contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4,477</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash (used in) provided by operating activities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fd2d46d0-2aa4-492f-bccc-27a33e2170f4" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">59,747</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e3de5dac-3e9c-4c65-a751-499230aae787" contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">18,099</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7087c6ef-d5cf-4287-a3ea-635a174772cb" contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,993</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Investing activities</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Acquisition of property and equipment</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5d76594a-b774-48b3-8ea4-7e02682ca904" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">648</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d0bedcaa-4324-4d60-95e1-d2d61f5b731d" contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,901</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_993ae14e-b72f-4825-b6b0-4fe757752f11" contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,726</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash used in investing activities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1189a8d1-a39b-4b3f-92d2-feab274e04c3" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">648</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d169ee1f-7910-4a0e-9123-5a4803d83e23" contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,901</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_32a273d3-5dc3-41f9-acb5-441ea6ae11f0" contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">7,726</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financing activities</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from debt</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8da78c42-2c92-4c71-8bc4-4e84654a3a5e" contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c" name="us-gaap:ProceedsFromIssuanceOfDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,000</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from exercise of stock options</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e5553b4e-bd64-440b-a850-21a77b957383" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,736</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c57a78b1-4cb6-4b82-8103-0e7082dbbb04" contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,668</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cde62ae7-f0cc-4989-9356-585ab976fff6" contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,730</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from issuance of common stock under equity plans</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_25f51d09-eaec-4690-84e0-c1cef7a16bc3" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:ProceedsFromStockPlans" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">682</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d11942da-9563-4495-bb79-41b6e917233d" contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c" name="us-gaap:ProceedsFromStockPlans" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">609</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8db0f404-5928-4163-a301-e12b3d6c1fe4" contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812" name="us-gaap:ProceedsFromStockPlans" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">411</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Payments on debt obligations</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ff3ff2fd-1731-4b24-9d42-297b1159b951" contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c" name="us-gaap:RepaymentsOfDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">47,364</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_66dddf77-c22a-4e2a-b2c8-01cf0db5533c" contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812" name="us-gaap:RepaymentsOfDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,000</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash provided by (used in) financing activities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_63161f28-d21b-4886-a09d-0fa72dfeaa8d" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,418</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_617c95a4-19e5-474c-8af4-b1f25a9ce80f" contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">24,087</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_876c2bdd-204e-4f08-aa36-5adc0821f361" contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,859</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net (decrease) increase in cash, cash equivalents and restricted cash</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7b025730-2cf2-4d34-86ee-4c95bde3e12f" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">54,977</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_904a841d-26cd-43f9-ac85-6600ab64d2e7" contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">45,087</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6201a377-a30a-44e6-b444-4543ebad1207" contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,408</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash, cash equivalents and restricted cash, beginning of year</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f8695c6a-93d7-45ce-b964-5a9d9cb9fb6a" contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">348,890</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_afcf3578-21d4-4af7-a892-7ee8759c6d1d" contextRef="C_9b6438ac-a4af-4cb1-a7e8-04fc1dc8917f" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">393,977</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e25c928b-907c-46cc-a9d5-83ba40ea239b" contextRef="C_12470630-daf9-4fdf-a875-a3affca4b6e8" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">372,569</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash, cash equivalents and restricted cash, end of year</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d2ea77af-b226-4faa-b9a1-69d498dfe6c3" contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">293,913</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_60fcc6bf-b1fc-4e7b-81e0-b2b90c59a7f0" contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">348,890</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ef180a3e-c465-4c2d-8093-16c24b9b027e" contextRef="C_9b6438ac-a4af-4cb1-a7e8-04fc1dc8917f" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">393,977</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Supplemental disclosure of cash flow information</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash paid for interest</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d2f7fd42-14e8-48f7-9504-c5be16a14205" contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,127</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_886b92af-eb6e-4a27-875e-9a1cc2ce7e68" contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">813</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash paid for income taxes</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7af2591b-fe82-4f93-bc01-557ee1f970a5" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:IncomeTaxesPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,407</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Non-cash investing activities</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Right-of-use assets acquired through operating leases</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1e40869f-748e-4fea-b913-2a6337c0ddb9" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,736</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d6a8fa2e-09ae-47ea-9069-c63b15da9f3e" contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,191</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-cash asset disposal</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8fd9f51a-2659-45a1-ad12-650042249423" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="arct:NonCashAssetDisposal" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">473</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchase of property and equipment in accounts payable and accrued expenses</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_49341366-78b6-4ebf-9754-5233fd4b2361" contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">68</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0cdd2a88-3774-4742-8f04-c5c273bff9b8" contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">573</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARCTURUS THERAPEUTICS HOLDINGS INC. AND ITS SUBSIDIARIES</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="notes_to_consolidated_financial_stat"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINAN</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CIAL STATEMENTS</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8ddeb960-3b04-4a08-ade5-d447a0032a31" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 1.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Organization</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Description of Business</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Arcturus Therapeutics Holdings Inc. (the &#8220;Company&#8221; or "Arcturus") is a messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. Arcturus developed the world&#8217;s first approved self-amplifying messenger RNA (sa-mRNA) vaccine, KOSTAIVE</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (&#8220;KOSTAIVE&#8221;). KOSTAIVE achieved approval in Japan in 2023 as a vaccine against COVID-19. Sales of KOSTAIVE began in Japan in October 2024, marking the transition to a commercial stage company.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recent Developments</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">See </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#8220;Note 3 Revenue &#8211; CSL Seqirus&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for further information on the agreement with Seqirus, Inc. ("CSL Seqirus"), whereby CSL Seqirus and the Company continue to collaborate on research and development, manufacturing and global commercialization of vaccines.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Liquidity</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has incurred significant operating losses since its inception. As of December 31, 2024 and 2023, the Company had an accumulated deficit of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7a5e272a-fdc5-4db4-b44e-b6a3d3fdb9e2" contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">448.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ed6feb65-8c8b-43e0-bd0c-05d7e56352db" contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">367.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s activities since inception have consisted principally of research and development activities, general and administrative activities, and raising capital. The Company&#8217;s activities are subject to significant risks and uncertainties, including failing to secure additional funding before the Company achieves sustainable revenues and profit from operations. From the Company&#8217;s inception through the year ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company has funded its operations principally with the proceeds from revenues earned through collaboration agreements, including the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_089f0bcc-8c38-498b-ab65-442b084905ff" contextRef="C_74cdb34c-62d2-473d-9ee0-84ce4b40931f" name="arct:UpfrontPaymentReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">200.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upfront payment received from CSL Seqirus during 2022, the sale of capital stock and proceeds from long-term debt. During fiscal year 2024, the Company received milestone payments totalin</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">g $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5e0c48b4-444f-486b-ac5f-e154b87b15ce" contextRef="C_74cdb34c-62d2-473d-9ee0-84ce4b40931f" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">96.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million f</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">rom CSL Seqirus. At December 31, 2024, the Company&#8217;s balance of cash and cash equivalents, including restricted cash, was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_42dfbf61-27fb-4bbd-ad64-f5c8f73bd2fa" contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">293.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Management believes that it has sufficient working capital on hand to fund operations through at least the next twelve months from the date these consolidated financial statements were available to be issued. There can be no assurance that the Company will be successful in acquiring additional funding, that the Company&#8217;s projections of its future working capital needs will prove accurate, or that any additional funding would be sufficient to continue operations in future years.</span></p></ix:nonNumeric></div>
  <div><ix:nonNumeric id="F_1f88e937-24f9-4cfa-a2ca-7335c10f6bcd" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:SignificantAccountingPoliciesTextBlock" escape="true" continuedAt="F_1f88e937-24f9-4cfa-a2ca-7335c10f6bcd_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 2. Summary of Significant Accounting Policies</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_28183089-635e-445d-bd9f-d36117fb649d" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:ConsolidationPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Basis of Presentation and Principles of Consolidation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying consolidated financial statements include the accounts of Arcturus Therapeutics Holdings Inc. and its subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. These consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">), which requires management to make estimates and assumptions regarding the valuation of certain debt and equity instruments, the equity method investment, share-based compensation, accruals for liabilities, income taxes, revenue and deferred revenue, leases, expense accruals, and other matters that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Although these estimates are based on management&#8217;s knowledge of current events and actions the Company may undertake in the future, actual results could materially differ from those estimates.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4498fe3a-4cdc-4b22-851a-e4a9fbb2f0d2" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Segment Information</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company and its chief operating decision-maker view the Company&#8217;s operations and manage its business in </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_31bac339-9359-4510-9269-e61bee741835" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:NumberOfOperatingSegments" unitRef="U_Segment" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> operating segment, which includes all activities related to the discovery, development and commercialization of messenger RNA medicines.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Arcturus Therapeutics Holdings Inc. and its Subsidiaries</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notes to Consolidated Financial Statements &#8212; Continued</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_1f88e937-24f9-4cfa-a2ca-7335c10f6bcd_1" continuedAt="F_1f88e937-24f9-4cfa-a2ca-7335c10f6bcd_2"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_47bbdf77-2763-4b97-b851-4f7ed5a1c5bd" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash equivalents are short-term highly liquid investments that are readily convertible to cash with original maturities of three months or less at the date of purchase.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9c734a99-9dd9-408b-b5fd-675684d89930" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restricted cash</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restricted cash includes collateral pledged and held at the Company&#8217;s securities accounts pursuant to a security agreement with Wells Fargo Bank, National Association (&#8220;Wells Fargo&#8221;) (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Note 7, Debt</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">). At December 31, 2024, such collateral amounted to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_02c34040-41aa-4bed-8cd0-9f0ca02097de" contextRef="C_3e3c5d0e-9c24-4b1b-b7e1-d57a6036bc5a" name="us-gaap:DebtInstrumentCollateralAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">55.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restricted cash also includes cash required to be set aside as security for lease payments and to maintain a letter of credit for the benefit of the landlord for the Company&#8217;s offices.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At December 31, 2024 and 2023, the Company had restricted cash of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_379d2b38-eefd-4aa0-860e-f28b35f1c403" contextRef="C_dd07c4b0-0b2b-46df-8180-9141d3a4695f" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_14a09c70-d47a-44a6-9e7e-f432a0468338" contextRef="C_860c0a20-b573-41e1-a9a0-9d26576ca073" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.9</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in conjunction with property leases in San Diego, California, and such restriction is expected to be removed at the end of the lease term.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bf879196-fae7-4831-b851-d4733b61a668" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Value Measurements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. A hierarchy has been established for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Observable inputs are inputs that market participants would use in valuing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the factors market participants would use in valuing the asset or liability developed based upon the best information available under the circumstances. The hierarchy consists of three levels. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, and inputs (other than quoted prices) that are observable for the asset or liability, either directly or indirectly. Level 3 inputs are unobservable inputs for the asset or liability. Categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_edeb76db-f752-4409-8956-362b540e1329" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:ReceivablesPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Accounts Receivable</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accounts receivable are recorded at the net invoice value and are non-interest bearing. The Company considers receivables past due based on the contractual payment terms. The Company reserves for specific receivables if collectability is no longer reasonably assured. Estimates for allowances for doubtful accounts are determined based on existing contractual obligations, historical payment patterns, and individual customer circumstances. The Company reevaluates such reserves on a regular basis and adjusts its reserves as needed. Once a receivable is deemed to be uncollectible, such balance is charged against the reserve. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1efca346-6832-4115-b71b-14470cd24d8a" contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_411ff2eb-39f4-4ffa-85b0-a83dc6790c93" contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> reserves have been recorded as of December 31, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024 or 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_9b715545-8b8c-452d-9974-19dbd9eb6990" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:ConcentrationRiskCreditRisk" escape="true" continuedAt="F_9b715545-8b8c-452d-9974-19dbd9eb6990_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Concentration of Credit Risk and Significant Customers</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is exposed to concentrations of credit risk primarily related to cash, cash equivalents, and accounts receivable.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company mitigates credit risk exposure by maintaining cash and cash equivalents only with high-credit-quality financial institutions and investing in instruments with short maturities. The Company continuously monitors counterparty risk to minimize potential financial exposure.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Accounts Receivable Concentration</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024 and 2023, the Company had significant concentrations of credit risk related to accounts receivable from a limited number of customers. The following customers accounted for 10% or more of total accounts receivable in each respective period:</span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Arcturus Therapeutics Holdings Inc. and its Subsidiaries</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notes to Consolidated Financial Statements &#8212; Continued</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_1f88e937-24f9-4cfa-a2ca-7335c10f6bcd_2" continuedAt="F_1f88e937-24f9-4cfa-a2ca-7335c10f6bcd_3"><div style="font-size:12pt;font-family:Times New Roman;"><ix:continuation id="F_9b715545-8b8c-452d-9974-19dbd9eb6990_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">BARDA &#8211; </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_105989d7-c79d-4a41-a8a0-5405f5ddb84c" contextRef="C_ef9e3212-0c72-453d-8e04-d4b0bc08213a" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">60</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of total accounts receivable</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CSL &#8211; </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ee4d6e36-dc2b-44bf-a6c5-3057b3e78663" contextRef="C_988a9efb-2454-43a7-a157-c666550071c2" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">20</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of total accounts receivable</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2023:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CSL &#8211; </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_162ca301-fa2e-4443-9f2c-aded9d39af5a" contextRef="C_42551c33-9281-450d-a0e8-7a28c2252c4a" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">74</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of total accounts receivable</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">BARDA &#8211; </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_92ae8b3a-0f38-4bfe-ae81-7e99f2251dcf" contextRef="C_2b79e174-202f-44db-a40f-0080c01394ba" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">23</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of total accounts receivable</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company monitors its credit exposure through regular assessments of counterparty risk and maintains ongoing collection efforts to mitigate potential credit losses.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue Concentration</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company generates a substantial portion of its revenue from a limited number of key customers. The following customers accounted for 10% or more of total revenue for each period:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the year ended December 31, 2024:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CSL &#8211; </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aaf8be4d-672b-4c1b-bb66-3fb0adaf1174" contextRef="C_c8889a7c-69b1-4f25-be7c-2c7d95316544" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">91</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of total revenue </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the year ended December 31, 2023:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CSL &#8211; </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_97cc0bd4-b572-4b5f-8beb-1c99ad1fe54f" contextRef="C_29eee7a6-fd75-4779-badf-175826fe2dfd" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">92</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of total revenue </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the year ended December 31, 2022:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CSL &#8211; </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6414a8ec-14b1-40e5-8efc-7dd06dca957a" contextRef="C_e7cfc84d-4c9d-4d01-afc8-236747b0ea78" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">75</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of total revenue </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Vinbiocare &#8211; </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f75c436c-8040-4b6e-ac3f-34eb24e59481" contextRef="C_5f293e8e-a39e-4833-9e79-510818455bc1" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">12</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of total revenue</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Given this concentration, the Company&#8217;s financial performance and cash flows may be materially impacted if there are changes in demand, contract renewals, or the financial condition of these key customers. The Company continues to evaluate opportunities to expand its customer base and mitigate concentration risk over time.</span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e942e7b2-a0b3-4f00-9ccd-261adf67d993" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="arct:JointVenturesEquityMethodInvestmentsAndVariableInterestEntitiesPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Joint Ventures, Equity Method Investments and Variable Interest Entities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investments for which the Company exercises significant influence, but does not have control are accounted for under the equity method. Equity method investment activity is related to the Company's joint venture in ARCALIS, Inc. with Axcelead, Inc. The Company&#8217;s share of the investees&#8217; results is presented as either income or loss from equity method investees in the accompanying consolidated statements of operations and comprehensive income (loss). As of December 31, 2024, the carrying value of the equity method investment in ARCALIS remained at zero as ARCALIS' cumulative losses exceeded any gains from dilution.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1a35d833-b509-4563-8d9b-5928224c2904" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Property and Equipment, net</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment are stated at cost, net of accumulated depreciation and amortization. The cost of property and equipment is depreciated or amortized using the straight-line method over the respective useful lives of the assets, ranging from </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_a09c2b80-d521-40d4-b228-c34c98f0be33;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_94a13513-207a-4529-a7da-5e446641f8de" contextRef="C_de7f4b0b-b0a5-4403-a0c8-005d40a0ea9f" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">five years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Leasehold improvements are amortized using the straight-line method over the shorter of the estimated useful life of the asset or the lease term. Long-lived assets, including property and equipment are reviewed for impairment whenever events or circumstances indicate that the carrying amount of these assets may not be recoverable. The determinants used for this evaluation include management&#8217;s estimate of an asset&#8217;s ability to generate positive income from operations and positive cash flow in future periods, as well as the strategic significance of the assets to the Company&#8217;s business objectives. The Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_14f48dd5-aa84-4fa9-b2f8-e8cf4d26483e" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:GoodwillImpairmentLoss" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_f4ad6654-1a4a-4b6b-870b-a5e4bc4f27bf" contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c" name="us-gaap:GoodwillImpairmentLoss" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_450c39d8-cb37-43cf-befd-584ff3cb6293" contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812" name="us-gaap:GoodwillImpairmentLoss" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t recognize any impairment losses for the years ended December 31, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or 2022.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8ccd984a-f116-43c8-82bf-7c3148082ae2" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Comprehensive Income/Loss</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Comprehensive income/loss is defined as the change in stockholders&#8217; equity during a period from transactions and other events and circumstances from non-owner sources. There was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4eb99afc-dc53-4c81-9c81-fb77ea351d0b" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_3932011f-1b02-47d6-982d-0de21299e889" contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_d51d6eea-57df-4ee1-bc47-3ac3aaedd117" contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_1276c662-e5ea-4e1b-8d35-c81b70593c98" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_3d4146ce-63ef-4a2f-adf0-aa2463149497" contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_3a6a2670-49db-480a-a9c8-f7e2bbe9d861" contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> other comprehensive loss or income tax effect related to unrealized losses in the years ended December 31, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Arcturus Therapeutics Holdings Inc. and its Subsidiaries</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notes to Consolidated Financial Statements &#8212; Continued</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_1f88e937-24f9-4cfa-a2ca-7335c10f6bcd_3" continuedAt="F_1f88e937-24f9-4cfa-a2ca-7335c10f6bcd_4"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_afb3ea20-6b7a-41da-963b-7f93449bb106" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:RevenueRecognitionPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue Recognition</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At contract inception, the Company analyzes its collaboration arrangements to assess whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities and therefore within the scope of ASC Topic 808, Collaborative Arrangements (ASC 808). For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Company first determines which elements of the collaboration reflect a vendor-customer relationship and are therefore within the scope of ASC 606.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company determines revenue recognition for arrangements within the scope of Topic 606 by performing the following five steps: (i) identify the contract; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when, or as, the company satisfies a performance obligation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The terms of the Company&#8217;s revenue agreements include license fees, upfront payments, milestone payments, reimbursement for research and development activities, option exercise fees, consulting and related technology transfer fees and royalties on sales of commercialized products. The event-based milestone payments represent variable consideration, and the Company uses the most likely amount method to estimate this variable consideration because the Company will either receive the milestone payment or will not, which makes the potential milestone payment a binary event. The most likely amount method requires the Company to determine the likelihood of earning the milestone payment. Given the high degree of uncertainty around achievement of these milestones, the Company determines the milestone amounts to be fully constrained and does not recognize revenue until the uncertainty associated with these payments is resolved. The Company will recognize revenue from sales-based royalty payments when or as the sales occur. The Company will re-evaluate the transaction price in each reporting period as uncertain events are resolved and other changes in circumstances occur.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A performance obligation is a promise in a contract to transfer a distinct good or service to the collaborative partner and is the unit of account in Topic 606. A contract&#8217;s transaction price is allocated to each distinct performance obligation based on relative standalone selling price and recognized as revenue when, or as, the performance obligation is satisfied.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For performance obligations that are recognized over time, the Company measures the progress using an input method. The input methods used are based on the effort expended or costs incurred toward the satisfaction of the performance obligation. The Company estimates the amount of effort expended, including the time estimated it will take to complete the activities, or costs incurred in a given period, relative to the estimated total effort or costs to satisfy the performance obligation. This approach requires the Company to make numerous estimates and use significant judgment. If estimates or judgments change over the course of the collaboration, a cumulative catch up of revenue is recognized in the period such changes are identified.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">See </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#8220;Note 3, Revenue&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for specific details surrounding the Company&#8217;s arrangements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Grant revenue</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Grant revenue</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">consists of funding under cost reimbursement programs primarily from federal and non-profit foundation sources for qualified research and development activities performed by the Company. Such amounts are invoiced and recorded as revenue as grant-funded activities are performed, with any advance funding recorded as deferred revenue until the activities are performed.</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_b2ef6537-2a4b-4dcc-97d9-58665322d78e" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:LesseeLeasesPolicyTextBlock" escape="true" continuedAt="F_b2ef6537-2a4b-4dcc-97d9-58665322d78e_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company determines if an arrangement is a lease at inception. Lease right-of-use assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. For operating leases with an initial term greater than 12 months, the Company recognizes operating lease right-of-use assets and operating lease liabilities based on the present value of lease payments over the lease term at the commencement date. Operating lease right-of-use assets are comprised of the lease liability plus any lease payments made and excludes lease incentives. Lease terms include options to renew or terminate the lease when the Company is reasonably certain that the renewal option will be exercised or when it is reasonably certain that the termination option will not be exercised. For the Company's operating leases, if the interest rate used to determine the present value of future lease payments is not readily determinable, the Company estimates its incremental borrowing rate as the discount rate for the lease. The Company's incremental borrowing rate is estimated to approximate the interest rate on a collateralized basis with similar terms and payments, and in</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Arcturus Therapeutics Holdings Inc. and its Subsidiaries</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notes to Consolidated Financial Statements &#8212; Continued</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_1f88e937-24f9-4cfa-a2ca-7335c10f6bcd_4" continuedAt="F_1f88e937-24f9-4cfa-a2ca-7335c10f6bcd_5"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_b2ef6537-2a4b-4dcc-97d9-58665322d78e_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">similar economic environments. Lease expense for lease payments is recognized on a straight-line basis over the lease term. The Company has elected the practical expedient to not separate lease and non-lease components.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">See </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#8220;Note 11, Commitments and Contingencies&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for specific details surrounding the Company&#8217;s leases.</span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fcb4af55-14f7-414c-b75f-022e829ac9a4" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Costs, net</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All research and development costs are expensed as incurred. Research and development costs consist primarily of salaries, employee benefits, costs associated with preclinical studies and clinical trials (including amounts paid to clinical research organizations and other professional services), pre-launch inventory, in-process research and development expenses and license agreement expenses. Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods are received or the services are performed. The Company recognizes grants that fall within the scope of ASC 808 as contra research and development expense in the consolidated statement of operations on a systematic basis over the periods in which the entity recognizes as expenses the related costs for which the grants are intended to compensate.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company records accruals for estimated research and development costs, comprising payments for work performed by third party contractors, laboratories, participating clinical trial sites, and others. Some of these contractors bill monthly based on actual services performed, while others bill periodically based upon achieving certain contractual milestones. For the latter, the Company accrues the expenses as goods or services are used or rendered.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clinical trial activities performed by third parties are accrued and expensed based upon estimates of the proportion of work completed over the life of the individual clinical trial and patient enrollment rates in accordance with agreements established with Clinical Research Organizations (&#8220;CROs&#8221;) and clinical trial sites. Estimates are determined by reviewing contracts, vendor agreements and purchase orders, and through discussions with internal clinical personnel and external service providers as to the progress or stage of completion of trials or services and the agreed-upon fee to be paid for such services.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f94a6bad-5138-4123-8d3e-b719b6c81bc6" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="arct:GeneralAndAdministrativeCostsPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">General and Administrative Costs</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General and administrative expenses consist primarily of personnel-related costs, including share-based compensation, for executives, finance, legal, human resources, business development, and other administrative and operational functions, professional fees, accounting and legal services, information technology and facility-related costs, and expenses associated with obtaining and maintaining intellectual property (&#8220;IP&#8221;). These costs relate to the operation of the business, unrelated to the research and development function, or any individual program.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1ba86401-794f-4faf-8753-ee71b7a1fdcc" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="arct:PreLaunchInventoryPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Pre-Launch Inventory</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prior to obtaining initial regulatory approval for an investigational product candidate, the Company expenses costs relating to production of inventory as research and development expense in its consolidated statements of operations and comprehensive income (loss), in the period incurred. When the Company believes regulatory approval and subsequent commercialization of an investigational product candidate is probable, and the Company also expects future economic benefit from the sales of the investigational product candidate to be realized, it will then capitalize the costs of production as inventory.</span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Arcturus Therapeutics Holdings Inc. and its Subsidiaries</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notes to Consolidated Financial Statements &#8212; Continued</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_1f88e937-24f9-4cfa-a2ca-7335c10f6bcd_5" continuedAt="F_1f88e937-24f9-4cfa-a2ca-7335c10f6bcd_6"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8f172e73-190d-4273-9840-4ab75378b712" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Share-Based Compensation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company records share-based compensation for equity awards granted to employees, consultants, officers and directors within general and administrative and research and development expenses on the statements of operations and comprehensive income (loss). </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4fd36679-2a66-4ed9-8418-655ce35cf244" contextRef="C_f0e7f0b2-1598-4953-9f90-cc64a32fbc98" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Share-based compensation is recognized over the requisite service period of the individual awards using the straight-line attribution method, which generally equals the vesting period. Employees and officers&#8217; stock options have a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4227c422-ca7d-49ac-afcf-ad571923af6e" contextRef="C_f0e7f0b2-1598-4953-9f90-cc64a32fbc98" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ten-year</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> life and generally vest </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6fd662dd-2b92-4d01-aad5-d3407aa958fb" contextRef="C_55f99ccf-69c7-4793-a958-d0a9d4e65d04" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">25</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% on the first anniversary of the grant and in 1/36</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">th</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> equal installments on each monthly anniversary thereafter, such that options are fully vested on the </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_050c8337-061d-4080-8c29-d210d5c21400" contextRef="C_f0e7f0b2-1598-4953-9f90-cc64a32fbc98" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">four-year</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> anniversary of the date of grant. The exercisability and vesting periods of equity awards granted to consultants and directors vary.</span></ix:nonNumeric></span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of stock options is estimated using a Black-Scholes valuation model on the date of grant. This method requires certain assumptions be used as inputs, such as the fair value of the underlying common stock, expected term of the option before exercise, expected volatility of the Company&#8217;s common stock, expected dividend yield, and a risk-free interest rate. The Company has limited historical stock option activity and therefore estimates the expected term of stock options granted using the simplified method, which represents the average of the contractual term of the stock option and its weighted-average vesting period. For the nine months ended September 30, 2024, the expected volatility of stock options was based on the historical volatility of a peer group of publicly traded companies. For the three months ended December 31, 2024, the Company used its own historical volatility to estimate expected volatility, as it had accumulated sufficient historical stock price data. The Company has not declared or paid any dividends and does not currently expect to do so in the foreseeable future. The risk-free interest rates used are based on the implied yield currently available in United States Treasury securities at maturity with a term equivalent to the expected term of the stock options. The effect of forfeited or cancelled awards is recorded when the forfeiture or cancellation occurs</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_8e1a9b35-86ec-4ab8-8bda-cbc6c6d4d89f" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:InventoryCashFlowPolicy" escape="true"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Statement of Cash Flows</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e169f369-eee1-4bd1-b202-ea3a7f087e25" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" escape="true" continuedAt="F_e169f369-eee1-4bd1-b202-ea3a7f087e25_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets to the total of such amounts shown in the consolidated statement of cash flows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:56.66%;box-sizing:content-box;"/>
          <td style="width:1.26%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:10.72%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1.26%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:12.34%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1.26%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:10.5%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31,</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fd79bdba-7549-4324-b562-919c0b67777c" contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">237,028</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_08194fab-fc38-4444-abf3-cab1346d0b5f" contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">292,005</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1d5cdecc-6ea0-48cc-a2a1-9152c97c378f" contextRef="C_9b6438ac-a4af-4cb1-a7e8-04fc1dc8917f" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">391,883</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted cash - current</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_df1981fc-5752-4189-9f5d-6b430057c5a1" contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212" name="us-gaap:RestrictedCashCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">55,000</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c50429ce-8e21-40f1-9e34-33c1323877a2" contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc" name="us-gaap:RestrictedCashCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">55,000</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-current Restricted cash</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3e08fa6f-01a6-49bf-b565-d01cb9019775" contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,885</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c12b18ee-8355-42a6-89ec-09b9f671c21e" contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,885</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_860cfdbd-8f34-4c25-8fcb-0f2b263c8364" contextRef="C_9b6438ac-a4af-4cb1-a7e8-04fc1dc8917f" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,094</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total cash, cash equivalents and restricted cash <br/>&#160;&#160;&#160;&#160;&#160;shown in the statement of cash flows</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8ad4b348-ca84-4826-bf6e-6e49feffef0e" contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">293,913</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_063c54eb-7767-41f5-aa97-887b2e2c6ed6" contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">348,890</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b17f432f-02bf-4256-81fc-dd55ab765421" contextRef="C_9b6438ac-a4af-4cb1-a7e8-04fc1dc8917f" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">393,977</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></ix:nonNumeric></div></ix:nonNumeric></div><div><ix:continuation id="F_e169f369-eee1-4bd1-b202-ea3a7f087e25_1"></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ad20d937-66d0-4ebc-85f6-0424613fa328" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Tax Expense</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Income taxes are accounted for using an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial reporting basis and the tax basis of the Company&#8217;s assets and liabilities at the applicable tax rates, along with net operating loss and tax credit carryovers. The Company records a valuation allowance against its deferred tax assets to reduce the net carrying value to an amount that it believes is more likely than not to be realized. Management has considered estimated taxable income and ongoing prudent and feasible tax planning strategies in assessing the amount of the valuation allowance. Based upon the weight of available evidence, which includes the Company&#8217;s historical operating performance and limited potential to utilize tax credit carryforwards, the Company has determined that total deferred tax assets should be fully offset by a valuation allowance. When the Company establishes or reduces the valuation allowance against its deferred tax assets, its provision for income taxes will increase or decrease, respectively, in the period such determination is made.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is required to file federal and state income tax returns in the United States and various other state jurisdictions. The Company also files income tax returns in the foreign countries in which it operates. The preparation of these income tax returns requires the Company to interpret the applicable tax laws and regulations in effect in such jurisdictions, which could affect the amount of tax paid by the Company.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, the Company follows an accounting standard addressing the accounting for uncertainty in income taxes that prescribes rules for recognition, measurement, and classification in the consolidated financial statements of tax positions taken or expected to be taken in a tax return.</span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Arcturus Therapeutics Holdings Inc. and its Subsidiaries</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notes to Consolidated Financial Statements &#8212; Continued</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_1f88e937-24f9-4cfa-a2ca-7335c10f6bcd_6"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_302fb017-d2c6-4115-9e15-176bdebd091e" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Net (Loss) Income per Share</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic net (loss) income per share is calculated by dividing the net (loss) income by the weighted-average number of shares of common stock outstanding for the period, without consideration for common stock equivalents. Diluted net (loss) income per share is calculated by dividing the net (loss) income by the weighted-average number of shares of common stock and dilutive common stock equivalents outstanding for the period determined using the treasury-stock method. Dilutive shares of common stock for the years ended December 31, 2024 and 2023 were comprised of stock options and restricted stock units. Dilutive shares of stock for the years ended December 31, 2022 were comprised of stock options.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cdbbad2b-fdfc-40be-9c8d-3bd6349bb91c" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:Dividends" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_cd0e25c5-48ff-41ac-a49e-d6a18d54431f" contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c" name="us-gaap:Dividends" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> dividends were declared or paid during the reporting periods.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_302ef2a4-1871-44f4-a3cc-774fd0212a8f" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Adopted Accounting Pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires public entities to disclose information about their reportable segments&#8217; significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in ASC 280 on an interim and annual basis. ASU 2023-07 is effective for annual reporting periods beginning after December 15, 2023, and for interim reporting periods beginning January 1, 2025. The Company </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cc8aca20-67a8-490f-b009-60642815fe32" contextRef="C_7b5e8cb5-a2d5-4fd1-a235-2bb6e7524e95" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adopted</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ASU 2023-07 for the annual reporting period beginning on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4a1054ed-2ee9-4340-994d-1da364216cec" contextRef="C_7b5e8cb5-a2d5-4fd1-a235-2bb6e7524e95" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">January 1, 2024</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. See &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Note 12, Segment Information</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221; for further information.</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Issued Accounting Standards Not Yet Adopted</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. The Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on the consolidated financial statements and disclosures.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the FASB issued ASU 2024-03, Income Statement&#8211;Reporting Comprehensive Income&#8211;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, which requires public entities to disclose specified information about certain costs and expenses on an interim and annual basis. ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the impact that adoption of ASU 2024-03 will have on the financial statement disclosures.</span></p></ix:nonNumeric></div></ix:continuation></div>
  <div><ix:nonNumeric id="F_37efa941-31a9-43d7-80ce-b47bd991615e" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:RevenueFromContractWithCustomerTextBlock" escape="true" continuedAt="F_37efa941-31a9-43d7-80ce-b47bd991615e_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTE 3. Revenue</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has entered into license agreements and collaborative research and development arrangements with pharmaceutical and biotechnology companies, as well as consulting, related technology transfer and product revenue agreements. Under these arrangements, the Company is entitled to receive license fees, consulting fees, product fees, technological transfer fees, upfront payments, milestone payments if and when certain research and development milestones, technology transfer milestones or success-based milestones are achieved, royalties on approved product sales and reimbursement for research and development activities. The Company&#8217;s costs of performing these services are included within research and development expenses. The Company&#8217;s milestone payments are typically defined by achievement of certain preclinical, clinical, and commercial success criteria. Preclinical milestones may include </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> proof of concept in disease animal models, lead candidate identification, and completion of IND-enabling toxicology studies. Clinical milestones may, for example, include successful enrollment of the first patient in or completion of Phase 1, 2 and 3 clinical trials, and commercial milestones are often tiered based on net or aggregate sale amounts. The Company cannot guarantee the achievement of these milestones due to risks associated with preclinical and clinical activities required for development of nucleic acid medicine-based therapeutics and vaccines.</span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Arcturus Therapeutics Holdings Inc. and its Subsidiaries</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notes to Consolidated Financial Statements &#8212; Continued</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_37efa941-31a9-43d7-80ce-b47bd991615e_1" continuedAt="F_37efa941-31a9-43d7-80ce-b47bd991615e_2"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">
</span><span><ix:nonNumeric id="F_a08cf772-7ca7-42a9-b3e0-7a929c4e9fa5" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" escape="true" continuedAt="F_a08cf772-7ca7-42a9-b3e0-7a929c4e9fa5_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents changes in the balances of receivables and contract liabilities related to revenue generating agreements during the year ended December 31, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024: </span></ix:nonNumeric></span><span style=""></span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><ix:continuation id="F_a08cf772-7ca7-42a9-b3e0-7a929c4e9fa5_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:44.329%;box-sizing:content-box;"/>
        <td style="width:1.2%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.902000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.2%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.902000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.682%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.582%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Additions</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Deductions</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Contract Assets:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts receivable</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f975419d-51e1-48c2-a35f-ecb93c70d8a5" contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc" name="us-gaap:ContractWithCustomerAssetNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,064</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_24807bc9-5895-4a59-a2e3-e7bbccefb881" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="arct:ContractWithCustomerAssetAdditions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">98,430</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8f90a801-1092-485a-b90a-3a696ca1fe1f" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="arct:ContractWithCustomerAssetDeductions" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">126,520</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aefc4732-503e-4921-8a6e-52f74fbffcfb" contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212" name="us-gaap:ContractWithCustomerAssetNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,974</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Contract Liabilities:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred revenue</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_044c4727-54b5-4ec7-950f-341b3b52fe0b" contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">87,325</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_54925808-c444-4ceb-b4e8-f268a3166d40" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="arct:ContractWithCustomerLiabilityAdditions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">97,599</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3ccd6b22-05b8-49d1-b79c-0ee37ba3643d" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">152,806</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6ec4ba90-1f38-4280-8bb3-081ef10abd4b" contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,118</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2024, the Company recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f8d970ee-917b-46e6-9b64-b3c29cb7e1ac" contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">62.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in revenue from the deferred revenue balance as of December 31, 2023.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e849ddd0-6b1a-4b88-9411-c63df1a5d270" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:DisaggregationOfRevenueTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the Company&#8217;s revenue for the periods indicated. Approximately</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2d88030c-cf39-48a0-8883-492ef3710b93" contextRef="C_e6a54d12-2d06-43c8-a611-842ff0eff99d" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">138.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d4c134de-8a45-45b6-a363-62b35fd9446e" contextRef="C_e3934ce5-c321-4a31-b7d0-60e3e1ef8264" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">154.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6de99a51-f9a9-4ffa-b0a9-2e212d0a3097" contextRef="C_d88f1ae2-2110-4172-a005-770d3804d551" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">192.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of total revenue represents revenue derived from foreign countries for the years ended December 31, 2024, 2023 and 2022, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:51.33%;box-sizing:content-box;"/>
        <td style="width:1.4%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.957%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.4%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.957%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.26%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.697000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Collaboration revenue:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">CSL Seqirus</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b0de60f5-b114-4cf1-acde-64d281c163c5" contextRef="C_cb30b8bf-d65b-4a7e-8e21-e4aa8d48e2f3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">138,389</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1a4f60cf-9db5-4879-9cf8-32a8580b88e0" contextRef="C_cbbb84bd-f6c0-4979-a42e-6dd1dc94cd5c" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">154,264</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_854c6e64-1fa0-45e6-9894-0917b37a5f31" contextRef="C_596cb559-9f30-4570-b72b-2e4bf88511d2" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">154,425</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vinbiocare</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_67c1196a-08b2-4c39-bab0-58dc95fce8a2" contextRef="C_2d657502-e913-475b-9a66-3a5a4dec9710" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,571</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Janssen</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eb3cd49a-1ad3-4200-9b89-974a797c0144" contextRef="C_0a0009ee-75b0-4d6c-8c54-a3de804d67ed" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">660</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_24b07af1-c2b2-4b74-9702-844f97a2bc4a" contextRef="C_c25d021b-7bf8-40de-b1c3-f954fd411acc" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,201</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ultragenyx</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b28d4f24-1fa0-4b8c-95d1-2e400f11c95c" contextRef="C_6aef7a2d-0065-4f49-a030-b4de642f444a" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,837</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dee65b02-c4d0-462d-a185-8c8d5b8bd0de" contextRef="C_48e6c1d3-4d22-4c10-8a2a-1bdd49245c23" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,739</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Israel Ministry of Health</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b68385c4-d6a2-447e-9594-5cbd38660eb1" contextRef="C_eeccc958-3920-483a-bc18-4d732d1e801f" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,500</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f2dc037c-91a6-4ed0-8a10-c998a9a71f8e" contextRef="C_cdc3b296-383c-4f2b-8a23-fed8e5efc389" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">987</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ef19ead7-9756-4529-a28a-e4fbefe78e51" contextRef="C_a35204b8-793a-4f51-b6a2-2dad74d8547e" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,319</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total collaboration revenue</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ace94492-29b8-4c68-82ba-38010b3db31b" contextRef="C_200946b9-b524-4e78-9424-4e601b6b9f68" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">138,389</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0ac418e1-be8f-4766-a51d-9b5e0a19f28d" contextRef="C_e22ed845-7d56-4d58-bbda-cdb707f0cae4" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">157,748</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_edbb12fa-eabe-4710-8e13-703d72396c62" contextRef="C_e340decb-8e23-4aec-a50a-9afef8ee8eaf" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">205,755</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Grant revenue:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">BARDA</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6a6be758-07cb-43d5-b91b-7c3be0e47159" contextRef="C_8a8ee8e1-d0f5-45c7-a284-959089bf94e1" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,921</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f71f3d96-fc98-4dfa-a4f2-1f92d7273519" contextRef="C_db600b02-dfe3-4388-80ba-2f5ad5b53df0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,051</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_64672112-0791-48d1-9bfb-63d4944d756c" contextRef="C_f92977ac-e76b-4cb7-8d5a-5b699cbdb902" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">244</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total grant revenue</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c2487c50-2e22-4d12-b641-939e7d94fff0" contextRef="C_517ad6a3-e9ae-471c-a53f-67c77e50ab6f" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,921</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1aab2e7e-b488-48f5-992c-7f7e0fafada4" contextRef="C_3dcdc036-b6bb-44cc-9e78-55386dfe3195" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,051</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_27d2e00a-5177-4de8-9d86-999df14864fd" contextRef="C_45eb8bb7-286d-4047-9f32-b23ce157716c" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">244</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following paragraphs provide information regarding the nature and purpose of the Company&#8217;s most significant revenue arrangements.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">CSL Seqirus</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On November 1, 2022, the Company entered into a Collaboration and License Agreement (as amended, the &#8220;CSL Collaboration Agreement&#8221;) with Seqirus, Inc., a part of CSL Limited (&#8220;CSL Seqirus&#8221;), for the global exclusive rights to research, develop, manufacture, and commercialize vaccines. Under the terms of the CSL Collaboration Agreement, the Company provides CSL Seqirus with an exclusive global license to its mRNA technology (including STARR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) and LUNAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> lipid-mediated delivery, along with mRNA drug substance and drug product manufacturing process. CSL Seqirus will lead development and commercialization of vaccines under the collaboration. The collaboration plans to advance vaccines against SARS-CoV-2 (COVID-19), influenza, pandemic preparedness as well as three other infectious diseases.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company received a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8a243742-6bfe-41e3-849a-2d69e53f5d34" contextRef="C_7882f9eb-6eb4-4f9e-bdb7-9be9e4dde643" name="arct:UpfrontPaymentReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">200.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upfront payment and is eligible to receive over $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4617177e-14d8-476f-b294-7d683285f752" contextRef="C_07fceadb-01ec-4fd6-aff8-7976cff4540e" name="arct:EligibleToReceiveDevelopmentMilestonePayment" unitRef="U_USD" scale="9" decimals="-8" format="ixt:num-dot-decimal">1.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> billion in development milestones if all products are registered in the licensed fields and entitled to potentially receive up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_89d6d3e9-29d8-404b-883a-fcf636c4a61e" contextRef="C_07fceadb-01ec-4fd6-aff8-7976cff4540e" name="arct:EligibleToReceiveCommercialMilestonePayment" unitRef="U_USD" scale="9" decimals="-8" format="ixt:num-dot-decimal">3.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> billion in commercial milestones based on &#8220;net sales&#8221; of vaccines in the various fields. In addition, the Company is eligible to receive a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0acfe189-c7ca-467b-a250-3ff730931557" contextRef="C_46790da3-ab07-41f8-bb66-6d90294211d5" name="arct:PercentageOfNetProfits" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">40</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% net profit share for COVID-19 vaccine products and up to low double-digit royalties for vaccines against flu, pandemic preparedness and three other pathogens. During 2024, the Company achieve</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">d $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3311c16c-b1b3-459e-9d3b-22e3c39d810f" contextRef="C_f0949914-ab4f-42d5-bcb0-e24ecd07e8cf" name="arct:DevelopmentAndRegulatoryMilestonesAchieved" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">72.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million o</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">f development and regulatory milestones related to the CSL Collaboration Agreement, of which </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fb111700-0bad-447d-a7ab-716877395016" contextRef="C_7bb37bf1-61a9-4d5a-8bd6-2abfca1a4ec5" name="arct:AchievedDevelopmentAndRegulatoryMilestoneIncludedAccountsReceivable" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">none</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was included in accounts receivable as of December 31, 2024.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In evaluating the CSL Collaboration Agreement in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, the Company concluded that CSL Seqirus is a customer. The Company identified all promised goods/services within the CSL Collaboration Agreement, and when combining certain promised goods/services, the Company concluded that there are five distinct performance obligations. The nature of the performance obligations consists of delivery of the vaccine license, research and development services for COVID and non-COVID vaccines</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Arcturus Therapeutics Holdings Inc. and its Subsidiaries</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notes to Consolidated Financial Statements &#8212; Continued</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_37efa941-31a9-43d7-80ce-b47bd991615e_2" continuedAt="F_37efa941-31a9-43d7-80ce-b47bd991615e_3"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and regulatory activities for COVID vaccines. For each performance obligation, the Company estimated the standalone selling price based on 1) in the case of the license, the fair value using costs to recreate plus margin method and 2) in the case of research and development services and regulatory activities, cost plus margin for estimated full-time equivalent (&#8220;FTE&#8221;) costs, direct costs including laboratory supplies, contractors, and other out-of-pocket expenses for research and development services and regulatory activities.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, the transaction price primarily consisted of upfront consideration received and milestones achieved as of December 31, 2024. Additional variable consideration was not included in the transaction price at December 31, 2024 because the Company could not conclude that it is probable that including the variable consideration will not result in a significant revenue reversal.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company allocated the transaction price to the performance obligations in proportion to their standalone selling price. The portion of the upfront payment that was allocated to the vaccine license was recognized at the point in time it was transferred in 2022. The research and development and regulatory activities performance obligations are recognized over a period of time based on the percentage of services rendered using the input method, meaning actual costs incurred divided by total costs budgeted to satisfy the performance obligation. Any consideration related to sales-based royalties will be recognized when the amounts are probable of non-reversal, provided that the reported sales are reliably measurable and the Company has no remaining promised goods/services, as they are constrained and therefore have also been excluded from the transaction price. The revenue recognized in 2024 reflects variable consideration added to the transaction price upon the achievement of milestones, attributable to the license granted in 2022 and research and development services provided through December 31, 2024.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">T</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">otal deferred revenue as of December 31, 2024 and 2023 for the CSL Collaboration Agreement was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2316e8b0-4040-4802-b3b1-853ccae4d0eb" contextRef="C_7bb37bf1-61a9-4d5a-8bd6-2abfca1a4ec5" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">30.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_919df71b-8f59-4706-aeaf-cae6922d5211" contextRef="C_d4667b25-9ebe-441c-8ace-a7cddce91af6" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">87.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During 2023, the Company also received an advance payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7a21b84f-437a-4647-94ef-6926bc394225" contextRef="C_de7040c9-0664-4d4f-9974-fddd45db823c" name="arct:DevelopmentMilestonesReceivedAdvancePayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">23.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the manufacturing and supply of ARCT-154 drug product. The advance payment was for specified manufacturing runs of ARCT-154 which include the drug substance utilized, as well as the reservation fees and related manufacturing requirements. The Company concluded that the promise to manufacture and supply ARCT-154 drug product is a customer option as part of the CSL Collaboration Agreement and is accounted for as a separate contract. The Company recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3a703692-525b-4a95-9667-769d442f7b15" contextRef="C_6853a270-d4df-4f01-ae68-1bd1f016abe4" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">18.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in revenue related to this customer option during the second quarter of 2024. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_392b69be-f82a-402a-b92f-cd95a1c1d5c2" contextRef="C_8fd663c7-d616-4fa1-9c31-9db23c56c689" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> amount related to this customer option remained in deferred revenue as of December 31, 2024.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During 2023, the Company entered into an amendment to the CSL Collaboration Agreement, pursuant to which the Company agreed to sponsor and conduct a Phase 1 clinical study in the influenza field. As part of the amendment, the Company received $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4d41564e-4f27-4568-8dc5-550bbc900700" contextRef="C_6f2bd238-0b95-4b22-8c5a-121d7509ed58" name="arct:MilestonePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">17.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million from CSL Seqirus. The amendment also provides for up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3aa2bff8-5ce0-448e-82d4-d9327f8d1a95" contextRef="C_4a52e6bd-de03-4707-910b-3abb83ab2003" name="arct:AdditionalPaymentsUponMeetingCertainClinicalMilestones" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in additional payments which are achievable upon meeting certain clinical milestones relating to the Phase 1 clinical study in the influenza field. The Company previously concluded that the expansion of research and development support services under the CSL Collaboration Agreement represented an option that was not a material right. Therefore the Company concluded the promise to sponsor and conduct the Phase 1 clinical study is a separate contract and the sole performance obligation under the new arrangement. During the year ended December 31, 2024, the Company recognized revenue of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d3ae46a3-0112-42ce-8168-2c8008e95bc3" contextRef="C_3ca1293d-fd04-40b8-a46a-57af6a5ac7d7" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">12.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million related to the performance obligation compared to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_86d987a2-60a2-4fe1-89b7-cfb5d2319165" contextRef="C_6f2bd238-0b95-4b22-8c5a-121d7509ed58" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million during the year ended December 31, 2023. The remaining amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dd0cb973-7438-4094-822f-a38a89e15c4e" contextRef="C_ac8997ea-dc9f-4fed-83e0-b13eb0d07432" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million is included in deferred revenue.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the fourth quarter of 2023, the Company received an advance payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_35e5181f-101e-4a82-9ea9-8291b141efca" contextRef="C_86d66d5d-4c97-45bb-a084-bf8bbda66671" name="arct:DevelopmentMilestonesReceivedAdvancePayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million from CSL Seqirus for manufacturing activities related to COVID-19 vaccine product. During the first quarter of 2024, the Company received an additional advance payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f701ebf4-3c3a-4eac-9905-337348204a7b" contextRef="C_22f5e6fe-f31d-416e-a210-33674b90d66e" name="arct:DevelopmentMilestonesReceivedAdvancePayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million from CSL Seqirus for manufacturing activities related to COVID-19 vaccine product. The Company concluded that the promise to perform manufacturing activities is a customer option as part of the CSL Collaboration Agreement and is accounted for as a separate contract. The Company recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c6b50ee2-6046-4c72-9a38-eb82036f70f9" contextRef="C_c6809d71-13e7-4b1a-924f-d8abae76045c" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in revenue related to this customer option during the third quarter of 2024 upon the transfer of vaccine product to CSL Seqirus. The remaining $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_16fe7da1-ea7f-4564-94ea-c33aec6ae20f" contextRef="C_0fe3841a-f105-4a0f-a913-03e14cbebbf8" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million is included in deferred revenue as of December 31, 2024 and will be recognized as revenue when the remaining vaccine product is transferred to CSL Seqirus.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2024, the Company entered into an amendment to the CSL Collaboration Agreement, pursuant to which the parties agreed to, among other things, adjust (i) the development plans for certain product candidates, (ii) various development milestones related to such product candidates, (iii) provisions of the CSL Collaboration</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">17</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Arcturus Therapeutics Holdings Inc. and its Subsidiaries</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notes to Consolidated Financial Statements &#8212; Continued</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_37efa941-31a9-43d7-80ce-b47bd991615e_3"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Agreement related to specific royalty payments, (iii) provisions of the CSL Collaboration Agreement related to distributors, and (iv) proprietary payment calculations related to the foregoing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Vinbiocare</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During 2021 the Company entered into certain agreements with Vinbiocare, a member of Vingroup Joint Stock Company, whereby the Company would provide technical expertise and support services to Vinbiocare to assist in the build out of a mRNA drug product manufacturing facility in Vietnam. The Company received an upfront payment in aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_23fcb57d-d49c-4147-8359-b723c50ebdef" contextRef="C_8da6d6ac-b3ff-404b-afdf-8fd51a86a7c7" name="arct:UpfrontPaymentReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">40.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as part of the Vinbiocare Agreement. In October 2022, the Company and Vinbiocare executed a letter agreement terminating the Technology License and Technical Support Agreement and the Framework Drug Substance Supply Agreement (collectively, the &#8220;License &amp; Supply Agreements&#8221;). The Company incurred no financial penalties in connection with the termination of the License &amp; Supply Agreements and has no further financial obligations to Vinbiocare under these terminated agreements.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2022, in association with the termination of the License &amp; Supply Agreements, the Company signed the Study Support Agreement with Vinbiocare which provides that Vinbiocare shall continue to serve as the regulatory and financial sponsor of clinical studies conducted in Vietnam of ARCT-154 pursuant to the Company&#8217;s arrangements with Vinbiocare (the &#8220;Study Support Agreement&#8221;). To support the continuing activities of these studies, the Study Support Agreement further provides for the Company to conduct certain services and to compensate Vinbiocare to help achieve the objectives of these studies. In February 2023, the Company agreed to provide additional financial support in the amount of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_44196fb8-a8bf-4ee0-86de-fb54c35f5a08" contextRef="C_a8f29617-6dbc-47c2-bf34-7e091c3128a3" name="arct:AdditionalFinancialSupport" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to allow Vinbiocare to provide additional study support duties related to the ARCT-154 clinical study. As a result, the Company reserved $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_210cc31a-3016-4da0-8497-de3cea5e3e9f" contextRef="C_967a80b1-1866-4f20-95dd-a83f22149812" name="arct:ReservedUpfrontPayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">11.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of the original upfront payment to be paid to Vinbiocare over the future periods pursuant to the Study Support Agreement by reclassifying a portion of the upfront payment received from Vinbiocare pursuant to the License &amp; Supply Agreements, from deferred revenue to short-term and long-term liabilities, based on the anticipated timing of the payments to Vinbiocare, and removed that portion of the upfront payment from the transaction price of the modified arrangement. The transaction price was not adjusted for payments that are contingent upon the occurrence of future regulatory or sales-related events based on the information currently available to the Company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has concluded that it has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4d66d8d8-afa6-4cf3-87a3-daf30c7f41cd" contextRef="C_2b4a205f-e9c7-4a9b-9f7d-e2d74d8a8790" name="us-gaap:RevenueRemainingPerformanceObligation" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> remaining performance obligations under its prior arrangements with Vinbiocare as summarized above as of December 31, 2024. As of December 31, 2024, the Company has accrued liabilities related to this arrangement of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ecdd51da-b9aa-42cb-938a-ca516f083694" contextRef="C_eefa9a8b-a137-4b9b-a9bd-84d6397dcbae" name="us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in current liabilities that will be paid upon the occurrence of specified events through the end of 2025. Vinbiocare is also eligible to receive a single digit percentage of amounts from net sales, if any, of ARCT-154 (or next-generation COVID vaccine) up to a capped amount of low single digit millions. The Company had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f5a230e2-8d65-4489-8ef8-8c81c5dfa911" contextRef="C_2b4a205f-e9c7-4a9b-9f7d-e2d74d8a8790" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="6" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_0375b621-48c9-4dc0-a5c3-4676efec17dc" contextRef="C_4e71c9fa-246b-4174-807f-580b538d6c44" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="6" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> remaining deferred revenue as of December 31, 2024 or 2023.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">BARDA Grant</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In August 2022, the Company entered into a cost reimbursement contract with the Biomedical Advanced Research and Development Authority ("BARDA"), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS) for an award of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b4cadf41-1a7d-42e1-93ec-b28af3aecad5" contextRef="C_bf73fc87-a7ef-43a8-bf1b-0ee33d958d5f" name="arct:GrantRevenue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">63.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the development of a pandemic influenza vaccine using the Company's STARR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:8.040000000000001pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> self-amplifying mRNA vaccine platform technology. The Company earns grant revenue for performing tasks under the agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company determined that the agreement with BARDA is not in the scope of ASC 808 or ASC 606. Applying International Accounting Standards No. 20 ("IAS 20"), Accounting for Government Grants and Disclosure of Government Assistance, by analogy, the Company recognizes grant revenue from the reimbursement of direct out-of-pocket expenses, overhead allocations and fringe benefits for research costs associated with the grant. The costs associated with these reimbursements are reflected as a component of research and development expense in the Company&#8217;s consolidated statements of operations and comprehensive income (loss).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_509e5353-0fa0-4baf-9186-f01b17bb3f32" contextRef="C_2bb094b7-f6bc-4639-b097-78aa4e69c032" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">13.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_895d45c1-942b-4686-a978-c48807126263" contextRef="C_2b4e1b2e-3490-4f8f-9601-99e9e60ed774" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">9.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of grant revenue during the years ended December 31, 2024 and 2023, respectively, which is included in revenue on the Company's consolidated statements of operations. As of December 31, 2024, the remaining available funding net of revenue earned was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a4889f3d-9f64-4f4a-b26b-02ecfdb4e00b" contextRef="C_2bb094b7-f6bc-4639-b097-78aa4e69c032" name="arct:GrantRevenueOutstanding" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">40.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Arcturus Therapeutics Holdings Inc. and its Subsidiaries</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notes to Consolidated Financial Statements &#8212; Continued</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_63a6eee6-4d26-4078-b772-180587352a36" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:FairValueDisclosuresTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTE 4. Fair Value Measurements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company establishes the fair value of its assets and liabilities using the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company established a fair value hierarchy based on the inputs used to measure fair value.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The three levels of the fair value hierarchy are as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 1:  Quoted prices in active markets for identical assets or liabilities.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 2:  Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 3:  Unobservable inputs in which little or no market data exists and are therefore determined using estimates and assumptions developed by the Company, which reflect those that a market participant would use.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The carrying value of cash, restricted cash, accounts receivable, accounts payable, accrued liabilities and the Singapore loan approximate their respective fair values due to their relative short maturities. The carrying amounts of long-term debt for the amount drawn on the Company&#8217;s debt facility approximates fair value as the interest rate is variable and reflects current market rates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company's assets measured at fair value on a recurring basis consisted of money market funds. As of December 31, 2024, the Company's had money market funds with a fair value of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aad846b8-4210-4eb2-87d9-4e5b82b486ce" contextRef="C_44b8ebcf-fb2f-4241-9026-e24a66edc6b0" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">230.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">were classified within Level 1 of the fair value hierarchy. The fair value of these financial instruments was measured based on quoted prices.</span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0aedb48e-7e95-481b-a362-aa879ca63a9e" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTE 5. Accrued Liabilities Detail</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_143dd367-34c8-4fc3-962d-8d8370981e68" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued liabilities consisted of the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:61.08%;box-sizing:content-box;"/>
        <td style="width:1.66%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:15.8%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.66%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:15.8%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued compensation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fb40f7e9-82aa-4301-ac8a-07d60a0ffe19" contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,305</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fc4eeb67-33b2-4243-9eaf-a115fb9cdfff" contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,918</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cystic Fibrosis Foundation liability</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_51287b2f-13bb-4d86-9ab7-7068dc1d72ff" contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212" name="arct:AccruedCysticFibrosisFoundationLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,443</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f3d1ec53-c0bd-48e4-bf0d-a979ea0a6d28" contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc" name="arct:AccruedCysticFibrosisFoundationLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,633</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Income tax payable</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_80f41f4e-07d2-41cb-95d8-555affd5f314" contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc" name="us-gaap:TaxesPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">641</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current portion of </span><span><span style="-sec-ix-hidden:F_7bcaf8a7-146c-4002-845d-af462601018d;"><span style="-sec-ix-hidden:F_9747f896-2497-4837-848b-f002a89071bd;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">operating lease liability</span></span></span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c0609769-7a7a-45a3-adda-2719fc34ba18" contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,552</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_68569941-51b7-44fb-8246-e7d3a99e1106" contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,309</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Clinical trial accruals</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_782deb28-0311-4422-b7de-f80af56646d1" contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212" name="arct:ClinicalTrialAccrualsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,828</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_62cc314f-1389-4fe3-89cb-3283c3b25782" contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc" name="arct:ClinicalTrialAccrualsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,333</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vinbiocare contractual liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_850d604c-67b5-42a7-95ad-9e79c17d4757" contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212" name="arct:VinbiocareContractualLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,421</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ed66031d-a206-4453-b7af-e2cf34660152" contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc" name="arct:VinbiocareContractualLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,514</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Legal accrual</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_626ded6a-88f7-4488-8fc1-90219121941c" contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212" name="arct:LegalAccrualCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">130</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5b265660-1482-4c55-ae91-567d080d4209" contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc" name="arct:LegalAccrualCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">177</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other accrued research and development expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_441ecbba-3c8f-4325-a18f-ab0a7128b413" contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212" name="arct:OtherAccruedResearchAndDevelopmentExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,102</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_385b59e0-0884-47ed-a4d9-953bd26c2465" contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc" name="arct:OtherAccruedResearchAndDevelopmentExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,356</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2742b262-84d4-4324-a77b-1f3acdb74178" contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">38,781</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_027af7d5-31ee-49dd-ba0b-05bdaba669e3" contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,881</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_29cd3eeb-5d0f-4832-9221-f4a5c59a3d61" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTE 6. Property and Equipment, Net</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5047e589-b5e7-4bc7-a86d-a762fc0ec72a" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:PropertyPlantAndEquipmentTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment, net consisted of the following:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:61.08%;box-sizing:content-box;"/>
        <td style="width:1.66%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:15.8%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.66%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:15.8%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_23d26532-9110-4204-b4c5-626c1caf8dd4" contextRef="C_5a02c86b-64a7-48c8-9d61-fbfa2c4dde8a" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,864</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4c23db5c-6d51-4cde-b5ee-e2cb0676ceea" contextRef="C_7265865c-204c-46d5-a156-36e79a71f210" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,046</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computers and software</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5088a209-1389-4eba-87b0-1a39cf3f5f87" contextRef="C_9f995e84-394b-4f80-b22b-985e9d097bfd" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,131</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9ee38741-229b-4578-9760-c6e9f8887541" contextRef="C_0c651e95-fd64-4c52-a5f0-0d5b8015a505" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,275</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Office equipment and furniture</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b5a70934-fc7e-4c24-aee6-8e6624c96f63" contextRef="C_6e573c31-64c3-4efd-b469-ce13ad81a767" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">703</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9f8637dd-6bcd-4006-be03-b5b2717a6431" contextRef="C_ac4a66d0-a617-4eb3-97a5-5efc86181fd2" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">958</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7debdcab-b4e5-4ab8-910a-91aa4fc4c71a" contextRef="C_c9c5c093-9b6a-4d10-823e-777266370955" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,644</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_53137bf9-e4cd-44a8-af09-ab2648450c64" contextRef="C_486087ba-60a6-4677-9a46-887bc39af237" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,655</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Construction in progress</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4f70ac1c-a249-4150-a556-0caf11890cd2" contextRef="C_8a585c58-b141-436d-8855-b3bbdf1ff8a2" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">233</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dd52df36-19f3-434c-9aaf-5bec9b67a932" contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,342</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4caccdcf-66b4-4108-a59a-b375d58c53b1" contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,167</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less accumulated depreciation and amortization</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_34b54f7e-d307-43b3-b217-9dc13dbc4a07" contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,811</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7fc29068-855b-49ca-938c-d217c914864b" contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,740</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3e25fa3c-6f34-455a-94f5-1449a94339da" contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,531</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ca9c69c4-5258-4128-88e9-0a4bde6b1986" contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,427</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depreciation and amortization expense was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b31b7a4c-a51b-4eae-8712-f92237508f72" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f5d1a1e5-bb57-43e7-b397-fe58d59e6723" contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a4084ef2-5deb-4b82-becc-15e5e4d6dff0" contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the years ended December 31, 2024, 2023 and 2022, respectively. Construction in progress is primarily comprised of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> research equipment not yet placed in service.</span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">19</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Arcturus Therapeutics Holdings Inc. and its Subsidiaries</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notes to Consolidated Financial Statements &#8212; Continued</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f0f753ec-66d4-4825-9185-3d86ae344ee4" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:DebtDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTE 7. Debt</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Wells Fargo Credit Agreement</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 21, 2023, the Company&#8217;s wholly-owned subsidiary, Arcturus Therapeutics, Inc. entered into a credit agreement with Wells Fargo (the &#8220;Credit Agreement&#8221;) whereby Wells Fargo will make a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_72b08344-51f6-48a5-b41a-16b7789579e3" contextRef="C_86445ba3-f6f4-4676-90ed-50251dd3995d" name="us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">50.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million revolving credit line available to the Company (the &#8220;Loan&#8221;) and each Loan evidenced by a revolving line of credit note (the &#8220;Note&#8221;). On </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 26, 2024, the parties entered into Amendment No. 1 to the Credit Agreement, whereby the term was extended by </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c06b57fe-9649-4be3-bd9f-be61101d4481" contextRef="C_4c016b15-4aaa-4d51-bf03-ece9dddf38ac" name="arct:DebtInstrumentExtendedTermPeriod" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">one year</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to April 2026.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Borrowings under the agreement will bear interest at a rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f93a91f3-2e1a-4bf6-aa6f-6f418c170413" contextRef="C_86445ba3-f6f4-4676-90ed-50251dd3995d" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">1.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% above either the Daily Simple SOFR or Term SOFR (as such terms are defined in the Note), with &#8220;SOFR&#8221; being the rate per annum equal to the secured overnight financing rate as administered by the Federal Reserve Bank of New York. If an Event of Default (as defined in the agreement) occurs, then all Loans shall bear interest at a rate equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_93ee3807-1378-46b7-8471-4fd6b12dae16" contextRef="C_41912f33-1403-4518-9ac5-80cc445c3148" name="us-gaap:LineOfCreditFacilityInterestRateDuringPeriod" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">2.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% above the interest rate applicable immediately prior to the occurrence of the Event of Default.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The original term of the agreement is </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7a530f90-b214-4976-b36d-cd36710fd43f" contextRef="C_41912f33-1403-4518-9ac5-80cc445c3148" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">two years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, with an option for </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_88f18bf2-2dcd-4129-8e45-d99777bb2b97" contextRef="C_41912f33-1403-4518-9ac5-80cc445c3148" name="arct:DebtInstrumentOptionForRenewalTerm" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">one-year</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> renewals subject to Wells Fargo approval and the Company furnishing to Wells Fargo a non-refundable commitment fee equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6ecda0f3-1a23-485c-8984-b51a9c5920bc" contextRef="C_41912f33-1403-4518-9ac5-80cc445c3148" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">0.25</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the Loan amount for each such renewal. There is no penalty for terminating the facility prior to the maturity date of the Note. As collateral, the Company has agreed to pledge $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1d342396-0939-4aed-b0fa-be2b03fb7f91" contextRef="C_86445ba3-f6f4-4676-90ed-50251dd3995d" name="us-gaap:DebtInstrumentCollateralAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">55.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in cash to be held at the Company&#8217;s securities accounts with Wells Fargo Securities, LLC, an affiliate of Wells Fargo, pursuant to a security agreement. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_39de122d-aaba-4cf3-9e51-68fabf0d193f" contextRef="C_3e3c5d0e-9c24-4b1b-b7e1-d57a6036bc5a" name="us-gaap:LongTermDebt" unitRef="U_USD" scale="6" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> amounts were outstanding as of December 31, 2024.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Manufacturing Supply Agreement</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On November 7, 2020, the Company&#8217;s wholly-owned subsidiary, Arcturus Therapeutics, Inc., entered into a Manufacturing Support Agreement (the &#8220;Support Agreement&#8221;) with the Economic Development Board of the Republic of Singapore (the &#8220;EDB&#8221;). Pursuant to the Support Agreement, the EDB agreed to make a term loan (the &#8220;Singapore Loan&#8221;) of S$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9625418b-d73a-4037-8285-4d7c4d123300" contextRef="C_eacfa335-f40d-41a3-a10a-eb5d58e4252c" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_SGD" scale="6" decimals="INF" format="ixt:num-dot-decimal">62.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to the Company, subject to the satisfaction of customary deliveries, to support the manufacture of the LUNAR-COV19 vaccine candidate (ARCT-021). The Singapore Loan accrues interest at a rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2293efcf-f90b-4287-910f-9e5f2602463d" contextRef="C_eacfa335-f40d-41a3-a10a-eb5d58e4252c" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">4.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% per annum calculated on a daily basis. The Company elected to borrow the full amount available under the Support Agreement of S$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e9c6473f-2be2-4741-8e3b-b85796863699" contextRef="C_fdc06d4c-b98b-4078-96e6-528aa846af54" name="us-gaap:BorrowingsUnderGuaranteedInvestmentAgreements" unitRef="U_SGD" scale="6" decimals="-5" format="ixt:num-dot-decimal">62.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million ($</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ad32c25b-9d44-41da-95a8-fd37f23c7bd4" contextRef="C_fdc06d4c-b98b-4078-96e6-528aa846af54" name="us-gaap:BorrowingsUnderGuaranteedInvestmentAgreements" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">46.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million) on January 29, 2021.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the first quarter of 2023, the EDB agreed to an extension of the reconciliation period to March 22, 2023, with unused funds not utilized for the manufacture of ARCT-021 as of such date returned to the EDB. As of December 31, 2022, the outstanding balance of the Singapore Loan, which includes accrued interest, was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f1da9629-e808-4b09-bc94-9096dd31713b" contextRef="C_67ddf72c-3213-4f12-be1f-701d0566198c" name="us-gaap:LongTermDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">50.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of which the Company paid S$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a934203a-bca5-40c5-8f3f-d8b074ecc23b" contextRef="C_a3464474-dfd3-43d9-b123-3d9c2d59b71e" name="us-gaap:RepaymentsOfLongTermDebt" unitRef="U_SGD" scale="6" decimals="-5" format="ixt:num-dot-decimal">22.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million ($</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a60aec26-4913-413a-9e1d-1fb83227ef1c" contextRef="C_a3464474-dfd3-43d9-b123-3d9c2d59b71e" name="us-gaap:RepaymentsOfLongTermDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">17.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million) in March 2023. During the first quarter of 2023, the remaining principal portion of the Singapore Loan plus accrued interest, totaling $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7ba16ea8-47e8-424e-bb36-620900082881" contextRef="C_bc749b60-01c7-407d-a66f-0ad31c3e3223" name="arct:RemainingLoanIncludingAccruedInterestForgiveable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">34.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, was forgiven and recorded as a gain on debt extinguishment in the consolidated statement of operations and comprehensive loss.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0aae200b-f4fc-4570-a6c8-1b19d0802842" contextRef="C_18e8b3d8-b758-4fc5-9f07-48c66ed98d2a" name="us-gaap:InterestExpenseLongTermDebt" unitRef="U_USD" scale="6" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> interest expense was incurred on the Singapore Loan for the year ended December 31, 2024, and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d3ccf185-b53d-4721-8c71-0c3f61039264" contextRef="C_2d41c197-8a7f-4abe-8802-3f3779ba2106" name="us-gaap:InterestExpenseLongTermDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a4a5ef8e-a7bc-4a26-92fb-3f017a2d0842" contextRef="C_dbe29eec-3da1-447f-afbd-bdbab15adc3a" name="us-gaap:InterestExpenseLongTermDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of interest expense was incurred for the years ended December 31, 2023 and 2022, respectively. As of December 31, 2023, the Company no longer had debt or interest related to this agreement.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Termination of Agreement with Western Alliance Bank</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 14, 2023, the Loan and Security Agreement, dated as of October 12, 2018 (as amended and supplemented, the &#8220;Western Alliance Agreement&#8221;) with Western Alliance Bank, an Arizona corporation (&#8220;Western Alliance&#8221;), was terminated (the &#8220;Termination&#8221;) upon the receipt by Western Alliance of a payoff amount of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aac8962d-8ec2-479e-a516-acfab568a8ba" contextRef="C_21bee724-74a7-4507-ac63-b66c0326eeb4" name="us-gaap:RepaymentsOfLongTermDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million from the Company. The Western Alliance Agreement provided for a collateralized term loan in the aggregate principal amount of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e7b25916-e27b-4f08-998e-0e4a53f5d6bd" contextRef="C_4e721db5-40e6-4075-95cb-a09086f8814b" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">15.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, with interest at a floating rate ranging from </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_09b7df03-db62-42e8-9734-04c708fc2c75" contextRef="C_98a6fdf5-4340-4e1b-9ce6-86901cc3549e" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">1.25</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6d2fc73c-7c21-4a8a-a070-5722c63afd1a" contextRef="C_69de4a86-a3b0-473a-bcf9-e08244abbdd7" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">2.75</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% above the prime rate and a maturity date of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e9346541-1f48-4448-a883-022c23d7a05b" contextRef="C_21bee724-74a7-4507-ac63-b66c0326eeb4" name="us-gaap:DebtInstrumentMaturityDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 30, 2023</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The payoff amount was made by the Company to Western Alliance from available cash on hand, pursuant to a payoff letter, and included payment of (i) approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_42c8cc12-d2d0-4fff-81ce-4ab086ac85e7" contextRef="C_21bee724-74a7-4507-ac63-b66c0326eeb4" name="arct:RepyamentOfPrincipalAndInterestOnCollateralizedTermLoan" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in principal and interest, (ii) $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1b209132-3645-4a55-8811-f50112fda940" contextRef="C_4e721db5-40e6-4075-95cb-a09086f8814b" name="us-gaap:DebtInstrumentFeeAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million fee payable upon prepayment as a result of prior FDA approval of an IND and (iii) de minimis amounts in prepayment charges and various operational fees. The Company was released from all liens under the Western Alliance Agreement.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recorded </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_709c78d2-a6c3-44c8-978f-e565d8ddbfdf" contextRef="C_e555c3b5-c6bf-47e7-838e-8773ebae68d0" name="us-gaap:InterestExpenseLongTermDebt" unitRef="U_USD" scale="6" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> interest expense for the year ended December 31, 2024, and for the years ended December 31, 2023 and 2022, the Company recorded interest expense of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3094b3a8-39fb-4e81-b0da-14b9acaa59bf" contextRef="C_a64be24b-e012-4869-ab48-edbde5729fa1" name="us-gaap:InterestExpenseLongTermDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2f4c8f75-aa53-40bc-9ad7-090f6b416762" contextRef="C_dfad2efd-655c-4712-ad55-9208245cce2b" name="us-gaap:InterestExpenseLongTermDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">20</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Arcturus Therapeutics Holdings Inc. and its Subsidiaries</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notes to Consolidated Financial Statements &#8212; Continued</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9fc053f7-5bf5-4416-9672-2f20c9226d40" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTE 8. Stockholders&#8217; Equity</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Net (Loss) Income Per Share</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Potentially dilutive securities that were not included in the calculation of diluted net loss per share for the year ended December 31, 2024 and 2023 as they were anti-dilutive totaled </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e7b22a03-c041-42b7-9e05-56b54feeb5e4" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a1b69ee6-185d-4720-a0cd-0225f085e3bd" contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively. Potentially dilutive securities that were not included in the calculation of diluted earnings per share for the year ended December 31, 2022 as they were anti-dilutive totaled </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_25b17d12-01db-426f-9a4d-bbc47788d2eb" contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div><ix:nonNumeric id="F_ff20b1bb-44d1-463d-ae01-f6f2da6b71d2" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true" continuedAt="F_ff20b1bb-44d1-463d-ae01-f6f2da6b71d2_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTE 9. Share-Based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In June 2024 at the Company&#8217;s 2024 Annual Meeting of Stockholders (the "2024 Annual Meeting"), the stockholders of the Company approved an amendment to the Company&#8217;s 2019 Omnibus Equity Incentive Plan (as amended, the &#8220;2019 Plan&#8221;) which, among other things, increased the aggregate number of shares authorized for use in making awards to eligible persons under the 2019 Plan by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8695cd62-7547-4b2a-ad3a-63877d362edf" contextRef="C_79b86a89-0a00-45b1-8004-7d4dc0cdea25" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares, for a total of up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7376f0c2-a0ea-484b-a964-1cce0a012980" contextRef="C_f82651ae-69da-4140-af2f-5b915dc1aca7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">10,750,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares available for issuance. As of December 31, 2024, a total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_63c7a750-9210-4478-acb6-4fa0a3a0ba1c" contextRef="C_1a91ccd4-4bd8-43c2-8051-45a814608dfc" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,834,158</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares remain available for future issuance under the 2019 Plan, subject to the terms of the 2019 Plan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2021, the Company adopted the 2021 Inducement Equity Incentive Plan which covers the award of up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8aa8ed9c-70a6-4fb5-a60f-451ef4aaca39" contextRef="C_2cc45ff1-3360-475a-b5da-15ae2c8d66aa" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock (the &#8220;2021 Plan&#8221;) effective as of October 15, 2021. Approval of the Company&#8217;s stockholders is not required as a condition to the effectiveness of the 2021 Plan for so long as the plan is in compliance with applicable Nasdaq inducement plan rules. In April 2022, the compensation committee of the Company&#8217;s board of directors approved a proposal to reduce the total number of shares available for future issuance under the 2021 Plan to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d82feab8-4cce-4e05-a805-40deb99959f5" contextRef="C_e3cf53cd-b1a1-435f-8cee-4794f5764eb6" name="arct:ReductionInNumberOfCommonStockCapitalSharesAvailableForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">130,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. As of December 31, 2024, a total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_400dc19c-0a5d-4576-9306-9fcac87ef6c3" contextRef="C_d22dc742-0007-4f3e-97ad-b0aa9112af8c" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">124,697</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares remain available for future issuance under the 2021 Plan, subject to the terms of the 2021 Plan.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Share Options</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5e73e3c9-85b2-46e5-9049-ccaa080fda7b" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents the weighted-average assumptions used in the Black-Scholes valuation model by the Company in calculating the fair value of stock options granted:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.334%;box-sizing:content-box;"/>
        <td style="width:1.501%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.867999999999999%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.501%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.867999999999999%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.281%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.648%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Year Ended December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected life (in years)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_78dee1eb-5be8-4df2-ba90-29a0b1f5db8c" contextRef="C_f94c3743-e85f-4283-b541-3b2a49e36750" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.88</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_a650983c-060c-41d5-b884-876a6a5ce3ce" contextRef="C_e343b8cf-c999-46dc-82b2-5e281a84df00" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.04</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_6877d5f1-8330-4448-84bd-a96868b11661" contextRef="C_d50d4b6b-e748-48a2-99dc-da00925623e4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.05</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ff238f92-6474-4053-9af1-a54586c46366" contextRef="C_f94c3743-e85f-4283-b541-3b2a49e36750" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">91.4</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_11f0b526-3968-45b3-9d1c-d73a2d0948d7" contextRef="C_e343b8cf-c999-46dc-82b2-5e281a84df00" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">76.1</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0e1d5abc-05c6-4170-aafb-4d2685ce5aa9" contextRef="C_d50d4b6b-e748-48a2-99dc-da00925623e4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">82.1</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b41274f2-c6a0-49cc-9c8d-a22e4ce162ce" contextRef="C_f94c3743-e85f-4283-b541-3b2a49e36750" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.24</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_84f74c9a-0dcd-470b-b7a7-53de8d5c2f29" contextRef="C_e343b8cf-c999-46dc-82b2-5e281a84df00" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">3.91</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0234816e-49d1-478c-8d06-87f0c3678658" contextRef="C_d50d4b6b-e748-48a2-99dc-da00925623e4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">2.93</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Grant date weighted average fair value</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_07021d8d-fe50-4349-ae8f-c5266def208f" contextRef="C_f94c3743-e85f-4283-b541-3b2a49e36750" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">22.62</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_623dd13c-197c-419e-be77-8c052334c7ee" contextRef="C_e343b8cf-c999-46dc-82b2-5e281a84df00" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">18.87</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d2a977ac-6504-47bb-91f0-bcb71dd44152" contextRef="C_d50d4b6b-e748-48a2-99dc-da00925623e4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">15.56</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_55593d5a-daba-44b3-895d-d4c968956a0d" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the Company&#8217;s stock option activity for the year ended December 31, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:46%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of<br/>Shares</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>Average<br/>Exercise Price</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term (Years)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate<br/>Intrinsic Value<br/>(in thousands)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding &#8211; December 31, 2023</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d3ef3dab-f9d5-46cf-abd2-f5baca76d42c" contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">7,971,127</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_01fff371-fc97-43ef-b11d-263e0211dbb3" contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">33.55</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_3440d15c-520d-4670-92a6-e78682bfdd77" contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.9</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_334fbabe-48d5-4892-8662-8e998c6a9df5" contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">53,295</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9015bc2b-cc5d-49c4-bf9b-40cd8e248efa" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">740,594</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_545f3d36-9bfc-48c2-80e0-7e8929a4949a" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">22.62</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9e7cf2b6-b9ee-4464-954a-98744e34b2ed" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">228,328</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3a417277-a439-4da2-8570-4fc901888b32" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">20.74</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited/cancelled</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2fd310a9-5bbe-4f15-ad31-0c5d30732529" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">404,641</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4282339a-d14b-4cb7-8c48-62772dd87003" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">42.43</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding &#8211; December 31, 2024</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_38061d77-f17b-40b7-85d6-7cebc21c3d27" contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">8,078,752</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2956c632-c90d-461e-bce1-852b0d27d89e" contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">32.38</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_3f3379d4-ba43-4e94-bf08-b112324eb020" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.2</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_718ea3a9-36a7-4222-8936-d142fbcd7856" contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,247</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercisable &#8211; December 31, 2024</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_de855dc4-a400-433b-a3a2-234213bfc975" contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,983,108</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1c46efbc-a37f-4bd7-b415-7ea9948eddfd" contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">37.27</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_29c15b9a-4029-40ae-8e33-98c127e7b6c8" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.4</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4e2ccd24-5fd4-4a30-9ed8-d9b616037099" contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,796</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercisable and expected to vest &#8211;<br/>&#160;&#160;&#160;December 31, 2024</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_36ca5c19-6b69-4d84-b108-cb60a2a8dfbc" contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">8,078,752</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_07eb711a-689b-4f45-b232-bd48722a3e41" contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">32.38</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_1aed82ee-6822-4257-ac02-f89123648363" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.2</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c35a3afb-a5a0-42e7-ab87-50813d95591c" contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,247</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the total unrecognized compensation cost of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c7d898b2-c92b-4318-a78d-553d0872127a" contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">48.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million will be recognized over the weighted-average remaining service period of approximately </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1a3d7126-04d4-4205-a020-8f102c8725ea" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.6</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years. The fair value of the options vested during the years ended December 31, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024 , 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and 2022 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eaae903d-0fd8-41b9-95f7-d298e70eb9c3" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">40.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_72c834ed-ad53-4770-a5b2-9eef7e4a3a66" contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">35.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_577e8d49-abc7-486d-8ffa-2a59ecafdc46" contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">39.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively. The total intrinsic value of options exercised during the years ended December 31, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and 2022 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aa3f5211-e195-40be-b81c-b6cc58a56c45" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_693f53d9-be69-427f-9d38-411845f06e33" contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2fef3ee4-bbeb-4903-b15e-c090929c3737" contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">21</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Arcturus Therapeutics Holdings Inc. and its Subsidiaries</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notes to Consolidated Financial Statements &#8212; Continued</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_ff20b1bb-44d1-463d-ae01-f6f2da6b71d2_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restricted Stock Units</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In August 2023, the Company granted </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_59e4531e-d153-44e4-affa-a007f3934c40" contextRef="C_7c8f1ee8-0d0f-434d-9eb4-6868c4d8c3c9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">18,786</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> restricted stock units (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8220;RSUs&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) to its board of directors, when the market value of the Company's common stock was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_635e853b-9508-49c0-a6fa-04d532753ace" contextRef="C_415079ce-5509-40be-96cd-1470dad8f0d8" name="us-gaap:SharePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">34.92</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. These RSUs fully vested at the Company's 2024 annual stockholders' meeting. However, the release of the units remains subject to specific conditions and will occur only in the event of a board separation or a change in control.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bf45e103-dc1d-4363-a04d-8b03b36616cc" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the Company&#8217;s RSU activity for the year ended December 31, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.58%;box-sizing:content-box;"/>
        <td style="width:1.28%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.42%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.76%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.96%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of<br/>Shares</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>Average<br/>Grant<br/>Date<br/>Fair Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding &#8211; December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_65771d8f-783e-471a-9648-1e22d7e06a41" contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">18,786</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_79b4bb72-bdd4-4704-8326-0848d13d169a" contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">34.92</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Awarded</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Released</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding &#8211; December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5378d9b5-0418-400e-91d1-a710108e0b16" contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">18,786</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3a879217-c72e-44f0-b4f4-04c12ca6aee2" contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">34.92</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7b4898db-1b61-491c-982f-4a52e5969537" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" escape="true"><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Share-based compensation expenses included in the Company&#8217;s statements of operations and comprehensive income (loss) for the years ended December 31, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024,  2023 and 2022 were:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.58%;box-sizing:content-box;"/>
        <td style="width:1.4%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.82%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.4%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.82%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.28%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.700000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Year Ended December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_87b9756d-ec96-45b3-b870-b9724c9c6252" contextRef="C_8dcffe65-b98b-4723-af16-5b3daa5d33c2" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,456</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_67c79033-310a-4515-8458-0e414f0affc6" contextRef="C_152910ca-c407-48c4-8614-914f708479a3" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,950</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b71aac03-cdf8-4f3f-ad33-53ef73d6bfa1" contextRef="C_10ba438f-86e7-4bea-afe6-6381fb76f525" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,081</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_64cc021a-0278-4e07-9acc-1bc020030afa" contextRef="C_654bde4e-918b-4b9c-901a-10010de70313" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,532</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9697d042-ada2-4cc0-9a9b-0c9d154262fe" contextRef="C_ff7ed278-8619-4daa-85d7-a6142360937e" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,699</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f72be14a-5728-4b00-9084-8dbdcca2e100" contextRef="C_28c7b4d4-46b4-403b-a81e-106c6eae4759" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,530</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8e11889f-46ab-4ad1-94ad-f8f32e4e46d8" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">37,988</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4f5a41f6-4030-4fc4-ae96-f090b331e281" contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">34,649</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6dbeb9dc-67e6-429a-8644-9b507b38f1d0" contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,611</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:continuation></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_65b20b99-0a80-4494-94f9-18c0c40771d2" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true" continuedAt="F_65b20b99-0a80-4494-94f9-18c0c40771d2_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTE 10. Income Taxes</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_22f66645-416a-46f6-970e-0d88d1c0c2c9" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A reconciliation of (loss) income before income taxes for domestic and foreign locations is as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.791%;box-sizing:content-box;"/>
        <td style="width:1.26%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.642000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.26%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.262%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.26%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.522%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Year Ended December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">United States</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f072b85f-0528-4851-b2ec-e79471351881" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">81,050</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9a3a14df-6288-4886-894b-fe624860fff5" contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">27,890</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2f88fc81-680a-459d-a8f3-6c1dfe9c5f80" contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,644</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total (loss) income before income taxes</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_01b3af29-d75d-4fb6-a549-a8d6badbebaf" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">81,050</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ba5d3ddf-fd1e-4887-85c0-c1a00cd11077" contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">27,890</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eae7e8cb-f13c-4b68-acaa-3bcbc4dae9f4" contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,644</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c419aa25-d0ac-4696-819d-5c8adc7fad33" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A reconciliation of income tax (benefit) expense for the years ended December 31, 2024, 2023 and 2022 is as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.66%;box-sizing:content-box;"/>
        <td style="width:1.26%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.72%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.26%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.34%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.26%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.5%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Federal</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8ea14788-136c-4241-be39-c5d83187547f" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:CurrentFederalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">11</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ca816c84-4542-4aee-b166-2e8aee24a09f" contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c" name="us-gaap:CurrentFederalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,246</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_04943f6e-8e1b-43df-9b4e-3418260be842" contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812" name="us-gaap:CurrentFederalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,121</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6fe11ea1-00c5-44e5-b15d-ed6dfbea9e06" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f3b73f8e-f857-4784-bcfd-6b9133e599d6" contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">589</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_39f0b5a0-23ec-4b64-9102-51add4853d71" contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">174</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total current income tax (benefit) expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ca4e21e4-7fdf-4180-9f15-634615fdffca" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:CurrentIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cf8c303f-5d28-4283-961d-51b9f0075b80" contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c" name="us-gaap:CurrentIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,835</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8ddd3111-ebb2-4556-a0ec-952dd31a55f6" contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812" name="us-gaap:CurrentIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,295</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Federal</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred income tax expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total income tax (benefit) expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_76ef2162-6da2-4e6d-a482-50db8300a0bb" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_887981e9-1c80-49b0-9934-708b0afa10fd" contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,835</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6f6d74a5-ff9d-49cf-be73-239c64a07ac6" contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,295</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">22</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Arcturus Therapeutics Holdings Inc. and its Subsidiaries</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notes to Consolidated Financial Statements &#8212; Continued</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_65b20b99-0a80-4494-94f9-18c0c40771d2_1" continuedAt="F_65b20b99-0a80-4494-94f9-18c0c40771d2_2"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f72c119b-661a-4483-8d85-bd0e074f8cc3" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A reconciliation of the federal statutory income tax rate to the Company&#8217;s effective income tax rate is as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.451%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.982%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.581999999999999%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.982000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Federal statutory income tax rate</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fd47558d-9d43-4040-95c3-c61dc2f1c23e" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">21.0</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0541d8c7-dd6f-41d4-b50d-f4660f034f2a" contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">21.0</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ace850ab-9d2b-4fac-8891-bda66aac8882" contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">21.0</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State income taxes, net of federal benefit</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5185c5d4-fac6-42e9-9a5e-2e2a54fd3220" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">1.9</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_baee6e90-f69b-4b5a-9711-659cc3674abc" contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">1.9</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7474e7cd-752b-40cc-a86b-fcc49d5a25ca" contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">7.2</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Share-based compensation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eaa7350f-e1db-4ee4-83d7-42d6f2e74ab2" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">1.9</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a33634b6-0e43-4a2b-9727-8a143ec11382" contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">2.5</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_54377556-1d34-4029-a5e6-0f5bef9eb23b" contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">16.1</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Officers compensation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_930927d9-4a88-446a-9594-a176cc62be33" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="arct:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensation" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">3.4</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_44d79312-a34f-4594-929c-304d6248d77e" contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c" name="arct:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensation" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">7.4</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4388ec9f-fab7-434d-9c81-d91b340bbc7c" contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812" name="arct:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensation" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">21.8</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development credits</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a4b3cced-0baf-40c9-af2b-c1e7c40e3d2d" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="arct:EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentCredits" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">24.0</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2eaa181f-603e-4ce5-830c-5d50573e66e1" contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c" name="arct:EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentCredits" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">20.0</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e672bdc4-762e-4aca-9d0f-d5f249178304" contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812" name="arct:EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentCredits" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">40.3</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Uncertain tax positions</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_89574350-b313-4f27-b573-beb05eef0105" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="arct:EffectiveIncomeTaxRateReconciliationUncertainTaxPosition" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">3.7</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c69be6c0-9706-4f9e-8069-1b6cd4244104" contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c" name="arct:EffectiveIncomeTaxRateReconciliationUncertainTaxPosition" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">2.4</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f76340a3-0ebc-48b4-9af4-0126ca8c07fb" contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812" name="arct:EffectiveIncomeTaxRateReconciliationUncertainTaxPosition" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">9.0</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in tax rate</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e3b51f55-1bbf-4d48-9074-888f62169914" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">1.4</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7f30c88f-383f-469d-a689-bc7d047c4e95" contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1a60cd84-7747-480d-ae00-7606da469873" contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">12.6</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_deebb7b7-8f4b-46b9-9d62-5f562a20e0e8" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">36.1</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_11e8d4c1-4c76-41d8-bfff-a43b5a8e2b88" contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">36.5</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1a24b0b0-1f30-480f-ad8e-0168c1194c7d" contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">9.4</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fc9601eb-4897-4f96-ac0e-d03a4a6d6c38" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5881f5a6-ba7a-4917-ad92-e3dc8f0e5582" contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dbac3b76-6844-4f43-915a-5a30267b0cf1" contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Permanent differences</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_79efe3b0-9667-4980-8819-062b92577ae6" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="arct:EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bd12eb28-a1ba-4537-8440-c43f8177c65d" contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c" name="arct:EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">0.7</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8a175b34-3b97-450c-8c4a-0a3ef4788549" contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812" name="arct:EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.4</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Provision for income taxes</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_420d053f-d3e2-4371-b2b0-003bdec493ac" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.0</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_855bb6c4-0bae-44e6-9cbe-2049760e4170" contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">6.7</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6fac4338-dc42-4d29-8499-252645b33652" contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">12.2</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_46ca3fc5-c15b-45b3-b62a-2cd538050325" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The significant components of deferred income taxes are as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.7%;box-sizing:content-box;"/>
        <td style="width:1.46%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.76%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.46%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:14.620000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net operating loss</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7aa65770-dc4c-473e-94ec-f9aed7b21930" contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,413</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b97f7d73-eec2-40ff-a665-38674bcd86e3" contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,147</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax credits</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3d777a07-f311-4067-af7f-e6a91bc5adf7" contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,472</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_018ce71c-aee7-4177-824b-48ff6b3a7b8b" contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,723</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_57aa8270-9ca7-4b5c-a735-747677c091c8" contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,966</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a44c06f3-51f0-4c46-ad2b-fdef2eefe787" contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">943</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred revenue</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_87eaf2c9-3de1-4a9e-b607-72bb0da63981" contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212" name="us-gaap:DeferredTaxAssetsDeferredIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,515</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4a0e13f3-0f3a-4513-8644-79498cab4276" contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc" name="us-gaap:DeferredTaxAssetsDeferredIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,014</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inventory</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f11c81e4-7586-4e8b-851b-7d413ea60051" contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc" name="us-gaap:DeferredTaxAssetsInventory" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,961</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Basis difference in equity investments</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bcf9f880-5d7f-4f9b-b6d2-f8539c4200d0" contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212" name="us-gaap:DeferredTaxAssetsEquityMethodInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,127</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_793338fc-c0f4-4efd-b866-78f7dadba5c4" contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc" name="us-gaap:DeferredTaxAssetsEquityMethodInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,202</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Capitalized R&amp;D</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e39a3c69-0411-4d4e-bda9-31e8cfb25f03" contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212" name="arct:DeferredTaxAssetsCapitalizedResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">60,104</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3065df95-cc81-4377-9ed3-e20144abca2b" contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc" name="arct:DeferredTaxAssetsCapitalizedResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41,971</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Right-of-use lease liability</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2dbbd9ba-c4f7-4919-90ae-8553416508d5" contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212" name="arct:DeferredTaxAssetsRightOfUseLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,601</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_194e296f-d97c-42b9-8aa4-bf1f4ba15ebe" contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc" name="arct:DeferredTaxAssetsRightOfUseLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,233</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Share-based compensation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7451cdf9-2aac-4a46-b894-9e5773126773" contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,872</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a52412b6-71e9-4d7e-9083-0794cd1de357" contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,618</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total gross deferred tax assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_26f76e2f-9e22-4cfa-895d-fb614f4bcb75" contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">145,070</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ed99ad59-ad58-473c-942f-e5a683a73b2b" contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">116,812</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation and amortization</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_80d92e92-2782-4b69-84bf-07ace4685e83" contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212" name="arct:DeferredTaxLiabilitiesPropertyPlantAndEquipmentAndIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">858</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d5c871d7-e071-4a8f-a701-1fcaed2fb4d9" contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc" name="arct:DeferredTaxLiabilitiesPropertyPlantAndEquipmentAndIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,184</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Right-of-use asset</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c018343a-1c86-4003-8e0a-02537b1b415e" contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212" name="arct:DeferredTaxLiabilitiesRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,168</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_73d30771-23c3-4c88-b02e-57d1297efe95" contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc" name="arct:DeferredTaxLiabilitiesRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,822</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total gross deferred tax liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_18936f25-c260-47d1-83cc-6b4096f70224" contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,026</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7d52450b-b4b6-475b-a3e1-e198a5981e92" contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,006</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3a571c2a-0b23-4ce9-acff-f41f765d6a8a" contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">138,044</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_91439176-8647-46ee-9cae-398db92b61cc" contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">108,806</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net deferred tax asset</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In assessing the realization of the deferred tax assets, the Company considers whether it is more likely than not that some portion of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which temporary differences representing net future deductible amounts become deductible. Due to lack of available sources of taxable income, the Company recorded a full valuation allowance against its net deferred tax assets as sufficient uncertainty exists regarding the future realization of these assets. As of December 31, 2024 and 2023, the Co</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">mpany recorded a valuation allowance of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a9f4247f-d304-4b6c-b8e8-d813fe99fdfc" contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">138.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b94e2a70-fa67-4d1d-bd5a-3abe81a91cbc" contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">108.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively. The valuation allowance changed by $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1c154c2d-1ec3-45db-bf6f-719229ad6abd" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">29.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cb1ab376-7dee-42b8-8b2c-211055967438" contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the years ended December 31, 2024 and 2023, respectively.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At December 31, 2024, the Company has federal and state net operating losses, or NOL, carryforwards of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_60bd3b5e-2b7c-4339-9b24-8e17cdb33a90" contextRef="C_42b09082-30d1-4349-88f2-ae97e705f43e" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">47.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9c2cfa0c-9560-4c03-aac9-7ba67a02c6a1" contextRef="C_602adcc3-a068-4d86-ad11-fd96cb49a486" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">223.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively. The federal net operating loss carryforward includes losses generated in 2018 and after which can be carried forward indefinitely. The state net operating loss carryforward includes $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_63f085b8-571e-45a1-b95c-e4a2cd06dd21" contextRef="C_e570fa19-3556-454e-8682-69a04831b6bc" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of losses that can be carried forward indefinitely.  The remaining state net operating losses begin to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ef81da39-1caa-4ccd-9fa5-685fb53f9697" contextRef="C_26a8b21d-1c26-4459-a1ee-d89f9f331468" name="arct:OperatingLossCarryforwardsExpirationYear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2039</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">23</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Arcturus Therapeutics Holdings Inc. and its Subsidiaries</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notes to Consolidated Financial Statements &#8212; Continued</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_65b20b99-0a80-4494-94f9-18c0c40771d2_2"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At December 31, 2024, the Company has federal and state research and development credit carryforwards of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_80b014c8-4c54-460e-b547-d9f8267fd1aa" contextRef="C_37d3f9a9-91a0-4432-bb97-b21a720960db" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">19.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c93a75b6-482f-413f-a2b3-4121a9a5efaf" contextRef="C_a80d4900-cff3-43ef-a5a2-5effe03ec8b3" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">11.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively. The federal credit carryforwards begin to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_15b12fad-f843-4d51-8dcd-5daa53c4f5b8" contextRef="C_21d1b797-41f5-49d8-a548-8998a1e9873d" name="arct:TaxCreditCarryforwardExpirationYear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2037</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and the state credits carry forward indefinitely. $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_57dae61d-725d-4eee-823d-aee8ad178779" contextRef="C_602adcc3-a068-4d86-ad11-fd96cb49a486" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of the state credit begin to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1b4c264b-c7fd-49a0-8b78-9a0ff55b32f3" contextRef="C_26a8b21d-1c26-4459-a1ee-d89f9f331468" name="arct:TaxCreditCarryforwardExpirationYear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2037 </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and the remainder carryforward indefinitely. Additionally, the Company has an Orphan Drug Credit of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6c0135f9-42f3-40fc-94db-2225ca92cefe" contextRef="C_cab06b3d-053b-4c81-b42c-b2445cd0c158" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of December 31, 2024 which will begin to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_13759c16-01d3-4c49-8bce-294e73821084" contextRef="C_a772c31f-b8d4-430f-b45d-52b674305e78" name="arct:TaxCreditCarryforwardExpirationYear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2042</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> unless previously utilized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to Internal Revenue Code (IRC) Sections 382 and 383, annual use of the Company&#8217;s federal and California net operating loss and research and</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">development credit carryforwards may be limited in the event a cumulative change in ownership of more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fec4c5dc-8c99-4d04-9294-32137f2748a6" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="arct:NetOperatingLossAndResearchAndDevelopmentCreditCarryforwardsLimitationsOnCumulativeChangeInOwnershipMinimumPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% occurs within a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_08c6ab61-0157-48d0-89b0-4a556825f926" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="arct:NetOperatingLossAndResearchAndDevelopmentCreditCarryforwardsLimitationsOnCumulativeChangeInOwnershipPeriod" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three-year</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> period. The Company has completed an IRC Section 382 analysis through December 31, 2024 regarding the limitation of net operating loss carryforwards and other tax attributes. The Company experienced ownership changes in 2018 and 2020; however, the Company estimates that all tax attributes can be utilized. There is a risk that additional ownership changes may occur in the future. If a change in ownership occurs, the NOL carryforwards and other tax attributes could be limited or restricted.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The company accounts for income taxes in accordance with ASC 740-10, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Accounting for Uncertainty in Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more likely than not to be sustained upon audit by the relevant taxing authority. An uncertain tax position will not be recognized if it has less than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7694803f-0ab3-480f-be4a-a631f1ae1ce6" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="arct:MaximumPercentageOfLikelihoodOfUncertainTaxPositionRecognizedToBeSustained" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% likelihood of being sustained.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d94273b5-57ba-4857-8960-ec009453e3d2" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A reconciliation of unrecognized tax benefits is as follows (in millions):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.7%;box-sizing:content-box;"/>
        <td style="width:1.46%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.76%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.46%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:14.620000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Beginning balance of unrecognized tax benefits</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6c7576ff-09fa-48b1-b41a-7a3ece3c066e" contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.6</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_afcbb37e-3d65-461e-b2b7-f6429c20ca43" contextRef="C_9b6438ac-a4af-4cb1-a7e8-04fc1dc8917f" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.9</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Decrease for prior period tax positions</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ecdb6ce2-599c-4cfd-99e8-84891a6bae31" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="arct:UnrecognizedTaxBenefitsDecreasesIncreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.2</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1fb93638-9361-4edc-b29e-bf3e8930adaa" contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c" name="arct:UnrecognizedTaxBenefitsDecreasesIncreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Increase for current period tax positions</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_13805539-e798-49e5-b62c-2e3a8ec8c973" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.0</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_51d065d3-cc80-4e93-ac5c-06b50d98ba25" contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.6</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ending balance of unrecognized tax benefits</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a14fdf94-289d-481b-8f20-66da1c7e70c3" contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.8</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aef91a7f-5843-4cab-b89d-18e30522f09e" contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.6</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amounts in the summary rollforward would </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f9b890ec-d54e-4a0d-8bd0-b9c78a000e1e" contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t impact the effective tax rate as the Company maintains a full valuation on its net deferred tax assets. The Company is subject to taxation and files income tax returns in the United States, various U.S. states and foreign jurisdictions. The Company&#8217;s tax years from 2014 to date are subject to examination by the U.S., and state taxing authorities due to the carryforward of unutilized net operating losses and research and development credits. The Company&#8217;s policy is to recognize interest expense and penalties related to income tax matters as income tax expense. There was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7b85003d-735f-4cf3-9d52-a58759dec4e7" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_12338fa3-9c08-4e10-9de1-af567dca9ce1" contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_41d848b9-8375-40fb-a654-2ca985514095" contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> tax related interest or penalties recognized for the years ended December 31, 2024, 2023 and 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company does not anticipate any material changes to its unrecognized tax benefits within the next twelve months.</span></p></ix:continuation></div>
  <div><ix:nonNumeric id="F_ad965992-d0fe-4bc1-b68b-25134f938172" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true" continuedAt="F_ad965992-d0fe-4bc1-b68b-25134f938172_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTE 11. Commitments and Contingencies</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cystic Fibrosis Foundation Therapeutics Funding agreement</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On September 25, 2023, the Company amended its Development Program Letter Agreement, dated May 16, 2017 and as amended July 13, 2018 and August 1, 2019, with the Cystic Fibrosis Foundation (&#8220;CFF&#8221;). Pursuant to the amendment, (i) CFF increased the amount it will award to advance LUNAR-CF to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fb752ae3-50d4-4eb4-ae2f-15fd5186eda4" contextRef="C_801e363e-339f-4807-9e7b-89e95be99722" name="us-gaap:PaymentsForAdvanceToAffiliate" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">24.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million from approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8486db38-1f37-4e10-9005-24d5a40580c8" contextRef="C_35939c21-6356-4b16-b155-5ff282b4b400" name="us-gaap:PaymentsForAdvanceToAffiliate" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">15.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, (ii) the Company agreed to incur at least $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0921c9db-7cff-4967-8be6-04f36ebe7990" contextRef="C_d0748bb0-90f5-4425-beb5-86fdc83461e7" name="arct:MinimumAmountAgreedToIncurUnderResearchPlan" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">15.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million toward activities under the research plan. During the fourth quarter of 2023, the Company received the full payment from CFF related to the amendment. For the years ended December 31, 2024, 2023 and 2022, the Company recognized contra expense of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0003f33a-535c-4272-82b1-cabf8774d259" contextRef="C_794d8e75-547e-4d8c-b200-6302eefbd65b" name="arct:ContraExpenseIncludedInResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d6a6b136-2085-49b2-a6b6-aa391008b101" contextRef="C_6dcaeb74-849b-4892-8d45-1cf1c0c414a7" name="arct:ContraExpenseIncludedInResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_093e6ef1-6048-49dc-bceb-8b4e4483f8a1" contextRef="C_1b0157b0-3108-4ff6-bf3d-93b8178679dc" name="arct:ContraExpenseIncludedInResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively. As of December 31, 2024, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d52b39d9-628a-4a56-b3ca-2ec43792f631" contextRef="C_794d8e75-547e-4d8c-b200-6302eefbd65b" name="arct:ContraExpenseRemainingAmountIncludedInAccruedExpenses" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">million remained in accrued liabilities.</span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">24</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Arcturus Therapeutics Holdings Inc. and its Subsidiaries</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notes to Consolidated Financial Statements &#8212; Continued</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_ad965992-d0fe-4bc1-b68b-25134f938172_1" continuedAt="F_ad965992-d0fe-4bc1-b68b-25134f938172_2"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2017, the Company entered into a non-cancellable operating lease agreement for office space adjacent to its previously occupied headquarters. The commencement of the lease began in March 2018 and the lease extends for approximately </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d93ab2be-5f8c-4e87-9f88-112777f5dbef" contextRef="C_958a90b7-6a27-4c61-95d4-5f89fe769df8" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durmonth"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">84</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> months from the commencement date with a remaining lease term through March 2025. Monthly rental payments are due under the lease and there are escalating rent payments during the term of the lease. The Company is also responsible for its proportional share of operating expenses of the building and common areas. In conjunction with the new lease, the Company received free rent for </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d52e2e73-bf66-42e9-8d98-05c5a6263614" contextRef="C_958a90b7-6a27-4c61-95d4-5f89fe769df8" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">four months</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and received a tenant improvement allowance of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fdc4c78b-d7a3-4828-a0f6-e16e3eca0f6d" contextRef="C_b82657d6-82b1-4bfc-88e6-4814252b20d1" name="us-gaap:PaymentsForProceedsFromTenantAllowance" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. In March 2024, the Company negotiated with the lessor to extend the lease through March 2027.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company entered into an irrevocable standby letter of credit with the landlord for a security deposit of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b8df3870-be04-4ef5-8b73-355a5e24f750" contextRef="C_958a90b7-6a27-4c61-95d4-5f89fe769df8" name="us-gaap:SecurityDeposit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upon executing the lease which is included (along with additional funds required to secure the letter of credit) in the balance of non-current restricted cash.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In February 2020, the Company entered into a second non-cancellable operating lease agreement for office space near its current headquarters. The lease extended for </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_044167a0-03e1-453a-a1df-c40482aaa4f0" contextRef="C_6e132eb5-a5af-499f-bd75-b24d62c5092f" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durmonth"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> months from the commencement date and included a right to extend</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c1965a2e-e87b-4571-915a-44a49c166cff" contextRef="C_820e29f3-5ff7-4037-b94b-5b58fd071bfb" name="us-gaap:LesseeOperatingLeaseOptionToExtend"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> the lease for one twelve-month period. In February 2021, the Company opted to extend the lease through March 2025 to coincide with the lease term of the Company&#8217;s headquarters.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> In January 2024, the Company vacated this office space with no intention of operating out of the location in the future. The Company was still engaged in the lease for the property and obligated to make the remaining lease payments through March 31, 2025, and therefore recorded an impairment loss in the amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b6b5d9c5-7283-490d-b0c6-b15a604dc461" contextRef="C_adf77a8d-9580-41d9-9c8e-9064454e7c28" name="us-gaap:OperatingLeaseImpairmentLoss" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million during the three months ended March 31, 2024, as there was no future economic benefit from the lease. In July 2024, the Company terminated the existing lease agreement, in accordance with its terms, thereby ending their contractual obligation to pay for the premises. As a result, no lease liability remains as of December 31, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2021, the Company entered into a third non-cancellable lease agreement for office, research and development, engineering and laboratory space near its current headquarters, and such lease term commenced during the second quarter of 2022. The initial term of this lease extends </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5a1e1ead-bf44-44a9-a76f-2047fe0c00a1" contextRef="C_59dc916f-940a-4c84-98d4-897fc187a986" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ten years and eight months</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from the date of possession, and </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7c77feae-f0af-4438-aa35-5e1a15e2058c" contextRef="C_d4c6eb14-ee87-46e1-8ff9-0f1eee8139e1" name="us-gaap:LesseeOperatingLeaseOptionToExtend"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Company has the right to extend the term of the lease for an additional five-year period.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> When the lease term was determined for the operating lease right-of-use assets and lease liabilities, the extension option for the lease was not included. The lease has a monthly base rent ranging from $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_60da7fc6-34e2-4065-aa0a-7ca58538073e" contextRef="C_e0b98ca8-b4bb-4d0b-9631-02538172e7f5" name="arct:MonthlyBaseRent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6d3ca4c9-7079-4ca2-b773-36783a96c214" contextRef="C_e1270539-8c54-4b3f-a7ca-d75b1c8c8913" name="arct:MonthlyBaseRent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million which escalates over the lease term. The Company received a free rent period of four months and also pays for various operating costs, including utilities and real property taxes. The Company entered into an irrevocable standby letter of credit with the landlord for a security deposit of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_17210316-926c-4750-9aea-6ec3e43ff086" contextRef="C_59dc916f-940a-4c84-98d4-897fc187a986" name="us-gaap:SecurityDeposit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upon executing the lease which is included (along with additional funds required to secure the letter of credit) in the balance of non-current restricted cash.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating lease right-of-use asset and liability on the consolidated balance sheets represent the present value of remaining lease payments over the remaining lease terms. The Company does not allocate lease payments to non-lease components; therefore, payments for common-area-maintenance and administrative services are not included in the operating lease right-of-use asset and liability. The Company uses its incremental borrowing rate to calculate the present value of the lease payments, as the implicit rate in the lease is not readily determinable.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4e8eab2d-e148-4cf3-a3fa-7e35f5bec3b8" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024, the remaining payments of the operating lease liability were as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:75.855%;box-sizing:content-box;"/>
        <td style="width:2.06%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:20.084%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Remaining Lease<br/>Payments</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_74e1daca-7f42-4357-89e9-b5c1fc506c72" contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,811</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8392df9c-5e79-473a-be65-e952b3a303ad" contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,274</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d016176b-c05e-4dec-9228-a2435092e29c" contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,132</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_182cdb44-393f-43f1-864f-674b4e22061f" contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,822</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_477be685-b9ce-4038-9f6f-10e0e450aa42" contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,937</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Thereafter</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7d9273aa-e834-4c14-b53f-e11e48a18a99" contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,813</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total remaining lease payments</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_84bd3a62-e906-4e27-b811-a061410e1f70" contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,789</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: imputed interest</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_46b5fe15-f0a3-4ca2-83ed-0e0ec77548b9" contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,239</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating lease liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2e5350a2-4754-46ee-b6ac-df712dbb2c5c" contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,550</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average remaining lease term (in years)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_55ee4c3d-ed34-471f-bc6e-3399c7fd64fb" contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.2</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average discount rate</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a94c2173-4cd3-40ee-a044-dda2448ca7ac" contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">4.7</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">25</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Arcturus Therapeutics Holdings Inc. and its Subsidiaries</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notes to Consolidated Financial Statements &#8212; Continued</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_ad965992-d0fe-4bc1-b68b-25134f938172_2"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating lease costs consist of the fixed lease payments included in operating lease liability and are recorded on a straight-line basis over the lease terms. Operating lease costs were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d05196fa-4819-48fb-b998-5b63f6238b23" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9dae6d5c-4cbd-4fad-bf4b-468ce016bb6f" contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9449723a-7241-44a6-ba50-a2307d447e9f" contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the years ended December 31, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and 2023, respectively.</span></p></ix:continuation></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c606f05f-81ea-4646-83f1-70973d5dcc91" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:SegmentReportingDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTE 12. Segment Information</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company operates in </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a0342b5c-c5cb-4873-8f02-a6d2e1a34353" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="arct:NumberOfBusinessSegment" unitRef="U_Segment" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> business segment, which includes all activities related to the discovery, development and commercialization of messenger RNA medicines. The determination of a single business segment is consistent with the consolidated financial information regularly provided to the Company&#8217;s chief operating decision maker (&#8220;CODM&#8221;). </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_725d864b-c0d1-4a7b-b892-51a7e42e5e4b" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s CODM is its </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_806a8df4-c83d-4622-a6aa-7b9d8f050c33;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chief Executive Officer</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, who reviews and evaluates consolidated net (loss) income for purposes of assessing performance, making operating decisions, allocating resources, and planning and forecasting for future periods.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The CODM does not evaluate the operating segment using asset or liability information.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8c41b399-e622-4627-95d6-0e2d58ed4023" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents information about reported segment revenues, segment loss and income, and significant segment expenses:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:63.1%;box-sizing:content-box;"/>
        <td style="width:1.26%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.46%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.42%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:8.56%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.26%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:7.9399999999999995%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenues</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e3908165-651d-479f-8412-f79e05ea254a" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">152,310</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d50eeedf-4891-48be-8817-be1135ef2a3a" contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">166,799</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_58c6b6b7-1070-443a-8889-ccfeaf33b4ef" contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">205,999</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">LUNAR-COVID</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7b60f786-2a72-4098-b5fd-a1a28f8051b5" contextRef="C_06d432cd-fe67-4805-a95e-d98b0424bbc3" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">70,464</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7308ad7d-0270-47e0-81ab-13c90c298ee3" contextRef="C_79990b5c-27fd-44ab-a481-a933f3b6649e" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">81,262</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aa3a73a4-b405-47be-b9ec-102eb2b5ed4a" contextRef="C_a45712ae-2c2b-44d4-ae48-9d59250b85b6" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">65,136</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">LUNAR-OTC</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d88655ea-512e-4db2-9749-d859aeee4332" contextRef="C_0c35a6e2-43f6-4708-bba5-5173dbc3de2f" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,509</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b940988d-f490-4293-ae43-93f808a4e75f" contextRef="C_8dd3cd07-367a-4d33-a06e-49f7bc62341e" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,315</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a02d7dd5-1634-4680-8d9c-745a76315f69" contextRef="C_11fe4360-7e34-49ee-baa1-bb4e286f6f12" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,898</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">BARDA</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8e9bacc0-e426-4bcd-9948-58cc7ba846ec" contextRef="C_1a296724-396e-481f-8c86-b3b311ff76f9" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,807</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d8a042dd-c270-4058-95f7-2b5e11c18303" contextRef="C_57101dc7-2fbf-4d4c-8577-c3989e4bc34a" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,465</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_744dc1cc-9ab1-49bc-a4f0-41112178e4bd" contextRef="C_92f6052b-f423-4970-890f-aaeea914fcef" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">95</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">LUNAR-CF, net</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_df3a45bb-5a03-4194-9f0a-8c417b07e073" contextRef="C_e2d495bd-d213-4380-9448-1294459b3c51" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,227</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6781d333-81c9-44a8-b622-4470131fe77c" contextRef="C_f6556892-c686-4b0f-ad35-b323cfa6c9df" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,666</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_29c86b9e-41a4-4dce-b5da-769d1ff340c3" contextRef="C_08938b4b-8f37-4a42-96af-9374a057c857" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,931</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Early-stage programs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4c319d7b-398a-45ed-9e8c-90e429f7bb79" contextRef="C_8e8fb1ef-45cd-4aa8-9a33-0ec3e20793f1" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,096</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_09bd14a4-325b-4c6b-b156-ebfe2f39bbf7" contextRef="C_85b74df8-3891-4246-9852-23bd86a40945" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,460</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c6b1f33a-64da-4255-a4d9-0c43ce0aa725" contextRef="C_e809b54d-dd94-4594-8f54-a7a9ebc5e794" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,681</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Discovery technologies</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3989b73f-0c7a-4eae-9668-01f363780b77" contextRef="C_88537db2-a4c2-4868-aaa9-8f88cee3858f" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,278</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_010e9063-0831-4e7b-a29c-8ebcd8de3f05" contextRef="C_c0934e56-cff8-4842-acec-a05ccd4099a4" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,405</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_db7c3b50-0ea2-4c64-820b-1a750a703758" contextRef="C_e6b834ef-7cbd-42d2-9ba5-f1ffd18aff0f" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,082</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Payroll and benefits</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_318b5d2d-2ff9-423c-a0b3-dc36d875d231" contextRef="C_07a158d3-db39-46b0-b8a8-d157b269ad9e" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">57,474</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_46b8daec-0a94-4cc4-9dc9-dbe6ddd8c807" contextRef="C_384780c2-a461-484e-90b6-4ba525f2b0cb" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">50,924</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fa34d77c-8d96-43f4-aae3-25e1431c6802" contextRef="C_b73afaae-41c1-46b6-8616-4cdb808c1c4a" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42,466</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Facilities and equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fd908af1-eb59-4a3c-80ca-40730b85f8fc" contextRef="C_fe6dc61d-d3ca-490d-9689-8dcf10e0d322" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,301</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_55113225-b542-4956-96a0-e0318dbcaba0" contextRef="C_7f5b7d69-0f16-49c9-8312-5fabb8348a71" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,636</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fc877128-3f5e-46f7-bf38-43e453ff15c6" contextRef="C_ed799f3d-249f-4d51-ae92-deaa84f57abd" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,462</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total research and development</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b1ec607f-e4e6-4626-a29d-7185c8e88c9b" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">195,156</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2eceedd5-5351-4127-8c72-560ee479722e" contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">192,133</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9f8047eb-e713-4efe-981c-f0ab11e6b1a0" contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">147,751</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7328cc40-d95c-4c7f-bf4e-ef3f0e3b9234" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">52,823</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_95c549fa-6e0c-44ff-9c68-981f7e9619ea" contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">52,871</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d1b8a1b5-e706-4c63-8026-dc932561b541" contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">46,071</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_30349b9e-a90b-4868-8b5f-f9f68e52ad16" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:SegmentReportingOtherItemAmount" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">14,728</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9edd83ab-be78-4163-82d9-62024f18eaed" contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c" name="us-gaap:SegmentReportingOtherItemAmount" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">48,480</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_41de01e3-de04-4166-aef7-c6b8d1aed994" contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812" name="us-gaap:SegmentReportingOtherItemAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,828</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net (loss) income</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_82958dca-b56e-47cb-ab97-735d7a5c1638" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">80,941</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3d868e48-db5f-4903-adb9-06503844479d" contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">29,725</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4f28203b-b17f-4df3-8e06-49b566382622" contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,349</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) </span><ix:footnote id="FNT_e7673c3f-e0a4-4c88-8556-e697212050ab" xml:lang="en-US"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Primarily includes interest income and expense, foreign currency gains and losses, and income taxes. The year ended December 31, 2023 includes a $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6d599068-705c-45a7-8ac9-82ac53f579de" contextRef="C_2d41c197-8a7f-4abe-8802-3f3779ba2106" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">34.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million gain on debt extinguishment related to forgiveness of the Singapore Loan.</span></ix:footnote></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1c8519ed-75a1-4d67-aa32-34ff6a5fdce3" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTE 13. Related Party Transactions</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">See &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Note 2, Joint Ventures, Equity Method Investments and Variable Interest Entities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221; for specific details surrounding the Company&#8217;s agreement with Axcelead to form the joint venture entity, ARCALIS, Inc.</span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a1114de0-75a8-43a2-8c3f-3d20795fef96" contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716" name="us-gaap:SubsequentEventsTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTE 14. Subsequent Events</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">26</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>arct-ex4_1.htm
<DESCRIPTION>EX-4.1
<TEXT>
<html>
 <head>
  <title>EX-4.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="z-index:-3;min-height:1in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 4.1</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARCTURUS THERAPEUTICS HOLDINGS INC.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DESCRIPTION OF SECURITIES</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Arcturus Therapeutics Holdings Inc. (&#x201c;we,&#x201d; &#x201c;our,&#x201d; &#x201c;us,&#x201d; or the &#x201c;Company&#x201d;) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common stock. The following description summarizes important terms of our common stock. For a complete description, you should refer to our certificate of incorporation and bylaws, each as amended or may be amended from time to time, which are incorporated by reference as exhibits to the Annual Report on Form 10-K of which this exhibit is a part, as well as the relevant portions of the Delaware General Corporation Law (the &#x201c;DGCL&#x201d;).</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Common Stock</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of the date of this Annual Report on Form 10-K, we are authorized to issue up to 60,000,000 shares of common stock. As of March 4, 2025, there were 26,915,243 shares of common stock outstanding. The holders of our common stock are entitled to one vote for each share held of record on all matters submitted to a vote of the stockholders. The holders of common stock are not entitled to cumulative voting rights with respect to the election of directors, and as a consequence, minority stockholders will not be able to elect directors on the basis of their votes alone. Subject to preferences that may be applicable to any then outstanding shares of preferred stock, holders of common stock are entitled to receive ratably such dividends as may be declared by the board of directors out of funds legally available therefor. In the event of a liquidation, dissolution or winding up of us, holders of the common stock are entitled to share ratably in all assets remaining after payment of liabilities and the liquidation preferences of any then outstanding shares of preferred stock. Holders of common stock have no preemptive rights and no right to convert their common stock into any other securities. There are no redemption or sinking fund provisions applicable to our common stock. All outstanding shares of common stock are fully paid and non-assessable. The rights, preferences and privileges of holders of our common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any of our outstanding preferred stock.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Listing</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our common stock is listed under the symbol &#x201c;ARCT&#x201d; on the NASDAQ.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Transfer Agent and Registrar</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The transfer agent and registrar for our common stock is Continental Stock Transfer &amp; Trust.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Dividends</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have not declared any cash dividends on our common stock since inception and we do not anticipate paying any cash dividends on our common stock in the foreseeable future.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Possible Anti-Takeover Effects of Delaware Law and our Charter Documents</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Provisions of the DGCL, our certificate of incorporation, and our bylaws, could make it more difficult to acquire us by means of a tender offer, a proxy contest or otherwise, or to remove incumbent officers and directors. These provisions, summarized below, are expected to discourage certain types of coercive takeover practices and takeover bids that our board of directors may consider inadequate and to encourage persons seeking to acquire control of us to first negotiate with our board of directors. We believe that the benefits of increased protection of our ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure us outweigh the disadvantages of discouraging takeover or acquisition proposals because, among other things, negotiation of these proposals could result in an improvement of their terms.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Delaware Anti-Takeover Statute</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to Section 203 of the DGCL, an anti-takeover statute. In general, Section 203 of the DGCL prohibits a publicly held Delaware corporation from engaging in a &#x201c;business combination&#x201d; with an &#x201c;interested stockholder&#x201d; for a period of three years following the time the person became an interested stockholder, unless the business combination or the acquisition of shares that resulted in a stockholder becoming an interested stockholder is approved in a prescribed manner. Generally, a &#x201c;business combination&#x201d; includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. Generally, an &#x201c;interested stockholder&#x201d; is a person who, together with affiliates and associates, owns (or within three years prior to the determination of</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:1in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">interested stockholder status did own) 15% or more of a corporation&#x2019;s voting stock. The existence of this provision would be expected to have an anti-takeover effect with respect to transactions not approved in advance by our board of directors, including discouraging attempts that might result in a premium over the market price for the shares of common stock held by our stockholders.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Election and Removal of Directors</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our board of directors is elected annually by all holders of our capital stock. The stockholders may nominate one or more persons for election as directors at an annual meeting of stockholders, but only if written notice of such stockholder&#x2019;s intent to make such nomination or nominations has been received by the Secretary of the Company not less than forty-five (45) nor more than seventy-five (75) days prior to the first anniversary of the preceding year&#x2019;s annual meeting of stockholders. Any vacancy on the board of directors resulting from death, resignation,</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">removal or otherwise or newly created directorships may be filled by the vote of the majority of directors then in office, although less than a quorum, or by a sole remaining director.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Amendment</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The affirmative vote of a majority of the entire board of directors may amend and repeal the bylaws. The bylaws may be altered, amended or repealed, and new bylaws may be adopted, at any annual meeting of the stockholders (or at any special meeting thereof duly called for that purpose) by a majority of the combined voting power of the then outstanding shares of capital stock of all classes and series of the Company entitled to vote generally in the election of directors, voting as a single class, provided that, in the notice of any such special meeting, notice of such purpose shall be given.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Size of Board and Vacancies</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to our certificate of incorporation, and our bylaws, the number of directors constituting the board shall be at least one and no more than nine and our board of directors has the exclusive right to fix the size of the board and to fill any vacancies resulting from death, resignation, disqualification or removal as well as any newly created directorships arising from an increase in the size of the board.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Special Stockholder Meetings</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our bylaws provide that special meetings of stockholders can be called only by the board of directors, the chairman of the board of directors or the chief executive officer. Stockholders are not permitted to call a special meeting and cannot require the board of directors to call a special meeting. There is no right of stockholders to act by written consent without a meeting.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Requirements for Advance Notification of Stockholder Nominations and Proposals</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our bylaws establish advance notice procedures with respect to stockholder proposals and nomination of candidates for election as directors other than nominations made by or at the direction of our board of directors or a committee of our board of directors.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">No Cumulative Voting</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The DGCL provides that stockholders are denied the right to cumulate votes in the election of directors unless our certificate of incorporation provides otherwise. Our amended and certificate of incorporation does not provide for cumulative voting.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Authorized but Unissued Shares</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our authorized but unissued shares of common stock and preferred stock will be available for future issuance without stockholder approval. We may use additional shares for a variety of purposes, including future public offerings to raise additional capital, to fund acquisitions and as employee compensation. The existence of authorized but unissued shares of undesignated preferred stock may enable our board of directors to render more difficult or to discourage an attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise. For example, if in the due exercise of its fiduciary obligations, our board of directors were to determine that a takeover proposal is not in the best interests of us or our stockholders, our board of directors could cause shares of preferred</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:1in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">stock to be issued without stockholder approval in one or more private offerings or other transactions that might dilute the voting or other rights of the proposed acquirer, stockholder or stockholder group. The rights of holders of our common stock described above will be subject to, and may be adversely affected by, the rights of any preferred stock that we may designate and issue in the future. The issuance of shares of undesignated preferred stock could decrease the amount of earnings and assets available for distribution to holders of shares of common stock. The issuance may also adversely affect the rights and powers, including voting rights, of these holders and may have the effect of delaying, deterring or preventing a change in control of us.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Director Liability</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our bylaws limit the extent to which our directors are personally liable to us and our stockholders, to the fullest extent permitted by the DGCL. The inclusion of this provision in our bylaws may reduce the likelihood of derivative litigation against directors and may discourage or deter stockholders or management from bringing a lawsuit against directors for breach of their duty of care.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-19.1
<SEQUENCE>3
<FILENAME>arct-ex19_1.htm
<DESCRIPTION>EX-19.1
<TEXT>
<html>
 <head>
  <title>EX-19.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="z-index:-3;min-height:0.44in;position:relative;"></div>
  <p style="margin-left:67.08%;text-indent:10.676%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.074%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 19.1</font></p>
  <p style="font-size:10pt;margin-top:11.45pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.074%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Effective January 1, 2024</font></p>
  <p style="font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:20.893%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:20.87%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARCTURUS THERAPEUTICS HOLDINGS INC. INSIDER TRADING POLICY</font></p>
  <p style="margin-left:18.64%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:18.639%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and Guidelines with Respect to Certain Company Information and Certain Transactions in Company Securities</font></p>
  <p style="font-size:10pt;margin-top:1.65pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Purpose</font></p>
  <p style="font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.685%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Insider Trading Policy (this &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Policy</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) provides guidelines with respect to transactions in the securities of Arcturus Therapeutics Holdings Inc. (including subsidiaries where applicable, the &#x201c;Company&#x201d;) and the handling of material confidential information about the Company and the companies with which the Company engages in transactions or does business. The Company&#x2019;s Board of Directors has adopted this Policy to promote compliance with U.S. federal, state and foreign securities laws that prohibit certain persons who are aware of material nonpublic information about a company from: (i) trading in securities of that company; or (ii) providing material nonpublic information to other persons who may trade based on that information.</font></p>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Persons Subject to the Policy</font></p>
  <p style="font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Policy applies to (each of the following, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Covered Person</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;):</font></p>
  <p style="font-size:10pt;margin-top:0.4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:4.935%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.506022195340031%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">officers of the Company;</font></div></div>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:4.935%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.506022195340031%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Company&#x2019;s Board of Directors;</font></div></div>
  <p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:4.935%;display:flex;margin-top:0.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.506022195340031%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">employees of the Company;</font></div></div>
  <p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:4.935%;display:flex;margin-top:0.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.602%;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.506022195340031%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">consultants and independent contractors of the Company who receive or have access to material nonpublic information;</font></div></div>
  <p style="font-size:10pt;margin-top:0.35pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:4.935%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.506022195340031%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Family Members and Controlled Entities, each as defined below; and</font></div></div>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:4.935%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:7.731%;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.506022195340031%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any other persons who receive or have access to material nonpublic information that the Company designates as subject to this Policy.</font></div></div>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Transactions Subject to the Policy</font></p>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.685%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Policy applies to transactions in the Company&#x2019;s securities (collectively referred to in this Policy as &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Company Securities</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), including the Company&#x2019;s common stock, options to purchase common stock, or any other type of securities that the Company may issue, including (but not limited to) preferred stock, convertible debentures and warrants, as well as derivative securities that are not issued by the Company, such as exchange-traded put or call options or swaps relating to the Company&#x2019;s Securities. Transactions subject to this Policy include purchases, sales and </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">bona fide </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">gifts of Company Securities.</font></p>
  <p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Individual Responsibility</font></p>
  <p style="font-size:10pt;margin-top:0.4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.565%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Persons subject to this Policy have ethical and legal obligations to maintain the confidentiality of information about the Company and to not engage in transactions in Company Securities while in possession of material nonpublic information. Persons subject to this policy must not engage in illegal trading and must avoid the appearance of improper trading.</font></p>
  <p style="font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.565%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each individual is responsible for making sure that he, she or they complies with this Policy, and that any Family Member or Controlled Entity whose transactions are subject to this Policy, also complies with this Policy. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In all cases, the responsibility for determining whether an individual is in possession of material nonpublic</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.685%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">information rests with that individual, and any action on the part of the Company, the Compliance Officer or any other employee or director pursuant to this Policy (or otherwise) does not in any way constitute legal advice or</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.64in;min-height:0.78in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.56%;font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.44in;position:relative;"></div>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.685%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">insulate an individual from liability under applicable securities laws. You could be subject to severe legal penalties and disciplinary action by the Company for any conduct prohibited by this Policy or applicable securities laws, as described below in more detail under the heading &#x201c;Consequences of Violations.&#x201d;</font></p>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Administration of the Policy</font></p>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;text-indent:-0.014%;padding-left:0.013%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.685%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the purposes of this Policy, the Chief Legal Officer of the Company shall serve as the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Compliance Officer</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.&#x201d; The Compliance Officer shall be responsible for administration of this Policy. In the absence of the Chief Legal Officer of the Company, the Chief Compliance Officer of the Company (or such other officer of the Company that has been designated by the Chief Legal Officer of the Company in advance of such absence) shall serve as the &#x201c;Compliance Officer&#x201d; for purposes of this Policy during such absence. All determinations and interpretations by the Compliance Officer shall be final and not subject to further review.</font></p>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Statement of Policy</font></p>
  <p style="font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.565%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company Securities</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. No director, officer, employee, consultant, or independent contractor of the Company (or any other person designated by this Policy or by the Compliance Officer as subject to this Policy) who is aware of material nonpublic information relating to the Company may, directly, or indirectly through family members or other persons or entities:</font></p>
  <p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:7.731%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2.796%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.225612069058946%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Engage in transactions in Company Securities, except as otherwise specified in this Policy under the headings &#x201c;Transactions Under Company Plans&#x201d; and &#x201c;Rule 10b5-1 Plans;&#x201d;</font></div></div>
  <p style="font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:7.731%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.225612069058946%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recommend that others engage in transactions in any Company Securities;</font></div></div>
  <p style="font-size:10pt;margin-top:0.4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:7.731%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.204%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.225612069058946%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disclose material nonpublic information to persons within the Company whose jobs do not require them to have that information, or outside of the Company to other persons, including, but not limited to, family, friends, business associates, investors and expert consulting firms, unless any such disclosure is made in accordance with the Company&#x2019;s policies regarding the protection or authorized external disclosure of information regarding the Company; or</font></div></div>
  <p style="font-size:10pt;margin-top:0.6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:7.731%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.225612069058946%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Assist anyone engaged in the above activities.</font></div></div>
  <p style="font-size:10pt;margin-top:0.4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.343%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities of Third Parties</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In addition, it is the policy of the Company that no director, officer, employee, consultant, or independent contractor of the Company (or any other person designated as subject to this Policy) who, in the course of working for the Company, learns of material nonpublic information about another company (1) with which the Company does business, such as the Company&#x2019;s distributors, vendors, customers and suppliers, or (2) that is involved in a potential transaction or business relationship with Company, may engage in transactions in that other company&#x2019;s securities until the information becomes public or is no longer material.</font></p>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.685%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Confidentiality Obligation</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Everyone associated with the Company has a duty to protect the confidential information, including material nonpublic information, of the Company. Nonpublic information relating to the Company is the property of the Company and the unauthorized disclosure of such information is forbidden.</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:0.1pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.685%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accordingly, such information must be strictly safeguarded and not shared with unauthorized third parties including family members, household members and controlled entities, as described below. In the event any officer, director or employee of the Company receives any inquiry from outside the Company, such as a stock analyst, for information (particularly financial results and/or projections) that may be material nonpublic information, the inquiry should be referred to the Chief Executive Officer or Chief Financial Officer and to the other appropriate Company officers, as provided for in the Investor Relations Policy of the Company.</font></p>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.685%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Limited Exceptions</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. There are no exceptions to this Policy, except as specifically noted herein. Transactions that may be necessary or justifiable for independent reasons (such as the need to raise money for an emergency expenditure), or small transactions, are not excepted from this Policy. The securities laws do not recognize any</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">mitigating circumstances, and, in any event, even the appearance of an improper transaction must be avoided to preserve the Company&#x2019;s reputation for adhering to the highest standards of conduct.</font></p>
  <p style="font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Definition of Material Nonpublic Information</font></p>
  <p style="font-size:10pt;margin-top:0.4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.417%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Material Information</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Information is considered &#x201c;material&#x201d; if a reasonable investor would consider that information important in making a decision to buy, hold or sell securities. Any information that could be expected</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.64in;min-height:0.78in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.56%;font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.44in;position:relative;"></div>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.417%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to affect a company&#x2019;s stock price, whether it is positive or negative, should be considered material. There is no bright- line standard for assessing materiality; rather, materiality is based on an assessment of all of the facts and circumstances, and is often evaluated by enforcement authorities with the benefit of hindsight. While it is not possible to define all categories of material information, some examples of information that ordinarily would be regarded as material are:</font></p>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:7.731%;display:flex;margin-top:0.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.225612069058946%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Projections of future earnings or losses, or other earnings guidance;</font></div></div>
  <p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:7.731%;display:flex;margin-top:0.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:8.537%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.225612069058946%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Changes to previously announced earnings guidance, or the decision to suspend earnings guidance;</font></div></div>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:7.731%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.225612069058946%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clinical data or significant regulatory updates, approvals or rejections;</font></div></div>
  <p style="font-size:10pt;margin-top:0.35pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:7.731%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.225612069058946%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A pending or proposed merger, acquisition or tender offer;</font></div></div>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:7.731%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.225612069058946%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A pending or proposed significant collaboration or joint venture;</font></div></div>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:7.731%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.225612069058946%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A Company restructuring;</font></div></div>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:7.731%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.225612069058946%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A pending or proposed offering of additional securities;</font></div></div>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:7.731%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.225612069058946%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Bank borrowings or other financing transactions out of the ordinary course;</font></div></div>
  <p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:7.731%;display:flex;margin-top:0.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.225612069058946%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A change in executive management;</font></div></div>
  <p style="font-size:10pt;margin-top:0.35pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:7.731%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.225612069058946%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A change in auditors or notification that the auditor&#x2019;s reports may no longer be relied upon;</font></div></div>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:7.731%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.225612069058946%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pending or threatened significant litigation, or the resolution of such litigation;</font></div></div>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:7.731%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.225612069058946%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Impending bankruptcy or the existence of severe liquidity problems;</font></div></div>
  <p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:7.731%;display:flex;margin-top:0.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.225612069058946%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The gain or loss of a significant customer or supplier;</font></div></div>
  <p style="font-size:10pt;margin-top:0.35pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:7.731%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:3.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.225612069058946%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A significant cybersecurity incident, such as a data breach, or any other significant disruption in the company&#x2019;s operations or loss, potential loss, breach or unauthorized access of its property or assets, whether at its facilities or through its information technology infrastructure; or</font></div></div>
  <p style="font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:7.731%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2.537%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.225612069058946%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The imposition of an event-specific restriction on trading in Company Securities or the securities of another company or the extension or termination of such restriction.</font></div></div>
  <p style="font-size:10pt;margin-top:0.4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.12%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.685%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The foregoing list is illustrative only and is not intended to provide a comprehensive list of all circumstances that could give rise to material information.</font></p>
  <p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">When Information is Considered Public</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Information that has not been disclosed to the public is generally considered to be nonpublic information. In order to establish that the information has been disclosed to the public, it may be necessary to demonstrate that the information has been widely disseminated. Information generally would be considered widely disseminated if it has been disclosed through the newswire services, a broadcast on widely-</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.565%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">available news programs, publication in a widely-available news source, or public disclosure documents filed with the Securities and Exchange Commission (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">SEC</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) that are available on the SEC&#x2019;s website. By contrast, information would likely not be considered widely disseminated if it is available only to the Company&#x2019;s employees, or if it is only available to a select group of analysts, brokers and institutional investors.</font></p>
  <p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.167%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Once information is widely disseminated, it is still necessary to provide the investing public with sufficient time to absorb the information. As a general rule, information should not be considered fully absorbed by the market until after the second Trading Day after the day on which the information is publicly released. As used herein, the term &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Trading Day</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall mean any day on which the Nasdaq Stock Market LLC ( the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Nasdaq</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) or, if the Company&#x2019;s common stock is not then traded on the Nasdaq, the principal national securities exchange, automated quotation system or other trading market where the Company&#x2019;s common stock is then listed, quoted or traded, is open for</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.64in;min-height:0.78in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.56%;font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.44in;position:relative;"></div>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.167%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">trading. Nasdaq or such other principal national securities exchange, automated quotation system or other trading market where the Company&#x2019;s common stock is then listed, quoted or traded is herein referred to as the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Principal Market</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;. If, for example, the Company were to make a public announcement of previously material nonpublic information on a Monday that is a Trading Day (at any time after market open), the information would not be considered fully absorbed by the market until the close of the second daily trading session on the Principal Market following such public announcement, i.e., the close of trading on Wednesday (assuming Tuesday and Wednesday are Trading Days). However, if, for example, the Company were to make an announcement pre-market on a Monday that is a Trading Day, the information would not be considered fully absorbed by the market until the close of the second daily trading session on the Principal Market following such public announcement, i.e., the close of trading on Tuesday (assuming Tuesday is also a Trading Day). Although such circumstances are likely to be rare, depending on the particular circumstances, the Compliance Officer may determine that a longer or shorter absorption period should apply following public release of specific material nonpublic information. For the avoidance of doubt, the persons designated by the Compliance Officer as being subject to pre-clearance procedures (as described under the heading &#x201c;Additional Procedures&#x201d;) may not engage, or allow their Family Members or Controlled Entities to engage, in any transaction in Company Securities without first obtaining pre-clearance of the transaction from the Compliance Officer in accordance with the terms of this Policy, even after information is considered to be fully absorbed by the market, as set forth above.</font></p>
  <p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Transactions by Family Members and Others</font></p>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.685%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to all directors, officers, employees, consultants, and independent contractors of the Company (or any other person designated as subject to this Policy) (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">you</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), this Policy applies to all family members who reside with you (including a spouse, a child, a child away at college, stepchildren, grandchildren, parents, stepparents, grandparents, siblings and in-laws), anyone else who lives in your household, and any family members who do not live in your household but whose transactions in Company Securities are directed by you or are subject to your influence or control, such as parents or children who consult with you before they trade in Company Securities (collectively referred to as &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Family Members</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). You are responsible for the transactions of these other persons and therefore should make them aware of the need to confer with you before they trade in Company Securities, and you should treat all such transactions for the purposes of this Policy and applicable securities laws as if the transactions were for your own account. This Policy does not, however, apply to personal securities transactions of Family Members where the purchase or sale decision is made by a third party not controlled by, influenced by or related to you or your Family Members.</font></p>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Transactions by Entities that You Influence or Control</font></p>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Policy applies to any entities that you influence or control</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, including any corporations, companies, partnerships or trusts (collectively referred to as &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Controlled Entities</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), and transactions by these Controlled Entities should be treated for the purposes of this Policy and applicable securities laws as if they were for your own account.</font></p>
  <p style="font-size:10pt;margin-top:0.4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Transactions Under Company Plans</font></p>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Policy does not apply in the case of the following transactions, except as specifically noted:</font></p>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:7.773%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock Option Exercises</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This Policy does not apply to the </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">exercise </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of an employee stock option acquired pursuant to the Company&#x2019;s plans, or to the exercise of a tax withholding right pursuant to which a person</font></p>
  <p style="margin-left:7.773%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.685%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">has elected to have the Company withhold shares subject to an option to satisfy tax withholding requirements. This Policy does apply, however, to any sale of stock as part of a broker-assisted cashless exercise of an option, or any other market sale for the purpose of generating the cash needed to pay the exercise price of an option.</font></p>
  <p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:7.773%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restricted Stock Awards</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This Policy does not apply to the vesting of restricted stock, or the exercise of a tax withholding right pursuant to which you elect to have the Company withhold shares of stock to satisfy tax withholding requirements upon the vesting of any restricted stock. The Policy does apply, however, to any market sale of restricted stock.</font></p>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:7.773%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.417%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">401(k) Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This Policy does not apply to purchases of Company Securities in the Company&#x2019;s 401(k) plan, if any, resulting from your periodic contribution of money to the plan pursuant to your payroll deduction election. This Policy does apply, however, to certain elections you may make under the 401(k) plan, if any, including: (a) an election to increase or decrease the percentage of your periodic contributions that will be allocated to the Company Securities fund; (b) an election to make an intra-plan transfer of an</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.64in;min-height:0.78in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.56%;font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.44in;position:relative;"></div>
  <p style="margin-left:7.773%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.417%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">existing account balance into or out of the Company Securities fund; (c) an election to borrow money against your 401(k) plan account if the loan will result in a liquidation of some or all of your Company Securities fund balance; and (d) an election to pre-pay a plan loan if the pre-payment will result in allocation of loan proceeds to the Company stock fund. It should be noted that sales of Company Securities from a 401(k) account are also subject to Rule 144, and therefore affiliates should ensure that a Form 144 is filed when required.</font></p>
  <p style="font-size:10pt;margin-top:0.6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:7.773%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.074%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Employee Stock Purchase Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This Policy does not apply to purchases of Company Securities in the Company&#x2019;s employee stock purchase plan, if any, resulting from your periodic contribution of money to the plan pursuant to the election you made at the time of your enrollment in the plan, if any. This Policy also does not apply to purchases of Company Securities resulting from lump sum contributions to the plan, if any, provided that you elected to participate by lump sum payment during the applicable enrollment period. This Policy does apply, however, to your sales of Company Securities purchased pursuant to the plan, if any.</font></p>
  <p style="font-size:10pt;margin-top:0.4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:7.773%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other Similar Transactions</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Any other purchase of Company Securities from the Company or sales of Company Securities to the Company are not subject to this Policy.</font></p>
  <p style="font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Special and Prohibited Transactions</font></p>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.565%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has determined that there is a heightened legal risk and/or the appearance of improper conduct if the persons subject to this Policy engage in certain types of transactions. It therefore is the Company&#x2019;s policy that any persons covered by this Policy may not engage in any of the following transactions:</font></p>
  <p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:7.773%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.685%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Short Sales</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Short sales of Company Securities (</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">i.e.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the sale of a security that the seller does not own) may evidence an expectation on the part of the seller that the securities will decline in value, and therefore have the potential to signal to the market that the seller lacks confidence in the Company&#x2019;s prospects. In addition, short sales may reduce a seller&#x2019;s incentive to seek to improve the Company&#x2019;s performance. For these reasons, short sales of Company Securities are prohibited. In addition, Section 16(c) of the Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;), prohibits officers and directors from engaging in short sales. (Short sales arising from certain types of hedging transactions are governed by the paragraph below captioned &#x201c;Hedging Transactions.&#x201d;)</font></p>
  <p style="font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:7.773%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.685%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Publicly-Traded Options</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Given the relatively short term of publicly-traded options, transactions in options may create the appearance that a director, officer, employee, consultant, or independent contractor is trading based on material nonpublic information and focus a director&#x2019;s, officer&#x2019;s, employee&#x2019;s, consultant&#x2019;s, or independent contractor&#x2019;s attention on short-term performance at the expense of the Company&#x2019;s long- term objectives. Accordingly, transactions in put options, call options or other derivative securities, on an exchange or in any other organized market, are prohibited by this Policy. (Option positions arising from certain types of hedging transactions are governed by the next paragraph below.)</font></p>
  <p style="margin-left:7.773%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.713%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Hedging Transactions</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Hedging or monetization transactions can be accomplished through a number of possible mechanisms, including through the use of financial instruments such as prepaid variable forwards, equity swaps, collars and exchange funds. Such transactions may permit a director, officer, employee, consultant, or independent contractor to continue to own Company Securities obtained through employee benefit plans or otherwise, but without the full risks and rewards of ownership. When that occurs, the director, officer, employee, consultant, or independent contractor may no longer have the same objectives as the Company&#x2019;s other shareholders. Therefore, Covered Persons are prohibited from engaging in any such transactions.</font></p>
  <p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:7.773%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Margin Accounts and Pledged Securities</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Securities held in a margin account as collateral for a margin loan may be sold by the broker without the customer&#x2019;s consent if the customer fails to meet a margin call.</font></p>
  <p style="margin-left:7.773%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.685%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Similarly, securities pledged (or hypothecated) as collateral for a loan may be sold in foreclosure if the borrower defaults on the loan. Because a margin sale or foreclosure sale may occur at a time when the pledgor is aware of material nonpublic information or otherwise is not permitted to trade in Company Securities, Covered Persons are prohibited from holding Company Securities in a margin account or otherwise pledging Company Securities as collateral for a loan. (Pledges of Company Securities arising from certain types of hedging transactions are governed by the paragraph above captioned &#x201c;Hedging Transactions.&#x201d;).</font></p>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:7.773%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.685%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Standing and Limit Orders</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Standing and limit orders (except standing and limit orders under approved</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.64in;min-height:0.78in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.56%;font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.44in;position:relative;"></div>
  <p style="margin-left:7.773%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.685%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rule 10b5-1 Plans, as described below) create heightened risks for insider trading violations similar to the use of margin accounts. There is no control over the timing of purchases or sales that result from standing instructions to a broker, and as a result the broker could execute a transaction when a director, officer, employee, consultant, or independent contractor is in possession of material nonpublic information. The Company therefore prohibits Covered Persons from placing standing or limit orders on Company Securities. If a person subject to this Policy determines that they must use a standing order or limit order, the order should be limited to short duration and should otherwise comply with the restrictions and procedures outlined below under the heading &#x201c;Additional Procedures.&#x201d; A person who has placed a limit order or open instruction to buy or sell Company securities shall bear responsibility for canceling such instructions immediately upon becoming in possession of material nonpublic information.</font></p>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additional Procedures</font></p>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.685%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has established additional procedures in order to assist the Company in the administration of this Policy, to facilitate compliance with laws prohibiting insider trading while in possession of material nonpublic information, and to avoid the appearance of any impropriety. These additional procedures are applicable only to those individuals described below.</font></p>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:7.773%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.38%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pre-Clearance Procedures for Deemed Insiders</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Officers and directors of the Company, as well as the Family Members and Controlled Entities of such persons, and any other person that the Compliance Officer designates (collectively, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Deemed Insiders</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), may not engage in any transaction in Company Securities without first obtaining pre-clearance of the transaction from the Compliance Officer. Any Deemed Insider seeking to request pre-clearance can obtain the Company&#x2019;s </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">pre-clearance form </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">upon request from the Compliance Officer. A request for pre-clearance should be submitted to the Compliance Officer at least two Trading Days in advance of the proposed transaction. The Compliance Officer is under no obligation to approve a transaction submitted for pre-clearance, and may determine not to permit the transaction. If a person seeks pre-clearance and permission to engage in the transaction and such pre-clearance is not received, then he or she should refrain from initiating any transaction in Company Securities, and should not inform any other person of the restriction.</font></p>
  <p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:7.773%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.074%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">When a request for pre-clearance is made, the requestor should carefully consider whether he or she may be aware of any material nonpublic information about the Company. The requestor should also indicate whether he or she has effected any non-exempt &#x201c;opposite-way&#x201d; transactions within the past six months, and should be prepared to report the proposed transaction on an appropriate Form 4 or Form 5. The requestor should also be prepared to comply with SEC Rule 144 and file a Form 144, if necessary, at the time of any sale.</font></p>
  <p style="margin-left:7.773%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.63%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any pre-cleared transaction must be effected within the period of time indicated on the pre-clearance form as approved by the Compliance Officer (typically not to exceed 10 Trading Days), unless a different period of time is specified by the Compliance Officer. Transactions not effected within such specified period shall be subject to pre-clearance again before a trade can be effected.</font></p>
  <p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:7.773%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.056%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Quarterly Trading Restrictions</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. No Covered Person may conduct any transactions involving the Company&#x2019;s Securities (other than as specified by this Policy), during a &#x201c;Quarterly Restricted Period&#x201d; beginning 14 calendar days prior to the end of each fiscal quarter and ending at the close of the second daily trading session on the Principal Market following the public release of the Company&#x2019;s earnings results for that quarter. In other words, Covered Persons may only conduct transactions in Company Securities during the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Window Period</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; beginning after the close of the second daily trading session on the Principal Market following the public release of the Company&#x2019;s earnings results for that quarter and ending 14 calendar days prior to the close of the next fiscal quarter. It should be noted that preliminary guidance with respect to the quarterly results generally will not suffice to end the Quarterly Restricted Period.</font></p>
  <p style="font-size:10pt;margin-top:0.6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:7.773%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.685%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To illustrate the commencement of a Quarterly Restricted Period, if the Company&#x2019;s fourth fiscal quarter ends immediately following 11:59 p.m., Eastern time, on December 31st, the corresponding Quarterly Restricted Period would begin immediately following 11:59 p.m., Eastern time, on December 17</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="font-size:10pt;margin-top:0.4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:7.773%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.565%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To illustrate the commencement of the Window Period, if the Company publicly announces its earnings results intra-day or post-market, for example, on Monday, March 8</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, then the Window Period shall begin after the close of the daily trading session on the Principal Market on Wednesday, March 10</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. However, if the Company publicly announces its earnings results pre-market, for example, on Monday, March 8</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, then the Window Period shall begin after the close of the daily trading session on the Principal Market on</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.64in;min-height:0.78in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.56%;font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.44in;position:relative;"></div>
  <p style="margin-left:7.773%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.565%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tuesday, March 9</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:7.773%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.685%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The foregoing calculation of the two-daily trading session period required prior to commencement of a Window Period assumes all relevant days are Trading Days and is made using the same method of calculating the two-daily trading session period as set forth under the heading &#x201c;When Information is Considered Public&#x201d;.</font></p>
  <p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:7.773%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.685%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the avoidance of doubt, all persons designated by the Compliance Officer as being subject to pre- clearance procedures, as well as the Family Members and Controlled Entities of such persons, may not engage in any transaction in Company Securities without first obtaining pre-clearance of the transaction from the Compliance Officer in accordance with the terms of this Policy, even during a Window Period.</font></p>
  <p style="font-size:10pt;margin-top:0.6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:7.773%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.685%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under certain very limited circumstances, a person subject to a Quarterly Restricted Period may be permitted to trade during such Quarterly Restricted Period, but only if the Compliance Officer concludes that the person is not aware of material nonpublic information. Persons wishing to trade during a Quarterly Restricted Period must contact the Compliance Officer for approval at least two Trading Days in advance of any proposed transaction involving Company Securities.</font></p>
  <p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:7.773%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.25%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Event-Specific Restricted Periods</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. From time to time, an event may occur that is material to the Company and is known by only a few directors, officers, employees, consultants, and independent contractors. So long as the event remains material and nonpublic (the &#x201c;Event-Specific Restricted Period&#x201d;), the persons designated by the Compliance Officer may not engage in transactions in Company Securities. In addition, the Company&#x2019;s financial results may be sufficiently material in a particular fiscal quarter that, in the judgment of the Compliance Officer, designated persons should refrain from engaging in transactions in Company Securities even sooner than the Quarterly Restricted Period described above. In that situation, the Compliance Officer may notify these persons that they should not trade in the Company&#x2019;s Securities, without disclosing the reason for the restriction. The existence of an Event-Specific Restricted Period or the extension of a Quarterly Restricted Period will not be announced to the Company as a whole, and should not be communicated to any other person. Even if the Compliance Officer has not designated you as a person who should not engage in transactions in Company Securities due to an Event-Specific Restricted Period, you should not trade while aware of material nonpublic information. Exceptions will not be granted during an Event-Specific Restricted Period.</font></p>
  <p style="margin-left:7.773%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.685%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Closed Window</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. From time to time, there may be a risk that material nonpublic information is known widely within the Company during a Window Period such that the Compliance Officer determines to close that Window Period for all Covered Persons. In such event, the Window Period is treated as a Quarterly Restricted Period and no Covered Person may conduct any transactions involving the Company&#x2019;s Securities, unless and until the Compliance Officer determines to open the Window Period.</font></p>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:7.773%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exceptions</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The quarterly trading restrictions and event-specific trading restrictions do not apply to those transactions to which this Policy does not apply, as described above under the heading &#x201c;Transactions Under Company Plans.&#x201d; Further, the requirement for pre-clearance, the quarterly trading restrictions and event- specific trading restrictions do not apply to transactions conducted pursuant to approved Rule 10b5-1 plans, described under the heading &#x201c;Rule 10b5-1 Plans.&#x201d;</font></p>
  <p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rule 10b5-1 Plans</font></p>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.565%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rule 10b5-1 under the Exchange Act provides a defense from insider trading liability under Rule 10b-5. In order to be eligible to rely on this defense, a person subject to this Policy must enter into a Rule 10b5-1 plan for transactions in Company Securities that meets certain conditions specified in the Rule (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Rule 10b5-1 Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) and must be in accordance with the Company&#x2019;s &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Guidelines for Rule 10b5-1 Plans</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; that is attached to this Policy as </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Attachment</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.565%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. If the plan meets the requirements of Rule 10b5-1, transactions in Company Securities may occur even when the person who has entered into the plan is aware of material nonpublic information.</font></p>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.056%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To comply with the Policy, a Rule 10b5-1 Plan must be approved by the Compliance Officer and meet the requirements of Rule 10b5-1 and the Company&#x2019;s &#x201c;Guidelines for Rule 10b5-1 Plans&#x201d;. In general, a Rule 10b5-1 Plan must be entered into during a Window Period when the person entering into the plan is not aware of material nonpublic information. Once the plan is adopted, the person must not exercise any influence over the amount of securities to be traded, the price at which they are to be traded or the date of the trade. The plan must either specify the amount, pricing and timing of transactions in advance or delegate discretion on these matters to an independent third party. The plan must include a cooling-off period before trading can commence that, for directors or officers,</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.64in;min-height:0.78in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.56%;font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.44in;position:relative;"></div>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.056%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ends on the later of 90 days after the adoption of the Rule 10b5-1 Plan or two Trading Days following the disclosure of the Company&#x2019;s financial results in an SEC periodic report for the fiscal quarter in which the plan was adopted (but in any event, the required cooling-off period is subject to a maximum of 120 days after adoption of the plan), and for persons other than directors or officers, 30 days following the adoption or modification of a Rule 10b5-1 Plan. A person may not enter into overlapping Rule 10b5-1 plans (subject to certain exceptions) and may only enter into one single-trade Rule 10b5-1 Plan during any 12-month period. Directors and officers must include a representation in their Rule 10b5-1 Plan certifying that: (i) they are not aware of any material nonpublic information; and (ii) they are adopting the plan in good faith and not as part of a plan or scheme to evade the prohibitions in Rule 10b-5. All persons entering into a Rule 10b5-1 Plan must act in good faith with respect to that plan.</font></p>
  <p style="font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.685%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any Rule 10b5-1 Plan must be submitted for approval at least five days prior to the entry into the Rule 10b5-1 Plan. No further pre-approval of transactions conducted pursuant to the Rule 10b5-1 Plan will be required.</font></p>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.935%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notwithstanding anything contained herein to the contrary, it is the Company&#x2019;s policy that no officer or director, or Family Members or Controlled Entities of any such person, may enter into any transaction in Company Securities while such person has a Rule 10b5-1 Plan that is in effect; provided, however, that the foregoing shall only apply to a Rule 10b5-1 Plan adopted or modified by such person on or after January 1, 2024.</font></p>
  <p style="font-size:10pt;margin-top:0.4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Post-Termination Transactions</font></p>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.25%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Policy continues to apply to transactions in Company Securities even after termination of service to the Company. If an individual is in possession of material nonpublic information when his or her service terminates, that individual may not engage in transactions in Company Securities until that information has been publicly announced or is no longer material. The pre-clearance procedures specified under the heading &#x201c;Additional Procedures&#x201d; above, however, will cease to apply to transactions in Company Securities upon the expiration of any Quarterly Restricted Period, Event-Specific Restricted Period, or other Company-imposed trading restrictions applicable at the time of the termination of service.</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consequences of Violations</font></p>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.565%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The purchase or sale of securities while aware of material nonpublic information, or the disclosure of material nonpublic information to others who then engage in transactions in the Company&#x2019;s Securities, is prohibited by the federal and state laws. Insider trading violations are pursued vigorously by the SEC, U.S. Attorneys and state enforcement authorities, as well as enforcement authorities in foreign jurisdictions. Punishment for insider trading violations is severe, and could include significant fines and imprisonment. While the regulatory authorities concentrate their efforts on the individuals who trade, or who tip inside information to others who trade, the federal securities laws also impose potential liability on companies and other &#x201c;controlling persons&#x201d; if they fail to take reasonable steps to prevent insider trading by company personnel.</font></p>
  <p style="font-size:10pt;margin-top:0.4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.417%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, an individual&#x2019;s failure to comply with this Policy may subject the individual to Company-imposed sanctions, including dismissal for cause, whether or not the employee&#x2019;s failure to comply results in a violation of law. Needless to say, a violation of law, or even an SEC investigation that does not result in prosecution, can tarnish a person&#x2019;s reputation and irreparably damage a career.</font></p>
  <p style="font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.685%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Persons located or engaged in dealings outside the United States should be aware that laws regarding insider trading and similar offenses differ from country to country. Employees must abide by the laws in the country where they are located. However, all persons subject to this Policy are required to comply with this Policy even if applicable local law is less restrictive. If a local law conflicts with this Policy, consult the Compliance Officer.</font></p>
  <p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reporting</font></p>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.25%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consistent with the Company&#x2019;s Code of Conduct, it is the responsibility of all directors, officers and employees of the Company to report any violation of this Policy to the Compliance Officer. This reporting duty should be broadly construed to include any inappropriate conduct by their Family Members and Controlled Entities in respect of trading in the securities of the Company, as well as the sharing or misuse of the confidential information of the Company and any material nonpublic information.</font></p>
  <p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company Assistance</font></p>
  <p style="font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any person who has a question about this Policy or its application to any proposed transaction may obtain additional</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.64in;min-height:0.78in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.56%;font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.44in;position:relative;"></div>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">guidance from the Compliance Officer.</font></p>
  <p style="font-size:10pt;margin-top:0.4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.056%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prior to disclosure to any third party, any officer, director or employee of the Company who is aware of any material nonpublic information concerning the Company that has not been disclosed to the public should report the intention to disclose such information promptly to the Compliance Officer and obtain approval to do so, or otherwise act in accordance with the Company&#x2019;s Investor Relations Policy.</font></p>
  <p style="font-size:10pt;margin-top:0.6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certification</font></p>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All persons subject to this Policy must certify their understanding of, and intent to comply with, this Policy.</font></p>
  <p style="margin-left:20.893%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:20.907%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:20.893%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:20.907%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:20.893%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:20.907%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:20.893%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:20.907%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:20.893%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:20.907%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:20.893%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:20.907%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:20.893%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:20.907%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:20.893%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:20.907%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:20.893%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:20.907%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:20.893%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:20.907%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:20.893%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:20.907%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:20.893%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:20.907%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:20.893%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:20.907%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:20.893%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:20.907%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:20.893%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:20.907%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:20.893%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:20.907%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:20.893%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:20.907%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:20.893%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:20.907%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:20.893%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:20.907%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:20.893%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:20.907%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:20.893%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:20.907%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:20.893%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:20.907%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:20.893%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:20.907%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:20.893%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:20.907%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:20.893%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:20.907%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:20.893%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:20.907%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:20.893%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:20.907%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:20.893%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:20.907%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:20.893%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:20.907%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:20.893%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:20.907%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:20.893%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:20.907%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:20.893%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:20.907%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:20.893%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:20.907%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:20.893%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:20.907%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:20.893%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:20.907%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:20.893%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:20.907%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:20.893%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:20.907%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.64in;min-height:0.78in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.56%;font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.44in;position:relative;"></div>
  <p style="margin-left:20.893%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:20.907%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION</font></p>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I certify that:</font></p>
  <p style="font-size:10pt;margin-top:0.35pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:7.731%;display:flex;margin-top:0.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:4.537%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.225612069058946%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I have read and understand the Policy. I understand that the Compliance Officer is available to answer any questions I have regarding the Policy.</font></div></div>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:7.731%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2.398%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.225612069058946%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since the date that the Policy became effective, or such shorter period of time that I have been an employee of the Company, I have complied with the Policy.</font></div></div>
  <p style="font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:7.731%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.225612069058946%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I will continue to comply with the Policy for as long as I am subject to the Policy.</font></div></div>
  <p style="font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Print name:</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font></p>
  <p style="font-size:10pt;margin-top:0.15pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Signature:</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font></p>
  <p style="font-size:10pt;margin-top:0.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Date:</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font></p>
  <p style="margin-left:20.893%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:20.88%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:20.893%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:20.88%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:20.893%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:20.88%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:20.893%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:20.88%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:20.893%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:20.88%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:20.893%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:20.88%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:20.893%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:20.88%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:20.893%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:20.88%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:20.893%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:20.88%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:20.893%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:20.88%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:20.893%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:20.88%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:20.893%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:20.88%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:20.893%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:20.88%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:20.893%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:20.88%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:20.893%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:20.88%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:20.893%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:20.88%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:20.893%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:20.88%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:20.893%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:20.88%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:20.893%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:20.88%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:20.893%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:20.88%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:20.893%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:20.88%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:20.893%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:20.88%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:20.893%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:20.88%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:20.893%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:20.88%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:20.893%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:20.88%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:20.893%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:20.88%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:20.893%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:20.88%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:20.893%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:20.88%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:20.893%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:20.88%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:20.893%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:20.88%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:20.893%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:20.88%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:20.893%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:20.88%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.64in;min-height:0.78in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.56%;font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.44in;position:relative;"></div>
  <p style="margin-left:20.893%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:20.88%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Attachment A to Insider Trading Policy</font></p>
  <p style="font-size:10pt;margin-top:0.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:20.893%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:20.898%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Guidelines for Rule 10b5-1 Plans</font></p>
  <p style="font-size:10pt;margin-top:0.4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.565%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rule 10b5-1 under the Exchange Act provides a defense from insider trading liability under Rule 10b-5. In order to be eligible to rely on this defense, a person subject to this Policy must enter into a Rule 10b5-1 plan for transactions in Company Securities (as defined in the Insider Trading Policy) that meets certain conditions specified in the Rule (a &#x201c;Rule 10b5-1 Plan&#x201d;). If the plan meets the requirements of Rule 10b5-1, transactions in Company Securities may occur without regard to certain insider trading restrictions. In general, a Rule 10b5-1 Plan must be entered into at a time when the person entering into the plan is not aware of material nonpublic information. Once the plan is adopted, the person must not exercise any influence over the amount of securities to be traded, the price at which they are to be traded or the date of the trade. The plan must either specify the amount, pricing and timing of transactions in advance or delegate discretion on these matters to an independent third party.</font></p>
  <p style="font-size:10pt;margin-top:0.6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.435%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A Rule 10b5-1 plan must include a cooling-off period before trading can commence that, for directors or officers, ends on the later of 90 days after the adoption of the Rule 10b5-1 plan or two Trading Days following the disclosure of the Company&#x2019;s financial results in an SEC periodic report for the fiscal quarter in which the plan was adopted (but in any event, the required cooling-off period is subject to a maximum of 120 days after adoption of the plan), and for persons other than directors or officers, 30 days following the adoption or modification of a Rule 10b5-1 plan. A person may not enter into overlapping Rule 10b5-1 plans (subject to certain exceptions) and may only enter into one single-trade Rule 10b5-1 plans during any 12-month period (subject to certain exceptions). Directors and officers must include a representation in their Rule 10b5-1 plan certifying that: (i) they are not aware of any material nonpublic information; and (ii) they are adopting the plan in good faith and not as part of a plan or scheme to evade the prohibitions in Rule 10b-5. All persons entering into a Rule 10b5-1 plan must act in good faith with respect to that plan.</font></p>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.12%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As specified in the Company&#x2019;s Insider Trading Policy, a Rule 10b5-1 Plan must be approved by the Compliance Officer and meet the requirements of Rule 10b5-1 and these guidelines. Any Rule 10b5-1 Plan must be submitted for approval five days prior to the entry into the Rule 10b5-1 Plan. No further pre-approval of transactions conducted pursuant to the Rule 10b5-1 Plan will be required.</font></p>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following guidelines apply to all Rule 10b5-1 Plans:</font></p>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:7.731%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:5.463%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.225612069058946%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You may not enter into, modify or terminate a trading program during a Restricted Period, or Event-Specific Restricted Period or otherwise while you are aware of material nonpublic information.</font></div></div>
  <p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:7.731%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:3.87%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.225612069058946%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All Rule 10b5-1 Plans must have a duration of at least six (6) months and no more than two (2) years.</font></div></div>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:7.731%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2.537%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.225612069058946%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For officers and directors, no transaction may take place under a Rule 10b5-1 Plan until the later of (a) 90 days after adoption or modification of the Rule 10b5-1 Plan or (b) two Trading Days following the disclosure of the Company&#x2019;s financial results in a Form 10-Q or Form 10-K for the fiscal quarter (the Company&#x2019;s fourth fiscal quarter in the case of a Form 10-K) in which the Rule 10b5-1 Plan was adopted or modified (but in any event, the cooling-off period is subject to a maximum of 120 days after adoption of the plan).</font></div></div>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:7.731%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:3.065%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.225612069058946%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For persons other than officers and directors, no transaction may take place under a Rule 10b5-1 Plan until 30 days following the adoption or modification of a Rule 10b5-1 plan.</font></div></div>
  <p style="font-size:10pt;margin-top:0.4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:7.731%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:3.065%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.225612069058946%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subject to certain limited exceptions specified in Rule 10b5-1, you may not enter into more than one Rule 10b5-1 Plan at the same time;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.731%;display:flex;margin-top:4pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.602%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.225612069058946%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subject to certain limited exceptions specified in Rule 10b5-1, you are limited to only one Rule 10b5-1 designed to effect an open market purchase or sale of the total amount of securities subject to the Rule 10b-1 Plan as a single transaction in any 12-month period;</font></div></div>
  <p style="font-size:10pt;margin-top:0.4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:7.731%;display:flex;margin-top:0.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:4.667%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.225612069058946%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You must act in good faith with respect to a Rule 10b5-1 Plan. A Rule 10b5-1 Plan cannot be entered into as part of a plan or scheme to evade the prohibition of Rule 10b&not;5. Therefore, although modifications to an existing Rule 10b5-1 Plan are not prohibited, a Rule 10b5-1 </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.64in;min-height:0.78in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.56%;font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.44in;position:relative;"></div>
  <div class="item-list-element-wrapper" style="margin-left:7.731%;display:flex;margin-top:0.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:4.667%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.225612069058946%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Plan should be adopted with the intention that it will not be amended or terminated prior to its expiration.</font></div></div>
  <p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:7.731%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2.398%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.225612069058946%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Officer and directors must include a representation to the Company at the time of adoption or modification of a Rule 10b5-1 Plan that (i) the person is not aware of material nonpublic information about the Company or Company Securities and (ii) the person is adopting the plan in good faith and not as part of plan or scheme to evade the prohibitions of Rule 10b-5.</font></div></div>
  <p style="font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:7.731%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:3.463%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.225612069058946%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No officer or director, or Family Members or Controlled Entities of such person, may enter into any transaction in Company Securities while any such person has a Rule 10b5-1 Plan that is in effect; provided, however, that the foregoing shall only apply to a Rule 10b5-1 Plan adopted by such person(s) on or after January 1, 2024.</font></div></div>
  <p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.685%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company and the Company&#x2019;s officers and directors must make certain disclosures in SEC filings concerning Rule 10b5-1 Plans. Officers and directors of the Company must undertake to provide any information requested by the Company regarding Rule 10b5-1 Plans for the purpose of providing the required disclosures or any other disclosures that the Company deems to be appropriate under the circumstances.</font></p>
  <p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each director, officer and other Section 16 insider understands that the approval or adoption of a pre-planned selling program in no way reduces or eliminates such person&#x2019;s obligations under Section 16 of the Exchange Act, including such person&#x2019;s disclosure and short-swing trading liabilities thereunder. If any questions arise, such person should consult with their own counsel in implementing a Rule 10b5-1 Plan.</font></p>
  <p style="font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of January 1, 2024, the Company has a relationship with ETrade (through Morgan Stanley) that includes administration of the Company&#x2019;s Employee Stock Purchase Plan. Employees can contact ETrade at </font><font style="color:#0562c1;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10b51@etrade.com </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to help establish a Rule 10b5-1 Plan, or can use the employee&#x2019;s separate broker.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.64in;min-height:0.78in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.56%;font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>4
<FILENAME>arct-ex21_1.htm
<DESCRIPTION>EX-21.1
<TEXT>
<html>
 <head>
  <title>EX-21.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 21.1</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subsidiaries of the Registrant</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Set forth below is a list of subsidiaries of Arcturus Therapeutics Holdings Inc. (the &#x201c;Registrant&#x201d;) All of the subsidiaries listed below are wholly-owned subsidiaries of the Registrant and are owned directly by the Registrant.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:50%;box-sizing:content-box;"></td>
    <td style="width:50%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Subsidiary</font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Jurisdiction of Formation</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ccecff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Arcturus Therapeutics, Inc.</font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Delaware</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Arcturus Therapeutics Asia Pte. Ltd.</font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Singapore</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ccecff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Arcturus Therapeutics Europe B.V.</font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Netherlands</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;font-kerning:none;min-width:fit-content;">  DOCPROPERTY &#34;CUS_DocIDChunk0&#34; US_ACTIVE\129440967\V-1</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>arct-ex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html>
 <head>
  <title>EX-23.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="z-index:-3;min-height:1in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 23.1</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consent of Independent Registered Public Accounting Firm</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We consent to the incorporation by reference in the following Registration Statements:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registration Statement (Form S-4 No. 333-230353) of Arcturus Therapeutics Holdings Inc.,</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registration Statement (Form S-8 No. 333-232272) pertaining to the Arcturus Therapeutics Holdings Inc. 2019 Omnibus Equity Incentive Plan,</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(3)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registration Statement (Form S-8 No. 333-280860) pertaining to Arcturus Therapeutics Holdings Inc. 2019 Omnibus Equity Incentive Plan, </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(4)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registration Statement (Form S-8 No. 333-265925) pertaining to the Arcturus Therapeutics Holdings Inc. 2019 Omnibus Equity Incentive Plan, as amended,</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(5)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registration Statement (Form S-8 No. 333-240397) pertaining to the Arcturus Therapeutics Holdings Inc. Amended and Restated 2019 Omnibus Equity Incentive Plan, </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(6)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registration Statement (Form S-8 No. 333-240392) pertaining to the Arcturus Therapeutics Holdings Inc. 2020 Employee Stock Purchase Plan,</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(7)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registration Statement (Form S-8 No. 333-260391) pertaining to the Arcturus Therapeutics Holdings Inc. 2021 Inducement Equity Incentive Plan, </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(8)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registration Statements (Form S-3 Nos. 333-235475 and 333-269003) of Arcturus Therapeutics Holdings Inc.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of our report dated March 14, 2024 (except Note 12, as to which the date is March 6, 2025) with respect to the consolidated financial statements of Arcturus Therapeutics Holdings Inc. included in this Annual Report (Form 10-K) of Arcturus Therapeutics Holdings, Inc. for the year ended December 31, 2024.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">							</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/s/ Ernst &amp; Young LLP</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">San Diego, California</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 6, 2025</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>6
<FILENAME>arct-ex23_2.htm
<DESCRIPTION>EX-23.2
<TEXT>
<html>
 <head>
  <title>EX-23.2</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 23.2</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We consent to the incorporation by reference in Registration Statement Nos. 333-235475 and 333-269003 on Form S-3; Registration Statement No. 333-230353 on Form S-4; and Registration Statement Nos. 333-232272, 333-240397, 333-240392, 333-260391, 333-265925, and 333-280860 on Form S-8 of our reports dated March 6, 2025, relating to the financial statements of Arcturus Therapeutics Holdings, Inc. and the effectiveness of Arcturus Therapeutics Holdings, Inc. internal control over financial reporting appearing in this Annual Report on Form 10-K for the fiscal year ended December 31, 2024.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">/s/ Deloitte &amp; Touche LLP</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">San Diego, California</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 6, 2025</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>7
<FILENAME>arct-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 31.1</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RULES 13a-14(a)</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I, Joseph E. Payne, certify that:</font></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.	I have reviewed this Annual Report on Form 10-K of Arcturus Therapeutics Holdings Inc.;</font></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4.	The registrant&#x2019;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a)	designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">b)	designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">c)	evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">d)	disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.	The registrant&#x2019;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a)	all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">b)	any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:47.6%;box-sizing:content-box;"></td>
    <td style="width:1.2%;box-sizing:content-box;"></td>
    <td style="width:3.58%;box-sizing:content-box;"></td>
    <td style="width:47.62%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: March 6, 2025</font></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.25pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Joseph E. Payne</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Joseph E. Payne</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">President, Chief Executive Officer and Director</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">(principal executive officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>8
<FILENAME>arct-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31.2</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 31.2</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RULES 13a-14(a)</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I, Andrew Sassine, certify that:</font></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.	I have reviewed this Annual Report on Form 10-K of Arcturus Therapeutics Holdings Inc.;</font></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4.	The registrant&#x2019;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a)	designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">b)	designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">c)	evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">d)	disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.	The registrant&#x2019;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a)	all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">b)	any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:47.6%;box-sizing:content-box;"></td>
    <td style="width:1.2%;box-sizing:content-box;"></td>
    <td style="width:3.58%;box-sizing:content-box;"></td>
    <td style="width:47.62%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: March 6, 2025</font></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.25pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Andrew Sassine</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Andrew Sassine</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Director and Chief Financial Officer</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">(principal financial and accounting officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>9
<FILENAME>arct-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="z-index:-3;min-height:1in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 32.1</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18 U.S.C. SECTION 1350</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the Annual Report of Arcturus Therapeutics Holdings Inc. (the &#x201c;Company&#x201d;) on Form 10-K for the fiscal year ended December 31, 2024 (the &#x201c;Report&#x201d;), I, Joseph E. Payne, President, Chief Executive Officer and Director of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:</font></p>
  <p style="text-indent:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.44%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></p>
  <p style="text-indent:4.44%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.44%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:49.64%;box-sizing:content-box;"></td>
    <td style="width:2.72%;box-sizing:content-box;"></td>
    <td style="width:1%;box-sizing:content-box;"></td>
    <td style="width:46.64%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: March 6, 2025</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Joseph E. Payne</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Joseph E. Payne</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">President, Chief Executive Officer and Director</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">(principal executive officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>10
<FILENAME>arct-ex32_2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html>
 <head>
  <title>EX-32.2</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="z-index:-3;min-height:1in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 32.2</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18 U.S.C. SECTION 1350</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the Annual Report of Arcturus Therapeutics Holdings Inc. (the &#x201c;Company&#x201d;) on Form 10-K for the fiscal year ended December 31, 2024 (the &#x201c;Report&#x201d;), I, Andrew Sassine, Chief Financial Officer and Director of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:</font></p>
  <p style="text-indent:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.44%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></p>
  <p style="text-indent:4.44%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.44%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:49.64%;box-sizing:content-box;"></td>
    <td style="width:2.72%;box-sizing:content-box;"></td>
    <td style="width:1%;box-sizing:content-box;"></td>
    <td style="width:46.64%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: March 6, 2025</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Andrew Sassine</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Andrew Sassine</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Director and Chief Financial Officer</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">(principal financial and accounting officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97.1
<SEQUENCE>11
<FILENAME>arct-ex97_1.htm
<DESCRIPTION>EX-97.1
<TEXT>
<html>
 <head>
  <title>EX-97.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="z-index:-3;min-height:0.44in;position:relative;"></div>
  <p style="margin-left:59.987%;text-indent:45.12%;font-size:10pt;margin-top:3.9pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.065%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 97.1</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:23.973%;text-indent:-20.461%;padding-left:10.827%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:12.287%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARCTURUS THERAPEUTICS HOLDINGS INC. CLAWBACK POLICY</font></p>
  <div class="item-list-element-wrapper" style="margin-left:1.065%;display:flex;margin-top:11.6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:6.7387678778996305%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;" id="x__introduction"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Introduction</font></div></div>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:11.85pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.056%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Arcturus Therapeutics Holdings Inc. (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) believes that it is in the best interests of the Company and its stockholders to create and foster a culture of business ethics, integrity and accountability, and that, among other purposes, reinforces the Company&#x2019;s incentive compensation philosophy.</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:12.1pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.056%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Board of Directors (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Board</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) therefore adopts this policy to provide for the Company&#x2019;s recovery of certain compensation in the event of an accounting restatement of the Company&#x2019;s financial statements resulting from material noncompliance with applicable financial reporting requirements under the federal securities laws (this &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Policy</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:11.9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Policy is designed to comply with Section 10D of the Securities Exchange Act of 1934, as amended (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exchange Act</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), and the rules and regulations promulgated thereunder.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:1.065%;display:flex;margin-top:11.65pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:6.7387678778996305%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;" id="x__general_administration"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General Administration</font></div></div>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:11.95pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.037%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Policy shall be administered by the Board or, if so designated by the Board, the Compensation Committee of the Board, in which case references herein to the Board shall be deemed to be references to the Compensation Committee of the Board. Any determinations made by the Board in respect of this Policy, or to matters as to this Policy&#x2019;s amendment, enforcement, or otherwise, shall be final and binding on all individuals governed under this Policy as well as any related actions or procedures carried out by the Company&#x2019;s Executive Officers (as defined herein) that are deemed necessary, appropriate, or advisable to effectuate the purposes of this Policy.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:1.065%;display:flex;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:6.7387678778996305%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;" id="x__applicability"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Applicability</font></div></div>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:11.95pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.056%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Policy applies to the Company&#x2019;s current and former Executive Officers, as determined by the Board in accordance with Section 10D of the Exchange Act and the listing standards of the national securities exchange on which the Company&#x2019;s securities are listed (such as Section 303A.14 of the New York Stock Exchange&#x2019;s listing standards or Rule 5608 of Nasdaq&#x2019;s listing rules, which are each approved by the U.S. Securities and Exchange Commission (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SEC</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) to implement Rule 10D-1 promulgated under the Exchange Act).</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:11.9pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.056%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For purposes of this Policy, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Executive Officer</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Company&#x2019;s president, principal financial officer, principal accounting officer (or, if there is no such accounting officer, the controller); any vice president of the Company in charge of a principal business unit, division, or function (such as sales, administration, or finance); any other officer who performs a policy-making function; and any other person who performs a function similar to a policy-making function on behalf of the Company. Executive officers of the Company&#x2019;s parent(s) or subsidiaries are deemed Executive Officers of the Company if they perform such policy-making or similar functions for or on behalf of the Company.</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:12.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.056%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Policy also applies to other senior executives, employees, or classes of employees of the Company as may be determined by the Board in its sole discretion from time to time (together with Executive Officers, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Covered Persons</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.49in;min-height:0.61in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.94in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:1.065%;display:flex;margin-top:4.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:6.7387678778996305%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;" id="x__recoupment"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recoupment</font></div></div>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:11.8pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.046%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the Company is required to prepare an accounting restatement of its financial statements due to the Company&#x2019;s material noncompliance with financial reporting requirements under the applicable federal securities laws (including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements, or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period) (an &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accounting Restatement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), without regard to any fault or misconduct of a Covered Person, then, the Board shall mandate the Company&#x2019;s recovery, in the form of reimbursement, or forfeiture, as applicable (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recoupment</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), of any Excess Incentive Compensation (as defined herein) received by a Covered Person, </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided that</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:7.731%;display:flex;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.225612069058946%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;" id="xa__the_receipt_of_any_such_excess_incen"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the receipt of any such Excess Incentive Compensation by a Covered Person occurred after the Covered Person became a Covered Person;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.731%;display:flex;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.225612069058946%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;" id="xb__the_covered_person_served_as_a_cover"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Covered Person served as a Covered Person at any time during the performance period applicable to the Covered Person&#x2019;s Incentive Compensation (as defined herein);</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.731%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.225612069058946%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;" id="xc__the_company_had_a_class_of_securitie"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Company had a class of securities listed on a national securities exchange or a national securities association during the Covered Person&#x2019;s service as a Covered Person and during the performance period applicable to the Covered Person&#x2019;s Incentive Compensation; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.731%;display:flex;margin-top:11.6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.225612069058946%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;" id="xd__the_receipt_of_the_excess_incentive_"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the receipt of the Excess Incentive Compensation by the Covered Person occurred during the three completed fiscal years immediately preceding the date that the Company is required to prepare an Accounting Restatement, or during any transition period (that results from a change in the Company&#x2019;s fiscal year) within or immediately following such three completed fiscal years.</font></div></div>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.046%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For purposes of this Policy, a transition period between the last day of the Company&#x2019;s previous fiscal year end and the first day of its new fiscal year that comprises a period of nine to 12 months is a completed fiscal year.</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:11.6pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.056%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For purposes of this Policy, any Incentive Compensation is deemed to be &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">received</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; by a Covered Person </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">at the point in time when a Financial Reporting Measure </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(as defined herein), as specified in a Covered Person&#x2019;s incentive compensation agreement (or other equity or incentive compensation plan of the Company) providing for a Covered Person&#x2019;s compensation that is contingent upon or tied to the attainment of such Financial Reporting Measure, </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">is attained during the relevant fiscal period of the Company</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.065%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Therefore, under this Policy, a Covered Person is deemed to receive Incentive Compensation even if, for instance, the payment or grant of Incentive Compensation occurs after the end of the relevant fiscal period of the Company.</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:11.95pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.065%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For purposes of this Policy, the date on which the Company is required to prepare an Accounting Restatement is deemed to have occurred on the earlier of (i) the date the Board concludes, or reasonably should have concluded, that the Company&#x2019;s previously issued financial statements contain a material error and (ii) the date a court, regulator, or other legally authorized body directs the Company to restate its previously issued financial statements to correct a material error.</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#x2019;s obligation to seek Recoupment of a Covered Person&#x2019;s Excess Incentive Compensation is</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:0.15pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">not </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">dependent on whether or when the restated financial statements are filed with the SEC.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.66in;min-height:0.79in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.56%;font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.94in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:1.065%;display:flex;margin-top:4.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:6.7387678778996305%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;" id="x__incentive_compensation__financial_rep"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Incentive Compensation; Financial Reporting Measures</font></div></div>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:11.8pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.074%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For purposes of this Policy, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Incentive Compensation</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any compensation that is granted, earned, or vested based wholly or in part upon the attainment of a Financial Reporting Measure.</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:11.65pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Incentive Compensation may include (but is not limited to):</font></p>
  <div class="item-list-element-wrapper" style="margin-left:4.398%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.4863287378925123%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Annual bonuses and other short- and long-term cash incentives;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.398%;display:flex;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.4863287378925123%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock options;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.398%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.4863287378925123%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock appreciation rights;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.398%;display:flex;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.4863287378925123%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restricted stock;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.398%;display:flex;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.4863287378925123%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restricted stock units;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.398%;display:flex;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.4863287378925123%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Performance shares; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.398%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.4863287378925123%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Performance units.</font></div></div>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:11.9pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.056%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For purposes of this Policy, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial Reporting Measure</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a measure that is determined and presented in accordance with the generally accepted accounting principles used in preparing the Company&#x2019;s financial statements, or any measure that is derived wholly or in part therefrom. For avoidance of doubt, a Financial Reporting Measure need not be presented within the Company&#x2019;s financial statements or included in a filing with the SEC.</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:12.1pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial Reporting Measures may include (but are not limited to):</font></p>
  <div class="item-list-element-wrapper" style="margin-left:4.398%;display:flex;margin-top:11.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.4863287378925123%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company stock price;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.398%;display:flex;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.4863287378925123%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Total shareholder return;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.398%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.4863287378925123%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenues;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.398%;display:flex;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.4863287378925123%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net income;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.398%;display:flex;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.4863287378925123%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Earnings before interest, taxes, depreciation and amortization, EBITDA, or adjusted EBITDA;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.398%;display:flex;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.4863287378925123%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Funds from operations;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.398%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.4863287378925123%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Liquidity measures, such as working capital or operating cash flow;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.398%;display:flex;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.4863287378925123%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Return measures, such as return on invested capital or return on assets; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.398%;display:flex;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.4863287378925123%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Earnings measures, such as earnings per share.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:1.065%;display:flex;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:6.7387678778996305%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">6.</font><div style="width:100%;display:inline;" id="x__excess_incentive_compensation"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Excess Incentive Compensation</font></div></div>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:11.8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The amount subject to Recoupment </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">is any Incentive Compensation received by a Covered Person that is determined by the Board, in good faith and upon the exercise of due care, to have been based on erroneous</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.66in;min-height:0.79in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.56%;font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.94in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:3.9pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.056%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">information that caused the Company&#x2019;s material noncompliance with financial reporting requirements under the federal securities laws (without regard to any fault or misconduct of a Covered Person), which would not have been received by a Covered Person had the Incentive Compensation of a Covered Person been based on the restated financial statements&#x2019; results (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Excess Incentive Compensation</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:12.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.065%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the Board cannot calculate Excess Incentive Compensation received by a Covered Person from the information in an Accounting Restatement (i.e., the amount of Excess Incentive Compensation is not subject to mathematical recalculation directly from the information in an Accounting Restatement), then, the Board shall determine such Excess Incentive Compensation based on a reasonable estimate of the effect of such Accounting Restatement on the applicable Financial Reporting Measures upon which the Excess Incentive Compensation was received and in consideration of all facts relevant to the Company&#x2019;s Recoupment of Excess Incentive Compensation received by a Covered Person in the circumstances.</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:11.9pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.056%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company shall maintain documentation of any such reasonable estimates and provide such documentation, when and if reasonably requested, to the applicable national securities exchange on which the Company&#x2019;s securities are listed in accordance with the applicable standards or rules of the national securities exchange.</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:11.5pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.056%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With respect to Incentive Compensation based in part or whole on stock price or measures of shareholder return, the Board shall calculate Excess Incentive Compensation relating thereto in such manner as the Board deems appropriate or reasonable.</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.056%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In no event shall the Company be required to award a Covered Person additional Incentive Compensation if the restated financial statements&#x2019; results would have resulted in the provision of Incentive Compensation that is higher in monetary value relative to the monetary value received by a Covered Person prior to the Accounting Restatement.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:1.065%;display:flex;margin-top:11.7pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:6.7387678778996305%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">7.</font><div style="width:100%;display:inline;" id="x__recoupment_method"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recoupment Method</font></div></div>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:11.95pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.75%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Board shall determine in its sole discretion, to be exercised in good faith, and not inconsistent with applicable law, the method for Recoupment of a Covered Person&#x2019;s Excess Incentive Compensation, which may include, without limitation, one or more of the following acts:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:7.731%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.225612069058946%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;" id="xa__mandating_reimbursement_of_cash_base"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">mandating reimbursement of cash-based Incentive Compensation previously paid to a Covered Person;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.731%;display:flex;margin-top:11.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.225612069058946%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;" id="xb__seeking_recovery_of_any_gain_realize"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">seeking recovery of any gain realized on the vesting, exercise, settlement, sale, transfer, or other disposition of any equity-based Incentive Compensation of a Covered Person;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.731%;display:flex;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.225612069058946%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;" id="xc__offsetting_the_recouped_amount_from_"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">offsetting the recouped amount from any compensation otherwise owed by the Company to a Covered Person;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.731%;display:flex;margin-top:11.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.225612069058946%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;" id="xd__cancelling_outstanding_vested_or_unv"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">cancelling outstanding vested or unvested equity-based Incentive Compensation of a Covered Person; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.731%;display:flex;margin-top:11.5pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.225612069058946%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(e)</font><div style="width:100%;display:inline;" id="xe__taking_any_other_remedial_and_recove"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">taking any other remedial and recovery action not disallowed by applicable law, as determined by the Board, consistent with Sections 4, 6, 10, and 13 under this Policy.</font></div></div>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:11.5pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.065%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Board shall, in the exercise of its fiduciary duty to safeguard the assets of the Company (including the time value of any potentially recoverable Incentive Compensation), and, in the light of the particular facts and circumstances of a Covered Person who is determined by the Board to owe Excess Incentive</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.66in;min-height:0.79in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.56%;font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.94in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:3.9pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.056%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compensation to the Company, pursue the most appropriate balance of cost and speed in determining the means to seek Recoupment of a Covered Person&#x2019;s Excess Incentive Compensation.</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:12.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.056%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consistent with this Section 7 and Rule 10D-1 of the Exchange Act, regardless of the means of Recoupment used, the Board intends that Recoupment of a Covered Person&#x2019;s Excess Incentive Compensation shall be effected by the Company reasonably promptly. The Board further intends that the administration of this Policy shall abide by the Company&#x2019;s recognition that what is reasonable may depend on the additional cost incident to Recoupment.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:1.065%;display:flex;margin-top:12.1pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:6.7387678778996305%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">8.</font><div style="width:100%;display:inline;" id="x__no_indemnification"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Indemnification</font></div></div>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:11.85pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In no event shall the Company indemnify any Covered Persons against the loss of any incorrectly awarded Incentive Compensation pursuant to Rule 10D-1 and applicable stock exchange listing rules.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:1.065%;display:flex;margin-top:11.6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:6.7387678778996305%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">9.</font><div style="width:100%;display:inline;" id="x__cooperation"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cooperation</font></div></div>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:11.85pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.065%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Covered Persons shall facilitate the Company&#x2019;s compliance with its disclosure obligations relating to this Policy in accordance with the requirements of the federal securities laws and applicable stock exchange listing rules.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:1.065%;display:flex;margin-top:12.2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:6.7387678778996305%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">10.</font><div style="width:100%;display:inline;" id="x0__interpretation"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interpretation</font></div></div>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:11.85pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.065%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consistent with Section 2 of this Policy, the Board shall be authorized to construe and interpret this Policy and to make all determinations necessary, appropriate, or advisable for the administration of this Policy in accordance with the Company&#x2019;s constitutional documents.</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:11.95pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.065%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Policy memorializes the Board&#x2019;s intention that this Policy be interpreted in a manner that is consistent with Section 10D of the Exchange Act and any applicable rules, regulations, or standards adopted by the SEC (such as Rule 10D-1) and those adopted by the national securities exchange on which the Company&#x2019;s securities are listed as well as any other relevant law, in each case as in effect from time to time (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Applicable Rules</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.065%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the extent the Applicable Rules require recovery of Incentive Compensation in additional circumstances beyond those specified above, nothing in this Policy shall be deemed to limit or restrict the right or obligation of the Company to recover Incentive Compensation to the fullest extent required by the Applicable Rules.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:1.065%;display:flex;margin-top:11.65pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:6.7387678778996305%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">11.</font><div style="width:100%;display:inline;" id="x1__effective_date"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Effective Date</font></div></div>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:11.85pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.065%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Policy is effective as of October 2, 2023 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Effective Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) and shall be duly adopted by the Board in accordance with the Company&#x2019;s constitutional documents. This Policy shall apply to all Incentive Compensation that is received by Covered Persons on or after the Effective Date.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:1.065%;display:flex;margin-top:12.2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:6.7387678778996305%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">12.</font><div style="width:100%;display:inline;" id="x2__amendment__termination"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amendment; Termination</font></div></div>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:11.85pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.056%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consistent with Section 2 of this Policy, the Board may amend this Policy from time to time in its sole discretion and shall amend this Policy as the Board deems necessary or proper to (i) reflect any modification to the rules and regulations adopted by the SEC interpreting Section 954 of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 and the rules and regulations adopted by the SEC under Section 10D of the Exchange Act and to (ii) comply with any rules or standards adopted by a national securities exchange on which the Company&#x2019;s securities are listed.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.66in;min-height:0.79in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.56%;font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.94in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:3.9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Board may, but is not required to, reassess the contents of this Policy on a yearly basis as part of the Company&#x2019;s analysis of material risks.</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:12.15pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Board may terminate this Policy at any time.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:1.065%;display:flex;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:6.7387678778996305%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">13.</font><div style="width:100%;display:inline;" id="x3__other_recoupment_rights"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other Recoupment Rights</font></div></div>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:12.1pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Board intends that this Policy shall be applied to the fullest extent of the law.</font></p>
  <p style="font-size:10pt;margin-top:3.6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.037%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the Board&#x2019;s good-faith determination, the Board may require that any employment agreement, equity award agreement, or similar enforceable agreement by and between the Company and a Covered Person entered into on or after the Effective Date shall, as a condition to the grant of any benefit thereunder, be amended and restated, or otherwise validly modified or supplemented, under the governing law of any such agreement, to require a Covered Person to agree to abide by the terms of this Policy.</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.065%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All of the Company&#x2019;s actions or powers associated with Recoupment contemplated by this Policy are in addition to, and not in lieu of, any contract or other rights of a compensation-recovery nature that may be available to the Company (including, without limitation, any right of repayment, forfeiture, or right of offset against any employees that is required pursuant to any statutory repayment requirement (regardless of whether implemented at any time prior to or following the adoption or amendment of this Policy), including Section 304 of the Sarbanes-Oxley Act of 2002 (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SOX</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;)).</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:12.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.037%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any amounts paid to the Company in accordance with Section 304 of SOX shall be considered by the Company in determining any amounts recovered under this Policy.</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:11.9pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.056%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The application and enforcement of this Policy does not preclude the Company from taking any other action to enforce a Covered Person&#x2019;s obligations to the Company, including termination of employment or institution of legal proceedings. Nothing in this Policy restricts the Company from seeking Recoupment under any other compensation recoupment-based policy or any applicable provisions in plans, agreements, awards, or other arrangements that contemplate the recovery of compensation from a Covered Person.</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.056%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If a Covered Person fails to repay Excess Incentive Compensation that is owed to the Company under this Policy, then, the Company shall take all appropriate action to recover such Excess Incentive Compensation from the Covered Person, and the Covered Person shall be required to reimburse the Company for all expenses (including legal expenses) incurred by the Company in recovering such Excess Incentive Compensation.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:1.065%;display:flex;margin-top:12.15pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:6.7387678778996305%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">14.</font><div style="width:100%;display:inline;" id="x4__impracticability"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Impracticability</font></div></div>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:11.95pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.065%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Board shall mandate Recoupment of any Excess Incentive Compensation of a Covered Person in accordance with this Policy </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">unless </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">effecting Recoupment would be impracticable, as the Compensation Committee of the Board may so determine (i) in consistence with its fiduciary duties owed to the Company&#x2019;s shareholders and (ii) in accordance with Rule 10D-1 of the Exchange Act and the applicable listing standards of the national securities exchange on which the Company&#x2019;s securities are traded.</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:11.95pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.065%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under Rule 10D-1 of the Exchange Act, a company&#x2019;s obligation to recover any erroneously awarded compensation is subject only to the following limited instances in which recovery would be considered impracticable:</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.66in;min-height:0.79in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.56%;font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.94in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:7.731%;display:flex;margin-top:3.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.225612069058946%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;" id="xa__the_direct_expense_paid_to_a_third_p"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The direct expense paid to a third party to assist in enforcing the policy would exceed the amount to be recovered after a company has made and documented a reasonable attempt to recover;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.731%;display:flex;margin-top:11.6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.225612069058946%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;" id="xb__recovery_would_violate_home_country_"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recovery would violate home country law where that law was adopted prior to November 28, 2022, and the issuer provides an opinion of home country counsel to the exchange; or</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.731%;display:flex;margin-top:11.55pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.225612069058946%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;" id="xc__recovery_would_likely_cause_an_other"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recovery would likely cause an otherwise tax-qualified retirement plan to fail to meet the requirements of the Internal Revenue Code of 1986, as amended.</font></div></div>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.056%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Therefore, the Board intends that this Policy shall be implemented in a manner that follows the aforementioned exceptions (as applicable to the Company), and that Recoupment of any Excess Incentive Compensation of a Covered Person under this Policy shall be mandatory unless one of the exceptions under Rule 10D-1 apply.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:1.065%;display:flex;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:6.7387678778996305%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">15.</font><div style="width:100%;display:inline;" id="x5__severability"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Severability</font></div></div>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:11.95pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.037%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If any provision of this Policy or the application of such provision to any Covered Person shall be adjudicated to be invalid, illegal, or unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect any other provisions of this Policy, and the invalid, illegal, or unenforceable provisions shall be deemed amended to the minimum extent necessary to render any such provision (or the application of such provision) valid, legal or enforceable.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:1.065%;display:flex;margin-top:12.1pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:6.7387678778996305%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">16.</font><div style="width:100%;display:inline;" id="x6__successors"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Successors</font></div></div>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:11.85pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Policy shall be binding and enforceable against all Covered Persons and their beneficiaries, heirs, executors, administrators, or other legal representatives.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:8.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:18.227%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:18.222%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.43in;min-height:0.57in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.94in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:18.227%;font-size:10pt;margin-top:3.9pt;font-family:Times New Roman;margin-bottom:0;margin-right:18.213%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARCTURUS THERAPEUTICS HOLDINGS INC. CLAWBACK POLICY</font></p>
  <p style="margin-left:18.293%;font-size:10pt;margin-top:0.15pt;font-family:Times New Roman;margin-bottom:0;margin-right:18.213%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ACKNOWLEDGEMENT AND AGREEMENT FORM</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:11.85pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.046%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">By signing below, the undersigned acknowledges and confirms that the undersigned has received and reviewed a copy of the Arcturus Therapeutics Holdings Inc. (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) Clawback Policy (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Policy</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:11.6pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.056%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">By signing this Acknowledgement and Agreement Form, the undersigned acknowledges and agrees that the undersigned is and will continue to be subject to the Policy, and that the Policy will apply both during and after the undersigned&#x2019;s employment with the Company. Further, by signing below, the undersigned agrees to abide by the terms of the Policy, including, without limitation, by returning any Excess Incentive Compensation (as defined in the Policy) reasonably promptly to the Company to the extent required by, and in a manner consistent with, the Policy.</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:12.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.056%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, by signing below, the undersigned acknowledges that the Policy applies to all Incentive Compensation (as defined in the Policy); agrees to waive any legal right that might conflict or otherwise interfere with the Company&#x2019;s Recoupment (as defined in the Policy) of any Excess Incentive Compensation in consistence with the terms of the Policy; and acknowledges that the Company may seek Recoupment of any Excess Incentive Compensation through any method of recovery it deems appropriate or necessary under the circumstances (which may include offsetting against any compensation payable to the undersigned, among other methods of recovery), as contemplated by Sections 7 and 13 under the Policy.</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.065%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The undersigned acknowledges and agrees that by signing below, the undersigned agrees that any and all agreements and understandings between the undersigned and the Company are hereby amended and modified by and subject to this Policy.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:1.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:11.253%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">COVERED PERSON</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:6.85pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:19.36%;font-size:10pt;margin-top:2.55pt;font-family:Times New Roman;margin-bottom:0;margin-right:18.213%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Signature</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:3.65pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:4.627%;font-size:10pt;margin-top:2.7pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Printed Name</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:3.65pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:18.227%;font-size:10pt;margin-top:2.55pt;font-family:Times New Roman;margin-bottom:0;margin-right:21%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Date</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.43in;min-height:0.61in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>img267189834_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img267189834_0.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $G X0# 2(  A$! Q$!_\0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MX(_^7E-1D]5&37=)_P"0G**T<HI]FU_F>RT5XU_PT9^SW_T7?X-?^'/\$?\
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MU\"_L]W7A:SNA#K7Q0UFS\,P1HZBX70K%DUGQ'=(K$;K9H;6RT2[(5R$UU
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M+7]>&C>%/"][X8T:WO/#>@7=O/HNEB:"YT?3IX9A]CMVQ+%+;.D@W -AU(W
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M;>7#!I[OX<^"+F=@H4--/X9TR61@J@*H+NQ"J  #@  5\P_\%&#C]E'QR?\
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M3^L[X:_#KPK\*/!6@> O!NG0Z;H6@6,5K"J1QK<7UR$7[9JNHRQHGVK5-3N
M]Y?W3C=-<2N0%0(B[WB;PSH'C+0-6\+>*=)LM=\/:[92Z?JVDZA$)K2\M)@-
MR2+D,CHP66">)H[BVN(XKFVEBGBCD2'PAXJT3QSX6\/^,?#5XM_H/B?2+#6]
M)NEV@R66H6\=S"LJ*S^3<Q!_)NK9F\RVN8Y;>4++$ZCHJ\%MW;;?->[;WO\
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ML[6_LYMGG6E[;Q75M+Y<B2Q^9!.DD4GERQI(FY#MD1'7#*"+(         &
M .  !P !P .E+10 4444 %%%% '\I7[5KD?M*?'(<?\ )3?%O_IVN/>OG_>?
M0?K_ (U[Q^UA)C]I;XYC=C'Q-\6]O^HK<>U?/GF_[7Z?_6KW:?\ #I_X(_\
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M)(W62.15>.1&#HZ. R.C*2K*RD,K*2&!!!(-?Q@^;_M?I_\ 6K]./V-OV_\
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MHMQE);1:3\N:]OEI;U:/ESS?]K]/_K4>;_M?I_\ 6K.\X^_Y"E$PR-VXKD9
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MOQ+E_P"+C>/_ )O^9V\5=O\ J.W_ +56!WJ>D?SD3CMJ?K+\HG,^;_M?I_\
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M\A1YQ]_R%>X>(?MS_P $?WW?\-#\YQ_PJ7MCK_PLWV'I7[45^)__  1W??\
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M_7E<5^=7GM_>;]*_0?\ X*H3!/VM-84[O^1'\%=.G-E<>XK\X_M _P!O]/\
MXJO5H?P:7^"/Y'EUHR=:II]N75=_4U?/;^\WZ5_11_P4I^$__";_ ++?A3XA
M:?;>;K?PE?0]5DE0!ICX4\26>G:+X@MXU W$)J'_  CNJS-NVPVFE73E2"63
M^<+[0/\ ;_3_ .*K^TZY\+Z5XX^%LO@S78O/T7Q;X#;PYJL/&Y].UO0/[.O
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MZ^^:^ ?^"G&X?L=_$)PKLL>M^ F<HI.Q3XUT2,,Y'"J7=$W$@;G5>K &*/\
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M +'_ (]_]C7L867-0A_=O%_)NWX-'DXFF_;3>R=FOFE^M_N\]-K[1[-^=?V
M?L-:[;>(OV1_@)J%J5,4/@&PT1RCEP+GPS=7GAN\!8JN'6\TJ=9%P0D@9 S!
M=Q_CE\__ &/_ ![_ .QK][?^"4_[8/@'0/ ][^SS\3?$^D^$-0TK6]0UKX=:
MIX@OX-+T;5=-UR0WNK>&QJ5Z\-A9ZM9ZV;O4K*&YN86UA-:DMK*-[FQ99XQD
M'*DFDVX23=NSNGIY.S\E<O"6A4?,TE*+2];II7\[->;MWL?NW7\SO_!7CQ'#
MJ7[4>BZ7#(S'PS\)/"NE742RR,D=[>:_XOU]F\MD1(I9+'6-/#^690\:0LTN
MX>3#_01\1OCO\'OA-X:O/%GC_P"(OA3P_H]G%*ZF?6+.>_U"6)0WV+1]*M99
M]2UG4'!'EV.FVMS<L"7,8C5W7^/_ /:/^-%W\?/C?\1?BS<VLME#XMUUI=(L
M)I TVG^'=,M;;1?#=C<,F8S=6VA:=I\=Z\.(I;T7$T:JLF*Y\%!NHYV?*HM7
MZ-NUDOE=_=W1T8N2=-035W)/O:*Z_/2W?4\K^T>S?G1]H]F_.L7S_P#8_P#'
MO_L:[SX6^#+_ .)_Q)\!?#K2XY3?>-_%_A[PO"\6&:W&M:I;6$UXVY&1(K*"
M:2[GED'E0PP22RXC1B/3;23;T25V^R1YRIMM*^KT_+_@_AWT_L<_9FT23PW^
MSI\"-$G1HKK3OA#\.X;V-O-RE^WA/2I=07$T<4RJ+V2?:DL4<D:X1T5E*CW"
MJ]G:6UA:6MC9PI;V=E;P6EK;Q@B."VMHEA@A0$DA(HD1%!)(51R:L5X#=VWW
M;?WL]N*LDNR2^Y6/XY?VQY\?M5?M!##<?%CQF.OIK-R*^:_M'LWYU[[^V7/C
M]J_]H8;<X^+?C49W>FM70]*^://_ -C_ ,>_^QKW*?\ #I_X(_\ I*/%G!\T
MM?M/\_\ A_Z>GTA^RY/G]IK]G08;GX[?"(=?7X@>'Q7]G%?Q8?LKS9_:>_9Q
M&WK\>?A /O>OQ"\/#TK^T^N#'?'3_P +_,[\'%QC/SDOR/Y'OV_/A,/@O^U'
M\1=$M+46OA_Q9=I\1?"\<2^5 ND>+Y;F\NK:VA")'#:Z9XBAUW1[6*+=&EOI
MT04J08T^,OM'LWYU_0I_P6/^#YUWX7^ _C9IEHTE_P##[77\*^))8EY/A;Q>
MT?\ 9UY>2$'$.E>)K.TL+55VYF\4S%M_R[/YT?/_ -C_ ,>_^QKLP\_:4H/J
MERR]8JWXJS^9QUJ/+5FE9)OF6G26MOE=KY>>GH?@?QQK/P^\9>%?'7AV=[;7
M?"'B#2?$>E3;V""^T>^@OH$F"D&2WF> 0W,))2>WDEAD#([*?[5/AYXWT7XE
M^!/!_P 0?#LADT3QIX;T;Q-IFX@RQ6NL6$%\EM<  %+JT,QM;N)E5X;F&6*1
M$=&4?PT>?_L?^/?_ &-?TD_\$?OC=_PF7P;\4?!K5+G=K'PHUK^T=#CDER\O
M@SQC/=WZ0PHWSR_V5XEAULW,BL8X(-8TFWV1@(9<,;"\(S6\'9_X9:?@[6]6
M;X-N$I0;5I*Z_P 2_P U?[D?K_7QC_P4+T6;7OV-OCE90+(SVV@Z%KC"+[_D
M^&?&?AKQ'<,?E?\ =K;Z5(TW Q$'PR??7[.K@_BGX+A^(_PR^(?P^G,:Q>-_
M!'BGPF9)3A(6\0Z'?:5'<;@CM&UO)=+.DJ(SQ/&LD8WHM>="7+.$OY91E]S3
M.^<>:$X_S1E'[TT?Q&_:/9OSH^T>S?G5#4+>]TJ_O=+U*SFLM1TV[N;"_L[@
M&.>TO;.9[>ZMIXRN4F@GCDBE0\JZ,IY%5//_ -C_ ,>_^QKWCQ/9ONOZ_I_T
M]/W'_P"",'B)(O''QU\,&4K)JWA7P;KR0%D_>)X<U?6M/DEP09#Y+>*8TRK!
M!Y^'#,8RO] -?QV_L1_M&6?[-/[0/AKX@:VEVW@_4;+4/"'CE+!7FNU\,:ZU
MM))>Q6Z O=?V-K%AH^NR6<:O->1:6]M;K]HEB9?ZT/#OQ:^%WB[P_;>*_#/Q
M$\%ZWX<NK8W<6LZ?XETB>P6%(A-+Y\PNP+26V0_Z9;W0AN+-P\=U%#(CHOE8
MR$E5<[.TU&SZ724;>NB^\]/"R2I*#:O%O2_1N]UY7;7J?&O_  5'\00Z+^QO
MX]L9&C#^*/$'@'0K<.0'>:#QAI/B9EAS+&?,$'AV=SA)SY*R_N@,S0_RN_:/
M9OSK]</^"JG[7W@OXNZAX5^"GPNUVS\4^%_!.L7'B;Q=XDTFXAO- U7Q7]AF
MTO1[#0]2MW>#4[?0M.U#63?:A:/-I]S=ZK'!:SR/I\['\=?/_P!C_P >_P#L
M:[,)!PHKF5G*3E9[V:25_5*YRXJU2K=--1BHWWZMNUO5_-?=M?:/9OSK]Y_^
M"+>CL-*_:"\2/&I2[U#X<:':RLJF2-M.MO&5_?QI)O+A)1JNG-(FQ5+0QMND
M((C_ )_O/_V/_'O_ +&OZF_^"4'@"X\&_LF:7KM[;&WN_B7XR\3>-4$B[9_[
M-B:R\):8'R WD31>&)-1M0<*T.H"=!B?<RQDK46OYG%+Y/F_0,+3_?1>CY5)
M_A;\W^77;]%/$?B#2?"?A[7?%6OW+V6A>&M&U3Q!K5Y':7E_)::3HUC/J.HW
M*6.G6]WJ%X\%G;32K:6-K<WEPR"&UMYIW2-OR9^)'_!8KX*Z")[7X9^ /&OQ
M!O4$BQWVL26/@GP_(W2*2&>;^W-=E0'+R17&@:>VT*JR;G9HOUNU?2[+7-)U
M31-1B\[3]8TZ]TN_AR!YMEJ%M+:7462& \R":1<E2.>01Q7\/GQ&\'ZI\-?'
M_C3X?:Y#+'JW@KQ1KGAB^\R,PF6?1=1N+ W4:,6S;WBP+=6LB,\4UM-%-#))
M%(CMR86E3JN:FFW&S2O9-.]]K/1VZ]4=>)J5(*/(TD[IMJ[3TM:^FU^G0_1G
MXD?\%9/VGO&0GMO";^$?A=I\@,<9\-:'%K&M>4Q)83ZMXK?68/.*DQBXT[2]
M,=%PT0CF EK])O\ @E5^T!XK^,?PZ^*&A_$3QCKGC+QOX7\<P:V=1\1ZM<ZG
MJ(\->*](MH=/M+7[7)(8-.LM7\/ZXT=K9B*RM#?(B00^:IE_F-\\?W3^8KZ@
M_9%_:>UO]ECXOZ;\0;"SN-8\.WUK)X?\<^&XIDB;6_#-Y-!--]D:7]Q%K&EW
M5O;:II$\AC5KBV:PGGBL-0O=W95P\'2E&G",9:--+5M.]F]]5=:O=G)2JU%5
MC*I-RCJFFW975KVV5GKHMEYZ?V3U'-##<PRV]Q%%/;SQ20SP31K+#-#*I26*
M6)PR212(S))&ZLKJQ5@02*\0^%O[2_P)^,N@6OB'X?\ Q.\):M;SP+-<:9<:
MQ9Z7XATI]A:2WUGP]J4UKJ^F3Q;7!-S:)!,J-/:S7%L4G?XR_;H_;^^&/PE^
M''B;P+\-/%^B^-/BYXKTF^T"QB\+:I::O9>!X-4M)+6[\1:YJ=A+<6-KJ5C;
M3M+HVC>=)J$VHM9W-U:1Z8DTS>9&G.4E!1ES7LTTU;NW?9+K>QZ,IQC%RYDU
M;2S6ODN[/YH=6DM(-5U.'3W,MA#J%[%92B42B2TCN9$MG$HXD#PA&$@X<'=W
MK/\ M'LWYUC>>/[I_,4>>/[I_,5[AXOLWW7]?T_Z>GZB_P#!)]9KG]K?3FBC
MD=+7X?\ C6XN&'*PPM#I]JLC\\*;BY@B!&?GE08P<C^H*OYZ?^"+W@"XO_B!
M\7_BI-:NMCX?\):9X$L+F1,Q3:AXHU:#7=06V8_+]HL+3PM8BY*XDBAU:%<A
M+E@W]"U>3C&G6:7V8Q3];7_4]3"1<:*OUDW^2_-!1117*=(4444 %%%% !11
M10 5Y9\</B;I_P &?A!\2/BGJ7EM!X&\'ZWK\%O*=JW^IVMG(-&TL$L@$FK:
MN]CIL.71?-NT#.@RP]3K\6/^"U?QKC\(?!+P/\&=/O(DU7XJ^*?[:UNV$F7/
M@_P(;:^\NXB5@8EO?%=]X=N;.67Y)CH=^D22/#(\&E*'M*D(=)25_3=_@G8B
MI+DA*75+3KJ]%^+5S^<G6/$6HZ_J^JZ[J]PU[JVM:C?:MJ=Y*X,MWJ.I7,MY
M>W4I  ,EQ<S2RN0 "SFOZ>_^"0'P?_X0;]G"_P#B;J%J(-;^,WB.?4X79%68
M>$?",U]X?T")\CS=LNJ'Q-J<#,526TU*UFC38ZRR_P N7@;P[K'Q"\:^$? 7
MAR&*YU_QKXET/PKHL&XD2ZIX@U.VTJQ5\$E8_M-U&9'Z)&&=B%4D?W"WFJ?#
M+]E;X$6MSKVJ6OAGX9_!SP/I.E/?W(BB?^SM"L;32-/ABA4Q_;=<UN[6VM;2
MTBW76K:W?Q6\0ENKM=W?C)^["G'5S>R[*UE\VTUZ'%A8OGE.3NHK=V6KZW]$
M[^IB_M-?M(^ OV7/A=JWQ(\<7 GF0/I_A3PQ;SQQ:KXP\32PR26.BZ<'#F*(
ME#<:KJ312PZ5IL5Q>213R)!:7/\ '?\ &_X[>._V@?B1K_Q/^(>HB_US6YRE
MM:0O(FE^']&AEE;3/#FA6LCR&ST?28IFBMHF>2>XE>XU"_GN]2O;V\N.H_:_
M_:\\9?M:?%6^\;:\\NE>$]+-QIGP]\%&\,UGX6\/&8,ID5&6WN/$&K>7%=^(
M=56,27ERD%I$R:9IVF6MK\I?;QZQ?]]C_P"*J\-0C2BI.SJ22OM[J=GRK[U=
M]7MI8FO5=1VBVH+96W\W?YV[?>=7]L_V5_[Z_P#K4?;/]E?^^O\ ZU<I]O'K
M%_WV/_BJ/MX]8O\ OL?_ !5=5UW7]?\ #K[SGL_YG]R_R]?Z6O5_;/\ 97_O
MK_ZU?U%_\$L_V0Q\&?ALGQI\=Z2D/Q0^*6EV\^DVMY 5OO!OP_N?*N]/TTI*
MHDM=6\3LMOK>M(<2P6::)IDL=K=V>IQS?D-_P2\_9-_X:2^,O_":>+]+CN_A
M'\([FPUG7X[F,26/BCQ6[FX\->$"KN$NK0R0/K?B&+9<P?V790Z5?Q1IXAM9
M#_6Y7!C*VGLHO>SFUVW4?GN_*W=G;A:3_B2=^D4TM]/>_-+Y]4F%%%%><=H4
M444 ?R._\%0/A0?A'^UMXVNK.S%OH'Q1MK/XGZ.RQ^7$;KQ ]Q;>*8_,4>4]
MPWB[3M<OY(U"R16^H6;2H?-2:;\\_MG^RO\ WU_]:OZ2_P#@M3\(&\2_ [P3
M\9M-M!)J7PJ\4G2-<G564IX/\=_9K%KBX= 1(MEXIT_PY;6J382'^VKUXY$:
M1TG_ )B?MX]8O^^Q_P#%5[.&FIT8:ZQ7(]>L;)?>K/YGEUX.-623:3=TK+1.
MSMMT=U]W8ZO[9_LK_P!]?_6H^V?[*_\ ?7_UJY3[>/6+_OL?_%4?;QZQ?]]C
M_P"*K>Z[K^O^'7WF-G_,_N7^7K_2UZO[9_LK_P!]?_6KK/ ?CW5_AYXW\(>/
M= 9(];\%^)M#\4Z2S2,(SJ&@ZE;:G:I+MP6@EFMECG3D20N\; JQ!\H^WCUB
M_P"^Q_\ %4?;QZQ?]]C_ .*I.S5M&GI]_P#PZ^\=G_,_N7EY>OX=M?[[? ?C
M+1OB+X(\(>/O#LK3:#XU\,Z'XJT=W*&3^SM>TVVU.T681LZ)<1PW*1W$88^5
M,DD9.Y3765^37_!';XT+\1_V7I_A_?7:3:[\%_%-[X>\K>9)_P#A%/$KS^)/
M#-U,Q8D(+V?Q)HMHG CM-!A1?E4 ?K+7AU(\DY1_E;2].C^:L>M3ESPC+NM?
M79_C<****@L**** "BBB@ HHHH **** /P#_ ."W'Q%V3_ OX5VTI)2'Q3\0
M-9MBS!2)7LO#GAJ<*#M)4P>+(RS*2 P$;*#(&_ [[6?[@_,_X5]W?\%5OB=_
MPG?[:/Q%LXIDN--^'>F^&/AWIC[\%1I&DQZQK<++CY#;^*]?\06^ 6W"(2$J
M7*+^<_VT>B?]]BO9P\>6C375KF?_ &\[_JCRJ[<JLWS.U[*UME9?H_O];]5]
MK/\ <'YG_"O[ /\ @FKX&'@7]C3X01R0^5J'BRQU?QYJ+[2OGMXKUN_O](EV
MDDC;X:_L.WW9Q+Y'FJ%60(O\<6F1W>L:EI^D:;;_ &K4=4OK33K"UB;=)<WM
M]/';6L$:@9+S3RQQH!R68"O[W? 'A*S\ ^ _!/@33MG]G^"O"/AOPE8^6GE1
M_8_#FC66CVOEQCB-/(LTVH/N+A>U88Z2Y(13WDY:=DO_ +96-L)!\TI-MVBE
MKW=O_D?Q];];1117FG>?R@?\%:/"G_")?MD^)]32!8HO'_@SP1XSC54\N-C'
MI;^#+B5%"*I,UYX/N99I%W&2Y>=W8RM)7YH_:S_<'YG_  K]P?\ @N;X4^P^
M*OV?_B!'$&&L>'_&W@Z]FW8\K_A'=1T36]+B<$#_ %__  D^KO$5+?\ 'O,'
M"?N_,_!3[:/1/^^Q7M8>2=&F[[1Y?_ 7R_Y?@>56BU5G[SUE?I]JTOZ_X>_5
M?:S_ '!^9_PK^UW]C_XA#XI_LP? SQNTWVB[U+X=:!I^K3[U?SM?\-6__"+^
M(I<KD+OUW1M1;RR2\.?*<ET8G^'C[:/1/^^Q7]3/_!%WXD#Q7^S#XC\#W$^^
M^^&?Q)UBUMK<,76#P[XLLK'Q'I\@)8[6GU^7Q6#&JA (5DRSRN%QQJ3I*2WC
M)?<U9_CR_AW-<(W&HTVVI1?WJWZ7^_UO^9/_  5SG,?[8^MJ%!_XH'P*<YQU
ML+GVK\QOM9_N#\S_ (5^CO\ P6"N1%^V?KB$+Q\/O 1Y;!YT^Z[5^7'VT>B?
M]]BMZ#7L:>OV(_DO\U]YC53]K4]Y_&W^*T_K_-/JOM9_N#\S_A7]YWA3_D5O
M#7_8 T?_ --UM7\ _P!M'HG_ 'V*_OW\)'/A7PR?7P]HI_\ *;;5R8[_ )=?
M]O\ _MAT8--.=VWI'?Y_U_3;U-0T^RU:POM+U*UAO=.U*SN=/O[.X026]W97
MD+V]U:SQGAX;B"22*5#PR.RG@U_$%^T+\,K_ .!GQM^)OPGOHYC_ ,(5XLU+
M3=-FN6!GOO#TSKJ/A?5)=BJH?5O#=[I6IE0J[?M>W QBO[B:_F\_X+;?!L:!
MX\^&?QZTNS"67C;29_ 7BN:-66-?$?AE7U#P]=W4C94W6K^'KN\L(E4J!:^$
M@=@;<[YX.?+4<&])K3_$M5^%UYNQIBH<T%).S@];=FU?\;?CTN?BK]K/]P?F
M?\*]6^!GQ=U7X)_%_P"'?Q5TE)&N?!'BC3=8N+:!]LFH:0)#:Z]I&2\0":SH
M=QJ.E2YEC!BO''F)]X?/_P!M'HG_ 'V*/MH]$_[[%>F[--.S35FK[I_YW_$\
M])II\ST:?W6_R_'UO_H!:%K>E^)=$T;Q'H=Y%J&B^(-*T_6]'OX"3#?:7JMI
M#?Z?>0D@$Q7-I<0S1D@$HXR :H^,/">@^._"GB/P5XHL8]3\.>+-$U/P]K=A
M+]VZTS5[.:QO(@V"8Y#!,YBF3$D$H2:,K(BL/S1_X)%?'<?%C]E^#P/J=Z;G
MQ/\ !'5SX-N4DD:6X?PCJ*2ZKX)NV8Y5;>&U_M3PU91 @QV_A@94*49_U1KP
MYQ=.<HWUC+1]UT:MW5FCV(24X*6ZDM5^#7R=T?Q#?M(?!+Q7^S=\8/%OPI\5
M0.\FBWC7.@:N4>.W\2^%;Z2630?$%F2BHT=]:+Y=W'$76QU6WU#3'<SV,P'A
M?VL_W!^9_P *_L>_;1_8Q\#?M?> H]+U*6'PW\1O#4-U-X \=QVYFDTR>XV/
M/HNMP1E)-2\,ZI)%%]KM@WVG3[A4U+36$J7-K?\ \FGQ]_9P^-/[,_B:3PU\
M6_!-_H227$L&C^)K=)K[P=XFCCW,+CP[XDCA6PO]\*BXDL)&M]8L(I$75--L
M)R81ZM"O&K%)M*:T:VOM[R\GVW3\K'FUJ$J<FTY.#=T^VVC[-;)O??NCRS[6
M?[@_,_X4?:S_ '!^9_PKE?MH]$_[[%'VT>B?]]BNBZ[K^O\ AU]YCRO^9_U;
M_+\?6_5?:S_<'YG_  H^UG^X/S/^%<NETTCI'&@DDD941$)9W=B%5$5069F8
M@*H!))  )-?K!^QO_P $NOBW\==3TCQC\8M*UCX3_!\21W<JZG"=.\>^,;97
M#"S\/:%?0&YT6PNT'S>)-=M(8?L\L-SHNGZVDCR6\3J0A%RE))+SU?DEU>JV
M[E0ISF[1<F_P6VK>R6G7OUUOZG_P26_95OOB3\2$_:&\8:4T?@+X7WY'@U;J
M,B+Q-\18XPUM=6RO&?.L/!4<JZK+<HT6WQ&^AQV\EP+'5K>'^F*N6\$>"?"W
MPX\(^'O G@C1;3P]X3\+:9;Z1H6C6(<6]E8VRX1=\KR3W$\KE[B[O+J6:[O;
MN6>[NYY[F>65^IKQZU5UIN3T6T5V2_5[L].E3]E!1O=[R?=_Y+9??NV%%%%9
M&I_%?^VI<E?VM?VBUV [?B]XW&<^FMW7M7S%]K/]P?F?\*]Z_;<NPG[7O[2*
M83Y?C%XZ'+8/&N7?45\M_;1Z)_WV*]VFU[.GK]B/Y+_-?>>/*+YI>\_B?3S_
M .!_6M_HG]GRZ+?'SX(*4 #?%_X:C.>F?&>BC/2O[CJ_A*_9WO W[0/P+7"?
M-\8OAD.'&>?&NB"O[M:X<<U>GKTE_P"VG9@U:,[N^L=_3^OZU"BBBN [#R'X
M^?"/2?CM\'/B%\)M9:*&V\:>';K3K2]FB\Y-*UN!H]0\.ZR8L$R'1M>L]-U,
M1KAI/LOEJREMP_B8\;>&/$GP\\7^)? OB[2I=(\3>$M:U#0-<TZ?(>VU#3;F
M2VG"/M"SV\C1^=:746Z"[M9(;JW>2":-V_O%K\L/^"@W_!.S3OVH8&^)WPRE
MTWPY\<=*L(;2Y6^;[+H?Q&TNPB\JRTS6[E%;^SO$&GP*EMHOB%HY8Y+2.'1-
M94V$6FW^A=>%KJDW&;M"3O?I&6UWY-63?2RZ7.;$T742E&_-'2R^TKIVUZK6
MW>[6NQ_+#]K/]P?F?\*/M9_N#\S_ (5K_$KX;?$?X.>)KOP=\4/!6N^!_$EF
MS"33=>LY+0SQKMQ=:?= /9:K82!T:'4-,N;NQG1U>&XD1@3Y]]M'HG_?8KU$
MT]4TT]FFG?\ JZ^\\[E:T<FFNC7IW]/Q];]5]K/]P?F?\*/M9_N#\S_A7*_;
M1Z)_WV*/MH]$_P"^Q3NNZ_K_ (=?>'*_YG_5O\OQ];]5]K/]P?F?\*_9_P#X
M(]_LZZCXQ^)^J?M$>(--,?A+X:P7^A^#YKF*3R]7\>ZU8&TO+BSW*8)X/#'A
MV]NC=LXW0ZIKFBSVK&>SG,/RK^Q__P $XOC7^TUJ>D^(O$6E:E\+_@T[PW=]
MXWUZPEM=4\1:><2?9_ .BWL<4VLRWJD11>(+B./PU8H9[G[7JEY:+HMY_5[\
M,OAIX,^#_@3PU\-OA]HT&@^$O"FG1Z;I.GPY=RH9I;F]O;AOWM[J>I7<D]_J
MFH7!:YO[^YN+N=VEE8GBQ6(BHNE!WE+236T5U5^[V:Z*][.QU8>A)RC4DWRQ
MU2>CDU:S]$U>_7;75G=T445YAZ!_%?\ MJ7)7]K7]HM=@.WXO>-QG/IK=U[5
M\Q?:S_<'YG_"O>OVW+L)^U[^TBF$^7XQ>.ARV#QKEWU%?+?VT>B?]]BO=IM>
MSIZ_8C^2_P U]YX\HOFE[S^)]//_ (']:W^J/V4;DM^U)^S6NP#=\?O@X,Y/
M?XB>'!Z5_;?7\-?[)-X&_:K_ &95PGS?M!_!A>'!//Q'\-CIWZU_<I7!COBI
M_P"%_F=N$349W;?O+?R2_K_,\J^./PPTWXT?"#XC?"S5%B^S^-O">K:+;SS#
M*6&K2V[3:%JH&UQYNCZW#I^J0$HZB:SC+1NH*'^'G6;/4O#^KZKH.L63V.K:
M)J5]I&J64IQ+::CIMU+9WMK*!D"2WN898G )&Y#@U_>W7\CG_!6/X/'X1_M9
M>(?$-C:>3X;^,FF6OQ'TV18V2W37;F233/&=F)B2LUX^OV,OB&Z5<&&'Q)9J
MRX968P52TI4WM)<R]59-?-._R%BX749IVY7RNW5-IJ_HTU_V]VN?GK]K/]P?
MF?\ "OMS_@GG\=_^%'?M3_#S6-0NELO"OC.Z;X<>,)))FAMX](\6S6UM8WUU
M(6$4=MH_B2'0M9NI95=4L["Y \MG$L?Y\_;1Z)_WV*47^TAE*JRD%6$F""#D
M$$<@@\@CD&O0FHSC*+>DDU]__#JWR.*/-&49*3O%I^MK?G9_?ZW_ -!:BOE#
M]B+XZI^T3^S+\,/B+<WHO/$G]BIX8\<,TGF7"^,_"VW2-;N+KKLDUIH(/$<,
M>YRMEK-KN8L3CZOKPI)Q;B]TVG\CV(M22DMFDU\S^4G_ (*G?L\7OP5_:&U+
MQ[I.GL/ /QLGO_&&F7<: 6]AXP:5)/&^AS,BJ$GDU.Y3Q);;DCC>RUY;:!IY
M-.O6C_,C[6?[@_,_X5_<-\?/@-\//VD/AKK/PP^).F->Z+J>VZT_4+5DAUCP
MWKMM',FG>(M!O'206FJ:>9Y0A>.6UO+6:ZT[4+>ZTZ\N[6;^27]JO]AKX[?L
MIZO?S^)?#MSXI^&HNG31OBGX;M+BZ\-75J\BK:)X@2+SY_"&KR"2.)].UMHH
M+B[6X31=0UFV@-XWJ8:O&<5"32G'17TYDMK/J^C6[M?N>?7H2C)SBWR-WTUY
M=KI^3:=GMK;U^4_M9_N#\S_A1]K/]P?F?\*Y7[:/1/\ OL4?;1Z)_P!]BNNZ
M[K^O^'7WG-RO^9_U;_+\?6_5?:S_ '!^9_PH^UG^X/S/^%<K]M'HG_?8KV3X
M+_ OXP?M">)HO"GPB\!ZSXPU R1K?7EG#Y&@Z'"^3]K\0^(;KR=&T.U"@E)-
M1O(&N9-MM9QW-W+#!(G**3;:26K;:22[M_-?>"C)M).3?1)7;VZ?+\?6_0?
MSX4>*_CY\5O!OPH\'6I?5_%FK16DMX4>2VT7280USK6O7^W&VQT;2X;J_G&Y
M7F\E;:#?<SPQO_;9X*\(Z)\/_!WA7P+X:MOL?A_P=X>T?PSHML6+M#IFAZ?;
MZ;9+)(?FEF^SVR&:9R9)I2\LC,[LQ^+/V%OV%_"?[(7A&:_U">Q\4_&3Q391
MP>,_&5O'+]BL;/S8[E?"?A-;J.*XMO#]M<10S7EY-#!?^(;^"*_OXK:WMM+T
MK2_OJO)Q5959I1?N1VZ7;W?Z+Y]STL/1=.+<G>4K?)66GK?5_=TNROYTO^"P
M7[,.H>'O%]C^T]X2TR6X\-^+ETWP]\35MHF==#\56-O#IOA_Q!<B/(@T[Q)I
M=O::--,8H[>WUS2[?[1<R7WB2UB/]%M<]XM\)^&_'?AG7?!OC#1K+Q!X7\3:
M9=Z/KNBZC&9;/4=.O8FAN+>4*R2(2K;HIX9(KBVF6.XMIH;B*.5,Z-5TIJ:U
M6TEWB]UZZ)KS2OH:5::J0<;V>C3[-;?+H_)L_@S^UG^X/S/^%'VL_P!P?F?\
M*_4#]M'_ ()=_%'X%ZAJWCCX+Z9K'Q2^#[R37AM-/@DU'QWX'MRQ=K76])LX
MC<Z]I%I&28_$FD6TAAMHI9-=L-,2!;V]_)=[IHW>.1!')&S(Z.2KHZDJR.K
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MZ]Y?+?\ "Z-:*<*B;:L[Q>^S^7>Q_<!1117F'H!1110 4444 %%%% !1110
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M-7>I7%T"5-M!8V^IR74MQN5AY,<3294C;D&@#T2BBB@ HHHH **** "BBB@
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M2:I:Z/H]A%^\.'N]0O+> ,>%+[FX!-?/7]MGTG_[^G_&OZ!?^#=O]F\_&O\
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M;35F2VEUK4K6#R="\/P7$O[N"Z\0Z[<:;HEK+)E([B_B9@5!%?Q3_LQ? _\
M:=_X+;?M(_$'Q;\4_BY<Z/X<\$VUKK/C'QA?V5YXATCP-I_BB_OQX8^'OPV\
M%C5-,T[3EU(:1JAL[9=0T^TMK'1=0UK5KC5M7VP:K_0E_P '!GB'4-"_X)I_
M$.VLY?+M_$?Q'^$NB:LADD1;C3X?&%KXACA;9(BN%U30=-G"3++'N@5Q&)DB
MEC_EQ_X)K_\ !4KXN_L%>$?BAX=^%W[/_AWXMQ_$3Q'H.M:UK6HS^*8KG3'T
M+3+RQT_2PWAZUN(W@VW]Y=QK<LKI)<3&-=KL3TT8R=.<H13FVHIMI6VOOZ_>
MEH]C"HTYQC)OE6K2OJWMHOE^-M3VK]N[]BKXW_\ !(OXK_"7XB_"[XU:QJVE
M>+3JESX%^*'ARQG\">(]'\1^&)M,N-;\*^(=(MM;UVTN;.>TU#3;F);B\N-'
M\4:>^I6%]I'E6-[;2_V$?\$]_P!J";]L3]D7X0?'?4X;*S\5>(M)O]%\=V&G
M@1VEIXW\(ZO?>&O$,MM;JT@L[/6+K3!XBTVR,DK6FE:Q8P/([HQK^+?_ (*&
M_P#!4'X^_P#!0WX=>!?A[XT_9AT[X?1>!/&LGC/3]<\-6GC35=2N))]"U'0[
MC2I/[6TX+!8W"WT5Y/Y#AI;BPM-ZL(U*_P!'/_!NO%KUM_P3\O[+7['4]-GL
MOC]\2(;*QU2VNK26WL9="\"W8$$%W'%(EO+>W-[."J"-IY9V!+EZ=6,O91<T
MN=/=-.Z=]++3JGIIMW%3:]I)1OR-75[^7?UM\S]WZ***Y3H"ORR_X+5:K?:+
M_P $S/VEM3TV\N;"]MO^%-^3=V=S-9W,7G?'_P"%5O)Y=Q;O'+'YD4LD;['&
M^-V1LJS _J;7Y)?\%U)OL_\ P2M_:EFPIV?\*1^\<#YOVC/A$O)[?>X]ZNG\
M<.OOQT[ZHF?P2_PR_)GY4_\ !M?XLU[Q)XW_ &LX]9UG5-52T\*_"-X%U#4[
MW4%A:;5_'RR&);J:41%Q&H<H%+A5#9"C'U-_P<<^(M7\.?LN? VZT?4[_2YY
M_C[%;RS:??W6GR21?\*\\:R>6\EK+$[IO16V,Q7<H;&0"/A/_@UUO?M?CS]L
M480>7X1^#)^1MWWM9^(O7TZ<5];_ /!SC=?9/V3/@$^%.[]HF%/G;:/^2:^.
MSQ[\5LU_M-K=8Z7_ +JZF"M[!Z=?QYEK\M/N/HC_ (-\M<U/Q#^P?J]_JVH7
MNI72_'WXA6XN;^]N+Z<11^&_ +I&)[F2601JTCE8PVU2S$ %CG]RJ_ C_@V_
MN?M7_!/C6I,*,?M$_$A/E.X<>&/AV>OKS7[[UE5_B3Z>\].QM3^"/H@HHHK,
ML_)K_@JG^P=\:_VY= ^#.E?!KXF>%?AO<_#K6/&NH:_-XHU3Q9ID>K0>)++P
MW;:?%9MX5TG59)GM)-'NWF%ZL*(MQ&8&=FE"_P 1_P  _A!XR^-O[2/@;]G_
M ,(Z_I7AWQMXR\<W'@S2O$^I7NJV^E:?JL#7RO?W%SIEE<ZM';L;.7#VUI)<
MGS%S&,MC_35K_.+_ .":VJ"7_@JW^SO%Y:@O^T3J:9$F2/WGB(=-HS],UU4)
M/DFK*T8W7=-MOYZVT?IU:?/5@G.#L_>=I?\ DJ7H?V?_ /!+G]B[XN?L1_"+
MX@^ /C#\0O#7Q%USQ9\2'\8:7JGAG4O$VI6ECI3>&- T46%Q+XHTS2[R.Y%Y
MI5S<>7;PR6WE31MYGFM(J_IK117-)N3;>[[&Z2226R"BBBD,^!O^"I-_=Z7_
M ,$^?VK=0L;F>TN[3X6:A+!<VT\EM/#(-3TP!XIX626)@"1N1E;!(SS7X%_\
M&W?B[Q!XD^-O[24&LZUJNJ16WPL\)RPQZAJE[J"1._BV5&>-+J>58V9?E+(
M2."2*_=O_@K3+Y'_  3?_:^EP#L^$FHG#' _Y"NE#D]NM?SM_P#!L%?_ &OX
M[_M0IA!L^$G@]OD;<>?&4HY]*WC_  *FE_>6M]M8].MS&?\ %IG]FU%%%8&P
M5SOC#Q7H?@3PEXH\<>)[Q=.\->#?#NM^*_$.H,I9;'0_#NF76KZM>,HY9;6P
ML[B<J.2$(')KHJ^ O^"J.O:AX;_X)U?MB:GILODW$GP/\7:/(^^2/=I_B."+
MP[JL):*2-MMQI>J7D#*6,;K(4FCEA9XG:5VEW:7WL3T3?9,_D UCXB_M3_\
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M@G_XS7YI_P#$)M^VM_T<9^RW_P"!7Q9_^=Q1_P 0FW[:W_1QG[+?_@5\6?\
MYW%;?NNW_DS\OZ^;[:3:7\W_ )*C]+/^(KG]GS_HT_XR?^%KX)_^,U_,O_P4
MJ_;XN_V^_P!J[Q=^T!#X=UCPCX4N- \)^#_ /@_5]3MM0U#PQX5\-:3&LME<
MWEE%':SRZGXIOO$WB600KY<$FNO;*T@A$C?IY_Q";?MK?]'&?LM_^!7Q9_\
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M=Q5QJ0@K1TOK\3\O+T_I:)PON[V_NH_G-_X2)_\ GG-_X$'_ .)H_P"$B?\
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MA04444@"BBB@#^%G_@ZBU)K#]K_]G<%$*2_LVQE7D8H"R?$_QZ'53P"5#(6
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MX&>?N\^V37]HO_!;^?[+_P $KOVOY\*?+\'>#3ACM7GXK^ 5Y/;K^=?SX?\
M!(K_ ((9?\% OV.O^"AO[/G[1WQN\,_"S3_A?\.O^%L?\)/>>&_B;IWB'6H?
M^$N^"'Q*\":+]BT>"RAEO/,\0^)])BN-DB_9[1Y[ILK RG^FK_@J5^SS\2_V
MKOV!OVC?V>_@[::/?_$KXE>&_#6F>%;3Q!JT6A:/-=Z7\0/"/B*[6^U::.6*
MSC73-'OGC=XV#S+'" #("-9S4JD9+9<O7L[_ -=B5&R:OO?\58_F'_X-4-3^
MW_M _M6IB(>7\'/!;?NWW'GQK*.>>!7]NU?RX_\ ! 3_ ()2_MA?\$\_B_\
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MNUL=+L7N=#\2Q>-KRRTW2[,6T-GI^G>'/"FK3N;2V^SV\@M+=EC-U$3\B_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!_E#_ /! /_E,!^Q-_P!CQXY_]4[\1J_U>***N>Z]/U8!1114 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
D% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>img267189834_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img267189834_1.jpg
M_]C_X  02D9)1@ ! @$ D "0  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &3"Z<# 2(  A$! Q$!_\0
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MY_##_P":BC_ALO\ 9 _Z.L_9M_\ #Y_##_YJ*_QL:*/^(787_H;XC_PDI_\
MR[U_I:G]I2_Y]1_\#?\ \CZ_TM?]D[_ALO\ 9 _Z.L_9M_\ #Y_##_YJ*/\
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M$E/_ .7>O]+4_M*7_/J/_@;_ /D?7^EK_LG?\-E_L@?]'6?LV_\ A\_AA_\
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M^S;_ .'S^&'_ ,U%?XV-%'_$+L+_ -#?$?\ A)3_ /EWK_2U/[2E_P ^H_\
M@;_^1]?Z6O\ LG?\-E_L@?\ 1UG[-O\ X?/X8?\ S44?\-E_L@?]'6?LV_\
MA\_AA_\ -17^-C11_P 0NPO_ $-\1_X24_\ Y=Z_TM3^TI?\^H_^!O\ ^1]?
MZ6O^R=_PV7^R!_T=9^S;_P"'S^&'_P U%'_#9?[('_1UG[-O_A\_AA_\U%?X
MV-%'_$+L+_T-\1_X24__ )=Z_P!+4_M*7_/J/_@;_P#D?7^EK_LG?\-E_L@?
M]'6?LV_^'S^&'_S44?\ #9?[('_1UG[-O_A\_AA_\U%?XV-%'_$+L+_T-\1_
MX24__EWK_2U/[2E_SZC_ .!O_P"1]?Z6O^R=_P -E_L@?]'6?LV_^'S^&'_S
M44?\-E_L@?\ 1UG[-O\ X?/X8?\ S45_C8T4?\0NPO\ T-\1_P"$E/\ ^7>O
M]+4_M*7_ #ZC_P"!O_Y'U_I:_P"R=_PV7^R!_P!'6?LV_P#A\_AA_P#-11_P
MV7^R!_T=9^S;_P"'S^&'_P U%?XV-%'_ !"["_\ 0WQ'_A)3_P#EWK_2U/[2
ME_SZC_X&_P#Y'U_I:_[)W_#9?[('_1UG[-O_ (?/X8?_ #44?\-E_L@?]'6?
MLV_^'S^&'_S45_C8T4?\0NPO_0WQ'_A)3_\ EWK_ $M3^TI?\^H_^!O_ .1]
M?Z6O^R=_PV7^R!_T=9^S;_X?/X8?_-11_P -E_L@?]'6?LV_^'S^&'_S45_C
M8T4?\0NPO_0WQ'_A)3_^7>O]+4_M*7_/J/\ X&__ )'U_I:_[)W_  V7^R!_
MT=9^S;_X?/X8?_-11_PV7^R!_P!'6?LV_P#A\_AA_P#-17^-C11_Q"["_P#0
MWQ'_ (24_P#Y=Z_TM3^TI?\ /J/_ (&__D?7^EK_ +)W_#9?[('_ $=9^S;_
M .'S^&'_ ,U%'_#9?[('_1UG[-O_ (?/X8?_ #45_C8T4?\ $+L+_P!#?$?^
M$E/_ .7>O]+4_M*7_/J/_@;_ /D?7^EK_LG?\-E_L@?]'6?LV_\ A\_AA_\
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M /EWK_2U/[2E_P ^H_\ @;_^1]?Z6O\ LG?\-E_L@?\ 1UG[-O\ X?/X8?\
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M6?LV_P#A\_AA_P#-11_PV7^R!_T=9^S;_P"'S^&'_P U%?XV-%'_ !"["_\
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MV_\ A\_AA_\ -17^-C11_P 0NPO_ $-\1_X24_\ Y=Z_TM3^TI?\^H_^!O\
M^1]?Z6O^R=_PV7^R!_T=9^S;_P"'S^&'_P U%'_#9?[('_1UG[-O_A\_AA_\
MU%?XV-%'_$+L+_T-\1_X24__ )=Z_P!+4_M*7_/J/_@;_P#D?7^EK_LG?\-E
M_L@?]'6?LV_^'S^&'_S44?\ #9?[('_1UG[-O_A\_AA_\U%?XV-%'_$+L+_T
M-\1_X24__EWK_2U/[2E_SZC_ .!O_P"1]?Z6O^R=_P -E_L@?]'6?LV_^'S^
M&'_S44?\-E_L@?\ 1UG[-O\ X?/X8?\ S45_C8T4?\0NPO\ T-\1_P"$E/\
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M[2E_SZC_ .!O_P"1]?Z6O^R=_P -E_L@?]'6?LV_^'S^&'_S44?\-E_L@?\
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M=9^S;_X?/X8?_-17^-C11_Q"["_]#?$?^$E/_P"7>O\ 2U/[2E_SZC_X&_\
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M]?Z6O^R=_P -E_L@?]'6?LV_^'S^&'_S44?\-E_L@?\ 1UG[-O\ X?/X8?\
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M^S;_ .'S^&'_ ,U%?XV-%'_$+L+_ -#?$?\ A)3_ /EWK_2U/[2E_P ^H_\
M@;_^1]?Z6O\ LG?\-E_L@?\ 1UG[-O\ X?/X8?\ S44?\-E_L@?]'6?LV_\
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M$E/_ .7>O]+4_M*7_/J/_@;_ /D?7^EK_LG?\-E_L@?]'6?LV_\ A\_AA_\
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MEJ?VE+_GU'_P-_\ R/K_ $M?]D[_ (;+_9 _Z.L_9M_\/G\,/_FHH_X;+_9
M_P"CK/V;?_#Y_##_ .:BO\;&BC_B%V%_Z&^(_P#"2G_\N]?Z6I_:4O\ GU'_
M ,#?_P CZ_TM?]D[_ALO]D#_ *.L_9M_\/G\,/\ YJ*/^&R_V0/^CK/V;?\
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MQHH_XA=A?^AOB/\ PDI__+O7^EJ?VE+_ )]1_P# W_\ (^O]+7_9._X;+_9
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M_P!#?$?^$E/_ .7>O]+4_M*7_/J/_@;_ /D?7^EK_LG?\-E_L@?]'6?LV_\
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M6O\ LG?\-E_L@?\ 1UG[-O\ X?/X8?\ S44?\-E_L@?]'6?LV_\ A\_AA_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!]_\ _!*7_E)E
M^P-_V=S\ _\ U9/AZOK?_@XR_P"4RW[8_P#O?L^_^LL_!"ODC_@E+_RDR_8&
M_P"SN?@'_P"K)\/5];_\'&7_ "F6_;'_ -[]GW_UEGX(5\W/_DK\/_V3>,_]
M6F!.A?[I+_L(C_Z;F?B31117TASA1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !7]6W_!/?_E6<_P""L'_9=(?_ $T_LQU_*37]6W_!
M/?\ Y5G/^"L'_9=(?_33^S'7S?$_^Z9=_P!C[)/_ %/HG1AOCG_UYK?^FV?R
MDT445](<X4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 5[C^S%_R<I^SU_V7'X3?^I[H%>'5[C^S%_R<I^SU_V7'X3?^I[H%8XC_=Z_
M_7FK_P"D2*A\<?\ %'\T?NG_ ,'47_*4N3_LW/X0_P#I?XUK^;NOZ1/^#J+_
M )2ER?\ 9N?PA_\ 2_QK7\W=>/PO_P D[DW_ &+\/_Z0C7$_[Q5_QL****]X
MP"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /\ 1W_X
M-0/^49'C#_L['XJ?^H!\'Z*/^#4#_E&1XP_[.Q^*G_J ?!^BOYHXL_Y*3./^
MPVI^43Z'#?[O2_P(^3/^#P;_ )(C^Q3_ -E4^+/_ *B/A6OX.Z_O$_X/!O\
MDB/[%/\ V53XL_\ J(^%:_@[K]DX _Y)? _]?<;_ .I=8\G'?[S/TA_Z0@HH
MHK[,Y HHHH **** "OUB^!W_  0Z_P""H_[2/PF\#_'+X+?LP?\ "9_"WXD:
M/_;W@OQ1_P +J_9X\._VSI/VNYL?M?\ 8GBOXM:%XBT[_2K.YB\C5M(L;G]W
MO\GRWC=OR=K_ %A_^"'?_*)S]A__ +) ?_4L\35\CQCG^,X>P&&Q6"I8:K4K
M8M8>:Q4*LX*#HU:EXJE6H24N:FE=R:LW[M[-=6$H0KSE&;DDH<RY6D[W2ZIZ
M:G\&'_$.7_P67_Z,Y_\ -A/V5_\ Y^%'_$.7_P %E_\ HSG_ ,V$_97_ /GX
M5_1-^TS_ ,'77_#.O[2'[0/[/O\ PP5_PF/_  HKXW?%;X-_\)=_PU)_PCW_
M  E/_"L?'FO>"?\ A(_[ _X9TUS^P_[<_L/^T_[(_MK5_P"S?M7V+^U-0\C[
M7-XC_P 1CO\ UCG_ /-N_P#\F"O%IYMXC5:=.K3R#*)4ZL(U(2]M37-"<5*+
MM+.E)7BT[-)K9I,U=+ )M.O5NG9Z/=?]P3^/W]HW]G+XS?LE?&;QE^S[^T%X
M-_X0#XO> /\ A'O^$N\(_P#"0^%?%7]D_P#"5>%=#\;:!_Q/_!.N>)/#%_\
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M1:O33J#C)*[C)+NT[??\T>0T445N(**]_P#A)^R?^U-\?]+OM;^!'[-7Q_\
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MF032Q,CM_6U^RI_P=5_\,R?LS_ +]G7_ (8/_P"$W_X4=\(?A_\ "K_A,?\
MAJ#_ (1K_A*/^$%\,:;X<_M[_A'_ /AG?7_[$_M7^S_MG]E_VYJ_V'SOL_\
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M^X.,H[IJ^UTU^844^**2:2.&&-Y9I72***)&DDEDD8*D<:*"SN[$*B*"S,0
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MERQE)2=WHK+5Z&*C)IM1;2W:3:7JSY.HHHK80445];6?[ 7[=VH^&4\::?\
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M;[3M<\,Z[I>J0F6PU2('_-A_X+;?L4>%_P!@[_@H9\7/A#\.[.+3/A-XJLM
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MQ/JMIHFAZ=]OU2ZL=,L?MVIWUK;?;-1O;.PMO-\Z\NK>W225/U*^,'_!"?\
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M2^_[-F^+7_J0?#NN+.<=4R_*,?F&'5*I4PV%J8BDJBE.E-QCS1YE3G"4H/\
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MJL7]G?:9[&*TN[&XN?ZR_P#@SA_YR,?]VB?^_/U\<?\ !V+H6M^)_P#@IQ\
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M .]^S[_ZRS\$*^2/^"4O_*3+]@;_ +.Y^ ?_ *LGP]7UO_P<9?\ *9;]L?\
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MTC%J]G9ZIO[S_*IHHHK]+/."BBB@ HHHH **** "BBB@ K^K;_@GO_RK.?\
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M@5X=7N/[,7_)RG[/7_9<?A-_ZGN@5CB/]WK_ /7FK_Z1(J'QQ_Q1_-'[I_\
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MDC:-68>"TZ=6G6BITJD*L'M.G.,XNV]I1;3MZ@TUHTT^S5C]@?AG_P $$O\
M@K)\8OAO\/OBY\./V4O^$B^'OQ3\$>%/B/X#\0?\+T_9LTC^W?!GC?0;#Q-X
M7UG^R==^,6EZYI?]J:'JEC>_V=K.FZ=JMEY_V;4;&TNXIK>/\?J_V!/^"9W_
M "C?_P""?G_9D?[*7_JB/ 5?X_=?'\*<18W/<3G5'%TL+3CEM>A2H/#0K0E.
M-6IC(2=5U:]92:6'A9P5-)N=T[I1ZL30A1A1E%R;J1;ES--)I0>EDOYGO?H%
M%%%?9G(%%%% '^CO_P &H'_*,CQA_P!G8_%3_P!0#X/T4?\ !J!_RC(\8?\
M9V/Q4_\ 4 ^#]%?S1Q9_R4F<?]AM3\HGT.&_W>E_@1\F?\'@W_)$?V*?^RJ?
M%G_U$?"M?P=U_>)_P>#?\D1_8I_[*I\6?_41\*U_!W7[)P!_R2^!_P"ON-_]
M2ZQY.._WF?I#_P!(04445]F<@4444 %%%% !7^L/_P $._\ E$Y^P_\ ]D@/
M_J6>)J_R>*_UA_\ @AW_ ,HG/V'_ /LD!_\ 4L\35^:^)_\ R)\!_P!C*/\
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M]I/PGXBM=4^'WQ%T^V.K:1J'AWQ/XA\">(K9;JRED;3]?\+>,/#6L#PWXO\
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M;Q1X)L]7^(&C?$7P;XYT/PK:1ZCKVF1^(3X;\":EIOBRVT'^T_$CZ%)X6O\
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M=:?;X=T_T=OV>OC%\/\ ]H/X(?"[XV_"B*^A^&OQ/\':/XO\#)J6DQZ%>_\
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M1XFUOPJVE^*7U9=0N'L?"7B_P1JYU"$6$/V.5=<6VC+2>?:W&5V?CW&OUO\
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M&4J;=^7DG4=:*6BJ.4K)R;:Q%.$\9036DU>7][EYFK^J23\M#^DW]N_]O?\
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M7YK5IE/_ "*LL_[%^"_]1J1-3^)4_P <O_2F%%%%>@0%%%% !7VY_P $SO\
ME)!_P3\_[/<_92_]7OX"KXCK[<_X)G?\I(/^"?G_ &>Y^RE_ZO?P%7)C_P#<
M<;_V"8G_ -,S+I_Q*?\ CC_Z4C_4M_X*0?"/XA?'O]@S]K3X+_";P_\ \)7\
M2_B;\#/'G@[P/X;_ +6T/0O[;\1ZUH\UKIFG?VQXEU+1M TW[3.ZQ_;-7U6P
ML(<[KBZB0%A_GF^&/^#;/_@L-KVLVFEZK^S)H'@FQN2XF\1^)_CY^S_=Z-8;
M4+*;N#P;\3/%OB%Q(P$:?8=!O2'8&01Q[G'^CU^V!^T%_P ,H_LN_'C]I/\
MX1'_ (3W_A27PR\4?$7_ (0O^W_^$6_X2;_A&]/DOO['_P"$B_L7Q'_8OVWR
M_*_M#^PM6^S9W_89\;#_ "./_P 'CKE'$?\ P3I59"K!&?\ :Y,B*Y!VLZ+^
MS'&SJ&P6021E@" ZD[A^*<'8KBNA@L9#A_+L%C*$\2G7JXF=.,Z=;V4$HP53
M'X5-<G++^'45V[O[*]?%QPTIP=>I.$E'W5%-IJ_6T)=?-'] O_!&'_@FYK'_
M  3%_9"?X,>,_&NG^.?B?X^\?ZK\6_B=J'A_[0?!^B^)]9\/>%_"\7A;P;/?
M6.FZGJ.AZ+HOA+3!)K.K6-I?ZOK-UJU\MGI^GR:?IEE_#M_P<D_M%>#/VA?^
M"H_Q(@\":A:ZUHGP)\">"_@!>:Y87EG?:=J?BGP?<>(/$GC2"SFM,[6\->+?
M&FL^#-2AN'>>+6_#>IKN$ @1/I;]LK_@Z;_;)_:(^'VK?#7X#?#GPC^R9I?B
M;3+W2?$OC/PYXIU7X@_%?[%>I;PS0>$/&5]H_A+2O!3W%K_:%M/JVG^$[KQ1
M:"\M[OPYXA\/:GI\=_-_,%++)-))--(\LTKO+++*[222R2,6>21V)9W=B6=V
M)9F)))))K[3A7AO-<-FF,S_/94XX[%1J0CAZ<J<W%UI0E4JSE1;HQ48P5*E3
MISFE%R<FFHWX\3B*4J4*%%/DC9N336VR5]7JVVVEY'^SAX\^$G@[X]_L]^(?
M@G\0[6ZOO /Q7^%TO@#QM86-[<Z;>:AX3\4^'ET?Q#IUMJ5E+#>Z=/?Z3=7=
MG'?V<T5W9-.+FVD2>*-A^"WQ9_X.4?\ @F/^RYKGCS]G+X8^$?BMX@;X$^'_
M !'X'\&R_#;X:>%M(^!,OB;X>V=[H.C_  W\,7LOC+0]>M-#AU;28/#]EKVF
M> SX-73Q'J.D:Q>:3]GNI?WB^)/B:?P5^S/X]\96HE:Z\)? OQ3XFME@D6*<
MSZ#X O\ 581#*Z2I%*9+11'(\<BH^&9' *G_ !DZ^,X)X=P>?QS#^T)XAX?!
MU*/L:%*K[.#K5U4]I5EH[R4*%."M:ZD[O1'7BZ\Z"I>S4>:<7>35W:/+9+RO
M)O6_XN_];/\ P;W_ /!./P__ ,%'?CS\>_\ @H7^V)I.D_$[P9X8^+>O3VO@
MO6;"VG\.?$W]HGQG<1?$GQEKGB_1B#8WGA?P=9>*M*U1?"MS:RZ7X@UCQ;IO
MVS=I?AZ^TK6/W>_X*>?\'"_P%_X)K?&2V_9D\(? _6OC_P#%#PMH_AJ]\>Z/
MHOCC1OAAX)^&^F:[IJ:CH?ATZTOACQQJ%[XMC\.RZ1K9\-P>%-.T>ST/6M%;
M_A(ENIKC3[/H/^#8NPTZS_X)*_"JXLK:W@N=5^*7QNO]7EA55DO-1C\?:AI<
M5S=D<O<+I6FZ99JS_,+6UMD'RJM?)?[=5S_P:]77[6OQNE_;;6=?VJ5\4VMM
M\91<VO\ P43LY#XCL] T>TLF6'X6PP?#UX'\/P:.]K=>$T;2;ZU:&]AFN'N)
M+B7;&5Z&:<69C1S3+LVS3+\L5;"83+<HHU*KHJA4IT(SG"E5H2IT9-3G.4)Q
MDZLJ4&_9Q44H1=+"TW3J4J<ZG+*52K)*[DG*UVI)R5TK-623>Y^H?PN\<_L,
M?\%^?V$[K6=>^'L^O?#_ %S5=?\ !^N^&?%]MH</Q1^!OQ3T>QM_.O?#^NZ7
M/K">'O$]GINL:5X@\-^(-*NO*UKPUK-@FLZ=]DU#5_#R?YKG[4/[%_Q0_9M_
M;7^(W[$+VS^,OB3X5^+>G_##P=_9\=M93>/AXQN=*F^%NK6=K->R6VES>//#
M_B3PMJ\.GW>HL-*DUI;&\N]]M-*/[K_V0O\ @J7_ ,&X/[!O@WQ1\/\ ]E'X
MZ?\ "JO"/C/Q,OC'Q+I'_"L?V[O'/]I>(UTJRT1=1^W_ !(^'OC#4[/&F:=9
MVWV.PO;6P/D^<;4W$DLK_B+^T%^TG^QU^VS_ ,'''[$/QL^ /CRR^(/PG\0_
M$;]E:SU?Q5<>'?'?P_CU+XM>"_%=Q:^';";2_B#X=\'Z_/<I?Z7\/-+ME_LQ
MM,UE_LVEQR7OFW5O7K<+5,QRG'YU"EEN<X;(W@\5C<'2S/"5Z+I5L.HU(4W*
M5Z:G4@ZM.2A5<JJC2E)N4';/$JG5A1;J4I5N>,)NG.+O&3LW;?1V>JLKM=3^
MI_\ 8G_8@_9%_P""*7[&&O\ CWQ/'X=L?$O@CX:R^.?VH/VB[C0YM2\6^++[
M1]/.IZY9:.T%O?:]#X0TZ_:32/ 7@#0T8W3&R>6SU7Q;J^I:GJ/YL_LY_P#!
MUC^S;\<OVG_"_P $/$O[.'Q'^$_PS^(?C#0? _@/XR:QXX\/>(=2CUKQ->V>
MDZ/<_$7X<Z9H=K:^#=%?5[R.TOM2T#X@^/6TZV:/4+BU%L+HVGV__P '([W2
M_P#!'7]J5;<S"*36/@"EZ(@VQK4?M$_"N1!<;1@0_;4M"I?"_:!  =Y0'_+O
MKFX5X>P?%."S/-<YGB,3CJ^,JX:%;VU2'L'&A0JJM",)1C*2E7Y8TJBE1A3I
MQA&FEL\37GAITZ5)*,(Q4FK+WKMJUVGVU:U;;NS_ $+O^#EG]B#]DOXN?LT>
M,?VIM(\2_!KX;?M9_!B"QUAKRX\8>#/!^O?&OP3'J5CI7B#P+KMC=ZA8W/B[
MQ=I=K?1ZIX D-O?^)KC4["/P1I?G)XE@MH?B'_@SJ_Y&K]O_ /[%_P#9I_\
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MI#I_[*\%GEL2_8+BY_:(DU+8G\4?VBUTKS&Q\C>4/X^?DO\ X.Z)]>;_ (*
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M#G"BBB@ HHHH **** "BBB@#_3E_X-EO^41OP6_[*'\<O_5H^(:_!S_@M/\
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MUCK?A369;&PCA@_X2&?Q%>+!$MXBCZA_X-!/^3H_VMO^R!>%_P#U8EA7KO\
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MYJE?Z5?_  =+?\HK-9_[+[\'?_1OB.O\U2O)\-_^2>G_ -C'$_\ IK#FF/\
M]X_[<C^H4445]^<04444 %%%% !1110 4444 ??_ /P2E_Y29?L#?]G<_ /_
M -63X>KZW_X.,O\ E,M^V/\ [W[/O_K+/P0KY(_X)2_\I,OV!O\ L[GX!_\
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M6M[/Q+\2_CY\3[6[\0W]M<7.D>#O"VD^)O$FM>+?&6LQVQ2233_#GA[3]0U
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MVFZ]XF^'#>-?@UXIFU.QU_XV_!;QO?Z%#K>@/>>#?"D&N_$7P_?V]^]GI/Q
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M+;Q+XFOY9;1;V^F;2_!GP_\ #[6-A$WAOPKING64/^>)_P %*?\ @I3\=O\
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M_"NU_:U_:H\7^+?#OP+U3Q%K.B_#+X=^ ;K3])\0_$[_ (1#6_[&\1^(=?\
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M]FNC^,/#.I>&O&GA^\AO9M*LEG^VSV5WIMK=V4\2_P";!_P5D_9C\#_L<_\
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MZ.'HTI.+;BY4Z<82<6TFXMIV;2=MTGH<TG>3:ZMO[V%?[ G_  4Q_P"4;_\
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M'G_U:?BNOF\/_P E7F?_ &)<L_\ 4K'F\O\ =J7_ %]J_P#I-,^9:***^D,
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M2?2?&OBSQ2-/N8&TC4?$?AR74?#'@C2KFX@O;NZU6;Q)]DN]'T&XMK_^>?\
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M !1110 5^QO_  ;_ '_*7_\ 8M_[&OXD_P#JC_B=7XY5^QO_  ;_ '_*7_\
M8M_[&OXD_P#JC_B=7EYY_P B7./^Q7F'_J)6-:'\>C_U]I_^EQ/&_P#@L9_R
ME)_;N_[./^(7_ISK\UJ_2G_@L9_RE)_;N_[./^(7_ISK\UJTRG_D599_V+\%
M_P"HU(FI_$J?XY?^E,****] @**** "OMS_@F=_RD@_X)^?]GN?LI?\ J]_
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M)=:;Q4ZL(N#I3A:+I4:[<KR3LXQ5KZWT(PE>%"<Y34FI127*DW>]];M' _\
M.9#_ +R9?^_35_I'_P#!8#_E%W^WA_V;-\4/_4?N*_RBO^%Q?$?_ (7)_P -
M ?\ "1?\7<_X6;_PN+_A+?[(T+_DH_\ PE/_  FO_"1?V#_9?_",_P#(S?\
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M5:KG%*52E2G=)VE>"2>S:U.?$U8UJKJ14DFHJTDD]%;HVOQ"BBBOHC ****
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M5@!%I+XA\$^);'6_!NO7=@'E73;[5]!O+W3%GN5T^XMENK@2_5OQL_X+??\
M!53]H3P7J?P]^)O[8_CZ7PEK4!M-8T[P)X;^&OP>N=5L7WBXTW4=:^#_ ((\
M":Y>Z7>Q226^I:7<ZE)I^IVCO9ZA;7-JQA/E4>$^(LJS',:N1YM@L/@\RJ<]
M5XFE.IB:2=2I./)3^KU*4ZE'VU2,)^UIJHG><(NW+J\3AZE.G&M2G*=-67*T
MHO1)Z\R:4K*ZL[6T;/\ 4IT[0/!VK_ ^?P+\+]2TK4O!]MX!UGX9>%KK0M3L
MM8T^W@\.Z5?>!%TV'48+EK.>XT2\TR;1[Y7N4-OJ%A<VMVT,T,P3_,>_X(D7
MO[#NA_MQ0_"O_@HM\'_!OB;P1X_TRZ\!^$]:^*YUW3M$^%/QDT_7["?1X_&>
MD2ZYI&@Q:)XB-GJG@_6G\6Z)JK:/KUQH"RR:+HDGBF6X\E_9N_X+0_\ !2[]
MD;X.>%/@!^SW^TM+X!^$?@B7Q!-X5\(2?"/X#^,$T=_%/B35O%VO"#6_'?PO
M\3^(Y8K_ ,1Z[J^JF"ZUB>"WGOIH[2."WV0I^>/Q,^(WB_XO_$3QQ\5?B!J%
MEJWCKXC^*]>\;^,M6T_0?#WA>TU7Q1XFU*XUC7=4B\/>$]*T/PWI!U#4[NYO
M)+/1=(T[3XY9I/(M(E.VNG(.$<=E5+/<'B<;!X;,U3CA\7@ZV(I8ZDZ,J_)5
MG%TH1ISE&K&<XPKU8\T94VYPDY$U\7"JZ$XP?-2;<HS47!WY;I.[NERM)N*>
MST:/]%7_ (*A_P#!NG^SY^U_\//AS<_L8Z)\$/V1/B=\.#X@\F'PS\--%\._
M#CXLZ)XCM=->&R^(.H>!='3Q-'JVAW^D6=QX9\7K!XH73]-U3Q-87'AW4Y-6
ML;_1^4_X(D?\$.?VJ/\ @FO\9?$?Q>^-/[4?A+6- UOP?X@\,W?P'^"VH>/M
M7^'GB35M4N]$?2?&/BK5?&6D^![:YU+P_9Z7<QZ?;0> 9-1BN+R+R/$T%A#>
MV&J?QB?L[?\ !8#_ (*5_LI^#]/^'WP/_:Y^)'A[P/HT5I:Z!X2\3VOA'XJ>
M'_#6G6%G;6%CHWA;2OBSX;\<6GAC0+.UM((K7P_H$6G:);D2216"2SSO+ZC\
M2/\ @O/_ ,%</BMX:U3PEXK_ &TO'-GH^L6;V%\_@+P9\)/A/K9M9 XD2U\4
M?"OX?>#/$^G22+(R/<:=K%K</&1&TI154<4^&.,?J-7)_P"VLMQ&657*+J8J
M%:>+]E.?/)7GAJS3<FY)?6)2@[*%6*M:UB<)SJK[&I&HND6E"Z22VDMK?RV?
M5-G[K?\ !VK^V5\*?&4_P#_8M\#Z[HWBOX@_#7Q=K?Q;^,)TG43=O\.KN[\-
M+X>\#>#M5%M#+9+X@\0Z9KWB#Q%JNE37L&KZ!I5EX8N[O3S:^*[&=?U/_P"#
M;/\ X*(^ _VF/V+O!/[+GB3Q-I5C^T)^RQH*>!Y?"5W<066J>+?@[I,X@^'O
MC3PY8R3&35-/\/:+/8>!?$YLQ+/I.J:+8ZAJL-C;>*-$:[_S;]1U'4-7U"^U
M;5KZ\U/5-3O+G4=2U+4;F:]U#4-0O9WN;R^OKRY>6XN[R[N)9+BYN;B22:>>
M1Y97>1V8[O@GQSXV^&GBK1?'7PY\8^*? 'C?PY=->^'O&/@GQ!JWA7Q5H-X\
M$UJ]WHOB'0KNPU?2[I[:XGMVN+&\@E:"::$N8Y'5O7Q'!6$K<-X?(EB)*KA9
MO$4<;*";>+FYRJRE24M*%15)4U3C.\(JG)RG.#<\HXR2Q$JSBK27*X)_95K6
M=OB5KW:UU5DGI_:Q^V1_P:?^,_B;^T_XD^(G[+WQ^^&/@'X&?$WQQJOBWQ'X
M-^(VC>)_^$H^$L/B*_.IZQI/P]M/"NCWNA^/M%LK^[U!O#&CZ[JWPZFTK1UT
MW0K[7-6GM9M>NOU=_:;_ &"/^"-'_!/K]A8>+OVD?V8?@;XPT#X)?"W0O"D7
MB[5/ OA'0/CC\=_&^AZ-::?I-HOB+PO%X5U?Q!\3/B/KME'/?WB:C;6MK)?Z
MEJ>JW>F^&K/4[NV_B\T3_@X2_P""P^@:3'HMC^V=KL]G%"+=9M;^$?[/GB75
MC&(_*W2:]XC^$NJZ[+-MY-S+J+W!D_?&4RDO7Y[?M*_MA?M0?MB>*[?QI^TU
M\</'_P 8]<L%F31U\6:RSZ#X<BNEA%W!X4\):?'8>$_"5M>&WAEO;;PUHFE0
M7D\8N+J.6<F0^?#AKBS&SP-'-L^HPP.!:L\MGB*>,KQCRQM4J*AAO?E3CR*K
M*I4<+N?)4G*4GH\1A8*<J5!\\_\ GXDX)^2YI:7N[)*^UTMO -;O;+4]9U?4
MM-T:R\.Z=J&IW][8>']-N-3N].T*RN[J6>UT:PN]:OM4UFZLM,@DCLK6XU;4
M]1U.>"".2_OKNZ:6XDS***_1DK)+716U;;T[MW;?FVV^IYX5^S'_  ;X_P#*
M87]C#_L8/BQ_ZH#XKU^,]>S?L]_M!_%[]E;XP^"_C[\!?%W_  @GQ:^'MQJU
MUX/\6?V!X8\4?V1/KGA_5O"VJ2?V%XRT7Q%X:U#[5H6N:I8[=4T:]2#[5]JM
MUAO(+>XAXLRPT\9EV88.DX1JXK!8K#4Y5&U",Z]"I2@YN,924%*2<G&,FE=J
M+>CNG)0J4YN]H3A)VWM&2;M>RO9::H_T1?\ @Z6_Y16:S_V7WX._^C?$=?YJ
ME?I7^U-_P5__ ."BG[:GPJF^"7[3/[0__"R_AC<:_H_BB;PS_P *E^!O@W?K
MN@&Y;2+[^VO 'PS\*^(%^R&[N#]F75ELY_,_TFWF")M_-2O%X2R7%9#E4L#C
M*F'J57BZU=2PTZDZ?)4A2C%7JTJ,N9.F[KDM9JS>MM<56C6J\\%)+E2M)).Z
MOV;7XA1117TYSA1110 4444 %%%% !1110!]_P#_  2E_P"4F7[ W_9W/P#_
M /5D^'J^M_\ @XR_Y3+?MC_[W[/O_K+/P0KY(_X)2_\ *3+]@;_L[GX!_P#J
MR?#U?6__  <9?\IEOVQ_][]GW_UEGX(5\W/_ )*_#_\ 9-XS_P!6F!.A?[I+
M_L(C_P"FYGXDT445](<X4444 %%%% !1110 4444 ?;G_!,[_E)!_P $_/\
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MDZ9XU\:>-3J7@^#5[BYFB,4'B37/#=KX.TYH5E<^(/$>C+.L5D;NZM_["?\
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M!7CC]H[XO>&+CX->$] \(S7ND> -"T^_N+7QWXDT#PG?>*ET;Q#\2/%.L1^
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MPQX6\/?%'2;-);W1_B]^S[\<O"$EKXR\,Q:C=Z1=V,%Y)#IVHVUMXH\&>*-
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M.KQZ?K.FV5V^EZWI>I:1J"PFTU*PO+*::WD_87_B(T_X++_]'C?^:]_LK_\
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M4O#6B^)AXEM=9U2]O==TWP)KP\(6.D7US<:38^++30CIUKI'Z:Z]_P $P_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** /Z&_\ @U]_Y2P^ O\ LCGQI_\ 48CK\?OVUO\ D\G]K7_LYKX\
M_P#JT_%=?L#_ ,&OO_*6'P%_V1SXT_\ J,1U^/W[:W_)Y/[6O_9S7QY_]6GX
MKKYO#_\ )5YG_P!B7+/_ %*QYO+_ ':E_P!?:O\ Z33/F6BBBOI# **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_JU_;*_P"557_@
MF;_V=WJO_IS_ &YZ_E*K^K7]LK_E55_X)F_]G=ZK_P"G/]N>OFN(?]YX:_[*
M'#_^H6/-Z/PXC_KQ+_TY3/Y2J***^E, HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O1OA%\7?B9\!/
MB9X+^,?P<\::Y\/?B;\/=<MO$7@_QAX=N5MM4T?5+97B8A94FM+[3[ZTFN=,
MUG1M3MKW1M>T:]O]$UNPU#2=0O;*?SFBIG"%2,H3C&<)QE"<)Q4HSA)-2C*+
M34HR3:E%IIIM-6!-IW3LUJFMT^Y_8'\&/^#OC]H+PQX8T[2_CM^R-\,?B]XD
MLD6"Z\5> _B3KWP9&KQ1(42YOM"U#P?\6+&'5)L)+>SZ9-I^F23>:;+1M/@>
M*W@](\5?\'B?C"\TJYA\$?L">&O#VN-!.MIJ/BK]I#5/&.E073!?LTUSHVD?
M!3P+=W4$3!S/;1:[9R7 95CNK8H6?^+2BOEY<$\+SJ.J\IIJ3?,U'$XV%.][
MZ4H8F-)+^ZH*/2UCI^N8E*WM7\XP;^]QO^)]L?MT?\%!OVGO^"B?Q4M/BM^T
MMXTM];N]"T^XT;P/X*\-V#Z!\.OAWHMY<)=W^G>#?#/VJ]:UDU.ZB@FUG7-6
MO]8\4:X++2[?6==O[31M&M[#XGHHKZ3#X>AA:-/#X:E3H4*4>2G2I14*<(K6
MT8Q22NVVWNY-R;;;9SRDY-RDW)O5MN[?JV%%%%;""BBB@ HHHH **** "OV-
M_P"#?[_E+_\ L6_]C7\2?_5'_$ZOQRK]C?\ @W^_Y2__ +%O_8U_$G_U1_Q.
MKR\\_P"1+G'_ &*\P_\ 42L:T/X]'_K[3_\ 2XGC?_!8S_E*3^W=_P!G'_$+
M_P!.=?FM7Z4_\%C/^4I/[=W_ &<?\0O_ $YU^:U:93_R*LL_[%^"_P#4:D34
M_B5/\<O_ $IA1117H$!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% ']6GA__E4X\<?]G>6G_JV_"%?REU_5IX?_ .53CQQ_V=Y:?^K;
M\(5_*77S?#F^?_\ 929E_P"D88Z,1_RX_P"P>E_[<%%%%?2'.%%%% !1110
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M?\G*?L]?]EQ^$W_J>Z!7AU>X_LQ?\G*?L]?]EQ^$W_J>Z!6.(_W>O_UYJ_\
MI$BH?''_ !1_-'[I_P#!U%_RE+D_[-S^$/\ Z7^-:_F[K^D3_@ZB_P"4I<G_
M &;G\(?_ $O\:U_-W7C\+_\ ).Y-_P!B_#_^D(UQ/^\5?\;"BBBO>, HHHH
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M_E11_P 0@W[*G_1V/[0?_A/?#C_Y45_1I_PV1\//^A<\9_\ @+H?_P O*/\
MALCX>?\ 0N>,_P#P%T/_ .7E'U[Q$_Y^8[_P7@O+^YZ?CYA]>R/_ )_T/OJ_
MY>7Y]V?SE_\ $(-^RI_T=C^T'_X3WPX_^5%'_$(-^RI_T=C^T'_X3WPX_P#E
M17]&G_#9'P\_Z%SQG_X"Z'_\O*/^&R/AY_T+GC/_ ,!=#_\ EY1]>\1/^?F.
M_P#!>"\O[GI^/F'U[(_^?]#[ZO\ EY?GW9_.7_Q"#?LJ?]'8_M!_^$]\./\
MY44?\0@W[*G_ $=C^T'_ .$]\./_ )45_1I_PV1\//\ H7/&?_@+H?\ \O*/
M^&R/AY_T+GC/_P !=#_^7E'U[Q$_Y^8[_P %X+R_N>GX^8?7LC_Y_P!#[ZO^
M7E^?=G\Y?_$(-^RI_P!'8_M!_P#A/?#C_P"5%'_$(-^RI_T=C^T'_P"$]\./
M_E17]&G_  V1\//^A<\9_P#@+H?_ ,O*/^&R/AY_T+GC/_P%T/\ ^7E'U[Q$
M_P"?F._\%X+R_N>GX^8?7LC_ .?]#[ZO^7E^?=G\Y?\ Q"#?LJ?]'8_M!_\
MA/?#C_Y44?\ $(-^RI_T=C^T'_X3WPX_^5%?T:?\-D?#S_H7/&?_ ("Z'_\
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M /+RC_ALCX>?]"YXS_\  70__EY1]>\1/^?F._\ !>"\O[GI^/F'U[(_^?\
M0^^K_EY?GW9_.7_Q"#?LJ?\ 1V/[0?\ X3WPX_\ E11_Q"#?LJ?]'8_M!_\
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M?_@+H?\ \O*/KWB)_P _,=_X+P7E_<]/Q\P^O9'_ ,_Z'WU?\O+\^[/YR_\
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M_E11_P 0@W[*G_1V/[0?_A/?#C_Y45_1I_PV1\//^A<\9_\ @+H?_P O*/\
MALCX>?\ 0N>,_P#P%T/_ .7E'U[Q$_Y^8[_P7@O+^YZ?CYA]>R/_ )_T/OJ_
MY>7Y]V?SE_\ $(-^RI_T=C^T'_X3WPX_^5%'_$(-^RI_T=C^T'_X3WPX_P#E
M17]&G_#9'P\_Z%SQG_X"Z'_\O*/^&R/AY_T+GC/_ ,!=#_\ EY1]>\1/^?F.
M_P#!>"\O[GI^/F'U[(_^?]#[ZO\ EY?GW9_.7_Q"#?LJ?]'8_M!_^$]\./\
MY44?\0@W[*G_ $=C^T'_ .$]\./_ )45_1I_PV1\//\ H7/&?_@+H?\ \O*/
M^&R/AY_T+GC/_P !=#_^7E'U[Q$_Y^8[_P %X+R_N>GX^8?7LC_Y_P!#[ZO^
M7E^?=G\Y?_$(-^RI_P!'8_M!_P#A/?#C_P"5%'_$(-^RI_T=C^T'_P"$]\./
M_E17]&G_  V1\//^A<\9_P#@+H?_ ,O*/^&R/AY_T+GC/_P%T/\ ^7E'U[Q$
M_P"?F._\%X+R_N>GX^8?7LC_ .?]#[ZO^7E^?=G\Y?\ Q"#?LJ?]'8_M!_\
MA/?#C_Y44?\ $(-^RI_T=C^T'_X3WPX_^5%?T:?\-D?#S_H7/&?_ ("Z'_\
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M /+RC_ALCX>?]"YXS_\  70__EY1]>\1/^?F._\ !>"\O[GI^/F'U[(_^?\
M0^^K_EY?GW9_.7_Q"#?LJ?\ 1V/[0?\ X3WPX_\ E11_Q"#?LJ?]'8_M!_\
MA/?#C_Y45_1I_P -D?#S_H7/&?\ X"Z'_P#+RC_ALCX>?]"YXS_\!=#_ /EY
M1]>\1/\ GYCO_!>"\O[GI^/F'U[(_P#G_0^^K_EY?GW9_.7_ ,0@W[*G_1V/
M[0?_ (3WPX_^5%'_ !"#?LJ?]'8_M!_^$]\./_E17]&G_#9'P\_Z%SQG_P"
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M\_,=_P""\%Y?W/3\?,/KV1_\_P"A]]7_ "\OS[L_G+_XA!OV5/\ H[']H/\
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M #_H??5_R\OS[L_G+_XA!OV5/^CL?V@__">^''_RHH_XA!OV5/\ H[']H/\
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ML?V@_P#PGOAQ_P#*BOZ-/^&R/AY_T+GC/_P%T/\ ^7E'_#9'P\_Z%SQG_P"
MNA__ "\H^O>(G_/S'?\ @O!>7]ST_'S#Z]D?_/\ H??5_P O+\^[/YR_^(0;
M]E3_ *.Q_:#_ /">^''_ ,J*/^(0;]E3_H[']H/_ ,)[X<?_ "HK^C3_ (;(
M^'G_ $+GC/\ \!=#_P#EY1_PV1\//^A<\9_^ NA__+RCZ]XB?\_,=_X+P7E_
M<]/Q\P^O9'_S_H??5_R\OS[L_G+_ .(0;]E3_H[']H/_ ,)[X<?_ "HH_P"(
M0;]E3_H[']H/_P )[X<?_*BOZ-/^&R/AY_T+GC/_ ,!=#_\ EY1_PV1\//\
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M_@O!>7]ST_'S#Z]D?_/^A]]7_+R_/NS^<O\ XA!OV5/^CL?V@_\ PGOAQ_\
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M1\//^A<\9_\ @+H?_P O*/KWB)_S\QW_ (+P7E_<]/Q\P^O9'_S_ *'WU?\
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M)[X<?_*BC_B$&_94_P"CL?V@_P#PGOAQ_P#*BOZ-/^&R/AY_T+GC/_P%T/\
M^7E'_#9'P\_Z%SQG_P" NA__ "\H^O>(G_/S'?\ @O!>7]ST_'S#Z]D?_/\
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M_P"$]\./_E17]&G_  V1\//^A<\9_P#@+H?_ ,O*/^&R/AY_T+GC/_P%T/\
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M*G_1V/[0?_A/?#C_ .5%?T:?\-D?#S_H7/&?_@+H?_R\H_X;(^'G_0N>,_\
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M*3[6O?5G\SO_ !"#?LJ?]'8_M!_^$]\./_E11_Q"#?LJ?]'8_M!_^$]\./\
MY45_1I_PV1\//^A<\9_^ NA__+RC_ALCX>?]"YXS_P# 70__ )>5V_7O$3_G
MYCO_  7@O+^YZ?CYF/U[(_\ G_0^^K_EY?GW9_.7_P 0@W[*G_1V/[0?_A/?
M#C_Y44?\0@W[*G_1V/[0?_A/?#C_ .5%?T:?\-D?#S_H7/&?_@+H?_R\H_X;
M(^'G_0N>,_\ P%T/_P"7E'U[Q$_Y^8[_ ,%X+R_N>GX^8?7LC_Y_T/OJ_P"7
ME^?=G\Y?_$(-^RI_T=C^T'_X3WPX_P#E11_Q"#?LJ?\ 1V/[0?\ X3WPX_\
ME17]&G_#9'P\_P"A<\9_^ NA_P#R\H_X;(^'G_0N>,__  %T/_Y>4?7O$3_G
MYCO_  7@O+^YZ?CYA]>R/_G_ $/OJ_Y>7Y]V?SE_\0@W[*G_ $=C^T'_ .$]
M\./_ )44?\0@W[*G_1V/[0?_ (3WPX_^5%?T:?\ #9'P\_Z%SQG_ . NA_\
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M_EY1]>\1/^?F._\ !>"\O[GI^/F'U[(_^?\ 0^^K_EY?GW9_.7_Q"#?LJ?\
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M8?7LC_Y_T/OJ_P"7E^?=G\Y?_$(-^RI_T=C^T'_X3WPX_P#E11_Q"#?LJ?\
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M@W[*G_1V/[0?_A/?#C_Y45_1I_PV1\//^A<\9_\ @+H?_P O*/\ ALCX>?\
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M1I_PV1\//^A<\9_^ NA__+RC_ALCX>?]"YXS_P# 70__ )>4?7O$3_GYCO\
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MX<?_ "HH_P"(0;]E3_H[']H/_P )[X<?_*BOZ-/^&R/AY_T+GC/_ ,!=#_\
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M]]7_ "\OS[L_G+_XA!OV5/\ H[']H/\ \)[X<?\ RHH_XA!OV5/^CL?V@_\
MPGOAQ_\ *BOZ-/\ ALCX>?\ 0N>,_P#P%T/_ .7E'_#9'P\_Z%SQG_X"Z'_\
MO*/KWB)_S\QW_@O!>7]ST_'S#Z]D?_/^A]]7_+R_/NS^<O\ XA!OV5/^CL?V
M@_\ PGOAQ_\ *BC_ (A!OV5/^CL?V@__  GOAQ_\J*_HT_X;(^'G_0N>,_\
MP%T/_P"7E'_#9'P\_P"A<\9_^ NA_P#R\H^O>(G_ #\QW_@O!>7]ST_'S#Z]
MD?\ S_H??5_R\OS[L_G+_P"(0;]E3_H[']H/_P )[X<?_*BC_B$&_94_Z.Q_
M:#_\)[X<?_*BOZ-/^&R/AY_T+GC/_P !=#_^7E'_  V1\//^A<\9_P#@+H?_
M ,O*/KWB)_S\QW_@O!>7]ST_'S#Z]D?_ #_H??5_R\OS[L_G+_XA!OV5/^CL
M?V@__">^''_RHH_XA!OV5/\ H[']H/\ \)[X<?\ RHK^C3_ALCX>?]"YXS_\
M!=#_ /EY1_PV1\//^A<\9_\ @+H?_P O*/KWB)_S\QW_ (+P7E_<]/Q\P^O9
M'_S_ *'WU?\ +R_/NS^<O_B$&_94_P"CL?V@_P#PGOAQ_P#*BC_B$&_94_Z.
MQ_:#_P#">^''_P J*_HT_P"&R/AY_P!"YXS_ / 70_\ Y>4?\-D?#S_H7/&?
M_@+H?_R\H^O>(G_/S'?^"\%Y?W/3\?,/KV1_\_Z'WU?\O+\^[/YR_P#B$&_9
M4_Z.Q_:#_P#">^''_P J*/\ B$&_94_Z.Q_:#_\ ">^''_RHK^C3_ALCX>?]
M"YXS_P# 70__ )>4?\-D?#S_ *%SQG_X"Z'_ /+RCZ]XB?\ /S'?^"\%Y?W/
M3\?,/KV1_P#/^A]]7_+R_/NS^<O_ (A!OV5/^CL?V@__  GOAQ_\J*/^(0;]
ME3_H[']H/_PGOAQ_\J*_HT_X;(^'G_0N>,__  %T/_Y>4?\ #9'P\_Z%SQG_
M . NA_\ R\H^O>(G_/S'?^"\%Y?W/3\?,/KV1_\ /^A]]7_+R_/NS^<O_B$&
M_94_Z.Q_:#_\)[X<?_*BC_B$&_94_P"CL?V@_P#PGOAQ_P#*BOZ-/^&R/AY_
MT+GC/_P%T/\ ^7E'_#9'P\_Z%SQG_P" NA__ "\H^O>(G_/S'?\ @O!>7]ST
M_'S#Z]D?_/\ H??5_P O+\^[/YR_^(0;]E3_ *.Q_:#_ /">^''_ ,J*/^(0
M;]E3_H[']H/_ ,)[X<?_ "HK^C3_ (;(^'G_ $+GC/\ \!=#_P#EY1_PV1\/
M/^A<\9_^ NA__+RCZ]XB?\_,=_X+P7E_<]/Q\P^O9'_S_H??5_R\OS[L_G+_
M .(0;]E3_H[']H/_ ,)[X<?_ "HH_P"(0;]E3_H[']H/_P )[X<?_*BOZ-/^
M&R/AY_T+GC/_ ,!=#_\ EY1_PV1\//\ H7/&?_@+H?\ \O*/KWB)_P _,=_X
M+P7E_<]/Q\P^O9'_ ,_Z'WU?\O+\^[/YR_\ B$&_94_Z.Q_:#_\ ">^''_RH
MKL/AY_P:;_LO_#OQ_P"!OB!8?M3?'O4+[P+XP\,^,;*PO- ^'J6E[=^&=:LM
M;MK2Z>'25F2WN9K%(9VB995B=C&0X!K^@3_ALCX>?]"YXS_\!=#_ /EY5S3_
M -KOP#J5_8Z=#X>\8)-?WEM91/+;:*(TDNID@1I"NM.P16D!<JK,%!PI. 9G
MC?$)PFIU,=R.,E.]/!?"U[U[0OMO;7?S'''9)=*->C>ZMK4WNK=.Z7]-GY;?
M\%'_ /@@#\#/^"D?[1K?M'_$+X[_ !8^'?B!O ?A?P%_PCW@W2?!][HPL?"T
MVK36U]YVMV%S>_:[EM7E$Z>9Y*B*/RU!+9^"/^(0;]E3_H[']H/_ ,)[X<?_
M "HK^G'XC_M#>$OAGXC/AG6='\17MZ+"UU#S]+@TR2U\J[,HC3==ZG:2^8IA
M;>/*VC*[6;G'!?\ #9'P\_Z%SQG_ . NA_\ R\KFP&,XYA@\-# 3QBP<:,%A
ME"GA'!44ER<KG!R<;6LY-MJ]^II6QF40JU(5JU*-6,FJBDZEU);IV5NG33[V
M?SE_\0@W[*G_ $=C^T'_ .$]\./_ )44?\0@W[*G_1V/[0?_ (3WPX_^5%?T
M:?\ #9'P\_Z%SQG_ . NA_\ R\H_X;(^'G_0N>,__ 70_P#Y>5U_7O$3_GYC
MO_!>"\O[GI^/F9?7LC_Y_P!#[ZO^7E^?=G\Y?_$(-^RI_P!'8_M!_P#A/?#C
M_P"5%'_$(-^RI_T=C^T'_P"$]\./_E17]&G_  V1\//^A<\9_P#@+H?_ ,O*
M/^&R/AY_T+GC/_P%T/\ ^7E'U[Q$_P"?F._\%X+R_N>GX^8?7LC_ .?]#[ZO
M^7E^?=G\Y?\ Q"#?LJ?]'8_M!_\ A/?#C_Y44?\ $(-^RI_T=C^T'_X3WPX_
M^5%?T:?\-D?#S_H7/&?_ ("Z'_\ +RC_ (;(^'G_ $+GC/\ \!=#_P#EY1]>
M\1/^?F._\%X+R_N>GX^8?7LC_P"?]#[ZO^7E^?=G\Y?_ !"#?LJ?]'8_M!_^
M$]\./_E11_Q"#?LJ?]'8_M!_^$]\./\ Y45_1I_PV1\//^A<\9_^ NA__+RC
M_ALCX>?]"YXS_P# 70__ )>4?7O$3_GYCO\ P7@O+^YZ?CYA]>R/_G_0^^K_
M )>7Y]V?SE_\0@W[*G_1V/[0?_A/?#C_ .5%'_$(-^RI_P!'8_M!_P#A/?#C
M_P"5%?T:?\-D?#S_ *%SQG_X"Z'_ /+RC_ALCX>?]"YXS_\  70__EY1]>\1
M/^?F._\ !>"\O[GI^/F'U[(_^?\ 0^^K_EY?GW9_.7_Q"#?LJ?\ 1V/[0?\
MX3WPX_\ E11_Q"#?LJ?]'8_M!_\ A/?#C_Y45_1I_P -D?#S_H7/&?\ X"Z'
M_P#+RC_ALCX>?]"YXS_\!=#_ /EY1]>\1/\ GYCO_!>"\O[GI^/F'U[(_P#G
M_0^^K_EY?GW9_.7_ ,0@W[*G_1V/[0?_ (3WPX_^5%'_ !"#?LJ?]'8_M!_^
M$]\./_E17]&G_#9'P\_Z%SQG_P" NA__ "\H_P"&R/AY_P!"YXS_ / 70_\
MY>4?7O$3_GYCO_!>"\O[GI^/F'U[(_\ G_0^^K_EY?GW9_.7_P 0@W[*G_1V
M/[0?_A/?#C_Y44?\0@W[*G_1V/[0?_A/?#C_ .5%?T:?\-D?#S_H7/&?_@+H
M?_R\H_X;(^'G_0N>,_\ P%T/_P"7E'U[Q$_Y^8[_ ,%X+R_N>GX^8?7LC_Y_
MT/OJ_P"7E^?=G\Y?_$(-^RI_T=C^T'_X3WPX_P#E11_Q"#?LJ?\ 1V/[0?\
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M445]0>*%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?^CO']?(U?7/C;_DTCX6_P#8YS?^CO']>'G/\;(_^QU1_P#43&GIY=_"S/\
M[%U3_P!/X<^1J***]P\P**** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH *]J_9V_Y+/X&_P"OS4__ $PZK7BM>U?L[?\ )9_ W_7YJ?\
MZ8=5KS\V_P"15F?_ &+\;_ZC53KP'^_8+_L+PW_IZ!B_&O\ Y*S\0/\ L9M1
M_P#1M>7UZA\:_P#DK/Q _P"QFU'_ -&UY?6F7?\ (OP/_8'A?_3$",7_ +WB
MO^PBM_Z<D%%%%=ASA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% 'UU;_P#)H%]_V.2?^GFSKY%KZZM_^30+[_L<D_\ 3S9U\BUX>2;Y
MS_V/,=_Z1AST\SVR_P#[%F%_.J%%%%>X>8%%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 >B?"+_ )*E\//^QR\._P#ITMJ[+]I?_DMO
MC7_N6_\ U$M!KC?A%_R5+X>?]CEX=_\ 3I;5V7[2_P#R6WQK_P!RW_ZB6@UX
M<O\ DI:/_8CQ7_J?A#TE_P B>?\ V,J7_J+6/":***]P\T**** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^NOAS_P FM?%[_L8%_P#1
M/A2OD6OKKX<_\FM?%[_L8%_]$^%*\//_ /=<)_V-LJ_]3:1Z>5?Q\1_V 8[_
M -1YGR+1117N'F!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !6]X5_Y&?PY_V'M'_].%O6#6]X5_Y&?PY_V'M'_P#3A;UG6_A5?^O<
M_P#TEET_XE/_ !Q_]*1[[^UI_P E9;_L6M&_]#OJ^9*^F_VM/^2LM_V+6C?^
MAWU?,E>9D'_(ERO_ + J'_I".W-?^1EC?^PBI^84445ZYYX4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110!^F7[(7_)++[_L<-6_]-NB
MT4?LA?\ )++[_L<-6_\ 3;HM%?A'$/\ R.\S_P"PNK^:/U#*O^1;@O\ L'I_
MD<?^VA_R O O_86UC_TCLZ_/VOT"_;0_Y 7@7_L+:Q_Z1V=?G[7Z?P=_R(,)
M_P!?,5_ZDU3XGB#_ )&N(_PT/_3%,****^H/%"BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** /I']E+_ )*_I_\ V!-<_P#25:\7\<_\
MCMXP_P"QI\0?^G:[KVC]E+_DK^G_ /8$US_TE6O%_'/_ ".WC#_L:?$'_IVN
MZ\.A_P E%C_^Q7@/_4C&'I5/^13AO^P[%?\ IG#'+4445[AYH4444 %%%% !
M1110 4444 %%%% 'G'QB^)WA[X)_"7XG_&/Q:TB^%_A3\/\ QC\1?$(A($\F
MC>"_#^H>(M1AM@5;?=3VNG2PVL:H[RW$D<:([LJ'^5O_ ((\_LCZ;_P4R^)/
MQI_X*A?MW:9;_&+5M8^*&H^$/A)\-?%MI'J?PXTS_A'K+3=0NM0?P[?&XLM=
M\+>#[75],\$>!?#>HV\FB6<VD>(]3UNRUW6I;&_T_P#H&_X*:>&/$'C'_@GM
M^V9X>\+QW4^N7G[.?Q3GL[2R@2ZO-0CTSPMJ&K7NF6MN_,T^J6%C=:?%'"&N
MG>Y M$>Z,*-^?G_!M_XL\->(/^"9?A+1-$FM'U?P+\6OBQX<\80P!%N(=<U#
M7XO&-BUZ B/))+X7\4>'S#.YE#6Z10++_HYAA^<QT(8O/\MPF)2GAJ.#Q..A
M1G9TJV*A4IT8.4'[M25"G*52":?*VY=6>QA92H95C,11;C7GB*.&E4C=3IT)
M1E4DHR6L54FE&5FKI)=C]MM6^'7P^U[PE)X!USP+X-UGP+-;/92^"]6\,:)J
M/A*6SE$JR6DGAR\L9M'>VD6>8/ UF8G$TH9")'S_ "(?M[_!ZW_X(A?MW?L^
M?MM_LJVEUX._9Q^-OB.]\(?&OX1:4\UQX9M(8+^PU+QKX7TG3KBX=;?2/$WA
MF[NO$W@'3(@\'@[Q9X6NSI?V71$T[1HO[(:_ER_X.GO%&AQ?LN_LT_#XO:R^
M,/$O[0=UXHT2Q5Y'U:?0_"GP\\4:)KKV=K'+B6U.J>./#$-R[6TLGVF2PC@E
MB\R:.8XFHTHY75QL5&GBL Z-?"8B*4:E*I&M3BH1DM>2HG[.5._++F6EU%I9
M-4F\=3PSO.ABE4I5Z3;<)PE3DW)J]N:#2DI?$K:/5I_J[_P4Z_X*,6G_  3I
M_9Q\!_M#6'PIC^.=AX[^+'A?X:66@1?$#_A7<4-IXH\">/O'%MXGBUT^"?'1
MO(XX?!"62:6='MOM"ZN+S^T8?L/V6\^4?!O_  6B\>_&'XM^$]+^ 7_!.S]I
M7XL_LP^,OBIIWPHT/]K"S&J:-X/U*^O?%'_"*7'B^QT4_#[5-&'@.ROTFGN/
M$.L?$#1396\+V^LV>CZNLFEQ_)W_  <9Z%J/A?\ X)3_ +*'AG6(A!JWAW]H
M'X%:%JD )80ZCI'[./QPT^]B#,JDB.YMY4!*J2%R5!X']%W[//@;0OAE\!/@
MK\._#-I:V.@>"/A3\/\ PMI-M9VRVENEEHGA72M/A=+<22F-IA!Y\I>:>5YI
M)))IYI7>5Q5<RQ>;XO#4L:\)AL-AL!7<(X;#U:GM*ZJN5/FJPDU3FH2]I=.:
M<8>SE3]_F'#!T,!AZT\.J]:M6Q5)2=6K"/)3=/EGRPDESQYER6M%J4N>,_=Y
M?QX^(W_!>3X1?!K]H_\ :D_9V^)OP6\7)KWP)\2^'O _PML_AUXC;X@_$']H
MGQQXD919^'_#?P\'A'P[%X56U5UEO]2N_%VO6\0DM;.!+G5]2TG2[_R[6_\
M@OQXV^"GBGPP?VR_^":/[3?[+7PE\9:K#I?A_P"*&OWNHZW-(T_F2DWOA?Q!
M\-?AY:)?Z?8(=4UCP]I7BS6?$MG8Q74EMI%_+%!%=>"?L(_#;P[XN_X.*_\
M@H5XWUVPLM0OOA9X5\9:SX2^U6L<\^D^)O$NH_"SPF^NV$\@;[+=0^%=3\4Z
M(SQ*LTEMK]PBRI'YL<WZB?\ !=;PUH_B;_@E=^U4FK6J7#:'H_P]\2Z3/LC,
M]AK&C?%GP+/:W5K))'(87EA:YT^Y>,+)+IU]?6HD1;AF'%#$9U7P&98^.8PI
M?4<1F2H4/JF'G&O2P=6HU#$3<>=7C%T8NC[*45&-2<ZDI,ZI4<NIXK!X1X-S
M^M4\'[2J\15C*G/$PIINE%2Y='+VC]ISIN3A%0BD?3G[7_Q\^%OA']A7XM?M
M'7OP_P#!W[2WP?@^#MO\2;?P#KL^F/X(^+?@O6K72]4TBWNKC6O#7BW2WT77
M-.U&RU&"6_\ "^L0/$86:P8D%/S:^*'[96M7O_!%WPK\;OV9/V$U;PK\=/ 7
MQ/\ A[J/P$^#VMV6D^'/V=_AQKWAKXU6'B?XJ>=X6^%-KI6H^&O#&I>&8-0U
M73(/!W@ZTNKWQ:#/K5G-"T^H>?SW$]S_ ,&SZR7,\UQ(O[$]O;K)/(\KK!::
MG':VL"M(S,(;:VAAMK>,'9#!%'#&JQHJCUG]@W_E7XT?_LSO]IO_ -#^,-=%
M3%8C%XI4X5%AXXCAJ6,O"E1G.G6G7IW<9U*<IN*A)P]G*3IN_/R\Z4EC"A2H
M4E)Q=65'.EA_>G4C&4(TY6O"$XQ4N9*7,DIZ<O-RW1^=W_!M_P#M-?'71/A]
MX1_9DTO]D#QUXA^!/B_XO?%SQ%XD_; M?$E_!X$\"ZU;?#2UUR#PKJ7AM? %
MW87E[>:KX7T#P['<2>/],=;OQE83"QD>U2TU#RS]G[]N7X6_L,?\%5?^"LGB
MSQWX>\>_$'Q;\1/BUJ'@?X4?"CX7>'+CQ+X\^)'C&7XG:W<C1]%LT,5I;Q6M
MOBYOKN[N%D$;1VVF6>JZK<V6F77Z7?\ !LS_ ,HXM5_[..^)_P#ZC?P\KY=_
MX)A_##POXJ_X+M?\%0_B3KFFV.I:U\+O$?Q+A\(/>6RW$FBZMXX^)T.FW^NZ
M;(Y(M-2CT'2M4T,7"(93IVOZC LB)-*LGC8>EBU@.$XTL5S5JN)<J-2K1IN.
M%I3P%2,H1A35/VOLH*I.FZLI2E4DE.3@DEZ%:=!XS/74HVIPH)5(TYS3K3CB
M:;4I2DY\CFW"$N1**BKQBI-M^_7G_!?[Q1\'/&GA73_VV?\ @G#^TE^R3\-?
M&U]%:>'?B7XAO-7\2%H)991)=ZAX8UKX8?#IA/I5J(-0U[0= UWQ'XGTVS>9
MH=$OYELH=0_5+]O;X]?##X5_L*?%_P#:!\3_  I\$_M/_"K2O!/A3Q7)\,/$
M]SHLO@;XG^'_ !%XG\*P:*;J[UKPMXXT6;33_;&G^(K">Z\+ZS!+)96KQ0Q2
M-%=0?(W_  <%>']'UG_@E%^T=J6IV,%W>^$M9^"'B#P]<3(KR:7K%S\=?ASX
M5GOK5F!,4\F@>)M<TQG0JQMM1N(R=LC _,/QWN+BZ_X-G-#DN9YKB1?V+OV<
M[=9)Y7E=;>TUOX86EI KR,S"&UM88;:WB!"0V\44,:K'&BCV*F*Q^$J9O@<1
MBEC/99+/,<-B*F'H4ZD)/ZQ2=.I3IP5"K%3I*4>:G\/NS4TV<$*&$Q$<OQ%*
M@\/[3,88.M2C5JSC-7HSYX3E)U:;<:CB[3W]Z+BT??GA#]M+PA\/?^"4^B_M
MP> ?V>?#?@?P;X;^!,?Q-\._LX^$/$.F>&O#.@Z=%?M:Q>#M%\1Z+X!LM*TN
MRC9WFCO+'X>P0(SLJZ0"Q<_$V@_\%\E^+G@_P5#^RK^PY\<OVI_C9?\ @?1/
M&/Q7^'/PJU+4-2\!_!>XUY9)K/POXC^+EG\.]5DU'7$MHRTSQ?#[3M,2];^Q
M?MYURVU'3K#G?^=9S_NRW_W-5]4_\$"OAMX=^'W_  2X_9[O]'L+*WU?XD7/
MQ'^(?C#4;6UCMI];UW4OB/XHT2PNM0=09+FZTWPEX?\ #/AU)YG=FMM%MQ&(
MH1'#&J>)S+$XO+L'0Q<<+2K9%1QM>I'#X><U4]I3@W1C*'LX2FYQ5I0G1A!2
MY:2DXM.='!4*&+Q%7#NO.GFE7#4H.M5A%P4)22J-2YI1CRMW3C4E)QO4Y4TT
M_81_X+*?#?\ :]^->L?LL_$_X(_$K]D[]J71[/4KP?"/XFN]\-7DT336UK6]
M%TK5;S0_".OP^)=)T*.?Q#<Z)XA\%>'Y+CP]!-JNF3W\=M>1VOUI^W7_ ,%"
M/V=O^">OPUL/B#\==;U*74?$US?:=\/_ (=>%+:UU/QYX^U/3H89]1CT/3;N
M]T^RM=*TB.ZLGUWQ%K%_I^BZ3]NT^UENY=5U32--U#\5_P!O_0=/T3_@X4_X
M)F>*=)C?3]8\4^ -%LM=N+1EMSJ":9XA^,FF137+0K'+-<3Z3J+Z/>232R+<
M:7;6=BR""$J_Q_\ \%*/B]XIM_\ @O?X U*__9T^(G[8>C_LW?#?P5J/@W]G
M?X>:3J?B;5=7NIO 6J>.;?Q##H.G>&/%[*OAOQOXML?%NIWB>'[EID\,:1%=
MW,4%M;M;X5<YQV#P>,I5JM.MBZ&;TLKI8QT'R^SKTZ=>.)K8:A\<Z5*4[TZ*
M2G*,+0>JEI#+<-B,1AYTX3IT*F7RQU3#JJK\U.<J;HTZU5^[&I-0M*H[Q3DW
M):./Z(W?_!>#XZ>#=%B^*OQ>_P""2O[67P[_ &;GB6]E^,/V_5-0O+/2)W5+
M+5]1\+Z]\*O!N@:987IWFUO=2^(=GIURKV3VE_<I?P,?W*_9U_:*^$/[5GPA
M\)?''X'>+;7QA\/O&%J\MC?1(]KJ&FZA:N8-4\/^(-+G"W>B^(=%NU>SU32[
MQ%EAE59H6N+*XM+NX_$K5/\ @LI^U/KFF:CHNM?\$.?V[-8T;6+&[TO5M)U3
MP#\1=0TS5-,U"WDM+_3M1L+OX!36M[8WMK-+;7=I<Q2V]S;RR0S1O&[*?*_^
M#=7P%^T3\)-;_;:\$?$O]G7XY_L\_!OQ+XV\&?$OX.^%OC)\/_'/@R/3+G5[
MOQSI&MZ1H^I>+O#?A^W\2ZC:^%M.\ :=KM[81K(JZ'ID\UM"E[$J[8'-*W]H
MX;"K&ULSH8J%93J5<NG@IX2M2I^UA)26'H4YT:R4X<LE*I":A^\E=IYXK!4_
MJE:O]6A@JM"5-PA#&0Q,:].<U"2<75J3C4IWC.Z:A*/,N5-*W]/%%%%?5GA!
M1110 4444 %%%% !1110 4444 %?7/C;_DTCX6_]CG-_Z.\?U\C5]<^-O^32
M/A;_ -CG-_Z.\?UX><_QLC_['5'_ -1,:>GEW\+,_P#L75/_ $_ASY&HHHKW
M#S HHHH **** "BBB@ HHHH *J7M_::="D][.EO%)=6=DCOG#7.H7<-C:1#
M)S+<W$48.-J[B[E45F%NOF?]HKQ)):6OA_P]:3O%<3W3:Y<M%(8Y8H[(M!IY
MRI# 27,ES*A!&V6R1AEE!7AS+&QR_!5\4TI.FDH1?VISDH0CIK:\DW;[*;Z'
M1A:#Q->G13MS/WG_ "Q2O)_<M/.Q],45S_A37(_$OAO1==C*?\3+3[>>98VW
MI%=[?+O;<, ,FVNTG@;@'=&00#D#H*ZZ<XU80J0?-"I",X26SC-*47\TTS"4
M7"4H25I1DXR79Q=FODT%%%%6(**** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KVK]G;_DL_@;_K\U/_TP
MZK7BM>U?L[?\EG\#?]?FI_\ IAU6O/S;_D59G_V+\;_ZC53KP'^_8+_L+PW_
M *>@8OQK_P"2L_$#_L9M1_\ 1M>7UZA\:_\ DK/Q _[&;4?_ $;7E]:9=_R+
M\#_V!X7_ -,0(Q?^]XK_ +"*W_IR04445V'.%%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 ?75O_P F@7W_ &.2?^GFSKY%KZZM_P#D
MT"^_[')/_3S9U\BUX>2;YS_V/,=_Z1AST\SVR_\ [%F%_.J%%%%>X>8%%%%
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MC?\ L(J?F%%%%>N>>%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0HT8U%@L&L-4JPE3E6G7GB*D(2TE&BW"G&FY+1RM*=G926Y_-G_P=(?\H_\
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M1?\ "[_^"I7_ $>'9?\ A-^&?_G<T?\ "[_^"I7_ $>'9?\ A-^&?_G<T?\
M$-^,?^A16_\  Z?_ ,GZ_P!/0^OY=_T'4/NJ^7_3OS_#UM_6[17\D7_"[_\
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M_P /6W];M%?R1?\ "[_^"I7_ $>'9?\ A-^&?_G<T?\ "[_^"I7_ $>'9?\
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M'9?^$WX9_P#G<T?\+O\ ^"I7_1X=E_X3?AG_ .=S1_Q#?C'_ *%%;_P.G_\
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M $>'9?\ A-^&?_G<T?\ "[_^"I7_ $>'9?\ A-^&?_G<T?\ $-^,?^A16_\
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M1?\ "[_^"I7_ $>'9?\ A-^&?_G<T?\ "[_^"I7_ $>'9?\ A-^&?_G<T?\
M$-^,?^A16_\  Z?_ ,GZ_P!/0^OY=_T'4/NJ^7_3OS_#UM_6[17\D7_"[_\
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M_P /6W];M%?R1?\ "[_^"I7_ $>'9?\ A-^&?_G<T?\ "[_^"I7_ $>'9?\
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M'9?^$WX9_P#G<T?\+O\ ^"I7_1X=E_X3?AG_ .=S1_Q#?C'_ *%%;_P.G_\
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M $>'9?\ A-^&?_G<T?\ "[_^"I7_ $>'9?\ A-^&?_G<T?\ $-^,?^A16_\
M Z?_ ,GZ_P!/0^OY=_T'4/NJ^7_3OS_#UM_6[17\D7_"[_\ @J5_T>'9?^$W
MX9_^=S1_PN__ (*E?]'AV7_A-^&?_G<T?\0WXQ_Z%%;_ ,#I_P#R?K_3T/K^
M7?\ 0=0^ZKY?]._/\/6W];M%?R1?\+O_ ."I7_1X=E_X3?AG_P"=S1_PN_\
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M'O\ V;SI/_HWXFUY1_PN_P#X*E?]'AV7_A-^&?\ YW->50^#?VCO''QW\/\
MQP^/OQ4T7XF:_H_AVZ\+-J(M5T_4QHPLM933;."WT[PYHVFO':W^L7,S-*D<
MQCGE)FD,<4)][A?@3BG+N(<GQN*RJM3P^'S'!5:U3FIM4Z=/$TISFTIWY8QC
M)NR;LM$]C'%8_ /"8N$,91G.IAJT(0C[2\I2A:*5X):MVU:_.WN/BKPMH/C3
M0=1\->)=/AU/1]4@,%U;2@@@_>BGMY5Q);W=O(%FMKF%DF@F1)(V5E!JQ^Q1
M^V3XQ_X)Y>/K'X(_&K4]4\4?LF^-=7E_X1'Q?)'->WGPJU6_G,LURL,*O(-&
M>60S^*?#]K&0<S>*_#5L;LZQI&H[-<UXO\(>'_'7A[4?#'B?3XM1TC4HC'-"
M_P LL,B\PW=I, 7MKVUDQ+;7,9#Q2*#RI96_;>,N#L%Q7@7%J%#,J$']4Q=K
M7LW+ZO7:3<J$I7<96<Z$VYP3C*K3J_-Y9F<\!-QDG4PM1KVM*^J>WM:5](U(
MKT4TN67V91_JUTG5M+U[2]-US1-1L=8T;6+"TU32=6TRZ@OM-U/3+^WCNK'4
M-/O;9Y;:\LKRUEBN+6ZMY)(9X)$EB=D96.A7\L/[#G[;7B[]@GQIIG[._P"T
M%JVH>(OV7/%.IRI\./B+<)-=7'PJOKZX,DL%RJ"60>%9;B8S>(=#B#-HUQ++
MXGT")[>XU:POOZD["_L-5L++5-+O;34M,U*TMK_3M1L+F&\L+^PO(4N+2]LK
MNW>2WNK2ZMY(Y[:Y@DDAGAD26)V1E8_R7FF5XW)\;7P./H3H8BA-PG":MJK-
M--7C*,HM2C.+E"<)1G"4H2C)_9QE"I"%6E-5*51<U.:VDNJ:WC*+=I1=G&5T
MT6Z***\X84444 %%%% !1110 4444 %%%% !1110 4444 %?77PY_P"36OB]
M_P!C O\ Z)\*5\BU]=?#G_DUKXO?]C O_HGPI7AY_P#[KA/^QME7_J;2/3RK
M^/B/^P#'?^H\SY%HHHKW#S HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ K>\*_\C/X<_[#VC_^G"WK!K>\*_\ (S^'/^P]H_\ Z<+>
MLZW\*K_U[G_Z2RZ?\2G_ (X_^E(]]_:T_P"2LM_V+6C?^AWU?,E?3?[6G_)6
M6_[%K1O_ $.^KYDKS,@_Y$N5_P#8%0_](1VYK_R,L;_V$5/S"BBBO7//"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ME4C32A:+3?---IN*M?6^C_=6BBBNLP"BBB@ HHHH **** "BBB@ KZY\;?\
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M675/ACK=_:HSWOAD)XBAV EOLUBKKJ8)4$[$TR6ZN&&-NZW1FQM!'QN*PO\
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M_P NZ$!@V=C53SIO,,RPE6E&-#+\/5Q#JQ;<YJE[)R7*WRW:J.VJNTEU=B6
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M5U'0O$>DWOAW5+S4;_P_K6@:A:3:C>6\MC<S?K!7@?PG/[+MEXR^)VD? T_
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MKA=7L+-;BY=%#3S+:6MK:K+*7D%O;6\ 810QJO(_\%3?V\/VM]._:_\ V?\
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M?4/^$3UR(%);^3PW+/<>3![A_P $+/V\_C3^VE\!OBIX;_:+O++7_C'^SO\
M$&R\#:WXRLM/L=,F\6>']8TVXFT.^URVTB"WT27Q)8ZEHGB33-0U#1[>SM=2
ML;72;R>S&H2WM_J'C4__  16_:/^(EA=W?[8/_!7K]K#X@>%Y+2\NO%'A3P/
MJFI_#;P=;6*/+>WI=O$'COQ?X4^R00O>O-?W7@2RBALS;VYMHK+38TD^9_\
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MQ7\'V'B:TTV\EAGOM"U!GFL/$'AG49[;_1IM2\+^(K+5?#VI36Q-O+?:9</
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M-;JVMFMS^RBBO%?V=/BC;_&;X(_#CXCQ2K+<^(?#EJ-8VD'R_$6E/)HWB.+
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M:[\0]!L/B-XHO?$OB:S\*W*WO]I3ZEIEUH4F@VRM;VS0&>__ .$5LGM3-<J
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M?N_HNNZ)XDTVWUCP[K&E:_I%V&:TU71=0M-4TVZ56*LUO?6,T]K,%8%6,<K
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M]G_:J_:N\,_%Z]\.Z1X)M;Z/P_X<:^NWU35(UM+O4]0OTMXB(;)9I3;V5I#
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M]G,^#?\ U5GQFK?#?[Q2_P :-*7\6'^)'Q51117]XGYF%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%3$U5"-2KR\RIJ2@N6$8*RE*<EI%-WD];[+0_G>^#'["W[5'A/\ X+Q?'?\
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M_!,WXF_MTZ?XM^*'[/I_9_\ &OCOP9K/@:QL_B=J*?$#X/:-;:WXYB\ Z/\
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M'B'0A\3;ZPL]=U?P9%XGLM,EB\,OJ.AEM;NIX$LDDB^T3V_U+I_PN^&^D_\
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MXOW^&/B-I%EI6L:SJM[?_#*;Q1X4\,:YI=KJMYHGAW6KNTDO[FZK_'+_ ()
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MHX[^SWCOJ5GRO'K+%Q-9K.%P.O\ B('Y??\ !/+_ ()H^&/V&O&GQX_:'_:
M_:0T+XZ_M<?$%M/LOCK\7/&&N:)X5L_AII/B_4-.UG3?"VHVFM:]<W_AI/&^
ML66CW%EJ_BF?1(/$5IHWA[3/#.@Z+I^D3V]SXC^VG_P25U;4?VFO$O[<?[#/
M[6?@S]B[]I_0C9Q?&^/Q)J^AK\.KS5/&$,,.EZK\2[2YN;^'P)?>/T6P>[TK
MQ=X3\0>%OB'J%O9^((=%B\1P:GJVI_M?I_PN^&^D_P#"._V9X%\)V'_"))J\
M?AC[+H.FP_V"FO\ F?VV-*V6X^Q?VMYLO]H&#8UUYTWG%_-DW&G_  N^&^D_
M\([_ &9X%\)V'_"))J\?AC[+H.FP_P!@IK_F?VV-*V6X^Q?VMYLO]H&#8UUY
MTWG%_-DW5+).(9X2G@[<-TJ5.K[>E*$,YG7P^(E)R>(AB5BZ->K6I2KR;J>T
MHRQ7]GVD\-'.&LCE9EX4TZ\L3?Q)Q-3D]G-2EPIA:6+I4E%>RE1=#&T\%3QJ
MP"2@HX]95_K+=?VL^!T_$'^<?XE_\$M_^"DO[9=];^$/^"G?_!1[X!Z;\!OA
M5K_AO5OB-\.?@/>Z+H%Q87VIA1X:?X@OKO@#X2Z-X,UWQ.EW)#X-UKQ]IGBN
MQMFF-WX;T"YEEO(A_1M\.? ?PV^"_@;1/@YX ;PEX3\*_!;0?!G@&+P;;^(=
M*6]\"6-Q96FE^ ]$\1V=S?MJFG:QXM06R>'?[<"ZMXTU*Y:2R?5-1N9F9VG_
M  N^&^D_\([_ &9X%\)V'_"))J\?AC[+H.FP_P!@IK_F?VV-*V6X^Q?VMYLO
M]H&#8UUYTWG%_-DW.TOX9?#O1'\-R:1X'\+:9)X.&JCPI)9:'IUL_AW^W"[:
MPVCM%;JU@^IM)*U\]N4>Y,LIE9C(^[?+\KXEP5=UG4R*I.O*FL37K/-\5BW1
M4DW2A7KXBTE1C6ER6ITH5Y9?&4H4/[7:R/GQ^,\*\1AITJ"\0?:4:5;ZG%T^
M%\)@YXF,&J=6MAL.JDZ$,94P,9581KXNIE\.)90A6S)\$J?B!W-%%%?9GY@%
M?7/C;_DTCX6_]CG-_P"CO']?(U?7/C;_ )-(^%O_ &.<W_H[Q_7AYS_&R/\
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M^!W[9WP9U_4=4>T\+^+]?3X7^,<S00VK:%\06CT&VN]2GN'5(=-T#Q+-X?\
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M@6MO!J]T]PV"ZP)(Z R*HKL_^"E?BPZ=^V[\=K(2[?(U/P<-N>F_X;^#I/\
MV?-?TZ7O['_[*NHZQ=^(;[]G3X,7.NWVI3ZS>:O+\.?"S:C<:M=73WUQJ4EW
M_9@F-[+>.]T]SO$IG8R[M_-7?&?[*/[-'Q%\3:IXS\=_ GX6>+O%FMO;2:OX
MBU_P9HFIZOJ3V=E;:=:O>WUS:23W#V]A9VMI$TCL5@MXHP=J"O.?">,_LZ>
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M587BT[QOX&GNKA=*O#)"[;].\3^'I+C2=8%C<O<:9>2ZKI@N8M2T^1HND_;
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M%\$]6^ 7[-W@'P)XFMX;?QE/%?\ B?QI%#*)EB\0^(KR2^>Q>156-YM'TO\
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M3=N:3DVYMMI)62U_C1_87\7&]_;+^ =GYN1/\2["/;D'/R7G&!]/PZU]B_\
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MB?\ \.C\0O\ YH*/^(V5O^A)1_\ "F?_ ,C_ %9^5S_5["_]!=?_ ,$P\O\
MIYZ_UO\ D)_PLCX=_P#0^^"__"IT/_Y.H_X61\._^A]\%_\ A4Z'_P#)U?KW
M_P .6/\ @GS_ -$K\3_^'1^(7_S04?\ #EC_ ()\_P#1*_$__AT?B%_\T%'_
M !&RM_T)*/\ X4S_ /D?ZL_*Y_J]A?\ H+K_ /@F'E_T\]?ZW_(3_A9'P[_Z
M'WP7_P"%3H?_ ,G4?\+(^'?_ $/O@O\ \*G0_P#Y.K]>_P#ARQ_P3Y_Z)7XG
M_P##H_$+_P":"C_ARQ_P3Y_Z)7XG_P##H_$+_P":"C_B-E;_ *$E'_PIG_\
M(_U9^5S_ %>PO_077_\ !,/+_IYZ_P!;_D)_PLCX=_\ 0^^"_P#PJ=#_ /DZ
MC_A9'P[_ .A]\%_^%3H?_P G5^O?_#EC_@GS_P!$K\3_ /AT?B%_\T%'_#EC
M_@GS_P!$K\3_ /AT?B%_\T%'_$;*W_0DH_\ A3/_ .1_JS\KG^KV%_Z"Z_\
MX)AY?]//7^M_R$_X61\._P#H??!?_A4Z'_\ )U'_  LCX=_]#[X+_P#"IT/_
M .3J_7O_ (<L?\$^?^B5^)__  Z/Q"_^:"C_ (<L?\$^?^B5^)__  Z/Q"_^
M:"C_ (C96_Z$E'_PIG_\C_5GY7/]7L+_ -!=?_P3#R_Z>>O];_D)_P +(^'?
M_0^^"_\ PJ=#_P#DZC_A9'P[_P"A]\%_^%3H?_R=7Z]_\.6/^"?/_1*_$_\
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MQ/\ ^'1^(7_S04?\.6/^"?/_ $2OQ/\ ^'1^(7_S04?\1LK?]"2C_P"%,_\
MY'^K/RN?ZO87_H+K_P#@F'E_T\]?ZW_(3_A9'P[_ .A]\%_^%3H?_P G4?\
M"R/AW_T/O@O_ ,*G0_\ Y.K]>_\ ARQ_P3Y_Z)7XG_\ #H_$+_YH*/\ ARQ_
MP3Y_Z)7XG_\ #H_$+_YH*/\ B-E;_H24?_"F?_R/]6?E<_U>PO\ T%U__!,/
M+_IYZ_UO^0G_  LCX=_]#[X+_P#"IT/_ .3J/^%D?#O_ *'WP7_X5.A__)U?
MT P_\$&/^":3_L[77Q";X/>+3XIB\2+IR7O_  M[XFB$6AU*VMBGV(>)?LI;
MR9'7>8B^3NSN -?//_#EC_@GS_T2OQ/_ .'1^(7_ ,T%<F%\=Y8OZS[+(XKZ
MKBJN$J<]>2O5HJ#FX<O->#4URM\K=G>*TOO6X7H4/8\^,JOV]"GB(<M*#M"H
MVHJ5YJTO=E=*Z6FKZ_D)_P +(^'?_0^^"_\ PJ=#_P#DZC_A9'P[_P"A]\%_
M^%3H?_R=7Z]_\.6/^"?/_1*_$_\ X='XA?\ S04?\.6/^"?/_1*_$_\ X='X
MA?\ S05U_P#$;*W_ $)*/_A3/_Y'^K/ROA_J]A?^@NO_ ."8>7_3SU_K?\A/
M^%D?#O\ Z'WP7_X5.A__ "=1_P +(^'?_0^^"_\ PJ=#_P#DZOU[_P"'+'_!
M/G_HE?B?_P .C\0O_F@H_P"'+'_!/G_HE?B?_P .C\0O_F@H_P"(V5O^A)1_
M\*9__(_U9^5S_5["_P#077_\$P\O^GGK_6_Y"?\ "R/AW_T/O@O_ ,*G0_\
MY.H_X61\._\ H??!?_A4Z'_\G5^O?_#EC_@GS_T2OQ/_ .'1^(7_ ,T%'_#E
MC_@GS_T2OQ/_ .'1^(7_ ,T%'_$;*W_0DH_^%,__ )'^K/RN?ZO87_H+K_\
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M$_\ X='XA?\ S04?\.6/^"?/_1*_$_\ X='XA?\ S04?\1LK?]"2C_X4S_\
MD?ZL_*Y_J]A?^@NO_P""8>7_ $\]?ZW_ "$_X61\._\ H??!?_A4Z'_\G4?\
M+(^'?_0^^"__  J=#_\ DZOU[_X<L?\ !/G_ *)7XG_\.C\0O_F@H_X<L?\
M!/G_ *)7XG_\.C\0O_F@H_XC96_Z$E'_ ,*9_P#R/]6?E<_U>PO_ $%U_P#P
M3#R_Z>>O];_D)_PLCX=_]#[X+_\ "IT/_P"3J/\ A9'P[_Z'WP7_ .%3H?\
M\G5^O?\ PY8_X)\_]$K\3_\ AT?B%_\ -!1_PY8_X)\_]$K\3_\ AT?B%_\
M-!1_Q&RM_P!"2C_X4S_^1_JS\KG^KV%_Z"Z__@F'E_T\]?ZW_(3_ (61\._^
MA]\%_P#A4Z'_ /)U'_"R/AW_ -#[X+_\*G0__DZOU[_X<L?\$^?^B5^)_P#P
MZ/Q"_P#F@H_X<L?\$^?^B5^)_P#PZ/Q"_P#F@H_XC96_Z$E'_P *9_\ R/\
M5GY7/]7L+_T%U_\ P3#R_P"GGK_6_P"0G_"R/AW_ -#[X+_\*G0__DZC_A9'
MP[_Z'WP7_P"%3H?_ ,G5^O?_  Y8_P""?/\ T2OQ/_X='XA?_-!1_P .6/\
M@GS_ -$K\3_^'1^(7_S04?\ $;*W_0DH_P#A3/\ ^1_JS\KG^KV%_P"@NO\
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M4?\ "R/AW_T/O@O_ ,*G0_\ Y.K]>_\ ARQ_P3Y_Z)7XG_\ #H_$+_YH*/\
MARQ_P3Y_Z)7XG_\ #H_$+_YH*/\ B-E;_H24?_"F?_R/]6?E<_U>PO\ T%U_
M_!,/+_IYZ_UO^0G_  LCX=_]#[X+_P#"IT/_ .3J/^%D?#O_ *'WP7_X5.A_
M_)U?KW_PY8_X)\_]$K\3_P#AT?B%_P#-!1_PY8_X)\_]$K\3_P#AT?B%_P#-
M!1_Q&RM_T)*/_A3/_P"1_JS\KG^KV%_Z"Z__ ()AY?\ 3SU_K?\ (3_A9'P[
M_P"A]\%_^%3H?_R=1_PLCX=_]#[X+_\ "IT/_P"3J_7O_ARQ_P $^?\ HE?B
M?_PZ/Q"_^:"C_ARQ_P $^?\ HE?B?_PZ/Q"_^:"C_B-E;_H24?\ PIG_ /(_
MU9^5S_5["_\ 077_ /!,/+_IYZ_UO^0G_"R/AW_T/O@O_P *G0__ ).H_P"%
MD?#O_H??!?\ X5.A_P#R=7Z]_P##EC_@GS_T2OQ/_P"'1^(7_P T%'_#EC_@
MGS_T2OQ/_P"'1^(7_P T%'_$;*W_ $)*/_A3/_Y'^K/RN?ZO87_H+K_^"8>7
M_3SU_K?\A/\ A9'P[_Z'WP7_ .%3H?\ \G4?\+(^'?\ T/O@O_PJ=#_^3J_7
MO_ARQ_P3Y_Z)7XG_ /#H_$+_ .:"C_ARQ_P3Y_Z)7XG_ /#H_$+_ .:"C_B-
ME;_H24?_  IG_P#(_P!6?E<_U>PO_077_P#!,/+_ *>>O];_ )"?\+(^'?\
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M1_\ "F?_ ,C_ %9^5\?]7L+_ -!=?_P3#R_Z>>O];_D)_P +(^'?_0^^"_\
MPJ=#_P#DZC_A9'P[_P"A]\%_^%3H?_R=7Z]_\.6/^"?/_1*_$_\ X='XA?\
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M'_!/G_HE?B?_ ,.C\0O_ )H*/^'+'_!/G_HE?B?_ ,.C\0O_ )H*/^(V5O\
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M_ARQ_P $^?\ HE?B?_PZ/Q"_^:"C_B-E;_H24?\ PIG_ /(_U9^5S_5["_\
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M ",_AS_L/:/_ .G"WK!K>\*_\C/X<_[#VC_^G"WK.M_"J_\ 7N?_ *2RZ?\
M$I_XX_\ I2/??VM/^2LM_P!BUHW_ *'?5\R5]-_M:?\ )66_[%K1O_0[ZOF2
MO,R#_D2Y7_V!4/\ TA';FO\ R,L;_P!A%3\PHHHKUSSPHHHH **** "BBB@
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M#_V!X7_TQ C%_P"]XK_L(K?^G)!11178<X4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110!]=6_\ R:!??]CDG_IYLZ^1:^NK?_DT"^_[
M')/_ $\V=?(M>'DF^<_]CS'?^D8<]/,]LO\ ^Q9A?SJA1117N'F!1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'HGPB_P"2I?#S_L<O
M#O\ Z=+:NR_:7_Y+;XU_[EO_ -1+0:XWX1?\E2^'G_8Y>'?_ $Z6U=E^TO\
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M HHHH *WO"O_ ",_AS_L/:/_ .G"WK!K>\*_\C/X<_[#VC_^G"WK.M_"J_\
M7N?_ *2RZ?\ $I_XX_\ I2/??VM/^2LM_P!BUHW_ *'?5\R5]-_M:?\ )66_
M[%K1O_0[ZOF2O,R#_D2Y7_V!4/\ TA';FO\ R,L;_P!A%3\PHHHKUSSPHHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*JK1JU;2I0FXQG5A3=2<(MKWHKJK/[R^+/\ P2S_ ."$_C3X0:CX!^'/Q3^
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "M[PK_ ,C/X<_[#VC_ /IPMZP:WO"O_(S^
M'/\ L/:/_P"G"WK.M_"J_P#7N?\ Z2RZ?\2G_CC_ .E(]]_:T_Y*RW_8M:-_
MZ'?5\R5]-_M:?\E9;_L6M&_]#OJ^9*\S(/\ D2Y7_P!@5#_TA';FO_(RQO\
MV$5/S"BBBO7//"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ML31HUIXVO5K3Q--RG1@H\RK591DE*K6<[QC&33FN63G%M)[I_H_\"_A#X8^
M'P8^%GP1\%Q[/"WPH\ ^%? .BN8A#-=V?AC1K32AJ5VOF3%M0U62VDU+49I)
MIY9[^[N)YIYI9'E?U6BBO9A"-.$*<(J,(1C"$5M&,4HQBO)))+R/.E)RE*4F
MW*3<I-[MMW;?FV[A1115""BBB@ HHHH **** "BBB@ KZY\;?\FD?"W_ +'.
M;_T=X_KY&KZY\;?\FD?"W_L<YO\ T=X_KP\Y_C9'_P!CJC_ZB8T]/+OX69_]
MBZI_Z?PY\C4445[AY@4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 5[5^SM_P EG\#?]?FI_P#IAU6O%:]J_9V_Y+/X&_Z_-3_],.JU
MY^;?\BK,_P#L7XW_ -1JIUX#_?L%_P!A>&_]/0,7XU_\E9^('_8S:C_Z-KR^
MO4/C7_R5GX@?]C-J/_HVO+ZTR[_D7X'_ + \+_Z8@1B_][Q7_816_P#3D@HH
MHKL.<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^NK
M?_DT"^_[')/_ $\V=?(M?75O_P F@7W_ &.2?^GFSKY%KP\DWSG_ +'F._\
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M"[C_ ..5W?Z\9U_+@O\ P1/_ .7'-_JSEW\V)_\ !L/_ )4?,_\ PR?\7/\
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M[C_XY1_:>I?]!&^_\"[C_P".4?Z\9U_+@O\ P1/_ .7!_JSEW\V)_P#!L/\
MY4?,_P#PR?\ %S_GV\/_ /@[3_Y'H_X9/^+G_/MX?_\ !VG_ ,CU],?VGJ7_
M $$;[_P+N/\ XY1_:>I?]!&^_P# NX_^.4?Z\9U_+@O_  1/_P"7!_JSEW\V
M)_\ !L/_ )4?,_\ PR?\7/\ GV\/_P#@[3_Y'H_X9/\ BY_S[>'_ /P=I_\
M(]?3']IZE_T$;[_P+N/_ (Y1_:>I?]!&^_\  NX_^.4?Z\9U_+@O_!$__EP?
MZLY=_-B?_!L/_E1\S_\ #)_Q<_Y]O#__ (.T_P#D>C_AD_XN?\^WA_\ \':?
M_(]?3']IZE_T$;[_ ,"[C_XY1_:>I?\ 01OO_ NX_P#CE'^O&=?RX+_P1/\
M^7!_JSEW\V)_\&P_^5'S/_PR?\7/^?;P_P#^#M/_ )'H_P"&3_BY_P ^WA__
M ,':?_(]?3']IZE_T$;[_P "[C_XY1_:>I?]!&^_\"[C_P".4?Z\9U_+@O\
MP1/_ .7!_JSEW\V)_P#!L/\ Y4?,_P#PR?\ %S_GV\/_ /@[3_Y'H_X9/^+G
M_/MX?_\ !VG_ ,CU],?VGJ7_ $$;[_P+N/\ XY1_:>I?]!&^_P# NX_^.4?Z
M\9U_+@O_  1/_P"7!_JSEW\V)_\ !L/_ )4?,_\ PR?\7/\ GV\/_P#@[3_Y
M'H_X9/\ BY_S[>'_ /P=I_\ (]?3']IZE_T$;[_P+N/_ (Y1_:>I?]!&^_\
M NX_^.4?Z\9U_+@O_!$__EP?ZLY=_-B?_!L/_E1\S_\ #)_Q<_Y]O#__ (.T
M_P#D>C_AD_XN?\^WA_\ \':?_(]?3']IZE_T$;[_ ,"[C_XY1_:>I?\ 01OO
M_ NX_P#CE'^O&=?RX+_P1/\ ^7!_JSEW\V)_\&P_^5'S/_PR?\7/^?;P_P#^
M#M/_ )'H_P"&3_BY_P ^WA__ ,':?_(]?3']IZE_T$;[_P "[C_XY1_:>I?]
M!&^_\"[C_P".4?Z\9U_+@O\ P1/_ .7!_JSEW\V)_P#!L/\ Y4?,_P#PR?\
M%S_GV\/_ /@[3_Y'H_X9/^+G_/MX?_\ !VG_ ,CU],?VGJ7_ $$;[_P+N/\
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M_P# NX_^.4?Z\9U_+@O_  1/_P"7!_JSEW\V)_\ !L/_ )4?,_\ PR?\7/\
MGV\/_P#@[3_Y'H_X9/\ BY_S[>'_ /P=I_\ (]?3']IZE_T$;[_P+N/_ (Y1
M_:>I?]!&^_\  NX_^.4?Z\9U_+@O_!$__EP?ZLY=_-B?_!L/_E1Q7P)^ OQ
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M]?3']IZE_P!!&^_\"[C_ ..4?VGJ7_01OO\ P+N/_CE'^O&=?RX+_P $3_\
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M1Z/^&3_BY_S[>'__  =I_P#(]?3']IZE_P!!&^_\"[C_ ..4?VGJ7_01OO\
MP+N/_CE'^O&=?RX+_P $3_\ EP?ZLY=_-B?_  ;#_P"5'S/_ ,,G_%S_ )]O
M#_\ X.T_^1Z/^&3_ (N?\^WA_P#\':?_ "/7TQ_:>I?]!&^_\"[C_P".4?VG
MJ7_01OO_  +N/_CE'^O&=?RX+_P1/_Y<'^K.7?S8G_P;#_Y4?,__  R?\7/^
M?;P__P"#M/\ Y'H_X9/^+G_/MX?_ /!VG_R/7TQ_:>I?]!&^_P# NX_^.4?V
MGJ7_ $$;[_P+N/\ XY1_KQG7\N"_\$3_ /EP?ZLY=_-B?_!L/_E1\S_\,G_%
MS_GV\/\ _@[3_P"1Z/\ AD_XN?\ /MX?_P#!VG_R/7TQ_:>I?]!&^_\  NX_
M^.4?VGJ7_01OO_ NX_\ CE'^O&=?RX+_ ,$3_P#EP?ZLY=_-B?\ P;#_ .5'
MS/\ \,G_ !<_Y]O#_P#X.T_^1Z/^&3_BY_S[>'__  =I_P#(]?3']IZE_P!!
M&^_\"[C_ ..4?VGJ7_01OO\ P+N/_CE'^O&=?RX+_P $3_\ EP?ZLY=_-B?_
M  ;#_P"5'S/_ ,,G_%S_ )]O#_\ X.T_^1Z/^&3_ (N?\^WA_P#\':?_ "/7
MTQ_:>I?]!&^_\"[C_P".4?VGJ7_01OO_  +N/_CE'^O&=?RX+_P1/_Y<'^K.
M7?S8G_P;#_Y4?,__  R?\7/^?;P__P"#M/\ Y'H_X9/^+G_/MX?_ /!VG_R/
M7TQ_:>I?]!&^_P# NX_^.4?VGJ7_ $$;[_P+N/\ XY1_KQG7\N"_\$3_ /EP
M?ZLY=_-B?_!L/_E1\S_\,G_%S_GV\/\ _@[3_P"1Z/\ AD_XN?\ /MX?_P#!
MVG_R/7TQ_:>I?]!&^_\  NX_^.4?VGJ7_01OO_ NX_\ CE'^O&=?RX+_ ,$3
M_P#EP?ZLY=_-B?\ P;#_ .5'S/\ \,G_ !<_Y]O#_P#X.T_^1Z/^&3_BY_S[
M>'__  =I_P#(]?3']IZE_P!!&^_\"[C_ ..4?VGJ7_01OO\ P+N/_CE'^O&=
M?RX+_P $3_\ EP?ZLY=_-B?_  ;#_P"5'S/_ ,,G_%S_ )]O#_\ X.T_^1Z/
M^&3_ (N?\^WA_P#\':?_ "/7TQ_:>I?]!&^_\"[C_P".4?VGJ7_01OO_  +N
M/_CE'^O&=?RX+_P1/_Y<'^K.7?S8G_P;#_Y4?,__  R?\7/^?;P__P"#M/\
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M\CU],?VGJ7_01OO_  +N/_CE']IZE_T$;[_P+N/_ (Y1_KQG7\N"_P#!$_\
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M'H_X9/\ BY_S[>'_ /P=I_\ (]?3']IZE_T$;[_P+N/_ (Y1_:>I?]!&^_\
M NX_^.5]1_KQG7\N"_\ !$__ )<>=_JSEW\V)_\ !L/_ )4?,_\ PR?\7/\
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M[C_XY1_:>I?]!&^_\"[C_P".4?Z\9U_+@O\ P1/_ .7!_JSEW\V)_P#!L/\
MY4?,_P#PR?\ %S_GV\/_ /@[3_Y'H_X9/^+G_/MX?_\ !VG_ ,CU],?VGJ7_
M $$;[_P+N/\ XY1_:>I?]!&^_P# NX_^.4?Z\9U_+@O_  1/_P"7!_JSEW\V
M)_\ !L/_ )4?,_\ PR?\7/\ GV\/_P#@[3_Y'H_X9/\ BY_S[>'_ /P=I_\
M(]?3']IZE_T$;[_P+N/_ (Y1_:>I?]!&^_\  NX_^.4?Z\9U_+@O_!$__EP?
MZLY=_-B?_!L/_E1\S_\ #)_Q<_Y]O#__ (.T_P#D>C_AD_XN?\^WA_\ \':?
M_(]?3']IZE_T$;[_ ,"[C_XY1_:>I?\ 01OO_ NX_P#CE'^O&=?RX+_P1/\
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M/_CE'^O&=?RX+_P1/_Y<'^K.7?S8G_P;#_Y4?,__  R?\7/^?;P__P"#M/\
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M]?3']IZE_P!!&^_\"[C_ ..4?VGJ7_01OO\ P+N/_CE'^O&=?RX+_P $3_\
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M1Z/^&3_BY_S[>'__  =I_P#(]?3']IZE_P!!&^_\"[C_ ..4?VGJ7_01OO\
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M1\S_ /#)_P 7/^?;P_\ ^#M/_D>C_AD_XN?\^WA__P ':?\ R/7TQ_:>I?\
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M<'^K.7?S8G_P;#_Y4?,__#)_Q<_Y]O#_ /X.T_\ D>C_ (9/^+G_ #[>'_\
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MS8G_ ,&P_P#E1\S_ /#)_P 7/^?;P_\ ^#M/_D>C_AD_XN?\^WA__P ':?\
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M_P# NX_^.4?Z\9U_+@O_  1/_P"7!_JSEW\V)_\ !L/_ )4?,_\ PR?\7/\
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M[C_XY1_:>I?]!&^_\"[C_P".4?Z\9U_+@O\ P1/_ .7!_JSEW\V)_P#!L/\
MY4?,_P#PR?\ %S_GV\/_ /@[3_Y'H_X9/^+G_/MX?_\ !VG_ ,CU],?VGJ7_
M $$;[_P+N/\ XY1_:>I?]!&^_P# NX_^.4?Z\9U_+@O_  1/_P"7!_JSEW\V
M)_\ !L/_ )4?,_\ PR?\7/\ GV\/_P#@[3_Y'H_X9/\ BY_S[>'_ /P=I_\
M(]?3']IZE_T$;[_P+N/_ (Y65:>,(;_5-7T2S\1//K&@?8#K.F)J$WV[3H]5
MMVNM,N+BV:02K::A#'<?8KP*UK<S6=_;0S/<V%[% UQQG;NU#!M)7=L/4T5T
MKO\ ?:*[2N^K2W8?ZLY;_-B==OWL/_E9\^?\,G_%S_GV\/\ _@[3_P"1Z/\
MAD_XN?\ /MX?_P#!VG_R/7TQ_:>I?]!&^_\  NX_^.4?VGJ7_01OO_ NX_\
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MEP7_ ((G_P#+@_U9R[^;$_\ @V'_ ,J/F?\ X9/^+G_/MX?_ /!VG_R/7O\
MX/\ @IXXT7X'_$#P#?1:8/$'B/5A>::D6H+):-"(]"7,UR(@(FSI]Q\I1NB<
M_-QL_P!IZE_T$;[_ ,"[C_XY7H>BWEV_@3Q%.]U<M-'=@1S-/*TJ#;8<)(6+
MJ/F;A2!\Q]37-B^+<UQD*=.M'"<M/$4,3'DHSB_:8>I&K3NW5=X\T5S+1M72
M:W-Z&0X'#RG.FZ[<Z56C+FJ1:Y*L'"=K4UKRMV?1]&?$G_#)_P 7/^?;P_\
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MS8G_ ,&P_P#E1\S_ /#)_P 7/^?;P_\ ^#M/_D>C_AD_XN?\^WA__P ':?\
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M1\S_ /#)_P 7/^?;P_\ ^#M/_D>C_AD_XN?\^WA__P ':?\ R/7TQ_:>I?\
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M<'^K.7?S8G_P;#_Y4?,__#)_Q<_Y]O#_ /X.T_\ D>C_ (9/^+G_ #[>'_\
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M_JSEW\V)_P#!L/\ Y4?,_P#PR?\ %S_GV\/_ /@[3_Y'H_X9/^+G_/MX?_\
M!VG_ ,CU],?VGJ7_ $$;[_P+N/\ XY1_:>I?]!&^_P# NX_^.4?Z\9U_+@O_
M  1/_P"7!_JSEW\V)_\ !L/_ )4?,_\ PR?\7/\ GV\/_P#@[3_Y'H_X9/\
MBY_S[>'_ /P=I_\ (]?3']IZE_T$;[_P+N/_ (Y1_:>I?]!&^_\  NX_^.4?
MZ\9U_+@O_!$__EP?ZLY=_-B?_!L/_E1\S_\ #)_Q<_Y]O#__ (.T_P#D>C_A
MD_XN?\^WA_\ \':?_(]?3']IZE_T$;[_ ,"[C_XY1_:>I?\ 01OO_ NX_P#C
ME'^O&=?RX+_P1/\ ^7!_JSEW\V)_\&P_^5'S/_PR?\7/^?;P_P#^#M/_ )'H
M_P"&3_BY_P ^WA__ ,':?_(]?3']IZE_T$;[_P "[C_XY1_:>I?]!&^_\"[C
M_P".4?Z\9U_+@O\ P1/_ .7!_JSEW\V)_P#!L/\ Y4?,_P#PR?\ %S_GV\/_
M /@[3_Y'H_X9/^+G_/MX?_\ !VG_ ,CU],?VGJ7_ $$;[_P+N/\ XY1_:>I?
M]!&^_P# NX_^.4?Z\9U_+@O_  1/_P"7!_JSEW\V)_\ !L/_ )4?,_\ PR?\
M7/\ GV\/_P#@[3_Y'H_X9/\ BY_S[>'_ /P=I_\ (]?3']IZE_T$;[_P+N/_
M (Y1_:>I?]!&^_\  NX_^.4?Z\9U_+@O_!$__EP?ZLY=_-B?_!L/_E1\S_\
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M_EP?ZLY=_-B?_!L/_E1\S_\ #)_Q<_Y]O#__ (.T_P#D>C_AD_XN?\^WA_\
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M (.T_P#D>C_AD_XN?\^WA_\ \':?_(]?3']IZE_T$;[_ ,"[C_XY1_:>I?\
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M\V)_\&P_^5'<_L_> ?$'PX\#7.@>)4M(]0E\0W^I(ME<B[A^S7%GIL$9,H1
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M3_UUG_\ 22XKEJZGP5_R-&D_]=9__22XH J^*?\ D8]9_P"O^?\ ]"K K?\
M%/\ R,>L_P#7_/\ ^A5@4 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% 'I"?\DUF_["@_]*8J\WKTA/\ DFLW_84'_I3%7F]
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M^)?^OP?^@Z?7F]>D:'_R3_Q+_P!?@_\ 0=/H \WHHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *N:=_P A"Q_Z_+7_ -'I5.KF
MG?\ (0L?^ORU_P#1Z4 =C\1_^1C_ .W"U_\ 0IJX*N]^(_\ R,?_ &X6O_H4
MU<%0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 >\?#;_ )%Z3_L)7/\ Z)M:*/AM_P B])_V$KG_ -$VM% &9\4?^//2?^OF
MY_\ 14=>-5[+\4?^//2?^OFY_P#14=>-4 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% '<?#S_D98/^O6[_\ 15<OJW_(5U/_
M +"%[_Z4RUU'P\_Y&6#_ *];O_T57+ZM_P A74_^PA>_^E,M &?1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZAL0$L45GLI&P.HBBO7F?KB.-SVR/\.OI1<.<0<.^%OC9PS4HSIYYE/"'%N
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MO81RS'NO?1>Q6%JNI>^EN3FO?H?I;1117_2H?P$%%%% !1110 4444 %%%%
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MS^"7_/CXC_\ "@G_ /C-'_#&?P2_Y\?$?_A03_\ QFC_ (E<S_\ Z'F!_P#
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M^BX?"#_PY?@S_P"75?Y^/_#&?P2_Y\?$?_A03_\ QFC_ (8S^"7_ #X^(_\
MPH)__C-'_$KF?_\ 0\P/_@$OZ[_TM3_B(V!_Z!*_X?\ R7K_ $M?] [_ (:$
M^ ?_ $7#X0?^'+\&?_+JC_AH3X!_]%P^$'_AR_!G_P NJ_S\?^&,_@E_SX^(
M_P#PH)__ (S1_P ,9_!+_GQ\1_\ A03_ /QFC_B5S/\ _H>8'_P"7]=_Z6I_
MQ$; _P#0)7_#_P"2]?Z6O^@=_P -"? /_HN'P@_\.7X,_P#EU1_PT)\ _P#H
MN'P@_P##E^#/_EU7^?C_ ,,9_!+_ )\?$?\ X4$__P 9H_X8S^"7_/CXC_\
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MXC_\*"?_ .,T?\2N9_\ ]#S _P#@$OZ[_P!+4_XB-@?^@2O^'_R7K_2U_P!
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M_P!%P^$'_AR_!G_RZH_X:$^ ?_1</A!_X<OP9_\ +JO\_'_AC/X)?\^/B/\
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M!_X<OP9_\NJ/^&A/@'_T7#X0?^'+\&?_ "ZK_/Q_X8S^"7_/CXC_ /"@G_\
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M@_\ #E^#/_EU7^?C_P ,9_!+_GQ\1_\ A03_ /QFC_AC/X)?\^/B/_PH)_\
MXS1_Q*YG_P#T/,#_ . 2_KO_ $M3_B(V!_Z!*_X?_)>O]+7_ $#O^&A/@'_T
M7#X0?^'+\&?_ "ZH_P"&A/@'_P!%P^$'_AR_!G_RZK_/Q_X8S^"7_/CXC_\
M"@G_ /C-'_#&?P2_Y\?$?_A03_\ QFC_ (E<S_\ Z'F!_P# )?UW_I:G_$1L
M#_T"5_P_^2]?Z6O^@=_PT)\ _P#HN'P@_P##E^#/_EU1_P -"? /_HN'P@_\
M.7X,_P#EU7^?C_PQG\$O^?'Q'_X4$_\ \9H_X8S^"7_/CXC_ /"@G_\ C-'_
M !*YG_\ T/,#_P" 2_KO_2U/^(C8'_H$K_A_\EZ_TM?] [_AH3X!_P#1</A!
M_P"'+\&?_+JC_AH3X!_]%P^$'_AR_!G_ ,NJ_P _'_AC/X)?\^/B/_PH)_\
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MN9__ -#S _\ @$OZ[_TM3_B(V!_Z!*_X?_)>O]+7_0._X:$^ ?\ T7#X0?\
MAR_!G_RZH_X:$^ ?_1</A!_X<OP9_P#+JO\ /Q_X8S^"7_/CXC_\*"?_ .,T
M?\,9_!+_ )\?$?\ X4$__P 9H_XE<S__ *'F!_\  )?UW_I:G_$1L#_T"5_P
M_P#DO7^EK_H'?\-"? /_ *+A\(/_  Y?@S_Y=4?\-"? /_HN'P@_\.7X,_\
MEU7^?C_PQG\$O^?'Q'_X4$__ ,9H_P"&,_@E_P ^/B/_ ,*"?_XS1_Q*YG__
M $/,#_X!+^N_]+4_XB-@?^@2O^'_ ,EZ_P!+7_0._P"&A/@'_P!%P^$'_AR_
M!G_RZH_X:$^ ?_1</A!_X<OP9_\ +JO\_'_AC/X)?\^/B/\ \*"?_P",T?\
M#&?P2_Y\?$?_ (4$_P#\9H_XE<S_ /Z'F!_\ E_7?^EJ?\1&P/\ T"5_P_\
MDO7^EK_H'?\ #0GP#_Z+A\(/_#E^#/\ Y=4?\-"? /\ Z+A\(/\ PY?@S_Y=
M5_GX_P##&?P2_P"?'Q'_ .%!/_\ &:/^&,_@E_SX^(__  H)_P#XS1_Q*YG_
M /T/,#_X!+^N_P#2U/\ B(V!_P"@2O\ A_\ )>O]+7_0._X:$^ ?_1</A!_X
M<OP9_P#+JC_AH3X!_P#1</A!_P"'+\&?_+JO\_'_ (8S^"7_ #X^(_\ PH)_
M_C-'_#&?P2_Y\?$?_A03_P#QFC_B5S/_ /H>8'_P"7]=_P"EJ?\ $1L#_P!
ME?\ #_Y+U_I:_P"A/X=_:&^ *:]H[O\ '+X/(BZE9LSM\3/!:JJB="69CK8
M '))( '6M+QO^T1^S_+XHU.2+XY_!V6-OL6UX_B;X*=&QI]HIPRZV5.&!!P>
M""#R*_SQO^&,_@E_SX^(_P#PH)__ (S1_P ,9_!+_GQ\1_\ A03_ /QFC_B5
MS/\ _H>8'_P"7]=_Z6I_Q$; _P#0)7_#_P"2]?Z6O^@=_P -"? /_HN'P@_\
M.7X,_P#EU1_PT)\ _P#HN'P@_P##E^#/_EU7^?C_ ,,9_!+_ )\?$?\ X4$_
M_P 9H_X8S^"7_/CXC_\ "@G_ /C-'_$KF?\ _0\P/_@$OZ[_ -+4_P"(C8'_
M *!*_P"'_P EZ_TM?] [_AH3X!_]%P^$'_AR_!G_ ,NJ/^&A/@'_ -%P^$'_
M (<OP9_\NJ_S\?\ AC/X)?\ /CXC_P#"@G_^,T?\,9_!+_GQ\1_^%!/_ /&:
M/^)7,_\ ^AY@?_ )?UW_ *6I_P 1&P/_ $"5_P /_DO7^EK_ *!W_#0GP#_Z
M+A\(/_#E^#/_ )=4?\-"? /_ *+A\(/_  Y?@S_Y=5_GX_\ #&?P2_Y\?$?_
M (4$_P#\9H_X8S^"7_/CXC_\*"?_ .,T?\2N9_\ ]#S _P#@$OZ[_P!+4_XB
M-@?^@2O^'_R7K_2U_P! [_AH3X!_]%P^$'_AR_!G_P NJ/\ AH3X!_\ 1</A
M!_X<OP9_\NJ_S\?^&,_@E_SX^(__  H)_P#XS1_PQG\$O^?'Q'_X4$__ ,9H
M_P")7,__ .AY@?\ P"7]=_Z6I_Q$; _] E?\/_DO7^EK_H'?\-"? /\ Z+A\
M(/\ PY?@S_Y=4?\ #0GP#_Z+A\(/_#E^#/\ Y=5_GX_\,9_!+_GQ\1_^%!/_
M /&:/^&,_@E_SX^(_P#PH)__ (S1_P 2N9__ -#S _\ @$OZ[_TM3_B(V!_Z
M!*_X?_)>O]+7_0._X:$^ ?\ T7#X0?\ AR_!G_RZH_X:$^ ?_1</A!_X<OP9
M_P#+JO\ /Q_X8S^"7_/CXC_\*"?_ .,T?\,9_!+_ )\?$?\ X4$__P 9H_XE
M<S__ *'F!_\  )?UW_I:G_$1L#_T"5_P_P#DO7^EK_H'?\-"? /_ *+A\(/_
M  Y?@S_Y=4?\-"? /_HN'P@_\.7X,_\ EU7^?C_PQG\$O^?'Q'_X4$__ ,9H
M_P"&,_@E_P ^/B/_ ,*"?_XS1_Q*YG__ $/,#_X!+^N_]+4_XB-@?^@2O^'_
M ,EZ_P!+7_0._P"&A/@'_P!%P^$'_AR_!G_RZH_X:$^ ?_1</A!_X<OP9_\
M+JO\_'_AC/X)?\^/B/\ \*"?_P",T?\ #&?P2_Y\?$?_ (4$_P#\9H_XE<S_
M /Z'F!_\ E_7?^EJ?\1&P/\ T"5_P_\ DO7^EK_H'?\ #0GP#_Z+A\(/_#E^
M#/\ Y=4?\-"? /\ Z+A\(/\ PY?@S_Y=5_GX_P##&?P2_P"?'Q'_ .%!/_\
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M_H$K_A_\EZ_TM?\ 0._X:$^ ?_1</A!_X<OP9_\ +JOX^_\ @KIXN\*>-/\
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MSL]P**** "BBB@ HHHH **** "BBB@ HHHH **** "O2-#_Y)_XE_P"OP?\
MH.GUYO7I&A_\D_\ $O\ U^#_ -!T^@#S>BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ JYIW_(0L?^ORU_]'I5.KFG?\A"Q_Z_
M+7_T>E '8_$?_D8_^W"U_P#0IJX*N]^(_P#R,?\ VX6O_H4U<%0 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >\?#;_D7I/^
MPE<_^B;6BCX;?\B])_V$KG_T3:T4 9GQ1_X\])_Z^;G_ -%1UXU7LOQ1_P"/
M/2?^OFY_]%1UXU0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 =Q\//\ D98/^O6[_P#15<OJW_(5U/\ ["%[_P"E,M=1\//^
M1E@_Z];O_P!%5R^K?\A74_\ L(7O_I3+0!GT444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M*_##_@CSX1NV\2_&7QQ+#)':V6@>'?"MO*Z,$GFUC4KC5[J-&. 7MDT"T:0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P!?@_\ 0=/KS>O2-#_Y)_XE_P"OP?\ H.GT >;T444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %7-._P"0A8_]?EK_ .CTJG5S
M3O\ D(6/_7Y:_P#H]* .Q^(__(Q_]N%K_P"A35P5=[\1_P#D8_\ MPM?_0IJ
MX*@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M ]X^&W_(O2?]A*Y_]$VM%'PV_P"1>D_["5S_ .B;6B@#,^*/_'GI/_7S<_\
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M^+?C.Q+"]\(_#+XY_##Q[XGLRDDD+BZT#PKXIU75;<I-#-$PEM$VR12(<,C
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M:2Y97M[03"[U"RUG3(+[0=5_57_@H)_P;9_L'0_LD^//%G[&'PTUWX ?M+?
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MQXDU%3C4_$AU?42D+W30197_  1I_P"59;X@?]D/_P""@'_I?\9* /Z#;_\
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M+2/^$<&G1VFCI\__ /!K%XJL?CY\!_\ @II^PSXX\1ZI\:OV3_ OB3PUX7\
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M4L)GT"+0O!EQXB\;>%(R]U/#-K.@:WIFL^%4M4O+@W&L6(M(9KB21&?\-_\
M@V#^$?B_XB> _P!K_P#X*A_&2T\[XK_MW_'WQA<Z)J,LAN8H/ 'A+Q/K5_X@
M?09)&::RT?4OBCKGB;PP=,<B.WL?ACX>BMHH+6"%" ?U3T444 %%%% !1110
M 4444 %%%% '<?#S_D98/^O6[_\ 15<OJW_(5U/_ +"%[_Z4RUU'P\_Y&6#_
M *];O_T57+ZM_P A74_^PA>_^E,M &?1110 4444 %%%% !7\GW_  4W_P""
MC7[9?[57[=UE_P $</\ @E5XG@^'7Q'L+:2Y_::_:;M[V:TN/AUI\&E6FK^)
M-&T/Q)::??77@K3/!&EZII<?BOQ=X<6?QKJ'CO5M*^'?A.?0]=L[Z/7/ZP:_
MBH_X-F[&S\<?\%)O^"S/QC\57::G\2U^(TVF1ZG=13OJ-WIWQ)^._P 9?$OC
M:=+E8C:PP7.M^!?"4MW;R312S2+9-:PR0VMPT !]&V7_  :7_LY>-;&W\5_M
M'_MQ?MK?&#X\2P6]WJOQ0LO%?@72;&?Q"&-U<:E;Z9X[\%_%/QEY U%C=6Z7
M/Q&EO@P,KWQG<R)\X_#_ ,4_\%(?^""O[>_P(_9I^(GQ0^+?[>?_  3Z_:@U
M9=(\(:CJ>C>*O&WCKX<6MMJVB:/XFU;1-/BD\8>)/"7B#X5+KVD:[K_A/1M2
MN_ 'C_P=JDNH:9INE>+&D;PE_:Q10!XQJ7[1W[/.C?&#1OV>M8^//P8TKX^^
M([(:GX>^!VI?%'P/8_&#7=-.G:CJXU#1OAI=:Y%XTU2R.DZ/J^J"[L=%G@.G
M:7J-[YGV:QN98O9Z_D-_X.:OACXH_9T^*7[ G_!7?X1Z5,_C/]F+XR>%O 'Q
M/DT^-HIM9\))K\GC_P"'=OK5W;0J\'AN74;+XB^ M<EOYI;:]'Q,TC2%2(7#
M1W7] 7[5W[<?P]^ W_!/+XF_MY:!J=IJO@VP_9]MOB[\++FY>V6U\5ZI\0/#
MNG3_  ;TX[K@P-'XM\2^)O">G$133XBU)GA%R55) #Z.^'?[1'[/_P 7_%7C
MWP+\)OCG\'?BAXW^%6I/HWQ0\'?#OXF^"O&WBKX;ZQ'J.I:/)I/CWP]X:UO4
M]7\'ZE'J^C:QI;V/B&STZZ34=)U*Q:(7-C=11<5\4_VT?V.O@9XBB\(?&S]K
M']FCX.^+)T,L'A?XI_';X6_#[Q%-&&1#)%HGBWQ5I&I2('EC4NELRAI$7.74
M'^8'_@E=\#OV@?V6/^#?_P#;)_;&^':>(KC]LW]K?P%\:/VD],\3P6L6J>/D
MT?2=)UW2OA[K6G+ EU+J^N1Z4OC/XQ^%D>.]NYM6\=Q1FPEN7.GM\)?\$9/A
M'_P;P_M!?LU>'8/VV/%G@3Q#^W)XWUWQA)\:)_VG_C3\1_A9?:EK^M^+M=?0
M!\/]?D\=>#O ^KKK.A7.E72:MI>N:C\0=4\3WE\^LW%O?RZ;IMH ?WO^$_&'
MA+Q]X>TWQ;X%\4^'/&GA76H!=:/XF\)ZWIGB/P]JUL25%QINM:/=7FFW\!8%
M1-:W,L9((W9!K^.SXZ_\%-O"&M?\'*'[)&C7W[<7PR?]A'X0_#WX@W]W?6GQ
MT^'^G_LX>%_B7K_[,?Q^T#5[KQIXKT[Q!:^![KQLOBC4=(\-6,GC35[W7-#U
M+5K;PWHQT]]6%A<_I%_P2[_X)+_%+_@G+^V3^T)X\^ '[0/A7Q'_ ,$T?CCX
M<_M+X<_ BZ\7>+/&7BSP_P"+[A/"FI:3XJMK^71U\)2+X>N8?&?@_3?$%KXG
MUK6/$_@"^\/-XLFU7Q#IEO>Z=^#?Q@_X)U_L6I_P<_? C]CI?@-X='[-7Q&^
M%?B;QKXU^%/]M^,CHVO>*)/V;_COX_?5[C4SXD/B."9O&'AK0]<,5EK5M:_:
M=/CB$ M))[>4 _?_ /X+?_LO_LJ_\%(?V1?V?8/B%_P40_9]_9%^$9^+.E_%
M#X=_'CQGJWPY\6?#CXK?;_AYXNTW3-#\%Z_K?QH^%7AG6/[3T?6KGQ+8:GH?
MBC7/M6F:5/+;Z?+:O)?6W[\U_&E_P=B_"[P%\$O^":'[%?PB^%OARU\(?#CX
M;_M%^'O!W@CPM97%_=VGA_PUH7P4^)5CI.DVUSJEW?:C/!96D4<$<E[>7-PR
MH#+,[98_;G_!S%^VU\:?V;?V8?@I^SK^S;XFU/P9\;OVVOBI<_#'2_%/A[6'
MT/Q7IO@/P]%H:>+K/PKJEK/;ZCHVK>(O$/C/P!X9N=?LI$?3= UC6[>.6UO]
M1T^\M@#]L?&7[;_[%OPZ\:GX;?$']KW]E[P+\11,EN? /C+X_?"CPQXU%Q(S
M*D!\+:WXLL==$SLCJD7V#>S*P"DJ0/I:QOK+4[*SU+3;RUU#3M0M;>^L+^QN
M(KNROK*[B2XM;RSNK=Y(+FUN8)(YK>XAD>*:)TDC=D96/\[?P(_X-@O^"77P
M^^ >F_#7XP?"O6?CG\6=3\.00>/OCOK/Q!^(GAKQ->>+[BS#:CK'@;1?#'BG
M2O#7@_1M-UB6XN/#.E2Z/J]VVG1V5EXTU3QG+'=W-WN_\$0OV*OV]/\ @GIX
MO_:S_9?^-M]-XQ_8@T/QS<ZQ^QEXW\1^/_#7B+Q8FCG7]3M[FV@\*:+J>H7O
M@_1_%?AN?1-?UK0+RUT#3-'\;:;KM[HND9\4:E=S ']"-?P3_P#!PY\ /#7[
M57_!?C_@GM^S=XQUG7/#OA7XV_L]_L^?#CQ!KOADV"^(-*TKQ/\ M+?M)Z=>
M7VCMJEGJ&G+J$$,S/;&]L;NV$@4RV\JY4_WL5_!/_P '#GQ@\2_L_P#_  7X
M_P"">WQM\'?"_7/C9XJ^%O[/?[/GC7P_\(_#-U?V7B#XBZKH7[2W[2=[9^$=
M'N]+\.>+M1M]0UJ:-;.VELO#&O7*22*8M+NVQ$P!]T_\0<_[#'_1SG[6/_@7
M\'__ )V-?=W_  3G_P"#>+]F+_@FO^TG8?M-?"CXU_'CQUXML/!OBOP4F@?$
M.?X?2^'9-.\6P6D-[=,OAOP5H.I"]MA9Q-:L+_R,M()89,J5^$?^(E/]N?\
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M*XFX7H8'#YA5RFMBIYCEZHPS.@HRKY?SJHT\90BXSK8>-ZM*#4ZD8PU/T/\
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M]4S\?J_HWK^<C_@YY_Y,(^$?_9WO@'_U3/Q^KZ+A+_DI,G_[#(?^DR.',O\
M<,3_ ->__;HGX[4445_K,?S*%%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M2=8LS'<#PCX3:XB>&?7KR!XWNKMXKK3? FD74>JZG#=Z_?:+HU]\7QQQOE/
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M* "BBB@ JYIW_(0L?^ORU_\ 1Z53JYIW_(0L?^ORU_\ 1Z4 =C\1_P#D8_\
MMPM?_0IJX*N]^(__ ",?_;A:_P#H4U<%0 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 >\?#;_D7I/^PE<_\ HFUHH^&W_(O2
M?]A*Y_\ 1-K10!F?%'_CSTG_ *^;G_T5'7C5>R_%'_CSTG_KYN?_ $5'7C5
M!1110 4444 %%%% !1110 5XI^TK_P FY_'[_LBGQ4_]077J]KKE_''A+3?'
MW@OQ?X$UB>]MM(\:^%_$'A+5;G3)((=2M]-\1Z3=Z/?3Z?-=6UY:Q7L5K>2R
M6DES9W<"3K&TUM/&&B< _EO_ .#/;_E&A\<?^SZ/B9_ZH']F2OTC_P""U_\
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M%=_<76M^.]7M=5?1O&N@1SZ5;:;!:16-W#=7UX ?J)1110!_(A^P1_RM??\
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MJ\(>/O"VEZWJYEFDUK4/#&AZ!-K5Y<7>JZJ;S6+^^U"Y]9_86_X(7?\ !/\
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MO?"?BS298;^RBOXH;8:KHMZ-0\-ZTUGI\FLZ+J$FG6#6P!_-Q_P4U_X-R/\
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M,_@!\/\ 1/AA\)/">F^#_!N@Q;;73K!&:>\NW5%NM6UC4)FDOM8UJ_:-'O\
M5=1GN+VZ945Y?+BBC3^:[P;XI_X+8?LN_#H?LR>&/@IJ7BO0M$M+OPWX+\>V
M/A'_ (6!>^&=&N#)%8KX;\9Z/K3:!%I^GK*9=%7Q=IUW-HEMY-F\%G:65O96
MO[I?L':1^UOHGP"T/3_VR-5T'5/B5!.$THV4L=_XJM/"Z6ELMC;?$+6K&XFT
M76?%B3BY$]YI0E+68M6U74=2UF2^F3Y/Q&RGB&AALPS7,O$/)N),LS#/9XG+
M\MP?$M3,J^,IUU6E1S*GE4'4P^$AAJ$HX><6X+"\WL*3=-0YOM/"W.N&<1BL
MLR?*O##/>%<URWAVGA,SS7'\)4LIP^!JX?ZO&OE53.*D:>)QM3%8B,\3"251
MXIT_K%=*K*?)^3W_  <.X'P\_9E)&0/&/Q'R/4?V1X1./Q (KXB^!'[57_!/
MSQ%XB^#/PVOO^"<VDR^*M;UGX=^"+WQO-\2]1Q-K^H7NCZ#<^*9=.31$#&74
M)9-6>P%S&)"QMC<*&\T?JE_P6L_9J^.7[1_@OX!Z;\$OAWK/Q!O/"OBGQQ?>
M(;?1Y-.C?3+74M,\-16,T_V^]LPRW,EE=)&(?,.Z)@X7*;OUC^#W@V#P]\*/
MA7H^L^'K"PU[0?AWX%TO5+::QLC=6&K:5X9TNTO8'EC1QY]K>02QM)'(P\R,
MLCD88_58'CC(^'O"7@S UZ.*S7,*N*XJA/"Y1QAC^'L9E4IYC4G0KYAA\IFZ
MV)I8B-6,\/2QL(4N6$Y4FU6FSXS,O#WB'B?QKX]S##8C!Y-EE+!\&5(8S/.!
MLMXGP6<1IY50IXC#99BLYIJAA*V&E1G3Q-7+YSJJ52$:R3HP1_/%_P %7_\
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MTPHHHH **** "BBB@ KJ?!7_ "-&D_\ 76?_ -)+BN6KJ?!7_(T:3_UUG_\
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M_H%P?_@.&_\ F ^)_P"(?91_/5^^I_\ +C_.K_X7=\3O^C4_V@/_  B/$/\
M\HJ/^%W?$[_HU/\ : _\(CQ#_P#**O\ 14HH_P")F>-?^@7!_P#@.&_^8 _X
MA]E'\]7[ZG_RX_SJ_P#A=WQ._P"C4_V@/_"(\0__ "BH_P"%W?$[_HU/]H#_
M ,(CQ#_\HJ_T5**/^)F>-?\ H%P?_@.&_P#F /\ B'V4?SU?OJ?_ "X_SJ_^
M%W?$[_HU/]H#_P (CQ#_ /**C_A=WQ._Z-3_ &@/_"(\0_\ RBK_ $5**/\
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MB/$/_P HJ/\ A=WQ._Z-3_: _P#"(\0__**O]%2BC_B9GC7_ *!<'_X#AO\
MY@#_ (A]E'\]7[ZG_P N/\ZO_A=WQ._Z-3_: _\ "(\0_P#RBH_X7=\3O^C4
M_P!H#_PB/$/_ ,HJ_P!%2BC_ (F9XU_Z!<'_ . X;_Y@#_B'V4?SU?OJ?_+C
M_.K_ .%W?$[_ *-3_: _\(CQ#_\ **C_ (7=\3O^C4_V@/\ PB/$/_RBK_14
MHH_XF9XU_P"@7!_^ X;_ .8 _P"(?91_/5^^I_\ +C_.K_X7=\3O^C4_V@/_
M  B/$/\ \HJ/^%W?$[_HU/\ : _\(CQ#_P#**O\ 14HH_P")F>-?^@7!_P#@
M.&_^8 _XA]E'\]7[ZG_RX_SJ_P#A=WQ._P"C4_V@/_"(\0__ "BH_P"%W?$[
M_HU/]H#_ ,(CQ#_\HJ_T5**/^)F>-?\ H%P?_@.&_P#F /\ B'V4?SU?OJ?_
M "X_SJ_^%W?$[_HU/]H#_P (CQ#_ /**C_A=WQ._Z-3_ &@/_"(\0_\ RBK_
M $5**/\ B9GC7_H%P?\ X#AO_F /^(?91_/5^^I_\N/\ZO\ X7=\3O\ HU/]
MH#_PB/$/_P HJ/\ A=WQ._Z-3_: _P#"(\0__**O]%2BC_B9GC7_ *!<'_X#
MAO\ Y@#_ (A]E'\]7[ZG_P N/\ZO_A=WQ._Z-3_: _\ "(\0_P#RBH_X7=\3
MO^C4_P!H#_PB/$/_ ,HJ_P!%2BC_ (F9XU_Z!<'_ . X;_Y@#_B'V4?SU?OJ
M?_+C_.K_ .%W?$[_ *-3_: _\(CQ#_\ **C_ (7=\3O^C4_V@/\ PB/$/_RB
MK_14HH_XF9XU_P"@7!_^ X;_ .8 _P"(?91_/5^^I_\ +C_.O_X73\5/+\[_
M (9._:$\D':9?^$$\1^7NSC;YG]@[<YXQG.:C_X7=\3O^C4_V@/_  B/$/\
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ME%'_ !,SQK_T"X/_ ,!PW_S '_$/LH_GJ_?4_P#EQ_G5_P#"[OB=_P!&I_M
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MLH_GJ_?4_P#EQ_G5_P#"[OB=_P!&I_M ?^$1XA_^45'_  N[XG?]&I_M ?\
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M )&O5?\ MQ_]-MG1_P 3,\:_] N#_P# <-_\P!_Q#[*/YZOWU/\ Y<?YOO\
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M!ZX4444 %%%% !1110 4444 %%%% !1110 4444 %>D:'_R3_P 2_P#7X/\
MT'3Z\WKTC0_^2?\ B7_K\'_H.GT >;T444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MA';W-C:Z=^C5%% !1110 4444 %%%% !1110 4444 %?G3_P4E_X)B_L\_\
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M7=2\.MJ4*,,K>:5;WUE<)^\M;F>,J[?F-^U7^T#X+O/^"3^@:O\ LY_!J/\
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M%% !1110 4444 >D)_R36;_L*#_TIBKS>O2$_P"2:S?]A0?^E,5>;T %%%%
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M "%=3_["%[_Z4RT 9]%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M"K$PQ6)K8*%>L_K3I3K5L14]ES5%RE%%%?GY^FA1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH V_#7_ ",&B_\ 83LO_1Z5I^._^1KU7_MQ_P#3;9UF>&O^1@T7
M_L)V7_H]*T_'?_(UZK_VX_\ IMLZ .1HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "HH[>"%[B2&&**2ZE6XNGCC1'N9U@AM
M5FN&50TTJVUM;VZR2%G$$$,(;RXD59:* "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ KTC0_^2?^)?\ K\'_ *#I]>;UZ1H?_)/_
M !+_ -?@_P#0=/H \WHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '<
M?#S_ )&6#_KUN_\ T57+ZM_R%=3_ .PA>_\ I3+74?#S_D98/^O6[_\ 15<O
MJW_(5U/_ +"%[_Z4RT 9]%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !7I.J_\DWT#_L)M_P"AZQ7FU>DZK_R3?0/^PFW_ *'K
M% 'FU%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !74^"O^1HTG_KK/_P"DEQ7+5U/@K_D:-)_ZZS_^DEQ0!5\4_P#(QZS_ -?\
M_P#Z%6!6_P"*?^1CUG_K_G_]"K H **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** /2$_Y)K-_V%!_Z4Q5YO7I"?\DUF_["@_\
M2F*O-Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@#;\-?\C!HO\ V$[+_P!'I6GX[_Y&O5?^W'_TVV=9GAK_ )&#1?\ L)V7
M_H]*T_'?_(UZK_VX_P#IMLZ .1HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *](T/_DG_ (E_Z_!_Z#I]>;UZ1H?_ "3_ ,2_
M]?@_]!T^@#S>BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ JYIW_(0L?\ K\M?_1Z53JYIW_(0L?\ K\M?_1Z4 =C\1_\ D8_^
MW"U_]"FK@J[WXC_\C'_VX6O_ *%-7!4 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% 'O'PV_Y%Z3_ +"5S_Z)M:*/AM_R+TG_
M &$KG_T3:T4 =Q<6EI=A5NK6WN50DH+B&.8(2,$J)%8*2  2,$@<U5_L;1_^
M@5IO_@#:_P#QJBB@ _L;1_\ H%:;_P" -K_\:H_L;1_^@5IO_@#:_P#QJBB@
M _L;1_\ H%:;_P" -K_\:H_L;1_^@5IO_@#:_P#QJBB@ _L;1_\ H%:;_P"
M-K_\:H_L;1_^@5IO_@#:_P#QJBB@ _L;1_\ H%:;_P" -K_\:H_L;1_^@5IO
M_@#:_P#QJBB@ _L;1_\ H%:;_P" -K_\:H_L;1_^@5IO_@#:_P#QJBB@ _L;
M1_\ H%:;_P" -K_\:H_L;1_^@5IO_@#:_P#QJBB@ _L;1_\ H%:;_P" -K_\
M:H_L;1_^@5IO_@#:_P#QJBB@ _L;1_\ H%:;_P" -K_\:H_L;1_^@5IO_@#:
M_P#QJBB@ _L;1_\ H%:;_P" -K_\:H_L;1_^@5IO_@#:_P#QJBB@ _L;1_\
MH%:;_P" -K_\:H_L;1_^@5IO_@#:_P#QJBB@ _L;1_\ H%:;_P" -K_\:H_L
M;1_^@5IO_@#:_P#QJBB@ _L;1_\ H%:;_P" -K_\:H_L;1_^@5IO_@#:_P#Q
MJBB@ _L;1_\ H%:;_P" -K_\:H_L;1_^@5IO_@#:_P#QJBB@ _L;1_\ H%:;
M_P" -K_\:H_L;1_^@5IO_@#:_P#QJBB@ _L;1_\ H%:;_P" -K_\:H_L;1_^
M@5IO_@#:_P#QJBB@ _L;1_\ H%:;_P" -K_\:H_L;1_^@5IO_@#:_P#QJBB@
M _L;1_\ H%:;_P" -K_\:H_L;1_^@5IO_@#:_P#QJBB@ _L;1_\ H%:;_P"
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M?_C5%% !_8VC_P#0*TW_ , ;7_XU1_8VC_\ 0*TW_P  ;7_XU110 ?V-H_\
MT"M-_P# &U_^-4?V-H__ $"M-_\  &U_^-444 ']C:/_ - K3?\ P!M?_C5'
M]C:/_P! K3?_  !M?_C5%% !_8VC_P#0*TW_ , ;7_XU1_8VC_\ 0*TW_P
M;7_XU110 ?V-H_\ T"M-_P# &U_^-4?V-H__ $"M-_\  &U_^-444 ']C:/_
M - K3?\ P!M?_C5']C:/_P! K3?_  !M?_C5%% !_8VC_P#0*TW_ , ;7_XU
M1_8VC_\ 0*TW_P  ;7_XU110 ?V-H_\ T"M-_P# &U_^-4?V-H__ $"M-_\
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MJ** #^QM'_Z!6F_^ -K_ /&J/[&T?_H%:;_X VO_ ,:HHH /[&T?_H%:;_X
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M:/\ ] K3?_ &U_\ C5%% !_8VC_] K3?_ &U_P#C5']C:/\ ] K3?_ &U_\
MC5%% !_8VC_] K3?_ &U_P#C5']C:/\ ] K3?_ &U_\ C5%% !_8VC_] K3?
M_ &U_P#C5']C:/\ ] K3?_ &U_\ C5%% !_8VC_] K3?_ &U_P#C5']C:/\
M] K3?_ &U_\ C5%% !_8VC_] K3?_ &U_P#C5']C:/\ ] K3?_ &U_\ C5%%
M !_8VC_] K3?_ &U_P#C5']C:/\ ] K3?_ &U_\ C5%% !_8VC_] K3?_ &U
M_P#C5']C:/\ ] K3?_ &U_\ C5%% !_8VC_] K3?_ &U_P#C5']C:/\ ] K3
M?_ &U_\ C5%% !_8VC_] K3?_ &U_P#C5']C:/\ ] K3?_ &U_\ C5%% !_8
MVC_] K3?_ &U_P#C5']C:/\ ] K3?_ &U_\ C5%% !_8VC_] K3?_ &U_P#C
M5']C:/\ ] K3?_ &U_\ C5%% !_8VC_] K3?_ &U_P#C5']C:/\ ] K3?_ &
MU_\ C5%% !_8VC_] K3?_ &U_P#C5']C:/\ ] K3?_ &U_\ C5%% !_8VC_]
M K3?_ &U_P#C5']C:/\ ] K3?_ &U_\ C5%% !_8VC_] K3?_ &U_P#C5']C
M:/\ ] K3?_ &U_\ C5%% !_8VC_] K3?_ &U_P#C5']C:/\ ] K3?_ &U_\
MC5%% !_8VC_] K3?_ &U_P#C5']C:/\ ] K3?_ &U_\ C5%% #X]*TN)TDBT
MVPCDC8.DD=G;HZ.IRK(ZQAE93R&!!!Y!ITVF:;<2--<:?8SROC?+-:02R-M4
M*NYWC9FVJJJ,DX4 #@ 444 1?V-H_P#T"M-_\ ;7_P"-4?V-H_\ T"M-_P#
M&U_^-444 ']C:/\ ] K3?_ &U_\ C5']C:/_ - K3?\ P!M?_C5%% !_8VC_
M /0*TW_P!M?_ (U1_8VC_P#0*TW_ , ;7_XU110 ?V-H_P#T"M-_\ ;7_P"-
M4?V-H_\ T"M-_P# &U_^-444 ']C:/\ ] K3?_ &U_\ C5']C:/_ - K3?\
MP!M?_C5%% !_8VC_ /0*TW_P!M?_ (U1_8VC_P#0*TW_ , ;7_XU110 ?V-H
M_P#T"M-_\ ;7_P"-4?V-H_\ T"M-_P# &U_^-444 ']C:/\ ] K3?_ &U_\
MC5']C:/_ - K3?\ P!M?_C5%% !_8VC_ /0*TW_P!M?_ (U1_8VC_P#0*TW_
M , ;7_XU110 ?V-H_P#T"M-_\ ;7_P"-4?V-H_\ T"M-_P# &U_^-444 ']C
M:/\ ] K3?_ &U_\ C5']C:/_ - K3?\ P!M?_C5%% !_8VC_ /0*TW_P!M?_
M (U1_8VC_P#0*TW_ , ;7_XU110 ?V-H_P#T"M-_\ ;7_P"-4?V-H_\ T"M-
M_P# &U_^-444 ']C:/\ ] K3?_ &U_\ C5']C:/_ - K3?\ P!M?_C5%% !_
M8VC_ /0*TW_P!M?_ (U1_8VC_P#0*TW_ , ;7_XU110 ?V-H_P#T"M-_\ ;7
M_P"-4?V-H_\ T"M-_P# &U_^-444 ']C:/\ ] K3?_ &U_\ C5']C:/_ - K
M3?\ P!M?_C5%% !_8VC_ /0*TW_P!M?_ (U1_8VC_P#0*TW_ , ;7_XU110
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MJ/[&T?\ Z!6F_P#@#:__ !JBB@ _L;1_^@5IO_@#:_\ QJC^QM'_ .@5IO\
MX VO_P :HHH /[&T?_H%:;_X VO_ ,:H_L;1_P#H%:;_ . -K_\ &J** #^Q
MM'_Z!6F_^ -K_P#&J/[&T?\ Z!6F_P#@#:__ !JBB@ _L;1_^@5IO_@#:_\
MQJC^QM'_ .@5IO\ X VO_P :HHH /[&T?_H%:;_X VO_ ,:H_L;1_P#H%:;_
M . -K_\ &J** #^QM'_Z!6F_^ -K_P#&J/[&T?\ Z!6F_P#@#:__ !JBB@ _
ML;1_^@5IO_@#:_\ QJC^QM'_ .@5IO\ X VO_P :HHH /[&T?_H%:;_X VO_
M ,:H_L;1_P#H%:;_ . -K_\ &J** #^QM'_Z!6F_^ -K_P#&J/[&T?\ Z!6F
M_P#@#:__ !JBB@ _L;1_^@5IO_@#:_\ QJC^QM'_ .@5IO\ X VO_P :HHH
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M_P#T"M-_\ ;7_P"-4?V-H_\ T"M-_P# &U_^-444 ']C:/\ ] K3?_ &U_\
MC5']C:/_ - K3?\ P!M?_C5%% !_8VC_ /0*TW_P!M?_ (U1_8VC_P#0*TW_
M , ;7_XU110 ?V-H_P#T"M-_\ ;7_P"-4?V-H_\ T"M-_P# &U_^-444 ']C
M:/\ ] K3?_ &U_\ C5']C:/_ - K3?\ P!M?_C5%% !_8VC_ /0*TW_P!M?_
M (U1_8VC_P#0*TW_ , ;7_XU110 ?V-H_P#T"M-_\ ;7_P"-4?V-H_\ T"M-
M_P# &U_^-444 ']C:/\ ] K3?_ &U_\ C5']C:/_ - K3?\ P!M?_C5%% !_
M8VC_ /0*TW_P!M?_ (U1_8VC_P#0*TW_ , ;7_XU110 ?V-H_P#T"M-_\ ;7
M_P"-4?V-H_\ T"M-_P# &U_^-444 ']C:/\ ] K3?_ &U_\ C5']C:/_ - K
M3?\ P!M?_C5%% !_8VC_ /0*TW_P!M?_ (U1_8VC_P#0*TW_ , ;7_XU110
M?V-H_P#T"M-_\ ;7_P"-4?V-H_\ T"M-_P# &U_^-444 ']C:/\ ] K3?_ &
MU_\ C5']C:/_ - K3?\ P!M?_C5%% !_8VC_ /0*TW_P!M?_ (U1_8VC_P#0
M*TW_ , ;7_XU110 ?V-H_P#T"M-_\ ;7_P"-4?V-H_\ T"M-_P# &U_^-444
M ']C:/\ ] K3?_ &U_\ C5']C:/_ - K3?\ P!M?_C5%% !_8VC_ /0*TW_P
M!M?_ (U1_8VC_P#0*TW_ , ;7_XU110 ?V-H_P#T"M-_\ ;7_P"-4?V-H_\
MT"M-_P# &U_^-444 ']C:/\ ] K3?_ &U_\ C5']C:/_ - K3?\ P!M?_C5%
M% !_8VC_ /0*TW_P!M?_ (U1_8VC_P#0*TW_ , ;7_XU110 ?V-H_P#T"M-_
M\ ;7_P"-4?V-H_\ T"M-_P# &U_^-444 7(+:WM4\JV@AMXRQ8QP1)"A8@ M
2LC55W$  G&2  3P**** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>img267189834_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img267189834_2.jpg
M_]C_X  02D9)1@ ! @$ D "0  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" *,"ZD# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBO\Y'
M]K/_ (.(_P#@JC\*?VJ?VF/A=X*^-?@S3O!OPV_:!^,W@'PEI]Q\%OA7J-Q8
M^&/!WQ&\2>'=!LY]0OO"\][?36NE:=:02WEW--=7+HT]Q+)*[N?>R+A['<0U
M<12P,\-"6&IPJ5/K-2I33C.3BN5TZ55MW6J:CILV8UJ\*"BY\SYFTN5)[=[M
M'^C=17^8A_Q$P_\ !7C_ *+OX&_\,5\(?_F2H_XB8?\ @KQ_T7?P-_X8KX0_
M_,E7TG_$-.(/^?\ E?\ X48G_P"8SG_M"AVJ?^ K_P"2/].^BO\ ,0_XB8?^
M"O'_ $7?P-_X8KX0_P#S)4?\1,/_  5X_P"B[^!O_#%?"'_YDJ/^(:<0?\_\
MK_\ "C$__,8?VA0[5/\ P%?_ "1_IWT5_F(?\1,/_!7C_HN_@;_PQ7PA_P#F
M2H_XB8?^"O'_ $7?P-_X8KX0_P#S)4?\0TX@_P"?^5_^%&)_^8P_M"AVJ?\
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MC_B)A_X*\?\ 1=_ W_ABOA#_ /,E1_Q#3B#_ )_Y7_X48G_YC#^T*':I_P"
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M_IWT5_F(?\1,/_!7C_HN_@;_ ,,5\(?_ )DJ/^(F'_@KQ_T7?P-_X8KX0_\
MS)4?\0TX@_Y_Y7_X48G_ .8P_M"AVJ?^ K_Y(_T[Z*_S$/\ B)A_X*\?]%W\
M#?\ ABOA#_\ ,E1_Q$P_\%>/^B[^!O\ PQ7PA_\ F2H_XAIQ!_S_ ,K_ /"C
M$_\ S&']H4.U3_P%?_)'^G?17^8A_P 1,/\ P5X_Z+OX&_\ #%?"'_YDJ/\
MB)A_X*\?]%W\#?\ ABOA#_\ ,E1_Q#3B#_G_ )7_ .%&)_\ F,/[0H=JG_@*
M_P#DC_3OHK_,0_XB8?\ @KQ_T7?P-_X8KX0__,E1_P 1,/\ P5X_Z+OX&_\
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M ,,5\(?_ )DJ/^(:<0?\_P#*_P#PHQ/_ ,QA_:%#M4_\!7_R1_IWT5_F(?\
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M_P# 5_\ )'^G?17^8A_Q$P_\%>/^B[^!O_#%?"'_ .9*C_B)A_X*\?\ 1=_
MW_ABOA#_ /,E1_Q#3B#_ )_Y7_X48G_YC#^T*':I_P" K_Y(_P!.^BO\Q#_B
M)A_X*\?]%W\#?^&*^$/_ ,R5'_$3#_P5X_Z+OX&_\,5\(?\ YDJ/^(:<0?\
M/_*__"C$_P#S&']H4.U3_P !7_R1_IWT5_F(?\1,/_!7C_HN_@;_ ,,5\(?_
M )DJ/^(F'_@KQ_T7?P-_X8KX0_\ S)4?\0TX@_Y_Y7_X48G_ .8P_M"AVJ?^
M K_Y(_T[Z*_S$/\ B)A_X*\?]%W\#?\ ABOA#_\ ,E1_Q$P_\%>/^B[^!O\
MPQ7PA_\ F2H_XAIQ!_S_ ,K_ /"C$_\ S&']H4.U3_P%?_)'^G?17^8A_P 1
M,/\ P5X_Z+OX&_\ #%?"'_YDJ/\ B)A_X*\?]%W\#?\ ABOA#_\ ,E1_Q#3B
M#_G_ )7_ .%&)_\ F,/[0H=JG_@*_P#DC_3OHK_,0_XB8?\ @KQ_T7?P-_X8
MKX0__,E1_P 1,/\ P5X_Z+OX&_\ #%?"'_YDJ/\ B&G$'_/_ "O_ ,*,3_\
M,8?VA0[5/_ 5_P#)'^G?17^8A_Q$P_\ !7C_ *+OX&_\,5\(?_F2H_XB8?\
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M?^"O'_1=_ W_ (8KX0__ #)4?\0TX@_Y_P"5_P#A1B?_ )C#^T*':I_X"O\
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M1_Q$P_\ !7C_ *+OX&_\,5\(?_F2H_XAIQ!_S_RO_P *,3_\QA_:%#M4_P#
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MA_\ F2H_XAIQ!_S_ ,K_ /"C$_\ S&']H4.U3_P%?_)'^G?17^8A_P 1,/\
MP5X_Z+OX&_\ #%?"'_YDJ/\ B)A_X*\?]%W\#?\ ABOA#_\ ,E1_Q#3B#_G_
M )7_ .%&)_\ F,/[0H=JG_@*_P#DC_3OHK_,0_XB8?\ @KQ_T7?P-_X8KX0_
M_,E1_P 1,/\ P5X_Z+OX&_\ #%?"'_YDJ/\ B&G$'_/_ "O_ ,*,3_\ ,8?V
MA0[5/_ 5_P#)'^G?17^8A_Q$P_\ !7C_ *+OX&_\,5\(?_F2H_XB8?\ @KQ_
MT7?P-_X8KX0__,E1_P 0TX@_Y_Y7_P"%&)_^8P_M"AVJ?^ K_P"2/].^BO\
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M1_Q$P_\ !7C_ *+OX&_\,5\(?_F2H_XAIQ!_S_RO_P *,3_\QA_:%#M4_P#
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MA_\ F2H_XAIQ!_S_ ,K_ /"C$_\ S&']H4.U3_P%?_)'^G?17^8A_P 1,/\
MP5X_Z+OX&_\ #%?"'_YDJ/\ B)A_X*\?]%W\#?\ ABOA#_\ ,E1_Q#3B#_G_
M )7_ .%&)_\ F,/[0H=JG_@*_P#DC_3OHK_,0_XB8?\ @KQ_T7?P-_X8KX0_
M_,E1_P 1,/\ P5X_Z+OX&_\ #%?"'_YDJ/\ B&G$'_/_ "O_ ,*,3_\ ,8?V
MA0[5/_ 5_P#)'^G?17^8A_Q$P_\ !7C_ *+OX&_\,5\(?_F2H_XB8?\ @KQ_
MT7?P-_X8KX0__,E1_P 0TX@_Y_Y7_P"%&)_^8P_M"AVJ?^ K_P"2/].^BO\
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M1_Q$P_\ !7C_ *+OX&_\,5\(?_F2H_XAIQ!_S_RO_P *,3_\QA_:%#M4_P#
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MA_\ F2H_XAIQ!_S_ ,K_ /"C$_\ S&']H4.U3_P%?_)'^G?17^8A_P 1,/\
MP5X_Z+OX&_\ #%?"'_YDJ/\ B)A_X*\?]%W\#?\ ABOA#_\ ,E1_Q#3B#_G_
M )7_ .%&)_\ F,/[0H=JG_@*_P#DC_3OHK_,0_XB8?\ @KQ_T7?P-_X8KX0_
M_,E1_P 1,/\ P5X_Z+OX&_\ #%?"'_YDJ/\ B&G$'_/_ "O_ ,*,3_\ ,8?V
MA0[5/_ 5_P#)'^G?17^8A_Q$P_\ !7C_ *+OX&_\,5\(?_F2H_XB8?\ @KQ_
MT7?P-_X8KX0__,E1_P 0TX@_Y_Y7_P"%&)_^8P_M"AVJ?^ K_P"2/].^BO\
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M?P-_X8KX0_\ S)4?\0TX@_Y_Y7_X48G_ .8P_M"AVJ?^ K_Y(_T[Z*_S$/\
MB)A_X*\?]%W\#?\ ABOA#_\ ,E1_Q$P_\%>/^B[^!O\ PQ7PA_\ F2H_XAIQ
M!_S_ ,K_ /"C$_\ S&']H4.U3_P%?_)'^G?17^8A_P 1,/\ P5X_Z+OX&_\
M#%?"'_YDJ/\ B)A_X*\?]%W\#?\ ABOA#_\ ,E1_Q#3B#_G_ )7_ .%&)_\
MF,/[0H=JG_@*_P#DC_3OHK_,0_XB8?\ @KQ_T7?P-_X8KX0__,E1_P 1,/\
MP5X_Z+OX&_\ #%?"'_YDJ/\ B&G$'_/_ "O_ ,*,3_\ ,8?VA0[5/_ 5_P#)
M'^G?17^8A_Q$P_\ !7C_ *+OX&_\,5\(?_F2H_XB8?\ @KQ_T7?P-_X8KX0_
M_,E1_P 0TX@_Y_Y7_P"%&)_^8P_M"AVJ?^ K_P"2/].^BO\ ,0_XB8?^"O'_
M $7?P-_X8KX0_P#S)4?\1,/_  5X_P"B[^!O_#%?"'_YDJ/^(:<0?\_\K_\
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MJG_@*_\ DC_3OHK_ #$/^(F'_@KQ_P!%W\#?^&*^$/\ \R5'_$3#_P %>/\
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MH **** "BBB@ HHHH _H=_X-?/\ E+!X%_[(U\:?_4:@K\>_VU/^3R/VM/\
MLYGX\?\ JT_%5?L)_P &OG_*6#P+_P!D:^-/_J-05^/?[:G_ ">1^UI_V<S\
M>/\ U:?BJOF\/_R5>9_]B7+/_4K'G1+_ '6G_P!?JG_I$#YFHHHKZ0YPHHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K^K7_@M'_P H
M8_\ @A;_ -D<L/\ U3'PQK^4JOZM?^"T?_*&/_@A;_V1RP_]4Q\,:^:SK_D;
M\+?]C'&_^JO%'11_A8G_ *]Q_P#3D3^4JBBBOI3G"BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "OLG_@G1_P I!_V$_P#L\G]F'_U=
MO@>OC:OLG_@G1_RD'_83_P"SR?V8?_5V^!ZY<=_N6,_[!<1_Z9F73_B4_P#'
M'_TI'Z1?\'+G_*7OX_\ _8F? G_U3/@NOP4K]Z_^#ES_ )2]_'__ +$SX$_^
MJ9\%U^"E<'#O_(@R3_L58#_U%I%XC^/6_P"OD_\ TIA1117LF(4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_5K_P<V?\ (F?\$G/^
MS1+O_P!-7PHK^4JOZM?^#FS_ )$S_@DY_P!FB7?_ *:OA17\I5?-\(_\D]@/
M\6-_]6&*.C%?[Q4_[<_](B%%%%?2'.%%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 ?U:?M5_P#*J+_P3F_[.\\3_P#J>?MQ5_*77]6G
M[5?_ "JB_P#!.;_L[SQ/_P"IY^W%7\I=?-<,?P,W_P"RCSS_ -39G1B-Z/\
MV#T?_2$%%%%?2G.%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 =/X)_Y'/PC_V,^@?^G6TK^FC_ (.W?^4D7P;_ .S*/AM_ZO']HVOY
ME_!/_(Y^$?\ L9] _P#3K:5_31_P=N_\I(O@W_V91\-O_5X_M&U\WC_^2GX?
M_P"P'//RR\Z:?^ZU_P#'1_.1_+A1117TAS!1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M<N98UEW(LK:1"SQ@2&)&8Q+^=G[;W_!L=^W+^RQX5U;XD?![6?#7[7/P_P!
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MA# UY>SA&<)-/EDV_>MVO*2\[-+1/R/\Q2BOZ&O^#D_]GC]GWX/?MWP?$O\
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ML=4TC5]+OHH+[3=3TV^@GL[^PO((;JSNH9;>XBCFC=%_C9_X.#O^4PO[9_\
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M@ HHHH **** "BBB@ K^K7_@M'_RAC_X(6_]D<L/_5,?#&OY2J_JU_X+1_\
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M_A"?AQJFB^-==_LWPMJNN:UY6AZG:R6?]F_VE>-)IUG>0R?L3_P5+_X*2_\
M!8;]J+]E:\^%G[;'[ __  SK\$)O'_@[7[CXC?\ #+/[47PC\KQ3H[ZB?#^B
M_P#"7_%KQUX@\(I_:C7-V/[.?3CJ-]Y&+*:(Q2[O2S&OG4,[R^C@ZV7PRR<*
M+QE*O4I1Q<VZ]6-5T(2DJDDZ2IJ'*FG-22U3,Z<:+HU')3=5<W*TFX)6C:[6
MSO>]]+6/YJJ*]F^#W[.7[0O[0]WKEA\ /@/\9OCG?>&+>QO/$ME\'OA?XW^)
MMWX>M-3EN(=-NM<MO!6AZW-I-OJ$UI=Q6,]^EO%=RVMQ' TCP2A>GU']CS]K
M31?BUX4^ FN_LQ?M >'OC?XZTV#6_!OPA\1_![X@>'OB3XGT*XNM6LXM?T/P
M7K7A^Q\0ZCH!NM UZ&37;;3Y-)A;0M:\Z\C&E7YM_?EB</&<J<L11C4A%SG3
ME5IJ<(**DYRBY*48J+4G)I)1:;=M3#EDTFHMINR=G9O:R[N_0^<J*_9'5_\
M@WX_X+!:+X:N/%EY^Q=XGFTNVLY+Z2UTGXG_  )U_P 2M!'&\K);^#-"^*6I
M>,+J\*QL(].M="FU"60I#%:O-)&C_D9XH\*^)_ _B+6O!_C7PYKWA#Q;X;U&
MZT?Q%X7\4:/J'A_Q%H.K64AAO-+UK1-6M[34]+U&TF5HKJROK6"Y@D4I+$C
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M0:59Z_9Z1\ ==TJUUBWLK^&+4+?3M9U6RBNEE2VU"[B59G_G*K_7D_X)4?\
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M#:_]N?\ 9"_9Z^*G[2OQ*^*W[)VN>!?A#X;_ .$H\2Z3X&\=?&#4O%E]I_\
M:-CIGDZ'8Z_\"?#.CW-YY^H0OY=_KVF0^2LK?:-ZI&_\]E?ZP_\ P7$_Y1.?
MMP?]D@'_ *EGAFO\]7X-_P#!#G_@JU\>O ^E_$7X<_L;^.W\)ZW;O>:1>>.O
M%/PP^$6I:C9+*\<=]:^&_BYXZ\#^)I;"\"?:-,OET?[)JMC)!J&FS7=C<07$
ME\)<43S#+,3C,\QN!PSIXYX:E4JSHX.FXJA1J<J=2<8RGS3D]'>SVL@Q6&5.
MI&%&$Y7@I-).;O=KHM%H?E%17TC^TQ^Q_P#M-_L;^,K;P%^TY\%?''P=\2:A
M%<3Z,GBG3HVT3Q+;V:63W]SX2\6:5/J/A/Q?:Z<=1L8M2N?#.MZM!IMS=0VE
M]);W3B&OFZON*56E7IPK4*E.M2J+FA5I3C4ISC_-"<&XR7FFT<;3BVI)IK=-
M-->J>H45^IOP0_X(F_\ !4W]HCPCI_COX7_L<?$2X\*ZO'Y^DZIXZUKX??!\
MZK:%=\6H:;8?&#QCX$U._P!+NH\26.J6EG-IU_$RR65S.CJQW?BK_P $*/\
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MU_X.;/\ D3/^"3G_ &:)=_\ IJ^%%?RE5_5K_P '-G_(F?\ !)S_ +-$N_\
MTU?"BOY2J^;X1_Y)[ ?XL;_ZL,4=&*_WBI_VY_Z1$****^D.<**** "BBB@
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MIU(-\LU4I5:<E3G33T;<92QQ&&IPIQK49.4)6NGKOLUHFM59IZIOY+W+P?\
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M?!'P=_PHK_A7/_"7?\+D\2>//#_]H_\ "SO^$\_L#_A'/^$)^&WQ"^U_9/\
MA7NM?VO_ &G_ &1]G^U:7]B_M#S[O[%Y9_P44_X)U_&S_@F7\;/"_P !_CQX
MH^%GBWQ?XM^%FB?%S3=2^$>M^+=>\-P>&]>\6^-_!MG97MYXR\$> M4CUR/4
M_ 6L3W-M!H]S8)87.FRQ:E-<375K9_8/_!'#]MC_ (*/_L=_\-&?\.^OV2/^
M&IO^%B_\*A_X6Y_Q87X[_&__ (07_A$?^%G_ /"!?\D3\5^&/^$8_P"$G_X2
M?QI_R,WV[^VO^$>_XDWV;^R=6^T>(_\ !7#]J+]MC]K7]I#P3\1_V\?V=O\
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MQA>:_P")O WC'3_"WB/4&067BSQ'_P )!X0OO%L,]QI-OID\&L\[_P '</\
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MPJK_ (5A_P!4P^)']O?V]_PLC_J#?V7_ &-_S$?[1_T'^5?_ ((@_L?^ O\
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M .2Q?"?_ +*7X$_]2G2J\TKTOX+_ /)8OA/_ -E+\"?^I3I59UOX57_KW/\
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MPO\ \$IOAY\.M.\.?#VR^*7QS^+QUS_A7W@S4=2N-#\(^'?#7A0:;;ZSXO\
M%UUIMO-J$EA#>:KIVEZ'X=TXZ=<Z[<'46CU;3;?1KIY/PU_X,YKBP75/^"AE
MI)Y7]ISV'[*UQ9YC4S?8+6X_:*BU'RY2-R1?:+S2_.C#!9'\AF#&)2ORM_P=
MUZ%XFM_V\?V>/$UW:WB>#=7_ &1]"T+0;U[A&T^X\3>'/C)\8=0\6VMK:B9G
MAO+/2O%/@J6^N&MXDN8+[3HTFG-HZ6W7F6'IY[X@K+,QE*I@<%AX.EAG.4(5
M/]BI8J45RRB[SK5>:JX6E.G14&^6*<9IR=' ^TIV4Y2=Y63:]]Q_!+2^B;N?
MKI_P1\_X.$)/^"A_QTT#]E3]K7X-?#/P1\7]?75O%GP;\:_#BWUT> O$/BCP
M98:GXEG\/2>%_&NK^,-:\'^*[#PI8:IJVA^(XO&6IVFLRZ;JFF+!HE]=Z59:
MI]<_\'-/_*(WXT_]E#^!O_JT?#U?PY_\$.K'7=0_X*Q_L/V_AT3G4(_B^;ZX
M^S.8Y/["TSPEXFU+Q068=8!X:M-6-TG22U$T9R&-?W&?\'-/_*(WXT_]E#^!
MO_JT?#U<.<Y1@<HXUX>IX"G["CB,1E^(EAU*4H4ZGUZ5.3IJ<I.,)JG%\M[*
M2GRVBU%52JSJX.NYOF<5.*EU:Y$]>[5]^UK]W^-7_!G5_P C5^W_ /\ 8O\
M[-/_ *<?CE7D7_!WW_R='^R3_P!D"\4?^K$OZ]=_X,ZO^1J_;_\ ^Q?_ &:?
M_3C\<J\B_P"#OO\ Y.C_ &2?^R!>*/\ U8E_7ITO^3HXC_L'C_ZIJ!G_ ,RW
M_M[_ -RG[:_\&X7_  3C^'W[+O[&/@#]I_Q%X=TC5?VB/VI_"ME\0[KQA<V\
M-]J'@_X1>(PNH_#OP/X6OI[2&XTFQUOPV=*\9>+Q:".;5M?UB/3K^[U/3?"_
MA][?\N/VKO\ @[1^('@W]I'7_"7[+'P"^$OC;]GOP)XOU;PW=^+_ (C:OXIO
M/%_Q?T[1KN*QF\3^!M2\'>(M/\-^ =#U:YMM3F\-76K:1\2+C5-!GT76[ZRT
M:\N+SP];?U?_ +'%QX?\0?L#?LLW/P\A@7POJ_[(?P3?P5:V%L=.@BT2\^#?
MAH>'[2ULI%@;3DALWM;>.SEC@>RV"WECB:)E7_'EN;:YLKFXL[RWGM+NTGEM
MKJUN8I(+FVN8)&BGM[B"54EAGAE1HY8I%62.161U# @<G#&7X3B?..(L=G=)
MXNI1K4J=&C5G44:,*U3%14>6$XM>QIX>%*DKV@N9I<]I*\34EAZ.'A1?(I)M
MM)7?*H/K?XG)M]_0_P!//XJ_\%'_ /@CQ^WM^PW:>'OVG_VB/@#X4\*_'SX7
MZ5J_B3X3>*OB)X3USXL?"#Q;JFGAH<Z'H4NI>(-#^('PZ\1.\^CZO%I%G<&>
MP@U);4:7?/!+_!7_ ,$YO%_[$7P)_;[\%^-_VQ=0UOXI?LV?"KQ+XMU31-2\
M'> +S7_#_P 0_$?AY[NW^&GB'Q/X+\3W/AWQ1:> ;N[2V\8R:1<Z+J.NO?6>
MA^'?$GA4Z5?^(6L/E/P]^RO^T]XM\!:=\5?"G[./QY\3?"_6!J3:1\2/#WP@
M^(6M> M471K_ %#2]7;3O&&F^'KGP]?#2M3TG5-.U(VVHRBQO]-U"TNO*N+.
MXCC_ $1_X(N_\$P9/^"EG[6U_P##/Q]>>(_"7P6^$7AZ?QO\;M6T9(['Q$84
MU%-%\._#_2Y[^WN$TGQ!XLUQKA9KFYLI9-/\/Z#XHN8$74[6R1_J<)DV5<-Y
M9GB_M7%O 585'B(0K4G+!74Z36'Y(2J0Q4U*-%2D^:<X4TX\\4US3JU<15H_
MNHJ::Y6T[3V:<N\5:^FEF^A_3Q^WO_P=2? +X<>!O!,'_!/73O#_ .T!\1/$
MDNKOXIO_ (L^#/BIX+\&_#"PTZWTW^RH-0\/W=EX$U?QIJFOW-]>)#%X:\56
MFFZ1;Z'=/>ZA))?Z=&_Z#?\ !#S_ (*D_M&_\%,OA[\5=>_:"_9ST[X33?#Z
M7P?+X4^)_@;1?'6C?"CXL6_B>X\7VNJV'A6#QM<>(&35?!4WAFS36QIOCGQ.
MDG]NVIN8-%>.**]K?%ZS_P""(_\ P0[\'^!=9\6_!7X1_#3Q5XDL]8TWX>MI
MGPOE^,'[07C:#1!8W6O/;^,-?M?$7C*'34N9],^WZIXE\6Z'X8_M&?3;);R.
M=;*UC]I_X)C?\%A/@C_P5*\4_'/0O@;\+/BAX \/? O2OAW>W6J_%$>$=.U3
M7F\?W7C2ULK6R\/>$-?\6V.G1:9%X,FDGFD\1W!E:^AABMT6!I7_ #/&TLOG
MD5>IE7#..CA*<XR_U@S#$6K:XJ-.T:=*$,/54G)89QI2G"%VY1=6#J+T(.HJ
MR57$0YFK>PA'3X>[O)?S:I-]+1T/Y/?^#C3P#X2_8\_X*]? ']IKP-\.-.AT
MKQCX7^$'[1/BW1]*U"V\/VGCSXK?#3XM^(K?Q>K>3%JK:!?Z_P"'/"G@-M7U
MV/P^UK?:OJU]KSVFLZV^O23_ -D'_!+3_@H!_P /+/V5K/\ ::_X5+_PI;[7
MX_\ &/@;_A"?^$\_X6-Y?_")OIR_VI_PDG_"&> ]_P#:']H9^Q?V OV7R<?:
M[GS,I_(!_P '=_BJ.\_;=_9L\$"R>.;P]^RM9^*GU S*T=U'XR^+GQ,TB*R2
MW$8:)[!O DT\DQE=9UU&)%CB-LS3?NW_ ,&L5Y:7/_!+&R@MKJVN)M._:&^+
M]GJ$,$\4LMC=O#X2U!+6\CC9GMKE["^LKU8)PDK6EY:W(4PW$+O[.>X:GB.!
M<AS&O!SQM!4,+2K.I5;CAIRK+D<>=TY<T*-&TIQ<H\JC%Q3<3.C)QQM>G%V@
M[R<;+67NZWM?K+1.W74^"O\ @N/_ ,%X_P#A7WB']N#_ ()>?\,K?VO]O\!1
M_"O_ (7C_P +Q^P>5_PLSX8>%_%?]N_\*S_X4_>^9_8G_"5_8/[+_P"%@)_:
M7V#[5_:-A]J^S6WO_P#P:*_\F$_M"?\ 9WGB+_U3/P9K^6O_ (.#O^4PO[9_
M_8P?"?\ ]4!\**_J4_X-%?\ DPG]H3_L[SQ%_P"J9^#-=N<9;@LO\/\ #SPE
M'V,L=#)\9BG[2K4]KB:M&BZE2U6I-0YF_@IJ%-?9BC*C4G4QK4Y7Y/:QCHE:
M*;LM$K^KN_,_GJ_X.?\ _E+'\0O^R0?!7_U$Q7];_P#P0F_X)E?#;]@/]D#P
M7\7O'7A728OVG_C3X'M?B)\6O'FO:?8'Q!X \*>([&S\0Z3\)=&U!XGN?#^@
M>&=%ATJZ\:6=O=O_ &YXXBU74-0N;C3M.\-6&B_R0?\ !S__ ,I8_B%_V2#X
M*_\ J)BO] 7]MFPU_P 9_P#!/_\ :XTSX1Q7]WXH\5_L=_'NP^&,'ARZ%CJE
MSK^N_!7Q7;^"XM!O8+FW%G?S:C=::FEW45W +>X:"6.YC""5>7B'%8B/#'!V
M64ZSH8?,L-16*FG9.-"G@XPC-W2=)/$RJ2BW9RIP;^$O#QC]9Q=1J\J<GRK_
M !.3;7G[J5_-G\EG[27_  =R_$+2_CK>:9^RI^SM\,O$?[//AO7[[3CXB^+L
M_CF+XA_%/1K26"*#Q#X>AT'6?#NG?"RWU$QWLVGV'B/0/B!J9L)].NM4M-'U
M 7NAP?T??LZ?&7]DK_@N=_P3]DU[Q=\-[#6OAU\1XM8\!?%3X5>);O3M9\0_
M"CXGZ';VSZE8Z;XBL8HKC3/$6A+J>D>,/A_XUL+;0M=?1-7\->)1INAWE[+I
M=K_D\5_H+_\ !HA;:@G[$O[2MY)'.-*G_:GN;:SE9B;5]0M/A+\-I=3CA7<5
M$\=M>Z2URP4%HY;4,S!5"^AQ?PSE.39+2Q^649X/&8'$894\33K5?;5>:?*Y
M5).=G54K58U(1C*#BXPY8>ZHPN(JU:SA4:G":DW%I65E>R5MK:6=UUWU/XI_
MV^?V2_$'[#/[8'QV_99\0ZC_ &T_PJ\8FS\/^("NV3Q'X%\1:7I_B[X?:_=H
MMO;PP:GJ_@G7]!O=;L[5)+33M:EU'3;:XNHK1;B7_7#\4>"O ?Q'^!>J^ _B
MEI=AKGPU\6_#5M"\?:+JN[^RM7\'ZAX?6#Q%IFJA2&?3+[2FNK74(PRF2SEG
M0,N[(_SL/^#I35?#NH?\%5-<M-$N-/FU/0_@)\'=*\7QV2(ES:>(IK?Q!K=M
M;ZLRHC2Z@WA+6/"]W&\C2N-*NM,C#B..../_ $%_CO=75C^QW\9;VRN9[.\L
M_P!FGXAW5I=VLTEO=6MU;_"[6)H+FVN(626">"5$EAFB=9(I%5T964$>7QEB
M:^89;P5BJLG3Q&*P]:I.<;Q:K3AEG-5A:SBI3_>0MLFK-VN:82,:=7%06L8M
M))]DYZ/>]EH^Y_'?\1?^#MSQ=X8^.UCH?P$_95^&-Q^R/X2UN?08;#Q)>>)=
M$^*_C#P5II-AI.J^%;K1;^Q\%?"YY+:*.\L_#6I^"?'4=M9B'3);VRF+SVW]
M>_QN^&7PF_;S_8W\7^ ]<TVW\6?"[]I#X*)J&A/<6T$EQ';>,_#$'B'P+XJT
MK[2'CLO$&@W]UHGB30+X8?3M9L+*Z1@T-?XYU?[ G_!,[_E&_P#\$_/^S(_V
M4O\ U1'@*KXYR3+LAHY/BLJHO"UX5YPE5C4J3G5E2C3JTJU24YR_>PJ1<N>*
MBWS-/2,%%8*M4K2JPJ-2BXIV:22O[KBDE\+5M'V[MW_Q^Z***_9SR0HHHH *
M*** "BBB@#^AW_@U\_Y2P>!?^R-?&G_U&H*_'O\ ;4_Y/(_:T_[.9^/'_JT_
M%5?L)_P:^?\ *6#P+_V1KXT_^HU!7X]_MJ?\GD?M:?\ 9S/QX_\ 5I^*J^;P
M_P#R5>9_]B7+/_4K'G1+_=:?_7ZI_P"D0/F:BBBOI#G"BBB@ HHHH **** "
MBBB@ K^U#_@SJ_Y&K]O_ /[%_P#9I_\ 3C\<J_BOK^U#_@SJ_P"1J_;_ /\
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M"EMX(F_X5KXG\5:YJ5C%?ZA>:Q9>)K#P_H<,NC)!)XBO+K5;#1OUY_X(N?\
M!1?XZ_\ !2#]G?Q1\4/CY^S_ !_!;Q)X8\3:7I&B^(?#VD^,=)^&OQ9T+5=&
M6^7Q3X A\9MJ%^+73]1@OM-U*"T\3^++. MI[#63//-;0>,_'/XE_P#!$7_@
MAUIW@[0=:^#'PK^'OQ+U?PB=5\&>%OA]\([7XF?M!>*_#6B7$NF6^K:KXXU^
M.[UZ&VO]5MKVQTW7_B1\0=&M->U>QUE;+4KRXTC6&LOJS_@F/_P51^%'_!4G
M0/C+XP^#WPW^(?P^\+?"+Q1X8\+-+\2I?#<6O^(+OQ%I.HZL;D:1X7U;Q#IV
MEV]E#91Q 'Q!J,ES).YV6ZP*9_S[,:6!ED4JN6<,XVAA*=6$EGV/Q'[^HI5E
M"RITX0HU%-M4;4G.G3LWR^T4IG?3<U6M4Q$)2::]A".BLD[W;<D[:ZI-WT=M
M#^%K_@Y2_9]\!_ '_@J)X[?X=^'['PMHOQJ^&W@3XY:GH>DVEC8:/!XM\47/
MB/PQXOU+3K&Q5$MV\2^(?!>H>*M9:=%GN_$FMZU?D>5=PD_WF?\ !'__ )1=
M_L'_ /9LWPO_ /4?MZ_BB_X.N]06\_X*=>%[<1&,Z3^RG\*M/9RP83M)XX^+
M6J>:H"C8 NI+#M)8EH2^X!PJ_P!KO_!'_P#Y1=_L'_\ 9LWPO_\ 4?MZ]KBF
MI4J\%\+3JR<YOV2<I.\FHX2I&+;=VWRJ-V]6]7J8X9)8O$I*RUT7^),_'#]K
M3_@XH_9C_P""9_QLA_80^!W[)^K?$OP)^S99:#\*O$^L^'/B7H?P^\.>"F\/
M:%HL2^%/ >B#P?XUF\877A6":?0?$CZ]JO@F6W\5:3J-BTNH9FU0<W_P1+_X
M+M>,/VS?VEM9_90\=? V6V\0?%#QC^T/\=$^,,OQ3AO!H7AZ;5K[Q1X,^&D'
MP]@^&>GK<67@GP=_8/P^L-=D\<"YO++0+?5KNQ>[N)H*_B;_ &[-3N-:_;>_
M;(UF[YN]6_:J_:&U.Y(9W!N+_P"+GB^ZF^>5GD?]Y*WS2.[MU=F8DG]9/^#8
M>\M+;_@K1\,8+FZMK>;4?A3\;+/3X9YXHI;Z[3P/=Z@]K9QR,KW-REA8WMZT
M$ >5;2SNKDJ(;>9T^@QW"62X3AG&XKZK*KCEE;Q=3%5,1B95)XNG0G6=9KVO
M(KU)RE*FH^RG:/M(3<4S"&*K2Q,(\R4'4Y%%1C90<DN7:^R6NZULU<_MX_X*
MZ_\ !3K_ (=6_ 3X>_&__A2/_"]_^$\^+VG?"K_A&/\ A97_  K#^ROM_@SQ
MGXN_M[^VO^$!^(?V[RO^$1_L_P#LO^R;/S/[0^U_VBGV3[-<_P 9?_!./]JG
M_AMS_@X^^#G[5'_""?\ "LO^%Q?$+XB:]_P@G_"4?\)I_P ([_9O[+'CGPU]
MD_X2?_A'?"?]K^=_8GVWS_\ A'M+\O[5]F\F3R?/E_=K_@[J_P"3"?V>_P#L
M[SP[_P"J9^,U?RU_\&^/_*87]C#_ +&#XL?^J ^*]>=PMEN"I\'9OFD*-L?7
MRS.L+5K^TJOFH1I3E&'LG4=&-I4X/FC34W:SDTW?3$5)O%TJ;?N1JT9*-EHV
MU=WM?J]&['^B?_P4=^-O[/\ ^RA^SKJ/[8_Q_P# <7Q$MOV7]7M_'7PN\/\
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MU\UG7_(WX6_[&.-_]5>*.BC_  L3_P!>X_\ IR)_*51117TISA1110 4444
M%?Z)G_!H]_RC?^-?_9[GQ(_]41^S97^=G7^B9_P:/?\ *-_XU_\ 9[GQ(_\
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MM&M(3HANHY)+DS7MPKQ)#^-GB#_@[(_X*8ZS9SVVG> /V0_"4\L#0QZCX?\
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M'TC2%O[R_P!0%E]MO[RXG_K5_P"#.K_D:OV__P#L7_V:?_3C\<J[<QX?7#O
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MNYP2<G+D=2E"LHN3C&HDXI1C&*3G*K@)RJ/FE&2M)[Z3C:_G9M7ZKSU/7?\
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MKEVE"M*G45.M3Q$9)Z3BFUIJHRA+E;?2Z23M:V[_ )$/^" 7_!/7PO\ M_\
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M?M%7OC[6Q\8?AK;0^/O@II?PB\8^(_$OP]\87=E#=1Q:+XPUC2/"W@B]\4>
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M]6G[5?\ RJB_\$YO^SO/$_\ ZGG[<5?REU_5I^U7_P JHO\ P3F_[.\\3_\
MJ>?MQ5_*77S7#'\#-_\ LH\\_P#4V9T8C>C_ -@]'_TA!1117TISA1110 44
M44 %%%% !1110!_I5_\ !K3_ ,HK-&_[+[\8O_1OAROC;_@L?_P;_?MD?\%"
M_P!M[Q3^TK\%_B7^S-X8\"ZYX$^'OA>TTGXH>,OBGHOBR/4/">A_V9J,UQ8^
M%/@SXUT=+.>?Y[*2+7III(?FGM[9_P!W7V3_ ,&M/_**S1O^R^_&+_T;X<KX
MV_X+'_\ !P#^V1_P3T_;>\4_LU?!?X:?LS>)_ NA^!/A[XHM-6^*'@WXIZUX
MLDU#Q9H?]IZC#<7WA3XS>"M'>S@G^2RCBT&&:.'Y9[BY?]Y7X;1_MG_7;//[
M"^K_ %WVN.YOK/+[/V'MZ7M/BTYN;V=NMKV/9E['ZI1]MS<EJ?P[\W*[;=+7
MN+_P3"_X-A-<_9;_ &C?A;^TS^U=\<? GQ"U;X.:UI_CKP7\*OA-I'B"Y\-/
M\2]#N;>_\)^(]>\=>,-/\.ZI>Z7X.U6%->TW1]/\%Z3=ZCXALM$OKK6;33M-
MO]$UO[U_X.2?VQ?!?[./_!.7XD?")M?TU/B]^U1'9_"OP'X4-RLFK3^$VUC2
MM1^*?BN?3H+^ROT\/Z3X0M[OPZVJJ)[.'Q3XK\+V5Y:W=M>7$!_F4\3_ /!V
M'_P4TU_3[NRTKP3^R3X)N;FSEMH=7\,?"WXBW>H:?-(KA-0M(O&?QE\7:4]Y
M 65HDO\ 3+VP+1H)[&93(K_@#^T+^TE\=OVK_B;JOQC_ &BOB?XH^+/Q(UBV
MMK&Y\2^*+J%WM-+LGGDLM$T/2[&"RT3PWX?LIKJ[GLO#_AW3=+T6TN+R]N+:
MPBGO+F27Z3"<+<0YGG6$S7B;%8:5/ SIU*.'H.,G)TJGM:=*,*=.%*G2]K:5
M6<I3JU$O9M--3ASRQ-"G1E3P\97FFG*5]+JS;;;;=M$E9)Z^O]</_!G5_P C
M5^W_ /\ 8O\ [-/_ *<?CE7[C_\ !9__ (*O>"?^"4WA7P)XJ\,_"?0?B?\
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M*G*M&\[0C.\G&(\8X1J82I+WHW;D[:RBG3>W7=M+;5KJ?Z>G_!6?]L/]MO\
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MZY9^([O3M77Q&D4FD>'Y;*W.K_-O_!WG_P F;_LO_P#9S,__ *JSQM7Y%?\
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MT/X7_P#JS?C;7X"_!_\ :I_:?_9YT_6M)^ /[1_QZ^!VE^)+RVU'Q%IOP?\
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M#/C+4;>;Q3K.E^*]:LY'2^^(NI3ZH_BSQV9R+[^VO$CSZBD%_<W-I;?P3_\
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MY--M5L6JL*<8PY)4YJ2LTXKE344O33[OD?ZWO[3/P&_9T_X*M_L3^(/A:WQ
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M^4FW@W_LTSX6?^K"^,5?S*5X?"G_ "3F3?\ 8#1_)FV)_P!XJ_XV%%%%?0&
M4444 %%%% !7^S[X._Y-^\+?]D<T/_U";6O\8*OM"'_@I!_P4/M]/BTFW_;T
M_;0@TJ"S33H-,A_:C^.$6GPZ?% +:*PBLD\<K;1V<=LJVZ6J1"!( (E01@+7
MQW%O#-?B-9>J&*HX;ZE/$2E[6$Y\_MO864>3;E]B[WWNK=3KPN(CAW-N+ES*
M-K-*UK[W]3VO_@B]_P I4_V%O^R^^%O_ $5?5_>;_P ')O\ RAZ_::_[&#X!
M_P#J_P#X:5_F/>"_&_C3X;^*M"\=_#OQ=XG\!>-_"^H1:MX9\9>"]?U7PMXJ
M\.ZI &$&I:%XAT.[L=7TC4(0S"*\T^\M[F,,P209.?>OB5^V_P#MI?&;P=J?
MP[^,'[7O[4/Q7^'^MR6$VL^!OB5\?_BOXZ\':O+I6H6VK:7+J?AGQ1XLU31;
M^33=5LK/4[![JRE:SU"TMKRW,=S!%(E9UPU7S3/<GS:GB:5*GED\-.I1G"<I
MU?88OZRU"4?=CS1]U<VSU>@J6(C3H5:3BVZG-9IJRO%1U7RN5_V*_P#D\C]D
MO_LYGX#_ /JT_"M?ZE'_  6 _P"47?[>'_9LWQ0_]1^XK_)1T36]9\-:SI'B
M/PYJ^IZ!XAT#4[#6]"UW1+^ZTK6=$UG2KJ*^TO5](U2QE@OM-U/3;Z""\L+^
MSGANK.ZABN+>6.:-'7ZE\8?M_P#[>/Q#\+:]X'\?_ML_M<>.?!7BK3+K1/$_
M@_QA^TC\9/$WA;Q'HU]&8;W2->\/ZUXSO=)UC3+R(F*ZL-0M+BUN(R4EB=21
M2XBX:KYUF.48VEB:5"&6U%.<*D)RE52KT:MH..BTIM:]6NEQX?$1HTZL'%R=
M1:--*VC6OWW/L[_@B)_P4=TS_@FU^VAI7Q#^(,FKR? 7XI>';GX6?&V#2+:[
MU2ZT;0-1O['5/#_Q LM#M9!)JE_X$\1Z?:7EW%:VU_K$G@_4/&.FZ!8WFKZG
M:VD_]^__  4 _P""=?[)?_!9;]G[X;7NI>/$*Z5%+XT^!'[0WPEOO#_B9K+3
M/%EE9'48+::07>E>*_!'BFWLM)NM5T:.^T^:6]TC2KNSU73KJS<R?Y05>]_"
M3]JO]J'X V%[I7P)_:1^/?P5TO4;EKS4--^$GQA^(?PXL+^[=(XWNKVS\'>(
MM&M[JY>.&*-IYXY)62*-2Q5% G/^%:F99AALXRS'RRS-,/%0=;D=2%6,4XP<
MDFG&<82E3DVJD*M)JG.%E=E#$JG"5*I#VE.3O:]FMK^JTO;2SUN?Z$/[ G_!
M'_\ 8H_X(J>)=)_:"^,O[04?Q4^/7Q U[1?@9\*O&?C30](^'.EV_B/XH:_'
MX=TWPC\'_AE%XC\6ZI>>/?&$6H66C:WJ\_BKQ'>VOANTUNZL8O"GAF\\6_:?
M2?\ @YI_Y1&_&G_LH?P-_P#5H^'J_P WWQC^T3^T#\0_'?ASXI>/_CI\8_'/
MQ-\'WVG:GX2^(OC'XG>-O$WCOPMJ6CZE'K.D:AX<\7:UK=[X@T2^TK5X8=5T
MZ[TS4+6XL=2BCOK:2*Z191W7Q-_;9_;-^-?A&]^'_P 9?VN/VG?BWX"U*XL;
MS4?!/Q-^/?Q5\>^$;^[TNZCOM,NKWPWXJ\5ZKHUU<:=>PQ7EC//922VEU%'<
M6[1S(KCREP7F=3-\NSG'9U''8K#8FAB,4ZE!THN&'JPJ0H8:%/W*<$E/[,(N
M<[JG%\SEH\735*I1A1Y(RBU&TKZM6;DWJW\V]-^W]6?_  9U?\C5^W__ -B_
M^S3_ .G'XY5Y%_P=]_\ )T?[)/\ V0+Q1_ZL2_K^7;X.?M)_M%_L[2^()_V?
MOC[\:O@7/XLCTR'Q5-\'/BGXY^&,OB:+16OGT>+Q!)X*UW1'UF/27U34WTQ-
M1:Y6P;4;YK41&[N#)3^+_P"T'\>_VA-4TC7/C[\;_B]\<-;\/Z?+I.@ZQ\7_
M (E>,_B7JFB:7/<M>3Z;I&H>--:UJ[TW3YKMVNI;.SFAMI+EFG>,RL6/L0X:
MKQXMJ\1_6:3H5*2IK#<D_:IK T\)=S^"W-!S_P +2W,OK$?JOU?E=[WYKJWQ
M\VV_D?W9_P#!MO\ \%</A;\2?V?_  -^P3\=?'.D>#_CM\'HI?"WP5N/%.H6
M>EV?Q?\ AB)KB\\.>&_#]],EG82>-_A]:ROX73PL7_M76?".FZ#K&E'6[NV\
M5-I7:_M??\&L?[-_[2?[2/BKX\_#_P#:#\=_ ?0_B5XPU7QQ\2OAA8>!-#\<
MZ7/KNOW!O_$$OPZUV[\0^&KCP-;ZQJ\M[K4UEK>E^/K*QO\ 4;J#2+?3M%CT
M_2+'_.YKZ^T#_@H/^WQX4T>#P]X7_;?_ &OO#>@6MNEI:Z'H'[2OQGT?1[:U
MCB$$=M!IFG>-+:RAMXX56%(8X%C6("-5" "N'%<(8[#YGBLTX=S?^RYX[F>*
MP]2A&M2<YRYYRIJ2G#EE-RG&$J3=*;E[*I&$E"%QQ4)4XTZ]+VJA;EDI6=EH
MKVL[VT;O[VEU>[?^F_\ &'X[?L9?\$3?V&/"^@:EJNG^%_ 'P;\"-X5^#OPO
M74]/D^(_Q<\4P1W5Y%IFC:=#%!<ZSXE\8^)KN[USQKXL_LZ+1],O-5UGQ5XB
MGL+!+F5?Y'/^#>/_ (*5^$] _P""EG[3.J_M->(="\)ZW_P4 N]0URV\=:OJ
MK:9X;TWXS'QWK7C+1_!,EQJTSVVF:/XLA\7>(]$\-3ZAJJF#6]+\)^%;..[N
M-?@:W_EY\?\ Q(^(GQ7\27/C+XI>/?&GQ)\7WL4,%YXJ\?\ BG7/&/B2[@M]
M_D0W.N>(K[4=4GBAWOY,<MTZ1[WV!=QSQ=:8#@C#8?+<UPF+Q=7%XS.(KZUC
M>7E<)0J>WING"4I2ERXBU6K*<[UVDI*"22*F,E*I2E""C"E\,+WOI9W:2M[N
MBLO=\S_4U_X*Y_\ !%SX8_\ !5RV^&/B*_\ B]K_ ,#OBI\*K#6-#\.^-],\
M(Z?\0?#^K>%?$.I:9JE_H_B;P?<:_P"#[W47LI["XF\.W^E^,=%_LVXU?4IK
MZUUF&2&VAVO^":'[%7[#?_!*W6]2_8^^%'Q8A\;?M3?&3PP/BW\1)/%FIZ1)
M\3?%GA+X?RV^BV&HMX8T&!;7P3X!T*^\8WY\):3J,DUYJ-SK'B.YBUGQ'+8:
MC/8?YL'A7]O3]N;P+X8L/!/@C]L_]K#P=X,TJQATO2_"/A7]HKXO^'O#&FZ9
M;0K;V^G6&@:1XQL]*L[&"!%@AM+>TCMXH56-(U10H\D\&_';XW_#KXCW'QB^
M'WQD^*O@7XN7<NKSW?Q3\&_$/Q=X8^(]U/X@CEBUZ:X\;Z)K%CXFFEUN*>>/
M5Y)-49]2CFE2],RR.&\N/ ^<SRV>45^(N;+::G+#86GA5",JKFZM/ZQ-R=3V
M,:UJCH\U6*E[T.224C3ZY253VJH6J.RE)RN^71.RVYK:)Z>=UH?U3_\ !WU\
M*+[3/VF/V3?CD+.\.F^-O@7XC^%#7^Z1]/2^^%WC_5?%\=F5%JL5M>2V_P 8
M))@S7LLE]#$PCM8%T^26X_0;_@T3^+?@2\_9 _:,^!,6OZ>/B9X:_:4U3XL7
M_A>2X6/5'\#^.OA=\*_".C:Y:VKA6NK%==^'.OV-Y-;-,+*?[$EZMM]NL3=?
MQ ?%[]K;]JS]H+0]-\,?'O\ :;_:$^-WAK1M677M'\/?%[XS_$?XE:'I6N)9
MW6GIK.FZ3XS\2:U86.K+87U[8KJ-K;Q7BV=Y=6PF$-Q*C^4>!_'WCKX8^)]-
M\:_#;QIXL^'OC+1GEDT?Q;X'\1ZQX3\3Z2\\,EO.^FZ]H-Y8:K8O-;RRP2M:
MW<1DADDB<E'93[53A:MB>%:7#V(QE-5Z'*Z>*ITY2IMTJ\JM)3IR<9<OLY>R
ME:5TTJBO\#Q6)4<2Z\8OEEO%O76*3L_576GEIN?WF_\ !:O_ ((+^ OBYXB_
M;D_X*:CX^>,='U/2?V?=<^+;_!6Q\#:5>V,_C7X)?"&TLFNSX[N/$!NXO"NN
MZ!X$LY]1T(>%'U'3]6N-4U"U\3C3'M-%L.S_ .#17_DPG]H3_L[SQ%_ZIGX,
MU_#UX]_;G_;:^*GA[4/"7Q/_ &Q/VI_B/X4U>SN-.U7PSX]_:#^+7C#P]J>G
MWD;0W=CJ&B^(?%VHZ;>V=U$S17%M<VTL,\;,DJ,I(KG?A%^US^U=^S]H&H^%
M/@+^T[^T-\$?"^KZQ)XAU;PW\(OC3\2/AMH&J:_-966FS:YJ.C^#?$NBZ=>Z
MQ+IVFZ=82:G<VTMZ]E865JTY@M8(X^.IPKF^)X=J9)C,VH8B4:N#6$J/#N%/
M#8;"1C"-#W%&=1VBK3G>6GO2=[EK$THUU6A2<5:7.N:[E*6[UT5M=-O)'[)?
M\'/_ /REC^(7_9(/@K_ZB8K^E/\ X-__ /@L9\(/VE/V>/AC^R!\>/'VB>$O
MVH_A#X;TSX;>&[?QGJUMIT7QW\$>'[.;3_"%_P"%-0UK4)9/$7CS2?"FGV>E
M^-M!EN)=<U:YTZX\7V-O<V&HZC;Z+_GL?%#XN_%?XW^++CQ]\:/B?\0_B]XZ
MO+.RTZ[\:?%#QKXD\?\ BRZT_38?L^G6-QXC\5ZGJVL3V>GP?N+*VEO&AM8?
MW<"1I\M>>5Z6+X4P^8</X#)L76Y:^ H4(4,91A=TZU*DJ<I*$FG.E42M.FY1
M<DHM2C.,9+.&*E3KSJQ5XU)-R@WNF[VOK9KH[?*SL?Z$O[27_!IY^RQ\7OCK
M>?$[X/?'GQI^SM\-_$VOWVO^+_@KHWP_T+QGH]@^H2P3W&E_"?Q!<^(_#;?#
MO1%F^W36FDZWH'Q#LM+-Y%9:/#IVBZ?9Z3'^GOCSXO\ [ W_  0/_8@\+^ '
MUE="\+^"-!UE_AK\,9->T_6/C9\>?&US=?;-<U2WM)/LDVJ:MK_B'48[OQ9X
MI73M,\%^#K:]@A2'0]#M-&T5/\U;P[_P4!_;R\'Z%;>%_"7[;7[7/A?PU96J
M6-GX=\._M)?&31-"M+*.(01V=MI.F>,[6P@M4@ A2WBMTB6("-4"#%?.'C7Q
MUXV^)/B34O&7Q%\8^*O'WB_6'275_%?C7Q#J_BGQ)JLD4:PQ2:EKNN7E_JE\
M\<*)$CW5U*R1HJ*0J@#QI<&YQF'U;#9YQ#4QN6X2490P]*A[.K6Y$XQ]K6;4
MN?EE*/MJKQ%2,7*,'%RYEJL72I\TJ-!0J25G)RNEUT7:ZV7*FTF[['JO[5'[
M1WC_ /:[_:)^+W[2GQ0FMG\;?%_QGJ/BO4[6R1$T_1;)UAL/#WAC2PL43OI/
MA/PW8Z1X9TJ:Y$E_/IVDVTVHW%U?27%S+_KB?M _\F9?&W_LV+XD_P#JJM:K
M_&\K[(U#_@HM_P %!M6T6^\-ZK^W9^V1J?AW4]+N=$U+0=0_:>^-E[HNH:+>
MVCV%YI%]I=SXWEL;O2[NQEDLKFPG@DM)[21[>6)X79#Z?$O"T\Z_L:&$KT,'
M2RIU5&G*G-Q=.7U14Z=-0TBJ<,,XI/2SBELS/#XE475<HN;J6U32UO)MN_>Y
M\;U_L"?\$SO^4;__  3\_P"S(_V4O_5$> J_Q^Z^P/#/_!0O]OSP5X;\/^#?
M!O[<7[8/A+PAX2T/2?#/A7PKX9_:7^-&@^&_#/AO0;"WTK0_#_A_0]*\:VFE
MZ-H>C:9:6NFZ3I.FVMM8:=86UO9V=O#;PQQKMQ;PY7XCP^#HT,32PSPU:I5E
M*K"<U)3@H62AJFK7U%A:\</*4I1<N:*5DTK:WZGQ_1117UIRA1110 4444 %
M%%% ']#O_!KY_P I8/ O_9&OC3_ZC4%?CW^VI_R>1^UI_P!G,_'C_P!6GXJK
M]A/^#7S_ )2P>!?^R-?&G_U&H*_'O]M3_D\C]K3_ +.9^/'_ *M/Q57S>'_Y
M*O,_^Q+EG_J5CSHE_NM/_K]4_P#2('S-1117TASA1110 4444 %%%% !1110
M 5_:A_P9U?\ (U?M_P#_ &+_ .S3_P"G'XY5_%?7M7P<_:3_ &B_V=I?$$_[
M/WQ]^-7P+G\61Z9#XJF^#GQ3\<_#&7Q-%HK7SZ/%X@D\%:[HCZS'I+ZIJ;Z8
MFHM<K8-J-\UJ(C=W!D\;B#*ZF<Y/C,MI5849XE4%&K4C*4(^QQ-&N[QCJ[JD
MXJW5IO0UH5%2JPJ--J+=TMW=-=?4_KF_X/%?^1J_8 _[%_\ :6_]./P-K^*^
MO:OC'^TG^T7^T3+X?G_:!^/OQJ^.D_A./4X?"LWQC^*?CGXG2^&8M::Q?6(O
M#\GC77=;?1H]6?2],?4TTYK9;]M.L6NA*;2W,?BM'#^65,FR?!Y;5JPK5,,J
MRE5IJ482]KB:U=64O>5E547?JGT"O45:K.HDXJ7+HW=JT5']+A7]8W_!J%^V
M!\'O@3^T-^T1^SU\4/$6G^#];_:BT+X33_#'7]>O[#2_#^I^,/A+?_$.#_A
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MQKX&I@JE2"U4:N'E0E.*?5*3E%/K:YR*?+451+6,U-)^4N9)G^M%_P %7_\
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M+X3US6[RR\.>%]1NK?\ 'CXC_MR_ML?&+P9K/PX^+G[87[4OQ3^'OB+^SO\
MA(/ ?Q'_ &@OBSXW\&:[_9&JV.NZ3_;/A?Q-XNU30]4_LO7-+TW6=.^VV,_V
M+5=.L=1MO*N[2WFC^6JY,FX0C@\@Q^19C7AB:>.Q-2NZE",H.GS4<+&G*/M$
M_P!Y2JX958MIQ;Y5*+7,G=7%.5>%:G%Q<(J-I.]]9-IVZ-2MWZZ'^I#_ ,%1
M/^",/[-7_!6[3_ GQ9M/B;/\+OBYH7A:+1/"'QR\!:9HWQ"\.>+? ES=SZOI
M6E>*/#Z:UHMKXQT73;O4=3U#PUJ&B^+M!O+1]7O@=2OK"9+-/1_V+_V$?V/?
M^"-/['/C/P]XV^)&A:AX+;5W^(WQO^-GQIBT#0]+U[Q"-(L-#@%KH=Q+?V&A
M:);6UDMCX4\'VMYKVL276H7%N-1U_6-2DFN/\QOX5_M<?M6_ K1SX>^"/[3G
M[0GP<T W$]V=#^%?QH^)'P]T<W5T2US<G3/"/B72+(W%PS,T\Q@\R8L3(S$F
MN?\ BU^T7^T'\?)M/N/CK\=OC+\:9])>:32IOBU\3_&WQ&FTR2X&+A]/D\8Z
MYK+V3SCB9K9HVE'#EJ\C_4?.9X:EE-;B24LFI5E4C0CA;5E&,G*,5)S;23UC
M"5:=&G/WXTFTD]?KE)2=6-"U9JSES:;;Z+7S=DVE:_;ZG_X*E?M6?#']LO\
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M(\>U_C]U]@>)O^"A?[?GC7PWX@\&^,OVXOVP?%OA#Q;H>K>&?%7A7Q-^TO\
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M6(_57A^5W;^*ZM_$4]M^EC^@[_@TW_Y28^/_ /LT/XH_^K-^"5?JW_P>!_\
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MF:RU#3]0LITN;.^L;RV>*XM+RTN(H[BVN;>2.:">-)8G21%8?7MO_P %&/\
M@H/::<NCVO[=O[95MI"Q^2NE6_[3WQMATY8L@^4MC'XX6V$>0#L$07(''%>;
M4X.S' XW&8GAS.GE=''MNOA:E"-6$&W*5J4FI)*#G/V+]G"K1B^6-5IMFBQ=
M.<(1Q%'VDJ?PR4K7VW7G9<VK4K;'^D7_ ,%0_P#@HY^S[_P2A_9%NO#GA;4_
M"6G_ !B3X=0_#G]EWX#Z'+:MJ-I<:=H,7AOPGK5[X<L)8[C0?AE\/+*&SO\
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MHHJP"BBB@ K[)_X)T?\ *0?]A/\ [/)_9A_]7;X'KXVK[)_X)T?\I!_V$_\
ML\G]F'_U=O@>N7'?[EC/^P7$?^F9ET_XE/\ QQ_]*1^D7_!RY_RE[^/_ /V)
MGP)_]4SX+K\%*_>O_@Y<_P"4O?Q__P"Q,^!/_JF?!=?@I7!P[_R(,D_[%6 _
M]1:1>(_CUO\ KY/_ -*84445[)B%%%% !1110 4444 %?T+_ /!L!_REC^'O
M_9(/C5_ZB9K^>BO0_A?\7?BO\$/%EOX^^"_Q/^(?PA\=6=G>Z=:>-/A?XU\2
M> /%EKI^I0_9]1L;?Q'X4U/2=8@L]0@_<7MM%>+#=0_NYTD3Y:\_-<'+,<MQ
MV!A.-.>+PM;#QJ23<8.K!P4I):M*]VEJRZ4U3J0FU=1E&32W:3N?Z-'_  =+
M?\HK-9_[+[\'?_1OB.O\U2OI7XI_MG_MA_'/PJ_@3XV?M8?M*_&'P1)J%GJT
MG@WXI_'7XH_$'PK)JFG&0Z?J3^'O%OBG5](;4+$S3&SO&LS<VIED,$B;VS\U
M5YG"V1U>'\LE@*U>GB)O$U<1[2E&48I5(4HJ-I:W7LVV]G=&F)K*O4YTG%<J
M5G9ZJ_8*^O/^"?7_ "?M^Q%_V=Y^S7_ZN;P77R'6OX>\0Z_X2U_0_%?A37-8
M\,^*/#.L:9XA\-^)/#VIWNBZ_P"'M?T6]@U+1]<T/6--GMM1TG6-)U&VMK_3
M-3L+FWO;"]MX+JUGBGBCD7W<13=:A7HIJ+JT:E--[)SA**;MK9-W9C%V:?9I
M_<S_ %</^"XG_*)S]N#_ +) /_4L\,U_D\5]8^.?V]?VY_B=X3USP#\2OVT/
MVL?B'X%\3V?]G>)?!?CG]HOXP>+/"?B'3_.BN/L.N>'-?\8ZAH^K6?GP0S_9
MK^SN(?.ABDV;XT8?)U?-\)\/UN'<%B<+7Q%+$RKXIXA3I1G",8NC2I\K4]6[
MTV[K2S74Z,575><9*+C:/+9M/JW?3U/]@3_@IC_RC?\ ^"@?_9D?[5O_ *HC
MQ[7\2W_!JW^V3\'_ -G;]J3XT_ [XM>(--\&2_M1^%O .F_#SQ9KVH6VF:!)
MX]^&^J>*I].\$7M]=R0VMEJ'C/3_ !OJ7_"/S74T45[K6B6GA^W,NJZ[IEM/
M^$GB;_@H7^WYXU\-^(/!OC+]N+]L'Q;X0\6Z'JWAGQ5X5\3?M+_&C7O#?B;P
MWKUA<:5KGA_Q!H>J^-;O2]9T/6=,N[K3=6TG4K6YL-1L+FXL[RWFMYI(V^/Z
M\K*>"I83)<VR;&XN%6&93I3C6P\)1=&5'DE3DXS:Y^6K3A-QNE.*<6U>ZUJX
MSGJTJL8->SOI)[WW6FVETGKWMT/]17_@KG_P0Z^%7_!53Q!\.?B3-\7]<^ O
MQE^'7AF7P'#XVL/!-A\1="\2^ VUR[\166@>(O"EQXD\%:A+<Z!J^K>(;OP[
MJ6F^+]-BLV\3:T-2T[6!)8BP]1_X)L?LG_L+_P#!,74]2_84^"/Q3C\8_M)^
M/O"NH_M ?$V'Q3JVG:C\4O$WA7PIJ?A_P;:Z_KNF:!96^D>"O">CWWC*TTWP
M+X:NUM+W4X[SQ1JVG2>)+C3O%^LVW^:=H'[??[=GA/PU9^#/"W[:G[6OAKP?
MI]E!ING^%- _:.^,6C>&K'3K:"*UMK"ST+3O&5MI=M96]M!!;P6L-JD$4$,4
M,<:QQHH\B\ _'OXZ?"GQ]J7Q6^%WQH^+/PV^*.M+K"ZQ\2? /Q&\8>#O'VK+
MXBNUO_$"ZEXQ\.ZQIWB*^77+Y$O-8%UJ,HU.[1;B]$\RAQPK@C.JF6RRG$\1
M<^7T5)X3"T\,HP=3FYZ?UBHVZKHPG[ZH\U6*=O9NFTF7]<I*I[6-"TY-<TG*
M[M:SY5HE)K2^E^MS^G/_ (.V_AUXD\)_MT?LV?&T6MFWACQS^SAI_A31)[ZW
MMM4@N?&'PD^)_C76O$UI=Z3J5A/I5WIL&C?$OP'(UI>"_@OVO;Z"^LUM3&ES
M_3/_ ,$T_P!J3]@;_@IY^QK?^"/!/@+X.^"M?\3_  JO_AK^TS^S+X8T7PYX
M*UKPK'XF\/7GACQC;:=H_AZUT74KGX=>(XM2U9_!_C/1(H[9K&_^QS3Z1XJT
M_6-)TW_-+^+_ .U?^U+^T)I6D:%\??VE/C]\<-$T#4)=6T+1_B_\8_B)\2]*
MT359[9K.;4](T_QIXCUJTTW4)K1WM9;VSAAN9+9V@>0Q,5/COAGQ1XE\%Z]I
M?BKP=XBUWPGXGT.Z6^T7Q'X9U:_T'7M(O45D2\TO6-+N+74-/NE1W5;BTN(9
M55V4. Q!]3$<'3QF0Y9EE?'.CCLJ4_JV-PT9^R:=3FC&I1<X.2Y8TDI*:G3J
M0]I!\LI4Y9QQ:A7J5(PO"I;FA*UUHDVFM-[]-4[/74_NNO\ _@S\^!DWQ,?5
M]/\ VT/BG8_!Y[N25? $WPJ\*7OQ$BM&,A2UC^*W_"5VWATR1;HE%S+\()=R
M1N'A+R!X_P!G?^"BG[>?[.'_  2;_8L7PO=^++34OB-I'P@B^%G[-WP@U3Q"
MWB/XB>.-4T#PE#X2\*ZKXA6YNGUR;PGH'D:=J/C_ ,>:N8X7BCEM8;F_\5:U
MHND:G_FSC_@H_P#\%#A9?V:/V\_VSQIVPQ_V>/VH_C@++RV8NR?91XY\C87)
M<KY>TL2Q&3FOE+Q;XP\6^/O$6J>+_'7BCQ%XT\6ZY-'<ZUXH\6ZWJ?B/Q%K%
MQ%!%:Q3ZIK>L75YJ6H31VMO!;1RW=S,Z00Q0JPCC15Y)\'9MF>(PDN(L]688
M3!3YZ>'HX:%&536%XSJ15.W.H)5*CC5JN*:C.$I<ZI8NE3C/V%'V<YJW,Y-V
M\TG?;HKI=;='^J7_  11_P""B&G_ /!.#]MOPS\4O'$NI-\#_B+H-[\)_CA#
MIUO?ZG<:7X/U[4-,U/3O'%CHEC*7U+4O OB;2-)UB9+>QU/6)_"K^+-&T&SF
MU/6XHY/[]_V^/^">G[(7_!:C]GKX<ZNOQ(LYVT6.^\3? O\ :*^$E_H7BT:7
M;>)K.S&K:=(GGOI?B?PEKC6.CW&N^');[2]1COM(LVM-5T2^@N&?_*4KVGX3
M?M)?M$_ /[?_ ,**^/?QI^"W]JSQW6J?\*F^*7CGX<_VE<PHL<-Q?_\ "'Z[
MHWVR>*-5CCFN/,DC1556"@ >GGW"L\RQ^'SC+<?++,UPT8P]LJ?M*=6,>91Y
MTFG&:A.5.3:J0J4FJ4Z;BKF=#$JG"5*I#VE*3O:]FGI?Y72:V:>J9_IA?\$Q
M?^"0?[.?_!(?X:_&#Q1XC^+$'Q1\4>.M)L)_BS\8OB1HVA?#SP/HG@CP;-JN
MIV>GZ;X9O]>\1Z=X3T"U^WR:EXCU#7/%NMS:C>VEM=R7MC8V=II]K_$5_P %
MX_VU_P!GO]LG]LEI/V7/ ?PYT/X/?!S0;KP%IGQ(\%^"=#\+ZK\:?$5QJT^J
M^*/&FIZGINE:7J6L>%;:_=-(\"0:M]J$=K;ZUXHL984\:7%M#^9/Q7_:R_:G
M^/.EPZ'\<OVE_P!H#XS:+;W,=[;Z/\5_C+\1?B)I<%Y"NV&[AT_Q?XCUBTBN
M8E^6.=(5EC7A7 XKY_HR3A?$8',J^=9KF4\RS*M!P4HT_8T::<8TW+DBTIR5
M.*IPBH4Z=.#:4&W&42MB8SIQHTJ:ITT[VOS-];7:NM=6[MM[ON4445]B<@5_
MKR?\$J/^49W[ O\ V:'^S]_ZK+PW7^0W7UYX4_X*#?M[>!/#.@>"O _[;W[7
MO@WP;X4T?3_#WA;PEX4_:4^,WAWPSX:T#2;6.RTK0] T'2/&EGI6C:/IEE##
M::?IFG6EM965K%';VT$<4:H/D^+>'*W$>%PE"AB:6&>'KRK2E5A.:DI4W"R4
M-4U>^NG0ZL+7CAY2E*+ES12LFE;6_4\B_:$_Y+Y\</\ LK_Q+_\ 4TUJO(*N
M:CJ.H:OJ%]JVK7UYJ>J:G>7.HZEJ6HW,U[J&H:A>SO<WE]?7ER\MQ=WEW<2R
M7%S<W$DDT\\CRRN\CLQIU]33BX4X0;NX0C%M;-QBE?\  Y6[MON[A1115@%%
M%% !1110 4444 %%%% ']6O_  <V?\B9_P $G/\ LT2[_P#35\**_E*K^K7_
M (.;/^1,_P""3G_9HEW_ .FKX45_*57S?"/_ "3V _Q8W_U88HZ,5_O%3_MS
M_P!(B%%%%?2'.%%%% !1110 4444 %?7G_!/K_D_;]B+_L[S]FO_ -7-X+KY
M#K7\/>(=?\):_H?BOPIKFL>&?%'AG6-,\0^&_$GA[4[W1=?\/:_HM[!J6CZY
MH>L:;/;:CI.L:3J-M;7^F:G87-O>V%[;P75K/%/%'(N.(INM0KT4U%U:-2FF
M]DYPE%-VULF[L<79I]FG]S/]<W_@JO\ \HSOV^O^S0_V@?\ U67B2O\ (;KZ
M\\5_\%!OV]O'?AG7_!7CC]M[]KWQEX-\5Z/J'A[Q3X2\5_M*?&;Q%X9\2Z!J
MUK+9:KH>OZ#J_C2\TK6='U.RFFM-0TS4;2YLKVUEEM[F"2*1D/R'7S/"7#M?
MAS"XNA7Q-+$O$5X5HRI0G!14::@XM3U;NKW70Z,576(E&2BX\L;6;3OK?H%%
M%%?6',?[(?[/W_)F7P2_[-B^&W_JJM%K_&\K[(T__@HM_P %!M)T6Q\-Z5^W
M9^V1IGAW3-+MM$TW0=/_ &GOC99:+I^BV5HEA9Z18Z7;>-XK&TTNTL8H[*VL
M((([2"TC2WBB2%%0?&]?(<*\-5^'IYI*MB:6(6/JT*D/90G!TU2>);4N?=OV
MZM;^5WW1U8G$1KJDE%Q]FFFVUK=1[;?#^)_K@_\ !'__ )1=_L'_ /9LWPO_
M /4?MZ_AO_X)T?MA_#3]BO\ X+S?&7XA?&/4+'P]\,?'_P =OVH_@OXL\;:G
M>?8M,\ 1^._BCK,^A>+M6F>,VT6A6GBK0]!T[Q)?WMQ96.A>'-3U;Q)=7/E:
M,UO/^0W@_P#;_P#V\?AYX6T'P/X _;9_:X\#>"O"NF6NB>&/!_@_]I'XR>&?
M"WAS1K&,0V6D:#X?T7QG9:3H^F6<0$5K8:?:6]K;Q@)%$B@"OEK6];UGQ+K.
MK^(_$>KZGK_B'7]3O];UW7=;O[K5=9UO6=5NI;[5-7U?5+Z6>^U+4]2OIY[R
M_O[R>:ZO+J:6XN)9)I'=N3*^#I86KQ"L9BH5L/GD*M/EHQG"I1C5JUJG-S2O
M%SA[5<NCCS1U3BVBZF+4E0Y(M2HM/WK-2LDK::V=GYVV=S_6&_X*A_\ !,WX
M2?\ !6#]G[PG\.O$?Q'U7X?ZOX1\0-\0/A3\5?"%AI7B^RT_4-4T"\TB5-3T
M.>^T^V\6>#]9L[VTOKRPTSQ%X=OKNXTO2I[+Q#9Q1S)<_(__  3=_P""8W[#
M?_!&KXA^%="UCX]P_$7]L+]J:TOOAAX/U[QK%I'A36O$NBZ+:S>./$?A_P"%
MOPQTJ]U[4?#OAFY?PK8ZIXIUC6_$7B9)-4TGP[I;^(;.:ZT_2[[_ #MOAK^V
MG^V/\&?#%OX*^#_[6?[3'PH\&V?GFT\)?#7X\?%+P+X8M3=327%R;?0?"_BK
M2]*@^T7$TL\_E6B^;-+)+)N=V8^<3_''XU7/Q0L_C=<_&#XHW'QHT_5;'7;#
MXO3_ ! \62_%"QUO3$CBTW6+/Q_)JS>*[;5=/BBBCL=0AU9+NT2.-()HU10/
M-H\#YQ3P-?*)<1-93+VLX8:EA5&52K)N5-59RE*=.BZG+4K4H5)PFU)**E+V
MBT>,I.<:OU?]ZK)R<M$M+M*UG*UTFTFM-;:']P__  =_?"B^UW]GW]CSXUV]
MG>3V?PU^+?Q'^'6H7,#2-:6*?%_PGX?U^VDO84M9$43W'P=6WM[R6[MDAFD^
MRK#=27Z-;?0__!N7^WA^QS\</V8_AK^S</#7P;^$O[6WP3\/6/@[5_#5MX5\
M(^#M?^,>@>'X]N@_%/PIJ$-I:W?CGQ%?Z;;0R_$DQW-WXKMO&%IJOB;6+./2
M]=TC5+[^#_XE_MN_MH?&CP?J/P]^,7[7?[3_ ,6/ .KS6%QJW@?XE_'WXK>.
M_!^IW&E7L&I:9/J/AKQ3XLU71;V;3=1M;;4+"6YLI7L[VW@NK=HYX8Y%^9K:
MYN;*YM[RSN)[2[M)XKFUNK:62"YMKF"198+BWGB9)89X9462*6-EDCD571@P
M!'HPX,E5X;HY#C,;:KA<16K87%X:,^6'M9SJ.-6C.4/:P<JU52AS1O[DHSBT
MT9O%VQ#KQAI**4H2M?1):22=GHK.WE8_O_\ VD?^#2_]GWXL_&S7/B3\&_VG
M/%WP%\!>*_$]_P")=>^$TOPITCXBV6DC5M374-0T3X>^)%\=>!9/"NBQ))>V
M^BVFMZ%XS;2%FM5$EW:6*V4W[,:%?_L??\$/?V!?"'@?QM\5]3TOX1_!31?$
ML'AFZ\>:YINJ?$WXF^)]?U[7_&]_H/A71;6/2UUWQ'K>O:WJ(TK0= TVVTW1
MM.*27C6.DZ=?:G%_F5:5_P %%?\ @H+H5@FE:'^W7^V1HVEQ*$CTW2OVG?C9
MIUA&@B2 *EG9^-X;=%$,<<(58P!%&D8&Q% ^=_B/\6?BI\8]>3Q3\7?B7\0/
MBIXGCM$L(_$?Q'\9>(_'&O)8QR22QV2:OXGU+5-06TCEEED2W6X$*222.J!G
M8GBJ\&YYF4<+A,[XB^MY=A:D9QHTL-&-:?)%P7-6:C)S<)2BJM:5>45)V3;9
M:Q=&FY2I8?EJ235W+17L]M=+J[2LG;<^UOA#_P %"/%OPE_X*=C_ (*0:-X<
MBAUO4OVFOB5\=/$'@F.Y6<3^&?C+XD\6S?$?P19:@R6L:W.H^"O'7B;PUIVJ
MO#'';75S;Z@]JR1-;-_I _$3P;^PE_P7._8A;0+3Q=IWQ+^$GC-M*\2:#XH\
M(7]C:_$?X+?$S3]/N1INHBSU"VO;OP5\0O#EOJVI:1JNA^(=*,>HZ)JFKZ3?
M6=_H.M2-<_Y-%>C_  S^,?Q=^"NM3^)/@Y\5/B/\)?$5U;"RN=?^&?CCQ/X#
MUJXLPXE%I/JOA;5-*OIK82 2""2=H@X#[-PS7M9_PI#-98'%8'%SRW,<MA"G
MA<1"+G'V5*7-2IS2E&:]E)R=.:D[<\U.$U)<N-#$NDIPG!5*=1MRB]-7HVM&
MM5NM-E9JQ_H^_P#!+_\ X-Z_@;_P3;^-OB#]HS7?C5KO[0?Q!M=%\6>&_AY)
MKW@+1? 'A?X>>%_%=G;Z?K-[<:8OB+QG>:]XTDT%=7\.7/B@:UH.AR>'?$.M
MV7_"'PS7"WL7\\7_  <S?MU_LH_'7XC> OV8_P!F'PO\(O$]_P#"#Q)JGBKX
MR_'OP1X5\,M?7_C673[O0[#X6>&?B#I%I%<ZYH.A6M[J&K>/ELKW4O#]_P"*
M6\,V$=R-9\%ZI##_ #]?$+]N']M3XN>'+_P=\5OVO_VHOB=X1U6!K75/"WQ"
M^/\ \6/&GAS4K5V5VMK_ $/Q)XMU+3+R!G1':&XM9(V9%8J2H(^7:Y\KX6QM
M+-HYWG>;2S+&TJ?LZ$*5)8>C!*,HQ<U#EC)14YN-.-*$54DZLG.3*JXF#I>Q
MHTO9P;O)M\SZ-VO=ZM*[;;LK:!6_X4\+:_XX\4^&O!7A/3)];\4^,-?T?PMX
M:T:U:);K5]?\0:C;:3HVF6S3R0P+/?ZC=VUK"TTL40DE4R2(F6&!6OX>\0Z_
MX2U_0_%?A37-8\,^*/#.L:9XA\-^)/#VIWNBZ_X>U_1;V#4M'US0]8TV>VU'
M2=8TG4;:VO\ 3-3L+FWO;"]MX+JUGBGBCD7[67-RRY+<UGR\U^7FMIS6UM>U
M[:VV.-6OKMUMO8_V"_V$/V//AS^PA^RS\*?V:OAM96JVG@G0+27Q?XBAM5MK
MWQ[\1M2MK>?QQX\U<EYIGOO$>MK--;037%PNCZ-#I/A^QD72]'L(8OGG]H[_
M ((Q?\$W/VN/BUX@^.7[1?[/NK?$_P"*7B>'3;75O$VJ_'K]I'2T%CI%E%I^
MF:9I.@^'/B_HWAKP]I-C;1 6^D>'M'TO3$GENKP6GVR\NYY_\S__ (>8_P#!
M1_\ Z2!_MN?^)6_'?_YO:/\ AYC_ ,%'_P#I('^VY_XE;\=__F]K\FAP#G]/
M%5L;2XB5#%XB4Y5L10>+H5:CJS4ZBE.E.$G&4_><;\MU'316]3Z]0<5!T+PC
M9*+Y9)65E9-/97UW^]V_T&OB-_P;P_\ !'C0?A[X[US2?V0/LFJ:-X-\4:MI
MMU_PO_\ :BG^S:AIVB7UY9W'D7/QLFMYO)N(8Y/*N(989-NR6-XRRG_,)K[4
MO/\ @I-_P45U"TNK"_\ V^?VU+ZQOK>>SO;*\_:F^.=S:7EI<Q-#<VMU;3>.
MGAN+>XA=XIX)4>*6)VCD5D8@_%=?9\-Y1FV4QQBS3-ZN:NO*@Z#JUL36]@J:
MJJHH_6)S<?:.<&^2U^1<VRMR8BK2J\GLZ2I<O-S645S7Y;7Y4MK.U^_0****
M^G.8**** "BBB@ HHHH **** /ZM/VJ_^547_@G-_P!G>>)__4\_;BK^4NOZ
MM/VJ_P#E5%_X)S?]G>>)_P#U//VXJ_E+KYKAC^!F_P#V4>>?^ILSHQ&]'_L'
MH_\ I""BBBOI3G"BBB@ HHHH **** "BBB@#_2K_ .#6G_E%9HW_ &7WXQ?^
MC?#E?RU_\'/_ /REC^(7_9(/@K_ZB8K\??A9^V?^V'\#/"J>!/@G^UA^TK\'
MO!$>H7FK1^#?A9\=?BC\/O"L>J:B8SJ&I)X>\)>*=(TA=0OC#";R\6S%S=&*
M,SR/L7'EOQ0^+OQ7^-_BRX\??&CXG_$/XO>.KRSLM.N_&GQ0\:^)/'_BRZT_
M38?L^G6-QXC\5ZGJVL3V>GP?N+*VEO&AM8?W<"1I\M?&99PQ7P/$N8Y[/%4:
ME+&K%*%",)JI#ZQ5I5(\TG[KY53:=MVU;J==3$QGAZ=%1:<.6\FU9\L6MM];
M_P!=//****^S.0_M0_X,ZO\ D:OV_P#_ +%_]FG_ -./QRKR+_@[[_Y.C_9)
M_P"R!>*/_5B7]?R[?!S]I/\ :+_9VE\03_L_?'WXU? N?Q9'ID/BJ;X.?%/Q
MS\,9?$T6BM?/H\7B"3P5KNB/K,>DOJFIOIB:BURM@VHWS6HB-W<&2G\7_P!H
M/X]_M":II&N?'WXW_%[XX:WX?T^72=!UCXO_ !*\9_$O5-$TN>Y:\GTW2-0\
M::UK5WINGS7;M=2V=G-#;27+-.\9E8L?D(<-5X\6U>(_K-)T*E)4UAN2?M4U
M@:>$NY_!;F@Y_P"%I;G5]8C]5^K\KO>_-=6^/FVW\C^C;_@T>_Y20?&O_LR/
MXD?^KW_9LK[<_P"#Q[_G'/\ ]W=_^^P5_'#\(_CE\;/V?_$E[XR^ _QA^*?P
M3\7ZGH=SX9U+Q5\(_B#XM^&_B34/#=Y?Z;JMYX?O=<\&ZOHVJ7>AW>IZ-H^I
M7.DSW4EA/?Z3IMY+;O<6-K)%N?&3]IG]I#]HK_A'/^&@OV@?C=\=?^$._M?_
M (1'_A<GQ6\>?$[_ (1;_A(?[+_M_P#X1S_A-M>US^P_[<_L/1?[7_LS[+_:
M7]D:7]M\_P#L^T\FJO#E>IQ9AN(UB:2HT*,J3PSA/VLF\'7PUU/X$N:LI:](
MM;L%7BL+*ARN\I7YKJR]Z,MM_LO\#_3!_P""!O[9/P?_ &H?^"=G[/\ X&\%
M^(--A^)G[-_PS\(_!3XJ?#R?4+8^)M NO .E6_AG0O%,FF>8+N7PQXWT;3K'
M6]'UJ*%M.-[<:GH'VDZKH6IV\'YP^(/^#3S]C[_AH7Q+\8-<_:+^(6@_LURZ
MSJ?C&X^ EGX<\.>'KCP_;R:LVN7/AT?&J;6W2Q^'&G6)N=%ALE^']GXIL=!6
M!CX\74K5]5F_@@\ _$;XA?"KQ-9>-?A?X[\9?#?QEIJ7$6G>+? /BC6_!_B:
MPCNXF@NH[+7O#U]IVJVJ7,#M#<)!=QK-$S1R!D)4^P?%#]LO]K_XX>')O!WQ
MI_:L_:2^+_A&YEM9KCPM\4/CG\3_ !_X<N)K&ZCOK*6;0_%GBC5M,EEL[V&&
M[M9)+5FM[J*.XB*2HKCR?]3<TP>8X[$Y+GSR[#9E.4\33>&5:K!3G.;C3<I<
MLG3E4J.C53HU8*;ASM\TY:_6Z4Z<(UJ'M)4U:+YK)V25WII>RNM5IMT7^N;^
MSQ\0/V??C7\!_#&K?LT^)O#'BSX"06'B'X6^"-7\!R,WA5-)^&&LZO\ "F_T
MSPO<R1+%=:)HM_X5OM+T+5;,7.CZSI=I8ZUH5[JFA:AIVHW?^9]_P2M_:%^&
M/_!,[_@I%K.B?MD_#+P5XP\!:)KOCK]GGXNWNN^"-&\>W?PA\5:!XOBTP_$O
MPE!K&@7NMJ_A7Q3X7?3]<30HK'6+WP=JFN3VVG:IK%EI6D3?GY\,?VU_VR_@
MEX1M/ 'P9_:V_:;^$?@2PNKZ^L/!/PQ^/7Q4\ ^$;*]U.X:[U*\M/#?A7Q7I
M.C6UUJ%V[W5]<0V22W=P[37#R2,6/A_CGQYXY^)_BW7/'WQ*\9^*_B'XZ\3W
MG]H>)?&GCGQ%K'BWQ;XAOQ#%;B^USQ'K]YJ&L:M>"W@A@^TW]Y<3>3#%%OV1
MHHZ<DX->5QSO"5\7]:P&;0C37+ST\935.5;V<Y5$N1U>6O)RG%6]I",N1Q;B
MIK8OVCHSC'EG2;>MG!W4;Z;VO&UNSWN?ZE'[?7_!,O\ 8^_X+%_L^?"2ZT7X
MB:?H5GX/&J^)_@/\<O@?-X7\3^'H=(\8:?I5KKFFOIMG+_PCOBOPCKBZ%X=N
MKJRL]1TC5;2_\/:<-/US38O[4L]0^6?^"7/_  ;P?"W_ ()M_'BS_:8UG]I7
MQO\ '#XE^'-!\5Z#X9AM/!EG\(/ 6FZ=XLTG^Q]4NM>\.P>,?'VI^);RWTR6
M_2T6_P#%%OH5O<7,&J-H;ZKI6EW]K_G=?"?]I#]HCX"B_'P,^/7QH^"XU2XA
MN]3'PG^*7CCX=#4;NW54@N;\>#]=T?[9<0*B+#-<>9)&J*J,H4 =]X\_;F_;
M8^*F@:CX4^)_[8?[4WQ'\+:Q93Z;JWAKQY^T%\6O%^@:IIUTCQ7-AJ.C>(?%
MVHZ=>V5Q%))'/:W-M+!,CNDD;*S ^?'@W/Z&$JY3AN)5'**WM(RH5,'&554J
MS;JP4FY3BIN4W.-.O3A4<I2<5SR1?UN@YJK+#_O5;52LKJUGV=K:-Q;221_3
M#_P=(_\ !2KX'_M!3_"S]BCX%>)]$^)(^#OQ#U'XE?&/QWX;O;?5?#&C^.[+
MP]JW@[P]\/= UVRFFL-;U71K#Q'XIN?';V+SV.BZH^B:"+V37;'Q+INC_9/_
M  ;)_P#!5OX6ZK\#]'_X)Z?'7QUI7@[XH_#?5];E_9[U#Q9J)L-/^)/@'Q)J
MMYXCN? FGZ[JMV]I+XV\%^(=3U=-'\.RSV$NI^"K_0[#PKI]\OA36_LO\%]%
M>Y5X.RZIP]3R#VE6,*,O;TL6U&5:.,;G*5=PTBXR]I.FZ5U^YER*:FE46*Q=
M15W7LKR7*XZVY-/=OO?1._?6UM#_ $;_ -N#_@V$_9F_:W_:3UC]H;P-\:O&
M/[/*_$3Q;-XO^,G@#P]X(T3QCH?BC5]4NA>>)]6\"WE]KOA]_AYKWBB\DO=4
MU2\U"Q\=Z(NM7L]_:>&H(GELI?O#]KWXN_L#_P#!)/\ 85\,>%/B-X;^'OB/
MPW\*_AA9^ ?@)\$O&EOX?\4>./BYK'AG3H;/1]*MK+5].U*\O!?:N\&J>./&
M4FF-I.A_;;[6;T)-):V5S_FL^&_^"@/[>7@W1;;PWX0_;:_:Y\*^';*UBL;/
M0/#?[27QDT/1;2RAC\F&SMM*TSQG:V,%K%$3%%;Q0)%'&=B(%XKYV\=_$+Q]
M\4?$M]XS^)GCCQA\1?&&IB,:EXK\=^)=:\7>)=0$*[(1?:[X@O=0U2[$2_+&
M+BZDV+PN!Q7BQX*S;%RP-#..()XO+LODG0P]&BZ5:48I14)5N923<%R>UG*O
M4A"\*;CS.2V^N4H\\J5!0J5/BDW>*ZWM:SUULE%-ZN^Q0\7>(Y?&'BSQ/XMG
MTGP]H$_BGQ#K7B.;0O".B67AKPGHLNMZE<ZG)I/ACPYIR1Z=H'A[37NC9Z+H
MEA&EEI6FPVUC:HL$$:CGJ**_1TE%**5E%))=DE9+Y(\\_>C_ (-^_P#@IMX/
M_P""='[5?B73_C+<S:?^SY^T9H6@>"?B+XAMK5KJ3P)XE\-ZI>W?P^^(-]##
M')>7?A[0VU_Q1HWB2TLD-S#I?B>77H8KR;08M-OO[J?VX_\ @F)^PO\ \%;?
M!7PX\9_%&;4M:FTS0//^%?Q\^!'CC1;37Y/!GB&>VUC[-H_B%],\8^!_%_A7
M4Y$%]IO]M>'_ !%:V#WNH7GAZ;3I]5U">Z_R;J]_^%'[6'[4WP'TR71?@=^T
MK\?_ (,Z-/<37D^D_"CXR?$7X=Z9-=W "SW4MAX0\1Z/:R7$ZJHFG>)I9 H#
MLP KXO/N$JF89C3SG*\QGE>9PC&%2K&,I0JJ$/9QE>$HSA-4K4IJTZ=2FHQE
M!6DY=E'%*%-T:M-5*=[I.VFMVK-6:OJM4T[Z]O\ 5"^"?P&_8._X(R_LK>)X
M=!U;1/@=\$_#]V_B_P"(GQ&^)/BAM1\1>+_$\]I9:1#J.N:O<I'=>(/$^JK:
MV&C^'?"GA?2H5N;V6WT?PGX:2ZO4M)_\W?\ X*[_ +?TG_!2']M?QU\?M,TF
M?0?ASHVD:7\+/@UI%^"-8@^%_@^_UF\TG4M='W8=9\4:YK_B+Q?>Z=&#'H;>
M(%T%;C4/[+.IWOQ)\6/V@OCU\>KS3]1^.?QN^+WQHU#2?M(TN^^+'Q*\9_$6
M\TT7C(]V-/NO&&M:Q/9_:GCC:Y^SO'Y[(C2[BJD>0UIP[PI_8^*Q&9X[&SS+
M-,2I0EB)J2C3A-Q<^7GE.<ZDW&*E5DU:"5.$(KF<UB,5[6,:<(*G3C9\NC;:
MVV222N]%ONWT11117V)R!1110 4444 %%%% !1110!T_@G_D<_"/_8SZ!_Z=
M;2OZ:/\ @[=_Y21?!O\ [,H^&W_J\?VC:_F7\$_\CGX1_P"QGT#_ -.MI7]-
M'_!V[_RDB^#?_9E'PV_]7C^T;7S>/_Y*?A__ + <\_++SII_[K7_ ,='\Y'\
MN%%%%?2',%%%% !7ZQ?\$?/^"GOBS_@F!^TXGQ$DT[4/%OP/^)5EI_@[X^>
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M.?\ #07[0/QN^.O_  AW]K_\(C_PN3XK>//B=_PBW_"0_P!E_P!O_P#".?\
M";:]KG]A_P!N?V'HO]K_ -F?9?[2_LC2_MOG_P!GVGD]/\+/VS_VP_@9X53P
M)\$_VL/VE?@]X(CU"\U:/P;\+/CK\4?A]X5CU343&=0U)/#WA+Q3I&D+J%\8
M83>7BV8N;HQ1F>1]BXY*_"&)K<*8+AY8R@JV%Q,J\L0Z=1TI*6(Q5;EC#XTT
ML0HW>C<6]FBHXN*Q,Z_)*TXJ/+=76D$W?;[+/T#_ .#@[_E,+^V?_P!C!\)_
M_5 ?"BO[3?\ @V6_Y1&_!;_LH?QR_P#5H^(:_P TWXA?$?XA_%OQCK7Q$^*W
MCSQG\3?B!XDDM)O$7CGXA>*-<\:>,=>EL-/M-)L9=:\3>)+[4M:U22RTJPL=
M,M'OKV=K;3[*TLX2EM;0QI[5\,OVV?VS?@IX1LOA_P#!K]KC]IWX2> M-N+Z
M\T[P3\,OCW\5? 7A&PN]4NI+[4[JR\-^%?%>E:-:W&HWLTMY?3P64<MW=2R7
M%PTDSLY[,XX9KYGP[EN24\51I5<#' *=><)NG/ZIA)X>3C&/O+GE+FC?9*SU
M)HXB-*O4JN+:GSJR:NN::EZ.R5C[8_X+R_\ *7+]MG_LH?AC_P!5=X#K^[/_
M (-R_P#E#1^QS_W<)_ZU3\<*_P P;Q[\0?'OQ4\7:W\0/B?XW\7_ !'\>^)K
MB*\\1^-O'OB76?&'B[Q!=P6L%C#=:WXD\0WNHZSJMQ#96MK9Q3W][<2QVMM!
M;HPAAC1?=OAQ^W+^VQ\'?!FC?#CX1_MA?M2_"SX>^'?[1_X1_P !_#C]H+XL
M^"/!FA?VOJM]KNK?V-X7\,^+M+T/2_[4US5-2UG4?L5C!]MU74;[4;GS;N[N
M)I%GG#%?-N'\KR:GBJ-&K@)8)SK3A.5.I]5P57"RY8Q]Y<\JBG&^R33U84<1
M&E7J57%M34TDFKKFFI:^B7WGNO[;?Q*\5?!C_@KA^UU\8? MU!9>-OA1_P %
M&OCY\2O!U[=0FYMK3Q5X%_:9\6>*/#UU<6XDB-Q!;ZOI=G++")8C+&C1B1"V
MX?Z-OP!_:,_8G_X+>?L1^(/"]V_A[QGX5^)O@G3]"^._P0O-5AB\>?"OQ2SV
MM^L%[:$1:KIE_P"&_%6G6VO?#WQ[96HL+N_TC2O$&AWCW%J\4'^4GXF\3>)/
M&OB3Q!XR\9>(-<\6^+_%NN:MXF\5>*O$VK7^O>)/$WB37K^XU77/$'B#7-5N
M+O5-9US6=3N[K4M6U;4KJYO]1O[FXO+RXFN)I)&U/ WQ!\>_##Q'9>,?AIXW
M\7_#SQ=IJRKIWBKP-XEUGPEXCL%G79.MEKF@7NGZG:K,GR2B"ZC$B_*X(XK3
M.^%89OA,MC#%RP>8Y73IQPV,IP<ES0C3NI14H32]I2C4ISC-3I2O)*5Y1:H8
MET93O%3IU&^:#MUOULULVFFK-::;G^B'^P]_P;'_ +/7['?[6GAW]IS6/C[X
MY^-FF_"_Q);^+O@M\-?$/@7P[X:A\->)+&WODTC6O'_B>RUC6!X^U'PW?SV'
MB'PU+X?\-_#6'3_$>CV.H7=MJ=NAL!\%?\'/_P"W5^R0?AW;_L3_  A\+?!O
MXA?M ZQXHT+7_BY\0=%\*>%=9UGX(>'?"M]%JMCX5T_QM969N]$^)'B[5;:T
MM-8TS3M2DOM&\"6^NZ5XELK2/QCI0E_D\\0_\% _V]/%VAW/ACQ7^VW^UWXG
M\-WMI)87GA[Q#^TG\9=:T.[L9H&MIK*YTG4O&ES83VDMLS6\EM+;O"\#-$R&
M,E3\BUQX#A3,99KA\VSW.99E6P481PM*E26'IITVY4Y5'#D34)MS<8TU*K.T
MJM223A*YXFFJ4J5&BJ:G?F<GS/6U[7OJ[6NWHMDGM_;A_P &</\ SD8_[M$_
M]^?KXC_X.X?^4D'P4_[,C^&__J]_VDZ_G9^#?[3/[2'[.O\ PD?_  S[^T#\
M;O@5_P )C_9'_"7?\*;^*WCSX8_\)3_PCW]J?V!_PD?_  A.O:'_ &Y_8?\
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M34Y1AB(2HU%%ZIZIZO&4YQA[6@ISIK1\UHWTU:2V=DW%W1_K5?%B+P/^V?\
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M[6G_ &<S\>/_ %:?BJOV$_X-?/\ E+!X%_[(U\:?_4:@K\>_VU/^3R/VM/\
MLYGX\?\ JT_%5?-X?_DJ\S_[$N6?^I6/.B7^ZT_^OU3_ -(@?,U%%%?2'.%%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?U:_\%H_^
M4,?_  0M_P"R.6'_ *ICX8U_*57]6O\ P6C_ .4,?_!"W_LCEA_ZICX8U\UG
M7_(WX6_[&.-_]5>*.BC_  L3_P!>X_\ IR)_*51117TISA1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !7V3_P3H_Y2#_L)_P#9Y/[,
M/_J[? ]?&U?9/_!.C_E(/^PG_P!GD_LP_P#J[? ]<N._W+&?]@N(_P#3,RZ?
M\2G_ (X_^E(_2+_@Y<_Y2]_'_P#[$SX$_P#JF?!=?@I7[U_\'+G_ "E[^/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MC''9E2RVG3G5IU*BJSE%*GRW3C&+=^:4=->A^JWDQ?\ /*/_ +X7_"CR8O\
MGE'_ -\+_A7Y!?\ "\_BY_T/VO\ _@1%_P#&:/\ A>?Q<_Z'[7__  (B_P#C
M-?0_Z@YE_P!!F!^^O_\ *?7^GIYO^M.#_P"@?$_^4O\ Y8?K[Y,7_/*/_OA?
M\*/)B_YY1_\ ?"_X5^07_"\_BY_T/VO_ /@1%_\ &:/^%Y_%S_H?M?\ _ B+
M_P",T?Z@YE_T&8'[Z_\ \I]?Z>A_K3@_^@?$_P#E+_Y8?K[Y,7_/*/\ [X7_
M  H\F+_GE'_WPO\ A7Y!?\+S^+G_ $/VO_\ @1%_\9H_X7G\7/\ H?M?_P#
MB+_XS1_J#F7_ $&8'[Z__P I]?Z>A_K3@_\ H'Q/_E+_ .6'Z^^3%_SRC_[X
M7_"CR8O^>4?_ 'PO^%?D%_PO/XN?]#]K_P#X$1?_ !FC_A>?Q<_Z'[7_ /P(
MB_\ C-'^H.9?]!F!^^O_ /*?7^GH?ZTX/_H'Q/\ Y2_^6'Z^^3%_SRC_ .^%
M_P */)B_YY1_]\+_ (5^07_"\_BY_P!#]K__ ($1?_&:/^%Y_%S_ *'[7_\
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M_OA?\*/)B_YY1_\ ?"_X5^07_"\_BY_T/VO_ /@1%_\ &:/^%Y_%S_H?M?\
M_ B+_P",T?Z@YE_T&8'[Z_\ \I]?Z>A_K3@_^@?$_P#E+_Y8?K[Y,7_/*/\
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M*/\ [X7_  H\F+_GE'_WPO\ A7Y!?\+S^+G_ $/VO_\ @1%_\9H_X7G\7/\
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MRC_[X7_"CR8O^>4?_?"_X5^07_"\_BY_T/VO_P#@1%_\9H_X7G\7/^A^U_\
M\"(O_C-'^H.9?]!F!^^O_P#*?7^GH?ZTX/\ Z!\3_P"4O_EA^OODQ?\ /*/_
M +X7_"CR8O\ GE'_ -\+_A7Y!?\ "\_BY_T/VO\ _@1%_P#&:/\ A>?Q<_Z'
M[7__  (B_P#C-'^H.9?]!F!^^O\ _*?7^GH?ZTX/_H'Q/_E+_P"6'Z^^3%_S
MRC_[X7_"CR8O^>4?_?"_X5^07_"\_BY_T/VO_P#@1%_\9H_X7G\7/^A^U_\
M\"(O_C-'^H.9?]!F!^^O_P#*?7^GH?ZTX/\ Z!\3_P"4O_EA^OODQ?\ /*/_
M +X7_"CR8O\ GE'_ -\+_A7Y!?\ "\_BY_T/VO\ _@1%_P#&:/\ A>?Q<_Z'
M[7__  (B_P#C-'^H.9?]!F!^^O\ _*?7^GH?ZTX/_H'Q/_E+_P"6'Z^^3%_S
MRC_[X7_"CR8O^>4?_?"_X5^07_"\_BY_T/VO_P#@1%_\9H_X7G\7/^A^U_\
M\"(O_C-'^H.9?]!F!^^O_P#*?7^GH?ZTX/\ Z!\3_P"4O_EA^OODQ?\ /*/_
M +X7_"CR8O\ GE'_ -\+_A7Y!?\ "\_BY_T/VO\ _@1%_P#&:/\ A>?Q<_Z'
M[7__  (B_P#C-'^H.9?]!F!^^O\ _*?7^GH?ZTX/_H'Q/_E+_P"6'Z^^3%_S
MRC_[X7_"CR8O^>4?_?"_X5^07_"\_BY_T/VO_P#@1%_\9H_X7G\7/^A^U_\
M\"(O_C-'^H.9?]!F!^^O_P#*?7^GH?ZTX/\ Z!\3_P"4O_EA^OODQ?\ /*/_
M +X7_"CR8O\ GE'_ -\+_A7Y!?\ "\_BY_T/VO\ _@1%_P#&:/\ A>?Q<_Z'
M[7__  (B_P#C-'^H.9?]!F!^^O\ _*?7^GH?ZTX/_H'Q/_E+_P"6'Z^^3%_S
MRC_[X7_"CR8O^>4?_?"_X5^07_"\_BY_T/VO_P#@1%_\9H_X7G\7/^A^U_\
M\"(O_C-'^H.9?]!F!^^O_P#*?7^GH?ZTX/\ Z!\3_P"4O_EA^OODQ?\ /*/_
M +X7_"CR8O\ GE'_ -\+_A7Y!?\ "\_BY_T/VO\ _@1%_P#&:/\ A>?Q<_Z'
M[7__  (B_P#C-'^H.9?]!F!^^O\ _*?7^GH?ZTX/_H'Q/_E+_P"6'Z^^3%_S
MRC_[X7_"CR8O^>4?_?"_X5^07_"\_BY_T/VO_P#@1%_\9H_X7G\7/^A^U_\
M\"(O_C-'^H.9?]!F!^^O_P#*?7^GH?ZTX/\ Z!\3_P"4O_EA^OODQ?\ /*/_
M +X7_"CR8O\ GE'_ -\+_A7Y!?\ "\_BY_T/VO\ _@1%_P#&:/\ A>?Q<_Z'
M[7__  (B_P#C-'^H.9?]!F!^^O\ _*?7^GH?ZTX/_H'Q/_E+_P"6'Z^^3%_S
MRC_[X7_"CR8O^>4?_?"_X5^07_"\_BY_T/VO_P#@1%_\9H_X7G\7/^A^U_\
M\"(O_C-'^H.9?]!F!^^O_P#*?7^GH?ZTX/\ Z!\3_P"4O_EA^OODQ?\ /*/_
M +X7_"CR8O\ GE'_ -\+_A7Y!?\ "\_BY_T/VO\ _@1%_P#&:/\ A>?Q<_Z'
M[7__  (B_P#C-'^H.9?]!F!^^O\ _*?7^GH?ZTX/_H'Q/_E+_P"6'Z^^3%_S
MRC_[X7_"CR8O^>4?_?"_X5^07_"\_BY_T/VO_P#@1%_\9H_X7G\7/^A^U_\
M\"(O_C-'^H.9?]!F!^^O_P#*?7^GH?ZTX/\ Z!\3_P"4O_EA^OODQ?\ /*/_
M +X7_"CR8O\ GE'_ -\+_A7Y!?\ "\_BY_T/VO\ _@1%_P#&:/\ A>?Q<_Z'
M[7__  (B_P#C-'^H.9?]!F!^^O\ _*?7^GH?ZTX/_H'Q/_E+_P"6'Z^^3%_S
MRC_[X7_"CR8O^>4?_?"_X5^07_"\_BY_T/VO_P#@1%_\9H_X7G\7/^A^U_\
M\"(O_C-'^H.9?]!F!^^O_P#*?7^GH?ZTX/\ Z!\3_P"4O_EA^OODQ?\ /*/_
M +X7_"CR8O\ GE'_ -\+_A7Y!?\ "\_BY_T/VO\ _@1%_P#&:/\ A>?Q<_Z'
M[7__  (B_P#C-'^H.9?]!F!^^O\ _*?7^GH?ZTX/_H'Q/_E+_P"6'Z^^3%_S
MRC_[X7_"CR8O^>4?_?"_X5^07_"\_BY_T/VO_P#@1%_\9H_X7G\7/^A^U_\
M\"(O_C-'^H.9?]!F!^^O_P#*?7^GH?ZTX/\ Z!\3_P"4O_EA^OODQ?\ /*/_
M +X7_"CR8O\ GE'_ -\+_A7Y!?\ "\_BY_T/VO\ _@1%_P#&:/\ A>?Q<_Z'
M[7__  (B_P#C-'^H.9?]!F!^^O\ _*?7^GH?ZTX/_H'Q/_E+_P"6'Z^^3%_S
MRC_[X7_"CR8O^>4?_?"_X5^07_"\_BY_T/VO_P#@1%_\9H_X7G\7/^A^U_\
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M  O/XN?]#]K_ /X$1?\ QFNS_4',O^@S _?7_P#E/K_3TY_]:<'_ - ^)_\
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M_P"A^U__ ,"(O_C-'_"\_BY_T/VO_P#@1%_\9H_U!S+_ *#,#]]?_P"4^O\
M3T/]:<'_ - ^)_\ *7_RP_7WR8O^>4?_ 'PO^%'DQ?\ /*/_ +X7_"OR"_X7
MG\7/^A^U_P#\"(O_ (S1_P +S^+G_0_:_P#^!$7_ ,9H_P!0<R_Z#,#]]?\
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M *#,#]]?_P"4^O\ 3T/]:<'_ - ^)_\ *7_RP_7WR8O^>4?_ 'PO^%'DQ?\
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M ,9H_P!0<R_Z#,#]]?\ ^4^O]/0_UIP?_0/B?_*7_P L/U]\F+_GE'_WPO\
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M+_A1Y,7_ #RC_P"^%_PK\@O^%Y_%S_H?M?\ _ B+_P",T?\ "\_BY_T/VO\
M_@1%_P#&:/\ 4',O^@S _?7_ /E/K_3T/]:<'_T#XG_RE_\ +#]??)B_YY1_
M]\+_ (4>3%_SRC_[X7_"OR"_X7G\7/\ H?M?_P# B+_XS1_PO/XN?]#]K_\
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M]\F+_GE'_P!\+_A1Y,7_ #RC_P"^%_PK\@O^%Y_%S_H?M?\ _ B+_P",T?\
M"\_BY_T/VO\ _@1%_P#&:/\ 4',O^@S _?7_ /E/K_3T/]:<'_T#XG_RE_\
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MXG_RE_\ +#]??)B_YY1_]\+_ (4>3%_SRC_[X7_"OR"_X7G\7/\ H?M?_P#
MB+_XS1_PO/XN?]#]K_\ X$1?_&:/]0<R_P"@S _?7_\ E/K_ $]#_6G!_P#0
M/B?_ "E_\L/U]\F+_GE'_P!\+_A1Y,7_ #RC_P"^%_PK\@O^%Y_%S_H?M?\
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M/]:<'_T#XG_RE_\ +#]??)B_YY1_]\+_ (4>3%_SRC_[X7_"OR"_X7G\7/\
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MWU__ )3Z_P!/0_UIP?\ T#XG_P I?_+#]??)B_YY1_\ ?"_X4>3%_P \H_\
MOA?\*_(+_A>?Q<_Z'[7_ /P(B_\ C-'_  O/XN?]#]K_ /X$1?\ QFC_ %!S
M+_H,P/WU_P#Y3Z_T]#_6G!_] ^)_\I?_ "P_7WR8O^>4?_?"_P"%'DQ?\\H_
M^^%_PK\@O^%Y_%S_ *'[7_\ P(B_^,T?\+S^+G_0_:__ .!$7_QFC_4',O\
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M_P \H_\ OA?\*_(+_A>?Q<_Z'[7_ /P(B_\ C-'_  O/XN?]#]K_ /X$1?\
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M7_QFC_4',O\ H,P/WU__ )3Z_P!/0_UIP?\ T#XG_P I?_+#]??)B_YY1_\
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M+A:\Z$Z%>4H*#<H^SY7SPC45KS3T4DGINF?K[Y,7_/*/_OA?\*/)B_YY1_\
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MR8O^>4?_ 'PO^%?D%_PO/XN?]#]K_P#X$1?_ !FC_A>?Q<_Z'[7_ /P(B_\
MC-'^H.9?]!F!^^O_ /*?7^GH?ZTX/_H'Q/\ Y2_^6'Z^^3%_SRC_ .^%_P *
M/)B_YY1_]\+_ (5^07_"\_BY_P!#]K__ ($1?_&:/^%Y_%S_ *'[7_\ P(B_
M^,T?Z@YE_P!!F!^^O_\ *?7^GH?ZTX/_ *!\3_Y2_P#EA^OODQ?\\H_^^%_P
MH\F+_GE'_P!\+_A7Y!?\+S^+G_0_:_\ ^!$7_P 9H_X7G\7/^A^U_P#\"(O_
M (S1_J#F7_09@?OK_P#RGU_IZ'^M.#_Z!\3_ .4O_EA^OODQ?\\H_P#OA?\
M"CR8O^>4?_?"_P"%?D%_PO/XN?\ 0_:__P"!$7_QFC_A>?Q<_P"A^U__ ,"(
MO_C-'^H.9?\ 09@?OK__ "GU_IZ'^M.#_P"@?$_^4O\ Y8?K[Y,7_/*/_OA?
M\*/)B_YY1_\ ?"_X5^07_"\_BY_T/VO_ /@1%_\ &:/^%Y_%S_H?M?\ _ B+
M_P",T?Z@YE_T&8'[Z_\ \I]?Z>A_K3@_^@?$_P#E+_Y8?K[Y,7_/*/\ [X7_
M  H\F+_GE'_WPO\ A7Y!?\+S^+G_ $/VO_\ @1%_\9H_X7G\7/\ H?M?_P#
MB+_XS1_J#F7_ $&8'[Z__P I]?Z>A_K3@_\ H'Q/_E+_ .6'Z^^3%_SRC_[X
M7_"CR8O^>4?_ 'PO^%?D%_PO/XN?]#]K_P#X$1?_ !FC_A>?Q<_Z'[7_ /P(
MB_\ C-'^H.9?]!F!^^O_ /*?7^GH?ZTX/_H'Q/\ Y2_^6'Z^^3%_SRC_ .^%
M_P */)B_YY1_]\+_ (5^07_"\_BY_P!#]K__ ($1?_&:/^%Y_%S_ *'[7_\
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MUO=+V<OQ]/,:$J]*$X1C5E2:J<O->,82;]UR5K32WO=,A3[P_'^5?B[\0_\
MD?\ QS_V.'B;_P!/5[7[1I][\/?_ #^?'XXK\7/B'_R/_CG_ +'#Q-_Z>KVO
MK. ?][S#_L&H?^EL^?XG_P!WPG_7ZK_Z1 X^BBBOT\^-"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *U-#_ .0UH_\ V%-/_P#2N&LNM30_
M^0UH_P#V%-/_ /2N&HJ?PZG^"7_I+*A\<?\ %'\T?27[7O\ R5.Q_P"Q/TG_
M -.6M5\LU]3?M>_\E3L?^Q/TG_TY:U7RS7D\/?\ (DRS_L$I?DSOS?\ Y&>-
M_P"O\_T"BBBO9/."BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** /I']E+_DK^G_]@37/_25:\7\<_P#([>,/^QI\0?\ IVNZ]H_92_Y*
M_I__ &!-<_\ 25:\7\<_\CMXP_[&GQ!_Z=KNO"H_\E'CO^Q5@?\ U(Q9Z=7_
M )%&$_[#<5_Z:PYRU%%%>Z>8%%%% !1110 4444 %%%% !1110 445Y5\6OC
M7\-?@AX>_P"$D^(_B6TT.TE,D>G6(W76LZU<1*&:UT?28-UW?2J"OFR(BVMJ
M'62\N+>(^8.3'8_ Y7A,1F&98O#8# X6FZN)QF,K4\/AJ%.-DYU:U64*<(W:
M5Y25VTE=M(]KAWAOB#B_.\MX:X5R3->).(<XQ,,'E61Y'@,5FF:YCBIIN-#!
MX#!4JV)Q%1QC*;C2IR<81E.5H1E)>JT5^)OQ*_X*M:_/<7-I\)?AUIFG62LR
M6^M>.+B?4K^=<D+-_8FCW5C:63D8(C?5M37GD]J^6=;_ ."A7[56L7'GP_$"
MTT-!P+71?"_AJ*V4<_\ /]IE_<,><9DN'. *_!LX^DUX9976G0PE7.L]=.3@
MZN59;&.';3M+DJYGB<N=2*UM.G"=.:UA*2:9_I)P)^R.^ESQA@:&89S@N O#
MJ&(I1K0P?&?%52IF<83BI4_;8/A+*N*5AJDDUS4,57H8BC*\*]&E43@OZ6**
M_G)\,_\ !2;]IW0#"NHZSX7\6PQN"Z>(?#%FDDJ9!9&GT"30IAQD*P;*YS@]
M*_2S]D7]N6?]I#Q5>> M;\ +X;\16'AZ\\0OJ^D:JU[H=S;6-WIUG-$;.\AC
MO["9Y=1B,*BZU%&57#RQD+O]GA'Q]\/N,<RP>38/$9IEV:YA4C0P>#S3+IP>
M(KR3:HPQ&!J8["PE9.SKUZ,96M&3;2/@?&_]FE])WP*X3SWCO/LLX/XGX.X:
MPE3,,^SWA#BFCB(Y7EU*<(2QM?+<_P +P]G%:DI5(*4<!@,;5AS<TH*$927Z
M%45Y_P#$SXH^!?A!X5O?&?Q!U^UT#0[,B-9)MTMW?W;JS0Z=I=C"'NM1U"<(
MQBM;:-W"+)-)Y=O%+*GY#_%#_@JOXFN;NZLOA#X!TK2M.1FCM]=\;O/JFJ7*
M!B!.NBZ7=V=AI[$8*QRZCJZ\@L1RH^JXT\4."N ?9T^(LWC2QM:G[6AE>$I5
M,;F56FVTJCPU%/V%*;4E3K8N>'HU)1E&%24HR2_&O +Z'_C_ /25>(Q/A9P/
M7QW#^"Q/U/,.+\ZQ>&R'A3!XJ*A*IA8YKF$X?VEC*$:E*>)P&2T,SQ^&IU:5
M7$8:G3JTYR_;BBOYG]4_X*!_M6:G=O=1_$E=+1CQ9Z7X8\+0VD8X^5%N-'NI
ML8'62>1CU+9))ZOP[_P4H_:=T3REO]8\*^*8XV!==>\+6:22KD$J\VA2:))G
M&0&# C/>ORJC]*GPYJ5W2J9?Q5AZ5[1Q-3+LNG3:O\3A1S>I62MKI3E+^Z?V
M;COV-7TJ,+E\,7A>)?!K,L8X*4\JPW%/$]'%1DXW=*.(Q_!.$R^<U+W+O%PI
MMZ\_+J?T:T5\%?L;?MDZM^TUJ'B?P]KW@>Q\-:MX6TBSU:?5-(U2XNM+U!+N
M\%FL":=>6YNK"4/ND7=J-\CHC F-@-W'_MI?MF?$']FSQ[X6\+>$?#GA#6K#
M7?"*:_<S^(;?6);N*[;6-4TXQ0MIVKZ?$+?R;&)PKQ22>8SGS-NU1^HUO%3@
MRCP93X^6/Q-7ANI7AA8XFEE^+^L+$2Q3P;I2PE6E2KIPQ,94YRY73T<H3G!J
M3_CW ?0V\>L=X]XKZ-<N',JP/BQA,MJYO4RC&<2Y+_9TLMAE-//:>+IYUA,7
MB\N<<3E5:EBJ-*5:.(2FJ5>C1KJ=*/Z2T5^"?_#UGXV?]"'\,?\ P#\4?_--
M7Z._L5_M(^+OVE/!OC#Q)XOT;P]HMWX>\30:):0>'8M1BMY;:72[:^:6X&HZ
MAJ,C3"69E!CDC3RPH,98%CY7"?C9P'QKG>'X?R'&9A6S+$TL16I4\1EF(PU)
MPPM&5>JW5J+DBU3BVD]9-66I]CXU?L_OI(^ 'A_F7B9XD9%PU@.%,JQF5X'&
M8C+>+,KS;%QQ&;XVCE^"C#!864JTXSQ->G&<TN6G'FE+1'V?1117ZT?Q0%%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 5]=?'#_DB'P"_P"P+'_Z
M8]+KY%KZZ^.'_)$/@%_V!8__ $QZ77A9I_R,^'_^PW%?^H&(/3P7^YYK_P!@
MU#_U*HGR+1117NGF!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !7;?#3_DH_P__P"QV\*?^GVPKB:[;X:?\E'^'_\ V.WA3_T^V%<^
M+_W3%?\ 8/6_]-R-L/\ [Q0_Z_4O_2XGIO[47_)9O$?_ %Y>'_\ TQV%?/E?
M0?[47_)9O$?_ %Y>'_\ TQV%?/E<>2?\B;*O^Q?A/_3%,Z,S_P"1CCO^PJO_
M .G)!1117J'"%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MHHKW3S0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#W_]F'_DM'A;_KV\0_\
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M:IIA1116I 4444 %%%% !6IH?_(:T?\ ["FG_P#I7#676IH?_(:T?_L*:?\
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M=\-/!GB;QWXGOB5W6^A>%-'O-;U-XE9E$EP;2RE2VA!WSW#1PQ@O(H/YU?L
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M_P"G?G^'K;^MVBOY(O\ A=__  5*_P"CP[+_ ,)OPS_\[FC_ (7?_P %2O\
MH\.R_P#";\,__.YH_P"(;\8_]"BM_P"!T_\ Y/U_IZ'U_+O^@ZA]U7R_Z=^?
MX>MOZW:*_DB_X7?_ ,%2O^CP[+_PF_#/_P [FC_A=_\ P5*_Z/#LO_";\,__
M #N:/^(;\8_]"BM_X'3_ /D_7^GH?7\N_P"@ZA]U7R_Z=^?X>MOZW:*_DB_X
M7?\ \%2O^CP[+_PF_#/_ ,[FC_A=_P#P5*_Z/#LO_";\,_\ SN:/^(;\8_\
M0HK?^!T__D_7^GH?7\N_Z#J'W5?+_IWY_AZV_K=HK^2+_A=__!4K_H\.R_\
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M%W_\%2O^CP[+_P )OPS_ /.YH_X7?_P5*_Z/#LO_  F_#/\ \[FC_B&_&/\
MT**W_@=/_P"3]?Z>A]?R[_H.H?=5\O\ IWY_AZV_K=HK^2+_ (7?_P %2O\
MH\.R_P#";\,__.YH_P"%W_\ !4K_ */#LO\ PF_#/_SN:/\ B&_&/_0HK?\
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MR_\ ";\,_P#SN:/^%W_\%2O^CP[+_P )OPS_ /.YH_XAOQC_ -"BM_X'3_\
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MR_Z=^?X>MOZW:*_DB_X7?_P5*_Z/#LO_  F_#/\ \[FC_A=__!4K_H\.R_\
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M_P!"BM_X'3_^3]?Z>A]?R[_H.H?=5\O^G?G^'K;^Y?\ :G_X\OA!_P!B:_\
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M=S1_PN__ (*E?]'AV7_A-^&?_G<T?\0WXQ_Z%%;_ ,#I_P#R?K_3T/K^7?\
M0=0^ZKY?]._/\/6W];M%?R1?\+O_ ."I7_1X=E_X3?AG_P"=S1_PN_\ X*E?
M]'AV7_A-^&?_ )W-'_$-^,?^A16_\#I__)^O]/0^OY=_T'4/NJ^7_3OS_#UM
M_6[17\D7_"[_ /@J5_T>'9?^$WX9_P#G<T?\+O\ ^"I7_1X=E_X3?AG_ .=S
M1_Q#?C'_ *%%;_P.G_\ )^O]/0^OY=_T'4/NJ^7_ $[\_P /6W];M%?R1?\
M"[_^"I7_ $>'9?\ A-^&?_G<T?\ "[_^"I7_ $>'9?\ A-^&?_G<T?\ $-^,
M?^A16_\  Z?_ ,GZ_P!/0^OY=_T'4/NJ^7_3OS_#UM_6[17\D7_"[_\ @J5_
MT>'9?^$WX9_^=S1_PN__ (*E?]'AV7_A-^&?_G<T?\0WXQ_Z%%;_ ,#I_P#R
M?K_3T/K^7?\ 0=0^ZKY?]._/\/6W];M%?R1?\+O_ ."I7_1X=E_X3?AG_P"=
MS1_PN_\ X*E?]'AV7_A-^&?_ )W-'_$-^,?^A16_\#I__)^O]/0^OY=_T'4/
MNJ^7_3OS_#UM_6[17\D7_"[_ /@J5_T>'9?^$WX9_P#G<T?\+O\ ^"I7_1X=
ME_X3?AG_ .=S1_Q#?C'_ *%%;_P.G_\ )^O]/0^OY=_T'4/NJ^7_ $[\_P /
M6W];M%?R1?\ "[_^"I7_ $>'9?\ A-^&?_G<T?\ "[_^"I7_ $>'9?\ A-^&
M?_G<T?\ $-^,?^A16_\  Z?_ ,GZ_P!/0^OY=_T'4/NJ^7_3OS_#UM_6[17\
MD7_"[_\ @J5_T>'9?^$WX9_^=S1_PN__ (*E?]'AV7_A-^&?_G<T?\0WXQ_Z
M%%;_ ,#I_P#R?K_3T/K^7?\ 0=0^ZKY?]._/\/6W];M%?R1?\+O_ ."I7_1X
M=E_X3?AG_P"=S1_PN_\ X*E?]'AV7_A-^&?_ )W-'_$-^,?^A16_\#I__)^O
M]/0^OY=_T'4/NJ^7_3OS_#UM_6[17\D7_"[_ /@J5_T>'9?^$WX9_P#G<T?\
M+O\ ^"I7_1X=E_X3?AG_ .=S1_Q#?C'_ *%%;_P.G_\ )^O]/0^OY=_T'4/N
MJ^7_ $[\_P /6W];M%?R1?\ "[_^"I7_ $>'9?\ A-^&?_G<T?\ "[_^"I7_
M $>'9?\ A-^&?_G<T?\ $-^,?^A16_\  Z?_ ,GZ_P!/0^OY=_T'4/NJ^7_3
MOS_#UM_6[17\D7_"[_\ @J5_T>'9?^$WX9_^=S1_PN__ (*E?]'AV7_A-^&?
M_G<T?\0WXQ_Z%%;_ ,#I_P#R?K_3T/K^7?\ 0=0^ZKY?]._/\/6W]RWB[_DT
M3X9_]CG=_P#IP\>U\C5_*5=?M1_\%<;WPMIW@JZ_;:@F\+Z5=M?:?I!\+>#U
MAMKMWO9&F69/ADMTS%]1O6(DG=,W#?+A4"\O_P +O_X*E?\ 1X=E_P"$WX9_
M^=S7FY9X5\:8*&+A4RJ<GB,QQN+BX3@TJ>)K.I",N9Q]^,7:25XIZ*36IUXS
M-\LQ$J#AC:25+"8;#RYE43<Z-*,)-6@_=;NU>SMNEK;^MVBOY(O^%W_\%2O^
MCP[+_P )OPS_ /.YH_X7?_P5*_Z/#LO_  F_#/\ \[FO2_XAOQC_ -"BM_X'
M3_\ D_7^GIR?7\N_Z#J'W5?+_IWY_AZV_K=HK^2+_A=__!4K_H\.R_\ ";\,
M_P#SN:/^%W_\%2O^CP[+_P )OPS_ /.YH_XAOQC_ -"BM_X'3_\ D_7^GH?7
M\N_Z#J'W5?+_ *=^?X>MOZW:*_DB_P"%W_\ !4K_ */#LO\ PF_#/_SN:/\
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M .3]?Z>A]?R[_H.H?=5\O^G?G^'K;^MVBOY(O^%W_P#!4K_H\.R_\)OPS_\
M.YH_X7?_ ,%2O^CP[+_PF_#/_P [FC_B&_&/_0HK?^!T_P#Y/U_IZ'U_+O\
MH.H?=5\O^G?G^'K;^MVBOY(O^%W_ /!4K_H\.R_\)OPS_P#.YH_X7?\ \%2O
M^CP[+_PF_#/_ ,[FC_B&_&/_ $**W_@=/_Y/U_IZ'U_+O^@ZA]U7R_Z=^?X>
MMOZW:*_DB_X7?_P5*_Z/#LO_  F_#/\ \[FC_A=__!4K_H\.R_\ ";\,_P#S
MN:/^(;\8_P#0HK?^!T__ )/U_IZ'U_+O^@ZA]U7R_P"G?G^'K;^MVBOY(O\
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MD'! /((]172>*_VH/^"M_CC48=6\5?MLP:QJ-O91Z?#<S>%O!\+I9PSW%S'
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MPC^'GP^T6_@B62.W\):_IK74^^\C'DWQ$^)OPV^$'_!SA>^.OBS\0O _PO\
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M#0Q%"A5P^(JU9TZ]2-&-:-6,%"I&<K1E.GRR@X7YN5W5]$^"_:*UW0?V9?\
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MHH **** /Y5?VLO$#^)OVD?C-JKNSC_A.]:TN(L<D6^@S_V%;+[!+?38E [
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M)K2\MY[2ZMY'AN+:YB>">"6,[7BFAE59(Y$8%71U5E8$, 1BH*^!X+\5N.>
M9PI9)F]5Y?3FW4R3,5+&95*\KSC'"U)*>#E.5W4J8&KA*TG\=1[']*^/GT,/
MH[?25P];&<?\$8*GQ-B</&.&\0>%94LBXQI+V488:M4S?"T:E#/*5&DHQPN&
MXBP><X&E3=Z.'@VI+^QCP_XAT+Q7H]AXA\,ZQIVO:'JD"W6G:MI-Y!?6%Y _
M22"YMWDB?!!1U#;XY%:.15D5E'X9_P#!5S_DL?P[_P"R:Q_^I/X@KRG]@O\
M:1USX1?%30_ VJZE/-\-_B#JUKH>I:;<3.]KHNNZE(EGI'B&P1BRVL@O7MK3
M5C&$CNM.E>6=9)K&S:+U;_@JY_R6/X=_]DUC_P#4G\05_2/B%XDX'Q,\!LUS
M:CA_J&8X+.\CP6;Y=[3VL<-BOKM"I3JT*C495,)BJ;YZ$YQC.,X5J$N>5!U)
M_P"4?T8_HG\1?1(_:0<&\%YAFG^LG"V?^'_B!G_ _%*PRP=3-<H_L;&87$8/
M,L+&=6EA<[RC$P6'S"C1K5*-6C6P.84?8TL?##4/RSK]V?\ @E!_R2OXG?\
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MG[17_=(__5Z_#&M:'\>C_P!?:?\ Z7$NG_$I_P"./_I2/Q,^#_\ R27X7?\
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M/B8SV]]J</BF.U="T.BW5Z]HJ?U.T5PPR*K0A]7PN<9EAL%JEAHO#U)4H/\
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MO>#3:-_[15.,U@\)0PDZD7"=:$JU6JHR^*-*5:I-4E):/D7-;:2:3"OYT/\
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MPK8; 4)4XU*E/!8+-:^+Q,U*I%*E0I3J-WM'1GZ34445^PG\+A1110 4444
M%%%% !1110 4444 %%%% !1110 5]=?'#_DB'P"_[ L?_ICTNOD6OKKXX?\
M)$/@%_V!8_\ TQZ77A9I_P C/A__ +#<5_Z@8@]/!?[GFO\ V#4/_4JB?(M%
M%%>Z>8%%%% !1110 4444 %?F;_P6(_Y1R?M%?\ =(__ %>OPQK],J\I^-_P
M5^'W[1'PO\3_  =^*FE76M^ _&']B_V]IEEJFHZ+<W/_  C_ (ATGQ1I?EZG
MI5Q:W]MY.LZ)IUP_V>>/SHXGMY=T,LB-=*2A4IS=[1G"3MO:,DW;SLBH-1G&
M3V4HM^B:9_*%\*/'_@.R^%OPUL[SQMX1M+NT\ >#K:ZM;GQ)HT%S;7,'AW3H
MI[>X@EO4EAGAE1HY8I%62.161U# @=__ ,+(^'?_ $/O@O\ \*G0_P#Y.K]>
M_P#ARQ_P3Y_Z)7XG_P##H_$+_P":"C_ARQ_P3Y_Z)7XG_P##H_$+_P":"OV_
M#^,U;#X>AAUDU*2H4:5%2>(FG)4X1@I-*+2;2NTKVUMTOXE3(<+4J3F\577/
M.4VO8PTYI<S5_:=+O[OO_(3_ (61\._^A]\%_P#A4Z'_ /)U'_"R/AW_ -#[
MX+_\*G0__DZOU[_X<L?\$^?^B5^)_P#PZ/Q"_P#F@H_X<L?\$^?^B5^)_P#P
MZ/Q"_P#F@K;_ (C96_Z$E'_PIG_\C_5GY7C_ %>PO_077_\ !,/+_IYZ_P!;
M_D)_PLCX=_\ 0^^"_P#PJ=#_ /DZC_A9'P[_ .A]\%_^%3H?_P G5^O?_#EC
M_@GS_P!$K\3_ /AT?B%_\T%'_#EC_@GS_P!$K\3_ /AT?B%_\T%'_$;*W_0D
MH_\ A3/_ .1_JS\KG^KV%_Z"Z_\ X)AY?]//7^M_R$_X61\._P#H??!?_A4Z
M'_\ )U'_  LCX=_]#[X+_P#"IT/_ .3J_7O_ (<L?\$^?^B5^)__  Z/Q"_^
M:"C_ (<L?\$^?^B5^)__  Z/Q"_^:"C_ (C96_Z$E'_PIG_\C_5GY7/]7L+_
M -!=?_P3#R_Z>>O];_D)_P +(^'?_0^^"_\ PJ=#_P#DZC_A9'P[_P"A]\%_
M^%3H?_R=7Z]_\.6/^"?/_1*_$_\ X='XA?\ S04?\.6/^"?/_1*_$_\ X='X
MA?\ S04?\1LK?]"2C_X4S_\ D?ZL_*Y_J]A?^@NO_P""8>7_ $\]?ZW_ "$_
MX61\._\ H??!?_A4Z'_\G4?\+(^'?_0^^"__  J=#_\ DZOU[_X<L?\ !/G_
M *)7XG_\.C\0O_F@H_X<L?\ !/G_ *)7XG_\.C\0O_F@H_XC96_Z$E'_ ,*9
M_P#R/]6?E<_U>PO_ $%U_P#P3#R_Z>>O];_D)_PLCX=_]#[X+_\ "IT/_P"3
MJ/\ A9'P[_Z'WP7_ .%3H?\ \G5^O?\ PY8_X)\_]$K\3_\ AT?B%_\ -!1_
MPY8_X)\_]$K\3_\ AT?B%_\ -!1_Q&RM_P!"2C_X4S_^1_JS\KG^KV%_Z"Z_
M_@F'E_T\]?ZW_(3_ (61\._^A]\%_P#A4Z'_ /)U'_"R/AW_ -#[X+_\*G0_
M_DZOU[_X<L?\$^?^B5^)_P#PZ/Q"_P#F@H_X<L?\$^?^B5^)_P#PZ/Q"_P#F
M@H_XC96_Z$E'_P *9_\ R/\ 5GY7/]7L+_T%U_\ P3#R_P"GGK_6_P"0G_"R
M/AW_ -#[X+_\*G0__DZC_A9'P[_Z'WP7_P"%3H?_ ,G5^O?_  Y8_P""?/\
MT2OQ/_X='XA?_-!1_P .6/\ @GS_ -$K\3_^'1^(7_S04?\ $;*W_0DH_P#A
M3/\ ^1_JS\KG^KV%_P"@NO\ ^"8>7_3SU_K?\A/^%D?#O_H??!?_ (5.A_\
MR=1_PLCX=_\ 0^^"_P#PJ=#_ /DZOU[_ .'+'_!/G_HE?B?_ ,.C\0O_ )H*
M/^'+'_!/G_HE?B?_ ,.C\0O_ )H*/^(V5O\ H24?_"F?_P C_5GY7/\ 5["_
M]!=?_P $P\O^GGK_ %O^0G_"R/AW_P!#[X+_ /"IT/\ ^3J/^%D?#O\ Z'WP
M7_X5.A__ "=7Z]_\.6/^"?/_ $2OQ/\ ^'1^(7_S04?\.6/^"?/_ $2OQ/\
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M,/+_ *>>O];_ )"?\+(^'?\ T/O@O_PJ=#_^3J/^%D?#O_H??!?_ (5.A_\
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M/_A3/_Y'^K/RN?ZO87_H+K_^"8>7_3SU_K?\A/\ A9'P[_Z'WP7_ .%3H?\
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M)1_\*9__ "/]6?E<_P!7L+_T%U__  3#R_Z>>O\ 6_Y"?\+(^'?_ $/O@O\
M\*G0_P#Y.H_X61\._P#H??!?_A4Z'_\ )U?KW_PY8_X)\_\ 1*_$_P#X='XA
M?_-!1_PY8_X)\_\ 1*_$_P#X='XA?_-!1_Q&RM_T)*/_ (4S_P#D?ZL_*Y_J
M]A?^@NO_ ."8>7_3SU_K?\A/^%D?#O\ Z'WP7_X5.A__ "=1_P +(^'?_0^^
M"_\ PJ=#_P#DZOU[_P"'+'_!/G_HE?B?_P .C\0O_F@H_P"'+'_!/G_HE?B?
M_P .C\0O_F@H_P"(V5O^A)1_\*9__(_U9^5S_5["_P#077_\$P\O^GGK_6_Y
M"?\ "R/AW_T/O@O_ ,*G0_\ Y.H_X61\._\ H??!?_A4Z'_\G5^O?_#EC_@G
MS_T2OQ/_ .'1^(7_ ,T%'_#EC_@GS_T2OQ/_ .'1^(7_ ,T%'_$;*W_0DH_^
M%,__ )'^K/RN?ZO87_H+K_\ @F'E_P!//7^M_P A/^%D?#O_ *'WP7_X5.A_
M_)U'_"R/AW_T/O@O_P *G0__ ).K]>_^'+'_  3Y_P"B5^)__#H_$+_YH*/^
M'+'_  3Y_P"B5^)__#H_$+_YH*/^(V5O^A)1_P#"F?\ \C_5GY7/]7L+_P!!
M=?\ \$P\O^GGK_6_Y"?\+(^'?_0^^"__  J=#_\ DZC_ (61\._^A]\%_P#A
M4Z'_ /)U?KW_ ,.6/^"?/_1*_$__ (='XA?_ #04?\.6/^"?/_1*_$__ (='
MXA?_ #04?\1LK?\ 0DH_^%,__D?ZL_*Y_J]A?^@NO_X)AY?]//7^M_R$_P"%
MD?#O_H??!?\ X5.A_P#R=1_PLCX=_P#0^^"__"IT/_Y.K]>_^'+'_!/G_HE?
MB?\ \.C\0O\ YH*/^'+'_!/G_HE?B?\ \.C\0O\ YH*/^(V5O^A)1_\ "F?_
M ,C_ %9^5S_5["_]!=?_ ,$P\O\ IYZ_UO\ D)_PLCX=_P#0^^"__"IT/_Y.
MH_X61\._^A]\%_\ A4Z'_P#)U?KW_P .6/\ @GS_ -$K\3_^'1^(7_S04?\
M#EC_ ()\_P#1*_$__AT?B%_\T%'_ !&RM_T)*/\ X4S_ /D?ZL_*Y_J]A?\
MH+K_ /@F'E_T\]?ZW_(3_A9'P[_Z'WP7_P"%3H?_ ,G4?\+(^'?_ $/O@O\
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M/AW_ -#[X+_\*G0__DZC_A9'P[_Z'WP7_P"%3H?_ ,G5^O?_  Y8_P""?/\
MT2OQ/_X='XA?_-!1_P .6/\ @GS_ -$K\3_^'1^(7_S04?\ $;*W_0DH_P#A
M3/\ ^1_JS\KG^KV%_P"@NO\ ^"8>7_3SU_K?\A/^%D?#O_H??!?_ (5.A_\
MR=1_PLCX=_\ 0^^"_P#PJ=#_ /DZOU[_ .'+'_!/G_HE?B?_ ,.C\0O_ )H*
M/^'+'_!/G_HE?B?_ ,.C\0O_ )H*/^(V5O\ H24?_"F?_P C_5GY7/\ 5["_
M]!=?_P $P\O^GGK_ %O^0G_"R/AW_P!#[X+_ /"IT/\ ^3J/^%D?#O\ Z'WP
M7_X5.A__ "=7Z]_\.6/^"?/_ $2OQ/\ ^'1^(7_S04?\.6/^"?/_ $2OQ/\
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MZ/Q"_P#F@H_X<L?\$^?^B5^)_P#PZ/Q"_P#F@H_XC96_Z$E'_P *9_\ R/\
M5GY7/]7L+_T%U_\ P3#R_P"GGK_6_P"0G_"R/AW_ -#[X+_\*G0__DZC_A9'
MP[_Z'WP7_P"%3H?_ ,G5^O?_  Y8_P""?/\ T2OQ/_X='XA?_-!1_P .6/\
M@GS_ -$K\3_^'1^(7_S04?\ $;*W_0DH_P#A3/\ ^1_JS\KG^KV%_P"@NO\
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M4?\ "R/AW_T/O@O_ ,*G0_\ Y.K]>_\ ARQ_P3Y_Z)7XG_\ #H_$+_YH*/\
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ME;_H24?_  IG_P#(_P!6?E<_U>PO_077_P#!,/+_ *>>O];_ )"?\+(^'?\
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MB?\ \.C\0O\ YH*/^(V5O^A)1_\ "F?_ ,C_ %9^5S_5["_]!=?_ ,$P\O\
MIYZ_UO\ D)_PLCX=_P#0^^"__"IT/_Y.H_X61\._^A]\%_\ A4Z'_P#)U?KW
M_P .6/\ @GS_ -$K\3_^'1^(7_S04?\ #EC_ ()\_P#1*_$__AT?B%_\T%'_
M !&RM_T)*/\ X4S_ /D?ZL_*Y_J]A?\ H+K_ /@F'E_T\]?ZW_(3_A9'P[_Z
M'WP7_P"%3H?_ ,G4?\+(^'?_ $/O@O\ \*G0_P#Y.K]>_P#ARQ_P3Y_Z)7XG
M_P##H_$+_P":"C_ARQ_P3Y_Z)7XG_P##H_$+_P":"C_B-E;_ *$E'_PIG_\
M(_U9^5S_ %>PO_077_\ !,/+_IYZ_P!;_D)_PLCX=_\ 0^^"_P#PJ=#_ /DZ
MC_A9'P[_ .A]\%_^%3H?_P G5^O?_#EC_@GS_P!$K\3_ /AT?B%_\T%'_#EC
M_@GS_P!$K\3_ /AT?B%_\T%'_$;*W_0DH_\ A3/_ .1_JS\KG^KV%_Z"Z_\
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MK?\ 0DH_^%,__D?ZL_*Y_J]A?^@NO_X)AY?]//7^M_R$_P"%D?#O_H??!?\
MX5.A_P#R=1_PLCX=_P#0^^"__"IT/_Y.K]>_^'+'_!/G_HE?B?\ \.C\0O\
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M-E;_ *$E'_PIG_\ (_U9^5S_ %>PO_077_\ !,/+_IYZ_P!;_D)_PLCX=_\
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M^KV%_P"@NO\ ^"8>7_3SU_K?\A/^%D?#O_H??!?_ (5.A_\ R=1_PLCX=_\
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M\%_^%3H?_P G4?\ "R/AW_T/O@O_ ,*G0_\ Y.K]>_\ ARQ_P3Y_Z)7XG_\
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M"2C_ .%,_P#Y'^K/RN?ZO87_ *"Z_P#X)AY?]//7^M_R$_X61\._^A]\%_\
MA4Z'_P#)U'_"R/AW_P!#[X+_ /"IT/\ ^3J_8*U_X(J_\$]Y;JVC?X5^)RDD
M\*./^%I?$,95Y%5AD>(01D$\@Y':O=_VC?\ @@W_ ,$U/AWXXTO1/"OP?\6V
M6G77A6QU2:*;XN_$R]=KR?5M<M))!+=^)99%4P65NHC#! 4+!0SL3R5/'>5+
M%X;!RR./M<53Q%2DU7DX*.&5)U.=Z23_ 'L>5*,D[2NU97WAPO0G0K8A8RK[
M.A.C":=*',W6YN7E2FTTN27-=JVEN8_ ;_A9'P[_ .A]\%_^%3H?_P G4?\
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MB?\ \.C\0O\ YH*/^(V5O^A)1_\ "F?_ ,C_ %9^5S_5["_]!=?_ ,$P\O\
MIYZ_UO\ D)_PLCX=_P#0^^"__"IT/_Y.H_X61\._^A]\%_\ A4Z'_P#)U?KW
M_P .6/\ @GS_ -$K\3_^'1^(7_S04?\ #EC_ ()\_P#1*_$__AT?B%_\T%'_
M !&RM_T)*/\ X4S_ /D?ZL_*Y_J]A?\ H+K_ /@F'E_T\]?ZW_(3_A9'P[_Z
M'WP7_P"%3H?_ ,G4?\+(^'?_ $/O@O\ \*G0_P#Y.K]>_P#ARQ_P3Y_Z)7XG
M_P##H_$+_P":"C_ARQ_P3Y_Z)7XG_P##H_$+_P":"C_B-E;_ *$E'_PIG_\
M(_U9^5S_ %>PO_077_\ !,/+_IYZ_P!;_D)_PLCX=_\ 0^^"_P#PJ=#_ /DZ
MC_A9'P[_ .A]\%_^%3H?_P G5^O?_#EC_@GS_P!$K\3_ /AT?B%_\T%'_#EC
M_@GS_P!$K\3_ /AT?B%_\T%'_$;*W_0DH_\ A3/_ .1_JS\KG^KV%_Z"Z_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M(99['P?H%O.C Y!29+ 2J0>05<<\UZ4B)&BQQHL<:*%1$4*B*!@*JJ %4#@
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MX3_TQ3.C,_\ D8X[_L*K_P#IR04445ZAPA1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% 'UU^U/_ ,>7P@_[$U__ $3I%?(M?77[4_\
MQY?"#_L37_\ 1.D5\BUX7#7_ "),'ZXK_P!3,0>GG'_(QQ'I0_\ 4>D%%%%>
MZ>8%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?7/B[
M_DT3X9_]CG=_^G#Q[7R-7USXN_Y-$^&?_8YW?_IP\>U\C5X60?P<R_['>;?^
MI4CTLS^/!_\ 8MP'_J/$****]T\T**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH M6/_ !^V?_7U;_\ HY*^IOVQ?^2G:)_V(NE_^G_Q
M-7RS8_\ '[9_]?5O_P"CDKZF_;%_Y*=HG_8BZ7_Z?_$U>'C/^1]DO_8+F_\
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M@ HHHH **** "BBB@ HHHH ]_P#V8?\ DM'A;_KV\0_^H[JE?JS7Y3?LP_\
M):/"W_7MXA_]1W5*_5FOR/CO_D<T?^Q?0_\ 3^*/O>%_^1?5_P"PNI_Z:H%:
M(#>.".O8CM]37XP?$/\ Y'_QS_V.'B;_ -/5[7[/Q8WCD=#V4?R)-?)FO?!+
MX&ZCKFLZAJ6H^*$U&_U74;R_2&ZD6%+VZO)I[I8E&D2 1+.\@C'F/A !O;[Q
MY^%\YP>38C%U,8JW+6HTH0]E!3?-"3;NG*%E9^>M]B\YR[$9C1H1P_L[TZDY
M2YY.*M*,4K-1E?8_..BOT'_X4-\ /^@GXM_\"Y/_ )34?\*&^ '_ $$_%O\
MX%R?_*:OM/\ 7C).V,_\)X__ "T^?_U:S+_J'_\ !K_^0/SXHK]!_P#A0WP
M_P"@GXM_\"Y/_E-1_P *&^ '_03\6_\ @7)_\IJ/]>,D[8S_ ,)X_P#RT/\
M5K,O^H?_ ,&O_P"0/SXHK]!_^%#? #_H)^+?_ N3_P"4U'_"AO@!_P!!/Q;_
M .!<G_RFH_UXR3MC/_">/_RT/]6LR_ZA_P#P:_\ Y _/BBOT'_X4-\ /^@GX
MM_\  N3_ .4U'_"AO@!_T$_%O_@7)_\ *:C_ %XR3MC/_">/_P M#_5K,O\
MJ'_\&O\ ^0/SXHK]!_\ A0WP _Z"?BW_ ,"Y/_E-1_PH;X ?]!/Q;_X%R?\
MRFH_UXR3MC/_  GC_P#+0_U:S+_J'_\ !K_^0/SXHK]!_P#A0WP _P"@GXM_
M\"Y/_E-1_P *&^ '_03\6_\ @7)_\IJ/]>,D[8S_ ,)X_P#RT/\ 5K,O^H?_
M ,&O_P"0/SXHK]!_^%#? #_H)^+?_ N3_P"4U'_"AO@!_P!!/Q;_ .!<G_RF
MH_UXR3MC/_">/_RT/]6LR_ZA_P#P:_\ Y _/BBOT'_X4-\ /^@GXM_\  N3_
M .4U'_"AO@!_T$_%O_@7)_\ *:C_ %XR3MC/_">/_P M#_5K,O\ J'_\&O\
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MS+_J'_\ !K_^0/SXHK]!_P#A0WP _P"@GXM_\"Y/_E-1_P *&^ '_03\6_\
M@7)_\IJ/]>,D[8S_ ,)X_P#RT/\ 5K,O^H?_ ,&O_P"0/SXHK]!_^%#? #_H
M)^+?_ N3_P"4U'_"AO@!_P!!/Q;_ .!<G_RFH_UXR3MC/_">/_RT/]6LR_ZA
M_P#P:_\ Y _/BBOT'_X4-\ /^@GXM_\  N3_ .4U'_"AO@!_T$_%O_@7)_\
M*:C_ %XR3MC/_">/_P M#_5K,O\ J'_\&O\ ^0/SXHK]!_\ A0WP _Z"?BW_
M ,"Y/_E-1_PH;X ?]!/Q;_X%R?\ RFH_UXR3MC/_  GC_P#+0_U:S+_J'_\
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M!<G_ ,IJ/]>,D[8S_P )X_\ RT/]6LR_ZA__  :__D#\^**_0?\ X4-\ /\
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M_P )X_\ RT/]6LR_ZA__  :__D#\^**_0?\ X4-\ /\ H)^+?_ N3_Y34?\
M"AO@!_T$_%O_ (%R?_*:C_7C).V,_P#">/\ \M#_ %:S+_J'_P#!K_\ D#\^
M**_0?_A0WP _Z"?BW_P+D_\ E-1_PH;X ?\ 03\6_P#@7)_\IJ/]>,D[8S_P
MGC_\M#_5K,O^H?\ \&O_ .0/SXHK]!_^%#? #_H)^+?_  +D_P#E-1_PH;X
M?]!/Q;_X%R?_ "FH_P!>,D[8S_PGC_\ +0_U:S+_ *A__!K_ /D#\^**_0?_
M (4-\ /^@GXM_P# N3_Y34?\*&^ '_03\6_^!<G_ ,IJ/]>,D[8S_P )X_\
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MW_P+D_\ E-1_PH;X ?\ 03\6_P#@7)_\IJ/]>,D[8S_PGC_\M#_5K,O^H?\
M\&O_ .0/SXHK]!_^%#? #_H)^+?_  +D_P#E-1_PH;X ?]!/Q;_X%R?_ "FH
M_P!>,D[8S_PGC_\ +0_U:S+_ *A__!K_ /D#\^**_0?_ (4-\ /^@GXM_P#
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M (3Q_P#EH?ZM9E_U#_\ @U__ "!^?%%?H/\ \*&^ '_03\6_^!<G_P IJ/\
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M;_X%R?\ RFH_X4-\ /\ H)^+?_ N3_Y34?Z\9)VQG_A/'_Y:'^K69?\ 4/\
M^#7_ /('Y\45^@__  H;X ?]!/Q;_P"!<G_RFH_X4-\ /^@GXM_\"Y/_ )34
M?Z\9)VQG_A/'_P"6A_JUF7_4/_X-?_R!^?%%?H/_ ,*&^ '_ $$_%O\ X%R?
M_*:C_A0WP _Z"?BW_P "Y/\ Y34?Z\9)VQG_ (3Q_P#EH?ZM9E_U#_\ @U__
M "!^?%%?H/\ \*&^ '_03\6_^!<G_P IJ/\ A0WP _Z"?BW_ ,"Y/_E-1_KQ
MDG;&?^$\?_EH?ZM9E_U#_P#@U_\ R!^?%%?H/_PH;X ?]!/Q;_X%R?\ RFH_
MX4-\ /\ H)^+?_ N3_Y34?Z\9)VQG_A/'_Y:'^K69?\ 4/\ ^#7_ /('Y\45
M^@__  H;X ?]!/Q;_P"!<G_RFH_X4-\ /^@GXM_\"Y/_ )34?Z\9)VQG_A/'
M_P"6A_JUF7_4/_X-?_R!^?%%?H/_ ,*&^ '_ $$_%O\ X%R?_*:C_A0WP _Z
M"?BW_P "Y/\ Y34?Z\9)VQG_ (3Q_P#EH?ZM9E_U#_\ @U__ "!^?%%?H/\
M\*&^ '_03\6_^!<G_P IJ/\ A0WP _Z"?BW_ ,"Y/_E-1_KQDG;&?^$\?_EH
M?ZM9E_U#_P#@U_\ R!^?%%?H/_PH;X ?]!/Q;_X%R?\ RFH_X4-\ /\ H)^+
M?_ N3_Y34?Z\9)VQG_A/'_Y:'^K69?\ 4/\ ^#7_ /('Y\45^@__  H;X ?]
M!/Q;_P"!<G_RFH_X4-\ /^@GXM_\"Y/_ )34?Z\9)VQG_A/'_P"6A_JUF7_4
M/_X-?_R!^?%%?H/_ ,*&^ '_ $$_%O\ X%R?_*:C_A0WP _Z"?BW_P "Y/\
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MC_\ +0_U:S+_ *A__!K_ /D#\^**_0?_ (4-\ /^@GXM_P# N3_Y34?\*&^
M'_03\6_^!<G_ ,IJ/]>,D[8S_P )X_\ RT/]6LR_ZA__  :__D#\^**_0?\
MX4-\ /\ H)^+?_ N3_Y34?\ "AO@!_T$_%O_ (%R?_*:C_7C).V,_P#">/\
M\M#_ %:S+_J'_P#!K_\ D#\^**_0?_A0WP _Z"?BW_P+D_\ E-1_PH;X ?\
M03\6_P#@7)_\IJ/]>,D[8S_PGC_\M#_5K,O^H?\ \&O_ .0/SXHK]!_^%#?
M#_H)^+?_  +D_P#E-1_PH;X ?]!/Q;_X%R?_ "FH_P!>,D[8S_PGC_\ +0_U
M:S+_ *A__!K_ /D#\^**_0?_ (4-\ /^@GXM_P# N3_Y34?\*&^ '_03\6_^
M!<G_ ,IJ/]>,D[8S_P )X_\ RT/]6LR_ZA__  :__D#\^**_0?\ X4-\ /\
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M_P )X_\ RT/]6LR_ZA__  :__D#\^**_0?\ X4-\ /\ H)^+?_ N3_Y34?\
M"AO@!_T$_%O_ (%R?_*:C_7C).V,_P#">/\ \M#_ %:S+_J'_P#!K_\ D#\^
M**_0?_A0WP _Z"?BW_P+D_\ E-1_PH;X ?\ 03\6_P#@7)_\IJ/]>,D[8S_P
MGC_\M#_5K,O^H?\ \&O_ .0/SXHK]!_^%#? #_H)^+?_  +D_P#E-1_PH;X
M?]!/Q;_X%R?_ "FH_P!>,D[8S_PGC_\ +0_U:S+_ *A__!K_ /D#\^**_0?_
M (4-\ /^@GXM_P# N3_Y34?\*&^ '_03\6_^!<G_ ,IJ/]>,D[8S_P )X_\
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MWP _Z"?BW_P+D_\ E-1_KQDG;&?^$\?_ ):'^K69?]0__@U__('Y\45^@_\
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M_P#*:C_A0WP _P"@GXM_\"Y/_E-1_KQDG;&?^$\?_EH?ZM9E_P!0_P#X-?\
M\@?GQ17Z#_\ "AO@!_T$_%O_ (%R?_*:C_A0WP _Z"?BW_P+D_\ E-1_KQDG
M;&?^$\?_ ):'^K69?]0__@U__('Y\45^@_\ PH;X ?\ 03\6_P#@7)_\IJ/^
M%#? #_H)^+?_  +D_P#E-1_KQDG;&?\ A/'_ .6A_JUF7_4/_P"#7_\ ('Y\
M45^@_P#PH;X ?]!/Q;_X%R?_ "FH_P"%#? #_H)^+?\ P+D_^4U'^O&2=L9_
MX3Q_^6A_JUF7_4/_ .#7_P#('Y\45^@__"AO@!_T$_%O_@7)_P#*:C_A0WP
M_P"@GXM_\"Y/_E-1_KQDG;&?^$\?_EH?ZM9E_P!0_P#X-?\ \@?GQ17Z#_\
M"AO@!_T$_%O_ (%R?_*:C_A0WP _Z"?BW_P+D_\ E-1_KQDG;&?^$\?_ ):'
M^K69?]0__@U__('Y\45^@_\ PH;X ?\ 03\6_P#@7)_\IJ/^%#? #_H)^+?_
M  +D_P#E-1_KQDG;&?\ A/'_ .6A_JUF7_4/_P"#7_\ ('Y\45^@_P#PH;X
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MO_@7)_\ *:C_ (4-\ /^@GXM_P# N3_Y34?Z\9)VQG_A/'_Y:'^K69?]0_\
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MG_RFH_UXR3MC/_">/_RT/]6LR_ZA_P#P:_\ Y _/BBOT'_X4-\ /^@GXM_\
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MT$_%O_@7)_\ *:C_ %XR3MC/_">/_P M#_5K,O\ J'_\&O\ ^0/SXHK]!_\
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MG_RFH_UXR3MC/_">/_RT/]6LR_ZA_P#P:_\ Y _/BBOT'_X4-\ /^@GXM_\
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MT$_%O_@7)_\ *:C_ %XR3MC/_">/_P M#_5K,O\ J'_\&O\ ^0/SXHK]!_\
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M.OF36O\ D,ZM_P!A._\ _2J6OGY[_+[MSTZ?P]_^&1F4445!H%%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\RZU_P AG5O^PG?_ /I5+5SW^7^9G3^'M_PR,RBBBH- HHHH **** "BBB@
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M,M=3\._^1EA_Z]+O_P! %<MJW_(5U/\ ["%[_P"E,M &?1110 4444 %%%%
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M]HX3G4G>%*G/EJ.G_6WT4?H@\??2IXEQF&R3$4N&>".'ZE"/%?'&/PM3%X7
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M 4444 %%%% !1110 4444 %%%% !7I'BS_D5/!W_ %ZC_P!);>O-Z](\6?\
M(J>#O^O4?^DMO0!YO1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 5JZ%_R'-&_["NG?^E<-95:NA?\AS1O^PKIW_I7#0!O>/\
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M/X?^,_"FG^(?M>H?#[PA<?9O%5KKEG;_ -D>5:V\,%_J<=Z ?&7PO_X-]_\
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M1^(_%?@S6UDT.'5-;M-*\4^"/%O@^^T7Q3-HVJW'AG5_[5T;4- ALHGNK2$
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MM^*=)TGQ/=KIU^/"D$.M:IJ%FUOHUXB@'Z!T5_)-\"/%'_!R]_P4:^$WA?\
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M'B:T?2=:U#0_&OA+57\4^'[;2+72M4TVV /Z!**_D$_;7_X*[?\ !1+X ?\
M!:WXI_L2?LYZ):_M":9XU^#_ ,//"O[-'[.&L>'?AUH7A/2OCGX[\&^ O%=Q
M\1O'7Q$@T/0_B5<>"_"6AQ?$#Q-KVEW/Q$L=&-OMBN[WP]H]LVM:*S]JSQA_
MP<\?L+?"KQ'^VIX[_:/_ &/OCU\,OA[8CQ9\5_V=/!OPQT$:5X'\+F73Q>WM
MEJ+?"KX<?$/Q+X?\.H]P_B&ZL/BVVMZ;:&XU*W@UK3H)[W30#^OZBOR,^&W[
M3/[0'_!4'_@E%X4_:$_8-^(7A3]E[]I7XT^'/#S>&O%'C72M*\?^&?A/XX\"
M_%S3= ^-/AV_TS7_  5XOL];L+W2_"7C[PWX7O\ 5/!$]Q=Z?KOA_P 21V>E
M336U_9_G5K'[)W_!SCX>TG5-?U__ (+$_LCZ'H6AZ=>ZQK6M:Q\ /@_IFDZ/
MI.F6TM[J.J:IJ5[^R;!9Z?IVGV<$UW>WMW-#;6EM#+//+'%&[@ _J(HK^,#_
M ((9?MM_\%COVZ/VZO%8^(?[6>D?M ?L$_L[ZAX[T;XK_$6R^ OP;^&W@WXO
M:[?^%/$FA?#+1/ASJ^D?!+P/\1QJ<_B>[T'XGRV;7'AZXTWP5H,<?C2+39O%
M.A^'?$'W-^V[_P %*?\ @HC\5/\ @H/JO_!+[_@EC\-OAKH?Q \#^#;;Q?\
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M_P#7I=_^@"N6U;_D*ZG_ -A"]_\ 2F6@#/HHHH **** "BBB@ HHHH ****
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M#_P"/_R/K_2U^\O^(BS]J+_I'1)_X<KQ3_\ .TH_XB+/VHO^D=$G_ARO%/\
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M\1%G[47_ $CHD_\ #E>*?_G:5\&T4?\ $MW /;&_^#JO_P N#_7_ #KM0_\
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M_EP?Z_YUVH?^ 1_^1]?Z6OWE_P 1%G[47_2.B3_PY7BG_P"=I1_Q$6?M1?\
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MBC_B6[@'MC?_  =5_P#EP?Z_YUVH?^ 1_P#D?7^EK]Y?\1%G[47_ $CHD_\
M#E>*?_G:4?\ $19^U%_TCHD_\.5XI_\ G:5\&T4?\2W< ]L;_P"#JO\ \N#_
M %_SKM0_\ C_ /(^O]+7[R_XB+/VHO\ I'1)_P"'*\4__.TK\S?VV/VV?CA_
MP4/^.O[,/C7QE^S!J_P5T_X+ZGJEA++9ZKK?BJTU"U\4:UX=O;B^OKF\\,:
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M>6NIV]I=6+I)%>PP3121I^&O[:'B7_AIC_@KY_P3]_8)OVCO?A9\$? 7B_\
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M[\8_#?@^\@MO!>G_  W\500R^&]0U'6?'G@'6[RX\4>)OL?VK1;'4UUKH/\
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M&W__  4</QA\3>(/'WQ-^ 7P?_:8^#=E\1;^ZFU/QCXQ^'R? :R\6V5QXJU
MI]LU77-#T/Q/K7AS4-=NFGU'5=!TK3]1UB\OM:?5-2NOD[_@B3\'/^"Z_BK]
M@3P-K_\ P3X_:L_87^&?[/6H>._B8;?P5\6/#^K:C\2M'\9VOBFYLO$S>+[F
MS_9O^(,+76H_9M/U31D_X2S4F3PM>Z"&2QXL+;^N#]@3_@G)\#OV _V.M,_8
MZ\%I+X[\*ZE;^)+WXM>)/$VGVMG>?%SQ=XZTRVTCQQX@UW2;.6:WL;'5M)M+
M'PYI>B+>:A)H_A+2=%T2?5M7GL)=4N_P'\$?\$W?^"PW_!'+XM_%>3_@DT?A
M+^UI^QQ\5O$J>+;7]FCX[>,K3P_XG\$ZQ<JMK/-;W?B/QC\,]$77-+T>VT_0
M(_'>C?$&.;QCI-AHY\9>!KJ\T#2Y4 /GS_@I+_P3R_X+D?M._ [PI\./^"A/
M_!0C_@D[X9^$"?%;0M=\':AXY\7:O\%K>X^*=CX6\:6^CZ;H?BZX_9;\-37>
MMW/A.]\:3CP_9:A)<:AI5GJEXUG+;:9/+!^IO_!1;_@J7\4O^"8'[//["'[,
M?P@\#>$_VG?V[/VBO 'PZ^&/P_1-8U&_^&-UXET?0?!'@23QT)K:/PSJ?CBU
M\=_$#7+'3O >C1:AX+768;B_UK5]6T2'38M*U;XQ\1_\$R?^"MW_  6"_: ^
M$/C7_@KK'\)?V8?V3/@IX@3Q)8_LJ?!KQ58^*-3\:7Z7$/VR&[N_"WC/X@Z5
M'?>*-+A;0M<\=ZS\1KS4_#NBSW]EX%\&:/+KVJWD?VO_ ,%P_P#@DU\>_P!L
MF_\ V4?VF/V&_%OA7P'^U!^Q7KUOJGPX\,:_<66@>&]9TS2?$7ACQAX/?PS=
MW6FZAX:T/Q-X \5>%K._T33M<L+;POK.FWUY8ZK?6:Z;IL%R >-:?^RQ_P '
M/O[0-K#/\6_^"@W[+G[(_AS7([>2_P#"/P9^'.A>,/&N@17EOF\M'U,?"_S8
M+W26*PV[:!\:KV&[N);R4ZMY5KI]Q-\*_P#!M!X-\0?#K_@J9_P6!^'WBSXE
M:I\9_%/@3Q1XL\&^)?C#K<<D6M?%?Q!X8_:*\>:)K/Q*U>*;5_$$L>J>.M1L
M;GQ1?QRZ]K<B7>JS*^KZDP-[-]\:5XX_X.E/VB-%3X/^(_@3^Q=^P]%J=I_8
M_BG]IT>*]%\?>)K*Q<+;7NO?#SP;X3^,OQFM+'Q%+:BXN+2WU[PFEJU[-;_9
M=2\+-$+NVY'_ ((K?\$I?VL?^"9/_!1C]L6/QIX6UOXC?LN?$WX5:%IW@7]J
MO6?&GPREUCX@>.M*U;PEXGOY=<^'EGX_U+XEZ!+KNI>(/'\=S+K'AJ^CM;[P
M[;12^(=6MK^VU_50#RS]H'_@C=\9-9_:Y_:'_;4_X(@?\%'?A[\+/BGXX\4:
MAK'QW^"^G?$2*[\-Z=X]\3:I>^)_$ND:MKWP_C\?Z;#I_BC75OO$FC_#?XH?
M#NXT[2/$3WTMEK]AHOV2WT#R74/^"P__  6V_P""47B+X>:?_P %<OV8O!WQ
M;^ 'BOQ=:>#A\>_ 8\%:3XIOYF26\N[C1?$/PJU6;X97>NV^@6FK:YI?@'Q=
M\/OA_P"(?%4.B7PAU?2;:WU#4[;WWQ;_ ,$SO^"JG_!,7]LO]H#]I_\ X(_V
MWP9^.GP+_:BUV7Q9\1?V4OBWKMAX7DT/7Y=9U;7Q9:?-KWBKX=Z-<:;X<U#Q
M%XD3X>^)-+^)&BZMI>D:_=^&O$WAG6[32[?5]7YKXY?L%?\ !;'_ (+1>)/@
M[\.O^"D/A#]GW]A_]C[X8_$*Q^(WBCX=_"CQ7H_CWXG>--:TW3-6T!-0TN^T
M'QI\7=(?Q&^A:_XCT+0[W4?%GA;P]X9TSQ+?:Q?>&O%^LV%KIUR <7_P6E\0
M:1XL_P""W/\ P0C\5>(KJ&^^!GB;Q#\'_$'@Z]U1!'H%YXAUGX_Z!J+W31LJ
MW"-<17/PNEODU%5T]8'L5NE%N-1 _LWK\;?^"MW_  2*\"_\%(_V:?A]\-/!
M?B6U^"WQF_9WNX-9_9J^(Z6]_<Z=X3>VT[3=,N_!.N/8RG7H?"/B"ST/0!-J
MFD32ZYX?UKP]X=\1VD&KC2[O0]8_-S0/B9_P=@?#_P (6OP,F_9@_8\^+6N:
M=:6WANP_:ZU7XA>!$DFM((5LO^$KU[PO+\:/!E[K6M[(#>?;O^%-V*3S7,,N
MH^%-1G6\B< \5^'#Q2_\'@WQH/PVDA^P0_L_(GQD_LE?]%DE7]F3X9J\>I,Z
M&!YD\1O\._MS:<PVZQ$L-ZXU&/58JZC_ ((T:+IL_P#P7Y_X+A>(I;97UC2O
M$_BW1;&\).^#3=?^-SWVK6RC.TK=W7AK1I7)!(-D@4@%L_HE_P $>/\ @D#X
MO_86\6?&K]K/]J[XM67[0/[>'[3CWDGQ/\?:7%</X:\&:/K6NQ>*O$?A?PMJ
M=_8:3J.O77BGQ-::5JWBC6Y-$\.:2D7A_P ,^'?#/AC2=,T*YU#Q#YW_ ,$R
M?V$_VJ_V>_\ @K/_ ,%7OVF?C!\+/^$0^"/[2OBV_P!3^"?C;_A./AQK_P#P
MFEC/\2M8\013_P#"-^%_%^M>+O#F[2+J"[\KQ;H&@S+YGD-&+E7A4 ]4_P"#
ME>W@F_X(J_MDR30Q2R6LO[.MQ:O)&CO;3M^U7\#[5IH&92T,K6US<6[21E7,
M$\T);RY75O-?AI^WYX+_ .":G_!OM^QU^U%XO\-77CB]T7]ES]GOPEX!\!6F
MHKHS^-OB%XI\(6%OX?T.YUM[/4%T72HH;74=;UW5!87\]IH>CZB]C8:AJ!M+
M&X^P_P#@M]^S5\:_VO\ _@E[^T[^SM^SMX+_ .%A_&/XA_\ "EO^$/\ !_\
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MP3H[G2-$OP#TO]O?_E:^_P""5W_9IUG_ .G3]N:OZ[Z_G,_:Y_8._:N^)_\
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MAS]J^X6.:-)46>U^!'CRZM9E5U91+;7,,-Q!(!OAGBCFC99$5A^8?AS]A/\
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M?^O2[_\ 0!7+:M_R%=3_ .PA>_\ I3+0!GT444 %%%% !1110 4444 %%%%
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M70KKPQX^\)^'?&?AZ]5EN=%\3Z/8:WILNY2N\VFHP7$*RJ#F.9%6:)L/&ZL
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MB[ ?]@6%_P#3%,_F;$?[Q7_Z_5?_ $N04445VF(4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!)#_K8O\ KHG_ *$*] ^)G_(?M?\
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MNH65M>M$C75O9W]Q8Z9/?6L,YDCM[R;3=/EN8E2:2QM'=K>, _DE_P""HO\
MP1#\:_#[]DOQK^TY\'O^"@/_  4S_:)^/G['\VE?M*?![PG^U1^TI:?'/P9I
MFJ_"_5].\3>*-<\-^''^&NDZGIWCC2_!VF:SJWAB]TB^$M]J^F66BW=K/::E
M));]Y^UG^U)X9_;5M?\ @V\_:A\*FVBLOB_^V[\.?$6KZ9:S"XC\.^,X- CT
MCQ]X3:88\R7PGXWTW7_#LLI5/.;3#,JJDBBOZJ** /S-_P""J/\ P3VT#_@H
M+^S;J?A;0[U/ O[2WPLF?XE_LH_&W2[F30_%OPN^,GAUK?6/#XL/%M@HUK0_
M#7BS4=*T[1/%CZ?(\EI;-9>)K&UD\1>&= N+7\R_@M\0M5_X+N?\$>OVEOV.
M_C*UMX#_ &X_A;IDGP.^//A7Q)"=&U+PS^T;\(->L_$GPT\>Z[IMNGVO1] \
M>^,/ EDOBQM.M5M;+5;7XC>&M-L[BPTI+:Y_IFHH _GC_9F_X+?_ +/WP%^"
MW@3X)?\ !3T?$7]B?]K;X/\ @W2/ ?Q'\*?%3X3_ !6U70/B5JG@;3;70+KX
MC?"3QGX-\(^+="\<^'_&B6=MK]C;Z9J=W?23ZK);:(_B;2H;7Q#J/OO[#G[6
M?[8'[<O[87Q9^-.@>"O&OP:_X)?>$OACI/@CX*Z;\8/A5;>!_B-^T5\7SK$M
M]K/QE\-P^(+*W\?Z)\.K?2KNZT:V%Y*NAZM#IGA>2ST^R\32>/+#2OV?HH _
M 7_@XI_Y-0_95_[22?L?_P#I[\65^V7QA^$?P]^/GPL^(/P4^+/A_P#X2SX9
M?%/PGK?@;QYX9_M;7-"_MWPMXBLI=.UG2_[9\-:EHWB#3/MEG/+#]MT;5=/U
M&WW>9:W<$JJX](HH _(OX/?\$K?^"5W_  3#U+QQ^V;\'?@(GP6UGX1_"GXC
M:YXL^(4GQ=^/7C>/1/AMI?AZX\0>.Y9-!^(7Q2\5^'9431-#FN6N'TDWD*VQ
M^RW-NSNS?S6_"W_@K'_P3B_;W_:2?]K?_@K#^T];>#OAM\'_ !S>3?L;?\$[
M$^$7[07C_P"'?@*/2Y'M[#XV?'_4_ OPC\2^!_BE\4=:B/GZ7HZ:OJ^@:#;R
MW=M=1?V?=Q^&[#^\:B@#Y?\ V1_VQ_V:OVY/A0_QI_93^(J_$[X6VGBC5O S
M>(T\'>._ R0^)/#]II=WJ>E)H?Q$\+>$-?VV5IK&F.MW'I)TZ87 CM;J9X9T
MB_*7]J;_ )6%?^"6O_9J?[8/_J.:O7[]44 ?F1_P45_;"_:&_8GU3]F_XM>$
M/@@WQ@_9)N?B!K7AW]M+6_!_A'Q=XX^,GP>\$ZCI$$/@CXC^"/#7A?7+87OA
MC2O$,MY>_$6^N_#GB673M%TNVT[3K!-0\1VNHZ7^1_[;W[4OPC_X+.?$+]A?
M]FO_ ()UQ>)?CM_PK+]L3X1?M0?&7]J'3? 'Q#\&_##]F_X??"B+6+G4[*?Q
MSXP\+^&9!\2_%]OKB_\ "->&]+6Z>XN](73+U;75;FRGTS^J>B@#^9O5_B[X
M2_X)6_\ !7_]NS]HW]M'3O%_A[]F[]O7P%^SE>?!;]JZV\$>,/'G@/X;:W\&
M/!\O@GQ9\$/'^I^#]'\0:GX%O/$6J7%EK6ABYTPZ'>Z/H.A7MQ?6S#4#I_0?
MLN^,+7_@H-_P6E/_  4!_9K\&^,[#]C_ ."'[%E_^SM=?M$>)_ _B?X>Z#^T
MU\1/%7CV\\56FE_#>U\3Z9H.M>,O!W@K3[X37GB+4-/\BRU?0H(ELTL=5\)Z
MI?\ ](E% 'X!?\% +.7XP_\ !:O_ ((O_!WPV%N[_P""FE?M<?M2_% VR1&^
M\,>!&\&>&?"'@'5[J<*UQ;:/XF\?>'-0\*2Q(/*U"_GLTE*"T,L?[^U^>?[,
MW['_ (S\%?M6_M8?MJ_'_5_!WB?XV_''4],^%GPHM?!MYK.K:#\&OV2/AW)'
M)X!^'&GZIKV@>&M0E\3^./$7V[XH?%KR-,_L=?&5_9:1HM[JFG>'X-8U/]#*
M "BBB@ HHHH **** "BBB@ HHHH *L6G_'W:_P#7Q#_Z,6J]6+3_ (^[7_KX
MA_\ 1BT =S\2O^1@A_[!EM_Z/NZ\^KT'XE?\C!#_ -@RV_\ 1]W7GU !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!W/P[_Y&
M6'_KTN__ $ 5RVK?\A74_P#L(7O_ *4RUU/P[_Y&6'_KTN__ $ 5RVK?\A74
M_P#L(7O_ *4RT 9]%%% !1110 4444 %%%% !1110 4444 ?A1_P6P_9DO\
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M]&GZ,'A[]%7@_.N'N#\PSC-*F>YA#.N).(^),3@WC,95P6%=#"TE#!8;!8+
MY;E]!XB="DJ<ZL9XG%5<1BZ[G'V?I?P%^'FI_%CXT_"WX;Z3;R7%YXQ\=>&]
M$*QKN,-G=:I;C4KU_P"[!I^FK=WURYXCM[>61L*I-?K)_P %TXTB_:"^#\2
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MHH **** "BBB@ HHHH **** "O2/%G_(J>#O^O4?^DMO7F]>D>+/^14\'?\
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M5%))*R22IV22T26B1X[X=R9MMX"BVW=M\S;?=OFW/Y,?^(=/]J+_ *2+R?\
MAM?%/_SRZ/\ B'3_ &HO^DB\G_AM?%/_ ,\NOZSJ*?\ Q%3C[_HH\;_Y2_\
ME8O]7<E_Z%]#[I?Y^2^X_DQ_XAT_VHO^DB\G_AM?%/\ \\NC_B'3_:B_Z2+R
M?^&U\4__ #RZ_K.HH_XBIQ]_T4>-_P#*7_RL/]7<E_Z%]#[I?Y^2^X_DQ_XA
MT_VHO^DB\G_AM?%/_P \NC_B'3_:B_Z2+R?^&U\4_P#SRZ_K.HH_XBIQ]_T4
M>-_\I?\ RL/]7<E_Z%]#[I?Y^2^X_DQ_XAT_VHO^DB\G_AM?%/\ \\NC_B'3
M_:B_Z2+R?^&U\4__ #RZ_K.HH_XBIQ]_T4>-_P#*7_RL/]7<E_Z%]#[I?Y^2
M^X_DQ_XAT_VHO^DB\G_AM?%/_P \NC_B'3_:B_Z2+R?^&U\4_P#SRZ_K.HH_
MXBIQ]_T4>-_\I?\ RL/]7<E_Z%]#[I?Y^2^X_DQ_XAT_VHO^DB\G_AM?%/\
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M$V__ *5WU 'G=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P"C%H [GXE?\C!#_P!@RV_]'W=>?5Z#\2O^1@A_[!EM_P"C[NO/J "BBB@
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MT ;WC_\ Y&B^_P"N5E_Z20UQE=GX_P#^1HOO^N5E_P"DD-<90 4444 %%%%
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MKS^'_6Q?]=$_]"%>@?$S_D/VO_8)M_\ TKOJ /.Z*** "BBB@ HHHH ****
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M^&K/ W_1*?\ R?TW_P"5E?#=%'^IW#__ $!S_P#"K%?_ "X/]8,U_P"@B/\
MX(H?_*S[D_X:L\#?]$I_\G]-_P#E91_PU9X&_P"B4_\ D_IO_P K*^&Z*/\
M4[A__H#G_P"%6*_^7!_K!FO_ $$1_P#!%#_Y6?<G_#5G@;_HE/\ Y/Z;_P#*
MRC_AJSP-_P!$I_\ )_3?_E97PW11_J=P_P#] <__  JQ7_RX/]8,U_Z"(_\
M@BA_\K/N3_AJSP-_T2G_ ,G]-_\ E91_PU9X&_Z)3_Y/Z;_\K*^&Z*/]3N'_
M /H#G_X58K_Y<'^L&:_]!$?_  10_P#E9]R?\-6>!O\ HE/_ )/Z;_\ *RC_
M (:L\#?]$I_\G]-_^5E?#=%'^IW#_P#T!S_\*L5_\N#_ %@S7_H(C_X(H?\
MRL^Y/^&K/ W_ $2G_P G]-_^5E'_  U9X&_Z)3_Y/Z;_ /*ROANBC_4[A_\
MZ Y_^%6*_P#EP?ZP9K_T$1_\$4/_ )6?<G_#5G@;_HE/_D_IO_RLH_X:L\#?
M]$I_\G]-_P#E97PW11_J=P__ - <_P#PJQ7_ ,N#_6#-?^@B/_@BA_\ *S[D
M_P"&K/ W_1*?_)_3?_E91_PU9X&_Z)3_ .3^F_\ RLKX;HH_U.X?_P"@.?\
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M*^&Z*]+_ %.X?_Z Y_\ A5BO_EQQ_P"L&:_]!$?_  10_P#E9]R?\-6>!O\
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M*^&Z*/\ 4[A__H#G_P"%6*_^7!_K!FO_ $$1_P#!%#_Y6?<G_#5G@;_HE/\
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M^&K/ W_1*?\ R?TW_P"5E?#=%'^IW#__ $!S_P#"K%?_ "X/]8,U_P"@B/\
MX(H?_*S[D_X:L\#?]$I_\G]-_P#E91_PU9X&_P"B4_\ D_IO_P K*^&Z*/\
M4[A__H#G_P"%6*_^7!_K!FO_ $$1_P#!%#_Y6?<G_#5G@;_HE/\ Y/Z;_P#*
MRC_AJSP-_P!$I_\ )_3?_E97PW11_J=P_P#] <__  JQ7_RX/]8,U_Z"(_\
M@BA_\K/N3_AJSP-_T2G_ ,G]-_\ E91_PU9X&_Z)3_Y/Z;_\K*^&Z*/]3N'_
M /H#G_X58K_Y<'^L&:_]!$?_  10_P#E9]R?\-6>!O\ HE/_ )/Z;_\ *RC_
M (:L\#?]$I_\G]-_^5E?#=%'^IW#_P#T!S_\*L5_\N#_ %@S7_H(C_X(H?\
MRL^Y/^&K/ W_ $2G_P G]-_^5E'_  U9X&_Z)3_Y/Z;_ /*ROANBC_4[A_\
MZ Y_^%6*_P#EP?ZP9K_T$1_\$4/_ )6?<G_#5G@;_HE/_D_IO_RLH_X:L\#?
M]$I_\G]-_P#E97PW11_J=P__ - <_P#PJQ7_ ,N#_6#-?^@B/_@BA_\ *S[D
M_P"&K/ W_1*?_)_3?_E91_PU9X&_Z)3_ .3^F_\ RLKX;HH_U.X?_P"@.?\
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MTW_Y65\-T4?ZG</_ /0'/_PJQ7_RX/\ 6#-?^@B/_@BA_P#*S[D_X:L\#?\
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MTW_Y65\-T4?ZG</_ /0'/_PJQ7_RX/\ 6#-?^@B/_@BA_P#*S[D_X:L\#?\
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M5E?#=%'^IW#_ /T!S_\ "K%?_+@_U@S7_H(C_P""*'_RL^Y/^&K/ W_1*?\
MR?TW_P"5E'_#5G@;_HE/_D_IO_RLKX;HH_U.X?\ ^@.?_A5BO_EP?ZP9K_T$
M1_\ !%#_ .5GW)_PU9X&_P"B4_\ D_IO_P K*/\ AJSP-_T2G_R?TW_Y65\-
MT4?ZG</_ /0'/_PJQ7_RX/\ 6#-?^@B/_@BA_P#*S[D_X:L\#?\ 1*?_ "?T
MW_Y65N>&/VF/!FM^)?#VBVWPS^PW.KZYI.EV][]NT]_L<^H7]O:176U-.1V^
MSR3++M5T9MF%9201^?\ 7;?#3_DH_P /_P#L=O"G_I]L*QQ'".0T\/7J0PDU
M*%&K.+^LXEVE&$FG9U6G9I:-6?4THY]FDZU*$L1%QE4IQDO8T5=2DDU=4[K1
M]#[R^*GQ\\+>!/&NI>&M4\ _V]>64&G2R:G]KLHO.6\L+>ZC79-8SR#R8Y5B
MR9"#LR !@#SO_AJSP-_T2G_R?TW_ .5E>/?M1?\ )9O$?_7EX?\ _3'85\^5
MSY7PKDF)RW 8BMA)RJU\'AZM62Q.)BI5*E*$IRY8U5%7DV[))+9)(VQV>9E0
MQF*HTZ\8TZ5>K""=&B[1C-J*NX-NR5KMMOJS[D_X:L\#?]$I_P#)_3?_ )64
M?\-6>!O^B4_^3^F__*ROANBN[_4[A_\ Z Y_^%6*_P#EQR_ZP9K_ -!$?_!%
M#_Y6?<G_  U9X&_Z)3_Y/Z;_ /*RC_AJSP-_T2G_ ,G]-_\ E97PW11_J=P_
M_P! <_\ PJQ7_P N#_6#-?\ H(C_ ."*'_RL^Y/^&K/ W_1*?_)_3?\ Y64?
M\-6>!O\ HE/_ )/Z;_\ *ROANBC_ %.X?_Z Y_\ A5BO_EP?ZP9K_P!!$?\
MP10_^5GW)_PU9X&_Z)3_ .3^F_\ RLH_X:L\#?\ 1*?_ "?TW_Y65\-T4?ZG
M</\ _0'/_P *L5_\N#_6#-?^@B/_ ((H?_*S[D_X:L\#?]$I_P#)_3?_ )64
M?\-6>!O^B4_^3^F__*ROANBC_4[A_P#Z Y_^%6*_^7!_K!FO_01'_P $4/\
MY6?<G_#5G@;_ *)3_P"3^F__ "LH_P"&K/ W_1*?_)_3?_E97PW11_J=P_\
M] <__"K%?_+@_P!8,U_Z"(_^"*'_ ,K/N3_AJSP-_P!$I_\ )_3?_E91_P -
M6>!O^B4_^3^F_P#RLKX;HH_U.X?_ .@.?_A5BO\ Y<'^L&:_]!$?_!%#_P"5
MGW)_PU9X&_Z)3_Y/Z;_\K*/^&K/ W_1*?_)_3?\ Y65\-T4?ZG</_P#0'/\
M\*L5_P#+@_U@S7_H(C_X(H?_ "L^Y/\ AJSP-_T2G_R?TW_Y64?\-6>!O^B4
M_P#D_IO_ ,K*^&Z*/]3N'_\ H#G_ .%6*_\ EP?ZP9K_ -!$?_!%#_Y6?<G_
M  U9X&_Z)3_Y/Z;_ /*RC_AJSP-_T2G_ ,G]-_\ E97PW11_J=P__P! <_\
MPJQ7_P N#_6#-?\ H(C_ ."*'_RL^Y/^&K/ W_1*?_)_3?\ Y64?\-6>!O\
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MZ;_\K*^&Z*/]3N'_ /H#G_X58K_Y<'^L&:_]!$?_  10_P#E9]R?\-6>!O\
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M*^&Z*/\ 4[A__H#G_P"%6*_^7!_K!FO_ $$1_P#!%#_Y6?<G_#5G@;_HE/\
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M^&K/ W_1*?\ R?TW_P"5E?#=%'^IW#__ $!S_P#"K%?_ "X/]8,U_P"@B/\
MX(H?_*S[D_X:L\#?]$I_\G]-_P#E91_PU9X&_P"B4_\ D_IO_P K*^&Z*/\
M4[A__H#G_P"%6*_^7!_K!FO_ $$1_P#!%#_Y6?<G_#5G@;_HE/\ Y/Z;_P#*
MRC_AJSP-_P!$I_\ )_3?_E97PW11_J=P_P#] <__  JQ7_RX/]8,U_Z"(_\
M@BA_\K/N3_AJSP-_T2G_ ,G]-_\ E91_PU9X&_Z)3_Y/Z;_\K*^&Z*/]3N'_
M /H#G_X58K_Y<'^L&:_]!$?_  10_P#E9]R?\-6>!O\ HE/_ )/Z;_\ *RC_
M (:L\#?]$I_\G]-_^5E?#=%'^IW#_P#T!S_\*L5_\N#_ %@S7_H(C_X(H?\
MRL^Y/^&K/ W_ $2G_P G]-_^5E'_  U9X&_Z)3_Y/Z;_ /*ROANBC_4[A_\
MZ Y_^%6*_P#EP?ZP9K_T$1_\$4/_ )6?<G_#5G@;_HE/_D_IO_RLH_X:L\#?
M]$I_\G]-_P#E97PW11_J=P__ - <_P#PJQ7_ ,N#_6#-?^@B/_@BA_\ *S[D
M_P"&K/ W_1*?_)_3?_E91_PU9X&_Z)3_ .3^F_\ RLKX;HH_U.X?_P"@.?\
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M-?\ H(C_ ."*'_RL^Y/^&K/ W_1*?_)_3?\ Y64?\-6>!O\ HE/_ )/Z;_\
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M %.X?_Z Y_\ A5BO_EP?ZP9K_P!!$?\ P10_^5GW)_PU9X&_Z)3_ .3^F_\
MRLH_X:L\#?\ 1*?_ "?TW_Y65\-T4?ZG</\ _0'/_P *L5_\N#_6#-?^@B/_
M ((H?_*S[D_X:L\#?]$I_P#)_3?_ )64?\-6>!O^B4_^3^F__*ROANBC_4[A
M_P#Z Y_^%6*_^7!_K!FO_01'_P $4/\ Y6?<G_#5G@;_ *)3_P"3^F__ "LH
M_P"&K/ W_1*?_)_3?_E97PW11_J=P_\ ] <__"K%?_+@_P!8,U_Z"(_^"*'_
M ,K/N3_AJSP-_P!$I_\ )_3?_E91_P -6>!O^B4_^3^F_P#RLKX;HH_U.X?_
M .@.?_A5BO\ Y<'^L&:_]!$?_!%#_P"5GW)_PU9X&_Z)3_Y/Z;_\K*/^&K/
MW_1*?_)_3?\ Y65\-T4?ZG</_P#0'/\ \*L5_P#+@_U@S7_H(C_X(H?_ "L^
MY/\ AJSP-_T2G_R?TW_Y64?\-6>!O^B4_P#D_IO_ ,K*^&Z*/]3N'_\ H#G_
M .%6*_\ EP?ZP9K_ -!$?_!%#_Y6?<G_  U9X&_Z)3_Y/Z;_ /*RC_AJSP-_
MT2G_ ,G]-_\ E97PW11_J=P__P! <_\ PJQ7_P N#_6#-?\ H(C_ ."*'_RL
M^Y/^&K/ W_1*?_)_3?\ Y64?\-6>!O\ HE/_ )/Z;_\ *ROANBC_ %.X?_Z
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M4_\ D_IO_P K*/\ AJSP-_T2G_R?TW_Y65\-T4?ZG</_ /0'/_PJQ7_RX/\
M6#-?^@B/_@BA_P#*S[D_X:L\#?\ 1*?_ "?TW_Y64?\ #5G@;_HE/_D_IO\
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M*'_RL^Y/^&K/ W_1*?\ R?TW_P"5E'_#5G@;_HE/_D_IO_RLKX;HH_U.X?\
M^@.?_A5BO_EP?ZP9K_T$1_\ !%#_ .5GW)_PU9X&_P"B4_\ D_IO_P K*/\
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M2+?XSL= C$C$[0I?)/ S76\MS&,7*67XV,4KN3PM=12[MNG:WS*Y)_R2_P#
M7_D?:M%9>BZYHGB/3;;6?#VL:7KVD7B[[35=%U"TU33;I, [[:^L9I[6=<,#
MNBE88(.<$5J5QM--IIIIV:>C36Z:Z-$A1112 **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KZZ^.'_)
M$/@%_P!@6/\ ],>EU\BU]=?'#_DB'P"_[ L?_ICTNO"S3_D9\/\ _8;BO_4#
M$'IX+_<\U_[!J'_J51/D6BBBO=/,"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "NV^&G_)1_A__P!CMX4_]/MA7$UVWPT_Y*/\/_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** /KGQ=_R:)\,_^QSN_P#TX>/:^1J^
MN?%W_)HGPS_['.[_ /3AX]KY&KPL@_@YE_V.\V_]2I'I9G\>#_[%N _]1XA1
M117NGFA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M>&]?0^HK\9_B'_R/_CG_ +'#Q-_Z>KVOV9MP?-'RXX///I[FOQF^(?\ R/\
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MB3P?KITFW\<>&HWC%W;_ /"8:E#=2?+#:67[,?\ !>GQ=\8/VO/V_P#]F/\
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MGA> RPLP)CD,$\T)="K&*:6,G9(ZG\I?^"O?_"2_\.#_ /@E[_9GVC_A'?\
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MW=Z?\+XK?X8>&2SQV]S%%:ZKXOO(,X$MWJ=W%-9:<\B@,(-)M(YK5B4&IW0
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MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KMOAI_R4?X?_\
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ME\(/^Q-?_P!$Z17R+7UU^U/_ ,>7P@_[$U__ $3I%?(M>%PU_P B3!^N*_\
M4S$'IYQ_R,<1Z4/_ %'I!1117NGF!1110 4444 %%%% !1110 4444 %%%%
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M#Q-_Z>KVOV9M\^:/N]#TVYZ>W-?C-\0_^1_\<_\ 8X>)O_3U>UW<!_[YF/\
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M.*&_\.V.H:)XMN;U+SQ1HE[>16&MZ#!'')]KLAIVKZN'EAFT.WANXWD;S/\
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MX?\ ^5>7Y]V?-W_"J/C_ /\ 1Z/[0?\ X6?C7_YNJ/\ A5'Q_P#^CT?V@_\
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ME+_PJQ__ ,U!_;F:?]!3_P#!.'_^5>7Y]V?-W_"J/C__ -'H_M!_^%GXU_\
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M^-?_ )NJ/^%4?'__ */1_:#_ /"S\:__ #=5](T4?\0]X._Z$E+_ ,*L?_\
M-0?VYFG_ $%/_P $X?\ ^5>7Y]V?-W_"J/C_ /\ 1Z/[0?\ X6?C7_YNJ/\
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MPU_R),'ZXK_U,Q!Z><?\C'$>E#_U'I!1117NGF!1110 4444 %%%% !1110
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MSP?XL]OK7XS_ !#_ .1_\<_]CAXF_P#3U>U^S,'^M' Z'NI['T -?C-\0_\
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M]MBUE^*7_!6G_@D_\+-!"W-[\)--_:<_:+^(9@6,WGA[P:WA3P_X7\%ZG<3
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MAWE'_ARP7_RX/J&._P"@/%_^$];_ .0\U]Y[S17@W_#3OP)_Z*'IW_@MU_\
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M=?\ _E31_P -._ G_HH>G?\ @MU__P"5-'^L&0_]#O*/_#E@O_EP?4,=_P!
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M_P#0[RC_ ,.6"_\ EP?4,=_T!XO_ ,)ZW_R'FOO/>:*\&_X:=^!/_10]._\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#ZY\7?\FB?#/_
M +'.[_\ 3AX]KY&KZY\7?\FB?#/_ +'.[_\ 3AX]KY&KPL@_@YE_V.\V_P#4
MJ1Z69_'@_P#L6X#_ -1XA1117NGFA1110 4444 %%%% !1110 4444 %%%%
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MJ^6:\GA[_D299_V"4OR9WYO_ ,C/&_\ 7^?Z!1117LGG!1110 4444 %%%%
M!1110 4444 ?R2_\%D/^4W7_  2/_P"QV_9E_P#6MVKVS_@Z+U&]T?\ 9._9
MKU?3IOL^H:7^U'IFHV%QY<4WD7MC\-O'US:S>5/'+!+Y4\2/Y<T4D3[=LD;H
M2I\3_P""R'_*;K_@D?\ ]CM^S+_ZUNU>O_\ !T[_ ,F>?L]_]G*VW_JKOB#7
MP..;6$XS:=FL1AFFMT_8X?4^JP_^\<.?]>:G_I=0^I?@=_P0D_8JU/X1Z=K/
M[5'@OQ7^T5^T7\3?#^F^*/C+\8_B!\2/B-!XKO?'VOZ<FHZ\V@+H?B71+;1K
M+2=5OKFUTI[BSN]9N;2TLU\0ZAJTD(5?B'_@BAX8UWX"_MN?\%*O^":FI>(=
M<\;_   \"QZ[JOA;2/$VIF>2TTQ/%<7A59EBTX6UK9:EXV\#^-M(_P"$QFTA
M=+BN=4T*TN8;*SEW)#_5I7\QW_!.O_E/G_P53_[$RY_]2[X5UZN,R_!X#&Y#
M+"4*5"H\;/"U*E.$8SKTJF#KNHJ\DN:LYR@I.55SES-ROS-LX*&+Q&*PV:*O
M5G4BL/"M",I-QI5(XBDHNE':GRQDXI045RV5K)'P3\0?V!OV0M(_X.#/@;^R
M)IOP3T&U_9Q\4_"W5]>U_P"%J:SXM?2-2U:W_9_^,/BV&]EU*3Q"_B*)X_$7
MAS1=4"6^L0PF:PCC:,V\D\,OU;_P< ?"#X;_  $_9U_X)W_"+X1>%K/P3\./
M!/[2=U8>%O"UA<ZC>6>D6=Y:-JUS!!<ZM>:AJ,JRZCJ%Y=,UU>3N'G9598U1
M%T_BG_RM.?LV_P#9%M=_]9<^/E=M_P '+_\ R3S]AC_LY\_^F.TKQYX?#TLI
MXIE2H4:<H9Q6H0E"E"$HT(U,NE&C%QBG&DI>\J::@I:I7/2IUJL\PR.,ZM2<
M99?2JRC*<I)U'#%Q=1IMIS<='-^\UI>Q5_X.G?\ DSS]GO\ [.5MO_57?$&O
MZ>Z_F6_X.E-&U6]_8K^!VKVFGW5SIFB_M+Z2-7O8(7E@TT:E\-/B+;V$EZR
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M(]%TB:)-<T,3:KXLU321;^&(KE+SQ[J LI[M]:?0_AWX:DN/%FH:KIL'[/\
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M*G%-WG1<*56*E&/,J7LE4_>1C#^PR2]NM U72?%EA$\\^AR2K?VD8)DO]"O
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MU]@44>TJ?\_)_P#@4O\ ,.>?\TO_  )_YGQ__P ._?V(O^C5O@;_ .&]\/\
M_P AT?\ #OW]B+_HU;X&_P#AO?#_ /\ (=?8%%'M*G_/R?\ X%+_ ##GG_-+
M_P "?^9\?_\ #OW]B+_HU;X&_P#AO?#_ /\ (='_  []_8B_Z-6^!O\ X;WP
M_P#_ "'7V!11[2I_S\G_ .!2_P PYY_S2_\  G_F?'__  []_8B_Z-6^!O\
MX;WP_P#_ "'1_P ._?V(O^C5O@;_ .&]\/\ _P AU]@44>TJ?\_)_P#@4O\
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MU]@44>TJ?\_)_P#@4O\ ,.>?\TO_  )_YGQ__P ._?V(O^C5O@;_ .&]\/\
M_P AT?\ #OW]B+_HU;X&_P#AO?#_ /\ (=?8%%'M*G_/R?\ X%+_ ##GG_-+
M_P "?^9\?_\ #OW]B+_HU;X&_P#AO?#_ /\ (='_  []_8B_Z-6^!O\ X;WP
M_P#_ "'7V!11[2I_S\G_ .!2_P PYY_S2_\  G_F?'__  []_8B_Z-6^!O\
MX;WP_P#_ "'1_P ._?V(O^C5O@;_ .&]\/\ _P AU]@44>TJ?\_)_P#@4O\
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M::=TT]F:X>4G7HIRDTZU---MIISC=-=4SYX_:(_X)P_L%>'?BMKVDZ%^R)\
M=)TV"TT1X;&P^&WARVM8FGT>SFF9(8[)44R2N\CD#YG8D\FO$/\ AW[^Q%_T
M:M\#?_#>^'__ )#K]0_VHO\ DLWB/_KR\/\ _ICL*^?*Y,FK5IY1EDYU:LI2
MP&%E*4JDI2E)T(-RE)MMMO5MN[>K.C,FXX_&1BW&,<3648Q;22522226B26B
M2T1\?_\ #OW]B+_HU;X&_P#AO?#_ /\ (='_  []_8B_Z-6^!O\ X;WP_P#_
M "'7V!17I>TJ?\_)_P#@4O\ ,XN>?\TO_ G_ )GQ_P#\._?V(O\ HU;X&_\
MAO?#_P#\AT?\._?V(O\ HU;X&_\ AO?#_P#\AU]@44>TJ?\ /R?_ (%+_,.>
M?\TO_ G_ )GQ_P#\._?V(O\ HU;X&_\ AO?#_P#\AT?\._?V(O\ HU;X&_\
MAO?#_P#\AU]@44>TJ?\ /R?_ (%+_,.>?\TO_ G_ )GQ_P#\._?V(O\ HU;X
M&_\ AO?#_P#\AT?\._?V(O\ HU;X&_\ AO?#_P#\AU]@44>TJ?\ /R?_ (%+
M_,.>?\TO_ G_ )GQ_P#\._?V(O\ HU;X&_\ AO?#_P#\AT?\._?V(O\ HU;X
M&_\ AO?#_P#\AU]@44>TJ?\ /R?_ (%+_,.>?\TO_ G_ )GQ_P#\._?V(O\
MHU;X&_\ AO?#_P#\AT?\._?V(O\ HU;X&_\ AO?#_P#\AU]@44>TJ?\ /R?_
M (%+_,.>?\TO_ G_ )GQ_P#\._?V(O\ HU;X&_\ AO?#_P#\AT?\._?V(O\
MHU;X&_\ AO?#_P#\AU]@44>TJ?\ /R?_ (%+_,.>?\TO_ G_ )GQ_P#\._?V
M(O\ HU;X&_\ AO?#_P#\AT?\._?V(O\ HU;X&_\ AO?#_P#\AU]@44>TJ?\
M/R?_ (%+_,.>?\TO_ G_ )GQ_P#\._?V(O\ HU;X&_\ AO?#_P#\AT?\._?V
M(O\ HU;X&_\ AO?#_P#\AU]@44>TJ?\ /R?_ (%+_,.>?\TO_ G_ )GQ_P#\
M._?V(O\ HU;X&_\ AO?#_P#\AT?\._?V(O\ HU;X&_\ AO?#_P#\AU]@44>T
MJ?\ /R?_ (%+_,.>?\TO_ G_ )GQ_P#\._?V(O\ HU;X&_\ AO?#_P#\AT?\
M._?V(O\ HU;X&_\ AO?#_P#\AU]@44>TJ?\ /R?_ (%+_,.>?\TO_ G_ )GQ
M_P#\._?V(O\ HU;X&_\ AO?#_P#\AT?\._?V(O\ HU;X&_\ AO?#_P#\AU]@
M44>TJ?\ /R?_ (%+_,.>?\TO_ G_ )GQ_P#\._?V(O\ HU;X&_\ AO?#_P#\
MAT?\._?V(O\ HU;X&_\ AO?#_P#\AU]@44>TJ?\ /R?_ (%+_,.>?\TO_ G_
M )GQ_P#\._?V(O\ HU;X&_\ AO?#_P#\AU^%_P#P54^ _P &/@;^TG^Q7:?!
MWX8>"OAI:^(K_P 4W.NV_@S0+#0HM6N-.\0>#XK":_2QBB6YDM([NY2W:0,8
MEGE"D!VS_4A7\V?_  7(\(>//'_Q_P#V*_!7POTV_P!6^('BBR^(NB^%+'3%
M;[8VK7^L>#((;A)E^6RAL4:2^N]3F:.VTJTMI]2NIH+:UEF3U,EQ;PN:8'%5
M'.=/#8BEB)PYG>4:$U5DES.UVH:-Z)V;*2E452GS/WZ-6*<FVDY0DDWY*Y\6
M^$_AGXP_;[_:%TW]F3X<ZA<Z5\+/"L\/B#XW_$2Q@-Q:Z;IFFW2K/8VL[1O:
M3W[70&E>';&4O%J?B1I;^:%]'\/75['_ %T_#GX>>#_A-X$\*?#7P!HMKX>\
M&^"M$LM \/Z19H%CM;"QB"*TKX#W-[=2F2\U&_G+W6HZA<7-]>2S75Q-*_S3
M^PQ^QWX0_8K^!ND?#319+36O&&IR1Z_\3?&L5LL,WBOQ=/ J3?9W>*.Z3P[H
M46=*\,V$X5K>PCDO;B(:KJFJ3W'V773Q+Q!C.),TQ&8XN7QRY:-)-NG1HQ;5
M.E33VA"+T=DY2<JDOWE2;?/1HTL-1IX:@K4Z:^)JTJDW;GJS_O2:T7V8VBK)
M6"BBBOGS0**** "BBB@ HHHH **** "BBB@ HHHH ^NOVI_^/+X0?]B:_P#Z
M)TBOD6OKK]J?_CR^$'_8FO\ ^B=(KY%KPN&O^1)@_7%?^IF(/3SC_D8XCTH?
M^H](****]T\P**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M R.[HCW!\P1[U"Q@%5/XRR_#K]I+0_$!UGQE^Q[^T;<^*+O3_">@>(?$EO\
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M]O:0[+6UGD!FFC5B@12790?PP_X=V_M7_P#1/]/_ /"S\'?_ "\K^E*BNSQ
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MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KMOAI_R4?X?_\
M8[>%/_3[85Q-=M\-/^2C_#__ +';PI_Z?;"N?%_[IBO^P>M_Z;D;8?\ WBA_
MU^I?^EQ/3?VHO^2S>(_^O+P__P"F.PKY\KZ#_:B_Y+-XC_Z\O#__ *8["OGR
MN/)/^1-E7_8OPG_IBF=&9_\ (QQW_857_P#3D@HHHKU#A"BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O/[[X7^"]4
M^)GA_P"+FI:/;W_CGPGX4UOP=X7U6Z2.8Z!I'B:_T^_\1-I:.A^S7^L'2=-M
M+J^1OM"Z?;RV,#Q6U_J,=WZ!133:V;6C6G9[KT?4+M;.W3Y=@HHHI %%%% !
M1110 4444 %%%% !1110 4444 %%%% 'UU^U/_QY?"#_ +$U_P#T3I%?(M?7
M7[4__'E\(/\ L37_ /1.D5\BUX7#7_(DP?KBO_4S$'IYQ_R,<1Z4/_4>D%%%
M%>Z>8%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?7/
MB[_DT3X9_P#8YW?_ *</'M?(U?7/B[_DT3X9_P#8YW?_ *</'M?(U>%D'\',
MO^QWFW_J5(]+,_CP?_8MP'_J/$****]T\T**** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH M6/_'[9_\ 7U;_ /HY*^IOVQ?^2G:)_P!B
M+I?_ *?_ !-7RS8_\?MG_P!?5O\ ^CDKZF_;%_Y*=HG_ &(NE_\ I_\ $U>'
MC/\ D?9+_P!@N;_^DX(]/#_\BO,?^O\ @/SQ!\GT445[AY@4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >_\ [,/_ "6CPM_U
M[>(?_4=U2OU9K\IOV8?^2T>%O^O;Q#_ZCNJ5^K-?D?'?_(YH_P#8OH?^G\4?
M>\+_ /(OJ_\ 874_]-4#/M\>:,$]&[8[?4U^,_Q#_P"1_P#'/_8X>)O_ $]7
MM?LS;_ZP<#H>Z^GL ?Z5X#JVB?".35=3DO\ X::/>7TFH7KWEW):VS275VUS
M*UQ<NS<EYYB\K$\EF)/-<?#N>4,DQ&*J5Z-:LJ]*G3BJ7(G%PFY-OGE'1IJU
MKZFV:9;5S*C0A2J0INE.4FZBEJI0BE;E3[>G9GY:45^G?]@_!C_HEFB?^ =I
M1_8/P8_Z)9HG_@':5]9_K]E__0#C/OH?_+#Q/]5L7_T$X?[JG_R!^8E%?IW_
M &#\&/\ HEFB?^ =I1_8/P8_Z)9HG_@':4?Z_9?_ - .,^^A_P#+ _U6Q?\
MT$X?[JG_ ,@?F)17Z=_V#\&/^B6:)_X!VE']@_!C_HEFB?\ @':4?Z_9?_T
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M_P#+ _U6Q?\ T$X?[JG_ ,@?F)17Z=_V#\&/^B6:)_X!VE']@_!C_HEFB?\
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M?F)17Z=_V#\&/^B6:)_X!VE']@_!C_HEFB?^ =I1_K]E_P#T XS[Z'_RP/\
M5;%_]!.'^ZI_\@?F)17Z=_V#\&/^B6:)_P" =I1_8/P8_P"B6:)_X!VE'^OV
M7_\ 0#C/OH?_ "P/]5L7_P!!.'^ZI_\ ('YB45^G?]@_!C_HEFB?^ =I1_8/
MP8_Z)9HG_@':4?Z_9?\ ] .,^^A_\L#_ %6Q?_03A_NJ?_('YB45^G?]@_!C
M_HEFB?\ @':4?V#\&/\ HEFB?^ =I1_K]E__ $ XS[Z'_P L#_5;%_\ 03A_
MNJ?_ "!^8E%?IW_8/P8_Z)9HG_@':4?V#\&/^B6:)_X!VE'^OV7_ /0#C/OH
M?_+ _P!5L7_T$X?[JG_R!^8E%?IW_8/P8_Z)9HG_ (!VE']@_!C_ *)9HG_@
M':4?Z_9?_P! .,^^A_\ + _U6Q?_ $$X?[JG_P @?F)17Z=_V#\&/^B6:)_X
M!VE']@_!C_HEFB?^ =I1_K]E_P#T XS[Z'_RP/\ 5;%_]!.'^ZI_\@?F)17Z
M=_V#\&/^B6:)_P" =I1_8/P8_P"B6:)_X!VE'^OV7_\ 0#C/OH?_ "P/]5L7
M_P!!.'^ZI_\ ('YB45^G?]@_!C_HEFB?^ =I1_8/P8_Z)9HG_@':4?Z_9?\
M] .,^^A_\L#_ %6Q?_03A_NJ?_('YB45^G?]@_!C_HEFB?\ @':4?V#\&/\
MHEFB?^ =I1_K]E__ $ XS[Z'_P L#_5;%_\ 03A_NJ?_ "!^8E%?IW_8/P8_
MZ)9HG_@':4?V#\&/^B6:)_X!VE'^OV7_ /0#C/OH?_+ _P!5L7_T$X?[JG_R
M!^8E%?IW_8/P8_Z)9HG_ (!VE']@_!C_ *)9HG_@':4?Z_9?_P! .,^^A_\
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M?F)17Z=_V#\&/^B6:)_X!VE']@_!C_HEFB?^ =I1_K]E_P#T XS[Z'_RP/\
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M/_ .TH_L'X,?]$LT3_P#M*]'_7[+_P#H!QGWT/\ Y8<G^JV+_P"@G#_=4_\
MD#\Q**_3O^P?@Q_T2S1/_ .TH_L'X,?]$LT3_P  [2C_ %^R_P#Z <9]]#_Y
M8'^JV+_Z"</]U3_Y _,2BOT[_L'X,?\ 1+-$_P# .TH_L'X,?]$LT3_P#M*/
M]?LO_P"@'&??0_\ E@?ZK8O_ *"</]U3_P"0/S$HK]._[!^#'_1+-$_\ [2C
M^P?@Q_T2S1/_  #M*/\ 7[+_ /H!QGWT/_E@?ZK8O_H)P_W5/_D#\Q**_3O^
MP?@Q_P!$LT3_ , [2C^P?@Q_T2S1/_ .TH_U^R__ * <9]]#_P"6!_JMB_\
MH)P_W5/_ ) _,2BOT[_L'X,?]$LT3_P#M*/[!^#'_1+-$_\  .TH_P!?LO\
M^@'&??0_^6!_JMB_^@G#_=4_^0/S$HK]._[!^#'_ $2S1/\ P#M*/[!^#'_1
M+-$_\ [2C_7[+_\ H!QGWT/_ )8'^JV+_P"@G#_=4_\ D#\Q**_3O^P?@Q_T
M2S1/_ .TH_L'X,?]$LT3_P  [2C_ %^R_P#Z <9]]#_Y8'^JV+_Z"</]U3_Y
M _,2BOT[_L'X,?\ 1+-$_P# .TH_L'X,?]$LT3_P#M*/]?LO_P"@'&??0_\
ME@?ZK8O_ *"</]U3_P"0/S$HK]._[!^#'_1+-$_\ [2C^P?@Q_T2S1/_  #M
M*/\ 7[+_ /H!QGWT/_E@?ZK8O_H)P_W5/_D#\Q**_3O^P?@Q_P!$LT3_ , [
M2C^P?@Q_T2S1/_ .TH_U^R__ * <9]]#_P"6!_JMB_\ H)P_W5/_ ) _,2BO
MT[_L'X,?]$LT3_P#M*/[!^#'_1+-$_\  .TH_P!?LO\ ^@'&??0_^6!_JMB_
M^@G#_=4_^0/S$HK]._[!^#'_ $2S1/\ P#M*/[!^#'_1+-$_\ [2C_7[+_\
MH!QGWT/_ )8'^JV+_P"@G#_=4_\ D#\Q**_3O^P?@Q_T2S1/_ .TH_L'X,?]
M$LT3_P  [2C_ %^R_P#Z <9]]#_Y8'^JV+_Z"</]U3_Y _,2BOT[_L'X,?\
M1+-$_P# .TH_L'X,?]$LT3_P#M*/]?LO_P"@'&??0_\ E@?ZK8O_ *"</]U3
M_P"0/S$HK]._[!^#'_1+-$_\ [2C^P?@Q_T2S1/_  #M*/\ 7[+_ /H!QGWT
M/_E@?ZK8O_H)P_W5/_D#\Q**_3O^P?@Q_P!$LT3_ , [2C^P?@Q_T2S1/_ .
MTH_U^R__ * <9]]#_P"6!_JMB_\ H)P_W5/_ ) _,2BOT[_L'X,?]$LT3_P#
MM*/[!^#'_1+-$_\  .TH_P!?LO\ ^@'&??0_^6!_JMB_^@G#_=4_^0/S$HK]
M._[!^#'_ $2S1/\ P#M*/[!^#'_1+-$_\ [2C_7[+_\ H!QGWT/_ )8'^JV+
M_P"@G#_=4_\ D#\Q**_3O^P?@Q_T2S1/_ .TH_L'X,?]$LT3_P  [2C_ %^R
M_P#Z <9]]#_Y8'^JV+_Z"</]U3_Y _,2BOT[_L'X,?\ 1+-$_P# .TH_L'X,
M?]$LT3_P#M*/]?LO_P"@'&??0_\ E@?ZK8O_ *"</]U3_P"0/S$HK]._[!^#
M'_1+-$_\ [2C^P?@Q_T2S1/_  #M*/\ 7[+_ /H!QGWT/_E@?ZK8O_H)P_W5
M/_D#\Q*^NOCA_P D0^ 7_8%C_P#3'I=?0/\ 8/P8_P"B6:)_X!VE=]XFTWP#
M/X:\+0:QX-T[5-'M[95T32YH(7ATF'[+ HB@1_E11"(XL)QB,#H!7G8SC+!8
MG%Y9B(X3%1C@<16K3C)TN:<:F&JT$H6FU=2FF[V5D[:G7A^'L31H8RDZ]!O$
MTJ=.+2J6BX5H5&Y7C>S46E:^MNA^0U%?IW_8/P8_Z)9HG_@':4?V#\&/^B6:
M)_X!VE>C_K]E_P#T XS[Z'_RPY/]5L7_ -!.'^ZI_P#('YB45^G?]@_!C_HE
MFB?^ =I1_8/P8_Z)9HG_ (!VE'^OV7_] .,^^A_\L#_5;%_]!.'^ZI_\@?F)
M17Z=_P!@_!C_ *)9HG_@':4?V#\&/^B6:)_X!VE'^OV7_P#0#C/OH?\ RP/]
M5L7_ -!.'^ZI_P#('YB45^G?]@_!C_HEFB?^ =I1_8/P8_Z)9HG_ (!VE'^O
MV7_] .,^^A_\L#_5;%_]!.'^ZI_\@?F)17Z=_P!@_!C_ *)9HG_@':4?V#\&
M/^B6:)_X!VE'^OV7_P#0#C/OH?\ RP/]5L7_ -!.'^ZI_P#('YB45^G?]@_!
MC_HEFB?^ =I1_8/P8_Z)9HG_ (!VE'^OV7_] .,^^A_\L#_5;%_]!.'^ZI_\
M@?F)17Z=_P!@_!C_ *)9HG_@':4?V#\&/^B6:)_X!VE'^OV7_P#0#C/OH?\
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M$X?[JG_R!^8E%?IW_8/P8_Z)9HG_ (!VE']@_!C_ *)9HG_@':4?Z_9?_P!
M.,^^A_\ + _U6Q?_ $$X?[JG_P @?F)17Z=_V#\&/^B6:)_X!VE']@_!C_HE
MFB?^ =I1_K]E_P#T XS[Z'_RP/\ 5;%_]!.'^ZI_\@?F)17Z=_V#\&/^B6:)
M_P" =I1_8/P8_P"B6:)_X!VE'^OV7_\ 0#C/OH?_ "P/]5L7_P!!.'^ZI_\
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M(M?KSXXTWP#=1>'QXD\&Z?KJ0Z>8]*6Z@AD&G6FVWS;1>9]U"!$,+Q^['M7
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MK8O_ *"</]U3_P"0/S$HK]._[!^#'_1+-$_\ [2C^P?@Q_T2S1/_  #M*/\
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M )8'^JV+_P"@G#_=4_\ D#\Q**_3O^P?@Q_T2S1/_ .TH_L'X,?]$LT3_P
M[2C_ %^R_P#Z <9]]#_Y8'^JV+_Z"</]U3_Y _,2BOT[_L'X,?\ 1+-$_P#
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M'X,?]$LT3_P#M*/[!^#'_1+-$_\  .TKT/\ 7[+_ /H!QGWT/_EAR?ZK8O\
MZ"</]U3_ .0/S$HK]._[!^#'_1+-$_\  .TH_L'X,?\ 1+-$_P# .TH_U^R_
M_H!QGWT/_E@?ZK8O_H)P_P!U3_Y _,2BOT[_ +!^#'_1+-$_\ [2C^P?@Q_T
M2S1/_ .TH_U^R_\ Z <9]]#_ .6!_JMB_P#H)P_W5/\ Y _,2BOT[_L'X,?]
M$LT3_P  [2C^P?@Q_P!$LT3_ , [2C_7[+_^@'&??0_^6!_JMB_^@G#_ '5/
M_D#\Q**_3O\ L'X,?]$LT3_P#M*/[!^#'_1+-$_\ [2C_7[+_P#H!QGWT/\
MY8'^JV+_ .@G#_=4_P#D#\Q**_3O^P?@Q_T2S1/_  #M*/[!^#'_ $2S1/\
MP#M*/]?LO_Z <9]]#_Y8'^JV+_Z"</\ =4_^0/S$HK]._P"P?@Q_T2S1/_ .
MTH_L'X,?]$LT3_P#M*/]?LO_ .@'&??0_P#E@?ZK8O\ Z"</]U3_ .0/S$HK
M]._[!^#'_1+-$_\  .TH_L'X,?\ 1+-$_P# .TH_U^R__H!QGWT/_E@?ZK8O
M_H)P_P!U3_Y _,2BOT[_ +!^#'_1+-$_\ [2C^P?@Q_T2S1/_ .TH_U^R_\
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MM*/]?LO_ .@'&??0_P#E@?ZK8O\ Z"</]U3_ .0/S$HK]._[!^#'_1+-$_\
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MQ_T2S1/_  #M*/[!^#'_ $2S1/\ P#M*/]?LO_Z <9]]#_Y8'^JV+_Z"</\
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M#P37N=?$\19M1SG'4\70I5*,(8:G0<:O*Y.4*E:;DN1R5FJB2UO=/38^CRC
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M )"FI?\ 7_>?^E$E=/\ #_\ Y&.'_KUN_P#T6*YC5?\ D*:E_P!?]Y_Z424
M4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O
M1O%7_(K>$/\ KU3_ -)+>O.:]&\5?\BMX0_Z]4_])+>@#SFBBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K4T/_D-:/_V%-/\
M_2N&LNM30_\ D-:/_P!A33__ $KAH W?'G_(S7O_ %RL_P#TEBKCJ['QY_R,
MU[_URL__ $EBKCJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@#T;Q_\ ZKPW_P!@UO\ T&VKSFO1O'_^J\-_]@UO_0;:O.:
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#T7
M4?\ DG.A_P#83D_]':O7G5>BZC_R3G0_^PG)_P"CM7KSJ@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH DA_UL7_71/\ T(5W
MOQ)_Y#MM_P!@JW_]*[ZN"A_UL7_71/\ T(5WOQ)_Y#MM_P!@JW_]*[Z@#SZB
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M Z_P)_R,^G_[E[_Z17%?0-?/W@3_ )&?3_\ <O?_ $BN*^@: *4./,'7H>N[
MT]^*^;M9_P"0QJO_ &$K[_TJEKZ1A/[P?0_PD=CW)_\ K_K7S=K/_(8U7_L)
M7W_I5+5S^+Y?U_3,Z?P_/]%ZF;1114&@4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !5BT_X^[7_ *^(?_1BU7JQ:?\ 'W:_]?$/_HQ: .V^
M(_\ R'XO^P;;_P#H^ZK@:[[XC_\ (?B_[!MO_P"C[JN!H **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .V^'_ /R,</\ UZW?
M_HL5S&J_\A34O^O^\_\ 2B2NG^'_ /R,</\ UZW?_HL5S&J_\A34O^O^\_\
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M9KW_ *Y6?_I+%7'4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% 'HWC__ %7AO_L&M_Z#;5YS7HWC_P#U7AO_ +!K?^@VU><T
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M (3+_A7'P_\ ^%B_\E!_X0GPK_PG?_(*_P"1R_L*P_X2?_D!?\23_D-_;O\
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M1_\ D/Q?]@VW_P#1]U7 UWWQ'_Y#\7_8-M__ $?=5P- !1110 45^*/_  <
M?M<?M"_L2?\ !.CQ;\=_V8?B#_PK+XK:9\4?A9X<L?%7_"*>"/&?D:-XCUR:
MSUJS_L/X@^&O%GAN7[9;(L?VB;1Y+JWQOM)X)"6/VM_P3<^+GQ#^/G[ G['O
MQK^+7B#_ (2SXF_%/]GGX7^.?'GB;^R=#T+^W?%/B+PMI^HZSJG]C>&M-T;P
M_I?VR]GEF^Q:-I6G:=;[O+M;2")5C !]L4444 %%?B/_ ,%[?^"EGQ&_X)B_
ML6Z7\4?@OH^@ZG\8_BI\4]$^$/@34?%.G2:OX>\'M?\ ASQ3XLU[QE>Z0MQ:
M0ZQ=Z9I/A673=%TRZN/L;:UK-AJ.H6>IZ7IM_IEWRO\ P2N^'?\ P74T_P"(
ML/Q*_P""EO[3WP"^)WP#\;_!NXUOPW\+/A_X7\"V'Q(\&?$K5]4\)7_ANS\0
M:AX'^ WPVT4:7:>%KSQ7%JTNF?$+Q[:MJMEH]O;&XAN+C5% /WBHHHH ****
M "BO!?VJ?C1/^S?^S!^T?^T1:^'HO%US\!?@+\8/C1;^%+C4WT6#Q//\+?A[
MXB\<0^'IM8CL=3DTF+6I-"739-333=0>P2Y:Z6QNVB$$GP#_ ,$1OVX/C'_P
M4._8>M/VGOCC!X5T_P 9^*OC#\5]&M="\$Z1+H_ACPWX9\.:W;V&@:!I<-Y>
M:EJMW'86N[SM2UK5-2U2^N)999[KR_)MX #]>**_(S]B_P#X>K_\-X?MU?\
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MW_A,/@E_8G_)<O\ BK?^12_X7)_R1[_BHO\ G[_XF7_"*T ?KS1110 4444
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MK6YGB_C'_:V_;3^,/[7?C*XUGQMJ]QI/@NQO)G\'_#;2KR=/#'ANS+,L$DD
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MP?\ T%8?_P '4_\ Y(_:RBOQ3_XB#?\ @EU_T6GQA_X9KXI__,O1_P 1!O\
MP2Z_Z+3XP_\ #-?%/_YEZ/\ 5SB#_H2YI_X0XG_Y6'U[!_\ 05A__!U/_P"2
M/VLHK\4_^(@W_@EU_P!%I\8?^&:^*?\ \R]'_$0;_P $NO\ HM/C#_PS7Q3_
M /F7H_U<X@_Z$N:?^$.)_P#E8?7L'_T%8?\ \'4__DC]K**_%/\ XB#?^"77
M_1:?&'_AFOBG_P#,O1_Q$&_\$NO^BT^,/_#-?%/_ .9>C_5SB#_H2YI_X0XG
M_P"5A]>P?_05A_\ P=3_ /DC]K*_D4_X.;;/Q!?_ !=_X)]6GA/4[G1/%,S?
M&=?#6L6=]<Z7>:5KZZ]\&WT;4;34[)DO--N;/45MKB#4+1UN;*6-+F B6):_
M3_\ XB#?^"77_1:?&'_AFOBG_P#,O7X+_P#!7S]OS]F/]NOX^_L*WW[-OC+5
M_%]M\-/$GC.T\7OJW@_Q1X2-A/XK\1_#&;1%@3Q+IFFM?BYC\/ZH9&LQ,MN8
M$$Y0S1!_L_#WA_-(<8Y)]?RO'X?!U,14H5ZM;"UJ5.,*^'JT;.I."C%S=10C
M=ZRDDKMV/*SO&X=Y7BW1Q%&=6--3A&-2$FW"49_"G=I<MWY)G[C_ /!'7_@J
M6O[7WA&;]GG]H*^A\._MA_";3VL]=L]26WTY_B]X;TA$@?QQHUO&([5_$UB@
MC_X3C1;!1"S20^*]#B.B:C>6>@?N;7^=W\5/ 7C&T\1>&/CI\#]=U'P/\>_A
M?J%IXA\)>)M N%L=2OIM*8S6]F\K V\UW&OF0VBWT<UCJ%I-<Z%J\-SI5Z4M
M_P"O'_@E7_P4M\(?\%!?@ZZ:Y_9WA+]I+X:6UKI?QI^&R[[*3[4C"RC\>>%]
M/NG:[?PCK]W&R3VI:>Z\)ZX9O#VJN\;:+J>M>]XO^%F+X&S2IC,'3E6R/&3E
M4H58PM&AS22Y6E[L(J4E&<%94:DHJ*5*K0OP\+\1TLYPT:522AC*45&I%O65
MENKN[NDW%ZN44[^_&9^J=%%%?BA]:%%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !6IH?_ "&M'_["FG_^E<-9=:FA_P#(:T?_ +"F
MG_\ I7#0!N^//^1FO?\ KE9_^DL5<=78^//^1FO?^N5G_P"DL5<=0 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >C>/_ /5>
M&_\ L&M_Z#;5YS7HWC__ %7AO_L&M_Z#;5YS0 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 >BZC_ ,DYT/\ ["<G_H[5Z\ZK
MT74?^2<Z'_V$Y/\ T=J]>=4 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% $D/^MB_ZZ)_Z$*[WXD_\AVV_P"P5;_^E=]7!0_Z
MV+_KHG_H0KO?B3_R';;_ +!5O_Z5WU 'GU%%% !1110 4444 %%%% !1110
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M;>&KFTT:#7X[W3I-;UG^W]:M]7MM)GT;5OG2P_X(S?\ !6'QA\.M,^-NC_\
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M /"^M^&[74;3Q5XE/VW6?K/_ ()"_P#!37]L7]NOPE_P4&_8A_:\\+>'M/\
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MB/\ \%,OV.OV9_VB?VUO'/[=W['/[:/C33O!6DZ]\8UUG7?B)X<N/$GC31/
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M5T_P_P#^1CA_Z];O_P!%BN8U7_D*:E_U_P!Y_P"E$E %"BBB@ HHHH ****
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M<6T[)-\R:=M&U>-HM)>@4445^<GNA1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !6IH?_(:T?\ ["FG_P#I7#676IH?_(:T?_L*:?\ ^E<-
M &[X\_Y&:]_ZY6?_ *2Q5QU=CX\_Y&:]_P"N5G_Z2Q5QU !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Z-X__P!5X;_[!K?^
M@VU><UZ-X_\ ]5X;_P"P:W_H-M7G- !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110!Z+J/_).=#_["<G_H[5Z\ZKT74?\ DG.A
M_P#83D_]':O7G5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110!)#_ *V+_KHG_H0KO?B3_P AVV_[!5O_ .E=]7!0_P"MB_ZZ
M)_Z$*[WXD_\ (=MO^P5;_P#I7?4 >?4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% '7^!/^1GT_\ W+W_ -(KBOH&OG[P
M)_R,^G_[E[_Z17%?0- &?;D^:.3T;O[5\XZS_P AC5?^PE??^E4M?1MM_K1]
M&_E7SEK/_(8U7_L)7W_I5+5S^+Y?<94KN+NT]>GHO0S:***@U"BBB@ HHHH
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M\?:7XJDC\":7H?@'Q'X>U.X.GV4L*)X@\4>&(S>M'&TJP%KA/W0HHH _"_\
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M3_[-N[.[U?3O@)H&N#4I[>:;[3J]M\7[?Q5J,D,<E]XRD-Y>AOV;_P""7O\
MP3(^"7_!+3]GC_A2/PGU+5?&GB+Q)K"^+?BQ\5_$=E::=X@^(_C+[%%8)=_V
M592W5MX<\+Z-9Q?8/"?A.WOM271;*2YFOM6US7=2UG7=4_2.B@#^7+XM_P#!
M#;]L+]FC]J#XE_M7?\$6_P!K_P &?LNW_P ;=2.I_%']G?XQ:'-??!&[O;O4
MKO4]2?1!IW@7XE:='HD-W?W]YX8\/ZC\-[G5?!<^J:S:>$O&NB:+?PZ38?$_
M[:__  ;I_P#!5']O+PAI7Q9_:9_;Y^#7QI_:WL?%>AZ1X?\ "FL)XM^'G[-'
MPK^#<ND>,KSQMIO@J3P;\(K[5-6\9:UXPD^'"V%Q'\*_ T4V@:)KUSXLUOQ/
MK$F@C3?[9:* .=\'Z1<^'_"7A;0;UX);S1/#NB:1=R6K2/;27.FZ9:V4[V[R
MQ0RO \L+M$TD,4C1E2\4;$H.BHHH **** "BBB@ HHHH *L6G_'W:_\ 7Q#_
M .C%JO5BT_X^[7_KXA_]&+0!VWQ'_P"0_%_V#;?_ -'W5<#7??$?_D/Q?]@V
MW_\ 1]U7 T %%%% 'Y,?\%JOV#_B]_P4>_86\3?LQ_!#Q'\-_"OCW6?B)\.O
M%MKJ_P 5=7\3Z'X0CTWPCJ\NH:E!<7_A'P?XYUE+Z>&0+8QQZ!+!+*"MQ<VR
M8<^E?![]D#XE_#[_ ()2^&?V%]9USP-<_%K1?V)]0_9NNO$6F:GK\WPZD\<W
M?PDU#P%'JMOJ]WX9LO$S^%%UB[CN7OI/",6KC35>9=":Z"V;?H[10!^3'_!%
M7]@_XO?\$X?V%O#/[,?QO\1_#?Q5X]T;XB?$7Q;=:O\ "K5_$^N>$)--\7:O
M%J&FP6]_XN\'^!M9>^@AC*WT<F@1012D+;W-RF7'A_\ P5V_X)A_'O\ ;Z_:
M1_X)A_&'X.^+OA#X;\,_L5_&_P 2?$OXIV/Q+U_QGH^NZ_H6L>//V=_%%K:>
M +7POX \9:?JNK1Z?\)/$D,\'B+4_"MFMY>Z)''?RP7-_<:;^Z]% 'X4?\%\
M?^"8?Q[_ ."IO[-WP=^#W[/OB[X0^#_$WP]^-\'Q+UJ^^,FO^,_#^A76A1>
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M#J^C:E'?Z+I&JZ-K>EWUANN/R6U3_@G/_P '*'CCP1=?LZ^.?^"K_P"SY:?
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MP>^#OQ5U\>(]7_9P_:4T/4?$?@KP]=DR0QVNG:[)X$^,B:RVEV;QV6D>)?\
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ME[ VM:K/X/\ AA!_9FHWNDV+^+K;_A7M_P"(O%6G6MOH4WC"PT>(6M?U'44
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M?7]B'_!'3_DQKP1_V.7Q$_\ 4GNJV\$O^2QQ'_8BQW_J7EQYO[6K_E&#)?\
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M@ HHHH **** "BBB@ K4T/\ Y#6C_P#84T__ -*X:RZU-#_Y#6C_ /84T_\
M]*X: -WQY_R,U[_URL__ $EBKCJ['QY_R,U[_P!<K/\ ])8JXZ@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ]&\?_ZKPW_V
M#6_]!MJ\YKT;Q_\ ZKPW_P!@UO\ T&VKSF@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH ]%U'_DG.A_]A.3_ -':O7G5>BZC
M_P DYT/_ +"<G_H[5Z\ZH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** )(?\ 6Q?]=$_]"%=[\2?^0[;?]@JW_P#2N^K@H?\
M6Q?]=$_]"%=[\2?^0[;?]@JW_P#2N^H \^HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** .O\  G_(SZ?_ +E[_P"D5Q7T
M#7S]X$_Y&?3_ /<O?_2*XKZ!H S;;/FC)'1NV.WU-?.>L_\ (8U7_L)7W_I5
M+7T7:EC,,C'RMV([>]?.FL_\AC5?^PE??^E4M7434M;;+;];&5'X7I;WGW[+
M76YFT445!J%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 58M
M/^/NU_Z^(?\ T8M5ZL6G_'W:_P#7Q#_Z,6@#MOB/_P A^+_L&V__ */NJX&N
M^^(__(?B_P"P;;_^C[JN!H **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#OUEN/#WBO0Y)4EN=$U^PCEA-Q:R/&DUO/#+!?:?=QQ7=C<P3QAC_2'\)O\
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M1_\ L*:?_P"E<- &[X\_Y&:]_P"N5G_Z2Q5QU=CX\_Y&:]_ZY6?_ *2Q5QU
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Z-
MX_\ ]5X;_P"P:W_H-M7G->C>/_\ 5>&_^P:W_H-M7G- !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Z+J/\ R3G0_P#L)R?^
MCM7KSJO1=1_Y)SH?_83D_P#1VKUYU0 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 20_ZV+_KHG_H0KO?B3_R';;_ +!5O_Z5
MWU<%#_K8O^NB?^A"N]^)/_(=MO\ L%6__I7?4 >?4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '7^!/^1GT__<O?_2*X
MKZ!KY^\"?\C/I_\ N7O_ *17%?0- &9:MNF QCY6/7V^E?.FL_\ (8U7_L)7
MW_I5+7T7:E3,,#'RMV [>U?.FL_\AC5?^PE??^E4M:5%:6UM%H_3^NWH8T/@
M?^)_DC-HHHK,V"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*L6G_'W:_P#7Q#_Z,6J]6+3_ (^[7_KXA_\ 1BT =M\1_P#D/Q?]@VW_ /1]
MU7 UWWQ'_P"0_%_V#;?_ -'W5<#0 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 =M\/\ _D8X?^O6[_\ 18KF-5_Y"FI?]?\
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M[X\_Y&:]_P"N5G_Z2Q5QU=CX\_Y&:]_ZY6?_ *2Q5QU !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Z-X_\ ]5X;_P"P:W_H
M-M7G->C>/_\ 5>&_^P:W_H-M7G- !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110!Z+J/\ R3G0_P#L)R?^CM7KSJO1=1_Y)SH?
M_83D_P#1VKUYU0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 20_ZV+_KHG_H0KO?B3_R';;_ +!5O_Z5WU<%#_K8O^NB?^A"
MN]^)/_(=MO\ L%6__I7?4 >?4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% '7^!/^1GT__<O?_2*XKZ!KY^\"?\C/I_\
MN7O_ *17%?0- &9:[/.&.NUO7^M?(GB']H[X8:3K^N:5>>!-;N;S3-8U/3[J
MYC;3Q'<7-E>SVT\\8>_5MDLL;2+N56VL,J#D5]<V@'G#!S\K=B.U?C9\0_\
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MHH_U,R'_ *!ZW_A36_\ D@_UBS3_ )^T_P#P33_R/O+_ (:>^$__ $3W7O\
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MPT]\)_\ HGNO?]]Z;_\ +"O@VBC_ %,R'_H'K?\ A36_^2#_ %BS3_G[3_\
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M1_PT]\)_^B>Z]_WWIO\ \L*^#:*/]3,A_P"@>M_X4UO_ )(/]8LT_P"?M/\
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M3_R/O+_AI[X3_P#1/=>_[[TW_P"6%'_#3WPG_P"B>Z]_WWIO_P L*^#:*/\
M4S(?^@>M_P"%-;_Y(/\ 6+-/^?M/_P $T_\ (^\O^&GOA/\ ]$]U[_OO3?\
MY84?\-/?"?\ Z)[KW_?>F_\ RPKX-HH_U,R'_H'K?^%-;_Y(/]8LT_Y^T_\
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MHH_U,R'_ *!ZW_A36_\ D@_UBS3_ )^T_P#P33_R/O+_ (:>^$__ $3W7O\
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M-;_Y(/\ 6+-/^?M/_P $T_\ (^\O^&GOA/\ ]$]U[_OO3?\ Y84?\-/?"?\
MZ)[KW_?>F_\ RPKX-HH_U,R'_H'K?^%-;_Y(/]8LT_Y^T_\ P33_ ,C[R_X:
M>^$__1/=>_[[TW_Y84?\-/?"?_HGNO?]]Z;_ /+"O@VBC_4S(?\ H'K?^%-;
M_P"2#_6+-/\ G[3_ /!-/_(^\O\ AI[X3_\ 1/=>_P"^]-_^6%'_  T]\)_^
MB>Z]_P!]Z;_\L*^#:*/]3,A_Z!ZW_A36_P#D@_UBS3_G[3_\$T_\C[R_X:>^
M$_\ T3W7O^^]-_\ EA1_PT]\)_\ HGNO?]]Z;_\ +"O@VBC_ %,R'_H'K?\
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MI[X3_P#1/=>_[[TW_P"6%>(?M1?\EF\1_P#7EX?_ /3'85\^5SY9PGDN*R[
M8FM0JNK7PF'K5&L15BG.I2A.345*R3DV[+1;(VQN>YC0QF*HTZL%3I5ZM."=
M*#:C&;44VU=V2W>K/O+_ (:>^$__ $3W7O\ OO3?_EA1_P -/?"?_HGNO?\
M?>F__+"O@VBN[_4S(?\ H'K?^%-;_P"2.7_6+-/^?M/_ ,$T_P#(^\O^&GOA
M/_T3W7O^^]-_^6%'_#3WPG_Z)[KW_?>F_P#RPKX-HH_U,R'_ *!ZW_A36_\
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M-;_Y(/\ 6+-/^?M/_P $T_\ (^\O^&GOA/\ ]$]U[_OO3?\ Y84?\-/?"?\
MZ)[KW_?>F_\ RPKX-HH_U,R'_H'K?^%-;_Y(/]8LT_Y^T_\ P33_ ,C[R_X:
M>^$__1/=>_[[TW_Y84?\-/?"?_HGNO?]]Z;_ /+"O@VBC_4S(?\ H'K?^%-;
M_P"2#_6+-/\ G[3_ /!-/_(^\O\ AI[X3_\ 1/=>_P"^]-_^6%'_  T]\)_^
MB>Z]_P!]Z;_\L*^#:*/]3,A_Z!ZW_A36_P#D@_UBS3_G[3_\$T_\C[R_X:>^
M$_\ T3W7O^^]-_\ EA1_PT]\)_\ HGNO?]]Z;_\ +"O@VBC_ %,R'_H'K?\
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M_P"B>Z]_WWIO_P L*^#:*/\ 4S(?^@>M_P"%-;_Y(/\ 6+-/^?M/_P $T_\
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MPT]\)_\ HGNO?]]Z;_\ +"O@VBC_ %,R'_H'K?\ A36_^2#_ %BS3_G[3_\
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MBS3_ )^T_P#P33_R/O+_ (:>^$__ $3W7O\ OO3?_EA1_P -/?"?_HGNO?\
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M_P!]Z;_\L*^#:*/]3,A_Z!ZW_A36_P#D@_UBS3_G[3_\$T_\C[R_X:>^$_\
MT3W7O^^]-_\ EA1_PT]\)_\ HGNO?]]Z;_\ +"O@VBC_ %,R'_H'K?\ A36_
M^2#_ %BS3_G[3_\ !-/_ "/O+_AI[X3_ /1/=>_[[TW_ .6%'_#3WPG_ .B>
MZ]_WWIO_ ,L*^#:*/]3,A_Z!ZW_A36_^2#_6+-/^?M/_ ,$T_P#(^\O^&GOA
M/_T3W7O^^]-_^6%'_#3WPG_Z)[KW_?>F_P#RPKX-HH_U,R'_ *!ZW_A36_\
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M-;_Y(/\ 6+-/^?M/_P $T_\ (^\O^&GOA/\ ]$]U[_OO3?\ Y84?\-/?"?\
MZ)[KW_?>F_\ RPKX-HH_U,R'_H'K?^%-;_Y(/]8LT_Y^T_\ P33_ ,C[R_X:
M>^$__1/=>_[[TW_Y84?\-/?"?_HGNO?]]Z;_ /+"O@VBC_4S(?\ H'K?^%-;
M_P"2#_6+-/\ G[3_ /!-/_(^\O\ AI[X3_\ 1/=>_P"^]-_^6%'_  T]\)_^
MB>Z]_P!]Z;_\L*^#:*/]3,A_Z!ZW_A36_P#D@_UBS3_G[3_\$T_\C[W@_:;^
M%,D\,:?#[75>26-%8MIN%9G"J3_Q,#P"03P?I7J/Q@^,?@CX>^)K+1?$GA74
M]<O[K0[75(KNS:T$4=I/?ZG:1V[?:+J!_,26RGD.$*[95PQ.X#\P;'_C]L_^
MOJW_ /1R5]3?MB_\E.T3_L1=+_\ 3_XFKR\1PMD]/-<MPD*-54<30S"I5BZ]
M5MRPZPSI-2<KQM[6=TG9W5]D=M'.\PG@<97E4A[2C5PL*;]E!)1JNMSIJUG?
MDC9O;IN>A?\ #3WPG_Z)[KW_ 'WIO_RPH_X:>^$__1/=>_[[TW_Y85\&T5ZG
M^IF0_P#0/6_\*:W_ ,D<7^L6:?\ /VG_ .":?^1]Y?\ #3WPG_Z)[KW_ 'WI
MO_RPH_X:>^$__1/=>_[[TW_Y85\&T4?ZF9#_ - ];_PIK?\ R0?ZQ9I_S]I_
M^":?^1]Y?\-/?"?_ *)[KW_?>F__ "PH_P"&GOA/_P!$]U[_ +[TW_Y85\&T
M4?ZF9#_T#UO_  IK?_)!_K%FG_/VG_X)I_Y'WE_PT]\)_P#HGNO?]]Z;_P#+
M"C_AI[X3_P#1/=>_[[TW_P"6%?!M%'^IF0_] ];_ ,*:W_R0?ZQ9I_S]I_\
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MOA/_ -$]U[_OO3?_ )85\&T4?ZF9#_T#UO\ PIK?_)!_K%FG_/VG_P"":?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *U-#_ .0UH_\ V%-/_P#2N&LNM30_^0UH
M_P#V%-/_ /2N&HJ?PZG^"7_I+*A\<?\ %'\T?27[7O\ R5.Q_P"Q/TG_ -.6
MM5\LU]3?M>_\E3L?^Q/TG_TY:U7RS7D\/?\ (DRS_L$I?DSOS?\ Y&>-_P"O
M\_T"BBBO9/."BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** /I']E+_DK^G_]@37/_25:\7\<_P#([>,/^QI\0?\ IVNZ]H_92_Y*_I__
M &!-<_\ 25:\7\<_\CMXP_[&GQ!_Z=KNO"H_\E'CO^Q5@?\ U(Q9Z=7_ )%&
M$_[#<5_Z:PYRU%%%>Z>8%%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %?77QP_Y(A\ O^P+'_Z8]+KY%KZZ^.'_ "1#X!?]@6/_ -,>
MEUX6:?\ (SX?_P"PW%?^H&(/3P7^YYK_ -@U#_U*HGR+1117NGF!1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7;?#3_DH_P /_P#L
M=O"G_I]L*XFNV^&G_)1_A_\ ]CMX4_\ 3[85SXO_ '3%?]@];_TW(VP_^\4/
M^OU+_P!+B>F_M1?\EF\1_P#7EX?_ /3'85\^5]!_M1?\EF\1_P#7EX?_ /3'
M85\^5QY)_P B;*O^Q?A/_3%,Z,S_ .1CCO\ L*K_ /IR04445ZAPA1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'UU^U/\ \>7P@_[$
MU_\ T3I%?(M?77[4_P#QY?"#_L37_P#1.D5\BUX7#7_(DP?KBO\ U,Q!Z><?
M\C'$>E#_ -1Z04445[IY@4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110!]<^+O\ DT3X9_\ 8YW?_IP\>U\C5]<^+O\ DT3X9_\ 8YW?
M_IP\>U\C5X60?P<R_P"QWFW_ *E2/2S/X\'_ -BW ?\ J/$****]T\T****
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M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110![_\
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M=>"-<\7Q:'+JB6FH/IL6K/HZV$FH)87S6:W!N%M+DQB%_BC_ ()&?M>?%/\
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MMXZL+2&)Y':*)K?0H+B4Q1DE(VD-\AD* %\(7SM7'P;_ ,%&21^U9XXP2/\
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MP?KBO_4S$'IYQ_R,<1Z4/_4>D%%%%>Z>8%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 ?7/B[_DT3X9_P#8YW?_ *</'M?(U?7/B[_D
MT3X9_P#8YW?_ *</'M?(U>%D'\',O^QWFW_J5(]+,_CP?_8MP'_J/$****]T
M\T**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M6/_'[
M9_\ 7U;_ /HY*^IOVQ?^2G:)_P!B+I?_ *?_ !-7RS8_\?MG_P!?5O\ ^CDK
MZF_;%_Y*=HG_ &(NE_\ I_\ $U>'C/\ D?9+_P!@N;_^DX(]/#_\BO,?^O\
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MN;O%?P]U;2M>LO#T\_A^T\4^&_'&C-&FN>#ULM!U:ROH6L-(LY-*:]U?S?\
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MH;3-+>_\6ZOX@T_4KOPWJ*Z5J$)M]3MEN?$UEJ^D>!] \,ZOX7N-9LO#>O\
MBW5O%QL38Z7IM_\ X)0_\IE/^"Q7_8YZI_ZM76ZXC_@W*N8?!WQN_P""G_P?
M\87,5O\ %[1OC+X;OM?L;R3?J^JVGAKQ7\7_  WKUZD]ULU+4;?1?$EXB:A/
M<Q*MM/XDT^5B)M5=1AAZM;$4\KP$\17IT,=FN=K$U*=6=.M4IX2MB*E/#1K1
MDJD(57:,E"2DX0<8M+1Z584Z4L;BHTJ4ZN&P&6.C"<(SA&>(A2A.LZ;7+*4%
MJG).*E*\DW8D_:1_9D_X*O\ _!,7X>:I^UC\#_\ @HE\4/VP_ _PNAM_$GQ?
M^$?[1-OXF\4BX\'VL\,>NZKI]MXH\<^/)+K0+&U*WWB%/#^M^!?$F@:+!J.L
MZ5K=U+#.J?:G[5'[<EW^T1_P0^^*'[97P'\3>+/A1XK\0_#+P[?17_@SQ3K/
MA[Q?\.?'&F?%/PMX4\;Z#I?BK1)=&UJ!],U6#6M)M]5M&L'UC0YX;P1)::EY
M1_1/_@H%XM\+^!_V&/VO_$GC*XMK?P]:_LW?&6QO$NEMW34+G7/ .NZ#I.B1
M0W3QVUS>:_J^IV&AZ?:3R1Q7=]J%M;2.BREA_+[^SAH&NZ-_P:__ +3>HZNT
M[:?XK\7^+]?\+"629XTT*V^,/PS\+7"VJR'9% ?$WAKQ$S1V^(3<M<2L//DG
M)Z,7!Y;B,;@L+6K_ %7$9#F.*="I7JUWAJU!<D*U&I5G.I3C54W&4>;E<XJ2
MLU99X9K&TL+B:\*7MZ6:X2A[2-*G35>E5:E*G4A3C"G.4.5-/ENH-IZ.[_I$
M_P""6?C+Q?\ $+_@GI^R7XU\?>*O$GCCQEXD^$>CZEXB\6^+]<U/Q+XFU[49
M;N_66_UK7M:NKW5=4O9%1%DNKZ[GG=44-(0H _*7]I?X[?&_0?\ @X=_8_\
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M$/ASQ)X%\07]MI&JVJZ7K'BCQ'KMTNO:[I^O6>A>#/#FBK;E-^[_ &[/B/\
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MO_$WB/3-0TKPSX9\.:U?R6?VFXM+[3OQ5_;^_P""9=[X0\.?"_P]_P %"O\
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MBC^PDC\,ZA_:'A_7_#J6]GKDFEZ3^U-?S4_\$EOV5O@_\'O^"@G[4_CK1O\
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M/P7IERT@L-2OK8)+++!MN6<PM(L;+]0T4X^&'"$)*4<#6C*+NFL553379_)
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M"%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MY@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M(****W,SZ1_92_Y*_I__ &!-<_\ 25:\7\<_\CMXP_[&GQ!_Z=KNO:/V4O\
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M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !7UU\</\ DB'P"_[ L?\
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M_P"QV\*?^GVPKB:[;X:?\E'^'_\ V.WA3_T^V%<^+_W3%?\ 8/6_]-R-L/\
M[Q0_Z_4O_2XGIO[47_)9O$?_ %Y>'_\ TQV%?/E?0?[47_)9O$?_ %Y>'_\
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M_P"G)'#Q)_NV%_Z_U?\ TW X^BBBOTL^0"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *U-#_P"0UH__ &%-/_\ 2N&LNM30_P#D-:/_ -A3
M3_\ TKAJ*G\.I_@E_P"DLJ'QQ_Q1_-'TE^U[_P E3L?^Q/TG_P!.6M5\LU]3
M?M>_\E3L?^Q/TG_TY:U7RS7D\/?\B3+/^P2E^3._-_\ D9XW_K_/] HHHKV3
MS@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>EUX6:?\C/A__L-Q7_J!B#T\%_N>:_\ 8-0_]2J)\BT445[IY@4444 %%%%
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M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'UU^U/\
M\>7P@_[$U_\ T3I%?(M?77[4_P#QY?"#_L37_P#1.D5\BUX7#7_(DP?KBO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M6/\
MQ^V?_7U;_P#HY*^IOVQ?^2G:)_V(NE_^G_Q-7RS8_P#'[9_]?5O_ .CDKZF_
M;%_Y*=HG_8BZ7_Z?_$U>'C/^1]DO_8+F_P#Z3@CT\/\ \BO,?^O^ _/$'R?1
M117N'F!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/<?\\)O^_3__ !-?MU]JG_YZ?^.I_P#$T?:I_P#GI_XZG_Q-'^O53_H50_\
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MU^W7VJ?_ )Z?^.I_\31]JG_YZ?\ CJ?_ !-'^O53_H50_P#"^7_S$'^KE/\
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MC_GA-_WZ?_XFC[/<?\\)O^_3_P#Q-?MU]JG_ .>G_CJ?_$T?:I_^>G_CJ?\
MQ-'^O53_ *%4/_"^7_S$'^KE/_H.GT_YA8]>7_J*\_ZMK^(OV>X_YX3?]^G_
M /B:/L]Q_P \)O\ OT__ ,37[=?:I_\ GI_XZG_Q-'VJ?_GI_P".I_\ $T?Z
M]5/^A5#_ ,+Y?_,0?ZN4_P#H.GT_YA8]>7_J*\_ZMK^(OV>X_P">$W_?I_\
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M7[=?:I_^>G_CJ?\ Q-'VJ?\ YZ?^.I_\31_KU4_Z%4/_  OE_P#,0?ZN4_\
MH.GT_P"86/7E_P"HKS_JVOXB_9[C_GA-_P!^G_\ B:/L]Q_SPF_[]/\ _$U^
MW7VJ?_GI_P".I_\ $T?:I_\ GI_XZG_Q-'^O53_H50_\+Y?_ #$'^KE/_H.G
MT_YA8]>7_J*\_P"K:_B+]GN/^>$W_?I__B:/L]Q_SPF_[]/_ /$U^W7VJ?\
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MIQ?UV;LT_P#=8]XO_H*??S^=M?SI_:[BE?XI612*1Q_PB&DC*HS#/]HZUQD
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MB+]GN/\ GA-_WZ?_ .)H^SW'_/";_OT__P 37[=?:I_^>G_CJ?\ Q-'VJ?\
MYZ?^.I_\31_KU4_Z%4/_  OE_P#,0?ZN4_\ H.GT_P"86/7E_P"HKS_JVOXB
M_9[C_GA-_P!^G_\ B:/L]Q_SPF_[]/\ _$U^W7VJ?_GI_P".I_\ $T?:I_\
MGI_XZG_Q-'^O53_H50_\+Y?_ #$'^KE/_H.GT_YA8]>7_J*\_P"K:_B+]GN/
M^>$W_?I__B:/L]Q_SPF_[]/_ /$U^W7VJ?\ YZ?^.I_\31]JG_YZ?^.I_P#$
MT?Z]5/\ H50_\+Y?_,0?ZN4_^@Z?3_F%CUY?^HKS_JVOXB_9[C_GA-_WZ?\
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MKS_JVOXB_9[C_GA-_P!^G_\ B:/L]Q_SPF_[]/\ _$U^W7VJ?_GI_P".I_\
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MZ]5/^A5#_P +Y?\ S$'^KE/_ *#I]/\ F%CUY?\ J*\_ZMK^(OV>X_YX3?\
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M_19]6_\ #?Q?_-37]H'VJ?\ YZ?^.I_\31]JG_YZ?^.I_P#$U^??\0X\)O\
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M;_OT_P#\37[=?:I_^>G_ (ZG_P 31]JG_P">G_CJ?_$T?Z]5/^A5#_POE_\
M,0?ZN4_^@Z?3_F%CUY?^HKS_ *MK^(OV>X_YX3?]^G_^)H^SW'_/";_OT_\
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MJY3_ .@Z?3_F%CUY?^HKS_JVOXB_9[C_ )X3?]^G_P#B:/L]Q_SPF_[]/_\
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M6-F!QH=@#@@$<'@U\_?9[C_GA-_WZ?\ ^)K]NOM4_P#ST_\ '4_^)H^U3_\
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MH?\ A?+_ .8@_P!7*?\ T'3Z?\PL>O+_ -17G_5M?Q%^SW'_ #PF_P"_3_\
MQ-'V>X_YX3?]^G_^)K]NOM4__/3_ ,=3_P")H^U3_P#/3_QU/_B:/]>JG_0J
MA_X7R_\ F(/]7*?_ $'3Z?\ ,+'KR_\ 45Y_U;7\1?L]Q_SPF_[]/_\ $T?9
M[C_GA-_WZ?\ ^)K]NOM4_P#ST_\ '4_^)H^U3_\ /3_QU/\ XFC_ %ZJ?]"J
M'_A?+_YB#_5RG_T'3Z?\PL>O+_U%>?\ 5M?Q%^SW'_/";_OT_P#\31]GN/\
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M_P")H^U3_P#/3_QU/_B:/]>JG_0JA_X7R_\ F(/]7*?_ $'3Z?\ ,+'KR_\
M45Y_U;7\1?L]Q_SPF_[]/_\ $T?9[C_GA-_WZ?\ ^)K]NOM4_P#ST_\ '4_^
M)H^U3_\ /3_QU/\ XFC_ %ZJ?]"J'_A?+_YB#_5RG_T'3Z?\PL>O+_U%>?\
M5M?Q%^SW'_/";_OT_P#\31]GN/\ GA-_WZ?_ .)K]NOM4_\ ST_\=3_XFC[5
M/_ST_P#'4_\ B:/]>JG_ $*H?^%\O_F(/]7*?_0=/I_S"QZ\O_45Y_U;7\1?
ML]Q_SPF_[]/_ /$T?9[C_GA-_P!^G_\ B:_;K[5/_P ]/_'4_P#B:/M4_P#S
MT_\ '4_^)H_UZJ?]"J'_ (7R_P#F(/\ 5RG_ -!T^G_,+'KR_P#45Y_U;7\1
M?L]Q_P \)O\ OT__ ,31]GN/^>$W_?I__B:_;K[5/_ST_P#'4_\ B:/M4_\
MST_\=3_XFC_7JI_T*H?^%\O_ )B#_5RG_P!!T^G_ #"QZ\O_ %%>?]6U_$7[
M/<?\\)O^_3__ !-'V>X_YX3?]^G_ /B:_;K[5/\ \]/_ !U/_B:/M4__ #T_
M\=3_ .)H_P!>JG_0JA_X7R_^8@_U<I_]!T^G_,+'KR_]17G_ %;7\_?VI8I7
MLOA#LCD?;X.<-M1FP?*TC@X!P?8U\C_9[C_GA-_WZ?\ ^)K]NOM4_P#ST_\
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MZN4_^@Z?3_F%CUY?^HKS_JVOXB_9[C_GA-_WZ?\ ^)H^SW'_ #PF_P"_3_\
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M%4/_  OE_P#,0?ZN4_\ H.GT_P"86/7E_P"HKS_JVOXB_9[C_GA-_P!^G_\
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MJY3_ .@Z?3_F%CUY?^HKS_JVOXB_9[C_ )X3?]^G_P#B:/L]Q_SPF_[]/_\
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M7*?_ $'3Z?\ ,+'KR_\ 45Y_U;7\1?L]Q_SPF_[]/_\ $T?9[C_GA-_WZ?\
M^)K]NOM4_P#ST_\ '4_^)H^U3_\ /3_QU/\ XFC_ %ZJ?]"J'_A?+_YB#_5R
MG_T'3Z?\PL>O+_U%>?\ 5M?Q%^SW'_/";_OT_P#\31]GN/\ GA-_WZ?_ .)K
M]NOM4_\ ST_\=3_XFC[5/_ST_P#'4_\ B:/]>JG_ $*H?^%\O_F(/]7*?_0=
M/I_S"QZ\O_45Y_U;7\1?L]Q_SPF_[]/_ /$T?9[C_GA-_P!^G_\ B:_;K[5/
M_P ]/_'4_P#B:/M4_P#ST_\ '4_^)H_UZJ?]"J'_ (7R_P#F(/\ 5RG_ -!T
M^G_,+'KR_P#45Y_U;7\1?L]Q_P \)O\ OT__ ,31]GN/^>$W_?I__B:_;K[5
M/_ST_P#'4_\ B:/M4_\ ST_\=3_XFC_7JI_T*H?^%\O_ )B#_5RG_P!!T^G_
M #"QZ\O_ %%>?]6U_$7[/<?\\)O^_3__ !-'V>X_YX3?]^G_ /B:_;K[5/\
M\]/_ !U/_B:/M4__ #T_\=3_ .)H_P!>JG_0JA_X7R_^8@_U<I_]!T^G_,+'
MKR_]17G_ %;7\1?L]Q_SPF_[]/\ _$T?9[C_ )X3?]^G_P#B:_;K[5/_ ,]/
M_'4_^)H^U3_\]/\ QU/_ (FC_7JI_P!"J'_A?+_YB#_5RG_T'3Z?\PL>O+_U
M%>?]6U_$7[/<?\\)O^_3_P#Q-'V>X_YX3?\ ?I__ (FOVZ^U3_\ /3_QU/\
MXFC[5/\ \]/_ !U/_B:/]>JG_0JA_P"%\O\ YB#_ %<I_P#0=/I_S"QZ\O\
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M;_OT_P#\31]GN/\ GA-_WZ?_ .)K]NOM4_\ ST_\=3_XFC[5/_ST_P#'4_\
MB:/]>JG_ $*H?^%\O_F(/]7*?_0=/I_S"QZ\O_45Y_U;7\1?L]Q_SPF_[]/_
M /$T?9[C_GA-_P!^G_\ B:_;K[5/_P ]/_'4_P#B:/M4_P#ST_\ '4_^)H_U
MZJ?]"J'_ (7R_P#F(/\ 5RG_ -!T^G_,+'KR_P#45Y_U;7\1?L]Q_P \)O\
MOT__ ,31]GN/^>$W_?I__B:_;K[5/_ST_P#'4_\ B:/M4_\ ST_\=3_XFC_7
MJI_T*H?^%\O_ )B#_5RG_P!!T^G_ #"QZ\O_ %%>?]6U_$^QM[C[;9_N)O\
MCZM_^63_ //5/]FOJ3]L**63XFZ(4CD<#P-I@)1&89_M[Q,<9 (S@@X]Q7Z&
M?:I_^>G_ (ZG_P 31]JG_P">G_CJ?_$UPUN+JE7'X+&_V="/U.EBZ7LOKDG[
M3ZTJ"YN?ZHN3D]CMRRYN;>-M>JGDE.&$Q&&^MS?UBIAY\_U:*Y/8\[MR_6'S
M<WM=^9<MMI'XB_9[C_GA-_WZ?_XFC[/<?\\)O^_3_P#Q-?MU]JG_ .>G_CJ?
M_$T?:I_^>G_CJ?\ Q-=W^O53_H50_P#"^7_S$<O^KE/_ *#I]/\ F%CUY?\
MJ*\_ZMK^(OV>X_YX3?\ ?I__ (FC[/<?\\)O^_3_ /Q-?MU]JG_YZ?\ CJ?_
M !-'VJ?_ )Z?^.I_\31_KU4_Z%4/_"^7_P Q!_JY3_Z#I]/^86/7E_ZBO/\
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M5#_POE_\Q!_JY3_Z#I]/^86/7E_ZBO/^K:_B+]GN/^>$W_?I_P#XFC[/<?\
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MY?\ J*\_ZMK^(OV>X_YX3?\ ?I__ (FC[/<?\\)O^_3_ /Q-?MU]JG_YZ?\
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,6I>W)>_-UM;2[__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>img267189834_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img267189834_3.jpg
M_]C_X  02D9)1@ ! @$ W #<  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $Q!88# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?LK>%OB!KMU=?#_XE_#WX.:?X_UC48S;PP^%_P!H?P7I.C>-]ZPA(;Q?A_\
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M\VD/;:EI@TM]5AO-:O-06YFU&X5+@>2?D;Q7^W1^UGXB^-__  47UGXI^%-
MU?\ 9D\$_L?_ +%'Q,\'_#OPQ\9/%OA+7?"^J_%O7--O]-DT+5O#_ARQU6RO
M?$UQJ?B";QEJ(U'[3;0^&O#VEVHN=/U2ZCM #^JVBOP5\??\%1OVP?#?BS]J
M_7/A_P#L<?#CQG^S7^Q1\<O#?PM^+OQ%U7X\7?A_Q]KGA?4O ?PD\9Z[JW@+
MP0W@O4H=3\2^#=.^)3ZEJUCK6L:7I>IV%KIUMI>I3:A=W_\ 9U#Q'_P4'^*G
MPR^+GQ@\!?L[?LXV?Q8^)'Q-_P""C3?LVZ7I'C?XY^(=(T.ZNY/V,?AK\9H_
MB +C7-)UC3_A_P"&])MWM['7O!OABTN+3['I^K>(M*M;_P 2:Q-93@'[\T5\
M3?L1_M*_%/\ :#\-_%W0OCQ\*?#WP=^./P"^+^J?!_XF>%/!GC2?X@>![G48
MO#'A;QQH'B'PCXIO-%\.ZC>Z1KWA/QEH=^;?4=&L[S3[N2YLI?.\D2M^4_A/
M]M'X_? "[_:6@^&_@!_VC_'_ ,6/^"OOB/\ 9G^'_@WQ[\3M0\*Z)X2TGQ!\
M+/".LV<UGK^HV>OQ:'X8T*[LY[NZTFQL5@AMKJ_N+"SGO9%AF /Z,:*_FK^.
M/[<_[7'Q!M?@UX8U7X$V/@+]JGX!_P#!3OX1? WQG\*/AU\;;V3X4?%*R\6_
M#*[\=>&+Y/B1?:+X;O)O FHZ/K]G-XHTS7?"]Q-8W>E7$,6GZG.D,2^U:9^W
MY\2_B1XE^'OPU_:+_9\L?AK\=?A!_P %%_A5^SEXUTCX;_&WQ3J'PZ9O'/P]
MG\?>$/B/X:\0V>@^&=0\<:%+HM\;?5? WB[0K/3CJ=M(EU)/Y49C /WJHK^;
M/_@G[^VM^V5\)_@=^S3-\;/V?X?$W[+OQ"_:0^)WP#'[0NL_&V]\4?'@^+/B
M#^U1\6?"WP[\7ZM\,[[0[W/PM35+G0_!\4EQXT/B;1='M$U)M"M]#M;&.7P;
MP-^V9^U/KGQ"^!EO\//!&CZ=^RKJ7[*G_!1CQWX_\!>(OV@/B%J7C'4KWX4_
M&SXI>%/$?B"W\5W?AV\\22Z[#/HUK'X(MSJL%IX<L-?NK?39+*/0-,9P#^L6
MBOYV_@1_P4D_:,\;_"7X'?#3]B/]E#PK\5]?^'7[%?P-_:/^.UC\7OVA_$^D
MGPCH7Q7\,WVL^ ?AAX*\::OX2\4>(OBC\2-9TG0-7N;C7O%!TG3K:2*S&M7P
MNK["8D?_  6E_:@^-'CWXC:3^R!^QY\.O'W@GX6?L;?"7]L7QCJ?Q?\ C5J?
MPT\5:9I/C6#QA+XM^&(T/3?!/B6UN_&>B7/@G6]*TB\BO4T:YO+3S[^>WMKB
M L ?T?T5Y3\"OBMI?QU^"_PJ^,^BZ?=Z3I?Q2^'_ (4\>66DWS(]YI47B?1;
M/5O[,NI(P(Y9[![IK26:,".9X3+&-CK7JU !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 45\X_MBZGJ&B_LB_M3ZSI%_?:5JVD_L
MX_'#4],U33+NXL-2TW4+#X9>)[JRO]/OK22*ZLKZSN8HKBTN[:6.XMKB..:&
M1)$5A_-'X)_:9_:!^&G_  34'[)G[0WQI\1Z[\?]$\&?L>?&W]GGXVMKFJ:#
MXW^.?[-?Q&^.OPIL[N&XUF&\BU+6?'7PDGU*Z^'/Q0:&^NKG4]&NM"UG5#-;
M>(C)< ']=5%?S8_&[_@X*\(_"3X^_%?P;I?@_P"%&L_!;]G;XHP?!_XJ2ZW\
M6-4TW]I7Q7K6DW6GZ=X\\2?!KX+Z=X-U>Q\6>'_"%[>S16UMJGBK2M;\7C2M
M2DT.S -F+G[,U?\ X*=^)K#X.?\ !1WXJ6WPET*>3]ASX_6WP=\,:5/XGU*W
MC^(VDW?A_P"%FNP>(=<F.CF;PW?[/B+-$^F6D.I1I_9D6;C=<2+$ ?L%17XT
M^"_^"AW[4_Q$^*'[<6E^#OV9_A%/\'OV-/'7B+X:3^.O%7[0$/@/5_&_C"#X
M;^!?'>@0&VU_PM_PCGAG1K5O%DJ>,-;UK7X+:PTP6-QHL>KZ@;C3A\L^$/\
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M?BWXQ?L>^ OAO^S9^V5\3?'/P.^'WQ#\)?&^X\6?$7PYX[T&3QM'X9U[Q5X
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M#\/M6U"'QAKFA:7J&JV^B:WJ]K8+;Q:G#?I9"\AL)YJ /T'HK\E+?XX_&O\
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ML8K6>ZTZ[N%U&*&4I%/<1!96P[&@#\G?^"4EY9^)/B%_P5$\>^&U#^ ?%/\
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M!>QGECE^-?$'_!$FUT23Q;\6_B1\7_'?[6.K:+^QM\8OV5-$^ WA3X=_!_\
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M_"967Q)M?A!J/C[1_@C)IS75]\(M*^(ERVD76N3>(;;7;C3H9-:M-$DM%=4
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M33>";7P4? 'FB]+_ -A+;6JWPU;;]N,[F+[*$ :O /A1^WC8?M\_#S_@G/\
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M'_M!^,= E^&W@_\ :S^&WB>]D\&>']47XC_#K]K7QKXS\>^)_#E_;7&HQ?\
M"/W?A77O%R2Z'K6FSSSW$6DPQW5L@N90GYZ_!O5OC?\ \% ]6^ W[$/Q%_:@
M^/\ X(\!_!F/]KN+XW?$;X3^+5^&GQF_:#N/@%\6M%^%WPF36?B'I.G'4M$M
MM+M?$^C^(?$S^'H;?_A+=9T1O[1G:VNKBV7S_P")VN_M8?M,_LZ_LK?!.WTW
M]N'X_P#AWX1?M2?M;_"SX_>/_P!E?Q]:_!SXQ>.M&_9\TO5M*^"L?CCXLRZM
MX5\-^'W\5ZMK&B6VM75[=V]IXEN- N)B8[JZDD4 _2FQ_P""/<_P_P##?P[T
M_P#9Y_:_^+7P!\4Z3^S#\.OV2_C'XP\*^$/!VN3?&WX9?"[3+W1_!NL76D^(
M6N;;P-\0]!T_5=9LM(\7Z!/<R6=KJ+QS6%Y)!#,OI7P/_P""2_P<_9Y\4_&S
M5OAIXX\66'AGXO?L:_"_]C.U\*ZE;0:M+X5\+_#+1O&>EP^.'\17=XVH^)?%
MGB2Y\;:EK.NMJ,5M!+J2L\3K'-LB]6_X)B>(_A9K?[)/A/2/A3J/Q\GLO 'B
M;QC\//&F@_M0>,=0\>_'GP)\2O#&L21>-/ GQ'\4ZC=ZA+JNL^'-0N$@@N;>
M^O+";39;&>PN9;6:)C^@U 'D?P#^$MC\!?@I\*_@MIFL7?B'3OA;X$\-^!;+
M7+^VBL[W5K;PWIEOID-_=6L$DL-O/<I;B66**61$=BJNP&:]<HHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /.?C%\.K3XP?"/
MXI_"74-2N=&L/BC\.?&_PZO=8LX([F[TFT\;>&=3\-7.I6MO,\<5Q<V,.IO=
M002R)'++$L;NJL6'YW?M+?\ !)GX*?M.?LY_LL? SQ9XJ\0:)XE_9%USX3:U
M\+OC+H>GV</C-(?AK-H!U?P]J$ NHH)_"OQ#M?#NGP^*- >ZEL7N;+2M11)+
MO2+-Q^J]% 'Y.3_\$O+[PY\:OB?X_P#@E^U5\2_@E\+/CI\45^,WQB^"F@^!
MOASXJM]9^(=^-/\ ^$PU7P-X]\9Z5K'B#X<V/CV338;CQ/I&G6>J60N;B_GT
M5='DNR4X;X\?\$@!\8?%?[3[>'/VNOC%\*O@_P#M<>+_  7\3?BY\%/#OACP
M1JFB7WQ-\%Z9X+T>+Q#IWB?4+2+Q%8Z-X@LO >@/XE\,13"+4;VV%Q'J5K$T
MMM+^SE?S$R?MT^(G_P""E]Q^T_'\?O#]M^S+IW[25M_P3!;]G^X^(>CJFJZ=
M>6%M(W[2L'@EM0%XFN67[4#O\+(=66V+7'@F8,X6%7=0#],_$'_!+WP#XD^%
MG[<OPNO_ (G^+(K/]MOXVZ;\==6U:VT;1_.^'OB?0O#WPTT?1=-T_3;R2\TO
MQ9H$-[\,=)U'5-*\06XL==M;_4=%U&V>QF8M\WV'_!%"+4;[]H'Q#\2_VM?'
M/C_Q7^T/\"/"?P#\07-E\)/AI\/?"?A#PQX(\>6GCOP[<> _ W@A-,TC1Y$O
M4U.'58[V;4[K5)=5:YDU*&&RLK&+F/\ @J+\5O&>H:+^W+J7P[\=>*O#EA^S
M)^S9\'?!MY?>%/$>J:-%9_%/XW?%_0?%VJ6;-I=Y;F/Q)H/P\\+^#;O[1A;N
MTT7QZ(8Y5@U*=)$^.W_!5/\ ;&^'OQG_ &U/#7P?_8Q\!?%/X&?L#:Q\+IOC
M/\1M;^-C^#_&&O\ @WQM\/=#\=:TG@'PE-X<OH=6\:>'["]U2[^PWM_::/<V
MEG90?VA_:&H)%& ?HUXN_8B\-^+?CK^T=\<Y_'6MV>I_M&?LF>%?V3]7T&+2
M[*2Q\-:%X6U;XGZK!XOTV[>Y6>\U:[?XFWL,NGW$4-K&NEVK).QGE"?%'A__
M ((G?#CP_#<0P_'+QM<"X\6?\$W/%;-)X7T9"L__  3A\)R^%/"%H NI',7Q
M+@E-WXCD/SZ+*HCT];Q3N'D/[=_[?G[6/C/X??MIZ3^RM^S/'XM_9Q^ ?@36
M/A_\6?V@O^%NIX%^*NF?$W5_A]HGC:^;X.>!(M/9M>M?AQX=\9>%-3\2W>H>
M(=$U&XFO9[?08+N:W19_1/''_!1C]K?P]?>,X_V:_P!D?PY\>?@5^R'X,^'L
M7[4WQ/\ &'QEA\"^.=5UZX^'^@^._&>A?!3PE)HFK1^+]?\ !O@G4[37=6G\
M4:KH5IJVIW]MI&G323R/<* ?3'QK_P""9/@OXU_%3XH?%+5/B?XCTBZ^*'QI
M_8T^,NHZ);:#IMY8Z?>_L<W7B>YT+P_#-->Q2W.G^.1XGN(=<N)4CFTZ.W3[
M''<&1]OC5C_P1\BT;7?AQX>T/]KGXSV'[-/P<_:=TC]JCX5_LTOH/A&7PYX3
M\96WCW6?B+J_A5_&=O%9>)]6\!77B'Q)K]WH&A7>V3PS<:D9H[S4UMX(5\8^
M*G_!6W]K-O%_[1^K_LQ?L:>!_C-^S_\ LN^$/@7\6/'WQ%\4?&AO 'BCQ#\,
M?C'\-$^)TEMX&\(2^'=3?5/'>C>'VDO5T^[NK31Y8XX[.34!J%U;PMYQ^V!_
MP<#^'OV?/V@]4^&/@3PA\$M=\'?"SP]\-O$7QDMOBI\;)_AS\9=??XCZ!HWC
M*+PW\!_ =KX5U[3/%^O>'_"&M6=[?MXBUW0K&_U>X@T;399'?[30![1HW_!#
MNP\/>+_AU=:)^UKX\L?AC\(/VH+?]JCX>?#=/A'\+EU23QHOC;5?'%QI7Q(^
M*=O;6WC_ .)FEQZAK>IVVDS:QJ-E>:?:R6B7DFK1V%K$GT8G_!,2X\3?M)>#
M_CE\;/VE/%_QQ\,?#+Q5XO\ %_PT\!^+?A;\*M)\5Z%>>+M,U;19-!U_XU>&
M]$TWQSXL\&:3H^M7NEZ?X:GCTV&YLA;PZU<ZJL"Y^=_%W_!87Q='^WEX-_98
M\!?"[X-MX'US0_@YXA9OB[\<;;X._'GX@>'OB]X>C\2MXM^"/P_\5Z);^%/&
MVB>!;&ZM(/$EC<^,;#7+K4/M=CIMH;F!(YL>+]N7XC?"[1OV_/$GP7^%?PWN
M/$G@#_@H+XO^$&N>(/VDOVIKGP)\']'L--^'?@O7K[X@ZGK/BJQOM0\+:9=+
M>1Z1I/PO^&VD:PJZD&U%1;PW5W, #ZR_9H_X)Q^,?V:?&'@RUT3]L'XH^(_V
M>OA??ZW=?#7X!7_P^^%FGG2M/U2>]N-,\,>*OBI:Z#-XU\7>&/"LE_*OAZQ7
M^P[^***VAU'5=1B@"-])_'3]D[0OCE\??V1_CWJ?B_5M!U3]DKQ7\3O%6A>'
M['3[6ZL/&$_Q-\"CP->6FK7<\\4^G1:7;#[?;26L5PT\_P"ZD5$^>ORK^#O_
M  4:U7_@HK^QSX,5+70?A3\2_B#^W#I/[(_B6?X,?$R?QQX5UB+X?^)=*\9^
M-/'/P>^(-A9Z%JNN^#+_ ,&Z<L\U[)I^GW=I975[::@B131O-\Q_#S0/$7PV
M_;5U#]HW]LWX!_M^>%;?XB_MP>,-&^'/QJA_:%O;7]F[P=8^)]?'ASX%>%-:
M_9[T_P >?VPG@34K2&WTZ?Q->>#VT&76KZ"ZG'D7*21 'Z\^$?\ @FSX/\(_
M"+]B_P"$<'Q.\27EA^QE\;9OC9X=UB;1-.CO/&VI2R>/Y#H>LVZ7C1:98J?'
MUT/M5G)<S$:?;_NAYS[,WP9_P3'\&^#/@Y^Q/\'K;XI^)KVP_8J^/TGQ\\.:
MU/H6FQWGCC59(OB3%_PC^MVR7K0Z9IX'Q(O&^UV<ES.3IEL/* FDV?-_BGX(
M7W[7/_#7GQ?^-'[6GQ<^ '[+^G?M#ZAI6OZ%\//B'<_#W3]3^#_[,GA&3P==
MA_B/%?6U_P##[PIXI\;KK?CKQ7=^&);2^UT65OIUY>PVRBOAKX<V_P 7?C5\
M&?V._P!DSP_^T/\ M&>'_P!DS]IW]L3X^WGP]^*7B'Q=KVC_ +2WQ(_8@^$W
MA-_$W@CP7_PLN^MK7QII6E>//$=[#=Z5XJECM/&=_P##_3K&-]0B2^>2< ^[
M/!G_  1GUSX/2_!S7?@!^VY\7O@WXZ^#O[.OBO\ 9LL/%.C^ ? OB"T\2>$/
M&7QM\7_&O5=5UWPWXBDO=.?7+#5/%C:9X>G@E1-);3XM2D%\;B:Q'6^'O^"*
MWP(\(13:3X;^(_Q!@\-7/[ OQ%_83O;#5DL-:UO4[;XH?$/Q+\3_ !9\:]5\
M1SO#+>^/K_Q?XIU#5)+$Z?'I!G6/:(X%%NOYSZ(_Q3\;^,G_ ."3EK^T5\?=
M(^#?P]_X*"^)_A%XE^*LWC_5%^/_ (Q_9UT;]G;2/C_HOP>@^,00>)%,>O>+
M-.T'4/&-M-'XHN?#NA-I\NI(\]P97>.O"G[0NN?!?XS?L!_#)_VO?VBO G[-
M'_!1_P"'WPUUC6O!?Q:G\/\ [0UQ^S+J?P-M/CE'X0U/XXZKJ>B7 L-/\5>*
M?#G@B3Q=K6J"]?1LQZA<2SQ[Z /T%U#_ ((S>%O%]U\2_%'Q*_:1^)7B7XI>
M//A5^R!X+T7XI>'/#GA_P/XE^'_Q$_8NUKQ5X@^%OQB\-V]G=:KI<NNWNH^)
MBOB'P[?VLVA7]A;W5A(KP:E+Y&[J_P#P2.M_B#X6^+=U\<?VH/B/\8/CE\:/
M%'[-^H>*_C5JOA#PQX?&F^"OV8/B/:_$OP!\._"/P]T2YC\/>'M'O=<_MB?Q
M%J,=W<ZCJE]KMW?S,1!:VD?I7_!*C5OAG;?!CXC?#'P7X(_:'^%7C7X1?%C5
M?"_QC^$W[3GQ.OOB_P#$SP#XYU70="\4VEJGCVY\0>)K+7O"NN>%M9T/Q!X8
MO=&U>;3)]-U%)8HX7>1*_4.@#YZ\)_L^:5X4_:6^+O[2<'B/4+O6/BY\+?@[
M\+K_ ,,2V=O'INCV7P>U?XF:OI^K6E\LS7%Q=:R_Q*O(;RWEACBMDTNV:)Y#
M/($^A:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BO/OBUK^J^%/A5\3/%&A/''K?AOX?>,]?T:2:)9X8]5T?P
MYJ6HZ<\L#%5FC6[MX6>)F59%!0D DU^.X_X*H>$O$'PR_P"">\?@_P",_@W4
M/BO\;/C+\!?"OQQTY_#>J6T"^%=?\&^(M;^*9MI+^QM=+T5K*[TD3)>0WLWV
M6&"3R!,C;J /U3^+7P/MOBKXX^!/C6?Q)=:'+\$/B!>>/+;3K?38;V/Q)+>>
M'=1\/'2[JYENH'TV%$U!KH74$5U(SQ"(Q!7+#\[-&_X)!^"OA]XS^._B_P"$
M7Q?U3PM9?%S]HOP-^TEX7^'GC+P+IWQ(^%_PS\3>&O"6I^&_$/A2T\'7WB+0
MX?$'@;Q)J.K7GBG2=!>\T:/P7K<C2:-),K$UZMX__P""J7P#^%GPSU_XN_$#
MP9\9?#'@BW^'&K_%?P%?ZAX#N$NOB[X,T/Q#H?A[4I_A_8"Z^TWVMH_B31=:
MM?#M\MEJM[X;U"WURW@>T?(Z;3?^"C?PSD\7:SX0\2?"_P"-/@>Z\(^-OAMX
M'\>ZMXJ\(0V&@^";WXQ:6NL?#+4=8U--1EADTOQ'920FZGLQ/)H$\\5OK$5M
M*X6@#YFTW_@D1JD'PF^+'P<\2?M+67Q&\(_''XF?'GXD_$*P^(_[.?PZ\4V5
MEJWQWU>?5-1UOX:0S:W;WOP[^(7A".Y;3O"GC:TU/5K6QMK+2+A?"R:CIHO9
M^R_X=5C2]4N;'PK^T1KVF^ ;_P".'PD^.NJZ?XA^'FC^,OBCK&L_"RX\.S1^
M"=5^,FI^([?6;OX:ZH/#EG]@\+-H2GPO(Q_LJ_>U$EG-)^TS_P %,/#GAK]G
MCXN>*_AEIOC+P?XKU7X+_';QC^S3\0_&O@UAX!^)GB3X0>'KW4K_ /L9Y;@E
M_FA74M$L-;BTUO%&EP75SIGFI XKV/X;_P#!03X9Z[I'@XZY9>+;K13K7A#X
M3^./C3:Z L'PGTCXWZGX9TS4-9\)W&M-<AH(M/UB[?1-4U=+=]$TC7G31;F^
M6XYH ]:\.?LF>&M+_9 U[]C_ %SQ)?\ B/PKXE^&OQ$^&6K^)FTVVTW4Y=*^
M(L/B*VOKZ#3TN+NVM[W3HO$,ALB+AQY]I!/N1SA?F:3_ ()@^'Y_@?\ L9?!
MZ?XS^*GU']E#XC^&/&_B'Q^OAO3(]:^.6C:9>1Z[XM\%^*K-=3,7A_3?'WBS
M1O!/B+6[[3+N^GBG\(6EHL$\-[,\7?V__!2GX'K<I/K?A?XJ^'/">K?#+QA\
M6_!'CC5/!DQ\.?$'P?X/\0:%X6E'A22VN9[N\\0:_KGB31;/POX>FMH-1UH:
ME8S6\8BNHF;9;_@H3\)=)\:^!?ACXZ\(?$_X=?$WX@_%7X9_"O0_ OB[PM]B
MUAKGXN>&?'WBCP1XM:2&[GLYO!]Y#\-/%VCZEJEM<3/HWB32Y]$U""*[0B@#
MPCQS_P $OM8\8?$7PMXKL/VE=3\'>&?!G[5GBC]K30M*\._"3PJ?'LWC?Q7H
M_P 0],ETKQ#\3M4UW4)O$.F^%Y?B-JESX%:]\+!/#]O9V6F7=GK-E%&L-.S_
M ."46DW/Q5T+XV>)OB_I+?$;2/'/P4\4ZGJ/P[^"/A/X4Z-XZLO@KXK\6^+-
M/E^(/ASPWX@N--\3_$3Q'<>+)M.U?XERK:WD&EZ?9V-AH4%JBP)[CX@_X*1_
M K1=?\2^%;+2?'?B'Q-X0\3?&#0->\/Z/HMJ=7%G\#-9L=#^(&MZ-97FH6LW
MB."TO-0A.EZ5H8O=;U>))7L]/8)SZ/\ M-?&'Q_X?M/@!X'^"TFEV'C3]I'X
MJZ7X#TOQKXATQ]2TSP#X1M?!?BCXE>+O%\OA^2>Q?6-73PQX1N=%\/Z/<7%K
M"=?URPN;]Q:65S&X!Z?\&O@K;?!_5/C/J=OXBN=?;XP_&'Q%\6[B&XTZ&P70
M+CQ!IFB::^A6[PW-P;^WM1HJS)?S+;RRM<,C6Z"-2WAOC[]BG3O'7PT_;7^'
M,GQ%U+3(OVR]>O==U#5XO#ME=3?#U[SX:^!_AS]FTZSDU**/Q"D</@J+5Q)>
M3:<S3:C+:%1';I-)\L_M*?M%?M<_LA>)?AII'B.TO_C!\-O&'[2OP&\%^%/&
M_A/PEI=Y\1_'^D?$?1/B?!XV^$$G@K3;OR[37] U_P *>%]:TKQM&MO93Z%X
MD>VN8XVT6]G/TY#^WU\-[WP[:ZAIO@/XGWGBE/%?Q1\&>)? <N@6FFZWX)UO
MX./:KXZC\5:AJ6HVOA_3H;=-1TB?0W_M61_$EOJ]C-I$=PCRF( \DU[_ ()I
MV3^-M3^(W@WXIZ+H7BVS^,GB7XO> )?%?P=T7XB:)X8?XC_#/PW\.OBQX3\0
MZ)JOBO3HO&FC>+YO"VD>+=)N!<^';WPEKUK ;5]2MX50^I^&OV*-<\,3?$O6
M]-_:$\9:=X[^(_P#\+_!D^/]#\#_  ]T;6?#&L>&O$7C?Q+'X]T+1H]'N/!>
MYKOQH]A9^%KWPQ<Z?::/I5K:W=_JEW/<Z@_RVG[?WBCQ?\9_#M_X#\6:._P$
M\7>//V4;O1;S4-!CAOX_AO\ %_X3?%+QYXJ-_<2S>=:WYF\+Z1(V]3+I;6MW
M:*)#(S#UGQE_P5G_ &9?A_X0U/QKXNT_XCZ9I$OPLO?C7\/X(/"ZZGJ?Q8^&
M>G>)_"_A6\USP+8:=?7,MU?PWOC7PK??\(]J!L-:ET?6K74HK22W2X,(![S^
MRO\ LC:7^S7K?Q8\7_VWX3U3Q9\8[SPI>>+8OAQ\+=%^"OP^^T^$+35[.RU>
MQ^'GA_6==T^'Q3K,6LS-XK\32:E+?>('L]-\Z."*Q@B'V-7P9!_P4"^&OVX^
M#M3^'WQ9T+XRW/CKPYX T7X'ZOX6CM?B'X@U3Q3X*U7XBZ;J.EV@OGTY]"M_
M!/A_Q)KFLZI)?1P:,GA[5K6]"7-N(WR+#_@I#\'-9\&^$_%.B>"_BMJ.J>(O
M"/Q(^(&J^ G\+0Z;XY\%^"OA/X\UGX;>,M;\3:+J>HVOD20>+=#OK#2-)LY[
MO4];C0W%A;O$"U 'Z%45Q?PX^(7A'XM?#_P3\4? &KPZ_P"!_B)X5T'QIX1U
MN!)8HM4\.^)=,MM7TB^6&=(YX#<6-W#(]O/''/ Y:&>-)4=!VE !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^1?Q2_:%_::^%'
MQ,_;<U#Q-XE\*3:-X*^ 7@KQ-\"/!&@::]SIG@J]\2^*=2\(6/B;Q;?ZE%:W
M/B;Q)=ZG<VFM:MIT30:+9V.GQ:-837(FEO!^NE?%GQ:_9'3XO>,?CYJ^M^)X
M;#0?C/\  C0?A):6]K9S2ZIX;UOP_K.J:[IOBHEI8K:]BL=4NM/O8M/\R+[0
M]BT$TBQ3%@ ?GKXS^+'QV^ 'CC1/V0-4_:"^)WQ$U#X]^,_V6+#0?C'KQ\+C
MXG?#2+XV:KX^L/B?'H6J6GARQT273?MGPYNI?!%O=:%=3^$K+7/L0DU1K2*X
M7[U_9B^-6F^'OAO\3]#^+_Q7:]A^"'[0'Q&^!UM\1?BIK>BV&O\ B/3?#FJ(
M_A2X\4ZZMKH.CZMXHN])NTBO+NQT[3Q>R6K2_8HY/-)\@U']A/XH>.KZY^*7
MQ2^(_@C6OCQX3\0? '7/@[J6CZ!J]KX'\+S?L^+K,FF3:[;S2KK&IR^/M3\4
M^+-5\26\0^SZ%)J\5GI#7T%A')+]4_![]G32O#7@'Q+H/Q;TGP)\1->^('Q1
M\9?&/QI:S>&K;5?!UOXQ\9:F]]-#H%AXDMKRX>QT:W\JPTR^U",:B8D=W\LR
M%  >F>%/CA\'/'>MIX;\%?%+P#XL\02V=SJ$>B^'?%>BZQJ;V-DT*W=X+*PO
M)[@VULUQ L\WE^7&TT0=@74'U*OS0_:(^ _PJ@^.O[-UCX6^ OAC4Y[W1_C=
M)=:+X NM(^#VKWD=GI7@<QW=QXI\/S>&+VYL[!IGW:.=3\NZ>Y6Y-O*+1MNY
M_P ,^:!_T:=X[_\ $I-?_P#GEU+SW@C+G]7XAQ_'N&Q_\14^&_#'.>+LN^KR
MTIR>;8#,<+06(;C4]KA?9<]&*IRE)JJN7UL%D.:YE1^LX.IP_&CSRIVS/BOA
M_)L3SPY7)K!YGCL/B73M)<E;V?LZC4HPDW"5OT3HK\[/^&?- _Z-.\=_^)2:
M_P#_ #RZ/^&?- _Z-.\=_P#B4FO_ /SRZ7^M?A7_ -#;Q<_\43Q+_P#/GU_I
MZ=?^J7$'_/W@_P#\6!P?_P#/7U_IZ?HG17YV?\,^:!_T:=X[_P#$I-?_ /GE
MT?\ #/F@?]&G>.__ !*37_\ YY='^M?A7_T-O%S_ ,43Q+_\^?7^GH?ZI<0?
M\_>#_P#Q8'!__P ]?7^GI^B=%?G9_P ,^:!_T:=X[_\ $I-?_P#GET?\,^:!
M_P!&G>.__$I-?_\ GET?ZU^%?_0V\7/_ !1/$O\ \^?7^GH?ZI<0?\_>#_\
MQ8'!_P#\]?7^GI^B=%?G9_PSYH'_ $:=X[_\2DU__P">71_PSYH'_1IWCO\
M\2DU_P#^>71_K7X5_P#0V\7/_%$\2_\ SY]?Z>A_JEQ!_P _>#__ !8'!_\
M\]?7^GI^B=%?G9_PSYH'_1IWCO\ \2DU_P#^>71_PSYH'_1IWCO_ ,2DU_\
M^>71_K7X5_\ 0V\7/_%$\2__ #Y]?Z>A_JEQ!_S]X/\ _%@<'_\ SU]?Z>GZ
M)T5^=G_#/F@?]&G>._\ Q*37_P#YY=>;>%/@=I%UX]^*6GR?LQ>.[RWTR\\(
MBVT[_AJ'7O\ B5"Z\/F>91-_PL9"XO)2;AD$D@C/[L[3'BC_ %I\+Y:PS7Q8
M<8>]6<_ [B2G*--M03I0>;MUZGM)03IQ<6J;G5<K4W%R^%,^BXIU>$;SERQY
M>/N$)*ZA*;YVLUM"-H22E*R<N6%^:<4?JY17YV?\,^:!_P!&G>.__$I-?_\
MGET?\,^:!_T:=X[_ /$I-?\ _GET?ZU^%?\ T-O%S_Q1/$O_ ,^?7^GI7^J7
M$'_/W@__ ,6!P?\ _/7U_IZ?HG17YV?\,^:!_P!&G>.__$I-?_\ GET?\,^:
M!_T:=X[_ /$I-?\ _GET?ZU^%?\ T-O%S_Q1/$O_ ,^?7^GH?ZI<0?\ /W@_
M_P 6!P?_ //7U_IZ?HG17YV?\,^:!_T:=X[_ /$I-?\ _GET?\,^:!_T:=X[
M_P#$I-?_ /GET?ZU^%?_ $-O%S_Q1/$O_P ^?7^GH?ZI<0?\_>#_ /Q8'!__
M ,]?7^GI^B=%?G9_PSYH'_1IWCO_ ,2DU_\ ^>71_P ,^:!_T:=X[_\ $I-?
M_P#GET?ZU^%?_0V\7/\ Q1/$O_SY]?Z>A_JEQ!_S]X/_ /%@<'__ #U]?Z>G
MZ)T5^=G_  SYH'_1IWCO_P 2DU__ .>71_PSYH'_ $:=X[_\2DU__P">71_K
M7X5_]#;Q<_\ %$\2_P#SY]?Z>A_JEQ!_S]X/_P#%@<'_ /SU]?Z>GZ)T5^=G
M_#/F@?\ 1IWCO_Q*37__ )Y='_#/F@?]&G>._P#Q*37_ /YY='^M?A7_ -#;
MQ<_\43Q+_P#/GU_IZ'^J7$'_ #]X/_\ %@<'_P#SU]?Z>GZ)T5^=G_#/F@?]
M&G>._P#Q*37_ /YY='_#/F@?]&G>._\ Q*37_P#YY='^M?A7_P!#;Q<_\43Q
M+_\ /GU_IZ'^J7$'_/W@_P#\6!P?_P#/7U_IZ?HG17YV?\,^:!_T:=X[_P#$
MI-?_ /GET?\ #/F@?]&G>.__ !*37_\ YY='^M?A7_T-O%S_ ,43Q+_\^?7^
MGH?ZI<0?\_>#_P#Q8'!__P ]?7^GI]5_#S]H'X6?%+XD_&OX2>"O$+:IX[_9
M[UGPGH'Q5T=K&[MO^$=U/QMH,GB7PW +F>)(+X7^C1/=B2T>5(P DA5R!7M%
M?"'['W[,6G_ CXA?M->/K#X86_PR7X[>*? 'B":SD\;WGCO6]4E\(^%[SP^;
MC6]7N]6UAEDMQ,$LHH[LJMM+Y>/W0-?=]=6(SCA?/JD<RX.R[C'*\@J4<-A:
M&&X]RW#Y/Q-5QV6X>EEN>9EB,KPU:O' 97G&>X3,LWX;PU:K/&T^&L=E"S'E
MQ_UF*\[-,KKY-C9Y?B<?E&95Z='"5ZF*R/&PS'+4\;A*&.6$IXVE>CB,1EZQ
M*R_,)T)3PZS#"XJ-"I5HQA4D4445@>>%%%% !1110 R22.)'EE=(XHU9Y))&
M5$1%!+.[L0JJH!+,Q  !)(%5[74+"^@:YLKZSO+92RM<6MS#<0*R#+JTL+O&
M"@Y8%@5')Q7S)^VQI.L>(OV6OC!X8\/^,/"O@+6?%VA:;X.L/%OC:_OM,\+Z
M/+XN\2Z)X;:35;W3"NH0I=1:I)8VHM&2>:]NK:%)(S)O7\Z_BQH_CG7?V*_V
MT_A':>+(?@OJ'[,GB/6[/Q#XD^ <%QX;'Q1TW1_A)X/^*^C6$=_K$M_?^$X]
M1N/$>C:!\0!I;7-QJMAH^M:+:W5BFL2W< !^V;W5K'/!;/<P)<W*R-;6[S1K
M/<+$H:5H(BPDE6)2&D,:L$4@L0#FECN;>66>"*>&2>V,:W,,<J/+;M*GF1">
M-6+Q&2/YXQ(%+I\RY7FOQA_:P\%Z7XZ^,OPT^'?PA\2>(=9_:]^(6L_L]?%F
M/6%U[7ET?]EW]G[X(^)_#OB'QSXHEATBY6PTBS^*BZ7KW@71M!UJWGF^(?BC
MQC>03K/H>A7CV/-?L=N^C>,/V(OB/H>J:YJWQ._:)_9Z_:;\:?'G1W\2WTZ?
M$;Q7I_B;P)XEO-;UVQU2_NM.TK5? WC_ %>Y\':%Y2V%KX6LO%6H>&G46L5M
M;VP!^Y-%?G5XF_;-_:"\!#PUJ7Q!_80^)'A;PKKWQ#^'?P]N_$B_&CX(:TFB
MW/Q'\;:+X&TK5KC2=*\2SZE=V5GJ6NV<]Y#9Q27/V</Y2,X /W8=:\0 D?\
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M^E:=86GGW,D3W$OU-7*_VUX@_P"A0O/_  ;:3_\ 'Z/[:\0?]"A>?^#;2?\
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MVVBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MCQZ4+97 /U?N_P!E3X#W7Q0U7XSKX&2Q^)NO6O@^PU[Q9I.N^(])O]=T_P
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MHMMJOF7^G07$@!]M?MR?\D;\*?\ 9QO[*W_K17PUK[%K\B_VJ/VLM.\<^!/
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%?/?[1?C/]HKP3X5
MT?4/V;?@IX4^./BRYUM;36?#OBWXH6GPJLM+T(VD\C:M;ZS=Z'KT=_<K=I;V
MXTY;:)FCF>;S@(RK?F7-_P %)OVJM%UN'2_&'P/_ &'_  S%:Z_I^C>(_M?_
M  4<^%7]JZ()M6M=,U!'T9_#,5[-JUF;ADAT<I%=W=^(=/4)-.N #]N*K7EY
M::=:76H:A=6UC86-M/>7M]>3Q6MI9VEK$T]S=75S.R0V]M;PH\T\\SI%%$C2
M2,J*2)T;>B..CJK#K_$ >X![]P#Z@'BODW]O&XTF']C+]IJ'6[[6M-L-4^#7
MCCP]]M\/QQ2ZM!?>)M'N/#VE-;1W#I;M&VJZG91WGVEUMA9/<FX/DAZ /4=$
M_:%^!WB3P=XB^(&@_%7P1JW@OPC,EOXF\1V6O64VG:'-,8A:)J4BR;[;^T1<
M6SZ270+J\5S;3:8;N*X@>3OO"'C'PMX^\/:;XL\%Z]IOB7PWJ\33:=K&DW*7
M5G<HCM%*JR)RDL,J/#/!*J3P3(\4T:2*RC^87P]X<^,/PX^-_@GP9\;]&\%^
M&?%?Q%_: _X)>#Q-X+^&"_VM\,+OX*>#/A_\3/ PU/7[C[)"O]LZM\1/#]C'
MJUMJ4']G6MI8^'(],GEMW1S^QG[->O\ Q'\,>%OVG9/ _P .[/Q^UA^VK\<-
M+\-^&8O%.F^"DM] ?6X)=4NA?ZE875A;PZ=JQGCM[""W!N5G:5'4J^X ]O\
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M&:4&YN85=8F6-GE:.-_U"/BK0@2#>/D<'_0K_P#^1: .AHKGO^$JT+_G]?\
M\ K_ /\ D6C_ (2K0O\ G]?_ , K_P#^1: .AHKGO^$JT+_G]?\ \ K_ /\
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MF2ZYX9A\:Z)'>PV>D^*M&@4SW_AS7K&\OM(U8V<MIJEC;7;ZAI%Y:ZE:VT@
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MIKUNZ6MLU[<7=T8U>1V!GN9GRQR^,  'V_1110 4444 %%%% !1110 4444
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M7_QG'COPA\0-%:R?5[SP_P"$M(\$^';73M6TJYM+=];EO;B2!K:"=4 /0_\
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M.AN+2!]+\7?VG=WP:6Y:_@CTO7K-[*RU*[MKVT73872-V^SJ "BBB@ HHHH
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M0 4444 >(^&?^2[_ !0_[%/P'_Z#JM>W5XCX9_Y+O\4/^Q3\!_\ H.JU[=0
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M!6O_ '\N?_C]=A10!Q__  @'@_\ Z 5K_P!_+G_X_1_P@'@__H!6O_?RY_\
MC]=A10!Q_P#P@'@__H!6O_?RY_\ C]'_  @'@_\ Z 5K_P!_+G_X_7844 <?
M_P (!X/_ .@%:_\ ?RY_^/T?\(!X/_Z 5K_W\N?_ (_7844 <?\ \(!X/_Z
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M7H4Z=>6&Q$:,YRHU%%G_  @'@_\ Z 5K_P!_+G_X_1_P@'@__H!6O_?RY_\
MC]=A17KGC''_ /" >#_^@%:_]_+G_P"/T?\ " >#_P#H!6O_ '\N?_C]=A10
M!5LK*UTZUALK*%;>UMUV0PH6*QKDG +%FQDGJ35JBB@ HHHH **** "BBB@
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MG6&H:BQTCP#(3?7MK;17-V3(3(3<229D)<_,2:^PJ^6_B9_R=/\ LN?]BO\
MM"?^F7P!7U)0 4444 %%%% !1110 4444 %%%% !1110!\/VOB#XR^"_VN_C
M3JFO_#[Q;K_P2UOX:?"V+X>:QX2T31M2>3Q9I\FMIXQM+^9]5LM25H%FL&A2
MYB:WV,Q@?.Y:^F/!?Q.TGQIJVLZ#%HGBGPYK6AVMA?7FF>*M)BTRZ>QU$RK:
MW=MY%[?0S0L\,D;'S5='7!3!S7I%>):)_P E]\=?]B!X1_\ 3CJE 'MM%%%
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M[7_P'B_^(H^PV7_/G:_^ \7_ ,15G(]1^8HR/4?F* *WV&R_Y\[7_P !XO\
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M.U:SU[PQ<Z2?$$!CET;5["[OK._LS+YH2>WNYXRP90Y*D  ^\Z*** "BBB@
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MOKNK:Z4;1=3U#0]:2_N-3TO3XV,>J:=,;&XT^2\M;JS>.0RI,)(D_G+^,?\
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MC7Q3;/X4O"EC-<^(K*ZN-)$<45U )]*:&=_MQ=F+P0E?;?A!_P DH^&>>O\
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M.I1)8:+J7@OP)H47A.>WTR[UB+Q+JFJZIKYGTJ PZ6/4?%/[5/C*U^*)\$^
M/@[_ ,)_X?\ #&M_#+0?B/J4/CG1]!\76,_Q%M=-U?5-0\!>#]6M(D\;Z3\*
M_"FNZ%XU^(=RNM:5-'X?O+R'0;?5=7TR;3Y<;X$?MG7_ ,8/B!X)T'5_A;<>
M#_ ?QO\ "?Q-\=?L^^.8_$L.N2>,?"_PL\7:7X<OY?%^C)I=@O@_4_&6AZ]H
MOC_P+I]KJ'B#[;X7DU6'5YM)U;26M+H \I_:Z_95_9Q\$?#?P1XE\)_!GP'H
M.O:?^TC^RS+8ZMINC1VU[:R2?M"_#F"1X9T8.A>&::-L'#+(<@D C]*CX<T$
MDDZ599)R?W*]37RK^W&"?@WX5Q_T<;^RK_ZT5\-1_6OL2@#$_P"$;T'_ *!-
ME_WY6C_A&]!_Z!-E_P!^5K;HH Q/^$;T'_H$V7_?E:/^$;T'_H$V7_?E:VZ*
M ,3_ (1O0?\ H$V7_?E:/^$;T'_H$V7_ 'Y6MNB@#$_X1O0?^@39?]^5H_X1
MO0?^@39?]^5K;HH Q/\ A&]!_P"@39?]^5H_X1O0?^@39?\ ?E:VZ* ,3_A&
M]!_Z!-E_WY6C_A&]!_Z!-E_WY6MNB@#$_P"$;T'_ *!-E_WY6OB+_@I%X$\-
MZS^PW^TC#)IMM;W&F_#^7Q-HU[#$HFTOQ+X2U73/$WA?685;,<LVC>(-*T[4
MXX)U>VN'M1!<QR022(?OBOCC_@H3_P F2_M-?]DF\2_^B8Z^P\/*E2CQ_P #
M5:4Y4ZM+C#AFI3G%M2A4AG6"E"<6M5*,DI)K5-)G/BDGA<2GJGAZR:[ITY'\
M/_C[2V\*?'KP?XMU?]J?PA8>.-=O;'P]K7]IV?@>P?PMHGA?PQXPU;2[2?3+
MBZC-M;:A-KNK6US]O0-,^L^?"Z7,&GO!Z)XI^%$UU\/?BE=ZI\3'\>7/C+3?
M@QX@\/>+;/1_#D,&@ZCXH_;;_9/\'7GB#0/[/MY+*_DN_"VNRZ1']I:YL#86
M\#0PK--<SS?0WBK7_A)HNL16'BNW\.MKES9V=[=?:- 75+FULYPUM;:AK5U!
M8W0TJQF>WFB@O=4EMK>06TX25A!)MK?$R&V@\*^)X;.*"&TBT#]GM;:*V1([
M>. ?\%!?V-!$L"1@1K$$VB,( H7&WBO]MLSSG%SCPRHTJF&FL\X/PLJ\\%E]
M*.)P]'BG*91AAYT<#1J1H1C4C1E1C4E2G1CRU5-5)J7YQ"DDJS;O^ZKRMS3;
MC)T)*\DY-7T;O9--Z;*WR[\4?@!\1M?UOX.^%->^.MQJ.F0+XI\*6<;>"_#]
MN8[.;PCJD-Y<W:P[?MEY>:+!+H<DDO$-O=374 2](GKW/1O"'B31?&?B!O&O
MC:?Q]J,/P'\"QZ==SZ-INC0:;_9O[<?[(-H]S;V^G1KYEYJ<=[(=0EFDDC;9
M"+>*$*<V_'GAS]G!/%L\GCGPSX2N?%%[+'>W]_?:+/>O9_:MUK;WFM:G#;36
MFC)<I&T44^HW%HDL<;[69%;'7WUI:V'BW5K&Q@BMK&S^ 7A&VL[> !8(+6#]
MNG]C.*"&%02!%'&J)&!D!0,<5CG>9XG$Y7E=":E&FL9D]N?)\OP,)2J\2Y=B
M:U3"5\.G4<9RJ0C4Y%25114II^T<$Z<(J<VFKVFG:I*3THR24D^JL[7O:YZH
MW4_4_P Z_4#_ ()+Z9IU_P#%K]I$WME;W+)X&^#81YDWE5?4/B!O49.,,8HR
M>,_(,'!.?R_;J?J?YU^IW_!(S_DK7[29_P"I&^#'_IP^(G^%?S[](?\ Y,MQ
MU_V!Y'_ZUG#QZV5?\C'"_P"*I_Z8JG[??\(WH/\ T";+_ORM'_"-Z#_T";+_
M +\K6W17^4)]P8G_  C>@_\ 0)LO^_*T?\(WH/\ T";+_ORM;=% &)_PC>@_
M] FR_P"_*T?\(WH/_0)LO^_*UMT4 8G_  C>@_\ 0)LO^_*T?\(WH/\ T";+
M_ORM;=% 'QQ\;-,T^P^-7P1-E9P6Q?P-\=-YA0(6Q-\)@-V.N S 9Y ) P"<
M^86/PZFM+VPMY/$M]=>$M'U:36]'\+O96"):WS&9X(I=3CA%]<:?I\ES-)96
M[R!]WEBYEG6- /7?CO\ \EJ^!W_8C?'7_P!'_"6J%?R_Q9@<-B^-.+YXBFYR
MHYYES@XU:M-.+X/X0G*G55*<%6HRG1I2G0K*I1G*E3<H/E5OZ7X=S+&8#@W@
MR&%JQIQQ'#F81J*5&A6LX\;<:PC5HNM3J/#XB$*]>-/$T'3Q%.-:JJ=2*J2O
ML?LTQQ_\)7^T9/L7SG^*'AB-Y,?,T:?!KX9NB$_W5>21@/5V-?6%?*7[-/\
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M7W_R70!O45@[/$W_ #\Z'_X"7W_R71L\3?\ /SH?_@)??_)= &]16#L\3?\
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M#W_J'GAZ>2?\C!?]@];_ -*I'ZJ45@[/$W_/SH?_ ("7W_R71L\3?\_.A_\
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M37,L?Q0M$DN)4@2*!)9G4RR)!%%"KL5BC1 JC]*J ,#[%X@_Z#5M_P""N/\
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M$\TPN(VC1(R[ !<CP#Q;I/['RP?#G]ISQKIWP.-I\*_#T2_"GXQ:[:^%&L_
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M?_!MJ?\ \EUNT4 87_".Z=_?U'_P;:G_ /)='_".Z=_?U'_P;:G_ /)=;M%
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M-R:BHMM+5QJ=7_S[J.R6R5VWIW]#TMNI^I_G7Z@?\$F-.MK[XM?M(^>;D%/
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MQ?\ #]/AM8:$UK_:5WXUC\3>'8O#MEX5M]/&IMK,&LP3';9[@ ?IY17YK_M
M_P#!1OX9> ?@+XZ\>_#R#QGKWQ!T;P-\3]>MO"2?#3Q;K&K^!=2^&=S9:-X@
MG^*7AZSLUO\ PGI>D:]K&B6ES+JC6R7D>JV-Q8R3VMW#.WW=\+_$6H>+_AG\
M._%NK+;KJOBCP+X2\1:FMJACM5U#6] T_4[U;9"SE+<7-S((4+N5C"@LV,D
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M[$?_ *#.L_\ @3!_\C5NTUW2-&DD941%9W=V"HB*"S,S,0%50"68D  $DX%
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M?^CGKB-9_P"16_;;_P"T;WCW_P!:%^%5=O??\?MY_P!?5Q_Z.>M\)_R,L_\
M^QKA/_6/X.%+X:7_ %[?_I^N<1XZ_P"17NO^PWX'_P#4_P#"M>Q_&/\ Y.9_
M;#_[.J^(W_J,_#^O'/'7_(KW7_8;\#_^I_X5KV/XQ_\ )S/[8?\ V=5\1O\
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MZBY14<3.<7-J:]S7]!J***_L@_D$**** "BBB@ K\;OBEX9T_P"-G[<?CO\
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MW#PI'H_P"::)51EN5;_@H'^QPB1R%AE%CD9)PR?,7B53\K-7KJ_<C_ZY1?\
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M/WQGU+49YM(L;:6::7Q#!'\]K:W4UK 5\DL%@E=?WA&?E%?6O[3]O9W7P/\
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M $^VM?AOTKU_QJ"?EQ?P\_\ RSSQ?J>EDG_(P7_8/6_]*I'Z1_V?K'_0>/\
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M\#-,L?!7Q\GTK6+KXN_#WXBC6[V72_ :3:>FG^#KB6\L/LT*K<&[NT%O)O\
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M5X7]G*K%4\_H17LLQG@+59P=:E-J.78_GE%86<(UH.A7H1JU(TIM5ZCA^B\
MX^A@J/%?M7%7X?KUVI9;#'^THTJD:%2C)RS/+N6E.6,IU*F&G'$8?%2HTIUH
MJ6&I*7TJ8/$&3B_T[&3C-G)G';/[X\X]Z\CTR'7/^%X^+0+ZP\W_ (5KX/Y^
MQR8Q_P )!XGQQYO/1\G)^\H &"3[QTKQ_2_^2Z^+O^R:^#O_ %(/%-?19S_O
M&0?]CRG_ .JS-/\ A_6SZ'S>0K_9>)O+AVI_ZN,G_IGC'QKCU!/C3\$?MUQ;
M3$^!_CIM\B!XL#SOA/G)9WSDE>PZ=\\)5_X[_P#):O@=_P!B-\=?_1_PEJA7
MX-Q'_P EEQI_V.\M_P#6-X47]>9^T93_ ,D?P+_V3V8_^MQQC_7X;&O^S2)?
M^$K_ &C"70PGXG^%PB!2)!*/@S\,S(S/G!1E,850 5*N23N&/K&OE+]FG_D9
MOVBO^RI^&O\ U2_PPKZMK]<\-_\ DC\O_P"PWB#\>(\V?ZZ=EIT/S/Q+_P"2
MNQ'_ &).#_\ UC\A"BBBON3X(*I:G+-#INH36\]M;7$-E=RP7-[N-G;S1P2/
M%/=A"'-M$X62?:0WE*^T@X-7:KW8C:TNEE\LQ&WF$@F4M$8S&P?S5 ):/;G>
MH!)7(P: /Y^?@+X'_P""A7B7XC_!#XHWGQN^/_Q#\$^*?B3X'\4^)9=-^,/P
M.U;X!#PUH7CSQUIGQMTJ;3_#/@>/5[_P!XC\(W?A37?@WINEZNNNV=QHDWAO
MQ3J2ZRM_YO\ 0=7\^OPXU_X6_"3XL_ WP/\ L_R_!'QCI^I_M#Z1H.H_#7X4
MW_[15KJO@_1?%OB[4;WQ;XWT[1M3U>3P/!8>&-2OKSQ#XIM]2A@T".T;4)+2
MW>5K>UD_H*H **** /'OCUK&DZ#\*O%6JZY\6)O@AI5K;V[7GQ-MX]+EG\,Q
MM=0H+B)=:M+_ $T-.Q6VW75I.BB8D)NP1\P_\$XM4T[6O@KX_P!5TCXE3_&+
M3;W]H;XS36?Q.N5LUG\9Q'Q#"HUB1=/M;&R#2E3%_H]I!'^ZX0')/V?X\\3Z
M+X/\*ZIX@\0Z;JFKZ38QQF[T[1M"N_$NHW*R2I&J6^BV,%S<WI#LK,D<+[5!
M<@!2:^4_V$==TGQ-\.OBOKVA6.H:;I&J?M)?&BZL+'5=%G\.ZC;0-KUNHCN]
M$N8XI].E#*Q-O+&C $,1\U 'VY1110 4444 %%%% !1110 5S_BW_D5?$W_8
MOZS_ .FZYKH*Y_Q;_P BKXF_[%_6?_3=<UMA_P#>*'_7ZE_Z7$4MGZ/\C^(W
M]FO_ )-Q_9__ .R)_"W_ -0G1*]QM?\ CYM_^N\/_HQ:\._9K_Y-Q_9__P"R
M)_"W_P!0G1*]QM?^/FW_ .N\/_HQ:_W.S;_D89G_ -AF-_\ 3]4_-:?\.G_@
MC_Z2CRKX=?\ 'EX._P"R%^'?_6J/VUJ].KS'X=?\>7@[_LA?AW_UJC]M:O3J
M\K#_ ,3,/^QOF_\ ZL<26OAA_P!>Z?\ Z;B<EK/_ "*W[;?_ &C>\>_^M"_"
MJNWOO^/V\_Z^KC_T<]<1K/\ R*W[;?\ VC>\>_\ K0OPJKM[[_C]O/\ KZN/
M_1SURX3_ )&6?_\ 8UPG_K'\'%2^&E_U[?\ Z?KG$>.O^17NO^PWX'_]3_PK
M7L?QC_Y.9_;#_P"SJOB-_P"HS\/Z\<\=?\BO=?\ 8;\#_P#J?^%:]C^,?_)S
M/[8?_9U7Q&_]1GX?UQU?^2KRG_LFN,?_ %;>&Y2_@U/^OV'_ /3>+.)K]Z/^
M"27_ ";!XG_[. ^,O_I]M:_!>OWH_P""27_)L'B?_LX#XR_^GVUK\-^E?_R:
M"I_V5_#W_J'GAZ62?\C!?]@];_TJD?J!1117^9!]D%%%% !1110 5XU\?O\
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M#XT^+/!GAJ\^)%SK6K76HZIXHUVR\1RZ?-JVA/K^M:UK5]/9Z5?P6\2ZC/
MZO(7 ,K]I3XZ_!0? WX]Z$WQ;^&ZZS;_  N^).F7&E'QGX?.H0:DOA?6+8V$
MMFM^UQ'>?:1]G^SM&)1-^[*ALBO:_A#J^DCX4_#3_B9Z>1_P@/A$@B[A .=
ML.S,I]N1UZ9'-?B#_P %JOAS\*_"/@?P=JFA_L^?![5=5\0Z3\7KO5]<ETWX
M2>$M7AOAI>@3#57N/$7B7P7J?B&_::>:Y_XE\7B*]CN$WM;Q3W<8NOV]^$.D
M:0_PH^&3G2M,RWP_\',<6%H!D^'M.)P%B"CG^[QW&1S0!Z+_ &OI/_03L/\
MP+@_^.5\.?MG7UE=:Q^S(EM=VUPX^,GB=BL,\<K!5^!'Q;#,0C,0 70$G@%E
M'<5]Q?V-H_\ T"M-_P# &U_^-5\.?MG6%C:ZQ^S(]K96EL[?&3Q,C/!;0PN5
M/P)^+C%2T:*Q4LB,5)P2JDC*C !XY7$^/I8H=+\./-)'$@^(G@K+R.J*,W5Z
M.68@#D@?C7;5Q/CZ**;2_#D<T4<T;?$3P4&CEC25&'VJ].&1PRL,@'!!Y /:
M@#*^"I!^#'P=(((/PG^&Y!'((/@O1,$'N#7JMC_Q^V?_ %]6_P#Z-2O*O@J
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M5 "_VOI/_03L/_ N#_XY1_:^D_\ 03L/_ N#_P".4G]C:/\ ] K3?_ &U_\
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M\Y?$'[!EIXH^/EIXTU/5/#EE\%8/B=JGQCE^&_AFSU/PGJLOCVW^#/A+X/\
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M'F>)/^??1O\ P)O/_C%;M% &%YGB3_GWT;_P)O/_ (Q1YGB3_GWT;_P)O/\
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M72RZC@,3@Z=*>=Y?]7>&Q$\3&5653#PH5*G/"'LYU:E)QYJ:;]C^*VMPZ_\
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M8WVML<*VTXP=L/\ [Q0Z_OJ7_I<>XI;/T?Y'\5'[-?\ R;C^S_\ ]D3^%O\
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MEUT> -:@>676;"UD%\+OP4+F[1DO)VW37;R>9M9F<@F@#Q;X+_ML_'B'XH>
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MDUJ\\1>"M,T'PY8V7@^%+>[N[.WM;2[TFXNUM]/CAL$1[N>2;4X=4CF#-*@
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M<.IQ0M'K?@]+>$:QIOAG2-1,=B/!W]GQ^?8>#]!A7RK.)XVMII [-=3[O.]
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MC:1J>NZBVKZFF@6&G"W&EV=QJDDM\;:*5PL\LA#[6VT ?(-W^V]^TE;)J/\
MQ<+X%R/8VWQ,<2)X<G^SR3?#R""\25'_ .$H)^PZ[!-]CT^4Y=M61H 6CXKM
M_#?_  45\?>&=)^+"^/O#_ASQ]?>#/ .F>-] U/P1:7&EV=K/K%EX:DM]*\=
M))J>H1Z/8VUYXFL;.?4+0RW!O$N+;[."\#)Q]_\ \$U?V<8/VH- ^&2:W\<1
MX7U#X(Z[XLN-/'QI\6 2:Q!XTL].2X=C(UPT7V665'A6=('E:.9T,D>7^HM.
M_P""8G[/>CV5[IND^+OV@-.T_5(Q!J]I;_&KQ2T>K6HO],U46>H-<&>:>V&I
MZ+I-^(Q*F+G3[9MVU65@#YKUO]L[]I'3-/T+4T^)7P F_P"$@\*>(O%"6UMH
M%S/!IDFCV4&IQ6$EP?%(DFM9H)_[.BN6"3MJ2!6!1BM16W[>WQT\-7ZZIXD\
M0_!OQ/H.GZ_HNGZEHMCIEUHVJ7^GZUX-D\6.FGWJ>(+L1:SIJ6\]A+ T$ML;
M^:R64"-W1F_M3_\ !-3]G3X<_ ?XD^//#>N_'"R\0Z%I=G<:?>/\9_%DJ027
MWB+2;:Y'D7$LML8I4NI2\+0F(LVX('"LONWA_P#X)6_LPK86.HP:Q\=8KF_T
ME#/(WQJ\73EQJ>FB"[9EEE:$RS6\SQ/,(5?;C;L"H% //O&O[=/Q2\3>-/B[
MIWPPUCX7_#S0/A')JVCR6?Q(M9M0\0^(=:T*:ZM-4NKF.'6-.ATG2OMUC=6U
MB8H[F65/L\\S#S&C' 0?ML_M*7%U;0#XA?!*-+K4/#%HN[PK-]IAB\4:2^H(
M98SXIVB\T:2)O[6@SLCLI$N0R'Y3]+ZK_P $L/V:]>GN+O7?$7Q[U>^O;W5]
M2U"^O?C5XM-UJ-_KU_-JFLW=\\$D"W$NHZC<37EP'3RC-(S)&@.*^6/V>_\
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MR21V\D#/Y<I*@'WY<?%HV]EJ%[_PK+XN3?8/".C^+?LEOX-62]O?[7N#;_\
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MYMGX2_=31>7\#_#\>9H]@DQ^U-^VFWFP_,V^$[MJO\N75UVC;D^IU^\>G?\
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M=TK4])TGQ;I5G:VVE>(+>YM+W3].;^PI);6".TNI+>V_>.\4>T;F(Y\PMO\
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M03;P)08WW"./!4@FOI;_ (9I\>?]'6_'S_P8^&?_ )0U8\7?&_\ 9EA_:3\
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M4 ;_ ,,T^//^CK?CY_X,?#/_ ,H:^=M-_8Q^(</[5?BGXCO\>?CO#:7OP/\
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MKL6FO:UKXT[PKX!L=-LI!).VHZS)J=AI^GZ;8VOVBYFG#/#E)&3Z7H ****
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M#VM_\6L\2^"8_B)IGB#4(6L@WA*6P?4X]4G@<L\*O8(;@1DE]I4#+$"OQ_\
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MWB;PJNH>6918MX@T6]TD7GE9!D%L;OSO+W MLVY!.:_);X$_!OX[_!+1;A_
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MB:&S36M(\-Z;8:A';QO+.5CBN;>2/_6R*2I*MM(K\R=2_9I^*&L_&S4%\$_
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M)8/!VK>!=!N]82Q6V@NH(-,D?S+-J^P:_'[PW\!/$UC^TWH^JZ/^S;J/P_\
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M;S+_ ,*LT;Q)?V;1 2?\(CIVKB+=80W '[UUYM?_  =^%>I_$'3OBMJ/P_\
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M3<V\-P;6[18[NV,T:R&WN8T>1([B$MY<R+)(J2*RJ[ !CS/B+P#X*\7>$9O
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MFGABA'!EDD1(P<XP79@O4$=>M?-/[9GQAU[X#?LO?&GXG>#[1M1\?Z-X*O\
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M%KT?QCCND^+6JVQ\17$][=V^G_%VTUJP>*V/V2PMY;&...%)40_MK0 4444
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MY^$_PDU&^\1:UK7AWQ+X7T[2]0_L_2?&LWPQ\.17]CIVGP6EQXKMH(XT"LS
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M>&]:^*'QB\(^&/!_B7P/+,NH7'A_QOKT_A_P/9ZG=O)9^"IK6TUEXTAA22,
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MBKP[-::YJ*ZI UO+J.FB%69HXR@!_3N"" 0000""#D$'D$$<$$=#2%T&TEU
M;[N6 W<9^7GGCGCM7\[7PQ\2ZIXM\0>!=&TK4?$/PY^!/[37[>^J^ _'G[/=
MWXDFN=3^ NH?!GX+ZY9^(?@+XBOS<;]+O_C#\3/!=U\3-7T/P_+%91V4'V'3
M;[4K#4;NYN/?_P!JWX>?!OP]^S%^WUX/\$?$#5/%]_\ "/4M"\0VG@&XNKT?
M\,S^(_'/A/P+XA;PKX/UN/R-0BT[Q7IFHP^/H],DU"^31E\4-8VOV2Q-M:Q
M'[3JRL,JP8<\J01QP>1QP>#2Y'7(QZ_CC^?'UKY U6Q^%^E?"'4?@'INL^(/
M@[INM_"K4=6U/QGH>E:SINB>$M#O=':]\4:\?'U_;-X9T:_2R_M"YGN;[6(9
M[3?)>81D#C\^/A7X9\'?%;X>_&/Q[X1T+7?&OP-\=>/;[QS^Q#^SY-\0M0\!
MCX[Q>"/@OIGA#Q)XXTV;7)8+ZW\)^-O$CZSXV\-6%Q$=/A$5CX_>U2YU=%0
M_<:BOY@?A/X\UKQS^RYXG_:!\2_%?XH7?Q;_ &9K+]@CP'X$\6^*=2OM%\36
M.M:;KG@=?B-H&L^'K/4;[3=0U?XJ^,?$_C'X6^.]06;5!XPTM;33%O;AK"%E
M^YOV4_VG[+X[_P#!17XIZC!\3;NY\.>*?V8?"][\./@]=RW5HWA/1O#OQ/\
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MR?&6O:A^SE-\(_&7B[7_ ![XS_9G\?\ B_X":KXW\6Z9J.B>*/&^@>#[Y9O
M/C/6-'UBULM5LYM;\$:CHD1EOK9)KZXTZZO2TGG%S^B% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M? W[='[7GQ*_9?E_9V\*_!SX'6?Q[^*'[2'Q>O/A/X1\)ZG\0+3X;:38W.G>
M!/%'CR^U?4O$EYHNNQ100Z?X8N(5@%B6DDF7#C&#D_LU_MY_\+"E^.W@K]J7
MX7?\,=?&/]FO3?#_ (L^*OAGQWX^\-Z_\/Q\,/%\.K2>%/BOX6^*<"Z/H6J>
M#=1GT#7=.U)[^VTN^\/ZGIK6FIPHUS;EO$?^"I.O:G\._B;_ ,$Y/C8?A_\
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MCXVOM T7Q1I6I^&8/$^NZIIMS?6NHZAI-]9VU_?SW5S872,T+@'[]?$GX5_
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M2M[F:.:QEC>.Z2)U8"WHGB'0/$MFVH>'-<T?Q!8+,UNU]HFIV6JV:W"QQ3-
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M1=/UZ\U+5H3;ZI?3ZK:V45Z]SJ4!,=_*9MUV"?/,A)->ET44 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
=HHH **** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>img267189834_4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img267189834_4.jpg
M_]C_X  02D9)1@ ! @$ W #<  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $J!70# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 1F"J68A54%F8
MG   R22>  .23T%?@WX^_P"#EO\ X(Z?#7QSXQ^'?BC]J&XC\3>!/$^N^#_$
M4.G_  Q^).IV-OKOAO4KG2-7MK74;3PU):7\-MJ%I<0)>6DDMK<"/S;>66%D
MD;]VK_\ X\;W_KTN?_1+U_E=?\$0OA5^Q1\7?^"P'[9GAK]NO0O@YK_PF@'[
M0NH:59_&O5=/T?PPGBJ+XO\ E6DUE=:CJ.F0_P!K)8RWPA5;GS?),S(NY00
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M?&NQN-?\+_!&;6=0MY+"P37]%-A-XMU[2Y!?>"K?5-%EN7@;4X=WO.D_MK?
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M"JH'))( [FOQ(_X)]?M(^-M.@\(_ ^[.G:GH+? _]M/X]R:[K5S?77B(^(?
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M.5-S+OC=77<C%77<I(W*P*L,Y5@0<$$5\-_\$^?VAOC#^T5\$O$>I_M ^%_
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M"'Q'UZ'5;$^#DT7Q-9^!;Z&^\*6-Y=ZCI#7,,\NHES]G'[V4 %%%% !1110
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MOACXH>(/$WBO0O!W@K1KV^\-W7CO4?AUX4?3_#]UIWAK2;R^CM;+15U*_O\
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M?VK?&/[:.J?M<?M?_"'6_!O[>'@[PIXSL]$TC]EJQ_88^!?POM/AU\<-%O\
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M"[-MXH72'\+WPOY396]OJ7VMRGDLU?N%10!_,0TWC_\ ;Q^-?_!,CP1\,?V
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MN?"FI7^MC0?&>O0^)-.D+Z!9V4_J'[/O[;O_  4'MO'_ .R'\7/CU\6?V?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M<^!8=>L/$GA_2=(\9>)_$%_XF\/'P5JFF64O@B;1-4L6\,B)CIP2::>62O\
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M[?3L-^HV[1>,=< M)\1J9XB#^Y2OJ&BB@ HHHH **** "BBB@ HHHH ****
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M_P"&B/V?_P#HN?P=_P##F^"O_EW1_P -$?L__P#1<_@[_P"'-\%?_+NOD/\
MX=T_"3_H1?A+_P"&J^#G_P YVC_AW3\)/^A%^$O_ (:KX.?_ #G:/K?@]_S]
M\5NG_-/9%Y7_ .9EZ_=]Y_JSA/\ HM>%>G_+G/?+_J6^;_'MK]>?\-$?L_\
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M']AZM_T-&H_^ UG_ /&Z/[#U;_H:-1_\!K/_ .-T =/17,?V'JW_ $-&H_\
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M=ODU+0]<LH=1TN_2*X@2[L[A=\,RPW44%S%O7GRYX8I5.0Z*010!M4$@ DG
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MHA*(7*(2BB@#U"BN8_L/5O\ H:-1_P# :S_^-T?V'JW_ $-&H_\ @-9__&Z
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M2]'OKVYEFNK*5BNWZ9_L/5O^AHU'_P !K/\ ^-T?V'JW_0T:C_X#6?\ \;H
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MVVU'2O#LEM'J\EM?7]NEN\]JUW 3;[Q*ZON12 : /IRBL'_A(;7_ )\M6_\
M!;<?_$T?\)#:_P#/EJW_ (+;C_XF@#>HK!_X2&U_Y\M6_P#!;<?_ !-'_"0V
MO_/EJW_@MN/_ (F@#>HK!_X2&U_Y\M6_\%MQ_P#$T?\ "0VO_/EJW_@MN/\
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MPD-K_P ^6K?^"VX_^)H_X2&U_P"?+5O_  6W'_Q- 'XX_#7_ ()(2_ OQ+X
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M\36UKX@T_P +:7INCVUAX>TN$S:I.3<Q7[/]D[XS^#] \7_!/X7?%?P]X+^
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M_!?AOXV^&?"VEV^BZ#I/[37QCM].TVU:=X+6(ZEILC*C7$L\Q#2.[G?(V"Q
MPN /KZ@ HHHH **** "BBB@#PCQ+_P G(?"+_LDWQP_]27X(U[O7A'B7_DY#
MX1?]DF^.'_J2_!&O=Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH _#7_@M=HFES:7^R5XQ\?\ PB\>?'+X,^ OC+X@U?XA
M?#_P;\;_  M\ 8/MNI>!=5T/PAXGOO&WB#Q7X+O;Z\\.:GJ%Q>V'AC2->MI-
M9M3JL=PDRQQQ-Z[_ ,$E/''P"\8?#OXNV_P'^#?C/X+66B^-](C\3:!XS^.-
MI\=KO4=1O='EDLM3M/$5AX[\?V>E0?9X)8)-+CU6WE\R/SIK-2RNW(_\%@_@
MMX(^)6A?L_\ B?XK:K\ XOA/X<\2_%#P1XVTS]H?Q7I/AGPKI_\ PN#X6Z]X
M*T#XB>%K?6XY['Q%XX^'NLS6VIV.BQVTNHR:)=:[=::T%S;+,L'_  1?BT2;
MX;_'G6_#/A#]FKX::)K/Q+\+))\._P!F7QGX7\=^$[?Q)H/PX\.>&O%7Q"U'
M6/"FFZ;8:;/\3M6TB37M,\,SQ/>Z3IUNES>.+O4[A: /V>EFB@C::>6.&)!E
MY976.- 2 "SN55020,DCD@=35(ZQI"ZHNAMJNFC6GM?MR:.;ZU&J/9!VC-XN
MGF7[6UJ'5D^T"$Q;U9=^00/AC_@HWX1O/%'[/2W</BSQ9X>M/"OQ&^%_B:YT
MKPK?R:7_ ,)5<:?X^\/_ -G:1X@O+8&]G\.Q7DD>H:AI$#1PZL]I!;7K-:&5
M&^*OC=;?#CQ;^U-\16^#-]>W_BKX!>(/'7QA_:;\<P>(+@_$J[\1ZC^SUJ/A
MCP/^S!\#UFO(9&FN])O=+\9^+K&+3[[P[X;T=Y_)9O%WB2W:T /VS7Q)X=>P
MO]537M%?2]*GN;75-275+%K#3;FS*K=V]_>"<V]G/:LRBYBN)(Y("RB55)&=
M6">&YABN;::*XM[B*.:">"1)89H95#Q2Q2QEDDBD1E>.1&974AE)!!K^8_\
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MHW^+O^>/A_\ [^ZA_P#$4 =)17-[_%W_ #Q\/_\ ?W4/_B*-_B[_ )X^'_\
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M_LJ.O_\ JF_BC7M= !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MG9VFGVMM8V%K;6-C9PQVUI9V<$5M:VMO"@CAM[:WA5(8(8D54CBB18T0!54
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M?A77B-06STCQAXCLY=-NS,1:W OUE8Q.'MXQM)^V?^$HE_Z%;Q7_ ."^S_\
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MX!N=4T;P)!X=\&W.B>"1XSGU'XD:=+)<>)&EOKRSBT3PA:6VJQ6MQ-:BR?\
MM2YN/M4EO=7NEV\=F4G:1_G/0_VIOVCD\2^&=/U'XJ_ Z_L]>\)WGC&=[CPZ
M;6PTL6GV<#PS?W-IKMM,-0N!>PS17@FMI#!I^KN-,(2-H/U')/"3B7/<FH9W
MA\7DV&P^)I5J]"AB\1CEBJM*AAUBI24<+EV*H1<L.U5C&IB(3=_9RC&JG37C
M8G/LOPE>>'JSJ^TIM*?+2E*,6XJ25]+Z-;)H_8"BO(_A]\3KWQEX(\+^*;OP
M7XGL;K7-(M;^XM8+&"2VCGD4K*]G)/?1S2V$[HUQI\TJ+)-92V\K ,YKL?\
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MV4'VJ_NY9)8[>ST_3[7?&+B_U"\F@LK.%I(HWN)XQ+-#%OE0 F_X0WPO_P!
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M_?,G_P 77344 <S_ ,(;X7_Z MG_ -\R?_%T?\(;X7_Z MG_ -\R?_%UTU%
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MV2T_Y]K?_OS'_P#$U8HKQ3H*_P!DM/\ GVM_^_,?_P 31]DM/^?:W_[\Q_\
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MA?6=/^&?@G5?B#XN6RUS0[W3YKC2_"VC7%K?ZG<P+/YUO;Q3Q"6=$C=U1CD
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MUH__ #[R?^!5U_\ 'J^>_A1_R<E^U1_UQ^"/_J+>):^HJ ,'_A&M'_Y]Y/\
MP*NO_CU'_"-:/_S[R?\ @5=?_'JWJ* ,'_A&M'_Y]Y/_  *NO_CU'_"-:/\
M\^\G_@5=?_'JWJ* ,'_A&M'_ .?>3_P*NO\ X]1_PC6C_P#/O)_X%77_ ,>K
M>HH P?\ A&M'_P"?>3_P*NO_ (]1_P (UH__ #[R?^!5U_\ 'JWJ* ,'_A&M
M'_Y]Y/\ P*NO_CU'_"-:/_S[R?\ @5=?_'JWJ* ,'_A&M'_Y]Y/_  *NO_CU
M?,7B_P#91L/$_B_Q!J,7BVZT[P9XUU_P_P")_&/AC^S_ +5J5YJWAR#1;>V3
M1_$+WJ2:58WL/A_3ENXI+*]N(&$\FFW-BTG'UW7$7OQ+^'.FWTNF:CX]\&V.
MI02R0S:?>>)M&MKZ*:%BLL4EI->I<+)$P(D0QAD(.X#!KWN'\TS_ "K$XBOP
M_+$1Q-7#>QKO#X2&,DJ"KT<1&7).A75.5+$X>A7HUXQC4HUJ4)TZD9(YL3A\
M-B80ABH0G"%6%6"G)Q2J0ORM6:ONTXNZ:;331\L?M9^'+J%?@T_A2]M-&UB+
MX@:K]GO-3LY]9L_+C^'?C#,,MJ;NWE DPO[ZWN(9E*_?*,ZM^;/A_P"#?[3/
MA[QEXH\66OBSX2O+XPT^[TK6 ^D:TVRWN=6U'4DNK2V$BI'+;#4[B(6HD\FY
M"QO=---NF;]3_P!IZ6*=_@K-#(DL,WCS5Y8I8V5XY(Y/AUXO9)(W4E71U(96
M4D,I!!(->*5^\<!<49AD7"&7X3#87*L11S#!XRCBHYCE>%QLY4Z>?9C6C352
MK#VJBJT8U>24I0C4A":BG%W_ #_B9)YK/_KS0?K[NC\_Z\CR/X/?LF7?CCPE
MJ-I8>/8=%\9?"'XL:;9:'K\GAZ34M&O=*M?A?\&9Q9:AH;ZQ:W$\['1;-?[0
M?5&NANG;>2R>7I:)^R?\4=>^+?QOTZ3XP^%[:Y71](BO;R/X<:BZ3+\0-)MX
MKG[/:R>-!' +"S\'6,4*R27*RSW%S<M\Q%8]SI4^LZ_?6*>*_B-X;M9?BOXR
M6[A\ ?$KQQ\.QJ7E_!SX.7-NVJOX*US1)=3>TEA!LFO9)OLB2W20!%NIP_ >
M#O!.GW/Q;^+%BOQ)^.@DMK/P%EK7]I'XTPZE,'M-;$@U"\M_':7^H+ 0J0+>
M2S+9!W2W$*RNK?<_VCQ#4IYWC9\6K#NIP]A\;AL/+@S(LV_L[ZWGN1PQ?L\5
MBJ]&I4I8G$1Q-9X65*GAJ,L9.=-<\/>?M\II4L)#$Y?4K5EAZ+JU85I052#H
MM07+&<4I1]Q-V3:CN[V/5?B#^SUIOP[\2_"WP=X=U^Z.M^"?!%_XFT_Q'J4#
MW=O<Z]-XI2*Z>[TA;E%;3Y;>\GMXK9;H3PY2Y6Z-VOG5R^E_"+7+87]EJ7C"
MTO\ 1-=\8)X_\164&@"QO+GQ%"UG,(M,OTOG-EI+MIMINCN(KS40?."7Z*X"
M]3X5DOC?>&+>_P!:\1>()-/\/?$[3+?4_%?B'5_%6NO8V'Q=N[>QM[W7]?N[
M_6-1%I;)';027UY<2I;Q1Q!]B*!Z8/XO]R3_ - :O"K9UGV7NG@:^9QQ]>G/
M$K$8^K@,&J^(Q"SC'5Y8FFZE&K4PG-BI3Q=*C1JJ&&KU)2I/FO)^;F<J<\9.
M=&#I4IT<+*G3O?DA+"T)1BWJVXQLF[N^N]SZA_9_\/Z5/\%_AO-);N7D\,63
MN1<7"@LS2LQVI(JC))/  [=*]@_X1K1_^?>3_P "KK_X]7G'[//_ "1+X:?]
MBM8_SDKV6OYGXD_Y*+/_ /L=9K_ZG5S]2PG^ZX;_ +!Z/_IN)@_\(UH__/O)
M_P"!5U_\>H_X1K1_^?>3_P "KK_X]6]17BG08/\ PC6C_P#/O)_X%77_ ,>H
M_P"$:T?_ )]Y/_ JZ_\ CU;U% &#_P (UH__ #[R?^!5U_\ 'J/^$:T?_GWD
M_P# JZ_^/5O44 ?,O[0FC:=9:!X#DMX65S\5O!_+332?\L=8'221AT8YXYXS
MT%?'.O:'>2>(H_#\.I1PZ'XWDO=4UJ!K,27Z3Z$NG7"I8WAD"11W;>6K^=!*
M\ 5S R;E"_;7[1W_ "+G@/\ [*MX0_\ 16K5\DZO_P COX+_ .O'Q7_Z2Z97
MZ=PM.5/+*#C9/DS2>L8R7/0@Z]&:4DTI4ZM.$XR2NG%:VNG_ $CX:5ZF'X<P
M,J3BG[/B.JN:G3J)5<)2GC,-52J1DE4H8K#4*]*:2E&=*.O*Y)_0W[/>DV-[
MK'Q9^TPL^S6_!R*1-,A"Q^#-/"@E)%S@,<DY)ZDDU],?\(UH_P#S[R?^!5U_
M\>KYX_9P_P"0Q\6_^P[X1_\ 4-TVOJ6OC^)?^1O5\\'E+?F_[)P.I^2>(?\
MR5>,?5Y;PW=]_P#C&<G6OR27R,'_ (1K1_\ GWD_\"KK_P"/4?\ "-:/_P ^
M\G_@5=?_ !ZMZBO!/B3!_P"$:T?_ )]Y/_ JZ_\ CU'_  C6C_\ /O)_X%77
M_P >K>HH P?^$:T?_GWD_P# JZ_^/4?\(UH__/O)_P"!5U_\>K>HH P?^$:T
M?D?9I.00?]*NNA&#_P MO2OS8\<QI%\#/B#$@(2-O'B*"2Q"KXRUD ;F)8X
MZDD^]?J+7Y>^/?\ DB'Q$_ZZ>/?_ %,]:K\,\;?^1=A_^Q!Q=_Z8RH_<O!+_
M )&J_P"RJX)_]2<W/9Y+>*Z\0?#F&92T;>/]!R S(>+>^<?,I!'S*IX/.,="
M:^V^E?%2?\C)\-_^Q_T+_P!)=0K[5KZ'PN_W3//^QEA__5=A3YCQ&^+(?^P+
M&?\ J;,*^4_VRO"'A#6_@)\2?%/BSPOJOC:'P%X"\9^(K;PC9>+O$?A33O$
MM]!NGNM,UU_#VI:<U_I4\$;"\M[KSE^SK+Y"I,RL/JRO.OB)X1\5^+K*TL_#
M/Q#O_ 2(UP-4-GX;\+>)(M9M)X3$;.[M_%&F:G!' N2S>0D;2@E)2T9*U^I'
MYH?F'^QA\/\ X71V_P "/%?@?]I#X+Z_ID_A7P_J6@?#WP#XW\:ZA:BTO-#B
ME30?#NEZU\:O$BM::.9)+.&VU#0;RXMTM&BN+6"XB=8_T&_:%USPU<?#WQ=\
M+[OXPZ;\&O&OQ.^'_P 0-*\$^*)-0M;?7=(N;/PU=R:CXHT.RFNK2?4'\)P3
MQZQ>+:3P3PV\1>.YM9"EQ'QWPZ^#YT7Q3IFKVOQBT+Q1#H]S<K-H>E_#GX/:
M2TDENHCN+8W_ (7\.VFJZ<]L\R&<6D\$L;.JRX$F#YO^WSJW[$VE?#G11^V1
M8Z?JL.H:C<Z;\,-,T+0O%?B/XWW7BJ]@6*0? _3?AG9WWQ9C\7I#Y;-J/P_B
MAU#3X0L]U=VUL#)0!^2/[$'PU\?6G[2.A:=K'Q:_96\.Z%IOQDT+XC^'M?\
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MW!U&!(SJ9(:0?T0_ 3X<3?!WX&?!GX27'B:\\:7'PN^%7P]^'D_C#47DDO\
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ME%$<FP+Y98'+"OTHKXP^(O\ R?#^S=_V2CXW?S\,4 ?6OV36O^@O#_X+H_\
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M7M% &+]DUK_H+P_^"Z/_ ..T?9-:_P"@O#_X+H__ ([6U10!B_9-:_Z"\/\
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M=XET.WN[+6+H2K;0:<9S>'[*92/F;]@W6O\ @G]J_P"T!X1E_9^_X)2_%O\
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MPEED 0)]C_V7J'_0P:C_ . VE?\ R!7SQ\*/^3DOVJ/^N/P1_P#46\2U]14
M8G]EZA_T,&H_^ VE?_(%']EZA_T,&H_^ VE?_(%;=% &)_9>H?\ 0P:C_P"
MVE?_ "!1_9>H?]#!J/\ X#:5_P#(%;=% &)_9>H?]#!J/_@-I7_R!1_9>H?]
M#!J/_@-I7_R!6W10!B?V7J'_ $,&H_\ @-I7_P @4?V7J'_0P:C_ . VE?\
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M.H< X)CDP1C(_=MSSD<>X(]:\T\+_P#(6T7_ +!GQ9_]7%>UZ8/XO]R3_P!
M:OF,Z_Y&4_\ K_B__5IC@QG\:'_8+@?_ %"PY]1_L_:=?2?!7X;.NN7\2MX7
MLB(TM]-*("TN%4R63OA1A1N=F.,DDFO8?[+U#_H8-1_\!M*_^0*\U_9Y_P"2
M)?#3_L5K'^<E>RU_.W$G_)19_P#]CK-?_4ZN?JV$_P!UPW_8/1_]-Q,3^R]0
M_P"A@U'_ ,!M*_\ D"C^R]0_Z&#4?_ ;2O\ Y K;HKQ3H,3^R]0_Z&#4?_ ;
M2O\ Y H_LO4/^A@U'_P&TK_Y K;HH Q/[+U#_H8-1_\  ;2O_D"C^R]0_P"A
M@U'_ ,!M*_\ D"MNB@#YF_:%L;N#0/ ;RZM>7:_\+6\(?NYH;!%_U.KCK!:Q
M/GD$?-C(&01D'Y<U?_D=_!?_ %X^*_\ TETROK;]H[_D7/ ?_95O"'_HK5J^
M2=7_ .1W\%_]>/BO_P!)=,K]+X9_Y%E#_KUG/_J/4/Z+\.O^2:P7_7CBK_U!
MQ7W?+UW/HC]GNTN;C6OBTT.IW5D!KOA ;((K)U./!NGY)-Q:S-DY'1@!M'')
MKZ9_LO4/^A@U'_P&TK_Y KYU_9P_Y#'Q;_[#OA'_ -0W3:^I:^2XE_Y&]7_L
M#RG_ -5&!/RKQ#_Y*O&?]BWAO_UF<G^[Y>NYB?V7J'_0P:C_ . VE?\ R!1_
M9>H?]#!J/_@-I7_R!6W17@GQ)B?V7J'_ $,&H_\ @-I7_P @4?V7J'_0P:C_
M . VE?\ R!6W10!B?V7J'_0P:C_X#:5_\@4?V7J'_0P:C_X#:5_\@5MT4 8G
M]EZAS_Q4&H]#_P NVE<''!_X\.QYK\U?'",GP,^(*/(TSJWCM6E<(K2,/&.L
M@NP150,Q&XA5502< # 'ZBU^7OCW_DB'Q$_ZZ>/?_4SUJOPSQM_Y%V'_ .Q!
MQ=_Z8RH_<O!+_D:K_LJN"?\ U)S<]GDCDE\0?#E(YY+=SX_T'$L:Q,ZX@OFR
M!,DB'(!4[E(PQ/4 C[;KXJ3_ )&3X;_]C_H7_I+J%?:M?0^%W^Z9Y_V,L/\
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MR7.Q<>X?"WCX9?#D#I_P@GA#_P!1_3Z .[HHHH **** "BBB@ HHHH ****
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M\*? ^WMY=:T2PU5M%AF^'R74^GZ#<WEL]SING1:B9;RSCMFA:&X87:A+DEZ
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M79+)N(3[(\[7_P#GPTK_ ,&5U_\ *ROG;X4?\G)?M4?]<?@C_P"HMXEKZBH
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M6K5\D7G@#P]?Z@-4N3K#7J-<M%+'X@UJ 0?:PBW*V\<-]'%!'*L:*T<:*F%
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M&],C08\[^%$5>>>,L2<D@'J.]/[R_P#?0_QHWI_>7_OH?XUC?\(YHW_/D/\
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M&J-:G*E5I5N(*56G4BX5*=6G7RZ%2G.$DG"<))QE&5I1DG%I-'I<)?[GBO\
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M_OH?XUC?\(YHW_/D/^_]S_\ 'J/^$<T;_GR'_?\ N?\ X]0!L[T_O+_WT/\
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ME7^%2>5'8$"@"W_;^N?]"3KO_@Q\+?\ R_H_M_7/^A)UW_P8^%O_ )?UU=%
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M1\*?#/AKP=I>C^(=9L=/N?%GBG5_">BV>L^,_$36MO)-J-Q!IS0"#3+::?\
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MQ\>_@Y\&8/VJ+[3OAYI>NZ9\0[JT\0W?[2.C? R_M/ ,/AR3P+H][H^B^&_
M=]K?A;Q3'X?\4ZEKNA_\)#XEDTV9K+[>_9Z_:-UQ/V<OAAXC^(&@?%OXG>)K
MK4_B;X+O_$'@OX=:IXSU74_^%6?$[Q=\.;3Q!XLC\):9;Z=IVL^(M/\ #-GJ
MM^]O8:=87FIW%_)I]E:VX2WBU/!/[!WPJ\#_  0L?V?K3QM\8M8\ >&I/!]S
M\.3K?C/3F\0_"G4/ 4HN/"^J_#_7-)\-Z1<:?JEA>*M]/?:PFN3ZI>^9<:JU
M[)<W9G^IOAU\/_#/PL\%>'_ '@ZTFLO#OANTDMK&.ZNIKZ\GEN;JXU#4=0U"
M]N&::\U+5=3N[S4]2NI"#<7UY<3!$#A% /E']GGXBV?C+XZ_M2Z[;>%/B'H$
M;2_!>S_LSQAX)UOPQK@:#PKXB)N#I.J6\-VMG)NQ!<L@CF(8(3M;'V/_ &['
M_P! S7/_  4W?_Q-?//PH)_X:1_:GY_Y8_!'_P!1;Q)7U%0!A_V['_T#-<_\
M%-W_ /$T?V['_P! S7/_  4W?_Q-;E% &'_;L?\ T#-<_P#!3=__ !-']NQ_
M] S7/_!3=_\ Q-;E% &'_;L?_0,US_P4W?\ \31_;L?_ $#-<_\ !3=__$UN
M44 8?]NQ_P#0,US_ ,%-W_\ $T?V['_T#-<_\%-W_P#$UN44 8?]NQ_] S7/
M_!3=_P#Q-']NQ_\ 0,US_P %-W_\36Y10!\N?M,ZM'<> =#B%CJL);XB^!#O
MN-.N(8QMUJ-L&1U" D#"@D%F( ZU^8LOB/QQXW^)F@>)=(NO 6C6'A#PIXIU
M>UTS7+V\&HW5EXAU--*M[2Y>-%6/48QX7N)]6C1&326O+*)3=>867]3_ -J'
M_DGNB_\ 91O 7_I\BK\W_&_@3P9=_&WX7W%SX7T.:;5-)^)5SJ#O8P#[=/$G
MA602W2@*D[F1FDD,BL9G)>;S&YK^F/"'$8&CP].&)HJ5>I3XLEA\0\/3Q<:-
M+#Y-&MCJ#PU7$8:G)XW"QGAXUO:<^';YXIWDC\[XK_Y&5/\ [!*7XU:UON9'
MI.O)XB^+7AS6TM+BU77/!WPJU18)%+?91<Z-^T5*8)9  -ZF;:N0"ZH[ ?*V
M/I*O"KQ$C^.EO'&BQQQZ%\,TCC10B(B:9^T@JHBJ JJJ@!5     &*]UKV.*
M94YU\IG1I^QI3R+*94J3DYNE3EA*;ITW-ZS<(-1<WK*W,TKG@5/@H?\ 7I_^
MGZQY;I\P/B^]@V3!A\5/&<OF&)O)(/P8^$B;1+C;Y@*EC']X(0Y^4@GU1/OK
M_O+_ #%>8V'_ "--Y_V5CQI_ZI7X15Z<GWU_WE_F*XLZ_P"97_V*L-_Z76-L
M7\6'_P"P3#?^FT>6>$YQ)K6E1B.9#%IOQ6!>2)XXY-_Q@O&_=.P D"_=<KD(
MWRM@D9]1S@.<$XCD. ,DXC;@#N?05YIX7_Y"VB_]@SXL_P#JXKRO3!_%_N2?
M^@-1G7_(RG_U_P 7_P"K3'"QG\:'_8+@?_4+#GU%^S]K,<7P6^&T?]GZQ)L\
M,6:[XM,N9(V*O*I*.JX921E6'!4@C@U[#_;L?_0,US_P4W?_ ,37FW[//_)$
MOAI_V*UC_.2O9:_G;B3_ )*+/_\ L=9K_P"IU<_5L)_NN&_[!Z/_ *;B8?\
M;L?_ $#-<_\ !3=__$T?V['_ - S7/\ P4W?_P 36Y17BG08?]NQ_P#0,US_
M ,%-W_\ $T?V['_T#-<_\%-W_P#$UN44 8?]NQ_] S7/_!3=_P#Q-']NQ_\
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M^@9KG_@IN_\ XFC^W8_^@9KG_@IN_P#XFMRBO!/B3#_MV/\ Z!FN?^"F[_\
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M5AK&@Z7KC(+*ZOK>59K:)4?R[N\M+VUM9)I[:1*\]_:+_P"3DK#_ +();?\
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M\(>,]0\<26VI>=:Z1I__ !((XM/8+]J\JSA\ZOV2HH *\%^/%G\4KW3O#R^
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M-<B.*:-CS/QT=)/ ^G21NLD<GC7P$Z.C!D=&\3Z8RNC*2K*RD%6!(((()!H
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MFOK+^SM/_P"?&S_\!H/_ (B@!G]J:;_S_P!I_P"!$?\ \51_:FF_\_\ :?\
M@1'_ /%5XGXC^/WP%\)?$C7/A%XB\8>&M*^(_AWX3ZK\<=4\)W-OMU2+X6:'
M?/IVL>+H8Q;E+JPTV\0Q7<=N\ES""LC0"([Z\WTW]M3]E?5/&%OX+M_&EC%>
MW7B'P[X/MM:N_#>JVOA&;QEXLTC3]=\.^$O^$JFTU=$A\0:MI6J6-U:6%Q=P
ME_M$<'F"X=(6 /K3^U--_P"?^T_\"(__ (JC^U--_P"?^T_\"(__ (JG_P!G
M:?\ \^-G_P" T'_Q%']G:?\ \^-G_P" T'_Q% #/[4TW_G_M/_ B/_XJC^U-
M-_Y_[3_P(C_^*I_]G:?_ ,^-G_X#0?\ Q%']G:?_ ,^-G_X#0?\ Q% #/[4T
MW_G_ +3_ ,"(_P#XJC^U--_Y_P"T_P# B/\ ^*I_]G:?_P ^-G_X#0?_ !%'
M]G:?_P ^-G_X#0?_ !% #/[4TW_G_M/_  (C_P#BJ/[4TW_G_M/_  (C_P#B
MJ?\ V=I__/C9_P#@-!_\11_9VG_\^-G_ . T'_Q% 'SE^TY?V,WP_P!$2*[M
MI'/Q&\!E42:-F.W6XB< $YP.3[#-?$6K_ [X6:YK,OB#5?"TEYK4D]Y.=0/B
M;QA!-%+?NCWAMDM?$,$%FEPT<?FPVD4$+".-?+VHH'V_^T]96<7P^T1XK2VC
M<?$;P'AD@B1AG6X@<,J C(X.#R.#Q7SNW4_4_P Z_=>!,QS'+>&,)4R['XW+
MZE7,,XIU*F!Q>(PDZE-T\MO3G/#U*<IP=W>$FXN[NM3\\XJ_Y&5/_L$I?^G:
MQX%/';6GQRL[*$B..#P]\,88(FD>1Q##I?[1T:C?*SR2;%V*SR.\C%E+LS-D
M^^5X5?HA^/,+%5++HGPV"L5&X Z;^TAD!L9 .!D X.U2>@Q[K7W'$K<I9+*3
M;D^'LF;;;;;>"I-MMZMMZMO5L^?J?!0_Z]/_ -/5CR_3Y8CXMO8A(GFCXK>,
MW,>X;PA^"_PC4-MSG:6!7.,;@1U!KU)/OK_O+_,5Y?8(G_"5WDFQ/,_X6MXT
M3S-B^84_X4O\(F"&3&\H&RP4DJ&)8 $DGU!/OK_O+_,5RYU_S+/^Q5AO_3E8
MVQ?Q8?\ [!,-_P"FT>7^%9(WUC2%21':/3?BN'56!9"WQAO& 8 Y7*D$9 R"
M",@YKT_( 8G@".0D^@$;9KS'PM'&NL:.RHBLVF?%C<RHH9MOQAO%7<P +;5^
M49)P.!@5Z<.0V?[DG_H#49U_R,I_]?\ %_\ JTQPL9_&A_V"X'_U"PY]6_L^
M:EI\?P4^&J/>VJLOA>R5E:9%(*M*"""0000001P017L?]J:;_P _]I_X$1__
M !5>/_L]V-B_P4^&K/9VC,WA>Q+,UO"68DR$DDIDDDDDGDDDGDU['_9VG_\
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MRA<R072B%\YD3RB6VKSP0>D_L[3_ /GQL_\ P&@_^(IKZ?I^UO\ 0;/[K?\
M+K >QZ@QX(]0>#65>C2Q%&I0K1YZ56#A4CS2CS0DK-<T'&2NNL6GYFV'KU<-
M7HXBA/DK4:D:E*?+&7+.+O%\LU*+L^DHM/JCY^_9^A(\(6'BC6?B#XK\2ZEJ
M?]L6ES#XEU^SO[*,6>O7UM!-;VT.GV7DSI;6T,1;>P*[B5R^1] ?VIIO_/\
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MCX?\+7_C3Q6VAMXAU>"TU73M&L]#TUV*6?VR[U(D2W5^06M[>WC?$0\R1TR
M?B^(,VP'"U*=;/J_]GQAC*>7\DJ5>O7GCJU1TZ>%HX;"TZ^(KUY2C-^SH4JD
ME"%2K)*E3G./SV!X5S_,<VQV283+JD\SRRGC:N8X>K6PV%A@*67OEQE7&8K%
M5J.$PU*A/EINK6KPA.K.E2IRG4JTXS^@Z*^)X?VP;V9(I!\(-81)5TA]S^,?
M#HV)K.IW&B6K.!&2-FKV[64RC+(724!HR2-6']L/PW?P>'=.TKP9KU]XZU[4
MI]/F\&/J&E6CZ/';VL=Z]_?:[+*=,>TEM9HVMOLWFSS2B:%H8WA>OC*/BQX?
MUU)PX@C"T(U(1KY;G&&G752O3PU.GA:>)R^E/&5ZE>K"G3PV%C6Q%1\SA2E&
MG4<?J:GA%XATF[\/.:C.<*TJ&:Y)B8854Z$\35JXVIA\RJPP.'I4*<IU<5BY
M4,-2O3A4JQG5I1G]AT5\4WG[7FJV%UJ-G=?!G6TN-+;6ENT'C+PTP4Z#;6NI
M7I5@F&#Z1>0ZG:]//BWQ+B92E3G]M/P=:V&NVNK>$M?T_P <Z1?^'[*T\$K>
M:;=RZS'XK?4X_#U]9Z[%(NE0VE\VC:D)/M;136C10K+%_I41I0\6/#Z4ZD)<
M0PH2I1KRG]<RW.,"N;#T*N)JT82QF7T(U,4J%&K4CA*<IXJI&G+V5&;30WX0
M>(O)3J4N'7BHU?8.#P.:Y)F#5/$8BCA:6)J1P.98B5+!O$8BA3GC:JAA*+JP
M=:M"+3/L^BOC#5/VMM4TC7F\-W?P>U<:F%T*0*GC+PXT)M_$KZI::+<&;RP%
MCN]4T>^TQL@-!<)&\@$,JO7:?"#]I?2OBGXIC\'77A#6/"&M7WA/_A--&2_U
M#3M5MM4T6*_72KX>?IQS97MCJ!:"6UNHT,@CDDA=U4BNG >)O!&99EA\HPF=
M.688K$3PE##U\LSC!JIB83=.5#VV,R^AAXU/:KV48SJQ<ZSC1AS591@^7'>%
MO'6799B,YQ620_LW"86&.Q&(P^;9)C73PE2FJT<1[#!9EB,3.G[']_*4*,N3
M#QE7GRT82FOINBBBOO#\_"BBB@#X;_;/_:=^(/[.VH_LR:7X%^';^*;7XT_M
M2_ ;X,^-_%^IL(?#7@/P9\3/B9X;\$ZM>;EN(;B_\6:D-=CM/#.G6Z2I&PO=
M7O5-GIDL<G#7'[5'Q0L_C;:Q:A;^%H?@=KW[16N_LHVT%K87;^+_  WXNL_
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MC%PQ?U%1I0G.<,/3E2P-.K4IT(TX5<54KUYIRJ)0^T_[3TW_ )_[/_P)A_\
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M&^._C[1_ )UIO%LOB2&]\37OAV:_EU:&WO;*U2_;;9L0H#5^B'[''[.WQ<^
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MTJ<\70Q=3%8;VRGC9X2K6I3G2H.-=X:G4K55%87"O$SI?5:<H2Y:U7]+?V<
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M5#&"0*_/OP7^T?\ L[+H(#_'SX+QEM5U5U63XG^#(W9'G0QN$DUE6*2#YHW
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MDYR;;;?H@^&'AC51J][++K=H=:\4>)M2U.TT_5I+;3KN_L?&GB)+6Y>Q:&:
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MM&[L_4AE"CJ37L_P0,K?')S.B),?@M<F9(V+HDI\=67F*CG!9%?(5B 64 D
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M[W_M7>'K<6MY)?Z<9[-0OPUN3,L!"@7#>090V3;1<9^CO^%U?M]_]&.?#O\
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MVUF8=#L?%OP1\+MIE]>I9_9;/6/$VKF6-UEG=_6K_P#:L_;>T[XD>&?A;/\
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M^T-XM\7^&?VSO!>C_#CXR?%L-X#^$GCK]JKX]_#&+7+?4/ ;_";PII.M>%/
M7A&P\-W&F'[+<?$OQ_8:QON[*^?4K7_A#[J2-!%>8.U^QU\3OC?/\8-.\!?%
M'XGM\5=,^)_[+'@3]I?[;=:/INEMX0\:>*/&WB#PUKOAOPRFE(D-OX$.EV.C
M/I&D7+7-UIVI6VJ3&[D6^:.( _3ZOF;]HOX?>+O'7B#]E^^\*V*WMO\ #O\
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M9D\3W_CY=0\5>(KS0]-'AY9-5URPTSXE-X=M;.&#;9:OI$&JVUS#:W-U)/&
M?H?XD_9.U2]O?'OB#PA\2+72?'6J?M":%^T5X/GO]'BU#2-'UW0?#W_",?\
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MN;2"+P9!\-[+X>VTVBV^DZHMV\U_KWB/Q5:Q^#;O1$MXYK&WGO=2N6:S@Q*
M??WP*^+&O?%O2?'M_P"(_ TWP^U'P9\5?&GP[31+G6;/7+J[T_PQ)8_V;K]Q
M<V,<=M;2:]97T.I#35\R73HIX[6XEDN(Y6K\]_\ @HUXEU+PY\4?A?!8Z?-+
M;>+?@U\:_!6K:_%J2:>/!MAKS^%T'B*2, W5^D<\$=FUI:,C&.YD:9C#N%?H
M!JWP.+>$?'WAKP;\0_&GP[U+Q_X]NOB!>^+?#,VGG7M+U._.DK?66F'4+.ZM
M$T^[M](BM9(IH)'$4\Y5PY5A\A>./^"<>J_$?Q9X6\6^,?VP_P!I/5+OPCI^
MI:?IEJM_X+AMBFIW=E>7$D\9\,2Q3$O86\;131202P@QRQNIQ0!^9FH_'BXN
MO'?P3\4V?[0W@GX5:_XWT6_\%K<?#7Q1;H/"=C8K'XAFN?$6G:I-/H.I9O[!
MO#6G:9K\4>D6$=W<S6142%F^@)OVH/B'\8=&U'PCXC\?>'IM"\!?&*"STW]I
M^RTWPE;>'FL]0\)ZS<:;HU]X9F>W\-W%_<75GJ=I#X@M;E-'Q (Y46X =^A\
M8_L.6>A_M+_!WX1VOQW^)[>&OB#X%^)?B'73-X9^#SWSWWA-=(.E_9[K_A7:
MB*'_ $^?[1$T$@DVQC<NYL?1S?\ !-#2FMY-.3]IGX]Q:-/<:;=SZ'%_PK>+
M19+G1[35['39#HT?@5-&*V]OKFI!DDTV4RR3)([;X(BH!^2WP\^+/B+7YOB+
MX]U+]J[P#HWBBS\--:6VG/X-^'^W5(-#U?6+:SM_*N=25!)$;6TAGFLF>6>;
M4H)XE-JC./L3X1ZSJ&N>(++4-0U"#7Y;WX?^*-2E\46=O:V-EKE]J7Q2^U:B
M;73[,FVM!IMV\FFR"W=[::6V>>W=HI%)?X"_X)RZ%K?[2GQ^\*77[1/QN^Q^
M O#7P9?2G6R^%!EF3Q5I/B6_U&*]W_#Q[>6-)]+MOLZQ6L#+%)+$[NH7/U1I
MO_!-FVTG4;C4K#]JK]H^UFFM]0M$C@U3P-%;6]KJFLMX@OK>WM/^$-:SMHI=
M6=KE(K.WMHHEVPHGEHH !C:?_P ?]C_U^6W_ *.2OF_X $FV\397:?\ A&_@
MF,9!R/\ A777(]>N.HZ>]>Q?!3]D/Q3XZF^*TNJ?M9_M$QOX%^-WCCP'HQM;
MWP%"1H_AG^R'T]KG/@R43W0:\E,TY$?F87]VN.>^\+_\$S['P@EW'HW[5G[2
M\"7L6BVUPKZ[X,N"]MX=TT:1H\6^[\'W,BFUT\>061T61BTK1AV)(!Y'\6O^
M22_%C_LEOQ&_]0S6Z_17P'XO\;V/PT\'3?\ "M;B6VLM$T"S2X7Q3HN)_#UM
MX,M;]/$XB*"1$FNHUT[^QV'V])7\XDQ#G\\_@C^Q5K/QP^!.F:UXR_:O_:+F
MD\:Z;XPT+7K>QO\ P'96T^FRZKKGAJ>WB5/!TKQ";2X_+>5)5D$DCNA4A37U
M%:_L<_$6STFVT.V_;/\ VCHM,L],@T>W@%UX-+)86UFEC"GG'P[YC2K;HH,Q
M;>TF9"=QJZ;BIP<US04XN<=?>BFG):-/576C3\T!^37Q-^/>C>%1X:\5^+M'
MT;7[O6/$VM>(]<^(WA3Q<R>)9)]>CNYM&T7QQ;V9L?%OAW2M+NKZSL;ZPO=5
M@TRZATZ!M'TUHDC5/IGP-^U[\1?A;<:MX;\,_$+1_P!IK1X/@[XN^(EII=LN
MBPZAX'U#1X7U:"UDUW1Y[E[S0(+-I8H])UB>;7$M+,+'+YK<UOVK_P!C_5?@
M+\#5\4^$/VD_C-<7TGQ*^ G@JYBUW3?A=K%MJ&E^-/B_X&\ :C-J:W/@19=2
MU"UT3Q#?R:=?7\]U<6]\L,VYOGS](R?\$V=-5;A-._:7^/&B+>6>K:=>#1%^
M&NBFZL-<L9--U.WN'T;P)ITMP9[*5XE>X>81L1($+@$?U#F/C'X:YMEU++L?
MP/F&+HT5BXNEBL1@L3AJ_/)U<!6I1K4IX_):N#G.M3G'(LQP%'%4'2HSIPPU
M*.%/C,)D><8;$JM'&TX*4Y2J\E:J^=2UES0E2Y)-NS]Y:-76MK_*OB/]M7XH
M:/I'A#4;7]K[X=WUYX@T1=1U6V@\&?#6"WTZ_-YH\)L[>UN6EU2TC<7]]'%!
MJS&^A:PW7!9=\C9&C_MB?%3XR?#KQ=\/?%/BG1?$.G76N?"O5;KXV:+I/A_3
M-/\ AA9Q^*]#U=KS5M-ME&@ZY:/XCTO2-"M"LL5S8WFOP/JRBVA,E>C_ !;_
M &(H_!?Q+_9W\,:=\?\ XI2V/Q4^(?B#PSXEEO/#/P<N;M['2_ 'B/Q+;O;7
M+?#F-X;IM0TBU66X=9W>!I@1OP:]XN/^":^G36\EC'^TW\?+/3+F.RAO=*L#
M\-]/TR\AT_7])\3VJ7&G:?X%M-/N-NMZ'IEU+]KM;E9X[<VTBF&616QAXL>%
M%*A05'P[5/,,/F6#Q^%S6GE/".#Q.!GA<TI8ZG5HK*LER^5>IAJ4/8TJ&(JO
M XITX+'X:OAYUL/4TAE.?/GA6S&-2E4HUZ4XRKU9J7M*,X13C.DU;FDKM).*
M3<=;7_,;7[>.Z\=VFAVGB+Q1J4FC+/:#XY6(O)=$U[3=2OO"UY+XLNX+2];0
M;F+PS.^NZ1KK6;C0[B>?2[F0F-)6C]#\1^)O'.E?#OXB^"/"GCS3?$FEZ]\9
MM'\4+^T1?ZIX?T;3+SQUX2^$7@:'3_A8L%E,-('B;5/"F@W/B"U\1/=#3DFB
M2XB8:E#$R^U:K_P3U2V_:4\)_#R']JS]I6#0M8^#WCKQ1+;VVL>!K:*WFL?%
MWA73ETNSMK?P;#86VBSPZK</<Z:E@8))(H <)N6O?D_X)CZ*B36@_:8^/O\
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M?+;_ ()U&P2(:?\ M5?M#V4L%S;74%Q:S_#BSN$>U\P0HT^G>!+&YD@42.3
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MS7-E\*/'7A#0O#=T=(^%#:B]IJ_@RQUVY;4;R?P!<R7MPE[<,D$[")H[>.-
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MEO\ VMXJM[C7]3BUOPWH>JN\<4>H:;#&C^1IV^_U,&6*)5BGA=>^T*;6M/\
M%?PWO]$T#5[O1;CXQ^'/^$7\/:U=KINJQVMQX#\76NM7[S:C)<FTLK<RW6IQ
MV<\CW%PMK+'#L>YB5?/_ (^_LE^*_@[\"=?\3^'/VK?C[=7G@F/P^="BUO\
MX5SJ]M:2ZCXKT?3)IU2\\$-,+@0ZI<F.X%PLZ.48RN5PWND/[$GB.\F\,ZS+
M^UU^T?-=Z%J5CXBTXRWO@)(EU!+"ZLF>5+;P;!*T<UEJ5];21"Y"E+A@2X4
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M_M6B@#YL^/G[+'PZ_:,GT*3QQKGQ+T:VTNQU/0M;TOP!\0=?\%:1\0?!VM/
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M#?"L-W;^#_AUX2GU1B^@^ /!]OJ%_#X:\-VV;?3H[R<"24LI7Z*HHH ****
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M\6()XO%]XGB2WM(_$&K:47OM4GT;1M0G>#2Y-1E EG2&W2/YLLO^"DNH:_\
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MLTT8N[1]5M(IY[8WB7<:;[5 WYW_ +!_P.O_ (:_$CPQ>>!/V;O'/[*7PO\
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MG^T!XG\;>%/ /V[P9X"\6_$.._UBTT'QCIGP]U2VTOXBZ+X)URTO]-UCQ9X
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MIMCJNGSQ7,"FO5OAI\/?#7PG\ >$/AKX/MY[;PSX)T#3_#VC1W5P]W>-::?
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M,6I_#/X:_M#^/?BS\7_'WQI\%_%7]G+X+WGP0T75+73[+XL_#37/@!\/M?\
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MZN6DF6PTVRM0XAMHD7>H **** $9E52S$*J@LS,0%50,DDG@ #DD\ <FLO\
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M !M+X<75]!\$ZIH^E6T'Q,U/6)-.\,V'A74;G79$7P?%>:;'87 N #]\:*_
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M+P39Z;IOA/28KZZTJ?4-#M- TK2K72--;0[BREM]*4V*,(0@3Z*\(?#KP+X
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M$ /Z&J*_,3]@W]J3Q?\ &GQ9XL\$>+_B5<>-=6TOP!X8\<:YX6^(WPAU_P"
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M.WPWT;QOHG@'PO-YC6D5IX?M=0EO_%5U<&>^9M1\/6,#V[1:HL_Z>T %%%%
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M $C6KWPJNH3>!(]&\)^&/#:P7.^\2XU8-)X?>[A:VN-/$"W2QH \9D< UO\
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MHH **** "BBB@ HHHH **** "BBB@#^6N_\ VF?V>O%?_!,WXT?L>>%?B_\
M#OQ%^UM\3_C7^T%\+?A/\%-%\0Z=JWQ2MOB_XC_:=\7W'@G4U\*6$EQK6D?\
M(I>26GC:]UF[MK2UTG2=)GU.>\@AB,@\6^*7[0/B_7O^"C'A+7/!WQKM_!'B
MOP9^WK\(/V>/%'PH\1_M!_&+Q7\==<\ 7/B'P9\/?')L/V>]#GT?X0_"7X'Z
MW#KESK>E:YXGTKQ*?$O]H:;J\&M6_B'7[.-?ZM-#^#7PB\,^);KQGX<^%WP\
MT'Q??2W4UYXIT?P;X>T[Q%=37TAEO9I]9M-.AU&66[D)DN9'N"\[DM*6))K9
MF^'O@.?6[[Q-+X*\)2>)=2.EMJ'B)_#FCOKEZ^AW$=YHDEYJK69OKI](NX8;
MK36GG<V4\,,MN8WB0J ?S1ZCKGQK^)>E_M5?!OQI^U+XO_9@T'_@FM\*?CE\
M)?&GQIU"_P#%HMKKQ9\=O']IXC^ 'Q/\1ZIX>NK?6[G1_!?[+FD646L:_87D
M.I:!<_$BYUJ'4;.[TJ6:#[__ .".WCS3?$'PS^.W@71/%>E_$'2/AE\4M-TN
MU\>^!OV@/&_[1WP?UZ;7O V@ZU>0_#3QK\0DF\2Z+!9W$C7/B3P9/K7B.VT/
M6]2DE@UB5[^:"#[J_9Y_9<T+X%V?QANM:\9^)OC+XU^/'Q#U3X@?$_QU\1K7
M0'U+Q!YFDZ?X6\,>%!I6B:7INAVOA7P7X*T?2/"VBZ;'8L9K:UN+_49;K4-1
MO)I/H+POX1\*>"-(BT#P9X9T#PGH4$DTL&C>&M'T_0]*BEN',D\L>GZ9;VUJ
MDDTA+RNL0:1B6<D\T ?S'?L!?LC?M9_M3?LNZ)X1\4_M)?#?PM^Q2W[8_P"T
M?XRUCX1^&?@_+)\9/%6D^ ?VS/BAXG/@C5/BIJ_B.YTO2]*\0^+]&$VI:MHO
MABVUN#0I?[.L[J*5GN#QOPW^,LVI?&;X4:]I'[5WQB@_;\\>?M4_M.?#3]JO
MX)R^-O%7B/3/A?\ L^>'[SXMVEGJM[\"+B8Z#X1\'?"CP!IGPZ\<?#OQ;8Z-
M9OK6JW5O<6-_JMWK<L5?U7Z-H>B^';%=,\/Z1INB::MQ>7:Z?I-C;:=9+=:A
M=S7]_<BUM(H81/>WUQ<7EW*$\RXNIYIY6>61W.;;^"O!MIXDU#QE:^$_#5MX
MOU:RBT[5/%-OH6EP^(M2T^ YAL;_ %J.U74KNTB_@MY[F2%<* @"K@ _C2T\
M?#?Q5^R5^V/\&/B!^TK;_M,>%M+^!_PP^-?CW]H7X0_M8_&3QEX0OM1\,?%/
MPW8WOBSXI^#_ !MJ-YJ/P'^*?BRVN;GQ!K/A[1?%,FBZGINFZW#=Z'HUMHEG
M;K^XO[0%U\:9?@2UAXBMO@Q>_LVV7Q._97M_V;?%WP^\:>,O&WC;Q=X(3XH>
M!X=!U;Q_J?B*!M*OIM0\.+9WBZQI&IZD=5N)OM<MQ*)VE;]5[#X8_#;2M/\
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M7_A^7QM/J'BRWU'2[*QDL[_Q)<?$#Q%<ZAIT$2Z79326JZ5!:06ZPGY1U_\
MX)'^&?%5U-JOB?\ :$^(OB+6[#2_!GA+PA>:OX+^%D]AX<^'_@OP7XH^'EEX
M3N=$C\*0Z9XA-UX0\575E<ZWJL#:JU[96>H-,[R7D=P ?6.A_MZ?LZ:KK'Q.
MTJ_\5W/A^#X9>-]/\#W.KZCI&K76F>)[C4? VE_$1/$'A6?1['43JOA*V\*Z
MO::G?^)8E_L?3;<M-J-W:1;';2\1_MY?LD>$[Z^T_7OC1H=G/IU_XBTRZFBT
M7Q;J&G?;/"&@6/BOQ7';ZMIOA^[TJ]B\->&M2L->UVZLKRXM=*TJZBO;V:&
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M8TNP1(%\UB6:3:%QYC,26?&XDDDY)ISPPR8\R**3:Z2+OC5]LB?<D&X'#I_
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M^=#=K#;^4?!K]K?]KRT_:)_;)^"WBCPMX-\8^._!OC36/BCX<T?5/&VH:?X
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
I44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>img267189834_5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img267189834_5.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $O Z@# 2(  A$! Q$!_\0
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M-4*FSNIHBL<V#SM)KM:I1HZ;V_41M_MQZ;XSF\)V=SX#U[4-%UV&.:XVVDI
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MM6M>^/\ X9T*U\,[C=3ZEXDXTS2XHO\ 29O7*_PXYSFOB+Q)^S+JFB_"?P;
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M-]E^9I/^&L/A4.OB^S_,U5T+V=3^4]>R*6O'C^UI\*!_S.%E^9I/^&N/A/\
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M"_?'NX*-Z2.I:[69OO5<@E\L#FN/M=0S,HZGZUMF^V+GBO+2U/<P]/J:MQ?
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M:2/.#P#7-WGBZ96/S9K/U'5-P?YL\UR^I:HJJWK5*[.R&'5KM'32>+B?O/\
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M>K*YS))QS7U5^R_X;MM TV]\2:@?+2-"VYN,*!_C7@WPK\(OXN\56MML)B#
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M  S_ &,;>75Q.O\ :EN6D\AP6\WV..U=/\4IM/UNSNM.DD5]3B;="B+\W/\
M"*\4TG7I? >L7/VQ9BNS:\0QEJ^ERVE[7!N,5[ZV7<\VM4L_>,/Q->ZCXH\0
M7$S(WVFX<GRE) 'MBN,UBWNM-N7AN$V2*,XKK=:^(TD_B1-4LK5;9HU( ;D_
M4UQ^M:W-K%T]S=/OF?JV,5]W@8UHI6@E'JNIXU646FKF-<W1K.FF)Y)J[=%&
MZ5DW _/->Y$\^5R"XFZU41L2H?\ :'\Z60G>0>E5O,*S(,_Q#^=;?9,9;'[U
M_!S_ ))7X3_[!L'_ * *ZYEW=\8KD/@W_P DI\)_]@R#_P! %=B.]>6SR>IX
M5^UL"W@*R ."+O\ I7QG=SC=ME&#ZU]D?M=3^3X$L#_T]C^5?'EXR72G( ->
M3B8WJ'H49<L3$N&522*I23;U*MSZ4^^62W<_W<UFM(-Q(KGCN='M+%*ZF:-S
MGD=J@36KG3_FAN)(O]QL5:NF#J<C-8EXRID"MO9J1W4<8Z?F=-!\2-3A10\D
M=R%Z><H)%2M\0K2^D5[RP4L,C=&^,9[UYO+>!FP&P:C6Y.\<'.:7L5%J78]R
MGB:575GKS:MX?UJV6"&:.WN&[S+C/XU7N]#N=/T^'[--)Y]PY!>!RR!?4XKE
MHOAGXCN/#XU=-/86IY7=PS>^/2L&W\4:SX4N/+2>6V9>L4G3\JQE3YO=@]@I
MU,//FA%IMG;S>,_$^EP-81:C*\;9"A1N/ ]:\\U356;S))'8EOF8L>375Z+\
M2;*ZNLZO;B-W&PW, Q@'U%3>)/!-KXCBN;JRN8?(;[CPD'&?45M&:IN\E9&2
M@L.](_<>!Z]XVF,KQVY  ;&:QX?&5Y%(&:3<.XJMXK\,WNAWERS(9+=9,+(!
MR?>N;99)\!%))KT(ZV:.>5:5[1/7-*UQ=2A$BM@]ZO\ VK_:KC?#<;6=F _#
M&M<W@]:[8QT.E-M79UOA?Q=<^%=:AO[8AG0X*$]5[BO<]%\66?C?2WO+-?*D
M1L2P9Y0_X5\N&Z![UIZ%XNU#PW<&>PN/)9AAAC(->?C,#'$*_4\G,,''%1TT
MD?1_V6*..2XGR8HQD[1G/M7A_P 0/&4VO7Q@5&M[.!B$B;J3ZFK.G_&K68KP
M27?EW%MTDA"@9]ZU_%WAW3_%FAG6M& ,I&YU'7/<&O+P]-X&K^^6CZG)EV4J
MA^\D[R/)YIMQ.3522054GOMLC(W#*<$8Z5%YQ*EARM?51ES+FB>LWK8G9N>M
M0S3>5R>:B,V%SFJ<EV'DQ71'4\[&U_90LMRQ=2JPX/-9TLU,NICYN0:@:3<O
M7FNR)\M#$._O'IG[,+?\9+?"O_L9]/\ _1RU^^"C /UK\!OV8'/_  TQ\*O^
MQGT__P!'I7[]>M>;B_C1NY<VHM%%%<8@I&Z4M(W2@#QSXJ3[/$2#_IBO]:Y%
M;FNB^+TVWQ.@SSY*_P S7$K<>E>=->\SVJ?\-&Q]I]J<+@>E9BS$\U*D@/<?
MG6?+8LO>=3PU4UF1<=*/[05>X_.@#17 ZTY9 O3FLU;LR_=Y^E;NCZ%)?2(9
M,HA[]ZKE!NR*ZLTK8'6NBTC0FDA^T3_)&.WK6W;:'9V,8^4,WO1?W0\O8I"J
M*F1AS2D5;C4!&H2,;(UXQ65=:MU^:DO)!R,UCW3+W(KFE$J,2&^U9G)"G-9#
MR&1OWAP/K4US*J;CBL#4-1;&,X J%$[::NCI;;4+6S(( W#O5EO%\'W/,&:\
MPO->"[@7Z5R>K^(GCE8QR5T)NUD=,</SZL]9\1S1/;/<02_/C)YZ5Y'KWB::
MXF97E)V\=:Q)O&-UM=/.)4]17,ZGK7FDD-SWJ/9MO4]"C34-RYJ6LEI&R^:R
M6U-'^\U8]Y?%V.36+<:@T>,'BMHTCHYCI=4U2WAC.9-S'M7":OJNZ1L-]*CO
M-09B<L,5BWDV[O7H4J?*<]21(VH;B165?WGS<57NK@@$>]95Q<G)KT81/+G,
MGFO.M9\MW]:K3714FJK7!;K76HV1R.1^A_\ P3!F,FB^,LG_ );Q?R-?=E?!
MG_!+=BVB^,_^N\7\J^\Z\ZK\1X];XV)7Y=_M$2;?C5XL_P"OL_R%?J)7Y6_M
M'2;?CAXN_P"OP_R%<5971W9?\;.(\[WI//JB)O>E\ZN3E/=<B^)ACK2?:,$8
M.#V-4?.K6\*Z++XEURVLH\XD;DXZ+0XZ:F4I'TW\"]8G^)'AY=-O0RW-E\B7
M#=)$_P 17HFH3Z)X-C=8;-;JZZ-)*.A^E>*:]XI3X=V%KI^C.()8<$LO\1KH
M_#WCRT^)%B+=W6#6U7F-C@2^X]Z\YT^35;,CFYAWB#QE=:C(VW;&/[L:X KC
M-2O))&8N X]Q6])I-R9VB,3;@<'BFW'A&ZDCW;&''I773HJ2NC&53E=F<!?V
ML5TK-&/+?TKF[AVA9E88(-=OJFDSZ=,0Z_+]*Y?7K7='YB_>'6NB,+$\W,M#
M&DNSSR?SJA<7).>?UI9&^4U0F?K77&)E=H;-/UYJC--UI\C57.2:ZHJQFW<B
M8[N:KM&\GW%+?2NC\+^&KKQ1K,%A:IO>5@#D=!WKU'QQX!T_P'8Q6=OB>^9<
MROCH?:CVBB0>$-I\[9^7%$>BW$TB(%SN.,5WVB>%Y=5U%(MK8;J,5Z'?>!]*
M\%Z>-5U,[4C'R1?Q.V. !6%;$J+]FMV;TZ#^*6B,W3FT_P""?@<ZU.5_M*9-
ML,9QEV(KY6\1:]=>)-8NM2O)&DN+ABS%CZ]A[5V7Q.\3ZMXSU@W5ZK);1\00
M]E7M7G<R^7P?UKHP.#E1O5J?$R<17C4]VGLB%Y*K3-3Y&Y-5F>O8B<(R0FH)
M#BGLQYJK(_-6)D;M7ZE_\$JSGX*^(/\ L+'_ -!%?EA(U?J=_P $I^?@EXA_
M["Y_] %<^)_A&538^VEZ"O._C^=OP;\7G_IP>O1:\Y_:";;\%_&)]-/>O&EL
MR:7\2/JC\N(;C]VF/3^E3K,3CDUD17?R+SVJ5;KWKQI*Y^@0?N(W%N0N.*N6
M6K"TNH9>&,9W;6Z5S2WA_P FK^GVS7P9Q)&@7JK'FN6K3BXOFV+C)]#T^Q^(
MPU[4[2VO;2W@M,;#(B9?\ZV[/0XO#L-QJD]Z5T69C&P!^?!Z<5XNNHOIMXKK
MP4.<-5W5?'&I:RSK-,?**[?*7[N!7CU,'4JM1HRM"Q;DHJ_4]MT7Q/X1U2UN
M=*2%DBC4O'._'ZU5L_%ZO<V6BZ&!=6SOES@D\>_I7AUG<3<B-B@9=I[9KW#P
MU;Z?\/?!R:K*VW5;A0(UZA@3VKR<9@X86*C?FD]EYA[9O0]%&J+97GFRK]E:
M%5+HF/F]N*ZS3M:L[_+VLZPW'#L&/./3%>'R:7KWB9H=019=]RW 3.U5]:Z7
M0]%GTO7(DFGW@)ND+MS7BRP<$_:<_O)&\;25F>I:UX@EN[R**%GG&X+MP?3F
MJ%_J4VG3,%;:TA C5>F.]8&GZX;>UU";4)%@B1]L9C.3BK&CW!OI8IH+D7<*
MYY8<K64HRC!U6M5^(X*,?=:.VM&N+I5E"LBH.0> :PY[R6'Q% /*DBB?AAC.
M?>MRVU:18[>!&4YXP>E<AJFMW:I>2Q2Q-<VLI5@PR6'M7'AJ<)\ZBS).5]=N
MAU4VH_V;=.CM'(DGW$/6L/5GN869;:W4+<<9W_=KC-4\07\UU83&189)!\K,
M.,5LKJ$DFCN6NXYKJ-L_O.,CT%:5*,52C)R][\S6SCJA;J--/ODMY \<VS=Y
MRG.<]A7FWQ&\2ZEH<OE(&V03[][J<,<<5HWWQ.@;6%$SI!;1C;O<?Q#N*XKX
MK?%"VU71/L%DZ79D?<SGJF/\:Z<LPV)J8F+G3]W\/O,JU6T=2'PYXTMM4UB[
MU6[6!;^",R)'C 8 ?SKQKQAXDE\1ZM<WLBJGG'.Q.@%02:M<6SF6)FB<J5SC
ML1TI?#[:)/:W!U2;RI5^XN<9%?J-/#T\&W6@KGDRE*LU'H<A?8*D@\UAW,CJ
M/FZ5T/B.:T^WRBQ;-O\ PFN=N&W9'>OJ*+4HIGD5%RNQ5W$^]1_9Y[ICY,;2
M8ZA1Q7<?"_X;7GQ-\3VVDV7RACF63'")W)KT3X^Z7HWPOCM?#NA*F8XP)[D#
MYY'[\^E:<^MHG.W%?$?/-QI\B9+E8V]#UK,:%A,G(;#C^=7YI1<,S,=Q)ZTV
M/299I(S$,G<./Q%=48NQC*46?N[\&_\ DE/A//\ T#8/_0!795QWP=7R_A7X
M44\$:; #_P!\"NPKR);GFO<^?/VSI/)^'NGGO]L'\J^+_MV>]?8O[<$PA^&^
MG$G'^F@?I7PU]MQWKEJ0YI7.FF[(WI)UF4J^"/I6/?:<6RT)_"HEO"W>GB\Q
MWR*Q=,KF,6XE>*0JXQ5"[C6XC.S[U=!>+'>#!&*YZ\M)+=OE)(%4E8GVAQM]
M&\-TU?0G[//P9_M>./Q'K\'_ !+8^;>*0?ZYO7'I7EWA_06\4:W:V"I^]N)-
MH..E?8T=]'IVGV>C6JCR[2!8QM'H*Y<37C35EN<>*Q,^7DI[E3QW>"]LO*A1
M888EVHD8P%'I7@'BOP_::YI.I1RVZ_VC"C.LW<@5[9?RO<,RMG;WKS+QG&MK
M(9(3AQG/^T/2OG?:2A5Y[G'3E4HVJ1>J/E)KQHW*L<$'I6CX>UB_CU2"+3II
M$N)&"*JG@YKJ]7^%\6K74DUI=>2[DML8< GWK1\!_#J3PG=W.K7\D<\D"?N5
MC['NU?13QE"5+>[/KXYW1]DY7U.\O-!T"2UAAUR**:_:+;.\2X3)'IZUY!XP
M^$<=EJEQ-86RI9A=ZR+]W']#77W>L-<7+.S9;.:YCQA\0+SPU=6VW;-9W"?O
M;:3E37G87$5I5&H'FY;F?UG%.-75'FETLEJV'1D7MFJ+W1SUQ7MWA^X\&?$.
MUEA,ZV%VR@+97' /^ZU<UXL^"=]9RN^G*_E]%BDY_(]Z^A6.A3?+4T9]=RSE
ML>:_:3_>IPNE[GFK6I>#=9TR-I);4E%&2R'-<[]J;GVKNC5C55XLQFW'1FS]
MI^4^M=#\)_&%QH_BG[%*YDT^]Q&R-T#>M<.MV>AI^GW!AU*VF5L%)5;/XUS8
MFE[:DXBC.SN=9\7-!BT'Q6_D)LAG7S !]:XOS#C&3BO4?CPR/-I,HY=X02WK
MQ7DIFQGZU& ES4(HBM:,VR6YN_*CP:RWN&W9%%W,7?':JV[YJ]V$;(^.QM9U
M)D[73.U1SRF)@1U-*V%7DXJK=2CY0#6J/,9ZG^R[()/VEOA21U_X2?3\_P#?
M]*_?ZOY^_P!E60+^TQ\*LGKXGT__ -*$K^@.O.Q7QHZZ.PX=**!THKD-A:1N
ME+37;:M '@_QFD"^+$!_YX+_ #-<0D@]<5TOQXU&&P\91"60 FW4X_$UYI>>
M,-/LX6)F5FQZURR5V>Y2_AHZ*XU2&V3+LH'KFN%\5?%ZP\.L<S*%'4\5Y=\2
M/B1<SJ8;";&>!S7SOX_C\3ZK"[K,90>=HJXT7+<MR4=SZ[E_:(TB33WD%R@8
M=.17'V?QWD\4:H+33G:5]VWY>E?!NJ:KJVGR"UF,T+L< $D5]6?L^^&O^$8\
M-QZA<C=?7 R-];>QBATVI.R/KOP;XF_L^UA%T=]PV!M//->Y>'3+]C6YF79O
M7*I7B_P7^'\UYLU[5U;RV^:"%N_N:]IN+P(I'0 < 5QU=-$16E%/E1;N+X;>
M>M8UY?BJMYJ QUK%OM2"]ZY-#-+L6KS40,YZ?6L2^U9$R0:H7VK'::YC4-5.
MWKBI.J%)LT]1U]54@']:Y/4M<9L\\?6J=_J&W<Q-<W?ZIG/-6H'I4Z20:OJS
MG=@XKF=0U1L<_P Z-0O=V3NKF]0OMQQFNF-,Z+J)--J6"<G]:SIKX,Q)K.GO
M&9L55FD?')P*ZHTUL9.HT6;FZ4L?\:RI[E&4C.*S=0O&20C)Z5DS:@V#@D5O
M&CU,_K%BYJ$^UC@UD3W6>]$EP9N^36;>.R-@FM8T[&,JER*\NN#]:RI[CYC4
MMU-FL^=J[::2.&<KL9),&;J:B:0>M1MG)IC,:U(9^B?_  2O?=HOC7VGB_D:
M^^*^!?\ @E6/^))XU/K/%_(U]]UY=;XV>15^-B5^47[2<W_%\O&"YZ7I_D*_
M5TU^2G[2TNWX\>,O^OUA^@KFDKH[,"[29PHF]Z/.]ZH>=2>=2]F>LY:E_P"T
M#UKUOX$V\<;:EJ3<M$FU<CO7C"R ]Z]?^#-XG_"/:Q$I^8<FLJT?=(NWH8_B
MS6)-0UJ>1V+*&('-4=-OI;6ZCEAE:&5&W*RG!'TJEJDA74IQVWFFV\C!LKPV
M.*Y*R<:;:5RJ=G9'TY\)/C3H^M3)I_B",&90%%[C'_?5>RZKH<%U;_:=/*SV
M[#(:/D8K\\/#VL3:/JLK,"2[\@]J]Y^&?Q7U7P_>*L$SRV;#]Y!*25_"OD,M
MS*I&HX3UU.W&816YT=SXXT7S(7<+SST%>/7T?^LC(KV2_P#B_P"'-2CDCOX)
M+<G/SQC-</)%X7\073'3]>MU?_GE-\AK[BI.RNT>)1B]DSQV\4QW#KVS5*2,
MMG%>DZQ\,[IKQWMY[>XC_O0RJ?ZU7M?A;J=TV$A+4EB816IT>QFSS?[$\A^Z
M:N6N@RR_\LV_*O7=+^#VIB0>=''&OJ[@#]37=:=X(\,>';;SO$&OZ;8HHR5:
M92WY9KDJY@UI35S:-&,(\TV<?\$?"ES9M=7T</[W&Q&(SBN\O/AI=:]?&2>,
MR-W9N /QIEK^T+\-/!]I/#HADUN:/_GFFU,_6OG7XR?M5>*_&5Q-8:>XT/2F
M_P"65KPS_5JE8?%XJ-U[IQ.M&,]$>K>,/&G@_P"$*R!IXM1U< @00,"L9_VC
M7GUIXP_X6A>?;+V;?M^Y#GY5'H!7S9K$EUJ%JS$O+*QR[DY+?6N@^''B.[T.
M15DW*@ZY%>)1E7P>+M+74]2K36(PZE?4]F\4:+8W5JT01=^/O8KP/Q-IOV.X
MECQT/%>F7WCJ.Z8-OQ7FWB;5!J%\2IR.]?JCES),^3HQ<9--G)/)ZU68\T^=
ML2-CUJLTE)'4Q)I."*IN:DFDZU79LUK$0V1^*_5'_@E(V?@CXA_["[?^@"OR
MID;C%?JI_P $H3GX(^(3_P!1=O\ T 5S8K^$9U-C[?KS;]H@_P#%E/&9_P"H
M?)7I->:?M&';\$/&A_ZA[UX<MF32_B1]3\EX[C*C!XJ5)N>363%<#RUY[9IX
MNAZUYUC[J&QL_:A0+QE8%3C\:R/M6[O2_:#4\B>C*YK;'7^%[6+7]>@M+J=H
M8Y#RY.:[+4K70[+5+1;$K/!"YBF9L88XZUY7I%PZZA P?80X^:O2/B=/I]M#
MIT5F(O.F42R/'P,X_G7A8C#N.*5I.S0XNZ;?0O\ B[Q/IFK3Z?;:;I<=M]E&
MUVCY\P_A7KVG^$;WQWH>CH(%AL[/:S2MPOTR>M<-\*?AJVG:8OB36YA;JX/D
M6[ $L/4UU^M?%2)M/_LRSB6"!1A?+..1WKS\5A7*5-?R]28U+[(]6L?[+\+V
MXBFUN&>&/_50QKC;QR,]ZS=%DT*X\2BYGF7;+U5#GOQ7B^E22:Y+.&N77RD+
ME1SGV%4U\0/#F2%3 R\;E)R2.]9_V=3G-SI;]2XU%&+4MV>Q?$3PKINH:E,;
M/5XK=I"/]'EX 'X5Q6GW-QX+UR.PO[G=H]QAO-]#]:Y&2\OM69[DSE]OS22L
MW3VK;L+R[U?25M[ZT>>W8;59AR/0@TZV$H4Z:IS>C+C.3WU/6H]6TIM/62RO
MBT>\A"IS^)]*\UD\4IIOB"6!?WT=RY&YC]U_4UQU]KDG@FWFLE1I6D<.LS'@
M*#TK?AU_3M:T:75[NTBC6%1GRF^9C7@U,O\ JO-.UX/16[^9U4ZKDN5;HO:Y
MXE;Q$)M+EFBB>W.4F'!9AT%7M/@OX=)B6:XCEGN"RQJO\)QU)KCM<\36EOIL
MTVF:69X+@*?/W?-N'8>];,/Q TS4O!S1A%TJ[W")X9)5!;CD^HHJX*I)0=%7
MBF9>WBKI[GE'BRSUB#5+J.X@DD^SG=(<?*!ZYKG(='N[ZT^UPK\C7"P(N/O,
M>]=O\1M6?P[9HNFZY'>_:(]DEOD2;%QTS6!X'\73V^G6MA=VGG:?#(91-&N6
M1O4U]B\14HT.>G!:Z=CSI)2EN2^+-#CU.&WMK:W:*YL[E8KI&(!VD#! ]*\N
M\763:+K5W9NGE^6^%'7Y?6NYT_QMIC:YJ[W\Y,AF,L<TV06(Z BO,?%&M3:S
MJD]Y,V2Q^7']W/%>IE<JTZOLI0LDOQ9QXB4>6Z>IF32E<D'CTJE-<=>QIS2&
M5L*<$\4[Q-):1S+%!S)&J[V!X)KZ=SE&48Q1YZLU>Y[3\"]>F\)^$]1O[5O+
MN[J3RQ(.NW^E>7_&#Q%<:EK&Z5VD=CEF8\UO?#?6UD\,7-JS?-#)N'TKAOB,
MPEU!''*D8S733@DI/JSBEK4MT,"V0",3W,OE15ZO\/+/3+Y86#+*S,/YUXAX
MF\Z;386MR=L8VL@KI?@_X@N-/NHDE5@JN.6X[U\Q/'XFE5;EMM8]FI@Z<J%X
M[G[T?#F,1> ?#Z*,*ME$!_WR*Z-:YKX8S>?\/?#LG]ZQB/\ XZ*Z7=VKTD^;
MWCY9JS:/F?\ ;P<K\,=-/_3\/Y5\#-><\U]Y_M]2>7\+]+][X?RK\]KFXVL3
M5VN=,4^2YLI>X]:=]N]ZYY-0VGKBG_;AZU7LS"3:.@6\]Z&NE;K@_A6"M\/6
MC[</[QI>S,7(ZSPOK4?AWQ%9ZFJY,+Y/T[U]'Z!XDL/$,:R6,Z222C.S<-P]
ML5\B?;O>M;PIXNF\,ZY9WT#\PN&*D\'ZUYV)P/M?>6YS5'S+0^G;[58(UEA#
MJ)_[IX->=:Y"U[*V\$#WKJM6,&N7EEJ,816ND$@\OIGO2ZII@O"HV[2..E?(
MU%9M$4WI9GE6H6@L\[.M58_.968DC(VX/3%=Q<^%/,FRYPBGO6+K\,5G'MC'
M"UA8B5.$M;'%ZEI\ AW!=KY_AKAO$FA6?B*W$-P#]ICR(Y%/2NTOI&D8C/&:
MPKS31YCO%(K.!N(%=-.4Z;YH.S/+]I*A44J;L?/6L6MWH&I26TNY)HFX;/7W
MS72Z)\;O%.A0I FH-<0(,*EP-X ]JW_'GA6[U[4H[JV19%V89CVKS"\M3;R.
MCI@H2"*^YH>QQU).2NT?:8?-7)*[U/9_#7[0%GJT\-CXBTR&.!V"FYMQC\6'
M>G?%OX=VOV,ZSHXCV;/-'D_==>N0.U>#2>63P"OXU[_\%?$W_"4>&+GPW<2"
M2>W5C'YG4QGJ!7!BL+]4:K47IU1[>'QT,1^[EN]CP<WN&P3S4UC=-->0(#G=
M(H_6M'XD>$V\)^))K:,L\!^9&8<#/;-5_AUI;ZUXPTVW'S@2AW [ &O6<E*A
M[1=C&-=1J<C/2/CM=/$VCPL -D/KZ"O&YM0^;&:Z_P".GB 7_B]X(I-R6Z;.
MO0UYD92<DGFGEU'EH1ON>=F6,]_EB;'VC<Q;.11]L&TGM62LQ4$9IRL>F[BO
M8MT/G>?FW+\EX9!@"J\TP+#FH&:3GRT8@?Q8X%-T^UN=4N!%:PR7$K#.V-2Q
MHDN17EH0]79'KG[*IW?M,?"<]O\ A*-._P#1Z5_04O\ 6OY]?V68I+7]ISX4
M131M'*/%.G91A@C_ $A*_H+4<_C7E8B2DTUL==%-)W'"BA>E%<IT"TV3[IIU
M-?[ISTI@?#/[;6M3V7Q*MH8I#$/L*,<'W-?*7B+XD?V?"RM=%I,=CS7T+_P4
MAT_5]!\56'B.*WDDTNXLA#YR*2$=2>#Z=:_.#6/%4TEQ+))O9R?[IKHA&.YZ
ME.?N)'>:Q\2M1N;IBDI"YXKJ/ OQ%CQMU.0,N?XZ^=KSQ8__ #SD!_W#4=KX
MHFDD V2 9_NFM^9+8T?++=GUI<^'?#GCK48'CC6216W# %?3?P7^%C>(KZW:
M= NE6>W=N'#X["OFG]D7P>/$6H)<3<M(=H5CC [FOT:\.VMCX;TF.TMF140<
MG/).*Y:]32R,>;DV9T:21V=JD4:;$4851Z#I63>:D1GM5*ZUV#G,JY^M<_?:
MU#SB4'\:\B14%S&A?:H?6L&\U(MG)K.O=:BQ_K5_.L>[UB%>?-4_C6'*ST*<
M"[?7IY^:N=U"].TY/>HK[7(>?W@_.N<O]:1U.&[]<ULHZG?!*)'JFIMR,\5S
MEW>DJ?FHU#4$9C\X_.L.ZO5 (W<UTQ@:.20V_OMH.<FL"ZN?,;-2WET&_BK,
MFN%4DD\_2NJ,3"4R6/!;+G K/UC5D5MD9Z56OM0/*BL&:Y^8\UU1BGJ83J-;
M!>71F8MFL>:4C/-6IIQSBLN:8<_X&NI<IS.3>HOVIH^]))<+-C<:HS3>G\C5
M5KC'?]*=EW,_:%V[CC[-S5!XA^%1O<;NN?RIC3;1G)/X4XV747,ADF!G-59&
M6I)I=W8Y^E4I">>&_ 9K5-=PYD?HW_P2I8-H?C4#_GO%_(U]]U\/_P#!+_P+
MK/AWP'XBUC4;22TM=2N$^S>:NUG"CDX]*^WQT%>55^-GDU'>3"OR(_:=EV_'
MOQF!_P _Q_D*_79L[>*_)/\ :X\/ZAH/Q[\4/>6LL,=W<>?!(5.V1"."#BLT
MCHPKM)GE F]:=YE4=[>A_*I%D..GZ&M$D>ES^9:$F.]=U\*?$ TS6);:23$=
MRI7ZFO//,/\ =/Y5);W,MK<1S1[ED0[@11.FI1L2IJYZ?K]J$U&7W.:SX\1L
M"#R*M6NK)XFT^.>,;;F,8DC[GWJC+N5CD'.<=*YXQ6S$[]S1CCT^YN(VN8\X
M.3MXK7O/$$%JAAL$\I,8]ZY3+'LW_?-*K'IM)^HKDCE^&A4]I&&IK+$5)QY>
M:Y;NKZ>3)+D$UBRMLE+DX YS6Q;V=Q?G;#"TA]A6#XN9]$A\EEQ<2#[O7 ]Z
M]"ZD^4QBFCGKS6+D7DC17,L?/&QR*?#XTUVS4"'6+V,>BS-6(6+?,01^!J*2
M0CL?R-=7LJ=K-(Q<G?5FO>^,-;O/]?J][+_O3M_C6/<7$EP=TLLDK>KL6_G3
M"2W4'\C44C%<C!_(U4:5..J21+E?<T-'U8Z;<$!L1R<$4[4IA+.7ZAOXJQ)&
M)).UOR-/6\95VL&8?0UTQ:1G)71H+<>4>,8]*9-J+XP,*/:J+3;QP&_(U$[/
M_=8_@:3ITG+FLKD<\E&URZLDDTBHN26. />M#Q#X9FT'35O+@C+CA<\\UA0Z
M@+&9)6SN4Y VFH/$7BF]\0,BS%O+3HN#14YI-*.PZ<8Q5WN84DAR<]:KM)3W
MW?W&_(U6DWC^%L?[IKK$V)(W>J\DE.D8^A/_  $U"VXKG:W_ 'R:I$C))*_5
M?_@DZV[X'^(?;6&_] %?E$^X_P #8[G::_6W_@EKX:U3P]\!=2GU"TDM([_4
MVFMQ(I5G0 #=@]LURXMKV5B)ZZ'VE7F/[21V_ OQN?\ J'25Z8N=HW=>]>?_
M !ZT6Z\1?!OQ?IUC&9;RXT^58XUZL<=*\3H13=IH_&>&Z.T GC%2"X]\U2FM
M;NQGDM[FWE@GB.QXY(R&##J#2+YG_/-S_P !-8<I]E&7NHT1-EA4\<H#=>*S
M SY&8W_[Y-3"1\?ZM_\ ODTN4.8T_M!'0>]>I? _P>/%FMMJ6HY?2]/^9A(<
MAF[+7COF2/M4(^3_ +)KZ;TZ(> /A796JH1<W,?GR[0<Y/3-85(+16,Y2TM<
MM>/?';ZA>_9+4XC7Y51> H]/I7#-J6UBH;Y@<'ZUR<NK327#2_/N;GH:?:7D
MD]PJE7Y/)Q7(Z7*W=Z=BHM)63.[T>YNWF(M9'1F&&*>E=MI?@D7^FN\L_D2
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M [^#]'/_ &ZK2?\ "C/A_P!O!^CC_MU6N]HI\S[AS/N<"?@5X /_ #)^C_\
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M\<:"VFR:BNK6;64;;&G\X;5;^Z??VI2C)= -^BN6F^)_A6WCBDE\0Z9&LO\
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MK]BEZTLA^S;@P96 Y(8=*M5V[70'@7@OP+:WOB;P ]MX5GEMM+DO?[1FN[5
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ME4=,C.-P[&IK3X5^'[&Q:UAL6^;;F<RGSOE'R_/G/%5[2F^@'G$?QFOM6NO
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M[H/@'1_#NH37]E:[;R5/*,TCEV"9SM!/:NC6N6;3=T,6BBBH **** "BBB@
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MPWT;4M>T?6KB"674=)B:"TF,QRJ,,,",X.0*Y^\_9U\#7RQB;1L^4TS1JL[
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
F*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>img267189834_6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img267189834_6.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X0+T17AI9@  34T *@    @ ! $[  (
M   .   !2H=I  0    !   !6)R=  $    <   "T.H<  <   $,    /@
M   <Z@    $
M
M
M
M
M
M2WEL92!38W5R;&]C:P  !9 #  (    4   "II $  (    4   "NI*1  (
M   #,3$  )*2  (    #,3$  .H<  <   $,   !F@     <Z@    $
M
M
M
M
M
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@#(_9TTRU_X3+Q]?Z"OEZ.+K[-I\@RRF/S)&7&>3A=G4]QZUZWX \#6?P_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH *\@UO]I7P?H.OZAI%YINN/<:?
M=26LK100E&9&*DJ3*#C(XR!7?W/C[P?9W4MK>>+-#@N(7,<L4NI0J\; X*L"
MV001@@U\.>/KF"\^)/B6ZLYHY[>;5KJ2*6)PR2*9F(92.""#D$4 ?H'1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% 'B7P^M_B=X[\":?XC_ .%G
M_8/MOF_Z/_PC]M+LV2M'][Y<YV9Z#K72?\(3\3O^BN?^6U;?_%4?L^?\D)\/
M?]O/_I3+7I- 'FW_  A/Q._Z*Y_Y;5M_\51_PA/Q._Z*Y_Y;5M_\57I-% 'F
MW_"$_$[_ **Y_P"6U;?_ !5'_"$_$[_HKG_EM6W_ ,57I-% 'FW_  A/Q._Z
M*Y_Y;5M_\51_PA/Q._Z*Y_Y;5M_\57I-% 'FW_"$_$[_ **Y_P"6U;?_ !5'
M_"$_$[_HKG_EM6W_ ,57I-% 'FW_  A/Q._Z*Y_Y;5M_\51_PA/Q._Z*Y_Y;
M5M_\57I-% 'FW_"$_$[_ **Y_P"6U;?_ !5>;>(-8\:_\)-<^#M:\;:A<_9_
M$VBV(U#3HDT^7RKJ&=I /*_X#]XL,H#CM7TE7S;XN_Y+MJ?_ &.?AG_TFFH
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M$)^)W_17/_+:MO\ XJC_ (0GXG?]%<_\MJV_^*KTFB@#S;_A"?B=_P!%<_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M&V:\F=6(*I_<5589!()8?@ ?4=?-OB[_ )+MJ?\ V.?AG_TFFKZ2KYM\7?\
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M:>!?$WB+Q-XMT&X\7^([*=[E$U*%C AC;R[=!N)&!C@=\#G:#6Y^SEKNDO\
M"K2]'75+)M31[AVL1<)YRKYK')CSNQ@@YQWH H_'W_D8O#?_ &!?$7_IO-;O
MP*N&M/V>=&N8X)+AH8KN188AEI"+B4[0/4]*POC[_P C%X;_ .P+XB_]-YKI
M/V?/^2$^'O\ MY_]*9: ./TOX??$KXB02Z]XO\9ZGX7:>1_L^D6:N@@4$@;E
M#KCH<=21@[N<5I_#/Q!XL\._%#4/AQXTU(ZT([3[78:BYS(R_+PQ.2<@G[Q)
M!4\D$&O0?''CW0_A_H3:EKUR%+ BWMDYEN&'\*C\1D]!GFN,^%?AG7-4\4ZE
M\2O&D L]1U:$0V.G\YM+;C&[/\1"K[]2>6P #'^(5IK'CKX[6?A'2/$>H:':
M66CF[NI;*5U.XN1R P!ZQ\GU-:WAOX-ZGI.OV&JM\2-<U.&UG65K:61FCF /
MW3^\(Q5;6O@;=^*_B7K>N^(/$$T&D:D(U^QZ>Y221$555'8C&WY<D ')/8C-
M<MXB\)3? #Q%HGB+PAJMY)H>H7Z66H:?=N&#;N<C  /RJV"1E2!R02* .P^.
MMYJ=W=>#O"NAZE=Z==ZWJN'GM)&1UB0!7)*D9 \S=C/.WVJ@OP(U=V94^*_B
M)BIPP$KG'U_>5M?$;X5ZOX]\>Z/J<.O?V5IFGVS1-]GW"YW.6WE#T&5VKGMS
MUKB/&WP8A^&.@R>-/ASK.I6>H:2%DECGE5UFCW#=T ^I!R"!C% 'T+$ACA1"
MQ8JH!8]_>OG'XU_$W5K_ ,2VND^%+FYM]'TO48K>^O[64H)[ILGR=P()"J&R
M.F>O1<]KXK^)][>^!?#EAX9\J+Q5XNM(VMT+_+9HR@R2D]@OS 'V)P=I%<?\
M7_#6D^#/A9X0T+1YDE2WUN-YI=P+32%'+R-[D_D,#M0!['\2O%4O@KX<:QK]
MK$);BTB40JPR/,=UC4D=P&<$CT%>3:%\,?B%XK\+6GBNY^)VI6VK:C;I>6]O
M$\@A177<BG:P R",A5P,GAN_IWQ3\1Z%HGPQU:\UVV75+&6/[,;1)-OGN_ 3
M</N^NX<@#(Y KQ_1/AM\9/\ A S#HWB2/2=/GC+VVCRW3&:*)N0GF[/E.#T!
M'OCF@#T[X(^-]4\;^!9)O$"K_:>G7;64\J@#SBJJ0Y X!^;!QQD9[XIG[0?_
M "0GQ#_V[?\ I3%53X ZKH\O@FZT+3=)?1[_ $6Z:#4K267S',QR#(6P,[BI
M'3C80. *M_M!_P#)"?$/_;M_Z4Q4 <W\./\ DJ?A3_LF5G_Z/2O;:\2^''_)
M4_"G_9,K/_T>E>A_$?QS:?#WP5=:W=J)90?)M(#_ ,MIF!*K[#@D^P- '!_'
M;QM?KI=[X/\ "9+:@UA)>ZK.A(%I9JN2">S/]WZ'_:!KJ?@?_P D4\-_]>[?
M^C'KSJ&X\,Z-\%_%<VI>+M$U+Q;X@L9Y[]X]2ADD>5D.V% &.0N< #OG'&!7
M;? C7=(NOA9H6DVNJV4VI6]J[S6<=PC31+YIY9 =P'S+R1W'K0!A_%+XD^(;
MB'7O#WP^TJZ\S2[>5]6UF1=D5JB1[V6-NA<K^([ ]1O_ +/G_)"?#W_;S_Z4
MRUTGQ%4+\*_%>T 9T:\/ _Z8O7-_L^?\D)\/?]O/_I3+0!R6N0ZQ\9_BMK/A
MFVUJYTOPIX=VPWGV-\-=3'(*GMG(<<Y V=,FI;#X3^)/AAXUT:]^'%]J&JZ'
M/-Y>K:?>74:[(R0#(,[58X)(P-P*CJ":XWP+X1U;QYX_\=Z*==NM(T2#6)IM
M26S.V>Z=Y)%1"QZ*-KDY!'J#D%=;7/"5]^S_ *]H6N>%-<OKK0+Z_2ROM.O6
M#;BV3GY0%)VJV#M!4@<D$B@#H?B_>:QXD^*?ACX<V>JSZ-IFJ0-<W5U 2IFQ
MO/EYXSQ%TSC+C(.!7*>.? C_  $L]-\6>!O$>H!5O5AN;"]E4I=!E)QA54$8
M4@@@GG((*UT7Q>AN/B+\2--^'^@65K%J-A$-0GUJ8L)+%,C_ %>T@_W>#D$L
MO3&X<YXO^'/B3X;S6'C?7-8/C^QTB13+;:H90UN&8 .@,C X.WKD X)4XX /
MI:-_,B5RI7< =K#D>QKQ3Q1_R>3X,_[ LG_H%Y7L>E:C;ZQH]GJ=DQ:VO8$N
M(21@E'4,OZ$5XYXH_P"3R?!G_8%D_P#0+R@#VVBBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBN&^+GQ!/PX\#2:K;PQSW\\JVUG')G:9"
M"=S8YP I/OP,C- '<T5\I7?Q ^./A[0K/QIJLJMHUVRE(YK>#RRK<IN10'52
M.AR#TYYY]YT[XEZ==_!]?'T\#16HLVGDMPV2)%8H8P3C/S@J#QG@T =I17RO
M;>/_ (W^,M-U#Q9X;(M]&LV8^1!# 5 4995#@O)@=>N>0.>*]A^#7Q0_X6-X
M1GN-26*#5--81WJQ\(002L@&> 0&_%3VH ]'HKYCE^*'Q2^*/BO4;?X6J+32
M[%B5VK$&9.0C2/+_ !-@D*,8]\;J[3X)?%K6O%6M:EX3\;1HNMZ>K,LJQB,R
M;&VR(ZC@.I(Z  C/''(![117@?Q.^*_B^[^)"^ ?AA&JW\9"S7 1&=Y-N\JN
M_P"555>I/.<],<T_!/Q5\=>%_B=;^"_BOME-\ZQPSE(PT;/Q&0T>%9&/'/()
MZC!% 'T117C_ ,<?BQJ7@F2P\/>$XU?7=27>LA02&%"VU=J'@LS @9!'RG@Y
MK@)/B7\6_A;KFFR_$I/MNEWQRT16 MM&-^QX\8< C@G!_6@#Z?HJ.VN(KNUB
MN;=Q)#,@DC<=&4C(/Y5)0!\0>/O /C&\^)/B6ZL_">N3V\VK74D4L6FS,DBF
M9B&4A<$$'((KS^YMI[.ZEM;R&2"XA<QRQ2H5>-@<%6!Y!!&"#7Z/U\ ?$?\
MY*GXK_[#5Y_Z/>@#[_HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MP2C $X(!!Z]"#WKBO%GQZT70O$DOA_0=*O\ Q)JD#%9XK!<K&PZKG!)([X!
M/&<YP >J45XK?_M+Z%8Z"]S)HE_%JT-TEO<:3=,(94#(S>8"0<J"H!X!!89
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MCTG18LGAKBY<?O+A^[,?Y#H!0!TM%>?_ !#^,6@?#Z\@TZ>*XU/5[@ QV%F
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M@U*&.ZF!,DH55*;L #*K@9XSU.*RK3]H/5=/TQ-.U_P%K9\1Q1A&ACB*QS2
M8W<C<H)&> WU->ZT4 >6?!+PKKVEP^(/$_BV#['JGB:\%RUH>#"@+E01_"<R
M-\O4 #/.0+7[0?\ R0GQ#_V[?^E,5>DUYM^T'_R0GQ#_ -NW_I3%0!S?PX_Y
M*GX4_P"R96?_ */2O4O%?@[0O&^E1Z;XGL?MUI%,)TC\YX\.%90<HP/1FXSC
MFO+?AQ_R5/PI_P!DRL__ $>E>VT >-^-/@+X%L_ ^M7/A[PO*VJ164KV@ANK
MF5S*%.W";SN.>V#FKGP*^'^F^'?"MGK4_AV[TKQ%+;M;74MV[JTR%@^1$7(4
M951RJG*'C!!/K%9NE_\ (1UG_D'_ /'ZO_'I_K/^/>'_ %__ $T]/^F?E4 4
M?'UM/>?#;Q+:V<,D]Q-I-U'%%$A9Y&,+ *H')))P *Y_X&Z;?:1\&-"L=5L[
MBQNXOM'F6]S$T<B9N)",JP!&00?H:] HH \0\1Z#XS^&OQ-U3QEX%T;^W]'U
MI0^HZ;&?WJRC)+* ">N2" WWV!'0U1EM?'GQJ\4Z*/$7AB;PMX5TNY%W/#=D
M^;<2*>!\RJQR"0/E  +$DG:*]]HH \;^(GACQAX>^)UM\1?A_9IJKO:BTU+3
M3]Z1!W'.2" OW>0RJ<,"0,#Q#K7Q+^,6F+X7M_ ]SX5TVYD3[?>Z@7^XK!N-
MRH<9 X ).,9 S7T'10!2T;2X-$T*PTJTW&"QMH[:+<<G:BA1G\!7C_BC_D\G
MP9_V!9/_ $"\KVVO$O%'_)Y/@S_L"R?^@7E 'MM%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %17%K!=Q&*Z@CGC/5)$# _@:EKS7XX:CXV
MT7P;%JO@&YDB>UE/VY(;9)G,1'W@&5N%/7'8YZ T <!^T%!XZN+6XMSIJ0^
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MVX8 Y(&7! YP^>QK+U+]IO3KW0C;>%M!U2;Q)<*8H;22$,L<IXS\I+/@\@
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MA72/@QH5CJOB71[&[B^T>9;W-_%'(F;B0C*LP(R"#]#7H'_"Q_!'_0Y>'_\
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M72_\*X\$?]";X?\ _!7!_P#$T?\ "N/!'_0F^'__  5P?_$T <U_PT'\,?\
MH9O_ "0N?_C='_#0?PQ_Z&;_ ,D+G_XW72_\*X\$?]";X?\ _!7!_P#$T?\
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M\/\ _@T@_P#BJ\_^.7C7PKJ_P8UVQTKQ+H]]=R_9_+M[:_BDD?%Q&3A58DX
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M",(OY"K%% ".BR1LDBAT88*L,@BJECI&FZ8SMINGVMF9/OFW@6/=]<#FKE%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 45R/BOXD:1X/U6+3]3MKZ662
M3AK>-&7:69<<L.<J:P_^%Z>&?^?'5O\ OS'_ /'*[J>7XNI%3A!M,ZX8+$5(
MJ48-IGI5%>:_\+T\,_\ /CJW_?F/_P".4?\ "]/#/_/CJW_?F/\ ^.5I_9>-
M_P"?;+_L_%?R,TOBQ_R*=K_V$8/YFNXKQ+QO\4]$\2Z'#9V-KJ$<D=W%.3-&
M@&U2<CASS71_\+T\,_\ /CJW_?F/_P".5U5,NQ;P].*INZ<OT.B>!Q+H0BH.
MZ;_0]*HKS7_A>GAG_GQU;_OS'_\ '*/^%Z>&?^?'5O\ OS'_ /'*Y?[+QO\
MS[9S_P!GXK^1GI5%>:_\+T\,_P#/CJW_ 'YC_P#CE=QX>UVV\2Z#;ZM8I+'!
M<;MBS !AM8J<@$CJI[UA6P6(P\>:K!I&57"UJ,>:I&R-*BBBN0Y@HHHH ***
M* "JUJNVYO3Y-Q'NF!W32[UD_=H-T8W'8O&-N%^96./FW-9JC8- ;W4Q!'9H
MZW2B9K>0,[MY,?,P &U]NT $GY!&<\X !>HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MXMDY^M '=?V]I'_05LO_  (3_&N%^-6L:9<?!GQ%%!J-I+(UNH5$G4D_O%Z
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M ',?$;_D0-2_[9?^C4K?^$W_ "2_2?\ MM_Z.>L#XC?\B!J7_;+_ -&I6_\
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MB1_^7+;?_$T?\)M\3O\ HD?_ )<MM_\ $T >DT5YM_PFWQ._Z)'_ .7+;?\
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M ,N6V_\ B: /2:*\V_X3;XG?]$C_ /+EMO\ XFC_ (3;XG?]$C_\N6V_^)H
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M_17/_+:MO_BJ /2:*\V_X0GXG?\ 17/_ "VK;_XJC_A"?B=_T5S_ ,MJV_\
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MTN]\?[^12D9P4Z,.A!YKUZL<+0C*G>7YL]+/,TJTL4Z=+1K>\(?)J]WL>?\
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M@#[_ **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \2^!O\
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MWH5WK&L3B"SLXS)*Y]!V [DG  [D@5PWP;^)6H?$S3=9O]0L[:TCM;WRK:.
M-D1D9&\DG+>X 'M0!Z317DGC;XOZO;^-V\%_#?0%U[7(4W7+S$B& X!P>5SC
M(R2R@$@<D\.\*_%C7X/%UIX5^*7AQ-!U/4!_H5S;ON@G;^Y]Y@#VX8\D @9&
M0#UFO-O!/_)=OB?_ -PG_P!)FKTFO-O!/_)=OB?_ -PG_P!)FH ])HHHH \2
M^.7_ "5/X3?]AH_^C[6O;:\2^.7_ "5/X3?]AH_^C[6O;: "BN8^('C6V\"^
M%)M3EC-S=NP@L;->6N9VX1 !R>>3CG -<'^SQKVOZ]I?B:7Q3?W5W>Q:H499
MY2XA.WYD09(50<\+QZ4 >QT5XYX[\3^+O%7Q,_X5[\/+]=*%G;BXU;5-N6B#
M $(...&4\<DG&0 <Y4FC?$[X4ZUI=_%XAU3QWHMS<K%?VIMI9YHE/5U7+L
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MOP)^*PC8P_$5G?'"MJ-TH/XX-'P*M/%4'Q9U;3O%?B*[DN]'A=)M,NKN27S
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M+P#0!TNH$_&+XCG2(B7\&>&9\WY'W-2O!TB]T3OV//JI%;]G8!1XV & -=D
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M?^QSU'_VG7I- !1110 4444 %%%% !1110 4444 %%%% !7&?%S_ ))9J_\
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M_$\UXA_PUS_U)/\ Y5O_ +37N_@O29=!\"Z'I-Q_KK*P@AE_WU0!OUS7EO\
MPRIX(_Z"OB#_ ,"(/_C- '-?\-<_]23_ .5;_P"TUX!XCU?_ (2#Q5JNL^1]
MG_M&]FN_)W[_ "_,<OMW8&<9QG KZD_X94\$?]!7Q!_X$0?_ !FOE_Q9I4&@
M^--;TBS:1[?3]0GM8FE(+LJ2,H+$ #.!S@"@#]#:*** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH \2O/@#KG_  E6MZSH/Q(U#1/[8O9+N6&R
MMGC^\[.%9EG7=MWD D=STS1_PHWQO_T6CQ!_WS/_ /)%>VT4 >)?\*-\;_\
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M?^A9_P#)^Y_^.4?\,^?#'_H6?_)^Y_\ CE>DT4 >;?\ #/GPQ_Z%G_R?N?\
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MF/>N@KAK#XM>$VTVV:_UA4NC"AG5;68@/@;@/D]<U8_X6SX*_P"@U_Y*S?\
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M&0$9!'!&:\DU+3[K2-5N]-U"+R;NSF>">/<&V.C%6&02#@@\@XH _1JBBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'T(/(JS6L91G%2B[IF\)QG%2@[IA1115%!1110 4444 %%%% !1110 4444
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MJ_!'_0*\0?\ @/!_\>H ]MKRFR_Y.&\1?]@]/_0;>LC_ (:K\$?] KQ!_P"
M\'_QZN)M_CQX8A^*FJ^)6L=6-E>6JPQQB&+S P6(<CS,8_=GOZ5SUXN7+;H_
MT9[.55Z=%5_:.W-3:7F^:.GX'T517C?_  TYX,_Z!FN_^ \/_P =H_X:<\&?
M] S7?_ >'_X[5V9R^TAW/9**\;_X:<\&?] S7?\ P'A_^.T?\-.>#/\ H&:[
M_P" \/\ \=HLP]I#N>R45XW_ ,-.>#/^@9KO_@/#_P#':/\ AISP9_T#-=_\
M!X?_ ([19A[2'<]DKDOBA_R3?5/^V/\ Z.2N(_X:<\&?] S7?_ >'_X[6'XR
M_:"\*^(O"5[I=EI^L1SS[-K30Q!1MD5CDB0GH#VK.K&3IR2[,[<OKTJ>,I3G
M*R4HM^ET?0'@W_D1=!_[!MO_ .BEK9KP+0/VG/!FE>&],T^XTS76EM+2*!V2
MWA*EE0*2,RCC(K0_X:K\$?\ 0*\0?^ \'_QZMH*T4F>5B9*5><H[-O\ ,]MH
MKQ+_ (:K\$?] KQ!_P" \'_QZC_AJOP1_P! KQ!_X#P?_'JLP.P^*W^I\)?]
MC-9_^SUTE>"^-?VA_"?B2/0UL=/UF,Z?K$%]+YT$0W1Q[LA<2'YN1C.![UK?
M\-.>#/\ H&:[_P" \/\ \=KBJTY.;:1Y]:G.51M(]DHKQO\ X:<\&?\ 0,UW
M_P !X?\ X[1_PTYX,_Z!FN_^ \/_ ,=K/V<^QG[&IV/9**\;_P"&G/!G_0,U
MW_P'A_\ CM'_  TYX,_Z!FN_^ \/_P =H]G/L'L:G8]DHKQO_AISP9_T#-=_
M\!X?_CM'_#3G@S_H&:[_ . \/_QVCV<^P>QJ=CV2N:^%/^J\6_\ 8S7G_LE<
M!_PTYX,_Z!FN_P#@/#_\=K(\$_M#^$_#::X+[3]9D_M#6)[Z+R8(CMC?;@-F
M0?-P<XR/>M*5.2FFT:4:<U43:/I2BO$O^&J_!'_0*\0?^ \'_P >H_X:K\$?
M] KQ!_X#P?\ QZNT] ]MK&\8?\B/KO\ V#KC_P!%M7E?_#5?@C_H%>(/_ >#
M_P"/5GZ]^TYX,U3PYJ6GV^F:ZLMW:2P(SV\(4,R%03B4\9-:T6HU(M]T:4FE
M4BWW/0/#/_(I:1_UXP_^BQ6I7BNC_M#^$]/T.QLYM/UEI+>VCB<I!$02J@''
M[SIQ5S_AI/P?_P! W6_^_$/_ ,=KOJ58.<FGU.NI4@YMIGKU%>0_\-)^#_\
MH&ZW_P!^(?\ X[1_PTGX/_Z!NM_]^(?_ ([6?M(=R.>/<]>HKR'_ (:3\'_]
M W6_^_$/_P =H_X:3\'_ /0-UO\ [\0__':/:0[ASQ[GKU%>0_\ #2?@_P#Z
M!NM_]^(?_CM'_#2?@_\ Z!NM_P#?B'_X[1[2'<.>/<ZY_P#DOOA__KQ?_P!
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M:%6Z6RY5^MSTXX#-<%AN3#5KJ.RY(_F[GTG17B7_  U7X(_Z!7B#_P !X/\
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M . \/_QVBS#VD.Y[)17C?_#3G@S_ *!FN_\ @/#_ /':/^&G/!G_ $#-=_\
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M$'_@/!_\>H_X:K\$?] KQ!_X#P?_ !ZO2/6/;:*\2_X:K\$?] KQ!_X#P?\
MQZC_ (:K\$?] KQ!_P" \'_QZ@#9\7?\EXT'_L'-_*>NKKP;7?CSX8U/XEZ9
MXA@L-76TM+0P.CPQ"0M^\Y $F,?.._K6W_PTGX/_ .@;K?\ WXA_^.U[%:M3
ME3I)/:*3^]GIU:L'"FD]H_JSUZBO(?\ AI/P?_T#=;_[\0__ !VC_AI/P?\
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MW_E)_P#MU?25% 'S;_PR-_U.W_E)_P#MU'_#(W_4[?\ E)_^W5])44 ?-O\
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M^P?;?-_TCRO-V;(FD^[N7.=F.HZU[;_PR-_U.W_E)_\ MU>;_L^?\EV\/?\
M;S_Z32U]M4 ?-O\ PR-_U.W_ )2?_MU'_#(W_4[?^4G_ .W5])44 ?-O_#(W
M_4[?^4G_ .W4?\,C?]3M_P"4G_[=7TE10!\V_P##(W_4[?\ E)_^W4?\,C?]
M3M_Y2?\ [=7TE10!\V_\,C?]3M_Y2?\ [=1_PR-_U.W_ )2?_MU?25% 'S;_
M ,,C?]3M_P"4G_[=1_PR-_U.W_E)_P#MU?25% 'S;_PR-_U.W_E)_P#MU>)?
M$'PC_P ()X[U#PW]M^W_ &+RO](\KRM^^)9/N[FQC?CJ>E??]?$O[0?_ "7;
MQ#_V[?\ I-%0!VWAS]EW_A(/"NE:S_PE_P!G_M&RAN_)_LS?Y?F('V[O-&<9
MQG K2_X9&_ZG;_RD_P#VZO;OAQ_R2SPI_P!@6S_]$)724 ?-O_#(W_4[?^4G
M_P"W4?\ #(W_ %.W_E)_^W5])44 ?-O_  R-_P!3M_Y2?_MU'_#(W_4[?^4G
M_P"W5])44 ?-O_#(W_4[?^4G_P"W4?\ #(W_ %.W_E)_^W5])44 ?-O_  R-
M_P!3M_Y2?_MU'_#(W_4[?^4G_P"W5])44 ?-O_#(W_4[?^4G_P"W4?\ #(W_
M %.W_E)_^W5])44 ?$OQ<^$?_"J_[(_XG?\ :O\ :7G?\NGD>7Y?E_[;9SYG
MMC'O6E\*O@7_ ,+-\*W.L_\ "1?V9Y%ZUIY/V'SMVU$?=N\Q?[^,8[5VW[7/
M_,H_]OO_ +0KI?V5/^26:E_V&I?_ $1!0!S7_#(W_4[?^4G_ .W4?\,C?]3M
M_P"4G_[=7TE10!\V_P##(W_4[?\ E)_^W4?\,C?]3M_Y2?\ [=7TE10!\V_\
M,C?]3M_Y2?\ [=1_PR-_U.W_ )2?_MU?25% 'S;_ ,,C?]3M_P"4G_[=1_PR
M-_U.W_E)_P#MU?25% 'S;_PR-_U.W_E)_P#MU'_#(W_4[?\ E)_^W5])44 ?
M-O\ PR-_U.W_ )2?_MU9OB/]EW_A'_"NJZS_ ,)?]H_LZRFN_)_LS9YGEH7V
M[O-.,XQG!KZDKF_B/_R2SQ7_ -@6\_\ 1#T ?&WPJ^'7_"S?%5SHW]J?V9Y%
MDUWYWV?SMVUT3;MW+_?SG/:O6_\ AD;_ *G;_P I/_VZN;_94_Y*GJ7_ &!9
M?_1\%?6U 'S;_P ,C?\ 4[?^4G_[=1_PR-_U.W_E)_\ MU?25% 'S;_PR-_U
M.W_E)_\ MU'_  R-_P!3M_Y2?_MU?25% 'S;_P ,C?\ 4[?^4G_[=1_PR-_U
M.W_E)_\ MU?25% 'S;_PR-_U.W_E)_\ MU'_  R-_P!3M_Y2?_MU?25% 'S;
M_P ,C?\ 4[?^4G_[=1_PR-_U.W_E)_\ MU?25% 'S;_PR-_U.W_E)_\ MU>
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M>@ZT?M5_\E3TW_L"Q?\ H^>O;?V?/^2$^'O^WG_TIEH \V_X9&_ZG;_RD_\
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M]O-I[VJK9RR,X8R1L"0T:C&$/?TKW*BB@ HHHH **** "BBB@ HHHH ****
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ML:*** "BBB@ HHHH **** "BBL_7M=T[PUH5UK&M7*VMC:)OEE;MS@ #N22
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M4\^1-COZ-WZCG('TCX$\=Z/\0?#<>K:++@\+<6SG]Y;OW5A_(]"* .EHHHH
M**** "BBB@ HHHH ***PO&WBFW\%^"]2\07:>8EE%N6/./,<D*BY[98@9[4
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MO&>U>AW?@'X0_!::QU+Q&;F]N+B;;;?;R+ADQR7\M% (7C)*DC(QR:R/C/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MW4MN\RQJF?E4Y&0 QW'!QQG% 'TG\7(K?2O@;K]M96Z0V\-@((H8E"K&N54
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MQ@G Q],JH50J@!0,  =* $BBC@A6*&-8XT&U41<!1Z "G444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"GJVDV&NZ3<:9J]K'=
MV=RA26&09##^A[@CD'FN(^&GP>TCX:7VIWFGW=Q=SWK%$:4X$4.<A,#ACGJQ
M_ #G/H=% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>img267189834_7.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img267189834_7.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X0+T17AI9@  34T *@    @ ! $[  (
M   .   !2H=I  0    !   !6)R=  $    <   "T.H<  <   $,    /@
M   <Z@    $
M
M
M
M
M
M2WEL92!38W5R;&]C:P  !9 #  (    4   "II $  (    4   "NI*1  (
M   #,3<  )*2  (    #,3<  .H<  <   $,   !F@     <Z@    $
M
M
M
M
M
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M_.-N\9SZ8H EHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MM^+=5\91>#OB!X?:SU!XI'BNC"T#-L&3N0\'.#\RX'3CO6XG[1/PT9@#KLJ
M_P 1L9\#\DKN="\0Z%XLL4U+0+^UU*"-L"6%@QB;'((ZJV#T.#@T :U%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 ?+WQ0\/V'Q"_:(A\(:):06%R<2:GJ>"SR'
MR@YX)QA4"@ 8RQYKM)OV5_!C:;Y,.I:Q'= <7#2QMD^Z[ ,>PP>.M<E\:_#O
MB;P)\58_B9X7C>2WD*/+(J;U@D5!&RR ?P.HZ^I(R#BJ\W[66LMIY2#PS8QW
M>W F:X=D#>NS ./;=^- '.?#SX8Z'J'Q5UGP)XT^TF[M0_V:YLI@@8H>>"#G
M*D,/3!!Z\=1\(+";X??M(ZQX.M[J2XLI(9(R6XWA5$L;$#C<%)'_  (TGP8\
M.^(GUK7?BMXGBF41VES<0-,A5KJ5E+,RKQ\@7(';D =*T?@/X=\3^(?B5J?Q
M$\6VLL'FQ,L3S0F/SI'P,H#_  *@QGW R<&@#Z-HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "O(?BC??%O1O%T>H^ +7^T-$%J@EM?+CE_>AFS\O$G(V_=->O44 ?.U
ME^TWJ>D7"V?Q \%7%G*1\[0;HF_"*4?^S5UWA[XL?"#7+E)T_L[2[TX;_B86
M*0NI]Y,%<_\  J].U"/2[Z![354L[B)N'AN0KJ?JK5Y[KWP1^&.O*Y.G0:;,
MP($NG7'D[?<)DI_X[0!Z/9:A9ZE:K<Z==P7<#?=E@D#J?H1Q5BO&_ ?P0L/
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MHBC5C_>(!./8^E 'TY1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0.<\YP*W?V@;NZU_Q/X/^'UM<M;6VL7:R7C(<$KO"K[$#YVP>I"^E0_M/?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P#M5'_#4G_4G_\ E3_^U5\_44?ZK9/_ ,^?_)I?_)![>IW/H'_AJ3_J3_\
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MS3?^O2+_ - %7ZJZ7 UKI%G;O]Z&!$/'<*!5J@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *\,^,7PV\?\ BWQO'J/A#4/LU@MFD3)]O:'+AF).
MT>Q'->YT4 ?(M[^SY\4]25%U&\M[M4.5$^I,X4^V1Q4\7P)^+L$2Q0:JL<:C
M"HFJN ![ 5]9T4 >!?"CX7_$7PO\0;75/%.H_:-.CBE5T_M!Y<DH0ORGWKWV
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KS;]H/\
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MD8'0!N*[CX:?"[3_ (<V=V\=Y-J>JZ@P>]U"X&&D/7 '.!DD\DDD\GICN:*
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MUK2],E2/4M2L[1Y/N+<3K&6^@)YH NT4B.LD:O&P=&&0RG((I: "O-OV@_\
MDA/B'_MV_P#2F*O2:\V_:#_Y(3XA_P"W;_TIBH /V?/^2$^'O^WG_P!*9:])
MKS;]GS_DA/A[_MY_]*9:])H **** "BBB@ KC/BY_P DLU?_ +8_^CTKLZXS
MXN?\DLU?_MC_ .CTK'$?P9^C_(]+*?\ D8T/\<?_ $I'S-1117RA^_A79_"/
M_DJ>D?\ ;;_T0]<979_"/_DJ>D?]MO\ T0];8?\ C0]5^9YN;?\ (NK_ ."7
M_I+/IFBBBOJS\ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M('^+^F:MXH\4:Y>QS2730QR*H=Y9 JL78MU4;@ !CH1D8J#P]G_ACSQ3C/\
MR'DS_P"2U>Q?LT&/_A3<'EXW?;9_,QZY'7\,4 <%^SQXCU3PY\0]6^'6JW)F
MMHGG6%"<B*>)R'">BL Q(]0#W-?3%?*?A1U?]M.<HP8?VE?C(.>1!,"/SKW;
MXJ_\)W_PBMM_PK#_ )"WVU?._P!1_J-C[O\ 7?+][9TY_#- ';5YM^T'_P D
M)\0_]NW_ *4Q5YM_QD[_ )_LRN;^(/\ PO;_ (034/\ A//^0!^Z^U_\>/\
MSU79_JOG^_MZ?CQF@#VW]GS_ )(3X>_[>?\ TIEKTFO-OV?/^2$^'O\ MY_]
M*9:])H **** "BBB@ KC/BY_R2S5_P#MC_Z/2NSKC/BY_P DLU?_ +8_^CTK
M'$?P9^C_ "/2RG_D8T/\<?\ TI'S-1117RA^_A79_"/_ )*GI'_;;_T0]<97
M9_"/_DJ>D?\ ;;_T0];8?^-#U7YGFYM_R+J_^"7_ *2SZ9HHHKZL_  HHHH
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M_:#_ .2$^(?^W;_TIBKTFO-OV@_^2$^(?^W;_P!*8J #]GS_ )(3X>_[>?\
MTIEKTFO-OV?/^2$^'O\ MY_]*9:])H **** "BBB@ KC/BY_R2S5_P#MC_Z/
M2NSKC/BY_P DLU?_ +8_^CTK'$?P9^C_ "/2RG_D8T/\<?\ TI'S-1117RA^
M_A79_"/_ )*GI'_;;_T0]<979_"/_DJ>D?\ ;;_T0];8?^-#U7YGFYM_R+J_
M^"7_ *2SZ9HHHKZL_  HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M->;?M!_\D)\0_P#;M_Z4Q4 '[/G_ "0GP]_V\_\ I3+7I->;?L^?\D)\/?\
M;S_Z4RUZ30 4444 %%%% !7&?%S_ ))9J_\ VQ_]'I79UQGQ<_Y)9J__ &Q_
M]'I6.(_@S]'^1Z64_P#(QH?XX_\ I2/F:BBBOE#]_"NS^$?_ "5/2/\ MM_Z
M(>N,KL_A'_R5/2/^VW_HAZVP_P#&AZK\SS<V_P"1=7_P2_\ 26?3-%%%?5GX
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%5M1N9;+3+FZM[9[N6&)G2"/[TI R%'N>E)NRN5&+E)174LT5YM??
M%35=,@6;4/ ^I6T3.$#RR;06/0?<ZUL:)XSUG5-9@L[SP;J.G0RD[KJ9CMCP
MI//RCJ1C\:Q6(IMV3_!GJ5,GQE.FZDHJVOVH]-^NOR.QHHHK<\D**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M"-1+"S@H2> WSG'T-0^-M0M?B/\ M1:/;^'KA+VVAGM8!<0L&1TC/FR,I'4
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M/A[_ +>?_2F6O2:\V_9\_P"2$^'O^WG_ -*9:])H _/VBBBOZ1/'"N@\ ?\
M)2O#/_87M?\ T<M<_70> /\ DI7AG_L+VO\ Z.6N;%_[O4]'^14=T?<5<9\7
M/^26:O\ ]L?_ $>E=G7&?%S_ ))9J_\ VQ_]'I7\XXC^#/T?Y'U&4_\ (QH?
MXX_^E(^9J***^4/W\*[/X1_\E3TC_MM_Z(>N,KL_A'_R5/2/^VW_ *(>ML/_
M !H>J_,\W-O^1=7_ ,$O_26?3-%%%?5GX %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 8WC+_D1=>_[!MQ_P"BFKY,
MKZS\9?\ (BZ]_P!@VX_]%-7R97AYG\<3]2X(_P!WK?XE^04445Y1]^;/@W_D
M>M!_["5O_P"C5KZSKY,\&_\ (]:#_P!A*W_]&K7UG7N99\$O4_+N-_\ >*/H
M_P PHHHKU3\_"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MC_Z4CYFHHHKY0_?PKL_A'_R5/2/^VW_HAZXRNS^$?_)4](_[;?\ HAZVP_\
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ME=G\(_\ DJ>D?]MO_1#UMA_XT/5?F>;FW_(NK_X)?^DL^F:***^K/P ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Q
MO&7_ "(NO?\ 8-N/_135\F5]9^,O^1%U[_L&W'_HIJ^3*\/,_CB?J7!'^[UO
M\2_(****\H^_-GP;_P CUH/_ &$K?_T:M?6=?)G@W_D>M!_["5O_ .C5KZSK
MW,L^"7J?EW&_^\4?1_F%%%%>J?GX4444 %%%% !1110 4444 %%%% !1110
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MJN"J$C!:1AU'I7T#0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M117JGY^%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5R/B+XH>%/"WB:VT#6K^2#
M4;I4:*);=W#!V*K\P! Y!KKJX?Q3\)/#?B_Q=:>)-6-Z+^T6-8_)F"IA&++D
M8/<F@"'Q#\;/ WA?7KK1M:U26"^M2%EC6TE<*2H8<A2#P16;_P -%_#7_H-3
M?^ ,W_Q-2>*/@)X.\7>);S7=6;4?MEXRM+Y-P%7(4*,#:>RBLG_AF'P!_>U;
M_P "U_\ B: .I\,?&/P7XQUZ+1] U.6XO959DC:UD0$*,GEE Z"NYKSKP?\
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MH_S"BBBO5/S\**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1TV[=R_W\YSVKD?@=\'K_P #W%YXA\52K)KE[&8EB63S/(0L&8LW1G8@<C.
M.IR:]DH ^;?^&1O^IV_\I/\ ]NH_X9&_ZG;_ ,I/_P!NKZ2HH ^;?^&1O^IV
M_P#*3_\ ;J/^&1O^IV_\I/\ ]NKZ2HH ^;?^&1O^IV_\I/\ ]NH_X9&_ZG;_
M ,I/_P!NKZ2HH ^;?^&1O^IV_P#*3_\ ;J/^&1O^IV_\I/\ ]NKZ2HH ^)?B
MY\(_^%5_V1_Q._[5_M+SO^73R/+\OR_]MLY\SVQCWKTC_AD;_J=O_*3_ /;J
M/VN?^91_[??_ &A7TE0!\V_\,C?]3M_Y2?\ [=1_PR-_U.W_ )2?_MU?25%
M'S;_ ,,C?]3M_P"4G_[=1_PR-_U.W_E)_P#MU?25% 'S;_PR-_U.W_E)_P#M
MU'_#(W_4[?\ E)_^W5])44 ?-O\ PR-_U.W_ )2?_MU'_#(W_4[?^4G_ .W5
M])44 ?-O_#(W_4[?^4G_ .W4?\,C?]3M_P"4G_[=7TE10!\V_P##(W_4[?\
ME)_^W4?\,C?]3M_Y2?\ [=7TE10!\V_\,C?]3M_Y2?\ [=1_PR-_U.W_ )2?
M_MU?25% 'PE\*OAU_P +-\57.C?VI_9GD637?G?9_.W;71-NW<O]_.<]J];_
M .&1O^IV_P#*3_\ ;JYO]E3_ )*GJ7_8%E_]'P5];4 ?-O\ PR-_U.W_ )2?
M_MU'_#(W_4[?^4G_ .W5])44 ?-O_#(W_4[?^4G_ .W4?\,C?]3M_P"4G_[=
M7TE10!\V_P##(W_4[?\ E)_^W4?\,C?]3M_Y2?\ [=7TE10!\V_\,C?]3M_Y
M2?\ [=1_PR-_U.W_ )2?_MU?25% 'S;_ ,,C?]3M_P"4G_[=1_PR-_U.W_E)
M_P#MU?25% 'S;_PR-_U.W_E)_P#MU'_#(W_4[?\ E)_^W5])44 ?-O\ PR-_
MU.W_ )2?_MU>;_%SX1_\*K_LC_B=_P!J_P!I>=_RZ>1Y?E^7_MMG/F>V,>]?
M;5?-O[7/_,H_]OO_ +0H S?#G[+O_"0>%=*UG_A+_L_]HV4-WY/]F;_+\Q ^
MW=YHSC.,X%:7_#(W_4[?^4G_ .W5[=\./^26>%/^P+9_^B$KI* /FW_AD;_J
M=O\ RD__ &ZC_AD;_J=O_*3_ /;J^DJ* /FW_AD;_J=O_*3_ /;J/^&1O^IV
M_P#*3_\ ;J^DJ* /FW_AD;_J=O\ RD__ &ZC_AD;_J=O_*3_ /;J^DJ* /FW
M_AD;_J=O_*3_ /;J/^&1O^IV_P#*3_\ ;J^DJ* /FW_AD;_J=O\ RD__ &ZC
M_AD;_J=O_*3_ /;J^DJ* /FW_AD;_J=O_*3_ /;J/^&1O^IV_P#*3_\ ;J^D
MJ* /FW_AD;_J=O\ RD__ &ZO)-!^'7]M_&27P%_:GD>7>W5I]N^S[L^0)#N\
MO</O>7TW<9[XK[MKY)\!_P#)Y-U_V&M5_P#0+B@#I/\ AD;_ *G;_P I/_VZ
MC_AD;_J=O_*3_P#;J^DJ* /FW_AD;_J=O_*3_P#;J/\ AD;_ *G;_P I/_VZ
MOI*B@#YM_P"&1O\ J=O_ "D__;J/^&1O^IV_\I/_ -NKZ2HH \V^$?PC_P"%
M5_VO_P 3O^U?[2\G_ET\CR_+\S_;;.?,]L8]Z])HHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** / _CE\*M?OO$]OX[\!+(^IPA
M/M$-N<3;D^Y*G]XX 4CK\HP#S7#2?%KXW3V_]F+IU\MUC89(]%/GD_3;@'Z+
M7L_Q/^..C?#;4(]+:QFU35'B\XP12"-(U.=N]R#@G'0 \<]QGSO_ (:Y_P"I
M)_\ *M_]IH Z'X"?"?5_#-]>>+?&0=-7O49(H)7WR(K-N>21LGYV(''4#.>3
M@>XUXQ\-_P!H/_A8/C:W\/\ _",_V?Y\<C_:/M_F[=JEL;?+7KCUKV>@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH \2_:+^'WB?QW_PCG_"*:9]O^Q?:OM'^D11;-_E;?OLN<[&Z9Z5[;11
M0 4444 %%%% !1110 4444 %%%% !1110 4444 ?._[/_P +?&/@CQ]>ZEXG
MT?[#:2Z9) DGVJ&3+F6)@,(Y/16YQCBOHBBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ KQ+]HOX?>)_'?_  CG_"*:9]O^Q?:OM'^D11;-_E;?OLN<[&Z9
MZ5[;10!B>"M/NM(\ ^']-U"+R;NSTRV@GCW!MCI$JL,@D'!!Y!Q6W110 444
M4 %%%% !1110 4444 %%%% !1110 5\[^$OA;XQTS]I>X\5WVC^5HCZGJ$ZW
M7VJ%LI*LP0[ ^[G>O&,C/.*^B** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^7?&.A:1%^ULA\>H/
M[%U(QS0O.VV*0B (@<_W1(FTCITSP37O<7P[\"20JT/A#P\Z$?*PTV!@1]=O
M->2?%+X(>//'GC:]U"VU^P.DLX:SM+V\G_T<;%#801LJY*D\=:XO_AE3QO\
M]!7P_P#^!$__ ,9H ^G--\&^&-&O5O-(\.:1872@A9[6QBB< C! 95!Y%;5?
M/WPE^ WB?P'\0[77M7O](FM88I49+6:5G)9"!@-&HZGUKZ!H **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Y\_:FUS5M%_X
M17^Q]4O=/\[[7YGV6X>+?CR<9VD9QD_F:QM"^#WQ.U[P[INL6_Q#FBBU"TBN
MD1[^YW*LB!@#CO@U:_:Y_P"91_[??_:%4?#?Q ^-EEX4TFUT7P>EQIT%E#':
M3'3Y&\R(( C9#X.5 .: ,N3Q;\1?@=\0+73_ !5K4VLZ?*JRO')</<1RPEB"
M4+_,C#!X&.1SD'GVKXX_$:Z^'?@N.;2!'_:FH3>1;O(NX1 #+28[D<  \98$
MYQ@_.\VOW&O?&33[[XXI?:?%"$_T<V1C545LJI1L$1D[B6&XGGUR/LF6WLM3
MMHS/#!=P, Z%T#J01P1GVH ^7-.\#_&3Q'X0'C2+Q?>*\T)NH+3^TIDEDCP2
M-JK\BY'(7('/.*]$_9Y^)^K^.-.U'2O$DGVJ^TT(\=WM :6-LC#8XW CKW!Y
MY!)N?&?XL:9X \-R^']$:-M;N+<PPP08"V,97 <@< @?=7Z=NN5\!?A]J7@?
MP-JWB#5H)+?5-2@W0VLBX:&- Q7<.H9B<X[ +T.10!B?$WXU>(]6\:GP1\+D
M?[0LQMI+J% TLTH/S+&3PJK@Y<^A.0!DU6^#'QF-H;W_ (3V3[<?F\D:O<AO
MINQC/;T]ZP_V6+>"Y^)FIW-P0]S#ICM'N.3EI$#-ZY[9_P!H^M>\?$KXKZ3\
M,/[,_MBQO;O^T?-\O[*$.WR]F<[F']\?D: /+O@_\8/$\/CL^!?B)YL]S)*T
M$,\RJ);>50?D<C[RG'#<G)')!X^BZ\4\/_M&^$-9\4V6GV.@:E!>:K=Q6OGM
M%",L[! 6(?) R/7@5[70 4444 %%%% !11574YY+;2;R>'F2*!W3CN%)% 'S
MU\1/C#XI\3>/#X'^%A>)TG:WDNH@/,GD7(?:S<(BX/S=?ESG'6G>_";XU:+I
MS:M9^-;B^O(E,CVL&J7#.W? W@*Y]C^M9/[*T$<_Q)U6ZF.^>/3&V;CG[TJ9
M;USVS[FOK&@#Q?X#?&*\\>BYT'Q)M?6+2'SX[E$"BXB!"DL!P&!9>G4'H,&N
M(\4>./&_Q6^*USX.\"ZG)I&GVLLD?F12M#N6,X>61U^8@G@*/49&<U]-6]K;
MVD92U@C@0G)6- HS^%?(\MYJ?P(^/=[J>IZ=)<Z=>23[&48\^WD;=E&Z;E.W
M(]B.,@T :)\5_$/X$^.K.P\7ZM+K>D70$C*\[SK)$6PQC9_F5UZ[>G/.<YKZ
M!\?^/].\!>")?$-R/M0;:EI C ?:)&&5 /88RQ/8 \'I7RG\:/B:/B;JFG7E
MEID]EIEDDD,#SXW2N=I?)' P-G )QG/>NB^.5Y<O\+_A; [L8I-&69R3G>_D
MP#)/<C)_[ZH MZ'_ ,+D^-;2ZG::ZVC:2)-JM'.]K 2.JHJ99\>K$\\9XJ+Q
M-8?&+X-+#K$GB>XU333($>3[2]S$A[+(DH^7=R,C\P2*^@_A9;6]I\)?"T=H
MJK&VEV\A"XQO= SGCON9J\WU']I[P<9)[&]\/ZK<(DA1T>*%E8JW7!?U&: /
M2/AIXZ@^(?@BVUR&'[/,6,-S #D1RKC(!]"""/8BNLKC_AO\0],^(^A7&HZ-
M9W-G!:W'V<QW"J#D*K9&TD8PPKL* "BBB@ HHHH *PO&?BRQ\$>$KW7]4W-#
M:H,1I]Z5R<*@^I(Y[<GM6[7A/[5MS*G@'1[="1%+J6Y\=RL;8'ZG\J .+T>]
M^+OQRO;J]TG66T/1X9=G[JX>WA0X'R H-\C8Y.<C)ZC(%1Z]/\7/@;>VFH:C
MK[ZQI<\OE@RW#W$+M@GRV$GS(2 3E<=#SUKVKX"VT-M\$?#X@Y\Q)9'/JQF?
M/Y=/PKOY[:"Z0)<PQS*K!@)$# $=^>] 'GVJ?%RR@^"'_"?Z?;EC-"%AM9.=
MLY?RRC'C(5P<GC(&1U%>+>'/#_Q@^*FC7'BRT\6SVJ^:RVT)OI+<2E3SL6/Y
M5 / )QDC\:]S^,WA.\\8?"O4M,TA-]ZFRX@B'_+0HP)0>Y&0/?%>%_##X\Q?
M#GP7-X9US0[J>XLII3;>61'@DDF.0-RI#YY /7&..0#N_@%\5]9\2:E>^$?&
M+M-J5G&TD%Q(H61@K!7C?U89&#UP#GI7*?$[Q%K=G^TYI^GVFL:A!9-=V"M;
M173K&0Q3<"H..<\^M<I\%KV\O/VE+&ZOHVM[JZN;U[F'!7:[0S,RD'D8;L?2
MK?QRGO+7]HT7&EQ>??0M9/;1;2V^0*I5<#KDX&* /L"OF#_A(M;_ .&NO[,_
MMB__ +/_ +3V?9/M3^5M\K.-F<8S[5I?\+)^/?\ T)$?_@LE_P#BZX#P7?ZQ
MJ?[3FFWGB:T^QZK-J&ZY@$93RV\L\;221QB@#[,HHHH **** "BBB@ HHHH
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M%>*?L_?">_\ !EO=>(O$T/DZO?Q^5%;ELM!"2&.[T9B!QV '<D#VN@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7@&K^+K3^U+B'XT_"U[W6+>0K'?Z;:D).@Z<DC</0[B.>@Q0!>T+QEIGC?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
%HHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>img267189834_8.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img267189834_8.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X0+T17AI9@  34T *@    @ ! $[  (
M   .   !2H=I  0    !   !6)R=  $    <   "T.H<  <   $,    /@
M   <Z@    $
M
M
M
M
M
M2WEL92!38W5R;&]C:P  !9 #  (    4   "II $  (    4   "NI*1  (
M   #.3D  )*2  (    #.3D  .H<  <   $,   !F@     <Z@    $
M
M
M
M
M
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M+'%$@1$48"J!@ ?A0!\F_P##*GC?_H*^'_\ P(G_ /C-'_#*GC?_ *"OA_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M44 %%%% !1110 4444 %%%% !1110 5Y]\;?^2:3_P#7U!_Z&*]!KS[XV_\
M)-)_^OJ#_P!#%95OX<O0QK_PI>AZ#1116IL%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%!.!DT4 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<G\3?&,
MW@+P%>>(+6TCO)+9XE$,C%0V]PO4?6NLJ.>WANH3%=0QS1GJDBA@?P- 'S%_
MPUGJ_P#T*]E_X$O_ (4?\-9ZO_T*]E_X$O\ X5]%7]CX<TK3YK[4K/3;6U@7
M?+--#&J(/4DBO.I?C3\'8IF07-K)M.-R:3(0?I^[H \Z_P"&L]7_ .A7LO\
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M\;?^2:3_ /7U!_Z&*RK?PY>AC7_A2]#T&BBBM38**** "BBB@ HHHH ****
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MW?VB?^>.N?\ @NB_^(KZCT%KQ_#FFOJ>X7K6D1N-ZX;S-@W9'8YS0!?HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH ^)?V@_\ DNWB'_MV_P#2:*OK;X<?
M\DL\*?\ 8%L__1"5\D_M!_\ )=O$/_;M_P"DT5?6WPX_Y)9X4_[ MG_Z(2@#
MI**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]![_ ,DY_P#XBC_A='@'_H/?^2<__P 11[6G_,OO#V]+^9?>=U17"_\ "Z/
M/_0>_P#).?\ ^(H_X71X!_Z#W_DG/_\ $4>UI_S+[P]O2_F7WG=45PO_  NC
MP#_T'O\ R3G_ /B*/^%T> ?^@]_Y)S__ !%'M:?\R^\/;TOYE]YW5%<;8_%O
MP3J6H6]C9:UYMS=2K#"GV28;G8@*,E,#DCK795491E\+N7&<9_"[A1115%!1
M110 4444 %%%% !1110 4444 %%8NNS>(XI8?^$=M[&9"I\TW1((/;&"*ROM
M?Q _Y\-&_P"^G_\ BZRE5Y7:S^XI1N=?17(?:_B!_P ^&C?]]/\ _%T?:_B!
M_P ^&C?]]/\ _%U/ME_*_N#E\S4\7>$-(\;^'9M&U^W\VWDY5UP'A?LZ'LP_
M^L<@D58\/>'M,\+:';Z1H=JMM9VZX5%ZD]V)[D]S7-:AK/CG3-/FO;JPT@0P
MKN<J7)Q]-]26VI>/;JUBN(;#1S',@=<EQP1D?QTO;J]K/[A\IVE%<A]K^('_
M #X:-_WT_P#\71]K^('_ #X:-_WT_P#\73]LOY7]PN7S.OHKD/M?Q _Y\-&_
M[Z?_ .+K:T*7798IO^$B@M(7##RA:DD$=\Y)JHU.9VL_N!QL:M%%%:DA1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1163XE\3:7X0T*76
M-?N&M[&%D6258V?;N8*.%!/4CH* /.?VD]*M-3^%9:YO[>SN+.Z6YMEGD"?:
M&",&C7/5BI8@#DE0*QO '[17@RW\%Z9I_B![C3;VQM8[:11;-)&^Q0H92F>"
M!T(&.1[GK]=A^'OQJTBUTYO$$%Y'#,+B.*SNU28-M*C*$;@,,>HK#_X9A\ ?
MWM6_\"U_^)H TO\ AHOX:_\ 0:F_\ 9O_B:])LKR'4-/M[VU8O!<Q++&Q!&5
M89!P>G!KR3_AF'P!_>U;_P "U_\ B:]:T^QBTS3+6PMMWDVL*0Q[CD[54 9/
MK@4 6**** "BBB@ HHHH **** "BBB@ HHHH **** /B7]H/_DNWB'_MV_\
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M_)R?_P"+H_X4OX!_Z /_ ).3_P#Q==U16WLJ?\J^XZ/84OY5]QPO_"E_ /\
MT ?_ "<G_P#BZ/\ A2_@'_H _P#DY/\ _%UW5%'LJ?\ *ON#V%+^5?<<+_PI
M?P#_ - '_P G)_\ XNC_ (4OX!_Z /\ Y.3_ /Q==U11[*G_ "K[@]A2_E7W
M'"_\*7\ _P#0!_\ )R?_ .+KC_BC\-?"7ASP/+J&C:3]FNEN(D$GVF5^&8 C
M#,1TKVJO/OC;_P DTG_Z^H/_ $,5E5IP5-M)&-:C35.345MV)_\ A2_@'_H
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M_;E_Z5/7N=94$E*:7<PPZ2G-+N%%%%=)V!1110 4444 %%%% !1110 4444
M%%%% !1110!A^-?^1+U3_K@?YBKVA_\ (O:=_P!>L7_H KY^^//QNC,-SX0\
M(SARWR7]]&<A<'F-#Z^I_ 5L? GXV1:]:VOA3Q3,L6J0H(K*Z8X%TH& C?\
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MZL^-O\*@G\*^QE!50"Q8@8+'J??BK-!:*** "BBB@ HHHH \,^)__)PG@_\
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M8?6OH*JFE:9:Z+H]IIFG1^5:V<*PQ)UPJC Y[GCK5NF,**** "BBB@ HHHH
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ME">01R=ISP,Y/. #U>BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
MX7XT?\DBUK_MA_Z/CH^"_P#R2+1?^V__ */DH^-'_)(M:_[8?^CXZ/@O_P D
MBT7_ +;_ /H^2N;_ )B/E^IR?\Q7_;OZG=4445TG6%<AXHT?QO?ZN)O"_B>W
MTNR\H*8)+1)27R<MDJ3Z?E77T5,H\RL3**DK,\W_ .$:^*G_ $/EE_X+HO\
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M6NFZ/K)TB2*Y\V23YOWB;&4H=I''S?I7B_\ PR9J_P#T-%E_X#/_ (U]0T4
M?+W_  R9J_\ T-%E_P" S_XU])Z)8-I7A_3].D<2-:6L<#.HP&*J%S^E7J*
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M 9 X.<] #WJBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH X7XT?\
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MJG_7 _S%7M#_ .1>T[_KUB_] %4?&O\ R)>J?]<#_,5>T/\ Y%[3O^O6+_T
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M<)X&_:YAU?5"T-C-=0W/G'H(I(Q&S_0-OS_NFO?/A[\+/#OPWM9ET2.6:[N
M!->7+!I7&<A1@ !?8#TSG%2^/_AGX=^(]A%!K\,B3V^?(N[=@LL6>H!(((..
MA!_ T >2?M1^+-(OO">C:-IVHVUW<27HO&6WE63:BQLH)P>,F3CUP?2O7/A7
MI,VA_"GP[872LDR62/(C=49_G*GZ;L?A7%>%_P!FKPAX>UJ+4KRYO=7>!@\4
M%UL$08<@LH'S8]"<>H->Q4 >)?\ #*G@C_H*^(/_  (@_P#C-'_#*G@C_H*^
M(/\ P(@_^,U[;10!\$_%+PI8^"/B5JGA[2I;B:TL_)\M[EE:0[X4<Y*@#JQ[
M=*^TOAQ_R2SPI_V!;/\ ]$)7R3^T'_R7;Q#_ -NW_I-%7UM\./\ DEGA3_L"
MV?\ Z(2@#I**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#A?C1_R2+6O^V'_H^.CX
M+_\ )(M%_P"V_P#Z/DH^-'_)(M:_[8?^CXZ/@O\ \DBT7_MO_P"CY*YO^8CY
M?J<G_,5_V[^IW5%%%=)UA1110 4444 %%%% !1110 4444 %%%% !1110!X9
M\3_^3A/!_P#VY?\ I4]>YUX9\3_^3A/!_P#VY?\ I4]>YUS4?CGZG)0_B5/4
M****Z3K"BBB@ HHHH *S/$O_ "*>K?\ 7E-_Z :TZS/$O_(IZM_UY3?^@&HG
M\#&MSF?A-_R*=S_U^O\ ^@)7<UPWPF_Y%.Y_Z_7_ /0$KN:RPW\&)4_B8444
M5T$!161K4^OQ2Q#0;2TG0@^8;ARI![8P:R_MGCG_ *!>E?\ ?YO\:RE42=K/
M[BN4ZNBN4^V>.?\ H%Z5_P!_F_QH^V>.?^@7I7_?YO\ &E[9=G]P<I?\:_\
M(EZI_P!<#_,5>T/_ )%[3O\ KUB_] %<OJL7C75M*N+";3M-2.=-C,DQR/IS
M4MI)XWL[*"V33=+988UC!,S9( QZ^U9^T_><UGMV*MI8[&BN4^V>.?\ H%Z5
M_P!_F_QH^V>.?^@7I7_?YO\ &M/;+L_N)Y3JZ*Y3[9XY_P"@7I7_ '^;_&MC
M19M:ECE.O6UM X(\L6[E@1WSFJC44G:S^X&K&G1116A(5YG\8/\ F#_]M_\
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MZ3K"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#PSXG_\ )PG@_P#[<O\
MTJ>O<Z\,^)__ "<)X/\ ^W+_ -*GKW.N:C\<_4Y*'\2IZA11172=84444 %%
M%% !69XE_P"13U;_ *\IO_0#6G69XE_Y%/5O^O*;_P! -1/X&-;G,_";_D4[
MG_K]?_T!*[FN&^$W_(IW/_7Z_P#Z E=S66&_@Q*G\3"BBBN@@**** "BBB@
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M55_U-_B+_P "_P#ZU2JU1MI0V\S:>78.%.%26(TE>WN/H['H%%>?_P#"JO\
MJ;_$7_@7_P#6H_X55_U-_B+_ ,"__K57M*O\GXF/U7 ?]!/_ )(ST"BO/_\
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M&/AS7M0EL-%URPO[N%"\D%O<*[HH(!) / !('XT ?,7_  GG[0W_ #Y^(/\
MPG$_^,5]3Z#+=S^&]-EU,.+V2TB:X#IL82% 6RN!@YSQCBN8^)'Q0TOX96MA
M/K%E>72WSNB"U"DJ5 )SN(]:ZS3+^/5=(L]0A5DCNX$G17Z@,H8 ^_- %JBB
MB@ HHHH **** "BBB@ HHHH **** "BBB@#XE_:#_P"2[>(?^W;_ -)HJ^MO
MAQ_R2SPI_P!@6S_]$)7R3^T'_P EV\0_]NW_ *315];?#C_DEGA3_L"V?_HA
M* .DHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ."^)7_ "%O!O\
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M444 %%%% !7E_P"T7_R1#5_^NMO_ .CDKU"O+_VB_P#DB&K_ /76W_\ 1R4
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MX-_[#L'_ *$*[VN"^)7_ "%O!O\ V'8/_0A7>UA3_B3^7Y'K8O\ W+#>DO\
MTH****W/)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#A?C1_R2+6O^V'
M_H^.CX+_ /)(M%_[;_\ H^2CXT?\DBUK_MA_Z/CH^"__ "2+1?\ MO\ ^CY*
MYO\ F(^7ZG)_S%?]N_J=U11172=84444 %%%% !1110 4444 %%%% !1110
M4444 >&?$_\ Y.$\'_\ ;E_Z5/7N=>&?$_\ Y.$\'_\ ;E_Z5/7N=<U'XY^I
MR4/XE3U"BBBNDZPHHHH **** "LSQ+_R*>K?]>4W_H!K3K,\2_\ (IZM_P!>
M4W_H!J)_ QK<YGX3?\BG<_\ 7Z__ * E=S7#?";_ )%.Y_Z_7_\ 0$KN:RPW
M\&)4_B84445T$!1110 4444 %%%% !1110 4444 %%%% !7F?Q@_Y@__ &W_
M /:=>F5YG\8/^8/_ -M__:=<F,_@2^7YFE/XD>F4445UF84444 %%%% !111
M0 4444 %%%% !1110 4444 %<A\4?&%UX#^'U[X@T^WAN9[=XE6*?.T[I%4Y
MP0>]=?39(TE0K*BNIZAAD4 ?'GB_]H/4_&WA>[T+6_#FEM;7 &'1I \3CE74
M[N"#^!Z'()%,\(_M&^+?"N@6FC&UT[4;6SB$,#7".)%0<*NY6 ( X'&>G-?8
M/V&T_P"?6'_OV*/L-I_SZP_]^Q0!\N?\-7^)O^@!I/YR?_%5].:'?OJOAW3M
M0F14DN[6*=E7HI9 Q ]N:G^PVG_/K#_W[%3 !5 4  #  [4 +1110 4444 %
M%%% !1110 4444 %%%% !1110!\2_M!_\EV\0_\ ;M_Z315];?#C_DEGA3_L
M"V?_ *(2ODG]H/\ Y+MXA_[=O_2:*OK;X<?\DL\*?]@6S_\ 1"4 =)1110 4
M444 %%%% !7F7QX_Y$6S_P"PDG_HJ6O3:\R^/'_(BV?_ &$D_P#14M<V+_@2
M/;R#_D:4/\1S.C? W^UM"L-2_P"$A\G[9;1S^7]BW;-ZAL9\P9QGKBKO_#/O
M_4S?^2'_ -LKTWP;_P B+H/_ &#;?_T4M;-8PP5!Q3<?Q9Z&(XFS:%:<8U=$
MW]F/?T/&?^&??^IF_P#)#_[91_PS[_U,W_DA_P#;*]FHJ_J.'_E_%_YF'^M.
M<?\ /[_R6/\ \B>,_P##/O\ U,W_ )(?_;*/^&??^IF_\D/_ +97LU%'U'#_
M ,OXO_,/]:<X_P"?W_DL?_D3QG_AGW_J9O\ R0_^V4?\,^_]3-_Y(?\ VRO9
MJ*/J.'_E_%_YA_K3G'_/[_R6/_R)\]^)?A)_PCUWHT']M_:/[4OX[/=]DV>5
MN.-WWSG'IQ]:WO\ AGW_ *F;_P D/_ME=3\2O^0MX-_[#L'_ *$*[VL88.@Y
MR3CM;JST,1Q'FD,+1J1JZRYK^['H[+H>,_\ #/O_ %,W_DA_]LH_X9]_ZF;_
M ,D/_ME>S45M]1P_\OXO_,\__6G./^?W_DL?_D3QG_AGW_J9O_)#_P"V4?\
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M "LSQ+_R*>K?]>4W_H!K3K,\2_\ (IZM_P!>4W_H!J)_ QK<YGX3?\BG<_\
M7Z__ * E=S7#?";_ )%.Y_Z_7_\ 0$KN:RPW\&)4_B84445T$!1110 4444
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M?$__ ).$\'_]N7_I4]>YUS4?CGZG)0_B5/4****Z3K"BBB@ HHHH *S/$O\
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M-%7UM\./^26>%/\ L"V?_HA*^2?V@_\ DNWB'_MV_P#2:*OK;X<?\DL\*?\
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M "2+1?\ MO\ ^CY*YO\ F(^7ZG)_S%?]N_J=U11172=84444 %%%% !1110
M4444 %%%% !1110 4444 >&?$_\ Y.$\'_\ ;E_Z5/7N=>&?$_\ Y.$\'_\
M;E_Z5/7N=<U'XY^IR4/XE3U"BBBNDZPHHHH **** "LSQ+_R*>K?]>4W_H!K
M3K,\2_\ (IZM_P!>4W_H!J)_ QK<YGX3?\BG<_\ 7Z__ * E=S7#?";_ )%.
MY_Z_7_\ 0$KN:RPW\&)4_B84445T$!1110 4444 %%%% !1110 4444 %%%%
M !7F?Q@_Y@__ &W_ /:=>F5YG\8/^8/_ -M__:=<F,_@2^7YFE/XD>F4445U
MF84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% 'Q+^T'_R7;Q#_P!NW_I-%7UM\./^
M26>%/^P+9_\ HA*^2?V@_P#DNWB'_MV_])HJ^MOAQ_R2SPI_V!;/_P!$)0!T
ME%%% !1110 4444 %>9?'C_D1;/_ +"2?^BI:]-KS+X\?\B+9_\ 823_ -%2
MUS8O^!(]O(/^1I0_Q':>#?\ D1=!_P"P;;_^BEK9K&\&_P#(BZ#_ -@VW_\
M12ULUM3^!>AYN+_WBIZO\PHHHJSF.8U;XC>%=#U2;3M4U3R+N @21_9Y6VY
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M?*O9J\9_YNF_S_SY5QXK_EW_ (D?29!_S%_]>9_H>S4445V'S84444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MUZ97F?Q@_P"8/_VW_P#:=<F,_@2^7YFE/XD>F4445UF84444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7
MSO\ '+XB>([OQ]9?#SP1>26<\IBCN);>0I(\LN-L>X<JH4J21_>YX%?1%?*T
M(^T?MJGSB3C46QS_ ';<X_D* *OB2Q^(_P !M4TO5W\2R:K973[9(VGD>%V&
M"8W1_4=&'/!Z=_J/0=8M_$/AW3]8LLB"_MDN(P>JAE!P?<9Q7D/[5:@_"[3&
M(&X:S& ?0>3-_@*[+X(LS_!7PV78L?LS#).>!(P% '>45\2_\-!_$[_H9O\
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M3O\ H9O_ "0MO_C= 'VU17Q+_P -!_$[_H9O_)"V_P#C='_#0?Q._P"AF_\
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M3O\ H9O_ "0MO_C= 'VU17Q+_P -!_$[_H9O_)"V_P#C='_#0?Q._P"AF_\
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MT)OA_P#\%<'_ ,37244 <W_PKCP1_P!";X?_ /!7!_\ $T?\*X\$?]";X?\
M_!7!_P#$UTE% '-_\*X\$?\ 0F^'_P#P5P?_ !-'_"N/!'_0F^'_ /P5P?\
MQ-=)10!S?_"N/!'_ $)OA_\ \%<'_P 31_PKCP1_T)OA_P#\%<'_ ,37244
M<W_PKCP1_P!";X?_ /!7!_\ $T?\*X\$?]";X?\ _!7!_P#$UTE% '-_\*X\
M$?\ 0F^'_P#P5P?_ !-'_"N/!'_0F^'_ /P5P?\ Q-=)10!\-_'+3;'2/C/K
MMCI5G;V-I%]G\NWMHECC3-O&3A5  R23]37U!X!\ ^#[SX;>&KJ\\)Z'/<3:
M3:R2RRZ;"SR,85)9B5R22<DFOFG]H/\ Y+MXA_[=O_2:*OK;X<?\DL\*?]@6
MS_\ 1"4 '_"N/!'_ $)OA_\ \%<'_P 31_PKCP1_T)OA_P#\%<'_ ,37244
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MT)OA_P#\%<'_ ,37244 <W_PKCP1_P!";X?_ /!7!_\ $T?\*X\$?]";X?\
M_!7!_P#$UTE% '-_\*X\$?\ 0F^'_P#P5P?_ !-'_"N/!'_0F^'_ /P5P?\
MQ-=)10!S?_"N/!'_ $)OA_\ \%<'_P 31_PKCP1_T)OA_P#\%<'_ ,37244
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M(_Z$WP__ ."N#_XFNDHH YO_ (5QX(_Z$WP__P""N#_XFC_A7'@C_H3?#_\
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MDYJS10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M68C^)BV57T!7U)/KP^#OPP\)Z;#J=YI,,,>E%;EKVZN9"<ISN?YL-S_#C!Z
M=* /1;.ZCOK&"[A618[B)94$L91P&&1N5@"IYY!&14U?*^N_M.ZN?B'#>Z%
M/^$<M28S92@!KM">78]5;CY<=.^<FOH_PIXKTGQGX>@UG0;D3VTPP0>'B;NC
MCLP]/Q&00: -FBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M5 '"[LD >X/'2NH_:"6#QA\"H=:T&<7EE;W4-^LD/(:,AHR<=>/,Y';!ST-
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MMP >$5?X85_-CGDY)KZ:CC2&)(H46.-%"JBC 4#H .PH 5$6-%2-0JJ,*JC
M ]*6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M *^5?CS9ZGX&^.&G^.+&,M'=&&XC=ON&6$*C1GTRJK]0Q]*^JJPO&/@_2?'/
MAJXT3782]O+\R2(</"X^ZZ'L1^1Y!R"10 SP5XUTCQYX;AUC0YPZ.,30L1YE
MO)W1QV(_48(X-<)^TLFG-\'+DW[(+E;N$V(8C)EW88#_ +9F3\J\HN_@S\4O
MAOX@>]\!7,UY QPMQ8S*C,O998F//T^8=ZT=/^#?Q*^)FMVU[\4M2GL[&W&
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
JHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>img267189834_9.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img267189834_9.jpg
M_]C_X  02D9)1@ ! @$!2@%*  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" /B"%@# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MR\O3\?,/KWCI_P!"GA3I_P Q%?R_K[[[NWOG_#S+]F3_ *&ZV_[[_P#K4?\
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MA3PIT_YB*_E_7WWW=O?/^'F7[,G_ $-UM_WW_P#6H_X>9?LR?]#=;?\ ??\
M]:O _P#ASS\#/[]W_P!_C_C1_P .>?@9_?N_^_Q_QH^J^%O_ $,,^_\ !5+R
M\O3\?,/KWCI_T*>%.G_,17\OZ^^^[M[Y_P /,OV9/^ANMO\ OO\ ^M1_P\R_
M9D_Z&ZV_[[_^M7@?_#GGX&?W[O\ [_'_ !H_X<\_ S^_=_\ ?X_XT?5?"W_H
M89]_X*I>7EZ?CYA]>\=/^A3PIT_YB*_E_7WWW=O?/^'F7[,G_0W6W_??_P!:
MC_AYE^S)_P!#=;?]]_\ UJ\#_P"'//P,_OW?_?X_XT?\.>?@9_?N_P#O\?\
M&CZKX6_]##/O_!5+R\O3\?,/KWCI_P!"GA3I_P Q%?R_K[[[NWOG_#S+]F3_
M *&ZV_[[_P#K4?\ #S+]F3_H;K;_ +[_ /K5X'_PYY^!G]^[_P"_Q_QH_P"'
M//P,_OW?_?X_XT?5?"W_ *&&??\ @JEY>7I^/F'U[QT_Z%/"G3_F(K^7]???
M=V]\_P"'F7[,G_0W6W_??_UJ/^'F7[,G_0W6W_??_P!:O _^'//P,_OW?_?X
M_P"-'_#GGX&?W[O_ +_'_&CZKX6_]##/O_!5+R\O3\?,/KWCI_T*>%.G_,17
M\OZ^^^[M[Y_P\R_9D_Z&ZV_[[_\ K4?\/,OV9/\ H;K;_OO_ .M7@?\ PYY^
M!G]^[_[_ !_QH_X<\_ S^_=_]_C_ (T?5?"W_H89]_X*I>7EZ?CYA]>\=/\
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M[M[Y_P /,OV9/^ANMO\ OO\ ^M1_P\R_9D_Z&ZV_[[_^M7@?_#GGX&?W[O\
M[_'_ !H_X<\_ S^_=_\ ?X_XT?5?"W_H89]_X*I>7EZ?CYA]>\=/^A3PIT_Y
MB*_E_7WWW=O?/^'F7[,G_0W6W_??_P!:C_AYE^S)_P!#=;?]]_\ UJ\#_P"'
M//P,_OW?_?X_XT?\.>?@9_?N_P#O\?\ &CZKX6_]##/O_!5+R\O3\?,/KWCI
M_P!"GA3I_P Q%?R_K[[[NWOG_#S+]F3_ *&ZV_[[_P#K4?\ #S+]F3_H;K;_
M +[_ /K5X'_PYY^!G]^[_P"_Q_QH_P"'//P,_OW?_?X_XT?5?"W_ *&&??\
M@JEY>7I^/F'U[QT_Z%/"G3_F(K^7]???=V]\_P"'F7[,G_0W6W_??_UJ/^'F
M7[,G_0W6W_??_P!:O _^'//P,_OW?_?X_P"-'_#GGX&?W[O_ +_'_&CZKX6_
M]##/O_!5+R\O3\?,/KWCI_T*>%.G_,17\OZ^^^[M[Y_P\R_9D_Z&ZV_[[_\
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M\=/^A3PIT_YB*_E_7WWW=O?/^'F7[,G_ $-UM_WW_P#6H_X>9?LR?]#=;?\
M??\ ]:O _P#ASS\#/[]W_P!_C_C1_P .>?@9_?N_^_Q_QH^J^%O_ $,,^_\
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M7R;BO*LBCAN),5/"T:F K595*4J?(YRDI=4I)I=;Z[G]<%%%%?D!_0H4444
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MO3\?,X/KWCI_T*>%/_"BOY?U^>[M[Y_P\R_9D_Z&ZV_[[_\ K4?\/,OV9/\
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M_P#UJ/\ AYE^S)_T-UM_WW_]:O _^'//P,_OW?\ W^/^-'_#GGX&?W[O_O\
M'_&CZKX6_P#0PS[_ ,%4O+R]/Q\P^O>.G_0IX4Z?\Q%?R_K[[[NWOG_#S+]F
M3_H;K;_OO_ZU'_#S+]F3_H;K;_OO_P"M7@?_  YY^!G]^[_[_'_&C_ASS\#/
M[]W_ -_C_C1]5\+?^AAGW_@JEY>7I^/F'U[QT_Z%/"G3_F(K^7]???=V]\_X
M>9?LR?\ 0W6W_??_ -:C_AYE^S)_T-UM_P!]_P#UJ\#_ .'//P,_OW?_ '^/
M^-'_  YY^!G]^[_[_'_&CZKX6_\ 0PS[_P %4O+R]/Q\P^O>.G_0IX4Z?\Q%
M?R_K[[[NWOG_  \R_9D_Z&ZV_P"^_P#ZU'_#S+]F3_H;K;_OO_ZU>!_\.>?@
M9_?N_P#O\?\ &C_ASS\#/[]W_P!_C_C1]5\+?^AAGW_@JEY>7I^/F'U[QT_Z
M%/"G3_F(K^7]???=V]\_X>9?LR?]#=;?]]__ %J/^'F7[,G_ $-UM_WW_P#6
MKP/_ (<\_ S^_=_]_C_C1_PYY^!G]^[_ ._Q_P :/JOA;_T,,^_\%4O+R]/Q
M\P^O>.G_ $*>%.G_ #$5_+^OOON[>^?\/,OV9/\ H;K;_OO_ .M1_P /,OV9
M/^ANMO\ OO\ ^M7@?_#GGX&?W[O_ +_'_&C_ (<\_ S^_=_]_C_C1]5\+?\
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MT-UM_P!]_P#UJ\#_ .'//P,_OW?_ '^/^-'_  YY^!G]^[_[_'_&CZKX6_\
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M_0IX4Z?\Q%?R_K[[[NWOG_#S+]F3_H;K;_OO_P"M1_P\R_9D_P"ANMO^^_\
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M  \R_9D_Z&ZV_P"^_P#ZU'_#S+]F3_H;K;_OO_ZU>!_\.>?@9_?N_P#O\?\
M&C_ASS\#/[]W_P!_C_C1]5\+?^AAGW_@JEY>7I^/F'U[QT_Z%/"G3_F(K^7]
M???=V]\_X>9?LR?]#=;?]]__ %J/^'F7[,G_ $-UM_WW_P#6KP/_ (<\_ S^
M_=_]_C_C1_PYY^!G]^[_ ._Q_P :/JOA;_T,,^_\%4O+R]/Q\P^O>.G_ $*>
M%.G_ #$5_+^OOON[>^?\/,OV9/\ H;K;_OO_ .M1_P /,OV9/^ANMO\ OO\
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MG'(R#P1_.N<^%?Q%^(6KO=IXTLH[4QE_)_=JF<$XS@8_I[UV4=Q%J*NUK(K
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M_P *<YJ#Y973_P _^ T_F$<%7E9V6KMOMMO]_P#73OZ*X+_A(9_[I_\ '?\
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MK%_/8],696&1W]/\BI:Q$<H<'( !X(/7/7'^>*OQ3\X;N<]O;Z<_I6Q!<HI
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MH4DFXJ-DISFMK:[*R(<G3G&?-*2DXI1M>\II6?-]E*[;TVOO8]<\<>+)]/\
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MK]7?Y6&%*"1TI**8#M[>OZ#_  J16R/<8S4-21]_P_K4RLE=))K_ #6_?^K
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M''XCCTQ@'UI*K!]?ZM^.]M+Z@<C3' P3W'^-;MUI%[9J9)48I[+S_(?RK'+
M@LV00,8Z?GUYR>F?PK1:I/N!28G@ XSQ_*E+ '!S4IV<G.2<XZ]?R_G498 X
M)_0T 1,#QD@_Y^@]:]S^"O\ KKSZ'^8KPPRXZX_(U[I\%CNFO#Z@_P!* />-
M9_Y ^J_]@V^_])9:_DD\-?\ *3+3O^P^G_I6U?UMZS_R!]5_[!M]_P"DLM?R
M2>&O^4F6G?\ 8?3_ -*VK]<\+/X7%_\ V3^)_P#29'\_>.G^\^'7_97X/_TY
M1/ZZ8?\ 51?]<T_]!%25'#_JHO\ KFG_ *"*DK\C/Z CLO1?D%%%% PHHHH
M**** "BBB@#^:S_@OG_QZ_#+_KO;?^E5?JS_ ,$U?^34_ G_ %Q'_HB&ORF_
MX+Y_\>OPR_Z[VW_I57ZL_P#!-7_DU/P)_P!<1_Z(AK]GS[_DT/"G_8SQ7YR/
MYPX5_P"4A./?^Q)@/_3=$^^J***_&#^CR.1]BY]>.N/0?U_#K65-+DXSC(]?
M0Y_PXS5NZD ^4Y]0..Q ^O7^=9%Q<6EK%)<ZC<QV=K$ADDN9F"1JJCDEC@
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M).G&D[>^TEKOM+SWN>;-2QV)6%I5Z=+"RBH5*BE:3J+[%WUOV=[,\_\ AU\
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M9K1ZKY;]3V;[,+<)&'WA44YZ[N,G\Z8ZXY]3C&/;_P"M3@_13DD?+G\:;(P
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M/U)Q3#(@ZRQ?@?\ [+^5?D_H?[5W[1?CF[AMIOAQ?:7;2.%:3[)(F%)P3G8
M,9['/'/-?<'@6#Q=K6F17&LM/9W$B O&S,I5C@XP1D'GT_\ KZPQD:O\&G4G
M_BBX=OYEV>C\NIE4P%2BVJU6E!K?EG&=MK[77Y_Y>^BX0,/WD9R>Q_#U]_\
MZ]:\$N]1TZ?SY_Q_SQ7G=GH%Y"\;R73/SSEB?;N2/7C'Y5V]DKQJ%))/3(SV
MR/Y#%;TY5)7YX<G;6[>WW=58Y9PC"RC453NTFNW_  ?T-6BBBM3,**** /-?
MB1>Z1HNDMKFLRF.TL5\QP#@MMR<8[]O;UKYUO/'6B^/M/BETH^9IK2>3M7YG
MR#M)*]1CIV'7->W_ !AT^UU+1Q:ZDP&G.C?: <;2I)!!S[=NG6OC[PEI.F^"
M_$*SZ#(-4TNYG -BIWK$S,.=O(!!)'(!ZY]:];"4<+/#RG*51XV%Y4(K^$Z:
M^*+?V9MZJ3=E\/77JH.HHM))4I-*;WE>Z5_1=5YV\W[';:7IMC&-+L[GR9+F
M L5W889'<=B/<?E6!X7NK7PQ>ZL9"E_=*7$;2$2&(DY'.#CG^7O7>:IX"N-3
MU"#Q/;W'V8-;\6H?&TLG VC\.#W]J\^TGP3/H'_"37>N7>\:GYGV5W?)BR&V
ME<G@#U_^N:QISI5*5=/$7E.-/G@XMSE-U+2@I)?8C=MK=:=SLY'SPY864+M3
M;TLXQUMTUOH_Q.S77O$%];17>F21O.T@#H7!&W)X R!T&.G3K6'XDT"^\2R6
M\.LPPPVV5>6X(4,I4@G#$\'CZ#Z<5S_AOP3XA2V%SI^JN\/GL^[>Q&PL2%QG
ML,CI^%:WQ!C\1G18[&WED20@)),O;(*L<C\2/\*J"C2Q%.GAZM+F4I)5>64)
MPNE9RUWBOA3OL]-Q-R=-RFI[)\E^:,MK)::=[]CO;&'0[JRM-%M;D2+8A$4H
MV[)'!SCJ,GO@UV,5K';0&W#B.,C&YL*<D8[X'.#7S]\/;:R\&69O-1U0WNH7
M&6\EGW%7..!DYX/7N>!VK0'CR^\8:Q+H4H;3+:+)2[P4#@$D?-P._4_D.E85
ML)5E4JQI3G4I4E[2I6E%QU;7-*,+<TGS/9>J717"JN6'-&TY)1C!--]+)O9:
M7?RU.S\5^!M)\2:=+9W+HD8)F:[B(,H"Y) 9>?7&/IZXK?#P^%XXWT'3)C/+
MIF8WEN^OR;@<%NN<9]*UM&@2P@EA>]-\H# [GW;AG!SWZ?\ Z\G!\>\5RW<>
ML*/#UFVFQLX-Y=1J4W@D!F) [\^W6HHPE74\*ZLY13YZ4[J-.,K+F<HM7;E%
MV44]]+6N5-<O+44(I_"U9<SV:2:NKI]7V/0_BWHB:SIME_9MO%'?6L@>&>%1
MN>13D L.<<#KG_#C]#TCQ?/=V>L^*"\9L8UBMH?F".BC +#IS@$\^IZ@5;T?
MQI$DL>DW$IN6CQ^_8;B'X)P?8X'\N*VG\6:K=ZG'I8MFGL9%V"Y*Y"!N ,X[
M9_G6U-8NC!X?V<)0C&4E4J:3C3DUS^S;V<EO&]^BMK;.T)34N:497C>,=4Y*
MS]Y*[=M==NY5UCPI8ZGJ,/B)]0-K-9E9!!&^U6V\X*CCKV]^>G#M8U*"_@2Y
MO;<7EK H1UD7>BHH(+8(.#@?C^E<1XHMM7T[5!!]H?R[M_W4>XD')R!U]\8]
M_P _8O#FGV9T%[#485,\\."&P3AEQG)P3UZ#'L<BLZ[G2IX><JOM(QLJ35TX
M4W;FY6M=+N[=[-)7Z&T$I.<>7ENW?=WEW:7=_>M=4SY8OC<CQA;Z]I<\D?A2
M#Y+J!&(17'\.SCH3CI6I\2/&B>%_"6K>)8447 @9M)1?]9(Q4[1C().?QQ^9
M[?6/"7]B-<)#^\TRXEWO!U7.[.1QU' [].O(KXK_ &H?B'IGA'5O"NF:E.(]
M#N98$N(VXCC4NJD'.!@9[_XFNO'XJF\'[:E)15.A[&-=V7+&R:<VK+VKDVG-
MW35K-W,\)1E+%0IRCS<U2,G!=6FKJ/\ =:3LEO=WZG)?LY_LT:]\4?B%)\=_
M%+S1RR7S216LJL$5/,)4@-],\>E?LY;JMO9VEDO"VL*QKWX4 =?P->6? R_\
M-ZA\.]-N/"5Q#-IDEM$Y:(H0'* ]%[YS[YY/2O5\#KCGUKXS 8*EA*<YTVYS
MQ4O;5JCES.<I:WOM96TLCV\?BZN*JQA.*C3PZ5*E32453BK637H[]6]%ZE%!
MZ'O2 Y&<8]J[CBBK:)62>M][Z=M/Z0M ;DX)!'7&1_GI12 8).>IS_/_ !H*
M7XK?U..\:>#=&\;Z9<Z9JUI#B6)XTG9%+@D;00Q!.??^5?!/C?\ 8A":??:A
MX:U:Z35&F::VA1G"]247 (XS@>F#Q[?I,RA@,]CD5(LK(ZX]O3MD@=/;UKGK
MX2AB-9Q<9I:5(2<9Q:MRR5FDY1M=7OKZ'30Q=?#KEIS]RZ;IR2E"2OJFFGH^
MJTOW[_C#'\0?B!\ K_3M#^),-Y_9>\1PSA7(*!@%+,?8?EG%?4^D^/D\8V=I
MJ/@2\6Z-PJ?:+>YD!$8< DA23R 2?7/;U^HOBK\(/"7Q=LUM/$5C#-. 1#,Z
MJ"K8."#CC&?_ *XK\]_C5\(]1_9FTJW\2^']6EBT]I-Y@B+,NP,,+M7V';/3
M.:[,#FN.RSV=&K3CB\#2LE7KN\XTI-*3K_SR4]8N-K);L5?"X7,6I4V\/C*C
M:=*G=4Y32T5-?93CJTWOVW/K;3/#5C8"/7+N?.J[1)-&#]UL;FV@'UR,=.._
M6NPT?7],U.9FL"K7\1PXE/(9>.,GKD__ %SS7R#\&OCKX<\?:= U[K$:ZL(P
MK6DL@1Y7.!@*Y!))S7L&K0:I;7MMJ.DP&V$C*[>7DB;H1]TX(/UZ^QKZJF\/
MF475CC(UE**5.K3G'DI[/V4XJ[Y=_1K>QX,X5L+)TYT94Y1=I*<6I3LTG)7Z
MO6_ELFK'TE(ZQ6DU\%5]12,F)1U+@9'3)/0 8/\ *J6A^+M9ATN^U+Q' T<,
M+,(< @E!P.#ST_E7F9\2^(;'3S>RV32%8P55N2Q  Z$]^>,]:9X7^)S^(&DT
MSQ%IPM;,L$PR84AB1U(],?YS7+]0K*E4G[.G5IPG#GE&<74C&+5XTTGK?KII
M?U-(UH.45=Q;3M%Q=FW9)RE>V[TWZV.7\:ZK9^,=2AU72GN1J%@_F6T6'VLR
M-D#T]/7O]:[_ ,#:SXO\2SI9^)@;.&U"K$6)0,B  =2"<X'ZC'IW<.D^&+1X
M);&PA"38*2C83\PR#C))ZG'^%+XD\/3M;QW6F3B&3 8A"!D$<CC^O:B>,HU:
M4,,J:C"*<:-6LE*K1;:;C&W1O5IIN^][@J,HMU%)N4FG.,=%/;76^J[[-=#M
M%U&RMD%O+,FV,! Y888_7/.0, ?SJEKFL6VAZ;-K!\H6D";Y>1EP 3P.,GGG
M'KQSD#R>7PSKVOQ1VRW#P/$59Y=Y7(7!.3GC.#Q],<5S_C^_M(%TCP]/JA9H
M-D=W:[]PN2,*P8#.?;/6L*.$IU*M*/M5-R=ZL(INT(\NNGVIV:CHK:%RJ2C!
MRLDK)1;=O>;22:OLM;][6U.V\-:[IOCUKB_LS]GCC+^6)/D)D!(XR1GD<?A4
MNM:IXVT'39I;%!+L<K"#U* _ETQ]/;MPMW:7MC;Z?_PB=DUNH,;31Q*1D<$M
M@<?-SU'MUXK:G\?Z<NK:?HWB#4/LDA1!)"Y"[I",$'/))/J!R.F>*W=!*:G0
MHJM2DY26'FO:U81IVOS**VEU>B_"\*22Y9OEE=6G%VC)RM:S:V36S5]=234/
M$?C"YTJSCU&'$5_@3Y!VJ&SG=G@8]^H_ 5Z#H;:=X=T+SS+",IYA","2Q&2#
MCG/IWR?>N&UK5X]49M+L9?-M7&R&X7!" ]"&' ZCGVKP'Q(OC_1M0CT[3!-J
MUE-(-Y!9A&C'GIT"@GD].0154L++%P]G%TL--<U1TY?NXU(V3WEHK+1)[VTV
MN$JGL7>SJ:*/-?F:;MLDMN[2_$^E-1\5:AJNF33Z:6(23:"I/W<X/]/Z\9%3
M0:->:KI4-Q,JS7&T$Q2<ACD8R#_D_6O/M$U6?0=,@L]0A\M;E5>>0CA&.-RD
MDY&#VZ_@,5[!H^HZ7J-E"MG?@%0,[6'4 9YZ'D=\_GTXZD9T:<5&'+:H[5$G
M[T5:/Q;;WUO=_BKBXU'K=OE5X2T2=TVUOJK=M]?3BM:\(V%[I4S:A,VG2VR,
MYCMR44A!GHN!SQFN6T+4/#&K>%M1T.6YD6.U\Q3,&_>%EZ<]^AQ^=>C>)[ZS
MM;=[:XD\P7BM"';G.X;<'TY_/'/K7EPT+PYX+M9K[5+A8;;4&+8)R"7.1T)Y
MR<>F1SZUM0DY491J3JJHZU.6%A36CDFN:*TO)]KWVU[!+22<5!<L7[1R;NDU
M'5M:>6G;SU\O.KZIJ<LGA/1"_P#9Z$Q&X<D,PR0"#[^WX=*S+GPGXHT4M!=A
MIM(P)))3DE%."2"<\C/8]O;GW*T\(6%Y#'KFCR+;PRD/"RG'G<CH._I^''%=
M%XGLI%\.)%>M@S@1#('S9&/_ -0Z#Z&N_P#M&G"I"-&E3LY<E55(MUE4TYY.
MRLY[ORU6IDZ,W&[E):<T>79KW6E;MUMU[G,_"?6/ \V=$M7:[U-L;FF&\QO@
M9 /) !Z=*]VUUXO"_A[4-54'_0X&<JF<\J3Q^&?Y"O!?!?AKP_X*E&O7:) 9
M/G\[(SC@Y[=??W]:][BU30_&>F7%I9W"WEO<(RS)D'@C&#CKZ'CMZ5Y&.C36
M)YZ"KRPW-#VDJEI)N\>=1DE9)V:2T?WG11;4;-Q51Q:BEH[75KK?\.W4^2_#
M<\NO:M/XSAM_W?GL)F*_.54G/;ZCWY[UZ/XG\2ZA?:"Z>%H3OC&+A,')P/FX
M].N?88QZ[VBZ)!X7OM4MWMA%H<,4LS_+A.-S$YZ>I[<>N:^>-'^/'AG5/B>_
M@C00ODR7)@F*I\N2Q4@GIU[GD'/7!JJ^/HRJTY5Z:C:4889-\\)4TDHQFEO)
MKKT7<=/#59QG[+WDH\U9KW7!]6G:WSZZVUM;Z!^$&K2ZK"\-S9+#?0G_ $AR
M@!)YR2<9Z_IS7L,^B6-S-]HEA0NI[J#R.1C(]>E1Z9X;L]''VFRC2)[E0[LI
M4%MPR2<=.OX5BP>.=&FUQ_#S7"B_C/S)D9SDY_+FN*O*5>O5GAX348QO**=^
M1*RDV[Z1O:VUKV]:2Y(04Y*[LH[)-65FN[M;:U]'TUO^*[^71=!DO+9"7@4E
M549X R, 9/6O.? WQ3_MV22UU"*6.6,LJ;P1D@[>^"#Z>OO7LEQ;P7<30W$8
MEA8$;6Z$'@_7C_#BN>@\%:#'=K/:V<<# Y9E &3R>P[X[URMQE3A!6C*-1RG
M-J[G"RM%66CNO3Y;:Q:3;:34ERQ2TM+2[WV>J_,X^ZUJ*UU6>YNRQC()@5LA
M<CI@G ['C\*\9UCQWKO_  DAFN!(MBH*P!2=F<$)G'R]< G.:]&US[=K/B:?
M0'L/L^GVRG9>XP#@'D$#KG%>6:Y'>QZBWAZSL6OR6;;<A"Q0C./F].GY=Z][
M T*3J6G"#;PZF[U(VA3DD^:,K64K7O%^]T]>2HY1C+E;^)NUG=RT6SW6UFM/
M,XF2?Q;=:S>:KXF:18BV_0%A)(<Y)3=CC'W?;O7V-\.M0U*^\,I-K;I'=1J-
MJLP#>6OW203D':,].2,?7Q'P9:WMC;Z@WC"U,T5@K&R,HYC R5V[N>./:M:U
MO=1U6-KK2[IA;R/Y/E D!5S@<#ICV&.#6V8<F*7L8PI4H4'34:U-?N[**M&F
MD_=YUK4O=N7DB<->DTW*4E+F;A*_-=M7<M5>RLE:VFY[C?\ B2RM[:9H?G95
M='*_,!U[C/8_H/2M#X36&DI-J.I6+LUQ=G,RMV))/^?7\..&T;2(["P:*[/V
MJ2Y&68G<5+<GWXR1D]S7K/P[TF'3DN7A 42] .W^?\BO(@Z=-580E-<SY4T_
M=J133L^MM&UW:0\=S.C=I+5/S5VE;_,]0HHHH/'"BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH XOXC_\B!XS_P"Q9UK_ -()Z_ED_P"":_\ R>?X
MZ_[&.X_]*VK^IOXC_P#(@>,_^Q9UK_T@GK^63_@FO_R>?XZ_[&.X_P#2MJ_7
MO#__ ))/CW_L!PO_ *7(_GSQ;_Y+WPE_['.-_P#2*!_6?1117Y"?T&%%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% 'RM^V3_R0CQI_V"-0_P#2<U^5
M?_!%CK\4/^PK=?\ HUZ_53]LG_DA'C3_ +!&H?\ I.:_*O\ X(L=?BA_V%;K
M_P!&O7ZCD?\ R;;BO_L-P7_I<#\-XG_Y//P)_P!BW,__ $VC]_:***_+C]R"
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@#SKXD>(=,\/:1%/JC*L,\ODJ
M&. S'''/'(/-<Q9QV$EA;WMI:0QQ74:R1LB*-RD=<@=>?7K57X\^#)O&?ARR
MM8IFA-I>"X)4D%@NTXX^F/Q]N><T[Q)!I.EZ1HEQ@"RMXX&E;.&95 )W'Z _
MIZDZ5J--X:C4I2<L1*I-5J=W:-.+7*[=W:[T>AZ6 G.TX3BE233C+JWO)?+7
MKHKL[![6*:/RW4;6^\!@ @^OX5Y?XF^"7@OQ"9+Z6RMDOT#21S"-?,,O)!W8
MSG/8]>/6O5[=TN85GB;=&_W6 R#^.:<Z\XST(.<>W_UZY,/B<3AZG-0JSI2U
M3Y)6TV:MVMI8]"5*E5]VI",TK-*236RU3LM;[/\ 4\<\&RS>$+*[TFZD<^7N
M2TWGY0HX4+GV Z?@*M:5X[O+/5?LWB8I:V$[E;>ZE(2%%+8!>1L*!ZDGZXQD
M=;KOA5=<4;'\B8,"'&!TY[8ST[Y_&N#^,?PFNOB+\'_$7@31[^33/$U_8RP:
M;K,;%);68QLJ2+(OS#!((VD$=O;LI2PM:JHUYJ*Q%2,*E7K1YG&]5][/WG;=
M*VYC456G3?L8N7LH\T(WTG:UHW]/QZ6.[\>_$/P/\,_"UYXL\1^(-*GT8VS2
M));WD+[OESM4H[ M@#@'K[YKY,^"=A\.OVAO%UW\6O"U[>QOH=P7CAG!$4P1
MLAD_A<$XP0?KZCX,^&O_  3^^-^M:</A+\3_ (I:CK&GV.L-J!N+B]F?S;,2
M&06^7<[E*C;CVQBOV=^'/PT\'?"'PII/@[P=I<.G?V=:0VM_<PJ%-])%'M>5
MF RQ=E+9/X\]/<S#"Y=DE"I0PF8+'XS%)+VU&/+1IX5I-<W,G>51.R2VUOW7
MDX>OB\?6@Z^'5&A1U:GI)U=+62MHG9?-.SL=U-(9W61A@A57 Z?* .?RJ(D#
MK2GH>]1N<12SN-L%NIEG?^XB@EB>F !FOE'=:)7[*^J2LM%N_D>W:Z;Z)=7_
M %T_*Q)1P 7<'RU!+D#. ,&O(K#]I#X"ZKXL_P"%?6'C.VD\:;O+.EM(JN'!
MPPP6Z @\X_7BO*OVD/VN?A_\%=-NM#TJ_CU;QK+'M@T>+]\[2N/E4!0>"3Z=
M.@KT,)E.:8W$T,-0P5>52NE*'-3G&+@W']YS227(KWYKV7F<\L9AJ4)59UH)
M0DXO5/WDKVLG>_EO>QV_C_Q!KMY-<Z1%/%'HTZ/#N#@2C=\OW0<]S]<>E?G+
MXGN[KX.?$JQU60"[TJ]NXVFGD^9X_,<$D$_YP.,=:J>$O'/QC^(S3^-;ZVN;
M O*;B+1&RG[DD.K",XP"N#V]SS7FWCGQ%K?Q"\<:?X8U*UECO5D0+:F-N65C
MCMSR?QZ=.:_4LCR&MEDJM"I/#UZ3HSCBXPFG9V7,DT[/EZ-:?<SY_'XRGB(Q
MJP4X2]HG2NM6O=LUI:SLKK?7HS]Q?!&MV/B;P=I6OV$B207D,1 5@S#Y%SG'
MIT_/GK72')CEB))CG0I*O9E(P01Z$5\6_L_7_BKP);C0]=@F_LR-%$4<@;;"
MI P?FZ8'^.>*^O;?7](NU#QW*$GYF7(R,D\8].W3MUK\MS3"/#8^O&DU.E[5
MRA.#NN1M22>KUCMYO8^APM9U:%*<DHSM:::Y;[*]NJ;^?4^9_C/\)K"RT*^U
MC0)/[.GE<S7"6W[L2$'<^X)M!)[YYZ>U?,7AKP;\/OB6+.SBG2/Q%H[XN&)4
M.[QG!W9Y))&2>WT%?<WQ2N9M3TFYM=,8S&2)T,:Y()*L,< \]SG^E?'GP4^#
MFOZ-XJUS7+B"6U%R\TD9(90Q)9AP>!GMCMCJ37U^48V4<HQ-6OC)4<53Y?J\
MN9*<KV7))/64.735M?+4X,51BL535.C&=.HK58V?*MFI1Z)I]=+GH9^&^L:3
M::K'J@MET"[TZ6T29B-Z*\90."3U&<Y_+&0!P_[)GAGP/\)_%OB+2;+5&UC4
M/$%[+-'YTGFFW,DA(5,Y(QNXQCH.G%>*_M*>/_C=X6N+G3;*RO)] =9$CF2.
M5D &0,$#'0YX/;\*R/V2SJ=A>7'Q \:&:WB@8R^9,KKMPVX*-V.F.<8]^>ON
MO+<35R'%XS$XVA*GC*<%3H8>2E.K5C;D4HW<E--NZ5K];[GG^VH+'4:=.C-U
M*,I-SJIQ4(M)2Y7L]-GT1^QFKZG!I%S%#<!LS[=IP<<\\D#WQ5^.19$25.58
M!E^AY'^>M?&7B+]JGP]J&LVD-[;B/14=4.I;,@("!NW #CJ21QU/3BOIKP[X
MX\,>(M(AU'PY?I?V9@4F16SM?@A>,XZ9Q].U?FV+RG'8*E2J5\-5@JC7OVO#
M7ELF_LR:MH]7J>]1Q5&M)QA)2E%7<=GYZ:-VOOK]UKT/$\^LR:A%;Z;P2V6)
M.%"CKV].>OU-2)<-J*Q:/]JADOG^6=%D#*,#)W88G&,@YXQ[5S'Q-\0SZ=X.
MOM7TTE=34-'$J\L=P**0!R1SGI_,5XY\+/#?B2QT>]\6ZGK$L^HZV)?)B>1L
MVIER%*JW3&?IGJ#DFNG"8&$\)/$5:D:/)-0IQU<IST;=ELDO6P3KN-3V4$YM
MJ[6RBM+/S;?YI)[E6]_:7^#?ACXG/\(9HXV\;1LQ;R K*6R 02.<Y_7/;FO9
M)?$EEJ@FGCFC@\F"22-2=KLZ*64;>.IX'<Y/7I7R9X=_93\-V7Q'UKXP:TR:
MKXJ=9I[=Y'+2%SEU0*2<\@  =\\=J\_L_$'Q+UWXCW>F7.ESZ3IL%PZP*%98
MYHE8CK@+AE'3)."1VKZ>&4Y7BY1678FI.5#"4ZF,J8F=HRKNSJ0HQ>O(MDE=
M]>FGGK%8RE&^)A"/M*LHTH4DVXP;BHRE*W^;?X&GX9_:"_:-\3?&6^\%V&C[
MO 5A=M'<7DZ,$-LCD$B1AMQLR>,_EFNO_::\0^)->L+?PMX9NA!%Y*F[-O(
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MG@?YQBNW 8JEA\;6IUL)C%*<_9TJKI-TW'9/M&^E^]MNIAF&65)X##XC#XO
MSA[+GJT85(JM">CDFMY6^5FOD?5*Z%/( EU:6+*QP1]GCZ9]U_+TS[FLR_\
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M],\UKR^%M'E0RWUZL$A WVZR!4S_ !?+G!R2?_U9KD=;U31_#$7D:7!',[,
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ME4;.JW:4;>]>WVM[=;;#4;-)3LT[Z0M=.W3R_P M[Z\GK.@7/B&WBNXYU6]
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M_P#2<U^5?_!%CK\4/^PK=?\ HUZ_4<C_ .3;<5_]AN"_]+@?AO$__)Y^!/\
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M)XYF;6/"V@0W,Z.6>00*\V0<YR 6S]?7W(KZ*^"TT@\$3>.-91-.U!X2LJW
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MW"MI=I7?9IZ=M-?/7[AU(L4LI8+SL1G./0 Y[#G'\_K3 _/. /Q_^O5FTNA
MTK,!\\+H!V)96 _5NQK)_BFNG=J]GZ=@>STO^OE?IO\ D>"7OQAT";Q+/X4C
ME3[=!(T3H"H8$':01DCKR#U[5U$>GDW<5Y$2TDFUA@X^7TX_7_&O@?XL_#7Q
MKX)^,,7C/3UN)M/U>\#LL89E19)!^ X/4C^=?='A>_O)O#S7+#.HIIOF6\;
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MWRAL'/.<8'/^?>K&FW[0D*^[D<D]R0.G//Y^YKY%TCX\^#Y@]Q<7\#%<M@S
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#B_B/_R('C/_ +%G6O\
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M7?;M=O9;_0&F>(X[J6*)W ,KK$26Q@MP3DGL.O3DXZDU\8?''X_^._AK\?\
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MCD#\*_*:T_9$\>>)-8F\3>/O$,][J=M<M=Q.ERQ5(P^X*<,!C'7(''?O7O\
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MR_Z[VW_I57ZL_P#!-7_DU/P)_P!<1_Z(AK\IO^"^?_'K\,O^N]M_Z55^K/\
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MK*A=6 (PZ!L@YP<8ZU] 6?PC\*:?H=]I-M80HTMG-%$X51M=T95((Z8/YU\
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MOS^_GGA:]"7LWRR;]YR<T[_#HK=7V^X]17['X+GGN=*NXY+O4 2RB0'#.,]
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MY\UK)*UOBU27I97;M^2,\?\ P+6=DUUV]Y:;_P":/9****W/%"BBB@ HHHH
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M.WBN1-5LIM)NRS6=S&\4F.1L==ISQZ9Q^->[^.%G;2PL 8L6(( /MR<=,?\
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M][;9/3JKFY>:?+K7A^]L_$&@0--:Q,(KPP*UQ(1T);;N8GK^8SSQX)X=>_\
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MG*)_73#_ *J+_KFG_H(J2HX?]5%_US3_ -!%25^1G] 1V7HOR"BBB@84444
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ME3G&$/>4GS14MTK+W4]W9O7=_DMB;P_XRO?& USPSJ)70[8*TR1N?+9$()&
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M6UQD/:6RJQY1(5" >R@<=ORJJ=+TQEP+*V4#KMA4<=^W?O\ RJ\. =O//?\
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M.=&2C%R5US2L_=5T[7]='^5CZ1HHHKG/*"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH XOXC_P#(@>,_^Q9UK_T@GK^63_@FO_R>?XZ_[&.X_P#2
MMJ_J;^(__(@>,_\ L6=:_P#2">OY9/\ @FO_ ,GG^.O^QCN/_2MJ_7O#_P#Y
M)/CW_L!PO_I<C^?/%O\ Y+WPE_['.-_](H']9]%%%?D)_084444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 ?*W[9/\ R0CQI_V"-0_])S7Y5_\ !%CK
M\4/^PK=?^C7K]5/VR?\ DA'C3_L$:A_Z3FORK_X(L=?BA_V%;K_T:]?J.1_\
MFVXK_P"PW!?^EP/PWB?_ )//P)_V+<S_ /3:/W]HHHK\N/W(**** "BBB@ H
MHHH **** "BBB@ HHHH **** ,#Q#_QY#@'+$<].@K@P<XQU4;N?]D9KN_$7
M%D#Z,?Y"O/U)X/?'\Q7/52<M6OF[?R_\-\SV< KT'Y3ER^MD^GR/BK]K7X":
M]^TC>^';"&[GM/#VBS0G58(9&C^T11L"X.,;MP!]1QBO7OAMX/\ !OPE\)P>
M&/":?8[2QM(UNVE(!,L4?[QB6QW&2??C@5[J\BQ(^/W8<-O*\9^N/U]?TKRG
M7/#@U#[9'%(R1WD;QNZ$\>8,$G&<=<\<Y.>PKUHYKB,1@J&65*CA@J#YHTHI
M).3DG*4[:2EU5]E9=4*.$I4JTZ].-Z]3E3<]6K:I1;TBN^NO8\*\3?M5:!!X
MC_X0""-;F61BLFI(,Q1$$A@SC*C'3GVSQTS8_P!J'PGX?U$^&!I$=W)*VR?4
M88E*@-M&7<  CG.23SR.AKEO&?[/>BZ1H.KRZ/<1/XDOY)9(KRX.)8BY)PKM
MR#SC'3T')KX#^*WAKXH_#C2H)].MX=4,Q)U">+$TZ(3DD,-Q!"^XY[^GW^1Y
M!P_FE.-/#U)4IR2IOVM25-U*R2?M%T44[I1;WZZGD8O&X[#OGK03L^:+@E)0
MAHN72]W;=ZVZW/UOT>Q\$>(I$US38;22\F F>2*.,LK-\QR5[\D?X8%>@27T
M&E::TXAC*1<;G4-RON>.N/7^5?E1^R/XO^)&J:V+>Z@O!HN0)&N$?Y6(YQN'
M09P.G3!K]89=-MK[0+BVN_E9U?G'4E1MQQUR>W'U'7YOB++)91CU@J^)>(IK
MDY7"?-RTW9\M_)/:_P!]CNP&)CBZ#JPH^SEK]GEBY66O9WT^]ONCRWQ]X;TC
MXEZ5!<WMM;2WEHI-BT42%PZ#*G(Y///'Y]C^/OQ/^)WQ6L_BHGPQU'5FC\-K
M.+>.R,A4^2&VJ ,\?*..#D]>F*_5:WO=7\/S:D$+,EIYILP_W2<<9)^7KCG/
MH#7YQ^/?A/K?C#XFWGQ$U"XAMKNT=IHXRZJA"%F7G..>.<9!]<#/V7!GLJ57
M$TL4Z53#4Z#>$=9<[HUI<O*Z:E>TN[6SL_,\O-5[2%*=.,XUY3M4=.Z4HQMS
M<W?T>Z]=<_QXWAKPEI5EIMYIDCSZA$@:Z9"5#2*/F+XX"DYQGMST%>F_L^?"
M?1;^QOM1BURUECO$=DMO-5F@W L,KDE<9(],XZ'@>2WGB6U\67AT/Q3;(T%D
M?LRW485@JCY-P;MT]1CZ<GNO UKX8\ F\;P_JU[=37P/EVZN[(A;L%!(&#QC
M XQW%?68Q8JGET\.JM6.)JR4W)+VM*<;IQL_L63U7X6/-H>SE7C6M!TX6CR-
M\DXO1NZ5^9M]=++7JS<\6_#R>QUB6T:ZWV&]CN+Y0#/IG SV'J..E>B>!?A]
MX9ATZ34=9OK>WTF$?OQ.Z@'N0-Q[@?[/%9'AZWU?Q;<&ROH[A(_,\P32JP)4
MG."Q'OUZ'FO3M<^$)\2^%+KP];7UQ;;XF^>)F4D@=\$=P,?CZ5\SC\PJT<-"
ME5Q?+4BXJ<J<;Z:)RT;N[+3>VIZ-&A3G.4H4;WORN3MT5D]+6UZ[^1T?A30?
MA[JUV#X6EM+B.)Q@Q[& *]LC/!QC].>^_P"+?!%E9H=8AM@98%+AM@P,#...
M,< \Y_,U\7^ ]#\1_ SQ";6^U&0Z69B3+>2[05+\'<[#M[C//N*[[XL^/?C#
M>6"ZCX,C2^\-RQ_O)82) %(YY!(]2._0^]?(X?,5CLS^KX;,(R<7RR>)GR-I
MM-\U_P":^FO?J>K6PDJ&#]K4P[2DERNG"ZOI\+\GHO)7/%/%OBZYO?BAI_\
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M^%?B*S\0IXFU6&^C:WF\X/(9-B_,&.[</ICCDYQ[?JMX]M=)TG3I+FXM8)Y
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M7T&'XHPN(A.6.R_!XBM&ZISJPC)0C)I)0ALTD]=M>M[GG5<L=*<8TZM6$/\
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M"B_9A\%^!?(^)[>--5U+1M+(O;RP:YFDCEC7]X4,>]@1U&"#QD8P#7R\>'L
MJ5-XG'5J<ZEE0IT:3K4ZTM/<Y[JSE+W4]-]#TJF.Q4I_N:<?9QLZCFU&45HG
M)IK5):V5K;-K8ZOXC^(_&_Q4UM-:$SZ7X+LKHF.PF)03)&^ 51L JP'&!W..
M]?9OP;UNQU;P];6EO&MN;" 1CC9YNP;<XXSG&<=#7Y8_%7]J#P[\66@\-_!^
MTELI=*/V2XC1/+$DD1"$LH4$EL'U'/)]/0_AG^V)X,^"6E0Z3\5;._.LL@2(
MVL,C*6/0L5&.2>_\N*]O,N',PJY-0IT,&X5:;3IX*'^\*#>M2<;WFVGK)V\T
M<F%S+#T\5.4JKE":_>5Y)^S;TT3^PNR2[[,_83P^CFXR%.-V?PQC)KT4=!]!
M7P/\'OVE;7XSZI;OX!MIX[$R*+CST(8(>^&'H>>_!Z8(K[VB+F.,R</L7?\
M[V!G]:_/L3@<1@)^QQ4/957JZ;?OQT7Q+I?H==>M3K5'*E+FC96:V=TK6?4?
M1117.8A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% &;K/\ R!]5_P"P;??^DLM?R2>&O^4F6G?]A]/_ $K:OZV]9_Y
M^J_]@V^_])9:_DD\-?\ *3+3O^P^G_I6U?KGA9_"XO\ ^R?Q/_I,C^?O'3_>
M?#K_ +*_!_\ IRB?UTP_ZJ+_ *YI_P"@BI*CA_U47_7-/_014E?D9_0$=EZ+
M\@HHHH&%%%% !1110 4444 ?S6?\%\_^/7X9?]=[;_TJK]6?^":O_)J?@3_K
MB/\ T1#7Y3?\%\_^/7X9?]=[;_TJK]6?^":O_)J?@3_KB/\ T1#7[/GW_)H>
M%/\ L9XK\Y'\X<*_\I"<>_\ 8DP'_INB??5%%%?C!_1X4444 %%%% !1110
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M#Z>P 'T'2BIOV;Z?A_ET%>UUH_.WY7_4D$KC)#=>O _S^'3VJ-\R*5<[AVR
M<'U%%%(TB[Z>6JLK=%_7EZ%#[!&Q/FXD7.0I'IV/K4S6ENX56C#*GW01D#'3
M_)JS2D$ 'UIMM[MOU*222Z=][=->O](8BA%"*,*.U2+]X?C_ "--IR@$@'_/
M%(KOM^/X?\$<YZ8/KG!^G6FKC/..G?\ #UIS)QD<8SGK35 )Y]/\* N[6Z7N
M2%01C 'OBF;3SDGY>F>_T_*GD-G@@#_/L:7MSSQS^7/I1L&]E>WKY_\ #$7(
M (;\,].OO_3O28/3!SZ8I0-Q..._/I^M2G ^8CD?Y_K75%MQ3TVU[OEM?O;R
MM;\$<[5FUV =!GT&<_3O3"P!. /J/_U4X$-GK[Y]Z85RQ XQ_P#6_P :J]U%
M]4]5?I=;W\[?\&PA.H))Y'&#U_G[TT=1VI2"#@T@ZC/3O4J]_=?71/>VG1=/
MT5^@"D<D#GZ4F#UQQZU*"H&X \\?YY]JC##_ %?=N1_G'M2:ULEUM\]NOF E
M%*1@XI*$[/6^EO+9K1_=]X!1112 ****+O3R=UZ_T@"BBB@ P!T&***;DD\<
M8/.>_P!.OH?2LW9J_IS/6RM;IU 7@<\#W_\ KT84'H ?PS00#UHP,Y[BH[ZO
M^K6ZZ?II8!:***&FEY=_EW_K6_8 HHHI#6CZKY?/;0EAFDMV+1-L)ZD?YX_#
M\*S=8U:\MH3*JF8G 88!X)P>,'_/2KM-=%D4HX#*>H(IQLFKJZ3VV+?O+2R=
MHWE;6[M:WY/33H<7J/@[PGXTL"VMZ/!<74BMMD>-2T9/N5Z@^G\A7EUW^SCX
M=F8C3Q'9-OW;DPN01G&1Z].^<5]!QQ)$,(NT>@J7)'0D5+C%2;C[K;3YHMPD
MVFFKN+3=FMVS2,Y<J7,VM6HMMI='9-Z7ZVM?\OD+Q7^S NKVS6]GJ#0D(<,K
MX)?:?FR#USWSTYKTC]E7X2^)?AA/KEOK&IS7]I,7%JLCLRH-W&-Q/IV[>F*]
MUW'U/YFNV\-G,3\ >X'-7*+Q&*IXBM4JSJP2C&\Y.+6WO1O9NU];:F.*KSIX
M*M0@H<E647+W5S*S3TE:^O77LCJ:***[CYT**** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@#B_B/\ \B!XS_[%G6O_ $@GK^63_@FO_P GG^.O^QCN
M/_2MJ_J;^(__ "('C/\ [%G6O_2">OY9/^":_P#R>?XZ_P"QCN/_ $K:OU[P
M_P#^23X]_P"P'"_^ER/Y\\6_^2]\)?\ L<XW_P!(H']9]%%%?D)_084444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 ?*W[9/_)"/&G_ &"-0_\ 2<U^
M5?\ P18Z_%#_ +"MU_Z->OU4_;)_Y(1XT_[!&H?^DYK\J_\ @BQU^*'_ &%;
MK_T:]?J.1_\ )MN*_P#L-P7_ *7 _#>)_P#D\_ G_8MS/_TVC]_:***_+C]R
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#G_ !'_ ,>(_P!X_P A7GR]
M!]!_*O0?$?\ QXC_ 'C_ "%>?+T'T'\JYZD>:6^W^2/:R_\ @/\ Z^2_])B0
MW<(N;=X 0C.N ^<$'N?\_P LU1M=/6PLW29Q*?O!S@GG_([_ (U>FCDD*A&V
M]CSCK^'^?RI)HG:!X6.2RE4/<$@X/Y^E--I**=E=7NK[?=_5SH;]ZZWV6[3Z
M/UZ:^O4_.3]JS4?B5>R?V9X%MKA)'.!<VZOD=LY3WSSVQZ"O+/@9X*\=1.!\
M69);NUD.3%>9*N#@XQ)['IC^8-?II:>&9/[3>:\2&9&&5$B!SWZ9!]NWUX!K
MY]^,7ACQ?>:@#IL+)9QLN! FP8&">% &./R_"OO<JS]?4X9/3I8:A%QO/&MV
MK7TVENG?=W7JCQ<5@I2KSQ<Y5:B7P44O=MIHTG:2[]MNB1W?A?0?!VDRJ_AV
MPMK2, $K$B*"PP<G: 2/?IV%>F^8)X_+VX4\=.@X/],<^OX5\_\ PT\.^(H9
MT>]>3R5 +*Y)Y &1SC_ZWMP:^B(A&BA&49'4_@/H/UKYS,DHXB25=XF44K3E
M*4Y;J]VWK=]/R/0PS<Z=Y4_9:KEA:RTLKV27;T>FAQOB+P;#K&G7$4<HMY)4
M*B4$ @D')SZ_Y]*_,O\ :B\%:[X2\*S-HNNSB[<R;FB9BQ!+ #Y3Z''7GC&>
M_P"IWB6YFM](NKFVRQA1FV+C+%58D#![XP/J:^4?!GB[P'\4_$VL^#O&>EF!
M[!)F\RX3AMF?[W!Z9_#/T]_AC'8O U'C/9O$X7"SA4KT8J,I.$FOLN[:5ULF
MOR.+,*5*K3]CS1HU:BY:51MI-NVFFG1W;W^\^ ?@)HVB7O@34W\3SB?6V1BD
MEP/WN_L?FYSD@GG^9KM?"*:'X9U%KR\MTO(HG=]K#<% 8D=0>G';'/2NO\=Z
M1X*TSQ#JD?A9TM[#3[B2%XHV"JX5B.%!QVQG%<%I-YI#B^-ZZK'(KB(,0,\=
ML^O^/J:_47BGCXXC$<E6G2Q/)-4/>BX*22Y%;9V>MDM+>I\W"#HN$/W;G3DT
MZBM>5K>\[][;Z^5STB\_:&LXM8MK'1=$2)))$@:1(P,88#J%'ZGZ]S7U?X9\
M3B2&Q:1%1[R)7?..-PY!S_4G^E? 7A32=*N];.U4QYQ,1(!*DL-IR>PSG\#S
MTQ])Z?X4\237-K]CUE&VE1%"LF"J]0,#IQCMG-?+YQE6"IRIQIJ5!>S<INK*
M4N9Z6MJ[6[/177F>GAL55FG*7OR<HQ7(HKE6E[Z=FO/]>U^,O[/L/QU@@L;7
MQ#_8,JA0\T<@C)/!Z@CJ<_\ UN:[[X9_LT2?#_PE%X2NO$K:Y   9))/,R .
M1EF;KTP3W[=:HQ._A_[##JVIBWN790Q=]N[IZD#M[<UZU9^(ULUMVCN//C<*
M-X8L,''0YYZCKVZ=J_-<3E%*E7>,H0DJM6Z]JN91DHV5T]M]FNY]'#'UYTHX
M:I4O1IV:ARKW6]FWOL]NEOFF6/PET_0[5ET]%AEDX)55&X'(/3'4GUYS[TVS
M^#_AA9C?SZ-!+J+9+731HSDY/))'8C/7G^?IUAKMM<F'>PRRCJ/SSUXS_D\
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M_G[QT_WGPZ_[*_!_^G*)_73#_JHO^N:?^@BI*CA_U47_ %S3_P!!%25^1G]
M1V7HOR"BBB@84444 %%%% !1110!_-9_P7S_ ./7X9?]=[;_ -*J_5G_ ()J
M_P#)J?@3_KB/_1$-?E-_P7S_ ./7X9?]=[;_ -*J_5G_ ()J_P#)J?@3_KB/
M_1$-?L^??\FAX4_[&>*_.1_.'"O_ "D)Q[_V),!_Z;HGWU1117XP?T>%%%%
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MVX_'%1[&]/U'^-.0'!ZC(&#^?(IXXXSDC\Z8N_X_>OUL0A2>@_E4H!P01CC
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M#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^"'[/_A3X,R7<VC11"2Y+LQ3!Y=MQ/3&.IZ?T(^ERW%9/0RC&QQ="5;-'/\
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MEBOK%%JE.5N:G&25M7HTKINWG?HCA@W*=+V4U1]G)<Z3]V;35VUK^%[ZG?\
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M-J/LVK\JLT[WUVW7<^EPSC0M))5KP2?M%M+W>BU_X&[/G[X(ZK\1K^22+Q?
M\5HA^4NK <8_O#.,Y''X<U]&ZB_EP2M%DJ 0N.3R,<8_'\*9"L,:[(4"+UP
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M!_-9_P %\_\ CU^&7_7>V_\ 2JOU9_X)J_\ )J?@3_KB/_1$-?E-_P %\_\
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M<6!VYSQU]^F::22<F@DD >E ]7_P7_F3+C QT_\ KTU6SP<DDG_&HP">E+D
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MK:OZF_B/_P B!XS_ .Q9UK_T@GK^63_@FO\ \GG^.O\ L8[C_P!*VK]>\/\
M_DD^/?\ L!PO_I<C^?/%O_DO?"7_ +'.-_\ 2*!_6?1117Y"?T&%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 9NL_\@?5?^P;??\
MI++7\DGAK_E)EIW_ &'T_P#2MJ_K;UG_ ) ^J_\ 8-OO_266OY)/#7_*3+3O
M^P^G_I6U?KGA9_"XO_[)_$_^DR/Y^\=/]Y\.O^ROP?\ Z<HG]=,/^JB_ZYI_
MZ"*DJ.'_ %47_7-/_014E?D9_0$=EZ+\@HHHH&%%%% !1110 4444 ?S6?\
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MWHK7 ****7Z )DY(QQZ^O2EHI#G''6@!2,@CU&*0#  ]*0MM SR?;_(H# G
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M3_R0CQI_V"-0_P#2<U^5?_!%CK\4/^PK=?\ HUZ_53]LG_DA'C3_ +!&H?\
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MQ]^U!^U1J?CZV^'Z_"J]G\*7L@2_UPVDC1VZL<,Q?9MX!)R3C'>OLWQ7XE^
MOP-TX>./AU#!K^I2P^9+9P,MPWFE02FQ=W.<C&/UZ^=^%O\ @H%H/B:*ZTGQ
M%X*MO"L=V_EC4]1L(X1AV"EEED08R/0],9]]\!&IS5,5A\BJ9M&+Y:=7,*CA
MB:,KJ\HQ3O)0WBDM;+U)KN$N2C6QRPLVTY1PT4Z51:>ZY/1<VTG?T-_]FOQ!
M<:+X^M=-U'?;S33(3&5P \C*6&<=CD8[8[=:_:VW8/;PN.C11L/H5!KX@^!W
MA#X8^(UL_&%M]GU"XN6$]O=V^QD+-M88*YSR<]>Y]>?N*-51$1.$555?]T
M?I[5\!Q3F$,PS'G5&5"I1BZ-6$E9<\>5.VBVL[W2.JE0>'CR\RE&5I0:=URM
M+Y?</HHHKYDU"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** ,W6?^0/JO_8-OO\ TEEK^23PU_RDRT[_ +#Z?^E;5_6W
MK/\ R!]5_P"P;??^DLM?R2>&O^4F6G?]A]/_ $K:OUSPL_A<7_\ 9/XG_P!)
MD?S]XZ?[SX=?]E?@_P#TY1/ZZ8?]5%_US3_T$5)4</\ JHO^N:?^@BI*_(S^
M@([+T7Y!1110,**** "BBB@ HHHH _FL_P""^?\ QZ_#+_KO;?\ I57ZL_\
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MV26S=NCL[;/3_A]MR^"#TI:KPD\<GJ>,^W3]*L4.U]'="7Q+5^\KWZ]_T\]
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M+O**5VW=;=VK7_SZ_,[$K_UOZ>9+C!&0<5X!\9M!O];O-+DLLLD$B&2,?=8
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M&>*_.1_.'"O_ "D)Q[_V),!_Z;HGWU1117XP?T>%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &#KO%L3_ +/]
M'KSP$G<3_>(Z?C7H>N\6Y/L/R^;/Z9KSXONSZ;OY#'KZ5#M=IW5FG?=/2.C7
M4]3!7]E*W\W]=';^D!)/6@D<8'/?/<_K245*C?I;U6M]+^325[?/0[ HHHH2
M3U6EGKITTNUV>[TNUTZ!_7Y?E;0****I)-*RVZ2\];VZOMMN 4A(! ]:6D/
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ML#67LZD,5SJ-%<SE"4$U[\GTE))OE>SO;N?;M%%%=Q\Z%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!Q?Q'_ .1 \9_]BSK7_I!/7\LG_!-?_D\_
MQU_V,=Q_Z5M7]3?Q'_Y$#QG_ -BSK7_I!/7\LG_!-?\ Y//\=?\ 8QW'_I6U
M?KWA_P#\DGQ[_P!@.%_]+D?SYXM_\E[X2_\ 8YQO_I% _K/HHHK\A/Z#"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MG;=;7U;$L5BIU%7G4Y$ES./M+.3T=N73?TT[GZ>_#+QFFM6=O!)*'RJ[7##
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MA1B0#D'\\U^L8#+ZN4X9PQJPE7$SH\\*_-:-.G>"]I5YO^7:NKI/G:U2VO\
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M=;VJM_*OD[+3_A_R%HHHIG&%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 9NL_\@?5?^P;??^DLM?R2>&O^4F6G?]A]
M/_2MJ_K;UG_D#ZK_ -@V^_\ 266OY)/#7_*3+3O^P^G_ *5M7ZYX6?PN+_\
MLG\3_P"DR/Y^\=/]Y\.O^ROP?_IRB?UTP_ZJ+_KFG_H(J2HX?]5%_P!<T_\
M014E?D9_0$=EZ+\@HHHH&%%%% !1110 4444 ?S6?\%\_P#CU^&7_7>V_P#2
MJOU9_P"":O\ R:GX$_ZXC_T1#7Y3?\%\_P#CU^&7_7>V_P#2JOU9_P"":O\
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MBQTGPM#='3='N%,4T"OY<@1CP[+P0<8(//-?=7PY^)NA^.M$U+PGK.LMI7Q
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M_P#8;@O_ $N!^&\3_P#)Y^!/^Q;F?_IM'[^T445^7'[D%%%% !1110 4444
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M+#QY?:TZE-TE&3?2\F[7]Y/1+M=Z'L&B>$O"?QEUB#XF>!]-FT#7[&5)K^4
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MY$WJ[*UE?78\?$4H4JC4%9/5KI=I7?S%HHHK P"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,W6?\ D#ZK_P!@V^_]
M)9:_DD\-?\I,M._[#Z?^E;5_6WK/_('U7_L&WW_I++7\DGAK_E)EIW_8?3_T
MK:OUSPL_A<7_ /9/XG_TF1_/WCI_O/AU_P!E?@__ $Y1/ZZ8?]5%_P!<T_\
M014E1P_ZJ+_KFG_H(J2OR,_H".R]%^04444#"BBB@ HHHH **** /YK/^"^?
M_'K\,O\ KO;?^E5?JS_P35_Y-3\"?]<1_P"B(:_*;_@OG_QZ_#+_ *[VW_I5
M7ZL_\$U?^34_ G_7$?\ HB&OV?/O^30\*?\ 8SQ7YR/YPX5_Y2$X]_[$F _]
M-T3[ZHHHK\8/Z/"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@#E/%WABR\4Z7-I]U"KF1"$=A]S/'7GZUX7!\
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M&%-TYUHJT>?F<VDV[22U>C6NYR8FI6K8/ZNE3YW&TV[J+=[JRCT[[7\S\/\
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M]81^G^%+_8]@/^6(_3_XFCV?G^'_  0>.HO[$U\UMI_P?2W71'F_F+Z'\O\
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M_P!-T3[ZHHHK\8/Z/"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#EC^![?I0JTNJU>W3MOOY_?]R>!IZ:R[W3>JT\KJV[_X8]$&LPGD./R% UJ
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M9)+JXPFV6J***R/0"BBB@ HHHH **** .<\613W&@:C!;+OFEMW1%/0Y4_\
MUO;UK\(/V@+K4/"FN:FJPE=4DDG(55(7))QTP/KTQ[]#^_\ (@D1D./F4CD9
MZU^7'[6WPG2;4)]8%MN0[W\U4R>=QZCV!_IVK]?\(<ZPV79S6PN)@G#&4G%-
M2Y9\Z:4;-NUENXV;?W(_D#Z7/!F*X@X6RS.,&ZCGE&+BZ\>7VE!T)N[C4IQ7
M-[S5E*_*NJV/Y^?BCJ^M:LMW;^(5E2WEWLKH"2I.XCG\1Z=\5\_> /$&G:+J
MUS8ZWJ-W)H[.RK%)(Y 4L1@#J" >W?GUS]>?&W[;INMK86^EF[MB6$C&(L%
MX))QV],\?EGY;L/".G:KXFC<0AH_,!N8=ORQX;)!P, =<U_7,9PE3HU8U'*G
M&,>1Z2O>R5]_>6S?3SM<_P ]<MCRX3%T*^&CAG5BY2C3Y8NDX]8J5W3<DM+]
M6M3V/P/#X<LO%:ZQHL=U+I\[9RZ,4!)ZYP1T/.?7\*^[?!TVDF]L+F*X<7+R
MQ,(MQVJ-P.".@QDY''\\_,6B>*- T1K;PQ9:'"ZLBH+H1 L),8SD#CD>N.>>
MU?>?[/7P7O/&6J6<LL#I;S21R*^T@*F0<#C Z]^">E>3GN.H8'!XG$XRK3P^
M'ITN9S;7M)W5U;6[OH[:/\CERK*\;G^<Y;E^ PF,Q6,Q->%##P<N:$Z?-%)U
M915H);RD[66K[G['?L[ZM97_ (-M(H WGQ0H)"<XX SC('?TSCGIS7T+7GWP
M[\#V/@C0[73[55WK"@D<#DG Z]OR_,UZ#7\)Y[B</C,VQV)PKG*A6KSG!STD
MTWVZ+LNQ_M%X?Y;F.4<'Y%EN:TZ-''83 T:-6E0=Z<.6"48IW=Y)?$[ZN["B
MBBO)/L0HHHH **** "BBB@ HHHH **** "BBB@#Y6_;)_P"2$>-/^P1J'_I.
M:_*O_@BQU^*'_85NO_1KU^JG[9/_ "0CQI_V"-0_])S7Y5_\$6.OQ0_["MU_
MZ->OU'(_^3;<5_\ 8;@O_2X'X;Q/_P GGX$_[%N9_P#IM'[^T445^7'[D%%%
M% !1110 4444 %%%% !1110 4444 %%%% &3K%Y+96WFQ<MDC^1S_G^5<B/$
ME\0#@\@?YZ5TGB/_ (\1_O'^0KSY>@^@_E64I-2=GV_1_P!?=L>EA*5*5)RG
M3C)\[5WV7*[?,WO^$DOO0_Y_"C_A)+[T/^?PK"HJ>:7=_P!?\-^?=G5["A_S
MZAT_3_)_>S=_X22^]#_G\*/^$DOO0_Y_"L*BCFEW?]?\-^?=A["A_P ^H=/T
M_P G][-W_A)+[T/^?PH_X22^]#_G\*PJ*.:7=_U_PWY]V'L*'_/J'3]/\G][
M-W_A)+[T/^?PH_X22^]#_G\*PJ*.:7=_U_PWY]V'L*'_ #ZAT_3_ "?WLW?^
M$DOO0_Y_"C_A)+[T/^?PK"HHYI=W_7_#?GW8>PH?\^H=/T_R?WLW?^$DOO0_
MY_"C_A)+[T/^?PK"HHYI=W_7_#?GW8>PH?\ /J'3]/\ )_>S=_X22^]#_G\*
M/^$DO1U!'Y?X5A4QWRNW@X.<_GT.??THYY;)W^?33_@:==>[NO84/^?4?N]/
M\G]_W[__  DM[_G'^%+_ ,))?>A_S^%<Z,;A@Y'_ -8^PJ4D#J0/K4^T:M>3
MU2>W33_*[^?S%AZ-U^Z@_*V^W^7]79N_\))?>A_S^%'_  DE]Z'_ #^%8.1U
MR,>N:"0 2.<>]$9R>[=_3=::]NW]/5^PH?\ /J'_  UO\G]_W[W_  DE]Z'_
M #^%'_"27WH?\_A7/>9ZC [G/3]*7>G7<,>M4Y2Z/7S^7^7]78>PH?\ /J'3
M]/\ )_>SH/\ A)+[T/\ G\*/^$DOO0_Y_"L)6'!'(_\ K?\ UZ4G))]3FDI3
MTN]+:O\ O::?=;[_ ##V%#_GU'TMVY=?G9_?]^Y_PDE]Z'_/X4?\))?>A_S^
M%85%/FEW?]?\-^?=A["A_P ^H=/T_P G][-W_A)+[T/^?PH_X22^]#_G\*PJ
M*.:7=_U_PWY]V'L*'_/J'3]/\G][-W_A)+[T/^?PH_X22^]#_G\*PJ*.:7=_
MU_PWY]V'L*'_ #ZAT_3_ "?WLW?^$DOO0_Y_"C_A)+[T/^?PK"HHYI=W_7_#
M?GW8>PH?\^H=/T_R?WLW?^$DOO0_Y_"C_A)+[T/^?PK"HHYI=W_7_#?GW8>P
MH?\ /J'3]/\ )_>S=_X22^]#_G\*/^$DOO0_Y_"L*BCFEW?]?\-^?=A["A_S
MZAT_3_)_>S=_X22^]#_G\*/^$DOO0_Y_"L*BCFEW?]?\-^?=A["A_P ^H=/T
M_P G][-W_A)+[T/^?PH_X22^]#_G\*PJ*.:7=_U_PWY]V'L*'_/J'3]/\G][
M-W_A)+[^Z?K_ )&/TI?^$EOO[O\ .L&BCFEW?]?\-^?=A["A_P ^8?CY?Y?C
MZWW?^$DOO[I^O^1C]*/^$DOO0_Y_"L10">3CCZ?SI5(QM/0G.<]/\XH<I6W?
M]?\ #?U=A["AI^ZAI^.V_P!WX^M]K_A)+[T/^?PH_P"$DOO0_P"?PK#/4X]:
M2A2DDKR;?]?U_P .P]A0T?LH>:MM:WWWL_O];[O_  DE]Z'_ #^%'_"27WH?
M\_A6%2@X(/H<T<TN[_K_ (;\^[%["A_SZC_5O\G]_P!^Y_PDE]Z'_/X4A\2W
MP[<^F0/YBL?S/;]?_K54)8N 5(R.N#QU_P ]:5Y:^\^EO)=?O'["@[6I05M[
M]=N_I^?F=$/$U]D?+W_O#^@IW_"2WHY(_/I_C^M8(4#' X[X_6FR<+SZ_P"-
M-.5TN;=K>_\ GW_#34(T*%]:47>RV]/O_4UY_%UU#U';MSS[Y_SZUR&J?$?5
MK=C]G3(Y[?D,>^/P]:J:PY\LE.2 #Q[_ .?R->?W4X8GS!M52V2P]OI[FNRA
M3YFKN_=/7M?Y;_B[Z$5*%!7M3BMK:/RZ_H_/S.LN?BKXBBA9UC&0#SC(Z<8]
M\_\ ZZYZ/XS^*2S!HAQP,J,_E@_Y]LUS-]>6XB;RG#+CJ.0,?3MV/I^>.4MY
M%FG)P -_Z$X'7Z?_ %J]*-&E9-4HNUE=[W5G=W[_ .9DZ-.Z_=Q2MKIZ6^_?
MT_'U*;XS>*5C8I"N_'&1WY/3I6?%\:/&ACE9XE!0$CY0?I^73TYKE6MX0H+M
M@$=SZCZ_S_PKBM=\06FDJZB52"-K<CC_  _/C'<UTT,-2JSC3A1C*3DNCO9-
M75O.VOG;J14A1BN9P4=.566C;MK+[M.WWLY;Q[^V)X]\*7KPI GEJ^TY4<]>
M0#C\OUKRKQ)^W#\8;?33J>F6\1A4%B0JXQ[CCH?\<]17.?$?P_IGBF&;43<(
MJ1EG8AU/(^;/!'OQWKYEUB=6TR\TG3I//C13&Y!+;<<'G/MVP.AQ7Z9E&3Y)
M7HT)5,MH3JPE&-:,Z3V7+S7UUT;Z>NC/FZ\J\)33G^[=W3E&7O-Z:6U>GX'N
M'A/_ (*/?&37]=&C#3/,<2B-FCB# '(!Z#_ZW7T-?;7@[]H+XM^()8?M-JD$
M;1>;(70*% 7<1GC/&,^G\_A']FCX<:#9ROK5W9Q75P\V2S!6()))(SD\=^>V
M#7VUKMG=P6;KX?B,<\R%$6,8VJRD$?+C&,G/;KUKSN(Z>00QDL'@,KPN'<%R
MU*O*TDTE=QUW2]-C? 0KNFZM:<JL4_=BGO'1+I?775?\$]L^%/[1_P#PGOC*
M\\%N%;4=.<I<E<8!#8/W>.O'_P"NOL$9P,]<#/U[U^;?[-?PCF\&^,KWQ9J&
MY]2U65FDSR078'/.3G)[X[_2OTD!R ?4 _G7YOFM+"T<4Z>$=Z:C&\ELYV7-
M;R3.Q<[C%U(J$FV^5*S47K&]^MFO^"+1117F %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 9NL_P#('U7_ +!M]_Z2
MRU_))X:_Y29:=_V'T_\ 2MJ_K;UG_D#ZK_V#;[_TEEK^23PU_P I,M._[#Z?
M^E;5^N>%G\+B_P#[)_$_^DR/Y^\=/]Y\.O\ LK\'_P"G*)_73#_JHO\ KFG_
M *"*DJ.'_51?]<T_]!%25^1G] 1V7HOR"BBB@84444 %%%% !1110!_-9_P7
MS_X]?AE_UWMO_2JOU9_X)J_\FI^!/^N(_P#1$-?E-_P7S_X]?AE_UWMO_2JO
MU9_X)J_\FI^!/^N(_P#1$-?L^??\FAX4_P"QGBOSD?SAPK_RD)Q[_P!B3 ?^
MFZ)]]4445^,']'A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110!SWB XM\XSQCZ<G_/TS7GFPGJ>>_>O1/$!Q;X
M]1_+->>KW^N3]2 36%1OF6ZT[;]KO6R^7?4]7!:TI62TEKJ_)?UTU^8*N.N,
MYX-)D'=\H^7GZXS[>U..#\I[]N?\]J,C!QU&:BZT=G=Z:I]7]W7?[KG6M=+>
M7Y;?E]X Y&<8HP,Y[BD4DC)[]NW7\_UI00>E._=K2R[Z;*_G_P .#3O:]K;I
M]?+_ "]0Y&23D=>G3_&D+< XZG'IZ_7TIQY!'K4>-A)YQT'3/8_T-));OW;]
M+V5_E;L/2WG^%O\ ,DJ(L ?N]"><^_7W_&F\J?0T[>QXXYX_/\:%'YWZW=^F
MFFZT[_(:MU6V^ZOMMYK\5OW%8Y4'W_QI#S]T''< <9_#CTI-S+QZ=OU[4[E3
MM7G///\ D>E"26RZ/TOIOYZ*WS$E=Z;7Z]O.VWFP"L!GC!&2.^/3IUIIV\8!
M'KG_ /6:=][.[C;Z?KZ^E'"C<O.>.?\ (]*3:>DDUTZVN[-*ZZ_AN596U:4M
M$M=-E9_=UV%R&7DXSP?P/]:0QD<X)7//^'^'J<UR7Q DU=/#DC>'@6U/=\@7
MJ>W4=O7]*\VT37?'5@FFP:Y$^^X*ASM/ ;_)'X>F:ZJ6%E5H>WA.DK3E!TG)
M>T?*DW*SL[6V>M[=3)S49J+BVK7;2=K/;6UUKOMV[GNA'&X=#T'?_/'K1G)!
M;G_/X5&@?RXV?&YT#'\1S4@(VD=R?\/\*Y?*^[LKZ:)V:NNK_K4M^3W5K7[:
M:^O07(!& 0.X]1^9]Z4A6'RX!ZX/M[#/M3!C!SP1T]_KU_I2J<'VZ&AK=J]U
MM_>V>O5]OP*:271;:W;N]-=MDK[ 000#R<<8R>*>@(SGOC_)I"?XQSC@YS_G
MO0&8GVR,].GX\TM)+2RUMJ]MM%N[?<)W3U5[:;77E^?4<5.20<9]L_YZ4Q3A
M3S@Y]B>W8T.#DGL?\*;@XSV%-QV;=EI=6]-&^OJ]@2U\K7=GTTO_ ,%$V-P'
MN.I'J.M1,"..PZ<?Y]^]'+  #[O^>Y]J7('RO@ ?7K]0?>I2LOLO;2R>[6JZ
MOTT6OWR(#DC=_AZ_2G84@X'W0?\ ZQZ\^V:?PP//'^3WIF6.5 &!QGVZ?Y_E
M35];7YDDK/M==+*R_P"'\QZJVC6_K?3TT[>KU')]T?Y[FD"8[\]CCI^&<4JK
M@>_>E QGW.:G5-ZV=K]-7I?R\[ K:[[=.CTU]-QH!).[G!X.,?YZ#UI  SMD
M?Y&!4E)D9QW%%[[:/2\KV[7NNUQI-:K?16[WM]RU6ORZD/RE2",D_ECCWJ(I
MC)!]3CVJT,,=W/''^?SHV G//7-%]=K._3>VFBV_I_?6S25ULK:.[T;^=FM?
MQ*6#@'L?_K_X4E7MB_\ UL_Y/ZTPQ%#@<]_\Y/M2MOK:VMG^*]?EK85TFTMF
MXV[6TO>_?\?0J@9.!3E0C.[YLGCKQDC]!S5D)UW#TQS1L.T'OW'^>/UH]+:6
MOWOWOHTN^NE_,=VM%K=7ZOLM[JRM^FU](A&N1GC/?)]_?VJ41CN 1V^G^<=Z
M41CC)(]?\@&GD;0/3''N!_GVIJ[MJ^:W6_EJO7KY7&V[KJGK;^MEU^^X =@/
MZTA!)&#@=_>DR2 5'7U_'WI3G!QU[?Y-*W31:O>WDM?TMYV(79W_  :6UK^7
M=>2TT#(SCVS^O2EIJC'/<]?K3F*JH/.<X(_/_/6C=[WV7;R_X!HDET23M9WO
M=Z6_X'I<3/S!<=1G/Y_X4O6DR,@=S_\ 7_PI1U&>G>C3II9?>_T$KIZ)/FLU
M9:[QT[)6\_F  ' I,_,%QU&<_G_A3CC/&<>_6F%@#@YH6O=WVZ:OU_'8%9-7
M3;:6MKZJRW\MV_QZ$@( .1G(X]NM-QBBBE;\%^=O^!<')65M=59)V\UM^7<#
MGL<>_6@9[G/OTHYR.F._K[8IF WS#.1P.G4<C^=*_O;.]OD]OD]^PWKV:NM.
MO3=]+7N]/G9CZ0]#SCW- SCGKW_,XZ<=Z0_,IQS3;5]>_3>U]6E_P!6U7:VM
MGH[62OW7Y]K ISD'MW]<DTUP.O?CC\#_ /6_R:?@<>W2C R3W/\ ];_"FM-K
MW_+YZO\ (I-WU5DGI=Z-W[;_ ->@$ ]1GG_ZU=MX: $;X]OT'%<*Q.,-G.<Y
MXQC'MWKN/"Y_=R=>B]O08_SWK2B]4N]M'TUCKZ[I_B<>/_@/UC_Z5'];_@=;
M11176>(%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Q?Q'_Y$#QG
M_P!BSK7_ *03U_+)_P $U_\ D\_QU_V,=Q_Z5M7]3?Q'_P"1 \9_]BSK7_I!
M/7\LG_!-?_D\_P =?]C'<?\ I6U?KWA__P DGQ[_ -@.%_\ 2Y'\^>+?_)>^
M$O\ V.<;_P"D4#^L^BBBOR$_H,**** "N.\6^+[/PK:R7-WPJQD@D@ '&?4>
MW?\ I78U\5?M.^+H[.%M+\SRE>-@6)V\X_/KCH?>O?X:RAYWG&%R^S<:LO?:
M=FHIJ[\_3J?F_BOQK_J!P7F?$<7%5L-&$*$9)/GJU'RQCKMWONK'D'Q,_:0O
MYY+^ULKK9:@.% ; VC(]1Z_IQQS7RN_[0#Z.TLSWC+([,3NE())/Z>OIVZ$5
M\[>/?$5\+R<6=P'AC9PWS EAWZ9_3\*^0_%'B/7#J;SW<YCT[)" N!R3CD'G
M!^N/4>O]A91P7D.5X6C0CA:4'.,'*4X+]Y)**?,WK=ZN[V?F?Y&9WX@\=<:Y
MGB\SQ^?8R?-.JZ-.A6G%X>C.2DJ-*">BC'W7;L[^?ZA:;\=]0URZ$GF3&,D%
M90YV@CWR>G'' QR.<"OIWX2_M ZCHMV%U:Z,MF2 J.Y(QG&.6Z]"?Q.:_#2T
M^(?B+2=)S87$#6Y(4-O7>,GCOGL1CGZ=:][^%_Q UF_>P_MAG1;AD$1.<-\P
MQ@\]1GDY)_.M<ZX'R;,L'6PSP]"BG#F32CS1M%:QNKJ^J\M]3/A?Q XSX/SG
M#YUA,SQ-:-&<:/L_;U%"I&+BTZD6[-Q=W-/25G<_IH\(>*;3Q=I,6JV8VQ2@
M8'U&21[9KJJ^3OV:O'VB7_A^U\.QR_\ $Q1$8J6R3\OU[Y'3D\5]8U_&.?Y9
M/*,VQF!E2J4H4JTE1C4OS2I7]R2;W36SZG^P_AUQ12XPX/R3/(XW"XZOBL'2
MEC:N$:=.GB^5.K1E%:0J0;M*&MN^H4445XY]P%%%% !1136=%^\ZK_O,!_,T
MFU%7DTEW;27WL!U<MXJ\(Z/XLTZXL-4M4F62*1$8@$JS*0#R.<''<5TPDC;[
MKHWT93_(TPW$ .TS1[O3>,_SI1QT,'4IUXXJGAZD9)TZCK1IOFNK<LG)7;=M
M%OL<^,P&'S'#5L'C,-#$X:O!PJT:U-5(3C)-:QDFGH]'TW1^)G[1?[)^H17.
MH3Z1IS3++)(T3I'NV(23@$ XXYZ<#FOB72/V8[BQNF863KJ$SGS8]IWN23D+
MP3R2>GKG%?TR^*=9\,:=8R2:Z]F\+ @I+Y9<@C&>?F'7\>_'-?/ZV_P7GU2'
M5U%N)E<.L8\O82#DYYP0<8''MS7Z7AOI)Y+PS365<0Y]E6!QD*$)T(UL13=6
M:5ES2IN6BJ:>\]F^:]F?R?Q']#*.>XY9KPQ1S*K@,5C)RS"C^\A!1FT^6E5B
MG=46^:,-FDHOR_&CPS^R7KEIK-GJVIZ9/#:W,R+$)8R-I9A@\CCJ,'WS@U^V
M'P"^#=IX"\.6CW:1RW$T$4D7 W(I&0#W'&/YCUKS+XJ?M!?#6UDLO#EI9++=
M0S+Y3PQ1[8]A 7!C48'RY)8GU.,U[?X)^+.BWOA^TFG? 2! BKC(55'RMUZ
MC^6.]?BV>?2NX+XDS''\.XKC3)*3PTGBJE3ZY"%%0=FL.ZKM%.DK7UM+I?<_
M>N$OHE4_#EY=Q2\BS&I5KX6EA<)]:HVBY124\5&GK?VVFDMN6_9'N2J% 4=
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ML_\ !-7_ )-3\"?]<1_Z(AK]GS[_ )-#PI_V,\5^<C^<.%?^4A./?^Q)@/\
MTW1/OJBBBOQ@_H\**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** .>\0?\>X^A_]FKST,<$@9R>GX#VKT+Q!_P >
MX^A_]FKST, "<8!/0?0?3TK&H[/;71)7M?7_ ()ZN!_AO6R<K?E^6X8R0S<8
MXP?\\=>F*:,@GC@GKCC&?RQC\*>!QM8Y)]^<?S[4UFQP,CJ.1U'3BLU?KO\
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MN*_^PW!?^EP/PWB?_D\_ G_8MS/_ --H_?VBBBORX_<@HHHH **** "BBB@
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M!M]_Z2RU_))X:_Y29:=_V'T_]*VK]<\+/X7%_P#V3^)_])D?S]XZ?[SX=?\
M97X/_P!.43^NF'_51?\ 7-/_ $$5)4</^JB_ZYI_Z"*DK\C/Z CLO1?D%%%%
M PHHHH **** "BBB@#^:S_@OG_QZ_#+_ *[VW_I57ZL_\$U?^34_ G_7$?\
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M[2]*7))WM4J5+76NC2O;1.RT1_6W\,O /PIO=,M?$/AZVM(M5FA$YV1QAPQ
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MUH86<$XJ3;Y*ETY)-VO%ZZ_AU/EQ?B-XQ^(]K=:+#:3Z7/"&43A6B1@,@ $
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MY?";0]'L;V2VM[K5/)C99P$)#E0=V>>A.?PZBG_&+QXGP5EWI?H-/N1B&(N
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M9].W->?CL/B,1%TZ%3DDXZ.W-9WM=K\+]/N1VX*I2HS7M(J6JOK9M-KF5_\
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MS\0H/%5O9ZOOET^0J9) AVX()).!UZ?Y%?0J6P\URPW*@&T8X)(!/7GJ.?\
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MA5^R!\8?"OB:[TK7-,U&(6UP\EK=,DJ@["=KAB!GDCISU]J_9?\ 91U+XE^
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M6'-6H8&O-8F<XJ7^S3]DXU(7LTHMZ:,\.-[X<T728()RFHZI=JOEJP#-&&&
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MO 7QZN_ WPOM&$8N)(EM81EE&_:#M7_/Y@5_DQPIQ5E'BGQ/B,NR]X_ RP^
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M]NNG_![^:%O=C&*3MHK*]ETT]7MU.,A%_HE\;2W=[A9"5!Y(^8GH>G?/?I[
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M3O\ L/I_Z5M7ZYX6?PN+_P#LG\3_ .DR/Y^\=/\ >?#K_LK\'_Z<HG]=,/\
MJHO^N:?^@BI*CA_U47_7-/\ T$5)7Y&?T!'9>B_(****!A1110 4444 %%%%
M '\UG_!?/_CU^&7_ %WMO_2JOU9_X)J_\FI^!/\ KB/_ $1#7Y3?\%\_^/7X
M9?\ 7>V_]*J_5G_@FK_R:GX$_P"N(_\ 1$-?L^??\FAX4_[&>*_.1_.'"O\
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MH+>[D#K&#S@X."#UZ_T]\>*>#OVJ?A]XKUFY73-7:_@E=AY;9*KN.,8/'?/
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MWMM+QG0;9<(?, !/W^F#QSVYQP:]+M=6T*VT\7_V*WDO#;F&WO4",ZY4JIW
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MHPZ%'/YER[7%RK )$QSDY!R!QCGD=OSKZE\-?"SPWXFT*1-9UE;2^-H["$R
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M['>6DL4\*7,IDW*CALDD\' QT'?MWYKDO#G@GQ;)]FL=52\%O9OF$@/B7!!
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MW:W-K( 4N8)8'!Y&V6-D.1Z8:OY4_P!LW0;/]E+]MCPM\3S$8=.O]6LY99$
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M@Y.?Q.>/3P/P3XP^('@*_>"6.;4]/C?RXVDWLJI^9'Y?AZ#W*+QS=ZW)'<W
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M%?A/Q9=_&3XT1QIXVFF::WC*C 5B6& .!@,.WU& :^L?A3X+M-+AM%MHXQ+
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MSS[]OPYQ6-##T;+V]6HDU?W%=Q>GQ*VZVWW%*<T[TXIV=O>T35TE]Z5V^A]
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M(-+O(3IUAPIC*A%5!@<*<#IV_KST2W2Z_:A=HNK9!M++AER,\<>W\Z\K\/\
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MVU\3^%IKB!?/CEFMK?<J$[LD%5P/7J.W."1C])OV>C<CPTBW@9;@1(KAQ@Y
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M>N,?X/\ PI'Q,CU9[.*:R:U,T41N4:/,D98 _,.>0<?AQUK8TS]G:PLKJ_\
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M0<\#N<5<T'X8>%[T:ZWBV[EF+F>;3RSEPJ?,4 Z@#'H>_>OD:;Q#%HWB[5]
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MK5)U:L)1G)*@Y-.7)-/279/?;H?I1^S1\6]/T?P%IFD:A:1V<-LA50R^6RX
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M5_M1X#<>8GC[P^RO,,QHSHYK@(1RW,.:'LXU*V'A&,:M-7?NS@HN_5WZW/\
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MJ4Y1G"<5*$XM2C*,E=2BUHTUJFMPHHHI%!1110 4444 %%%% !1110 4444
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MJT<HXIH8OB'@CGY,KX@P\)UL5EM)M<N'QT5S2E3I0U<W=**?O=#^O^BOR_\
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M649#!%(7'?OD=B?UZ_C6K:^#=/N59&1!E<G( Q[?D?KU_#W9OA^VTA95&?\
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M_O#U],_ISUKZ^3[B_P"ZO\A7D7AOX9_V%?B\\Y6^;)P1_($?G^G KUX#  ]
M!^5>9BIPJ5+P=U97>N]EIKV_.YA6J*I.ZVMU%HHHKF,@HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#-UG_ ) ^J_\
M8-OO_266OY)/#7_*3+3O^P^G_I6U?UMZS_R!]5_[!M]_Z2RU_))X:_Y29:=_
MV'T_]*VK]<\+/X7%_P#V3^)_])D?S]XZ?[SX=?\ 97X/_P!.43^NF'_51?\
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M9T_Z$?2__ 6+_P")H_M;PQ_Z)_-?_"J/E_P?Q\@60>-FG_&69#T_YE\_[O\
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MO!G_ $+>K?\ @-)_\31_P^2\&?\ 0MZM_P" TG_Q-?H-_P ,'?LZ?]"/I?\
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M3_P%D_\ B:/^'RG@S_H6M4_\!9/_ (FOT$_X8._9T_Z$?2__  %B_P#B:/\
MA@[]G3_H1]+_ / 6+_XFC^UO#+_HG\VZ?\QB_N_Y?GY L@\;-/\ C+,AZ?\
M,OG_ '?[WDK^C/S[_P"'RG@S_H6M4_\  63_ .)H_P"'RG@S_H6M4_\  63_
M .)K]!/^&#OV=/\ H1]+_P# 6+_XFC_A@[]G3_H1]+_\!8O_ (FC^UO#+_HG
M\VZ?\QB_N_Y?GY L@\;-/^,LR'I_S+Y_W?[WDK^C/S[_ .'RG@W_ *%K5/\
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M^??_  ^4\&?]"UJG_@+)_P#$T?\ #Y3P9_T+6J?^ LG_ ,37Z"?\,'?LZ?\
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M_0CZ7_X"Q?\ Q-']K>&7_1/YMT_YC%_=_P OS\@60>-FG_&69#T_YE\_[O\
M>\E?T9^??_#Y3P9_T+6J?^ LG_Q-'_#Y3P9_T+6J?^ LG_Q-?H)_PP=^SI_T
M(^E_^ L7_P 31_PP=^SI_P!"/I?_ ("Q?_$T?VKX8_\ 1/YMTWQ:Z6_R_/N@
M60>-FG_&69#T_P"9?/\ N_WO)7]&?GW_ ,/E/!G_ $+6J?\ @+)_\31_P^4\
M&?\ 0M:I_P" LG_Q-?H)_P ,'?LZ?]"/I?\ X"Q?_$T?\,'?LZ?]"/I?_@+%
M_P#$T?VKX8_]$_FW3?%KI;_+\^Z!9!XV:?\ &69#T_YE\_[O][R5_1GY]_\
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M^?/_  ^2\&?]"WJW_@-)_P#$T?\ #Y+P9_T+>K?^ TG_ ,37Z#?\,'?LZ?\
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MZ?\ ,OG_ '?[WDK^C/SY_P"'R7@S_H6]6_\  :3_ .)H_P"'R7@S_H6]6_\
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MB!GL,CG\Q7SC^W%XRT+4_ACK4$]O:W%REG.8BH#SY\M@,<$[N!W)ZGZX.M^
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MP_\ \31R>#_\W$'3[7IY>3^]B]I](7^7A'I_RZEY?WO)_>P_X?,?LN>NJ_\
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M_P"'S'[+GKJO_?:?_&:/^'S'[+GKJO\ WVG_ ,9H_P"'0'P"_P"?:T_[\/\
M_$T?\.@/@%_S[6G_ 'X?_P")HY/!_P#FX@Z?:]/+R?WL/:?2%_EX1Z?\NI>7
M][R?WL/^'S'[+GKJO_?:?_&:/^'S'[+GKJO_ 'VG_P 9H_X= ? +_GVM/^_#
M_P#Q-'_#H#X!?\^UI_WX?_XFCD\'_P";B#I]KT\O)_>P]I](7^7A'I_RZEY?
MWO)_>P_X?,?LN>NJ_P#?:?\ QFC_ (?,?LN>NJ_]]I_\9H_X= ? +_GVM/\
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MCD\'_P";B#I]KT\O)_>P]I](7^7A'I_RZEY?WO)_>P_X?,?LN>NJ_P#?:?\
MQFC_ (?,?LN>NJ_]]I_\9H_X= ? +_GVM/\ OP__ ,31_P .@/@%_P ^UI_W
MX?\ ^)HY/!_^;B#I]KT\O)_>P]I](7^7A'I_RZEY?WO)_>P_X?,?LN>NJ_\
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M_P"'S'[+GKJO_?:?_&:/^'S'[+GKJO\ WVG_ ,9H_P"'0'P"_P"?:T_[\/\
M_$T?\.@/@%_S[6G_ 'X?_P")HY/!_P#FX@Z?:]/+R?WL/:?2%_EX1Z?\NI>7
M][R?WL/^'S'[+GKJO_?:?_&:/^'S'[+GKJO_ 'VG_P 9H_X= ? +_GVM/^_#
M_P#Q-'_#H#X!?\^UI_WX?_XFCD\'_P";B#I]KT\O)_>P]I](7^7A'I_RZEY?
MWO)_>P_X?,?LN>NJ_P#?:?\ QFC_ (?,?LN>NJ_]]I_\9H_X= ? +_GVM/\
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MCD\'_P";B#I]KT\O)_>P]I](7^7A'I_RZEY?WO)_>P_X?,?LN>NJ_P#?:?\
MQFC_ (?,?LN>NJ_]]I_\9H_X= ? +_GVM/\ OP__ ,31_P .@/@%_P ^UI_W
MX?\ ^)HY/!_^;B#I]KT\O)_>P]I](7^7A'I_RZEY?WO)_>P_X?,?LN>NJ_\
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M_P"'S'[+GKJO_?:?_&:/^'S'[+GKJO\ WVG_ ,9H_P"'0'P"_P"?:T_[\/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M8N*5G-VO):MRZG['@:-3+L,G)NI5E6DU4JQ46G.SYU':R;25]+>9SOB7P?\
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MI--V:=FNJNK'N?A3]F'XA^(/ ":AH=U<:4EK"+HQAVC+B)0V>V1\O.1W_/\
M2_\ X)S?%WQ+J;:K\+_$<S7%QX=$D0D8L3F+Y<DGKP/?GV%>!^!/C]:Q>&[+
M0F,*SW-JMN%BP 3(H4G"D>V>/\:^V/V/OA!I_A#4-?\ B$7C$FM)+,V""0)<
M$Y[GJ3S@]_:OM_H6YOQGF?C-/*L6\-@/[.KUYXKZORT7C,ME#]QA)133Q$87
M4K/:=VM;G\.^,^:3CPQQ?0XIP^$G.IB(RR*I"*J5,/B(U%[2<:[UC%TD[WM;
M9[6/T.K&U77]*T:,R7]W%#C^%G ;\<].AKYL\=_M#V'AR_U"R@D3]S'((V+
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MPF+4 UP2JR6X<8). 1MSU].N1VZ54N+M=1TH>$[>3_21'AI<]">#CL,9.?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M1_;7AQ_T2>;_ /AUI_\ R'K_ $M3_5OQA_Z+OA_I_P R.KTY?[_]W\3\P/\
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M_P!W\3\P/^'QG@?_ *$O7_\ P"?_ .(H_P"'QG@?_H2]?_\  )__ (BOT_\
M^&9?@#_T2CP?_P""[_[91_PS+\ ?^B4>#_\ P7?_ &RC^VO#C_HD\W_\.M/_
M .0]?Z6I_JWXP_\ 1=\/]/\ F1U>G+_?_N_B?F!_P^,\#_\ 0EZ__P" 3_\
MQ%'_  ^,\#_]"7K_ /X!/_\ $5^G_P#PS+\ ?^B4>#__  7?_;*/^&9?@#_T
M2CP?_P""[_[91_;7AQ_T2>;_ /AUI_\ R'K_ $M3_5OQA_Z+OA_I_P R.KTY
M?[_]W\3\P/\ A\9X'_Z$O7__  "?_P"(H_X?&>!_^A+U_P#\ G_^(K]/_P#A
MF7X _P#1*/!__@N_^V4?\,R_ '_HE'@__P %W_VRC^VO#C_HD\W_ /#K3_\
MD/7^EJ?ZM^,/_1=\/]/^9'5Z<O\ ?_N_B?F!_P /C/ __0EZ_P#^ 3__ !%'
M_#XSP/\ ]"7K_P#X!/\ _$5^G_\ PS+\ ?\ HE'@_P#\%W_VRC_AF7X _P#1
M*/!__@N_^V4?VUX<?]$GF_\ X=:?_P AZ_TM3_5OQA_Z+OA_I_S(ZO3E_O\
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MA_I_S(ZO3E_O_P!W\3\P/^'QG@?_ *$O7_\ P"?_ .(H_P"'QG@?_H2]?_\
M )__ (BOT_\ ^&9?@#_T2CP?_P""[_[91_PS+\ ?^B4>#_\ P7?_ &RC^VO#
MC_HD\W_\.M/_ .0]?Z6I_JWXP_\ 1=\/]/\ F1U>G+_?_N_B?F!_P^,\#_\
M0EZ__P" 3_\ Q%'_  ^,\#_]"7K_ /X!/_\ $5^G_P#PS+\ ?^B4>#__  7?
M_;*/^&9?@#_T2CP?_P""[_[91_;7AQ_T2>;_ /AUI_\ R'K_ $M3_5OQA_Z+
MOA_I_P R.KTY?[_]W\3\P/\ A\9X'_Z$O7__  "?_P"(H_X?&>!_^A+U_P#\
M G_^(K]/_P#AF7X _P#1*/!__@N_^V4?\,R_ '_HE'@__P %W_VRC^VO#C_H
MD\W_ /#K3_\ D/7^EJ?ZM^,/_1=\/]/^9'5Z<O\ ?_N_B?F!_P /C/ __0EZ
M_P#^ 3__ !%'_#XSP/\ ]"7K_P#X!/\ _$5^G_\ PS+\ ?\ HE'@_P#\%W_V
MRC_AF7X _P#1*/!__@N_^V4?VUX<?]$GF_\ X=:?_P AZ_TM3_5OQA_Z+OA_
MI_S(ZO3E_O\ ]W\3\P/^'QG@?_H2]?\ _ )__B*/^'QG@?\ Z$O7_P#P"?\
M^(K]/_\ AF7X _\ 1*/!_P#X+O\ [91_PS+\ ?\ HE'@_P#\%W_VRC^VO#C_
M *)/-_\ PZT__D/7^EJ?ZM^,/_1=\/\ 3_F1U>G+_?\ [OXGY@?\/C/ _P#T
M)>O_ /@$_P#\11_P^,\#_P#0EZ__ . 3_P#Q%?I__P ,R_ '_HE'@_\ \%W_
M -LH_P"&9?@#_P!$H\'_ /@N_P#ME']M>''_ $2>;_\ AUI__(>O]+4_U;\8
M?^B[X?Z?\R.KTY?[_P#=_$_,#_A\9X'_ .A+U_\ \ G_ /B*/^'QG@?_ *$O
M7_\ P"?_ .(K]/\ _AF7X _]$H\'_P#@N_\ ME'_  S+\ ?^B4>#_P#P7?\
MVRC^VO#C_HD\W_\ #K3_ /D/7^EJ?ZM^,/\ T7?#_3_F1U>G+_?_ +OXGY@?
M\/C/ _\ T)>O_P#@$_\ \11_P^,\#_\ 0EZ__P" 3_\ Q%?I_P#\,R_ '_HE
M'@__ ,%W_P!LH_X9E^ /_1*/!_\ X+O_ +91_;7AQ_T2>;_^'6G_ /(>O]+4
M_P!6_&'_ *+OA_I_S(ZO3E_O_P!W\3\P/^'QG@?_ *$O7_\ P"?_ .(H_P"'
MQG@?_H2]?_\  )__ (BOT_\ ^&9?@#_T2CP?_P""[_[91_PS+\ ?^B4>#_\
MP7?_ &RC^VO#C_HD\W_\.M/_ .0]?Z6I_JWXP_\ 1=\/]/\ F1U>G+_?_N_B
M?F!_P^,\#_\ 0EZ__P" 3_\ Q%'_  ^,\#_]"7K_ /X!/_\ $5^G_P#PS+\
M?^B4>#__  7?_;*/^&9?@#_T2CP?_P""[_[91_;7AQ_T2>;_ /AUI_\ R'K_
M $M3_5OQA_Z+OA_I_P R.KTY?[_]W\3\P/\ A\9X'_Z$O7__  "?_P"(H_X?
M&>!_^A+U_P#\ G_^(K]/_P#AF7X _P#1*/!__@N_^V4?\,R_ '_HE'@__P %
MW_VRC^VO#C_HD\W_ /#K3_\ D/7^EJ?ZM^,/_1=\/]/^9'5Z<O\ ?_N_B?F!
M_P /C/ __0EZ_P#^ 3__ !%'_#XSP/\ ]"7K_P#X!/\ _$5^G_\ PS+\ ?\
MHE'@_P#\%W_VRC_AF7X _P#1*/!__@N_^V4?VUX<?]$GF_\ X=:?_P AZ_TM
M3_5OQA_Z+OA_I_S(ZO3E_O\ ]W\3\P/^'QG@?_H2]?\ _ )__B*/^'QG@?\
MZ$O7_P#P"?\ ^(K]/_\ AF7X _\ 1*/!_P#X+O\ [91_PS+\ ?\ HE'@_P#\
M%W_VRC^VO#C_ *)/-_\ PZT__D/7^EJ?ZM^,/_1=\/\ 3_F1U>G+_?\ [OXG
MY@?\/C/ _P#T)>O_ /@$_P#\11_P^,\#_P#0EZ__ . 3_P#Q%?I__P ,R_ '
M_HE'@_\ \%W_ -LH_P"&9?@#_P!$H\'_ /@N_P#ME']M>''_ $2>;_\ AUI_
M_(>O]+4_U;\8?^B[X?Z?\R.KTY?[_P#=_$_,#_A\9X'_ .A+U_\ \ G_ /B*
M/^'QG@?_ *$O7_\ P"?_ .(K]/\ _AF7X _]$H\'_P#@N_\ ME'_  S+\ ?^
MB4>#_P#P7?\ VRC^VO#C_HD\W_\ #K3_ /D/7^EJ?ZM^,/\ T7?#_3_F1U>G
M+_?_ +OXGY@?\/C/ _\ T)>O_P#@$_\ \11_P^,\#_\ 0EZ__P" 3_\ Q%?I
M_P#\,R_ '_HE'@__ ,%W_P!LH_X9E^ /_1*/!_\ X+O_ +91_;7AQ_T2>;_^
M'6G_ /(>O]+4_P!6_&'_ *+OA_I_S(ZO3E_O_P!W\3\P/^'QG@?_ *$O7_\
MP"?_ .(H_P"'QG@?_H2]?_\  )__ (BOT_\ ^&9?@#_T2CP?_P""[_[91_PS
M+\ ?^B4>#_\ P7?_ &RC^VO#C_HD\W_\.M/_ .0]?Z6I_JWXP_\ 1=\/]/\
MF1U>G+_?_N_B?F!_P^,\#_\ 0EZ__P" 3_\ Q%'_  ^,\#_]"7K_ /X!/_\
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MG_\ PS+\ ?\ HE'@_P#\%W_VRC_AF7X _P#1*/!__@N_^V4?VUX<?]$GF_\
MX=:?_P AZ_TM3_5OQA_Z+OA_I_S(ZO3E_O\ ]W\3\P/^'QG@?_H2]?\ _ )_
M_B*/^'QG@?\ Z$O7_P#P"?\ ^(K]/_\ AF7X _\ 1*/!_P#X+O\ [91_PS+\
M ?\ HE'@_P#\%W_VRC^VO#C_ *)/-_\ PZT__D/7^EJ?ZM^,/_1=\/\ 3_F1
MU>G+_?\ [OXGY@?\/C/ _P#T)>O_ /@$_P#\11_P^,\#_P#0EZ__ . 3_P#Q
M%?I__P ,R_ '_HE'@_\ \%W_ -LH_P"&9?@#_P!$H\'_ /@N_P#ME']M>''_
M $2>;_\ AUI__(>O]+4_U;\8?^B[X?Z?\R.KTY?[_P#=_$_,#_A\9X'_ .A+
MU_\ \ G_ /B*/^'QG@?_ *$O7_\ P"?_ .(K]/\ _AF7X _]$H\'_P#@N_\
MME'_  S+\ ?^B4>#_P#P7?\ VRC^VO#C_HD\W_\ #K3_ /D/7^EJ?ZM^,/\
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M1_;7AQ_T2>;_ /AUI_\ R'K_ $M3_5OQA_Z+OA_I_P R.KTY?[_]W\3\P/\
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M'!91D4Y9G-^WIX)TW]OWJ<7=.,=8\VU_7OKMZ'^VF_PXBNM)\0:9?P:=IT9
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M /P7W'_QNC_AYU^V#_T2^_\ _!?<?_&Z/^(5\3?\_,IZ?\S*AUY?/^]^ ?\
M$=^"?^?6?=/^9+B^O+_<_O?@?TKT5_-1_P /.OVP?^B7W_\ X+[C_P"-T?\
M#SK]L'_HE]__ ."^X_\ C='_ !"OB;_GYE/3_F94.O+Y_P![\ _XCOP3_P ^
ML^Z?\R7%]>7^Y_>_ _I7HK^:C_AYU^V#_P!$OO\ _P %]Q_\;H_X>=?M@_\
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MNG_,EQ?7E_N?WOP/Z5Z*_FH_X>=?M@_]$OO_ /P7W'_QNC_AYU^V#_T2^_\
M_!?<?_&Z/^(5\3?\_,IZ?\S*AUY?/^]^ ?\ $=^"?^?6?=/^9+B^O+_<_O?@
M?TKT5_-1_P /.OVP?^B7W_\ X+[C_P"-T?\ #SK]L'_HE]__ ."^X_\ C='_
M !"OB;_GYE/3_F94.O+Y_P![\ _XCOP3_P ^L^Z?\R7%]>7^Y_>_ _I7HK^:
MC_AYU^V#_P!$OO\ _P %]Q_\;H_X>=?M@_\ 1+[_ /\ !?<?_&Z/^(5\3?\
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MAUY?/^]^ ?\ $=^"?^?6?=/^9+B^O+_<_O?@?TKT5_-1_P /.OVP?^B7W_\
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MZHOYL0* 'T54&H6!(47MH2> !<PDD^@&_-6@00"""",@@Y!'J"."* %HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "FNB2(T<BJZ.I5T=0R.K##*RL"&
M5@2""""#@C%.HH _/[]H;_@G9\!/C=I'B.Y'AB#2?&.KQ2M#K5LR0E;E\D,0
MD:%,,VX-N.,8(YR/QSL=,_:Q_P"":OB<64UWJOC'X56UZ\\$$4L]W#!9[OD)
M*EUVB+&#D\<\CFOZC:Y'QGX&\,>/M$OM!\3Z39:G8WT$EO(+FWBF=%=2I:-G
M4E2 3QG!SR*^^X?X\Q^74I97G$%GN0UVE7P&.;K2HI)053"5I\TZ$X1ORJ&C
M9^4<5^%659MB(9YPY4?"W%.%4I8;-,LBJ%.O*4O:2I9AAZ:C3Q5.I-+F<TVK
MMZGS+^RC^V3\._VGO#<-WI%]:6'B6)$6]T)Y0MRLFT!]L3'>&W?PX'7  QBO
MLBOYFOVM?V3?BS^Q'X_/[17[-\FJ3^%+34(KS6-$LPXC$1<RS+Y,1*C:N00
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MC\F&255D;&-@)4$Y'8'ID]_I76:AXIATZZ26TU6,32P)YB%P6^9>G)Z\[?\
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MC!]>W;..!D=_TY\,?M/Z3'H>G^'=!MXYKB"-8%M(4 >,A0@!"X/U_'ZC\9O
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M%_\ $5Z=11]=QG_05B/_  ;/_P"2\E]P?V=E_P#T!83_ ,)Z7_R/DON/,?\
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MV7_] 6$_\)Z7_P CY+[CS'_A3GPX_P"A7TW_ ,!XO_B*/^%.?#C_ *%?3?\
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M\!XO_B*/^%.?#C_H5]-_\!XO_B*].HH^NXS_ *"L1_X-G_\ )>2^X/[.R_\
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M/^@K$?\ @V?_ ,EY+[@_L[+_ /H"PG_A/2_^1\E]QYC_ ,*<^''_ $*^F_\
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M_P"2\E]P?V=E_P#T!83_ ,)Z7_R/DON/,?\ A3GPX_Z%?3?_  'B_P#B*/\
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MS_H*Q'_@V?\ \EY+[@_L[+_^@+"?^$]+_P"1\E]QYB?@[\-QU\+Z8/K!%_\
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M_AZO^Q#_ -%J\+_^#*S_ /C]'_#U?]B'_HM7A?\ \&5G_P#'Z /T8HK\Y_\
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M:=FK23WMV?F3/*,TIO#1J9?BZ<L9%2PL:E"I!XB+:2E24HISBVTDXW3>US]
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MA7XP^&O.C)!C_M&T+9&?^FWMZ59T_P#X*6?L>ZC.UO!\7?#9F7C8=1M"2?\
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MIT:CINUIJ,U%N+NK2M9]#^L&BOY'?^(M7]DO_H5F_P# R7_X[1_Q%J_LE_\
M0K-_X&2__':HY3^N*BOY'?\ B+5_9+_Z%9O_  ,E_P#CM'_$6K^R7_T*S?\
M@9+_ /': /ZXJ*_D=_XBU?V2_P#H5F_\#)?_ ([1_P 1:O[)?_0K-_X&2_\
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MW/M7BOBWPAK.DWD4;0M);$@,,,RC/KU  [_AZ5^<VD?\%F?"/A?1_#?P_O\
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M6*4XSC?VW-9R:6K6B:[::WZ?G,L)'!W=T]&^72R6FC8?%'X00^+)8;O2Y1&
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MVK:Z7ZWV/VT^)/\ P7'^/WB+5YX_A?:7'V,.X1@&*[,';C''3Z8]SU\6O_\
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M  >ZI_\ )5'_  F?C#_H;/$O_@]U3_Y*KFJ* .E_X3/QA_T-GB7_ ,'NJ?\
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MEX)9970"^TS*J>&/VP\GG_Z]?D/7Z^?\$4O^3T/!7_7]IG_I6: /]DKX>?\
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M&_@+QEX5L[C4/$<6KV%S<PVT)E*+YJ,Q8 $@#DDXZ\C!R*_MJ_9GOIY/@?\
M#/2+Y##?66BV<-U PVR1NMM&&5EZ@@C&#VS7\LG[#/QX\/>$/'FDVFN:5!K=
MC<)!%LN421(6;8-PW@\@G/KGCBOZB?AWX@L[C2X?$N@[/[.G5)OLT1&RW4JI
MVA1P ,GY1CIWS7QF:87'5Z&'^K2<(4<1*I7Y7:4H73@FMWMZ[7/SKC6&.K4L
M$J$.?!T6Y59)^_&4DERM+[-]$N^NA[UXI\'W&H6CRVV5=4RI7@[L9'?&?0\
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MXFN=+U));>\\XW+ N58EE)P<Y'(^8Y_+ZCSS4+ZVN;^0V\A5IVW9SCODD?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\.^(=0LM7M]0NDN;=@T\'FL%)!R01Q_%^/<U);:MXWD\4P)#?K'X:@V!HQ(
M2B8!R >A4 9[\_0_K'LU0@O9J,:C:C*7LXQ2A:+Y9+KS6UW?>^Y_/[RZ52FH
M?6I0A3I2J.G64E>HFER02O>4M;/IK8^W_ OCZ&V-SH6N.DD<[&#?/AU8,2O\
M7!R.<@]>X-7O'G[._P .&\.:IXYT;2+677&A>XBNHH(@RR$;\AE&1C/4$'U[
M&OF[6M1T^26QU2VG LK<QBY=&P?,!P<X[YSDY/'Z?6>@:KK6I_#2]CL'\VUN
M;206S2'(&8B!R>._<'/(]*_#/&W@GA_.N$\US/&4(4\52PN(J_6)T8U:E"I&
MD^65"33<&VHZ+:UUK8_IGZ,?BAQAP;Q[P[E^68JJLLK8O"8:> 5>>&H5J,Z\
M%5I8B,6HU='*;4EM=6:W_+7X@_'O0OAIX5U:+3=+,OC:%9HI[@J6)101MQR>
MG7H!TZYK\0?BU^U?K?B>XU:&#2I;757N)5><(ZG<QY(( P,]*^U?VA+/QSX<
M^)FKR:D8IM/GN)]R'!3RRS]OITS7QIXE\)6'B&^DGT_3XO-F8B5DB'WVSR..
MN3_C7^ >/S?+Z_$F9T,QKX+'4LOQDHX.%62A1I2IU'SRK1DDI59K=/6ZUN?]
M6/!N8Y%0R++JF%56CB<QP-+$8K$PFY.]6G!O#PG9<E&#OR1C9(Z3]GO5O$>M
M:-JEW)>/<%XY6NX"Q<E2"Q4C.?4>N>!6#?EO#WCK1/$-K!Y:VVKQS3;EX79,
MK%CGMD9SSTZXKWO]G'X%>.=!U)KB.&1M*U1CYJ,K;1&Q)/RD8Z-QC'YG)]:^
M*_P0&E7+7$MHPM94+,WED!7;DD'!YR>N>WT-?"8WBW*:7%6:+^U,/B\#B\+[
M&MAZ,[QPGN>SG"G37NRT;:2]%T/N,+FN5YK1P^2T'&EC.>4J=9VOB;JTHU)N
MS<KNR>]K['ZZ?#']JWPIXJ^%^@Z%=:M:236VE1126X=-Z-'"HP5)['.0?3VK
MYX\8?MIZ=\,-7EM](U%+^-)&W6L4FXQC<0<JI(&/3&<U^.LJ^(/!-\[^'+Z]
MVR*5,?F.$4-G. >.G^>]>*W5QXGMO%3ZIJ\MU<I?R$RB8ET4,W.-QP, \=Q^
M>/S[(O O@W'YICLRP^8SQ&3X]SE7RVI3AS2KU)<Z47O2BF_XBU>JN?&8O@JM
ME>)E3Q/)*A-RQ$72O:\I7E&;2LY.[=K6N[Z)Z_IA^T9^TCJ7Q[\/7,6DRIIU
MU!"\B29"MN ..3C)SUQDGG@\@_+O[/\ XDUO5Q?>%_%MO)J%RLC0P:@5+J@!
M(!WD8P !GG')XZ"O.;.:[U::>STABI\GY@G\1/)7&?KQSSD5]%_L\:AI-G>W
M/A_5;9;?597(2XF0*=QSR'('7CUSG!Q7Z!#@_)>&N',RR# 950PV#UKT:+K6
MJUJ^CC.%>_,W=IJ*Z^I]UE4,NH8?"1P4:L/9VE4KQ@W4I0;7.ZO-:3@ELNEM
M%N>N6OPY^P7@N(+<F-2&>8H-N"<]>X^A],"M[4([OROL]O&98@H4B,=" 1T
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M3:3SY6A)""3:1GU(SQWZX_PKVSX-&YL/$^AW,2']_<Q!SWQN'?H,')^A^E?
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M+(K(LH."N1V'Z<]Z_;C]FO\ X)7&Q\//>>-H9)9S 6\F4.6W>7D## =SCO\
MIFORU_;=_8B^)O@;QEJ%UX%\(ZE?Z2IE$26UO,X(!.W!1,=.W4_3FO/HX!49
M5W5DZBKZ6E*[2:Z:NUGMZ=SNJ9A&HZ"IN$'2M=P25]M'IM?OY]3^O_\ X)]?
M\%%_A'\7OAWI6A:]J-C#KD=C%;O:S7$*F60QJI)#G)^;(_O<\].?;/CKX/L]
M>G'B/PG:V;+N68&W,;;@3OSF/K^?KDU_GJ?"5OVK_A3KL.H>'?!WBNQDMY58
MAK>[B0;6'"E&<'V&!UZ]A^]7[,7_  48_::T2SATGQSX&UK4HPBQGSK2YDR
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MJ::--OB2/LQX_P!@_P"%'M*;_P"7D/\ P./EY^:!4:^G[FKK_<EY>7GO_P
MS:*T_P"R[\?\NQ_[X/\ A1_9>H8S]E;_ +X/_P"JCVE/_GY3_P# X^7GYH?L
M*^_L*O\ X+EY>7G^9W?@ME5<MU /^<_G^.,9KNY6DA>*YM93'-$=P*D@EN#C
M@CKCW[&N,\)6LELK"XC:,L#MSQVP/U'//ZUV2+Y<FUP6!/'MU'T/?WQ^GQ&9
MROCJKC:7*U;9QDFE?JT[>K1^GY,F\KPB:E&2C=IZ2C)-->:LU?U/I#P7XPT+
MQGH3^$O$L<<5WY++#?2;0X;&!AV&>P. <UXWJ&ES^#M:NM+F3S=-F<K:SD$A
MU8Y4AC[=,9_PY&YCGM7CNK21DF21'R"5^4')'!''3C/6O;HY5^(_A^V6&'_3
M='C!E8 ;Y#&.<]R>M<$:OU6<JTY59T:UHS@THQPTU9QFEH^6;T5NES[S!XRK
MF]*G3K*G/,,#",<'6Y;5<9137/AZFB4G3C>7,[RMI<X'POKS>%O%UFL$I2UU
M*XCCN@&P/*D;:=PSC'/X9XKZL^(-U+IUOI&G>!K..W34UAN;[6("%DB+!6=B
MZX.1D\Y^G>OC74-+F.H)(Z-%+9R98'@@(QYSG( ZY]@>]>CWWB/Q1?>' =$E
M8BWB,3(N6; 7! (YSQQVSW&>>_V.%S##RI8B'M:J<*M!SE*,:<X2O&?*K1DK
M6W5GL^Q]OPGQ9B^'\#Q%E\85XPQ"IU</4P4(SQM+#*SS##83VJDZ,<2K1KSI
M\M5*W*[Z'W#HWB%KCP$VDVFLGQ'K<-NR3+/,)&A?RR"!DDC:><=N1BOA=KW4
M_"_BW4-2UBS%U>&61K>W<;\/G* *?7I^( ]N.\%ZS\1=$UB(6,5U =0DQ<2L
M7VX9AD@'@=\9/OG.<?1$7PQO=4U6TU[7M8C+$I,\+./F/#$8XYZ@]QUQP*\]
M4%0KXAUY89T<1!0A.C)QKU)124HR46H03DFDX).V_E[&:\7\4^(.%RB>7Y+C
M*%7A:26$I3A;#4J3BE"KB:F+7M,15]G[[=1S2DO=:;1N^%/B#<:YIDUSJ7A:
M*+6(26L97@VLJKRK*2!T !Z]/3'&]I?BGQSXSNEL]>DE?1[(X:UE8F)(\XQ@
MG;@+GTSW&<UN^,?$?AW2] AT[2[)(M62$1I<*@&25V[L@9.3GGKU&<FO,O#N
MIZC;:3J$-WJ"6UY?J_D;V"L2V[9C//?CVYS7#A,)^]Q5>E@Z6'G&$53=>HZR
MMS)2=.[ERQM9KE:E?5WV/:R;+\HRI9?0Q&+S+-(YY">)XFCE]6-##5\72?M:
M.'Q,YRB_:NJE3E%>Y*"M:UT_>;CP;X9GLGU"PB@62U3S/*79@R#G@ 8SG\SQ
MP<UXQJ?CV34$NM*FTE;6>W+V\%X(]K'C8N& !P2!WZYP,U!HFMZWI^GRV-XT
MBA"TCW;DA9(\YZ].03T/3WK1M=<\(ZO:R*\T NHI!YC_ "@EU/+$^H.?Q/UK
MT\+AJ-5)WCC?JRJ249RM)3FHZ0:=U=_PU==GHSUVZ&8U<+@\NK4LFKPJ5L51
MI9A*E3YEHYX9<K4HQPRTIR6C;NGNS@]%MW\)0ZEJ/B>V\ZVO1(UO)(I;?N!V
MYR#^??)/2O,]-\9^'M)\2+J%K8Q2K-.0L>U2$)8<CKCTZ=O7-?8DMGX5\6>'
M)-&EOK?4+PQLMI#$R&2-BO P.>./R.#7Q_XC\%Z/H&K6^EW$BVMZ+K<4<@/L
MW9'7!_/ZCVZ<#5J4L9]<G&O&4:U!4:D[M:2A?E@EJJ<K*4FK7Z]3X/B"693G
M2H9:L)#!Y#B;4<7C'0J8BOC<1-3J<E:-X2C*3:IQG)R4'KJ?;_P=U.:3QEIW
MB6*/S4,2E;7'R<@80#ISG'&><<=:\:_;JGFO]?T^_N-'72Q,5*2+&(S*3SG.
M "3U'XY[5ZM\);VVL-8\/V=NZ.'EM4>0'(P74$'MTZ_R->X_\%-OA9'<?#KP
M+XHT%%N/)MK>6^>!0=@V(6+E >G.<]!SFOW_ ,8L_IK@G@/"XC#5*_M.(Z^(
MKYWBE.%6A4KX*E2A0IRC^Y^JR;48J33YGHKG3QE2JU^")5YX7#8JO0Q$*M=4
MJE3ZSEV(G&*GBO9Q;I.G5C[K;32[7L?BR@^1,\C8N,\YXQFGU5M)UGA4J<^6
M!&WLRCD=JM5^"R3BW%Z-/8_"EJKIW7?O]Q'*@="IZ''OGGICOG_/%?IC_P $
MR-;TV7X@:QH6H0I=>9 PMH7PP9V#!0%/4D@ 8'MST/YI5]2_L-?$32_A?\?/
M#NIZ[*L&EWFIVT%S-)@1QQ&;YBV2   3UQ_AR8_,99-@:^=T\-6QE7)'#-J>
M$H-JMB'@I*M*E2MKSSC"2LM]M=CR<ZQ.9X#+L7F&3XZKEN98&C/$X7'4)5(U
M:#HI5)M.FU-J<(RIN,;WYEH]3[__ &C/AYXNT7QW>:]'IK6%@;MWA"HR*T98
ME3TP1CO[_45YQHOCS4O#UQ!-<*9D;.^ D,'XS@@]>1[]>?;]/O\ @H=KVB>(
M/#WA3Q+\+);?7](N-.BFU&73PDBPR-"I<.8P<$<YSGZU^..F7S2:C:7&HMO6
M1SNMSP4R<'*GT[Y%?Z4?1T\:^$/I!<!8/,\)@L9E5'Q FN',XR?-Z$7AN'\5
M@(*E#,JRJQYJ=>K5ARKF2J--/5-6_3_#SC]<1<-\/\:9)B\5AL904:KJ252-
M1XM5%A\5#DGJE-QG4E3J*[4KM6U*LVLZ)XP^)5W/A-/O#GRH#B,&0]#]<_EZ
M5Y]\;/&'COP[IC:%&)(HY)@8;R L2J @K@KGM[\Y^IJ_\7O#<*7#>(O"=V+/
M58D,I*-M8D#/(4C@'_#&:^?]+^+=U*TUIXZD756@#11[UWD,N0"2<X[#//3T
M-?P_XD\+5.$^/N(L@EC:68?V3F^*PU#%4K\M2@III\M](16G*^ZLK'Z/FG'M
M2CEV-R#,,9B,EQN>5*^(6?8.<8X&O1KI.I'%Q@U.%96M'V:3C*VUSZC^#NOZ
MUKWAJ"XU*!M0;38RTEQ*"[KM YRPSFO%/$OB;QM?>/Y#8S7,VD22F!K?Y_*5
M=VT@KG&,8QV'6MOX+_&;3O#FJ:CI-W&@TK6BZ0*RC;$LA*CD]#CV]>F"!WFL
MW%S:ZG=R:)X?DO+2Z1Y(;V.'>B-(<@A@"/XAD9X[<5\3BH4Z4Z6)CAX5N2,Z
M=?%5))1I.]U35-Z.+NFW:^EO)_2TL=1XJX+X>I87C#,8XG+,PA#,\/@Z-:IC
MZU3#)4L.YO#Q=2KA\103M*KS)*7O]3Z]_9B^&&GP3W7BB6Z2"_;39I'ME<9+
M>4S'*@]0<]OZ"OQD_:1<O\:/'1/7^UY1S[&OVF_9!\->)9(-;UC6[YC']ANF
MBMF?[B^6^%"DC@ >@.!UK\6/VD6#?&GQV0,#^UY1^7%>UDV.J8_"2JU%"].H
MZ<)4E:$H):-::VVU_'<_FWZ0V4X+*N+,D>"RG$9/#'\.T,95P^+FI8FO6=50
MEBJJ3:IRJZRY$E9-7U1X=1117K'X(%%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M<%YIMB-LEOLC%Q(H^ZV ""1W)_'O7Z3?LX>!+75+Q(?[/<V<)7=,5)5E7T)
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MQ IXOAG Y)Q1FN#PF>9-@,/0YIWA2Q].E!*I.E*5E[2+7O*3ULG'<^'/A?\
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M;H]6.$7-J*3;;ML_P_3\SWN.[CGBCN(9%>*50T;JQ;@\CD>Q_K[5967@9(Y
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M1N";<X]Q]?8<UV'AK68+C0@YMT=I4&20#C('MVZ]\^E=M\6_"UA=Z8IBB!E
MR6 '' Z$\^X/?K7CVEG^R--6S=B-V0K$_=)Z_P _RZCC->='#3HUVYZK=-[M
M*S2^Y[_AN?:T\1[91C2LI-75I:6C;=='^>UF>7?%+2VN[&Y^0"*3(."I&#G
MX]S^G>OQ;_:A^'LME:7NIZ; &N!O?S5Y92"2>1SQU[>XK]IO'%QY=G-#<7J!
M)%;8Y8?*#T]QC@=^_:ORM^/>NVVC3SV6HW$<MA<;SYSE2BJV>222.0?KTX)
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MYVW_ *(2OPG_ ."D7_)VG[/7_82TK_T=#7[L:=_R#['_ *\[7_T0E?H'%?\
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MBD[QYF^;H?+-;/@O34USQOX;T22X-I_:FJ06@N%.TQ>;(%W[^Q&1Z'I5G1/
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M88"EA,[P6'<OK?LYWQ=;"QDN6LJ*;FYQMS/E5XI:W2/[+RCZ1O">?UL!A?\
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M6D*W-C/'\_D@,B*RG)^7@>W/X"OS#^!7[$'QTU"#1O'?A3PY=&*\GB>5A;R
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MY7FU6%?,<55A=1E5=KJVR2VZ)=/(]:A%QI03M?E5[>>OS]0KQSXDW(@N;?)
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M(91G@J1]<'_/X4^16:5]5:_S3\NW2PDDKOOU>O96N]?SU-%'3'!^O!ZX%*7
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MY.$(RDE\4KNS?Z'X=Q,Y2S6I.3BFL53LDDE9RC9O;73TM\S]@;C_ )%BY_[
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M!?\ )<>*O_8\RS_U7(N4445^?GZX%%%% !1110 4444 %%%% !1110 4444
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M?0'A[Q:-?E6.SMWM5; W*I0'\1@')SQ]/:NXGA6V*M=RMCEBQ;@9.>3GH?\
M.*X<RX@SJO4PU'%8B5+ZE;ZK3C;GI:1CI46LKJRMY:[D4</0IQJ.G"_MDHU'
M)W3UC+6+5DK[:M6VV/F.;]E#X=3^5!#IT MHRI(,:%B!VR1D],]0.?7BI-9_
M9V\'Z/:(OAL6^D72H )RJ(-V,9SD <]>OZ'/?^,]9U*TD1M$O(RA;YE609QG
MD$9Z$9SU_"O'?&FG_$SQ9;PC1KJ5(L 2F-V&>,')#9]<8'!]LUVX/%YOB)4)
M5<X]A1E)N7MYR4%W52#TEV2=T_FS&LJ,.:,<.I25E[J2;=EK=:JU]^AH^%?A
M'XHL+M;R[\20:AIL;9FA1E8>7D\$#/Y=,<=:QO%OPOU;4=?34?#GC2ST:U#!
M6M!(L;%QU  (&>IYY)KI_AIX*^(>D0O;:K=S2P7 Q)YCEC@CYL D_7V.!UJY
MK7@;2+K47M#=WT>H ^8"CN$,G4Y (!!XS[<9KI>,KT<=4:S"A6Y:3BJF'PE.
MI3E!I7E.D[1NG>TGJELC)4E*BFJ<TF[M3K24N9<ME&5[[7?XLR[/P5\0-',-
MY?\ BA;ZR7!(\P,&48X SZ=_3C/7'H*_$4Z3:):F!+V7:%RJ MD Y)/)ZCKD
MCW)KY=^(>H?$?0YTT_3&NI[*,A$*EV^7[OJ<=/<UT/PUL?%]ZPO-4A<JAW,L
MJG)[GK[G@#\1Q7/F&68W$X:&*JX[+E3W@J5.G1FUNN:,;/F>E]EYVU-</7H4
MYN/U>M)Z:.3<FM/M=ETMO8[_ %?QOXCFDEGM(F@X)5 ",_H,C_\ 77G$7QK\
M<:9?-9RZ3<W>X[5E5&8 $X'.#W_+TKZ#AMK9W62\ME50 ""F <<?W<?IUQ[5
MMP6GA^)U86=DSMC!:-"W7&>0<Y]O?GFOG8RQ]*+H2AAY1:^-4XMZ-6]ZVCTZ
M[VZ,[[X5MRM-MV?*Y-);:.ZM?OKW]3Y \2>-/%FO7,9N8)X=Y7;%\X/S'.#[
M#Z<\#TKUGP7;1)#;R7VDSF_8HPF8-GL02<<CC(/)SZ=:]=OO#VA7]Q'=):Q"
M6([MJ1@ GKZ''\_PXKH+.6RBDCC^SPJ4 4+M&1CH>@/;DX(Y["O8JXZE.A1C
M3ISIU*=.U10FZ<.=))R2CH[M-M/TULCB5-\\VN6TI+ENN9VNM&WJME;\M$?9
M/P*>=_#69MP "A%;.0,\<'I@8&*]SKQ[X/21R:(YC 5>. ,#DXZ=NG^<U[#7
MYUC'S8JNVK7F]+6MM_7GO9;'HP5H179+^N@5\\?%R1(]4L]P'2,\XX //6OH
M>OD3]H+4YK+6-/2(D%E0'!QP0OY]?6C"QYZR7D_T*,==0@5P,CKCDC';I^'Z
M9[5N6U[&Z@I[]..^._&?;\NAKPNTU">:8-*S<-R,]>GH>F,_X5ZAI4Z/&,')
M SUR>0,_X_H/2NV5%Z/FT6[VLM$E;JN[T]%U4;7;?N]+]-.KVNM]=SL#.?4#
M(XY'X=A4+ @%R=P;G'US_DD>E9OG!CAB?ESU'0#\/_K>]/-UL0\CI\I..<GG
M'KP:I1:2LNVMM]5]]_F1%I-I?#T?=Z=?Z^X=N",2..PR<$=*?/-F)CD_<)ZY
M'3//Y5G?:/,)W<#&>G<8'4?6N7\2^(K;1]/N9Y)439%(<L0,;5) ZC^?US6<
MX7WER.R;_#[M_P"MGM[S5E?SMVTLK;?=^A\6?M)?$Z;0;Y-/M9_+\US&<-C&
M3@G@C\^.O&<BOE*W\87NEW":J]^[K(!(5$A/7L<$@]>O!/X9KA?VDO'1USQ7
M.+><.L,S8(;(&'R<<\=._M7D%EJE[J4$47FLR@*H&[(QC'3/KG'OGUK\WXIK
M5'C(TZ#<H044Y1;2<G:][=GI;3S\_P!$R/"*& 5248KF7O.44W:26S:?DWZ>
MA]Z^#?BC-JM] RSL &7(W'& ?J.?Q.>HS7W[X&\6&ZLX49\_*O)/0X7/'^'_
M -:OQ\^&]EJ$5Y 4WMEESC) YZ\_4]Z_3_X;6<RZ9;22[MVQ?J<@$_S]!W]:
M.&G4C4E"TY233E*;;WM+2/16?W/J<6?8>E"C'WHQ;6DDDF]MW;OMY=+GTXNK
MH% 5LG\_;MW_ ,_5W]K$#)/'XCW[_P JXZSB9RH)STR<\\ 8ZX_R36X+;"@Y
M/0=<8_3FOT5)N*O?9.]KMMVMY;ZH^*Y8+2]^S_)Z+\]#<355902.PQTY./H>
MM/\ [2& <<^GIU]JYN3*8ZC&>GMC'Z>M-:[ ]N>N/Z9]_P"7K0E!12]Z4FU=
MK1]%_6]R---/5]SM8+^+ )(W<?F<C_/-2-=@DGL>G(';MWKBX[KD8/4CC ^O
M!K?MF2503VQD\CC_ .MQ_P#7J:D+6:DW>WHMMOG;[NH+6ZMMUNNMOZU[W--K
MK@\'\<>OL,U5>Y.TD9& 3C(P?\_K1YB[0N?KP?4G_"LVYE6-QZ8]./7Z^M0D
MN9IZ[:M7TZK72]K?\#8(_$O731/MI_5SG[RZ8W602,9)Y'OG\CQU]JXOQ?XN
MGTFWW0ELJ!G!SS@>A'_Z^XK8UJX\MRT9P>?KZ],]"37B'CK49%LIW;G"'@@<
M=_7.?RKS:TW0E5<6FG%RT7PV2U7?:UOFCOHT8U)4XR5US);WOS.*VW[+7SZG
M76'Q4MC8O)<S*LB\,&/MZ<8R<]:Z_P -^-K#5%W^<O?)!ZC(_P _YR/S$UWQ
MA>Q75S&LKK"KMD*2!UQQ@X''/IZ=3CF[/]H&3PT9;?SVW*"H&\]<@>I.?7\N
MM?(?ZS2I5(WISJ*E.49\J=XI6L[;6[/N]=3Z1\.SE14J,=96Y8M)ZNRU:VL]
M5=[Z]#]H;+7[.3Y!*&] "#Z ]^.OX_3BMR'4(Y#@<CH/7H<?T[5^7OPH^.6H
M>*;R- TI7>%R22,$\^V, 9S[Y]*^^-$UII;*.5\EBJDGOT!Y_#_&OJ,JSJEF
ME.3ITY02=KM6=URO3UU=[:=;=?G\PRS$X&?)7Y>:R:BO.W]?D>L+<*PZX'3M
MQ_D?C3&D"N>I'H#QTKSJY\2Q6VT-( 3V+8QUQ[_7CW/:K7_"3VZP"6211G!^
M8\<_7VSC\J]:%2"E9N]TTM;):Q2=[Z]%]QYUFK>Z]='=>CTZ_P!=3N6N%&-O
M(]3G^F:>LRE<GC_]6?KS],UQUMK]K<1[Q(A&,\'CW_IZU<76+=U&UU' !^89
M]._ICL:I27-?F3NNG3;?>W]7L2TTUHW'=WZ;;_BCIA.#\N#C\/KZ TYY0HR3
MGKW'X_2L*"]CD&0P;GKD<_CGMQV_^O-)<#:Y##/)QCGGM^'^<ULDI<MUHW9J
M^]K:W\[^6G82MNE9;VV^_OY_H3RWZQRI@@8(S[<@\G\^GI7T-X,E\[1XG]<?
MJ"1^'/%?)>H7JPR(,DEF].<C'./3^OIBOJ3X=2>;X=@<]]O7Z&HQ%/EIIQNH
M\UO*_P#P_6^O4GF7-RZ7M\];?U_PVO>T445PE'Y6_M5B\N?B4MNB,\/\7&0>
MG4@'@=>>E>O_  (L[>Q\,W?VK9'&T$H.[@ E2,'.,C/K_4FOF+]M'XKMX&^)
MK1/H5]J$:JQ\VW@DD7C=CYE4@>N?3CL,]'^SU\59?B-X.U)+?2+^PDC#$"6&
M2-CC/8@=?QSFE&AAH58UHSO7WY;W:V5EZ;=/7H?$Y1%QXOK2FFHRJ5(Q;B[/
MF44KNW*D^CZ^1^47_!4?X>7][=W6LVUONLAYCJZI\C8).<XP<X]/0 ^G\Y_P
M5\;^%/@S^T$WBGQ3'%;0R7 B5Y0%4$N 2<C 'U_3M_9K^U7X%N_BIX-3POIN
MC7$FK&-HQ+Y+$ESE222OOGKP?7-?R_\ [9_[!/B3P?H5]JFL>'=9GU)O-FM3
M86LK2;@&9,%$X/0< >IR:[_8_6$ZD;2?+>46TK)6_*VME]Y^M0J*$5&7NRNX
MQ2:UU2[);;WTON</^VQXTTWXF6EOXD\-7L=_IDT?F_N&5EB0C=M.W.,#'ITZ
M5^,OB^\M3:W#SKN6WWG/&.#Q@GH??Z&OKKP"_CKPEX%U[PQXA\">+[\NDR:>
MT]A<NRI@A ,QD]NG3\Z_/OXA6WQ1OKO4-%TKX8>,6>Z>1(G&DW97+. #GRO?
M&,^X'.*Y)4N6=I<DH->]%ZQ3T:2OHU;IU^^VTJG-JFN;NFK;);;:NV^VG<^G
MOV--!TS7?'<VN:W:";2;0[X3(H=%=2,'YOEZ@?UXKVO]J3XFS7NH/H=I/C3K
M5C%;Q(V%6->  %., <'C& <]J\O^!VA?$WX=_"F>&\^'7BE=:N$9U(TRX$OS
M $ GRMV<@?TZ UX5XJM_BUXAU26>Z^&_C!_WA.3IEV3U8D?ZDG\_UKRLRJJ"
MC1II*#2<VKIW;2LFM^]NJ.G!QM#GG:[75ZZI6ZO[O\V84:/?7$;<XC8,<YYY
M]_?)S7[U_P#!-?3+6#5=+O[B(;/.A!<KD [U^;/H!^74\8K\3/!'PX^*'B35
M[2PM_ASXJ@WR*LCOIER%V[^3DQCT[_\ Z_Z"?^">O@7Q7I_BN/P?JWA#6[,Q
M6Z3BXFLYHTW*J]V0<].?^!8ZBO*H.4*T(I:RDE%M-*[M;6WIOW.]."IU9SE%
M*%-O=75EI9=6_P#/KO\ L_\ &;4=0L++1KK1KDSQ"*(LL1)" *./E/4<YR?P
MQS6C\)/']_>>+O"%M-'*&:]MU<D'/#H"22.>>I[X'8UAKHOB'4+Z[T8Z)J,L
M5J_EHTD$C* I(!7*D 8'MQCCKGK? >@:IH?Q#\+QW6@WJH;Z "06S!5(D'+'
M9P!SR3_,5X^8\/93BLPAC<=23?M(2<Y)N,9J4'&R][7FMJ[Z:Z)'\_9S*5?,
M9U%?EGB8]+WM-=;/HEU_X/\ 0C&Q?P<6/5O#TC'_ (%I['^M?R;^&_\ E)II
MG_8?7_TJ:OZR(_\ D3NF/^*=DX]/^)>W'X=*_DW\-_\ *333/^P^O_I4U?TY
MX4)+#<7J/PKARNETT5.:7IH?G'CE_O'AS_V56"_]+HG]=</^JB_ZYI_Z"*DJ
M.'_51?\ 7-/_ $$5)7Y$?T+'9>B_(****!A1110 4444 %%%% 'X-_\ !2+_
M ).T_9Z_["6E?^CH:_=C3O\ D'V/_7G:_P#HA*_"?_@I%_R=I^SU_P!A+2O_
M $=#7[L:=_R#['_KSM?_ $0E?H'%?_),<!?]BO'_ /J9$_(^ O\ DN/%7_L>
M99_ZKD7****_/S]<"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K^#C_@
MZ<Z7_P#N2_R:O[QZ_@X_X.G.E_\ [DO\FH _ST9/]9)_OM_Z$:93Y,&1_0NW
M\S3* "MOP^A?48@!N/8>I[#\3_GFL2NF\)PR3ZO"D0)?[P [X(ZCO]*PQ+Y<
M/6:5[0EIJ[_=J=> _P!]PN_\>GMO\2MMKOV/8HS=QHL0CVJ0.!P#QCW_ !_#
M.*ME)K.,-+'\L@P2>P/4_CSS[_FY[DP2I!-@2H-H! ST]Q^OXU9N[T7$2PLH
MX (/Y=\<^P_ C%? .I+GBW"RYE*2O=.*MWU[VV\MC]:BXQ@W*Z:C[B2=Y/W5
MKY^JO\KF?OB$96)C\Y.<#.#UY/OT] 32?*$Y8$@'GC.,'D>_; Q5R);5(<;1
MOQR,9]!G]<\?_7K*<'S,C.USC:.P_ =,<54VI-U8R4+R34$M$E;1.S?Z[-V3
MTJUTKKM]^]GW^?\ D2-*2%!.1G@GCOC_ #^'K5J':9E(;(8 8_#_ !/'YCN:
MIS)\JH@Y!SD?U/4<\\U/ WEE<CYN".GH#U_ UE-.I'G>^UGHWLOR5^G<+:)*
MUKK[O\R>[L)8CYP&$)X'3)SGVS_/^E!5*?O<<GCVZG\?3\JT[FZFF0#)V+_G
MT]^YZ52$,DR[4SA>ON2?\_TJX/F35DFERN3MJW;2R]-'Y_>RS!:I<QERP!4E
M^PZ'MGZ<CKS7K?A1[G4= OX;3)6VC<.3Z*O..WKUX'IZ>6>'K&35-533/-$2
MG!9B2 1QD9R/UP<GO7K&IZ_:>%K5M TV/R[BX39-( /WA(P22!ZY]S]13JT'
M[!S5^:,H.Z6B7,FWKTLM?+4^BX>I0IU*V-Q-?V.!G"="<T[5)5N1<L(6>CO:
M_-9?>>/7-W]F:XCE;?)YD@V]<-D\#H>V#CIZ>GH?PV\*Z@+A_%SH4M;7,HR,
M9V<X_3''7BLK1/!LGB/6;6W&6E>=&E'!.UCDY&?0^V1^GJ7C?Q(?A?=Z=H'D
M^;ID\:)<H "-QPK9Z^O<XZ<BN]0DN5VE4]I%:7O+DT:Y;^ZE;HTDWIJ?0Y+E
M--1K9_F]6IA<HP-:%+!XN$7)/'5G:A4J-*\E3E9SL]%>YSOBSXI7_C);W3"6
MTZ*Q!2&4 QF3RP5Z\$\ $]?8Y'/E_A'QIJ/A_51]LG>_MGE"LLAW  G:2!R
M/?\ GUK1\>W6GZC]FN/#:#SKO:7MH@-Q+$9&%Y[@<^H.*L1_"36(_#S>(]29
MK$",RK#)N4L>O&<'OT'X9%76IX::=XSE0J4U&I2J6YFXJ/\ +JDWOK9^B.;%
M8OB7$Y['%X>O5S3&Y3^_GFM"3^K5*#:G!5.;]PN6FN1TW:3UZ[:6I^*M*T_Q
MWH_B2WM$NHS-"9K4)O7YF&[Y>1W^GOTQ^@'B7Q3X9\7^%-#TVPTR&Q;5X8UN
MI$C5#%N4 Y( *\DDYS_+/Q/\!_ VC:_JKZMK5PER;20(E@S!GDP3A@A/L.W;
MWK[VUCP3I4'A#4IM*C4:B\#'3H%^_"^SY"JCD'(&<#\S@5Y6,G"C2HQI<U-8
M2W)I>-JC4>6[O)J"?-)KHO4_H[P9RC/<YR7BS-)_V6LKX@Y\37RFI2A/$U%@
MX^TK?5ZD8WA/&\DJ,:2:DI2343Q6U^%T>CW*Q>&[E UF1>7MS%(-TL8.YD+*
M>XZ@\>F#BN9\;_#GPO\ %!SK4UX=/BT>-H;M5^19IXP06;L264]>OMUKRVR\
M;>,OAK=7CZ[=/+)>2R1O;2%RQB9B-I!Y^[T!Q[<5ZF/B9X2U+X?:CIFGVJPZ
MW?K)(T( $KNX)R!C<<EL^GM42Q.:SHNF\344?:4U'$4(0]^FVER^]%R2@MI;
M+O9.WP6>5^'\[=7!9=EN"RJM0IXC$8OA;-W*#;PUOJ=&C.E:U:3N^2_/-Z23
MZ=O^ROX9MO"+>)I;2S@O[!!,(I'VOE?F&<YYZ>_3'3KYE\4OAZOCWQ6U]X8U
M1UU&*Z+76EH^$A0-EOD&,8&>W';O7B/P[^+?BSP/KLGA^::2WMM3F,>UB1M6
M5B.2?0$>G\J^FM!MT\,:K<>)(;Y9+S5XLD%@V&E'H3@8SV_2OL>%>%L;G_$6
M#<JLXX14X4\=6PTH\\,,W%.=2+:]I*<[1E9-J[5DEIS8:7"'%/"&39'A,+B<
MKIY-CY5>(XM4Z>+P^.<E.DL%4ERU/9K2"4WK%W>MR[H^GWVG167A\7LC21"-
M;E S;0R@!AU)SP<D@YYR1FO?W\4:+I^APV4ME!'<VL8#2X&96"GD]SDX]>W7
M(KP>&.>QGN-0GE\RZNF>=6ST!.[@G&,<\#\>,XS%-_XKU$6MK*[>6P$VTG (
M/5L<8'..YK_0[A3"8/(>&Z7#M')\'C\ZPF)P^/IK'TZ3P^'HN4$J\]/:1J4H
M+VU-2]Q5/B6K-<2Z%*I@<3BJ.+KUJ53V>3TZ.)JJK2<$HTX)0ERSG)*+K)W2
MC)MZ(WM>\;7>H?:+>SMV5,.L>Q3@XSCIR>V/P]<5S_PT\/ZY?^)1>RV+M<*X
MD3S$920IR,9]<8[=>F*]H\.:/:Z1J6CV4^C/J!GN(4GD$3/M4L Q)VD8Y[G'
MU)K]0/"W[.WPFUEM"UC_ (3;2O"^H2VT4DVG3SP0RY9 2-C.#D G@C.1WK\L
M\5O''P[X"SW 9MGW$68XJK*>(P=')<7AY5<+BLPM&,\33I8>+4:%.=N2;C&*
M2O?J?,\4\7Y'POF^1UN/\VE@*^(Q=.I%9?AY5<9A(-ITY5:?*^:-)6<IPC;=
MW[_%?_"#-\0]-GL[N(VMY8K\ORE<E!P >G./\.!75>"/&7A[X6Z9+H'CZ0VM
M@F5@N9!M4XR!M8_I@_CS@?6_CK0? W@WQMX8\#^!=6L_%&I>(IH8;J>R>*8Q
M%B%8ML+8QG)SC^E?'/\ P4@N?A[X1M?"WPZN8XHO%!DMIKS8525PY0E6*G<<
M[B.3SWXK^1<^^DW@N,L3G6295B,9EV?8RGB%D5?#4TL95RSD:Q6*A2FDU0HR
MO1C*<5HTT]K>U6^D3E.(QW$=?(<BQ6>N&%IX;*<_?^RU,17<8X>G5K02A-PO
M-1Y6FVVFDV?&WC'0=#^,?Q[L)O"FKW#V"S+*DJ[PNT,I4!N!@X^F.V!7TYXL
MTJ?1-/?2;J5II--A586<D[RJ<')W=3C\LUZE\)?!'PXTCX::1XMT;1EMM:BT
M^/=<LHWR.(\[MQY.3@\5QOB2/_A)Y76ZE%I)=91)G..IVJ<_3^O?%?K/T6*B
MX8R]<4XBCB<7CW1IU:.(QKI3Q5/!QQ<G.522NJE:I-2?+=R@FM#[S@_(\3EG
M!>-R_.<)C,!Q%G,<1F&*IU)U*K<<33=6E0=>JW5?+SQG&G*35VDH]#\X?&4^
MH^*/$":=>[K"VCN"OGJ"ORAC@@CMC'3(SR179)H=OI=QI]EI>IOJ&Y(PX+EB
MI &1UP ._0^HZUZEXL^&']F7\J^>+]I S(Z?,<G..1G!/4\^]<#8^'=0T*]>
M1K>0R@&2,,&)55R>,^@Y[8'IUK^K<RR'A_CC-:/$^$P6$QV=U\PCF$\?FF,Q
M%'.,)&BU*GA,"Z52-!X9->]3GK:R:/R#*Z>;Y \=1S##XY4<;5H4:V,IPG.G
M1H0EK[2FDX<\X[.UU;76QZ'=:;<6^GPB*8JY13+"#][((.1WZGG']*FO? 'P
MW\2^'OL_B%8+'4;A-L<K;4+2,.I8X/7GKD\^M>>Z7XQG\1:A/I\9*36+%95Y
M!^4\@CI_B*Z7XH6.GW?@ZR:"]%MJJLI#JY4J_J2"#[\X'/T-?F_B1G.!S;AK
M%5\S>7<0Y]PKB*^ A6QU>2PV%HXB?M(4<(HR3FZ4?<J+7]XMM;'[=PYB\GK8
M;/<9@LEPV,R7%Y-^ZP>81A.GC*F'<:-:I2E-/V&)<]8J#BK[V/I?]FCX5^ ?
MAY#JZQ74,^K7-A=266&5CM,;%,8YQCGO^=?B#\>0&^/'C 3G"_V[(&S_ '>W
ML..?3M7Z]_LOV]]'=3#5IWU.==+F$-R'+K&!$PP3D^M?C_\ M"1O+\<O&D:9
M:1M;D"XX))&?\FOY:X?Q6'GCL)B%@85</3S+#RJX-2?L\4E6IRJ4-7>$:RO3
M6J]U]-S^0?'ETH\59-2P65X?)XT,AHQHX3#P;J*3J\T98F27+6K*37O4W)-6
M5[W/3K'P[IEQI5M/8WBQS[%;8K@%FP."/PX]<]^M=#8^&YI0C:@XAMU ^;(^
M?WZC@CU'XGMX%IMEX@A6,I=R0[%5E0L1G&3T[]>F3Z8[5V&F>/-3AO$TS5Y6
M,0P@+<=R"2<]??H.N:_K.&!X6I<3XBE5X<Q.09'F>!HXG*>'LSQD\=E=/B#$
M4XJE3AB,'4G3P5+$U$^2E.<)2>E1/0CA?C#*X4<JQ/$&%QD,TPU7ZD\P4*="
MG5PT5&-55*,E&4H4HVYI)7>ZOH:7BW1H[.\CM;.;S+:Z8!V!S@$C(X/'7J>?
MZ=%I^HS>%["*RT<&*295$MU'\KC< "25P?Q]JIO!#?7*W$=VDR AEB!&X9YZ
M9SCU/MR.,5IBUGWQNL#2QY&] !D(<^ASQZYXYKYC/N$YX+-Z68Y=E6%R^ABZ
MU.GBLHS%5<QPN6R4?8XK&4J2]M%X#FE.HHN-TTNUE]+BLNP7$.)Q52HY5*,<
M33>!Q6#<)M8:ZJQA%?;DW&,M;N*N]S[!^!OQ[^(?PYLVM[/4KK4M"N(MUU!(
M[-& 1\P(8D?T]>*]8\'?M0:'XQ\92>&->\,6ESI.KS>1J%W-"C"V20[9&+%?
ME"@]<XR/7-?#=_XH.F^'6T[21Y<LJ[9/[P+###CGZ]^>]7/ ,]CX=\.:SJ.H
MR#^T;J.1HI21N5F!QAC@CK[D>W.?YB\1?HQ>'^=YGQ1B89/1P&>5\ J629YD
M<*^6Y;GF-BWB*N<8CG5)_6J+DXPA2T;@DU:R73F7&-'@7"8^6%PT<PS/.J.9
M82OC\33IXG&8.KGN7O)G3PD*BG!UZ%*:K*K47/3LN62M=?HG^U3^QK^S/XT^
M']I?_ [Q#9WWQ*N85N9]'MIHV:.YE 9HBB8/WVVD >HY[_DGXN_87_:4\$^&
M[CQ;KO@2YM_#]L'9KY9)&4HAY8((<<@[L!C]3UKVKX-^.M2\&^(CXLM+Z::Z
M^T.X\R9Y%.6+*NUV.0 J@#IP>YK[S\>?\%.[J\^'#?##Q9I=O>VDY5))/LL9
MS&3AD+;.X'?DGCUS_+U?AKZ2'@A7R7AG+\#6\0<BQ^(H9E6S?BKVU+,*65XM
M\U2GEF(P[C0JTZ%.-J,:LI22^)7W_GB?@7G'!?#OAID' 7&\>)L9C<\Q'_$2
ML]X[K.6&X<RO,*SG@EE?U&2JS6#BVL1[:Z::4=4?SVS0W-K(T5S#+$ZL4*R(
MR$,I*L!N49Y&*9GG&#]<<>O^?>OW+F\7_LM?&GP+::!8^![3PYXA6%EFUJ2V
MCA,LK*/G#D _>Y!Z'(]:_/KQ_P#L_P!NFJ7>G>#9EU,QL\B-;;7)7/R(-N[)
MXP.!U S7ZUP_XI1S#$5<#Q+PQG?!>/I2FXT<ZA#V-?#1FH+&4<137LG0J.SA
M>7,D]>MOJ\M\*_$+-</F>+P7#6,Q5#!\4_ZL98\-.G6KY_>E.O'-\NPD&ZZR
MV=&FZBJU(KEBTI-,^.2P'4_SI>M=5KO@/Q;X;FECUG0M0LXXG9?.G@948 \,
M&ZX/^/:N1#X.",#IWR*_4</B</BZ:K86O1Q%*2352A4A5@[Z_%!M7\KW74^(
MQ.$Q6#J2I8K#UL/4C.I!QJTY0O*E-TZBBY)*7).+C)Q;2DFKDE%%%;)66GSO
MU[LYDK+3YWZ]V%%%%)V:5]+NUG_P'^(GJM=$VE;_ (9[WZ[!1115%!1110']
M7[A1110+JO1^G3^E\PHHHI=?SV_'K]WS#6Z[6UMW\[].UM>X444A. 3Z4PUN
M]K=._G<7 ]**0'(!]1FEI-VU?_# W;5WLW]W_ _S"D) ZG%+2$ ]1FAW^6FV
M][_EW!W^6FV][_EW%HHHI)+7K[SZ;/3^KB26O7WGTV>G]7"BC!(.,].H[>](
M!@8SGWH4HO;7Y/\ R]!W6GFKKKI_3%HIN#N!SQCD?GVZ4ZJ]1^H4444E?6]M
M]+=O/S$KO5Z;Z>MM_-!1111^>OZ7_0/SU_2_Z!12$@#)I]O#-<.5B1WR<< G
M&3P#CIG-#:BKR:22U;T^;*C&4GRQC*4K7M%.3=E=NRNW9*[\D,Y)"J"7;A5
M)))X   .23VK[/\ @/\ L7?%KXH16?C8Z!)!X&L9XKR_U&8E5>")UD=<,J@
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M-?I_A)_R5-7_ +$V:_\ J.?B/C[_ ,D/A_\ LI,A_P#4R)_0A\'?^2;>%/\
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MC'OUK.OM,\/*YEO=-C9B/E;8,@D\=NO^'2O2](OM"BTVU\R%;>&.(* X4$8
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M_7[CO+MM#UBY&D:E:0WBR'#;P' YQW'Y\'TI][;^%O"<"Q?V;;VD2 %7C4<
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M1*^BZ*3C%[Q3]4F5[2I_//\ \"E_F?/]E^RM^SIITHFL?@]X(M95.0\6E*K
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MHX>+I17/-.M+W8.44XIOJTMVC^&G3/A9\)_!FF-;>.I([C7;I08!$P<[G/'
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M.M??7_!%+_D]#P5_U_:9_P"E9KXI^,VHZ5+;+!9LF]5^8(0<D<?U(]Z^UO\
M@BE_R>AX*_Z_M,_]*S7@^(."QN#XBKO'1IJMB:5*NG3E'E<)07+&-**3H1@O
M=C2E[T5HV['X)XF4,OPO%.+P^78BEB*-&,(3E0_A1J124E%JZ;=KR:>LKWLS
M_9*^'G_(B^$_^P#IO_I,E=E7&_#S_D1?"?\ V =-_P#29*[*OB#\^"OYH_\
M@J#_ ,GH_"O_ *Z:3_Z##7]+E?S1_P#!4'_D]'X5_P#732?_ $&&OT_PD_Y*
MFK_V)LU_]1S\1\??^2'P_P#V4F0_^ID3^A#X._\ )-O"G_8+@_\ 0!7IE>9_
M!W_DFWA3_L%P?^@"O3*_.L=_OF*_["*W_IR1^P99_P BW ?]@>&_],P"BBBN
M4[@HHHH **** "BBB@ HHHH **** "BBB@ HHHH \A^-%YJ-KX-U!=.++))
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M6Y)2SLHW2 DG /?CT]_I7I'A[4;A-&2#68C=>()T M[7!:4L>@ P3UQCWKR
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M[8T@RP1P 2%' &?\^U>5^(_&R:@6M--E6S6$E0X.W<![Y'&/?D UQGC'Q_\
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MDDERJ-E)/7;:_1V=K>MT>1_M&>+?$^OZ%J6F:9>2P1&-UDVNPW*!ST..>_\
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MK<(L.\@1XW #>.F!QG/&/U]@_:;\8>#K7P]I'BG1]0TC^U[.**XEB@DC&1$
MQ5E5ADMSD'@GVXKV<1BY8;-,%AIX.$Z>+A[/"U5%NE1G3LH4XZ./+*UI-V:;
MLD*,8M6;^%W:3UN[7TT_"_2^[/B2]\;^*!J#:!XWBGTV"X<_9FN24\Y"?E*[
M\9X],>Q[UA>(_BO)X"MVT^PTF;4;27"FYC#.B@\9RN1QU(].O3CP_P#:$_:"
MM_BQ%IMQ8+!:ZGHBI$SVN$\QHN,L4;GD>^>?2I_A3XBU/QEX6U&PO$MYKB"%
MP))PC.#L/0D$@@=#GKW]/J)8"'U;#9ABL)"C7IR7M\'"K*%"G)S455C*/QW7
M*[62U^0Z=*<92M>\U^[G92E**:;BUM'MI^5DNBD\3Z5XD@6\G'E,',A5FP5)
MR<=<\>O;FO3O!?[23>$A'X=M9T-M(!#YCD.J X Y/3'O^/(KX]MH-135-2TE
MV;<'FVE#@<EN%Q_+CIQ7GDJWMKK3V<PEYF!#=P-W!SC/Z?CQ7TDLMPN/PZHU
MX*K!)58P;NM;<LEIT[-+SM8V37)"2M%[-J]^96NFM?5=K'[@?#O7M6U:\M=:
ML]8$\,Q622))/E&2"1M4@ <G/ (/4=J]F^*(O+_PZ+S10?MZP_OEC'S/@<XP
M.Y'4GJ?PK\^OV<_$L^BVT$4\[R(V,!WR0">G.>W;].]?I7X.GL==M5821,TB
M@-$Y4C!7I@]>1],<#-?E_$&$EEF-IU_9PE##27(XP2C*+:?)-):[:7O:Q:7-
M=7NI).S:5]K-;._IKKI;6_PK:>$KCQ:[QW%I<6VHK)AI#O4%P<9Z G!P>0?K
M@5]A> /AU<^!O VIZUK-T62VM7D@65\]$)7&X@]\\<CMU->@7_A?1M-N!<I!
M$DOWSL4 $CYNPZ__ %NN:\%^-'C_ %:\TEO#>F3BVADC,4AW;4*A2I!]N^>.
M??&.*IF&+SQT,'A;8?#RJ0G7E)-\M.$HN:A)ZI-)K;N1[L%)\JNE9.UES.R3
M>NK5TV]]-F?+:_&+6_"_C>;Q3;7C+:27SP"(,0"HDV] >_T /3WK[+_X2O5/
M&?AR/7[=I%DDMS*64L!N*D@\ '.3Z>OK7Y9+H6N>(?&=KX7MU:X2.\6:XEC^
M9 N\,V2,@=\D?SS7Z8Z9?OX4\.Z7I=I92WEO!;Q1WH@C+[6P ^[ /3G.0/J,
M"O?SW#8&@\#+#TJ53%<D5SZ1MA8J/(JE[6<M5&[5^QE"T825VUI9)7O/3G:>
MUO+U1\F:IXU^+EMXDO422]GTV.1P@#R$!02 .N.G; Z5Z'\+?'/C>?Q.AEFN
M5_>#=&SOQC;GCIT)SP.^*[7XN^*M,T[0+>'PQI\::SJ:A KQCS$D? .X$ CD
MGJ#C&<@\USWPB\#>.-#>'Q-XG: Q74@D6--H(5R&'&",@$#/IZFM'6PE7+9U
M:N!PN&=6$J-*G4454KS@DG+EBK6ZIW=UYV9"IQ3;7-=--W=UT6GW:ON_O_0'
M2_%6NW-M!!<>9M=4#2-N(7('4]@,^WOD5UEWH5YJFF.5O54O'\K!@"I(/4YP
M,=3GZYZ8=X3@L]:\/%D@&X0LV\(-PPI/WL9X/I7SKKG_  LS7=4U'1_"-\+2
M.U>10)'*9"DC@$C!X'?IVP*_*8TX5*N(]E+#X#ZK/GK3K).GRWBD[J[3OT2]
M;:7J4I)JT93<GHH[MK7\O/R.WL/!/B;2]0-PFL/+ )"^Q9,X&<XP#V QW'OZ
M^X:?K\FC:/->:AY<QMX6.UU#,2J9)R>3G_#ISCY0@\<ZQ\)=/A?XAW@NI;F4
M1+M<O\SMC.,GH2>V#SZFNZU3Q>NKZ$FI6;>987T.Y50YPLBX((&<<'G@_7C%
M;5\)B,Q]A.K[*IAJDU3I8FE!4Z=51<>:,)6UE;5???H$9Q5U%.,HI2G&^L;V
MT=M%MHN^A\,?M-?MG^*]"U>[TWPT6M!"S*-FY02"5_A_S^8->0?"W]M;QIK%
MQ_9NO*;SS&VEI$+$ @#JPXYZ'IT[=?1?B/\  V#Q[J[ZE"T,<9<LX?:&8;B3
MC//(Z=/7&3QR-[\-/ _@?3"\$<+:TB8(15R64#&!M[]<Y]/>OU+!8'AFG@L/
MA(8"-7$.$(R4:=ZL)I1]^<[7BD]W=^>KUB%.2DZKG)2W5Y6C:R=E"]K[:[^G
M7Z_\-^,;/Q7I,T<R!8;J-A*F/ERXP>. .N/S/O7S=\1/V1/^$RN;C7?"6IBQ
MN\M)LCD"N6)W=B#U ]QCKTKOO@O>:=>^'K];EUAN55A&KL%88!Z9QSP,],'V
M/'E?C+XYZC\,]6G*W$C6\3M\AD.TC=GIG&".,=/UKDH8+&+'8RGE4W0JTI*]
M.I'GA4C9>Z[JS72_2V]V:24'33J*\6KRDM''6/6V^_E\CT/X1>'_ (F?#*T.
MFZIJ-R(8CM,LDKE611@XR<$8'Y<8];GCOXI:A8.YCN"TN#N(;)8CN>>IQ_/W
MK%\(?&NY^)U@UR[116^T@D, V?7J:\U\47^A2:P+*YNHBTCD9+*0O8@C/7G'
MZ\XYVP.&HXC&U7C*&'6)IW5>%&"LY*U^;16;:3Y5=)].C(**BG!24))<KD[M
MI;/OZOJUKV.4N_BYXDO[]WB:6-(6^9LL =K>_!QUZ_AUKZK^#7Q,UZ],6)Y)
M-I4%0S=L=>?0\YXQ]!7G^B_#72-4LC):QI(C+N:1!G(QDDD#G)/4'CU]>%'C
MZ/X6^*;72K#0M0OU:X59WMX'D54W89B0&  Z9X]>G [\91R_'T*N$H8:E[:$
M?<A-1C:R3:;=K-W=K^A7P23;>J7-=Z*]G>U_-:ZZZVZGZ97OC359+)9 S[PO
M(!;J!GU_I_7/!WWQ*NK5!'-(3*<\$\Y]O\,'-=EHUQI_C;P)!K>C0F&Y%H)+
MBW92LB-L#$,#R#G(YYSQ7RGK6I1/JDUK<_N[B)F4!N#\IQT/!_7MC'?X#*\#
MAL3/$49X?V<L/5:JPLN>G;:Z7V7;?JNKZ.Z3BKKE<KW?7:R6CUZ:?<?0&E_&
M$@M9N=LI#9;.,]N#Z<^O4\U(^LVFL2->7%Z$D#<1E\%L]OO=""/_ -?%>':%
MI O[U'S^\8C[O QG&./?^?/OU&H^"=8;5;,V[3+;AEWA20&Q@'@?IV'3IT[*
MF79;0K.,)_5YN#E*32=[)7C'M>UEU71ZF<^:;3TLMK/;5:OO\O\ (U_&W@.S
MU[3)+^!!YBJS"48SN S]X<]/R^O%? 7C#PRD&HRQW<I=8I"1N8G&,]?;CW_,
MU^O,6A1P^$C;R+^\:#&6'.=GKU&>2<D\8YK\^OB-\-=3U+4K@6P9%,KG)^I(
M],_I[]L=_#6;KFQ&'J5G&E2FU!R>R3U:?3H[>:LM=*E&-HV2;MJV]6]-]._7
MKYW/C/Q%J][8P^1IZGRTPHD . ._(R,]>>3Z]:UO#E]</ISW1U%?M$0#"(O\
MS'KC')Q],=>N:].U/X9ZG;VCV3*L\TF0!M#-SGV)&.W^&*Y:T^%UUH<4DUT)
MHYY!F-&!"$G)  (QSV ^F.:^VACZ%2,(*K"S:Y7&,7*HO=3>KO:R=VN_<R?,
MY)MVLM5T236G77;?R,F+6K[5DE@E#*YS&#SSVST_$?RZU8T+X5RZI>!Y?-DE
MFD5ARQZD'@?I[GIWIVE:?>0:JMO/%AC( #@\J2 #R.3TZ^WX?>?PF\#K=_9+
MIX-Q(0GY,].,#C\>G//X\V:YG' 8:4Z3A"#6Z2UT5DFGL[._F^XTXR=FKM7T
MW2O;5]?-;):=M=OX(_"*XT"VAGD!.\*0",XS^'I@G@<#/ Q7U?\ \(-:W,$3
M746\KSRN?;)R/\#TX%=?X5\&WZV:SP6S""% 6.S@8&<],?R[=,5-K>K"UMIX
M8AB:)6&!QEAQCJ#VSP1QZ<5^(8[.*^88V3IU8SFI)3<'9P3:23ZKY=ELC6G%
M*R2LKW6ET^KW_#M]Q^E/['NF0:7X+GMX%"KE.  ,8[<?4_IZ5]B5\,?L0ZG?
MZEX0U1KT,/+F4(#W&XC(R21QV_'O7W/7X5Q-"=//,PC.2E-5ES-2YKODB]S6
M+4HIK\K?=Y=@K^>;_@KSJKV/Q"\'HH;#06P..>J( >G_ -?TK^AFOR@_;X^$
M/A?XB^*] N-9G@BN8(H!&)6 )"JN-N>>0,CMGL>,?1^&.987*>+<'C<;&4J%
M/#XJ,E"+FTY4[1=ET3W=M#CS%3EA91@TFY15WZ[6??\ JY^'?@W5]1>:%X3(
M(QL)P2.. >GX]B>V<U]K^$OCGH?@BPB-_<1B940,KNN>  <DGJ/SX/'K<U3X
M)^'?!VF33V\UN=D?RME3QLX[CTY..N.O;\XOBO/;)JMQ";TB-9"H5). !GC@
M^OY\U_0:PF3\;5)TIPJK#0GS.4(M3=[-+H]GMWW5[(^<KXC$9?*G2P%HJHKU
M'+K+1/E?_!MYWM?]3(OVP_!LK!&F@)([E1[GG('_ .KW.+UU^UCX,6TFD%S
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MHQ4MSUR+Q'X:U! TDJ-*XY0E>">V"#G\3W_"LV]C:5P=+M8I$8CE<?=)'/\
M4_KZ5XA)92^:6L@Q*GHF05[\<]N,C\?2K=OXBUK3F"QW+)MXVMST^OU]*^0S
MC"3K+ZY4IU)0E7=/VD(NG@<74I-)U:-5*,_;*R;496C>[Z'V.&\4I5XPPN=9
M;3H\JC_MV64Z4L6HNWQ*NG3L]6^OZ^ZVNFML66:3[-,N"54^@]OQ[]?7!J2Z
M@TFZB>*]"M*ZE!(1D\C'7]>"*\DL/'%_&Y>[5IP>N!QQUZC_ .OQTQ71)X^T
MR<(DUH5;(!8KP,]3GIU)[ ^O>OL^'?%+B7@GZOBLGRO!XNE3HRI2PN;SQ./H
M8JC*+IUZ<:.,=7#T^:,I>_0C&:;TDNO?+&^'W$>%J8?&XU8.K7>OUJBJ<G.Z
M]G5E+#Q24[6WTU[&W:>#;:VCEGANBP8EECW' ZGI]20/RIUM'J5D)5M;F20'
M(\C)(..O&>0/3&*T;#6=-DC#"X158<*6 (R/\CW/>K$/V<3--#<H2>0N0>#G
MW_\ KY/3C%?I='QFX5S3!Y+4RO@/*^#*^#I8C!9OB\JJ8YY@Y8M-8O&X:GS>
MP3JQJ2CR35DK<J/,CX:4,-5=?+.(J]=UG"K0C0Q5%4E&+3A3E&4^9Q35^6W2
MS1#8^(KJP>-=0LE*HX8[DXZ]>A]![=?2O;HO&FA:OX;DMH!'_:/E%(X#@?-C
M .,=2< 'MZGDUY%?6CSV[3&(SD D@#GO['\NG;K7 F*XCD::T+V<ZL<9) X[
MXX_Q/2NG'\34<@H?V7ALTQ."R?B*C@YTLRJTL/6Q_P#9N#]Z6'PKK1EAX8S%
M1DU+VEG%I-69]/D_$/%?"E7$<U##9]1EA<5AJV#Q5&5*MSUXJ'UF%:G%1E]7
MWIQ<G!W:>FWJO@;1/$,NM3M=Q!K>60F-3RJ*QYP"< <C''/3K7<^*=)O=)62
M:T&Z3RR6"\@9X(&.#P?R[<BO'M%\1>(=/PW]H!WP. ?IP/7CZ>V*[IOB!=7M
MJMI-;M-<@ 22;2=W<CD'TZ@=,YZ<^E0R7@+/(T(O$YQ.G%QP]'-,]QF&KYCA
MZ5=*?M;4)N=3'4JO+]74;T88=.-HL6$X@R^/#^'RVOA\PP6+I8JKCY^TINI1
M4I2UA0E1BU&$KM2]IKS6MHM.*T:3Q#=ZA(Y215#$LV#T&<C_ #Z\5U=[I-KK
M<,T4TOE7$0.]@<-D ^O/8YQBGV?CBUL)#$UB$9P0Q*<Y(Z]!^OMP,UAOK<+7
MDTD9 6X)W+TQNZ_AUZ\9]*^DRGPQP64_VKC(9I@>.<!BX8.AG6"K8GV%?.*U
M*O&=/"\/8:K-3IUX0Y(U9SA:4DU=ID2XLX>CEV!R^MF>(=>>(Q7/'$4:RAEE
M*I1Y:=7&55&W)*;]WEES)+R.=T/1[VRU6:"*ZD>'Y@A)/)SP.I_EWKT630M;
MO=,DTN2)@DS$H^#R"!@]/_KC.162DUG 4N8Y5\Q#O9._8\]^V#QSW(YKT#3/
MB'ILL2*TD1G@7 0[0Q*CGC.>Q_+/-?8X[P8A1A#(LPS/,N&Z?$4GGW#658C,
ML-4J<E)1J5LDSJM"JY1H85>YAL+AY*:YN5PNW;S^"\ZX;I8FNL;F>%^JX6%?
M+\;5H-N&(I8NRE5P?M&VY]7*?;KH9UE=2?#W2%@UJ+?;LHPKC@@\]/H0/;GF
MLRSU;_A+!(ZW3V6DP;I(8D8JN[DC R/T!K2UO6+3X@RQVES$(XK7 8<*'V\9
M/(SGWZTNF>%8;=I(+)PT"J6%NI&X?Y[<>W%?@'&/AEQ'#&Y56RW*/[:X:J4L
M7*GA,QE3K?4WA*ZI8MP3YL2XNLG*A%^_R65K-H^VX9PV"QW%]3,LOQ<<QR3!
MNEA,%4CS4*E6JJ5Z7,X\LG[)+EER?%))K0T=(UG488);FTF>6ZLP4MIB3O 0
M8!!&".G!!_''3:T3XM_%*!YXY?%FIV]CR)+)+F18Y!GHR,2",<=,^G'-5-/T
M.ZM+"[NU0QHF_*_0'GK^.?KQZ>?7<=Y)+/+ Y<LQ.Q<\_7IZ]..?K7P,^&\@
MP.82H<2\&99GV5TOKV.KT51P=:6"Q&+PKPU&K7<HR>&I8:?+*--N$E*/,ES.
MYW9KD>98_BW#YQF\_P"T,5AJ%#$99#,,-'%<E/#8B-2E2IQQ4)SK3IN"Y9)-
MJVCT/;]8^,[6VA26D>A0W-]=HT<M\R*92SC#.S;<DY)).>3S7HW[*?QP;X">
M+9/'MYI,6MQW$3A["=5DC4R$G&U@0",@YQG(/7BOE2XD%UHPMU(COE!)0@!L
MX/..O?O]!FK>EW4ECH$Z7<P,_(5#UR>G7\/\*^"RWZ+? O&6$S+A?%9U3H8#
M.<!7S#.8*I5A&67SO.-"A5<DX.G!J"]FURG[/Q_XU\:\48:%'/:];&8##</R
MRO*?JV'PN7TLL=2E"GB:26$ITISQ=5)).LG)-66K;/H;XS_&K6/BAX_U;QQX
M>L%\,OJ,YF1+,"'RP01\HCV_W@>,#K]!X9<Z[JVB7DVL:VC:W=ZNAMFGN/WK
M1K( "V6R1C()]".N17-:7J&I7%S#$KGRY6P%YR.>OY '_/.KXIO9/]&TV0"2
M7*[3MR5)[CC/!_,<_7#%^&7AKPK@<OX-P.18_+)4<$\MPV=XZC7G2EAZ*C]4
MG5QBBZDXR4(RA"-1MJS:W;\+!<19KF.,PGB.\<L1G/#F4X'*,JQ%6AA*F*I3
MA1I8=X>%"4'!RGAW4ISE*+<G)RD^:S7[0?LMZY\!?AU^QSXWT[Q##IUYXP\3
M_:[FWAE\HS0O<Y<! 06&"P'&,?A7Y&^,I?$_A/49-0\-ZK<V6BZK/*TMC [)
M"T;R$E2H(&-I Z>@QQ6+;:WJVD6EI:WMTTE@&5_)#$$ 8^4GJ!C/ QG'Y]IX
MJURT\4:+:PZ>BK]F100!S\HYYXQT]#GL.A/YAX7>"%#P]S[CKB3B+,*_%?\
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M-H#'H>A !],YS^0JY\*?AU<7>I3W_B2%97D=F42("1SD !@#@ @#';VKT/\
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M9.<<#!/.?IGBOS0\+?#WQ=I/B-VU"YF15NB/+9G^Z&'!!Y_/V]:];(IX#-<
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M-X%&[9(!M()QP=V1UZ'(]_BS]I3XB>./ &LOKWA@7-O;3NSR>0'^8$Y.=O\
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MEGCTQZ*/@IX(O<>?I4!.!SY2#\>@Y&?;Z<UY%3QHCA*M6E6P+G%-QBZ22O\
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MS:M9+JTK*U_RW/4O@%X0M+R>RNI  R>6<8[C:<D>^/UYS7ZIZ-%;VFD10D
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M3:?\/]=AOTBCADEW/@80D]AZC(^@^GM]@ZOJC3R&5U"H?4>HQQZ?S/J<5J^
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M)'[!EG_(MP'_ &!X;_TS ****Y3N"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** /E?]LC_DA/C+_L$W_P#Z3FORM_X(L?=^)_\ V%+O_P!'M7ZI?MD?\D)\
M9?\ 8)O_ /TG-?E;_P $6/N_$_\ ["EW_P"CVK]2R3_DVO%/_89@O_3L3\,X
MG_Y/1P)_V+,T_P#2(G[]4445^6G[F%%%% !2-]UOH?Y4M,DR$<CKL;'UP<4
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M;&,YQ@ ?3J.E>F:1XE7Q9X4LM7RK*Z*3*><Y4$Y/Y@@=NO/%?DWX[^/&H?M
M>.-/\&Z%8W$A^TPHDH@=MRA\9+ =>O?@XSQ7ZQ>&OAMK_AWX266BB!_[1-HG
M&T[U9HU/ID<D]NV,=!7=F5+!8+!99"K*C3QTZJ4^64;>S=DY-Z/E6M]UNMPB
MU[TEK'9);N6G77>_XZ^66OAB?5U>XL[DD#[VQCM4X]CTSWXQQUK*TS3K*'6%
MT6_NDENIR$51("P+$#D9/(]#VR.*XWP[+\5O"\]SI<NG2R6D[NOG,A^5&/+
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MSYUN_B*MEXBM?#-EILS[)%BEE,;&,@-M/S;?Q]_3'7WR33([FU@=45&EB5F
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M** ,W6?^0/JO_8-OO_266OY(O#?_ "DTTS_L/K_Z5-7];NL_\@?5?^P;??\
MI++7\D7AO_E)IIG_ &'U_P#2IJ_7_"K^!QC_ -D]B?\ TB9_/?CK_O?AW_V5
MF$_].43^NN'_ %47_7-/_014E1P_ZJ+_ *YI_P"@BI*_(#^@X[+T7Y!1110,
M**** "BBB@ HHHH _!O_ (*1?\G:?L]?]A+2O_1T-?NQIW_(/L?^O.U_]$)7
MX3_\%(O^3M/V>O\ L):5_P"CH:_=C3O^0?8_]>=K_P"B$K] XK_Y)C@+_L5X
M_P#]3(GY'P%_R7'BK_V/,L_]5R+E%%%?GY^N!1110 4444 %%%% !1110 44
M44 %%%% !1110 5_#5_P<O>(K_PWXB$VG.8WFE96VG!/) ' Z8^M?W*U_"S_
M ,'.,(FUS=QNCD<KGU#/_4>O05SXN,98:NIKFBZ<N9/9I='ZNR/8X>J8FEGV
M4U,'5G0Q4<91=&K3;52FW4@I2BUK?E;7G>Q_(?:Z-IGC26V?6XA'));JYNG4
M+ABN=P)/48'_ ->LBX\#!4U/3=-U5+]!N$44;B0H , 8R<#GIVK,&KS#1O)>
M40NEN54*V'QMP,8P>G]>F:\1\+>)O$FA^+Y7@DN)+669A(TS,4VD]3G*]#T)
M SCI7PSP,*M-2IJ5)-1O%S<X-QG%Z3:;2<=&ME<_MC,^(,MRZOE]''9?4S&O
MF%54<7F%"]#%T(5L/"$HU*-/W,1:4F^>HT[ZJSU?KT_A[PMX*T+[9JL$<NK[
MBP5@I8-DD$]^"?H<9]S\_>*-5G\4:C'Y 80JP$<2DX"D],#&>.,=<=N]=+\1
MM>N-9UHEY68$?<4_)GTP#CJ/S':J_A?3HHI%O+A/F'W01UX.#S_/^G->S1A1
ME44,-1Y5.$/;.%2=3EDE[W)*2O\ O=?=^%;=3\^SJO2SC,WDN6TX8'**#A3J
MS]FHSJJE9^VKR5KR=WIWON;OA_PK::59K<W*AYI!D1MR06 (_#(ST_QKJM-T
MNZFD-PF(8HSD$CTP3@<9Z9]OP-2+=6(D3SF4%B JY!'IC!Z#U]SC/2MB*ZGN
M#]BA*QQ,  ^0.N!U&!T[>N"*^TP&79=5HPG7QT<I@Y7I^^[.<8J7[Z>Z3DK-
M):-V7<]_ TLNPN(PF#PV&6+=**A3H4$G7Q%9VY9U)J_(KNZN[);NQS.JZY=-
M>)IRKYB A"X&>V.OIQ_G-7[CPAK&IQPFS1T@<#S77( !ZYQ@8Q_G%;[Z;IVF
MJ'F1;BZ;#*5&\@GD'\__ -56;K5O%T5O';:3;.()P!G:<C=Z<8! )Y[FCZMF
M6=9=C:N5957QL8U71KYCC9RI4HS:5./U*2?-5C'2<K[QO?8]^EE&78;%8BIQ
MCF>(K2JTE4IY;DM'ZWC<-#3DP^*2O&DY:1;C)M:Z:6*NG_#K2;2(&]O8Q*V
M<N,AN_)(P<YZD\4VZ\.>'--'[VZ24GHH?G'0=S@=<X]/SH7&F:JZ_P"G-.EP
M<.W+  \]LC'KT.#ZU#_PBLEW")Y9Y3)PH4L>I[]1Z\^G'O7ZCE>0\:T^&L)A
MZ;X=R_\ L^G'V5;"X/#XC$XNI4_B1Q=2:4G)/X4[V:UZV^>QN8\(QQ3HY3P?
MC<56FE%4\;7K4W1BK.H_9/W>:2WMYG06;^$[!08D5I&49P<\C'N?3..WOQ5N
M>31]0C"?(R+SM!Y4=,GTZ]_>NO\ !WP7NKJQDO)[:ZNC*K&,1HSXS@C. ?\
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M>:YF'QA\-;U(WU#3@UPD2K\L?R[@H_V3Z>O;C%9-O\2]&L-42S2W,?A]FVL
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MI7UW\3U\/Z[=V^HW+6L22$$JH4. ,=>.H'_UJ\WETWX;PKOFF!G90  1C=@
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M1#D9'(Y&1CMQZXJU#X,\,2W)EAMQ&Y.6XQT/(Z>AKZ-GT/39%V,D<2\<(H
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MQW SW///O_.LMH;<'+*B_@!_3Z5J7*1$9SR/?H=OY8]*P9XW<DJ2.!R/\?\
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M^*+JUR"N]/[I((/J.1W_  J6Y\3K=.C-:(NT@GA3G!Z9Y//].M<C17IXK/\
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M@45.-XAS?,'5>*QDY^VA"$U&,()1II*"@H1BH645K&TGU9FL36C!0C/E2O\
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MPD_Y*FK_ -B;-?\ U'/Q'Q]_Y(?#_P#929#_ .ID3^A#X._\DV\*?]@N#_T
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MUM?E;2S5*FI<W*F_/5:6[^F_KW/G:W^ FF6Z>6DP5  %7)P .W'TJ=O@3IC
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M77EZ??MU[A[&'G]Y^2GCC]C;7?%FI03S0LZ1R*S!@2#A@1UZ_3TX%?H5\$O
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M_P!@N#_T 5Z97F?P=_Y)MX4_[!<'_H KTROSK'?[YBO^PBM_Z<D?L&6?\BW
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M=!U_S_A7G@"L =H /MG']:<% 4X48SR?R[9_Q_2DU>[CY:/>SMTU[_\ ! ]
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MK7$ KM(( XP..O'TXJ$JH.3TZ <]?K^='(M?*VG?;[KZ]5;<2;Z[_P##??\
MC^AZ /%F3V'UI#XM S^/XX].:X0X)S@#C'\_:F%5/;^8Z_SI./+JTVM/S5[[
M=REMKO;\3O1XMR,X_P _G3V\5@'CGCZ_RK@E12<8[?YZYH8+GC!X[X--J.C3
MM?:^O;1OIKOZ^0KZVZV[:=/OWZ'='Q:!C(Z_YYYH/BT 9Q^7_P"NN#*CT^G;
M^76EVH5QCD'/U[?Y[TG%*U^MK6N^9:7M\[V_X8/>TU7G_P #S_ [P>+5*D\@
M@],=N/K_ #I%\7JVX$$$=/\ Z_YC_&N%.S!& ">@]>GX4S: #@8)[_Y_#\J5
MEKOITV?36^O?MTUL,[P^+@!G!P3CI]??VH_X2]?\@UPAVA-I'?@]_P!/Q_.D
M$88''(ZDY!X_EV/8TTHR=DFM.KUOI_P?O\@.\_X2]?\ (-._X2Y=H//)].._
MXUP'EICH/3/TX_3\J-B$ 8&!WX]_:CD=]U_EHM._I^/06^SZZ];]T=Y_PEX]
M#^0_QH_X2]?0_E_]>N$V+Z?J?\:;MC!/O_GM_6E))+SO9ZW[=-][_P!-69WO
M_"7KZ$?A_@33F\7(#@<C'7\_\]*X#]WG'?ZD?S-*RK@G Z8IJ*=[+72R5]$[
M6];=;=_2R2VN]EJN[TU^5OQ.]_X2]?\ (-(?%XQP,^W3_$5P"(I/('&".E/V
MC)XX[')]O?Z]J%%)-RO>]K:>6W_#]PUNM--;^78[W_A+U^GX?X9H_P"$O!.,
M'KCI_P#7K@ JMU STQ_^O)I0%R !G'!YQC\.A_"FE!W;V];=%^OF%U>W7?\
M&WYG?GQ< <'^1IO_  EZ^A/X?XD5P03D@C(['IZ=L_6@!<9(Q^?3CWH48R3L
M[-=&[]NVGY=[6!NVNK\O6R_K^K=[_P )>N"?0$XP?Z9I/^$Q7:&QU.,<^_M[
M5PNU2.G!^M-\N+/.![?_ *L'\SBDU%:7?-V6NNE[?\/_ ) M?\NVFQWO_"7K
MZ'\O_KTO_"7K_D&N"PA.!SUQUY_'C-&$.?;KR:2Y=+IZ_/73M\]-]4']?EI9
M]SO3XN  .,Y_SW(I/^$O'H?R'^-<$ I8C P!P1GV[YYJ58XR.>.?7'\Z.779
M\NE[Z/7S_P E\PZI:N_7I\WMJ=Q_PEXXX^OM_C3_ /A+/:N"9(U(Z'.<<DD=
M.X]<^U&P8!QQV/\ G^1H=OLINSU]-+[VMZ_==-69WI\68(&,Y&>.WU]Z0>+@
M<\=.OZ^_M7"  \;03VZ< 4I0?W0..>O;.3R /R-4HQLG)ZOI_7=>?Z";2]>W
M5G=#Q;D9Q_G\Z3_A+AG&/Q[?SKA2@'!4?H?\:;M7T_G46LU>Z3?7>VG^8-[I
M-7['?#Q9R,CCO2-XN4-@ G.,''K^7?VKA2%*D8 (''UZ>G;K@4Q4! XR1UQS
MW[X^HI^[?J^RZZ6ZWZ^2Z^@)2:OHK+7JM6K?KU\SOF\6;1G@_3J/K^=-'B\'
ML1]1_P#7KA057D@$#L?J/\.U)\C$D <]O3\Z$NZ:7?ITMY=UZL%=[KE^?IY=
M=>FAWG_"6C)&.1_GUI?^$L]JX+:O7 _S[=*=M7:3@9SP./;MUH2C?5Z=/^#I
M]^PSN_\ A+/:C_A+/:N""@D# Y]A2E #C S]/7\*.6[5G=;/377^OS[ =Y_P
MEG!/'';O^ IJ^+@2!@\^W_UZX<*%/( '.>G<>G6FE4W< 8^GY_Y-.,+[V^3O
M_7]:"OK;\>GIZG>OXL50."<_0CO]/2F#Q>"<8/Y?_7KB&52, !C]>?7/;/I3
M0FT'Y.>QSDC/'K348NUG?JUU>B_#S\]Q+FZV>O\ EK\M=+'<GQ< <8.>/U_&
M@^+@#@@_Y_&N%,>?F*^_)]/;/]*41QD9/!],X_S]?\*EKWDHJZZJ^WE?_@O4
M;=M;Z?AK_6^VIW@\6#(R.#_GU['_ /52GQ8O&,GUS_D5P;!%P.QQSV S[#![
M_3K2_N\= >.,@^G'^1BBR:5F[NVCVO>V_;<;T:5GJK^6W?SZ?<=V/%B]\@_I
M_4TT>+D*DG((S@>O'^>]<,@4\8Z<]Q^GXU$RKDD<+Z8_S_+_ !IM)?9;L];_
M (6MY_Y/="2>K>S>G]?-?B=ZOBX,>A XS_G)IQ\6#/ Z=?K_ )Q7!J H)VY#
M=\^F?KC]*!C=D+GVZ]L=:5ES6LTK*VJ>KMOU_P" QW2W=CNCXMP,X_S^=.7Q
M:I&2#[#UZ_YZBN(D*\?(.>N3Z8]JC,>>508P#T!QQ^="6K4E;31W6NVVMM!+
MOT;T]/EY^O\ EV__  EX]#^0_P :</%H(R!_G\ZX91'CD#CIU/'7_&I'CC"Y
M7&",^O/&/SXZBG9*WNO7;5-6TU_K37[DWK;2^E_PTVU;3^74[;_A+/:NBTO5
M%OUR/3_#\O\ /X>3QJK(0 ,CZ#OS^G\_6N]\+*50\8'3]12DDO+7;U2_X/?H
MA]=];;?=K_E\SM:***D84444 %%%% !1110 4444 %%%% !1110!FZS_ ,@?
M5?\ L&WW_I++7\D7AO\ Y2::9_V'U_\ 2IJ_K=UG_D#ZK_V#;[_TEEK^2+PW
M_P I--,_[#Z_^E35^O\ A5_ XQ_[)[$_^D3/Y[\=?][\._\ LK,)_P"G*)_7
M7#_JHO\ KFG_ *"*DJ.'_51?]<T_]!%25^0']!QV7HOR"BBB@84444 %%%%
M!1110!^#?_!2+_D[3]GK_L):5_Z.AK]V-._Y!]C_ ->=K_Z(2OPG_P""D7_)
MVG[/7_82TK_T=#7[L:=_R#['_KSM?_1"5^@<5_\ ),<!?]BO'_\ J9$_(^ O
M^2X\5?\ L>99_P"JY%RBBBOS\_7 HHHH **** "BBB@ HHHH **** "BBB@
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MQ_>Z<^N?3H:V8[1]7UF/<^Y8Y/,8?W5#9P>G^?TT]>\,3:;>SW[.C)<'= B
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MM-?>KH491FN:$HRB]G%J2?S3: J<GJ<=S]/>@ X+ \CMC/\ GOVI5;'!Z?\
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MYZ?E30" 6!Z''3Z?XU(.N1]TY_//^?\ "H: #K1110 4444 %%%% !7Z^?\
M!%+_ )/0\%?]?VF?^E9K\@Z_7S_@BE_R>AX*_P"O[3/_ $K- '^R5\//^1%\
M)_\ 8!TW_P!)DKLJXWX>?\B+X3_[ .F_^DR5V5 !7\T?_!4'_D]'X5_]=-)_
M]!AK^EROYH_^"H/_ ">C\*_^NFD_^@PU^G^$G_)4U?\ L39K_P"HY^(^/O\
MR0^'_P"RDR'_ -3(G]"'P=_Y)MX4_P"P7!_Z *],KS/X._\ )-O"G_8+@_\
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MKWN_RNW^']: WK^+2M>]U;3MW\AZN.A_/UIQVGN#CGK_ (57&<#/7O\ Y%2
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MWN9ZMZ:75[7Z_/6S!I-6>MAS'.<GC)QGMFG;SM !/H2.XY&*C.,'/3O_ )%
MQ@8Z=J-Y.Z=ET:ZZ77ZZ?YAI)=U_3_K_ #%R,XR,^G>E1B1D@[0<8ZC_  IN
MT9W=_P#(J0/A2OKC!_$Y_GCI2=I-1UBU9)I[/3\//[T"2_)7Z_>M09B@WJ2
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MJ//1KTX\].46UK9OM_25\%?^":'PM_:3^ #>(+)+.#7[?36D5(U3S6D$1/(
MSU ZX&?4XS^&O[0O[%FJ?"+QK>^%9%>.47+QV@D!CW?/M4#/U'3/7J:_7/\
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M_P!@N#_T 5Z97F?P=_Y)MX4_[!<'_H KTROSK'?[YBO^PBM_Z<D?L&6?\BW
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M\*(N4KS26JM9]7IMY>OXD[R4=KV=_FM/\P!/3!P,\DC)Q[<=:7(SC//^?UJ
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M?\?OL=W1114C"BBB@ HHHH **** "BBB@ HHHH **** ,W6?^0/JO_8-OO\
MTEEK^2+PW_RDTTS_ +#Z_P#I4U?UNZS_ ,@?5?\ L&WW_I++7\D7AO\ Y2::
M9_V'U_\ 2IJ_7_"K^!QC_P!D]B?_ $B9_/?CK_O?AW_V5F$_].43^NN'_51?
M]<T_]!%25'#_ *J+_KFG_H(J2OR _H..R]%^04444#"BBB@ HHHH **** /P
M;_X*1?\ )VG[/7_82TK_ -'0U^[&G?\ (/L?^O.U_P#1"5^$_P#P4B_Y.T_9
MZ_["6E?^CH:_=C3O^0?8_P#7G:_^B$K] XK_ .28X"_[%>/_ /4R)^1\!?\
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M4_9@^)'P9\=^,9= T2X\-&+2I#;R_:6MS&JQDJ?O$@8VG/?GH:^D?C5^R?\
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MD]QSWX]CS71>$O"AM?%>F7ET0$:9#$3C'+ ^_?''_P!?'[)DOAADV&RB?#.
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MK?\ IR1^P99_R+<!_P!@>&_],P"BBBN4[@HHHH **** "BBB@ HHHH ****
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M7.XJ\8VNWKJ[;7W>OI;\;/F#.'S@>PZ_ASWITK*$9L\@$\#_ .MSBJ8?:Q#
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M8 Z @ ]?Q[TIEY*@Y YQS_\ J[^E%EI;=-;Z/?2^E_3RVN/\_P RTC9&YR2
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M,<8Y_P#K9]OZU4W!6R3P3[]\]?IUJ1Y%7YA@'IQ^/IS567+%M-Z7;2MO;?\
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M .N<U[M\+;6]T?PBVK2.8Q$@5EZ9SCL>.?;OP!TKY@^'6B7EC&GVRZ%QYLF
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M )/0\%?]?VF?^E9H _V2OAY_R(OA/_L Z;_Z3)795QOP\_Y$7PG_ -@'3?\
MTF2NRH *_FC_ ."H/_)Z/PK_ .NFD_\ H,-?TN5_-'_P5!_Y/1^%?_732?\
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M* "BBB@#\&_^"D7_ "=I^SU_V$M*_P#1T-?NQIW_ "#['_KSM?\ T0E?A/\
M\%(O^3M/V>O^PEI7_HZ&OW8T[_D'V/\ UYVO_HA*_0.*_P#DF. O^Q7C_P#U
M,B?D? 7_ "7'BK_V/,L_]5R+E%%%?GY^N!1110 4444 %%%% !1110 4444
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M]IV>VFIX31117J'Q 4444 %>E_#286VL1SF,,R.-I/KV_7U_ET\TKM_ SO\
MVI'&G+.PVCO_ )]^M..%QF-G##9>I2QE6<%AU&]W44E)+W==;=/0^KX'QE/
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MC75)^]675)JS<MG>[9X!?1K%=3(GW58X_P ]OIVJI6EJ^W^T+@I]W><?F?\
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MD)\9?]@F_P#_ $G-?E;_ ,$6/N_$_P#["EW_ .CVK]4OVR/^2$^,O^P3?_\
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M<=\'J3_GOBN8OKPP E6QCKSZ8]^/;IGZ9KE#XT@M;D0W,J@D]6/8'W/H./\
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MZ23UZ7MKT^?STON]"[^MM+/H]/GMYVZ'KM%%%0 4444 %%%% !1110 4444
M%%%% !1110!FZS_R!]5_[!M]_P"DLM?R1>&_^4FFF?\ 8?7_ -*FK^MW6?\
MD#ZK_P!@V^_])9:_DB\-_P#*333/^P^O_I4U?K_A5_ XQ_[)[$_^D3/Y[\=?
M][\._P#LK,)_Z<HG]=</^JB_ZYI_Z"*DJ.'_ %47_7-/_014E?D!_0<=EZ+\
M@HHHH&%%%% !1110 4444 ?@W_P4B_Y.T_9Z_P"PEI7_ *.AK]V-._Y!]C_U
MYVO_ *(2OPG_ ."D7_)VG[/7_82TK_T=#7[L:=_R#['_ *\[7_T0E?H'%?\
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M)S4J<8MMV<F[7;U;5^VJU>AD1:.]O\UY(I1>2,]OP)Y('09JS+-;>6$A"K$
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M10 4444 %%%% !1110 4444 ?*_[9'_)"?&7_8)O_P#TG-?E;_P18^[\3_\
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M)%=KI'PQ#3)<S8E@;:3MYPN>?3TZ?XU^B_Q=_9-N!+/=:;9FVE4LP\J,KTY
M&T=/?MQD8.#\FWF@^*? 0FM+ZSFEB7*!V1CP.!U'89Y'OGV[:GA;A:^&E5PF
M+AB'R.^J51.*6J;OVW_&QT8?B*FZU.,L+&G.Z3E+^'+ELFFM-[+Y;Z$VC>']
M#\/P?:+ I]L5/NL1N# <'!]"1]/P%>3>*+[5_P"T9;B<NJ,3L'0<9(Q]3@X[
M'I[<MX@\9ZCI>L"?,PB+_-'@@ $XP0>/8XX_*N@D\5:?XML2'*QSHIP<@$D
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M!7'QN?PY.Z:;-M+,Q!1_N^QY/'^?3'>^&/VK]=NX6T^>9U7 5)"YX(.!@@C
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M?]BO'_\ J9$_(^ O^2X\5?\ L>99_P"JY%RBBBOS\_7 HHHH **** "BBB@
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M 0,$ ?J/IGZXX^1;:'4H;5M0>X*RHNX@L=VX#)&"1S_+Z5RTOBR_GN&66X;
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]A7X\_"R:\FM!!902B1=H+;2,GH3GKS_ /6[U]Q_#W1?$DL*M=-*J, 06S^
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M']7IQ;K5>=I1C2CO.34N;EC=V39\R:#HFM>++^/2]!LYY[R3&T>4Q7DXY89
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MKUU6X4444R HHHH *_7S_@BE_P GH>"O^O[3/_2LU^0=?KY_P12_Y/0\%?\
M7]IG_I6: /\ 9*^'G_(B^$_^P#IO_I,E=E7&_#S_ )$7PG_V =-_])DKLJ "
MOYH_^"H/_)Z/PK_ZZ:3_ .@PU_2Y7\T?_!4'_D]'X5_]=-)_]!AK]/\ "3_D
MJ:O_ &)LU_\ 4<_$?'W_ )(?#_\ 929#_P"ID3^A#X._\DV\*?\ 8+@_] %>
MF5YG\'?^2;>%/^P7!_Z *],K\ZQW^^8K_L(K?^G)'[!EG_(MP'_8'AO_ $S
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MC)5@QQR<C')/]/Y=#7VQ^T6Q71K4 X)5L?F<_P!.@KX0N/.CW.7."3Q]1GW
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MD@;44*,=,#'J>WK[8KLY?!^EW:^:JHSL,E2%P,\].><]O4]37F'AWQ/!?("
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MQ_0\>M7;1)I_-BDD1<HV,GV^G7\_KBJMIHNLROOE4J"V1G*X'^1^..#711:
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M[@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZOV>WF?FIK'PC\0:+(6LK=P(\8V(1T/0 #T_ #GJ>.?OO"WBJ>%5W7$;H!D
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M_KD?@:\&MF.-==55B*E1VM+F;DI;-;[;:/M<[(X>@[1=-)K9Q6EU:]O2VO\
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M_)<>*O\ V/,L_P#5<BY1117Y^?K@4444 %%%% !1110 4444 %%%% !1110
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M6].NGGUMK_P][7$N9)W4W=6U]SRT?N_Y+L?XL/\ PRK^UESGX)^,/PTF4?\
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MGOY'^+7)^S!^UP6 3X+>+U!Y.-(G'3\.W'<?CFK7_#+W[60"!O@KXM;.,_\
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M0\>?^"A__BZ_VVO^&6O@)_T33PS_ ."VU_\ C5'_  RU\!/^B:>&?_!;:_\
MQJM3E/\ $E_X8O\ VIO^B(>//_!0_P#\71_PQ?\ M3?]$0\>?^"A_P#XNO\
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M\,M? 3_HFGAG_P %MK_\:H _Q)?^&+_VIO\ HB'CS_P4/_\ %T?\,7_M3?\
M1$/'G_@H?_XNO]MK_AEKX"?]$T\,_P#@MM?_ (U1_P ,M? 3_HFGAG_P6VO_
M ,:H _Q)?^&+_P!J;_HB'CS_ ,%#_P#Q=21?L:?M4Q.KQ_!'QXK*00?[(?\
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M/X&>,-GI_9$H!SVR%_IZ"GVOP5_:MLS\OP+\88/!QI,IX';.S^6<]Z_V5O\
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M<7%[7MKM;30_QQ4_9_\ VE[B\,W_  HWQ>B*V0!I$@ Q]0.?7H/2M.^_9_\
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M Y^72'[=/X>/?T]>>?\ 9@_X9:^ W_1-_#G_ (+K3^D%+_PRW\!O^B;>&_\
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M0?\ D]'X5_\ 732?_08:_3_"3_DJ:O\ V)LU_P#4<_$?'W_DA\/_ -E)D/\
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M=6-X3]A52LHO1*UFU:SW7R\V?E-XD^ ?B+29I+NVTRY#Q2$^8HD' .<G&,9
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MM+>RMHS$(@%X&X_CDGOGIG]1TKGI[L/J@A1U*;\#!'K_ )![5VZV*!5*MD[
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M?]BO'_\ J9$_(^ O^2X\5?\ L>99_P"JY%RBBBOS\_7 HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ K^:/_@J#_P GH_"O_KII/_H,-?TN5_-'_P %0?\ D]'X
M5_\ 732?_08:_3_"3_DJ:O\ V)LU_P#4<_$?'W_DA\/_ -E)D/\ ZF1/Z$/@
M[_R3;PI_V"X/_0!7IE>9_!W_ ))MX4_[!<'_ * *],K\ZQW^^8K_ +"*W_IR
M1^P99_R+<!_V!X;_ -,P"BBBN4[@HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@#Y7_;(_Y(3XR_[!-__P"DYK\K?^"+'W?B?_V%+O\ ]'M7ZI?MD?\ )"?&
M7_8)O_\ TG-?E;_P18^[\3_^PI=_^CVK]2R3_DVO%/\ V&8+_P!.Q/PSB?\
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M[>_17TTUUOK:D\<DI4I4Y)?'"6KLK)\O1/\ KR.ETW]IKX3SL$DU,QL0 ,L
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M_7-/_014E1P_ZJ+_ *YI_P"@BI*_(#^@X[+T7Y!1110,**** "BBB@ HHHH
M_!O_ (*1?\G:?L]?]A+2O_1T-?NQIW_(/L?^O.U_]$)7X3_\%(O^3M/V>O\
ML):5_P"CH:_=C3O^0?8_]>=K_P"B$K] XK_Y)C@+_L5X_P#]3(GY'P%_R7'B
MK_V/,L_]5R+E%%%?GY^N!1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7\T?_!4
M'_D]'X5_]=-)_P#08:_I<K^:/_@J#_R>C\*_^NFD_P#H,-?I_A)_R5-7_L39
MK_ZCGXCX^_\ )#X?_LI,A_\ 4R)_0A\'?^2;>%/^P7!_Z *],KS/X._\DV\*
M?]@N#_T 5Z97YUCO]\Q7_816_P#3DC]@RS_D6X#_ + \-_Z9@%%%%<IW!111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ME:_DOP?YF(=1Q&6V(>OW?3)&>#^!^O>HDU%"K.RX(['/3.1CGUYZ<5]-:?\
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M_!53_P"1\U]X?7,)_P!!6&_\'TO_ )+S7WG7T5R'_"P/ O\ T.'AK_P=:?\
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M5/\ Y'S7WA]<PG_05AO_  ?2_P#DO-?>=?17(?\ "P/ O_0X>&O_  =:?_\
M)%'_  L#P+_T.'AK_P '6G__ "11]6Q/_0/7_P#!53_Y'S7WA]<PG_05AO\
MP?2_^2\U]YU]%<A_PL#P+_T.'AK_ ,'6G_\ R11_PL#P+_T.'AK_ ,'6G_\
MR11]6Q/_ $#U_P#P54_^1\U]X?7,)_T%8;_P?2_^2\U]YU]%<A_PL#P+_P!#
MAX:_\'6G_P#R11_PL#P+_P!#AX:_\'6G_P#R11]6Q/\ T#U__!53_P"1\U]X
M?7,)_P!!6&_\'TO_ )+S7WG7T5R'_"P/ O\ T.'AK_P=:?\ _)%'_"P/ O\
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M O\ T.'AK_P=:?\ _)%'_"P/ O\ T.'AK_P=:?\ _)%'U;$_] ]?_P %5/\
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M_P#!53_Y'S7WA]<PG_05AO\ P?2_^2\U]YU]%<A_PL#P+_T.'AK_ ,'6G_\
MR11_PL#P+_T.'AK_ ,'6G_\ R11]6Q/_ $#U_P#P54_^1\U]X?7,)_T%8;_P
M?2_^2\U]YU]%<A_PL#P+_P!#AX:_\'6G_P#R11_PL#P+_P!#AX:_\'6G_P#R
M11]6Q/\ T#U__!53_P"1\U]X?7,)_P!!6&_\'TO_ )+S7WG7T5R'_"P/ O\
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M:?\ _)%'U;$_] ]?_P %5/\ Y'S7WA]<PG_05AO_  ?2_P#DO-?>=?17(?\
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M** "BBB@ HHHH ^5_P!LC_DA/C+_ +!-_P#^DYK\K?\ @BQ]WXG_ /84N_\
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M9=_Y\=8_\"(__D>C_A^+^R[_ ,^.L?\ @1'_ /(]'_$.N-_^B;S+_P %P_\
MD_ZL_*Y_Q%[PT_Z++)>G_+^?6W_3O^\OQ/VJHK\5?^'XO[+O_/CK'_@1'_\
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MHK\5?^'XO[+O_/CK'_@1'_\ (]'_  _%_9=_Y\=8_P# B/\ ^1Z/^(=<;_\
M1-YE_P""X?\ R?\ 5GY7/^(O>&G_ $662]/^7\^MO^G?]Y?B?M517XJ_\/Q?
MV7?^?'6/_ B/_P"1Z/\ A^+^R[_SXZQ_X$1__(]'_$.N-_\ HF\R_P#!</\
MY/\ JS\KG_$7O#3_ *++)>G_ "_GUM_T[_O+\3]JJ*_%7_A^+^R[_P ^.L?^
M!$?_ ,CT?\/Q?V7?^?'6/_ B/_Y'H_XAUQO_ -$WF7_@N'_R?]6?E<_XB]X:
M?]%EDO3_ )?SZV_Z=_WE^)^U5%?BK_P_%_9=_P"?'6/_  (C_P#D>C_A^+^R
M[_SXZQ_X$1__ "/1_P 0ZXW_ .B;S+_P7#_Y/^K/RN?\1>\-/^BRR7I_R_GU
MM_T[_O+\3]JJ*_%7_A^+^R[_ ,^.L?\ @1'_ /(]'_#\7]EW_GQUC_P(C_\
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M_/CK'_@1'_\ (]'_  _%_9=_Y\=8_P# B/\ ^1Z/^(=<;_\ 1-YE_P""X?\
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M*_%7_A^+^R[_ ,^.L?\ @1'_ /(]'_#\7]EW_GQUC_P(C_\ D>C_ (AUQO\
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M6W_3O^\OQ/VJHK\5?^'XO[+O_/CK'_@1'_\ (]'_  _%_9=_Y\=8_P# B/\
M^1Z/^(=<;_\ 1-YE_P""X?\ R?\ 5GY7/^(O>&G_ $662]/^7\^MO^G?]Y?B
M?M517XJ_\/Q?V7?^?'6/_ B/_P"1Z/\ A^+^R[_SXZQ_X$1__(]'_$.N-_\
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M9=_Y\=8_\"(__D>C_A^+^R[_ ,^.L?\ @1'_ /(]'_$.N-_^B;S+_P %P_\
MD_ZL_*Y_Q%[PT_Z++)>G_+^?6W_3O^\OQ/VJHK\5?^'XO[+O_/CK'_@1'_\
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MHK\5?^'XO[+O_/CK'_@1'_\ (]'_  _%_9=_Y\=8_P# B/\ ^1Z/^(=<;_\
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MEB/J>-JX>G-TH\L&X4Y13:2W=WTV/Y7_ /AVK^UU_P!%"\4?^!-U_P#%T?\
M#M7]KK_HH7BC_P ";K_XNOZH**]3_B,7$_\ T#Y3_P"$%#_Y#R7W'B?\2[\$
M_P#07GW_ (=,3Y?]//)'\K__  [5_:Z_Z*%XH_\  FZ_^+H_X=J_M=?]%"\4
M?^!-U_\ %U_5!11_Q&+B?_H'RG_P@H?_ "'DON#_ (EWX)_Z"\^_\.F)\O\
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M^GGDC^5__AVK^UU_T4+Q1_X$W7_Q='_#M7]KK_HH7BC_ ,";K_XNOZH**/\
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M'RG_ ,(*'_R'DON#_B7?@G_H+S[_ ,.F)\O^GGDC^5__ (=J_M=?]%"\4?\
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M(*'_ ,AY+[@_XEWX)_Z"\^_\.F)\O^GGDC^5_P#X=J_M=?\ 10O%'_@3=?\
MQ='_  [5_:Z_Z*%XH_\  FZ_^+K^J"BC_B,7$_\ T#Y3_P"$%#_Y#R7W!_Q+
MOP3_ -!>??\ ATQ/E_T\\D?RO_\ #M7]KK_HH7BC_P ";K_XNC_AVK^UU_T4
M+Q1_X$W7_P 77]4%%'_$8N)_^@?*?_""A_\ (>2^X/\ B7?@G_H+S[_PZ8GR
M_P"GGDC^5_\ X=J_M=?]%"\4?^!-U_\ %T?\.U?VNO\ HH7BC_P)NO\ XNOZ
MH**/^(Q<3_\ 0/E/_A!0_P#D/)?<'_$N_!/_ $%Y]_X=,3Y?]//)'\K_ /P[
M5_:Z_P"BA>*/_ FZ_P#BZ/\ AVK^UU_T4+Q1_P"!-U_\77]4%%'_ !&+B?\
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MZ_J@HH_XC%Q/_P! ^4_^$%#_ .0\E]P?\2[\$_\ 07GW_ATQ/E_T\\D?RO\
M_#M7]KK_ **%XH_\";K_ .+H_P"':O[77_10O%'_ ($W7_Q=?U044?\ $8N)
M_P#H'RG_ ,(*'_R'DON#_B7?@G_H+S[_ ,.F)\O^GGDC^5__ (=J_M=?]%"\
M4?\ @3=?_%T?\.U?VNO^BA>*/_ FZ_\ BZ_J@HH_XC%Q/_T#Y3_X04/_ )#R
M7W!_Q+OP3_T%Y]_X=,3Y?]//)'\K_P#P[5_:Z_Z*%XH_\";K_P"+H_X=J_M=
M?]%"\4?^!-U_\77]4%%'_$8N)_\ H'RG_P (*'_R'DON#_B7?@G_ *"\^_\
M#IB?+_IYY(_E?_X=J_M=?]%"\4?^!-U_\71_P[5_:Z_Z*%XH_P# FZ_^+K^J
M"BC_ (C%Q/\ ] ^4_P#A!0_^0\E]P?\ $N_!/_07GW_ATQ/E_P!//)'\K_\
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MZ8GR_P"GGDC^5_\ X=J_M=?]%"\4?^!-U_\ %T?\.U?VNO\ HH7BC_P)NO\
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MUSYW/>$N'.)O8?V]E&$S/ZMS>P>)I\_L^;XN75;^9^./_#F']G#_ )Y+_P"
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MW9^./_#F']G#_GDO_@*/\:/^',/[.'_/)?\ P%'^-?L=11_Q$#C+_HH,P_\
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M?\\E_P# 4?XU^QU%'_$0.,O^B@S#_P &^GEY?U96/^(3^'7_ $264?\ A/\
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M]%!F'_@WT\O+^K*Q_P 0G\.O^B2RC_PG_P"#Y?GW9^./_#F']G#_ )Y+_P"
MH_QH_P"',/[.'_/)?_ 4?XU^QU%'_$0.,O\ HH,P_P#!OIY>7]65C_B$_AU_
MT264?^$__!\OS[L_''_AS#^SA_SR7_P%'^-'_#F']G#_ )Y+_P" H_QK]CJ*
M/^(@<9?]%!F'_@WT\O+^K*Q_Q"?PZ_Z)+*/_  G_ .#Y?GW9^./_  YA_9P_
MYY+_ . H_P :/^',/[.'_/)?_ 4?XU^QU%'_ !$#C+_HH,P_\&^GEY?U96/^
M(3^'7_1)91_X3_\ !\OS[L_''_AS#^SA_P \E_\  4?XT?\ #F']G#_GDO\
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MX?\ /)?_  %'^-?L=11_Q$#C+_HH,P_\&^GEY?U96/\ B$_AU_T264?^$_\
MP?+\^[/QQ_X<P_LX?\\E_P# 4?XT?\.8?V</^>2_^ H_QK]CJ*/^(@<9?]%!
MF'_@WT\O+^K*Q_Q"?PZ_Z)+*/_"?_@^7Y]V?CC_PYA_9P_YY+_X"C_&C_AS#
M^SA_SR7_ ,!1_C7['44?\1 XR_Z*#,/_  ;Z>7E_5E8_XA/X=?\ 1)91_P"$
M_P#P?+\^[/QQ_P"',/[.'_/)?_ 4?XT?\.8?V</^>2_^ H_QK]CJ*/\ B('&
M7_109A_X-]/+R_JRL?\ $)_#K_HDLH_\)_\ @^7Y]V?CC_PYA_9P_P">2_\
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M #T?_OIO\:/,D_YZ/_WTW^-%% !YDG_/1_\ OIO\:/,D_P">C_\ ?3?XT44
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MQH\R3_GH_P#WTW^-%% !YDG_ #T?_OIO\:/,D_YZ/_WTW^-%% !YDG_/1_\
MOIO\:/,D_P">C_\ ?3?XT44 'F2?\]'_ .^F_P :/,D_YZ/_ -]-_C110 >9
M)_ST?_OIO\:/,D_YZ/\ ]]-_C110 >9)_P ]'_[Z;_&CS)/^>C_]]-_C110
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M 'F2?\]'_P"^F_QH\R3_ )Z/_P!]-_C110 >9)_ST?\ [Z;_ !H\R3_GH_\
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MIO\ &CS)/^>C_P#?3?XT44 'F2?\]'_[Z;_&CS)/^>C_ /?3?XT44 'F2?\
M/1_^^F_QH\R3_GH__?3?XT44 'F2?\]'_P"^F_QH\R3_ )Z/_P!]-_C110 >
M9)_ST?\ [Z;_ !H\R3_GH_\ WTW^-%% !YDG_/1_^^F_QH\R3_GH_P#WTW^-
J%% !YDG_ #T?_OIO\:/,D_YZ/_WTW^-%% !YDG_/1_\ OIO\:*** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>img267189834_10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img267189834_10.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X0+T17AI9@  34T *@    @ ! $[  (
M   .   !2H=I  0    !   !6)R=  $    <   "T.H<  <   $,    /@
M   <Z@    $
M
M
M
M
M
M2WEL92!38W5R;&]C:P  !9 #  (    4   "II $  (    4   "NI*1  (
M   #,3@  )*2  (    #,3@  .H<  <   $,   !F@     <Z@    $
M
M
M
M
M
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *\C_:-UO4]"^'MO<Z/>S64S
M7:J9(6VDCTKURO%?VHO^29VW_7ZO\J .[^%5]=:E\+="N[^=[BXEM@TDLARS
M'/4UU]<3\'?^20>'?^O0?S-=M0 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@#/U^:2W\.:A- Y22.W=E8=00IYKX;_P"%K^.O
M^AGO_P#OL?X5]W7EI'?V,UI/GRID,;[3@X(P:\F_X9E^'_\ <U+_ ,"__K4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MKP6<9;:?0GUK!7XX>(;M1+IGPZU::$]&9>M 'L]%>-Q_M"6]C.L?B?PGK&E
M]9#$6 _#%>D>%?&6A^---^W>'KU;F)3AQC#(?0CM0!N4444 %%%% !1110 4
M444 %%%% !7BO[47_),[;_K]7^5>U5XK^U%_R3.V_P"OU?Y4 =I\'?\ DD'A
MW_KT'\S7;5Q/P=_Y)!X=_P"O0?S-=M0 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_$T_;P\_N9']EXCO'_P.'^9VU%<3_P )7XM_Z$YO_ L?_$T?\)7XM_Z$YO\
MP+'_ ,31[>'G]S#^R\1WC_X'#_,[:BN4TSQ%XDN]2A@OO#!M(';#S?:0VP>N
M,5U=7&:FKHY*^'G0DHSM\FG^3844459SA1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?\SV,L_AXC_KV_\ TJ)Z)11170>.%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\3;3Q DOB[6M/N]-V$-%!%M8MVYKT,,"2 02.M>+?V9\<O$!:*\U72]#@;O
M@9E_K^M=]X#\&W7A'3YEU+7+O6;NX;?+-<'@'T4=A0!UE%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!4U75;+1-+GU#5+A+>U@7=)(YX KE;CXL^%+;P8GB>6]8:?*YC
MB^3YY&'8+6+^T%87U_\ ">]73T>3RW5Y$0$DJ#Z5XXT]E\3/$G@CPOX<MI5T
M_3H4:^/D[51QRQ(_#'XT ?0O@OXE^&_'@E70KIC/",O!,FQP/7'I76UX-X.B
MCUG]HV]U+PYI\EII6G6C6L\GE;%D<<8 []*]YH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"@]#CK110!X_K'B'XR+JEW!I_A;2I[$2,L32/G>G;/-9-IJ'Q?TZ1I+'P+H%
MK))U:/"EOUKN_C#XNO\ P7\.[O4M(4?:R1''(1D1Y[UY/8>'=3TOQ)X%\07W
MB>^U.YUFX$DZ-(?+&5)P!G% 'HG@74?B3)XC$/BCPSIFF:;(K-)-:\,7[=^:
M]/KQ?PSJFIZ!^T)J/AG^UI-2TZ_A>Z\IVW&V;T]A7M% !1110 4444 %%%%
M!1110 4444 %>*_M1?\ ),[;_K]7^5>U5XK^U%_R3.V_Z_5_E0!VGP=_Y)!X
M=_Z]!_,UVU<3\'?^20>'?^O0?S-=M0 4444 %%%% !1110 4444 >??&C_D0
MV_Z[+7SI7T7\:/\ D0V_Z[+7SI7S^8_QOD?L'!W_ "+?^WG^@4445YQ]B%%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?4?PU_Y)SH__7#^
MIKJ:Y;X:_P#).='_ .N']374U]91_A1]$?S[F7^^UO\ %+\V%%%%:G %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MWN$:YL9HQ@H@_A->IUY5\./ \&F>*)_$/B#Q-#K_ (CN(RFZ-QMC7N%%>JT
M%%%% !1110 4444 %%%% !1110 5XK^U%_R3.V_Z_5_E7M5>*_M1?\DSMO\
MK]7^5 ':?!W_ ))!X=_Z]!_,UVU<3\'?^20>'?\ KT'\S7;4 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4C?=/TI:* /EGPMXQU#X<?$3Q1<3^%M5U&.]N6V-! V ,]>G
M-=O_ ,-%S_\ 0@Z]_P!^3_A7MIC0]47\J/*C_N+^5 'SEX&UB^\7_M%+XA?0
M=0TRV>T=,7,+#!QZXQ7T?7D,/B[6O^&D#X;^V8TH6C/]G"C&[UKUZ@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !0>G%%% 'D^J:9\9GU:Y;2]5TE+,
MR$PJZC<%[9JI_97QR_Z#&C_]\"O8R0H))P!U)JH=6TY6(:^MP1U!E% 'D7@S
MX;^-K;XKKXN\87EG<-Y#1-Y!QUZ<5[15:'4;*XD\NWNH9'_NI(":LT %%%%
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MHH **** "BBB@#*\4?\ (H:Q_P!>,W_H!K\\G_UC?4U^AOBC_D4-8_Z\9O\
MT U^>3_ZQOJ: $HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH ]W_94_P"1VU?_ *\U_P#0J^K*^4_V5/\ D=M7_P"O-?\ T*OJR@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MT?\ (AM_UV6OG2OG\Q_C?(_8.#O^1;_V\_T"BBBO./L0HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** .;\<7^MZ=X?,WAK1XM7O-X
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M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'U'\-?^2<Z/\
M]</ZFNIKEOAK_P DYT?_ *X?U-=37UE'^%'T1_/N9?[[6_Q2_-A1116IP!11
M10 4444 %%%% &5XH_Y%#6/^O&;_ - -?GD_^L;ZFOT-\4?\BAK'_7C-_P"@
M&OSR?_6-]30 E%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% 'N_[*G_ ".VK_\ 7FO_ *%7U97RG^RI_P CMJ__ %YK_P"A5]64 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M>3_ZQOJ:_0WQ1_R*&L?]>,W_ * :_/)_]8WU- "4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 >[_LJ?\ ([:O_P!>:_\ H5?5E?*?
M[*G_ ".VK_\ 7FO_ *%7U90 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MY/\ ZQOJ:^^M1GU>;PMXC&L6L,"+:SBW,3[MZ[&Y/I7P*_\ K&^IH 2BBB@
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MR3.V_P"OU?Y5[57BO[47_),[;_K]7^5 ':?!W_DD'AW_ *]!_,UVU<3\'?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 5XK^U%_P DSMO^OU?Y5[57BO[47_),[;_K]7^5 ':?!W_DD'AW_KT'\S7;
M5YU\-=*76/@?H%H]S/;!K53YD#;6')[UV6I:(FI:.FGO=W,*KM_>Q/ASCWH
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MZFOT-\4?\BAK'_7C-_Z :_/)_P#6-]30 E%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% 'N_P"RI_R.VK_]>:_^A5]65\I_LJ?\CMJ_
M_7FO_H5?5E !1110 4444 %%%% !1110 5\9_&#_ )*CJW_73^E?9E?&?Q@_
MY*CJW_73^E?<\%?[[4_P_JCFQ/PHXFBBBOU@X HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@#H/ G_(^:/_ -?2?SK[A7[B_2OA[P)_R/FC
M_P#7TG\Z^X5^XOTK\NXW_P!XH^C_ #.W#;,6BBBOS\ZPHHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#YJ\.Z=:>/_VE-9_X22$7
MEOIX=8K>7E>.G%17EI;^ /VGM/A\/1_9;2\(62WC.$(88QBM76]&\1_#'XRW
M7B[2=$GUC2K]6\V.V&6!(H\*>&_$7Q#^,T?C;6M'FTC3+0YCAN?ON0. /QH
M]4\:?%'P[X"O+:V\027"27,9DC\J!I!@''4"O$/CA\6/#/COP5#IN@/=27*7
M*R$26S(-H]R*^EKO2[&_96O;."X91A3+&&Q^=5_^$<T7_H%6?_?A?\* /%?A
MW\<_!OAOX>Z/I&I2WBW=I;B.4+:NP!]B!72_\-'> O\ GXOO_ .3_"O1?^$<
MT7_H%6?_ 'X7_"C_ (1S1?\ H%6?_?A?\* /.O\ AH[P%_S\7W_@')_A1_PT
M=X"_Y^+[_P  Y/\ "O1?^$<T7_H%6?\ WX7_  H_X1S1?^@59_\ ?A?\* /.
MO^&CO 7_ #\7W_@')_A1_P -'> O^?B^_P# .3_"O1?^$<T7_H%6?_?A?\*/
M^$<T7_H%6?\ WX7_  H \Z_X:.\!?\_%]_X!R?X4?\-'> O^?B^_\ Y/\*]%
M_P"$<T7_ *!5G_WX7_"C_A'-%_Z!5G_WX7_"@#SK_AH[P%_S\7W_ (!R?X4?
M\-'> O\ GXOO_ .3_"O1?^$<T7_H%6?_ 'X7_"C_ (1S1?\ H%6?_?A?\* /
M#?B1\;?"'B;PJUAI<MX\YD# -:NHQ]2*\?\ ^$FL/^FW_?HU]I?\(YHO_0*L
M_P#OPO\ A1_PCFB_] JS_P"_"_X5R5L)3K2YI7/H<NXAQF74?845&U[ZK_@G
MQ;_PDUA_TV_[]&C_ (2:P_Z;?]^C7VE_PCFB_P#0*L_^_"_X4?\ ".:+_P!
MJS_[\+_A6/\ 9U'S/1_URS+M'[G_ )GQ;_PDUA_TV_[]&C_A)K#_ *;?]^C7
MVE_PCFB_] JS_P"_"_X4?\(YHO\ T"K/_OPO^%']G4?,/]<LR[1^Y_YGQ;_P
MDUA_TV_[]&C_ (2:P_Z;?]^C7VE_PCFB_P#0*L_^_"_X4?\ ".:+_P! JS_[
M\+_A1_9U'S#_ %RS+M'[G_F?%O\ PDUA_P!-O^_1H_X2:P_Z;?\ ?HU]I?\
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M'S#_ %RS+M'[G_F?%O\ PDUA_P!-O^_1H_X2:P_Z;?\ ?HU]I?\ ".:+_P!
MJS_[\+_A1_PCFB_] JS_ ._"_P"%']G4?,/]<LR[1^Y_YGQ;_P )-8?]-O\
MOT:/^$FL/^FW_?HU]I?\(YHO_0*L_P#OPO\ A1_PCFB_] JS_P"_"_X4?V=1
M\P_URS+M'[G_ )GQ;_PDUA_TV_[]&C_A)K#_ *;?]^C7VE_PCFB_] JS_P"_
M"_X4?\(YHO\ T"K/_OPO^%']G4?,/]<LR[1^Y_YGCW@SX\^"]$\'Z=IU]->K
M<6\6V0+:.0#GUQ6Y_P -'> O^?B^_P# .3_"O1?^$<T7_H%6?_?A?\*/^$<T
M7_H%6?\ WX7_  KOC%1BHKH?)5JLJU6566\FW]YYU_PT=X"_Y^+[_P  Y/\
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M *!5G_WX7_"C_A'-%_Z!5G_WX7_"@#SK_AH[P%_S\7W_ (!R?X4?\-'> O\
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M_%]_X!R?X5I>'_CCX/\ $VN6^DZ7->-=7#;4#VKJ,^Y(XKL_^$<T7_H%6?\
MWX7_  J2#1-+MIEEM]/MHI%Z.D0!'XT 7J*** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
K **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>img267189834_11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img267189834_11.jpg
M_]C_X  02D9)1@ ! @$!2@%*  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" *@!UH# 2(  A$! Q$!_\0
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MA_\ *&OT;HH_XBYXG_\ 1>\5?^'G&?\ RWR_/NP_X@[X5?\ 1O>$O_#)@?\
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M^'G&?_+?+\^[#_B#OA5_T;WA+_PR8'_Y4?G)_P .J_V0_P#H%?$G_P +X?\
MRAH_X=5_LA_] KXD_P#A?#_Y0U^C=%'_ !%SQ/\ ^B]XJ_\ #SC/_EOE^?=A
M_P 0=\*O^C>\)?\ ADP/_P J/SD_X=5_LA_] KXD_P#A?#_Y0T?\.J_V0_\
MH%?$G_POA_\ *&OT;HH_XBYXG_\ 1>\5?^'G&?\ RWR_/NP_X@[X5?\ 1O>$
MO_#)@?\ Y4?G)_PZK_9#_P"@5\2?_"^'_P H:/\ AU7^R'_T"OB3_P"%\/\
MY0U^C=%'_$7/$_\ Z+WBK_P\XS_Y;Y?GW8?\0=\*O^C>\)?^&3 __*C\Y/\
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M_*C\Y/\ AU7^R'_T"OB3_P"%\/\ Y0T?\.J_V0_^@5\2?_"^'_RAK]&Z*/\
MB+GB?_T7O%7_ (><9_\ +?+\^[#_ (@[X5?]&]X2_P##)@?_ )4?G)_PZK_9
M#_Z!7Q)_\+X?_*&C_AU7^R'_ - KXD_^%\/_ )0U^C=%'_$7/$__ *+WBK_P
M\XS_ .6^7Y]V'_$'?"K_ *-[PE_X9,#_ /*C\Y/^'5?[(?\ T"OB3_X7P_\
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MGW8?\0=\*O\ HWO"7_ADP/\ \J/SD_X=5_LA_P#0*^)/_A?#_P"4-'_#JO\
M9#_Z!7Q)_P#"^'_RAK]&Z3(SC(SZ9&?RH_XBYXG_ /1>\5?^'G&?_+?+\^[#
M_B#GA5_T;WA+_P ,F!_^5'YR_P##JO\ 9#_Z!7Q)_P#"^'_RAH_X=5_LA_\
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M^4-?HW11_P 1<\3_ /HO>*O_  \XS_Y;Y?GW8?\ $'?"K_HWO"7_ (9,#_\
M*C\Y/^'5?[(?_0*^)/\ X7P_^4-'_#JO]D/_ *!7Q)_\+X?_ "AK]&Z*/^(N
M>)__ $7O%7_AYQG_ ,M\OS[L/^(.^%7_ $;WA+_PR8'_ .5'YR?\.J_V0_\
MH%?$G_POA_\ *&C_ (=5_LA_] KXD_\ A?#_ .4-?HW11_Q%SQ/_ .B]XJ_\
M/.,_^6^7Y]V'_$'?"K_HWO"7_ADP/_RH_.3_ (=5_LA_] KXD_\ A?#_ .4-
M'_#JO]D/_H%?$G_POA_\H:_1NBC_ (BYXG_]%[Q5_P"'G&?_ "WR_/NP_P"(
M.^%7_1O>$O\ PR8'_P"5'YR?\.J_V0_^@5\2?_"^'_RAH_X=5_LA_P#0*^)/
M_A?#_P"4-?HW11_Q%SQ/_P"B]XJ_\/.,_P#EOE^?=A_Q!WPJ_P"C>\)?^&3
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M .B]XJ_\/.,_^6^7Y]V'_$'?"K_HWO"7_ADP/_RH_.3_ (=5_LA_] KXD_\
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M<BTWQ7%YGAKQ;X3N+N6XGM-.GFDM+*[L#<S6THU"QN[,1DW /V5^QS_RA?\
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MW_LJ<X_]3*A_L?X._P#)JO#W_LDLD_\ 4&D%%%%?G1^DA1110 4444 %%%%
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M?_P0)_U'[2W_ %^?#W_TEU^OQ*_:R_Y.B_:&_P"RP^.O_3W<U],_L _M_?\
M##S_ !+2;X8R?$:U^(?]@2C[-XCC\/W6E7.@I?Q(&:>POX;JVN4OBS )'-&\
M0PY5B*^(/BKXYF^*/Q+^(7Q'GT^/1I_'OB[7O%<FE03/=1:6^MWLMY]BCN)
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MPC#?D3^VOX"\:^%_VN_V@?"WB#1]6D\1ZW\6/%>J:1"UC=RW/B.Q\6:Q/?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M/BW]KK_D?/V"?^S]O@'_ .GEJ_U.J_RQ?VNO^1\_8)_[/V^ ?_IY:O\ 4ZK_
M $R^B_\ \FER[_L<9Y_ZFR/\N/I6_P#)X<R_[$F0?^H$0HHHK^AC^;@HHHH
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MO#.NPVIFN(E>ZM90#^W>BO\ .Q_X*R?'#_@Z,_8N\??M9?M(S_%_Q_\ #/\
M8:T']HCQ_:_"7Q-9ZU^R5K]II?PK\5_%#5],^#EG;>&[2TUGXBK;3>'KS0+*
M!-9T9]8LHRG]ONETEU,?U-_X(0G_ (.*?%O[2/@[XK?\%(/%WB_Q/^Q7X_\
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M-JB-&C:=#H%EK\VH7%\7EBC2TMX99Y))$C2-G95(!]AT45_%A_P5I_X+'?\
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M\J0_9X8OZ^J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** /\GS_@E7_P FAZ5_V4GQ]_+0:_1NOSD_X)5_\FAZ
M5_V4GQ]_+0:_1NO\C/%W_DZ''O\ V5.<?^IE0_V/\'?^35>'O_9)9)_Z@T@H
MHHK\Z/TD**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** 'Q2RP2Q3P2RV]Q!+'/!<02/#/!/"ZR0SP31LLD,T4BK)%+&RO&Z
MJZ,& (_5#X<?\%D/VT/A_P"';'PW?ZMX%^(D.F6L%C9:MXX\-SRZ]]FMHUBB
M^WZGHNH:5)JMUL4>;?7ZS74[$O-([G=7Y645]%P]Q;Q-PG6K8CAK/<SR6KB8
MPAB7E^*J4(8F%-R=..(I)NE7]FYS=-U83=-SDX.+DV_G.(^#^%N+Z%##<49!
ME>>T<+.=3"K,<)3KSPTZBBJDL-5:5:A[50@JJI5(*JH051248V^\?VA/^"DW
M[67[2?AN\\$>-O&]AH'@;4E:/5_"G@72(O#MCK=NSI(;+6[Y9+C5M2T_?%&Q
ML)[TVKLF9(WW.&^5?A!\3]=^"OQ.\$?%?POI^AZGXB\ ZW%K^BV/B2Q;4=#F
MOX()X(&OK..6"206YG-S:R13136U[#;74,BRPH:\XHJ,QXIXDS?-L/GN:YWF
M>99QA*F'JX7,,=BZN*Q&&GA:JK8?V$JTIJC"C62JTZ=.,:<9WDH7;O>6\)\,
MY-D^(R#*,ARO+,EQ=/$4L7EN P='"X;$PQ=%X?%?6(T8PE6G7HOV52K4E*K*
M"4>>T8V^M/VKOVTOC1^V/K'A75/BQ)X=L[/P7:W]OX=\/^%-/N=.T>RGU5H#
MJ6HNMY>7UW<7]XEK;0O+-<LL<,*11(JYS\ET45Q9OG&:9_F.)S?.L?B<SS/&
M2A+%8W%U'5KUG3IPHT^>;Z4Z5.G2A%)1A3A&$4HQ27;D^395P]EN%R?),OPN
M5Y7@H3AA,#@Z2I8>A&I5G6J<D%]JI6J5*M24FY3J3G.3<I-A1117FGIA1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110!\6_M=?\CY^P3_V?M\ __3RU?ZG5?Y8O[77_ "/G
M[!/_ &?M\ __ $\M7^IU7^F7T7_^32Y=_P!CC//_ %-D?Y<?2M_Y/#F7_8DR
M#_U B%%%%?T,?S<%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110!_+U_P5Y_98\#_MB?M^_LW:C^Q+^WI\
M-OV9/^"QW[+?@_4=8^'_ ,/?%CZA?Q^-_A)J%GJ7BR;3];TVVTC64LEM]-U/
MQ'>&0:/XAM-;\,Z[K6FZ[I']GI#?6/QIHW[6'[8W[.W_  42_80\!_\ !?']
MB3]EGXA^*/''CFZ\ ?L=_M_?"2TLSK7@#XA7VKZ=;64%Q%9Z@^BP0:AX@OO#
MQN=+70/!.NZ,=9&O6ECK=H)+2#UW_@X1_P""?G[>=E^U7^S'_P %<?\ @E]X
M?U'Q7^T7^S]X>N/!'Q#\%>$])L-:\7ZMX?LI-:ET;Q%:^&+V53\0-'O= \2>
M)/ OC+PG9Q3ZM+H=SIDFE6EP6O9K/\NO@'\#/^"Y_P#P7!_X* ?L:_%__@HG
M\#O$_P"S=^S;^QY\0M'^)\B:S\*_$?P%\.?;_"WB70_%5Q:^'/ _CK4-0\:^
M+/'7C;4_#NA:*^L3I<:+HV@VMW+!<Z9&9(-2 /WZ_P"#KK_E"W\?/^R@?!#_
M -63HU?I;\'?C)H'[.__  2C^#OQW\47-G::#\(/V!?A?\1=1EOYEM[1XO"?
MP!\/ZS':S3,R!/ML]I%9I\ZEI)T52&85\+?\',_P@^+'QS_X)&_&WX<_!3X9
M>/\ XO?$#5?'/P=NM,\#_#/PCKWCCQ=J%KIOQ TF\U*ZLO#OANQU+5KJWT^S
MCDN[V6"TD6VMHWFE*HI(^:O^"PUI^T_I7_!O7\(?V=_@/\!_C;\1_CA\9_@M
M^RA\!O$W@'X=_"WQCXT\8^#]"MO /AC6?B8/%_AW0='O]3\-6]M8^$+WP?J=
MSJ]M9QZ?K&L064[QW3+&0#^+_P )_MC?L%>,O^",_P"W/\'?C9\2O%S?\%!?
MVF_VM1^U7H&G0?#OQ=JVE/K7A;5+&W\*Z-J_Q!2S?1,ZCI7B+XI7LUS-=QQ6
MO_"1VUM/"MQ'(6_I8_X*K_M3I^V;_P &G'PB_:!N+W[?XC\3V?[,N@>/)GDC
M:Y;XB?#_ ,<VO@+QS/=)&S>1+J7B3PYJ&L0Q,0WV/4;60#9(A/Z0?LZ?\&O?
M_!([3_V<O@OHWQI_9'C\5_&:+X1>![;XG^-;[XL_'?1-9U;XAR^%=//BS69M
M'T7XFZ;X<TR].OR7LHL;#1+33+:1%BCT](5\FOYK+7]DK]O'P'_P1+_X*<_\
M$SM1_91_:;\2Z[\#OVZOA[XL^ <NF? /XE77_"W_ (=ZE\2#X>\3>)/AW<VF
M@74'C72;63P38^+YW\,2:G;V&B>(XM3ED%M.)Y #Y,^,7_!2K_@X;T#X1? [
M]BC]HGQC;?LQ?!/]JWX8^%?A!\+/&'Q+^%OPJ^$'A/7?A+JFB:)X8M7E^-=K
MX9:?0M$D\+WNEVOB;5SJL.K0Z'JCS:BL<.H%Y/U,_P""V7[!\O\ P37_ .#=
MS]BO]E:W\767Q!\8^$OVI?#OBKQ;XNT=&;0M>^(/CO3?B+XKU8^&H[B..27P
MYI]WJ-OHN@S744=QJ&F:=;7UY%%<7<T2?T-_\%!/^"9*?\%%O^"+/PY_9OU;
MPX^B_'SX;_LY_!WQS\&FUW2A9>(?"?QK^'_PJT> ^$[R*_MA?Z,WBJ%=7^'_
M (CM'%M-;_VJS702:P3R_P":K]J73/\ @HE^V3_P;X_LM? CXH?L=?M=WO[4
M_P"RI^UKX"^%OBGPWJWP"^+<OC?QG\*_"7A'Q6G@#XH6UC=>')]4U_2++PY<
M:=X+\3>*+=KVV/B/06U#4[JW;7K+S@#X8_:D_;L_X.'_ -I#QMX,_P""6?[=
M'C_0_P!ER']L)]!\)QVWQC^&?PN_9_\ #/B;PUJ^KI9Q6=[\2?#OA:*4Z!JF
MJ6L6AZAI.CZA+-JM]<6OANZMB^IQVLW^C/\ L&_LA:+^Q/\ L4? /]C^SU^7
MQ;9_!_X86'@C6/$_DFQ/B/6;E;J]\4:O;V^2]G:W^M:GJ4VGP,3+;636T<A,
MJ,3^97_!P_\ \$R+[_@HS_P3^U23X9Z#=7O[4G[,QF^,OP"DT:TW^*=?OM*T
MQ?\ A-/A;I<L1CO?.\>:+:0OH]I:S122>.?#_@Z4MY<$L<GUQ_P1K_:!^/?[
M1/\ P3Z^!GB']J;X3_%KX/?M%^!]%_X57\6_#OQD^'OBWX<^)M<\1>!8K?3+
M/QW::9XQTO2]0U/2_&V@-H^OMJUNEQ;/K%WJ]@]P;RPND0 Z7X:_\$H_V//A
M/^P[\3O^">'@WPSXTM?V9_BZ?'I\::#>^/==U'Q1=?\ "RKJ"\\5"R\7W,C:
MO8"YGMXS;>2^;0;Q&3O8G0\/_P#!++]CCPS\:_V0/V@=)\"ZY%\2_P!AKX*/
M^S_^S_J<WBS5[BPT;X;GP]K'AJWLO$>ERR&T\4ZI8V.OZQ<6.L:HKWMOJE]+
MJ2N;H(Z?HG10!\F_L=?L5? C]A/X;>*/A1^SWI'B#1O!WC#XH^-OC#K=MXD\
M3:EXJO9?&WQ!N+.Z\27<&H:H[SV]C/+8VYMM/C/D6N'V9:1V/\XG[4=K:_L*
M_P#!TA^R!^T2R6>A_#'_ (*(?L\^+/@;\0=6D']F:5'X_P#"FCSV^G7-Y<HB
MV^I:UJ&H^%OA-90QW+>>(;W,<KL$MS_7;7\Q7_!U#^QK\:/VEOV'?A7\7/V9
M/!/Q#\=_M%?LK?'KPSXZ\%:/\*-!USQ/\0CX:\80MX7\4W/AG0O#5G?ZW?WV
ME:PG@S7Y396LQLM.T:_OW54MVD0 _)C]@+X+_'G]O#]FW_@XY_;Z^ UGJMU\
M>OVR_&GQ-^!G[-=WHE]_9&H:WX%\$R77B#5](\$^()7MR)/&V@ZMX:\)VPBO
M(+4ZMX>M+))[4IYR?F+^QK\2/^""GC7P)^S/^QY_P40_9(^.G_!/3]K3X&ZY
MX.3QG^TQX8N]>\&ZA\0?'6D3?93JOQ,\4FVC^(?P_L_$=]-!XGN1<>$K:S\#
MWUK9MX?\8V6GV8G;^QO_ ()]_L=?M7_L9?\ !!_X9_ O]EVW\+?#G]MU/@AJ
M7Q/TK3_BAHDU]HMM\;?B%J$WC_5/#'BS2=7ELGTK5&M=13P?(=506WAS6H(7
MU"P>TL)[.OY;OVM]?_X+K?\ !5SX/>!_^">/[0__  2(73_C_I'C;P;#XN_;
MF\3_  KNO!GE6GA_4@MQK<?Q"?2+#X7:%IUQIUW:_P#"677@7Q?J]EK.F6-]
M;:'X:-S<K9Q '^CSHALFT;2&TS4&U;36TRP.GZJ]^=4?4[(VL1M-0;4S)*=1
M:]@\NY:_,LAO#*;CS'\S<?XU?^#9A=-U?_@I'_P7L\2^))!??$I?VCM!T^UU
M'5<-XA/AF\^*?[0<NMQ"2=!=BQDO]+\*_:0"L3R6VFF169(67^N']G_X8R_!
M+X#_  3^#,^N7GB>;X1_"/X;_#&;Q+J$CRW_ (AE\ ^#=&\*R:Y?2R?O)+S5
MGTDW]S))\[S7#L_S$U_%A_P4S_87_P""JW_!+S_@I3\5_P#@J5_P2,\":O\
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M^"7A'QQX@WV1BF^T3W$FN74]I"T4%T\\EF2EM,2//OV:Y_\ @YX_8PL/!O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 ?%O[77_(^?L$_]G[? /\ ]/+5_J=5_EB_M=?\CY^P3_V?
MM\ __3RU?ZG5?Z9?1?\ ^32Y=_V.,\_]39'^7'TK?^3PYE_V),@_]0(A1117
M]#'\W!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH _P GS_@E7_R:'I7_ &4GQ]_+0:_1NOSD_P""
M5?\ R:'I7_92?'W\M!K]&Z_R,\7?^3H<>_\ 94YQ_P"IE0_V/\'?^35>'O\
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MZTW4["1XEO\ 2KHM+ LUO<1RSVUQ%*WJ?[0'[7'[1$O[9WC#XA+\4O%L.K>
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M&>?^ILC_ "X^E;_R>',O^Q)D'_J!$****_H8_FX**** "BBB@ HHHH ****
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M_P#)JO#W_LDLD_\ 4&D%%%%?G1^DA1110 4444 %%%% !1110 4444 %%%%
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MST\/CJ6'K8/ZY1E3DZ='DH6ECJ4OZ)_BM_P3S_X)Z_&[Q_XE^+?@[]L_P3X
MTGQQJUYXHU/PS:^+?AOJ%A;ZIJT[:AJTVE#6-<TK5-,MKZYGFNQ97=O=-;3S
MR['*!84_)/\ ;:^&/[*OPB\=^#/!_P"RS\2[_P"*FEV7AMI?B)XCN]4MM8MT
M\6#69%AM[.\T_2]+TT(-,C2:2WTY;N"%'@#W<LS2&OB<VEJQW-;6['U,,9/Y
ME<U. % "@*!T   'T X%?G'%?'G#_$6#QE++O#?AKAO,\QQ4,7C<XP.+S/%8
MGG5=8BK' X;$UEA,NAB:O-&M&C2FG0DZ45'22_3.#^ >(^&L=@:N9>)O%'$^
M5Y9A9X3 Y)C\)E6$POLW0^KTI9CB<+0EC,SJ8:DHRH3KUH2C7A&M)SLX/^D7
M_@L5\=_@O\4/V9/A)HGPY^*?@7QQK$?Q"T/5Y=+\,>(M/UC4(-,B\,:C'+>W
M5I9S2SV4,<ES!&XO(X)%DE6,H'5U7^;NHTBB0DI'&A;J415)[\D $\\\U)7E
M>(?'.,\0^)*O$N.P.&RZO5P>"P;PN$J5:M&,<%15&,U.M[[E4LY-/2-U%7MS
M/U/#?@+!>&W"U#A; 8_%9EAZ&.Q^.6*QE.E2K2GCZRK2IN%']VHT[*,6G>6L
MFE?E7U/^Q!XG\.^"_P!KK]GOQ5XMUK3_  [X;T3XCZ7>:QKFK7"VFFZ9:?9;
MV$W-[=/\EO;K++&CS2$1IO#.RJ"P_0S_ (+9_%CX9?%/XG? Z7X;>/?"GCN'
M0_!/B6+6)_">MV.NVVFRWVM026D-W=:=-<6T4T\<4CI"93,$0LZ*I4M^)9 (
M((!!&"",@CT(/!%-2..,$1HB G)"*J@GU(4 9J\NX\QF7< <0>']/ 8:I@N(
M,WP.;ULPG4JK%8>I@G@W&C2IK]U*%1X*G>4_>BI3LG>+C.8\ 8+,?$3AWQ$J
M9ABZ6.X=R7,,FHY="G1>$Q-+'QQD95ZM62]M"I26.JVC"\9.%.[BE-2?7](G
M_!+OX\?!;X??L!_%WP?XY^*7@7PEXJD\6_&"]A\.^(/$>FZ7K-Q::UX0T>WT
MJ>TTZ[GCN[R._GMYH;<VD4^^6-HP-^%/\W=1M%$[!WCC9E^ZS(K,,<C!()'/
MH:GP]XYQ?A[GU7/L%@<-F-:KE6894\/BJE6E25/,(TE.JI4??YZ;I1<8_#).
M479M25>(W 6"\1N'J7#V.Q^*RVA2S?+LV6(PE.E5JNIETZDHT7"M[G)5562E
M)/FBU&232<78L[FYL;FRO[.3R+W3[RTU"RFVAO)O+&YCN[2;8>&\JXABDVGA
MMN#P:_J?M_V@_P!BO_@IA^S)X5^&WQ]^)^B_"KXG:4-%U#5K;4]<T_PEK'AK
MQUI=F;&YU_PQJGB%!HFJZ#K237B>3)-(9+*[DM+N*VN(HYJ_E<ICQQR#$D:2
M#T=58<]>&!]!^5=7 7B)CN!EG>#_ ++RWB#(N),%# YYD.;*K]4QM*C*I*A5
MA4HRC4H8FA[6LJ=5*HE&K)\GM(T:E+E\0?#C <?/(L:\VS/AW/\ AC'U,PR#
MB#)Y4?KF K5U2CB*4Z5>$J6(PU=4*#J4I.FW*C!>T5*5:E5_JI^&/B#_ ()_
M?\$L/AQX\USPA\9].^,7Q'\:VT<PBT?Q%X>\7>*_$K:6EP-#\-:?;>%))=+\
M.Z)#>3R7%]<ZC<QD&:6^FEG\NW@'\^O@#]HO5;/]L'PE^U/X_C?4=3B^-5C\
M4/%MOIZ+N:"?4V.H6NGQ$*'33]+F-O9QMB2:*TB5F\YR]?+\<,461%%'$#U$
M:*F?KM S4E=_%7BGF.?QX8P659/E?"F0\'XI9AD61Y5[:MAZ.8_6(8J6.Q=?
M$R=3&8AUXRE&<X0Y55K<W/4K5:D_/X2\)\MX>EQ5CLWSK-N+N(.-,(\NX@S_
M #?V%#$ULL^K2PD<OP=#"P5/!8949)2A"=2\J5!Q<(4*-.']:'[7OA#_ ()Z
M?MN^'O!WQG\9?M.Z!HD'@#PGK[Z:?"_Q"\):3JNJZ1J,<.JC3-4\+ZY;7>OB
M^M[^WC:&VM].M]0+37-H8V9T>'\[?^"3W[=7PJ^!^C>.?V=/CQJ,.@?#WQQK
MUWK/A'Q5>VLTNB6=]K=K_9?B#0O%,T"N]AIVKVMO97-GJ4B&WBN)+JUNC!&\
M4J_AV;> OYA@A,F<[S&A?/KNV[L^^:E(!!! ((P0>00>H([@U]!F/CEF6(XT
MRKCS*N&,AR3/\-3Q-+.ZF'>+Q&'XGAB\+A,%4I9E2JU(2IT*>&PD8X>G1J>T
MI5)>VG6JU(Q9\YEG@-E>'X'S;P^S?BKB'/>'<55PE7(J6)6#PV(X5G@\5B\=
M2JY76HTIJIB*F)Q<Y8FI6IJG6I1]C"A1A*2?]"7B#_@E_P#\$\M2UO4?%>A_
MMP^&/#G@6ZNY]5@\+1>,?A?J-UI>F22/,^F6.JW&M17WE6ZDP60N-&N+J*%(
MHY$NI 7?\Z/$.G?LS?"/]O;X.0_ +Q_+XC^!?@GXI_!#4M0\?:]J/VRVCN],
M\2Z)?>,]1GU1=-TN*73M-DBFDFN+;3X[2/RK@6QDA16/Y^_9+7=N^S6^[.=W
MDQ[L^N=N<^]3X&-N!MQC&!C&,8QTQCC'3%?-9YQYP_C_ *E/(O#GASA;%8;-
M\'F];&X+%YIC,1B)X.<ZD<'2^M5E1P.!JU)\U7#X:DD_9T5"5-4DG]3D' /$
M67O&PS_Q,XGXLPF)R;&9-0P./P>4X+#8:GC(4Z3QM;ZI0=;,,PHTZ;A1Q.*K
M:*K6=2-1U+Q_='_@N1\6OA?\5KWX%0_#/X@>$/'TFCZ/\0/[57PCKVGZ^NG?
MV@NDI8B\ETV>XA@>[>"988Y)!(QB<[ N"?>?^"F/QW^"WC[_ ()]_"KPEX(^
M*G@3Q7XI35/@]/)X=T#Q'IVIZW##I'A]X]3ENM,M9I+RS6P?"7(O(;=HG(1E
MW_*/YLTCCC!$<:1@]0BJH/U"@9I%BB1BZ1QJS?>9456.>3D@ GGU->UF/C1F
MF8X[Q*QT\ER^E+Q*RO+LJQU.&(Q,HY93R[!_4J=7"R=G6J5*;<IJLHQ4VFO=
MBXR\/+/!'*,MR_PNR^&>9C5AX79OF6;Y?4EA\+&6:U<SQL<;4HXR*=J%.E4C
M&$)47*3A?FO)J4?WK_X(B_&#X5?"VY_:#@^)/Q$\'> YM:_X0>YTA/%NO:?H
M(U*"RCU>*\>REU*:WAN#;23PK+''(TJ^8K>64RP_''X^:MIFO_';XUZ[HE];
M:IHVM?%KXB:KI.IV;^;::CIM_P"+=6N;*^M9< 2VUU;R1S02  /&ZL."*\C>
M..3'F1H^#D;U5L'U&X'!^E/  & , < #H!Z5\AF_'.,S?@GA7@FK@<-1PG"F
M*S;%8?'4ZE66(Q<LUQ$\1.%:G+]U35&4Y1BX7<URM\K3YOL,FX#P63<=<7<=
MTL?BJ^,XNPF3X3$X"I3HQPV#CD^&I8:G.A5A^]J.O&E&4U424'S).2:Y>P^'
M>IV.B?$/X?ZUJ<XMM,T;QUX0U;4KDJSBVT_3?$.G7E[<%5!=A!;0RRE5!9@I
M"@D@5_6E^UMJW_!._P#;2\+^#?#7Q-_:H\/:+IO@[6;KQ%I,W@GX@>&-(O9[
MK4-/%C)'?G6M%UQ6@6 ADBC@MIDESO<X*#^/VHO(A_YXQ?\ ?M/\*]C@/Q-J
M\$Y/Q'D-7AO)N),JXGEE\LPPF;SQ<:;672K3I02PM6GS0E.JJC4M5.E"SLVC
MQO$#PMI<=9UPQQ!1XGSOAC-^%(YE'+<;DT<'*JGF<</"M-O%4JG).-.C*G%Q
MT<*LTXW29^S'[4_[(O\ P3D^&7P)\=^./@;^T]KGCKXH:%:Z?/X7\)7GQ \'
M>(X=<N)M4L[:ZLSI6C^$M*OY6^P2W4R2Q7L2P/$)9!(JF-OL/P+\:?@1_P $
M]/\ @G7>67PQ^)WP[\>?M%?$+28]0OHO"?B/2]<U,_$;QG8QPQ75S%83R7MM
MHGPYTB4):F\CBMWO=-=C#')JL\8_FE6*)3E8XU(Z%44$?B!FA8HD)9(HT8]6
M5%4GOR0 3SSS7I8'Q9HY+FN:9WPSP/PYPWF6.X;J\/X*OEE7'<N45,34KRQ6
M<82GB*E52S*K2J4</&I)QC2IX:*2E&K6A/S<?X05\]RC*<BXIX\XEXGRO <3
M4>(\?0S2CE_/G-/"TL/'"9+BZN'I490RNC6I5\1.G%3G5J8J3;A.C0G#^H?]
ME+]J?X(?M@_L,>(?V?\ ]JOXF^$?#?C;2]%G^'NLZGXX\1Z;H^HZ[;6L,=WX
M(^(.FW&K7-N;S5-/EBLFO)+=Y)4U/29#<.1=EI.1_P""$^A_\(QK/[9GAL:M
MI>OKX?\ %?POT9-=T2X6[T?6H].'Q+M8M6TNY7*S6&HQ1I=VS@G$<RJ22I-?
MS3/%%)CS(XY,=-Z*V/IN!Q^%?LW_ ,$C_P!L7X"_LGQ_'JU^-GB74?#'_"=R
M_#RZ\-367A_5=;M[I?#%OXNAU.WE.DV]U):W ;6[$VRS0K%,GG'SD,05OT#P
MX\6*.>^(7A=B>,%E665>$,LSS*,3Q=C,<\/4S' U,@S*A@:>:U<3*-!5*5><
M84JSJ<U7$8JM)^_B&C\[\2_"*MD'AOXLX7@O^U\UI\9YGD.<X7@[!8!8FGEV
M/I\1Y3B,PJY12PL98F5.KAZ<ZE6A&DH4<+A*,5>&&C(_0MOV>?\ @EQ\:/V@
MM8_:#F^*NB>$?$_A7Q_?S?$#X3:_XY\-^!_#UY\1_#.LRK>W^M^'/$<=OJ4L
M%[J%B=1OH]"U(:+K32)<NR&YN[>;X$_X*_\ [;G@']HG7O _P=^#FO6_BKP)
M\.K_ %'Q#XF\56$;G2-=\975N=-LK'1KF55-[9>'[!KP2ZA J6UQ>ZC/#$]Q
M%;1S-^3'QDU[0_'/Q<^)_C+1T-SHOBGX@>+O$.C37MJL5R^EZQKEY?6+S02;
MVMY7MYHWDA+%HV)5CD&O/@      , #@ #H .P%?'\7>,=7,\DXBX6R3A?AO
MAS#\0YJ\3Q%FV1PK0K<0?5<5[6A4]G*3IX6G7G"-:M"G.M"I[2JJ2HQKUE4^
MSX.\%:.59]PUQ9GO%?$_$V(X:RB.%X9R?/IT)T.'?K>#C2Q%/VD(*KBZN'A.
M5"A.I"A.FJ=%UG7GAJ#I_P!(7Q2^.WP7U'_@C1X6^&UA\4O MY\08O@M\,?#
MLG@FW\1:=+XICUS2K_1%U+3)-"68ZE'<V36EUY_F6RQ*L#N)&0HS_@S\!/B[
MJ_P%^,_PV^,6AVD6H:A\/_%6GZZ=.G8I%J>GJ7M=7TQI!S%_:&E7-Y:+*I#1
M/*K@@K7D'E1!_,$<8D_O[%W_ /?6-WZU)7QW%GB)FG%.:<+9PL-0RG'<)Y)D
MN3Y?5P=2I4<IY'6J5\+CY>V34*[K34W32E3CR17O:M_9\'^&V4\)93Q9DOUK
M$9Q@.,,^SW.\RHXVG2I14<_H4L-B\NBJ#3GAU0I.G[1N-2?/)VAHE_4O\??#
M_P#P3V_X*@:+X#^);_M':+\)?'OAO2)='$NN:MX:\/>(K71Y[J6]G\,^*/#'
MB^\TZ.YDT_4)9[FPO=-U Q)]JN'CGO()X_*_-3]JS]D/]A+]G'X)>)+OP3^T
MX/C)\?+J[T:+P;HVB:[X9O=)%M+J,/\ :LUSI?A5-6@C6'2S.TUS?^($6-UC
M$5MYKX/Y'2002G,L,4A]9(T<_FP-+'%%$"(HXXP>HC14!^H4"OH^)O%?*^*J
M>8XW-/#;A27%>:X*6%Q?$].OFL9>VEA8X7^T:.4_6?J4,?"$8SHXB<JKIU80
MG)5.7E/F^%_"3-N$:F68#*O$_B]<(91CHXO!\*U</D\H^PCBGB_[,KYS]5^O
M5,MJ5'*%?#4X48U:,YTTZ;DY'['_   _8H_86_:4^ /P\UV7]JS3_@G\:K+2
MIK?XJ:'XHUCPS/IYUJ/6+XP3VWA_Q=J7AF2%I-,%B8;C1M;N=/:(Q2-;1W(F
M+?8_[9'[2W[._P"SY^P=/^Q?\-_C,G[0/C[6?!4/P^AUJVUFS\32:?HUQ>B[
MU+Q'K^LZ?->Z1:PP0I+8Z%H]MJ%Y=PYM8MPAM3<M_-1)!#+CS88I<=/,C1\?
M3<#C\*<D:1C;&B1KUVHH49]<* *C+_%FCDF09CEO#_!.09+G6<\.KAC-^),+
MB<TG5QN7RH0P^(K+*:N)EEV'Q^*A#VE;%PA)RQ$ZE;V=Y<L;S'PAK9[Q#EF:
M<1<=\1YYD>1\2OBK)N&,7A<JA1P.91KSQ&'HRS>CAHYGB,NPDYNEA\'.<>3#
M1IT/:6BYR_;CX:_L&?L#?M!_"/X9>,_"O[8NG?!WQQ_PB'A=?B=X>\4ZYX3N
MI+/QS#IEN?$9T_2_%>L>%-4TB8:J+EH;BTO=3TZ-5@EL5BC94/O'_!27]K/X
M"^'?V1M!_8S^%/Q.7XW>*S9^!=#UWQ;#JD'B5=+T#P1=Z9JJ:EKGB2W\S3[S
M7=9NM+L[>VMM.N+J2&V:Z:YFB$<8G_G-D@@E(,L,4A'0R1HY'T+*:>J(@"HJ
MHHZ*JA0/H  *(>+-' <.9UDO#O!'#_#N/XER>ED7$&=X'$YI5EC\!&BZ-;V&
M5XC$3P& KXF$JBK5J,9W=6K.,54<)4U/PAK9AQ-D>><2<=\1\2Y=PMG=7/\
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MW_LJ<X_]3*A_L?X._P#)JO#W_LDLD_\ 4&D%%%%?G1^DA1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% 'Q;^UU_R/G[!/_9^WP#_ /3RU?ZG
M5?Y8O[77_(^?L$_]G[? /_T\M7^IU7^F7T7_ /DTN7?]CC//_4V1_EQ]*W_D
M\.9?]B3(/_4"(4445_0Q_-P4444 %%%% !1110 4444 %?P9_P#!>K]HO]OK
MXO?MI?LX>&]>^'-W\$_V /V=_P#@I=^SK\%/ ^O'6-6L=>_::^-NNQ6'BN\\
M<QV\EOIKZCX+\"^'TUGP_:1VL3Z!9ZGJ]TJ:MXAU.:ZA\/\ ]YE?R^?\'/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% 'Q;^UU_R/G[!/_9^WP#_
M /3RU?ZG5?Y8O[77_(^?L$_]G[? /_T\M7^IU7^F7T7_ /DTN7?]CC//_4V1
M_EQ]*W_D\.9?]B3(/_4"(4445_0Q_-P4A95&68*,XR2 ,^F3WI:_S]_VJ_\
M@GU_P4<_X+B_\%7?^"BFG^"_VO(_V?\ X+?L4_$CPE\#?!^BZQXF^(46F6MK
M=>%8]7L+7PSX*\&7D%L+G5?+O?$WB7Q'J$UD]Y=:U;0P?;?),5H ?Z P=&.
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M=?F)P)(Y"1G:/E  X&2 >"3_ (E_\'_^B*PG_ARSS_YYA_Q,5XS_ /1<8O\
M\->0?_.H]R;_ (*.?M-H<-^R[X'4^A\;WP]>/^0MUX/'7@\4S_AX_P#M,;2_
M_#+W@<* 22?&U^.!UQG5<G\,Y/ S7@[R#>C%I 9 0&D_>(#MR$)SB)@N1\V
M1SU-4Y)(P=QC4(9%0_O=[,!CY3CHN[HH!"G&[&:/^)?_  ?_ .B*PG_ARSS_
M .>8?\3%>,__ $7&+_\ #7D'_P ZCZ!_X>1_M*]?^&8? OI_R.]_UZ8_Y"OW
MO]G[WM4$O_!2S]H^''F_LR>!DRQ49\:ZD<D=<8U,Y [GH.<G@UX%YB(/W4H=
M79_,'!E12 45 XX92 2R9//!(!K!UBZABB25@5PTA)0J\T953N15Y)+D?,QP
M>3D8-'_$O_@__P!$5A/_  Y9Y_\ /,/^)BO&?_HN,7_X:\@_^=1],K_P4O\
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M/_!2G]I$*S']F+P/M7.YO^$TU+:,=?F_M/! ]02*^5?#EZM]%(Q15DB\L,Z
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M^5E_Q,1XT?\ 1>8[_P -7#OE_P!2?R_%GVZ/VYO'I8K_ ,(Y\.>"0<Z'X^&
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MV_=&",=\UP.L:M<VFL>%MLS"V>VM]\,A50QEOY8V8KD.[B/: 00%)R!UR?\
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M/ Y[8-3_ ,2_^#__ $16$_\ #EGG_P ]!?\ $Q7C/_T7&+_\->0?_.H]U/\
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M2W%M;W1C\E3M$D:2D!A_=)9<D$@*#G.:/^)?_!__ *(K"?\ ARSS_P">8?\
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M-1\DF& W*610?[HP0,CI1_Q+_P"#_P#T16$_\.6>?_/,/^)BO&?_ *+C%_\
MAKR#_P"=1^EX_:3_ &S3T^"7[()XR?\ C-W]GOCG'.?C3V/6C_AI/]LW@_\
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MAW1\$P>.+?PK<3VOP_LK/1X$E\)2BXL((;J1)KK%T?ZO*_BD_P"#E7_@A?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MR04 VJ[<!<\<#J:\0LI[B+6;^"!0?GNU:1%9W";CG?A2$ 7@EE&/7BOG#8]
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M9< 9("R$*&SC!(.,[<]AS7]87_!H ''_  5.^(C.-H?]C;XNLB,I!5?^%J?
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M"LLD:$#:9W4#)R?E!&>"0HYQ0 EU<:Y<3F.SNYHDDE98H9[N8_(2-WSLQ;G
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M8;-\-I_%$MO;+XEM_#2:A%\6#?V6E1_V!.K>%4M96,E[(TB?V#5^+/\ P<3
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M*,SPM++,SPU?%/"X#@WA++<1CJ$</5E5]CA,THSP57$0]VCC:<J,I1JQ<5^
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110!_C ?MSJ#_P4\_X**&17=5_:U_:C9555.TM
M\;O& W9( P6^7!8GG(Y(%?'7C9RVG0!>?].^5BP"J5C/ &<@8X4=3@\@&OLC
M]NA@?^"FW_!1H%GVC]K']J(N5' "?'+Q<I7=@D$9[9^\" "./B_QFC#3K<,1
MO:\;9M8%CF-B2S9*_*,*0>I&>AKZ/C'_ )+#BV__ $5/$7_JXQO]=S'#?[MA
MO^P>A_Z:@>I_ ,H-!\9. X(TZZ5QDC<-DA!)^Z,GG>,G  4#/'FW@4DZ[KTA
MB65V@U2-<H,.<!?,8YR!@X5#@%R"<=#Z3\" Q\*^,Y"KA%LKA<*, C:QWKS@
MKUX8#/7MBO,_ DH&LZZT<0D_T75<8DP"#+&-\@X.\'A4XR1@D#-?.&Q]$>#/
M!^L^.IXO"?AZRDO=9UC5H;2VMXSB-F<PE&D.TJ8XU!D=CM$:J>" 2?T1\+?L
M":7 VFC7-:;7M978-3L(TFMM$BD"(3:Q2VY^T-=(X*,[L%R2ZK@ 'D?V"O"S
MWGBG5]9GM5CM]&L3<C4KB(DVQE=%58Y4!$?G#;&HY=AN5<\FOUE\+:9XACUV
M&6+0]6L] N!',FH2QPFTNKV2X5MSH'%TIE&!%O01"+#EM^: /Q=_:1_9MUSX
M(>*/#M[;Z<\/@[Q)'</H[O<27S:=>Q0J]QIEW?/#%N:1B9;9G"GRV\L'<I)^
M$KMT9/&XBB=51D4\A@S;\NB $,^XD!B#\H'IR?ZJ_P!L[X>Q>+/@1XH%S:1&
M70;*+6[2<Q+N5X)$9)E!96$JLLD#!,8V;B&SS_*M>R+"GC="8XY9KA#;L5<K
M( YSL*#K(O(((VGC& : .5\*L?[+\9,[$XTX .$!6$MM;9'M(##/&004!)Z\
M5YEX01_^$JTX@[R+\-G<N"VV3A1D$A\XP<$#/->E^'(VDT7QP0 0+.! V"#P
M%#-N!R0#@C&=V#UR /,_!8SXJTM7;EM1; 4?,7"-G&06#8& P*XR3VH ^BOB
M-))'HURK>6B77ANQWB5(W9B"<-;X&^/##YCG+X(/&#7DWP3D9/'=L5<1K]BO
M1A4;)"0D%EP=P5S@LOW@ ??/IGQ*W0Z-+C+Q_P!AVRDH-Q";B) Q;=N100"5
M^?OU!->9?!5(V\=6Y55C M;MB3N*F/[.QWH['!SP JG)."10!M:.(S\08O,6
M0B37)7=5(!97D9@%9LJH)PV<': 5(->U>$K>:ZU;Q!#:1M=W=Q?W=K! JEWD
M\[8B*B*A=B[G:%'!;!.*\0LI3'X_8X)1]9E5PWRL@#D[EQDKD#! (&">F>?N
MO]CSP1J/C3XTZ;#I^D7>IF+Q0)KB.*%I@D41BD,DBKD>7&@W%W.5"]=S9H _
M4S]F3]C32_AUX#TKQ;XA29OB%KVFK/J-R9&%IHNGR.9H+*R@D0K;W#(0MU<X
M,DCAXD(7(JI\=/V3?!_C_1O$-Y:ET\8V&G2:KH>M+=2"/=9Q/</I-Q;QC;+:
M7KC)=E:>&0@1LJ@K7ZC^(='D\*>#KF?6-/EBO;[3T,.G(S23011R[+:W6.-2
M6D8$2(B*7 ;[[8)'RII*>)+>*Y/B'P]JNCP7[7B64MY;3"P*70=85-TR@Q$G
M&U6'WFX(S@@'\TNN64MGKLMM<0B.:V=X)8FW"2)DM+CS!M92X'F;E)(# =
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M"CP_I%]Y M])#WF@SV4-Q;ZG<WEN(H)QJ<@\ZUATIPSR1Q*PGP4.&:O<-/\
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MP2*_._66CF\6A4WX_M>V^\=SA3*'PI/"\G &00 I[#/(9G(?$X(_B^[C(PJ
MID @C=$G^K49^;( /!&<GCBO9?#Z6L'A+1V.G0S1I<6;364L:Q+=D6C .S*
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ML203EACH #(^#D8C\=7#1!=ITZ[9Q'E7(#'G9GYL=3QGD8Z5XGJ"12>.;Q9
M)(&U[8X="%D479W1G +*&)&_')S@8/%>V_!;GQ?J$C,A/]DW>\D@%0"%3RR/
MEWX ("YRP&0>*\4N0X\<W#>8 [>(8RN<$?\ 'PV"<X)+'#'/H.#G@ ^@;^TM
M;+X=?$I((8H8O-T7=$&,?E@R2/&D2$,LGS\L,KC'F%B!BOFWP&<^(H22K"2*
M8%>2P4P]EXQP,87!.01FOIG5XV/PW^(:RX:0OHLAD)) <SNBR$@],[E .-A.
M!W%?,_@#CQ&CL0?+@G8,F0-PA8,XYW'/RX(&S..U 'IW@>PM+G6+-+JVCN$-
M]<J\4Z E TCE?FYP2 !\V1WZ@UWWA+2K!]/\82M:0/-#JMY% FU7<1JQV@$#
M!"'D!L#;D$\YKDO ,J_VU9QM\[275R[*PVL6\QVW;\'Y6^Z%'S<DL,UZ=X/M
M\Z7XR9U*%=8O70P ^80CKD L.6P=J*V5..5Y& !D&EV#6\/GZ;"0TB%'>)<L
MSJ5"$*#EEQN#94'&.@S6#=6EN=1N)'TW;;1K=0JYA9(TV1D/''(5$7GL/X 2
MRL<X-?IO^R]^R#JOQP\-2Z[=W:Z+X.@UF&.[U&0#^TI?+MQ--:6H>,JDA5]I
M9P0N20H.VON;XR_ ;P%I'PQN?AOH-M;66EV.C3V=I<MIEG/-+=2(2-0N;YH?
MMDUXT\AF>X4JX *JP0** /YJ-?L;*;PE;@6Y7RXV\K&"\<;:C<-LD<8PQ'WP
M ,[<[<XSVV@HB? /64C)+)J$D?[QB-JE<H%W $#(X('(PV*D^*/AJ?P9!J/A
MBXGCO7TB\EL3=PEPMX@OI7BGP0#^\1E9 W*C(;CJ_1]Q^ >NLN7(U25CE5W(
MYP $;C*E#V;(;*D^H!X+X/TVWO)]2,X(\K33.C@J<.LB98!<$DC.XCDXSBO]
MQ[X2?\DI^&6#D?\ "O?!>#Z_\4WIO-?X>'@8 R:HL3(0=)D69B, H\L981@G
M(DQE<G=R2%()K_</^$>!\*?ACCI_PKWP7CZ?\(WIN* /0J*** (Y(HIE"RQQ
MRJ&#!9$5U##D, P(# ]#U':OYD?VC_\ @X)TGX+?MA_\%)?@IIOP4TG7?A#_
M ,$[OV1-3^)7B7XC:B-;AO\ QU^U+J'BGX;:#X(^$#ZE#:_\(WX;\.ZVWCJ[
MTVUEOIIO$&O:GX:UZ;2"8=/DMD_IRK_-F_X*^_L^_P#!272_V\/V[/\ @GM\
M(OV??$?C7X(_\%8/VG_V?_C[H_Q4\/>!=>U5)=.\$M!<2:3-XPLP/#FFZ+X2
M\33KJ'BZW\07-HVAKX8BU)98++67FD /WS_X($_\%T_C]_P47^+?Q*_9Q_;*
M^ _A/X*_&"#X8:5^T'\%=:\'>%?%G@C1/B#\'-8U"RTV0QZ)XUU;6M1U,0R:
ME8ZIX>\6Z)J$FA^(-'_M*-X8;S2#<:C_ %35_(U_P3A\ _%[XT?\%[OV@_B7
M=_"S4?A_\ /^"87[('A__@F9X"\8/8S)I7Q/U/P3KMM>6&I)=R1P69U;5+'4
M_$/BM]+TC[5#X=\-2^%K'4Y1?:A'+<_U6_$WXB^$_A!\./'OQ7\>:@^D^"/A
MIX.\2>//%^J16MQ?2:?X:\)Z/>:[K=Y'9VD<MU=R6VFV-S*EO;QO-,R".-2S
M 4 =Q17\(OQP_P"#L/\ :]_:'\:Z]X)_X)+_ /!/'QW\5_#VF-/!8_$7QOX
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M<9P9GT<+F[<5[7$93_;&61_=YE5C*<QH5*E.GB<.KXO!3]O06WM59QK89O\
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M93F%%IQK8+,,-A\3!J[I\KC)K1117TA]:%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_C'?
MMN0^9_P4W_X*/Y5MH_:M_:D). "6/QS\7!5C)X*DYWX&X<^U?&/B[2]3O(8H
M[.TFN9H9SNMX$,LK(L+,YBB4,\B*@\R0D9"*Q/?'W;^V[;RK_P %,_\ @HB\
MENP!_:C_ &H9HF)RCQCXY>,R6"GC)"G!R/F  &>*^/+F2_%\;RPN)[:XM6D>
M"[M96CG0/$8Y41T/FDN&,;-C."P8E<BOHN,'S<7\6O;_ (RGB/\ #.<:OT,<
M-_NV&_[!Z'_IJ!J_!64IX1\: L=L5A<AT"R*6*A@5. 3@,,;F R1DC %>8^
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MY8U'PH\3 1Y+$D_Q $9Y)SG(K]7/^#R_;_PF7_!-S<I9?^$G^+.0,C.(/"V
M#TSG''6OS"_X-DC,_P#P5E_9YD$<:6R_#+XY01L@1 [0_"OQ.#\J@,77<58]
M",')P*_47_@\J1O^$O\ ^";DA4^4OBOXL!I.RM]D\,L!D@C.U6;'4[>".M '
M\1^O6\Q&K1")DEN%NTB5R3OC;S%4AQ@ALY!'(YSS@8SO@Q;7FE?$&*SN[*2R
MNH[=_-M[V)XI4S'E3(C /ET.]&P5(8$$@@UT?B-Y'N;L*&0-+/'&=^Y@6D(
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MW=Y]NM+6SF,;-9$3JB&,[8H@5+,0Q9MI9R@)+9(X )Q/@NDJR^+3RC+HTOF
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M\-7FF73ZG9WTL=_O\N#R989G+JI1F$\8#D),A(=3D^E9?PX(;X9>-055)75
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M2[2"%O$.M7/AC7+VVN0AM[6S_J%K_.!_X*Z?LB_\%2;C]OG]M;]@[X(_L_\
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M:5<7NHA8[V!G:U";CNVGA/\ @F3_ ,HW?^"?G_9DO[*O_JB_ E8?_!43PO\
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M4 %%%% !1110!_CL?MP1&;_@I7^W\BD;S^TE^U(2S8**H^./CD[1@DJY&>6
M!R0.>*^%[NX*/<%7\O:P<%=JNH3AE!.#L8$#R^K.?;(^Y_VW=R_\%-?V](X]
ML2S_ +3?[3Z,[!G=]WQO\<ERFS@(2-N&&0><@9S^=_B.X9=1GM.'6.?][L<;
MLH ?W04\[\ L1D=, G)KZ#B[_DKN+?\ LJN)/_5WCC'#?[MAO^P>A_Z:@3:#
M<&?62SB0[XWV1Q@M@L0 J#)Y)R0""0<D#@5_7E_P;\?LF:;I6NZQ^T#XXTX0
MZF\DUCX92ZC2<6>E74,+37K1SQL\6H7;[5B<$[85RJJ&(K\$?V'?V9=1^(OC
M;2KQ](CU0--;"1I3+);VT<LT9DQ\N#M0JCE<&:1RJ,H1L_W"? ;P_HOP0\!^
M&]$NULK:W:QMD-I9F.R64&%%^3!$C-$B,1\S8VL"/FKY\V/H']HT>;?2:M$L
M&I:9:1,TD)5)2\,A$<JPMC,DS1KQ#&F]7.0,@&L.PE\.>*M)TH^'=!U!+J[L
M=.TYH(8Y%"/(L<7GS:><A(WF8,LA X9C*5ZUP_CK6SXRAN++PS>RV<&H[M\D
MS6\>R,HJ;(1)DP>8@(,B'>%.05<C/K/PAO=-\$ZYH.A"ZN(;Z2VM6%W;7$=W
M9-!,B(QU"0H9$D,ORN68[$*L<*I( /8OAI\,O%/@5W\1W=O;Z+9SW:1R:?+=
MQN)(]JQ6H6-\?))*TC3-\V_L,5^,O_!7S]DJT^-7@WQ_I=O#$VH6L7_":Z->
M6Y2,V^IPZ?.Y(;R\)!(H\F6*(A9<J7.%S7[C^+_B]I]QXB7PO?"*::WT\)IC
M;X4CGN8VDCG:W?)CE<Q':DH)SD%2#@C\R?V@?B$$T7XBZ=?1RR3V_@[5[G1I
M9,RI.;9)4-M,^6.R))'C=1N8DD'C:0 ?Y[C:7<^&]6O-%NH=EUIMY-8W$;AO
M/MI(G:.XBF215$+F7)3(*,C;URK!JW )+8*VQ9MVY0SHA^1P5?E "64_/$%(
M;UXSGZT_:Y^&^K:+K/\ PGGV>&2"[L[NXO+NSMG#SI;2JQBU*"-");VSBD5;
M>X!/VBWV[LM$QKXAM?%2W$:3)INK86!IT9;<')4?*B8; =RW"A23R 0: .MU
MP#R].2W)9191Y4G(W$E6D()R!MW%F!RK=!U%<!J\\D=K/$K*S%?+1_E1B>GR
MD<MM7C< 03U'3'3:WJ?EZ7HUR;&\+7%M+F".-&DAV3-M0KG<N<_,22=VX$#I
M6?X?T.3Q0^HZM<VEPFC:'-!:-:'(N-2U"Z(\FVMEC+M@;E5^0Q9M@#%LT ?>
M'_!,_P#9>UWX[_%OP[K<NA3MX.\,:PFM7DUY$PM-5N[&X06]G;K,FRXB-UY;
MRD Q@1MEBQK_ $(O@W\+H_"?P-C\/Z3911ZC?^1=WDCP@R/.(OGBMMJHK0?+
MLVLXVC'!Z'^:/_@D9X6UGP3?W4'B^YLY;N\TG1[*TT2R2-K72?F^U"SCN8E"
MO=Q6[(=0"IMAN2(6<R!S7]7-GXN@\*>$X6EN3+9M9QJZ)",P*UO\OVA!N">7
M(59I%(('S$_+MH ^/YO"]UIFN1SRZ+<7-XVJ7-Q=NV%=;>-!Y3*I4<%@4\M"
M><%CWJKX_P!:;Q)>Z-865C!#J6E1VT5U927BN(TGF\MF$8W*6\HJ(X\[UDQN
MQBOIC4]:FUO3GN-!N+*;6+F*&%M1,"/9VDDR;Y8+>4E4DE7AO-C#*LK;02^1
M7RWJ7AVZ\#>-K#4GLOM;^(EB:^GNI&7;?Q.QNI(&F+"5@HW@YCB_@5E/! +/
MB;X51^)/A)XJ\*:]%#=6NOZ'J5K)8D':?M5M-$P9I%>%I564F-F0*CJ.O!/^
M?;^TG\'[CX&_&/QWX U57BETZZNHK%A(KSRV$D@GMGG*(L",(3'&RK\RGYR
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M$@8WE!@%UZD#..E=)XKE-OJ.H#S%51O,2J/F9F8LK CJH4Y(P" .>!47P?\
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M3&5-/B2-H6=W24>;+NS'M&[.3S^)6J:U)J)(CM;FW4M&L1,6TL9B%(?:^=S
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M:ATFACCGAV#S",211ARL,DY"O(1\S(HWDXQ7I996RJA4QD\VP.*S"$LNQ=+
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M:E87VF75M^R)\6(I[#4+6>SN[:6/XH? M'CN8+J..=)@>H9<8!P2,4 >O_\
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M>%"(SD#J?Z/+WP7X9\&?"^UT*UTAM/&EM$T*"4-\L<6-HP6PS8. !SR2P(H
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M@:G:ZAH]LT^N3^%9?+N[R&66.W6^DLQ"UI=K8[E:XX61HMQ+[E(K^Q2#XO\
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M^/W]A5?%,WQZ\"W?@UG%W9Z\(=0:,[I&TF^>*UOK:2-LM*+H2B%2,MYA^4C
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M8@=%KQZUTG7-9-_K6GQR^'99VGO+G23(T]O) DI6SF@.52.6)G0A@0<$9R:
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MV632(=5\<I>W$FF65QJD>E:?X>\":7>>(+VZTV\US5IHM*\B*+^Z*O\ .?\
M^"YTO[=7_!.?XX?\%1OAUX?^!%W\7?V*_P#@KG'X-^)5K\4-.\/:_>GX9?$/
MPE)X<;6[4^(O#UOJ=MI>L6.H6ES8WGACQ;!:6VO:'J6AZQX>NK>2RU,3@'])
MW[#W_!0;]IR__P""M?[47_!/7]IO1;>W\">(/@3\-?VJ?V./$LT&BPZQJ_PZ
MG\/>%/#/CL376B +K.D^)/&G_"4>(+.;5TAUW0-8TCQ#I5\)H;NS6S_<CXRZ
M7\2-;^$?Q/T?X-Z_I7A7XMZIX \76'PQ\2Z[ ;K1- \?W>@W\'A#6-8MQ:WQ
MGTO3M?>PNK^(65V7M8I5%M.3Y3?R2_\ !"*;]L7_ (*,?\%!_'/_  5H_:<^
M L_[/'PN^&7[)'A7]C?]G'PS/9^(],;Q)I]KK<7B'5=2L)?$EEIVH^+M/LVN
M/$6I:OXJ>QLM,_M7Q/I>C:)#-%I%ZUM_9)0!_(]<_ML_\'*/[(%M'IO[87_!
M,WX.?M^?#2PN8WUGQU^RKKT,GBG4+2 &2*>W\'Z8FMZF7M9HH[B>\O?A!I\$
M883J8/(EQ[1^SM_P<H_\$X_BO\=/ '@_]H?X!?'G]C7]K#Q/<:?\&/#*_&_X
M%7&HZBMSXM\4Z78Q?#S0_B+X8L-0\56>A:CXKET:;4H=9\-^%O#JWG]GZEJ;
M)]F\^U[;_@OG_P %7?VJ/V*M0_9Q_9#_ ."?7PNE^)W[;7[7$_B"Z\%R)X73
MQQ-X+\(^&KJRL)-1T;P;.KZ=KOB37M4NKF&RN=?BG\+^'](T+7M4URVF7[&8
M_P 3_P!GS_@H[_P5_P#V??VP?V5OAK_P7A_9)\*^/_@!^T5\5_"GPS^''Q-^
M(OP(^$?]O_"CXF^(-5LCX0UOP+XR^'FG3:/!?:9XJO=!G\0:#K8_M>TT>"ZU
MCP_<64VEN;D _OSHHHH ***\(^/7[3O[/_[+VE>!];_:!^*_A'X4:7\2OB'X
M?^$_@*Z\67[VG_"6?$;Q4EY)H'A+1888;BXN]5U&+3[V6-%B$,45O))<S0IA
MB >[T5\Z?M,?M<_LS?L;>!;3XE_M1_&SP!\#_!&H:O!H&F:]X\UJ+3(M6UJX
M1I8],TBS19]2U:\6%'N)X=.L[I[:V1[FY$4"M(.%^,/[8_A_P3^SSX/_ &D?
M@9\*OBM^VSX-\>ZCX=B\):5^R1I_AGXCZ[K?A_Q%;:E<IXTL3J'B?P]HT_AC
M2VT[['J]VFK&ZLK^[MK.2T\\7"0 'V+7XL?\'$__ "A7_;^_[)1X>_\ 5I>
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M='HL[:I<_"GQ1?@QQW&EZXXG7P_/J9GL-,U2\N[&^B;P_P"(-?AF^]\,.&.
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MLO$-ZDI>U6'2_&5]&4L9/$?V"?@O^Q!\??VO/VB]*\/>';K5_!7AE/ GCOX
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M2/YY_P#@H!\1?"/P<F^(7BB+2=+\'G6M1GT_4-8M8+:WU?0M/-C)86VO+;O
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MU((KVB^@\/S>/M$M/$]T=,\//=Z*-=N(1OEMM-D6"2X8HF<#:OER@*WR.QY
M(K]]OA1\6_V1/C'>P? O3-(\ ZWIFGP16&EZ3?Z18,NL//%#(USI2/9K]M-H
M8G\YK:19'(W.V%( !^C_ /P0]M=4\2?!J#Q?XLMX=&-].DL-DDIE_M"U@M;8
MPZHC,J&**ZD^1( &"A696P1C]7_C3X[MI\>'[*W@BMD26:\NDC+&&U5)%&X
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M49_>R#E]N"3^8'B;4);#XF?8-(N[F*SUZZCDLWA<B/1;VY?<S,^T*0'4^7"
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M?C/29O%GA36K:X_T6YTFVFNH[SR@UQ:36ZR-$@F 4RI,, AF)1PH4')%?/\
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M)/[/'[0_PQ_X*??%KX@_%CPAHL/A;X_7MAXH^"_BKP)X:&E^&_%_A33[#3]
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>74M6TG7KGPOK>F0:E8:U!+9YCCGL;U9K34/L]Q%'((YHVAC=48@.H(Z,)+
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MX0OP]H]M8V$Z17:Z[<:W87$JZQ)J(WK9'1)+$0_87A472W@GDGW*4-?R+?\
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M?9EHO%7Q/<N3@1I]F\. DC&&R2 ,Y ZXK\<?^#6R'_C<)\%)#L3;\-?CD51
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MOA151A#)$/*="1(&!*,5X&MJ'AAO"?A>VALK@7LT4D:>;< /'NEV/M!QN6.
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MBI^TYXNUZ&7[9:I<26$:I,-ENZW#RO!'R?+"F0&12,ERPSS7[D_\&AT;1_\
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MQ^+'[+WB#PKX^E'@R]GU"(Q126EOJ,GD7,$,AEN-L9R$98C&D:L^URSA"#N
MK^@^Q\-7MA"SZ7-$T-A!+;M$UPC11S1Q.1&%E97,=VA98V0#9(0 *^/?B/'&
M?$-SJB6:F>&RM9DA=-[?99(IBA21UVLXND55''E1KAU!;) /SV^'?Q<UWX4^
M7)K\LNG311F"[FWD(TS*8(Q)L*8974,<@J-Q<.QSC^6;_@O[\:X/B%K.DVMH
MUI<?VEKL,][?+,S+Y]O'(S(FZ3S'4$[?,*G!X8#BOWB_;8\0:]IVC>()1%*\
M^HVDCRO",?9@C37'[R*( P+ 8U:)^%+ C)R17\/7[9'Q@O?B/\3M6L[QOM-I
MX=>338;\@B1Y&VF^/DL3 Q=POS@;UQE&!)! /ZG_ /@L^=G_  05_P"")<0V
ML)/@W\)8RVU.%_X9W\&G*;ONDX'(#';NX[U_&%<D&9UW8*OE,XDZ$\<'D9QG
MH #P 1FO[0O^"S2 _P#!!O\ X(BX(./@_P#"155@07!_9T\(#KC:F  6+#@<
M#!K^,&['E3,PD5-KNLB[<H96W!@N>>?O-C*\CD<4 >I_!/5YO#OC_0M6MT1V
ML]:T^Y93)L24&Z@\R,!>6#Y*?*=S,,=#@_V__LL>+X_''@73;0WJV4T(@FO4
MDS-))86\4;36V%#,0&;8(V.XL 1GBOX6O 4TQ\5:1%"$DE;6]%2%'7<1/+?6
MR1',7106^501T#L, U_;/^PYI3^%-:,!M#<1:MI\K)',RF%;S3A%]IA3>2%D
MF3>T>U=K!!G#&@#^@KP+J4WAOX=:/K&F3/)'826B6%JL4B/<P31R07SRVJDI
M<QBRN)H98W((#%\!XU%;\D=KI/@W3HK::"+2M"NTTJ>"_G2&;4KS4KR[O]-E
MLBQ4W0MM,9I+I0"(GB&\X*@^-VWCJ[GT[PQ;PS)INEW;">TC= DB(Z((Q&H&
M>1(RSJPR2$894$5Z";>+6_BE\./"NIZ;++HNHRZ?<3^>^8;6:X:4,K KN;^T
M8K=;6.1AMC5MA.TYH ;XC\:R67@_6[6.SDM[J2UN7\Z6*2T1T>)97:<[1(8E
MA;<BK&KDMP2"*^(O&7Q3;3+L16:WMS:?V/&\MP;5H[)2(F^TND\K)%-(2JJ$
MP)!L)<G-?0GQE\7:A%9:A*VF/>ZOXE\4ZYI.IM;GR[?3])L[R6QT6PC\UI-T
MMC9E'OS"JK)&%;S&#($_+3]NWXAW7PU^$7BW6H)YYI=!\(W_ /PCUM:;$@:=
M;2=H;B:-"&9TD!FF\T_O?+"],9 /Y%/^"H_Q@O\ XS_M:^-;>:]GN=,\&W;:
M-9QO*0+20/'/=&U3<<LS[89@H7<%4,3LKXU\/$+X!\9<&,?VCH3;5R0"';[O
M3+,..<G:2">3CE=:\0WGC7Q9KWB/5IS=ZMJU[=:CJ=V6VR7EW=S---,"64*[
MDKE.@P54]J[_ ,)0B;PGXM79&T8DTV0\DON67R2N<8)C$@*GKR#G@T >_P#[
M 7Q+O?A=^UC\,-=L[V^LHIM<CMY_(#P*T 56>"4QNA9&3+%<DMZ'I7^BK<?%
M[1=?\)Z)>V5V+JXU\V,2VZ"0I.J62R*I )Y5AF17/8$C)X_R_=-\0WO@?Q1H
M7B.P!^W:'JL=W9QEMWF3PNNTR ?ZS*;DR0,%L\@<?VH?\$_?CU-\6OA78^*9
M=1\Z"P@LWMW?='#9W]LABO#Y2%S<9F5K9<@#@DD@B@#]/_"W@34[B/5K_6EE
M@WZ[<W\,4;*S2(;L3M/*TFX96)C"J1G!^9@ H)/T[<?!_0/&'P]AT+4K6XEM
M-?\ $>GRV<* -)/:K,J*9)D!,<*>20JLFR,R,3P<BOX!TF;7OAV+QY4D,D[S
MQ2D^8#OB1)!&Z  I"9.(U)(+$'(&*^J/ \>FZ9I7AN"[!-WING26PD7YXI&0
MA9IHX5W*\TZ)&Z$@H5W%=I+9 .*\-_ 7PU\/-4C&@RPVPWPM<,J1.EL\<0$T
M$<L:$3B5?E9B3M&"6(!KS[]H?35%CJXMK(+&;-%EE4HJB)%C:63",22[!<,I
M!<*/0@_6.J^*-(NI8]+T&>.;Q!.)&DTFY@"RNA&Y$:104CEC&TO(&PD>R-@I
M;%?(_P =-&\47^DWD<MM+%9_9I?M#$;979P 56-<N4!^YYC@9 *@ C(!_-W^
MV1X:@\9_"CQGX5N[99(M4^WW(MU5Y'D$DLL*,!\K+'&J*T8.</D\YY_CMTJU
MFT+Q;K&@RM,IL]0NK<(3N(>VN9(F+DX^8A<' .>,KBO[UOBM\++K6'U^]>)H
MH=-TRUG3=&0[O$TENZ+$V8WB=6#! 3D\G+#(_C(_;5^&*_"?]JGQ)I.GQ?9K
M.]N(-:AB4Y,1O2[W*D-M&UY"72,XV $9(H X&6V\_P /^*&1WB,>F&XF!P J
M0E6D '5T"DDE00< <<5L?L/QVLWQ^^'UB8?/%UKUBC33D1HJ2748#LC90^6@
M9XQ)NRX/  %5;53<^'/&THDX3PY?289D)*A(V7 "D%5SNEC4?-TR21GR?X#^
M*AX.^*?P[U^?<MO8:UI3W7E.R2-%)=B'+ $;B1)G:!\JEAQA: /]2S]G F3Q
M-9Z7ISVWV:Y\-:;8V!AF+P$PQ(OF(78K"KA61I!P\AVQ@ BOJCQ%\+WUC4/M
MEXUS>6,%MNUEI7"VL%K8Q!A%&K9CE82[5"@ 8)!0L<C\Z_@7J.HVF@?#[QSX
M<N(6TR]T#2'@6,D1&)((B]NI .)8V<2(Q;>4+'D@$?J9I/BH^*=)M=#B*Q6>
MI.LNK77G0J-TD*M.+>0LLC&5R(Y(%1V8'$*[PQH _$[QSXK\?> /'GB^[\$>
M&HM=T>?4IK(PZG 8I[)VN-GGZ3?VQ:2"&.([VMA$RW+*J9!4Y\7\3?'OQ?<>
M+M-L=8L[6SMD,,NIV-M"\,4CVBJTEPR.3NN%&'4R ,6.T* 0!_0UXO\ @]X+
MT/PI_;>H:3:02-L$EP6W*]IO+E)/ER]TS*&C9@S#!5SN? _'SXJ_"'0/&?BJ
M76KG3(M-CU*&<I>6\WE1K9-.ZP2O;Q@LDQA505897!9CM(H E_9AM[74M6UW
M5KNX*0ZQXC@U?P]>11%9M/LB\;310&1CY/VU;>:)F<H8U=@N%SGU[_@HQ\2O
MA5\,_A'J'QT\<^-3HNG>'-"O98-(BC-S=7\\<H2&QL+?>AWWTK())(E;(S(3
MA #\@WVM67P#@NO(UYKRV79=VB-AC9V9VQB)V) =G#>>50A$60!L$D#^>_\
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MP4F_X(V:!_P7H^-/[<'PT_: ^%'[./[.7AG]CWP_\$]3OK7P)XR\(Z9^T?\
M'KQ%XTU74]<\=^&?"7ASP7,__"/>&_ VE>%M#U37M<TW0+S4-;TG3IK?3KZ.
MZDU(?VS_  1^-WPK_:/^%/@GXX?!'QGIOQ"^%/Q'T@Z[X)\::1#J%OIOB#21
M=W5@;VU@U6ST_48HQ>6=U;LEW96\HDA?,8&"?Y)]3_X-N_\ @WSTW]J7PO\
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M3#YF_JG#G&JHTTWR9A#(,XKR:B\;C:KO+]>:*_&SPI_P4=^*_P  -?L_AO\
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MV%SM;."Q%=/X_P#B%-%KUQ_9=P\%[J5M(WG@*T=R241(V"X\HI'*6P&57;+
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MA&!6_P"$O#&I6\L#3,)+T01MJ]XZF-<39E81D$#;;XCC8 *\B $KU% 'RO\
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MJMY)=ZA="PT^6TO/U#K\@/\ @I5^R3\$/VY_B7\!/A/H/[5WB/\ 93_X*"?
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M+#6/!VM>$];2&<NL=QJ%S##--%"LK?GE_P %YOVD?AMX:^,'_!,C]EWXE?\
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M38$N[15N_M3RQO&%_P"._B/(Z^3YUFV68ZIDV"Q&4X:@N3 K.J.!S.IA_J.
MK/*(YSAH9E6Q%>K4K8[%1QE+!T8SH9G]7CAZ=+#8)_SEB\/*AB*]&H\/3G0C
M&_LO;QI590]E2E[#V\?:RE*3E4G[10BG"MRJ,8PIGRS^U=XF\(?!_P +7_C?
MXB>(]+\,Z-]NN87OM9O+73I[^73H+G4[C3M&ANI(TU'7-2MK:7['80OYMWM$
M<)!&1_(7_P %#?VN+7]ICXOW%S\/?&'C"^^"6FV^B7_A#POXCLAHT6B^)&T&
MVT[Q+?VNDK+.UM/?7"2++/\ :9/M$9#8"[0/VB_;J_X*F_##3OC7^U%^R_\
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M&<')!.#GTG]AZV@F_:N^%T,S(8O^$CFD4EQN#_8YVB;<1L=%P79"<.VUB2V
M//O&)9]*TB4L)H=J?>W[AF)2VT@G&.0P!QP0#AL5U'['-^-+_:H^%UTSB.W7
MQ7$7,H!1Q/$\<"1KMX9Y7Y5?EVC/7K_F.?DY_I5_L[6UI/X%T..!-TUOIMJD
MH<D8Q @$K-A3&JG;GKDL,#&<^X:_X022\MY66/SFCMIK>:4'?B$?.PB&&*,!
MN!Y!V,6?.*^/OV<OB[\,](UW0OAAK7Q"\*V'Q%\6^'K2\\,_#R?6([?Q/K,K
MQ37$"6.F2J;B:.^MK2YGMRC@-!:3,O"&ONZ8K=RVL5QF)4,5M&S&2:7!38T<
M<PX)7!.&R 1DC&<]V,RS,\NA@JF89=C\!3S/!T\QRVICL%B<)#,<NK3J4Z.8
M8">(I4XXS UITJL*6,PSJX>I.E4C"I*4)):5*-:DJ;JT:M)5J:JT74ISIJK2
MDVHU:3G%*I3DTU&I"\&T[-V9P%EX-O&N-3M<QJ;VX$D<H#O';E!YAGBQA8X9
M.-XSEVP<9!SYS;>!?$%UJ-V^KY-K'=RAX"K*Q>1]R3)E2H"J 5)^5OE&.0:^
MN=)MI,M$LF\VTD<,@\L>:$ &R1V?!(*X<H,X;Y6!/69]!F?4 (2V_P QPH9,
M2DO$OEM<Q@&-7E&[;L4HK$8'7'"VDFV[):MO9+NS,^!?CE=:%\'/AUXD^)WC
M2#59O!GPWL1XE\2/HMH+O6/L\5Y;0/\ 9;:::W2YN6ENH5$4L\4,AW@/A,5^
M7G[='Q*^&/Q@^"447AZ#7-,D\;_#H_%?0XO$EG::?/HNFZ'K-O97?A?Q7 MX
MYT/QI?&8W6G>';H&]O+#?>P(T,>:^W?VX/%VD>-_#/@SXQ^"O&FA>-_V8O@5
MXG\<1?M9>#O#FN_VK!XIT^QTZQL(?!NHZ+&([3Q+J6@^*9+6^GTB]NH(].F"
M79D+*H'\OWP_^-EMKDGQ$C^(%[XB^*GC'XO^/-+CA\-^+RUYX::]U&*XTZW^
M*-YJ?VEKIOB!X82:#2]!MC9M:/I][>"6X58HHC_?'@K]$.AXI>#'&7&G)G=?
MB[A2OC*F,RO+8SI8K U\0L;EN X2S++<RA@,+EV=Y31P"\0LUQN9YC@\"^',
M]X5P$YT(YECL?E_Z=PYP&L\R#,,P2Q,L;@)3=2C1C:I"513HTL%5I5O90HUZ
M"I_VI6J5ZM*D\+7PE-RBJLZD/R<^,GAJ3P3\7O&&BF KI^I/8:_I# .J-9ZI
M9QRD*[ &1HYMZNQR!C:#7*ZD[-X3BE\ME1=<.6"X"$6AY(4+N3?\RYQMX#9.
M*]>_:GU>&^^*OAJWE.[4]-\.W'AW5(W+))-<Z7=.L#R;0 'V+M4#!!4ACMP*
M\6\17DEGX(G#M)&3K1 'S;OFM2 JC.UBN><XP.?3'\"Q?-&,M/>BGI>VJOI=
M)V]4GW2/S!.Z3[I/[SM/V-/!9^)'[3_P^T0J[+/XHTV(R!BRJL=Y;RW&&4?,
M943;C(P3CH":_P!2#]G/PW#_ ,(O9:-]GVQ16-BBA4"RB&$+&F2!D(70<YY"
MMR3R?\W#_@CGX?E\4_MD_#A2(_LUEK4^H7TQ4;((+:!G+3Y/]\@(% W'H<BO
M]*[PCX@C\(0:1JJ*T6CW2_98I(U*^4;;YXVD(5G,,J_,JGHV<\L,T,G\9^"O
M^$=\6_V?!$HAUZ"*\LYU"O%%=R,SRQ*S8V2/MV@' +$D'.!7/Z]HMQIK:6#&
M(UOI09(I?F2*0+EY3GG<,!E.2IRN,#D_0WB>]TKQ_=:+=Z7,)6M%M7F>)>;B
M&9?,60!E5XF63Y25PZLH!7&<Y_C_ $C3;672M/M]L\<-CY]Q++$\LC( K&)%
M#;O.8F--QZKE<G;0!\VZCX?.H^7&T?V6#Y5DMK@_-=3HRR2NR[1A9-R;0"&+
M\<9YGF\'S/#;3?:7MX()I9D,L9AAC1-L"@J> %^=OF4%@%!SU/O)TJ"XBMS*
MA81QQ3F<J"X# QJR;CQLEW;&;#9"@Y*BO+/']Y<SV^KVVG!U<6\OEALF1$C4
M112F-20'9 2.@#$$\\T ?(7QBE231_%KP(!;6&G7[O.Q&7G6%BIR2>6?#)$>
MSG@X%?YS_P"W5=Q7O[8OCZ\0H$?7X89Y8B%<7$%O#'()W8?>SAAGJASZ _WX
M?M.:WJ'AOX7ZD8[DQ3ZI/<P3,[9S%'!+)<!LYW':C;G)/3:OI7^>+\?=6M_%
M7[2OQ'U=)DN()_%^H21,S%MT<#K"A''!79C'/&%.2* .@\.122:G,NZ-BUG>
MKDG./]&E"[0W]Y25R21)D $8&/GC2KZ>TUK3Y@KK)/:7UF"7X51<388*, A0
M,;22<$#)-?2_A"%CXAL5$1EN62:).0RR*UK,4C54&96W,0V2 ,#'2OE>>8V]
M[82A"JQZG>6S _+M$MW-&06;/S'KC^$#J3F@#_2G_P"" &GW$'[#_P (8[?8
MIM(SK+?NRS.)KS-P$.-RS=#(&)4D8(PP _IN;5+>/2X);.4 3KYA4X#A9G+.
M=JCAP#]T_*/4\9_F:_X-R==LO&'[$G@[2[&4O>>'K_4=-E*9>02QHC21!\JH
M6/S Y W_ 'B6P>:_IEBT1;2R08,CNL<31LY7R%?:C);D]D7+>6V0S [6P: /
MA7]H7XR^&/@Y\/O%/QC\<#7;[PI\.;:34+GP[HMI;ZAXH\0F"4(VB^%=#GN+
M677M9N!)Y]KIMK*TK6L,\ZJ(HG(],^'5]I?C;PIX5\;VEAJ5KH_B[POH_B72
MK/5;=K+6]-L/$FG1:C:6VJV4C%K&^CM+A(=2@)+6D@> Y,>X_E/_ ,%,_P!N
M+]CWX!_'_P" 'P]_:"U+XT:/XO\ @K\3O!G[4VBCX>>!='\3Z'XGM['3O%?A
M?3?"NKW.IZYI,VGI<1WM]-?/9V\L\#6]NJAQ/E?T6_9*_:(\)?M=?!Z\\;>$
M?$WPMO\ 6;75KEM:\/\ PL\62>+H/"OAO5[B_P!1\!VGC":YM+.XT?QMJ?A2
M.TN/$NA%9(-'UE;_ $ZVGN(K8R']LXA\'>*,@\'N$/$K%<&\38;+.(L9B,95
MXLQU"OA<BJ99C:GU/(<#E=*5"5+,*57ZJ\RQ&?4L7&E2K9Q@<EK86GB(4:V+
M^AQ60XS#9%@<WG@<5&ABYRF\94A*%#V51\F&IT4TXU8S4'6E74DHNM3HRCS<
MK>'XG\$+XFU/4X[:,F,6Z%HK>-FD9Y)&$F9%) 4Q* K %6.2XQBOA[]HKX2Z
M%H\%I':Z?$QA6YM;V! %$@FW+*KKP%9Y79F1",%RW&#7ZT^$]&&GWGB8QK(_
M]GQM-!*(AQ=2NIBAE#9_U05F<9(((  '%?%W[4FE6T>C&>V86US?SL]P^QB\
M(5)OMDC-R$,DC;0 -R8#=!FOQ-NR;>RU9\\?YL7_  5 \!Z9X"_:XUS5=/M9
M(K7Q9!<7EQLW934[>\:S-RAP-Z&".&.>-.4;#D_/FOV5_P"#36X6X_X*=>-V
M*N7_ .&.?BKF1QM/_)4?@:&!7))W85E+#D D8Q7YE?\ !6ZPUWQ5\9M.NM!\
M'>-(9M)U7Q)8.+W2)()KI+>[C1=3MAO<2:?=$;K>Z8J9XSYC*AZ?I3_P:63B
M;_@IOXR#%1+%^QK\5DVK@$C_ (6C\"]_F  ?/'("A]"#GFO8S3A[/<DC0J9M
ME&88"ABIUZ6#Q>(PU18#&U,*J+Q=/ YA%2P..G@WB*$,9'"8BL\+4JPI8A4Z
MCY#IKX/%890EB,/6I0JN<:52<)*E5E34'4C1K).E5=+G@JJISE[.4E&?+)V/
M;_\ @\;UR.V_:D_9%T,Z7I\DE[\#K^]CUF2(G4[3[-\2?$*FTMY>@MK@'=-'
MPS$<'L?Y&-55SI-G<E9&41HJEN P)9=[J<L#D @$[.G3//\ 6;_P>2P[OVN_
MV.Y]^WR?@%JF S*$;=\3]?W;MV3D*/EP.2<'K7\H&KAY] LVC(182Z.6)8L&
MD8E'3 38 0P.<J2  2,USX_-<?F<,MIXZNJT,HRZGE.7Q5##4/J^7TL5B\;3
MH2>'HT98B2Q./Q=1XC%.OBI*JJ4J[HTJ%.G%;$5JZH1JR4EAJ"PU%*%.')1C
M4J55!N$8N;52M4ESU'.HU)1<N6,(Q\H\7 "UL06;8EPIW,H5% 7E22<A54DY
M^8 G(&:_J1_X(Q^%!+\'H+J&+]]J.M27[3IM,[E#Y$.6SN021H1G;@HRY R*
M_EG\6.TEII[L6"^>R*#EEDCB4D9.,@+@]>N0"2*_KV_X(P:9=:=\ O VJ-$K
M#5;:^O'=@660F\N!&5P-N#M3)QPJ@!< UYYB?O?X3\(L+FSU&UTU7MFG5V0J
M/+F<_N9HYE!!+E0"CXVDA6Z#)^@+8ZGH&V$%T1K<SQ+-&&M[DR8#PQLJ' C
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M#_7*_9O\-"R^&^BWMLBJMUX5TZ.>VEPGFQQ6T,>R)E)=7&6*NHR#U&0,]/\
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MKKQ)X:N=7\-7MIXFTNP*:2GB'3]=*76CVMC97ND7,EI#=* ?)G[%B_"O0?\
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M1:I?SK=0W,[0Q+;M'%Y7+*7.1\S_ /!/S_@C9_P0 _90_:K^$GQVT+_@I=X
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M:-M3GQ>&CB\-6P\VXJI!J,X_%3FFI4ZL>TZ511J1?244?.O['O[3/@G]L?\
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M%XO\-:I$DVGZYX=U.TU;3+J-XTE'EW=E+-%Y@21&>)F66+<!(B-Q5/QY\.O
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M\,:'X)\$>*M-74)7_L;7++P_X<TZ[\;C47N(M4UV6_NM-:*"=(XU_P""DO\
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M!1_&_C9^TZ^BG]&KZ0GAU]%'C'BNAB/%_P 0LSR;+7DF K8?$U\HI<15(X;
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M\=N&7?(<D$D[B@!W<*,9)K_0+@UFQUKP))ITNGQ6MVNG7?V:W=%WVL]KM 9
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M$J;K6R0@%XK>3#>9@"5@<;: /TF\/:DDL-M!;L+N1HHXR5"JC1EWCF9O22)
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MVFEWJ^_4****_4#]E"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M 7Y<@L"".N>]='X-TH:?';C))4MNZ_,QQP">2.!SCUJI>ZKIB3KYCE)=[!<
M8VM@D$9ZA>&'KD&NMT.YMIH86B?()W!@1D 8!4G/WN^/3)K^Y,;6E# RIT<)
M]5I5I2J5>6,K5*DE+FDY23;W=M596222L?SEX6>&_!W"/$5=Y-B<-5Q"K.L_
MWJG73=6E)\]ZDY74Y6=U912TUT[Q)]EON8C 0@#C@*.,GK_CQC'2O$_'.MSW
M%Q'IL0(CNG$#-M!*M,I0$<?,H#9)!'(QD=O5;I]T!Z%2K;L==N/E/;YB<;N,
M=AQ7B7B4O;:MIER[$0)?6QEV<E85?=(67 &T <\\]#7G<.T*;Q;J2BI2C&I*
MG%[<ZC=6WN[K2ZU=GLS].\?<_P VP7 V.AE<JL9QP\>>5+652-HJ4'9.T)7L
MTN;7F@EU/[/O^"4.N>'_ (3_  E\#:K!:FXM[37-9\^3S,SVE]=^#]"AN+E8
MFD*.ESY8B43$)'EC$-P.?>?VG?BSINLZ%\3OB5J=N]KHMOH^L1:2I"QSSW&I
M6:Q0"Z21XXHAYUJV=LDGR'<%)XK\>O\ @G7^TEX!TS3->\->)-<C.CR6=C/%
M"ZQND=U##"K>3NF 60I&!(,<J <9&:\\_P""D?[;NA:YX-F^%_P]UBVDL+F>
M]M_LD5FN^_DB1/LDLCQW;>:D!GE#R!!M#<+R:_Y0N//V/'$?C%^V=QOTM>),
M35QO#%/%<$<0PPN+PF:.I1S3A[!86A2A+$2E]5='#RR^.,24H0I5/9Q=*TY2
M/^3?,:'CYQUQ;B/HH83+\9'P]S?QIK^*F<9JLG5.KBIYY0RI5J>)S&G@OK5>
M5"GERHTXU<1)\_L^6=&A2<)>H_\ ! 358?$?_!;#2M?M&;[+?:7\?Y5#!0%D
M;X?Z]O1"I96C7/RON.X<XK["_P"#SAUB7]A2:1V6.*X^,>54 [F>Q\-H!DD<
M\X(7+$$@#FOA[_@VKM<?\%./A#>R0/%<W?@3XS7-T64*K7<_PYUYIVC _@8\
MIGY@,@GL/MW_ (/0<"U_878[?EN_C"1RNX;K+PTA9588. W4G"MM(Y-?L7[6
MVE3PWTFN&L%1;=++_!?@S+Z;=KRC@\_XSH1=U=.ZA>]WZG_2KP_PO/@[@CP[
MR"I"O3G@>!LCHRIXFG*C6INBL1AN6=*?O0TH)Q3WBTWJV?Q0>((&?P>DB%B6
MGF6/*D;!MSGGI@<+G)/&Y<8->V_LVIXKG\*:A=ZDEK_PC+FWM_#$EM'8"<R1
M2W1U)+R6U4WC2K(T;QQZB[2!"&A5(R,^-7ZF;P5J"LVY[1Q<)M+,09(,G"G[
MJN"&?()+!,G:1C]J/^"07P+^%'Q/^#7BK1OB7X:-]>MK]WK]C>?VA=Z?'9QZ
MKI*VT=XKPSVZW+V45K#<M!,QB!BR^(R]?RQ]$3QLX?\ H_\ C=P_XC<4X;BO
M&Y#@<!G. S#!\)8["T,7B(9CEU:AAXX_+<;['#9]EU/%_5Z\\LJ9CE;I8NEA
M,VIXFO5RRGEV-_0> ^(L)POQ%A\UQT,PJ82-#%8>M3R^M"$YK$494X^VH5%&
M&,HPFXU%0=:AR5X4<4IS>'5"M\A6<3H=KDECDY; PQ(X],#!Y_, U]S?L$:Q
M\2-/_:.\&6GPXTV37;RY:^.IZ/+K;Z3I\6AFW2+6M<F5IXK>ZGT?3C+=06\B
MR23R1K$@RPQL_&#]D'2OAU^S]J/QMTKQ%XFUV:S_ &A/&'PDCM'T&%=!N/"7
MA^R2YTSQLNL6K2(R:K<.MJDB,=*>1E2VNI)&"U]+?\$]/A!;^'/$WA#]H:T7
MQ5J&E:#JZ?!KXH>&[C07CU[0O'_Q8#6GP^O/#NG0>9<:CX(.D7%AJGB7Q%J#
M6$FD"61X+.[MA%,W_0#X]^,_AYQQ]&;Q4S;(IX;B;"9WDO%_ >5Y;FV6YMA<
M+C^,GE5;"X')<71C++,?@Y8W,\1@LMP.)6(P2K9IC\OP>'Q<<3BZ$9_T_GV=
MY+5X'SMX6<<=2KT,?E6&I8BAB(*KF#P[5/#5HMTJT'4JSITJ=3VD'.O4I4XS
MYY1YOZIO@IX_O-0T5_#U_<(;O39)(T"D^8MJ@<!QN)8'D-C<<,Q1!CI[#X"F
M47VOS7J3"<2I*MT4_=+ \3'><8)+'Y&53T^;!4U\)^!?$D7P^\?2:-K5NT,O
MFM:72!]NGW#J3''=6-[)B6:&5@Q65<(V0K\J37W!?^-O"_@U+O6M8U/3]/TR
MYAM(_-N[ZRM%NI[I/+M[.V>[GAB:YE<QQVL"L9;N8M#&KOP?^6.G&53DC34Z
MTI)*"A%SG4;6BC&"O*4ND8QNV[)=#^+DF[)7DW:UE=OY):M]DOD<;\=I]&L?
M!VMW&N3:0]C+X=O9M4CU\6L>CPV#VSRS27HOS]FVQIN\LSD%)A"8 )1&:_CI
M\6>"/$FCR?$O5/#'PR\.?&/]GKXS^+9I?AF]UXU@'B#1_$VIV]]I?A#Q_>7%
MOJ5Q\0M+L]"$VH"ZLO%TMGX:D!B?7L(D$E?T1:YXU;]H;0?&WP\_:&T'P5HE
MKXMU/7?"VE>"?#_B[498?%_A*QGCN/#DUW>7KV6KQZ]?S+#+K&GZ,DQL(P9+
M;=&,5^-_PY\!_#3]GC]H#XAK+X<U^UT[QC8:W^SY\0_A=X>@OM5L= \1>/;Z
M"-8_AUJUY<QZ_P"+/A'::':S0:UX]U(VE]IVH7<,'V9_-AE;_1/Z&O$&&\.<
MN\8<92QF.S_B;"X/),7AN#L#"KF7"?%.797CZ6-P6-X?XEX;XRR3,LJXRH9]
M0CALJXFHX?$9/EL*53(:N,>8\4X?^SOU?P^QD<HI9].-2KB<9"&&J4\OIQ=;
M!8ZE0J1K4ZF%Q>$Q^&K4,?#%04:&+C"="ERRPLI^UQL?8\O-^RMH7PGT/5]=
MTXQ^=KG@;PG8>(O"SSP:C86.M6^F6YURXL]76XNH]2MM3U!KJ4^26LC%,?LC
MRVWE8_F ^(VEVVDZ3\8O"U@B/::#X_1[= 0B0V<]W<S1VZ*H 4VK2>4 HSL1
M0 ",'^LK]J'QK;_#/0M2\(>$X-,DM?#6E6&@Z59ZA?2)96>CZ1';:?!!]K1Y
M+BXDM+&%$MMY9IFC4RO\YK^2+Q?J;Z]>_'RXCCD9I-9CU!NBH4_M%U,A8'+#
M>Q"#[P3YFP>*_BSQ&XQXG\2.(,9Q_P 6<12XDS/.<5/+88W'XC!K/7E^08'+
ML'E+S++J6)Q6,P]".55,%@\)C<=7QE3'U<%C83S/,L7@\;B9?GV;YCC<YQ53
M-<?C'C:^(J.@JM:=/ZTZ6%I4*=#VU&,YU(15"5*G3JU95'5=*JG6K5*=29_1
M=_P;^>,]/C^(?AO[7-"(K/PU<65QYS8\JZAD58D!8CYECQAL[5&T'[QQ_;1\
M18;BY\/:7=6GD3V[E8Y-DFQECND##)0C<%9MS$9;)^4=<_YTG_!%W6=6?XDW
M6D6,]Q;Q_P!JV]O/<QY98$OXXDC9F #!1(N6'3:0<GO_ *%WABYE_P"$$\-Z
M)?/)-JMA%'#>S$XPL;@QR9.7<,I2094 QL%7K7Y^>2:_@'48= :RC>;R[VSD
M9H9X?E9S(%+QREMH; (QD;6P6P"<GTSQQX@O-6UC35B'FW4=H_S0 .9(KE%\
MLL6Q@*X.X*6*_>^;'/CFO^#=4U*:RO\ 0;B)9K67==LZO(#'_&KQ_=&W/F*
M05. 3M) V=(UM[?5["UU"XVOI3964L/](M\G]R3T?9R6WD%0=H!P* /4+"T;
M0])CN[PK->.LTPCC5=T9(WJIR!G>&V J5)4#(&./F[PY?>/+GXEMK=_?&+PY
M+>VUJ=(BS'D2.Q1G;);!4$C(*@Y+';S7JFL_&'PG91>)&DDDDDMD:&-9$+A7
MEC<M(JCY=G\*NOS+EB1WKY@T3XB/?I<M9R6ZVD9/ES,[YDGWN(RTI8$_*P4Q
MX .%&1Q0!WW[1/@ZW\>Z'XBT"TN1/;&"290Q1A#=QB:2)(U;Y65#^[=5RF"P
M'#G/^>I_P5&_9I@_9P_:<O\ 5=,M/[.T+XMQW>N1V5M##%IUOK=B\0U-+5(E
MCC@BNC*MRT(',KN0<5_H1Z1<)9027NLS.T(MY&C+._!F^?:RDG &6+MAPN 0
M0.1_%G_P<'^/O"^K>*?"?A^W$<OBC3/$.I7.GM;21GR+!3#]I!P2060HAVJ
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M/X]O] \(7&I:=:-J5Y C(;2$KC[1,%P3(H8.' #,74G"[57&:YB\^*=UHWA
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M2-<^'_A7Q)IMM-90V>A"\MIYL-+;20R^3>P7>0'2Z5XW8DD*RY))+<_P9_\
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MS!\._ NEZ7KLA^(NO:3>WOAB?Q-HUG:WT7@]9[.2-DUK4K2Y\^V0Y1(XV:3
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M?POUVY\(7:>/CH?B:ZF@LK0R).=/EL=5\NWBE>Z3,:10QE+C>P.R9-CL,XH
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MP6/'?A3P%X.E6-O#C);>(+T;EDN@[ 7,Y9@$:/(^<H0&8#^[Q_-C_P $D_\
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M_+<TVO\ $\DM-3\1:]=:G>2F:.34KEKF\F)"W1-Q(Y#' 9BX&['!(8+QBO\
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MU_J]"K7]AAJ;K8FM[*G*I[+#TDTZM>IR\E*FFG.HXQ35S\W_  =_RE[^+/\
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M%/,:$%;"NM07M*BJ)K5HHHK]G/Z""BBB@ HHHH **** "BBB@ HHHH ****
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M%>85\"Z%^R9\:+74=2\5:%H:>%OAIK^EV4:IXA\":6D._P +ZI=;O,@\2Z3
M\TFEZDP(F*1PNZH2" ?GG^VQ\0O$WPD\(ZW<WMK;7/B_1]2'@ZYCN(BEQ%?R
MW#6D=W-; QNGEPJRD#DN<L-@&?PFU+6_$7B1KEII;F:]O6VGS21&LJL79E9B
M=B)M3A>1ENHK]K?^"V_C.+Q#\3[:>/3YM,U2]\0+!XHW6JZ<NK7>E0J-.U9[
M&,^5%?7FG"W74]J[)KZ.25.),G\<(+B*2:VGB=75K8JZC;NAW %G*KD*PSL5
M7^;=D8% ':? [XM?&O\ 9^\5:9XR^%/CG5_"WB#3YH[AK6VO[HZ#?Q*0TUMJ
MFFF5;.[MYQ&894D0GRV8@Y%?TL?LM?\ !8GX&?M 7FA?!;]J70['X=^,_$MO
M9:3;^(/$NEV6M?"[QAJD^RUN=)D18[IM-DU*:98[%KV(PA23))'M%?S"7#ET
MPJ;3'N)"-@NPYD" <%2#\R,=J$L!G@BC;SV\-SIM\EM#=2Z7JUGK5FK*'$4^
MGW$=U%"V<$+NB 9$(!0\$@T ?V4?\'/6C>'_  S_ ,$WO^"9/AWPG9:99>%M
M'UQ=+\/Z?I97^R+31[+X/Z1%IL&G"#,9LK>UCB6U,?[M853;A<5_(1^S]^SK
MJ?[2_B'2_!,7B*#PEH-BDVHZ]XDDLFOI;"SFNDM8;6ULE9!)>S2%Q;M.\5LZ
MQ-O() /]6G_!P-XCL_&7_!'C_@D!XK18XK?Q'X5\%:S#'!&Z)&-3^ GAFZVP
MH<N@02%4#-P/O9K^:/\ 9.^+=A\+/#_QETS4-?M_#5QXC\%3KX>O+Z*!T_X2
M'38;BZT\6Q=3*9Y)=A^23RV<*I4,X- 'ZU?#/Q5\#O\ @G[\'O$'@O4==N[W
MPOJ5OKNB37VM';?>+]1U*SFMM6NHK.W$L=JMQ&7C@LX@8[<H=\F>:_GQ^$GQ
MB\1?"KXBW'BSX<:GJ.EZ/]NG.E6S2)!+<Z.M\\MA87(^96)M?+C:0*2'&XG)
MS7,Z[XG\7^.[J?7/&7B#5=<N9UFN?+O[N5HDNG0M/]DLF=HK>.X8X*11KNW$
M$L216)Y,12RFA@2W\F"!O*(P\9 7='SMVJ<C+8RI&TGU /ZU_P!EW]M"?XD_
M"K08M6U__A'HM8@#74^H3*CZ;>&&6WN85N448+3*[LFY5*_,!DU/XU^+_A[P
M;HU_H7C'XB>'[S3/#UN]WIT\=^JZCX@A6.6]7_1R6D*V!(B+Q_-*^-XP2*_,
M[_@F#X';XM>'OB7X?URZFM-#\)WMG<60"^:8;J_M]\PCY PQ92(SNVYWA?F.
M?E;]O[3M/\)_M ZUX'\."2:/PWIFG0W]^LDXN[J35+-))(I%:79'# H"$1##
ML2QQTH \'_:0^.>H?M ?$2\\4ZC<LNCV._2_#^GO=K+;65E#.Z"<Q K_ *3=
MJ!)-*RED 6,8(Y^J/^"6=S\.O!7[6%EXL\6:O9PS6'AN]_X1V.YG11)J\]Q;
M+*8 6Q)-!;@LD3!F*]%X('YV6OAG3-Y:]L+8%<>7"%(CRN<R.4(,BD\GC(;!
M8BKD>F6NE7T5U:VDFGW,+-/::A9/-;20R,"%>&YB=)5=2=Q(8'=Q@A6H _9G
M_@IC^R-\0/VG?CQ%\7/ _BKPJVFR:)%I[V6HO-'=R'[4]U)*)HU9=A+F/:Z!
MEQ@_*1C\UM>_9 ^+_P *9]&\5ZSI^D:GX;L[MWU/5-"U&.Z73(XH7C NXG"%
M5=G"%HPX7# \9KE]&^/_ ,=_ L#6ND>/-9N[+?'/')J#C5W@CC;:T$-Q=^:\
M4$RY1MK;&<$DDYQ];_!KX\:[\6OA'\:O"?C.5;W4A:6>H:5)&%B2(7C2>>95
M V*$F0)&BG:4) RQP0#X'\;?%;Q-XPT+P_X1U[5H'T3P:;T:390,(8A-.WEK
M?WL*,$GNHX0MK'.5W>2"&!(S7,^ I?#DOC/0(M:DTN33W:Y22XOWA>SM+G[/
M(\-Q(LC!)FW*(H@W D9=H) K)U/2H!K-[Y<%NA%Y,A<1J?*D#,A#%P1@8;<C
M DY!5<G(V/#=GX<T'6]'U74]&MM3LM)NVO)HEC57G*Q2+#Y23$1EHK@K,%/!
M,>#DX!^DX-AE-3B_A2&?+*GD<^)<ACG2SVMFN&R1Y3+-<(LR6<8C(H5,[H94
M\$ZZS&MDT)YK2P;K5,NC+&1H)]N6K#RS++XXOZN\(\=A%BEBYXBGA7AWB*?M
MEBIX12Q<,-[/F]O+"QEB8TN=T$ZJ@C]A?@=\*-4\6>(/A%<VL-W'=>--2CNM
M$LI+,&-]/TNY$0DN720K:SS^2&AMVRVTA@"*K?\ !6"_U[X:>+O!WPGCU&Y@
MTK4]&O\ 4KZW:8JLU[8W$,3%GFP^(R[#9D#+;E!QFO6/^";?Q%\,_$CXS_"3
M1-*NO$4UWX2\.ZKJGB/2=07]S;W%SK,=K:WEG,C[&E<3%=JC,<2*H1.2?)/^
M"TUU!JO[8%GIDENMQ9:+X6U!+:*7]XA:;48 S@@$@J@"J69F,BD\@\?IGCUX
MR<6^-'%U'/>)^+JO%>%RW#X_ <,4ZV28'(Y\-\/U\YS#%8'AQTL%A*$<6\#A
MIX>;Q53%9JW[945F>*E2J5'[?%G$>/XES)8O&YA+'TZ4:U/ J6%I85X/"3Q-
M:I2P;C2IP51TH.$G-U,0_>Y?;U'&3/D#]A/XSZC\)OCEX7N+#XEZ!X3\/>,;
MVWT+QVVI7T<6DR:)''<212WDTNX07%A*2UDZ!?\ 2'1';8Y-?T*?MG^//A'X
ME_9-^(][K5WHDUHWA6XGLM/UJ:WGN;*^M;/9X7.GE#Y,6M7UU-'J)N;24^1!
M*D<A)=@?Y8XM&T4A%.CZ?(K1Q*^ZR@8LZ8;S22O&\D\!5+;3@&NG\3>(/$VL
M>&[?PW=Z]K.H:'82MOT:]O;F\L(H,J (X9&=').TJLK/Y:HJJ%"J!^'GRYY%
M)K.C7EK'#<:II^\^4)8VNHE.V/CSI>2J(0<8& 2,DU;GN]+L'>W^WVEFD<<4
MMK&;B/;,O#R/ 22"QR)78Y('\1XJ_ID&A6\,UI<:98(9/F6:6UA/[O(S"[%
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M: /O7]D7_@KIX9\3Z#:+?W21Z[IEB+35E%TKSPZO:H$N([F!HL0K'<+-;S@
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M?B=\4+ZVN]0T+P]<RV6G37NEZ%8V-E;27SV-I%>:S+K%W8V\.FSV<2 'YT?
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MRSNX8[BUN[6XC:&XMKFWF5XIX)XG>*:&5&CDC9D=65B#_%E^U[X3\/\ @/\
M:4^,W@[PEIL6B^&=!\?>(++1M'MGF:TTZR2_E>&TM5FDD9+>W#^5;Q[BL4*1
MQ)A4%?U!X0T<)XF\0Y?C,[E7P_%?!D<'F?\ ;F'A3J?ZQY9A:]'#8?"YW"<H
MRGF6#E.E3HYK3<JV)P?[K&1JU:%*M/\ H#PSH8;C_.L'B<TE6H<1<++"X_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M93]H3P'X0^&FB>$(_"O@[P%JIU6U>2XCEO=3GM=/;3+>[:-(]T*SQ,TTBEB
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M*H4_+Z_S.'"9(VJ04#1,I8+L.TX).-Q'S* =N#C&17[R?\%P/&%R-/\ @UX
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M8(VY*G:2V2"#GO7Z,?\ !-&V^V?MJ_!>*4!K:"^U9I^.&(M845RX/".SA<
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M>L:M9Z1IDGV>Y'A;0/#'_"1S,EM>7;6^H ']^E%%% !1110 4444 %?Y\_\
MP<R_M-?\$9=-^*/[<7P#\3_LA^/]5_X*D7/A'X1VUE^TM::%9'P5:^(-0\!_
M"OQ!X5O;K5Q\8K.[)TOX0RZ7X8E=OAC.RW,$=L(;J%5U-O\ 08K^+S_@Y0_;
MW^&&C?"7]NO]CJZ_X)O?M#Z]X_NO 7PXTR+]N>S^ /AV]^"=E+K5G\-/&UOJ
MC_&66U?6HK30M/NU\ 7URLRR67B&SN-#B9(H5( /Z8_^"9/_ "C=_P""?G_9
MDO[*O_JB_ E?<%?#_P#P3)_Y1N_\$_/^S)?V5?\ U1?@2ON"@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\8;/Q]X!\._$31=9\,Z#XM\'2V.D^,+VZM/#EEK&A>.=.TS6]*O-9LK:'7;
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MZQIILT(ND%>?WW[,OQST.\^'=MK7@*\T:[^+/Q1\7?!KP/:WVI:=]LU/XC>
M];TOPYXRT:_LTNI9]#M?#^IZUIJ7VL:HEGIBVCS:HDS:=;3W" '[Y?\ !#Z%
M?^%%?$V\("Q?\)YK?E&1C$C;-/M0R;NSH03C("C( !XK^?;]H"ZW_'3XT7$.
M3')\2_%*%T??'(L>H21[&R"-JG&7R<_*&YP:_I7_ ."77PU\2? W]G;XW^&/
MB%80Z-XO\%?$#XEZ+XETZ&_MM0T^#4]!=+66ZT?6[&673]>TJ<(+S2];TR>Y
MTS5K*6*]T^YGM)XI6_EL\<:C)JOCKX@:LDS%=:\=^*M0!8EU83ZW=-'+&3G.
MY "V."V&SD&@#*^529A(ABV1EM@)3$JG<2H.%4+O P,DL">3QD73B0[#&I4R
M C8OS.Y_U<NX<@*5#9.T,P .!C-F.8[V3=\I./E7;ND'S98$!3N) XP">#@$
M9N2-&D22-ND\QRI *)E027R0"QVY 4)P"HQ0 643[6+2.7>-EDW;5&UB 0@4
M+NC)^;&?E!(S2+:VWDOO #-&V'4[V?)*CJ"46+ *@'*G/)W"K(F0-\T191&B
MJNX!&!  7.X %,%GR2>Y%0L8U6.*)QN9VEE+M@@9&8D(P.&!"\_.,E\&@#D]
M*86VI%?,)7>45\DAFZL64]#R%( P N>F<=B\0DV,LC>>$*H^ J[I&.<[CRNW
M/S+S@D'  JJ;.V$B.5$"A'1?E Y.';=@D;F8D  Y*C<IR=H'1R!$V.6VI*IW
M[?-&!("PRH)&UCGJ.QYH @UNS%]"J;_+<IY=NA&65XCN91C#8=B<,2,@Y&1G
M.?HZRI:&"4NB0R2+%%( -\A(W*"I5P 1N&3TPHR>*V924*%F628R;&8[0R1Q
MC9NX^7Y3D\' R=QZ4R06^>!C:B'< SE'W %WR,[MW,9#!77D\4 1SW&VQF#+
MDK;2("Y"&.0;D*'<"=KCE@!D'#[L#%.T2S,5G:S^4B&=(PH=48R+*=D6UAGS
M)(64D;@.0O SS7F@61;F.:17>7S,1N"&;?&6\Q1T5B &\MN  1SDUT?A/3IM
M2O?#FB6D9:34]?T/2$P&$GG7NH6MJCQ(<EMXE7S-@VC:  >X!_81^VM<1^'/
M^",/AK17N+.UN[;X8HLL$C20W,C74NG0JT"N"/OR;)4(7/S<MQG^.:$LUM:6
MP5<"%,L<JPD$0"$OA2P7:#QUSP*_K&_X+"Z]9^"_V _A_P#">&26'59M"\,:
M5)<3.%%_;WM[8N\,8)\YUC,&6C./D_>' &3_ "=H&C\H#A?^/<%Y-@1U.%++
MDD(Q#A<8X7/3)  V.-HV:4,L4Q"J-H#1.$(;<&)!)DR09"1D@#!Z5_3K_P &
MJB1-_P %'/&-P&C\Y_V4/BVI2/ "QCXD_ TEF& Q9W.<%G QE< U_,D(Y0NX
M_OBJB0C*N/NX57!)PB$!F?#  #!)(K^G7_@U2@DC_P""A7BBY$;BVNOV7/C-
M$DV]#!-=6WQ&^ S7*0Q\R1O"LT8E<D1R[EV#*F@#N/\ @\"6:7]J;]E^&..W
M<2?LV^(-QNT+6P(^)6ND-*5(*>6 7C9OD$NPMD#%?R,Z6K00IN\P2/E0I(,L
M7RX+ L,E6!+*1E.<=\5_9I_P=3_#:7XH_ME?LZ:7<:W:>$O"?A#]D'QU\1/B
M7XWO[.ZU:#P;\./#/Q+U-?$&NP:!821ZCXEU.*6]L;/2/#^GR17.IZE>6L)N
M;2W\ZYC_ )H])_9@\'>+;?PXO@OXV3:O>_%_4M:\._LI:?XA^%NM>%]6^.NK
M^$39VGB>R\4*==U*V^#$,'B&\C\(^'K_ ,07.NKXAUTJS0Z;ICM>Q@'Q?>/F
MUF54<M(5_>N%+R#'RXW $ Y)XXW^HR*Q+&U:65RI!D5BQ5R2J8SM&3D%V&W@
M$ L."!S7ZM_$+_@FO<_"?2OB9XO^(7[0/@[2/AY\/;[X-0Z;XJL?!OB#Q!J7
MCZ#XC'3-/\=P>&_!^D:A<ZY!KOPC\4ZSI/@R?0[]8/\ A-?$>I6D&D7=A 99
M8N-\7?L&V/@RQUZ]U']H+PKI]QI^B>+?B+I-MJ'@?7[6V'P?^'6I>%-)^)_B
M3X@7=G?:G+\/OB9X(O?%NGV%[\()+/7]4N=3MK^P&NV\L&2 ? ,4R,"LC%93
M'EPJEBQ(  P#@ K]XKNV@<XK]7/^"0/A=M7_ &FM=UF:W26VT#P.\23!5(2X
MU"_MV"K(_(Q$F0HZ8SG;FO.;?_@GHVMWNAV?A'XX:7?ZG\4'ET_X$:+XD^'&
MO^%=;\6:_I/@67XE^(] ^,.F3:O?S_ .[L_!T,>N:*-9;Q-/XAMM2T3?:Z9_
M:"B+]A?^"3O[$.H^#KCXR?%7PWXW7XD?#S0[W7_".L>(=/\ !=_H6NV'Q-^&
M.L7?A?QGX(3PM>ZM=WDWA^U\0:9?G3?',%XUMJ6D6K:D=%M972Q8 _++_@K_
M ..8?$G[65QH%O.[6W@?PQ;Z>L?FF1HY]0GCEV%<84&)48@ CC' K\N S-LA
M/F2@!D1=VQ%=.6W '+EQRFW@!2,'-?L;^VG^R[X<\=?M?^/]6U+X]6^G#Q1\
M5]7^"^JV&G?"?Q5XF\0:1\:_#'A70O%3^"_#^F6FKPQ>*O!-KX9UNWU_Q+\4
MIK_P[I/AW2K34[F;2+DV;*_S;<_L3^'_  V_AVS\7?'^S-])XG^&O@OQI!\.
M/A7KWQ&M=#\2?'/1-4\0_ Z/P'?6VO:)%\3M'\=:1I-U<:QK-L-!B\'E[-;B
M+5(IS-$ ?GHNGS274\DJL%*J$8C+E1DE4CY/R(F2I;^(G;\Q-;8N&5$+L2!'
M@D,?,CB"X4J =N]?O8;Y> H /7[U\7?\$_O&_AGPY)\0I_'^BO\ "G4?VH_
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MZ'7N#&]PRQR@QHB!5D01F3 !<JH!.-O'F$*'(/(X%/81J )#(2YDEC,:!]^
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M5 )8S-!OC$B%MP /Z<Z*** "BBB@ HHHH *_C@_X.3/^"V/['/A/X#_MV_\
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M_P!++^ON/#3_ )+_ (0_['V7_P#IZ)]9P)_R67#7_8XP7_IV)^@MI_QZ6O\
MU[P_^BUJQ5>T_P"/2U_Z]X?_ $6M6*^(EN_5_F?*2W?J_P SY"_:G_8]\!_M
M+:1;ZF9Y?!/Q9\.(D_@GXGZ&)+76M*N[23[196FIR6<MM<ZCI"7($D:"XBOM
M+G/V[2+JUN ZS?.?P*_:_P#'GPI\;V?[-7[:\$?ACQU&8K+P/\7YR(_"/Q$L
MA(MI83ZEJWEP6,5]>OY<4>MA;6VN+R06.MVFC:LR+??J37B_QU^ 7PU_:*\#
MW?@7XE:)'J-DXEFTC5K?9!KGAO4GB,::IH>H%'>UN%&T3PL)+*_A7[/?VUS
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M'Q5J=OX U"+5+FYG=]8U/PBFE7^O6@DQ8ZI/<VRI&L80?24-U:W!86]S!.5
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ML?%L/CN.7QA+I^HWL>G2"18RWZ^?'S]EC]H/X@?L=-H6M_L,^./$GB_5=!\
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M_P#A#/K'V[Q5<Z?;W?P1\*>([W3OAO?Z+:Z5=PSVVG:KXAFUW4K03M_I6T4
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M_@)KWAW4O#GPW\,?M?\ A+P_I7P7T/7=%^)-QXAUF?7?&/B_4/#FL6L_PG\
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MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_%G_@I7^UI\(KC0M0^
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M8K,<DKU?@P&=8>FVJ4[WAA\=37U+')<U*5.HW0A_-)_P<:?L_P#Q"^!?Q/\
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M3Z/ 5,OPE72[LGBJ>)E\[ZGK?1JQ^,XA\:<7Q7F:J+,<P\)*W#=>-;F4XSX
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M+*,FFW_?1/<V]JBR7,\-O&TD4*R3RI"C33.L4,2M(RJ9)I&6.) =TCLJ("Q
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MPZ^(NM?"?QA\;]?^)7Q!N/".B?#SP+?VFG:\OAWPUX2U_P ??$?QR]Q>V=[
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MHULWAC_JT*U12QD*5"I2I8&I\O\ _!9K_DQSQ3_V/WP[_P#3V:]F_P""9/\
MR8[\!?\ L7]7_P#4HUNO;?VG_P!G#PA^U7\)[_X0^.-6U_1= U#6=$UN6_\
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M'QE_MSQ%:;XEU&7P_J_A/0K'P]>M$<3RV2W^C^(+=)@'BCN/,3<K2 -]A?\
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M44 %%%</\3O&]O\ #/X;?$+XCW>GSZM:?#_P/XL\;W6EVLL5O=:E;^%-!O\
M7IM/MIYP889[R.P:WAEF!BCDD5Y 44T =Q17XX_\$<O^"PW@+_@L+\,_C'\2
MO 7P6\8?!>S^#WCC0? ]_IOB_P 2Z)XEGUNZUW09->COK*?1;2S2V@MHD^SR
M17$;.[L'1MH('['4 %%%% !1110 45^3/_!9/_@IU/\ \$GOV4]#_:7M_@Z_
MQO?6/BWX5^%[>$(_%+^$3;IXDT;Q/J[ZT=430]?+BT7PX;<6OV%1*]XC&>,1
MD-_+K_Q&[WO_ $CLO/\ P^<O_P [*@#]T;3]L+]I&3_@Y2U7]BI_B?JK?LPV
M_P"P9:_%B+X4&PT?^R4^(,FHPP-XC&HC3QK?VDQLZF!M1:T(88@4C)_H?K^
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M-]!\*);2ZQ=-JFB7E@DD4=Y/;0/#;/,MQ.'E!\N,E06 %?TD_LW_ +<'A_\
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M[<_Q/^'W[?7QK_8Q^$?[*/[3?Q-_8[_9J^&WP$TOP=;V7B'XB_ )-*L_B/\
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M6?&.I>&_%L'AF\O+R'2/#'Q'73?!/B#4EMXXM0M;VXU?1%O;:$*WT';> _\
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M\2Z;\(IT\;7O@\69\1P:;X!^$T+:6+^6[@M//.H:)9(QGELKI%$+2D&%RP4
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M/NZE"45/S]I&:WTU/XA(?^"E/[-GPM\11?"S_@K7_P $MOC'^PQXUN;G9/\
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MF_\ MW&?59+=+WDMS];J*_)1OVSOV[M#0S^)/V$M0O($VRR'1-7\2Q,(.$=
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[PKI&I:.?&7Q$^*>LVVH:KI$VNW"Q^'] CFM(I+6#29;;4>P_9"\5_M=?\$
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M6(+S1[C7=/EU?3=9T*RU.Z_L]K.2&"SUG3\2?WBT4 ?RG?&#_@CS^VG\2?\
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M[//^"9/_ "C=_P""?G_9DO[*O_JB_ E?<%?#_P#P3)_Y1N_\$_/^S)?V5?\
MU1?@2ON"@ HHHH **** "BBB@ HHHH **** "BBO*?&WQV^"OPV@N+CQ_P#%
MGX<^#H[3?]H7Q%XRT#2YXC&&,@:VNK^.YW($;>HB++M((!H ]6HK\S_B%_P5
MZ_8&^'KRV\GQJC\97L:;DM/A[X:\1^+%N&X/EQ:E9Z='H@;!R&FU.*(]%D9L
M*?F2[_X+9Z1XRGCLOV=_V/?VA_C%-=R&"POIM.@T+2[B5\BWFC;P[9^/;MK:
M4 2*;BWL692(V,,C?* ?I+\6?VVOV4_@7X]TCX8?%CXV^$/!GCO6H[.:V\/W
M[:I=SV<&H2B&QGU^[TK3K_3O"\%XQWVTWB6\TF*: &ZC=K96E'T_:W5K?6MM
M>V-S;WEE>0175I=VLT=Q:W5M/&LL%Q;7$+/%/!-$ZR131.T<D;*Z,RD$_P";
M7\>_%7C_ ,:_&SXI^+?BC9:GI7Q$U[Q[XGU/Q?I.KQW4.I:-KT^KW1O=&N(+
MU([JW.C2K_94-M-%&UK;V<-LL<:0JB_T,_L+?\%8K[]F[]FWX9?#S]HCX"_'
M'4O"?A[3+N+PO\9/#^E1ZAHFI>$9=5O#HL MM>C\/6SVNAP$Z4MSI_B#5F>V
MM(BMO"?+MR ?U!45^=GPP_X*M?L(?%3R8=-^.NB>$]1E>&'^R_B-I^J^!;E;
MB<HJ6PNM>M+;29Y?,D6/=:ZE<1-)E4D<@X^\?#?B_P )^,K$:GX1\3^'O%.G
M,%(O_#NLZ=K=F0XW(?M.FW-S#\PY7Y^1TH Z*BBB@ HHHH **** "BBB@ HH
MHH **** "BBJ-OJFF7=W>V%IJ-C=7VFM$NHV5O=V\UW8-.GF0K>VT<C36K31
M_/$)TC,B?,@*\T 7J*** "BBB@ HHHH **** "BBB@ HHHH **** "OFC]HW
M]C7]E;]KKPZ_A;]I7X!_#+XQZ7Y;QVTWC'PQ8WFNZ4701M-H'BFW2V\3^';O
MRQL6\T+5]/NT3*+,%)!^EZ*]#*\VS3),=A\TR7,LPRC,\)-5<+F.5XS$9?CL
M-46JJ8?%X2I1Q%&:>TZ=2,ET9$Z<*L7"I"%2$M)0G%3BUV<9)I_-'\LOQ$_X
M-LKCX)^*[SXL?\$I_P!MSXZ_L4^/C-]JC\%ZGXFUOQ=\,[\FZ>Z;3;J>SNK/
M7)-(QL@CT[Q3:^.K4J6:ZBN(\P-YQ>_\%'/^"Z__  3=L+NS_P""A/[(W@O]
MI?X+:+;>7J'[6WP1^T-8>$M-2U>-_&7Q"L?!.FW21:-I,KQ:EK\NJ^ / *-9
MQ3V]C>R70W/_ %PUQGQ&N/!-G\/?'=W\2H=)N?AU:>#?$]UX^M]?M(;_ $*;
MP7;Z+>S>*(M9L;B.:WO-*?0TOEU"UGBDBGM#-%)&Z.5/]#8/Z2V>Y]##Y=XT
M<*<*>-6505.A+,N*\NC@O$#!82+BI?V9XA9(\OXBG7A%<U*.?8C/,'*<8QK8
M6I2<H/S8951PM:%? 3J8.4*D:KP\92G@*[C)2=.OA)/D]E42Y*GL'0J<K?+4
MC*S7\3FF?\'#_P ']/\ VD-<_:*@^)7PX.O^(? D7PZO-"E\#?$P:(-$@NM(
MOK:9&.GK=Q7T=_I$,YN6NS"T4\T#P*NR2/\ HZ\$_P#!;O\ X)6^*](\/3R_
MMT_L]Z?J^JZ+8W]Y9:GXKFT!+*\ELXIKVTG;7[+3Q926]PTL(M[UXKG*;-C/
MP?X6O 7[('_!/FV_X*!:?\2/$GA?XD7G[&K_ !MO->A^#%]?Z6UQ;> KNYD;
M1]!UN_14O;OP]IFJRPW>JZ5;ZA#J=UX4@?0H=5;4\ZC/_;[/_P $/O\ @CCX
MMTZ#4;?]BSX(&PUF&TU:SOM"N_$^CQSVMVD=[:SV9TOQ19I#:7,$B.L4*1P-
M#( (P,8_5_%3//H/9Y+ARGD-?QKD\+D]*E7QG#N3\*X?ZE"$*=#"9+F&'XBC
ME4L76RVG2E)5\OJ5L-*-7D6-Q#=Z/OY[Q5Q-Q,L&\1P]P?DLLNI1P="65K.(
M3Q&#HTZ=/#4:DL3F691]CAH4W'#I0I5%SS=3G]VWTIH/_!4?_@FUXE%K_8O[
M>7[(]U+>RF"UM9?V@/AC8W\TH8KL33]0\2VM]N8@[-UN X^9"R\UZUHW[9_[
M'_B)/,T']JG]G/68_M*V>_3/C7\-[U?M;[-EMNM_$D@\]O,CVQ9WG>N!R*_,
M/Q%_P;J?\$;_ !$;YC^S!I>B?;HUC(\/?$WXB:6+3:J+OL0OBV7[/(VS<S#=
MEF8X^8UY'JG_  :]_P#!'347>2'X8_$?22\/E!=,^._C8(C88"X1+_4;]1,,
M@X8-"S*I>%LON_)%DWT2<3_#X\\>LJOK;%^'G V:\NSLWA./<!S6ORW2C=Q<
MK6DHKYWVF?+?"Y7/_#B\3#MK[V%GYZ>FKW/WOTSXK_"W6S.-&^)7@#5S;%1<
MC3/&7AV_-N7W;!/]DU&7RB^UMHDVEMK8S@UU,&O:%='%MK6DW!VA\0:C9S'8
M>CXCF;Y3D8;H<]:_F5UK_@T__P""4NH-;'2M8_: T$1)*LZV_P 6]*O_ +4[
ME#'(QU'PM.83"%90L6U7WDN"57''-_P:E?L=Z?M;PC^V7^VAX.E ,+RZ/\1_
M JE[+ \NR/\ Q1<9$$)5-BAL?*H8' (%P+]&+$I/#_2 XZR]O[.;^!\Y*'3W
MJF4^(.8.2T;]VG=*<%:34^4^LYU'XLJPL_\ KWF7II^\PD-N]^GI?^J]'215
M>-U=' 971@RLIZ%64D$'L02#3J_DUN/^#:W0?#C/%X$_X*]_MK>#;W3W^S:;
M'<?$6R+:78D[9K%TT?Q-X;E5V@)3, LH<G+VA0[*S'_X(%?M5Z [/\/?^"]7
M[3>C?9&6?15\1:KXH\0+:W1"F5[Y(_COI\=[$SF5DB5(%4,@.XJQ87A9X!5U
M_LOTHLLI-NR6;>$/B'@XI:6<Y8"EG#6ZORQG9*HU?E@JA]>S5?%DLVO^G>/P
MDNW27L_T_.W];M%?R51_\$A?^"NGA=6M_!?_  <$>*[NUS]L U_P[X@MG?4%
M^Y&ZR_%;Q21:G9&&;S77!?-D^,/#)_P3[_X.#]%*C0/^"WGPDUI;E<W9\0V!
MB:U>(GRA9BX^'WB LLHD?SBK6G*1@I+PT9_Q!'PTQ-WEWTH_""JGK%9ED?BO
MD\VG9^\L3P!4C!I<S:E/1J,=932#^TL8OCR3'KOR5<#473MBDWOVZ,_K5FMK
M:X!$]O!.",$311R @'(!#JV1GG'3//6L.^\'^$M3&W4O"WAS4%RQQ?:)IEV,
MLI5CB>UD&64E6/4J2#D'%?RFQ? 3_@Y[\),+C3?^"C?[#/C8R+]C-M?S6,AB
MB496^D35_@#IL G?: YAN)I SG",N6J";5/^#J_PWEK;XG_L ^/DLG%M'"=0
M^&=F=5C(,8OBTVF>$I$V9$Q62ZL9&*_-;R$F)]*?T?,%*5\M^D9]'>KMR.KQ
MUQ#D\W)V2BGF?"&#A!MVCS3J0BE[TI1@G)7'.Z])W669U2:ZTZ$)6T6J=+$M
M_<KZ6WT/Z>=3_9X^ >M;O[7^"GPIU+?&L3?;?A_X5N-T2.9%C/FZ4V45R6"]
M Q)QFO/-2_8B_9'U9BUW^SU\+T)DDD/V#PU::2 \@VMM72OL2JN.410$C;YH
MU5N:_G1M/VB?^#J#PP8EU+]GW]AKXAII[-/<W.G_ !%^$VG+K43;I?LL-M'\
M;M$OHF@5Q ?)M+:65X"8S+O#R:,O_!0[_@Y0\+YM]:_X)D_LO^+70&\>X\/?
M$73[IFM\ FQBDTC]H*[MA=X1_+4PRS!Y5WQ2#:I].CX%<?T6EDOCGX)8SK'^
MS/I \+X.36EG[/'9KEM6%XN,N6<(2BI*,HQFI0CZ5'C7-L-;V6*XJPMMO9QS
M2G;967L9M=KVNM-]CY;_ &G_ (?1?#GX[?$_PQIV@-X9T#3?B#K^B>'M.G>2
M*%+8:O?1Z386<M].\URTMG%']D7SIIKB)0Z&3EC^_P#_ ,$=])U32_V;_%W]
MI:?=V(N/BGJAMS=0/"+@1>&_#2RO!O \Q(I&,+NN5$R219WQNJ_QL_\ !1K]
MHO\ ;6_X*+^//"<'[8=C>?LHWGP"U:=?!WP!^%&L73IX4^(-K<B6Z^(OB?6[
MW4=5>_\ &*^78VV@S6%S&/#^G6T@L)+>ZU'4'F_L_P#^".W[3OQB_:F_8P\.
M>*/CQ%IU]\2?A[XIU;X2:QXXTR[BDC^*$'A+1_#UWIOQ!O\ 2U_?^'M?UK3]
M;MH?$>E3F2*76[*]U?3Y?[-U2TA@^B\:^,,FQ?AM@>$Z/$G#N<\993C\%A.-
M\NRK,Z^883+J^ ;HX7$Y!Q$\-'*.-:>(J0DLZQ&3XNI3RO$U::PE3/,"\1FN
M&_5N)/&7&<9\,TN&\1PS4R^DHY=4AF];-)8FMBYX&FE5E7P,\#1JX6>(G^\B
MZV(J2LY*;]HTG^IU%%%?QH?E@4444 %%%% !37=(T>21UCCC5G=W8*B(H+,[
MLQ"JJJ"68D  $D@"OBC]L[]LL?L?Z5X"U,_!;XD?&0^.;_7K$6GP\MXY9="7
M0K?2YVN-4>:VGC1+XZHL=FFY'D:VN64,L3[?YU_^"F'_  57^(_Q[^&WAGX3
M>"/AA\6/V=M"UR]U"_\ &\WBRY.EZKXVTZS2VAL]!LI+"*V>308I[A[G7(3(
M%NYO[.MIEDMFFCE /Z^K:ZM;V%;BSN8+NW?.R>VFCGA?:2K;98F=&VL"IPQP
M00>14]?PZ?\ !+W_ (*%_$S]DOQAK_A&7PQX_P#C+\+/$>AWMR/A=X5F-Y?Z
M-XEMKBUFM_$V@6]U'<0Z?$;8WMKKL5LD,>H)<6EQ<%YK""OZ8_V0_P#@HJO[
M5_Q+U'X<?\,W_&/X1FP\)ZEXI7Q)X\M(DT6Y_LW4-(L'TI)H+.)([^X_M9;B
MV228-+%:W1CC81.R 'Z45^6/[?/_  47\?\ [(GQR_9+_9N^#G[)WB;]K#XR
M?M>#XT/X$\*Z!\5/!?PI@TV/X'^$]+\;^*7U#6_&]G/I+^;X;O-0O[<27-F,
MZ1+;*TUS=VT3?J=7\U?_  5^^+'B?X'_ /!6'_@B1\3_  ;\$OB9^T7XD\.1
M_P#!0./3_@[\'HO#TOQ$\5+K/[/&FZ+>3Z$GBK6?#V@&+P[9WT_B+5_M^L69
M_LC3+W[*9KOR8) #['^%W_!4OXL:=^T7\&/V<OVW_P!@KXK_ +$^J_M)ZGK7
MA7X ?$?5/BG\,?C?\+_'/Q&T+1[OQ#<_#76?$?PWN1-X(\7:GHEA>7OAFUUJ
MQ>#Q$\$MM8S!X+EX/!_A9_P6%_;0_:%L/BAXP_9M_P""1'Q-^,WPM^&GQC^*
M_P &?^$VL?VK_@+X0O/%&O\ PA\2W7AGQ%/HWA7Q?#INK1"XNK7-C#>M$DLS
MF!;IU3SVI^(KO]L3_@IK^U#^PW?^(OV&?B_^Q7^SU^QQ^T1%^U)\0O'_ .TA
MX@^&?_"<^//&7A/P/XH\,> OAI\./ '@?Q1XIO6T[4[SQA>ZEXF\9W^HVUE8
M6>FBPCM6NIHTN?@/_@D_\?/^"GOP\_9\_:CT7]DO_@G_ /"K]HSX>VO[>'[;
MU]X?\?>,/VMO"_P?U75_$UQ\6-6FN](D\$:MX2U.6WM-/U$16L=[=>(;"/48
MV9P]@BBY8 _:W2O^"P'[.&H_L)P_MOR^%?BI:>9\0I_@&W[.0\+B[^/[?M4V
MOBV7X?7'[-=GX4M[AK:_^(*^-8)M/CGAO1H[:+&_B>6Z@TN.8Q><>"_^"LWQ
M5\(?%KX._#O]N[_@GM\:_P!A;PE^T-XOTKX:_!WXS>*OBC\(_C%\-KSXJ^(W
M9?"?PT^(NI?#35IY_ACXE\7O&UEX9?6X;K2]6UMX=&M[[[2TKP_F%^S#^R7\
M4/VU_P#@F=\1]%^&7Q7L/@Q_P4]^$'_!3;QC^V+\5M-\?^#VTOPA\&_V\_"7
MBP^)KKX1:SX>L;KQ"=0^%4G@/6],T[PMXLL)M>&NZ'JNG>+GM[R9[S3D]6U'
M_@HS^TQX3\9_"']G/_@N]_P3#\.^!OA=XQ^,OPQTGP#^UW\'_$4?Q>_9BL_C
MG:^)K:X^#^L^)M)WZIK/PWN[KQ9:VEUHNN7_ (D_M'1]1>W>X\-VUH;]], /
MZCJ*^0?V_?VE=0_8[_8L_:9_:=T70[7Q/X@^#/PB\6>,?"OAV^DEAT[7/%UO
M8FS\(Z7J4\&98-+OO$MYI5OJ5Q'AX+&2XF4@ID?EM\(OV;/^"IGP-U/]EK]K
M"_\ VZ?B'^U3-X^U'0-8_;P_9W^*T'P\\,_ [P?\+/&WA6\\2^+O$?[,&A^'
MO#NE:SX8\2?"'7/[-L/"^C7GB75SXRT1+G^T&2622TF /Z!Z*_D\\&O_ ,%.
M/VGOV(/BA_P6%\+?MZ?$'X3_ !$CTSXO_M!?LX?L8Z#H/@R?]DZU^ _P=UCQ
M/+X:^%'Q;T?5-!;Q9XV\5_$_PCX,OKC6_B!%XH\/W.B:IXBTEK6TMX])O?M6
MI-\:/VP_^"C'_!1+]FOX;_"3]K[XR?L;?L\?'K_@D;\*OVPOB;X6^$I\'ZGX
MLTKQ%XS\<:,\&B?#_6O&7AS7;/PKXEEO==MM(UKQY!I5]>R^%-!OM*T^WL;C
M78]2M0#^AS]J?]JWX2?L=_#C1/B?\8[S7(- \3?%'X8?!SP[:>&]&EUS6-8\
M??%WQCIG@GP=I5M:)+;00P2:IJ:W6HW][=VMK8Z99WMP7EG2"UN/I.OX*/VQ
M=4_:+^/_ .Q[XY^!'QP_:[^./C#Q'^P)_P %TOA%^Q]X=^+.E-X4\->*/B_X
M#\8^.?A7J7@+Q_\ %2VM-$FT_4_BO\(Y?$&I3^#M>TV'3K&._@M+O4[#4S+.
MH_5[Q]\/OVT/C1_P5IUK]@+P1_P49_:=^"OP&^"O_!-O]G'XF>*_%G@^Y\!Z
ME\8?B)\1],^(?CCP)#XQU#Q#XC\(:EH6F:WXZGM;?6OBI>Z3X<M?^$I_LVST
MNWBTJQ=E4 _IYKXAU3]M/2=,_P""AGA;]@!OA_JTVM^)_P!EK6?VGH_B<NMV
M"Z)9Z=H_Q$_X5\_@^3P\;8ZE+J,\^-435$NUM$@S;M 9</7XS?"[0_V_/^"E
M'A3]J/\ ;1^&/_!0#XS_ +*FF_"[XR_'7X0?L9? ;X>:-X#U+X2:GIG[,_B;
M6_!</B[]I.R\5^%[O6_B?>?%KQEX<U&37K6WU?PW!X=\/7"VVG&6>&-H^+_8
M2_:=US]LS_@JQ^PE^TUXKT"T\+^,_BK_ ,$5_%&I^.O#^G2&72=+\=:1^T[>
M>'?&$&C2EG:31GU_2;Z?2R\DC"REA4RR[?,8 _JKHHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "JUY:I>V=W92LRQW=M/:R,F ZI<1-$[(2" P5R
M5R",XR".*LT4;BE%2C*,E>,DXR7=-6:^:9\0_LE?L)?#3]C[6_B#KO@+Q/XR
M\0W7Q%BTN'5H_%,^D2PV::3=ZC=V_P!A&EZ7IS!WDU.99GN&G9E2( J0Q;Z:
M^+'PI\"_&[X?>)?AA\2=$B\0>#O%=DMGJNGO++;R@PSQ7=G>V-Y R7%CJ.G7
ML%O>V%Y;NLMO=01R LH9&]$HKEHX+"8?#?4Z-"G#"VG'V'+S4W&JY.I&49<W
M,IN4N9.Z=VMM#Y;)>!^$N'>&'P7DV09=@^%)4<PP\\A]C]8RVKA\UJXBMF5"
MMA\5*O&M1QM3%8B6(I57.G45:<7'D?*?B3X?_P""&?[/&E^,;36-8^)GQ.\2
M>#K&\6[B\$70T&P^T*KQO]DOO$-A91W3VLHABBN#866G7;Q*1%=02".2+]<?
M$7PE^'7BGX8WOP;UKPII5Q\-+[PS%X0D\)1PFVTR#P_;6T5K96-FMNT<ED=/
MCM[=]/N+:2.XL[BW@N;>5)XDD'HM%88/*<MP$:T<)@Z-&.(5JR47+VD;-<DG
M4<FZ=FU[/X-7[NIX'!O@]X8^'^&SK!\(<%Y+DV'XBINCGE.G1J8K^T\,X5:7
MU+%3Q]7%5)Y>J=:M".7J2P4(U:BC07/*_P"'UM_P0J_9\B\8G5KCXI_%"Z\%
MC4%NH_!7E^'X;DVBRB7^S9_$J6)EDA8@QM<1:3;W?EL6699\3C]&_C!^R)\*
M_BU^SG'^S D>H^ _AG:0>%[72[?P<;."]TRU\)ZG9:KI\,$FIVNHPS&XN+)/
M[0N+N*XNKQIKBXFF:ZE>8_4U%1A\DRK"0Q%/#X&C2ABH2IXA14FZE.:M*FY2
MDY1IM?8BXQ6Z29Y_#O@5X1<)8#B7+.'> \DRO!<7X'$99Q'2HPQ-2>9Y;BX5
M(8C+JE>OB*V(H9?4C5FOJ6%JT,-%M2A2C*$''Y^^%_[.OA/X5?L\67[-^B:O
MKM]X1LO"?B?PA'J^I263:^UAXIDUB6^N&DMK2"Q%U VM7 M2EFL2".$/&^UM
MWF?[+_[$OPZ_95^&WQ!^&/@GQ)XNUS1OB)=W5YJMYXCETEM1LWN]%.AR+8MI
MFFZ?;*HMV,JF:WE;S<9)10M?9M%=*P.$4\-45""GA*,L/AI>]>C1G"-.5.&O
MPN$8Q=[NRW/J(>'_  93Q?#..AP_@8XO@W)<1P[PQ77MN?)LEQ>"I9=B<NPE
MZK7L*V"H4L/+VJJ3]G3C::=V_CS]D']B_P"'O[&NB>-]#^'_ (C\5^(K?QWK
M.FZWJDOBJ329);:YTRTN;2&.R&E:;IL:PR)=2-()EFD+! '"C!R?AO\ L,?#
M;X9?M0^/OVJ]&\3>,+WQM\0U\2+JVA:C+H[>'+3_ (2:ZL;J[-BMOI<&IKY#
MV$:VZSW\ZA7;>&*H5^V:*B&6X&%/"T88:G&E@JGM<)!<UJ%2\GSPN[WO.3U;
MW9QX3POX P&6<)9-@^%\NH97P)F7]K\(8*'UCV.0YE[3$U?KF"O7<O:^TQ>)
MG^^E5C>M/W=K?!W[7O\ P3R^!?[85QI_B'Q=_;/@[XA:3:#3[/Q[X0>RBU2Z
MTZ,2&UT[7;*_MKFRUBSLI9&ELG9;74;0L\,&H1VLLL#\/^R-_P $OO@3^RCX
MH'Q"M]3U[XF_$>WBF@T?Q/XMAL+:U\.1W$1@GFT'1+"-H;;49H'EMFU*\N[^
MYAMI9(K(V@FN#-^E-%9RR?+)8Q9A+!4'C%)35=Q][G2251QOR.HK*U1Q<TTF
MI)I,\[$>#'A7B^-J7B+B.!<@J\:4JT,5#/985^W>-I**I8^IAU46!JYC2Y(2
MI9C5PL\;2G"%2GB(SC&2^(_VH?V%/AK^U9X\^&/Q \;>)_&.A:I\+!C1;3PW
M-H\=E??\3FSUO.HC4=+OY\_:+)(LVDUL?)=N=X1U]-_:;_95^$/[6?@1/ OQ
M8T>YN(]/GFOO#?B/1YX['Q+X5U*=$CFO-%OY8+J%4NHXHHK^PO;6[TZ_CBA^
MTVKRV]M+!]'T5M++\%+ZWS8:E+Z]R?6U*/,J_LX\D'-2;5X1246DFFDUJDSV
M:_ASP-BGQ@\7PQE6+7'ZP:XRABZ#Q-+B'^SL-]3P+Q]&O*I2E+"8=*&'E2A3
ME2E&%6#56$)Q_'?X)_\ !%_]G?X6>/['QUXK\6>,/BW%H=]'J'A_PKXHM='L
M/#L-S!*);237+>PADFU];9D1EM6EL-.N'0?;;&YAS ?J+_@H/\8OAA\&_P!G
MV\N/C/\ "K6_BM\*_&^M6G@/Q5HV@SV%M<:4FHV&HZGI>JE[V>U\AX-0T:"+
M3;RVNK6XL=8?3IX9XI C#[FKD?'G@'P;\3_"6M^!/B!X<TSQ9X0\16OV+6=!
MU>#S[*]@$B31[@K)+#/!/'%<6MW;2PW5I<Q17-K-#/%'(O*LIPV%P.*PF5T<
M/@Y8B$ES2I*M3E-Q:7MXU.=U:;3<'&7,E&4N6.MG\G2\'N&N$. N+>$O"7)>
M'."\9Q#@,9&%?$Y7'.<OQ.85:$Z5&.?4,S^O5<TRV<)U,)6PN(>(IT,'B<0L
M+1C*7++^8 >"?^"5_@?]GSXD?&7P!\1O$GB;XD^(? 'B/2OAY\*OB5JVE:CX
ME\%>,-7M9]+@*Z!H.AV%O<:C837!N+;7M1O+[2[;30M_;NUZ$FK]'/\ @DMJ
M.A_!;]@:^^)7Q,U*V\%^#]1^(WB_Q9-KVM^;:V%KH1?PYX,M;Z5]CD6L^L:/
M<013)'L8NISM&X>H6?\ P1[_ &'K37XM</@?Q9=PQ7@O!X?N_'FOOH+L)3*;
M>2**:'4FM&!$)@_M,*(E&PK(SR/]S^,_@?\ #3QQ\'M5^ ^I^'+?3OAAJWAN
M'PF_AOP\?[#@L-#M3 UI:Z2]BJ'3VM'MH)+:6 !XY8UDR6))\/*LCQV$Q3QE
M3#Y5A:F'P-?#X:C@O;*E7Q-:49O$8F4H*48MP4.6#DXQ=H\JBD_P?PE\!O$+
M@_BFIQMF/#_A)PMF'#O >?<.\+9%P-'.895GW%&<UL-BZW$7$]?$X:C7P^'K
M5,%A\(\/@W6J4,)/V6&CAZ>%ITZO\TWQL_X59^W-_P %4? &G?!N3_A*/!5_
M?>"(?&?B;2[>5-.UNT\'63:OXPUJW6ZMH&:P3P_81Z+'>2J([R[M$>$M'<P2
M3?U8HB1HL<:JB(JHB(H5$10%5550 JJ  J@    # KY+_9O_ &'_ -G/]E6Z
MU75?A)X,EM/$>LV[65]XJ\0:G=>(/$7]G/)'-)IEI?7IV:=83311S7,&GP6H
MNY(H3=M.MO;K%];5ZN2997P*QV(QCH/&YCBYXFNL,I>QIQ_Y=TH.:4I*+E4F
MVU=RJ.[DTY/]:\!_"[/^ :7'G$G&L\@GQSXE\7XOBG/Z?#$<3_8N74)*2R_*
M<%5QE*CBJ\,-4KX_%5*]6"E.MCIJ4Z\X3Q-8HHHKW3]_"BBB@ HHHH ****
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MO#-#>KIEO+Y;-=7PE]4^-_\ P3>^)'QE_;[_ &=OVT9_B9X)TBR^$=G\-?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !7XL?\'$__ "A7_;^_[)1X
M>_\ 5I> :_:>OQ8_X.)_^4*_[?W_ &2CP]_ZM+P#0!^07[%W_!7#_@KK\/\
M]CO]D_P'X _X($_&CXJ>!/!7[-?P+\)>"OB?IO[0EAI&G_$?PGX<^&'A?1_#
MGCRPTF3X0:C)IEGXPT>SL_$-KI[W]\UG!J*6YN[GR_.?Z7_X?/?\%HO^E<WX
MZ_\ B2NF_P#SE*_:W_@F3_RC=_X)^?\ 9DO[*O\ ZHOP)7W!0!_+E_P^>_X+
M1?\ 2N;\=?\ Q)73?_G*4?\ #Y[_ (+1?]*YOQU_\25TW_YRE?U&T4 ?RY?\
M/GO^"T7_ $KF_'7_ ,25TW_YRE'_  ^>_P""T7_2N;\=?_$E=-_^<I7]1M%
M'\ML_P#P67_X+-W4$UM<_P#!N/\ '"XMKB*2"XMY_P!I'2IH)X)D,<L,T4GP
M2:.6*6-F22-U9'1BK J2*QO#O_!73_@KUX0L6TOPG_P;4_%?POIKSR73Z=X=
M^/OAS1+%[J4*LMRUIIOP+MK=IY B"28QF1PBAF(48_JKHH _ER_X?/?\%HO^
ME<WXZ_\ B2NF_P#SE*/^'SW_  6B_P"E<WXZ_P#B2NF__.4K^HVB@#^7+_A\
M]_P6B_Z5S?CK_P")*Z;_ /.4H_X?/?\ !:+_ *5S?CK_ .)*Z;_\Y2OZC:*
M/Y<O^'SW_!:+_I7-^.O_ (DKIO\ \Y2C_A\]_P %HO\ I7-^.O\ XDKIO_SE
M*_J-HH _ER_X?/?\%HO^E<WXZ_\ B2NF_P#SE*/^'SW_  6B_P"E<WXZ_P#B
M2NF__.4K^HVB@#^7+_A\]_P6B_Z5S?CK_P")*Z;_ /.4H_X?/?\ !:+_ *5S
M?CK_ .)*Z;_\Y2OZC:* /Y<O^'SW_!:+_I7-^.O_ (DKIO\ \Y2C_A\]_P %
MHO\ I7-^.O\ XDKIO_SE*_J-HH _ER_X?/?\%HO^E<WXZ_\ B2NF_P#SE*/^
M'SW_  6B_P"E<WXZ_P#B2NF__.4K^HVB@#^7+_A\]_P6B_Z5S?CK_P")*Z;_
M /.4KP_]HC_@XQ_X*6?LG?##4_C/^T?_ ,$&?B?\(OA7HNHZ-I6J^-_%W[3=
MK;Z'8:EK]_%INBVMQ-:_ N[E274-1EAM;8^25:>1%+*6!K^OVOYGO^#MO_E"
M[\7/^RQ_ '_U85C0!QEK_P %I_\ @LW>VMM>6O\ P;H_'2:VNX(;FWE'[2FG
M*)8)XUEAD"O\$E<!XW5@&56 .& .14__  ^>_P""T7_2N;\=?_$E=-_^<I7]
M+?PZ_P"2?>!/^Q-\,?\ IDL:[*@#^7+_ (?/?\%HO^E<WXZ_^)*Z;_\ .4H_
MX?/?\%HO^E<WXZ_^)*Z;_P#.4K^HVB@#^7+_ (?/?\%HO^E<WXZ_^)*Z;_\
M.4H_X?/?\%HO^E<WXZ_^)*Z;_P#.4K^HVB@#^7+_ (?/?\%HO^E<WXZ_^)*Z
M;_\ .4H_X?/?\%HO^E<WXZ_^)*Z;_P#.4K^HVB@#^7+_ (?/?\%HO^E<WXZ_
M^)*Z;_\ .4H_X?/?\%HO^E<WXZ_^)*Z;_P#.4K^HVB@#^7+_ (?/?\%HO^E<
MWXZ_^)*Z;_\ .4H_X?/?\%HO^E<WXZ_^)*Z;_P#.4K^HVB@#^7+_ (?/?\%H
MO^E<WXZ_^)*Z;_\ .4H_X?/?\%HO^E<WXZ_^)*Z;_P#.4K^HVB@#^7+_ (?/
M?\%HO^E<WXZ_^)*Z;_\ .4H_X?/?\%HO^E<WXZ_^)*Z;_P#.4K^HVB@#^7+_
M (?/?\%HO^E<WXZ_^)*Z;_\ .4H_X?/?\%HO^E<WXZ_^)*Z;_P#.4K^HVB@#
M^7+_ (?/?\%HO^E<WXZ_^)*Z;_\ .4H_X?/?\%HO^E<WXZ_^)*Z;_P#.4K^H
MVB@#^7+_ (?/?\%HO^E<WXZ_^)*Z;_\ .4H_X?/?\%HO^E<WXZ_^)*Z;_P#.
M4K^HVB@#^7+_ (?/?\%HO^E<WXZ_^)*Z;_\ .4KPGXH_\''7_!2;X*?$3X*?
M"7XJ_P#!![XG^!_B/^T;K^L^%O@=X0UO]INVBU;XE^(?#R:/)K>D^&HX?@5-
M#<7>F1^(-%>[2>:W6--1MFW$,2O]@=?RZ?\ !;C_ )2[_P#!N-_V='\=O_0/
M@%0 W_A\]_P6B_Z5S?CK_P")*Z;_ /.4H_X?/?\ !:+_ *5S?CK_ .)*Z;_\
MY2OZC:* /Y<O^'SW_!:+_I7-^.O_ (DKIO\ \Y2C_A\]_P %HO\ I7-^.O\
MXDKIO_SE*_J-HH _ER_X?/?\%HO^E<WXZ_\ B2NF_P#SE*/^'SW_  6B_P"E
M<WXZ_P#B2NF__.4K^HVB@#^7+_A\]_P6B_Z5S?CK_P")*Z;_ /.4H_X?/?\
M!:+_ *5S?CK_ .)*Z;_\Y2OZC:* /Y<O^'SW_!:+_I7-^.O_ (DKIO\ \Y2C
M_A\]_P %HO\ I7-^.O\ XDKIO_SE*_J-HH _ER_X?/?\%HO^E<WXZ_\ B2NF
M_P#SE*/^'SW_  6B_P"E<WXZ_P#B2NF__.4K^HVB@#^7+_A\]_P6B_Z5S?CK
M_P")*Z;_ /.4H_X?/?\ !:+_ *5S?CK_ .)*Z;_\Y2OZC:* /Y<O^'SW_!:+
M_I7-^.O_ (DKIO\ \Y2C_A\]_P %HO\ I7-^.O\ XDKIO_SE*_J-HH _ER_X
M?/?\%HO^E<WXZ_\ B2NF_P#SE*/^'SW_  6B_P"E<WXZ_P#B2NF__.4K^HVB
M@#^7+_A\]_P6B_Z5S?CK_P")*Z;_ /.4H_X?/?\ !:+_ *5S?CK_ .)*Z;_\
MY2OZC:* /Y<O^'SW_!:+_I7-^.O_ (DKIO\ \Y2C_A\]_P %HO\ I7-^.O\
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MLZIX?-I?6UM]HU"3PSH$DXOK>\BWZ5:.D:,A+?GI_P %<_VL/VY_@C9_LR_
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M9S?R3WL>K2^*KWQ'->/XDN?';>((8/$H\:2:H?$,6OP6^I0WT<MO"(P#\:?
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M74=.O8&W07=C?01W-I=0M@;HKBWECEC; RC@X&:NU_,#_P %%/\ @X8\&_\
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M/_"T/&GP]_X1+0_$=[XHL3!X5CTAXM3&IW^G:9<>;>?VFRR6YM0L1A!5V#<
M'ZVT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MMG]M[]EO]HC_ (+??\%7_'WBSP;X#&@6'AG]DOX73V<^AZK\3O&'C?7+?2/
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M]4B3Q)XI/B'4+&;Q+XSM?#_A^/4M=5?#^@6^A7=M8S,_BFU"!9?Z8J_Q'_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_MH;RQOXKBSO;2YC6:WNK2ZM_(N;:XA<,DL,\+O%+&X*O&S*P()%?QY^*_\
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M(>/O"OB'P5XJTIY985U/PYXITF[T/6[!IH&2:$7FF7US;^;"Z2Q^9OC=756
M!_FG_MO?MR>)?VH/^"3?[2US^R#^R!_P3[_8D_X)T>*/C(FJ3^'M4^*.@:W^
MU[\4?B':?$OP\DFL^"?AAHTEE%X-UN_>VTK5-;M[CPXS:?X/MM2B\.>)+W13
M,\WV9_P62AA;_@WM_P""',S0PM-_PL;]EV'S6BC:7R6^"OC-FA\PJ7$3L SQ
M;MCLJLRDJI'VQX#_ .#,#]CKPEK_ ,<=5UW]HWXF>.],\9^!OB!X7^!NA:YX
M-T.W@^"WB'Q=:367AWQWKMS;:XZ_%#6? 5K<2+HUA>6?AC3+W4(X=;O(5OH+
M-+/](/VEO^"#H_::_P""<W[$G[ 7BK]JO7M-/[&7C;PAXJL/B[!\,],OM2\?
MV'@C1O%?A[0=%U#PO-XH@MM#^S:-XCM+;[;!J^HN[Z+#++%*+N=% /RZ_P"#
MARUTS0?^"A7_  ;K^*M6BT?0_!VE_&;4[37-?U,Z;I7AW3C-X^_9FO8X]6O[
MLP6%I;+;6M]=,]X\=I!#'<RN\:>8U?%'[<?B3]I.Z_X.?O%/B']EWXP?L7^
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MB/A)]%^(VGPB_0<W%H/&%_X39(ARM\+*?_EA7YA?\'#'Q/\ ^"<GBC_@@_\
ML5Z%\%O$?P*USQVMS\!9/V=M(^&USX8F\3^']&T_P+)%\53<:=HSC6= TN.P
MFFL?&%KK<-M)+XRN-,35H)-=B$D/]J?[6W[*_P 'OVV/V=/BI^R]\>=!D\0_
M"_XM^'6T'7[:UF6TU73;BWN[;5="\2>'[]HIQIWB/PQKUAINOZ#?^3,EMJFG
M6SS07%OYMO+_ "*Z?_P9,?LS6/@CXG:/<_MB_%/6_''B.ZT!/ACXROOASH=E
M8?#72]/U^WU+7O[3\,:=XMBA\<:UX@T6%_#R7USJ6B:;I*7%QJ=MHLMX\ M
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M[E/C#_Z(\*U_&W?>*_\ @A1XM_:*_:#_ &G?C%X3_:\^!/BC1?$'Q)\0V/\
MP3NO/ ?A?QCX"U_XS7=KJZQ>'[+XO6FJZ+J/A'X=Z1\2;@W&J^ ?%GA"RU'2
M--LYM&M]=OM.MQIS?VP?\&D7P\\1>!_^".OP]U;Q#IU_IB_$?XR?&+QSH$5_
M:26IN_#DNN6GAW3]4M!*%>>QU&?P]>3VER!Y<\6V2%GB978 _ILHHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MCO\ 3+:6&?4+;1=1N;?49;.&:*2Y6W\I9$+[@ ?Y!?\ P77_ &H-<_X*%_\
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MA<PZ/::A;-9W)NXKS\U/!O\ P:-_\%*->\$:'\ ?C'_P5#\+Z7^S-IEY!/\
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MA.3Q1XMMRH;]YH"J0 Q(_P PG_@A_P"'_P!G'4O^"F7[-7BO]K+XL?#/X._
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M^&_P]_:*F\5?M":G\<?C_P",;;QCXA^%7A'1K.Y\3^(?$FBW%P)9-'\5^(;
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 45_%M_P<4_\%AOV_\ _@G]_P % OV4_@/^RO\
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MA_P;!?\ !2']KW_@I1^S3^T9\1_VP/B-I7Q'\6?#_P"->C^#?">H:5X"\$>
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M?T@T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 1Q]9?\
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M?]WJ* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_F_?\'?'_ "EC_8._
M[(I\./\ U?\ XQK>_P"#C;1--\3?\%^/^";?AG6HXIM'\2^$_P!EGPYJT4T:
M31/IFO?''7-)U 212!DD7[)>391@0W0US_\ P=\LH_X*Q_L(991M^"7PX9LD
M#:I^/_C+#-D\+\K<G ^5N>#74_\ !Q+)&O\ P<&?\$Q]SH-ND?LA[LLHQYG[
M06J*F<GC>WRIG[QX&30!D_\ !$?]I]_^"2OQL_X+T_LE^-]2;0;#X!?#;XP_
M&KX;66H7'SOXH_9]U_7_  5I$.GVDC[[W4_%F@>./ NI/%$)9Y+#PZSC>L1)
M_G:\=_ VYL_^"/OAK]KKQ5;BX\8_M!_\%)/&7A?3M6N(&2ZN/#OP]^!][JNN
MWMO,P(EL]:\:^-=2AFP[8O/#;H0ICW/^F/\ P=@_ _7/V:O^"MGC[XB>$);O
MPUX?_:U^"?A3Q]=R:5<2VR:X]U97/PW^(>FZB8R$N8=4U3P8E]?VDFX,M];R
M.@!A=OJ;_@MK^S:?V4/^#>3_ ((L_""[T[^RO$(\8W_Q"\96;*%G3QG\6?AK
MXC^)OB6.X. \LEGJ7BR33EDD&X6]I!& B(D:@']]/_!-?_E'3^P)_P!F5?LL
M?^J,\"5X1_P6[_Y1'?\ !0O_ +-=^)G_ *:#7NW_  36(;_@G/\ L!LI#*W[
M%/[*Y5@000?@7X$(((X((Y!'!'2O"/\ @MXRI_P2-_X*&,S!57]ESXFDLQ"J
M!_9!Y). ![F@#^)/_@C/XC\0^$?^#;K_ (+9^)?">O:SX7\1Z/KMM>:1X@\/
M:I>Z+K>E7:>$/!JK=:;JNG36U]8W*J[*L]M/'(%9@&PQ!F_X(M?\$_OVX?\
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M_#K7K!/&*>'3J^G76LZ4=/,/EP7Y\K;^+?QM_P"#=[Q'^T'\"/@'_P $YO\
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M_P 0^?[.K(4V?\,">(VW*5V?\B1XL+-D<<G)8]SDDYS7\[W_  8Y,O\ 9_\
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MB;JNL^ _&G@+P'X;B\'?"35?AMX)\)>&KWQY9VNH>*?%%[K=KHPU"TLWNKN
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3 HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>img267189834_12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img267189834_12.jpg
M_]C_X  02D9)1@ ! @$ W #<  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" (7!9,# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%/VBM*CT'QOIV(\ VU]KUUJ6I7(Y(N)F.,A*_P!,0$$9!R#R".A'K0 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MSX4W]]=Z;X>\17&DZ9+-;V/BB:.YTQD&I:B]F) VTG^^?X2>+OC-_P %2?\
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M786TA\R80JP_8:B@ HHHH **** "BBB@ HHHH **** "OYR_^"DUUX>\'_\
M!3C]GSQ]\2?B=^TY\!OAM_PR+\3?#!^+/[.'A#QMKNH2^*+WX@Z+=VGA#6-5
M\)> ?'HL(KJPAN=3AAGL;>9YK.%XKA!S7]&E% '\<.D?"3]IN7_@G/\ M4?#
M/X._#WXY>,?V5[/]MSP!XYT;Q%K'@S6O /[4G[4O[+&O^*--\5?M*:AXETEH
MM$\7>,-2U'4I[VV36[S3M(\1>-/#=E<0&S5"(C]%^"?A[\+?'7[8WP?\?_\
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MU6X.K:K]JM+V]O[^&VEFN]EO'&/V!HHH **** "BBB@ HHHH **** "BBB@
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MWARSTJ_NO&ECX>M+JYU[P)):ZO8W]L[^(-)-RFGND*W":G#9^4X9L$ ^/O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !7XV?\ !2K_ (+-_"G_ ()>>,_A1X5^./P#^-WBK3_C?KA\
M-?#3Q7\/)_AMJ&CZYKT4MA!>:?=6FL^.-&UG2#:2ZG9JT^H:=%#,LAD@:1$)
MK]DZ_P Y3_@\!_:4^,^D?M0?LB?"SXB_#/X<Z7X=^%FH:Q\;OA=XD\)^.M>U
M_5_&>@2:_I>G-IWC72-2\*Z';^%-12\\/D>3I5YKT+0SF5;UL*@ /]$/P3K^
MI>*?"?A_Q'J_AN^\(:AK>EVFI7/AK4[[2M3O]':[B69;.[OM$N[_ $JXGCC=
M3(]C>7$ 8E5D8@UU%?+_ .QGX_\ BQ\5/V:/A!\2/C+X8\ ^#_%WCCP/X9\5
M0^'_ (<>(M<\4>'K#P_KNA:=J>A1R:KX@T70;Y]6%C=(-4@CLGM+>Y!CMKJY
M0>8?J"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M>G17&E:5?61O[7SM*OK^'4X_-!>T4 U\(?MZ?![_ ()P:5^VC^R7^V!^U)J
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M\;_L]K-*8_V@-/\ @#J6F>"KO38G8?VU9VVHRI>2::\:F=);B2U;ROF=4((
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M$:@#\?O^&TO^"UW_ $AV^&?_ (GOX(_^=?1_PVE_P6N_Z0[?#/\ \3W\$?\
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M2.3_ $0T4 ?AO_PVE_P6N_Z0[?#/_P 3W\$?_.OH_P"&TO\ @M=_TAV^&?\
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M^)[^"/\ YU]?EY_P6 _X*2_\%L/@Q^Q?K_Q!A_8<T?\ 8ZNM)\?> 8K/XT^
M?VIO"GQE\065U=ZL\4'AM?A[9?#W3Y=<L?$C9LKU&F>*.(;GB=<U_05\(/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
M^4/[0GC'_@KSXNOO%7PB_9T^"7[-'PJAU;4]2T[1/VLO'/Q;U+QEH_AOPC=3
MM'8:_I?P3LO"]EXCO_']I8MO.D:OJ;>%X]10.;^[M=JG]7J* /S(_P""?_\
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M\+VDO_"$K>6=M\/?B=X/O;W6KK0=1UR]MTE\+W=MJ>W5K);HP6:-&#7$Z/\
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MR0S1I+#*CQ2Q2HLD<L<BE7CD1@5='4E71@5920002*_S@O\ @ZA_X)A_LT>
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MS6?FK9FWNXT2Y*-,'C#*?0:* /A;^SO^"EG_ $-7[$7_ (1?QS_^;6C^SO\
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MU?Q9X[U9]FHW<ED]G8ZE-X8TJXC'AG0Q976K0:0UA+:7PM+N2;> ?T 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445#<)++;
MSQP3&VFDAE2&X$:RF"5T98YA$^$D,3D.(W^5]NUN": /P/UO_E9$\%?]HR_$
MO_JXM.K]]J_SN?$_[3'_  6DT_\ X.-M(^"4EG\);OX_IX=NO@?H7CF'X6RI
MX%F_9+U3Q3'X^E^*,FF?VCA9X="@5VU6:54BUG&F20;G5#_H>6,=U#96<-]<
MK>7L5K;QWEVD*VZ75TD2+<7"P(2L*S2AY%B4E8PP0$@9H M4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% 'B'[37_ ";=^T'_ -D0^*__ *@>OU^9
M_P#P;V?\H?/V)?\ LF#?^G[5JN_\%V?B/^V;\&_^">WQ>^*_[&!\)ZAXB\&Z
M%K3?%;POXH\)MXJEUWX0:YHU[H?B^[\/PQW%O/9ZSX=M+XZQ'+$)BUO#.SQ-
M'"X/YD_\&F/Q!_;;^)W[#MI??&R;P?HO[*_P[@_X5E^S5H&G^$1IGC'Q&VD:
MA=7?BKQ;K?B![IY;[2+:\NO['TQ!:Q"ZN$O)UD:.!-X!_611110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M3_[6TO38M7T^34-2TO&[^TK"S2X:XO-/VD-]LMXY+;!SYF* .3M/@U\(M/\
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MVXO-%6/3%&BSW-R#>3W%B+:2:X!N'=I,O7Z@^%OV/_V4_!'Q)NOC'X-_9O\
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M$*J@EF)   &223P !R2> * %HI%97571E9& 964AE92,AE89!!'(()!'(I:
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M<>'/$/A7P[XEO4^&WAD^&;VW;Q9HUOKWG2V_B/4K#1+R&&."#4/M<^Q/T_\
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M']TM 'X*_$W]JK_@H)\;?VB_VU_"_P"S[:^/?"][^RQXR^'W@WX1^%M$\1_
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M6Q>!K?Q5J?C:V\,VN@BSTRU\4:S;)9ZMJUI%:3P/:RZA9QQVMW!;O%:36R+
M]N8@%KZG\+>%?#7@?P[HWA'P=H.D^%_"WAW3[;2="\/Z%86VF:1I&FV<:PVM
MCI]A:1Q6]M;0QJ%2.*-5&,G))) -^BBB@ HHHH **** "BBB@ HHHH ****
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MZ?9'2M%U*XAUF"ZT>606%]!;&XM+JTN;:62*4&@#]<?@%_P5U_:E^)7[3O\
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MBI-?NM+_ +%U?7H/&T>OC28HX_$HNO%UA8GPZ[OX5L#82,;B8W:_GC_P1O\
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MD\96NH#QM]C>7_A(BMU<:J#>:<98MTP^XM%L_B;<_P#!QI^W!IV@3X^-4_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **0G'X\#ZT9/H?T_P : %HI,GT/Z?XT9/H?T_QH
M 6BDR?0_I_C1D^A_3_&@!:*3)]#^G^-&3Z']/\: %HI,GT/Z?XT9/H?T_P :
M %HI,GT/Z?XT9/H?T_QH 6BDR?0_I_C1D^A_3_&@!:*3)]#^G^-&3Z']/\:
M%HI,GT/Z?XT9/H?T_P : %HI,GT/Z?XT9/H?T_QH 6BDR?0_I_C1D^A_3_&@
M *AA@YZYX)!_ @@CT//0TWRU]7_[^2?_ !5.R?0_I_C1D^A_3_&@!OEKZO\
M]_)/_BJ/+7U?_OY)_P#%4[)]#^G^-&3Z']/\: &^6OJ__?R3_P"*H\M?5_\
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M^- "T4F3Z']/\:,GT/Z?XT +129/H?T_QHR?0_I_C0 M%)GU!Z@=NYQV-+0
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M\2^*/C;X^\3^&-6MM?\ #7B+5?B;J%P^M)?:!KEI#JFE06RQ:;;W(8O8S*[
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M4?C]U:* /S@C_P""6_[,\4?[>\22_$)4_P""C5_-J/[00'BH#RKB?0'\-O\
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M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 AZ?BO\
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MIN/%_AG2;GQ?H$'BC0+:/6TU:RAO9K[0[F"^1;:.1?+D0!F8@5[M^SE^TO\
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M7SVTMXFA^'K!1)=7]TEK"\]PT<7V>UC,9N9HC-"' /6J*.M% !1110 4444
M-;^'_>']:=36_A_WA_6G4 %%%% !1110 4444 %%%% 'XH?$;_E/I^S=_P!H
M]/C3_P"K2T"OVOK\4/B-_P I]/V;O^T>GQI_]6EH%?M?0 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6VMV5>\_:6^/OB'P%^RC_P %EO@[XI\5_%K1_P!H/Q_^TAX7\<_!7PI9Z?\
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MJ^$7A/X?0_%CQ)\2_!&B_#.ZMK6\M?'>H>)-+M_"UW;7H)LY+366N?L5U]I
M;R$MY9))-CA%)1@/IJ>:9?5C4:QF%A.A0AB<51J8BA&M@Z52"J1EBZ:J-X=*
M,E>52T>TFM3\-QW G&&!JX.$N&\\Q&'S3-<5DV19AA<GS2KEW$6887$SPE2A
MP_BI8.$,VJ2K4VJ=+"*I7=TI4HS;BO33T_%?YBEK\Z_V@?\ @J#^R=\#/@MI
M/QNL?B)X<^*_AW7O%MAX1T73OAYXET*_U74;V:XBCU2X@BN+N(?9_#\$T5YJ
MX<++;V\T+E,2H3]I_##XJ_#[XR^$-/\ '?PR\6Z#XT\+:EN2#6?#NIVFK6 N
MH0HNK)[JSDEA%U9R-Y-S#OW12JRL 16>%SO)\=C*N7X/,L%BL91PU#%U,/0Q
M%.K-8;$\_L*\>23C.G/DD^:$I<J<'+E52FY=^?>%WB-PMPW@>+^).">)<BX;
MS+.<UX>P>;9ME.+P&&GG>2+#/-,LJ+$TZ=;#8O"O%THNGBJ5'VM2.(IT'5J8
M3%QH^@T5\V7_ .V-^RII7C__ (59J/[0GPDL_B&+Z/3&\)7'C;0X]734I7\N
M/3Y(3=[([YG.P6DDBW ?Y3&&XK\^/VQ_^"DOBCX;?M;?";]D+X$>)/V?M+\3
M>);*XUCXC>.?C/XEOK?PYX/DC;S-,\(2VVC3Q3P>(O$-OY7]F1W$A>62]M#'
M'LWM7%FG%.1Y3A)8O$8^A6A'&X?+?982K2Q->6/Q554J.%]G"I[E5R;E-594
MU3IPG4J.,(2:^FX%\!?%3Q!S^CP]E'">:9=B*O#&<\:/'<18',,DRNGPID.!
MEF&99]];Q6#OB,!"BJ=.A/!4L5/&8K$87"82G6KXBE"7[-45XE\<OCMX*_9N
M^"/C#XX?%?4H;'PSX$\-KK.M2:=^];4+YDB@M-*T2.0A[F[UC4YX+#3(B=TD
MEQ$7(4.P_.CX'_MZ_MO_ !?O/A[X]D_X)Y>(-&_9Y^).KZ-#I7BU?B9H$OC_
M $CPMKUPD=CXUU?P5<1VUTVBQVLL>H3K#$DYM#YT8,3I*;Q_$F59;CL-EN(J
M8JICL316)CAL%E^/S"I0PLJJH+%XM8'#8CZGA76;IJOB73IN4:G+)JG4<>3A
M'P5X^XVX8SCC3)\)D6$X6R7,*F35,[XFXOX3X/P69Y[2P,LSJ9!P_4XJSG)W
MQ#GD,O4<94RO)HXW%TJ-?"NK2IRQF$C6_82BOP9F_P""N/[0NM:Y^U#JOPS_
M &*_^%A_"?\ 9-^(/B?P?\3?%%E\5])TKQ)'IWA?4-2M[S6=/\.ZAIJM>$Z?
MI=SJLEO:R7#06ZE#YDB,H^@$_P""I?AOQ+\0OV!M ^'GP^NM:\&?MO:?K%];
MZ_K.I#3-7\"2:/+)97EC<:7'#/#J-S9ZG;W=G<,D\<,OV?S8'*2*:\NCQ_PM
M7<E#'UHM5:%*'M<OS&@L1]8S2GDT*N$=;"TXXNA',ZM/"5:^'=2E1J3C[64(
MM,^\S3Z(_CSE"I2Q7"6758SP.9X[$_V=QCP;FTLI_LG@7%>)>)P.?TLLS[%U
ML@S6KP/@L5Q!@,KSBG@L=F>#H5%E]#$U82IK]9J***^R/YL"BBB@ HHHH **
M** "BBB@"AJNIVFBZ7J6L7[3K8:387FIWK6UG>:A<K:6%O)=7+6]AI\%U?WT
MXAB<Q6=C;7%Y<R!8;:":9TC;^(;_ (*$_P#!3W_@A_\ MK_MA^&_/_;%_:%_
M8[^-7P!^'M[8^"?^"@OP*\,_%CPS=%]0UTKXF_9_\3_#^Z^&LOC368[&Y2YU
M*277/"EOH]K<FX@M=5=Y'@7^XBOA_7OV6OV!?#'[4&F?'7Q/\+O@=I'[4GQ9
M\*R_#+0]=U\Z9%XK\=>&]&;^VKO1-$\(:C?'2=7FL1']LU#4]-\/2:LD "WN
MH&!@A /P:_X(>_%;_@FM<_MF?&+PG^RA\;/VEO\ @H+^T7\0OA-9^,/C1^W[
M\<=-\6Q6::+H.LQ66B_!_3;?QCX:\)7GAI8!<PZA'9V&C/:WPMT5=3F2V2V@
M_K%KQWX6ZU\ ]3U#QGI7P8O_ (4W&J^$M:/ASX@:9\.7\*KJ7AW7[52W]C^+
M;'P\$NM,U*)"6CM-6BAFV9:-2N37L5 !1110 4444 %%%% '\W'_  =;?\H@
M?B%_V7']GG_U9>E5_1OI/_(*TS_L'V7_ *315_.1_P '6W_*('XA?]EQ_9Y_
M]67I5?T;Z3_R"M,_[!]E_P"DT5 &A1110 4444 %%%% !1110 4444 %%%%
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MF34M!&B7ODMNMH-8,[7,5NZ>7<2P/,IWID5_?E?Z+5?+?HT1\5</XD>SS/\
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M6W@_PL+LZ?8[-/B5[S6-;OUCED@TRVDE@MQ#:QR7EU/,%B5(XY94_,[]EO\
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MLU7Q'<B#[??>)+SX>VVJW6L3"*&.V^USZB[7;A+=(?-8[8@GR5_,GJW[7_\
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M6I3;G.2;249-6CO/2T4]>>VK:Y8P2M9M]=>M&I1PL%AJ%*48SE*M2C.-2O\
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M 4444 %%%% !1110 5_)M_P>-_\ *+/PU_V<3X"_]-?B"OZR:_DV_P"#QO\
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M.%A'#TY1I+D"BBBO</RT**** "BBB@ HHHH _*W_ (*@?L :U^VGX*\*ZO\
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M@_$S0?VL?C(GQ1CU/^V]0\8ZMJ6GWE^EPMOJ7A^XN&?0[O2FF+1R::-+-I%
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M@ZP['=XC^$YOK%_"-]< 2ZMX.U"P1YY9+/;'^A^L>//VFOVYO^"B'[1?Q?\
MV?OV9_AU^TM^S1^R]\/?%?["WA2;XB_&"W^%NA:E\0/%=A;7/[1/B+P\C>'/
M$T'BFVE6]M? <FJ02V\*V>F26GEK<K-L /WM^/G[7'PY^ _[)7C/]L:YM-6\
M<_#3PE\/--^),%IX0-E<ZOXCT+6'TQ-,31C<7$5C)<78U:U:,RW*0A2Q,G%?
M"^L?\%5OC%X4\!O\6?&/_!+;]MW2OA7I^A1^+O$7BS1?^%->+[S0/!2V)U;4
M?%4WA/0OB/-XDU"PT?1UEU/4;32[&ZU..UAD,5E*Z,H_%CPU\:/BIH7_  1U
M_P""G7_!-W]I;21X"_:4_87\*Q^%K31X]:3Q(NH_ 3QQXMT'7_@OXN\/Z]+:
M6H\2Z7I6B78\.)K4UK"+R71()I[6%;A8J]-_;2_99_X*#_ 7]CCX=?&X?\%$
M/VROVE/V4-+\'>#Q^US^S_X(T+X*_#7XL+^S]KFC6%GXPU[X7^.O!OPW;Q!<
M0^%-"N[AO$GALD:AJGAF._N(=6$D4[* ?U4?"7XI^"?C?\,_ WQ=^'&J_P!N
M>!?B+X:TGQ;X6U4V\UI)>:-K-I'>6<DUI<I'<6LXBE"3VTR++!,KQ. RFOR^
M^*/_  6'\!_#/4/B7XG7]E/]KCQC^S9\%O%UWX+^+'[4_ACX;:>_PQ\+ZEI.
MKIH?B/5M.T34M>L/B#XM\(^%=1D5/$/BOPYX5O=)L8%GO!+-:6EU/#]^?LF3
M? V7]FCX(R_LTW5E?_ 8_#;PJ?A7<Z=>RZE#-X.&DVYT@O>7$LMS<7GV?:+Y
MKJ0W7VWSQ<;9@X'XD_\ !0SX^_LS_MT_LF_'.\\+_M]:]^R39?LXZC\3/#7Q
MB_9_\;Q>%O \GQ.\6^ -7-S!\-/C1\/M9GL?BAJ_@'XC7&A0:;I%K\/M=T:[
M\8>&/%IN]/FO[B[MK:  _HA\+^)M#\9^&]!\7>&-1@U?PYXGT?3M>T+5+4EK
M?4=)U:TBOM/O(2P5O+N;6>*5-RA@K@, <BMVOE?]A_X@ZY\5/V1/V=?B%XC^
M'EM\*-9\5?"7P9JMW\.[&UN['3_"GG:-:B'2].LK\+?6FG1VZQ/86UX/M,%H
M\,4Y,J,3]44 %%%% !1110 UOX?]X?UIU-;^'_>']:=0!YI\7?BGX8^#O@'Q
M+XZ\3ZGHUE%HNB:UJ&EZ=J^OZ/X=?Q+JVF:1?:K:>&]*O-:N[.TDU;5OL36U
MG )&=G8OL*(Q'\WO[.'_  5!_P""L7[5'A7X;_&?P1X#_P""7/@;X4_$W6+6
M[LO!WC?]JG5?^%N^&/#3>(9-*O-(\1:/:1"VA\<VMM;7"OI 5 -0\J KM<&O
MTE_X+1?!^S^*O[%'BW49/V-_ ?[;^J?"^^F^(NC?";Q]X[U'P!8Z-<Z5X?UR
MTO/B!INHV#PC5[_PGIM]>7K^'+FXMX]9L6N[:&5;DQ9_CX_81^%FA_MG?"?X
M!ZI^S-_P18_81U#XJWNN?#_5O%_Q[M_VLK">T\,C3?$L%WXJ\6:E^SO;>*X?
M%FA7\&FV-S+;:1/)<FRO(X[B0W$9$= '^C<I)52V Q + '(!QS@]QGH?2EIJ
M#:BKQ\J@<=. !QGMZ4Z@ HHHH **** /Q0^(W_*?3]F[_M'I\:?_ %:6@5^U
M]?BA\1O^4^G[-W_:/3XT_P#JTM K]KZ "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O&?CE\<
M_"7[/O@T^//&^D>-=2\.0W:VM_<^"_"FH^+)])1T9EO=4M=-#36FGLX6W%TR
ME/M$L46,N*]FKY2_;?25_P!EGXNK$KLW]AV1(C#$[1K>EY)V\XZ9SQTH ^A/
M!/BRU\<^%M'\5V6D^(M#M=:MOM<&E>*]&N?#_B"TC,CQJNI:1=YN+*5PGFI'
M+\S0O')T<5U-4=+#+IFG*X(<6-H&#9#!A;QA@P/((.0<\YZU\!_MQ_MM^%?V
M;?#&H^'=,\2:5I'CJYL[*75_$^IP/J&A_"S0]8G^QV>OZMI]N)+SQ#XNUF;=
M8?#KX=:1!=^(?&>O/!';VBZ;!>72 '<?M$?'W6[76KSX(_!O4M*L/B!_8LNO
M?$WXH:U<6D'@?]G3X>?9Y)[SQQXOOKV2*R?Q!<VL<@\)^'))5EN9\ZMJ'V?2
M;.:5_P ]/A1#XV_:T\-:I\"OV)=;\6?!C]BVWOK^#XR?MQZA%?Q_&;]J7Q-J
M%Q(/&=M^S[J&K+#?QV>KS_:;?7OCOJ<+VEO#*=,^&UD\5I!?PQ_L\?L9_$/]
MK'0X]9_:/T'QU\)?V3=0\3+XVT_]G/Q9JP7XT_M6^(?M$=Z/BW^VCKNFSO<P
M:)K%Y%#?^%_V?].O8]*T;2(M-M/%2YMAHR?NGI>EZ;HFFV&CZ-I]CI.D:79V
M^GZ9I>FVL%CIVG6%I$D%I96-E:QQ6UI:6T")#;V\$<<,,2+'&BHH  /+_@9\
M!?A)^S;\.-"^$_P5\$Z1X%\$>'X2+?3M,A+76I7\WSW^O>(=5G:74_$7B35[
M@O>:SX@UFZO=6U2\DDN;RZED;(]>JI?W]CI=E=ZEJ=Y:Z=IUA;37E]?WUQ#:
M65E:6T;2W%U=W5P\<%O;P1(TLT\TB1Q1JSNRJ"1\%ZA\9?BK^U3JLWA+]EN[
MD\$?!F"2XL_&/[4^I:<TK:R$<P7.A_ '1+Z-(_$.H9$B7'Q!U*,>&=,(+Z1'
MJ]TL3'S\=F5# ^SIN-3$8O$-K"X'#153%8EQLI.$'*,:=&GS1=;$UYTL-04H
MNM5AS1O]?PKP7FG%7UW%TZV#R?A_*%3J9]Q3G-2IA<AR6G54W1AB<13I5Z^+
MS'%JE566Y)EF'QV=9I.E5CE^7XCV59T_3OC3^T]'X-\20?"'X.^%+GXT?M Z
MO'$;7P)HMTEOH/@BRN2JIXL^+7BG#V/@OPS:JWV@6\[2:_K006NC:;/).DR0
M?"+]F.;1?%[?&KX\>*D^,WQZNH?)L=?NM/6S\$_##3G^<^&_A'X4E,L'AVS1
MF*WWB.X,_BK7F42ZC?QQM]D3U?X*_ CX;? +PM)X7^'FB&S_ +0O9M7\3^(]
M3N)M6\7>-?$5V=^H>)/&'B2]:74]>UJ^E+22W-Y.Z0JPM[2*WM4CA3V&N2AE
MU?%5:>-SF5.K6I257"Y?2E*>7Y?-?#43E&#QV-C_ -!E>G&-)K_8\/A6ZDZW
MT.:\9Y5D67XSACPVHXS+\NQM"K@L^XPS&E2P_%W%V&J.*JX2:H5L33X6X:J\
MO_)-Y5C*]7'QF_\ 63-\\C3P.'R[X5^*?_)^_P"RI_V2OX\_^DWARONJOA;X
MIC_C/?\ 94/;_A5?QZ'4?\^WASMU[U]TTLG_ -[XC_['B_\ 5+DQ?B-_R(/!
MK_LUDO\ UY?B0>-?&3]G_P"$WQY\'^*_!7Q(\(Z;JNG>,]"E\.:UJMK;V^G^
M*/[(F(\RVT_Q-;PKK.FG:#&LEI=1/'&\BH5#FO&/V:/V _V7/V3-"UCP[\(/
MAW#!IFM:W;^(IU\77DWC:YL]6MK=;:.YTF]\1B^NM+S&D;.EG+$C2HDI'F#=
M7V91754R;*:V/I9I5RW U,QH4YT:..GA:,L52I56W4IPK.#J1C-R;DE*TFVV
M>%@O$KQ"RWA/,.!,OXVXIP7!>:XS#9AF7"V%SS,:&0X['8.-*.$Q>)RRGB(X
M2M7PT:-*-"I.DY4HPC&#2T,S6M9TOP[H^J:_K5Y%IVCZ)I]YJNJ7\P<PV6G6
M%O)=7EU*(T>0QV]O%)*X1';:IVJ3@5^9G[.7_!5/]G_]H?\ :H_:"_9LT/Q/
MX6A?X6Z_\,M"^&OB"SU'5KN;XLS>.O R>+=6-E83:/;1Z6_AN\,ND2I<7&+E
MHFG1ME?J')''+&\4J)+%(C1R1R*KQR(X*NCHP*LC*2K*P(8$@@@U\X?#+]E7
MX2_"?XT_'?X\>%-+N(_''[0NH^ ]3\;FZ^Q2Z99W/P[\*Q>#]!_X1RTCLH7T
MA'TJ%'U 1S2&[N\W#D-@#TCXDX7]L7]J[5?V6]#\%W^C_#73?'-UXTUJ]TEM
M8\7_ !8^'_P4^'/A"*QLQ=M>^*_'7CZ_AA6:^9EM=)T;0]+UC5M1G\PB""&)
MI3\#^!_^"TFG?%7X;_!;Q!\)_P!E_P ;_$7XF_%W]IWXE_LG-\,]!^)'@(:9
MH/Q'^&.@W_B+6/$$7Q)NI8O"VN?#N?2K!M1B\362Q21V,FXV$EPHMY/MK]JW
M]BS_ (:-^)OP,^,OA_XDQ^ /B%\!AXTM?#:^(?A[X;^+'@?4;#QW9Z?9:O+J
M/@GQ3/:V$?B&P73;>70/$=M<QWNENT\82:&>2,_.7P"_X),^'?@;XA^'OB27
MX\^-O'NI^ OVN?BY^UU]KUSPKX9TJXU[Q1\8O UYX,U_PO?)H1M-/LM%TYKZ
M;4]*ETW3[=X@L-@]N8D,S 'S=\5/^"JW[1GBG2_@SI?P0^ -MX*^+F@?\%&-
M$_8P_:@^%WC;X@>"=171[^/POJOBG^R?"7C:&WN=&U71O&6CK9:Q9>+;.SMK
MC2H+=M/FMXKJZ\P?H9^RM^USX.^)-M\?)?''C!O"$_P^_:>^+'P<LK;XH>*_
M FFM-<^!KRPM[JQ\(R6$6B+>^'+.6[\G3?MXOM;,?SW]W*TB8\$UW_@D]HMQ
MXC^,?CKPK\=_%7ACQW\2_P!NOPO^WAX>UJ7PAH6MZ=X)\=>&?!4'@1?!KZ+=
M7L$?B/PS?Z,+MY;BYNK"_@NKI)86_P!'4/[_ /"'_@GC\#/ =K\38_B1H'A;
MX\7?Q&^/?Q&^/T%Y\1O GAR__P"$0\0_$JZL+W6=*\.174>HBVL8;FPC>&=6
MBN)%*K+GRU- 'Y;Z9^U[XC\:_M0_\%"O!_Q;_P""C?C+]FW1_@)^T#9^!/@W
MX$\'?#WX9:_9KX#E^%'@KQ9#JUPNK_#+Q9K7B6XN?$.M:JJ1G55ENX(4M(8U
M#(YU/@Y^T!^W+^TEX\_81^%GCOXV>./V>[[XM?!3]J+Q]XUUGP?\,O NA>*?
MB-8_"[XA^&O#WPG\<7OAGX@>&/$@\$CQAX.U5/$=_P"'[2TM&@N-12,I&D:1
MI^L_[//[&W@K]G[XD_M3?$:PU8^*KC]IWXT6/QCO-*U;0-)@MO MU8> O"O@
M.#P[H-Q$)IKG38[7PK;WT4TX@DBGN98DB"(K'FOVA_V1/'/Q5_:&^#7[2_PK
M^.A^#OQ ^#_@#XB_#BUMK[X<:3\1-!U[0OB/?>';_4Y+RRU'7=#DM+RRE\.6
MJVDL$TBE)IA(OW: /G+X1?'C]J/X2?MA_&_]AWXB^+M-_:@U>R_9@TS]J#]G
M/QYK6D>'_AGXJU)+CQ7K_@/5/A7\4[KPO81>%HS%XDTO3[S1_&FG^'[-YM(U
M&XCN].GNM/;=C?L5_M=_M!KX>_X*4^+/VX?%GPZ@G_90^-NM6D5I\/-/DL_!
M/P]^'^D_ WP+\19_#=GJNH6UIK/B>32KO6-16[\0:NJW.J7;N]O%;6K06\?U
MM^SK^QK%\'_C#\4_VD_B7\5/$?QW_:)^+?AWPQX&UKX@Z]HFD>%-'\+_  W\
M&W.HZCX?^'W@#P9H;3:?X;\/1:OJ^IZWJ3O>:AJ.L:M=O=WMXVR.-?,O%/\
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M3E_['7]IC_TT? RN/#?[QF'_ &$4O_4/#'TF<_\ (FX1_P"Q3F'_ *T6<O\
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MCO?$7B_7M*\-:%:27,JP6T=UJ^M7=EI]N]Q,ZPP++<(TLK+'&&=@#TU?G_\
M\%)?AJWQ;_9RU/P+)^S=K?[2UAK6HO:W.@>$]6\#6/C/P)<W6D:I8Z7\2?"6
MF?$6.3PIX@UOPSJ%W"\&G7ZN\*3O?PQ2/:X !]C7?Q0^&FGZ[X5\+7_Q$\"V
M7B;QU9G4/!'AV[\6Z!;:[XRL%C69K[PKI$VH)J'B&S$++*;G2+>\A$;+(7VD
M$V_#?Q!\!>,M0\1:3X0\;^$/%>J^#]2.C^+=,\-^)=&UW4/"^KA=YTKQ%9:7
M>W5SHFI! 6-CJ<=K=;1N\K'-?R5Z!_P32_;IM?"/PG\#^+O@EH3?%G5OA=^R
M%X4^'7QL\+>(]"O=&_9&_P"%#>+O$^H^-HKC6-7U>X\4Z7K6M^&[_1[_ %,>
M"S>:7XH\1R:C8VQ6T@@AC^CO^";?[ '[:OP0\3^+5BT33OV6_'/AC]D[Q-\"
M]>^-FHZ?X2^)FD?&[]H'5?CSXH^(>D?'2?PK9:U!+XYLM/\ !^JVMO)J7B^Y
ML-7ENKB319'^S6FR@#[&^(W_ "GT_9N_[1Z?&G_U:6@5^U]?S/\ P3^&?[6O
MPS_X+H?!6P_:U_:A\*_M0>(]1_8'^+UQX5UWPK\#-"^!L'AG2XOB1X?CO=-N
MM*T'7M?@UJ6[N]UU'>S3PR6Z$0B,CD?TP4 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?D7_
M ,%P_A3X)^)?_!.CXYZCXML=5N;_ .'NDV7BWPC=Z3XC\0>'+C2M>.JZ?I)O
M6ET#4M.:^C^P:A=P_9+_ .TVFZ03>2)8XW7]=*_CQ_X.M/VPO&^F_!#PQ^RW
M^RU\5O&D/Q6BU)_&'[17A3X;6;:KHGAWX0W-O!:Z)'\8]8ALKVR\,6^M:YLN
M_#6D75Q:ZOJ<]@;J.V:Q4RM,IQA%RG*,(JUY3DHQ5VDKRDTE=M)7>[2-:%"O
MBJL*&&H5L37J<W)0P]*I7K3Y(RG/DI4HSJ3Y81E.7+%\L(RD[1BVOV"_:1_;
M ^'O_!/7X-?!3]E']F7P+K?Q<_:I^)OA:'2/V<OV;_#NI:KXN\521SQ?:-2\
M>>-M4UJ]U*^T+P#X?O+N>[U/Q+XGOXK'S!]DBF*(8DJ?L/?\$T/$_A?7]._:
M=_;S\3:7\<OVK=0UJY\;Z7H$<UQJWPK^"'B'5(/(,_A6UOPL7BOQ]8:<5TI_
MB#J=FATNW633O!MEI&FHD]QE?\$1?V=+;PI^RCX$_:9^+J^(_B'^V'\=?#BR
M_&GX[_$]+N]^)'B.STC4+G3]#\-Z;-JT,5UX7\":396=LFC^&-+@L+"38-2N
MHKFZF$P_:RB,HSC&<)1G"<5*$X24HSC)7C*,HMQE&2:<9)M----H*]"OA:U7
M#8FA6PV)P]2='$8?$4JE#$4*U*3A5HUZ-6,*M&K2G&4*E*I&,Z<XN,XJ2:"O
M)?C)\;_AO\!_"R^*_B/KT>EV][>1:3X>T6TB?4?$_C#Q!=$+8^&_!_AZUWZG
MXAUZ^D94@L-/@E9%)GN6@M8Y9T\G^,'[3@\-^,$^"OP6\+R?&+X_WUD+U_">
MG7!MO"GP\TR8^5!XH^+?BJ-9+3PGHWFLIM=+#2^(];(\G2]/(D6Y6+X-_LPM
MX=\20_&+XZ^*4^-?[0<\<YC\8ZCIL5GX6^'5M>DM+X9^$'A5S/!X1T:WC86D
MNK-)/XFUU$:YU74B+A[2/QJ^95\36J8+)H4Z]>G)T\5CZRE++\OG%QYJ<W"4
M)8S&Q3;6"H3C[-K_ &S$812I*K^E95P7E>29=@N*/$BOB\MRK&T*>-R'A/+Y
MTZ'%_&&&J*;HXO#+$4<11X;X:JR@HRXGS;#5GBXS;X<RCB"5''2P'FME\(_B
MO^UE>?\ "1_M-Z???#GX(+<P7/A/]F#3]44ZEXJMH9$GM]8^/VM::ZKJ!N'2
M.6'X:Z5<G1K  )KUWJ5RLMNOWIIVFZ?H^GV6E:38V>F:7IMK!9:?IVGVT-G8
MV-G;1K#;6EG:6Z1P6UM!$BQ0P0QI'%&JHBJH J[177@<MH8'VE12J8G&8CE^
MM8_$N,\5B7&[C&4HQA"E1IN4O8X6A"EAJ/-+V5*+E-R^?XIXTS/BA8/!2H8/
M)>'<I]HLBX5R6%;#9%DT:T:4*]:C0K5L1B<;F>,C1H_VEGF:8G'9UF<J5+Z[
MCZT*%"G2****] ^0/G;QK^R;^SM\1?B7IOQC\:_"S0/$'Q.T;^S1I7C*\FU9
M-6T]=))-@EJUMJ,%O#'"22\:P".XZ7*S  #Z)HHKGH83"8:=>IAL+A\/4Q53
MVV)G0HTZ4\15M;VM>5.,95JEM.>HY2MU/8S/B+B#.\-E6"SG/,XS;!Y%@UEV
M1X3,\SQN/PV39>FFL!E5#%5ZM++L&G&+6%P<*-!.*?)=(****Z#QPHHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "OX</^"K/_*4']I__ +$3]G[_
M -1C7Z_N/K^'#_@JS_RE!_:?_P"Q$_9^_P#48U^OEN,_^2?Q?_7W"?\ J52/
MY/\ IM?\HY\9_P#8PX2_]:O)ST3_ ((?_P#*4S6/^S+O$W_JU_#U?VEU_%I_
MP0__ .4IFL?]F7>)O_5K^'J_M+K;A+_DG\!Z8C_U*KGT7T1_^4=/##_L5YK_
M .M)G04445]&?T<%%%% !1110 AZ?BO\Q2TAZ?BO\Q2T %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 5_*Y_P %7/C5^Q1IW[<OQ)T'X]?\$^_V
M:?VB="_9J_8<\1_M+_M(?&WXQ>&]*U;Q[:::EU+X=^!?PL^'\=W#(;O_ (2#
MQ?<V5MJ]Y<QZ@+*RU)OLEE"]G)+<?U1U^47[>W_!&;]B[_@HU\1O!7Q2_: T
MWXE6'BKPKH5MX-UR3X9_$#4? EA\4/A_::XOB.W\ _%"QL;:XB\4^&H-907E
MO&QM-1M=SPV^H10E40 _GQ_X)4?#']FG]IOX]>'OV>OV[?\ @CU_P3E^&^K_
M !T_9>TC]LS]G#6/@E\,[&XCM_A!KGB!_#[^$OBAHOB*?5[BR\66DIAN+34K
M.:QAO;<R!].*M%=-_:!X&\"^#OAEX/\ #?P^^'OAK1O!O@CP?I%GH'A;PMX>
ML8=-T30-%T^)8+'2]+L+=4@M+*TA58H((E5(T4*H %?)/P$_X)W?LM_LW?'O
MXK?M+?#3P;JD/Q=^+FA>&O!^KZ_K_B35=?M?"O@/PA86NG>'_ 'P[TF_F?3O
M!7@^RALK>5])T>"(75TGVBZEE<U]PT ?R^?"[_@I9_P5._9\^/?[7W@+XZ_\
M$Q?V\OVL/A$?C]XMO_V:?B;\./AWX T2YTKX71M!IMAX5ETT:I9:9K/AY+FQ
MN-;\-^*#KUWJ]_I^KI#J=C:26ZQI^V_[%/[5/Q"_:Q\!>*_&?Q$_9"_:(_8Y
MU/PYXO?PQ8^!_P!H[2?#^C^*?%%@NBZ5JH\5Z'!X>U?6+>70&N-2GT=9IYHI
MCJ.F7R>7L16/\@7QW_X*&>,M"_X*&>-_%?[8W_!1'XN_LL>,/@)_P47\&_#G
MPE^Q?#>W?P]^" _8W73)S-\:=?N;;0+I_B:FN(EO>7<HU!K>VDE!N;;4A-&8
MOZ O^"#O[07QA_:&_9U^/6O>.OBEXU^/_P '_"?[5?Q7\&?LI_M#?$/17T3Q
M?\9?@)IKZ7=Z+XCU*%[>T:_MM+UZ^U[PUI.K&VA_M#2]'M950*   ?N/1110
M 4444 ?S<?\ !UM_RB!^(7_9<?V>?_5EZ57]&^D_\@K3/^P?9?\ I-%7\Y'_
M  =;?\H@?B%_V7']GG_U9>E5_1OI/_(*TS_L'V7_ *314 :%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 5_)M_P>-_\HL_#7_9Q/@+_ --?B"OZR:_DV_X/&_\ E%GX:_[.)\!?^FOQ
M!0!^RO\ P1G_ .46?["W_9N_@'_TVK7*?\%T?^40O_!03_LW+QA_Z,L*ZO\
MX(S_ /*+/]A;_LW?P#_Z;5KE/^"Z/_*(7_@H)_V;EXP_]&6% 'SK_P &SO\
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MQ0^(W_*?3]F[_M'I\:?_ %:6@5^U]?BA\1O^4^G[-W_:/3XT_P#JTM K]KZ
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M^X^OX</^"K/_ "E!_:?_ .Q$_9^_]1C7Z^6XS_Y)_%_]?<)_ZE4C^3_IM?\
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M/O W_8H>&_\ TSV==G7&?#G_ ))]X&_[%#PW_P"F>SKLZ[#YL**** "BBB@
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M)E',6J=>G*EBJ;K8:ES1A1IP=2BW0:IR=)5*:C)N3J^Q0\//$O&SX#S'B/\
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M_0=XR\+VWC7PEXA\(WNHZOI5MXBTB]TB?5-!OY=+UJP2]@:%KS2]0@_>V5]
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M_G*_X*C_  (_8(_;,_;O^ G[)OBC5/VGO!O[;_CKX-^-K6Y^*O[)&J-X?O\
MP)^SEJ46I0ZQIO[0FJN;C1;KX>^*;YKS2])TG6])U29[F^WHL-M/ S 'E?\
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M;G39[^0K=W6KZ;J)G,A42, ?H;1110 4444 ?S<?\'6W_*('XA?]EQ_9Y_\
M5EZ57]&^D_\ (*TS_L'V7_I-%7\Y'_!UM_RB!^(7_9<?V>?_ %9>E5_1OI/_
M ""M,_[!]E_Z314 :%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^*FC:%J?]M:+I?CSPUI?B:QTK6!!);#5-/MM5M[F.TU!;>62%;N!4G2-W59
M&->L44 > Z1^RI^S1H.H_#?6-'^ OPET_6/@]:7%A\+-6M_ ?AP:I\/K.ZGE
MNIK;PEJ#:>UYHD374TURBV,T0BN)7GAV2L6/7^ _@G\'OA;K/C'Q%\-?A=X
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MXA>(-$OQ''*;+5]&\):OJ6FW8BE5HI3;7MM#,(Y%:-RFUU*DBOY3_P#@F_\
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M%% !1110 5_)M_P>-_\ *+/PU_V<3X"_]-?B"OZR:_DV_P"#QO\ Y19^&O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M-;^'_>']:=36_A_WA_6G4 ? G[?G[:7@W]CWPU\%--\8R:QHB_M/?&?3/V;?
M#_Q%TW4_#^E6?PF\1>-?#'B;4-.^(^NS^)2-,ETKPXVBM<R6\AQ-<>0LG[GS
M*_&/4/V"=8^,=]X5\'?M(_\ !P_XX^/7PF@\<>#_ !/KOPDBU?\ 9D\&'QM?
M^%/$%CKVA:-)XA\)2VOB"SBFUBQLPZZ=*9Y@/+C0N4Q^KW_!3?\ X)Q^'/\
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MWGK'#3P^(HXE0V]K/#UZ5*K2H7O%8BM&G0<TZ<:CJ>X?48K@S/L%AZ^.Q-+
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M.9)2IX>KG.8YMFDX2DI5&\9F.*J*4Y)5%34(1****V/-"BBB@ HHHH ****
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MB^#3/[?U!-3U>]U>:2_&G6UO9^8DUZ\2>3$@\J.,'D5]B5_('_P7/_X*Y_\
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M ,$9_P#E%G^PM_V;OX!_]-JURG_!='_E$+_P4$_[-R\8?^C+"@#YU_X-G?\
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MDM6WLEW8TG)J,4Y2DU&,4FVY-V226K;;226K;LCT,D $D@  DDG  ')))X
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MG*.&P_UG$5,575"BY2A1C.K4=XTU%.,*:E=Q3"BBBM3A"BBB@ HHHH ****
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M:'<:2^O0:UI,^AI%/.^LPZC9R:2D%JSI<S/J*3-9K%;O%(D\AF"1-&ZR%2C
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MM-\2RQ33V^BZEX@TF:VT^^O+>!XYKBPCO/(%_;QN&GLVGB&=^" ?R;?M%?\
M!X5^R3=?&*+P-\(_#_[3NB_#+0-:O='U#XR^$='^$E_;>);5IHH%\06/P_\
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MN'N;*,1(S8%?S)1^$],_9?\ @]^RC\3?BC\(/V:?C'\"O#WQ4^!$'PX_;/\
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M_@+PQ>>'=$M]-?0/!7BG7X_%/B#PMI"0;8K#0]4\0Q1ZM<Z=;1QVWVR-'C1
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M3$B=!0!VYZ?BO\Q2TAZ?BO\ ,4M !1110 4444 %%%% !1110 4444 %%%%
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M?$'@>TOS:MXFN]>TW2=6U"U20J^H6&A&VNHX8W3]Y!;W^HP7##B986(6OO\
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MXF:)HOPO\#76H^!O%-YIL6L6N@^(H#X[0V>HSZ5/!?QPJ95-M-&Y<;U![_\
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M:Z;-X)E^ &J? K7];E\1:%J%Q+J3ZM)JX?1!I"V%SI^HW%Q*T:_O=0 4444
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M ,$[_P#LTWX-?^H?IM?J)7ZH?P.%%%% !17Y"?\ !5[_ (*B7W_!/W0?A/\
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MFIW7A'P)I<%Q>W-S)ILUA)J$EC:N+AI/LTG\M?[1_P"UKK_P(T7P+K_['/\
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M35_2RD:1J$C1(T!)"HH506)8D*H !)))XY))/)K^*#_@VU_X*M?\$YOV4/\
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MJ<@?DO\ \%Z_^"OG_!,S]I+_ ()*_M@_!3X%?MG_  5^)WQ6\<>'OAG;>$?
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M_:GB\7_#*X\7:K>V47C7PM'>>.W.O:(8].F,^GE-2L6#R"*4"YCW1+FO2_\
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M9IF@K/(TS.Q>$&4?0VG_ /!;S]@^X\*_%OQ1KFO?%OP)/\!]8^&.G?&+P?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MX47FK:>CJT=KK^B:5IEUX1UEX0NRVU"]\.R:K;1,\,-^D3%*]\_8^_X(R_\
M!-_]B+X>W/P\^#O[,GP_UB#5+M+_ ,0^+?BOHNE_%3QUXCO(@ZP2:IXD\86.
MH3QV]JLDBVFFZ7#IVEVHDD,%DCR.[?J+10!\X?\ #'7[)'_1KW[/7_AF?AW_
M /,[1_PQU^R1_P!&O?L]?^&9^'?_ ,SM?1]9&L:_H/AVWBN_$&MZ1H=K-,EM
M#<ZQJ5GIEO+<2 E+>*:]F@CDF< E(E8R, <*<&@#P?\ X8Z_9(_Z->_9Z_\
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MS\-OBIX&T7Q[H1\:+8:%J&E:'K4"36::XBWUSIVGW$:ND<J+?RPHY"),V1D
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M:3<:1>V.B:E-92O;6T$,_G6U@V[3A/%$TEJX0"O:?,C_ .>B?]]+_C1YD?\
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M7H(8WT^TL@9A_6_YD?\ ST3_ +Z7_&D9H7!5FC93U5BI![\@D@\\T ?R=_\
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M\]$_[Z7_ !H\R/\ YZ)_WTO^- #Z*9YD?_/1/^^E_P :/,C_ .>B?]]+_C0
M^BF>9'_ST3_OI?\ &CS(_P#GHG_?2_XT /HIGF1_\]$_[Z7_ !H\R/\ YZ)_
MWTO^- #Z*9YD?_/1/^^E_P :/,C_ .>B?]]+_C0 ^BF>9'_ST3_OI?\ &CS(
M_P#GHG_?2_XT /HIGF1_\]$_[Z7_ !H\R/\ YZ)_WTO^- #Z*9YD?_/1/^^E
M_P :/,C_ .>B?]]+_C0 ^BF>9'_ST3_OI?\ &CS(_P#GHG_?2_XT /HIGF1_
M\]$_[Z7_ !H\R/\ YZ)_WTO^- #Z*9YD?_/1/^^E_P :/,C_ .>B?]]+_C0
M^BF>9'_ST3_OI?\ &CS(_P#GHG_?2_XT /HIGF1_\]$_[Z7_ !H\R/\ YZ)_
MWTO^- #Z*9YD?_/1/^^E_P :/,C_ .>B?]]+_C0 ^BF>9'_ST3_OI?\ &CS(
M_P#GHG_?2_XT /HIGF1_\]$_[Z7_ !H\R/\ YZ)_WTO^- #Z*9YD?_/1/^^E
M_P :/,C_ .>B?]]+_C0 ^BF>9'_ST3_OI?\ &CS(_P#GHG_?2_XT /HIGF1_
M\]$_[Z7_ !H\R/\ YZ)_WTO^- #Z*9YD?_/1/^^E_P :/,C_ .>B?]]+_C0
MX]/Q7^8I:9O0X =221@!@3U'8'/^<T^@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K^.W_@X
M'^$7A34/VP_A!\8_$WQATJSGT+X(:[X?TKX"_M3_ +/7[0/Q-_8X\<K]ON[R
M[U'P_P#$#X&B_N?!WQ?(9;2W2XT@ZIN73[BPU>QV!&_L2I"JL,, PRK8(!&Y
M6#*<'NK ,IZA@".0* /X4?B)XH^(?Q3_ &#O^"#VK6/[,GQ;_9S@\._\%.O!
MNF_\*YU36OBMX\=?!VG6/B 1^.M,U/QY%/\ $'3?ASXCN;R>[T*P\:RR7&DV
M)>UGN9+:,/79>._V-?A[\??C5_P<S>/?B_\ #3QQXLU[X=ZCX9\0? :XN+OQ
M]8Z?H_B:V^"VK:A;^*_ &EZ;<VNG:CXKLM3TJQM[36=-M[Z_M;8FQA*07FV3
M^WMD1BI958J=REE!*M@C*Y!P<$C(YP2*!&@WD(@,ARY"CYR!@%^/F. !SG@8
MZ4 ?P1ZGJ7CSXB_!#_@WP^(/_!0/P[\<O'_[!&F?!?QQHG[2T!\/?$SQ-HJ?
M&O3KG4O#OPLOOCEH'A:VNO%E_ILVC:)I\=I=:S:7-C(T5Y(?GG!EYGP'I?AG
M5OV4_P#@Z?T#X)^&/BM;> IK[P':?#+P9X\T_P ;W/CFUT.?PN\FF6,>A^*F
MO?%EO:/:O%+H-CJ"-?VWAEM(CE2.&&-8_P"SG]JW]AWX6?M=7/P^U;QEXW^.
M_P -/%/PNU"YU'P7XO\ @+\9_&OPAURRFNS"TT&IKX8OXM)\16!DMX94LM>T
MS48(I$W0K&6;,W[(G[#'P)_8KTKXDV_PEA\;:YXF^,WC67XB?%[XE?%/QOK?
MQ'^)7Q*\92VR62ZUXL\6:_++=WTEM9HMI96T4=O:6ELHBAA510!_%#^VQX ^
M(M]\:/V.+K]J+Q!JG@;]DA?^"5OP;T3X#WGC[]G;XS_M"?"NV^-,7@+24\:Z
M!;>!_A?XE\)/X3^-S[[23PSX@\6-)-;726]M:+;R*SK_ %@_\$2/ /QH^&W_
M  3?^ /AGXX>-OBSX[\11Z=K%_X8U/XY^#9/ 7Q6T_X=W^JW%QX(T+Q?X9N?
M%GC34;&ZTO1FBBL1J^O7&JMI+6 OH8)E,8_6':N NT8&,# P-I!7 Z#:0"/0
M@$=*6@#^![]JGPM\(;?XO?\ !;[3/^"BGP[^./B_]L'QEJ'B>[_8*U73/"?Q
MM\36ES\$#X,GC\#6_P "M6\&6T_A?1M+MKZ!1XQL6ELW>QCN8=;CEWO&^Q?^
M#O'EG^Q%_P &^%Q^TMX0^,>I_P#!,3PE\+8%_;(\'^#=%\>W-E8>/#I>IP?#
MB]^-?A/P1 /&=]\/K6\EB2XMI+.?3UD>X:ZMW1SN_O(*J3D@$X*Y(!.UL;A]
M#@9'0X&>@H5550BJJJHP%4 * .  !@  =@,4 ?Q8? 'X6W/Q)^#O_!;71?V;
M=:_:F^ '_!+#X@>'?!EG^S#XE\)^ /BGKGBWP_X]TX:=<_&GQ)^SU\+?$-QI
M?Q"O?A=>W5FEE?Z3H3:5#=:'<ZM_9"PO^\'FG_!&[5O$7P\_:O\ $/P=^ _P
M@^''Q:U/6_V3OB)86'[87[-'AK]IOX&>%O#&MZ3I9D\!VW[3?P?^-6G67PWU
M3XJ>(=?@LE&L>'9;G7]+OGN%DNM5M+B\:#^YND"JN=JA<DL< #+'JQQU)[D\
MGO0!_FI_L3_!GX]>(OC3^S!:Z]\4OC;X0_X*0:-^VQXP\0_&72M$_9.^,^J_
M';3=!TOQC?R>(YOCI\?/$WQ1\-?##6?@#K'A:4164-KI-U;6-C<PVFF:?=74
M4@?_ $J8A((HA*P:41H)&4;5:0*-[!<G:"V2!DX!QDT_ R3@9( )QR0,D GJ
M0"20.V3CJ:6@ HHHH **** "BBB@ HHHH *_/;_@JY\$M._:$_X)T_M@?#*[
M^'T?Q/U/4_@7\0=4\(>$#8RZE=WOCG0?#NH:MX0N=)LX666;6=/URUM+O2TC
M+,UY%$H20,4;]":* /X&?AU:>#/V;?\ @D[_ ,$UO^"A7['_ ,+/$\WQB_X)
M\?%>./\ :G^&/ACP3XT\-^+?&\WQ:T0>#/BQH&MZ-KFDVLVK75S=2^%[R\U>
MS@N]+M4M_M,4R&U8)\D>#OV9/V]M&\8^ /V'_$NG?$N[\%_\%QKW]G[]I[XO
M?$62'7[A?@Q)HOQ"\1^.?C3X*U"2(03:5IUGX+NM,T::TOVTZ2_2^LTF:1(;
M>U7_ $G"JD%2 0<Y! (.>N0>#GO1M4L&*KN4$*V!N4-C< >H#;5R!P=HST%
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M(VXQ@C@C&* /X:/ WP=\3?$_]C;_ (*]^'?AYXT_:L_9S_X)>>,/B[X)U/\
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M20,T >M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M1ZWJNMZG=:QK6O\ B+5A!:_VEK.J:A>3375W]GB#*(XU14C44 ?E3_P<A?M
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K HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>img267189834_13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img267189834_13.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X0+T17AI9@  34T *@    @ ! $[  (
M   .   !2H=I  0    !   !6)R=  $    <   "T.H<  <   $,    /@
M   <Z@    $
M
M
M
M
M
M2WEL92!38W5R;&]C:P  !9 #  (    4   "II $  (    4   "NI*1  (
M   #,S8  )*2  (    #,S8  .H<  <   $,   !F@     <Z@    $
M
M
M
M
M
M                                            ,C R-3HP,3HQ-2 Q
M,3HS,#HU-  R,#(U.C Q.C$U(#$Q.C,P.C4T    2P!Y &P 90 @ %, 8P!U
M '( ; !O &, :P   /_A!"!H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O
M #P_>'!A8VME="!B96=I;CTG[[N_)R!I9#TG5S5-,$UP0V5H:4AZ<F53>DY4
M8WIK8SED)S\^#0H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O
M(CX\<F1F.E)$1B!X;6QN<SIR9&8](FAT=' Z+R]W=W<N=S,N;W)G+S$Y.3DO
M,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/CQR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2)U=6ED.F9A9C5B9&0U+6)A,V0M,3%D82UA9#,Q+60S,V0W-3$X,F8Q
M8B(@>&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O
M(B\^/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](G5U:60Z9F%F-6)D9#4M
M8F$S9"TQ,61A+6%D,S$M9#,S9#<U,3@R9C%B(B!X;6QN<SIX;7 ](FAT=' Z
M+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\B/CQX;7 Z0W)E871E1&%T93XR,#(U
M+3 Q+3$U5#$Q.C,P.C4T+C,U.3PO>&UP.D-R96%T941A=&4^/"]R9&8Z1&5S
M8W)I<'1I;VX^/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](G5U:60Z9F%F
M-6)D9#4M8F$S9"TQ,61A+6%D,S$M9#,S9#<U,3@R9C%B(B!X;6QN<SID8STB
M:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B/CQD8SIC<F5A=&]R
M/CQR9&8Z4V5Q('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P
M,B\R,BUR9&8M<WEN=&%X+6YS(R(^/')D9CIL:3Y+>6QE(%-C=7)L;V-K/"]R
M9&8Z;&D^/"]R9&8Z4V5Q/@T*"0D)/"]D8SIC<F5A=&]R/CPO<F1F.D1E<V-R
M:7!T:6]N/CPO<F1F.E)$1CX\+W@Z>&UP;65T83X-"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" \/WAP86-K970@96YD/2=W)S\^_]L 0P '!04&
M!00'!@4&" <'" H1"PH)"0H5#Q ,$1@5&AD8%1@7&QXG(1L=)1T7&"(N(B4H
M*2LL*QH@+S,O*C(G*BLJ_]L 0P$'" @*"0H4"PL4*AP8'"HJ*BHJ*BHJ*BHJ
M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ_\  $0@"
M P-I P$B  (1 0,1 ?_$ !\   $% 0$! 0$!           ! @,$!08'" D*
M"__$ +40  (! P,"! ,%!00$   !?0$" P $$042(3%!!A-180<B<10R@9&A
M""-"L<$54M'P)#-B<H()"A87&!D:)28G*"DJ-#4V-S@Y.D-$149'2$E*4U15
M5E=865IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>H
MJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KAXN/DY>;GZ.GJ\?+S]/7V
M]_CY^O_$ !\!  ,! 0$! 0$! 0$        ! @,$!08'" D*"__$ +41  (!
M @0$ P0'!00$  $"=P ! @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P
M%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E
M9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6V
MM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#
M 0 "$0,1 #\ ^BGN'%WY$<:L=F_+/COCT-.W7'_/*+_OZ?\ XFH?^8S_ -N_
M_LU6Z (MUQ_SRB_[^G_XFC=<?\\HO^_I_P#B:EHH BW7'_/*+_OZ?_B:-UQ_
MSRB_[^G_ .)J6B@"+=<?\\HO^_I_^)HW7'_/*+_OZ?\ XFI:* (MUQ_SRB_[
M^G_XFC=<?\\HO^_I_P#B:EHH BW7'_/*+_OZ?_B:-UQ_SRB_[^G_ .)J6B@"
M+=<?\\HO^_I_^)HW7'_/*+_OZ?\ XFI:* (MUQ_SRB_[^G_XFC=<?\\HO^_I
M_P#B:EHH BW7'_/*+_OZ?_B:-UQ_SRB_[^G_ .)J6B@"+=<?\\HO^_I_^)HW
M7'_/*+_OZ?\ XFI:* (MUQ_SRB_[^G_XFC=<?\\HO^_I_P#B:EHH BW7'_/*
M+_OZ?_B:-UQ_SRB_[^G_ .)J6B@"+=<?\\HO^_I_^)HW7'_/*+_OZ?\ XFI:
M* (MUQ_SRB_[^G_XFC=<?\\HO^_I_P#B:EHH BW7'_/*+_OZ?_B:-UQ_SRB_
M[^G_ .)J6B@"+=<?\\HO^_I_^)HW7'_/*+_OZ?\ XFI:* (MUQ_SRB_[^G_X
MFC=<?\\HO^_I_P#B:EHH BW7'_/*+_OZ?_B:-UQ_SRB_[^G_ .)J6B@"+=<?
M\\HO^_I_^)HW7'_/*+_OZ?\ XFI:* (MUQ_SRB_[^G_XFC=<?\\HO^_I_P#B
M:EHH BW7'_/*+_OZ?_B:-UQ_SRB_[^G_ .)J6B@"+=<?\\HO^_I_^)HW7'_/
M*+_OZ?\ XFI:* (MUQ_SRB_[^G_XFC=<?\\HO^_I_P#B:EHH BW7'_/*+_OZ
M?_B:-UQ_SRB_[^G_ .)J6B@"+=<?\\HO^_I_^)HW7'_/*+_OZ?\ XFI:* (M
MUQ_SRB_[^G_XFC=<?\\HO^_I_P#B:EHH BW7'_/*+_OZ?_B:-UQ_SRB_[^G_
M .)J6B@"+=<?\\HO^_I_^)HW7'_/*+_OZ?\ XFI:* (MUQ_SRB_[^G_XFC=<
M?\\HO^_I_P#B:EHH BW7'_/*+_OZ?_B:-UQ_SRB_[^G_ .)J6B@"+=<?\\HO
M^_I_^)HW7'_/*+_OZ?\ XFI:* (MUQ_SRB_[^G_XFC=<?\\HO^_I_P#B:EHH
M BW7'_/*+_OZ?_B:-UQ_SRB_[^G_ .)J6B@"+=<?\\HO^_I_^)HW7'_/*+_O
MZ?\ XFI:* (MUQ_SRB_[^G_XFC=<?\\HO^_I_P#B:EHH BW7'_/*+_OZ?_B:
M-UQ_SRB_[^G_ .)J6B@"+=<?\\HO^_I_^)HW7'_/*+_OZ?\ XFI:* (MUQ_S
MRB_[^G_XFC=<?\\HO^_I_P#B:EHH BW7'_/*+_OZ?_B:-UQ_SRB_[^G_ .)J
M6B@"+=<?\\HO^_I_^)HW7'_/*+_OZ?\ XFI:* (MUQ_SRB_[^G_XFC=<?\\H
MO^_I_P#B:EHH BW7'_/*+_OZ?_B:-UQ_SRB_[^G_ .)J6B@"+=<?\\HO^_I_
M^)HW7'_/*+_OZ?\ XFI:* (MUQ_SRB_[^G_XFC=<?\\HO^_I_P#B:EHH BW7
M'_/*+_OZ?_B:-UQ_SRB_[^G_ .)J6B@"+=<?\\HO^_I_^)HW7'_/*+_OZ?\
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MDM=*OUGGC7<T9C=#CID;@,CW% &S16#=^-_#UC+/%=:B%E@E,,D8AD9@P )
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MEHJO-%L8; PRISC!_ T 7:*YCP-KEQJ7P^L]7URZ5I665IYW"HH"R.,G  &
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M$A.N?9%_M+R_+\_<WW<8Z9QTXSC-&L>'M+U](EU:T6<PG=&^YD9#[,I!'YT
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MAI]RM[=27\/E[G7[J*#][DGGWKOJ* ,/QK;S77@G5H+6*2::2V94CC4LS'T
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MUJ_H.C1Z%I2VB2O.Y=I9IW&&ED8Y9C^)H TJ1V"(SL<*HR3[4M% %3^T[/\
MY[?^.G_"C^T[/_GM_P".G_"K=% %3^T[/_GM_P".G_"C^T[/_GM_XZ?\*MT4
M 5/[3L_^>W_CI_PH_M.S_P">W_CI_P *MT4 5/[3L_\ GM_XZ?\ "C^T[/\
MY[?^.G_"K=% %3^T[/\ Y[?^.G_"C^T[/_GM_P".G_"K=% %3^T[/_GM_P".
MG_"C^T[/_GM_XZ?\*MT4 5/[3L_^>W_CI_PH_M.S_P">W_CI_P *MT4 5/[3
ML_\ GM_XZ?\ "C^T[/\ Y[?^.G_"K=% %3^T[/\ Y[?^.G_"C^T[/_GM_P".
MG_"K=% %3^T[/_GM_P".G_"C^T[/_GM_XZ?\*MT4 5/[3L_^>W_CI_PH_M.S
M_P">W_CI_P *MT4 5/[3L_\ GM_XZ?\ "C^T[/\ Y[?^.G_"K=% %3^T[/\
MY[?^.G_"C^T[/_GM_P".G_"K=% %3^T[/_GM_P".G_"C^T[/_GM_XZ?\*MT4
M 5/[3L_^>W_CI_PH_M.S_P">W_CI_P *MT4 5/[3L_\ GM_XZ?\ "C^T[/\
MY[?^.G_"K=% %3^T[/\ Y[?^.G_"C^T[/_GM_P".G_"K=% %3^T[/_GM_P".
MG_"C^T[/_GM_XZ?\*MT4 5/[3L_^>W_CI_PH_M.S_P">W_CI_P *MT4 5/[3
ML_\ GM_XZ?\ "C^T[/\ Y[?^.G_"K=% %3^T[/\ Y[?^.G_"C^T[/_GM_P".
MG_"K=% %3^T[/_GM_P".G_"C^T[/_GM_XZ?\*MT4 5/[3L_^>W_CI_PH_M.S
M_P">W_CI_P *MT4 5/[3L_\ GM_XZ?\ "C^T[/\ Y[?^.G_"K=% %3^T[/\
MY[?^.G_"C^T[/_GM_P".G_"K=% %3^T[/_GM_P".G_"C^T[/_GM_XZ?\*MT4
M 5/[3L_^>W_CI_PH_M.S_P">W_CI_P *MT4 5/[3L_\ GM_XZ?\ "C^T[/\
MY[?^.G_"K=% %3^T[/\ Y[?^.G_"C^T[/_GM_P".G_"K=% %3^T[/_GM_P".
MG_"C^T[/_GM_XZ?\*MT4 5/[3L_^>W_CI_PH_M.S_P">W_CI_P *MT4 5/[3
ML_\ GM_XZ?\ "C^T[/\ Y[?^.G_"K=% %3^T[/\ Y[?^.G_"C^T[/_GM_P".
MG_"K=% %3^T[/_GM_P".G_"C^T[/_GM_XZ?\*MT4 5/[3L_^>W_CI_PH_M.S
M_P">W_CI_P *MT4 5/[3L_\ GM_XZ?\ "C^T[/\ Y[?^.G_"K=% %3^T[/\
MY[?^.G_"C^T[/_GM_P".G_"K=% %3^T[/_GM_P".G_"C^T[/_GM_XZ?\*MT4
M 5/[3L_^>W_CI_PH_M.S_P">W_CI_P *MT4 5/[3L_\ GM_XZ?\ "C^T[/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M'_3U=?\ ?R@"W153[!_T]77_ '\H^P?]/5U_W\H MT54^P?]/5U_W\H^P?\
M3U=?]_* +=%5/L'_ $]77_?RC[!_T]77_?R@"W153[!_T]77_?RC[!_T]77_
M '\H MT54^P?]/5U_P!_*/L'_3U=?]_* +=%5/L'_3U=?]_*/L'_ $]77_?R
M@"W153[!_P!/5U_W\H^P?]/5U_W\H MT54^P?]/5U_W\H^P?]/5U_P!_* +=
M%5/L'_3U=?\ ?RC[!_T]77_?R@"W153[!_T]77_?RC[!_P!/5U_W\H MT54^
MP?\ 3U=?]_*/L'_3U=?]_* +=%5/L'_3U=?]_*/L'_3U=?\ ?R@"W153[!_T
M]77_ '\H^P?]/5U_W\H MT54^P?]/5U_W\H^P?\ 3U=?]_* +=%5/L'_ $]7
M7_?RC[!_T]77_?R@"W153[!_T]77_?RC[!_T]77_ '\H MT54^P?]/5U_P!_
M*/L'_3U=?]_* +=%5/L'_3U=?]_*/L'_ $]77_?R@"W153[!_P!/5U_W\H^P
M?]/5U_W\H MT54^P?]/5U_W\H^P?]/5U_P!_* +=%5/L'_3U=?\ ?RC[!_T]
M77_?R@"W153[!_T]77_?RC[!_P!/5U_W\H MT54^P?\ 3U=?]_*/L'_3U=?]
M_* +=%5/L'_3U=?]_*/L'_3U=?\ ?R@"W153[!_T]77_ '\H^P?]/5U_W\H
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MYCCE$$L#R?NY0R%HU;'F?,!QZ^G>I?%L>G3^&Y[?6;E[6VG>-!,BDE'WC8>
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M )&% %NBJGVB\_Y\?_(PH^T7G_/C_P"1A0!;HJI]HO/^?'_R,*/M%Y_SX_\
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M^"/XLV**J?:+S_GQ_P#(PH^T7G_/C_Y&%<1Z);HJI]HO/^?'_P C"C[1>?\
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M'_R,* +=%5/M%Y_SX_\ D84?:+S_ )\?_(PH MT54^T7G_/C_P"1A1]HO/\
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M/VB&.N#U]\#L:[;XE^-U\(: 4M6!U.\!2W7/^K'>0_3MZG\:XOX.>"'N)_\
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M[7;_ //>+_OL4 2T5%]KM_\ GO%_WV*/M=O_ ,]XO^^Q0!+147VNW_Y[Q?\
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M:[?_ )[Q?]]BC[7;_P#/>+_OL4 2T5%]KM_^>\7_ 'V*/M=O_P ]XO\ OL4
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M(-7O#6C2:)I+17,JSW=Q/)<W,B#"M([9.!Z=!^%:]% !2$!E(8 @C!![TM%
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M_P!\"C[);_\ /"+_ +X%2T4 1?9+?_GA%_WP*/LEO_SPB_[X%2T4 1?9+?\
MYX1?]\"C[);_ //"+_O@5+10!%]DM_\ GA%_WP*/LEO_ ,\(O^^!4M% $7V2
MW_YX1?\ ? H^R6__ #PB_P"^!4M% $7V2W_YX1?]\"C[);_\\(O^^!4M% $7
MV2W_ .>$7_? H^R6_P#SPB_[X%2T4 1?9+?_ )X1?]\"C[);_P#/"+_O@5+1
M0!%]DM_^>$7_ 'P*/LEO_P \(O\ O@5+10!%]DM_^>$7_? H^R6__/"+_O@5
M+10!%]DM_P#GA%_WP*/LEO\ \\(O^^!4M% 'F_Q"^%5MXB5]2T)8[75 ,O&
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M_P">$7_? H^R6_\ SPB_[X%2T4 1?9+?_GA%_P!\"C[);_\ /"+_ +X%2T4
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MY!%6Z* *GV>\_P"?[_R"*/L]Y_S_ '_D$5;HH J?9[S_ )_O_((H^SWG_/\
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M _\ ]:G11Z1-((X[:W9CT'D#_"M*B@!% 50J@  8 ':EHHH J?\ ,9_[=_\
MV:K=5/\ F,_]N_\ [-5N@"I_S&?^W?\ ]FJW53_F,_\ ;O\ ^S5;H **** "
MBBB@ HHHH **** "BBB@ HHHH *\2^+_ (UDU/4!X4T1FD19 MUY?)EDSQ&/
M7!Z^_P!*[7XG^-U\):#Y%F__ !-+U2L !YB7O(?IV]_H:Y/X-^"&=_\ A*M7
M0LS$_8TD&23WE.?Q _$^E==&*A'VLOD<&(G*I+V$/GZ':_#KP5'X.\/!)U5M
M2N</=2#G![(#Z#]3DUU]%%<TI.3YF=D(*$5&.R"BBBI+"BBB@ HHHH ****
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M-T+?NX]IX+*?0<8Q] #I- \1:GJ?B:_L-1TY+"*&WCGAC9MTN&)'SD':#QG
MZ>M43XFU2YUJ^M(-6T"Q$-VUO!!>JQFEPJG=@2#/)(X':M"RM;A/B1JMRT$B
MV\EA B2E"$9@SY /0D9K%U@0-8:WIS>#[G^T+QY1')#;^='.S#"2F;&%['!Q
MMH W=6U?5&\11:)H*6BS_9OM4\]XK,B)NVJ JD$DD'OP!5KPUK,FMZ2TMS$L
M%W;SR6US&ARJR(V#@^G0_C6!Y%YX;\26>IW5E=WT<VE1V=S)9Q-,ZS(<[BHY
MP0<9'<>]:W@VRN[;2;JYU"%K>?4+V:\,#_>B#M\JGWP!0!T%%%(Z[T9<E<C&
M0>10 M%5/L'_ $]77_?RC[!_T]77_?R@"W6?KVMV?AW1+C4]1?;# N<=W/91
M[D\5*;$*"3=W( Y),O2O _&^NW?C[QA!H'AZ66ZLXY=D&Y\B5_XI#_L@9P?3
M)[UM1I^TEKMU.?$5O90TW>PWPYI-_P#%?Q]/J6K;EL48/<%2=J)_#$I]_P#$
M]:^AHHHX(4AA18XXU"HBC 4#@ 5@>&/!UIX8T*'3[.>8$#=,ZMCS)".6Z?E[
M 5K_ &#_ *>KK_OY3K5.>5ELMA8>C[*-Y?$]RW153[!_T]77_?RC[!_T]77_
M '\K Z2W153[!_T]77_?RC[!_P!/5U_W\H MT54^P?\ 3U=?]_*/L'_3U=?]
M_* +=%5/L'_3U=?]_*/L'_3U=?\ ?R@"W153[!_T]77_ '\I'LUC4L]Y<*HZ
MDRX% %RBL&YU72;7/F:Q*Q':.7?_ "%9%SXMLTR+7[?*?5Y0@_K0!VM8VH^(
M8=/UNUL& (E_UKY^YGA?UZ^U<?+XIU.7=]G=XU R<,6(_&L>>>6ZG::XD:21
MSEF8Y)H ];GN[:V&;FXBB'^VX7^=9MQXKT>WSF[$A](U+?KTKCM#\-/KD#SK
M>)&%?:PVEF'OVKH(? =B@_?W,\A_V<*/Y&@!MQX]M%S]FM)I/]\A/\:S9?'&
MI3MMM+:&//3@NW^?PKH8_!^DQ=(G)_VFW?S%78M)A@7;!+-&/1& _D* ..\_
MQ9J7W1=*#TVJ(A^?%*G@[6;Q@UY-&I[F64N?TS7:?8/^GJZ_[^4?8/\ IZNO
M^_E '-0> 8A@W5\[>HC0#]3FM.W\':/!C= \Q]9)#_3 K2^P?]/5U_W\H^P?
M]/5U_P!_* %M],L;7'V>S@C/JL8S^=6JJ?8/^GJZ_P"_E'V#_IZNO^_E %NB
MJGV#_IZNO^_E'V#_ *>KK_OY0!;HJI]@_P"GJZ_[^4?8/^GJZ_[^4 6Z*J?8
M/^GJZ_[^4?8/^GJZ_P"_E %NBJGV#_IZNO\ OY1]@_Z>KK_OY0!;HJI]@_Z>
MKK_OY1]@_P"GJZ_[^4 6Z*J?8/\ IZNO^_E'V#_IZNO^_E %NBJGV#_IZNO^
M_E'V#_IZNO\ OY0!-<6MO=ILN8(YE]'4&L2\\%Z7<Y,(DMF_Z9MD?D:U?L'_
M $]77_?RC[!_T]77_?R@#CKCP3J5J_F:?<I*1TP3&W^'ZU"-9\2:*<7BRL@_
MY^$W _\  O\ Z]=O]@_Z>KK_ +^4'3P1@W5R0?\ II_]:@#G+/Q["V!?6CQG
M^]$=P_(XK=L]>TR^P+>\CW'^!SM;\C56X\):7<DF1'#'^)2 ?Y5DWG@%3DV%
MX1Z+,N?U'^% '8T5YV^F^)='7$!N#&O_ #P<NO\ WS_]:BV\5WD+[+\328.#
MLE*,/SS0!Z)17+V?B+2;K DO[RW8]I6X_,9%;4-O%<1[[>_FE0_Q),"/TH O
M454^P?\ 3U=?]_*/L'_3U=?]_* /F;XD&,_$76!! ENBS[=B* ,@#)X]3D_C
M7,5[;\2_A7>ZI?MK7AW-S/(!]IMG<!G(XW*3@=,9'MQFN"TOX6>+-3O%A;2Y
M+--V'FN2$5!Z^I_ &O:I5H>S6I\Y6P]556K;L[WX-^#M%N]#77KRU^TWHG>-
M/.P4CQC!5?7GJ?PQ7KU87A[PK;^'="MM,M+JYV0K\S!\;V/+-CMDYK2^P?\
M3U=?]_*\JK/GFV>Y0IJG34;:ENBJ;60526O+D =29>E9-[K6DV60VJ7,SC^"
M&3=^O3]:R-SHJ*\]N_%L[MMT\3IG@-++N)_ ?_7IJ:=XDUL?OC<>4W_/=RB_
ME_\ 6H [&]\1:789$UVC./X(_G/Z=/QKGKWQZ3E=/M,>CS'^@_QJ6S\!1C!O
M[MF/]V$8'YG_  K8M?#.GV;!K82(XZ/N&[\\4 <GCQ-KW_/<1-_VR3'Z9_6M
M"R\!'AM0N_JD(_J?\*ZC[!_T]77_ '\H^P?]/5U_W\H KV7AW2[#!AM$9Q_'
M)\Q_7I^%:=5/L'_3U=?]_*/L'_3U=?\ ?R@"W153[!_T]77_ '\H^P?]/5U_
MW\H MT54^P?]/5U_W\H^P?\ 3U=?]_* +=%5/L'_ $]77_?RC[!_T]77_?R@
M"W153[!_T]77_?RC[!_T]77_ '\H MT54^P?]/5U_P!_*/L'_3U=?]_* +=%
M5/L'_3U=?]_*/L'_ $]77_?R@"W153[!_P!/5U_W\H^P?]/5U_W\H MT54^P
M?]/5U_W\H^P?]/5U_P!_* +=%5/L'_3U=?\ ?RC[!_T]77_?R@"W153[!_T]
M77_?RC[!_P!/5U_W\H MT54^P?\ 3U=?]_*/L'_3U=?]_* +=<GXZ\&:+XCT
M>YN;^UQ=V\+O'<PX63Y5) )_B'L?TKH?L'_3U=?]_*1M.5T*O<W+*PP09.H_
M*JC)Q=T1."G'E9\@5-97EQI]]#>6<K17$#B2-UZJP.0:]!\8?"#6M+U*67P_
M;/J&G.Q:,1D&2(?W2O4_49_"CPA\(-:U/5(9=?M6L-.1@T@D8"24?W0HY&?4
MXQ[U[7MJ?+S7/G?J]93Y;:GOFG7)O=+M;HKM,\*2%3VW*#C]:L4B(L:*B#"J
M, #L*6O#/I%L5/\ F,_]N_\ [-5NJG_,9_[=_P#V:K= RI_S&?\ MW_]FJW5
M3_F,_P#;O_[-5N@ ID4$4 801)&'8NP10-S$Y)..Y/>GT4 %%%% !1110 44
M44 %%%<[XW\6V_@[PY+?R[9+A_W=M"3_ *QS_0=3_P#7%.,7)V1,I*,7)['&
M_&+QU_9=D?#NERE;RY3-TZG_ %41_A^K?R^M7/A'X%_X1_2?[8U*(#4;U 45
MAS!$>0/J>I_ >M<;\,/"5QXO\23>)O$&Z:VAF\S,@S]HFZ_]\KU_(>M>]5UU
M9*G'V4?F<-"+K3]O/Y!1117&>@%%(2%!+$ #J36?<Z_I5IGSKZ'(ZA#O/Y#-
M &C17+W/CNPCR+:":<^IPH/]?TK*F\;ZG<MLLK:.,GH I=O\_A0!WM07%]:V
M@S=7,4/^^X%<+Y'BO5?O_:54]=S>4/RXJ:'P-<D;[^]AA'4[<L?UQ0!NW/C+
M2+?(25YR.T2'^9P*R;GQ\YR+.R4>C2OG]!_C3DT3PM8\WVIQ2L.JO<*OZ#FI
MT\0>#M-_X]W@W#H8X&8_]]8_K64JU*/Q22^9O'#UI_#!OY,R?[9\3:K_ ,>J
MRA#_ ,\(L#_OK_Z].3PGKFH,'OI0GO/*7/Z9K0G^).CQ\10W4I]0@ _4UGS?
M%!>EOI9/O)-C] /ZUSRQV&CO(Z8Y;BY;0_)&E;> ;=<&[O))/41J%_4YK7MO
M"^D6N"MFLC>LI+Y_ \5P\GQ(UB9MMM:6R9Z81F/\_P"E,_M[QK?_ .HCN@I_
MYY6@ _/;_6LO[2HOX4WZ(W_LFNOC:7JS:^(ES+I^FV=M9;(89G;S$5 ,[<8_
MG7GOVV?^\/R%:.O0Z^D<,FOFXVL3Y0F?//&<#/':L:O'Q.+K.JW%N*['O8/
MT(T4I*,GWW.N\ ZE=?\ "31VPD'E3(WF+CKA21^M>IUX9I&EW&LZDEE:,B2N
M"09"0.!GL#71?\*XUP=+FT_[^M_\379@\7B/9_ YZ[W.#'8+#>U7OJ&FUOQ/
M4:*\N_X5WKPZ7%K_ -_F_P#B:/\ A7WB =+BW_[_ #?X5U_6Z_\ SY?W_P#
M.#ZCAO\ G^ON_P"">HT5Y=_P@'B(=+B#_O\ M_A1_P ('XC'2XB_[_M_A1]<
MK_\ /E_U\@^HX;_G^ON_X)ZC17EW_""^)1TN(_\ P(-'_"$>)QTG7_P)-'UR
MM_SY?]?(/J&'_P"?Z_KYGJ-%>7?\(7XI'2<?^!)H_P"$-\5CI.?_  *-'URM
M_P ^7_7R#ZA0_P"?\?Z^9ZC17EW_  B'BT=)V_\  L_XT?\ ")>+ATGD_P#
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MNOD6Z*J?:+S_ )\?_(PH^T7G_/C_ .1A74<18>*.3_61J_\ O+FJ[Z3ITO\
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M#*K+]TI:[WW_  /.?^$S\5-]V#\K4T?\)7XP;[L,OX6?_P!:O1OM%Y_SX_\
MD84?:+S_ )\?_(PK7ZG5_P"?S_KYF']H4/\ GQ'^OD><_P#"1^-6^[#<_A8C
M_P")H_MOQTW2*^_"P'_Q%>C?:+S_ )\?_(PH^T7G_/C_ .1A1]2J?\_9!_:-
M+I0C]QYS_:?CMO\ EG??^ @'_LM'VKQVW\-]_P!^0/Z5Z-]HO/\ GQ_\C"C[
M1>?\^/\ Y&%'U&76K+[P_M*/2C'[CSG=X[;_ )_OR H\CQVW>^_[^ ?UKT;[
M1>?\^/\ Y&%'VB\_Y\?_ ",*/[/[U)?>']J/I2C]QYS]@\=M_'??^!('_LU'
M]C^.V_Y:WW_@<!_[/7HWVB\_Y\?_ ",*/M%Y_P ^/_D84?V=#K.7W_\  #^U
M9]*<?N_X)YS_ ,(_XW;[TMW^-\/_ (JC_A%_&3?>FF_&\_\ KUZ-]HO/^?'_
M ,C"C[1>?\^/_D84?V;3_FE]_P#P _M:K_)'[O\ @GG/_"'^+&^].WXW9_QH
M_P"$'\3M]Z=?QN37HWVB\_Y\?_(PH^T7G_/C_P"1A1_9M'N_O#^UZ_11^X\Y
M_P"$ \0M]ZX@_&=O\*Y%U*2,K=5.#7NGVB\_Y\?_ ",*Y1_ 5@\C.;2ZRQ).
M+I?_ (FN7$99M['YW9VX7.+7^L?*R/-*Z;3/ ^JZIIL-[:SVRQ3 E0\C CG'
M9?:ND_X0"P_Y]+O_ ,"D_P#B:Z/3H)M+T^*RMK)O*B&%WSJ3USZ>]1A\KES/
MVVWDR\5G$>1?5]_-'!?\*ZUT=+FU_P"_K?\ Q-'_  KS7QTN+;_O\W^%>C?:
M+S_GQ_\ (PH^T7G_ #X_^1A7;_9F'\_O//\ [8Q/E]QYS_PK_P 0CI<6_P#W
M_;_"C_A ?$8Z7$/_ '_;_"O1OM%Y_P ^/_D84?:+S_GQ_P#(PH_LRAY_>']K
MXGR^X\Y_X03Q(.EQ'_X$'_"C_A!_$PZ3I_X$&O1OM%Y_SX_^1A1]HO/^?'_R
M,*/[-H]W]X?VOB.R^X\Y_P"$)\4#I.O_ ($FC_A#/%0Z3_\ DT:]&^T7G_/C
M_P"1A1]HO/\ GQ_\C"C^S:/=_>']KU^R^X\Y_P"$.\6#I.W_ (%&C_A$?%PZ
M3O\ ^!?_ ->O1OM%Y_SX_P#D84?:+S_GQ_\ (PH_LVEW?WA_:]?^6/W?\$\Y
M_P"$4\7CI-)_X&?_ %Z/^$6\8CI--_X&?_7KT;[1>?\ /C_Y&%'VB\_Y\?\
MR,*/[-I?S/[P_M:M_+'[O^"><_\ ",^,QTFN/_ W_P"RH_X1OQJ.DUS_ .!W
M_P!E7HWVB\_Y\?\ R,*/M%Y_SX_^1A1_9M/^:7W_ / #^UJW\D?N_P""><_\
M(]XW'2:Z_P# X?\ Q51W.A^,XK65[B6[,*H3)F]!&W'/&[GBO2OM%Y_SX_\
MD85%=F[NK.:W-GM$T;(6$HXR,4GEL+:2E]__  "HYM4NKPC]W_!/#J*[K_A6
M\O\ SVD_)?\ &G1?#5WD DNI(U/5MJG'X9KQ_P"SL3_+^*/>_M;!_P WX/\
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M_P"^Q1]KM_\ GO%_WV* ):*B^UV__/>+_OL4?:[?_GO%_P!]B@"6BHOM=O\
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M_P!]B@"6BHOM=O\ \]XO^^Q1]KM_^>\7_?8H EHJ+[7;_P#/>+_OL4?:[?\
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M]B@"6BHOM=O_ ,]XO^^Q1]KM_P#GO%_WV* ):*B^UV__ #WB_P"^Q1]KM_\
MGO%_WV* ):*B^UV__/>+_OL4?:[?_GO%_P!]B@"6BHOM=O\ \]XO^^Q1]KM_
M^>\7_?8H EHJ+[7;_P#/>+_OL4JW$+L%26-F/0!@30!)1110!4_YC/\ V[_^
MS5;JI_S&?^W?_P!FJW0!4_YC/_;O_P"S5;JI_P QG_MW_P#9JMT %174)N;.
M: 2O"98V021G#)D8R#V(J6B@#SRW\,^(;[5)K'6)K=K6/[&TMZ%<R7 B+%=N
M1@.>-QR<9]ZU=2T7Q3J>F7.C75[I\ME<L4>]*LLXB+9QY879N XSD?2NNHH
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M\(O^^!4M% $7V2W_ .>$7_? I5MX48,D,:L.A"@&I** "BBB@"I_S&?^W?\
M]FJW53_F,_\ ;O\ ^S5;H J?\QG_ +=__9JMU4_YC/\ V[_^S5;H **** "B
MBLC7]<.C)9I#:F[NKV<6\$/F>6"V"<EB#@8'H30!KT5SG@W7;_6-(M_[6L9H
M+@6L,OV@C,=R'0'>I  !]5[9KHZ "BBB@ HHHH **** "BBB@ HHHH ****
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M[_R"*/L]Y_S_ '_D$5;HH J?9[S_ )_O_((H^SWG_/\ ?^015NB@"I]GO/\
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M(JW10!4^SWG_ #_?^011]GO/^?[_ ,@BK=% %3[/>?\ /]_Y!%'V>\_Y_O\
MR"*MT4 5/L]Y_P _W_D$4?9[S_G^_P#((JW10!4^SWG_ #_?^011]GO/^?[_
M ,@BK=% %3[/>?\ /]_Y!%'V>\_Y_O\ R"*MT4 9]J+RYMEE^V;=V>/*![XJ
MQ%#<I(#)=>8HZKY8&?QJ=45%"HH51T &!2T %%%% %3_ )C/_;O_ .S5;JI_
MS&?^W?\ ]FJW0!4_YC/_ &[_ /LU6ZJ?\QG_ +=__9JMT %%%% !1110 444
M4 8NLZ]/8ZE::9IEA]OO[E'E$9F$2QQK@%F;![D <537QI$OAVZU"YL98KJU
MNC9/9*X9FN,@!%;H0=P.?2F^+_&-OX>:"PCFACU"\&8FN&VQ0KT,CGT'. .2
M16'=0Z</!UO<Z!>G5QIVJPZA?S1-N>9@X:1B!['.!T ]J .DL/$LYU"YL-=T
M[^SKF&U^V 1S>>KQ X8@A0<@\8QW&,T[P[XG/B"_U&#^SY[);,Q[#<</(K@D
M$ICY>G0G.#VK+L;VU\1_$2#4=(E%Q96.G.DEPBG:9'<83)[@ GVJ[H?_ "/G
MBG_MT_\ 11H K'QO<?87U==%9M#CE*->?:1YFT/L,@BQ]W(]<XYQ76@AE!4@
M@C(([UY3K$6D2Z-J.DZ/?:O#>SRO'%H+O@"1GY; !.SDM][;C\J]2MHC!:10
MDY,:*N?7 Q0!+1110 4444 %%%% !1110 4444 %%%% !7/ZAXCODUJXTW1-
M(_M*6TB22Y9KD0JF[.U1D'+$#/8>]=!7%^*_&5I!JC>'8-2AT^=E!N[V9@!;
MHPSA ?O.01CL,Y]J +[>,HYM%TJ[TNRDN[K5FVVUHSB,Y )?<W( 7!R>:B/C
M4PV5V+S3)(]4MKJ.T^PI*'\R23!CVO@#:02<D<8-9MV^E:4WA/5],EWZ#I_G
MV[7$1WJ@=-@=L=MRD$]B:BB\4Z?I5]XC\4R;GT^ZDMK6S95V_:9$1L[2>,?,
M?F/&%- '0Z?XFE;4+NPUVP&F7-M;"[.V<3(T.2"P8 =".1BJMCXQN9YM.EOM
M%>ST[5)!':7+3AF)()3>F/EW <<FLO2FLO$-CK;)JUK?:_J5@\;1VTN5MH\$
M+&OL"XRW<G-5H]5MM;TOPKHMCN;4+.[M7NX&C(:V$ R^[TY7 ]<T >CT444
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M_(Q>*O\ L(K_ .BEKJ: "BBB@ HHHH **** "BBB@ HHHH **** $9@JEF(
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MVCCIG'6MWP1---X'T@SVSVY6SA10S*V]1&N'&"< ]<'GUH T_P#F,_\ ;O\
M^S5;JI_S&?\ MW_]FJW0!4_YC/\ V[_^S5;JI_S&?^W?_P!FJW0 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% %3_F,_]N__ +-5NJG_ #&?^W?_
M -FJW0!4_P"8S_V[_P#LU6ZJ?\QG_MW_ /9JMT %%%% !1110 4444 %%%%
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M;N/'G*D@18\C(!;!R?;%7"$INT49U*D*:YINQWU%<SX+\=:;XULY9+)'M[B
M@36\I!*YZ$$=1[UTU*47%V9491FN:.P445SK>+X5\<+X>^S':5"F[W_*)BI<
M1XQ_<&<Y]L5)1T5%<]JGB+4+;Q/'HFE:5%>S-9F[9Y;OR0%#[,?<;/)%1VGC
M. :7JMSK%J^GRZ2XCNH0XEY(!7:PQNW9 '2@#I:*Y:;Q5J]A:K?ZKX;>VT_@
MR2)=K)+$I[M'M'KR 211?^)M;M-;M=/AT&UG%ZTOV67^TMH=4&=Q'EG;D8.,
MF@#J:*BM7GDM8WNX5@G9<O&DF\*?0-@9^N!4M !1110 4444 %%%% !1110
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MK)(TFB>*50Z.I5E89!!ZBL[1M M-!66.PDNO(DVA8)KAI$A SP@8G:.>WH*
M-.HKN)KBSFACD,;R1LJN.JDC&:EHI-75AIV=SS!_AIK+2,?M=DV23N:1\GW/
MRU2U7P+J>D:9-?7$UK)'" 66)F+<D#NH]:]<HKS)970:=KW/8CG&)35[-'S]
M72Z5X%U/5],AOK>:UCCF!*K*S!N"1V4^E>N45E3RF$7[\KK[C>KG=24;4XV?
MK?\ 1'EW_"L]9_Y^;'_OX_\ \36AK.D7&B> [6TO+@3R#4[9LJ254>:ORC/;
MC]:]!HKMHX.E0ES0W/.Q&85\1#DJ6MZ'F/C:TF\.075O:Q,VDZQ=02!5'%K<
M"9&;Z*X4GZCWJ36VT$?%&^_X26[^S0'3HO+/VJ2'<VX\91@3QVKTJBNPX#R6
MZROP[NHK7S&TJ+6(5TZ21-K/%O4D]!D;MV">37K5%% !7E7Q"^%VN>+/$[:E
MI^I6H@9%58;IW7RL  [=JG@XS7JM%:4ZDJ;O$RJTHU8\LCP#_A1'B?\ Y_M)
M_P"_TO\ \;KD_%/@G6?"%VL.J0AXW *7,&YHF]MQ Y'H0*^JZ*Z8XR:>NIQR
MR^DU[NA\S^&OA9XC\3V#7END%G!G"->ET\SW4!3Q[UL_\*(\3_\ /]I/_?Z7
M_P"-U[_12>,J-Z#C@*26IYG\/_ ^I?#W^TM2UW4K=[7[.28;9F91C#%SN4<X
M!'XU5&G^)W\'/K(L[$2/=_VV',[^<"/F"[-F/N?+C=_A7JU%<TYN<N9G93IQ
MIQY8[' S(OB+XCV,]CJ-U91S:!YZ2VC(&93,ORG<K#'/IU%4)=*NVT+Q'HT$
M1O-1T_4(;PR$YDO4)5UW9ZMA6'''& *]-HJ#0Y6?X@Z2]F/[(WZAJ,F%CTY5
M9)2Q[-P=F.Y/'%2:UN/CKPKO #8N\@'(!\H=ZZ:B@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** *G_,9_[=_P#V:K=5/^8S_P!N_P#[-5N@"I_S&?\ MW_]FJW5
M":>.WU4/,VU3!@'!/.ZI/[3L_P#GM_XZ?\* +=%5/[3L_P#GM_XZ?\*/[3L_
M^>W_ (Z?\* +=%5/[3L_^>W_ (Z?\*/[3L_^>W_CI_PH MT54_M.S_Y[?^.G
M_"C^T[/_ )[?^.G_  H MT54_M.S_P">W_CI_P */[3L_P#GM_XZ?\* +=%5
M/[3L_P#GM_XZ?\*/[3L_^>W_ (Z?\* +=%5/[3L_^>W_ (Z?\*/[3L_^>W_C
MI_PH MT54_M.S_Y[?^.G_"C^T[/_ )[?^.G_  H MT54_M.S_P">W_CI_P *
M/[3L_P#GM_XZ?\* +=%5/[3L_P#GM_XZ?\*/[3L_^>W_ (Z?\* +=%5/[3L_
M^>W_ (Z?\*/[3L_^>W_CI_PH MT54_M.S_Y[?^.G_"C^T[/_ )[?^.G_  H
MMT54_M.S_P">W_CI_P */[3L_P#GM_XZ?\* +=%5/[3L_P#GM_XZ?\*/[3L_
M^>W_ (Z?\* +=%5/[3L_^>W_ (Z?\*/[3L_^>W_CI_PH MT54_M.S_Y[?^.G
M_"C^T[/_ )[?^.G_  H MT54_M.S_P">W_CI_P */[3L_P#GM_XZ?\* +=%5
M/[3L_P#GM_XZ?\*/[3L_^>W_ (Z?\* +=%5/[3L_^>W_ (Z?\*/[3L_^>W_C
MI_PH MT54_M.S_Y[?^.G_"C^T[/_ )[?^.G_  H MT54_M.S_P">W_CI_P *
M/[3L_P#GM_XZ?\* +=%5/[3L_P#GM_XZ?\*/[3L_^>W_ (Z?\* +=%5/[3L_
M^>W_ (Z?\*/[3L_^>W_CI_PH MT54_M.S_Y[?^.G_"C^T[/_ )[?^.G_  H
MMT54_M.S_P">W_CI_P */[3L_P#GM_XZ?\* +=%5/[3L_P#GM_XZ?\*/[3L_
M^>W_ (Z?\* +=%5/[3L_^>W_ (Z?\*/[3L_^>W_CI_PH MT54_M.S_Y[?^.G
M_"C^T[/_ )[?^.G_  H MT54_M.S_P">W_CI_P */[3L_P#GM_XZ?\* +=%5
M/[3L_P#GM_XZ?\*/[3L_^>W_ (Z?\* +=%5/[3L_^>W_ (Z?\*/[3L_^>W_C
MI_PH MT54_M.S_Y[?^.G_"C^T[/_ )[?^.G_  H MT54_M.S_P">W_CI_P *
M/[3L_P#GM_XZ?\* +=%5/[3L_P#GM_XZ?\*/[3L_^>W_ (Z?\* +=%5/[3L_
M^>W_ (Z?\*/[3L_^>W_CI_PH MT54_M.S_Y[?^.G_"C^T[/_ )[?^.G_  H
MMT54_M.S_P">W_CI_P */[3L_P#GM_XZ?\* +=%5/[3L_P#GM_XZ?\*/[3L_
M^>W_ (Z?\* +=%5/[3L_^>W_ (Z?\*/[3L_^>W_CI_PH MT54_M.S_Y[?^.G
M_"C^T[/_ )[?^.G_  H MT54_M.S_P">W_CI_P */[3L_P#GM_XZ?\* +=%5
M/[3L_P#GM_XZ?\*/[3L_^>W_ (Z?\* +=%5/[3L_^>W_ (Z?\*/[3L_^>W_C
MI_PH MT54_M.S_Y[?^.G_"C^T[/_ )[?^.G_  H MT54_M.S_P">W_CI_P *
M/[3L_P#GM_XZ?\* +=%5/[3L_P#GM_XZ?\*/[3L_^>W_ (Z?\* +=%5/[3L_
M^>W_ (Z?\*/[3L_^>W_CI_PH MT54_M.S_Y[?^.G_"C^T[/_ )[?^.G_  H
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
$@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>26
<FILENAME>arct-20241231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-03-06T16:06:57.4215+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://arcturusrx.com/20241231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2024" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:arct="http://arcturusrx.com/20241231" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2024" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" namespace="http://xbrl.sec.gov/country/2024"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" namespace="http://xbrl.sec.gov/stpr/2024"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd" namespace="http://xbrl.sec.gov/ecd-sub/2024"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" namespace="http://fasb.org/srt/2024"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" namespace="http://xbrl.sec.gov/dei/2024"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" namespace="http://fasb.org/us-gaap/2024"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" namespace="http://www.xbrl.org/dtr/type/2022-03-31"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd" namespace="http://xbrl.sec.gov/cyd/2024"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd" namespace="http://xbrl.sec.gov/ecd/2024"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2023/calculation-1.1.xsd" namespace="https://xbrl.org/2023/calculation-1.1"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://arcturusrx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" id="Role_StatementCONSOLIDATEDBALANCESHEETS">
        <link:definition>100010 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETSParenthetical" id="Role_StatementCONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>100020 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://arcturusrx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome" id="StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome">
        <link:definition>100030 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" id="Role_StatementCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY">
        <link:definition>100040 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" id="Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>100050 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://arcturusrx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" id="DisclosureCybersecurityRiskManagementStrategyAndGovernance">
        <link:definition>100060 - Disclosure - Cybersecurity Risk Management, Strategy, and Governance</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureOrganization" id="Role_DisclosureOrganization">
        <link:definition>995455 - Disclosure - Organization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>995465 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenue" id="Role_DisclosureRevenue">
        <link:definition>995475 - Disclosure - Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurements" id="Role_DisclosureFairValueMeasurements">
        <link:definition>995485 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://arcturusrx.com/20241231/taxonomy/role/DisclosureAccruedLiabilitiesDetail" id="DisclosureAccruedLiabilitiesDetail">
        <link:definition>995495 - Disclosure - Accrued Liabilities Detail</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet" id="Role_DisclosurePropertyAndEquipmentNet">
        <link:definition>995505 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureDebt" id="Role_DisclosureDebt">
        <link:definition>995515 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquity" id="Role_DisclosureStockholdersEquity">
        <link:definition>995525 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensation" id="Role_DisclosureShareBasedCompensation">
        <link:definition>995535 - Disclosure - Share-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>995545 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>995555 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://arcturusrx.com/20241231/taxonomy/role/DisclosureSegmentInformation" id="DisclosureSegmentInformation">
        <link:definition>995565 - Disclosure - Segment Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRelatedPartyTransactions" id="Role_DisclosureRelatedPartyTransactions">
        <link:definition>995575 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSubsequentEvents" id="Role_DisclosureSubsequentEvents">
        <link:definition>995585 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>995595 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>995605 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueTables" id="Role_DisclosureRevenueTables">
        <link:definition>995615 - Disclosure - Revenue (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://arcturusrx.com/20241231/taxonomy/role/DisclosureAccruedLiabilitiesDetailTables" id="DisclosureAccruedLiabilitiesDetailTables">
        <link:definition>995625 - Disclosure - Accrued Liabilities Detail (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables" id="Role_DisclosurePropertyAndEquipmentNetTables">
        <link:definition>995635 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureDebtTables" id="Role_DisclosureDebtTables">
        <link:definition>995645 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationTables" id="Role_DisclosureShareBasedCompensationTables">
        <link:definition>995655 - Disclosure - Share-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>995665 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" id="Role_DisclosureCommitmentsAndContingenciesTables">
        <link:definition>995675 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://arcturusrx.com/20241231/taxonomy/role/DisclosureSegmentInformationTables" id="DisclosureSegmentInformationTables">
        <link:definition>995685 - Disclosure - Segment Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureOrganizationDetailsTextual" id="Role_DisclosureOrganizationDetailsTextual">
        <link:definition>995695 - Disclosure - Organization (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesDetailsTextual" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesDetailsTextual">
        <link:definition>995705 - Disclosure - Summary of Significant Accounting Policies (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://arcturusrx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails">
        <link:definition>995715 - Disclosure - Summary of Significant Accounting Policies - Schedule of Cash and Cash Equivalents and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://arcturusrx.com/20241231/taxonomy/role/DisclosureRevenueSummaryOfChangesInBalancesOfReceivablesAndContractLiabilityDetails" id="DisclosureRevenueSummaryOfChangesInBalancesOfReceivablesAndContractLiabilityDetails">
        <link:definition>995725 - Disclosure - Revenue - Summary of Changes in Balances of Receivables and Contract Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual" id="Role_DisclosureRevenueDetailsTextual">
        <link:definition>995735 - Disclosure - Revenue (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueSummaryOfRevenuesDetails" id="Role_DisclosureRevenueSummaryOfRevenuesDetails">
        <link:definition>995745 - Disclosure - Revenue - Summary of Revenues (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual1" id="Role_DisclosureRevenueDetailsTextual1">
        <link:definition>995755 - Disclosure - Revenue (Details Textual 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual1Default" id="Role_DisclosureRevenueDetailsTextual1Default">
        <link:definition>995755 - Disclosure - Revenue (Details Textual 1) [Default]</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://arcturusrx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsDetailsTextual" id="DisclosureFairValueMeasurementsDetailsTextual">
        <link:definition>995765 - Disclosure - Fair Value Measurements (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://arcturusrx.com/20241231/taxonomy/role/DisclosureAccruedLiabilitiesDetailScheduleOfAccruedLiabilitiesDetails" id="DisclosureAccruedLiabilitiesDetailScheduleOfAccruedLiabilitiesDetails">
        <link:definition>995775 - Disclosure - Accrued Liabilities Detail - Schedule of Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://arcturusrx.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfComponentsOfPropertyAndEquipmentNetDetails" id="DisclosurePropertyAndEquipmentNetSummaryOfComponentsOfPropertyAndEquipmentNetDetails">
        <link:definition>995785 - Disclosure - Property and Equipment, Net - Summary of Components of Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetDetailsTextual" id="Role_DisclosurePropertyAndEquipmentNetDetailsTextual">
        <link:definition>995795 - Disclosure - Property and Equipment, Net (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureDebtDetailsTextual" id="Role_DisclosureDebtDetailsTextual">
        <link:definition>995805 - Disclosure - Debt (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityDetailsTextual" id="Role_DisclosureStockholdersEquityDetailsTextual">
        <link:definition>995815 - Disclosure - Stockholders' Equity (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationDetailsTextual" id="Role_DisclosureShareBasedCompensationDetailsTextual">
        <link:definition>995825 - Disclosure - Share-Based Compensation (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationDetails" id="Role_DisclosureShareBasedCompensationDetails">
        <link:definition>995835 - Disclosure - Share-Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationDetails1" id="Role_DisclosureShareBasedCompensationDetails1">
        <link:definition>995845 - Disclosure - Share-Based Compensation (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://arcturusrx.com/20241231/taxonomy/role/DisclosureSharebasedCompensationDetails2" id="DisclosureSharebasedCompensationDetails2">
        <link:definition>995855 - Disclosure - Share-Based Compensation - (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://arcturusrx.com/20241231/taxonomy/role/DisclosureSharebasedCompensationDetails3" id="DisclosureSharebasedCompensationDetails3">
        <link:definition>995865 - Disclosure - Share-Based Compensation (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails1" id="Role_DisclosureIncomeTaxesDetails1">
        <link:definition>995875 - Disclosure - Income Taxes (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://arcturusrx.com/20241231/taxonomy/role/DisclosureIncomeTaxesDetails2" id="DisclosureIncomeTaxesDetails2">
        <link:definition>995885 - Disclosure - Income Taxes (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://arcturusrx.com/20241231/taxonomy/role/DisclosureIncomeTaxesDetails3" id="DisclosureIncomeTaxesDetails3">
        <link:definition>995895 - Disclosure - Income Taxes (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://arcturusrx.com/20241231/taxonomy/role/DisclosureIncomeTaxesDetails4" id="DisclosureIncomeTaxesDetails4">
        <link:definition>995905 - Disclosure - Income Taxes (Details 4)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetailsTextual" id="Role_DisclosureIncomeTaxesDetailsTextual">
        <link:definition>995915 - Disclosure - Income Taxes (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://arcturusrx.com/20241231/taxonomy/role/DisclosureIncomeTaxesDetails5" id="DisclosureIncomeTaxesDetails5">
        <link:definition>995925 - Disclosure - Income Taxes (Details 5)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual" id="Role_DisclosureCommitmentsAndContingenciesDetailsTextual">
        <link:definition>995935 - Disclosure - Commitments and Contingencies (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesPaymentsOfOperatingLeaseLiabilityDetails2" id="Role_DisclosureCommitmentsAndContingenciesPaymentsOfOperatingLeaseLiabilityDetails2">
        <link:definition>995945 - Disclosure - Commitments and Contingencies - Payments of Operating Lease Liability (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesPaymentsOfOperatingLeaseLiabilityDetails" id="Role_DisclosureCommitmentsAndContingenciesPaymentsOfOperatingLeaseLiabilityDetails">
        <link:definition>995955 - Disclosure - Commitments and Contingencies - Payments of Operating Lease Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://arcturusrx.com/20241231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails" id="DisclosureSegmentInformationAdditionalInformationDetails">
        <link:definition>995965 - Disclosure - Segment Information - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://arcturusrx.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfReportedSegmentRevenuesSegmentLossAndIncomeAndSignificantSegmentExpensesDetails" id="DisclosureSegmentInformationSummaryOfReportedSegmentRevenuesSegmentLossAndIncomeAndSignificantSegmentExpensesDetails">
        <link:definition>995975 - Disclosure - Segment Information - Summary of Reported Segment Revenues, Segment Loss and Income, and Significant Segment Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://arcturusrx.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfReportedSegmentRevenuesSegmentLossAndIncomeAndSignificantSegmentExpensesParentheticalDetails" id="DisclosureSegmentInformationSummaryOfReportedSegmentRevenuesSegmentLossAndIncomeAndSignificantSegmentExpensesParentheticalDetails">
        <link:definition>995985 - Disclosure - Segment Information - Summary of Reported Segment Revenues, Segment Loss and Income, and Significant Segment Expenses (Parenthetical) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsEquityMethodInvestmentDetailsTextual" id="Role_DisclosureRelatedPartyTransactionsEquityMethodInvestmentDetailsTextual">
        <link:definition>995995 - Disclosure - Related Party Transactions - Equity-Method Investment (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item" xlink:type="simple"/>
        <link:roleRef roleURI="http://arcturusrx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome" xlink:href="arct-20241231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome" xlink:type="simple"/>
        <link:roleRef roleURI="http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:href="arct-20241231.xsd#Role_StatementCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="simple"/>
        <link:roleRef roleURI="http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:href="arct-20241231.xsd#Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple"/>
        <link:roleRef roleURI="http://arcturusrx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" xlink:href="arct-20241231.xsd#DisclosureCybersecurityRiskManagementStrategyAndGovernance" xlink:type="simple"/>
        <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#IndividualsOnly" xlink:type="simple"/>
        <link:roleRef roleURI="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureOrganizationDetailsTextual" xlink:href="arct-20241231.xsd#Role_DisclosureOrganizationDetailsTextual" xlink:type="simple"/>
        <link:roleRef roleURI="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesDetailsTextual" xlink:href="arct-20241231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesDetailsTextual" xlink:type="simple"/>
        <link:roleRef roleURI="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual" xlink:href="arct-20241231.xsd#Role_DisclosureRevenueDetailsTextual" xlink:type="simple"/>
        <link:roleRef roleURI="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueSummaryOfRevenuesDetails" xlink:href="arct-20241231.xsd#Role_DisclosureRevenueSummaryOfRevenuesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual1" xlink:href="arct-20241231.xsd#Role_DisclosureRevenueDetailsTextual1" xlink:type="simple"/>
        <link:roleRef roleURI="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual1Default" xlink:href="arct-20241231.xsd#Role_DisclosureRevenueDetailsTextual1Default" xlink:type="simple"/>
        <link:roleRef roleURI="http://arcturusrx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsDetailsTextual" xlink:href="arct-20241231.xsd#DisclosureFairValueMeasurementsDetailsTextual" xlink:type="simple"/>
        <link:roleRef roleURI="http://arcturusrx.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfComponentsOfPropertyAndEquipmentNetDetails" xlink:href="arct-20241231.xsd#DisclosurePropertyAndEquipmentNetSummaryOfComponentsOfPropertyAndEquipmentNetDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureDebtDetailsTextual" xlink:href="arct-20241231.xsd#Role_DisclosureDebtDetailsTextual" xlink:type="simple"/>
        <link:roleRef roleURI="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityDetailsTextual" xlink:href="arct-20241231.xsd#Role_DisclosureStockholdersEquityDetailsTextual" xlink:type="simple"/>
        <link:roleRef roleURI="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationDetailsTextual" xlink:href="arct-20241231.xsd#Role_DisclosureShareBasedCompensationDetailsTextual" xlink:type="simple"/>
        <link:roleRef roleURI="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationDetails" xlink:href="arct-20241231.xsd#Role_DisclosureShareBasedCompensationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://arcturusrx.com/20241231/taxonomy/role/DisclosureSharebasedCompensationDetails2" xlink:href="arct-20241231.xsd#DisclosureSharebasedCompensationDetails2" xlink:type="simple"/>
        <link:roleRef roleURI="http://arcturusrx.com/20241231/taxonomy/role/DisclosureSharebasedCompensationDetails3" xlink:href="arct-20241231.xsd#DisclosureSharebasedCompensationDetails3" xlink:type="simple"/>
        <link:roleRef roleURI="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetailsTextual" xlink:href="arct-20241231.xsd#Role_DisclosureIncomeTaxesDetailsTextual" xlink:type="simple"/>
        <link:roleRef roleURI="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual" xlink:href="arct-20241231.xsd#Role_DisclosureCommitmentsAndContingenciesDetailsTextual" xlink:type="simple"/>
        <link:roleRef roleURI="http://arcturusrx.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfReportedSegmentRevenuesSegmentLossAndIncomeAndSignificantSegmentExpensesDetails" xlink:href="arct-20241231.xsd#DisclosureSegmentInformationSummaryOfReportedSegmentRevenuesSegmentLossAndIncomeAndSignificantSegmentExpensesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://arcturusrx.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfReportedSegmentRevenuesSegmentLossAndIncomeAndSignificantSegmentExpensesParentheticalDetails" xlink:href="arct-20241231.xsd#DisclosureSegmentInformationSummaryOfReportedSegmentRevenuesSegmentLossAndIncomeAndSignificantSegmentExpensesParentheticalDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsEquityMethodInvestmentDetailsTextual" xlink:href="arct-20241231.xsd#Role_DisclosureRelatedPartyTransactionsEquityMethodInvestmentDetailsTextual" xlink:type="simple"/>
        <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd#eedm" xlink:type="simple"/>
        <link:roleRef roleURI="http://fasb.org/srt/role/srt-eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd#eedm1" xlink:type="simple"/>
        <link:roleRef roleURI="http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" xlink:href="arct-20241231.xsd#Role_StatementCONSOLIDATEDBALANCESHEETS" xlink:type="simple"/>
        <link:roleRef roleURI="http://arcturusrx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails" xlink:href="arct-20241231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://arcturusrx.com/20241231/taxonomy/role/DisclosureAccruedLiabilitiesDetailScheduleOfAccruedLiabilitiesDetails" xlink:href="arct-20241231.xsd#DisclosureAccruedLiabilitiesDetailScheduleOfAccruedLiabilitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails1" xlink:href="arct-20241231.xsd#Role_DisclosureIncomeTaxesDetails1" xlink:type="simple"/>
        <link:roleRef roleURI="http://arcturusrx.com/20241231/taxonomy/role/DisclosureIncomeTaxesDetails2" xlink:href="arct-20241231.xsd#DisclosureIncomeTaxesDetails2" xlink:type="simple"/>
        <link:roleRef roleURI="http://arcturusrx.com/20241231/taxonomy/role/DisclosureIncomeTaxesDetails3" xlink:href="arct-20241231.xsd#DisclosureIncomeTaxesDetails3" xlink:type="simple"/>
        <link:roleRef roleURI="http://arcturusrx.com/20241231/taxonomy/role/DisclosureIncomeTaxesDetails4" xlink:href="arct-20241231.xsd#DisclosureIncomeTaxesDetails4" xlink:type="simple"/>
        <link:roleRef roleURI="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesPaymentsOfOperatingLeaseLiabilityDetails2" xlink:href="arct-20241231.xsd#Role_DisclosureCommitmentsAndContingenciesPaymentsOfOperatingLeaseLiabilityDetails2" xlink:type="simple"/>
        <link:roleRef roleURI="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesPaymentsOfOperatingLeaseLiabilityDetails" xlink:href="arct-20241231.xsd#Role_DisclosureCommitmentsAndContingenciesPaymentsOfOperatingLeaseLiabilityDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://arcturusrx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:href="arct-20241231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:roleRef roleURI="http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETSParenthetical" xlink:href="arct-20241231.xsd#Role_StatementCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements" xlink:type="simple"/>
        <link:roleRef roleURI="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureOrganization" xlink:href="arct-20241231.xsd#Role_DisclosureOrganization" xlink:type="simple"/>
        <link:roleRef roleURI="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="arct-20241231.xsd#Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenue" xlink:href="arct-20241231.xsd#Role_DisclosureRevenue" xlink:type="simple"/>
        <link:roleRef roleURI="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:href="arct-20241231.xsd#Role_DisclosureFairValueMeasurements" xlink:type="simple"/>
        <link:roleRef roleURI="http://arcturusrx.com/20241231/taxonomy/role/DisclosureAccruedLiabilitiesDetail" xlink:href="arct-20241231.xsd#DisclosureAccruedLiabilitiesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet" xlink:href="arct-20241231.xsd#Role_DisclosurePropertyAndEquipmentNet" xlink:type="simple"/>
        <link:roleRef roleURI="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureDebt" xlink:href="arct-20241231.xsd#Role_DisclosureDebt" xlink:type="simple"/>
        <link:roleRef roleURI="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquity" xlink:href="arct-20241231.xsd#Role_DisclosureStockholdersEquity" xlink:type="simple"/>
        <link:roleRef roleURI="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensation" xlink:href="arct-20241231.xsd#Role_DisclosureShareBasedCompensation" xlink:type="simple"/>
        <link:roleRef roleURI="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:href="arct-20241231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple"/>
        <link:roleRef roleURI="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:href="arct-20241231.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple"/>
        <link:roleRef roleURI="http://arcturusrx.com/20241231/taxonomy/role/DisclosureSegmentInformation" xlink:href="arct-20241231.xsd#DisclosureSegmentInformation" xlink:type="simple"/>
        <link:roleRef roleURI="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRelatedPartyTransactions" xlink:href="arct-20241231.xsd#Role_DisclosureRelatedPartyTransactions" xlink:type="simple"/>
        <link:roleRef roleURI="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSubsequentEvents" xlink:href="arct-20241231.xsd#Role_DisclosureSubsequentEvents" xlink:type="simple"/>
        <link:roleRef roleURI="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="arct-20241231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:href="arct-20241231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueTables" xlink:href="arct-20241231.xsd#Role_DisclosureRevenueTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://arcturusrx.com/20241231/taxonomy/role/DisclosureAccruedLiabilitiesDetailTables" xlink:href="arct-20241231.xsd#DisclosureAccruedLiabilitiesDetailTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables" xlink:href="arct-20241231.xsd#Role_DisclosurePropertyAndEquipmentNetTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureDebtTables" xlink:href="arct-20241231.xsd#Role_DisclosureDebtTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationTables" xlink:href="arct-20241231.xsd#Role_DisclosureShareBasedCompensationTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:href="arct-20241231.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" xlink:href="arct-20241231.xsd#Role_DisclosureCommitmentsAndContingenciesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://arcturusrx.com/20241231/taxonomy/role/DisclosureSegmentInformationTables" xlink:href="arct-20241231.xsd#DisclosureSegmentInformationTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://arcturusrx.com/20241231/taxonomy/role/DisclosureRevenueSummaryOfChangesInBalancesOfReceivablesAndContractLiabilityDetails" xlink:href="arct-20241231.xsd#DisclosureRevenueSummaryOfChangesInBalancesOfReceivablesAndContractLiabilityDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetDetailsTextual" xlink:href="arct-20241231.xsd#Role_DisclosurePropertyAndEquipmentNetDetailsTextual" xlink:type="simple"/>
        <link:roleRef roleURI="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationDetails1" xlink:href="arct-20241231.xsd#Role_DisclosureShareBasedCompensationDetails1" xlink:type="simple"/>
        <link:roleRef roleURI="http://arcturusrx.com/20241231/taxonomy/role/DisclosureIncomeTaxesDetails5" xlink:href="arct-20241231.xsd#DisclosureIncomeTaxesDetails5" xlink:type="simple"/>
        <link:roleRef roleURI="http://arcturusrx.com/20241231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails" xlink:href="arct-20241231.xsd#DisclosureSegmentInformationAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_RevenueRecognitionReserveTargetExclusivityPeriod" xlink:label="arct_RevenueRecognitionReserveTargetExclusivityPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_ForeignCountriesMember" xlink:label="arct_ForeignCountriesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="us-gaap_RevenueRemainingPerformanceObligation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_ContraExpenseIncludedInResearchAndDevelopmentExpense" xlink:label="arct_ContraExpenseIncludedInResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_VinbiocareMember" xlink:label="arct_VinbiocareMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_SeptemberTwoThousandAndTwentyOneLeaseAgreementMember" xlink:label="arct_SeptemberTwoThousandAndTwentyOneLeaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_COVIDNineteenVaccineDevelopmentMember" xlink:label="arct_COVIDNineteenVaccineDevelopmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_DiscoveryTechnologiesMember" xlink:label="arct_DiscoveryTechnologiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:label="us-gaap_DeferredTaxAssetsInventory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_EmployeesAndOfficersMember" xlink:label="arct_EmployeesAndOfficersMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_IncreaseDecreaseOperatingLeaseRightOfUseAsset" xlink:label="arct_IncreaseDecreaseOperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemAmount" xlink:label="us-gaap_SegmentReportingOtherItemAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_DeferredTaxLiabilitiesRightOfUseAsset" xlink:label="arct_DeferredTaxLiabilitiesRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_CollaborationPartnerCureVacEnteredIntoCoDevelopmentAgreementMember" xlink:label="arct_CollaborationPartnerCureVacEnteredIntoCoDevelopmentAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_RoyaltyPaymentTermDescription" xlink:label="arct_RoyaltyPaymentTermDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_RepyamentOfPrincipalAndInterestOnCollateralizedTermLoan" xlink:label="arct_RepyamentOfPrincipalAndInterestOnCollateralizedTermLoan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_OperatingLossCarryforwardsExpirationYear" xlink:label="arct_OperatingLossCarryforwardsExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_JanssenMember" xlink:label="arct_JanssenMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_CommitmentAndContingenciesLineItems" xlink:label="arct_CommitmentAndContingenciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_OptionToPurchaseOfAdditionalSharesOfCommonStockPricePerShare" xlink:label="arct_OptionToPurchaseOfAdditionalSharesOfCommonStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_GeneralAndAdministrativeCostsPolicyPolicyTextBlock" xlink:label="arct_GeneralAndAdministrativeCostsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_LUNAR-OTCMember" xlink:label="arct_LUNAR-OTCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorOpinionTextBlock" xlink:label="dei_AuditorOpinionTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_MilestonePayments" xlink:label="arct_MilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryCashFlowPolicy" xlink:label="us-gaap_InventoryCashFlowPolicy"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_CollaborationAgreementContractualTerm" xlink:label="arct_CollaborationAgreementContractualTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_UpfrontFeeReceived" xlink:label="arct_UpfrontFeeReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:label="us-gaap_EquityMethodInvestmentAggregateCost"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_AdditionalFinancialSupport" xlink:label="arct_AdditionalFinancialSupport"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_LiquidityPolicyPolicyTextBlock" xlink:label="arct_LiquidityPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_StockIssuedDuringPeriodValueUnderEquityPlan" xlink:label="arct_StockIssuedDuringPeriodValueUnderEquityPlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_ClinicalTrialAccrualsCurrent" xlink:label="arct_ClinicalTrialAccrualsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_ContractWithCustomerAssetAdditionsForRevenueRecognized" xlink:label="arct_ContractWithCustomerAssetAdditionsForRevenueRecognized"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_NonRareDiseaseTargetsMember" xlink:label="arct_NonRareDiseaseTargetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_CysticFibrosisFoundationTherapeuticsIncMember" xlink:label="arct_CysticFibrosisFoundationTherapeuticsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_CslCollaborationAgreementMember" xlink:label="arct_CslCollaborationAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:label="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="us-gaap_ContractWithCustomerAssetNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_PaymentsForMatchingFundsForRemainingBudgetedCosts" xlink:label="arct_PaymentsForMatchingFundsForRemainingBudgetedCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_FebruaryTwoThousandAndTwentyLeaseAgreementMember" xlink:label="arct_FebruaryTwoThousandAndTwentyLeaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_RevenueLineItems" xlink:label="arct_RevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_CSLMember" xlink:label="arct_CSLMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US" xlink:label="country_US"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_OptionExerciseRevenueRangePerTarget" xlink:label="arct_OptionExerciseRevenueRangePerTarget"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_DisbursementPeriodThreeMember" xlink:label="arct_DisbursementPeriodThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_ReservedUpfrontPayment" xlink:label="arct_ReservedUpfrontPayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_ResearchCollaborationAndExclusiveLicenseAgreementMember" xlink:label="arct_ResearchCollaborationAndExclusiveLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" xlink:label="arct_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_CollaborationAgreementTransactionPrice" xlink:label="arct_CollaborationAgreementTransactionPrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxesPayableCurrent" xlink:label="us-gaap_TaxesPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestments" xlink:label="us-gaap_EquityMethodInvestments"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:label="arct_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_WellsFargoCreditAgreementMember" xlink:label="arct_WellsFargoCreditAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_LoanAndSecurityAgreementMember" xlink:label="arct_LoanAndSecurityAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_Early-StageProgramsMember" xlink:label="arct_Early-StageProgramsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensation" xlink:label="arct_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_PayrollAndBenefitsMember" xlink:label="arct_PayrollAndBenefitsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerDurationDomain" xlink:label="us-gaap_ContractWithCustomerDurationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_OptionExerciseFeeRevenueReceived" xlink:label="arct_OptionExerciseFeeRevenueReceived"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_AdjustmentsToTransactionPrice" xlink:label="arct_AdjustmentsToTransactionPrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:label="us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="us-gaap_ReceivablesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_ContractWithCustomerAssetDeductionsForCashCollections" xlink:label="arct_ContractWithCustomerAssetDeductionsForCashCollections"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_NumberOfBusinessSegment" xlink:label="arct_NumberOfBusinessSegment"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_UltragenyxMember" xlink:label="arct_UltragenyxMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_DevelopmentAndOptionAgreementDate" xlink:label="arct_DevelopmentAndOptionAgreementDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_ConcentrationRiskNumberOfCustomer" xlink:label="arct_ConcentrationRiskNumberOfCustomer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_AdditionalPaymentsUponMeetingCertainClinicalMilestones" xlink:label="arct_AdditionalPaymentsUponMeetingCertainClinicalMilestones"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_ContraExpenseRemainingAmountIncludedInAccruedExpenses" xlink:label="arct_ContraExpenseRemainingAmountIncludedInAccruedExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_SGIMember" xlink:label="arct_SGIMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_OctoberTwoThousandAndSeventeenLeaseAmendmentMember" xlink:label="arct_OctoberTwoThousandAndSeventeenLeaseAmendmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermContractWithCustomerMember" xlink:label="us-gaap_ShortTermContractWithCustomerMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_SummaryOfSignificantAccountingPolicyLineItems" xlink:label="arct_SummaryOfSignificantAccountingPolicyLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_WesternAllianceBankMember" xlink:label="arct_WesternAllianceBankMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_OptionToPurchaseOfAdditionalSharesOfCommonStock" xlink:label="arct_OptionToPurchaseOfAdditionalSharesOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_DisbursementPeriodTwoMember" xlink:label="arct_DisbursementPeriodTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_FacilitiesAndEquipmentMember" xlink:label="arct_FacilitiesAndEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets" xlink:label="arct_DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_Covid19VaccineMember" xlink:label="arct_Covid19VaccineMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_OtherMember" xlink:label="arct_OtherMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_UnderwrittenPublicOfferingMember" xlink:label="arct_UnderwrittenPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesFairValueDisclosure" xlink:label="us-gaap_AccruedLiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_IncomeTaxesTable" xlink:label="arct_IncomeTaxesTable"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_RareDiseaseTargetsMember" xlink:label="arct_RareDiseaseTargetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="us-gaap_LossContingencyNatureDomain"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_RevenueRecognitionPotentialMilestoneRevenueRecognized" xlink:label="arct_RevenueRecognitionPotentialMilestoneRevenueRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_DevelopmentMilestonesAmountDueForAgreement" xlink:label="arct_DevelopmentMilestonesAmountDueForAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_TwentyTwentyOneInducementEquityIncentivePlanMember" xlink:label="arct_TwentyTwentyOneInducementEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_EligibleToReceiveDevelopmentMilestonePayment" xlink:label="arct_EligibleToReceiveDevelopmentMilestonePayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentOwnedBalanceShares" xlink:label="us-gaap_InvestmentOwnedBalanceShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_GrantRevenue" xlink:label="arct_GrantRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_DeferredTaxLiabilitiesPropertyPlantAndEquipmentAndIntangibleAssets" xlink:label="arct_DeferredTaxLiabilitiesPropertyPlantAndEquipmentAndIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_DevelopmentMilestonesReceivedAdvancePayment" xlink:label="arct_DevelopmentMilestonesReceivedAdvancePayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_EffectiveIncomeTaxRateReconciliationUncertainTaxPosition" xlink:label="arct_EffectiveIncomeTaxRateReconciliationUncertainTaxPosition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMember" xlink:label="us-gaap_LongTermDebtMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_PotentialTargetLicenseTerm" xlink:label="arct_PotentialTargetLicenseTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_ManufacturingAndSupplyOfArct154DrugProductMember" xlink:label="arct_ManufacturingAndSupplyOfArct154DrugProductMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_NumberOfReservedVaccineDoses" xlink:label="arct_NumberOfReservedVaccineDoses"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_PreLaunchInventoryPolicyPolicyTextBlock" xlink:label="arct_PreLaunchInventoryPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_AchievedDevelopmentMilestoneIncludedAccountsReceivable" xlink:label="arct_AchievedDevelopmentMilestoneIncludedAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrantMember" xlink:label="us-gaap_GrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_UpfrontPaymentReceived" xlink:label="arct_UpfrontPaymentReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_TaxCreditCarryforwardExpirationYear" xlink:label="arct_TaxCreditCarryforwardExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_RevenueTable" xlink:label="arct_RevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_UnvestedRestrictedOrdinarySharesMember" xlink:label="arct_UnvestedRestrictedOrdinarySharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_CollaborationAgreementConsiderationReceived" xlink:label="arct_CollaborationAgreementConsiderationReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerDurationAxis" xlink:label="us-gaap_ContractWithCustomerDurationAxis"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_ADAIRTechnologyMember" xlink:label="arct_ADAIRTechnologyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_SeqirusAgreementMember" xlink:label="arct_SeqirusAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_FebruaryTwoThousandAndTwentyOneLeaseAgreementMember" xlink:label="arct_FebruaryTwoThousandAndTwentyOneLeaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_CA" xlink:label="stpr_CA"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_RecognizedContraExpense" xlink:label="arct_RecognizedContraExpense"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_BARDAMember" xlink:label="arct_BARDAMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_ContraResearchAndDevelopmentExpense" xlink:label="arct_ContraResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_ResearchCollaborationAndLicenseAgreementMember" xlink:label="arct_ResearchCollaborationAndLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_AdditionalClinicalMilestonePayment" xlink:label="arct_AdditionalClinicalMilestonePayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_NumberOfPerformanceObligations" xlink:label="arct_NumberOfPerformanceObligations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_ContractWithCustomerLiabilityAdditions" xlink:label="arct_ContractWithCustomerLiabilityAdditions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:label="us-gaap_PaymentsForProceedsFromTenantAllowance"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_KeithCKummerfeldMember" xlink:label="arct_KeithCKummerfeldMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCollateralAmount" xlink:label="us-gaap_DebtInstrumentCollateralAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_AgreementAmountAgreedToFund" xlink:label="arct_AgreementAmountAgreedToFund"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdate202307Member" xlink:label="us-gaap_AccountingStandardsUpdate202307Member"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_GrantOneMember" xlink:label="arct_GrantOneMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_VinbiocareContractualLiabilities" xlink:label="arct_VinbiocareContractualLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_UpfrontConsiderationReceived" xlink:label="arct_UpfrontConsiderationReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_NumberOfReserveTargets" xlink:label="arct_NumberOfReserveTargets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_CureVacAGMember" xlink:label="arct_CureVacAGMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_AlexionPharmaceuticalsIncMember" xlink:label="arct_AlexionPharmaceuticalsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_GrantRevenueOutstanding" xlink:label="arct_GrantRevenueOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_UpfrontFeeAndConsideration" xlink:label="arct_UpfrontFeeAndConsideration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" xlink:label="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_NotSubjectToExpirationMember" xlink:label="arct_NotSubjectToExpirationMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_MaximumPercentageOfLikelihoodOfUncertainTaxPositionRecognizedToBeSustained" xlink:label="arct_MaximumPercentageOfLikelihoodOfUncertainTaxPositionRecognizedToBeSustained"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_VallonPharmaceuticalsIncMember" xlink:label="arct_VallonPharmaceuticalsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_UnrecognizedTaxBenefitsDecreasesIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="arct_UnrecognizedTaxBenefitsDecreasesIncreasesResultingFromPriorPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireInterestInJointVenture" xlink:label="us-gaap_PaymentsToAcquireInterestInJointVenture"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_MinimumAmountAgreedToIncurUnderResearchPlan" xlink:label="arct_MinimumAmountAgreedToIncurUnderResearchPlan"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_MonthlyBaseRent" xlink:label="arct_MonthlyBaseRent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentOwnedPercentOfNetAssets" xlink:label="us-gaap_InvestmentOwnedPercentOfNetAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_LackOfMarketabilityDiscountRestrictedPeriod" xlink:label="arct_LackOfMarketabilityDiscountRestrictedPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_OtherAccruedResearchAndDevelopmentExpenses" xlink:label="arct_OtherAccruedResearchAndDevelopmentExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseLongTermDebt" xlink:label="us-gaap_InterestExpenseLongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_DisbursementPeriodFourMember" xlink:label="arct_DisbursementPeriodFourMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_IL" xlink:label="stpr_IL"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_ContractWithCustomerAssetAdditions" xlink:label="arct_ContractWithCustomerAssetAdditions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Dividends" xlink:label="us-gaap_Dividends"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_DebtInstrumentOptionForRenewalTerm" xlink:label="arct_DebtInstrumentOptionForRenewalTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BorrowingsUnderGuaranteedInvestmentAgreements" xlink:label="us-gaap_BorrowingsUnderGuaranteedInvestmentAgreements"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_ConditionalPayment" xlink:label="arct_ConditionalPayment"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_NetOperatingLossAndResearchAndDevelopmentCreditCarryforwardsLimitationsOnCumulativeChangeInOwnershipPeriod" xlink:label="arct_NetOperatingLossAndResearchAndDevelopmentCreditCarryforwardsLimitationsOnCumulativeChangeInOwnershipPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_DevelopmentMilestonesAchieved" xlink:label="arct_DevelopmentMilestonesAchieved"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_TwoThousandTwentyEmployeeStockPurchasePlanMember" xlink:label="arct_TwoThousandTwentyEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_ReversalOfRevenue" xlink:label="arct_ReversalOfRevenue"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_OrphanDrugCreditMember" xlink:label="arct_OrphanDrugCreditMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_RemainingLoanIncludingAccruedInterestForgiveable" xlink:label="arct_RemainingLoanIncludingAccruedInterestForgiveable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_OrganizationAndSignificantAccountingPoliciesTable" xlink:label="arct_OrganizationAndSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_PercentageOfEquityInterestInJointVenture" xlink:label="arct_PercentageOfEquityInterestInJointVenture"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForAdvanceToAffiliate" xlink:label="us-gaap_PaymentsForAdvanceToAffiliate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_PercentageOfNetProfits" xlink:label="arct_PercentageOfNetProfits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_VinbiocareAgreementMember" xlink:label="arct_VinbiocareAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_LanceKurataMember" xlink:label="arct_LanceKurataMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="us-gaap_DebtInstrumentFeeAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_SG" xlink:label="country_SG"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:label="arct_OrganizationAndSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_DeferredTaxAssetsRightOfUseLeaseLiability" xlink:label="arct_DeferredTaxAssetsRightOfUseLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_LUNARCFMember" xlink:label="arct_LUNARCFMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_AcquiredInProcessResearchAndDevelopmentExpense" xlink:label="arct_AcquiredInProcessResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_DevelopmentAndRegulatoryMilestonesAchieved" xlink:label="arct_DevelopmentAndRegulatoryMilestonesAchieved"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_ReductionInNumberOfCommonStockCapitalSharesAvailableForFutureIssuance" xlink:label="arct_ReductionInNumberOfCommonStockCapitalSharesAvailableForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentCredits" xlink:label="arct_EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentCredits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:label="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_AdditionalMilestonePaymentsReceived" xlink:label="arct_AdditionalMilestonePaymentsReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_PhaseIClinicalStudyMember" xlink:label="arct_PhaseIClinicalStudyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_TwoThousandNineteenOmnibusIncentivePlanMember" xlink:label="arct_TwoThousandNineteenOmnibusIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_PharmaceuticalCompanyMember" xlink:label="arct_PharmaceuticalCompanyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyLeaseGuaranteeMember" xlink:label="us-gaap_PropertyLeaseGuaranteeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_EligibleToReceiveCommercialMilestonePayment" xlink:label="arct_EligibleToReceiveCommercialMilestonePayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_IsraelMinistryOfHealthMember" xlink:label="arct_IsraelMinistryOfHealthMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_NetOperatingLossAndResearchAndDevelopmentCreditCarryforwardsLimitationsOnCumulativeChangeInOwnershipMinimumPercentage" xlink:label="arct_NetOperatingLossAndResearchAndDevelopmentCreditCarryforwardsLimitationsOnCumulativeChangeInOwnershipMinimumPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_IncomeTaxesLineItems" xlink:label="arct_IncomeTaxesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:label="arct_DeferredTaxAssetsCapitalizedResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_StudySupportAgreementMember" xlink:label="arct_StudySupportAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_DrPadmanabhChivukulaMember" xlink:label="arct_DrPadmanabhChivukulaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_UpfrontPaymentToBeReceived" xlink:label="arct_UpfrontPaymentToBeReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_ContractWithCustomerAssetDeductions" xlink:label="arct_ContractWithCustomerAssetDeductions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuePracticalExpedientRemainingPerformanceObligationDescription" xlink:label="us-gaap_RevenuePracticalExpedientRemainingPerformanceObligationDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_PaymentReceivedFirstInstallment" xlink:label="arct_PaymentReceivedFirstInstallment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_FinalPaymentOfDisbursementAmount" xlink:label="arct_FinalPaymentOfDisbursementAmount"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_OptionToExtendInitialTermOnAnAnnualBasis" xlink:label="arct_OptionToExtendInitialTermOnAnAnnualBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_CslSeqirusMember" xlink:label="arct_CslSeqirusMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_CommitmentAndContingenciesTable" xlink:label="arct_CommitmentAndContingenciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="us-gaap_OperatingLeaseImpairmentLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_NonRefundablePaymentReceived" xlink:label="arct_NonRefundablePaymentReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrantsReceivable" xlink:label="us-gaap_GrantsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_MRNATechnologyMember" xlink:label="arct_MRNATechnologyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences" xlink:label="arct_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermContractWithCustomerMember" xlink:label="us-gaap_LongTermContractWithCustomerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_ScheduleOfSummaryOfSignificantAccountingPoliciesTable" xlink:label="arct_ScheduleOfSummaryOfSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_AchievedDevelopmentAndRegulatoryMilestoneIncludedAccountsReceivable" xlink:label="arct_AchievedDevelopmentAndRegulatoryMilestoneIncludedAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_LUNAR-CFNetMember" xlink:label="arct_LUNAR-CFNetMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_PrepaidExpensesAndOtherReceivables" xlink:label="arct_PrepaidExpensesAndOtherReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_ExpirationOfIntialTerm" xlink:label="arct_ExpirationOfIntialTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_DirectorsOrOfficersExceptChiefScientificOfficerCooSvpCcAndPaoMember" xlink:label="arct_DirectorsOrOfficersExceptChiefScientificOfficerCooSvpCcAndPaoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_CollaborationRevenueMember" xlink:label="arct_CollaborationRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsEquityMethodInvestments" xlink:label="us-gaap_DeferredTaxAssetsEquityMethodInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_DisbursedAmountUponExecutionOfAmendment" xlink:label="arct_DisbursedAmountUponExecutionOfAmendment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossRealized"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_UnderlyingAgreementMember" xlink:label="arct_UnderlyingAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_NonCashAssetDisposal" xlink:label="arct_NonCashAssetDisposal"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_JointVenturesEquityMethodInvestmentsAndVariableInterestEntitiesPolicyTextBlock" xlink:label="arct_JointVenturesEquityMethodInvestmentsAndVariableInterestEntitiesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_StockIssuedDuringPeriodSharesUnderEquityPlan" xlink:label="arct_StockIssuedDuringPeriodSharesUnderEquityPlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_LegalAccrualCurrent" xlink:label="arct_LegalAccrualCurrent"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_DebtInstrumentExtendedTermPeriod" xlink:label="arct_DebtInstrumentExtendedTermPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_DisbursementPaymentUponAchievementOfRequiredManufacturingPracticesAndINDApplication" xlink:label="arct_DisbursementPaymentUponAchievementOfRequiredManufacturingPracticesAndINDApplication"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_SeqirusIncMember" xlink:label="arct_SeqirusIncMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_LUNAR-COVIDMember" xlink:label="arct_LUNAR-COVIDMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_ContractWithCustomerLiabilityAdditionsForAdvancedBillings" xlink:label="arct_ContractWithCustomerLiabilityAdditionsForAdvancedBillings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_AcquisitionOfResearchAndDevelopmentInProcessThroughIssuanceOfCommonStock" xlink:label="arct_AcquisitionOfResearchAndDevelopmentInProcessThroughIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_GrantReceivableNumberOfInstallments" xlink:label="arct_GrantReceivableNumberOfInstallments"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_DisbursementPeriodOneMember" xlink:label="arct_DisbursementPeriodOneMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_DisbursementAmountPayableUponAchievementOfProjectGoal" xlink:label="arct_DisbursementAmountPayableUponAchievementOfProjectGoal"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdate201912Member" xlink:label="us-gaap_AccountingStandardsUpdate201912Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_GrantTwoMember" xlink:label="arct_GrantTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:label="us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_AccruedCysticFibrosisFoundationLiability" xlink:label="arct_AccruedCysticFibrosisFoundationLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditConcentrationRiskMember" xlink:label="us-gaap_CreditConcentrationRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_OtherCollaborationAgreementsMember" xlink:label="arct_OtherCollaborationAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_GriBioIncMember" xlink:label="arct_GriBioIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_RevenueRecognitionReserveTargetExclusivityPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue recognition reserve target exclusivity period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_RevenueRecognitionReserveTargetExclusivityPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Recognition Reserve Target Exclusivity Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_RevenueRecognitionReserveTargetExclusivityPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue recognition, reserve target exclusivity period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Board of Directors Oversight [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accounts receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_ForeignCountriesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Foreign countries.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_ForeignCountriesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Countries [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_ForeignCountriesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign Countries [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Deferred Income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue, Remaining Performance Obligation, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining performance obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring and Nonrecurring [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenuesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenuesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenues [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total (loss) income before income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_ContraExpenseIncludedInResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contra expense included in research and development expense.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_ContraExpenseIncludedInResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contra Expense Included In Research And Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_ContraExpenseIncludedInResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contra expense included in research and development expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Operating Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating segments for research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">First Year Anniversary of the Grant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_VinbiocareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Vinbiocare.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_VinbiocareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vinbiocare [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_VinbiocareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vinbiocare [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in tax rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_SeptemberTwoThousandAndTwentyOneLeaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">September two thousand and twenty one lease agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_SeptemberTwoThousandAndTwentyOneLeaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">September Two Thousand And Twenty One Lease Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_SeptemberTwoThousandAndTwentyOneLeaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">September 2021 Lease Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price, Exercisable - December 31, 2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_COVIDNineteenVaccineDevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">COVID-19 vaccine development.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_COVIDNineteenVaccineDevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">C O V I D Nineteen Vaccine Development [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_COVIDNineteenVaccineDevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">COVID-19 Vaccine Development [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_DiscoveryTechnologiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Discovery Technologies [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_DiscoveryTechnologiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Discovery technologies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_DiscoveryTechnologiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Discovery Technologies [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other non-cash expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Noncash Income (Expense), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Noncash Income (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other non-cash expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsInventory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Inventory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsInventory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_EmployeesAndOfficersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employees and officers.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_EmployeesAndOfficersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employees And Officers [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_EmployeesAndOfficersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employees and Officers [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_IncreaseDecreaseOperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_IncreaseDecreaseOperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_IncreaseDecreaseOperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease Operating Lease, Right Of Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_IncreaseDecreaseOperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease operating lease, right of use asset.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Federal Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Gross [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term Debt, Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingOtherItemAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Other Segment Item, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingOtherItemAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingOtherItemAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Long-Term Debt, Current Maturities, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Current Maturities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current portion of long-term debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward, Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax liabilities, right-of-use asset.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Right Of Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Right-of-use asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_CollaborationPartnerCureVacEnteredIntoCoDevelopmentAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration Partner Cure Vac entered into Co-Development Agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_CollaborationPartnerCureVacEnteredIntoCoDevelopmentAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Partner Cure Vac Entered Into Co Development Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_CollaborationPartnerCureVacEnteredIntoCoDevelopmentAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration Partner Cure Vac Entered Into Co Development Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock, Class of Stock [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Stock By Class [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_EquityMethodInvesteeNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_EquityMethodInvesteeNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment, Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_RoyaltyPaymentTermDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalty payment term description.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_RoyaltyPaymentTermDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Payment Term Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_RoyaltyPaymentTermDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty payment term description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_RepyamentOfPrincipalAndInterestOnCollateralizedTermLoan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repyament of Principal and Interest on Collateralized Term Loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_RepyamentOfPrincipalAndInterestOnCollateralizedTermLoan_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Repayment of principal and interest on collateralized term loan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_RepyamentOfPrincipalAndInterestOnCollateralizedTermLoan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repayament of principal and interest on collateralized term loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards expiration year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Expiration Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Loss Carryforwards Expiration Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cumulative Effect, Period of Adoption [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cumulative Effect, Period of Adoption</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes Integrated [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Benchmark [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk Benchmark</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_JanssenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Janssen.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_JanssenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Janssen [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_JanssenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Janssen [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title and Position [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_CommitmentAndContingenciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitment and contingencies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_CommitmentAndContingenciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitment And Contingencies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_CommitmentAndContingenciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitment And Contingencies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_OptionToPurchaseOfAdditionalSharesOfCommonStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Option to purchase of additional shares of common stock price per share.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_OptionToPurchaseOfAdditionalSharesOfCommonStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Option To Purchase Of Additional Shares Of Common Stock Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_OptionToPurchaseOfAdditionalSharesOfCommonStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase of additional shares of common stock price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_GeneralAndAdministrativeCostsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Costs Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_GeneralAndAdministrativeCostsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">General and administrative costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_GeneralAndAdministrativeCostsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_LUNAR-OTCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">LUNAR-OTC [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_LUNAR-OTCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">LUNAR-OTC.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_LUNAR-OTCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">LUNAR-OTC [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares, Forfeited/cancelled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorOpinionTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Opinion [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorOpinionTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Opinion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in assets and liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Capital [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_MilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_MilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_MilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryCashFlowPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory, Cash Flow Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryCashFlowPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement of Cash Flows</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_CollaborationAgreementContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration agreement contractual term.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_CollaborationAgreementContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Agreement Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_CollaborationAgreementContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contractual term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_UpfrontFeeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront fee received.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_UpfrontFeeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Fee Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_UpfrontFeeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront fee received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Purchase of common stock, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentAggregateCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investment, Aggregate Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentAggregateCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment in joint venture</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_AdditionalFinancialSupport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional financial support</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_AdditionalFinancialSupport_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional financial support</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_LiquidityPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Liquidity.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_LiquidityPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liquidity Policy Policy [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_LiquidityPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liquidity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_StockIssuedDuringPeriodValueUnderEquityPlan_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period value under equity plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_StockIssuedDuringPeriodValueUnderEquityPlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Under Equity Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_StockIssuedDuringPeriodValueUnderEquityPlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock under equity plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net (loss) income before income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_ClinicalTrialAccrualsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Clinical trial accruals current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_ClinicalTrialAccrualsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Clinical Trial Accruals Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_ClinicalTrialAccrualsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Clinical trial accruals</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_ContractWithCustomerAssetAdditionsForRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract with customer asset additions for revenue recognized.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_ContractWithCustomerAssetAdditionsForRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Asset Additions For Revenue Recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_ContractWithCustomerAssetAdditionsForRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract Assets, Additions for revenue recognized from billings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_NonRareDiseaseTargetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non-rare disease targets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_NonRareDiseaseTargetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Rare Disease Targets [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_NonRareDiseaseTargetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-Rare Disease Targets [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Revenue recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deductions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability, Revenue Recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customer Concentration Risk [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer Concentration Risk [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_CysticFibrosisFoundationTherapeuticsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cystic Fibrosis Foundation Therapeutics, Inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_CysticFibrosisFoundationTherapeuticsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cystic Fibrosis Foundation Therapeutics Inc [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_CysticFibrosisFoundationTherapeuticsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cystic Fibrosis Foundation [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Exercisable - December 31, 2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_CslCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">CSL Collaboration Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_CslCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">CSL Collaboration Agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investment, Nonconsolidated Investee [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Method Investment, Nonconsolidated Investee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive Income/Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation allowance change</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerAssetNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accounts receivable, Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerAssetNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accounts receivable, Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerAssetNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Contract with Customer, Asset, after Allowance for Credit Loss, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerAssetNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Asset, after Allowance for Credit Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Option to Extend</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee, operating leases, option to extend</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_PaymentsForMatchingFundsForRemainingBudgetedCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payments for matching funds for remaining budgeted costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_PaymentsForMatchingFundsForRemainingBudgetedCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments For Matching Funds For Remaining Budgeted Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_PaymentsForMatchingFundsForRemainingBudgetedCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments for matching funds for remaining budgeted costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Acquisitions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock related to acquired in-process research and development (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Cash and Cash Equivalents and Restricted Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Share-based compensation expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_FebruaryTwoThousandAndTwentyLeaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">February two thousand and twenty lease agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_FebruaryTwoThousandAndTwentyLeaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">February Two Thousand And Twenty Lease Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_FebruaryTwoThousandAndTwentyLeaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">February 2020 Lease Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_RevenueLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_RevenueLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_RevenueLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_CSLMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CSL [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_CSLMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">CSL [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_CSLMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">CSL.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock reserved for future issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_US_lbl" xlink:role="http://www.xbrl.org/2003/role/label">UNITED STATES</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_US_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">United States [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_OptionExerciseRevenueRangePerTarget_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Option exercise revenue range per target.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_OptionExerciseRevenueRangePerTarget_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Option Exercise Revenue Range Per Target</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_OptionExerciseRevenueRangePerTarget_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option exercise revenue range per target</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash (used in) provided by operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax effect related to unrealized losses on marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares, Exercisable and expected to vest December 31, 2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_DisbursementPeriodThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disbursement period three.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_DisbursementPeriodThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disbursement Period Three [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_DisbursementPeriodThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disbursement Due July 2020 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Term of Contract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee, operating lease, term of contract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_ReservedUpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reserved upfront payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_ReservedUpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reserved Upfront Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_ReservedUpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Reserved upfront payment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxPeriodDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Period [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term of agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2028</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recurring [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_ResearchCollaborationAndExclusiveLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research Collaboration and Exclusive License Agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_ResearchCollaborationAndExclusiveLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research Collaboration And Exclusive License Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_ResearchCollaborationAndExclusiveLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research Collaboration And Exclusive License Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Deferred revenue, Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Deferred revenue, Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Contract with Customer, Liability, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">BARDA [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Biomedical Advanced Research and Development Authority [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Biomedical Advanced Research and Development Authority.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_CollaborationAgreementTransactionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration agreement transaction price.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_CollaborationAgreementTransactionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Agreement Transaction Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_CollaborationAgreementTransactionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxesPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxesPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Taxes Payable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxesPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Taxes Payable, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity-method investment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due After Year Four</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease liability payments due after year four.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of warrants for shares of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Employee-related Liabilities, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee-related Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_WellsFargoCreditAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Wells Fargo Credit Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_WellsFargoCreditAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Wells fargo credit agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_WellsFargoCreditAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Wells Fargo Credit Agreement Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Related Party Transactions By Related Party [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted stock units granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer and software [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_LoanAndSecurityAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Loan and security agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_LoanAndSecurityAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loan And Security Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_LoanAndSecurityAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan and Security Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_Early-StageProgramsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Early-Stage Programs [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_Early-StageProgramsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Early-Stage Programs [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_Early-StageProgramsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Early-Stage Programs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Shares Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Shares Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current income tax (benefit) expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Federal Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax rate reconciliation nondeductible expense officers compensation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Nondeductible Expense Officers Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Officers compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability, net of current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_PayrollAndBenefitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payroll and Benefits [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_PayrollAndBenefitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payroll and benefits.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_PayrollAndBenefitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payroll and Benefits [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerDurationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Duration [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Consideration Received Per Transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consideration received for common stock purchase</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Tax Jurisdiction [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_OptionExerciseFeeRevenueReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Option exercise fee revenue received.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_OptionExerciseFeeRevenueReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Option Exercise Fee Revenue Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_OptionExerciseFeeRevenueReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option exercise fee received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_AdjustmentsToTransactionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Adjustments to transaction price.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_AdjustmentsToTransactionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Transaction Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_AdjustmentsToTransactionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to transaction price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">SOFR [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReceivablesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Receivable [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReceivablesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net income (loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net (loss) income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net (loss) income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon exercise of stock options (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares, Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares, Exercisable December 31, 2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableRateDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Rate [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_ContractWithCustomerAssetDeductionsForCashCollections_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract with customer asset deductions for cash collections.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_ContractWithCustomerAssetDeductionsForCashCollections_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Asset Deductions For Cash Collections</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_ContractWithCustomerAssetDeductionsForCashCollections_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract Assets, Deductions for cash collections</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Financial Statement Error Correction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Financial Statement Error Correction [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">General and administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_NumberOfBusinessSegment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Business Segment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_NumberOfBusinessSegment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of business segment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_NumberOfBusinessSegment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of business segment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_UltragenyxMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Ultragenyx.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_UltragenyxMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Ultragenyx [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_UltragenyxMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ultragenyx [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_DevelopmentAndOptionAgreementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Development and option agreement date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_DevelopmentAndOptionAgreementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Development And Option Agreement Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_DevelopmentAndOptionAgreementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development and option agreement date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Nonoperating Income (Expense), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance income (expense), net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred State and Local Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share options expiration period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Furniture and Fixtures [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office equipment and furniture [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation of Revenue [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disaggregation Of Revenue [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_ConcentrationRiskNumberOfCustomer_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Concentration risk number of customer.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_ConcentrationRiskNumberOfCustomer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Number Of Customer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_ConcentrationRiskNumberOfCustomer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of customers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes Integrated [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_AdditionalPaymentsUponMeetingCertainClinicalMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional payments upon meeting certain clinical milestones.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_AdditionalPaymentsUponMeetingCertainClinicalMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Payments upon Meeting Certain Clinical Milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_AdditionalPaymentsUponMeetingCertainClinicalMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional payments upon meeting certain clinical milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Revenue, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercise of stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_ContraExpenseRemainingAmountIncludedInAccruedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contra expense remaining amount included in accrued expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_ContraExpenseRemainingAmountIncludedInAccruedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contra Expense Remaining Amount Included In Accrued Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_ContraExpenseRemainingAmountIncludedInAccruedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contra expense remaining amount included in accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash - current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Revenue, Noncurrent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue, net of current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price, Exercisable and expected to vest -December 31, 2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price, Forfeited/cancelled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Non-current Restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-current restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Other comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cumulative Effect, Period of Adoption, Adjustment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cumulative Effect, Period of Adoption, Adjustment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive (loss) income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Shares, Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Shares, Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility, Current Borrowing Capacity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revolving credit line available</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Reconciliation of Income Tax (Benefit) Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_SGIMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">SGI.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_SGIMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">S G I [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_SGIMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">SGI [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Benchmark [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_OctoberTwoThousandAndSeventeenLeaseAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">October 2017 lease amendment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_OctoberTwoThousandAndSeventeenLeaseAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">October Two Thousand And Seventeen Lease Amendment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_OctoberTwoThousandAndSeventeenLeaseAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">October 2017 Lease Amendment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermContractWithCustomerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Contract with Customer [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_SummaryOfSignificantAccountingPolicyLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policy.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_SummaryOfSignificantAccountingPolicyLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policy [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_SummaryOfSignificantAccountingPolicyLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policy [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Foreign Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Restricted Stock Unit, Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_WesternAllianceBankMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Western Alliance Bank.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_WesternAllianceBankMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Western Alliance Bank [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_WesternAllianceBankMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Western Alliance Bank [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_OptionToPurchaseOfAdditionalSharesOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Option to purchase of additional shares of common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_OptionToPurchaseOfAdditionalSharesOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Option To Purchase Of Additional Shares Of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_OptionToPurchaseOfAdditionalSharesOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase of additional shares of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_DisbursementPeriodTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disbursement period two.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_DisbursementPeriodTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disbursement Period Two [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_DisbursementPeriodTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disbursement Due April 2020 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_FacilitiesAndEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Facilities and Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_FacilitiesAndEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Facilities and equipment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_FacilitiesAndEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Facilities and Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents and restricted cash, end of year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents and restricted cash, beginning of year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents, including restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total cash, cash equivalents and restricted cash shown in the statement of cash flows</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transactions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research Tax Credit Carryforward [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research Tax Credit Carryforward [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets property, plant and equipment and intangible assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Property Plant And Equipment And Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_Covid19VaccineMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">COVID-19 Vaccine [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_Covid19VaccineMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">COVID-19 vaccine.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_OtherMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Other.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_OtherMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_OtherMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Settlement of prior period tax positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_UnderwrittenPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Underwritten public offering.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_UnderwrittenPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Underwritten Public Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_UnderwrittenPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwritten Public Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Assets, Fair Value Disclosure, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets, fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related and Nonrelated Parties [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation of Revenue [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments of Operating Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_IncomeTaxesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income taxes.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_IncomeTaxesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_IncomeTaxesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_RareDiseaseTargetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Rare disease targets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_RareDiseaseTargetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Rare Disease Targets [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_RareDiseaseTargetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rare Disease Targets [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares available</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average remaining service period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyNatureDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingency, Nature [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_RevenueRecognitionPotentialMilestoneRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue recognition potential milestone revenue recognized.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_RevenueRecognitionPotentialMilestoneRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Recognition Potential Milestone Revenue Recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_RevenueRecognitionPotentialMilestoneRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue recognition potential milestone revenue recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_DevelopmentMilestonesAmountDueForAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development milestones due</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_DevelopmentMilestonesAmountDueForAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Development Milestones Amount Due for Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_DevelopmentMilestonesAmountDueForAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Development milestones amount due for agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Costs, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Income Location, Balance [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_TwentyTwentyOneInducementEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">2021 Inducement equity incentive plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_TwentyTwentyOneInducementEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Twenty Twenty One Inducement Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_TwentyTwentyOneInducementEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 Inducement Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_EligibleToReceiveDevelopmentMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Eligible to receive development milestone payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_EligibleToReceiveDevelopmentMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Eligible to Receive Development Milestone Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_EligibleToReceiveDevelopmentMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Eligible to Receive Development Milestone Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentOwnedBalanceShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Owned, Balance, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentOwnedBalanceShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares owned</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_GrantRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total grant revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_GrantRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Grant Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_GrantRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Grant revenue.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected life (in years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxPeriodAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Period [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Long-Term Debt Instruments [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Foreign Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total gross deferred tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total gross deferred tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Adopted Accounting Pronouncements and Recently Issued Accounting Standards Not Yet Adopted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Equity Method Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Loss from equity-method investment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Loss from equity-method investment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementBusinessSegmentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segments [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Maturities of Long-Term Debt [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Maturities of Long-term Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_DeferredTaxLiabilitiesPropertyPlantAndEquipmentAndIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets property, plant and equipment and intangible assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_DeferredTaxLiabilitiesPropertyPlantAndEquipmentAndIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Property Plant And Equipment And Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_DeferredTaxLiabilitiesPropertyPlantAndEquipmentAndIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Depreciation and amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_DevelopmentMilestonesReceivedAdvancePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development milestones received advance payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_DevelopmentMilestonesReceivedAdvancePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Development milestones received advance payment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_DevelopmentMilestonesReceivedAdvancePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Development Milestones Received Advance Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Share-based Compensation Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_EffectiveIncomeTaxRateReconciliationUncertainTaxPosition_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax rate reconciliation uncertain tax position.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_EffectiveIncomeTaxRateReconciliationUncertainTaxPosition_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Uncertain Tax Position</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_EffectiveIncomeTaxRateReconciliationUncertainTaxPosition_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Uncertain tax position</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Face Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term Debt [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_PotentialTargetLicenseTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Potential target license term.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_PotentialTargetLicenseTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Potential Target License Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_PotentialTargetLicenseTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Potential target license term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Remaining Contractual Term (Years), Exercisable and expected to vest - December 31, 2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_ManufacturingAndSupplyOfArct154DrugProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">manufacturing and supply of ARCT-154 drug product.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_ManufacturingAndSupplyOfArct154DrugProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Manufacturing and Supply of ARCT-154 Drug Product [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_NumberOfReservedVaccineDoses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of reserved vaccine doses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_NumberOfReservedVaccineDoses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Reserved Vaccine Doses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_NumberOfReservedVaccineDoses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of reserved vaccine doses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_PreLaunchInventoryPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pre-launch inventory policy.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_PreLaunchInventoryPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre Launch Inventory Policy Policy [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_PreLaunchInventoryPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-Launch Inventory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Private Placement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Private Placement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-Based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Construction in Progress [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Construction in progress [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation number of shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued liabilities paid upon occurrence of specified events</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_AchievedDevelopmentMilestoneIncludedAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Achieved development milestone included accounts receivable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_AchievedDevelopmentMilestoneIncludedAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Achieved development milestone included accounts receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_AchievedDevelopmentMilestoneIncludedAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Achieved development milestone included accounts receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current State and Local Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average discount rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant Revenue [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Grant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_UpfrontPaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront payment received.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_UpfrontPaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Payment Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_UpfrontPaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront payment received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon exercise of stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseContractualTermAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Contractual Term [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts Receivable [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes Paid, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income Taxes Paid, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_TaxCreditCarryforwardExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax credit carryforward expiration year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_TaxCreditCarryforwardExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Expiration Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_TaxCreditCarryforwardExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit Carryforward Expiration Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_RevenueTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_RevenueTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_RevenueTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_UnvestedRestrictedOrdinarySharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unvested restricted ordinary shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_UnvestedRestrictedOrdinarySharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unvested Restricted Ordinary Shares [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_UnvestedRestrictedOrdinarySharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unvested Restricted Ordinary Shares [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, at Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_CollaborationAgreementConsiderationReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration agreement consideration received.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_CollaborationAgreementConsiderationReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Agreement Consideration Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_CollaborationAgreementConsiderationReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consideration received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2029</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management, Strategy, and Governance [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerDurationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Duration [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_ADAIRTechnologyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">ADAIR Technology.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_ADAIRTechnologyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">A D A I R Technology [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_ADAIRTechnologyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ADAIR Technology [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_SeqirusAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Seqirus Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_SeqirusAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Seqirus Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_SeqirusAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Seqirus Agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">The total intrinsic value of options exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Total research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_FebruaryTwoThousandAndTwentyOneLeaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">February two thousand and twenty one lease agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_FebruaryTwoThousandAndTwentyOneLeaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">February Two Thousand And Twenty One Lease Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_FebruaryTwoThousandAndTwentyOneLeaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">February 2021 Lease Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_CA_lbl" xlink:role="http://www.xbrl.org/2003/role/label">CALIFORNIA</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_CA_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">California [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_RecognizedContraExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Recognized contra expense.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_RecognizedContraExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Recognized Contra Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_RecognizedContraExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contra expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_BARDAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">BARDA [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_BARDAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">BARDA.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_BARDAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">BARDA [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_ContraResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contra research and development expense.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_ContraResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contra Research And Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_ContraResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contra research and development expense recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_ResearchCollaborationAndLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research collaboration and license agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_ResearchCollaborationAndLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research Collaboration And License Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_ResearchCollaborationAndLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research Collaboration And License Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Gross, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Gross, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Gross, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_AdditionalClinicalMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional clinical milestone payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_AdditionalClinicalMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional clinical milestone payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation and Principles of Consolidation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_NumberOfPerformanceObligations_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of performance obligations.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_NumberOfPerformanceObligations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Performance Obligations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_NumberOfPerformanceObligations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of performance obligations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_ContractWithCustomerLiabilityAdditions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_ContractWithCustomerLiabilityAdditions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Additions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_ContractWithCustomerLiabilityAdditions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract with customer liability additions.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Leases [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Weighted Average Assumptions Used in Black -Scholes Valuation Model</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForProceedsFromTenantAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments for (Proceeds from) Tenant Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForProceedsFromTenantAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tenant improvement allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_KeithCKummerfeldMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Keith C. Kummerfeld [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_KeithCKummerfeldMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Keith C. Kummerfeld.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_KeithCKummerfeldMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Keith C. Kummerfeld [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentCollateralAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Collateral Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentCollateralAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument, collateral amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining research period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_AgreementAmountAgreedToFund_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Agreement amount agreed to fund.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_AgreementAmountAgreedToFund_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Agreement Amount Agreed To Fund</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_AgreementAmountAgreedToFund_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount agreed to fund</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Comprehensive Income [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reconciliation of Federal Statutory Income Tax Rate to Company's Effective Income Tax Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management, Strategy, and Governance [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate202307Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2023-07 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate202307Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2023-07 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_GrantOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Grant one.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_GrantOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Grant One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_GrantOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant 1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_VinbiocareContractualLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vinbiocare contractual liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_VinbiocareContractualLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vinbiocare Contractual Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_VinbiocareContractualLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Vinbiocare contractual liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Depletion and Amortization, Nonproduction, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation, Depletion and Amortization, Nonproduction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_UpfrontConsiderationReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront consideration received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_UpfrontConsiderationReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Consideration Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_UpfrontConsiderationReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront consideration received.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_NumberOfReserveTargets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of reserve targets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_NumberOfReserveTargets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Reserve Targets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_NumberOfReserveTargets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of targets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and Stockholders' Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_CureVacAGMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">CureVac AG.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_CureVacAGMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cure Vac A G [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_CureVacAGMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CureVac [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by (used in) financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_AlexionPharmaceuticalsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Alexion Pharmaceuticals, Inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_AlexionPharmaceuticalsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Alexion Pharmaceuticals Inc [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_AlexionPharmaceuticalsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Alexion [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ICFR Auditor Attestation Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ICFR Auditor Attestation Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Provision for income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive securities excluded from computation of earnings per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_GrantRevenueOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant revenue outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_GrantRevenueOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Grant Revenue Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_GrantRevenueOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Grant revenue outstanding.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_UpfrontFeeAndConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront fee/consideration.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_UpfrontFeeAndConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Fee And Consideration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_UpfrontFeeAndConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront fee/consideration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investment, Ownership Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity method ownership percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total income tax (benefit) expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">(Benefit) provision for income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_NotSubjectToExpirationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Not Subject to Expiration [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_NotSubjectToExpirationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Not subject to expiration.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_MaximumPercentageOfLikelihoodOfUncertainTaxPositionRecognizedToBeSustained_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum percentage of likelihood of uncertain tax position recognized to be sustained.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_MaximumPercentageOfLikelihoodOfUncertainTaxPositionRecognizedToBeSustained_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Percentage Of Likelihood Of Uncertain Tax Position Recognized To Be Sustained</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_MaximumPercentageOfLikelihoodOfUncertainTaxPositionRecognizedToBeSustained_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum percentage of likelihood of uncertain tax position recognized to be sustained</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_VallonPharmaceuticalsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Vallon Pharmaceuticals, Inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_VallonPharmaceuticalsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vallon Pharmaceuticals Inc [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_VallonPharmaceuticalsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vallon Pharmaceuticals, Inc. [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableRateAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Rate [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders&#8217; equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_UnrecognizedTaxBenefitsDecreasesIncreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Decrease for prior period tax positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_UnrecognizedTaxBenefitsDecreasesIncreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Decrease for prior period tax positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_UnrecognizedTaxBenefitsDecreasesIncreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unrecognized tax benefits (decreases) increases resulting from prior period tax positions.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_UnrecognizedTaxBenefitsDecreasesIncreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Decreases Increases Resulting From Prior Period Tax Positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_UnrecognizedTaxBenefitsDecreasesIncreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">(Decrease) increase for prior period tax positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total gross deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireInterestInJointVenture_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Interest in Joint Venture</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireInterestInJointVenture_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash consideration paid for equity interest in joint venture</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other non-current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-Based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units (RSUs) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Units [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity method investment, sale of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Number of Shares Issued in Transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management, Strategy, and Governance [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Adopted [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, accounting standards update, adopted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Compensation cost not yet recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_MinimumAmountAgreedToIncurUnderResearchPlan_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum amount agreed to incur under research plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_MinimumAmountAgreedToIncurUnderResearchPlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum Amount Agreed to Incur Under Research Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_MinimumAmountAgreedToIncurUnderResearchPlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum amount agreed to incur under research plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_MonthlyBaseRent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Monthly base rent.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_MonthlyBaseRent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Monthly Base Rent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_MonthlyBaseRent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Monthly base rent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentOwnedPercentOfNetAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Owned, Net Assets, Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentOwnedPercentOfNetAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of owned shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SecurityDeposit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Deposit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SecurityDeposit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security deposit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred income tax expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_LackOfMarketabilityDiscountRestrictedPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lack of marketability discount restricted period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_LackOfMarketabilityDiscountRestrictedPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lack Of Marketability Discount Restricted Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_LackOfMarketabilityDiscountRestrictedPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lack of marketability discount restricted period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Exercisable and expected to vest - December 31, 2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_OtherAccruedResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Other accrued research and development expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_OtherAccruedResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Research And Development Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_OtherAccruedResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other accrued research and development expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration risk, percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementScenarioAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementScenarioAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scenario</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Changes in Balances of Receivables and Contract Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Tax Credit Carryforwards, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Credit Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cumulative Effect, Period of Adoption [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cumulative Effect, Period of Adoption</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Issued for Services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock issued, value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingenciesByNatureOfContingencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingency Nature [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less accumulated depreciation and amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Interest Expense, Long-Term Debt, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense, Long-Term Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest expense related to long-term debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_DisbursementPeriodFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disbursement period four.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_DisbursementPeriodFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disbursement Period Four [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_DisbursementPeriodFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disbursement Due October 2020 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant date weighted average fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_IL_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ILLINOIS</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_IL_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Israeli Ministry of Health ("MOH") [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders&#8217; equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gain (Loss) on Extinguishment of Debt, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain (Loss) on Extinguishment of Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gain on debt extinguishment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gain on debt extinguishment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use asset, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosure of cash flow information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold improvements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_ContractWithCustomerAssetAdditions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_ContractWithCustomerAssetAdditions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Asset Additions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_ContractWithCustomerAssetAdditions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract with customer asset additions.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Dividends_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Dividends, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Dividends_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Dividends</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Dividends_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividends declared or paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits [Roll Forward]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_DebtInstrumentOptionForRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument option for renewal term.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_DebtInstrumentOptionForRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Option for Renewal Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_DebtInstrumentOptionForRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option for renewal term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BorrowingsUnderGuaranteedInvestmentAgreements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Borrowings under Guaranteed Investment Agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BorrowingsUnderGuaranteedInvestmentAgreements_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term loan draw down</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_ConditionalPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conditional payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_ConditionalPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conditional Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_ConditionalPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Conditional payment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_NetOperatingLossAndResearchAndDevelopmentCreditCarryforwardsLimitationsOnCumulativeChangeInOwnershipPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net operating loss and research and development credit carryforwards limitations on cumulative change in ownership period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_NetOperatingLossAndResearchAndDevelopmentCreditCarryforwardsLimitationsOnCumulativeChangeInOwnershipPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Operating Loss And Research And Development Credit Carryforwards Limitations On Cumulative Change In Ownership Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_NetOperatingLossAndResearchAndDevelopmentCreditCarryforwardsLimitationsOnCumulativeChangeInOwnershipPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Operating Loss and Research and Development Credit Carryforwards Limitations on Cumulative Change In Ownership Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_DevelopmentMilestonesAchieved_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development milestones achieved</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_DevelopmentMilestonesAchieved_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Development milestones achieved.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_DevelopmentMilestonesAchieved_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Development Milestones Achieved</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioForecastMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Forecast [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock, net of issuance costs (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance of unrecognized tax benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance of unrecognized tax benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized Tax Benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_TwoThousandTwentyEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand Twenty Employee Stock Purchase Plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_TwoThousandTwentyEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Employee Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_TwoThousandTwentyEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Employee Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_ReversalOfRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reversal of revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_ReversalOfRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reversal of Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_ReversalOfRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Reversal of revenue.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_OrphanDrugCreditMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Orphan drug credit.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_OrphanDrugCreditMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Orphan Drug Credit [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_OrphanDrugCreditMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Orphan Drug Credit [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_RemainingLoanIncludingAccruedInterestForgiveable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining loan including accrued interest forgiveable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_RemainingLoanIncludingAccruedInterestForgiveable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Remaining Loan Including Accrued Interest Forgiveable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_RemainingLoanIncludingAccruedInterestForgiveable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Remaining loan including accrued interest forgiveable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized tax benefits impacting effective tax rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_OrganizationAndSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization and significant accounting policies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_OrganizationAndSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization And Significant Accounting Policies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_OrganizationAndSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization And Significant Accounting Policies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_PercentageOfEquityInterestInJointVenture_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of equity interest in joint venture.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_PercentageOfEquityInterestInJointVenture_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Equity Interest In Joint Venture</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_PercentageOfEquityInterestInJointVenture_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of equity interest in joint venture</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForAdvanceToAffiliate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments for Advance to Affiliate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForAdvanceToAffiliate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments for advance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of options vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: imputed interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-Based Payment Arrangement, Noncash Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_PercentageOfNetProfits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net profits percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_PercentageOfNetProfits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Net Profits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_PercentageOfNetProfits_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of net profits.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_VinbiocareAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Vinbiocare agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_VinbiocareAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vinbiocare Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_VinbiocareAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vinbiocare Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related and Nonrelated Parties [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_LanceKurataMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lance Kurata [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_LanceKurataMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lance Kurata.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFeeAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fee payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFeeAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Fee Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_SG_lbl" xlink:role="http://www.xbrl.org/2003/role/label">SINGAPORE</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_SG_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Singapore Economic Development Board [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_SG_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Singapore Loan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_OrganizationAndSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization and significant accounting policies line items.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_OrganizationAndSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization And Significant Accounting Policies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_OrganizationAndSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization And Significant Accounting Policies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Maturity Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan maturity date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_DeferredTaxAssetsRightOfUseLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_DeferredTaxAssetsRightOfUseLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Right-of-use Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_DeferredTaxAssetsRightOfUseLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets right-of-use lease liability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_LUNARCFMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">LUNAR-CF.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_LUNARCFMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">L U N A R C F [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_LUNARCFMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">LUNAR-CF [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_AcquiredInProcessResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Acquired In Process Research And Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_AcquiredInProcessResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Acquired In Process Research And Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_AcquiredInProcessResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquired in-process research and development expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_AcquiredInProcessResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Non-cash charge recorded in acquired in-process research and development expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_DevelopmentAndRegulatoryMilestonesAchieved_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Development and Regulatory Milestones Achieved</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_DevelopmentAndRegulatoryMilestonesAchieved_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Development and regulatory milestones achieved.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_DevelopmentAndRegulatoryMilestonesAchieved_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development and regulatory milestones achieved</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Useful Life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, useful lives</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_ReductionInNumberOfCommonStockCapitalSharesAvailableForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reduction in number of common stock shares available for future issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_ReductionInNumberOfCommonStockCapitalSharesAvailableForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reduction in Number of Common Stock Capital Shares Available for Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_ReductionInNumberOfCommonStockCapitalSharesAvailableForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Reduction in number of common stock capital shares available for future issuance.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Research and Development Credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax rate reconciliation research and development credits.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investment, Nonconsolidated Investee [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Method Investment, Nonconsolidated Investee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated by Reference [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents incorporated by reference</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_AdditionalMilestonePaymentsReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional milestone payments received.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_AdditionalMilestonePaymentsReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Milestone Payments Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_AdditionalMilestonePaymentsReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional milestone payments received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Remaining Contractual Term (Years), Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net (Loss) Income per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_PhaseIClinicalStudyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Phase I clinical study.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_PhaseIClinicalStudyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Phase I Clinical Study [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_PhaseIClinicalStudyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Phase I Clinical Study [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_TwoThousandNineteenOmnibusIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand nineteen omnibus incentive plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_TwoThousandNineteenOmnibusIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Nineteen Omnibus Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_TwoThousandNineteenOmnibusIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 Omnibus Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_PharmaceuticalCompanyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pharmaceutical company.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_PharmaceuticalCompanyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pharmaceutical Company [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_PharmaceuticalCompanyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pharmaceutical Company [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyLeaseGuaranteeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Lease Guarantee [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyLeaseGuaranteeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Leases in San Diego [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill, Impairment Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_EligibleToReceiveCommercialMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Eligible to receive commercial milestone payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_EligibleToReceiveCommercialMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Eligible to Receive Commercial Milestone Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_EligibleToReceiveCommercialMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Eligible to receive commercial milestone payment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Acquisitions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock related to acquired in-process research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Role of Management [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_IsraelMinistryOfHealthMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Israel Ministry of Health [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_IsraelMinistryOfHealthMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Israel Ministry of Health [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_IsraelMinistryOfHealthMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Israel ministry of health.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_NetOperatingLossAndResearchAndDevelopmentCreditCarryforwardsLimitationsOnCumulativeChangeInOwnershipMinimumPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net operating loss and research and development credit carryforwards limitations on cumulative change in ownership minimum percentage.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_NetOperatingLossAndResearchAndDevelopmentCreditCarryforwardsLimitationsOnCumulativeChangeInOwnershipMinimumPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Operating Loss And Research And Development Credit Carryforwards Limitations On Cumulative Change In Ownership Minimum Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_NetOperatingLossAndResearchAndDevelopmentCreditCarryforwardsLimitationsOnCumulativeChangeInOwnershipMinimumPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Operating Loss and Research and Development Credit Carryforwards Limitations On Cumulative Change In Ownership Minimum Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Share Option Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_IncomeTaxesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income taxes.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_IncomeTaxesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_IncomeTaxesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase for current period tax positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_DeferredTaxAssetsCapitalizedResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized R&amp;D</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_DeferredTaxAssetsCapitalizedResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Capitalized Research and Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_DeferredTaxAssetsCapitalizedResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets capitalized research and development.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&#8217; equity:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Components of Property and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_StudySupportAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Study Support Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_StudySupportAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Study Support Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_StudySupportAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Study support agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_DrPadmanabhChivukulaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Dr. Padmanabh Chivukula [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_DrPadmanabhChivukulaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Dr. Padmanabh Chivukula.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_DrPadmanabhChivukulaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dr. Padmanabh Chivukula [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net (decrease) increase in cash, cash equivalents and restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">(Loss) earnings per share:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State income taxes, net of federal benefit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseContractualTermDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Contractual Term [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">(Loss) income from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Interest Rate, Effective Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan accrues interest rate per annum, percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_UpfrontPaymentToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront payment to be received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_UpfrontPaymentToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Payment to be Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_UpfrontPaymentToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront payment to be received.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_ContractWithCustomerAssetDeductions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Asset Deductions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_ContractWithCustomerAssetDeductions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract with customer asset deductions.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_ContractWithCustomerAssetDeductions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deductions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenuePracticalExpedientRemainingPerformanceObligationDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue, Practical Expedient, Remaining Performance Obligation, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenuePracticalExpedientRemainingPerformanceObligationDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue, practical expedient description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Remaining Contractual Term (Years), Exercisable - December 31, 2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility, Interest Rate During Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loans interest rate, percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term Debt, Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Deferred revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Contract with Customer, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_PaymentReceivedFirstInstallment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment received first installment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_PaymentReceivedFirstInstallment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment Received First Installment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_PaymentReceivedFirstInstallment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Received first installment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Adoption Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, accounting standards update, adoption date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repayment of term loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repayments of Long-Term Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Repayments of Long-Term Debt, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase of property and equipment in accounts payable and accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capital Expenditures Incurred but Not yet Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Reconciliation of Unrecognized Tax Benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit Carryforward Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_FinalPaymentOfDisbursementAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Final payment of disbursement amount.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_FinalPaymentOfDisbursementAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Final Payment Of Disbursement Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_FinalPaymentOfDisbursementAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Final payment of disbursement amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_OptionToExtendInitialTermOnAnAnnualBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Option to extend initial term on an annual basis.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_OptionToExtendInitialTermOnAnAnnualBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Option To Extend Initial Term On An Annual Basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_OptionToExtendInitialTermOnAnAnnualBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option to extend initial term on an annual basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal statutory income tax rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_CslSeqirusMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CSL Seqirus [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_CslSeqirusMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">CSL Seqirus [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_CslSeqirusMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">CSL seqirus.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_CommitmentAndContingenciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitment and contingencies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_CommitmentAndContingenciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitment And Contingencies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_CommitmentAndContingenciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitment And Contingencies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseImpairmentLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Impairment Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseImpairmentLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Additional Paid in Capital, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Jurisdiction [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_NonRefundablePaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non-refundable payment received.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_NonRefundablePaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Refundable Payment Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_NonRefundablePaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-refundable payment received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GrantsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Grants Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GrantsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grants Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_MRNATechnologyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">mRNA technology.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_MRNATechnologyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">M R N A Technology [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_MRNATechnologyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">mRNA Technology [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Reconciliation of (Loss) Income Before Income Taxes for Domestic and Foreign Locations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Permanent differences</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Other Permanent Differences</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax rate reconciliation other permanent differences.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Components of Deferred Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current portion of operating lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermContractWithCustomerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Term Contract with Customer [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermContractWithCustomerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Contract with Customer [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Jurisdiction [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Acquisition of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of summary of significant accounting policies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Summary Of Significant Accounting Policies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Summary Of Significant Accounting Policies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_AchievedDevelopmentAndRegulatoryMilestoneIncludedAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Achieved development and regulatory milestone included accounts receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_AchievedDevelopmentAndRegulatoryMilestoneIncludedAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Achieved Development and Regulatory Milestone Included Accounts Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_AchievedDevelopmentAndRegulatoryMilestoneIncludedAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Achieved development and regulatory milestone included accounts receivable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_LUNAR-CFNetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">LUNAR-CF, Net [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_LUNAR-CFNetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">LUNAR-CF, net.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_LUNAR-CFNetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">LUNAR-CF, Net [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Stock Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock under equity plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price, Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_PrepaidExpensesAndOtherReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer. as well as trade accounts receivable, notes and loans receivable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_PrepaidExpensesAndOtherReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expenses And Other Receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_PrepaidExpensesAndOtherReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_ExpirationOfIntialTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Expiration of initial term.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_ExpirationOfIntialTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Expiration Of Intial Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_ExpirationOfIntialTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expiration of initial term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration of Credit Risk and Significant Customers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Firm ID</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restricted Cash, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Liabilities Detail</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment, Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment, Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted- Average Grant Date Fair Value, Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted- Average Grant Date Fair Value, Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-In Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_DirectorsOrOfficersExceptChiefScientificOfficerCooSvpCcAndPaoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Directors Or Officers Except Chief Scientific Officer, Coo, Svp, CC and Pao [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_DirectorsOrOfficersExceptChiefScientificOfficerCooSvpCcAndPaoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Directors or officers except chief scientific officer, coo, svp, cc and pao.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_DirectorsOrOfficersExceptChiefScientificOfficerCooSvpCcAndPaoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Directors or Officers Except Chief Scientific Officer, COO, SVP, CC and PAO [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_CollaborationRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Revenue [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_CollaborationRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration revenue.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Income Location, Balance [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsEquityMethodInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Equity Method Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsEquityMethodInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis difference in equity investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Description and Accounting Policies [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_DisbursedAmountUponExecutionOfAmendment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disbursed amount upon execution of amendment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_DisbursedAmountUponExecutionOfAmendment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disbursed Amount Upon Execution Of Amendment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_DisbursedAmountUponExecutionOfAmendment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disbursed amount upon execution of amendment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossRealized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Realized Gain (Loss), Foreign Currency Transaction, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossRealized_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Foreign currency transaction loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_UnderlyingAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Underlying agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_UnderlyingAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Underlying Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_UnderlyingAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underlying Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation of Revenue [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disaggregation Of Revenue [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_NonCashAssetDisposal_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash asset disposal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_NonCashAssetDisposal_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non - Cash Asset Disposal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_NonCashAssetDisposal_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non-Cash Asset Disposal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_JointVenturesEquityMethodInvestmentsAndVariableInterestEntitiesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Joint ventures, equity method investments and variable interest entities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_JointVenturesEquityMethodInvestmentsAndVariableInterestEntitiesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Joint Ventures Equity Method Investments And Variable Interest Entities Policy [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_JointVenturesEquityMethodInvestmentsAndVariableInterestEntitiesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Joint Ventures, Equity Method Investments and Variable Interest Entities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scenario</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_StockIssuedDuringPeriodSharesUnderEquityPlan_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares under equity plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_StockIssuedDuringPeriodSharesUnderEquityPlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Under Equity Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_StockIssuedDuringPeriodSharesUnderEquityPlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock under equity plans (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title and Position [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">United States</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock: $0.001 par value; 60,000 shares authorized; issued and outstanding shares were 27,000 at December 31, 2024 and 26,828 at December 31, 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_LegalAccrualCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legal accrual</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_LegalAccrualCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Legal Accrual Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_LegalAccrualCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Legal accrual current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_DebtInstrumentExtendedTermPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Extended Term Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_DebtInstrumentExtendedTermPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument, extended term period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_DebtInstrumentExtendedTermPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Extended term period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Lease, Liability, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accrued Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Operating Loss Carryforwards, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_DisbursementPaymentUponAchievementOfRequiredManufacturingPracticesAndINDApplication_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disbursement payment upon achievement of required manufacturing practices and IND application.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_DisbursementPaymentUponAchievementOfRequiredManufacturingPracticesAndINDApplication_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disbursement Payment Upon Achievement Of Required Manufacturing Practices And I N D Application</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_DisbursementPaymentUponAchievementOfRequiredManufacturingPracticesAndINDApplication_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disbursement payment upon achievement of required manufacturing practices and IND application</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Reported Segment Revenues, Segment Loss and Income, and Significant Segment Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Receivable, after Allowance for Credit Loss, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Renewal Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease extended additional term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total remaining lease payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Third Party Engaged [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average shares used in calculation of (loss) earnings per share:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Benchmark [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk Benchmark</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Information [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Floating interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Basis Spread on Variable Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest of the prime rate plus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_SeqirusIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Seqirus Inc [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_SeqirusIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Seqirus, Inc [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_SeqirusIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Seqirus, Inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_LUNAR-COVIDMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">LUNAR-COVID [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_LUNAR-COVIDMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">LUNAR-COVID.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_LUNAR-COVIDMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">LUNAR-COVID [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repayments of Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payments on debt obligations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_ContractWithCustomerLiabilityAdditionsForAdvancedBillings_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract With Customer Liability Additions For Advanced Billings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_ContractWithCustomerLiabilityAdditionsForAdvancedBillings_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Additions For Advanced Billings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_ContractWithCustomerLiabilityAdditionsForAdvancedBillings_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract Liabilities, Additions for advanced billings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foreign currency transaction (loss) gain</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Foreign Currency Transaction Gain (Loss), before Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign currency transaction gain</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Loss from foreign currency</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_AcquisitionOfResearchAndDevelopmentInProcessThroughIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Acquisition of research and development in process through issuance of common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_AcquisitionOfResearchAndDevelopmentInProcessThroughIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Acquisition Of Research And Development In Process Through Issuance Of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_AcquisitionOfResearchAndDevelopmentInProcessThroughIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquisition of in-process research and development through issuance of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_GrantReceivableNumberOfInstallments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Grant receivable number of installments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_GrantReceivableNumberOfInstallments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Grant Receivable Number Of Installments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_GrantReceivableNumberOfInstallments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant, number of installments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_DisbursementPeriodOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disbursement period one.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_DisbursementPeriodOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disbursement Period One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_DisbursementPeriodOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disbursement Due January 2020 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_DisbursementAmountPayableUponAchievementOfProjectGoal_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disbursement amount payable upon achievement of project goal.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_DisbursementAmountPayableUponAchievementOfProjectGoal_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disbursement Amount Payable Upon Achievement Of Project Goal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_DisbursementAmountPayableUponAchievementOfProjectGoal_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disbursement amount payable upon achievement of project goal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted-Average Exercise Price, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted-Average Exercise Price, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201912Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2019-12 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201912Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2019-12 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_GrantTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Grant two.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_GrantTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Grant Two [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_GrantTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant 2 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State and Local Jurisdiction [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use assets acquired through operating leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityCommitmentFeePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility, Commitment Fee Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityCommitmentFeePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-refundable commitment fee, percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_AccruedCysticFibrosisFoundationLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued cystic fibrosis foundation liability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_AccruedCysticFibrosisFoundationLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Cystic Fibrosis Foundation Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_AccruedCysticFibrosisFoundationLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cystic Fibrosis Foundation liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditConcentrationRiskMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Credit Concentration Risk [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditConcentrationRiskMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit Risk [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_OtherCollaborationAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Other collaboration agreements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_OtherCollaborationAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Collaboration Agreements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_OtherCollaborationAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Collaboration Agreements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Remaining Lease Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average remaining lease term (in years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_GriBioIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">GRI Bio Inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_GriBioIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">GRI Bio Inc Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="arct_GriBioIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">GRI Bio [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accrued Liabilities, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accounts Receivable, Allowance for Credit Loss, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accounts Receivable, Allowance for Credit Loss, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable, Allowance for Credit Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Allowance for Doubtful Accounts Receivable</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_RevenueRecognitionReserveTargetExclusivityPeriod" xlink:to="arct_RevenueRecognitionReserveTargetExclusivityPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_ForeignCountriesMember" xlink:to="arct_ForeignCountriesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligation" xlink:to="us-gaap_RevenueRemainingPerformanceObligation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_ContraExpenseIncludedInResearchAndDevelopmentExpense" xlink:to="arct_ContraExpenseIncludedInResearchAndDevelopmentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_VinbiocareMember" xlink:to="arct_VinbiocareMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_SeptemberTwoThousandAndTwentyOneLeaseAgreementMember" xlink:to="arct_SeptemberTwoThousandAndTwentyOneLeaseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_COVIDNineteenVaccineDevelopmentMember" xlink:to="arct_COVIDNineteenVaccineDevelopmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_DiscoveryTechnologiesMember" xlink:to="arct_DiscoveryTechnologiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNoncashIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInventory" xlink:to="us-gaap_DeferredTaxAssetsInventory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_EmployeesAndOfficersMember" xlink:to="arct_EmployeesAndOfficersMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_IncreaseDecreaseOperatingLeaseRightOfUseAsset" xlink:to="arct_IncreaseDecreaseOperatingLeaseRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingOtherItemAmount" xlink:to="us-gaap_SegmentReportingOtherItemAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtCurrent" xlink:to="us-gaap_LongTermDebtCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_DeferredTaxLiabilitiesRightOfUseAsset" xlink:to="arct_DeferredTaxLiabilitiesRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_CollaborationPartnerCureVacEnteredIntoCoDevelopmentAgreementMember" xlink:to="arct_CollaborationPartnerCureVacEnteredIntoCoDevelopmentAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="srt_EquityMethodInvesteeNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_RoyaltyPaymentTermDescription" xlink:to="arct_RoyaltyPaymentTermDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_RepyamentOfPrincipalAndInterestOnCollateralizedTermLoan" xlink:to="arct_RepyamentOfPrincipalAndInterestOnCollateralizedTermLoan_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_OperatingLossCarryforwardsExpirationYear" xlink:to="arct_OperatingLossCarryforwardsExpirationYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_JanssenMember" xlink:to="arct_JanssenMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_CommitmentAndContingenciesLineItems" xlink:to="arct_CommitmentAndContingenciesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_OptionToPurchaseOfAdditionalSharesOfCommonStockPricePerShare" xlink:to="arct_OptionToPurchaseOfAdditionalSharesOfCommonStockPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_GeneralAndAdministrativeCostsPolicyPolicyTextBlock" xlink:to="arct_GeneralAndAdministrativeCostsPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_LUNAR-OTCMember" xlink:to="arct_LUNAR-OTCMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorOpinionTextBlock" xlink:to="dei_AuditorOpinionTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_MilestonePayments" xlink:to="arct_MilestonePayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryCashFlowPolicy" xlink:to="us-gaap_InventoryCashFlowPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_CollaborationAgreementContractualTerm" xlink:to="arct_CollaborationAgreementContractualTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_UpfrontFeeReceived" xlink:to="arct_UpfrontFeeReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentAggregateCost" xlink:to="us-gaap_EquityMethodInvestmentAggregateCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_AdditionalFinancialSupport" xlink:to="arct_AdditionalFinancialSupport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_LiquidityPolicyPolicyTextBlock" xlink:to="arct_LiquidityPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_StockIssuedDuringPeriodValueUnderEquityPlan" xlink:to="arct_StockIssuedDuringPeriodValueUnderEquityPlan_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_ClinicalTrialAccrualsCurrent" xlink:to="arct_ClinicalTrialAccrualsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_ContractWithCustomerAssetAdditionsForRevenueRecognized" xlink:to="arct_ContractWithCustomerAssetAdditionsForRevenueRecognized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_NonRareDiseaseTargetsMember" xlink:to="arct_NonRareDiseaseTargetsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_CysticFibrosisFoundationTherapeuticsIncMember" xlink:to="arct_CysticFibrosisFoundationTherapeuticsIncMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_CslCollaborationAgreementMember" xlink:to="arct_CslCollaborationAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:to="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetNet" xlink:to="us-gaap_ContractWithCustomerAssetNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_PaymentsForMatchingFundsForRemainingBudgetedCosts" xlink:to="arct_PaymentsForMatchingFundsForRemainingBudgetedCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_FebruaryTwoThousandAndTwentyLeaseAgreementMember" xlink:to="arct_FebruaryTwoThousandAndTwentyLeaseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_RevenueLineItems" xlink:to="arct_RevenueLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_CSLMember" xlink:to="arct_CSLMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_OptionExerciseRevenueRangePerTarget" xlink:to="arct_OptionExerciseRevenueRangePerTarget_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_DisbursementPeriodThreeMember" xlink:to="arct_DisbursementPeriodThreeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_ReservedUpfrontPayment" xlink:to="arct_ReservedUpfrontPayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_TaxPeriodDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_ResearchCollaborationAndExclusiveLicenseAgreementMember" xlink:to="arct_ResearchCollaborationAndExclusiveLicenseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiability" xlink:to="us-gaap_ContractWithCustomerLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" xlink:to="arct_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_CollaborationAgreementTransactionPrice" xlink:to="arct_CollaborationAgreementTransactionPrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxesPayableCurrent" xlink:to="us-gaap_TaxesPayableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestments" xlink:to="us-gaap_EquityMethodInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:to="arct_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_WellsFargoCreditAgreementMember" xlink:to="arct_WellsFargoCreditAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_LoanAndSecurityAgreementMember" xlink:to="arct_LoanAndSecurityAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_Early-StageProgramsMember" xlink:to="arct_Early-StageProgramsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensation" xlink:to="arct_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_PayrollAndBenefitsMember" xlink:to="arct_PayrollAndBenefitsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerDurationDomain" xlink:to="us-gaap_ContractWithCustomerDurationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_OptionExerciseFeeRevenueReceived" xlink:to="arct_OptionExerciseFeeRevenueReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_AdjustmentsToTransactionPrice" xlink:to="arct_AdjustmentsToTransactionPrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:to="us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesPolicyTextBlock" xlink:to="us-gaap_ReceivablesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_VariableRateDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_ContractWithCustomerAssetDeductionsForCashCollections" xlink:to="arct_ContractWithCustomerAssetDeductionsForCashCollections_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_NumberOfBusinessSegment" xlink:to="arct_NumberOfBusinessSegment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_UltragenyxMember" xlink:to="arct_UltragenyxMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_DevelopmentAndOptionAgreementDate" xlink:to="arct_DevelopmentAndOptionAgreementDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_ConcentrationRiskNumberOfCustomer" xlink:to="arct_ConcentrationRiskNumberOfCustomer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_AdditionalPaymentsUponMeetingCertainClinicalMilestones" xlink:to="arct_AdditionalPaymentsUponMeetingCertainClinicalMilestones_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_ContraExpenseRemainingAmountIncludedInAccruedExpenses" xlink:to="arct_ContraExpenseRemainingAmountIncludedInAccruedExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashCurrent" xlink:to="us-gaap_RestrictedCashCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_SGIMember" xlink:to="arct_SGIMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_OctoberTwoThousandAndSeventeenLeaseAmendmentMember" xlink:to="arct_OctoberTwoThousandAndSeventeenLeaseAmendmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermContractWithCustomerMember" xlink:to="us-gaap_ShortTermContractWithCustomerMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="arct_SummaryOfSignificantAccountingPolicyLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_WesternAllianceBankMember" xlink:to="arct_WesternAllianceBankMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_OptionToPurchaseOfAdditionalSharesOfCommonStock" xlink:to="arct_OptionToPurchaseOfAdditionalSharesOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_DisbursementPeriodTwoMember" xlink:to="arct_DisbursementPeriodTwoMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_FacilitiesAndEquipmentMember" xlink:to="arct_FacilitiesAndEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets" xlink:to="arct_DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_Covid19VaccineMember" xlink:to="arct_Covid19VaccineMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_OtherMember" xlink:to="arct_OtherMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_UnderwrittenPublicOfferingMember" xlink:to="arct_UnderwrittenPublicOfferingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesFairValueDisclosure" xlink:to="us-gaap_AccruedLiabilitiesFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_IncomeTaxesTable" xlink:to="arct_IncomeTaxesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_RareDiseaseTargetsMember" xlink:to="arct_RareDiseaseTargetsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyNatureDomain" xlink:to="us-gaap_LossContingencyNatureDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_RevenueRecognitionPotentialMilestoneRevenueRecognized" xlink:to="arct_RevenueRecognitionPotentialMilestoneRevenueRecognized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_DevelopmentMilestonesAmountDueForAgreement" xlink:to="arct_DevelopmentMilestonesAmountDueForAgreement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_TwentyTwentyOneInducementEquityIncentivePlanMember" xlink:to="arct_TwentyTwentyOneInducementEquityIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_EligibleToReceiveDevelopmentMilestonePayment" xlink:to="arct_EligibleToReceiveDevelopmentMilestonePayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentOwnedBalanceShares" xlink:to="us-gaap_InvestmentOwnedBalanceShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_GrantRevenue" xlink:to="arct_GrantRevenue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_StatementBusinessSegmentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_DeferredTaxLiabilitiesPropertyPlantAndEquipmentAndIntangibleAssets" xlink:to="arct_DeferredTaxLiabilitiesPropertyPlantAndEquipmentAndIntangibleAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_DevelopmentMilestonesReceivedAdvancePayment" xlink:to="arct_DevelopmentMilestonesReceivedAdvancePayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_EffectiveIncomeTaxRateReconciliationUncertainTaxPosition" xlink:to="arct_EffectiveIncomeTaxRateReconciliationUncertainTaxPosition_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMember" xlink:to="us-gaap_LongTermDebtMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_PotentialTargetLicenseTerm" xlink:to="arct_PotentialTargetLicenseTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_ManufacturingAndSupplyOfArct154DrugProductMember" xlink:to="arct_ManufacturingAndSupplyOfArct154DrugProductMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_NumberOfReservedVaccineDoses" xlink:to="arct_NumberOfReservedVaccineDoses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_PreLaunchInventoryPolicyPolicyTextBlock" xlink:to="arct_PreLaunchInventoryPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" xlink:to="us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_AchievedDevelopmentMilestoneIncludedAccountsReceivable" xlink:to="arct_AchievedDevelopmentMilestoneIncludedAccountsReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:to="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrantMember" xlink:to="us-gaap_GrantMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_UpfrontPaymentReceived" xlink:to="arct_UpfrontPaymentReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_TaxCreditCarryforwardExpirationYear" xlink:to="arct_TaxCreditCarryforwardExpirationYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_RevenueTable" xlink:to="arct_RevenueTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_UnvestedRestrictedOrdinarySharesMember" xlink:to="arct_UnvestedRestrictedOrdinarySharesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_CollaborationAgreementConsiderationReceived" xlink:to="arct_CollaborationAgreementConsiderationReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerDurationAxis" xlink:to="us-gaap_ContractWithCustomerDurationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_ADAIRTechnologyMember" xlink:to="arct_ADAIRTechnologyMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_SeqirusAgreementMember" xlink:to="arct_SeqirusAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_FebruaryTwoThousandAndTwentyOneLeaseAgreementMember" xlink:to="arct_FebruaryTwoThousandAndTwentyOneLeaseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_CA" xlink:to="stpr_CA_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_RecognizedContraExpense" xlink:to="arct_RecognizedContraExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_BARDAMember" xlink:to="arct_BARDAMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_ContraResearchAndDevelopmentExpense" xlink:to="arct_ContraResearchAndDevelopmentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_ResearchCollaborationAndLicenseAgreementMember" xlink:to="arct_ResearchCollaborationAndLicenseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_AdditionalClinicalMilestonePayment" xlink:to="arct_AdditionalClinicalMilestonePayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_NumberOfPerformanceObligations" xlink:to="arct_NumberOfPerformanceObligations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_ContractWithCustomerLiabilityAdditions" xlink:to="arct_ContractWithCustomerLiabilityAdditions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:to="us-gaap_PaymentsForProceedsFromTenantAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_KeithCKummerfeldMember" xlink:to="arct_KeithCKummerfeldMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCollateralAmount" xlink:to="us-gaap_DebtInstrumentCollateralAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_AgreementAmountAgreedToFund" xlink:to="arct_AgreementAmountAgreedToFund_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate202307Member" xlink:to="us-gaap_AccountingStandardsUpdate202307Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_GrantOneMember" xlink:to="arct_GrantOneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_VinbiocareContractualLiabilities" xlink:to="arct_VinbiocareContractualLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_UpfrontConsiderationReceived" xlink:to="arct_UpfrontConsiderationReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_NumberOfReserveTargets" xlink:to="arct_NumberOfReserveTargets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_CureVacAGMember" xlink:to="arct_CureVacAGMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_AlexionPharmaceuticalsIncMember" xlink:to="arct_AlexionPharmaceuticalsIncMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_GrantRevenueOutstanding" xlink:to="arct_GrantRevenueOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_UpfrontFeeAndConsideration" xlink:to="arct_UpfrontFeeAndConsideration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" xlink:to="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_NotSubjectToExpirationMember" xlink:to="arct_NotSubjectToExpirationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_MaximumPercentageOfLikelihoodOfUncertainTaxPositionRecognizedToBeSustained" xlink:to="arct_MaximumPercentageOfLikelihoodOfUncertainTaxPositionRecognizedToBeSustained_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_VallonPharmaceuticalsIncMember" xlink:to="arct_VallonPharmaceuticalsIncMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_UnrecognizedTaxBenefitsDecreasesIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="arct_UnrecognizedTaxBenefitsDecreasesIncreasesResultingFromPriorPeriodTaxPositions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireInterestInJointVenture" xlink:to="us-gaap_PaymentsToAcquireInterestInJointVenture_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_MinimumAmountAgreedToIncurUnderResearchPlan" xlink:to="arct_MinimumAmountAgreedToIncurUnderResearchPlan_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_MonthlyBaseRent" xlink:to="arct_MonthlyBaseRent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentOwnedPercentOfNetAssets" xlink:to="us-gaap_InvestmentOwnedPercentOfNetAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_LackOfMarketabilityDiscountRestrictedPeriod" xlink:to="arct_LackOfMarketabilityDiscountRestrictedPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_OtherAccruedResearchAndDevelopmentExpenses" xlink:to="arct_OtherAccruedResearchAndDevelopmentExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="us-gaap_LossContingenciesByNatureOfContingencyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseLongTermDebt" xlink:to="us-gaap_InterestExpenseLongTermDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_DisbursementPeriodFourMember" xlink:to="arct_DisbursementPeriodFourMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_IL" xlink:to="stpr_IL_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_ContractWithCustomerAssetAdditions" xlink:to="arct_ContractWithCustomerAssetAdditions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Dividends" xlink:to="us-gaap_Dividends_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_DebtInstrumentOptionForRenewalTerm" xlink:to="arct_DebtInstrumentOptionForRenewalTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BorrowingsUnderGuaranteedInvestmentAgreements" xlink:to="us-gaap_BorrowingsUnderGuaranteedInvestmentAgreements_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_ConditionalPayment" xlink:to="arct_ConditionalPayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_NetOperatingLossAndResearchAndDevelopmentCreditCarryforwardsLimitationsOnCumulativeChangeInOwnershipPeriod" xlink:to="arct_NetOperatingLossAndResearchAndDevelopmentCreditCarryforwardsLimitationsOnCumulativeChangeInOwnershipPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_DevelopmentMilestonesAchieved" xlink:to="arct_DevelopmentMilestonesAchieved_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_TwoThousandTwentyEmployeeStockPurchasePlanMember" xlink:to="arct_TwoThousandTwentyEmployeeStockPurchasePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_ReversalOfRevenue" xlink:to="arct_ReversalOfRevenue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_OrphanDrugCreditMember" xlink:to="arct_OrphanDrugCreditMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_RemainingLoanIncludingAccruedInterestForgiveable" xlink:to="arct_RemainingLoanIncludingAccruedInterestForgiveable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_OrganizationAndSignificantAccountingPoliciesTable" xlink:to="arct_OrganizationAndSignificantAccountingPoliciesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_PercentageOfEquityInterestInJointVenture" xlink:to="arct_PercentageOfEquityInterestInJointVenture_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForAdvanceToAffiliate" xlink:to="us-gaap_PaymentsForAdvanceToAffiliate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_PercentageOfNetProfits" xlink:to="arct_PercentageOfNetProfits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_VinbiocareAgreementMember" xlink:to="arct_VinbiocareAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_LanceKurataMember" xlink:to="arct_LanceKurataMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFeeAmount" xlink:to="us-gaap_DebtInstrumentFeeAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_SG" xlink:to="country_SG_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="arct_OrganizationAndSignificantAccountingPoliciesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_DeferredTaxAssetsRightOfUseLeaseLiability" xlink:to="arct_DeferredTaxAssetsRightOfUseLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_LUNARCFMember" xlink:to="arct_LUNARCFMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_AcquiredInProcessResearchAndDevelopmentExpense" xlink:to="arct_AcquiredInProcessResearchAndDevelopmentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_DevelopmentAndRegulatoryMilestonesAchieved" xlink:to="arct_DevelopmentAndRegulatoryMilestonesAchieved_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_ReductionInNumberOfCommonStockCapitalSharesAvailableForFutureIssuance" xlink:to="arct_ReductionInNumberOfCommonStockCapitalSharesAvailableForFutureIssuance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentCredits" xlink:to="arct_EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentCredits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:to="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_AdditionalMilestonePaymentsReceived" xlink:to="arct_AdditionalMilestonePaymentsReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_PhaseIClinicalStudyMember" xlink:to="arct_PhaseIClinicalStudyMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_TwoThousandNineteenOmnibusIncentivePlanMember" xlink:to="arct_TwoThousandNineteenOmnibusIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_PharmaceuticalCompanyMember" xlink:to="arct_PharmaceuticalCompanyMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyLeaseGuaranteeMember" xlink:to="us-gaap_PropertyLeaseGuaranteeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_EligibleToReceiveCommercialMilestonePayment" xlink:to="arct_EligibleToReceiveCommercialMilestonePayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_IsraelMinistryOfHealthMember" xlink:to="arct_IsraelMinistryOfHealthMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_NetOperatingLossAndResearchAndDevelopmentCreditCarryforwardsLimitationsOnCumulativeChangeInOwnershipMinimumPercentage" xlink:to="arct_NetOperatingLossAndResearchAndDevelopmentCreditCarryforwardsLimitationsOnCumulativeChangeInOwnershipMinimumPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_IncomeTaxesLineItems" xlink:to="arct_IncomeTaxesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:to="arct_DeferredTaxAssetsCapitalizedResearchAndDevelopment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_StudySupportAgreementMember" xlink:to="arct_StudySupportAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_DrPadmanabhChivukulaMember" xlink:to="arct_DrPadmanabhChivukulaMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="us-gaap_LeaseContractualTermDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_UpfrontPaymentToBeReceived" xlink:to="arct_UpfrontPaymentToBeReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_ContractWithCustomerAssetDeductions" xlink:to="arct_ContractWithCustomerAssetDeductions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuePracticalExpedientRemainingPerformanceObligationDescription" xlink:to="us-gaap_RevenuePracticalExpedientRemainingPerformanceObligationDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:to="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_PaymentReceivedFirstInstallment" xlink:to="arct_PaymentReceivedFirstInstallment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermDebt" xlink:to="us-gaap_RepaymentsOfLongTermDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_FinalPaymentOfDisbursementAmount" xlink:to="arct_FinalPaymentOfDisbursementAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_OptionToExtendInitialTermOnAnAnnualBasis" xlink:to="arct_OptionToExtendInitialTermOnAnAnnualBasis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_CslSeqirusMember" xlink:to="arct_CslSeqirusMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_CommitmentAndContingenciesTable" xlink:to="arct_CommitmentAndContingenciesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseImpairmentLoss" xlink:to="us-gaap_OperatingLeaseImpairmentLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_NonRefundablePaymentReceived" xlink:to="arct_NonRefundablePaymentReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrantsReceivable" xlink:to="us-gaap_GrantsReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_MRNATechnologyMember" xlink:to="arct_MRNATechnologyMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences" xlink:to="arct_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermContractWithCustomerMember" xlink:to="us-gaap_LongTermContractWithCustomerMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_ScheduleOfSummaryOfSignificantAccountingPoliciesTable" xlink:to="arct_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_AchievedDevelopmentAndRegulatoryMilestoneIncludedAccountsReceivable" xlink:to="arct_AchievedDevelopmentAndRegulatoryMilestoneIncludedAccountsReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_LUNAR-CFNetMember" xlink:to="arct_LUNAR-CFNetMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockPlans" xlink:to="us-gaap_ProceedsFromStockPlans_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_PrepaidExpensesAndOtherReceivables" xlink:to="arct_PrepaidExpensesAndOtherReceivables_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_ExpirationOfIntialTerm" xlink:to="arct_ExpirationOfIntialTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_DirectorsOrOfficersExceptChiefScientificOfficerCooSvpCcAndPaoMember" xlink:to="arct_DirectorsOrOfficersExceptChiefScientificOfficerCooSvpCcAndPaoMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_CollaborationRevenueMember" xlink:to="arct_CollaborationRevenueMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsEquityMethodInvestments" xlink:to="us-gaap_DeferredTaxAssetsEquityMethodInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentDomain" xlink:to="us-gaap_SegmentDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_DisbursedAmountUponExecutionOfAmendment" xlink:to="arct_DisbursedAmountUponExecutionOfAmendment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossRealized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_UnderlyingAgreementMember" xlink:to="arct_UnderlyingAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_NonCashAssetDisposal" xlink:to="arct_NonCashAssetDisposal_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_JointVenturesEquityMethodInvestmentsAndVariableInterestEntitiesPolicyTextBlock" xlink:to="arct_JointVenturesEquityMethodInvestmentsAndVariableInterestEntitiesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_StockIssuedDuringPeriodSharesUnderEquityPlan" xlink:to="arct_StockIssuedDuringPeriodSharesUnderEquityPlan_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_LegalAccrualCurrent" xlink:to="arct_LegalAccrualCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_DebtInstrumentExtendedTermPeriod" xlink:to="arct_DebtInstrumentExtendedTermPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_DisbursementPaymentUponAchievementOfRequiredManufacturingPracticesAndINDApplication" xlink:to="arct_DisbursementPaymentUponAchievementOfRequiredManufacturingPracticesAndINDApplication_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingInformationLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_SeqirusIncMember" xlink:to="arct_SeqirusIncMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_LUNAR-COVIDMember" xlink:to="arct_LUNAR-COVIDMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebt" xlink:to="us-gaap_RepaymentsOfDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_ContractWithCustomerLiabilityAdditionsForAdvancedBillings" xlink:to="arct_ContractWithCustomerLiabilityAdditionsForAdvancedBillings_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_AcquisitionOfResearchAndDevelopmentInProcessThroughIssuanceOfCommonStock" xlink:to="arct_AcquisitionOfResearchAndDevelopmentInProcessThroughIssuanceOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_GrantReceivableNumberOfInstallments" xlink:to="arct_GrantReceivableNumberOfInstallments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_DisbursementPeriodOneMember" xlink:to="arct_DisbursementPeriodOneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_DisbursementAmountPayableUponAchievementOfProjectGoal" xlink:to="arct_DisbursementAmountPayableUponAchievementOfProjectGoal_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201912Member" xlink:to="us-gaap_AccountingStandardsUpdate201912Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_GrantTwoMember" xlink:to="arct_GrantTwoMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:to="us-gaap_LineOfCreditFacilityCommitmentFeePercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_AccruedCysticFibrosisFoundationLiability" xlink:to="arct_AccruedCysticFibrosisFoundationLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditConcentrationRiskMember" xlink:to="us-gaap_CreditConcentrationRiskMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_OtherCollaborationAgreementsMember" xlink:to="arct_OtherCollaborationAgreementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arct_GriBioIncMember" xlink:to="arct_GriBioIncMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://arcturusrx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorOpinionTextBlock" xlink:label="dei_AuditorOpinionTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="73.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="74.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="75.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="76.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="77.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="78.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="79.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="80.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="81.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="82.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="83.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="84.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId" order="85.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName" order="86.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation" order="87.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorOpinionTextBlock" order="88.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_PrepaidExpensesAndOtherReceivables" xlink:label="arct_PrepaidExpensesAndOtherReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestments" xlink:label="us-gaap_EquityMethodInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCash" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LongTermDebtCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="arct_PrepaidExpensesAndOtherReceivables" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_EquityMethodInvestments" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETSParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://arcturusrx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_CollaborationRevenueMember" xlink:label="arct_CollaborationRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrantMember" xlink:label="us-gaap_GrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="arct_CollaborationRevenueMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_GrantMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareAbstract" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_StockIssuedDuringPeriodValueUnderEquityPlan" xlink:label="arct_StockIssuedDuringPeriodValueUnderEquityPlan"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_StockIssuedDuringPeriodSharesUnderEquityPlan" xlink:label="arct_StockIssuedDuringPeriodSharesUnderEquityPlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_10"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_11"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="arct_StockIssuedDuringPeriodValueUnderEquityPlan" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="arct_StockIssuedDuringPeriodSharesUnderEquityPlan" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_10" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_11" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_UltragenyxMember" xlink:label="arct_UltragenyxMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_AcquisitionOfResearchAndDevelopmentInProcessThroughIssuanceOfCommonStock" xlink:label="arct_AcquisitionOfResearchAndDevelopmentInProcessThroughIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_IncreaseDecreaseOperatingLeaseRightOfUseAsset" xlink:label="arct_IncreaseDecreaseOperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_NonCashAssetDisposal" xlink:label="arct_NonCashAssetDisposal"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_AcquiredInProcessResearchAndDevelopmentExpense" xlink:label="arct_AcquiredInProcessResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossRealized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="arct_UltragenyxMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaidNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="arct_AcquisitionOfResearchAndDevelopmentInProcessThroughIssuanceOfCommonStock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="arct_IncreaseDecreaseOperatingLeaseRightOfUseAsset" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="arct_NonCashAssetDisposal" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="arct_AcquiredInProcessResearchAndDevelopmentExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockPlans" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfDebt" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossRealized" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://arcturusrx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="ecd_AllIndividualsMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_KeithCKummerfeldMember" xlink:label="arct_KeithCKummerfeldMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_LanceKurataMember" xlink:label="arct_LanceKurataMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_DrPadmanabhChivukulaMember" xlink:label="arct_DrPadmanabhChivukulaMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_DirectorsOrOfficersExceptChiefScientificOfficerCooSvpCcAndPaoMember" xlink:label="arct_DirectorsOrOfficersExceptChiefScientificOfficerCooSvpCcAndPaoMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember" xlink:to="arct_KeithCKummerfeldMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember" xlink:to="arct_LanceKurataMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember" xlink:to="arct_DrPadmanabhChivukulaMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember" xlink:to="arct_DirectorsOrOfficersExceptChiefScientificOfficerCooSvpCcAndPaoMember" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureOrganization" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenue" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://arcturusrx.com/20241231/taxonomy/role/DisclosureAccruedLiabilitiesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureDebt" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquity" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://arcturusrx.com/20241231/taxonomy/role/DisclosureSegmentInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRelatedPartyTransactions" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSubsequentEvents" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_LiquidityPolicyPolicyTextBlock" xlink:label="arct_LiquidityPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="us-gaap_ReceivablesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_JointVenturesEquityMethodInvestmentsAndVariableInterestEntitiesPolicyTextBlock" xlink:label="arct_JointVenturesEquityMethodInvestmentsAndVariableInterestEntitiesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_GeneralAndAdministrativeCostsPolicyPolicyTextBlock" xlink:label="arct_GeneralAndAdministrativeCostsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_PreLaunchInventoryPolicyPolicyTextBlock" xlink:label="arct_PreLaunchInventoryPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryCashFlowPolicy" xlink:label="us-gaap_InventoryCashFlowPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="arct_LiquidityPolicyPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ReceivablesPolicyTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="arct_JointVenturesEquityMethodInvestmentsAndVariableInterestEntitiesPolicyTextBlock" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="arct_GeneralAndAdministrativeCostsPolicyPolicyTextBlock" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="arct_PreLaunchInventoryPolicyPolicyTextBlock" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryCashFlowPolicy" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://arcturusrx.com/20241231/taxonomy/role/DisclosureAccruedLiabilitiesDetailTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureDebtTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://arcturusrx.com/20241231/taxonomy/role/DisclosureSegmentInformationTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureOrganizationDetailsTextual" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_UnderwrittenPublicOfferingMember" xlink:label="arct_UnderwrittenPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_SeqirusIncMember" xlink:label="arct_SeqirusIncMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_OrganizationAndSignificantAccountingPoliciesTable" xlink:label="arct_OrganizationAndSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:label="arct_OrganizationAndSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_UpfrontPaymentReceived" xlink:label="arct_UpfrontPaymentReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_AdditionalMilestonePaymentsReceived" xlink:label="arct_AdditionalMilestonePaymentsReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="arct_UnderwrittenPublicOfferingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="arct_SeqirusIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_OrganizationAndSignificantAccountingPoliciesTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="arct_OrganizationAndSignificantAccountingPoliciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_OrganizationAndSignificantAccountingPoliciesTable" xlink:to="srt_CounterpartyNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="arct_UpfrontPaymentReceived" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_OrganizationAndSignificantAccountingPoliciesTable" xlink:to="arct_OrganizationAndSignificantAccountingPoliciesLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="arct_AdditionalMilestonePaymentsReceived" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesDetailsTextual" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_WellsFargoCreditAgreementMember" xlink:label="arct_WellsFargoCreditAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditConcentrationRiskMember" xlink:label="us-gaap_CreditConcentrationRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_SummaryOfSignificantAccountingPolicyLineItems" xlink:label="arct_SummaryOfSignificantAccountingPolicyLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdate202307Member" xlink:label="us-gaap_AccountingStandardsUpdate202307Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="us-gaap_LossContingencyNatureDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyLeaseGuaranteeMember" xlink:label="us-gaap_PropertyLeaseGuaranteeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" xlink:label="arct_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_ScheduleOfSummaryOfSignificantAccountingPoliciesTable" xlink:label="arct_ScheduleOfSummaryOfSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_EmployeesAndOfficersMember" xlink:label="arct_EmployeesAndOfficersMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCollateralAmount" xlink:label="us-gaap_DebtInstrumentCollateralAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdate201912Member" xlink:label="us-gaap_AccountingStandardsUpdate201912Member"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_CSLMember" xlink:label="arct_CSLMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_VinbiocareMember" xlink:label="arct_VinbiocareMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_ConcentrationRiskNumberOfCustomer" xlink:label="arct_ConcentrationRiskNumberOfCustomer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentOwnedPercentOfNetAssets" xlink:label="us-gaap_InvestmentOwnedPercentOfNetAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:label="us-gaap_EquityMethodInvestmentAggregateCost"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_UpfrontFeeAndConsideration" xlink:label="arct_UpfrontFeeAndConsideration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireInterestInJointVenture" xlink:label="us-gaap_PaymentsToAcquireInterestInJointVenture"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_PercentageOfEquityInterestInJointVenture" xlink:label="arct_PercentageOfEquityInterestInJointVenture"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Dividends" xlink:label="us-gaap_Dividends"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arct_WellsFargoCreditAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CreditConcentrationRiskMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate202307Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingencyNatureDomain" xlink:to="us-gaap_PropertyLeaseGuaranteeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="arct_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="us-gaap_LossContingencyNatureDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="arct_ScheduleOfSummaryOfSignificantAccountingPoliciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_ScheduleOfSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="arct_EmployeesAndOfficersMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="us-gaap_DebtInstrumentCollateralAmount" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201912Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="arct_CSLMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_ScheduleOfSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="us-gaap_RestrictedCashNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="arct_VinbiocareMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_ScheduleOfSummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_CounterpartyNameAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_ScheduleOfSummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="arct_ConcentrationRiskNumberOfCustomer" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_ScheduleOfSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_ScheduleOfSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_VestingAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_ScheduleOfSummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_TitleOfIndividualAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="us-gaap_InvestmentOwnedPercentOfNetAssets" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_ScheduleOfSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="us-gaap_EquityMethodInvestmentAggregateCost" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_ScheduleOfSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_LossContingenciesByNatureOfContingencyAxis" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="arct_UpfrontFeeAndConsideration" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_ScheduleOfSummaryOfSignificantAccountingPoliciesTable" xlink:to="arct_SummaryOfSignificantAccountingPolicyLineItems" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="us-gaap_PaymentsToAcquireInterestInJointVenture" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="arct_PercentageOfEquityInterestInJointVenture" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="us-gaap_GoodwillImpairmentLoss" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="us-gaap_Dividends" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://arcturusrx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RestrictedCashCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://arcturusrx.com/20241231/taxonomy/role/DisclosureRevenueSummaryOfChangesInBalancesOfReceivablesAndContractLiabilityDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="us-gaap_ContractWithCustomerAssetNet"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_ContractWithCustomerAssetAdditionsForRevenueRecognized" xlink:label="arct_ContractWithCustomerAssetAdditionsForRevenueRecognized"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_ContractWithCustomerAssetAdditions" xlink:label="arct_ContractWithCustomerAssetAdditions"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_ContractWithCustomerAssetDeductionsForCashCollections" xlink:label="arct_ContractWithCustomerAssetDeductionsForCashCollections"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_ContractWithCustomerAssetDeductions" xlink:label="arct_ContractWithCustomerAssetDeductions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="us-gaap_ContractWithCustomerAssetNet_5"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_ContractWithCustomerLiabilityAdditionsForAdvancedBillings" xlink:label="arct_ContractWithCustomerLiabilityAdditionsForAdvancedBillings"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_ContractWithCustomerLiabilityAdditions" xlink:label="arct_ContractWithCustomerLiabilityAdditions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability_10"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_ContractWithCustomerAssetNet" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="arct_ContractWithCustomerAssetAdditionsForRevenueRecognized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="arct_ContractWithCustomerAssetAdditions" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="arct_ContractWithCustomerAssetDeductionsForCashCollections" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="arct_ContractWithCustomerAssetDeductions" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_ContractWithCustomerAssetNet_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_ContractWithCustomerLiability" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="arct_ContractWithCustomerLiabilityAdditionsForAdvancedBillings" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="arct_ContractWithCustomerLiabilityAdditions" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_ContractWithCustomerLiability_10" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_ResearchCollaborationAndLicenseAgreementMember" xlink:label="arct_ResearchCollaborationAndLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_RevenueLineItems" xlink:label="arct_RevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_RareDiseaseTargetsMember" xlink:label="arct_RareDiseaseTargetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerDurationDomain" xlink:label="us-gaap_ContractWithCustomerDurationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermContractWithCustomerMember" xlink:label="us-gaap_ShortTermContractWithCustomerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_PharmaceuticalCompanyMember" xlink:label="arct_PharmaceuticalCompanyMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_RevenueTable" xlink:label="arct_RevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerDurationAxis" xlink:label="us-gaap_ContractWithCustomerDurationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_JanssenMember" xlink:label="arct_JanssenMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_ForeignCountriesMember" xlink:label="arct_ForeignCountriesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_VinbiocareAgreementMember" xlink:label="arct_VinbiocareAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_UpfrontPaymentReceived" xlink:label="arct_UpfrontPaymentReceived"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_NonRareDiseaseTargetsMember" xlink:label="arct_NonRareDiseaseTargetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermContractWithCustomerMember" xlink:label="us-gaap_LongTermContractWithCustomerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_UltragenyxMember" xlink:label="arct_UltragenyxMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_IL" xlink:label="stpr_IL"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_SeqirusAgreementMember" xlink:label="arct_SeqirusAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_NumberOfPerformanceObligations" xlink:label="arct_NumberOfPerformanceObligations"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_Covid19VaccineMember" xlink:label="arct_Covid19VaccineMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_CureVacAGMember" xlink:label="arct_CureVacAGMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_CslCollaborationAgreementMember" xlink:label="arct_CslCollaborationAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_UpfrontConsiderationReceived" xlink:label="arct_UpfrontConsiderationReceived"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_ManufacturingAndSupplyOfArct154DrugProductMember" xlink:label="arct_ManufacturingAndSupplyOfArct154DrugProductMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_CollaborationPartnerCureVacEnteredIntoCoDevelopmentAgreementMember" xlink:label="arct_CollaborationPartnerCureVacEnteredIntoCoDevelopmentAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_StudySupportAgreementMember" xlink:label="arct_StudySupportAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_DevelopmentMilestonesAchieved" xlink:label="arct_DevelopmentMilestonesAchieved"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_PhaseIClinicalStudyMember" xlink:label="arct_PhaseIClinicalStudyMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_SeqirusIncMember" xlink:label="arct_SeqirusIncMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_ResearchCollaborationAndExclusiveLicenseAgreementMember" xlink:label="arct_ResearchCollaborationAndExclusiveLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_AchievedDevelopmentMilestoneIncludedAccountsReceivable" xlink:label="arct_AchievedDevelopmentMilestoneIncludedAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_VinbiocareMember" xlink:label="arct_VinbiocareMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_MRNATechnologyMember" xlink:label="arct_MRNATechnologyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" xlink:label="arct_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_OtherCollaborationAgreementsMember" xlink:label="arct_OtherCollaborationAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_PercentageOfNetProfits" xlink:label="arct_PercentageOfNetProfits"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_DevelopmentMilestonesReceivedAdvancePayment" xlink:label="arct_DevelopmentMilestonesReceivedAdvancePayment"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_MilestonePayments" xlink:label="arct_MilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_AdditionalClinicalMilestonePayment" xlink:label="arct_AdditionalClinicalMilestonePayment"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_AdditionalPaymentsUponMeetingCertainClinicalMilestones" xlink:label="arct_AdditionalPaymentsUponMeetingCertainClinicalMilestones"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_RevenueRecognitionPotentialMilestoneRevenueRecognized" xlink:label="arct_RevenueRecognitionPotentialMilestoneRevenueRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="us-gaap_RevenueRemainingPerformanceObligation"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_OptionExerciseRevenueRangePerTarget" xlink:label="arct_OptionExerciseRevenueRangePerTarget"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_OptionExerciseFeeRevenueReceived" xlink:label="arct_OptionExerciseFeeRevenueReceived"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_RoyaltyPaymentTermDescription" xlink:label="arct_RoyaltyPaymentTermDescription"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_NumberOfReserveTargets" xlink:label="arct_NumberOfReserveTargets"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_OptionToPurchaseOfAdditionalSharesOfCommonStock" xlink:label="arct_OptionToPurchaseOfAdditionalSharesOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_OptionToPurchaseOfAdditionalSharesOfCommonStockPricePerShare" xlink:label="arct_OptionToPurchaseOfAdditionalSharesOfCommonStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_CollaborationAgreementConsiderationReceived" xlink:label="arct_CollaborationAgreementConsiderationReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_CollaborationAgreementTransactionPrice" xlink:label="arct_CollaborationAgreementTransactionPrice"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_LackOfMarketabilityDiscountRestrictedPeriod" xlink:label="arct_LackOfMarketabilityDiscountRestrictedPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuePracticalExpedientRemainingPerformanceObligationDescription" xlink:label="us-gaap_RevenuePracticalExpedientRemainingPerformanceObligationDescription"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_RevenueRecognitionReserveTargetExclusivityPeriod" xlink:label="arct_RevenueRecognitionReserveTargetExclusivityPeriod"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_DevelopmentAndOptionAgreementDate" xlink:label="arct_DevelopmentAndOptionAgreementDate"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_ExpirationOfIntialTerm" xlink:label="arct_ExpirationOfIntialTerm"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_OptionToExtendInitialTermOnAnAnnualBasis" xlink:label="arct_OptionToExtendInitialTermOnAnAnnualBasis"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_PotentialTargetLicenseTerm" xlink:label="arct_PotentialTargetLicenseTerm"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_AdjustmentsToTransactionPrice" xlink:label="arct_AdjustmentsToTransactionPrice"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_UpfrontFeeReceived" xlink:label="arct_UpfrontFeeReceived"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_CollaborationAgreementContractualTerm" xlink:label="arct_CollaborationAgreementContractualTerm"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_AgreementAmountAgreedToFund" xlink:label="arct_AgreementAmountAgreedToFund"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_NonRefundablePaymentReceived" xlink:label="arct_NonRefundablePaymentReceived"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_NumberOfReservedVaccineDoses" xlink:label="arct_NumberOfReservedVaccineDoses"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_UpfrontPaymentToBeReceived" xlink:label="arct_UpfrontPaymentToBeReceived"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_EligibleToReceiveDevelopmentMilestonePayment" xlink:label="arct_EligibleToReceiveDevelopmentMilestonePayment"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_EligibleToReceiveCommercialMilestonePayment" xlink:label="arct_EligibleToReceiveCommercialMilestonePayment"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_DevelopmentAndRegulatoryMilestonesAchieved" xlink:label="arct_DevelopmentAndRegulatoryMilestonesAchieved"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_AchievedDevelopmentAndRegulatoryMilestoneIncludedAccountsReceivable" xlink:label="arct_AchievedDevelopmentAndRegulatoryMilestoneIncludedAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_DevelopmentMilestonesAmountDueForAgreement" xlink:label="arct_DevelopmentMilestonesAmountDueForAgreement"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_ConditionalPayment" xlink:label="arct_ConditionalPayment"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_ReservedUpfrontPayment" xlink:label="arct_ReservedUpfrontPayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_AdditionalFinancialSupport" xlink:label="arct_AdditionalFinancialSupport"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_ReversalOfRevenue" xlink:label="arct_ReversalOfRevenue"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_GrantRevenue" xlink:label="arct_GrantRevenue"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_GrantRevenueOutstanding" xlink:label="arct_GrantRevenueOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arct_ResearchCollaborationAndLicenseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_RevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="arct_RareDiseaseTargetsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContractWithCustomerDurationDomain" xlink:to="us-gaap_ShortTermContractWithCustomerMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="arct_PharmaceuticalCompanyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_RevenueTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContractWithCustomerDurationAxis" xlink:to="us-gaap_ContractWithCustomerDurationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="arct_JanssenMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="arct_RevenueTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="arct_ForeignCountriesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arct_VinbiocareAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_RevenueLineItems" xlink:to="arct_UpfrontPaymentReceived" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="arct_NonRareDiseaseTargetsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContractWithCustomerDurationDomain" xlink:to="us-gaap_LongTermContractWithCustomerMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_RevenueTable" xlink:to="srt_StatementGeographicalAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="arct_UltragenyxMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_IL" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arct_SeqirusAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_RevenueLineItems" xlink:to="arct_NumberOfPerformanceObligations" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="arct_Covid19VaccineMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_RevenueTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="arct_CureVacAGMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arct_CslCollaborationAgreementMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_RevenueLineItems" xlink:to="arct_UpfrontConsiderationReceived" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="arct_ManufacturingAndSupplyOfArct154DrugProductMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_RevenueTable" xlink:to="srt_CounterpartyNameAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="arct_CollaborationPartnerCureVacEnteredIntoCoDevelopmentAgreementMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arct_StudySupportAgreementMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_RevenueLineItems" xlink:to="arct_DevelopmentMilestonesAchieved" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="arct_PhaseIClinicalStudyMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_RevenueTable" xlink:to="srt_ProductOrServiceAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="arct_SeqirusIncMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arct_ResearchCollaborationAndExclusiveLicenseAgreementMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_RevenueLineItems" xlink:to="arct_AchievedDevelopmentMilestoneIncludedAccountsReceivable" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_RevenueTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="arct_VinbiocareMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arct_MRNATechnologyMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_RevenueLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_RevenueTable" xlink:to="srt_StatementScenarioAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="arct_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arct_OtherCollaborationAgreementsMember" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_RevenueLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_RevenueTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_RevenueLineItems" xlink:to="arct_PercentageOfNetProfits" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_RevenueTable" xlink:to="us-gaap_ContractWithCustomerDurationAxis" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_RevenueLineItems" xlink:to="arct_DevelopmentMilestonesReceivedAdvancePayment" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_RevenueTable" xlink:to="arct_RevenueLineItems" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_RevenueLineItems" xlink:to="arct_MilestonePayments" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_RevenueLineItems" xlink:to="arct_AdditionalClinicalMilestonePayment" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_RevenueLineItems" xlink:to="arct_AdditionalPaymentsUponMeetingCertainClinicalMilestones" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_RevenueLineItems" xlink:to="arct_RevenueRecognitionPotentialMilestoneRevenueRecognized" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_RevenueLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligation" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_RevenueLineItems" xlink:to="arct_OptionExerciseRevenueRangePerTarget" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_RevenueLineItems" xlink:to="arct_OptionExerciseFeeRevenueReceived" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_RevenueLineItems" xlink:to="arct_RoyaltyPaymentTermDescription" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_RevenueLineItems" xlink:to="arct_NumberOfReserveTargets" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_RevenueLineItems" xlink:to="arct_OptionToPurchaseOfAdditionalSharesOfCommonStock" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_RevenueLineItems" xlink:to="arct_OptionToPurchaseOfAdditionalSharesOfCommonStockPricePerShare" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_RevenueLineItems" xlink:to="arct_CollaborationAgreementConsiderationReceived" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_RevenueLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_RevenueLineItems" xlink:to="arct_CollaborationAgreementTransactionPrice" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_RevenueLineItems" xlink:to="arct_LackOfMarketabilityDiscountRestrictedPeriod" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_RevenueLineItems" xlink:to="us-gaap_RevenuePracticalExpedientRemainingPerformanceObligationDescription" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_RevenueLineItems" xlink:to="arct_RevenueRecognitionReserveTargetExclusivityPeriod" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_RevenueLineItems" xlink:to="arct_DevelopmentAndOptionAgreementDate" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_RevenueLineItems" xlink:to="arct_ExpirationOfIntialTerm" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_RevenueLineItems" xlink:to="arct_OptionToExtendInitialTermOnAnAnnualBasis" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_RevenueLineItems" xlink:to="arct_PotentialTargetLicenseTerm" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_RevenueLineItems" xlink:to="arct_AdjustmentsToTransactionPrice" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_RevenueLineItems" xlink:to="arct_UpfrontFeeReceived" order="32" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_RevenueLineItems" xlink:to="arct_CollaborationAgreementContractualTerm" order="33" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_RevenueLineItems" xlink:to="arct_AgreementAmountAgreedToFund" order="34" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_RevenueLineItems" xlink:to="arct_NonRefundablePaymentReceived" order="35" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_RevenueLineItems" xlink:to="arct_NumberOfReservedVaccineDoses" order="36" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_RevenueLineItems" xlink:to="arct_UpfrontPaymentToBeReceived" order="37" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_RevenueLineItems" xlink:to="arct_EligibleToReceiveDevelopmentMilestonePayment" order="38" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_RevenueLineItems" xlink:to="arct_EligibleToReceiveCommercialMilestonePayment" order="39" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_RevenueLineItems" xlink:to="arct_DevelopmentAndRegulatoryMilestonesAchieved" order="40" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_RevenueLineItems" xlink:to="arct_AchievedDevelopmentAndRegulatoryMilestoneIncludedAccountsReceivable" order="41" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_RevenueLineItems" xlink:to="arct_DevelopmentMilestonesAmountDueForAgreement" order="42" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_RevenueLineItems" xlink:to="arct_ConditionalPayment" order="43" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_RevenueLineItems" xlink:to="arct_ReservedUpfrontPayment" order="44" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_RevenueLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" order="45" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_RevenueLineItems" xlink:to="arct_AdditionalFinancialSupport" order="46" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_RevenueLineItems" xlink:to="arct_ReversalOfRevenue" order="47" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_RevenueLineItems" xlink:to="arct_GrantRevenue" order="48" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_RevenueLineItems" xlink:to="arct_GrantRevenueOutstanding" order="49" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueSummaryOfRevenuesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_CollaborationRevenueMember" xlink:label="arct_CollaborationRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_CslSeqirusMember" xlink:label="arct_CslSeqirusMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrantMember" xlink:label="us-gaap_GrantMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_VinbiocareMember" xlink:label="arct_VinbiocareMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_JanssenMember" xlink:label="arct_JanssenMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_UltragenyxMember" xlink:label="arct_UltragenyxMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_CureVacAGMember" xlink:label="arct_CureVacAGMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_IsraelMinistryOfHealthMember" xlink:label="arct_IsraelMinistryOfHealthMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_SGIMember" xlink:label="arct_SGIMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_OtherMember" xlink:label="arct_OtherMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" xlink:label="arct_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="arct_CollaborationRevenueMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_CounterpartyNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="arct_CslSeqirusMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_GrantMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="arct_VinbiocareMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="arct_JanssenMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="arct_UltragenyxMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="arct_CureVacAGMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="arct_IsraelMinistryOfHealthMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="arct_SGIMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="arct_OtherMember" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="arct_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_ResearchCollaborationAndExclusiveLicenseAgreementMember" xlink:label="arct_ResearchCollaborationAndExclusiveLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_RevenueLineItems" xlink:label="arct_RevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_RevenueTable" xlink:label="arct_RevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_JanssenMember" xlink:label="arct_JanssenMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arct_ResearchCollaborationAndExclusiveLicenseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_RevenueLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_RevenueTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="arct_JanssenMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="arct_RevenueTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_RevenueTable" xlink:to="srt_CounterpartyNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_RevenueTable" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_RevenueTable" xlink:to="arct_RevenueLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://arcturusrx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsDetailsTextual" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://arcturusrx.com/20241231/taxonomy/role/DisclosureAccruedLiabilitiesDetailScheduleOfAccruedLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_AccruedCysticFibrosisFoundationLiability" xlink:label="arct_AccruedCysticFibrosisFoundationLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxesPayableCurrent" xlink:label="us-gaap_TaxesPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_ClinicalTrialAccrualsCurrent" xlink:label="arct_ClinicalTrialAccrualsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_VinbiocareContractualLiabilities" xlink:label="arct_VinbiocareContractualLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_LegalAccrualCurrent" xlink:label="arct_LegalAccrualCurrent"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_OtherAccruedResearchAndDevelopmentExpenses" xlink:label="arct_OtherAccruedResearchAndDevelopmentExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="arct_AccruedCysticFibrosisFoundationLiability" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_TaxesPayableCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="arct_ClinicalTrialAccrualsCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="arct_VinbiocareContractualLiabilities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="arct_LegalAccrualCurrent" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="arct_OtherAccruedResearchAndDevelopmentExpenses" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://arcturusrx.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfComponentsOfPropertyAndEquipmentNetDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetDetailsTextual" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureDebtDetailsTextual" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMember" xlink:label="us-gaap_LongTermDebtMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_LoanAndSecurityAgreementMember" xlink:label="arct_LoanAndSecurityAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:label="us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_WesternAllianceBankMember" xlink:label="arct_WesternAllianceBankMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_SG" xlink:label="country_SG"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_WellsFargoCreditAgreementMember" xlink:label="arct_WellsFargoCreditAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_DebtInstrumentExtendedTermPeriod" xlink:label="arct_DebtInstrumentExtendedTermPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BorrowingsUnderGuaranteedInvestmentAgreements" xlink:label="us-gaap_BorrowingsUnderGuaranteedInvestmentAgreements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_DebtInstrumentOptionForRenewalTerm" xlink:label="arct_DebtInstrumentOptionForRenewalTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:label="us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_RemainingLoanIncludingAccruedInterestForgiveable" xlink:label="arct_RemainingLoanIncludingAccruedInterestForgiveable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseLongTermDebt" xlink:label="us-gaap_InterestExpenseLongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_RepyamentOfPrincipalAndInterestOnCollateralizedTermLoan" xlink:label="arct_RepyamentOfPrincipalAndInterestOnCollateralizedTermLoan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCollateralAmount" xlink:label="us-gaap_DebtInstrumentCollateralAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="us-gaap_DebtInstrumentFeeAmount"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LongTermDebtMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arct_LoanAndSecurityAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_StatementGeographicalAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="arct_WesternAllianceBankMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_SG" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arct_WellsFargoCreditAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="arct_DebtInstrumentExtendedTermPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_CounterpartyNameAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_BorrowingsUnderGuaranteedInvestmentAgreements" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RepaymentsOfLongTermDebt" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_RangeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_VariableRateAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTerm" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="arct_DebtInstrumentOptionForRenewalTerm" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityCommitmentFeePercentage" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebt" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="arct_RemainingLoanIncludingAccruedInterestForgiveable" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseLongTermDebt" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="arct_RepyamentOfPrincipalAndInterestOnCollateralizedTermLoan" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCollateralAmount" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFeeAmount" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityDetailsTextual" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_UnvestedRestrictedOrdinarySharesMember" xlink:label="arct_UnvestedRestrictedOrdinarySharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_AlexionPharmaceuticalsIncMember" xlink:label="arct_AlexionPharmaceuticalsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_AcquiredInProcessResearchAndDevelopmentExpense" xlink:label="arct_AcquiredInProcessResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="arct_UnvestedRestrictedOrdinarySharesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="arct_AlexionPharmaceuticalsIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="arct_AcquiredInProcessResearchAndDevelopmentExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationDetailsTextual" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_TwoThousandNineteenOmnibusIncentivePlanMember" xlink:label="arct_TwoThousandNineteenOmnibusIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_TwentyTwentyOneInducementEquityIncentivePlanMember" xlink:label="arct_TwentyTwentyOneInducementEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_TwoThousandTwentyEmployeeStockPurchasePlanMember" xlink:label="arct_TwoThousandTwentyEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_ReductionInNumberOfCommonStockCapitalSharesAvailableForFutureIssuance" xlink:label="arct_ReductionInNumberOfCommonStockCapitalSharesAvailableForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="arct_TwoThousandNineteenOmnibusIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="arct_TwentyTwentyOneInducementEquityIncentivePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="arct_TwoThousandTwentyEmployeeStockPurchasePlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="arct_ReductionInNumberOfCommonStockCapitalSharesAvailableForFutureIssuance" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharePrice" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationDetails1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_11"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_11" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://arcturusrx.com/20241231/taxonomy/role/DisclosureSharebasedCompensationDetails2" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://arcturusrx.com/20241231/taxonomy/role/DisclosureSharebasedCompensationDetails3" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://arcturusrx.com/20241231/taxonomy/role/DisclosureIncomeTaxesDetails2" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://arcturusrx.com/20241231/taxonomy/role/DisclosureIncomeTaxesDetails3" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensation" xlink:label="arct_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensation"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentCredits" xlink:label="arct_EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentCredits"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_EffectiveIncomeTaxRateReconciliationUncertainTaxPosition" xlink:label="arct_EffectiveIncomeTaxRateReconciliationUncertainTaxPosition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences" xlink:label="arct_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="arct_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensation" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="arct_EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentCredits" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="arct_EffectiveIncomeTaxRateReconciliationUncertainTaxPosition" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="arct_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://arcturusrx.com/20241231/taxonomy/role/DisclosureIncomeTaxesDetails4" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_DeferredTaxLiabilitiesPropertyPlantAndEquipmentAndIntangibleAssets" xlink:label="arct_DeferredTaxLiabilitiesPropertyPlantAndEquipmentAndIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_DeferredTaxLiabilitiesRightOfUseAsset" xlink:label="arct_DeferredTaxLiabilitiesRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:label="us-gaap_DeferredTaxAssetsInventory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsEquityMethodInvestments" xlink:label="us-gaap_DeferredTaxAssetsEquityMethodInvestments"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets" xlink:label="arct_DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:label="arct_DeferredTaxAssetsCapitalizedResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_DeferredTaxAssetsRightOfUseLeaseLiability" xlink:label="arct_DeferredTaxAssetsRightOfUseLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="arct_DeferredTaxLiabilitiesPropertyPlantAndEquipmentAndIntangibleAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="arct_DeferredTaxLiabilitiesRightOfUseAsset" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsInventory" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsEquityMethodInvestments" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="arct_DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="arct_DeferredTaxAssetsCapitalizedResearchAndDevelopment" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="arct_DeferredTaxAssetsRightOfUseLeaseLiability" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetailsTextual" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_NotSubjectToExpirationMember" xlink:label="arct_NotSubjectToExpirationMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_IncomeTaxesTable" xlink:label="arct_IncomeTaxesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_IncomeTaxesLineItems" xlink:label="arct_IncomeTaxesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US" xlink:label="country_US"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_OrphanDrugCreditMember" xlink:label="arct_OrphanDrugCreditMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_CA" xlink:label="stpr_CA"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_MaximumPercentageOfLikelihoodOfUncertainTaxPositionRecognizedToBeSustained" xlink:label="arct_MaximumPercentageOfLikelihoodOfUncertainTaxPositionRecognizedToBeSustained"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_OperatingLossCarryforwardsExpirationYear" xlink:label="arct_OperatingLossCarryforwardsExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_TaxCreditCarryforwardExpirationYear" xlink:label="arct_TaxCreditCarryforwardExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_NetOperatingLossAndResearchAndDevelopmentCreditCarryforwardsLimitationsOnCumulativeChangeInOwnershipMinimumPercentage" xlink:label="arct_NetOperatingLossAndResearchAndDevelopmentCreditCarryforwardsLimitationsOnCumulativeChangeInOwnershipMinimumPercentage"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_NetOperatingLossAndResearchAndDevelopmentCreditCarryforwardsLimitationsOnCumulativeChangeInOwnershipPeriod" xlink:label="arct_NetOperatingLossAndResearchAndDevelopmentCreditCarryforwardsLimitationsOnCumulativeChangeInOwnershipPeriod"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="arct_NotSubjectToExpirationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_IncomeTaxesTable" xlink:to="srt_StatementGeographicalAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="arct_IncomeTaxesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="arct_OrphanDrugCreditMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_IncomeTaxesTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_IncomeTaxesLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_CA" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_IncomeTaxesTable" xlink:to="us-gaap_TaxPeriodAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_IncomeTaxesLineItems" xlink:to="arct_MaximumPercentageOfLikelihoodOfUncertainTaxPositionRecognizedToBeSustained" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_IncomeTaxesTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_IncomeTaxesTable" xlink:to="arct_IncomeTaxesLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_IncomeTaxesLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_IncomeTaxesLineItems" xlink:to="arct_OperatingLossCarryforwardsExpirationYear" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_IncomeTaxesLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_IncomeTaxesLineItems" xlink:to="arct_TaxCreditCarryforwardExpirationYear" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_IncomeTaxesLineItems" xlink:to="arct_NetOperatingLossAndResearchAndDevelopmentCreditCarryforwardsLimitationsOnCumulativeChangeInOwnershipMinimumPercentage" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_IncomeTaxesLineItems" xlink:to="arct_NetOperatingLossAndResearchAndDevelopmentCreditCarryforwardsLimitationsOnCumulativeChangeInOwnershipPeriod" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://arcturusrx.com/20241231/taxonomy/role/DisclosureIncomeTaxesDetails5" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_UnrecognizedTaxBenefitsDecreasesIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="arct_UnrecognizedTaxBenefitsDecreasesIncreasesResultingFromPriorPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_4"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="arct_UnrecognizedTaxBenefitsDecreasesIncreasesResultingFromPriorPeriodTaxPositions" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefits_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_COVIDNineteenVaccineDevelopmentMember" xlink:label="arct_COVIDNineteenVaccineDevelopmentMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_CommitmentAndContingenciesLineItems" xlink:label="arct_CommitmentAndContingenciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrantsReceivable" xlink:label="us-gaap_GrantsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_GrantOneMember" xlink:label="arct_GrantOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_CysticFibrosisFoundationTherapeuticsIncMember" xlink:label="arct_CysticFibrosisFoundationTherapeuticsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_FebruaryTwoThousandAndTwentyOneLeaseAgreementMember" xlink:label="arct_FebruaryTwoThousandAndTwentyOneLeaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_SG" xlink:label="country_SG"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_CommitmentAndContingenciesTable" xlink:label="arct_CommitmentAndContingenciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_DisbursementPeriodOneMember" xlink:label="arct_DisbursementPeriodOneMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_UnderlyingAgreementMember" xlink:label="arct_UnderlyingAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_ContraResearchAndDevelopmentExpense" xlink:label="arct_ContraResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_GrantTwoMember" xlink:label="arct_GrantTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_FebruaryTwoThousandAndTwentyLeaseAgreementMember" xlink:label="arct_FebruaryTwoThousandAndTwentyLeaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_DisbursementPeriodTwoMember" xlink:label="arct_DisbursementPeriodTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_ContraExpenseRemainingAmountIncludedInAccruedExpenses" xlink:label="arct_ContraExpenseRemainingAmountIncludedInAccruedExpenses"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_LUNARCFMember" xlink:label="arct_LUNARCFMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_SeptemberTwoThousandAndTwentyOneLeaseAgreementMember" xlink:label="arct_SeptemberTwoThousandAndTwentyOneLeaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_DisbursementPeriodThreeMember" xlink:label="arct_DisbursementPeriodThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_GrantReceivableNumberOfInstallments" xlink:label="arct_GrantReceivableNumberOfInstallments"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_OctoberTwoThousandAndSeventeenLeaseAmendmentMember" xlink:label="arct_OctoberTwoThousandAndSeventeenLeaseAmendmentMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_DisbursementPeriodFourMember" xlink:label="arct_DisbursementPeriodFourMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_PaymentReceivedFirstInstallment" xlink:label="arct_PaymentReceivedFirstInstallment"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_RecognizedContraExpense" xlink:label="arct_RecognizedContraExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesFairValueDisclosure" xlink:label="us-gaap_AccruedLiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForAdvanceToAffiliate" xlink:label="us-gaap_PaymentsForAdvanceToAffiliate"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_PaymentsForMatchingFundsForRemainingBudgetedCosts" xlink:label="arct_PaymentsForMatchingFundsForRemainingBudgetedCosts"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_DisbursedAmountUponExecutionOfAmendment" xlink:label="arct_DisbursedAmountUponExecutionOfAmendment"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_DisbursementAmountPayableUponAchievementOfProjectGoal" xlink:label="arct_DisbursementAmountPayableUponAchievementOfProjectGoal"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_FinalPaymentOfDisbursementAmount" xlink:label="arct_FinalPaymentOfDisbursementAmount"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_DisbursementPaymentUponAchievementOfRequiredManufacturingPracticesAndINDApplication" xlink:label="arct_DisbursementPaymentUponAchievementOfRequiredManufacturingPracticesAndINDApplication"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_ContraExpenseIncludedInResearchAndDevelopmentExpense" xlink:label="arct_ContraExpenseIncludedInResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:label="us-gaap_PaymentsForProceedsFromTenantAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="us-gaap_OperatingLeaseImpairmentLoss"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_MinimumAmountAgreedToIncurUnderResearchPlan" xlink:label="arct_MinimumAmountAgreedToIncurUnderResearchPlan"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_MonthlyBaseRent" xlink:label="arct_MonthlyBaseRent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arct_COVIDNineteenVaccineDevelopmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_CommitmentAndContingenciesLineItems" xlink:to="us-gaap_GrantsReceivable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="arct_GrantOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="arct_CysticFibrosisFoundationTherapeuticsIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="arct_FebruaryTwoThousandAndTwentyOneLeaseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_SG" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_CommitmentAndContingenciesTable" xlink:to="srt_StatementGeographicalAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="arct_CommitmentAndContingenciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="arct_DisbursementPeriodOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arct_UnderlyingAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_CommitmentAndContingenciesLineItems" xlink:to="arct_ContraResearchAndDevelopmentExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="arct_GrantTwoMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="arct_FebruaryTwoThousandAndTwentyLeaseAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_CommitmentAndContingenciesTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="arct_DisbursementPeriodTwoMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_CommitmentAndContingenciesLineItems" xlink:to="arct_ContraExpenseRemainingAmountIncludedInAccruedExpenses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="arct_LUNARCFMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="arct_SeptemberTwoThousandAndTwentyOneLeaseAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_CommitmentAndContingenciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="arct_DisbursementPeriodThreeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_CommitmentAndContingenciesLineItems" xlink:to="arct_GrantReceivableNumberOfInstallments" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="arct_OctoberTwoThousandAndSeventeenLeaseAmendmentMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_CommitmentAndContingenciesTable" xlink:to="srt_ProductOrServiceAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="arct_DisbursementPeriodFourMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_CommitmentAndContingenciesLineItems" xlink:to="arct_PaymentReceivedFirstInstallment" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_CommitmentAndContingenciesTable" xlink:to="srt_CounterpartyNameAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_CommitmentAndContingenciesLineItems" xlink:to="arct_RecognizedContraExpense" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_CommitmentAndContingenciesTable" xlink:to="srt_StatementScenarioAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_CommitmentAndContingenciesLineItems" xlink:to="us-gaap_AccruedLiabilitiesFairValueDisclosure" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_CommitmentAndContingenciesTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_CommitmentAndContingenciesLineItems" xlink:to="us-gaap_PaymentsForAdvanceToAffiliate" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_CommitmentAndContingenciesTable" xlink:to="us-gaap_LeaseContractualTermAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_CommitmentAndContingenciesLineItems" xlink:to="arct_PaymentsForMatchingFundsForRemainingBudgetedCosts" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_CommitmentAndContingenciesTable" xlink:to="arct_CommitmentAndContingenciesLineItems" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_CommitmentAndContingenciesLineItems" xlink:to="arct_DisbursedAmountUponExecutionOfAmendment" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_CommitmentAndContingenciesLineItems" xlink:to="arct_DisbursementAmountPayableUponAchievementOfProjectGoal" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_CommitmentAndContingenciesLineItems" xlink:to="arct_FinalPaymentOfDisbursementAmount" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_CommitmentAndContingenciesLineItems" xlink:to="arct_DisbursementPaymentUponAchievementOfRequiredManufacturingPracticesAndINDApplication" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_CommitmentAndContingenciesLineItems" xlink:to="arct_ContraExpenseIncludedInResearchAndDevelopmentExpense" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_CommitmentAndContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_CommitmentAndContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_CommitmentAndContingenciesLineItems" xlink:to="us-gaap_PaymentsForProceedsFromTenantAllowance" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_CommitmentAndContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_CommitmentAndContingenciesLineItems" xlink:to="us-gaap_SecurityDeposit" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_CommitmentAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseImpairmentLoss" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_CommitmentAndContingenciesLineItems" xlink:to="arct_MinimumAmountAgreedToIncurUnderResearchPlan" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_CommitmentAndContingenciesLineItems" xlink:to="arct_MonthlyBaseRent" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arct_CommitmentAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseCost" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesPaymentsOfOperatingLeaseLiabilityDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:label="arct_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="arct_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://arcturusrx.com/20241231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_NumberOfBusinessSegment" xlink:label="arct_NumberOfBusinessSegment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" xlink:label="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="arct_NumberOfBusinessSegment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://arcturusrx.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfReportedSegmentRevenuesSegmentLossAndIncomeAndSignificantSegmentExpensesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_LUNAR-COVIDMember" xlink:label="arct_LUNAR-COVIDMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_LUNAR-OTCMember" xlink:label="arct_LUNAR-OTCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_BARDAMember" xlink:label="arct_BARDAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_LUNAR-CFNetMember" xlink:label="arct_LUNAR-CFNetMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemAmount" xlink:label="us-gaap_SegmentReportingOtherItemAmount"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_Early-StageProgramsMember" xlink:label="arct_Early-StageProgramsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_DiscoveryTechnologiesMember" xlink:label="arct_DiscoveryTechnologiesMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_PayrollAndBenefitsMember" xlink:label="arct_PayrollAndBenefitsMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_FacilitiesAndEquipmentMember" xlink:label="arct_FacilitiesAndEquipmentMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentDomain" xlink:to="arct_LUNAR-COVIDMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_SegmentReportingInformationLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentDomain" xlink:to="arct_LUNAR-OTCMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentDomain" xlink:to="arct_BARDAMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentDomain" xlink:to="arct_LUNAR-CFNetMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingOtherItemAmount" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentDomain" xlink:to="arct_Early-StageProgramsMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_NetIncomeLoss" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentDomain" xlink:to="arct_DiscoveryTechnologiesMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentDomain" xlink:to="arct_PayrollAndBenefitsMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentDomain" xlink:to="arct_FacilitiesAndEquipmentMember" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://arcturusrx.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfReportedSegmentRevenuesSegmentLossAndIncomeAndSignificantSegmentExpensesParentheticalDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_SG" xlink:label="country_SG"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="srt_StatementGeographicalAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_SG" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_SegmentReportingInformationLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsEquityMethodInvestmentDetailsTextual" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_ADAIRTechnologyMember" xlink:label="arct_ADAIRTechnologyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:label="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_VallonPharmaceuticalsIncMember" xlink:label="arct_VallonPharmaceuticalsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:label="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_GriBioIncMember" xlink:label="arct_GriBioIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentOwnedBalanceShares" xlink:label="us-gaap_InvestmentOwnedBalanceShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentOwnedPercentOfNetAssets" xlink:label="us-gaap_InvestmentOwnedPercentOfNetAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="arct_ADAIRTechnologyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:to="arct_VallonPharmaceuticalsIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:to="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="arct_GriBioIncMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_InvestmentOwnedBalanceShares" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_RangeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_InvestmentOwnedPercentOfNetAssets" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://arcturusrx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_CollaborationRevenueMember" xlink:label="arct_CollaborationRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrantMember" xlink:label="us-gaap_GrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="arct_CollaborationRevenueMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_GrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_StockIssuedDuringPeriodValueUnderEquityPlan" xlink:label="arct_StockIssuedDuringPeriodValueUnderEquityPlan"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_StockIssuedDuringPeriodSharesUnderEquityPlan" xlink:label="arct_StockIssuedDuringPeriodSharesUnderEquityPlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="arct_StockIssuedDuringPeriodValueUnderEquityPlan" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="arct_StockIssuedDuringPeriodSharesUnderEquityPlan" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_UltragenyxMember" xlink:label="arct_UltragenyxMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_AcquisitionOfResearchAndDevelopmentInProcessThroughIssuanceOfCommonStock" xlink:label="arct_AcquisitionOfResearchAndDevelopmentInProcessThroughIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_IncreaseDecreaseOperatingLeaseRightOfUseAsset" xlink:label="arct_IncreaseDecreaseOperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_NonCashAssetDisposal" xlink:label="arct_NonCashAssetDisposal"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_AcquiredInProcessResearchAndDevelopmentExpense" xlink:label="arct_AcquiredInProcessResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossRealized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="arct_UltragenyxMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaidNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="arct_AcquisitionOfResearchAndDevelopmentInProcessThroughIssuanceOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="arct_IncreaseDecreaseOperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="arct_NonCashAssetDisposal" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="arct_AcquiredInProcessResearchAndDevelopmentExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockPlans" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossRealized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherNoncashIncomeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://arcturusrx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="ecd_AllIndividualsMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_KeithCKummerfeldMember" xlink:label="arct_KeithCKummerfeldMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_LanceKurataMember" xlink:label="arct_LanceKurataMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_DrPadmanabhChivukulaMember" xlink:label="arct_DrPadmanabhChivukulaMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_DirectorsOrOfficersExceptChiefScientificOfficerCooSvpCcAndPaoMember" xlink:label="arct_DirectorsOrOfficersExceptChiefScientificOfficerCooSvpCcAndPaoMember"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllIndividualsMember" xlink:to="arct_KeithCKummerfeldMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllIndividualsMember" xlink:to="arct_LanceKurataMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllIndividualsMember" xlink:to="arct_DrPadmanabhChivukulaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllIndividualsMember" xlink:to="arct_DirectorsOrOfficersExceptChiefScientificOfficerCooSvpCcAndPaoMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureOrganizationDetailsTextual">
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:label="arct_OrganizationAndSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_OrganizationAndSignificantAccountingPoliciesTable" xlink:label="arct_OrganizationAndSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_UnderwrittenPublicOfferingMember" xlink:label="arct_UnderwrittenPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_SeqirusIncMember" xlink:label="arct_SeqirusIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_UpfrontPaymentReceived" xlink:label="arct_UpfrontPaymentReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_AdditionalMilestonePaymentsReceived" xlink:label="arct_AdditionalMilestonePaymentsReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="arct_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="arct_OrganizationAndSignificantAccountingPoliciesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="arct_UnderwrittenPublicOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="arct_SeqirusIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="arct_OrganizationAndSignificantAccountingPoliciesTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="arct_OrganizationAndSignificantAccountingPoliciesTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="arct_UpfrontPaymentReceived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="arct_AdditionalMilestonePaymentsReceived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesDetailsTextual">
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_SummaryOfSignificantAccountingPolicyLineItems" xlink:label="arct_SummaryOfSignificantAccountingPolicyLineItems"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_ScheduleOfSummaryOfSignificantAccountingPoliciesTable" xlink:label="arct_ScheduleOfSummaryOfSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_WellsFargoCreditAgreementMember" xlink:label="arct_WellsFargoCreditAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditConcentrationRiskMember" xlink:label="us-gaap_CreditConcentrationRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdate202307Member" xlink:label="us-gaap_AccountingStandardsUpdate202307Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="us-gaap_LossContingencyNatureDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyLeaseGuaranteeMember" xlink:label="us-gaap_PropertyLeaseGuaranteeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_default"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" xlink:label="arct_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="us-gaap_LossContingencyNatureDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_EmployeesAndOfficersMember" xlink:label="arct_EmployeesAndOfficersMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCollateralAmount" xlink:label="us-gaap_DebtInstrumentCollateralAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdate201912Member" xlink:label="us-gaap_AccountingStandardsUpdate201912Member"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_CSLMember" xlink:label="arct_CSLMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_VinbiocareMember" xlink:label="arct_VinbiocareMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_ConcentrationRiskNumberOfCustomer" xlink:label="arct_ConcentrationRiskNumberOfCustomer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentOwnedPercentOfNetAssets" xlink:label="us-gaap_InvestmentOwnedPercentOfNetAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:label="us-gaap_EquityMethodInvestmentAggregateCost"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_UpfrontFeeAndConsideration" xlink:label="arct_UpfrontFeeAndConsideration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireInterestInJointVenture" xlink:label="us-gaap_PaymentsToAcquireInterestInJointVenture"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_PercentageOfEquityInterestInJointVenture" xlink:label="arct_PercentageOfEquityInterestInJointVenture"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Dividends" xlink:label="us-gaap_Dividends"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="arct_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="arct_ScheduleOfSummaryOfSignificantAccountingPoliciesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arct_WellsFargoCreditAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CreditConcentrationRiskMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate202307Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingencyNatureDomain" xlink:to="us-gaap_PropertyLeaseGuaranteeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="arct_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="us-gaap_LossContingencyNatureDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="us-gaap_LossContingencyNatureDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="arct_ScheduleOfSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="arct_EmployeesAndOfficersMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="us-gaap_DebtInstrumentCollateralAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201912Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="arct_CSLMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="arct_ScheduleOfSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="us-gaap_RestrictedCashNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="arct_VinbiocareMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="arct_ScheduleOfSummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="arct_ScheduleOfSummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="arct_ConcentrationRiskNumberOfCustomer" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="arct_ScheduleOfSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="arct_ScheduleOfSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_VestingAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="arct_ScheduleOfSummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_TitleOfIndividualAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="us-gaap_InvestmentOwnedPercentOfNetAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="arct_ScheduleOfSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="us-gaap_EquityMethodInvestmentAggregateCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="arct_ScheduleOfSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_LossContingenciesByNatureOfContingencyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="arct_UpfrontFeeAndConsideration" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="us-gaap_PaymentsToAcquireInterestInJointVenture" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="arct_PercentageOfEquityInterestInJointVenture" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="us-gaap_GoodwillImpairmentLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="us-gaap_Dividends" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual">
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_RevenueLineItems" xlink:label="arct_RevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_RevenueTable" xlink:label="arct_RevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_ResearchCollaborationAndLicenseAgreementMember" xlink:label="arct_ResearchCollaborationAndLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_RareDiseaseTargetsMember" xlink:label="arct_RareDiseaseTargetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerDurationDomain" xlink:label="us-gaap_ContractWithCustomerDurationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermContractWithCustomerMember" xlink:label="us-gaap_ShortTermContractWithCustomerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_PharmaceuticalCompanyMember" xlink:label="arct_PharmaceuticalCompanyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerDurationAxis" xlink:label="us-gaap_ContractWithCustomerDurationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerDurationDomain" xlink:label="us-gaap_ContractWithCustomerDurationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_JanssenMember" xlink:label="arct_JanssenMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_ForeignCountriesMember" xlink:label="arct_ForeignCountriesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_VinbiocareAgreementMember" xlink:label="arct_VinbiocareAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_UpfrontPaymentReceived" xlink:label="arct_UpfrontPaymentReceived"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_NonRareDiseaseTargetsMember" xlink:label="arct_NonRareDiseaseTargetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermContractWithCustomerMember" xlink:label="us-gaap_LongTermContractWithCustomerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_UltragenyxMember" xlink:label="arct_UltragenyxMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_IL" xlink:label="stpr_IL"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_SeqirusAgreementMember" xlink:label="arct_SeqirusAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_NumberOfPerformanceObligations" xlink:label="arct_NumberOfPerformanceObligations"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_Covid19VaccineMember" xlink:label="arct_Covid19VaccineMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_CureVacAGMember" xlink:label="arct_CureVacAGMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_CslCollaborationAgreementMember" xlink:label="arct_CslCollaborationAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_UpfrontConsiderationReceived" xlink:label="arct_UpfrontConsiderationReceived"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_ManufacturingAndSupplyOfArct154DrugProductMember" xlink:label="arct_ManufacturingAndSupplyOfArct154DrugProductMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_CollaborationPartnerCureVacEnteredIntoCoDevelopmentAgreementMember" xlink:label="arct_CollaborationPartnerCureVacEnteredIntoCoDevelopmentAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_StudySupportAgreementMember" xlink:label="arct_StudySupportAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_DevelopmentMilestonesAchieved" xlink:label="arct_DevelopmentMilestonesAchieved"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_PhaseIClinicalStudyMember" xlink:label="arct_PhaseIClinicalStudyMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_SeqirusIncMember" xlink:label="arct_SeqirusIncMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_ResearchCollaborationAndExclusiveLicenseAgreementMember" xlink:label="arct_ResearchCollaborationAndExclusiveLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_AchievedDevelopmentMilestoneIncludedAccountsReceivable" xlink:label="arct_AchievedDevelopmentMilestoneIncludedAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_VinbiocareMember" xlink:label="arct_VinbiocareMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_MRNATechnologyMember" xlink:label="arct_MRNATechnologyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" xlink:label="arct_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_OtherCollaborationAgreementsMember" xlink:label="arct_OtherCollaborationAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_PercentageOfNetProfits" xlink:label="arct_PercentageOfNetProfits"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_DevelopmentMilestonesReceivedAdvancePayment" xlink:label="arct_DevelopmentMilestonesReceivedAdvancePayment"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_MilestonePayments" xlink:label="arct_MilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_AdditionalClinicalMilestonePayment" xlink:label="arct_AdditionalClinicalMilestonePayment"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_AdditionalPaymentsUponMeetingCertainClinicalMilestones" xlink:label="arct_AdditionalPaymentsUponMeetingCertainClinicalMilestones"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_RevenueRecognitionPotentialMilestoneRevenueRecognized" xlink:label="arct_RevenueRecognitionPotentialMilestoneRevenueRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="us-gaap_RevenueRemainingPerformanceObligation"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_OptionExerciseRevenueRangePerTarget" xlink:label="arct_OptionExerciseRevenueRangePerTarget"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_OptionExerciseFeeRevenueReceived" xlink:label="arct_OptionExerciseFeeRevenueReceived"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_RoyaltyPaymentTermDescription" xlink:label="arct_RoyaltyPaymentTermDescription"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_NumberOfReserveTargets" xlink:label="arct_NumberOfReserveTargets"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_OptionToPurchaseOfAdditionalSharesOfCommonStock" xlink:label="arct_OptionToPurchaseOfAdditionalSharesOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_OptionToPurchaseOfAdditionalSharesOfCommonStockPricePerShare" xlink:label="arct_OptionToPurchaseOfAdditionalSharesOfCommonStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_CollaborationAgreementConsiderationReceived" xlink:label="arct_CollaborationAgreementConsiderationReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_CollaborationAgreementTransactionPrice" xlink:label="arct_CollaborationAgreementTransactionPrice"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_LackOfMarketabilityDiscountRestrictedPeriod" xlink:label="arct_LackOfMarketabilityDiscountRestrictedPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuePracticalExpedientRemainingPerformanceObligationDescription" xlink:label="us-gaap_RevenuePracticalExpedientRemainingPerformanceObligationDescription"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_RevenueRecognitionReserveTargetExclusivityPeriod" xlink:label="arct_RevenueRecognitionReserveTargetExclusivityPeriod"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_DevelopmentAndOptionAgreementDate" xlink:label="arct_DevelopmentAndOptionAgreementDate"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_ExpirationOfIntialTerm" xlink:label="arct_ExpirationOfIntialTerm"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_OptionToExtendInitialTermOnAnAnnualBasis" xlink:label="arct_OptionToExtendInitialTermOnAnAnnualBasis"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_PotentialTargetLicenseTerm" xlink:label="arct_PotentialTargetLicenseTerm"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_AdjustmentsToTransactionPrice" xlink:label="arct_AdjustmentsToTransactionPrice"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_UpfrontFeeReceived" xlink:label="arct_UpfrontFeeReceived"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_CollaborationAgreementContractualTerm" xlink:label="arct_CollaborationAgreementContractualTerm"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_AgreementAmountAgreedToFund" xlink:label="arct_AgreementAmountAgreedToFund"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_NonRefundablePaymentReceived" xlink:label="arct_NonRefundablePaymentReceived"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_NumberOfReservedVaccineDoses" xlink:label="arct_NumberOfReservedVaccineDoses"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_UpfrontPaymentToBeReceived" xlink:label="arct_UpfrontPaymentToBeReceived"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_EligibleToReceiveDevelopmentMilestonePayment" xlink:label="arct_EligibleToReceiveDevelopmentMilestonePayment"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_EligibleToReceiveCommercialMilestonePayment" xlink:label="arct_EligibleToReceiveCommercialMilestonePayment"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_DevelopmentAndRegulatoryMilestonesAchieved" xlink:label="arct_DevelopmentAndRegulatoryMilestonesAchieved"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_AchievedDevelopmentAndRegulatoryMilestoneIncludedAccountsReceivable" xlink:label="arct_AchievedDevelopmentAndRegulatoryMilestoneIncludedAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_DevelopmentMilestonesAmountDueForAgreement" xlink:label="arct_DevelopmentMilestonesAmountDueForAgreement"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_ConditionalPayment" xlink:label="arct_ConditionalPayment"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_ReservedUpfrontPayment" xlink:label="arct_ReservedUpfrontPayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_AdditionalFinancialSupport" xlink:label="arct_AdditionalFinancialSupport"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_ReversalOfRevenue" xlink:label="arct_ReversalOfRevenue"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_GrantRevenue" xlink:label="arct_GrantRevenue"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_GrantRevenueOutstanding" xlink:label="arct_GrantRevenueOutstanding"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="arct_RevenueLineItems" xlink:to="arct_RevenueTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arct_ResearchCollaborationAndLicenseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_RevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="arct_RareDiseaseTargetsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContractWithCustomerDurationDomain" xlink:to="us-gaap_ShortTermContractWithCustomerMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="arct_PharmaceuticalCompanyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="arct_RevenueTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ContractWithCustomerDurationAxis" xlink:to="us-gaap_ContractWithCustomerDurationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ContractWithCustomerDurationAxis" xlink:to="us-gaap_ContractWithCustomerDurationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="arct_JanssenMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="arct_ForeignCountriesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arct_VinbiocareAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_RevenueLineItems" xlink:to="arct_UpfrontPaymentReceived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="arct_NonRareDiseaseTargetsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContractWithCustomerDurationDomain" xlink:to="us-gaap_LongTermContractWithCustomerMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="arct_RevenueTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="arct_UltragenyxMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_IL" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arct_SeqirusAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_RevenueLineItems" xlink:to="arct_NumberOfPerformanceObligations" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="arct_Covid19VaccineMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="arct_RevenueTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="arct_CureVacAGMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arct_CslCollaborationAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_RevenueLineItems" xlink:to="arct_UpfrontConsiderationReceived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="arct_ManufacturingAndSupplyOfArct154DrugProductMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="arct_RevenueTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="arct_CollaborationPartnerCureVacEnteredIntoCoDevelopmentAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arct_StudySupportAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_RevenueLineItems" xlink:to="arct_DevelopmentMilestonesAchieved" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="arct_PhaseIClinicalStudyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="arct_RevenueTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="arct_SeqirusIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arct_ResearchCollaborationAndExclusiveLicenseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_RevenueLineItems" xlink:to="arct_AchievedDevelopmentMilestoneIncludedAccountsReceivable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="arct_RevenueTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="arct_VinbiocareMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arct_MRNATechnologyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_RevenueLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="arct_RevenueTable" xlink:to="srt_StatementScenarioAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="arct_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arct_OtherCollaborationAgreementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_RevenueLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="arct_RevenueTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_RevenueLineItems" xlink:to="arct_PercentageOfNetProfits" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="arct_RevenueTable" xlink:to="us-gaap_ContractWithCustomerDurationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_RevenueLineItems" xlink:to="arct_DevelopmentMilestonesReceivedAdvancePayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_RevenueLineItems" xlink:to="arct_MilestonePayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_RevenueLineItems" xlink:to="arct_AdditionalClinicalMilestonePayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_RevenueLineItems" xlink:to="arct_AdditionalPaymentsUponMeetingCertainClinicalMilestones" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_RevenueLineItems" xlink:to="arct_RevenueRecognitionPotentialMilestoneRevenueRecognized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_RevenueLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_RevenueLineItems" xlink:to="arct_OptionExerciseRevenueRangePerTarget" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_RevenueLineItems" xlink:to="arct_OptionExerciseFeeRevenueReceived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_RevenueLineItems" xlink:to="arct_RoyaltyPaymentTermDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_RevenueLineItems" xlink:to="arct_NumberOfReserveTargets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_RevenueLineItems" xlink:to="arct_OptionToPurchaseOfAdditionalSharesOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_RevenueLineItems" xlink:to="arct_OptionToPurchaseOfAdditionalSharesOfCommonStockPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_RevenueLineItems" xlink:to="arct_CollaborationAgreementConsiderationReceived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_RevenueLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_RevenueLineItems" xlink:to="arct_CollaborationAgreementTransactionPrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_RevenueLineItems" xlink:to="arct_LackOfMarketabilityDiscountRestrictedPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_RevenueLineItems" xlink:to="us-gaap_RevenuePracticalExpedientRemainingPerformanceObligationDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_RevenueLineItems" xlink:to="arct_RevenueRecognitionReserveTargetExclusivityPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_RevenueLineItems" xlink:to="arct_DevelopmentAndOptionAgreementDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_RevenueLineItems" xlink:to="arct_ExpirationOfIntialTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="29" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_RevenueLineItems" xlink:to="arct_OptionToExtendInitialTermOnAnAnnualBasis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="30" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_RevenueLineItems" xlink:to="arct_PotentialTargetLicenseTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="31" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_RevenueLineItems" xlink:to="arct_AdjustmentsToTransactionPrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="32" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_RevenueLineItems" xlink:to="arct_UpfrontFeeReceived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="33" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_RevenueLineItems" xlink:to="arct_CollaborationAgreementContractualTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="34" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_RevenueLineItems" xlink:to="arct_AgreementAmountAgreedToFund" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="35" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_RevenueLineItems" xlink:to="arct_NonRefundablePaymentReceived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="36" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_RevenueLineItems" xlink:to="arct_NumberOfReservedVaccineDoses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="37" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_RevenueLineItems" xlink:to="arct_UpfrontPaymentToBeReceived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="38" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_RevenueLineItems" xlink:to="arct_EligibleToReceiveDevelopmentMilestonePayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="39" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_RevenueLineItems" xlink:to="arct_EligibleToReceiveCommercialMilestonePayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="40" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_RevenueLineItems" xlink:to="arct_DevelopmentAndRegulatoryMilestonesAchieved" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="41" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_RevenueLineItems" xlink:to="arct_AchievedDevelopmentAndRegulatoryMilestoneIncludedAccountsReceivable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="42" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_RevenueLineItems" xlink:to="arct_DevelopmentMilestonesAmountDueForAgreement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="43" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_RevenueLineItems" xlink:to="arct_ConditionalPayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="44" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_RevenueLineItems" xlink:to="arct_ReservedUpfrontPayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="45" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_RevenueLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="46" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_RevenueLineItems" xlink:to="arct_AdditionalFinancialSupport" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="47" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_RevenueLineItems" xlink:to="arct_ReversalOfRevenue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="48" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_RevenueLineItems" xlink:to="arct_GrantRevenue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="49" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_RevenueLineItems" xlink:to="arct_GrantRevenueOutstanding" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueSummaryOfRevenuesDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_CollaborationRevenueMember" xlink:label="arct_CollaborationRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_CslSeqirusMember" xlink:label="arct_CslSeqirusMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrantMember" xlink:label="us-gaap_GrantMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_VinbiocareMember" xlink:label="arct_VinbiocareMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_JanssenMember" xlink:label="arct_JanssenMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_UltragenyxMember" xlink:label="arct_UltragenyxMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_CureVacAGMember" xlink:label="arct_CureVacAGMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_IsraelMinistryOfHealthMember" xlink:label="arct_IsraelMinistryOfHealthMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_SGIMember" xlink:label="arct_SGIMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_OtherMember" xlink:label="arct_OtherMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" xlink:label="arct_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="arct_CollaborationRevenueMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="arct_CslSeqirusMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_GrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="arct_VinbiocareMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="arct_JanssenMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="arct_UltragenyxMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="arct_CureVacAGMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="arct_IsraelMinistryOfHealthMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="arct_SGIMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="arct_OtherMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="arct_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual1">
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_RevenueLineItems" xlink:label="arct_RevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_RevenueTable" xlink:label="arct_RevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_ResearchCollaborationAndExclusiveLicenseAgreementMember" xlink:label="arct_ResearchCollaborationAndExclusiveLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_JanssenMember" xlink:label="arct_JanssenMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="arct_RevenueLineItems" xlink:to="arct_RevenueTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arct_ResearchCollaborationAndExclusiveLicenseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_RevenueLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="arct_RevenueTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="arct_JanssenMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="arct_RevenueTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="arct_RevenueTable" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual1Default">
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_RevenueLineItems" xlink:label="arct_RevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_RevenueTable" xlink:label="arct_RevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_ResearchCollaborationAndExclusiveLicenseAgreementMember" xlink:label="arct_ResearchCollaborationAndExclusiveLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_JanssenMember" xlink:label="arct_JanssenMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="arct_RevenueLineItems" xlink:to="arct_RevenueTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arct_ResearchCollaborationAndExclusiveLicenseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="arct_RevenueTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_RevenueLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="arct_JanssenMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="arct_RevenueTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://arcturusrx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsDetailsTextual">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://arcturusrx.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfComponentsOfPropertyAndEquipmentNetDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureDebtDetailsTextual">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMember" xlink:label="us-gaap_LongTermDebtMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_LoanAndSecurityAgreementMember" xlink:label="arct_LoanAndSecurityAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:label="us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_WesternAllianceBankMember" xlink:label="arct_WesternAllianceBankMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_SG" xlink:label="country_SG"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_WellsFargoCreditAgreementMember" xlink:label="arct_WellsFargoCreditAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_DebtInstrumentExtendedTermPeriod" xlink:label="arct_DebtInstrumentExtendedTermPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BorrowingsUnderGuaranteedInvestmentAgreements" xlink:label="us-gaap_BorrowingsUnderGuaranteedInvestmentAgreements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_DebtInstrumentOptionForRenewalTerm" xlink:label="arct_DebtInstrumentOptionForRenewalTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:label="us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_RemainingLoanIncludingAccruedInterestForgiveable" xlink:label="arct_RemainingLoanIncludingAccruedInterestForgiveable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseLongTermDebt" xlink:label="us-gaap_InterestExpenseLongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_RepyamentOfPrincipalAndInterestOnCollateralizedTermLoan" xlink:label="arct_RepyamentOfPrincipalAndInterestOnCollateralizedTermLoan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCollateralAmount" xlink:label="us-gaap_DebtInstrumentCollateralAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="us-gaap_DebtInstrumentFeeAmount"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LongTermDebtMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arct_LoanAndSecurityAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="arct_WesternAllianceBankMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_SG" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arct_WellsFargoCreditAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="arct_DebtInstrumentExtendedTermPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_BorrowingsUnderGuaranteedInvestmentAgreements" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RepaymentsOfLongTermDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_VariableRateAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="arct_DebtInstrumentOptionForRenewalTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityCommitmentFeePercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="arct_RemainingLoanIncludingAccruedInterestForgiveable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseLongTermDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="arct_RepyamentOfPrincipalAndInterestOnCollateralizedTermLoan" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCollateralAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFeeAmount" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityDetailsTextual">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_UnvestedRestrictedOrdinarySharesMember" xlink:label="arct_UnvestedRestrictedOrdinarySharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_AlexionPharmaceuticalsIncMember" xlink:label="arct_AlexionPharmaceuticalsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_AcquiredInProcessResearchAndDevelopmentExpense" xlink:label="arct_AcquiredInProcessResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="arct_UnvestedRestrictedOrdinarySharesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="arct_AlexionPharmaceuticalsIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="arct_AcquiredInProcessResearchAndDevelopmentExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationDetailsTextual">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_TwoThousandNineteenOmnibusIncentivePlanMember" xlink:label="arct_TwoThousandNineteenOmnibusIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_TwentyTwentyOneInducementEquityIncentivePlanMember" xlink:label="arct_TwentyTwentyOneInducementEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_TwoThousandTwentyEmployeeStockPurchasePlanMember" xlink:label="arct_TwoThousandTwentyEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_ReductionInNumberOfCommonStockCapitalSharesAvailableForFutureIssuance" xlink:label="arct_ReductionInNumberOfCommonStockCapitalSharesAvailableForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="arct_TwoThousandNineteenOmnibusIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="arct_TwentyTwentyOneInducementEquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="arct_TwoThousandTwentyEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="arct_ReductionInNumberOfCommonStockCapitalSharesAvailableForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharePrice" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://arcturusrx.com/20241231/taxonomy/role/DisclosureSharebasedCompensationDetails2">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://arcturusrx.com/20241231/taxonomy/role/DisclosureSharebasedCompensationDetails3">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetailsTextual">
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_IncomeTaxesLineItems" xlink:label="arct_IncomeTaxesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_IncomeTaxesTable" xlink:label="arct_IncomeTaxesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_NotSubjectToExpirationMember" xlink:label="arct_NotSubjectToExpirationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US" xlink:label="country_US"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_OrphanDrugCreditMember" xlink:label="arct_OrphanDrugCreditMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_CA" xlink:label="stpr_CA"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_MaximumPercentageOfLikelihoodOfUncertainTaxPositionRecognizedToBeSustained" xlink:label="arct_MaximumPercentageOfLikelihoodOfUncertainTaxPositionRecognizedToBeSustained"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_OperatingLossCarryforwardsExpirationYear" xlink:label="arct_OperatingLossCarryforwardsExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_TaxCreditCarryforwardExpirationYear" xlink:label="arct_TaxCreditCarryforwardExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_NetOperatingLossAndResearchAndDevelopmentCreditCarryforwardsLimitationsOnCumulativeChangeInOwnershipMinimumPercentage" xlink:label="arct_NetOperatingLossAndResearchAndDevelopmentCreditCarryforwardsLimitationsOnCumulativeChangeInOwnershipMinimumPercentage"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_NetOperatingLossAndResearchAndDevelopmentCreditCarryforwardsLimitationsOnCumulativeChangeInOwnershipPeriod" xlink:label="arct_NetOperatingLossAndResearchAndDevelopmentCreditCarryforwardsLimitationsOnCumulativeChangeInOwnershipPeriod"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="arct_IncomeTaxesLineItems" xlink:to="arct_IncomeTaxesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="arct_NotSubjectToExpirationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="arct_IncomeTaxesTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="arct_OrphanDrugCreditMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="arct_IncomeTaxesTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_IncomeTaxesLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_CA" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="arct_IncomeTaxesTable" xlink:to="us-gaap_TaxPeriodAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_IncomeTaxesLineItems" xlink:to="arct_MaximumPercentageOfLikelihoodOfUncertainTaxPositionRecognizedToBeSustained" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="arct_IncomeTaxesTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_IncomeTaxesLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_IncomeTaxesLineItems" xlink:to="arct_OperatingLossCarryforwardsExpirationYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_IncomeTaxesLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_IncomeTaxesLineItems" xlink:to="arct_TaxCreditCarryforwardExpirationYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_IncomeTaxesLineItems" xlink:to="arct_NetOperatingLossAndResearchAndDevelopmentCreditCarryforwardsLimitationsOnCumulativeChangeInOwnershipMinimumPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_IncomeTaxesLineItems" xlink:to="arct_NetOperatingLossAndResearchAndDevelopmentCreditCarryforwardsLimitationsOnCumulativeChangeInOwnershipPeriod" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual">
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_CommitmentAndContingenciesLineItems" xlink:label="arct_CommitmentAndContingenciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_CommitmentAndContingenciesTable" xlink:label="arct_CommitmentAndContingenciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_COVIDNineteenVaccineDevelopmentMember" xlink:label="arct_COVIDNineteenVaccineDevelopmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrantsReceivable" xlink:label="us-gaap_GrantsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_GrantOneMember" xlink:label="arct_GrantOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_CysticFibrosisFoundationTherapeuticsIncMember" xlink:label="arct_CysticFibrosisFoundationTherapeuticsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_FebruaryTwoThousandAndTwentyOneLeaseAgreementMember" xlink:label="arct_FebruaryTwoThousandAndTwentyOneLeaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_SG" xlink:label="country_SG"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_DisbursementPeriodOneMember" xlink:label="arct_DisbursementPeriodOneMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_UnderlyingAgreementMember" xlink:label="arct_UnderlyingAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_ContraResearchAndDevelopmentExpense" xlink:label="arct_ContraResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_GrantTwoMember" xlink:label="arct_GrantTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_FebruaryTwoThousandAndTwentyLeaseAgreementMember" xlink:label="arct_FebruaryTwoThousandAndTwentyLeaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_DisbursementPeriodTwoMember" xlink:label="arct_DisbursementPeriodTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_ContraExpenseRemainingAmountIncludedInAccruedExpenses" xlink:label="arct_ContraExpenseRemainingAmountIncludedInAccruedExpenses"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_LUNARCFMember" xlink:label="arct_LUNARCFMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_SeptemberTwoThousandAndTwentyOneLeaseAgreementMember" xlink:label="arct_SeptemberTwoThousandAndTwentyOneLeaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_DisbursementPeriodThreeMember" xlink:label="arct_DisbursementPeriodThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_GrantReceivableNumberOfInstallments" xlink:label="arct_GrantReceivableNumberOfInstallments"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_OctoberTwoThousandAndSeventeenLeaseAmendmentMember" xlink:label="arct_OctoberTwoThousandAndSeventeenLeaseAmendmentMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_DisbursementPeriodFourMember" xlink:label="arct_DisbursementPeriodFourMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_PaymentReceivedFirstInstallment" xlink:label="arct_PaymentReceivedFirstInstallment"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_RecognizedContraExpense" xlink:label="arct_RecognizedContraExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesFairValueDisclosure" xlink:label="us-gaap_AccruedLiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForAdvanceToAffiliate" xlink:label="us-gaap_PaymentsForAdvanceToAffiliate"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_PaymentsForMatchingFundsForRemainingBudgetedCosts" xlink:label="arct_PaymentsForMatchingFundsForRemainingBudgetedCosts"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_DisbursedAmountUponExecutionOfAmendment" xlink:label="arct_DisbursedAmountUponExecutionOfAmendment"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_DisbursementAmountPayableUponAchievementOfProjectGoal" xlink:label="arct_DisbursementAmountPayableUponAchievementOfProjectGoal"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_FinalPaymentOfDisbursementAmount" xlink:label="arct_FinalPaymentOfDisbursementAmount"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_DisbursementPaymentUponAchievementOfRequiredManufacturingPracticesAndINDApplication" xlink:label="arct_DisbursementPaymentUponAchievementOfRequiredManufacturingPracticesAndINDApplication"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_ContraExpenseIncludedInResearchAndDevelopmentExpense" xlink:label="arct_ContraExpenseIncludedInResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:label="us-gaap_PaymentsForProceedsFromTenantAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="us-gaap_OperatingLeaseImpairmentLoss"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_MinimumAmountAgreedToIncurUnderResearchPlan" xlink:label="arct_MinimumAmountAgreedToIncurUnderResearchPlan"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_MonthlyBaseRent" xlink:label="arct_MonthlyBaseRent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="arct_CommitmentAndContingenciesLineItems" xlink:to="arct_CommitmentAndContingenciesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arct_COVIDNineteenVaccineDevelopmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_CommitmentAndContingenciesLineItems" xlink:to="us-gaap_GrantsReceivable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="arct_GrantOneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="arct_CysticFibrosisFoundationTherapeuticsIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="arct_FebruaryTwoThousandAndTwentyOneLeaseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_SG" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="arct_CommitmentAndContingenciesTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="arct_DisbursementPeriodOneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arct_UnderlyingAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_CommitmentAndContingenciesLineItems" xlink:to="arct_ContraResearchAndDevelopmentExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="arct_GrantTwoMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="arct_FebruaryTwoThousandAndTwentyLeaseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="arct_CommitmentAndContingenciesTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="arct_DisbursementPeriodTwoMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_CommitmentAndContingenciesLineItems" xlink:to="arct_ContraExpenseRemainingAmountIncludedInAccruedExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="arct_LUNARCFMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="arct_SeptemberTwoThousandAndTwentyOneLeaseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="arct_CommitmentAndContingenciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="arct_DisbursementPeriodThreeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_CommitmentAndContingenciesLineItems" xlink:to="arct_GrantReceivableNumberOfInstallments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="arct_OctoberTwoThousandAndSeventeenLeaseAmendmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="arct_CommitmentAndContingenciesTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="arct_DisbursementPeriodFourMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_CommitmentAndContingenciesLineItems" xlink:to="arct_PaymentReceivedFirstInstallment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="arct_CommitmentAndContingenciesTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_CommitmentAndContingenciesLineItems" xlink:to="arct_RecognizedContraExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="arct_CommitmentAndContingenciesTable" xlink:to="srt_StatementScenarioAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_CommitmentAndContingenciesLineItems" xlink:to="us-gaap_AccruedLiabilitiesFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="arct_CommitmentAndContingenciesTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_CommitmentAndContingenciesLineItems" xlink:to="us-gaap_PaymentsForAdvanceToAffiliate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="arct_CommitmentAndContingenciesTable" xlink:to="us-gaap_LeaseContractualTermAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_CommitmentAndContingenciesLineItems" xlink:to="arct_PaymentsForMatchingFundsForRemainingBudgetedCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_CommitmentAndContingenciesLineItems" xlink:to="arct_DisbursedAmountUponExecutionOfAmendment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_CommitmentAndContingenciesLineItems" xlink:to="arct_DisbursementAmountPayableUponAchievementOfProjectGoal" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_CommitmentAndContingenciesLineItems" xlink:to="arct_FinalPaymentOfDisbursementAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_CommitmentAndContingenciesLineItems" xlink:to="arct_DisbursementPaymentUponAchievementOfRequiredManufacturingPracticesAndINDApplication" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_CommitmentAndContingenciesLineItems" xlink:to="arct_ContraExpenseIncludedInResearchAndDevelopmentExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_CommitmentAndContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_CommitmentAndContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_CommitmentAndContingenciesLineItems" xlink:to="us-gaap_PaymentsForProceedsFromTenantAllowance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_CommitmentAndContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_CommitmentAndContingenciesLineItems" xlink:to="us-gaap_SecurityDeposit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_CommitmentAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseImpairmentLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_CommitmentAndContingenciesLineItems" xlink:to="arct_MinimumAmountAgreedToIncurUnderResearchPlan" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_CommitmentAndContingenciesLineItems" xlink:to="arct_MonthlyBaseRent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arct_CommitmentAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseCost" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://arcturusrx.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfReportedSegmentRevenuesSegmentLossAndIncomeAndSignificantSegmentExpensesDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_LUNAR-COVIDMember" xlink:label="arct_LUNAR-COVIDMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_LUNAR-OTCMember" xlink:label="arct_LUNAR-OTCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_BARDAMember" xlink:label="arct_BARDAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_LUNAR-CFNetMember" xlink:label="arct_LUNAR-CFNetMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemAmount" xlink:label="us-gaap_SegmentReportingOtherItemAmount"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_Early-StageProgramsMember" xlink:label="arct_Early-StageProgramsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_DiscoveryTechnologiesMember" xlink:label="arct_DiscoveryTechnologiesMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_PayrollAndBenefitsMember" xlink:label="arct_PayrollAndBenefitsMember"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_FacilitiesAndEquipmentMember" xlink:label="arct_FacilitiesAndEquipmentMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="arct_LUNAR-COVIDMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="arct_LUNAR-OTCMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="arct_BARDAMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="arct_LUNAR-CFNetMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingOtherItemAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="arct_Early-StageProgramsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="arct_DiscoveryTechnologiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="arct_PayrollAndBenefitsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="arct_FacilitiesAndEquipmentMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://arcturusrx.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfReportedSegmentRevenuesSegmentLossAndIncomeAndSignificantSegmentExpensesParentheticalDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_SG" xlink:label="country_SG"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_SG" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsEquityMethodInvestmentDetailsTextual">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_ADAIRTechnologyMember" xlink:label="arct_ADAIRTechnologyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:label="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_VallonPharmaceuticalsIncMember" xlink:label="arct_VallonPharmaceuticalsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:label="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:label="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_GriBioIncMember" xlink:label="arct_GriBioIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentOwnedBalanceShares" xlink:label="us-gaap_InvestmentOwnedBalanceShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentOwnedPercentOfNetAssets" xlink:label="us-gaap_InvestmentOwnedPercentOfNetAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="arct_ADAIRTechnologyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:to="arct_VallonPharmaceuticalsIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:to="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:to="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="arct_GriBioIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_InvestmentOwnedBalanceShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_InvestmentOwnedPercentOfNetAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/srt/role/srt-eedm/ExtensibleEnumerationLists">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_RestrictedCash" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LongTermDebtCurrent" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_EquityMethodInvestments" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="arct_PrepaidExpensesAndOtherReceivables" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredRevenueCurrent" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashNoncurrent" order="4" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="4" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestments" xlink:label="us-gaap_EquityMethodInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_PrepaidExpensesAndOtherReceivables" xlink:label="arct_PrepaidExpensesAndOtherReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://arcturusrx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="4" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationAndAmortization" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="arct_AcquiredInProcessResearchAndDevelopmentExpense" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockPlans" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfDebt" order="4" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="6" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossRealized" order="7" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="8" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="9" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="arct_IncreaseDecreaseOperatingLeaseRightOfUseAsset" order="11" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="12" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="13" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="14" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="15" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="16" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="17" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_AcquiredInProcessResearchAndDevelopmentExpense" xlink:label="arct_AcquiredInProcessResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossRealized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_IncreaseDecreaseOperatingLeaseRightOfUseAsset" xlink:label="arct_IncreaseDecreaseOperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://arcturusrx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_RestrictedCashCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_RestrictedCashNoncurrent" order="2" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://arcturusrx.com/20241231/taxonomy/role/DisclosureAccruedLiabilitiesDetailScheduleOfAccruedLiabilitiesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="arct_AccruedCysticFibrosisFoundationLiability" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="arct_VinbiocareContractualLiabilities" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="arct_LegalAccrualCurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_TaxesPayableCurrent" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="arct_ClinicalTrialAccrualsCurrent" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="7" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="arct_OtherAccruedResearchAndDevelopmentExpenses" order="8" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_AccruedCysticFibrosisFoundationLiability" xlink:label="arct_AccruedCysticFibrosisFoundationLiability"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_VinbiocareContractualLiabilities" xlink:label="arct_VinbiocareContractualLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_LegalAccrualCurrent" xlink:label="arct_LegalAccrualCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxesPayableCurrent" xlink:label="us-gaap_TaxesPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_ClinicalTrialAccrualsCurrent" xlink:label="arct_ClinicalTrialAccrualsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_OtherAccruedResearchAndDevelopmentExpenses" xlink:label="arct_OtherAccruedResearchAndDevelopmentExpenses"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://arcturusrx.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfComponentsOfPropertyAndEquipmentNetDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" weight="-1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails1">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="1" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://arcturusrx.com/20241231/taxonomy/role/DisclosureIncomeTaxesDetails2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://arcturusrx.com/20241231/taxonomy/role/DisclosureIncomeTaxesDetails3">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="arct_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensation" order="4" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="arct_EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentCredits" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="arct_EffectiveIncomeTaxRateReconciliationUncertainTaxPosition" order="7" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" order="8" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="arct_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences" order="10" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="11" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="13" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensation" xlink:label="arct_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensation"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentCredits" xlink:label="arct_EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentCredits"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_EffectiveIncomeTaxRateReconciliationUncertainTaxPosition" xlink:label="arct_EffectiveIncomeTaxRateReconciliationUncertainTaxPosition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences" xlink:label="arct_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://arcturusrx.com/20241231/taxonomy/role/DisclosureIncomeTaxesDetails4">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="arct_DeferredTaxLiabilitiesRightOfUseAsset" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsInventory" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="arct_DeferredTaxLiabilitiesPropertyPlantAndEquipmentAndIntangibleAssets" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsEquityMethodInvestments" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="arct_DeferredTaxAssetsRightOfUseLeaseLiability" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="arct_DeferredTaxAssetsCapitalizedResearchAndDevelopment" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="arct_DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="7" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="8" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="9" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_DeferredTaxLiabilitiesRightOfUseAsset" xlink:label="arct_DeferredTaxLiabilitiesRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:label="us-gaap_DeferredTaxAssetsInventory"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_DeferredTaxLiabilitiesPropertyPlantAndEquipmentAndIntangibleAssets" xlink:label="arct_DeferredTaxLiabilitiesPropertyPlantAndEquipmentAndIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsEquityMethodInvestments" xlink:label="us-gaap_DeferredTaxAssetsEquityMethodInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_DeferredTaxAssetsRightOfUseLeaseLiability" xlink:label="arct_DeferredTaxAssetsRightOfUseLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:label="arct_DeferredTaxAssetsCapitalizedResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets" xlink:label="arct_DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesPaymentsOfOperatingLeaseLiabilityDetails2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="1" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesPaymentsOfOperatingLeaseLiabilityDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="arct_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="6" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="arct-20241231.xsd#arct_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:label="arct_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://arcturusrx.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfReportedSegmentRevenuesSegmentLossAndIncomeAndSignificantSegmentExpensesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_SegmentReportingOtherItemAmount" order="3" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemAmount" xlink:label="us-gaap_SegmentReportingOtherItemAmount"/>
        </link:calculationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="arct_CysticFibrosisFoundationTherapeuticsIncMember" name="CysticFibrosisFoundationTherapeuticsIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="arct_OtherMember" name="OtherMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="arct_DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets" name="DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="arct_UnvestedRestrictedOrdinarySharesMember" name="UnvestedRestrictedOrdinarySharesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="arct_PaymentsForMatchingFundsForRemainingBudgetedCosts" name="PaymentsForMatchingFundsForRemainingBudgetedCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="arct_RevenueTable" name="RevenueTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="arct_EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentCredits" name="EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentCredits" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="arct_DevelopmentMilestonesReceivedAdvancePayment" name="DevelopmentMilestonesReceivedAdvancePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="arct_LUNAR-CFNetMember" name="LUNAR-CFNetMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="arct_OptionToPurchaseOfAdditionalSharesOfCommonStock" name="OptionToPurchaseOfAdditionalSharesOfCommonStock" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="arct_PayrollAndBenefitsMember" name="PayrollAndBenefitsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="arct_RecognizedContraExpense" name="RecognizedContraExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="arct_OrganizationAndSignificantAccountingPoliciesTable" name="OrganizationAndSignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="arct_WesternAllianceBankMember" name="WesternAllianceBankMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="arct_ReservedUpfrontPayment" name="ReservedUpfrontPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="arct_FebruaryTwoThousandAndTwentyLeaseAgreementMember" name="FebruaryTwoThousandAndTwentyLeaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="arct_EligibleToReceiveCommercialMilestonePayment" name="EligibleToReceiveCommercialMilestonePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="arct_DisbursementPeriodFourMember" name="DisbursementPeriodFourMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="arct_VallonPharmaceuticalsIncMember" name="VallonPharmaceuticalsIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="arct_StockIssuedDuringPeriodValueUnderEquityPlan" name="StockIssuedDuringPeriodValueUnderEquityPlan" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="arct_PercentageOfNetProfits" name="PercentageOfNetProfits" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="arct_StockIssuedDuringPeriodSharesUnderEquityPlan" name="StockIssuedDuringPeriodSharesUnderEquityPlan" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="arct_NumberOfBusinessSegment" name="NumberOfBusinessSegment" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="arct_COVIDNineteenVaccineDevelopmentMember" name="COVIDNineteenVaccineDevelopmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="arct_GrantRevenue" name="GrantRevenue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="arct_MRNATechnologyMember" name="MRNATechnologyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="arct_Early-StageProgramsMember" name="Early-StageProgramsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="arct_AcquisitionOfResearchAndDevelopmentInProcessThroughIssuanceOfCommonStock" name="AcquisitionOfResearchAndDevelopmentInProcessThroughIssuanceOfCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="arct_BARDAMember" name="BARDAMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="arct_SeqirusIncMember" name="SeqirusIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="arct_CslCollaborationAgreementMember" name="CslCollaborationAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="arct_CollaborationAgreementConsiderationReceived" name="CollaborationAgreementConsiderationReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="arct_CommitmentAndContingenciesTable" name="CommitmentAndContingenciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="arct_ReductionInNumberOfCommonStockCapitalSharesAvailableForFutureIssuance" name="ReductionInNumberOfCommonStockCapitalSharesAvailableForFutureIssuance" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="arct_PaymentReceivedFirstInstallment" name="PaymentReceivedFirstInstallment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="arct_PercentageOfEquityInterestInJointVenture" name="PercentageOfEquityInterestInJointVenture" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="arct_UnderwrittenPublicOfferingMember" name="UnderwrittenPublicOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="arct_OrganizationAndSignificantAccountingPoliciesLineItems" name="OrganizationAndSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="arct_ClinicalTrialAccrualsCurrent" name="ClinicalTrialAccrualsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="arct_ContractWithCustomerAssetDeductionsForCashCollections" name="ContractWithCustomerAssetDeductionsForCashCollections" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="arct_DebtInstrumentOptionForRenewalTerm" name="DebtInstrumentOptionForRenewalTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="arct_DevelopmentAndRegulatoryMilestonesAchieved" name="DevelopmentAndRegulatoryMilestonesAchieved" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="arct_RepyamentOfPrincipalAndInterestOnCollateralizedTermLoan" name="RepyamentOfPrincipalAndInterestOnCollateralizedTermLoan" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="arct_UnderlyingAgreementMember" name="UnderlyingAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="arct_IncomeTaxesLineItems" name="IncomeTaxesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="arct_LoanAndSecurityAgreementMember" name="LoanAndSecurityAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="arct_DeferredTaxLiabilitiesRightOfUseAsset" name="DeferredTaxLiabilitiesRightOfUseAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="arct_DiscoveryTechnologiesMember" name="DiscoveryTechnologiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="arct_SGIMember" name="SGIMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="arct_VinbiocareMember" name="VinbiocareMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="arct_StudySupportAgreementMember" name="StudySupportAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="arct_UnrecognizedTaxBenefitsDecreasesIncreasesResultingFromPriorPeriodTaxPositions" name="UnrecognizedTaxBenefitsDecreasesIncreasesResultingFromPriorPeriodTaxPositions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="arct_LiquidityPolicyPolicyTextBlock" name="LiquidityPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="arct_IncreaseDecreaseOperatingLeaseRightOfUseAsset" name="IncreaseDecreaseOperatingLeaseRightOfUseAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="arct_NumberOfReservedVaccineDoses" name="NumberOfReservedVaccineDoses" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="arct_CollaborationAgreementContractualTerm" name="CollaborationAgreementContractualTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="arct_AdditionalPaymentsUponMeetingCertainClinicalMilestones" name="AdditionalPaymentsUponMeetingCertainClinicalMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="arct_TaxCreditCarryforwardExpirationYear" name="TaxCreditCarryforwardExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="arct_UpfrontFeeReceived" name="UpfrontFeeReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="arct_CureVacAGMember" name="CureVacAGMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="arct_RareDiseaseTargetsMember" name="RareDiseaseTargetsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="arct_GrantRevenueOutstanding" name="GrantRevenueOutstanding" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="arct_OptionToPurchaseOfAdditionalSharesOfCommonStockPricePerShare" name="OptionToPurchaseOfAdditionalSharesOfCommonStockPricePerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="arct_ConditionalPayment" name="ConditionalPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="arct_DisbursementPeriodTwoMember" name="DisbursementPeriodTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="arct_AdditionalClinicalMilestonePayment" name="AdditionalClinicalMilestonePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="arct_IncomeTaxesTable" name="IncomeTaxesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="arct_AcquiredInProcessResearchAndDevelopmentExpense" name="AcquiredInProcessResearchAndDevelopmentExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="arct_MaximumPercentageOfLikelihoodOfUncertainTaxPositionRecognizedToBeSustained" name="MaximumPercentageOfLikelihoodOfUncertainTaxPositionRecognizedToBeSustained" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="arct_ContractWithCustomerAssetDeductions" name="ContractWithCustomerAssetDeductions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="arct_PhaseIClinicalStudyMember" name="PhaseIClinicalStudyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="arct_NumberOfPerformanceObligations" name="NumberOfPerformanceObligations" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="arct_OperatingLossCarryforwardsExpirationYear" name="OperatingLossCarryforwardsExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="arct_AdditionalMilestonePaymentsReceived" name="AdditionalMilestonePaymentsReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="arct_TwoThousandTwentyEmployeeStockPurchasePlanMember" name="TwoThousandTwentyEmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="arct_LackOfMarketabilityDiscountRestrictedPeriod" name="LackOfMarketabilityDiscountRestrictedPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="arct_AdditionalFinancialSupport" name="AdditionalFinancialSupport" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="arct_CollaborationRevenueMember" name="CollaborationRevenueMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="arct_RoyaltyPaymentTermDescription" name="RoyaltyPaymentTermDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="arct_LUNAR-OTCMember" name="LUNAR-OTCMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="arct_RevenueLineItems" name="RevenueLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="arct_KeithCKummerfeldMember" name="KeithCKummerfeldMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="arct_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" name="BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="arct_UltragenyxMember" name="UltragenyxMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="arct_EmployeesAndOfficersMember" name="EmployeesAndOfficersMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="arct_LUNARCFMember" name="LUNARCFMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="arct_UpfrontFeeAndConsideration" name="UpfrontFeeAndConsideration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="arct_DeferredTaxLiabilitiesPropertyPlantAndEquipmentAndIntangibleAssets" name="DeferredTaxLiabilitiesPropertyPlantAndEquipmentAndIntangibleAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="arct_TwentyTwentyOneInducementEquityIncentivePlanMember" name="TwentyTwentyOneInducementEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="arct_ContractWithCustomerLiabilityAdditionsForAdvancedBillings" name="ContractWithCustomerLiabilityAdditionsForAdvancedBillings" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="arct_NumberOfReserveTargets" name="NumberOfReserveTargets" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="arct_OtherAccruedResearchAndDevelopmentExpenses" name="OtherAccruedResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="arct_JointVenturesEquityMethodInvestmentsAndVariableInterestEntitiesPolicyTextBlock" name="JointVenturesEquityMethodInvestmentsAndVariableInterestEntitiesPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="arct_AchievedDevelopmentMilestoneIncludedAccountsReceivable" name="AchievedDevelopmentMilestoneIncludedAccountsReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="arct_WellsFargoCreditAgreementMember" name="WellsFargoCreditAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="arct_DevelopmentMilestonesAchieved" name="DevelopmentMilestonesAchieved" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="arct_DisbursedAmountUponExecutionOfAmendment" name="DisbursedAmountUponExecutionOfAmendment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="arct_CollaborationPartnerCureVacEnteredIntoCoDevelopmentAgreementMember" name="CollaborationPartnerCureVacEnteredIntoCoDevelopmentAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="arct_ResearchCollaborationAndLicenseAgreementMember" name="ResearchCollaborationAndLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="arct_ContractWithCustomerLiabilityAdditions" name="ContractWithCustomerLiabilityAdditions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="arct_ManufacturingAndSupplyOfArct154DrugProductMember" name="ManufacturingAndSupplyOfArct154DrugProductMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="arct_TwoThousandNineteenOmnibusIncentivePlanMember" name="TwoThousandNineteenOmnibusIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="arct_OptionToExtendInitialTermOnAnAnnualBasis" name="OptionToExtendInitialTermOnAnAnnualBasis" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="arct_LegalAccrualCurrent" name="LegalAccrualCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="arct_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" name="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="arct_ContraExpenseIncludedInResearchAndDevelopmentExpense" name="ContraExpenseIncludedInResearchAndDevelopmentExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="arct_LUNAR-COVIDMember" name="LUNAR-COVIDMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="arct_RevenueRecognitionReserveTargetExclusivityPeriod" name="RevenueRecognitionReserveTargetExclusivityPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="arct_DisbursementPaymentUponAchievementOfRequiredManufacturingPracticesAndINDApplication" name="DisbursementPaymentUponAchievementOfRequiredManufacturingPracticesAndINDApplication" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="arct_NetOperatingLossAndResearchAndDevelopmentCreditCarryforwardsLimitationsOnCumulativeChangeInOwnershipMinimumPercentage" name="NetOperatingLossAndResearchAndDevelopmentCreditCarryforwardsLimitationsOnCumulativeChangeInOwnershipMinimumPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="arct_RevenueRecognitionPotentialMilestoneRevenueRecognized" name="RevenueRecognitionPotentialMilestoneRevenueRecognized" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="arct_Covid19VaccineMember" name="Covid19VaccineMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="arct_PharmaceuticalCompanyMember" name="PharmaceuticalCompanyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="arct_MilestonePayments" name="MilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="arct_NetOperatingLossAndResearchAndDevelopmentCreditCarryforwardsLimitationsOnCumulativeChangeInOwnershipPeriod" name="NetOperatingLossAndResearchAndDevelopmentCreditCarryforwardsLimitationsOnCumulativeChangeInOwnershipPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="arct_OtherCollaborationAgreementsMember" name="OtherCollaborationAgreementsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="arct_CSLMember" name="CSLMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="arct_DevelopmentAndOptionAgreementDate" name="DevelopmentAndOptionAgreementDate" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="arct_MonthlyBaseRent" name="MonthlyBaseRent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="arct_OptionExerciseRevenueRangePerTarget" name="OptionExerciseRevenueRangePerTarget" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="arct_IsraelMinistryOfHealthMember" name="IsraelMinistryOfHealthMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="arct_FacilitiesAndEquipmentMember" name="FacilitiesAndEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="arct_FebruaryTwoThousandAndTwentyOneLeaseAgreementMember" name="FebruaryTwoThousandAndTwentyOneLeaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="arct_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensation" name="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensation" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="arct_ContraExpenseRemainingAmountIncludedInAccruedExpenses" name="ContraExpenseRemainingAmountIncludedInAccruedExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="arct_DisbursementPeriodThreeMember" name="DisbursementPeriodThreeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="arct_ReversalOfRevenue" name="ReversalOfRevenue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="arct_AgreementAmountAgreedToFund" name="AgreementAmountAgreedToFund" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="arct_ContractWithCustomerAssetAdditions" name="ContractWithCustomerAssetAdditions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="arct_GriBioIncMember" name="GriBioIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="arct_DeferredTaxAssetsCapitalizedResearchAndDevelopment" name="DeferredTaxAssetsCapitalizedResearchAndDevelopment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="arct_SeqirusAgreementMember" name="SeqirusAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="arct_PrepaidExpensesAndOtherReceivables" name="PrepaidExpensesAndOtherReceivables" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="arct_SeptemberTwoThousandAndTwentyOneLeaseAgreementMember" name="SeptemberTwoThousandAndTwentyOneLeaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="arct_UpfrontConsiderationReceived" name="UpfrontConsiderationReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="arct_ResearchCollaborationAndExclusiveLicenseAgreementMember" name="ResearchCollaborationAndExclusiveLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="arct_PreLaunchInventoryPolicyPolicyTextBlock" name="PreLaunchInventoryPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="arct_ExpirationOfIntialTerm" name="ExpirationOfIntialTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="arct_ADAIRTechnologyMember" name="ADAIRTechnologyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="arct_ForeignCountriesMember" name="ForeignCountriesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="arct_ScheduleOfSummaryOfSignificantAccountingPoliciesTable" name="ScheduleOfSummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="arct_DisbursementAmountPayableUponAchievementOfProjectGoal" name="DisbursementAmountPayableUponAchievementOfProjectGoal" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="arct_MinimumAmountAgreedToIncurUnderResearchPlan" name="MinimumAmountAgreedToIncurUnderResearchPlan" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="arct_LanceKurataMember" name="LanceKurataMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="arct_AccruedCysticFibrosisFoundationLiability" name="AccruedCysticFibrosisFoundationLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="arct_DrPadmanabhChivukulaMember" name="DrPadmanabhChivukulaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="arct_CslSeqirusMember" name="CslSeqirusMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="arct_NonCashAssetDisposal" name="NonCashAssetDisposal" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="arct_AchievedDevelopmentAndRegulatoryMilestoneIncludedAccountsReceivable" name="AchievedDevelopmentAndRegulatoryMilestoneIncludedAccountsReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="arct_AdjustmentsToTransactionPrice" name="AdjustmentsToTransactionPrice" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="arct_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences" name="EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="arct_CommitmentAndContingenciesLineItems" name="CommitmentAndContingenciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="arct_RemainingLoanIncludingAccruedInterestForgiveable" name="RemainingLoanIncludingAccruedInterestForgiveable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="arct_UpfrontPaymentToBeReceived" name="UpfrontPaymentToBeReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="arct_CollaborationAgreementTransactionPrice" name="CollaborationAgreementTransactionPrice" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="arct_DevelopmentMilestonesAmountDueForAgreement" name="DevelopmentMilestonesAmountDueForAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="arct_GrantOneMember" name="GrantOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="arct_NonRefundablePaymentReceived" name="NonRefundablePaymentReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="arct_DebtInstrumentExtendedTermPeriod" name="DebtInstrumentExtendedTermPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="arct_SummaryOfSignificantAccountingPolicyLineItems" name="SummaryOfSignificantAccountingPolicyLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="arct_UpfrontPaymentReceived" name="UpfrontPaymentReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="arct_VinbiocareAgreementMember" name="VinbiocareAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="arct_NotSubjectToExpirationMember" name="NotSubjectToExpirationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="arct_DisbursementPeriodOneMember" name="DisbursementPeriodOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="arct_DeferredTaxAssetsRightOfUseLeaseLiability" name="DeferredTaxAssetsRightOfUseLeaseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="arct_DirectorsOrOfficersExceptChiefScientificOfficerCooSvpCcAndPaoMember" name="DirectorsOrOfficersExceptChiefScientificOfficerCooSvpCcAndPaoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="arct_PotentialTargetLicenseTerm" name="PotentialTargetLicenseTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="arct_NonRareDiseaseTargetsMember" name="NonRareDiseaseTargetsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="arct_GrantReceivableNumberOfInstallments" name="GrantReceivableNumberOfInstallments" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="arct_GeneralAndAdministrativeCostsPolicyPolicyTextBlock" name="GeneralAndAdministrativeCostsPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="arct_FinalPaymentOfDisbursementAmount" name="FinalPaymentOfDisbursementAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="arct_OptionExerciseFeeRevenueReceived" name="OptionExerciseFeeRevenueReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="arct_OctoberTwoThousandAndSeventeenLeaseAmendmentMember" name="OctoberTwoThousandAndSeventeenLeaseAmendmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="arct_ContraResearchAndDevelopmentExpense" name="ContraResearchAndDevelopmentExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="arct_EffectiveIncomeTaxRateReconciliationUncertainTaxPosition" name="EffectiveIncomeTaxRateReconciliationUncertainTaxPosition" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="arct_AlexionPharmaceuticalsIncMember" name="AlexionPharmaceuticalsIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="arct_ContractWithCustomerAssetAdditionsForRevenueRecognized" name="ContractWithCustomerAssetAdditionsForRevenueRecognized" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="arct_JanssenMember" name="JanssenMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="arct_GrantTwoMember" name="GrantTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="arct_ConcentrationRiskNumberOfCustomer" name="ConcentrationRiskNumberOfCustomer" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="arct_EligibleToReceiveDevelopmentMilestonePayment" name="EligibleToReceiveDevelopmentMilestonePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="arct_VinbiocareContractualLiabilities" name="VinbiocareContractualLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="arct_OrphanDrugCreditMember" name="OrphanDrugCreditMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45846714895296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 04, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ARCT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ARCTURUS THERAPEUTICS HOLDINGS INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001768224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">32-0595345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">10628 Science Center Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">900-2660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,119,823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 602.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents incorporated by reference</a></td>
<td class="text"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain portions of the registrant&#8217;s definitive Proxy Statement for its 2025 Annual Meeting of Stockholders are incorporated by reference into Items 10, 11, 12, 13 and 14 of Part III of this Annual Report on Form 10-K.</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Deloitte & Touche LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">San Diego, California<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorOpinionTextBlock', window );">Auditor Opinion</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Opinion on the Financial Statements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have audited the accompanying consolidated balance sheets of Arcturus Therapeutics Holdings, Inc. and subsidiaries (the &#8220;Company&#8221;) as of December 31, 2024, the related consolidated statements of operations, comprehensive loss, stockholder&#8217;s equity, and cash flows, for the year ended December 31, 2024, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024, and the results of its operations and its cash flows for the year ended December 31, 2024, in conformity with accounting principles generally accepted in the United States of America.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company&#8217;s internal control over financial reporting as of December 31, 2024, based on criteria established in Internal Control &#8212; Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated March 6, 2025, expressed an adverse opinion on the Company&#8217;s internal control over financial reporting because of a material weakness.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorOpinionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X<br> -Number 210<br> -Section 2<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorOpinionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45846713635728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 237,028<span></span>
</td>
<td class="nump">$ 292,005<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">55,000<span></span>
</td>
<td class="nump">55,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">3,974<span></span>
</td>
<td class="nump">32,064<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_PrepaidExpensesAndOtherReceivables', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">9,977<span></span>
</td>
<td class="nump">7,521<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">305,979<span></span>
</td>
<td class="nump">386,590<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">9,531<span></span>
</td>
<td class="nump">12,427<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset, net</a></td>
<td class="nump">26,674<span></span>
</td>
<td class="nump">28,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Non-current restricted cash</a></td>
<td class="nump">1,885<span></span>
</td>
<td class="nump">1,885<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">344,069<span></span>
</td>
<td class="nump">429,402<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">7,194<span></span>
</td>
<td class="nump">5,279<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">38,781<span></span>
</td>
<td class="nump">31,881<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
<td class="nump">19,514<span></span>
</td>
<td class="nump">44,829<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">65,489<span></span>
</td>
<td class="nump">81,989<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">12,604<span></span>
</td>
<td class="nump">42,496<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="nump">24,998<span></span>
</td>
<td class="nump">25,907<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">497<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">103,091<span></span>
</td>
<td class="nump">150,889<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock: $0.001 par value; 60,000 shares authorized; issued and outstanding shares were 27,000 at December 31, 2024 and 26,828 at December 31, 2023</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">689,758<span></span>
</td>
<td class="nump">646,352<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(448,807)<span></span>
</td>
<td class="num">(367,866)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">240,978<span></span>
</td>
<td class="nump">278,513<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 344,069<span></span>
</td>
<td class="nump">$ 429,402<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arct_PrepaidExpensesAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer. as well as trade accounts receivable, notes and loans receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arct_PrepaidExpensesAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45846715674496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">60,000,000<span></span>
</td>
<td class="nump">60,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">27,000,000<span></span>
</td>
<td class="nump">26,828,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">27,000,000<span></span>
</td>
<td class="nump">26,828,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45846714733760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 152,310<span></span>
</td>
<td class="nump">$ 166,799<span></span>
</td>
<td class="nump">$ 205,999<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development, net</a></td>
<td class="nump">195,156<span></span>
</td>
<td class="nump">192,133<span></span>
</td>
<td class="nump">147,751<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">52,823<span></span>
</td>
<td class="nump">52,871<span></span>
</td>
<td class="nump">46,071<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">247,979<span></span>
</td>
<td class="nump">245,004<span></span>
</td>
<td class="nump">193,822<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">(Loss) income from operations</a></td>
<td class="num">(95,669)<span></span>
</td>
<td class="num">(78,205)<span></span>
</td>
<td class="nump">12,177<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss from equity-method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(515)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Loss from foreign currency</a></td>
<td class="num">(471)<span></span>
</td>
<td class="num">(229)<span></span>
</td>
<td class="num">(598)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Finance income (expense), net</a></td>
<td class="nump">15,195<span></span>
</td>
<td class="nump">16,591<span></span>
</td>
<td class="num">(420)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on debt extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,953<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net (loss) income before income taxes</a></td>
<td class="num">(80,945)<span></span>
</td>
<td class="num">(27,890)<span></span>
</td>
<td class="nump">10,644<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">(Benefit) provision for income taxes</a></td>
<td class="num">(4)<span></span>
</td>
<td class="nump">1,835<span></span>
</td>
<td class="nump">1,295<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">(80,941)<span></span>
</td>
<td class="num">(29,725)<span></span>
</td>
<td class="nump">9,349<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive (loss) income</a></td>
<td class="num">$ (80,941)<span></span>
</td>
<td class="num">$ (29,725)<span></span>
</td>
<td class="nump">$ 9,349<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>(Loss) earnings per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic</a></td>
<td class="num">$ (3.00)<span></span>
</td>
<td class="num">$ (1.12)<span></span>
</td>
<td class="nump">$ 0.35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted</a></td>
<td class="num">$ (3.00)<span></span>
</td>
<td class="num">$ (1.12)<span></span>
</td>
<td class="nump">$ 0.35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average shares used in calculation of (loss) earnings per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic</a></td>
<td class="nump">27,000<span></span>
</td>
<td class="nump">26,628<span></span>
</td>
<td class="nump">26,445<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted</a></td>
<td class="nump">27,000<span></span>
</td>
<td class="nump">26,628<span></span>
</td>
<td class="nump">27,093<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=arct_CollaborationRevenueMember', window );">Collaboration Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 138,389<span></span>
</td>
<td class="nump">$ 157,748<span></span>
</td>
<td class="nump">$ 205,755<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 13,921<span></span>
</td>
<td class="nump">$ 9,051<span></span>
</td>
<td class="nump">$ 244<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482014/830-20-35-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481839/830-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=arct_CollaborationRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=arct_CollaborationRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45846719355168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-In Capital [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 228,211<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="nump">$ 575,675<span></span>
</td>
<td class="num">$ (347,490)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,372,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">30,611<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,611<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">1,730<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">1,729<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">161,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_StockIssuedDuringPeriodValueUnderEquityPlan', window );">Issuance of common stock under equity plans</a></td>
<td class="nump">411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_StockIssuedDuringPeriodSharesUnderEquityPlan', window );">Issuance of common stock under equity plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="nump">9,349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,349<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">270,312<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
<td class="nump">608,426<span></span>
</td>
<td class="num">(338,141)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,555,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">34,649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">2,668<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,668<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">238,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_StockIssuedDuringPeriodValueUnderEquityPlan', window );">Issuance of common stock under equity plans</a></td>
<td class="nump">609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_StockIssuedDuringPeriodSharesUnderEquityPlan', window );">Issuance of common stock under equity plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">(29,725)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29,725)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">278,513<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
<td class="nump">646,352<span></span>
</td>
<td class="num">(367,866)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,828,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">37,988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">$ 4,736<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,736<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="nump">228,328<span></span>
</td>
<td class="nump">228,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_StockIssuedDuringPeriodValueUnderEquityPlan', window );">Issuance of common stock under equity plans</a></td>
<td class="nump">$ 682<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">682<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_StockIssuedDuringPeriodSharesUnderEquityPlan', window );">Issuance of common stock under equity plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">(80,941)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(80,941)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2024</a></td>
<td class="nump">$ 240,978<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
<td class="nump">$ 689,758<span></span>
</td>
<td class="num">$ (448,807)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,096,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arct_StockIssuedDuringPeriodSharesUnderEquityPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares under equity plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arct_StockIssuedDuringPeriodSharesUnderEquityPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arct_StockIssuedDuringPeriodValueUnderEquityPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value under equity plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arct_StockIssuedDuringPeriodValueUnderEquityPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45846713928240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">$ (80,941)<span></span>
</td>
<td class="num">$ (29,725)<span></span>
</td>
<td class="nump">$ 9,349<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">3,544<span></span>
</td>
<td class="nump">2,957<span></span>
</td>
<td class="nump">1,527<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation expense</a></td>
<td class="nump">37,988<span></span>
</td>
<td class="nump">34,649<span></span>
</td>
<td class="nump">30,611<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss from equity-method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">515<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on debt extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33,953)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossRealized', window );">Foreign currency transaction loss</a></td>
<td class="nump">471<span></span>
</td>
<td class="nump">90<span></span>
</td>
<td class="nump">375<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other non-cash expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">502<span></span>
</td>
<td class="nump">2,173<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">28,090<span></span>
</td>
<td class="num">(29,300)<span></span>
</td>
<td class="nump">603<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(2,456)<span></span>
</td>
<td class="nump">1,165<span></span>
</td>
<td class="num">(3,584)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_IncreaseDecreaseOperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">4,562<span></span>
</td>
<td class="nump">4,045<span></span>
</td>
<td class="nump">3,264<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">1,915<span></span>
</td>
<td class="num">(2,238)<span></span>
</td>
<td class="num">(3,112)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="nump">5,932<span></span>
</td>
<td class="num">(588)<span></span>
</td>
<td class="nump">9,443<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(55,207)<span></span>
</td>
<td class="nump">38,606<span></span>
</td>
<td class="num">(14,694)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Lease liabilities</a></td>
<td class="num">(3,645)<span></span>
</td>
<td class="num">(4,309)<span></span>
</td>
<td class="num">(4,477)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash (used in) provided by operating activities</a></td>
<td class="num">(59,747)<span></span>
</td>
<td class="num">(18,099)<span></span>
</td>
<td class="nump">31,993<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Acquisition of property and equipment</a></td>
<td class="num">(648)<span></span>
</td>
<td class="num">(2,901)<span></span>
</td>
<td class="num">(7,726)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(648)<span></span>
</td>
<td class="num">(2,901)<span></span>
</td>
<td class="num">(7,726)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">4,736<span></span>
</td>
<td class="nump">2,668<span></span>
</td>
<td class="nump">1,730<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from issuance of common stock under equity plans</a></td>
<td class="nump">682<span></span>
</td>
<td class="nump">609<span></span>
</td>
<td class="nump">411<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Payments on debt obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(47,364)<span></span>
</td>
<td class="num">(5,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="nump">5,418<span></span>
</td>
<td class="num">(24,087)<span></span>
</td>
<td class="num">(2,859)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash, cash equivalents and restricted cash</a></td>
<td class="num">(54,977)<span></span>
</td>
<td class="num">(45,087)<span></span>
</td>
<td class="nump">21,408<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, beginning of year</a></td>
<td class="nump">348,890<span></span>
</td>
<td class="nump">393,977<span></span>
</td>
<td class="nump">372,569<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of year</a></td>
<td class="nump">293,913<span></span>
</td>
<td class="nump">348,890<span></span>
</td>
<td class="nump">393,977<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,127<span></span>
</td>
<td class="nump">813<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income taxes</a></td>
<td class="nump">1,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets acquired through operating leases</a></td>
<td class="nump">2,736<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,191<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_NonCashAssetDisposal', window );">Non-cash asset disposal</a></td>
<td class="nump">$ 473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchase of property and equipment in accounts payable and accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 68<span></span>
</td>
<td class="nump">$ 573<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arct_IncreaseDecreaseOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease operating lease, right of use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arct_IncreaseDecreaseOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arct_NonCashAssetDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-Cash Asset Disposal</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arct_NonCashAssetDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossRealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of realized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossRealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478345/912-310-45-11<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45846720271472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management, Strategy, and Governance<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><p id="item_3c_cybersecurity" style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1C. Cyber</span><span id="item_1c_cybersecurity"></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">security</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risk management and strategy</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We recognize the critical importance of developing, implementing, and maintaining robust cybersecurity measures to safeguard our information systems and protect the confidentiality, integrity, and availability of our data.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Managing Material Risks &amp; Integrated Overall Risk Management</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have implemented tools and strategies to promote a company-wide culture of cybersecurity risk management. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This ensures that cybersecurity considerations are an integral part of our decision-making process.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Our IT Department works closely with our leadership and key operating personnel to evaluate and address cybersecurity risks in alignment with our business objectives and operational needs.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our information security function and our Vice President of Information Technology help identify, assess and manage the Company&#8217;s cybersecurity threats and risks. This group works to identify and assess risks from cybersecurity threats by monitoring and evaluating our threat environment and the Company&#8217;s risk profile using various methods in certain contexts, including, for example, manual tools, subscribing to reports and services that identify cybersecurity threats, analyzing reports of threat actors, conducting scans of certain environments, evaluating certain threats reported to us, conducting threat and vulnerability assessments, using external intelligence feeds, and using third parties to conduct tabletop incident response exercises and other tests.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depending on the environment, we implement and maintain various technical, physical, and organizational measures, processes, standards and policies designed to manage and mitigate material risks from cybersecurity threats to our information systems and data, including, for example: incident detection and response, disaster recovery/business continuity policies, encryption of certain data, network security controls and data segmentation for certain systems, access controls, physical security, asset management and tracking, systems monitoring, annual mandated employee training, penetration testing, cybersecurity insurance, and dedicated cybersecurity staff.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Engage Third-parties on Risk Management</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Due to the complexity and evolving nature of cybersecurity threats, we </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">engage</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> with a range of external experts, including but not limited to cybersecurity assessors, consultants, and auditors to evaluate and test our risk management systems. These partnerships enable us to leverage specialized knowledge and insights, to help ensure our cybersecurity strategies and processes remain at the forefront of industry best practices. Our collaborations with these third-parties includes regular audits, threat assessments, 24-hour monitoring, and consultation on security enhancements.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Oversee Third-party Risk</span></span></p><div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because we are aware of the risks associated with third-party service providers, we conduct thorough security assessments of all determined high-risk third-party providers as deemed necessary, before engagement to ensure compliance with industry cybersecurity standards and frameworks. This includes assessments performed by our Vice President of IT, who oversees the Company's cybersecurity function.</span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risks from Cybersecurity Threats</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have not encountered cybersecurity challenges that have materially affected or are reasonably likely to materially affect our operations or financial standing.</span></span></p><div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Governance</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have implemented standard operating procedures to define the channels by which cybersecurity threats are communicated to the Company's Board of Directors (the &#8220;Board&#8221;). This ensures that The Board has oversight and effective governance in managing risks associated with cybersecurity threats.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Board of Directors Oversight</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Audit Committee of the Board (the &#8220;Audit Committee&#8221;) is central to the Board&#8217;s oversight of cybersecurity risks and bears the primary responsibility for this domain. The Audit Committee is composed of board</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">members </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">with diverse expertise including, risk management, and finance, equipping them to oversee cybersecurity risks effectively.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Audit Committee receives briefings on cybersecurity risks from the Vice President of IT or the Chief Legal Officer as described below in &#8220;Management&#8217;s Role Managing Risk.&#8221;</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Management&#8217;s Role Managing Risk</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Vice President of IT, Chief Legal Officer (&#8220;CLO&#8221;) and the Director of IT Infrastructure and Security, play a pivotal role in informing the Audit Committee on cybersecurity risks. They provide briefings to the Audit Committee on a regular basis, with a minimum frequency of once per year. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The current Vice President of IT, who is responsible for assessment and management of cybersecurity risks, has over 20 years of experience in information and technology security, including senior roles at several companies in the pharmaceutical industry, and possesses the requisite education, skills, experience, and industry certifications expected of an individual assigned to these duties</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. These briefings encompass a broad range of topics, including:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Current cybersecurity landscape and emerging threats;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Status of ongoing cybersecurity initiatives and strategies;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Incident reports and learnings from any cybersecurity events; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compliance with regulatory requirements and industry standards.</span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risk Management Personnel</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Primary responsibility for assessing, monitoring and managing our cybersecurity risks rests with the Vice President of IT and the Director of IT Infrastructure and Security. Our IT Leadership team oversees our governance programs, tests our compliance with standards, remediates known risks, stays informed of significant developments in the cybersecurity domain, and leads our employee training program.</span></span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Monitor Cybersecurity Incidents</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Vice President of IT is continually informed about the latest developments in cybersecurity, including potential threats and innovative risk management techniques. This ongoing knowledge acquisition is crucial for the effective prevention, detection, mitigation, and remediation of cybersecurity incidents.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> In cooperation with the Vice President of IT, the Director of IT Infrastructure and Security implements and oversees processes for the regular monitoring of our information systems. This includes the deployment of advanced security measures and regular system audits to identify potential vulnerabilities. In the event of a cybersecurity incident, the Vice President of IT is equipped with a well-defined incident response plan. This plan includes immediate actions to mitigate the impact and long-term strategies for remediation and prevention of future incidents.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Reporting to Board of Directors</span></p><div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Vice President of IT and the Director of IT Infrastructure and Security, in their respective capacity, inform the Chief Financial Officer (CFO) and Chief Legal Officer (CLO) of cybersecurity risks and incidents.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Furthermore, significant cybersecurity matters, and strategic risk management decisions are required to be escalated to the Board, ensuring that they have comprehensive oversight and can provide guidance on critical cybersecurity issues.</span><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"></span></p></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">See Item 1A &#8220;Risk Factors&#8221; &#8211; &#8220;Risks Related to Business Operations and Industry.&#8221;</span></p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Managing Material Risks &amp; Integrated Overall Risk Management</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have implemented tools and strategies to promote a company-wide culture of cybersecurity risk management. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This ensures that cybersecurity considerations are an integral part of our decision-making process.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Our IT Department works closely with our leadership and key operating personnel to evaluate and address cybersecurity risks in alignment with our business objectives and operational needs.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our information security function and our Vice President of Information Technology help identify, assess and manage the Company&#8217;s cybersecurity threats and risks. This group works to identify and assess risks from cybersecurity threats by monitoring and evaluating our threat environment and the Company&#8217;s risk profile using various methods in certain contexts, including, for example, manual tools, subscribing to reports and services that identify cybersecurity threats, analyzing reports of threat actors, conducting scans of certain environments, evaluating certain threats reported to us, conducting threat and vulnerability assessments, using external intelligence feeds, and using third parties to conduct tabletop incident response exercises and other tests.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depending on the environment, we implement and maintain various technical, physical, and organizational measures, processes, standards and policies designed to manage and mitigate material risks from cybersecurity threats to our information systems and data, including, for example: incident detection and response, disaster recovery/business continuity policies, encryption of certain data, network security controls and data segmentation for certain systems, access controls, physical security, asset management and tracking, systems monitoring, annual mandated employee training, penetration testing, cybersecurity insurance, and dedicated cybersecurity staff.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Governance</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have implemented standard operating procedures to define the channels by which cybersecurity threats are communicated to the Company's Board of Directors (the &#8220;Board&#8221;). This ensures that The Board has oversight and effective governance in managing risks associated with cybersecurity threats.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Board of Directors Oversight</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Audit Committee of the Board (the &#8220;Audit Committee&#8221;) is central to the Board&#8217;s oversight of cybersecurity risks and bears the primary responsibility for this domain. The Audit Committee is composed of board</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">members </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">with diverse expertise including, risk management, and finance, equipping them to oversee cybersecurity risks effectively.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Audit Committee receives briefings on cybersecurity risks from the Vice President of IT or the Chief Legal Officer as described below in &#8220;Management&#8217;s Role Managing Risk.&#8221;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Reporting to Board of Directors</span></p><div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Vice President of IT and the Director of IT Infrastructure and Security, in their respective capacity, inform the Chief Financial Officer (CFO) and Chief Legal Officer (CLO) of cybersecurity risks and incidents.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Furthermore, significant cybersecurity matters, and strategic risk management decisions are required to be escalated to the Board, ensuring that they have comprehensive oversight and can provide guidance on critical cybersecurity issues.</span><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"></span></p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Audit Committee of the Board (the &#8220;Audit Committee&#8221;) is central to the Board&#8217;s oversight of cybersecurity risks and bears the primary responsibility for this domain. The Audit Committee is composed of board</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">members </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">with diverse expertise including, risk management, and finance, equipping them to oversee cybersecurity risks effectively.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Vice President of IT and the Director of IT Infrastructure and Security, in their respective capacity, inform the Chief Financial Officer (CFO) and Chief Legal Officer (CLO) of cybersecurity risks and incidents.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Furthermore, significant cybersecurity matters, and strategic risk management decisions are required to be escalated to the Board, ensuring that they have comprehensive oversight and can provide guidance on critical cybersecurity issues.</span><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"></span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskRoleOfManagementTextBlock', window );">Cybersecurity Risk Role of Management [Text Block]</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Management&#8217;s Role Managing Risk</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Vice President of IT, Chief Legal Officer (&#8220;CLO&#8221;) and the Director of IT Infrastructure and Security, play a pivotal role in informing the Audit Committee on cybersecurity risks. They provide briefings to the Audit Committee on a regular basis, with a minimum frequency of once per year. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The current Vice President of IT, who is responsible for assessment and management of cybersecurity risks, has over 20 years of experience in information and technology security, including senior roles at several companies in the pharmaceutical industry, and possesses the requisite education, skills, experience, and industry certifications expected of an individual assigned to these duties</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. These briefings encompass a broad range of topics, including:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Current cybersecurity landscape and emerging threats;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Status of ongoing cybersecurity initiatives and strategies;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Incident reports and learnings from any cybersecurity events; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compliance with regulatory requirements and industry standards.</span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risk Management Personnel</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Primary responsibility for assessing, monitoring and managing our cybersecurity risks rests with the Vice President of IT and the Director of IT Infrastructure and Security. Our IT Leadership team oversees our governance programs, tests our compliance with standards, remediates known risks, stays informed of significant developments in the cybersecurity domain, and leads our employee training program.</span></span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Monitor Cybersecurity Incidents</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Vice President of IT is continually informed about the latest developments in cybersecurity, including potential threats and innovative risk management techniques. This ongoing knowledge acquisition is crucial for the effective prevention, detection, mitigation, and remediation of cybersecurity incidents.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> In cooperation with the Vice President of IT, the Director of IT Infrastructure and Security implements and oversees processes for the regular monitoring of our information systems. This includes the deployment of advanced security measures and regular system audits to identify potential vulnerabilities. In the event of a cybersecurity incident, the Vice President of IT is equipped with a well-defined incident response plan. This plan includes immediate actions to mitigate the impact and long-term strategies for remediation and prevention of future incidents.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Reporting to Board of Directors</span></p><div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Vice President of IT and the Director of IT Infrastructure and Security, in their respective capacity, inform the Chief Financial Officer (CFO) and Chief Legal Officer (CLO) of cybersecurity risks and incidents.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Furthermore, significant cybersecurity matters, and strategic risk management decisions are required to be escalated to the Board, ensuring that they have comprehensive oversight and can provide guidance on critical cybersecurity issues.</span><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"></span></p></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">See Item 1A &#8220;Risk Factors&#8221; &#8211; &#8220;Risks Related to Business Operations and Industry.&#8221;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Vice President of IT, Chief Legal Officer (&#8220;CLO&#8221;) and the Director of IT Infrastructure and Security, play a pivotal role in informing the Audit Committee on cybersecurity risks. They provide briefings to the Audit Committee on a regular basis, with a minimum frequency of once per year. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The current Vice President of IT, who is responsible for assessment and management of cybersecurity risks, has over 20 years of experience in information and technology security, including senior roles at several companies in the pharmaceutical industry, and possesses the requisite education, skills, experience, and industry certifications expected of an individual assigned to these duties</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. These briefings encompass a broad range of topics, including:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Current cybersecurity landscape and emerging threats;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Status of ongoing cybersecurity initiatives and strategies;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Incident reports and learnings from any cybersecurity events; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compliance with regulatory requirements and industry standards.</span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risk Management Personnel</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Primary responsibility for assessing, monitoring and managing our cybersecurity risks rests with the Vice President of IT and the Director of IT Infrastructure and Security. Our IT Leadership team oversees our governance programs, tests our compliance with standards, remediates known risks, stays informed of significant developments in the cybersecurity domain, and leads our employee training program.</span></span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock', window );">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The current Vice President of IT, who is responsible for assessment and management of cybersecurity risks, has over 20 years of experience in information and technology security, including senior roles at several companies in the pharmaceutical industry, and possesses the requisite education, skills, experience, and industry certifications expected of an individual assigned to these duties</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Vice President of IT is continually informed about the latest developments in cybersecurity, including potential threats and innovative risk management techniques. This ongoing knowledge acquisition is crucial for the effective prevention, detection, mitigation, and remediation of cybersecurity incidents.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskRoleOfManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskRoleOfManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45846815526512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (80,941)<span></span>
</td>
<td class="num">$ (29,725)<span></span>
</td>
<td class="nump">$ 9,349<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45846713094208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Rule 10b5-1 Trading Plans</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the year ended December 31, 2024, none of our directors or officers </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adopted </span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">terminated</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> a "Rule 10b5-1 trading arrangement" (as defined in Item 408 of Regulation S-K of the Exchange Act) intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act, other than as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Keith C. Kummerfeld&#8217;s</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Rule 10b5-1 trading arrangement </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">terminated</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 18, 2024</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> upon the effective date of his resignation. </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lance Kurata</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, our </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chief Legal Officer</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adopted</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> a Rule 10b5-1 trading arrangement as of</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> June 12, 2024</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Mr. Kurata's trading arrangement provides for the exercise options to purchase up to an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock and subsequent sale of such underlying shares of common stock, until </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 12, 2025</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dr. Padmanabh Chivukula</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chief Scientific Officer and Chief Operating Officer</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, cancelled an existing Rule 10b5-1trading arrangement on November 11, 2024. Dr. Chivukula's trading arrangement provided for the sale of up to an aggregate of 152,000 shares of common stock. Subsequent to this, Dr. Chivukula </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">entered</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> into a new Rule 10b5-1 trading arrangement on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">November 20, 2024</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The new trading arrangement provides for the sale of up to an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">120,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_28c68eba-ea54-404a-a9d6-fb19a33b35b4;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">beginning on June 2, 2025 until </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">November 10, 2025</span></span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There were no "non-Rule 10b5-1 trading arrangements" (as defined in Item 408 of Regulation S-K of the Exchange Act) </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adopted</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">terminated</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> during the year ended December 31, 2024 by our directors and officers.</span></p><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=arct_KeithCKummerfeldMember', window );">Keith C. Kummerfeld [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Keith C. Kummerfeld&#8217;s<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrTerminationDate', window );">Termination Date</a></td>
<td class="text">March 18, 2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=arct_LanceKurataMember', window );">Lance Kurata [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Lance Kurata<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Chief Legal Officer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text"> June 12, 2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrExpirationDate', window );">Expiration Date</a></td>
<td class="text">June 12, 2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">35,000<span></span>
</td>
<td class="nump">35,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=arct_DrPadmanabhChivukulaMember', window );">Dr. Padmanabh Chivukula [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Dr. Padmanabh Chivukula<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Chief Scientific Officer and Chief Operating Officer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">November 20, 2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrExpirationDate', window );">Expiration Date</a></td>
<td class="text">November 10, 2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">162 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">120,000<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=arct_DirectorsOrOfficersExceptChiefScientificOfficerCooSvpCcAndPaoMember', window );">Directors or Officers Except Chief Scientific Officer, COO, SVP, CC and PAO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MtrlTermsOfTrdArrTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MtrlTermsOfTrdArrTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrDuration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrDuration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrSecuritiesAggAvailAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrSecuritiesAggAvailAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrTerminationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrTerminationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=arct_KeithCKummerfeldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=arct_KeithCKummerfeldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=arct_LanceKurataMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=arct_LanceKurataMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=arct_DrPadmanabhChivukulaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=arct_DrPadmanabhChivukulaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=arct_DirectorsOrOfficersExceptChiefScientificOfficerCooSvpCcAndPaoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=arct_DirectorsOrOfficersExceptChiefScientificOfficerCooSvpCcAndPaoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45846719809632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock', window );">Organization</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 1.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Organization</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Description of Business</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Arcturus Therapeutics Holdings Inc. (the &#8220;Company&#8221; or "Arcturus") is a messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. Arcturus developed the world&#8217;s first approved self-amplifying messenger RNA (sa-mRNA) vaccine, KOSTAIVE</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (&#8220;KOSTAIVE&#8221;). KOSTAIVE achieved approval in Japan in 2023 as a vaccine against COVID-19. Sales of KOSTAIVE began in Japan in October 2024, marking the transition to a commercial stage company.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recent Developments</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">See </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#8220;Note 3 Revenue &#8211; CSL Seqirus&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for further information on the agreement with Seqirus, Inc. ("CSL Seqirus"), whereby CSL Seqirus and the Company continue to collaborate on research and development, manufacturing and global commercialization of vaccines.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Liquidity</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has incurred significant operating losses since its inception. As of December 31, 2024 and 2023, the Company had an accumulated deficit of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">448.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">367.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s activities since inception have consisted principally of research and development activities, general and administrative activities, and raising capital. The Company&#8217;s activities are subject to significant risks and uncertainties, including failing to secure additional funding before the Company achieves sustainable revenues and profit from operations. From the Company&#8217;s inception through the year ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company has funded its operations principally with the proceeds from revenues earned through collaboration agreements, including the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">200.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upfront payment received from CSL Seqirus during 2022, the sale of capital stock and proceeds from long-term debt. During fiscal year 2024, the Company received milestone payments totalin</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">g $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">96.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million f</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">rom CSL Seqirus. At December 31, 2024, the Company&#8217;s balance of cash and cash equivalents, including restricted cash, was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">293.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Management believes that it has sufficient working capital on hand to fund operations through at least the next twelve months from the date these consolidated financial statements were available to be issued. There can be no assurance that the Company will be successful in acquiring additional funding, that the Company&#8217;s projections of its future working capital needs will prove accurate, or that any additional funding would be sufficient to continue operations in future years.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and accounting policies concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45846815193568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 2. Summary of Significant Accounting Policies</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Basis of Presentation and Principles of Consolidation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying consolidated financial statements include the accounts of Arcturus Therapeutics Holdings Inc. and its subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. These consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">), which requires management to make estimates and assumptions regarding the valuation of certain debt and equity instruments, the equity method investment, share-based compensation, accruals for liabilities, income taxes, revenue and deferred revenue, leases, expense accruals, and other matters that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Although these estimates are based on management&#8217;s knowledge of current events and actions the Company may undertake in the future, actual results could materially differ from those estimates.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Segment Information</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company and its chief operating decision-maker view the Company&#8217;s operations and manage its business in </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> operating segment, which includes all activities related to the discovery, development and commercialization of messenger RNA medicines.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash equivalents are short-term highly liquid investments that are readily convertible to cash with original maturities of three months or less at the date of purchase.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restricted cash</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restricted cash includes collateral pledged and held at the Company&#8217;s securities accounts pursuant to a security agreement with Wells Fargo Bank, National Association (&#8220;Wells Fargo&#8221;) (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Note 7, Debt</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">). At December 31, 2024, such collateral amounted to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">55.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restricted cash also includes cash required to be set aside as security for lease payments and to maintain a letter of credit for the benefit of the landlord for the Company&#8217;s offices.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At December 31, 2024 and 2023, the Company had restricted cash of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in conjunction with property leases in San Diego, California, and such restriction is expected to be removed at the end of the lease term.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Value Measurements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. A hierarchy has been established for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Observable inputs are inputs that market participants would use in valuing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the factors market participants would use in valuing the asset or liability developed based upon the best information available under the circumstances. The hierarchy consists of three levels. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, and inputs (other than quoted prices) that are observable for the asset or liability, either directly or indirectly. Level 3 inputs are unobservable inputs for the asset or liability. Categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Accounts Receivable</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accounts receivable are recorded at the net invoice value and are non-interest bearing. The Company considers receivables past due based on the contractual payment terms. The Company reserves for specific receivables if collectability is no longer reasonably assured. Estimates for allowances for doubtful accounts are determined based on existing contractual obligations, historical payment patterns, and individual customer circumstances. The Company reevaluates such reserves on a regular basis and adjusts its reserves as needed. Once a receivable is deemed to be uncollectible, such balance is charged against the reserve. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> reserves have been recorded as of December 31, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024 or 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></div><div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Concentration of Credit Risk and Significant Customers</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is exposed to concentrations of credit risk primarily related to cash, cash equivalents, and accounts receivable.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company mitigates credit risk exposure by maintaining cash and cash equivalents only with high-credit-quality financial institutions and investing in instruments with short maturities. The Company continuously monitors counterparty risk to minimize potential financial exposure.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Accounts Receivable Concentration</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024 and 2023, the Company had significant concentrations of credit risk related to accounts receivable from a limited number of customers. The following customers accounted for 10% or more of total accounts receivable in each respective period:</span></p></div><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">BARDA &#8211; </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">60</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of total accounts receivable</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CSL &#8211; </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of total accounts receivable</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2023:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CSL &#8211; </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">74</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of total accounts receivable</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">BARDA &#8211; </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of total accounts receivable</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company monitors its credit exposure through regular assessments of counterparty risk and maintains ongoing collection efforts to mitigate potential credit losses.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue Concentration</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company generates a substantial portion of its revenue from a limited number of key customers. The following customers accounted for 10% or more of total revenue for each period:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the year ended December 31, 2024:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CSL &#8211; </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">91</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of total revenue </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the year ended December 31, 2023:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CSL &#8211; </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">92</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of total revenue </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the year ended December 31, 2022:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CSL &#8211; </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of total revenue </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Vinbiocare &#8211; </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of total revenue</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Given this concentration, the Company&#8217;s financial performance and cash flows may be materially impacted if there are changes in demand, contract renewals, or the financial condition of these key customers. The Company continues to evaluate opportunities to expand its customer base and mitigate concentration risk over time.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Joint Ventures, Equity Method Investments and Variable Interest Entities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investments for which the Company exercises significant influence, but does not have control are accounted for under the equity method. Equity method investment activity is related to the Company's joint venture in ARCALIS, Inc. with Axcelead, Inc. The Company&#8217;s share of the investees&#8217; results is presented as either income or loss from equity method investees in the accompanying consolidated statements of operations and comprehensive income (loss). As of December 31, 2024, the carrying value of the equity method investment in ARCALIS remained at zero as ARCALIS' cumulative losses exceeded any gains from dilution.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Property and Equipment, net</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment are stated at cost, net of accumulated depreciation and amortization. The cost of property and equipment is depreciated or amortized using the straight-line method over the respective useful lives of the assets, ranging from </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_a09c2b80-d521-40d4-b228-c34c98f0be33;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">five years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Leasehold improvements are amortized using the straight-line method over the shorter of the estimated useful life of the asset or the lease term. Long-lived assets, including property and equipment are reviewed for impairment whenever events or circumstances indicate that the carrying amount of these assets may not be recoverable. The determinants used for this evaluation include management&#8217;s estimate of an asset&#8217;s ability to generate positive income from operations and positive cash flow in future periods, as well as the strategic significance of the assets to the Company&#8217;s business objectives. The Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t recognize any impairment losses for the years ended December 31, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or 2022.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Comprehensive Income/Loss</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Comprehensive income/loss is defined as the change in stockholders&#8217; equity during a period from transactions and other events and circumstances from non-owner sources. There was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> other comprehensive loss or income tax effect related to unrealized losses in the years ended December 31, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue Recognition</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At contract inception, the Company analyzes its collaboration arrangements to assess whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities and therefore within the scope of ASC Topic 808, Collaborative Arrangements (ASC 808). For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Company first determines which elements of the collaboration reflect a vendor-customer relationship and are therefore within the scope of ASC 606.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company determines revenue recognition for arrangements within the scope of Topic 606 by performing the following five steps: (i) identify the contract; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when, or as, the company satisfies a performance obligation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The terms of the Company&#8217;s revenue agreements include license fees, upfront payments, milestone payments, reimbursement for research and development activities, option exercise fees, consulting and related technology transfer fees and royalties on sales of commercialized products. The event-based milestone payments represent variable consideration, and the Company uses the most likely amount method to estimate this variable consideration because the Company will either receive the milestone payment or will not, which makes the potential milestone payment a binary event. The most likely amount method requires the Company to determine the likelihood of earning the milestone payment. Given the high degree of uncertainty around achievement of these milestones, the Company determines the milestone amounts to be fully constrained and does not recognize revenue until the uncertainty associated with these payments is resolved. The Company will recognize revenue from sales-based royalty payments when or as the sales occur. The Company will re-evaluate the transaction price in each reporting period as uncertain events are resolved and other changes in circumstances occur.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A performance obligation is a promise in a contract to transfer a distinct good or service to the collaborative partner and is the unit of account in Topic 606. A contract&#8217;s transaction price is allocated to each distinct performance obligation based on relative standalone selling price and recognized as revenue when, or as, the performance obligation is satisfied.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For performance obligations that are recognized over time, the Company measures the progress using an input method. The input methods used are based on the effort expended or costs incurred toward the satisfaction of the performance obligation. The Company estimates the amount of effort expended, including the time estimated it will take to complete the activities, or costs incurred in a given period, relative to the estimated total effort or costs to satisfy the performance obligation. This approach requires the Company to make numerous estimates and use significant judgment. If estimates or judgments change over the course of the collaboration, a cumulative catch up of revenue is recognized in the period such changes are identified.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">See </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#8220;Note 3, Revenue&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for specific details surrounding the Company&#8217;s arrangements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Grant revenue</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Grant revenue</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">consists of funding under cost reimbursement programs primarily from federal and non-profit foundation sources for qualified research and development activities performed by the Company. Such amounts are invoiced and recorded as revenue as grant-funded activities are performed, with any advance funding recorded as deferred revenue until the activities are performed.</span></p></div><div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company determines if an arrangement is a lease at inception. Lease right-of-use assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. For operating leases with an initial term greater than 12 months, the Company recognizes operating lease right-of-use assets and operating lease liabilities based on the present value of lease payments over the lease term at the commencement date. Operating lease right-of-use assets are comprised of the lease liability plus any lease payments made and excludes lease incentives. Lease terms include options to renew or terminate the lease when the Company is reasonably certain that the renewal option will be exercised or when it is reasonably certain that the termination option will not be exercised. For the Company's operating leases, if the interest rate used to determine the present value of future lease payments is not readily determinable, the Company estimates its incremental borrowing rate as the discount rate for the lease. The Company's incremental borrowing rate is estimated to approximate the interest rate on a collateralized basis with similar terms and payments, and in</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">similar economic environments. Lease expense for lease payments is recognized on a straight-line basis over the lease term. The Company has elected the practical expedient to not separate lease and non-lease components.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">See </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#8220;Note 11, Commitments and Contingencies&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for specific details surrounding the Company&#8217;s leases.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Costs, net</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All research and development costs are expensed as incurred. Research and development costs consist primarily of salaries, employee benefits, costs associated with preclinical studies and clinical trials (including amounts paid to clinical research organizations and other professional services), pre-launch inventory, in-process research and development expenses and license agreement expenses. Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods are received or the services are performed. The Company recognizes grants that fall within the scope of ASC 808 as contra research and development expense in the consolidated statement of operations on a systematic basis over the periods in which the entity recognizes as expenses the related costs for which the grants are intended to compensate.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company records accruals for estimated research and development costs, comprising payments for work performed by third party contractors, laboratories, participating clinical trial sites, and others. Some of these contractors bill monthly based on actual services performed, while others bill periodically based upon achieving certain contractual milestones. For the latter, the Company accrues the expenses as goods or services are used or rendered.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clinical trial activities performed by third parties are accrued and expensed based upon estimates of the proportion of work completed over the life of the individual clinical trial and patient enrollment rates in accordance with agreements established with Clinical Research Organizations (&#8220;CROs&#8221;) and clinical trial sites. Estimates are determined by reviewing contracts, vendor agreements and purchase orders, and through discussions with internal clinical personnel and external service providers as to the progress or stage of completion of trials or services and the agreed-upon fee to be paid for such services.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">General and Administrative Costs</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General and administrative expenses consist primarily of personnel-related costs, including share-based compensation, for executives, finance, legal, human resources, business development, and other administrative and operational functions, professional fees, accounting and legal services, information technology and facility-related costs, and expenses associated with obtaining and maintaining intellectual property (&#8220;IP&#8221;). These costs relate to the operation of the business, unrelated to the research and development function, or any individual program.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Pre-Launch Inventory</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prior to obtaining initial regulatory approval for an investigational product candidate, the Company expenses costs relating to production of inventory as research and development expense in its consolidated statements of operations and comprehensive income (loss), in the period incurred. When the Company believes regulatory approval and subsequent commercialization of an investigational product candidate is probable, and the Company also expects future economic benefit from the sales of the investigational product candidate to be realized, it will then capitalize the costs of production as inventory.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Share-Based Compensation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company records share-based compensation for equity awards granted to employees, consultants, officers and directors within general and administrative and research and development expenses on the statements of operations and comprehensive income (loss). </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Share-based compensation is recognized over the requisite service period of the individual awards using the straight-line attribution method, which generally equals the vesting period. Employees and officers&#8217; stock options have a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ten-year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> life and generally vest </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% on the first anniversary of the grant and in 1/36</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">th</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> equal installments on each monthly anniversary thereafter, such that options are fully vested on the </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">four-year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> anniversary of the date of grant. The exercisability and vesting periods of equity awards granted to consultants and directors vary.</span></span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of stock options is estimated using a Black-Scholes valuation model on the date of grant. This method requires certain assumptions be used as inputs, such as the fair value of the underlying common stock, expected term of the option before exercise, expected volatility of the Company&#8217;s common stock, expected dividend yield, and a risk-free interest rate. The Company has limited historical stock option activity and therefore estimates the expected term of stock options granted using the simplified method, which represents the average of the contractual term of the stock option and its weighted-average vesting period. For the nine months ended September 30, 2024, the expected volatility of stock options was based on the historical volatility of a peer group of publicly traded companies. For the three months ended December 31, 2024, the Company used its own historical volatility to estimate expected volatility, as it had accumulated sufficient historical stock price data. The Company has not declared or paid any dividends and does not currently expect to do so in the foreseeable future. The risk-free interest rates used are based on the implied yield currently available in United States Treasury securities at maturity with a term equivalent to the expected term of the stock options. The effect of forfeited or cancelled awards is recorded when the forfeiture or cancellation occurs</span></p></div><div><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Statement of Cash Flows</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets to the total of such amounts shown in the consolidated statement of cash flows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:56.66%;box-sizing:content-box;"></td>
          <td style="width:1.26%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:10.72%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.26%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.34%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.26%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:10.5%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31,</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">237,028</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">292,005</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">391,883</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted cash - current</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">55,000</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">55,000</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-current Restricted cash</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,885</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,885</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,094</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total cash, cash equivalents and restricted cash <br/>&#160;&#160;&#160;&#160;&#160;shown in the statement of cash flows</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">293,913</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">348,890</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">393,977</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div></div><div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Tax Expense</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Income taxes are accounted for using an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial reporting basis and the tax basis of the Company&#8217;s assets and liabilities at the applicable tax rates, along with net operating loss and tax credit carryovers. The Company records a valuation allowance against its deferred tax assets to reduce the net carrying value to an amount that it believes is more likely than not to be realized. Management has considered estimated taxable income and ongoing prudent and feasible tax planning strategies in assessing the amount of the valuation allowance. Based upon the weight of available evidence, which includes the Company&#8217;s historical operating performance and limited potential to utilize tax credit carryforwards, the Company has determined that total deferred tax assets should be fully offset by a valuation allowance. When the Company establishes or reduces the valuation allowance against its deferred tax assets, its provision for income taxes will increase or decrease, respectively, in the period such determination is made.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is required to file federal and state income tax returns in the United States and various other state jurisdictions. The Company also files income tax returns in the foreign countries in which it operates. The preparation of these income tax returns requires the Company to interpret the applicable tax laws and regulations in effect in such jurisdictions, which could affect the amount of tax paid by the Company.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, the Company follows an accounting standard addressing the accounting for uncertainty in income taxes that prescribes rules for recognition, measurement, and classification in the consolidated financial statements of tax positions taken or expected to be taken in a tax return.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Net (Loss) Income per Share</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic net (loss) income per share is calculated by dividing the net (loss) income by the weighted-average number of shares of common stock outstanding for the period, without consideration for common stock equivalents. Diluted net (loss) income per share is calculated by dividing the net (loss) income by the weighted-average number of shares of common stock and dilutive common stock equivalents outstanding for the period determined using the treasury-stock method. Dilutive shares of common stock for the years ended December 31, 2024 and 2023 were comprised of stock options and restricted stock units. Dilutive shares of stock for the years ended December 31, 2022 were comprised of stock options.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> dividends were declared or paid during the reporting periods.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Adopted Accounting Pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires public entities to disclose information about their reportable segments&#8217; significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in ASC 280 on an interim and annual basis. ASU 2023-07 is effective for annual reporting periods beginning after December 15, 2023, and for interim reporting periods beginning January 1, 2025. The Company </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adopted</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ASU 2023-07 for the annual reporting period beginning on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">January 1, 2024</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. See &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Note 12, Segment Information</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221; for further information.</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Issued Accounting Standards Not Yet Adopted</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. The Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on the consolidated financial statements and disclosures.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the FASB issued ASU 2024-03, Income Statement&#8211;Reporting Comprehensive Income&#8211;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, which requires public entities to disclose specified information about certain costs and expenses on an interim and annual basis. ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the impact that adoption of ASU 2024-03 will have on the financial statement disclosures.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45846719627456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTE 3. Revenue</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has entered into license agreements and collaborative research and development arrangements with pharmaceutical and biotechnology companies, as well as consulting, related technology transfer and product revenue agreements. Under these arrangements, the Company is entitled to receive license fees, consulting fees, product fees, technological transfer fees, upfront payments, milestone payments if and when certain research and development milestones, technology transfer milestones or success-based milestones are achieved, royalties on approved product sales and reimbursement for research and development activities. The Company&#8217;s costs of performing these services are included within research and development expenses. The Company&#8217;s milestone payments are typically defined by achievement of certain preclinical, clinical, and commercial success criteria. Preclinical milestones may include </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> proof of concept in disease animal models, lead candidate identification, and completion of IND-enabling toxicology studies. Clinical milestones may, for example, include successful enrollment of the first patient in or completion of Phase 1, 2 and 3 clinical trials, and commercial milestones are often tiered based on net or aggregate sale amounts. The Company cannot guarantee the achievement of these milestones due to risks associated with preclinical and clinical activities required for development of nucleic acid medicine-based therapeutics and vaccines.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">
</span><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents changes in the balances of receivables and contract liabilities related to revenue generating agreements during the year ended December 31, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024: </span></span><span style=""></span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:44.329%;box-sizing:content-box;"></td>
        <td style="width:1.2%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.902000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.2%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.902000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.682%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.582%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Additions</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Deductions</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Contract Assets:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts receivable</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32,064</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98,430</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">126,520</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,974</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Contract Liabilities:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred revenue</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">87,325</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">97,599</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">152,806</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32,118</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2024, the Company recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in revenue from the deferred revenue balance as of December 31, 2023.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the Company&#8217;s revenue for the periods indicated. Approximately</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">138.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">154.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">192.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of total revenue represents revenue derived from foreign countries for the years ended December 31, 2024, 2023 and 2022, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:51.33%;box-sizing:content-box;"></td>
        <td style="width:1.4%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.957%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.4%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.957%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.26%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.697000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Collaboration revenue:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">CSL Seqirus</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">138,389</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">154,264</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">154,425</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vinbiocare</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,571</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Janssen</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">660</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,201</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ultragenyx</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,837</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,739</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Israel Ministry of Health</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,500</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">987</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,319</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total collaboration revenue</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">138,389</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">157,748</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">205,755</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Grant revenue:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">BARDA</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,921</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,051</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">244</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total grant revenue</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,921</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,051</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">244</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following paragraphs provide information regarding the nature and purpose of the Company&#8217;s most significant revenue arrangements.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">CSL Seqirus</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On November 1, 2022, the Company entered into a Collaboration and License Agreement (as amended, the &#8220;CSL Collaboration Agreement&#8221;) with Seqirus, Inc., a part of CSL Limited (&#8220;CSL Seqirus&#8221;), for the global exclusive rights to research, develop, manufacture, and commercialize vaccines. Under the terms of the CSL Collaboration Agreement, the Company provides CSL Seqirus with an exclusive global license to its mRNA technology (including STARR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) and LUNAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> lipid-mediated delivery, along with mRNA drug substance and drug product manufacturing process. CSL Seqirus will lead development and commercialization of vaccines under the collaboration. The collaboration plans to advance vaccines against SARS-CoV-2 (COVID-19), influenza, pandemic preparedness as well as three other infectious diseases.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company received a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">200.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upfront payment and is eligible to receive over $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> billion in development milestones if all products are registered in the licensed fields and entitled to potentially receive up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> billion in commercial milestones based on &#8220;net sales&#8221; of vaccines in the various fields. In addition, the Company is eligible to receive a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% net profit share for COVID-19 vaccine products and up to low double-digit royalties for vaccines against flu, pandemic preparedness and three other pathogens. During 2024, the Company achieve</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">d $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">72.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million o</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">f development and regulatory milestones related to the CSL Collaboration Agreement, of which </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">none</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was included in accounts receivable as of December 31, 2024.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In evaluating the CSL Collaboration Agreement in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, the Company concluded that CSL Seqirus is a customer. The Company identified all promised goods/services within the CSL Collaboration Agreement, and when combining certain promised goods/services, the Company concluded that there are five distinct performance obligations. The nature of the performance obligations consists of delivery of the vaccine license, research and development services for COVID and non-COVID vaccines</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and regulatory activities for COVID vaccines. For each performance obligation, the Company estimated the standalone selling price based on 1) in the case of the license, the fair value using costs to recreate plus margin method and 2) in the case of research and development services and regulatory activities, cost plus margin for estimated full-time equivalent (&#8220;FTE&#8221;) costs, direct costs including laboratory supplies, contractors, and other out-of-pocket expenses for research and development services and regulatory activities.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, the transaction price primarily consisted of upfront consideration received and milestones achieved as of December 31, 2024. Additional variable consideration was not included in the transaction price at December 31, 2024 because the Company could not conclude that it is probable that including the variable consideration will not result in a significant revenue reversal.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company allocated the transaction price to the performance obligations in proportion to their standalone selling price. The portion of the upfront payment that was allocated to the vaccine license was recognized at the point in time it was transferred in 2022. The research and development and regulatory activities performance obligations are recognized over a period of time based on the percentage of services rendered using the input method, meaning actual costs incurred divided by total costs budgeted to satisfy the performance obligation. Any consideration related to sales-based royalties will be recognized when the amounts are probable of non-reversal, provided that the reported sales are reliably measurable and the Company has no remaining promised goods/services, as they are constrained and therefore have also been excluded from the transaction price. The revenue recognized in 2024 reflects variable consideration added to the transaction price upon the achievement of milestones, attributable to the license granted in 2022 and research and development services provided through December 31, 2024.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">T</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">otal deferred revenue as of December 31, 2024 and 2023 for the CSL Collaboration Agreement was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">87.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During 2023, the Company also received an advance payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the manufacturing and supply of ARCT-154 drug product. The advance payment was for specified manufacturing runs of ARCT-154 which include the drug substance utilized, as well as the reservation fees and related manufacturing requirements. The Company concluded that the promise to manufacture and supply ARCT-154 drug product is a customer option as part of the CSL Collaboration Agreement and is accounted for as a separate contract. The Company recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in revenue related to this customer option during the second quarter of 2024. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> amount related to this customer option remained in deferred revenue as of December 31, 2024.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During 2023, the Company entered into an amendment to the CSL Collaboration Agreement, pursuant to which the Company agreed to sponsor and conduct a Phase 1 clinical study in the influenza field. As part of the amendment, the Company received $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million from CSL Seqirus. The amendment also provides for up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in additional payments which are achievable upon meeting certain clinical milestones relating to the Phase 1 clinical study in the influenza field. The Company previously concluded that the expansion of research and development support services under the CSL Collaboration Agreement represented an option that was not a material right. Therefore the Company concluded the promise to sponsor and conduct the Phase 1 clinical study is a separate contract and the sole performance obligation under the new arrangement. During the year ended December 31, 2024, the Company recognized revenue of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million related to the performance obligation compared to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million during the year ended December 31, 2023. The remaining amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million is included in deferred revenue.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the fourth quarter of 2023, the Company received an advance payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million from CSL Seqirus for manufacturing activities related to COVID-19 vaccine product. During the first quarter of 2024, the Company received an additional advance payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million from CSL Seqirus for manufacturing activities related to COVID-19 vaccine product. The Company concluded that the promise to perform manufacturing activities is a customer option as part of the CSL Collaboration Agreement and is accounted for as a separate contract. The Company recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in revenue related to this customer option during the third quarter of 2024 upon the transfer of vaccine product to CSL Seqirus. The remaining $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million is included in deferred revenue as of December 31, 2024 and will be recognized as revenue when the remaining vaccine product is transferred to CSL Seqirus.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2024, the Company entered into an amendment to the CSL Collaboration Agreement, pursuant to which the parties agreed to, among other things, adjust (i) the development plans for certain product candidates, (ii) various development milestones related to such product candidates, (iii) provisions of the CSL Collaboration</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Agreement related to specific royalty payments, (iii) provisions of the CSL Collaboration Agreement related to distributors, and (iv) proprietary payment calculations related to the foregoing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Vinbiocare</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During 2021 the Company entered into certain agreements with Vinbiocare, a member of Vingroup Joint Stock Company, whereby the Company would provide technical expertise and support services to Vinbiocare to assist in the build out of a mRNA drug product manufacturing facility in Vietnam. The Company received an upfront payment in aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as part of the Vinbiocare Agreement. In October 2022, the Company and Vinbiocare executed a letter agreement terminating the Technology License and Technical Support Agreement and the Framework Drug Substance Supply Agreement (collectively, the &#8220;License &amp; Supply Agreements&#8221;). The Company incurred no financial penalties in connection with the termination of the License &amp; Supply Agreements and has no further financial obligations to Vinbiocare under these terminated agreements.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2022, in association with the termination of the License &amp; Supply Agreements, the Company signed the Study Support Agreement with Vinbiocare which provides that Vinbiocare shall continue to serve as the regulatory and financial sponsor of clinical studies conducted in Vietnam of ARCT-154 pursuant to the Company&#8217;s arrangements with Vinbiocare (the &#8220;Study Support Agreement&#8221;). To support the continuing activities of these studies, the Study Support Agreement further provides for the Company to conduct certain services and to compensate Vinbiocare to help achieve the objectives of these studies. In February 2023, the Company agreed to provide additional financial support in the amount of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to allow Vinbiocare to provide additional study support duties related to the ARCT-154 clinical study. As a result, the Company reserved $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of the original upfront payment to be paid to Vinbiocare over the future periods pursuant to the Study Support Agreement by reclassifying a portion of the upfront payment received from Vinbiocare pursuant to the License &amp; Supply Agreements, from deferred revenue to short-term and long-term liabilities, based on the anticipated timing of the payments to Vinbiocare, and removed that portion of the upfront payment from the transaction price of the modified arrangement. The transaction price was not adjusted for payments that are contingent upon the occurrence of future regulatory or sales-related events based on the information currently available to the Company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has concluded that it has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> remaining performance obligations under its prior arrangements with Vinbiocare as summarized above as of December 31, 2024. As of December 31, 2024, the Company has accrued liabilities related to this arrangement of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in current liabilities that will be paid upon the occurrence of specified events through the end of 2025. Vinbiocare is also eligible to receive a single digit percentage of amounts from net sales, if any, of ARCT-154 (or next-generation COVID vaccine) up to a capped amount of low single digit millions. The Company had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> remaining deferred revenue as of December 31, 2024 or 2023.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">BARDA Grant</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In August 2022, the Company entered into a cost reimbursement contract with the Biomedical Advanced Research and Development Authority ("BARDA"), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS) for an award of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the development of a pandemic influenza vaccine using the Company's STARR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:8.040000000000001pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> self-amplifying mRNA vaccine platform technology. The Company earns grant revenue for performing tasks under the agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company determined that the agreement with BARDA is not in the scope of ASC 808 or ASC 606. Applying International Accounting Standards No. 20 ("IAS 20"), Accounting for Government Grants and Disclosure of Government Assistance, by analogy, the Company recognizes grant revenue from the reimbursement of direct out-of-pocket expenses, overhead allocations and fringe benefits for research costs associated with the grant. The costs associated with these reimbursements are reflected as a component of research and development expense in the Company&#8217;s consolidated statements of operations and comprehensive income (loss).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of grant revenue during the years ended December 31, 2024 and 2023, respectively, which is included in revenue on the Company's consolidated statements of operations. As of December 31, 2024, the remaining available funding net of revenue earned was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45846864280192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTE 4. Fair Value Measurements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company establishes the fair value of its assets and liabilities using the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company established a fair value hierarchy based on the inputs used to measure fair value.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The three levels of the fair value hierarchy are as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 1:  Quoted prices in active markets for identical assets or liabilities.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 2:  Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 3:  Unobservable inputs in which little or no market data exists and are therefore determined using estimates and assumptions developed by the Company, which reflect those that a market participant would use.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The carrying value of cash, restricted cash, accounts receivable, accounts payable, accrued liabilities and the Singapore loan approximate their respective fair values due to their relative short maturities. The carrying amounts of long-term debt for the amount drawn on the Company&#8217;s debt facility approximates fair value as the interest rate is variable and reflects current market rates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company's assets measured at fair value on a recurring basis consisted of money market funds. As of December 31, 2024, the Company's had money market funds with a fair value of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">230.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">were classified within Level 1 of the fair value hierarchy. The fair value of these financial instruments was measured based on quoted prices.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45846714489296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities Detail<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Liabilities Detail</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTE 5. Accrued Liabilities Detail</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued liabilities consisted of the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:61.08%;box-sizing:content-box;"></td>
        <td style="width:1.66%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.8%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.66%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.8%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued compensation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,305</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,918</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cystic Fibrosis Foundation liability</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,443</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,633</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Income tax payable</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">641</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current portion of </span><span><span style="-sec-ix-hidden:F_7bcaf8a7-146c-4002-845d-af462601018d;"><span style="-sec-ix-hidden:F_9747f896-2497-4837-848b-f002a89071bd;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">operating lease liability</span></span></span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,552</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,309</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Clinical trial accruals</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,828</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,333</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vinbiocare contractual liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,421</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,514</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Legal accrual</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">130</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">177</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other accrued research and development expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,102</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,356</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38,781</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31,881</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45846715141888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTE 6. Property and Equipment, Net</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment, net consisted of the following:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:61.08%;box-sizing:content-box;"></td>
        <td style="width:1.66%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.8%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.66%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.8%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,864</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,046</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computers and software</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,131</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,275</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Office equipment and furniture</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">703</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">958</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,644</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,655</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Construction in progress</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">233</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,342</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,167</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less accumulated depreciation and amortization</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,811</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,740</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,531</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,427</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depreciation and amortization expense was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the years ended December 31, 2024, 2023 and 2022, respectively. Construction in progress is primarily comprised of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> research equipment not yet placed in service.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45846719698320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTE 7. Debt</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Wells Fargo Credit Agreement</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 21, 2023, the Company&#8217;s wholly-owned subsidiary, Arcturus Therapeutics, Inc. entered into a credit agreement with Wells Fargo (the &#8220;Credit Agreement&#8221;) whereby Wells Fargo will make a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million revolving credit line available to the Company (the &#8220;Loan&#8221;) and each Loan evidenced by a revolving line of credit note (the &#8220;Note&#8221;). On </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 26, 2024, the parties entered into Amendment No. 1 to the Credit Agreement, whereby the term was extended by </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">one year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to April 2026.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Borrowings under the agreement will bear interest at a rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.00</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% above either the Daily Simple SOFR or Term SOFR (as such terms are defined in the Note), with &#8220;SOFR&#8221; being the rate per annum equal to the secured overnight financing rate as administered by the Federal Reserve Bank of New York. If an Event of Default (as defined in the agreement) occurs, then all Loans shall bear interest at a rate equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.00</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% above the interest rate applicable immediately prior to the occurrence of the Event of Default.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The original term of the agreement is </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">two years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, with an option for </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">one-year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> renewals subject to Wells Fargo approval and the Company furnishing to Wells Fargo a non-refundable commitment fee equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.25</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the Loan amount for each such renewal. There is no penalty for terminating the facility prior to the maturity date of the Note. As collateral, the Company has agreed to pledge $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">55.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in cash to be held at the Company&#8217;s securities accounts with Wells Fargo Securities, LLC, an affiliate of Wells Fargo, pursuant to a security agreement. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> amounts were outstanding as of December 31, 2024.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Manufacturing Supply Agreement</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On November 7, 2020, the Company&#8217;s wholly-owned subsidiary, Arcturus Therapeutics, Inc., entered into a Manufacturing Support Agreement (the &#8220;Support Agreement&#8221;) with the Economic Development Board of the Republic of Singapore (the &#8220;EDB&#8221;). Pursuant to the Support Agreement, the EDB agreed to make a term loan (the &#8220;Singapore Loan&#8221;) of S$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to the Company, subject to the satisfaction of customary deliveries, to support the manufacture of the LUNAR-COV19 vaccine candidate (ARCT-021). The Singapore Loan accrues interest at a rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% per annum calculated on a daily basis. The Company elected to borrow the full amount available under the Support Agreement of S$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million ($</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million) on January 29, 2021.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the first quarter of 2023, the EDB agreed to an extension of the reconciliation period to March 22, 2023, with unused funds not utilized for the manufacture of ARCT-021 as of such date returned to the EDB. As of December 31, 2022, the outstanding balance of the Singapore Loan, which includes accrued interest, was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of which the Company paid S$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million ($</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million) in March 2023. During the first quarter of 2023, the remaining principal portion of the Singapore Loan plus accrued interest, totaling $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, was forgiven and recorded as a gain on debt extinguishment in the consolidated statement of operations and comprehensive loss.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> interest expense was incurred on the Singapore Loan for the year ended December 31, 2024, and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of interest expense was incurred for the years ended December 31, 2023 and 2022, respectively. As of December 31, 2023, the Company no longer had debt or interest related to this agreement.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Termination of Agreement with Western Alliance Bank</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 14, 2023, the Loan and Security Agreement, dated as of October 12, 2018 (as amended and supplemented, the &#8220;Western Alliance Agreement&#8221;) with Western Alliance Bank, an Arizona corporation (&#8220;Western Alliance&#8221;), was terminated (the &#8220;Termination&#8221;) upon the receipt by Western Alliance of a payoff amount of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million from the Company. The Western Alliance Agreement provided for a collateralized term loan in the aggregate principal amount of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, with interest at a floating rate ranging from </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.25</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.75</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% above the prime rate and a maturity date of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 30, 2023</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The payoff amount was made by the Company to Western Alliance from available cash on hand, pursuant to a payoff letter, and included payment of (i) approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in principal and interest, (ii) $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million fee payable upon prepayment as a result of prior FDA approval of an IND and (iii) de minimis amounts in prepayment charges and various operational fees. The Company was released from all liens under the Western Alliance Agreement.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recorded </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> interest expense for the year ended December 31, 2024, and for the years ended December 31, 2023 and 2022, the Company recorded interest expense of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45846719785504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTE 8. Stockholders&#8217; Equity</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Net (Loss) Income Per Share</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Potentially dilutive securities that were not included in the calculation of diluted net loss per share for the year ended December 31, 2024 and 2023 as they were anti-dilutive totaled </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively. Potentially dilutive securities that were not included in the calculation of diluted earnings per share for the year ended December 31, 2022 as they were anti-dilutive totaled </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45846815386752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Compensation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTE 9. Share-Based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In June 2024 at the Company&#8217;s 2024 Annual Meeting of Stockholders (the "2024 Annual Meeting"), the stockholders of the Company approved an amendment to the Company&#8217;s 2019 Omnibus Equity Incentive Plan (as amended, the &#8220;2019 Plan&#8221;) which, among other things, increased the aggregate number of shares authorized for use in making awards to eligible persons under the 2019 Plan by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares, for a total of up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,750,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares available for issuance. As of December 31, 2024, a total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,834,158</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares remain available for future issuance under the 2019 Plan, subject to the terms of the 2019 Plan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2021, the Company adopted the 2021 Inducement Equity Incentive Plan which covers the award of up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock (the &#8220;2021 Plan&#8221;) effective as of October 15, 2021. Approval of the Company&#8217;s stockholders is not required as a condition to the effectiveness of the 2021 Plan for so long as the plan is in compliance with applicable Nasdaq inducement plan rules. In April 2022, the compensation committee of the Company&#8217;s board of directors approved a proposal to reduce the total number of shares available for future issuance under the 2021 Plan to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">130,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. As of December 31, 2024, a total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">124,697</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares remain available for future issuance under the 2021 Plan, subject to the terms of the 2021 Plan.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Share Options</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents the weighted-average assumptions used in the Black-Scholes valuation model by the Company in calculating the fair value of stock options granted:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.334%;box-sizing:content-box;"></td>
        <td style="width:1.501%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.867999999999999%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.501%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.867999999999999%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.281%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.648%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Year Ended December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected life (in years)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.88</span></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.04</span></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.05</span></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">91.4</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">76.1</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">82.1</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.24</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.91</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.93</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Grant date weighted average fair value</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22.62</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18.87</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.56</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the Company&#8217;s stock option activity for the year ended December 31, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:46%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of<br/>Shares</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>Average<br/>Exercise Price</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term (Years)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate<br/>Intrinsic Value<br/>(in thousands)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding &#8211; December 31, 2023</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,971,127</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33.55</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.9</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53,295</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">740,594</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22.62</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">228,328</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20.74</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited/cancelled</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">404,641</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42.43</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding &#8211; December 31, 2024</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,078,752</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32.38</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.2</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,247</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercisable &#8211; December 31, 2024</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,983,108</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37.27</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.4</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,796</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercisable and expected to vest &#8211;<br/>&#160;&#160;&#160;December 31, 2024</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,078,752</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32.38</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.2</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,247</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the total unrecognized compensation cost of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million will be recognized over the weighted-average remaining service period of approximately </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.6</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years. The fair value of the options vested during the years ended December 31, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024 , 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and 2022 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively. The total intrinsic value of options exercised during the years ended December 31, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and 2022 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restricted Stock Units</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In August 2023, the Company granted </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,786</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> restricted stock units (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8220;RSUs&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) to its board of directors, when the market value of the Company's common stock was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34.92</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. These RSUs fully vested at the Company's 2024 annual stockholders' meeting. However, the release of the units remains subject to specific conditions and will occur only in the event of a board separation or a change in control.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the Company&#8217;s RSU activity for the year ended December 31, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.58%;box-sizing:content-box;"></td>
        <td style="width:1.28%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.42%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.76%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.96%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of<br/>Shares</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>Average<br/>Grant<br/>Date<br/>Fair Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding &#8211; December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,786</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34.92</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Awarded</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Released</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding &#8211; December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,786</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34.92</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Share-based compensation expenses included in the Company&#8217;s statements of operations and comprehensive income (loss) for the years ended December 31, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024,  2023 and 2022 were:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.58%;box-sizing:content-box;"></td>
        <td style="width:1.4%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.82%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.4%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.82%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.28%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.700000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Year Ended December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,456</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,950</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,081</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,532</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,699</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,530</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37,988</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34,649</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,611</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45846822011824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTE 10. Income Taxes</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A reconciliation of (loss) income before income taxes for domestic and foreign locations is as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.791%;box-sizing:content-box;"></td>
        <td style="width:1.26%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.642000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.26%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.262%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.26%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.522%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Year Ended December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">United States</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">81,050</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,890</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,644</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total (loss) income before income taxes</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">81,050</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,890</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,644</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A reconciliation of income tax (benefit) expense for the years ended December 31, 2024, 2023 and 2022 is as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.66%;box-sizing:content-box;"></td>
        <td style="width:1.26%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.72%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.26%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.34%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.26%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.5%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Federal</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,246</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,121</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">589</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">174</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total current income tax (benefit) expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,835</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,295</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Federal</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred income tax expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total income tax (benefit) expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,835</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,295</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A reconciliation of the federal statutory income tax rate to the Company&#8217;s effective income tax rate is as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.451%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.982%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.581999999999999%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.982000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Federal statutory income tax rate</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State income taxes, net of federal benefit</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.9</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.9</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.2</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Share-based compensation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.9</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.5</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16.1</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Officers compensation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.4</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.4</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.8</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development credits</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40.3</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Uncertain tax positions</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.7</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.4</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in tax rate</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.4</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.2</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.6</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36.1</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36.5</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.4</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.2</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.3</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Permanent differences</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.2</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.7</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.4</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Provision for income taxes</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.7</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.2</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The significant components of deferred income taxes are as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.7%;box-sizing:content-box;"></td>
        <td style="width:1.46%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.76%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.46%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:14.620000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net operating loss</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,413</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,147</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax credits</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,472</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,723</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,966</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">943</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred revenue</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,515</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,014</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inventory</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,961</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Basis difference in equity investments</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,127</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,202</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Capitalized R&amp;D</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">60,104</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41,971</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Right-of-use lease liability</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,601</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,233</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Share-based compensation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,872</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,618</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total gross deferred tax assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">145,070</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">116,812</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation and amortization</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">858</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,184</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Right-of-use asset</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,168</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,822</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total gross deferred tax liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,026</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,006</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">138,044</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">108,806</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net deferred tax asset</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In assessing the realization of the deferred tax assets, the Company considers whether it is more likely than not that some portion of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which temporary differences representing net future deductible amounts become deductible. Due to lack of available sources of taxable income, the Company recorded a full valuation allowance against its net deferred tax assets as sufficient uncertainty exists regarding the future realization of these assets. As of December 31, 2024 and 2023, the Co</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">mpany recorded a valuation allowance of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">138.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">108.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively. The valuation allowance changed by $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the years ended December 31, 2024 and 2023, respectively.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At December 31, 2024, the Company has federal and state net operating losses, or NOL, carryforwards of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">47.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">223.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively. The federal net operating loss carryforward includes losses generated in 2018 and after which can be carried forward indefinitely. The state net operating loss carryforward includes $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of losses that can be carried forward indefinitely.  The remaining state net operating losses begin to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2039</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At December 31, 2024, the Company has federal and state research and development credit carryforwards of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively. The federal credit carryforwards begin to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2037</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and the state credits carry forward indefinitely. $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of the state credit begin to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2037 </span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and the remainder carryforward indefinitely. Additionally, the Company has an Orphan Drug Credit of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of December 31, 2024 which will begin to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2042</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> unless previously utilized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to Internal Revenue Code (IRC) Sections 382 and 383, annual use of the Company&#8217;s federal and California net operating loss and research and</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">development credit carryforwards may be limited in the event a cumulative change in ownership of more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% occurs within a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three-year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> period. The Company has completed an IRC Section 382 analysis through December 31, 2024 regarding the limitation of net operating loss carryforwards and other tax attributes. The Company experienced ownership changes in 2018 and 2020; however, the Company estimates that all tax attributes can be utilized. There is a risk that additional ownership changes may occur in the future. If a change in ownership occurs, the NOL carryforwards and other tax attributes could be limited or restricted.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The company accounts for income taxes in accordance with ASC 740-10, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Accounting for Uncertainty in Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more likely than not to be sustained upon audit by the relevant taxing authority. An uncertain tax position will not be recognized if it has less than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% likelihood of being sustained.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A reconciliation of unrecognized tax benefits is as follows (in millions):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.7%;box-sizing:content-box;"></td>
        <td style="width:1.46%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.76%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.46%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:14.620000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Beginning balance of unrecognized tax benefits</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.6</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.9</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Decrease for prior period tax positions</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.2</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Increase for current period tax positions</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.6</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ending balance of unrecognized tax benefits</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.8</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.6</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amounts in the summary rollforward would </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t impact the effective tax rate as the Company maintains a full valuation on its net deferred tax assets. The Company is subject to taxation and files income tax returns in the United States, various U.S. states and foreign jurisdictions. The Company&#8217;s tax years from 2014 to date are subject to examination by the U.S., and state taxing authorities due to the carryforward of unutilized net operating losses and research and development credits. The Company&#8217;s policy is to recognize interest expense and penalties related to income tax matters as income tax expense. There was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> tax related interest or penalties recognized for the years ended December 31, 2024, 2023 and 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company does not anticipate any material changes to its unrecognized tax benefits within the next twelve months.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45846815431840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTE 11. Commitments and Contingencies</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cystic Fibrosis Foundation Therapeutics Funding agreement</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On September 25, 2023, the Company amended its Development Program Letter Agreement, dated May 16, 2017 and as amended July 13, 2018 and August 1, 2019, with the Cystic Fibrosis Foundation (&#8220;CFF&#8221;). Pursuant to the amendment, (i) CFF increased the amount it will award to advance LUNAR-CF to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million from approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, (ii) the Company agreed to incur at least $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million toward activities under the research plan. During the fourth quarter of 2023, the Company received the full payment from CFF related to the amendment. For the years ended December 31, 2024, 2023 and 2022, the Company recognized contra expense of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively. As of December 31, 2024, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">million remained in accrued liabilities.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2017, the Company entered into a non-cancellable operating lease agreement for office space adjacent to its previously occupied headquarters. The commencement of the lease began in March 2018 and the lease extends for approximately </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">84</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> months from the commencement date with a remaining lease term through March 2025. Monthly rental payments are due under the lease and there are escalating rent payments during the term of the lease. The Company is also responsible for its proportional share of operating expenses of the building and common areas. In conjunction with the new lease, the Company received free rent for </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">four months</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and received a tenant improvement allowance of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. In March 2024, the Company negotiated with the lessor to extend the lease through March 2027.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company entered into an irrevocable standby letter of credit with the landlord for a security deposit of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upon executing the lease which is included (along with additional funds required to secure the letter of credit) in the balance of non-current restricted cash.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In February 2020, the Company entered into a second non-cancellable operating lease agreement for office space near its current headquarters. The lease extended for </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> months from the commencement date and included a right to extend</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> the lease for one twelve-month period. In February 2021, the Company opted to extend the lease through March 2025 to coincide with the lease term of the Company&#8217;s headquarters.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> In January 2024, the Company vacated this office space with no intention of operating out of the location in the future. The Company was still engaged in the lease for the property and obligated to make the remaining lease payments through March 31, 2025, and therefore recorded an impairment loss in the amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million during the three months ended March 31, 2024, as there was no future economic benefit from the lease. In July 2024, the Company terminated the existing lease agreement, in accordance with its terms, thereby ending their contractual obligation to pay for the premises. As a result, no lease liability remains as of December 31, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2021, the Company entered into a third non-cancellable lease agreement for office, research and development, engineering and laboratory space near its current headquarters, and such lease term commenced during the second quarter of 2022. The initial term of this lease extends </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ten years and eight months</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from the date of possession, and </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Company has the right to extend the term of the lease for an additional five-year period.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> When the lease term was determined for the operating lease right-of-use assets and lease liabilities, the extension option for the lease was not included. The lease has a monthly base rent ranging from $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million which escalates over the lease term. The Company received a free rent period of four months and also pays for various operating costs, including utilities and real property taxes. The Company entered into an irrevocable standby letter of credit with the landlord for a security deposit of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upon executing the lease which is included (along with additional funds required to secure the letter of credit) in the balance of non-current restricted cash.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating lease right-of-use asset and liability on the consolidated balance sheets represent the present value of remaining lease payments over the remaining lease terms. The Company does not allocate lease payments to non-lease components; therefore, payments for common-area-maintenance and administrative services are not included in the operating lease right-of-use asset and liability. The Company uses its incremental borrowing rate to calculate the present value of the lease payments, as the implicit rate in the lease is not readily determinable.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024, the remaining payments of the operating lease liability were as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:75.855%;box-sizing:content-box;"></td>
        <td style="width:2.06%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:20.084%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Remaining Lease<br/>Payments</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,811</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,274</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,132</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,822</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,937</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Thereafter</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,813</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total remaining lease payments</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,789</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: imputed interest</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,239</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating lease liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28,550</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average remaining lease term (in years)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.2</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average discount rate</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.7</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating lease costs consist of the fixed lease payments included in operating lease liability and are recorded on a straight-line basis over the lease terms. Operating lease costs were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the years ended December 31, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and 2023, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45846864282016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Information</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTE 12. Segment Information</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company operates in </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> business segment, which includes all activities related to the discovery, development and commercialization of messenger RNA medicines. The determination of a single business segment is consistent with the consolidated financial information regularly provided to the Company&#8217;s chief operating decision maker (&#8220;CODM&#8221;). </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s CODM is its </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_806a8df4-c83d-4622-a6aa-7b9d8f050c33;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chief Executive Officer</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, who reviews and evaluates consolidated net (loss) income for purposes of assessing performance, making operating decisions, allocating resources, and planning and forecasting for future periods.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The CODM does not evaluate the operating segment using asset or liability information.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents information about reported segment revenues, segment loss and income, and significant segment expenses:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:63.1%;box-sizing:content-box;"></td>
        <td style="width:1.26%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.46%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.42%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.56%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.26%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:7.9399999999999995%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenues</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">152,310</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">166,799</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">205,999</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">LUNAR-COVID</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">70,464</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">81,262</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65,136</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">LUNAR-OTC</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,509</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,315</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,898</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">BARDA</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,807</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,465</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">95</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">LUNAR-CF, net</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,227</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,666</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,931</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Early-stage programs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,096</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,460</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,681</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Discovery technologies</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,278</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,405</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,082</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Payroll and benefits</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57,474</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50,924</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42,466</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Facilities and equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,301</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,636</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,462</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total research and development</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">195,156</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">192,133</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">147,751</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">52,823</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">52,871</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46,071</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,728</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48,480</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,828</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net (loss) income</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80,941</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,725</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,349</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Primarily includes interest income and expense, foreign currency gains and losses, and income taxes. The year ended December 31, 2023 includes a $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34.0</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million gain on debt extinguishment related to forgiveness of the Singapore Loan.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45846822294320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTE 13. Related Party Transactions</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">See &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Note 2, Joint Ventures, Equity Method Investments and Variable Interest Entities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221; for specific details surrounding the Company&#8217;s agreement with Axcelead to form the joint venture entity, ARCALIS, Inc.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45846822326608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTE 14. Subsequent Events</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45846715171152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Basis of Presentation and Principles of Consolidation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Basis of Presentation and Principles of Consolidation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying consolidated financial statements include the accounts of Arcturus Therapeutics Holdings Inc. and its subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. These consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">), which requires management to make estimates and assumptions regarding the valuation of certain debt and equity instruments, the equity method investment, share-based compensation, accruals for liabilities, income taxes, revenue and deferred revenue, leases, expense accruals, and other matters that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Although these estimates are based on management&#8217;s knowledge of current events and actions the Company may undertake in the future, actual results could materially differ from those estimates.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Segment Information</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company and its chief operating decision-maker view the Company&#8217;s operations and manage its business in </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> operating segment, which includes all activities related to the discovery, development and commercialization of messenger RNA medicines.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash equivalents are short-term highly liquid investments that are readily convertible to cash with original maturities of three months or less at the date of purchase.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restricted cash</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restricted cash includes collateral pledged and held at the Company&#8217;s securities accounts pursuant to a security agreement with Wells Fargo Bank, National Association (&#8220;Wells Fargo&#8221;) (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Note 7, Debt</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">). At December 31, 2024, such collateral amounted to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">55.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restricted cash also includes cash required to be set aside as security for lease payments and to maintain a letter of credit for the benefit of the landlord for the Company&#8217;s offices.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At December 31, 2024 and 2023, the Company had restricted cash of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in conjunction with property leases in San Diego, California, and such restriction is expected to be removed at the end of the lease term.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Value Measurements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. A hierarchy has been established for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Observable inputs are inputs that market participants would use in valuing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the factors market participants would use in valuing the asset or liability developed based upon the best information available under the circumstances. The hierarchy consists of three levels. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, and inputs (other than quoted prices) that are observable for the asset or liability, either directly or indirectly. Level 3 inputs are unobservable inputs for the asset or liability. Categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Accounts Receivable</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Accounts Receivable</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accounts receivable are recorded at the net invoice value and are non-interest bearing. The Company considers receivables past due based on the contractual payment terms. The Company reserves for specific receivables if collectability is no longer reasonably assured. Estimates for allowances for doubtful accounts are determined based on existing contractual obligations, historical payment patterns, and individual customer circumstances. The Company reevaluates such reserves on a regular basis and adjusts its reserves as needed. Once a receivable is deemed to be uncollectible, such balance is charged against the reserve. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> reserves have been recorded as of December 31, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024 or 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk and Significant Customers</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Concentration of Credit Risk and Significant Customers</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is exposed to concentrations of credit risk primarily related to cash, cash equivalents, and accounts receivable.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company mitigates credit risk exposure by maintaining cash and cash equivalents only with high-credit-quality financial institutions and investing in instruments with short maturities. The Company continuously monitors counterparty risk to minimize potential financial exposure.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Accounts Receivable Concentration</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024 and 2023, the Company had significant concentrations of credit risk related to accounts receivable from a limited number of customers. The following customers accounted for 10% or more of total accounts receivable in each respective period:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">BARDA &#8211; </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">60</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of total accounts receivable</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CSL &#8211; </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of total accounts receivable</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2023:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CSL &#8211; </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">74</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of total accounts receivable</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">BARDA &#8211; </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of total accounts receivable</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company monitors its credit exposure through regular assessments of counterparty risk and maintains ongoing collection efforts to mitigate potential credit losses.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue Concentration</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company generates a substantial portion of its revenue from a limited number of key customers. The following customers accounted for 10% or more of total revenue for each period:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the year ended December 31, 2024:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CSL &#8211; </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">91</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of total revenue </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the year ended December 31, 2023:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CSL &#8211; </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">92</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of total revenue </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the year ended December 31, 2022:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CSL &#8211; </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of total revenue </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Vinbiocare &#8211; </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of total revenue</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Given this concentration, the Company&#8217;s financial performance and cash flows may be materially impacted if there are changes in demand, contract renewals, or the financial condition of these key customers. The Company continues to evaluate opportunities to expand its customer base and mitigate concentration risk over time.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_JointVenturesEquityMethodInvestmentsAndVariableInterestEntitiesPolicyTextBlock', window );">Joint Ventures, Equity Method Investments and Variable Interest Entities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Joint Ventures, Equity Method Investments and Variable Interest Entities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investments for which the Company exercises significant influence, but does not have control are accounted for under the equity method. Equity method investment activity is related to the Company's joint venture in ARCALIS, Inc. with Axcelead, Inc. The Company&#8217;s share of the investees&#8217; results is presented as either income or loss from equity method investees in the accompanying consolidated statements of operations and comprehensive income (loss). As of December 31, 2024, the carrying value of the equity method investment in ARCALIS remained at zero as ARCALIS' cumulative losses exceeded any gains from dilution.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, net</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Property and Equipment, net</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment are stated at cost, net of accumulated depreciation and amortization. The cost of property and equipment is depreciated or amortized using the straight-line method over the respective useful lives of the assets, ranging from </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_a09c2b80-d521-40d4-b228-c34c98f0be33;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">five years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Leasehold improvements are amortized using the straight-line method over the shorter of the estimated useful life of the asset or the lease term. Long-lived assets, including property and equipment are reviewed for impairment whenever events or circumstances indicate that the carrying amount of these assets may not be recoverable. The determinants used for this evaluation include management&#8217;s estimate of an asset&#8217;s ability to generate positive income from operations and positive cash flow in future periods, as well as the strategic significance of the assets to the Company&#8217;s business objectives. The Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t recognize any impairment losses for the years ended December 31, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or 2022.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Income/Loss</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Comprehensive Income/Loss</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Comprehensive income/loss is defined as the change in stockholders&#8217; equity during a period from transactions and other events and circumstances from non-owner sources. There was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> other comprehensive loss or income tax effect related to unrealized losses in the years ended December 31, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue Recognition</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At contract inception, the Company analyzes its collaboration arrangements to assess whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities and therefore within the scope of ASC Topic 808, Collaborative Arrangements (ASC 808). For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Company first determines which elements of the collaboration reflect a vendor-customer relationship and are therefore within the scope of ASC 606.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company determines revenue recognition for arrangements within the scope of Topic 606 by performing the following five steps: (i) identify the contract; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when, or as, the company satisfies a performance obligation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The terms of the Company&#8217;s revenue agreements include license fees, upfront payments, milestone payments, reimbursement for research and development activities, option exercise fees, consulting and related technology transfer fees and royalties on sales of commercialized products. The event-based milestone payments represent variable consideration, and the Company uses the most likely amount method to estimate this variable consideration because the Company will either receive the milestone payment or will not, which makes the potential milestone payment a binary event. The most likely amount method requires the Company to determine the likelihood of earning the milestone payment. Given the high degree of uncertainty around achievement of these milestones, the Company determines the milestone amounts to be fully constrained and does not recognize revenue until the uncertainty associated with these payments is resolved. The Company will recognize revenue from sales-based royalty payments when or as the sales occur. The Company will re-evaluate the transaction price in each reporting period as uncertain events are resolved and other changes in circumstances occur.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A performance obligation is a promise in a contract to transfer a distinct good or service to the collaborative partner and is the unit of account in Topic 606. A contract&#8217;s transaction price is allocated to each distinct performance obligation based on relative standalone selling price and recognized as revenue when, or as, the performance obligation is satisfied.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For performance obligations that are recognized over time, the Company measures the progress using an input method. The input methods used are based on the effort expended or costs incurred toward the satisfaction of the performance obligation. The Company estimates the amount of effort expended, including the time estimated it will take to complete the activities, or costs incurred in a given period, relative to the estimated total effort or costs to satisfy the performance obligation. This approach requires the Company to make numerous estimates and use significant judgment. If estimates or judgments change over the course of the collaboration, a cumulative catch up of revenue is recognized in the period such changes are identified.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">See </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#8220;Note 3, Revenue&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for specific details surrounding the Company&#8217;s arrangements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Grant revenue</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Grant revenue</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">consists of funding under cost reimbursement programs primarily from federal and non-profit foundation sources for qualified research and development activities performed by the Company. Such amounts are invoiced and recorded as revenue as grant-funded activities are performed, with any advance funding recorded as deferred revenue until the activities are performed.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company determines if an arrangement is a lease at inception. Lease right-of-use assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. For operating leases with an initial term greater than 12 months, the Company recognizes operating lease right-of-use assets and operating lease liabilities based on the present value of lease payments over the lease term at the commencement date. Operating lease right-of-use assets are comprised of the lease liability plus any lease payments made and excludes lease incentives. Lease terms include options to renew or terminate the lease when the Company is reasonably certain that the renewal option will be exercised or when it is reasonably certain that the termination option will not be exercised. For the Company's operating leases, if the interest rate used to determine the present value of future lease payments is not readily determinable, the Company estimates its incremental borrowing rate as the discount rate for the lease. The Company's incremental borrowing rate is estimated to approximate the interest rate on a collateralized basis with similar terms and payments, and in</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">similar economic environments. Lease expense for lease payments is recognized on a straight-line basis over the lease term. The Company has elected the practical expedient to not separate lease and non-lease components.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">See </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#8220;Note 11, Commitments and Contingencies&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for specific details surrounding the Company&#8217;s leases.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs, net</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Costs, net</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All research and development costs are expensed as incurred. Research and development costs consist primarily of salaries, employee benefits, costs associated with preclinical studies and clinical trials (including amounts paid to clinical research organizations and other professional services), pre-launch inventory, in-process research and development expenses and license agreement expenses. Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods are received or the services are performed. The Company recognizes grants that fall within the scope of ASC 808 as contra research and development expense in the consolidated statement of operations on a systematic basis over the periods in which the entity recognizes as expenses the related costs for which the grants are intended to compensate.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company records accruals for estimated research and development costs, comprising payments for work performed by third party contractors, laboratories, participating clinical trial sites, and others. Some of these contractors bill monthly based on actual services performed, while others bill periodically based upon achieving certain contractual milestones. For the latter, the Company accrues the expenses as goods or services are used or rendered.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clinical trial activities performed by third parties are accrued and expensed based upon estimates of the proportion of work completed over the life of the individual clinical trial and patient enrollment rates in accordance with agreements established with Clinical Research Organizations (&#8220;CROs&#8221;) and clinical trial sites. Estimates are determined by reviewing contracts, vendor agreements and purchase orders, and through discussions with internal clinical personnel and external service providers as to the progress or stage of completion of trials or services and the agreed-upon fee to be paid for such services.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_GeneralAndAdministrativeCostsPolicyPolicyTextBlock', window );">General and Administrative Costs</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">General and Administrative Costs</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General and administrative expenses consist primarily of personnel-related costs, including share-based compensation, for executives, finance, legal, human resources, business development, and other administrative and operational functions, professional fees, accounting and legal services, information technology and facility-related costs, and expenses associated with obtaining and maintaining intellectual property (&#8220;IP&#8221;). These costs relate to the operation of the business, unrelated to the research and development function, or any individual program.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_PreLaunchInventoryPolicyPolicyTextBlock', window );">Pre-Launch Inventory</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Pre-Launch Inventory</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prior to obtaining initial regulatory approval for an investigational product candidate, the Company expenses costs relating to production of inventory as research and development expense in its consolidated statements of operations and comprehensive income (loss), in the period incurred. When the Company believes regulatory approval and subsequent commercialization of an investigational product candidate is probable, and the Company also expects future economic benefit from the sales of the investigational product candidate to be realized, it will then capitalize the costs of production as inventory.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Share-Based Compensation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company records share-based compensation for equity awards granted to employees, consultants, officers and directors within general and administrative and research and development expenses on the statements of operations and comprehensive income (loss). </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Share-based compensation is recognized over the requisite service period of the individual awards using the straight-line attribution method, which generally equals the vesting period. Employees and officers&#8217; stock options have a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ten-year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> life and generally vest </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% on the first anniversary of the grant and in 1/36</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">th</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> equal installments on each monthly anniversary thereafter, such that options are fully vested on the </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">four-year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> anniversary of the date of grant. The exercisability and vesting periods of equity awards granted to consultants and directors vary.</span></span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of stock options is estimated using a Black-Scholes valuation model on the date of grant. This method requires certain assumptions be used as inputs, such as the fair value of the underlying common stock, expected term of the option before exercise, expected volatility of the Company&#8217;s common stock, expected dividend yield, and a risk-free interest rate. The Company has limited historical stock option activity and therefore estimates the expected term of stock options granted using the simplified method, which represents the average of the contractual term of the stock option and its weighted-average vesting period. For the nine months ended September 30, 2024, the expected volatility of stock options was based on the historical volatility of a peer group of publicly traded companies. For the three months ended December 31, 2024, the Company used its own historical volatility to estimate expected volatility, as it had accumulated sufficient historical stock price data. The Company has not declared or paid any dividends and does not currently expect to do so in the foreseeable future. The risk-free interest rates used are based on the implied yield currently available in United States Treasury securities at maturity with a term equivalent to the expected term of the stock options. The effect of forfeited or cancelled awards is recorded when the forfeiture or cancellation occurs</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryCashFlowPolicy', window );">Statement of Cash Flows</a></td>
<td class="text"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Statement of Cash Flows</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets to the total of such amounts shown in the consolidated statement of cash flows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:56.66%;box-sizing:content-box;"></td>
          <td style="width:1.26%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:10.72%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.26%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.34%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.26%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:10.5%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31,</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">237,028</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">292,005</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">391,883</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted cash - current</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">55,000</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">55,000</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-current Restricted cash</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,885</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,885</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,094</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total cash, cash equivalents and restricted cash <br/>&#160;&#160;&#160;&#160;&#160;shown in the statement of cash flows</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">293,913</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">348,890</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">393,977</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Tax Expense</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Tax Expense</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Income taxes are accounted for using an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial reporting basis and the tax basis of the Company&#8217;s assets and liabilities at the applicable tax rates, along with net operating loss and tax credit carryovers. The Company records a valuation allowance against its deferred tax assets to reduce the net carrying value to an amount that it believes is more likely than not to be realized. Management has considered estimated taxable income and ongoing prudent and feasible tax planning strategies in assessing the amount of the valuation allowance. Based upon the weight of available evidence, which includes the Company&#8217;s historical operating performance and limited potential to utilize tax credit carryforwards, the Company has determined that total deferred tax assets should be fully offset by a valuation allowance. When the Company establishes or reduces the valuation allowance against its deferred tax assets, its provision for income taxes will increase or decrease, respectively, in the period such determination is made.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is required to file federal and state income tax returns in the United States and various other state jurisdictions. The Company also files income tax returns in the foreign countries in which it operates. The preparation of these income tax returns requires the Company to interpret the applicable tax laws and regulations in effect in such jurisdictions, which could affect the amount of tax paid by the Company.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, the Company follows an accounting standard addressing the accounting for uncertainty in income taxes that prescribes rules for recognition, measurement, and classification in the consolidated financial statements of tax positions taken or expected to be taken in a tax return.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net (Loss) Income per Share</a></td>
<td class="text"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Net (Loss) Income per Share</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic net (loss) income per share is calculated by dividing the net (loss) income by the weighted-average number of shares of common stock outstanding for the period, without consideration for common stock equivalents. Diluted net (loss) income per share is calculated by dividing the net (loss) income by the weighted-average number of shares of common stock and dilutive common stock equivalents outstanding for the period determined using the treasury-stock method. Dilutive shares of common stock for the years ended December 31, 2024 and 2023 were comprised of stock options and restricted stock units. Dilutive shares of stock for the years ended December 31, 2022 were comprised of stock options.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> dividends were declared or paid during the reporting periods.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements and Recently Issued Accounting Standards Not Yet Adopted</a></td>
<td class="text"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Adopted Accounting Pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires public entities to disclose information about their reportable segments&#8217; significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in ASC 280 on an interim and annual basis. ASU 2023-07 is effective for annual reporting periods beginning after December 15, 2023, and for interim reporting periods beginning January 1, 2025. The Company </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adopted</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ASU 2023-07 for the annual reporting period beginning on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">January 1, 2024</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. See &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Note 12, Segment Information</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221; for further information.</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Issued Accounting Standards Not Yet Adopted</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. The Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on the consolidated financial statements and disclosures.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the FASB issued ASU 2024-03, Income Statement&#8211;Reporting Comprehensive Income&#8211;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, which requires public entities to disclose specified information about certain costs and expenses on an interim and annual basis. ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the impact that adoption of ASU 2024-03 will have on the financial statement disclosures.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arct_GeneralAndAdministrativeCostsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>General and administrative costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arct_GeneralAndAdministrativeCostsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arct_JointVenturesEquityMethodInvestmentsAndVariableInterestEntitiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Joint ventures, equity method investments and variable interest entities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arct_JointVenturesEquityMethodInvestmentsAndVariableInterestEntitiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arct_PreLaunchInventoryPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Pre-launch inventory policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arct_PreLaunchInventoryPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryCashFlowPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining where the cash flows related to the sale of inventory are classified in the statements of cash flows and explain the nature of the receivables, notes, and loans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482888/230-10-55-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryCashFlowPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481569/310-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45846821518944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Cash and Cash Equivalents and Restricted Cash</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets to the total of such amounts shown in the consolidated statement of cash flows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:56.66%;box-sizing:content-box;"></td>
          <td style="width:1.26%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:10.72%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.26%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.34%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.26%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:10.5%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31,</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">237,028</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">292,005</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">391,883</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted cash - current</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">55,000</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">55,000</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-current Restricted cash</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,885</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,885</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,094</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total cash, cash equivalents and restricted cash <br/>&#160;&#160;&#160;&#160;&#160;shown in the statement of cash flows</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">293,913</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">348,890</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">393,977</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45846719912992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Summary of Changes in Balances of Receivables and Contract Liability</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents changes in the balances of receivables and contract liabilities related to revenue generating agreements during the year ended December 31, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024: </span><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:44.329%;box-sizing:content-box;"></td>
        <td style="width:1.2%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.902000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.2%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.902000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.682%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.582%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Additions</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Deductions</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Contract Assets:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts receivable</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32,064</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98,430</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">126,520</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,974</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Contract Liabilities:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred revenue</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">87,325</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">97,599</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">152,806</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32,118</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Revenue</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the Company&#8217;s revenue for the periods indicated. Approximately</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">138.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">154.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">192.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of total revenue represents revenue derived from foreign countries for the years ended December 31, 2024, 2023 and 2022, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:51.33%;box-sizing:content-box;"></td>
        <td style="width:1.4%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.957%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.4%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.957%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.26%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.697000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Collaboration revenue:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">CSL Seqirus</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">138,389</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">154,264</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">154,425</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vinbiocare</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,571</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Janssen</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">660</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,201</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ultragenyx</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,837</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,739</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Israel Ministry of Health</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,500</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">987</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,319</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total collaboration revenue</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">138,389</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">157,748</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">205,755</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Grant revenue:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">BARDA</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,921</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,051</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">244</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total grant revenue</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,921</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,051</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">244</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45846815518672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities Detail (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued liabilities consisted of the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:61.08%;box-sizing:content-box;"></td>
        <td style="width:1.66%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.8%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.66%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.8%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued compensation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,305</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,918</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cystic Fibrosis Foundation liability</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,443</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,633</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Income tax payable</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">641</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current portion of </span><span><span style="-sec-ix-hidden:F_7bcaf8a7-146c-4002-845d-af462601018d;"><span style="-sec-ix-hidden:F_9747f896-2497-4837-848b-f002a89071bd;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">operating lease liability</span></span></span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,552</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,309</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Clinical trial accruals</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,828</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,333</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vinbiocare contractual liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,421</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,514</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Legal accrual</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">130</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">177</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other accrued research and development expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,102</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,356</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38,781</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31,881</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45846715448064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of Components of Property and Equipment, Net</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment, net consisted of the following:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:61.08%;box-sizing:content-box;"></td>
        <td style="width:1.66%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.8%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.66%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.8%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,864</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,046</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computers and software</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,131</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,275</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Office equipment and furniture</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">703</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">958</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,644</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,655</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Construction in progress</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">233</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,342</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,167</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less accumulated depreciation and amortization</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,811</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,740</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,531</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,427</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45846719614880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Weighted Average Assumptions Used in Black -Scholes Valuation Model</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents the weighted-average assumptions used in the Black-Scholes valuation model by the Company in calculating the fair value of stock options granted:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.334%;box-sizing:content-box;"></td>
        <td style="width:1.501%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.867999999999999%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.501%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.867999999999999%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.281%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.648%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Year Ended December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected life (in years)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.88</span></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.04</span></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.05</span></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">91.4</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">76.1</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">82.1</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.24</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.91</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.93</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Grant date weighted average fair value</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22.62</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18.87</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.56</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Share Option Activity</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the Company&#8217;s stock option activity for the year ended December 31, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:46%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of<br/>Shares</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>Average<br/>Exercise Price</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term (Years)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate<br/>Intrinsic Value<br/>(in thousands)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding &#8211; December 31, 2023</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,971,127</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33.55</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.9</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53,295</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">740,594</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22.62</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">228,328</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20.74</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited/cancelled</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">404,641</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42.43</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding &#8211; December 31, 2024</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,078,752</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32.38</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.2</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,247</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercisable &#8211; December 31, 2024</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,983,108</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37.27</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.4</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,796</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercisable and expected to vest &#8211;<br/>&#160;&#160;&#160;December 31, 2024</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,078,752</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32.38</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.2</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,247</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Summary of Restricted Stock Unit, Activity</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the Company&#8217;s RSU activity for the year ended December 31, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.58%;box-sizing:content-box;"></td>
        <td style="width:1.28%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.42%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.76%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.96%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of<br/>Shares</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>Average<br/>Grant<br/>Date<br/>Fair Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding &#8211; December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,786</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34.92</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Awarded</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Released</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding &#8211; December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,786</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34.92</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of Share-based Compensation Expenses</a></td>
<td class="text"><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Share-based compensation expenses included in the Company&#8217;s statements of operations and comprehensive income (loss) for the years ended December 31, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024,  2023 and 2022 were:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.58%;box-sizing:content-box;"></td>
        <td style="width:1.4%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.82%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.4%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.82%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.28%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.700000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Year Ended December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,456</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,950</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,081</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,532</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,699</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,530</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37,988</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34,649</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,611</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45846714778992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Summary of Reconciliation of (Loss) Income Before Income Taxes for Domestic and Foreign Locations</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A reconciliation of (loss) income before income taxes for domestic and foreign locations is as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.791%;box-sizing:content-box;"></td>
        <td style="width:1.26%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.642000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.26%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.262%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.26%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.522%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Year Ended December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">United States</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">81,050</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,890</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,644</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total (loss) income before income taxes</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">81,050</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,890</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,644</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Summary of Reconciliation of Income Tax (Benefit) Expense</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A reconciliation of income tax (benefit) expense for the years ended December 31, 2024, 2023 and 2022 is as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.66%;box-sizing:content-box;"></td>
        <td style="width:1.26%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.72%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.26%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.34%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.26%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.5%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Federal</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,246</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,121</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">589</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">174</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total current income tax (benefit) expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,835</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,295</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Federal</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred income tax expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total income tax (benefit) expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,835</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,295</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation of Federal Statutory Income Tax Rate to Company's Effective Income Tax Rate</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A reconciliation of the federal statutory income tax rate to the Company&#8217;s effective income tax rate is as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.451%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.982%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.581999999999999%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.982000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Federal statutory income tax rate</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State income taxes, net of federal benefit</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.9</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.9</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.2</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Share-based compensation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.9</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.5</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16.1</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Officers compensation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.4</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.4</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.8</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development credits</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40.3</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Uncertain tax positions</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.7</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.4</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in tax rate</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.4</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.2</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.6</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36.1</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36.5</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.4</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.2</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.3</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Permanent differences</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.2</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.7</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.4</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Provision for income taxes</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.7</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.2</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Significant Components of Deferred Income Taxes</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The significant components of deferred income taxes are as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.7%;box-sizing:content-box;"></td>
        <td style="width:1.46%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.76%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.46%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:14.620000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net operating loss</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,413</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,147</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax credits</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,472</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,723</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,966</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">943</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred revenue</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,515</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,014</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inventory</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,961</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Basis difference in equity investments</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,127</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,202</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Capitalized R&amp;D</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">60,104</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41,971</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Right-of-use lease liability</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,601</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,233</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Share-based compensation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,872</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,618</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total gross deferred tax assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">145,070</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">116,812</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation and amortization</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">858</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,184</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Right-of-use asset</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,168</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,822</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total gross deferred tax liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,026</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,006</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">138,044</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">108,806</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net deferred tax asset</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Summary of Reconciliation of Unrecognized Tax Benefits</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A reconciliation of unrecognized tax benefits is as follows (in millions):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.7%;box-sizing:content-box;"></td>
        <td style="width:1.46%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.76%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.46%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:14.620000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Beginning balance of unrecognized tax benefits</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.6</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.9</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Decrease for prior period tax positions</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.2</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Increase for current period tax positions</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.6</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ending balance of unrecognized tax benefits</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.8</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.6</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45846864273984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Payments of Operating Lease Liability</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024, the remaining payments of the operating lease liability were as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:75.855%;box-sizing:content-box;"></td>
        <td style="width:2.06%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:20.084%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Remaining Lease<br/>Payments</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,811</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,274</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,132</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,822</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,937</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Thereafter</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,813</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total remaining lease payments</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,789</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: imputed interest</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,239</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating lease liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28,550</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average remaining lease term (in years)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.2</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average discount rate</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.7</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45846713708944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Summary of Reported Segment Revenues, Segment Loss and Income, and Significant Segment Expenses</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents information about reported segment revenues, segment loss and income, and significant segment expenses:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:63.1%;box-sizing:content-box;"></td>
        <td style="width:1.26%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.46%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.42%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.56%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.26%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:7.9399999999999995%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenues</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">152,310</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">166,799</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">205,999</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">LUNAR-COVID</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">70,464</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">81,262</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65,136</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">LUNAR-OTC</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,509</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,315</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,898</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">BARDA</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,807</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,465</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">95</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">LUNAR-CF, net</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,227</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,666</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,931</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Early-stage programs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,096</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,460</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,681</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Discovery technologies</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,278</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,405</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,082</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Payroll and benefits</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57,474</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50,924</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42,466</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Facilities and equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,301</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,636</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,462</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total research and development</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">195,156</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">192,133</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">147,751</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">52,823</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">52,871</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46,071</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,728</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48,480</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,828</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net (loss) income</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80,941</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,725</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,349</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Primarily includes interest income and expense, foreign currency gains and losses, and income taxes. The year ended December 31, 2023 includes a $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34.0</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million gain on debt extinguishment related to forgiveness of the Singapore Loan.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45846712889216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_OrganizationAndSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 448,807<span></span>
</td>
<td class="nump">$ 367,866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="nump">152,310<span></span>
</td>
<td class="nump">166,799<span></span>
</td>
<td class="nump">$ 205,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, including restricted cash</a></td>
<td class="nump">293,913<span></span>
</td>
<td class="nump">$ 348,890<span></span>
</td>
<td class="nump">$ 393,977<span></span>
</td>
<td class="nump">$ 372,569<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arct_SeqirusIncMember', window );">Seqirus Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_OrganizationAndSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_UpfrontPaymentReceived', window );">Upfront payment received</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="nump">$ 96,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arct_OrganizationAndSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Organization and significant accounting policies line items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arct_OrganizationAndSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arct_UpfrontPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront payment received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arct_UpfrontPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arct_SeqirusIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arct_SeqirusIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45846718944672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details Textual)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>Segment</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 21, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_SummaryOfSignificantAccountingPolicyLineItems', window );"><strong>Summary Of Significant Accounting Policy [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments for research and development | Segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Non-current restricted cash</a></td>
<td class="nump">$ 1,885,000<span></span>
</td>
<td class="nump">$ 1,885,000<span></span>
</td>
<td class="nump">$ 2,094,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance for Doubtful Accounts Receivable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax', window );">Income tax effect related to unrealized losses on marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends declared or paid</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_PropertyLeaseGuaranteeMember', window );">Property Leases in San Diego [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_SummaryOfSignificantAccountingPolicyLineItems', window );"><strong>Summary Of Significant Accounting Policy [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Non-current restricted cash</a></td>
<td class="nump">1,900,000<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=arct_WellsFargoCreditAgreementMember', window );">Wells Fargo Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_SummaryOfSignificantAccountingPolicyLineItems', window );"><strong>Summary Of Significant Accounting Policy [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCollateralAmount', window );">Debt instrument, collateral amount</a></td>
<td class="nump">$ 55,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=arct_EmployeesAndOfficersMember', window );">Employees and Officers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_SummaryOfSignificantAccountingPolicyLineItems', window );"><strong>Summary Of Significant Accounting Policy [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share options expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights', window );">Vesting description</a></td>
<td class="text">Share-based compensation is recognized over the requisite service period of the individual awards using the straight-line attribution method, which generally equals the vesting period. Employees and officers&#8217; stock options have a ten-year life and generally vest 25% on the first anniversary of the grant and in 1/36th equal installments on each monthly anniversary thereafter, such that options are fully vested on the four-year anniversary of the date of grant. The exercisability and vesting periods of equity awards granted to consultants and directors vary.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember', window );">First Year Anniversary of the Grant [Member] | Employees and Officers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_SummaryOfSignificantAccountingPolicyLineItems', window );"><strong>Summary Of Significant Accounting Policy [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202307Member', window );">ASU 2023-07 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_SummaryOfSignificantAccountingPolicyLineItems', window );"><strong>Summary Of Significant Accounting Policy [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in accounting principle, accounting standards update, adopted</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate', window );">Change in accounting principle, accounting standards update, adoption date</a></td>
<td class="text">Jan.  01,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_SummaryOfSignificantAccountingPolicyLineItems', window );"><strong>Summary Of Significant Accounting Policy [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful lives</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_SummaryOfSignificantAccountingPolicyLineItems', window );"><strong>Summary Of Significant Accounting Policy [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful lives</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember', window );">Credit Risk [Member] | Accounts Receivable [Member] | BARDA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_SummaryOfSignificantAccountingPolicyLineItems', window );"><strong>Summary Of Significant Accounting Policy [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">60.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember', window );">Credit Risk [Member] | Accounts Receivable [Member] | CSL [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_SummaryOfSignificantAccountingPolicyLineItems', window );"><strong>Summary Of Significant Accounting Policy [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">74.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Revenue [Member] | CSL [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_SummaryOfSignificantAccountingPolicyLineItems', window );"><strong>Summary Of Significant Accounting Policy [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">91.00%<span></span>
</td>
<td class="nump">92.00%<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Revenue [Member] | Vinbiocare [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_SummaryOfSignificantAccountingPolicyLineItems', window );"><strong>Summary Of Significant Accounting Policy [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arct_SummaryOfSignificantAccountingPolicyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of significant accounting policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arct_SummaryOfSignificantAccountingPolicyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether accounting standards update was adopted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477123/405-50-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 326<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-3<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 326<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date accounting standards update was adopted, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477123/405-50-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-2<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 326<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 326<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -SubTopic 10<br> -Topic 250<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCollateralAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets pledged to secure a debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCollateralAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Dividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -SubTopic 405<br> -Topic 942<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477787/942-405-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Dividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after adjustment, of tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_PropertyLeaseGuaranteeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_PropertyLeaseGuaranteeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arct_WellsFargoCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arct_WellsFargoCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=arct_EmployeesAndOfficersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=arct_EmployeesAndOfficersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202307Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202307Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arct_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arct_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arct_CSLMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arct_CSLMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arct_VinbiocareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arct_VinbiocareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45846715091824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Cash and Cash Equivalents and Restricted Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 237,028<span></span>
</td>
<td class="nump">$ 292,005<span></span>
</td>
<td class="nump">$ 391,883<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash - current</a></td>
<td class="nump">55,000<span></span>
</td>
<td class="nump">55,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Non-current Restricted cash</a></td>
<td class="nump">1,885<span></span>
</td>
<td class="nump">1,885<span></span>
</td>
<td class="nump">2,094<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash shown in the statement of cash flows</a></td>
<td class="nump">$ 293,913<span></span>
</td>
<td class="nump">$ 348,890<span></span>
</td>
<td class="nump">$ 393,977<span></span>
</td>
<td class="nump">$ 372,569<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45846720258656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Summary of Changes in Balances of Receivables and Contract Liability (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Accounts receivable, Balance</a></td>
<td class="nump">$ 32,064<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_ContractWithCustomerAssetAdditions', window );">Additions</a></td>
<td class="nump">98,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_ContractWithCustomerAssetDeductions', window );">Deductions</a></td>
<td class="num">(126,520)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Accounts receivable, Balance</a></td>
<td class="nump">3,974<span></span>
</td>
<td class="nump">$ 32,064<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue, Balance</a></td>
<td class="nump">87,325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_ContractWithCustomerLiabilityAdditions', window );">Additions</a></td>
<td class="nump">97,599<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Deductions</a></td>
<td class="num">(152,806)<span></span>
</td>
<td class="nump">62,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue, Balance</a></td>
<td class="nump">$ 32,118<span></span>
</td>
<td class="nump">$ 87,325<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arct_ContractWithCustomerAssetAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract with customer asset additions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arct_ContractWithCustomerAssetAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arct_ContractWithCustomerAssetDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract with customer asset deductions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arct_ContractWithCustomerAssetDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arct_ContractWithCustomerLiabilityAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract with customer liability additions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arct_ContractWithCustomerLiabilityAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45846709146304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 01, 2022</div></th>
<th class="th"><div>Feb. 28, 2023</div></th>
<th class="th"><div>Aug. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_RevenueLineItems', window );"><strong>Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 152,310,000<span></span>
</td>
<td class="nump">$ 166,799,000<span></span>
</td>
<td class="nump">$ 205,999,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,118,000<span></span>
</td>
<td class="nump">87,325,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(152,806,000)<span></span>
</td>
<td class="nump">62,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arct_SeqirusIncMember', window );">Seqirus Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_RevenueLineItems', window );"><strong>Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_UpfrontPaymentReceived', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arct_SeqirusIncMember', window );">Seqirus Inc [Member] | COVID-19 Vaccine [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_RevenueLineItems', window );"><strong>Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arct_VinbiocareMember', window );">Vinbiocare [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_RevenueLineItems', window );"><strong>Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arct_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember', window );">BARDA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_RevenueLineItems', window );"><strong>Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,900,000<span></span>
</td>
<td class="nump">9,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_GrantRevenue', window );">Total grant revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_GrantRevenueOutstanding', window );">Grant revenue outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=arct_ForeignCountriesMember', window );">Foreign Countries [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_RevenueLineItems', window );"><strong>Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">138,400,000<span></span>
</td>
<td class="nump">154,900,000<span></span>
</td>
<td class="nump">$ 192,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=arct_ResearchCollaborationAndLicenseAgreementMember', window );">Research Collaboration And License Agreement [Member] | Seqirus Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_RevenueLineItems', window );"><strong>Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_UpfrontPaymentReceived', window );">Upfront payment received</a></td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=arct_ResearchCollaborationAndLicenseAgreementMember', window );">Research Collaboration And License Agreement [Member] | Seqirus Inc [Member] | COVID-19 Vaccine [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_RevenueLineItems', window );"><strong>Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_PercentageOfNetProfits', window );">Net profits percentage</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_DevelopmentMilestonesReceivedAdvancePayment', window );">Development milestones received advance payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=arct_ResearchCollaborationAndLicenseAgreementMember', window );">Research Collaboration And License Agreement [Member] | Seqirus Inc [Member] | Manufacturing and Supply of ARCT-154 Drug Product [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_RevenueLineItems', window );"><strong>Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_DevelopmentMilestonesReceivedAdvancePayment', window );">Development milestones received advance payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=arct_ResearchCollaborationAndLicenseAgreementMember', window );">Research Collaboration And License Agreement [Member] | Maximum [Member] | Seqirus Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_RevenueLineItems', window );"><strong>Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_EligibleToReceiveDevelopmentMilestonePayment', window );">Eligible to receive development milestone payment</a></td>
<td class="nump">$ 1,300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_EligibleToReceiveCommercialMilestonePayment', window );">Eligible to receive commercial milestone payment</a></td>
<td class="nump">$ 3,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=arct_VinbiocareAgreementMember', window );">Vinbiocare Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_RevenueLineItems', window );"><strong>Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_UpfrontPaymentReceived', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_ReservedUpfrontPayment', window );">Reserved upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_AdditionalFinancialSupport', window );">Additional financial support</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=arct_VinbiocareAgreementMember', window );">Vinbiocare Agreement [Member] | Vinbiocare [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_RevenueLineItems', window );"><strong>Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=arct_CslCollaborationAgreementMember', window );">CSL Collaboration Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_RevenueLineItems', window );"><strong>Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,700,000<span></span>
</td>
<td class="nump">87,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_DevelopmentAndRegulatoryMilestonesAchieved', window );">Development and regulatory milestones achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_AchievedDevelopmentAndRegulatoryMilestoneIncludedAccountsReceivable', window );">Achieved development and regulatory milestone included accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=arct_CslCollaborationAgreementMember', window );">CSL Collaboration Agreement [Member] | Phase I Clinical Study [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_RevenueLineItems', window );"><strong>Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000,000<span></span>
</td>
<td class="nump">2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_MilestonePayments', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=arct_CslCollaborationAgreementMember', window );">CSL Collaboration Agreement [Member] | Maximum [Member] | Phase I Clinical Study [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_RevenueLineItems', window );"><strong>Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_AdditionalPaymentsUponMeetingCertainClinicalMilestones', window );">Additional payments upon meeting certain clinical milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=arct_StudySupportAgreementMember', window );">Study Support Agreement [Member] | Vinbiocare [Member] | Short-Term Contract with Customer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_RevenueLineItems', window );"><strong>Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized', window );">Accrued liabilities paid upon occurrence of specified events</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arct_AchievedDevelopmentAndRegulatoryMilestoneIncludedAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Achieved development and regulatory milestone included accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arct_AchievedDevelopmentAndRegulatoryMilestoneIncludedAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arct_AdditionalFinancialSupport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional financial support</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arct_AdditionalFinancialSupport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arct_AdditionalPaymentsUponMeetingCertainClinicalMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional payments upon meeting certain clinical milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arct_AdditionalPaymentsUponMeetingCertainClinicalMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arct_DevelopmentAndRegulatoryMilestonesAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development and regulatory milestones achieved.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arct_DevelopmentAndRegulatoryMilestonesAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arct_DevelopmentMilestonesReceivedAdvancePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development milestones received advance payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arct_DevelopmentMilestonesReceivedAdvancePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arct_EligibleToReceiveCommercialMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Eligible to receive commercial milestone payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arct_EligibleToReceiveCommercialMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arct_EligibleToReceiveDevelopmentMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Eligible to Receive Development Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arct_EligibleToReceiveDevelopmentMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arct_GrantRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Grant revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arct_GrantRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arct_GrantRevenueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Grant revenue outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arct_GrantRevenueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arct_MilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arct_MilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arct_PercentageOfNetProfits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of net profits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arct_PercentageOfNetProfits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arct_ReservedUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reserved upfront payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arct_ReservedUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arct_RevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arct_RevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arct_UpfrontPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront payment received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arct_UpfrontPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized arising from contract liability from change in timeframe for performance obligation to be satisfied.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arct_SeqirusIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arct_SeqirusIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=arct_Covid19VaccineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=arct_Covid19VaccineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arct_VinbiocareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arct_VinbiocareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arct_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arct_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=arct_ForeignCountriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=arct_ForeignCountriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arct_ResearchCollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arct_ResearchCollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=arct_ManufacturingAndSupplyOfArct154DrugProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=arct_ManufacturingAndSupplyOfArct154DrugProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arct_VinbiocareAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arct_VinbiocareAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arct_CslCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arct_CslCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=arct_PhaseIClinicalStudyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=arct_PhaseIClinicalStudyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arct_StudySupportAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arct_StudySupportAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerDurationAxis=us-gaap_ShortTermContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerDurationAxis=us-gaap_ShortTermContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45846708417296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Summary of Revenues (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 152,310<span></span>
</td>
<td class="nump">$ 166,799<span></span>
</td>
<td class="nump">$ 205,999<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=arct_CollaborationRevenueMember', window );">Collaboration Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">138,389<span></span>
</td>
<td class="nump">157,748<span></span>
</td>
<td class="nump">205,755<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">13,921<span></span>
</td>
<td class="nump">9,051<span></span>
</td>
<td class="nump">244<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arct_CslSeqirusMember', window );">CSL Seqirus [Member] | Collaboration Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">138,389<span></span>
</td>
<td class="nump">154,264<span></span>
</td>
<td class="nump">154,425<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arct_VinbiocareMember', window );">Vinbiocare [Member] | Collaboration Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,571<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arct_JanssenMember', window );">Janssen [Member] | Collaboration Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">660<span></span>
</td>
<td class="nump">9,201<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arct_UltragenyxMember', window );">Ultragenyx [Member] | Collaboration Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,837<span></span>
</td>
<td class="nump">3,739<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arct_IsraelMinistryOfHealthMember', window );">Israel Ministry of Health [Member] | Collaboration Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arct_OtherMember', window );">Other [Member] | Collaboration Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">987<span></span>
</td>
<td class="nump">1,319<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arct_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember', window );">BARDA [Member] | Grant Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 13,921<span></span>
</td>
<td class="nump">$ 9,051<span></span>
</td>
<td class="nump">$ 244<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=arct_CollaborationRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=arct_CollaborationRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arct_CslSeqirusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arct_CslSeqirusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arct_VinbiocareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arct_VinbiocareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arct_JanssenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arct_JanssenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arct_UltragenyxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arct_UltragenyxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arct_IsraelMinistryOfHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arct_IsraelMinistryOfHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arct_OtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arct_OtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arct_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arct_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45846719632528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details Textual)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring [Member] | Money Market Funds [Member] | Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">$ 230.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45846719493520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Liabilities Detail - Schedule of Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">$ 13,305<span></span>
</td>
<td class="nump">$ 5,918<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_AccruedCysticFibrosisFoundationLiability', window );">Cystic Fibrosis Foundation liability</a></td>
<td class="nump">7,443<span></span>
</td>
<td class="nump">7,633<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Income tax payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">641<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liability</a></td>
<td class="nump">$ 3,552<span></span>
</td>
<td class="nump">$ 4,309<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Total<span></span>
</td>
<td class="text">Total<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_ClinicalTrialAccrualsCurrent', window );">Clinical trial accruals</a></td>
<td class="nump">$ 2,828<span></span>
</td>
<td class="nump">$ 2,333<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_VinbiocareContractualLiabilities', window );">Vinbiocare contractual liabilities</a></td>
<td class="nump">2,421<span></span>
</td>
<td class="nump">2,514<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_LegalAccrualCurrent', window );">Legal accrual</a></td>
<td class="nump">130<span></span>
</td>
<td class="nump">177<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_OtherAccruedResearchAndDevelopmentExpenses', window );">Other accrued research and development expenses</a></td>
<td class="nump">9,102<span></span>
</td>
<td class="nump">8,356<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 38,781<span></span>
</td>
<td class="nump">$ 31,881<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arct_AccruedCysticFibrosisFoundationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued cystic fibrosis foundation liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arct_AccruedCysticFibrosisFoundationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arct_ClinicalTrialAccrualsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Clinical trial accruals current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arct_ClinicalTrialAccrualsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arct_LegalAccrualCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Legal accrual current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arct_LegalAccrualCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arct_OtherAccruedResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other accrued research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arct_OtherAccruedResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arct_VinbiocareContractualLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Vinbiocare contractual liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arct_VinbiocareContractualLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45846720337936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, Net - Summary of Components of Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 21,342<span></span>
</td>
<td class="nump">$ 21,167<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation and amortization</a></td>
<td class="num">(11,811)<span></span>
</td>
<td class="num">(8,740)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">9,531<span></span>
</td>
<td class="nump">12,427<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Research equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">16,864<span></span>
</td>
<td class="nump">16,046<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer and software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">1,131<span></span>
</td>
<td class="nump">1,275<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Office equipment and furniture [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">703<span></span>
</td>
<td class="nump">958<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 2,644<span></span>
</td>
<td class="nump">2,655<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 233<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45846720345744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">$ 3,544<span></span>
</td>
<td class="nump">$ 2,957<span></span>
</td>
<td class="nump">$ 1,527<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45846713030336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Details Textual)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 26, 2024</div></th>
<th class="th">
<div>Apr. 21, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 14, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>SGD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 29, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 29, 2021 </div>
<div>SGD ($)</div>
</th>
<th class="th">
<div>Nov. 07, 2020 </div>
<div>SGD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arct_WesternAllianceBankMember', window );">Western Alliance Bank [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseLongTermDebt', window );">Interest expense related to long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=arct_LoanAndSecurityAgreementMember', window );">Loan and Security Agreement [Member] | Western Alliance Bank [Member] | Long-term Debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_RepyamentOfPrincipalAndInterestOnCollateralizedTermLoan', window );">Repayament of principal and interest on collateralized term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Loan maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Oct. 30,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Fee payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=arct_LoanAndSecurityAgreementMember', window );">Loan and Security Agreement [Member] | Western Alliance Bank [Member] | Long-term Debt [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Interest of the prime rate plus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=arct_LoanAndSecurityAgreementMember', window );">Loan and Security Agreement [Member] | Western Alliance Bank [Member] | Long-term Debt [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Interest of the prime rate plus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=arct_WellsFargoCreditAgreementMember', window );">Wells Fargo Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity', window );">Revolving credit line available</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_DebtInstrumentExtendedTermPeriod', window );">Extended term period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Loan accrues interest rate per annum, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod', window );">Loans interest rate, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Term of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_DebtInstrumentOptionForRenewalTerm', window );">Option for renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Non-refundable commitment fee, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCollateralAmount', window );">Debt instrument, collateral amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_SG', window );">Singapore Economic Development Board [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62,100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BorrowingsUnderGuaranteedInvestmentAgreements', window );">Term loan draw down</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,600,000<span></span>
</td>
<td class="nump">$ 62,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,100,000<span></span>
</td>
<td class="nump">$ 22,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Loan accrues interest rate per annum, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_RemainingLoanIncludingAccruedInterestForgiveable', window );">Remaining loan including accrued interest forgiveable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseLongTermDebt', window );">Interest expense related to long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arct_DebtInstrumentExtendedTermPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument, extended term period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arct_DebtInstrumentExtendedTermPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arct_DebtInstrumentOptionForRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument option for renewal term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arct_DebtInstrumentOptionForRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arct_RemainingLoanIncludingAccruedInterestForgiveable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining loan including accrued interest forgiveable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arct_RemainingLoanIncludingAccruedInterestForgiveable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arct_RepyamentOfPrincipalAndInterestOnCollateralizedTermLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repayment of principal and interest on collateralized term loan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arct_RepyamentOfPrincipalAndInterestOnCollateralizedTermLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BorrowingsUnderGuaranteedInvestmentAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the sum of the obligations to contract holders to provide to them an agreed upon rate of return pursuant to the terms of the underlying contract. These contracts represent lending by the contract holders to the entity in return for a guaranteed (primarily fixed) interest rate until maturity, unless called earlier if the contracts provide that option to the contract holders (usually institutions). There is little or no insurance risk for the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BorrowingsUnderGuaranteedInvestmentAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCollateralAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets pledged to secure a debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCollateralAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee that accompanies borrowing money under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate amount of interest paid or due on all long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1402<br> -Paragraph a<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1402<br> -Paragraph b<br> -Subparagraph (1)<br> -Publisher SEC<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arct_WesternAllianceBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arct_WesternAllianceBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arct_LoanAndSecurityAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arct_LoanAndSecurityAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LongTermDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LongTermDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arct_WellsFargoCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arct_WellsFargoCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_SG">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_SG</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45846713704960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details Textual) - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">1.4<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">3.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45846708414992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Details Textual) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Apr. 30, 2022</div></th>
<th class="th"><div>Oct. 15, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Compensation cost not yet recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average remaining service period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of options vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40.5<span></span>
</td>
<td class="nump">$ 35.3<span></span>
</td>
<td class="nump">$ 39.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">The total intrinsic value of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.3<span></span>
</td>
<td class="nump">$ 4.3<span></span>
</td>
<td class="nump">$ 1.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Fair value of common stock</a></td>
<td class="nump">$ 34.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock units granted</a></td>
<td class="nump">18,786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arct_TwoThousandNineteenOmnibusIncentivePlanMember', window );">2019 Omnibus Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based compensation number of shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arct_TwoThousandNineteenOmnibusIncentivePlanMember', window );">2019 Omnibus Equity Incentive Plan [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based compensation number of shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arct_TwoThousandNineteenOmnibusIncentivePlanMember', window );">2019 Omnibus Equity Incentive Plan [Member] | Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,834,158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arct_TwentyTwentyOneInducementEquityIncentivePlanMember', window );">2021 Inducement Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_ReductionInNumberOfCommonStockCapitalSharesAvailableForFutureIssuance', window );">Reduction in number of common stock shares available for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arct_TwentyTwentyOneInducementEquityIncentivePlanMember', window );">2021 Inducement Equity Incentive Plan [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arct_TwentyTwentyOneInducementEquityIncentivePlanMember', window );">2021 Inducement Equity Incentive Plan [Member] | Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124,697<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arct_ReductionInNumberOfCommonStockCapitalSharesAvailableForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reduction in number of common stock capital shares available for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arct_ReductionInNumberOfCommonStockCapitalSharesAvailableForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arct_TwoThousandNineteenOmnibusIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arct_TwoThousandNineteenOmnibusIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arct_TwentyTwentyOneInducementEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arct_TwentyTwentyOneInducementEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45846716453104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Details) - Employee Stock Option - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (in years)</a></td>
<td class="text">5 years 10 months 17 days<span></span>
</td>
<td class="text">6 years 14 days<span></span>
</td>
<td class="text">6 years 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">91.40%<span></span>
</td>
<td class="nump">76.10%<span></span>
</td>
<td class="nump">82.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.24%<span></span>
</td>
<td class="nump">3.91%<span></span>
</td>
<td class="nump">2.93%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Grant date weighted average fair value</a></td>
<td class="nump">$ 22.62<span></span>
</td>
<td class="nump">$ 18.87<span></span>
</td>
<td class="nump">$ 15.56<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45846713913968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Details 1) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares, Outstanding</a></td>
<td class="nump">7,971,127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Shares, Granted</a></td>
<td class="nump">740,594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Shares, Exercised</a></td>
<td class="num">(228,328)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Shares, Forfeited/cancelled</a></td>
<td class="num">(404,641)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares, Outstanding</a></td>
<td class="nump">8,078,752<span></span>
</td>
<td class="nump">7,971,127<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Shares, Exercisable December 31, 2024</a></td>
<td class="nump">4,983,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Number of Shares, Exercisable and expected to vest December 31, 2024</a></td>
<td class="nump">8,078,752<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Outstanding</a></td>
<td class="nump">$ 33.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Granted</a></td>
<td class="nump">22.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Exercised</a></td>
<td class="nump">20.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Forfeited/cancelled</a></td>
<td class="nump">42.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Outstanding</a></td>
<td class="nump">32.38<span></span>
</td>
<td class="nump">$ 33.55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Exercisable - December 31, 2024</a></td>
<td class="nump">37.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Exercisable and expected to vest -December 31, 2024</a></td>
<td class="nump">$ 32.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-Average Remaining Contractual Term (Years), Outstanding</a></td>
<td class="text">7 years 2 months 12 days<span></span>
</td>
<td class="text">7 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-Average Remaining Contractual Term (Years), Exercisable - December 31, 2024</a></td>
<td class="text">6 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-Average Remaining Contractual Term (Years), Exercisable and expected to vest - December 31, 2024</a></td>
<td class="text">7 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding</a></td>
<td class="nump">$ 9,247<span></span>
</td>
<td class="nump">$ 53,295<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable - December 31, 2024</a></td>
<td class="nump">8,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Exercisable and expected to vest - December 31, 2024</a></td>
<td class="nump">$ 9,247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45846719701168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Share-Based Compensation - (Details 2)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Shares Outstanding, Beginning Balance | shares</a></td>
<td class="nump">18,786<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Shares Outstanding, Ending Balance | shares</a></td>
<td class="nump">18,786<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted- Average Grant Date Fair Value, Outstanding, Beginning Balance | $ / shares</a></td>
<td class="nump">$ 34.92<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted- Average Grant Date Fair Value, Outstanding, Ending Balance | $ / shares</a></td>
<td class="nump">$ 34.92<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45846714882320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Details 3) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expenses</a></td>
<td class="nump">$ 37,988<span></span>
</td>
<td class="nump">$ 34,649<span></span>
</td>
<td class="nump">$ 30,611<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expenses</a></td>
<td class="nump">18,456<span></span>
</td>
<td class="nump">14,950<span></span>
</td>
<td class="nump">14,081<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expenses</a></td>
<td class="nump">$ 19,532<span></span>
</td>
<td class="nump">$ 19,699<span></span>
</td>
<td class="nump">$ 16,530<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45846815495488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details 1) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">United States</a></td>
<td class="nump">$ 81,050<span></span>
</td>
<td class="num">$ (27,890)<span></span>
</td>
<td class="nump">$ 10,644<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Total (loss) income before income taxes</a></td>
<td class="nump">$ 81,050<span></span>
</td>
<td class="num">$ (27,890)<span></span>
</td>
<td class="nump">$ 10,644<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45846815496240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details 2) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">$ (11)<span></span>
</td>
<td class="nump">$ 1,246<span></span>
</td>
<td class="nump">$ 1,121<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">589<span></span>
</td>
<td class="nump">174<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current income tax (benefit) expense</a></td>
<td class="num">(4)<span></span>
</td>
<td class="nump">1,835<span></span>
</td>
<td class="nump">1,295<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax (benefit) expense</a></td>
<td class="num">$ (4)<span></span>
</td>
<td class="nump">$ 1,835<span></span>
</td>
<td class="nump">$ 1,295<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45846719365312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details 3)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal benefit</a></td>
<td class="nump">1.90%<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
<td class="nump">7.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Share-based compensation</a></td>
<td class="num">(1.90%)<span></span>
</td>
<td class="num">(2.50%)<span></span>
</td>
<td class="nump">16.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensation', window );">Officers compensation</a></td>
<td class="num">(3.40%)<span></span>
</td>
<td class="num">(7.40%)<span></span>
</td>
<td class="nump">21.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentCredits', window );">Research and development credits</a></td>
<td class="nump">24.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="num">(40.30%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_EffectiveIncomeTaxRateReconciliationUncertainTaxPosition', window );">Uncertain tax position</a></td>
<td class="num">(3.70%)<span></span>
</td>
<td class="num">(2.40%)<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Change in tax rate</a></td>
<td class="num">(1.40%)<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
<td class="num">(12.60%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(36.10%)<span></span>
</td>
<td class="num">(36.50%)<span></span>
</td>
<td class="num">(9.40%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(0.20%)<span></span>
</td>
<td class="num">(0.30%)<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences', window );">Permanent differences</a></td>
<td class="num">(0.20%)<span></span>
</td>
<td class="num">(0.70%)<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Provision for income taxes</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(6.70%)<span></span>
</td>
<td class="nump">12.20%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arct_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation nondeductible expense officers compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arct_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arct_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation other permanent differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arct_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arct_EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation research and development credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arct_EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arct_EffectiveIncomeTaxRateReconciliationUncertainTaxPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation uncertain tax position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arct_EffectiveIncomeTaxRateReconciliationUncertainTaxPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45846720270864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details 4) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss</a></td>
<td class="nump">$ 25,413<span></span>
</td>
<td class="nump">$ 19,147<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credits</a></td>
<td class="nump">27,472<span></span>
</td>
<td class="nump">10,723<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="nump">2,966<span></span>
</td>
<td class="nump">943<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">5,515<span></span>
</td>
<td class="nump">7,014<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInventory', window );">Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,961<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsEquityMethodInvestments', window );">Basis difference in equity investments</a></td>
<td class="nump">2,127<span></span>
</td>
<td class="nump">2,202<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_DeferredTaxAssetsCapitalizedResearchAndDevelopment', window );">Capitalized R&amp;D</a></td>
<td class="nump">60,104<span></span>
</td>
<td class="nump">41,971<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_DeferredTaxAssetsRightOfUseLeaseLiability', window );">Right-of-use lease liability</a></td>
<td class="nump">6,601<span></span>
</td>
<td class="nump">7,233<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Share-based compensation</a></td>
<td class="nump">14,872<span></span>
</td>
<td class="nump">11,618<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total gross deferred tax assets</a></td>
<td class="nump">145,070<span></span>
</td>
<td class="nump">116,812<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_DeferredTaxLiabilitiesPropertyPlantAndEquipmentAndIntangibleAssets', window );">Depreciation and amortization</a></td>
<td class="num">(858)<span></span>
</td>
<td class="num">(1,184)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_DeferredTaxLiabilitiesRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="num">(6,168)<span></span>
</td>
<td class="num">(6,822)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total gross deferred tax liabilities</a></td>
<td class="num">(7,026)<span></span>
</td>
<td class="num">(8,006)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">$ (138,044)<span></span>
</td>
<td class="num">$ (108,806)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arct_DeferredTaxAssetsCapitalizedResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets capitalized research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arct_DeferredTaxAssetsCapitalizedResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arct_DeferredTaxAssetsRightOfUseLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets right-of-use lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arct_DeferredTaxAssetsRightOfUseLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arct_DeferredTaxLiabilitiesPropertyPlantAndEquipmentAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets property, plant and equipment and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arct_DeferredTaxLiabilitiesPropertyPlantAndEquipmentAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arct_DeferredTaxLiabilitiesRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities, right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arct_DeferredTaxLiabilitiesRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45846708140320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">$ 138,044,000<span></span>
</td>
<td class="nump">$ 108,806,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation allowance change</a></td>
<td class="nump">$ 29,200,000<span></span>
</td>
<td class="nump">10,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_MaximumPercentageOfLikelihoodOfUncertainTaxPositionRecognizedToBeSustained', window );">Maximum percentage of likelihood of uncertain tax position recognized to be sustained</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits impacting effective tax rate</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_NetOperatingLossAndResearchAndDevelopmentCreditCarryforwardsLimitationsOnCumulativeChangeInOwnershipMinimumPercentage', window );">Net Operating Loss and Research and Development Credit Carryforwards Limitations On Cumulative Change In Ownership Minimum Percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_NetOperatingLossAndResearchAndDevelopmentCreditCarryforwardsLimitationsOnCumulativeChangeInOwnershipPeriod', window );">Net Operating Loss and Research and Development Credit Carryforwards Limitations on Cumulative Change In Ownership Period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=arct_OrphanDrugCreditMember', window );">Orphan Drug Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Credit Carryforward Amount</a></td>
<td class="nump">$ 4,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_TaxCreditCarryforwardExpirationYear', window );">Credit Carryforward Expiration Year</a></td>
<td class="text">2042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="nump">$ 47,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal [Member] | Research Tax Credit Carryforward [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Credit Carryforward Amount</a></td>
<td class="nump">$ 19,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_TaxCreditCarryforwardExpirationYear', window );">Credit Carryforward Expiration Year</a></td>
<td class="text">2037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="nump">$ 223,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_OperatingLossCarryforwardsExpirationYear', window );">Operating Loss Carryforwards Expiration Year</a></td>
<td class="text">2039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Credit Carryforward Amount</a></td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_TaxCreditCarryforwardExpirationYear', window );">Credit Carryforward Expiration Year</a></td>
<td class="text">2037 <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State [Member] | Research Tax Credit Carryforward [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Credit Carryforward Amount</a></td>
<td class="nump">$ 11,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arct_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arct_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arct_MaximumPercentageOfLikelihoodOfUncertainTaxPositionRecognizedToBeSustained">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of likelihood of uncertain tax position recognized to be sustained.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arct_MaximumPercentageOfLikelihoodOfUncertainTaxPositionRecognizedToBeSustained</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arct_NetOperatingLossAndResearchAndDevelopmentCreditCarryforwardsLimitationsOnCumulativeChangeInOwnershipMinimumPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net operating loss and research and development credit carryforwards limitations on cumulative change in ownership minimum percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arct_NetOperatingLossAndResearchAndDevelopmentCreditCarryforwardsLimitationsOnCumulativeChangeInOwnershipMinimumPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arct_NetOperatingLossAndResearchAndDevelopmentCreditCarryforwardsLimitationsOnCumulativeChangeInOwnershipPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net operating loss and research and development credit carryforwards limitations on cumulative change in ownership period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arct_NetOperatingLossAndResearchAndDevelopmentCreditCarryforwardsLimitationsOnCumulativeChangeInOwnershipPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arct_OperatingLossCarryforwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards expiration year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arct_OperatingLossCarryforwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arct_TaxCreditCarryforwardExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax credit carryforward expiration year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arct_TaxCreditCarryforwardExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=arct_OrphanDrugCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=arct_OrphanDrugCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45846719073472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details 5) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Unrecognized Tax Benefits [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning balance of unrecognized tax benefits</a></td>
<td class="nump">$ 3.6<span></span>
</td>
<td class="nump">$ 2.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_UnrecognizedTaxBenefitsDecreasesIncreasesResultingFromPriorPeriodTaxPositions', window );">Decrease for prior period tax positions</a></td>
<td class="nump">1.2<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increase for current period tax positions</a></td>
<td class="nump">2.0<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Ending balance of unrecognized tax benefits</a></td>
<td class="nump">$ 6.8<span></span>
</td>
<td class="nump">$ 3.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arct_UnrecognizedTaxBenefitsDecreasesIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrecognized tax benefits (decreases) increases resulting from prior period tax positions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arct_UnrecognizedTaxBenefitsDecreasesIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45846708172736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">50 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 01, 2019</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Oct. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 25, 2023</div></th>
<th class="th"><div>Feb. 29, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.5<span></span>
</td>
<td class="nump">$ 5.6<span></span>
</td>
<td class="nump">$ 4.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=arct_FebruaryTwoThousandAndTwentyLeaseAgreementMember', window );">February 2020 Lease Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease extended additional term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">13 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Lessee, operating leases, option to extend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> the lease for one twelve-month period. In February 2021, the Company opted to extend the lease through March 2025 to coincide with the lease term of the Company&#8217;s headquarters.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Impairment loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=arct_SeptemberTwoThousandAndTwentyOneLeaseAgreementMember', window );">September 2021 Lease Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease extended additional term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years 8 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Lessee, operating leases, option to extend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company has the right to extend the term of the lease for an additional five-year period.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=arct_OctoberTwoThousandAndSeventeenLeaseAmendmentMember', window );">October 2017 Lease Amendment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease extended additional term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">84 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, operating lease, term of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromTenantAllowance', window );">Tenant improvement allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=arct_UnderlyingAgreementMember', window );">Underlying Agreement [Member] | Cystic Fibrosis Foundation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_ContraExpenseRemainingAmountIncludedInAccruedExpenses', window );">Contra expense remaining amount included in accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_ContraExpenseIncludedInResearchAndDevelopmentExpense', window );">Contra expense included in research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="nump">$ 5.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_MinimumAmountAgreedToIncurUnderResearchPlan', window );">Minimum amount agreed to incur under research plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=arct_UnderlyingAgreementMember', window );">Underlying Agreement [Member] | LUNAR-CF [Member] | Cystic Fibrosis Foundation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForAdvanceToAffiliate', window );">Payments for advance</a></td>
<td class="nump">$ 15.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | September 2021 Lease Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_MonthlyBaseRent', window );">Monthly base rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | September 2021 Lease Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_MonthlyBaseRent', window );">Monthly base rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arct_CommitmentAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitment and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arct_CommitmentAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arct_ContraExpenseIncludedInResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contra expense included in research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arct_ContraExpenseIncludedInResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arct_ContraExpenseRemainingAmountIncludedInAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contra expense remaining amount included in accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arct_ContraExpenseRemainingAmountIncludedInAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arct_MinimumAmountAgreedToIncurUnderResearchPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount agreed to incur under research plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arct_MinimumAmountAgreedToIncurUnderResearchPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arct_MonthlyBaseRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Monthly base rent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arct_MonthlyBaseRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from impairment of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479365/842-20-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForAdvanceToAffiliate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from advancing money to an affiliate (an entity that is related but not strictly controlled by the entity).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForAdvanceToAffiliate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromTenantAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net cash outflow or inflow from monetary allowance granted by the landlord to a tenant to entice tenant to move into landlords building which will enable the tenant to prepare the leased premises for tenants occupancy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromTenantAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=arct_FebruaryTwoThousandAndTwentyLeaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=arct_FebruaryTwoThousandAndTwentyLeaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=arct_SeptemberTwoThousandAndTwentyOneLeaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=arct_SeptemberTwoThousandAndTwentyOneLeaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=arct_OctoberTwoThousandAndSeventeenLeaseAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=arct_OctoberTwoThousandAndSeventeenLeaseAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arct_UnderlyingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arct_UnderlyingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arct_CysticFibrosisFoundationTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arct_CysticFibrosisFoundationTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=arct_LUNARCFMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=arct_LUNARCFMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45846715561680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Payments of Operating Lease Liability (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 4,811<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">5,274<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">4,132<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2028</a></td>
<td class="nump">3,822<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2029</a></td>
<td class="nump">3,937<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">11,813<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total remaining lease payments</a></td>
<td class="nump">33,789<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(5,239)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 28,550<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term (in years)</a></td>
<td class="text">7 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">4.70%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45846713645264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>Segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arct_NumberOfBusinessSegment', window );">Number of business segment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription', window );">Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description</a></td>
<td class="text">The Company&#8217;s CODM is its Chief Executive Officer, who reviews and evaluates consolidated net (loss) income for purposes of assessing performance, making operating decisions, allocating resources, and planning and forecasting for future periods.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration', window );">Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]</a></td>
<td class="text">srt:ChiefExecutiveOfficerMember<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arct_NumberOfBusinessSegment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arct_NumberOfBusinessSegment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates title and position of individual or name of group identified as chief operating decision maker (CODM) for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of how chief operating decision maker (CODM) uses reported segment profit (loss) measure to assess performance and allocate resource.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45846714256752">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Summary of Reported Segment Revenues, Segment Loss and Income, and Significant Segment Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 152,310<span></span>
</td>
<td class="nump">$ 166,799<span></span>
</td>
<td class="nump">$ 205,999<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">195,156<span></span>
</td>
<td class="nump">192,133<span></span>
</td>
<td class="nump">147,751<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">52,823<span></span>
</td>
<td class="nump">52,871<span></span>
</td>
<td class="nump">46,071<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherItemAmount', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(14,728)<span></span>
</td>
<td class="num">(48,480)<span></span>
</td>
<td class="nump">2,828<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(80,941)<span></span>
</td>
<td class="num">(29,725)<span></span>
</td>
<td class="nump">9,349<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=arct_LUNAR-COVIDMember', window );">LUNAR-COVID [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">70,464<span></span>
</td>
<td class="nump">81,262<span></span>
</td>
<td class="nump">65,136<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=arct_LUNAR-OTCMember', window );">LUNAR-OTC [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,509<span></span>
</td>
<td class="nump">9,315<span></span>
</td>
<td class="nump">8,898<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=arct_BARDAMember', window );">BARDA [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,807<span></span>
</td>
<td class="nump">5,465<span></span>
</td>
<td class="nump">95<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=arct_LUNAR-CFNetMember', window );">LUNAR-CF, Net [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">17,227<span></span>
</td>
<td class="nump">14,666<span></span>
</td>
<td class="nump">6,931<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=arct_Early-StageProgramsMember', window );">Early-Stage Programs [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">16,096<span></span>
</td>
<td class="nump">12,460<span></span>
</td>
<td class="nump">9,681<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=arct_DiscoveryTechnologiesMember', window );">Discovery Technologies [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,278<span></span>
</td>
<td class="nump">6,405<span></span>
</td>
<td class="nump">6,082<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=arct_PayrollAndBenefitsMember', window );">Payroll and Benefits [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">57,474<span></span>
</td>
<td class="nump">50,924<span></span>
</td>
<td class="nump">42,466<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=arct_FacilitiesAndEquipmentMember', window );">Facilities and Equipment [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 10,301<span></span>
</td>
<td class="nump">$ 11,636<span></span>
</td>
<td class="nump">$ 8,462<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Primarily includes interest income and expense, foreign currency gains and losses, and income taxes. The year ended December 31, 2023 includes a $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34.0</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million gain on debt extinguishment related to forgiveness of the Singapore Loan.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingOtherItemAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingOtherItemAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=arct_LUNAR-COVIDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=arct_LUNAR-COVIDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=arct_LUNAR-OTCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=arct_LUNAR-OTCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=arct_BARDAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=arct_BARDAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=arct_LUNAR-CFNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=arct_LUNAR-CFNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=arct_Early-StageProgramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=arct_Early-StageProgramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=arct_DiscoveryTechnologiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=arct_DiscoveryTechnologiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=arct_PayrollAndBenefitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=arct_PayrollAndBenefitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=arct_FacilitiesAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=arct_FacilitiesAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45846718909072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Summary of Reported Segment Revenues, Segment Loss and Income, and Significant Segment Expenses (Parenthetical) (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on debt extinguishment</a></td>
<td class="nump">$ 33,953<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_SG', window );">Singapore Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on debt extinguishment</a></td>
<td class="nump">$ 34,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_SG">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_SG</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>88
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( .*$9EH'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " #BA&9:&X/85^\    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+/
M3L,P#(=?!>7>NG_8A**N%Q GD)"8!.(6.=X6K6FCQ*C=VY.&K1."!^ 8^Y?/
MGR4WZ"0.GE[\X,BSH7 SV:X/$MU&')B=! AX(*M"'A-];.X&;Q7'I]^#4WA4
M>X*J*-9@B956K& &9FXABK;1*-&3XL&?\1H7O/OT78)I!.K(4L\!RKP$T<X3
MW6GJ&K@"9AB3M^&[0'HAINJ?V-0!<4Y.P2RI<1SSL4ZYN$,)[\]/KVG=S/2!
M58\4?P4C^>1H(RZ3W^K[A^VC:*NB6F5%G17K;57*^DZN;C]FUQ]^5V$[:+,S
M_]CX(M@V\.LNVB]02P,$%     @ XH1F6IE<G",0!@  G"<  !,   !X;"]T
M:&5M92]T:&5M93$N>&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M
M3A^%$5B-;'EDD81_OT<V$,N6#>V23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R
M>&#9+]O6N[<OWN!7,B0103 9IZ_PP JE3%ZU6FD PSA]R1,2P]R"BPA+>!3+
MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,!
M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K
MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2
MBW <!.!1NY["G?1LOZ1!";2C:=!DV/;:KI&FJHU33]/W?=_KFVB<"HU;3]-K
M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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ML&Q:R=T 42IBT-8XIA J$HJ-Q'4J5[I"JQ-7R96!76VLB;M+(68V\/8+6J&
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M+4^MCO19S7YU>W[D%>9A3F'^8O(,IL[A\5$/\?P4:?Y%LE2?JWQB4K*E_KB
M.29<W0"_/S.(>,47U4!YEO?R_U!+ P04    " #BA&9:,#K/NF@%  "W%0
M&    'AL+W=O<FMS:&5E=',O<VAE970R+GAM;*V8;6_;-A#'OPKA%L4&)#%)
M/2>.@=3)T )=&]3I]IJ1Z)BH)+HD%3?[]"-E1[)$2DZ O$DDZ^[TO]/Q?I1F
M6RY^RC6E"OPN\E)>3M9*;<ZG4YFN:4'D&=_04E]9<5$0I4_%PU1N!"59[53D
M4PQA."T(*R?S6?W;K9C/>*5R5M); 615%$0\?:0YWUY.T.3YA^_L8:W,#]/Y
M;$,>Z)*J'YM;H<^F392,%;24C)= T-7EY J=+W!H'&J+?QC=RH-C8%*YY_RG
M.?F<74Z@441SFBH3@NA_CW1!\]Q$TCI^[8-.FGL:Q\/CY^A_U<GK9.Z)I N>
M_\LRM;Z<Q!.0T16I<O6=;S_1?4*!B9?R7-9_P79O"R<@K:3BQ=Y9*RA8N?M/
M?N\+<>" _ $'O'? +W7P]@Y>G>A.69W6-5%D/A-\"X2QUM',05V;VEMGPTKS
M&)=*Z*M,^ZGYXMO7Y;<OGZ^O[FZNP<>K+U=?%S=@^>GFYFX)3L&/Y37XX_V?
MX#U@);A;\TJ2,I.SJ=)W-O[3='^7C[N[X(&[7-/T#'CH!&"(?8?[XN7N7M=]
MJO-MDL9-TKB.YPTE70E!2P6(E%3)<U<^NP"^.X!96^=R0U)Z.=&+1U+Q2"?S
M#^]0""]<V;U1L$ZN7I.K-Q9]OB!R#?13 ZDYH+\J]DARG;SS*>Y"174H,P >
MY]B+((YGT\?#?!QFB9X;06/64>HW2OU1I=^I5(*EBNZTNO3M @0'-PX""&%/
MWC&KCKJ@41>,JKM*4U[ILNG9E5)=P_N<NA0&UKV])/)[ AU&&(:^6V#8" Q'
M!=X*NB$L _2W'O&2ROJA<[6F0L^1PWYWR0XM14D213W9ME$48.16'36JHU'5
M=UR1_ 4"([MD,$BBI"?181:'03+P[.-&9'RDM!J;0CW5)35+:*-!IDY 295+
M:VP7,_!03ZEMA+"/([?0I!&:C K]IF42Q<H'D%/--B ,Q$[YZK32)W5Q!T4G
MEAX<AE;G.JSB8&AI(=A""([J_LK+T^<>$,?'P#Y:IWAQ'/2T'K/J:CT )GI!
MQPYWZMZ]TX.^#\-^JSKL?)SX$ \(;.&&7D:WG)%[EC/%J!MQZ$T9]U;1NDFW
ME$/CF&O&\X8\#<WF?8C. $-)O\4=5@$^&#1=@2W<T#C=M$!1Z9X^>"I.C3:\
MO#B*^]/#9::;>V 8HQ9R:)QRUW1%=?=D>A4^TK)RE]'&%TH"9-71-O/]& \5
MLL4<&N=<EQC'RFDS*PS\V%J+MEF,DGA(:PLW-$ZW?CGKZ0OXJI&_X<*\S3BE
MVRQ#.(16F6TS'_M).""]11X:9UX?)<^%?GI5#C;EM+:DOY]TF6EH#\ 0M31$
M1W!8[W[* [@<:Y?1>*\>B38M_60@*=RR$H^S<M?_1Q+!#O9!#R;].>*R"V \
MU/FXI21&HQ!:*I[^7/,\HT)^>!=C%%W4.R?UY'[=&F7NJ]^WWBA:-_>#M\M1
MULT7O"AX":0IP3EX#\\@1)I+ N@WKXI>@!">Z-<1(-=$F&UZI=9<L/]H=@&8
ME(81]<Z]4E+I [,"]Y9;*BC 4>U,%-!OQ;2XUPW^_&)=^^'P),:QZ[KG+#RV
MEUY_WS]NTRU2"VQ\!-A9QLS8T+UL7EM.6:FW>QNF>]LITX9R&"=1T)\D+CL_
M](*!315N\8V/XKLJJIR8;6E&5RQESETTMKE\JJD70ZNF#D,OC.)P8'#C%N%X
M'.&[^2 'UY]3MLUJ[,,DLLKKL(OB 'D#HENHXY= _6"HU;W\RB1"Z[.$<^/M
ML'-NO*<'7]7,)\V_B7A@I=0\7&E'>!;I,HC=5\+=B>*;^D/;/5>*%_7AFA(M
MWACHZRO.U?.)^7;7?*N=_P]02P,$%     @ XH1F6H24Z/*. @  *P<  !@
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M7<B?Z>M74@@R4SZ?ABS["UX+K#8 _HYQ&A7!8@11$.>?^*U(Q%$ M#H"4!&
MF@%&1X!>!.BG!AA%@)%E)I>2Y<'#'(]'"7T%28H6;.F7+)E9M) ?Q.ESG_-$
M_#<0<7P\F3W.9]_NO9N7J0?F+^+C8?KX,@>S.S![FC[?O-P+ +AY],!D]O#T
M//TZ?9S?_YB"LV^S^?P<W#^*VU-P ;[//7#VZ1RP#4X( T$,7C9TQW"\9)_!
MI]KU:,C%P-.?'_K%(&_S0:*.04($'FC,-PQ,XR59U@F&0G$I&QUDWR(EHT?\
M2Z##SP!IR) ,:')ZN"X)]TX/1PHU>OD0]8Q/[^![)GL2[\B5++-YI"&/3+O*
M%=MBGUP/1-M@)-F3P?COOZ"E_2/+2I]D7D]DM8P99<8,%?OXA7(<BKZ5Y4V6
MMCS<SL+3WKD?0Q/I4!L-]\<)D< LRW;=.LQKPY!FND>PF@BS%&$J'_ML2Q+,
M@W@-R)M8!QAAT@HP^ZR /LF\GLAJR;/*Y%G*"G@6C#CQ-T"T)+%0[,4*N!7K
M&?\,8L)E:<SIS.-'[9K0M!H5(8,AJ.N-BI# #-LVH;PB[%*4K13UA<2B),),
M$UZ*Y2)@/"V1O;3&[=883.2@QD@G4I0-&WK:*,/2[ XY3BG'.6&6TE:9R\0X
MK0$@PW;MQDR<R&"FIAD-.6T8='4G;=8R/6ZIQU7J.?M&&3L7BZ%/(P)6"8T.
MXF@L%>6VAG'AFI;5%"6!V8[H, U1;1A$T+;EFJ!6.0A-J2H5E8LAOW<!_W,1
M$;ZA2R%S3QA/YY1TQ5>2?K0M]<KF%6RUA(JIWI&H(ZL%3TR4\.O"D,;"X"4)
MB?T_T@3!]B",YKR;R% (-=<?&<ITG0Y!J!*$E(+N@AC'/CD4]%DQ/\\[>VC!
M5RM!4[31IB@)S#+=9L^1P"X,I'6HJLP45#J/\1?QM@3$*\F2++AH.6GGV05L
MTUG(O3JL@NU8DZZ[9G/YZ.M'ZRFJW!-4VZ='\4)Z%AXWLP5):_IPQ?&;O$L7
MO+5'YFBNT:H "0[9CJLU\]#&0<TRC(X:J)P55'J/\=FM6$E7 3\'VX3N@^PM
M5PA\7Y\I*<FFMC8&.GJS6<M0R.WJ097K@6K;TWIR4A5M=Y(]I5;SD>"0:Z.6
MEC;.U8T.]PLKLP/5;F="(U'=FW038D].4&6W7+A<E00G5=7&*515G@<Z2E=?
MF 1A3F/1>1@0!B%_JY::>ZAT4!_N/GVR>7VQU1-9F2VH=ENWF 6^-&=N^P$W
M76^!<8\Q\!*B9@VT8=JEWC%+466ID-I2>4&XX\V-CF)?0WM_\ 7FO<%+8(K!
M5S8'064!_\SVVLCR N^%MUV3PY[0CI'4% (?A_XNS$POH*O#O#VQWI'28GVT
MWGME\_IBJ^>]<F-([<8ZZQVU?1*R-:VYER&#619RFE4C@QE&5]E4M@NI;9>J
MYMNF2"I  I,)D+*Y>H> RA0AM2F:T##$"YJ_SH%B3P[\^T"B!4G^D^I2$GZX
MF/MD\_IBJR>S,F!(O;>EVM)$O>YH]<KF]<563UME[Y#:WKV[KUG$UW8L=4=W
MFEL*,IQIVT9K,K5Q2#-MLZL=5.8.O;.5E>"8GS:+E$0?+H<^V;R^V.I)K+PD
M4GM)Y2SJU3GVRN;UQ59/6^4<D=HYOC^+V@X2ZBYJODE(8*YF-K<Q)"C4>H,=
M'AWQ12199T>E#/AT%_/\V*N\6Q['WF2'D(W[M_#*RP]5*YK\C/<!)^L@9B D
M*T&I7=JBE27YL6E^P>DV.TA<4,YIE'W=$+PD20H0_U]1R@\7Z0^4A]?C_P%0
M2P,$%     @ XH1F6D11B'_]!0  &R<  !@   !X;"]W;W)K<VAE971S+W-H
M965T-2YX;6RU6FV3FS80_BL:-],F,W6,Q'MZYYF+31)/[ZWQI9U.IQ]T6#XS
M >0 ODO^?04F8"%9!Z[R)39F]UGMH]6R3XZS)YI]SC>$%.!K$J?Y^6A3%-LW
MDTD>;DB"\]=T2U)V9TVS!!?L,GN8Y-N,X%7EE,039!C.),%1.IJ>5;_=9M,S
MNBOB*"6W&<AW28*S;V])3)_.1W#T_8>/T<.F*'^83,^V^($L2?%I>YNQJTF#
MLHH2DN8134%&UN>C"_@F0&[I4%G\&9&G_. [*%.YI_1S>;%8G8^,<D4D)F%1
M0F#V\4AF)(Y+)+:.+S7HJ(E9.AY^_X[^KDJ>)7./<S*C\5_1JMB<C[P16)$U
MWL7%1_KT@=0)V25>2..\^A<\U;;&"(2[O*!)[<Q6D$3I_A-_K8DX<(#F$0=4
M.Z". T)'',S:P>PXF,X1!ZMVL+H1_",.=NU0I3[9YUX1-\<%GIYE] EDI35#
M*[]4[%?>C*\H+0ME663L;L3\BNGLYGIY<[F87]P%<["\8Q]7P?7=$MR\ [,/
M%]?O@R587+,;-[/?/]Q<SH./RU] \,>GQ=W?8 P^+>?@Y8M7X 6(4G"WH;L<
MIZO\;%*PA97PD[!>Q-O](M"11=S1 L<2MYG:;4:3A-7:LJ#A9_#/%4GN2?:O
M!&:NAKE8K:*R:'$,;G&T&B]2,,/;B"U)!1H\ QJ&NV07XX*LP)RLHS JCJ!-
MV(XUVX::;4,5O'4$_BV.<1H2@ N&'KX&)OP5( -!&?=[)+="*OO&XQ0A#T%F
M^WC(M<3,X4WFHHGMVHYK\V:!:#8V+=?RC<:.R]EL<C9[Y?R2%5N^P1G)7_7*
M7XE:-N(W^1:'Y'S$.FU.LD<RFO[\$W2,WV05N0>S.99,E[5EH\.5SJB!)C".
M=JNAW5+2OBRI'I?-> 5"FK G5([+XR*CVA+8,0U'J#1EO('4S'N%##2%Y BT
M&P)M)8&+/-]5A4O7)8%ER\JKEK7;LJ_D*\G"**_N[G^FVY)>:1NUA62A:W8J
M;V8+QZ_#QEP&@_P.9<JD3J3,:2AS?@1EAZU!1I\RZ-!.X(@D.E#L SIC!IK
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MOA^U:;2[S[E>H5=E1J'(T^?,VISJ1UN@NZ<JD0U$0X0P2[J2/I!(90\^$,/
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M=6T*?IEQ;:(!^'YM$#_A#6T0?^_PQ;\ 4$L#!!0    ( .*$9EJLODA-90(
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M <(DZ/,EYVH;F +=IR?^ U!+ P04    " #BA&9:)$9P#P@'  #?)0  &
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M_Y"A;?(U*;U$U_+59.,B+CK\6.-FJ3Q-P/?2X:#0OY"#\:YZ^A]02P,$%
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MD V/S9$$;[YB+65G"A"-+?Q?AT'+:OL=*'Z_5D*0,=O(Q95I885-0X2:K9"
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M ]K5%1]_O(1/-;BE%L7BJO1K>HW^> -V!W:#-IN^,,D7*!I^#=IQ#/N_*=:
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M656INGIU-$L2%G-$F/A.3">#T=4%+FYO!A?3$2Y.Q'AR-;B<C,0I/1_<7D?
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M1W@0",(D16[_6*]3*JK5"X1G1,!R"5AK!3M/;:J^!?QEYNWES8#W[6S%W8U
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M.]N5_[ST2.X_TKWC>DTE)<4*K!C9DQ'3_L.7O["J<1^;ELI:5;G3C> H72+
M\Y52MK\@!</7Q\O_ E!+ P04    " #BA&9:Z?XF-/ *  !A'@  &0   'AL
M+W=O<FMS:&5E=',O<VAE970Q.2YX;6RE66MOVS@6_>Y?060Z10.HCB3+KSX"
MI$D'&V!G6O0QB\5B/] 2'7,JB1Z2BN/Y]7LN*2F2(Z>9+A X>O#>>^[[DGJS
M4_J;V0AAV5V1E^;MR<;:[:NS,Y-N1,'-6&U%B3=KI0MN<:MOSLQ6"YXYHB(_
MB\-P=E9P69Z<OW'//NKS-ZJRN2S%1\U,511<[]^)7.W>GD0GS8-/\F9CZ<'9
M^9LMOQ&?A?VZ_:AQ=]9RR60A2B-5R;18OSVYB%Z]2VB]6_"[%#O3N6:DR4JI
M;W1SG;T]"0F0R$5JB0/'OUMQ*?*<& '&GS7/DU8D$7:O&^Z_.-VARXH;<:GR
M?\G,;MZ>+$Y8)M:\RNTGM?N'J/69$K]4Y<;]LIU?.YF<L+0R5A4U,1 4LO3_
M^5UMAP[!(CQ"$-<$L</M!3F45]SR\S=:[9BFU>!&%TY51PUPLB2G?+8:;R7H
M[/EUF:I"L"_\3I@W9Q8<Z?E96E._\]3Q$>HH9K^JTFX,>U]F(NLS. .4%D_<
MX'D7/\KQ2J1C-HD"%H=Q\@B_2:O?Q/&;?%<_=B5-FBM3:<'^<[$R5B,B_CND
ML^>8#'.D+'EEMCP5;T^0!D;H6W%R_ORG:!:^?@1OTN)-'N/^77\\3OW;AR_O
M612.69<-NT#VI*I,92ZY2P6U9B]@"7/*I%^W$DAOT=Q91X4G+,.ML3)EO,SH
M 6*\9+E*'1O#I&&<%N9(;?-JA#1A=B/8OP77/B 8W"F*E=#DTM&+ZQ+O567
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MX%\)/7=\*^8(L6.?5)]@1.IP[ !,?X^K#<AI#Q+_ B2*V1>MW,*R"U6+^F>
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M84@ _\^T=ML-&=C-S<?_ E!+ P04    " #BA&9:U<=QI9,"  "M!0  &0
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MX#TRFK2LS["A8"=S@!6RC2R(K))N"%H0-W)MKIDY3J/:KQB>X5N[S+#21Q\
MD4<6\!IB6GP6Y$37H-<2-P&&;6[01P!W^1,,!)89?!$#8H!BZ3RWMW$MI,E
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MXRC'.#M^@&>0:R 73VPFP%P..Q91W5BGV"%<UPCT#828DCLE[=*0C[*$\M\
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M4CL:8(/8T!\#C5>@^[76;K_Q#@[_H.4O4$L#!!0    ( .*$9EK:4"U=# ,
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M#TFZT486E3(@*$3I[NRNRL-+%()*(;"XG2.+\I09=KBOY"U1* W6<&%#M=H
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M:#M#*#"UCH'1WQ->H1".B&S\WG$&M:0#'L9[]D^^=JIEP0Q>*?'(,YN/@WX
M&2[96M@[M?F,NWJZCB]5POA?V%2YW3B =&VL*G9@<E!P6?VSY]T^' #Z[5<
M\0X0>]^5D'=YS2R;C+3:@';9Q.8"7ZI'DSDNW:'<6TVKG'!V<J6*@EO:96N
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MEFOZNT#+ O1]:8S?;?B"_?_*_&]02P,$%     @ XH1F6ES7.ZRU P  '!
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MI];80CDL<4G55[[['9H-A88OXU16WVA7VT:>A;)2*EXT8!U!05A]Q4^-$'L
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MX/HTR_3+@6E@_>VJX?\ 4$L#!!0    ( .*$9EJYN\RO)0,  -D*   9
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MRU3-GL"U@3I/&).O&SU\U--L^!=02P,$%     @ XH1F6FDWM;@U P  )0L
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M[1UYX_6JS.?UX.H5S+/%PY_IM_H7L3.@<MH'!/6 X- !_7I __F P0L#!O6
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MLMQLYR2AO0Q4BU!-H)I$M1C5$E13J*8IS0Y=T\L8!LC^X!!]E@JJA:@6H9I
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MIM@L4'W_-L_+QT\V*_B:%[]M?\R+_P%02P,$%     @ XH1F6D(VV\LL!0
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M/<"!H-4X*(U6-/-MZH=XCYF;2AO;2^V_6*H43T]TLO4<1PL'2:-0-%/?I@G
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MFEOA>=_KVBHEN42O#YN /MVJ:/160B;^':JTAO:'H?6TO18%B6%NJ7DI@._
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M4A.$U\=;]8UD175"],"D9%EUN06R!JX#U/N$,?EXHP^=VD/&Q?]02P,$%
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M_DM V0#<GTEIUH9-T/V=DG]02P,$%     @ XH1F6D>:IY X"P  &I<  !D
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ME2Z)&21FDIA%8C:).23FDIA'8CZ)!2060EBG^">;XI_4^EBUS^&FRR)?E5V
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ME,_?95GQ<J>:P5.6?ZM?YO5_ 5!+ P04    " #BA&9:0'X1S98"  #"!@
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M,BAM@-DOA="[B4TP_+;2?U!+ P04    " #BA&9:--7W8 \'   D0@  &0
M 'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6S%G&MOVS84AO\*X15#"[2V)=^S
MQ$!B759@68.D73\4^\#(M"U4%Y>BG&38CQ]UB63:"FMA+Y!\2"R9YR&E\X9'
M?"WK_"'FWY,-8X(\AD&47'0V0FS/>KW$V["0)MUXRR+YSBKF(15RDZ][R98S
MNLR#PJ!G]OOC7DC]J#,_S_?=\/EYG(K C]@-)TD:AI0_7;$@?KCH&)WG';?^
M>B.R';WY^9:NV1T37[8W7&[U*LK2#UF4^'%$.%M=="Z-,]><90%YB[]\]I#L
MO2;9H=S'\?=LX^/RHM//1L0"YHD,0>6?'5NP(,A(<AP_2FBGZC,+W'_]3'?R
M@Y<'<T\3MHB#K_Y2;"XZTPY9LA5- W$;/_S.R@,:93PO#I+\-WDHV_8[Q$L3
M$8=EL!Q!Z$?%7_I8GHB] ,EI#C#+ /,@P!R^$# H P:'/;P4,"P#AJ<&C,J
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M;"C-@=)<%$V5V9ZY9IPZ,>4EB:3YQ+26&GOANK $CO:+]W0R/2C?"WV_K?6
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MAL(MXR0KP6(%69(7;_Q4"E$#F-X)@%4"K&. <P)@EP#[M0"G!#A*F<(5I4.
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MQ)U!BZJCZ'"R47GXDG"1U:MF+"HUH-) ?%\1P@\=.4%5^TW^ U!+ P04
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MTCL[UYG)MIFW!HK:MK>Y0-TL[;#0[Q](XZ#7%T+@QC !^A<U^0M02P,$%
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M55:7H*JAQ:Z\1SP)C;>2\G&+%T>0Q@"_KX70KPUS-6FNHO/_ %!+ P04
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M'LEA3E?<W,G-%ZCS&5B^3'+MGF13Q?;//9*MM)%%#48%!1/5FS[5/K0 87(
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M[/E#M%I5S:2:&%FZ>CR3!JN[&RZQ_X*R ?A]+J793NP&34=/_P)02P,$%
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MH$RH20ZEV5": Z6Y4)H'I?E06@"EA2B:JI7&+C?USNR\JJ0)>UZQK&"$,[D
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MP@+'VS'XV=)/MX\T5M366]$'^%.\_B49+I+T17Z.3%=3H<XDYT2PY_4'RK(
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M9G=,-DUCJ&XZ&=<!_4TUI[TI>_DJW:#DCX7^.C?3D;8/E<UN%<OXPO8766,
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M<F]P<R]A<' N>&UL4$L! A0#%     @ XH1F6AN#V%?O    *P(  !$
M         ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ XH1F
M6IE<G",0!@  G"<  !,              ( !S0$  'AL+W1H96UE+W1H96UE
M,2YX;6Q02P$"% ,4    " #BA&9:FP>M@,L*  #7.P  &
M@($."   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ XH1F
M6C ZS[IH!0  MQ4  !@              ("!#Q,  'AL+W=O<FMS:&5E=',O
M<VAE970R+GAM;%!+ 0(4 Q0    ( .*$9EJ$E.CRC@(  "L'   8
M      " @:T8  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4
M" #BA&9:B^][*T4&  #('@  &               @(%Q&P  >&PO=V]R:W-H
M965T<R]S:&5E=#0N>&UL4$L! A0#%     @ XH1F6D11B'_]!0  &R<  !@
M             ("!["$  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4
M Q0    ( .*$9EH=:JX<2P@  +TI   8              " @1\H  !X;"]W
M;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " #BA&9:__%7K5T.  #[
M4   &               @(&@,   >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL
M4$L! A0#%     @ XH1F6JR^2$UE @  A@8  !@              ("!,S\
M 'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( .*$9EHD1G /
M" <  -\E   8              " @<Y!  !X;"]W;W)K<VAE971S+W-H965T
M.2YX;6Q02P$"% ,4    " #BA&9:.>!5PX0&  "W#@  &0
M@($,20  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( .*$
M9EH[E=$%Q2$  )QG   9              " @<=/  !X;"]W;W)K<VAE971S
M+W-H965T,3$N>&UL4$L! A0#%     @ XH1F6K#1GY2R%   QC\  !D
M         ("!PW$  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4
M    " #BA&9:US-IM: $  #%"@  &0              @(&LA@  >&PO=V]R
M:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( .*$9EKZI+B%& ,  *0&
M   9              " @8.+  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL
M4$L! A0#%     @ XH1F6L/Q*%9? P  ; <  !D              ("!THX
M 'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " #BA&9:S_\'
MLBP)  "!%P  &0              @(%HD@  >&PO=V]R:W-H965T<R]S:&5E
M=#$V+GAM;%!+ 0(4 Q0    ( .*$9EJ*Q3.VN (  ) &   9
M  " @<N;  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @
MXH1F6J3U2,<:"   B10  !D              ("!NIX  'AL+W=O<FMS:&5E
M=',O<VAE970Q."YX;6Q02P$"% ,4    " #BA&9:Z?XF-/ *  !A'@  &0
M            @($+IP  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4
M Q0    ( .*$9EJ#VN-RG D   \:   9              " @3*R  !X;"]W
M;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ XH1F6L1#J B*!0
M0PL  !D              ("!!;P  'AL+W=O<FMS:&5E=',O<VAE970R,2YX
M;6Q02P$"% ,4    " #BA&9:U<=QI9,"  "M!0  &0              @('&
MP0  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( .*$9EJ!
M+?_5! (  *T$   9              " @9#$  !X;"]W;W)K<VAE971S+W-H
M965T,C,N>&UL4$L! A0#%     @ XH1F6AH+T]<B(P  SG(  !D
M     ("!R\8  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( .*$9EJ(1:'D+ 4  (,-   9              "
M@9+X  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ XH1F
M6O/PJ\IP!@  3Q(  !D              ("!]?T  'AL+W=O<FMS:&5E=',O
M<VAE970S,"YX;6Q02P$"% ,4    " #BA&9:HP^16>X"  !Z!@  &0
M        @(&<! $ >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0
M   ( .*$9EHB<'@M6@0  +L(   9              " @<$' 0!X;"]W;W)K
M<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ XH1F6ES7.ZRU P  '!
M !D              ("!4@P! 'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q0
M2P$"% ,4    " #BA&9:@NL/6[L)  #'2@  &0              @($^$ $
M>&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( .*$9EJYN\RO
M)0,  -D*   9              " @3 : 0!X;"]W;W)K<VAE971S+W-H965T
M,S4N>&UL4$L! A0#%     @ XH1F6FDWM;@U P  )0L  !D
M ("!C!T! 'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    " #B
MA&9:.0N4*@(/  !@W@  &0              @('X( $ >&PO=V]R:W-H965T
M<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( .*$9EI"-MO++ 4  ,8F   9
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M970T,BYX;6Q02P$"% ,4    " #BA&9:1YJGD#@+   :EP  &0
M    @('Z0@$ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    (
M .*$9EI ?A'-E@(  ,(&   9              " @6E. 0!X;"]W;W)K<VAE
M971S+W-H965T-#0N>&UL4$L! A0#%     @ XH1F6C35]V /!P  )$(  !D
M             ("!-E$! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"
M% ,4    " #BA&9:=P;,BS(#  "A"0  &0              @(%\6 $ >&PO
M=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( .*$9EJ@-N3ZQ 0
M ,87   9              " @>5; 0!X;"]W;W)K<VAE971S+W-H965T-#<N
M>&UL4$L! A0#%     @ XH1F6OW)[$>! @  B08  !D              ("!
MX& ! 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"% ,4    " #BA&9:
ML!J*"4@#   '#@  &0              @(&88P$ >&PO=V]R:W-H965T<R]S
M:&5E=#0Y+GAM;%!+ 0(4 Q0    ( .*$9EH\:V<3F@(  %T'   9
M      " @1=G 0!X;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%
M  @ XH1F6@I?AIGJ @  [@D  !D              ("!Z&D! 'AL+W=O<FMS
M:&5E=',O<VAE970U,2YX;6Q02P$"% ,4    " #BA&9:]1Z]'@,$   "$
M&0              @($);0$ >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+
M 0(4 Q0    ( .*$9EK==@?1!P0  )8.   9              " @4-Q 0!X
M;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @ XH1F6LC41'L^
M!@  [2\  !D              ("!@74! 'AL+W=O<FMS:&5E=',O<VAE970U
M-"YX;6Q02P$"% ,4    " #BA&9:=%TS7-,"  #=!P  &0
M@('V>P$ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    ( .*$
M9EI"FJV/=PD  #9K   9              " @0!_ 0!X;"]W;W)K<VAE971S
M+W-H965T-38N>&UL4$L! A0#%     @ XH1F6BG9Z]0H P  -0D  !D
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M<R\N<F5L<U!+ 0(4 Q0    ( .*$9EI4Y)5(U@0  +,G   /
M  "  :2= 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " #BA&9:F!M:GOL!
M  #+(P  &@              @ &GH@$ >&PO7W)E;',O=V]R:V)O;VLN>&UL
M+G)E;'-02P$"% ,4    " #BA&9:=-+&8MX!  !:(P  $P
M@ ':I $ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     1 !$ ),2  #II@$
"   !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>195</ContextCount>
  <ElementCount>363</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>74</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="arct-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcturusrx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="arct-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="arct-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="arct-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcturusrx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="arct-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="arct-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="arct-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100060 - Disclosure - Cybersecurity Risk Management, Strategy, and Governance</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcturusrx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance</Role>
      <ShortName>Cybersecurity Risk Management, Strategy, and Governance</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="arct-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="arct-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="arct-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995455 - Disclosure - Organization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureOrganization</Role>
      <ShortName>Organization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="arct-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995465 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="arct-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995475 - Disclosure - Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenue</Role>
      <ShortName>Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="arct-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995485 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="arct-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995495 - Disclosure - Accrued Liabilities Detail</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcturusrx.com/20241231/taxonomy/role/DisclosureAccruedLiabilitiesDetail</Role>
      <ShortName>Accrued Liabilities Detail</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="arct-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995505 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="arct-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995515 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureDebt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="arct-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995525 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="arct-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995535 - Disclosure - Share-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensation</Role>
      <ShortName>Share-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="arct-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995545 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="arct-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995555 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="arct-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995565 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcturusrx.com/20241231/taxonomy/role/DisclosureSegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="arct-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995575 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="arct-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995585 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="arct-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995595 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="arct-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995605 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="arct-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995615 - Disclosure - Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueTables</Role>
      <ShortName>Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenue</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="arct-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995625 - Disclosure - Accrued Liabilities Detail (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcturusrx.com/20241231/taxonomy/role/DisclosureAccruedLiabilitiesDetailTables</Role>
      <ShortName>Accrued Liabilities Detail (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://arcturusrx.com/20241231/taxonomy/role/DisclosureAccruedLiabilitiesDetail</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="arct-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995635 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="arct-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995655 - Disclosure - Share-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationTables</Role>
      <ShortName>Share-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensation</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="arct-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995665 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="arct-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995675 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="arct-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>995685 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcturusrx.com/20241231/taxonomy/role/DisclosureSegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://arcturusrx.com/20241231/taxonomy/role/DisclosureSegmentInformation</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="arct-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>995695 - Disclosure - Organization (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureOrganizationDetailsTextual</Role>
      <ShortName>Organization (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureOrganization</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="arct-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>995705 - Disclosure - Summary of Significant Accounting Policies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesDetailsTextual</Role>
      <ShortName>Summary of Significant Accounting Policies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="arct-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>995715 - Disclosure - Summary of Significant Accounting Policies - Schedule of Cash and Cash Equivalents and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcturusrx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Cash and Cash Equivalents and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="arct-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>995725 - Disclosure - Revenue - Summary of Changes in Balances of Receivables and Contract Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcturusrx.com/20241231/taxonomy/role/DisclosureRevenueSummaryOfChangesInBalancesOfReceivablesAndContractLiabilityDetails</Role>
      <ShortName>Revenue - Summary of Changes in Balances of Receivables and Contract Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="arct-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>995735 - Disclosure - Revenue (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual</Role>
      <ShortName>Revenue (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="arct-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>995745 - Disclosure - Revenue - Summary of Revenues (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueSummaryOfRevenuesDetails</Role>
      <ShortName>Revenue - Summary of Revenues (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="arct-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>995765 - Disclosure - Fair Value Measurements (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcturusrx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsDetailsTextual</Role>
      <ShortName>Fair Value Measurements (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurements</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="arct-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>995775 - Disclosure - Accrued Liabilities Detail - Schedule of Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcturusrx.com/20241231/taxonomy/role/DisclosureAccruedLiabilitiesDetailScheduleOfAccruedLiabilitiesDetails</Role>
      <ShortName>Accrued Liabilities Detail - Schedule of Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="arct-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>995785 - Disclosure - Property and Equipment, Net - Summary of Components of Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcturusrx.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfComponentsOfPropertyAndEquipmentNetDetails</Role>
      <ShortName>Property and Equipment, Net - Summary of Components of Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="arct-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>995795 - Disclosure - Property and Equipment, Net (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetDetailsTextual</Role>
      <ShortName>Property and Equipment, Net (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="arct-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>995805 - Disclosure - Debt (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureDebtDetailsTextual</Role>
      <ShortName>Debt (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureDebt</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="arct-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>995815 - Disclosure - Stockholders' Equity (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityDetailsTextual</Role>
      <ShortName>Stockholders' Equity (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquity</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="arct-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>995825 - Disclosure - Share-Based Compensation (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationDetailsTextual</Role>
      <ShortName>Share-Based Compensation (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="arct-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>995835 - Disclosure - Share-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationDetails</Role>
      <ShortName>Share-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="arct-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>995845 - Disclosure - Share-Based Compensation (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationDetails1</Role>
      <ShortName>Share-Based Compensation (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="arct-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>995855 - Disclosure - Share-Based Compensation - (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcturusrx.com/20241231/taxonomy/role/DisclosureSharebasedCompensationDetails2</Role>
      <ShortName>Share-Based Compensation - (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="arct-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>995865 - Disclosure - Share-Based Compensation (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcturusrx.com/20241231/taxonomy/role/DisclosureSharebasedCompensationDetails3</Role>
      <ShortName>Share-Based Compensation (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="arct-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>995875 - Disclosure - Income Taxes (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails1</Role>
      <ShortName>Income Taxes (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="arct-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>995885 - Disclosure - Income Taxes (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcturusrx.com/20241231/taxonomy/role/DisclosureIncomeTaxesDetails2</Role>
      <ShortName>Income Taxes (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="arct-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>995895 - Disclosure - Income Taxes (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcturusrx.com/20241231/taxonomy/role/DisclosureIncomeTaxesDetails3</Role>
      <ShortName>Income Taxes (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="arct-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>995905 - Disclosure - Income Taxes (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcturusrx.com/20241231/taxonomy/role/DisclosureIncomeTaxesDetails4</Role>
      <ShortName>Income Taxes (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="arct-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>995915 - Disclosure - Income Taxes (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetailsTextual</Role>
      <ShortName>Income Taxes (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="arct-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>995925 - Disclosure - Income Taxes (Details 5)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcturusrx.com/20241231/taxonomy/role/DisclosureIncomeTaxesDetails5</Role>
      <ShortName>Income Taxes (Details 5)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="arct-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>995935 - Disclosure - Commitments and Contingencies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual</Role>
      <ShortName>Commitments and Contingencies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="arct-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>995955 - Disclosure - Commitments and Contingencies - Payments of Operating Lease Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesPaymentsOfOperatingLeaseLiabilityDetails</Role>
      <ShortName>Commitments and Contingencies - Payments of Operating Lease Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="arct-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>995965 - Disclosure - Segment Information - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcturusrx.com/20241231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails</Role>
      <ShortName>Segment Information - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="arct-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>995975 - Disclosure - Segment Information - Summary of Reported Segment Revenues, Segment Loss and Income, and Significant Segment Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcturusrx.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfReportedSegmentRevenuesSegmentLossAndIncomeAndSignificantSegmentExpensesDetails</Role>
      <ShortName>Segment Information - Summary of Reported Segment Revenues, Segment Loss and Income, and Significant Segment Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="arct-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>995985 - Disclosure - Segment Information - Summary of Reported Segment Revenues, Segment Loss and Income, and Significant Segment Expenses (Parenthetical) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcturusrx.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfReportedSegmentRevenuesSegmentLossAndIncomeAndSignificantSegmentExpensesParentheticalDetails</Role>
      <ShortName>Segment Information - Summary of Reported Segment Revenues, Segment Loss and Income, and Significant Segment Expenses (Parenthetical) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="arct-20241231.htm">arct-20241231.htm</File>
    <File>arct-20241231.xsd</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img267189834_0.jpg</File>
    <File>img267189834_1.jpg</File>
    <File>img267189834_10.jpg</File>
    <File>img267189834_11.jpg</File>
    <File>img267189834_12.jpg</File>
    <File>img267189834_13.jpg</File>
    <File>img267189834_2.jpg</File>
    <File>img267189834_3.jpg</File>
    <File>img267189834_4.jpg</File>
    <File>img267189834_5.jpg</File>
    <File>img267189834_6.jpg</File>
    <File>img267189834_7.jpg</File>
    <File>img267189834_8.jpg</File>
    <File>img267189834_9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="620">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="15">http://xbrl.sec.gov/cyd/2024</BaseTaxonomy>
    <BaseTaxonomy items="40">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="21">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>95
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "arct-20241231.htm": {
   "nsprefix": "arct",
   "nsuri": "http://arcturusrx.com/20241231",
   "dts": {
    "inline": {
     "local": [
      "arct-20241231.htm"
     ]
    },
    "schema": {
     "local": [
      "arct-20241231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    }
   },
   "keyStandard": 310,
   "keyCustom": 53,
   "axisStandard": 26,
   "axisCustom": 0,
   "memberStandard": 31,
   "memberCustom": 43,
   "hidden": {
    "total": 8,
    "http://fasb.org/us-gaap/2024": 4,
    "http://xbrl.sec.gov/dei/2024": 3,
    "http://xbrl.sec.gov/ecd/2024": 1
   },
   "contextCount": 195,
   "entityCount": 1,
   "segmentCount": 74,
   "elementCount": 792,
   "unitCount": 6,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 620,
    "http://xbrl.sec.gov/dei/2024": 40,
    "http://xbrl.sec.gov/ecd/2024": 21,
    "http://xbrl.sec.gov/cyd/2024": 15
   },
   "report": {
    "R1": {
     "role": "http://arcturusrx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_c45ae1f6-f871-404f-8826-2b495a729716",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_c45ae1f6-f871-404f-8826-2b495a729716",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS",
     "longName": "100010 - Statement - CONSOLIDATED BALANCE SHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "C_4903df66-6bad-45f9-8151-6f6455ee1212",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4903df66-6bad-45f9-8151-6f6455ee1212",
      "name": "us-gaap:RestrictedCash",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETSParenthetical",
     "longName": "100020 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "C_4903df66-6bad-45f9-8151-6f6455ee1212",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4903df66-6bad-45f9-8151-6f6455ee1212",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://arcturusrx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome",
     "longName": "100030 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "C_c45ae1f6-f871-404f-8826-2b495a729716",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_c45ae1f6-f871-404f-8826-2b495a729716",
      "name": "us-gaap:OperatingExpenses",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
     "longName": "100040 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "C_12470630-daf9-4fdf-a875-a3affca4b6e8",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_12470630-daf9-4fdf-a875-a3affca4b6e8",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "longName": "100050 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "C_c45ae1f6-f871-404f-8826-2b495a729716",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_c45ae1f6-f871-404f-8826-2b495a729716",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://arcturusrx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance",
     "longName": "100060 - Disclosure - Cybersecurity Risk Management, Strategy, and Governance",
     "shortName": "Cybersecurity Risk Management, Strategy, and Governance",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "C_c45ae1f6-f871-404f-8826-2b495a729716",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_c45ae1f6-f871-404f-8826-2b495a729716",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "C_c45ae1f6-f871-404f-8826-2b495a729716",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R9": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "C_c45ae1f6-f871-404f-8826-2b495a729716",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_c45ae1f6-f871-404f-8826-2b495a729716",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureOrganization",
     "longName": "995455 - Disclosure - Organization",
     "shortName": "Organization",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "C_c45ae1f6-f871-404f-8826-2b495a729716",
      "name": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_c45ae1f6-f871-404f-8826-2b495a729716",
      "name": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies",
     "longName": "995465 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "C_c45ae1f6-f871-404f-8826-2b495a729716",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_c45ae1f6-f871-404f-8826-2b495a729716",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenue",
     "longName": "995475 - Disclosure - Revenue",
     "shortName": "Revenue",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "C_c45ae1f6-f871-404f-8826-2b495a729716",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_c45ae1f6-f871-404f-8826-2b495a729716",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurements",
     "longName": "995485 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "C_c45ae1f6-f871-404f-8826-2b495a729716",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_c45ae1f6-f871-404f-8826-2b495a729716",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://arcturusrx.com/20241231/taxonomy/role/DisclosureAccruedLiabilitiesDetail",
     "longName": "995495 - Disclosure - Accrued Liabilities Detail",
     "shortName": "Accrued Liabilities Detail",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "C_c45ae1f6-f871-404f-8826-2b495a729716",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_c45ae1f6-f871-404f-8826-2b495a729716",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet",
     "longName": "995505 - Disclosure - Property and Equipment, Net",
     "shortName": "Property and Equipment, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "C_c45ae1f6-f871-404f-8826-2b495a729716",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_c45ae1f6-f871-404f-8826-2b495a729716",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureDebt",
     "longName": "995515 - Disclosure - Debt",
     "shortName": "Debt",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "C_c45ae1f6-f871-404f-8826-2b495a729716",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_c45ae1f6-f871-404f-8826-2b495a729716",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquity",
     "longName": "995525 - Disclosure - Stockholders' Equity",
     "shortName": "Stockholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "C_c45ae1f6-f871-404f-8826-2b495a729716",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_c45ae1f6-f871-404f-8826-2b495a729716",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensation",
     "longName": "995535 - Disclosure - Share-Based Compensation",
     "shortName": "Share-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "C_c45ae1f6-f871-404f-8826-2b495a729716",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_c45ae1f6-f871-404f-8826-2b495a729716",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes",
     "longName": "995545 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "C_c45ae1f6-f871-404f-8826-2b495a729716",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_c45ae1f6-f871-404f-8826-2b495a729716",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies",
     "longName": "995555 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "C_c45ae1f6-f871-404f-8826-2b495a729716",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_c45ae1f6-f871-404f-8826-2b495a729716",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://arcturusrx.com/20241231/taxonomy/role/DisclosureSegmentInformation",
     "longName": "995565 - Disclosure - Segment Information",
     "shortName": "Segment Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "C_c45ae1f6-f871-404f-8826-2b495a729716",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_c45ae1f6-f871-404f-8826-2b495a729716",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRelatedPartyTransactions",
     "longName": "995575 - Disclosure - Related Party Transactions",
     "shortName": "Related Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "C_c45ae1f6-f871-404f-8826-2b495a729716",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_c45ae1f6-f871-404f-8826-2b495a729716",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSubsequentEvents",
     "longName": "995585 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "C_c45ae1f6-f871-404f-8826-2b495a729716",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_c45ae1f6-f871-404f-8826-2b495a729716",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "995595 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "24",
     "firstAnchor": {
      "contextRef": "C_c45ae1f6-f871-404f-8826-2b495a729716",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_c45ae1f6-f871-404f-8826-2b495a729716",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables",
     "longName": "995605 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "C_c45ae1f6-f871-404f-8826-2b495a729716",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:InventoryCashFlowPolicy",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_c45ae1f6-f871-404f-8826-2b495a729716",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:InventoryCashFlowPolicy",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueTables",
     "longName": "995615 - Disclosure - Revenue (Tables)",
     "shortName": "Revenue (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "C_c45ae1f6-f871-404f-8826-2b495a729716",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_c45ae1f6-f871-404f-8826-2b495a729716",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://arcturusrx.com/20241231/taxonomy/role/DisclosureAccruedLiabilitiesDetailTables",
     "longName": "995625 - Disclosure - Accrued Liabilities Detail (Tables)",
     "shortName": "Accrued Liabilities Detail (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "C_c45ae1f6-f871-404f-8826-2b495a729716",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_c45ae1f6-f871-404f-8826-2b495a729716",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables",
     "longName": "995635 - Disclosure - Property and Equipment, Net (Tables)",
     "shortName": "Property and Equipment, Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "C_c45ae1f6-f871-404f-8826-2b495a729716",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_c45ae1f6-f871-404f-8826-2b495a729716",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationTables",
     "longName": "995655 - Disclosure - Share-Based Compensation (Tables)",
     "shortName": "Share-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "C_c45ae1f6-f871-404f-8826-2b495a729716",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_c45ae1f6-f871-404f-8826-2b495a729716",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables",
     "longName": "995665 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "C_c45ae1f6-f871-404f-8826-2b495a729716",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_c45ae1f6-f871-404f-8826-2b495a729716",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables",
     "longName": "995675 - Disclosure - Commitments and Contingencies (Tables)",
     "shortName": "Commitments and Contingencies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "C_c45ae1f6-f871-404f-8826-2b495a729716",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_c45ae1f6-f871-404f-8826-2b495a729716",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://arcturusrx.com/20241231/taxonomy/role/DisclosureSegmentInformationTables",
     "longName": "995685 - Disclosure - Segment Information (Tables)",
     "shortName": "Segment Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "C_c45ae1f6-f871-404f-8826-2b495a729716",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_c45ae1f6-f871-404f-8826-2b495a729716",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureOrganizationDetailsTextual",
     "longName": "995695 - Disclosure - Organization (Details Textual)",
     "shortName": "Organization (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "C_4903df66-6bad-45f9-8151-6f6455ee1212",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R34": {
     "role": "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesDetailsTextual",
     "longName": "995705 - Disclosure - Summary of Significant Accounting Policies (Details Textual)",
     "shortName": "Summary of Significant Accounting Policies (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "C_c45ae1f6-f871-404f-8826-2b495a729716",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "U_Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_c45ae1f6-f871-404f-8826-2b495a729716",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "U_Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://arcturusrx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails",
     "longName": "995715 - Disclosure - Summary of Significant Accounting Policies - Schedule of Cash and Cash Equivalents and Restricted Cash (Details)",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Cash and Cash Equivalents and Restricted Cash (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "C_4903df66-6bad-45f9-8151-6f6455ee1212",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_9b6438ac-a4af-4cb1-a7e8-04fc1dc8917f",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "div",
       "us-gaap:InventoryCashFlowPolicy",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "unique": true
     }
    },
    "R36": {
     "role": "http://arcturusrx.com/20241231/taxonomy/role/DisclosureRevenueSummaryOfChangesInBalancesOfReceivablesAndContractLiabilityDetails",
     "longName": "995725 - Disclosure - Revenue - Summary of Changes in Balances of Receivables and Contract Liability (Details)",
     "shortName": "Revenue - Summary of Changes in Balances of Receivables and Contract Liability (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc",
      "name": "us-gaap:ContractWithCustomerAssetNet",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_c45ae1f6-f871-404f-8826-2b495a729716",
      "name": "arct:ContractWithCustomerAssetAdditions",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "unique": true
     }
    },
    "R37": {
     "role": "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual",
     "longName": "995735 - Disclosure - Revenue (Details Textual)",
     "shortName": "Revenue (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "C_c45ae1f6-f871-404f-8826-2b495a729716",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0fe3841a-f105-4a0f-a913-03e14cbebbf8",
      "name": "us-gaap:ContractWithCustomerLiability",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueSummaryOfRevenuesDetails",
     "longName": "995745 - Disclosure - Revenue - Summary of Revenues (Details)",
     "shortName": "Revenue - Summary of Revenues (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "C_c45ae1f6-f871-404f-8826-2b495a729716",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_cb30b8bf-d65b-4a7e-8e21-e4aa8d48e2f3",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://arcturusrx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsDetailsTextual",
     "longName": "995765 - Disclosure - Fair Value Measurements (Details Textual)",
     "shortName": "Fair Value Measurements (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "C_44b8ebcf-fb2f-4241-9026-e24a66edc6b0",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_44b8ebcf-fb2f-4241-9026-e24a66edc6b0",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://arcturusrx.com/20241231/taxonomy/role/DisclosureAccruedLiabilitiesDetailScheduleOfAccruedLiabilitiesDetails",
     "longName": "995775 - Disclosure - Accrued Liabilities Detail - Schedule of Accrued Liabilities (Details)",
     "shortName": "Accrued Liabilities Detail - Schedule of Accrued Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "C_4903df66-6bad-45f9-8151-6f6455ee1212",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4903df66-6bad-45f9-8151-6f6455ee1212",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://arcturusrx.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfComponentsOfPropertyAndEquipmentNetDetails",
     "longName": "995785 - Disclosure - Property and Equipment, Net - Summary of Components of Property and Equipment, Net (Details)",
     "shortName": "Property and Equipment, Net - Summary of Components of Property and Equipment, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "C_4903df66-6bad-45f9-8151-6f6455ee1212",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4903df66-6bad-45f9-8151-6f6455ee1212",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetDetailsTextual",
     "longName": "995795 - Disclosure - Property and Equipment, Net (Details Textual)",
     "shortName": "Property and Equipment, Net (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "C_c45ae1f6-f871-404f-8826-2b495a729716",
      "name": "us-gaap:DepreciationAndAmortization",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R43": {
     "role": "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureDebtDetailsTextual",
     "longName": "995805 - Disclosure - Debt (Details Textual)",
     "shortName": "Debt (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "C_e555c3b5-c6bf-47e7-838e-8773ebae68d0",
      "name": "us-gaap:InterestExpenseLongTermDebt",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e555c3b5-c6bf-47e7-838e-8773ebae68d0",
      "name": "us-gaap:InterestExpenseLongTermDebt",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityDetailsTextual",
     "longName": "995815 - Disclosure - Stockholders' Equity (Details Textual)",
     "shortName": "Stockholders' Equity (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "C_c45ae1f6-f871-404f-8826-2b495a729716",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_c45ae1f6-f871-404f-8826-2b495a729716",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationDetailsTextual",
     "longName": "995825 - Disclosure - Share-Based Compensation (Details Textual)",
     "shortName": "Share-Based Compensation (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "C_4903df66-6bad-45f9-8151-6f6455ee1212",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4903df66-6bad-45f9-8151-6f6455ee1212",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationDetails",
     "longName": "995835 - Disclosure - Share-Based Compensation (Details)",
     "shortName": "Share-Based Compensation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "C_f94c3743-e85f-4283-b541-3b2a49e36750",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f94c3743-e85f-4283-b541-3b2a49e36750",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationDetails1",
     "longName": "995845 - Disclosure - Share-Based Compensation (Details 1)",
     "shortName": "Share-Based Compensation (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_c45ae1f6-f871-404f-8826-2b495a729716",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://arcturusrx.com/20241231/taxonomy/role/DisclosureSharebasedCompensationDetails2",
     "longName": "995855 - Disclosure - Share-Based Compensation - (Details 2)",
     "shortName": "Share-Based Compensation - (Details 2)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://arcturusrx.com/20241231/taxonomy/role/DisclosureSharebasedCompensationDetails3",
     "longName": "995865 - Disclosure - Share-Based Compensation (Details 3)",
     "shortName": "Share-Based Compensation (Details 3)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "C_c45ae1f6-f871-404f-8826-2b495a729716",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_c45ae1f6-f871-404f-8826-2b495a729716",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails1",
     "longName": "995875 - Disclosure - Income Taxes (Details 1)",
     "shortName": "Income Taxes (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "C_c45ae1f6-f871-404f-8826-2b495a729716",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_c45ae1f6-f871-404f-8826-2b495a729716",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://arcturusrx.com/20241231/taxonomy/role/DisclosureIncomeTaxesDetails2",
     "longName": "995885 - Disclosure - Income Taxes (Details 2)",
     "shortName": "Income Taxes (Details 2)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "C_c45ae1f6-f871-404f-8826-2b495a729716",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_c45ae1f6-f871-404f-8826-2b495a729716",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://arcturusrx.com/20241231/taxonomy/role/DisclosureIncomeTaxesDetails3",
     "longName": "995895 - Disclosure - Income Taxes (Details 3)",
     "shortName": "Income Taxes (Details 3)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "C_c45ae1f6-f871-404f-8826-2b495a729716",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_c45ae1f6-f871-404f-8826-2b495a729716",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://arcturusrx.com/20241231/taxonomy/role/DisclosureIncomeTaxesDetails4",
     "longName": "995905 - Disclosure - Income Taxes (Details 4)",
     "shortName": "Income Taxes (Details 4)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "C_4903df66-6bad-45f9-8151-6f6455ee1212",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4903df66-6bad-45f9-8151-6f6455ee1212",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetailsTextual",
     "longName": "995915 - Disclosure - Income Taxes (Details Textual)",
     "shortName": "Income Taxes (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "C_4903df66-6bad-45f9-8151-6f6455ee1212",
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_c45ae1f6-f871-404f-8826-2b495a729716",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://arcturusrx.com/20241231/taxonomy/role/DisclosureIncomeTaxesDetails5",
     "longName": "995925 - Disclosure - Income Taxes (Details 5)",
     "shortName": "Income Taxes (Details 5)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_9b6438ac-a4af-4cb1-a7e8-04fc1dc8917f",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual",
     "longName": "995935 - Disclosure - Commitments and Contingencies (Details Textual)",
     "shortName": "Commitments and Contingencies (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "C_c45ae1f6-f871-404f-8826-2b495a729716",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_c45ae1f6-f871-404f-8826-2b495a729716",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesPaymentsOfOperatingLeaseLiabilityDetails",
     "longName": "995955 - Disclosure - Commitments and Contingencies - Payments of Operating Lease Liability (Details)",
     "shortName": "Commitments and Contingencies - Payments of Operating Lease Liability (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "C_4903df66-6bad-45f9-8151-6f6455ee1212",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4903df66-6bad-45f9-8151-6f6455ee1212",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://arcturusrx.com/20241231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails",
     "longName": "995965 - Disclosure - Segment Information - Additional Information (Details)",
     "shortName": "Segment Information - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "C_c45ae1f6-f871-404f-8826-2b495a729716",
      "name": "arct:NumberOfBusinessSegment",
      "unitRef": "U_Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_c45ae1f6-f871-404f-8826-2b495a729716",
      "name": "arct:NumberOfBusinessSegment",
      "unitRef": "U_Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://arcturusrx.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfReportedSegmentRevenuesSegmentLossAndIncomeAndSignificantSegmentExpensesDetails",
     "longName": "995975 - Disclosure - Segment Information - Summary of Reported Segment Revenues, Segment Loss and Income, and Significant Segment Expenses (Details)",
     "shortName": "Segment Information - Summary of Reported Segment Revenues, Segment Loss and Income, and Significant Segment Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "C_c45ae1f6-f871-404f-8826-2b495a729716",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_c45ae1f6-f871-404f-8826-2b495a729716",
      "name": "us-gaap:SegmentReportingOtherItemAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://arcturusrx.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfReportedSegmentRevenuesSegmentLossAndIncomeAndSignificantSegmentExpensesParentheticalDetails",
     "longName": "995985 - Disclosure - Segment Information - Summary of Reported Segment Revenues, Segment Loss and Income, and Significant Segment Expenses (Parenthetical) (Details)",
     "shortName": "Segment Information - Summary of Reported Segment Revenues, Segment Loss and Income, and Significant Segment Expenses (Parenthetical) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "C_652488b3-7499-4d63-b634-9c1ddc35880c",
      "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2d41c197-8a7f-4abe-8802-3f3779ba2106",
      "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "link:footnote",
       "p",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arct-20241231.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "arct_ADAIRTechnologyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "ADAIRTechnologyMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsEquityMethodInvestmentDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ADAIR Technology.",
        "label": "A D A I R Technology [Member]",
        "terseLabel": "ADAIR Technology [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingStandardsUpdate201912Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingStandardsUpdate201912Member",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASU 2019-12 [Member]",
        "label": "Accounting Standards Update 2019-12 [Member]",
        "documentation": "Accounting Standards Update 2019-12 Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes."
       }
      }
     },
     "auth_ref": [
      "r486",
      "r487"
     ]
    },
    "us-gaap_AccountingStandardsUpdate202307Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingStandardsUpdate202307Member",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update 2023-07 [Member]",
        "terseLabel": "ASU 2023-07 [Member]",
        "documentation": "Accounting Standards Update 2023-07 Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r260"
     ]
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureAccruedLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Liabilities Detail",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r59",
      "r64",
      "r1129"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Accounts Payable, Current, Total",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r897"
     ]
    },
    "us-gaap_AccountsReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable [Member]",
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold."
       }
      }
     },
     "auth_ref": [
      "r821"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Accounts Receivable, after Allowance for Credit Loss, Current, Total",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r1082"
     ]
    },
    "arct_AccruedCysticFibrosisFoundationLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "AccruedCysticFibrosisFoundationLiability",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureAccruedLiabilitiesDetailScheduleOfAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued cystic fibrosis foundation liability.",
        "label": "Accrued Cystic Fibrosis Foundation Liability",
        "terseLabel": "Cystic Fibrosis Foundation liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureAccruedLiabilitiesDetailScheduleOfAccruedLiabilitiesDetails",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued liabilities",
        "totalLabel": "Total",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Fair Value Disclosure",
        "terseLabel": "Accrued expenses",
        "documentation": "Fair value portion of accrued expenses."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r1146",
      "r1147",
      "r1151"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfComponentsOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance",
        "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance",
        "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less accumulated depreciation and amortization",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r144",
      "r676"
     ]
    },
    "arct_AchievedDevelopmentAndRegulatoryMilestoneIncludedAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "AchievedDevelopmentAndRegulatoryMilestoneIncludedAccountsReceivable",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Achieved development and regulatory milestone included accounts receivable",
        "label": "Achieved Development and Regulatory Milestone Included Accounts Receivable",
        "documentation": "Achieved development and regulatory milestone included accounts receivable."
       }
      }
     },
     "auth_ref": []
    },
    "arct_AchievedDevelopmentMilestoneIncludedAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "AchievedDevelopmentMilestoneIncludedAccountsReceivable",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Achieved development milestone included accounts receivable.",
        "label": "Achieved development milestone included accounts receivable",
        "terseLabel": "Achieved development milestone included accounts receivable"
       }
      }
     },
     "auth_ref": []
    },
    "arct_AcquiredInProcessResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "AcquiredInProcessResearchAndDevelopmentExpense",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityDetailsTextual",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquired In Process Research And Development Expense",
        "label": "Acquired In Process Research And Development Expense",
        "terseLabel": "Acquired in-process research and development expense",
        "verboseLabel": "Non-cash charge recorded in acquired in-process research and development expense"
       }
      }
     },
     "auth_ref": []
    },
    "arct_AcquisitionOfResearchAndDevelopmentInProcessThroughIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "AcquisitionOfResearchAndDevelopmentInProcessThroughIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquisition of research and development in process through issuance of common stock.",
        "label": "Acquisition Of Research And Development In Process Through Issuance Of Common Stock",
        "terseLabel": "Acquisition of in-process research and development through issuance of common stock"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r977"
     ]
    },
    "arct_AdditionalClinicalMilestonePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "AdditionalClinicalMilestonePayment",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional clinical milestone payment",
        "label": "Additional clinical milestone payment"
       }
      }
     },
     "auth_ref": []
    },
    "arct_AdditionalFinancialSupport": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "AdditionalFinancialSupport",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional financial support",
        "documentation": "Additional financial support"
       }
      }
     },
     "auth_ref": []
    },
    "arct_AdditionalMilestonePaymentsReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "AdditionalMilestonePaymentsReceived",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureOrganizationDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional milestone payments received.",
        "label": "Additional Milestone Payments Received",
        "terseLabel": "Additional milestone payments received"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Additional Paid in Capital, Total",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r897",
      "r1209"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r734",
      "r1070",
      "r1071",
      "r1072",
      "r1074",
      "r1145",
      "r1211"
     ]
    },
    "arct_AdditionalPaymentsUponMeetingCertainClinicalMilestones": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "AdditionalPaymentsUponMeetingCertainClinicalMilestones",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional payments upon meeting certain clinical milestones.",
        "label": "Additional Payments upon Meeting Certain Clinical Milestones",
        "terseLabel": "Additional payments upon meeting certain clinical milestones"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r990"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r990"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r990"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r990"
     ]
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update [Axis]",
        "terseLabel": "Accounting Standards Update",
        "documentation": "Information by amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r137",
      "r188",
      "r189",
      "r190",
      "r191",
      "r202",
      "r259",
      "r260",
      "r273",
      "r274",
      "r275",
      "r276",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r299",
      "r300",
      "r309",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r566",
      "r567",
      "r583",
      "r584",
      "r585",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r624",
      "r625",
      "r626",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Share-based compensation",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r46",
      "r407"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "arct_AdjustmentsToTransactionPrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "AdjustmentsToTransactionPrice",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to transaction price.",
        "label": "Adjustments To Transaction Price",
        "terseLabel": "Adjustments to transaction price"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r1035"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r948",
      "r959",
      "r969",
      "r1002"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r951",
      "r962",
      "r972",
      "r1005"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r1036"
     ]
    },
    "arct_AgreementAmountAgreedToFund": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "AgreementAmountAgreedToFund",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement amount agreed to fund.",
        "label": "Agreement Amount Agreed To Fund",
        "terseLabel": "Amount agreed to fund"
       }
      }
     },
     "auth_ref": []
    },
    "arct_AlexionPharmaceuticalsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "AlexionPharmaceuticalsIncMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Alexion Pharmaceuticals, Inc.",
        "label": "Alexion Pharmaceuticals Inc [Member]",
        "terseLabel": "Alexion [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r990"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r997"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r952",
      "r963",
      "r973",
      "r997",
      "r1006",
      "r1010",
      "r1018"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r1016"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureSharebasedCompensationDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Share-based compensation expenses",
        "verboseLabel": "Share-based compensation expenses",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r439",
      "r448"
     ]
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Accounts Receivable, Allowance for Credit Loss, Ending Balance",
        "periodStartLabel": "Accounts Receivable, Allowance for Credit Loss, Beginning Balance",
        "label": "Accounts Receivable, Allowance for Credit Loss",
        "terseLabel": "Allowance for Doubtful Accounts Receivable",
        "documentation": "Amount of allowance for credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r265",
      "r284",
      "r285",
      "r286",
      "r1176"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r210"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureDebtDetailsTextual",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual1",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r515"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r116",
      "r145",
      "r177",
      "r213",
      "r221",
      "r246",
      "r250",
      "r271",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r516",
      "r518",
      "r568",
      "r669",
      "r764",
      "r853",
      "r854",
      "r897",
      "r926",
      "r1096",
      "r1097",
      "r1163"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r152",
      "r177",
      "r271",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r516",
      "r518",
      "r568",
      "r897",
      "r1096",
      "r1097",
      "r1163"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Assets, Fair Value Disclosure, Total",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Assets, fair value",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r545",
      "r546",
      "r887"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r931",
      "r932",
      "r955"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r931",
      "r932",
      "r955"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r931",
      "r932",
      "r955"
     ]
    },
    "dei_AuditorOpinionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorOpinionTextBlock",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Opinion [Text Block]",
        "terseLabel": "Auditor Opinion"
       }
      }
     },
     "auth_ref": [
      "r1039"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r1013"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r1014"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r1009"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r1009"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r1009"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r1009"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r1009"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r1009"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureSharebasedCompensationDetails2",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationDetails",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationDetailsTextual",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r410",
      "r411",
      "r412",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r1012"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r1011"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r1010"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r1010"
     ]
    },
    "arct_BARDAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "BARDAMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfReportedSegmentRevenuesSegmentLossAndIncomeAndSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "BARDA [Member]",
        "documentation": "BARDA.",
        "terseLabel": "BARDA [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "arct_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "BiomedicalAdvancedResearchAndDevelopmentAuthorityMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueSummaryOfRevenuesDetails",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BARDA [Member]",
        "label": "Biomedical Advanced Research and Development Authority [Member]",
        "documentation": "Biomedical Advanced Research and Development Authority."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BorrowingsUnderGuaranteedInvestmentAgreements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BorrowingsUnderGuaranteedInvestmentAgreements",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureDebtDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Borrowings under Guaranteed Investment Agreements",
        "terseLabel": "Term loan draw down",
        "documentation": "Carrying value as of the balance sheet date of the sum of the obligations to contract holders to provide to them an agreed upon rate of return pursuant to the terms of the underlying contract. These contracts represent lending by the contract holders to the entity in return for a guaranteed (primarily fixed) interest rate until maturity, unless called earlier if the contracts provide that option to the contract holders (usually institutions). There is little or no insurance risk for the entity."
       }
      }
     },
     "auth_ref": [
      "r1174"
     ]
    },
    "us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessDescriptionAndAccountingPoliciesTextBlock",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureOrganization"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Description and Accounting Policies [Text Block]",
        "terseLabel": "Organization",
        "documentation": "The entire disclosure for the business description and accounting policies concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r88"
     ]
    },
    "stpr_CA": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2024",
     "localname": "CA",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CALIFORNIA",
        "terseLabel": "California [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "arct_COVIDNineteenVaccineDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "COVIDNineteenVaccineDevelopmentMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "COVID-19 vaccine development.",
        "label": "C O V I D Nineteen Vaccine Development [Member]",
        "terseLabel": "COVID-19 Vaccine Development [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "arct_CSLMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "CSLMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CSL [Member]",
        "label": "CSL [Member]",
        "documentation": "CSL."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase of property and equipment in accounts payable and accrued expenses",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r22",
      "r23"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r142",
      "r838"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Restricted Cash",
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r104"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureOrganizationDetailsTextual",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Cash, cash equivalents and restricted cash, end of year",
        "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of year",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "terseLabel": "Cash and cash equivalents, including restricted cash",
        "totalLabel": "Total cash, cash equivalents and restricted cash shown in the statement of cash flows",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r84",
      "r173"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net (decrease) increase in cash, cash equivalents and restricted cash",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r84"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Non-cash investing activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Accounting Principle, Accounting Standards Update, Adopted [true false]",
        "terseLabel": "Change in accounting principle, accounting standards update, adopted",
        "documentation": "Indicates (true false) whether accounting standards update was adopted."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r127",
      "r137",
      "r187",
      "r259",
      "r272",
      "r273",
      "r274",
      "r280",
      "r281",
      "r299",
      "r309",
      "r488",
      "r498",
      "r499",
      "r507",
      "r508",
      "r510",
      "r521",
      "r522",
      "r533",
      "r534",
      "r566",
      "r567",
      "r584",
      "r599",
      "r600",
      "r624",
      "r625",
      "r709",
      "r710"
     ]
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Accounting Principle, Accounting Standards Update, Adoption Date",
        "terseLabel": "Change in accounting principle, accounting standards update, adoption date",
        "documentation": "Date accounting standards update was adopted, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r127",
      "r137",
      "r259",
      "r272",
      "r273",
      "r274",
      "r280",
      "r281",
      "r282",
      "r299",
      "r309",
      "r488",
      "r498",
      "r499",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r520",
      "r521",
      "r522",
      "r523",
      "r533",
      "r534",
      "r535",
      "r538",
      "r566",
      "r567",
      "r584",
      "r599",
      "r600",
      "r624",
      "r625",
      "r709",
      "r710",
      "r1049"
     ]
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]",
        "terseLabel": "Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]",
        "documentation": "Indicates (true false) whether effect from applying amendment to accounting standards is immaterial."
       }
      }
     },
     "auth_ref": [
      "r188",
      "r201",
      "r277"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r988"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r985"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r983"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class Of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r149",
      "r150",
      "r215",
      "r362",
      "r363",
      "r364",
      "r366",
      "r369",
      "r374",
      "r376",
      "r725",
      "r726",
      "r727",
      "r728",
      "r869",
      "r1041",
      "r1065"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsEquityMethodInvestmentDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share price",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r377"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsEquityMethodInvestmentDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of warrants for shares of common stock",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r377"
     ]
    },
    "arct_ClinicalTrialAccrualsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "ClinicalTrialAccrualsCurrent",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureAccruedLiabilitiesDetailScheduleOfAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical trial accruals current.",
        "label": "Clinical Trial Accruals Current",
        "terseLabel": "Clinical trial accruals"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r989"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r989"
     ]
    },
    "arct_CollaborationAgreementConsiderationReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "CollaborationAgreementConsiderationReceived",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration agreement consideration received.",
        "label": "Collaboration Agreement Consideration Received",
        "terseLabel": "Consideration received"
       }
      }
     },
     "auth_ref": []
    },
    "arct_CollaborationAgreementContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "CollaborationAgreementContractualTerm",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration agreement contractual term.",
        "label": "Collaboration Agreement Contractual Term",
        "terseLabel": "Contractual term"
       }
      }
     },
     "auth_ref": []
    },
    "arct_CollaborationAgreementTransactionPrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "CollaborationAgreementTransactionPrice",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration agreement transaction price.",
        "label": "Collaboration Agreement Transaction Price",
        "terseLabel": "Transaction price"
       }
      }
     },
     "auth_ref": []
    },
    "arct_CollaborationPartnerCureVacEnteredIntoCoDevelopmentAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "CollaborationPartnerCureVacEnteredIntoCoDevelopmentAgreementMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Partner Cure Vac entered into Co-Development Agreement.",
        "label": "Collaboration Partner Cure Vac Entered Into Co Development Agreement [Member]",
        "terseLabel": "Collaboration Partner Cure Vac Entered Into Co Development Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "arct_CollaborationRevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "CollaborationRevenueMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueSummaryOfRevenuesDetails",
      "http://arcturusrx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaboration Revenue [Member]",
        "documentation": "Collaboration revenue."
       }
      }
     },
     "auth_ref": []
    },
    "arct_CommitmentAndContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "CommitmentAndContingenciesLineItems",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitment and contingencies.",
        "label": "Commitment And Contingencies [Line Items]",
        "terseLabel": "Commitment And Contingencies [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "arct_CommitmentAndContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "CommitmentAndContingenciesTable",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitment and contingencies.",
        "label": "Commitment And Contingencies [Table]",
        "terseLabel": "Commitment And Contingencies [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r313",
      "r314",
      "r822",
      "r1086",
      "r1091"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common stock reserved for future issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r917",
      "r918",
      "r919",
      "r921",
      "r922",
      "r923",
      "r924",
      "r1070",
      "r1071",
      "r1074",
      "r1145",
      "r1207",
      "r1211"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r752"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued",
        "verboseLabel": "Purchase of common stock, shares",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance",
        "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r70",
      "r752",
      "r770",
      "r1211",
      "r1212"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock: $0.001 par value; 60,000 shares authorized; issued and outstanding shares were 27,000 at December 31, 2024 and 26,828 at December 31, 2023",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r671",
      "r897"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r994"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r993"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r995"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r992"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive (loss) income",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r158",
      "r160",
      "r166",
      "r664",
      "r682",
      "r683"
     ]
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Income/Loss",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfComponentsOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer and software [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r48",
      "r49",
      "r258",
      "r821"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r48",
      "r49",
      "r258",
      "r722",
      "r821"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r48",
      "r49",
      "r258",
      "r821",
      "r1048"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk and Significant Customers",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r119"
     ]
    },
    "arct_ConcentrationRiskNumberOfCustomer": {
     "xbrltype": "integerItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "ConcentrationRiskNumberOfCustomer",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Concentration risk number of customer.",
        "label": "Concentration Risk Number Of Customer",
        "terseLabel": "Number of customers"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk, percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r48",
      "r49",
      "r258"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r48",
      "r49",
      "r258",
      "r821"
     ]
    },
    "arct_ConditionalPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "ConditionalPayment",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conditional payment",
        "label": "Conditional Payment",
        "documentation": "Conditional payment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation and Principles of Consolidation",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r842"
     ]
    },
    "us-gaap_ConstructionInProgressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConstructionInProgressMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfComponentsOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in progress [Member]",
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service."
       }
      }
     },
     "auth_ref": []
    },
    "arct_ContraExpenseIncludedInResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "ContraExpenseIncludedInResearchAndDevelopmentExpense",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contra expense included in research and development expense.",
        "label": "Contra Expense Included In Research And Development Expense",
        "terseLabel": "Contra expense included in research and development expense"
       }
      }
     },
     "auth_ref": []
    },
    "arct_ContraExpenseRemainingAmountIncludedInAccruedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "ContraExpenseRemainingAmountIncludedInAccruedExpenses",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contra expense remaining amount included in accrued expenses.",
        "label": "Contra Expense Remaining Amount Included In Accrued Expenses",
        "terseLabel": "Contra expense remaining amount included in accrued expenses"
       }
      }
     },
     "auth_ref": []
    },
    "arct_ContraResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "ContraResearchAndDevelopmentExpense",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contra research and development expense.",
        "label": "Contra Research And Development Expense",
        "terseLabel": "Contra research and development expense recognized"
       }
      }
     },
     "auth_ref": []
    },
    "arct_ContractWithCustomerAssetAdditions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "ContractWithCustomerAssetAdditions",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureRevenueSummaryOfChangesInBalancesOfReceivablesAndContractLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions",
        "label": "Contract With Customer Asset Additions",
        "documentation": "Contract with customer asset additions."
       }
      }
     },
     "auth_ref": []
    },
    "arct_ContractWithCustomerAssetAdditionsForRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "ContractWithCustomerAssetAdditionsForRevenueRecognized",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureRevenueSummaryOfChangesInBalancesOfReceivablesAndContractLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with customer asset additions for revenue recognized.",
        "label": "Contract With Customer Asset Additions For Revenue Recognized",
        "terseLabel": "Contract Assets, Additions for revenue recognized from billings"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Changes in Balances of Receivables and Contract Liability",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability."
       }
      }
     },
     "auth_ref": [
      "r1099"
     ]
    },
    "arct_ContractWithCustomerAssetDeductions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "ContractWithCustomerAssetDeductions",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureRevenueSummaryOfChangesInBalancesOfReceivablesAndContractLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract With Customer Asset Deductions",
        "documentation": "Contract with customer asset deductions.",
        "terseLabel": "Deductions"
       }
      }
     },
     "auth_ref": []
    },
    "arct_ContractWithCustomerAssetDeductionsForCashCollections": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "ContractWithCustomerAssetDeductionsForCashCollections",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureRevenueSummaryOfChangesInBalancesOfReceivablesAndContractLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with customer asset deductions for cash collections.",
        "label": "Contract With Customer Asset Deductions For Cash Collections",
        "terseLabel": "Contract Assets, Deductions for cash collections"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerAssetNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerAssetNet",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureRevenueSummaryOfChangesInBalancesOfReceivablesAndContractLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Accounts receivable, Balance",
        "periodStartLabel": "Accounts receivable, Balance",
        "totalLabel": "Contract with Customer, Asset, after Allowance for Credit Loss, Total",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss",
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time."
       }
      }
     },
     "auth_ref": [
      "r379",
      "r381",
      "r392"
     ]
    },
    "us-gaap_ContractWithCustomerDurationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerDurationAxis",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Duration [Axis]",
        "documentation": "Information by duration of contract with customer. Includes, but is not limited to, short-term and long-term contracts."
       }
      }
     },
     "auth_ref": [
      "r875",
      "r1100"
     ]
    },
    "us-gaap_ContractWithCustomerDurationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerDurationDomain",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Duration [Domain]",
        "documentation": "Duration of contract with customer. Includes, but is not limited to, short-term and long-term contracts."
       }
      }
     },
     "auth_ref": [
      "r875",
      "r1100"
     ]
    },
    "us-gaap_ContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiability",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureRevenueSummaryOfChangesInBalancesOfReceivablesAndContractLiabilityDetails",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Deferred revenue, Balance",
        "periodEndLabel": "Deferred revenue, Balance",
        "totalLabel": "Contract with Customer, Liability, Total",
        "label": "Contract with Customer, Liability",
        "terseLabel": "Deferred revenue",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r379",
      "r380",
      "r392"
     ]
    },
    "arct_ContractWithCustomerLiabilityAdditions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "ContractWithCustomerLiabilityAdditions",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureRevenueSummaryOfChangesInBalancesOfReceivablesAndContractLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions",
        "label": "Contract With Customer Liability Additions",
        "documentation": "Contract with customer liability additions."
       }
      }
     },
     "auth_ref": []
    },
    "arct_ContractWithCustomerLiabilityAdditionsForAdvancedBillings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "ContractWithCustomerLiabilityAdditionsForAdvancedBillings",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureRevenueSummaryOfChangesInBalancesOfReceivablesAndContractLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer Liability Additions For Advanced Billings",
        "label": "Contract With Customer Liability Additions For Advanced Billings",
        "terseLabel": "Contract Liabilities, Additions for advanced billings"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued liabilities paid upon occurrence of specified events",
        "label": "Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized",
        "documentation": "Amount of revenue recognized arising from contract liability from change in timeframe for performance obligation to be satisfied."
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureRevenueSummaryOfChangesInBalancesOfReceivablesAndContractLiabilityDetails",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Revenue recognized",
        "terseLabel": "Deductions",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due."
       }
      }
     },
     "auth_ref": [
      "r393"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureDebtDetailsTextual",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureOrganizationDetailsTextual",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual1",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueSummaryOfRevenuesDetails",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesDetailsTextual",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "auth_ref": [
      "r180",
      "r181",
      "r336",
      "r364",
      "r610",
      "r620",
      "r668",
      "r839",
      "r841"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "arct_Covid19VaccineMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "Covid19VaccineMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "COVID-19 Vaccine [Member]",
        "documentation": "COVID-19 vaccine."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CreditConcentrationRiskMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Concentration Risk [Member]",
        "terseLabel": "Credit Risk [Member]",
        "documentation": "Reflects the percentage that a specified receivable or amount at risk from a counterparty under a contractual arrangement is to a specified benchmark, such as total receivables, net revenues, pretax results. Risk is the materially adverse effects of loss attributable to (a) the failure to collect a significant receivable from a major customer or group of homogeneous accounts, or (b) a failure by a counterparty to perform under terms of a contractual arrangement."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "arct_CslCollaborationAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "CslCollaborationAgreementMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CSL Collaboration Agreement [Member]",
        "documentation": "CSL Collaboration Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "arct_CslSeqirusMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "CslSeqirusMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueSummaryOfRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CSL Seqirus [Member]",
        "label": "CSL Seqirus [Member]",
        "documentation": "CSL seqirus."
       }
      }
     },
     "auth_ref": []
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]",
        "terseLabel": "Cumulative Effect, Period of Adoption, Adjustment [Member]"
       }
      }
     },
     "auth_ref": [
      "r134",
      "r186",
      "r194",
      "r202",
      "r276",
      "r283",
      "r300",
      "r486",
      "r487",
      "r501",
      "r503",
      "r524",
      "r526",
      "r527",
      "r529",
      "r530",
      "r531",
      "r536",
      "r539",
      "r541",
      "r542",
      "r602"
     ]
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Axis]",
        "terseLabel": "Cumulative Effect, Period of Adoption"
       }
      }
     },
     "auth_ref": [
      "r134",
      "r186",
      "r194",
      "r202",
      "r276",
      "r283",
      "r300",
      "r486",
      "r487",
      "r501",
      "r503",
      "r524",
      "r526",
      "r527",
      "r529",
      "r530",
      "r531",
      "r536",
      "r539",
      "r541",
      "r542",
      "r602"
     ]
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Domain]",
        "terseLabel": "Cumulative Effect, Period of Adoption"
       }
      }
     },
     "auth_ref": [
      "r134",
      "r186",
      "r194",
      "r202",
      "r276",
      "r283",
      "r300",
      "r486",
      "r487",
      "r501",
      "r503",
      "r524",
      "r526",
      "r527",
      "r529",
      "r530",
      "r531",
      "r536",
      "r539",
      "r541",
      "r542",
      "r602"
     ]
    },
    "arct_CureVacAGMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "CureVacAGMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueSummaryOfRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CureVac AG.",
        "label": "Cure Vac A G [Member]",
        "terseLabel": "CureVac [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureIncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Current Federal Tax Expense (Benefit)",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1052",
      "r1068",
      "r1139"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentForeignTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureIncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign",
        "label": "Current Foreign Tax Expense (Benefit)",
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1052",
      "r1068"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureIncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Total current income tax (benefit) expense",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r485",
      "r1068"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureIncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current:",
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureIncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "Current State and Local Tax Expense (Benefit)",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1052",
      "r1068",
      "r1139"
     ]
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r258"
     ]
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r940",
      "r1029"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r940",
      "r1029"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r942",
      "r1031"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r942",
      "r1031"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r944",
      "r1033"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r942",
      "r1031"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r935",
      "r1024"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r936",
      "r1025"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r936",
      "r1025"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r934",
      "r1023"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r934",
      "r1023"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]"
       }
      }
     },
     "auth_ref": [
      "r934",
      "r1023"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r937",
      "r1026"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r939",
      "r1028"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r939",
      "r1028"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r940",
      "r1029"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r943",
      "r1032"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r941",
      "r1030"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r938",
      "r1027"
     ]
    },
    "arct_CysticFibrosisFoundationTherapeuticsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "CysticFibrosisFoundationTherapeuticsIncMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cystic Fibrosis Foundation Therapeutics, Inc.",
        "label": "Cystic Fibrosis Foundation Therapeutics Inc [Member]",
        "terseLabel": "Cystic Fibrosis Foundation [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureDebt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r175",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r321",
      "r322",
      "r332",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r348",
      "r355",
      "r356",
      "r358",
      "r581"
     ]
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureDebtDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Floating interest rate",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Interest of the prime rate plus",
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentCollateralAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentCollateralAmount",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureDebtDetailsTextual",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Collateral Amount",
        "terseLabel": "Debt instrument, collateral amount",
        "documentation": "Amount of assets pledged to secure a debt instrument."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "arct_DebtInstrumentExtendedTermPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "DebtInstrumentExtendedTermPeriod",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureDebtDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Extended Term Period",
        "documentation": "Debt instrument, extended term period.",
        "terseLabel": "Extended term period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureDebtDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Term loan",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r333",
      "r581",
      "r582",
      "r865",
      "r866",
      "r895"
     ]
    },
    "us-gaap_DebtInstrumentFeeAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFeeAmount",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureDebtDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fee payable",
        "label": "Debt Instrument, Fee Amount",
        "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureDebtDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Loan accrues interest rate per annum, percentage",
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r360",
      "r581",
      "r582",
      "r895"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureDebtDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r182",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r339",
      "r344",
      "r345",
      "r346",
      "r347",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r357",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r895",
      "r1066",
      "r1156",
      "r1157"
     ]
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentMaturityDate",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureDebtDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Maturity Date",
        "terseLabel": "Loan maturity date",
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r864",
      "r1149",
      "r1150"
     ]
    },
    "arct_DebtInstrumentOptionForRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "DebtInstrumentOptionForRenewalTerm",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureDebtDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument option for renewal term.",
        "label": "Debt Instrument Option for Renewal Term",
        "terseLabel": "Option for renewal term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureDebtDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Debt Instrument [Table]",
        "documentation": "Disclosure of information about long-term debt instrument or arrangement."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r38",
      "r41",
      "r52",
      "r97",
      "r98",
      "r182",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r339",
      "r344",
      "r345",
      "r346",
      "r347",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r357",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r895",
      "r1066",
      "r1156",
      "r1157"
     ]
    },
    "us-gaap_DebtInstrumentTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentTerm",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureDebtDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Term",
        "terseLabel": "Term of agreement",
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureIncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1068",
      "r1138",
      "r1139"
     ]
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureIncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1068",
      "r1138"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureIncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred income tax expense",
        "label": "Deferred Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r125",
      "r1068"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureIncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred:",
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureIncomeTaxesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total gross deferred tax liabilities",
        "totalLabel": "Total gross deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Gross",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r67",
      "r106",
      "r476"
     ]
    },
    "us-gaap_DeferredRevenueCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredRevenueCurrent",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred Revenue, Current, Total",
        "label": "Deferred Revenue, Current",
        "terseLabel": "Deferred revenue",
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r1056"
     ]
    },
    "us-gaap_DeferredRevenueNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredRevenueNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred Revenue, Noncurrent, Total",
        "label": "Deferred Revenue, Noncurrent",
        "terseLabel": "Deferred revenue, net of current portion",
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r1057"
     ]
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureIncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1068",
      "r1138",
      "r1139"
     ]
    },
    "arct_DeferredTaxAssetsCapitalizedResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "DeferredTaxAssetsCapitalizedResearchAndDevelopment",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureIncomeTaxesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized R&amp;D",
        "label": "Deferred Tax Assets Capitalized Research and Development",
        "documentation": "Deferred tax assets capitalized research and development."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsDeferredIncome",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureIncomeTaxesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Deferred Income",
        "terseLabel": "Deferred revenue",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income."
       }
      }
     },
     "auth_ref": [
      "r1136"
     ]
    },
    "us-gaap_DeferredTaxAssetsEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsEquityMethodInvestments",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureIncomeTaxesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Equity Method Investments",
        "terseLabel": "Basis difference in equity investments",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from equity method investments."
       }
      }
     },
     "auth_ref": [
      "r1136"
     ]
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureIncomeTaxesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total gross deferred tax assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r477"
     ]
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGrossAbstract",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureIncomeTaxesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsInventory": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsInventory",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureIncomeTaxesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Inventory",
        "terseLabel": "Inventory",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory."
       }
      }
     },
     "auth_ref": [
      "r1136"
     ]
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureIncomeTaxesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax asset",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r1134"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureIncomeTaxesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1136"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates."
       }
      }
     },
     "auth_ref": [
      "r1136"
     ]
    },
    "arct_DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureIncomeTaxesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets property, plant and equipment and intangible assets.",
        "label": "Deferred Tax Assets Property Plant And Equipment And Intangible Assets",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "auth_ref": []
    },
    "arct_DeferredTaxAssetsRightOfUseLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "DeferredTaxAssetsRightOfUseLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureIncomeTaxesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use lease liability",
        "label": "Deferred Tax Assets Right-of-use Lease Liability",
        "documentation": "Deferred tax assets right-of-use lease liability."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureIncomeTaxesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred Tax Assets, Tax Credit Carryforwards, Total",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "terseLabel": "Tax credits",
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1136"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureIncomeTaxesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Share-based compensation",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r1136"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureIncomeTaxesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities",
        "terseLabel": "Accrued liabilities",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities."
       }
      }
     },
     "auth_ref": [
      "r1136"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureIncomeTaxesDetails4",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r478"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesAbstract",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureIncomeTaxesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "arct_DeferredTaxLiabilitiesPropertyPlantAndEquipmentAndIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipmentAndIntangibleAssets",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureIncomeTaxesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets property, plant and equipment and intangible assets.",
        "label": "Deferred Tax Liabilities Property Plant And Equipment And Intangible Assets",
        "negatedLabel": "Depreciation and amortization"
       }
      }
     },
     "auth_ref": []
    },
    "arct_DeferredTaxLiabilitiesRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "DeferredTaxLiabilitiesRightOfUseAsset",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureIncomeTaxesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax liabilities, right-of-use asset.",
        "label": "Deferred Tax Liabilities Right Of Use Asset",
        "negatedLabel": "Right-of-use asset"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetDetailsTextual",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Depreciation, Depletion and Amortization, Nonproduction, Total",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r31"
     ]
    },
    "arct_DevelopmentAndOptionAgreementDate": {
     "xbrltype": "gYearMonthItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "DevelopmentAndOptionAgreementDate",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development and option agreement date.",
        "label": "Development And Option Agreement Date",
        "terseLabel": "Development and option agreement date"
       }
      }
     },
     "auth_ref": []
    },
    "arct_DevelopmentAndRegulatoryMilestonesAchieved": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "DevelopmentAndRegulatoryMilestonesAchieved",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Development and Regulatory Milestones Achieved",
        "documentation": "Development and regulatory milestones achieved.",
        "terseLabel": "Development and regulatory milestones achieved"
       }
      }
     },
     "auth_ref": []
    },
    "arct_DevelopmentMilestonesAchieved": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "DevelopmentMilestonesAchieved",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Development milestones achieved",
        "documentation": "Development milestones achieved.",
        "label": "Development Milestones Achieved"
       }
      }
     },
     "auth_ref": []
    },
    "arct_DevelopmentMilestonesAmountDueForAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "DevelopmentMilestonesAmountDueForAgreement",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Development milestones due",
        "label": "Development Milestones Amount Due for Agreement",
        "documentation": "Development milestones amount due for agreement."
       }
      }
     },
     "auth_ref": []
    },
    "arct_DevelopmentMilestonesReceivedAdvancePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "DevelopmentMilestonesReceivedAdvancePayment",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Development milestones received advance payment",
        "documentation": "Development milestones received advance payment.",
        "label": "Development Milestones Received Advance Payment"
       }
      }
     },
     "auth_ref": []
    },
    "arct_DirectorsOrOfficersExceptChiefScientificOfficerCooSvpCcAndPaoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "DirectorsOrOfficersExceptChiefScientificOfficerCooSvpCcAndPaoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Directors Or Officers Except Chief Scientific Officer, Coo, Svp, CC and Pao [Member]",
        "documentation": "Directors or officers except chief scientific officer, coo, svp, cc and pao.",
        "terseLabel": "Directors or Officers Except Chief Scientific Officer, COO, SVP, CC and PAO [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueLineItems",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueSummaryOfRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation Of Revenue [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r391",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueTable",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueSummaryOfRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation Of Revenue [Table]",
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r391",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Schedule of Revenue",
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r1100"
     ]
    },
    "arct_DisbursedAmountUponExecutionOfAmendment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "DisbursedAmountUponExecutionOfAmendment",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disbursed amount upon execution of amendment.",
        "label": "Disbursed Amount Upon Execution Of Amendment",
        "terseLabel": "Disbursed amount upon execution of amendment"
       }
      }
     },
     "auth_ref": []
    },
    "arct_DisbursementAmountPayableUponAchievementOfProjectGoal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "DisbursementAmountPayableUponAchievementOfProjectGoal",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disbursement amount payable upon achievement of project goal.",
        "label": "Disbursement Amount Payable Upon Achievement Of Project Goal",
        "terseLabel": "Disbursement amount payable upon achievement of project goal"
       }
      }
     },
     "auth_ref": []
    },
    "arct_DisbursementPaymentUponAchievementOfRequiredManufacturingPracticesAndINDApplication": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "DisbursementPaymentUponAchievementOfRequiredManufacturingPracticesAndINDApplication",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disbursement payment upon achievement of required manufacturing practices and IND application.",
        "label": "Disbursement Payment Upon Achievement Of Required Manufacturing Practices And I N D Application",
        "terseLabel": "Disbursement payment upon achievement of required manufacturing practices and IND application"
       }
      }
     },
     "auth_ref": []
    },
    "arct_DisbursementPeriodFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "DisbursementPeriodFourMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disbursement period four.",
        "label": "Disbursement Period Four [Member]",
        "terseLabel": "Disbursement Due October 2020 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "arct_DisbursementPeriodOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "DisbursementPeriodOneMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disbursement period one.",
        "label": "Disbursement Period One [Member]",
        "terseLabel": "Disbursement Due January 2020 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "arct_DisbursementPeriodThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "DisbursementPeriodThreeMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disbursement period three.",
        "label": "Disbursement Period Three [Member]",
        "terseLabel": "Disbursement Due July 2020 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "arct_DisbursementPeriodTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "DisbursementPeriodTwoMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disbursement period two.",
        "label": "Disbursement Period Two [Member]",
        "terseLabel": "Disbursement Due April 2020 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Share-Based Compensation",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r405",
      "r409",
      "r440",
      "r441",
      "r443",
      "r882"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "arct_DiscoveryTechnologiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "DiscoveryTechnologiesMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfReportedSegmentRevenuesSegmentLossAndIncomeAndSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discovery Technologies [Member]",
        "documentation": "Discovery technologies.",
        "terseLabel": "Discovery Technologies [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Dividends": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Dividends",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Dividends, Total",
        "label": "Dividends",
        "terseLabel": "Dividends declared or paid",
        "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r99"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r931",
      "r932",
      "r955"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Financial Statement Error Correction",
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r931",
      "r932",
      "r955",
      "r998"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r976"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents incorporated by reference",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic Tax Jurisdiction [Member]",
        "terseLabel": "Federal [Member]",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r458"
     ]
    },
    "arct_DrPadmanabhChivukulaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "DrPadmanabhChivukulaMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dr. Padmanabh Chivukula [Member]",
        "documentation": "Dr. Padmanabh Chivukula.",
        "terseLabel": "Dr. Padmanabh Chivukula [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r987"
     ]
    },
    "arct_Early-StageProgramsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "Early-StageProgramsMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfReportedSegmentRevenuesSegmentLossAndIncomeAndSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Early-Stage Programs [Member]",
        "label": "Early-Stage Programs [Member]",
        "documentation": "Early-Stage Programs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "(Loss) earnings per share:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic",
        "label": "Earnings Per Share, Basic",
        "totalLabel": "Earnings Per Share, Basic, Total",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r203",
      "r205",
      "r207",
      "r208",
      "r209",
      "r212",
      "r505",
      "r514",
      "r542",
      "r543",
      "r665",
      "r684",
      "r844"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted",
        "label": "Earnings Per Share, Diluted",
        "totalLabel": "Earnings Per Share, Diluted, Total",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r205",
      "r207",
      "r208",
      "r209",
      "r212",
      "r505",
      "r514",
      "r542",
      "r543",
      "r665",
      "r684",
      "r844"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net (Loss) Income per Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r25",
      "r211"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureIncomeTaxesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Provision for income taxes",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r458",
      "r886"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureIncomeTaxesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Federal statutory income tax rate",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r458",
      "r491",
      "r886"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureIncomeTaxesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r463",
      "r886",
      "r1069",
      "r1130"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureIncomeTaxesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent",
        "terseLabel": "Change in tax rate",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates."
       }
      }
     },
     "auth_ref": [
      "r462",
      "r886",
      "r1069",
      "r1130"
     ]
    },
    "arct_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensation": {
     "xbrltype": "percentItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensation",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureIncomeTaxesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax rate reconciliation nondeductible expense officers compensation.",
        "label": "Effective Income Tax Rate Reconciliation Nondeductible Expense Officers Compensation",
        "terseLabel": "Officers compensation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureIncomeTaxesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent",
        "terseLabel": "Share-based compensation",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r886",
      "r1069",
      "r1130",
      "r1132"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureIncomeTaxesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r886",
      "r1069",
      "r1130",
      "r1131"
     ]
    },
    "arct_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences": {
     "xbrltype": "percentItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureIncomeTaxesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Permanent differences",
        "label": "Effective Income Tax Rate Reconciliation Other Permanent Differences",
        "documentation": "Effective income tax rate reconciliation other permanent differences."
       }
      }
     },
     "auth_ref": []
    },
    "arct_EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentCredits": {
     "xbrltype": "percentItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentCredits",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureIncomeTaxesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development credits",
        "label": "Effective Income Tax Rate Reconciliation Research and Development Credits",
        "documentation": "Effective income tax rate reconciliation research and development credits."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureIncomeTaxesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State income taxes, net of federal benefit",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r461",
      "r886",
      "r1069",
      "r1130"
     ]
    },
    "arct_EffectiveIncomeTaxRateReconciliationUncertainTaxPosition": {
     "xbrltype": "percentItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "EffectiveIncomeTaxRateReconciliationUncertainTaxPosition",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureIncomeTaxesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax rate reconciliation uncertain tax position.",
        "label": "Effective Income Tax Rate Reconciliation Uncertain Tax Position",
        "terseLabel": "Uncertain tax position"
       }
      }
     },
     "auth_ref": []
    },
    "arct_EligibleToReceiveCommercialMilestonePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "EligibleToReceiveCommercialMilestonePayment",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Eligible to receive commercial milestone payment",
        "label": "Eligible to Receive Commercial Milestone Payment",
        "documentation": "Eligible to receive commercial milestone payment."
       }
      }
     },
     "auth_ref": []
    },
    "arct_EligibleToReceiveDevelopmentMilestonePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "EligibleToReceiveDevelopmentMilestonePayment",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Eligible to receive development milestone payment",
        "label": "Eligible to Receive Development Milestone Payment",
        "documentation": "Eligible to Receive Development Milestone Payment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureAccruedLiabilitiesDetailScheduleOfAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Employee-related Liabilities, Current, Total",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Compensation cost not yet recognized",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r442"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted-average remaining service period",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r442"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationDetails",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationDetailsTextual",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "arct_EmployeesAndOfficersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "EmployeesAndOfficersMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employees and officers.",
        "label": "Employees And Officers [Member]",
        "terseLabel": "Employees and Officers [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r928"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r928"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r928"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r1038"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r928"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r928"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r928"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r928"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r1040"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r981"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r1034"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r1034"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r1034"
     ]
    },
    "us-gaap_EquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquipmentMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfComponentsOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equipment [Member]",
        "terseLabel": "Research equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r134",
      "r162",
      "r163",
      "r164",
      "r183",
      "r184",
      "r185",
      "r189",
      "r196",
      "r198",
      "r200",
      "r214",
      "r276",
      "r283",
      "r300",
      "r378",
      "r486",
      "r487",
      "r501",
      "r502",
      "r503",
      "r506",
      "r513",
      "r514",
      "r524",
      "r526",
      "r527",
      "r528",
      "r529",
      "r531",
      "r541",
      "r573",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r584",
      "r586",
      "r604",
      "r681",
      "r711",
      "r712",
      "r713",
      "r734",
      "r796"
     ]
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "EquityMethodInvesteeNameDomain",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsEquityMethodInvestmentDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name"
       }
      }
     },
     "auth_ref": [
      "r268",
      "r269",
      "r270",
      "r497",
      "r1043",
      "r1044",
      "r1045",
      "r1140",
      "r1141",
      "r1142",
      "r1143"
     ]
    },
    "us-gaap_EquityMethodInvestmentAggregateCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestmentAggregateCost",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investment, Aggregate Cost",
        "terseLabel": "Investment in joint venture",
        "documentation": "This element represents the aggregate cost of investments accounted for under the equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestmentNonconsolidatedInvesteeAxis",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsEquityMethodInvestmentDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investment, Nonconsolidated Investee [Axis]",
        "terseLabel": "Equity Method Investment, Nonconsolidated Investee",
        "documentation": "Information by nonconsolidated equity method investee. Excludes information consolidated by reporting entity."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r177",
      "r271",
      "r568",
      "r627",
      "r628",
      "r633",
      "r640",
      "r647",
      "r648",
      "r659",
      "r661",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909"
     ]
    },
    "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestmentNonconsolidatedInvesteeDomain",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsEquityMethodInvestmentDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investment, Nonconsolidated Investee [Domain]",
        "terseLabel": "Equity Method Investment, Nonconsolidated Investee",
        "documentation": "Nonconsolidated equity method investee. Excludes information consolidated by reporting entity."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r177",
      "r271",
      "r568",
      "r627",
      "r628",
      "r633",
      "r640",
      "r647",
      "r648",
      "r659",
      "r661",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909"
     ]
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsEquityMethodInvestmentDetailsTextual",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Equity method ownership percentage",
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r268"
     ]
    },
    "us-gaap_EquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestments",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investments",
        "terseLabel": "Equity-method investment",
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized."
       }
      }
     },
     "auth_ref": [
      "r213",
      "r231",
      "r250",
      "r267",
      "r1054",
      "r1084"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r991"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r948",
      "r959",
      "r969",
      "r1002"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r945",
      "r956",
      "r966",
      "r999"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r997"
     ]
    },
    "arct_ExpirationOfIntialTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "ExpirationOfIntialTerm",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration of initial term.",
        "label": "Expiration Of Intial Term",
        "terseLabel": "Expiration of initial term"
       }
      }
     },
     "auth_ref": []
    },
    "arct_FacilitiesAndEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "FacilitiesAndEquipmentMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfReportedSegmentRevenuesSegmentLossAndIncomeAndSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Facilities and Equipment [Member]",
        "documentation": "Facilities and equipment.",
        "terseLabel": "Facilities and Equipment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r545",
      "r546",
      "r559",
      "r887"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r545",
      "r546",
      "r559",
      "r887"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Domain]",
        "documentation": "Class of asset."
       }
      }
     },
     "auth_ref": [
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r560",
      "r889"
     ]
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByAssetClassAxis",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Axis]",
        "documentation": "Information by class of asset."
       }
      }
     },
     "auth_ref": [
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r560",
      "r889"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r346",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r544",
      "r546",
      "r547",
      "r548",
      "r549",
      "r558",
      "r559",
      "r561",
      "r615",
      "r616",
      "r617",
      "r865",
      "r866",
      "r878",
      "r879",
      "r880",
      "r887",
      "r891"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r545",
      "r546",
      "r547",
      "r549",
      "r887",
      "r1149",
      "r1152"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r554",
      "r556",
      "r557",
      "r558",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r662",
      "r887",
      "r892"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r346",
      "r396",
      "r401",
      "r546",
      "r559",
      "r615",
      "r878",
      "r879",
      "r880",
      "r887"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r545",
      "r546",
      "r547",
      "r549",
      "r887",
      "r1149",
      "r1152"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r346",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r544",
      "r546",
      "r547",
      "r548",
      "r549",
      "r558",
      "r559",
      "r561",
      "r615",
      "r616",
      "r617",
      "r865",
      "r866",
      "r878",
      "r879",
      "r880",
      "r887",
      "r891"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recurring [Member]",
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r887",
      "r1146",
      "r1147",
      "r1148",
      "r1149",
      "r1150",
      "r1152"
     ]
    },
    "arct_FebruaryTwoThousandAndTwentyLeaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "FebruaryTwoThousandAndTwentyLeaseAgreementMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "February two thousand and twenty lease agreement.",
        "label": "February Two Thousand And Twenty Lease Agreement [Member]",
        "terseLabel": "February 2020 Lease Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "arct_FebruaryTwoThousandAndTwentyOneLeaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "FebruaryTwoThousandAndTwentyOneLeaseAgreementMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "February two thousand and twenty one lease agreement.",
        "label": "February Two Thousand And Twenty One Lease Agreement [Member]",
        "terseLabel": "February 2021 Lease Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "arct_FinalPaymentOfDisbursementAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "FinalPaymentOfDisbursementAmount",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Final payment of disbursement amount.",
        "label": "Final Payment Of Disbursement Amount",
        "terseLabel": "Final payment of disbursement amount"
       }
      }
     },
     "auth_ref": []
    },
    "arct_ForeignCountriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "ForeignCountriesMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign countries.",
        "label": "Foreign Countries [Member]",
        "terseLabel": "Foreign Countries [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign currency transaction (loss) gain",
        "totalLabel": "Foreign Currency Transaction Gain (Loss), before Tax, Total",
        "terseLabel": "Foreign currency transaction gain",
        "verboseLabel": "Loss from foreign currency",
        "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r569",
      "r570",
      "r571",
      "r572",
      "r793"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionGainLossRealized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionGainLossRealized",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Realized Gain (Loss), Foreign Currency Transaction, before Tax",
        "negatedLabel": "Foreign currency transaction loss",
        "documentation": "Amount, before tax, of realized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r772",
      "r925",
      "r1154",
      "r1155",
      "r1210"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r952",
      "r963",
      "r973",
      "r1006"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r952",
      "r963",
      "r973",
      "r1006"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r952",
      "r963",
      "r973",
      "r1006"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r952",
      "r963",
      "r973",
      "r1006"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r952",
      "r963",
      "r973",
      "r1006"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r986"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfComponentsOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Office equipment and furniture [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfReportedSegmentRevenuesSegmentLossAndIncomeAndSignificantSegmentExpensesParentheticalDetails",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://arcturusrx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gain (Loss) on Extinguishment of Debt, Total",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "terseLabel": "Gain on debt extinguishment",
        "negatedLabel": "Gain on debt extinguishment",
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r34",
      "r35"
     ]
    },
    "arct_GeneralAndAdministrativeCostsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "GeneralAndAdministrativeCostsPolicyPolicyTextBlock",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Costs Policy [Policy Text Block]",
        "documentation": "General and administrative costs.",
        "terseLabel": "General and Administrative Costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfReportedSegmentRevenuesSegmentLossAndIncomeAndSignificantSegmentExpensesDetails",
      "http://arcturusrx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "General and Administrative Expense, Total",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative",
        "negatedLabel": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r775"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureSharebasedCompensationDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillImpairmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill, Impairment Loss",
        "terseLabel": "Impairment losses",
        "documentation": "Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r287",
      "r293",
      "r297",
      "r862",
      "r888"
     ]
    },
    "us-gaap_GrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GrantMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueSummaryOfRevenuesDetails",
      "http://arcturusrx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grant Revenue [Member]",
        "label": "Grant [Member]",
        "documentation": "Award of money not required to be repaid."
       }
      }
     },
     "auth_ref": [
      "r1101"
     ]
    },
    "arct_GrantOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "GrantOneMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant one.",
        "label": "Grant One [Member]",
        "terseLabel": "Grant 1 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "arct_GrantReceivableNumberOfInstallments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "GrantReceivableNumberOfInstallments",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant receivable number of installments.",
        "label": "Grant Receivable Number Of Installments",
        "terseLabel": "Grant, number of installments"
       }
      }
     },
     "auth_ref": []
    },
    "arct_GrantRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "GrantRevenue",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total grant revenue",
        "label": "Grant Revenue",
        "documentation": "Grant revenue."
       }
      }
     },
     "auth_ref": []
    },
    "arct_GrantRevenueOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "GrantRevenueOutstanding",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grant revenue outstanding",
        "label": "Grant Revenue Outstanding",
        "documentation": "Grant revenue outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "arct_GrantTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "GrantTwoMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant two.",
        "label": "Grant Two [Member]",
        "terseLabel": "Grant 2 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GrantsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GrantsReceivable",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grants Receivable",
        "terseLabel": "Grants Receivable",
        "documentation": "Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants."
       }
      }
     },
     "auth_ref": [
      "r1058"
     ]
    },
    "arct_GriBioIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "GriBioIncMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsEquityMethodInvestmentDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GRI Bio Inc.",
        "label": "GRI Bio Inc Member",
        "terseLabel": "GRI Bio [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "stpr_IL": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2024",
     "localname": "IL",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ILLINOIS",
        "terseLabel": "Israeli Ministry of Health (\"MOH\") [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r931",
      "r932",
      "r955"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "United States",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r457"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Net (loss) income before income taxes",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r110",
      "r115",
      "r666",
      "r679",
      "r846",
      "r853",
      "r1075",
      "r1077",
      "r1078",
      "r1079",
      "r1080"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Foreign",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r457"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "totalLabel": "Total (loss) income before income taxes",
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r685",
      "r846",
      "r1075",
      "r1077",
      "r1078",
      "r1079",
      "r1080"
     ]
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromEquityMethodInvestments",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://arcturusrx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Equity Method Investments",
        "negatedLabel": "Loss from equity-method investment",
        "verboseLabel": "Loss from equity-method investment",
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss)."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r77",
      "r109",
      "r213",
      "r228",
      "r250",
      "r267",
      "r678"
     ]
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureSharebasedCompensationDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "terseLabel": "Income Statement Location",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r301",
      "r308",
      "r310",
      "r551",
      "r555",
      "r560",
      "r706",
      "r708",
      "r780",
      "r834",
      "r890",
      "r1178"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureSharebasedCompensationDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Domain]",
        "terseLabel": "Income Statement Location",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r308",
      "r310",
      "r551",
      "r555",
      "r560",
      "r706",
      "r708",
      "r780",
      "r834",
      "r890",
      "r1178"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Axis]",
        "terseLabel": "Income Tax Authority",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r458",
      "r459",
      "r468",
      "r482",
      "r886",
      "r1135"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Domain]",
        "terseLabel": "Income Tax Authority",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r458",
      "r459",
      "r468",
      "r482",
      "r886",
      "r1135"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r452",
      "r458",
      "r464",
      "r465",
      "r466",
      "r473",
      "r480",
      "r492",
      "r494",
      "r495",
      "r496",
      "r730",
      "r886"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureIncomeTaxesDetails2",
      "http://arcturusrx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit)",
        "totalLabel": "Total income tax (benefit) expense",
        "terseLabel": "(Benefit) provision for income taxes",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r128",
      "r199",
      "r200",
      "r213",
      "r229",
      "r250",
      "r456",
      "r458",
      "r493",
      "r686",
      "r886"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Tax Expense",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r454",
      "r455",
      "r473",
      "r474",
      "r479",
      "r484",
      "r724"
     ]
    },
    "arct_IncomeTaxesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "IncomeTaxesLineItems",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income taxes.",
        "label": "Income Taxes [Line Items]",
        "terseLabel": "Income Taxes [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes Paid, Net",
        "totalLabel": "Income Taxes Paid, Net, Total",
        "terseLabel": "Cash paid for income taxes",
        "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r172",
      "r481",
      "r482"
     ]
    },
    "arct_IncomeTaxesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "IncomeTaxesTable",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income taxes.",
        "label": "Income Taxes [Table]",
        "terseLabel": "Income Taxes [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts payable",
        "totalLabel": "Increase (Decrease) in Accounts Payable, Total",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Increase (Decrease) in Accrued Liabilities, Total",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Deferred revenue",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r622",
      "r1063"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities",
        "negatedLabel": "Lease liabilities",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r1051",
      "r1063"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "arct_IncreaseDecreaseOperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "IncreaseDecreaseOperatingLeaseRightOfUseAsset",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Right-of-use assets",
        "terseLabel": "Right-of-use assets",
        "label": "Increase Decrease Operating Lease, Right Of Use Asset",
        "documentation": "Increase decrease operating lease, right of use asset."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r952",
      "r963",
      "r973",
      "r997",
      "r1006",
      "r1010",
      "r1018"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r1016"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r933",
      "r1022"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r933",
      "r1022"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r933",
      "r1022"
     ]
    },
    "us-gaap_InterestExpenseLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseLongTermDebt",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureDebtDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Interest Expense, Long-Term Debt, Total",
        "label": "Interest Expense, Long-Term Debt",
        "terseLabel": "Interest expense related to long-term debt",
        "documentation": "Aggregate amount of interest paid or due on all long-term debt."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r130",
      "r131"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r170",
      "r171"
     ]
    },
    "us-gaap_InventoryCashFlowPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryCashFlowPolicy",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Cash Flow Policy [Policy Text Block]",
        "terseLabel": "Statement of Cash Flows",
        "documentation": "Disclosure of accounting policy for determining where the cash flows related to the sale of inventory are classified in the statements of cash flows and explain the nature of the receivables, notes, and loans."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_InvestmentOwnedBalanceShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentOwnedBalanceShares",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsEquityMethodInvestmentDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Owned, Balance, Shares",
        "terseLabel": "Number of shares owned",
        "documentation": "Number of shares of investment owned."
       }
      }
     },
     "auth_ref": [
      "r736",
      "r742",
      "r805",
      "r812",
      "r816",
      "r919"
     ]
    },
    "us-gaap_InvestmentOwnedPercentOfNetAssets": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentOwnedPercentOfNetAssets",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsEquityMethodInvestmentDetailsTextual",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Owned, Net Assets, Percentage",
        "terseLabel": "Percentage of owned shares",
        "documentation": "Percentage of investment owned to net assets."
       }
      }
     },
     "auth_ref": [
      "r738",
      "r740",
      "r741",
      "r806",
      "r811",
      "r813",
      "r814",
      "r817",
      "r919",
      "r1208"
     ]
    },
    "arct_IsraelMinistryOfHealthMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "IsraelMinistryOfHealthMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueSummaryOfRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Israel Ministry of Health [Member]",
        "label": "Israel Ministry of Health [Member]",
        "documentation": "Israel ministry of health."
       }
      }
     },
     "auth_ref": []
    },
    "arct_JanssenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "JanssenMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual1",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueSummaryOfRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Janssen.",
        "label": "Janssen [Member]",
        "terseLabel": "Janssen [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "arct_JointVenturesEquityMethodInvestmentsAndVariableInterestEntitiesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "JointVenturesEquityMethodInvestmentsAndVariableInterestEntitiesPolicyTextBlock",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Joint ventures, equity method investments and variable interest entities.",
        "label": "Joint Ventures Equity Method Investments And Variable Interest Entities Policy [Text Block]",
        "terseLabel": "Joint Ventures, Equity Method Investments and Variable Interest Entities"
       }
      }
     },
     "auth_ref": []
    },
    "arct_KeithCKummerfeldMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "KeithCKummerfeldMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Keith C. Kummerfeld [Member]",
        "documentation": "Keith C. Kummerfeld.",
        "terseLabel": "Keith C. Kummerfeld [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "arct_LUNAR-CFNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "LUNAR-CFNetMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfReportedSegmentRevenuesSegmentLossAndIncomeAndSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LUNAR-CF, Net [Member]",
        "documentation": "LUNAR-CF, net.",
        "terseLabel": "LUNAR-CF, Net [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "arct_LUNAR-COVIDMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "LUNAR-COVIDMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfReportedSegmentRevenuesSegmentLossAndIncomeAndSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LUNAR-COVID [Member]",
        "documentation": "LUNAR-COVID.",
        "terseLabel": "LUNAR-COVID [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "arct_LUNAR-OTCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "LUNAR-OTCMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfReportedSegmentRevenuesSegmentLossAndIncomeAndSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LUNAR-OTC [Member]",
        "documentation": "LUNAR-OTC.",
        "terseLabel": "LUNAR-OTC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "arct_LUNARCFMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "LUNARCFMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "LUNAR-CF.",
        "label": "L U N A R C F [Member]",
        "terseLabel": "LUNAR-CF [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "arct_LackOfMarketabilityDiscountRestrictedPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "LackOfMarketabilityDiscountRestrictedPeriod",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lack of marketability discount restricted period.",
        "label": "Lack Of Marketability Discount Restricted Period",
        "terseLabel": "Lack of marketability discount restricted period"
       }
      }
     },
     "auth_ref": []
    },
    "arct_LanceKurataMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "LanceKurataMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lance Kurata [Member]",
        "documentation": "Lance Kurata."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseContractualTermAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseContractualTermAxis",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Contractual Term [Axis]",
        "documentation": "Information by contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r598",
      "r1050"
     ]
    },
    "us-gaap_LeaseContractualTermDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseContractualTermDomain",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Contractual Term [Domain]",
        "documentation": "Contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r598",
      "r1050"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfComponentsOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r597"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "arct_LegalAccrualCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "LegalAccrualCurrent",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureAccruedLiabilitiesDetailScheduleOfAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal accrual",
        "label": "Legal Accrual Current",
        "documentation": "Legal accrual current."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r590"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "terseLabel": "Payments of Operating Lease Liability",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1160"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesPaymentsOfOperatingLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total remaining lease payments",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r596"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesPaymentsOfOperatingLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r596"
     ]
    },
    "arct_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesPaymentsOfOperatingLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Lessee Operating Lease Liability Payments Due After Year Four",
        "documentation": "Lessee operating lease liability payments due after year four."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesPaymentsOfOperatingLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r596"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesPaymentsOfOperatingLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r596"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesPaymentsOfOperatingLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2028",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r596"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesPaymentsOfOperatingLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r596"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesPaymentsOfOperatingLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r596"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesPaymentsOfOperatingLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: imputed interest",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r596"
     ]
    },
    "us-gaap_LesseeOperatingLeaseOptionToExtend": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseOptionToExtend",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Option to Extend",
        "terseLabel": "Lessee, operating leases, option to extend",
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability."
       }
      }
     },
     "auth_ref": [
      "r591"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Operating lease extended additional term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1159"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lessee, operating lease, term of contract",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1159"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r58",
      "r59",
      "r60",
      "r63",
      "r64",
      "r65",
      "r68",
      "r177",
      "r271",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r517",
      "r518",
      "r519",
      "r568",
      "r751",
      "r845",
      "r926",
      "r1096",
      "r1163",
      "r1164"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r108",
      "r673",
      "r897",
      "r1067",
      "r1085",
      "r1153"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities and Stockholders' Equity",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r141",
      "r177",
      "r271",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r517",
      "r518",
      "r519",
      "r568",
      "r897",
      "r1096",
      "r1163",
      "r1164"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityCommitmentFeePercentage",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureDebtDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility, Commitment Fee Percentage",
        "terseLabel": "Non-refundable commitment fee, percentage",
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityCurrentBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureDebtDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility, Current Borrowing Capacity",
        "terseLabel": "Revolving credit line available",
        "documentation": "Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r62"
     ]
    },
    "us-gaap_LineOfCreditFacilityInterestRateDuringPeriod": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityInterestRateDuringPeriod",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureDebtDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility, Interest Rate During Period",
        "terseLabel": "Loans interest rate, percentage",
        "documentation": "The effective interest rate during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r62"
     ]
    },
    "arct_LiquidityPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "LiquidityPolicyPolicyTextBlock",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liquidity.",
        "label": "Liquidity Policy Policy [Text Block]",
        "terseLabel": "Liquidity"
       }
      }
     },
     "auth_ref": []
    },
    "arct_LoanAndSecurityAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "LoanAndSecurityAgreementMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureDebtDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loan and security agreement.",
        "label": "Loan And Security Agreement [Member]",
        "terseLabel": "Loan and Security Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermContractWithCustomerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermContractWithCustomerMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Term Contract with Customer [Member]",
        "label": "Long-Term Contract with Customer [Member]",
        "documentation": "Contract with customer in which duration is classified as long-term."
       }
      }
     },
     "auth_ref": [
      "r875"
     ]
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureDebtDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt",
        "terseLabel": "Long-term debt",
        "totalLabel": "Total",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r107",
      "r345",
      "r359",
      "r865",
      "r866",
      "r895",
      "r1173"
     ]
    },
    "us-gaap_LongTermDebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtCurrent",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Long-Term Debt, Current Maturities, Total",
        "label": "Long-Term Debt, Current Maturities",
        "terseLabel": "Current portion of long-term debt",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r146"
     ]
    },
    "us-gaap_LongTermDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureDebtDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt [Member]",
        "terseLabel": "Long-term Debt [Member]",
        "documentation": "Debt arrangement having an initial term longer than one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureDebtDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r1087",
      "r1088",
      "r1089"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureDebtDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r33",
      "r1087",
      "r1088",
      "r1089"
     ]
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingency Nature [Axis]",
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r315",
      "r316",
      "r317",
      "r320",
      "r449",
      "r721",
      "r863",
      "r1092",
      "r1093"
     ]
    },
    "us-gaap_LossContingencyNatureDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingencyNatureDomain",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingency, Nature [Domain]",
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability."
       }
      }
     },
     "auth_ref": [
      "r315",
      "r316",
      "r317",
      "r320",
      "r449",
      "r721",
      "r863",
      "r1092",
      "r1093"
     ]
    },
    "arct_MRNATechnologyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "MRNATechnologyMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "mRNA technology.",
        "label": "M R N A Technology [Member]",
        "terseLabel": "mRNA Technology [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "arct_ManufacturingAndSupplyOfArct154DrugProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "ManufacturingAndSupplyOfArct154DrugProductMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "manufacturing and supply of ARCT-154 drug product.",
        "label": "Manufacturing and Supply of ARCT-154 Drug Product [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureDebtDetailsTextual",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsEquityMethodInvestmentDetailsTextual",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationDetailsTextual",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r316",
      "r317",
      "r318",
      "r319",
      "r403",
      "r449",
      "r549",
      "r621",
      "r705",
      "r707",
      "r721",
      "r743",
      "r744",
      "r804",
      "r807",
      "r809",
      "r810",
      "r815",
      "r832",
      "r833",
      "r861",
      "r869",
      "r881",
      "r891",
      "r892",
      "r893",
      "r894",
      "r911",
      "r1098",
      "r1165",
      "r1166",
      "r1167",
      "r1168",
      "r1169",
      "r1170"
     ]
    },
    "arct_MaximumPercentageOfLikelihoodOfUncertainTaxPositionRecognizedToBeSustained": {
     "xbrltype": "percentItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "MaximumPercentageOfLikelihoodOfUncertainTaxPositionRecognizedToBeSustained",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum percentage of likelihood of uncertain tax position recognized to be sustained.",
        "label": "Maximum Percentage Of Likelihood Of Uncertain Tax Position Recognized To Be Sustained",
        "terseLabel": "Maximum percentage of likelihood of uncertain tax position recognized to be sustained"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r989"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r989"
     ]
    },
    "arct_MilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "MilestonePayments",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payments",
        "documentation": "Milestone payments.",
        "label": "Milestone Payments"
       }
      }
     },
     "auth_ref": []
    },
    "arct_MinimumAmountAgreedToIncurUnderResearchPlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "MinimumAmountAgreedToIncurUnderResearchPlan",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum amount agreed to incur under research plan.",
        "label": "Minimum Amount Agreed to Incur Under Research Plan",
        "terseLabel": "Minimum amount agreed to incur under research plan"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureDebtDetailsTextual",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsEquityMethodInvestmentDetailsTextual",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationDetailsTextual",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r316",
      "r317",
      "r318",
      "r319",
      "r403",
      "r449",
      "r549",
      "r621",
      "r705",
      "r707",
      "r721",
      "r743",
      "r744",
      "r804",
      "r807",
      "r809",
      "r810",
      "r815",
      "r832",
      "r833",
      "r861",
      "r869",
      "r881",
      "r891",
      "r892",
      "r893",
      "r911",
      "r1098",
      "r1165",
      "r1166",
      "r1167",
      "r1168",
      "r1169",
      "r1170"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r1009"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r1102"
     ]
    },
    "arct_MonthlyBaseRent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "MonthlyBaseRent",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Monthly base rent.",
        "label": "Monthly Base Rent",
        "terseLabel": "Monthly base rent"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r1017"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r990"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by (used in) financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r169"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r169"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash (used in) provided by operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r85",
      "r86"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfReportedSegmentRevenuesSegmentLossAndIncomeAndSignificantSegmentExpensesDetails",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://arcturusrx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "negatedLabel": "Net income (loss)",
        "totalLabel": "Net (loss) income",
        "verboseLabel": "Net (loss) income",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r86",
      "r111",
      "r139",
      "r156",
      "r159",
      "r164",
      "r177",
      "r188",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r199",
      "r200",
      "r206",
      "r271",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r505",
      "r514",
      "r543",
      "r568",
      "r680",
      "r773",
      "r794",
      "r795",
      "r925",
      "r1096"
     ]
    },
    "arct_NetOperatingLossAndResearchAndDevelopmentCreditCarryforwardsLimitationsOnCumulativeChangeInOwnershipMinimumPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "NetOperatingLossAndResearchAndDevelopmentCreditCarryforwardsLimitationsOnCumulativeChangeInOwnershipMinimumPercentage",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net operating loss and research and development credit carryforwards limitations on cumulative change in ownership minimum percentage.",
        "label": "Net Operating Loss And Research And Development Credit Carryforwards Limitations On Cumulative Change In Ownership Minimum Percentage",
        "terseLabel": "Net Operating Loss and Research and Development Credit Carryforwards Limitations On Cumulative Change In Ownership Minimum Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "arct_NetOperatingLossAndResearchAndDevelopmentCreditCarryforwardsLimitationsOnCumulativeChangeInOwnershipPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "NetOperatingLossAndResearchAndDevelopmentCreditCarryforwardsLimitationsOnCumulativeChangeInOwnershipPeriod",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net operating loss and research and development credit carryforwards limitations on cumulative change in ownership period.",
        "label": "Net Operating Loss And Research And Development Credit Carryforwards Limitations On Cumulative Change In Ownership Period",
        "terseLabel": "Net Operating Loss and Research and Development Credit Carryforwards Limitations on Cumulative Change In Ownership Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncements and Recently Issued Accounting Standards Not Yet Adopted",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "arct_NonCashAssetDisposal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "NonCashAssetDisposal",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash asset disposal",
        "label": "Non - Cash Asset Disposal",
        "documentation": "Non-Cash Asset Disposal"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r989"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r952",
      "r963",
      "r973",
      "r997",
      "r1006"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r980"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r979"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r997"
     ]
    },
    "arct_NonRareDiseaseTargetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "NonRareDiseaseTargetsMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-rare disease targets.",
        "label": "Non Rare Disease Targets [Member]",
        "terseLabel": "Non-Rare Disease Targets [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "arct_NonRefundablePaymentReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "NonRefundablePaymentReceived",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-refundable payment received.",
        "label": "Non Refundable Payment Received",
        "terseLabel": "Non-refundable payment received"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r1017"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r1017"
     ]
    },
    "arct_NotSubjectToExpirationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "NotSubjectToExpirationMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Not Subject to Expiration [Member]",
        "documentation": "Not subject to expiration."
       }
      }
     },
     "auth_ref": []
    },
    "arct_NumberOfBusinessSegment": {
     "xbrltype": "integerItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "NumberOfBusinessSegment",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Business Segment",
        "documentation": "Number of business segment.",
        "terseLabel": "Number of business segment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments for research and development",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r854",
      "r1076"
     ]
    },
    "arct_NumberOfPerformanceObligations": {
     "xbrltype": "integerItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "NumberOfPerformanceObligations",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of performance obligations.",
        "label": "Number Of Performance Obligations",
        "terseLabel": "Number of performance obligations"
       }
      }
     },
     "auth_ref": []
    },
    "arct_NumberOfReserveTargets": {
     "xbrltype": "integerItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "NumberOfReserveTargets",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of reserve targets.",
        "label": "Number Of Reserve Targets",
        "terseLabel": "Number of targets"
       }
      }
     },
     "auth_ref": []
    },
    "arct_NumberOfReservedVaccineDoses": {
     "xbrltype": "integerItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "NumberOfReservedVaccineDoses",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of reserved vaccine doses.",
        "label": "Number Of Reserved Vaccine Doses",
        "terseLabel": "Number of reserved vaccine doses"
       }
      }
     },
     "auth_ref": []
    },
    "arct_OctoberTwoThousandAndSeventeenLeaseAmendmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "OctoberTwoThousandAndSeventeenLeaseAmendmentMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "October 2017 lease amendment.",
        "label": "October Two Thousand And Seventeen Lease Amendment [Member]",
        "terseLabel": "October 2017 Lease Amendment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss)",
        "terseLabel": "Loss from operations",
        "totalLabel": "(Loss) income from operations",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r846",
      "r1075",
      "r1077",
      "r1078",
      "r1079",
      "r1080"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease costs",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r592",
      "r896"
     ]
    },
    "us-gaap_OperatingLeaseImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseImpairmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Impairment Loss",
        "terseLabel": "Impairment loss",
        "documentation": "Amount of loss from impairment of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r1158"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesPaymentsOfOperatingLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating Lease, Liability, Total",
        "label": "Operating Lease, Liability",
        "verboseLabel": "Total operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r588"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureAccruedLiabilitiesDetailScheduleOfAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion of operating lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r588"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureAccruedLiabilitiesDetailScheduleOfAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r589"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liability, net of current portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r588"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use asset, net",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r587"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesPaymentsOfOperatingLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r595",
      "r896"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesPaymentsOfOperatingLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term (in years)",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r594",
      "r896"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r483"
     ]
    },
    "arct_OperatingLossCarryforwardsExpirationYear": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "OperatingLossCarryforwardsExpirationYear",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards expiration year.",
        "label": "Operating Loss Carryforwards Expiration Year",
        "terseLabel": "Operating Loss Carryforwards Expiration Year"
       }
      }
     },
     "auth_ref": []
    },
    "arct_OptionExerciseFeeRevenueReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "OptionExerciseFeeRevenueReceived",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Option exercise fee revenue received.",
        "label": "Option Exercise Fee Revenue Received",
        "terseLabel": "Option exercise fee received"
       }
      }
     },
     "auth_ref": []
    },
    "arct_OptionExerciseRevenueRangePerTarget": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "OptionExerciseRevenueRangePerTarget",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Option exercise revenue range per target.",
        "label": "Option Exercise Revenue Range Per Target",
        "terseLabel": "Option exercise revenue range per target"
       }
      }
     },
     "auth_ref": []
    },
    "arct_OptionToExtendInitialTermOnAnAnnualBasis": {
     "xbrltype": "durationItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "OptionToExtendInitialTermOnAnAnnualBasis",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Option to extend initial term on an annual basis.",
        "label": "Option To Extend Initial Term On An Annual Basis",
        "terseLabel": "Option to extend initial term on an annual basis"
       }
      }
     },
     "auth_ref": []
    },
    "arct_OptionToPurchaseOfAdditionalSharesOfCommonStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "OptionToPurchaseOfAdditionalSharesOfCommonStock",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Option to purchase of additional shares of common stock.",
        "label": "Option To Purchase Of Additional Shares Of Common Stock",
        "terseLabel": "Purchase of additional shares of common stock"
       }
      }
     },
     "auth_ref": []
    },
    "arct_OptionToPurchaseOfAdditionalSharesOfCommonStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "OptionToPurchaseOfAdditionalSharesOfCommonStockPricePerShare",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Option to purchase of additional shares of common stock price per share.",
        "label": "Option To Purchase Of Additional Shares Of Common Stock Price Per Share",
        "terseLabel": "Purchase of additional shares of common stock price per share"
       }
      }
     },
     "auth_ref": []
    },
    "arct_OrganizationAndSignificantAccountingPoliciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "OrganizationAndSignificantAccountingPoliciesLineItems",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureOrganizationDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization and significant accounting policies line items.",
        "label": "Organization And Significant Accounting Policies [Line Items]",
        "terseLabel": "Organization And Significant Accounting Policies [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "arct_OrganizationAndSignificantAccountingPoliciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "OrganizationAndSignificantAccountingPoliciesTable",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureOrganizationDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization and significant accounting policies.",
        "label": "Organization And Significant Accounting Policies [Table]",
        "terseLabel": "Organization And Significant Accounting Policies [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "arct_OrphanDrugCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "OrphanDrugCreditMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Orphan drug credit.",
        "label": "Orphan Drug Credit [Member]",
        "terseLabel": "Orphan Drug Credit [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "arct_OtherAccruedResearchAndDevelopmentExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "OtherAccruedResearchAndDevelopmentExpenses",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureAccruedLiabilitiesDetailScheduleOfAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other accrued research and development expenses.",
        "label": "Other Accrued Research And Development Expenses",
        "terseLabel": "Other accrued research and development expenses"
       }
      }
     },
     "auth_ref": []
    },
    "arct_OtherCollaborationAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "OtherCollaborationAgreementsMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other collaboration agreements.",
        "label": "Other Collaboration Agreements [Member]",
        "terseLabel": "Other Collaboration Agreements [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax, Total",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax",
        "terseLabel": "Income tax effect related to unrealized losses on marketable securities",
        "documentation": "Amount, after adjustment, of tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r154",
      "r155"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other Comprehensive Income (Loss), Net of Tax, Total",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "verboseLabel": "Other comprehensive loss",
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r12",
      "r157",
      "r160",
      "r165",
      "r196",
      "r573",
      "r574",
      "r579",
      "r663",
      "r681",
      "r1059",
      "r1060"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-current liabilities",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "arct_OtherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "OtherMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueSummaryOfRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other.",
        "label": "Other [Member]",
        "terseLabel": "Other [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNoncashIncomeExpense",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-cash expenses",
        "totalLabel": "Other Noncash Income (Expense), Total",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other non-cash expenses",
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other Nonoperating Income (Expense), Total",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Finance income (expense), net",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r989"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r950",
      "r961",
      "r971",
      "r1004"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r953",
      "r964",
      "r974",
      "r1007"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r953",
      "r964",
      "r974",
      "r1007"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r978"
     ]
    },
    "arct_PaymentReceivedFirstInstallment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "PaymentReceivedFirstInstallment",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment received first installment.",
        "label": "Payment Received First Installment",
        "terseLabel": "Received first installment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForAdvanceToAffiliate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForAdvanceToAffiliate",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for Advance to Affiliate",
        "terseLabel": "Payments for advance",
        "documentation": "The cash outflow from advancing money to an affiliate (an entity that is related but not strictly controlled by the entity)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "arct_PaymentsForMatchingFundsForRemainingBudgetedCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "PaymentsForMatchingFundsForRemainingBudgetedCosts",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments for matching funds for remaining budgeted costs.",
        "label": "Payments For Matching Funds For Remaining Budgeted Costs",
        "terseLabel": "Payments for matching funds for remaining budgeted costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForProceedsFromTenantAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForProceedsFromTenantAllowance",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for (Proceeds from) Tenant Allowance",
        "terseLabel": "Tenant improvement allowance",
        "documentation": "Net cash outflow or inflow from monetary allowance granted by the landlord to a tenant to entice tenant to move into landlords building which will enable the tenant to prepare the leased premises for tenants occupancy."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r81"
     ]
    },
    "us-gaap_PaymentsToAcquireInterestInJointVenture": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireInterestInJointVenture",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Interest in Joint Venture",
        "terseLabel": "Cash consideration paid for equity interest in joint venture",
        "documentation": "The cash outflow associated with the investment in or advances to an entity in which the reporting entity shares control of the entity with another party or group."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Acquisition of property and equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "arct_PayrollAndBenefitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "PayrollAndBenefitsMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfReportedSegmentRevenuesSegmentLossAndIncomeAndSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payroll and Benefits [Member]",
        "documentation": "Payroll and benefits.",
        "terseLabel": "Payroll and Benefits [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r988"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r988"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r980"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r997"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r990"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r979"
     ]
    },
    "arct_PercentageOfEquityInterestInJointVenture": {
     "xbrltype": "percentItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "PercentageOfEquityInterestInJointVenture",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of equity interest in joint venture.",
        "label": "Percentage Of Equity Interest In Joint Venture",
        "terseLabel": "Percentage of equity interest in joint venture"
       }
      }
     },
     "auth_ref": []
    },
    "arct_PercentageOfNetProfits": {
     "xbrltype": "percentItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "PercentageOfNetProfits",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net profits percentage",
        "label": "Percentage Of Net Profits",
        "documentation": "Percentage of net profits."
       }
      }
     },
     "auth_ref": []
    },
    "arct_PharmaceuticalCompanyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "PharmaceuticalCompanyMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pharmaceutical company.",
        "label": "Pharmaceutical Company [Member]",
        "terseLabel": "Pharmaceutical Company [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "arct_PhaseIClinicalStudyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "PhaseIClinicalStudyMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Phase I clinical study.",
        "label": "Phase I Clinical Study [Member]",
        "terseLabel": "Phase I Clinical Study [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1127",
      "r1128"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1127",
      "r1128"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r981"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r1037"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r980"
     ]
    },
    "arct_PotentialTargetLicenseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "PotentialTargetLicenseTerm",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential target license term.",
        "label": "Potential Target License Term",
        "terseLabel": "Potential target license term"
       }
      }
     },
     "auth_ref": []
    },
    "arct_PreLaunchInventoryPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "PreLaunchInventoryPolicyPolicyTextBlock",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre-launch inventory policy.",
        "label": "Pre Launch Inventory Policy Policy [Text Block]",
        "terseLabel": "Pre-Launch Inventory"
       }
      }
     },
     "auth_ref": []
    },
    "arct_PrepaidExpensesAndOtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "PrepaidExpensesAndOtherReceivables",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer. as well as trade accounts receivable, notes and loans receivable.",
        "label": "Prepaid Expenses And Other Receivables",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsEquityMethodInvestmentDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Private Placement [Member]",
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfDebt",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Debt",
        "terseLabel": "Proceeds from debt",
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt."
       }
      }
     },
     "auth_ref": [
      "r1061"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r10"
     ]
    },
    "us-gaap_ProceedsFromStockPlans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromStockPlans",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Stock Plans",
        "terseLabel": "Proceeds from issuance of common stock under equity plans",
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueSummaryOfRevenuesDetails",
      "http://arcturusrx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "auth_ref": [
      "r254",
      "r623",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r836",
      "r871",
      "r910",
      "r911",
      "r912",
      "r915",
      "r916",
      "r1094",
      "r1095",
      "r1100",
      "r1177",
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1185",
      "r1186",
      "r1187",
      "r1188",
      "r1189",
      "r1190",
      "r1191",
      "r1192",
      "r1193",
      "r1194",
      "r1195",
      "r1196",
      "r1197",
      "r1198",
      "r1199",
      "r1200",
      "r1201",
      "r1202",
      "r1203",
      "r1204",
      "r1205",
      "r1206"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueSummaryOfRevenuesDetails",
      "http://arcturusrx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "auth_ref": [
      "r254",
      "r623",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r836",
      "r871",
      "r910",
      "r911",
      "r912",
      "r915",
      "r916",
      "r1094",
      "r1095",
      "r1100",
      "r1177",
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1185",
      "r1186",
      "r1187",
      "r1188",
      "r1189",
      "r1190",
      "r1191",
      "r1192",
      "r1193",
      "r1194",
      "r1195",
      "r1196",
      "r1197",
      "r1198",
      "r1199",
      "r1200",
      "r1201",
      "r1202",
      "r1203",
      "r1204",
      "r1205",
      "r1206"
     ]
    },
    "us-gaap_PropertyLeaseGuaranteeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyLeaseGuaranteeMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property Lease Guarantee [Member]",
        "terseLabel": "Property Leases in San Diego [Member]",
        "documentation": "A guarantee of performance by a third party lessee under terms of a lease agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfComponentsOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r597"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment, Net",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r120",
      "r123",
      "r124"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfComponentsOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance",
        "totalLabel": "Property, Plant and Equipment, Gross, Total",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r143",
      "r677"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfComponentsOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property Plant And Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r597"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfComponentsOfPropertyAndEquipmentNetDetails",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r597",
      "r667",
      "r677",
      "r897"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment, net",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r120",
      "r123",
      "r675"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Components of Property and Equipment, Net",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfComponentsOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r597"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property and equipment, useful lives",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r978"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r978"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureDebtDetailsTextual",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsEquityMethodInvestmentDetailsTextual",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationDetailsTextual",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "auth_ref": [
      "r316",
      "r317",
      "r318",
      "r319",
      "r395",
      "r403",
      "r435",
      "r436",
      "r437",
      "r449",
      "r549",
      "r618",
      "r619",
      "r621",
      "r705",
      "r707",
      "r721",
      "r743",
      "r744",
      "r804",
      "r807",
      "r809",
      "r810",
      "r815",
      "r832",
      "r833",
      "r861",
      "r869",
      "r881",
      "r891",
      "r892",
      "r893",
      "r894",
      "r911",
      "r919",
      "r1090",
      "r1098",
      "r1149",
      "r1166",
      "r1167",
      "r1168",
      "r1169",
      "r1170"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureDebtDetailsTextual",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsEquityMethodInvestmentDetailsTextual",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationDetailsTextual",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "auth_ref": [
      "r316",
      "r317",
      "r318",
      "r319",
      "r395",
      "r403",
      "r435",
      "r436",
      "r437",
      "r449",
      "r549",
      "r618",
      "r619",
      "r621",
      "r705",
      "r707",
      "r721",
      "r743",
      "r744",
      "r804",
      "r807",
      "r809",
      "r810",
      "r815",
      "r832",
      "r833",
      "r861",
      "r869",
      "r881",
      "r891",
      "r892",
      "r893",
      "r894",
      "r911",
      "r919",
      "r1090",
      "r1098",
      "r1149",
      "r1166",
      "r1167",
      "r1168",
      "r1169",
      "r1170"
     ]
    },
    "arct_RareDiseaseTargetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "RareDiseaseTargetsMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rare disease targets.",
        "label": "Rare Disease Targets [Member]",
        "terseLabel": "Rare Disease Targets [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReceivablesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReceivablesPolicyTextBlock",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivable [Policy Text Block]",
        "terseLabel": "Accounts Receivable",
        "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable."
       }
      }
     },
     "auth_ref": [
      "r262",
      "r263",
      "r264",
      "r266",
      "r1083"
     ]
    },
    "arct_RecognizedContraExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "RecognizedContraExpense",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recognized contra expense.",
        "label": "Recognized Contra Expense",
        "terseLabel": "Contra expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r945",
      "r956",
      "r966",
      "r999"
     ]
    },
    "arct_ReductionInNumberOfCommonStockCapitalSharesAvailableForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "ReductionInNumberOfCommonStockCapitalSharesAvailableForFutureIssuance",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reduction in number of common stock shares available for future issuance",
        "label": "Reduction in Number of Common Stock Capital Shares Available for Future Issuance",
        "documentation": "Reduction in number of common stock capital shares available for future issuance."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Domain]",
        "terseLabel": "Related Party",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r261",
      "r402",
      "r608",
      "r609",
      "r670",
      "r674",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r769",
      "r771",
      "r803"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsEquityMethodInvestmentDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r261",
      "r776",
      "r777",
      "r780"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "terseLabel": "Related Party",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r261",
      "r402",
      "r608",
      "r609",
      "r670",
      "r674",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r769",
      "r771",
      "r803",
      "r1162"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r605",
      "r606",
      "r607",
      "r609",
      "r611",
      "r731",
      "r732",
      "r733",
      "r778",
      "r779",
      "r780",
      "r800",
      "r802"
     ]
    },
    "arct_RemainingLoanIncludingAccruedInterestForgiveable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "RemainingLoanIncludingAccruedInterestForgiveable",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureDebtDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining loan including accrued interest forgiveable",
        "label": "Remaining Loan Including Accrued Interest Forgiveable",
        "documentation": "Remaining loan including accrued interest forgiveable."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RepaymentsOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfDebt",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayments of Debt",
        "negatedLabel": "Payments on debt obligations",
        "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation."
       }
      }
     },
     "auth_ref": [
      "r1062"
     ]
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfLongTermDebt",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureDebtDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repayment of term loan",
        "label": "Repayments of Long-Term Debt",
        "totalLabel": "Repayments of Long-Term Debt, Total",
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r728"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureDebtDetailsTextual",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureOrganizationDetailsTextual",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual1",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueSummaryOfRevenuesDetails",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesDetailsTextual",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "auth_ref": [
      "r180",
      "r181",
      "r336",
      "r364",
      "r610",
      "r620",
      "r668",
      "r840",
      "r841"
     ]
    },
    "arct_RepyamentOfPrincipalAndInterestOnCollateralizedTermLoan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "RepyamentOfPrincipalAndInterestOnCollateralizedTermLoan",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureDebtDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repyament of Principal and Interest on Collateralized Term Loan",
        "documentation": "Repayment of principal and interest on collateralized term loan.",
        "terseLabel": "Repayament of principal and interest on collateralized term loan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfReportedSegmentRevenuesSegmentLossAndIncomeAndSignificantSegmentExpensesDetails",
      "http://arcturusrx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Research and Development Expense, Total",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development, net",
        "verboseLabel": "Total research and development",
        "negatedLabel": "Total research and development",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r451",
      "r834",
      "r853",
      "r1171"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureSharebasedCompensationDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs, net",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r450"
     ]
    },
    "arct_ResearchCollaborationAndExclusiveLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "ResearchCollaborationAndExclusiveLicenseAgreementMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research Collaboration and Exclusive License Agreement.",
        "label": "Research Collaboration And Exclusive License Agreement [Member]",
        "terseLabel": "Research Collaboration And Exclusive License Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "arct_ResearchCollaborationAndLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "ResearchCollaborationAndLicenseAgreementMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research collaboration and license agreement.",
        "label": "Research Collaboration And License Agreement [Member]",
        "terseLabel": "Research Collaboration And License Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research Tax Credit Carryforward [Member]",
        "terseLabel": "Research Tax Credit Carryforward [Member]",
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes."
       }
      }
     },
     "auth_ref": [
      "r1135"
     ]
    },
    "arct_ReservedUpfrontPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "ReservedUpfrontPayment",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reserved upfront payment",
        "label": "Reserved Upfront Payment",
        "documentation": "Reserved upfront payment."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r946",
      "r957",
      "r967",
      "r1000"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r947",
      "r958",
      "r968",
      "r1001"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r954",
      "r965",
      "r975",
      "r1008"
     ]
    },
    "us-gaap_RestrictedCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCash",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Restricted Cash, Total",
        "label": "Restricted Cash",
        "terseLabel": "Restricted cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r1053",
      "r1064",
      "r1172",
      "r1175"
     ]
    },
    "us-gaap_RestrictedCashCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashCurrent",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash, Current",
        "terseLabel": "Restricted cash - current",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r1053",
      "r1064"
     ]
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesDetailsTextual",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Non-current Restricted cash",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Non-current restricted cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r1055",
      "r1064"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureSharebasedCompensationDetails2",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureOrganizationDetailsTextual",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit",
        "negatedLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r99",
      "r672",
      "r715",
      "r720",
      "r729",
      "r753",
      "r897"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r183",
      "r184",
      "r185",
      "r189",
      "r196",
      "r198",
      "r200",
      "r276",
      "r283",
      "r300",
      "r486",
      "r487",
      "r501",
      "r502",
      "r503",
      "r506",
      "r513",
      "r514",
      "r524",
      "r527",
      "r528",
      "r531",
      "r541",
      "r584",
      "r586",
      "r711",
      "r713",
      "r734",
      "r1211"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfReportedSegmentRevenuesSegmentLossAndIncomeAndSignificantSegmentExpensesDetails",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureOrganizationDetailsTextual",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueSummaryOfRevenuesDetails",
      "http://arcturusrx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaboration revenue",
        "terseLabel": "Revenue",
        "verboseLabel": "Total revenue",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r114",
      "r213",
      "r222",
      "r223",
      "r244",
      "r250",
      "r254",
      "r256",
      "r258",
      "r390",
      "r391",
      "r623"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenue",
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r394"
     ]
    },
    "arct_RevenueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "RevenueLineItems",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue.",
        "label": "Revenue [Line Items]",
        "terseLabel": "Revenue [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenuePracticalExpedientRemainingPerformanceObligationDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenuePracticalExpedientRemainingPerformanceObligationDescription",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue, Practical Expedient, Remaining Performance Obligation, Description",
        "terseLabel": "Revenue, practical expedient description",
        "documentation": "Description of consideration that is not included in transaction price and not allocated to remaining performance obligation. Includes, but is not limited to, variable consideration that is constrained."
       }
      }
     },
     "auth_ref": [
      "r389"
     ]
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r774",
      "r835",
      "r843"
     ]
    },
    "arct_RevenueRecognitionPotentialMilestoneRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "RevenueRecognitionPotentialMilestoneRevenueRecognized",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue recognition potential milestone revenue recognized.",
        "label": "Revenue Recognition Potential Milestone Revenue Recognized",
        "terseLabel": "Revenue recognition potential milestone revenue recognized"
       }
      }
     },
     "auth_ref": []
    },
    "arct_RevenueRecognitionReserveTargetExclusivityPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "RevenueRecognitionReserveTargetExclusivityPeriod",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue recognition reserve target exclusivity period.",
        "label": "Revenue Recognition Reserve Target Exclusivity Period",
        "terseLabel": "Revenue recognition, reserve target exclusivity period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRemainingPerformanceObligation",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Remaining performance obligation",
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue."
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period",
        "terseLabel": "Remaining research period",
        "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date",
        "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "arct_RevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "RevenueTable",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue.",
        "label": "Revenue [Table]",
        "terseLabel": "Revenue [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue:",
        "label": "Revenues [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "arct_ReversalOfRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "ReversalOfRevenue",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reversal of revenue",
        "label": "Reversal of Revenue",
        "documentation": "Reversal of revenue."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets acquired through operating leases",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r593",
      "r896"
     ]
    },
    "arct_RoyaltyPaymentTermDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "RoyaltyPaymentTermDescription",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty payment term description.",
        "label": "Royalty Payment Term Description",
        "terseLabel": "Royalty payment term description"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r1017"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r1017"
     ]
    },
    "country_SG": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "SG",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfReportedSegmentRevenuesSegmentLossAndIncomeAndSignificantSegmentExpensesParentheticalDetails",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureDebtDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SINGAPORE",
        "terseLabel": "Singapore Economic Development Board [Member]",
        "verboseLabel": "Singapore Loan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "arct_SGIMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "SGIMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueSummaryOfRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SGI.",
        "label": "S G I [Member]",
        "terseLabel": "SGI [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockConsiderationReceivedPerTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockConsiderationReceivedPerTransaction",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Consideration Received Per Transaction",
        "terseLabel": "Consideration received for common stock purchase",
        "documentation": "Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureOrganizationDetailsTextual",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsEquityMethodInvestmentDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsEquityMethodInvestmentDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity method investment, sale of common stock",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalesRevenueNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SalesRevenueNetMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Revenue [Member]",
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r258",
      "r1047"
     ]
    },
    "srt_ScenarioForecastMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioForecastMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]"
       }
      }
     },
     "auth_ref": [
      "r404",
      "r1073"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario"
       }
      }
     },
     "auth_ref": [
      "r202",
      "r404",
      "r1042",
      "r1073"
     ]
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureAccruedLiabilitiesDetailTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Liabilities",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Cash and Cash Equivalents and Restricted Cash",
        "documentation": "Tabular disclosure of the components of cash and cash equivalents."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]",
        "terseLabel": "Schedule of Share-based Compensation Expenses",
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Summary of Reconciliation of Income Tax (Benefit) Expense",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r1137"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Significant Components of Deferred Income Taxes",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1134"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Reconciliation of Federal Statutory Income Tax Rate to Company's Effective Income Tax Rate",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r460",
      "r886",
      "r1130"
     ]
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsEquityMethodInvestmentDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment, Name"
       }
      }
     },
     "auth_ref": [
      "r268",
      "r269",
      "r270",
      "r497",
      "r1043",
      "r1044",
      "r1045",
      "r1140",
      "r1141",
      "r1142",
      "r1143"
     ]
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Summary of Reconciliation of (Loss) Income Before Income Taxes for Domestic and Foreign Locations",
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions."
       }
      }
     },
     "auth_ref": [
      "r1068"
     ]
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureDebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]",
        "terseLabel": "Schedule of Maturities of Long-term Debt",
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfComponentsOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r597"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsEquityMethodInvestmentDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Table]",
        "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]",
        "documentation": "Disclosure of information about related party transaction."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r51",
      "r776",
      "r777",
      "r780"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfReportedSegmentRevenuesSegmentLossAndIncomeAndSignificantSegmentExpensesDetails",
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfReportedSegmentRevenuesSegmentLossAndIncomeAndSignificantSegmentExpensesParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r30"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureSegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Summary of Reported Segment Revenues, Segment Loss and Income, and Significant Segment Expenses",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r30"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureSharebasedCompensationDetails2",
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureSharebasedCompensationDetails3",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationDetails",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r406",
      "r408",
      "r410",
      "r411",
      "r412",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Summary of Restricted Stock Unit, Activity",
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Share Option Activity",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r9",
      "r100"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Weighted Average Assumptions Used in Black -Scholes Valuation Model",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock, Class of Stock [Table]",
        "terseLabel": "Schedule Of Stock By Class [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r37",
      "r38",
      "r39",
      "r40",
      "r41",
      "r95",
      "r97",
      "r98",
      "r99",
      "r148",
      "r149",
      "r150",
      "r215",
      "r362",
      "r363",
      "r364",
      "r366",
      "r369",
      "r374",
      "r376",
      "r725",
      "r726",
      "r727",
      "r728",
      "r869",
      "r1041",
      "r1065"
     ]
    },
    "arct_ScheduleOfSummaryOfSignificantAccountingPoliciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "ScheduleOfSummaryOfSignificantAccountingPoliciesTable",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of summary of significant accounting policies.",
        "label": "Schedule Of Summary Of Significant Accounting Policies [Table]",
        "terseLabel": "Schedule Of Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Summary of Reconciliation of Unrecognized Tax Benefits",
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r469",
      "r885"
     ]
    },
    "us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureDebtDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SOFR [Member]",
        "label": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]",
        "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap that has its variable-rate leg referenced to Secured Overnight Financing Rate (SOFR) with no additional spread over SOFR on variable-rate leg."
       }
      }
     },
     "auth_ref": [
      "r1144"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r927"
     ]
    },
    "us-gaap_SecurityDeposit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SecurityDeposit",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Deposit",
        "terseLabel": "Security deposit",
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease."
       }
      }
     },
     "auth_ref": [
      "r1055"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentDomain",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfReportedSegmentRevenuesSegmentLossAndIncomeAndSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r114",
      "r115",
      "r116",
      "r213",
      "r217",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r234",
      "r235",
      "r236",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r250",
      "r251",
      "r252",
      "r258",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r298",
      "r311",
      "r312",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r849",
      "r853",
      "r854",
      "r862",
      "r914",
      "r1177",
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1185",
      "r1186",
      "r1187",
      "r1188",
      "r1189",
      "r1190",
      "r1191",
      "r1192",
      "r1193",
      "r1194",
      "r1195",
      "r1196",
      "r1197",
      "r1198",
      "r1199",
      "r1200",
      "r1201",
      "r1202",
      "r1203",
      "r1204",
      "r1205",
      "r1206"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfReportedSegmentRevenuesSegmentLossAndIncomeAndSignificantSegmentExpensesParentheticalDetails",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureDebtDetailsTextual",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetailsTextual",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical"
       }
      }
     },
     "auth_ref": [
      "r256",
      "r257",
      "r627",
      "r629",
      "r630",
      "r631",
      "r632",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r737",
      "r739",
      "r741",
      "r806",
      "r808",
      "r813",
      "r817",
      "r820",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r837",
      "r872",
      "r899",
      "r900",
      "r901",
      "r902",
      "r904",
      "r906",
      "r907",
      "r908",
      "r913",
      "r919",
      "r1100",
      "r1177",
      "r1179",
      "r1180",
      "r1182",
      "r1183",
      "r1184",
      "r1185",
      "r1186",
      "r1187",
      "r1188",
      "r1189",
      "r1190",
      "r1191",
      "r1192",
      "r1193",
      "r1194",
      "r1195",
      "r1196",
      "r1197",
      "r1198",
      "r1199",
      "r1200",
      "r1201",
      "r1202",
      "r1203",
      "r1204",
      "r1205",
      "r1206"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]",
        "documentation": "Indicates title and position of individual or name of group identified as chief operating decision maker (CODM) for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r220",
      "r852",
      "r860"
     ]
    },
    "us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingCodmProfitLossMeasureHowUsedDescription",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description",
        "documentation": "Description of how chief operating decision maker (CODM) uses reported segment profit (loss) measure to assess performance and allocate resource."
       }
      }
     },
     "auth_ref": [
      "r243",
      "r849",
      "r857"
     ]
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureSegmentInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segment Information",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r213",
      "r216",
      "r217",
      "r218",
      "r219",
      "r221",
      "r233",
      "r235",
      "r236",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r254",
      "r255",
      "r258",
      "r847",
      "r850",
      "r851",
      "r853",
      "r855",
      "r858",
      "r859"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfReportedSegmentRevenuesSegmentLossAndIncomeAndSignificantSegmentExpensesDetails",
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfReportedSegmentRevenuesSegmentLossAndIncomeAndSignificantSegmentExpensesParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingOtherItemAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingOtherItemAmount",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfReportedSegmentRevenuesSegmentLossAndIncomeAndSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Other Segment Item, Amount",
        "terseLabel": "Other",
        "negatedLabel": "Other",
        "documentation": "Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss)."
       }
      }
     },
     "auth_ref": [
      "r213",
      "r235",
      "r236",
      "r250",
      "r853"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r253",
      "r256",
      "r848",
      "r849",
      "r856"
     ]
    },
    "arct_SeptemberTwoThousandAndTwentyOneLeaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "SeptemberTwoThousandAndTwentyOneLeaseAgreementMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "September two thousand and twenty one lease agreement.",
        "label": "September Two Thousand And Twenty One Lease Agreement [Member]",
        "terseLabel": "September 2021 Lease Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "arct_SeqirusAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "SeqirusAgreementMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Seqirus Agreement [Member]",
        "label": "Seqirus Agreement [Member]",
        "documentation": "Seqirus Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "arct_SeqirusIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "SeqirusIncMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureOrganizationDetailsTextual",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Seqirus Inc [Member]",
        "label": "Seqirus, Inc [Member]",
        "documentation": "Seqirus, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Share-Based Payment Arrangement, Noncash Expense, Total",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based compensation expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r882"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights",
        "terseLabel": "Vesting description",
        "documentation": "Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Restricted stock units granted",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r425"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureSharebasedCompensationDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of Shares Outstanding, Beginning Balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Number of Shares Outstanding, Ending Balance",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r422",
      "r423"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureSharebasedCompensationDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodStartLabel": "Weighted- Average Grant Date Fair Value, Outstanding, Beginning Balance",
        "periodEndLabel": "Weighted- Average Grant Date Fair Value, Outstanding, Ending Balance",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r422",
      "r423"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r436"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r435"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r437"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureSharebasedCompensationDetails2",
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureSharebasedCompensationDetails3",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationDetails",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r406",
      "r408",
      "r410",
      "r411",
      "r412",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Share-based compensation number of shares authorized",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r884"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of shares available",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Number of Shares, Exercisable December 31, 2024",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r416"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price, Exercisable - December 31, 2024",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r416"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Exercised",
        "verboseLabel": "The total intrinsic value of options exercised",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r429"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Number of Shares, Forfeited/cancelled",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r420"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Number of Shares, Granted",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r418"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Grant date weighted average fair value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r428"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Outstanding",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number of Shares, Outstanding",
        "periodStartLabel": "Number of Shares, Outstanding",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r414",
      "r415"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted-Average Exercise Price, Outstanding",
        "periodStartLabel": "Weighted-Average Exercise Price, Outstanding",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r414",
      "r415"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Exercisable and expected to vest - December 31, 2024",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r431"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "terseLabel": "Number of Shares, Exercisable and expected to vest December 31, 2024",
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r431"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price, Exercisable and expected to vest -December 31, 2024",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r431"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureSharebasedCompensationDetails2",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationDetails",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationDetailsTextual",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r410",
      "r411",
      "r412",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price, Exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r419"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price, Forfeited/cancelled",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r420"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price, Granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r418"
     ]
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "First Year Anniversary of the Grant [Member]",
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Share-Based Compensation",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r405",
      "r413",
      "r432",
      "r433",
      "r434",
      "r435",
      "r438",
      "r444",
      "r445",
      "r446",
      "r447"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharePrice",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Price",
        "terseLabel": "Fair value of common stock",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Vesting percentage",
        "documentation": "Percentage of vesting of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1103"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Share options expiration period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r883"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected life (in years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r434"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Exercisable - December 31, 2024",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-Average Remaining Contractual Term (Years), Exercisable - December 31, 2024",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-Average Remaining Contractual Term (Years), Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-Average Remaining Contractual Term (Years), Exercisable and expected to vest - December 31, 2024",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r431"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Fair value of options vested",
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock."
       }
      }
     },
     "auth_ref": [
      "r429"
     ]
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermContractWithCustomerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermContractWithCustomerMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Contract with Customer [Member]",
        "documentation": "Contract with customer in which duration is classified as short-term."
       }
      }
     },
     "auth_ref": [
      "r875"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r174"
     ]
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State [Member]",
        "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax."
       }
      }
     },
     "auth_ref": [
      "r458"
     ]
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfReportedSegmentRevenuesSegmentLossAndIncomeAndSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r114",
      "r115",
      "r116",
      "r138",
      "r213",
      "r217",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r234",
      "r235",
      "r236",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r250",
      "r251",
      "r252",
      "r258",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r298",
      "r302",
      "r311",
      "r312",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r849",
      "r853",
      "r854",
      "r862",
      "r914",
      "r1177",
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1185",
      "r1186",
      "r1187",
      "r1188",
      "r1189",
      "r1190",
      "r1191",
      "r1192",
      "r1193",
      "r1194",
      "r1195",
      "r1196",
      "r1197",
      "r1198",
      "r1199",
      "r1200",
      "r1201",
      "r1202",
      "r1203",
      "r1204",
      "r1205",
      "r1206"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r70",
      "r73",
      "r74",
      "r134",
      "r162",
      "r163",
      "r164",
      "r183",
      "r184",
      "r185",
      "r189",
      "r196",
      "r198",
      "r200",
      "r214",
      "r276",
      "r283",
      "r300",
      "r378",
      "r486",
      "r487",
      "r501",
      "r502",
      "r503",
      "r506",
      "r513",
      "r514",
      "r524",
      "r526",
      "r527",
      "r528",
      "r529",
      "r531",
      "r541",
      "r573",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r584",
      "r586",
      "r604",
      "r681",
      "r711",
      "r712",
      "r713",
      "r734",
      "r796"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfReportedSegmentRevenuesSegmentLossAndIncomeAndSignificantSegmentExpensesParentheticalDetails",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureDebtDetailsTextual",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetailsTextual",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical"
       }
      }
     },
     "auth_ref": [
      "r256",
      "r257",
      "r627",
      "r629",
      "r630",
      "r631",
      "r632",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r737",
      "r739",
      "r741",
      "r806",
      "r808",
      "r813",
      "r817",
      "r820",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r837",
      "r872",
      "r899",
      "r900",
      "r901",
      "r902",
      "r904",
      "r906",
      "r907",
      "r908",
      "r913",
      "r919",
      "r1100",
      "r1177",
      "r1179",
      "r1180",
      "r1182",
      "r1183",
      "r1184",
      "r1185",
      "r1186",
      "r1187",
      "r1188",
      "r1189",
      "r1190",
      "r1191",
      "r1192",
      "r1193",
      "r1194",
      "r1195",
      "r1196",
      "r1197",
      "r1198",
      "r1199",
      "r1200",
      "r1201",
      "r1202",
      "r1203",
      "r1204",
      "r1205",
      "r1206"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://arcturusrx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r184",
      "r185",
      "r214",
      "r586",
      "r623",
      "r723",
      "r735",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r752",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r771",
      "r774",
      "r775",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r796",
      "r920"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario"
       }
      }
     },
     "auth_ref": [
      "r202",
      "r404",
      "r1042",
      "r1046",
      "r1073"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://arcturusrx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r184",
      "r185",
      "r214",
      "r261",
      "r586",
      "r623",
      "r723",
      "r735",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r752",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r771",
      "r774",
      "r775",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r796",
      "r920"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r949",
      "r960",
      "r970",
      "r1003"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Acquisitions",
        "terseLabel": "Issuance of common stock related to acquired in-process research and development (in shares)",
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r70",
      "r99"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock, net of issuance costs (in shares)",
        "verboseLabel": "Issuance of common stock",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r69",
      "r70",
      "r99",
      "r725",
      "r796",
      "r818"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationDetails1",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock upon exercise of stock options (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Number of Shares, Exercised",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r69",
      "r70",
      "r99",
      "r419"
     ]
    },
    "arct_StockIssuedDuringPeriodSharesUnderEquityPlan": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesUnderEquityPlan",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period shares under equity plan.",
        "label": "Stock Issued During Period Shares Under Equity Plan",
        "terseLabel": "Issuance of common stock under equity plans (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Acquisitions",
        "terseLabel": "Issuance of common stock related to acquired in-process research and development",
        "documentation": "Value of stock issued pursuant to acquisitions during the period."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r70",
      "r73",
      "r74",
      "r99"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Issued for Services",
        "terseLabel": "Common stock issued, value",
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance of common stock upon exercise of stock options",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r70",
      "r73",
      "r74",
      "r99"
     ]
    },
    "arct_StockIssuedDuringPeriodValueUnderEquityPlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "StockIssuedDuringPeriodValueUnderEquityPlan",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period value under equity plan.",
        "label": "Stock Issued During Period Value Under Equity Plan",
        "terseLabel": "Issuance of common stock under equity plans"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders\u2019 equity",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r73",
      "r74",
      "r90",
      "r754",
      "r770",
      "r797",
      "r798",
      "r897",
      "r926",
      "r1067",
      "r1085",
      "r1153",
      "r1211"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Text Block]",
        "terseLabel": "Stockholders' Equity",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r176",
      "r361",
      "r363",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r375",
      "r378",
      "r532",
      "r799",
      "r801",
      "r819"
     ]
    },
    "arct_StudySupportAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "StudySupportAgreementMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Study Support Agreement [Member]",
        "label": "Study Support Agreement [Member]",
        "documentation": "Study support agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r580",
      "r613"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r580",
      "r613"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r580",
      "r613"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r612",
      "r614"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureOrganizationDetailsTextual",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsEquityMethodInvestmentDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "arct_SummaryOfSignificantAccountingPolicyLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "SummaryOfSignificantAccountingPolicyLineItems",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of significant accounting policy.",
        "label": "Summary Of Significant Accounting Policy [Line Items]",
        "terseLabel": "Summary Of Significant Accounting Policy [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosure of cash flow information",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r996"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Credit Carryforward Amount",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r483"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardAxis",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward",
        "documentation": "Information by specific tax credit related to an unused tax credit."
       }
      }
     },
     "auth_ref": [
      "r483"
     ]
    },
    "arct_TaxCreditCarryforwardExpirationYear": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "TaxCreditCarryforwardExpirationYear",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax credit carryforward expiration year.",
        "label": "Tax Credit Carryforward Expiration Year",
        "terseLabel": "Credit Carryforward Expiration Year"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardNameDomain",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name",
        "documentation": "The name of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r483"
     ]
    },
    "us-gaap_TaxPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxPeriodAxis",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Period [Axis]",
        "documentation": "Information by period subject to enacted tax law."
       }
      }
     },
     "auth_ref": [
      "r1133"
     ]
    },
    "us-gaap_TaxPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxPeriodDomain",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Period [Domain]",
        "documentation": "Identified tax period."
       }
      }
     },
     "auth_ref": [
      "r1133"
     ]
    },
    "us-gaap_TaxesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxesPayableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureAccruedLiabilitiesDetailScheduleOfAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax payable",
        "label": "Taxes Payable, Current",
        "totalLabel": "Taxes Payable, Current, Total",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r59"
     ]
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "auth_ref": [
      "r1081",
      "r1161"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Domain]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r988"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r995"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r1016"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r1018"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r1019"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r1020"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r1020"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r1018"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r1018"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r1021"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r1019"
     ]
    },
    "arct_TwentyTwentyOneInducementEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "TwentyTwentyOneInducementEquityIncentivePlanMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2021 Inducement equity incentive plan.",
        "label": "Twenty Twenty One Inducement Equity Incentive Plan [Member]",
        "terseLabel": "2021 Inducement Equity Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "arct_TwoThousandNineteenOmnibusIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "TwoThousandNineteenOmnibusIncentivePlanMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand nineteen omnibus incentive plan.",
        "label": "Two Thousand Nineteen Omnibus Incentive Plan [Member]",
        "terseLabel": "2019 Omnibus Equity Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "arct_TwoThousandTwentyEmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "TwoThousandTwentyEmployeeStockPurchasePlanMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Twenty Employee Stock Purchase Plan.",
        "label": "Two Thousand Twenty Employee Stock Purchase Plan [Member]",
        "terseLabel": "2020 Employee Stock Purchase Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfAdoptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfAdoptionMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update [Domain]",
        "terseLabel": "Accounting Standards Update",
        "documentation": "Amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r137",
      "r188",
      "r189",
      "r190",
      "r191",
      "r202",
      "r259",
      "r260",
      "r273",
      "r274",
      "r275",
      "r276",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r299",
      "r300",
      "r309",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r566",
      "r567",
      "r583",
      "r584",
      "r585",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r624",
      "r625",
      "r626",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureDebtDetailsTextual",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual1",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r515"
     ]
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "US",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "arct_UltragenyxMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "UltragenyxMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueSummaryOfRevenuesDetails",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ultragenyx.",
        "label": "Ultragenyx [Member]",
        "terseLabel": "Ultragenyx [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "arct_UnderlyingAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "UnderlyingAgreementMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underlying agreement.",
        "label": "Underlying Agreement [Member]",
        "terseLabel": "Underlying Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "arct_UnderwrittenPublicOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "UnderwrittenPublicOfferingMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureOrganizationDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underwritten public offering.",
        "label": "Underwritten Public Offering [Member]",
        "terseLabel": "Underwritten Public Offering [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r1015"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureIncomeTaxesDetails5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Ending balance of unrecognized tax benefits",
        "periodStartLabel": "Beginning balance of unrecognized tax benefits",
        "terseLabel": "Unrecognized Tax Benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r453",
      "r469",
      "r885"
     ]
    },
    "arct_UnrecognizedTaxBenefitsDecreasesIncreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "UnrecognizedTaxBenefitsDecreasesIncreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureIncomeTaxesDetails5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Decrease for prior period tax positions",
        "totalLabel": "Decrease for prior period tax positions",
        "documentation": "Unrecognized tax benefits (decreases) increases resulting from prior period tax positions.",
        "label": "Unrecognized Tax Benefits Decreases Increases Resulting From Prior Period Tax Positions",
        "terseLabel": "(Decrease) increase for prior period tax positions"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureIncomeTaxesDetails5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities",
        "terseLabel": "Settlement of prior period tax positions",
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities."
       }
      }
     },
     "auth_ref": [
      "r471",
      "r885"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense, Total",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense",
        "terseLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense",
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return."
       }
      }
     },
     "auth_ref": [
      "r467",
      "r885"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureIncomeTaxesDetails5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Increase for current period tax positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return."
       }
      }
     },
     "auth_ref": [
      "r470",
      "r885"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "terseLabel": "Unrecognized tax benefits impacting effective tax rate",
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate."
       }
      }
     },
     "auth_ref": [
      "r472",
      "r885"
     ]
    },
    "arct_UnvestedRestrictedOrdinarySharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "UnvestedRestrictedOrdinarySharesMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unvested restricted ordinary shares.",
        "label": "Unvested Restricted Ordinary Shares [Member]",
        "terseLabel": "Unvested Restricted Ordinary Shares [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "arct_UpfrontConsiderationReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "UpfrontConsiderationReceived",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upfront consideration received",
        "label": "Upfront Consideration Received",
        "documentation": "Upfront consideration received."
       }
      }
     },
     "auth_ref": []
    },
    "arct_UpfrontFeeAndConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "UpfrontFeeAndConsideration",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront fee/consideration.",
        "label": "Upfront Fee And Consideration",
        "terseLabel": "Upfront fee/consideration"
       }
      }
     },
     "auth_ref": []
    },
    "arct_UpfrontFeeReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "UpfrontFeeReceived",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront fee received.",
        "label": "Upfront Fee Received",
        "terseLabel": "Upfront fee received"
       }
      }
     },
     "auth_ref": []
    },
    "arct_UpfrontPaymentReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "UpfrontPaymentReceived",
     "crdr": "debit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureOrganizationDetailsTextual",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront payment received.",
        "label": "Upfront Payment Received",
        "terseLabel": "Upfront payment received"
       }
      }
     },
     "auth_ref": []
    },
    "arct_UpfrontPaymentToBeReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "UpfrontPaymentToBeReceived",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upfront payment to be received",
        "label": "Upfront Payment to be Received",
        "documentation": "Upfront payment to be received."
       }
      }
     },
     "auth_ref": []
    },
    "arct_VallonPharmaceuticalsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "VallonPharmaceuticalsIncMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsEquityMethodInvestmentDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vallon Pharmaceuticals, Inc.",
        "label": "Vallon Pharmaceuticals Inc [Member]",
        "terseLabel": "Vallon Pharmaceuticals, Inc. [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Valuation allowance change",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r475"
     ]
    },
    "us-gaap_VariableRateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VariableRateAxis",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureDebtDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable Rate [Axis]",
        "documentation": "Information by type of variable rate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VariableRateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VariableRateDomain",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureDebtDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable Rate [Domain]",
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VestingAxis",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1127",
      "r1128"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VestingDomain",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting",
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1127",
      "r1128"
     ]
    },
    "arct_VinbiocareAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "VinbiocareAgreementMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vinbiocare agreement.",
        "label": "Vinbiocare Agreement [Member]",
        "terseLabel": "Vinbiocare Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "arct_VinbiocareContractualLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "VinbiocareContractualLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/DisclosureAccruedLiabilitiesDetailScheduleOfAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vinbiocare contractual liabilities",
        "label": "Vinbiocare Contractual Liabilities",
        "documentation": "Vinbiocare contractual liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "arct_VinbiocareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "VinbiocareMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueDetailsTextual",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureRevenueSummaryOfRevenuesDetails",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vinbiocare.",
        "label": "Vinbiocare [Member]",
        "terseLabel": "Vinbiocare [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r984"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r204",
      "r209"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Weighted-average shares used in calculation of (loss) earnings per share:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r203",
      "r209"
     ]
    },
    "arct_WellsFargoCreditAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "WellsFargoCreditAgreementMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureDebtDetailsTextual",
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Wells Fargo Credit Agreement [Member]",
        "documentation": "Wells fargo credit agreement.",
        "label": "Wells Fargo Credit Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "arct_WesternAllianceBankMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcturusrx.com/20241231",
     "localname": "WesternAllianceBankMember",
     "presentation": [
      "http://arcturusrx.com/20241231/taxonomy/role/Role_DisclosureDebtDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Western Alliance Bank.",
        "label": "Western Alliance Bank [Member]",
        "terseLabel": "Western Alliance Bank [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r982"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "SubTopic": "405",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477787/942-405-45-2"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482888/230-10-55-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-2"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-4"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "210",
   "Topic": "954",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-5"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(1)",
   "SubTopic": "10",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "326",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-3"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "326",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-3"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-12"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-6"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-3"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481664/323-10-45-1"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-2"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-2"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477123/405-50-65-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-3"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10A"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478758/740-323-25-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-5"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-17"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-5"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-2"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-11"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-15"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-33"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-35A"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-6"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-12"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-34"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-3"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-7"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r951": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r952": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r953": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r954": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r955": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r956": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r957": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r958": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r959": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r960": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r961": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r962": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r963": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r964": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r965": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r966": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r967": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r968": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r969": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r970": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r971": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r972": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r973": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r974": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r975": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r976": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r977": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r978": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r979": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r980": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r981": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r982": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r983": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r984": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r985": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r986": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r987": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r988": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r989": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r990": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r991": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r992": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r993": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r994": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r995": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r996": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r997": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r998": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r999": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-X",
   "Number": "210",
   "Section": "2",
   "Subsection": "2"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1131": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1132": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r1133": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r1134": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1135": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r1136": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r1137": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1138": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1139": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r1140": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1141": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1142": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1143": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1144": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480682/815-20-25-6A"
  },
  "r1145": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1146": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1147": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1148": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1149": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1150": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1151": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1152": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1153": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1154": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1"
  },
  "r1155": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1"
  },
  "r1156": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r1157": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r1158": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479365/842-20-25-6"
  },
  "r1159": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1160": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r1161": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r1162": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r1163": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1164": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1165": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1166": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1167": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1168": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1169": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1170": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1171": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1172": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r1173": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1174": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1175": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1176": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1177": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1178": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1179": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1180": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1181": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1182": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1183": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1184": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1185": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1186": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1187": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1188": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1189": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1190": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1191": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1192": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1193": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1194": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1195": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1196": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1197": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1198": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1199": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1200": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1201": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1202": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1203": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1204": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1205": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1206": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1207": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1208": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r1209": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1210": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1211": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1212": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>96
<FILENAME>0000950170-25-034787-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-25-034787-xbrl.zip
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M*<T#\<IB0HDR1(7"$5 )!7=2RT+UKF[!NJKY]>8,"#;!,Y-ZDG%%"0\R$"5
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MFEHI#!&Q?+*TDB@G& ']J5/+G?.RMQKS5J>=]],,<XWG-[F6G,:8%HU%&UG
M.C/ 6:FGTN2NT-)LW%N^/<LZI"KSTA.=*>R%@V&NOE D9U0RR?/<6-97LNQK
M<</U>[E[7>-P.PI0T%0[:\%LI4*"!2(%T8Z!/'4(G[C2O+\*L$=%<S<C4D6>
M<BE-1@JN%'9XQS8!&4 4RYRS62XE[8-([8$Y)G)NG,=48"8-V&3*$D69)@S>
MC3I?T(SU+GC@ 54,WHYW1!3.A2*U)$NQK$R @8UG@124.9H+P93LW?G[5DH
M;<:W*62>Z13,9L==@.4'$M >E 0SCL$?0AO?2]_F5^S:W_1X%M!:PMAQ/,Z<
M32:C<SSSM%.6\Q?U[+B[>XB/W8@4X3>6(A>.(N\D110H!HVX)C-812[3Q-B@
M")@E*>?:&-??W/4?)P9@,U%T?8@NZ$$K'Z&\RUV: QS"0C9: SH2&@P.D.]&
M*CR2WW@_A=NIL1Q?GJXE#D-H'PJ=.D*IR$&-<06V3D:)X<X+G@;.^W?&\@-'
M7F_)?C"Z<-8P(B5F>E(L5&&U)DI1;JD0P?'>'1;T*5ZE#YX,9[4W&-W)%9B
M4J5$.@XRSP9FJ>6,Z][J^<=87_"!"@+/LM2;G.A<@]&C5" &^]68%+1D:G.J
M-A^U]]UH\>L'0J^\J6>Z/K_J/.@>#X,HH2E)U5I4N\^+S&:,"&XS;(WJ0*L+
M12QLHG:2Z4+TEN5O=1CT:E:/2[!:T9OYJOR,GS:;^;9.)V9(C4LS2:A1@+\,
MR'QI<PT/8,!8%*'I@ZS>,F3?;%82%ZG(I<@M20&"$2X<R&26"Y()7RA=L)#V
MKZATCT]ZUWC867#K3 :;(E*7HD?%$>4]!>!E/99Q5AGKG8[LD0]L"Y[T I,-
ME#=$>#R;AX^ :DQ!E/'*8]"$X+T]'AD\J-NN,% H[J0'$)SSPN,9L268C4M$
M1E/O@W$B[VT8^F!9]48&*:6H07U> $Y'SSO17#*B59:%S C!56^+:=TDUCG6
MPR?[;_]Q\.)QXC%EI-!2$:HIQM.BLXQ23@K'G:76>9WVKB3.5WOF+*S@-["E
M4^_';T_'I8EB')]X#^URUFAE%2;WTJ+?(G7HY7; 6&F6D]08P,MYRGW_*NTN
M \W_-6NFD9]>5?4;_ZDK+PB"&8#T&#ZVW8PNQZ<OK@+V!$%:N^;C!.2I1[JG
MQ</9.9,5)C BF,8@'S"-):A4DFH3K&::>]O;G=N$?=R?C;$R,.\EH8X&K/Z(
M9@[ 9R&%M(B",MO;+N1M\M07IB;@Y6E=VJEW\1S@X[B<-N\//VY>7\D;ZZL+
M58/OI*]";@J'#08"$X0KJXC,@#CR$ O*<*F+WH;DW@1OO-*V')73,N;I;="'
ML!7H,0/*C/OX\6@RJY>X\+0M OE+-P9\G \P_V7^-XYPQ6@-YAHVUXS7_GC+
M$0__^N*+X<JFXBDK=N&WVX[6[LP7(W9V9OSQED-^/+Q^@O#;;4>#CR@^8"\;
M$/VGL(U6OT!!7S<QD7/QK)A:ZE>'>#.#R_6TJK]S.E_<CU^^\./JM!Q?->Q-
M=_7"$,\NSO[":I2?=VL_BNJL.2DGR:@<__Z^&EV4#WC#3E4?/\.*5<]J^/D9
M7O<D@3VLOWYQ=\4SC%$CH:JFXVKJGR33ZKT/S5^>O'KSX<@7 L\\ O%4<\Q8
MDD3FN2!>J")E*<4L_B=)J*O3[IZCC&9<&>7!TJ)X,"K@#I,'$E00TN>I=DPD
MKXXX<YXRGV']+<S?$()@Y 2QPDC'M'=*<;A,>>>P'!<QV,@!+LN(3)TB I5O
M8-+#E4^>P;K%M6JJ66U]T_YYXK6+0@C6]I?_2)(_PW^39GJ.2_+?I 1K_/,N
MR9[#3I 37QZ?3'=9.7X^ 5,9%[Q;^3/__,G*$)/Y !/M'$!!8JKIM#K=99/I
M\P RA33E?_M=1N'/4UT?P]#3:K)+V]^"/BU'Y[L?0  W">#.Y'UUJL?S"[N1
MZ'- ,##O^=_I3II/IHFK9F;DDS_0^+_G*+R('I7'X]V1#U.<8S/1X_GL;#6J
MZMWYQ9].@(<(_&[][J3VY!,8_RNSS>9SOV9^\;???3V&]]T=5V,?E^Q3Z:8G
MNZ&<DBA+QSB'VD^J>CKY\S.<"ZS:Y.*:K6N!5EX>32=??^_K?VJWW50CM[I[
M?&T+\O'-P8>7+Y+##WL?7AX.RS)?EL.7^Q_?'WPX>'F8[+UYD;S\K_V_[;WY
MZ\MD_^UOOQT<'AZ\??/0UXJN;:W^J4'TCX^GU?AI\F)G?R<!F<O5=>O3O2?*
MA%U.__C\WL04C)PTU:AT\^OJN"XXAV^N]3?D4[JVM?Q??V""/K\];7UK!O=-
M76QM*_+J[?O?DOF"K,[P%D][$H$*/";BI=)&Y/;J2%.5:6$%L;%T/L?>RB(U
M)%#)16:H505]DG1 ', #&E&6Y]JS($B0!<;%\4"D3 5)#5>Y+E)5,/$D&6LT
MD9PO=U]4=H80%4W/OBXQH^3O"Y*[L%"_#%Q\GUS\W1KB+@CK:O(J=O*U+<=/
MV+\A>3OV/U^W)/%5$.^.I[N$[Q1<+4FJI;&=/,O^N#::^L;2W9)0_O1/F"?.
MM?G3TP;8)MR55*;80&8^F8[^<38X&DP>?R4C?5[-IKMZ-JV>MP,S2G> #;KK
M+5J@D\;O-GZBP49$*P'&AL'K^<AG95,:=)F<[\ZO[BZ"J]QB,>+@' ?^C.^/
MD^CF#POZ^3G8-E??HL2W[OGSLVE]>5*=H2-AC:_<AD_P>L347O^^&_]-\(LK
MICTGGT@<8#6=^7J*\4'=ML/7EX467@6$<-]\NGR,O$Q7A_ZX\LG'@^3P_!3X
M$ZA+CQO2DMAU.LWEP@3M2:$4Z">3TS9'S?'4")I:ZG*[+IVV-Q[/].A]-*G
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MMP(,;D2GY>EQTM065,'I<2H*)I7,^!'=^=?D^$FB1].K?[B 'U(I)Y^?=WA
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M+DFMQ=*M8BV^DV?9'[\"N,3W2X&[0*YU+]Z'D[))]L;C&2S@>S^IZBD6+5I
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M?4&-M*HF:HXO^6[PI@W4?L\'X:V5@O2XM$Y G,_JSJ:!Q_EF"B-VIL9X7,W
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M4]>#<EX((\;'P&3CF=1\6/A]A(FH<>67W'G3MYL_-[8B_!H1=HWQYDT@OVC
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MUKL_--S_IX\@2R<P0./'Q[Y.WK_9:ZL%(7&W3?6PRT5E9QT0BX?(*\EZ +,
MQ4;\,6OP"!V@H?]_[+WI<MM(MBW\*HB^72>HN"2MT4,YSHV09;OL/IX^RUUU
MSO?G!DB"),H@P,(@F?7T=Z\]9"9 R'8-KJ)L_N@N2R*!1")SYQ[67HOBSZE<
M@?T[%[?"2U<1F8P.HM)BQ75:2@=3R3&'7 3N:RB]ASM?%V4V<\"/>5I6M2>Z
MK9)L/HJA-3O?(#YL/]6@BD<K^L>!#6[H6-U_YXJ]0EO5-,[TS58-A9W!B[H[
MOO=G'E](D^V2!SO0RD-(C2^H!ON-U>EGGOW8*:K0/XX/CT\$L:@O)(H7%(#1
M&[UX_>/SQZ.C!^/HDELM:(VY:TXH_,];UWD]K8L)O62ZWJGD2BPY4%,L)KX/
MP]U;>BDU^5JVOO<Y@+91X!"THC>'^/X]1;<43=2(5-OJG!PE4FR9\2<729?K
MUZFB>VUE,$C2'AQ)7->R$BTQ9B2=M\V*8]81.X$8'VRJ]%?V8JV!EV84L"IT
M2O;0GXVC"\6NK=K&CI^ZOBZB*> \^#R6!TU57E??2]M]VZ#H!L!E;/%S,:TN
MD7 *A(?6Z2S*X[P0V2RL:/ONBU=OW%<%M;-,LC7-HIA'OBGNA9F5.1BY+E *
M)Q8)JF%5U:BQM"C_6@W[JE >#+:;]*($;D2;AE;A$I^)Y8O\[+0>$]HO5XEO
M&360CXB'JS5G50S7E,WC\X\=YAD[;+:T$.K-VBT"OY@VAA.LMFUXRW2/H]?"
M;+!&>C.F Z/W\\&%;>4R;HA,R-NWM\78[Z*MYPFT!3OTJ;-9LN(%8!P5R%'Q
MQL\*;)=1%E<BC@7!W[+ *HR6S:J ?6%9:\G?%-R/7].WKA/6$$H,#D:F)M<J
ME* *_RXGDV_U/6#)Z?3WN)V[\#9[+/#VQB++9&:(=MFFHK!G*!)E^PWT.\(.
M9_ Q@WX'I15G/O.9[!MC[12.EY\+[))REK$9AF&#D'6[^Q]UUVS3@69P(CR>
M)_X%DLEEPQB>L9]SIO!PN7:;<+K7ZW;E#1UDZ-Z>TN'F#E'![H9B%\YQ\V)Z
M[/.%I[23<=4SD+YJ6G>FB\?/Q.;'F?1V]4"/B(B,2A)D__E>@,30*YHW&?UY
M%J-M9AP]37-\8NAR[N&(_ &(^])X&GYZ'%.CI<!9NH&0L4H%+/*2\_\@44XQ
M::JZ0S=%TP3H"E?.N<=A)CZ4/_US((SD<>S O6'F=VJY[\/L3E7-U3><*ZQU
MSZJ[,5ML-H5O&L<NAV8].3(YA]")Q#?3N)S$JTV&L'OP^MW% 2.OT%PP5480
M,MYTV7E*)V]%!F=P\90L#SN G7#[N=19+!Q3JAV_0Y2@@58I>W:7R2\I(&L"
M)S,+=W'YPO[B[9Q(QF+UXL\O(&6C#(1%[E!D[> >SJH6J[,FR7^-PW%=I=)[
MW).0N)$]B,V#"SD015B<.0QNPE_7,K4@<'KBD'W V X85X  A?:3EPY.,HGS
M3\?<#A%JE?8']6$L[T^,R29ZF:0_I[2NTO=Q]&89EZO8+3C^DU]JG?7'?%,?
MN-W%KV!W:9\OX%8&SB=U55553\G 62.?D5(T 6^<I\FD;. XT=#/>,LPHULK
M^Q$^LG86)=&3!F LND'8,/+DXL#:.'2U4]S;E*(;*Z=C2/5FX3G76675AF^C
MA[MVLUOGQ7X_^<GP'I,X@I,2-@F.GD]UNJW!+4>\@MBBF72Q+1Z]A$H-FZ$U
M7XGMGS.K=& 4GC@3.)RZY$Q9R;9P'EV>O[T<710_CHY5JRRK"KYKLQ;P,%!'
M,6:$ GYN; LECAE@I??BG .\2K3VN>=57+7[MIV9=/*I!Y3(/"CH@'P[_[S\
MK^.3PR,>FOUTPCCA=,:==AND&MLS8>/9K[^6/4^1J^?IIB!< :UL=^EU'77;
M]F >HYR69:9TPISGM?/4UIJM,N?=""=4#SD?^Q:!%9?%GIMQ/65S^YB,Z\IG
M?:][QBQF^^;[6[:9IGR6 ,X77Z5\"MG0!Q.P3=%/!^WGE\<&<81O!7V4%I9E
M/)>TYRQZ:Z 8K,C'@8MR;D;8G6&/SM\^=DG$_6IL-VI@B9!CV_)'#4X5OFU.
MZUCG)R^;\V:!H,N\"7N%Q_2EAN*YT816\LS%M"/.. %-MG$R\/>/#GF]L6$"
M\',6_4(K$>T0]!&W^"A>C"6(I\_93=P^T8&'%Y553M-+ECL?L6[CL'<@:L=[
M-F1K"XS]E9&5<[['ZW*-U-EC) X><Q(W@'UBL$\?GPN.6#[X4N))&O0;A4KV
M?LLY+2]=^OQ\P1%'V.OZY*5/C,^Y*9GB%ZL:XHWZ2*45RS^-Z:6]*^/I^];=
M,<RWB%C>T$UC2&-&C[7>>-.C[;?2]E:Z>-K:29]<6NV=XQ) <35-A#JG9]L<
MGAQKS4 3POX$YL047J7/5_$%Z"[KI,"5Y0  &"YZ'@WR)LL.:-#OWM*]0ZRT
M^+EX&OJE\+<N"P-B3LAAH*>7Q2!?IN7,3K $NO]JLHW?OUOF1 I-659<@R3\
M*JU2U>9!62P7"D*P >1B:.2Q%)==%QDY*YH&TD-CXJV!S!1]">_P_T_BC!\F
MF#A<;\989IF)IV/_M\_:W'HF_::MK=^A+2M;=9FTM^O%T^$?VH"[L '^4!;^
M[ZP:[$&BMQ$D>KH'B7Y](-%OT7$ 3@RQ?KK2]$,KZ=3"A 2X#Q7%C<ML,Q*X
MC>L2"/B!VQ(>05%D*ZGKNWHX?>"[2LCYS@H%D+E1M;[M;M?5!TFXM&.Y-/)@
MH0V9H%W)R*1RFB^IBK%;@ 1,/%TJR6N9?+Q"!?6G;-;*X8,,N4I0BF*,RTPY
M@+R'VP'7!40ZULKDI=&*DNZ3I04:1JMB*/X"LRNCNX(GTW$J7[=D(V;1](>7
M;Z*!\3AQ;T7W/6#>Z%4<1).XQC-'FS3A#O)6=I'BH;R6EXF:5SLY8*Q*,NA%
M5DS4 ]*/<_C?D3AT3Q'RX[82N[XDD=#*HBBN6B9M1669*LRIK[&97V-I_VZA
MXZ_M.=UI+.\KK3&>H\;H8SS>W3FYS[6?WX!@PO+M;VP3O@M,PZV9W"_OU_7/
M[CY4W9ZA=HU;(7IH8'=4VF@5Y;*HPP@R81PGY@P@Z.+&T/R[SS.,47FI)AKU
MR/=#P!%C+RJ?>:Y69,XIJ,R2:6-TX).4U_J4F^<=.P:46=T3S)M\:O&65';L
M* )(06R4&"\^;ER&I(XV24UQ:"W&K4ZXBY9^<47&_R>!5,?1-,FR8?08@+RX
M+ 6CF423K$G69-+K8<#9M=(#CUD8$;!)H@D/I=</-+!X6%DZ%U@A%PJ2V3AZ
M0B<A7\,5;?$'+CIP9;I,)URK8.A?&[:@\T;CS#+Z#%*TKF:1R]G)'"OT0.[B
M@ BN@"G. 6D!# ,<(.4BSEE<E]92(5>?-*D<4Y.LF+[G,OHJ?I]$2L;.$)'@
M(9.94DKF:,;,W&N4)"^_KMT,8_>6HF,I6OBFDA8];3[X?RU_1=W3E32[JW.7
MA&9&E!$%_NSV<.O:W)N:L!EQU>")-:IKIWEZA2J#0,Q3@T99UW3!26IA2V_?
M051%&1OR_<WQ_YZP][/7RYZPMX>P%QA=<>( T\6J=-P(@V2\& \%+D-&\3%:
M9OB,%+LO9U3L3&-P((%L,Q':2I2F)[SYZ,-TB&FF5S^Y9TC?+_ OOL!+8$JY
MO:UGJ8IWR"PN<)<TY#=8P+0H!8_.7@3O#J$7<>1.^IEI'8 )>,=4R2\-2$SV
M2WR_Q/^")<X&G $[*PB-"QA#4=Q!G!!;D0P+?Y+*NJX+33A5=!)L'/*GJHJI
M% 3U.M*#@R1/Q8J)C^5@D B(03KSA#-&85=4E09M40=[&8+]COA+=D3R8<VX
M4Q?><6Q[A:1APL)$39Z2@?9_9W[L.>T=!M5-$1E(6[)0\-!_\I'\%@!@Q*/5
M]EG _4YV%/"EQ=WAWB:FZU*LD4?&I<R=%-?+@HX7'IDV0JVXMHJT=I;2@[KD
MM Z-1_!)&8/;'/;]SJ3:HS)-YENIR;[T_#O?'FB9RGUVTD]DJ\EKGV+XQ_\Y
MYQ[HZ1*I*C#[<ZJH/T&I>-L^C$O0BL6-/;WI,,Z5R18/F?-8A@H-6+ YS;KF
M9)8ZG7KOX*O#K1M4_O97R1(MR.2G)I(94W.U/2BVG+-D4<:*-G<LO+@+C<>8
MX-@1R1@&LG61=;S)BABVM4IGB<OIC3UKZC*N@B2*(4FY:7KD;&&G$]'2AKQ4
MK4LM%;X*",O-Q ]:I1]87(!^F*2%/@H+PVQR&@E2PWP?R?B0J6VD::P ;QM[
M-/)GNH-^C"[F4[Z2."Y8C"):;F9E@5X<@R=QQK%92P:VDY T'#:W3)N(NTL-
MTU_I:?%Q70E//J##65)%.F#-$$7S&"W718JW?AU_T.35>EE4]#\W>IN?$)+E
M>@UA#:7=W59X!146\P?#A7O3J@]6K51F18Y*SF.C>,O221G+=5H=W)UW0:LW
M*>G:T?F[_[:*)KKA3@X/N3F.UH-UJR8M3%5J!8)JB4RQ**.0;0?JBT%C4[22
M0.F"XL(5V8B9JP@J1Z"58-7OY65N'>OLYY*GW.;IX[)XN_O9J//"9PR&X<K;
M]#JD75 Y]Y"NY+P__4(>4%Z;JVC+^W-)=4ECS^@&:28DV[>G?OGE#[%6J__^
M$),F1'%_ G:$M-I:JOT$# CWC#ZGAUT!1),)&O17$V;0%'#S=O^X%<_$''S4
MPO/BEY-L:]@X,K:J@-8B@EBWXX$'[ +(1I;I52N=[P)E#1[TP%VS9ECM?'<#
M,+?I=7WWY&5GYGR7/>9WN<D83N$[$/VA)]V4\I1EN@#!" H!,Z.L91:%&2M0
MT5.&PU0R)3+WM<8F4D-#;XTVCGTT'@EZ&UTLX@E!S+S2D1C85$E^X4V[V*3K
M80?O"D97XB76A_+,#BU5-R%N 25 ZB,A3PG!Q*Z5TK/VO"TNLFCW=*MHN\UT
M, QF2'O: [ (:J)<_RVC*\ DY<PUG C&78G=I;%/WV>[W46WAXO>*KCHV1XN
M^O7!17?.K_CR-)!TMK]1DH-;XY#^#>#^4*+FM\_37[EE/O5._L".^2NE/=+5
M(JK*Z7_^@_YQ?/?>T?T']T]._^_1^.?UXA]@<^__0ROW???H[OK#0[6#]T_H
MWV1&]ZN[YTW_J.[63KWKXYO>]7'?NSX^]>_ZZ.3N;7G9?SKW6WH0D'=PVL38
M![X)\_Y;ECLZZX DWV-YP_3Y=%J45G!&\/@JUNCL*<INVC-8L(B1!:/:5HC4
M)G)_9X=#&K/UA\[2)$H /=U 36HFB4:-T48:M7-@UZ(-94]5N@367DU&"WAM
M2=^8 NX$"?B0%&B=)\VJR-,8&N5)Y5I!A-@B;[A?%@D!"A^753! 3@87K+R%
M?F^4^-(L$^D;\A?368/VB-Z!<!0^2R6?+6P=59IKQ7^2T-O/ ]2*ZVMPC :#
M"[:( MFR5LV+ C4R46!^([-%@SD0?.+C!!TCUGSR+('*"7_R64-O/;H4!;+*
MJ6IHPO/D1-Y0QHC&:S3&5/&5%PEN/Y:^LDX?AI-B.CX\/K)W\+JI.7CA.!R]
M.#UL3$-'M8K<OP3L3$12208Z%?))+0(/HRE'^$C;&ITL+BPU7]0>?)./UD<4
MC>TR-PRHX%<Z1>*E3;S'F8$$TD]YGI0[G2#XILW2N]X=@]3BD@X+%C)7/@=Z
MOV0OP%$@3=ZRWCA#AUP:9-$YI71#=43+#MR4X P5%N!5DR%ER2FH8FUE"B\>
MUFE/XK%9;66F2Y-9MKA62+OFL-/0W\/5CNL*S55OHG>;)26H$&[3<W>(6(Z9
M"H,+)0[V?]'B=L&CO2 #@JS>.8U=4-@A=5S[\^XSGB6YPP[SY;CEK#BD36N>
M1*S$VJBD[&G2]CK-P[#';HN*+OGHI%=;$]SEI:N7-!LWL]*)+)>,%K"5OA&[
MA1ZD>WDGW#SUEM:O>JG5@OX[O;5;0[X=;[O)DX9?QK[^R6^UVT;6_D:;DI-.
MON**,T^:<O[H<N9EQSEJ5V;H;5\=0_#/V_856:"E4F+3)$^;*N2.^LB4#>GR
M?-96]+Y$,<0X44PW)%3U/?+JOF]Q'C<RXL[%RS+.%YHO]\J/+[7!TM_\IDL'
M;V^L']D?3CMZ.)%A?46^B!G6DZ%C.J.C9 HJN-^LAA'N!V$VP6\YCG.7")D*
MW0VE)8V\/=HU4D#ZU1MSYM>=%.0&65VG]Y2X3-9UR-?5ONU+.K)8TLZYG,/H
M!58^W^(G>A  +P8OG[WXZ2!:L,!>P*K(PQ!&K5]],$'OT-'2><XWXYH;^K:?
MG@,.<_NO5^.C"#E,-*Z#KHB,9DD7J9J)\R[Y/L+4<G2?G7TABURHKEU&!\GX
MMQ)2,IWE4"DQ9YB7=-+4AL;P5'M31?U\2@CCIH7BS3-HDIWZ=HL;,&R2;C]L
M\'PMQF>0.SO1OK8!9[U"CY6PL?W2,"&S'I9D;&DI@4BJS=!G1;JA #(-]\'K
M$<<8^5JU2B+:6_R<-Q@R<@[PA0-QO]P-$G@#B+BJAE5L;-0!W4]G#*U+3E*:
M%#X0'IV/3^^<:0=UFUMQB_!M7[B[586[N_O"W==7N/M&O0[18NU&1>2KY],E
M^=[#C]* ,O/(-@6H#R9Q.OCPM,/K^=F$H,H^&S%IYDAY.#\^JF=GKXY\[$,#
M^]B@VL2*.^4C?Z:3?'1O%Y?K%\_"_T$]MZU!WBK)DB\OG<@QJ;F%G8K'/GCS
M$W51D)L96\^1*"S*13DWK;\WVA%.1FDRR>D@IEF6<V+O':=\[#N<34\KNYHP
M()$7O_"9]C6X4^MK&LE&(I+OR6Q>(2%_/FW(VKT-[G*YR6<EB$H&1NU-[N_+
M= ;%F2>X3O^'7SYQ'V;(WR<O?^QO,#H^$% G/Y)!_(!YWJ9G,GO-LP"I]:*I
M]1GE#WRE4L&*+$15->5",'N6'\M9)#S 0"ZEIK&B<ZHIK<8"Z+SD#*_C'-0F
M_\ZG4B9!FX$T:U6T:NA-(0N;J1Z\U'&$]XHS<!QH70-U:24)"L-]E[!<R%<G
ML 2DIZ 4V'R\0$9OZ+)S>$::%HAUC*-++OV@BL4EDF'XC'X*9@5WC0DA12?6
MP8!<&,2QA\$A0\R^1 S3A!&PG&&<IN64\].@_N+O5;AZ<J5I5 <K!5"3IXE3
M<'@J3IZC\Q12.ZW&.0Y:48M!M%BFU7ONTX##6\OK]L\7*-FY]#F]) ,9R$2J
MZ)@*[7!G:R/9]2W8J[&><8L.]H^4=_Q$T71,::N[S/2/KR^<F@EO6I;I:W?@
M!J/%O;7:-FG(IY:4!$NN\/KU-"'X45?D%"M!T,^5YE*SO31E%UJVE9=PCMPP
MR.ZD01:B<,CW05^2N!?0[FHP[1Z,<?2\9G\Q;*0AV[(BZ])%+5=6[B:#^-XU
MG-HN]/90+*$81:<\:14-;RG%5B!M5P4K#1V.:%;:+2]UOV;_-C6/<&=\ X(>
M>PV/FXO;'U?A4P'FH=8"O))%^+6/)]$E8]J35SW0$AW'U-:^WE55ZHR$WG@L
M[/^F<^2;W;B[;<B>4J]LH$//A-1>&OE[P2_+84C&&B3J>=T_20-7^]"G/@CI
MT=MIBS,K&5=_LD#34'C@@P9@;J6T_>Q[GWK%SNQ9]@?#KF[1QU(5D:5O;'/I
M"D4&5E!C'U%1:@RHTAYK1;(IGHY3;M+\:J<$;Y-F1=/ 8,UV:^@N//E'^I3V
M!#![ I@_EL!^&9NLQZN8H27 +C>YVTJ\KQBN(L%HY>4JCAXPAE$%A%2G@]8>
M++=X:3^F29VS;HHJF_,%NC5-]$A>%]'9?_ROH_M'#Q?:-AB6U'D_0^UF)%HA
M=, .PSJB-7Z*\%]'6+&V*%.#6:?(8I&Y846Y^/X.7EI@3!0'ZZ,3?LK.6=N%
MCOQ%UN-W]AJ\2:\*\.)J">#.\9V3Z-)$5O25[2#@9>SMX)X0:V\/_P(8$1G%
M?/VS2YNAF*=&\HTI"40_DT=!(=HP,)2,K%9;1[9%MMG)U.+/=<_VJSK;;]@Q
MDH#8)OV-WD&JUH"W+=L9]GHC9+8@.B;OL>!<R>B*OE_TI(H&CU\__SXZ.AP?
M'9[<OU.=TN6.1C0MH\.CPZ-[H[.#_9;<;\DOOR7;.*T7B%CKON:7SA;T<F0L
M/I:)S-[1W8='QR/:6^20K!&M,GQ**&MZ$I*],-GN1JF^CUH1,(WIT:MW1W>/
M)\?V$4.R#99UO:Z^OW/G^OIZ3*/,^&G&M$GOJ"6I[M#OTGQ^1T=]Y\WSYY='
MI_=.1B>'#QX,CD\/#@_O'IV-[MV9-UF&M7L0%"7F*?M>,?DE-2"&>=(@B<5X
ME6WSH1X1$.%YDK537,X]@M <O6*%,M+%.0T! FZ%MPF<46DYMNT._UI(, *F
MB1!O/'33Y42<]<W,F!&JB(Z.(WYE]([I7J.@ 2:4*."LAF JD^CL4!&&+>C=
MU^_<R6FC#AV]T4<*J8M^[,M(=>O3!]&% WITVQ9WP1RH7_I)0L>O+$/R.Q?#
M^<=2FOOD4D_5H2>5Z>0C@1!66:L6?-KE1-,."MV'RLYDW@3=;MK8;2XJP)!5
M3,]T YC<<.0N-=P'L/XLY+' ' ,*(X$&\_@MU^9FQN7/O.6--1DP"H0^M_K
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M.':22//\CG*.WJ% [01'\.EG'?3!D=![IBF[F_THC?K2OQ">9>[\\@=((AX
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M^*T 9G]#,8!-2]N1!DXMC](Z45DT R$YN4;EJ'/=.LF'M>F;;5'3"MQ'D0*
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M\<6[.Z!Z^";P89U$]!M-B2G!U+;VX4X^SAZQT2'Q$9EO8[GLZ+$[Z7;1HVZ
M2A\M.7L'R$%9IV)%+3W*YQ2C0Y747-#QV/LB;NVT'+WA>Y\7UWFHZRAR9?3T
M F5(@\V[K3]=%[-XPQ@(M@P!@*TBLP'5(P5_*?=LY2[#!%)-;K@VD<5+ @X7
MA3MP4Q);%64RP@5$7L\>>^(3@9@.D5R"!;LSI1C+'4:X[8'9H*U'";4JFSQ0
M)BN3!5M#<@G3*P/)60V(Q\Z/CG2E422Q9FP"^875A,]>-K "A^0;5\DO#4"
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M0UA!L <MRD)>N))2[^AK#KL'>LD]XTE5;9'4SYB.J$[ X,I;28BKM?K.]ZE
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MA"Z4)282CV-&V=3M:EVY:"_V''PG3FBU%4+LSM\77SI6+6HF%6RIP_D2!2;
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MS22E/20[DL^"?!;\/F>!B!/86?"T#60PIQ32MA)/2PTE:!F$C<[@."D.NOT
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MV%D,)>I,-;A\ZA5W\)LF@ "T'&:0 YW[80B&KGG$!"?M)"$>D'9X-3UV8X0
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M*'^R..<?6WYLJL@*VS.)+*O2+NI^,:YQU9M.S_BGWH")>$& <[YT2_+E?;V
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ML27&%"MDZOCH&M<,C3"AY-MGKIQ"LBY=/YGJF-H0X]>8'"G%,%Q1LIMXR/(
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M<[O0/_<S^B>C?_Z04<LS4)AOR(V=H,F;75&4-^SGZA2O@]7CM+LP]=/$"<7
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M]FS9"5DK>HX8WFQJ'LY9NG^-V%#TO]!HT]HQ_8O[\/[;R@^@J;W"=5K!30+
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MI[:S]+#N+XO5,R2854H0WBA)+///K.'$E60-8H_6+]SY[<IV!6Y?MT?\=L@
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M3MTL:C/+92\!@$#J;0!C.*<$BB["I"OT4^^N@Q2=/H%$9F6X35T*>_@X+=8
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M'2S*88S$,7WQ%B%5%\$&]J37$I:#*$F=6PI/2A"!"V"DC*6U&#TY$M7[+Y,
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MDADE>>MBA80Z.W:I%-2A-TBIE@\KNUYHLS^804.I2%I,$C!9&'RB)&]*SW1
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MT4[.R.9\*%_+J7"J,[ZB-'_U@*G::A8/RN;ZJ<R59]P/#AJ)K$8VPVR&'T6
M+3T:*9Q4K+K0;4CUBZ*!S:@J5B'<8?D8BH7ZKEHRX71?GV$DA(?QZ#N6CDG)
M,1I"05@VZ&S0']F@&2365)BJ9S7LR@_9#8E $3ARI H;=*<HB*9_+/Q.T+#W
MLN+[R%%"MN:/$-3JJ*W6O"QOY?98"!PL6TW0CKD6EBWTVBV4A]IC% )9'S0
MA<4'OQ K+9@BXLJ\+%>[#@I!S6A)",D5#_97S=!YQ0Y4:B[=//65+VKU<[+0
MS,RVHB=2O0]1Q3C(V7,F[$)*1U_*;YQ4VIAJP"LV+HVS4\E^K.#%S/[#XMPM
MQT;1@YSW'!>O(\\\9?.1I^%G5@6(\ZX'%P_7Z>BAN^50+ 4NHV1Z+C"&PB+=
M.PH F.VI!^W(E0(1DX*;?&,%,(+)UFQH&5DA$<_=1R(__!-9YTSFD\E\?J?7
M]\47F<PGD_G<.C=V*L1_+#J;DIQ"<*3NISH#!Y6'#YW.HB623+^I6NV>9E/
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MJ[I,57?TK4]DRV  @U Q:WL!>>D[XV;^NJ2U3<[7B)89BI1=CU1PA-*8W &
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MC .=60J!BY,):Z81F4:H,ED[\>$DS@F90QE<?UWSV!@^#Z8DF:M4J0*M[<G
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M3Q]#%M>E_QA#ZT"@<<KY(!8HHGR&!X2G!I4PH#F>>,I,4/-P]I#D-Y37":6
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M>O-Z,B$D^EP$9C<\J3K]?AN)Y(K=)U);D]W,:%Q)@UOOOE%AC]#)3,9Y3-&
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MLQ$(A/2@EE6PI1%((Q6L6K_T@\1LBY_I6.0;F9/0<INGY=<P"(,N@-9X9JW
MRG-*NA5>$#6QB+-HY]K;6Y/;Q>X957 9 ,UD5@&NO/ @!JUL&Z5FW^G&_*K8
MZ3N/H-&H<2YW>9N]=59^ISG:]6,A5U[ LG(_3C15PLOWJ'CIW\=F4S*XN?&;
MTA7_FJHK1G"2Z3-.!_$7PS/HL!(RTJC?%1 6C! A<,JNK&[O:8(:V_3WS]2M
M982J9D2&E+(7FKQ<66="3M+QW7&'EZC^0#*&G>8"L" ^)K@6W+G7N+H-A+D(
MKDS$!C,0Y!;O^O0(6%.8XV"9N2"D% =>@[M@I;YVR]PT)2-% DA85+>9G"-
MH$@KJML?IA$S7MZ,;PCR/'3;D?\+7WJ!EJC/-93.PE+6ZWA9URC,5X<EYIJ
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M7M6Z?/9[B?]%KO6B(OZFH__/R[:B#_O_?+/S!\PXO/'W\9?&ATI_\.'HICS
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M*H7]B>*0>2JU5DAEU?:N]P?7?,329S)Y):&4*"J[B%)DNC:E[C<6MA]BUI-
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MA,%Q+:IEAE<F7BXK"@.715#AFH#JA4&H* 'C=4D*#JR&?9/U2N&U+3=C<\%
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M2)(_$(,N'8VW'+,_/*P2A>*G8$DJ#/)9L%PG*+*^^/#I]*47418)M46ED@<
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MJBYR-X3@CWS[.R362V\#JAI6P40;@W6VDNR%43">:*#!^HM6([NZST4W9&-
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MK"A+S'0Q46JOM,*]P,S&)1GL>'\V9^.]SX+43 F7)H*POCY\Q!/4AR3D\.'
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M)#.Z\[;0 *K6E"KC)%=$W^2RV56(E4.H<86V/G%'BBW!_5H8P+)2BIFJ:@_
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M<A7D\-M57"[P$X-N_RZ?&/K6D>9BG@A>6)R&N0@*>&.UI; -'[$750+WHUC
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M4BB89KH^E7\ACZIE$42+\5(&_>&_S=XD:VF.C'%C8'1+@=*<K[%TU.UE"17
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M-]<\YUBRYJTK;JQXV\I]<<[ :TH^WEP,/+,J.9K?-\J#^R8RA]MAFH)JMRB
MC2$X=P(+"D.1Y:S(<R+R/),R.24OYT$5=;T3_24.)/$1H0#ML(K>(KMBX:UF
M\9:N[<C'1N^ZWBG53#6UNWQ:9S KLJ0JA=\L"XN@E:FFIKJT8WTF7'M E%WO
M;94CC'*1'YX+]T=OO+"LL!F?U1\<S;YV@3$N/EO 1H9LZR7=I;2*_\T  X >
MBEH\#7UW)G2:K)"-@N)+5:(PSMGTW/5^%F$@N[=RNW$).8D%.;(:7GWV!>V\
MJ/5>T#.P=UIM:G-/[4^21"=CAE(N$4]+HD.GYJQ!NO8MMJ1*G5&[VF+GO%4
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MXT(&+B[$Q87<8=D@;W+%HL_'L\]9_MF2A=MJX^'RVC]W/2HST.ZXTG=F.[<
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MET:_P9]: I;_PH9@WFG7^U>UA/V8BR12_LQ]0,\;H/.1>&]O- BF_?&T,XE
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MLW<VV>-VU*W6CR;OS#D$R+W,YD(VD)G=3YR6U K::RR/9!.8O_ZM;LG&!D/
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M\A]>6A#\7$_^F S:$?VNQ\>'4>#&(@$O[? ((E^J2!@E#HDB&@7"=EC"EJ1
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MI%P[ 2K"./."^;43?]M$Y',&)RYGAIH2A]N'C<E.HW&F5S(H*W&]=[^KQS^
MI<"YK'W=HT-SC(]R^,?CW3AZ+^G"\<2"S&H4978W+K*4CKL!E$<7< )9RCI8
MBHLLI7/F6!=+H0[W["E+X<%%X(MMTY2OJE"F;*(:-3V8%'IYY7,:J6&AYCG+
M/6[R% ,QM.=V"-P"7K1^5</L:O9FSU))HB>SP%FFE(%Q0QG\9W(7W@]F6T:9
M33[-5X#<6I0_EW^\4.C/%RIVK6B["T%Y= %CD.&L@^%XR'#J-L?M*LMZZ VE
MP&^";?.;SVH\!H:Q.H\Q"9+;0A.93VF89T5: /. "S)7-DWE&.+A35G,<VD,
MI;7P&&09#3%C9!G/4HYGSK.I2SJ/C+/YR60UWK>9/?^?.QVUAJ2D@:3$1U*"
MI.3!KAHJ;(=1SYM;&?(NJ.=NFY4LMH WM2(;(BI586NU=^8%BT7>C*I0F_SW
M@TK9BJT()"9--&4D)KOHZZ<F!S_U8%;S*X[4;M=(;0]':G=FI#9.4U[Z,9RF
MC-.46WN#.$VY:0P.IRE_P&G*6\E!!9B#ZER@5MO:F.?;[MW:&&] @?)K2GQZ
M>JIR,8DB51193DR( 7&$*L8Z3?2[S-.AM#ZFV5A%E[-/P%=_R3,(#,JWYC=H
ME4?,SVN^:_]>SKIASRX.HGQA5>W]_KUM5-3&A;6.NP&41Q=P EG*.EB*0);2
M.7.LAZ4(VPYLP>86R_B%&SC;)BI+]VW_+0/"8?T=CICDJF?-RI@/=)(JK$YJ
M/K*$Y\SSC)(23&MM7KCF!G3F.HT-!7G-1BS^:&N\AZ.B7]<M;[[%S2A/!U,R
M)) ,==;;H#RZ $=(AM9!AJB-RM<Q:UQ/-;-W$01;;V[S6<E7[<G:_WI$S@Y-
M(SPS8*]O<2 ^GS\?W-^1_M+]6![6,>^R#:,\NN#DD6&LA6%0-,9N&>.:^OTS
MYX(S;]L4XU.:%^.YO(.I3%Z!==P;]?<D^ZC(QR<5YA.9WY;%R<\>(*Q[7CLX
M6P"Y#+K/5KA/Y#+MY3(,UXXZ9X_KHC/\PFG 1JLH4J.QZ9U7;K"ZV["M\9R7
M<+XRI='\X0C.IOO; 'NX5H-L9&C3QTSFL5Y>.H,/2" ?Z@5LYO'E(&0SB-[(
M9IKD/9'-M)?-.!MG,VB.+2$S+G/9')EQG NQ]58VO\OA))&:F,"AUMED9%C
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M'"O">*MDUTZNN#/H'0@GB ,5DUCX@-XT9"3P!24R2FSJJI#YKJ@C6KMS)1K
M:X)IUP64MA&EVVQIZ,Y;);MV*MG.N/.8R2CF3!$6^>":N1\1P;A')(M<ER7,
M3QRGCF ,W7DK+ U7S=H7=%63%'2#T4BEU[I'0S.<*")UJV2'2-ULI$YHZ(44
MHB894$#=P"&A4GH@6R@#6_J>Y&X=@=?4G7R=>9,3-:[*)&O";:<G?(ZPW6:S
M0]_>*MFU4\EVQK?[/H]L'86Y4BC"(>XB802^/?%\Z3LTL)4*ZXC"-N';6<_V
MT+GC0MA.QV1?<C62J9XN,%+#HIK_D9FY!M'"CI-F.%I$\U;)#M&\T6BN:"!<
M(3T2A0Y$:E*%1%!/1UV.X]H^!%[. S1_2:0F\VB\5WF8H\K![ _C4^U>[I"]
MJ G0!01K/N)YFRT/W7NK9-=.)=L9]^X$P@N9ZY"$18SP**9$!#%X[H@KU^:Q
MPR5[3;"V6??N]UQ&T;UW9PF-;3)<8]T(U\ZSL1Q@9+9!Z*[:KI7">[S9'?J7
M-4H1@?]EP"\2ZB5)1(DK/1OB.D!_$0>*"#?TJ:W\B*I:2A_+/F\UIV5M%^(X
M\6*@?TS#'O1&1$M%M$"T:+0.(EIL=)N;")V "X?0.(0P,0"TD+$KB!,K)U*!
MQ^SXP;;FE=;TUH$6@==SQ<LK*Q$MVK7,M\XPL8UQX)<\&\'=WYKE.MU_9%3.
MTAZJ,0(\9G*WCN (T?665/J^[=@)!&=N A#-I2*!<BB1KATQQQ;<C1]L?E@E
MH)NZE2\#.1SO#^.CJ6<Y474AMNBY#J9Q6VUVZ-M;);MV*MG.^'811)3:-B6.
MYX"?EK9# M<-B T>6](D8=))Z@B_-N#;*>MQAB48+5^CPUAK\>F<@MG(,1QF
M#90LE&5NCF0)F< ?9@FN&1X38;E5LD-8;C0L<^K*2')*7,Y=PATE2!@X'A$)
MC5U7!(IYM31[G'F7S]JY?-5W>YI\*Y3)EM;5],OK>;B/K=V&A]Z]5;)KIY+M
MC'<7- A$Q!F1PK<)]V-&@@A\MILHEB2^0SU/UA%T;<2[!ST7FXO@"M?615^K
MW9YD0S*M<\RQ6R,"<@/\ @+RV@ YD8PSP3GQH]@AW!,)A$YA1 *'"N5&*K ]
M57^W1G R4:WU*+07!-A<N=4FAWZ]5;)KIY+MC%^WF52"VI2$ 3AJ+B!RDFX4
M$&5S2I7T8ID\\.NO;]N(?KWI)H<+6]L/L<K-9+B)K&O; JJS5:^P/M-GC+-)
M.% /3KEM\:]M%LZF]Q"L+/2=H0*^'TIJLX $"0-8MWU)A QM0F/IRIA)6T:T
MOEUI=6TPX+QG>\W?CO:D^CTXZ;:MOIVD'=$)T0G1J:/H)'S/C6,N"/6E(CR0
M-A$T4,3VJ6M'GF 0 -:W"ZXF=.),]+C-$)T:ATZK+R$N4^Y7!+W=C&]_E*(,
MLT'\ LO_G,HP':3CM.IS>3;.HC\NX3M47OSY3P&C_@=+ET6/;S<^Y+YSW *>
MI'[G+V^ GZ]+:,T IVUE[U%VVY(=&BLJ'!IK?;);?3$ R5)=45'5E\,:W'&D
M/72LZ%BW[AS0L394=FBLJ'!HK-MD03@^9=NL:3;2<B1O<9XEEC V:Y4):QGK
M72(*HR3R(T:"4->HQY03F7@A21S'$2*1G(H'G3I>,]CR2^E3ZNV8Z/>HP*W
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M[<SYJ^MYK+VHY6TZM,:7V:20P[CH6>HF4J")$#J5XPTL"*OD*CLP:^N],I5
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MIAX_R5/JN^FX#8>V)\7!\_^6DJRNTITK\D/<;:$";@7<1ZZE%7 KX#X05:Z
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M?&SVRZ'([N"MDVI[W*WMD0(-7 :,J+6YV9$FY+SWB"K+6*1$X;2QK<(V46
MM*> 9Z\'$/O+Q>^ :VL&R,D*QW9>U6I&BN_=^CB4!5_=XTHOE5XJO=P3O406
MH@C6(Q:-1]Q+@:P20!K&4(:MC4JK7<1G]T<O1(^PV7N$]E 6?*672B^57AX=
MO=RR_S;.G7$QH2!\0ISJ//X_6B29L 1L<D7]1MO<-G'-NP#_SU>6D)$QM;=^
MAZMP^UK6FQ3W.P*7.PI)'EC,\6,O2C<=AV]8U2\F'V+W_5'&HU/HNZ5D>&?Y
MF__S ^#870GM,"AF7Z9-E=V^9%<7:U6XNEB/1'9UL5:%JXMU=[+;>YU%[<?;
M8F. ?RW:KBU!BVG*-1;G(*N+QDY"$^&K\S,X[C#"1@\.KFM4I,8F'W#J2P0E
MA>$6.:4XXCFAI:/E2$5,I:;>&KR3RHK7]B*#5/=N6L!L%E\/(/9Z;"?SDTEX
MOL2Q'44_):\SI&NZJU)*I91**??<[89=#-[FC>HHSY41&!D1"0HT2)*$4XR$
M7513W#NET)'!I))*)95**I54*JG<*ZD8P\#GX!'\%)K 3Z$"",)AQ%-40BE!
MTVZV0+UW4E$C1>M0R\/H*-OQY+':4;9]1]G04 ;_MY/JCFI!?#4U#AVHO?!N
M;[-^8,AS6%*L]L>AV1^$:&-UR(-;C$/<L80,#12E:!U5/&+NV1UVH*V*W.ZN
M16";@.EM6K[1JO[ T*(ZOY6Z#D:TAR7%2EV'1ET!O. (/(24(> P6QR1(90A
M8;G&+&@6Z09U[;"[[1ZH:[O ;"6O2EZ5O"IY5?(Z8/)BU%+% K 5T [B)!ED
MO1.(<Q*M!/>*I(WYSSOLSKL'\MHN %S):R\1XF4M;.WGN[-^OE_;B9WX[X[X
M'IUFUZZ# Z^<KUT'!RJ[NEBKPM7%>B2RJXNU*EQ=K/OLYZO[Z^V[RN7U;.IC
M#%V39M.S)D17F_=J4>S^8Z<U.+JU%FI*:%7#8U+#BG5');OC5+('B'4WIVET
ML$I[3A'UAB+N%4':>8YXU%P*;ID5<2<]7X/E]"L83B^Z;F$G/KY*S\""VE6/
M%QZ!D&H]_C&ON@KM1R6[XU2R!PCMU8RMPY4>>S F?HHSWW8QSUGJYE/_1S,]
MSQ9 ;3JJU%:I[6BI[99]/X00S.6FXB#!5^'8(:L%1I18I9P1BNF=-/6L>RUO
M,ZB\ZC'E^0 V84?."Q\I5GN)CWKM58 _*MD=IY(]&H#W0EFE'>"T=Q)QIRG2
M!#.$H\*:!N?<YG2[[PU+W27 TY&4=:S=4:^]"O!');OC5++' _ A2FJC0@E[
MC[C1!ADF)!):6&>43"GM9%/Z^P)X A9\S3[L-2)7RZ,.*R+7#FF^')'ST[.S
MZ60(S,$[B[,R_WQ^T9R/;8W158:O#/_0&)Z*)$@ CHXV L-+@Y'F$2-/?$S*
M$NEV,WAG@^'SP+]=;<4H-:VD?LS+K6+Z4<GN.)7LT6!Z(,1P&BPR0C+$ 921
M<\H@3IR,ABC*V&XFA-\IIN.ZG_I1+[>*Z4<EN^-4LD>#Z3HXG,#41L)0#4@.
M^&P9)B@2ZEB0GJ2XD6K9221NEYC.2=W?H9;#/>[@VS  OX&5G3L3FZF#"]M:
M W=LO#U,B%I^\IEA:/N6[L$S^Y:B?(#<OY\2\<_(?V/>657FBJD54P]?#2NF
M[GNT9DHL)9H"(HH1Q!WER(3<PFF4(T089\3&EDK;1.'>Q//!IMQIIR97(R;Y
MOMVU8Z*F.OBY<E3EJ,I11\114H80DE+(4VH1C_ ?1[U&F/B$@Q.",;^+J.(=
M<90XA&$"CY:B]E[[5S< W'X#P/-A$GOC+IH?A]T ?VK2;H9#5^ND9A,/W/9X
M+);%+;P/'$X2U2A0XA"XG!)9; +"R2H:4K16;U2(['"[O=4,^FVV??B"1<!)
M[> ZZD58D?ZH9'><2O8 D7YO/B11'@B (V*B '^0>Z1MXL@!P0AK?-0XW>'^
M=]_%)5^Y_QT?8:TJJ]0P9Z672B^57NZW\%%)3UT(B&(>$4]8(VN91,(&CS4E
MB<F---H.=ZB[#WH9:5%KW0\C0OG]!9)W&9 \UHCCCZ#K(,8N_M2TD_XO^*,$
M(D=].#*W&7^ 190K(^TD-+/8S6>MG\=0OC\,5*^FPU')KIH.C]QT4 Y3H1A&
MU"<*7B8XF%I&,"+ 7W4ALDCHAF>Z390SVPWY_Y]?@MB;%7[E+TXFX>H':T>^
MCK-V"H9&#XO/!J"$?X\763F>?_*G=O(^OK'S^#REZ+\A=_IUYH?@(Z.J=UN]
MVTI1E:(J1=TO11G,K>8$O%OI ^*L[+^N!9(28^LD#S2J701/CYNBN*@!V$I1
ME:(J13UBBKHE^T8QL4RIW UN$>=1(L<Y1UQP%IT-A.(- MDF/'JH!/+YR"H9
M<5S+07:XDO=1\UDCJE??SM.O#IN.&A?A-O,I\WC'BVAGAP'/U0:HO2:UU^20
M[(BDI1%>6F18 )M ^(B<D1P):X+QSB0G[74[0H#KBA.CR%D'%@=)#EDNP8Z(
M6#L1E-5NMX[HCLP"QO5(F]HX\I#6]Z$(JM+,HU;#2C.?IQF;?&)":41) ,JP
MX']:;2A2,6HEC)>!;#0>&"<YT]8#N=B4MYHAR*JH$>;)D^"U(2H=),T8=@B9
MM4HSE68JS3PL-:PT\X6=)ZGPAFJ'#%9YJKT'\C!!(,V<Y3A:RHR[3C.$<H4E
MPRC89!!/(0$U*8$LLREYRYV,^B!I1M&1D'LO('UL-%-K2X\K$AKAPQH#/7:K
M@3ZA&5C"=.'&\>#LAFTS\_^Q9P/B&Z3Z:$R(0*-5"AQ.1ZD$<\!:Y(PE2)K
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MQ2.NWCRD7,W=%@\>O9E195<7:UVLAZQP579UL=;%>B0*]\!EMX^A'.5AVTF
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M;RO5*GTV738 P]7ZN/+6-B]2\L5%J0=U[;7]XO*,&<%[ .]IKU\ WB]F-UX
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M+.#+Z_1C#X9[6YTK>_7E\3_GC.3'SJOT'%Y/C^TWLW>V%/*\Z @LVZV))Z_
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M5C"=TV#2A)+;<(Q>[\P_WZPO:;(%SN/9I1]_CU;-[.*W2)?50##RW2'LVTJ
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M.U5+P)N4[1B_KYOZ-\F-^TJGC)ZF=/KJTOMEES)>MY[N9C\U%735911T7RS
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M\Z?B-HRNRJH==9F>6W]R8"3G@77"5M/PRNMKP+DT7"D^*8T>G&1Z.H<7I<&
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MY9<? .\F;6"R'N=:#X%KP=+H9X"HVOFSD97WYOBUIYJ&A29^G 9:AS(.3_5
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M+YKYGYM?P+G7']>(F+*_= #@O];3C_JF:N8@]C%RPP^6$*R'HUNX=ER4&LJ
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MKM(S,'JG=93Z+/MU:VTIRJRSJ!5._9Y5I'!^/PH4@QZU(NLZ$+07U  K9QE
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M*<&Y/PCO3\TXX!<]6/.[+P]2C/V5)^F*=OSXHE.3LO_<IS5^Q4H?HSN$=*H
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M!RQ9O2J=F_H78Y#>-0WFRW6:IP;(V\/L(2NFOQ)J+Z9BVF#G!0X<&4)B1Z=
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MV8:0N6K!465E -DV;>46,':PZ,#,*ZM674Z2IE'=7!9*/W55PDEX4+F<PF>
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M\A#JMO\ZN(!D<)QH*71AB\<;4,).9C[)5BBAA[6=P$IM]W^QRWFDHMU9;)$
M>K?Y3]ZN4A9?-O7+Z-'MJ#/-)0--KVO>^GX]+ZP=V!:?]KXCLW<-86W&,^*M
M -4K_W&^^&?V722<=UU1U[NFD&H]^"U.46K+/S=&O[7O_/_TU?6;G1N[P6U;
M[5O;;ARS>18ZM?7:SYI6&6G^P6Q6V_TU.VI'LJ6MK_NC?.'U::M-MXL0P_H
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M/\1<"P!SPV*J%6A\O6W+,\QP[S]RS%R\@KT9U+E4?AJ0OKJ>-K[*E#S2%9F
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M2B8)2(Q-B;O5#*PZU-VP&T.T.9QCTO;LWRS0[EH>SK9LBEM)LB_$7'HMR;K
M;P#M-WX2O<=)T-;OC\ISE-BG,15) RFHD#ND0IQE$9@&JUB F4N]#0YH >/=
MOC)?P5!W3.-?5LLT'S"6Q;ZP-.H-+^583#P6$S_$:H@<BXF?637L6$P\%A.?
M8C$QO//G%:C"T?N;E V1:^&]CRFR%'Y@4,5-45!$).:RR#G5N=CIO\6X]B2
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M0T5LY>18M#D9TD5A$ FYMLX4C!1':8#2J 0/-@0HEY-"#B*=\[,X]VPU@5'
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M)GDL6%)(N)RV GL#&:DHHHEB;RB583.<\I"1.1]G$__'"2A4G-9Y7/3L(NM
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ML9Y:RW.RN,[G9AQ%>+FO6L]%@?T]RSUO4XE'5'O^6]7\]^?V!5TN$,_JU%:
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M4-S=Y@*R6_8=F>]U>WS"J_*RMMU=L7XHV%ZPO6![]["=D(2=H!(Q<+1RAR?
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M?AZ2*F[;$:X+170NZ%GJ0'>Q]G^/=825>-(,C SQ/(XF9WGV8>6G,0QG=7>
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M16=U.8VK;'2'X..XIY([Y,$@ 2 !JT,[I1%\2$D(QVC:F%7WI^.%^P4^HSU
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M^+Z,'JC8Q)(,>3*K\K\E#WLM,6]PTP;%??^X,>CKG>GKZ(.3/E(DC/&@>U-
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M(%"M>(RRS50?@T;HZCW/55077\URFTN<-H4VPU-NV]!E5<>O57.9F37NLFV
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M\3 ;.Q_B23W+\I.#A9.Z6<RN,U?U:LOQGH:H[M[Y>?_IU8C0@U%'-_ 66_@
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M1>F^*'0S;_V$\<;,G,!$31S6BK]-[5L6[5!]H0!CS$,!W.LJ=F+5'_ &)O#
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MBMBA@UT.\B#%X2&C]UAF]-A_OM!9ID>4W;;Q'28N_=79-*JLM./2O;!XMW<
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M/Z#+*SN6-[>U=R>(7.LB>Y>2K+7Y;6SOI_F>^!4'07SED$W$$^!V$+3:NLS
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M&Z_]+"-;K=^8&9RZ,U:Z3S[%X54IHV0B0&%#BO-:(56\P4!(M@W A5S,/<W
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MG5D0D ^U<.@]P;S\>-IU+O;5S88V\%8?;]_SP>;DL#L2;L.FQ *U[2TFY4C
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M%_933Q-$N;,UXFKXEQIJZEIKOG:48DR\$E/F;PZS>2>,O:"[KU?;]H8QLXQ
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MA0',/]F+- ;\#R65 ?_B[P\?2Z0I/QA5O-SCC0^">YC4!!Y5-K,HYM8Q[2,
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M2KF5GKYCO0'.3%W8E.RIJ8>I]*?@<4-?P_/(JTQYJOX\A_I(S04E*AIJ?FA
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MRIFPN'FWR2^^2\\9N&P>ZO1[>FFV IB/V%TH]U"HY]!5\FZ ,)%X!YM&*#5
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MN"+3PPH4V'OK0I+2(,"3S8J2OF6YH^\/Y<M',C(RBXL 9T2PUDA%54(: =-
M@;-"NJ/K,+/FB\)].E(W\/H,[,#QQ%6,^S"9PV$Z.L46S'(YO9$HH!*;DLY*
MH#&0BH,]/9_\ %.A,L3B.AFEM,N 2=?A:3./C1Y[Z;4_'/ZTS_[H\0?E:;^;
M>-KS8R(R:T*!RZL@>N&"QXAX#0;M!+&"F0#0@DRIF;BB:8L^JM+C,Z-QZD*+
M2C!D%MXHE;JI$X OJ]:8W:R@#+.S""S,;]5@7*XN2C-CBTIA'B6J0&?.V\='
MX&%5Q'R]ICYBS-L&>ZS.Z74<IZS0^AKR<PP/OF, N1U%@H33=F$@(8<^<DJA
M> I-4R8689OL\X[B"9,K#&6XL/^,>XMAI<M! $1KC!$1(*>]",:3(+:3'#J%
MA"2HF8]<W3E5,V\BJ%M81;BL" =A\ *H!J"33/CD((^$DK(U6UIO3J15QS\F
M:IXQ>8PJS55N!6V3EP^LK(V]V-"G$=07H* >YUQU4&G\!&70F?[[""FLCBD&
MZ?,?D4\_ ->;3FQ?S:VI5WY(GTG?"1[2'632&JK2R8VE:PD1Q1SDD5!2>C:M
M473CTSU'<>^G,)UEP"?6I&NE09HP)% IE$K9U)2A4R]5!7.!A#SI^-GKP]^=
MBY3XX8;KIEE1B\^AAPF_[>Z"T;&FW). OZS(8[@0K["%GED)C130(<QO^5TP
M=7CIA)1+HP>CF*- '(>,PN%%0Q@:X4Z+ -&Q$EQXOQ0)K^ :<["^!G1A997Q
M'<$[Q_=DCCB1C1R*=$#,)B]P,\XN(S!DY89X!146$>J*[)335GXP1'PGW;F<
M#)GUG94M87.QF'0.<DL_?;)IFYAI^9:$RNW/?CBX**VP]0N85/@!J"@B2,(]
M%GHJ'!C,$Z5LU&B+(?!4NK;Z80H9A[GA)0KC,[R.2%Z/',>77Q/B1,2C3!C9
M,V=C*!\&FK(HH"@V,D? \-W,"J#!F+[/_7_YL% ^+O3(!J;4-P!1N#B4++7$
M[V@:U;3)MSA!;P(VD3Z?)C%IXJ\$!C*MBI9^X[M.L"*475^X+DF=(!Z8;+BL
M9!>@40*PD2. RYM^8MVZ1KJD;D?2PV B"50FACX:<@H*GNHU,AY:.;KN0$5
MI='2 QHI:HD3G;($@;#:',9/,(Y$2OC@KR-B(>ZQ&VU"R/,RVB*GAI"X,H2$
M<8.99WF,Z.6(B @](1GNJ<UT)N8CW\=\'GXMA-(P?%G,00SN3$B&X.0XOX%I
MJ++N974]%RW[@',CCSY[GZ=]-RDO<.\0""4%?G[ED T=H1;?30KYE$ E'X_#
MIDP  S[M)M=(C]C)MW!A 1T")A) S?C3:J1'W9*P.%:(4MZ9@U,H,[GO1Y^^
MHK7D_N" '3=UQ6I+D"X6[I+CIJG\;!0B,$^R4@/[$X//14:Y&,8!;S0N 9M\
M$RMX(V.G4"]EQ>1$]LG['.9'GLK"9[P:89P)QW<X= )6]RS/.*BA>KR*EA7*
MD(A/U"*)&?)B;DJ!WU"9(8,S%.B;G&]H5@IN(S.>&LXZ[^/$=Z_\1Q+%/F63
MT]!CIWKUA(FSPRG]$29)3SD2A@M)9"C'AE1T;&HFEINFI%H^!MVH!6(-%1*9
MDNC".U%/N=$(JB$)FD78S^573%P_AF()]#@2/XQ]EQG<WL\@D$H9')P5,3QN
MF_S]3&PA="=S)"I-1V&RT"D4.V<;$/WX_@1]>/?AIVE/7!Q4^QF/NU@>;E"=
M#[69BT0O6>57HIZ\R1Z%9A<Q;ER)H\#WP& L2U&,4@K7.\65L"&)SIB^V, D
M%.R8O6=B2FOM>?2,R<B - ;#0+39Z/$6-9K/TY=VA3>#X"?Z;/C/PJ"ITZNL
M %XPV"<6PYZF(K?D!WU \UNP)D]^33@D!%VVS-5#>1;?'4,) W 4HY9WN("5
M)U(Z0<=#A*K>J*7$D,X">#7.2@1!] )>:$HU4&9BX7',U^&H0N,9&I3A.4&%
M^J<,%Q- RVY1INJ/3ST5A:HQV7PX$AER&70;FF=&W&W_.K;<&?4RE)Y\"]>%
MB8E%G X7D\Z<P#'@$Z6?KH?$(<DW1IEZ]=29!\1)=-8)V)BS[0G655%Q&AXY
M0_>33N);S"+=Z)Z:X!M(W([S$A9P!<I$?I=?$QP.M09QP"=*=@8&6VHW(,4C
MAW]\%!:"  2945YV!1#$\(VD$T]*)Y/49?*"JXA\<A+WB0[D*@T][@X!@AO]
MXBSU-C@!?4X\.MV#Q,>VZU9@1&M *?PB!%+T*+":R/(V^2R(O9U1#RXP$A-B
MJ(17C*1>8ILV[YL9X@OQU0/7?^K#GAUS85*)1TKX^>TE 1H0][434UU)2 9
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MLTE37E@8!2H. Q7&D5V!<B0%(>>;G;-":KZJ[6(N-6OA(J'TNJ-<%YO21N;
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M;>RXU9UB?/#W#H%-#M?*RB$;RJ]ID10!+/(X7+IW&.!I=X\N0B0#" 0(>$@
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MV1:F:1&OPAU>I]X.$]&&&H5B'R]?HY#5^7F&"N#K$ >#@MN*.B%*KB?:>V&
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M%Z>Z\M)LR*X#W/OZQ$PL1I Y.$?5$E6K+4;46@9E(O@L2>PM'F,FH\^,SQ=
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M:O_5L!15N1D!E7](;EKJ75NNK% 6'Y\& 6F3\7_<AS'^?.$",7J(4YJ(?T%
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M.3 8&&20AO^00_5:D%'!UF=*P9RT'01O7"4M !77A+C9X*TA&1*62)41;FH
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M- X&*U"BD)7F%_.Q4T,STW3)1C6^[)?0$+Q^\<(X \L_SI;QW7<0T(HPVU(
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M@(5.^TM<+HQQ;T)?0.MED6>Y1Z-G%W%.)/PL]%T!$5?&-D%R=-<!%#[8O%9
MH3:;E+ZO]=FHS)71X_,MC%_#Q"><2Z2 06(Q2KK($X3-VBD'XX3O?(4#2=!.
M2,9@G%1"PL9@IT34H95?'J%>]8H<N0Q<5^14W1S47WJ4+N1D2O,&^T\@2UT#
M5BH8FN.R&O]0\F8VJN,>K&E_+HAZX?7#*J3V1D;(S@GJ/?+:;:9R8!X KH+/
M,\?X,AVVHK!C#/@;)@-"!AX]WSHUO*0) D[LJ-<\LE(&G1"9D$+2DIVP?(W"
M#=T:H#OYY#2NPAUILEP_D[]F:W;N::X/N QZW6MT$!-4QKXHXT#E0"9(# 6Q
ML8#@JHYF@NAX6($66_?AF#-8CRL>?AI-S1\UVZ2'OSU_N51H7SQ\F3XNG^[<
M&V%%?R?SZ^T3(I'<^4F<[(CTJR(,W"00P&_ZO;B<E6H>:<D,C<ZS%_'ZA#=0
M\,:+\P=O=W'Z#@L9+6DA(.;ZX#5!KY8X.#L<YOY2AU_/:"@4@6,OA)[="8RZ
M>#+X;CT_-.C>O'O3WBSTBY*R,!72Z.)O<5!$F+SJQ\PO69O]I4\0G>B?/N(G
M&+*R3DN6Z0"ST6>M\C:+J5ORJ4/'IN[F4&DXRM15E8^O7EZDY%'H$=74T#\$
M32NQ0,.Q4P'9!_ED)_@(3,<+-S)ERZ(P59=E+P%?K0;#"L0(P&BS-A)CW,D-
MV,R1KC!+>RD=TM?); ,XC3,- >T,ZZI:[Z>VPL8DFU)0O=OA=$,>TB]I\IYO
MX1;TXI[Y98(D8C01)WHEO&AD;\L,B5OR:Q+CPU<O_17G\R(.^M55H<00HX8H
M.6M&\EKUV8<">N5"@.I_@H@]O\]R40)7S0U?K$8-8M:+%/>RJLOQ^OE68U@N
M8=YP' NSO;\\3)]F\V'L[D#KPVQN5G7M-6+AXT OZ %-T1.:H;DE)T>?85<$
M0C[+UFXZ#D_1"P]70%R8AKX=9,P:; ZC6V/J_U:$*0W[3!,(_M.C0?/(KYZ'
M5'0&R3J\NW8\;</!9A:XY_OOGXSK2MB*8#V,/^PYZVD;<+V-6#RSK%?M_ ])
M_(&&3?KDD26O+N3GI@&+#O=<FQB%>0H)OP&L]"0]&$&$9ECNH@N; -&&>>V
M]68U&R3/8Z)\#\QT&T#[<8Y-O\0SBM)*(?>8H#LM\FV20HK\Q756*.[K,X.]
MY=)S2?6*&*J6O5'!?!ED+_*L<=6:[O22X741W8?KB],9NS.\&'T$'5PACZW9
M7+CDL& <1N&;.0!J#O 2%#3L81$+15;9K#-O'Q)MDN_9-R^,P,@_3])Y <G+
M EFY7^ &'P \K[%4<%6@9KFSQ0!H+NB:#D%B5_]XLQ1I)JBT *@W&N(CD!=;
M9:+8*-#BAYVH!HC0\1WE\PD[96>9?=]/@235"[L,>:UGU%1G,2JS5X]USH5Q
M_D0@VV-EBWZPV:F=HG*60C9+ GJ(ZD/*++6J/WP/&8^FG9'18"CL3*<DS'Z]
M.:S(=SUB,BL4$9!$0-%24.6 _-1J).J8,@ZY3 %0OF(BE"I%*R$S,8FS) K!
M.\U_P'W6C./*L(Z48ITL"U+I"XG.+"VG\0FH^.G.G@5K6!J+>%_DV3U<$)_Z
M%:-1D#$8T0FB9-$G:_;M ;FJV.DMLP'A)[=AYD<) (GTA#.DD30E-0L AN#P
MON7/5@;O9+I/X(D*(!]GC5,,,#0]P48D?:1V &%DL@OT5PL8(T9YK9B"),-A
MC>%4]#-Z*F=K5!S/Y?P"X<&9@,2H.6SOON/4#S/\F(87*V7]8PV5K%DV6A5\
MI.'Y%6-&=-#_Q/.O[E1!]X-^EOC$&C9*3P-1_UA:9 5D%1'6<=C?&EWV4-IB
M1:UE\#ZP3LQJJ0:X%%ZVDCM)&DG0+T'\VIBK.--.6C_748:44)/:>9895T3#
MH.]]X4503O[SH&>[S.M2ND&T;/U/ -^7_6PEI?Z*IO.,I^HB?(?&(]6^1,9U
M+"^%?C/RWE VAL&9$U3A66;3,R:XW, \UG%I?H)JW3\+D]A><&R:JR\X)ILG
MFL;!--B1S9-1 \4;YI[\7HHBITT-4U7J(ES#FJ)EA$UU"3MXM0<!P9.!*9PY
MW!C#'$-.=XPS-SA+FI1EI% WBZ,$E>L6,_+WT/>BY[P(#H.$<%*Z:(%\3AEE
M0-HP9/50O B',^=!4$24I)THS\%XJ3B6QV%(&I:D&8@Z *70P:%-9E!GN"$?
M93T-4$?P\"P8I.I%*A_"&.<8Q\M='+X68+8AXR!W\J"U27-1IC/FO:&$=0<&
M'-8?VD<6ZY(.SS5?X$I14M$+XMT@V<\X!4F'Y[I:C?33'R2G$D/?/L/D7DEW
MGH^+'&X5GO\SU#.B4*9PCX2T\6=D*&[*AT3E@I.\NK6I/25CL%2/P*+YAU\*
MC]KT^BD&,NJ*I59*HE?)DS:<C!*F)N5G*-07XDUB3]=)DN ]C"*HE12F<,)!
MM;Q4A^/$)J@DAX#>=7"A+H[" !&-,L.!?7=1N E?([Q*N T3XK# /-ZT<O9R
M./-NH-@$-V722"O64]/@>:T\1TUV>1^H[*1IP;Y6=NO!0&>NLGD078CB@WA!
M'-P6J2RIS(IV0(Y&1O7I2V\=%E7)Z"/6@?3-B9H<2B_7RFWE=N+1CHU028&T
M29;^G.P78VA>A^!OL\,KC-RG^!80R?24 )C*5R_VF*K7U^14Z8#%2D$7,#=E
M)U;<_O2@+[+4P^1,4Z/>8;G^(_:B?-M?7&!TD2 ,[#'2=N35(=F*?CB.:E<P
MYVRG<+:EU(W?M4U<JYYV&BUHE1W;S /.RW(:1 BC*57M0;0S+TT/ZR0%-UAV
M'^Y"MAK9,IX5.TB0@D=W"P:F1;Q\C\G1VH9[6/Y=L2L1YGNN/'AG$EF?!$1'
MGJ+5&7>+?'7L*"H'#^6B?#E\R'(DXP=5(1$<T%U&6%"*%)C5PZ]B6:+26::4
MBX'EF-*\R);,8%X@O3)FI P:+6-4#ANQ<4/.L1PYXD-'CW9J1ES%:M3]E[4E
M\=0ET<?O7\F2G H:1X5$[JF?0N0^$5TH)EM?8>AHF1G6*8C$K%>.!6?346=_
M<BI0>L5NY[$WF0'DL9[DA)B5.41^R' 0I N9\6&ZV/(0@Q>BGTSFL0D'.@0#
M%9'<-A?B!$E&!HL'5[*KK$:%'ZGE3H:54NLH>1Z*"%Z,>9KL>$%8IEB3UH])
M/PM":YE[R%E@ T!R &A-1H!$35HV!OJ1',6/.5>UC<]F!3(P?3X5>S85D'JV
M-ST5>OQ#GK(*\Z*7@7JE9)7$T=._>+O]?]]>.7=\]^LP+2O,MDAF5\[]"2"7
MOC(+;1J<'>OI-HD"LA>9+[GG5<^($ DPS]/PM<@];BM^]%([@1?#<U:1[Q2J
M__*___/SI]__-R_L_E_&DT&];#N/DG=>RI%E[;&2T_,P]F(?_IV)F2'.!GN[
MH5L$_99%)&77=+O*SE'9^SC/O.T9JBB> BHJ+"='=F6#<<(D_ .V^IL7L8P%
MPE8(]4WTO[, QC[; I:?_HM"%>JNB'Y11ZOQPJ=MSE8-8D&=%_,7H)<S%T@?
M5'U!Q!H@?J]15Z]JVT/'&^CN">^35-K(#\-$/G/:2!(?\P 98;2R=)S;14S+
M-IF,ASZ*[C2T60AL44E,$[[(?U50GQ1<JP=LO.;9\!SSO=H)V671(DA%?1KL
M_%SL8:L.6&&3Q5!SNK9KA@[(4_1CL5-3NQA;&6?+?&W:$G9_'D8<#KQ?W0"@
MPZ&^7!ZTID" A9&WO4>E9#_XLUM1;$9\<@=@<:0'EQE@TD<OV'FQ][J=;<.W
MXM<BZE=V]C;]5R1)(DG3S@4V'#=ULY&>*\,PLX-Q4\$2&6F!5*7OF,97_8.J
M^U'CL[!+WV+V3_+?40$)T'??6>0$P+(QL+0>2O7DN$8]$3[MBII=U:Z9N5R:
MTG\2@_Z9>AW8N)$8.,.\8T/_YUX(M>@&S84.Q+Q!"A6;RS!&/ET%:N_!Y>A$
M,(Y8%M^"EL]31ZDSAJ?:_Q+FVUF1Y<D.ISV-?R(QE7FE.'WT'D+!']Z#1?M>
M/>^]KZFZD=1_A;RH=RQ/W,>"+TC=I["FQFW3#8<*>(_YWWAB>P4<(PZ$7U$?
MI %9H<,YG";,\RQ^X .:5#$PX.R6GME6J P8V3_#;%:D0SH9-#^7)N,)NL;/
MR G I]3*1V;@/O&]2 G!,(P(2TN#D[_"KJ%=(S5<8R*"P7ZD&6K85A4X6& Y
MAN#4-5KC@,)/O+(M:7H&:'I;#1^G5ZTAE@C80!:R57I(6JV7:^ZS\B(15=$W
M*5X:Q,DR2>(RLL3BXT?V7S-@M ?B*QQ2322G)5C7P;A13U@+2Z9YD;&S[*+H
MD:Y91N'RFY%))U? 0+5^;I8QZ9?'W5N(P!J"!46-X5(AOZPM\W(4/[(-/E+"
MZA()J-BQ<%V0?4"Q^I9 .#84@WVZO-KS &!H)?PP4D8Y06*<J!PHE2'^"2>[
M8A@6T_(F29JW:3]O<20 $/J9XBDE>X5[^PQ<8XZW,GI]+?-%3,:#L[RTR@ 6
M2M_DFT:U=M$-/6H35$KR]A(SC/+=*.ON^7Y:4&@'SCBMR0!*OQ?'Q6ZBY&P9
M-1B_[,FC$N?\0EDE-W@(K%1.5>210PSA*S:.D3HP0U&5E\<*+U80;8?CI>:;
MZ%X?"RY6(B$O D ]6H<^'=,0_E80NZM4K7E?!^)'<_=;9TKF"U/K5=\<818N
M;4\[[3?J"MXSI63T?&N-_M#MK:A]U:/T#3/W_U(Q]U/BJ*1^;=S5KK&J4\,7
M7-(8?13(7LRZ7 VP62WI:7JQREN,9P3)0 4P.A476V/9_272H<HH#$;U6KC1
M7,FV6:JY"Q]AMP&&&^AD04A9Y(C=1$"E,2"QCY>O4;BAY^069WX:4L6PGR=Q
M@F372/8]4?#"E>Y1V?\$*2/X\>9(@P5,I'<Y45@,@%Q(UF:A+ZP]K\ !P9XG
MPMI_<@#67AFU4[#V5[ :O6LV*&-$'\B!]VED$/K=IPGZ_/'SOX\6#SU<.&%W
M9/1(H84F^6XM<&PWU/T^C %]FKI3YIY/38^J=4:%4KO4;0CY^1#>SWPVHI>:
M6:J*('?-;->M434SE WCDV0SB3<YN'WQ:]ZSW">0^D!O)2 VL5GK<P@NJHM"
M6,FKK!A_I8K7#/]6D&6_>\,#H+A+<HC1LV@$:,88ZI2T^]![I<?J9 [_P#B,
M\0:@%*6"QD.34B;\72MS#=2/>O IQ$[JPP@G2'9WY=Q7-6\["YNEN4@1^(*3
M3>KMMZ Y] J$40D9#W\9E(%J-9R2FHV"G',B-'D1B+1S\I=+WR%!#3%R".@A
M2O *>-"5$+7'",._9QJ0<'7,PS2CCCDOB@9 \Q#*HW!VH#70)W>;[,!PK8)A
MN1/*">=*D$64+E((7Q-359-*VSH93W;@8(<*<"H1N?UP'^'R3\]01P^ !U_V
M4)![&B149[^]/+9E)H$\58!5T?-$_:OL'+'>R8^\?W1K(63%]@15,)?D+'GE
M?.S+65+^FLE9*O@L>6*6 @NS](1%D=#E&N3Z%=<3^AT*X;DE6BO5$R*BQET+
M)U&-"9I,7]7>KH45-5:OBQ^BPD%+\_E9%):*YAD$85Z0YD1@!G=%<%/D#TG^
M%YP_>F$O@\$CZ9]6)2-,[E6S$);&L/)49A!B0(V"T((%O034)AX;K)QA>CK$
M3<W((Y4^$AV@UR)'I MTP! [$IJO#"RQ4UM0 )^2*)JS2.1A &5YA[ 16G$2
M 7 _0G,1TSTBHJSI66F!#*GF<W3.U3BQ[CLXI\/&[A,YA%*](H8JLH4F&\$L
M0Z# S0#E+L7>+ DN%AW!.PTT$!!Q=;"5J;8RXM*FSLQ"(<ZX#_]BAX$D-!'A
M .X/7A56J#@B 5JCDK91/1$2ER*N+"[7MV'V6I"]0/V=%YW:FFY/R2-%- Z4
M'I!'NS"KW0_-(-]OC#&AY"_72*5L^&XRPI=Z!YRR:D:98V[V57+W/2=RW )J
M.#,W^C*>DO^+"R^Z\;+S/3JUW<G1Y/.$R+_0$1&3:4],@:-9S#3X&_(OH3NS
M.]44TWS'<F97"6(=(-X#"QM8QF@*_T^9I=U<):_J+CYW=5W(+I[F<Y;P2^/7
M\B0]5!H;3\/V<L0'@.0(ZA\YE8X]\(15;D$^$9F<B#)#FWKES0:Q9M$S_BU,
MBZP_6M#L^1YQ8G8@G/H./KK2<=>CH<GX,T;/./3X,MUX1('E"!5QED1A(/ L
M'@$0G8]*2827&>Q](PO4O@$'1.F=6IG4_JO9\N40+ 0C@)I$81L>MTG<#T^0
M@510.A8R6OH.NAK(8FOD/!9_MPMS*I;& 00&A/$&QU"9[B)$XD:Z@:!.]YFO
MTC>=8S H7^+"*_F!:F<5NJ9QETVP57F$1N2M@05 84D&J:.ME$<#FM;+:0_)
M4D=1;>-98D% 85- IPV)0L M^7T,*B5):NVGP5*,JB7?ST \1<?8N1(^*JE\
M)3-DFP4?* B@%6:D>C M\FT"98A[!+@JFM&?BC3,@M#GV#\V8ER'845?) U)
MFF8K8B;Q$UX7<0#7?RUFI:=L "5$4DE;6K.,IU0/SA??:X0D*FFB>GS1U;!3
M+_/2L4:F#]"7U*-XJ=!;#ZF-D4$E'=?'78GHM#UX>6L-4\JCO++&K.$Q%%,M
MES&'J31ZQK\^/4Q7V-_&291L#H/8/W:$),HE3;-7[A#CYWOJ*WI"#VB*2G)V
MS$]#L*#N(#K_%IEHAGBP/7R#UTE:6G%OR3^R//2AD!CY>[B)!X]^X6?GE7:,
MU#M"=,Z*K;'N1XV"L3)%)X?"<'@[/F,W]?DCJCJ4$=5.(EB6K*#@E9:$K&ZE
M&*Y.7]D'J[A6,5=8K<='KX93?"'+?(O31PR9]#3?E'R2D@'WPZ:5]%!0$OQQ
M6#W30X9HQZB<E-L?<5)JSW@Y.34'& CJE?N#3LY>MV/,EUZ5%VH#[QO0FLMP
MFL'?&EU-7@ID7?8YZ@-C=#XJ#PMY!2@F%EGZ:ETV.47J2V+7,BH3$/O%F37,
MO9*NM;"S8?FJF.A%=7  T6'R0"+YC6CR:60KK53D .B22?M+QF4N0%L9#DNB
M\O!L1HYQV+12]LJC;36Y6D*4'XJ=L<RN9;Y-3D:- U$YI==F$\20+ )C:W<-
MPT;%->$3X:>( $\ WJW0#\T7;I3@,3Q=:95,_=^*,,6M:#)]'&.B%PB-X_V@
M&I;.I XK8\5A9H[]Z%+.KY!E+28&I<XK4[2FB1EW)+)LLV;<?%],4Y[%IDL"
ML!17)#+S5ZD7LVEF6(1]$0M*>AS<\!J8T$(66..DK&5#M!W<(BV+<W=;8 !1
M6+TG%Q>X@5X \ZY=,6!@SN \GS#(!M+=E7.O+O'GCY__PZCQH]1EN>V2_$NI
M:RK)[N!\&2BT3-7PL])BFBDZKIKGSGLVZ^*P,@]U"\=RC83%&/Y5X5]%0^ ]
M6@E2LS(-%<.&NW,Q];<A?L/!+?F?*-GSR+TGO $)-DD/7\,($X4OYE4]<< '
M.I#W6'2/@K)_7K=3C #MQ!# ?$C'4.:BI\;=SF/-4E2;H-O:!)6=(]D[$MV+
M[63#+S_6!-7NV^%VDMD[^/[E8?KT839_P'D_^PRG0Q$[[;B7>P^]MF0E"S$V
MG,79>^@5XY_5J5> 87V,@PQJ"S_GB?\K:'B7^JL$,5: C)*CZJMQH_HP7-2
M;!56PBPK*%HYD;7\9+<CVD)&N2OB *=4525:Z]X&JT?K?V5M!<"J*-$ <<)0
M86M8T>+WQS3T3=9=R\Z$ZZ9%D#BHK@:V6[1"=-S_W*O0B=)=G:AR>LW&:CZF
M&$*J><@8./NH7[A\J/NZ@U=;C*@YD6>"HZ" /R#2"\*L'@-X&L@6@I?Z /HN
M8&*17U^]B)[M;(NA' AXD']*4MJL]#/Y!Q_@PL(UBA*RQ.G/O,ABD6=A0+ZE
MC)/-&HHR]6(8I!-69R3%S'I+QN23#1 &O#PC#36G4$C!&QT'A++X20;VP*V7
M@U'L#;H IW:R"WU1=#<3_'AH70"F$+BXR4:B_C')8DI9C*&00=3!SK^20:)W
MJ!Y'_IFG'NE/(\.0)S7),?,C1Q0/VI9\,_SVD4\6)2QB&3.:!<3"*13B5\9;
M]2%C# HL+;IX+"1"H'IX1BL8G5'P_ EG.'VC4T"-IUZ4-8VS%Y<2/+EDO!@&
MG2HQD G2V'-_U#FK>9XHV[:P7PA?8<J3@A>Q0&#H&RPDB<+UJ$(NF+VWAF&&
M;V&%B24$DTJ<C"M@H58CMF4QS,=HQ@ 1P3I_"K-?&807_-OE!=1*B@@(3032
M&?N/\:+_!V2VFC&K<EQ6PP"Z],:L!%SQN ZCD-93(G#E23H/T]WBTCPF3@/P
MD'=H<>OL<"LWLYTQ VS[5W)*=\6N7_X"HV'<M-%[O.H<VQJT&D6>Q-2&T0^D
MA%DIF WF:@9?S\RWS@&1IG*B%A,];>9EVWXHOX(2 E*68E7ZC3_2#MWM,5?A
MKN7 ?0L#%]Z&1P9=+"3PBN0]7%TQZ7QY5)"2-3K)6"7&+,V&3C6I< ^A=\;.
M&2UA(AV]=]3N^Q7GVR18Q$0)HZDYS;]B_.#M^I2L*HE/$) RG,IOF\MJU&F5
MU=$MN6V&7#8!4+TB+1A"/!A55ELOYB;>AX1-2]VT2W.;H:[!W O3;UY4F+2R
M'S&R,R:0P@4W?N6$C]($+UG1&-XI.[2.! *&$.7H?U:MN6K,//N<>VE>M\UW
M3^8$+8N<5J<(X\T$W>!-&-,RFS?,<OT_D]TVV7=QT&NJ[^@_;<US"Z)-+SV@
MAL_SH<3GL293#\I6"UP/Y6UACS=J&;L-4^P3!3Q;ILOU.O3)T.Z^^WB?S[8A
M7C_[4,T9#"'\QUF2/+_M9Y ]_>@EO595]HR6*1)](]8YHKVCLGO1 # 0DPDB
M8R#_-F,0B%[RPTY5S0)<3AGX]L24839E/IVRK)RR1$R9#U.6P93Y+*]\[R5F
M3<8C3%4E,EJ=IS.VUG))MM:WQW)K39?&MQ98T^ZH;_<7'$5_CI/W^!E[61+C
M8)%EQ<7'B]%$0/3#KT 5";*(T;T:ABIF][&XXAB.$?G/A%NC6:7,GA8NA2#B
M%"T!\@[&2P,Y5.6)UQ,UGJ0^#?Y>,)4K6R4B>1\_X)QE  +VQBH!V\PC"T4(
M;@XO1-);Q#*.?PJ)^%3_[ILS4PX% B7D8&A,'$](Y& @Y&<8$Q*# DWG)Q@7
M"N.?E<2'<FP6*PN[,*554:DRKZF<UYC,ZT\1G5 !HY#0/X(!#?U4B/G<*[-<
MAI%X<I#_92?#52(S"UB77EF[DIH"SB,(3X34;SF'=R .-8F\);>"M"O9/@_X
M>[YZQ]$;_IK$^?;BPNZ7)#TM8_/EA"Q-0RW[Z?]:CT[16PH'C=CA!BO6!U(Z
MN59FU46CQ444?!J("N2QQ:$]3F^*+(S)EKW%F9^&>X[6KTE@ZNG0$/T@I2/A
MU-!D+=GS9!B?@$H]&*5*@7%#'BN^WN_-9#0RX\\B5X99B2=>K>]EG\1WW[%?
ML'"D*1E),$"M;]F+"-HM2#\(BXYH#*_HRK3R;X1?:382?#+R".@CV0%$E<DN
MKI'-JAWC]#4U?>XX%B'+_?</-.?<HP Q7\@) F7@"7L1U/F\V&///D= CRM(
M$PF!*/I%2L<3@4))WK,K9%^+)B'X]06_>=F3T7(!=$^_0"I0= #5;9-B*F@/
M8A,HZ2)/$#9["0W&"=^="@>2H!U#S6"<J#?+*.R4ED$ER(IZW3+%8]7/WJE&
M7$V8USA3_6'7Q9O&]#D6@U*'"#-O0[;,AH=3<]/A/9$V%T0UOUA1JI!E"+K<
M&@JD$:5M7&H>FKG:8ZYRN+3+H2@V /8ZJON1X>R3K%^M$2@R0&UL+#LLX"2=
MYR&2PT<?F &6DD.WU\* IB"';3;^E(1Q_HV,H2"M6NP(1./\YJ4AA-(M8K)Q
MR-_I+4;TSIYH_K4)H(-!;WPT$V%PV#$+BV)WH+KY&Q\3^8$-BB57&@>9&7?*
M^*9G4R5&T6Z+HDF$8BA(C 6)P<B<$ LV#0<F3[WUJC/88<ZCFZU]"LU&/N*8
M=)R\Q-D>^^$ZQ$$_BPFG9]QB,NC@JTA#C*A9_"20RJ@C.K@M4C"SL7@Y*J51
MF9MM%H!VZ(NB17,*0MH7"FAG(GDZ8T)A ]?!,(260=ZEKPMX9GT@U@D'4Q""
M,.U'G$CHZ6I9KCB_3H?N0#^%,=\ /YL\HZLP9R4V@O M# HO GCE)X '@)C(
M;;A?)4QAZ77MT%Y8*$["$0YM7$"&F5.7EG%(7;>B,SL^6C!9 =0,*[]1D,W+
MG7N$PUK)%)R)JB3]3 XAA%Q3#ZYQ_X]%'OE6K09V4&"-LEM4]MNLG ,RA.C<
M8G9;GZC]JA&"1QVSB]!U#C3I>?0N_2_T_WW\UX\?/Z&]EQ(-@5#^;_0?'R<?
M/WX4[ZG' ,3_@8/_%N\NQ:$H;2^BY3L1]-#GW].//:*/89\:UM#O/DW0YX^?
M_YU^]_D_)O_Y^3]UO__.+. 7WG@1AUD8H+(!)0= *ZG!JVNH@4?JF#DIT\4E
MAAI['2).G7<!@V+8L8=?\S(1XNY[CHGX$0"2 I-[+HZ1>,V5[!U <V*4*2X$
M%_"NBK&Z:Q88#!4&L6 0\"*XU'Y=2U>%PFAR,U*EEC[)SET15U;RG@?B*3K&
MSI7P\8;3UZ24DRDL6EO-' LP1C*+Z^;PE?1=I-1G-D^)\@5^VAZ)L0HY).E9
M*G1=9L@V$YT'+^>E2W4>LWS7T"QK@:WU?%N/]"L/)=%/9EZ:'H@6 OF-Y_NT
ME#M3&]ZHW#RD+U3IS-)5:I#]Z$+.KYCEBLL/Y^HM;#H@141 P>7(HXPAT(I#
M6L-_@I.6EG<)OGIQL?;\G%GB(-L@]"FFW.+A=KK?1R$+&!\HSHY>UZ*L.HW+
M\LI!P:E/^;#03AT7VHN!4260# UYY=CL!.:-.)GB]*B3*-+Y:2"?,ACF(N>3
M6!D/D@.B7JH%>D"W2!G5CSZ+NAA!(_O1]*552YE_*, ,LES?AE%!_CIH^ RG
M>>4<\?/3 +!@_< R-R.")NC'X%T5/"Z; $O21W?)E+X"]='2*!9%:2.,ME14
M/\*X/;6!9P^P4EMD"(MX#=#4<%_>'/B/0ZI-G"22'2*EQPD%Q^$MQE2FC,Y*
MRY9@G8%324X1C:@CHKCX"Q7$Z<M&_2V3!KJG:"B@JVU!C)70V$2DOM0.K]R(
MFKHVA-DUF3DTC:+D7<*R<ZA3F!A9RL_2Q3@D[]$ ;%\3OS7,.%M%GKKR/Y]P
MC-][H4&W9KMRTD:1H0VQ5DF,J]DKI>'?*V%_;&!&GYJ]:R5I^5J956];9HY.
M,81_E,O+U2]C;XA_"/XV.[S"!O,+*&4->-5$Q_08A-EJ&Z;!HY?FA[MX0_X6
MS"/O4@VCT@W#Q2X[0K0G1+M"O"_T5^C-N,#1HF,TE(N>&!Z7Z1<6P3E,SX.V
M_([')T,$&#)@#>1[D5]$,G&#0W%@4;"<'$3VA7%\C09:_ V._2V1%G_M%876
MQ,='DK U9(VA>6N'PZ\R:#YAZGGG19'(5^^7_45)(4'+\:%KDKOLC+^62J]3
MV>Y[IG-UZJQ6$IZ.O)6T-AZ1$[)YDH*_),M@ @**"4=S+>. -B;_NMJFV,M[
M&VZZ7U0Y'JJLR!%-D#(FIKR*82$^+JL6GVH<"<7Z>-Z3803+6"0Z/'DY_M3/
MV3^/$B9&R@0=<C495W%,\28]AK4P)X:4PKI Y%3(3)&G*V:VBMG$5X\7J=NG
MX0[3I43[J+#@$7W-AX.NI\LW$BS]0)Q4W"&$I-G<"/Q;F!;9(O;[9ZMS6F##
MLY-SWW?P467<D^L9>#W)2&' 2AGBY;?%[1#%GX&.U=+/EP]<7_H9Z#D^XYK"
MSU:FO:RY(NPMRS5<9Q?CS@@R\$Z9O!=[#UR+&/,H1Q^C !ZIY#4*&<B V=@<
M2&\!TP(D1XD::=+.)G#-J7S-BL(&-V$4@46@-\ LZQ=!Q[(Z6VEK1+)O0 ]"
MHG<DNO\Q)J6T3?S/9-2-&6Q&E'#+B3(-H%]Y8AI>#4_#Z?!1+!]MY7V_<"-T
M D=QD]R&]'7%G*H&^"Y<L"J"6(D19LG+:7(&E'W>N>!7OM)5<P#UX=.,RG6-
M9Z.WU]3_K0A9UC%$]&68_'4[C8-;_(:C9 \OTB+F=IO5-DV*S58D:B_72IIB
MS^=.&08+XV,#H;:@H!P*&.+W;#!$V::CH5F*NKQQLX+E6//&+T)UOF@$*9\O
MB!15AD!4&F%T0WP42.;9D^_4%-<?<KJJ 065/1;&'\16:MUNQ_:8T3FC=8^4
MJ KN_0*#EA=%%V$8UTX=JZQ4QE>@6#H 0Z47LR?) )O\D##V2M+"OTEK<I?4
MKXT[=4]3\I.6=;,7(4[3(9?Q,+4UJL'>#/DDB<U5UQB:'6%+K83_,S8(35ME
MG 9CIS4._[; Z$]>7$"<XN>/GS_:YXR!$O,ZIHW\!/*<_!W[^9>D-_1<A6V.
M4KSGQ5UU60A[UC/:D*[M;5MCLZ';T!R76I2XU:6U\!X1='G]D]!Z#,[<#Z85
M%@B^U)2KF8<Q$6 &+U<CR2H59JZ?0[[A(0VPHW)1R?LHE8LN+O;)2WHJ\5.U
M.*N[[SCUPPP_IJ$_8LE;6=2V$H76"%H3HT5TN/^DL]Y:154_2Q.;8,I.3YFV
MRJ\#DU8F_SQ#CY#1_+(/O!Q__OCI#Y\^#U"3]?D% :T/GS[;*S!K@BEI$9'9
M4I(X8M2M\ZG :- T]5GD95D/\ R&>$RI&(;,*'76U?LPY5R9$IZ_&R[&VF_,
M%8,!H6)'E>DWYH89 -G;X T<AB]IDO45M[1H$Y2P1:EJ6,ZJP4B<O9RP1['D
MS==BI#B44R(5)+X7_:E(PRP(J?.B7\0/4*6V4DH7J82M;<&!6:M$8E'^K$5X
M@-"Q7!.U@FZXY6ONA5!&.+[[[F]!1)HGZ5!(8 J3M-L/R?I#0>0;MAV)#L?1
M$X3=NP9%95RULS@746T:2)^\LH#H%9Q-HE_J4*]E?MD#&[LGPUFN67+GW/-I
MG^ 4"2D$^QSC1R*GPI.[N3BY#6+5D[5((!6=3%#9#2+]H+*C*^:Y7MTCQ>N"
M"(Q@O?%+=M>0[+>WQJ^4&77 :[TR>UJ@UVQ4!>2@8+,#P/[.PU?REH;9/('9
M9@D8%Q[>AO>888_YM!^TYAV10RMZDB!Z!]-N83,,ETH.99311Z(#5/9@_E(R
MRF<EQJF=R<C6S<ONGT9:6B_QB=^QFGPT6R+'H%Q5EHRQ9I69AL0.MR@S,0EL
MA#XL26K($^2ND*,N%:OD<'J-'&KCA2VN&KT/E_D6I[,D(G]+V(&2%0>S0<PH
MM ,BGB@]E%4F#4=H#,\<WXZ,J0KELE)C9L<(,SQS%6R,<3G4HQ77K.A/ N"!
M_@AH()=F_S6@,1K.&MD75Z%L0)^89KX31:".GD'APZ%\S0%[J;GJ-;U]+_1_
MOD&YCGA#=>2+DZ3[.P+I/Q ?#&*C^8$GKB)]<*:#LL*]<<Z+UXPJB?D=U!H<
M"N).$$6,ZM5P$;4P8"4W]EA^/Z\7E2U39AK),<Z><+8G?PI?(VP,&D=VC !T
M3':-E+XM0>4(E# >\3,DQAPG.19^7#^.HB/,7 <76CPX'FEE7$FFAM]%K(!^
MIF'LA_L(M_JQ%[L=^=\T]**[]1I?[ EC78/]6<4 %;U/4(>O>X+*,2 V"/37
M/"TP6GM1ALV;%D:8M8H%XOJFCON"PYLP&2JE_<O3 A%RYC/:>PZ;[W=EN(@1
M<GG0%<<['[DM18X,.@4]XA:S?]*#5JOOT>?Q$_313Z*'G_E9JA?WL/0:FF X
M.I?7:V2R]G12EBQ6$I)VO'F2WB;%:[XNHB92;-\P1RTP;@<D[AVK8'CC13:L
MG";G0(U;/'<6;O FC..KGXBZB'L2]]?):N4P5U@3?2#--)S ZS3U*]R1]U&,
MB_SKD:'Q%O_F@R-IGW]@"\(_AU1F_MYRP'(RL&034[T1,D#3-[SRT@W.[[[[
M49%! /V!I2K)"4\N)$"G]]]&8KD2H 0RV;V &53Y:F\UZN"U!H>;!(*QU[=A
M2D3B),V6;^1W,&U)HXK*V84DG%@S[4-<.[NZ53SE.R<8A"+M#]X.L^ /'2O5
M%J,.FIY] <  LYD2P84)VHTK0M_,B3EO.#O%'UBU!MTB'/ED5+9*8-AI$)#7
M,'M,(.7X_P_WLR2H<-/=TM%[3EHSE^ES\>J+_U*MJDEZZ0UX(7$GMK%\A+E#
MBSRU%.P6(!HD&)=N,Y_TH1,LRA@\=N@@NKC4F'@87; DP@= LS#\W(<D3L5_
M4H#15=L;,1AQ1TX_7$7IGCNUJ1C#+M]#^S70^8D3.T#4UA$!_QW[N9H4,/;
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M!7"*02:VFJB&[,2)J6,^6^[7ZMH VH9.L*"$NO"(/":,\N(* =$KY@5$58I
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M5P_XG?YTCN.I]J433+:(;SJN6IJ.?ZLI=3-9T4R9/P+K\,B#"<"WTV*4/Y>
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M$#P@1OO^*S@QY]AL-] D<Y'S? [81YO9=%@\LUF4'GBD !SMW'";#SKE>S\
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MW;)(D<@._3]!L_Z43 ][ED%RX4HO(6]MS_39A?:DNMAQ371]1),Z:K-PG="
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M*#T> T+W3E!PQX=P&\%#)N$+6*MD;X-7=A98C]]1$/TS;^=Z*W.A/#F&.#L
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M@U<[ #M<U1;3K&2-1!D'GE;;M;\+B24[3-K0C(O)M.<OX!R<#L;8 7<_1#Q
MLK,=!U^\7;4L()*XS.<(OX W$*8&0\R[D'<^:9R]D99\2'!@97L;.[V""8K.
MKW1W.TZPXF;6DT[* C6? WWO^/"+$Z3@$W#P[X8-DEWHOUS">56B2YC;Q=A!
MILU*='KY?>PXLC(;5,M:QL=APH>SDERHE8?T%B2.'XSK:+97D:6B2\1"LJ"?
ML4/:2&>>:7?-K2JW471\NXYFQ\&6WMY:><.N $[XW#<NY:(&>[7\.JF<-Z:S
MSRPD+SC[XG[&SCYS:O('7FD(.TZY]$8VJI<H0#6?HYUEN![3.<8S9M>G:) W
MH[&Q$UN?C^APLEK;<0[Y&U$OMLY8]7S.&:F8M(\"#S_PD9(=XSIU[?D_18GH
M] DZF;,O4^<E?R[E^]MQ4N4VKUZ+5AJA&9UA1OW8,9WCRD/ZMKJ*%Q#@.+ME
M%"<Q6><K7N=S7A1'=,M>-JBYVUAVWC?5>0MO[0M'M8-GZ"&4FA1P*=KSX325
M*O7C8B_EQ*4E=%X/8XR!,BG1J>=VL>-(2VQ.N\X<"X3Y',8L+"!C;Z&'7^K\
M< ?"\?F&<!8B?5S5QC!V@*6F*3K2BH/8<<@[;7*M_(0B=!-F!!71'^PP(I62
M.^,Z^OG\LV F'.XC4-Q9S<VI[(T9*2CK$CWM.+JB3:HIZ#)X3/AHMOS B Y!
MDA14JHJ-[()FK4+H$2;H9M 5C#XS^=.K,H(=IUAV$^N>8 HXS>=4K]/7&/R1
MHK'OWL;G!]:<O>C.934W=^<V9B2\:9GM[3B9H@VI%UQDKGU.YT\F0.(:**$[
MD-O_(_4]1%?DB_)_68=/IH=!-;P2R\1?AU07:]0/F9U1ZVMNC[+BTHV2TI*;
M)=77LJ6UZFI3IZ^T8LDAS7MR5[SJ54A8OK]!5<,%".[7 $C2+J>#27[I AP)
M0M[%_/CW)1(@_ 3_Q&:7S!Z:KZ5_1WZ8?$%?AOW?,Z> 3R#91UY6H;:P&'YQ
MH(]1Q<E;4</D#MV9B2_:E3Z^P3Z_3#G*E.YNTKR.Q+L]"&/_+7^L5&$GTMU-
MQ[#ALL)(\I677L3]C"WI$6>- Z3"N22'Y/4PN#,Q0,P"7[*W".P@.A9Y \,8
M<*]NF9Z:6>9'$ +H!#BFP#OX(4F3ER":)[X.TM)]AU$TK^,9(N4T#5U2C#Q$
MO>15$]FNYD1[JE?7JLB5\$#N5X0VYL9\V;#+2 9='/+M*,K-<Y?&:FW>0T..
ME3&;&UO G0-#I S&SP 2NI%;AZB7L>4\@6\5 PF,0O2CFT7OJD@&RL/885F4
M2^,@9=P9SKIH/5YR5J0^ZD&,'#!):U4?I0A&CIRD,:R/]/:31$[6UM9'QO21
M ZI@L^LCV?;(T>.9 _M(ECURN+B&QS[R78\4KUX,H3F^_[KBJVX"+<#[^0J>
MNGFUE)VOVH:*";>$[:ISR!F+2\"NJH::.;H$[JII=+>%ER!>M0M%FWR)W%6S
MN,S*7P)YU3G$;PHE6%>%0^(!HT3KJC[(/Y.4H%W5A@O>7DH#\M45.H=W0PQ.
M5T?HP1>Q=O? 2W&A:[J=F6R,T%%7;9 QGG%5G.83ZY"K_6,\P1//)T^=51P#
M;!<L<K2>I YXEY%,)B=R=CL(=GGEERJ!2J0@DNAK!P.[((%^)\J8A8/%!:!*
MTMUP;A<69CT?XRTQP=SG9VFF/4E%B4\X@!WGNE.&<Q68YB/P,9*:C_%HSRFU
M>>?@&=N.LMXTYK,\PCBO]!C/ZZA3F)]ODT\.VC)RBZRVCU&XVP!X*+=$_NJ5
M',:.4RN?]%P=I_D<7/H;VBB/\C6?,HTUM/+X+KXYT"-9Q;.7TAB[MF8'-X[3
M0_8W1<:AY4NL JNZV=5U+-S$?Y.U<FD8V%I0SO[D9!6?0Q_1/=YUK0BI?HL%
M<%6GC_G#?03;QP-")]SE1:,#,B-BX:&#0+C,#9$T55]/!IR+)5*!]F3INEGI
M+*R>PVR#*I.>18#:\- K7P6S"'?K<Q\&O6.&"[$SK0Q5BCV,40.:2,F',YEG
MT[L!VZBR-[?H/W'BNXO00V0/_)VJ4-1M5 O@P.<U"O%Y+A:!)IZ[J=^ $&Q]
M58./^H@6P'"WW0)\L9PW[P4Q5!PE$KI^X)\-&/(X=!C2 B!N<XZ+IDO>VN/*
M8[OZNYO::!8L_W,(L\B@/\FD<WJ-$4\/T!'&\H<B LH#VB%H*!:3N9B]SD*!
MZ0QJ!R8]"[6D,Z!=V/TL%(S.B"K>&[-(L=$93/5;:+@,&Z;U*4X!HS'J5S.J
MVI7%$*^. ,=TACL23%SZ<>:OJ'(6_BXCV<$2+J[?U0G$"3\]\XIXC9$?C+^4
MU]FPVYA;96=N3OF'"F]Y2J/9<=J52GYUQ6W"A[MQ]:_@SD$R$1DX\]0FA5M2
MO+Y1G7&';#-^UWAR#NC'2E$HI"H[?L@Z#>*.FE,#?T9 P6^(J!!DS^EKX+LK
MI#I!1)6?P.$5P,9$Y?KHY4TQ3"J@H]_.@*-?T(V;X@Q-1UQ\"X.V>/?CQJR9
MS0:=*#KO*73WZ#Y?[" @;RS-25&)0ZVOT7)3ON<[\%2A8LIFB-MK)O$U^,-'
MG @I:VR2;K71/(<J9T-RH3@*F39)]4$,K@*Q9?"0@$-S^R\8R&#2>G07A< K
M\A*@2::'E+S(WB+%W?79P9G"CL865=V#6HI>M"'/E?MUM;WW0P=I,$ZP1G\!
M,AZ0>L;6?=4=D? 6)OE+=Y9A$GC4"X[>TG0Y"U8XX-V[&Z0>%C^1ZHC^ATU*
M3()4'TGS-BP\S\^$UD\^TMZ2* 2%'P-O3V2Z&:U4)4J=6_]#I27+Z'/1F);H
M1]*"<)G<2BR03OHI22318IP4A<D^\ HL@$I:\*QIX1(4.7D"4]9$RM/9EJ4G
M#=9ELGNS("V#2*\(<O6&>M)-L2"N%<Z?,SA#G$XA;VL)U],JOI?GNP.M7\F7
MRP#8%WH?'APVW,MZCCQ799NT\\OE-'?)#DS:"T;W;=1!+>\#WXF=>BD+P:0=
MC/32Z876B?FX'LEE"1WSRV0MOB?TGM#>G?]2485CZE-)UU$T6Q!_ T$0WSMP
M%V5E;DHEEOV^(^IB3\GPF],-"-T]HD/>XYFPFT4+*N;%??D6=AOTJ7:##S-V
MQ?;\-]]#IYSQJ$QO9W:J6 0AX8+X .[]XR:ZPY6+3LRW9=41["&M#?HR-:JJ
M]#"W#,*!6E/C<EQ^'V-+^8*C/I" RV94U1:FI\DEE7J;JP?+5#Q81$O"8@OU
MZ#4_'71:GYQW_Y >F!.K?V[L8&%VNMI6Q$$.)Z"WU>WK(Y;@3RU=J>8(I#2
MN7K=*=[XU;;T$\_=1EG@L]N;IATO4R&YMQ^UJ;&)G\EAG3BAYT O_GSTG 2@
MEG_[ZS_YFI-4W^$Y(./*.7]F+J@DBN-S& 6Z)W#93NY-SNMA/"$JB>?XF#J(
M"R: ?O%(=3%'_=Y_T[Q(ZGT$.45G.%>!VAB:KX@;/SH@8=I%RIKWYJ!O\NBE
M_!9ILB?6+K95H>M0EAPF'\0W^?' (<CEB>'LG,( YAR1J;EJ2&XA;)MR]V 5
M\D^>R@CV:,,W)WQ/JAF-RAX6W*;FZA>QA,ESQ(Y\^2BJ4-EI(,VKN3L<@^@$
M +;8KK;HJP&D6WE%K4V32GPN#B\C:[6;FSNR^<N@HNU'T&M8Q=0/^8II[7-S
MU7? :_(0(K:09H:& /L(X<*S!TP2#* %G4S3/4UI^/#SAQ^[*AR5OII9S7+]
MR.8LYP_-20A. .+\]?X)T)^-^&T-A@)4WVF?$$O("H@P_?T9S37O^!<_?/51
M>TAGR?0VY@Y4$$3?L+R.M(_;*'U-MFG0OBU8)TJNL^XCU63^A46GN!VH1TW8
MR1[I]1E _ =G!S[(BJ_5+L86@ETEL&*'-#P/ET3.]-K5MQ )3'O_>)XC8U7R
M_8TML3XM+Y_2:HO8898*B+$T<3_+=FV1%TXCY>B5]JO>LY_ M7L LI0BL>^!
M[!30#CVGM3GK5^Z^M8D6+L(/9XY#DA7"[B'\=^2'R1?T80I91T2VMV;8ST=O
MM<UV76K6:GV-&R1;I8@^QP#=:(_^EKD=$CV-+>MC%'G?_"!X.!P='^)989,5
M8R6,QN9"<I,]5O,.1PCV !W<(GT=GA5BFJLM.[!3JJN5"UN\.7Z 12:<CQH)
MVVO@YN5VNJV6/YXY@6>/WU(>PJJIVP]=_Q@ IHY&7KQ:X; Z1AP?##@^#_VL
M&XMB6+/6ZM>6K?G\3'YS:B5\)Y;HN_>CG]WKZ++Q(Q:5Z!O?-H-^:PFM*AOD
MG]RQ)UL$2[?0^A7CHZ7J*E[\W3Z)A7I+/]\U;AK+EM,GB>7?,"KV_7 X8#NJ
M[P195EZ-++PUM,%R[V](SPH]UNZ?/[<C?+1C($ 9HR/TP9]T6"CG197JO=^H
M>B]PD)\T=$+W^B)H5MFQ?=*P,:FG[0-?(S:^K_DL(*,XJ5<A:CB'3QJ2:W89
MM3PI;>?P J&&@_:DJ:8X*5QO[^J14A8NIDI$W7W2JW!RG+WG1'=43_$:V<DY
M9D\:,ZI'=\G6J_QLTC#0_56IWN-5"N)[:<\"L4[^W54,Z:=UTMA=EE.MLT/Z
MI#'M[K)>JZ;!._]3E3H8FDT;'25/^5E0FX13/=>64]7&9P&8V'W_G#NRFSO]
MI&&\/,Z ;UJL4.^D<;P@$T9)G[P B4F#)V^99NI<E)B,>4(F,,>* D FG=A0
M9%*KAY9,&@H]AB%1E,ND(=1H':I&T4P:L\L4U4I8SZ11ZETH:[P13QK,2X0+
M1IS6I/'2<S.PP\0FG=_W,O[6#F*;-%AZV)PPO[E6\&PPK^DYH;(QB-//<ZR%
M!"MO7C- K"OQ.9*AI,.E?!XMT75\+YL!LI=R1GYH< [@3Q,&4!=IUAS?9H#;
MI82G$,J=H_F/":.IXU9F./K. +U+:5$BYCY'\9\31E$7)V1X+O:!X'0T%*D<
M"3F$_[H2H9 (53Q9^H!U_)3IB+)AY+#]?*5&?FTPQ1V8 :R7,DOI#">%\7J:
M[^(:SK=\VI4"RNM# (<N9=*\%$!.V<Y]*9"LQ#(%=E=S(QL[N;PV!9):;6-O
M +Y&<\%2D$JG /AJ ^(8'R])TU, ?#5L] "P7R0 *E">LN'C4I0U9A4JX)ZR
MBJ\%;FT9B@K$K_I6#P3.3W54^"Q<M;.>B;U(E50 ?M7A]%Z9[:1+!=)7)8_C
M4'W.XE3 -8!>-WC9:]6*UV>C8UXMO%$CO%4_/"^174(\CMK8%E2BN3Q!&WV#
MDJ4#X0G-](L3I,PDFE)]+2E]L%2H>["\L.B!YJD/7[5!"UDUZ*(^R18+J+3D
MD%OW,>WP:I<+?U4\G+.(G%-#CG'V)QT)H .IOCW_+3*O=C^2%S"V7GR-H\0)
M;!(2\PB<4E;,])'X(;QQ NS!'J^V9X_U.'N5)X _^LZK'^"(ZS'*@_FR[Q%U
M%0O"$>6%E[1 .)3M;;("3WM6V+7L"3!3]/*ZZ"]X1/^NA>?Y)*+_/H(YR(CZ
M(J2^_-E*E7_)2(.OI]O<!YOG+5(!W0(NPC:C( "N^M2Y PV_FHYSG\S!_?J3
M74LI+PV%M9S[#$ _Y9=5^4>1NNO&#]"H.VFJDAO,R*JZ+\%2@A+=%AT'L7.Q
M7=;V]<-?+1'B%66O1O@0ASWVH5L?R</=.G%@8I,BU '#BR2O62CC_8$Z\6CS
MW@#DRZ63#@8> -.)1ZSV?-\@V;J7P,OLQKD+O0EC6)%D^H@7G,&E+:FH3#J.
M<!A<)QX'U_<)9PN3TW2!ZQM/K,?U$VC$OG@&?Y]X0?]\;3U2Y"\-&_">I'AY
MQA\<8IA4='GTVUF/QQ'RSS#"HM8*K@%\\]U:INE<=6<VTVMXD)LH?M[)YQ#7
MTVBU9TMI:\Q6TK'>7=/C1W$4S7:[HBX R?3Y&F5^VF@>CPCAL)+OC+J&+B-H
MGS\YHX]-%[SZ#!MM##KM<+GSW;L;I![.KX*$??0_CUVNNLM(NJ%'EQ%BEKBN
MR<:!.Y#0"9W?=E"&PZM35N$UU&:#3E0YX6!E]O)]S57&35]C\$>*9G;WAKE<
MHQQ"@]19K6V:/G4WQ.VMLO/?IAGOYJY%HJ/!@LL13#8 4CDB]Q*6Z3DL VCG
M-*\>\<JG@TZK4:*P-;'ZY\8(@5M5L+'U]+;#;S;C+CI_9E!HP3G@O6=\>W!Y
M Z6A9I'C>>_ @^."-,&UK7"LD!.>V%('KWD_<F@M-PI%!LT^MY+M<\Z(L)LM
M5S&?R5/;#GK2UPDZ()C)? 31#CK'/2G11C_Y[+;#3CDK#%J=!%/T9+<U@_(:
M:: .]",1PK5VPTXU_^;/87P$KK_U@<=&E]E6,R_[MQ,BE3%D\]5Z RLNIJJE
MY.94_83#UQ0&L-5D8-AEF$%!]Q$$_BXD>B?T <<PP&AIY!#BN;A.3+]%. TU
M@W>N&2!A?6,WUCRK/$=>'GR=.>?3G:,9+37/YRD*50Q0O.;&SO9C%.XZZ:L2
M'8?5"^MUMMIZ8>USW909( QV(#R]L[>_U48+/#%PO]]%;S_$R1%F\."?*M"@
MW[X^/#8!R?^J&88U^,.':2S!,Q@M=1_0O 3 ,X#;"*EAH0M6KX&_<YB>P((>
MVCV6WWSOP\]?'-?U0[JMA=U.]UQ2"- 7+#YRIM%HHGL&<5!_P!&3D:A+/Q=0
M+3VKQ#5$;Z]Y;I^<,-TZ^(D9/[F$WCH]'H,3-BNYR8>?_GX+TUW^@,F&4WD,
M[>>ALI=8\ T!S(GNCF3+]![")%I&U?+A$D1R^:BZ^622>B<,;@1E%L!KKGEF
M%0P^^0% UWD(XH6[]P&#Q/D=]-O>8O"P1 VQ7D]@X5K>&(W[N?4>0E=XWYW;
M#/2&3AYA<3K%RQ_314-I7E%!0S0"0S &J0<\6F6I]H(ZCM2;2B6C2?6#Z:>7
MI\4&N/LP"J(=Y^A0VUEE,;8JG.[&1\-[Q#::NZ$69P@=F^JMDB9[XK'&1K[K
M4)I7E*=CI4E6' 57HI>=1&19"!WK]JND$'\""9+$MGXK#0VOY1"R0B'>YN2;
M6V"D)0=&=]U\L/B^(K\]E0FV&NF^X7(_:R<HA)3F5U)O,W&OWN99(/'YB$M2
M YR-9 E@XOAA:RY42#N.U,\[:7Y0B5(0)6@R?N5+I5(P=!O(M!G_!> 'FRPS
M:]O&P3?B"_KJOH6(._?=.^)F?EPBB;T1T-=G]E/J-231K=>9WH/*MC.- \(^
MNLD^.CE!<LI/'C;=WH+8A?Z1LNT2'7HRU6%Q![X5UG&>B:[1LI<=W43/N2/C
M:GMF7B0/;(SK&QT.4;A.(O=W]@;+#V%V!<\0J77H@)"/-"RG/EZ?AJ**CZFD
M74ZENSF_$H?40\)84F>&F=GYP9CE<*(VR"#;5/E"0B3R.]3JJ7F^CX[[^VK[
MR8&_@Z3(\>7'Q#)PSI969)!O3UJENVDIX!GK,5C.NGL_(H63O)+R[G;V7:%Q
MX-X%O=J=41BTT#:Q]U1YC/Z4K$7H93RX/ ]9Y0BN:L7HI'F6Y_H*N"PJ%H"Q
MN$";&J-E3W??'0E^>\ ;EWW1*ER@_PM3)[AQXI93CEI?W>I]H3MDE)5;65DX
M<EIK5__*4N";2(9W\SOT\R1'Q&?A0URUU5 2"3$8I>P#(==1]YX6W[,XX-N)
M_.IMHOLTI,+':]Z#3PW8HH&Q#5["TX?;OE\=Q<O?XV^CF&[NX+;OU3=J$]W(
MG =::]TW [KG?;0UFRC_!IK9CV/N4NK?]]RQ>H/5=3E+G4KW7J6&%[!+ ]SW
MI/RF*^K=_Z,??087OP J#SO(0SMAK[<IKG17\ESY5W=J;_U)%ALV7/JEUFK5
MPX,WYJEU3L9ZSZ:TM/,EJBB*L_$/8 N= Z#J3&OT;XR=[[4\7%W\G;V]-]S[
M(9H$XI>Y\PO_3:'5N@=U$L9.@"]T @%+7ZPWTCR+CTB@3C@3J'W>XW>OTB3&
MQ9F07B^:1K6IV10UHMPD.!>-("W(/,I8=,LK4N:74DWI,6E0JW:D1UZ=KDZI
M.?J +K  -:GL/&>"8\9A3)JT1!E%"GZFD,QCTGA)9O^HU85D9]J8!53R:3KJ
MU30E\F!,F751LF<4A[&1P6(65,1-AU$E'&7)8]+P45-SE$R]2F*3AD&<!J04
M!+CI.28-4E7,K.4 J1XOQCF<-#"JF4=$"4F;M]]4KS'I7&,<<6D6)T\JK4K!
MM3G)3.8#$BTK2@D0.Q_)5$]:IWR+Y977R)4R:2KJGG>E;FAIRQ$S@:U;OOBZ
M6#%IJ*023I7 L++,3!\B4=:H)CMO9K:9*B_794+GI."9=$DJH;7<:3NPG%U=
M)@V-FDF<FYUHTCA=9KJ4R8@T:?A$YLMZHJ5)0\&UJ0C4ODD#<YG&TDZ7-7FP
MI$3*,EG7I.'0)2&QLHU-NN"DG'@D2GPV:8C4Q"1Z#K8^ +)!.Q%>:)77ILD3
M2?<+K)4L;])8Z6+8P@1_?92UM>W4"75:1A3SI$O^JK%L]52'<R L*CNG.X=-
MGI8NX.P:4E!.&EYMTCLO!^:DJW/+W0:"3)R31DCM.N!D!9TT2D+F3X]TF#0F
MES'_=B;728/5=[2',/ELCNY/DT17CLUW37,[&^B8KHQ,'_Y)0W,9@VLG(9XT
M6+H8'#UO<@[=/R8)G9![269GG@U(_.?!NL-C'Z#88(ZXC#EU3J,]:1K3Q<-D
M4GKG0/YSDD#JX6B4C M]H/8&X&MD'VY,84S%'W?>5):9+!BIW'-H_C5Y:)B$
M) [2Z0,C&R[/"\R"K*3[.50_SX^<&&#.!A V 5%J'Q3>1M/T5I>TPT@48RAP
MTNJ6-1[6T[4.1 ';-)TCY+#K6'.B@&Z:3XG2$KEDY8H"K6E:Z^4(3:IF1@'4
M-*U^78"BE>PH4)JF74&2;_&+AA00S5F78U4N*;"9OC(G.F0*550*T.8LH5]6
MN*7P1)VS,*]4'J8 ;)K!%M(REFJYF0*V.4OULO5M"JQF*L:3!DJU=0K 9BK)
MZZS54T Y9UE?O1!0@=J<97^)TD,%3'.6_UFUCPILKO*_3!VF JTY"_Z\"E!%
M3,&<Q7I!):H"HID*\DXEAJQ6#JO Y2JI"\MS%5#-65#GU@8K )JI8.X4B778
M)<H*A.8L;_,+I14(S5FVYI5K*_"9M5"M5#:N0&S.HK92L;H"L#E+VRHU\HHP
ML%E+WSIJ\Q5 SEE&5RG]5^ U;]F]77*PP&7.@CJK!&*!S4QE]('J+!8HSUG.
MYU5J+/"97)"3_)-#HUAD@<B<Y?IZ]<H"D3G+[<R:F@4X \CH__-#"QLTX=\K
M#:B?YTNI 877E,(TAN_?N]'AAZ*&Z ^)\QZ%T>&43>,%_?,5/_\&49S"PO5N
MG1X.#CR51R:^!8GC!V?,_ 1_4W,:?ZEM(B!/#8A#:ZWO&\/DAW-M7_3;N:ZO
MJ*9HD.T+LYG>0L1R$V5G56G/EM)6>TWIBG$VW_MZ%&,^*U'K0:'DU5VLH$AM
M-NA$E2-R*[.7[VNLGC9B(\X.36Z7O\'20H+R%4EUT4W<<9"GE>&0=+.-,3 5
M"X0T<)7M;1NMM&YG.7HY=[-UO^@E@[OL'74D8\LF0A/U/-%::#[1[20J[1/=
M:J-Y#HV:3^T)U!MH_O9V_O;V!%IM=//59@I>"EMM--$\@X<8.B# Y1 06T-2
MZR_ "9(]>SK<]IKGMO[XP)[(^4/-WTIR3+"_M_JQYF_NG#ND/<NN0YE/O<+3
M0AHY 6D*P%0K,JGF@V<K(U-&Z%I&7CTGCXSJ(96)>9HP79B)N:4X31JL"THT
MRI'C+-"35? H419J.E0?:%J4]$GZSJ1J9+,H7Z3"_+F9F">73J2G'*57<I)@
M]A5.-^F:-'V4S+XBI5"J;YJ>-_V4A9JF)\YE6/&M9Y-.2WUAD8*S:6_2B6\O
M0ZEFBIQTQE&S29<'<-VQQ#LE=T;9@'<<+_;! J<4A0>SCMFC&X]JJJ-H-O)W
MKC/2-O)W'4K[BKCOS_0VIA^;^<DG<(X*G,ICXQ]0D]4V\Z'- W5)=H4/#.K2
M-OS5#6B&;D"X_@LN 5GR(\I&\-OV<[9I?DCMS\?I'G!U-^J98:X3=+QPJA4.
M,6O^$CNL8:9+DDWSE80K<R@GW)6ZZ2>-Y_7=O-OIYM[553I49@.3AH\I5E0A
M8V [:6#Z> R8)E(7>!E0J&_24'%/F]"C9YJ/E5(<2+?4.^G7.2ZB#'EMN!>X
MP4VO9ZOKO>/#+TZ G2\=_#N1 >HVV'&98,L%83\B(LX4T>@^B/-%>BN<;SF%
M$+L;$7D'%K^2/(F\H"9]XQO3E\LEW)PJNWX/29E?]\11@F5ZVK"L\L=?? "Q
M@GIZQ&\L<BOC=3:_N.HY;<^4:EKL-H;YI9ZY5"PP47&[F%](QBHHS(%P@\]A
M](I3C&"F\! >4YSE+@I=Q%((C[TYD>[+P(GI0<2]?YTQ #]%(3AEN<QQ7D3^
MJQFCL?G=)R#'A(=\X*Z U\/\,BZX[UI&L![NU$?S#W?9["F\B/7.RVQO?K=I
MU[ORY=+L:7Y95>XF)PTTVIM?0O7R+D^$'%_A=;7#8*)=>J]JS%)R[U2#S[I)
MR53XY$30V0#)$5.I\%U.VK.!MB?!N;HM+!ES-ABK*)14>J;)MY,V6?<J&M?>
MY=@"Y;P %ANJ1!=52XB=S?EFB;R<NTDCPYT-S&*%22A+M:3Y>1WRGD7^YBF8
M:ECHT+ARM8@^'A7G![(>^:*/]\S67AA\RERX+DQ!%:/L'7/M[H&7XK*KK!8V
MI#Y5L3.VEK%$.XY]D/BO).)^QJQ;=X=C$)UP.:W 26A39"Q)W$^SRW>.X?(4
M)[Y[[[_""!VR^PB7*<JH)<]\3O,&E^YKSKO?>0?QLW/"'(D//*VEL6FOCJ2*
M<KA[1$P1G+//<U<@Z&3I8M:(*Q%I<;4MD\$_(SK*G'T08XIQ=9I'/^ZV;(7A
M=2<:1$UP?.0&HJ\D)\4)&(=?W+ZW5)254G857D.;G["/YCD^@EV) P<V6K,^
MTA/FO(X>Y8J]TL*8CIM";W,/?:R+5/7BM42*E18HJM*IQ)4]"_U5"3Q%&6+2
M7JX741]54IFT"^M%<(DDI$EGF^D1.15QK(\L-3;90M09(5_FFW1RFNZ@B871
M2>>KZ0X<54*>=,Z:[EBIR/##I:@9"X02>D(.FMZJ4U&".(%%%MEG&*';,SGA
MB/ _4I_0S1-(R@)4R^APC$+\]+7:,MJ.TD!;K.4Y<$CUUG)!CP)'6(F.QI1>
MYMP^(OU%>4%9)_L6<W/"D;T<UU"9GO8M"T^-Z[XKT]/8LLXO..QI<D*VI+N;
M>_XHYL'UXVVVLH_,! ]0XGXF37KI(266K%N KA<W<VE!/P<@3VJR.$0P\?\D
M?V>NA&T!U#.\,8#P79TBL4R.5%FM[2-9)&.H4BON8BX.((6AG^#G[M"[]]_Q
M3_RX*$X'8XL@MI1]%'@/AR.,WC+W)^XJ>#T,GHD0\:V41-,_X$.[0]CRU\'M
M8H>J(R^]5G4=D7@XB[< !;%2"KNJV#8+ %4E/2D4J^#/ D4%-:#VHM>\VN<-
M%L^R(T^G\\:0>V7HD[FUOI/^G($<XIH?>5M+8.Z%.SZV/$2G_=S<D3DR]9]Y
M@]9-)B1*5R^O]503N(W \:F-I^7-PLNA(VY<Q7(63@Z=V1M/E1VNP([I*A3\
M9ZA19D2;H+6V*BXVI$3&8G@]+#^XW%JD/""&4SU,G]I;\#KJ(_H8A3N$[ &O
M0_A4QVALSIB+YK/)Y\.WX;8;FGOOF4*EGL?("4G96#?%IUNB((^@AT&&_IH\
M$ E$QDV"U=K<$4!36&V7B(GZR;WC5CU$;R((HV]^N%LZ1_1)*S*LTQ#7TCLS
M++WSQ8$^MNZ\. G_@J T-.>Z@3D-\%9O "FTNWV2>TF'.SRY=;2%Y2</Z 9^
M7W]SCO@3+M>];,QA21)?!M3%-#\==%JX'N@A/3 G5O]\AL6FNF\V@SN>/[/D
MCN4Y3-%:#HID&5;Q$40[Z!SWI'(F'5EV6RLX-8=D6\V&Q1CLFJ@Q;T=V6\T2
M[6\@1E=NN @"'Q<RN''"W]G"++NQT3-6R4C!-[ P&AM5Y*J*)8=TJ4VU3#P&
M[O>[Z.T'%TM?\)3-.__E/.7\#U_7'QL3K'R@G32#(+YWX"[*A'0);4O41?,,
MZVS[+C=J8(T[JQ-&FZ*PS[!RB?/.ETMJGUMRDR)M#2P.F.ZDKM-*<V,+*#7*
M^#/:;O@Q=9#8E #@/81OB*D2\:F@518+4!O#8''(HW,Z9#$F50,48U7,YI80
MVP-621&\6&:XVVZ!F_AO !U5%ULW=W("G6@,J\PHU<G>IC K=-1F9IV&L&1/
M,8W)2>*X8:^7QHH\"]Q'\ 6$X)L34*8FV\LJ*EI&AX-/>-(]$!\7E1&L,+M+
M&-SUUUW.ZXYAD_)#Z :IAU/091&/Q8E#)+%#O(5=FUEQ#&-@%Y/)HUXEL.?U
MT+X5QY.3)2%X1MS-]8]( 0Y+ %<A*<^+?G$"_\],N,. TW>DVU"6<-+S[!0$
MLE8G2Q;SR4G((PTNT2>UD%H'2Q9!DE"NCQ XWBJL&CP^2"V)T]V2!:+;0$7X
M!QS9WX#3 ?_AN>9917GEG85O\Z4UTD6/M+, 4?"^6R,TI;?42:-W+7S>C=K8
M+Z6U&([+GB8GC23C[;(@N,;[X:2AD'J,K(6UJ%X8DX:/^C!:,JXJB4T:!HE'
MV (4SN/G+"!BO9Y6SQB-PT^UU(C4@WA)/.Q7W4D33R?_KU)&YSP[3QHUN6?K
MNL,YA7_- B/>ZWA34::IU),&2<JA!*-4?;B?-"*ZS ="MX-9Q)]*V \D72 F
M#9=(;:N[5TP:"DF!6Z#=S1 BKG&.[?DRBZAD">V-;J^;(3I<.E)T0)I%Y+8D
MIZ++H3-$B$M@;+>OX6+9K4&*RJ@J1KD90J)PRPE=[F91J$"2.[6-=WV@8X-9
M3M/3)MN_<19E'"3)B@GR#$%28%V9^^8L:EQTLQ#0_5UG4='B4I<,ED=M+Y4M
MQ@P>3?K\,&VCI^QA5'<B+O"[6F1D/),+M&9O=W N\I,N8+QJUY)>UP5@5XU2
MPK.[ &M.^J,"6#P/\@*ZJ_@O\DTOD!I "3"=#&Z=1.[O. <HFAU.HH?.V8A3
MPYUS/I-UW9R6@1/'<N6.VCT,AN&2/-_/^%FD^NI]<ZI^PLDXH#" N:1R8>)[
M?I!B V'N[^^#F)EW2KJ;YGBQS^2-A11V3*#OHI]6$,G=#CRM]PZKG(Q*3\LV
MX.X=*Q; NT=<-4OC30[[:GOG0*Q\Q$A])?._.=$'X)!EG]]HQ6'E4BZEH69:
M703@'>?^1V ='!<@F%PGB)&JR"9241=SN=!:%]-3E(B2Q @ZF:M]A"^5_(II
MB22--=#;FMV'ASA.@5>UN&<L[ E\(Q^QUB+9V;;%?7&"%&1_OH_@&L WWU5=
M(V,,W2?>150.L?GG&49H_)A;?YC* -1&&.MMQ0T[U3.V'?J/A A<?_J7%S7G
MX8(J*9:6AC)9 7'&Z&F5*6O18\+-F@7J;!&TI%*A:#@+H.2$2GKM,@H[G05F
M7-FU!I6DI-@':F\ OD9VX:9NQ&'=R[/B98KR2Z\7SBP<VB\]WRQE:1;@*5(K
M ^M9.+P+Z:R30ML'=!9>)M*'5).:/)R'O/$','(-.#'P,#"(J/*RJN-]!,,U
ML83/*(U&FLU2FV_19A^EL1-Z3XA:$P#"U2'T7U.L<2#HL$\XF@#;+*TV@#G[
M(95X*H%Q-Z=SD^<LQF+QS8&>R BL8>#Q@?*4XMU$7(YH#(LW= +Q18JDBH\X
MX$DW5**O,P9@<38Y+VFU)M<B+6:3H8^[TDE%A!6=I)AUE"0]+"X<WUP2RU):
M6&VK4\^5]&44)S&9^&MEXK&HH,5E@VJ_L='HI^S?%;I"0B]UR9YD9C+I:UMY
M%'-OLM'A$(5$HEXZ1S]Q@NPBP H'?"/*['V*:TECW18GNF&]URJ/<ZU>17G>
M(\><7T>EWJ8_D36CW[O#,8A.(/.0>\YS)4E+K7)CC%Y&2Y,]T@[_!*P* _J_
MQU[(F+?7F6Y#3THYZ^6KM.=1]XH"Z,5>L3AA5;3FLE2- QLCD]J1SR+FN/49
MV>W-+R&SY=*I\2G*W[T)R<6;".U*]7,LOSQ%R7] \@+<:!=RF$1_WV?0*;!P
M!B#[^CGTD_AE_9E+"?P^TZ.&[/F A).2/^%VK$3W T_"["7S*KXO7YN,/^,<
M\1>R_H<P7Y;C0_(\PX*UMZ^S]Y9FW9SYBN[> 73]&,3%H@@5/83H9(:Q[Y+E
MZ99U5+YZ?, 6JE\19Q.ODCV F[T3YNLFUK9RT;K!5?UZLP _HPN 2U]9 SL>
MI>BR;/F4I_@(, _O!FT/!K67^=XL[K/8%)J]O0IOD\XG#4JGK)@3A^*:C;^7
MAP+:&9N1I[F>5P6&L^JE.S2+'1 *,.IO(O/P>NM%BNGP(#-IM#N5%9HF%(-<
M08TGJ%D *J_"23Z*S<*5U6XMKO(F-XO=H#X=*P';Z>6NP/;[:<M(O;!<>DKE
M:9.I7J:A\PUV%NG0^WR^KS(;SOMO@?.58W07TG2<HBN]=Y91>G0-F$5>_:&X
MD,#_H,!ZZIQH7&> X1 QBXH)/:I4O;A3S"*5OF5ZKI*+1A]Y_"T,#+5LBY2=
M/691/:#'3<H=1H:K(V!UO&X)TR@"=:_1HSH](,O;>1''Z:&X*HX "\$X.[UV
M'TCQ%UYC^NR-Z1LNX.@:?F@%T^0=UR\16C2IU/-"J@SHY:H*WSPM6&_]-]]#
M=^S0H-:^UUY()QHP9A<MOOCQ[_<0@&KIP"%HD?J]YH-XQAN5=JG9H*YY_@;\
MW1Z;YY!.[^P ^1!7F"FWLJ<@#]593%Z![4G4GX7_H@%WJ&D#>G7)-;T#EMDS
M592&63@,CN5Q?^*[,)Y34M<!9^'I=75(G#GMTW7.J]O1U<UNNN>@JY8]G-N7
MU2^7Y>O4.)XNKT\2&BU3JS2)$R?$U=PS-^Z>;$_M[QDM9'4V\Q%&L?:W<,XW
MV5:O+G/QKUR%I8\4,YV*^D"CI97["&Z!CT,>>DLRP_FFT<)FC"M]_?MX0<N/
M"S9P] I:^WM&"UGF8XN$_M*"'^$_#86D]->/%N#* 6O(XP5S%V:=&N#;[867
MJ;'*J#Q:(-8X@_'"W'+[-H&TVB3&"S9%DC$!M^HT[ 5\"CSZZX?Q)_;$%[H!
MA&6_?;3PBL4H ZA?.*GQ^< +S_,+P 9U]/=E%!*K6>H$V&/F1]W.\1?,9+2P
ML^F*M=B^\C)WF<EH85<^Y4/OAL8)CO9^J#""09)IL[]OM'1>H9?ZD@;@(LTO
M'"T=BL_B8K>#8.<D8! Z[3X?.UZA>_"8U&^W[L-S\I@]F"0.3&SR"K!O/ZA/
M=;/PTNMA+SJ\_VEUN?LY@SHD#,F;.-A]O#MJ=0*[[L9ESXR].!]E%\-=>-T/
MU9?2620ZLF\GY!]@9Y'TR+X-DGX<Z"/GT57.[>,=>!9ICRS<(\5'Y.'2*EVW
MZ:+GYT*?G+;+_VBO)OQR7.Z15J7_*FWK??TN-FG:$7KV;="E[^?%ODT[NJRG
M?1OZJ;W8K&GGNK9OLSH]"1>;=35+#+M9.I_UBSV\6BZ,B8>,_,P?M!HKYK(E
M/7D1%'MR-4O8)OPQG1**+9MBYN=&Z'2+Z//0Z=)W<1RATYV)Y7'J69^[S%V8
M<+XLQ-%/%)GR]U]S0E]S0E\3,%RY1Z?O_SI&STOY10Z>E%7GU.S=F&N>Z2M%
M=YC:U[^9VQI!_3HJ9OP^=NB>^H3_8<HUM>Z_&;E2CSV[<F 1EK-+K&P3^"-G
M.E\_]!,O8*7KP"SS*U\/RS"B9A_9ERV]O">5@_EZ/@;2=WK)T6SG/=.CT4"]
M$+GF7,VM\V+KT]7?KD]7HW^Z6@1D7.#1%X&?=,.89>>1[&QL<0\A(G* ;O>$
M;,,C_A*\,^SW$5X/VY;!M77R^UR?\>Q]QKN^C=4MJ0#=67MT6]^"-Q!$1SRQ
MG+&([*G"GL:6]1&$2(P+T-P6WL$/?0QSXK\!F87)]1V)G-9)W):]L_JPC"'Q
M^S6RRR-,XI:KHB>X3>91IZU/.Q5W/V8![^SLY=;M@)3(V-!TQ1?M+*";I0W;
MNEU0)F!)D6HX\$P7;,H0W#CO(!YGE:9R ><U";0<7@_#VOMC%,?WB,)Q=(\?
MIGZX6QT!)-#'-V ;U?<+_1 GOLM=9K<1QP3#/?K5W_$M')T&'!,(G_R0L*FB
M&B-B</51LC>$3R#91^@3_%I KB9]J'6>@4TW"9>-M*7WCL=U%@)2_X"6!W]&
MHDZ?>';G(;U4/(X2)S O+O$DI9$%92U3B(FL7$<N\]X@D7CK)S02$0A2%PQH
M[&[-YWP//*P'M";-7RFSE[EG@/Q(Z=O42T8T#D.^08RY"U8LZ&Q8'!R]AI.?
M(:*LHZL%Z^JJYT_0USCYU>;7C0BEAC"]A[GDI<H]6;V,[UL^LXYL@]_9/-N0
M6HUUT^<+%YTD$O.$UHW"%)9C0#&Y7*RLZBU"^6P6RK,&L:X*JJQX- ML%17I
M2\A[%GCV<OY%4N(L3#X]<0$Y*746""OR@HLV9!: ]B,,,-6-7@R/MF':ES @
M4'IF@6TGJ_I08%$MX%,[W")(]2;[M0W2GLZV!:!:]5(SLABDB5A\[[9;X&+O
MJG)V+TCR? %N%+I^X&?GK%#UL52:HCF<:HT9R]4QLM6PT&5TP/+7N&A(JX%X
MBO!)3%&SUZ#PTJ.[1V)_X0O@4?RBKJ!A7O9=P<$(&O@OG6>XVFY]%PE5U?DU
M0- _OH&UTQV/E^B*\EM.3)H&-;#*SR'"&EU86-5YCF+_DMVDCF7U45_NL7OS
M0W@7.B0_\,4W &/ 48!02'*HT2*.01+C\/WL7@N"Z)L3NCJ0D?D6J^$BF1 6
MWG]3OC]CIZ$,,  RAV< #TZ(IG#KHRY(@W!;][Z& 2W;5IJFH[29U 'L4/(4
MC0Q:Q.99/#WT "Q;\)Z%_;8'1%4E^*O=\8QS#[I!+Q:@J<,K4#_Z*+$]>4SI
MRLXLZF/WP&59RM,LREGWB*>4'M9'3>HY@-S6WF91,UHW)^5HC;,H[JR%,ND*
M:#\UE^U_,/O[N![,*ESZT7=>T<%(?" ;Z<+HI-G\0_^V9Q@A:DM..,DD#KC#
M(79$MB3!=PFZ@[! G]T\-!N0AE'-.ZB/^Y6S)2%\A%&L0'NT3O8L)F>&X0X'
M@2X="$_;".)4(RSKG,H(@QRQ%YP2=[7]'&<$+W^*FAWMV13T0Z9[=MH01F_C
MRRM/=V4/9",CJEV,+T3]S<;J=Q@: 15_RTU-V#X"W]#E&7H+UX6I$\3DOT@@
MDM[+BX>W!Z#*K)Y:'$>VESW+J9\VV>4T>MFS')RZ(,1/)K(K.7>P9Q%J^5RD
MN_=W(V??JU'>[3!@WZM;.D<?J7;^G\"C6XREEB0>I>]UG"6?1^"@?W+&U#PP
MBIWM.3SM&Z;Z1H+ SOUE8V5/LUZ^RA[@B):BI-)88B*2,Q"45C<=RKK6%_B?
M,Y--2.JC6U5DHV,(%4M;GH7?@IS)@ L;3R^?&X;=3W3+-J#5R6.*AY:*]2Q<
M8S0<6I;=9F[X"0ZLG&%(JY]0_:AN; L3N_22Y3Q:]X&?3=#I.;;=[%U75S8)
M=)O&LEG%?5Y E4VKW"P<^S3@5C'_S<)O3P-DHL2OT_;6DP=0A\US%@Y[ET(J
M86B=A4_>I3BR#;VS<,3K13;L8$J>A9>>!K!S\_.4G?)>(D%YE@UX3U*\O!RO
M4?CG40T?[:+*C1<%42_C]2:E2DN:KB*)PRM(=6X1UK56FI\8GZ)DG;[^%[C)
M)D)\TL\<;*GXB=MKGEOEC-&*QM+;Z-W.&":5K42_G;<1_?*U+'#U$40[Z!SW
MONL$E/K$_+;F*9!34KG>9EATP:Z)%_6H\-OV1Y2/C,+B[';V/!A/PP-N(I[*
MU/N4?R89[;4L(0;N][OH[0<W2L,$GK(5Y+^<)Y__X>OG=6.6E0_,$\8B3?9$
M$!56C6\UMFCR$K7B*<W-<9N\HM8RHP2N-$9OJYEIK^!Q[X2W,-UEYX8MWS!:
M&H.RS6V;#+D(B%P<,((,E)6'T<I(XN0(L\7BGRJ7//KMZW+1O,[SOQK#O)9J
MXM\I]&//=YEBL6POS23]R7GW#^D!R68NUB]W8+5]]'\'@;^/(F^UI05QX^#$
M78AM<YOH!JS3&'\./-HQT#BZL6W\',+SE)SWPMY3LLMG$#H!>>HFYEY26JTL
M/D_=XDM&M V&S=Y)?HO2P'LX')'P4\9>;KC9O3H.9FSQRE%2/01%#1G[15?/
M945[Y7%U7]/,[S]_YW^ 0[^X9?M:)N7S;FU>#\W04[]*C+I,-]T6*Y#4]AKQ
M6EX6F!HI//H'/[/%QJMPF1[2P,%LJI!]5M]" ..]?_SDA_7KCVH*,S*1$:*9
MV8],09A_NQUO+9+V]NIC2].F/0LG8H9MO'PPY9NM^X HL  =KE4<8R.P2<^+
M=*H6G^J!:M'65,E%ZH6B)!NVL7W29",TZG?UWYTF7(K.I0R.-0N(A%;]!E/B
M"P:3ADSJM0_#57UTF#0B<@\9U!)(K5>#F0+%%JD9[Q.SP$E! ^$^G4PZ-$HH
M:(N.YZS0X8I,Z@]8D\9.^J8KW\8F#4<7[BU\GILT8M*LJ:$']Q'R9H.2*\6,
MM+^83CJ 4(7$6!K.I(/>E"[ BYZA9P5CB\XX.$\Z0E '?0G?]Z\(RC@)3#J0
M\C+;I[H70A\AE..20>0]'"8=)JE$>%R_B4F'0\K3E93[QJ2C&>6Q,N1 TD]P
MY!5^GL=)@?D I@"KJD3\5*(^BBC41M64+4.DO7MW@]1#9),Q__@YT]?1'["8
MX1RP:H[%6X#0"^.7* CN,[IAN-?U_K6V^?RJ.?5:-_U;X$*<#2%&_"(-,/^X
M1[QG#1)$XR3OR6]^LD?M\5;E9D1V=G.]WZ'9*T\T.73B*;-\QBPN8WT5&Q8U
M.E'O%]A&*/39+U.(;R\A0)H'MPT<M=5^_;LE+P1#W1$2II5^7HJ/A'36B0,3
M&P0Z"W'ORO\G_1YD8I_ZN*/Z>%%Y _ UFN\VZ;XE)_T88>$&H;NW%RM]=M/<
MA>UTL*:S*BVC U+P"2]?A%Y6^7$'T'98F&5)D+SD&4:X[/<*K@%\\UW R I#
M;39HEI5\!ACP? XQ,\L*NZTQ*7<!(3;^%#3SA [$^2\;]%/L$.>0F!N\K3J*
M9GUON?KR</N$>$8"0/C%<5WT8\42QDY7(-=1]VS+4]H\I"VK7VVN$MV,D=%'
MM,<)N@E=X+]1<DTQFVF&EHR_"@%[QQLM!F45Q%\60'2))B?L,LK@:=1F@T[T
M!1Q3Z.Z1<+/804 .<7-23!XGW]=<@HKT-09_I&AF=SAE\@9]%2>]#:NU3=/G
M)KAAMQ^6J/!]0#V8S4\'G5;NUL:<6/US<]'O:.S5MG+/\O);4=L.O]D,_G;^
MS!B:)"LPOD-QP!62AS< 'CB ,IM;M0 N$^!TL(61\=,#4=O./ENEU2D@+T-Y
M[0*D1?B1".%:NV&GFG_SYS ^ M??^H">BY;?5K=V<<*A6??^*XQB/[Y'HI='
M]/K-'J!M!2GZ$)NN.#J1T@":9W\/7F'JP-/F6[391VGLA![2=C;?T#Z?D-1.
MN%@I5[+7T&48 [D?UQ\;DZ]\,)C2R<P-+.IB[-[@F;ED$YFJC:&[,*T?OZ8P
M)M2768JY.BNON?:7<P_ X(0-L^)3QFZLG7BQW$)W<Z*GG)/NUH<! G$=@0'B
MW&)872=SJV/K.K7/!V3M.OBZ5J8N?7"Y>\UKWLL1*<NX';+'E.QU!=W60>KA
MBEIY,;>\&</,V&4@S:MY_/RT>%G>LY&M-]#\[6MP3,C %THAG<;IGV)1>Z7+
MIMJA#W9Y-@<_I?A+5MN',$Z<(,B+<3%XJ*";[MR*;A*U=G(-L"X*0)CM)/IB
MCT\1'4;IG1Z0A ]5R*'27O/<GIT3_IIL8X%W[\,XJ>PI;7JB+IIG> YHK;%)
MVLQ83<V]]+4*>=X[/L3Y!<!9XF6][TGU-;:TG J0L@H7WAM.DK")%MLM\4)@
M+8G?IQ_*QE_VR4G</78607HU_KV\8F]2;P<23"XQG>NI#](3[\BCASX?H_#N
M';AIYNE1,BX>&Q%U[9';9=^,0,17!I[  D&(6"_^;+5]AA$.N/L8G9TC6&Q0
M?B#=$K0?.D%.!:MM>TI4B5G4I\_[)?O:%D0OX(_4A\#[Y(3I%INC(:+<9ZQH
M8X\(',?]=+LX'@/?I:5?[NUK^I3(SY)S1RU6<1R##Q-Q#, Y0@F+-"\@!-^R
M)P?FZP2_EU7+P3-:;8NW%(45-3K:<%TB;N4"@.X0&!TV(,2%7 4%C20[6[5C
M*^+IAST+L2>;PHXU.II[*4-7)<GJ X[8GY3U1M9H94'9  PBSJ#@0TPTCZ3,
M)77NW"ZZ:W]D9J[L B3ZM[>)$&=-(;%H%IP5US6F,625[KIGCGC'/CC=9.R1
M>N$WFUA"!%E!6(FM)PW-)QGC^9\6.7\YKI^SR(78T7>T#(&0=-N<-):J'J%5
MO_>VT^6DH9+RMBZ)J^D*.GEH>-ZE!<=2<.R<-%Z2GJ"UM(ELK\LI)\"G>&T6
MQ-3PG)P%P7#=,*ODHGPW3AH^JDMHR92J)#9I&&3=3ZN$Q//TG"KCD?9TYS#H
M61#4M42)*D@TK](2(+8_Y^0!4@[Y.6MQ:@ZGDT92WCV_A*^3Q^ND052N9H+=
M:">-B,!(<*UC1CF"G9R$STQ-!/:D,90*;BBQXGHS3QHG7890CM?UI)/O=#%^
M5M[$!4_IDX:N@S&TXJH\>6AX9JNZ$_RDH= LCW*%T6DBV$7TJEBZ)HW-I6+"
M7!C2A=><<E#'I*OKJ%U\C4"222/3@=EWBW29-(JJ#%_P,C1IK"Z^ *JA2)-&
MJO,5(!4A-8O,D@ILK4NPUJ0Q["+%TCW@)@W3I?RL&DHW:: ZLS-AB-_TRZHI
M'D.Z6]><86)3%S,\<_IEZ+J^#M7?P^>,$Y6L%(-G^ZC0-Q;\F)H1T\ERTO4,
M.Q*:()1Y^F4-.Q 8VYVN#[C&2F%5^4LE$'WZ)2(52$X>^#G#QJ8_Z10"TR^V
M>0E\BOD,9E [LPN:XGP* Q; '!-PO21Y*+"^&H#9;X#2:20*,*_FI[:P*$A0
M44!WM:W(0-=,AE&@=S4A<#0[;M:- L%9&A&4Z:^9VJ- ;Y8:,A>]5@Z1 JJK
MBM*$BI^_I,#MJIO4!!6EK"K%8_]5(ZECV,SO4N!T54#X9S1++U.@-8 *87&I
MQT+06&WK&!6/%Z>\%F2)JKDBD*H5;V)!5O]&(ZN2D)7P%_MSFX(G!.OF&PC>
M #GY[/I#'8>S'H#_H#MA\RVZ<-W%*.-8+G9ZT[%@,LXHEHS]8C2LF PSC@7[
M;SJVF QC_8(76W1%:EIU?2S=5064)]&FVPL&LGXC+]P[2Q>(M \D-1$O*N_N
MW45-J=F2+QO+DBR+Y409BV.UMF3ZOP%_MT?0+M[07W?GB)?2TOA!:ET2P]BY
MX-N<N%Z<!#P#Z (FE2H/8Y$/=TN(%]GXY"3G642:ZP.PE+PG'7K7$VZ9"#_I
MB)5^D,LDJDG[QO<$')&M)^WVK1^XAF8R:>]F,7J7Z$"3=FS63W@].>I&B1-,
M"#"V9J;5>?+G#+T0[) \[(T+/Z9ZUX=_)-(>7J.Q'4EU#7+:WI":D*.JH@.Z
M0P[^OG9^6LMS#SZ$VP@>LBWS/#];7.6/HWQ%R]?V HX1Q%LO>$]C-M=LF2W"
MVF_2V _1/9!_+\WVRFIJL#9/':-EY!V>8;3UB;O()W2V$$W]$GW[' /O%L0N
M](^9PZL4XK*C6;7\!W2QO_D>#L7!IV(1>L_8Y0C[^,./,$J/*YB]7R< X)A6
MXKP5^Z\!N O3 ^%*2@#I^3X[^+;HA):2///,S,(0)@/3Q2>T#].8#>%CND#4
M=,[[L*.U8+9*H%BGAX,#3SA* L,)O!+=-Q"FH#C+F#QQI$2(O@:CN_9WH;_U
M72=,\A9%TJ^K,&)D >X>>&D 5MOFW"I[?7/*/ZP%$S;7UF$D<\LND@<TKIZX
MFE2_N4!N']/22SW#"YWN\C:Z?1)P@KKO2"4T=A'V=B/3@-'(\['IKBDXO]2N
MQA:6LUX<DE%$L_SF)_ME&B>(^<*[=QQYA;E.'&.;EK=QWAGK[#)2+U2UVBQ%
M-'5N8A!X^8+(<GTT@WFS>+E=L(&L?FP,Q(\@1.)4@/!8> <_]/'-F/AO@ ^C
MJ%<_O.[^"21"7E=I9 VO6R5[ #&;XCH0B7II!O7.@<'I.W2][@#2:7;0.<1L
M<-F-C8&,]CF3;SG%@>MM]%>L=Z,W $\;X.[#*(AV/N! R&NN>6;/S@EI$OAX
MWJ"#BM15SK28;37/Z=YQ\P1(Z*ON_DC]6JG6]KRX[4>H!7>1^"=?IDU&'Z#8
M$F93QJZ[FEA#C0_SY%&DJ6KU1-]U/6J6=E">/E8EID[JSCP0U71:I39F)A9F
M[J&MJ*FS\$7M?F0'+W=DH4<(GZ)JNOHL_'.[4I/08C G]/A"1=5@,0O7Y:XT
M)328S D]!DUQ[#6S\.[N2EL-.U$O6-GF7\NG)*[A:A:^[GQ\V.:S67BS\\'A
MV_&&2S,];;>,9[)+>Y"0 M97'PT3"YB0CT8,D\J2T6_GY0I*?M<6Q&\[[)1%
M==ZK4V:VU3+E&+C?[Z*W'_*J\MFL\U_.DZ[6G*_-L/*!-0^6DW'.^(AV.<9L
M%\2K\.X=3S#UXWV6:?@6O++8D;B?57?U]0G*D-%6P#VGBI[4I5'BPV;5D\9'
M=$-A?*JW0A]@V&N'5;<[BEGY]9EIE,],IE-BOH  !_@^XTIY&^B$,:XU$(4Q
MUFZ3TR>0[".DL[V!F*3-S+6Q#=*P4KQXXTJ90%)NKR*+J6"*RX(.FOV"%K>+
MAY?2$'5B.P31&QKT/J42C4A<%G8SMB ZM:^^A8@![OUC'LOK[%A:KGQ_<VJ.
M0]AF$KF_8X)>;2L[P/?D%W<TMJAGZ+_A6.O <6O%UJD+832VC.B>HM!%_#<*
M? \?EH()<;>HRTB:6=D7)PBB\'GOH'O4!2FQW<4/H<OF:8(>%MB^6'?CS:GV
MB93U2V6L88U)Y13I5,2Z$5DFLDN&&W3A+TZX U3R;'XZZ+0^.>^X(@!S8O7/
MAT>,L>_GS\P=W/0U]CW?@:?*E<6+KF.VMTVP$F5P%W8;QQW'V2OU<33?;Q^A
M?^-'W NMV<0*42_/=[!&URR('^(XQ3!5:$1"Z!,.,2Q_S"JFL/EC[7-C>[ ,
MG#A>;7]S( (J6<$7G"BHA#*K*N2#>(F$(.#=G/)V<=Z0=0PN'=48''6ER+MQ
M ERW*R,IQEJY76Q92*[9K;9/(,%>W\R=$_>SBU3OWM$,_1@@I<D%Y8<E);%R
M2G<;R[S!6LY05#J", PWL[#!RAI_J@97!?O*+#"4-\;4BB$RK!VS@.P":TEY
M;$5&BED >9%]HWS7O,AJ,&F<&;:% KF&?C\/*&A/XS6,)@V#M(&B]D8I<45,
MU85 U1Q"]_118F^S(,#.UABQ+">XB"<-KRXS>L$91<K(Y,%4U,9:MKE91,1V
MT</4+(.S@/%B<5CB=I]JP+I(U*V;:F=!3EU.Y<6VXGE$'>LZJ!VDH%D W(5T
M^7;]>40NZ["G5+3D68"F@=9H3R_S" ;7Q0C%FS +/+5=V>(WL^$"S"7]RCVP
M14):PZN\X;"=_[6#KWD9)K.LW*SE'Q%^>34=;-()O65T0-/=XV3W;R1A018K
M;"Z*MYAHBQ*:SA+MAN;3C'/=$NN-3*>/%KLW-9J9GO#(\EUW\K-YAI&7NHBU
MK0%\0_R,X?=';69BHIB#Y'.(F>$=[+;CF_)7Q+N=-+"AC'J1N4%PCMGMKWG4
M67Z'RRA 7Q]EMV3.--@NB)S6YEQ '8B+"<9(7B=ZH8!(F,VM6<"-$_NNY.RS
MML:FWJA/6+?YKM(D3IS0$R<H41[&^@7S]E!MC&OU DW+P;H2-WZKVL(:9G#K
M!VER5I($[*!H;=OYR.?5(G&U$\(<Q;R$(JR60&MI?MJ%H"0K4)GTBRY@PRH-
MW<3.]HV6Z6ML:?<11/0>+E,(0>A6340X+0.>]@W8HC9L94]E!'-$A_../D5A
M5#\)_.M$T&D>N8],G#!L-/##%.>++6UH&1%E[1 I@1@M #H11#S8@2=BF,I>
MN1*<XI%L5@(0JV:!T><W&H8133:GT3S-)1>"=NL95/ZY/*ZD:L_-)H1FMMJR
M^22O!V499^,U]:7@[&^ E^ E_P>G/ '>__XE@2DX_Q$1)WA/[@)B$/W?O\3U
M*MK-AX;2 .^'R0^>?RC?&9R@S(?"*/3"?5!HVFTY[P.=D?AK"XFM$YQ9N_12
M/6)_^NY0$]:[++IM_QWYLED&[8N+B%B-BW_ )S8*O_-J1LRSCQ#/EER\@'-L
MHB-9?&Z.U;OZTLIK-PKBHR$T%BM4[1@I%%*F_]*KE6?YM1F /1H9NNDK^*X\
M&X([@NH10S\U-B]<XA"(;.$U-S6ZV7GD"'2U2%>1433R]H%86Z@T+$IQV.O(
MUZ]T<0B-XB,%0_KJH)K31[IH'5RSM,^/'(,>^2;;^-\'9C]:RSFK=I61KUR)
M9U)>&_I8_M]LVWC))XL^L/B[;5@HO7'T@<A/MB$B>@[I X1_V :"Q#-*'SC\
MTS8<>GU[Z0/!?]F)(.79I8_5_VS;ZANO-KW(HM99][GO/[U 8)U6SM9<>EF_
M=;*UNM8BATL>W5*/7ADVMH7443@'N*R>UJO'A]O%YNYVO4'_?KI[VJQ7]\M?
M%D\?[]8/3^O-:OGK+ZO'V[N7]=W__?RP^<\UKF6R<2TD]'\?!>A4YH4TF!-N
M-1PT$&&9'M(@,Y!MM\!-$)_R(V^U77C9J6-&)4AVM&HQ"^^_::;5,9/'*@]A
M_CQD9(/OVBC$"BLOX36WC^$<T>5L)"H=--N.=^KF@WC0A Y12!@1U_NZW<ZN
MPTT/3Y/J9M5"+F2YY@E*UHG<(C?QA>?YF9#Y[/C>0[ATCG[B!-SSP.]C<"G%
M#15O(L8<"?*O#E(0,#="^EGN8H 85.PG(']<RNCK!;C1+I.BOSA!RI*\>O]:
M@Q&""3I6P"M4.2Y1,!J;%42SW%ZW*40SRM ED"[<#'ALO>*)IS+=;5M@QENZ
MKY#2W[8EDDT@GZT(^X^+[!.L6"3U<6Q;<K8K&M;,&TAS_"X/]<\ATOLRL? Y
M<)IWOG+W86:>8==]ZO3^X_:GOSJB6^MO)KOHML%FI M7US$*CTMU^XG5$'&]
MTI7,*.WD@2V-?R1(T%S4]4(Q&7]UKFFG\<S5-*!8O71AM(:*J466=TS@G/0+
MS3C.C0;??DEV,W)W34FQ8QB7RR%==66YIL#D9C,,F@)<Y'C)R!U1Y<Y!_T;+
MD<,H?:Q8ULI9./3*6SMGX=.K8!N=A4=O!T/J+)Q\NUA;)^WUJVZXG;0+;P=K
M\-6I=_R>BXOU+_>/J]_65S_%R?HI(@I>.O'^&49OOH=+RWR.<>63,B!LX2+U
MA-2>$20([3"0R010$" ]XA9D_ZU,,U<U!(M5&,"B12Y<-TJ1@H5T(^"_<8A3
MJNNXW^MZ].["0 %XQ+4DFN7]JKY<M&:#3O0%'%/H[M'^+G80Y$4:ZI-B>J+)
M]YW>DLS[US%X;1:SJH%I\P8RMNAGYU28A[#B"@&:-6*ZF;R9+$(/2Y_'ZGMY
M8[$* VCVH_@<)#CV)3R]L_.VM]J8DU_2XS'S0' "3!WW0?3M(=Q&\)"5Y.&3
ME&QO@_=B%G6)38N(_IE78+V5.>?L'$,<.HI^/!_-T+OW0R=T:\?TUH^Q:I0*
M<^Q?/*PY;TP<3[;:(DY%2GZM7C-SYT-X]XZX=[@#]Q$LI;%'++X\^LZK'[!#
M<"X9T0XO7VSM1EL6@)K<LXGTB/:]?)4QX&[!$0+7S[A1Z"T.$4S\/\FOC/7S
M>M@F U .;S<9@#>0.1D 1BX '@G!QY8H7&F2F\R9T\$BQ>P9@B.Z9V[SFF]Y
M?#PB-9*!HJAL**FJ20UF&]E2),Z+158+$DR#6"1EM!IJ%CTKCSRX6"0MIR8F
M&71*$!/?PRC=[<_GI.+71!-9M8UM-E#IIOFBS))LZ8VM8(8J'O'B?IIIL,FC
MZK)40_JB$9K: +;Q-HH4=+$-5?<6(34 ?S,!$ G[QRAV MI.4-OUP;(@7GC.
M.U0JM'49P9X3C"T1+.)@-#:JF.+_QU:3-R< Q#J,!$3?31"'Q$02>O4_5%IF
M3X=MX25/?%XH7B].DKM&<=38 2=AD<Q86.2?G5,G2W[1SR#]D(<2<@@]/TDA
MP-5^<?8Y[R9-GJ+D/X!87Y@[+]G=DFHMDZJ']()4C%->P)FC?;6:C9-9]<%[
M+&,E, 5>8=1BRR=27:\%GTP8>2XV[MA$D+2B*"(CKNHH%M>2>P%.X/_)U-\4
M!K!H3]5,\O+]C1?+RYY/Y.ODM=M?PXFMB6[2Z1FH_/@R<F#4O:H:V6$EW)5&
M#E%W;[N!4\D.&&K*<9<JXJ04W'I& @8SNE0G&N,(*.U^;"3\G:K'1L6!:*2
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M=9C 1^IJW3_M*IC,IX3A.&BW9_ '<%$>4)U7L>"/U _7_%5&,?Q;X(!;>_
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M5T%);LQ #T,"ZD#],7#P%RP;;U3[?!07.88<[URR[!93'P5@-)%@.G7;1\$
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M'RN:3:Y)ZOA!\INY&L'1%3I;*E1L"Y.T:&=:O=R4TV;K;"=8V9K3EE%KRK"
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M4N:QUYX^&X#"=7V*H\1XQ_))^("Y.D*,E<0NKS,3'UBP-*FQ76?FQP1K?G=
MM2BIY;\]:CX7JNMF>^BR!\WW#O1&SD5A^N^ %!'+BWT4I_Y_V>_"+1!Y7(=Z
M_6P(@BLX2TFLMZ^BT?A.&Q4=3(\93)G/S9;%5"*C,A-=T:W_#O^2QUQ()LP&
MQ#T5A<DN"KR[_2&.WG)]2@J%;,:,9R),TCAC0<=W<&BW%+=R.*13K'5QZ@N_
M=85&7[JTW.K0#STJV10U4K2LA 8"JQ9BZI*3)=B1F?[&0X\=]CQMLXNIFJJ%
MK3J2,6/I'/[3537JJ.F(>I@-G*.QX>$T@X^*/CD5"14'S!;?Z2]UIH=\5)3(
M*42FTEA:$/],C$CU(TN+XY_-1F2ZEC4^CU8)HVORFB+)=(2EW#$<ZW@M1*/G
M:VK<6)"TES%GY'R6D"C<TLMQ#XM2&GX%@V==_+I8C]QZTQUXJ9%T3M69^\@)
M6;\E-P.VIU$*23%C/AJBK&.U6<;$\]-;!V)0TN,RBV/0P*(XCK[YX7;I'.B3
M]"BB+I-77.JB?8=UT;XXL0]\_HEJ<5(.RQDXG_,=CBKQ5F^$BL?;77KKAT[H
M4EJ&Q3U'F[AZ<D>%DO?G;\X!GDC9UGGOG)8D@9MR@6D_G719T)EHG^V%"VL^
MOQ22,]AL 7<\/9MT2<\I)7QF;B=4UW ..]9^A[]$\5@4+$^R]YUA*!9LR*-'
MBG90$4CN1:MON?".%(\=6##\A23TX@T70>!#0:TK)_PJE@G%@]'H0Q+2Y0Y%
ML_ >BMRP9)P0][?;Z.U'%V2Q^)C#4/QQ6G[QPZ_/GUI+K3T8G$2#(+EUXFV4
MB^P:RHMJRL K;%H(;@JK#RBP>>DYWA*5<Z:54IQWN932>([$:$-U-[+8 ]UI
M66YJPV<#H-(ODQ>ZW?&GS('^QH1X=^$;9:Y,F"II5<3'S-XQ8WW?@W/<YS'8
M=7N. "KA<"3$=@<**D4O2!$WFPUQ4_^-T*/JTF?.5L]VJ'H'*J-*?;'769P7
MWNPRLUZO0+*G0&-Z1E\8..JEL6+NA]LH?B(A^>8$G*7ISD)%1<MHO_<93[HE
MZN-B\@845FP-^_7PY>Z+.KA@H;T+W2#S(#/(=>,,KH#\Q%&2V%+>(N[\8/B.
MV9!=+@;J^X8)T<"];,;@6W$X.NP<;AXI=W/] ]7BPPJ!JY 5L:9_.('_WURX
M X3S=Z3?JY!PTM/J# 2RSB0DP'QV4N;S@(XW6H T)B !@N4&/A]BXGBKL&X"
M$35,T)Z.!$!Z&Y@(_T0B^]L1-*UPN->#'[C.;<N#$N4&DT8T#,?-;#GPYW95
M4/E_+4>/P='@BIA"_S%JO%PZDQ@1B=AAT$@R.<^+:BF.! [4DDA:3DS40'[
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MWB7+,3*.C-S#:64I'N?O*(.)6 :2AQ1>-LQ8Q,&T6[>JY3'I^D8-39>GY?C
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MUFUD$\6,H.FD8PW! C.B4/>/G3!ML\]Q.=M\C1EGTY^@'J*4Y3FB?8A.[B3
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M5J<]DE8+^$^Q925)3"%O=%XYQ9#1?P>$$TRFKM#QDWDNR&310Q^C99:*6,U
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MU76N,;!.<RPDE[7-GIOJV"*"XQ4D;]>TY<[/:%B74M_)D7_S#@T'DNKB!T9
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M'I>M4E:;KI.K\GLJQV%AU+J-=<I, ]:,JDQ(;$B%ZG%HY$,-H.F%THD.>@:
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MWDK0.RJ+WN;3F<@6T;MLE!=3@4HEPJ_:OW\J1*9%C+_7D??YCS*N"M!!4C]
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MTX-4Z?) IG(J\=; 7D!/?M/%K"?]-\=@\B=*SU*Q.!^E\J;)JG]4NE2CA=T
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MC6E>8+00_*;4O"+U-TKV,>I&R$S+/RL)2HP"1/^C\I0=K[Z-G88,2<BXW9V
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MV,>O<5<&-7<8Q3FAH*CIL!:+YH6DV<:-QX4<_-?1E5V0'1M!Z'@2%?K!H$/
M-6-M>CD71;)S.M3V10%#%/4;$0OW:J2,APASC!QQ9^!=1)23&W<42X2"VWX#
M-WW%>PN:07X7\>6+F0YJA$C]UQ<2@_[)8"-%Y$\B(4X.!WN?]\G;WR6I8--A
MQ),=667CH"[9@.9UT12DKBOX8P^YJ$J)/:D:CP)K7&.I8@XEJZ&#SYW"MIU@
MPG4:4H6_*Q88$8Q NU=<Y4<BADHL[V*GQ++ ^D'W+4UB"FL;*;U:5T=VOHT+
M,Y]'>V*?#&>S#JX-?RVDR2/"7>-_F]K.&&@OQB185M/ A-SGV,HZE%1>&=L4
MHB\[O<,8P8XOHKWATF9LW;+" IT#(B8%#T8TE3':KBL9FL-V7#N\\.:PD^?5
M'+83*OU1#I(@I"F-R(F?:"A2P4@$(%.QJ:N>8+1:&L=+TIAG)!D%)Q E5Y>L
M"#P]XQYJBF327&2L#%B+,A ,(UK72'7Y5)I:?*=<5NS,OLP%I<3VDJ5=(FW1
M7Q:\'7J^V8OY$W6_M+?$:LKLA[Y$W0<RT6W%Q18^[J4?O2N]7!Z%K%G[H?V]
MRO0@&T)8FEER$:(*]IQX88X/%5CQ@Y.37JN62HQ&*E4X.]P^768$EF.:0W[,
MBRE^#TM_#&H.MN$9SR-YD!-P%IR +Y,8AZ].=M8)N+*150X2O+>U9B_%*VA%
MEEVMW:.Y"12PL$*-C7L$6&04-6J2M&)29NA*D$@SN_<WU20(R9?[4Z7U7F"/
M OM4T[;5GR\]O6?A:Y*Z#,>+^'(GG)HA1-QP4:]K171"LV>YX:PN??!>F(E[
M-Y^)B+5.+%LJ+"<*&@0-110A([D:[XE"_1\5+".*R"^>V"XI>5FWM+BRX=6V
MBF_\Y.N9J&4JH5&#HJ:[1^9AP<@7$(W<SO*1)R]&^HCU(2(E8_A]D4_44*$F
MZ6*S$-[^BKV"VXQ-^LF31A/J(3>-](E#I04917 '''&@>6FI'"-"GM*?\;)]
M9[O>9S.O45M->9 #FD$8QG5.IFE_Z99YIG,<;34;Q2T7,U/OZ5UD<BUKCX^1
M5#I*%GA1]OO@%>W#X_R:^KFI"K5^>+/]W7:OKRW0>E )5L@K;TG_[=/(:42D
MB#ZBF;!=9@]O;)W]LO>5-OS XBO$,]DFDC+JATTVB\A-XG&(WUJF*<A(YW3F
M\XQ1."3ZA2A*,7QW YJ]=%A!%B6EAH>A-;PU/5@-2J/%=*5!G%V+M)+M<)E+
MV]?C>C _CSW<J;583=Z\O>]4Q)\)(&-D=KLJ0@"Z ,M7L=+(:T_O,3J+N7+X
MV@6F_"3C#<,#Z@54AMDU[.3%O4E)-02D8ZY70&V!K"<8#_BB0V;1V*XI-!76
MZEMO.YKG,V=(M7;^T40?!F<8"C9'X5"V+V,ZGL&;XQ-"!!%3'@?1@-SV/^WU
M2MA':M>K3P?F>OC9ZR =98:D>*_2C_9\-A:@I%UD8DFC3F0R;BLT>NLQZL>L
MQC:!ZR;&P":3:"@1#B865%0%'[#O\@^SE&]M]MU+!4\F*,G[T?"]03H^^,10
M>%S&O&4*\^\*08-*&A',>;=T89B1()@1!<Z^AT6<G9FZ_C;H@/D#2<&8NI[:
M1K7)7E@YX* \:B0/'\B#(=T[83S(7#; 74,*Z8$<NP6C#B70*(\K[>W R5JW
M%>\W=D_>K^K-^=]<M<M:DHN2]!)K/R+O 9'7D_ V]HNJ,JN;*I:4 N*"'9C#
M(?\#827Z(( 1)@KH@6'1]LG,,!UHCRVF'-S,#;KC,!$PA+KF24#:Z[HGNCDL
M27Y5K^8U+\8BHPEX#CNJH7%:[@F(=E/,;].]&Y/O&;!X6\CW5TKMKUFA_6IP
MO+,RK$LG;I< LSN$FXD)EU+]VPS8\2],#'<8*Y7BF"#6],0;%".BK$*, Q)U
MN684C*G$"Z\TSCBIFW;]V3(5L^A(9<"\/- *IS-RT:>#2BGD3*@$C%:02P9=
M@\IO0;C\6:$9K>=B1G(E386QDARS80(:./OC$KX%"M@9!CDV)$P9EJ-4646V
M*7:4=@VM(T@[CW(N9S:4F81SX?8*)U+F"O%W"*/&0.-1#*)*.>["+UM(H@>2
M$A[+/<_]B(8[D;+(8WB^04[<P)MR>,1B*SJW00O,MSEI:O%IEV2O&2N*I<!8
M[(O &%BVRUY(#S[/,9GW%A^E*0N7C%ZJ-6B?;BCS#PFH-?3ZF5Z#U'V%HH9"
MY2D(02SP=\RZ73+:$R(3F29<(,3G45?':!:")8TNP?X9]Q&JU3$3R#3A7K'*
MYVZ=AG2QH[M]N&HPINIB)3?;>R142MFLJ91E_2PTCE9RX/UNXQ<CDV]S:Y?)
M@**QZ05K9N8B(JC>9#%#<4F5P?N=Q[MTKHK&04@[&,P<&1>ED8DZ$B#BM8T@
MX??[T=_@$:B,W1%RL*IH+$6_PT>1/HG("Z$BB_E$VIH*V#H[%@ZWZC;0:T_1
MV=$<K)9M,?0Z/*N[* O;4=)=R++$0XT-T0NM^/*JTP#[G&7)ZGC2AH,QA"Y[
M[V!,:'()P9C[=I*+S #O)-%/"DWG7[$(?MLTI;_-E+9)M?HZVC,H"GKE)[@I
M1,PHH)QLTWN%OHD=%S@OO&_B-/1-/ ^KE<OM#X>G!P-&-Z+,5CUU@**&^S9X
M[96+<,!B1($%0M)WT>=KE:<,X19I4Q5H$HXF0M2TT6S @.U%BU(7H7UD*W]-
MD[!7LVLK\B@B8CH:R )SRH"#3[&KT[50!@9<&$/>YGN>X\3CV>4-F'<EVL_^
M4 *RBS<5J5<4[W7C/FXSK+D5VEJ?=9:WSBJV;6<B!FB!F(9-6*+ PQL*,N\R
MQ'%0C@/T6%72XVJ*M,L?+Z(IZ)"(/0_OD0G/[/ >S,$K_DO=2D(?8#>!TRU)
M5=1Y"O.YVIJGP.6BG@!AV[Z5Q>'U)FF ,YQ2H(XSG?<<I>&L[.C24@71G;&T
M"BF,D.C^VY'3@8/\O"M(K405EY+*-*W[:FI'@F=0#J4H:O1AE6)$%)DLQH1(
MZB:_-&ZWFDYE@JTQ0 YJKA^"*3DU$;5[7;/@1(3:U+L3L)-9PA4*DRO65J."
MF!9#DW$2]0WRI#4FSDF0$HXK @\U"NQ-.9)(X(GPM\)U,#9&_\!W1Z#]0("B
MX1+7@X1(81" J-6>QEQH&#% GU3>5WZ:(JR<9T5UU,_2]JF&ME"RI$XE+%_J
M)@-U1]8]0/70=X1/ M-"7:ND$NF2M1:D^%,8^<>O=S82]!Z>_M;-XZI%.1D>
M/T@)UD7TCOECRX)#OW;7TC4+1<BCF:/599*8'5.7N@"+L4>;INRQ25U/)6D,
MQG'5DQVSRMS0G!92=6]7L:FW^#)XM9;=%?]/,Z^.^\Z:=*-25\H*Y-2?#AJQ
M]0RLSN#G=V?=G^K:W.DDFJ^"RG&K<#/)0[)D7W]R]<?RHG5"M=L*#K*7WUHQ
M]K&,</ D"(IYWIAJ2I<SN?8O%EH'.=;O>3>L]O_;TQ!MD#O+X<* YA%N0AA'
MO5M!C'JS2Z_$\JTY>!.YB(>TH'?;NO:M. '<:=TB$GGA^%VVG]P,26O"^3LC
M'Y_$;6,)DT0$R2Y!="84.<BB"8]\F;AS*.2H0&ZA\P2N+17C2MZ)\7M^@ &?
MQB;=LJPW)^1%&D)IRM,5 VP(7.)1"/4[!PM7RP\SH*AG+A1]+'?1L!AL?QY(
M:N>48OB1KF)]]4V=@,O-,Q3B^H+?H2T+,5S @F7I^02:@"X&UBIT/)K\N-&(
M40WPN?"X WDCI[/2F3;YC +Q0&6Q< &TYO@HT+<6OP&%HU8W6+%83IH<.91<
M-6@F>\ _J19[A:@T];DD_L#+POT3-,P)[IW^=;KNI5L/\X.,'Z_>.G0:+IU&
M%[%&GB&XA P$E=:B0*NSB5QA@78W4TOSI1C)QQM"<'V<P!)V=5IV:1TOQ9CA
ME-SU\V\1SX!&,8U$MQ<X<0U6RY:)T"X_O&9L\UZYF-48_:3(;A G*1H<-H>4
M]T =$SPR)@I@AT4-V5%ORZ'^KWMFOU'HP?9LZY5)7=9+N0G8'$=>/6*:8*SL
MF#EA:G),0;!]1E!L3P.8A/GC'0TC_'<E<"@[\(AEB0]>2F:;7(!^]$O>RIAQ
MBX[I:F]9C6BE7^?IM07F67+'_&9:-AC+">J@)4:O1^7V+-*/< JSII^'4/V>
MF-KISZ&$VT).Z> $*S-EEH@B2M"3 &7GH?AG)&^D  DQ4AH^&?W)RW-!O2F8
M,26B:5YWUVB)5( E,41BHZ$N LIR]#WL'#&,TNAG;B'UVN@)XIT,CT*F4JQI
MVP%QA&]BL9;LD$K8E-DJ-6<R/><YM0BTLYQ4OYBE]<G=8>JKA["THU&8WT&Q
MY7-S-;:)KSJN*=5Q;/4M\QEB/5,UWH"ZJYJLM1H:$<B.">(,[,)HC""0+A&!
MJ5Z77I=V)1IFQ]OE(0DI&:%I:I"%R$1@?YK3#&MD1T ^##4_K8P<^'9I6E'J
MC+M]P,V98JL_(<P1JL&:"]6S9>A+O#;*JZ)<4CAP1YLU"C4?#P;GIV^B67_:
M[T57X +"[LE&IB[+'\"5HC:TXX$N>V:?!==&$+>NV2,H#.9"+#3ZDF</7CU0
MP(*B*M%E,.>O*S#/O>,\Z[_:V'F6DVU2 @$M\,DB8EL-2G6KT,'?-4R;MJ!Q
M??>@LK.\@J^"7"D[5#Q#YR>"ZJUFN2X/;"\V*G]Y(\#99C[_&42)6/30P@!+
M^77@]0=@X63+)^>"$%3GV6T"WL_V@]__+I-,:N^X!H?AO.[='&[A81_(6KB_
MP$P[STS;]-ZA%V;'39X7W@MS]M)Z89ZWG5HU;(PW08M]!?<OY(V><[B)<'8+
M.<[1-@&>B*O4J]F66!1UT&W F)2F'>)2AV.7 U9-DPFLAPKW*VC@32JO<;0!
M172Q6*)1@87A7U.-$57:1I<)_V8JRPDG;MVNS9]OW3+F?BADC0&QU?U&5"?R
MSJO04-C*Q24?&,PBJ]R&U4-.-O!6BT8_6IAN;#BP581)7@T1=P[NOL7&=I7(
MZZH<X,X.);>8-2H'HKITH&Y/V%A5]395ZT:F+;7P,C3T=5E,]5*+B42@2)?&
M;0B@D'0)G-JDT6^D RQ #)B'"]?P&JLBKJ;8,1L37W6TWJY-R-A*P ZD'7,[
MB>/6IG00E(XRZ5Y<J,4;\"X(^^=U_-J-FB+=.Z($]5WZ?J[TQ-3!-[9[R]MB
M!1@25L0K.R\(P(?JNG!VQAVKKRD.UE526)=_='1+!Z7\9'[DT>ZB[UR![B@/
M/G)Y4+Q\R[>L7NI'TIE8O8B\2EE2!,'%E_! Q$@ND"UM^+\]&HE-[<\9XFD.
M3>F.B$:P)=>\Y7 5/+CA!LRP*0[NQE9 <% &L[1F">^QD%,<W5GO#)>HI5,3
MP?V6H_$ZC6H9>$<3:]G8N;UBJ851WYUY=Z"K-E!O4>2H5D3!&Z5>=3A!I?$H
MN@KQ.5H9>SS'GFW2^*-*QGZ*;OFM>OZ[NU$P'8T9/M+G'2JUR+[2.=Q,4U!W
M2Z6+UPA+(&I$.!Y-JLI*-,G7?3!J1$>GZV.MT2V\!A$'8W=+.6#/6:D)4#C-
MG7O) PM,+5*SHX2*TVF<K71Z*;KM3D9F(1!E,K/-RNO5J"LGPAX"D_19&EA.
M."GS29[*I2:9(6=PJTRY4>?MAID^[7N-28%]!+B6=W]P7B(]U4/:\)YZ'\8!
M<T+RMFZE7X^>NW3"W 5^9[OFB@#)3&]#3=TQ[!0?9:V;V[>S'3T".PQN]S8E
M(XY]LJU7I03HX_IY> 87R9U;VGF<+H4G2=.FTA1**]Q3@[&\MG6YQO?)3:Z1
M/M]<9V0&6+<*<TGRTC-(_?8ZDIHTKD 2RQ.[KQ-5K*P?IV*[[MB AU19J=*[
MD800?I9>*T2_ U+U&J/?Z8?M$DF?&I7'-J*]!*A%O'R@K=;J_%R2-^<L,UI)
M@S7AM_!R)']6S:UN@= Q).[J*'JC4XH#+5;^$:9=#>#U(Q:H6@ RDU8@X[:C
M';J\#U6B>Y*E,8N!A5AK"K-K2_,A^F8,T5>39C51EI#]'!5"Q.*A&$WWCU@\
M%ZROI=L4%%V8.KORAM12J3$\#P6:P@"R0.1ZFNED !N:X%M@>!GH0U[(+GUP
MRBUA%AP,^U6!#C2?ACK#TP77O"EM'] =3F_,A\5P,KP"97\HU-X6N.RFW^YN
MLLDN9:E=G!]%NYGJ5+<"&A.='K,G=K4+K2T1MLFD<2$ZQC0Q+>,KDGM+SL&F
M#^1)!/;?*_0)R5O!Z[M2?F_3<;D LBA+$4]L.*KF5?%@Z*.G <BDUT#[\MFH
MCJ>AXS9=5H(]HL _J@86]RUO@DH%/(Y;'C_8H3WJ- K%O>LQ+$W$8=)4I$1,
MJ):V<?<9+2%"\13<MR%<AT>AT:=\"4O;5KB();WAE.D=4%-(]TI9WL8>=G3U
M:DU\FS)S%7)H'IJ.Z;6[;W#1BAAIFP/I.YR]:K'>O8H??N6QKQ[C)OFL--!F
M]EFT3\IWW,@B1KAS1KX=I15GA2PZOICRG*.1#R7.IC$/IS7+%HKGJ=K(BUQ0
M):3_29M#2K!!KZZ;2B0'B&:.?E)1CH<-VH6WC1X]1YE1+#5P?UOZN9H+#*JF
M<HP/Q 19(;UQZ!HCXF6)M62<P_$SOF 4% EE,!?MW?%P2HRCQWF.B.D'^6AD
MRS(-Z(UU-!#TQI:2FJPGWB\/2;2HT]';I(1"S\R.ZZ$7WC/SRB?%[O?,O%SC
M@< =[/1!U'PH[]\<FEI[UZQ(.LXK^5]2S*A[VM5Y3;P74T%1%:NQ7I:K8*B:
MF)#[6 $08 SA!]K2BU;IB\IJ%<E*92Z<BH[VL$S25"A[F4W7G]"A<1#MS:_C
MG(H;-:UHC/S@J$&G-HWPZ?L],Z2]< 4I'L!4MYZ*CLVR3?K5R^-<Z 1S%:X+
M8]E2ZM>S3NJ:)1<C0_,C!0N00+[:Z8EHSWMA&PB3+O6U[W!FJ?S+7Q6]2%@R
ME0=<?K%T2UP%Q0*(=T!8D8;._>@'1PQ!X%<&&;QE$\#IP]V API;6@ZT4<LF
M)6T<]!E33Y3GT9[:K^VFAL5W._#F!>UI3_E+\'E8,".R!<%VS3&I+M .YZ0W
MC8%%.X>/:69X1<<3R14$\AHIQ3:>&6=@K"P_:GKI]0(T[=A51C(6US8WM(Q7
M)'C ]<-<RN!3/N-J=T3P7.E\-4&HE\NT1Z!S.S'MRF)1.U_+$NN7/!IQ?I=2
MN6[AM@?2G6_M5$M4QC6L)7R(GGR]U&GKNK\YWM[K_DM>HG3T)I$N2NILH#8%
MFCR&)5XJ<U!R.58L(TJPHH!WISDSXZ WR5G$=S=A%<]!I2ESK<:KO%C5=T4(
MQ'7O%;=>^9FON_5=44VDMPZ%)3O4B WFH_8G5-D+FP!,>M'$XI"X(K2Z193Q
M+K@XW!9,=*QOC3)GSW PRM\96SML7OU39!7B[PUZT='AT4F J0JSSNY!P/>(
M(O6)ZO_8<O1KCH)2> +S9S/-/X\34?=2EOA;E54<E>VN_UK3_6 \:._>4:2W
MN#;XGY[>X'$<F3<9[ &#1CGHC=O/$>^_J)]EMH %LRS8Z\<\I*G%E=J*LO'\
M"34APQZ6 *E(T/.,6.SOH9X-?A43 6[T_7ISU.K"BWO._71I::H_]'06684Q
MP<[>\U!I^ PW:LQ4/;D./[6V/?/V_@6, )#I:YYZH*:ND;&C<+&>*]<:4V#;
MG9?OVYV:$F[E^0VKT)U1((CJ@!,G"%H-B/H_;DIRT!Y/Y5)L<SD=B30S\-K.
MNVZE^>[5G=1SZ;U&'/46=8!1.90JFNH/")]NM92_M=-"U3,WZ\3Q2":8KN7V
M,AK6B<,Y^VY86L=8<7QA<MUAE6LUSHN\TB WS8(?K][VHM_Z'_O1)1Q[D4D#
M\L*+2WP[ QPCJG*2NQE0-9S%BL_@.Z*7 E<E^@->2B=&G/:C]U6F],15DJ\9
MB8[Q8-0BIJ&.)X[;^"1VP5%@%M>A=#>UNDYG\+ \P^7[T>]TZAQV'B,F30Y.
MC;]+[-/'6(G!654%NE]Y4;HXO3\[E(ZUH$E$><$_J9G9_[J;4+CA1?;\O(M)
MTU5YAA I(3!!\%;C-:M+.W-*O<)E4>8U67U9C6SFP-/(:Q.Y=/J8&PH7&)?D
M'F/QV;94DDK3I9QI@UY"[;_M\Q@NS+,79NU,IL$A?#(Y?#)XM;5RN-%[W3"O
MO;P3W,.*JRF:E31>E;%8U'F@!@_BM]HVFP8;EL1%SX@&O+0@N'&2'GR#!\)7
M6-UL9W/E!;>MHFEINN;7[<_/C]72"14"\&X?""43:HJ#;VA!A4#M#Y&\8!^%
M$VPJNP8+TTT@1,/>-?7PX\@9*7(4%$Q.++\H$6%63UR9=KWK0LXJDZ8A*5C0
M7"Y@\$64B"GJ($&#TF01$A A =&.UYAD5YJ;"6"%,5RH_#Z1(B58X[PJ2=,A
MW_R6D5GRL:2!O?4<#S:PZ$*38@.U*XI$=0P-)RM#P<X%I6.Q_T";.6#<Z!!C
ME52Q8$:D?_:C*PMR8?)N0]R/,67H><:RLM^=4[.P2R.:%_20G7W<KQ4]#_A%
ME[1>([6D:=_WW$5\7HH;0TN&9(1S+ EQ ;.4]6?@0$;PS5(OK>T@/594#P9<
MG1"@O5?[$95UP,>"._U49MP61V0)4Q,15<HU?3]O\X1\XK><'_9S<SQU1BOK
MNXQ(RG: %G%+L!/IS4HE;WPI_M0PJ7RQNW*0-$8ZE39KD$U8E0M/50V+7"1F
M:FQ95"S<7?$+51#[@U$M>@)K&[642ER%X:@R5P?"N?7$@OI,I.\'-M]^"3%2
M3P35H6 "3^FJ1K-'K:$2XS'Z3FB+G+B_VXMO@B8)FN1^LH)OUZ5&D8'L%]R+
M7;I CU'+U&K"$A'-CO9':M?2&^-_I4NQV.#92G!)JH0D]%H7:!!IZ#4(O0:A
MUV S]'@=>@UV[]#<E-0U:-TA8A^Z45I1/ULO["4Y;6%CW3'88Z!*!UYJO#B*
M$1K/K>UIH.+W>ZQO]SHX#4=[;KJ &$>TN)=4Z6+V6H-OFL4<@BHYC)PTH#0:
M&Q3V:USPZ#\9S(SIK$S7^)&<;S-&ARV3QC5S,*SK6I(Y-9YR(\"=D#/>40X
M.W2ES7>R413P\'=)F#^]"T;--\9Z#@&]';HZ&W>^;D]F\#P ;M<R<2RZI*X:
M/Q]9R' * #;S'3U_K3N5N!T=]E^_>3S@75C^S6$S'QY3D?XN7,I FT";0)M
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M.24M)Z^1E*P*\XD:*J>,?$//GX#=5/<=%AJ1#+1::T/4F@_$FSF[#]0N7:8
MC/;5%=51?W"TO7JJP^I>DN;=UOQ:>Q9$$C@]L.9PL0KDB80/6.JW&>J1@9$"
M8VSLG'/@$V#EE8\'"315)2H*0J6@S0#'C]2U9(D,1F)>6%@*>&BQJ$WJ]JK]
MZ)<\&E4%B7L\#K=>VZY$7Z:*\;&SJM"5R!SRQ=)."55C6&NLP)DON4,;G9O:
M2*BO.5Y=4,TH_.&Z+ 6C'@1K^+PNS18C'/E*X+1_<G;\$O'-2(L<';ECVR7L
MHW_E58?-W6.C?4&>DBS@RQ@[$,YM ]TP+L346<C1!Q,0 K7PGBQD@D.[0J_E
MX",KWWCY0^1)H,J98^@%7AIX?P$;(H/TCH&>+P%:.@ERX@GDQ''_]8O$/=UE
M,7'9I9K9%"6@0H&BH/;PRRB5 OZFU4VT=[8?D>^LC1,)/Q628PH8A=D[VH\6
M4A0Z()KN&B<?O50(XUUFY1^]\!UQI OL]9 Y/6>/#(-2?*: $'BUG+'K\(BK
MK%1I,RJ[)_9;D=EU(<%.]Q$^MS?<?[1(;02$F,(##_X;GV1_^+^K8K5[W4OG
MZ#-WQ'7QTS$P$0?*W.K[S9COLLOLQ7\=G5;'@C<? @Y">->$\''_$$L'@A#>
M-2'<D6-Y%+F\D0S-%[E902P$L1#$PEV05Y>SBJF:*K0&ZNQB,YO1*/=9=$9S
M/(<+LYY+8L( VVO$L\>2G(L5S/Y8-Q_EPT;O_J!_=G@4[O[+N_L8,K1?HAP_
M50TVKWPB-5P _@!/;\"JC7PF4:\6GV6)B:UX0K9[ 4R1UE5:>0E&?F<I6 L$
MWB6[+8=A7217&S04N;'H6]4%J_@O*-LM'^A$0B9(G5V2.I3_N%N%R;*!C75+
M2]HT%AFJWZ6"UP<4SOA5 G^!12].J4:TH!JZ7B12K-<=3QKVNRWCE#? *NV2
M*19&IF+(/@B+5YOO=KO^#RUTNR!!7WH+W6!G6^B"WGM<O7>MM.(^E/.)2A*9
M;483[J(&))V@09&D"56UF>BS&WVDZ(.*RJ[!4U0EUW49'0<^8V:;&FRA0%*7
MGJE2@R::J2(DZW<SC/1BAQ;NLE'KEY_69?OK:\^-YVH;Q$Q,B#JTT&2]<[28
MQ E)"E.B;BO[[]? %8DAMJ+Y6X)'=[2O^:7LWJ,>4,]^YVIVSRH_. V3WG9.
MIAV'0L7=DVF_Y#8[%GD-8E1F^".M'?TLIT/)[4EOX6M%GJ9@BER![4*" @-V
M.)Z5942/XN1^;S"(E59HKD/:<(TB_M);*YI0?*];"BJJ-N! XX5MDP:/>Y+/
MY;4L>O5@673JQSG*+#W!4FB*7M;%T1V.O#'5AHW=[.G]B 4UI_G_*;)*%(MH
MT(O@\$^"#?:D#9UGK[>WH?.3K__-7/.EBI?N%#4;%U/,2=O@?5V80QR ;9$C
MA=4JU$,2\X:6BPK[MGFF_81F=0\_D#+?E D'#C&\95NXG26![2=2E\U&'?Q0
M/59]N;315@'-J@(\=3)8>'UK4[@V3/\]<Q[@SAE]_P^-2?#XD42"OC)]X=1K
M RX3UEC7\ JQ*N)JBH/D8ZD?U#H3N+6.>#R#<-:5 !GO*3[/R.<+]Y$CK-'@
MS $VT'7".Y1X=[#N[6H6@0GJ_$(S&--C8$FE?JT_\'"61W.!?)-4,=]VB=DV
M]/FUKX(\:0%V_=C$I?EJ>YLT'.WCB/2,@T):L&M!K]P/7YQFK1]HKFII08P0
M1 -&R^G!!)^!G$?"@#8D"H4H(KXF-W$0(#H6"KH@B *C8XZ=ZE4&9$%2J.F,
M[5K3_]#.##RH:RGPZS/I=;LD==6RO'H-!< V(P=_X;9-U(QOV]4GZD;?*R<%
MY79^SHLQH@H #Z?2PLL8+Q[=7-@">%E%HY1V26E?P6W-%U+",GG\.7IO$]R<
MQ+)_U0:.(2LQ&68V D];-U;U].PH'GQ56+SAZ>#_2 9,B?/IVLU][6,'=3Z1
MZ2P" 2- \.E)AV0@CP7I7&D.+4A#_?JTM)R) HV!89'#<]NR)*3A=DP8OO0T
MW-%73\-]_]TP3Q9__8_OOYN4T_2O_Q]02P,$%     @ XX1F6A\(QH$ !
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M4"FQ&9 S&'-C-;YR'M!/FW@Q?$6P6&;NJJ#8. ; DA1K3$9B$*HDW!!*!$+
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M%P:;U\8S4N12,ZYGK-;>UH #X!Y*;(V"PEF)5U9BV J>XRW+3(D9QILH=TM
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M C@%RD:8SW"EW?0_[MM[)!]>C?ON!LI_4$L#!!0    ( ..$9EH&&(;]%Q$
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M[?6SQ?E""W8X]L.Q'1WLD:H_;DQU9YSXH>L^.KW*J5U60-64>@:<4&^@MHQ
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M@*3ND",KD^UPT[*OA?*&7S!@LYG67M]AP.9PK8#-(7;&HU856QVLN7'F4+M
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M9\1-<>I'<_OM4P[&QQ\QMI([/0'/O:S6)7VE;\$R2:2WNY79"T_+BA2::NW
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M1[4KU<.Z[2#3MO"S49[O*Y*%">7K'ERJA!OQ6DIK_P&VU$$EYS<UC"H/[--
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M5(8<=N +J4BTX9UJX>C9.U1W2&ACV(8I0=^3#ES.Y^F]SK@7065Q).I5(X6
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M@!<RJ0PTT(^\(+@ZG"!%=:T<O.OS.EPB5 ]X2?E  YT432*?F_-9SZ^$>]!
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MJ^/&J$JRF.^)?=[R#M=C&F#^WE3WE*Z?2$%A+E&.Z:ORZ_55KSGV#G6(\?L
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MUU<FZ^3=%0Q!L0/#-Z/]<O';@KGLCIFN;*TV?T*U<Z+V?+1.+Z3!M/:E4>_
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ML,8J^ <19"<5.5^;9V7W( "A>OVC LAH5Y@&.K-,24,M&XW!";5$'QI(J93
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M_M)7KZ*XH(\I8H3HN&JH$." IEXDC.*QR_HR0XH:+=(KSR*D,C[X"/]4D%<
MIS[E@$NO3N3\K&U(<@B^UL?]>;FTS6NZ%JNQ.3E# ^5NAO0H2"(6*B'^-=5.
M&> T=HP@3J.[330A_!+@O:6^KRW]6?HW4J8-<8#.+N/TR.;M0,C:+C0X:F[.
MS!P6,&B,G&^*8;Z8!N-#KK#/T4#K6CA1C"A^+),HV"FB,N:O)-_7_MPG6D.8
M$5VK"2GQ.+ /+RYSZOZ<&WA;JW9?8=_,<*9S5D!JKD_XBS;T<6_H  R D>3(
MC, 5I25"(+J<PY./="X4@C2<D2!R9(&.X[%68_:;9A?GNQXF&SIJ_\DS:-Q%
M0IS/?Q#<,0FEDP.7_K$-RI%,PY(NSS3$[C,Z:[NNM.9(:K+_XXX-E>4E3C1>
MY"P1&Z^1:]HF(C.L+QC4U%8@@3\-A>:;#&WN]2M85=7_7JKPNN+06LY9V3Q>
MGA&FK?"Y #$;G7VA4HZ213S^L@! 7A\EJ^'-5 ?L?VM0-'>,Q_QSK_'F]9D/
M!YP4P6S_6N7#X?)81+2$. 3E[[R0<(K['Z2]9U@3:Q<V&A4+("+2I @J3:5M
ME:)2(J(@($1 "$6(2@<CBM)#HB"]*55!B%*58E0(':)4!1'ID@ AH9= 0@D#
M*9Q8]M[O>;_WN\Z/PX^Y!L+,/&6M>]WWFN=9&2LV[\_,2K&O&+63)T*G"Z(/
M];UA'#MV_*QMI5\2T3$;63BEDLJ00?:@RM(*[X*=56.1._H:).M'7Z'RF=*L
M5P_BW6QZZH[(O[J[#O7+%J151KZJH5T3]^WH/"/NTYG7)E,[/#>849%[7[>@
ME":ZT,&XQ>Z!>^>R>W&B;%$F&( ?S9G/WL/*4G.X[96MT#M!H)<*6M#2XY4G
M^M6\M%Z/!JC"2Y;4*4?I\NZ+Y827,U1DMKGEM_4>%A[*8&PLA7C[;$"S:AT(
MA1OP.9_L753P8[8X8'B>JO"H7$N:C^-KXH@@U^B<V>Z4BC*L0:!DFE_@6Y6W
M;V4SEMF;4T88==[YV,SYH>G:J@PWQ>*<O/].FNR>!C.%>LDQ@.*8I"YW6;6
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M19<$T>=4&VJZT67%W# S9S3@F&A6H[7YW#JR//_,VKV:-3M,B^V&])>*_PC
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M\Q2%YAX(MIWZN5(B.#/0.90\&I M-I8M>K)C;_?EXI_[3C\82135G$N]<5
MAG= NB/QQ'?6J;0:97TRM+%*Z8%T[-U&U[[RQAOONY&'\\Z7*:]FBBB#6[1V
M=>AX&IC SY?XV1&.JIU[FS42T;R,SS)<9#U'J7Q18(V,; ;!FZ*;SE9:H%N\
MVL&=4[CZ$=\UXL;H;Z3J^S//F8[=6 SO_#ET),*P #83M!@?J($NFA7/SQNP
MBT 'WYF4KZC%9JNEB3G=;*^)"Q7S*>'^\@?K9KW?3Z%]D)_1%6ZQ8%?<?L-\
M3^_7 >DDC5(_9]KNQTD7@[-.!;8K91^F8O#.,;P.=G*7-*T/0+P+Y^^^J:P-
M]LHOZUM Y4-V!O0V@06T%5\!@Y_P]6^K21@!&_W7LW:IN8L)[G)<:A:OFM,&
MT\J4TBH'H+R'^N,G3@^-7!)N/M6*:P7_'10:4#<A>/HZ/8C6["A,NY.K3=S-
M=$,)V3$/!"8K/%[S""7@ 1PD:GMWB]A^ I PNJUFQ=BJUN8.IKQVC^QX,ZFO
M]X5P =8C!+L%^N(7XA>B/!31?$:=N_;33":#?POT=+'F3@UQTRTG-\+]SI$8
M\JC-=&A C[M"^("-:X05O^3[R^%)ER<,H(8&)^;TCQ\.LX"F!3WZ'QLYML&^
M^C.%FLA?@'"&J5?&SOCNS(N ?;X-(-Y]ZXEZ[;S 4G\=Y*Z@K%R?74.N?/2#
M %=VXV.!Q\(L,805C9U)Q9 P"0TR<Z/V-H!B(WXP*B_4B L&SS1]GQ&LHZ&I
MHZ*NU5_92TGQ61<]>72Y$1>7N#\@W8)F4%\*I-M5IZW8TO9AWGAE8 DWU <*
MBQU-4:B[3?>:(+[WE/*<EUMKWUVMRS>G"+?7.Y8RDRI9=?><G#><]K *OZ[-
M5$#Z:SD4LW 81S7K"D]"6+$*ZR34^ZO1>H!/,M-P("[JBN.=1\IU2,G'NGM=
MW6A64['WZ('[7,O*&URL;6#2??'(*ZA/LDC!1#Z$! W:4LSP,S4DHZ+,LO*,
ME-S U!A Q:1>]^S+IYF3H@VR-30N347Q\"<>UF;+QI^C=\_KN,2B=3Q4GJQ#
MBX &Q"!,YHJRKK$1UDWS*^L<4IS9&*-((A+TZ=W4PH5*DO?"R)FA@%CR4E1)
M'HHGP#QOY7"O\O 7'J"PA7=OM'I%+/S4N2';R(B59M$G]:G)G^"["M]X5%TX
M\"+EUEOBFO^02LFHA;F9A9_))H-#J_'3]$8JA'/; /;W)P')9#.<EQ9@^,G\
M.I?K5=EHWRV0@#9\VH,M65&M+S5)""P>;E-.>+8[^37, _?5L)D8,WH6^#2N
M#&U#[\<RZE'-066OTZ;@3PE#^(OV"S6NZ2XB!+B6R0>H,_8]-N&,TXALB51@
M08:996NV-@W<#!&:=U2C%52^YF@_]I'ZI"V0=3]F@E_GZ_)-*RNHL\9 !4W)
M;\#:^GV3FY/;7A&_NWIP+G,%5?HC-I'C%BU0S(7'[F]7O$;31W(6RM>"&Z(#
MK>;Z2NCEHDT2F/IU5.AL?SU,!U='S)<*1@7BC-L9Y[= WAQX)A>O^;.YNQ@B
M_''B]86MQ&B\4V7C%FB?I^H6:$]K>(A0M&ABG7YAN]5;!?UR",EA%^UDP(Z#
MZO&.._*^3-O:SHM\\+#(\_CTS5XERWXF/9.I[GWQZROC^TDQ=@WU!^9&:F2P
M+$Y?QK(TT?O9@D A&=)R1J6\T[)5EW> TL /^$QV8GXL8N'B-U]Q8HF#E;RY
MA$,G_-[+V:2H)MOBN4'S]O1SWND;PG[I?J+^&IKO3>&!+O?4\T?*.SYX<5!6
M7&PLE?^XK$5NZUR@M07_45P%=?O#(M#5WY6W?[^)>ZBX8?FS&!2"TZ-P<X9E
M %W+RZVR6QLQL 4Z4'[JE;4F1*B^R>O5]B=13X"*WF:!2P<>31*4&Z[MNKY,
M*F[/-WI3/Z@&O007ARF@M [9Q&E[](:%UF?&9:?[]VNNJT\&2XL'4EA3K&,K
M!$;GIC44OYN!XC 98<._3QP*I65KD8K,SO\] :__/=MGY,>$;J"+T%3CQ%@P
M-0H1TJ][B.APL!P3PQ:O^E 1/R'0C+ D7:P>5/.0?+_<H?L$8>K$<^B#B6\(
M7.B*PV.++9"A.M.<J4-;+*82VY#\-/;CK^JH70')!C3ET-,I,<'Q4FS>26R5
MC-^\?4MXZ9W<$_/*Y3VM,S,+A0P=:F'T XP8 &M"_O6]4-1.(:;\D$QST*6/
M)RYNNE;>]'YCTY'B>KT>^_7*A3*0$>@%]'E\>*%8:4$)Q_P.@86]@D[W?/JR
M?$:'O(CC&-"7478!2\C\NN&-_YF=6>$PY)WW:;/]R-,(7:J0X'/E.L$Q6ZS'
MN$6>_1S[=+^SIOE?>R_[]2"T7G[SW]EN*B8F.;@J!_N<2,FE[4%<9+W150^(
ME_>@W*3E+T6H;0AN%^VM$^;#A2U,/O*_>;,F4M_^W7E+Q>O:R\?2;!4Q.R7Z
M?=B7*^H=T<EN\B=QSCF5*:DL$5Q68A:"SEY!I@X$\%Y,;I4Z2W5[G/S5C688
MJZU%ZK,2<X5[VY3U"E]3>GKRUIV'(!.Q+J/]S*:NAN]@ @L,%*WQAZ+VJWE'
MH$1U)9D7!\N+*?=-J.#859@P)-^F [YS9*%&>"(H_L5=4[\/]JWS(=YP^>GK
MX?KO<Y.=,&\4\_!0#RV51;Q,9YSTJ9J>.08\))A]A?VMWTK87-A<X$+.,9ZB
M(I"5%6BGU>]WRP<Q[6! L3!2?'T,]A!AM==EBDIL[@CFSKK@RJ?5["@YR+6<
MYLKW;D[<('7;Q;U?5PR:=\8_NX>B;DA'H%8-ZCCX%4;9L06*PKQ >2X!QY::
MNO"GQ]*CD:(>6Z"]"/N7GOC\GQL:E!5L^WSA(G/MK?,&@[=5%\4#E,<U5534
MJM9XCS$CX@>\GCT?;I2+9]:H*5XHD1WKL8#Z)T3/C+*>SPX4&S\H%%:L%'7Q
M4,2ZIHU0<%UNWNVH_P^C+^[7;OAM]OT0IF!FFV&;] ?OID_:%!U.@PL'$?S(
MKRTQ?()6V2%'I0S;CU!'7^48B"J!KNJ!PF'5BK33[#WCX[WW<Q'N@)=:GG)$
M(0DG.7OWP+Z5(OS(C/CJ2S>9=G'-2,'#^T>]Y8SCB16^9+),AUT.?GD*1E^O
MWV16Z&3L6_4@^@J+SA\"ZV^\X"!%GK$E'3, DD6U"(R5M;$"KT.GH=G$4>\>
M'$>[CA4)<K%*U<.U<!.&5*C9BZ'KP3',\?_HS2NF.&PL<2+0-U?!K@!]QP&*
MLH1V>2]ISL*Z#9E"A20P4WX+]($8KGO$@SYZIY*:NJIC;71UUS/ LCDMR"^6
MS!O0Q]<L_[,FZ6+QZ3L$OH+4!Y.7Y9(W&O]]!L.LFMJ0.IX8_@$X[1#;U8VP
M'].@3A7S2Z#-!E;Y%^8_/IY0RK[4\8Q0=,:::_^>Z1;3WFPIKX7JRME%^0:/
M<GA$8:?X=R]RG 7A 0$RL= U+O&K@8:_.EG1<#@ 8@7<'T>+ KL=C9P&M"7(
MIFY-=A%.[FGV65+L8-'J\$/1&H.W!'R]#KL9E1;$V$PD:4+OZ%-VL' <Y1;S
MMF_Q;450;G*222$9]Y4=#QY+D18#D_X"M,BJCS>S>DU*$,H#R/Z\O&_:7[2/
MD(?>+E%R'_^U(B]^![>K*OF=F[U7,$N%*"!SOG2S#/9E:4& ]@;)A^S5Y>K#
MW,D@-&6?K@+O8U[MN?S>OB"+G!EK'Z)+GS)\>BN&8$P3.J?RQE]KNOU#><TG
MB6C,/$]=G(.N<2G!B-'1SX0EX-2"JFRK+8SMFT8V5".]E77U8*W3;5[ZN0AO
MX$MN%/N;&CH&MW^U>WO5TQLBNBH#RHC4Y/M+-LS21^L58[65&CZH#^?8E\%W
M3,7J5!EV3-]>6:A!%:U\]/".1RDTUZQ"H$A!NC8L^NB ^:<?/@>E-5!KRUZ/
MD,S! (5U-9RE]FW[./%9^8:U+1!H(_/7B#O@FI3U2MBR"-TZAJ5=2'HK6ZB:
M <M09G=,> T<8.5V#6<;)E=^7:G$I%<B)PE/IU#NTA0VFFEE][Y?MG?I]M+8
M5+!B<?#GBV$/7.T]DMR;7OLJ97;[@]J-)[;SJ\^J/QCT=>HR3_(@N-9@5L!5
MYTYDHT.\W_RPF;..LQN\6E;14.%4J>SMSW/]0IO7J8FVH\G8YSX!M\YJ*DYW
M/3B&V<DJ9"O.P7:PMS,O X6YA@6=)0$0PW+TY4B;&-O5+UA3B&VOFNDYQ1^'
MZWJG,\2\U8\YG=0/]E:+:W]Z]DE1Y31_HS>@)/H(:U7>VW":>6X H1!$N(5N
M1G(_U]9_6?:$U^&Z>\;CBJ#1]-NZSLNW%YFF]Y[$G7K;>.BF01YY>L^*[ +%
M:_0+I78$?O^LU6/97 77_G[Z2.DF?*#C*^M93ITWR9O"3;4<MRJ!2N]%R@+V
M+?>-!)Z7QSKHW68:P<4+Z,%$WKE8)[*B$,_!I=K>(_H?3$M&[<>'%#5>.&1X
ME/::@JO3,CQG"VH+?7]7=65?Q'E5/T=Y\B=ZI8V3T7'GG-BAZ_(-#W[%=6@]
M\H?@(X8% BD-EA9&W#HSV_K>1^<2@O0/ ZN%  ^V0)^D67)2DN,J'AYTM-7(
M1G8O5<4/+('<%VJ_FUS8]#T(]9V0%SQ(-X*U@C]F/D1J,B6DP6!AI-2^$:9#
M[A8("QMJ^7NY#I);78RXD3XA9'[I[J'"E3><B/D@I9 B,_:$6PPX0BIK!<\@
M@!1P/M+V%_]07-O!YF$<@^"AGT"+TV/>$8F'P!-(X)F.83[2*N0EJG(31;/Z
M-]N&N.@\?ZV7XN^0_KQXNG(]<Q6SH$!W.<O*Q+DUS5/U27I,YNZ7XNPSR#_1
MCMVZ!7(51 \5TP-U<3N0@E)!*V.'0"O7@:50-(">\ XU-?.'N2#=JJ$K)$Y+
M$4\*6[LB F3=2+<>T&G>4?.;_)CI9#8O[[&?A5#VZHUT->9IHWZ,D/7F=!31
MNYDN;#&DH<%Q30,C_T1V2F*[ZO]7V!C0?OL[; QJ+ACX(]NE=W!/Z^[!:C-&
M1P?[UI:7%BSAZH4+KZA29S_R*S2-'*7<)>#N(UT;*F43XN"+1U5PC<UOS13G
M3OPL@84:3V>G=-W)3AG#54M_D?Z<3O$_K4K1HU%\AA&6M,@KJ.^.$X/?LG\U
M9AU#V'X7[ E);)H>)V/B# ^=&5 Q?(UYH?MGG/YS94_K"Y=.9=W>N5K<Z1G(
M4)HKN#QQ 3@US/0&KFKYTZ8>*JYIL7E6J*^>(-0!8N'Y\U\YEVJ;RYIOLBIA
MU-+F_-VLN+1DB"9+'][/)D,GMD +36? Y9B%95TD\BQ"7G)<$F"<EUR!]0U2
M(-04#HKMH)TF#?_%O19BV=0[)W70''L] ',^8*UKGT%2F>J3](S2\ JT[[&;
M[+! 7XG=\2,2:76LK*!3LZ[Y;)$%-H5M:,5C]D#1 %_Q(L2B9@ND^ISY^#^I
MK=-7\^>'7#C*=V;<2_'XS^\HL$H)W7-XOQZ7:^8_;N#1]D6%&+,%.KU9PWJ(
M/)D8ARHS#+V#N1/>%L7D%0-\R:;+8BKBTTT:]&[W]>2R1[(?YG3%T09U5=4A
MC5X;JM<Z9)\:&^)]F9S>?E) JBN$L=7G43SJ)F7[XFE.EY3S9;]RF0-=C>\=
M/.V"%+5#S^S*?V6$P5=\=ZG#11IBSR\ZV;'CBUN;FX8&DF95@W23B(O^,)D?
M35^^I=B/J-@&85:L47]A'N'&"DS+Z'HTFMANAO?'+/#"O>[YI0Q@-YOG7A6R
M#;7_A>*'ME* ^T5.\GM(_(/+36<E3Z0_,&U^5-T?]&[7OT6Y(NWMK,"?5#^S
M;_XBDBF_'5'Q[U"8^_<)YBZM6HY @TTA9SC=DG#F2!$^B20S,.GJVCI'E;QB
M"S,"89%@JL%9+C2UY\Q(&_/X8L,6B%I>XQ.BN"Y>AX R6GX5T;H</7_3\MKA
M;/8Z.UUFG$A8H+">(#4$6M5T]M(HX_S[!I>3?SOS'(;-(^C+AUZX3ZOPBM:N
M^O:45.Q[^^37P>QSU/JL#WPO7W3<TS8/O?NR2LE*[R83S?H#$$./V$*X^?$M
M4,\-GW%+7QD7.I@^*][PR_1_5DH//7<9UHR6VB8[?I'*?QW5Q>E<,4WAGW[B
M,8#,]1S( 6;0#G]QZ8?GMD _]%N04^4MJ-J^7SO.JIZ1R/V>\+>8(K8UDO8K
MZ_;QYQI)FBCE$4,$T*)G?,_K7^UU(L%B@ZS*[\TXGER^;C^7-L!H=Y=23!BQ
M,QE1.;]0D3XK69,6J_$%CNQVH]>?6M](I:V':M^DXEKPQ$<(WUQ' -7,EJ[U
MTC$QK;,:+GU('29<"7]9]Z[N46[-.QPVR=YDWNA6=47:96=#,%X'>0_UR8"#
M;GPRXPJ-.DYDZ[#\'.95P"%W>%X#6O$TQP&(;#SGG1F""?#92/&N$_$S8-A^
M?Q*M$&D1X24!45;/[&0]NZX?=FUJ:5=/+,JE7@37ODDG5K=%-[TIM.#IM2MO
MP&^!)M(-!]VZ,5/)_\&U/OPM)73_D12:20XX8;;;ZL\7 \W Y'T:9.SB*/>@
MJOA2,W$WAH+0<$G3DVOI"EL[*%]-#6^>J+X[X.51'( 4WK/?UMWZCG.2A_S0
MIA'LFRKS@%:KI0>J'!R#.-;S60EQDSIHY2W#7V%JWX1OC7UM<Z5%__6RVA#V
M1]OSR3>:VD:XVS_5H]4X^<8K.R/WK+QTKU*41':#N-DUI\ZZD,%ECF"3P[*I
M.3&*+X;_^WL*F>D<PZA%P""[F7NIQ,9:WG<9N!:8X"6-?&_)V"GI/8 Z!1O<
M==*J[D=+6[0<M?WC M?]-B_4?N7)S[D;7=\?=$*:\5/QI/H#/<$LMV;QBJP<
M#Y&_0GL=YX)*)S1$1)Z>".U4[AQIOMKZ\H#M1U!R#,.;S>-/BV2+H"@.9);*
MM[%A=QC/P@);?/;1]3VMKW+KUAL4_:(UCPZWD+,,K7LF4]+2;-1J+SUY&7TD
MUHG-[4)]RE9@]V4H1*O>;AZ5 @SS1P,669-6 1+V.Q@*C=9#VOG#=BTS@Z67
M=[,O;7QHOS ]D).Z5_,T,;4/>0?&L^:5IEOXW$X%&ZR0WR>2*5=+Q)T&%T >
M;X'X'^#"I?<RN:D$PSVWM85)(=)-LVH>DZP*<N.W8YBULT++"OVJ[-[7P\D=
MUQV,V[C(];MB  ;],PNC+<U00.B<ZUPF>!'W(RZFBR"W4Z_6))Q=D^B+?YPQ
M6E*T!?+ 4EL3IC3Z[I#COOC>EWN;[MG=Y7='N:X\W\)(L=T"%1P"FR*:#LU4
M'C18NMP2TN&</I'@1<>SRIDG&<<! RW%/12$/LV[1>,T+@RAK*AE9V._&.Q'
M@T;'74G2S[$=5LPO33(2GJH/X?V!UZDO%T_++]@"*4EIT-9C&F0"BJ_3*N.Q
MQ5L@@8#"9O\>3_$&S&MC*?(4^;RPE=5V?;@7G,?0R\7%2U+#3^3N)S<W+I%W
MEPY<!<)IBJU@88336X#1AA^9CF)"R5JM]?WJ)D/;W&YQ+H/S'-5S*1PZ_Q3O
M@??-NSOTP[:)+S_OI-Z!HS0DBB$-<-#1R;&>1R!7*L&;G#Y3LXQIF6.HGJJ;
MM+.KU4.<K"2O];/M54HI(;E#N'.ZW0O$K%L;G#")&B>RXH-V-W9%ZBH#;;3=
MC40^;;Z"+,/F4>7^([UJP/,L>.F3B(QURS[YRWE><%6C]S'C%GV+=94,G?B2
MY<=/4\TKX;*$;CD_ANR--Q4]9I1:.3AA WT-V4S\4%#)N,:$))I6FXQHD="/
M1WLM@4CR,9]PI0E_+U6^V63I=,;]9F5OM?UG/O>6','U.[AX7596V0*5H/@#
M@B]2L\-S :<F.X?L6!)KAUE9CQI<OO'(SNRL@A_GTP;2TFC\M9)_M49Q*U%"
M%[\N?$6DTWT ;I+T4"W),!)Y,,! [?D#H&&$K'/OI8VJMB6Y^/,-\:XH[Q2U
M.(R_[$G"#X(V!SA<9T5J_-(E>YI<)-#W,1("M@/9Z5?M+J$H79ULGHY:9"G/
MB3C?LLP!R!8(;C^#$WT-'9]FBO"2#.GKC1 NQ(U>B@F1>8XFX2X^T7W,6DJ4
M]BSBH(I*7NNLS#N:<D2RAX>$I*$\[L%\F,PT?5]=[GAADR(X#K>[01:A6K\_
MG%;X&!LBU>[1IVUMUT%0V]Q5T*ZWL[S4AP]LD=AC8J53=!PRU/>X1@&3V\W>
M6_..GC*];]Y4U14+BV9>^W<:K_8I+STH9HRH6I1E=)CWWEF\K;JPN"TAV(1P
M-GMT#A_0/BD?&C 1<TV[./?XA!4$S$ID!F^!WG,"+0N-YA!0+CS#L SYX-<-
M6U8X86@+U(9CB&MO@>A@VA*[]2$=B8ID"GI1I#HW!M=V<BXH!:JW0+RB=.<R
M:M;:E\SK@!%F3FK_<Y<;@P<"D!L)]:3, OQE$9H]<=1=X^5CE.KY&^T_#G0P
MW_]C;T@.?_\DU_#7%JB1EV%B-"8Q'[8KEA;6!*T!Q;]0VM$B=2@!)1#@,^5Z
M9J,S3^IP-\4R66Z@DH?_>8H4XMK9F8ZZD,EE(K6Z06+=]]:2KZIOL3\!8^BT
M^8@#N6TZ5__' L<=D4#6N)9W))B/&4+;OG*S@@H)TS8E5UM].FI%9<<&%T5=
M""V5^3:0<Y"L/V4B4W)O<D2/+>NMKI7)J"V>_^)255M?E;TX%WA03*&Z.K4@
MV^WPM@9;AZQWH [);;"^+J:P1!N'@X0AVT8URV.\CS+:-HGA=3MO?:*?9N$L
MQ.G%VYGM,(J4%'6J;,=+OF=Y3SZD6LML7/QWL%>I)\L5P%-))CV*3 (C$2P6
M:";0\#06=1:\;#"(U\E<R?TY^@.J:'8;6X=SU6 _;@?.21HO38^AIBXEZ H'
M:#3940?0F!' ,YBQ!1(*\+_@VK]P^\&(P=Q!9=_X"]_F FYA^TN,:F/DL1Z.
M]@]2"RJK+M?*'6MQ-+T$]^NQVRA[:I&2E5N\D!R"P]0VH#7^M:\0&H=K5[#*
M43,OW,' 7:;@%JBC"$P:(%8DL@3C=W,^E Y%;?B:4UYO@;KP*$ 2U=6ULM"^
M60^;2.<(8EP7=:WRXQ;(G>[]+;$\6'/:'B: X"5CPATU:=)-71*ST?D!F,:,
M,(^,_L?^%97=A!$E<[,<Q8[C"N75,9?E8]RG0MT,C83"7CQJ^<=^W#,\U(L\
M9]>O)+H.+(ZL<CH,FYW=A'-,\QT0O@7:DTCQ(K%$;.LRP5&C0C18Z/2I=\L(
M8"&7YI?UY.OV+G4.D7SYOL*7[TAP[W:2BBQFSA@7Y1V*WH\F1;;R1TCO[_M@
M.-8E%0!MAMYT^)AIUK-6K)5EUL_$KNS5S/!QL#-[LU)^^G)QQ.%!^F)"THF:
M4S7GBG-S=T$-0,6*V_45M_.\D]VOMUMXRBG7\TGZBL'H6U5FAH[DH?ZSEU93
MV1:PJ>?,.H[]0^6'& Y>BBNHS]%C89\^3K5.X320/P<<&8/Z9.LRQ(#-FU2"
M:7J ](OQTO"V]YA.Z;]]]^W<GYUIPNZ:UKDU S[,+1!F'H[Y.;RPX43.$$S8
M4I=8#\L369J$0>J;:<XU6Z!$%%V=U1\ 95]*W(?ZL=MP"]0;4N_CM 6:'&0U
M;X$(^UX(!3J8^INS(-.:;!X2-9F]/S%17+29=>Y[4R[S.G7.*$3)Z3:*^BQ
M1UDMQ.;V^0-'[K\R)067MGF-C.KF:^U^<F5Z.?(W3)ASA*T:H(U49+>SE?MN
M*['[R:KAZ7\AC'KVWCM]73TAGJ^E,J:T?]PZQ1Z]E\->XIX\[#:]GS^D%B-^
M<#)V0^=?UR#RZ@8=UR$MXBY1V2(P&4E31:MDN^.,CFD:4A/E?_^V@_"1E*H;
M>EPGN?;[[#D\L3^0RX</=0O]?JGU$6V)[@=XTWBF)N]HZVDDJ$D?1!#R82(
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M5_?%^09\\ JYBFH @A^2&*[ 5WAJ"A)O&K=*EFG43SWD#(N;.:. C@99K7B
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M.T> T;?@F'3\?_P]TXMS8)9&XASW6S:GKMOT:R9U--:?K49$2/\1#TDYB=Q
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M+%&%R/(=/*%6'1K^IT?O)<G5_^YY-.,:2(D+N(*/0%$AV5S FH[WG=LU*UP
MEN&T=;"CA(,G)X\YV[CLF"7.< %.\P&^J70TL)NY+[$<DS:-6*LEE;;(O)_>
MCO</W'J\+N.A>\[;)>-U8W'053+V,++F>BV5"XC1/B36O'/XXPM]MG"SGF5<
M^6>8T8D_XM:A_1^K2JHN??L#\LE'<->>4Q(C&<\, +0<UK%UNA2M?&PDC-B@
M)B0$ZVI)1^QC)+1,'"^[:651(B5PG7B*.EZ]^AKR3MN%Y&W!\Z'R(/-OKK#?
M1S(.H<PPG354XU<Z0UN-O!8/A,@BLT\<;)Y.UQB16HGU*B&C_,Z([3:\=*CV
M-209G--OR31)PH&X *K2]L0O/>^)HJ-<P#?KJ6S\V5EPF$P)<*F;>L4%:"#&
M$J4"PWWL;V6/-FMDH3P8V:1[W]= UA2(#_K8-0' S^*%:*D!J2:MT[!,Y8RL
MBO%1]RV/U54G^?@2B.8/V^#O/*!>_3TO]4<.%1]>E)TT,]M4+=+9O-('!>T8
M8;0)UV<UY$M^>'3+%4^G#16#XJ&&_V\P\0LF;7(!@O63)<ML%"2X=:_C<6JM
MEK&VP<D>V10ER/TD#1FSN.N?8T/EWU2/[C<VVO6F/]P*\()_/VXNX_5_2(ID
M1&R]#%*(8A:K%!%RFG&V<>)"3Y9ZYV<D[G(?ZVK. 7$3_]X1MPK<S1:]O&U-
MV6LI9\/C#/_D9\2T@*DFJT/.+;I:CN"&L![-Z?$9"!DACIR]5J$?NF]M(Q=T
M;4<#G_33(:0SNRE>Y.&ZW,W0#:WHK O&Y+?)F2[))SHHKV!?S->-IV=^'VH8
MR(XLR';5#)*9<K ]&":Z$]$,/FIX\'5[RT!9WL:/CB,'CQ!*W!^=OAKFL^-,
M3EX",Q58,C6A%E2A;ZA=\SN%F6T:2:6%-N/([KM?4V1-S',60W1J:(<+<[JT
M+J=WK1UX%U2P]''7IN7Q<1.T\06=T?=#)FDZ9;+XY0%4+6\T7C1&*W\45&$!
MR?EY6555U)4P+T_]L@1S@S<YG=I]%SH@ZB7VI=^7_)U]U<WE$RQ0C:?)X!T1
MECXO^D!UN8 W^1D9:20_-JH)6*E>@X+UP3Q#A<)JSR"TK44YDCU_IA\XYJ(4
M<9U 21'/^)/6<3S* ROYIOKW#A^C76]?["I<4/Z\RQ:W<P[]Y5WJG;ZR<<BG
MPZ?AS)/V3?Q/LYJ-*"J"]]KSGKP3M/3Z(.AJ\?_7<F^7$):TOT,KTAXXYXPF
MNPJ*6O6,7'GXYZ?/9RZ]R:8?_(3QH(A<EM]EK<RSV??RGIV2KSLE3(_G\IH;
M^;NUB<A?1OL<I"#61OML(7N/7,_IO20C&72%UP/!(:T8X2+G.IKQ$A<PB02N
MF-9N31Q%WV8$>VFOZ;[;LCXT>=&X*<K'>TU("[+2Y_<^QG_&,MX0M:N:5_AB
M2+.?F*FGV,M:A-.Q;?^2<D88A:\\.$*C:O4ACZV[4*#)\.><_ X0<4%#Q"W+
ML.Q7LH<SHC+"+'6@46.KQ& _%<42%J!+4IWZK0=1NS<*/=94]L8 7X$,IX1$
M1RKZ6N22C8FUEP,_=DBLG"I(N>T?BOC@-)0:,DZ=#0?I3"[+$ILX1ZGT"++#
M_F:M89=TR;['VA=E.QUBSI<3O#L"[=6>+)G^$7Y<L#DAH=/# M)^BY&E$E#!
M!9QI/8-N$I&YEDQRYV$G3_EW[%&;%8HFE0@M_:!5S\S>9*11;W]+EQ]$Z :7
M-EO,PX8,5&O&+G,!)C3K\*Q>EK'GUQ?WU\N-UTS;[P\YO<7W;MR&YGB/!!-*
MF3TIYD8)#BE5VZB\WX>:X.\+;+-&S?<A.ZZAM61*YC%'6%#U$W[J^36VU0,K
MGL<PFN"-V!: 5EF)4[<7&<Q0P"SID-7>K=YGJ.W'^XN>,Z5TBR%'FT6;[X,*
M4B[.1IJ%&<R@?VH8),N]6)/5:IRXR>;+R.O/Y8S]=GR,1>S/1),48CR8<9!3
M[ZPVN;J;H42>B>&+ .TA"PDRU"Y5S!P2:TP1?4]F:YYK%2B,2W2'N\_H6K]M
M?>BKD/8^2NG+7^:T^[]^0K/K'(%5VB9(@0HG^WT[I'3SJ!OI..@V^!7+'+&W
M(0O&ASPD!]7KXXS&:^A@1=TJ=.E:E2-;!H>K[\PHM:U%L+-)Z_U< *F<"Z#
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M(_WL_YQ&"&M;94E:>I]BYW#X56X.,P2$G4-(V[F.VE+G,":<4%XT25Z=036
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MY*UO*4LZG^JR$C,3'4R<(M)X N#SQ[^]R'E&VR3;FB+3"(Q.!_0@EC<*O=K
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MM9@!J[>/$N_.8Y,9+T$6[W:^>N2?VT3,9![_6S-N#6P*Q? 7C4A19Y$->/U
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MM;7.6^@5,);XP9IM%?DM>=A&Q;)]+>;OM?VA9YYM,L_"^7U8Q@Q</!><T[@
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MU+XO#S: '8<D/\L869)>69FC&KWCG8!+E!NF^62T+=FD"IZ6<D^Y*K5X$5C
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MX)^@@L= TV$'\BA!%W83F[2^">.M'8)F1L.6,>UDBJO(T$]5-/Q@3;Z#:Y0
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MDE0N\7P6GF;[>>6KQ5!'@ZFN7JO#0*,']"?R*XY4Y@\AT1%(01\,Q]84_D]
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MP(YM@GD-D2\&[>EUAAJA#_#1"_T)#??#$1W6ST.QS<_]R7<>.RA"['@D0@S
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MJUW?VA84IMPN_7C+NJ:ZM*+2R+G49_88MBZ=RD>J=1M*5^TW#+4=)PU9\L;
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M85Q<SJU15X;KJ)DT)3>WW/J#\P>SO4=:%G0+5E-<A#!W]2-O!J_.MXP=$L8
M6/0V\%C#VU!3?O/P_-PD-_(\ISDY';ME4$=G^0XO<_QSJ-KPV[&QL9"H+WDU
MY_=';,J--WRDXV&K_CYG0HY28)TXFBF7M%\<INW2AYZF#SMB[.[^=]9^1?A8
MA!A/$"$JE]ET#L,)K.*K?7N4%9[/66ZDZO11]V*_U1?XI5,]TIV;\?@9B&T:
M?A0G3. B63H/M-N)99_"4!SV/"_N19I!$HI'I#^C)G_I61T;F23_YVQB R$,
MSO5E038P@1%F3#<1A5;(,@]  ^#<S!?D87@M(D1-B @Q8 <B,4K)-V5TY)L=
M*HSMDF5.7MB@0''45FTH;#*]]/G*3/.EIT6="3&/#O@^[[Y?'9=J4H"S;6S8
M[6.;D)#XP<;\A2V^K49):CEZE)I_E G'A\XR)#')(FVX3MI>CJ2CV-!V+C)"
MB['G^C!-@"+14P?9&?+]7Y_CZO2L^>NG6["AU@RVG$N3#L:]IO0>M ^ZP'OE
MK-Y$B^L7/B88P"6;0F.N X^.$Q]@.&^0PS1.A. (9["1")X'F(50HS ;3HC+
MX8=KCPK+A/#Z;!D-YJ$K0HG?*N]P$,9KT:"#-\,+S:3%#7]=T#?>/IBL[?5Z
MRR&)(^E*=_'>+7[E\B5L%PMG3\U.-:U@OP+"K1Z[Y8 2N1T7><<31RR' PY5
M86JP(8\98_.E*XE6&!-84,2AX=P;-[:'V$+;@/9 #YNQYN][QL_N)CAQ&L>]
MX.!!XCT=BE]XEM5%GPYIR)#M+\^/[_DRQAJ8U:[1\ ]8]]YTY^5T^Y$"NZ3=
MBP,%%HF:*=HF+3MJZE*T4NUOW[:O*3MJ4GDM+33>%Q+O*+>WG<"L!4>8E5':
MJ T"0TY0=*T82[BO1P/3D*'-X9&9_CN]K<WD.J3N)(>_<!CR248I:L9GN3C"
M>;?HN=J;#+L2;<5<F=P]BA.*O>;:@;V.6@,%)7(R(^'27QBP8WET#6-YOY71
M^@S$H$[2/NJ)R][VQ'R?(,9&: ?A9_"Q5][LCI&1T39W(&"<(8D]0A]3RAW-
M[1UQU@\HJ>NO?7?O5+;G)%55( VV<8Z[1C8PY UV"LS!TZR0&,_:2LYT,WH-
M6,3DU9W.NL";QVU[S!I5/]^G5.$P@9<+K+R>? T?(VZ=K>UZ__FGPK[T:R]F
MU'['[31E5WLO*GEF%'D:.#CR;L][^=/<W\%UL^_,WSV.?47C^"\+X#S+TX"9
M YEE"3T7(:+ZP<E_=&5RFK2@U(F>L_\#F%5R=T2VPNZ#@5G'S$U]?V@SG,)5
M380UM+D):#\PTTG3+OJ:_[VS%_(A0P<O80P'LQIW/I745 "= F8NJ&1%?]WX
MU\- -K1'<))+:D%%(26I.P0GNVG, V XU[(%D@)OCJ,E18CK,X[&O/E8@3_Y
M,MZK856'5U$3FOOI#H:75U5XF0Y<_ZR;G)[K$"Q">/?YEV@<2&49'*!^$"'N
M>0%OSZ/'221>"*DT!2(#:^QV%Y9F1S39W;.X=-VN2%KQ@W-!;V)/O/F)--,9
M+7:94]*ZW)/-;%5%=EW:>7X M+\='@0^NF'^,M40!G,:@>!;+_,M.+O!->NK
M%WKE):F4)D*@)40($]*(&.\>7-:LA"EA^F$] .=;"S6<-"3,F"G1!@?@%[)"
M^+T;*P6*#$[<S (&@"5R@Z$PAH6>PU2LA-GS(GDR);P;\_PMX!"0X"(.2<J^
MU]0.V:UO!>N#E?ZOH6M-+OLX)M_G7W3 )]B7/S#<;W(X\+3QN&3X#<HF1S<I
MWZVM#[6:+F>8/.CD%N^$G))O>LE[2?D,MM^*S=]E^D"8;J)YQ^+XI,WD17*:
MS5.2NODM(Y.Q-L:Y[H+P^AX?;;7^F/AJ^DR(OYPYZHF@#NJA<4QIH IF+IQY
M=((QO(MG!SX>]U^;N9;?DHSA$/'S#7<.39_/,E#BRC:6!#17H\,'6 X[Y8VY
MTE/)E0E'(OHZ4&T84A+TAO8*8"?P=6%B=8'FJ0[$,B1\NQX:[ -K/X\AP+N<
MQ=943^+-8KP7YE[+&%I*H ?>9X)^2R4'3#Q[M&,V]][P\R]G!S3J?DDI/.OQ
MLO^ N& (&*]@O#(.%R&NS(,J7LU=#]#;YEB]!KOPA>T_@S1.FJ%9P9>/G/G[
M^J%;WZ4HR'J^OG?J0#FG,C:P2P8?=";N"TX]@M/R)/,#9E9'+G'Y'OH9\]'A
MIJFA#W8VJ5>8]]Z]?/7T@W?AXWQMTYOY=FGY=K;*%B4Z)RG\MI:<O3E5ET[/
M'=U]N>>!3R_I]"D'E^'9V9G1Z[UEGU)O.WX5_/%MS[(>^8K&#N;JO&GGHIFT
MN1+^><(9T&<&=T!PCF/\9CYJ[##GN+&'?G+E(ZK&>P(*>';,T;E1HZYWZ\_%
MNYH5K1,?[S$>[BLRC;U49)MOJO&\X-)3-UGE<IL$D\INO\Y?TN@ZG\@K2)UN
MRV35_?'G/>-8J<KXW.A+US]&GQ\J:CUP9,NC6(GJ(UN*-_ZTW3!4E=/+TQ"^
MHFKA;P^V(,6!:XQA#*OK ?F7EO9F]%:#=01K+B/2K[FN*3EEPZ 3IS(<YW)L
M_ Q.JJ(WV-YRTME0$57QB\=ZT[[GK1DECH'/ADUME7<;5I9.)9C.9[U6'"DU
MI[:=$"'$IJ+5WU.5" ?!$HX7!K-)< 5TYVYF&D>[]NA]Y0PVD=>#"6^J^9??
MSN^U+\K&9YOW+,F4QY_/.?]E_:OP,1W;6W^^"69?\MC3;+$SEJF$?ZMA>LRE
M+\&;K-74ZZCM10^7?H^W;W!5XPX^#"1O! \V&OS$38E>&KGOE85W;Z@^D<U"
M;O\L>U7UT(EJNY@<)U<?Q_ W$:H>1QR=S%6B3RF.O-I-+-2$@S8=S;F(W:KU
M64>$>$EB/_;(.>P:XE,)E$FVM/MJ7QGJ"6Y9]5^G]#RFW0XXTEYVM<SK^J&R
M@JC&[O@XGZ_>IJ;<.-.7^:KJPS.F)I10S>I/VGM.7W)RZ?%?,- A4]#N9% 9
M8$?QPT8%/Y<*X\.V PWT:M#)GUE$WM<L0FP68P;=1;]\QGV0.F>P-P& :P[^
MQ&E+OI'E5JQ9I7'H&;9!<]HDQ2GM'+HEI<(^U7=R+/WYL/.0CXSL<3KF\EB]
M1LEDTF0Q>7U_[FCQS%[>X(G>%D[7NC_C&]7T;QVH_AU=#H#'BR C,DRO(?A^
M]'P1P@*]MZB-=:&3:AGO'G#XL$H?.?)RD(7VQ*GNE(KFBYF:UWL+3/W>%RDK
M.#Y>CO>;G?E\]JG/0/BI$XEI-7$)/1HS@8,6K0MT/@:JIU&"YJ19I$UX%.\E
M: LGM?RF,=WWFK563!<=:!<I CH%];\OINS12DN;KR"<X$;&!O*1ZA>CV%#'
M\U&',0/&";V@WZ(DJ6'O:!RC>5!5DAW'B3$$Y_DGH4X,YU68%!AC-1B8CFS&
M<"JI8J Q.S4R@F(6)^M8"35R&<V26_"/&'..Z;G-E6FX[/JM72G3CB:G:W)*
M^+"R$0\5(=JZH38T[^=:.%46[82H87#BAE5<?2N2\X5(EZ_'E-($1UL%FBCP
MG,!P(CT$VD4#KV- >]HPFI.*S[;BHNAHYFZ8DNZ;()8"GD+:G"L@4-3!W%B@
M]GX<7LDX&WQI,>RGUE_',$\F+^^543_>;*X[%%QIME5.#?_0(K#_AN\F556;
MG'A\5&7'H:S!QJ+<L[NC$V<[;^9+?VG#*A_*FF-O\O9"E58X+D-WJ/H"<;"$
M?XS@PJU\0WRD( U3UX.LRL82HT$3;DHX4*FOP\+,A9Y=-GLY4 )+V$K]@\58
M:&^??L=QFU=5BX$E5U>E%@5/%,T>YD6C#Y!?T/S1P_F0? "O"J3S+P$-F^#E
M:8=D91^6UX5 VRU!4S13"[Y%$%^G854R@MH&JV.TX"!U%S2X2'ME, )+N8;3
MN2N #U\G03EANGU!(]1.YG(4\]?>YM[PPY=>?O6(RC7/E\!'V<246&RUR/HU
MW%BEN3!IEXGC+9!TN.I23M9(=,*D?Y#\I[$8N]J4+ GU(6A'6">M7)8M%E0P
M1-@ 2G.)$[Z\A[^;%-,)!T#W"?\HG3MG70YWW%A-K[P?:.Z#7??:"1MQ]T7\
M?K7ZH[$OH][V@66<71/Y;\QM++L-= FRX"L.QK$_J^IUSU=B#'H;P8TS?:GO
M6=GUG0N^:$MN!#';9<S09_E$6X!2[3'%K3?7OGWK$:L=<L=@<"C$QY6N7FW0
MHS P,$4KHYVNPM55#%Z93*HJ9H]U,L):Y<?)XG@B2SFV5HD#^\MP$*\UIA;'
M\A6O'Y/N,:"[P4'D@R<VK9;D167.,/S[-8L#VY&5/D$#%8P;??XWYC1J&;H+
MLV.CBDEH:^H1H![&?KR0M,9 %K\X8=Q,HGM!.RPC2%MJCQ?B6UL5%&$/8_!/
M86E#&7N[?8<_V_0!KP3:W!"'P254V<]QRD-?X]0@Z(9O)27I3YN52HX]"R50
M%2%B29O"8&+V%UV U[:2Y?\;](U/H(69PL="6(9O-(X.)._ZQB=\A)$VT#NH
M%WK'EX7YA%\F#X5FH]UJ%JA=RDNJ_"M ?2_ Z6>4SK<2Z670;GMH.PITH6VI
MM>)\AG99@MX,T!3X)LX?)%C&M_+=H1T,T(N\#? -C7FW")3!OAA(*I_P&GG6
MR65Y@H\.9,>\.:?\QNTH7C?![$C1PZ?NU@].EVB-*AWVVU,YEV[B;5%9)YU/
M#[%^M*_%KWAR#_FNX8D,(G#+Y4:E\0+:4'J.L0GP0@[+3LREQF+6AHD)/,%^
M3:)2K6XML"E,%F2P]%.=!]U2!S0,]?=E?M9P5WJ;3:EV?IAZ)=9]B]3$:/IY
MZYATDX:G![D6MRY&UY36YO38^VJXKN[.@>M29:DI6_!X0LN^&Y "W.>'1\9O
M1Z*B(.VP=J <UNM;?^9U6[*0T>AU5"4!^CTSGL?2,SLYV5_KP$P_U*!34Y.J
M[G0MY+=>6$,?%7_<;]F96-"?ZZC_U<>F:/-(QM.)DPSS4UG#U"*SI9][G?+J
M;&E'LJI)&_#(%MH.@7$^J,><OB^PF>B2]6$?\':5X7A%+OE+X8DV^*O!4^;H
M<^_9*(K>0/3NCZF&%93$G/,+1S86&_>C8)[WC;=&&7MJBPOOH7T57Q[)?4,%
MZ-B)>'I:L+3CJ>8VCLJ#Q@.EI68T=W55NY]BFYTMY&(3L5=5K!/LK8KLTD]I
MA[BHMIT@YPZZK#&RM)49#$P3$&.P,Y9TF[\>&_G2HH\19(5_A"D #1U@BFP$
M#MA-^]MCH_LGP("SKWM+<"[&?'>6;%2M\C-D:5>1-U<8ZY,' >5^%90G!]*S
M.31IO%FSZWKNMB(F4A[T:E+8RG4-__7P$FT+OLBHCW":M4]AKGEOPZ!M-RX$
M>]K,\O61=JFLS377/8Z:[$V[K9L@A!-M?2&PD&@VSS_A'X-9_9V@]^+P]#X;
MU-NC*Q'[K MLMH87/,PI5+5(_.#>H>!A\6OB,UA_GZRH>!QXI=#V@5)@KF)Z
M.;9GYO,"^C :R_B7)WT;0)T&$6([VF?^+L IK#TX@=ZE<[]6^V^/^B9(;-2.
M%TDA)17I/$G8WNVU;@7TB0N]9,TP.N"!O4(@*;K(1QV(@KD\5K@6&)]'KQP'
MZ #4Z0D(;3-.D!=Y+Q1D.KBGQBR-CS0WA.OVJPT^R(Z,.V]MFF2_D2*7Y-/)
M5G^[Z%T7[R@;E2NG[7*R2BO1Y6/OG:*O)F&P^K+OWKU>RNKG;P?RN[W&W^U*
MUFE,@Y,SS]H3LVJT^U,3T$[DB\,BK1(>!G,^(/QO _[KP/_QC42P>OE^KR//
M2838T Z\/1BV&:"? R?AJFO<I+VH(Y#"0MOL8!&$$)9"1Z$_10A.\U]-@-;P
M,M2)$#'W18BM<'K9B!0H(CD9!'4.NJEK11K-_ 7?Q5?GJT.[T'.6*WMPJ$K
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M$#9#CFOP^/EUA9^ZR=D2/0X^U2>*_+V?SPQ>?U',&TQ^_RXSL11A=#/_8>-
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M%[$U@7VK2":VX\N^U,#1CE,ZKE^>')[38[^ZE$/6_8L__+S4C:(<9E8?:%_
MTKX<-YM8KM,K64>NW*@>/![$OQM= GX3E@46)HN.?7N0K/WW+__WBUX. 0!=
M6'X*JBM_B&'5\S)@#N&F.>B"WJR#PB9&#.NM(7'=900&?XEA\Q2^'S673=CX
MO0GLF= "*1_-?V4>$,,6^S BDX%9S9_]$$ZU_S\FSHEA-Y" AM/RJB 2D.I$
MR(EA_@A(JW-I%M(LI-(G0 8YAF %XI2YB'$+#U118.NAUX/T&LLCP@M<_*N(
MV:_@H8^KEE/^E$\H*G^@ALSQ\9XZ*S%')A0$"%7TQ#!-.<$YPL0T-@4"T8&V
MG!_]NOT_=W:[_MI^+M[N0^6YG$>'C;7LLRI^W/B$<BLZ3::5I,>48!+(*B-N
MITX='<YC#T;K04I5XIO2?]K'I_"L[+^BM4]]:VBD0"4HS'H?:M<\0840('WG
MWDO-C5_&+@ =+ZYF^[/WQVG:)XH^21XCZ1/^H'/=G0 S"5 M1O![(+R&*CR!
M%!K"EP?B+)6 <JCZ$X6&1,"=X/_SGGDG:,J=X\L(CT!.*<$?C/IW;VC<Z642
M@S3YEX@BL%D2PR8^W",.-'Y#C)\&]\2)\A!H3!H>!DCQD#.FT,1O,O?C7'@:
MB;$X.;8B#TSCG6<M@;JC56 ;JT_.A[>%.]#1@KE ZO2*J_-R?':G56$X?'UD
M=7F9NK)4*4FG$BF=SZ-<M^[N5U;W]-AJ[CMMC"KMO5.8$1*4&N;IX6Y;EZ?N
M'WP]HME2TFFB<41^:+:F>@SM,S@K=/HV#[SB1K+I;PBJ"R3I5B.A&:^^G0H/
MK!3#Y QW H*.Z/IXVB(VQ[,@@1<NNCXZ&)-FOOSWLPKCT_ZYCL.'SY])&^G<
M?L-R47 0_W.Q<'F135+"&O*=?BX62GEW3F__H(]S9E?^UV+A#K#W S5B__=<
M]&H=SI:7&%LK6#6]E*D/]E%\?'TU5TWLP_]4EMA4)[1U(%_6=Q 85%!2Q".P
M1T;O%WD)T:(LB[U4W#4@BK-1JU<QB75MXQ%EA79<JY'ENG>Y?1*=>-F7HP;Z
M1I,E.;T#7>[1FE6O.O]H0-%)),!(#G0D\J&4J-[.(HBN9"DL?N0H<\R\X7FL
ME]]+.=4;N]QNKS<L7.)7EUKI=+6'E]D]F1^YDSR76F36J__6RB[*?E=!$L7:
M)43!V,7=I:[>QVW(IV+L$SU?9E()E&0*KN/?>!!DENAH3!R<6UK5JN,-9"V^
M>4QH?P/X<.C+XQ9PS7B9AY^9W('NZ1/$W\'^C,Y&W>51N%,,O>Y+5T@68ZF-
MYT,(@N('ZT_K6TVESY!,[M[]-C4U]95>&T^KK*QU<0H+"[,LYQIHZR_/)/EZ
M4G(\KK"3C5%''V?NM9>566M[@7\#KW_TF#6!0Y:!G4Q:]S.6F;Y_*ZE+)7%I
MBI?^KN/EQ+ET>^//C5,#L8>'_&@)9C?3O1,;]EH_OKC"<GZX<6+W[!=/DZW'
M>P:D$JFI;JL[[<<'0[)T:=M*K6E>&?BE@Y\;/O_(#7I;_(IJ,S&:9Z9C]^OL
M2#D]^GCTA$;3W8_P(Q^M++6+<RZR$DRS4#Z'D[4?%Z=['OVC]$#@WS5-KW8]
M_+OF..R7BPK?=VS5IKZJ10): 4)YF<Y&G H]D7 -,ZF*'*QR\YIT_4BXB4B+
MKB+=IJK8I6U?)C[0JLOTTCGR^/<[+P,_VVPK+[54X-G/$+JI]QOS'B7QJ"R)
M+G@LH[]TVX9YR&.>/4L,2[&$!T6GT<I[U/JZTA)3C/(.KZQ(16DFGYJM3[[(
MCO+S5/8</J##?DD+6)J_'GBYE-K@2#LUX(!L4C8M')FGN#R_D?GI1O;='.0]
MHD%A,I\4QZS!+,OQOBU#5Z>P]1<<"A@295K<;:0(=3'QK:> -%%NV(EC?TTR
M(5T +T C_/*O3-QXI$HTL-V;F6GWEV.FKBM9R;PFWDQ_SL4YSNV[QY,<NU6'
M*^G!$YK,&U7@9RQ-8=WC$>(:8C*&]2@QADU(0KRB+[MQ-SJ\(FK'<A(?XD(%
M%L*KW/S$:Z@0\HH!-2(XIEWE7GQE[4ZI/HN-O5W['O3W[D#/>ETN=Z8JZ1JC
M1I/OWB&[&!\FW9QAT#/;2NH=HDOHOQ8F;Y:W(7Z>@.2=[# GI.$/X+LA4NO1
M*;-C8521497)9FX#!Y!*%AZL/"?[EC]]/!>\\"U_ Q#\V[6\;*H[S&:L,5;L
MHV8.!Q9C^Q=T1XO.ZKB7VZ5Z5V=Z/2[)77K.</BA?U:3[["I*88=F?72>\EC
M=C#A. .>_D:LI286W@W?TWRM9&<_F>6D!J"]N,2D<-Z)U3AFH._!ZJ%U^[.Z
MPH^Y*5<VJ'J/^T+70Y_X*VB_M?MY6P[5;;N0$S1?0G,([*IC62D($)#4EA-E
M@]OQPTCNI8&M*&1M0LT,E'I,R6;#2IS_2+,61X2V&31R2LH_R!VM9$U)M/EN
M2U?S<WF9Z%V7V]6J\U%H7P&$MY5Y BD=TRHCS6?*44/ST;3I4Z% ;Q1>1BZM
M7+DW7S%UT4Y^S&CNK>+PP<;>.[5^,7JUDW9++\X./_^CXGEQYG2O")D^E7_H
MWRU.4!F=*4'0, _"!Y+@6Z&*28)C$]]$?Y;U!0A=>.U1"TENN15/,S<2I;:>
M_XJ52T_QU>>>P&:<:Z%EG;I%FY(1G+=I_G2DKB7KMTNWH<MB(]RWR!>*DG$(
MF10ZBC"1T4/:(U36Z'1/!Z8'%]M!2ZX)*3(L8GMF7@F-XY30>I"7&/]=M=)Z
M;4'*QV#2:Z1"<\3@J.S\V[##U=3-@X0V#\1,+<01$#-9K6J _W6FC+$,$;X/
MU)U8R*$\$&YE813G\V6XR]0XX>F(  IR$3S$H_,-4SQL:M+7OJ(V%?*?L>[=
MN6>WT"]2.Z9?4=Q )=.O&4Z>G#$4*N3R3V%2O)S^_ !H=7M8Z@#.O)B9N<YM
M'RW<U&/9#N:]_V!);98'U_;YZ"$'(_2E?#[2IG07V+WMP:X=O@<'#:G?@]7Y
M['LGAKYI]5C8V,4?8.Y]S/)[/-9I_NMS?^?K:N2C[++&5>_VT#3/F0*[L)14
MKX"B=8O3&62507ZO*:J8,^1]IVI^PJ&6N':\L'4#8CT%X#M0491*QS 9,?Q@
MKOZG>M\=0"3O%QV<W($U7Z=0,A;1/7W@0^LA++(CVS0G;609)$>P@J6ZLM15
M&T:H!B4-(W.#Q<-S_NG+C_$[J<,OQY.QS29P!:MZ&[ES68<S@OJ&*AV-#S*^
M?KJ1ZZ.>F*O]NM<YINLU_3)4YF4+D_6N_=_+<]MCB$M=8IB6CN ,82+TY\&W
MTI7[OFK_;_L9=S/B1K08MOZ%"CX^7,#K$3H+/PHH8IB$,Z'7Y;,85A,&G!?#
MR* Q]<L*O=@),$\!7;*U1+FD=KC(D%=),(W@<.G"C 9340I7#-L\9PQ)UF:H
M"JONTBYLX<"@](?S'42Y%I&"/\!!Q Z(<Q 27L1"0]MO$5P"N ^"@8-HI,R\
MQLWA9C?V\KFIE5N,.7MN0/PQ8[IB4-W+JQJS_7E%/F>O5T_;;CMAY57[=;#4
MJX+CF*D25NY>G%>T*YP]=^KM]]3KN9C"\[9O7Y#O,FSU)T/>&KH'@>\(K[*7
MK01H+.,;:V.IGNO]KU5[LE?'O2KI'6<03M" $VZMQ(^-A^"\.8B]S*^MTMPG
M*AGCTV?)MFR'&#L?]P4&VL%LZFKW1YFIJ:V@]$GH,F>C5<*5&HF=F'%!>_:)
MG@/I*!4Q#)IT<K9Y6HWY2F! =CMSJX5M<>U?I/3SP657SWD_)6=:!H$CENI"
M<U$JE+"IS)=?RHXY9'?(_$G?]N]JD2E1&$#8A<32V1(IF$G'04T>_&&(/CMY
MM8NT%W>/:E_\U5PS-R1)U6?JJ^5>[E36LX+Q>17_[#4TCP#N61<5K8"'C>A;
M$/[T![[J@$- Q2?K+(32:G,D!_XP_S#WNWFRE'W=2+,R>W4K%MV6TU]4W+T:
M2DE3ZLDR-R@*?VQ3NLAG1.6Z"'M)<J$VLF.=EBIOKI7Z ZA&@F?7VK?AS(SD
M)V67TXQ/=0_QC4K[+Q>9">RH.?J;,M()!?M%U^^$936_G#"HL_4=$SB43U[(
M"13B1;6(F7@"UYDT'M:>D]V)28)+AC,?$G:%ZTD,0Q3L_ R^\>>J^$F6]\4C
M^>C) 044IN1KOCGW"Y'B_5M(!%QN45VFAIOW_$YG#?K=J4!7'I\^X@%*_KR/
M10!LH=^>0"3G0C4WN*>=E,;<+>> 3(+<&*'F!.YS,'"00J*;@I6Z+:5Y>O.-
M+MC$]LT*OD?C7;)?),5ST7?_2*$*GHHRR7L!1/KP)'AI4+!#W,]<*"W8#8Y;
MJO+FVO(D'+G9;9#P_HTG\<CBU$R?[G$T&:O%AL<;JYF\8Q,2FD^5_*1/F+C/
MEH>YI.1:!\MI5F7M,Z%KZ5>5X$?9!8&,,Z_6S2*30X'G_55G2=<.Q?6AK%TH
MNO99>2$78SS/79HK53"UV1A><'G^8J2D>#"^:" /9VPVY/;5H3\79;3A<;=E
M*8]:Y*"9NSCT@P,E40IK=>F,( AWE3N;F(J7!_^!TY0Z5W<NO-0?S6:3$NDP
MRV/8H8Z<S/*:PY_&T?FJW"QRB>]O_8]2C%N&']<<T;Y^^?Z& MJE2$%W!#68
M<M>EW&PHY5Y&AAWHT="=$?+61'!T4BB3'4B] &1S$]D#;?>B$;N$UP$D3XZ%
M2-:L<;"&2POMN1Y).$FJ/>7=L9<V!'4B.^^DW?"-FG2L5KQ!UJ<W:QW'@F8Y
MMULCW92M0UWCBLQL?4^DN*1F1QQEH/N.&XVF>?*O62FL('?2;\(9'OS[L2X-
M@!1$,>X D\%%5_5+7H5R4UBFQ-:C;62?9IW;=8PGK=(?C%\LA:A,#48DS!?^
MU3ZO[9*ZORQ39S ES[/]N0+5/#WU<-425<<H<SIYU>/OP?]#;8(5OB+D+/<)
MW0!]=@#7HQN10)#%RV%[3YM%*%MH\$ZVY1_A:B5E.#7DL*>G?WR'R\\WNI?5
MA0T$1&XSU0\\F(7V?OAQ8B;38Q!4 'M(-'J/ PQ;/I.]1!-8XZYS&_*_C&,S
M6,@V>!))MG9K6(#IQ,IR]RN6X>Z@S=#\4<*GJUU\T@E)>J1NN9!V@GI.?L1S
ME*SB4J_O>3D.]2X7[?#6BDG.;]EB[3!A53^A16@*FS/7J^9M=) >(G<U.\3,
M4)/5M_&R.PC*J%*,01'+$(Y%>G,)215'FI(":.D;9WG2C_+*&.3W>VJ\F_F/
M*SZ>>*M\XQ!1U<O:^<GE(@WMMUK*5A1EK3)4>4G.B'&1XF2\O,>HNQCV$K$\
M%,$*Y[50E[P%GI\  WN-X2+>/?K2'"\!(_668F%_ EE"A\?FVJ(UX[/\&[UK
MMEYX=_"O@ATUI5YIZLA@KTR#R$"!W5^))Y?5;U:M>^FU6&?$:"ZW9-P5$#,"
MRW/NYKT(VHQ_E%$\/AT474*)"J:@&D/R@HU7"EX$*=60:7EI:7G5]J&149&A
MQ^[R1T=Y;XV^_?/X O%(&:ETG3D.YR]PZ0D&PF V9KR>7\-=C3UVC#),;?:I
M ON1^\.)NSU1HR_[PL((D=0@]3WU@Y45E<O+<Z_S%]"U#_;_D>-Y] KGK@LY
MVNBYGSM-UR6W5L'NK]C<1O?D#$?'93V]A;';SAE-MK7U*%.,Z^=>[4*:K#/R
M"M:&+R5J:":PFN#[ 1G^KZ(*BV"6FF.[M*L#SR..$(!, 8]RIPM*?'XSJ*2I
MJH59<R-6GD5>"[UE]5[IMH\MYM@VAP-IRM)("V#L3:L)$,QVL&^C[\6IL:DP
M@&X3GN+!I:3ASI0#WITYE].[:ZS4R07HK+LJY)2W4L4OLMU?G>Q>6-CU4FO_
M=6VWYZ6#5.MB%AY[KEC+S'/BF_6)D)^=,FAW55/3FU)LEQ@HQ+/>CU8*+Q\D
M;[IV(E\1E^-GQ# 8*;E57_2$@'*2$AJJ_#%*["3NQ4D!!878;8%+#ZQ&B*G&
M""DO (M*4]XG]>V%Z$G!;@W&66K.HGD$RLUAL-2Q+/7YC?G^D\[IT_I=M<6-
ME#)5AY"<UK+Y\JK->(7U[%C"'\3)(K9!+ 5;#A51'X$G=K5]LR6OJJ@8R&BC
MUY"Z9>2^FN>3[LGF]XIACJ-&3A)(U%A=Y%][C2M':)TOKUZX\%=301\6TTF(
M8RI8[D&_96%2Z-*6!W%Z/(NL) (\T?((8-J)EQC+[[8]FGQZ>-#"J60^.M;+
M]IA+=[94R+6H(X\5WAW9\FLG:\%AB/*PR*48T^>H@.H-K=N(N_&Y<G3QWQY3
M[,&5(?M50Z$28,S3XB< Y3/(!T@)H2E4% B=JTG1(FJ\4(Y%6DZ3^ UDC&$N
MI*']1#1VFNL%+IC[Y>%S$<5]I.+8$&;50/8QJ5D,0R& (TI"^7+^.> ,FT"D
MU]HL38EANS98AK%51E+(?=@:4$GFC9,B(<")391%Y2M^* +;N8@N0SELUK=E
MQLHKRI65EQ^KTB>7X4'-Z!BS@-<IL]1Q.I\($8YSHC+\=G (R4V A%N[&!:O
MSQ'I]2"X<?^UWW(G27B4/I$$D7M_Z U;42(;LX1!] ],$EX:(PU#+-]J+A&G
M"8 .0GC@L1@F(R4B6FJ";R&-V(WDOB"P_(+4M]#%L#@!J*(%RHEA2QC@K)#
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MF)\0PZAP09?-.3'L\:T6PL8)RYM0=;*ASQZ%0ZFV] ]XE+"P(<K56QX +&+
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M\^]:UF -5YGM"(FQS<_#4W#P>,'ZD0=DS'R!A#+O(-*6_DO:)T WH^_Z:C>
M(7Q(OH&J;=FJ=TVZ<9+M/^=)?PQ;R3S#66C17HE]A]U]?'Q/^+4CCPEL[A8)
MF(E&-,8WL>UK;%U9<1)B#5:@D(*"6K\!.17:?*C*77XTXKQ@/4Z,;<;S39U"
M_ ;>^VE;(QW]N&"%Y_T33MM,@'B\K@LC>Y&E=>3C_B%#A@.2>U9.^H2LG&E6
ML:?GRPOJU(1AI</!=(<#W2;E/[H-R_MM#1\=]G]D<]5S8C0SXJKG/X]L#V9#
M**P 'E1JH +VO:/F+V[?AE?IMK;MF/>(36%E5G3\77'0,"3?.J5OE^O%S1<V
M"?).QO#$Q]S_N;Y\^'!G@TLJT>?\6:^,BMV/-:\GI3\M?.?-/MFU5+O_%]7D
MVOQ JWMNY,78P4AS=T-E9R?W&OWJV8G%ZLQ12'WTCB6T6G1"Y'I\41@)P!/S
MT^ [";K"9M">IWE[3\.BOI$?BZQNA2H(#+$1_F-4;O5V\6;QQ9\+95_9,CF;
MT'6FD+*!@X8RXOQ%(?"?J"G($%Y*VLDY">*OIZ4_KJ_!F Z8&3@D*?Z&A(&/
M=!(NO,E11BW#W]).I]Z8]=^[S]G-\<7+GD+&='*K[7C7_'UUAJ'S0OB*];DU
MF)4"N!\M5DKNE&ZW%]V80<F+P^H>HWY#JGQ#"-!3T1VY)[[GAKP&<0Y#80M'
M;< HOS+/35EV@^*H,DZ+GZ%PY+8%@QEG:.7]ZEO$[=6B#+P59A(M5E:0;C<7
M[8/65!&Y46P(W,X 'NG1B/:XU]\X&YG^E-A,=9M[])*PWFWC'M4U97->O:,W
M^HG:O%*#'G?KJL'PS '(6RK.J5=7UAQ3EZ\+8H@FS  7Z8ZO]UH8&/"0S_L\
MC/"%!7F>MCG/6U%RCS\M3$QW'J6VP]E&8;3#%3_,'J,HU$?K65F3EK_^I[;)
M!L;;H'/@5?CH8FOZS#9]1Y/PD7*2*3&$TA9T=3Y_B*$SL$ T-+T8EQW&<-CS
MZ56G=DGTT4#,G,+>SH.=@Z62G+]9'?FL4R]*.EY_B2E.>IR3XN 86K;'$<>Y
M6'*\]0+^B3YZ]/)$@/:"KDYM=KT]-7,R&9KNB8D%OU7\>DP1N06",_]>T$ E
M5>#>;%'36MNT0WP6@,<;,3@:8F,!)XEX0K"Q!>*;T;1 /*\[U_NDP(1M$T])
M#&NTO%#7'T95'05C6BQV'#/3.@1(RJIPAP.5;(/$U\DM+:@*F_D^T7[22#:R
M5G2(4,-K6X/)DBP"U#OOXTE*!(V./+A F;FE(>+%;)\76'PF@<4^,3'!B6G8
MR-<>,FG$-]<%Y[_#;IX6ZVAI I^.D;0 1GR.'WCT;#32I?7BK?/L:I1QQW#!
MW3*'UDCO^Z]<2'S;NF6#KEM_O6PL--._5:+\!<T^_HZ37:XW_.*Y\W87Q]G"
M^17IQ4?N7I:6)S3+'TH3R< Y,MM,NG7]O:Y0$DLW0K.8#/_YY5!!_C3O$41&
M"QILPFEGBXE7!,RT!?$?4MT1\3:>@CRA]QQ IC F=%M_&O7&-*F!"C; E\+)
M,E-&0^>Y>D%-4GCI!#H6E(4\Y64Q'.P3G0=EN'G/15KBTP >ZBR)N9.( !8A
MIZSD!Y;Q%A4)12,N FIB&$7NFU=64M.>XA@3'S.'_N>-0^I3WD%POG_BXOS-
MH/O9X6F,T#_HCM[2;=-KL"VUTAZD&GB:ATYF A=2%E6(I\ L/F+'.(':1MYJ
MTJO*(5J .*"U]\+ /./H,S % V0(<Z:@35[,JB@;1/X^/$^\_IQP=5MA;06]
M'Y\_<$6PY;E0ET49-Y/*C4@H4@0(Y]'FAPI)/9 3T6APHH'>O)789>889,"#
M3"6KDR<64\,EEG_VWT3QGG$!8>&SQL(/KV_>&+J*3S[:HSC>0G[I?30ZS9:,
M;&<E5'B\9Q.(6E'M'NQ')6;),;E6QQ1]?TRG7D(99!PW#>@JU^0-682D:G>7
M<."OK94?%]O(;7KTI:_+WL'(X 7GNC&N,=P2PO^?0D/04W02VL%63<;BT#K@
MQJ/UU+PW<C7LP+M<1*)*791N(@\HRTI:"D#^3D!?'#0T>L$<;#"*Y,E.A+HE
MG&\Z@JWS3X0PPPMQ15EU14'<1/[?BVW1%D*ELHA2=@ $R/#Q\A]+=E=RA'<$
MY0_R[+;!%^Z(_P@XMJGDVF_[HDN\GW .=L(>G76_OI73#O]OP?)S//;R*P"^
MJ[_$W#$//G<X_\7X19Z5J5K74P30XE#[HTSYE2W[QS7W^VYF\OVV71]\;Z?;
M,I%9/WZ@@E'_I<H6;0ER4#$-:[#//?_)MR(R?[(&6W8CL)F]["8F:_&7SE],
MX:[[$$7Y81ZR!EM47(/M0/V>GVRPD/;'_W.0M'&5#J&U^%7(%$5DV8V6>)-V
MTKX8,TO1D#[K*M8ZOG[9CKX&&ZKA;9<ZSWT%0XD0)^HZW[T&.\?2W$/Y!35[
M>8DIY$*-SLC_]?\^H5IO7&).YH[A?YW!M^!%A\A[F<L!8#Q3YC])%8&S%%"/
MLH"#_,%A22$Y #&V(@Q<@\6NP7@*%.B/([GU '\1O$2&$0TD96NPK;1F>!QI
M&V1[_)-3^.0\#<&)A%$K-*\1=Q[:0GDIUX6TBNCJ[@7UZ/;"3Q!/( ,W:\3Y
M9MP:B(2D85;IQ-.8H^06:R;W"QZ\K#".F(+/0]WL\(90""?=C1 ;<,"W**"/
M"MQ=@[5"%K5MNI6Y40RU_=!%JFP#S6$ELY+).[I>P?YAEK,H0H@79JW"QY$M
M.#!8OBDB80JY+^]T#,LO)*W<3_UQA?-]O<X=@J5+L[J&;KM"7U44*#>^H!I^
M^6X9:L,N43_2>L%U^M#IS'1'_<6<,4NC R>,(FH<1.+U,TQH1F/"F3<5[F(8
MO1#A81<+Z]*;.;)61P&,$UGC&U6.CMB#;;(4K"19W<R^6,W>DE,R2;#V.=V2
MK153X#M[)/!.1R&.WWA[=G7N;,J9ROX; XPD4PE*Z"Z5=Y+D-QP&[*7;<(+0
MYIKLA7+J5"_;S!M MV(25D];UT1DTT,(G7\*LMJV#;]O"?F"'48IB,UH8Q.!
M/V5Q0687ATT.J?PXX>[4'_1]#:9BY0,A6B+X?>5\4THS]8U[;(/9ZW?7#>\$
MK<%2F %!?AWLZT7Y;DYR0\*'!40XL'GX^76-?]2]MYHV'HET,W<-/W3^7X#\
M![RZ<V%*M'ZV_Z?4</W$G5Z31DE:SM&P7:)N(_B?JU+7O4N"?U.::)S[AI0%
M!H_TJN3<^%G9^/UY5&@)(<$SP.C:2'B9,\X[TF]U!T)!<"R<>KF*=* XOJ6_
M>]JZT$+9WYHH;2VE.68<=RI-M%-\O>@5_JKVK>]A],27Z0SB"76EPH1;.=G8
M=T5-!_/'@VR\;^:718?-2=S(+4]1/Q]21'2TY->J9/TBQDOI!,3YW<6*W1V^
M2I+74AVB&CX%#FWM=G*",W$WB/;//^L?Q'\G52,>'PGO59N][4P8]ZX>I"_&
MYVVM$6#:7D#VG;D&.S. ;[#A]]BX DOH9X3LSE8]W?@UV"[F_U(^:UV(A\ZM
M-G:*E66XJG%?FS(=-MI(TAIT:3-U6(_88]G,)*0I\=8 H_O;)VL=;+@L8CM(
MFKS^R#W)Y7PL:V_P3WH3"6%8F$-(H;1<U74^CNU[;G5>[V*&GGLAVJ"E>[3K
MKT [I9+YB3/9P;NPQ[MZL-O3,G]32K[TCJ'2CS5SLQ-&.S<VB.FH5RCP($6L
M@N#AQ;MC6"CEW_N:E,$8+K.M-Y8*4!RF,# <<C]#,!D7REN#[;$M&_]VIS->
MC UZ!GK,[31A[Y8455PI(7B?KA^8CG)2OA-7]F\=YK."5/ZV) FI1NJB5B?<
M;=(E:@*3*5SJ9NF@UN9A*VP9B/J3H4Y*+Q([ ;1$5%5#>"G6Z]H&0Y-&L[9A
M"TZ<Z9.;-P_$*X#G_ 6[^2V*D_LI+\G<C^A?%BCVN/1?U3@(!*]ZN)=#-L5G
M_C E-<.%"&D_9S4$U/#Z0O#RA">B#;MS[3S4P<B2"QFV@Q2#[DFCLUVW'A<]
M]]U^X?&GXCTU6OZW/PWFE/T=KN_YX8A;QJ.17&NAET'1 "/KX?#Z@43>,<@>
M[$C=3%AO^V(*AEX\O\"CC*/YQJ5EXX3J.4AY)-TD*KT6'P)\\AA1101<<Y/\
M4-,^-H%L4Q7C73' %Y!3&+3MG DYWVF/@; RC%M]!?"5@L<N8)3(W._,O[44
MP8G7!(-F<B690M(FJO19G23G,SO.2?4#2'L$*DS_(@['XQT?M4UL7 M8E_J3
M\V=#QKUF+6 C30<)?BX- [2,91_+TPUQ\SE3:/  2JQ!!D:$CT%5+H(])9P8
M:;A!-!(<FT0H$PU!)6Z9$U&_COEWH<^I\?,"=!M-Y20^A*]016C7ZFU#JGYL
M4(WBU7<;;==$7!P4VQ,G?W\+"%-6N_F(9#@09"-6VMCV  SDL,B58HQ*$SS0
MK'HG&_3C?:\572!> HJ3Q*BC[$"5.Y2T[R;,I#O4>PW>?K<KQSYU\E%["!&N
M]SY?8IM3NMXF6QT]!PAUK=Z/MTX_=:$\G99)8/UDR<4\OG[((FSNRB>#XQ>P
MSC%"UT.G#@<[EQJ\&S+S-<&*!O\:[$=GN]W*OAV!G?"U6YA],3XSL+0&$RY)
M,J6;UT-545?@>]:S">^N'-DG(+?*,I-1&XD^)0'OK;R!E8Z5R>U9;50%HD^^
M;; UK=B7%1)Z!<_75.SX<;SA;/ZEV2:5(94YQ\'R*^EBJ%5N#*="E]4[7B/=
MKL%%QS-5@UP\0%=@NA6I TY,<;;9O3@YE8MH,<N6SWA!.+7J^C:.W\? J$(4
M"\\_/F6?% Z7]YI=/8,+6$T<G$<-O%\_^S("59"Z 0]]63R\$E%'RZK_<BTC
M>=PIA;4Z$@/YP7UODJ,.%6=N1;@XUB9I,]*^GLM_:F)KF9^D\ NQ7B)N#1:,
MT2"W6))QZ 0,G1,3EBAVPO'Z2L"(SKRM>0MA(#$46&P;GKO.Q\O+G1OWJ<XB
M[39<+I-Q]M!-ZVR[<^QA:"2.7-P963S1M#4R[8 V_[[\]D*[<-[6:&O%ER,5
M;5?UKDX=;PWNRK6-T@^9OO3*5#D0Z7Y[3Z^_^MO =-LBCJ4]__XE]:! ]J6>
M<1^3P368-074-Q,KK\&:(2=OLWZ?5>9#BDB?,,(G)S2X;JGA4;9@R0K6&0"'
M.\(:QV\>)Y XYX'.I(8K0<\(]WI;TN=45M\[@4=/#EAIOBR3I,71&F2#ZYS;
M4=WD-ZKBO121LG2L6FH&,!=D@GC4T>)VJ>;''"\+_PZ(%*@.->TA3+%&++(#
MLFYK[0$?E@5,;J /BAT":U:#.DJXN>XL==_BB"+,) 8D$BCV'ZW04042O.@(
M-).0 N)F,:M5$^AS)\R$R8 JBZJ(^XB][9752F8?F;('W?F'PGUN'#_CJV9K
MY1>J>E?L_U*CUOKI?@"=;.6*#;VC*!M9B%UH:\1WHL #$6+% 6%9O^Y@@XOH
M$%&SJF[D6K0;'"Y6KDSA'6-&1!U;#O*!/$><NY9FM4#Y4=6Y_E22YJW663SG
MTCC:)&#FQ\?BQUQ@<6.;F@XNYKVFK5FV<YG[.&HR%'NOK<X#>_;DR]H.E\<#
MT_?3 [X%O_[2>XJAU\IA8;UQQ) &&BGMW<V!]6(3H+%[+(I+M4 O1,+3F-S<
M-9ARDR;(XO6V*\B]XR,2X0HDE3%,)Y<<1]UUDV&^U',*M762]7RF29G2.FE"
M3^;X5@"<!%,C;^FNA:OPG>\^?YM4&Q+#BQ%+.9#B6#_UTT;N(:"X^#@4]]D:
M3,MJ5Q%8/Z7;;I!ZVAG<7 06=6C:.X#N ,>!F>XPT!!:&# R7,162-0R'[R)
M6/8YVM8K["Z#KQM*6DU\>=@3\6G^]29I)(I;#0>LRURDVZY/,3> E&9?D^$F
M'6D/<X_V4!AG$R&]_=BP$V&Z16H,2!AEPZ5<FB:Z +N*3V"8TY;F,H;%1GPC
M'=99G\#A<<P;*JON9I.&V6KOJA(TWB./!M 0=.-(S4%XE>XP21*D%C3&_!CQ
MW@G8:?  MW1\.DTV+#/RNTY])M\M?L_G;,^)AP>P>[2CJ<I?)SMC;V5[^EY)
M;.<)!E;I L;U[N324[&ZO:>J[F/?]N9:9UP<,>'9=MQZ66R.3I=S!.O*"X]W
M7+C4)>M18DN+])5HX/(;AUZ7@7=%T"!:AC!5[LT(-KX-LY&H*K(2_PD.05R<
M-YVR3-Y$M ';"\#ITT!!$8,W_BNLD82.)\D,BE$E-E,+1UA.-?45U8/+'#6B
M%6.HB/YHSCXJ5SU*SNOGXN(X3;A7DL'D5E/?K"20#H$JG6=S^#(I32K>8AM)
M)M*B/%<ECK\@ZSJX%!D>O;$5B6@\UC^+X);Y.3\ (_@R]Y;#&REGZJ(6T([5
M%8+@A*) -VH"7-"1]6L-EO!R9-9]_@M$V2%I<V^#]!UF"U%#A)3V,NDT\>_P
MK<0-$&]6$.]'0CPVSER$!4M%NE)%VFY<WK%UWDZ>PL>1#@I.K,'&Q6B^ \YE
MG;@SHH28:DER]_QJ=&/A"RV5HQN6SWT!\]3_/5ZS^0EW]N1PV]7*^5/%2?=2
MOCX=LACZY:_WLN/B%4=E?:?<<SV6VD8\9#"!;\#S=[1E'R[1:!<.V=C[3*XX
M]D22LSMJ\F>E&L/A9/FYU:#OJ>7?+'*E*64SZAD-F=EI&:4S$<ZCLUY!DM==
MZ=Z^HY,G3<N&&EY5GK9RMIY5.Z>6L32R4#9%W2!&2RK).$P29OORR7+B'V""
MR($8*>AEI=[$KE8_,J5L &OXU.1E2* $QMB-O [K"3VOGI# D+.8QZY^R"F>
M'3Z%KPH\=BSK80\>_IXA2E7K*E1WU95Q#-=S>3KSSO20W07GQ^J/G!V-WM+[
ML:6FH1U8G?X(6SHU/+IWB D>H*S73_BY?B_5"P>G1[11-X&]?/D'G,WB**ZF
M 0LI$RTO9[?8EJ<]2#2*+FQZ'DT+M(@NS\G7_^9^>%8]CN[%D%1D;JGN6[S[
MP$94(U(FMX2@<&A0SU^L(B,T!503'7,!=V%H3 =9B6$/OTO:,$@K7PBO+U7X
M&Z-<;C+7FS1YN#8!/4C:[XNM$4CJ':NBC_X)9*1^MB 5!O&.+_<@-2^MP=1,
M18<A/  AR7B%[*<@VH,T),_^#=(P9FUJQMXNLD]O#/WUII02[Y!:Z,APUWMU
MN#BV[7C=Q7'A7R61J,D?=2D!7?HS2U?F+KH4V-J^M/@89(2([%B)8A2-1Z J
M4*"%M]3)\_4:;"P:M%R#%1!M,%]+,#/ND&.Q)W<9F%)%"*8,>0F?."<>,G@'
M<*2V,VNPT4YHMQ>]^?K/&FR%(KJ%>NET=O?*],[_OU9<'*<"YQ=_V<J(E7Y*
M>T.%SM X%KGZ:S!G#J@GTXI*Q&A!.KN7/<!EMN(A9=[J+D#P\<V]6@3+9JF&
M=/CC$F*!N6O.RVJX[D:NI(+O8V_]T81#_S ''S>-=FMMW?O];5W2ABM2+\Q_
M[\8=,[Y1>&\-%N\DR2)9D?K)0"+42=0:;+L]+RL9N1_Z1U7"A&R\1GR0 Z3.
M_,"0_=;SO4I2^*AY3/4OTGI:5I4RX<U%T0YPE+Q/(.]:D N(WP"IY\]<+3RE
M=#MVSM#'S$XQ^(+=$:I^>FA\JJAOXLY;V2CU3Q_ZZNN]"]^5CBW]("7\:@7]
MI')5$+BP<.R>HJQ7TO?9,O=N!MLG08*)3*%62293KS!D]>IC6IA*5MY\5<4_
M=A6/AFGT:T+FK34-_S0MWI4@W5;[FMQRF'Q-%SP\A5*?D9J#U*E%^"Q31:H;
MJ 47G01(*?QH?]:D*M#@JP+<7!FV""Y^^>V.<0K/Z _;U[/#Q[)6FZK"2S%&
M>=3B=\4SF9C> 0BMI\J=VLB 8X;G]C?69/;G?Y,_:[[^QJS:>W-68_,#6[7+
M6^5??(=OE8YA@##.0KKH#!$YU*0NW@*&\N!C1^T%QYY$O0"S.DA[!8ZE AD^
M<Y3F/*GV#$BX3Z.3MV%]MT>E8!9DL<M!J-8(WT-TU<P5Z)<*"8P32,M?U>\!
MJZBVL!GNT1WRF"SN%[?=^A\R O=FQ?VZ[I*ED4K3UJ@]Y)+L_.C2N(Z#.??-
MP@>E$F<WK$[N\C?:5J.HJJ]4T%P7(C3^"[(0<MN #V7NFLKZX,Y O!^]60QK
M&#%$&"[2%]#M2(6W IDD*^SFI\-/V)/J GRJ*75+X(5/EKTJ-;Q&AXBMF[92
M9U# BDV%0*%Y<>,W]6RKNN!:H(#EA7R^]Y;5$5N_$O!45]?"@>PC6KI1D9]=
M'VX-NZIV[G=WL*';,-WVX,"Y'ST&#97=!O1']@?O>WY^.)H9<5L[=S3SQL%'
MMCK,L7L?OD^C)9D+^/DON*ANQ-\7?-@?[MJS0H. A1OW7'>HV=OH&[R\;I"A
MMBGD$C'Z;AHF"ZC&6 =URNYPTS)5IQ<>.KU1U?7%Q-/I2'IN^FVO@[Y;@@LO
MG6%7Y=Q_7>?3C7XH;B>L2.6QDG@(HY*/H2J+YUFB S@M0TE.T\[ &N2&07$D
M,-Y&4@7#GX^6WT6-FEHRX^#R-X">>2WD0-.87%=Y/1^C1O@-KSC1?JR\QJRZ
MYF/@"I6)8JC.3XDLR"V0/[L::65$FV%C[C?!Q7C0LY!X#CPP]<N$)U_+E;AW
M('<EM*%V-.D2[&:_'V+(*;G2$UP'$,75?CLLRM-#R#SF3J_) '9F<?$E\H-V
M,DWWOUQ-]PS)/!O#ZS)WO)+1JV2_M^*(:XA+FVN)6V/ 25>/)[7O7KI.I^#'
M#IVR<SA^HC.69O&]T"+9>.^K/B=;;>#'3%U-%/.HN)AYG;I1K"E87- #_)N9
M='*;AU1>O&M8NO^;>D0[$^[K,>>N2,"W/. 83OX>OX?N<,![\*:ICQM[$JTP
M4_=B]>*J;\RK0+>ZSD3UD=,#RP8O47U^4PIB%7_I-MLUV*9IR4.BWAIL1RF?
M%D-5,W'X;?$<@&*1QT:$>$%GC!(FJ>C-H''A2(-/D#"ET9^EOM<)JV3+1VL0
M$JR'PE/1/H,FR[4);D,,JBGS'C..6FG31A[/D6X_7$9Z#Y?UFNQM8RI*D40T
MHUX@)V&T?WC(793%(G4$.@P^1PUW>%SYD0.*E:<UL"SWI]>VLB]#>+^JOB =
M;XG=1S/A"A<!_DX6[_K/>T.@HYO?NQ :52@^I:6:V1?.3('35]K&B > 7^*3
M)7\**[!W\'^'.6!:FV28]Z08NO%='GG7&&':*_-JD4:CG90]R8<_F[)XHAWX
MZV*HUZ_<.WD?3$NNU1+]CO-WVWHZ%D@&G^L_<KSOKUY>?/#@RP'GT,=O6O6[
M3'T.#20WY@:FEGM[GV&PQ>Q27.GH<B]XD"96937#@8OXE#P$N,ML?I%/@1B\
M8H,95Q/#OY''!-Z$+28C%88;C)[CFE0!8;$2& >-5>0V8 HN-G@7.>"+;7FX
M1B2_RV#,D;'[_07V)3(* X0OSOL#!=R$CL6Q:6$&Z,0-(,*C1><\B2[])$1Q
M@DG;@%C[)6&1M]!YER&GT9YU6WC;R6.4T-W!=D]EA U?4STT>5!+/NC:F*8;
M8F?@'<K2^']>C]0QN0\YBLC#<\S*++$2Q1J,+@)C' %\$G(_(;=)00QK!,]R
MDY:HLG-(56"R))),"_3="9QOTA\L-X7O#/@XQAECSSV8=?MHR@_$8^7H R03
M<@LO3WN@C*0B96G)/X9H!6ZN"05^X7NK>#QFRUFVDC1!?.'LO<C[=Z=J<53U
M@*_#VDG# 9F"R7/WMU81/YS4CINZN=M0WCOUW9O15ZY^5DQ59_JKKI26D9)>
M)S?)]('<0\.QNGH_NG('RZ[5&8A&S6L'XSS/MHO.O62+!7V>;.'MNFH1')(Q
M0# *<I \U?EIT0ZQCJ3P>X-V_BR5;K.@QZOGP'&<G;0R0U--/*L))MA2: $:
M-.<I#2$_&-,=?IMJK2,E\.&*GB</U0X275X%ZI5<NN0Y4V=:E"M(:.L%+5V:
MR3ND9G.H'<NT4:4IMU0>679NQ4(U>1FN23S7UR GB#J5_2'JGW*_.O!H!-<!
M[1CC?*Z_WZDH$*,<UK$&L\VX5IMT.=F>28'$:AP9^ O= A]+YR+BUV!^F/$;
MTQB $D?2Q 16B.$@KR# @I.RE +?AJMK8 _F;0/CGG]S"I3J5^?\.1SNXX:6
M)Z2P5I&EQ>]XM0LFFC;V?536F]FFWZ65-XD.T!J/05XXC7!S;#R06@E?2,WW
M_G751W^F245\:=#$?/)0^57[,BU)>%!$ZVKVV<\?'G[RPF;?WW[@@2'!^8^>
M-S^:_9^4&R157KJ!BVL;>0F\K?-X:JV5JB[_8D+7KM"@GVJDYGR/-5@*O\HO
M./A]\>+G8NO'?RT_=W1*=HZY?VV\L@X[RT!/VO[$.$Y_L1$KAPI+H=%HDUM.
MDZ_FHFU ALB+]($=W,C')\A-86)\]7)<*D:DQ\0J@D9IG'S-LQ/3,42]+?4"
M5=:*<&71_P4DK2*-4AN'JP+KBA/*%TB<W8WMQ8 /])1K,,D#*R=1A'2$LVD]
M,<D.7]L"6AM%>1>?J?CB2)>5+B!B9:J2= 0K24I!A9_@;/6(.)-4=^DN4=12
M/.NBP(1MG!H:$9"=^)8B*I#4,[FC"J.T*6HLT86/&=-%-TBRFLRTXTM*"*'G
M!Q@3>"]0CY]*;-];?0>=3#0J[^;+V;>J^WRJ_MJA:<-;F,SP?R8[PS"WTN,?
MQJEDZ?(08O49KD-H,PIPH]S7VBCXGLC6397N)7W ["4:T;[5T' G. D-5WBT
M9,XV\6&^YO$>[(F>%UG9Q)E2;'JW?T@(?G_T,Y;)FS</)+H*7\V#,2S/+S>S
M---H+K*G"(G<GUO[79J'GNIN#]>SSGZLZQA*+YIR#GE<8AS@_)A-/7$G7#?Q
M6>FI;79VQF'?!_NQ],4;V5X&A?55C^PXP[3.WOMKL#?3XIUFPOT?\0TG@":\
M KBEVZ?/:AL7GT!6,#3I%"RV]R:NK)[OMWT%9K59/*W6*YD[$E G_YROH ;.
MM:OV]ZA0BQH9][WBBY%W>>.+3\C<+#B H?V- 2["D]29\^-\SCVOK&9R2EUG
MO/CD:S"T)>]W05Z*P+Z9J4@\4>#U1'RV )NW/X>%W-)4*S J3\2;EG)D?0G:
M"\96YL4XKUB+LD&OH,]Z2S)B%161=)LF/!8I,\,$W*XU(.7K!;JIB":Y?[,C
M%AR,\_)T!I9ZMG#:;4-+2>^%O=H9G[-]BPM-TW*G[/]5<HDWLIYF#8\$O<#=
M&B.=D?:2Z7"Q^A61 ?$*@.GD_-UDO :+5>*/L,93O>9:I(;KU<[O91 *1/NC
M0UFK-7$,6]2;ANOY8 K+*X%--PJ]6#'^*F"D1(;=-!3\9O(D/D3AW\M_>5B1
M'!)I&!T^L=.\W7Z7<QHNOM6MC;<[H,NI$(Y5GW&->>K<[A@6Z'H_]ZQ#L7*X
M8VA<0(?IFZ69TQEV3XL*+#W-"KPL4>$ZZ6Y-TY\A59($F7<Q&"52('H!J@MJ
M(@O"U76)+GD>;A1J,T+<_(*%Q_,H<4Q5^MLM53I9/._KV6;]X@-3$]L6EVD*
MA*O]_0Z6K2/2/0*'3&I(\3=5I/I'$^97:V8U&CRN(=V^'N(]"%G\%2,$SV9^
M4; B5:&T<W80;X-D@0;+"P:Z"C@M1D'8H@#?8T!GHNFQ8:L(8*355S/[4!A:
M9=*[.B?\%;U&\1(K%.=OVO/8^:38863NTC[O(Z4/>5,Y3NW.'5>F7>2EM=9E
MZLMZ+MB^$E-/ZU#)IPQ4P-#7F1I=O9^VOPB%#FY9E2%_8>T_8=N/,>S81N$U
M]C/7KQ55U]96UM8T5+W-Z__>3R@/"BXK?"2;@_OGH.?EMS5Y.K97\M2<KB6O
M%QP\ZVZ]8P/<?A93W;N0\YK@AP&L::)+I($Z6HR5:\%LGJ; )C8<02'OQC<<
MYJ,5YFXO8LL"O*1WP_FU865^-D,+!Q^-7!PPU;!/,3HU:7/O^[;\&RX_=Y.2
MR"TF3&X.9B^*6T2&!Y%VBO63B"CNHGQY;IGX&ECSRO-=.(\9-RG74)>YJ:GV
MKG:UQ4AR^#"]J1+ Q!J5ERU:G7[)GG X,9S!6SC0YOM[7_3[H/,J6K$"PAKL
MBOH>C[JJ,M]=C[$'!QKP:DA_[=U[6LR[B!7)MT*L_W!Y_'C?^R^ZU_)7EG]X
M330JUM]19G*S40":DKR>PWT-QHYJX6PB;BB<=9-NJQJDYT9-00309FR)&4^6
MO3IX%;,3=R30Q2/P& 9X/)OI-#'CN^'C5_K;H*AV179[R.ZF./_RV57W51-(
M$N&8./A64CL'<,!3V(R.UW41*5)M\8GA]2"2F+J+9K>[RP*U3, ,WL3IU@>!
MZI<B;L5#5A.KRZI1[TPS5;O=4]G+JMQG&VP<Q,W);1AF<O.H #YA_F0Q5L'$
M5QV0Q*HJC6'?D*_-DK50V-YD)[979TD@7BW(J,&>C_MUG>X]/I-C#_BSUF *
MC-18!QYS^TQ=^&/4-&3YF_76,Z>);Z]?S!='9/$Y[;4NK+R= #_0 M6R&,-&
M%B"?\]!Q2.5!W>K,V8Z.66_<EA&B4SDCGAH^A5;WP0K-)G6:*BK2##3A+#8J
MP<KRN13KN*?<\L.;?Z9/>01K=1G8?LSU8!<="2PT'[SONIR!=2I63S9B*=@9
M&P?3'V7E?_KCXG79$O=7C9^K[V$+25UF0>'I4=ZNOR;.*KO/=O[SOU\+WRWQ
M)K><6(-]\>P%#60D6>?(2P.BPR,_TC%#-6(ECM3U*?0H;\AC80EK, =4E2:1
MH[0&J[O.$2+?H9:127WQX/0:S!='GJDFZYDXG8W>]^%_]""-^V]W=,5+<Q)9
M%+</\^L/*EM)^N%G&V:UB+1CA 5"/1T<(HNVMY)G!JHV2 5PH/<'\NH:+":.
MR7U$!2[@Q].%7X"$#L08GBLC-E)(L,#,?^&B-G# %*D*K06UZ9>601\Q7&#O
M.;A$FZ<D4A6MM,N[A4%F;7=,>\>?#QP<N"'R3\='&@I7G$[^P(B5(.W_3%(;
MQF&[0WP5Q>X::"%OD&H0]< $'CZI;B3>B!C)H\+%=H+=TW\WH(-H 9.J Y>!
MS8M)8LTK07S9":U>D;UWK2#*]L6WB!Y31MS72DK1. F:EQ9/%)<+!\,7%PX_
M(WU@ N_(0 .Y!KD3Q/!I8AT4T(3B>4JRI(IH)9##HHZB (A?M3X![TY+4J0[
M%ZO)@>3@TT+J KP*FK>30A1R[D?Q>G;"]@;[$-Q^ DZZ3?1\1K5(3<4@-4*8
MS13L?N5H]\O9UK]8+ ,T]+?^_<>CS4U)G[7M/IVE)_PB5C.UW/Y]\X]5O6'S
MZTU <B9\SRM>IO;'[,>1[+)_WG8$F96VMA>E.]DXG+V7BG4LM*TMF;Q KXU,
M'[>+(H]W+JW?_JV1/",JB*S6HQ$AFKR Z;C36$T-%]AP%U.;-A .G(]<2'<2
M(%))IB#.#="B%F)5:C:9+JV2GI3BM/2&]E>[OV4 (PGA/4ZG"F/^I7:[B]4A
MB]"U$7F3QWX#F-+7]MO%.]<#TL@M#N3 7E /00EC[I'V^1H.Q,?P0L+R?@,]
MN:4:N1MYM+L'FCR<I4&J9VN90Z:R"WY..VTD!7S$KEGV</U?R9E.G/$9-^&=
M<-HB^7_VL5#*6CX>=;<J^WCR@Y*4]BCU94E.<*Z!.^N4\G.=_*_<]-#<1Z'I
M3@U^:O:HX-*I0V^+"E2[-;XO!57787"W?6]C!K/$NY6$K]:SNE G-4&<Z*:T
MGRE'::.E:&VM$\BT+HXQ[?O#O.7\.P2X-=C._0,,S)[BF.#E8LII /,DGV#'
MGFN3FM=G#PM9)P>^ %**Z9<U6-(!8#$1&0X]_CEH?B.:=I-;G,614]281T05
M@6HSXGZ> I#:VV:)V'$)[$(DY:D*;.XN2?QM/YJFVIP7%#)CK12T\RH* DF_
M?U19.35D9180;!1^L:[?5,[),-SUC=AWW7!HP1_J(?\I&7!HHUZAV$J*:&Z#
MQ_:)+M50?_L]*MXI]4?D'YWJ1[__&"%0\#D0N>C%@Z9HJ7-2]!KL1L_ZPS@K
M)(1/73F.0]":ET.?VM244M(T=GO+.8V\?!Y?'-_N%AO@G/^B),HB3:G$)5LQ
MZX1GEV+*X"0A.67/RXZNO7W.;N[ICUWJ;S?V8PU./&KL?8GBSC%'$WA9+;1D
MYF\H'":.M+M?O"]$L(K1(%A.:5'S3^*+L18U%.*!+3&E(+XCJ=#;^\7A.>FA
MCXR@X,YVU3?OE,U^$##G!K4905YK,+=!!"2D8G ,/*A=W)RJVXFAHQ=<17^*
MMP/,!4P(OW0]?1VPTB%WC7!K@(=B-5J>']#.:9N$,P5Y204$!ZO0J5POD4MU
MW?"2#[E-U<L=(MT(^_[%)8,)?*?ZV=YOZP5KH(VM@Q=!.V#L?>\:[%55Q]"O
M]:S^**ACDMA %"DV8$C*R($45;"&Q?QM&;T+9X%@(1)(&^H&EJ@[Q8Z0*SKM
M+>T0P!.AU=X]X1W8'X"43?!=C^J4*<]X@17F'1H*-S)S9M:,$%'8*WXZ-?.7
M*_ZY(X7W24?>5Q LD,-%"N.\1K$#8:#-->Q-DJWMAR/%6K8GCR/\[ :R7Q03
MB[?9[)5D'.]R<Z'3[^.5GT[4G\"7UO?Y=LX5+T 22^8*J1>^&7F"D,*S:<&,
M37E*"I%PT*RM1DM-(-/1J#NEDL)ERN/2L5E_>>$L:EHEQSC-)(L:P6+"\\>!
M>OFX$>0^H#J#3ZGPQGP;"26072M'-%:"(>1B5OF+=R<(58&,%8I4JZ=<K"HI
MDBI]0Q[_N(17P];=)!T%K)H,/O:+;(;#YNHM4^W@"H25EI4([WE&F8S+VS0-
MD8W(=.%[3LC^3Z3SX/2I]95$<3/8GWP5!",QS!MREOSB&%.<+9QU9SK."BUR
M%_L#(TEG=A+2'6J'RY8-X"F^VH#*RS?O_$L#5K+%32KT"B5L66%/0!466K@F
M5-5(!P)R+G1XBT(<1X.D?#9:@85)DLKWB3'<:X/T?Y8,.*!U."[DV*.?W_K>
MZ<_<\$8;7ZPP/%B3VF_NE^Q*2.=5A?_-XE7.N]D_OO$KL-C96*WI6*&'U;6I
MS<<='RL7GS)%J+K:RSG_D3R04?0T2B^TR_6 5YE^MF?_/71Z05.RVPSV@+B,
MS,VE5LBGBVRA;7X!*4]JHZKH-L3\29V2H5B9"9!&AVDF]1/VIT&]YX21#M+Q
MCS>GGRPMH*VSVKSPK 7W/]- V6AO&VF_ZH-Q4\GKVSW2%'C-R$(64"S=.B7:
M#]IT:&V29!'/3BDD>*E4%1/- 2J+$J/N^Y#;^QM!<9M)H_5J]P5!9NV6W&A_
M+F7'I4\>Y9EU780H[[I!J].O/%N,Z"/NO9;DIW]*2L48D0$T1B>K4-$EL5Z\
M1AF9-[* %T1U9EMGE.:?#J*!9'?P+E^$VDGP=L7K"UX'B5UY<O[NP(1D(M\V
MJJC]E4-DL5U6]?!/Q.IVZ3L4\)>"6.FHD X,Y\@S!/4L:E4OA1;6309MD6JD
MOHAJ7U@,NKX>7W%I9C6B33.H3*I&J/X0%;-_3 [55O+ZTDS_R?!78(1U)O;F
M,U&P6>M7C_N.:$K)W;:OD6<-C<RO A[8H7L>3QQOE>FGQ?H[)Y<X7GR^O4O1
M27@KE3]1V!F3<;SCM?*48VF.T]-'$6G)>GHFA?X1W5'UQ33T8]1E!&C>*W24
ME#6$E(J/2YXW["XBM:TVW-$I*?NF90!2!.DL7VW0MKRE\*"B3T $9Z<I58YX
M1$M+</8+O495W3KC98#B#+MU[)('&^?P^A.VSG4-]M,;VFOR,QB(IBH1[P#N
MG>A1U2F95I0R@<9W(>0IL'5YTZTR];5 K*]>E85;X7.Q2Y]Q&$8><??*8,/5
MNKP*OREP:0VFW'FLA(:M<T\THLLV^KL()JO);ZG_!W/%@X\@G_,56N@=]%Y0
MIR.+AV'+<N'WK>RG,&/UG;Y'(+B".W]L\/^, 0=XF/OAWB?\?3[>##9M-'"L
MJ!@1[R[%UED77"G"F0F]2*40NU>YXU:&K(I\/3:K^ /(,XB?C'(LPACVZK0-
M%^L;&):ZNC?SKW$7;?DZL^XYSI+/^SQ=2,.[PJ8C]<]>]4L4&EV\^*K#6-JG
MJ];N@^LJ@^MV1YMY79)L@+# ;PW&?<3<T:0'7OTIW:XJL@'-' 7M13E3]FNP
M'=+W4AF!:49:"<]C&2&#WHO4 =^]PAX]\:6<\7*&=$@)=&_.O--(WP6&^D"J
M4.P8)NHYVZ#Q&L*%(G(-A.I[>T1(4CN*7EXO,@'A7)MD<H"/.X^:6"8V$J2W
MKZ+;-)6:??<":14R8Y3$, 49:ZFZ(*,S56S+4S+J2*=A[SP$CN5B^3C9GHVB
MFXUE0Q-,#ADX=<+@7-_ZJ#$5IN5)6)P_-@08N304?* *9F-,*R.>%131:#[_
MGKPYX3L74;,2$?M4\@I[5S8U!:0)?F! DVQR&E/='YP]B$D=('J!%$2':38<
MU,MM8/%?YQT>QO!W9G):2U3CN \(;V?YYXAFRG=V.#SNZS-9KG&:OMAVX</;
MG.,E3Z^/#8?&MPS1XEHO_WAE:F!HI>>>H7[K58E[@;Y32-'T=P=]QA<]]!.#
M$\K7;11LG4NL'Q<5Z#F6.GT-TC.AJ4:4,;S.8K^(C/[/YX@G9Z$[\+&3AT$Y
M02@_H@61Z/9@%)SCZ5*(GL!T>_4PS:K:GJ^P92Z+O:5$)S<D-,C_Q.23D(@K
M1AU/[@BKUV!! U^JZST>ZKC"O_T?314/0D+NWO]%V[O',_G__^-[O3J3)*2(
M59(B5B$Y[MT!(80<<MJKY#!B"5G,]BK''%_E%&(OI^0P2XPP6\RA\A(Y9F*V
M=6+D6F6N;+OVF]?O??O^;K_;Y_/[\_?'KMW&[79=U_/Y?!SN]^MZ/A[W3M$M
M4%=HMUXN2I!BWRQB4W^:2A]Q"Z0)%G2ML1*IEXJVW!?I&Q4>!/WG,@UZ6FW.
M\DO3V<N[YA?-O:\V=/-J@R><S'HFW0?T<@63N\3&&VQ.=G%_7-P(F+2H',X-
M2AN0P"C'*4_MTC.Q72Z?'\<_K'//\POYJ_I4Y=?V!R@U$W[#XS*[D*@J[PMC
M49_VHF;&YTDY7K[!)=F#M4?(UF T$,?YTB<[O63 UNX>2F4I4?1.Z%6--4M@
M*7Y;^<:9RU'@LI]G_4=:,_"VL&8HN.#6&</;0Q'[0LT8.N=]*VXB[7(KMK8Y
M.B>Z?\]Q3IM@MHQXS==]^/$0<[Y!J+F,  \-B12K(8T[0E<__-LFG!MQ[C.Q
M0G2<;]RKY]$KF)5)Z"] 5*\_N,A*T4_'E'_ TKON;UQ[/*M[]^"X=1E!3#QD
M?ZC(2*1W-$6\!U+!J8'27++11_SG"D9&I IB^ QNX%V@;[I'PV"] O1/JF8-
MSAID\#']:\NYJVN4E90DP^C&T4WLYM%Z?2/;8U%2L@UZ,$S=:EZ@/9P&)W^E
M?=4XLMY%:*X40DX0&@/%901_8MHL$@Q>4Q9-FMID0MM$MN.0"C:AISV\]OI(
M.,5>7AYL&/C/.,YY3O=PBN]P0).Q,6U?^_,$YX"$2ZV8I3I([D_IPJ?CQ^"4
MR11D,.L>O+FU)PS#510IC-+V8K/97WK@>X?$=?S?+=1ZPSB9BE> H32<VU'5
MZHRK+>W2M%8W;\JZ?VC<W"6<8A&KYX$:NY&5C:Z"@OH?'1M02(9&/-^<SDC9
M=DS/JS#:M/2M6Y5.6L9"[<]Y&A[M=LEV[&'U#O2H78S3NR['QP&+O_:%.A7J
M9/IJA58%_F2NMC1,MB-3$,QEP2-^ZU*FT%X4* 57!QB8( XYP]*(SK?JRPG:
M7SK$:#_;BZG">G?G>YQEOEN^0=5B^QI; >,E(L$[7]8TVMG/[VA':2#R].1/
M]OI.!OPKI#PRB#B->4G8B]_[E6F3])/.)+XT;<TP#V)W:DPNNA,!BKE:0W\E
M2._]:ZK;I7L0%U 5:JDT9G2DGL0.75::!@MZ5#['V_BVE3I]MJ3QM/JN-OYR
MW*"26+5X?/SFV+B.FG"3;9R*E9EN[<EJG1!;+2WE0WF+$>Z)->./#R]K'9Y>
M)L1*8(;+/V2.E'>>._[_ZC81(7Y$__@)&406ZB.WT5<LAG49=1\(@8A?)DY3
M/&@@NQLC=HJ2Z5> EE$0=5T^X-!ER],26!JR""DUF+D%Q"\['Z(@G+"5\)/>
M1Q'-3/Z4NO869\(;EX\26%,D>$X"JX*,R)^_4?$J$MC#F,/2"(>'2V 7K%\0
M5]/HW*M62A[4/Y3%!H2NIWX[1G!.4A)\FN_7^I0Y_<%OO>\\7@?;?R8?FV][
M(SIT65VD"1*,QBN>GTAF_T2HA[H[Z.QYS_3S/>M3V9 M^F?R9X4$MKE&9#-L
M+B<]SYDQG D)Q;R"POF)"VFZN-- L[$>9<4"S^AAR4$ZME<#+SY(B)' MBXS
M$#M1FW3U>7&Z29ZK>0^11$Z5,:/PS9/B@K%07^NE[X=*'-IU<&_]/&C)8&A<
MK >$79Y=PYO=(5*)P.W53/,S95 7?0,.7K6@XFYJG$5 +^T$2V71'Y.,XA#;
M1:?!A%HTTW?M@&Q,]9-&H_Q& 3K]O)&>YL6.]X&4)*X$9EXK@5D10#,XVR/-
M7!H*-_X (_B*_WE6*H'9@49"&ZR]#Y_ZX.36GQA9;']WZ7% [TGKK3V;@VTR
MH^E;ONIHQG.X/<<5%?LT+A#>EE,Q.V:,&9=S]]VI2.^M;:&,.V)?'R7$3=D5
M3_IY:.0;];-X\B*%UBK2KP\_LY,DL+V6")'"I!%<4:0"UO$UV?+WC>)W<1FF
MK:EX%?!+#P2;-'*2FUE0#21%L\4V[L"3FDK6[-<"TX;TBI 858?!GA;%$%7'
MPCBM#I_W7J]W.V59:N+.@L5UV3MQ%_BL#-I^7C>B*1/3KZ$](;I2EVK<3+LP
M1N'QA%TJCY:U\P]/=4X)OEUSFC<6[4J MKGQ52"9:KX-A_RGN2:7ATQ<V]*=
MG<P'![S I#K0':42[-^SUM?I7P$:OVQMV8T_"$!E5R,X'9ZB*_7>O%,,MZPW
MHUWMN;?FF^PC;^AJ0C(VTMG,$S^ASQ4PLQD@9!E*V&9N^[?(C<H/(/^).P-,
M]C6%D.NRMZAK./@VB$YP'.#=L_K/=D_,[G]WO:,C_1SMW;%O1K*A>RE$RH>I
M_NB?1.:=LX,:OBL9AI$>6UNM^O.IY?/MC6G%]UQ#'D:;:!H?Z1Z)L*W[(32E
M#3%O#4RAXH2MG2WT>$38T%<>)$>61C\3W%%^"D-=&Y)1%#J#BO9\00T9?+@*
M[2UXJ:$WZK?*T("/X#2?SLQ+_44ENE-&5&+6X_6MAA/J+43\[K6P%OVVF-V!
MVM'+#3O-6EB;3%D6&:QMDEK[%BF *R0$DM]7<[,H0C/1,="$#(V6'@>CR=G;
M<1X3ADX:\\@=N US)+_>;V%2*BSSU>L'%M5O7*K/STXDZW%'S<]46)5]C=U1
M4E/<J2[R$#=6+A1%5_.(HEVSTQ>E:>]>"/32&7U4Z399J 8-MIZLU]P:;<9*
M]-M%G7B<(3_[NGZ(<.@+W'!)\_H7;5&6*(Z$9?24FO*K4VD'AFI]0 G,CQ^4
MND+>]X&73_(G?< R+D\@$%0'R\;K@%=G:8T^Q6*Q**G.VYO2.>V@>&;;.54H
M+/>/8'[VSJ!']0MNH>SO"P_*DKITQH^>W5GCWFD:X3?8'9%Y^FIQS>(GAS&2
M*]-QJ5DLTX2U4_*W?I=G-7ATZA33.8P779=?T/GP.7)\RYQ3'_D]')(=%>X+
MC8FE,[ BS)SV.%D$YPXETW?]+#:#IQ*WBK!%4;=Z[U2&QEI\^M!^F'0X[ZEW
MJ,8N/NL>I2>T6(UXT#Y=W7W(;SAJ^4>^=$I*H:Y9;>GW+?Q[@@(A<";(N9,O
MG[18/DI% \5]!7SFF1@N*LGOJ+$#FQ0BD#VL<*YNOC5?M3\19[V;V3>+4@2#
MO%Z,DA1MBYT>HKZRH.U VY@B![$T$[0O)U.'L GW>QOU_N5BCS$](U9:(_KA
MQ6F[^]R6SO'\*?O?WPU$N7GJ*J^+%P 6NHQG(H(XTZ@C--X"Y_T4IP'F5(7&
M1+2KNV-V?(6,WGT3(3!Q>R(/H@7MI6V<7X;]P>\.M76,YQL_*']P;?[5ON\[
M#/IN?E8E>14&Q(:3=(RN?WYZ&7O!W_\T"VUE,IS[L-/SA5W5ISTO:@7DQ,P[
MAVJMIBC5)[]\#'V[9C>COO1$ F-J37:3946WQ0\:\%NQ'Q9TY^@9Q*9<E@S5
MCVDQ\GYA@$U()6R?[C;]-;+LIY;8-&:=5^];K/NDM23L&ZZF:.]9)<SG;@:T
MPU7\)S* F(57%&=:_H8?5,TG"@_CC/GG"3+Z-&.L60]- UA-PIF%/0EAO5>1
MQD(4HRY,T>,%GW6W_(6M41Q=):349-C<EB-G%$X!?V9Z"1:4:-"C9IXP$R'X
MHW%L:8_6; FP>P(:?Q3N]J(9C"W8V:1O_9^'1H>N7]]^/9K,+R0KWKNU;W=L
M$S90O_.BI6H5PO]L26QN3;]"JF?JP*YQ$YLBTFGG1/2/'V='BG*OEV1&Y%5;
M.4<M5AWZQG3XWI_WG?<\W(LY9%4#]2$IQ,4KPF,0TW(7L-[2-@29)(VIV7]C
M-_3&VF1'R9)NJJG-[%@]T]DZA@DK\&O.GW1N!892]8Z]+>#J;9]]\H"CKORQ
M97S_7UVA%JUSV0P,:#(J,*.)&_ :T"N4#"$H>_<4-.35FB$R!CRZD.J&#BC&
MK,9(F%&F:P^ U644,+6[O.-_5PP 'G7V$0FA#? ]\[/:+>^TT/*,1PU_['8A
MG$%JD#%Z!/_EC+5,TLQ@2UF8T$ADU=E*:RWUQ.RGIK#QC>;&-S_T\<P]3CC6
M&496U-?HU*>Q7QI!9U%-+%'!T%T)3. !J1(6T.5C-\-MDH9N7BG_ISJ59/^;
M\C[E3:EU,J=CWZ>ZE?B</]H78KXT4GU= KN]A$!O:U5122?IG*R<?UKM/(O)
M,[&UZGL7/GV%;CDHC4QV3N#I4($>&/#O;FHS2P.1X[C(K-**GR"X"B17\5/8
MQ)[?JIJA_2-1!-D!3!WN+)" NO*(_ 683,<="*VSBJR:<=#/1'-D4?)@^<*[
M+\/['R!S6?_+DU;Q:^D%_K>.;J?^1[EH VU?CUO-RP\.9R-S:]A<U/L^!WJ0
MZ@NLW<U,:(])M:5;>6ZUKI]#&UFI\<7MO,>DF-G!*D)^:6F*0'K%3?_A9R\Z
M"8^#&':!2$E7T 4DSEJ,$P(.< FRN-^!7'>F(SFN#G<1_!(S=Y(%I&'C?%XT
MCF"H,>BK0!O",#,06CMMKLE.Q85R3B]][GS>].+YKV5HV[J\YR!X57ITX4_V
MHI).T3>ML.XB%?'J6 RT>W,!6WRN?S=JY\^A/3B3;-]1G!&!/!WJ/JL"1*VY
MD\MY7JLI>M$EF^,UODT<FOSY*TH<YSH=F[_>B;9K5F558;TDLLGQ4?VF*M:2
M_2;10/:C#VC6-IJF-_/9#6"WA<OB\:[7T29J-PE[D'.C0>L/UA_ASLC\4^XT
MM85S[[3[?E/Y-/C&?;I_WGRCKM#]./,K*>.I9LZ&O_YHQ"FD#S;J=_H$JIXF
MUMA./*UAHYU[3.SR3'7L<C)#<DBF61$YGY]^,/'JJ)E\?.)!E;+RMM,_OI*-
MCTR=6HKK/91'= AO1DUL6>J,D&;W2>EUG4.1"LBYIQ+83MJ&X$S^%XX#*QE2
MG=\%(JQ&M?B$3%',G<V=3R] .T>C==,1VT'7GB)!.OKI G$7#G>/<6D\"K'=
M2L K<?4L4C?V)4+;UM%C(1@G/?J-6NK.K\5T#>W$;0?S@#LXXZ=@=K=J2L8Q
MV@$LP17XDMY X5FH>0#+&6$BL[GI@8YT],]MY9/-,_;=IC:"J%9F\.BRT:.J
MMJ+)[_Z0_&_M[4Y37P3&S^T+)]YRN<8]9C5+N]&[)^+JD!O1[[Q\!L/W6!T3
M-*+\>L,,*FPWQA38*NI\L(.SAT!#1<@Q>YV3/]_$)H@]\Y5J/C[R06V\9O#A
M,G]/QIN2BA22AX)[!(,-O*_%7KA:YC PU>Y8E)=;H;UY4C,M\Q'/<<^K=VD9
MZ-9E+:6VJB,_3(Q#9\6M+:V6TE$F5""OL9)13<9+V< 7KG8W:L>\ABRPNN0\
M1]Z%K>@M51J.:ADUQ$(ZH*9O4Q._.NW&_C^?Y(3@_)^ %=WM^>2K3YC3!F"1
M>ER/5TI)'.?*8<PP'3QE!FTS %I[67)ETA6Z#PWC=PV+"#4\#1TI%)FJZ,8?
M;&P9%UFPBS&_A\9XJ=RWU/6;;TVWR"_C5/.?%-9@X[IE8\(D,*5"@%8F=>3F
MD-B^G.BR6W0 2Q9EHIYM$?];4@H]QF^>_-DOM8/P9Z/-+%"+N*B->>+MS9RV
M%9IB=T">I#SW4V/1WMKC1G'YLETOJ.-D!$;_O6@HQORM!&9@%&N2'YE5Q88<
M!OS*2=DUKEN\VG/<-%3D/%0V.3AXV;Y5"A[-S:'6U'0[U'3TFA['+DRF-2L%
M*8^6VNT03%M_G P*&A;5BU_0Y[[*3_$$%\35YDY"$RQ\3CX#CSP'T'L++&5
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M0=,_ISO2,:W!:Z7$&J]?I=$EGZA?'Y+K2H"^H**AY(6S#;\__EX4E6_DV'#
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MT;VT([7_IW_QFIK4 5&$3\<LI8GEN0F_6@)S3N7QA8()"2SGM9A$6/Q,,Y?
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MBCX +IN5L)).1MCP=S1*T<?,6:X#H26^;)&Y,#N!/8GT7P:/]B\QA!N#-0P
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M")8.+\2N)OWL/!4W[6W646@S[">-&PE_TN<:_(X"@:W JI^89,EBRRN _BY
M>%,EH3M97$C"3[$[47;$\V-1K-8IT=[6<3WH7=4'AU#!@/U[!)OUY4RT<G=E
M'3CC=9.^C7/R\0[,W<&@Q!Z7?W[MYR;5>(5.Q9F.+1PU;3YR^LVX8L*]'(=(
M7\.DU%[KRJ=OBG)]]>(_ME*]*)7?FB<$R E%P2=QM@062 ?U8A;/L<4;&$0E
MDC8P08^HPGF#&_@#7<>,A$@YD*:NZ3JR&*U^[JPPO$#<5NDS'SM+6E<@P1JX
MM8U0= -+ TX&XX^\NX$P7/Y2)S@I':4#%3V7G3T+Y[.6,OD#;$26I1PHV^<^
M>^ 9& 8T.? =*00^QN$=QN'S@W+1?]KX_<DBXRK0^/SXDWNO0/J9D3!J+#/_
MKS5BRHUHWEY]-E^._/VN\ 1^!DE970RH\0M!-LDO;>%KLK?'Y@W,+C"WI*P\
MN#-7$BY>6EHB-%.64]9^JM+O4F8<S;R]XT+C[3V!E:659H5#IU85K$\16T1!
M4E->%S.\1\<N,R:A/1,26!AR]_OY]LS' F,5R^U@)&##'DKU3V9OO&61DD[3
M$)T$Z&D_.WHO;5=-+B1=83%?%X8U7,TM,%<Z[9WVO=;H^V*Q>5?_,;+)"ZJ#
MZ8/>8;=CM:8^CV+Y&1^B;B5YH=^N'%!US7DXXOE8ST,U+WB(:3WYJ2F]I78U
M-YS\KOI)9C/A#R00@1$I:[+IBTW"8[@SXK]$OW$<='W$3Y#!$MAF%*AX"7A;
M?&O2 '<<1')XMC^)JF!3KZ93V]WF3)L>_+X"9Z#_GF%=<2HB_!OE"M568-\)
M/_.BA0[=D<#F1@F_;+.E*[TX#!V1HNE!4 LUJ)U*M>+(J_"8_6FX*PT\RR-\
M9"I%=S"H1T.3O[LFCL1C?FM\^G;5*YE4'ZJ:NVJ:7%V#FK'7&ORTLM2SZN'Z
MZH>3[JO%_J].4\;_4NRK]/M%_W:GDE)L'0DLE5F=:.3T;W>J=8X]/00\H=1\
M+7I;O<ZQSP/T]*@CM-$:;*2UE&.;7H_-1?I_#UL^>(^S<%2,0VZS^8WA*2K8
MXJ5\ KOF&AWA]JMF5+KF)QR>6M?/OTN\5K&URID<Z_C]<49 6F3/V?K12PGN
M:4TANO&+Q1CWF8XH9).4&,M#%^"+ =(,0N $066Q6@0+.!".$CU!":1LN2-1
M IMP!]DH=>@]$G#-GDX1K Z;[V43F /<&)%>O"S[6V,-;W9GHQ2FA0'I+^E3
MJBV- 9M+I%"VFDW^$Z=^AR H-@N^^MW(/GTZ^/:=O\XIU7]CF:_O+L#T8:9T
MN<8)_ZIL]:& /W%^P!;1(220"G9 "LLR_^W3+\,K_:^^5IA\3^D>NI"0;&Y+
M0A/Y!N\P^ $!JV4JGGBIM;DCX4;3_KX_7C@I/'"K2\[7;U$T8/15F8QC \Q#
M>G0<7?/VN#EG4[*;0])#1CYE+#;4>B3RG>MSVY3F7S\I,"H;B%<,63,+Y?D+
M9Z5.^8+P24UJ^,C%54OI]T*JN)(G6N3]=!*\6&>#>!:K-8@1K\B&+[GQ?T"[
MB0S6#I#E &978 F0<E 79F-\=E^L=0('M7V>.21H962G6.Z<U+<<*@/I/>ZH
MJ4FOW+7+="827=KGW6&OEHYY^V:!?9&H_"!@Y\MK"Y=JO$ZGK?@\&ZDQ]:'L
M\W')\[H<\ ^I]F-KX*N>\<R0ALK+#T-T1FPME-M/T7>N"YQM_SWMR-__?NAU
MJ&E=R,U->I.!$MC4S )]+5+<QOME1UZ8%+R1P/+<"'-2_!\32U[?B!<>^ZOA
M@ 1VATT6'KDI@:TE91M7 !PDKX?^\Y/!+[OU4U_\/Z?^[T=^.ALT1D"N".$^
M"6RFF\#3Q=TD\X:@'?D26*Y[*%* PDMYWU>6PN0O-O[_AS7FL9C%D,QZ0-JD
M)*98*CL ]H)"<9D$Q@X0G7@Q^9.@Y, F@I?I&W!J=-]AN0&T"FO:#P8&L5$[
M$5-R,UW"DPL#0<A"* =S_/PTWZ1?CMNTX\@;@W:CFP^ZYXZR#WB5>.55I.:4
MI?=,$I\G'G%\G),4_/3'>-+'RB+;PVOSUPYL-_+2LWT3[F!8H$.]EC?],*YW
ML?!7C962Q_2^E)5STOA#Q+^#9$$W88C(#SS 57>Z,/P-&<Q*7(LFWXU6=UG3
MU1XWCP=8/7)U:&C[:&]/X[D( D=^.YC>6Y17+TM;X' 9-Z\PK7_X)F+F$9!L
MP7IM"-]&I(QDP+?@;(%B#B%9RK&O@P?-KSX)GD#M+!_O9[#V@)B^Y;]]%G:K
M3I#8@]I^?/D4(P?X)>!3R41.S?S:CHXPBTY!C7]\5=-K__BKT'73P.J:X*+\
MDOJOS$S!@WJTRD11:4X=NB!FMVI^88VGCTV,_]/YR8F'5M$!\0'12AZG"FZ/
M]$:$12A%GCMX(8VQPNN2P  4'=3]<I=Z(H"MKB@8X4?/YE2_MWHR_0%L9;.Z
MD'#P :DLY95-!Y^8;;D7S.DS35HN&%CP6%MZ6W'H;R>MZ;<;$^:::"J#ND'-
M+Q(T^]@WW_=N[:X_\:#FU0>TN5FNSY%)ETP[.==<+4=S*O4=T6 U+IB#[LMX
MZIY8M7G:<7=GL4M31U:M5S7^S82-8'W+[Q]2J[? >D#;#"(X3@HB;W"0C4EE
M-?]?W+U[.)3KVS\\K39"2)(B9I4DQ*RR*S2SVB#$E&V(6279Q21DRIB[E1BR
M6R'*;HH8FYC$(+O)OI)D,X08,Y.]8489=V;CO:WG?=[C]Q[?Y_WO^>O]8XYC
M9N[CN._K.J]S\_E<]WF=)X.CY(.="#0:;4WO]T/N^M*@S[11H:@$>.[B[AW,
MJ^99QE/TIOL*>?!'>-NBV37%XOXJA*RK.\[G?.['Y758&QS"-US<JI!-$B\N
MK<,B']">J<+%4OF0!F[KI?F*4/QJS$A49R:#LRG?UVTUQ@"^']?7TY*+JN(R
MB&:7 E1S&U_@,,UJ)[E+L4UPG)?5P+4X-7>9S2V9857A[DO/DW2&O6L)/OQ.
M:/B)A&& >U$.=$%QA^![(:4.!%H@:/^0)E9<%;HSH@F;H1^ 6*$'-(<NZJS#
M4GPF@&V /\28UV$M^YB47S+K,+](HL!8K$'S$D ^?>3UNUN%839QK^^*KS[]
MBY=D,&_F_JC8.J_803*VI25=.<$W0M,BS<=<RZY ZR/]$+,[Z%[NX?C6S]$F
M(=$CDXV9;]*N?R,9_LK)_5!&K6:,$/__\F[_WCY UNMUMNO3::HV4^-AAWV9
ME"/3I$=!Z1+SF\=YZX=^AQH3*%UNZ,O#IO4^#O*25_UZK:]P_:K[)ONS?#XQ
MG'KA0R["?:WKL)/0,M6?6X<Q2)38C9ZY&SFGS6C!<50,Y%$;H=4P$5J*DE 3
M^9AJS,9K3?$>8^%Q5 <*\E'<:AIS)R22J'78GE4F)AG%A%#O0SGQKF30'/6]
M$ ?O (8QPQCN,S!#_"=IF!8D[EN'Q66,(CNO\CW5^;4B*LHO>;2291''"^&7
M@$_68=)HEA(1+U\H/-';<!H2!O:^F3P?M<U/>34.;TOV90RC9,UTF#*R[(6U
MZ7BA>80H/ZRPIZ1+E,_W6RJHJJJHJ2XQ,TTD=YQH.O#DBDZS2VM'FI86?:TO
MI9GYFO-1]L'+_!X+N[EZ?+G>4- 17*S9(5^W*[-C]7J8Q"Y"P,(Z+"-$M!,U
M,4X!CR1OM&R6X_\.85BT$T\F 5Z%6*B?R)%C8I*$^X [LI44G'2+4?6X*GB7
MIVD5,S?%^N':2T7O.)OO2S@\('G\*VX43<]KK*YZ33=#(<F@2. ,-!<03O(
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M(M["TV@J\.^?K:DSC@X[-!!6V(L,%/V+!)N#:%@T> 2QD,_+X NX .</QE;
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ME+J8D%_9?G6NR$;>.NCE48KTB:[RXH\FQA2=QO*^>Z3A)>%^%8&-N NHE%M
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M4<SW!U/8S6N'[FU]$I,?N*4N@__IC3MA+W3K3GAUQD+K*\+P.@Q&4!3W$*1
M[](YTIODA.2$IE/@CW>>\MP[&44@B25/QVN$>7/K$+'W//\9R<TSD\[#!44
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M#3WK2+VH ;4PW'0$F$,%8[[/<WM8J 2QK/ \&,D+8794;O2M:D-$YQISR6W
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M)\G %8=B=PK/\^PJX/<YADX-@#0N*%+]]!?#L)I>GT<1@IDF-<A#M32I8>8
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MR)2A@Q7'R_9^:+EXT6_8QL:TU*C&8\7EJ[@)Y4<##2W9QAU+HS:LSO9D:<(
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M@ITM-6XDXA1/+['0W]@DJ9C)6&#LP=V;MFD<7(E+660Q[-]6IWX!)C;.T=H
MPS_$D@>X(2Q%8@P^))(MIP .5S$4A#[_%WMO'M14UJV-I]M6%!14)@4DK8A,
M @X@BD!:;$! B,P*0D1%"#%&5#1(R&EE!H%6)@4!94:&R"QCA# HJ,P@8TB8
M9$X$XI$D)]_A_=U?U7??]MZOZE:_MV[5Y8]M43MRV&<]:Z_U/!OV6N#P&+B,
M$3YU+XMXU+Q6QB\I(T!G)W9D*PL9]$2 :-#]8)\05Y'O/#@TJYL_DL\\^46A
MR!RY5,!/ D8+ 9:-6#^ZSM&=%O5 @"@MC^+ICUH(C\@BQ4";1AF3!V35+\FR
M77B\:U%)!^^H&QM73SX>3DO8$YNWP^C*RR\/:::% RZ=+;OW#%<  \&0,*RS
M-PKSB_4T2-NX)N1NL@&;_B CX<1B]8[,?A#-H/MK/[OT)NQK#^\T Q5D ,,6
MS#/ER+YQK>KJ<^DJE>Q:2(UDOG/Z$#:V1%A1"IT("K*P,:#I16K;UB1$.#@]
MMN6$?[-\6&G#'_<PE_G2E)%>ZJ O5N#:G>1F[-*?Z]ROGD\].IVELP_OX;?6
MK)#_CWX'IR'AG[A>SI[ %F]3[:@'U)]X!PVVDT[T*<2I:+7)8B[@*LLH8^B0
M =T\E7U8@P,]B_CE&M$+&AK2-JR^P.4]>.L6"VN<,DK4(Y5JWLK2.C(D)?M3
MD,6Y^LX(Y=LG6^Q[;1)-E72C;ST?,#UA6O*DR,7/M"5]X@3AP"!_YU=SH_&'
M8<H%]?^NQE--,^>R !$=PT^FSKWA'1 @NK_]1A&E>/&?4L<G4.X4K@9J"W5%
MOUU-SH1; ZPN.0@09QZ? \<@9<B#WP6'QFSJA,HMH+^"MU> Z!0@9/J6[F$Z
ME7A[C 0(%?-HZ&,;0PR*!WNIB95L$ .9#B5"C2# WRO#!$94!8B(0 DK%_8?
M#@6D#2"=+<+!@5VLYK&I^B2[.T (L(7DGDJDU_=%B\07QI_KN-')*/GH,M(Y
MT^++W^!4*BVC&7*GI*K<V>$TM5NKW^U,P?.^QQTVQPW3E2S3;:>['[T\;NIR
M-*#K4=K^94\KO';/X<PNBY-:718W$GI0CZ$29*'.?"-7X1\7*MSTSUUP!!T:
M0IF4C4H! H2' -%/;;2AY<P:"->R-R5<7Q$@1&?O>S?8.]QO#J LR,P1S9OM
MI>)Z=7M*#@\[OL\@!C5;=9:D-&B&T5D>#G.+3'3(& 8TXE[@G0.=6)VS]I74
M[EHY,)XQXL]&72CI6J 8U7\A2[!!-N'!>.=<"?=:/+KK1C6:$24[D[JQ)-&V
MMJ> 49G,!1U /-N$Z5!'W86% ]\.WF_L+)J8O =:X<O(41!@^N'J(.6NK>\N
M)UWW'OZ90[,NCV3N:Q]JE&QIO+U![VCZXY-[^6X=U%%&%'C0WC^K.?,\U%_9
MP.DP+CQ8V5;7UC_8</^![2/CK0G4$/(.SX2\3LESCA<H+@[11ZI*\CX!V@*$
M3?%<FK@+23/)NI[A=>16G.RN]![]SK!:V=V6Q0_QAGDY-KF[!M3?%_C<1SJ]
MM#]\/D'#.K(SL'0)?-&SFEOZK1]X29D+Y\I#[U L4W2_OR.+\F!%7^<M4I1T
M8F-;)%D3#AI9S&WRK0YLXRRWJX4N(+494DG8@S0I??CIDV1)9TFK+%['J%,=
M4=9U76IR9L&W;0F.M@^'@3K3>>IHN@!1=N#E&/#S1<\<K@'O0,<XB&=IM-J6
M5G9.]92<H4S4LI4:G(:EY@-6KV6P-SBZ50;)5OFJVR.W8 W$NDJK1-2=+*K*
MPL<T!P .CU^,NCX]C^0\YZ<9*/(N=)5\QR_<613!R33<1_]1,LNUJSFCC4<Q
MZ$'J):B?S\_B1--\;JP.9P6[]DR6Q#A:^"J6G(-3C/;L3?H6VQ9V[!*I:S?_
M9:*#C4O/[<H[?AFQIL;>.W.LTSO';6ZFOS1;'A,QFSUHK&(7@+4)+LZ0Q?8,
MNKFEFOLZ#_?33_-%J:/]*:!*\Q\&1Z$/,$T-A X0BV@F(!Q^A>GVG9 L=J!Q
MW+X/*0YMS1^;J90E^HV,?!J8=0:)E1%M 13>R>M]NG^RDJ,8L)3/I6\I;>Z$
M2+#9HH&Z_!%5_HNUVHDR/#]^I,%1TC&6?"P[N*DR. )2(!T&/XP<*>[B:<+D
MD$Z?-=!F"_U1;<?0W]!4GI 45)X_7)9S913O?KHC7\MT45L$CVKT\GB?X3%P
MCU68/C-0\.#5=,)"8,Z,C$9YZHR48UE4'E:G7/=N;OI,I?>'>PGDK$Q/J5NG
M[[EFGW>F;>N)G<_KN#@PU"C',I4KS!7KI0:C6"Y44"VKOFT;%A)G4>=SQA+Y
M2F?+(WL["2'R(J )&]>P:5?0=F>PBEE.H\L0BZW^%(MIR\8YV!3]D;_7#G&+
M^<;AV-O)S\\'@V[+'=MY?DKE\NNGGTW;;SVOF!QEF-6,J49T!S@KFT7?>J1Z
MR[3.UDLKRTRK4&)"PURY1:KF25'-$#XS8IAN#A,DG[6R]!A0:>TP LZGY_@Q
MM8HS+KI@,8-O<J$WB;R/W($J$0N[?@?^T&,#FE4:,2XOWZ[U6:FJMAJF :.#
M)_D.7*E6JYX5O(,]&QE".OW*R>0:]&L)BY/$^P6HNTH=?6%/9UDM#OHWT65)
MA_'>5UCQ]0D:SUB)HTD%+S?V9.9XL>CU]U:;7A*8ZM=:9NYQI;+&Q';B( 6V
M::&3[XD[^3KV75KFG[.HG0N$ LB;GP.,OD259<V_&B!A8"TWOYLMS:R-SKAX
MRC>3B+:J+6S7VY@U8\]V/B5:Z,Y:JI>2EV=IUU:6?8NWSW(.I[7FZ>>U>7[+
M)X0T-_4,TX8.8S2;+Q<_']PM1SO>V%COK=+8%+C+//Z9S>0CN?3NO9M+S6*P
MG5%%@=I2@V'@TT\[TLPT)-(Z!A/L!S@U>0LC!8OV"T!1'V\@F#_8!BUYPO[F
MR(\3($(> J,4)"M4@*@7$R"V$6#N3^4I4%EA@!L\%;BF&\=_XB?R'W/$RN")
M> @FX'_>6T4-U/9QZ-_QG!34MU*PRZIN2">2,?$L#W]1$5/03?L4W^-IGZ*:
M,?^])JOTI>%'[OFO7Y>RL,ZY:M4N^R1[%#<JOLL@7XW]7J&.@XF;6LU\.RS4
M40-"T-G6,0(_4;HAA6_GV /\29_[)D H+HT"_%@!(BAE-<&C=-7M[RL>\.=:
MZ12"\.PJ,DQ+EOH:5RO;J_71UZCVJWI!;6.NQ[?7GKK>]'Z*ZYOB-US]B>JC
M/M)WEP8MBEN3=U]V-X[<P<@CGPKZ\&5,E:':*JMZ(YIFFW^\T3#I/,ICICVU
MMU2RPG;9DM-Q5#PDT-VTSO26$OS&BZVEZ5S].:# _0>=,&GN/)DL.%'_7ON/
MT@YP7,T1HE6"*<QRGG04)%S!KF*D1$&B/#3_%96A!-YFGZZ7_Y6%C*P^*4 (
MG^00.H!R/15FTI$IX[X2RCP@1D)V>@\?G5_%#S>6#Y;XH='=^:0VW4]?1^Z8
M.C H_3:<6GXJ<!D==H3DP7]*AAE#?1$8KQGD#0BA0E&,G2R=1]^(MYW?=!64
M.I_D(IG20:0++\1*T>G37_U>8PTAL>+YLLI Q:2KS/>@R9%6$-!KP3F\;=WQ
M3$55/,-AA^JA&DD+7RQZF_#C;['\%F^MI?;*-Z]N4XQ?/>K&\DRSE_2=.E2T
MOY7\\/QQS($G _NBRF&V ,%/0#8B^1>HO^1^U?F[3Q&;J%?I@TJ<Q_P@Z( G
M<A?5C1H"QYE<2,$S>7N/GA# U 1_UQ,:(Z#J$WJS4G&ZR;'\QVSQ>DB]/95K
MF<'X*#,UWS[]>.8</^I]>7682'AVUF+=S9&3V^J//W^8<5&AR3Y(]7"N<&SR
M;MV5BXR/)\Y%V#[IM$^=XU1VAS+W'K3%96B<>3.L55'34_"\EX>>:X7$-@@0
M3X2XNX%^#/A,@,AV"<7L^-%!^ENQ02%(V(M[$QI9%?+7T^1>(-T0( (I+TGZ
M:RWBZJ50K/S:'41IKH)][\$77:6RU!*>-DO,GZ()=;GCMQH8YWCYXD7;CFR^
M')LT&/)W'LE?4[[YR2!>R(XQ;5^OAS>R[K$S:X-]-W<G12?8CKS1W5.,WN'L
M6W?P=WEU![.+H<WF&GB%UG+M\J7/$$P?1MF8[S+42V)<:0$"2^ ?YVVCE .C
M?6A0&0-+#G)++_5U<T0U^DHFR9.?HBTF/DS2[]3.O[C'ABE6MRB.ZX,T@J9.
MR03D>F6/@!LP?=I4,4]=]> !:4-6#'E[@F1DXWA0,YC)+P3^<2U^GGN/!7WC
ME*U=BQ>Y-LO 4T/QI"W_=BW^%ZC>OVFGAPTQ4C]E*T]\]/,*:GZWGG9JV;RK
MME )5^J@8\^-&PT"A +HW@ ILC A6H 4\62#[E0 SX8QR_5S^(T-;R8<7ZA!
M1C['@VGN;&[2>Z<JW-GD++7LSRWJBP<++KT)?$L<MT=T16W6,]G".++5V_-<
MHZN;?>E!2V1ROJKWB(*X]4ZS=.5/-^_D5GKO&Q-:-&TLW_4^2B(M+)9H].:]
M\IN6]V^^-NH_?W(O#.<7M0! PCJP#GY#I'""^3D\)_8BQP+L88TQI@+(6N#7
M;\T8R>J-[&NH7<^J=S.1DC-],M0HDA&+;LWJ#6>Z,IV<W6UK:OKNT'_&T>JE
M=(U6/C9%7V&V6FR>[JTTF2Z M]XO:\UU?B>_1;Z^$>T'N]PV?@H/QZ#_ 6P=
MBV(BF]$RI..LR5CV469*>!)%6^1[OG:X:7SC0$J8'I:99#9EQI+V'V,?HV3W
M.PV!OG4#%O.-R=&7X8PBOE9ESO\!,/K:0*1]7D\_;:W%7O7K(IATRD9)D8Z
MTF/#7HSR1XVRPV!B,TJDVH1I83@=,^D[RW><Y,R<M;CM=?#%<9# 2>&_$2!P
M48.G+Q3VP@XD0$11M]=JMJ:_B3?JX)UZ9>0VRM\T]AZ'U=1#C:+$!CV@+>V:
M"Y?NAGT[UU&-NN)+"E ?7PJ\Z-/!B%1OS!,5.]+VY;1&G9G&D;=FU8=+]VY\
M+ZF;XD ;\4QBR$3GVL3QE@(OS"P3GQ^\.&7I[WV@U,9JW&)FCJ*NF6NJ-M :
MJV]0O];@;399BHWB23EPK-F:#ZKWB-':?@&#.:]EIOQKD8.>E9%5A%&"B.=
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M.\/B_%E)"*TVHHR,$(.;=*L-]M0X8Z[J1O#;VTE[&6I8[R3/,8O2=I)>].S
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MA&D)@1\![ 163'B6E&;5_^ #37BS/-;P@GV_&F:R5FHR[9 ^<G6MHHUYZ!C
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M\4IJS^6>XW$GC@W4K";8-[EMS[66S+6../_^59AE1G?<=+]3EH4!Y^_7;<[
M/XFH9_'K4G%=\*^CN([B.HKK**ZCN([B.HI_*XJ3*)8%&E3*^@-^QC,!HG@D
MAZL'<^QOX;4*7W0I#=2=)(MX##LC.<(MMS$;C/Z=51;JE=DL&DS 7[V>SV#E
ME[17&;MC;V2)-DH=$N;*,B@-> 5F<' &6S[4/>=\/RUG:!HOFAU7./1L_D5I
MTK@(UON>=$SKO5W6;J(7,,H(ZT:2@:N>V]D;!WS\$YM:\I(5NZULO,E]1QY:
MH:FJ9U:^M,1,VR1)99A9628Z%$<94_)KT E4O-CWGXC24/U ,_2XOV]JGOR
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M_B>G$9B2/$ZAI7#D.P2(90;AO'8- _-]-^^$ .$ZCQ0@+*56D@@,.P&"<EN
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M8ZZYGO)[?L^:SWPLV>HP<VR#](-V=.'=S#[4:>0:[D=[X?_\ZS)? OVE,PM
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M$WE.SRHF)!>Y0E]>V"QX^*TJM_C=2YSE-7;0=5_X>_ZUTH??\0=R(S=#W[
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M31<YX$O28D0'((^\)J&]T'^MVGETV$1/K ?11!:1^^+ETW^P -&=R*^>$BP
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MOV7X;QG^6X;_9\KP+N@4]GOYSS.6M4/=V*.PQIHA2C8+D#Z["*%EL0#[9[]
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MY(N==<Y[D9FVX^F?N1B""$3P&3Q=O2-OV?4@I[%B6/V_ED"H);V4XS1Y\+)
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M@:L&!]H@[,LTAD3H]543F5-C]@3EH.;QB:X$3_+RAP@_IF C:2L#8,L"](F
M*7VV)@]7=5S\%Q^47@A";^W<X&TZ]K!!A^/9\OGU#G5L^%]SL'=KKHXOCNU_
MO/;-J#* Z]H#'BW2>^M?+GW/[TM<3Q6I#J F[OQ8;[G:M%,!1WIS !7*!V<'
MUN=5JCNXPA:P727;^)Q2O0P6@#MQ1][9_\O:P,5N#?JR(Z\T?MTU_MU2_ ]O
M6OBGC:#2X$\/AWA,ER2N5)QT9UXA95;MNGG 2[NSIC5WVK2$=S<>WU7K5+]M
MZWPOT:(X7<$[7)[<4EGX:]4OQQT;BY&P8O_IH[Q9(<QX50WZA[.W$LSW>+;
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M44'CX?SY#VGEQQ>M7F-O/XXX6L9OOJAD >[#@3VA67*#9/?:D% 6X$J* @M
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M& O0Q;MR"&3'E:<)-)$^%@ 'O+.+C%I&=EU@8X$6B@)#;3)]7]-0US[X=4N
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M?A1/EDP4>1BZF33>8K"I)R^JL0G\*W,N.PG&-3="NST["PZK-5&1;6(S.NW
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M42C4*3M?UL+OOS#WGF%-;>V?<(X- 2'2%80<%41!1*1*RU$$!(1([^0@(B5
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M?2W9WORQ/&\/RB='TZSO0[5'J<G\]ZQ+?ZXZG<XDN203#Q"//2CI(!\=[-A
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M"$I/\(MX$-QV(5_MK,S5'.NKN<:7OWZ=KRVOW5%75U&KO>. [-X_IZ2(O%,
MLD+T]V;\1_-P\6E<MWH1&7N >RJIJH=_5T0MC_BM!O4%"^MPZEP$A;I'*ANU
M[+BLM'GU\Y<EO1%5>]R,^XV:V!+EFDT)D_:FK-DO+L1#AK?TJ@_T$R</!6M%
MN737'2E1M%BXL5%+_W7]0N@5B((+H^;EPXG,[C'Z]B]'"85GQ[5&4X^T!J61
M7*4\4*<W=+)]8O6N5^ZC<<-&ZT^I"KH8N'X<H*G)DR,P".L6W"M8&JT9TD_(
MQ#5EHO47E#)T428_1J1Y#N.>(O^V+X@]T@?9CY[M]A""#D20X73HWK" W>UL
MZ?SGT[-?:XU:<-*D9_'LL)@Y7VM.*S^27VYN'+) NH-K]NPY@$&RUKJW.=6L
MVCXA"-SRFG(0&+GX(1:?UK[1!Q9;[82P+A%DGRO[%M/VK&QO?:L-._7(J)*8
MF>TQ/KAM\;S\9*04ZA:N>R-U&\8[2IDIV\TJ3>,=L:L=H.,;OYI&0*=/D'X1
M9H/L9Z(L^_CU2T/\QW]/3P7$SD7CC!S[":S7],X'(J;?X(3<P6@&BA[EAK.!
MH/5VZ6(P1P(A".%,C[;ZXAMPB/A&(2CT@)'A5*EQ"7SX05Q:RM#+6LE4M+TA
M^D;IP<'FHOQ#H^1JLMNR:=EFKS.G<]#KT0V1FYVMZ]#EP)EI_+0MA0:LS,3S
M!H7##)LCE1IVQXC=@.$]+Z_^TV,S0=C*K8G;GJ*"2..$;/\^EXL45.@"]Z $
M(4A4^#/Z?3@6##?-I(2,X"%REGMA"] T-0NVYCU,8C5@RY#>V(?6FF+85",3
MYH?@2G/ K"W+II:.8&*/68\^Z#4]]0A9:_>GLO7P=AT),D)CN>$ C8EEIB,;
M^0;7@GNC2T5VP46'QPSDZONB0\Y-\KP9>-F5[9"TYL13"QZ4*:RJ%5OZV^B/
M5;AT2VVV WSB\ =#J;B+X^OFT8]7-]$W-^PI8\R_N<;KTO_^A$;_^U61]SU'
MH_9V9<%[/Y,7XT_L#2AQQ4[/54?;&JLE7O0%+KM4'9QP=#0%R_%+0[:"2]Y>
M+3R$2QYO<.VW1M_W:<I;A.)27KSHJV3W7XZ-_MC5H_;"T:3EX4D2_UJ[8 HC
M3;@'O7LK;?V@2+IY\I\TXV5YIW]?KR(B]\N6XFCM>9LDM?L5F&@6;GVR$\PJ
MS-QR/-J;'M[N=(>MW]\^U4-(;L08M;&W[3F3!=2YTEHTHK?US-M@2*HAPG?V
M602_32 .%^G$-78;3\Z8@62.$8$V1MKZ-BY$9#2 C:ZBD3MU$0+-\!/LG?.<
M[,AZ8$D7]%4(4JGC!=*')6&LTI\9O*,,&IBZTF8\=WIBRGTBUMLIW^B)*G-X
M%4M9$1F93I45*"M'"+J&5NJ^"6&E'R-!4BV''J^\$(GZ*LH2+C);._@E5XG3
M5JS+N9,4Y!\_%M_'FS%6_C=K:L;Y'Z"@[$BJ[MI!]08WOU]Z!])#O*@OLGUN
M5*P,ND=?=Z_^F'/,\;SVO@:YH7':1&6)\?W/ET:Z0VR>0V;0:2[)>?'5SGCQ
M15:OJ5RVM7KUASZ^/7HE>/7[@W<!WFH:T7#JT%U9MMCW)(%X-7</[P(_Q=("
MUV4O.(&)!&JYEI0T45*!LRS%V>\)(732O9]67H!O58"((7'WFLT@V1X"/18M
M*8(L5@.4#3'P:5=8O9J7)R*V7M<F^I\DE:GXQF]8X 02&]QC:!)GFI_S>\-*
M MCR&&8_2RSKAZX:[Q0;G-D"S8+OQ]%E60-W= (GI+[E(Q9>?X;8LD4EI[VA
M8!TM 3@:UBM.TOSO_]/RBIIKBKT=]G\_#K.V6@Q4X?B00H!JJF)S]/XBCG>E
M]YA7>[[61+.@P7HBEIA).)5GT3[$H,S@6F@<-:0J7:O/Z@"=87'KA_\)ZTU6
MIZQ)87+R8<F!_X*GZ<5!(4A$<3/X]&*1#<%M'<;UGA,YIU3^;>Q^P2CNA6XJ
M- A&U1T0B+%:FUA6]*FN2!4_X$XE4-LS^-L)G40CWG#4%%FD3-W"/KG0!V'*
MR R?1%?'T9-D[TAZ)EX9[>L[?O)DY9ANE.-DZ2\2G3!-$4@^88EU%Q5VP7;B
MNB[CKII@P1B=%Q_()^(8^$S(S+\PSH #G1D@$S3/A<@2T[$R0/="]V9XJU0P
M..E/-J'7]XE!@#\A#:7>.D8_P0?_!\(P,_4672SCHE!P]&BW1_:!P,\1ZDTU
M*(L,(&PBMB%6\9@)+N*37_Y!3\&(!QK.Q -6[=[XY)=H>T(C&ZSB9*CJ#I-1
MDZN4F#@<%=;EE'IV<4-U2]4MP"*8LJ;?_AXZC@>FH25PEA,,T!3K(0":J+0!
M716,%;!9CO'G5PB.KE&=&K@.O!#VU+T?2"D'^A!>)ERI:""UV0()F^39/IM#
M&X$5UDPGEAK;1S)1QUO@]VX-CWO.3DXYCL5V:'^!4I4$XF;LM/EEI@X;P7DI
M0KX0P0Q\W^\+]>^I'7O=]IK_M%.>YSGQPY65,]"KIC\N3:J:0W?H&HB$@ _Z
MV," <LL7*C[MAZX2(,O6V=)Q=28#N-H5Q=SL8R,_0V" /XMF)Q)0<5S]-YUR
MHA DVQFB>7H<?S''-.[O+0STN1%AOCH#TY06\@RN>9^*\MK[XO>Z2V]?C@F4
M,,:C.+JJX!U+-WD=2I=U#(#N2RP\-Q8HZ'+$O1/,*GL,17-TF4@C.'/GGO[V
MS:K-S%^-49JYT?*L\=,-0I#GZ1^L[ZC38^7[%M8.^+2HW*B%R1SR5YX(/\=0
M7[5WK6#C_XCGP[DB"@M\MA0@[UKO\EH(NG<_LX3QQ,<0(A&X$A1HFW_</NM9
M4/7\DTRO7>4*A^(X]@Q?6ZXO_Z(0E)W$$X)6*"Q[,#6-<Q\8IE,R*"POR"QN
M?JJ/M ?[OJ@UO\8?.P*50EEH=^/V\?3KUK[/4E+&&-G?B$]XIY*ZC;"ZIZ=E
MVVE)TI2%VA/P<PUL_]8'X2NZS;_WKX'.%_AL,,78RUV45L_U/JXS(,GQYM="
M0Q*AW7.J;*<6AA"T?X4*3VG.]+XV?@Q(@.*1]2%D,A!?LSI)9?Y,6Z>S=5.W
M2B49FBG(\@^:8\<:&E[F;'+@_X&0X->E#^=+-&M:0I R'J6W7F809KVR_!"N
M BGW]()3^3ZYW0D(5^<"-<."@-$<A1!701^%"9,(]"CU&N@-KP6+CZ4<P-4\
M/&EQ*WQNE-#@IO>B:T!O.W\9]="\A:VS4=RY!\^[ .Y*M.* 1.E;BATUQ=VS
M/(3KLH/.5]'V\ Q9DCW@)]X8!(#@&E"2R7+/$:(/2$@=[1&"%,VCZWA0P#V&
M)>@9T!N6]U!4.SIJ2),&<N06O8";\?L*]R=,\61Q G$A:$$( H[E5')# 2C#
M5B2*9Y9@2>U"4)_N/G13E_93C-.X4C]$TB"!*U)66,51P5DO8*HG0*69Y5'.
M($GZ \?1F$] N4^:RX2.(3I"%W7\$>H@SK?Y=]L]J1\$P!;79"Y)-P,#%QYX
MXGL@P1]BIW$O7.&;T-;^_,9/B9E<W^%"[E]=#<_)*V2&(*(X&TJ/ZTG4%,C0
MUD=V $X] AGUB076P$RLJA%D77Z*-\)LJ(QH@UP13&X&"SZ<CD"03)$FE.)C
MR[9'&3Y>128C=5=O]+EP,DRR+C25!'OUMQ@[CN75,)XPJS_D''YY7EM*>7-H
MG)E:$*.9J_6H,/E]MI]9)4/57O;+C4I[<\W"'ADMV:QQQO]'W\NW[5W^B[Z/
M+78BU<0<>L&#2$"=N'Z4#1:(C]%%E&X%<-F>'.RKUVQ<?^+1@?;D,BD '\L1
M@J1C2?M71D+HKR$9L 6\-%H1OCM\3KU@29'UP_C#4'!=N1R1]NF,Z7,*3Y'$
M.<S>8/[DZGZE[+94PK@"8JR-/K@X%HH68R![(ZT60GJ]>1"Z$+3GZP.>!5!*
MMU"!L1TG4T2O**U:'ICD.3\#-JT)W9,"]='F3*D;@SKG'2SLB&T9U(4MR?]
M67P,/G3I^U1^0H!:JFSLHB,IN,B]VLGPVJI=#/]*9MW7P==-+>"ZDZ_^N[N
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M2R/D..WKF:S=EYP@<B;<FJ8<%2HJ17WBDI7GQU<#N268+[/M6?=__F22N!@
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M7'%5SW47;_&\:#EXV/M5(B-XY?J/;QK;*N@/.*"TP86  R8W=][M*I],G&Q
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M H:ZC 7D!EFG28(<$'D8B.6 !HY _G:2)J&(&4K#LH4&.:!4=B6S&E/Q"7[
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MGQM@*?!$)M'LY5OET&<A_+Y=+=U9Y:-*Y/NA57IP;=&F6\/AJ<:C:"Y5^W%
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M\D):1J1 _@+^ P<D0%J(@E M D#L6;?#0%X9>S0'GXSR9&BC!($"WU) 8,$
MFZA!X@<$NV&B1#^R[J7YWCE-FC,2'0FU:VT989XE8^(.S//\\!LB@X'" V/V
M@U)Y*U.^;K-<GY7$2FX_C>F09_HR+K _PVLF4BN9HA.;[<I]7#) JMVDA25
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M</?-MY'VI9V^M0\,$6L>M\0[966PHDF01;N;L(^8P8TF6QB5LYS.XDR0'V0
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MM1N_(%-/+Y@<_1P.;KT%MW3!2DYJ90 \D.GO(% 4#6.Z;B:=#T*<IFXC4 R
M"0ZFSMIJRY_-_;4S6^0TE-S/R3[&#""9:0?Y'>1WD-]!?@?Y'>3_&N2]8;N#
M=E//4P+)^[L;@TZ&Z1FJ'%,U+[U?W-,WYZGR8Y?@V:>7@_.NKZ@L)?A$K*"/
MT-M'N95AG)0PBY+RK]%%V45N_>O-AM<Y+WGZH[R]#]X[?2S&*=9/SJCO8VM3
MX/4Q@?D!JC:KSXB#(5]9E9A81=)E4=UG^M6)'\\=.KMHWY>?YR:=-R=5OO$F
M'X5XD^][UM+4^SCS'U< \&</X"6=I&F7@N>#\B?Q?+=Z9<"N--,1/]"9IM?0
MN5YN5FOCL*+46V*EXK]_OS7B>BIV8;8WSQ92@U8]=Z7A3/7Z_=)7 M+2&G,_
MD._^ZQ2H]Y< :(;LQ.Y_@]C=07X'^1WD=Y#?07X'^;\0^?G1&@.2>0M_S@?Y
M/52-TD@#+=&OFKJG<G)U3_V1=TO6UIC[[>EA_\L&IY0C(<^.SXM#JJ?=MXW-
M&, ?T1OT?4,H<MOJ.:/EQ2"A&2B+KU=Q75;;BLQR>)J?VZCT%8$'[(D(&=VV
MNB>"%>FRG[W-&KZ\:<@);FSA-DB*ZEI_FV.6,ET+12SW)G85UZ:MJF8^&W/5
MJ;DV_YU#^RM&^4IYJ^1%SZ2>WFR$+M37?0:I]Y<SFYV(_U\8\3O([R#_/Q)Y
M4\-"1[O+*T-N_:<O\7Z*-T3)F!Y?\Q>RU!9:.)^'$;JU2E!/%-J==E;'_.6T
MCFGP":ZA;#7]JB@GKM2$5#W1[_?Y"5%UACKR7!.#>E*Q'F4+<?J)WSTO)Q5B
M5%#_@7Z^'T):DYI*H@73U8M=="0:1J%Q"]*'WG3 13\>6$KB7>HK5>H0FDUI
M?[J*Y?D.^V2D&>D!OUG182_@[3V-;E: *3XAX\4^*8P./#\D-U9P_V;VQV6J
MD'?2#>\V^ !^+L&'CZ@6#[^[K3$\V/(*^O#-U\RUB,T[OKJ'NMQJ[94#[MFZ
MS6[;$!)D^O)6;%N>_$<,_K<=$_BKZX7\_GO[?B?K_@<B/]^E=9C^992#RD<6
MP N=ZAOKC#?H*I)WKG;WL)039]%*#H0+)Q\(,8A7;KP6C6=)6G1\]6L_[HT<
MPM6E-E;9WQT9;A<P..LZ4?FB\V'IRX=M7RS&'NI<F-C38V4=<^8S64GZ^IPN
MT\+/:9<YLGQY=RV#7\E!%],P,FEI:>EEMQ(J_';I%*I_31))3[QB$3VG7>2J
MIZ_J^-G!03H_ORBG0Y@3=:LC/%V"/!U!O91](4,EK< =FMSGH57P[-.UM(T3
M<2(LO*/'+.+1ML3?X+*EI)K@T(W\-=ZCCCKA@>H98I\^1KRJ8'XS)G'L(6#%
M\R?X9LBOO2\F2IV.88^+/FL6IGRP\FYW1/"=7F>_FT4+15O,.8><UZ2,LK*?
M3N6I&5GE<57FB(L[+PPGCJ1@_HK(@/\2VXT[F?/?,W-VD-]!?@?Y'>1WD-]!
M_C^,O(X2;)^F%Z9XL1\?&GF5 00GP3CD7L=&7S!,'M#)]+RK5[W\5K@MNLX0
M\V"/9O_#WS1$W7>#=AP%:C84^&:Z@_^Y*00CGU:^R!%==V=QV[M9U4D0FOYK
MQ^TK[LA^]L)8KQLPTTLC\B/S.W0\-TH3N'H\+&V//G[OY^Y@4XL,VP/[ME+%
M "I>L6JJN6D_2!AZ:8\U''%<J;8R-N3X"R"!0G\)%MZ=6/]?$.L[R.\@OX/\
M#O([R/]?CGP$9<^Z*P5#Z!!$Z,)Z"E>UNU<].>#\:?.7\K.*6>RD9^Z(*UP^
M;B[R=-PC]\"0UQE%!^%FU, 243XF2 P1WZ3.Q:\Q:YNS#AFPG;<P@'=\*V&3
M-L)\"FYH4O"!GX8]_W$>V[S ?HWT(S-7#^M*;@U$S&PEIE2=^_0IZO6]?38V
M'Z_I[CU\X9B[0?/&QE<*QCQ"H+TB$_;.(T8Z/%/["\:UQ4TZA.^&]1AKG-Y$
MRA32+J7FIO=0A;$GJPPI_ '?\@.I1'A?XOBB9T>'D0JR3W]N<-B#]NC15G7#
M"*[8-],!!Q<*0C18=.'$*OUO_BA\,##ZBCS]7V=$QK\R(@:PDRK_"U)E!_D=
MY/^ER5:6.5$G<+W*@9P=C<9:[_X(?#BO?L/M2&"U$=JRW+WP#)$XD,59^/H5
MJY_PC1KFOG)%F]'OEQ2'OCDV[;'W3JLN9170<_C.;JY]KX@!!&94ZR_E&]P'
M769'_99VG[8 V;19^:^7*C,&X*B(G:Q'C8%@+H\Q *N[2U.-8!>_H98SIU"_
M];'S]RC9<OIU/@:D9$U^Z\ H:LRAA0$(9M(07W#)^QC 8Q#,]B<TFW9<*NC!
M)]<90!OZQ6^/Z^C^]C^,6?3B.0/Z8]51"H\W VB1H'?WX&9$ AG (S]AZEWT
MVK@ZW9Z'?@## .38UUSDZ+>-Z6S@V:2T7'['0OC/48)]_2=K_]25_JCY32\8
MY22*6@'I?5F]^0Y"41&FYFYB_AQ=J[^K^>=_LO37;NS@OH,[B+LC>&GPV/2S
MG4%,U/,DME7;:V2FIVO7_5]GV3YN=?WZ=%7L4__)XR=OSVX(2^K,O*0.W68
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M :O!#"#.7946PD1/:'+T_.M?S?G_-H$@?K#+3[09P-NT9#I:OYL\2HT.P-+
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MSUEVH8=]NRH"PA>$YWAA-F>UB=$1:[TM1LQ?UQ2]ZZ'2@2J%BIIL/>P#?F
M2Z@C8&XF!U<.I7K5=,^I\#90]LA<>F(CW15!M2]J&>XOZ@9RB;+(SHX_-"+<
MPLZO/NN8=YB]9KP)H&L%4XX&$+#B3^-ZUYJ.U=@%FZKFGBES>^RQCI56O*_E
M=D#OM<%JH\ON7K&:'D>_O=L[GG3Q892*^3NH>$M3X,\=,3M&S]_C]"D?X)KD
M&#\7E_85NY<'3;]4#[?<X;S-Z^[ /N=GN9/VFFZDO8G'_TOGML<HZY>N)7-Q
MBJ"X=<K;_+]MN/A+B^J!,)Q!U1**]',)]<WSJI_BOUVS\6AYQK;__>(]9$#[
MQA5'C<08>?[L%?K\49C&^C;R?_SXB1C[:_L>NFQMJN*V4>J>)=1Y)&D$/'F#
MZ5@-,LJIW?#;_XE>\?]77EKY99.+P4G/2!$V[^=K'Q2%U?;ZBT3^_QBR:]GI
M<7:W]L%:G@YVV5Y[!_+ONM3X>Q_KL9SZ3/)^7=M7_=Y:Z-<X-57OI1?A%WJ"
M<ZO3:+V6I].QD^EK'M^_8DT_0_K(DI!AK=N21G\19CW51IZ&WQ@!L+*H@9JN
M@>54Y\&=[^*46O :$6D%&^>G_C' -312*JM%R\-TW"8;'N+BY=+,0A*5M.D"
MUZ-IR/Y<Y^XR=.0;;*GXU.O% 6O7MH2W>;>=?U2&WPK/MWWS.?Z7-3'CPP4W
M?G?F\09I3>13HP%3MH5W_(3FPZ(G@[/3^V1H^"C"E2]@-UTIE[L9BI:IPA;@
M&B<)7;V=43Q%TK(:7ID= N0FG[VKNZ\F;/2616EXPJZ8)=3R"6]GNZE8B;W#
ML1=U"C%7GVH#X%J(2A0_<3&?J#)AH )@KE4GN"JW*'2Z*[SZ7'KFRBR'M3AJ
MR[NVWMIW2_+CQU?GV5B5H4KL[/==Y*B0NEO8%*:JW0H@NBE $R(!O)8&IVMV
MRT:S#(;W ^SD:C-Z55C#L?OA&\HOI(29UM?7W?_*Z8_5&ZJ,-?=VJV_LG[=M
M?'W@^]>O 1+>^^^X,:HHVR)^*"?(E_;F \F+3_I42 R5E?SX^4.XW>ES,>:B
MSD(10;3G1J'*;?'I5'ZSR2WI7?/98WZO RIP9>23]J2#&=N></^</_#_U<Y_
M?[TV0N3E+;J$M AC%M<Q \@!-Q\OH=X00*R<AI8K$Q^A<?]#NQ9097EQ\/6=
M]*D?@B644Y''?WV+ND3XK[LGRE[_/HW$"".O^[W;PL-[Q?_8;3<&(#"L<)P@
M3!O_WBX1&5HH9L.9O?2/1\:74 >%/7]M9&K2Q[J<$6!ZP)1KZ5,&$K#_[=:-
M__]C*<4S9DLHDW%0IOBGN(THWQ\[*6WX E\0F^,Z1E1 ^E6K]-G(:H8N1&HU
M4!^(BGFS.=6=W4=U>OKYVT+?Q$]_OP#?M@2MBG]?^3I'A\0M/_:R>K"O7=<4
MI?!;0HUVD7\=2NW R/",=.;B(WKP$;G1[V9YQ#:8P;^;\7'RN_,5.@=ZJUVQ
MTD>01]!SJ$H:!R5=6&N=.U$I;(EB*39.Z?;N^.PTVI46MCR,[;SSE6\HS=!?
MN>V)4.*J[>+7]92 R"7 M>LJ#W!A7>7N@)8!2FTD+9@T*M*!O07X/R?CF>WZ
MT2T&FT%+ Q-0^;J=RFA9IYY>UPJ*CEAZ5SM9^RX@.U176UO74QG[1_^NV'U!
M_5]K\WI[.^>TKQ#NT2&<AF+-[ZY98:&8GLD[0Q RO04ZTG;YG4)N;V44-=JV
M.(MF1-W3'1L+]+-IF[-AQS)_BDP<W#"H6 U.Y]VX..E]J0_R.S6 C=6/=@?7
M#BZA;G#-Y'<)9_3U%.OVR%GX%4@X3B@,PA;9+41AP>P)Z($,!_6U!>"AQT!A
MRP_*N"2J0MRE13GJ**&G%NP!3GA,Y+W(E2CS-^Z"'4JMLPL(P)?:FVOXSS\?
MTEO, KUA-9S4Z_>FE,=Y1%BSHTFTGA"*O8:IMF*FQ3 UIA:=FI=06M1]/7@=
M:-:3W??@ .@!=;2,&$-NDL^^D^CT$;U;B<J2@[J$]+F#X!^X..%[MC0D8UYE
M=OVG1'L9DGG->PEGL="VCJMS]#]H QB52/C,B':>=+Q)8=DS;XLH'W@_8#[X
MU%S@3E]+81W.T?OG7,V6L-!8>^43C!/ 2(EY?M:'PD)__S"IQC"*MI?V$7'5
MAT00KDR*T*-BBZ)'A-COH$3,(8!]C8,KF8S?=3M:YD;K'[3I:"5H.IVV4VP"
ME).VY(Y5OYKDFH!13W*$ ?=5BVK>77KRU=7/#<FVT_0$,@'6L)4RY 6\(!%D
M1.^@#X]+W9'D(U.0R*!;IDCJE&)),6PQS^J8W4@])>":?:38$%91]-HQ6C$$
M _BX8H#78[?],;\(RAZ1&/?^?3*&EY(W6!/YQ-FZ.#R*S35  E$J HZ25U'8
M!T&=&_.SPN*QRF3QFUY7M)C5ABQS@W['%<MAG_&??4?8-5 <\%,L2D^Y>8>=
MX6\/'P<^[X]8B[LFUATERC5"#?X G)+MM)["5D!'$KQ;/)L:KY-J3M5_ FD<
MZJY^CVM>)%XOKY[O/0?O+J9$?1C4-^CZJ[:WQ_);3-K.WA9;+>VRJ,UZVY1^
MW88P2Z@_OB/SW$%OCB6$V"M+ZP'>],(3JAIT?RQG0$-2F2_#4QUOM^"M(7]P
MX[R]DT)=%=U.T^^-&2:DYN6\3J1@6KT,MH&8%A\RQ_LI:6)17O_@6+_3@U\O
M92@8#S)^G\BD6/<'X UKE$D/R8NI<;+]BDX\'J"GS9.R\$J#5A'VT4< 53$4
M,4;7[B2/F:'7=F&NS3'2%*L'J19BLU]V(<7?\#K]WV-XVGX4FY_',ER#_?Q$
M'\F9!" B%UDUB7*K?: $RW_O+;TGSV5936"#^CDXV5[JR6X[*[&)37(OR;^Y
M>*( #UT&368=>D>^[_V:Q%_4+GI&B2.J^0U/-+CF%U54< A/Z"^PL'J(%(&:
M:^?\*-?&I6>AP-C38V0='X>G$$M2G&TU)=*E'A;$)"0D-V8Z*H9YZS^&ZAI]
M=B+')A12G)R [[FE(R<_!DP.Y@KB$V](1S$?#')EOM1M\EN\T>]8X4\WZ+WD
MM5$35Q4:!R+$I*95<(C$[)[E$DKUFX$QB)V>DFV%IEI8K$G!GC9R8=CB8"/P
MM9.O-LEVFK:.SZX_([Q3ZQL1$&Y-[T/\_VUI!^0DTT),M1X-!Q\!+R45O8)Q
MX*6[0->!AH%S6P;P6V''02KNN1_%HGE$HRK'Z<%)[L"\2Z;SKI'VD1_VI@ZN
M#JVZUYR>AK%S$8KZLR%WNAXPE78LH9**Z*.%2R@4+U24*O1N9:88[)+?@M<N
MIJ0_?Q,7%'>ZY"-567[#I!?>+_X<?;2N:I"#D]@;7NR=:/B:F1CTW*\\5[L]
MY%4CI[9.;@<1EU KZY'D_Y.F1SW8P[DL^=T5G-A'W1T;&2TF)2^A]&D[0A6&
MD+_XVW3E^YF"!RNOBC'+(8SGH.6&(I] )I^[0P#O?QQ^Z87YLY?%D]9](XX7
MER'II)XJI8.L)A%D]5.Z(( CBT5A>Q0]I&4\,D.HQ+>)*@J7QMVDF/G(<^EB
M7TK$<>L?R0^F\<:OH%/4DT\^'\[(RTYBA<7G/\YI_S$89C^N6-6WA-K12?UK
M"?4**8H5J"54+U*4=^4F< 2T9;0KFX["FRO>CQA&$OET-'XWU0"<;5:-A=6%
M7HSR;_BU4-)HA7=3?"'%D56=3W+HG;?'.@R,VR@%A/H^NQL8N^)Q72\YTC!A
M'XTDOX] RD.,$@):I(^!/DBRT6![T+LM,F1TD"TFW3!8WP#B;LQWK9HD: 3V
MT:S>2TYR/.VY58\A/3Y7RV7&'O9\CD9WFB89LVM\SJ441I;>&\>A,/=X0'@'
M_,2BB23U5>#HDZYD$I, 7,"TDC3A<\@_N4]OMN>-/L!HX:TIN:.8:0<PES^R
M F2V8]6^^8I@PX:03"L6 FT@+VEV;E9MRN8>627 69QOUH3?E-22)7&)]#X
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MR7Q""6Q1J/FQUH=;""<:O!B7GY-V>F-N,X%00MH<>@/5%1EN+:6Q)6\3;0/
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MD/3\]R,R5UU4$4/]]PP/8[KL,(L/B^6H_8DP7\P!%S0:-*4PX/LFO8U;O)_
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M10S>#8RFG!^&V0+-'1)$P2%^BY  K2*\BT%998:CQ4./61A-'=BRH 8GQAX
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MM;]>?AK=C'+*/KX@)H,QU. WJ\&-79[I/7YOJ^M-R$/NL7MUT\<D1]3TB4F
MID[?<\3#SQ\]794IB@)UTT-L.US6/2P!YRDV4B]"5BN)$D;SCI7+/_\4+L>
MGK@6*E[2P]VN1C:4H(@/IC2(NG%9J ]LSQ\N*0":#75CN0Z8>:F]D^SINMYZ
MYSG</%XJ#6\\EJ$?+J/MH$IJ)>V]>):J\/,<<^R?"J&NH059D+,FV2R(NR\+
M,FJ1^J6J G"D9XC"&>$X%L1,6?9W?"KFL]<D9IV)87#6*F!Z8=]5UV&[+ B,
MF>#T?UD:MCW%IN-RJ/.]\]J,!*; J@<W@$^FNU>Z,B<-#XTK:RQP^T45$S&'
MXA$<S/.N%C&:Q;D!$2&"CQV%[S1_=R,$<%J&!O/K1)8X,!-D\4;R_8,*0[<>
MQ2/E1[L=[.WES+HL2Z<4LM(?1RSD[HE<]ZLVYLP1?R5X^?NV5+1_T69X3'L)
M?8WMTB+05BQ(B2WC"0Q(IO*R(+(OV'+H$_4\,P-.^XL%Z3[; Z,_P^_8/2,^
M@5%\4%/,N[<PX#$Q%N0A;PH+DAR3@S% =++IG#+L'9XI'-&SM:<)FSW @AS!
M'F=!OJ=B0?<%?N+7<39UY:6?T3=B00;D61!C<UD6).71$F+O$%LA+^H$,Z_Q
M@DDSIML3^VN8[TO_-6!8\%&Q)@ORQ W*/)#(@BQ#_H;U-ZR_8?T-Z__CL(A,
M87@O7.4="Y)HQ7BJ?__.(PSY(!6:WZXSMXRYMOD.U1=:@/TWT(FC(;#/!<,L
MB.<%%J1,U;&0S<CXU?N(.UQQ+,CK6POTUU J;SUVI>H'^^Z^]/^<8(/Z!A:Q
M(";E^W]BR'P4*-/:F@7A:J=$,$1QF[^Q(/&FR9B?QHBO%<90JKI^  OR9RN,
MSL'#@@RQOSR^+\N,(L; F6Z8(@1=>2ME8<<?T\C!Y),XS?YY02C0WBF#^5#!
M? \%+Z&26) <>V9JCO7?D/Z&]#>DOR']#>G_?Y F\7TCJ<H#*>R??F^U<;$2
M?Y=^<6@(]9N=WZ4L..2W; N9/F*JM6XF8L:(%I<Q)98%/X!*.77[ '>5WY_I
M]XZ\^7S<]##Q0P,)\?V<'Y'&7\^"?%AUB3W/@CS V[,@+5"&ULS_(J1U_N_W
M4/XW?$]_0_H;TK^!9$%6F3V\C0#3RM :5([N$7$T;&K7E6O82@?MC53&AN4)
M-4>TF(5IS,V==YVYUA9]LF:QR-H3><+M<I^P.0MR:8^I@EEL0'Q_B&"S6EI
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MA-=DM0VIX%VQ='5#R4%5%/I2W8RI\*TF3N:82M;>A#;\\+I-@K=)C>YU><\
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M@U!$.W[ AQ%GQ6B_@_D13U$#(R31\G1-!$]/RYW9J02Z_>+^W )XR?#,UZC
M-]^=USR@KSH#E.[T!GGXA9^'G0AP?/W0_O%/'3Q7K9,*;ZV^F<-S+]MDV:L#
M(-9@4&Y?\R+NJ*_(D(/P4=NC<E?;AI!C3XU.IMC+#WM^O5XB/^XE>')PK@OL
MP/:#C[!D%XWZ2K1Z2H^OO@KI58>I-<6?^MSX7I>7:@ZU+E-Z1+'*41!Q(#[L
MZUB>#%^\?T;D@$W\KWJP2=.QKQ$[5]'>+$CB0B^&GC3;44YVI OTTRS!$?)"
MFJ$\()R&-GOAMW!(GS>"RM\_]@E4\1@KK05Z[Q>]5 Y\\JK%.5PA7N@[']*_
M1AVB%9>-[<:"2AP;/P&C15QO\$RH&6@!M'1A>,,6!&91CPAF7F1WH3FSELEA
M?#)=-?CF;/J=@7M?GM[[MB8R>Z6^7R/YV-C=?<2^9>PP M)Y.+8?VD2K B+(
MT+N=8FMZ/S:VJ&=(SAU 7@*RU,W?P6%>>$)9:3-8LN6J3ZK<VUS!AJ2?;93V
M[4Q^H"_1M"LRTSUQ2?8Z:D70(=-5W,<K9[SD7B+'^2[OUJG,#$5N&3G[$I?&
MVG?QRT^U.>PUA867;^@C*5]B3R]]Q&OU I) I\2UKU/#Q1SR[RH<AF0> C1M
MS=<8WW?-WC;G,KB-.55[JXUU=$?#SQH_7])A&.QKQ8XCCL "5 [X8_ABN=9%
MBYO(,6=[6HI/=+1/-%H:_=EJZ=]O-=KDFFPS9I,J5YH0V%1X5(ALUS-\MN\8
M^)@7RU1E0;H\V9*2+><\Y(A ^%2FOBF5PV7TYG+MQ B)EP?+MZH7_H60(4#;
MQ*^)9B8\\U?BKU)X^W1-M%I^L6\T13 7<Q+C T^)E04=V5K,BE&EN<4Q[[[:
M-E]''84?RK#I<[[6-M9(%%G%'6D\=<?/-R'/(E*YT:+#R-+L0RXE^@O;^=MY
MTK;H)SAH_(Q'!.=]>53T$J8'G]C)#=8MX5)<6M*$*,%BJW=BY<?0JJ4H3$]4
M?F+UCJ6ZR<3UUM'J+6F]*VU-M&>!F>5RX]=;A"V0P9RG&E2.@0H)CL*^'XUM
M87V?=4V%6)!*9PG[/,JYG&UN#Z5K<CZ""LLB>ZWAYD4B5U_\%)07*)<;RYHP
MY\L[Z9@J\4=(_MX#TF,5B\1:?=,BP&;)X\P[=3<MO>?.=U\/JE;D69.\'\6(
M6]38\MOR68;N!QK[72QR:AH87^$=Q\YDTU9_I68,R.EL 56IORN9]A38O^B<
M(/#AI]U1$7UZ,0_",O"8>I5QTXIIDF1M;^@+/^VHIH32L2Z>B7&U$4X8U_X%
M3)<YQALZDT2Q[._&ILTK4872EL3<5<PF?9O&"&+X@#M(SYI+8TZ#M$V]6;^3
M!5)*BG[.2_NE0F^@]W MOMUX3DR7(6;Q&:QAJ@<V\_(3_;0OI82,%W-#"5L4
M^]35MK928TO(P?Q?H\)X);-ZR5CAKU1+OUG;=J-@J?FJH.M!&UFC\U,J3,XR
MH- 6_)44 _[>D->O(.-E=C7="""2>+F1H@E[YYU=UPHR<R.$BH,/^J+OX.^<
M3J78S;\W/CM4(8?UBM*%)8@+%O@^,M'U<?YD>'0$/*]#0:OC';F,= 85;K16
M"W*3>-*JX$>3GWHD2NCDZXR7)=E4^(H,/"NMG/J^/7*2_N< *D)_D 6I!V/+
MD\75^W6%CU"6$LO2>FXX-XFS(!P9/=X/"3SRK1^U9'B3>RUX1*QR RTR%"K,
M-3XYFO(RC-&7&$\Z!>FJX%G,_B44MD=ZB:R9E+3#*X [\57+46^:\!X-CRAS
M_AJ5B?.]@0V/Y-EIFWR\^J7_U>G'@V<J2S8I3''F%/&0H0)=8HRIBQ)SG&S"
M' @0;:Y[ACS4R+5_*MAFO%%.QM)<+$9Z]UJ!SJ+0V.6;W^9GA\X\B8[/\O/*
M_GD'Q.P[HI(N,?YB00)YI\66'N>W07M4$D5C[H)!WI3#?KM'-C7@:1+\AII@
MJ&+VY0@/\.;>^9H HR8CN7RS;)=['!8&9P:D?YU^[Q+=X$/L&4R7OB$46? V
M3[.9S=9[JI+=S[:T)MXH=&MK:JL=#PP^73QF/8I_&GIJ,Z$GVGM&X,%;;J!7
M'KUU G3-![ \RY$O@UQ/N?+%+Z4;PO_J):^-[B5ZD9R&'OF@%/MR-2_:%/F/
M9B6XY-2=*#._BK]X+M?<;67\%BY=-U^,Z@'/_CR-[LP4.T5>5C$8NH4JL,_S
MSJ5Z'#!T-H$IUEA3SG*&G0-L*DQR S4"[-,!,&4\06]^.+83I=Y7P($-4\ <
M!V^O?@N4"9:;]"O@*G3%2HO%!8=S\=<;!8<$AW(_(#3_<,C7FFH._>C\L4N_
MR#VD\R!@F VP(!>P%T8EVXI5-&5:VSI0\Q2*4V!@8[O]'/<M$D]38O;SU38K
M7+" >?/>'1R2OW%,,O\$S1Y\+G75?JU:H9"T/3C=EK?RN?/QI(7'N[=-/J,1
M%C_H"CT$3>$TNTFI,6R+'7YCPB+Z8\OMEH+E+*LUM2SS*\]2%0X\^==A,85_
M7D*HD/>RO OQ70,)VYW$,"1;GW!V_DN%AAH61( %>=-?S8),T5F0/<%K_^_'
M3/YO&D>I##W;F;@A"]MY+K\=M1//@F0%:#,2.)@YO1[!_VVIX<5B1=FW'&?,
M@M06Y3.QYF/4!7I&%/[7MO#5YG<-^IHLR-G#:>SH<EZ%(9%;OD3\*;J+V ]A
M0<:"BB"W-?XKA1OH+NQ A0Q6"ONUQV"!M+^^_E#Q5Z8S[Z#?E[]]6[:[-S\[
MST5,J_\U4S H;FTLVO#V;'VE?-YUB#2QL9)ISR:QI1C $I.& :YN@0HF<<_\
M;/P-.4$I,FQFCHR@*T/3$-Y* :7(!I!(,>ZGGXD]R:\R$XX_%3#Y-@-FZ:7T
M/-N_WVU*P*D_"%D1>Y=<')I(_J;0O8)Z=5$'_3*GKF$E.Q4WL4Y>,RE FKM-
M> M:R?/E?)&3$AFPE*%0#Y] ;=0W'ROZ256RME1H>E<FK."N8*PU%R29.V>^
M0:]GY&&\,6E$P$$E/1O%\;I%E/@7Y@8^J:"CD'X-)"AQ!U?KW\Q7!0-(1\/%
M7/V+%2:N<2FGE,+%)SV@]5DP850EQ[N4IVO0CPNO1^X2N3 ^6PG%?* JX-OM
M@KG'E !E+"W/&W^H%GST^?J5EK:753%RT1U>'I,J$D&F+I--1WW'-=U-*-&#
MKS[GV?CS_H7[S5" .43DU)<"7!=;XC?08FPC[,KC\BY;S8L;>M7>&KKL+SK?
M\N(RSV0#Y93_QEM,];KVB-+RTVB-;'-P.F5#,U^"^BVH/[(C,%:O>BDA?6'B
M7$NC7)?[A59I2NFSV7C^'*3Q6SFKTG6'RN]N^5S9GIX7XQT;0SPFGW^S089&
M3UH^'PUJ#]5HM$X_>R)5%A]O</]_53L!?_D]"_(9!^8SB1S,N/*IPJE2/\QW
M.-V"!4'$L3W(V-<#PU__FX;EY9>+6)#37- ]>M.O27"[M7\^_O,4]E\F"+9B
MS_YR"RS(32'BGL!$UW^?5R"@M=CV&07?/^K&@GPM=)$%@UB0,SLXVHE7;&A:
MC5</^_Y+J0:/0:HI4W\'M_?SUW]83V7\]X'[SXZ8_T>:8^D:\;OE#N_^T19F
M4K5CX3\?7^4H_#<G_=9-MQYMXHD@XWK<>2\W1P\[.@,R:8TU:L,2&M$=1M8
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M6ZB0_76M8GIF#H=TZ[K5NS6DW$Z_(\93Z#BPXA!>?G>(.#W/+YP4+F]7(1K
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M''^.L2#WVC%=:H:GT7[@K[QVV(4&[;NF*71W2I@[!Z4_?J=]6/AR*X%0VW3
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M^/39[K\ -P#L^3C'#=" ]PZ UTK [LVYO[3Z<0" IO<MZR-7+=UOWW*RA ,
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M9YJ!S\E]O]_?\X].RDYT:3LCXR>N#GTG0<!CL=F[R)?$6GX/.B,,7;IKU%;
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M52DWOYC1B2.IU[9[LL!QNF+T38%QEL1BF<:M[PL!J'P4<0L[QTY]#N5$$+N
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MGS:$!GCW.QE+_)5*OVL7%/442&*$2], Q9$]4/*#CS3 ?O&OS']:K8+ 5=
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MHN!R\F,YM;[@\$(!4F#L3_FUEL))\T)?.=D/.VS#,Q-IM_M_#AN8?01[1@V
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M4<IM/=&R:(RWC*GYBLE/#%FL;+?UQ!*VNNJ51#S7?US:2?+&5Z\G-+:W'M(
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M2*'^ME73I@'J;I[&59YIY7K<-8>>LCU!90;FJ:O -AI@Y<TRT1*5@N6F@K;
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MUVS8C$!1^!+L)NU6:("=WRN!-V?V^O(PO0LC$,CSTE0_*8]2F.,OXW9LND0
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M\E!J^&/O:AJX!R=5$UZLV'Q(^S$V41!L:_K%D\WS+[F-^*R[?!J#X>\46S@
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MD0_*KLZ\6F%QXI'$VD3S]SFB+<^;V\!2_A^B$;'V;(*^%)P!LX"430A-) T
ME!B,I^KGQ!<Z),79(;?S2!M*^NJZ[;&&HKTE.7[^2?^^!-5'.RD)F$=S*DH'
M]IY;T?]T*\WUK G=A29.A4Y_-,T[N<1ACN?J%^H_*M4;K-A^X53[1_F4R%0'
M?#F\*TQ@QGVBA,T-.'HVHC2Q(N7C&]";!D7NV>%2H2]?'5?E^=3 KM#3)><O
M>\?C)=HSZ%-OQ</]Y]I_?T>GGM1.:?F[_SR*@:CH @J06G=F_KI /HR7!,PM
M-5,I"<7&]_-:3K1Y1F:\@MMHOKF-]T.S@QVK>YJ?F1=?DC$I\XI^8:SS)O5"
M] OVK8)=_0W&+1%+<W";HINKP,6?G\@J.;U'6OH_ 28=SN&E*2U7U7/47;4G
M0IY.:N<L'WI'.=0^CWMOO.>+]^E=$=Z)YJW7:W],MC6[9Q;M?%NM?OA*POD(
M(,?SK2NZ\D'(:%IV5EH)9>>AYTU^C/]#S_W^'UHV(;J]__V%K;]?9OS?7^WZ
MP[2=^<M*/5K\0Z?034A%#I2':&7^,O?]O:7\X"/B@LP^<0;^6;SZX'G*(<C_
M2]G*HXEVN(B;/<:U%/T[2=W(0;O^6!<H'J:=+^ !X(JVU>U2N&,TV^9M:_ET
MC[Q?*V.?]<$4R?37..M+K"^:Q\@OB*QXQ(]PF#QQ*;U;;(5;#NHYD0(3*,F?
M%.83K'&+K)S1I?4J\/-,J^FW\UT<+VQ2_O5DB5)A1?'8PL>N,B3;YJP7=I^O
M]"W-'\%?3??IJUW=A'A^>8_8%8 Z':+6QD4IO9)M<9EI^OQ!O>O+XZ7U"<X,
MTC3N3Z)KR\52MSP;_9RJZ*BNP<S7O."PBZFHSE]?(]H]8 ,N*2;>6JV]Z6$[
MFS5GS4Q4KO:^5K<%QOYR^ZB/U%AK:BOT-(\I# H_%..[Q_7@6F9@?OI?>V'
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M7_"T8DA-?,C4GW[:Y=N<+TU<-L(KWQPJ"Z)6VWNYQ1R!C-O:6WYS;J_=$[7
MF%!&^L-FM^:.<3.<G#[>%SX$4:QV1%P"M,MNUWFRX:TU[1'WWF'WM:1F'N\4
M7;910%G;3:^D,-3LX^IV)]>D]"U9_GF[3NL BQ1[4V"7Y!_5,9Z"UD8!)X]
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MFL#H39R;@*S.?3&A&V4DZT,]T60S%$RD&LW. MU*^_M]?7QM>7Z3"@'*#X6
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MZ&.Y"SH^7I1WQ*=\E*LG7*(1/K5I\2#0Z231N/?.#Z13TO]:QZ,5>IO:U%X
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M3@8FT)F>J](48 ./6"PRTMTANFA-R.B(>&S]OK'*^ 3[*)4,?5P9H7@$ZL,
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M1-/!-R?^#HI5?-6F=<3%J3T,F\^LDU-A8%5OT+,OWIK*8[\UY\_DS.\,;/<
MX=29?V]':([TMQ&B/@4:9*G^6D.B?\^U9G9-)-]7'8F=Q,J?\=2*#U^",3Q
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M2K2\E7$Y,++/K-J@ SNU#Q:B7:.WO?^W8=S/94Z5Y?G$N__>Z<B@8I:X\*[
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M24L[X0B,@RDS5>[9 Z<B =>KI,>;<J%.K@,VT#KTTPJ+(D,.JQ9^)JN:"N?
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M-( .& <=)P=2]!S@YQP-_P"!"==#U<#Y9M@A@D0(0><C=F;6"?@MO#.J"CL
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M2=QF'!(K/MN(]E>"4?H4614&1T3*95VMB;VOU9I2?SO8ZTW,U*7T!?<<,0=
MO_4F#X']UK$)UJ&4&9NP9QN.D4^<Z[[6.@<5PS\,$_CD:Y336^_N_<:GFR?9
M6Q;T?K!>?.3]PZ"!EG*ZQ5QQ^W"#KXJ_H8&#Q;;1.$9QY!*0#AG<814:UU P
M/;D=K*+0LN5>Z.Y7QEKJ(GSOH/9KKA^SPR;+^^^PAMN8"KY1Y0J/?$SD9J).
M8!ZX&D&@BD'*MBF.A.YR2ZA5]1^!^TH9.?0E1W!\M#R).%/1R"N7[S?DS:*9
MI/L>"KO2>Y@]6^<O""N!/R+7K,3KQ$S)5S4^6J4O*NU&GM3Y<&LYIHHJK?BH
M!]G:]2N8N+5W9$O>>\!QJ('D^,)?:*204KS..RC587173]'8:O&1H7AGP'#A
M!"=&:L+LF4AQE>:(GF*R=<CS%T925^W]Q5K<%V0VX'RD[V3R;$,<-@W @"1N
MF[OY]WV]T7OR]MVL G[@(L2-%_>[;'/;#^PHI#8O7%<]2"#+0N1[4*/^LY7M
ME:%!72E<VK=VXA*4'_NHMO5$(E3RHK,OXJ^6!X]R,M>B+7(IXB!6P6CGA&+=
M=<&== UKN1K6Y'B):V.N2::O;-P3\RZU34G?;7O5"=*>['+&UL4M8?J%18.L
M[EL!N8$\_1U_*?H:SS^8E;.I43^V\&J3>'7W![1\RCDEA"PT[ G6&)4D75KH
M@+.0KLA("%K&_I/Y[,Z=:<?B]K3U#NS/./3W2W%]W+;B';=%]EP%GC;#$-?)
MUSE")0R^@$6/;?"AV+Q!%!7B#7YA<R]B]L>HVRVX/>Y1AO#1C5;+%X@[MM\O
M3!G(.$L20I%^QNO#DKA 'HM/SS6<GX(KE*NO')L-CLDBUB>( H-BLVU-=_#Y
MO[*P&-XE#5?6(9UP:R]$K(X.1A:=NGI;L,]6ET?ZY*-ZAIG/!*%>_3?CF0W$
MB9Q&"U[PYOWXL-4D)V9B4=BJD'<91Y=EZ!G@NZT3WL37E*TZL<O7&[E\Q31I
M6B)5W-[F71<H$H7'^'LXTKA\V_P8WO]^.(FH >UO.P>TO*L^4R7H=!';?SE3
MXZ..B_*N^9*XY7*P!T^T,'U6$Q\W7A;Q38M_;;GFTE,8QC5=]='^B=ZZ^=[&
M760-%;Z=6$,2(3C@ZW$(M-HG7,60-WH_4>WD "QWXHQ-2'SP$3O[@BYVO>NK
MWTM\:"1J_\.6EE.&Z^/ %FW&>DJ-VX,-$1%OQX/#WSC>C9#XM?SGF#HB/&P_
M'7@!PHR-Q;3UIX',B*^[Y-U.:5:JZNQ;4T)QKD;3ZWE"5 /<!\:"6O[[:?*_
MO/PK<0'YU</B93;&GZQ-6WP%OHCLH>2K6,D*.%@^11!$>HL%)FC^C$(#+W@4
MZE)@EZ'":)W 8_GXW_J4'K]UK5/B(TO=?BD\;RKEJR_<F+_F%W$<[UNT\?W.
MXM7[L9\/" TX5@ ILXMU0/@JN"D;$UR8P.R*ST\Z^&S*Y$ZP3.Q#!6M6.;0E
MA$"YA]R_Y?+GOK=H^JCQ-LZ4.29>K?Z.G@#'[ON5E7?\</G=:V3]4%NV_/#_
M EWTM_43_BM$%(\YNP]%:+$FPSV<V: 34+Y.G#P"E%1VL3F#5^X3)DIE1@7&
MO:4U]N=6@.#!#_Z]V;1@[J0Z//3@L[.-H\."HTJ(<6!X,-4MF2AV6.]MF \]
M0.KL*IXOY@<,I=D)()2W2]@ "-4ZCT[Y_YPMQ74[]O@SL>W=:',JS!>T$*_"
MP-?:128<$6GL=3I?KJ#0ED<E7>E0.WPP3+<*Q2A3UUFA@YV,\%GOC12WMU4K
MSP$S=KAJR-I"'5@,*>$@#) "(M4?',$Y,XBM%WPD%2P<H=>MSE;@\;XAN12H
M//"0U.BDX1?.I%5O:7Z_;E?2K&IB;>MKM< -:$,V&(<>O)NS'FEE/8 O%G;,
M1RJT.W"S\STR-N>%J$HKI$DKED!:Z[T'B_VYI%ND+;R=[N=TPLBJ$C$ ]R:0
MRR*F-F0J$WG5ZPN.6L)DX%\<:.BDIA.ERK"XAH4@,B,BY,! 83CVQ:KK(6EV
M:&ZZ6V;80]PU4E3)L#&D,9>MU(8R$Y6896FC'(9YI+G#=%<B;VUXRI#:?E$R
MI/=%N0CAI:A[!@T#M>8X9/-/WZ)8LFB[_1"$72^%'7X^ J%=NCS/ :\P/.>
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MEW9$J4=K$EPK^.#QUP8"9\5QM@N 6-#%/+RDC'&\K;?$4=SZ!L!+5]-05&2
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M+XN??:=!R$7>\E@2 QS[X!6U-X055\]U8X)+EQ-?,A(4R=SCB,@&T F= VQ
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M]OHYP!PF/U 6D+'X8J@JF2R&-;&;3V],)&!0T;2[A^@'%X;N\*="EW5!(^>
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MG03\U!AYK7-/:+BQ;W14^=)MA**&2P&OV)'+C5Z^Q9G8O\,3/X6,^V'-"4/
M%."'87P6"C1OC8(_)7&19H 72-+XV/Y3T%[NF=:.LMV6,"_N:M'.U>"'$H,R
M-1MM35^KNV;X9*]6=^?N60F W2/8VDYGOZ\L^%A9/4XO"V5>CR_W#8QRCPA
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M@;:2K*9&%]Q N0&H:?%51K="AFA<1&#[&6#U\7\6/?^OR_0ZX44&,D6,2D5
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MRDE#E,,/WR&VCDL8CI(L8-A9A@P[X<.7#,*NLN\%R96WZD=L(FA7FG2#24R
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M$R#GMX.2'OKC!?$:0,3 //;%O&J61&(!$S52*D<)@_F,K->T];DRA[@A]0;
MGLEE_BW6 > ))LLV8UJ9.][9Q!_]=,FWF"-T@EJ%R^;.1D]+0]H#,N7?FG>D
M.8R2-IAZ4<.VCL@/::G32HYC.W1%X[X-N%89)'\V,4.KM6,+B./RK^'1N5*C
M=41ZUT(%K#08$--LG,;:$BX3DU@3SQOY5'1,]:-4BD-BR8/:)RF<I:>O=/9+
MBJ &[&\:-BE8SD"O[:W>D5#=3UVM5/P>R'"<$]3+02\4=M:=%YS=R/69C8;Y
MQM^LP?$XW<@?,,J,:IH.C"*7)W$74*%)TQYL5<KJ<IQ::$;709? V&#\BC&
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MJ>;,5;PV?IKU:56;[/'>D?)5P&"F;/P5(V;R/KT"BC[4[7:8H=J71V;XJM.
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MF)?+<(MZMD>F:6XV&\JL5K8I&L[S,M[$2!GB%>CR <#R#!BK@?T=02WFGR1
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MVF10C=W>1&E8IV/LJEZG>O;M8X._MG]96029]3/ ;1_!49H 2518&Z8)GV+
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MCX!=-T2_;'3E;HI*8ZYX>!%S(C.)M6EZAW_=4(-42K=:99_U NA5;[%A'7O
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MUG9C8F3RJ=U7MPT2 JA0(<7VPQFP'=W;66:^2= !]89,M]_@A=<K)77;3ZD
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MNQ&A23[830*;P<>CI+I*DRGEX'Y.'93 8=YE6J)'%3)PV7">%/*D*^'Q":6
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M7>%?<[ZN735)S]\63DSPBY1<\(1F T5EMKF:VZP2%?]8L+&+3B);>6Q(W@[
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M'P_R1]/"%SMF==3W&GL7Q>0,S_018=]:MG7[CL:HL>!-GY,S,:>[! P!BF"
MG499["MZ 7Z0% QD0%M8).A7_,[#P\A=2J5\FZ76(Z%K[XI5K)TNF- ,]3J8
M[(@7P'I^[G?<!W=(+E1!&^ZDD=RM;./<4:&M=ZR69PK88S!27]"O#X8B'B-'
M+\V^W%9;+=2$J+P>U&_I!75PN!?PI#*49//#_&4Q&3O;*^0[:L?3"!_]'7(,
M]=#HSRX20^[V+:[;0F6;*I6'YNP!DH;E'%L_O:Y=6S<8"-5T]JP%^E191S<>
M;HDT)O;.VFY0.T#9<.#*[VB34T$(=Y(:/'F$_Z>:[(I'X*RA18\)4^?C<X@O
M;TT01D10&O&@5U'R>8Q_J(WBO$?89I+#($K#X&EX!:[_C!PKZ=G((U(K5WX$
M4GZ&K7HP0A392JI\\(1ME&,J(*MT&"W(\-HX<A4\9<^<Z#GR_+H5,E_47,J^
MFB=TH7;YX&:B/T)4T1\00+0I.QM$+?Q& 1/>T&DG>C.P):_WYSN!U9(<X; U
M?F-5#1DH*(3WK,E3<:6M\/!5I,O6;]U!ZULQ7''2,MK_<(E"6P/77X,E6OYQ
MGS\\0A2^)3G9UX(.DB[Y!"]Y_F-XX9T*BQL.+3G"L5D9#SP_LK>R9G141\W\
M) 6L8JM@[7<M%P/^'2=_#Q"\6WGX),D^OQ18RF9G?,8V'_\R:^=EN6V?W*2$
M>.DG5X4XNGR08S.I+#LU?MWA><=X+<US!]UPC_\_J.G_R(-U)['=MJOJCJ'9
MOB-6R_(IO:R]K2*2!V2KL6!L:9WYHLL.(O#ALZT09\2)V(N>>/[C$][./,:9
MWV"*2:''@U/[_!^EQI)BIM(STI.&_XUN]K6=]%0_0(O40^D2>K*/L6X?C+,7
MXQ>GP#0&]-Z.I*7 #K? P-A5%, ]"7V^KX^"^ F+\K5UM'JRD71;62O\4-96
M>,Y*GJ<?+]'L+"_,D#56_V6'8!J*L;Z\!R17)-P#2 ^8^C19Y&[:F.\&?D4>
M5C+UX;D*P-F9L$>]S>DY?P@G658ZFL*HHX:8/Y%F9(KCA:5%X>C5_FZJT9EX
M8].AO3)F.R[I(D4]":/JQ&%)QZK6O;[+(8/6O14M 9%A7A28X.5&AE/3"<O&
MS>CYE'U5'^#CAKUQ/ZY&VHPZ,$2(>+"389B_?-^O1Q3XS@Q*YTD'QR_K%<OE
MG!-)?6R.@=39^G [)E,[*'I'/HML /:'\XJMU@_U\K8TQH>_@<I]=;-(M-]'
M;%3I*Y"Z-AWZB9LE!R:?%/2X]>G_28N3_'7'GK?PO$FK*^>6B4L)2DP7P-+D
MD[L[F&6XXAJTE_PM:H/M1O<V*8+Q;G(;MX<13M"W+.- -^G)="0W]UONQ7N2
MLL=[GX$)N/'CM)\]DN1'F 4[=U0(HC!<90/2EU*_UJ;:2$C_=;EN_AW.D;W\
MUQY**;WV44I_G_!,9 \H(;)JJ@L'CWC@%/^,=$OA&U7#,S#T<:^WU2^W73G*
M1MX6PGG;.O&?1C_U7'[RA1%+:2'WQ93Y(R&T[&WU'5U1]#V LI<+HI+*G,BS
M$-*]W/Z)2W#2[5_3QFK-LQJH<UM;<"R=0J@"-Y7Z/4#[/7GL'34ZK4S'IWRV
M>F(Y8/(>0&1@WEY?,5DU$.J+:KFI72.P*>^DLJ6)S7=,5U<"H?,?VJG_;L9"
MC:!75K6Y= C<2X+"->$IAVZ<V]IIU*S.*GQO?I/+6,=KGJ E3]WLV$W#06I,
ML.,7?3 :WP.2$EW-F[/X%T-JUE:%+SM&6O&5B",ZK%X6Z=R ,O\$Y?OL\^=S
M3]G&!*YKNZ\!5BH-+)]T-V-AOC;X=]N<#.?7V^I75?YDU]#',=*,KDHXV#;"
MWYZ(X> E0BV0A>EMBH6%B9[*V (\V9Z[5LJSTD)$O#S1QX+/*K4F,C*E.F X
M3>B,U^U,6BWB:W9A"QX_HE#JN]F>GQ*^XJ;Q_*"J(<Y\4J7\P3X "8K$\(Y%
M"RNNV5'5=YK+608>13G&CS)P,7(FU#NA+//TE71W>/9!_*3.3BTN*= A?'8I
MR*KI#72<3U[F@"FD8#^K-@5DF&JGBBIUI98=29L,H32RI@-0C?>5AHPHY0&@
MK3TVD>S4+'+4$R&>Y9D,)1<.'N2=^/L#I)*/"+F+3*1N5?Z;DD'GL26VJ Q"
M=$]RLI42)/A)CY>)"X#_C'G[U)URD?%)&&D0FD*FL.S5:3%38&LB%U1ITY#(
M,#!HGW[-:C?LD>S?,<Z9I>3LR:94H1O]AZJ91 P%'FZ3[*+<$S$O$&?DVZ#E
M[.O1A. 3/O-P.8W&S.L9OK:VO#6&]QM;4#<.ZIF9NO/>0?&O46I&=PH8_OFZ
M5E;>?SJ&,<_;4D>!+U@T]CU^&#PI\9D;5\1?49\@')MX=[ +3.DE[VA<"/Y.
M:J4O,O7/G&X<H [(V#65F&;^<-&F1Q;5"7 G)KRAAS8.AJ0P#VZQ9/\ZO&RH
M82J'+M3\D]3RS6WK2CK=8SJ:]U,)X%NQEBM@@/*[<%A$0_30.M^.+,2/V+B;
M4+SY=*?2"Z*Q ]YG7.WIX84(?GAP>BZ'8*J+R?Z+?7JG1^IJN?< M%#1T+14
M?Z$4\K+Y97EM;TGU+Q!;.6N9?N_I^7COA!B?Z17N%SZ/_,Q'_?@VM.AQ)&XC
M"N9).8D;."X_%.^T-X";EAY5XI!2]BC(83$20PNZY$'1_ALP15_!F&M#[>Z@
MLMF%PG,R-LVO1()S\[0S#W03*CY3M!5->#*NYND.Y4?3JTUNQXOYM9!I']@U
MM2?6_^G&?ME>^-BYR^VS][<]]?2KY^E<XSR?8\:EL0X<*-)R=DY E"[W ,\&
M(J9WKB&=(@L9F?*^.E-ZRI0.NF!>Q)OO]LX\*;L:/7((K$3LLOIVO0X. </U
MX?)7.WOL\BI"@Y;W (_?.8I+\XBCN[.I3)ZTR12K,M%)+,$I60F.^ '?JQ'@
M?"&A [I2))<%YG&-QG&JKI;-"L;RV087<X@QL.7" !"A\EW0<H17"U7K&C5+
M6=4349(3XKY0=XVQ<19WF:.UW6;-;]MI(OL;ER9&7$.*'=Q?&MQ([:Y6.KB$
M.A"-J0D7=AJOJR0WUB<'H=@-'\.ZFP5[<:@B+O"570*2EG_Z3-&WY;PP,&BO
M99Y)2%+.3MXS4^?SN$H8*B1P[C F.&K'4 O!XOI."&Z>@T6'3!MR_Q0]6M>H
ML5]I<0HMF+\D]#EQ&^*GM&O[ZVHW+*J+%25SNP)Y<9O'^2."W)/"(WMNX/:3
MMV^K[LY;3DN1+['"C61%/:M[5Z^^E;Z29(P/!%Y0WP-P26X_13Q&UR-$_HTT
M5CN@Q0:6VZJ^>/R[;&NSR%'EZ]%?.5CD3)WYA;7G.:^)&^!0DP3?S98>,P%=
MCZ.S0^H)T)HF12-L$A]L%H-WPL)D"\#3C_*"2ZAIHI$V$RE!00SKHBN6<FO.
M!O0DT5B8:TS DC0Y(;IM'3Z:Q-DQWTI.SUM*\"ZXTUL4KV#0IM1VQGZ7RV9M
M%(<F4\#-E==4"7_'(4T-:5ST5G,PFXT%/>K?W+.V&XBV/M8G/NVF6WXF[+<;
M$&6V0TH[-OR^X18F<7-V\Q0].M3+B4R9J8@,_^8E4+ZE>E6&_'.=_?W2,- &
M)*)L::>=N?V])3202VT5H4D:.,F=/!=/=,%^,GW#C#[8>7<\LB6#U*[T:ZW'
M0SO?F(*)0462RZ!:ID6=$(KO+F1DOSD^]F.?3.*^^@5:&9T;C'1S 4_16>0Y
M+CV3Q^"[?]H)"$:%1?@4P!J;H.;90.*P5^0WJJDDW-/R;\B3)ZL1%[9/1A1S
M/XP\'W+[9-M',&<N?9M*5RXH\^!"/"VJ3;R"JQ&>2T$?ALJ?%36E",MX"PL^
M__A[VM2WN8K!/$XP<E0LZH&DX@9>MKAI+4]J=W"+;Y7M"LP\P>Y@%ZS:(/."
MO/D0.5Q@U5 "X)7XL%=*:QO'3?1(?<W2Q;WP;V&?-[(ON62):73\IW2!44"
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M;S$R9KZG)!]\!#"$6=_AH'ZNZY[N0,UUZ<,<XP=?G%@1PFMG2L 5FK6;P:'
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M);Z:1.$N!>P)K86.7*'&P;0L"Z?B0A]0U/"G\'@1W]G2&"+165C['>G4CZR
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MG*%!;QT;DF[B$-GIP3G&183WA)6\MV:I<8("GW^[$-P$/:,-9W7[^.I+1;1
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MDBBMFF0:2,]IY/:&.&)O\RNPNO^V5GU<\9,?7I8%0I;SL[$'=^ST 7]GF4Y
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MF#D7O*T#(R[HEYV<&9O"5U10BQ+>3ZI >YKMJF 6AXB!<)M1P&ZD'LCSYR/
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MP"/@I1 ]DAT(Q_YPKPF5)S'=,@7]$_PF("BP+V.;1Q^BIOF=SO#V6X?NG]@
M5CPHVJQXDJW[7PD@L.34VWS]+)6[(W,B1\_(-U.Y[$"]LW#%MV?19:-$L:)0
M]%_N(P!3%RX^&5RX @/'__E\_K5AWG[A7M/+E1Z_I?G. G+FRT98RU0X%:2>
MSN'32X\C=>\=/R0Y+NLJD5"I[L;(%2?U*][F"F<H786A1D1'L3LF;"I1,C,9
M6)9M//'=<$17HA_6A*,I.#S?KP^Q+XF(Y9]OMM?$31XQ#';7UD!JD7VQ>#LP
M=T,^#'.UK30<6H#(*KEYJ!C:/N_\4V8FF*6V$.-V)V@VGY3R,B,C>;-$0W?]
MI:N0*\\(V2>; W!Q-V&I-:BU4.SG'WB3&UUJI&>V]QB,YZ!=VVSN?D%XW&3W
M@^P5%8#"V$"DE K$A [_%4>VI[/4BLS1ZTX5Z^U)9:5LS3_0,#.<+^-O3*#M
M"Q* A#5^QZO"= GC6/0L713?R&K.H\^$GLP*2J"5Q6Z;V[SY$&F]_<R;(DK$
M!.YCWME:!/70U(]:&48)S3<O92AEO.?3ZDX%DVPI)JLW1=$,I;^6N<2?[*[#
M<>1'H[%I6*WI[!JV.:X2WV:FC?7S_[YL!6&.J8\8AF22ZM3*+ W:@0R,I%_5
M4HL;QQP!8U]^S MPUK#XLY[<X:9X+IS394Q6(>Y:*?2./*.GGNKVVQY'WD/B
MDT^*AD]98Z&DPH!WRGV0N:IC)K+VUB5Q:RKK==:F>6.J.)/F:0G3*43^VHO1
M:<,K$3,E&VVP;R$F/"X'.J8]I-$:F"?>7.U8<:O9&N)K%/@Y;B@L:KP[H_^%
M;0'Z_>\G,<?T[T._ET$ZPLYT1M5:%U:,5LHZ(_(3SCVG$\T4LVN]K\@20GVX
M:$>>[9WS?N>SGK])@WG(J,/#5MJHTD*_6TS>U(JQC5P.T*9/I6\.JO'3G*43
M!VS]!!"SYE[JCNC&,[$C(]]#O]A=62.X(BN"[:UTJ7'"Y%^Z(H*+C](WAU D
M"'X#\YD5%%UG*M33B[_$A3/O>&8K0X\:A$P;3</__0\\0+_3^MK&N6M9+"I.
MTR-'6WQJ(GS6J\58#9HJ':25K"'A;827 386 ],%^UG#:Q<[RUJBW)ALO159
M&A0.P@,4-9_? EP&I*2=;$3X+A\!-YUID'_ED; +4M>W--<>6& 9[?G=0G5W
M0?ZS7^J>A.O2+MFN8_X)9_8&X1:M:)1S0$JK%@9!IM+%[[M[QC0NO/XEIWM6
MS0V4;PM8Z;)"JF;>ZC0?:^!>OA[!5;:HTM&/X;B@<]/ &S?5T/&PY-C:W_B;
MWW):TRS_7-[E8NW?'<SY=/H),^+5*TPM+;>/<C)<N+QKEE=>B&P-\[N13ZF3
M[HTY\,Y4V,@Z]25] 6KTP<L[8 *"EWPNUXR,=>Y"L$N*2:\ PJ'T9L]YH<GV
MKX+MCAAG3C2_[N;FY5@V0$R,#:%=^+=GU\(M-35?G;L[T_=8/4A8!?!&U%QQ
M;<):N)?[LN21O/&G>T'P_+V8(I+F6G3#!GC04+[2]BR(I:5EI51D_%V3F'Y6
M@B<UX3,9)U/)JQ79?>;/Z1![6; KU>^%<;:IS!@]FPEF2:>?OII1:H"(9[$C
M1.!R:Z38$LO3NKX@_XQ,'0JM/M%7HV-6]/-,6%!_FXTF6G+Z3X<&S(01OML2
M^$6<K"E,\Z1''L)$AZ#^0,!NO_';3/GZ3J%!\$!=;APC?4!4:(IT6S(S@^+*
M>G[GGB[ X[L)>,! CL/$S9AZW7&I[30!8??\5!S?]/3\K"P-%M_?''QNTYDJ
M/6_S+L["AH%,6(&I[PD"(TCZVN1/Q4;4GO1Z,''E6=S=1MI0K3^6-,VJ?-+'
MX*.Q^OTDZR!M:SWEL:T .7H;SD]3)@ @RS,T1_<H+,#HL[[:)Y!]G2>_ ;SA
M^N2.UX?6LGNP*(41IK:B88/>8RWMLJ5P8"X0H0QF9Y*]4\XNW59S)9B*$L,C
MR&C>(@"E3+.C1Q3_"GSE@IX7HK7^$$7*T=ZN5IQ(WG'@*]KF%C=SP^K7DM"/
MCM7W[0+)47$:4NO6>2]/=J]<,@T*A5&UM?W<[4ATJ6B8^\9]9C#F&//QKP$/
M3K_GB]$E31+P\S['BTBZ\Z\!(;#<T^;/3@OAHTV&*]1325K9,+5RT'NFZ;3\
M[R"]P4-U#@<U]\64>4%O<,?%:M_@-BU\NPC>RTCKD4L]V"IL9M6ELNVF2OW/
MZJL4YM[T5)SJ+&^5M>O>1^+2>TM['Z@N@<GOEUR9WD)L$1"YXHT,+P%;+.X/
MO%6GXRP$HE+'<NYIA$F[01_V?@9,/KPQ-K=_%X<P6]K6S,YPV/+B'(80]BM-
M9R6HJ"S\B A^P$=D'-%- 0$"B;J.'&S/J=3*1)O3;QV+66<"SR\7PO$J.2*;
M,Z_^)MX#RUS>!9:4]>Q\^=6]G,-/B5D;3=9@/M@NP%_KB28R\>*#FI'3-"#,
M^5NPIGD# C.9RSA#K<0\*%U2NB</.F&QJ2V!.X6HG&1N5\$/X(9[H?"S[N25
MH7UT8:^07QQMO?])?O#'+R(,?O+QCU8FFV6#DXX<3:=KO"E/R0[Y#W^E@''5
M^N.^ 3I@C)6,^6UI8JB+78:K4ZIRQG,N/=GN%^-Z%:%2_'C2NX'UD_^U(+J
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M)AV8DS&P6(&7K7B'%TUF2+&'PY]?2_$-+-X!8EGG=#27[D__Q4T3U&_K@UM
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M+YLD#(SG<Q\?O=2'1U?? A0;'A4]X[L:R?&>![GD5]*7Y<Q!1(85&3!Q6[<
M4LAUG_Q"2BSV\;8'Q:\-051=K.28RK^0-L3FPX/%?ZU)7WYJA^V9;Q[\]?^K
MUT R+&?B7?V.(K<WCQ+SY.Q.FS_&36P^ZG72Q7!,GSRIU0U&LUWJ+DBQ,>$F
M%?D6&?I$ACQ^!@WFQO;..LR2;9BO32 TI2R8EYJ::82+P+6;3C\45C%J!R6X
M]*.B(5:\:L0TDP-4CN6=C^LGO7Y'%J&BV1AAYCA9=84!PTD,6&G S/NS@YDQ
M)Z7Q5X96%&0A_MM""U3(5'6K09LQ)LK=6BLK0_Y/T9 ZE6:[<;F([!L=WLO2
M":FR=)*[R7\F_U^TWOUVW?]*6RFR0:U1M25;*7&%5#- 9X2;SO/.6:D)R<Y(
MC8[S6CCWE7#S-898R.VSJ:Y;L.LM $A/U2:U/F-JZ[GLZL[:2L,84Y+0CW1^
MG<Q)'E?^NH?U*U.J5Y56"U-#@7QS)=VVO$]BZ=/6LEQ':0G"R$G1]D0*)=+H
MD;<-OBXV:%.@/8EIOC!/E&F[44GLP&+BK\52 _+A<OD/'WGIMI\V'X?P@&\!
M#7]/=*XICP+N!,$MP$:)?O..?$!2,_/=NM>2F+U3'74HR:RF/XXAS2+/Z4)A
M.(%J2"IQ12:>> 4N$_?88 '7>)-Y1X^?0 2]3M6;F!=2"UV89^C.?N/Z145:
MS,EP0;!B)9Z\I3*B0.U40;8ETY#1?W8O?&!0>GRY8U;%QIW[YEY=(LQ%=UEW
M2_?$R/'RC,YI%F.!%(H?XHE Z_:3TN4AU\4/EWR66["QU1Y(9@%G#=_&A4R3
M&"<WQ=-^!$=["GHEGW PG]@ <D;B->_X\;=6J\" -?N0,?29T1W@W1A/68*W
M90UII?<.$(%>@?B'.GQO/;U>?\%2UT5#K1!PK9RL<+,DXAWH[[HD5$R\6'9,
M_\)\^;21I[4?=]R(IYITZ;YOO64VCJ' /$Y;Z)MJ$.3&!@E[!/'H,Z<H1Z;0
M'W7J1D-E2ONSF&J[:D$6SKG&!?CIJN[IUIM68[1?NSV /_KK!./A@I]#,]]2
M)O[$+<*:"$H"G&WLKI]CV;IZ>CK"OX_/KB(IHQW:.[LZ,VS:6L.?7M %.A0Z
M:GQ*NN?H;Z2G>;^7'<>.R;O,OTGO?EP#I;YIP;)5A2ST-FS&;C?,.&":$-I)
MQI0,$ ^UYN[6WKDY4&\X<E,_\LZ-KW0THLD/M:P7;&:Q]L&,VHQ ]4MBC,CU
M0VCP39V2TU>!@8W'G0M86L1'%&\R#K"\ 584G14^_C/%Y$49?VH?C<1MZG6+
M'@7DXDV :UH&:GS$B1(Y7D$S[;8]'B(AE=$0DR>CY\!2^>]B7N--KUFV)QW
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MD\&3-$TBQGA56U,1/1#^_1"[Q#1(779+4OACOAWC=VD\SER>@_R!DT33&WV
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MT83+U2^X2UDPON;->/>V)Q=>J+<.P @3Y1P@W.L#B45*A\]*%4CL40H_7?A
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M N=&:B+7S;]SR2M%_'&U;$UQM59_J?*!],""E%.41),(@"OKM;4 6[V?T.E
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M!"L.(3+PAG]#D$M:V8R%97.JIK_@H TM>Q[%J 9%M/J:1.[D3 ^G!R8+<4<
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MPP_]1_&M2ZQK*[.@OK@+<$^;/P9:&ZP:(\R/IN' Y.!K\_Y4/(P5.KU2K]K
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M_&G_#N"<<EOA=QGS@U22W[<1E7F:F=EE<G)R@A<V33M_+M*Z&CH[.D=7K'-
M;L/0X(_GT&5K]9EP+O2H\8*/-U%[A)JU]>K-Q_3*I!G]J75U.G<S@G1&][P)
MU<=D-]TU"ZL@0G6WK^QMF:5Y7H0YI ,%G;_2#8\=G0"0*N[(/Q/^+2W"1 K
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M^2VW\5"G1! E6O>BNQDM!__>Y:;(KHL@C!()%R9N=$ P0>2\ D/@\M(E2?O
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M_@Z09B> ,OQ*8SD<Y$7[+GSV54J;6<1WU?A35(U;CCH<Z'"0+,\3Q%$(;JL
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M98Y90!&H%NW+)=FOA_)Y9LY-@MO$Y<U89*I%&TP''"1+9KB&1#V:T!:($X>
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M"Z>[ZKB$1LU< ]#6)0"PZ#;LZ.#R)E18X:NB&SC96K>SFK\&N&=R$-9@=T*
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M*TL="^3PF9:8_+P;4&5"DYQ'8D5O25>K++<@/%'WY4S(-/#]Y\522P5(GI-
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M+T=]Y35CLS_UMHS]*Y!9_X5="P@-])?,9Q=XHK>@S5 IQT?B>B<C6NK.WV\
M2#PFY7F.+L9G(-K.VFOY]]\FUO E)I$@_=T2RBRN[V!%1D+P-:##XH<5K%TR
MLY'VH^XR(B'<^;Z]_6-_RB"RC<3-[RP>-1P71%>XJ/FBS5($+/XB*V-G1+U:
M;8I>ICV8(<"0?\!W/W MO6M<3;ZQ EHL.;9ANS4";&T<CG00,$P2Q$25\CV=
ML@L)4!Z*"QQT>#NFZF2L]Y$Z%IZE+U E_3L]U6:S0?^[QFP%1:O"O]R\<3[]
M-[=86,Y1!OW%\[;S>^2'?-B"I1<%B.?V1@GD#TF?2;5F!SP:ESN%Q=UW0;(S
MWF/ULQ%(5J)L%K6=,I-[SIK7(465#1@8,SAW#$_O.XXK):][]6&WA>C/,=W&
M-U;B=QI2AYD(HFJECS2G5=> &(#7/]HH^#6 U*5CI7).IJ[C]Z1,<J-, "TJ
MZ-O,5Y8\OA=I#XDN_$!FFVH29+Z[ .-^)_-HA'O0]Y>?$0,:(?BR!4S)G@^!
M:GS9M]?ID@ZL8MB4V[>?V'C&*6]6&'ZGZ9-L%LG$9VO\P [5-0"</[@'J[1N
MU6YM?AS+VSU&K_/=ZJO56EK^#E9[,AST9HIZ:? C33S4$YC6SW*#Q)<C&BSX
M +GU$W*(4GO.LR[T[U0O_\_@LF$!,DWY5(0#=42J3>BQ^[;^_MI!>W-KO0_E
MWYJD3T%J,HA%; '*GQQL-8K-9\MKR$2>4/PD\,_5G=F];%XZ7:>A\YKUEL]?
MJ\]-LQV]4#&,2S2+SE[*)HG>&>LDF/_/.'X_R95_V]QCUX!H;AJHI[@A2B<3
M>1,O&'TOZZ6Y9QEB_W4(E/YGE&!'TWRO%2)28:B[[WM5@Y>,UT$@Y_'I\K2'
MOQA:KJ_[<Z"ZU:D=UN#JDRK_I0.$JQ?3$0<Q0M_T+9NVQ08[V__^QYUFTD?^
M5!5%]#G>W,$4S5F5)M#5VM(YBP=5X\Q4##/I?FJ[QNHN65X#C-N+D:(N]Z]:
MDB"<R+38P=^T&%'&P5ZCA$G%5-:D40OD5"@YSCZETB:]^DPUD2AO+H_,;$K8
MXJ)VJHGU3,S>RZS^_8L@VQ5;<))I?>H%AZ56&MS5FF,3S/'<TWE?N-=-SX!!
M+4]W/*%*6Q9E*?,LM,)!7ZA[X>>$ZH]Z!*YDD (),C'/6)-V8?II*PI>+??(
MUJ%SU^8CEA(B'V!TR4:Q-";"/!OCNIDRB<M?=D.>.MF]LUNA):8CZQ"K.1RP
M#'<HS"(=#/KQ8OG0).[4J6H3_':T60,+ <G2)24RFW6_+<V5ARX2NP=FD_(
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M9.RT00#?[%A^F85][I^U:",Q/W5NL/=WP?:"\=GZ!M/!'VYKGZOI_%C4]7A
MSSCV>>CT/])8XB*VU2+@V+^3#Y*/G">^\9&FB?T;=:8('!>Q&5UZ0[5-G_,M
M0GRI\*K6B^X)D8.=]1A(O)K85I]IXY.7_!?>%V%ZNWR0 >KXU[5,^=UQFPQ+
MYD8W2[,5LM*W[ONV4S:=-LF&WY-S'9F>S/\^6&ST"AH?TN4G[NO?)A0S74WQ
M!%"J#YF,U\F_7?4OZGF\32Z3C:50LLL;4@!Z0V,@"'B8_]"K@M_3Q4MBINPK
M:(HO4X!?<3V0KVFWZW[,[2K6Z99UW$OLNN&3N\*_S\C<?,XI0%Z?X%IW/..(
M&$S'!)"KEN)I[ZV<N_D;WH4B.3UT[+_.KXMU^ Y\JN@K>]1D)_#8)_GMY\S[
MA0X;*QSNW9*D8!_+)=#.H@1HDTRK]AO 253I14V33J+B0])K +A$2) RG.<9
M"1S:1D0E.43E]: F,EON]0;\5J>M8LIS2Y7@]W6]V8\!Q6<$GRVT17V@''1M
MS'9^":C6VL=KTAX6EYCZ+=LN,8L/83_U+N4+7TPYI(N1D%[2<??SFD9\[^-P
MR!^[]0-LSGG:T2%KWY-\D]SQK,MF=0A1#PLG,?2M_W$\2C'J/F$!2'NV;@/!
M4??Z6D:.T:F]D_6ST&77RG_"X;J3-?B1#"(!J>6T50T74F6O>41&":F_B,A2
MO,/YM;Z)0?A\T#?ZKD_N57I(8#T^ A?L]I"*&\_7;3BU\I<1%7/!^MCOD06H
M)["')^M]FI7+Q^,GL P=%BCI8<U$E',J5Z&H$^$%D8QTO'F\8'1;!('LKS\[
M82:*-'R1S6*Y]:W!U.USIT;S0!(>$(]$\/+[D(\T9Q-7[_"R8OWL/SO:O]9T
M.#+.EQ6OV0N^X["<&6L6,'.P=TOI3HM=<*4\O0;0.T5*ZLR>Z;>Y5!U<N)=1
M+>ZVUC6-!-643H%XB5=F^$8?==$1L6Z??-/ 0N9/2&)4*3OX]%V+Y!KP=VG[
M6O.;DG;$.XEU"L@2=KMC@A[]ZE=96?=^)<9F<71W;TCP4LMNE,%0'/YDIC2K
MT*!7)''?N?:K!=_V#,DT+;C7F\[^5P>S2!'D7\=::%ZA( 4'9:7#HZ"IP7K[
M<*/L#&JD5!90$J*W_!JVS#2JY.H)G07Y:;)"%J3H7\X3Q8N*?A&1:A/'HCXV
M&LR=GI<MA>JYIOBWKHR 0XZ%:MM:GTDENR0\-R;ZDBIMP"#"&__,ZFZ]5]3=
M1//EWD>;]\TY,TH\;L4[M3O_FP/J-#@%?$L4](:S"\PTH13'&6[A(AKP:MG7
M )1E27#XG?GVTIIIN0$!B[9+6>P)@[-114H<WWG$K:>467^MD"5XQBTL>,%/
MU@B*!'VHRY'/J^6?L;F7!S1.$!*S]=S"F=%]+&0,6%=WBO&Y6,"<P)/$(%#J
MVD GQK;>!+ND5AS*869-LW*-]+>-P<<B@:N_(&=KO8>D)-P%4+2Y) G.&QC[
MJI?MG<Z%&RSQ[#+20$YO$ZGC^A=I8?IA5$"$^7YS%>_[9R3HJE)'O[2[MT:/
M&.Z;.N_O_8@C$=/C_ZX7W); \$9CK0QA@L\^2=BX!B!?H\-4H3,]5:\"SP.!
MR,+RX1SOM4\D.H8.FH@'%CSAL[HAD_X\/&XR9)8O]#6C8[.IH&U50Z69\=<
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ME@C[[*J&0 =Y.0/;KM@$7)7U\^.81RXDRM")B).4?@T(D<-=8'*0HZX70MS
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MTG/*G[HK[.A^#0'T]4S]T?^9K&*UT+O9R$XD';37E!]ZCY7!,CB[^=>O5^X
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M,='3P?_QR,SCMV15.7WA6?%K7X&\VKDC+XT_#YQV!] NJQ#&>6*MK_%OE^X
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ME/SO<OE_GJZ%*1C9S]+Y8;>\LU!E_P#6Q7RD&WAQP/Q-L@[%%7?%G\W(7W<
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M(Z]&WW/1(F?,DZ*55$_5Q28C,08%]Y=C>9%761#VD0TRJ#Z"C'WX#D#195F
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M00*&+HJ;8L/E$Q;W5P\[9_\FZ"5]2*A6<L5J(NP/4G*@_9O7^:W+!XMS#*A
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MS-WGI"_#N!5<@><",W;3BJ(8=V^[UJQKJ[$!+0J:TA^0IK#\DD_C+-1-F7B
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MTQ.GVGX[XT5X93_S2$!@YZFC*\Q)U?3KH@<-1JM"'!\R3B>:]C63J-)L\!A
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M#BK05=K=&>]64RT7(5885I;J$OMWE[/?UM,:G<8)V$@+'*BKF$Q(!/94GOG
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MX[O5&'W^NE[=\W#$DIC&'0#OOWR1K)V\@248&]3@!WHB%?C!SH9D2JQ\JO<
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M9,L$J^=+4-ODU?;KKL<(B4#>+M8YS:)I0$M;+:JGII4GHB2R0\7-A\GU9@\
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MZ@!OQRMIE;^\Y<<GY8JC7D*(NMC3#<.G3^M*S'QB?[VI21J# 6?KD7+GDFG
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ML4!BJ-.)3JPB1;?;:E;Y]E9X#U,TC.[L2X1'O9RZ0&'%^J [W+5M;GWM55"
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M0)JL6ZA7K!SK>/6^05A^#R63M5P5@]H+KW()9,O^>/X$N'6!(J<W_(EF@VC
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M)QM3_P</(I#(F4%:)\[70I(4_JO9G?$-RY0O@YT.0;Z-_&?M'OQ.T,J".G>
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MO#(XUIHO;IR^B1+R=JJ/?!54Q90D7V3KAJKMFI_T!C]KXSCFXS+Z4-_52 F
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MO'NV&$?D("37$._C8(H*U"0AY.S2G@H^,Z!73\1Z5E+0DJ&@V"M)('"P25)
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M;M"$H;1E3"'Q0;^O]TWXNM+,!CZPMOG,T7INE+TD,<L?O+8S_I5<\P[-]FX
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M^83Y ^J!-U-#!)\_&..1Q2?8U84:=W0/U<;8]=F__S!RJJK+OYZO&D4\\?/
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MY_PP/D*8:M6'&DR=Y(=/D%ON765=,[YMWYK&Q>3?17'0?W]//JD&@'GAJ/O
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M9Q_P+C&TL1%W%12/^CDW5'-$N^RW&B?!\Q) T4?(P]WJ[[S1X.00ZDJ=!+/
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MO2@+FSJ72UZ;TOP'N'C9V38CKBKXV9F]2&60JM7$0/40OY1^#Q"Z QJR.A=
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MR_-P:<+T3V#*.$9RS:G0@^4=,A3\\<3AY337"G>23J<2'47HZ>1I!#X=X#!
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M^BQQ@6&+/OAMP]:+\1<9!GDFC@M?3GDWP+," <R+,0K6P(S([@B^?U6QP7+
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M/GTUHP/7\6&L0-#/8(2V\&; 91!J 1ES>?OP L7H5RSD_R5.W#V 3$(X8H
ML8O*&QE/1\N@WI9NN5PU,!_T5*CWXD:M'%Z^RJATWF9 #+F+JRX*=M#V9UOH
M&'?'K]U$E)#ME6%(>1<5GF%^%G<$H*FZ, 1KB!AXR,0P&2YF)3U8'05&'H^1
M)]1P+/<3(:8I?&VJ+(U-MXU9*$Q^7>8))_IM@@C-+89L&@+SA(EF0B0>5XZ)
MA3H'+F >>\,]45([ER</L09AED%M^*?T#TD17XP#=CZ'\ _= UH])SRQ4!<D
M_"HKGG_!<5<(EUE/HQ$*R*\!SN\-IP[=2*XDW/FT)V6E@74C'^U_;,TPP_)V
M+G4PI,QWB8KN3;1NX%9A-'4"YC'8[5-#Z JX>> ;?,@;VL PO&:(Q$_$T*-F
M79:L*G-*MK.ZD'Z=";YV->N!,4-6DFNQP:+P.Y<3FK._ZZ=G()9[@$/W \.W
M@1"6*9MEETI(\.GYK;SNK7CHA&*+])BN^&YC5_D$HFIB!U=>$5X<&TK<V[:"
MEG.RJ4#KK?HM, 8NC'T<;W J=TD/*=H+-%-"3*"!OF)FEA8= R58=S>OU:@!
M_\\PNOYS#QB:!;>OH2ER=%%EM][!V$C%DYC=.R,,89HOC.6S_ZI5>T=EE'TP
MC1N<1'401(A6AIEM-I@'V[;U<>N@5(5R8'$6 W3S,[XX_L.,U09^4O< Y7B,
ML")TGVQS!Q:=A,BY/+Y+;@1#\W?:%;[MWC9A!<LLL=_UG&  */\K:&%F[TKQ
MB!ZCV5$*,MO,:/5K^_?VVPX$[K_IV5:3P.CY7=6X=)YW862_4S"/,^X!/%O_
MW8L%;:1CIL$W7]&/K;R,1NX!B)?%U^KG:*H_F-F<2X-[P HM5/LVXO][%P),
M  CZH'K-YGEX?;N*$(E@[6@X2RR(NKWO':(NT-'X8'%G;$W\/&!ES23P;'%<
MT\RU,=]CZ<4[6A.:7/!7/O3%0U"Y]X"I?N?B2R,,,^BWPUUH!?2<_.":EMF^
MW:??:*7F,/#G4X-<C76;XQ [;",:[?I?V]_XDK,.7Y%!7G\XJC/1Y5JZ(QIA
M.A>?0O7Q5>38AC81K]%&S;0@+]^YW@8SOU1[EE[Q<?GH64 F^_5OF7>&K>FZ
M9;L@TM 1Q?:U$PV7>P!1S*4?JIAVC/&8-GEW'$RD%W/V-U^1%F4J@_X-B]$-
M<7IC88E9IK?O2MZJ]ZLFNBM3SS9+$RH,N7&X%0U=520!/\Q!HO<)EKNCBFR,
MJ,%/"GWJ>B%@R8;80M@1MQ)8V(9H:'SZLA^]:1#!J<S.:/;KO>>BSHL;CR7,
M<T'0\3;+W9..Z_/;5Z%C :&\R&?!H+M\R5C,D] ?'QF_H?J7]BVDE9%_!*QU
M[> $:0R+S-H8H)F+'V-"T(FD\24$%0TYX&#^EZ/VBF\&_:)&@/LI7&0#1#YW
MX6#NJ8JO0?)*;%&B]8Q[V-IYL2IVAKF'QS&3Y\Y7X-N1*LWG@RJ](.03HJ1#
M 6FZU=*(^?)KGS/!BJ@J=8J/ZD7XBB,VO&^CWF-W"3*%,%B9#DH'35!$'T0I
M_B#DAZ9LV%TNM:$::LW1S*BYK]+#*1#Q$4J%_ :4G)'Z4CWZM;=S;LX;1!.D
M(#O/>:6Q\@?Q&F4]]VF>P7Q=A=@V]_:_Z\M/J8[]TE_>S8@'BX_ V>@,JF2F
M);W6^R4-YE09PT>7?,H2AN!LY]]'OQ?\7DZ.JU%_G3+F1"]EEV;G%#:+.(L*
M')?DG=*6Y+%U?F>^[&W\4DV:S[A ,-#T@]N/S)IY8?7R\C0U:J/$(*<_%@]U
M8@S!':MHGY((;K5"/P%!,4DAOG#A#=_Q&^'A!4B*QO>R#]W(M9,I))5^OFI_
MAN&M9'_TOKPTJ,'R]Y.+K;A5R.'81X723IZ_-'DLOU(&G\HAFL;(L ,5X1KA
M?@EZY('B$P/T/^1M8!8^XVK92P:(>T!L^V:(D18X_,>7]SVMO=$JY6=)7\:A
MSYKI0/2AE"B.W85A4.Q#7 .<SI<W]X"P4%Z4^*@"+M(CS2<>N>T<"EP2DNC;
MUQ\\Z8[GCWQ>/A/3U1M/O^N0+FF#XK\'X-"@NN#GD92ABV"$9G$RI' /3 >V
M+G[J.H,8N#5)?QV$Q+ZT1T;7WE2%]ZM5/D[G+%I2"3&=\C<9[_1_1AL?S.WB
MT1W_FN6OI"=J8P!O<?1V!34S^#$3$9A4%3O;SPY_OZB':]+@NI+R"%FI4$E9
MWO&N=4!L2/7G\'[H83IXO4VJ<^0@)]U,G>Y&Q'RF]6;U*=/,MY?R79D+OQ;C
M>9H.,U;_3_0^^?_5)V4B!T-(3R1]>GSKHA?+<K+3Z70J9># ,J"6LZN1LISO
MHYSBVTF3&VMOU:M.&JJ;;)0J5I_<(* -4&(FY[#Q^I1Q99),^DK/SJJLN--H
M^#GCN-7#!)M(?#C9F-YC-"'J]0.%;^9?9B""B\F#S4I1?6-NC<%J/:@:)+YE
M&T(]"E:,_3MO .P7^ $WPV3%3];==O%# E[7I_QBJ2.>!0K$U24E,F6TF ZE
M PM-0NK .I.0;RUZ$(UU#V4VQG2N*;Y!DBQBAU#>T;T"<3BNR.PFZN+KW(5A
M3'FY+!$"^J_U^]AV%?R<R/EF/VJ\INJZZ,/K$'Q:T)3%&/C2P)L;TX@<EP%=
M!2O>17Z_!RSI*U#-AIH^^/1'E4@A@WR!D=EIF(\/;0FGYH+$.:N:-_.RF$ \
M*\44 R]IP[>/((H%QI:,H7D-R1NRVH>*)X\.@)[*#3+DC*4D@$A":?60PG#A
M45"4)1/BK*PR<&G,4K1_#4T&<J\*M-)O0RQ\E@@QO7WW/90_:/%HFVI98/Z4
M9625]N8\GDJO];.<3Q'K7:QD"LX&T3D+V@>E 7OR74B> ?RD =:%C(DO0]E]
M1;^,',T(YE\5$$:+E^V8H,U[4>D#U"MEW^6?(^9UK<SB=T^>=*6-<>[)#02O
MHUH(%0ZV7R:J[WLG?Z*DC9 Z/#)*S,.$@: IEH*=*PI4P5HHBT^=<#BSV:BA
M_X&ZDT/+:OM>;Y=1EZ$2N783DUZB_;]YDF "16A^,8W3FB*,LAF5@FA[C8KR
MR<N)^P#":5B(I=0U@YY%PC6#^9O0)B!RD&,2D>I3EE5+,T$C6%&3+_ZH,7=[
M;_LSX[ZXKTT#(&A><9O3Z/GG8FK)\]B/_M\J4;>7GY!-T6A.Q9&=^ >Z74M\
MJ)X8MN-MMA6NYHX6"^[7BS:K\@"(O51OS.7<80IT46!7LT%A3G#D2 H>IOAD
MX#G*))@>F0&OBIH.R=,5'G]6O/'=WG;[PJ"O*\DF+7GXB26C]T]2M2"5*1[^
M@T<;VY-UX7&OO;24J"_>827R @KR[O[[7#T>,Y14%;IVD^@=[(9R@_U2$#8]
M'AD2.7JFD7CF@59%B@_2ICL/\"&>#^17_FK;^LT BBE:_XF*A/NWNLMCE_U.
M>5H15-.03T\+SP7;W)[BOT$TYNYZIH!(@OE!=8$+#V1!V&^$F_(9PQ'X,Y!V
M5S%97LX)_I#-.\3[5H3. 2!$OM8N"Y&54(/3KB=!QWGDWS:6#4D=E%.>V" +
MOB7P3Z\.&U\TR6;X=MJCG>#QQ^])OAQA"68<&YPF3#*-&M-M&-,"1*'4#OQ_
M?,QFB6-XP[P(#O^"AD$(7<]$!=EE^7PR^D"NS>&\G'$KFN"G"'"B]2+:K9Z,
M615Z#\!'/2 )B*J?&>8NK)XQ:@H.^W>(( 7#4@C9AWMW8M%F%(L?9AX'YSHT
M277=)9W"FU%@D!-R9_B-!L(2/@]BW#P&D0P(HG0,$%?1;'GCFZ,*'$C#7+@>
M"<0\D/MU2U]_]M*()0Z2K0OI.6HBL;F,\"L\L"7%@IL&C.TD& XP@?!3XIX*
MIHPT,*I+:'8DQ)Y8 +ND+C:O77)X+L=&$_K>#]CX<\9QCW;D+Q?]_O&8PJQ:
MY6RFN66&N<K;*]2Z#\#7(Z!'\Q<T?AZY6HR+UH5:<(SL4/5+(J,7)K:Q$.>C
MNK0FB/E(^ Z^CETY:OCR:&DDVW0\:K=0[N7JW[HYQVD(L__@@H=-AAJXO<=3
ML/"KE?^R(K0 (]+>NRS<P9*T0_CA8?-^/40($T[I?RL4LSLSXXF#^;X&V8Z$
M-8A#"R!JE=$W$[%GY__N 50N# %H 8M'D-U!?]L@3X\.@M/3/0FLZ_'LY"=$
M%6_LTI64W#?]>=0@NU&$KSXF_ITGV.U(.5A74HK"(V>ORDLD-5%FW5=7.84$
M_23@H/G;D7,2M'NKZP;5^/ROB3H0^^6R@GA@$_P\2LB#UK1[N3Z40G%P@=XJ
M4 ]>V8%4@,^O[+8M]K.X5[H."/7KTKE*-\!T6+K4B'-HR3?74H(U$4^:$!-P
MX20%!C=I4_^J^D ]J_R1SIO&G(.Y,E3T>CFM*7YLNWHF\!ZP/B#PX_POF-Q9
MUX^)-MWE8T.^A3+Q') 'ZP[O0?-(0FD&LF +B3M,Y[->R@T:52A/E9Y"D2?,
M"D%?OV4_YAIN3MM7],[5YX*K,J5,[:!XG,8446;W@(Z)T2T/HN+VW]M$@6C<
MRFDA^5_3OZ6I0II.+JIY.%SL6?CV^)/U/F+"0I]6I)P\4"3.6HN[">5S3V44
MJ#:PRD 9DWSAQE#O*9E):FL[OR"XR,=KBZ4+)<U"9^C5;!U=Y8VWU?2G?(*3
M&-X#S/MSZ!S[5H3V^KR!Y0?J^D>?#\,>LV+E 5H;3?9X*><N(I!?)FWHS;'X
MDZG'L62A:5/G;R88ZW*5<W_D1LH 9*X![/*):?N/Z'-;C\3TM$M,X.$LGX3S
MNVV*/71LE&S[!_!6?J[/R]!)VO)B2ZV0$"1)UXD?B!P"!%S"NZV9[*G22?W3
M>1XI<N&D^\Q]ZQ*()"2:K-5,? (\U7^&7$I7QZJQCF)5%#\C#C<+I33(D#67
M^-0_,L&_;EU0 )M'GOZA4V_588OWY#\@+.$%I'VG88RG82KXN'ABQ]!I-M.E
MSM9-&&UKT&P022DB&OYY"CMR$*<^399=/63A()<Z:2C<2I!&)[CT,8"D)/MV
M C]O@D&WL(^?8$"IE5\L-7CPVE-,9(20BDM,W_X4YX)O6^7+);:0P14>=Z!R
M.IA'AI2,3PLW,R.9H'*:,(QF;F3\>)^>.BF.=:M5-+4$#U?#8K2+U?H[OIC$
MAQ1],_K$EG6"_O$\,?FI%Y'[1@'3'DEQN.^B.;K,[QIN\7[K56/6P6VO<EQ+
MV(.-$-^6>'[Z.KG[L@4!]/O*V:CYFN?A6OCT39FVQH7:FO5"6 [V@^G2/U]M
M](\,$FZ\[4JM5;#;/+-"<0TD<77<>F+FLQ%J/&X@IDU7TG>G[IW*N>5:5(SL
M;P+P6!,/G?>^XY_BHYG<:NF-H,FQS*PF_3J?O"6$8E_=*8R+TQLF,I__L1D)
M^[77"!=SNP[E6Y+.X;7AD8N\MC68N@<8JE0#1+F=WP>7_!F'8!) 4/AS#\:%
M>/"CO\?ZT90#4M^\TPLV[XHVN-U'S_W=8<;6Y[A*.(28#VQDG;AIS$Y#W@=_
MOCE8LT/"HAT-L)WG?T1HG2H]N8K==8QM^D)8GA]HSW*Q-*N.<Z%$UAPQ_1$*
M7>&]70*_UVYT?/Q4QR$LT=U?]<O4N.WD!BK>I//%[*1=FCW!+S-1S-^N:5(%
M1ZX7?/0Q6\ "Z%M;D"13QS2'-9\0M (G*BO#&RL6G]$8V=V(_Q%P=W4/B'3>
M]WW@:"N4&I4,WP V:GGR77"C(LP8E>B=B-552F=>X#<6F@\:VG7/O(NQOGCR
MRT(7F<?AX2"2JW%I&38NZ8>;$T@G4-),3[2\=J"!9M2@Y$;3Q,#H+J:R%%C0
MKKAY!EL,9-%%;%C333M.W#9 K @SW&BW?S$8TGU$0&QP"#QEG6SX*?F/LW\[
M-&Z]*>,Z@HRZ'?91]K[EO_1\?0,^\8]Y5OSN#?DZ!ZH]6LL8JOK]T:]C[M]?
MQ.;@&4 QNI"0#M@1[9;UAD/T^O77UL]9!LIJ6Z.QD26RQ(#=Q*=QF5K 0<U9
M6EOQSK^DW4+&N% I&4:EZQXF>Z,?$-!)'-(2?FBZ^(%$!WH5MS:<YUCTXQA#
MC9J!"GH./Q5:\R,B2K@5C@&3RK_&^RI1_!3])GT8\JD*@1_CT+MFTR4UYY7V
M?+]V;JWIA.W6:(JT3!1E0RW5*SV4 @C];IJ_@\I162IM0]DAQ2TZ$6M138X]
MRYZ"#6]'D:Y=QDCA< A,7A?&2. IR1R@U][6D:>$A<0KB9 ;?E<;86LW]/.Q
M>4X&6[+4DY?5?$K<B?#V]@JM%(C!^*'9EXGI!!8@KV_!H]F2<E=UTD!9O('Z
ME7N C2)$DFVE0RZ$<0BRDI2<)RE,XAK*A$J",7OJH8:J1JJV76^*T3Q]?3I_
MR,8"$..Y-C5'3P421O1X$7?).=4_=WHGG$]-GX";FTY)WRD45Z*PC9:L7M(R
M*,;^M8H?>+S<SPW?H;K[>K,*BGI*CJ1I++]QBL6(0[9_YQ452X_H2FEUH)HD
M9GY)96#98EVHG;S/INSBD^*-"LB&]$W,#FD)C,CYK&\4?@77Z:4$_#%YJ E"
MDK^;(WX/D 0ZBBU04$CX2A54O$4%M&;_W,#AH:.7OP<\AQR>N-\J_>;].E*+
M<AK)DW@V7UQGZ=9;6;K;1&KF_%!CS]H%I9;,E_^R)$' D.TEF&*\^X>Z8R(P
M2EW^+9"A</%(BAPR(3@V70%ZN=,.&FIB/-Y!Z,@)"FN#\%UBQEB(T(^!O3L)
M:!?8#CX*--+K44%2>)H2&^S2<$SK91JH,W)34=A^\=LTN?;X20V=ZOMD$R\L
M=)09DQI##VMSG-1G0AW<GY]%6=B3E7U_E?A75W6:Y?<%$2B84S2S1MD!XP=;
MB-5]B+C,TL>TSYCU5JY86@).L4LV$LZI712P$!^>0/J?O2K9ED;EPLA(=<M1
MH2$OG#\&C EZ$-VNN(M#QQL:)0?BOJ+U"H1C//_)S?!K<@I[E6^B<F^I@WU0
MBM [C0DP>8=B!(0VNB3Z4P-SPX 4BN7=:G\ $X-'>/V\ OTOAI"?-SF)'H+M
M#Y3QRUVP,I\6 G';#S.[;FG]CC\] ^Q[E^DBUA"]>5%]LG$8I->O;Y^J ?36
M-=ANU4['<W+/C\7Z60.I+K%G2@W5[UE_MK;<@AEC:?]::+OV&L&9$_/O.>/P
M-@W2^GNP&GR!]/=3ME4H$AQ5@=P.+PG4T<K0=TNA0,'U<,SFX'=V0_YF'5M$
M*O$Z#=J0K1]P*VE4 X)C H33[HD56#=FNC:B"QK>H13HV-(;PK"CG) <PSL4
M?Q-^!0L+9@UTYT@K,/9V,[SKI)6^;)[,<:Y[/FRQ.0),W[ $*CTU &KMV]>
MLM"S[)W&=C,\?8$&+(&/1/#-#YHYNXAJ5'WIQ/BIJ415>SH;=[8!U(5EA%K<
M\E GO(&Q1;!M$X3]9D=I>3X&.L>OL_)A,\3,=,7O'A 72OZCO3CZ]=$SQ\)Z
MYU40@R31YCH49=* JM-=_?#I/[@;X!2U<$,<,[BTJ0BE&A7OA,Z"F?[*+<3X
M0];"FB3<P F*U,$6"+?!RRY(=N'EG!Y<.NS?-^&1(K$?32>+1R9_Y:S(CCZN
MYN5 QJNS/]I"Y"%?7T+\VJ\(L&[W'R!&(0H$4PO6[6<5L$(4N86^3DO4W)2X
MU9_J:RO%V67EF00\Y;^^O"L1ZD)_0/WP)GWI$ZR#U*;5V&%*>%H*_,3(FE3K
MG3.U,,U8P(#)N@= <ZQ(@K40TI?^J!U82JPA^:]M8831*%G<1^&X#[\\3SM(
M%$CTE#]T9!]KK)XXY.BMM=<,$\T)FRUQ]RQ)NO':?ELZ<VHOXC6[?H\<+^.J
MVVV*96A].>;7Q(RJT\>-\[-1Z/KP8X9>=GX/T"DC&#VO7$+<E*7U13-:,"U[
M_?%+[2IO/E(:E7-L;& S=\:XVE(<Z0A#EM@C*>'9,]#*3+?/HRR2C'9Q "F>
MN*-L\J7N#J_,M9'';_RY;!Q<N3CLQ$>!,CB.>TD,+]*E?LM/\"GQY.IK!:<2
M,?=@J7@1)NIC.5"=VB[*!B1EZVZ^<[?%(J 6^E^TO6=44\\7+AQ >@F]"@$%
M4:IT$"0J2A5!0#I$I8,8E18U)$CO" @H",$?33I*+Q)Z*"*]"R1!D2J)!8^D
M<.-_K??;^_'>#SE9R3K9LV=FE^>9S-FS-?+W'>:%H)9Y2\N:U0%(RW0QS'#I
MAV5Z\0OG!JZH1Q5&A7TU2<_UQ@5\!/ZK^LXDS@]R_PX2[O4;46P7X1:?\TI6
ME'JU[&+5PB$AD<310WC&/?%)$\8697#Q7%Q+J=-'A8@73B-R!=6B]I,_A*/.
M,W\K?[C8=<4Z];U>$7^5,7/=MO@WPPSE5JCFS^C+/<Q5!89W3AG<9(X-A;W@
MNR'=>CNS_>5SD(&2WKF1978SV:N+7UM*JR+V?YJ>B&H8C3:=-]@QE/%GYKW_
M$7:E$COVJ,BC0R#7*?&[CWC_G<77&J=EOWC[&1Q=&,V-Y[3ZST0^1=@.I#=L
M_KFXT@DDT.;]JR^U2-G7SO:-K\L9S7N^AB;R#],*VOZB[+-[>T8^/[&7%_V+
M]PJ4^\QB8/:9*6+XT_[G(1/6L"_D2P(3#UN&;H]EM4S+JET1_R+U_,UGSN6-
M7)#W2>,]'OLF*RV1PAJZG5SA:2[IFZDIYY9$YR5^RL>]R&SCNT+2&G]<["*Z
M:5#J]!CYT10?'TS._2D<ZBC+]F,EBNGDEP4SPL4+P99_^O,52GU*9W_3P.;7
MV00?+W3$U589F3]R0^0@QV/\ET'L;>R' I0@=S/"!' :'-_DU-;8W-D"W$U1
M$=1^_GEXP6Y[LOI2'0?EQ[T<#G?JYU8)NL$;E?GYW%XG9N&QD]6<)R[)J<>I
MB/D;A4TP8VO@@(K:!S\\=A%,. ;U(;QSI1V#N?LE'?*$]&^BX4^?WCW@N8TQ
MF-=B<]7*R/Z3 /(^!BGZ2T+/\HG1+_8^UCT1IF\WEG5%@T],G! R(P_2U5_6
M#3!1L>>OTHV:TK\B]>#NY3/7GWO+>T>=?^+T:_<8Q%8E;\V 42?):3W^U&^T
M%\:JE>8DYB%C>2JOPLO;&GXAKT4?:.3TZ%!'.+YRM]&!JB2.T39*VZT'%GUR
M3*](/:#S%J>P%3! QY+S]#$H.@[QWQ=3XO+NH3LP+FC]@4?(PPUI"O LG.-!
MCDCU-9HJ/+KZZ+M'C)(_2QL#PO7D!J #X4LH\8W6AXI[*T3>H7UN-V9CA:!2
M[3+S<U^C/'7ASZT:6BX-HD]?<&WB+S\X;_[7MC1&!:;&S=ROX"PX:FK_.F(0
M[8LAA4'[ U!GZ4NPQO*\A[7+"*L^%#_M.3*,+$2$I1WL?6_V-Y(B;?1#!7_K
MD-DZV9[=D7^2D12F7_;A7>.T$;1B1.131:6G:]_]8%7J[LMC4/Y%Q</;I(B4
M8*I^-S>PI%O_E(RVF^\RI)P+H,L!;K4(F".P6PU<75I&%(T-<H6M6J[@!\XC
MXG] .8 GQZ !L0L[0(*'TCA?0;FAYQ 3.7)C<]['X=&T"&TW3ET6-Y;6P\]G
ML9%&+SGU3B78U<6]DNW:W4'WK,K4?0D#UL5@/#\W'\?)A9WU 77@S(>)ODAE
MHE\*70XU:<PW;2R#O-@-Z/ 5$*LA;$#,@&1>1C&0&CH.Q3U P'N/3-^$U%VN
MHYXFWV@L!30C^6BWCT&Q"P-/<DHEKZW&LKG<W4!Z4-@6 4V<YX=9M+\ZU_8?
M2502<3VQP[KE#3X2-;^(A !AE0A["P!#M$D4"X]8?HT%=Y]!G/HSV!$9=]#'
MJ?*;9O?-O@7;(+G?U> =A601'NZI276TEW%7RE4Q!_&P1''1B)TMSSXI_PZA
M<[(0PAD8+Z VPB5_5:%ETHB/+-_K$-LVJ[Z_J#1,3;WZBNN"E\%*_L\"-*!8
M$A31(8V)1>D'1!QA!MGS; "!_X!LPA"6X $?S*=GXUU0"D#&):"_W+IZ?8+$
M]WVB=Q)7YU_B A>R(4H%6UU=#RI'^Y]-.12C<QI2^'>,^=J $;)3/TH/E@0!
M:QNNHOLNX!)#&>:^ON6ZGS"P'G]A<#V.ZH>/)35_KXUXK)>PC[Q<#BO4PYWW
MU&DI*W5M*0UU<_%0<6;Y,4;G.@9MO$1:4%S<_45_=KHA(/VB1T]PFZ\D#7YS
M;N3=<;]S.>EF(BA=HZ=^+.KCBIRQ=S';58\5 0^#X)Z3[0]'@_&LI]EU*%*4
M /I8]TGRPCYZ@^9F!_R&5X"%D4YS=.Z=%LF(/K0(HF! TFP(RX-PND*V!]3[
MCWS*ZWD\E4C6]?%AG9'H :QP.9;T/9NPJC1CWUY@WJY[K_YG\,2>#2-:\&(3
M[E$]R/2/ZQ9$='PW-[D4PF<LLKLN4!L*%42&3.G8\%/Y,GHBYI</D\0&]B$X
M5]/LL(<U0;K]EU-ZO^[-$U7MSGV< J&>J&&T\^Q'E!KLJ@02QW(D%.R,;8:3
MLLJPB858#9T6-8F;W.]DS:)-()KZT03+J/ #V(?XOP@NT$74;W($58@R1)<@
M?<'P5Y#IR0S$$099SNCY5W?F6;>")\)J<%Y2,3FT7AR1XDD*0H;FNKEYV,V8
MD?CR-B#@0)1H\,4P7C./>1TW%]B-=&NCE=7/I"=Z>YG0Y+P-]5BJ(ID/(DCU
M!6YNT& ]RQ']JH:]^=-+B$\;-N0F%/-D*(",# D3S2Q!?"/JULOGH7E1TE*J
M]O9DF5<5.PM.3AT!,U_,0 #=W_&[1.U @<Q5L-"^KQK(1<9L0T+\;TZB22I/
MZH;F@O6/@=YABC9I_^Y[Y$>1UI)3S]JTAB5>0UX\L#&!V2 1M%?4"(HQ,FP:
M[??AJ6WC?)=3[1:6\^#7OLV>Y'J"]KD#E.KVD<]@6G,[F36MO%(WKWCG2<I6
MZ]'$8ESSZGC<_MP+WONG>'\+_EM25_U>]&ES;.-[9EAQ4!%T%L6,L'?,)N 2
M5>XW9RS#+.>I)H1"&\(J/?UH]CT0T<,?)",^=ZH5:-69VR_\7;%T'Q<O1[%(
M/P\>JQ5E"8Y QBU:.ING*8ND99IR^!B(+_-)031.L*0''44R8K.BNS:4&:6D
M/=S -F]D2\YZ^"UAROF_O=/^K']/WC^K&0)+H7/0,J0&T0)T3D#W&$0\B/D5
MR4*L[TG)R.@^ V3#"32T^Q1*& @?&UB3)5FO/:O?/F_F5P,4.+\CM^24(>YO
M!C.S^#<BTI>_LUR,QSPV^%?/+MK0_V@]KEL8-=4-)HL\>T=6C#/R(XOU=<P7
M90\:-,Y3H4&/RP/GL0$92)5[!WOW[PBM&)K)VCS/D4MD_]E(#G\,)=RCVN3[
M($?(+ .5LI\CGH>=$PF/NC&3?O[AP@]\_JIBCH*3C'U>VAM;DZCPNOT2II$[
MG1'Z0U(M3[!)@RM$Q8&(S%<^<&E$VK+[:PFWFR]]%OE!0\8D5N=WBOIUJE<+
MKL8M<=A_S8[SU%>6H-1]N5V)SRH-TV8JD1*Q3BTXY:C :?M,E[E8[N2YG"CV
M-R?X+XA61B?VNA2,I9Y*53IX5>@0Q_> C?"\K '&9/IX,S6KZJ/63]";I7A+
MDK%)$[6ZZ<>%G'MAH.1,;Q]''XWXYX1^W;VK X(1 H5?'G#Q>/'TGXJ2G)\<
M#SX,?RF;F:AU?ZG=_L^S6S<>6;!_!44-O+X=XZ"]JMJTH241FWE;;E0$_JH5
M^84G[X8NM004O;@5]IT'_F#L9/%0XC/'JP*OSC,]JF+27\&]O)(@^T-?^%#@
M+;.)G)IWKI8D^WK4U;CH++' JF@WP-3@$2_H[(^BJP+4CR<A2B8_.LIO@4!J
MCE<X-C:')7IKQE:X@P:*UD)]O5XMYH),3F%>9#U:8:*+&)I_$1JIG.MU%_NQ
MX;3V_M1WI^6:X2JMMNK;@F:CFH_83Z3:=EW5U-QSS/1P5XI>NF7XZ*>HXI?/
M#ZI[>X69"DO=(I-'$5]65%*4WY\>?H9\CZ]68I7W]I)_S@<2]\)M0:A"-G:B
MF);6GJ[@O\UC.1G^ZF?\6I/"H]9WA6D_HNY<DFT ^1$XO:[<#;WRSJA-R/!4
M2:BA+4^+L<='<9'3J0M+&)*-&Z"-61'#^\P?1LBHID^).# /_="YZI.3.*SZ
M^FTO5W'Z699?NW0^" >:P<+CX$D1915)L0=M>US!3?.Q<<\%),XU-[0K'H2?
MPF*JQ]R"9L>JQ1<;2RDW4^^)^_%I?/HLHA^\%(P7Y*#'H_&$ NT6X"OI_F_V
MHIE>(E2C_$I6M_8'O?C5/X>")2$L/T3V7Z,OQNL/J I)MSEFGKC4ENOS][4$
MZ&^XLO2HF '(3YCIBC*LD8FK<"K>+.V5[HMKON+B)W2A7_/?;40TB)2P;?%1
MXWO5(G1-FHK?W!4'?>+D,9$1%F0SK[IR4T*@*57.VWZ3U4!0*U;C_7.0++*G
M4KY-@MO)0VY5OOM)>P*WKOBI$T;E^)7+.0U\Y,(/^J>BH#5H0/6I.M5 F<[Q
M]M-@'EVDHC_:V_;2,*T(J=2#_\$B,/GZL'<;-OR&R_)&;*/AOD.:^1KH1*4=
M5]0#]K%GT38S1\1_!=2L!!A7!72OD)W%Z62W^GA&XMF(UMSIOI=P&$&J?OSP
MOD$XR/O$V'/]G:"_PC_QMT7J-F0_R5G(%5W<?2PNO\R<JG5>XJ,RY;/W>Q[?
M*)FOB3GA>UJB'"+/OBCG76^U:Q<_@;_MG>K;GFAD4/ZQ?'^?&*#J^E"%%9QK
M'Z!R)297[3/\3K2Y+-F#)\)6>UB2N!P@]=1,ZGK&A^"QQ]^%!<>__GZ9&A=F
M?,<S1\C355O0@G6P,JC@:73TN=-G=JZE?=K2S?[&08I(3'GL[7OY60_[KQ**
MB#.OV"&81"_Q:N$@DG!)86SI^+=<QOTHZ;M)J/#=Q*4478LM#MQ/AWR9W!\7
M_QP&7ARGK;TQRCAM+NJEL/?CA(86_D[BR)WG9J/F!O7;BH=/YPHL_^V7VM(3
M?>]68&$LA"BZ0O1?-LO<4R,6W+FRY!TY&#7&-O+M-5IO?D'@,EP@:T<V7$5.
MOCU6N.B^([]$CQA?J>: L^63N&_"3)Y0\-;8.>8^5M[W9L-JP]S,X;PX-0BK
MF6TQV>)I\39W@'9 A6M-P;QOY@SR)3)U?X0502.^94=[L@7^BA =/XS/^C$O
M(9?YILBW/4[TW$DF'KX:F^P'%B>417P5.4KQ#DD1WIUCJ\N:*W\#PFLCV+9.
MMB4VCP1P#WD_8')AQC\/^>3/G),1%VINV[3L4S)Q^L#PE)H(>#S6OO/.K=[=
M(O/O2KV3H2;G(4NYO>X:=TEBJ08&]C'M+'I_+@BD\B1WM>:>LCCM]E: X)CE
M7T1D#;7K_#-ZXF7RB2MU/\Z+V[$]Z!&V-OUL?>@5<O_/5?G)-[GJ&E//.^[%
MP9")Y*RME? <P][E:Z"KW=*3GS/A=X(31ZO;GSGQB%-KF\ZS+H#(([_P3GIO
M_2]$UDRZ*^1TW9'&AJM.A3_?Z;]].R+)^![D4@\>[Q2L,.UF>3K ]O'8YG]B
MYN7/35F,4K@*]P4+":_9' P^]^O<")#KN'W:_UNTJ5]4TLT?(-;8>]QPAR$W
M7W)TQ-THJ#4:GY7I&H!M=BH(X&VNAC[[$G+H?.5Q%CK()8=B[M&9S'8O^%-_
M4Q233AD#5SZ;N?>-5N>=M:/Q"$H05;W7JE&Z9F7S-JU?32^81_/2S73:-2]T
M[SE!J?KE(HV3[[[+L,^^>+D:P9Q?F"S^HE).45'NF80MR- -%,0 !Q[E+NB@
M]IN^/XTP;!S]D7\LC-=[4!Q^XDPO\1J?;UF(%X/'6J9#:T0B]6S&ZGYL!TCT
MJK8]Y_KJ7'=C\Z3 LPF7^+0RY'_6>A:C7W,\/VG(@=B^Q$(,>I9O1(C*AE>4
M=FH^RQDV+TD*?QW5_LC\=$BH7)+^,"A]R/9JH<@7)XXJB#^"9&RW9_X)!M%]
M),RW&76JX,:,?+III-H 6[3)YE@0B[[_S#T3E8+K"'DE\$N]40X)YN;< N_<
MKVEQS_N$!9I?6\?"\BUNF,ZNRLD]_MPF+\A[3R[>]/J/+:F/0J^'Q$]^\:IZ
MS5S'9H5\_3-_8+Q!L$S&)=FT-#C _D24J7D::")WJ5_&8N<LD]S[F0'[JRJU
MMN9Z!M'+:I=[9.X[R%QBC7\8LQ/BDC=/5L\1C]=)K<AKN"PSN2JFZ,NOO_IL
M,HII9+@VJMOE+Q]!WE+^EJVS52>;IB9_X<M@FD3":1'7K<_F!(MK B*\F^W9
M 2=YJXQAK[,N>0VQ<8@/L_.^#7BXG6WIE:Z9+<(TM"3B[4SW_BFL?57YI%_6
MJ,.#1T$MS;?GYPMN^GBW6DB,1E41-.(X:L3KV%C"N$)^\(C7!<OELS<';[*S
MCYYX=M;HZ\M*9MW/[2=2GQN2KE?S-+CU<DA-*_SH-S7WN]U^Z6&L;^@W<95B
M4+M\--,PHOZ\]<DMCI_%UPQ/WG692]34E[ [OV)[7NK!I0V1/XP$N3N@)W.6
M08GJEQ9NQMQH(.4-8*2WCNKJ:\Z)YG?0HI^&!XF7*3G4CEV->>[VX$Y6Z<+@
MT5QVX).@'I%3^:=$]2AU>VDO7PNDX?S_QIO?D]$+\?#KXPUR)8D-'(,2C#5:
M!H00]D,HR?GN*>$X=Y. JI7FT=9/;#-B+Z6Y@Q_<> "^B.!!Z2GA\(W76\42
M>WP-[JOS9O1X->3XF8C$#!&4303B!N]4SSRL-.V6^:!_J\Q1T"[.W/1F0&F
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M5\+#;E-\*:IN"#NZ0N?P8O2<FY$(4N@?CT%2J+. U>%50(%8OZ*V0LS-0&_
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MA&""KX:(!(;30;.GYM3N^T7,ZT YRG/0]:Z<&EY5-B'W*B6'^",5>.=J>^_
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M_%M2F)P-TE85*VJ\.BFB=L:%?[#!3W63V=Z_=\R/A5TQF7X3I44?8= "8U:
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M,3D([:\YK)4YYS@(34)J1Q[S$*O-O9PK^;9QZ0,_O OV4E<B(U &'@*A7H(
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MP ]$((8(QEIU\"C2T#?YJ;D!3;5QI_9,]9(J*YD\Q=")>S<^;;E^/2+U]L0
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MC2E9<B0P)#SK:9BDYA$O^DDD-N7=:/^:4^]B*S$G2TDFH>91\J3VLSN$YZ1
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M:)#P/+QNY]G6<Z;%A>R1(49T^<A*X6Y;)>@>L,GF"688(]*[=UVGXSO.("V
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MN4V?](=(?OJ9O,@M-.KTHN11WUR$!Z%#(11SXEHME+O B_[7.C"AA#>APN:
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MI?.0N0I,*E0,:4[]8*+VLSC^F_M%'VKZX0*B@[#+(-XG3^&YL]:Z?R*41,0
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MN_* <#-^A]H@\$_>FG$-:F^2M^.-P0-W:[ZLAEF'WH]VUY94JCW5XZ#USSE
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MG.KJ2$MU,B&D-L*GK:.XY+D?;>%P3&5(G-+G?$'ZDD1\6')8@@C"RK+=^]>
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MIA?:86]C #^0X],7FT&10IQ)J&JY%5TY\1@,2SGLLC=.4&$KE9W8Z'US@%>
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M&T<NF8_8I8AP48+\#5B$;"8!\!#:-J6+HH:U+7,&:SEKW)O"!Q5BQIBH=$+
M^QAXG[TF^+T.+,2GKQ=&*I?FK<<\A.?LZ6PK5DTPK W(57WJ4.,0SIQ#I;;0
M0;TU=B@0VX\&4/0\O-P&C/&0+";L+0,3P(SE*Y@RT$LU>ETH56&H/?<T$MG4
MSM9@Y+NN>',*>K7TG,%R"WC&>L.].4.IS[;4CK4\TF%3[)F(6.9*U,XR#YYN
MYP^Q7J0B,HJHAGLO'#9E!L48;N9YPF<2F6M+E4*C=Q/D\&4 !VXCI<2I@V/5
MAT^?M0%+A&[9?SV4DI. E/6=I^EE):"W+Q1&DN&Q\A_]';3K&N4TST].CK=S
M=84];.40<G":$!79NES EV5I>?4$'P+02W.<W#YM9<Z)S$,S4?;:4[]16Z.N
MW[I7-^^SH_#)X8RRY%B9ST_J-9ZCY \ZP=+XI$@ZX(X&]7=T EZ0I,TCS!HW
M&0RHX+L+A(.,)7ZTY18#\'1[4;"$6DP07R)K8K:N]?AHFP/MZ7KCA+]>N16D
MK>\K@&>V#K&]'#_LY137/PU>7-?-NQT9MPNJPL=LP#+M#X+=/"7<)%R2K!TA
MAN9\[XV=7F1]3\5J/:Z?J+\SP7=CH46C_)URJZ6&IL\VMUJ5IG_:F;3FY1BK
M+/CU;U9=E\@?'&=2Z+W;3H(R@ @D$<$+_BCT$Q?[_2!A+I$]Q%$1VJX81X&Q
MW(L7PRCTPIM1?YOC:<[,I4E_9#;V(*-61E8H.1[/%:3_&@QEU1;(1\WJC3>0
MDEBU;MD69UI'8S7<&FJY;UX(JO"AT;*09#M/5C@!C3@+Z"-='-+%=\M3P@MH
M5*K_=[9X^<X.(?Y1"[+*E<971S+L=3_\M@OIAC2!X7)(FA-:_DJY9ON-C@L[
MPZW4L<K<T/>(0BA+2 T;*6R-N>5I,TA\ J +S7WO!"*,9[IY"^@%I0!G$SX7
M^+Z^()5D".3VN#SE'QF?7?@&&0;YAEL]ZHG^G1UK8AI'?F-S^]L+/*,:W8AF
M&W)6N#<$1%(44,E\2S8 1GHIX.XIM@5/%V-Z,C?PO9&&OY &S(UD>RY"2H#F
M-5IY99A%2VE#X=.O%KE]:8Y_9Q;%XZ4S%;?\2MQ,O]E&UZ!<)'P<$,+]%0K@
M1J U.W#:>^DWD2*0"#1,D<>98C(94S>$D0NEB?4=AS0P>"= $]H/%F(3:^#;
M,0%]"GT[7CVUROK][M#:Z=&;;7=RW>Z^+)WJALR$"V7&MP*&NI% S !?(9%;
MUOH!@0]CF6;1VZ^E<X:GG.]^#D<#I?Q+H!3'AU5R"\F4)9-:<T+;@;!;_ 0L
MM'V2-JHQY&*NI>&;86W"*@C[+<?"?W3X2_ ,R;AG+RU(1X9[:%UU$X1Q3X%G
M@)F@VU(>0O1A3O69;L<B@<_D?%;^GF^S/JE!Z"Z<[8=ZBP##6JDG;D_'2E5C
MTCO';/@]((J'P'<?Q^DO$@ 'E!QNG++=U(BL!W43-#=%G3@T"B&T#P&XYFI,
M6;<E'98PDD&0(EM/>X36MDY6JO2VI,A91*D:!_@T<QPBVU7\$QK*S!5VB5'Q
M\F0;OAL!DOB;!?\HPKT[T6"!HK5#$D)>O6V[X 99!%P.&-<4U+)*NK,I$<2,
M-71S^X &W)Z5_+K3:@ NNZ=IK.'GMZ2?VUL?S3X\^BU@,=L7^ALW!M^)O#A"
M\X&D4"QT&K(%U8],#Q8!S80>UE5N#00W/^$?!<N8A*T/\7-H]F(,I,[1?A@=
MPDI!N[5,3#D(RG]'V?[3*J5@-YO[#$,8O!U0=C<>!4G%"SE: _B9YX+%"PHI
M4:;34JZE:_UM<&5( FLM:$2H5"\>ML]6Z1V9'NM"*O,M./B>8!-RKO_+IA<3
M"2,WM8T $OO"BQ,(AZ0J3+Y1G2YOQ\.$L(2?\!<#?/DQ)KW7D$#[SKV[&8)P
M@T@Q?A+O*&X<WF;:C\]>=\KG%'23MX+-M4**M;N*[HN18E3_W9)R!:*CVUI'
MQ=*P^F(YYYN;7^8<A_?VSZZ;EW]T@(G%;L"V\[#Q2$4*X\'L#A#U'"0>YQ#R
M\>='A')+4?BG#.8>&8]."%((; ,E6*]'9+'VD[^U7$>__=(*^&O<7OD=X\E8
MPK\Q#?6K)2VO2:G?SKYU9K_#[8/ZD(VH?,IY65 _DUVOTKV<5JKW-^4LA9;)
MC.U&YY3O%#(A(TS8$2"1.D*390KNC0A%ESK&ZCC@5)88G5CQ$:RD.J X/H20
M"N>G'L\$SRRZ4NXX\T+_VO:?7<__U7Q85NQS'"'6##S"QG$$U4LKS*C/#HR)
MO,E#X(EU60F^R;A.LM+[WW]:%;B4G=V6C5?FG\LXQ[WLEFJROOV\ 6,FC;VR
M?K#>R-),L<K3BXLQT)ZM"\BK&MD?W_/>U=@&[<2JK_FS <N:W7V.9#5X^=6D
M83HXE:O/:E9/NM)UV=(!>O'MKJZ73$ZO(%XA;7U28?KL;DW#*B\%]M['P6W:
M!!UN.[K=W.=7"9#(71"N6A,61^:8E $Y5SFMRVE]]SF:ZK$W< I':;Z4XI]2
M*,2"NF[AP?( PR>>4JY'TH>VP10$8KC^=0I;H0$K^;X53BM!I9C-B78,9$UY
M-Q>=>-]2HS,:,K$O2'0PC/G"_.ZUL6..LS!U[Z%_131W:-8BJ=]6OE*99NI7
M/]N,W]*1R\A'F+_24W65JY=LW;,0[\*C?'Y(BVL$< J"W=:Q_4;X"4QL&M9E
MZ(#\$.=5^@X=EKT:]2O?+&<]XU"&F%QJSW=5]YF#U*F!.L>(OG./RC9@H7TU
MPPJ/]R-KGE7DK*'H6W,,F2/@?DH_/0O?/+)4/8?/P4LE1$4K]/OO:V74VLH<
M770;L_CG?-LDUJ<JXGJJADSP)+?'J?C-0OC$U[;;O6_W%ES*J;/A^)9B$)8Z
M2F=<QJ@?:OPC)6Q>>N4^N'NZ2O'+:-,)3Y_/534KGP)Z7^Z08>)VLSY-EANT
M^5']3$++ORF^,)\_TS_>_17C^O+ML0,MM9-4SYJL>P:'3I_SD7-Z\-RZ9J):
M^0MYKH+L(<@@&X!3<XE+M4 NJZ#7PY7NPRG)O?KPXDK >'3+HI:!QOUHK&=#
M1%N?D?E'X[KHM]<LO3\@I]E,%VW+?RI(^6B_,^<6J0J9C[.?/JEA[1\E;C._
M>]>@QV+/DZ+"4YZ%'1Y/EB^N63%):V)]FK:W.99!THY&E*RF2T1$UUA?ST-$
M$$([.O5Q =5!X<0]_]\UK-W.<N*3Z8=7:_HK[I[S?G*J;']%SD=NZG^22?*C
MA*93!'U$:B/#3//IS06I9$5,!753U/2>*U"@?09CJ1UCLU9\7=J)HE<F"0\/
MK2],X/J2C (N/6VUV><!71Q 3;NRJ',_6(V^2[K6XV>N_/E0'31\\.3=VC'N
M"V[TB5.%GJ.!']++LRUJ@ <6+&67OD"? 1*\Y.3;^8OE6B%7W+<G!:@YR+B)
M9-430@O?7;XR9##:-U4?_!!A'GCP4"\3N)(>Y?0@DKKVMZ.B3\3:?Q\/^M\U
M)=7B?<7'O7UIX<56Q;L60O-U#XF7'^_^E*N?XZEQ8,O;*]OT0LXV3WFTXERY
MK_^T=/K*>[I'G'>^955H41@$G;ZT0#3I^P3YRZMQ3=_RCM!(#R13E*]'D&O?
M!=422Z,F#DC^J62M+47SC/A8,)N!SL6K0:+\PV 1QY19Z#O D%4'B4<SO:9(
M>TMCFF9WCTTYD>ZD^>?:1=.]TB2QK]LC?+;=PMTM]F7><GEZ9T_&WJ308A_?
MN1SK\>9!G4;)K!PIVT;)YQ)[81Z(G4Y'_D6D'I9;#,[P*_WVRD1O<=H^])]0
MZY%0M,SJVV:U[*[S*1G[BBJS'Z_F&;N>2;EWW>R>P>]7?PQ&R]*/OY&/Z)WO
M>9(4>51)Y^J?,*7]LR:<:X61\T_&/ELD//-$_QN[]#<O 3<5C-B I151(DVG
M=?KAVHAH(O1N5AJIX9P.[:2[/25(AM<REW> ,<O'E.,<JP>P.\KB$^.-9'27
M,J^.O+YR6TRHO1L'J'#0:/OF=R5O034BFN>.F0J<P#,(ZN-H5><NHDPP9K&+
MUG_OZ6#*7(%,(/:@9;#JJ!A?5SUQFJ^[X]5.:$S2B-^?NGAUU&E@S=Y@W?X;
M0K71D[4#P0A\K2 K@0GKJR-NRWO;B$&@=Y[%5* 6 LWN?.@[^V,(WCNNWW^F
M4=75A2FX&VK@6YIM]NYQ*54A-C2]SR/E>MO6*WDZ^T?O2<5[/Y_3&W1L#Q]<
M3&$5T \;Z']/I:F9F%S,F16_2VI&[7&4/GZ85'C\C)SSM8NP1 MCO/TTC7LM
M^LFZ97T";F%!T/"Z_)FGYSMS;XY;7)S1Y2.BL>9C[HN*)_OD2PK]+ERIT8RK
M:'[]>IOCMG]N2%3HGR_?_RWU^+>,"R[G2_7\]A3;*!YRT<QR/7SX]K\+KDVW
MC^Q*<WQ(#(NB<4=Y-%XP[:/$_HK'*LIL6UH=T/K6T]F\F'7:;$"Z?H^C88_&
MV^-5F"K?+Z&2;,W-ZM>B99U%UWRN!1A6)4X'5>'86RP4/8__/Z>7_F/*_2YX
MQ'?A&6V6>U$F(T#G8Q\0CBQX)NU$R;.(#JNL?. #,93"V5[TY'@[?;K=LN2I
M-7-\[SU1E0/-;NI;F6X^*T5,(FCZG3W"JC5,B17&T\;O?V-1CUP0=[2<J60M
ML#4E['(T/?3MSLAKU\F/PXN.T?=F7OBFPF3I?25^0EBL(\ 2UH#LW$M"&N!G
M=ZG2]-WS"_\\< HC?$U"%(>@)-('7&_J?U/-V1'!Y-S552->\QC6GY5O7T1(
M,*JU,?E%YU<@U9[0A"N?E$,0SSLOX>)+OA:NLQ&6<.4?/:JT\0?+S@JNGJ78
M^E>&O,+VU0E'/%+(VI%\%0T/0379.@+?3.D7FCEWLSII(JOFYV_Z]D5_^]?X
MFA_^!=G1.B]?VBM.F7>&N3>.\Y$UP4=B]_J'?B"-[R*-WXX8HX;8]54_W-2#
MRILUNK .@@Q*Y/)VK%H3&,; *_$MQQ$'&<M*8*W?>"A'$D/6LO6?3+"UBS%6
M_+AP.<(M/JQZ_IUEJ<EO7E4INS=1U/'?>;030;4$;BJ] )#VQT4'ILGU?D1H
M!4X98A #NM1V-=:OI>%B@P9T[K=:M9/YZIB"2[4]5R.//F"QKN)[Q3AV<86,
MPZ]$]W-TW4O;\.G4TV^OK*4/A)[6R&NT-NHIWO-42NZ=I^O=B!Y*RYE* Z^\
M?:7(Y!]$63"-4TAU$921$GA_89$E;IP3#ROYBAR?OI'M0T9-]@7$F7F<V#@"
M_5@J.UK7A=S]K+ZS*; LJ?+A[N(CFMD&J?:;F3B\<9^1.Y&QZ#2R/9C/D>W1
ME@6NU3#A6;&,15O3[?AH*:G7NN^O=@:P$PWK%_RK>CZK$;_DR@6*DYZ]7]KA
M._4=@Y8%"6K=?+<!\Q>GF;<O%\?=^V+SU17,.7WPG\ 1JWOA9X'%+9X#"J=6
M'GM;5(E;'/5L/>$]DD4%+N*SF0_6<FN8$0/[F*01T\&5I FB:[&A;,';K][6
M_H9BG@-RIWY5GK((5;5PZ1]K7$]WQ+GCNWV$PJFR@\Y7^-Z%EXHE23#Q$N 4
M2[9W1'%ALI@&S_TZ4>31#)1D_.XE!$T>#6]O4RFX6MI6P_QL/W'AY7$UTUC=
M/<YM$L%K0N;]5="(8@_P#F!BYRY6/?DQJ\6Y,45R89IJ86*/%/_T,'7D[$C'
MDS\;45I,3(C%,Z< -C>]KK_=[ VG[?'>/7ZBMK6C?2!JP!HN<V5$F6/CFBGR
M[4^?>\&V^W7>VF>J\X6XJ6+#"+'*J;I9K&/:QWR<^]#BJ&^.:TZ)^7Q-(@MK
MP_JDM_4LPH58LA\H#KT_HM\S5[PG[_F0D@1KWF9$_ E'$1BM3^UESF4_4-+W
M>5JC'W]"$GW-TU'I3S?0_7\7)M%O?/C:MANP_;D?-F!+;$@:OZ#'\:;4^D.G
M* P._<^QX *AEHP%0C9@GLB<EBV?A"IQ/UD!WVV20 3W?%\JJH7&";+(\[;_
MFN O2D4MYY8N]V[ 9/BJ0O*=YU? KIY8A<LM=MRK "MF?%-'#CVM,#T_5?>S
M6,VH.@.R5L,38D'STWXT8:^G-F"Q <C44PL*T$@N$#_0.'_EL\50G^E--F06
M(0$\3VYZ^\'R*<V%L-046/R:9][Q3_Z_A<O7T'R%*4A&&1A@M_+@T#MZ:T,S
M+V%Q=DL;R 9XKIS5#1B5;<I-'EL=Y-LI/TY($BVUJ\YM@ [,<^B#JJV?2O-F
M5=I/H;=WI0_AP_" FRRXUW1I\R#.;? @BYY)V/J$HY*'#>/L^"D3PB+TFVH]
MM..'S277&] 69!3<W5),:#,>P%KZ5?&&Y1T%3+:EU?&?L43BJL9GMY,=A0LW
MD*ETT#*$NWF),08:@:LA8VR7P?U/7P.RQ][S/2NQYJU@X 9,B[3M*69A^/OI
M4;X?9P=:42]S]SC)C.59_=DY(J7"L@+HBYPZ4'9R>7_[%CL=2(HY!P?U2OB*
M!=SG@@Q(5#AWFB0I!D4#>K^>4<]"2H#+?<AF8L]]TC:FS*F!WH[,F]6 3#V_
M%)E)LMGQ^AE&/2I6&2SPY=BUE7)G%=Z;F#A5U=_-7**A[^"[6PF :\%''B0I
ME'K<3\ :.XZ)5P7+W$'D$[[5)'9GN1QG\A4CVXC(/\>B9%E>GZ%[5/R;_\R(
M.PL?FTLU?#@8VY:8)U9T1> F1,J?PM>V^\^I/#C&BQLN>(EG/*1KX"RPVF N
MLG\5D/;?5\N1XJ&"6E[CI<',_L/X' 2\@3:_'MP4;3X!S/W Z;]?3;*(AGN/
MM2:++^N(3UVCW19;P/.U#0$'%K=:N$P,P1V23^5,I+8.@.]"Y:I'$_L#AA3L
M>BU]#@M7?APHR42<>6Z  ^;K65+)G_<N*#QR2Z;+^3DM:Y9D:;S!AR)!(UG^
M3C?NC.#&[P)0[SM[-[#6A6ZT?U7#5V@"45?*K4&OQR[ S%%.G;VZAS(\&[<%
M;'P4T7YMW9(81NR&Y]6O+FLATQ*R5E5F4NHB?8P34N+6(S@KFZ>-#_*W;AX$
M@[J0<D+;)MR@[R3K.PBG14Q0BCC(HBB"Z!Y[$: ZFZP51 _$A'6/8E9.</9J
MFT]=#=H?L=8>K!L4Y3*69W4E:%Y\S?N#SA'UJ6%\VW>^>O)F_5E!!:0&"O7/
M4BX+J8![JZTWB55XAG4"+D'R''7,"&-'N]:W#&C/AY@&_D&6,YGR@63XC&;1
M[!#/&%$*YZJGW.R!9 ZO>BVMP'"U^&ZA5F84TW<@&27(YN^W2%I ,O?A!#)B
M)(.@A?5[Q _Z@' SN<]\;2HSO2##3$;M6#B<>9.(-:M=M#S<<(]E:&?F?/N3
MH)XK8R#J<R<O']V2J# 0+;IVJ'!/>X;?EUT7LEA.=_X5*3Q:T_430V02(>EZ
MP6.R(9C&G&)7\?3!]F *!TE%I]KK@HESJ(QEW:7U\B*FAM Q1N92=/K]M=.3
M=! G?^!VO08:[K.,+7L^]D6VUS0L7#X:.F'R8 ,6MY[^C/RBL\E(,=@_D%:\
MZW8%2R4W#I;Z%_W!5EE-N;_@W[<(I^P:J .L05)"L-O&%KS"1\;21JAM:&4R
MG*\Q00KC:&Q^V@Z(W5?)=./]@'9W RN,XGR6EN2ZR]*JK R(["ZUFZU 6%PE
M/IE=[(@I7YOT\=[#'<4O!$"2F]MXHM*"4@JC&B[&EV,6;/E!D<9?1.=MP&1)
M7H]13$H>61Y$5QF_1<M6'IK!$+K\&S*9N0623U]7S?JY*(UD,L=-W;7ADT:/
M7C7+S:#PT8G\<7QW7?">,:$"+@"-T'Q%+RX"?)@$ST DL=Z9#I!5-ZMMF47\
MPJ3U4D0ATP6SSQ'^%Q+SFH/0=(Q7X 06];3+:C"Q(J)DJK$E6_4B-"!<X.=(
MP&LD#0^XFDX/G!!4D ^ ^ !.7WDK1Y8*EVV1S83D)LP]D/TXW=>3LZSO/J^!
MWX=7WU6E<X#)S-"4>OH1BXDG*&FYF4YV[:<^75C22"[.B*\KM'!Y?+<!7_<9
M[CU<B1_*J>VA-%&H]5+,D@S$D5J_"/6P7F1NZ7=:0\MR!EWV=XJ]Q*W[V]8_
MEL%W^'[RB+O<@4XGV=F_K@L,DK&'DI!%?X0#730%#1^4:\32O@U!$IW,\ W8
MN8_\TU<=6']("IQ;>(G6EQV6>NY%<WGQ#LS6*?[ <7R+@K/ZJ2A8@-;!L82B
MZ\Y\K6C>J0A*&XHO7PM)=//<^*KMG/X[ 'PNL=]4 =,U;V\V:D(ZV-#::R\Y
M\9LN/D0,-XZ+VR[B#[9%:Z_J=;227[QJFS"OS:Y+4"Q%+>@X CY=1X1K[#;&
M5R\-NXEG$F8@B3[YP?#;$07,(N9]9-@&C&W[\$CEFWGVU:E\DWICZJ&W"4UK
M'GMFO_VUI1H@0)(IP KWT29WPCIL;H1 PX<OJ=P!0[A7P<\<)SIS.<\$.U,@
MA3T)VC)B%:(Z*%2TQE#EH"+EA_;N]^=;.CK':)];T;*S'Q=+PW/HIUIT_EP!
MA1 KYH7O=J1$COPM#^*YCL*.D_VQ5P3U6-MG8'4?6OD"&,^@9Y>;@&B@G0$]
MU"K$>$,>"B?&8U8[47WE>SIS ^2'$HG^$9[^M!E:Q#JNLO8$AP:.\#4":D'R
M'"2>)O25-Q\L1#"SVT;)RM@P,O#X?H/]O^3=$T*[E,V* _N,Y0:F3QT)K0+M
MW2ICV#KFC5(WE,X:KXL(*?9)3,!QH?V>P]-*^M[[^^?']Q):WI'O/XO<2K/H
M+#D!K%$),I;W0W3I9FX14?;U-8$S,X6-1^Q6Q[->?[_SC\BBD%^4\%7H+#A?
M<841RPY]C/G.&,@D&?/.XX8(.RSP\ CR#N!*U"@8P!I^<#7_BI;8DC:\LWRQ
MU]^R/6+.8]\0%:?[06?<%/%MZG=2R_VSI4E+;&0N_N,,=]-?4S/X!X6_P[@/
ME-:!'N+'-[%9A#:5/ANR*97CPXU";\6ZDDNZ#F"F>F=5QA%QMACT\9?:EJ-B
MZ::_/UM^_C*Y[XZ1(]/CF*UK*N4JGO&Q-BH9"9K@^4H_)T?%ZZ,?C9(/.V\C
MB3<>D8[B^84GA^3LW2*G>/G9(X-;BEOZA LG^DQ(I.4P^&X7&T0?#RTR^ 7?
MTP/&WDAI$@L^)-8*2UD63KV74*S<W<S.W&V!9%25&PD*J\%M#&0V6KP%GM8!
MS[V:7&9#\HKEV/8BY1!1P-#I2:P2L^]5*YG@V/R!:+_'_N\G"T5]C]#H /!:
MP!_VJ3G/G<=2Z) $6]CW6T%%P@;L(YK[48B%C!KX5G/4=',7LAF=Q[=CCL!^
M!&L#[?DD^%QLEC\E"VL7W5"=6H<]R-FQ^I1"*8]5P(BX >3Z:$1<Y*E%VI/U
MVZETI^+K_ 0!B:11 2Y#LGL%=W\C=_K-H.>+U^C-J&SUX9_B/Z.K.X%,JAVJ
MS_]DJ<29RCLA$U>3]6\DA'Z6+Q176A="B5C%)\P;4W!?>_?QJVH_SP.M(VPT
M\S1G_.20P9'X4#B5GG7EAWZB^H%;X7-3H\/AQ2>[]8Y_^4O+ 2;[SLX-VM$B
M7- V3"T5TA'40JKX;BN^.;T1?I/O85)4@^E9ZT:K(AR9M8;'8_*V4GL)ZBV#
M1EBSD/J[+UMO<7^.',_U>$'1=O,_7G&<OMXB>$AA/*:+"Q&= K@2<^&MR!Y;
M-XIL=P-6&OS*I&B"8F=([>0I>TW^D??V\,5&3%K/]:IWI,NZK&-Z+>._4SRC
MZT,FS8V=/<8+9S]]:I&+@+K*I4%I/",'V6QU\Y)PI)(H .XCN('8O0&3.%-7
M<Q[2&#<OD,-J>KBQ0K^1)7B[7XTGI#CTTC)SM;_49=>AGG=^+[G2' VY(AEC
M,CY]QCPEH5V$F8OG_Z9(+>&T_2+)&B\[%/9>P52?!%&<TJ% 8W&O4*45,-D5
M*)H5UXW(^2-A\,=SIAF6(F3TVX_A!Y_C9@C<RW#9#=AJT#OT3!]>2 * "\[\
MTFKV*R'GWP)LNLF93Q,"TG_)A>W!Q,<_RG>U!F@E.X^NOM:]IQ=@AT:UC-=[
M8ZBB]Z.7=Y?N-A [6R@Z^_B?K5MLOE&8OECS#5A%$B.6O[=%%O*9BG>$Q1]&
MI9(T'GU.>7U4*+FN!BP;,WD7BQ[-^R=,%>U#_$O^$!8A/1O #IJG1$5K_-W5
M4/K?2<N%C;^Y7_U8^.91.&GAKPW9$!HB- ^7,=DZ<WBV%.\X]@* _#L6IS(_
M:]L&O%OKV8!E0/H3=>91E!SM R_;A:P[+FPW9=+\'[X.,XJ-="?T"U_[4K!_
M9/&U4L28^Q9>B"/.%M^-PC-J_:>6].=B_T8VT[M0TV'""-I&8?_-<Z2!KWN1
M.\A;,"*!N3ULE1O\+3$EP2:<@FR$*PV>_70L>E?>B'91U/:T1,&C=5R]T9KE
M@8CA%6PC)Q>22GJ"=16^P$%P!)*4X9EE0W+8 /A.K!P@P]?@Z%&-YSS0C.4!
M.Q_62"I?80XM$P4IM+3?BE6?Q<13#W^K8D5K>(Q=FB-QE)Z4GCXZA!J_^*JY
M"0;E&7)"H!UZ&["[AA"=SG5%V&W :MVZ+'X7\.57YFY1>,=P0Y,4!9(#SQ=$
M<GM)XX@$ED '4O:Y2=X># V? G$>VQ=D#FWNQ>7:RR]TW*JL!T/Z[>7'&:3V
MR4>3I33!NU[IR1[XO@ARS&:YU@W85R'G:5\3%!;(XA=& 9G_V)3HH'  ,9NI
M#Y!+@_A0M, 3)TI\:<C<@('[4/S*1$A"&-LONO$,-F +N8!N2O?_::/E_X?F
M;.2)4KP]HACO8&!^I<_ Z,[QO .#>V/4M%3EU7QW'ND6/7WW9-F)^>EZKX#J
M3[(#RS-BD+CGYN5Q07/ J4E^-"!R#(S@J&_ L!2@Q5XL"2V-.!TKG6@;LVIK
M)_D9:\B2"&8Q/GT>:<!<7X=^'MNR?->LF'^#X\R7%X$DUW@[CEX4W*1$H;9
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M?YC#U1& .W[2E 25-#B&49;LRB<DY=DDFEE20XJ'*@^NI[0A2]#KI'+#LGN
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MB%[;BLI?Z <-9#C\,DP8ML]/G/T&%S0[*4/MB>,(W6@_17=.X&BB)1%T3E4
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MWET3)K@U<TO'C,04PE'N&LEUR#K.><@D-4,E'P=R^']Z006!&;'DVPT@B:-
MX+T:9N:2VG<#V"B3_N_&Z1G##\&TMT,$SR/OQKT-;KBD2V=%$,]_P\#)5T$W
M<R E(:KS4D'^08J?R]-K7O(R9TBC5!28A-'S:\<E?PW*TKB!OA?=J/'A$G7)
MNGY9RUP^;<%)?P$6Q 9=+GA/^\Q,^<QX.\KUE?XX,NW]PV)926_JAW4M2=]5
M78/>*U/1O61?^^Z*K4(9@1[].M]1?RCD=>60M_[0B/Z?D!5<3KK^9 CWWP;7
M\P9>%Y67M7(IRN.'_PL[.<R-8,I>->OJ?FY &+(?1LQ.O&<@<S^>9%DV@MO
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M@K] =#]8#\!^W2Q7&$G;?KS;^A!Y:ZV^0LTC.>W&:;P?+.#3Z-,WE;AK];?
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M5-NL[.*5>*MC5MN%XORCP_>(S'@]4<_:[F(<<>>'*'D1EDM8N^GIW!"K7<P
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MVN9'"5DHGK:MM'+E[#HPJO>]N:EQ\-N;Z($I[QF+"(GJQ?!.VF01.Q+LVS;
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M:HNSU@ R]D_M]2,H7@&C3[5W\5WTSB:.X5/O<_L2.R,M158-MG Y_$$DX$6
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MN-EX88%UUJ\U2)7->Y'AY/8MY\?BK?/.WQYMI9$O7A#^._ 36;NVM*<*&YK
MQB0PK%*#^)II$0:>O%U1BG_E;5.](N05O_' ^Q5TX%M;X!J:"3L^Y^BA2=7]
M=<TUT9IG,0<'SN!C+@287%+,71+AG$FSE##J5F*5@#$4AX .MHY;YF( RXX1
MGZ,#.W65H^Q8]T&%G)-YTB0'WK)5JS/>05'$_8S!<YES%Y3C]-.Z3G_5/B[\
MU.FG$/";K^P*G.2G2[,?"IPAHX/&[1W<@.S2 54V(%8BG',;$(85 \WW6UC;
M)1@[TPU(@BQWUP:D*);W$@\4 4T;D*-_\)1DOC!^L ,W! <=-G,T/+G+HP@F
M4^J%8'IV\S\N*Y**6/[L'!+)IV4>P-#:#Z<D(=RQI6;*EUJN7O8A/F*M99S6
MY!['LVTW("\*.(*_C @ZGG_'D.,K<$=-/$7 5Z^2U[5I]62^?*'P!N2'K]7_
MG,OQPIO5N[C2Y<SJQ0;6L)- 6<>8PEC0'IHHUBE<A49![#G]<@93QG&*GS\N
MWB+7&L[@*<Y,FSH1O6W861YI9I_F'2J,J5BIKF,5\.$>KI0P.P",X1SEO[^+
MBV/9VN>?9E5GM/E58L^2@*X//I&,@F-.P_5!,(NAAG--1\W+>WU?Z%7B(9V-
MZ-*>DB_W0WSVPDK/"J7>NWEZ#X2>'NO_7"7#P?;_G*@<NX\3Q>_ [>2U\.4"
M9J#CAD_:U&81.Y'3*#,(ZZ5<"J[%@K<H.35O<J?T\M7[R_6Z5W0BG4G12HEZ
M^PN'/K)GS'5?)2-;?SZ#?H"!&H)OEZ)0D#6?B4QX8J$&ZRE<DJ\'9ECG4B[,
MK]_)-\IB](MCKD7V1D[U2NP?^Q6P7*V_BDK1$1X)T^F^[Z)S/.C&XO,=\Y'5
M8_.;.9/VXU'DR;I91&<U>% P%G!V H",N3J&@_+[:G!3Y2Q"5V]9@$LI_3M8
M"VS#&+_;]V>JO#GL%((3WHEGZ2,76SW)M03:3,1AW K9ZY6@PYS^"<UN,N!8
M#6KV4/K3-B!;87P1?19Q-M9L'Z\*'T!(]98%'S(0&1N0NIXXK'X%Z,_LZ4PS
M[_16B#!8EL;4AG&VYDB9JW/LKEY-/K$E743=-1'O>/N"\&^QXLW<['AT%(*>
MD$X.+/?R91 Z^D$M =4FTU^LX-O/88\!CL/==ZMJ 3VJBLZ[.S3A1;)?M0JX
M8-TX_*N!I]E%$S/@A#+UY3RH*6)H9;S_M.?C/_F1'?Q25O_FYN!'@@=<X)X
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M.'5]@=%W^!)X=V;<+7WN S]18&+?4BS S2R8MWD$N.]R,ADXAX]#UB5$X[1
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MA2R!K,]*68A\WS3GDOZP:)_NW\TP&\JK@ ?CHXWP=?KOD*!F;OL"7A$W0&C
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M<*CAXO^W-:[_Y^L.H7(!,^BQ@'FRY2Q5T(JLA0&IKQ%UK"VWGY&JWB318$]
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M^)&LV@DO;6&:$"-(-YCZ;MB(F!=P03M@3K"@^@K\'DXHX@@EY=2N@\(IYQT
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M^^).TTQD7;J>5TN&J2$37SXE9MF9^77CI]EG\D['!0T?2++%[]8\Y$O>EJ9
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M0> -Q*W! OXB'9# M30K)($;V&V.P*&@]4)?+F/Y^>L$K9= S[BLZP5LVY8
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M: &* '%:!R,#;]<7>;J^#W*7,=-@$X4/ZX'?1)#GPX#QZ98*5OG4U%@ E^'
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M\KME:U,-M%@&/V_N##J0L/^>@5;@=2L39ZWKM)*@R5;ZJ>#,;]O;&8]<YO8
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M__VY[7_L/_8?^__'T(MC_P-02P,$%     @ XX1F6DYR7X_05@( "I<" !,
M  !I;6<R-C<Q.#DX,S1?,3(N:G!G[+P)4%-;MRZZ$!#II <%(2HH*D)L:!0P
M$1$1$2,J($&(BC0A0K8B)$),E+X1HJ*@L"$JG0@ATBM=A-!L145Z"4)(L*61
M%86P)-W-ON^\<\][]_]OW?-NG7OJ5KU08U516<PYQYAC?./[UDR0?I!. II'
M#KD= N16R $?93^ = QP!N3^%U]_#_*_.H:<]"6@M6J%@6*6O-Q&8(66G+R6
MG+0#@ & G.+_=0/P+R^Y%?(*BBN55BFKJ,INJ-,$5LC)RZ]0D%=45%"0O7M-
M]CZ@H*6HO6&GTTH=SW-*&R_I[KIQ^]$JTP-5;7HG^D"SW><OQRFKZ!NL66NX
M:;/YEJW;K&UL[?;LM7<^Z'+(];#;D9.GO+Q]3ONB R\$!8>$8L,BKT1%$XA7
M8^(3$I.24U+3[F3=O9>=<_]![N/"HN*2TB=E3ZMK:NOJ&YZ_:&QG=71V=?_U
MZG7_P.#0\,B'43:7-_7I\Y>OW[Y/\W_^6E@4+$&_E__V2PZ0_U?7_Z%?6C*_
M5B@HR"LH_>V7W K"WS=H*2ANV+E2V\E3Z=PEG8V[;JS2/7#[456;LNGN$Z#>
M^<M]*OIFUMQ-_+]=^Z^>_<\Y%O?_R;-_=>R_^<4&U.3E9)LGKP4@ 8EDR^,T
MX/^W_SUFP85#6^%SXZ 4D"BW"&$B+W&Y9 -6"H"WT)#VZ]<#+,3J]./I1YOY
MS)N+/7\MS*\FHE\+3G_QNQJE^L+][:5/1RWGUC_/OY7R]MH8YNM7*:!$EPP4
MF TV>PG723H*U@W:?B/H+TN!;HHAUE.[.@QAVMB,!T1[?4=76>*PV$M36'+O
MYF\37Z;94V?O#!L\U)B>EZP22P%%37Z#2%<H.-(@+FOV!3>BKC=&-$Q1M(BX
MMF4+Z#Y4@-3Y1H;IWW+GX?Q*!VI?/:S+.9G]"Y6Y=WW0[=F@[*V^1O(_:&Q5
M00JT5;A-9,YW[8:S#7B;$\$:KFO\QKJ<CH+=?*UF^^A\P<R3BHOG-+'##>S$
MS^-SGT#VZ.AIWW'_C[T;7=6LNO6XLE!X2('17RCQ/>;9WE&+2?7$G ^;H"C0
MG/LCO]+O[BH.F!-FKUC2-+7W3V!U"#^@K.*-?-"0L6>J1:[$E3G)9[*E0$?!
MUD9Q-F7R/E/Y:X'L5XPNR;.8=!+**OI>W9QCGU =%MC.5":97L49'NYW*<.-
ML'-259YHNR*HQ6YO(EY>IYS@5)N+]#@2Y0%A-"0%CD->PNV2@59UZ!'?W./]
M/,G=+HZ^T*L'Q0;0]@\4U24?'[HBQ.M^,]P>DU]W,R>;Q[_R.R+"\HZ3->@*
M[-)@DK#EN!B->-')2B+N %Z7F.P*"FJ>AI(-_8JK*)IAPX;7.H=ICXNGNK>A
M6TNC=+W=_NAK[!A0VO+RK!2XRTA!*!-[).JOI4!</_D5NZ2,,6V?$S]+0H+Q
MG05;1SZ-&=<SN)24UG75(+-+K&*1DN YCHV!I7SFFQU'KKXR$RN_8=?GWF5F
M*+LKAV=L>F1DP7TF_*3+B/68<>#AP8I/OG0;8_C)NC1!^_+PA4U!]4VU!18I
M9B>\#Q=Y*RD<5_HU(P44PF23+T$^$I4'_,"I[MFE*5I<O^0MTUBB=FCY3Y,5
M@R(_@Y00OE5Z"<X 8<R_&#UOF91CC5Z*7WP^1Z^C[UH54>\W?JWJPNFS]QD+
M>S%?"$*W\5*1CHYD->L]*7*28=$N487H_.0VDZU#"T)KH4GNA*[X<>V3!9C1
M]P]48 R#&T%G%U_>NY$7O.>O(U+@Z'ZGM4KK?Z[ZYDH'=#U=_H\Q/6_)<J][
M5?-@G=']BPMB^W[>\O)/;D>T(#OZ5DOGVS<_;?7WG(VSR_8YO^+Q;A-%-*,+
M ^W1$#P9HEQ 0F928,Z';\HB_,*2X7Q4HB5"D^AZHNY:#IK<P/=>ABM30OW4
MZ:U^EK9"SQ?K%%';7W>':>Y'7)!MW1]2H(U$%>GF2524^$S!4<A9:#?N!)Z<
M_%R:8:-*9:\5!3>XQY9"D3XHC6\& \0+V)VNZP)V#B6PCAZVV1M@9./W@)#1
M@RFFU;F*]' 2Y2FA-E$*H"!?X2GR$&RU9#7)><A:%:/K"[EV:$*TX\-&K*6:
MCWZ^85EMW%Z-&?>0\*O[Z*_1>=T-L=2-P8G&IL&P=TJBM5BA_2@1); 1/T)B
M\WI.7QB6[!0%(10'X&P;@QU$ K>$&CP2G;K>H8 ]XS?R.?_GBM_#33[W/]!8
M2,B^Z6A?% VR*F6%PSIN^WEPQ_VXKK.LDAEPHE?@M_>*GQ0P@)(&O#)_?'V;
M/#O<?]K='H7,U\C2NNKX03 /P#Z6)B(GF3#0%6XX4V]B]!Z)Y\1IE(<1M-BC
MKN4]/([::(_C.^T]'&^^79)UQF9.I*;=&<[!M%UOVIQ,%]-9K>;@TDW2OA*H
MO*WQ1SJ/N1J7O7,:K<_DSGGW^+Q?S-MZMZYE(J\<.W#FPP0:1;WSA8T][WBK
M6\$'])2A[=B_;(DB8H7LNH^$X3L+8F KR0;D@=RC ?JHQ&S8*K+M=,'>(5%X
M94"8K?+34'1OO%\W>?M 27]1_Z=!O)4-J\3W56E=\\4<[IH#G$(F&$+.$Q[]
MS@&/X4TH[=.U_*#2=ASCI@\!67.>6,70HK71'[/AZ6;@>.5#<I]2HAD?_6[Y
MS.VB: ,[CR<]I<GQNW8H#3"?440&/T<$1;+UW2(%R:X1))PXOU2<C]A*0@PZ
M1A83$1(IT/4>ND'"E$$&GE$M_5_KKEEX^#G,H9R4&=]QX?O>/Z_7[M*]R\'T
MC5-RDT7K_,\Q9#[:2X')5EA-Z1P+Y 6]W\3_S&QG9KC,/CX>$:6Q"F?^$J.]
M\?FG5%3*@KM%"EQOY)+'L4.?[ /%&TEZO'0-(\BAO6!W_WW$ QY'_5O!IH'[
M.ZX-H[_DA9>Q\Z>2WAAL_4L>$7?=/FS+X^LJ_VI/OF2]2O(]_'%CQJ?U40ZZ
M]<AUYZ^;/6;*VH&J;#U!R- \?)*W%*BC=,(_Y!UXSSSO2]Z!$6T=E&PC6DQ]
MN<=CIIGHUR?S/$981A@C'%/YAVA38?/R-EP]O^?)]V6?E(BZV%B'^U_C)C[+
MF0O<.S!U/K,C7)C>=XD\'].-220;\;O*&=_(^@/-1I5$SOX!TLFK/*2V;S?E
M46CVLOK00LR?C9EEV.TGV7[%-=9E9L0O!]7DY@=]NCFKF#ACTXY6>7X#%6'G
M"LY/!CS@4C,DUI!#B3^'=!:DI-7N"T"MAN+\-9Q;6_EZ\:/8W)5-/'G8 V2"
MC3*E[HI?W+!/Q< &FV*EN3&A_D=H=X<4T J7 F&,Z[N)!FTQKXF$3O(V*J\T
MGN;R/FK4=]C8PK/%_W2GXH+D3 8^PBTVA9=]^.#M3M,M2D,+/G>G,<:M*M\X
MJH^@L:>BT]#54I')\P'+NCQ\Z@@9_OXA:/GNP=4;V*OA/"P\*>N2W@#,BO.J
MD9"+_]A%W[+U)&DS- K&3_4F(;G6D"5_=QM,MWF+U9<!#@:$IRPPM;&W.&-_
MHH(N19:<^6A9]]%7<:[2L>S>X?-YA\WD!_\QC6+:,&7M:.Q7-TT.&8I,YM38
MM3%'57D$&3@BNS%JCB[\"#^8O R?N#G7+Y(<N##UF6&R<7/NLI!G55/$(A!L
M'U'";OGY&@1K5_+VKI=?*$F3]7C!;G%-J[%D5 HHVS!36_7>._J ,UX@/$.$
M 9F\;A8M9;@^)B0=82 Z BK.?)_8 3)2 M[]^.7V0O+Z!6J7,>98*\V#64UD
M;+CG.:KSK5=)Y 81^,KP3Z &M=E@*J&_5&A;(M'@'TOF71BHO,R:79I[S E(
MW_NSPK$\?MT#[]_$/<#<EDH36"I'/<(18\>:H:0$*-&ZZ_^Z\!P\B-@N*QJ2
M5@49YV:7E'4\/-A,2VM#2+675OZGN2\5TTA-DF(1,><8&$R?HJS"%NP8FHRE
MF[?G4E.OX.#:T]E]R5@KZSF5+P++$P*%TY]"LMG#IP=-L\_J/9,;Z<-L%VT4
MUS&#YC.9NF0+D0'DS\]J"]@*/0 #.SV)N[L1.C4CUMRGSI6O'J&AS,.U[M&-
MOQQ=<2'%X]V;'U$>6\X5)[:?0?OWJ+]M[BL=' 0\773_P\SG-Y72-KX3A9.A
MZ'5(CE!N47_;KHT2_VMLRYO8V7#)>AR?\_0PQ^IHWT?U2>Z:7S?/,P>2F D:
MT#X_P8&1*+PB^36SP371LNC."'>802>I05F;Z.6O]F7DI =3.Y$:)"?"%>:F
MNL3,AB)<H]:NE1I/B%3W@Q]\FU]J_+@C8Y+V)K>Y3;UZF##];++A@+4[5=-_
MFK%Q4T9]:LCYY9M+<UM^ZP\;K6)//O]]T/UV)^5V3@<>VFI2)G2BM%UV/"=;
M]+IX 87/F/.:1"5R#(+X!BQ,8H".1X2S.4L*)$>Z<WL3[99&8O#)S2Z7BK[?
M>8L/Y*46OAA8N[+X2<O]6[;]E%9*0H$5]%8VDIL4B*>05$.$.Z&1]@)=Z#._
M0>#UOE5#1OKY06)PP)JB'VKHSV#-ITP=;^J?8\"WVUBB+4U/-M=) =>[[,JJ
MBT';:3NYR,EQ*0!M[,Y 3M[A*+?:GA%%#TE,(.94:5>O;FCPDA?H$##M;6(,
M:B1>_.%S&/R$KB\K_;ZDW?JH/,R@L;54KWG%4%'Z,<7/=X9\]R/34)"5%!#I
MSG?!0*]Y==):?D,J<S*?J<\,QAN05C7R]?*_=AK'4/1Q:-O228QN9]A/".=M
M)P4T2)9!9\.;G8*"RK#+B9VS!3X/8L-N2X'B;,S<DD2=*FZP0EZD0)N8[72+
MCN4!'$Q;"@27H5[BUWI$78ZPV;I 4QL[Q-%8M.!U;XMPW#B,#F_5\WK<5[VK
M[2VY3?(!5N.:0,'11N.G<F9'>!^V%_8A=HKV\LWCBIH*AO=F>;0.;=_D8>Z]
MRC1$O7@Z'1MCN.'+#=55DL!XT22EK9D#NC#&9&K E,^<^MS;Q4B5 BN;44*$
MR ?T2OR3;1"WV*N%"<M!V(/#E9O!KVESL_"%</N18S^O^-$#4:UV!.W#@H8>
M0_B#B(K]2)HLW'OKLF4*4'5>Z.@;NE8R3G45YYR[WW&0*GA%NLP([=K3>]^V
M\V89\.QDPU[&PMOJU?71Z>;+G?77D9C6C?O'KPI'9]Y2'O#:*9-T)AA5UU4Z
M68S7(FV%]O%S^W%SERT(+YY1N9S9M^>SV8D+/^=PIQ\.D@)+/XYB,\SBC+XT
MU9XV<;/2A2V\>;@B;<O_.<:\-P\YKC8^@8+,,C[67YQ"Q4\MM2<-M9?KA1;,
MG,Q\LQ=(7#';=:H*J =>=5).V?R6<4#%2O'M2F0X$]KL,^<%[G:K]>,8>$RJ
MTDR@%>._ZC'K1';W' .Y8Y>]3/;CK:Q+JTQ.U!:- VF??E^4^]TIV^7,<6P.
M$G352'Y5:C5JB; 18>L&VRZ<C]HT,OOE7DK R6O-PY5/I8!M.WW)%_?[I*PD
M*QWM2J$>B6H.*&PW+#_6B$F3:)+?2(P&<X<Z"!:E,ZT6?),<XO#/7<\S+^&C
M-B2^?N:VHLI;7DG@+%&K%!<E/0*1@J=B*LDI4H#2).V&,L[Q?5C+EFVA>--^
M1[\@C>3FDU_01[U/90\$O)\-O.>]X_@;[[,5A8A>F;.#LOFC*3@DM-5@;H#;
MRQ8*KD C8%Z;K0"FUJS(->AWC(2G6H\3#O!A+#'*NW5@,7_7K\/]4>Y^3ZS\
M3B3Q-D<J"')L$W3OF7D?US 6TRF3O;0/5!:G!M/!3$.N0-B+L+*>IO.2J6;#
M3+%W9&K645=#M)<-/@4&X%QO2L3%J 5#JWM/L0)TW&B/DB"QI+C)XZKV9%OD
MNG"=2TPPE";24Q54BA\VX_B1@FW0TA0=Q_MZG;Q&9-,O"@%K.B3F64+7#K)2
MS<#B84<D,CZS^;N@1PJH>X0)^K]EHV^.:&.I.&O]$]VA$P=*TRF3UY'@'\ES
MJEQU=Z[&G+(L !']#(DF%*?JC^R0K&OD=W=:XE'#5X@%.S?G$PJQ,2LS<^G5
MW=I3'H.,PH$?OEY6J]_D2I*1DU0*Z (;G9(HJX+S'8T4ECC6%RKF%_*.&EZ@
MZ))W0ME=8T<:AR8'U+)\H5B6":PV]P=,'4*_GL:&I+V:7S2:&;OIS^'TK,_<
M<QV9Q8#VO<.9BV4<^ASN\*G\LZ2U4/+N/4$OJ_.ZZSW]MCK]BAOQ/*.';XS>
MLZZ,,6\NL*H9O"(%1@T$0=5#->)"/&C.O4"XJK;J+G&WJYGFRQU[3-??R+QO
M;"%:I$S6*77(<)4"[9GAFL]&@E]"%SFK23M'9!'4;,ZZD'7ZVS(Y,9H4RR_U
M;"P8F],JSD^P,^S8-JMM_J(^3MG?[+D<I9_!8F^B)M4:Z[!R+Y"/Y3W$VD=G
ME+*Z?U34-NVY2 ^<E/OII(![*9\)Z,I5N>@>E_N_S>O'4.[P9R_";K\W3Q]>
MJ%GS05&^%;5FJ5SWN-(O&:0I3,K4@M]I8I,@%I1QS;E+3R7]=MZM)C)FQ7?G
M!="$EJ3]_+IW.: WRW>@U1+*\P-1*7#$N@\?V*WTH'IWE!:VWOY=V;62WBAK
MNW[TWM.#U]R$VR4]T?I2 #Q)@;;,SRGSC2:#<L9(3I>$^T*92JT6$*-]. ?U
MA!A[!#SV6+*Y!K2ED[)2PF<7FZ[!A>CP?99?#:*'L=O?;'2!5=W+J0QP+PUM
M['H$G-R7F?,DX,"Z"&=+>M% E_'E74U]!+6;-V^F 1)_D:]P(\F7WSWKS),"
M"1-6D!RO5[N;QX2V1Q?SS<^ ^G1N_0O#^;:>>3: \T'L9 Z@G00T)?]O%Z9W
M3[SX^?G99M<#16E"G6/B))$:!T2/!_*&.+,M7 *T-URXXKMD;;^CKQU+;"31
M:\;H;(#N!97D[V)W^*DKBOQ@-X);GFF[E;1\(L.R>1-[AU<&,0IENBD3)NO8
MG8RQ0H$&=$GH(HI J95VP/6(63S]>V6,!.L'UOYJ:"BDR[ DM41,0V5/+TYE
MS7K_\?M'"-[6OS?QG<7BYNO(S"5Q.C(LPT'@(+Y]T@.ZQH]L-P'$N<S)Q\PZ
MC0Y4"D79T0!<8@7LYG=2V_UQW3!-.ED;&FN#*3N&J,\GD0(?0K;[W%%#5S"K
M]_W9$UZ$Z2[[)J"%UF;X""PDRK?!DP? D0XJVW5J(H]!'LPMJ./?A52Z.]WY
M\Y.4>&;(O'H8FIJPO<X"MR^DW401S,QZQ(IZFN[0%L+ C: OGO1/K$U^<_]
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M!8\X] !/[Q%<"_.U]MC\SJ_,TG#:/XP[:--272KPWZ^HZ_G/C0Q(QBD__\1
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MIZZA'69 5;=V6F&5%L6,;\@H[10^7W*ZV/?RLV;SQ5-:8C//_;!WLI2$IV/
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MEX_Y(^CJ=X7:S!HB<TBF.\\,2 $GO=_B$DK;-N1D?JZ,TC ,L,QJ9+N#!R6
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M=!_WJLT%S^!WV9?]W%[D'K*1,.M$+RAMG3#P"&U40_ 79,1WYR4E/B1BVJ5
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M#@*H+9)NHXZHC+L*69+,I<=9@[3L(:FGL-%3'&QYR],V/Z/$,M&\(KDC,>R
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M=\2:8+DM,)],TIY>@H%U3R($<.5+0<R#H&G&DXB;%HF4ET'JGZJKWQWDV$2
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ML5PXMR#.>-8G&H=5/90_.]!8VJYFT:M<8Z/+4VC%5@C7*C[5K<)VTCB)6BB
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MHF#M4!HT&KK54NE-Q$W7<?);>2]&C='P\Q[+,](T5U]_T&X:28<GK,)D;5S
M!EY*1F.VM% ?"$BP<>'A-$-<3+^S3M]^O]ZXTB;WVJ=W_ ]C%ER-S?Z!/\Z%
MW O]\:^-8LG\=>HWA<[);D>'86#CCT_R9$-#1;C#4!)W0>%JZZ7GMNQ4<[9T
M,$N+C-4^&!]->NKE*??6\]IVQ74KK?:!P1K4AY29F%NMQ;,7K7HRJ\:]0JQ\
MJ\I][&(K9BW4[I5UERT\_-+P9N-(S3M%G7Z7K=G*=6UMI@92OEC0=)K9R4Z,
MH=&SX<(S4#J7M&&.IM:!@=^F;O_.^OHDET7)LL'8-K;<+89B.H_EN2V?")7M
MNS;0S8]U?Q?P-2BC/P7VZ]F^N7]?W#:GI8BXHN#A43%B.>57Q?_NKG@I#-QO
MEXKYR558T$]H:!56Y728PEJ1O#US%;;_IZB MJ!%UB#]"@Y2$6#^O:3X_] '
ML9UP<A7V8$*4CY[/)TBBB@&-C7%D3!JI"9Y*"Y-%0/K+\S@.+;G0!(*7$XS!
M"CHB0^-O"RH20*1'DC2"5Z+NS#?*DK4\+2CE4!;S=.Z<;Q;O+5KNDVYI1#!<
MI9.6 )U\M@IK^G/=;V=)R+)=]"<ME);-WAKY'L%16UA7_=%W5LL"Z*%4X->5
M#HJU9E9\,RL>]135$8[TEV1W6QIIUG]H5COW%]+3;@?]ZCX#N%B&*= FCB-@
M'>LV%8!S_,11WZ]LWMX:RB2D:O#8E.>?_++(^]A=934M2W#'6>C!"<L<GEO]
M4(5[M?A#U68&!5/;>$:ZDPR<1\#Q*=TDP(7"&J)3E?O-*<I0^@7(EJ<9IT>?
MVC%D_.MQE%N;6]-?'C.>%^Z<\YU5R]$)O]+4E'SBBT&S6< N-R9)D6@#A?XK
M9Y@@=!4]0LE"F&F+,K#]O.@>\F<FHHLE$6),.@(NGN3)P5^Q(IM&$P-Y"#7(
MY6A_3[O1)V3PY4OFQUZ\;&-84/UVC"V\5%XGK",<'A:CB0-L);&,K_@=>RLI
MB+P)W_"*!$@FB:7&5:G([+@!,)D8V9L+VM,U/>F<2=18EP:QAC=I?<H%.K6A
M[58)KG1VH,1C;Q%_V9-889+LD)X.Y0$4[MX2@0[!$QB;?R10)0Y-;87ZT5=J
M,%V8'3:7T8GBO4*;)AJ4I%K%F?&BHTR!Y;M&VGG3E.Z7@0P+%K^B J(<SO.D
M#9J-M+<5N.?079N;TU<&GMQ&9RZEL^L<F(%K>XQ%4 4_!M+DD3;@A[HQ2B3.
MXP>S5'T@A2[H16OA)?&&;DLG+6DE>\&:RTZIM[-(>8K_&.+9G5NBQT#(!&ET
MUQ;SJM)];M 7;JB6Q;S^N I310<@5$)680WPA;HH8#WB_V#MS>.A_,-_X2F5
M(J:L99L4R9X0,<VT(8DILB^3)(:8A(P:,T7VK12^$9,DR3+9BV%B!M]2V<F2
MV8ILN2>9[LSB3.=WSO.<WWE>SW.>Y[R>/^[Y9^[7Y][>UW6]WY_/Y[JNC)M]
MB90PH)YID= (2UB';$<&H%*H=6,T]9BNP\0&R7CC9?S))V" [PB:[C76Y0OM
ME#A7R_6K9QDJC?8'NPU\K R)L1AUU%N'!)F=DUS9QH\D]!7()G ?L$AOL=*B
M#RHQ\0@(#LL++EA^*S(:0 9FJXE&\D0&8"$;*[_P ,QG9=^!2P2^@"61I.'X
MVYX++<GT;-6Y)?)\SL)!BLJWLN>%\ 2V+;B9:W=!F$>]9$C\6PL#869!)VX4
M?4"8_TU+V>J^I,TWPCL)R]JWSGN5D>FD'74X"[J&$ACV<A+O IKSCQW.E<T/
M93%2;_HP+H=M;E@XJN-"7*RK%E:*K;4'2T<GPAJRLT0&N-!N1N/O3I*\X"!H
M0Q;UB*T+?P309S6]X9N+QV^&&P.EW2WAI&IO_'D@+N.FTJOI R"1BSTWLN5^
M!:9=AWO6%,P^-T@Z4X?:Z>V'43Y/8I#BVS>!O<QL<'\48E,M-XA.5<9?'OS;
MWU$5T[Z#J]Q5M 4IA3];Z)=/N\D"+FOH]!<ZCWP=;(P[4C9DX#S-=VZEIAHR
ME8=4:XV0ML%[=AS?+1D//7%4!D(TF9"\*X"1"1_1P&FR@N \Z,TABQ5/K44"
M8C-(=@)GF<;;<<@NI%R4T)03W9<(MR['>=.)"@15G!OCW*C [GEPNUX]=S5S
M$CUG55V<S?;^7K.JKZGK65I1@3<'% B6PG_@[MQ\GJWPZ=]M%]A@/P5AJ1EC
MLP#*)26*-/&7'W2L0^0I)SE%&W^_U;#B_NZ4T>MUX[HG"W384$ER2AA"*5A#
M:S#Z=#O,YF!CU&"-<1CBHU!%< AT9*(3UMQ:2_!'!Y*3?R%WX%KI"(O6 >;K
M8E^K,337]?.P^5Q4JV?1T-F&8?-]B#+MQ/+\X/RQF,@N.=5DQ>^_-@@:\4K"
M>W '+I+-6%1D96>3-B+VS8MA79S+H4X.T0D;P&AN (IKLTJF,>)%FNFTCV):
M3U0T,*Z9/1QQ)O6%#^C>B3A<$'NU8=Q,:.6MJ9W] *;*-![O1,K.PU[QWG #
M>!@NH8T)&Q\32?GRO<6GEU\ O=DD-3^\$6C--I2GOP-N.DA;U(Y$5YNR<G"#
M')M\VD2+9K_9H[!?_-S7S<T-=J@%#3'G=H7OXZOYX>QX!P'CK%7D.(-M5!K-
M)DX2NT5:PJ9?:-GO?OIOP $NFA==#RYSVNRCBMP=&M\D=R., 84=11)>A1T3
M^HWM9:Q_O1>5E _Z.*KW6+-)\=,FH_! KAV=6$=^RQ"[1*K_QU!>H?#.*BJ9
M*!UMG"0Z!$07]749;\.??-,"TKC>+ ;->,?GB5#"5C VC-6WV&LL/TT,"%X[
M7%TY65.]?4/8E1QJU<0!B9_63('*EQZ!$IK7,DR!\<B@VRBQ3O*M.HS=.V$A
ML+\"3D\;<A67X^4 71-[MBHJ2<?57DHD8J"*=_W8^.=^T QC(KE3)#^ #"5G
MB$RYY8G$<.@XM/LF+YTE3=PD&J;6QC5GMVN"RKSD_H8OASRN-C#2IK<"Y 0*
MEL7'IA1OIL1&%9FBN,CDO?G. ^'YBUZ4_MV&"[Q9UG(G<@/>J(7;7L+\LM-,
MZ,*V2R?C(SEQ?ICG;2-X&[;#=\,EE=_GVM_$ZN18>UM[WSJ*Z+>:^.Q%UVQ,
M,P_ZLM*W])$?+=@M!C,!KS4H.B0('Q)$OL0%>'+S,IF^5C36[^0E@1UY*K1E
M?LH\35JZ"&6?&'9C\LR5HIJ>_,0_NQIMO!I>N%1X-9Z)"AZ\^]*UTBVB_$RN
MI<W[:+T+A1F:6VV..%T/,4D+=]0:'[GSEE-_-AQJT'L01^DY],'DPD&/[=0-
MR=49/0&UKU^^*DGL8 +_X"[0+]5Z%*PDJB$T$H^,5KM=*W>2>YQ#).G8"E]0
M(L6B,%Q8(SC*3>[0V#,LTL.ELWJ6%,L$UDWH)!4L;1V2M@Y1$.P64[ =H&17
ML37HR=*/"'V*=^86E0I+?0<6E_:VM5*":VK"-%M;<S8E\UK$@6X=DH(&4*C/
M9-Y^\ C+T=T)O,]W /69[C1LBEB5IXJMUUM\8;P!B&62DD6[N;"N?=P _NZJ
M:!F57K?FP?P.TCB6^)PQG^^5^2-?XD_Z(=E]- 9PO7Q1D0V3 ]&T;4S4!-'A
M#3<H57"492TM]&9=2=_R**P"+'2O'S ;HQ9#5:<^;BZ?)#_QG,F:#E ()/5>
M-$'WWSL"R;HK\6=LOX1I;Z27"SEWQE+M?8;.XJSWAG0:1_=$N4'0XJP+U/G9
M/O-MMDXR%0?>&XT&_P;K[[R>O%W[&5^?]=HZ[;7QH2Z6F[5T/A<+O2(XDD5G
MEKF5;>4<!,_.2L;3W3I;?H6>]TB+^F8S4N960#IZI$Q P_6Q4$NU_$-X9^$K
MO#07^K9X$Y@()/!6A9GM>IZX$.-Q%U8Y/12U06 D?$*0P6L.4XQ9;=*^@P*[
M*K!F'7(6ID#9,6IUI2A2_4M1<4G-=]YHA(WVJ,2*!E*8^7=1<ZNH UF+S30G
MIZQ#&AA+4$"Z@PAMW]:\=(>_):3V,Z9]'Q=+FXS;1ZMGZ-RU2Q)8!W \HV&)
M+5W5U;PRH'W>^S7>_REF3.4J>WIM!+\\GY3V ^$A(N"U^0:$?N3N=BMBQVEX
M$&#,BP<7^%H^N$\KS,?KD(W1U?J=:]$DFO"F _'.Q 4OV]H*\%97N\IKRHBA
M6>'K)8$%V=L#A8DI[5%HZE6[F5GW9&U2M$V]U$?LJ2*Y%O'X4 #+ENQ8GI"@
MD10I0>L0F8,(S1"KV;1PD8X@>!BKQ*%3=U&LN5#/YCOX.)9QBO_%T5\R7AT%
M,HA.CP:,\Y$J;^)\XG]4:ON/::;!_[:'Y7])H!56U:UH[D/+#47.GR;/#YE;
M6U=;GQ]:]L^:^;36R9-LHM2W-N=ZZ2[55'_+V<;*]3IR*<;.N>JX0!I<7H=L
M88DZVJW&!#9<95[0",*$\):Z"VX39MZXG+4.N;P,"YF6&L2R6BYA%U>7D\?D
MIT!WS\%&[5@V=9"NI/33+C+BJVJLVFE2_V8BDM1,6@KE7\=[_\TBQ5F(MD6+
M[>(/F KT\FYPJ\EO4XG!V9G4!O<NY.9FNK28GOXNF SV@XGI&6F+HWE;7OE+
MWS-[VT;,,5_7(3;VA/=)8__F88[]770]];?D\=\.& S $:U@L=C+E>?=!DVX
MZQ#>QK\2G^)>(3 =,5N6] &M.<AD>&@-[G;HM@"R]]G? [YS^1N7S^?-!)M7
M.^UOO6>O,E[ZQUPH,<:T6Y3@^Q*FJ++K$*QQ*A%P8( '8!D()?Q-\$Z)0&&0
M&(R\"VO([\1NM[@#3</+Q%3T/)EO5P63F1>*V4,GQQJ^V/TNB/O6JDN]\PRC
M,J<BG<!?_L_"YF./0#UL'7+@#IBX#@GLX<6N0T;RR]Q_89^M0_[5/[L.>167
M+WI@@_YD]__JO&,J_U_RU?Y3[MI'D-JMH0Q()D53=X-#OD-X4Q9:%K,RWS+3
M6CG5$U2.:5+J;0]-?_15T_58Y]/,08=]6N?W_3M?_HS\2:R_\CN(J40U,1R0
M8NG \OH2HJ$Y%!VF2O^MH5*7WTOA.N4_==3NFGEPI?7>U/0!W=C02^717T=[
MI9)NN&(KF3[9^NQP4Q9!X]-*@<_1AT&>/[SS9CR_$&P<##K8W O?Q[K>N_H$
MT\:''GRK\#I?XN1D6GU@,&.")N\6=6WUY=#S^>%RI\A$<\HWA8FL@ODU0[]>
MESS@MT#)E*? E4PO["0!M8T?E4RO\?IQI6@@J?XYZ!QCITOEGW^:XX#3N@BO
M^%%]T6Y[U9F,^_.F8ARAD/ZGX?9AK!AA"64/UNB*0P3A7JC.\7B,IYMYRYC3
M/V:]N,]U,VR'.Z&[K,L*S#=ELWZ?!3%<"<^Q<(%I&6A!;Q9IUBJ'W2KU#OZ]
M7.%EF&:OO>#KM4O).[ Q2]>/^:DV)1=&V-IU_8$'VO-+H70Z9HD<D&?I-7@A
MN,;94RJ%??#P^*DLWXW[^S_YGDAX'23T)O_: *!4T[[VON[+^'X]$'@,--2'
M:W1?F*W\\.**Z?5W;<^"7;\]N/#0_TQE.L_57X&-MV(_[M9GT%A?9I9TG*I<
MSHS%"[\5NC.BHZ/Z?N4--:HC/5[5CT05+C@ZG!T.>]+V:MC :&]K75O]F\PK
MS2V-;^Y,JZ;'LJ-S=)_>R#H5&'AIJ_D-ZE$J,Q\!!0N9V9^I+*=T[GEL]6I3
M\W"T#,QQN%E:J--9D,CY@KOE]"9S_-D=5MU]WXL/KM[KVKOOZ8X+A+MC?XYV
M>\JJ)H+-J3BL9('_"L7(IOA*K!/,HM/3?T7/<GO@57-XH/;NX;1$W)"KH53N
MGL(011U51^$GC4KRB4S,\:%<KW,OYGK9"8\O//:;])LT/B5&+7[@U7F;ZP1$
M*U>6Q$2KH$';S]-@36\G86\K\+& QDMJX6YNRHX]G'EUSSHD;R;.QK!TQSJD
MUWD2F?8\\@+K2*/N 5N7$+V?(;I-3UO>3;R+OF$+^L!K<56'E>3+SG@4_+K&
MK? +*5*Y7NUL-KQP ?,RZLG7,N<P\ZTZ^QO@+ASW+,K.)X(3H.*SA6(3H#WS
M)9(N_6[(<21ZZ5#GGR=$25S6IG^\IJ9Z#J;.%AQPMCV6;? BK>L?J357=2V;
M' OWS&$KJX.7HRY*U=7E5%5MU;RS)WZK)7GE#YC-SE8!>[NGM;E0NJ&=VP@E
MH&*^N2[TMQ>G;_^SZ T1!]XTOG;(&3QFN']ECX.!P8V0XE,1MB\4B!>0@!UZ
M%_X<-VBQBT#=$;[JZV#;3PFX]0PGX3*Z__6;%A+MU?C$T:XJ=XLC.:%'+5QO
M]>JCBT8/E.[4]S^(/,!D[ R@/Q)9&,2ZGM6*D'JN#_5TCR[;ZE]Q_BDG+;DN
M_OGL+EU=6^>,$'MG_)@+D;$.L3<N*<-NQFNRLHYDPRZNK(V?!3PU(O)Z#3RC
M#6SWP7L"ZK>Z_QN!1M/[5%$RWO)6UTN]$O4:7UTH^T?7^7RQ$K+JUWD;0AV1
MI/D_3C5Q0]<ADHFB*6(C<I$!9(O5.@PP[B;H@=Y,6%8=^(F8VBXFXM\^I5?C
MDF#0ZKM*A"W9]!O&2B7/,4-V1*/2EUX>4]Z.%=V&[ *[QC0/$E@N#@]G1%_6
M(8W-BYE\C$!N!+$!;\M]ERTF;HIP319)36">[3$<;;P=[S1(<2"/8R:>%[*A
MLE-]YDDE1+C[(<?0REWN%^K?V!2HTM'F:"$1*;[%S\V\4&&K:$<(6H(:8ISD
MA:3W0= ^1B68,/R0Y[Q(8S0@[?2>OYWLQ^%6>0G5WET&J8JK&=QZVR6%=P:G
M2@3SPE1QN)K&@MJ_%Q6YER8YR1W9">V:7$FZ<.]Q9"(<Q0WH;LFF;Z/(7[<@
M3U*T V,W%Q<]#T'X9*O,7_?R#3$I$8X,'MP.05Z]&I0W\_[3#,YK K-TL2 T
M9D^#7*\<_%ZMFE+F/R7[XNW47%\>> +M04U^<R!VG* R[[]VIN-=A4\\F'(G
MLN_>KN4\@<BACFU!*:Y2!0JQOM2+V$GYR]?/N/"BP6I3K?.4NMAS.#N7@BL>
M'+>8<87P147[B6=B0/ ZA?&BG82)?.(V\^R48A-P$ECI0F^"'Z_!Y;/Z,@F;
M!.='VA7!5IMA@<VS3&7W+U5SAW\?FIKTQ3!/C/[<__;ZU*\J]&T8@%J6$$B,
MX5&55/'WF%CA%)/8R])^(-(3P"YIB^,W&NQB8J(R3^6V!>--:SR.!RHN?6QU
M"#)_9^3W"5,]+G4Z>.,Z9/%=]???5, )%;^V^KPL""%FAG4Z=\EC%^PY2B?>
M(Q,/U[V[/I2W]5Z72OW[3Q=L=S8OZ;TE&FKL$#XFP$2#Q%=HP0YIIDZWX=XX
MA[<D1801GJ!\?]S71XR$XI;D9'A$#2Z 7F NV*);95ZDLL*W\!D,[Z_KB=QT
MME?KZGM&OSCR 3;&X]IA9+C^4QR?UPAD=_B>N#5TBW\8Y\ K 0M+1'TKF)9<
M>K-5<O(^0+']R: G>&EIYI%VOX%YNJ/9<8.\@0[UUEU]XQK[_^8J+\O-$^L^
M"@A*%*"K?!%;X[O V(@_RA0Z$Z$@EC8TC?.DJ(QZ93VXFJU4__QX26W:].!<
M=^\=WO/[W[3N0;\NBZ2V\6WQEP#R8A? %VVC\:]\L64T,!9G^;=$M+%UR/9V
M+:>?AOE+KGQ+:E=%U/)F@4__U]P3OKCZTXV-V<?!DN=O3\X5[VFV<#XIA;Z*
MJJ)BL[.)DL10+'@ G=X.$=B .OPSA'YB/7DQ%H!UK4.@JS2^->&3G[6PI"',
ME/<*Y+ ^AQG5-/:2-HL?NSD)C@)*W];/_0QFKRRN%26GD,-G[E!J<X4CP@8J
MLU#\L<A+*[< =T]QQ%5_.4_8+R01]@8SY!'*N-;.EJ6>1 &J)'1";%PO;0*,
M*H,4ZM#@C9]KW9\XYP:,<AP\9YK3<()'PPY^17Q#T;_H+=3+4%F0+U9S6ZLH
M)P8%SF )!YJ!W(%WX*@39KO\C+A!692P.-X7;^=1^/%;:C$QUR:ZF];"LX.9
M765SA_/RE,"TG?>@,[TT4B.OC7^:V-$.:\KO9*0H(73[UR'!R^/2';\9]3U=
MV5(")V#T#3-;U>8%[F07006=/+V7B[Z[.AD:%G,"JX0[]OUF[K>R#ZAH3+2P
M-&3P:%>]LVB,V, 0**ZPC!<? )P.:J-D9Q^H [TCYD[H[&)%H+P#FD)LB$GF
M@"O<4B=0AM674J"=GVPF=NRGP3CVZ2@'Z71[#='HUFB,RCJ$UN)6UX^J\.E0
M.?93]$/P-W$*+7K/4*;$\5%X&Z[&(TZ;L;?P%6$W#LD*ZBF$2>$8YX#?R0+O
M4E#NY^@"S>O73?,JP[!RW. [ ]:K!W3>Y[:6H=^34ZG2]:0J?!"@P\+2L?%6
MC,4ESK+49UPO2R<5OH4AL[HL!699KCJ$N7=^+'N>T_0[,U)UF9*TM>1-T_#&
MZI'GI9O;2\*TW*_9Z$$BB779G>H23-CB).# 9"127(VSX$>!959S(MRD%.P,
MV()W\"_''![P7CAOV/# VR[TQ7ZC,,WF/(^+C3D'GN:<L@D  ]<AFX\+[R,4
M<::\(?$C1HJ&3:?!W]W4W?A0_BV<P_'&,4$L)RZ4[N5^&ZX:P\J6F^YE$I/:
ME?."X4>98J'5]N'PBH]-0'E[29PV!4I\X?//TYVB9=$G&(0"XQOCE0#86V+R
MVEA6-&.3P&)@B"92:@73V:T,%? EXU1SGNW0K]X^N9 #^1.)3;GA<^5SU) 5
M[>:AI:7J L]-Q[-@/=3Q4+'FU:S&[QP3:4^"27$G>7%@Y7/!9?!&E.'-V5-)
M,!6,5]R/1QBC1ID6JP45C\9AHTT%5[_YYYS(4=J\&1*GU";93]3SDH1 S_P_
M[3'4__.W;G_BWZHW(@T<C]9#K(]99'"1O&X 12<GKT-V4!R>"6RYQHM]@+0=
M5R<-[LY$)Q;8+(WU' ?*V1;T6X7&&^<<@!>]_A&<S%BUA='KIUK0R8O8_12+
M:VR\@GAP'<('M+IHE\!"^!PA)[[0"7&4>K%6-MN%W0K>8J,2$ :]?#]P9M*E
M_177B(2MPDQD,A+)B[*/L+H.B7RG](BKHS=62B=W>5EV'T,^:]&?08X[,/NZ
MC>_ 9&9 (C>;]X ;L^3P8FYM9+A]-YC-E>@4J0++61R ?I]NT(!2],5YJ3J:
MTEMR,]*-EG>8)^9^F;<2/I??FX\M/P A?\H&=:G95 QQ,WYCOP'U<E\*3!JQ
M6X#F)G=!MWXW >O9S>EX59:^-'I+)S8:NWL"=,.JCS- H@NW473_8IB9#.+'
MIZB5P#S6@ZM:V0,W5QBIU&T$90$&H+1O UN!E0Z2/%[SZ)=J0;L*=RS9C*00
M7!UW6118]GVH,=V[-;"UZ;J7],/,*^F1FZ[MO@,1><&/BK%Y35@.=V4AMPG\
M 65ZW F4E& _4+XX:B22%9P!(YD'VO>(1E5FNV$PL/GM.F1GN/9(U+8P9)TW
M+8:@@J/($('.CPUQ)XSUG8?WYAJ=W?>=".J0!0K+O*=@$1F73J<JC?)Y:0,"
M+%\'S.=5U8)' !2K+[D:3P3<Z06P'N1.O&X#*/^4%E39$<FNK+8[/E!MOE6U
MV]V-H)GO[3 74_TX+9<_@ESD\)%38,);/WT2D]19 7< FCK5]5E-+=,;@1Y>
M^1VSR7-N@[3.F(2S\L&'\V(#@K#/&REN61^UZ^B+'@LX22:Q@YQXLR\=;P/T
ML=QIC.2UW]G1$I6X,7&HOFL&DPTAZ T_FG9K&R-'%:HZ9#K=*+#?']2:XQR4
M8Y\5>/_+;20)%D]LU*CFGQ?C*@HAA4MP_YMB!QU_CI41=<"4?WW^A9Q =JC$
MQ)N3=Y:-T;.A7]3M:*,%A#<UVM.D$-1XS94<W",CA1<GCL"&-A,."&RUQ /%
M(:_TV^\A=AQ%F%^4?]O790AY+#L.?QQ#GIC__[4,AFZ.O9H)I:[%1N'TH+U6
M1H5:Q-.\F)A+BCL5E*Y<4KP@=WKCX].0G&,0.7M+B*R]%@!1R[GI_M;O('<_
ME1^ J_<&[8 >O[9^8A!*BM'T@%O);D]:EEFF9SJ/7C2'W47*F$=/U,[UOIH0
M^[7#,GJ3;W]^OWEV9MX[]8+$GU%A=:/QI"J'*% :XT5QDQ>_L-$I5LN=6G5@
MXE,!8O076@YS4R=QV0PI.0D2&!P?@GR^QYM:7SN;U/<3(;_S"-$UY CYX\\=
M8[1.01=S+38=8^#T?JQ#;DD@JPFV>#]@.IDE%O%! OD$FH;RH$&#L6PP#((,
M$1K;#9KU1C<-_9J4=I3H/-@1%K;]XMZ]>\[9][;*:V7\M#8EM/1OL"&<%?-*
M8N#?RF9+%@"'8TPCWZ8V9L<3-H-8>HN6!5(V7&#"@BH%$Y4H1]GJ*F;#!M5#
M;*=,C@Q"'V=>Y#Q^U7B_RL4T0ZN?KO>U/D>RB<!9X\\TD50N7Q^O 6)8Q D8
M[R.0W>WHX,+=QB5W6R-3UB33V[5 WL"JJ\TP7(:%3O7*SG"LPQ3XG#M6$/UY
MD/"A_EWTWLFP>W(;^*9<)!L=3Y 1P+FD+G2JRA1!!5 6<P.H&*[<&U3#,N&O
MF[8)I9-MTZ4$GI=O]8_2*$-F)NG?NH8W;_)5-9/L-%'O89)$9BFIKJ^'I(0[
MV4':ODI,GWA>S7E]5Z1,&:5>(4Z<[&C?16T*.^SKI_\&'\ Q3O2")IHM6*=O
M]0KU;G/P;&AN"4K:I96#865^%?O81^-^\T@ U3>YA>;8W-(Z;"3:(#C17-=4
MUYC'^Q'Z*,I^5*&Y/E$K;R;LVYGC*J9G;-_*AOZ[#KE"32(VH>.)5\@RN&1W
MX?-JA#X*MEA_N1@"!JU#I%0[-3907G''00S&.$%IELZS^C)3&KT_MZ('XV]>
M_2WC/.-(4.O/SP>?0(> [YX/#^6=Q9Y[6Q>^VY=VQ/>MW*$MQ_Y])J<9=J>_
M?</$KO".30G-1SH@]R+^W9251'VP#KD3XZ5=3.9O62#58],0E@N,9F(J8>]\
M$ZGY1SX'ND/@-?+L#1AGD8 /C.#>1&>W:W#C/A3O "@JT#1-8 U_B&0S%!4;
M0%$ZB+LZY>%XW4E9_!R%AG:\4^+W$3 _L\*9?L0A303Q!H!GL(;LC*OM.@+O
M9NY8*@46!NOV9BS*7!'%$3!X?99R8W-M__ZZP>J&T*C^&0?+&?MIU3*(J/EN
MRHU[WT_.^F^7%6QTFH(50N0BBC<<W6ST[>N/77[;_F6NP5#=U QJ*E7"'+I!
M(/8<\=T+(AFJ\$E4FSM/2UA#D.WAR]J%<NTX-E^)DE%Q!'1\NQ8WBBBS&,15
M[Q-H%=BV5H*E70<77BU4LBN5A\I?#^WS]@Z]X;J,Q&"SVS4!Y<52<2S( ZW9
M)$6!UX"8*"+%VD)#F=O7@9;RG!,[_ADNH0)8Z#J(W]S:R'6G];89C7HL4F3[
M M@NQ)BGZ F,UX7[\VYC[\+,NG??1E90D]8A&@1YO"\7*:;86\0 CB.G".P!
MU1X3P6&P_OG)@)?CU+OP4./D7V2%YZG1B-( 3&B<?K#5=/Z+N/(SQ6O_VD75
M%MZW<I +Q=N 5+'3-J3>-1+M _ML@$QJ-CZ"U9<T+9OO6F"#W@'.=HT9!K'Z
M9.:F3[GL-E[UOAN5<.WTCGWOX .GJCA_K$?-O[AT-I.:>,ELLBR8--1)5/Q;
MR(^XW8RT$YSL\M,#*X'?3$9R@S=J',82WRYO'=+]T86%/]P.Y]K1OJ \AL:.
M9Y\>B&Y3HKEP?=;P7MWUBA1YVW7('HR&["#<']F%WH;W] WH0=8KOR6!>N6+
MWFRJI$.0Y)+$,X$> .TDJX$G#HBT<<DL#LBA6XBYCB%B5XA75XOR:$UTY1>$
M:N9:<?[AQ\UDK=NPJ;&[@EA6GTISFLOQ_ L!3(9"" $ZYE3Y)'1BHUWUW,[)
M=WBSWV-12T?,JTV<Y_=A:[XOQ3WU@YE<7=TVL3O^AFH^Y,>N?7N^7LP(VO-K
MG]K7&S/4AYA&U8\NW0C# 1%<K/X5JZC^TNL04'=LR32 >\NY=HR@A6G9 #22
M:- M'P%3&RXJ!8^,5$YKZ$MP+QCR<2B4.=%+:[9ZYH6_6=21ADGXBHOL\&)T
M87?C=<#C3Q:(&N;0SSI_Z3O))YA:OSK<;@I6/@UIUP1U)1=_OPC5. PTDC-F
MAA<%<15X*:1\Z<@OAHQ/J%?[9*5D:^VK8<<G=;G'D-6; R_N/AUX4:KNWG')
M>\?5=MCMR9*))=*0F3 9Q$%J=BD8R;Y%E$-VKD-26I8[B6I5A[UR[_>W[\%=
MH=D-K_;)OA.6!07QWOWBJQ-/O\Y;1O']BA=PZ8I363E5Q$(BX! &<P4C.'W@
M >Q;7Z1(7I]X%[EY'1+ZYA<Q7L4X?96J .;"S9G4G0(3 )F";8!*+TP?;!U>
M+>R3GL!ES5YX_>K.JJ^MJNZR$3,I\/PKPC[!Z4&"TG<>&KC V &B?<'5IW^;
M/891P]#J(>C:&ZDL&1<V+U^[+Z-0[+"ED^-KVG?C DZ'$I,1.D/PDU4]MX*X
M9U:\ZD<-5$\VIIK/-#3&CSR6X!M,/9'S/(:F7#^(*&_FH!7^MLR.3R-TBZV3
M$LF%L<;HY(PU8C(%!1 [;\9DB'1MBY6YW?6E.$G;T:>Q#5OACNPP:9H5*=EL
M>0<N<R>5I0X\+JC@VKZ>#!C\E5ZAKD@E02>(G'5(%F&WJ(<$N&<G4.7Q+EP=
ML5X,RA#I!?N9@J',CUOZ>GZW[VWKI]@QD?&\%3"!E3B3'AJ)A=YA<HT><#:]
MIO0OEPR9)83>'.N]&GX!M=*\Y,O?)=#@_FU17 ]RO$ +<BC"H!ZL6(=L6GX-
MS+QL:>Y"'N:A=F&F=R..4AKK:KD*;E:<J=U&A"_Z$^C]&8$/)V2.=M9!B%>(
M,@AMG M[[([ @BO?\6#^)QC0U82>4-$JU@3Z4@2[JU!7+^<<'"/LYB;EEH /
M'!XV.-DT591Y3EW=B-+O#0SXHG3^MN?Q*Q,;]@2^<AIXT'M1_LZG#99OR9P5
M7B$@F6K6-^'.>PG>XKJPLY-$FW!85E,1DRI+H"]S8>>%9/0Y $6SA&NJM;BG
MB\/6;]""[?$+IH);A5_&3M*;BO<V<X/2?V"KHX2(M>$Y>:VPW\L"^2%F4QM7
MF<<0/D-H$081!\!$+I9MUP%-1-:J4V_#@ZH_<O>Q>A+"!?9LU-UB8U*/QI&A
M=CF?D%$-V)# D>VY&/5'8(.IG'-O+@@<'ISP\9YPT.\Z!NNW(5JB@<A\P3]C
MG0S^$6H2:4W'@_R=1WUL#![I%9T-96&%CQDTE%"^ROU31+(@!^^X#KFTG;$.
M.6<BN<BP,_YS&OEW@@G B<V^.N\L4=E/[/ERTH$$4:][Q[+00Z1"7KV->DW]
M0?ZI*$*)_N__!,<&6D7V:K.B]U*D-?);TES04M4ZY&$2,"3Z*"N_#O'Z<4#=
M1O&/*]^3P& HB[831I RR,O+\;#Z[D?<\A[23H%,',=AFSDVQ:U8LBG-$,%>
M,JJ^^[M)6:G#OZDAML ^R/9&X&G.53EDY"?3QUML$I-,38J"SU>DT2Y6&""4
MY3/([HKI+UZPO@_26+IN9.?H$/-=+USRQ/>@1SD"C*7C7?NX:A8=K\]2Y1]=
M_'EV-M5DQ/3JBA:+4K_A_C61;&Q2Y"/.2I9FS[=';E#IVQU#Q7O;SMH:%55T
M.^H$84>\]'^Z\#+_JE.\AS 7&2"VB##ADW8H#L9"]7@77>'0_DX[05%<4R=N
M(#D]:&61G>V2?F&PM"EO1E7:N\)<W:E[8/OH*%<SYY3G<9@NWET\5BW^ N@.
M$'DW!Z@L?U%/\2'QB CP_8^)A2Z$!I?P2AP518J@C*&!T9-1RF5'VGR\2'=Y
M_Y"1!TJF8 KSVT?Y0.EL/70'+M2@R M'L=V?Z[6;H'R(;/M<KE'-1@4G.--Y
M\=KJJ\^Y=CL==J=5+:%DK,X7685.7CJ:J7OBNC#]+B%%XW!$M^J&3-9B^;X>
M9J3?P3Z<L?Z'5_B3^5<>V09ELGQR9P7G"[^-C]K#AW1ZKDV?S-?BQDXKP]RE
MT[HM\@.1$QYKKL PM21-_^L*WU6P'T0Q84GYZ(;F'N2=:2AW+)UB6#;?+(\A
M&,3W=8KVO'G3G/G#'+O5[N64NC-19LHZU8 <[A+TD(:GQX=^IISD5K*4[XI@
M)[D!=)*<8.=3@6E+4R.ED3M=PG8T8G2.W1A[4GC$T#SO#5]Q;.(85M/P6X[]
M84L;[5W0Y^4%@:L!YZNN*,F7G-CUV%7EG[2=U0EESE+/ M.?O[1(/G/(/=?!
MKJ%@6&"A_O:Q_YW*A+NOL7"Z_\K9,<4'ESV3E'4^ZGV;LOG'/\*T\T()#:RX
MR-H^\:S2):3(8&^%[Q==YXS)M%]#0USTC&[H"OF_=EE_(GK'D$!(8Y"J582]
MN$@V-3EZ6>DSSLYFJ%T#EW^".A*M.EZS-_O"ZWC]]-?)XP+DI@&_$%9G+Q9K
M9N0B5X+$" Z*206?8WS7;!VB+CC$#4_@H*1#O'-D@F@M1<^K+QJ52!E5%<]_
MLO=7=KMN\2!25CAPIJIJ@V*QLO4[[N?W;PC00QV7:A]>&S:)/OC+1&'^HW\M
M7-1)B=7B6$5^?3!SM^S]8[4WKF?"??_\3IS>=ZU9AHFCIEKJI%XW4OU0_W@L
M^55L4]A#-K +,QN[EP8?,GA1:S8W2KL$D)7/&!7KY<)"G2W3HM2]_CGK$[PF
MH[@2N Y9RN3K8?R0ZY!$SQ>B?M(V Y%F^O=?W4!N3V:#Y6K4<!G1Z"CBM./T
MO\N//G5@M-*OP;Z9)+&I".15(JAKG(90)8PRME$O&]_1T!*2&JCRN+SW' \P
MDT/*$&FW-P.S"5\S*1]-.^4F@X>ZX!I[N3+47.$C=7KBMQQ>?X_&QR4?SW*%
MK[%.<AX46T1BL)UJ<F]<GERU@6-L -?55<\2'215_,U]_S=SMPLC5M>*SF0=
MO%NP%KX94.Y"[8A<@Q]]>*T8DW])#^B.[,Y6IWNHT;3>SP'/3][)\W\4Q/#N
MNKB<\O9$6KG37>!"K4OWI=I=/OOEBD+ M'/YBR.*;+1:NS5.GQ<.[N- LV"*
MJP>NXDV9*)F:^FK[<L)JH_3,Z2<-@PVGOVK^"%_-=,(9F/V;^D4K?Z>RYLE7
M@N\@C']3-+D.45Y&:( \%*B3GV*&'9]E.Y%+3Y;A&@G[@^7 =<AIH*GMVOW/
MX)@[X$J_,>;XM"?4X.;=A>WV1QH041?I<[H4HER@9[BU3!Y;[]++@%HSM_V6
M5Y70V1_TSG6^?_FD%M=XAW8)49X87?B\DNUK%7Z^HG=_Q7#$5Q9L,XZ?^3K
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MO(+7C>O>:5:\E :I/II;-'S/(1H3&FE8^2=O$(55&/3^-^+1GMB=!<J6,+-
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M5AGB#_LGD$\4ZT@87(@8O[PPE GO->AAZ;A#C7]VC)BGDV2*]G6Y64S<(+T
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MSGL/C>/9WU><A0_%U*O,K9()+'"22UE%;,)LH+< -+X:O'MEL[M&0,Z+Z<9
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M4ZQ#):U06C/B5DP+S)R364H*:=V5-CN [J<!_[W?G3UA_;2@M'8+!HW^PMK
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M\E%)2_,'O_GH'@7H\:85/D=7$6=R?NH9C+Z74FD3R!*5&-F)3UQ%: U,*M:
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M&S$GD1D$RPG-4+8P_N%=8J.V.Q+V/L\FN^"='T=Z;+&N+NO61&U16_N+JY!
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MMBW89=0?"Z@@9,TYCPOZ'W/\8>8HB_\PVP<>QJBS^C7^Y=+]+ZQ;:>/IZYO
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M:UM]ZQ3+@!*+=5_YO1-3^W0E3#_3K=J?"6>*<R8AAW&!X%U([ !*!')'BZC
M.#?!.D?Y3>M'/^:"_-:5\3N0E"B[6^V:V6_1$C_N(R.=IS2^?9:AVF,L7,KS
M5#.*RV#*N?42Z,U]=!*'_PA50^#O-TJ"\X5$LP.GXMX-IIGL1O68L61I2[VP
M^BB#%I1PS 'A+_.A0Q]),@AF?M#N98Y266LR/")<94)F@6AEVM8\$3?Z O=:
M"SBVL;Z/GLA(8!?$& <N& *E5!B:1Z-8RDQ'EC/-=ZV<>2GJTBCL,ATU 'N4
M%[@<_I"'"2H>"Z/8]<:NATP/VE16E:P?JE&W2W[*\<)KT"XF^O]76R7_&T^K
M^LX0]NLL1UCVKP,5".1\4GX/VPFD[P/%?.!1L"-__;6HNA8>5WR$VB(V?4#U
MA**^'<;1KD&9!EK2J!_#?W/\+J9Q09NID"]NG!'2>\A.D.LWR&([9#,)!J@H
ML_-STR!;WO&@J-5_OT>O/F1QO4;G.MT=S1+%DYLP:5%>BUWJE/+UB(HH0[I2
M^6)!S&_3R>G+]$C6N<]:92TY"] &ZTC?H J"R:MIQG08[28YCR_]6P9T#/6?
M/;M_OO$JU!'U#V^H[O7A@AIV1B';QP#'"P=Y8@G0"V?8 -XEKD"^%;L>!4^W
MC[9V'&7I3SW\W8_E([E>\J?D_]-8E?]B3#BQ68O!/*OI&GAD>"V#+&H1_YX(
M.8=;K.<I&#CZ/1I03ES;1P]D5 ,6S)LQL]VJ=-*C;6&^67]#973W*3^#!<DV
M=)_)L::Q>QQ2T&O@_(6)^:(GY)(6/SW+BU=2[EA=R\;^]*4.LI(,P>P,+HAG
MA;>X("]8&I@6ZLQZ@V8\Y8+J!O%@MHWN!WI=#1=T[_MP^40PFJVEPP7I+-&"
MN*#J-LHR._]I1P3SYC<P$M4CA]5"\.P5=DTBNH($"W#^C7K'!?6Z_-S85A\N
MN,CY&6&D6MZ8-;^P8&T\.;&IK7%R?/CD.^U3/ZV4<(5H0$.+51WQ5\7R@.4A
MB0MR$NX+X,3B%M-AFRFX+P*<D4"R%*?H833*!$)SA?VY\8MS@#=,;F_C.-7@
MI,DUS 64R]]HUM=@0((+\C[TKP35SG0W7F/@N: A(Y[A#.8UTBKS*FJY>-$;
M%0#[[US^@(Q;T!%F'BCE@BJ07LLZF#]B]]'LE!!AME]#%C/CW_@^C]"6.%:_
M'^/6KM%(G)=KJPVU^.__*_(*#Y$ ->AZ/94TX]5;*$##]98VUM%;^I0FEE!B
ML!F-G1^&2B\4$IS&-<JXH,M93FT=K<E>.2OGR,TM&<Z;KLY)Z"'P3#B'_PW3
M%AE.68H_%:.,)&Y0?!^SK"E".N;3C>EA>-O 5;=HITUUK68_Y_;H@N>,W+!W
M<R=7!?XPWA49*>W;=X4+N@AN!J_YTU89_31C= ++/2*:QS"189&I)#Y@^$J*
M;.J(S,IW;;F1IOGGWXY/;*5.7I<*T]+H?$S-B S,CZ Z0_9R1B T<PQ?E"*0
M7L*Z"!33I5D\T1GGYI#H1",EA!8(-1J?"+KXR4XC?BE)J;-SXA[6J^F9?>AX
MC<FPP,TBH]\Z?=VFK/#D=_###V["$OJ_ BL3FS%1)RL^%!KJGGYQ)712+R5!
M9_^*^8UDVP>5^MDRG"FQ-/%B7VE4B0D?\'++^)_NC B",#*]=R9,IR_",V3'
M)?N4KX#CR-E8R,#ME=N%%K#$UHRS5R;>Y=T($.OYG)KCE6V$$TFL2<XV+!S3
MJP<WG[Z:>QAO=.?%]V3%BZ9[2U+D@@_L/2K2 YIH?+1OUW40"+3K/4@0Q'>+
M;W<.[K9;8-4*HXT#[W#?+,N>SPKWAUV>SR:Z=:@S+*B#ZQL/'H!9XK*<@XJ"
MS@:G\0_HSM3-N4M"'VGXX$K:BS,:'[7_J9]3,QB1^5@KPKFSJPU;@UHL#A[B
M6^.I81O!L=EAJ;4_=&-JX1&/@T4(6O-K)\OOR9F6!98?V@W?/7MJ>@2KRNZ"
M>,$RP(V):)PW*95G7@8'-O:RQ($WS#-(_$"A\FB3<!)8Z"='"0ATCQWHEH8)
MDFYX^(5YG*1UTG7UR64)9#W!ZKBH5S[5+&UV 2X()_F%90-$,A]P1L&[NHU8
M(D VC=HGOWLB2HJ&6U1JH.5Z.-$UJG<\RL,A21LQQY%-2DW12BN4 S7%=0DW
M:EW/9[]:^V(J7\P\:WT*0X-R0;$A1F/#.IP/'H>?E4=X6!5>HK6/=$Z]?%D2
M<:3;ZWCPM^[;_6W8KP/3B^6I.+\-0!G+.NQ UDRF6P^"#T8%4C8R<')ZV'U1
M-C0&-J9]*3'*B]P!D4%B>@SGA_7PS=@2(?O>3QK6T,XS%A'%<_,7WEA7@MOR
MM%ABJ1Q^@T5P/)[A!GC_30D]MH6:B2%8Y;_O/M)%-UCC23>QF%'.(<#JE%#9
MI45C XH_O0F=N!T-O4IC9?KE03,0\ ,% 6,GFSKUQVZZJ;6,&? L[=6-O7ZJ
M/*NTQ -VN/C((B$11X.2) -=?Z:_#FB&UJX4GJN;[!1"D)5;.B?C^XMF D(\
MW$=J2"1VGM]/39^<L^MD)_?7X'A(R^#Z$ 5-M.8<9/YU]D,&C,_\(J/6RYD:
MJ!Y+U&WA>$R3,K[B>]OX@UI(WS/Y++I8KX-ZCU(+;9J2D2L*Q.+;2P[<)1':
MQE\<.74)]QE#<X8F8T"H0!@1_S>Y "D9U\BS6!P0H+.H];X+Q8BG=]=3A%.<
M<(*:ONS7+.LRC=RUZ1+3BKF '9?)Z=YPD2'JB.\5!UW[+PO$2]H668'1!%ZE
MF?#*, # ''X1NOHBW\"&$.M2UB*F'Q>+$XV11>;WYWU+2-AISJ8GOB<)L9R%
M4[>@>Y%4V\:)T++N?/-)T>]0P57G,^Z$HMHWX>)VNOO/3D^CO&& (J$7'3>-
MD^<<BQDEPO$P8CDU=UV(WM"/DHSRHH,'<0)1YRHT<TM(0_*81<PN9* M_:C'
ML6B%BS18_-J:;E+F)\J"[.J+GW#BU/[6S8D]OQP&8<T)+YEW>62A'=9HT >P
MS (I$#!PGGRHE"<W?R$CKR?XHI(AAZ*\R5R0 )!G+70)VMXW5:CL9KE=(VN7
MX+<XT3CB,_5SP;REX"9K%[T*CZESCN/PLY2!JY#%--A1CB0KAEW<>;P,N8<1
M =13C",O ZKD5&QZ'B;A.%QP!4^- TL(X>+U(J/]UZ/,?/?U77*<(C]>;V3K
M7.MX?F.(Z4XE  J.<7D8EKC6!4"1;GT9,*5=8NS0E!]3ITP.^<?LBT.&D+$#
M,/ZY9>T DFBG#KR,M,RX2.@GFF?M->Q^+%3ZW#^JG@ W-!6]@(N.&>7!(K@7
M1VQA0"9X7 ::=K_ #3_=S?>Y44.]/TP[.@M&0Z5WJI;/:L7%*"+-%\]A+.E:
M\=NSY]U#KA3*Q@>-&C_?M/(/"3GZ2#Z=J0+H4,)[N:"9W$7,8\XY9!%8(LJ!
MYHO7$OA!.LRZ1GR>]]PP,4FWZ\2"G--/&Y_UX[EV-[ZF3[G;AZ9CC9H[GFJ]
M>,"JXE6^#RH *A4S!]G;B:*28KD@B1,TOC4WIG94)*\IW 6<1Z.\BF^L@IL(
M X'0M$(>.4Y#R JH1VY/>@$:M/9S6HT= C/%CZ,<*4B$W.W)TC'=67^+;1?F
M&98V@*'A&)% ."V?VM*7+YS>;41+C#]&2TPV.7GIC16O40';&ET 8]LPB0B2
M<1NF'ZJ)+BEM7S4___)8&\Y IT]$D1]RF@NZ2P".X=;TF.910E/=TBQ%0)$6
MNPA.:X))(L_WG8ZZ\)DEH?>U6=]5.)4W>D20L5<2K9LG[]ZZP;+Q"HHHF=,-
MDNEKV836OPQ[*CQ#V._A&B O0AM93Y^O89<.Q)8,[?N6_=$@I^7 U.G;-S1K
MON8<H=ZK.A5L>/:K-I_>V+0(;9J\$6\B!@CTPH18PD7+'#D:YLF6QGG\CF1J
M:>_43@RF?'EJ&2XH6=?PSVC?FX..OL$ZPV(C85O_4ZW^:_6:P[]B"!>.:O4+
M U80LBOK(@]A]?UK.F%<T %H"HHLV=K2.KZN'-L'^Q).^M)P*;Q*W3]LS*PR
M^N58M)GK@)*=XN?3ZBD<<\@=51QOW,07*@,A= BUG"4"9VC0E]9A@2C?<M9%
M=OT6E&C!L*5A,HPL6QZV2:$.-QG+6HEJY*:\&5>6,NS+._ELN((T:_/@'MTJ
MU Y5"TN)D9LP@M&&*<KQNB]T9PN<^Q;VTWT>E[D%:ACZ2\EDU+_F=>MK*^@
M^EP91F.DSPK)^)E5TV$Y>OI^&8Y01=Y@B>:[3K*D:&B&RQ1DD8=H3?O13$\D
MBE*>^ WH8CHCL=3N5B[HG4\3V0TJT\C1F=30XE%5<%854MB)]BC+EC8=?ZKQ
M_'FFB\F@KF$6[!16A6_GI(N'ZXIDSN]F9_WIG%R[4Y_=70@2D]7TNG\R!9)<
M*'DZGV84PIQ6A%RP_V !A?"U23J*AQM[Z*CW$%$C, 42W[U_ N*/3G7E@M;H
MM/!^W.%[)LJ!),&8?385Q&7.H=&?+.=P5.7\T*%:8O12TEIH?M5,K6Z@AKW
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MC;[\-A&1G.CPL6PU1%P#$&.#HLC6"U.K 'MM %3 "$J[L&[ D70 "@K:LO
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M"$T-;K-V6C23M>RF6"=WUKD_H(ZBL^%ZM)O,122WL3$"CSS&FC4@B]PZ3PN
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M'/4Z&LV_N&A.W#)1*#+Y]$-X:]?CUKEGB]93-:;)5/*E$.4GCY.0A_!L"#U
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M_\_\XG_H+]]TTF7T_BAM\ARCV/8^YM<<B8O9$O3/Q>XO@%LP9%,D2]5OJAV
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M3G=FI!E95@ M4+X #%^_&I!RD2+32?(X=5[+MM]6)& O5CBK[+#![3GG&(G
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MDW(E:^8/2K(T[7I.]<QOY"=PU>HGP0=&XN28D\N;"</OEE,CK9P,%0:GAU:
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MC(3EQL<@-ZM]B2M&VR^PM0MOJJI$7JQ%:JTK:;F^<-H6>F24?/.Q=FB+L.)
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M(9LF' 5FZ"XZ9Q^ M Y M,H#T(\UP@'H/6L!6+_X+MTNY/P&T\&W%4% SA^
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M9;CD70P4+E>.]G>J_EJ4D*=,KG'("=0,+TQ/_Y;31YJD30CW'J,8#EHAH 5
M.M91T^U9DT2UBMJ(W2A!RPHC;I-1A^7G<J&W"J8/U0,!LR@I4YGHDVYE[2@]
M#IM&_0E3%OV"TY_\=S-2>4I!9QHID9>'9!18/C"+;H*".0R6\GQLMQ6$U0QW
M?_MJ@'A<[F^@4]RY7UI7N_39*/Q/$U(3U2E+V?O"X9I7.6K03R"AZ(6A;2J&
MD84,L%U(L:5(P,SL@&]DY"CR6!M>8%QH:O%[=T&J]K/&-MK&.$Q&OTE5MG>'
MG=$;*A&G6WJR!#@!?M.Y)7P XDA"O-&#BE60]88@?,RI;@VL&IM;WZ==OHQ^
M_D], >@B+'^F.HV=PIZ-/0!)N][8L ^851.:<AOMICZ^5XL;[VH\];>IY/Z?
MC[YWZ-; 8]H-.AN@1W-Q9<X4C@V#0723%+?94^0AN"99-&6SG5=ST7U&NT<:
M8E=FDQ7B;#[]O*.M,\3^Z(_++P/_@H7+@CI_>],=6 \30 XZ]PO1O6?Z>0*A
MS6&C2('UPBA<$0Y8'.P7[6$1NSYGLRG94I+M_T'=>T8UV79M@U%N16E1D5YB
M0T!*1)K4W(J"@(" ]!(1$4*$B( $#8E*[XH4 2$B302, J&)1 A%142ZA!(2
M1*3)%:5<DI!\\7MGUIIGYI[O?9XU,S_F!VO!%<ZVSW,?^]A7]KGW'@^.=1T2
M-+L6]O[:D]N=-OXN@_!^1*CNXPADXW-8;=^?:T%"3FQ)SE&@;VF&;<C]3,MI
MI\11Q#B6I(41;UA_&!0:"+LV0@XZ,[$H^IR^V.Q='!GEJSMQIK-,V\QGN]3/
M9?O9W F!K9+%?PZ"0U[D0=J:Z( +(8$ .)'&0KOUB?(Z"H;4&<H2#\*T@;9-
M(5B(^"7Q\P ]_1KG;+EWH*D\RZ0L5[[&HF3AUZER;P\T#;?=Z&"$2(3SWNX=
M_?>@6?]_N2OWS^%V!&^^!K-6!+="DGF0O]VY.,+T=WY3_64E'L2'%(?<S)LG
M;PEZ\"#=+;"U+OC6-O1OOB)$%Q-F1>AU.5MQK3*$!7399\$)"F!.^GT6N<07
MP54RP._,WL240H3]/ZOG-[1M*PY-@!IO8T;9V8T:6T]C!,%X]X%UO=S*Q4*9
M_O @1]LK1GQZ)LQ62WY](O5#?F3QL4AI78X^H0UX"Z=20.4#$(@QBFU]!_+V
MSQ?" A"(&$3@CJ 5%W!YL@F=1;;Q(!P8E _<O[B[>W@07]*R%G\/TN]F[2VW
MW?>X:)>YDVRXDG37B7RK][TEC_/<E8_2W!4D7CUJ.:MN(L2'R%O2YZP*)5,#
MUP(=J(Z/F^9$3 P^7"C>;3V5B7K6Y3!<MO;O7C"K??S_QOVR?ZW@J];'^>/_
M$CHT/#K=H7>XA["'N_+H=\GP)8S,O*(DRSR9%.@M,?R*N+2RQPV5T^ B>_9[
MV\ZIS9-*(B]BS8J?03CW_[%:>Q)L+V76E%@;L54\.&/'K=;83D%__U^_XJST
MGAJ;'\EQCRN*"/+Q\<7H3BZO+;'<:6ZT\:Z!"<])ST\L*@;SU[F!7IT7#SIE
M:U\?JSC,BF?&+\^RQM?K6)@$/%\WVN!U4?OFS#Z7$<^!;_AZM!W,+_5L6)H%
M"J*EX:M],<Z_\D^Q5I@V.2L2/OU7>9"8PV;-%Q^ZC@3O,0[(M[=IN)(U_CUC
MLJ'&NO+605I_YKA]C..-QP7%^\E![[]7D5='?><QX^5<(7M >UUA8#55P+5A
ME O'?_8V)/#!(892BVA'*[.0G2L)MS[R(*]KTP:I>=<;FP?"?(W,-=>6'=2"
M3&F'?LJXV8\A##B[^4=^Y$^AC.FGL#UA4!J<*S3+].OGRJ$:+O")@@ABNA A
MMM93"D8Q$CPUNH@\B/!@1W-0A\V,R<U)XX?/P C+1NY'-!D;KF#[4V6JEUNZ
ME4GP3_]BM"X^U')V)LJ,N=S03:&][G:P#&>AUS/!V.?ZG? T;[VA%[LCJ]1]
M@579&:Q<^ZMS*Y*YT_3=;J@\I[H=AYK88:\2%Y=R*8'P?6!J-C0&69O3A8')
MN%:YTQ/JWB 8_C&NXC&/T*;:KZ/ML^%,S.'3#]HO/5.Z0WK<&>(BVI]?9#PJ
MFM)QEN8J3W;ZI-7ROEH1F378Y7MDL#XMVF5DU 6I[9(.^JI7'PL+G= \#%,,
M:-$\5SF7VZ%K'UB(S'#L_J8S#OH=PX;K/7XR]VY.BK]I+8<9R&U8]%D <\_8
MX"G6HATO_S+:^K.Q/J/W1)]%OTZ4X=C-4W[EJ.P];2@41G;K"R-Q_ZNK!E<O
M1Y1>/5<2]L7+]^:IP]?2;U2HO?E-RQ4(O;3L63C\LP,)?.&JGXFT:[.+T1MX
M7,>'W=U2'9/X,>DP?QXD"7TJX\R:>4 /E.G=E,.#U/ @B2T^\LM\02: /3/Y
M;CY9P<:J#!O'\Z =PV@H0\]-O;P>""IH?:-;M] KK-&=Z)E)R+TW:QO:]TO^
M#&P=*>(OG79EJ_"P5C94J;VRLL(I[D1+[:V0E?</AY\5%G[:L-@/YNMV.A*^
M3"@0+S>-_GAE4/72V.2>BXL#R0Z66'C;7.UYW"GOY^-C^D6]7/[A(F?Q 9>4
MB)0TWG&#/_-#/$BL1Y570(3:=)]B'],&[9@GPVE<\P@R##+]I/_YW23:9'7?
MIY>!]M:!'7M*MCJ1"<@:&$<\M*U5$*QE8=S!!X!@YRUH/+ER? 5TD8TK9\6)
MNFM J>D136$5AX#P'P]?V%1Y-NHC:"X;.7N5RG.$*YJAVOA8:[XIEC%[;4X!
MFQCQGYPX)BP*\TU>F>F/=YK&;I&!VPO__JE5^&2T$QN5#V8E,YZ[IAU\5[,P
M]O"CMJN-;VA*GUI7BZYQ%-9'O.TR%B$L8;?P(;_8J5?]K*;[X'KX,=M4Q">.
M1A_.N_MZK#Q2XOJ((U(_LBS<]NG'4,[,T8_X"FOM#L>WY3DS)X4%):P70DJ
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MF>^O&<.K0)>.6T4#Q@:,+1>JHA88MU[]=%Y18QAG"8]97=D3F(YBJCT0J3C
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MRSC8W>YR?6(\T>^AS<LWM5F%!D^.&N HU_@2^4SXH(R8+J*OHP@RE#7H4(#
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M!;9V\6T^0N[\9$577TY%\BUX!T"AK$T4^-H>?PS="(N*RXM7^'VC_$]=T$6
MBVI<2#>& D&7YV1N9!.@1,?E0KCF%G?.]H)22R+V9%OA6.>C\;7KE#]R1_;H
M9(I>)OQY^N2^O/ .")"4R#+HKN)0=VB!(#D9M3MXE[BNY=)+ZSHPSQZ*%H3M
MZ:AU>[Z\].A$BW7M'YD/3KD6FY+=$J[6E#G7?M79:0S\1B['3Z%N9#%&]H1
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M/11%5\AONAP:&+@VRRHJ,RK-NM1<CU3A %<A*$>K*N6 1G:@.4>Z O47 9P
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M?7UF03:;@E<Y%&0=3E+:^KY[I@%5@67H&]< 31; >0ZT1GNR!@6J0U-9($G
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M]78":8 GK^6GWM?$)0TA:CE]>[..E2>XU-Q8LI829O79_>6#!2LRC*)O+[[
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M*>_!.T>HV_+4_SB#))5+#L$X;JJ.UIL2W.';EB_KCT9&[DX)4F;+&]LH,+E
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M2XX_8--98-GOKD.Q%EI55%+JY(1.LX4H@"O?CUTTNO^BZN#S'?>L?GISB-U
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MY  T)A0,)M1C)T#Z%!'@H/[T_'HU0D'#P,(]@T= 1$)^FE"- 4!#P<! P\+
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MWSABNNMVFD^J?@FX@P-,K%(-KO)61 7Y.RP="(F1K3>_Y2_(.D.(YBQ<.'W
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M)?9NLK1/WTY(8(6MDNJ\I(HWZB5+:.MW @!XG:U08"^_E*"C,Y6A=:*:^+F
MD(RNC)SSZ6&2Q"VWA&YOP&UGJB<DM#[KJELY<T_YZB->1N,HE5,]SNSK5\]$
M=$Z'WQ$ >Q9E G'=X(W2Z(;)Z0NBA&0U]>^!+K?2XCY@:DL#= KH&HY'X(65
M6E)N "A]ML/]OH1H '9 V792J23E^-FJ/&R*@0*\JI@#)\%#*WPHFG^96)YW
MYNIH*?U6%7HEK7UU!]'MNE&%U_,'<A\<T)Z]O0%$P@L.O!_' _:9-&U1/!\$
M/*BP(U;3,'S:>;*\"\BXN%Y(UUR,P$2QJMUF"03I]Y67-HFN"J'UF]NO>GIS
MR@INFGZ4HG<-JC7;EEMU1;</!?;S2Y75(<\:22.>^6?,@F5;VFR]Y@)-,5]0
MO&;P__D# -CBIK&I \_OY?;T)IR$,$2M$J<L8HL3/)OJ,9N3H\4 IW-8W)I:
MI4'BD@$V*1CKKQ31+!'->&A!,Y,V=N^2U<=ELPD"NE,U_2Q+@M%KZ^!KO$%Q
M5_:&:(E%5YG=TZYQ<">91S8#[YNE#BU@OK=,GBTPYT]4(VNS/@)..G+EAS<F
MIVJ&273!:AJ44L;V\4X&HN@*8HX%*\2\ G:J4^?C=OF$*5BW*D!)E;3@=B\%
M\:F?YB. "I^8L>O8CJ+U+NG3F.7>2PIKGEVV40?T/6'BC_,_IF6M*[O-Q5!&
MX0D_DWR*K"LL!X'?7J:9^*N6QVYQGRAM(&^-6_"4:K>#7>\H&]0:BQ9D^&'T
MOF:%2GZ!ES'I(X/U][]L="T6PI_93C*+QPVJNL<N+E5=D>0(2<?LPO])-7 O
MM8M>GXZN;(:4\\47Z*4\RR^Q/2@K25CM7J7[0LIG&M!19+"\'(E.%MHW[<7-
M+XI:C.L1/^$2XW\1;#-#UC#$C!<Y3P)?8GI'^PC$FN;XS-G=$YU!3<HXPJ(3
MR//;5Y74<+@"]6?XNU;54_79,PO(H 6E/K#CV.M23+P'V,WZC4<@Y*CKE5TS
M:.76&LWM]FW'#=D=JGI<NP=N4!-;X<+59Y$"*38I@:[U$=]][<P"RFA/%)(J
M*'!5<,Q7XGA%\=7.9:B]I"+C8LNDY ;+AHB<.8G+KJ:]E_JEZ-B;%3T?EE"?
MBM==67)BN0L:6X=.%G]'9OW;+;MQ[)+5 ]:.#H*RP&IO<C =CNX;OM=B#;"G
MY.\=$(CMJ\Z?:M>3U4UD&=?40XOE0);$6'&D0@$I?B0GI>Q1RN\-O83Y)DX\
M*.AOT.UU)#JCT+U;WTQ4TY6\V<FHJ6; #FV9^>1+^LWWMF>L>-?.+0V>R[*Q
M98P]_V+_]H>U[LSE7!*PG3G-_O5(-H7W6TJB\/*/1 3]A^LAJW-WN=P69/E
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M9YK]=A1V?#EUU"#6%8@U0?Z(RP]X@U(FV#=: Q?UT:_4E4>;WIF$5W<JL.-
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MPJ97-WT\-P&9+Y+'9WQ Z"CH0/-&!>3%L!2@_C]J<+]#L?L[$DY0?P%%P2/
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MZ?O?V6A_S[I4_R)1_9MO,R'/S=GP]FDW[B0@NR4Z_MP*P([*<.N7F2;9Y-[
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M=D<6>IG@)W5U,<RXL"8);G%0@O3V]=26+"2M75=R'OQ3JROYJP)N;>(([R.
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MC/E\N8L9W?JF57X9H.<X2'\F%/24A)TU<A^HT)#_[5;WWQT/()"GOE"T3%O
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M*/2 &-Y\/2[_ #[C]@;_$G# YEB8&N'LM&AB[G2AWO*;O=)3+[#$CBQI&C=
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M2AM8T% T-_P@^2E&ELGH=\9!=U0P?41X*GFS3(?Q59(>R::_D"-"AZ<J,]?
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M4A+3<"1A8;99";F3='M%(C1"=CC'>M@FM?X>12&Q;U7OO*I"S$@F7Q&=0&=
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M?P5QB!8F^0''HO&E![AQP[A+I#2E_< -%DXQ$+N734O660V+6Z<F&9%$WQ"
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M8K4P&]GI+^YU;?RH>1;P;\?)DE%27KZ)'PYER^>>DN]]K\ (N?#2/1$CPG,
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M)]?'^T0G%F6;',OS?5.:Z6@X-.!=6M!M679/QF->OE47V)_#ETV83H@S7%(
M)+FZ0()(PFK@I1<#GX$$EF[\Y%:*0U[@984/9PD)EGKHR5<%!WU"LE$(Y(M,
MNY.1YO(I+@,%\\A<+<*R+@,'BKI!PZJH( VC YH*BG 7:8E*F]B&TIVAN.D8
MRYG6R9V->XJZC=K<KU>P).4P!AS)5 R".=3<4+#7T<PQW'F -5A5DC[1\DTU
MTGJ&;ORVW,,S^$8!RE7J\^OG[ YFB>][[J<S16Z#UYJ?E)LT9VOW/RMZ][7;
M]M\*MO_W.5HQ/!W'#AE97.,A^-( G3/=@9*G^2\B6^&;03G,,> EBVA"MT0
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M$X.7 CPZ*6(0=!:A=J[IBI _#'^9(O[AR;L'W&J<131>O_X=G7P&:^KRJ;O
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M^)OK?1D7\RO*K:O"F]T0\C^J5Z2Q[ET"$;8L>58(DP=#O("X1)Q1^92_X"A
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M0'4C?MY</*30S/AOJW[;DA:&.9"US7 DS.;.<,+SU86PD5\<)NF;3ALZ%O$
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M+^N:,[LOA(I'$6<[#4]2$';!R@.JLQDJL!FY;P6WP>R:#Q?/W#HQWOD"HCF
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MM+/)8C>@U8\1S(RG@ ZT3[0+X@*Z)!3&[HXS(^#Y)]]X2R?;0L6%Q"Q/L#R
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M[B[T@VO%0U46&>'++&V5J;RG+O%(V:-(08;7:7J^_]?/YUZM*CB2H/T8X2,
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MZ^M?-H*(>P>*8VD#\T4WS6BN,)>7MWM^![C)\\^:FHMZ6#)==G2KQH#@FTC
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M#A9?O@C#O3""L(4>CO?X"CL[L*6?E!WZS4&.NFI0%AI4E&@HBFC)OH-7<7\
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MY"[KDO-.U:Q=*[9J8Y^P]V4)<B,QDVW!DFMC);N4 !0/EB+;C;<2'()0X(B
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M=.;9.9'//3I#=F = _^F;#IA&JQ52COQ+/N=J9__)V9O5P%N:@S72[:2XT$
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M<;Q$UX#0-B[G;7?GJH(6<0>^H(VHS@29++G56Q:IL5L<GX]5AN5G-L>62.+
MK9788,KLGV.!].'"I^%Y#[\=WS4LBG*^1RO."]$BK"J8O+L>J//N\#V+6<^R
MK#*3^X4F-"-/U2J.*+LVVL# 8J&Q>'.%26FPH?6#+R>JK3_>B[G,_O,&MMR
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MZ3]34Y]WCE3I/H]]2GS+5"+JN(J-B6_0R4E7;6%BXS<4R1%0[SX_ <W&8+9
M/1X-!9W6[_,$K>'O'5T64YH>K)1 ==TAUQ',^I;3WV>--TA[>\L: /?_NO@]
MB2:/^LJVG@4;A.H"%>L$7Q9F$S/,?935I6?RHBZE[_D%O%L/KZ]]4XNW-!=&
MOE(7<0@?-^E9<.H>=K(AYUQF_X%8_T?>3!7&-MDPB>X^_[,DO&@7I"0^0_R
M6F]K5Q,>Y#],0]Q%[63H$Y#]](S+Z+9+R 0O%R TU<)?]Z27AN7P\"79@E)-
M8G6+A@!CN+^?T"W0[""ED#0D0=5R[5L]V;=3X@K=$CB9&X*:F<0]^)(+("4]
M9N:*A=C5L"L@HF-B'V.07NWI8F[2WGV&%C\WRAESKZ75W2VCTPZ572;L]#)Y
M5[?+1Q^^-+LSZ5?&5HIMZ"Y7ITNAR>6!=*>&_1/7*=ZCSIX7P);/[$B?SHH7
M%"U6]KFITBKVO2^N#@A7^\7[L@8FK>\U;I0MV]P@5H/N\",(O[EO)VA ,\5X
M7 =Q.T0&F&@VTO@*CA80Z@JZ)TJ<B@.%#/:!,C8]X?"$KK\C,^7G\+17/R[[
M[<RXD*DM9YM]T%['^;5:KM>@##Z3(Q;=EU;"LAA[OG*6^N[8P^8FK-D6N+MZ
M&_HE'N#&"<SFF>$)./"[G@&8]/^P]IX!3:7?OV_&&<6&J%1!B(J @("%HK2,
M(B @1+J$DE$$#!$B(A AD!F5WD9I(PJ1+C52DDA+I/\$$0@0))201$1*)%&(
M&U*X8<ZY]YY[___[ZIY7R:MD[V<_:ZW/=S^K-+,A21/1-I75=V@&6BD&AJ]/
M$RP<O#([/:):(@H)I5N@7^&[)>X&3D?QL0UCAHP_&4U!?=A'L,C::'IN]4UN
M)FNU6R:!!LLMI@U[$<1%R#G&P:]O_/P(901"M:]/W\DO]-G=^Q-.E;C/DW4P
M=X%!WJCOXQZ(2IR>T GH82&]/>H)/,4>J!I0S5)H#;G]X_T#_KU@L=XX(?:R
MBF=SKG<"*8-Y"S'_[%:";:#Y#3^IP7O9]1=#U-0K;35[G.[77BY4@-RH/-)Q
M^7IX-JXQ0KO,J:9R\'+IK>9%PPWW@2/V3D9JJJ8C]M3[/UUA%0'MA56;=1F;
MN'_?"VAC3&B6QR6*3$-L,O,U.D!<&\5E]X+W6I[TF4(LGFR\5+*H=F'4T!'K
MFK^[*&?^S<@:]!!\B9Z:M3_2P]A3.6UT]]W/MF([RMPG2!H9!&R/U[A,?; %
M B-I<1+LC^_AVK),.@UVS2Z=$[V -O/(936 >B_=)BLLYH0HGQIRJ^]=?MV+
M,E&=]P,RK>[!C";=+D+Z<C^-_3U\NUKH.G:*T3NK-"&494.FL/QV7M1CC'MQ
ML)\RS_9)&U1@+PR<$)YE00\@C5T1+>2_\%]-\>GZ:[7^5\8?+">O&.GI.C>]
MK2<W%"*]7VL\LDTG7\9[GF+"/NF#/]P_ZJ=?<)4=Y'>]^_J3T=+JD3)'/WEE
ME\^5=FX-SQ8<>]Y^"_ \7.%7@.ZHV*G2ZX@,G%T.46WY^1TR'B3>NR#994^X
M4*'\XTO G@H@E25NY/I[ [(LO$*PA]IQ"7B TS\2F."D@V@_ Q6T[X-JG#P
M&[@V1M#&R#-3:[6Z?TK72BN$6-XV52M"Q8;OPQ[#<J]AZ5-=$*XU&-"%<LP$
MYA@W&N'3%BBP%LY*S(0$08ZB\=YOTHT<=0:8"]VJH5-S0[VU@7U.;QY^TU.G
MSC?G>9&H+OMN,AEJ2_GSM;7L15A$-B7-@\*]3IGZUG<EM<L83E+D_!7$?*M'
MI8%EZ&*J),KIK5T-N:7C3TRU3^VMO*G:%G"P5#M4_7**N\U(9C:A%N7%T\17
M(L4GQM<M8GQIJ% C/;@W#?^-X AW'PO]C*C#K^O9;WJM&N!# R-S64M+B*!\
MFZ!G-K?LAK28UT)E]7L^3Y8'0%5S/(M,W<Z,O=9QZ?I8AD+I<*M/SG^L(KF<
MS:I4&FO*R1DK\+FFX2*/&+U7>41+VR3N=D[-!!)15D>1V9[:\R@;VZ$#"< "
MIW&=$KD59TX$7IH;L%'27Z-(8"G('7S\4#'PPWI,J,&Z([UTIT6<I5")*,5<
MXAJV9,'0B=!'7=VF!QHKX'V1A@:RB\;YJTFU$0&2GT5C.\Y  J" >MX*AQ>W
MT(.5>X!7RE32SV%)-*NJY9E) -FA=DA9ZU%3K?W0U=':![HB6]<1(7BN?3\R
M3F/L9M-XFQ5+SV_!F:=?3A(?HQ!\3W0Y;8'.@Y](^,J <Y&KT,]V HX(;"2T
M=K9B9N8]-N(F%\?ZV0U.]/ T&;U,'/6;A@&0;E-S6=^!T.3?\@[;C)KKU)_/
MOEYLD(IM^LG1Y6W.]@ZQ*1QIW@#;M_PYVDC5>(+%Z,&#,5=)H^L["3$:Y/K'
MO9;':+>:VA1<WM_1_^/&@D*#Q5NL]J1,GKAD >[N9<6RP]ZJJBKNJC%8=7.W
M=K>VC"FMBEE2FQQQ/UQ5&7X'N=YO+AZ_N06*#6QN;FJOC26,.M#YU$W< VR'
M9)'N8A_!B20.B6V0A&W,[,K<@X$ NG,BS0DFZ5&$@32@>YGKN 7J46J2]O0B
MCUOJ KD#]M2FJ8TZH6]5\(3M[]"#H32.^9&;S+<$;T<M3TF8(@K+BE-$LE+Q
M97]U,KD/+K;G*F>?ZOCH%![VR"'_?G3__:CLPN3WK2=K\G[[O*#MY-'V(K1_
MP&_@C;.U//7JORF694()!C[KX>+$_?"_(.O:U.I!7:IXWQ;H_2U $H(##-[A
M-K,7W0M03/<M$#Y\"T2]P6Y9AS\7'<1V?()\ST+MV@)-EF-.2] ZGI=">6XO
MSM\"S:V -^Q(C[$KHY8*V*5.H ?^H0R-T9;PZ!?)#?YAB-4,D6 ANEIL+.=L
M'?O+G_]7IRB!)6 F=A1T,OBVAA#1Y1"D\(]JSF[L7"F8>UT0:ZFGR>"OB9J.
M45\U.II*GP/3,]E/8!A3S/5]=VI.-$"/UC9%ADWI3)5573EV%91\W6;'1%\8
M:O\$RRBO2JGJ JH2>D@[YH831CSUR<LV*Q1^:S7V6^W8<B=+/3$\5-^GW[C1
MGD;^N6Z!%^]NWP)INXKB*2MDP'O[C8GGSQ<2!Z\IT1)J% 1>H&3YBP2>MT
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MUY)P IDZ= "-ZOHYJE'PI- $B$7J K[FI^$"3R]NQHM7R\K.M&^<-C>Z)U(
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M/A2,]USTC \."[N7DEZZ&GN;'OEUK)91E[CY]W:36\A<&J314RC?"N5J];R
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M@#>N&:S<E,1JJ9Y,T76P_+) =KL-+65>/G](E,=X3-DTZ8X0W]L"R<2I"ZT
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M<4T)"Y%<T-N/T4U5O=(Q9HM:[3]A(674Z)\D*Y$U=JX.R[7"Q\.Y[M"#F(M
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MAD"OC@H1+(O@4<<QS:8H0B[_HU+H;6+D7Y_/GG5EDX_P;),QBGA$G XW*HG
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MS2?W?X[S;+R3=YP'0Z+W4?W@(S;TZ4@$YQ#3F47E%C7(8TWL[I8%H?AQIZ$
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M%B^?ZA:A]+;J8-7(TK="UO<B4E?P33P8PWY\.TZ;26H5IZCX^*K_L@**<'#
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M/LR-$_IZ$D<:;.JQGUK@'P:W36L?&VB:TC>/:O98RS\Z8V'W\&F^AXI7WX5
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MRNX<HS,_Y$^>I:BWYL^['6=\'C048DQ'^A=4]>=5#R[I6WV)/21]< U."[P
MA>'1D%O\92WL^$P:>;&7[>YS1_UT]6*>#[QJNNW5J%K9@,R/;ZZKXOQ5BL,O
M7PN_HG9]O_!!UP<Q /CUZU?6'U8N]-6KVJG:NKK:%--O?GZ>C_*SZ/00QZFT
MD/S;"8Y7KR68BF=^JI % /R^]VJ.*8)J=*EI-FINKZ! 9&%DW$$=FX2,0R;2
MYY:+VTX4)<OK?E.P+?;P+*VX$:=CDVT^M#*>9NG29>>)&5V\17DQJO0:64T&
MU"/!FVH\V&T(.A6)AGQ8XV?D<H+@/1+K*D& !UL+!7N". L<26X!P5MP:! 4
M0@*>X\-\D\%OR,!YP@LD394'"]=B.K>3]A!H"CS8@U"V#7O;]]M.!RT*L@/9
M4',"?P=[V0XL?U9#,0LAPSZ]]*$9J&5V3'HN_D W1XCCL$ S$S7I&;O:N7>D
M6=<_I@$R=TS_%J*0-RA92>VC.",%AS!9)_K7,JU[SU3UK66Z6U?W7*J+;^+G
M.EO7QXRJ(LKS4GORFY-GF=?DH[*.)F:[/?!6/O& 6^IRXS%.\S.X(Z.HUO&6
MMW^@5A2*7PJI5.>[XNH\>7,$7XWLKP1W0>"^GQ9Q+P9L(NW%.=#"SISNSQYH
M$)FE[L%KXS3OV\>LV#'$'EYAE!J*,\?O<D[Y[)'(+\M;\/N&TRE&.U[4BN(H
M%'E+'ZD,5Z$<NP?" 7E0 ,V- F$<AT%#0XAX%^$<Z1"A+*2M?<9KWZ>1XE?]
M=W(,NV]EBIVZVJ>Z:'@"YYKN]O(Y$WF?>G/2SE6F"2T@EXY">M3V[ZY:1G%D
M<?_@:<)ZA%@T)7C1E+E^OK(;KX?O(<$;-+V&@^@^$OA$)F82WH**VO2(XUB9
M[PD>N"VMQI2NQ/B&2*EW";DT"IU_9*'L0Y.]@?.1$GDR!93ZO%/?F#C!P2TY
M)30K/GYL8YT8IVV;5-9E86D5<40HU\IH+JMXCIDT?3#4:7=@015N(&X54I;;
M%JVC\'D[YA7$-G"(!WO>WOI:G:9:ZSLI",/W$BKY6J@"6&&W;NE0?M_0TT Q
MH\.-P2(&%QITWG?Y%/LXZ''+45_-KU4W]3ODL>_E.:.$B?$23#H"4 Y>"/ ,
M\3?('RV,!E5'7)T^M\J*G1P\COL)J#S 6M]G5JRLWJRH<;/U2.FCWTOCL^]N
MFX!X&CB&KI%OZMHY0Q($#X)#5$IP,^D'X-JP.4( D']#J$*U+NW$FC2S;G[N
M"E$IB*91!8%F5'=5NC="U<\O[U[3NS'YVI=9M\] \3&V*P(\P4$S_%NZF>0F
MN A>%G"8_'F TK6?&.LFR>R*7D5&Y[88RA.M(EO2&,ROJ<^<@"*,V^%(A_Z<
M04W4(KK&IWLN+0;==:.FYHC;^]0'%3K&VPP[&FK-*%(#X4X7'5]:JC^=/K/_
ME-F+&N61."<_7$IEP4):PE3:RZ+^S-T9<69)B0EU5:632B;5Q?GX./A,^W]R
M?B;Y_SL_4_O?YF<>RVEX^.;[#A8N%%;=OXZ<.DZJ-.'&4J4A W.*<XZ\MH.\
MO/&_^Z6I_CP/]@B4!%LO$KAF;5D?7#F[>+#!(<+L/HC>'T*.S(,H,JL/8F55
MW%SJ6@#V'?53T=X[/P _<*+)S'YN _7+)@_FBV+KH8;U># 'L8<EU*:E]<\C
M8"/$0S;O7-->HO7R8%+4U<<DN6XC$;;:US]_:OZ'VQUT(V%#&0WA7L@'A'DP
MZTS%^I[7B DJ)P7Q@ =C67_O4K%ELN, *(+>7$=RY>+UR'8;I&X^SJ'[4*1S
MDN'/3?-LZN)>1!\LV4@BSY+!O8T\6%(Z5@OL5*=Y@J6(AW:<=PZ13:1ERZOC
MK&TFR]<^D=9CJ).7C0XX?#SX3^_0?Y4*UO^,ANXG<T2)X 5(;WY2@4B2#D0?
MG[G3X@@*=EPGR"%Z03'E'@+C]#A;)@6^66!X<+#3$[VL1?-G'YPDK#G$Z![C
MP?BA076#NEMXA*!@:V44IO#A@)41[)_=1%@HCG N:"W(AJ;+T!?P/7+S%4X0
M+>DPA&18$C?.(1?D(;DGLH_S8'.+#(.;D]3/%206?Q0/UJNN2F)"[CD>N6F-
M/$>=F.K:,!^'.LP6-OP)NOD)PQ6_VV$)S9&JA08T%/BC&KCG&Q+7QI"?W&@V
M01O?V'>5Q%)\0YA3.<*$MY?Q8&CH5?G'<V*4AM3^R*'_)S=D"1K0J03/=@&R
MT]PTN7$PK>& PW+R][&2@MS'$4^.4"#8*;3$@UF@=RMMF)'3:? -^>=P.D3O
MYIH/W+I"'5,DC) VSYZ..4;.^]>JB?_$)CC7RRKAP9*M"!,9XZS@+$@@?2LL
M.GE*E5J"&B:#=D80I0@D#(UA21!?[QJ)H2;5;90?!'?X\V >TB&0PE?JJDEV
M0[[P#G+S]'<CF33]GR%*70(TQ+]/T^!L\55!KNZPP^KW#'X_'NS=N0:(]0PE
MX4[R8/V3;./!%<0$:4.*(\.#N1O>A2:SLQF8AIQ8'-\P%6NDLD\0(\8WZPE>
MPQOU!$X2!\F#7=*9GDK-U.#!1C'0U").RVS<^+ZO<.^E/^TK_&>U;>L84. Y
M9$F:\)UPEBHG%,+-QSQ"[9.@=DS_[W[9S50'30!_M@BDUFM*$J$ZP0QHI- >
M/%C>+U=^0XG/SN3V?K0^F".;*'4UR_18K7P?\]R#Z1K4+\@4)'D-GNQV$NAB
MHE!,4FRI<KU_N;/C)X"$KJRJB<&VW'!V]JFYT;CG4LNY<SEGSXIKVVW37!Y2
M-8WZ,.>0'UEFG)B]T]*RQB M(\.:*'OT6^G(ZX<!0\G*U9DZ_876.24Z1HJX
M&DNUV."O2;<&LS?+OK3R8/JY/%B#&.?8\A4>+,N*!QOG!T4VMD,&IHL^S16$
MW"?X$S2MVB";%#[-# 0C%PD\V(]'>+!)S57DW%ZH4Z<>PQNHD!*O@5E9_IN]
MD/=XBD.!UI -BYQ?2A3C+!-! ,W(?1L+AD 1,PX!.'P1XR"0L:15)#2(P'XQ
M'DP\%Q0CM79MPBD\&&=G+ _VL!M\^A6]*GZ7/<^#+9/0LS.$,FWD)E\+]%0$
M>!'?L*%&Z(*LX%(X#[9;_S%U.HFPW@0AQ)\B-*T D$DYPX(@W=U/8*8A:2$<
M%QXLFXWFP=Y$48%.^)]11VZ!W@*]!7H+]!;H+=#_/X)^%W4K'LFF$9JH/U/_
M_!PO;[AD@S+JV>QO%I.O[YPKZ%/.29; LNIONK3$Q['+'^;=7_#Q>!/R\,H7
MYF,EHY-KY&Y7'JR#A&YNB LP%JAJ($?WYU-4R6 #O*Q30JWCB-ILR@5+@Q-&
M\O_R>O(]@C<YVDV?06PQMT TNQWKU_ UX*@5C!GD9Q3]1GE?,UQZ\_P9X_;0
M/#4EJ<F=]0Y=<$8]J$KXR"7S8!-GT9QKM<_UQ8GMEX\#[["ELH>C"B4J'G)K
M]-U5DFJ]-8/*.\LH@Q85^D;A371%VO3I^GQC/Z&D,)(2YEE];\TSD__XZ VB
M-^\_(7R\QK<$ 7D71B@L@,];"H)WF<@-<QXL!4YN.(]>>?>'8(E'$1M3<"Z#
M2D/_AOX3>B+@1A!#SN '>3#&$02H;O*GIV:#51,\V P<BK.2J!N7-]G_$%G2
M(!3II')W7,)O0MTH'-R\LX5Y"_,6YBW,6YBW,/^WPLRI:"M4C"KLMSO%>9.G
M=M;TJ/9;_02KFZAB.M40Z8F(@>_3MV.>[#C'%(M9\T6?3S3MGP[5J[6B>5^J
M$=@3;J^IE^N>/'W?S8&^%(<44<8YTD.54%*8WYR&@%@G2O4]G<G]S?[^Q2ZM
M>\[M,=DEY564*[\[-VTRDL^],+[LUXNE1XI-!$R$%:B^O].<@A2*R*.!@4:]
MB<&FCB4&B]VJAYM-!% '9AR^E-CG'VP--?10#'B0CN>6;O38^\XLN:_Y_RO5
ML/H;V2LM\_^%(_YE #"5W%/OJ3/JV]8A44T94GM[25SO1A[LHZ$\1/4(R\UK
MZ__ TZ'AO1"(V-SSAKO&@VV@R*NKR($,.'<;G;"<RH,I(]&X?R6BTO\RL'^'
M.?Z9I1'7^$Y !/2]X#AT1Q(T55!GMF!OP=Z"O05["_86[/^YL+5S]AW(^4WW
MQZ=W5W^ZA!?9^.&O'GV6&$O87Q^0@Y,%U,MF#>7Z%C1]0\WB?:^ NZP\^^1T
MC3-U0B/4?GOOD6)ZXD?.!XL NK;>H8B62\]76B_+*0<Y)7F_,QQ)$2H\'?1E
M^H[W4-M>I62MVV2/T%O6="E-GXMI%=FN)@*6(D=)E?5)<\9I5E7#=3<M1O,]
M/K-3MXC(UH3>@KT%>POV%NPMV/^C81^+^?G4_K:=.C\=N;=SYE3[3PY?!/^\
MR%%>^08MWJ#@XZ;+<,LD3(;=G&N_P/2,5":KY&>IB[3F#U1X;F\1^F'?49WL
M1Y,W=LI=_-7(T^9NH(3MG%V*^D_]VF:^\FZ+IU4ME'K,6):#F(+!GNR63V:)
M#T3A0AG3!X]RDQ,33;78G12D[<. BHXC:FN*>>#5:XE_L_ R[;^XBXFBPR,,
M%>;KM"(YSB7>3JZ4@AB&HY-9]$^H@#S'+G7%JNNG$KREC;],/1Z,^<M:6,>N
MQHN<:V*"L1$(OH-7O'K(.SL'OC[T:5(WL\\;/&%=6>DS;^(9>-YD/^W&VOR%
MY#UG\XWS9M]9L7!E398J)9UZ)ZOJ+$<%!\?_Y5N5R;^N5?V.^/-7JK](D/27
M\3Y/^)\VD[9@;\'>@KT%>POV%NS_?K"YCR0E'SE+";S;R_?T]TE&P=]NLP$P
MK"@@=I+([X0[01#$IMKTH!T8E6X^OMZ*A^OK]GL_0)W\XMOU)%_G('NQ%=?U
MUV\BQ!\:/RTT[S(7,Q=Y\$"Q+D:M>+%VL+)$UY)3E=;?9.'X6B7TY&)W#%U*
M5;1^QC(\Q&RWP#O#KN25)DT1LL:JM>ELG><_L"7%\T^+9H7(_V%[E;9 ;X'>
M KT%>@OT%NC_VJ"I2:>SS12LNLWB<F?4[O;U_@V?P:G3_:/&M*NX3^JWT>?]
MA7UN *DV3+O.9/!%PM/Z.HKYN+CQ<[.O)_)_O.A8],.IUGH<(W#EKU\:],7X
MW"LJR+K84EE1N%ATXUO4B&N7@%5O1FZ'*3O!^^78AX$Z5ZV6@+UB>V<5+I 1
MF-/Q1_0;NLX-W,NXLJ2Y)+NP&!26_A\G6J^0?5(=X/WCR# ":#//-3C.@SG=
M(*P*1D/4 \UYS@W[FXU$!T+^9@0Y]_[.%J*_#.2_?;C@6B$?#_8+0.+D\V =
M_^&O,[E_6K'ZN(5Y"_,6YBW,6YBW,/^WQ*SX_V*V].J.=]P?K_9'?LVIR43T
M(U&2E*&*P>@S)%'SJ\G+</'SS,O)^1?>@-/9/]U'G\7W(87T@R9XL"@)RR<T
MHO!<FLH#<%_O4C[E1;*0@NK40! [1/6@QG5<>\3PV(G N J$E!2S?^)SD/(U
MX>W*]OO[6GM;^A[TEKT5";?-Z".;FBVS.E+>%GK>KM(]W*+M2)NGV^V>.R!O
M+!3+PO4$U6ZXA+$=0[5"*764-</%?T@D"W_Y=#2]-4VV,&]AWL*\A7D+\Q;F
M_]:8\?O_R.OI4[R_<3<M#!^([QH7,3P,I-/)D56^A-:ZAI+\T5-EE-:XS]WU
M0I2&Z"*77USM-67;]:U^?RFSYU>VPTPG[D- TL#;B@M-#B5FI=.G1?J*5I:+
M/@3]G+,Q*79KMGJ5DC:P;C[4P5Q=D1 BFPD_<+>W32ONZ,2V"?F/WK2OZAE;
M/Q]NR. 0DO&JG#,\V",>K!W)TL:F\V H!PK;F!3*6.?!D"1XO!(SD [G$$$=
M'JRBN65\\\YK<ND$?+V^&6PL(LQ>WP#E>;#@)L+@''7S[%[#F&/DWJZX?WJA
MFSY(@E\T<WFP3S8H'JSG)4:5HH'<$/#BP5@'>GFPU7*)&%)S,;B+,*M<A O@
MP0X0-,+DV&X\V%N;"@@WTI0'ZTVAH)4'^\8I2YQD/3A;>)7$U<'8+7>&Z!OP
M8$?.5X*-"OCS2YW0>SSC>##R"O='J"]75^[]9]06RB-X(#:4-@G<NYI=7#DG
M)D&*!_M]<5*0+8$[Q8,58NI8Q"%ST PD\6"7+ )Y,%/[>G0[<ED/VPRVD?81
M9H>_U2LBEZTFJ0MV=WFPOH>.L_W0$!H+@\T!Z$W,WIM]5D:AA8__?J$I-SLF
M9A+=C+XG+<V#/4BD(Z-]-?1,SS^:'9 )&J@L<SF;G39HTG-I-#A,\5[#]:A8
MC,^AJ_4O:Z(V[B<>(KZ9PIXWOOSD"N/3GKVBZ271;>Y*-LVT(INXQ$RG?H_=
M-^*&'9*21TQ=JXB82*Q_E#95KP.+";]Y?C!:.U*[I9DO^6J(]#:1M&NU\8K>
M+S\V3ARW+;D2("+EKO"RIU#^H+%-<K:XZ9TR$2"=J03NII"[ @*]&:FT@2>%
MCDHGG.?=M%^2K*F9-T]W<J-S1R\..^H</*+53]&<3AQN<!S@P2:RT13[BH#I
M9N:/O6=.O:%TXQ"THK(D2(#(80]NLW3 $U6IB=T<2>U-"ZQ'\D#F'CF7>8-;
M7R;FIARONT?ZZIDGE'M&=V2>*_/5O9&I4W99X>@3,.&&_$+\I@LS8D?$Y8R)
ME_S-15<4C*N.XSQ;[12O!3R@YZ-&+@'FBO3DB&+90<T]=G<.QIRH5^K.M])&
MS%Z) 6_BU'FP[4>YA;>V[9[3[0KG.._QXR^,PJE=2S![LOU1X4?9CP525Y5V
MO)O6-E!:K609<6L]N7GZ=B$3*OYO^&G4_1>Q=U9:$"6S$B5N,\$G![3N!&5T
M2^K][DY]_F2J[\KQHKH^JV07_8K?7G&S]C/7F[^IO7\><E)P?YK'4/EE:XWC
M6/U>U0SI(_6)/@_5#DH\7E"6N[HP/Y@K[M2=Z"LS@?/GIJ%-QW]\B3*8K&<K
M3X#R$]\DFFS?JR^L/] NB#^BX^9J=N-!!67Y,P_&WSS4ZF-F]W.^U(YMDO92
MGWON/?"0VQ0Q"N'!6KIB#+<#IVC.X^*<4X.+MP3VOH\:,*TQ#R;<GNO<FYG_
MJ4EZWJI/?F>;DK/7:)-RHNG42*MR\88@\PRXFTS'I+\J03PP_*&GJDQ'/+=F
M$.>W,I>6_V['SY9UJJG!GI<+*PXJ2=7%E]??:[F9._>RMW7O[@FX)RJJ$MO3
M-E"XZ.6!-;-3JTUV\JUZIJ]Y@!NN0)&SK%;%WM&4$S<6D3OV%M%6_^,F'("L
M1#+V(2H\0Q!]J!E01O6M[$5\J,!>CPP_CBTJ,BL0U2F_K$WP=C]FG*] OR&N
MLJ<+'E%HG^QB+)&I6S6-&(E1VB#U(R>>$BC7"F^O6W%,754.,CWS ?>FC\/&
MVAM6?AJAQ15W!TR_N/=5F\J7,)8X!W)9F=WZ^=0!?27ZX\E+KD%+_(YY">6G
M%%>\K+T2/,5_N/^C^AA5,7>UF/$U/]BL -UZ\8Y#58#FB86Z6\/4%IJ)5K&C
M$B9?QYQ=R/+38VF&*1ZOQ:EAW>08F!-MV@HHQ>8 E'!WJ[&EUJW<J':&I3 B
MH^]U1[V+0@T9J5JXBC'"B; E\4.Z-8N:15A2\_#ZW06<9@G6^5QE?V&_1IPU
M?=Z\3^@;P[%T5Z&;<WK)KC/?'@7[:/T^\W!7W*^C[> PNMJS!3Y4V=X@RJAY
M@-.A"?@TNS)B,.OJ0,3XQ91O2M4#FA;:K?S>PPVD?37+UZ_<(!]("'DX_7Z$
M8C*G66\[\4Y?'$5,00H[1,PY1(AJISGB$?/\^Y5M&NNLF^SRS>INM+393JLZ
MH$R.6=[P00'K/ZR>9,X?FAQ3FAE4E7KWW%#Y\HGAVM?G<\5;:A&L6R\^>6BL
M#&/K0@:$Q6([,@)T['PN/M/(=])^4%#LD&M<EWD,3.A&WR,PUDAQI-7#'#4>
M[ WR &'% IU+K4 ORM"7AFT:&XXSY6-7_06]:O#23 T)N3SI0[%6,6/.WK=>
M8;ZF3/CH1N3*G)=[DG3P2YS^\Z=M%T4-'78!0V]PF$P:0#C<=DVD4ME"V<C'
MEBE^34; M)G?V&ZNQC[G2ZPM?1CEJ.E1S#+4Q'<MY1%_E89_=3N*??3HQL"V
M\!.EUQSNMETY,:;\;N6Z2X!XP\EX]+V'QR\ZFE5-ZEO<"<CHF2J4]C8_&T8R
M.N P;\+\Y?MI1/^GYC"(ED)^B<+]R(,]5R9LNO?,?W':G)^,Y#P2_!7-VD[D
MP<[?<<4Z%G(> H0_7,+=* -],786Q$\N]2'7%*.752 _,/O/KX3YO=T>%T!^
MR?U>0*YBI(FT&?:\_.@K_PC2LA4(A]SW(@W%-?SD8(C@]HI :-:HJY_CGD.$
M[0!R?@W!594O /O0RX[U)CR8FQMT?^^A<-P&^M3?N>@2(L^)?D%FB]&0JZWJ
MN9"5?12O!S:5\&"S;R$<;ME-_QDU&L."V#804TIM$F0+HWFPL[,BRRI_[QK6
M1?,[J8"7*_%@-FI\A1F$W]OWST(\RVIV^W^:Z.$NP"O00IA&XL8'$S9O,!=Q
M<>B_7G(3/<6!.&][2 V8?VZU$DF$".^5SWQ@;LNQG)AUE,:?SR7^9S2*.P\&
MKR:LK?GS8+D)#07<"L*70B\2Z\@L89/ U,15_I]_QV*[-N!7J2Q^B)W.:LOT
M-D-LB0SI-QD0[-J'^ZXU+T/N_KL*@N+%L [@;HWQ[=2)?"2<X$%Z6/?^. [.
M#";J:Y/VXE#%GV5%>3"!>O=RK&23F-"LUJ"-2,Q(8Y9JOU]!FO?4(Y550:$Q
MPV*U6-2 9GH'<E2BY]84*O6)M[9Q0)A$ FK)H=*5D^:7SR>)]C8R-8S3(-%"
MOU?1/''Z_X8=$KB/"5^JL,[@ZWIHQA1]*T:7:&Y8?*_[^=:+4<,-Q49"\VC4
MFFJ/63;4@^9])YPM!O'C7B!W"8L&C=8("ZJ%8-K3TZ0[5#'\84A64.1#8DOI
M6T#4LF28FW/^VY?XR!H@<3,0N/;W[EC\&WK_A4Y8Q\ES\27?"RI.SN3$</6!
MC_^V<",G@0>[=XD':[3FP6A?I&6XA3A(^7<CP .#'/7XFHE#DHL$1B65=H70
MY,&#[6J%^,(\HHI+ D66[E)ITF '%*8%?-TPO%W+&E_,S/(M9-UF?[OSLMY
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M*-O37$$2"X7TYC1#J ]XH,XO' Q7A=O+ ]'Y)9+JR><TZ,ZN<:0=_Z_.+K[
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M'SAS,V/,KP3J%[9WI; Y9#\PW\$#B;&5J(3G2J)L:QRBM\/TPE E\@H5+8%
M[8E8FTWH>5H=?%<[&KXZ'8DH:2I0.W#L&BX.XV1I-X0ZPFDCS961:J/8XA.V
M-0U /RT("@,RJY<'RA%^<TMDEK5-6.]>=9Y7($*_RERX==W0@MX4?[?MJ;M_
M1*I80$L4,]&=4OT$7O5UN6G\[2-]QJU[^@()!*_,<T96MI6+&;+9Y'Y-UB>W
M!Z4S?<MF!D.]5K$!8TZRCDM&5?5E/5I]J]'5"8^+UW!CN*T'&"X\E2U-9J:?
MMYSGM^>Y%'1#*UOFUV!^X?23PRI6[K_..I\?H:Z5S7R$%NJ1F=3!TK'ZI8W>
MX>!7+W_AZ'!B^,>4\T"U(6P)66&.&E7I>016"'GS\QJ10A.-08M5KNF)*KFY
M]@Q(CI?AKOF6K;1 ,%O6\,]5_*X9WV ]G:^C?@_;9109K[_=4,?PKFLC2#OK
MG:5E-^9S\HWJ*Z@+SM,L<*4]?CV:NY%K$VD4Z/MN2F+&+4.I+K77* SO=IZ(
M;0OW,[7Q;.=ZAD,LOQ/^&@3.EK E#=" 6E0/>+*U4]$0.#3+KV*,#7L;31>
MJM3%I']$']7>HHC#W?R2I%@=@_0EKX9Q%_+LB8EZK-27!&0@=5?_>P^AQ$*Q
M(.>WECQ*]=GETQ4X35QYB]%YW_#?A6K?GM%Y>[)BWY4#QT(],VH0C[89%Q\Y
M7:KP5K&]B D63RQ>(4\YC(=B\OQ$'/]<4,PFQE^VDH2/X-SN-YA<S<7IG_U@
MXY!]ABMC*"WC/Z\BHSWN4UHM2L-VH861"@"<L9\VF+R1;4./(D,/(?@E68VH
M$N7^W4MB:$._W8;F["OF(6>M;C]U+&KP_A#Y!/ATS.X8ZV\2;<%V9P6C^B!\
M\1O \6'>AQPRT9JSILA, L:_Y=(J"RYA:3J :.<J 1%CUS0Z3<4^G?^\5;I]
M29IL,%'S974VN,RW*AZC.MR66%BL*VI]'"ILE$5PSG3[7/S&WF88%P*WMW_F
M*QOJ\4'-WFXI?2%>+_W*D<L!&25>Y]LUPF(OV?1IC)2AKN/5U2U;#78=%MSZ
M^AVVS3'L3CX_NH7NN ZA+O!  L13R%L\4*P^GR,Y<(]!$AX@C;GO^0L)/)"P
M$LNEGTZ*;[/FU'#X]/RPX1]<,G9]HP;MQP/=G?59(\%9\)_LY_P$*H/,M<&.
MF^[G?D&?(-T!Q\'H4!Y(%C5$5 8LPXH%(T+V(5TG#C55P;-GI>F]SZLC7IN(
M\+G:'UZ7B,/G]);;H('X0>. O5A2CM9B&DV@/67*U.KUN+NU8'PO]-BXM+0^
M5-1>[X)NA.KH% 8OI%.9Z[C$<,",M+K,RD3J(##O;@W9MA_^.1938:YQO,WI
MZX*=PZ-/D".Y$Q^F]\X7DK*GL<#%:\QL.ELG4)'/+9Z:<(=FQ>CYSQYXK!:<
M;F9DI[;EJ_:=G?G6FL[R87K3N;D+O?4R(HMUWD(61/.\>U.4<@@=2@$T*&MU
M?!XG7C-63XF5+6B>X]=W+]FWLH0$HBCR2E/-"-(G$,=Y$R37971D+X*)PR'J
MR GAC"MAZ$)*_^.BR^,%1.7A>HLQO:ZV/(.'F;15"]%K$NUM&Q^L&N3-92/.
M58_I)^"MI_0:ZB_EIT?61D;4?HQ4S*VPCV': 26V>(VAV/7@*/.(2^(M=9E9
M%0Y;/9BSA%M4(8U+Q7%3,L':*AAAQ.DT^%*.&>:$=X)U_[G:9L>4LT.NWUY.
M.DE:7P")PS(AM6"V9!@U:AW'\N5^QM;N= P>KB;,09^@CJ./?4$^:F0D14U!
MNQY?@S*DGE ]'XR0B6*)9+LS7O*-8]O1W4-(F%+BMG&(V*WEFH LHSMNJ#+X
M_;;M&@3R\HW+LF,^0N_*4[(4<^T?5.A+7SI3F(\[4='WH/[TU]O?\&=+JHPD
M SJKK.X_B#VL/I:%.9^8AFD-\FP<MG-)'\/[-Y*<2ZO!-' 7;#_R#!V,(:HB
MK1GF+^=(OR"4S=H9HI@VA^JOB39@\^%SRCH>GAY6URR5L5ER[M:(Q39B:Y:P
MG%QT8O_SD^F[VR/H.1)?.G=7 X4[3$.^MWVY(]@&T4[PH15I*:.=;I'3+,?/
M,@>QV7H]_>0"6<";H?/)\^H2].[H%D$4!E3<8*BLXZ9RDU4[+8M3)N3O^CU]
M;Y5WP6E7P\D^?/EJ?L#V71S#TOZ-;96MV7BPAJ9G^-UW2$4UB1(-B5V<;5]8
MQO+(,_<I[0C?PV&F+^T7'Z=^W\.P>2!.#'JN"%*WQ)80)9NJM@+N:L_;3C&D
MJ=L?(Y7$44?8UVIBS('XN<0RM8(![>![53^"U_4]CP:NNE=<C @R6KP6%"7Z
M):)?2]HQ8F0%NR[#NH(T&T4'*DV2F9K 09HU6@1!Z<Z:X('JI==%YJ_KM0MT
M\=L.83*7RJR"%QN\]L8C4FW&PQ.#T/,A*<'W4 IPM['%3+3J$UQ)0H3U":T(
M])JG<P^1%)LE6Z"1:>:5#!\I,1NJSW?+U-"P>^80:F455%;VCJ4OTY)7+A:
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M8/7QU'_)W=64_PB?,,Z_\?AO5O^+XK\H_HOBORC^WX?B @\4@ 8V@2L\T.U
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MYCGH41@9DH#4K5QUME3@?)4]FJV_E&BB;E+;/IY0M;Q/1(?60W$=.T*Q1G=
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MH3+@5Y>(V6JKJ-_2&"7W]JF@KP^]0Q??+O%Z%=R!X[(;'D@U?3WD%YDC\CY
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M+9#1%YRT"[UPQL@WX46:G,8;SSW9N!HOT;%AO/,&)+S"!\ &)'%V+ZZ,P#J
M*Y-A [J+0=T+/QZ#035@R#W&=>B"J95D%.1'=,GNMMC[+(!&?.S<4VM!<VT>
M/T0?\GQ.%[O@J563#,7%V/T,(>JW2-[J3F_!"J:!75]A<S+GLW6O:#;P7$X^
M(\/AV;EL*>TM07.^-!<Y;X[[$7F"DE,<LCWF$2FFBBUYDM]2KO6U7IXZJ'_:
M8:]A2X[ZHY930@,)<?ZB-Y2ZI%.\@UY^,],37)1P^[.Z_>_PVL[R]&+REC3C
M)+."#;B"<-8'DH!0D!=_Z\F+75GTB$:1EX/:PI1%.60%QK55],2%GNSD:J47
MN=^':XN;"MQ]/305/^>YYEU*V8R)^% HYS]KF67'EV?T2LHT6Y)PL-&]U<RS
MU*2(62['GWZL,>>TAND!BX=)M 2'/D?W EP[L0$F"C9X@!-Q(W(, /*WJZ.$
MT?4U3^K59"$TM[8!M6C+%JIS7M+];URM*N_U"R+QN$L<IQ5%OVC@B5<(%J55
M-HF;.QP@O^AEJ% X:[6<7;Q]3K5YQY*H=LIT.9F'2T176"BZN#("=$(_1/,=
M3F[""6D'T)+-:=+1A=UDX]R'=^KC?2CP@W1E\F -+'05,^AYQO,"%=%TU[O9
M;BKT7<\XT\^X\(H\:9XK@DHLSI=#6\;X/&U3KI09\ [WM:Q8XVNIAMM&*Z%]
M#-*)KM^^VZPBRG_]6@)3;JBUPXZ3UCN4@K8,SEI:INLSYY='<>.5NA0"769]
MP60"_HE[S9T:N\"<"/I*VST5W3+]N!:<#(H4\9LGB3-^&SKPR;/^:$:'<.K"
M;7?>]+#(Y[/+E\:1+^F^YWL5E+P)WPJGZ]\P@IF%Q(EGN'(VL-"R98/!L[@$
MH5CR?+!6FZ5$ZT^)R:1EK;G0N(=M9AS5J@:^]5G1+E6KV17E9;OI'/Z(1>6?
MT];-HYLOV5(K'V$1%*M4:ZKP(ZEJ8M]*.O>F]8N:DH.F^^J%8:%F&1(:.@8/
M"L)3\6AN39^IJ%G+@>_VAKYYK0&U_3G7WK@[TP0*!HJF1'L)[TOV%PIJ^D_*
M!.IGJUG7ETQ-W1Q15(1]S4%,%".HEC.3WKLO@0W\.J?;:>)G2W6.A4Q37F!5
M61_MS53>H""!INB;I9->J_H+3N"]0LOU9(M3NK[.K"XX]0)N5&NMF?D**[6%
M@32:;;DRS-T<JYG19D8_LZ6(N3%ITJ_FQ;LR.A_MW'1[Y(N=4.&KF7HXM>)^
M@;$W9>?S^CH*01C3B8H9@</G!I-2O+Y&O@)-^E$GVEWL_'*>?M6H;4WD>E)@
MS&NM<4<C0$.-K/FQJ?<E;1^OC*"YJ7#=1)\;:4O/(FH0QJG+J?GD9KJ;4;E=
M_@EZEI%5OHFYN9V.7I=7=LH%^0VH?@D9#>XFEL%"ZU58;0BJ&>+3)!D=I2/+
MN$/GGCR&Y::0N!@Z5/0C;5\*C _#?_&!]>#*,763G8UV_JP:!%0U@(?HR&;A
MFRW'PD8IXBG!%(T1,Z9PC\-&&-?!,"&,^P>_U$3-A'F+RK(LN^CS SG6J4%&
MJB&K)FW7/ER2EK8QHA6*M+XPNIE^FB%XK/]AI@:R.N$J4QRG2P-9>VVWCM#;
MUAR94?S-.!$UV/X9N 0;<.L^1'\P"6LQ0;3><6'%3YJ(.'S6B24K[\/$M5E5
ME@Y<7YKH67"A.;!P^2--N;,C2U&KG5HY,(EFYD4Z"4^:(^UF*;O;626.X_/F
M0&X&B)^MOH'S4I]B98*!9!.[D0\='1^&):MJ:FJJXC04"Y_'&.)3?H^0#/"W
MF!.P<KKI1WTJIR%GLJ5I:24H<\-=2UTSKB+M>WS"5$_'!:L2?L+C#&EWWP_X
M,A][J:!6[JV2"+-8MVQ0$Z1Z$1K@T?!?V( +.B9#G#Y*C:2 #:3]'E".$6PM
MSYY!"VKOI!##JUOSLBJ;8G?:1-N;]FG;9\\*5U8[U975E JO?33VN%%X0[&Y
MWN_$$58P]NH0Z-7]:9K%C=JR8PW!.8B7X2,R:TE47&29//J7&>&,@W0'VG6,
M*NKU(!9&C;/O\C6@$4)9XI@:DX%D$R(UL3594LA8$NUQRLS87V#0FQMT64$E
M*X0AAC=N[XDY4<[I4C[I&":M-FN:E7;43CZ%WQSO33J5[ZGW<MJC"SY(P^0_
MO>,O="(^Q_S'RO1"LY7N>GELH+-\X$;W%,N;KA#.$(QMEO7SYH#\7ZC^E%OP
M$:*M4^\J4H1N/-F)N='[Y:Q\FU*^=[T YLA[^Z/YI0HLV=Y=G[;4 LRZM"_4
MD(IQ#'[46@-]>LO%!FPP0DSD\<_<QO'5JO#F=#<0[Z=<'_'_$@P;4$M.9>U?
MU+U8UK.T&@UKDI"@*H\LK79S8>R&; :U=7TGQ3YIHRCIYD,VQ?V*Y4NS$1&Y
M7TKS[*(OM9UH^2H/,U?/_9@G*G!\[I4"V3Q'^XQLD.W9@J8,TV.5F)K7+D];
M!>9T.1]D/O"_/-M?P&F59]N7W++WPZNI]H.%4AU%6R]_Y"?\4T'&CW=D3@;O
MQMZ@*C.$?%E<GC3C5C; H2-'UR(GQX+D*U %QDT3;D'#L [DI5\P?8LDD5J5
M?%NP48:RB#Y?2F4#CUC#+T>[<T?8@/.<,,ZM),2SJG*T=5EY)5/O)H5ZO&7H
M[5#"%,?]9F.^O2W2^4:6>.,DD[E$?%#AC5=^'YL[0K5-U 6E'F?G&5;T15@=
M-9\;K6E1O*-*[J;+#BU$^V]YL]Z!@@C71>'FK(9QE:&%!74B0$^QC^ST0IC2
M<.'*_&:]7OYOKA]Y4X/>1P^1K*6V/<H8[UVFD'X?7/I6>+WHV_.P<60K[#Z<
M>C&6+I>\D$E]T$!ZO=[R0ZZLMY%B0 '(D+XF] "R=Z0$4$OCG6Y:$G(+%JMP
MX&X2KI>E(4*#Q1EGJ6_J^U:"Q&17%>\,M9IB36EWZ]=(YVIK4BC(.:Z(-N&D
MC@HIY^.?1NB'D"6;=8:]H:+%A7HF'^3\2B!#9!RX=3-/(#LA#:WFIY89%:VI
M#+.'&?/K6:X51QM:/LSK=]<W5<W1Z$SR,33:1_.2+E1$3X ,?L2: !/_C0VX
MDR(@B64!I\O^KJD4OV7(L.AA V01NBLU7K<N9,N4?FHB*%5+4=/LYG5U<7N3
MOG)^\J)F4Y.=T /W@KG*.]:QB$?^RD)SIUC*M).9$K%;3RA+.^G*E#V)>\(G
MN_?^RROB%80L3,BH 2T@? 5WP-UZ<SU<7=[+M6GDLVAPJ7N0NQ#A^;S0[92B
MZ#P#KO'9.XF%Y:M1'QW."A3TF]E/% L<MPD(QW=;F?H6V.7<SK=JML[?R!\H
ME)<ZW;7DEIN=<"7!W%A!7_JE='Z!DHU&ZWX\EWNC0%Z?=:BFQV*KBKW'V+=1
MKPH#M>.?FQ3KFLV0WMKFNMK\^J^;U$[D&5Y)DN&)TSNB*OFD^G5UB?6N _(X
M:O@#[&'J>I.F<DCM3C*:EPYOJ!=['6M"77I8>SAS-D.4^N$!_O?W/39NU?LB
M/5URW&^;E=88>#J[[]K[H<5Y]^,S4H+#+O[R2E=3S%]7F[SL#<H>,2E,-=HZ
MREUC]VVHCI ST'M[9/84(95+]L73D#_?G,X&790WY#=!YGWU;J:4'0T\! G)
MQ4G8EBCV+!O >U:OQ0X;LXQ8D*J\;.(+Z4GK6G0;8ED+T\1JQ>T'9T>^U<HA
MELTFB0M6]]E ?Y3M[  ;>*+/SVKR06]Z[KO5_R_$_%OA^*\-U(!3S0@[D!-+
M(_;-HAUO:;/UB%XUM."GS@=3VI0N-1-K]1MA>OU^S[Y)F744?KY FM^!X$"M
MA&YA61\JT8>"!=H*Z8[-8_0M<N>XIZ9BF4J!@^<=]68S-N ]<]SI0MSG3L'R
M^BS\.;S?4 6WZWY>;"LQ==T@>OPT7]SOUPP,S(MBLL.LS7=8F^_]]=[97:)L
M0(41.+& XJ2'IZ'\7 X1'M'4OW\NW?]B0"Y6S&+TF@BF74D/Q1F;9W<B.S7A
M^.KQ\JM9HA^)S-NL+J+X,B@:',G@36J#Z^-%,%:)+N.':+=MY4HP[]5.\,B]
MI=:[:]Y*KLC@UR2_5^(JU+[Z/,_Z??&;^@-I<Y9O49ZKTRS.\*VS[G=XQRNI
M1ULT'UH;4L3/TQ^\#1#V5;AI7&@(%1<EY-7 O;]7]?]:7E;7=YAGU_IQ=&--
MT8W"R?BU06+T>9F40<P-KY=)XY1QF^D0C"3F98A;FK9YBYP@9BIZP/$TWX.C
M0,=98&@&UTBD'PMH@^]POSTB$ZG@AW@\>-)'\N30YO<Q]W$I/OV3V0&B4_<Q
M2QU%.][T^XUV;NP=._/EE2\Z'Z.\<K\#XWJDZ29.U$ 8R9WTO>G8AYME,E'1
MVI+3<I&[8YK,ZZ44U*8UR 7DV:$Z#B[^+,.+T7;$5A*2,!S?6J](CTVA#TT(
M7H@73O-!%S?[$'9\W0@]%/-21CLS/.=A!MCT+$,Y_EA"J9V:VT#7,J.;/_G6
MM?W-US2P-Y1L0R](\V^*O"#N4R?1Y>&Q2EZ2D4TX3NRQ;,?7@L9U:,>!\D_.
MM_:2UK3L'795](5D%CV:"-LE.H]P\AXQH+2UP4<L+H&/)>2K!Q1CF]#[#7/<
MA/(DTLEC2C:K).XW<6WGRSBO*VGC3JC>O:6DSO$XZI9#=1SL6Q4\FP-PU3X;
M=_/K67N5KI)G@SHQ>S*.:'#1#PD)#M2L)4X_->!]%-^7M#\SK*#[E+MIRGKL
M]^1'Q&O>O>A[C!.TG2W( Z]90A-ID?<T? \V:Z15$ ZX?-;%N7)SS;8XO5Y
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MHOS@Z]+(IMCRB0<_N80$BFWYJ8D%)2I^;M329>]P]0SN5#_STI/92(@)J_T
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M77/Y&5*R(P[YAP:O0D.'V )-)>I^GHAM!%Q0HI"?EA A\'.1$G4QFBW#PQN
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MWD1OJ.$8  :T#QMB$RYH&Y%>N$DRI7WCD\MR!R@G"AY<[T4!GK->".V5:_;
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M'1EF',_([+C.C@B]USS0B0%M1+ ?M(DV?3I:YD*) 'M:T6K0^+#()15>TU%
M6=]+\7H"G?R:H]_;8/SLO>\>^AT*4=1U9K(*+S0::,@.;ZN^O[',T\@HPM4/
M>,;F/R-\3T%#&^F*O]@SB'J>JPJ74!%(4H#[GC1&@+L9PGGX*6]%H,I"Q%-V
M N;]*+R\$QFH D5%TPYXD%W!F!Y6HI8/"TGMZ!7R&U!B&'K&0-+9DJ,* D@R
M"Y-&@SV) 6#JK4)C<T%1[#4BPPAJY9C\[E7;GR_1312-44X']7\8)8=QTF,Y
MANS;T7I2NJ(!X->Q06>F"<4$RD*$_0;= XVD L6]IDWD[\/-?FN'J<9D3$O3
M$HEY'"G_Q:M!L8-]WAER@(#7+&O$M#\(M#O"%J*7US3FD^=;N#/IL<7O@PWC
MDX$M^#\7*4Y0WP/5P[=QY_$CL2)@QDG4:#=_&NQI)BT*'M]1]^[::,*6.;3F
MI"[LD4&3[SQ_XUJESVE?*(-C6^<91XH*7?UNI/.9Y3]W_[FGS_BY@&2_:T#S
M$<227O)J21QL+$:/)UVBR*88(V!A#LH3M9Y_+O?T)1UC033$IVE2[ZXA6ND4
MUXJZ%E*<%:+UN_R+@X;KHFNJ\BEJOEH+GZ@#O\>ZL>H;W1!_P\<J42'B!*""
MP"'=8:. ( ;-T4@16^:H MD?A7B@SU'PXJT2,ENHD-9*W)R:P/D$^281 BEI
MAD/LW/?1#SQ!WS>Q>,EPW/V3?5L;.EULPQ15?RE1L22J)M!\V*IG9%3JB_21
MQZT7T'[MTF,8,EN8"2\H>Q2/9I%6QO4JH41!RG'2&G)JCUOC "6,!.8=D9C)
M/7/,JB4KRZQL<5JL]5&^Q\?'GF9:D,LL7SM.(@I!<%*S.]4!N;LY&,L\()J(
M>;M)$SHRSP_H" /9+<<H9N\H_KG>DW:JTC/SO$L2+7)'Q[A#NOC4CW,>L@./
M'._Y?TK'C,@20F59A#=BN2'B5^M;X>5F2E0 !9@S:6"6 _Q83&W C)<LD"R&
ME[OG4?MXJY4HP84)-HH=J+!_35 +80M4H5"^&-HO-W>LD!P?\K7H!M&W'2Q#
MR\6UX'@R9K3!?6M5,?9];9FPL6T4P4RK>PD]3/D:NHP$#^!>V$[O!DM$Z.D,
MB3VLX\(A:5$'QY="Q#)R,KR*3<NQDY%BPNFW<<8.QYY]98]@M!K,19;+1V?L
MQ+$4VVA%7E#AWA(G1;8T$"NL:F#7UBT,2]M_X3$R!E9#F/_B29 T<TOR?%-#
MN BK*<=!YXN@G<VZMG8D&@N?C#%P"../^@;S]M?F&&TO"O2^;#G7HT-F'*OL
M^Y*\#VQ**3T39+>U %CY*)>'HC[O);REMY"@)'MI+P3DP_TY^M!/F3G,@5=+
M&N^8;(5"9+O)3,'UE.BRR1R]1DL@M^C.18E7<\\=JB58T/2JT"QVU*C'8)3\
M:(;EEISMM@]LY'C62!0(J5K\#.ES!>4:]$6V3WX.^3L,:':"=;YB%BM1).!6
M>D0F[&"Z8BAG$53/3]Y;\.%M::!N_V3D@&[F6%,R,]!D0W6TN?> %<X0<O,
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MJAHT B3L9IR4*!1=B3*=4EA2O_\;/=#_55T6?"ZBL<3+?)/W/+FQEQ*5H;J
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ML>H&*3B+&_%_GV(15GXX<V;2<,GT=V"+]4?J;U";! .K?9$=@DC2%F@[Z0;
M'YUZ4XWGJ@I8V1TCLST&9*>3C3<GWUHYFZ@'E7_2#+;S>]:[_1WE/+$H^'*M
MC6%\@;]YK(@=]TYXIJ9(\Y/5^36CB]Q[-/6=L:7'D\[TIZ77WCD97)MO>:11
M9$BF$T>:'Q\ ]1,^0<6U\65FAD?PT%7208N)^LOJ)5<+RS\MP<RN>=K X >T
M\VB8ZH@6_&^4$,B-V2;$TQ"SL+*(CFI=N%_TX,J]-SU+OF4\/YU^PVHF;/_
MG_6]<UU;+^Z<J&.E?'HX<G^I^9 %M*Y@=U^QG<?9S>&;NH\6JQ49M%RYO./.
MTVG1QK=6_8-6_;@@=]=-SD4&Z_N/3!269T:?\"Y<?<SYCY;_KGGR_X&:)Z%
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MU%&>;EG3$KA3B:H&Y%O$21&12UG"9$ =:'D"_>"S=^X#IZ^XE1* $/D^R%>
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MF7WM[A[_G!1' "T8,;C*?/Z6?"Y1<),$A'F 8=Q8R![T9'I]?U#=7^#)1DM
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MR)EN>B3A6IA(<AN'E=L.B*=+IG@2TP]&6=UUL!R,IX@[1SFYO].\<6G?;/>
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MY7?.LU4K_QG3E<S])>EA?P+Y9WC[&=Y^HN(G*OX7HZ(7'\N0-SK,5#-2U"Y
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M3P8CST_K<0P\9R V=;!XO[H-N<S*UJFSDWYIER^JQQMVW_@IXP_RKP<A;&T
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M9@ )2E'\2:&9?*@D8;:6PN' S7!1'L@WD3"\PKI$Z[[+ S7Q0*]XH& >Z&8
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MBA&DCVXB+&,Q= <>* WS*U>7?8GSB#_SL$=Q 0/A"Q943FW)2^&Z5HD?2Q)
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MLCJ1H$%81B95S5:X;X/G =YX0W, <X%0[AIHO%#)D<\E'0\UH^P5ZOJ Y>?
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MPM4A8"2M_LT<+/?\K==RV%;A>.DACDRF"!*$R"3_ CS""QI8%%7,8;'Z@1Y
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M6D!Z87A-_6?L3^]4^YMGWON%F*FK37ZB?<I&='*T*H'DWN,EQ^9]2??"\ZO
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MC+QRR!F5 /=\!BER&%*VG^\\,]K<X;P;HZ.L]14="]P&SI:X_&:QUK&4T2(
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M55;_/[SV;:#$D&^>_JKBU_1NFPNPE37&/L+\8V/O:U!\$?+#MBX7,%DK6Q!
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M0@-RU&N@^8-7V$^Z^)EG E%B\/UDTD&6=?85QH7.@SSH!9J%DV-!%.6_/D]
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MJ)'QFK'-L=!&;D)X%A^8DMU-1NZ*3?$&W8G:"WIP\2.">M?B8),,81$T1)#
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MZL&@@^[MF1QQQ%O.?FI-DA&HBN%"O)_P;;!BD?&RKX VMXX4C$3R!TX7'VC
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MGEGS6NK='V5V(9U5(B1TLX&N'-YLB;NBM4GBGI.BG5FJ3L-[[8SK/MH8TZ$
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M($#LZRJ$A+X<2PW3J[\'H->BMG@J"H&BS"$C>:>\2)(^1KI8XP%+Y$U5<<&
M.YO=PE"(3SS[*PKW_PS4];P"@B::H\W_@*@ YL2]Z)-U3OY,F5%D"SQ1FK_U
M90_-*+QID:L.AC*0VPSI4Y4QLX%'->]7YFONZ;[4TVW1H]B@83]UQ6=PYSKB
MCUIUXA0?> + /#/_*:2;G06."45">9@<6#@&;PZ3[S_!M+RCD?RCF)$;-6.X
M/NKF8X^K(\Z>]L6?KTO7ULV9V_=JJ5NM,NQ<LV9:%[Q'83S<4XH2"LK;P1 *
M5SMZKE< $[TI@.TUY-4'"6";(;*Z%XJ3.U#@Z4IXF0#V[H  %O]* -N5_ GU
MI1C(!=K1X(/OO:L3?^_GI;@Z7H@J$ZY,.[L.DFX.GX8JI<VJ<+#<(TR9*-3E
M]ABB."D  <>?!K$<U)"'/9):+/2FSUFL*R 1U90N@)57-\$E9T(BBU8K;P77
MS VW?6:_.];\,4]S6AK]3 L1063B9&YX[V$YHBJ59RM93Y9BQFL$L$B_/)PO
M.ZB[A&LZ;KC[UGNUPOF!5OHY\7=JNYJW&.AVO,LX175\1G!Y++0L@!D!.BCF
M*0JH(90H@'G.)RD>YD$/[XL*9V/+T7-CS*_'['4"U$*]3:@C\N!COFP5QS>F
MHDV/ZKR+TE.)%L--G.ZHPI5J%JI[-87 $_![%//'D"*T\^Y]AF@$)-,&R*SH
M,T1F/>HW)!B$Y=Y!@PZZ\UQM#/<AP+U+ T\;" ,7@7?7!+"X:KX1$G0D+IA0
M&$\%,"(%?  TJOV*(/TKOOBGI>A%* D<D9HEVJD%EP"KG3NY!^ES>S>\ZEEN
M ZS*NS0?B@2.M@8]Q[:M+ZZY%+G!#N._I3!M!^(HN,)J?PV4IS>V2W+MP41"
M'P'!''^Q4+SC8%5>R?2*7G97W;'LXTHMU;HEA=?6'9G\>,=0-H/][=3^8A^W
M>/ -KYCBC4I 5=(22K2("IXK\NA;L[Y[ 2'ND2Z2,GHSSN=#^7X)4]A"NEU_
MUC:1^2W8IOZ44UUOW-/D@92\AN\"V#9<>/I55_D )Q3I*YCADZNP9E-<1J3:
MRR)+C>)GDQW7K!)UGIOE!+><O97@8E6,FO-]JMR1ET1(E<LZ?"@OR1%!+S&,
MCX(?&].W%#L_^+((V*.[\!;T109>97XH/T^?[BI.*,:(&ZY-O3#361R7;UN/
MWRLDQU/@VOVEY-M;K-BW;Q7MFX;!-XQOV9YSDA:CF1)Z%FL_6D>=+0&SYHT<
M[A^?"LRQ\[S>A6S??#=_'3>P&&@(=3%?P8KQVQ(-TC:*MQ;CS:2K9^M<G]UZ
MT]!_G97UTN;E/?B\H@#V,4Q6^?%>"I$U<L"/K/$LQU AHC7_E;/F"]QFS3&I
M3O^Q"PF%R"-?2U;5D]G$", 5"@-JT0?.O?A.V>2GO&U,R?1$B4O39Y<L>J'-
M\Y[@:1.1QOM9\J^MZU*^Q#6^:T2F?O0= 7J4;U)&:U'KM8ZJ[P##F4$,9,2@
M4V%@*+W-Y%=66&HMHGYGTH*OR$B%VAOQAOWD.Z4,BA7@UCY8.XJ:,\J9MB<V
M)&]S #.<Q/14](]G.WJLIB62W)7.:(NX\?)RIJO2RHN"X!Z!V[1M6[Z^=[ME
M$_7U1!0E?+]XST5*-A'<D7O_M@>BHCTF5V6K\3P][;[;G5N[<HHI2<@\C=D3
M!<;E31^:;CP>CY%BCRCBTIOE)L3'ORMZ6*]/H%X<BP\\"!>6ERT ;!LN'CQX
M;T]4JKSBTF3+(6OJ>U;*N-]UMP6@&YB$+P4SDU^3#[-\J9\14E=;0JDVX#79
MS6G;C&(^Z@ (_96XLBM1Q=ML-K.37!\V=U*_!I;*!E_PC]NDM>_XN<CS1XT$
ML..Z;,H3G(-)#]Z0X>UFSF3??&;_+K1@QKZ75Y*>XU%U-:$U,.RY<ZMH<9%X
M<OW^A:>;;UB>(KT'XBE,.\H DMZ[/')GE#Z&2I!/?$82&0919M7=^$.NIZ.$
M2;B[$Z?3ONV@B@3F3-FG/GH\?XMQCHIH\@7WS<\-,$B#Z8SKE:.03_;"I"'6
M<"6+/D^-2'9<F<!YZ]L%YUKLJ<C2Z;<Z<O8Y^KG978O'#I]]HTVZG->L.^@I
MHYO:W/XUT*UYY/"8RIB?K)AT3F22 MPJP-DC-I<E=?!PN%_JZ3TR>XPSQ2[Q
M'LT8UQ6:I'EN31D/0QG[#E@W?OHF^0[7.B5Z?Z)W\</\^J@/4[C@VV/2YA%O
MF2]KSI ,A9H>/%.Q:3OX@%+Z2/&P<)KM^^?CJ<.G=Y?J?&_H35Y"AT%T\MLC
M['M-VD"!=+<^]4O]2M.4!$A-"=]_G2]\=_V]DD/Y2H^/R<8MMV^ 7"9T;/J0
M/76,%(Z5T$=^O>+PD +W=-[.<BW:C M>%Y0".D\QG%^>RK+2V?B&M&@!I?J_
M@$/-=UJ1D7@$@RC1['.]?>]-.L_A_"D'A5*UJ;YT$;F&C]O"DT)L+Y?2>4'4
M?M3%_B4GAY-UL!2/PJG^$.^W:^7VBKR]<&_-G4=Y<E(L3;P-ZY?P\W$/[I*,
MK6IL%NI^>:).D-(];W^X&GV]@!#4PR__ +@A.DA:"0N.B#4][Q?-MLX='5?<
MZ8=?C,/<,BMVU+C0=#13S,O>H^^U6>;P]VU.Q)4PCAZ_![L!Y>F[V=-9#=1B
M>"QSMDLLT"S[BY%+8=8G>Y8L3GP3>EE=0:[HF?L-XW$AR20I5(ZT_[-2Q*N+
MS^ 9*'=?4%5H=H9SF'NNWV +WK"3K^R$RZ:R0]3GYMY$<?6>>.KJWYZIL<@M
MO:Q>0L);YSK6YA1_4;NZNRS6RGLR4;5D<0'+W1)O>1"_'FPK2%6:HTG/%:V]
MLQ+U8)0G@5_;$^EM0XYX%*CUW0G2%B" I<R"#P2PBRO49-ZO2_*\(/VQ#QPA
M^HAALZ;2S9P'7\\/:OJ)K]9-1+*MDR[.6Z::=3URU8K,UJLI,WUE=ZTB_7LZ
M7;ECHN&CRJH?2%T*_JCFY^-"7_F%6>+V\%(EI>K%2^<=P5'2E+4F*0KW1\O>
MRWHNO5AD;&L7>[)YO8R.-=4L.]7>/Q,]D R&T6:AWOP*3P1 $]!- 'L8QY/D
M/1+ W-%K(;8F4D&+!\3F\,?=Z(D8Z[Z PO/Z:!>W/,_&,4-R"KHVV/M*X';;
MX0O!V9=OIK$&QG;4& \<YXKVLW="O!>*C"GR3!->$E8<M:Q<0]*C8K> \7&X
MJ!*[C-9US([W+)V7/*S(K&>HIPTS@![,,>7454[@AC"M)1F\-]W]DT:C09U#
M#?K5R?I'GS0'+'(QB$N.1VWM:! []_P-8B_^F[-C2E]&;M/N><&M',:7;Z9C
M!@W.AYY:((>2>N+V/:7@4&]V_#D3W2STH#([''3BJ'&WL:+?$!/E>R>B"?(X
M2;XX1/1, ^-%%6Q8ZX>)W-U\E4Y]A>Q@>^-8K]#\85XVEB66ZJ4\4)S#T;>N
M[QE2IZ>=K#DW;9MOF2AK66Q?'JE[;JKY?:#JN;L).S<V:ZM\M# ^:%HU:.H4
M9Y7@HF+ZO$7EO97W'MF<ZT,AN^_6^IY,]GI*V2J ,7;0P#W]/&FB+$#/ /,$
ML _U"-867Z[$##\>G8!BMN&M!;"OSO7 LG\,:M(\ Z"+*0M@J8]HS@T"6(<M
M LI8H N^) ^^5V.A^;M$H6#K!'1ZL*+Y<J0X@-O:*8")__ =&I3)"A#*-#?W
M-Z/XKI,"&$8GG!_Q*H^_A0%\/Q\6*@3Y[_, =SO$:N^BO/:1FE%@C#9?&$H4
MC?):$.!ELHH MH@TX9Y4@ P$XI)/N\?@W,-8Z F^IV?S'!GP58FO1- P5@ ;
MO[ \B^"MAW)D9B"*?XI7]%]YSN0_/F9T_PM@22H:ZG\/!*3$+J- //%H57N3
MC  F XP2;;,D>[X%H+=^H,GU4^V;,Y<_I@?G>,V0\ IA"F<K>F8?(#6''AXS
M\B[9T:.^W>=*3J+&;[O.IU'0_[ _!!$(!XOR;1](9L^ ',XF&J&-?*B7B_5F
M=C=E':Y@A4Z/P%DF$8D1?#46@BI78713WSS7HYB@X<+D/[_D=?#0T/TMEF?:
MM@#ES)7HQ5-^2:;+7!(BNJ&GZ=P3Y^(KZI[GQC:!(157IBTW'?0/W*H45/3L
M;NUU_:)YA>A@9_7.IK.9Y[NM(URL)+P;SQ(;,P<=JPFFQ)>0'$VPH*H]OW]$
M_"$[F/>8](0Y/Q?-?(CV.G:]W<HA["@?B?,]=?(FUR_;H46I$I \_SB9+YDH
MW7!R?Y<AHUY,Z:FG=EJ(T#=O()/6C%Z#:^EN<I8%IY@HIQX\G#5/)SSQ8""$
M<0]_?>FPW6S56R6AC^VKMM97Z[/75T/WZLXVE^?V%OY//)F?IS YZM!H0X![
ML-RMU8T(YAEL>$G&!#LH@N*!C$KKJ\&V$*-:R>_1E4HB^[C!]#"#J<$YKA)I
MN.7=L7R/;W7*)7)UQPIJ6P8U\HI#1Y"@7?SHE:[<PT*6-F7ZE\:M(L\W=CYI
MV_W*WGEV5\X>N0:[L_G[GN>8%8LPF13QKH]7.W.LS&3?GSV;+[V<FC;][=N4
MMDSA/6L*18Y8$'#6B+ OS/T_._-H^\=/<]@%YC\1P-YZF0A@+W*) EC.U8X-
M\W^<?.W]]#>SLW_:!*#BWTZ^:OWM].R?!QW_'$ICCW8(8+/*RORDWIF/A9V!
MB._*N@A>Q!>(,P_6!_?^:0NJIO#53Y29I\#DB5I:+&IA>Q4D !L*/Y6&6?\?
MG3DC1/R3YJ7_,C?=#TKRC<-0O%8:;]=+TF.OB?E?@+?MD*MX%0K9 $9J213F
M-I0O<<O$A5LXL=V-;RA/XD60*$L%]JM'AGCNJ]H+I$=_6#7WS&.A9K[QJU^E
M*ERKQ3)"5Y&O?ZR96YSX_1H.)=$7/#+&MW*!V$:[ %:VHLTGS0\>H91E\-4$
ML-$(\HY*$')4ZS]"GKZ%_X& HE1V<+U92 :\J5T>5*5:G2PE-@\"X0;:(*7Y
MB-5D;NCMRS6]^FM8EJTM537Z!X>='7'714UL1;?G1H?MA/%[U, G/$COXY#?
M$^&_:X\$ED]PW4ES(92XZKX 8!#)AV]B-J_<Q*!92&C47$9%\I4ZR3NFSS@J
M#.DYN31"X5PY$7_L>86QGJ^&NF$C19*@@@MJK&8OF,>K^YN2-WQQ.EGUV]I>
M8'2T?0C-;N*E0$_QE,*T&$(/H%LH6TA:@!S.K3GC\@,FW!),'D-LYNX#J2QD
MT\C!*B:*.H2,=1;IA#(F'-!2=7UD5_]2'D>L[KG&XQL>K053*JBAN3!#!H8K
M(<07L6&TKYFF;?-!C58#\B9S'K[/1G E[:/MU!E FFO NU^B;R%5L7('K]?M
MC=<: ^ @?NJ0T\$7I:S+A4S,;!=R8*Q'7[:TT-ED@L:TKU4X9L@7J8:"W;YJ
M<E74-UF^$L[G^ZY,Z9/F;8?'DB.7U0W&;6[^XJ7',?=J#>)T.A[?6F"X0VF5
M^1@^L<@7Y4+:><PUX5%0%TB*N$7VDUY-$NB +7=+TO)=RS4'PZ53W>A#<!F<
M<7NC/39!$QLC_^UASN"GR0SCNBJ,/#N=X75,HK'U-(W^MO+Y_B)*E44D:3QO
M=H6ES-\4#\5\4:X5.,9R@'*>N3LL./_'*O*Z[Z YZY=%.HT:""*]BSRPTOI!
M179OW$J&'*8'YR/U,:.\D)6F?'J8(36$EEQ2H@_ (^JTD#$56#B(;;2?_CRS
M6O!]A;O%JS%+C47C2J+Y(I6CP"\BX6/)<IZ4"F2DOKRZY(=: S66S&O4]BG%
M[=*E7X+3A3!UY5MRC;\?*3'VQV:CF!Y 0MUVTE\*17,//G;\)( U6HRB![49
MN9EC]08[/<2RI7-*SH/HII"].<&;K11>S?ERM9][5!W1S?GL7BWAWC_H6OXV
M0_/6 ?B$"U]L,P@%G/7[>7<(6_ 2O(> )W'P^CQ[D)=628GM!\0)&PD=BH>9
MXRU$5A#50)=)B:P4P.!>E,WXL$)'+_+.7I+%?#37129&<ZA=$@QO3O'*MGQ)
MI-:4W)&^PU#?@)B<YXL= H=9V:-"7 D].B:)OP[O!!*9UF\D\([@^B>F8\B(
M+ ,6E@I(D6.?XX^Q*E96#X/1#8-5B855J6''$N_U9_@[*Y@_N#)W*4,F%!>'
M@W,5D0S$YB&@ ?+9;G#A8><I%MAJSRO51S&V"UG>IO(* ^G$S7@IL#,7K&)_
MT%X]WCVKA97!J8J>;N;<\<_WV 5D%L]  @S/!L8W \*0+W[)_TA;+3'8<4:H
M \4\#X JZ2WMH'(Z5R)Y5*B9&%Z^1P![0TKJ0PF19=RQXG68=81]BB*4?KZ$
MIX$V"]UDWGKLBO,@2&Q.]*87/K20%R7H#>M:^-KQ:7W%RZ'>>\,4;+]W4?D;
MVR!)7V!%4XL/C_DD0W^O\IXN^R8;[&36IR<%A E15XE)NWGW*RU\;3M2SG0O
MJ:MN%V*PF)43MWQ=:^(4$/(>-)&OW3Z:WW>PUA-O['8130SKYP2]@>SR,XO$
ME?1B^X"B/W0))N=Q-4%?5OIKU,;]9#E<#.!+90PK,)*C^0AW0S,6^L:RN@@U
M2]E)N4D14=7OFA3:YF7^DCF[JE&</T7855G?$2AJV85]]Y $:A?R-Z5RI)W)
MI1 *%*MO%>+*T<R/Z;NK,Y0A=AROFY> %Z:#%\46MA]:-.U",*(;D0K86I^,
MD7DGT(U^[&B)AK/<D[+$W>27,%X1]/L#A$Y$-:TE>2"]V=Z-NS5[E)1 EL0'
M@:@Q+\I&9!+7;=07Q!S NS(OV>.#I E'Y4\,>H0HLW,SGSO,R-M6YX-N%MU<
MM?Q/#4^\0BYM#-0K(BB#,NPXZ,X/@08 \$@>%#+A)0.>PPYL2+&WKG'7L!YE
MK2L#\YGOJ6?"&?U-G*B[7Z9T,[,JLZ?Y"JPP6FR=>:X=*C:O.X"D@$,TDF%,
M<C6]ULFXN]EY#\J[[\<:WZT3T&"S *Y@ATB-6.89WT_1[#IF=72% #8DPK9A
MMB?A15")>$GO"_1>EDQ,$*Z;GE29#2:CF<W-[5%7ZESHZ)@0$2-$#'Y3#1"M
M52AJO*$[P%PXP(W2Q\WF;_[&$KL!A5OM.;71<UGK6-51E"N^6\#H)GOSIR8%
MY]T55<"#3%\3YH>5TB,:V;=F;)DF"7/%5@'G'!*USYPOW_5Y/6P!D9BU#^KF
M<Z!AK8$N_Z.!+FM^+I+ES]_DP-G,O09&^C)KWY 1("D'E]P,R.HK%W]V&,:E
MG$FF5LM38NK"QE3TT4(1%>W2N.S7W9-9ZD3JZJR!?+_^409)V(-E[RY?OAK$
MW<J>%ID'C\KP-S:'>BD_] YF?FN<'G$JR;HDHW@(I.X_=.6.U4F:0J'W':E^
M'5?;=? I-+N05P9<!CY%T_FQ+#3[.4C*YNY@PF.XKGEX@TY]HZ(IPIZ^'3WZ
M%PJFY+_5NV0;N=&=))U[[II6 *)>Z?-!6O="PNIT\42/VL@O-_?PW2FC.8,M
M#QD(4(?&WUA(FNQ7"WWF1=RL&>9B5G?^:Z3/TC"ZF2A#NN)CJQ;#R-J3U8?+
M$6_?:KTCK*PE2>Y7(<A1,AV(H*K0'(*CS[7@/0)&LRA,- ]IVD/Q%L &&5X>
M 22)Z<'KQ&(JD_1ZL*_\.<[:D+4^*;7P>.A3P-LK9"25X3!6 J98].*/T9&B
M..4F>W)>-K:R+8&-TO<D,HVPX/ZTE-$IPC[0A2]2RSDQ@ZV8M9TA:=_0*J3%
ML*$XGLJN2:NE-59=EP'$*[TE6DVU[U"ER/5^3(\*SOTTZ\!1!T3UZ3Z^ L?Y
M<P.SG"\VP@O7#V2=F%;7?CUR%%3R>@HJG.L='WY65<Q(CD141#<"HN[L%$]%
MF\2J;&1SF%F+SG[OO<%T2M]2*SC&N9[WBRDO]8S0X@PT>G\L,I'PYWFE7#C'
MA"O$*\<?=J.CAJS9._H#X:)<][*.I8?>.\ 9HTY?K>)?5IIHS,2!0^Z#Z$1-
MWZV@BP.3EKB4#*]3E/4VLX"?9_*J4O)PD9KJ,@M8]O8>RN@S&O-J JU":$Z>
MQH32S!C(HK$-Z&BLK$_=6J8 Q@[BI7_I"2#)3=I?(2MVZQL]<\)5.S*!)((\
M+FW>.-VLSWO_7-U91J$ )IF7R+7+ >F:WH<;[7VCO9?>KK:#NVD)^,,DH*$1
M8-K[#J*HJ\OUU:^1:_ Z8.TSL+OI=D4L_4O?%0,D_D :(/Y.D3@QB'4H H3)
M^Z:OASQ]UA^49N7L[*"V_<2<W1UH+&\&+@%#7C:LE;E:2#"FD&!B00[;7Y?2
MA)*8'$PEW?#&![LR)TZQ>C.F,B9BZO:,\OQ/]9"EN99@:+;)WMI<W*V^@?0W
M&7L>R4=6$J.N%"T=Z?ZMZX9!#2]%$PGN7^%*#O$WJ3#;V=9@.TMA3(:[-9TM
M"E+I/6GH04P385T_:;G]5DA"VFIE8NI* C[P^;2!<N^2D]OI_HI,U?ZF&G@<
M>2>.8M+'E2MI8,S!ID9VR9=D>LU STX!5>%S2DPD8V66!74=RF-NA7C8'\GG
M7"/TSO@&NS&*?;K->JX0)'%*=CV56+B[?5MJ5KU4>Q1 W]FG)2K2+%^W6AT[
M%Z@NTT"68A)RBCSMQ9X%9NX-1;;.2;(AKG.K"VB0%<"\? ?TV$'0OXEXZ)DY
M6 (4NBIHB4^9$$?Q<P40,5R7#9E>4$X+8II"/MX<JZ5MQB$8FEFJS$M\?>;E
MVN))2)%+1"D/>SX1T$BA\ZXIS,1G!IDMM(-J;@W86*PD1%'':0/EKYUE>,_T
M[3CRN+PQF=?MZSUH&U$><#%W&47E7CRRT)R.2"#(5[SH"'B+=QM5>?:PA:S<
MK>4;E>.MCW8Y5CD?9]3J,+S[J\@->&>8-7\C% O7IS*CPS4,U$&(KN9S3N#*
MV<]>=".<D^EOXF@M=_D?[2=BZ&4>)A'[ETCB^),LF<B*X2->;R'KPYOD<W<0
MT2]%CK6MA =\Z2E93QR"AC0:5.V'K-F',B" C5DF<\YZA*"HR8-$]@'6]C>W
M4!Z%7KCBI7J)Z8_OU<.N\)5$#PW:%6O*Y;UB!B54 #+NJP'5\K:9))R] ':F
M*S$KN=@CQ"*Z%<O\@@15\WC[K3GG 'H:"RV &17C72&-SO#B"'#<83J-*_T5
M.Y#"W^2BS=VZEAT/5G(.XG&@'^MB5SL;8%$:$WVI*(5 'FHL,.TA@^?01%"&
M#"(A8!XQ/;(?O"D3UY*>[\Z9K0Q,FF^2MRQ_/B5?6=G;L0Y13FN"7""2NTV;
M93Z6W.P;+H!5F32A0&5EKN0$'=DDTAX-B/:/UE>5YN#/LT9*W;9GU7K[%GJ1
MM[*PX<LS-(F\R&6XZ S!H.8EBVL@P>PA[^K$H^B L%>A/VFZ\/L%B#EOP$O_
M6- FO*5L-! FM%$JT7-Z01QO0JL]K6F&$D-9AW*'RX'7QM!@+9VX'8=M'!3
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MFVT![OQ?[+U96!-;URX:EPT"(M(K750$5$1L0!20+&4A(F($%)0N(@OIA*B
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MT911W9"JX&L*D3*;]G">[RN4#7F>_$%^E^*$K]!77"TQG%RZVC%$&#*1R,F
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MD0F*6O(/K-R(=V<9R83EK07*L&8526&MCB8I_O1^^KO\O)Y%9]2+[<!Q7W+
M8T ,$SQ%C=75 8M2&#8O$2/X$UCBS(2P;XD9NII5YNP%%G5=$&%PMMC=>S(8
M>,Y,M-(O[\R?J-%LRUA+RP]RXDS4'2G)#[[N-1\_G?$NQ$4BVR7%R&PEC39I
M$"IIZ0 7I>R5WXK>-MBA7"W6Y32<S^/(!>-%ME-Y:Q\TA7>4& V[#G&!./I
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MF=\U8[*3K^Z2C-,9^# Y+W-3NFEHO1"Q8IT*0PPO7\WC.@UK?5U>/IK#8%A
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MML@H?;M#4IT-0'Q>%HA'%AITGV\*7C7=S,[^E*'@EE_ 2P>4;SM0G*Y&CI=
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M/#C2RU_LMO[[F6?-C=&J^^N7\$=J2[V74G\K4#_F<=MV.VB->'O! :@+?XP
M3/"R#< #K.AXW+9/=C$TRDAS2IX0Y$-HMB'6&['V>,](S@_69<"^Z;$#W_&U
M.4TLW(L)$.MW.7 "3_6)7]C*%W9>M+L+Z7ZB?[56X.6T+;,?7W#[E\IN=?A3
MD^.4?PT/^WMH6OK80/\R*CR$H"N83"&H0M.WS84(5:9?S-^?<RG(Z8M3MB\'
MY8A72JB4G-&D)658AA\)_;S_LT=\%\/;'K_5-MOE],Z!N[[J5\?AF*I_R12M
MVG]K"R,AZ#_"GC_<^P<</^#X <=_%1Q06XP4+X ID];B%D@7@L0X%D[]ZZK7
MB=7V[*6J%'6I^M.6'A"S#P,!]VQE=IA'_*&>,@KU$8O=]"15^32Z;QG5TJKG
M.YRO:7IF/LB&G2S[,+)Z+I\("*0CUQ>:G)Y2?E50[R!?T]Y0W\3R[^CW\940
M+*P\T/"E:3&N'/H44(_\FE?PS :8QJS4W1!?KLB%W9HHB_'A9KPS"673%!RL
M-VUK8#/F0FH:-UT^EH8\L_?)&=H0=;1,>?&1E\B-,I6R RYZL^JMDR^YRO]*
M:4+^76DB__"N'\'V XX?</R XS\!#CB!,SF]/;I%=PKW$RK7B=E6]MC'7:W6
MM?!PQQ9OY<$K!@:-AT_<51H*RCA<!,B.T"-W;RH$W47F.*V/=HMM' :#R(N[
MP(+[:\TKK ^:F>^Z9B15^Y_@&2S].;AMJ_.,",IJ^$KFS19$P>%Q1#VA[L2-
ML8G+<-%TO,D?P93^,A-_^V@K>Z)MOK^2U]=7E9!O'[Y"_R6XU8?^%F_%Y/\B
MF_UPX1]P_(#C!QS_T7#XHP+9*1R/*D[R;_V+Z)T$VL1\\TAV^=A'*QHVVS\T
M*FHKH96:KUW(>W8M^TC4XUZ2[;#';:SI0@/'1PA2 @/*BI\V\7U;Z:58CX0I
M7EJAR+IB?%69B+ZR-$L_SSY%22FTMQKO[6.1H&L\4K;3J7S:Y(^4W)KR^JR,
MB'&;_=]FJ4)0FCN("4LA@?<L3(@-DZ)LWXI"+)<)B)>GU#Z^;P\5>9RWLE]7
MWK[4_W[WFXK]LLI]0M _/+%D@$DRO)Q <2%H-#<>Z&#W920$#G'I"-=2UWIQ
MQ>_\D_G1CLL+CG[BSJIORU1L;<RL7AD;+-:[*EX/B+S_KNO*X\'*K;;9$?53
MA2H&)?M)DN/P6]9AE?^RY:J7_]8!C+'_33[T(Z1^P/$#CA]P_&?  77 J*(O
M,>%WZ,SO0U2QZYJ734^5-)24$_#UVUZ_5RJ1/;I:_>C RV<IF,5F7OSG.=R1
M/]%K8EP'(:@[MT.,*X$$/IB36M$,#]?>=97SH4XTD6I7J39\$!,FMWX%=_0H
MR8AV/,/J70P\?WC^[8?N$V^.O7\]Y.,87;'5.MOD?.;%(9^W"%)8N"59\U^%
M^8?L^N]TW1]P_(#C!QS_<7"LZSISVJ<JQ6**Y%C\OMAUU1;CJ@6=N1$3M0.P
M!H2;11#Q]\'7B+E+[_O*W)Z.Z39H>;R>O36I]"=51Y2QO*$'B\.RC3\*07.4
M;M**?G@X#*@ZS:@QYQ)GVS2O=(H#*:*&)'\RS#;+K:S2SOEF1&.E5X"AZ1L5
MZSWXH6BG8Q>L!EM53@Q5FNOFPQ'*1VG69K7_,E1$A[_!*DW[_U'$?SC@#SA^
MP/$#CO]J.%JG^.4"R5>FQRLH2Z'NEAYF5V@!4@\Z\%#6,=.?3YF"RR+2N\12
M,#LXD0P_31EJD=30>@^7L&?4,>EK+^$7.QH,BZ=9!$QZ-]_A47->A^_96ST&
MWVT[!3UV'3O-[A.T ?BMW80/339H\[*6) 14-VTA""8X2M06[Q@[:3JJV7$Z
MU<E"XLPQO+-6J_.'IPN[Y_25U;LF1L(LQSXBK][J?[NZ<RHH>\9>82#UHH8J
M^=HO6;[-'^8J728S# (#\HMB_Z&[)7^'*G);OWO%YH,_A*!W)P-YJD![7LDC
M%Z1]A" H<$SE83]%S?PK-['XVWMLW^S,P_;1L)RCN UP^#]XD,J?U.7V>CM!
M^57HFICK]RTHL"NG!#6>N%4V3K"S0F Q@?P']_F'T34IIK\D%O] C+\%,&-'
MWB3O#VR52P6/7R$$10-]N?<M]^\]*/T?O!1]P P\[WE&"/IMG<PL;Q2"CH!_
M@/$#C!]@_ #C/QN,N7B*=AI.C.<W?5*;DB=SE^2O[-"6?CXRDEM>>^QT0U[4
M\(=VJF&FY8/+T6=SKWM]#BK8?6_=#.. >0-=09AJ"D'N$T"E'0IS) [G\;A)
MM1^..MT?I%RBJ]CG[,OV+#-V1*]4NHNNVC0&7#!S]=<>QL'O3:M//PTF)&1=
M,V(HVQAUGKK95:BJY%U*##]YKO)48ORO/,([+GS:BPK= /."A2"/^$3RVGHD
MLM89NQ#/)? J68T,,"]=8"P$U5"HDYL1K43L'>QD\($%0>\9)R$(>03%LQ0L
M 26.N(Y=^[ 'DJ1"'!3[X]^^6-D_7RXP"4?!"W9BYS0>HX.$($FL7I02%[#*
M*X<:H.E02R%H,(>$U!@=FB0M\[)/@+D2:SB^L9_32F^XZ4DAZ/"Y.D&[*N;<
M<B_P.UZI0'=6^3\#?;FZ&OT7K+,G5HK])V]<LM/'K 56 IP0=,D&,(NE<PNR
M&[IR D41=.'V8N=H7UO4H"MVT^1%ISN 0Z2XS T#<6(N(: $(3?]]MP<LC.+
MK+C_5\P?E/K[]W0VI-N:.70@WLY,R?#O>  X*^2Z?X\\10A8"'KZ 2YX>$4,
MME4PFP<83U^,;U6,3C:3A#>'W_DKEAEP:Z3 -H"X%!."%F\Q*P2XZ^J)U>/T
M"E[6][7LV"=0#@"U:Y#J2Q:"0CJQ[T\&\@T5KT.YG6*;?&LAR#IQCOPGPZ_O
ML']R4@%PJ</7*P6='!C_^+DO;P"_\4@#.OQ$"-J\>0KHX>,;_]+&M?\_#[ ;
M9D@(8LTP[PJHHT 2-3%#)R/_Y)R[C"CV9>;VA23 /=Z<FIL%KQRG1IP'_HDX
M]9>AOWT4HB4$9?[.\0(22>&DH, T$JD(_].3L7]@M^L @3GA+P3A[4]J]$VW
M ^[1^),0])@%!'SK8.]?L=ZAY@4AJ'L)QX\"DO.73T0\^3IR0Y6FS$]H1@IP
M/!NDQOO_Z^?N"KH"BS%M?O1GP,:V.]:80"E2?X-=$&Q9I8*5^\VDOBI<^JMF
MR2X+075BO)ST7=C1Q@3L^L%A]75/LBK9$[SQ/]M$$@/W"D'S)Y[ YWLQ%MW8
M%6,@55[9!&]B):.6=P&YI8W(CP5\9-!Q=SYT?7K,=>,*^0 &J"4OA:!I'%?>
M%*BA%94T?@:@VMS)7QNP:CS_[RN&* I!:=C%&RQ#01'1KW\*^>U#MS6V[OQ@
MX_*1&RQE;H.,@ PDGL$;1ILJQ61KR&]_NQ@)&02=NB<$-4PNG>3:"MZ#F?;0
M6+(\YBA0Y .G8+>Q$E>9WSK<=@GV]L5/R E!,3 +9!)8VM1$0PBJYQVBG]SB
M,AI4@O+ZO8YKD1@JZKG W[6T#4NZ^+$OJ!MYP%HLL?VREUQ:N4DHOC_([D;*
MX_YLG^;4MSJ6'9H6.;H!SC9*^%8-T_E^ZDAR=)R<WJR=)>GH$T?'Z9=9"'\K
MRS:O@]J>$_'+?$GX:BL+QY[C/S$%BOM6!D><*\O!,G+9V,71:>C.+WFX1,P!
MH,7BS,\+7"OV*AU'!>_] !2AG;'+,0'H2*_/?G(*N6$S[U'E(Y)<[;'I5'^O
M9]$>!]+*[J0I.)786TLD/[H;7V?G[T2U[-J'TZ/[^A"CJGV4ZJ_57+BN><[Q
M25=^C)N<5-"^V9N6'1FV5J8UV9\&OSG41EU-_Q*7I%)-N?\_8!([H!SMQJ5<
MKJ6@$UH7V-X'QKS![8/2$:C&3J3\(2:&7(GM $]I[X\B4XA3VK(+-A51=QG;
M8UO@Y8A9AX$J+<SH-:] M&GZ$;==X9Y)L$KRU$,X(-'/:\+9IYG?UQW_926W
MCU]*TMZ'-B4/5ZP(1,QF48=7*8C.[N1K*VV&I9B?T]\,E[Z;[&E(.^EFZ#\H
M[A_+2#<H][*2"EI3/".%J$::QT;4?[%/M1Q).ZR;;71YZHFJX^-LXV!S*Y&E
MFTU^ <^F9E4N^YK4JU)D[ DJ5J4?%&T&;MAG^Q@A]GX;SKO9?Z*L#$C!CZNM
M7X"9V=B.[5,XCBWY4QC@&!84+/,^X*PG!.;$13]MSEGL)R#![TO?V,6O$YQ"
MLH $@P.O!:HUT]8<FFU[W90]JX:'%T?-&_Q*C!%UOG-CI- GM^9QCIM !CUW
MRDR*X\3U$HR!Z^,[L!SUQL4M7&T>E)/*O\/4G0Z,NSP$44:!!>)B/\V3F9GN
MT(06[*5!;(<- 86T9\4EY]M(G$ON87Y+T+L?/X9^$6U9K>!^T5,G1Z1 ;3C5
MTKQ<42S>*B\YH^AHE7<[2?74354;X_IQN^=VF?W+\90^">.._.@;9<YUP?Y:
MB&/!&1=K,C_[Z$L.V'P=&.(/%R>I/W[Q=S&T ^"O;9,-R"5EKJ2@E[S=-(JK
M@SXK!,7Z,":ET#?BVS<% %7=@;W=<HTM!.TAWV[Q(!@4LL42%*19[@_\"F%6
M3YNX;MF%K<P5TWLAFC-YJL;'W[]VP>QKTZGWM<I1D%]-5=KOZ/? XJ-#UN&/
MGQH+G(CXM@-BIFX1%R("CA>ZW.SL)4DN3K9,[]>K:C;#/<^"&T\M<%OA'1#I
M8>V9U662]A[OL&]U&T%FLVX3/CF-,CH;YTMO='^V423G2@91\QNZDFZK?%G
MGR@==<1-7%KSOP5DXOO_NZ3]LWW;S6!T(&_]0E[+<808"4%)T#Q(!I^(_80'
M4O5[7"EP30^"F.,W'TC[)K J3.<G;L($!:0G&YXM10H )3KJ C"H+/+1,"!E
MK^AV 15\0P"4/GAM>+L9QDH(:O<C^Y#3P+70155&8 JN;C253$>BSPX*#J.-
MWU7Q+ !D)V/0\$]S"':-9G6E'S]].FH+M7DWSO>.,Q3BIOGU4M>"SZ.;%_@^
MW*UH6U9W%^Y]'?LBA\32!4I(3"Y#C!H($#0QT\O3VGNQGG-RANR^!%+?GC&D
M;W,ZV_E.Q1SB*(Y=B2_-7<QSSO?PV+:4,_*T2VJ[?-!063H^5V6(O?9TB'4S
MTXYM6VB542&+#UYMPILU%$CZ^UFV[HF/P\MK'/>GC+VM_Z)2H15J9&;3T!0>
M[J_D6?IQ.:01T@#XT]-9$?450\$N*!?#61;L7.8JSTV*0R1](K0>L1P84*J;
M,CW];F"+Q97-\GBZ1_A#3C*UN2^I>HU41-.T_TRQ87[*D;/%!4/'; E/QI!(
MQ+Q<5.QG7.A;;+O1]RUIMR;6LH8@4#X9ZXV,GMS;M@M%IE_<;+O#G&UW/\@,
MS4TW59WFP^R8O5_O^A$F.&>F^F[7WZN@<6XM4&OF;_H(C%B%34,$O6>:;U@P
M2'';]3H3ZV."MQ7QG7""K$-A1+U/.YW93^A=_!B16;G3HM#<1N5T26UK_:W%
MM#V!N]:;G![9YF=-6TDI*SG75?3T+3Z2M83 C^1G/2*^%H)JZ^W,(BQD_Z>"
MNNMR+= 7\J<,%U=9L]/9;?$RB=60W6A93@GKBIAH[V.#3+$$3T[H5&IP)\O[
MYGRBSV-(OG35ILE[R\=*L:LNA/9GKM:9LK$"@%I&FV-&<9)"4 !T3&2<'<LA
MB\4MHN$,6!)R7TAE%+@#<34/'E\/%ON"J)>.T$JN, L-Q>(OEF4WH,?YKG;D
MH8#9#,NC32N\QY=G<K12@K*>:O8L2'D[4LU4VIRLLN@[C:U_S\\:2'$:KPMX
MW;LL?]+R\FRB9:1:Z"'+!OZL<9>]I46DDO3X+5?$(O]D,?FX$'1-C!,NQC.
M+P&D5M1,"#J:R">%"D&[,[^+8,%O0)+/=N?G"RQG>1<G-Z0AW4*0DC9?71"!
MI5)ZB8-)+?K8*H?0DZD1TGAG7!UUD.T$KL6KH><-<[_.WUP=R.9OWDRI(E[Q
MLV<[G&=G/9G8B]/?O]H>W&F=_5P;(S-3X/_UE7Z8'\!U71_\#5F5XMWVQ9%@
M/.E,=A& 6C*&!JT=70SFGN?L:B]2X&R?QBFX?:&!J6+QV%^6UCXJOVC63O4W
M52^?RT'PEU_T'4#%P]L:\NUKD;H7FHH^>^_SJ=;?Z7F^-K+W&P7*,5%LOS7
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M?8!3P&*AHABD OH,8' OM?W725$WNR;M[YU]Z1U2H^ZK^[/Q-G7X=A(&COD
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M<*4LIGTF(-5$)/B1O9.7B>23UZ7.AXL=Q_'[$2:0 '<7JSECQ/%&1AA/_(1
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M\1C6L7(\9=^P]/#TCM-Y>$N(B]''5T:K2M>P3[!3U5CF^<ET\!;!K[P=_'B
M)Z=";<C\:B'(I\E_!NB954<//)G>?7?=W_D;)0+2Z%,^;^<V!Z;1&HCE"]]P
MXW+K<66/.%Z_,=.:\/-R3O1G=7F#E% PYT@?3PIVCEF%$__^^MG6>YS)2LR[
M>R^:>U#JSL]9GZ _:^MG-TP(Y$EU3:R)BE*:3]R\4<E=EWRZ76V14M8'E$G?
MTLUZ!2@7]N$,<U:PQX>?PO-@[6.HBVWG4.@'V[*G^!8.F29^OIA#'#_6+)T8
MO_;<)[#EN9%V&2<3ZR5O<&N@OM]]?C.*H3RNO\-)"'KRY N%?CF?L>HS[<O
MCAT?:+_L;=<)IU#$;+/E=%-17;%6Z&$_J]**);5@GD%J<94'HKZ6!_G9R#<$
M2SO63QVMM(]5&R 8#Q6XJ5I5*?F&3$LIG+W)LVD8;^+< W);.I#;,GE6?#SO
M$&MZ:G3)E;Z %,6,(&N/UD0]1,-)_6LO]?HXY_0(1Q><^P-XI_AW/7O*?(HT
M!EHLZ$O(4ZQ;N<6F$ 6_#;THA]\;!Z^' A?@>L7&M@E!;("E1T_TL.JFFX _
MXE"K;!V.]10R":ZPBPE[,3DVL[PV*?6%O<\[ O.\_"(G%\XDIZ!_(GZ8L_=I
M)A"J% ZQ#BXG.'0"O+/%/<\91\\7%1&%0'(%.RL8A"T(X):3 !.\(##]DO=&
M&K!4B\P4-)'FE:S/2:Z.:R;D4H6@^ R;ZI9;D%#2IY^A<3AQ_5UN9LZN^946
MS<UW+%N;[-\#L9J.K%->"L*C!MG-P!TM!!\$>IQ]H3#YA4TG/CEZJ>6:SY2-
M=I=T9<7\YG(<6KMR+B^>0DR [!BPM_& C6H2WJ-ZSI+B-G<AQ6B(+TN7]^3/
M=)5##\2^,'L=GG+L?<K;6+3&\84M26\>TY\\,4(C"KQL1E-_(4<JA,IE9EW3
M\K&V'977DFM3?=R]4VWH1J@J'(4DG&\?(L!HS@_I*KT.H8%?K;-?[[4Q[\%6
M0#U3P0*1)NY>S$<P0.(\EY,$)S@5W$A,%U:R7NF> .K7)CI"#$V/:5PYA:<A
MW#@578:C$X>&]0KAL)'ZCR;CR/X6RVFLQ!R"'!N:@+8I/G PQ-=96O    \0
M;-'QZ C."=:9J<#%0UPQ'YIM"1<I&/#;.DQ,6(_T-Q$,THDQH?YG[-^M^3L/
MC+JD88$V!/CFTJ ))$L2=._XY!Q$BCD;2URWYLN<-ZG.UZ^83<ODNF/;+Y"G
MLLCU?8O#3$/V$B=V*IUV=\IP:2OC"^\@G2A#<R]_SKA_W7^]3Q05Z#8<@MSO
MQL%V*)S BG.< _>C'%R&U\@)$8$):TN^76P;W=^'&2U%TRZ#Z%F!B!<SOWMR
M+WF*3 ;Q9.C+Z9"C_&Q3,Q8,*'TQ51@97OB[$!?>*3PJS#Z7 I;D0?VOE?@P
M.<3VC)8V3=8>'!X%2D;N'>L-#&,<O_'N0U77_M?WY_I[U.E/[=_,.8>7BVV'
MBR;CI5)?V'?=M'Y/9^G[6JE)*4H_7:]T1B<1=;-D-.[MUE#S4!VA:DA966]!
MBHL,'9XX(.4@%C+O],A6'/TN8!WO4-Y4"'':[U;RM=5"L!/0[EN=F-VQRIS\
M*2)' PY(W'V"?@-$Y,)QCA@UE?$*\LN"W)ISZJ_,UO+\:LZL&W,F-J;1SA4Q
M[M<<W[%15;Y+[UN1U%/7N5CB*)1IF<Y156CE>J E.75E@GZY6]E3,)HNVVZT
M@IF^M"7PEQL^-+/>LM*( 1IJ@0N9L/2O]_%\QFQ,JB=+^-S2@96_7X#(M[0-
MVE3G5OK0_'/?XIA?TCDJRWQE"W::$$2!,6""Q+P-:[8,/T,@S7%X,<F$6_!Q
MV*F'^P3CX(,0)4$?=C]Z.TN--CJ%2Q8<\)T <YH(+NB+]4]9YF75G/BN-M6G
MK.HR!O* &>-4A:^<2Z3-.:6WI/+YQDWWLL"@H$$SCV.RB^J/[G1.?7&J2+I0
M #'4IUS)41I\.#^(/YU5,[Q@^KM:EUKIXVY$,'I.TUD?0DRBP)V"C-!F%VSO
MEL'%[A!.]3M4R@6G(I)%K?+*5*PN)I6X\YSR,7,R[6)@;/OOV*EG9'&,-N\L
MQXWKB)IEB_,3!'*HD847$UN0L7M]FP.I1-GYAAK:@C33%]$=Q[.D^WNN(I%B
M[E_DR*E:RJPJ=[EW1T9#"B4H;?M'?ME\6THN(#-=<3%"4./L8B>33 >_@-%.
ML&.:^-50+QM7AE1?6MM>WG66^]V3Z=1E,4XW94)^I/XD(#12]8W7"X/MGQM&
M*"<ICBQJM9PA<'+</!8E>A_Y(BY&N#\O,>,^^K>(JTQL^Z#);/P24!'3;POD
MFI[7PJ1\)TE:B=7>(SJRY/H -)2^'#,IM6AJ$^9[X-OGUSUV+&@,?6@WMEEB
M<JXXL/!A]6[//49I,I5YPYV,BE3JY9($@@NCTL2!G>W1&XO"8"N?' L<ZQ O
M+U"6K?^:%^5X?%]9X>"+CEA9.MXYQ&?0T6>U.V//,+]1NR%4*2#<LA=O;F_C
M\A%K@1,C?SK%M. G*<@)08.:V:'K+]$0(>C>]G8P6P7E)P2=:W :'?VREZ,H
MD!6<W; ,X",_2]J9G?_?+WK__9OE/00;,<$9!)0?JR<$\=7CBBN8\]AHY*:U
M&E@>VPGN!5MB1LDKCHO81=@ =FV& ._17S=<BA2"E&R[!52^LA!DBQA&U[G#
MQ+ O,S6$H*=6R,P3J]B-_=/8!9X0]%MQDOJ8Z30S6+ ':&:6!ZI'\'JR0YL/
M[7.?X^KXF9#CL5,)V#VFI^A\N/T[TM(NP<Z/P55?\B92HT++?3<-B.5HL:'
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MF#Y!ZSBD5WFPZ=DH;5ADJD\I"J:ZZ!W!85&\V><*A#)Q:3C)]@#6#IV6%JZ
M2A+L9?ME89P9.OO1,G.FRH&<0ZB%=;$5>?+7%'JR0Y_::KZV1%^??E.&=G>R
M_8U(V5[2#)6S)!)"H> 330YZ>_VC*G,OM!&R^H-K",,^QP3RRYJ&M-=Y'K5
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MKXBKU%B2B9K/(GUKD8>G0E]D0X\L0V84(5,\XWQ.U.="[QRN(V((QI/PX+@
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MZ?U]5\S;#WU.Q&VM%O%TO#QP3]M$62-WR;F^VJ[XI7.(?1W3ZWV>M-VQ8#R
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M[3^Z+N](N7 U2H"\ZF]K><4R)R0W[="R@:P4JP=D_7Q4V954<C_=2!I7+Z%
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M3;WWIX2=52*:B,Y6G,;'"=O"GX5.Q$8F3^U$AM_R2=_3:SUMCZ3SDX5GR]%
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M #AU^"F(7Q,;8+L84$=2BL0)@IAH9')P@.S@S;UY1UE0.3;D7#774G@5U].
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M;&&CZ@"D^?AXS7D$XM190-E%KR=.!8.O^'1#Q%SY]=.\(R&Z2#*:]1VK!SN
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M-0YY$W_-O_V\H=;%=;JL4"%1_/@Y>_=U"\8W?QE+$J.Z#,7I4(OZ,,]BIHW
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MQ7:YBQO+?YKKTP-3.MGOTU0/-*7:C? ^J%*]EQ*AXD-U0%4[#R!@"O#/:+E
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M+8#BFW'W-F_]<Z[I1ABT8OAP0GY6=O#Y"@+JJFC9#KBJ'%FB)]6^''JE-;.
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M %.$R679T1S@74\AIGH[[ 4&W;I= TI#68?[DGG9U][4#(_ .Z L^9(O$0>
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ML)O9V=*:2/<2'-9?(J\LP=1CT]/"SM<TIG-.U_=,G>^1O6%T2JU7=N_PU(/
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M*K0H*4?[K_KS:]U]6)E@_+(L=.;=HTJ$E5"6I]VA[FWQ(C9_/S0M:M+\K?_
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M%$=)H:.>NZVN>#9>:5MQ],T&Y+>8GQG6"0*;+W%M5)$> KXGB1N#Q%,9#+L
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M4;/?VJS'[M'V\9;H#9^SWWZN[8^:1(1D?=GR)V?'-K/?"[;]QM(=K18%&EQ
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M?H!>05DH4KT*E<K8D<(QV=?), F=OQ1!WU4 DMG]N5<+G@\,QJ;K'^NY.&G
M:^V+R/L[#\DE.*_G,)@CT?\%O%^,QKF(6I\\D[/T>!VLN2XMOB"ZG=F*H1Z6
M&QQ P,&!WW*Y2DSIS#+5FR)C)%/-N=E/?IO!W9>M*ASM"G3(H)Q9F)>BP3&
M? + ?AL$#$4J[#:F'LY42@==@ 915H,@P>58919?>.F)T".(E;\=C#XG6;+-
MNX*S/: ME->6X=Q;,)=K:P/-^[Y%P37NY'#U=[DNFXN9;'4%'81GM9!B4V+P
MI138S!6T&N;;,=E?2Z7$B\R!6I$E2P%9#KHTDS6FX-63GM+;2]FBBJHZ,!9P
M<4^.W:QT;D8=VPV74$WVV1JZ-S86KO[Z53<Z+=L^UF\O?VX-6'IH92+NAQ%L
MUDI)=)P?JR>GCS"%VSN9(W,*B&3=WY?5;O^]QUAZ2 $A*]W[Z_]=[;]3C1&Z
M1%5 0MV0P0K(C3AFRQLGLV&'^@H ><W).D385=KRQ+QOA$3'/@:W]XL23OG[
M]]74](QP3\D_4\NZWZYJX&AM-,8,_7-3F!FD?!U7-&BYE!4=@3RRXC2PF@)$
M"FSCU'-V!_KXCSLFYP$QS8X3O([G[1<Z?5K[_<X,QLXL5RUI,:"_W *KE@Q:
M-EV!ICIIWK[@0Z1^J6/J?MYW]5QR='AG)EX=OH=UHM7S?ISNUOXG:\^-G#Q>
M[=A+.:9?;/#GE:]G/[Z[4W"3W7>S+N1XDF^SU_'N6X89E1X.466Y,7&^WPCV
MLJ"EIP@5L%:,;AKR/*,<,T&F92UB&N)=N/0K& 5DK5=^NSCBH%P7+.I7Z85O
ME@0WC'WM'Y^L#K%_7AP;OR$WM+U+7W4Q;W&-G+N+T.D0N _$8"28HR"R4+99
MPK]^H7.6KXY+[_'K_-PE.SJ\Z65U3QG5.BI"-ZJBD 2%#5DWL';$G'S CSMF
M]<,,) 'ZK7'VC5 2W5E@9>6Q1XK+. 7 LZQG%1!MYX0K)1]Q/2R_FNL4LMJE
MEYDF[EB$>\-S[*,UFFMN)K[WAM7Q)2Y\XW #8JL"PE-E,36BXM'K<2EGP2")
MF.UG7G0W_HK(T"I3E44P!6QNE[C')& OI(4E1!!% =M7UD9OF=YG\:IFRU[S
M%4NK%P[A7)KK0A('LJXDMNW:TRKY</*:K\<QNB][(_VRW?8K1U>)OAQ>E=4!
M@.'MO\=6V\15LKSNKU>[:'MZC 4]:DOPW,;AYI];]T?N2>JIP*[M.F$SY@>?
M4[:>RD#3*4\] H]Y#+VM7=+L.CLO,_?3E\F9\F5H!63:&B:Y'XJ>65! P%5$
M!>1-M?P\+#3*UOO W^N@E*U(F@)RS5L!D66X_./_(/_+*WE%)-,HXQ%;?(_W
MV/YB>ZTI4KV3 TETVK5ZY/DIUZE;_??_[12JKH0Y.5B"(:R7Y#2C,@Q@&7AS
MX2 YB;RARCAJE+&K'W^PX".XX!'CPG4R#A*T.\@U&S!+ASVYU<8N;/O(T863
M/=C)[]\G3Z.6LS-MB5'>;_G5\S>JD%J@8;.)90.82)'M_/L 5FH^#"1)!EOJ
MOSZTJ1,^P&.>NL2KY=\540U6[>&#D8$5=$:W75"(=5%Q4,35A>3;L9ABOT%7
M"-*>8"C3 1Q8*%W"6WL"LJY+KB?OESN!;>5X%[ "N#HO(F8Y_<K4P6^,$ >X
M>#%!=!$J>CDNR)^+, 6WBSTD//"XU-@"KNH?]O(L+DZUMKKFPA*7]LZ*K#V!
MK"*ST=?EAF M4"J-J900K\FW@MJB[#PA\:9]/K(!(&?)K4"5,Z0S$H\4*2>]
MRW9R15-&&9']3MZJ&C8WY#HP.!8Y?F*L5G_BRD*#DOCGV-0]9=D78NUIA2U7
M"GQ;GD]HN!,Q1CPO\FZ4F0/O'G9KO.&^H.HZ7/FEFR?>9,^\K//YW4H,TT"&
M,6^0U0E0#-]X#FD4YJB L%#JPV/UP=)&06D#2G]'?3FU?(Q@]+*[[.[1NE?^
M5+>YB//-:W?<.>BTS2%ORXX@VV7C)@Z2=G*&;$\QJ"2G_ES9_K#G+@;N9<J9
M(+/JA_[,.OWG@:P*[.*@P_GK&WNF3'>;&#!.+B5%&:+6XYW RL<^X?4?:L,*
MY=UH ^O?^N@'RQ#,,O[1^KF&M7-JY_K0)UZ9IS\<.+B]Y-4/S#@JE:B.UP:"
MF@V8UQA;<'%M+8%0KBA++>A0K\&7'5.B]-_S;1]2+6O^6IEK>^7+^Y3MNUW?
MT.X3?^M8!7H*^2QL.F.MQ#XQ6$A:BXN4W@:[**%^J__B>@05?BQJO#2&N<BM
MU8\Y:A=K?#W_:TB;$6,G1&5P]M^=F_Y715<V(7-6NL9DPCLDE!D!AX77,E\D
MUQ*!4B5AS:PF)N\F= :=DMB3A4,A;+^(1_>VUU]JB+_ZI]J%A>[O^U4CCHT<
M]S@8.#QR/,'# +I# 7'6E?U*Z&-LX$8@0V&\X06D=AXMQ63UTG.G& )9S4;8
M.6MM,<QU>R'AI,/M5)F&;\-B:=9)C.(2?CCI&<?HQE<7]]"WIYVQX^2GY%67
MN48 ?$/P6=<9V&^O?+>?:)OY:] \6IS1OM/'Z3A,TW\;S64B"M-<M46R8=Z(
MP:BD!6840L.$(P]R/X;OC;L7"Y^<&Z$<+ZP[M\WB_I$??N$R8)[K7(KI9X;2
M!F^@TY&5E!:26AA_S5R"7B@Q@FF /Y'C 4#9-!478<>&$HSW.;GQQ-6K&GS^
M^ 7!^*YQ>WLI+V&IL95:X/L&>'OIS@8%Y#>B(#7N/C\-^3M1$WSW#?54*3'M
M\ =/2L:M0.PL-(7TI.U<@5L1+O;IBY[U7@N":I36N&:>H<_QXI* ZBI53:CE
M-$=PP%T$8^\OS=PH-QF'J=-_8>K.,4F(E8!E>K0A]&7 6'UO>8U?8?;-#*=A
MTRX]U;2(Z@T!L]1CYG4WO@X/ZYWH6_)70)H,G/;$/).W(Q" .C,^K 3DMJ!A
M"%,%I-FW=.S%69^QF&XPK(JI'MI&";O;[O"1.FF+,70_[[;H_"EUW@&[8UJ/
M-@9[-J(B45(UG'[6V]T7#S@9L*]\]7BP]_!&[SW%C@_H%C9["K??QXC"3K$^
M;-C 7>C%E$4XSNHM.]>OK^GW#'\K1]-;]^'1PJ.?Q4G%:D%O[F0D>IAOJ(4G
ME-J]ZQEA[G9=NO(TW4K6@GC_<ZE207<N_XA#'^S'NY0D/!^KUWL87XI6-=S_
MZ.@<]:+UY[J'.[[M>)K[73K6O;M&6M/E=H!=N"5MX\=UD(&GS+TRR\4K(%>$
MOD;7CA&0;^CG0EO(:4A#N9ULBV2>14Z+DQFL ,_W"+)+1?XH#5P*Q]OO8ASY
MXY1%;6?99@2LQZRN+O$4H%9&#,^V4J7*R"P:CRCBM'1D$"N9+>>>3 1J+N4B
MMN*T629:*'6_B7R3/+:?PR2\!"T+,=DO26&KZ9:1O>G*B;Q915H)7N4>[ZLJ
MS7./Z?_2^.K.ZIH;T;] #RL!E]:^>."PQ)/-E#3(U(=W]0T*1UHT)=._2QQ2
M\;]%'4#+-6^/#.<]4G_WU7BM&E=Z)'GJ1"[/8G'G;??"JB;"Z[\_JFY&%I(I
MLDTF&IR>Q16HP86@K((G7^LZ>$ZNQ!!FUGF-KX<EB:)?3FXX_YFL,@%)4ITQ
MNO59?6 R -YLBY/KXNW<-&]S7Q.TO%Q.E979&JY/]H+<V']CF<ZRT2BE8\ S
M 7_I7]V(#6#E*0F;H-DG.PE+BK)V8,N=>J,F#Z->8M5"ZRMZG[V,MU(=JL1E
MG(CW,#W9>/=XQ9V-IC>V'KS7%JD3,F:]Q_-%?]70?I_N\J>,'CN,H0?J>..U
MNVI?DI;H,5XQ)^[H/"BW_I+E\Q9R[[*K2KI,"LX!5M)=>2*GJT1]O)N(J8YK
M%>E(OE(*_,=,G+J46JIPS)M[<G",L2FYS=F^OC]3K6]RKK!L!J5&;UX0=5L]
MU+NR<7&P.?<[282"AL5]N*[[WN# $,,6A-N6#JGC(B8?37I9=%>K8O8WF*<V
M=W%T:KJ6&11GXE\^NQ9)U)&;A_+7.9E>$35>&!Y?O/JD<#0.<3?H1> $83,7
M>[XGRL.$YW9EI18:[6'D$7WY;01&_V'D_K*3N\KC!?.M"5:B]R9;*@W.R@T
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MQJ3DI38K*[*@<<Z[Q\'K(XCG"J9'SL@A'HOK)!M;5OH:I(/BC'(TEF;)R6U
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M ]" [EYK1F,^)=66TD=^XGSS8\BB;1=V/9S\)T*6!5,:P5Y_H!$9T\O%K.
M11WNH=2WX[C^7#QW9Q</0K9_F6K[)^&XB?F/P_\T?0T@S7W95HP[&#P(XS!+
M)(O]A[HMOHV1;%/G#^NPYP7_7S+VY*O36_6 *OYK9_90Q?B5=NVUV[7WP@'
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M* #;=B(!MA63LLR:?<ZV%&U62\+H '5=5&2LSG<F-BG;_1&(L&-FQN)]B0A
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MD8?MM@(?E_\P=BUNTLAE>CRI5EJU>$K:Y08$3)W'707B..*,\&@6CB'?AI#
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MQZH0WO<5%U]X$OQDY<QRL2(Z^EO,PCZ^WUMTTRE*.TP \PB %S45HZ'7T^V
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MY0R_$8=<3,=''?KEN*>ZL;CG>-!HY6RY!$PPW4L:["L$(55T$=_3(C73"2"
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MUE52ZAK<U376PJ>M<^,"C$@T_C;DF"O3$?J]:<ZZQ%!NGS/RG$:-ECN -Z8
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M@6%-L)5,)%&-='D&!:')!2HGY5F85!U\15Y6'NQ_FHZES.5IM=F+>1'7OH"
M(,',+Y5ND[]T;O^VV)8JNGYE9W" 2/2CR"+=#%)-5)23W]O19*)&%DJM/>#'
MOET9-6=.2//_OK#5Q?C-Y+-]3H=VW$40"'?)_#R!BL9DTQ$ML 1=@C09P3(#
MD0DX!0C>8:*8;0.U@8:.T#8C[0+,[RX7[\ZO*@&(-A/^5"<*R!_'.A1&LPF;
MGLPMGE^H&/OBDXY!=Q@\6E#%_^ "IL.L#98>E2/&4H"JP;_<<ZM9E&U8SY)Y
M?(U)VK-YA"!.=(K3[]A(BEI%B4%-=F\9Z.35)6F'X6^@D9B<Q!")9&1&SXVT
MDM#:N21]_M' U^_^$9<0S\K^MN/!6$YUZ4Q_QF-VCN456.?<Z9A,?W0@E2 2
M,#/PG=!VK';HL,9!=[\!+F C:+B_[FNHK\'AQP]S*RT^(D!;=0?;$?)NB M<
M'#!11#(2;=ZR"\@G;+P9!M]OC. EV[%FNY.OF@\NW;@1976A@Y/JNPW?2-O2
MC?"&?K=O:$:Q5,LP4>T&@:7E<SK'.@-Y?3[5Q- HO/7:*JW,]6?=4;<ODP\7
M7W7+:-::W@+L_;\C1BW<![ VX *=_+; >5XJ,*T,-X"2TGBE%NHNAA>:U_FL
M\S;PN>';?3_T2@:+!5[9-%<5 F;"O\_S3V3\1R*)_THHT0?5<\Q1(OA1RBLN
M,-?XHW'W+(N'0PZ2XBF+J!'\ZM=@URM<8/(PGCJ/VG S5R<4LE+INDR>54L/
M8A-XEBJ>Q5O10\JG24&U7" U%[^Q#.,DN8#+8R2.31<3SU/'RF ]%SB?M^]M
M)Y5C$L S$<V(C6/^[$^]E&]7GG"!T>N\%8L<1FB7L SPTZF<1ZDJ$$]_RGD(
M_4V53[']4B=<WAHT=]&HK'",(><]*A:_5H8(\%N=7ZGD NT?$8OH7)[4=NUS
M@7A=]9CCC:/A:58U;Q#U2[PW^TPRECDUFJUE2\N4&>9O#KD"L1I,%>8-]SUQ
MD]>=<=WF""Y W .6-44L0^QF+D J3V7+K/7\2R:1?_ 9$)XA_=G_B[*H.XUG
M(UFJ'EV,5(ZM-Y/'=*K+H&0N\+*O;8/1)XM_3^(-Y KEKUT$/,V%B4C"KP0C
MZN#L/*=V-/L,#DZ51?U162%L*C5T<0''2>D,2I0#A\(;Q.JD&MU_O9"S2Y$+
M*+70\9MZL"3*1F0MJ>7.O\TN,E6,9^7L)C"=P'5.P6SL/VWXWS,7=?KS,/+A
M?QW62L;B>+K@$AVV\><S?I5GEYQ>4__[O3Z&-^O1%TN>PI"9XBUL*&I.3Y=C
M]8O'"5]'\<SI<(P,8^3?[(DW=OZ[C?)<!O[78](F/Y'WY&^XM0S\^SY5GM6,
MX<V,_4M">+_Y?O9E_-'H?TSDXPE%.;SI#U'W=*H>T&29AK_PS:X?R1'+., 9
M& DD$K_E3%E7ZAYONU'O]/N@JZGBQ\\370IEOWMDK'XUB9[G_YYZ%^]'&D?0
MT=%D2<AVW0J* ,MG+-KA/"KZ$'(@6:D'LB)HA"V0_[1)%7U"O+XZ0=WZ+$H4
MBEGBC5[(N0^+KF$;( V=F^_O/^;2^L6IE9*<C:JQZ-0<T^RL9EF005)G"9A5
M$,RPF [,GKGB!6ZVYLN %84,UW>3)B/JS=K&P\5]26N:\01A8DC>H;;C?HZ-
MT9/9A5CM7/M!\7,1@EZUJ((*+G -+NVCLX&*-Y%AG?JL9J((.3$S(#9CJLUI
M4@EDCQ30$O/$9W[4TLO9P>\VAO,RAW1YA/9Z"UW0("+ KSO_-OGS@=1NZ\A3
M]+-OK:>5%Z/ Q.F2>V3AG]1),9#0CHSC6;]5R9!-6+*)&N@=0S)1<%MPJ1TI
M+,,4NK]FR#1BQ^L>;'!JB?Y.@V-S3J!K>V,2",ROB ,?V,4F!BQ1.!_.^*<-
M TUK7-#A GO("G/94G8,0NRG@AU%9/$1]>0'=?XXJO!D9%$D87%)(L-F\W7!
M:]5QSM[YC;.0 SC(4;H3#@?O0J?O:]" V9.5BQ]+)M*H+RRTH2@>D2^#@D%2
MJPD_>+NT@--'X*]U=VHW0'8LO$6Y\0R%)4W=0YI6_%-$\.(O(W,Z:OL\[@#%
MMR1GEJ/(P"0P#1],CC"081*-[+>069$O#"RDI>>IGNO!(L!@&6>7+>FT);VG
MV^,.SVXVATG*?.;G03S_.<2J"$]GO&M 0-^Q^IO>J$ON_O#J@Z[N$VYZ4#?]
MMJH XT.+T[1%1^7'4R?V;@G9EK_%2[8CLH.=S,.-GU5M>$VE41QME!!N;$1,
MI[%K\3VSSC'KTY2DT;DDT-5L3R9B*T[CF'W_\RK[]TD7GNXK._LA"<!\#S(Q
MR3H<0A$R&K#8!XO+W]WS?C[A1.@=_>OR0F?AR;>'VZ&-PR\&6/HR_19: 0R1
M%M/"+*U,B<BR55I:FZK W9NFW_C&[QXG[WZ($\#*RM^'M>)CO@F_EX<T3[?P
M-VC/UR$8F]Y< .7(@]K:JA_(N^^:\.H! #^OWO26=P!&\_0[OLK]_USO,-\/
M^-BD\S<Y>>'WCR18<'!#?^O1@$<P:19&$0X/O>NEB)077D!9.?7BJ]N#.K5_
MRP1U7@/Q;7\41A-ROZ%YU00/+?$%5U[</J%VZJ7"7=4Y*V">"W@WE?NCQW.@
M+VYF +PZLT=$JU1B'*<R_E+_-M_VN/.1F 54(6%\ \G>MH@ -6 <?=135/77
MXF+JDLT=C8" "G[6B<SW;):PS3NHU.\DFZX+K/"?#/^KT>@X@KVU9HJUI?:O
MHQ8 Y1\?8L$D\U"XJ2&,M8>WKE+L\9X^/"6Z>Q /[J!R@62[?_E^)^$?ZI>B
MM$YPIO!UN>8J[Y/I^+O7C(X?^8-B^D*^,1;V)Q6N%0I,)S%)/?A=K!--#'2<
M%V1))RSZ-&MN&D[-53DO;&SO+ R@+TN[04VMC(6Z?0NW>GQ%I?R<-4C;.<_J
MJ&%==@RQ[!(_(1T7TI.-T$U?#U\Y.+L)$4 \Q:&WG1EXA;4$A:S+NUGEUH;.
M%HMCX&?^G)-E<?>F@/PM-X1J_]# OTZ'Q$+]C#5JEYS4$:(_1:"P?]3/[L:P
M C+697MB<6):W?=':S:%<=T3-P5L8K;!F!.M\9Y7:"4[+[39E^O;@TUM9:L+
M]H7V@2F*-[L$+G^9^[3K9>_E:ID;:A,U*@;-92&E0[&S$FOBR15%(PU?7'QK
M2/  1T?_>JU#ZZ[7^S=Y<[7-!>PMN<LQP UEB4]J,U"))+3)7EP?=66!LC>4
M:.A ]4)"-C@CESV8V<%5XA[D_=8!B1L!,S%4VP=5N]0'OWP]^YM")8!VL-'L
M+GRM;@H.SCH)!=.78PQ*P>4'H9K /&XK5%OJT4&3U9ER'IXXG]LE)R?ED5XA
M1BU.F-G4;=>I%QM9+OV9X_$DP"M"M,I2E L8XEL4U!9_47R0XR'NE\:_+$'J
MFX9+NF*?/[Z7[D+42'J=R93,="L3OWC K>C&NXQ3B A\50U^8[LO!>+S_^N4
M &N-T92B%WL/E\8C56(W.0>C969V9=_\:G#QF)Z+7HY0EN:]%3?U.[?:/JGL
M37HYG''U9^.MDA*%YQ6$X>\-?LY/GV?N+FV\E><XD&[+:!]Z%#85&AF(65]<
MF[9&WX?SF>S#PH>P=R;UADRD6 B0$J6)195['!@R,@M]YJLSCMTHHOL_^6$:
MK*#VN4OMM[6HW(5;-JKEAA'B_V<+&-73L!BH?+QSYH3,M6$W#\3^N$YZV6&'
MHK*K01=+/)J'#>RB5?Q"_:RL1&F[;R*SA)/LK<>3+AR2,'<YFI!T<>)U@J5J
M4_WSKTWD?U6*\'^4*LM_>:L%4R>5"YPD\O :$("'AF]E:/YSM^W8I")> UL>
M$-HZS9/2C'\1VG\9U7G^(S-?7:W16Z$AC<*K71QA^#X9]2&!FXW:<\I;NJ>W
M(I]MHW91!,XB!,A2#V_!VOKX]EJ<0M#$!L))E=B(PCG5:914YL#JM,6#9LO[
M:@'W9L^\Y>=<"I.!VW5@(\'V+6 /[24 F,AA)( = %_KN"W =Y?_LH$3C:.,
M[[9N8U,J?Q/8R&XN,,VS^??^PUT#Q;3[GL4%VJY[X0>F3E#^<LHH1_^G4\;$
M)L)&M!**_9"E;T2!8;;JZQC4=8O;00]==%L,W<V.J(0#26ND(B)BYA>50S[
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M/=&B1TCDHG\GP\/T1ZH$B R X;-AZDF?]1#VJBWC;_%LG'ZB/ ER6[+_MP=
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MC0:O+.@S"3%KD'[M7XL__C__#P@[!N D;PB<CL>)MU!4\P2I$IF7?Y_[<X<
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MR-I:C\%[XSD)%Y$_@M:7_^L*]ECB4*,P=W27#,L_TP:?+SX;KHV6B$*UWV0
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M6G@2U+5J6"3?E.0K;MV^5'N6BYN+4M69>W7D6RDA_DF/?34OAMO71>GMI1R
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M%MT\]^>!PB%+5%?RX](3&?.7AKTK#9)\Y>NZ92S6+$B8RY<&&BX\+6_;)#
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MG&%15]>HV984!(,/KZ>/]_H-%1A[M<PTR_W*29=S36KS)4MORI&;.YO&RPJ
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M:+(3H;W7XSHLZM]/,A\1=8_IAQ&J<NF8-R_\5:$XG3KQ\_V2<1A(Z[VA81L
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M[')%Q_OQJWEWW CQ[^0KP>LPQ!WF"OC?:2,0MOWN4DEI8XL!,V,/\,^8_P:
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M:K#<9($EN.P-/2HC:'1;2S8.:2UT>AI70IW#IQE45J,"/NH%>_(</;_^3J-
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MN3DR7FU$^/5YYFP__<OUI-/8 I'+&D;R$:UF:2J](1, GXETFQF0_R)E$)O
MC%G K+J2: %:IS(#)Q^,$ST#N:9DIR)>& 8+%'[-]PU.M\RIH:28"P+K@95I
M6E28R:94:1P1B8>AUT#53V$NL-R%3II6@:*>]8-WY=9AF\L?T**T^Q#*/H[<
M,,/C.*Q*R*%>DW48V_L-)NXV<68@IG)J'FY]P)B/GB!SHP4&:Q982*]#L@.8
M[<7J$OJX>4GKL"!WJ(]KK@JE.9/OH0X-?@-1K;SE>#:&Y=C@6#ZTN%+H%.95
MP[ FEWKWDK<KG!SOSE"H/KECT\K"3'GOLJPH(KUK,"@?\5!D0".@^':4+G\5
M4!B//,YSL9+>M(FN'M!6:OHX.@_0-HVU:TJ3?*H9;$KXW4@7CN7=? ?[;2.:
M%:=88'3689WOQ.6H/?.-4ASHO8\Z &6WDPY\,H1& ]3*,RTX.[JY1W^MPS0)
MMF=N/<*ZS,"W^G<KIG/?XO<XXS2OMM$'O[8,"[^\6SWT%T*/& 6- [:=ZS E
MT08N.M5?;9SH6"D5+G]9*#68A]/1,OYO'9K>.!)7L; .DQ7)\9@J\YC*"<=2
MYQH.E.P#]*>S@BN>\$9O%'W;5C,1B*U>IKW\U6?<[WS^;=H0"]/PMJVUI;#S
M!"XP6&[@=L21(I5]5S*^/AK8GN8XX_DO4W ;F.6958)'^,Q$QO$9K"KAL628
M#"<'#L@0$%UWS_T]+MD%2*IGF*G1JH11ADNE7**6?)$F\ ZOZ37E^\)CO/1R
M0UV6RPEO&['KB.[D":#P5WYBS71#X'/H[M?ET)K0=5@]O@$79NMRIZFA<?@=
M.KR%F::1IGT8PR[+N:R__ R>$(X.A4^0>3<*2XCG0,_[HN@=3-E%QAZP;N;K
M;#H1(<Y["57U\@K'JH'HCFESR"?0K#:+XTNH^MWM25)H?#.6=Z8U@^%P#6\B
MX+?%1ZUI<!'=9#CQ&I -U;'&;+[];;*R#E,F8/R =5CJKU]#TF1B[H"</9L_
M,4X_6[ ZY.O7H;!44.G5+V?9.M7/&/QSV^Y([]Y\D:WD U2XYB+:!?%!:H_N
M%JB2RTSW1X^09+Y[8SL*$,FKR<DKM(D"H2^ Z#T.[U8.;ML0=_)CGR.([1%8
M#0V[2D%"Q_M];%X]N-D[/(_[?4MRLL43 [&L^&^1'NC#PM;E=0N,6=6UEPC)
MOE V6-Y%W<KP Y]_#!(%\IX0KU1.+=R%9Z*,YL"P%EP!4SE$(^M OT)C<0QW
MS<_*I\\6]_3:_;]0\9_:]$7;(29_'99RT,MWCLU)6X==PVN_>T:@>C$>LL)F
M,!I0,G<TMZ7*(;!"\X&*(R*>Z*[61M.K[;-J:FKXV^15BP(V$5V/[61FH#?5
M2_/1F"ND1U03]XW^(JM "4[@YC$-=940+:/$%1VL"W.$^[KE4FW6=(R%S[N7
MN;RC@?E?.G^<ECOC2C9$R9$^(AH]I6G*I9%VS4W+0H%<@5$O8B<*'E*D!\JD
M$#&\5OL%OGG2,VC_3 LZ=?PF]'@RO2 #WVLC+ I%>O&,WS(&426\EC-Z2=^,
M-9^O)@O_@B) C(M46"+GR?(28^(!^I H\/8+TB<M&Z(IL-025>Q8%;3Z.P,9
M@Z(\9^.B#[UD*_2T7*]XJ17WPVS2V;E:>X1U"+9I'K.)Z 28]R#D@YB[I/&0
M+&4??\J,GRY9%[*6.GIED_K^P[S)DZ#&@Q6XP(7L[(?V&O%@&P*M_?UM9?G)
MCTP9GC>L'MJT&.%G,)E81=1>XHY/Z" T'$<&<4CGF2>2O<%%NT?VX'9/J^1V
MK!Q=<9RY-;"]-5[[OJ:!,&>3R5^TWG483/*1LZ,ASIPGO3[SQCHL\?<Z;#OY
MAD+T?P?24Y/#49M$ET>0&.X@SUP%DCL%/=+H+H0[76P9L=1!GQT+,X+<9V@Z
MG*=;*!3!+U/_:<VS>WT6F"_:5$6:T"2/ QEL1F]@8+BMMMSE;G&@$ _*L 36
MK-6PT0^XXGD-&X4EZO/3)GERJI_G7?-2+ Z<4L_;:.F@7/N7S"L*&SO#R1@_
M!17' GB^PGA&&V*^2#.!6Y9723S60@=SJS5Z==37SGVRI&TM%U*%9_/1J9'[
M&K9%I1>ZN;[.9@&37QQJ)N>&MVU>AUT@&D#E7'0&&LY @^8=JM,8[H"RP@7;
MZR-AI.[*2_-:Z@T5T&W_(4M;].$KN,KO1;N'+%T0%^A>96=HH8%GON6H7</W
M+2>PQ[NI221UJ!15R,6PH_T@\\H)HC;0/SK^<,5X;1V6SH$C7:N"_ \,2HX2
MUMH][CYJ&UV6:J[<-'6;_Y?/<P>$5/:CD/R\I+"E9XYZV0OFD-%  FH/$27.
M%6ESX2G"U2ZMS&P>)M6<^X[H%A!0!G$N %(=5.UB#R2LT!"?YZC?#T(<G\&5
MG99X)8;^0'0, 1]EVES3_V.?#+L!S$U8<R$-^.\6EUX%CM=FT]@BYY$RL+QC
M0%[D,(*TM:0_0%ZI%1VO;P3',R5:A,"NYTLG8BNA\/YL7X9/ALTPICG6^;-%
MO]/JTOO8ZVM6S)U$#:"/5\_1),F)=-]"P;PI&\0#9L-R#YE",H,*XLKMX D%
MW"5:*8Y-23!C6-?&56$$MA3->;:(M)/JD.IYX95D8-3,TIA@PDLL@XDO076@
M<R=U*W)3K<@>?)%_[U.DVANOL%_IFI8N :ZM(\N"R!ISYR&+ST_UVT8:=.Q_
ML(>&IOS47CRVR')08:2#8TUK5T@?40@&A7^N6*J</#GB)7H#**U\6"7"G>'.
M.^/8'0P#+B7QZC@/WE6 50IVI"F@X/($I[&E@>[HO#N>XW58NZB0R">T\H+%
MOE\(@1]H[0_9 G">1A=6EF@RTF9!Z&7E7SM"L.5^S"MSKNJG$:J^_9 SE5T2
MS*3AGM07FDEXIIY>+?49--/(%N.F4#!RCZ54Z);O:8VGHC1$^T=7_-R$]\97
M\*KSG'IF.@E)](-.SQQW9ODC6R$N&-BAY9]A'A_)D<.I"YMKJ8!/EZXO2FEH
M<<M+=GCU]9*YB 5VTC]&3:WGX=]5645FP'(Z4J^8L'QR-(R&-.)A%.?:3(8L
MR\A[A_BLU<8"15I I>W US_J/X+'E7U;,%^?G*=:[/'8Q!?H"0O%E"4)?'X=
M!KCB7/Q[!MJC_;<7=&J@U99^M2SX8;T!?"+C=O6<4$NMJ&#/FOM7QK3%VY',
MU,UW^HXOTJMOOC2]YN'[68*0#-WE+&(!6^YTZG.1#>#051"VB>N1 &(ZV#D]
ME;AG+.D\G*QK; 2Q"?7:4SL_L,_1*X.M;$C9QLK195X.$2^]3G_K%08G?Q4F
MK]E*V-8<X-R  J2"C9>Z#<$U )6\]M< HJ/?SA7<=;<%*G %Z2E[H=M5P1[/
M->J:M!#)2X9O/[T,5_.J-7_^UNROE-TR2S+_K8C0:R?#)-NQQ#M@#C,%S] +
MDFRE-PXSCI4JN'6Q&TM 1#=J%X!_4-]J[62MOF ID+3R"O=.NV=]VQ>V)XLW
MS[L6S_;<A<Y$'19I0#K <B^Z8;;'7#Z$LTWOS> OK +$<@-1!;O:#K8,O62<
M9&,?U%\?KG<6>]OR8VL)#\HH>-R>OQN?__2K5W*P^/L/7G (F![GR2PF /Q.
MJ6?<!J7S==-?S*,WKBRGH>5$LCRY_B/>:>.=GFS#RLIY[TCE@< 8WB1&%N?A
MD=]8PCT4'191.^>A\:CKA^]I'<8Z["E6A1R(9__NPKZ9[<FPY?:RTF/78?=G
MN\E:C$  ,>/0?=RS2X_GGQ[&0ZL[K,.V&?3G_',+VUU.<'/Z-'EA%+EAQO;=
MA748*V)A7"E$17G+0_5VA'1<)8DIY,DMOQ_&B*7U5OM=FH_VWS7T2T?C]"LM
M2BKR-(W0^&,8 _Q.KG<Q<5%BC*X8]WV^FJG^-FUG@-=2>&#2V'1P]K\9MX7#
M8BH17NY/#&^#<&#\N-\(PQ8T-$_MEV'I7(*JN<OQY!LU_KQ)'JH45-D?SA]>
MC#3?B,5%YUEE!?W.[QY(-5T*-T?NW]H:GCD7*RR%;O.Q.I*/")FPP'HP+F<V
M7A0&1/>052.EQ<CSMY7D6"/P,>&*97F&*5+U;H;BL_$['+:\T9IQ66E$\>DJ
MAQNZ2V?XY&2&:S XVXU]8]Y%O8=61<+7, / ./]TKT"'RWS 46(<NAW(@V?F
MXUE2[^18Q)DI9Y%3V?;/.R4+9Z$2KL[)68RUOW[3%>LDP21KVJ;M=;Z8=D9F
MR2JU)IBD-UA/4?J>]RC$QJRE[!+.QKYX0\ 6X=-*=G?LE6C9RS5??=D#.]XU
MN3>^_?+L7P6G'Y3[5JBC0Y+M(L-AE&'PJE4.*'<.BIY9@VL%%^EF[JP_CNYJ
MO*N0T4:[7GHZ? O#PVK\49\"PV,=]AVTO[_;T.!DW/_EE<L,:3_QQ+!$C;!)
M2@9*EB[&/N-A2,O+>=C/;=JOXC"^H[7AX8)?:PJV+F\>)IAV?Q5/-;R]8;Q#
M5N_+V3[Y<ZPVFC[TDX=/F5: CH$:TB&V,6007<NIJPY)^%JDS(QC;?&;!A">
MMDM?RZ5!\.$G^WFP<-S-0/*\\C8>V6B5I\3N5_OPR.8>,:R"-.V_K1Z\/OZ
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MKFA7W+EWQ$3ZC0=8UY:QI";]D\.NHZC)4*5S9RG?L(UW$D R;Z!K.0FQY2H
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M%86JKFA8>HX(&:@(N=47>FK_FV=BN@3&$;E !< FGM2ETGPA+L#A?DP&6^S
MV<[_%@TD1OH%>K:"LPF+%NNP+2%WA!<X<^JK# ^MUIRO#X??54_T<0<$U\=K
MGC.R1DO^4EQS$U=9X)/AQ2%&PKM0(9>\B5"VW+XZVX77\ ^R"4P>[D"901W5
M#J5>[(75/86T%?'=2:^LCW!MWSG36Y'1+0WYP>;6KS!O%T!X%[-N68#EPQ.9
ML#9ED1- 2VF@[13M8T);0+D9*3UO)9YHC4=L@098=WN64]CFO:FTJ'TUQ"M7
MB@E^U-.?B!G:E^K 7:=UYRU&7?'#PA_WM/5>G/EQIN."1>"=XVI*ZC=0[1LQ
M0\PCZS N%[LMBKI]#JM"VBO:#2XGB!#6\5',3,3&*,JN[W<.+O@??0-,TZ[/
M.#1)7=M-<B-1AK>63M$)NM.H[OW+8[@Q@[\M,'=^1^PD@>E<1C;;C^V+N6._
M_-6^^$5>2/;7GI?N7AQM=Z_'ZKM5-O23ML\SMZ"#E]EZW'+!"1#'L^Z@:!..
M""L@)E?!F$MY@-*%$LX#*[TL6B*G3C$1#'0<99P LMOOBFMK8LL&P  >XAZG
M.[_G-1]\<<D1_9#&.+2EIC^1DF0QJ"2S,-O.R?A;='V8X9]7I#2.W/#?J[)I
M4VI'FR40SCR>LS+]J"K#^MRXQ9^:%5/+Z5[75Z/U.MBSHR9+5WY\=HCZMU_^
M]BE>'3D(SW;F_E[DEHFLF\'W\YYY9'64&6'33&_"KSC=+WX<+"&/I]B*>^X]
M]<7^DER8ZAGGW+8Q2UF9;+Q*1SB&;1Z6(\(+U2!TE6@7,- M.&"^G<#L0,!%
M+B#^ AC-HLB+',:&N\C*H;\$;JQ5>9)A"WBN?GRU8:HSQ/]0P]@R$AT86\5Q
M*0M2N>2EU[TYXF31L;5;I ^(>@>IJX2L>8A.IBIDZY5^ DI=LU70Z]3=#WR=
M6IS>]HFQ!TQF20Y!"3P_Q54%_X^??7$>C5;C_GL"&W!K F-6LW].V#[UP>I[
M<6X1:PY$0\!<:H?KA/N&(A>JR;H0:V:<(C'Y/J9EEI\K40?H]]LT%U"RP)?<
M:+KRRSMCX^Q"3H9)3W:I=U*^K;%<>O63&7K1NR5;&EN/[Y^\=DRD CT"Z5W>
M8=_HI41;8&JLU3"YW'=B8E[KZQ#2H_E.>D!TA:-:1L-T=<47]F>?@>@#/MVF
MG8R72EHBX1#Z.IJ-8U$!5_/[9%W+ 37(F0=G36*W2=CF_ $-!VY39%CL26Q:
M/F=QD:1)V.YN4S\XY3/GKP.1FN')M%"!Q]'(Y:TAJO-@6W'-BX'?U@*_F3ZF
MKD@.C$X.(^T@^/"S&F83HZ36_,'T0>HBVS/3@J((T4^-KX3ILJ-SM2^"&X9_
M3:;3Y#).]^09I=3\^E_#[M"BB+]T@T%M(0U M*_#)LIY%$$AF-R1V[;S4QN"
MX+3F.@)_0+3C+J>LCJ<2T25OWI7->5LU<?\.70X/7UE8:+52,/]X[373Y^F2
M_[X/M=2KWU<?>W]\5+J@9 _:5<V-V3P^Y$RQ.DJK>=Z<><SJ7_RIQ\8SC][N
MBL .C/<,?,8(_X&J 0?A]Q&)=K -FH55(%[%9^CN@4S7#A#*WEEN+-H-RBPN
MSY ?>)/3KFG=:-!-F*'N@)+]/R&C*X+]$?7Y/UGYQ*(C"=T:8"WCI[/&L@8K
MP[I+.M(Z;/,<RJ2H9[:+'9@8^7\(>\^HIK:H;3384"FAHR!$146%D*.T(R51
MD29B!)0JQ(:4&*+2@H1$I?>C'.$(!Z(B11$"TI22 $E Y2 =) @IJ$B3O:7M
M0T*X\;WC+>..^WWOR)CYD9$?V7/.-9_G65EK3AV,+^U,_<-A;-;YZGYD^;S6
M1ZY7P,,=5M\_[R,:QA\7M=]%XS$U[5F__F LT,KB![")ZN*CB2Y0_%-O\HGJ
MWK"Q:%8#+UFBYC4V[?TM#Y78U3)XX\9\N*^F.[ 25YOW"?V>3BH[33 ;V[U0
M_@-7N$9;AP6),.D, R@>F/"!;DU@XYBJC)U0J" GW<J)3]M9'L\9T%6"6OV%
M/LR-P4XO@MRP5TQW%@.1*29=T3;71==C7P:I^/RSHMPE/__OTI-?JJG&G,7,
MT-489FR'%+$*I,XVGAHSF)I$4V7H0V6<4&=@92+R/GH_"=OA@=G&V#7N-3+M
M7/K9/@B4\X.B2WT]S7)*Z'&R]RJ6#)PZ'QN=B40<EW1(OWB %+V<M%9$,9]A
MR((=;<RMXC" V;KFPZ9L N?3D>++5CR=12><J@THYP%<5/J,8R:2Y8JGAAMT
M8XM?XHII0L>G!#^676^:IF.8S*J;K=HYF?]ALM\^EHLND"]!D<)HZD[2,CQ1
MJ[X5JR8.@C(!)YO>FK^6K.4Z&+K#9)1F,I&,>L6;R64\(YM3GP5'%,"'RL6G
MN@B;AC3K<P_UIWT8=I\KH %N4FC,?]XEVT9+6JTK+[<M_SS%]4@D\(<X2YGQ
M1HS=GJ0.E_ZO"3N(Q-FF0U%\ARQW/.'0#PV$)G0VD%!DD?-G03K8L4Q<RY?J
M.TS*.DS=-#.N5WQB4'PVI^XAB>@-ZI:M/;HEA"<S]O>&E3U]MO_+2FYD[ ^K
M$T*G9MT8#[]^0XT?O<BN?\Z\?&B/ZG@=A-:!=H)._)4XQE%)MT5D8I/Y.FPK
MHH.XM8C9RIQ#:09JF>9D6CD"$NI.LN. E=.KZ2'T?JEH3ECZ5(M2G,HM2OOY
M>2:B8+=4>,G)W HPM/L-WCO"L'9^)?F'8@0M"9H/<#^('*&8"93Z5*[MW*+6
MW*L[F8DF7:>_C8__).CT>0GQJ28BV[\RNL\G&7,O>GO[%;)I>I#<\B24\_1[
MI =5C:(]76":,',6M,\46POAVTGV%Z#K*XBMDETD7(LWG4-5&R-%=MQYQ!E_
M>HM?3NS0:/!/<W<NH2<)#^GD;BL/,;K^DQ"Y_'GML421;,2 L,"PH#15\"TK
M]  --#\%FI67M'$I]R;H:J0#+!_0[D5IH/=\TI<WC"%#<50Y/I=]I^AK<:W.
M7.S:ZS[EFUJ-M&1>+6+6&JQF%2@-D&_]:CV(4#*93VS(229>C;5]W5];R*?)
M0@%M%$WP%Z.>,.B6A]KP6QD(9NP/LG49*=:>P6307+3([II<M>&(^QMDIB3;
MUV'W$Z'0=FXB*]]'HH3$MC(5Q.XTI0HK+R%."\>@";$RHZ2SK+;00.69<=G8
MLSFXJD&RE'H_#7N_.)-'-&KSP=6,XH(MR. XK1=OV1@M<O*9.79J.:<.&//^
MY^DC__HWZ?X)%SPNW-R7/GC7WQW&OWO;X"="RJ"TF9?H\4I3?M9]Z!VDG-;7
M,]R/.1/T#<&,O?7]8<GD*,$Z3 O2]XTQ9C,T&D#[5'X=$P@$, DA7RI[P[?-
M&1D*J_L(Y2:/&"*3H%4"G1HB/@$H/OYU#&_ 3Y[F5]M;VZS)L6?E4I,*+9!?
MSHT_,\HLFZWE+/U9^O*GS'X&_]W1(\=UE0'F1.(]TVXN?(+9ADJ@RJ.N,(%$
MML%!B@FTVK? JK,@3+(M>?%,>.V7YC?]F!IMOZ']L:W<^GMAVLV7#=VY<J6[
M^_=1CW:5S6J)*0"O!:OJ*>F_@RXKE'0U9$K+:=(RIC:$*24S]G.'"H.5L7Q>
M"D_>%!4?2HJ8<'D[4&%:/WAUN,FCGL50'Z#L/)"0:YXX;[)_<''TKSDDH5/2
MTB/[@:E#,:9TT^ ,%*53(@?E!RA6@T2A)KO9S1Y2#L(_ZRP/9NP"=7CWQ;;%
MI$1.EN])>8IZ'T:@QAPB6X:6\ZR.C+\O+TX--#(BGL$O72#'B\Z2CX&R:58!
M(M3,N#I0B/?0A:\];=I#AZH]JN]SB":X+9^"[D!-3<V-!0XA>8[W5Z/-LX=D
M_ZYEV1P>-3ZPM+I\UZI?N))10TO$P9?F569TM4!$6GFV9<P!Q%8(:_MF6/KA
M^$S]D2 -;V1&_H99#/%-DT.($7%??65UG;&OWV?6IK.#'9(NB16 2F?LDD/!
M(,MS4&@)^=CP$C5!B\EJ=CL;>Z81,$\B[R/TK<-8!;;/AS6.COJ<B H(OQIY
M^99I4=>CSRKM'SC"3/P$HQF$LS *M>E7!;18(S*5[N,;Y%@*X9P&?>S _2OQ
M1N%;D4U>YK'$IAE23GN$EMIP_?B.A&_?N.,QWN/<0P%IOYDN,,6J"X* -"F=
MW@L.)Y)=UV%JH_:#%'.Q+4AD/0!9%W$JY$M8&"DML#Y;3ZC[AFBJW6SOE\7>
MR,[BF!65^DT?>NY4U'KK)OGY*9BHF'$2L.=D;B"?7"NQBBF&\ +KKNXT],Y/
M8V0],*#]6(787&W9.Z:J7^RO'R>HU(HKV)]WDH!SJ<X/P.]XE?%2]"AYT_!P
M[;_[GXH501-$[3A-B-I&^9C#VTX^X2]R%-M!Y:#V!./Q"Z<H 3:%JD"VYSLA
MX-R.\!>^> ^M].[D)I?]=7E%. @ETM5!L#;:.-NU7S/._F/C4MVOJ<764'TT
M/]]<@&6/V0M]TXM? $*68#X=1=D=E /8AUXMA0X,L^[\*3&H:JY[]- @U:EY
MNZ4H^J]]X1F>UTACCSP?3.*J,9PR>!I&O@:N"D4*Q@N!E9;YPD \'^\TAF6M
MQGDP=L08C2W&XC43Y^F"?I5^K,A0UOGMHQ""Q[7;>Q_MK93"/"UA':8BV0W)
M"4.R!%TVI\'$..D"CNT85QU@;,1K1#0<R =/KL/\@!\E)=1+.+)]K3\H&X\T
M%>%+>J\W]@-USV;FC"(,8A?68;.6 -T%P&:@]4E9+-I&LJW(C+Q_L&DS0&QK
ML&^C*W7B5;$3U$U0L"^*C=[3MUAFC?.ZW^]4U7_VD< RYOSG$YAD#UNM9@YC
M9>'BQL4,QGG(%*0O4Z!X4+2<"\BVI9K0A &L?*Q@EJI#=O%_UAE4C&?H,8'*
M:F LC;+GYF[05(I+3>9%HX'<N&P[3Y.HR[Y[O2C#!"N7-0^<CO@P1!!BY"3#
MN!IZ6E[;[<""C6#D?8:\-^FJUWUM.8*!]V -'J."4"EZI?'ZWW48OK:1$3__
M[4UM7+=IRQ].EAJ79);WDQ^+L.2K4#2PS+/M%5,!6CM.+<S7[",U36OM8ZS@
MUJM '#P,$9_[,;6,GE&;?_*GC\^.)6NXQ\/."SV+>9;)M8W=LV6B3CSQ,"<7
M^VIF(5&R'2' I?#4*+K3/-DF)'\^K5ZR$RRY'S[:#2>-\N%IL@EDGZ?D@-[G
M<OR8C4(K3:WL_( 8X*HOX02*[+9KPJ7FK:0]N_M\?PCRZ]W?9+\7I7]E%/H'
ME'IC\O Q>&(4X<#V?[-77/8!C"&9'')(^7V9G:T[*P*$FNF+Q 2I!VALK/+.
MA%@^46Z&@1QR;BB\2+U.HIYY.X@Z):?7L?//4>X[/16'I(OI'\L>&D$6PSZO
M@9SX6;$S\OFX7@WP(Y5 =[YRW^!0^%\F,X&UQY!ZN_97CS_OVEZA?O6PFLQ=
MJ\;E B!^A0T?&9X@WEOD;0RBJM*M?(&.=C^=3,''^G(<%.H("H.Y.E\?=<29
M*D2?R99;.S#*=N]W>OZ>BC=Q'4TM%YZ"5<(X:SFF\PI0JN!^\+@\=(8"ASR\
M0=ED\M620+EHP<RG6@)6J-M<"JW#.(P#5P6-HS,'PU%*)":[X1N=;F\HC:;%
MUQ]/][<EZY1]GX8PR\90#%6 52%'@$:I0"&;NH&A2NIP@XB:K/EXRJ'[_6<&
M3<:<V@JV9YX$<Y+:8TNF5\<R,H/*/Q<_*/'^5W.T]A0 #DXF'"*>G6\Z"*-G
M88+AJ3QY-'P&(;.$V0&ID5:$^DF,_<&479!^R0ETXN474Q*C!@"18D2V??$I
M6+*;45G9EXW8X$/*0)[\\J'/.JZ_I8KVVX.E?,H5R0!S<Y--.53-'TY%H\0:
MU%&G5HHBN,*>PSGWUUCK._4T^0*7R5Y (\=/M9>^B-CN,\VU>P1NL;X67,X?
MN^HV1'_&!#@)=%32C4=?4X[#,(XFR),+%WIKNIQ<^D)JM&=F#AJ%+/J,7"J8
M=RHXK[#_$7OHU?+/SHTJ&4"C'=M_VZ8+.'4HEE6@#GQL%F(UI]TM[.,7G0^(
M7(:7D(YMGB-3[D/S^V>']>6]CVP-__E U^MQ]HZK#[V4M5G,:_"-T*B .=L/
MQ+8BE/J^C7(HN@!SQ&BQL<NQ-J];<>KUM'?\9()8/[+,^$.X-FTK*7C2 6A:
M*0AK$_KN^>+US5V%V:N9[7XGO2;[3GQ1[=+S4:M1GW=[W];G=#[8G_G/?7\2
M[5K5\]2W9X=M+R><.R[;S7R-XV!BI30&$T!+X*FA98+<OC-EF[PNEU^$5,^^
MZ=4'/E<%65!33+MT@S+BPZK&IARC2Z>&ZWN]QFTW?W&Y6,*=*Z\X4VF_Z$N.
M$FV"Y-IQ\DQ_YD;(N$.BPP#H*34\#3*>P>Q94@T.F2-8V8+]0FRRB>,7,P]-
M]W&_HB?3J]=+0O0>)]4UQ9VN^J"[3Z1X%VW<ASY&/C2 "<9!]B$,-5+C">C>
MRQ&HC,]+H!S%%Z@3+,^ =\36@4VA0NI&J>+\D9O&5<Q#/^<R\E]:E_::II\@
MYC@W9#M%;1,=91J98K>(H\'YN5: *=R_$D<Y!)U *T%E0EP"G9['Z7!;RY,N
M*!3;0BG3!CSP6)#:?#*R!AI\R4O5MIQZ%59FF6XTWO9-+G4F==N$RVKF<<0A
MRA!.39J8>FT2.0#+1B420#],ZKAY7Q/J*4FYN&?N1KB.Q_$'5@'X%],YE#W-
M5?W(&S4&:W)G!_1RO;Q/O# JV)/^Q5]]<3PS.KQTRCM\[4?>K<*Q<:_1SY^G
M/%QM3#_F6_4:O ^PJIL%')&-JMI-1KW5APYR'$P!WEP)L'(&#$BB;(%RV+QJ
MG>XY P%"]K/8M6[@U:)E3J.T'IMF:D)'=519JQ]3!9;E>)N>I3E+C_ !$U^J
MVT!%P7S;']B@LJ#?'G,C<#%K.62="50BK[JCE;=)?.*AEU6 @";SW=L^:=-J
M;'#UZ#AW=+.&6_ 9)[_WEV42.#_,?WM0_EYQ0K%%=^'_(_/^_TR67S*G>C"O
ME5>;&#_K-\@PG*8"KHB1*YAM05_:)/I2SBB^#%#9!0B"A2F&>'0=UO:JM\F1
M>KU71E^\UR*B8N_898461'/XM^%UF"Q%?9JJ%#:?POW%1;?[D>W[+CG%6+9'
M:IG^W;#VS)9@_;>*/;GWL4)7[:/!KD?E$S\::ZO?%/1Q2>5?2:-]@?\Q/&&A
M8_D;Q D"AF9:)!L@:T'F=E+9\M>U9V$83?'NM?S=0R;OZ%^!C@0ZPIX)/0+U
MV\T/)LQC(1N@;\]3J+I=0W+#A93I^1H83D3VQ=B<J\-3*RB;Q4:5T'X@0!#0
MIF#L0O.HA +X*#G2WM$+;V4"!K)8N=;%V<0OQ[VNFA-O]"<]2F'O4SYT^.X@
M*@E1/=F*32G0[Q'C0;B@)-[*1[@.D__.I24V60L)/F>]PL>T3PZ%E*/"8_3.
M#DR0Z,BPM;,_VC\(5X<.N6N_(" +_$/EHV.PI_L6UU2=*WL7RSQGP[J.]LEI
MR_T>&>5>E]W[ZMP)W6_71]2"2QL?9\CN*PC<L/;KABR*\LF<JI+8BL3]\J3X
MD+!;C938<6<EGKRQ#,M_;'@5U(RS4A9VW>ET!.<S:KXRF?U7WC8"]+B2P24#
MRX,5PK?-S1E<[K:]49M>+.B+5=#]K#OFL[07$+:5L65(H@/9M.)J].?V"S!R
MD(]//R&LOF]1!S&!2BU?;#1PBO:U<74C7@[<6_E@G&H\%S%\D-S%"*.5/.J&
M\&T%6D!XW*I'?)CUKS-Y0V5E,_4:WA=>163WX[4DA;?*9KS_?'!*W7OA_,"/
M'\3Y #WRBENGP<./SK"P7].1;V+4L^<DFF1'9[3F&R81!G%NE$]$77T870?\
M>(9\FN%P(M<\^TI2IM+1LM\"6R]MIOA2V%+YS] +1*@PKS/O%9@W0+= 15X'
MILH*HQ8F974D_;:A7+,JX"5.GI1W NB:CYT<V//0I]F^-?>?E2LC\^$>DKXW
M8'LBV7^_8P;\T]%? WOU-NF>D"W5>V/Z;7P[9 E4"S[2A0K4E@(9H#[>E*[V
M;A^XY<6S(+,ZCX8"HP.-/TO>)&\LIW-_Z#>:W?RK7.%SW^>_R"M!6V6?]]JJ
MP3P6(D%-1U"!-V< A@J+BLL$9=C[6@BQ.GR9DLB11B]$&=O>%2H,B)/H>I+1
MKT'SQ-I"J^L=+*V/3U\&C1_L:SIBEA?^<KH WKODU*7G4=WW_*&&Y('!AWF&
M+!DQ(-G-%7L,H+5)Z 6A]=_9U:.D#Q.GJK,N9DRW??2U:(/&:J*RSE7V3^:V
M=YQ[Y+?\\:-'75W!0<\BV)VB7]>M*?O$-@ \T4I/Y+$.:[U@?X]L32C"ZYI)
ME3A>? "\WFB4_;"N2(C0Q/OIK]6QN44#%3^QMZ*-]VD,?=AAOTFI%4_8=;/]
M0>9H\#<]P"/N"HBNG3@/?,M@&(*(Q,7,[?CQW2)YV?-#5J9/?&<\N$;QI6-'
M=QK5-!]=8-]9ZLK_N^AI@B_N7/BYD&N?9?[M%%E=="Z3?&[X426P3+6DPW[M
M ,ZN_6FRYC?IO,'9#*M\D6P#C91"?N/CTPI#A%L$P6-BR<.MSXUM+L>46+VL
M[ [&+6UI6H<)5MI^,?KM-VJ1E@+F_29K?J..WU*XSNE1UFJ8F;*?W[Y#!+5J
MP^/^E^K3=]?%*6^N,?C:NBO0 7U/ZI%(R3!E&Q!+Z<-4:K(/D3'%3A-)F, N
MF[;E OU<A+%[#;#6W8I+K1^^8_OG#PZA'&4D2!#.74K?]X:T1Z5QW^G"Q9.5
MIC0Y4BC;G*$[$-ZEZCQ(%.\OJVL6Y#7.>%;H]]06]\^'%0^:O-_G.I13XCQ
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M%2!2<8#+.BP>5\V<HXJ.D"(Y'EH?'P!.3D! *R;)8NQ/S?'?/,.<\%WFR_?
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MR(Y@9MN\%M0PR:D<P8VC4IHL38O?EE:\V.C363KU3/UZX,1!F37+^ULW*9V
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ML "B*FZ2D[T.DP\3Y1^>$03$-7EKX53&@L;U&M\ 8P,&BK0(F345LNG:<V8
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M_WUQLMRZ?MI:UGQT949T00\WU.+)C?3[!OC_W-WX__R?L#GR;U!+ P04
M" #CA&9:'"';Y&]- @!3>0( $@   &EM9S(V-S$X.3@S-%\T+FIP9^RZ>5 3
M:=@O&@1$10P["D)44%2$C+*-+,DH(B*#45$1$#**RB9F'$ "-(F"$%:C.,((
M W%A41&BK,J2 $E@'$:1-1*4;*.L,=T*H8=L)_/=6^?4N??6/><[I^Y_-ZFW
MJJNZ\Z:?]WF>W_)VJ]^K!0C#PP?]#R*T5F@A/FB^"/4$P@>A];_Y^7>2_]TY
MM-1="*-56CMU$[6UMB!6&&EI&VFIV0@4 J&E^W]<@/@_/UHKM'5T5^JM6KU&
M7W-!LR%BA9:V]@H=;5U='1W-V73->82.D:[QYMW[5IH<.ZNWY8KIGNNW'ZRR
MW?^BV^SX(&CG?.Z7C-5KS"W6;[#<NLU^^XZ=+JYN[M_O]? YX'O0[Y#_X: 3
M)T\%GPX)C3Q_X6)4=$QL0F+2U61B2FKFC:QL2DYN7M&=7^\6E_QVK_3AH\JJ
MZIK'3YXV-#8UM[2^?-76PV)S>OO^>/WGT/#(Z!CW_3A/*!+__>GSU/3,+/3U
MV\*B; G^9_G?N+00VO\U]/_'N(PT<:W0T='6T?LW+JT5R?]>8*2CNWGW2N-]
MQ_3.7C'9LN?Z*M/]MQ^\Z%YMZWP<-#OWR^ :<SL7X5;HW]#^([+_N< R_I<B
M^Z^!_;>X>(BUVEJ:Y&D;(; (E6K[PSS$_S_^OQT'?WH:DG/R:,AOOR,0K^TJ
M$-I%N'WX3!)&C<@L5B,$-VD&0((812%M5SZ^; NY7_?"U<-8]M$9-6(MR6[V
MJMNR-'O1H=PVN*5Y)-[+=6N5PHV75<5>G1)CU]*Z NLV&7+V_&WF5;H:(>Y=
M4G4ZD1<"N/^$D[L-&68D#LJ"+'B.:HG*9E[NU!=\9H*E6O+]LY8G:;V=P;A!
MQ7<5._-%:L3=&->[8X\>S]Q2(^*V%K3VF(71W%\[[W'ZI(,@/Z#,QZD1NE?4
MB RBBI\ZRKVA1ES@\R*[5-[0F_*FU@:%-\.#>@-(=\QJLW@ULLO+5M3N;1LR
M>LGQQ.7VSJ$Z0GS=/GQ3@,WBP(PNN=A>8@U:R=+>805"Z?A %Q[TU?<= QSO
M$_L%A)RDWQBK8 H>HF0 %F)]@N'K*Q F$,LQB@U]5LQ8.^RUJR799F=*<VZB
MMT= 81ANS]:&LI-J1%#;_WL&Z%-^/:AF<M\ KU96HJQ7K<=IPK&$ ^1KX$8!
MM@]OJD#!)^6NL_C5"@,1TF8.8P)*ZG]7V<!,<1HU+\(>7)06+%!S2BR&)J-+
MDZ]C^JKV58?F1]:18[S9;OPJ_FILC!J! AQ!]'P=*)5)<*N):;('ROL=*6+D
MC0H;PHTKX42*<(#:X2,,P!O#^8>@[)*$^*U<Q9;4X (&*MIMTB$=??+EU4%7
MAYD%6Y?>556WM!=6Y,$3(J9D2OX]8%8BJ\H7Z>4V%SJHUO.%R2QI =FZ,I.5
M6C6/L0%1[%$H 0X.&K9KS2T)KT@$_7(BOO;A]IQY7]>T+1'?Q*%Y*6E,00VY
M08V0[!!3*9,K8("T:Z:4RNE'6\?BU[A2<["K  (H[U$CC)OXE-*+6?5QR]2,
M1:EI3+%YZJ>"98N<2TF=ZT3O?^6Z/'9U^(A]2PELC^["^FRGO\'S+&13L(.0
MG^.AUR,G%V*^AV-$^%6J,68CK0MM&D%,$U(5VRPM"E2V0-R+EUP%&CP8'W6T
MM:BGVU5I^CY0]#$MX!:>N)-_8O#"*Z)5$"6Y8P;;TMIE'2Q <]0('E9E[!WT
M(QP'HL+A*B$Y+R'.<MVCZKE)<PC5+3DN/015%R8(Y3G<H\7+#NTGTFVV1Q(D
M[0%*IV]'G,-FW=X*4*<'\25X*ZR SFS0ZTJ/0!K 59B]Q#+.*;R!UVXHH8]A
M#N-!I"B979<LF,KPPE<Y-3^,4)QK BLR'Z-9DB/IW[_V*EW9O"OU[QWQOPR<
M_<0^ QTE?>3BS=6(RP38GD)A( #?P8XP^0[5J!K1:-_'+VB(.#WSW2OH3(5Q
M [C8EYGDD":?BVXNMPQT"Y!/I ?X)S97.+R?:AB)%[]L*7)!*%,?,JR5#&PT
MU1+0A?V%\18".9&$XR%EU^ : 6%<@Q".K;EW:P8=.](AO>/R717;QRZ=N_"2
M\4Z!%,ZE1W%2FW9?^-'RG&-W6/(MJCW,UU3W8>5=->(\+:<$U8CG$$P5(3 %
M6NI&Z2LVBZ6&<)"0UDW>H#@(T7, VZ=A_- SP+Y\EDIK<'']V:&BJ0,C:-=_
M'H2E8P\6G:[S*2F>M$<H/1XR/;S\-#/[*$M=-$B U=7<[XH9_$:2%[ =EI]-
M?PPCV=C&I2Y-)RA"2]<GOH%BOX,;#X-O2]RJA%;]5M.7$VMK':_RACX;A Y)
M<<5;7UX?(;JSU0AX%X[EB)+%*ZM4SD03 5VR^2&1(HAB&8D^6N%@)6@ELN_&
MZA-KV&VRY@M"]*KI4Q5;(-*]"_' 5V+^R><OQQPOA==+$@_1"23?@N\0REL/
MF>7X<2M9I_(A@),?!0Q 78K"%"O[2=F2A-S B_.15<%&0NE:8K#06MIS:%U!
MVZ\1>Y5E"E^;%VGI4!R+H0-MP!A#!Z_Q>;SRQ4Q.7>=8R2]WQGV6O>4[2<,5
MNR"L!"W'DWII%D[D)M(VU=M0Z0VO-($:85I77E> \8;UH.H_E\+ =97Q\V>S
M1Y-H*_DAL16K(=O>%_EEM58.S06N[.IKFN;Y7R"2G>[%VWDN*;9^=_/8-V?K
M''86.U@6Z3\_>CI+)TOG]O72(J8Y4_"$9L2P4S@KJYF"7Y>EFJ:F1#C#')&]
MLI*Q)XS<4P7Z%7CM$)3C^K[#SL^([Z;%N))MB)0>U9JO+DG)W%"TX9SY\^^&
MWX>^Z(PVNX:-5K"=(M=E^Q[][,TB'MQZ\L^HGT]=^&E]@7&E]JV84<6XXHRF
M&@J *&4%"4V:P#9Q.?SQ !&ZVS%.2)W'RW?%8%;!OA!2A+J.V11"+,-#4Q(+
MJ+;'PZ_@/.%ZA"V<KUN<'U\;YW8KKN6JVS>X_UC#X/F689>)>Q>';WUEZF(%
M3?@F)AL]7BO+Y 9U,=< :="2H%53-^,X5H7-J N?PD2IU@!VT)=".4X1FBG\
M3!-.#6$\X*B>"N\A8)\PNV74,0EMR./-ENKD7ZF*!>WRAF<6M)2>Q_!OT52R
MX $>/"'-6,;U!<:)<#W4]\S00>PY:CYS32*.%Q0,)N>K'/K<.<@5 *$5-'\E
ME#@(2'>>3J]VRQ(QM8C)(O.*R6VC'0D>,16;1IY96B-QAS[???B)'$V#=[5*
M]H$U,OZPUVIP24CIX>>2&RZ6R']4;%?^UI'\;!IC#(N?PI0?N)C-1 K+QF1L
ML3-27$7-IG0YZG%LS+B*X\5[%'M4[T<6V9W/\P^/7M[E:O5:W(A0W=,P6GLO
M&3R&GUB>Z%.MA%\+<11FPSSVN1IQDTFP-I$Y-C\?<U4C-H:3AD+C6\JALB 8
M*Z+F6EQUFXD3Y));79GKY@(>P,=YLL PW^%/ST<77=H*+\</K68*'M+ HP[4
M?&QC,/LWE8VJ_RKY!4J"D\?BY#MA-S8QLY=+;DK.=C&PY6"\P1L,-\BZ,1^K
M^P$//USJLJP:\;"YXSTJS=K\JCG\N'YYJ\$JO86=17:U#'=_PV*MVYE/=G).
M7SY^\.3U4QO^^&G?WY9V1=_?_G1W:/M@@%?1GH=;;@9XOECS5,^N"/$E#K)5
MK5Z4'X(GCF3V8+6_O"U_,NT(8F7#\-*V]KHS_'!B#DSIHK5<?B(HM \L^BI:
MT-#%JH54OUPGKP5BQ_L(WNO-+[,GG4U(D8HK2@WW79+F>>#S2=YQ&DS-85Y4
M(PS5B&XSC)T"@*1=:1(?T=N[YITB$_&^&CRC)$'HG78HSBI?XIMHI1]_CLL^
ME<JA9YWGWF\<=21$M:0B5!W[UFKOT#VD8[A/Q^C6OHV&?IMNKJJNO/U'^/$#
M5W-;#AF-%A"N36Q<<=AM[!3O_?<_7<EP^.<Y7*4!T&U*!L/"5^X#'(##P$>R
MT!'F!?3[8K'L\@M(E2OBFP _#JOVP/P>O@EI/:P=SDTDK\#%Q=03DW%,L$"U
M(^19$LTT8F ;/7[MJ>,A;WYV0E.?P#39,V65P@&J$;OW4,?UA(0N AR&,F4*
M*FV<8;.D9T $A&;WD_7\J^ TF3.HQ\FGY4YN\;CZ0.3YWK70^E'+"\):HN>A
MH:;"N"/#9S.L'*Q/?5T*_DU[275OXXL?VX5%>X,2G."/X<FV9DD?*@O_[*I=
M^^FTX<_[S$"^PF1*E@VSY+Z ,613(_\!QG=5F,.C8*U8CTVXSC0^!Y]]$KM,
M8WTDL&GKZ,_J/D'8&WA\:\O8LP4-GQYK;*<$CK"YQ7ONW2].^6XW/"K?3AK$
MM\@*03\9 ;:0VYT&D) ]&WV3N1$KJ&PK?B6F\@@1\'7[;(51->"@?(C9'/A@
M0"?"(/,DM.[E-F?.HXGI%YRUW_5L/IL>&7?9%T'&;3O$RLF_?_O7AMX0GX;,
MC&[GEX_M5OS09:\S;/<R8\N!1M:&$\;?%1W8_Z)DU<;LG_9;;-9&_?I*__??
M@[_Y1LJ#2)/DI@&J&A%)RT,U4C,9*X@)LER(-M\G#YI&&3;1\DC?0>.PGA!K
M!%C!,TB6&F$4EWJ!DCV/XI!VX$WB*DQ>MH"5"6$A 96AL;5N=>G6'<9-'5&2
MO?((6"Q>FN\727,M4.N\/ 7T_(I=&BQ-(";TI6;Q*4""J-;GK!AOH/J@6="$
MIT23@+'/(XXN^FB=68;=X!?"0\B;2REA7W5S;W=J#DG\H[KIEO;RG:+3#WSL
M&OQ,?WJ,MGVZ:=?^Q[O83AKSL>'O6RO]35URLK3;-E]==?VW'<F;;N46N>]&
MW'ID=^W01DO5SVI$-)FW)&L"HUAHGHF (GD%YLLN0=A"8'>EZD\UPH9A@^ZF
M;5"<)&B? =SAN_(31 >A%\D,:A[O ,EY8FCJ6L?^@S6$VNG47TGKH= PNX9Q
MS&]<<XN-R?.?H %910-4TQN.EU6,8FP4(6#V'4TOM,-9X"-AE.SB \@U29J=
MZG>C0U=LC3]&]?=WC7?&M0VY>._I'>OO9EB]# \XZ-]L<#$PR*_TZO"7+0C5
M[]OI74P*&3S*GWBJK2FWY%X:!=MH4R[?0QIKP1M=(D>]T1<.Y'5<H0/1&DV*
M7 >C>B.^!W?QS<^/NDBPW:I=PUY!U40/J<K8!8Q_\XQATEYA%6+7%B],&WA_
M1S:B9)"V*(XI[]4QX_":B;'9C/6J<?)*KW0()30KZ<8;P4O!$)^EQ N+:<(Z
MPHEADBU.5.C&_6'T+*0AAS*K?EOAD\I 2]F.9U%MG5V_7B-]..9KBOC/C>,C
MN>$>RNN;ZNX.ZFPT/&!LN&]C!O+*#R9UG'8?65:%>>9:8/'NVN^/GZ266ETT
MNW[*\_FJ35\-?EQEN^EOFWW6JQ;IX@2!GP88\S32-%AAXM?+7*-R@"?8I4L]
M5-Z2(+B7G(=M1'+JTM@ER9;\#)5;Z)S'ERH(*TL=3<JM#.C?WAP0C62C;SC[
MIW[#A[H7='C'/E(9O6]5.D*-*OU[D*> +R$\5AB!M.M>6Y\!]K"UB)F%6D/:
M#,<=@^/EOL0241\[W:_79B-X0=8L(J]4' 3QUY,(&1B]5K"'^'MG-54L-?9-
MTWC7BUZM)C%7\+QF!/E84_#?4[E, C9GV9V%Y WWF2^C,K+4B"[:1(D0/]\O
M](QK9IQV1>K!2QQ:XUAN"KGN_L@I?R^<00GG36P ML'+O#K-V[5TZ/30%?=L
M8HUJC9&FVX*[F"T#?>EA+%1C!14D"-PY6%/26[Q.8GGHG"A0RD;GD"WB2=N(
M<3W+3LSZF0C3(<6^A"OW&7=$OD,N ]JP7^"H5X+&*YO-?&E+JKI;+KG_,_)C
MK,,_I;"VII1CE)VD38 %_*9*8RK1/;]A8_C9M&;W^1H0W2UC; .G>@G7)[4@
M5:8\D%B#&]RU6)?<@S5>B&9L@]<9K'.XUS6Z;=@UF'D3W<*+_G;6L69^ 0MO
MIRM,62S,9JX=_ ILE'FK$3=,9-'*!H85Z;4:T:2B"PAFBJ!77(8=LJ"-PKH(
M3A60=&=2&5EQ!.$H>+ 0PAY,3_X1^CA21*0<;7II"10?;:][J;> W_CB\(:'
M17OWMQ_L=0_6WV)=7W#BEO5ZLPO8/;<SM.[WK[]];L^FNZ/E6YP>'CRPTWIT
M]8<_JWYU1NPO/GK(+OB;.]@O^T/YG. JU0=6*'-4%J2_-"A0TDO@T55K"!?J
M9]4(RXY]4/92=ZDM:8!I]JBE!:K-=PSC5-AUCGF%7WD<X$87=CK+/5DM2ZT.
MROQUUZLFRF*'A[&"QS;;1Q)QUS1>G:K2(6[&[ PAL5"M [F+']$_0"4%YX<E
MF$V:&9MH+.;U)949*'MP):T&!HC(OHKM0R7L9 ]NKM>.QT0JBW?IU-524LT*
M<@PY^AKY,.8\*>KN9_NRQK^^MM+O-6Y.GG\K*<NQ>E%PR[DTG>S2HE&8DD=R
M+]4(OBF9@YLX0'IS5>4-!ZL1.A^9D&;1-\'^8G).I*"W4UD'U>['(<>)5']N
M4ZXBK(9(#1QY#2I:/3!WGGXDMFR(Q*^MO+.WD5JAK" +Z/Q6;@'&6C49BJ1B
M+V(-X';9=669R@3PAED@P1_DLK!4U.I+"K)0FK/<+"NX-8M:2W*8/D4S<SW4
ML6U7S9@OEY)8W09EU=6]R<ZMR7]W34-GB<%?[Z9H"FX)+A.BWD_X0OB\8 $^
MAQR+W$@:\I=_3_Q%C>C!(IG1TQU6@KA\JAZ>*%>9X/)IC9]K!*/*1PL;A.]<
MTB\:H'K:@BF+&X#@)(+!Y_(GOM5U'R 5D]R]4V-L!XQ5DWA$1Y 8;PT?F6!%
M8.!(R!D/!XO* PZ 3#92C^C>]\MT2VJ2DDKU,A/2\E+M*:3-1+(/-[Y9&R6S
MR$\LBX\,[&QX%;)V;(CWEP!5?:7?M+O@>-]VO^@/O;-".Q]*8=Z=YA'PCY__
M3+U^>.C@LYRW>5\O&SW:DWWK\8=NTUMAL5\G]G7]+0C^V@DB997*!HQ-=QH8
M)3LYK#(F,D5XR0[-"D1JV#(?\+242BSJB.,=U@*4@>)[L GC\7Q$1-9OEK5[
MU]_SOM::R6HQIUI_2$@O7NWR"9U8OE4JN2Z_HAJQI"E,6O'P60'MNLI"6=>$
MXCG(OBHK,)M.$\MZ,>X4&4&3^CM"9$^GSSZN:DNEI1LM01R>QJ+:F?.8V<".
M*^==#TF=>%:%^_^:*'NHI<3XN^PVW%J\_77PSW:WC_Y:</EVUSG,B8WMB<?Z
M#7>$GA[#NE;ZYFR/M/7(Z:GP(=A?'EJU:4K/.^Z?WZ%DR2/(0O:KLLS+543/
MQ1MTH(3(PF'56S(81,M6N8QY&8B8YH5H%M\0&Z5&K-TG+(P\#A.2,+75IS6Y
M=A6'=1LL-JF<A@BNA2M1NT(G3P>N73)>.*8:9;;@6=)K$78P3GY>X:0L750C
MD$2QS+()%H-'L#=0AJ1M<4&\&,R*YZ#-71$. 42.2!^!V:V/9TN*>:/%[3%B
MJC;_]$QP<D-XC.'K[V]$O-52;O)Z<="LLL@E^,*!J*2C7]2(*R=>:-UC9AT,
MN+JRDO[)J@=EQ8QYJ4;$HGFS_6+' 18YEZ:W2V,L^. 1-2*;K*<PY2UQT@)H
M67N(8@'_QF+ZGBG63!0]>ADP+\5E+UIOD1\?KBR5L<*@OWB?:^K?QYESCP[8
M3V#7_NO56I@Y0#+H)^;FDS:JWCK(=?]MVF/*WTEFTZ'(7,4E9M-2QF5I$MV2
M2&!A#8%+K:&7&(BQNL6ZJ"ZN&L%3&0Q^<4S"(T_C6;O;.XJ'1)NTY-V^I-6J
MM_S6&H6I X=I3(Y";P3BX MR= RMH4:R Z*+4/-RH2=>"[[3QT5M=(DGL*CB
M6OHJP(_[8/02+O..+^1*NTYXP "K"C]-/JIT_<NY_W$)-@K5^>M_@ND!6TU%
M.VO0IA>=C7K.[QNP5 U,[FX!]7K+W0^!6106=?WD#(]4=_8^7,(F&W58"\L"
M.GV.C.Y*<K#JW'OG=#'_Z,VP'7_+-PYW/K_YZ>Q=!.;+0^9&Q@;2)-X(B'NJ
M&O#HRU5XB\+U.38;X;WRTS'\9NR\4BCQ_'',58ZG,E>@!%4%/*=[+F/@!__8
MRPJ_^ME)0V8+<[BI,)A%LFT<;=;>^NQ8(.%5/;G[)XVG/Z5&A(#,/*\-=3,V
M7H,:ZML.ZLKR&&XPX3$<=/@EW"^D61++NDOY>:3MI^$BS>KY^/U.U,>_^_*)
MNQCGOPG2G[$,K:37CK=?([T<Q)<QS?YU*\:P+U@Z(+;/)2&!_<U@(;.'; 3\
M! 7V/GD&Z_\0:,&:-'\U(AA-[%SQ[13DXH8U5/C;6?I./JF:J5C]<O3.B<&I
MH22KM <K7_QTX1/S KV 9HZ-Z716K<%5S3#-FLL]L$@@9<Q+5^X!-TSX@D.Q
M>'W 080?#Q:0"Q5H3$D,)M>QHO;*(V)KGV5K[D/,CA;N^:*ODODOO*DC>?K?
M=V&/3]-9: JSQ;T/::S *8L9FS1L9U18TV-@)2#TX U([R;UPRU8]$IBC1C5
M.Z +'!_%"K<SH14QXJ!WBS1=F"ZDWFCJ]/0=DKHHM\SR14Z/V[(J&WVK<M+U
MNLBM*B9H)8L&43>9T77VO31#Z1>528CJ'<D;OIN2#DYU7S5GK(<?B) F1/I^
M,#FC*6Y":O"1*#T&)PG]AA78I!IBG'\'X^98OV_X894F0:-L+@+UXM?@OY>H
M&O>$V0A57Y?C8'>!K%!4Z*F1A:N!#=##(6YO0+)@K@['(J'A)$$<W3AL=IG/
MZN\\.,=I0U*2_&\<(_JQ>6H$!<724'C<JDVW1:.[_IJ<DF]1<4/IO?T23R&>
M3<ZJV L'0W$_POH@31SXAEZ0A-:=[>-4&,'7VHIO(W,>W>GVZ'T2\S V*N3=
M%[M1P/VI;TVLY961^$?RG;]-W40@VQ_3_WH-.$.G4!-"+P0YELHS8EBU=M$,
M@9_O=&W#9>KMMU2V<@JU?5O!A6 \6-V7TW<C?B$\=.K'O.[%SZ,%.W0:YHK"
M;<]@LV!/3<;3JHAJA"@J#SAV'Q9-R9)!:A<-2:QAM5I*^JZ=AUI>0 [A\)*8
MGO7==(-OY>1[IX]Q0>_JFCK7A(B:AA>43MN=%F/&A/47[R-YJ0[?M(]KR*9T
M^M3D)I#)^F@E0+/)%HHP"-M+7J= 979AS" _5N"IL3&L&1'%CO >[ !4GC@S
M^XQZ8 L/=T.Q+_YQ^IW@DM"A9@.O;G)53ZM;$6X&U:@G61)0>25]'B697IL%
M*/.88S-C)'21-.S5:,?F.L[]V,G54  1=QKLHR:2U\V5WFP'E]C!P="9C].G
M(K8/SPNYB1-1;<-?+CANO*RUU&EZ[ ?=_\$P0_]W3XGVJQ'=-FJ$X'=\HT9K
M\E5KQN7G 'UE]2:H2:4#*I?Z-+XO!+D"OD7$GPQ/#H3;EN-KS\3JX49\QO_Q
M^%4H^!H,9#M_7ON3&O%,!UHM+#4^G/NP: OKL?'F_0>)?^C9NBJVA&G^X@D>
M/(K*(C=1>G%4?@-?87JGFZ^]B,NM<(&OUX;,3EH-D;9,VSA1>TC.T 5I[I9W
MKF4?S=TR@@L"8TM>QSOS^A,NV>5()JXA_Y3"CO;SKE6:.=O4B.::^1I(K%K-
MD?L"/X(7U AV'-HH+HAH$0$EAE)SFTK E;7"SVVMW//#]X?O0U06WG);_:7+
M"SB3Z&^A?LEG$]:X0N?3T O5RE+5MEBF)3,*>PV_P?6C8Z(W0330C<^BF;@6
MFAD?&O8;!9(%\?H<C^SB7'?IL5U.BR%U1A>4HF<_8-^4J@Z1H^BP2S^;X:A\
MT(3DZ:O6D.4_PWTRSBNP65G\@"#H#U&$)Z'R5I;\@EZH0[$K7*#)FO1GX\0C
MD_ & H"^/U,\QBOLN!-2]>E&PE\#2EK,<OK-.V<CJV*N7N5=O5<=,A&S?)5V
M0>?JV%4WMY^KFJO*JYIVW@Z;" OKVVBXSWC7E0.YECN?7D,X#OX'DUA[O-/R
M-3WZ?QUZW_#R_<0E5JBJ%0H0)"O, E2K=T/.LCIH6YE(NKZFF\I#RA*5Q6J$
M\&=BG*BF)QT7,6(/1]7,1.P%T]]#_!YRKH=[]M\:G!&]V9E.]AU_/#-3-_%Q
M7]SC[HT11@]5 YJ$T.>9<E=R]UZ5&[%&@.VCYE2L_'?&RWR- ;7X2?F[PMM+
M<Z!&1/.OT1K0'*H^+&>AUBH<TF.4C\C/X&^GX>B*S4-?O/P?A,R&5C0*W]@>
MM?3PN@5?3<Q<[GMX#7N'>3,4+=D@#X*#5/KMD,>P+ "6@$L'8#5";J[Z V.D
MK/"R%P^L'(B$]$25-J84,3MU"+GJ -<BU2]W,W/L81QS)?YVW4SIJ0<//L1>
M!5\_L8M<3),-P5@H52S;#%M#P0)DYN=19@SM?=N T*]OX 8?^; Y+CR@UT*%
M  %++!N7(7O7;5$6=P5R$+Y](.(C?*/69SL_CG4[]=5E-_T>:L[55$O1KCBB
MO*4),QTI\]4 Q^58DBU(*,!L4KUCFF %SS1NO$9"EY]HR7WP$8\GHH[!F>+"
M $Z%+95MV#/\N@I.$ QD?@;IK-K:U]5%P[AF\/<+=J>M$3("KTSV@[*ZPU^>
MRE.LA-,???27KU1]P!IC-JB&\4W2W/A-]^8[M#0N=?RIYU[5)@##F/@4-M$G
M#^)-,U<O9-/BYSX@5\$9GK\=_UA9A)O.RT.H\.18_GH5SZ-&<D6.5VP>4UC)
MB43/G@KGQD$7ZGALGVP]; $RAH7</@-SC0=W-T\NE?:1>0F<23/H\'3J&$VT
M8VJH8U\\_;7P;[ O>U.>M<,QXP@_.\!/82R578:5((M#!GTDGB*][H$<&Q/R
M->:+$@D5[!,MCM&%_?) SZX(%UKO+Z$Q'FZ=:3M33ATGW@CSGJ+8G-)_%J/A
MMP?$RB#\Z!M3+5BBD4@!X.+GNU"M:G48M'2T=#W&&C!0MC=Y$G)*@IV.#QQL
M@@? ;_\RFY>C*."?=9N;G@\JPD3>6]&N#JUYP[A69E',WT=/< D@34C-OX05
MU#-;_#CIN*[4.GJFPE^^5?4F @GVL1W>F%R\78>?5FV!)-(<P+DR[JNOZLZV
MWY<LTS5B@^5>8EK$&W#Q_>L2]@>5L\(*3I#O ]!02?= /F9C"X1G:6 SQCAZ
M<LO@9;M2;==V?VM.YVC5QT9.TMDG,=SG8;&6\<IG+SZ$X,/"/O0(Q68?B&0_
MC6LUS[_OD_8D]EATZ9'R2M_'<^Y11\?0XN%+PL: CZ>416Z=(_7%1MZ+$UM<
MW_3W.^\LV80@Z9&[OV>>9_(N?Y-9O_-"UBBBX&ZY"?R(Q6SB2L[29T./W ._
M=2]GUXF8!AI-HI?KBM0/3*XF2G_L#,0>2EL=='*PWN4/0=A$&N=V_L%@3*'\
MG 9;7;$QU)OD%VC)!1"%5](5"?) (E5$8SEX8BDV!G"5$$LAZ8$<>F&'@RC>
M@;.<&)S*S$S,UV^,%V4-H7J6>E1!%PB$)^EU?Z;L&I5G^2+(NPW<J6H$ 55(
M!G^DZ@"[E==47J0_EJGSKM =%G8]QEWAK\G<0U06"0F'"YG:L&<06/$$#!;Z
MY9R-U&/_@[&-X',(,:CLM0PKPEJ>0=R)Q(LW[>2M@IN/U A]$Y7^27DTD<:Z
M&AQ$C!10YJF@MB"Y -B?X3[XA;25V,ZQY'.^![SC$_3WO'XR'6%:-!08P3N#
M.[^<]>S24[LMS'.U?S , 21,!O>S>LTK5@Y_>=2NZ<D!8T4 U-M9&UX>P+;9
M"='ROJA&G\8NOWT,]3GV^UF&S2PGO3S1,IS8'Q!F=>A1MN$JO?K!__0>GRDB
M.$_AKZ2I+!6G80KH+J(4+/1/\"U(;QF.$*J083$9%FL2&C:3JD;D=6Q^2K0Z
M_9+17+!^<?M%4/8BG;#1Y-;SOV8\RJ=UTTZ::GVE]4K'\9JNJT%SR.; I7?S
MTB;-[_"K.^S!!)'!9*LH@(Z<L>V.,("2<X"S0OO&D3IIXFO%7GKTI!,4KWI2
M]>^.QK/F@,  N5N89TZ]XZ94D*ZCJ0D7['E<)FV-5["@K):?J]%!4[E>*2!3
M1,CW2H)H8CJ59 ?W2$_!>T5*YU[\VF?U0#)DP;;D2"A9'6CZC*PF\%V\?=-P
MJ6=^3J7_Q8ZB8)BETB= 6!;#E2+ SEO3 33\#Y30Q40E(4V!_<K*1.QX>W<I
M]R;)-IJY H.*7FH)1=^MB=[3G5Y%-0'"1Q6;';.;+D3_9&,P(OG4_.KF)W8B
M1HLTY,9LQ<Y'R=<K+.#K\?4Q?+.D 9ZM+^PL]U>X0,4E5^[#2T<ZE+>D!"!)
M+(5_!!ROOGX<T^(AF;I.L@Z/?<<_>)9V!,ZJFOA0;/FP;Y/>C!I!Q9ZGC;>+
MD9G8:#/(#ED+>\J>=H)ZA:2=L\N$O(Y.YW"LP0)V=0S#:'2A,&)\DGMDN"Z1
MJC-M'.#];"#^:O'7#UYE40GXS? CU2JQ&J&S"'.@R'#X70O-\$MS'#]?8\@^
M)0C1NJ1W-M@6V/^A(GYXT=ND%P2.-< GJ^";!*T9E2>T$0R)Y;U]X9;W;<Z<
MU\F!#]PY>G,>P*9<@/R$U"YF(0WT&U@%=\=WI&O0G_>P7\#LQAJ>>3L4VZ8W
M;R\_^&&.O*'YX[D_M;=V]M![!C)YR;W(S+:M']"F;KREK,1?F^]>#7,84S[!
MQDL+: WQ:@2'?IW?&)SE0E@UUR:5:%I^_%N/C3M(Z)(/%&"V@ ,97E9R2\ &
MSDT@IX 3 5P7"_BV^,W!K62#:6[J37IU6$R;J;EDET5<I<_&+G/%/DW@9'@"
M,E&MT19*"TD.X%(W30O8#%(D26?E)T+@@2Z4E<KSS\E=9:Q2!6/;NX4XW+CS
M*118I;""<&PZH2:&::)R/#WG/D3,GO1./OWBG:39\42.&&Q5&,V)KW9JN,$
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MP+D.. O_T9+Z@6;*L"8V'E?>:\*/HWI(VH.1=S@THR1J 4H73=H>.W;J>'A
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MCXU**NHF]WV]UX1)HXLD?+_1%/,+0Z(JI$0'!!L K?DY@&\)68.1=XGV0.1
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MPQ6TQ#JU(D+:DA5 BT29IYD84X*DT4.O?=?,)M- :W[;7X$IAD5$L43$"KQ
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M88R,!^AC4"U-<"'3(8KIBE$6J''$, 3TD1R#41"I$$QF!W%AVU0Q"E#Q)?!
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MC...<0]-/B(<L+J>L?LRRKY%U_.Q99ZY4]*YFT[VNZTVJH@\)-'O7+_4-*8
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M]O%,/M;3K&/X\F4EI*QVIXZYT3C+J*!C?MG.++0M8:>=&>Q_.)R^=@MVNMJ
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M-U!O#WJ7SR*>5*I^Z0;1+@.4J#K3/!><PTP?4[/^<66.R=4&KPSI#:<8C[$
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MFWAD05FN2#Z6/.T(8D6R\V+8#X]3:FZ*'\E-=DBAS)B.9$V'4<4PW3_OG+_
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M73O+\GM7JK.5IO'QVM:\ZYH>D\=I$8'^VW[72)L4PQR#IV12$H!4+\>4(-P
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M>D];F9_J-3_UR6H@R;_J8ZN8<]/;$ZRG#'"L@A1S9)#C"$@_YJC08:)EE/@
M%8#:_)*%,!T1+O%^4#^O%EKK]F4"9MB3X:8WYIG5VV^JG?3>\R[\L_\Y$NU-
MSE.@@TNSW'[).>9)#^^+/[N@=\Z%.ZQK[1L:]J.(\3&5B]499/VI7HSP8E_-
MLW7]8U]GSY<$N<H[F"K,O0($:6L?KKW&E.R7X:1"]K<_621KW-L:J#-,$^;<
M>6KJ73KFY"?=%"K8YC&!\%5/%,TPF1"[*-)[$9.*V5<;><Y]07>HIA>+8 Y,
M-^O^-;G< CKV8X@#"Y'D9(X;TQT*#R]]2W+4_/GMB4>43UE3SLT<W12,"<N6
MY/2"Y2W_S N/6M!><\6=*=0TN.@<_';612"],IK4<2,.GI0"U,6>ZI54L?ZH
MFI'B>T*N>V;M*[5 \-[]D;,<7;4O7077AJNS2K/6 \TZ[&$N8[]&0J!^D7*+
MQ(,&,'HXE&77LOF88SN]0^@):!UOZ./U CZRLU16<)7:9>&DIC#YD?4"PH:]
MN)/>ET(/ _LAEVMS8CYC[_]^Y_=B'T,5((=8TA\PT@9>$8Q4E<L#'",@1^,B
M*<Z-SR7-TL@EEP[M^.)?,T%JL<\89ZZI('R^!Y9W.=UM%%!>S$>>:3NR30A.
M3I=%C*LDH2]/1VB1"J7<SB[:4>]QI('4VA7U"J>TN@V7"QS]G@J+HI;Q]E#-
M\BA:+['QQB45:.%==ZE =\5S?>ZP3.]GGZ6<Y^T+[@4(R-C*.(?,TU7<HPJ.
MR*;IR<5W>GK$DSM2)+VLV>99OIUV]S=/C]5*H>YIF(^<O%$0%IC[=N.->5ZX
MRF?&C+2<]E>;QL3ER*&-Z*&E@+;3OO9Z4@\'QZ8X*L/+M<MYASE5SY0!R]('
MG6=C=U]%?:D4>K'G"5R)(]&O[K^.36RR@;U><%"0!'J;IK6$+*H7FEKJ?2 B
M^'Z#$U7&+^<Q]S)@;\<BVA;,2NU^ESDN>SZ\TY@@\A+J T^""$1WMLFSLA&5
MEC4HFUFZ1F=/S)9\ZE19I9]_X(R<&NJ>]K+L^5R[=R.%W_)M2R.R0T[^S%XN
M:S0;F &#T2*L/KH%38*U<C4"VID704F+5$&$_4A]5(D*V!@U:TI:(;G+O\$/
MKD]>6VG\:^Y!!6%0ZU@R:?S]N-]2%VU;-*)<B >JNQ]IC6W;1_Z4MN>,(QIB
M'562:)[JH^J8HNQ[P;/2+MHZ2^U&1TNRI/#-\]9!L3>[@]'*Z!GU">F3>*5)
MJ=(\WXHKF9;:X[YS/QO" B+?<_L>-O8P8?0J'7SS769KHA))P4SY>L;#5;-O
MA:6KCW!W_@Y@JUICL]QKN2086[(:\R)["<^AD+&KUMX\T(9^#V9=OWG+2GQ[
M=*>7MWYA?GTUYX'N-/! 6 2&O0;^*VO(F 9T=IS&Y>P(5/)(DEJG_L%_>X^3
MNXG_<L/ A@7L]T83#T0\PP,!.K>30&M]">XZ_9%'YJC.715%"V'OAO&M>B2J
M;&C\DO9B@<FBS8A@\=BA$(')L[WG+T4YY/FNW+XV\,!L'JZWB $WG"*$3KL4
M,>L95P0LP(?W!&R%/C;XS1U E)[TN<):+E83R7*&ZSJFR:/KCGV5'L+XK/R6
M-N#;4>PN'> M-7M<B@X/)#JWT09E9E=OWLMPGD"\<3?7"/A6]P9K%]6N_45'
MWOP\&#8T2_3YZFP4'K2WOJ#-N>FYPDK_><2I#[?OWR??;!\FCU::ZMAD^8TF
MI9[W>&UK?:-TT-SUIZ;52IZO2J1=Y"*==O#;[S1;"S!<M>:9)X)^/D_'2]!$
MUR#KU/=W+[1O5WKX73D3O9&F^2 YL\ N:RAXD#U+IY![1!@W1Q.JE]#R#*1P
M#_VY]MP.:]"5WS"7SG3K5OIN+*)JE 9"E@.]0AI\*IY=\SA4#8"<NE6W*O[E
MV1[]#*^/EZ5T$GB@_M .Z%;</'Y= ]T8'DN:7E-M.-TPJ2H@\KA*-N#!JQEU
M$W@LV<YUC9"W@;\[$U'B,SF^L@8YU_W&"2;*>',A1#J^PX@O<S16Q;[,FW_F
M[3VBO)MJ=IE^FF:;<E545NF,L./D^/=_D^LDOX'5_U?)U*&^\8Z7XU$3KUNU
M1V.3SNS=?_!/N^SS1T^K!D8=P'7#$C:Q4CK@Z$)#P@A$#Y6Q=7X9;5OQU1'3
M0609(WQ#D66(T:WKYJL3J%/(E^<N>Q]YVR!M=OQ3WW?]VJ^1KT>_KZ1COB6@
MK_) M86&/-!PGS..A/8O/'[!Z\ -RH]W)RV.,YKMXESR?SQW56L)/ML)6[1;
M7;HK=?A=NU5Q3."9FL.JV9X2V<Y)\!:4PAQ%S[;RR:<S0:ZP]BRZ[=F/9]'C
M-0>&.^]FO'J3'71=^&RYT'"VJDVENM(K\])*ZZSOIVQ*Z4ON"L,095^(!O/,
M"$1C,5)M$(^4]-W2K2CRX_*Q/"K&W<9HSNY2QS=)4V*#> O?HKR3Y8G3A)LG
M!!\H*KZ(:(=+JG!2L#NANX3I)_[*O8'#(^8XIZL2*Y_T>B10[CI^AYTM6?K^
M_,?S-(3]"^]<NM=)6]QS1EW(_. #PLAA.[NL[Q>Z#MKF8[08YL6+W[(K;[TE
M2"Q,!ZJ^_K3Z J=2=G.H:^1&@2O$-KK=8^%FBM?'Y0KSFZX21W_0#YB<0(^P
M;\XK\"&CL:(&'L Y6#.@]9@@PF13G&D)A,-M8"8MT3_DO2,'&MP3LHUE6*K9
M-KJ97KLVM6CU7L%.-^-1YA2_?\:UOD'\ZNRR&QT6M[G#X6BCF;YD6:UXSN7I
M]+A"$: B8=WMG!,SI"DE "XK\5%BW"NVY_L+6TLYS3'ML5(7-R=7ITF+O8*K
MN/G9']ZSIA\F:.(<-1:6K;"HH,=6*A3;+J?G#=$?<,X/1TJS7LSEFGXXQZ)9
M#:&-@^A]<>[@-D ZIA:MX7^L%:B(QBUIUVAZ^(QN#/HZ^(9![:$^2!$:"C<-
MW5'U\VV0=+K7!IXYU)47TD1^CMM?@)SVU32 1F*969,+^Q&8-TX^KRW7E^?>
M/:GQ]\@+SE-)N49\!GV;N[0VXP9F@-N)"95LM1U-C9G>UK-D8^((ERM8+O3>
M9 9N/PI!#K/IDVS+]W[9@]&*UT3NF,VFD> >,2[JV.><XPL_QD^O;*XL%U6C
M;"VWGT/.?4'12$11 TLZ4AQM "!CUPN@=&Q4R%^/,';1"#)J'?KQ;I"C4>+J
M3%L(/:W.#6DEV))/%(CIA9A< '%.;&<1O9"[YC%XOB4>:(8'BAE'/L9:YI/!
M0MR3KASK?FWLN.;OX$D72Y:9WI,V-991>TM:*[.K^P-<%+T/H-DDF[)BBUAK
M]D!-')8N]QQ9/E@=4E5PQ? *?![(=G.2-U+;75V]1TU-4/+6@P-'_[B\5_0^
M8G5TPYX5#6!(+5I+OYF]R$.L"8J[\%LF-IIS:B/58<.5&JF V&B3'S+0\)8J
MJ$1-.+P'\&VQ].0JM</WEO&HI6#$QY)AR>6B(;?N%FY9/]]W2F*D /HVL[<9
M4&&8)#)7%SL52<1&TUBNO@]$> #O?W#"'2"26K4^>'=LD17$+=AL^>/00Q2-
MF;XR7V=N19&S._Y%OR7&YVZ<\T\>Z"YV3,:#%>A=BT8/K!P'5I(ANFBK[6*=
M/I 3*V^>H_$201-#>_! _'>?TV&'OLS5C_LH[/!(C.E2GO&PBDT#L;X.V.MP
M]HO%_3>=CZ!S7A*[?O/ON'Q%ID+\-"R:)L:!B73NX!D$W KTQ;8IXJD[XCL9
MTV Y&_?S&<KO$>8M6H?>M\MO=4[6X$39%_60JO ($'E1).NV^),M"R;I"CZ3
MCB7EL.^^><D2:/^PJXJ6HLH*M;S9>^*&BX]<OH_ZV.VSENBG.RV>?$-LW2[@
MW+FWCDQWOO.0NY>5K?$)+='07WOOYQ#WT,47QL#>1:TC3UE!1Z.H0AN/TU'M
M9@=$QJ$"T&_/.!<6>:#CX!C]=1[H*0:VN+)X28X'8J;_E5?L9ST/%)UJQ .E
M#_! ![9Q'.XBE'5^&,K:#ABX=!C^?]]."F: K0TFGBC$0<ZDZO>Y 3L8&8O6
M>[WX,$_=F?JZYM571V?"P(?EO1E6;P)N; H)(D\WF5TW=SV)>VJ@PK9V<[2L
M;9^15R-#Q8);(5!!U\LS6E%E*PTN D1IN&'.<WI/@+Q#UQ/%8>6'>*Q%8>_J
MPW=#WFD_N%-?"+:NW*2S556*KUOTLX-OR3@YBG[Z=%FPFG^OZ.6]46?@>R*I
M[K+IEX8,Y"M<YL:;XKE"AML]*PG%K%M-^@I-6N1'(1%R7%';AX7R4J,9OAE?
MVUY^HNDT4V<&!G^5Y37#!SF0>*$?^!G2HRXS07>MLUWAYDZ9G5:I82@_[<K1
M0G%^JR/9WFDO[G]).BQH*/O+(ZWSKFB<1N_A>P;P[.<6XE>^C-]\S58W//7Z
MF;F=I\W-"KW#':%A95:<P<:!9,3#!\[(Y$@]!%A:?5P.EM*BOHD1;6"+L!P*
MCPYI+7,4O9F%B 1_'-[2R.VM]!0XV:&I[MRBQ:L)5-RBH_1"7MB7'F]V^;;
M3F!$CG(Q(5C.$3\P)[)9*YI"H="Q,5"ZSX%<BM%UKU%TO<S3I,FOM7F;4V:G
MA9PMCSJ:U6@TZW97X1<F,@^DM:H2-$_WW/_"B5!7D%/_=%_T8XF+VL:8L;&+
M0)JC7V\68H"L:N<%/S"B9R!OOM"F&KSP*00(^?VR\M>M5[U9*A=&R?9;G;"
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M[=I&HZBH-*5*,RH*TA4IBD!4!$0$!*27J$@)$2,"$C D*KTK""@*$9 F);2
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MKN.V97\M:EMTT.@Y<5O*;FPET"X@#_W'"2R9Q<?!94@[T6EMSRP*YKVM=RW
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MU??N0=S0XFR99)51Z"[,M\_2N^Y ,W5P?^794CR(A]'VO0/N6J0Z3C[YNQL
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M&"NCA.Z^9W[J2LC?[<QN)N?DGOKE0^260L\V69BC_+,T(7W[2%5U#A4%_?4
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M/?.:7Z@.G83!+ED)G\*Z#O]39CO1@H&"3";<<]MJ@U<X<LL,][EQ!K:E,GV
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MRW\;DMB@A4I\<NS>+M0E8\C2FQ*5"T=$]S(>PW*RH6U<98!+IN.%T2CJZ44
M-+XQQ#T.VC'\$.-/1MDA3'$P^M>B9G1#0>UXT$.IAAZ"4<V#G*/5U4T9Z":C
M*N<N_ULG'M_94IH=C<78!###NER;@:B?>(83V:LK_/J\HY2D;5SP$+.@>Q!Q
M.D&UZ^,G/6KY"Z.Q*Y<B]SE?W-2C>.P;->OH%0<?XA+(DH0@36$TLG7Z9.6
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M^Z6BH]PU_O'+8,HP_8'*J<X'DW^]0>61\JP^BL%[+6LI<S63*Q[8+3SQ:F*
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M943_!ST] WT@K,U1<61<P#/ J(#NG1.XR_Q@EC>7]K<@\]Y?V<8JPZ5M 9J
M%]/)EF+L3F$%%\:K<67W;B1=DG?XZ4O0&6;N20GA:RFJ]?M?>'OOJ*:V:&\T
MBHJ($)!>HW2I*E5:;(B & 'I)2HB38@H2)"0'$5Z4Q%06D0$I$8D@%(22@(J
M2*]!2H* -$E 8$M"\G+N=[\QWCGW?N.^,=X;;XSL/V:RU]HK:\WR^R5SK>G4
M9Q'<*_>V(DMAPY[_3M>AXP]WRCI^PEU=IRKL6W2T@GX]T=4>+Y 0>OOFN'/>
MAP[(K:3TN'T/<%WW,3@.Z/8/K.NU87!9U[C1O8W3E$/R_2JK.N\L>8+=+3II
MN]NUT&RC<F;@KM=,[^K^L]<YH!H5^J_TXJ4&8H-+N*=%HPU3\+2.JL+5$+86
M ^-:;_8_VZ+81DE+OMUL 0TG"IPGR<L/HO1Q_LZ4NCS]HN;MK;38QQT]U_ .
M>FX<4';=MA_._UY_M,)$KX9"#:BDPYQG<4II (<Z2U-CR^C$_NYZZ= >^!H9
M:4\?'2\>"M58?OEKTR:&/5#]Y.6ZIJ:24,XKS5F!>S,O:6E+*9$> RS]PB7I
MK=K0NH=>6<&CSEF'TU0^#\7L44SQLO+)O'BI(%'?7SEC0,^^>P]C^A%;JW[X
MSN:WO<N7A_6T@B=<1L+ZBP/ZS]7TO@G8J6WWWWD!"]*D/WD1FQCH>LMFXO0+
M<MB^RV>@>;[(RXDE\::*"61:A&Y !#J CC<K\QJX]MS%W.?+<;O[L:J&H=1#
M'\/2MO2][8W>S5SSBYJW2^BYT?(==EX@;J%+-;6KN1EQ>Y?L6)(\AY^5_GJD
M?<YKP*$H'@D)NG)M2FS6QWA:$'C>[CATAZT%,X_Q+_8;A4HW^;];?DBN7<(E
MAW:9J9*H:U5!QSZD7M*N4L"G>IHK!I5KM0Q6:0],*J??- \U_IT]_:0V$G?@
M"R*"SF[OR.>Q51AU:6J.)MDBBI%=;3LQ).-[ 7]9ET:8U51E!979BJXGB&'N
M'718W,G/,"@/9 BURV7T#Z -6=8C/P9KM3JO#'L/-IV/.#ZX]H!LH/BLSE8&
MKZON<9[_)?OJ8MLTX QKH/\@F#3UZT49.HZRO.DU3C7X03?72ORW?#-Z5/97
M('6 /^_<K0VE_-D5YHNOB[+=4B^YS.YVQ&WS3$,Y^'Z$C_/QWB7:G)T-V,W%
M&&%<:F?72:77M%ONMY%(3=;P068[GGP5JU('$3'UD378:\C&=>D>%J6/64MR
M(WG/>J*+XX'R@53M(H\W>:>=6IU)'4W5&2<^GK;.](XK/ZS"*V C')<J6(2Z
M\VS'27_W[E\8ZL'1"-#&.Z2+_,4(7OAG\]?K8-X#6/E/E:;/"I&Z[@F>_6[.
M0Z:G[)5O[GE&>KC\V6Z/9IM>>,LQNYQ#:*5ZAB4)LQ^@\U7HK[J3V+(VD^&T
M:P]3F\/$4V@0P6F;"G*))97??\I6<M+++%?"[7KJJ'7]>QLK3=POK?D,<BCT
M()'J#^2XT0V3M(\RT'GAI0&&QFLIM7*W?]VFUY5332:TKE)<%IT"(R,*-;<-
M)8R5M@P:/(0\_$M]0K:2*AN?+^\T:C,BP:]N&UTNCCN\@#A9^0K&F]C./'S>
M15;?]*+GD]+X<M>9V7,N%0:*)TIMY!XY>LLJ?6@:[I4RHO[L$F'UI] )=;P\
MB=W+(8)7WXO>%66X/&138AC(Q(^H!^H9DG:IZHZ%L:2KK>>JP%)?CM\L?#F7
M*NG2L.D$^:6N]H9X$ZKQ[QUC?U]0*'&F)/]('PO.E$.=JQ\AZ'RA*]CRN-$A
MR2@3AG5[RWT6C &.1=V@PJ3\**,QX&@V9 (^9D/KE5QRFZS,3Z<V2T9]0NB;
MC'D'G0(@2JP(YB$V%\I($U10-P$+ZEH2I,ZV/ND.01DI0HN+-SU)#^R$5(N7
M,D\CMSL<6+K#D#8OK;HTLG$6R?:>G$F'^=Z19_II8LBC?M\J!.0O-F6.])"5
M\W5N<D"/2]E#T ^J;8BX?%' CGF&/<!%7C7;)(08D-8.%4$+ ZFCK=)KI*[>
M@X$<T"&6\UMDG!600B/R^ADX7T>9]-5.!&H@A.'+VV[FR70/*YX .^NW)2_9
M[9#WHQUA#%PKG')^=GOU)!T[Z_R$(#')"@ *F'J+V)KI)SJF)C-1]Y:W2FH;
M/S)4240Q9)KKD+[)FC _]B"WN_ GO\UDV]_X;S4\&X+;#95<>@3:??\F40U4
M%=@AKY+6RI8?0EEH)]#@PBIYTI<HT">A-D1AY.,-5(+\-ZAEM5-#T[/PM=#X
M(]7EIZFVH?BKO)T<4'5]O ,9+05,X#H+@>BSMC9;V<"74XOFQ_M_X>4>=@O
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M[\3 G(\%$:]=#W_9W/0)I$QE4?/ K@R53^%BL4G470V[D<W(Q=2Q._AF]8%
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MO.?1$OYHH6;&Y/1?!(V2&%.),%J.3DKV*$MA<1=+-UAH]3+,:I%7JV=\FYY
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M9+0B<)\*3C$@"JOV5^K+3'351E]H9FA'^[SK;CNX%B8U/^1MA::,ZJ(34;+
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MM;ALK\9BU/D&/$-@>E6Q$'68B*<?-I=-;VDP^Y7V!D"TA%.F8YH<('$LA]+
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M!]?5VDYS0"*66RN8WX='H72'< Z(-#(G^O]/'Q!M]* Q/EQ^3Q]-W+A"F:
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M*(3$7733$@[(45)D \ME,#_*.S!C];$<T.:K+QR0)X8'S'P W3D0B 6.-W)
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M#8?T;;40!:DN3Z?]1C<6LY/WW+XT;;!=-WC./7ATXI/4B\>8,X4T2WF'K]6
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M?G.X-*R-:T+05L&M T"F3,Y!4RBUTL8#"&%@:*&VE;WW]1!'QH%(ZH%"Y95
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MW0'MZ8[,DUZ3R+AV KANI(IE6$8!+B*DD#67!C>G!0$;]I%2_'#_,<:!RJ*
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MB:1<5]W!HAD6MZ[6[%(YSGK:#Y4%C"@+]Y>*5U"CPVA@'4J*>&4:FQ9'D8O
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MZ#X6+@)A#)5\"Q/*>'(.<"4;(-.31C^EOW=\ 'EVU5"X-$8P26U#LUIT'O0
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M,.$4NXDQ$R0C^L)<$F#6N!2MH8-!M>)K1.M-S)[[X$[Y\EFQB3*F*VY D'\
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M]RVC+FC6IFG:NT+/]\MT#K?[UZG-E2;C+W_5RMN.C7SJ*<IX9=+=$]SL6((
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M2A,D0, $G'X[YIF'SR.+Y\S(^>P(S"/J6'?D.0!S'W9]^9[P19>0@8& ]7_
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MEWL^]M FWX\?.Q4V4#1%Z<3]PLM@WKR LZA-N/EN8 671-2!XD$BW;T!^'3
MU,82OFDNC]-#SS^\SHW""_<XXCWXX,+>FL":\0_$K.Z\0]VTW5(35]?#6\^-
M07-,([= M>Y0(9=\3\NOQSB>+-=J@&'3X/AK_.X_/?F9L7I@1B)'48O)F6LC
M:@YV7#[Y2F@Z4CQLENPU$!$=[+*/.H+^!SZV'Z!H0U:=3;0>TCU=$T;PB58M
MX'8BF-+?V7#JQZX@-Z'S"SR296L;<DZ0%8;,N2-W[(3N>;_N%8J5*$MHSZ6E
MT:I9'9E;"&@PN*^_$Z%-0#W!UW83MV+GY<F\MPLK!O+OL/17,U8!IV23'$K_
MEIOF]F[;\\^2P<_?Y"ER1JLYX3@P$A?$SF0:<+YA%4B!QLR@;J0.9,9=5)D(
MT-T#?LX"5-BR\1$Q)HN7 5;2XG)OJ&\YP1W,R)[<R?@^9'C@0'BEEMP\;U?$
M6[\TF3^G4OY:\+4A*A>7@:CIZ< FHY3U&13KB-<SEJ5YR2M&.Z7<=79X!0/'
M)[H"RTWO<A*FU2[,!I3VW.&_[]MVV''_B1.!3V-<PRR9XU>N-*%W>M@:\K8=
M>GP](L$\*WMOWG2VRR:7(Z-YM[;>\I>9AL=A-Q-\V5@F@D\'/[\KJZ3$M^[#
M]TQ-ET]YM$=NY96/X5VG\NZW[**<Y;\\FWMJ',LXP%O[2>;<CM^,[[YF*V9$
M5S$=JRTV%!X#4??,C)-T+89:KEX5V!$_-T7RX*+$2%Q93RG! EP_FFYFLPFK
MB#^#OKSK;1P=^]7/H=[39,GC\:YATSG1R;+#@2K=Y)-$)I-/E2)2!5>.:,8B
M;()"V:Y#*^0DKSU T<.FGB[XEE[= CW*O19%@/D1'U*YL$)3AEH7.O09.VO?
M#D?\J:\%^$]2=2ON3,F\$CU&(O ][)6&GB,M6)]Z%/"(.$C6;"&QJ1Z-"UW]
M\=9N'!?:E\7,W-/UT<V.-685G--X5QB S(_IVF8\N7\\=/3V9I2[T+%:5"J5
M8T&(3)2,(7%GD.Y>0%3ZA%3K>A^Y[ZL;/OIT)ELWE6.<1E0 3TI@J<N(%*T4
M"WY1%FCG!,K@9<1;"E'G4H*-SZ5>803G^I^K), ')+#ZAC3D03R6XTJ/\3XS
M2+3J$ECA9=BCG<9)*&T"!K#O;-4&^GAI(Y8]]\_E1%:84U2[RSE66'D\[BQ(
MK$3%U?G6%7C4#"W@%($'IQ*8-^$E*!\4#**Q,]L0LGC]GMO>&/! %HE[%'=C
M!#3.UHC :4.I;F\,PC3W<CQTCD_>>D6TS\EJ]36;1RB'%]ICH4ANG[Q]&KHB
M"*D(FN>\..&S)1FWHJ/&'QP\;$"HEM//-S6QV+B9VT9Y8(C<*_1I$C4)]P%\
M@3,@HK1AMH@_B8^"M+@Z*XT?3: YC6,#[T9L,BP!,Y-7]A5G6)U&=G$JWNF?
M^E)YGMJ8(KCPKLAU:'O*^,_,#%(=J6L<PQSM1&H.&"/W0G9L>%N,'S_D#8A-
ML39C4Q0#=3<4_>&Z)N%N4!]9!_E6OH\@:P7<J2]$IK(;_8#>F26A<5,V5N,]
M\_6@_-XVE"WM^N(F?&(;J7:TC28#U4L'J+B=M9&X#>_1Z7*-?6"DW_V+]8Z2
M /><5]^ZST;*!T<&&!J8^I2DW,O[L;.1-6[%_I,J-B!^E,!T6K?A-W1%H#3Q
MO>R%VF=0)":Z<=[E]X7FR_==>)&'E([MOA1AO$,^+O9F4)]8B7 >&J@BCO_/
M<ZX[*$GJ^>MI]'Y9X38161@,--"U=FJG5AX8[RXZ!*VP)X)<P,V4W:$V"U3.
M(2G8GAU2+&PRRLTJ2]5>=]BS)SH,E4BXW@11V*3Q=8'8S5(JNX1=2]"'C$%Y
M?AHT,^5H[T$%9>]'"**6WV$Z)# YHBK>CZX\ WYX:EL)Q9T#$>D1BK<FESP>
M-@!6OP:N1I27W)=9<0R[5]2HN<K-=Q<NB)())!!S>82*4!"BI0:><*81M&@S
M'I-JPCC+G)76/)VJ>QQ<F@O2@-PE3<32[@(%*Z%B4,3SRQ_8T08/K&;J6P/U
M/G'81;03_O]KM;Q/Z@D]H4C S[86M.BD*)]D5VJ?'S&LDY=/8*S$N$3S_"XH
M4XO(?F7^=XAEY5>^G7MSMOUJ;<3)]/Q3)S6K'M!U#P*T=%,=]4ZQZF@X+\P6
MW%RH5OE\UL5B$S"K1>@)O-)!J?GG^5GZ?@<M]+I9_N^2L.)NFKEXN+[U:"-B
M_8)8PU^L"N(RA5:@]UG0*VL*HP)-PF$-J:;OU,\,C78>#-#ZT9WWNGN4Z1O_
M:\BGUMQ$._5TF7;QIBO$?X1H48;8=,Y\U;Y3GJ6!WX%4)5A!%Z)B?%\*]SE>
MQZBPH+\1<%5\RF\[AGUBKJ/KE3<,I)Y%8O -=EQP+J7$]M7X%7I06,1N\"XQ
M$7K /S=LC"-$<^ ;":>I@X2(5\0O^>H\U:F_B\MXJN(N^]%P!)S4<4@JZD>3
MPJ$J[^:A<$67OL6KK8W4W)%5.;V4(%<5]U=U"-B!5AEB'_VT*#^B/R4?FX*T
M"/*2^CIOSCN,VX!Q^#A97>@!/486<VV<^)._+CNP^U#NP\$E3V:T=%JKS.P'
M#55N*+^OK09I8[7\<(@*9'+MZ?U)8J.F+\'61SF(V%;5 6M23%4@LZB"XQG$
M$5=[VRP\*X'"'%IRHP@Z.E5O7P;6!%ZHY"UD5;C;!VG$*IX9[<>=EGI=35M0
MMHNV3;P+G]BUNE+*;S OX& 2+!U[TB,\<(E(#5 JUQ'?\-?[NYL:XJ<\@CQT
MB.\G9O\UIZUG>'K,-&1_.W&M2&/L&#(/-&YGC=5/&WEW31I#EX S"P8O%\T*
MHSN+M@/Z]T+BA_PM9K5>5%0$:EU,^+Z7[CGIB=''F9\[Z54+R0E0Z*!@H\1V
M7!S%UW!+KY\>A9ZY7MNO/ML,K_NMJSCJNGI2\8D!8?RFG+^AV(P:<1M-A^!)
MP9,ZF_:0@=K3P.=J=K\FY-I#5GP!)7,RM2&#CE;E9BIMJ+)%>PJJ4KA] =_3
MK=6WD//RF]".,6(58W6Z2 ([.5S7=WSCC4WB=/R2!,9)G/\MV M5N#: -^YD
M9ICR+#HL+>*_#X<':_T\"T59)$=( 5NK%U-#9?Q36P^:DZ<^4-V,YW</;T57
M:A]Y-K2);O7\KA_Q(ZT61<^$$U2 R2PNY2Y-89FE[!%(- QJ=L2P*;&Y?[>_
M!5VJ(Z\QM@YD@'I/ &O#^4_;_8O7[=QI3+.8_R&P.7S8HHT49_@)?=A""@?K
MU*[;H%6>93LL.'R@%)%\<*FD+1&4%!:U9YX%(CIK";;#$I@O!4$P'C#M3\YC
MAA0\GQ4?_H(\0$  M*Y4LY'P0MV]=;T>$ICBQ!PS,7'0P\<Y^JJ?;X1)LL^-
M55>>9SG$L(-(\*2ZS+0BA(C<JHUW<O3KHFFW'@@<849,5[#)TN$'^*7X >B6
MSG6YY4?&.+,'90Y1I,BM@UUE8QA?WZ#0R)?==V6Z4==98_;LA/@JXB"<BQ@;
M97O&5[T5V.'[/0%"?EX':VT.#2CD):3J%D:7'1GPI-7Z1$?=5ZJ^9._FYNV2
MU1OCK#Z_ FR N<#OL639+D>OJM-1Z[OENDV.^]]5R3")ZB):7B9^P]8AA'LD
ML-J)Q+06;^,$@D,5WH+O/.0'H/'*'T?;Q<@\+CE-B&8O:@>B5 CGO\20V==;
MFS8\]GV%WT5WG@R@['G9Y$A]:&',:31B+3/XTR"YF[)&_(F('"7Y9<I#9=T(
M]04S;")R&U"5-?7.LN<2:*K6:@053"TJ0 W8P1M4AQT,O2: $DO%*4'YQCPY
MM4_(;)K_'I.VNU$_XTC7C1-':%1:#THY$ 43:Y^<TO&6DB#O,-WR"4NQ15V4
M$T7YQ1SM<FNQ#[YVZM\K7NX>L_E6@8K5A/<_JUT#U#:>P**EBI#8SW@3)5XO
MW/:XC:F%34!NRHK]7OB,?&*W0G;H$Y\'V"<H)5H -@.I*LKU&1%OGL1GBE4H
MB:PZ?3HK :MKELG<R3J+U<5OHE^"R@#NL5'3='5;8-G^%&C3DQJ.T3@FW@PJ
M6"C-',+CSGM&35G<8MKB5L6)^\N&;7]2MNOZR_1P1(42F!\D=Y"@ %G)74TX
M1# !+OK>_;[6^833,>NIT;A9;*T]W0$5:"P+Q<+O2F *!>UJM+4M,<6SEBE"
M<P#+]_'2;P59]/&) Y^OA<>P< 5G&52'RB3GFDGMIYHGJBC\8:+K%<)M"(1W
M>V0FR_8P\=#)JX+K,[0:WY[V4':AX;%)I1%KX]* V^*C&-5#XF\%/7*@U<6&
M8?<C$^'^+6IZ@_E?)W?G&:[Y\TQ$)JZM-6AH1]S78]SN02D2--PL%,Q'+ ^X
MWF2_.64O:S:%TB!=)R<TY74:CU7]H=/6M&IZSFBI=[WS<P8?\FF*A*TC?"T%
MEAQR=X#+'\NL&&V4=S#.:;"2NTE;_;?;F:UH!2=[?IWX9JQWR)9O&TN6UI4D
M?1J'/]QM\'N=<=W1;?&?CU(Z$!D(*HKG*4#-HC3J-)%&OR0PI7\ ,AV5@-P)
ML;@V,NWNFZM#!:9">^@Q6-SAI<$@: (-[:OABI&@0:>K!"9+_6^)B"Z!P5>2
M<"N"/G0[4JLUR$&[YY1F&^IJ 3\&VB2(%"I!)P0:E@M0\%0W<^YCT\^35FZ8
M'0D;YX.^T\:-^9Z 10IR&\'ZC92Y9=DC%:_=B(/86A=:A8<T'$6A1LAV(#.Q
M]3#>[C(8(?H2K+=F<#Y<WFJN\)*<;QXF@Z.><;D$3VX1Q1)-(#(WL:T/W2EU
MS=9BTSQI6&I( P)RP-KC%70;M1YJZ-35!.Q3%^L<5<Z#H[&JVPLZO P%AJCK
M+8R%2L.R84.C9=96H]>WQ=OOD3N0"H00:#12<$+H4 >5LR6P]-5-T#A'MAL%
M)_:)%4";Q 13^/VBO5_$ZOYJ!CAO7+E'Y6)2'0_MY:C2B3PT:"8*T:\=#A\O
M6*SMT@IX8WMSS9]H<3]KC8^+ W*C<&?XU01[:8>,N.BF53[_U[YZW:4+@B/B
M_NVQ2!F"QKHMM@CY%OB_MN^W2V!7 =OONMTMJ?Q]4!:8R?&C4Q"S*)TJ:R/]
M3N/-PA H<TK0BUKOT:^>$&YS^&0C WL&X#^V&;"X\V@@&+<^?J0VC+H2_37$
M;",W81)_#5.]5V:*/'Z8?PV*Y)#'HO_[L*5+6 ?A7N$9+D J$Q^-&9!J5;,(
M=,7T4!U_Z77RH/>X17;VFW]^7=SG^T^;UJK[?RIMRB'!+&\JK\.D>[?R/NE[
M]#77WZ7[#]SF'M60P?US"&M#'$6H"DG/A6=$#TE^4FC:TPA%51*'R%N(N_ A
M?S@Q"06E<W<H<:;8>/)&X270[[SCKE,CUPK.O1VR/F-MH79/YT>'Y4RH9Q^^
M^O3LTVC]^5JN!+95B($4I^ :$'.V_SP8_$UW^T"+;?E7MZXR]R M\GV":Q5T
M_*=')J9ASS@F.*#.F.?VVH@T8#C=DLT<DL<7P];^3"+YT>[QV!.WY.'WI+)5
M:Z;.\YS!WFM0P%2-._NU'QK/3?O5+!=P9O\S;8?M2BE+M+%F?A#D^4PH#_F6
MX'NG[.G:<)49L6;LN%OM$%$;.HCUF"CM:C\T$3PP=K;5[7A/F-KG:;UD,RX*
M. ]/(M6I=RBJBO=(I1S5=^K=KK-4("\1J2ZE/6OU$HC1C=V&/ H5=YLWQ9!C
M%VY$G&]0UU+]F5#R[N[E7V$>DV-*49SD!2>;S8>\U 6'Q:,2F+9XIYC9N@?R
MYF9J>E!3"6AH;LKJOR59O_C@4HC$QFTD' 3$<:_P!IU%FZ%JG<)&D)1&=<1>
M;&6T>#[O(D6953:A^87&CL';T=ME9_<3^VEK=FI[0[N !+,/P>7 :'N2Q2&]
M#/63,KNS'68==B\%M?W/@]O&R.RB5!P83W %$.S"!X$DA'C?G)>NN@2VV5K+
M<33>3,=IQ'$SGZ%E1WIZY7B-6=7-XVO-[\)>8\<CNR0PK18S5+L (XVR6SM3
MSFL6L<6,G+):UNZI3\^;W#_8@F)CY!1='=(IA'.<[FX=N_-1Q;',C:5#9A7O
M=S",M-0?O3^*@HL'6%NM P3VQ!YWU[L44^W^,3^.!-;.2B'J(P\-'W 1<&0[
M^Y6AZ ZBW-!RE/[@L_I8Q(9QO%<,VB71*R.J*H0:'.BM<&'<?4R\+#/7(RI$
M^7VX\L&XC1QWRRKF)RE!5RX25V&>X"!T=/C?&=WIU@FL@E!=0Q_F<W\ I@]3
M*+JY/GK]UC4 O+U_+([-SQ,<)WZU'$U"KB4<I0+D9*$O<&>Q3;V!MIFP+5QT
MCHZ&]-@ZNSJ5?]$%>BGC3"AEA#_(N]U-PV6P8[,_\5;@PL.+;>>G;0%[]I9_
M[TI-/ML#?SCJTH=-'@+U4%CV,7T9?1U'@K9 GSB 5;=V!%%LO<Q.BJ9%FJDQ
M,V\J,4UL GF?T-+-+.D!Z!Z ;.J\:;H'/3_X<X'6E5E=G7? GZ3E==08QP5C
M;1<&5;[[44PU!_N%EGI0>/8M%,;IQ<3E%>DRD'N\ I[W=E@VI#S-7K0=H,KW
M5D2[49OG]L;IV-8%:8:LH&TL;?G!QU<'F1_G*U__WK(&G'PL. !M0(VG=D\:
M%TRITTNA@"C!/L(!8))<0:.3974V8;?-T-1;#P;>Z2X(*7.PB@B*D;GTI8JB
M><V3'VF^YCO)2 WUJG]>!&C4O(7T@*2F#9MZV UQZ+TW0C;UG/R8T/9MC6;;
MYYL&8$4WK5Z_BZ: ]W,:",<RU;%@)-T*D<%2;5GSC#A U("\G^,KNL4'&B%?
M( 2C'MBZ#?AS?]D1&62LC$?1R>J5$?UR^+B>5<>'(ZE^SR[_,@D\3*\4U6-'
M27*$$^#M!L%A?YJJ[W\%Z[>QA!J)/3+V0$7[J_$@Y!Z2;&&@#NJXP+0?%R4J
M*U_74)VP[U/P[AG8PS6-L"C93-3US(0\,H*X9L[2M0V7X RYGOHB/DCG-'\E
M:N,-O[I="<PGQ:G09V*:[?L+PLQ>/*T_>>FQ^S[ -71BV8;<1HMUC^'EEEX%
M(MF^&<4O)NQBRK!C0AL@A\J+Y]4F&RT:5CT;5([V>+E[#;LQ]O1T<IM/Q"ZS
MO]52-L:)GEV%'$!$.U$?I;)"&\<<@W0 +B>&=8_F7P"'XRTZ;KI#@S^Q _:9
M=:< @FMNKAC!B'BGWOFS$[G)HWZT,H2@#T\<\=<;-ES9A^P4Q2+W0.-<S#Q:
MH$_PA')>V581CD-Y B1!'Z2EKQ1X[*T;]W3N\MH->&6]FFO@,PF(MS4-34-5
M57L21E#9&R>\MQG!8H)/;CV_1GK)WB6$BUZ(X<3/>>2-=;04W5TQQF[0#!C7
MAI5IU?2_K98=>*<_J2425/&D?C'UY[YI0(9KZ<7W?8OTVCZZ1]Z[^.N^?/:G
M&H]VI%D#[RKPZB?W(DF&0%-KIW@&K5)BE_O5KT A>.*V0 EL2YVQ EQS#K4Y
MG*6N^4D%SW $JBV'5GWJW]@:-3FL+^7U+9D]!7'C@BEQ,VAQ1I1')6W ;\!H
M0)0V4OW/^7@.S]Z)L2PP*,1VL!2%9B"WO6@/%%\54_.CN*C7CF&:KFKF&<Y$
M3SL$_(,*0[9K@OO$6PG.PZU6>!Q[D( $;8K2GXLG+'MXMA5"S-NZ6.,-ML!D
M+YM7QS1J??#*:+R/1,%G=KE40^:+)]#XZ>J&HC].;Z_7QBG?C1$!!ISN=R#.
M >1)8$E"10LZS[Z=K$H( 'BFZ,+K_5>:FAG"0WJ9_!!::)CWMMLC@T$CKE]F
M[1RQ)IZ6^[C4QEQTTH] X1\)+#8=G^<$_.Q"Q .79WZC@SFL.*R64+4B" QT
M*,O<\#6HGQVNNS/[H.+PJKVUTABUM'B7QH)/P"-ZH^NO#97 D8;[A!@V98/0
M#BRCOT/WB&V:H'O1')9"7UEA-'IH\7-VPXC[U2'#A4H53'/#X$YJ]KZG69W.
MGR_1<ZXNJ6>@II[<H722U/ >7:V'1&\DL  ;I\4.2V)IV4QN!6FJ,3@E,/*V
M:YXR1A/HK#Z+_NK1/>"X]5_TQD.]VN5=,.+U0)3N@0,MD0"FRYQ49Q%+5 T2
M6PS@A&H-"$7"A9"XCMOF!HBDZV]!M<)7CLBX\NOB]A:SLH!\X849-:6);WT^
M%T^[M=XMX#^%$L'$4T.$71P4 G\G6+X-J_&TED$*$!A9=+A,Z@;9V'7<Z>LN
M*,;BK_LU !-=HJ[AHK( >))1B+-]Y]JC%T)@D;\(WH+-;K](=;1VUOW;-!VQ
M?D-"ZW9(G8--BF!8)!#A-K]9>,?PN%)1T9Q8E9GT3 +#D'E*ILIRYMT6!Z9[
M!OJDQO?+8/ZDXU%4 #DSU)_Q+: A[%<HJ:,A]63V3_NZX?GPL<WIB'O.IPQP
MN*I VVQ'<V?#![LSQJ>27LI^;Z#WIR)WCDY#J=P)-+\*V)S.244IFI76/Q$K
M0J2&BW%VPRNI05:D_3^=+BJ?" [>412T)\JOP"D6_Y!9?$2@PM:M?1E4M+UF
MR$SQN"+1@Y4HWCM4"IXL?%>9GOLVIIS@)'!Y'APN, FNW%!P>RF@1CXR.J"T
M/HHW\3S+@727-O6D2:U!<(9 !$I'>2I@\SQQK50.Y T6WFC=JGD=HQJ U*,-
M77O' D#>CW3]05[KYVKWMMZMV9T+L^JHBP$TP+$@6/]"X]!K5""%B1P)J%R1
M/Y&AZ-PVX.'!G,WOQ<>N3DXRQ%M&:NM3/-V8/W;6-M2GZ(UOTL]-@6TP)TM@
M"#YJY>__<X(N#H(YU(/FK@$2V'W<U*-NV_=2B1,QNFNTRC*C:&4>NQ[E@]H*
MS>)2!F?)5#)/11M2YT9F6,L6:WNPUAP_E<DFSR<RF#^1"@\QX5I+SJ;?[:>O
MDFXW_FP%:$(59$^'7*1NNL"%. CHS;L;43M:FZ=Z8_F3.HQ36<5=K8OM?TSV
M41D]_[KIJ)TR,CBED[Q=UQX,$CL8_V\[<9==VXC&X+M,.D;640+;-,+Q"#)2
M.5:+C@?/I28+;8*G>CV6P2-)3[.4@UZ.GA/W7.4OYP@Y9^W(_:A85+5++4B?
M.O>X$M_+IXB>3S_H;L*EF1K=F>R6P-INNS!F:F:;?B:4-20[MP^V' \^@#+Z
MX>!BNSOCU\5XLQ55RGP8J-;O4/^%1[LA@3$MC4SZS\;9-]SUQ)O67/9P*TW;
M]Q.Q^6_Z_O'G<8>">7M\]$,K7G#*9,WZUA]YVX.]LZ],KQAS*:(8T[?FKQEH
MP9U,9U]@4U2A9OL!JN"==R=S-&FE/VER*QBFG^Q#]LI8"-8^"7:]>UP-XA+#
M*P_,KG[N7NWX<RGN;%/BN7MU,6;/3P\C'P,6O&A0G1W<7<FF*0B/#TA!H%(7
M'M=Z $H.*!T_D+KYV52,G7W\BK^1SVAXU(+7[V.Q?:4I-OJ7BX)#C0P[>HSS
MOXV(*B0P;Y'KE'';,(BYCPI I8VJ#Q+.0')3%8^H$Q;LV]7!+P.(IA!M"@<+
M/!P8%#9U,L]IR"@<LX7UH0R+[8\(Q1'>]+UM)8AVZ0M5_!PO-3I:\?,@\+G1
MCZ+*,B]%):+6KQ>S]"O5#QR'> N(4\">0J/VHH^NR5[L::5JY74'UB"&CF:F
M$;6FQR(,FQ%M?Q,.I*NFII:F=/Y3?210N!1Q4[7\%'4?=\F]\>AGZM&>G9]N
M;@V]J+/_<)F"V5XV)JW#)ZI;6[G"7OO<)N>'KY9<7OT=HN:9ZJ&S'9M14?[#
M(_6TCZV[1%3B7O]5^_MFVEBF@#VQ\C/)].10A(>_M28P(A]C*9ST!PJLHCUR
M\R[6I7>)ED-M*PZUQK^VN*+FN61^*E-PC7 1^@#,=;'@!&=.H7JG9<3(6X!R
MJ0D:>SZ#1#!,); $M5"(8C?,_.W""'[H;_FC&,I$#YH:'*_I"O..HK2MUJ3Z
MG\V1NFHU">S:7J$Z:,R/!+H+00F,\[ >I8K< <71D7JYO^DHV0,ADSUH0#9)
MB [ACQH!TQ8),U3%G<.^C1&%DQL>*=$VO.-PQ7*4,D><7AJICM73:V,R;;47
M%UXA [ P#.,=C!61?B>_/+0L0+R^CK%@/G=']W&$,9,7XH+G]=6E7,T]>>,J
MIR=^Z\OS%PE6%W\K('WC>MAA[E&8C5/@$4UVV)G+LQ'^KROT>G]XO=!Z:).^
M7R.%(I,2/E4-!4)1(_2A0<USA+]LCT/I9R[M'2T]\O&=6WGTF</WG=-FS$("
M#.H>I#CV>&!_:V,;,N9Z;N?KE"6U7"AW*#;DQW%SDEKR3HS639P1=(QF0S4+
M\NB1+R'7@$^+53-:<VZ-7Q;TR>BW_SX:=,G\(K3GX+;-8#>+=T*[.HJL&02'
MTCF69AUIJS'O?_!UKH%0;?'?GTX7)$WN14PEJ5SF))=BF$H(:42YCZD<N4S,
M<9"1,5/)_3*'PHE0[G*9Q"#&3,S@E,J=C!@ST\TM>X>Q8XS'>9[G[?__8KW<
M>^V]?M_U6Y_OVFNO)4]Y3J38#")1$7SD Y\="1C(_87'1:-[@F"7CERYWD1]
MTOD5JTMV10Z)_P0Y<7KF/6EBQ6%]5B!&1HQ*$%6OEU[KHU-C)\W \XTB;O>]
MFJ*FW.[.2>7!'(?ZQB;@EHD*5P^8:8*'E97>NV]WZ.[^(U]H9 QTQ#(YR?CI
M>IFEY0;LCU[A!?+!GJ*38O-@#0:.,'4>"E8I7T^?E#8S[&+"T\(7ZFK_.7CR
M.:]PJ>[K:&LBN/)@!E7[RP:?'(^]%&=KJWKOS8P++8TM_!/Z/E)Y9-@SW"_Q
MV7Y;T6VUTEW9)U,#-F!^;^/,3I2_2>!7=Z143Y!0V(L6]@Z987=ZLT[UY*:]
M4G.TZ_3AR>6]^O6X7!S3AU*.*IY%_R;V$B#CR;\/D$Z$/8=^KG7GCGM]Q!&+
M'#%G&]=N5A81J:X%O9P5M]S;.0+=RU&:N?U!&=Z!$CN5%=?1$^1)\@?*?LE!
ML3MT];\3C-I-)@_^ [T5M@] >;8C#6VZ#J!*5O%,CJ?!*V&5A4F8KD=WZ8RK
MVQUR\;-.HQK+4K\[X96>W7/+X.W8M3U-R9:GQ&Z 0?V:M?@::Y ASR?$M312
M0R.?B;5:AK9)=#"JMG=R5$=Q\)##V>K$!O6]MZ[+%WEQ_-(NO7^Z+C7%^^C;
M28&':P/=L91;2.Y)VSZM889M37NY+&N[_=\XB,91*TR.:'Q E67O=_+&YW85
M1\HU[.DD!#U,/)!VPUKYU[<DB?:?_OO_.'71Q(,=E2V;^/NKK.-5I]Z'GD)U
MJ[OH5SJHHWQV-P9>BE?72(S3NP+4O;X^6\FON(YU[\HW&Q*ZEM=D^D6E8UWQ
M\HD/@(&2H8".DJ_%;KF%>H_\I2M*I=];NN8%!XQ4]9!/B*U'0BR-B:WVHP*
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M&]9IMVW'EGO.5Q;O2Y]JW_L4?AAH8D<MP5,HRI:'+>N"(Z4XLHAM[ITEMK?
M3X%(ON,A+QE-P>=WT^AQQG+!8??KOW?!?(_,#\_2?VT!O%YSX9O-0UB7XF_
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M<$0E6[]BLK<2E^>N=7<R2/6P>LKX0S5:?MB)JX;OCTPCMH;MO[IZ%$:3AL*
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MZLK#_<<,D5_A*>BIHD*%!MD%;@*[I?P^RHV/V4O<VHVK%R4 *^=;@</,0W7
MAT+0!K-;SK6G6U.G3S+*_S)$RC\W_X47<SSP)(804O\ISN[3UF4O?E,'2YIT
MK(].W4VTGQ19(+$@)HEQO:*SDN=8^>9(O6#BG"/&XX]LH5YVYH3]5_6S:Q6'
M+)WEBAC%4PMS5."_A:TH7R%5QD[HB,&"(9FD$S=)OD(-MTX3GZV J:AFA&&I
M*3[5,.3QL,-2&GM;],T#N_O=VT*N@LS%SD/QIR2.D-S:'6^Q_?HKIKYXR^BR
MH\'@ZY:T[E3&24#*D7J^+>7*,,H!4(AV0*1&YF@>]C(>H->88[$W>WV H=NC
MBV\"RZ8]'SC;U-;BE\_=18WR5SHHTN(3T/5BTB$@,RB[ -YG9,Z"3R>%57["
MSO2Y^[1]>JCX_%_K'JSNY+M^[\S#B7/'_TKQ,1?0/O*F%I+(4D3XE'9JP2D
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MS:@2'2TAERQ-43<;)Z'L!;?B\EFE']OBNEKPKX13<HD*HYG-7%W($NCC<XW
MXK/#$.M0']JJ^' )81XD[3Y<YK?\1_MUC<83W_R/\#MJ']_KWO5;WMPX=RV
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M5%1WQAM9>N!DVQF"7B#9-@ JDG:PM,*R>!N(WO.A\7$NO1;'YP:B;])>%J_
M4ECO+LW7E2D'\*O1EF $<NB[@*G'14):$NM$D-2FU(;P1127:B&1:DFF>T(+
M$IP:Y/;30+0GZ=" 8Q@'&PQ\7SKN2C3G]PUU4C.BPT*R!M\6W::.0+;SUR%S
MX(L N0%%<=Q4J^*5 *DX>9"KT?L%=*@./Q.*U%<<=JJ6N]9'_7MUR>L9T9I-
MI92/;R77?,FR)?]S_(,V:1VUG;F:8B;I0I*UW('6_E$$]$B:AEM++D%YGZ_O
M__JENP(U]WP7JH(5L=!9^BYHF??\HY_GM;,2#KFJSZ"%@4\4=0ET,T3TZ5R
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M7FSP]&5=1E^KB=<W/T+2W*2_\@.RUJE>-:GOW]S [(>T!.NDR'4J]Z,[*S:
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MD2O#:I-C_/Y\,Z"PDNV?[3(8ZZ1%5GHBF.&+Q,I)O_8(H=.?E]!_EH[I3N\
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MK8 OYVZ#@F0=# 3$D\T(L.E<QX06/8H+($Y6;A&1$2T+?*3N=/26\L/2QBC
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M"U4P_R/;9>82^X4IB#DF.<'9GY$.34%C(LH%\UM)!V^AO):U#[N!QH4O%]!
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M4_?D0??0_=(7H=5ZLQ[[K^LFFL%EUGI?FA.^E-JU4AS/I5QH6,F1 6O1ATX
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M4&77,J3;X>>_#Y13X 1XK#\:8['V[<*(MH0<Q[Y9SV-<"S_U>ZM:+:6.)$<
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M'6884CR0IX=L5\DRW#G[4X-(G?;7D<E$>(<-[#;X,.L57$[G%/*%DM+HL1+
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M;Z"[ UGJ5)_4B(]<'SV)T]CQK([BRQL'N2?GJ;_4^_'.K50 MZHJ;"+T]/S
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M]::B6#[7#.>/64[:W/W*\?"M*,7XNC3)5]F@V:$4[I^\/K3KBU6!K:^+?@&
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MU1G"U!! H.9/<?;Q%C F3/I?Q1<>=2;2U8IZ_%_G]W^#@:H&C!>#.NEUR?.
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MZAAF31WW"5_H]]K0-J\AGJO6$*./;FQ>2#E('+XR2@_P8SH G11=#QN3!;2
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M[FEWW6.\M%+R EOR+OM,F+H[<V5L1MXLWG:J9G>:0GNL(7@(L+Q9^\6;3$5
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M)!(QF]U\2+G*6P46:" =SK@]?.^6^Y6Q-$5RKLMOIK@E.H5>4SBV,<!'KRI
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ME,/_GDQ)3H%,TQ'A:RKRH/8M_8G;\#+:W/JNM%Q^074\BK\/VMOZ+;$^OVJ
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M^%+/538B^]C0Q(28I;4NP6KD+^(+[_3N5S+O FOP-"DWCQ0XF>DS]JINR9]
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M/&<]\[C&^,H]J&(?X+^Q[=+O*]C[3TOW@3=D<2I.4A+8?CG<-]G3$$FO"(X
MZ@OZ4!9BBQM BC7C-S;FRYTV*$(*:%VV)48G/6G/Z_CBD$E\OF@F]FML4O"*
M4T@;$]8K9 \/+ :IN.7,BC@]DG&[?U_XT+]C,[)/*-K)-4X::]U+3F.$F_L
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M<W8^^3SG2G'PM@-5/.[E=E=53<-SK79:31$)=#7 V0(:YMC^_TT 4$L#!!0
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M*Y\XWQ6A:R*B(NR\$M(2PE*"PB+"OYD0D)&34U)0,E)1,0ISLG(*_U]?N$Z
MGIR0A.0>$0$?0$A/0$1/@.L!>/ 9@83@3]<_A$8"0B)B$E(R<@I**GR'!CJ
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M6^EO:[LH^*4-D4Q/?,8HF05N+%]!_9[:GV;V[YM8U']H9O\XL7^:URQ 342
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MB6>PPP77XHM\\,I3= AV 7KXWAP +U.@W^  #5\<(%;AB15.1=\*%X2.6>*
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MS]MGG"*E7 H$KQ]EZ 9 B97L:UP_0.*Z.\3?B!]YTEA?9%O4XU-.9UWI0.<
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M^W+;IX8G5[(M/Z9W$:]F=;(!) ,#G26]LDDJU)"1V_53& UON"?E=B#?MZ'
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M-;= P?"VAZAMC=$V'8FX0RYA?#616TQM JED$>&@K7A]27L_0E7)4;Z3K-S
M6@1Z?G?#1('JYT"A36^%NE_V";ON=W)[U2]#:X1J@U$%W 0DL:I?1NJZ)-YX
M<A;8!L?VO]< 'NLA=,5!/.9H,,- N:7Y*U@Z08I<WW*V&U+'TI:L]*B\@P,=
M7PBIZ&6?BGR7F-_H]+'>U-I-[8'/)_7ZE?4LF=Y0/.)+*(&?I&#PN.H&W7"+
M<J(COQUD,=6V\28.B&3O0@O=POBC7YM%D!RN9,Y=7+T#G'R^52:J"MAESC:G
M@C 6R,4$C!4X#G.SJ>5YX\IIDY<J34MDE^?U](/U".\1MQ37H397A*XC@B7^
M"A+4+1_@M-E759FTXS=,&06.+D7D@(A6!SPMD8*1-Z!Q"QRI.F-/!I:KQ2W#
M#Y;/ZWA6% A4N<28UG$ '5;2B0=4P_N]) 'Q8'(/D/SQ,,*,Z'.VX'L]@#IS
MT_(GM-XAT],QN 4'Q#4H@QY$S9=$#:.#GFR EDUY'^4%)W'WY +'=T1 77E7
M4_M4:+\WH-US)R6*Q"\[_GQ ;5I-&FRR^M^SV50\_>H/VTFZ &0JQ_/Z18U_
MT#<I\OO/R@5F S*?-8_<.9;GU&#0GOD<U<\]L25$U ]S5+RVBAR&P94U9]["
MIHZ"'#*#TWI5B1UY'=>"P I['0(0<SUVC/S4#:H@9OF]95)FWYA?]%FC##^8
M]4$-?H?Z9!'H0(1U[5([X71W^ VD9L-%1<GMQMKV^B"+B&B7U_F/2$V]E+4L
M34X^@T&0.&.4:7Q;&()+OKZL8=5,;,>2;I,R0JKS0,[(((VB2PY(.*84(EK7
MHT3GVZ!ICA<IT:^ZS5/*BL2^#CTN,^MOEFKRW/N5E*;-FSGQI*%-!<N'KD.%
M:*'<I^+\WZ)]NU&?&LZ?I%_YEJ3HMYVE9 >\'-8-J6(D0(1?0XTDA;-CM-L_
M3?EM7T"[3E 5YC*OA<T'.MD,58]&J(.(Z2!\'Y\T3V/ET.>W6C/5VL:4+K^U
MI.J^LC1[DA%%F60[QVE'T+HV0-B^E0"(K"VR0 <")O"8S!<Y@LW4M=$Q_:N-
MC0B5C%)/QH:DK8)LR>L ;=OOA[I9X<,M*B6%H6(W<Z?>!)987G28'G@L.>4[
M4T4W1,@AJC00/U0N0TS[M^'[9%>FG_F]2O2F68N=IC7A TX1J7+$NYRE@HH?
M:1'6#1I Z$6E'HH!$=0X*HX1],67HK3QX[J:KI\7W!**.<4/#<-4J9(B,WO]
MH4QM)-66LG%*6L@C/NP4<D"$YE4:LY,7Z=AKVIL(-C;JGRO49PV,!$LM)3UZ
M"7D28WM*BN]";[2/[7L@7(,:J++]XYEBI^Q%$PBZY!1?S<G,..$ $B49/,+=
M5D>.)%2!&U*R!3*_,0S0_;)S'];LLTQZ37U,U!ZLP4BP#&;L($'?O8=V+;="
M2WR>!E7UKUSDN)=\:DY;LZ-Y]K4Q_-9\"IER11'2M*N&+#6V\69+25QQ0ICA
MYW$K0S8/0:V@22*N;HB0>IT==;!MPI&"$-' T7X$&,2+7'@GGK,<)UL[>V=J
M64+<*BF2PE+BI8]OBN20$9H$N:@WVG;E,9Q&[]:G[YA[GR'O0XIN>-!]426]
MJJ@UR/*F8<=/GRP^- P'I"=V0X])4"S85T,N&+9)VU&8PQM%XUS9'-&J&D?)
M/JF1QJ"4L;W?+P7]#12NI/5YD>Y&'RIK.BF<'P*UG#J:>G%!*;?[?&Y&4V5#
MPX$SZ;6=]W2VP'0C1 +AD(.P85 OG'5B'WI>Q]^<N\=DUC<Y(B!Y6'.W,$+)
MUAK5G]S!AL8!#S)[V-UQ0+S2M? %]^=3Z==<Z3/N.;JD6CY.Y26D#3016RNJ
MP82@3)*=W9?/AS@^*QC/+OR<MWY+X_5U3$OM-;/E-;F?.CLB&^Q"1%_#!5SS
M%)".2:)*ZH7F>M40R^Y5F\T 5+2 WL@^ :4%:[]24A2M%(UWGA Z&<Z3Q*Z'
MX>,F05:_<V0Z%[;98AFHO9S(FY[>R5W\.CV-,;-_M%Z?+,?5AD#I"IPC[+*,
M(\QQO/Z'WT8N6Q1IBE*:=M=*]M6V(@19%P\M6E9C7%SI9N[S.JNM:^XW3Y6&
M:K.>:!- Y(ERSS(2 !0.8,+0U36AI<O0IEWA(?>FHPUC%<LBI>XP&;W? :0J
M(O.D)^ ?J\!.RJ9ZWQGN3V-(JO+I>UDU8^42^F]$V ;R^T1I0FB.9/;P$F6'
M7D)6M[_KAH,8T(V@VJV\JVTL8DZ0ZP7B1O0802G9KQ. ]+!JP[\ A,:;,FN+
M]3QX&$2' ^::L,][53D7NU-/A<,9<<!'>T<<4#3>?K<WG':TS?.=UGMT7O_N
M5/H]06W,>BHMTW/.(J*Q5TF(W(/%.)X#(\PU'& W.((#M-Z%N .0Q6050C3S
M2.?9Y$A<FX2(2_K#.\=1'!4YEH.,NY\]%5-"'JU5AU*BH>_1@9\;@R>P7*WC
M;1IBK196=P/VJJ280>GT/HSV1C[E/G%)='J5)AXO<,!E+D<L7GK4&0RUB:W#
M*B_C !L<H*L,WLS/4F4,#7-77N_VO#0[TRUPPN L:]#+J/UPQ98**"<3R/ "
MJJ%+'J_"BD-91RO]+103.9H[QM8L?O:,?<EI3DNJ #35R#9<1X4*0'0H[F@$
M.!;&X*_'!F'1Q"Z.';T#E6[6YB]4%@E\C*#8SB"G.?E!/SK)YAX:A*KH51!"
ML<1>13;%^+6F!RK)VITV7;JV%#I8Z4-!M H0]F0$))S,"A'U8?D@MGW<W.@W
M[BB6Y8M<E^KCPN^&W_46TLF\A[5Y)>97I,JZ"54[4;0-* D$\\L.EB:D\DB,
MWUP.P^Y)2R2TN9(C>3".C2B"0JY/=2B,3 ,P'*MOOJ%+V7VG_N>CVL:46;%^
M01<A@_Q.TU1T$59/L"O_F"03!ZBVU;C77$)I8?+THL$[5(+8R"!5[CD-1GV"
MOT4&EN9=@?0)6^3K24<Z=-?!D66N0^%R+BHWQT(YF"N6.'+X0A[JS65PV.5\
MNQVVQ&81H^S]8[W@!D%G^*@^9 L^!?^Y60:*<'L?F;.#J9/4+Z<0:;VLS@P\
MHB50,NJ0F_"C2IWAED%J/W<61JI]?!QO\+0K_UL_1^)!R*493GI+6#S,J0Z>
M'^.Y/++C?+\IC'+VYT@S:^K)&^ T\:;*'D#2\MKW!^3!LDKU8AUIQ?+Y%VLN
M"^/T!J$J.PYN6>Z'VG/*5.2Q:INPUT\B%$$S!WAXN7Q[PT9(Y?$G<9 B;%R
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MS[=I;ZL&Z+SSV==#A7)H:_>438&!!E./3\P?-V4,/CC1[+WG31GB\GA^;^J
M--#SJHH#0%/3Y 1D'I /!W6V&[E1KYT\^+57_(9D_%2RO?:9:L<]*%\M3SM'
MTTW4:Y9K&%: I?3?>,U%1*)G;*,.8JN?V@MVQ'YQTFX]U_E,?*+<7CN,#[J&
M;8K'92WMT<O#KVA:I<Q_N@@W<=PG>LR6I=>H)G=DL*G*+5CY \.C1R>U&3R2
M0!.MXLN5=+^<8H-MGH-HGN)L^GL^Z4XHC>-2^R)MR;EQW4!B13P4L;Q"5!P1
MH08@KY/2:EF^4N#YS$/@',[3]"&U.]CJK%)59G+RHZYH/V?',?&OZ>C(.<(V
MV')V.L]3J(L$ SJP.U9OQ[Y.0L#BJV@0O1S9M*N\JIZ<X$*$RK/_"U\E^B(#
MFS7M^O.9B5R/YA/VL(GLC_7ZM_YT:N)> 8(_*=)&"%UG'&V->M]4,5,<[UGJ
MPC!_^V,$E_&* T&$@"/9:P8;+4CJL16^,HON-:_&1R0*Z P.J/=T:#V ULF>
MAMN^F&L=8NOS?DUYVM03K(7AQPI/^GF"=WEFINO,@^9N!N59/)]O$L3WR%3E
M*;SQO^"HQ7\;F?+#8?'L6M%'9O47]V?/'MI%W&=?N&$_^_ %YX=U85<0EJ4D
M%KK>;X(#8/AJ C6X5_("OJ5QG\Y=NII55$.[3)/F?; QTQH,V:XDC0-4%)HN
M3E-Q0(H!'KQ^[P;_0E1 %U_BZZI5YXL7R3@@WPVV@S$]D+X+[\<D!,".Z:-/
M<_=$>MH\47JW4>)Q-&^2J]]RIL_WRDMK1K@;^LCY#OE!_\#9U/A>*S/R$%[6
M6B(QNI%'=FGCEC#M)FSTL%QD"+H<#''$AOI[GO_"0Q;.HC\*OXK]VH<#1AKQ
ME:$C'):>EZ415(.1T*/&WTNIP@'AMOB*)^LG),2J$24>[5EA5ES;Y=WZY!OP
MN"'A=83V5DG[8PN29]W]N97LFL9>#:7]N<5NR<)"A9]H'_V# 9=/532N'9[*
MTN^]Y/I^M_U/56-R_Q-4<K--CAEB[>>42W*TJJ>_)'& T[9?H4-3FG1KD.2O
MZX![6*LJ<7Z:IN\P0++U;QX[Q0&IW-RHP(10#O=BM-2@XI@2#MBLE8\(C;#7
MEDJ/;N4L(VW)CV=O/XY$SEE-^N5@1T*<G<;5Q7O=DQ27(\E03$.A_*B4)C@X
M.A5.$[#IZ<\H*_C-*8M@YDU!.0E7*=&@7SO5<>I8O5G]&SE++4?*(.\B*[-6
MOF."F41 @1:R:Z0DLP1-#:?+/?8$;>+UF*^?^:TE3V?'(<-A935/TT$I(_A(
M8!J/$]&9E:%W1OT5YP-F^Q8L[F;%D+SV*%>S_/7I56X/<C$5HUL:/GXV$B-^
M)"%]NU'GGDG';5MGRJ>ARX'<)64%M#7+8(PH>"<$;SOF-JCS]=2/.* ?=M;>
MA@/*$#4U-Q;CH4P[6!Z9ZGS2-[X5VR^^MHSWD8"O#W D B$I$9?"6J8+C,"V
MC>>!<^$C++-M,)&1'[([PP%[VTD9WJH\*H/X<""1S#I"[(5V&,*N/$RY1' T
MO*EVAMB\9T,:/MIR)Z<28TRSG1):%_!Q'9EU<WK,_VOH/13)24PXQS;[PG-;
MEFQOD1X[JZ\96_)<Z*L12B/WT#/P$?(%#7M4W.= 9CI%8O:JXMM]H&;BBD!!
M5\?4%M=Y^BGMR=%5,T)0:37+LLTS\8[+H<+U>$Q$4S7QHNJ&;^]*ZK5).WN@
M[(L2@=5X*3ZUDQA$D#U6I?I;.WS@_^PIXV#!Y'!2C,8D)@Q.<U</>?+&.:CL
MYPAQOGN3U<9!W;6N-/HT+6*'MDS#[WOUR2;[NA-\!QX[:Q#!5"_WE"3C6#7>
MI>@O<@6@L?+_Z3/9_XVD5-.[>&!]@^><3/8@KZ5E5>GW\1V$&KYF\(5>VZZH
M"88A-W! 9+C;T78H(^PS["8^NOIPKN>&&DUQ/Q3SLY#(U9[QN"J"$=PKN/ ]
M-75?KG+&8RW0G$TU4<MNEA:R>3EN_8S>$I04>BVDA"K9^"A?OJ;&=I%G)F+6
M)^!7,[(CZP?$]/.)"D?VX5!Y6(/XXC>[<[E4UY/'L<K0@AI7N@\XX$%44H.%
M9_7TYH79D8@PV#@A<3)XN^&,BXO1P/K:ZNO^'L]3.AF)<WL<4&38A&6 #DB,
M0W>;L"G!G6A\:.8C?8<#W&"'+OAH^=GS],J9WD4C#A@;L<K" 2L/<8 G#M@M
MT?4\ 9U##Q79A0K;B/K_43]5KC<R?BX4IWYZ\I(/5-<6HI4=Q_$2?E]'\07@
MZ+E@<G7(X$/D<OO$_- R@Y5(:7/Z0^# UN9GA([1X.O8KL4USD=1JA+_5L'6
MBWF$ S(4X= S)'33VAEIV[O ,8XETBW9"N<=W]G7FT6Y>X=PXM7-<XWWUVQ[
M74\N34V"DDQ8H<LE7:Z&PZMLW*0$G2I/HZ31[ <V:'L]/.@U[>%!T^-!,%L!
MK>>Q'4HO[A!$N:V_W;+WZOW=*UL?KZRN>-4E1]B1\O.]6N+8UKU[W#;M>6.[
MU&/7(<$A!2) FW*SY'(<:8OG'[A5IW;""#'22#R8+K(8JVEPWKLM1OOU4Y%=
MMZV2J(MO?Q40;&SR::+2[?65U=7VUNM?'MH;"P0?N P%-?7 HMD=>X:>?->?
M\+_;*MC0=,#$JW$Y%CXC?S9*YG_17@P=-?F* P@9,*XQZ,E*YQ<\I*$:C.S)
MQ1]E6F)NO]$!MUE'L"/ RYF_=W[4N?&K&8[  91_=0/8!COJG?*Q:UWX-_]>
M8.NWEON12ESN2V!R<W3XX)9%J7O.C/U+H-\W6UENWXKI;]803$BR'NBI<+@(
MWADFU[&IP1M*88A]UAF,#DJL*C]1YHO8\F1U48)0P[4L?@-IH)SH$4 *,*V?
MR$HO6-WU#[J1^?/>FHY]UE>EI/MW)94R= :N1H"U-OY=[X'_OTD',!;H &04
MNL.Y.!B\M?T<%8AY\7^X>\^PIKIU;70B HI !"E2@P(B B)-0$I I8F 2).N
M@M*[]!($Z4U 0)$J(B*]A"(E=$2DET@-"2 =$FJ D)SPKO6N<UZ_O=?:9W_G
M[+VO[\?\P61F9&2.,9[GOI\:2T5HZ<7GEY0TDKAT6RZ!XJ 248QY2%HO_$\=
MHXFQBC2^#]I\&0L_O<8KAD1$PT_/Q\1)%VGCM&>)0#9E(Q$(ND,$HCZ'<16K
M;2O;W+^JE]:@<P>=6<B4&6]M=V.XVZTBE @\NY7UX^4!PO:9#UV.)<5TH5/8
M"[KPGU'8WL!-G;'=^L+E%_)*(7+V#FS,7*;WW)0NRF6":N3M_5H5^&L'')R$
MG"7DS8I3GOLIQTW5Q9[M&]*ZY7N4MEOXV&+T<2Y61'(,F7J0&6O*<]B@%\AW
M2&)8RV\,^4G8&P_> 1!PS!DH5G\T))GJDZHO=D6GX-[4"D*N>R@#$LG1_Y^3
M3":&I.^P/H83@>JT,2) HG$UI'U>_B%*L%G.Y1^ ["8M6>-(._UX;O%09-J,
M8M_Z?->/9C+8WCK $*C$VB_-\@56-*3A[INHL!#U.$*A#[O.9<SA9!DIP[MA
M2I8!]WGT^MP_)0 O5I6]:]8A)2MLAFW1&O(*AF'"][:[ZU[P,L?PW/QQR$ 9
MH-AU?X"JN+KN8RY3@%;O(X[S3N?/0V\E(O6&-Q:VBIV+\Y-8QSF^=X$5[5LD
MB,"X[/VCTY")3-X&J6=*J6N8;,7IYCXM^=5RG!\&K([S0><AA"2C>^KNBH!2
MQ;A-;\K,D:A>P0D.^,'%,RQG@O6:JX:C:CV6JXHA:E16S]X_O9S\X+8 ^[MH
MI^YUY$4FTKND@9<0@0$BP$\@)TD&CB((V-Z<;PQJ$SV'*=1,01H-/SV2[.C]
M3%%2'<2:!]IRI+*+;<OXXA;XH#YK$E(5?WPJEP2H#>!X?<!/JJW_[)0W?\O-
M-*9?'SP$'&=4I/BH-Z<6OC+X6G/Z&6J;=K5UXW5<9]^KRWF="3<1X<\,XFZ>
M\3SN4]@0S/];1<W:TB@H@W @F[>>G:[)<<D&6OO*T*3GP&9,8E=%D R>RA]A
M;W1K,[1*Y$('8^"E(4=)WG"O-]>?@BH]Q51\N:BT[P$'$]JQT(L..]X-.GZH
M0IV<>_JOPCJ5HY\LN<-==,?CJ7A*E/T@H4T"2X3+.#.I6#Z#JIK*N#M^E+/K
M-!%B#[@.OB<OO^X9SG-%@@G<2S,L&.&ND*)J]0*+R:)SCN!I6'C\NT;IBSJX
M'0YL6GR8).@4X9MA=5JBG)1OXXZA[NVIBW?D_/2.UB/5.2-YJJ^2D:@0X:H]
M=H5M,[1!TODX]''7#\@SGU=VE&I>4V**+;*N04K2'(@*O  NR1DKV,K_\(9P
MQFY1IN;"U_)KL3%A#Z&AX0I3<:Y)24<*$[<#R9>^#P;77)G_?N8("4_PP0-,
M:#C@(5#53^NODLD =<^!-0-S0I$"%K]LR(M'FV[AD!WF0HW#@8PVKC-&1A?>
M_: T?$,>.S]_K0#RP@.2O4:@]7^:A:;HV(A$"UY=DUQE$A.[6U1XC7("*<B@
M_^;U&?XF51<9Z/C-&4D,(L+I=OQ-C=K<YUWZ>KR@WMC'WHY-;4=V,THVIW6F
MS,S.ZGO3OO=\37 05^1,[0#'^O;%SSW"LV#V[VNJ&E$8>'FGF8I?GXW(CGG]
MD:&+VTV60Q_#0J)?#* (>F\IM&<2<Y;/BU7&"[S/KQBQ;P@6\)Z? @SK.-T3
M?N"O0-<A$Y7M^UX\+Q(:C[HR/0-QW.#@=)TC52*0@[?"%._6CKL(HV2[ODR)
M6O1<"9*7FI/J^(5S=;9^DCNA&E"\ E3I]"0F7'%M^+P0Z03,2<MA0Q;'H)SX
M !3HO"T&_P"S96);\],1/9Z3?(&;V5S-L:[[MM2+Y;0"+$>L]EX#YKCXVQ59
MG[4'-"&OV7]T:;US2AX.',5>PC!'"SRP,M.VJW&AT5([IEI0Y%KEB!32X+W/
MR7E'D+R%*B??4 33YW-=@<G;W.AM?<8UI)"6>KN=F/TB&&<'9R>=.L$3+P.(
M=.RXLD'%A;.@""*PI8<G2;(GA?W'7+O+$,QHH!1)I!N>6.FYH 1Y<TCQ2N7J
M!"&G<(;7UO6SF;K'M?8SRM9/VZ_RIEMA$VW(=XS_VVOB_K^Y2#O@54\;>$=T
M&8+C9"$"3'J[SF"<L^;@1NFEL:K5NDL1%4JT$[+?IM\ [MU%TVI\GGVUC\MU
M$V-LZ^%77E09)OE+8 G=SE5$@'F5^8.ZJQ_%CQJ-,JH6F_T+04H\"RL*3R8:
MR0D71&B@ UT?B<#L"PN\OO(M3 &7_<_ESF>/BOB\U#N^3S_T?-[+9-"F-[S[
MR-CL^N'$GH1CT=ZVT$MM4X:/VP:%5L.C7 ZY5Q6,!&]\B!)(_)>Y"1;1\/D&
M&\@>G?."O(?'=^]Z@D9G"!%X_(N@BS TWX6B!DG #3^^.H83@(8&.I! P+Q,
MZ]]?"9TE6@H?P99Z3&*X@P4F)(4)GT]=ANQ-GB1A/_97(2DY<A(.J+8XE!2$
MHJ3PB<?\A$GHTF()B<-N"?VA]/:&/]4<A1_##SEC25B?;.X?QDH#V';3L-^O
MXUSK=+E2V9[)FA[M73^?R7HOY$&-$X$3]KSR1:WCTQ&/U&H-CQ234;\0VI:$
M=X1^ZI#+"4?5/\\[LE+<KC'@!FS_F475,#YPR%D""7*L6@U@T-3?*&E2C33*
M'$U69Z#-/DR66>ML#*O-BD+2\^#L9S?7G2NB>PKR3?QL6*L+94XGMGN2J>_/
MNJ8/4,4L0<$*EVW3Y!M3<F?K8 */8U3W4FK2I%Z3Q92UG#Y,B-H,9,.;8Z5B
MY<R_:E6B6(:$8T#\$T96'"4WX&(O^^S[4_>"<:77\^FR0"$.:5MHD2HE.XF>
M7*$$#M2H_X\*3.!CT0X/(G F4,![$PV*W7#T*+[5V:\YG/NLP<3FOC-'_BL#
MNK6V9*>0\E[ +Y;1, M_NQ;W_LD7XQF\7-4P3) IW+$C=IQL?!_\3EVP<PK*
MXO2&#,W%C<MC:4-.L+??ZHS^R)J;ZI&98R_1<K?D8R"60T @(WLV9+11Y586
MSEY3BA"J48JGL2!<@6EW"690JEB0CCZ=I# /#5/)["MU]B2D$&/@_=&?-A#F
M0#9<M-WXJO$+AO*N)-\L:X=#_]E3@:\&*!=)PH-5>0Y):8P+.R=5H9&2</<Z
MZON:6Z,B5_+0B.<O\E/O+83:VZY9=@[O=*C_;0OX(#KC(Z&88CQWXOBU[L(5
MFH%QGJT+Y+]>QZ'<I'>?K:?M&+=AJ4+D9-%UW%#Z9>:):)/@R^(EZT%STH>S
M@7ID6YNMR MXN2$/%JQ%N_SM?3VLT+#$EXI)B0*R?E!FS.)G>988FAA$):Y>
M;Y@@@:?%4N$O.<KWW$59&KXJE"N_N'"5<9=/C7P*09+=U%#4_C&UL?/Q84FX
M$F8F'N5'58'9RZ#,<N3]9!!%T9K*?0II>A4<"O@C,35S3?&S\:%N2VRP8N1>
M9OIP0"R]6*7STV:&0!1=EPSG#15MIN(C">_K?O$4N%3=1H,HI''TVLT?JGH/
M4#]]8W]0C6KZJ>1A5EN^-GV:",M'95S_M1ZWF*:A?^7.RI0_,L[^0]C%XNRX
M<]Y#5W,?1'+8,>FH L M:N#@SNQFNZ!VR 0\PE]F+MJO\.GSAS0ZS *7K<ZK
M^-ZXIL25^<J@IL7;22X >V2,G:U*Y%28_I1XTT7!\+7#787BA11^KDPT"8^;
M8U3#Y+1O::-I*=L>O*,<3;$A<Y&7\NB"V=KZ:F5]L%VVS/TY^=-8-;',Y"Z/
MHK;NRT[M8L"_Y;.=ZBQR7?;SZJW>XC9;XX])FK\ZZT0X%GV>+694N*B6[WV6
M4R]1QK;-$5Z"PK(S=GJ4&-2VNFKVU2\E&IU9N^$9L\OM);E#J$%-L[=7V]NC
M::\/Z[S4FM=XJ[_']<YT1P&=.^ OF(TS%^#![,5;?RJJW::MNG1N[A-:1KI[
M51&L0!@PJ&FZ@(.C2CF53R>.YRH^*E'<?I+D&E/CV!WCBVJDM?*WQN7F^QN&
M*&$6@]=%KC_S2Q \^_1,IP$[PPTQMT#+I.%\_IJ1_<. E$)+OI1\6XJ%HEP&
M)=>++UPW\D.,V/A?R@FBZMN\<KRAVN5UW/$*%QFEJ3[3CH">*#+C17/C0=[:
MZH-MSD<4Z08=\ :=4TFXA#0T')6E<!(<4$D$DO8A>+>_ER:S[@^#[) DX/QQ
M/PG&EKZ6L\^?6.92P%*^S^^8GS!:\;JAQ(6>I.=[II.H+@VX:=FO9/SKFGW?
M%81&'R,:;(M7]FPOFZRPO=K7$<JFTO=A#7I\]J2BTP#5TO]NY:C_RHN#"."Y
M3[(Z<ORTB$"S1XE))Y1Z;K3W-::Q).E3T77SIYC'W[PGI$] LJ\F4\R2;KJ/
ML;R<@GU,VZB^I4YU?35BJC_+_Q)F41>QMT+?G>?#;!SR,4'S[/'&4/W+UJW:
M)5GWH<9HPGD(-72@,1\Z>VN,OU75$#/S22<$M&X?IT0$7A !XXU5&F%JNS3/
MJ5WQ'\,L<E8%VU4?UHKSD8[?C9_'Y]N4R=W2?,/L*NML%7HJV#4&NU-8I6,6
MR5L4GY:^(..N/DU2:/=?_RO'T7?\7VUR);I_,=GM%Y+D;3R.Y5>_>4V+!EYP
M^XDRH^&EOC]UN#N8'CZO. )?3R7$WD/B-(D +UR=I':1AS*KY/]$0WO^WRPT
M0Q(^=5*D;6#-YD,4!L3Q)]^_]B\8YGM)8T3?D>;F^[W83)>MADT1)Z0P9'1]
MT6D="?TU78_S'*!(^V?F22QD(OINXPB!T\CB4?/VE0R_7Z:G6078>6@7?W)F
M']M/"D+,QG;@(!L$6PK<AS;CE>#1^',Y]T[1D:0!,A* ;)=SG..\";G@+XDK
MMJ=M-[[[P5[CDTT95O!4O=IFS'?O/L]YZ\NY).9IK\T<.)*V5XS2Y5EF87.Z
MDMIC970O8D1&-X:A+29F3N%3S:YV#)32(X!V1U/%>T.BK6L<7GE%CV/QVBG:
M?+GYQZ-$(#3P"N[AUY@T4-NCL7,% SW<1W(M\_J$G42:UU(N9^?X&<E6JDX
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M@]2K*ZM+&T-#^*W*OND@Q+FE>1):+G^=F%.X#NT6(BF0]7A"_+W.IC=Y2T2
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MZVH6'Z[ *Q472&MGSC.XQN?X<&;,.[.324QJPD N] &EFLQ#V>V5:PN;G<Z
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MK)HY@-N,+X($^[;VUK>&C\UG/#>F]PF.D_!P1\#HGU&@$BDTI+U8'/7IG75
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M9/,=$3BX'/_[*(X?7O\/VDC&YES'[_%G\VUN[GW=#=_KR^':O'G4EXGL[6&
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M%)07[Q0NNM\.G Q'B.^V8U;W'!X,'[B*)^=_:H5AXL]RN0R_.066:8:_#<>
M?G[0^\%>!4.Z8](*Z80A\[MP@&CT9.G?%:'F__E _TM\(#SQV@',L2[;/9>Z
MAU G,YK\&-;N;-7-H(W. A-.TE. Y=%JF^<:/Q>S'5;Y6P=<[(,#?QKIM8(@
M*;Y,Q\FK5QR4C*/2&&8N)C[1?O'NG8:]J4VO#@LE2A"=)B^FR@AW9@J2^*QQ
MH&I7&]*ZIK\GO*J03HLHOA:KH^6?1>2"ZV..\'\:(4;CSX$PL:"S73OK'9S0
MU;JPR* .PE]B.=!Q0SW-"?/TR-7A)\VT>N\Z?DO=BE< X ,D.\>)'[9N9E35
M)"AO<CES%'4LI"AP<[Y/.=OHE65-V_UG% H.?C,W%#B;[+.D!"L9,*TH'Z_]
M%$'"W,'P+)XHC6)P8OC=**0=5PC;L(+C?^/#HM><P\("2B=A0F,=M] >_3E\
M]PW>L2V8;N3.E0]76F OM0:!_I+9 (+J^#XD<P-,U,2BNC\4\'7*_4I-ON %
M[*.1;I#[-/YVON(W$(W5V&(&@<.R7CB]4L>* U<PY/T%P*2?56Q)IUND\E4L
M)O<4(-A%E@H.ZCKU.7B?I&D=IT'8NTQ1Y?#"KS?D9YR&O.P^O.<+&":.ICS9
MY8U'B;2^%M@+R9.29LEX;L,.+9'CN-!X>Z+UN!LRR>'MJ94T32RERI*Y;_G)
M7X=X;OGA.;Q5N4/8/?2PJ13^7)3]EWLGM:8T*HZ<7X]!$\_7UM##R>UZGZV?
M8"YA\->'N/D;'HCP#-NM?9O'[EG90%1\B(2XP["L*T>VM76QLY=?$5.]4"ZE
MO]"UM1W7#@KB58>W@LC9CJ4[T7?GIC8%60]NI[UV<+K5W *YJNGU" EK9HS\
MQ)4^[)H0\;W)W0_D @;P UKEUO1]*)&LH1C!AIG!;Q]5@A6J7LLOTFMR+Y I
M$A'L[N7XY_?8&4I?VD,GO0_[H ]WSN[JVMV/&=S3E[[CF;U8CA' X>_O:2->
M_+96V(C&00MZ=?I@40 K89CA9$P+FD]<3?T-V#C='@V_9JK<WSX%_+W*Z"\;
M7:OA.2:^:1Y[>%P-N3ZU$H^RKGKTY9-=7J%A?<SG"CS_HB  (34SF-""M,>$
M5.%H)HXW[ZH/=;DV3%TO7G2D>KKVF'I4%$;U.>Q&^(.$R)S,%?HUF5R(C0FI
M3'/THEF$RK,DLY#+]5*>6O88;A8:G$:G*IP"#:^-,9K.J9>NABVV-OXP4(AN
M%@CEOZ@T>8\WB^("VQZ!:PX,&80VP09V<9\" *Y;<S9Q&58*!EE,KQPOOIY0
M%[Z)T9_).=;EMR\](5R<D@L.LQDQ9/*@>DP./FABQ0?KZPPII,U2TH)?-'.H
M%>LF+G^69S-QLA6_S-!6O\2=-)QF7449X&)XPUM1#8F-92ZMVHP*2KU")13I
MY[WV%N>%M<X*G. +;V%HH-AKE:N:2UK1BIS6'9\7$N2OL)*#N>$0LE<56R(P
MBM6C^?WH$KMXJ@X3AV#KYIAJB4V  Q')*]#LT1I4,AUHQ%K^XYL+\9YGI\[0
MMDNYO^Y,DXGK)K$VQYX4TG.;%[S5XD.5^)#>B/)'23%G8U&7ZYA32R]%*G<'
MQ9;/M%&L%.^<*I$1V,?P2DN"?&YEY*VK _S\=[^/8'=XNC</ESV/9U8%@D3U
MF#:ST2^B^YKM _6Z8ZWFOKZ44C%)-["*UW\=8TV/8N4LBV:X$TFH<#O)V?C^
M&+B\08N^<&QD[8B\M,:$F%:LX#/;+L!$@JH]MS-+[]\G]D$T?9O,;L"6;%RQ
M:!T?U>*]UN>22]10-11+F):)ACR('IMU4VA5C5"^W'JW;C"7,8^DX_LPI=Y3
M1,>W[F L#93X%/C1DP:9:13 WB@IV=!6'=P8\^;"#AW1>4=PEG1>"ZH7YU2^
MW,#D.2QP"ERP#P(M&_1!D(0"6*ZO&/8@7AL0;8,]HSRM$7NU$D*>Y.M'-@#O
M!]Y85=;0NXR.WG$5ZNM=\FD_+#^'K=ZY6WA&LJ[)5.-,U!KTA'ZP6&?JUBD0
MQ6J(LZ*O6K%OK,>"42:K,"$]4!,T6P)&AG,+,](AP^&@(SZM#+-?B%I?+D;9
MH[@JLU5 #>>3L=_ZJZ&&0@X%ZEA/@?Q+N(YQY^OF<_WR(/M[>0;V_&%1X?3V
MUE_NF[US;_CWI,G]K[]!BK-@N:I2?[72LUX_'QG(Y_N9E!3#O03W(!^&4R",
M\2>>P=BS^+.O6*BT([V$<<PA $7Z&W/PV)=$]03AW%:?JY#?O-8> W#RG(.)
M&/3[;C;.W8Q4^ZM#\^L%OY57BZDTH/F/9P<USHXB^+\KX]+W;BW",9TUEI&S
M??0%GU_\V>L_N;N>@Z= L"*. 5KDZ\]D8.E^.R+Q=NFO)E8"&C*]S69MO-]Y
M"BADV&.X<'49I^,8G?T)TYX?Z@KV/KD*=A2R/( #S]?3VRJ[J;\O"U3SXB2E
M&#N-*_DX87J3=1_'-EUQSBB8*)+VB4%/)$;9?=:;Y,JDC#A'M$IL2.A E/\W
M3^J>#E[)4O8'%$ZCE[5R&84GE=<C$](J(A9+XW@R;E5_THQ2>'!1'!3H_A)"
M56,KK,QAQ!J*>$665Z9!5;_+MCFO 9N50?6<D(:> KY"IP!*<^D4L)H=&SWY
MC@/KLEM=M@*5R6*8:WH')Q3:L(-92$M%/OWHFIJ1Z ?1G-S5_>J "?.FD/X%
M]4\4@.-$TEL*!:=;_ 9>"JC8='*1H4 ":H$I=[Y%3>:JN.S]*6E4.'+R$:%?
MW96X";-M[BB&EYH=/LA  XH _*N1@LI2=#G/;\@UWE3&3"_V"-:QXVM1)!G@
M^%MY2DK$A[K+MG8[NN5Q0VL:98;R90:3<-MW$\0DX)G(#U(F";O&Z/NE6T=,
M^9"MQE,@PD&2.P*C_!%L?N'E;H6Q:K#K^ ?;>;:%=HEG]=YS\C?C$2#ZY9U.
MAD*QB]:"I8V<736O"Z5= 46&UOP'<')CRL?$JA^FO0=AS';=+[FXB1]01SPV
MG\J?TX*E#:WO3;*T+#WN;[I4]3KA]:?0G7G#](!Q.H^:?"S-%A-.,RM2T6=1
MY>D4,=Q3$CB[XPA"$D*P-VIU%G7 .1S814_'KH*"L##U_O:4+'G'*7R4>>:<
M;BE/J8TE_WSQ[:]*:69LR8=D#"D*TTN&$6Z]N8P#@THO>U0IC1C"K+^)0I X
M#==JF?WWJ/G?_HP!+\6S8V%SL&-R(\CR0?XSE,4&+X*9J"5A*LKBR[*]?>8J
MS5A37\-MUZ=1[^BOJ9UM%^=?&-K3W=N J UN713^2PI#@FO%A2]H+SX6!+<+
MXQWQ_[/O&FG@^#<W^9S ,5$F-L#>*/>7!P85J85K1T+3[:Y-.'>K_!3(N+^%
M ]T?<_\_?9VOXX&TBPV"-J#8R =GR//I#'F>XF05="3!>P/G9L>G29,5GV"#
MT8C#M-Q?^(,)6 Q[WY (VU!V"AQ=MS&ONHXA_8$JA&S121LOXF!&][N#,1UL
M *V";;$!G:2<A9?@A60AXT_"AR#'TBZQ2T-8=JFJ4Z 9PG:&UNR1J"UX->@*
MG"#"X>66;</3)"YDQV/7@C:,!(([5ZS>F((/0\6=9) XOC)L\ECCV=-NUZ_M
MFX2/W>MQ,$M;J;FIRF?_'?=90?_*_$#0:HW^*6 BLH1M-^1W-B:!#(++<<WH
M.8DN3</<M[F'SEET&W@B[T'T];]@6>!L<?3R7\\I,7GBX-T;>0J<@&%8/VF/
M+G>A7QYHF=4*X+RPV,A3(![R^_I>35KW7Q;<N6M+RYZ5B]UJ;#(EYB!1PEA)
M\.24/<Q@R&D?20G+.LG-A/2<Y)]@C5'?>/-9K;2&%R>U=*,>#R7<(L$R;?,F
MY E1RANE]TGP(I 5+LEZH<;?5WFRGZSIF1;RA7[5MWUVX7LVZ*XUZ?3%Y?T+
MN=(8;L=ZG7%W3)#U0D@:PXY$CD>:\HL"%%3J2_2>0@:='OQ)R2"_?'-XI_!]
M!'LXZUW*:]^&"M]9T/%4?[$G;G%4#ZAZ_M?5EO^W_ON_=_W7X%+S*7!(:PM9
M.P3M&L1.#9]'0;#R5XR/L*HGES@=%EDWBW>EUOM/.C(_9<YN'=(+PXYV@D\!
M63I7URC;>4LJJ4_$\MQXB4QD@P*4D+9"7-.&DT!'0"[C0B92X%Y8*A*Q[.X6
MZB679;1*M9*0FYM^;G3(ZOFQ8B?WYV(?:>G5\@"1Y,=CB*>]+HG2HHCO2=\_
M2]0_([.\X(KE8O+<&#?Z=#/^N50NQ[YHG]*D[JRZZIR\=D'_^K/::D_PN;88
M@%3OVPO09&;GE?-7XI.6^'>$R%"EX#CZS!)GG#F^P^+1H+6?EPDZ')GE1FZ%
M+2(74L+Y/BGQ)R<5)"N_C>.P2 EP_(RXA^J:V.\WI(O=,+UX]V%41";R2/M+
MK^8> T3H^/BE1J<5K/QFLJ?MC\R,3HA(B+?6V!V;B"8&A#><.=)Z@5;;6DM+
MFB&'UVCI-G(-JP"]!!F>P9FSA7S9?!#ZU2G KO@&MH:$+#L-?]0Z=#LNVH,D
M2@KF'R@=X4C.@S/RZ;[RAQRA?S9&\W"DE^<GC,R/4Z $(R<4Z#I*0)6W8O'2
M@D00=%$)?ZB"DMRG7X9Z^%6%RUJGR@;/A'@D[QO?7/HY!WPZ"8,4=/VF[&*%
M,90#'+/OB\P,RALI#3WFHV1X<<L\E<)YG+<\,^,EMG^*KE=X&F]Y+/+#%[U1
MU?-'HY_* DU8-.39;0]E9QA:I 6]+?&7]7C?HVVR'N5@!) +>^.74@QE6&_W
M:#W[2(]1ZG+OP8@8^X.6Z>8H,40!IP!4C4@_RXL<_2IGM=PC[M/LEN3FMD6*
MN\RXPV^'Y(F!RQQ(0EX$A'%EOTH16B/W907E+AKGD?R=2K&BK$E9]ZEI]&.
M*2;AR![+F-_ NDN"(L+B-YP"K3D+IP"]=8'-;[NIPE'\>^1W/;_&J>'_MI=*
M$#ZSXV^)ORL:AA) 6\,((#]XFUC1E$2G $O:+_5\Q1^WS+]X"@3E(!5/SM7(
MX0@>$H):!<UFGR6QE\VG@LQ(L6(\?*7+_EA7=M79]1+3_@5;[OM#W#6MFXA*
MG<_AJ:[:+T "G;F 9RW=SJ+?L?:*H!X,P\EX?IW&7Y19/#T;/G'GNO&PS"".
MV))KST"/SH-Q X6'DR/$ -Y&B7:W*VMI;+7-2Q$063M+G#+)_DYPLN*+I[.J
M=H*W5VT@?Z_]R:_RQUIZ!3ZS,",G^L< ,J@W3]B]U7-?9NXXQ^SF5IS1_O/O
MWW:FVW1>?5*I=4$'?P)_,1SJ10+L'_$VP7[I*O277GZDM/U<H_+K9_\P8L#^
MV':BP*&X/35D1!JT>\6C[0]%YFRQ4N 7K&$)^:%ZK5JBVG$Y9(XA+W;PSX<X
M27TW.;" 93@/OXGGKP+UIG1K&B73&8_=<=:P<J^S7$&SRC\Q$L.-E\1,SQ&A
M#0Q-27D*,./FTKDA=9=L&()D8<7>T39W.E9RDXX.0\'05CV$D!]".%^S'OQ;
MQ,K^%)R#^=&\^JPE./X^Q@<?NU>Y_DX;!['PQV AK%_"%A8?CNN8):[524B+
M$WR1:0P1#OLB>\U9^IA[3/-4YH)QMDH#.X+S-^;SV'_^M(Z/X,G'&MXY 6*C
M%5<]GT*FG?6Q_GM43\KD3:(YN#]*YT@6QF1R5 N5"^0_2!%\M\3+R5.^XN*-
M-S-]2.V"\_#&<95FY"8@^?'WDY#FL;.U0JH5_2)#<7U]/,S14Q<S8L]%"_$@
MKI7\*I9E_B7J%K&AT;'N'7=$3P&A/R7+W^K797[B:S-U(B>?,-QS2KLBA?U[
M[[M3O\EY"R03W'-QW&PS4/*Q4Q#RV]*;_L,8SN4\?FR;[KZ7U:UY16G_ 6_+
M*3";*749]Z4N-YQ XRP/H@3R\^C:@"QD6GQ:,DU&>?*O_&&D_S"_HST%GHS)
M4-//-?8_C[<B1G@I +1\.>\4F)$"85RA%C(-Z]:NTM$_,T0#HE_*%4G1'-]#
MJ\*M\D@W0+HQQ_=T4HX$N"Y$CDS;X9O+[3@XAT,]^F(EKG_IS6!TUJ2Q/%+_
MYPB24[)+:?O-G@'2!L5]9D02QVSD2]V-?\%!+9_:8]Q0/$4N9F2.KR2L=KI9
M\5WHL;^@]CU03OP=*D:OUUKDVK2+E7*&.O^!-/[/#)0W#?L#2]._>^>*1,F)
M67IY623W=8+[%[/Q6K<D';5!L^D85MRH3]ICSX(TM=K49>A(M&<.K&6I4]A^
M\=BCFP<A^WQP _K1#N<KG#&FLWE11H.P?E73)^BSH1_RZ6-N6X(Z#W_-Q_T[
M* 8).<%_!3M&_47+5'']W"4?.@6VFLX&VXIBMH=E*?^)$>YKY-PXX#HB7(,<
MS/T^+ZFXWBY?P6';= A.\W"Z T^1[JX\!>;KT!!LC3&NG2FUYG5Z]I%3ET$T
M)3#J-\SZZZZN7;2A\\V+%[7DZG=N0Y/<]O(0OXQR%F*U,;-XWJU$_7 R-CSK
M\K93]9@H1A>'EZ$0N"::'>MG='8J& Q"[[$B!WTNG&5'"@$A62BQTD:.C9ZV
MCCB1I,(V?YT8^RT\.J?E@7?:E;)HH8BZ0?BO%3AYN&V<G]57I3%>%;0Z:@B:
M;WNBQ5!.WLU@<?!^Q<C\^5YY.Y-0Z51>^\J.E%?_6L]H*^&&6TZ1J['0,&36
M'#+ ?0IP08Y),CP1TB#U6-,ZY*YS5=X//02.^=79])3:C[$W'#7[%47VZY9;
M,4/<^:C7C3R2BVB@'T7N'L\1!>Y6L%=6#*AO"\)OC52U7V=&M^%#U7F7"HNZ
MKJH+NU?V8]=M#X46G(DMGJZV!(N5J&/G;2&5ZQYB& X]UA,2G&K.R)TMRB9*
M/Q:GZX$T;J)M<(-N3 69QH' &1JX>8G@1D<@!+05<@J@]\ST>;[SZJ?&/VX7
M:&<G4[B7\()_0\)E/1KS.7(?KM]G^](D:$DV<E63R*5+AM0Y)=%&3+VJO*;.
M*I>?OOL:0)5CAP\U(%GX0[4JMJCIV:Z,#E7"B/QO44E9MYL<(%M[$F8,1U%/
MESK-1GFQQ&('L5+!0CD7^A*A-\K:C;>>/,),93K/YM.D4IRDG=!.A.ZC%M?'
MPX]9]:9.@< /IX!:*@;W=YVW!_8KT)3&S('&6!L]ZI*9Z,=\BO**@KF4KN$S
ML)<$#U4C KX[O).PU*S2OZEY-+&+\.URT+%[*&+S=;V2_; Z5;G7B/./EOA7
MF?!6W@\N^U,E 4];NCGC7V10\0^TZ/^"RGY9 G6 _5(USA^,A%A.7T G-KB-
MR0<EYRHZ.BZL6WT,81N_5MA^,:97U;JCR"D#9Q=A_%DD.JLB7.OO/H]O/V*!
M(F%8Y;KXWS<EA_6-06BQ?7]D?K 7IUG&U,I14TP#S/D>F?SCE<M!Q&]97KOF
M]OQB\"T>"#Z=2S5U7:1;>=JBF<3ILL!5>\6BZ)]S"#W=)*,S<_]/+<Z;6_MO
M-STYZ1"0/]A%T!^LH&YP2;!S]L_KMW5&O7728&-5=$8V.-J&W/#;%C\!=<O;
M)E,R H.H11/6:ND3WI(_V/)P*8,76Y/)$J76K[+[728W+@@DZ*7]*:M?1<FT
M/_;+6K FY)="%:P7O!R0T\$8C;GD!]NMFN!7;WI*]+^IM>AJ>T4$???%#V8F
MWC*H".DP*%-DX;J(TUN9Z'\Z5 7[SNO.Q_^:'?\S'$XZZ9BH,&MD_\&OCKG.
M'[G*O-1S%!SNPX92#"SEO<.L>;5W2^HX,(X!+K@545#QUM\A.(LY2U)C_>'7
M 1N3U8Y_SHKSE?:@?XX7C_Z4N;7FBB%Z9S9"=<[HPQP#G\BKDI*26Y)2MXE)
M?7;>$KQO[;YS-#3]JQ'UI,O1B)54EOX<<SRZ,IA#1&(EG794_*=L=>5)^IWW
MSJV5:P/:;W%4]R>CW_L'ZUT2[/ OD@#[?[Q07Z/8G,HJ)9"'-MIZ5%(PV&=5
M9FOU/(0'GL,T=]>#\D$_4G&#>9:5'"S:JES77YK%7;XC5G+K_M/-J/?//L@M
MPTM=AO(?ZT**5:>6:FLJ'X?%/D-ZA:YU06*A:3Q_0MQK3#JERRH$WIP"VSPX
MDS^\#5FNY(7^X;5%+[<S0MC,2"NJYY/ZK97#C?>Z4 ,5 PF\)#CUO3:7Z,44
M%L>P:LO9[]<[OM [^%=;[J?^O/2!(N?=CT8&1D+-K&XFYGY@*U=Z_XUJ)E:-
M N39'U;^*]SD@=43PAXQE2P/J"GG!1=I>IJ-.X*]LA"3M^YDQ'NT'Y=<>6MW
M1SO<A'2'4'S)V9WU%_W(&??IFR(+FT.= @5[EEXK 5MA%U14CTL,MXX;@@Y=
M]^QC+Z4TGB0=,WK>2(:^_*?J%E^<^FQ?Y Y+NSQX^E=-_$7]6+J] T8&UMU@
M%+!Y2Y3;B0_E"87>+LEA3F-JB4"@,+^%875U_UX\]$F2,E78A= GE3U='XA
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M?U]C<LRR<!,G(>*(&='FGSD%0GT84(.+GVQFQU'"0Q?I7!Q+VI*EFEB;/B!
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MS]WFQ]K;FK7VKW]_:Z^-^XY;!B[I:&IK @0$!, +_ ^ 6R$\U AT=@  /3U
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MJ?OC<OM?O[F)Z9@WD$P%V+9)QP/S[QOPR!=CBH0\JR7]---RT\/#/X:6V.E
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M]M-UD7?)1 G9>8Y$*B3^Z?OM.^?+Q36Y"5D)[-_&9[?@C'<K'P\V#%?(9IJ
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MA;W>JW9G6D"GW-+L2_<7!H; IUIN.IBZ3)#P$2"LF*A]>*R1+L\#B0C2\GS
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M:]<=F)*9'YUCHTY?1JM4C-N7)2X>9JE:U&NX^IV0?2VQ]%MQ+:$YS>'@%JS
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M5G/A_Y\(SE#%E(8C<\JR/2%"Y_C\TR)9-R7(_*D%:U*O+ND%XGB:W$N-ST<
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M'/U->GS.3:3,S6>>RP5N1RG/@P%1'A3$;?M)L]H::10C+XLUGSF3L-M)L%=
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MNI@?O?3J!R'DT@T!8(RTRGTF/2NQ(T#_XA%@BGX]!^,Q[GY$>P,QGWH104Q
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M5%P4?DU>:5+NO;_9C+=S]9QOIC3^3B0K%'3/'$226J*%9$A-)6%U.0[-IS_
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M3I)N*GO9WP0 34U $   *H"<Y!Q "E[1 0#)Y3![@!R\)@'_-TQ_O/\OP X
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M!$! BT!!\M/G+]!(0DI&3G& DNH@]2&P0/EA@)2$C(R4G(R"@APTX23^X/<
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MF,S]Y*JPWD^+'TH:SFD8-G_1HVJ:NG%F5G-<[%QIVT245=15RD=$X-NPJ;_
M$UA%P20>>C6.W,$3SKX<Z<+T.K1UR0AD\VI$H.\($> :^&(.B\]0&1>R&RI=
MG6:WXL@CV?P!1?33^/$.TO]Z-_LF-@S66RL\N??6UBCS?6F9YKJTKB\%615O
M(&5^%JV@T-<B)TSQ8.:U! )#YQ'-T'?LJIBM>'5#G\<Q6;:]Z3ZIFVOWB #[
MYEIX,F1(+N3U0O5PMGNXHM4;P/JAP -5 ?LN,EGY";+^'\6W]M-D@"2BC7L
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MM Z2UL;4B(8H'JE%AS5%"W[X*&X9ZE95G5!VAX>T%9JUS1VHB/XF.,]*!-)
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MN3,1NWO$#TH$@M[\]))R4R\>PKUQ>B(P44Q/X*^^?/*_I?[M2WU%#M]O3(6
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M@Q6S:CDW:ZF^\RA#VZ?G?_!G*V9Q9JB]1LYS>Q <GX_M"*$9N4P$%AB;2P-
M^IC\$WTLQ.K5#[,$2>9+CM,8XD-[C*+6(.GK-A]>)"1;^@BBT^^8N/W3_E#"
M]XF"ULFL5UXZI^L%/#G.R$A)@K<GG62>TD5;B9*_-H((W$)0B&3/B&06RK-A
M\$\O<E(1,#T[K4LKIBS1(N6PZ'%.Z"1=>8VOPQ&-#+68L7#N*:-P K]P(DS)
MH"]AJ7%BK9'^X,++1<_4*V=:GS%7P4<*4@Y^<*TBW):&-D9Q!KIET2N75L?L
MMAQZ<UTY9HHOD?S50^=CUH[7@?RY!RK*FC"A)639:G' B4;?;"7H)'LYOX3-
M29+B[@RS6'U'15.WM?3476A#AE"/G^WDO-3C S/:#F?J*<,B:G)B.A2@# _.
M9]&F_B-OS _"8 8U7Z5N7'T3,SQ,+GJZYZ6^,H>Z0%;^TBPB)N#$@+PK6JMU
M,BE$+++?)D($D&'LF%"<W;IV@4[!TYWK!MG+/N0M*/G0+7HG>_L"6$,8Q#Z(
MZ9J3.]T[P@V# B]/\U(T-*QPJ^C,%6%1G@WNC2FQNB_3?-J]P=U18%=+H+U$
MP'8M3$XKL&(W*4F4DW=48:NS/4>,/>F<(06[&[M5L7?)&6SPGJJY"?9)3^_D
M0J@"C\8#2H\HA[?O6KYXQ++3W,BHO7&5LD_20 BU-T47AV9IC,A?H']MW3!J
M?,YF9;Q[-WBH!N]"J?^/;5=X(5<.3A$!=J_+K5>J4"_\DR\S%HS>8O!;Y:5=
M;_F@PDS/OO$&E\O!)M **7M:H<A5]0E'D</_ O,L2:.J\;6$Z-CGB*!K"%\>
MZ)4C L%0N\>4+5%C$/1J\H%TT6L--C?'X2<=S[YQU%/,Y>F+!%;KF/P,>@/X
M[-)OEP\X//1_W0X->Y2R>(_ A?(],L^\#FF*#=T=K\]DJI]"4GS1DHP[.R_"
MM I7@:Y_T%X[,7]P(H9>P7]C4K797WKJ>D1+N]G-(=61TZ58[XB,/.TI>LI7
M7)QW_P5J1LZ27%'MGE[I$])QMJ*[>($_0RD\N._5!/6'3_+PR4Q&T[<5P27V
MN_?F#]H5K3*GDXS;R;8B+^_L3>G//D-;37]%-GXN)[-X.O3>Z@8DS":V(^[#
MC*,C==[<L2Y6J2X_?:P.M+[],4]3'5/_:@:DC*K'R"/B1CII^WO@\(7*8\OG
M/]H!E0.\V'-[&HL&<F7:F/^ON/.(:@+1PG ".D H,31#1P%Q0$"Z0"0@""+2
M%004E"+!T$*4&@EEI$O4#*@,&,H@BC11 FI(I"42$2D*$FH*+;0P0XG4YRS?
M3L^\<][BW]_-_]]_\9U[16J?2-:[.Q"+FY[7U4[\_O@UH[WFEB'+'XS 2L$D
MU@\:BA:;;QH7B/X1LE59=::RE,9)D&>1W";%3=F$]AK1R_GIQ=5= 7@;-'2T
MRML:4825C.BQ2'O/M?Y+%"R"B>8C8878#,EO-=[UE("@UTUA>P#)\K27)[LN
M6+X"CF ">,MI9(5M45R[9\%=AUMH<P5OC=;BJ7URFNKHC6AR6G1>D9?UEB$_
M@&W##SU2$9=N9IR3!KMN![Y??ETQL9@V>QI%EN7+L985X@KA$(Q?R^]V%2[#
M?L'Q3T#1!Q:_!3J3).)A FA_!QNQ&)Z]&*0:95<*.7#U@M4[0(PT8/-'PT $
M(.D,X"+JBLGF<1D^*RX=Q=K,O+2XL)HETHN8+7J6CW/4;E6581YG"P38V+KL
MWK9IGT??9# 'EH]Y:.=O)L?5Y2=I.27R1M8+<CK];!PCC>[Y=9CML,(@]&0"
MBTE^Y)-#PP)O[@'2WYSY'@S&PWJ#-'%8P8HQ:7TGIW;0S"]>-16X!#1N8?K+
MS*DH8\Q44C%8O6'2Z<A'1F/N&@"ZU4S>'_66P;/O@JXD6PFU=,(S=M7Y2MN/
MO%S[&B^"3*A:40EI8Q>5QZQEIBV/\N"I29!M\%!-<*K%<!T;T8_L%6LR+/IF
M%0C]FA2F>UP&]ZS.R"4##MV5Y>*Q;8<WO&1[T--SM0V=>J4(7_Z+O+-%,4>(
M1A-I$Y))FO,%&WL Z4:%' NH 2"_EWY^#4*E:(4(JJ?T1J&L%. -A'1=G=6Q
MP(ZAH^[:#<2"U]#Q _<7EPS.AWSQ(6=6)3CG!Y?.R3*NY4<4#,:\R&1E"8'*
M-[<VC*-_/*HKG[>B;I;Y^PX[3%WZ$'GX%)M_Z1D(*YC]W3-Z5'^IN =4\.3$
M;R^Z^VT7I8>B5 W.<:-&1)@'L-C<S93!H38*"!,X0%;U)4"YC&IS6Y1<Y4&O
M^3A\#$3LY:+ZXS,T4%2"JY#AEBF?9L?#91I'@N/N23E1R/<\M9^GU LYO6OC
M[ S@J7&::K5 .$)/=,Z'UO%1>:A5OQ5=RT4YK'_P];IDJ O2GP$^C.Q!;5@O
M%ZY%9OH#MDW9'R\T!CT.5W/'[]P@TJOQ>X!7[[$YHY#E0LZ-&B$F86&'A0S=
MMGY^^;K\5/>YJ_DE8CIJG CAUUJ^^6-=)U2O1)0(4T*6E>%9-[:6,Y(,<8OA
M^\1T!A>C_2!_D23 &XDA14%8X2<^29]\AC*2]"]R_22_,-JM[4U50B7$!B<A
M#TT(E&9%@6B3F9@SP :R%!46NW7V^F/#OC#.J[Y%'^^>*4&T@]P=:]J*B??[
M=>/5M7_-8/Z<+C3JG/UD/Q!A+.X^;>'K&&3@:%0)RK;H%9B88(0F8(88^=V>
M1.*LGW?%E:ILB_O(C^%P!"4C-J'MJ_A9EG2L<!/:I^&4P]S]>+>E=\ )&<ZX
M^HIF%AR!4]#+@&DU>/,C^MJ[U)-OBQ;%]V_B>S[O >;O(=E>;7K[XX28+<73
M#]1[N?/FI^J.33$V<$7YL\V"9JZ N5%7H1I''M+V+?_M'D!DX0%ZN0-MCQ25
M]C#/C;^=TN4NL-TBTA,MH?UHIVH/P"D(I:S+Y^P!;%TNS:120B\+6?&(&677
M$ZX],WOY*F\\L?%KU'E@VU(7(#&-=I8+1VBD454$2@=?R75.Y;=\-IU7AZ7G
MIN<6W61W<V):/]E8R93Q*RHQQ_FBS&2J1<OU^7-WJA?:$W*7DYAV6,GC%O=F
MX:(8WV?\H7<F/CU-%>3BF[KG.5=U 7-:8ASM!!5,T!7"?KXFSQTKTQ7.PBFH
MW_G3]N"")U[2Z:O_&^<$6POP]]4>6_?E:(Z\EEWI!3N9\U> <U:B/[K:7,?]
M1D('/?S\1T^'APL<+ B]I'4X[T_\.QECS)>5&?\OI. 5^#E^2%E/[\BWNSGY
M0ED:>#'1S:I#XKCH1!!@N982JI=1P$@A.HZ,_";^:M0&0877G5"_M1]%4<"
ML:R)!5P6%NR32)5=>7T14N!>%=MI_BNPP?#]?-M=\Z'+@5O&&#AQ0#65._C7
MTK3!$\>F-\&APF9J" NKD_JY;')\G=N;M_5]1M1FTN-Q*G78,E0#I8AZN@$#
M6JGH.JVPJ<I&O*)=4!.//H:,Y346#1TO&*5/J!&T(^E1SLX+ N@4;Q5I2UD7
MWLO3O,I,HQ'"D2U(!=-!-#XV&_9NUB4"/(!8JZN .=5<9RRW6]QQ9-XH8-R>
M&K7U[@X2UK\O]R"J%94*"!-;FTMC#JJ(66IAG =75_F$F\9$7&7]:(3\\25*
M!T2-2P-$1B3/:$)55>SCD.=OH=L2G&N.)7E,#-M$=^WTST)Q[<:5YU*ABS7L
MU'V03LG?;-W:GD(!'K,_3&!5+T-.=B0=_.)'BV5X]@1*C+]=5VK>1OD8N0IU
M$QJ"-J.Y9+7T4VD><5<1-A#\ 1U*));D >?);T:0[?FEDSKHR3T 3JIS5_SO
M0_V%6!.1@$LUY?K3!Y5,%"=#4B7,LU<CQ7<_)T'?],ELNX3&7GUF1R'EC>N9
MF+E4*7)"^E[DKIU$"*CD^D.WG2;U,M]<PR,CPR7PF1%3=W6_Z98=LWGB(D*O
M9S_.@+%:M#NQHC %-O)SRXILCE(G(YF"R+//^BK1[7IG(@_%(,<(N>^4[1I9
MWR :,!"RA]P^"-AZ<COK/PYT1[L(/DF\?83<5"(V)M3.<$DW>K@Z)M"F('KB
M&^14<]>:YG,5--[G_+]'=WY*P7Q\>V%(#@Q^LQQ9P&+US,6\F=GOXDI//!#_
M2^/1$O"=M7#-3L++IHZCRZ_F?-A.Q9G9 >#\>-GHP+L2>7#G,B))@3D6LIZQ
M,O8I<_MRS.&^8^K"X:7X?1+/01)5^A_,..LSE0.6&KS!!ZPQ ;;]4+CG=/_D
ME;3V0POTQ.,+2,Y'?X>5R(7%%9#%HHEG\T"ENHVAX)3?Z:*'',%R\,#3$K#]
M3AD,/NDO@3$E$E_VK^[ O?Z^&SJ/E/SSMO4.,RS:2ZXK;+LCMK9\/;'_GU<=
M*I'(6E^1\,B*XO*F9B<ZSXP*(C #F]FEXH_79@@2NTKS_E",Z_A)_N\]FTB3
M\)HS6DT 98@7_ZK_Q[QXLR/DPCRC=/5LZ8OLTZ"GY4"K6<#"4:#;?UT'_ FP
M\'N_@@USDW[A,ROY+*I!WQ@T0BUF*_WBJ7*[6P95%%=:/[FJ6@_*ASNL?$JO
M-7**D5S_:[OKL"),UW*^=,&>$R^D>L]*C.=UYP9..2Y"*="FR/Q$1^\+Y6!2
M<1\M .Z6>L*X+:F_J]*T]0,^Z;VNYY)4 #3W4>S5Y#T \9H+G52V//FI4R]]
M5S5Q GCI8[R@HDYG+CWWPW!P%@[N\C"V1@D^.=%1EU4XUKC<J7,VT4(!E:R1
M+W^Y4@Y")6A)I=Q'_5.6E'%;1A7T;3FB*9#41"IJ)2Q%M-*(WPU7D_#E0O_J
MAY,*9XD#-][+CO</:F1#'Y0]A0KN >H\G_XL@BE@-IG.'9M\G74D_;36ROO2
M_!2N, SB=RN6)\5LG"Z)X/ 8:OJC?>WH8RC\+JM></:X=A^B!&1NF?4D+M$)
MY]*[H+.@H[95WPJ]\.D9S6,IWCCA?_IM\\=5O8.VZB<Y5I#_J+O8?NO: K33
M@!.DF+: /)4-"'.SW_>K]-$7-/G;MM;))5$ I=OF_Z<Q?T*">\/_ 5!+ P04
M    " #CA&9:=0U;S_%I" #D> D $@   &EM9S(V-S$X.3@S-%\Y+FIP9^R[
M=U23W9<V?",H"@@V%)"F@#2Q(+U%5$! 0'HG*B "TGN-@B@BO2HM2 L]TGLB
M12(@O41Z"2V$%FJ E"_/S*QW?L]OO?/-]\W,'^^[EEGK9*WD/N<^][7/OJZ]
M]SD)Y3=E%CBGH:JN"M"<H*'1H-$  ,H$\!"@^6^^_KK)?_<>-)3OP/G3M/.G
M36AIK@,GSM/0GJ>AM ,\ $!S\E\[ /_VHCE!2W?R%/WI,PR,U [5YX 3-+2T
M)^AH3YZDHZ->#:)>!^C.G[QP[:[RJ8NZS^FONUT2?QOW]33?@_(65KV!+?Y[
M+]Q#SC!<OL+&SB%P0U!(6$1"4DI:1E;NX2,55;7'ZAKZ!H9&QB:F9M8VMB_M
M7MD[>'AZ>?OX^OF'O@M[_R'\8T1\0F)2<LKG+ZG9.;EY^;""PJ**RJKJFMJZ
M^H;6MO8?':B?G5V#0\,CH^C?8^-S\YB%Q:7E%>PJ?GMG=V__@'!X]!<N&H#V
M?T'_W^(Z3\5U@HZ.EH[^+UPT)WS^ZG">[N2UNZ<N*.O2/W>[>%W\[>E+#^*^
MEK><X;NGM\7ZPGV X3*_Q)P _B]H_X+L_QNPD/\2LO\%[-]QC0-,M#34Q:,]
M#X  ,EDH.P+XT_ZT_ZCA*4 $!>!2NAIXI3SB&'5$JHGB:DVN-9TZUQ.B>JF1
MR2;24V$?!Q;5I  GQ4A?YN(PD"MFBR9O/]+\Y&)655,,0DD>NE&O[=4CM.3G
MFIM+%T>*M/C5>6N_S$]R8^Q[!^^UH()%\TB1%&#V"^0T^7;@J:W-J"9UL=V&
MLF*&NW'YUO%\4;\7ZSMGT/A=.%J<?&[NB?1IVW2==K:U#IYQDX@J/C7ZT^KZ
M2<(2\%]E0QH;!\=EP31IOJ&HSS/G/!!GYF[";Q22/KUKFU]]X<%1_6*UM>K:
MC5*NBWKQZF*CQ]"<F:V=VV,)Y/<XE^--"E"J1E3HWK>A %\;)LC'% !G_)8"
MM&4&GX($;Y(I  \^A\RYLW7O^ !R0*  46XDX]:9(S:[&8)(2DH*#+/D$Q2
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M^)>(]J4Y3@6_5(N,X&#8QNW_W&.CJ.OK1[B2\*$11?)6@IKI_*-V2([\"_%
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M1#1CIP;*<5^\[L#J!FPXQNZ[>4&M1#5$H;J!11O9-?5^3M[K%9/AO#@+9<$
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MIG>1DJSN!JJPMTF2(G%1<)Y8#HEFR;@87@ENA4<64%3ZF@):Q^%N&"=8VGH
M'D'X6?NB"\/L#/O8YHU+7A'1QIAO0W+O'N9^JE,>"EO]O-4CDG"W2:X=*;:^
M((6C:<0]1#"$1XL!36W:39_PER4VV]DDS1V&L^1+P2=J9:,;3'GK>+7)K-(*
M)5<P#V .=K_3M)!9A6:AOR_P82^@SX0KB"0U9KC5MXW:9\6**W>J&]&%(,\0
M\JJ_Y[G=,T:=UL_4B%:%GU!'"EW02B%@VDAH_3C3E[5/J3;Y).KMV:K=A$'D
M8)H;)/J&]X"SZ<_)7ZZ;WXE42DP?&GJ*'K'FEA"?8^,N3Q?!XP(3LO[/U2ZR
MO5Z\T*8[WD4UFN$;17MDQ>7;G,2DK2:'*"-;5EW5N"NF9 +;D[_U3/DZZN6E
M)NPZE32[U[:WE-R$:F??B."Y?M3^@=<GWM7>V5SS%NLQ#]M159B[BG EA%Y@
M8?4A_<OP>WCY\TR^G95\=AQ-TGG3.P.9-@=BOT".E-3@4*+0$9SZNJNV6G,]
MBNZW;>R?@6:VU$KA+MDSJ9L,'+9;.S+G)G&ERMNB*<)<U^M(C?YINC#G%X\
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MN>[_XH[&PH]6KQ@T^6=FP2\EPB1# @[@.T<'6T<#'4)\+CZ_F%=-1FUEGC0
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MD\CT1Z71?6%<![!/]7":3TM*66IQ+KE1=VI%H)W:1W\O34@^YV'5ZS DNM^
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ML+@T'&9VT"K0-"?*E'2;5O^>"<A$O)3SDH,<=6+ N]HE>!)<FWCG$Y_6V78
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M/^H)H96>L":6IC:8M HNSZM-W!4X-8=4Q\S9>%#9J*<[3Y9^,RH0_+E65[;
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M'%;>6KH"="6L(8;*N0B[]+&^,7?H*3F "YYB0\'1TR#?6E\QO!SX.N++C6@
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MU2IX2\'X!>_;5/%:'BQ%R7$?O/I"D4#745<F" KF1C=;UKJKNZ[\_B%Z34Z
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M;,1#5R_011;CT\?NMVO]GP)&5@%_:(UN))MUVI+0G=H]T-A<=YW!5B<3I4V
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M?^8H(7K^]W7^<ECFS0F[[9><+?]<N*EY?__^OE#[_+XI-\/=K$L _O!4';M
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MOGJ7/;[EPRH'4117@/Z7;KL7GY]QG#E_/AFGU;&,Y1A9_+_SXPV));5?D>B
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M?R=7@*,#"WI.F7*++#[]= GFA[%%'4,6HDD.:IL0!'OZD:S#HD.'>Y9URH:
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M+@H.I4T/C V.]5P'#$>&-C >$>:1Q[L@[F!07XX8RT-(0#J9X>)L.^Y]K3=
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M:'BI_!@X_6\Z69A$0'=S99-*A-XY62?RE8$&-O990YY'OJO3[;NE @*<J?O
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M11T"> 9EUG@85.^ZSMW:S6H9_&YM>8F0PAH'4FE"Y "GHUY;KQ?FW>/=C@_
M/<\_S!6&F[X4VN_-SAS+T9JRX&<:/QDY'EE#Z&6*WN.9"OM6K,VN$&!8,T)
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MG)8@7<:?\U\^%O(]T-?S*&RJ0V45JAGXK^ZQ)F:4UB\F)(6/9D K9]?3]2X
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MTW]XI^6,QWW1:R#N]Q/S2W1V01Y)JO7X[8U4_ZDN\ZT01;VI8[O/P"_!^\
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M2^^_G?I&2I>K4"4B5Z4'BOI*37M[SC8#A+J5Y0V-OL:0#J:8 _FS-C4&:>+
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M0FM_=ECV_N5*WBFY#T>?X+O+2]=4"-$H-R<3A1GXNTP.NE^L]WITL]-C=F(
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MT+>70ZK5+R>[N/JILB.#_?C?>.QQU;=8"]A!AKDXZPLA&)!!E8?7Y.*Q&2#
M')M5'"#>#+]U=<(X.IW(,[M\I%@'4+9L%8OOG?VCM8!A1)/<@.HT< ^NPE.V
M' ;];XGJHP,*TNY'*R*C05,Y+SRJ:$T$3.MQ0)MM[[[*O=)W H2^C/7J.K_E
M*9SV!%FB@GM5I3Y/>*Q9VTO#U/F0"7PM&BF)0O[GYZ/./TI">S5[UNSDIJ!/
M4Y?Y84N[%N;9:!E0N>Y,?7)'YBYW=;N!&NPJ$+S8#F8IY&!/=N#9[S8*YJDX
M.Z-G7(L,O]6A#-V6#)5)*3$?^Q3]N?P[U=\C<)#I+8(#-3U=+^VW\@$;;*?#
M[MG4WDR8D/':I D'GK*".0S46S7K<5PAL9M%J9HLYB?4RQLGL;]CI3L_>P"(
M5S\ 4(W1U_R_0<%K<1*LTS'/#Z.?I>QUC:G)#HHD_WM-U[L[68Y);2EYRMW9
M0FPO59YV?IE];I+=:L<PH)F[-;2_6;F^9G,5.#T-:NBX648RD,G0!89IU2ME
M;[:VAUO#;#9TY5_EI.Q \)T=3IRI^_US]T"6:]/I]C1=S=26+UFMZ(X5--W\
MSZ$J;1AH'TFCT8[E!V]8,@/'R9"YL@<>[@-@]VC45:426]L#4H7IK,&_%K!+
M;<66,8$?T7S?=^^^$S8M)A-OTIBMX)7VIG7@3V@JN1FS9Z.1?V; >:8\M;L\
M*"VG9,_@Z>U?JCQI+]?<--F^X.>(^$@/4T"-LC__7M6<!DBR +7\I>G"<Y,M
M8YC9":+#9G%$W(IYU,[?Y>]Z!"\+.07^(R9@)4<TCTD[1AUOA9Z;T?UMNCB%
MI>N>'"6N'Q 0*UYV43\ @-?6D.R\14<JY(M0"4/*%Y\K 8\SF$Y\.#IE-0Q0
M&Q&I=ZD[ Q5% O91X:QKG#=2(K1Q>U47SFHWAKE%U /*:L#A"3=OT_/L_,;.
MD;(MF2?8F/(<,I7@2J,AD=A:JG@)[5KN0VD<ZML_=X[;JA\'34G 65&6/OR&
M(D;:X5X1&?AV3#A#K+9S]\:#T4 V^[4YI-$SZJWFI/<1 (H3>3]B\7$X])V[
ML7.( -]Y\(MLL3Y)S841BM]Q!F_TGG?3G ."(WCB"]_,=018L8CW@ 7V=[2_
M. @VIOM)27&).!;?/2?/EM)R.E3EX.*W]G:JL&TU$\C0>7O//F.1K.J$GZ H
MT#'[Z0-=+FNU&L[.=S\_C+%>%$S)\OEREKT+ZPV0E9<)-P.(T]8R)OL76@/-
M@S-/A%=J#+JM>15RX 'DQ1D3@'[HA1\9:S)AI>W0GR(Z$9P@?176S\./5B.V
M R.#/_OI97^DEQ.1G/#(!:/5WH*H-E&IAO&[ZFJVC=7(N66/XK.P+3>-3C'%
MDE=+%PU();-3&8M9R(71B/_(3WYR^21MD+9YGCX1>3P^'OG@%UEZ#-38,"90
MN-?Q/I(YBCUM0+2I1;P;SS(''GTM,"CY /A>OT*R7]/0V,;W(H09A[KB^\O<
M(;J$TTQL6S_C<59#+&;;$)AD9#STZXCEXZ_)J"XB?#K&+J^=')7'7)MO?E@K
M4U#0%F?;E\+3$67#2"<7%2>HBO% >1S5_M61/0>CGY+]86.6;EK;5?N^UV5P
M_9."? <J"&-KD]$/>=(ZM)\77MA?] DN@L[/NBGNEDOHKLU L6I6OVE SR%Q
M7XC8W^MR?%W&V!E_CXJJ%7385I*1^:$20=PI3!X+3L+>^5UG^<6*^D6 JHO?
M5+JB6->M_R3B6X1UH3%5>];-\JC2#QK1:B*.7P(."^%ZJ5^SZEIWZV>DA\(-
MP65*2TV%[%4C]&]WRG57#F4&CFWC/%Z-#/$RM2F]!@OU;HG/489TT<A$3K7]
MAYVN*7U[^PS#-=*LT3HO/%M]>:B'"W@*Q^UD$8=^K\\AV=VS%YFI^M>X_'Z)
MJ**9+ :.OX/@H#Y#2^+WR0ATVD$M9_FM5(DB,LG& B9?X88*_Q5GR8%3;B*&
M90,UL^DT?[#9S3KQG8H7KL*-E$&E]=5'_HUQ!3^]8/DY?*E?VV>KIQ"!;<BE
M!-C;O0@3-:,P!Y>UT-!?:K 7@K$O%%AV3"AG<R]T:Q6_;(SC*,AQY VB[]2$
M34E7QV,E(75%1K[(U^_R0$CT,-,?8ZYO:,Q1/&'U^:U_\7O/YVD7\+>[!+'?
M79OIB((".[(=>R!D,&YE$:Y3\6TT#9=JJ?<!/#C+G]ZAD';R,"T[4ZG-6]=O
MYVH^^U?Z@N:D$RQ-0+C -RO"P(<)#3PFL;A"4W10P7,CU5\O^;CIDXG%%R0A
MZ-]M2Y,8NS5"Q"8/G(-ZEHTU%[-K^A/%TJE-Q2]DU^'5;)+T^ZWQ>=X7/DYZ
M;XR<>AH/?]$,RN8TV&Q/NV1+FQ=?[0R,MD@5#5?-FQG9%SBJQ V+&19/U4.B
M^-H65(S&S[=AZI5(A6^SYE0_<3-86+BE \6[+_^>5T-7&RN>[YH9]=97LJZ6
MX8?LK<!I<#$'IU[MJ"JU7=VI]-Y+,>>;MBK8?I!PCGEP-6#GS+9K_&EUN*6K
MFQ-PGC]B2U-IH2T'?GM971(1P?A,P&':83QI2MEX>>H"EF7V/+DN9G9WV9:*
MO[#\X](LCX%8P9*!4</,4?XM2>YV?O0:</5_LT?^/P5N##;A <",'_L V#>8
M[3P+];LWD%W-? "<^-[_EY=_XM'_RZE9UOGSOR,FG_'[_FS'!X B!W0CY9X0
M^@#@R$%#;Z@/_V=K[?R(Y &PGH)>N<'I>0#LN,GF (T> ,F7/68W=.C@LVC\
M\QPY"KUUCK/_O3WV_S5P3IH.4AX K"P#.1<$T[)G8,2&V2VI);2?Y.;I4O V
M CJCOL!QKZ@0)[M/6AJ\(P$=[L0R#YI%,UY0MCX )J%FI>O!)Z!FZ'VOB]FU
M,4FO3\Z]NNRCX+DFX0< W.[N+C^:YP1]R?3_AN!6 E) "<-0M18G(TM,&'N\
MPIOQ"- / ^<YO81\2+I"B :Q8-U[&:BF]L]#,<L+<_DFK+\-B/:H\1)]ARS@
M])(7(O@'@1A_E'/W>"0A2C:\@R289F_<;5+T5Z)(+T%H]:NO$<!TX.K9Q=86
M8PC&!WT1,[F*L>T/)I(-/:>,LTY13F8/<P]+SB(6DO+8"^59* B/^]P:ST&U
MW?OX0[N*N&YHWQBH&+4C$-AMI"3%>JC+^&('D<:M4<$]PPP]')K\@KS$.B_Y
M<DR,PF58 I3^DP6/$WH:,TA]@GC ;XM,WL?*$.(=RPL?ND^C.F9R/M7-?*O*
M,&J(/ESMZ;#+_GA[([\?!DXHK9"4C7Q+\ARIX%@P)P=B!C!HRRUN47,P>8_+
ME"PP-\03+*KIYWQ+V$/"]GO?%$65*9EO!^JF49<.?%'5SM+5 \-!*_Z=F=*Q
MTC0]0A<-TI7ERD>_=QB&^(=WC$Q@]9AQR@"&":!2X;+]%\/W7SDB3" ?N.^/
M*_!N<MW!#'<5&/>^X.?W7 %DV!W+EW'\ H= OC(';@A#C$<<U2S8USRV%HT7
M!/2";K-3:9\6)L'JHSD295R$"F1+9"-+#&__8MLQ\H,H_ '55ST(W8_:]P,=
M<B'_+&#Y*0#B Y@E-9I: EJ\Q@MG5*L6C0[ML[".*,4PP W><\XKDWO7@5B7
M,]FK$V1%>B92[=6QGI2*_E+?[K:WIYTR&RX75,]E/P:\2&%\:J^YU%<SRI9*
M0ELZH)'DHLB0>_D H-UQZ,B,HTHKJJA>:GS#G=>%%"46C!>,]3C25<([%C2C
MU%7V=!AB32U7+6R,6QZ!G[;L]4B^_]9B68V8!+5V=,)Q8F//QF65Y9FLXK_;
MGM"=%]'+!]J92]"_I[[MMTE+:[A*15->2GLC5,R.3ECB?:Q7ZF_+"9PZ$W;,
MZ&XMIV%JP."UK&!"0LC$\B<1%@94OJS@1RJ6^/=;T!+*\_Y_CY#+>C_7TYPB
M[R#G?3[.RK49VLVM;2%66;Z<_W!)Q^D5Z!-6)>C;CBDM([*-/^71_HEE8[39
M/]R@I(?5.UH^G? T+RL37U964_%GSS+A\^<+N&%(_OZ,3^S>[Q4G4<L# )+U
MTGLOI^HC[)H$<6NOGPA8Q^G:FR #7%LV*!A++5UZGR),@M<R\LKK)MN,AB\/
M'P"/KTF6 _'W[M\ZRX2=_X>?-46+U@QT3_WDOGK0[@$@=J_<$\U9K*BE_4+B
MO^NGGA0X(66#E/T'E<3:SJQT22%) ^Z'_NYFB2P#$![&QKNCT'/6-@:J(2[>
MD/ 2K5N%]0'QP<X:RNMNU .@GD6.%6]@M]<1BO_='1+X/ST@V%-4T^UK;P2Y
ML<^'9_[0J M%N#%U3U;N3S'&MINQ,(F+T<"$9],EA"@N[?P]!<J(L@_"CHL]
MTREQ%<I&\H*["X9'BR>GXBKI:8K3%TYQBC..5?H5IJ0F_^6E02=_I!Z&<2TX
M F9U*6F5:*A \YS9A/)+5[7BT[D=2/.@./2?<PS5 X#TEAP50\_1,[%$+Z;0
MK$4QP7/EAF?96WO\?H  >&KF&2"!S<K#[GV:AG%4[O$5!;RK6Z$0=5)68BU+
MJG=F M<,-OJ[.0S$.08'>GJN)5#X!-"P+,:4J[S@[3I\>F]!,W0V[O0\T-3
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M\BR=R6X]$C0R1P80#$\SI_;^-48L>T5RQV7_TJ5[@<]H_/1&> W1Y2CPQ$=
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M<-7.3,\P!MZ),1]/%S!+^D;7S11&28Z_!&!-HK:LG^&O:\$8ZD%83?BRE-[
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M0JM4&*@BJ-+)\E:OI,_,3/ZS=IQD8E]=SQCQ"?+G#](O#_0LTBI)F^(V0!Z
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M.@? RAC'6_R)':I18&E'1Q?/T-W@_Y[;_15YYN@-_D+>/FD U8H<IEH,JY@
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M<_A&.[1LQMX54'IN&@UZ'O!YI8,O =89Y6@.6+];3N!87%9J7F->_VBE9GY
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M>I/A["_*]+K7_H=!SOB_-[4+-?A?>^-AYSDN 7T\/2U'9)&7@-'54 6_FDO
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M!(B!R0PY,/!T-\_Y_8M<@1G/M0,YU6J$H)Q_,%PF=>X)L^3HO@OZ.&5$&!W
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MO5_6&@]WG'-?#SSXBDH[Y'],O^?(SHY:0;UHL'\3.T'1_GB'J?<VN<&PW"5
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MHY_*K$X1#6LB$(T=$EC(QR6$4RDQ;:?9Z7TN8*71:4@<+=2YLU&>#<D//^0
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M9;^FZ+1;W3*+NLBK_[*/[]'!+5<2=,+GR7#G,_.;]4I=;MM6.3\M!-7E)6B
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M$VC$/F+DIWW-7@F'4_3(@RAG;V+'#IDZ/H"1!9GL6[[*CL%@T@(+@M?S=/@
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MN^FI2G0YQ&O0@@]H^>/GN'#MHND'FO4E.40;2I9":I+Z!!!KX$&1/JY/US
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M VU*J-*)UCM<*^KYUXL[C%V'H)1:?9CR'!\@Z:,+B:\H\C6Q:TP*4DG._:D
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M3\243IS!+XD7CK&P'?5NR]GYKLDJKYO^(J>5S%^"[,C38:\CTK<7"GR>2P,
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MV5^2PX%H\%D=)+B4J\!-4M&>S6#F@O*Y=5W\W4V0XYFD<26Q0W#67 ?O7,E
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M>8$CYI&Q$6=\&^&\;_'7:@M\9&H*MBM2^C;MG@7_XD2U*BF8[+5M=RR(NG:
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MRV-(H7_*9?#&AG7Z52M-HR6CD 3\ )P)5RLNA(@<PO_M:GCF(9JA.SL@F>O
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MVT3472^@L'Z+;B901Q[4M8E>&COVAO %=N-54!-Q]'DG-J0H0P6S&#:ZCY<
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MJEU&/Q'IQ@2K9Q4.C/Z2SFY<0N31'1?*?X]OGA+(1P_S.%P ;OY+<EA"N<T
M1[.PQE'DW'OYNIFO9W3H%U3 \!SUU>:=MA;A833U 7*ZXURS,KA(7%S/\:]8
MXG/G>C4$(>F[C/VU0%BG7SZE8)3)3G^U752G1].]K=P0_FT9=NZW+Y>YV*Q8
MXIL@K1F0>++@/  +[;SZ3SG8QV"/U61YGD?6!B1D<K1<A!DQSQ1N4NT?V<""
M9,+N@IY?VG;28%V7YQC4;>&I+-;)UV0V.FQ02JM'!U8[B4R>7:/0X'/$:1V7
MIM#W3C7H]#DKXRL9OS$8A'J/\JUWQT)&7U.2_G!0.8IU^Z\CE*Z:/#+3'L8
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M''RN4>=$64'12ZEH 2M:HD[&:XZ],!O OP"-CRIJF<%GYN*+M_:]L"PQW6?
MEH=Q>66D>#>C?($[N7XBCWJVTF0KADY$3=:5)']F&":(:K(J/.<.T<V.?5U
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MX_?^D^D&>6%1+ITO0:'D2!]UX7P==BRT&PX[D,^RCU.6+VB:L*HZ@KK,U4B
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M-W]):U1.5"+?XKXA\\-',_\,3>T[^$]1/-\_>Y^^_[X O%WQ#R ,2+FLTOB
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MMG3@PZEB<7$1+Y'ZBMI@3'?ZU<$%NXEM#E3//T=W=?=BT\]+G&,:-O''-85
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MN;!FCS%/?.@6UR.-)."1@W<D!6X3F:*JXD4&]6R^D*[QTZ7H%[W3^TMU6X"
M*8I(KGA1G>LHC;<&&IH;2@U,4#T<[&LN^!-XEAW478>,FH.R4+HYB9AD5;IY
MW)%;F6W*D]V#YT%:U++V>Q7#=%]^T5T/& ^8OB0&K5\=]:M$%+$L>GBIXH:Y
M1H5SJ42R6KG6H_Y'!NL0:)TA&F'4S6\%OWN0JZ?WM*40@NM^,]N$LUI>:GR5
M#YMU?TS0VV:BXYW07O:-=4>>0H_-"C$$B1YPOL_LK].]2FWOL7'QEZ4UIWJ[
MYR$$(VW[H9JNKVXC65TP; <4-G'LJB. :'_XTG >;48:0DD6P^5W%3[GD_P:
MLO0LWXY'03&EMMXYTS=&/13S'\,M<7J8OS/<A;Y='JP'_CS[;X%^> NYQ?$O
MOM0,WQE+*TG(/TTC*WER>@UKH1052GU,AB;NN/#RF3S]@Q+DKTI[ZP#_G<.6
MUV<--UYX'JUU;OU!CCA;X634$KT8/S64)E-W8EUI!\%6'</0:>.,O=:+#7 ?
M<*\31^[OC%S&@S.EM)6+MNVZ$,F1 J6VFAYUMN)@I##+KF_'J".U(VW7"3ZH
M+O'Z&;8HN=9K<-%FUT0'?C"E;7'7+\=36DT6L6>7.61B-6*^AQ+1I! >4Y;+
MBA=F*_-Y<XZ'>Q^-6B2?!YQ[2^5GHS.W,GM$@]W@6_"3G:B,[%/).(L\'L$?
MN,V!X_&\8N^Y1?_?*;QT:36^H0<9WBI7(2G1//-[[;6))5SZ'-;WU/7J^*/:
MV%Z!Z7V5B?*[R&"3)9LHR-J([@'F 5O<M[M50 !M'!O;-JSNUF6&+1Y9L0/A
M\Z%#>!0V?&ZI$+S-Z7C9]6-XPOYR;]=XX$U8;>A<__"XE;M,_(M-/0BOQ\MJ
M%<T5GR@)QQT4%GL>X&][)O!(*,JUQ,<@*.3Z')[QM ?OA3HP/'O0/5ES7^LQ
MQ.GI^Z\DI)FL2GRNE3 97-+^'JK0+V&ND)@AYRK"?P>$ .#6XN:CY0^#>82F
MLW03+VQ:Z;_DZ*7U5]?YQO!"=RQ.C^AW6+-JN[+[0(*D?%P%KG'II:_#+>[)
MBB'(3<S[9PH52=&%0 F+G+:L//'%\).0N:/FAKX_U9P@AR*SY?Q@-QOM@\O(
MC QX1FS#DS?Y06.GWH;/3(SXEE??D:N>[QRDEW=)]JX"VK'EX.8#>M_;]1;V
M2AOTY+P?V EAU6OWU%E#6U[B>+ZB:41-6U-$*1A!8I.?Q3[S';B0TH8'(M14
M+'_LL%SEECA[2SI*=THA[J58<H+=;SG1*F.R!MV^S$!3^XRK5;4XCNM6GIO&
MWQ,QK<K?3%T8_>(1Y*5^[-L]!]Z\6ZF9M9(DVVEKWK4YK;.)_'-9-."'3X^8
MT[^[J?M9SJM>"L 5-U&N<1.T11_)/R?N4Q=$E=06<\#5].G= />EH'-YU$V4
MRLU^X-].'*D%Y<YLV3QP&^*W]#^Y[Y,3Q) &V(2@^D!-PU!Q5>=JG7^ML8!G
MI0NWG'_:4!"L  =NOO1FR=DU-<YI,X,RN_*XP=]VNY9XJ;%/?"C-SN6'V]G6
M976U"[_NS+KTGOUT>89S.)>?BQ9P?V(;,]!@X873@WI3"!8$"O/T+UO""<IX
MV?5_@ 6'GPT.=VOGB+H+MWYJG[PT)/-5;E'U.Q@,)C[ PS%>'OWABLFJ0M#&
MKU\_3VTM2\QIO;'=]*4%."^E$V]\!C(H8OH&\3%EW6W!GH>=K=X2]U],:5%:
M<?%H!^Q-@RT<YKTA7O&_9<$OS'Z80^@8DA*T-)RP!PZ0_#W)K7 US['=+28(
MI96M7%!I5^EKI&B>2EJ1?&[*HNA.>6$=@0Q+[,"(#A.<,33\?W8"&M4_:>26
M+6A3NP;+?I3^ ^D*&XL*:J;O-;OSS"[EG>,=-@#U.BUD^Q(YKD%'O#\?ZMQO
MS1HGSK4L_LW*_!TI]O9Q5 "RQ<A0/1[>W-F=HH1)^\%?[;CAR%!T4F0?CB3S
ML2QBM_ KT:%+!&_JTW!(&\=73.>)Y#0U;;6YB)_UC-3_N%D6>*07X)=:^0C4
M 2I=]/$0;[IN=OE>I:N=+ 0N:L?X[BWS#A7=::?(^9YF_.B_)KB$4CTN8W.Q
M3B+?ZZ=B@& 4Q6@%$"- +EP>2KA"RF,T4ASH5*F<^&?DY>S<7Z6*NC@^;V#*
M,28+R'R,D<<,^0^8F;TUK;3V#]Z,]9]>\6JJRP35N=9FGK48M#$%N"M8=#2W
MBXKNP9Y!KNP\C:KP3N.[ARJ7UEI9OGU@3 7"<"7FZFS.H'P']W9DL89!__4W
MNC4^ >$9QU/5?X#W.T.A^HBY]M74!Y753\4Q\>R)J-A7@'I/1]<,HRW1#9]%
MJO.61*H E .IIM!9;ZL5[ZB.%WBB1<EDZ9+Z=,PGMCAM3+KI^(K2/X<C7?Y!
M4\+=WFKB?^@A<4"HT](QHM-?'*L&/2B!]D05PB*ZKHA):\J6Y\^E;#C9:RW(
M?J8PNW"&JMYA^PM$['HT?W*&W+K7I_' A8K/VZQRE\Z389C]?X8;NJY#<M!C
M#EJ3A"=HT86:W[TN-JZN)G&_.$';TQ _?/Z%PP>(Q%Q@%-=-K()_?8*.L;]O
M*0E"22TB?)LKW7J>W8BC/GOO:<W*RQ=!G U@E(1YF*(K?#D'!@TP-Y4N.Q L
M<,K,$^G:GRL2#3R^Y'' O;"95"5'O[W_9U]LH$6".H/T+5L'3XB7@X-](06,
M!_</D! 9@.E8836>9E&)8 G-#^._Y4(I9;4!B"YL'!+5Z)=V[Y;$/5_,2#7!
MP%,#AHYCR<Z&C14COP7N_,'DM[U"9WRPZ!;O;&YL^-+YR/4^A2\#.-KTQ^7[
MO]JK-XT(-?4OF[-2LX_Z<CS5/ UY*<:LX7IY\9L*)<.&!AUC]B.B\-,95%JH
MN66V[2OEC$]/E:M?5HY6V=D7*A=9A/*\E9.DD\@*N=O>VM2L<U)F=[3%#T:E
MZY(<$T)AE+B+]&@Q>WOE4(O9TL;8=>&14K340&0K%S7M2G<25]Y T2*O$=8V
M_'GP)_F!J_C))5LO"R'%ANIM$C#O:,6&4T<CKK'?GG7ZM/ISCK?W6:CSI]J4
MQ/OEQKY/V'\)=_NEK$/SW@#9C0<F)-.LT&4FIHGWE;0-6<[S+&TK W-77GK#
M13K_G"_V+4^E(FW\UR8VR[K?#!Y6Y!_%LO9' Z^Y+*T[^47?!QLK?V%U^^E)
M_V1GQRJ&(L:EA^3M16R$?NR?U/<AO#G$BC;'F]:]]'D,.*"(_.:;4]8@*Y%C
MKGBN;#+W6-?V"6>31^S(/!\S%ZU*$,%C1S(QADU5:7U,T0![MGFULM+^.!$U
MS^+\CDZP<$%8&')6^@_0A WS4:!B^'"NE&#=.+!>\2(+JC6=)S13@\;<VV\+
MGG=[5>8 :8BM--"^MZLD.OI%^$V>Q5'W/T#>I'77.?0;R*M\\6GYT(HYX]-;
M=P D61F/U1"VEC4$F9Z(^4/J)+%O?@49FI<\HB/R:_1N''-%GLT!);;+0W6M
MCH:<7(Z.Q)>$-MA+O$V90I'C_D';!KOGV64;P@$Y3[L<V24W;:@'&FZI"E_<
M:2HJ,D=B:WRP;W+R#2GDN_>BKVQ@O\[R'WYO4?7]W\<IK4<+X]&C*,1[51V,
MZ"6_;J":<D2]D(MY2!K([#*= BC,M<TMJF<&M:Y5ED-OFM:@# LLC@LV2NYU
MV>B.=(5;N<O_8"XMUDY0FJM6;'*;3BW8(&2_<%UW(+!88NQST*-KU-$3<PU'
M/9US K%O2SR;WP2E)1O'O)BWW-4@,!VMB\-^PMZMLD_S&3?L<;CD$$J\Z8X$
MZ"8 $!!!+2*:+)+]C\TY\:85+LFR&_O?"5>JU9>34?Z1Q#)]^$O04R-$@!=9
MM"?P9.K5GT [2>T6I;CG#2T-']Z#RSJ=Y($''T7/QE4J:7E0W3SK([(%?O3?
M&U7162$9<WZ4LN5U3>V6P2=&Q80;E(MR@=V0K1U:^T&!B.,N,DR2%MDB!J&[
MNRP*TMK-+LR,D&L)SY\QT8I6C]&\<\_D\1W-@(>)JV'ZI R# H=. +L/8UE%
MS]^4PY)[O"0SQ+$AJ,-B\6IE^^6GHYQ#;/5BGP',[.S+.LBSRSH)M"WYW0WV
MQ(@O2E$.Y-H&3WFYK1L,3,MHN,N47@I/!ZR@:N*X!Q;F2(1&U\N2A^;  F/8
M/E;;,Z&;>1V+:&WB8DBT.'X4QVN!S=IML8CF;8%8U0DF6NJ"=3<4^=['WNK=
M9AN_!1NF2X^A>X,M3"+P\]R:DP>5^N"O(7,OV6(73B@<?UZE=V+DSQ6*<99#
MJXJ3D4]@9?&3RW:7!S3(W-ZU $9:]"W!.$C;T6I'49S]K2F)3O**T*^#DX,!
M=7849D)#4W\Y!;F @A$8J+=6##C2'!TM$'=2<Y$L\N;S\K-&VV@!)HMXOZQ*
M988!,^]$]N/AJH!XP6:]Y;KMJ[ S6Y@82JSQ8?6[40^$:#_J^$KNH7&Q\ NN
MROY%)_>(M&$EX9JEYJY)_&P9P?X_'=V_O)6D-1<D6@EC'>E0M&3,-5VOCF5/
M/M01@&T ;RS1M+"8JGZT/HT(U1%3:'*+ZLG3!N;,ITK+3_[:U$7<%MV92.LA
M]XSTP5Q@FS_@;IJ)1Y'& [MZAUGO;I_N WF3Y/>48_:3*_":_187RCEY5]Y9
M]*$;KR_?F[1R%5SS:#RQU!RLQ#1PE=PIP-$ZI_0[X<QQ5K:-#/:EQ:82><HY
M\@\6O8B'IM;J+:H0^M'0&#&T\I?2AAH65K7?%:9]$[Q&=(9I8<;;&8UEUL9@
ML\JG%NX*\+F\MDL#S!$Y<7*5 ^E%"''=$FJ4L;6W6<RD6BSZ7&PNH&0+=H;D
MG,?LCUYKK;[<:[>H?56R:F5GQ69I)D[R3+CP+J.T"AFFE2NK(/_*J/_*/B>L
M+=(HF(?MZXA" //B;GQ:@LTWX#F0;:N=3A25^#5<7.Z(=L$M]Y B,_1[&G4-
M<.48)GA&\#O2E\)YW/F"C?;K_X*DF1S:_%P199&F["WM^^+"7$<8;AU1OG^8
M<U36XSP>J?1S:[Z3)B2MTHAEION'?69D9JK)15A0$/_AC.ED=,PK_ 21DK^=
M-_;K^*?O;=<R"1:1_L:21I6(YU?H;B5L>0Y*DLO#"W=BDKFZ;=75OL;%="^J
MYN#3Q?OS"<"M<;7H8/R7]36\5;?PC\FFS\_#A0LJ Y1CJSXE;FR7 \@AGR=X
M>BS?QI#(C9'TL2QJI\+8XXUU)#\V9+(XOONHM+^6&-T&^RW#PX[RID;-9J!F
MN>CHMWVK04Y[!F9#.G>WZSAD#?S[%C5";.RO5%3)[VPL2Z:%4LIE^1>(.'E,
M01].P3A2=N4Y%LIO]D:NS]7TAR"TV*0A([KN+QC."%$/-Z_/-JI4'/7^7YW9
M278*7-6W>B0.8IQX/T2SXG/43EF/6/LGX'*Y95S@GZ\%78FW'W,%7B$7I!<(
MCZ>$&)H")IQ)>QF(3K?C>KE_@"$!>\N64[D*R/"B]X>O9^45$S>>?+5QFA>,
M7W<\F:'>"%(374:-BZ*Y\FB2^Y$YJO8\<*4*,X2AO 5/N^UDH9+*RQ$+B[E1
M?0G(G(9H_ZN=?H;$ 565%VGLK[ _O,P2M$O>/K$;TKOP#S&R",T*)==KG/22
MZZ+=631+D<M]JCOZ[I:2,#+KO9UE(H$*Y7&77;[C9]"#M&:7"5MJIKUA@LJ5
M959O$*8L<PMA.+V1^W8S:S3+PR7VQ^*3BUWE#9XO=0YV;?B,<HSY;,V;9(99
M$J^ =[KD+= 71)U?H]SY3M%M*=4)?7,(PP:W=@NHA)M$C.N4A=&*W]0BY%3*
MO$2?+K$L+8?6YL%-331<J"0NRC0DQ"!<=J_H?0]MYT-U(9O=_+)]=:W:7YD/
M7?P:'M?=O6/$-A2*4+U ]T1$*M:%2E[SS*GHJXF36GSBOS2VR=3C8U]FB@'2
M%"ZH'@,1)V583*_U>*67,]JFR]Y+36C^;\<"A2KOD>L.0DUT1\T#W3.0<?OM
M.[R!,-)ZE<_J]G%A5==/8;#K90ALK'6-#_U[FC5IP*4)ZU]1^5"5LIH4*0\3
M!JU Z\Z#YWX3@W%9<;M^"BY) V((=E4%#H8RRD_FSMIISZ8J*4;$M<=#(H]@
M=B;G20>LF-9(.:W!-(+"AQ-2OA&&X$9:,ET2=B QRN-%OT-C45_,(LG/7.6B
ME-+4%ZV=J3(-80$RC)V?VA_+9A%429 DL WX>1M&8_$QR!G#.4R09NY<*O6W
MYJ<L<(P<3?_,Q0.!GUGV&WW@$<3+EKS$6_9=Q:_RI]^QPGSLT#74Y?8';:^I
M!L*R\NZXVBK%][OB.0(?XKA$#:W:V:RQ91D)K'28I]\]S,4Y]%$.,;\P0(T/
M&K.[0-4\SN1>BWY_<ZM%X^Q7U@QZV)S7\-@6A?/#_;"6 ^E_ -(I//,Z6=)
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M!EJ\0CVJC$U<BKE3"R0IZ5CLK6^:ZQ>899<,T407:_9K%,OK.YFB4"[I-9<
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M_PE_>$D@[?&CB/EC;4R&L"9'$F+1CC?^'%@^.XJUNKVC768E.%8 -]?S]O<
MR7E/UP./MG$</D/?G8+I%1E]:5\6S[R:=;DW4WMU(:L0I/-"K97#D^4$^D&9
MJ_2DT,Y0OWLX*X<W\Y/;_IKR^P[_IU*82G\_J:!3+>Z(XHCOT9$30OIIHF;9
MO[WXC)Q$G5Z MC2\O:MK>,C&G\&=HC42-[<>P_LK;M+<,O" G_G!IHI9>BB1
MW>)P5],&3 L?:K-W-V\#, B\=@MP WZPV16X1P8?FEP"7D-UM. KT?]*'O_U
MTF+CPW[_(YN^:IM,IX_6,T634/ )]9S-#:)O01P/WU>#>P]OP7#S"AY"@^B8
M'LA(_.N+"NO5Y;>=Q<.1U4>"FD:Q[VO&F_.],>8SI>\#I%7N N4M-,ZS%#OB
M[C.\$0I7ZS4D6B1C]/%&Q[[IJ,( YSD65--^P^BKMSWF3M?O)VJLMV^H( (%
M9ODHM?D##BR%#8>[O#_L6=YJ)>%:D9P-?B3N^4M 1]*.A)+I!C&S%_5F^)6+
M;OZOI'3 &1;Q'+> ,_LSJN((H1,JO0103'SZ;"*6XJJ$' 7+:$\]Y$Y.C:O-
M(W>^R/]Y ^)A$I3ZSKRF"GL;R\*<38B&2O/5-,NJ//^>:0^Y'Q5;<NI7!V\'
MCL046X%*+*(92Q(L/8VDA(,>\S7GA&A<717"8-G)M AW'%NW)!YQODYH>K##
M15?Z_9KV[>IZ76:$;01M&8 _^V.W/XG\I&ZRA1/^TFAT?E1*MM.[35C4/VF.
M/RQEB+1JZ?/I@L,IB+VJ-<74X]9/>8(\*5)H-S$P:M O2+HKW7X<%GM ]&AZ
M52'%9R1=JBG@KVE@32PQ@*7E\MKY0/7]#A2S2>)]/]E<'OM^XN-V&J(%FF(S
M33+3/JSJQ_%FIAEMS!SB]5,H']%_+^Y.&*F[?LL<.?Z4\H,74*ZJKN#GM9VP
M\WTA.&H8B_XSL]HJG:V7K\[XZQGK78;G0U3U71:_@UCA5OL0%'&J_IVH8Y:.
M\%('\M=;AF^W_+C.UQ>=FE[>BR-N@O\;=C#$U"1-R"22'DI>B3^7=\QMP_^V
M PH)#NQMX!E35U+7YHN'SY<?"TIT(O4RD< N_L,G!.] 48<4VXOJ)-5X!5'T
M2Y8-?E4#_NM:-Q?TYU/99XJDO9K'$360$T>*W ZNPR_C$_1:QKT*'0Z!^BL&
M"AT #R!_KM77ML/CVL.Z\7TQMO>JJQ]LQOAJOIK)1$B_Z]COM4B)90#Y#C4'
M/9D\"\2?<0<B_Z@5]?T<<N?X<,^(#I/(^((:E/N;_=0('-=[+ZW =ZO6^RB]
MEW?6SN6XKWB18U^.A,_>R3S3DB1G !>$271?2+ 2U\=(,QTZ8_IK%=4_",V"
M.V9%C>L*?Q&-W+$.L_2*C5'.CJ8.SA4H/2_G#MWLY&^+HQF\HR.6*7,ND:MJ
M&\,[KCK#9]<+G=C#?WB[33TRO-5B+@IHMYO[.,WXP7Y"9]-T)Z'#<>%\ >$O
M8)O.=N_JJP]]B\^N2=XUSO;<7UTG.X:U"-%[_UV]_;,VE"1T,S:\G8=[J)"Z
M.8#FU(B")0)W^(8^+5BJ!MZ]YA2FRNM@?86'E:34>'C$PJ&T8*2B3+2H9<EX
MUU>CK=@_9<>G)Q@A&@U;20/VG8T;[FM/:?NM8_4[LI4MNYDEG2\(P"C;>S)>
MCV2E#JQ&,*,CDAY!!^53+J<9]W'#73Y%%@7M?_"WR/(J/4SN-FT/K1DFMV?K
MMC\CF'^WJ*@5%OXD/QOY2B/(8EF3UL/KX0?#\__!XVI:;XM-:Q?TTP]@?J8P
M";?]B/5EO5(QARPBS393MU\(X,ONF3X<E58SXC]:O15Q6\DTI(UKI;90Z)0A
MDGYA-S/-G<WBGGE,^X(C.QRI)Y."U!9UTD]-+EO&YV155X\>958[&2)564I4
M&]*<=>.4'=AZM=(5?Z?X?$*5:H%?$CQU)KG;=9U/7&I&7J5/Z*OQNHE3N<>&
MWI <=%/ZQ^QUR+E19PI(N.HH]C>=D&,UQMS3,BG2ZR936+P&-YI3_L)P-4AV
MW,6V5J.PSEA"](YIG=P0SSK^#$0]+N_\8(B>[RRE+[.A4_E7-$ACJEM5U7=Q
M?Q^]$B_9OGSF0RLQX#Y2$-WG#)Q'ZC; S:*U!:1!A_K.^/3-]>*],VC'W6)-
MEEV*42E00[[.2TX;,V;FMS;24IJWUG#&=PFX?I/<'>G@"R72L?%$D'R^RO':
M[/IP#U$='*&[N=E0B,H575.[\YXE8T#%6\9"W[^!_V1 PQQ;P(T+49-1(IWF
M1-7=AW1U9\B'5+CO*T4'Z(_*2D$#+1R_FV09D M,PI\21QY3-;I(>%"[Y 1;
MX/>#/[&=W\H2Z*OS >*,BK^.+H<+5B9("^A#@?KAD--!@DBR^8<A?JK$=W4!
M\0C!9N!3*]U8CKEJ)"LFLYCS0_KZB2/V$L"@J 8MH,2/;*DO@Y^\BGM1]93?
MC2I$;>%@10X]=0GX))\1!5[8*BUZE6$L+WW^?<]FCJ<D7Q56QQ%K+0-;QY>K
M\"I*SY<R8E;7#@<.DZ2$'OT!3)LPP#D9)'-!>:W(UC_]\S,%*QW2M>.OT7^\
MZ#A4<JH\(B)_*NZE;*\.^(+5X_EZR7(@_;C.A<<K^M+Y+SAVJYU.Y3K ]36H
MKO)W1Y#7]4LD%F$182&TH>'W%TU"AF'X&;W8S)C:AMD:S;7U@J'N0(4%"ZO'
M>%<Q3&]7'FHZ6:G&6U(N,5G\8[(ZAQT29;$#QEG"%E[_4KYAGS[!AN_M7Z0Q
M")6UGN<XOWG6Y5?;_4 !'7$)P/# 7;'I]T?_8O7%>*8ZEV_,/.5U,'9BG?=W
M7 >S!\TB>%IR<2UWT__!6V5WTE3949*I^J-!9G&GJ]#U-36E]?'Y#45@@E0'
MEC,2&5, %H1O-%2#W^5K<O6)J&+LQRRUE<;.EZMWE2\!<EV_$=145KG";B9=
MH!\VI@7 TM?MI=7\O*/!Y",5C5:[&4?=<:_> Q&9S8%-[+:!VHJPSZTK%\'H
MK:.P"VE*S$)\P@\K2O+L? ?7X]'ZP,8K;+RU5E=4PH.?JE3I=(N8+\Q%!<AY
M.;6P;CVIW2/FU"Q*/K5^SH/_[3[16C#W&7Q7:ILM:$C>"BWR \*SNB.;RR[Z
M*N*9CPOKEAHO:1?=>6:]$+5T!FFGX+7UL6J<VM9+6AH+.[^+V3&K_HW=/X@_
M"%#>S*V,)0O3%W*#_"+Y\1U8MG2[TC(17X)@D\#49+V^G^S3%@1R&]RV'4/@
M[YJC,8/(O_K<#7QDFJ8.A(9X*,!PSX_QU?AYQS,F'I+DE#.NO7+-O9>>),BK
M(U'QUL1&<XOW]K.;I'5P2Z"?\:GNO"R7+?P4NX%^]NO]8#PDY)/'-#:3:U!:
MR&:!M1LE[;,U2"MZ;GDR?0E0;+*=C[:@[IZ,U_WD8NKUKN(K+#4;>6!&*!IH
MK6:#"7D:T2XU.<Z?,^$0'&--8L0'KYI&#A1\K1%L+*8@RNRS/]9J_4W9=ME>
MY871Y^5,.0(=!7*:+ *](*883/[3QFX-E+ZVI>1N-*9X BDO_9T]M:3C;3'(
M25/R4XI>;,IPMP9F=(:[QS4.=>9T";AV=/XSHC&?#>,:R?5P0@MHNV.NR&01
MAP5<:]/S2U98Q!]HD&.(+I$[D#:"6"R&KF@+)?U G=<[*BTD;4'-/8V?$G56
MNL0XM7+X'WEH4XF,-HPP-XCI8I=.K65_/28NEKV+JQ]^>:6NSN,FCI\3-A D
M%-3.77,_KM5>):KJ8@C,J;W4&CZG#U50;VH1CF&G%G^Q9O_032;1_TI8-^P4
MI!S^C^V]2W?Z^ G,O,C,HR:.%1*<C&#(#IQ^K5Q=HBJXZ3G./5 /$D6'94,^
M]^S)#7+0=9D4VWH$0!JQ2W)Q3OX4LU9'1E58BFY-@MIP[K@T2]*W=8)QE&<6
MO:MJ4^@I: QJTUB#F#5(8Q?XK?[UZ2\J@-OSQ=L0JU;F5 <:30F01(Q[JGVF
MN]-D(:(8F?_F(O73@MZ=8I!N-C_+4Y"(ID1LVEC>1)QT"<0M+UJ ^7];5?_?
M 9?=O$Z$;--1GLV9O!I]8^] ^)82*RK/L,()1T<IRJ(I_5W)70(:*,,VWI_6
M<MT>(" K#CW1JMH4C%R5CX@>7EN^7F/T[A>%)IMA$X?$/V[QM31O-[-] 'FZ
M27BU8 7X9LTE9R5Y"<!O6LW2W5=%W!DVT8%8#NH0INP)E2T$SSG]PG#!Y*:<
M($U9RMVC[')TH+>_BO[@C:Q2@H"37?)26_]M.A?6BSH<MV[FRK9T5HPW@< Y
MML7PK*)>Q>*4XT+NQ+A2:X<*V^!1E Z<G-J*:%]!!L'6DPQ:%QS@'G**H\@I
M=9-Y*O9:_=4QGR&264>U6FF[#&;<OW@#HXG?FSJPU(^U<60O,7=!.7KM!8+S
MUD?[,9> ^_!0\]31O-];>1&6^4]DYIE")3_^9@B;J_93M+I9/Y:OX1C>[L8:
ML9F43)M]2A5FUDJNDM)[V55H]H^$W^!YZY=M%[O"&WRR]GSGQ:1J0$X81PB0
M"I%M[<^(S^PH,-O2^(T]Y13)A]9NH5Q=,R_2$V/E@GV!O:L-E369T,I:U,$^
M+CA\Y]6MBFY9458;WR&E-MR'2T"V<09ESKR2S!F+/VE$Y1149O>+]=6]A?7N
MG]Q5P'];"^;"*,D'5[V)'>R\TNU[C8-+U7W[XY#?8H"EZ[Q*G/R;3/XH7@A4
M>5,]6?WB$'^L(\>QOXZS5J7WM#$2E7;J%\\WM'E@,1+:5&\L0M#R@6:D3WT=
M=XN3^:O)-<S_?H[8W.SM?_(W ">[&4;6XTN6JVY66OR<EABEO_1PH6H(C:\8
MD%4_+[FX2HE>^J 3N]_(Q/,9']@A]LM-(5&>=$8L4"&#="9M?455B+X!VJ.2
MK8,X)P^-?VD7J..W+-HZG]Y:"0&E(*.]X$\^GBV*#ST.;5MAN^;>#=SG:8&L
M-]=>.Y5)&5@P_)%W@?;7,!O$3V4MK3@@XU>R>N>2P^*C_B8[33G.B+8BB@,-
MOU-T5/$?,CI;[DW8CI=U1+6,0T4IX^*-O&&Q#$ATJW/\"E'MXWXQ_LV8(MB&
M?K<%_W'EOS6U_MB[C!Q!K6:-Y'4LUUV*RL($6>63F&@UO<#"J:2.QR9OJ$2+
MZ4/$Z?,36#<$=_;Z]$D _XYRK?N_]+GM?-M97T&33/-5UR2G4W"%XZ[X@8K9
M\9I'NR'*U';-EB<21''JSI V=2XKK#$SWZZ8/J^M"BNXOFEFL;,<4#+@58FO
MG2NO/8(HO7R!9Y9)0$W-J;>QJ-L;B2#"0G7T+SR$/N[X=&K-46E7DCHR,NNZ
M#4E1<P]O7YF'75"W7'^YP!CN=S^D/'G]56M#@_HS0-ID"ET/OQS5^JI5JTJ"
MU(I]Q!9.N\$38/M^^ \B\M%'Y; SB, IK9=>/HUMT:2"AKR'D=-Z7RL*4Y/Y
M>CQ-VON[OMJ[;4Z11M>@\R#'/GPN!G.D=_,;Q:8XGRI!<L/#>IXKZ.\_UC/C
M;@ F@N,"#):GM,A6WY%5@&LH5T$ 2,WA['2Y9;AZQR7E\6/<0B#?EX\1]Y)6
MZE<6Y8961BH5G^\@_R,S/]FV&,8$2@SX2NHP/Q,"2(8,,GO^E0B\[O6[6Q_$
M3)Z4++;$%'<8.HAZ;SKTC;1JJXBPI2!EN9SK,MVC)W8T!?BAA$W*E%%"IJ=8
M>##KF?&>]-F))\/I5\NORGJ^7!>X/5[VDY6%[8[5)B'K8O0;L?*^N$'01HW"
M/NFA(Y#$N=[]3U:'A@4 HA>=\#X3,B/)S!A81\E MOUMWQ6DU0W(I*+XZ?,S
MN9U.U17L20[JEP7+JQQ[6P8=@/@0!S<NDS1@ESM(/]%7,O_W?9:!G&%:9A.J
MH:&1T+\]1Z-/S>:!8V&OLI0;W:R=+]\L60U46/4<^\@&?1PKWG,]R9R-FM/?
MCALA[VY1L)Q4]N87_2^CX?F*@.L ^Y6'5T;/CLH"'4G(4$]'FR(K<U-2<7V:
M[:"2;*(X;L4*3!0C3,W/E&E?/VQ&?IEF%J.?-GU0R<"J(C>HW$SO6Z?8"BSM
MW_AIN/ZZL;[$19, -B><G*$*-CP-.VWR@YR'XVLL=JMG<Q2V,-NU^I5C39!O
M<%7+3 0* EOBGOWFQ9]@!1OER?8L]SLZC*;HW^Y$OY<-2.9.=),_.E12&YWJ
M.- 2BU1ASLO2(Q>B1%8(E3IIXDG/%0_YE=S;5ZWL8*>24[,\C3,S'E-U_/%-
M[J,GGBO2!T"+JB>5$3:?.VUV:/O<G3J&5/<G#@,#&KD"*EAKQ::[[X92''W>
M85KG@G+]JY20W5P/SS.;K&>#OBOG,N\NQ2Q+/1J2X^6ZR4]>G\8KS:/,YY%A
MK@X9&CM<.;<D[MKI*P;27+-?*2+5Z@1!L**M]C/LFU]%O<S_/F,<6)9_NID=
M_^42<(#_ D<?NI*-/XF(2M-= EC?]'XHF&!IXK*A2@3,(-P3+/;1/]J7CI7\
M7.E>ROYR!!E9X9+&XN8$-<!YWE#(#)?G2ERX#D2>U04R][4_K>9$%M)\"=#?
MI\,-D8]PRC3CBR/2"G0#( 6V'U$VXE55X0IJ?5KVB4K!.<$*LW+CBNXV1.@[
M[*DRD:  -2EH673C>RY^)0,?-O:N^6+],(<<V5Y:"X& ;SM/N/78I=CJ"'\(
M"8'%M85>V1YEZ7<&U_*WZ;"O>V<8S]*,I1MX.1V:M)C]YZ$5\,FEMU=N'4<=
M?8I@ZQ<_9EY_D4/[9X/OO:I;]ICMPM/)2=5SHRR_]PE"XIVCG1V*>\A(-'4_
MW_U?]0[VA"#+IEH5X^!WZBX'N>%^ LT:]U8??N[[E!W[C3K438ER((=&"F/&
M0Z<K&ZGUE/7@FQ\_)@3-?CE0H;L8:L5DA#?![)[DS =2Z_ZLK4V@6S%O@N"H
M $7;\8$)/]$_1!0UB#P"Z5I.OT2GZ>/:J'F^';">PUG1_9+33YZ8IHN/(=D5
MQPOT)WN[I(?XA!24/.=J"/LG'-?-Q+'ZSE;#W7<2)$"#O4_&MZ%0RIJ?X7+A
M3G"^;+K!05_L"G!QGF.7D5/PCC???Y^_\$P!4G L*V:XSQ>#I<(U>U$TU-=!
ML/;5T?A+0,*;/2-\=Z.=FLQ(K%?/0[? G?5]-/]:RMNX?-3XR=GVU-ZQC*>J
M.RRC)2?ME!>SE=:TY></MB18IWD@CG&L!]LX.R/IW,\U0??(2Q,HZ0K$^\?>
MM%?LVA3MI@_:5I#-;CS=Y)GPV"FYZ1>QM^93$M[L'ZYP^ALU-4#3*PI[[WTK
M2=]3;?^4?_,Y5^288P)NY//" IN^UVHM%WRO6\STM71@H.RHMOSCU)R"C>7L
MLHTEC&'Z^9QAH.NXUYG,.2;X SB6L(_/#.[0-@+?FGDUPM-33EY*^]R#4XQU
M5%X\P;==4.UP;\*(8 S$++++*-(DP?.S?;/;(%8$XQ!IX:9&],=OJ\6KV.7>
MI$Q9I2_?H9T:X&DJE ;<0< P02J+QAU@]DN 8S!M@-@$*1+4U!#W\,F+I*IP
MV^:7UTELZQ\/!H)?D,N].G8[=/O=OM#>Z1(4U8=ANU$:?/9XJ>KQ+?2*'1%V
M2]21%GW?J S)%:1>(&J"F3W4G@/E^/A4*>_^ ]> LU>4O[D,TLU:1*-:F>(G
MF18O1M2'5O(8:%?DKOMY;[:A1\2N!@3%=,(KZVK$-9%V"E<9GC]<X4%05O=7
MP<G@JM9-!S)R82@\%\LEDN $/PMW #*HT]+M\_/"DC8' J7)>T1\J!>:R6R-
MG7,S.U-IH^_BC02/!GNC_9;AAW+)L2L'!V>MT7 /DS*L9.=8OU*J;XZ99('V
M"XXH?L_\ L*,TPG7H6F\6\$+VH:6I.2LIM1R##YOM.=<MFYG,*K0/&; :O>!
MD'9!)E&/A076VTOZ.)UD,8/#S87\G6+L/+_NTHZ;#)J\09ZYNCF3O44:E3M@
M(;9B&BBR%I37S&9!)5+'8IO7E'VR>:QW"R4;W;IIABA>Z)4$W%Q%4&WANA:Q
M7^PS>]??^OK[[N9FX'[!#<8FT2X/\7A M^3J1$MP!)Q?C$C+(D@4KZX\5OVQ
M</.4RT$61+ R!Y<W>^UM_X)]4&4W(-$^0X&,]%,R>%.&K0BKY3D7C@?<U)V<
M3,;ZHDG%SWT_4,1UF$J%\[-9!$$OO0;=+7+C%1U*)IWH#Q^/*,^EJ6KT'O8J
MWK(.\B6V_B/ICH'&G6YP?W4RP6(F)NL1L\,VYZ=DYBLTQ_'JRF%__;*#HBG!
MZN-B/)^<5Y>OAJ5?*^;_O@C+-=N%*8;&:T2[%1M)?P?Y*3%EQF@HB"UK67HV
M'ZRV/+BOSZ910,U67FI0XX]R2:E%'#G^PAYV#"NSPZ,YJ8C*H?:CZ&Q5 JKS
M]?>/EI\='=VKO1?%5]C8@!RYMA->N9-8XF \'L%)^;[04R[VN&]UQ]*\K$)!
MU#N5/C<UF^L'US=/=FZ68,?<R%QFSRB,RCUS+/1ZG_R#GKSGBOX1$@EQ?<9R
M)*1=)J54Z]^2= RX0_$-A)6_5U;:N?(U9SEZ!OWDCE!*JW/Q!VN.C_$W@D*;
M;RG"_5G8O59M*^JM;+1QF@:6SBP69CY.JRR!&Q[C$0ZJ^0E5!5'?I=\AI0J8
M4?Y"2IN-,U51.[7M"]_6,_!FT+YUF?\TA&7=;-5[>@6?<W#$P]<8U/QVH51=
MRH]J)APJ$[7NFO<9"6^]+6$];.-J;FXP'FY ?\Y8R.FJ"?,8<687^&H-^=KK
ML_L2*KSEPP$=]( ?4#UNKE<4)[N:C: 47SLHI6CS7C7_3()/8EFF7P)@B;#8
M4(TAZ2.#*M-A['.[9P?B8VNJSY"?D72%><G+;OCT<R-$NF+M<Q!R2Z@C]=M4
MCEPC[Q;&>';PQ-4!^I4\%]?D1:2WV<0,"W^T>RA#=[5/IGC1[V-\\ZEQ.?P?
M1/Q?E)UG4-/1U^>CH"@B"(* -!60)DUZC8TN(""]2P=ITD(+TJ5+5Z2HE- C
M2.@0>N@@ 2*A$UH():$&"&'][YM]9O>9W=D7Y]7OSKWGSMPYW]_GS+WG&$S4
M%1<\?=5IV"#NH6N1F.^3#&X<>U1?%<*W[,D$:D1CG>/8/V0:AUR3]4[69>5&
M09EVR0(7WT("*HBAW/B\^9RL3Y0WAAH9:&4I<\\NQ,/#3>U\%&L9-VTAU"!G
M;8BH<^7/(F1K9=YT2V (XD6TIXL^7/Y;?-U;OPW7:1<73\/B@I?K;;HK"[#K
MW]O=,1KLV@W.[]19$79(EJ7SLTGR$V+464D2TU3&ES3)>06*1-M /LYN(*:_
MD@WZ=^CXXZ^VM!/]3*O^^H-..:L/WA$Z:E([5C07!:)/ZMQPU@QBPCYW!9:\
M,SMG\WW&(&OQ!KU><P+Z96IW8\N,&'3>%#MN5'J6)*CF-[0/&=HBDVW-? P@
M_"\\!N"UVPW;6;/@)!+$@>!XPT&]6HH'5/SY)4_P0'\_I8W3XEDR:+M5>WGQ
MBMM]36MS%7:SZ$FPK2Q;WJ?Y HLT#;(:+(@<?GZ?J&JI/N_*K%/?M3'Z9H;E
M8>25S:?!P9ADMXD0[?.GS\LNXNENZ2QN_C!\+DO#7!+DQY72."+G])5745O.
MMD(G*F>]?#+PP702GV<<MCS4:B6&[A_V2WTO:>]K""[:/A-.1U;4X%7C\ >Z
M@8D-)P*WBW1,4_O9QL5E65<+N@E[UNI$T3ZSZY\>_/E'O"(*KQS4*"-N4M)\
MIA4+'3A;FD;UA,T4]J ]HLS8(K++6!_:\?J$YWNCZD,O<,NA=W!HKI0'^/7:
MABM9._<TY*CM%J[(*7(^]4G%A5N5GQ7<62Z'5Y\[J.X?:_##/.OJ&@I#C4KN
MY5-7>NKH950VI?]!:-_[YKM_"'Q3318&R7273(D\J&]*>VOU*3$0L%'PNB#L
M.2Z$/+5(U_HD8LM$>,EWX!6Z+-<7VZ_4S!X9?]JR0M=]M[KSYQQ1$S?<)*:R
M46;SS/U[ R8W.1"7[VTJS[P-+0-539'T)'Z\9J108*/@EL50YNX')<OVALP.
M-7Z07"& <FKB,S)^SJ[K2.MFB4*A:PT?>C!K,M2^91"W+B,-W. T_.MF 8,R
M'TF86./N6>WJ[[_7_N8'C4L_'ZO<!A]?<F[R2E.;3Z^6P_<9$-UR7^[T2R.3
M$ZMN5L-/,A7\'3NY7% *J=D9\I"\XS<:?Z0F^16/I*M$PQH">H!#5@4'1+6S
MFKAXJUWY;3JL52_P^EE_XWF1]%-U"A2D7OO#]/#37";9ES>MZ>,*5;6[DC1D
MM)7DK([_S(L2GTPPUO@U7=0)='W0/'K2E(/\:AU:[];<_FV<*+5\$?#LS\Y[
M6%S2_-:U0+Z!]UG=[ URW, ?"-?#L?N@Y-O<ZBUNLYM5CT <>O8//-_1_I,U
MGKS6H$24TS*49D3H&RCO22'@>O[FJ?-W6@VG#A:$'$*W"B2S0T%06.*+6D[H
M LNUN6N9?>TQ$BT&YE;X]D0QL'QMI%$-MF/:CZ\\H!G<S3-#Y:3'<!9(%EYS
M AO^-!-IP$%T7^A(B@W2:HK\T=P=@16&SN?E5?TXX(MNO<V73#(-] F$:-O]
M#*R2V+KVVGNPO+=!:%6 DLZJ$ _51+8Z_9P!M:.ZE!GW]_C^%-U:3]1\*=!)
M>9 <?'!ZUUH<_ =85P)?$HU"<=[ 6_ZDHR?&28,<U^>]Y<U'J7L<[;MCJ)\K
M?-H;E?>[!/SBZZ:[AR;J>[*17K69PYGF3[/O(B3V4D.&&T<Q^1(I)4K>UJ'F
MMTS7#'TL?))N&*S]B.B$!!KZ:Z%'@,(<9PMC6OE/A/CB(='=$&6GD4\]O+M=
M@B-(W;:C\T5(/?';TE%!')F[%P-GJOFZG*CH/PQ6$90(YZ*F0Z)*A!9:><MX
MVW&WY1<'8(D928;/NJY2/1^G"?))SNQT;<[;(=>M=5-JW%>*IYUS^M7/M0&U
MQ8'I?\7SATRGT';D/^.Z $N<Q9_2C-$+V-I15TE=8V)1P7*I3*#J+P%Q.-NE
M0O.<'-C\7-Z>NTAF/;)D\!(0 "-)#&X-CI#4E%=7G:KE-G+._H"W+@'-P,R0
M"OSV@ZDW^<H>N4L4R06?.'!;1><)Y'\?'UK3)9 ?U=8G[*M^R71-"0T;<+\(
M].508306&/WODH?_-W/$ ?>IIL*VV4(O 46UJ'V-9>BI1E;>)<#V\!(P40_%
M>9I> CXK5UP";&;W+GBSX&FZM\,&7]?MG=-!R)DP<-.R$[X13AX@Z9+3N4_/
M$;HG!;3P;6CG)0 [R'>$I#LKA>-RPC8?%94N7P(,F2]\="\HWV:>LEY<X<C^
M28J(Y_]N^U]K?QW\6^W:P3\HL(ZQ/EJ8O01H5APYD6_^6_XQ9$GW; 5X^$KJ
M5/O_'.-)OEE=":\M^#C <IU3B4#)2GX'=QJ#KX[C(1>)!.O<E U:IDM 1A1F
M\9S!!G@X?W<OGO\GG 58V/7/@ZO_GT8G3TR':)<Y&\S.UFB8R:"[:SHISBX!
M26#N$"\\]).DDK];DKJ64F6ZG 8K2S3K&.7Q9A@]*N<"._6>D\PE?(.**LU[
M2ZDM[.76#?S8?1+51*N;Z[BKQJWTO,H7Z?V[NA 4@4-H4S9 @=S7%ZR!/,YX
M7&60*0(Z[=W-0;XZDLJ4-_Q%2G9EXN;C'0G6,H0X%!\M[@-OUHVAO^D3I<I,
M9LQ5I(LYAFN>C;/,3!FI A*#KU\([88QD&[C+P$[MDO:,KW-CK\O 3>FX=X>
MM:UZ ZOJ7([>B64#/$Y<G^2@]O^(.2*,R*;?K-72;Y/FO&9*GXQ,*KJCI !0
MSMR26?P=4U'HTNQ1L&2IX5M71\USU?9^_9\(,=/GE-X(S$#_B3?I^4=0/,OV
M3X,.QW@/0_'T*"?JN*(FP<X%Q7JD2C!93B^Q\'Y&C412B)!65J)',4<[<PE<
MP5?[+\FQ_2*[G2=$?NKH%L_4;NNK41[UD '[C > Z$Z><*+-"4)J8 '<'T8/
M:[NW9^INM:<]'7()D+^19LJ4<=4$\%3>ER3;"UZ=)U$2+(['!]&Y=*41[>^'
MMV9K3MK?Z>J'ZD)=N8G75F*:XS6.^.^+L]#\0'IX^70JMQ%RC0LO ?3<4L4W
M&E]>$YQBY[:J<T8L1BLX8_=+2T=D?#,/40:R2V(?/!<R'L$2'1Y/UR._&?\+
M55?:Z(8*H@MHE!^9;+XQ(3;TR*B.=@)R AW?1[]X^@$!#,@/RF]4"G7K";O3
MSHP%LZ9W,3=C6[/6[J,U3';_]MP!V^;:Y!+^>KGAM-V.K0GMD&!%;YRW2K$%
M0VW'[T=I44N)5)B4@XG:[./K>*6)T^;/=RVYOC2E!XP&Y:ZFH. 8BP29P9J[
MT2%(5D->TW<">D,N+ZCSM,JL"KVU-92J();"#B6_W/42Y7+E^.0G_HEHE0.;
M-60KY,H/W9\APN-';)< FIKI*ICP/C-@8&UO "V.9,6BDO,;P/2O0ER"RXCY
M&]T#PKV_);-63)[Q5-A?:?1;"@I5,[M@0P+MDJBT?\N_8UGH2/TRD]IN]>4T
M3DE\2S?,_1M\)EF;2RMMK/.@$](:__S!3Z</2QM4J&JE*R?EO02KJ\7LK_D-
MH(H>@D6/"%,ER^<9$Q<KT5DUM=DB]>W-=U]$%U,9^2YKYGC./)=N*MA?#/5O
MS\^97<_3[3F^OQB[\][O@OIF<;V?^ONOC!^-PZ.4Q,-3""NP5CD^M!G;S<.B
M7\BK@/KPJST#B8=]="RDMHH_BD+G?* NI%'6):#G_FJ =[93,E")18"'/IHF
M>&.Q(.CXMMJ2=+%RIN0]5*I:Z%KS<S$_MJ=%HB/Y,Z1VV JJUZ84&<,9\XB)
ML61#H,\O-)/U[5H+A!48+[^@:R[*XUM6IAP@Q.LPB&KCK["4AJ%@Y'50^Y?F
MVYGG9MCCX_&!SS=4GSW?!'%<A!)0BNLD&SQC/C>^CH#UOZ6$,Z]Q?$MCP?1>
MY-F8(FW[HJ:9S'8*P0C12V722-#7<'1<7 VMTAUJD45S(5,Z@HS19UP?17PO
MY(7<RM[E^"7IJ[UC\Z:@W$B=E<-@<U;[# NSWWDU)CZ6SW?@+S7,1A05#H%&
M!G=P;5#BH\TIB)%4V915'\.$,*0^X55K2\L% H/JV*-V4[Y*"!ZHFJU/LO<
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M\N=G*(NT.=U'KRO.FP"*^3TTWI< '#M8:M>+Q (+30+9I6+D]&^,A4'!BV.
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M6E;DB9$[Z$O IRR<3F(X#9<SY1.W$]5Y1(D<U2S$HV5%9KO-DW#KI?;=-_G
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M6LY_FY(S D,J7)JE?EMM-4RC0\N=0GLG*QBUDG5,DV4Y0H56@2G_N62P&+[
MVHP25;3\B0O(6JXI^;M0E);V?<U$X';+ QH1[[F-\-GP(>_33%=0""U#NV"5
M:>D+29?!@/0_CR?6K *<#R04-P0'?DUY!Y8 ;X5WCY=L3>8_JA/8[Q+<U7R:
MEE&'99S=3*GQ\+#YW9"SM66RU-"05)SC8L+CW1?Y9'CX&> *;J"#/8<4<M$,
M7(* J8FB/ZV)P&78*O@AH;V8J>\;I;^K"$_,UAL[-DJ5P>4XUJ74-"]:- E-
M/+\$7&,GGIZ;N$JW,USDDA0JL,U*N(NT_=T1CQ<W6+ONN=!K<%]+UKH[\+@]
M]R(I;"FC09^8/+1RLG/-1QH>!AHH[2U9'$3*ZWCSB6NWW((+-9:Q4BD!H%.U
MY)N#(/UH15PR01(C"S&XU3W)Q[I"8+*M=%G1]YSI;;'TUSE16V:%QYF><*ZX
M>2U&-\I/% H(RNZ*]DSD*5YG2-(6?-O95'INVB>CJ4D^,*HY,-YV.[\3\N:B
M@LP-082A[UB.04;\<[+RW,IN^O?>\>9Q+A,!S7X$K!ZR$ZPGF:,4^0I!?,^0
M)+GO:!4G"'::T,GH_>B[ J/("N.5]&39)<,Q.F*P*KX]VZW0V>B."]HO5XOQ
M'EZUM#Q>[/L.!0_@NCK6W)!@8=Y+W!7H[3*T8Q>QC+8:$ATJ/6\,$6;:[>47
M4ADI:BIVMSS_1UATL3/65]<.("_T^];_HG9^O\?0[ZT0_L:9C@P6?4LK*0:K
M6PV8\%=6S+N]_F6:-+)*KTC?FL*F3K%\7;T3P5<<4K 2AC;00DK%6;%EF"O(
MT>@_].MF6DI%E9V0W(8&/] @Y<OD0>Q2FLEWUC^LI25X+L?[3PWLN&7VM?-Z
M95^Q_47,O01(_'C^3IPZ2L @U]4P*><X4_"%<..+-%?]=4U=YY*Q&F=H4B7<
M=9YS987]!4_#UXA=+E^*Y \*/F.Z$,J48/Q8+Y"6F&X3O\*O]='8)]'^HW=:
MJ.XEH)(]J88DFK_V^?A+:WN;O(OT>N$(XU1U'JP9_NK8B8X.!%_>N+MB%S4H
MFW[-^JYT6YZ !C+SU7&&15U]_10$' O1TU8S9907<["A_B5'R1G%%>070IXM
M*"[)T99$:I3D(77?(LTDIX=)3?\B5")X=H'K(K?UEM_RB&QO&:C0.MY=]F\U
M*NVAF/A2*6_XAES'H9+0*>.TY&S8G9!W*;W*DL@07!C#T$7Q,2M&F-/1,9U2
MEIL8R\X%9;F8_#=A#'G82H)8<*[*]VF7/*DHY^#K\:;F\^SGE,;;D+6]TW!K
M,9(!47N9+=C]\;ZY^C\-UH"9VV<\BM L?>:#@.CB<BX!XLKIRL*3G=Z].DPC
MC.0&)J,LPX@NZ.*RP)"F[-;$_$1%< M)P-(\@!P)HL_P(NMV-_F]KO7I<PSL
M$3 <WNI<7,C_&PST5T:H^#D>K:-4, 57P4P@XQ71)-[[4AGW=;*+-$N"^8\1
M[)M)_0XL5%Y4]7*<1V?S5:!;R[P%W7_</)>K)+?HS3ZM*%N8D\?+O4ZY_3]<
M&6#E0\-%R'2@,'UBX IKZW/WTAO;GJLBQ^?M9QZCTN0\NB.H*ZI=V,JU_6%\
MEQ#2SHU-='#7T/[]0=\S.;Z2#R#HLH[XP,&3/>:LMP@GV4')TI4?HDZ155*?
M>HP_)+1"1DA"UE^MSOY>H"26$_V#"UZFLRD^-O@(H3ZTU1Z4SN2'R/N]=1^=
MFZZM:SY6YK_X";X#PKUM;F]&;A>Y^0;>SJ6&N):8E+Z1W1;_*#X!ER19+W,E
MRC]),]/XH<OQN^G:L,?UN;/4/?)UN'^K&^'>FNB.^QJHZ-E'=\%*^_^T(988
M4[1CVD]!B+*ZAMD\12R3S,H94 6.5^B]TWHC<NVR%,F99RDTWL4ATDXQ_<J%
M[*IWZ63'8Q[!GU;0JC]O ;;-DUY?T-W,,.QQ2.&X3RC\]-:C\%ZA3KGV<^WY
MD@UG2$FS^6]E'R(3U'61SM<@M-2-86;^Z<9VN]WMRD!L:J)/!R#%8E\$M(&Q
M*ES1X(%-23$WU6J\^F:?&I_YLN6SK@WP$9#N+IQP&_'IV 04-*UM=A88]4'-
M^19+'*_.VK,>&TRU_&&UEA%1@R#_CVR#/&,?(CT_;\4\W=_.OE,9=94EO(_"
M+A]T!)W8<I"[+LIF+'=68JHE78Y%1H=8\ LN]&4+8S2EF)!:.T(:>SX;RQD3
MG8YBB+=1%9I5K*VO"CF=53KYQGC2_[29IZ%>[@&C+P%<(0*8$5Y%EFPM]U*7
M!PCG>.^V<9L/"KET!TADG9)6+Q(G_M?\ZT:6G&&A0<N5*PKFLH?86<5#Z".B
MVSD/FB0:,=9C_/Y$OI-^Y,./!,GW8+O68"X]HD_.N><+^/C[PREX;;SH3BD&
MO1/]A#J1!I.[\6-+P1'.A:$!WG!B+9%ARUKA(8#N,^0KY]Y-=-.)?Y/A#-L=
M'-TR;E:;</@]_'1.THG]:57V2L7^<NYIH(LF+&\#*FG+LU?<VJ",N<@%2X$B
M._^8N;0_>E??HF<Q\$=5[/F<>/C9A4_*;Y(G@:];60;?MI!I_V?KT?[5-+./
MM51SK14IWWZ,>2(A*SL%*?8S@@LZQ?MOK\ERL_MQ;>Q+G0"W_0**<$%5W:[I
MIZ?O7Z5IP#U\$F.4X)RRG=#5!;'E.5Y/]V\.?^,;>;8$8<YU;>7E)4T.JFXF
M@UC+^KH=-VBWHC9^4:0CU"G93M4 &IG3,]V]7#AT<Q1;4N5D?]@\)=3VYT"T
MIP6#QWJX'^8](?IY//8/?)@P.+JBHP/8TL"A<*C5%'J25CP!_GM]LJ2M^6O#
MZN[[H BU]R>D9NJ+V8L2,"71#1'$46OZZ5UK9OVN=FM,!U6B'?1!LA)NPY/Z
M$M"IV"IZ\27[Y%/M%AWGX>>EI:7\C=R[R==".8U7'G/=C/I^<)+8JZA,*RN8
MH02I+Y/WUE2>-QV0TQ :LO(TYRR@ 75V9H"LK\4/8R<[, Z6$V_>(LL$,RIS
M-XS<\KK;UHA6BUE!HCU?*X?E0XSV&..?F5Z]8X&_,BHQ&G9A@9GU:-5><3=X
MYM#P*S@BU5[B(2^(Y0$&6##1'DZ,/I<'Z2[/_VEIB9>1WC9W9,P5];1:U#LU
M_BR:Z!L..I;WCD<OB.F-ER<--K)0C']4.^VXX'HT*@LV]:,Y$1DF2(D%1@F^
MZ1[_P:<*DQ-Z\:8:);B6T)R&QK4 M3N<_BKS=TSTK('N@S[UN;;6L)3Z3.CI
MB.9D(C.<X$(:O UII[6Z\<9!YA8N094,M[ZR_M ?!%OV)'W'A(]= LK;WQ%K
M\(N(!I0X,:&CWL!B(*1S0UR((8"CAZ,P\9X2WF<$'$TLZ,J_/74X VL2MI.A
MEU"0?2,CMB&'*.U7^GU*R#%.WFY5@K3>N7%?BE*5]:5[GRI $>_=@9DM]EO[
MFBAK?)<&G:D6_R-N/='YK7_BRL6N6:T9/-BIZJ3I6'(+<3<F4UXV* -G);EE
MN2#HHN+STF]HS;W9>>]4>"7OUDI^IE^)-*QHKA+GS3G<LYHUU^J[MY<<FWAT
MWMW9[)3@9WW3I4%^)[=^C*GVEJ^#[;I(9V1D9&Y^6,E-*,A\7J(7KS0_'=5<
ME-4S',-/\9Y[_797KAVAS\?$F.NN[[EL@6YKC"SZ[T4^6VCX:WNO4F,*2G8:
M,-5XJ/%=[S[CO%60XM,AER>O%V%ECT\S>:IV^X#W#=KWU1[?CY'/DO[I)S"9
MQ.OIH*HQTE1<B1EN8MC="0U03?E89VFMQ6V1]EC]/1RDR\T6>'0\-H[R"<
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M5L^"O%-/E87B6PW'#D3N_$C(]TR"Z-+K5]\K?LV[5-[7&LCWJ7S9N52_K5B
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ML5:O(E"+2IYE.,2YJ\ITTK=LHBXM75ME0*A*QJVAO]61B]ZHU4'G;EHB-[,
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MK;4E9NO,Q4S%:Y!(,]/W00UR"8!2!B$2+@&.551]9_9HZ:9Z=^4E^B<V1S0
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M0I@?9/S1X1AVS.SL5'GE$M ,[S=.!7DN%QPS$5L/,MO?Y]*3PKD*L!U0*PH
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M[@6FJY^B ?]=#_%%Z(2J-J<&3]JZH&S5_?K ;]U*IV*#\2HG3ZNK8-#L2Q3
MN1VST:\*A26BB];"C>^^QT:J@KDV-S12U_!DR5G?V-,B[[62S^FKKAWDY[EH
M1*^K[E0/1A)$A*UOMJC=3E/2]:BQ>9UBJGIDA0[_L.<B$M1]MT.JUO4PI\\9
M)7E^R12SE+3!T5#Q$MN%-A>>:_/2#89P+2_;70V]A5FH2I0_.BNE/1LO6V#*
ML":FN(V295;!(<T@@D0:TZCVX(+1SUG7]\+UKK[58PLZ0?]T3M!3, <&4R (
MQ))8X&"H KPR8?U\UYT*+HQ#DK9'\ GB<1!B(S9'(*H3:]R&@9DV7#,]GY$1
M.\?NSU[4^.MP?-D/&AM8(B5^J2_WMNPW\[;ON9:>C, [PI')>6:0M2+-R8Y0
MFWV-:T1?@I8^?@]>>+?8*KSP/*[EI^]"O8/)EE(+2B-SVR8G6JJ,].1I67YJ
M]J++=SG-#JA7GY*J]IPGXKOYI\"HV2L1IQ@+]6F@+E^F[[FU.-R<?;$2M!Q?
MAS A"N(YK0@:>7P5R_NV.D[:?#CWKV]/='/Q::DY5_OC"".R:Y+6FI?O%]R]
MJ9(JIG.W*JDQP 56,[&/M'.DU<P.>7<_S5BW69!W ([..V-@^#73*.Y*\K[0
MS\FF#\LC1\9[;'A5"^*'V[6UFLEZ&5?/KKFGG4HJJ,R<SP:'+JW:53>KX"N>
M3/./2/M=2ZMY-I:D'\+"E7K!-Q$U>W/I<G/8<0K(.009F1$:'%_/>J3WJ8H;
M&#$;ZZ5^#;R+@#>+K_(\B\#_?DE=?-'D4P>T,YMO0DH>,.Q:/L24)#ZGZ)VV
ME+K]]!E_@8J?E_)CX=M\.H5*1SR^\'5V[?SAV+Q-*_^\-6@Q4C.>94 )'.DS
M==I9CY4P7N-^F\V8QL;70&/:+Y='E\7@<<%&<UP."K-^3*A], :Y0@&T\F)O
MU+1NW@\1N2;5R>PT\2#:?G=): Y9!M(%V>>,FW]387GE-\,9>JLRQHS@D>=Y
M=K3Z9VM)'+T]T"GS/$.2TMR!^?QU%-:)P+L7AVS"^VE:K.W&1#GTUIUF2QOT
M3HS=)OHCANQ.04:_DV2&=C;/NKDI-]?4: OZ#[0[W<_+!K1TVK5=0;9 ^2M#
M%ZU5$QYP7'(H?U!SI:I(CU%Z9JQ@8*2 V:S 19)W$DX><593SG ,O"W5O>6J
MU,?8^O"J%C<#<*CCII+FU+!ED8OB2O%X*<_F=PJ@Q91,WSUWEO%V5*L>4)8V
M#C1DR%K(^)S^'ML69A'1BCP1&(#]G.K&G"=:25"</[H[E5 9''M2UGLFOEYI
M?V[9+A99W;]76CRQPO/>K8F!_D02O\T>T%YL*Y ORL[VKC^4F0)PH@#.0]"5
M5J3;PT9N++3-;55PK0'9P-78G66T<B<-GLQ1W)$IA_4'"G .'4::55X=S5\U
M6>PP:3%U+<'OII1-P,65.C:KLV%HO/F(DES4+V-<7YCPRSS-9XCHEZDJQ/?C
MQGD&LL05UU+._9_\83C0N?&S8E>KX&/^?OUM@H]4'1<U#D02<WRSJQVQ.:]+
MW->J&7,J) (45_HJ&F+GF?-R5TD-V:D[L-AF.B(-5KTD6!,&>A]0=7&;5\0;
M0#/()1*;\VTN$:L2GU P3@%\<N'EF2:F2K+2/?'<M&=54E)7YF]M^JHA0A/3
M/MSG99'QMG4.7V2A!LSK-8IVO?:J:'@B8U%7SRYRT'&G6:#O6GV-EDJ0O]C;
MMM'D++'=2VNY*C+)F5GJ1MY>#7IEW1Z240DX@NC7RN3[">M7A6XR*/*ZSCMR
M=^^0&FEL?3+*ZA24_?1T^!PRH.^<*DR^B"#50G;WEJ>>S#"K">?;ZH?PD17,
MC(6B'QUH!JF#,3!^DKDQ$,)=@]ZHUGZK7V2UP2@&Z#JSJY$IL&!EV&HO1__P
MEWE[_=R7^PC1,9BX<>%L<NIU\=7KE7JXR?IQE12\-;%/DJ<:/^SWD(?M92Q\
MQ,RP$+>S9SZJ]ZFIMOR7I0;L4Z!52ZW9OA=C\?+LP9L3[[ERZ<H%DP?.:*1B
M1;"0/-SKSQA)!*3776*@)6#]?DD K9+R,F:%3A?G+_ Z4OR]8V-BZ!NNDJ)V
MUB*+^/G8$SN;W\V?A#XC$'VFU67-%)W"02DZH'B6W,V=SN#9P'=SUY1B-45.
M+;SJ=;KZ$%[D;F)Z(=FH0;].U:9J(Z.F8<8I AY>S&3&DS^7T%>,3@VN%EX7
M5;$NGHKEK>*I3DVR<IMI_*[!%U8SKB;L_DP(V>!D*%8SEW;Q]( /<\@A&6E+
M%-\[->IO<WDBS-'T_&F;H3REG@V;;V&;@X)XQ" H"L1&[B"8:[E(M9OU"MUR
MSL(_GY\_K]VY*[)J5T_-]IJO/QF>U$1.W*]RD&_9UDJ#&'[?:.$F;0\C5>9"
M]V7:[+T"8Q58BCNV"M[ ]+LU<QKF:(?J-BD )HC.W)4 E)JR.2TX4D:CITSN
M+-#C"J3;)$LWW= ['+FQEGI@>-!+:)OE+\ 7&US=:.UA[5]RGK][+S-M^=M\
M]KOY(U(>-N:G:GMP[8]UA4)/*4&C%XZ)#SYYO\U][E%THZL%Q?(%@:8 )O5P
M2Q$>S4"WMU.PR?QT<-TY=<0FG\TG^S/B=>'[OH.&+8BVS?%PK>I(=$?S-1?I
M3X&;(B%^7Z4^7O6-RVVJYUJ"*2_O0/C-"CK>GW;/)O"VW^9^VY-RK=KE^T+>
M^UO+MQ0XQU-4JIN;'M1&A3YLYTZCH7O9[]6CG"V8-5*VR6\R$E14==BKY5$;
MDG,OX0RQ#=PX*HQ1, Z#47,PQQJ61ON6JV>ZEQ-_A9AG0)V(X=9(Q?/Y-8?!
MNC>>=9E9$S"8CWQAQ4,;9"&76H[\-S$_K_=T-UY,?'$8[[NZWF'XE: PGZ&B
M=_;+K=)$L:NTY4FR;73<@[=M!P0%(@?+%<HK6HV-6[ ?L6"6P-817(H#+C7S
M)T*XV&<%TODBSUBJ3>3*BFFJBX)1B8FE;^62X41W5>I.[?L!8CHU]W5&?RU<
ME%'1]!E';8"8\]3+NY;B(8'D,1M.0S=OC46FUMM)P4#^I9606 C[!LU]#,G\
M6<:3R&=)1I=C+SIFK9W,5O?-?K_<730M<1RIH;*B.(-/_%6#D71Y]NG^)T4)
MFI,&7LW'E9NKMC.GG ^8S=\Y>BOO/4R?'_4V<60J*WO8JVF0;[EX/[04UEN
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M2C ]?VD[NJX&7%"3@W^*T8W@0F!UXGSMN=&#U8/5418^#]1,U@/]+O2"OI
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M+XP(,^$;BEX>+ZZ=\1S+V/IJ=0*4J4%&GF7GNTK&_R !&F)"[UYN9[I#1U\
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MG\FH6^V6]]<,?=TGC; AO&JV'DI8HKA#2OQ46U.8T4WY("]K)$F^>Z-\-_W
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M)E'95QKH2?@AO+I9#TO1Q7FEF4HJCF9ZL'R3>*=.FL_9@7E9@_<B%:/RBT=
MY$0K$,>89[DA/7C[(YK%D3NAP:)R1<&C[>&,N\<O^E6!;40H2QL"E[;41!,H
M5)/%P6X\UUS\]?P)TXWB'\:T];+(9]=_DXM$Z@\/5G"">R)#8F"S5QQT-?QZ
M'7.-U[P<U#+U:PAYIZ_7!JK\FUS/HJV>6=/?#HYY4L3/Z&A2+)TKJ)6O/>9@
MD&A9/,3/!W)FC#\GU_Z4SH0T12OGK_-X6UQ<_JRI@_G//G\[5TBTK5%6NJK
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MGT\88F8LU.-"Y*F:FC]WPED]BLS7)/M4JL/=,Y'IZ?3&.)E#?HJ;86"?>S3
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M0P:K:GQ[:-]#._DT*>(_"/LE"N(T40H?L?),JV+I84L3)/>S22YGS>(J&S5
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MBF:$$+KZ_6"S;J-VN]6'6S\7-0!$D>X; FO@D*;;,%][B<N0DOG7-Y*_H;D
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MC]-^?IR?-QF%&J]<(^B(S1W9 7N^7L@DI9L)\\\>.^Q+"G0W0'#7N%QX@U_
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M= 7R.:WB_G"TX")/P%^!->8Y5G :2L?T[?G-#]NN#)/C-JH)M<J"?J?2Z-I
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MI^Z?6BH*%:L:U!4;R];%8?J(%.I8R9-8;$KLWO$^R5\5S^5A#Y^ GOKP7_=
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M]^24Z^;#CXR_YK8_REJ=!Y;C$LS"#"9I7;[KL8=>=C$Q,^^(96O"70#PTBN
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MMYJJ->/%6G3TUY/CU/;S+2(.?7=9Y'GQ-P($5/;VWHW;ZDF*)7^C]FP&+>?
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M,MF[ I2#LJIATC_71KV9FBLB3Y![ 5[U>00HM-,YR!'N8.\:Q.4V;RK]S:^
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M^O$]XO&KVSV ; S0PO]<=? $@G/M1I!L6S#];[2]9U133QPM&D4$E2)-.JB
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MYTU+-/)R0TBK-X5!2E&'^SN7@!4=+U/F!6:<1T=N]/#@[^Y*)M'*:_<Y5QT
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M,8M"1U.!VCI^)-@A#6&'V"XB0X+QS_F^,XM:!,N=CD&@(:ZTR#'PI&->ZJ%
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MEFX&;T%LO<":FK*PP"GSNE/WUR'NH:)=H6(CJ)::=M>U]TB.[\>7 &6!XIE
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M&UI5GBR+3U/Y%70UX"X!T5P3>9> [(^7@)_8M8WU]_K0BCVW[8NAX.#@_4L
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M2G@+D9D5T#D_>X'0$*9*V94:@RK-(<],#;FFCAUD/S>&YT56N)H+3X#V24M
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M^N7@%RE/Q+5!L@!?8LT B=I%A>Y@/^$8W^%5]?2=-D-X8:#5X'#OC9OW"]4
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MF=MM ^HCV*4,E,# ';W: $(Q"IH[4!3,8#NPN.(T.NIO3;'_CKQJ$:&7H/U
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M;VH3_^L'OP(_EX2CR2>[>T:&K,G%B%?+7+%1,_/RVQFOOZ"Z@!OV\ZV7<"<
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MO8"N4:5EM)[/RE1JH5&EZ+JS0E6"46*3+=%/ X22(+Z^J]P+3W<&%2L@]8Q
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MW[3[>PMT1C.<0N=:UI Y_JIF4F0(<5&K^#BKPB523TO4>10:%!S&]2];<WW
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MXYZ+)!M//>HW5//_B2\^(KY,];5CYZ?BCQ+2!E6? NQVX<>:G=%\;?='22<
MZ8QU@S:WY1UZNT?3&_YWH2C;O3HK[W.,H4^'E'I!RD59OS"D(/Y<+/'EV)?E
MB?[I-Y7%<_1COW/N"0/_@[+W &JJ^]Z%HXB@H"A%.JB -!'I'11?N@3I'51
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M5POQN^G=EY<+8MHAJX#NHQ+/ 709^$*1YJY75@W762)RY2K75FF'=<*-VNI
M/PA!3 IZ,F4*\L4U)G_3="R'9;T\_ ^;?I/?7YB@U-<82K??.6"++H>BURYW
M#A"61JC]5>TBFDR3W[2QX@I_AS9&29P#AEBA:R-]H/UT?2E*W\XYH$C??@["
M-*1W8V#26B]6="A4T<\=IR;^GRPP>6<B/^V)MDS$G5BRB?W1J-KA;2,3[W-
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MJ1_/C.UYZR$/ YX#GB5MCXE34YO?6I6O4)=VK4!QS$E7U=]-RYS)1@R%=]T
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M_A&G7%O%4Z%/^CS4;!2=$'HADII-2R;?O&$Q8Q.0FP87V/QAP',!838*+^$
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MQTD<4.-3IN;!96J5G)!XZ,;XH=4GZ3!BJ8-C)KC2H>SZ;@E?H@.OL[Z?'&]
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M32:.I+S$-_6U\DGB\,^A%CV>=F>:KJ<$1].9DIB<H,1U]2(9CHQRZZ_-I>>
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M!HL+\C>D0(+ID7%-Q]\>#\_$=3#'/_[Z6C28BZR&[5B@*[>.%7O *E+0]->
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M0Y:&$K0/1= >-/S*0:=T]2BBG!7$-)T!)VBP- AZD;0*89/+0L94*MGL3ED
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M?!^Z4UC2EY\\T0QT*NS1"ZR (H0M1T#:4Q:-PK4VY92OPQJW?J2[,#[G388
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M-(SDJ']\K#&%$/;]0ZGL1MUWFV<EU4@I>*U]J+PYEM*V6#P!52X=T\IXJV?
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MH13X-K'S$G!/)D"Z_B7.X4'Y2C_E+X?=CW)P^\)]7BPJ>'!TYT[H#36U@$M
M0@B]Z;ELVJO8"TQ>[+)F^J](E)U/O75-B^_8OKJ4@P:Z=FZ=>&Y^"@QH#$C=
M6XVW@4(9G>Z=[J*7R$9R@2(%:(^,^&]:'ZD#>&T Z+1VJIF$\)),\M9BFL8W
MH5)0/UI)7.\Y-?$BP&B 1 F8L-Y=AK.E@](WQ=Q75#VK:Q@7JI+=;MQ4X@;[
M-W&90;O4:L?+SV'/%(KZU"0+RH;L:U*SJ\? ;</Y19TITZ[/^G.$&])]D8W$
MWQM!OF7@F=GU'L6!@JH$.=(HBOJ*_[+G&'6-@L^3INBQ'K;)[QY]2S1F9B\$
M3-Y 6;^ZM"]F+7JMGQJ!"YL+\NQ_#2\B!H5F?&E#\;RT_LNT;A*64JZ+00%J
MV.B\I7/]S1IZT9.R =*"!*_W(A>D_>BPI&UI3<C[D46[LBV;S%*@LEJ&LZ:N
M^?I1Y<I^D$>76EXJG[;TD6=DJQ_C-K(_I][E>"V(1R85*#CZ,*>+23=>H^V1
M,6W'C'O2.J9H,[@ZBC_<J_>@L:L^7/%7DCRTSE X]#652CKW9*WT]W+1L@\:
M,U+7.^70O*(Z1+@$I:07*!"H.4&Y5G(4)&NA)DB'?OVGE:6'[LIQ&Z=&&S +
MHF#<I,;WWBWY;7K5*E+CW4JX!G) NZ_<>+O6R%19*X?W?O9_T[]!VA:UN4VE
MM=@ 2B+WK[/K!94!'[')TRKP <;?VP8/:VX %J&$GY22O_I+%JV?I5NEYZLD
M09$ERQ'#KS$@O\.#'5WR_9!;D/GKD]4BM'_!7SE.BFI7E18CH(<8%7-OE)W&
MIC/>^+W7NQ>1@(.VMAXY);HL.@6CHN^KC.L3\0JZ9>KWM+L-5I>SY//Z<WCS
M@FWF49G>P4<F^C]919SE%/<&WHTZ%OLX$#]6.?:>&+TEJ72!8_C$ B6\W4M>
M_G:!:"E&03F2H ><8=<\,65!?"1"#PU.D<69HN&PO*$99O/EC\"^@O77&Y)R
M&!YBEC>3[^8K-59:%[?^=M [$H0':?DC&(*2WPV).\!<FT-TMWQUL4UJ=\A+
M?,@PGIW'@@'.>F]UFS&;R<9V&G3HITGY&V<H514/N/HX3S.U[(2\4(OMK)4;
M3T9Z9?%FY368]V-]-ZJ##>51\2WR%62PNRW!04,$=B;@=^UYE)&REE48>M=_
M\8IY:V23'PEMV%A;+]%3RWR=KOO%\8(KIWR?_/K,:+.Z2<V_0^305K=4V^>N
MCS$-]E/]][P#[@99#,LQW_.T=%_2B80SDQC0UU>SL/OG/Z3U <:/2^XT$6H#
MK1+<YQO%*P?2P$I (99B>02_D#<C6^S$!(J5G[\_U<<'6_W%O7A#L$<7QBJ-
M*[/CS,XI1UFX!K@$,=.R>26U*\,RXOP8/+Y&K.J'K<GM0 ,.2XE;4IW]JV9S
MLK(?@(9_)6F4?(@7G,*C!W%;MT1DL8-1SDL)#W_(O54#L"B%Q##R#:&CJJ]W
ME'KL'J<[4-6HJT0'X&=R$KV+U?(^,98-XI;S9QR_BU@<$PFUJ!"AY$KW6KN:
MM/69 R5'W9;*T:<9N FH[ ^.7,H/ 6)26 +UR1:.[0_)+H$3USR>\;CLK$>^
M_VOP^RQ_PAAUN2=8E=S8R63:7%13F63].?&[.A7+FLJPHM7Q7KQ*6POGJ#?+
M%O\8W#;]W*EI,:73,SQ$:CT%K)IFV*&/5!B&?,99^^E[U3\8-RSK&^)=<%5<
MJ!_28^08#T+?F"S? FN+.)8W*VZ[Q;2U4,N^E[9XKJV<NVV%3N=)R=H+H0-^
M+R]96LV^7IX[>IO%VH8O<(_1. K-F[) #8<M;.302L?_F;/GV?P!D[JS$-!X
M53(@8H/FB#C\:8%>YBPT/F\CQ$8X_LS,P44\!-BTC^:"_=D=E_"R4X-LU)0P
M955HCN;/&.DMS^^1O4;G1+40<L-2T$>0JO,98K&_6-IY,+ZIT9G>N)Y-#>%P
M!]?K-M/F)H]V/R$%"1[77#"1LFXS'SDWY[^^8A2O#B"44W-2FQ*:E!?+=+0>
M'[]M?,9\LW[6.-G8/QGD=W!<\,G4>3[7!:MK6/<E^O&+9*-P%90.^G'3M[?Y
M2#;I73TX6W9]JAT?1G;4HR"K-,-TKJP9%"-O4ON@8'-& PPS4SL^$3%RUO)9
M8&[A,@/5I)LF]%PK! ?B64XC$N#GQ*;*R4!Y')_)P:_:NU<&[M)S0 ^.N9>Q
MD7\#F4AS^+@9(O]]5M\]G2+EOK8UB9F3H^AM=+L65R;" ;,B&25:;,;*8;.?
M *\_P#-"FIY<J:9M@11_2ZS>LE"QS35R*,BH'7RDYWY<+. QH-J?(SG%.]FP
M%:#H!PXQ$5^_2LUN'6'_$(:V#  HJPP+1Z7MM^F9-Z>5U;ZU4U1M*D:X07IN
M7@(.%[U1]W8Q77,AG?0/2/:U"I'W?\T6)K3=4";1R<DK5^8$$M9"F*JT^G[6
MMY*"NIZ)M<-RWT<OIB3G(<=/_0GFHJ^^%8O='2=H.E21)M:+BL[*%C+,-Z9;
M?2T'8[\5@S05"EKA(L@YA&MG!=&TM?T2$-/R.,ER[%5E.+]B[.=4*KBZ*N<5
M%;BJ>259X\>ZOW?/=X1IY_NC*$%"U]6OK]LZ::VIX<K7?>#L$YO5F=(-58F]
MUU_L];9;TG/Z'W U>>&*R3D63:.;'QT=[>#:^85O-189L-19!*Z%;+>&^JQB
M].W#V)VI(=-LT]]5-F5V3Q:$'2X!LNDMV47%(+I/]QS*D\R''*J3:_M01HYP
MN]Q 1B!K4XING$6RW[.3GX$X-<^Z)_);)Q\:?<9Y?5]OEUX?KWC/ QMSE^N(
MQG@F4(Z!N4W^ SWS8O!#:(-M;\R@U16U]2RZO+'9W12XA.79TAFLM8*9V7#^
MS:*==>A-GBS/L=H5C PV'@'-AYE[:T*^UW6K>:U<PP<(R]S(T3)KV),JP(MY
M9&3+['I4!\<Y%K3XG&S[J7?E1$A10*3S\6=LF>M_^NZQ,^F(N;P[ZCU$KPP%
M*B_N3#F^(3OB3+QO3-HT?3:7JOAH-RV50B3./%RT@V+77.-ERCY>2U@ J4,0
M;;9O#N2HM_>D-E5$*=KC7]<S0F9D./FVW\2:J@H80Z$5ROL+^WCEH,%,F:%?
MQO)+1;CI#MSYWZ4BH4\Z!MZ"VD\RYT_%S+X9(33U];Q2W*H)BLW2T_WG"J[!
MO7@99?"2T1'_$;"LB.EK.=NSX6?./0#E/04",0D[[ M1ELX<4E33%7[-ZLPB
MZO>H!L]!E4S->8*O_?470KUTW'43[HG(-"LWCD _M/&_ZXD&-9_@\N=OCC2)
M%#L<^31HS?;8O%B]_K3PRG(*U!VZ?RC'0FUJ(/Y@>;VA/G'26L55@?&3?CRS
MP+012%;;H?S4P3'I[)@9\N?=:JJUD&[@9,.%;4OMV9&2G>HYW$7)+F\ V,H:
MRY)=$#5[KUX*QH&ON4'-TGZCW-AD??Y6N/9UZ;4,EE<O?S-RB[->B0' 0Y/@
M'A)@G_\F27]??2RLZ/B#[ >8V]!&),S2=>[A6KQW=SJ%RXSTM098CSJ&FI/\
MN3S<QU L7+-GP\Q N.(]TVA@95ZDAV>>AFS16')MLS=*J@9;ZXZY6?02V).1
M-=><7Y"<BG)<]ZHV(R[\7'(@I0WTW '^I/[,-[:=[CD]PQLMK;9(R9/KE>-4
M3I#(Z!H!,@<:C36I4D^+ELM8B+*FWU!W8.BG1O&&WTKXOMZCK Q^1X+7\$1W
MJL>:!51UG.>[&,R=XYYOAB@<<].L63ZM(>W]-=]X/1TA<#+#GFK-4=&. =9S
M4"4(MS)F&7:^74T0NV/)J.(-BGZ<9;XVY@/*Y[^&8"D3\\G1$UQR&(>MO'SK
M/J')D*SG[_!Q-%@'J9VP\%Q\VJ'&+2A9V*P7#]7Z)3!P'9"2<$+=0E_@(>QQ
MBN,$36S.ORU]5R(GS[-R<:R[@&6A4([&.D\G8C5%JZFDM^FX@U\>XA=8UD\F
M$^*0%L8#O%@LT*.7!2]/A*N( D/=_+%=!IVZ'MGVN >K" R7I9V?;'ZJ'VH;
MZ9/B[\\5:2<LX%%5.IY[7)U<Z>/L7T[(W##E"D."&[3+W^PW2CWE^P)(]I!(
M&9/G/!>N(W55S"!3G*7ZRR&+BXOGU):2.LAFXTGIG6MF4I\RA@<\0EMS'EV!
M'/-S?CZU\<+5%0(E N4KDK:\S!H=9WJ_%;]@SU-D/$";9UE'+) .LN:%8 IW
M3X=,*W4-"XM>BCITF\IJJ4WOATCQ@:1GTANY!?:?.9;MA)C9M^K\>"CII]$<
MFP0EM#S?D)BE0FNVCUN/Z;UR>PB=D_PEN7B#P_^4UN9?5NYV,V7N"F@._ABM
M+:GUWP6S[2/WA)N+="_ZT&.UB@J1B$G#A30AG\17X=3!_IX+97Z8ZY\[C=S*
MLP77(3U&QV;:!6,;QT9&OA]'4C\)BQCYU/@[P8LH58Y%?"W?\\W[]RSYJ@@^
M(9"^KQZ>[00YPEZ1*[YJK&PY'10N<R_\I0 MG11Z8)S+/\!W.-AI5SV:XAQ4
M?+M,V#1 T>"KE.JJY#)5+\<E0 =5%D =C;*M'/M0-;Y];?_Z5361[%G/OL.=
M]O6=V!U4Q)$NPE#N&\Y\*U!2OUF9P0&YO868W!+3LYIQ$<WZ 9LNG/:M?5T]
M,7=8.>7DF1'3%2_*F'$')%,#&0A_?7LL*R&[)[AZ>"U8X,\AL8<M.->FSK"C
MBV5QOQ<_:PV_KD=.6<P4>U"D=3NJ)KMO=BD\I5'93?W5 C_E ]F==*Q)^N^.
M\F X;BOT_2,/-740\C3E9'=3+<V,EJJ,9CQ:U$7P_3LS"]'9_-+<8Q_?<_%4
M1X6L1&,SC8'E+=LC> FI.F&F>_[I1!,?HFK2,'IUZX^?P(.*#^H 6JX?='D1
M8;$1[:>MG[V5.8BGV96O@D&&?Q.*W=0'L!4\M9\VV!PY3<;G'O=^>-ASD_:&
M@AN$(VSF$H#*HY)+NB\0&NEVM9!JW(K>I?F,;7_.U+VS0>NVAF'J>/$D;$>
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M>N6.>%WZ6P( #=>AXKA@/2".-A/_VV6$5[LP/C%Q^192\I&U#VT-SU:X!$B
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M2I6MW*B!^]\&%HA"\JCT>/&PX+".*F/)6B)=_I7O,!XU7^LH@^O?OZQ=#=4
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MZB;]:>I/NWYJ=AHSC4^A ()%N 4)I1C4>%6'MID7SC3]ZFNC4MK]ZT-1P"Z
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M,2G3FK>>)IA]?&0'I;!I:5?A?#?"Q?[G$? UYL?%/*F>H-\[4Q][*UV]9*3
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MO%-6\$U\1$'Q3?]7YVN 6R :M06QP.+J+VC45@)'OK38+3=_M+8VQ'W.?*1
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MUY)[M,N&EB#7;_">'$+E76Z^<MG?4*QZL.;BSS1T&1=W6!N&']UU*A7\QKG
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M5OV4) ZH--1.5$\$\00X$2BCS3>=V#*,*-[R?FD-)-TZVL"$#O.M[U%"LWM
M#VN);C\T),KB644H^G_8T4NW;YU2'/Y&E@4$G_-_]&O+=EJ9RC]_:\++,*K@
M^4')@+B(#"ZH'T9P-8RU/>Q@@2_7*K5D?$S]>#KQ'5:N+)<-Z4+P)2)X= NV
M?U3R,?#"S=<BP?>RWLW.\+2FH"CK%K;JT:305.(0R_.K49S*VJD^A44*XV.U
M<YXWL>S,$:/+QEE<?G!'/MYH?19T*O1(PH62%,53ONI;_C4ZG#/VF%\D%%LG
M)4\Z1"H3O2M7^.)N3$-JM'OH_SNXP7\CCB7S>./HI.1EW"]2^ RV&R$@4EC%
MIO+H_<TUUW:/O@U,0KO4T=\KGD4SQ[8;=4V$O!])BIX&NL__I8$.D* _KG"D
MZ"_?'UB!RH?T(L6)5(&[M>6Q6-C3!:?#"Q?_"P[W81-)NA7"]PN'+JLJ?-S
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M@B9CKM#(T\$<]B1.[FFWR3J=I$0:2_6ZBV0C3X<T0_JW/DS8U*0KR006'J@
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M (HCYLH=2*J;9.CI"R&1;FN3UTG+4L$T^]ODLK<U[G/>&Z\X^MM9]U2<MRM
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M7J29=[YZ<8:\C/3J.,PROWK5*GT-X'N.4=Y6ZC@SG+ST_'\1%&,O^*^ 3->
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M[B[L3B]"EA/Y\NS<6\+4J[(;FPYB)O.DG&L3:T'BL$CF0V3A4*A8EZ/R3..
MTV=VV4X[7.2W/)MRN[#HT.4Z?F*>@@B];=F(3AY4-4W26<9<7]NJ^+_&FMB"
M;!N?LVGX$RR<DQ'-JL8RQ.S(GQ'D,MEOI-? 57RY8.;+U9H<J#JVZUYG]C5^
M4R-V[39( ;8GE[^ZT/9 F]JB#<,UOO+QP^O>@J7]VTR*RF=X6<:T=+-._359
MDV'5MO0.>W3X'P7?N62WW\_1<<'N/Y_6IC(O6=Z45[U7 )> H_;1DL<RN[>>
MJ-\9J*%!B^.:0]5X\[VGC.*&?TSR^^CKE5IPC9:KE&>\M35IBNG&K10W-5D*
MS[=>48\V>F;Q-/>O0<%E.%NP2/_DU]F8IUG"0T;>X6/UA,FAL.9U9S,KT-[)
M*U/)DH;9ZD2!Y-L*AV=W%)O6:@2/O$A:-Y,;=!T+NYI?V:GSMS1QDG,>WJJM
M:[/#+-/\G+'LY8S'DL52<7@Q*R02%BN%O^!,/69>"<*>4Q5%-Z<V1L#G0B#@
M=Y"4&$L-&D\C"Z$AY?I&UR)!RU*<!+-!Y9%T5%6IW1S#6F]C\^!0%+ACT-%-
M*J4>!Y.B9NL[DA#L>,B*XNIJ-GW-^.K@3:EQ65&PY:A"=?B@L)E/J#ZHDI:-
MTVS"]H-%+@AN42ZJ/V.GLW?'YH[Z[8TN(!&E7<FPO-CWC!VZ2G1">-D/I T*
M.YBN,*\/]'X00[T^@XP88@[ER[6H6^I467@ND+_9@Z]DSX@;!"QD 22XW[GZ
M2TS^H<)E</ A/K\RE(;D];AS[=ZWWE;F+.=I*Q&D??F8H;=_T8=>NSTDK7IE
MX+-!7*DMXM<SC.<]_11QRU%"@%OJFNF54 ^!N?4:4"MFZGI?C-E!@N8YQ#)C
M[T_<1)$F#/(&MJ63^V$U3;O\[:%BAREI=&KF?E;J^INY1:L"#:&#IU^T9'KD
MI>;2TT"R*P?62>=\%]Y>[^!"Z:B&G-?F<X%W94(H)QV27D?!/&Q><#XF, \H
M0I&9PEP/S44;]#G;WX!4 .Y+!\EMYY>W7!>R_;F3W\M9#=-<1*MB>1'@G@N!
MI>K%[XLWB%D,XKA08W^=&'+93I-AB<_\F;;,C@>M>)5H$ZZEC:X2$2<LW[DR
M!PG;WZH7$\UZW.;N1$[;LS^TGU]NN]<4)OASHH@*F@.RY1N'$?WU07*#@Y*.
MY>YGC_#*_97VR[$I1UZLT."N4/&SQ#4'+=$G^UTW0[\K=BP $^DZ7N*RY?Y6
M?K?6KG![.S._4!4SC6B\W%*O!E [5JN+4QYR5JGYFEM_*[6T[+G7M+_J3D'@
MA'=\ EX<E"_G3BN/U4X#TBRK, W<H+\R:. !ZZ5W'\D1AZ1:\KFB[5PQO:@V
M]-85ZG&&;DH2-$V#^94-\RSM$DIE!E7$HSCUZBMFYCNH*7K-JNP3NZ')Q%]W
M87MK!N^'Q"O4S)DT/Y<91+.8!L9&4[[L&H(&ZL-6GS7P\O(IN4F>OSP7VLHG
M"V<+1RE)8UI5Z?*"\/0,EU5K"\RA!<]%?+/)R"ABJ,GZQ4@F*UZ)143EJ"-F
M27K:S08I<^%RA4JA1+I!:O7]>X8EC^U=R!%?48P)'I6;,VI%194[&) -,WB0
MYB7 ?I6WA E-SHPBS$#++6N)Z@EN=/#X#B>UFV3H(5E"HM^A[+8<PVEL],+M
M-WLG2O@JKF7![@[&:T#5=*\OY>K$SI=]F]7!6"/O/P%E%<]%)YZ6J?FH?X?H
M>W6L0%,H%926KD27YP(!J#COS_GWM\:7=9YU$>]O&!9D0?X+$C#N62G+*^T1
M1G)M\OLS+JUM'\H(T2^C>KUN;7X[3+GG^D!*NI#KD]KSN*AZ,JY;Y$V;=/2O
MCX^4:;>P)G"Q2!.BY"_7X@V%D1-!,,$K5UELYW#EC,"("X[^^6'A(5RAPE.J
M778 %1INMH4M<C%'EUK_<C\N^LGT)NJ>:,'</\JDO 4>-\/&?J[(I_Z09=!U
M*IBE%)_$\KE5ZA']%Z<@;H<L.L,M@RA7+09]8>MQ"4]SKJR!"ZPBSO)^384Z
M5:8<I%?3NQ^T],,;P?T9A*SL+C+%&'$SFX4,UIX?'T<PD<Y[Y:RF?A9N*#UI
M_?U\1$^3V@U4F,R7^OZ1*2?%8V(^.!2;9#5HXV=0-*=[7#ZR9B^8E!7("W%/
M/_F2'*91I1UHDJ-[G!D_&.&)?9@J\C>W46:)HUA#5\<MV@LXMZ#;>BM>S;T>
M1&Z#SP^EN_351-Y\,VBKH*3692K(X[N]E_ POBC+3L#>5>$_EZL#EG5]'_\?
MV)4BGFM %/+G62S-WIJ\<$%R452O>CWX2W<,SQW_MJ@-+?K;W75R"3G/5TWR
MS!E*@TH69EC ]!<@WMBZ\J#6FI4;=_"\"LE!AVB#?QQN-US(TM*5!V-,-7C_
M&[.WW IDX"_E100+OG:>XS5FUSYD]L]Q][<%Q1[YC(/%64;IN' 1:/ :GU]0
M98%##<43'Z#1$NN>K,P6=B/^DD-XB9UGP#>Q.$L\B[W=3*=\Y*>ABQ$B.MDQ
MN4A%,EO(O#IJ>5PS3]-EWC4C*$5>J=MA;)GF5EBN$Y-[6>V/B.E4U&2I3NO>
M GHAT153P,L-_([@97/ >([N_CMID9"(,E1 :1<GUPDYQW!ZXC7@K&UFJV=_
M&L4V-]9?QDE><C,- &1-/PU3"\V^!E"'/3<K=#,<^A#PC$T6CYC@0+ >,F.5
MV?UW7L;_$O@LL5\L&D),#DO!I 2?M>HP=(?J1&0ZFQ71 8?<]),Y)?OU"UC#
M++N<_+\7:4KRS!9O_H99N)PW>!1",$3IJ/W7-TM^]Q."%APU&*QA8@Q%L:8!
M2^,(?A^(KZEK]DE:Z-1F<'L3SDH]9'#7GDJH>'! AESVA'Q1!K4:WU6SI[:0
M*[!IH$,!ZTS,)F=6#":B&]SC]U6)RGV!/B 6^<LO[9NX&+*3K<CTTZNGT2>)
MH?8EW>XWQRL['I/!FQ3888''HVX'V[-R>_&Q]_#$/Y9U)K\VC9*@6D*EDI\K
M["/]76T+S,$F9T6:21-E93RGZ7H@)GTBP[,^FR<?*]^A(69U%/KU[+G%6=9$
MB1Q(M G%#INP.O[A@SQX<SDRK'DR5 QG);[L,/' 0^5U=?$1EX.W*)TZD .7
MGI]W=.EZ;MGL(L2\<L"T*HO2 5Q9*>L-&X<_ZICH2KMR4>CVD9;M5^Q2; -.
MM5A8B6-U8IZ_>I<)=7F%3PG/4TR.T-RKN08PBL^A8B"RM'(B@CUOB@:U'E&-
M,A?[X UR8) ?!=P:<YIBN7I3_#,+J,SX3HC)(WO12<2[@AY+>:TL2"<N:/7!
M2G9M!<'XX/B([0C69'2U'4$+?:EZV?+FS?@G,08_WG7?E%^G)I9GCC7IW(-:
M:G$7946&XHG^9\?; O3ZQ/_J/]555MQ:@XQ]\NS7:, @K<-.EXL2^G(&I$76
M4%XP^]3DX AX1QRJWR&#GTAG%#7DS<SC\D4]S\R.*"G:Z&*87Q/@?XK0H?O]
M[9&,IFZ6LM<O!$?.'A8(PHE?\*/LFNZ[CB<&V?*?<2NH.56MK5RNCV=_#TDG
MX4U^^%O(2]V[?VK6N"FCD-PF?PW@O^3[__U-]32P<GW0]FW:T&PQ)(NWRC0$
MAF_BE3S[> VXJ7\-2/^]9W(9X9)_9NP">6 BB&"FD>C3[[U:NY?(]RL'^O9Y
MTS/CD!#3_J& \8VB[\H<Z /6 )<OQOWV>WO=QB7?)ZE<?T?+A\ :0+58DW+E
M:0$<X2*NG>$:\(,N]QI0.&B5">F@5UY1V\N_?.>W>,FCN5W>J? &N99R115Y
M#> MV$->-;LHG]%(7@J;'&A< RA>_O-HC&1R#;!ZGG]YB^52N5OWE-_U&O G
M5_(:,.%+Y."(6(GM^5>8@#[]GY[(ZZI+NQ?I7E01?X3I+P$FQ29?+MBN 6D>
M.-USBJYKP%>JPZ&++;:KT_A_+L4OGOEH;#,[7R1X<QP#8ZX!&%&J9]^;=);^
M+QK!_Z^5[<]8Z&QP_=;@1'U(W*2T9$WD0%::?L_Q%"9ZBC1[*+?]RR/MPU^Z
M&1\*O5*'-(?6Q*<U!^J,2/H=Z19, G4R]-2>_O]3NO[/Z#.O >XIIT^4Q/\Y
MJGT-N$K/N:C\MY."88O_-NKX?LLU8&P'7 :NU[CXE,\<\><?7%\#0"/AQM>
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MM>@E#Y8T8/T=*K__A4K'*MVSOMF(%>$<WA<0&UA984@#G!SO6DLNYP-_>56
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M7]R'X0''Y,GN/9]7G;(KD'7O,+'D?ZB;E9.Y5MP00WHNM;3SG\=7LE%1!#F
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MW&!#)_?W9K&'.A"A+7#8:@ZWEG9JK:3M&,A/P^DVE)M:4/G(L!VBE;)=M;+
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M*2S@#.*.F()D[3QZ!*_%>5DSA5'JRDGG[N/^-.^O8M!"?M[AF<W3-2_"<D"
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MXBP%K/R7U5;)XI!AD:9B<&F:8KX0QTKTJSW?0;Z"M XL;$PW1DM<@!,\D=
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M_$J/]K,CQ,VYNZ>I+.M8/I"+W&&#H5N9 W#-WBIE#AI)X*OBSHD*-P2?MLK
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MZLZX@-F)6K&Q)<%N59=\_TYH2"BR:G#.":K$F_EA^$H)^<J84-NM;[=EGR8
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M%-&*JI8Z*@T1I-J:P.?8%1?^G$TR0V\U;ESB(69)(,HB:\\*Z[!!*55*,H]
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M '59BVJE/.Z1=UWE[O!7ET*!,B?#AF>,"H0K9S\=GU[,BR9?H-\& CO:I*I
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M0M"M0*'_N"CLOPFB]/_)_JGD_ZI&.K\!A$%:,:P7G&6@\[?#&RW,P0N7LC>
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M7(XT*AWQJ?1,H"7C==-];#/SYI'M&2VN%9@OH[]W"Y=QYZJI;-*YA&4="0[
MGTW\3@Y9&GS\JBX^X@Y,\OW"%DL7)VT$B?C$ 2[WS'G=ISB4VQ486V=I#QK5
MS:]+02;'+7RC#!M54C5./+>X4S:2O6QJ&EV=E]H"/7%-_XOI]K_6HF)GK_:)
M;Y.QRQ:WV/*-H;\NOCEZ],TKN(%A6U D\RI:Q,@E]MR/0*$*ZTI=&X13QH21
M-4+2_U%A485II7P5'"7M'0E7R9R<LU&T:)BI36A?:0ALZ$=?TZH5+SZQ3_Y8
M!MJ:Q(;0*M4BXN7=[;7*.HVU"#H$"30'J*0'C=H%8#3X(SR3$DD]&3!OZ,$/
M.9K*_9DPIX9L']OQ9^9B+@\-:W^T(V,=\,2S3@5CT&\WCL-^*)\Z&F3_^"O1
M (39'0R>=_"\NV]8Q'_O7/ ,PJJ7 ^@2EJH"G(UR/7;UC?F..>9V/8QL_R1W
M/1-/S"V7$^O7I_AY@<+,&R8$JO5.V?D%PYR";,(23[;=S:C_5+<2FAZ1$Y1H
M'GI5+^X@5'5C=;S<Q0<[5%&F=8"0JBV*MK2RI#TULKSR(CBZ<RSBDSMQM>"0
MA;%:O'5I>GQ\XL,"#^%/OG)C[S]9/.Z\KK%HQO68:2O55]FZY'1YH'C'@T?!
MJ4DU?%CIIXY:T])-C1F15PGYF50BDXM[,D['*/CGX);XE3%6JF*Q8268+%3_
MI]XU/?\RJ\)%^DZNX;_8*JY^D+>TSLRP\5I>]UF/60E%;61-\CVZ&<^WU]\$
M$)&Q4$NO\Q2UY#M*CM)?Q!=4P<Y$$'%S8:FT%C;H5O2.Y5?9?;WV^YW,W"S=
M4-=-Q'73X=(\?&"BD%/XES$6(F7;^U5%GN:GC,2SI+&>=3_BO>#YEW)VA_=]
MMPRPE6?Q$<CWS#]-E?M/7SHVZAFO0Z8SN&GVIGS)R\&MB[8EBK]^&!&OV'@+
MRYFI?_!JF+/H.8,OMJE]W./0]N^BF%E14&+DPU5A#_R_K?[-98QB3$IJ7B0[
MGTCN*_%U78HK6TG6C0N$A9#NV=H=.?LRN2+KGISKI=>FOCK&BGW!RC9K&?;+
M[LMC8>VF2VM5%^JG&9=Q8)=PS:%R/16)5Y"%#%;,<NL4GTL)GVCG.IIP5[[:
M=D;3?5U.\/G[9MDII49WVR_"CW)AD]6?Z.F^JS-8BD>3?W45!QB]10FGB^70
MS_R4E!ZO25R^HOPY_F/O]Z/BC'%9(=)0".),9HEB<&(S0?N*F+&/JX?LHY+"
M,6\7_4?JF1*Z#FT6NKXRI&_M#M=**BPOY;XR)5?,W!E9CY7QOC)QAB1RR'WB
MTI]+?>A1V-Z6JY^[3,;3/@R44FKM-!_X#N;<3+GL86?OGVOWQW<-;ZIC<"4\
MUM/.$_;HWH\-FL;%N[=L-YJ\(\Q.EJW+WRZN.@2NRK$/8WSY\5L43?^#<D7-
M)H,W(9+\' "YJL$!S 9CK^'(Q/_S"2G5;C] OY7FB,P7':<XP&>!#QR@N,\E
M*Q E"%HPVLAGQ87,L"Z8K90!_P]KK5DJ]ELF'.# -0Z0,;QKSP%<-/-9!\^P
M0-^LZ(K>'.#7A\M<XP53I*2@"\^[N"K)] T'6':W6KHQN\[,\.>'_E(19 'V
MI?;OF5S:2O>=L]H[T,D!/O)3^YED"38]F3N@Y!E&D,F*F"?S58#4-M\S#H!5
MXY<O;+:<_7][T/V_T'@7H?^SM=4YJV\Y@(Q<#WC[,(H#C 2#LU ;1FFM%!#[
M6PZ485!)NYC!MD *<>_WT1$.8/F=J?&2 RQ0 ^18KS2L6/_(K8\)68.S\YO_
MZQL!\5!,4E%S:_9LQY%TJ$;^,A1]68KYSPDHYAJ5^+=,*<['R :67A.CO"DX
M.H])?"AG>'^5# <IND5<5^__-T_ RI P2MRLGD[6662==YS.KD=5<84_5]P;
MJ]+_BH%203YT_!E7-LIL3;[  @ER,0YXWMD+,?U*POA_YP!)4AO/Y7:>_^VJ
M>HW[&S,;5P,L9GOQE102''01*QA_'H1.*]C7OB\Y>G-]G.L7<NS72'R$P%BG
M_;G*H]K:.JZ)=F>C3^Y"+_Y9@PK\,@]#!]\:-G9N=,Y62@]>3R.Z=AK9^HPG
MT15'$2$9V\&9*CFQ=LA&ZWL&(Y#+%58F'<37W- X%!(UJ$BV_/SZXGY*C?2_
MPF9^SNXG4M]K(Y/;N-&TG^%_TELDYTJ'>IM35,9YAV@Z?^FVS/VC!+%5$JD[
M-L_:]1F?[H^::6C%0XDK6K!B@EC_\@3B\@7XAR*=883-),6R?Z TKXY40*_<
MV&$?)G^,^$>O1'<EI\;YT@.EVB^WTBVO %%$ZF#4Z:P]>2_& ^CNAS[U1D#C
MBA@5TQ[SULCGQ;PX041G]+N;HFWFZH^)M'_3:\SZQT<&*@_]+-F?>3]'91R[
MN=>:+V.UI^%T/]+QU=;.LWD>,AHK.1G2K3NS;;]1T]MXJFM_CO2Q/VK[%P0B
MR7U22,,9QV'G=2UT7<[XA:IQU:SV.C^MCG'<HN_%,45OY\ERE(%=]CH)A0PF
M^D#C<CU:(KW4;($#SC! +Y!:CI^U?/<U(< X1N,_WMV"S!C\R6CR;NL,WGQC
M<W.3AAL9&S@[D^7KVP)Y$KV, JB+,=\60N50(,=,YN$O,M"2-P>->0SS4%4Q
M1XRD)D11=)9R%9;9L?;-=K;>G,%^.RNU4?1)C6]"-PI&X\M(A?"?G0U-F#T+
M!WK4H0)3E3-+)32F:WY']@=?-GAL)BOU)E117SCVL,,_<;6;!KM,=0TX!R!>
MMB3,)IY44PJZGH#5(3 $,1,=SPJ34KOEH-[X+?-^#A"#ZHU^NTJN9IM@9KC]
M3:B]#C&Y!5N@KJ*K8[PO;?S3E8?S>+IB2D2"P?T=285IR(?98XY4\Y:8MA8^
MQ78.,%=G!\9-1_<%[FGL&B\_"-0\WC:;\$?X0(W&) > %WVN7-W@L]@<D6E1
M.'-4D3?NH-I!K;=T'K"QM:,^1G+$YOMHNI."H7O#Q)XOEIF0KCNAX(JK,=N>
MV*YG>PZ1-TZ9\PMA8-S4V+!H$8'X&G,)NMA@Y9S! <;EZ.%_N.,IVKLAQK7]
M(M)"&<M$E3PH*\'2F)A#5O&Y03PO:]'(!@/0D-Y=Z0V5WH$_9S-2J).!*<34
MB/6)CL3"=/3#+ X H9GJX1&TW2_:1G6KM7]7 L9@CKV:[7B'@AC)201!J"LZ
MZ^-U5;$G26'5$F9?&#QI/Z".V_R*DHJM+:$R6#MO1LBJW\R[E:PZ/(/]GG!E
MYO!%Y"/3,[X5B+4%0L*;B"&HV4S#+M3+ZZ31$: "Z/VJ?Q**671-,[I19>/<
M-O)G<8*EQ0%4NY\KNH J)^>@<\>=>?Z$B(H3Z"?,_V+R:KF GB<\SX!=/SEL
MC>'2'X[&<CYC91R F5U*^\<RF.$VG<$^<:!3\@&FVD1"J:7PPX>8EO"E]<F3
M-?5XFG;(1OS1M0R#2QGYX!LW(@P-"RVM7&\2MACV@48JD3[$70BO/1UJQQ0T
M_-!YW>AK)C=(5O-)MQHVM..R-?SD1JFD92O+*,)$^\EDI(^>(R.L$8%!&#^+
MI++Y&IOV6[SD6;G);F;ZG/9/@H3\[KPK5W0_<%=@AOTEP;712-;&>]L?O"N(
M_?@DXO.N.2" \I%1.Q<4L=\M+HI]=\Y5D94AAPMU*W?:C8^Z[?#E]87[ I8W
M@1.=5/(Z'.5O?7>U(K@G>IJJW$\=F<&!-R4F+$*@[Q?SCQA*HKJFQ$GI+NT$
M->?^%8=T00.K6#;,OGS8Z-\2A;Y^B^8K8=.K+Y2(::\XP%&3U[0CYAF/<R2O
MEQW("!1%0_TY -B,(9F,$WQ1F511:9V1=+,T,\/K]UIU+B39VL;.>YG$&B)V
MB4!K0[,6'CP:.>_V%-;3P0%6\EW1#'NIR#VII4:K/Q)G?HE33R!1>]+,>931
M$M(QYZ2GD(TM):NP53'#/'38U*L@HVLXW._$.,:CI,K':W&WX_D?7]R*$V(J
M/OZ;/%J;AX\W_]K3-/;GRVAO\&?EDBZ-;O[S"W$BO$RN-F/@R!+"2\.$5)FN
M*9L?BO+UGJ?7X/BICIF<AY*" AQ@<8(#/&ND0QV=-HT'MD5:L;\B3=]HI!J
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MUIB?L8?ND\)N,E=9CZ/C9PZNP^8*>G66FWJBB,Q\I%D%!^"]$)WQ))$@CN0
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M M4CAWA3!'0IU/D"Q8\+U"4^@UA4GO@KL)+7C'\+@V8W:=K!15@7EQ_2EB
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M=>W<MZ97GMO4EBY22M?=B$B^9<^;D;Y^YPV?P%0V3&^@=UJ"R?F6SQK<ZF+
M]]*"UQP6MD2AH3<\^1!TEB9M_:A%Z30F=B@EAR_D4)P?3VT*#^9)^#JU(C9\
M6PN^DSB_[*'XE35[R*"%"(\@T.DGJ^05]G2NVY7AU)W['8M7INK(/GB+W[MA
M(,'7 VJC0;!OQ7/BTGEFFH[F.P*NJV9O7P4&E:W*3Y5FA-6_C ZLP@LGW*I7
M_*9Y^,)T7*I P"$)@+KZ-'?K^[<RUX/:!@>NBA&;LB-%:\WPJ?.F8@N$3?+X
MIQJ$1- 4A$9 ^)5^SFAM]6W(PH?[<@#'Z+3T\BLV09GI=K[7E#-#J*NX 8N5
M]]%Y"%[<%V;@H(E&DN*AOD>\!I!T@1B4V;NC1^](OZSV_^=I5$T:1I^(!['\
MZM))PX[LY)F7A[56A3[XF]-B/5LC%,>B0:50;[0(_E[FI1?1WSV"KHE3&1#:
M.K(J(G5MYE:&8^I@U?X*^T=337(&S0NA\\U]JFM,U<*><3+Q=,KI%.:O[7,+
M"3 J8;QIAZ*"(BB9UM4WJJ%%05UU CI?OTKPS1DYZ&"+"T2;>A!:_P3M.#W+
MML3Y1GI7Q[[,>&3=7_/[@?PH4CQ,,7'1^+6BHAT2H6P6JEQ5..%-4IHIV-Y9
M<2NO1LQ'T=<\3PZ-WZF)OZ;4+$KX&2OYW. +';5G!NWSIN!82<7(GZJ_XKLU
M,:>]3^.>#N)^50-RVICLKX'81O\R":6MO>TL#%,%)4%$;M?E]]J/N?^\_>VR
MB,+UN^(?%]*=&TR#9+>M.G?))^R%/]RN?+'HD%8A/Y:<D4F0O0SU@=(C5L.R
M7VJV2 H;"=E_BG;X3Y7&FQJC\Y'OV<2E5/CN#A5Q,H[*-PEXJP<%FS<>Y763
M B-'XB0M@:][72F!)-)T4:?$-:DD[7U6UDGZ,1IX7 G(Y^8W33M/F?OR?3()
M7]$03?NH4'_:0U]5V4K_?W/"\%_.7C+LPC*3KPJ86*>K0:L<X=^V?]^8='2^
M_OS-YK_+"/9^8Y#C)_1YZ E:CZ*;_*"K>DI.1!UNNCI)S-@G]V1*X7:@MRD3
M^Y@?!D=(8+#3<0)'>'M74S@ G%5^]TOGWY2[Y,'6L;93&6RH8XRO?SYM-)P#
MZ%'IVV=,GP1$D+G_)Z1FBOM*:,!CHMB75?TB";D6E>E6BS_Y[^>M%N$83,B)
ME!,)3_/GJ1Q F[9^]6NO/C$N@H#4K+#WVD^08QJTEW?>3@6]Q]"9\J+?FL2&
M(M%;.XCTPQ-Z.^14#H =S[U-C+^TCJ/?N7EN]B?OKS< 7X,@RHSG=I'^7D 4
M?/0=2"623Y01>$.>5WH\CG>3,KG56B Y@T!"A%_H;\%"#12Z_MR!MZ6ARTB[
M=\*DK/^*7D!>.E)'%.W,4@A+\>WM6Q /9FY-O*];2%4',68(IO'&@6BK+?I/
MWKBAH*!3^#(I=H7+U^BO&Q%XK"2+9:"'53<VN;7AU:G^,;6#I;=W&Q#EZ>U;
MB>EHC_'BC5DSW*%AB.-)^+0/U3&,6*$\ 1,W-+$;4- _T*,6S-R+U7Q_]B9:
M9Y;MPAB!1\H:1P53=[HO"!Q>^=OU50&9!WH$#E!U\WL^@IN!N!K6M5[%KZ>P
M\PDWQ*.+/I+H4-H2SY5+A.JH^]"D\WWB5%?=D*5+S J+IOLFEAP R<5_RJJ<
MP6&9*&A^3]P)->Z0._2(B$4+(,Y!\KF$83[!1J!9*H2XA:%S /YG<0)U_^5)
M]'^L V!P_[C?A@-D_-RP9T&]\AEV/IL"*##H_[JH'X#6V'=AZ">BN6K^O@0W
MIS!-;U4DQ$I">U_-@?8 $HIQ*^OW;9[_73_]_Z?ZZ=RF;756_)J@]GXI__G+
MBT^Z A=B'[:#T,]/?\Z_Q@%JSVS>OT9R--8?QH;0.@:]=D(<8ULD8KGH8?-$
M> :<WQ/0P'TDK;,@-NL><CHZ0SH2ZAJCDF.WW@C8<H$>XX7_-1NXBBXOSLU(
M3F\!Q^R167[*R'!22<MJ$-47;CJ;2NRX6O *-"4!^OM(EPT;/9&N[?;S%(.(
M'7GKDKD@&9L/IE1ZN;0NK_JV94^0Z> _FF/9C2TC'$ YFCKYX8^L<4QJS"X)
M/QEH<ZJ1)T(:;K!U.V>_'TT_E4E$&*)*O:[M=[^-K'Y9C_*L_Q"&<H*^:1:N
M.KW^^\F'AO7JY1V4[^$N=W?*D$)^5""&5WN=3 \IPXOJ_.6F4J7JL)2-P-V_
M6PO80K!3$WUL"= L51*_3D30@K[>%PHW?+^C.?M;G +_35Z?^"CP\<UO$H.R
MY%5CVD;!(BR+]*%P!6.15M]J%V'XNH\_P^NG<BL.05O<O'AI,2!J*X%*MI2N
MUI;K4"PT/,0WZH;/S3;EXRUCHU[N%!A5G?*SJ&OU>323U< !GAU9;MR,S1^'
M)W[TY9/K"(I +!ICWP2G@E1TR'>S?G?8Z!)@@:F79AB/LLR8^-1 3*PN_%>!
M,<[?+OLE*&>1O*14TK'>& /"#% OGC3<F'5W:]1>Q3=XF?OI.,\*%%&HI+N\
M:P2XP7,L8W38\$<E+(&T2^GD "#7PH3Z\3VV8S1JCOG>,UXHW[(9#7*FS>>D
MA!)PH/&*YT<'TUHTTKJD7IN)F05$$G%[,RQO;Z_+@V?UR++%5216;%Q>O1?U
M]W(;&QQ0L1 8;X7C&M,FE+<AP"HZS:RJ*4LFP(2 /0C+\(SCX^5+&'4S(!7G
M361X+6&Q+GH0?[;C@*]W.C:*-C'S8?(+_"M;C)V?=3E5*(6 -V1G'0^RG)MA
M,O9L&NZ9AXL+6N$FAZ-D"I%1J/Y5MM1XW#3JE1FN?:QN=:87TK0$!3D&3D0E
MI$*X'&TO]A7CR@$6;./V 5)1*-?\@9&2UGL&$F.YX9NMK:A!MNX4_M\6?!29
M^.>FL;%&&N1JI#17M_?I<R.4 V3=^+-&#UR%06(-IS/7;OL1^/('\OWJFDO<
MZR%36HUTG\6*\%]VX>U[+LK($C855=V@#@">ANWJ.E20F5&7..\NK6Q_8APD
M5IQ=FO\&%A2,H9-(=\,'O$R,6L%*7ECVL;;GGI56]E4?6ES!A@WT)V8.,=/J
M""2=MAQ9.G+P&,PSS?%*W$U0=2 C>+JDH5ESV+>:;'7.%^\T/>#?:OY4;.BP
M&'JNS["=)$24WFOSQ,U0BP74@[&-' #,I?^K]P]"UF12H#2*_:?V\4^,6 D;
M'./ZJQ9[% 9)FRG[Q",."V9KOFW@$5N&1$%APUE^.J+$S]L[M-*D7KD.J,!8
M_K>QG9961_Q=#G"@=<;<H6!6ZIWD<VUFL,6DR.*RR1PN'Y(2=)56?#[A.,0M
M-2^"&>-=G.M;.AGB[Q0V/;5MM[G/3D[:RT!/"EEB+& Z>>CO4:UP;ZU'=]"S
M?/,&S4RO>VG]P;B,=2R.Z?WDT\3XH']M?0N$+?E@,09ZW9C?TL1ZE<8!)-]U
MZ[.Z,M(#H.J*QP@S3%:@584%2<7N0P-FI&\E/2HV3EY;ASL73,!%,_J^BA.H
M9'25B1$H7J'=;YPUU1[* 2X]IK%1R%T_PEB0!NP^@0E+<[S+I_QL'2>&<?5*
M_71\\Q([>!3R*+$_[J .&ES."!^464FO\5KWC F97AXHS3F]6NDR=2]FVC6V
M,-LOD6K0Q)WU(B=NGFWB+8W0WAG2N%WGID_3I] A47?ZWP2.YF_-D,S4S0M)
MK5%>4(-HU+6^2L,)7U0%G;R@\^)KI_B)GPQ>,R%)4XPD*R8X]U6)M)+O 4@X
M$<[]6?U1/1T=V4<<0-"JR=1+PK>A&F\(![]^?I280L17:2N);YK@]!FCUE_(
MHPFIL5FZEQY&$AA<VOKD/6+7CO=QBIG!094O(QH^<",@FP.<LT)(3?<(^K5'
M[0PIT/D*#A9X'86J\*PR$EA>AZ3Y#"!NS+V1/QGF[V4'=^JJH/F]YK[K7$+D
MI5Z0EA&GZK#!<Q:R3R7,4@,T4EF/]_ !L6L:L#UHDAX,'K$"4O5'0NS-S 8;
MQK*HN*D]=FS4QXX<B#)MB@L\L-)K@1N"<PR68%D!# 9,?\R_1:''*#R_>"40
M+47<*N$7.&2@\X1()9"OFVY.KVXW^N$@H;5,D;NA13XCI!FHA7ZB;)J8G"0L
M)=3 L*EDX/["&V-=6F<OH9G]KGCHL!*6LLWTNG'Q/7IZ%4<FT5:MPJM6A:BH
MPO&I%M3N:9]*MCL2FD,7Q S@=J'.4%TCZ-<='321P7]VUQZ7P!#0L/CV[!P5
MC7(UD$\VU<*W0IPBJE0W6_:>Z43>::+ B:1IV+[4=V([9';PK?Z0%0@W"FG;
MQ8_$W;C(<I(::!<?&E+<[LB9*<+^:8E\JF)R:XMTX[C3N5F!*0.N?$N^1MS]
M@L&"<DHTY]Z%]H DB=/I82WU>XCA*FXPGI-(#[K6,[F7P YD8+->!5E),_[6
M:6,I2O)T+@F2<@/.79)&T&D[52ICN>FF)85V+J<LJO-4=UZV^N/\.V7)[1TQ
M)Q3\XO(QXH$X:K?X\4@T'Q_2 ,4*%5-$%_01F%MW1'M=BT2ED?J"",?,#][6
MP\I"_E&-'JQ0OJ(1W2O5W%GJ(]] TY5%6C?/2VFY5%2.@:)J2]3;% )26@QD
M9KU5CI%:D-3%.EX1*6[1"VO(R\Z/D-EV.9T6ON-$N^"YP(-%69HX!^]B3<7%
MPSO%(6G$?,LITD?!' ,>J1RK19L_^@MI1/;^V'R"V= QO774= =+=ZWE2$5]
ML\TFA I6%NWQT'>#0=COUA1NWA9*>_*4 Y )!64U)36ZVV1L;J@X)<C"1Y14
M,].RB5\3S\BQ'YDV=;+"C09*@U1,I(CM\K?[35#@+B:49?OSL+;0I=OXJP8<
MX-;>F/&F)<9%8D]9:ZTEDGT.Z1&S.KV#9[!,]I5I?>'C^\4(U^YCN^@^S!)%
MRIQ$(:#^CDEQTH9Q(\_UU$PDVR"LF)@R>VS.]!](8VF.?3WC_V#O/<.::J-V
MP2 J5E ! 6DJ*%(%$21 B.@K58ATZ2H@37IO"4A3JG2E2HV4$'J'T"0@2(0(
M45J @#&$#H$00IB\,_-=YYQOKCGG.O-K?GP_]K_L\JQ]K[7N^\E::],I]:?3
M3(-_^0@0Q1)R'9N<IT=_L*A%)1%2XA((;" F<4QY.'!:V;\X2 7N,%;=9@UM
M@WUTOC4+@S"U@9RW?$("+:!40]0^LD' [@LS7KB/Y<T> P;+61=T: 2V+2 C
MD*0]I:?YO-$^.P0$Y@!WGM#=-B/O(]0_?IXK"??J)E2#S^T*GU=; D=@4'PD
M&R_)#Y^%"M2G 3#E7?#9>33Z*<<?>=IXNGWJGWI7_[;?E0^(?Z_JS&4>P&PG
MB5Y/N(PO_%?%_?]VQ3W3(&RW?Z&_N#ZHU2K\4578]R)<[05$+3+5QW:&&\94
M 9O>E)][V9W3W5I2MRY&#MQC+EDM,DY?0GO ,.$FMJ,D1]MOS 7O(?^7^JA1
M ,QEG['%M6P1K6KO8)APQ;N<WS)#7$QPKOSO!.T7XQ9%SJ[(.4O1M-1+W.UO
M2_?L+V_H)UH2$ EN^6CN[/.A,'39#9ZPS4&B[G+7ATC.7!$U[/EX92[6:X-I
M)V"UT5<?1&>)G/A"K/H &,D&JK=1N\=K=?NTQT6I?RI>22@;=Q9K&SYK*#6X
MS>"S+L6-,'(Q<A1)$V125<U/V5^J'+=Y.&*MZHJO56:HM]NLK W='@]Q3Y ^
MO6JNXR[@/GM#-#]P2(0/P\M+P5@<MFNFZ0N?5)!^86&I1;[P*>7MQBC&MC,%
MUVQ!IS]Z>KF"X],[ .NH-O-):6\](;9/<[[2UF(C'3:I;4YOJB_]P7L=U,EZ
MWU/F\%BV$>;4"!S)D?GV5]_7([%G,=L[-6'A+/R=WI/R![=>(TL;@UV@D.0^
MLZ]+$S4-6U?ZOI7=O6AC@C1\$ VT,6XM]_ZN'#?I[:*L0BI?JG\J@W27,7YI
MC3\G%WV0)->]^I"0)#YA,WM.#*0M>@Q()I"FJ@PSTAH\AKF*D)U%"&19;U30
MJXSI!CM!/ZI)<W 3Q:VF*$Y"YU]A="-G_1A08 !)7K\[_ND!TU'5B@J$9VQ+
MS7Y9'"';P\"VG^Y2D^ERQX#Q5VIQ=\KO_(<OB7OJ!Y*&F/PY^M8=44=!VH^+
M8L6B6&1U@Z %VAJ;5]2!=;3\\DGI%N%%MU?D3X[M4] OH2K4^B+HF!!GI/Z6
MP(<"?M+5HO,G\WYJD:^XG0H0*&C36@J@(+]5_-ADH"JI*J;QUC]D;"89BGR^
MKPV:150=!>7I/0*XC.SE9$'*&W_VCDWS=4M#!>^94%'"MS3]0(MU:9U ER&+
M$C_LD]8EN^TXWM77K'(F0IRRPZ]+HT9NE)",O./+-4(10(,O&7">\3VU2FK\
M0F;=SPUI]PR[CKK7,Y43[V8C4Y):U@[\U7Q<OZAZ5;1*&,\?SB?#(,2I=C<Q
MZRYJI+V?2N8#GAY6FQ&@E(EG/T-U)S]PMYK#H'XZY*:&9\5S-]YN$1'XRQ02
M=<?VBT.HN6&Z[._\<R5.?WS+#8=WP@2<31/-SN#&S+]8#V=\^SZ JP<7[D@5
M5J%8$HH-DR1BY$_I^%1&>GF5)T4KW#*4G>CIF;L77^\1YA9FWB6LMYC7UJ\J
MRCKRFK5M9WH'H_-7]<:60H-U,+KOU>^\XI27%XSI_2^#Q."J29'-IYM"^1&S
MT\Z&I'*^N[?-W.=TEDZHHS^O!U_^:>!51@V!_$3XW8X&-_2Q>45D0.$@VN[?
M0%%<6CS<-,DQ>\$S\-U":7PZJ4=2/S'8Q'EG6\.=GI4[5XV;Q#Q>K7O:EF_]
M=J%+8F$DU#.0^*YG,3 [<%!?8G?KDE'A(XX,_8H$8.N;Z<ZIVAGJ-]UR!24%
MR9SGA=$9 LK1^+0$KZ$E#B+:96M#V+DMJ50@>#G31L5A5-_[Q#YE#0W-*(<A
M5IJ#R58N 2H-[[*6PO-/1*#9(L*5%)(7/:X^"7LSV68\?+'FE/T[EAT.*R_\
MKXC=*J_63,4NSKLQ(N=C"E6;TN_1#$H;GV/W7?1+&]/S5PS;4$;M<;6A*CEJ
MD@A+V9$%W7L#)FBCPO=YO':5A!=II>\^%P_K\-X9?JZ.=/XV0:=*R^@]-KNY
M0GLM9[Y4!U1B"4*#8!S=6U:P=WXWOMAD)"QRGWJ4](E/\#3+DD#RLK4H=MC1
M3O9]3;TX1]+96=P!<;+C&.#\4H3]WHB^-@;YQM.'F>:1N>4ER\-WMD'%)U/C
MW8"VV]CF0<9K]**C8J&%G\N$:V:I19IW+H'_SNWE  =!:5C+&W (G7:MX,6H
M#QZ,4 ?<>"<FRHDYHIA6R@\RNA9XYSE)EC:\#:X(/5%6%:VUI(\;^6RX%$H5
MS\F\UL,9EOS< &%$0-M)V]]-'CX)NLE98OEY8:T4(O+-F.OO &</-WZS@VF/
M[=:N*P6-7\>B2H>UVR=<UJUJG=M#NZ!/28W.M['KUUW3=]YX=_E#7U1B?EY@
MQS\+<WTUO3J2&%+T,-_X'2LWZZUW?'^5]XC-XQT,;#_*K26S=S=H\?6+VFT(
M'ZN@%II5P#/,A6-MN.#"BK9[%*(*N=WMDRN'%F'*LU4@=RF^+D]!7Z>$>^%U
MNFC#I&5S67Y[ 2SVN^SSY^.(LV*9$K6%XBU?%ST_)HKP\)DS5F!<F:2N:>A[
MQN#D5002/SOS61=3,P-0%GCWD;BEZH6?1$F!G6]"!@H$4V5AC4N47:%&6OFA
MF.O5K.#5WP_KALN>/NS>X SC>"/ 4,LX,/]O.]H,D]U/(EV7NVQ,Q.=DW>F9
MB;EA_+C'6QO<IH)>[%>4G USKUKJ?4,H.)IZIV:!]-04LRUF?]N6+_@:/ EA
M^Z/^[Z:6-3&\0Q(<K_ $.Z^WO@K@W1,X=(3#(!;SY*FN"ZZDA2.GN:;9P>YR
M)=6(;B+]2'(04[E8<Z"AW'1.]5>+0=KG_%'X;U0&9BST]K=M 6*_#,]P8'YQ
MZ8?%>HEGWR4T9L9Z;2A!'G#Y.&=;W5\$U: %W>0SKJDD,]VZ)WKSOG]Y*,3\
M X1P#)-IT>VVS,RNW8WR'4[4V''WXC+4.:T<6>-/PUEN79^E[J"OON;(=M,(
M7!.9:OUC^HP=0.!%DD489TB'IYR@IS>/D(FA#F5/OJRT=;9]?^-^4_/Z3.C\
M2UQ$)!;@%1%'9T5S"-<Q%5*H5"PW\7)I_**4QE6N[56$8E=CHNX^ N]BG)&+
MS\]1@7+O]FQ!WM)/8@)3,_6 IC$.!8OW1D\,UU[4:7K)]UU*M:P07O\6>FCQ
MNWJ$H:YV/51^"]8G^$J/\VN;]4">?]6S]T6!?78BB?-^?")I]&X<U:/P.9X\
M96EU]^/;=0XY#K"X)[NWW(]C@!')=@))OXK=TZ2ZE@3Z=7B];E(V;6KZ8^3!
M&Z?H^#0B7%9_GN4E6C2.\5+M<H^;'4QZ><3&Q4++<IUR&7B=X7(&_2RP?#,
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M(6$BENX<,KJM_TW2\G8.+NS!Q&I7,!?EMZT'!HJ:[%\Y Q#>^2Y0&<UZ<E\
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MR_7*XW5PI-P:%,A.-'M;@(_XX@Y\F<Z":Q81>+\H,*VSW)J B9D78!\('#6
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MSQD;6'H.I9I>YOFSU7?52[-$NDD:[A?]:Z#,OTXOL5-G@9]-^D[B39#AU[[
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M=+3*1&4Y8MA.&@T.0S6'UX)47'<BU;5D"$M[OH-:?U9FDT\ VC5G_LS! A+
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M16OC\__Q]6WIZ17Z),JRQ+>#?8['\Q&DE?RN>YKK>5;H!2BJ7; 92 #T E)
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M7P_6?CN=U<9=?].KR[>A(=.^L )>'M:-4Y)HE9VE?I2A1<RY;]HPAHTO[EN
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M0KTJZ8YZF)5F)<3>QL?37+*,U_SY/?_F>$VHKT1XU;K&58L+K2<Y<!#7MW.
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MC*_3[F!.!!OW8_^'CS%;PIT,C\PSL<?N*7798.LM"U?O06/:*BUO^<,GMS!
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MB[G)&*>9IU@'UWYM?;%]6!A:6&";&G%E$Z5-.MR&8*#.S^MK?QA%=/&]BIS
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M'% P:)4.8"6/G0.Z7H:O'H:Q_@5O.OSG )5H9.'0_U%K"'ZB<0ZXKV-SQN*
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M<BOX:P]/7<+;)_KZ6=9+"X<OIL17KM;]MB"-'RFEC(4(WC\<L[Z2SU0R7]]
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MK+]_R^JG3Y[<1*',$>OWJ4R#'=EG\0\#1<KL/)NM+)%W8H?7,DQZUT[C@T5
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M,&MHV(4\/P'88:)]I[E&BM9LZVVX"$\$.U\'E *\2;S,)@58;:I>DW?)VX.
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M4+-@X"_]\9<:!^O.T<)FD^[O5??9]M?I0XG34\L^]9\0?=< 9SA4\"R8W1,
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MTU2<A WLV[OX2 \$.I.A:;XIO-41:1[XU(1C7ZP&0*8'<\A34GOJ=OAXW4H
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MB:E_A2/^Q?H#QL]2?@OIZ:G1S<K@D L,@7D^B9O-?C;^,?^\N6E=3KY)BL9
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M5+=M#4=1L8(**"A%!:1)[S56$! B76E1 1&0WENB(*" (%U:(M)K!.DM($U
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M86%RMLL/#1T*3XA135-]@,\J4MCK]H&4ZLK]@R!<'0-0@2QC $Z16&_^^L
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M@]9\FK_5?<VZ:B2BZ/\\S16V0H--._XNJ"3$=UZZ$5%6/GE\Z_U;G3L_ 9I
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MJ+VE?YAK$""1@.)-&J-D4'2(@6C7&^O]5MU%(.Z'@ 4*NR%0C;1](?6%OQS
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M%7S7((3)3F%8$%U>ARJ':0.1K[=>8@+ M9 !X"FD94?2[].F81!;:/8FS6D
MBE]HU,0-3>4N'FSFT&]LT?N!-8DX_W;01=_-/ ,T?Q\$_MXFB6A.*Q6^AR6
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MIBT@_5L:E*Q9NG<CB6Z X&2N]_DI!L"PDRK_C@%8V/40H<7(@VC71#9'.(W
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ML=K9!'RQ(?\28Y@7TQ#7EU\^\NW)Z9!] *\9 J?ZN>&/"(W#PKM#'XD+;41
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MNA[XOIZX"+Q7O0OP9&^(N#(RG/\,KGMW,E6<L?GDJ^(X3<XT/"EJ#JX]6AY
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M/G<K+@+,#708N$PU>*2;8F(0Q0=Q%YW[ VY6&F&%_10<F2F&.PM?/H.S("<
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MKVHZ-H=9^=3"$.M:N%G;U-JP2!L6?+B/\M ]<-W3,]_HVB3+T1474_BF21E
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M#-JV1RHB=/,A();S6VG$Z.TWV]9CG\]+TS?J_7Q'6!M^8MN.J4=O3S"W'!?
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M+3(P,C0Q,C,Q+GAS9%!+ 0(4 Q0    ( ..$9EH&JP^$5D(  ".8 @ /
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M   /              "  >[+!0!A<F-T+65X,S)?,2YH=&U02P$"% ,4
M" #CA&9:S2CYKSX%  "((@  #P              @ %8T04 87)C="UE>#,R
M7S(N:'1M4$L! A0#%     @ XX1F6@88AOT7$0  >60   X
M ( !P]8% &%R8W0M97@T7S$N:'1M4$L! A0#%     @ XX1F6@ G!R+')
MA6<!  \              ( !!N@% &%R8W0M97@Y-U\Q+FAT;5!+ 0(4 Q0
M   ( ..$9EKE&ME_Q.D  $3]   2              "  ?H,!@!I;6<R-C<Q
M.#DX,S1?,"YJ<&=02P$"% ,4    " #CA&9:)FH@20\9 P#@AP0 $@
M        @ 'N]@8 :6UG,C8W,3@Y.#,T7S$N:G!G4$L! A0#%     @ XX1F
M6C9 Z8L$2@  FX\  !,              ( !+1 * &EM9S(V-S$X.3@S-%\Q
M,"YJ<&=02P$"% ,4    " #CA&9:8V\'LV[P!0"L0@8 $P
M@ %B6@H :6UG,C8W,3@Y.#,T7S$Q+FIP9U!+ 0(4 Q0    ( ..$9EI.<E^/
MT%8"  J7 @ 3              "  0%+$ !I;6<R-C<Q.#DX,S1?,3(N:G!G
M4$L! A0#%     @ XX1F6I3UE'7>@@  DLL  !,              ( ! J(2
M &EM9S(V-S$X.3@S-%\Q,RYJ<&=02P$"% ,4    " #CA&9:V&\EOHF!! "D
MK 8 $@              @ $1)1, :6UG,C8W,3@Y.#,T7S(N:G!G4$L! A0#
M%     @ XX1F6IUYG!H9%0( (T," !(              ( !RJ87 &EM9S(V
M-S$X.3@S-%\S+FIP9U!+ 0(4 Q0    ( ..$9EH<(=OD;TT" %-Y @ 2
M          "  1.\&0!I;6<R-C<Q.#DX,S1?-"YJ<&=02P$"% ,4    " #C
MA&9:$B3P//_$  "*R   $@              @ &R"1P :6UG,C8W,3@Y.#,T
M7S4N:G!G4$L! A0#%     @ XX1F6KT7G<ZKS   .Q$! !(
M ( !X<X< &EM9S(V-S$X.3@S-%\V+FIP9U!+ 0(4 Q0    ( ..$9EKA%7(2
M='\  %>M   2              "  ;R;'0!I;6<R-C<Q.#DX,S1?-RYJ<&=0
M2P$"% ,4    " #CA&9:#,Q"D8=/  "/BP  $@              @ %@&QX
M:6UG,C8W,3@Y.#,T7S@N:G!G4$L! A0#%     @ XX1F6G4-6\_Q:0@ Y'@)
M !(              ( !%VL> &EM9S(V-S$X.3@S-%\Y+FIP9U!+!08
.&@ : &,&   XU28    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>arct-20241231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:arct="http://arcturusrx.com/20241231"
  xmlns:country="http://xbrl.sec.gov/country/2024"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="arct-20241231.xsd" xlink:type="simple"/>
    <context id="C_801e363e-339f-4807-9e7b-89e95be99722">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:CysticFibrosisFoundationTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arct:LUNARCFMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arct:UnderlyingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-02</startDate>
            <endDate>2023-09-25</endDate>
        </period>
    </context>
    <context id="C_820e29f3-5ff7-4037-b94b-5b58fd071bfb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">arct:FebruaryTwoThousandAndTwentyLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_85b74df8-3891-4246-9852-23bd86a40945">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arct:Early-StageProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_860c0a20-b573-41e1-a9a0-9d26576ca073">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:PropertyLeaseGuaranteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_86445ba3-f6f4-4676-90ed-50251dd3995d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arct:WellsFargoCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-21</instant>
        </period>
    </context>
    <context id="C_86d66d5d-4c97-45bb-a084-bf8bbda66671">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:SeqirusIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arct:Covid19VaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arct:ResearchCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_88537db2-a4c2-4868-aaa9-8f88cee3858f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arct:DiscoveryTechnologiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_8a585c58-b141-436d-8855-b3bbdf1ff8a2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_8a8ee8e1-d0f5-45c7-a284-959089bf94e1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_8bae3d05-d6e8-46f3-863e-be5c603f6fd1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">arct:DirectorsOrOfficersExceptChiefScientificOfficerCooSvpCcAndPaoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_8d83dff5-ceee-4639-a422-5542c54a34d5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_8da6d6ac-b3ff-404b-afdf-8fd51a86a7c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arct:VinbiocareAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_8dcffe65-b98b-4723-af16-5b3daa5d33c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_8dd3cd07-367a-4d33-a06e-49f7bc62341e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arct:LUNAR-OTCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_8e8fb1ef-45cd-4aa8-9a33-0ec3e20793f1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arct:Early-StageProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_8fd663c7-d616-4fa1-9c31-9db23c56c689">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:SeqirusIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arct:ManufacturingAndSupplyOfArct154DrugProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arct:ResearchCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_92f6052b-f423-4970-890f-aaeea914fcef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arct:BARDAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_9316938d-e4f7-4709-b45f-2d7d8cc44812">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_94fdde70-e99e-4e78-9fbc-8f8f22d0ba4d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_958a90b7-6a27-4c61-95d4-5f89fe769df8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">arct:OctoberTwoThousandAndSeventeenLeaseAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-31</instant>
        </period>
    </context>
    <context id="C_967a80b1-1866-4f20-95dd-a83f22149812">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arct:VinbiocareAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_988a9efb-2454-43a7-a157-c666550071c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:CSLMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_98a6fdf5-4340-4e1b-9ce6-86901cc3549e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:WesternAllianceBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arct:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-14</startDate>
            <endDate>2023-03-14</endDate>
        </period>
    </context>
    <context id="C_9b6438ac-a4af-4cb1-a7e8-04fc1dc8917f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_9f520c76-36f9-4e10-88ee-34a1bddaa46e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_9f995e84-394b-4f80-b22b-985e9d097bfd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_a3464474-dfd3-43d9-b123-3d9c2d59b71e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:SG</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_a35204b8-793a-4f51-b6a2-2dad74d8547e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arct:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_a45712ae-2c2b-44d4-ae48-9d59250b85b6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arct:LUNAR-COVIDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_a64be24b-e012-4869-ab48-edbde5729fa1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:WesternAllianceBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_a772c31f-b8d4-430f-b45d-52b674305e78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">arct:OrphanDrugCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_a80d4900-cff3-43ef-a5a2-5effe03ec8b3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_a8f29617-6dbc-47c2-bf34-7e091c3128a3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arct:VinbiocareAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2023-02-28</endDate>
        </period>
    </context>
    <context id="C_ac4a66d0-a617-4eb3-97a5-5efc86181fd2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_ac8997ea-dc9f-4fed-83e0-b13eb0d07432">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arct:PhaseIClinicalStudyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arct:CslCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_adf77a8d-9580-41d9-9c8e-9064454e7c28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">arct:FebruaryTwoThousandAndTwentyLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_b5b1f0d6-262c-46b3-85ce-a3305beaaa39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_b6a637cc-890d-47eb-bf8f-c3b46e805e7d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_b73afaae-41c1-46b6-8616-4cdb808c1c4a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arct:PayrollAndBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_b82657d6-82b1-4bfc-88e6-4814252b20d1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">arct:OctoberTwoThousandAndSeventeenLeaseAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-10-31</endDate>
        </period>
    </context>
    <context id="C_bc749b60-01c7-407d-a66f-0ad31c3e3223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:SG</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_bf73fc87-a7ef-43a8-bf1b-0ee33d958d5f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="C_c0934e56-cff8-4842-acec-a05ccd4099a4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arct:DiscoveryTechnologiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_c12666e5-df97-469d-b1e4-3c9a57cc9650">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_c25d021b-7bf8-40de-b1c3-f954fd411acc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:JanssenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arct:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_c45ae1f6-f871-404f-8826-2b495a729716">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_c6809d71-13e7-4b1a-924f-d8abae76045c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:SeqirusIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arct:Covid19VaccineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="C_c8889a7c-69b1-4f25-be7c-2c7d95316544">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:CSLMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_c9c5c093-9b6a-4d10-823e-777266370955">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_cab06b3d-053b-4c81-b42c-b2445cd0c158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">arct:OrphanDrugCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_cb30b8bf-d65b-4a7e-8e21-e4aa8d48e2f3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:CslSeqirusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arct:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_cbbb84bd-f6c0-4979-a42e-6dd1dc94cd5c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:CslSeqirusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arct:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_cdc3b296-383c-4f2b-8a23-fed8e5efc389">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arct:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_d0748bb0-90f5-4425-beb5-86fdc83461e7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:CysticFibrosisFoundationTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arct:UnderlyingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-02</startDate>
            <endDate>2023-09-25</endDate>
        </period>
    </context>
    <context id="C_d22dc742-0007-4f3e-97ad-b0aa9112af8c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arct:TwentyTwentyOneInducementEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_d2b6f456-3e1e-41e4-bd44-0e037c42e4ca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_d4667b25-9ebe-441c-8ace-a7cddce91af6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arct:CslCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_d4c6eb14-ee87-46e1-8ff9-0f1eee8139e1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">arct:SeptemberTwoThousandAndTwentyOneLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_d50d4b6b-e748-48a2-99dc-da00925623e4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_d6e35e55-99c4-447c-93d6-7979a6be6791">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_d82ff122-590c-489b-87d2-a9001b2499a6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_d88f1ae2-2110-4172-a005-770d3804d551">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">arct:ForeignCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_db600b02-dfe3-4388-80ba-2f5ad5b53df0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_dbce4aac-da09-4a9a-bdad-eed2250c6e8b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">arct:LanceKurataMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_dbe29eec-3da1-447f-afbd-bdbab15adc3a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:SG</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_dd07c4b0-0b2b-46df-8180-9141d3a4695f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:PropertyLeaseGuaranteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_dd47aa1c-68e9-4b16-9e78-294207b60f30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_de7040c9-0664-4d4f-9974-fddd45db823c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:SeqirusIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arct:ManufacturingAndSupplyOfArct154DrugProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arct:ResearchCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_de7f4b0b-b0a5-4403-a0c8-005d40a0ea9f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_deb1657c-7399-402c-8536-0419c46c6233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_dfad2efd-655c-4712-ad55-9208245cce2b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:WesternAllianceBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_e0b98ca8-b4bb-4d0b-9631-02538172e7f5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">arct:SeptemberTwoThousandAndTwentyOneLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_e0eeb777-c5ee-445e-89d3-2c8ed430397e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_e1270539-8c54-4b3f-a7ca-d75b1c8c8913">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">arct:SeptemberTwoThousandAndTwentyOneLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_e22ed845-7d56-4d58-bbda-cdb707f0cae4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arct:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_e2d495bd-d213-4380-9448-1294459b3c51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arct:LUNAR-CFNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_e340decb-8e23-4aec-a50a-9afef8ee8eaf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arct:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_e343b8cf-c999-46dc-82b2-5e281a84df00">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_e3934ce5-c321-4a31-b7d0-60e3e1ef8264">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">arct:ForeignCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_e3cf53cd-b1a1-435f-8cee-4794f5764eb6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arct:TwentyTwentyOneInducementEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <context id="C_e555c3b5-c6bf-47e7-838e-8773ebae68d0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:WesternAllianceBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_e570fa19-3556-454e-8682-69a04831b6bc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_e6a54d12-2d06-43c8-a611-842ff0eff99d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">arct:ForeignCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_e6b834ef-7cbd-42d2-9ba5-f1ffd18aff0f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arct:DiscoveryTechnologiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_e7cfc84d-4c9d-4d01-afc8-236747b0ea78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:CSLMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_e809b54d-dd94-4594-8f54-a7a9ebc5e794">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arct:Early-StageProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_eacfa335-f40d-41a3-a10a-eb5d58e4252c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:SG</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-07</instant>
        </period>
    </context>
    <context id="C_ed799f3d-249f-4d51-ae92-deaa84f57abd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arct:FacilitiesAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_eeccc958-3920-483a-bc18-4d732d1e801f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:IsraelMinistryOfHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arct:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_eefa9a8b-a137-4b9b-a9bd-84d6397dcbae">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:VinbiocareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerDurationAxis">us-gaap:ShortTermContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arct:StudySupportAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_ef9e3212-0c72-453d-8e04-d4b0bc08213a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_f0949914-ab4f-42d5-bcb0-e24ecd07e8cf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arct:CslCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_f0e7f0b2-1598-4953-9f90-cc64a32fbc98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">arct:EmployeesAndOfficersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_f6556892-c686-4b0f-ad35-b323cfa6c9df">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arct:LUNAR-CFNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_f82651ae-69da-4140-af2f-5b915dc1aca7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arct:TwoThousandNineteenOmnibusIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_f92977ac-e76b-4cb7-8d5a-5b699cbdb902">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_f94c3743-e85f-4283-b541-3b2a49e36750">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_fdc06d4c-b98b-4078-96e6-528aa846af54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:SG</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-29</instant>
        </period>
    </context>
    <context id="C_fe6dc61d-d3ca-490d-9689-8dcf10e0d322">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arct:FacilitiesAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_ff6d8148-36b1-4ba9-847e-b95829a0383f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_ff7ed278-8619-4daa-85d7-a6142360937e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_06d432cd-fe67-4805-a95e-d98b0424bbc3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arct:LUNAR-COVIDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_07a158d3-db39-46b0-b8a8-d157b269ad9e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arct:PayrollAndBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_07fceadb-01ec-4fd6-aff8-7976cff4540e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:SeqirusIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arct:ResearchCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-01</instant>
        </period>
    </context>
    <context id="C_08938b4b-8f37-4a42-96af-9374a057c857">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arct:LUNAR-CFNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_08b6efae-4fda-4db6-b9c0-371c0ef137a3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_0a0009ee-75b0-4d6c-8c54-a3de804d67ed">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:JanssenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arct:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_0c35a6e2-43f6-4708-bba5-5173dbc3de2f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arct:LUNAR-OTCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_0c651e95-fd64-4c52-a5f0-0d5b8015a505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_0fe3841a-f105-4a0f-a913-03e14cbebbf8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:SeqirusIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arct:Covid19VaccineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_10ba438f-86e7-4bea-afe6-6381fb76f525">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_11fe4360-7e34-49ee-baa1-bb4e286f6f12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arct:LUNAR-OTCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_12470630-daf9-4fdf-a875-a3affca4b6e8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_1431fd58-6694-4958-a082-b782f01ec3b3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_152910ca-c407-48c4-8614-914f708479a3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_170f1f48-3dbe-4cac-bfe3-571918df82a6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">arct:DrPadmanabhChivukulaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_18e8b3d8-b758-4fc5-9f07-48c66ed98d2a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:SG</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_1a296724-396e-481f-8c86-b3b311ff76f9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arct:BARDAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_1a91ccd4-4bd8-43c2-8051-45a814608dfc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arct:TwoThousandNineteenOmnibusIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_1b0157b0-3108-4ff6-bf3d-93b8178679dc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:CysticFibrosisFoundationTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arct:UnderlyingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_1e0106b2-7efd-48ca-85e2-4b61ddf65637">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_200946b9-b524-4e78-9424-4e601b6b9f68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arct:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_2177e6fb-ec81-4ef2-b37d-c5ed17225037">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_21bee724-74a7-4507-ac63-b66c0326eeb4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:WesternAllianceBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arct:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-14</startDate>
            <endDate>2023-03-14</endDate>
        </period>
    </context>
    <context id="C_21d1b797-41f5-49d8-a548-8998a1e9873d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_22f5e6fe-f31d-416e-a210-33674b90d66e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:SeqirusIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arct:Covid19VaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arct:ResearchCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_26a8b21d-1c26-4459-a1ee-d89f9f331468">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_28c7b4d4-46b4-403b-a81e-106c6eae4759">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_29eee7a6-fd75-4779-badf-175826fe2dfd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:CSLMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_2a5b949d-4097-4151-8f74-d5142e6df00e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">arct:DrPadmanabhChivukulaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_2acf2ac7-01e2-4268-a321-5c97d29be022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">arct:KeithCKummerfeldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_2b4a205f-e9c7-4a9b-9f7d-e2d74d8a8790">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:VinbiocareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_2b4e1b2e-3490-4f8f-9601-99e9e60ed774">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_2b79e174-202f-44db-a40f-0080c01394ba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_2bb094b7-f6bc-4639-b097-78aa4e69c032">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_2cc45ff1-3360-475a-b5da-15ae2c8d66aa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arct:TwentyTwentyOneInducementEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-15</instant>
        </period>
    </context>
    <context id="C_2d41c197-8a7f-4abe-8802-3f3779ba2106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:SG</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_2d657502-e913-475b-9a66-3a5a4dec9710">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:VinbiocareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arct:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_35939c21-6356-4b16-b155-5ff282b4b400">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:CysticFibrosisFoundationTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arct:LUNARCFMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arct:UnderlyingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-31</startDate>
            <endDate>2019-08-01</endDate>
        </period>
    </context>
    <context id="C_37d3f9a9-91a0-4432-bb97-b21a720960db">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_382d54f3-b7c1-44dc-b7ac-45940950e7db">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_384780c2-a461-484e-90b6-4ba525f2b0cb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arct:PayrollAndBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_3b5bfb69-0e34-4596-883d-6933762b5f1a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">arct:LanceKurataMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_3ca1293d-fd04-40b8-a46a-57af6a5ac7d7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arct:PhaseIClinicalStudyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arct:CslCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_3dcdc036-b6bb-44cc-9e78-55386dfe3195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_3e3c5d0e-9c24-4b1b-b7e1-d57a6036bc5a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arct:WellsFargoCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_415079ce-5509-40be-96cd-1470dad8f0d8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
        </entity>
        <period>
            <instant>2023-08-31</instant>
        </period>
    </context>
    <context id="C_41912f33-1403-4518-9ac5-80cc445c3148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arct:WellsFargoCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-21</startDate>
            <endDate>2023-04-21</endDate>
        </period>
    </context>
    <context id="C_42551c33-9281-450d-a0e8-7a28c2252c4a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:CSLMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_42b09082-30d1-4349-88f2-ae97e705f43e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_44b8ebcf-fb2f-4241-9026-e24a66edc6b0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_45eb8bb7-286d-4047-9f32-b23ce157716c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_46790da3-ab07-41f8-bb66-6d90294211d5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:SeqirusIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arct:Covid19VaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arct:ResearchCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-01</endDate>
        </period>
    </context>
    <context id="C_486087ba-60a6-4677-9a46-887bc39af237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_48e6c1d3-4d22-4c10-8a2a-1bdd49245c23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:UltragenyxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arct:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_4903df66-6bad-45f9-8151-6f6455ee1212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_4a52e6bd-de03-4707-910b-3abb83ab2003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arct:PhaseIClinicalStudyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arct:CslCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_4c016b15-4aaa-4d51-bf03-ece9dddf38ac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arct:WellsFargoCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-26</startDate>
            <endDate>2024-06-26</endDate>
        </period>
    </context>
    <context id="C_4e71c9fa-246b-4174-807f-580b538d6c44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:VinbiocareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arct:VinbiocareAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_4e721db5-40e6-4075-95cb-a09086f8814b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:WesternAllianceBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arct:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-14</instant>
        </period>
    </context>
    <context id="C_4e7cbee9-3838-4850-806d-710b2e45882f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_4fc38bda-72e0-4e2e-bcde-f14d64558664">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_517ad6a3-e9ae-471c-a53f-67c77e50ab6f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_554b9050-1f94-4300-aff9-82c1bde3198b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_55f99ccf-69c7-4793-a958-d0a9d4e65d04">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">arct:EmployeesAndOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_57101dc7-2fbf-4d4c-8577-c3989e4bc34a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arct:BARDAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_59320853-4bcf-4a90-99e2-d4b7e72b628d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_596cb559-9f30-4570-b72b-2e4bf88511d2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:CslSeqirusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arct:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_59dc916f-940a-4c84-98d4-897fc187a986">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">arct:SeptemberTwoThousandAndTwentyOneLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_5a02c86b-64a7-48c8-9d61-fbfa2c4dde8a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_5f293e8e-a39e-4833-9e79-510818455bc1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:VinbiocareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_602adcc3-a068-4d86-ad11-fd96cb49a486">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_652488b3-7499-4d63-b634-9c1ddc35880c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_654bde4e-918b-4b9c-901a-10010de70313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_67ddf72c-3213-4f12-be1f-701d0566198c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:SG</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_6853a270-d4df-4f01-ae68-1bd1f016abe4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:SeqirusIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arct:ManufacturingAndSupplyOfArct154DrugProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arct:ResearchCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_69de4a86-a3b0-473a-bcf9-e08244abbdd7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:WesternAllianceBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arct:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-14</startDate>
            <endDate>2023-03-14</endDate>
        </period>
    </context>
    <context id="C_69ed5d25-10c1-4aac-96a2-03a2b894d649">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
        </entity>
        <period>
            <instant>2025-03-04</instant>
        </period>
    </context>
    <context id="C_6aef7a2d-0065-4f49-a030-b4de642f444a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:UltragenyxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arct:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_6ba7dcb1-88d1-40cc-9caa-9904c066fd42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_6dcaeb74-849b-4892-8d45-1cf1c0c414a7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:CysticFibrosisFoundationTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arct:UnderlyingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_6e132eb5-a5af-499f-bd75-b24d62c5092f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">arct:FebruaryTwoThousandAndTwentyLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-29</instant>
        </period>
    </context>
    <context id="C_6e573c31-64c3-4efd-b469-ce13ad81a767">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_6f2bd238-0b95-4b22-8c5a-121d7509ed58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arct:PhaseIClinicalStudyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arct:CslCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_7265865c-204c-46d5-a156-36e79a71f210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_74cdb34c-62d2-473d-9ee0-84ce4b40931f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:SeqirusIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_7882f9eb-6eb4-4f9e-bdb7-9be9e4dde643">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:SeqirusIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arct:ResearchCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-01</endDate>
        </period>
    </context>
    <context id="C_794d8e75-547e-4d8c-b200-6302eefbd65b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arct:CysticFibrosisFoundationTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arct:UnderlyingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_79990b5c-27fd-44ab-a481-a933f3b6649e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arct:LUNAR-COVIDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_79b86a89-0a00-45b1-8004-7d4dc0cdea25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arct:TwoThousandNineteenOmnibusIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_7b5e8cb5-a2d5-4fd1-a235-2bb6e7524e95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202307Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_7bb37bf1-61a9-4d5a-8bd6-2abfca1a4ec5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arct:CslCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_7c8f1ee8-0d0f-434d-9eb4-6868c4d8c3c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-31</endDate>
        </period>
    </context>
    <context id="C_7f5b7d69-0f16-49c9-8312-5fabb8348a71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768224</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arct:FacilitiesAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_SGD">
        <measure>iso4217:SGD</measure>
    </unit>
    <unit id="U_Segment">
        <measure>arct:Segment</measure>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_87144c4a-992c-429f-9bb4-5fe503136d46">0001768224</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_9a775996-6ca2-4999-b2af-1ccbddaf3364">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_2abdfeb6-700e-492c-b255-9f95c11e5731">FY</dei:DocumentFiscalPeriodFocus>
    <ecd:TrdArrDuration
      contextRef="C_2a5b949d-4097-4151-8f74-d5142e6df00e"
      id="F_28c68eba-ea54-404a-a9d6-fb19a33b35b4">P162D</ecd:TrdArrDuration>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_1431fd58-6694-4958-a082-b782f01ec3b3"
      id="F_a09c2b80-d521-40d4-b228-c34c98f0be33">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212"
      id="F_7bcaf8a7-146c-4002-845d-af462601018d">http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc"
      id="F_9747f896-2497-4837-848b-f002a89071bd">http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_806a8df4-c83d-4622-a6aa-7b9d8f050c33">http://fasb.org/srt/2024#ChiefExecutiveOfficerMember</us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration>
    <dei:DocumentType
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_a093a6c6-cb2f-4497-862b-f08463b0c970">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_ad56bfae-7991-4b50-ae68-d42b602c0d5c">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_fa2aacf3-60f2-45e5-b4b7-771eac3bde67">2024-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_3d124613-de1c-4243-9e8b-4f7cf094e512">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_d2ac132e-a364-4c4f-89f1-61d079d9178b">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_bea4fcb0-3f28-49f5-b049-c8fd41f2cfc5">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_d041caae-afbc-405f-974a-23707a15ebe4">001-38942</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_69f7a15e-f55f-4512-9224-c2cc26ea2db9">ARCTURUS THERAPEUTICS HOLDINGS INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_8bd44b60-848b-4960-a029-c2d9810975ed">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_121825f5-7fca-4c4a-87d4-323c0da8fd67">32-0595345</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_ad3ac702-8474-430f-ba0e-f5a2f61d7063">10628 Science Center Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_cc77f51a-e8bc-4f38-97d7-ef0af0e1937e">Suite 250</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_477f3949-f445-43b7-9b3a-3d3f2900458a">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_bc96fa4a-da88-48be-b814-6df5316699bc">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_2502826b-7941-404c-ba19-f7076562b526">92121</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_03012218-5443-43e6-ad49-943d0b54c6a3">858</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_dad14bc4-4bd5-4d5c-8089-c87045f5635d">900-2660</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_447952d0-db78-4136-a060-7314312418ec">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_cef0945e-e447-43dc-99c4-6a785d407e2c">ARCT</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_38105c46-0f1f-4e17-882f-91567a427a12">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_5f1e1fa2-b12d-4911-9f0b-1b8ca82d9e87">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_65bc931c-8a1f-42e2-9756-69766d900566">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_158d064e-0a83-4969-8785-ad7173cc2a01">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_18287b7f-fbae-4b49-a616-9f1002737656">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_9c410ee0-b31c-4a76-aeec-340a7b800e03">Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_4da16c82-69dd-4e05-919a-3ea419616dfb">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_fc4ffd2a-4e07-4279-accb-1abdf2b03288">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_237ba54b-4325-414d-b3ad-76816c04a89f">true</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_5f34858b-07c6-4179-bf98-bd778a6c1218">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_88a54649-c515-432c-a02a-3edc970a4ff0">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_4e7cbee9-3838-4850-806d-710b2e45882f"
      decimals="-5"
      id="F_db8373d6-a35f-4f5e-a31f-d8a881f238be"
      unitRef="U_USD">602700000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_69ed5d25-10c1-4aac-96a2-03a2b894d649"
      decimals="INF"
      id="F_542b021b-128f-4f25-a8dd-14ef9ff3cd11"
      unitRef="U_shares">27119823</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_5efe96e2-1e42-43b6-8d54-5ef7a476e268">&lt;p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Certain portions of the registrant&#x2019;s definitive Proxy Statement for its 2025 Annual Meeting of Stockholders are incorporated by reference into Items 10, 11, 12, 13 and 14 of Part III of this Annual Report on Form 10-K.&lt;/span&gt;&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_23ad3ef7-8c39-4d4b-84fc-e7afeadb1226">&lt;p id="item_3c_cybersecurity" style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Item 1C. Cyber&lt;/span&gt;&lt;span id="item_1c_cybersecurity"&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;security&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Risk management and strategy&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We recognize the critical importance of developing, implementing, and maintaining robust cybersecurity measures to safeguard our information systems and protect the confidentiality, integrity, and availability of our data.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Managing Material Risks &amp;amp; Integrated Overall Risk Management&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We have implemented tools and strategies to promote a company-wide culture of cybersecurity risk management. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;This ensures that cybersecurity considerations are an integral part of our decision-making process.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Our IT Department works closely with our leadership and key operating personnel to evaluate and address cybersecurity risks in alignment with our business objectives and operational needs.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our information security function and our Vice President of Information Technology help identify, assess and manage the Company&#x2019;s cybersecurity threats and risks. This group works to identify and assess risks from cybersecurity threats by monitoring and evaluating our threat environment and the Company&#x2019;s risk profile using various methods in certain contexts, including, for example, manual tools, subscribing to reports and services that identify cybersecurity threats, analyzing reports of threat actors, conducting scans of certain environments, evaluating certain threats reported to us, conducting threat and vulnerability assessments, using external intelligence feeds, and using third parties to conduct tabletop incident response exercises and other tests.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Depending on the environment, we implement and maintain various technical, physical, and organizational measures, processes, standards and policies designed to manage and mitigate material risks from cybersecurity threats to our information systems and data, including, for example: incident detection and response, disaster recovery/business continuity policies, encryption of certain data, network security controls and data segmentation for certain systems, access controls, physical security, asset management and tracking, systems monitoring, annual mandated employee training, penetration testing, cybersecurity insurance, and dedicated cybersecurity staff.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Engage Third-parties on Risk Management&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Due to the complexity and evolving nature of cybersecurity threats, we &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;engage&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; with a range of external experts, including but not limited to cybersecurity assessors, consultants, and auditors to evaluate and test our risk management systems. These partnerships enable us to leverage specialized knowledge and insights, to help ensure our cybersecurity strategies and processes remain at the forefront of industry best practices. Our collaborations with these third-parties includes regular audits, threat assessments, 24-hour monitoring, and consultation on security enhancements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Oversee Third-party Risk&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Because we are aware of the risks associated with third-party service providers, we conduct thorough security assessments of all determined high-risk third-party providers as deemed necessary, before engagement to ensure compliance with industry cybersecurity standards and frameworks. This includes assessments performed by our Vice President of IT, who oversees the Company's cybersecurity function.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Risks from Cybersecurity Threats&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We have not encountered cybersecurity challenges that have materially affected or are reasonably likely to materially affect our operations or financial standing.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Governance&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We have implemented standard operating procedures to define the channels by which cybersecurity threats are communicated to the Company's Board of Directors (the &#x201c;Board&#x201d;). This ensures that The Board has oversight and effective governance in managing risks associated with cybersecurity threats.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Board of Directors Oversight&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Audit Committee of the Board (the &#x201c;Audit Committee&#x201d;) is central to the Board&#x2019;s oversight of cybersecurity risks and bears the primary responsibility for this domain. The Audit Committee is composed of board&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;members &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;with diverse expertise including, risk management, and finance, equipping them to oversee cybersecurity risks effectively.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The Audit Committee receives briefings on cybersecurity risks from the Vice President of IT or the Chief Legal Officer as described below in &#x201c;Management&#x2019;s Role Managing Risk.&#x201d;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Management&#x2019;s Role Managing Risk&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Vice President of IT, Chief Legal Officer (&#x201c;CLO&#x201d;) and the Director of IT Infrastructure and Security, play a pivotal role in informing the Audit Committee on cybersecurity risks. They provide briefings to the Audit Committee on a regular basis, with a minimum frequency of once per year. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The current Vice President of IT, who is responsible for assessment and management of cybersecurity risks, has over 20 years of experience in information and technology security, including senior roles at several companies in the pharmaceutical industry, and possesses the requisite education, skills, experience, and industry certifications expected of an individual assigned to these duties&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. These briefings encompass a broad range of topics, including:&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Current cybersecurity landscape and emerging threats;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Status of ongoing cybersecurity initiatives and strategies;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Incident reports and learnings from any cybersecurity events; and&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Compliance with regulatory requirements and industry standards.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Risk Management Personnel&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Primary responsibility for assessing, monitoring and managing our cybersecurity risks rests with the Vice President of IT and the Director of IT Infrastructure and Security. Our IT Leadership team oversees our governance programs, tests our compliance with standards, remediates known risks, stays informed of significant developments in the cybersecurity domain, and leads our employee training program.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Monitor Cybersecurity Incidents&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Vice President of IT is continually informed about the latest developments in cybersecurity, including potential threats and innovative risk management techniques. This ongoing knowledge acquisition is crucial for the effective prevention, detection, mitigation, and remediation of cybersecurity incidents.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; In cooperation with the Vice President of IT, the Director of IT Infrastructure and Security implements and oversees processes for the regular monitoring of our information systems. This includes the deployment of advanced security measures and regular system audits to identify potential vulnerabilities. In the event of a cybersecurity incident, the Vice President of IT is equipped with a well-defined incident response plan. This plan includes immediate actions to mitigate the impact and long-term strategies for remediation and prevention of future incidents.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Reporting to Board of Directors&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Vice President of IT and the Director of IT Infrastructure and Security, in their respective capacity, inform the Chief Financial Officer (CFO) and Chief Legal Officer (CLO) of cybersecurity risks and incidents.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Furthermore, significant cybersecurity matters, and strategic risk management decisions are required to be escalated to the Board, ensuring that they have comprehensive oversight and can provide guidance on critical cybersecurity issues.&lt;/span&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;See Item 1A &#x201c;Risk Factors&#x201d; &#x2013; &#x201c;Risks Related to Business Operations and Industry.&#x201d;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_e813b58c-9d98-4aad-b97e-bd5b3c96215b">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Managing Material Risks &amp;amp; Integrated Overall Risk Management&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We have implemented tools and strategies to promote a company-wide culture of cybersecurity risk management. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;This ensures that cybersecurity considerations are an integral part of our decision-making process.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Our IT Department works closely with our leadership and key operating personnel to evaluate and address cybersecurity risks in alignment with our business objectives and operational needs.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our information security function and our Vice President of Information Technology help identify, assess and manage the Company&#x2019;s cybersecurity threats and risks. This group works to identify and assess risks from cybersecurity threats by monitoring and evaluating our threat environment and the Company&#x2019;s risk profile using various methods in certain contexts, including, for example, manual tools, subscribing to reports and services that identify cybersecurity threats, analyzing reports of threat actors, conducting scans of certain environments, evaluating certain threats reported to us, conducting threat and vulnerability assessments, using external intelligence feeds, and using third parties to conduct tabletop incident response exercises and other tests.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Depending on the environment, we implement and maintain various technical, physical, and organizational measures, processes, standards and policies designed to manage and mitigate material risks from cybersecurity threats to our information systems and data, including, for example: incident detection and response, disaster recovery/business continuity policies, encryption of certain data, network security controls and data segmentation for certain systems, access controls, physical security, asset management and tracking, systems monitoring, annual mandated employee training, penetration testing, cybersecurity insurance, and dedicated cybersecurity staff.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_088e7c36-a9a3-4e98-9747-41317dbc866d">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_da68f034-dc2e-4043-9476-634013fbf0c6">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_369a6c22-5600-4cab-b1bf-29fe9398370f">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_41957a5a-1f49-4952-88df-f5e560886b88">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_0c7cb0d8-3f9b-4553-ac50-aff2ce79aac2">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Governance&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We have implemented standard operating procedures to define the channels by which cybersecurity threats are communicated to the Company's Board of Directors (the &#x201c;Board&#x201d;). This ensures that The Board has oversight and effective governance in managing risks associated with cybersecurity threats.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Board of Directors Oversight&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Audit Committee of the Board (the &#x201c;Audit Committee&#x201d;) is central to the Board&#x2019;s oversight of cybersecurity risks and bears the primary responsibility for this domain. The Audit Committee is composed of board&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;members &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;with diverse expertise including, risk management, and finance, equipping them to oversee cybersecurity risks effectively.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The Audit Committee receives briefings on cybersecurity risks from the Vice President of IT or the Chief Legal Officer as described below in &#x201c;Management&#x2019;s Role Managing Risk.&#x201d;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Reporting to Board of Directors&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Vice President of IT and the Director of IT Infrastructure and Security, in their respective capacity, inform the Chief Financial Officer (CFO) and Chief Legal Officer (CLO) of cybersecurity risks and incidents.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Furthermore, significant cybersecurity matters, and strategic risk management decisions are required to be escalated to the Board, ensuring that they have comprehensive oversight and can provide guidance on critical cybersecurity issues.&lt;/span&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_42e51b47-8e8c-439b-bb61-75092cac258c">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Audit Committee of the Board (the &#x201c;Audit Committee&#x201d;) is central to the Board&#x2019;s oversight of cybersecurity risks and bears the primary responsibility for this domain. The Audit Committee is composed of board&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;members &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;with diverse expertise including, risk management, and finance, equipping them to oversee cybersecurity risks effectively.&lt;/span&gt;</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_4d334d2e-ebd4-4928-a6e5-51c4e01c511a">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Management&#x2019;s Role Managing Risk&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Vice President of IT, Chief Legal Officer (&#x201c;CLO&#x201d;) and the Director of IT Infrastructure and Security, play a pivotal role in informing the Audit Committee on cybersecurity risks. They provide briefings to the Audit Committee on a regular basis, with a minimum frequency of once per year. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The current Vice President of IT, who is responsible for assessment and management of cybersecurity risks, has over 20 years of experience in information and technology security, including senior roles at several companies in the pharmaceutical industry, and possesses the requisite education, skills, experience, and industry certifications expected of an individual assigned to these duties&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. These briefings encompass a broad range of topics, including:&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Current cybersecurity landscape and emerging threats;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Status of ongoing cybersecurity initiatives and strategies;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Incident reports and learnings from any cybersecurity events; and&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Compliance with regulatory requirements and industry standards.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Risk Management Personnel&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Primary responsibility for assessing, monitoring and managing our cybersecurity risks rests with the Vice President of IT and the Director of IT Infrastructure and Security. Our IT Leadership team oversees our governance programs, tests our compliance with standards, remediates known risks, stays informed of significant developments in the cybersecurity domain, and leads our employee training program.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Monitor Cybersecurity Incidents&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Vice President of IT is continually informed about the latest developments in cybersecurity, including potential threats and innovative risk management techniques. This ongoing knowledge acquisition is crucial for the effective prevention, detection, mitigation, and remediation of cybersecurity incidents.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; In cooperation with the Vice President of IT, the Director of IT Infrastructure and Security implements and oversees processes for the regular monitoring of our information systems. This includes the deployment of advanced security measures and regular system audits to identify potential vulnerabilities. In the event of a cybersecurity incident, the Vice President of IT is equipped with a well-defined incident response plan. This plan includes immediate actions to mitigate the impact and long-term strategies for remediation and prevention of future incidents.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Reporting to Board of Directors&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Vice President of IT and the Director of IT Infrastructure and Security, in their respective capacity, inform the Chief Financial Officer (CFO) and Chief Legal Officer (CLO) of cybersecurity risks and incidents.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Furthermore, significant cybersecurity matters, and strategic risk management decisions are required to be escalated to the Board, ensuring that they have comprehensive oversight and can provide guidance on critical cybersecurity issues.&lt;/span&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;See Item 1A &#x201c;Risk Factors&#x201d; &#x2013; &#x201c;Risks Related to Business Operations and Industry.&#x201d;&lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_be53ea81-47a8-484a-b4ba-a6a224cb4b13">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Vice President of IT, Chief Legal Officer (&#x201c;CLO&#x201d;) and the Director of IT Infrastructure and Security, play a pivotal role in informing the Audit Committee on cybersecurity risks. They provide briefings to the Audit Committee on a regular basis, with a minimum frequency of once per year. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The current Vice President of IT, who is responsible for assessment and management of cybersecurity risks, has over 20 years of experience in information and technology security, including senior roles at several companies in the pharmaceutical industry, and possesses the requisite education, skills, experience, and industry certifications expected of an individual assigned to these duties&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. These briefings encompass a broad range of topics, including:&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Current cybersecurity landscape and emerging threats;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Status of ongoing cybersecurity initiatives and strategies;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Incident reports and learnings from any cybersecurity events; and&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Compliance with regulatory requirements and industry standards.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Risk Management Personnel&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Primary responsibility for assessing, monitoring and managing our cybersecurity risks rests with the Vice President of IT and the Director of IT Infrastructure and Security. Our IT Leadership team oversees our governance programs, tests our compliance with standards, remediates known risks, stays informed of significant developments in the cybersecurity domain, and leads our employee training program.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_2c730627-f654-472e-9b5a-f19df90cab31">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The current Vice President of IT, who is responsible for assessment and management of cybersecurity risks, has over 20 years of experience in information and technology security, including senior roles at several companies in the pharmaceutical industry, and possesses the requisite education, skills, experience, and industry certifications expected of an individual assigned to these duties&lt;/span&gt;</cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_220d208e-01bc-45b8-9324-a02c857c0e66">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_01f74851-11f0-4b6e-be0d-ecfd9392033c">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Vice President of IT is continually informed about the latest developments in cybersecurity, including potential threats and innovative risk management techniques. This ongoing knowledge acquisition is crucial for the effective prevention, detection, mitigation, and remediation of cybersecurity incidents.&lt;/span&gt;</cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_a44210b4-1803-422a-9508-fea3f0efdfcc">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Vice President of IT and the Director of IT Infrastructure and Security, in their respective capacity, inform the Chief Financial Officer (CFO) and Chief Legal Officer (CLO) of cybersecurity risks and incidents.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Furthermore, significant cybersecurity matters, and strategic risk management decisions are required to be escalated to the Board, ensuring that they have comprehensive oversight and can provide guidance on critical cybersecurity issues.&lt;/span&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_493808ae-5381-4422-bb40-4aadb60ea71d">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag>
    <ecd:MtrlTermsOfTrdArrTextBlock
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_c59422c1-e81f-49bf-a009-6f369b761bb5">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Rule 10b5-1 Trading Plans&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For the year ended December 31, 2024, none of our directors or officers &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;adopted &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;or &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;terminated&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; a "Rule 10b5-1 trading arrangement" (as defined in Item 408 of Regulation S-K of the Exchange Act) intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act, other than as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Keith C. Kummerfeld&#x2019;s&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Rule 10b5-1 trading arrangement &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;terminated&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;March 18, 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; upon the effective date of his resignation. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Lance Kurata&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, our &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Chief Legal Officer&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;adopted&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; a Rule 10b5-1 trading arrangement as of&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; June 12, 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Mr. Kurata's trading arrangement provides for the exercise options to purchase up to an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock and subsequent sale of such underlying shares of common stock, until &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;June 12, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.  &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Dr. Padmanabh Chivukula&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Chief Scientific Officer and Chief Operating Officer&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, cancelled an existing Rule 10b5-1trading arrangement on November 11, 2024. Dr. Chivukula's trading arrangement provided for the sale of up to an aggregate of 152,000 shares of common stock. Subsequent to this, Dr. Chivukula &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;entered&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; into a new Rule 10b5-1 trading arrangement on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;November 20, 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The new trading arrangement provides for the sale of up to an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;120,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_28c68eba-ea54-404a-a9d6-fb19a33b35b4;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;beginning on June 2, 2025 until &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;November 10, 2025&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;There were no "non-Rule 10b5-1 trading arrangements" (as defined in Item 408 of Regulation S-K of the Exchange Act) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;adopted&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; or &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;terminated&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; during the year ended December 31, 2024 by our directors and officers.&lt;/span&gt;&lt;/p&gt;</ecd:MtrlTermsOfTrdArrTextBlock>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="C_8bae3d05-d6e8-46f3-863e-be5c603f6fd1"
      id="F_40eb3675-6317-408d-8bc4-74a689942da3">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="C_8bae3d05-d6e8-46f3-863e-be5c603f6fd1"
      id="F_f0c4a041-0522-4d0c-ad94-968c8a3958b8">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:TrdArrIndName
      contextRef="C_2acf2ac7-01e2-4268-a321-5c97d29be022"
      id="F_8d40cb2c-8044-440e-9800-fac26b172807">Keith C. Kummerfeld&#x2019;s</ecd:TrdArrIndName>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="C_2acf2ac7-01e2-4268-a321-5c97d29be022"
      id="F_042a8158-7df6-4da1-b54f-2a93126a8518">true</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:TrdArrTerminationDate
      contextRef="C_2acf2ac7-01e2-4268-a321-5c97d29be022"
      id="F_701f6d36-b791-41d2-a6b2-7b063a5270de">March 18, 2024</ecd:TrdArrTerminationDate>
    <ecd:TrdArrIndName
      contextRef="C_3b5bfb69-0e34-4596-883d-6933762b5f1a"
      id="F_3b2149d1-072f-47d4-aed4-8c1ba48f8f2a">Lance Kurata</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle
      contextRef="C_3b5bfb69-0e34-4596-883d-6933762b5f1a"
      id="F_e6400d9d-12e7-43ef-872f-26fba874861d">Chief Legal Officer</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="C_3b5bfb69-0e34-4596-883d-6933762b5f1a"
      id="F_3d487b55-57c6-49f0-98a3-0699b3c6546c">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrAdoptionDate
      contextRef="C_3b5bfb69-0e34-4596-883d-6933762b5f1a"
      id="F_ad54e05f-807b-4e10-af88-00a470503d90"> June 12, 2024</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="C_dbce4aac-da09-4a9a-bdad-eed2250c6e8b"
      decimals="INF"
      id="F_ea9943e1-86a8-4fc2-b393-dff44888514c"
      unitRef="U_shares">35000</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrExpirationDate
      contextRef="C_3b5bfb69-0e34-4596-883d-6933762b5f1a"
      id="F_4c8099ba-3f8e-4221-9044-5883af7359b6">June 12, 2025</ecd:TrdArrExpirationDate>
    <ecd:TrdArrIndName
      contextRef="C_2a5b949d-4097-4151-8f74-d5142e6df00e"
      id="F_0ad909d2-8532-4c9c-a54e-27d72f88e315">Dr. Padmanabh Chivukula</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle
      contextRef="C_2a5b949d-4097-4151-8f74-d5142e6df00e"
      id="F_bc85d9f6-834c-431e-bcf3-cc1c89032f2e">Chief Scientific Officer and Chief Operating Officer</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="C_2a5b949d-4097-4151-8f74-d5142e6df00e"
      id="F_a2b518a6-962c-4479-9d35-9c46fff780b4">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrAdoptionDate
      contextRef="C_2a5b949d-4097-4151-8f74-d5142e6df00e"
      id="F_61044f6e-99ad-48c8-8dde-458854000594">November 20, 2024</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="C_170f1f48-3dbe-4cac-bfe3-571918df82a6"
      decimals="INF"
      id="F_2efa1a6d-a3d1-4611-a0d3-46b7c07644a2"
      unitRef="U_shares">120000</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrExpirationDate
      contextRef="C_2a5b949d-4097-4151-8f74-d5142e6df00e"
      id="F_394bcec6-ac12-468f-a475-d861283cd18d">November 10, 2025</ecd:TrdArrExpirationDate>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="C_8bae3d05-d6e8-46f3-863e-be5c603f6fd1"
      id="F_35eceb3d-99da-4dfe-ae09-c69feac4ba48">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="C_8bae3d05-d6e8-46f3-863e-be5c603f6fd1"
      id="F_8a9483b2-1533-4a4a-832c-bb2f68fab83c">false</ecd:NonRule10b51ArrTrmntdFlag>
    <dei:AuditorFirmId
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_de4d6e8a-abcf-429a-b5e5-c5a3ed321d32">34</dei:AuditorFirmId>
    <dei:AuditorOpinionTextBlock
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_1071075c-353a-4497-8cca-2b415f700f01">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Opinion on the Financial Statements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We have audited the accompanying consolidated balance sheets of Arcturus Therapeutics Holdings, Inc. and subsidiaries (the &#x201c;Company&#x201d;) as of December 31, 2024, the related consolidated statements of operations, comprehensive loss, stockholder&#x2019;s equity, and cash flows, for the year ended December 31, 2024, and the related notes (collectively referred to as the &#x201c;financial statements&#x201d;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024, and the results of its operations and its cash flows for the year ended December 31, 2024, in conformity with accounting principles generally accepted in the United States of America.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company&#x2019;s internal control over financial reporting as of December 31, 2024, based on criteria established in Internal Control &#x2014; Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated March 6, 2025, expressed an adverse opinion on the Company&#x2019;s internal control over financial reporting because of a material weakness.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</dei:AuditorOpinionTextBlock>
    <dei:AuditorName
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_9ac256b8-35f9-4bc8-b1d1-9cb7bc6575b0">Deloitte &amp; Touche LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_f7a63ff1-5572-4075-b5eb-dfb839954996">San Diego, California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212"
      decimals="-3"
      id="F_d5ceaae2-0787-44bd-b2cf-a5b8576ce5b8"
      unitRef="U_USD">237028000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc"
      decimals="-3"
      id="F_2edf19a4-e7de-4770-99ea-4d88e41d3214"
      unitRef="U_USD">292005000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212"
      decimals="-3"
      id="F_8938d8ed-d97e-41b2-8791-acf015eb2759"
      unitRef="U_USD">55000000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc"
      decimals="-3"
      id="F_d2acd42e-2c7d-447c-9246-a2c552f27f33"
      unitRef="U_USD">55000000</us-gaap:RestrictedCash>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212"
      decimals="-3"
      id="F_df1b6b11-6a81-4183-bee5-b5ba80a76a45"
      unitRef="U_USD">3974000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc"
      decimals="-3"
      id="F_774c042e-5a9e-42f2-bce5-f67a73180eeb"
      unitRef="U_USD">32064000</us-gaap:AccountsReceivableNetCurrent>
    <arct:PrepaidExpensesAndOtherReceivables
      contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212"
      decimals="-3"
      id="F_e18959a6-cb31-4aeb-9161-6f3350755e3b"
      unitRef="U_USD">9977000</arct:PrepaidExpensesAndOtherReceivables>
    <arct:PrepaidExpensesAndOtherReceivables
      contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc"
      decimals="-3"
      id="F_3896b253-f2c2-4cd1-98d6-6c4e504d34a2"
      unitRef="U_USD">7521000</arct:PrepaidExpensesAndOtherReceivables>
    <us-gaap:AssetsCurrent
      contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212"
      decimals="-3"
      id="F_9f16ffc1-5a60-4ac2-9d8e-95b710e7c1e9"
      unitRef="U_USD">305979000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc"
      decimals="-3"
      id="F_29b38493-1db2-48c2-ad59-3de3ce8620d8"
      unitRef="U_USD">386590000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212"
      decimals="-3"
      id="F_d77030f6-65f2-44ae-8e31-a50c230945d3"
      unitRef="U_USD">9531000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc"
      decimals="-3"
      id="F_98c11001-363d-4a03-8558-05f9a1ff2a3f"
      unitRef="U_USD">12427000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212"
      decimals="-3"
      id="F_415aca41-5445-43e9-b836-9f1d5598e268"
      unitRef="U_USD">26674000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc"
      decimals="-3"
      id="F_91889c42-a970-47d2-8cad-5fe2ff73166a"
      unitRef="U_USD">28500000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212"
      decimals="-3"
      id="F_fa242944-7cd3-469f-81bc-8319e5ce806e"
      unitRef="U_USD">1885000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc"
      decimals="-3"
      id="F_02ae9101-b866-49b4-a5c8-e0411ea6dafe"
      unitRef="U_USD">1885000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:Assets
      contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212"
      decimals="-3"
      id="F_77ba1028-8f24-407a-9ab0-1da5ad2a0ac1"
      unitRef="U_USD">344069000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc"
      decimals="-3"
      id="F_9765dd49-17ae-48a0-918e-07150c692885"
      unitRef="U_USD">429402000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212"
      decimals="-3"
      id="F_9bcfc7c2-8bd3-4d14-af6b-f33399fa419f"
      unitRef="U_USD">7194000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc"
      decimals="-3"
      id="F_64302058-7e00-4390-a67f-d983301c9a75"
      unitRef="U_USD">5279000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212"
      decimals="-3"
      id="F_dd1ab045-294b-4131-bd57-ebbdacdded54"
      unitRef="U_USD">38781000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc"
      decimals="-3"
      id="F_3b177764-df34-4ecf-9b94-b0f25ae7bf11"
      unitRef="U_USD">31881000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212"
      decimals="-3"
      id="F_84e8c78a-611a-4990-9250-6ede04c225ff"
      unitRef="U_USD">19514000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc"
      decimals="-3"
      id="F_6a2b0158-cdb6-4169-967f-b927edf8ea96"
      unitRef="U_USD">44829000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212"
      decimals="-3"
      id="F_aed003fb-aea5-49c6-83af-d9b684903d0a"
      unitRef="U_USD">65489000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc"
      decimals="-3"
      id="F_4c1a9613-e452-443e-93ac-e7119440fc89"
      unitRef="U_USD">81989000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212"
      decimals="-3"
      id="F_e8678f38-a54b-4c9d-84b2-901b9c8b1b37"
      unitRef="U_USD">12604000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc"
      decimals="-3"
      id="F_7930a13d-d7c7-4955-b821-6917165385bf"
      unitRef="U_USD">42496000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212"
      decimals="-3"
      id="F_4ac8e9eb-fe59-4768-89f7-c84cb87a3ca3"
      unitRef="U_USD">24998000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc"
      decimals="-3"
      id="F_5a2231ef-3734-4a5e-9646-32397e9465f8"
      unitRef="U_USD">25907000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc"
      decimals="-3"
      id="F_de6dbbdb-a8ae-4265-9625-9829b8434e0b"
      unitRef="U_USD">497000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212"
      decimals="-3"
      id="F_8f8dc7a6-a8dc-41c3-ba4c-7f6828dfc074"
      unitRef="U_USD">103091000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc"
      decimals="-3"
      id="F_01fbabe6-f20a-496e-a070-4335c0fbaefb"
      unitRef="U_USD">150889000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212"
      decimals="INF"
      id="F_5c09a45e-0e04-4336-b263-bb44b15f833a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc"
      decimals="INF"
      id="F_e2e2fe7f-5079-4f5e-850b-f511bf704ef8"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212"
      decimals="INF"
      id="F_5651927a-821c-40fc-9975-8eb5e92b44ac"
      unitRef="U_shares">60000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc"
      decimals="INF"
      id="F_50ec6de5-3285-4b83-8659-817d8dc5f18e"
      unitRef="U_shares">60000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212"
      decimals="-3"
      id="F_1917148c-01b8-47e1-baa8-d7fb380292de"
      unitRef="U_shares">27000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212"
      decimals="-3"
      id="F_6f5a3b25-6a3d-4375-a535-abce8e9bae5c"
      unitRef="U_shares">27000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc"
      decimals="-3"
      id="F_544ece10-c0c0-4cf5-96fa-4a7400dbeedf"
      unitRef="U_shares">26828000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc"
      decimals="-3"
      id="F_4626543d-5ded-4367-aea3-fd19388c71f4"
      unitRef="U_shares">26828000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212"
      decimals="-3"
      id="F_29363627-f5eb-4a47-8985-0a8d50231053"
      unitRef="U_USD">27000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc"
      decimals="-3"
      id="F_b652617f-8e3c-4883-b8f8-45f8b652dc79"
      unitRef="U_USD">27000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212"
      decimals="-3"
      id="F_26387e51-c41b-4d40-bafe-6e5e5a77d59e"
      unitRef="U_USD">689758000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc"
      decimals="-3"
      id="F_a9a55618-df11-4123-b57d-388bd9f2fe5e"
      unitRef="U_USD">646352000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212"
      decimals="-3"
      id="F_3af42f6b-2c80-4461-a185-1ab1f25ddb3c"
      unitRef="U_USD">-448807000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc"
      decimals="-3"
      id="F_9e9ab74a-d8bd-4058-b05b-baeb3a5f7a9e"
      unitRef="U_USD">-367866000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212"
      decimals="-3"
      id="F_b1c7cae5-2cb8-40a0-811b-8010f5900650"
      unitRef="U_USD">240978000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc"
      decimals="-3"
      id="F_dd3f32c1-f1a4-4f2e-99e0-e813c1039d94"
      unitRef="U_USD">278513000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212"
      decimals="-3"
      id="F_0da254b3-ff85-475e-ad49-e6ee98de7180"
      unitRef="U_USD">344069000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc"
      decimals="-3"
      id="F_bceefc30-f2aa-44a9-b677-9d68e05a50e6"
      unitRef="U_USD">429402000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_200946b9-b524-4e78-9424-4e601b6b9f68"
      decimals="-3"
      id="F_57608586-407f-4a90-9e99-c8106feb1046"
      unitRef="U_USD">138389000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_e22ed845-7d56-4d58-bbda-cdb707f0cae4"
      decimals="-3"
      id="F_91d1f09c-8c43-4231-adee-fa00653207f3"
      unitRef="U_USD">157748000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_e340decb-8e23-4aec-a50a-9afef8ee8eaf"
      decimals="-3"
      id="F_1c796c73-1d7a-456c-8533-e46a8f751993"
      unitRef="U_USD">205755000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_517ad6a3-e9ae-471c-a53f-67c77e50ab6f"
      decimals="-3"
      id="F_d8d22e59-4d3a-483e-a17c-edb57cc87de3"
      unitRef="U_USD">13921000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_3dcdc036-b6bb-44cc-9e78-55386dfe3195"
      decimals="-3"
      id="F_bd699231-6606-4206-bfa2-3c45203cd7fc"
      unitRef="U_USD">9051000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_45eb8bb7-286d-4047-9f32-b23ce157716c"
      decimals="-3"
      id="F_aee5e084-df0b-4ee1-86eb-383160382873"
      unitRef="U_USD">244000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      decimals="-3"
      id="F_7595175b-12d7-4ea9-a330-e4e37762c32b"
      unitRef="U_USD">152310000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c"
      decimals="-3"
      id="F_218b6747-ed69-4497-bd4e-e95806b450cb"
      unitRef="U_USD">166799000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812"
      decimals="-3"
      id="F_3e3654dc-8191-42e5-850a-542a3ccb4bd5"
      unitRef="U_USD">205999000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      decimals="-3"
      id="F_9ea2cd9c-61b3-4319-8567-00b40eac0ac2"
      unitRef="U_USD">195156000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c"
      decimals="-3"
      id="F_507e257f-51cb-4f43-aa2d-bdff79fcd2a2"
      unitRef="U_USD">192133000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812"
      decimals="-3"
      id="F_21683dd0-e669-4915-9963-bb676e5f8da3"
      unitRef="U_USD">147751000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      decimals="-3"
      id="F_d4d26522-a147-4d20-81b1-187eebb33521"
      unitRef="U_USD">52823000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c"
      decimals="-3"
      id="F_81f31a27-ea49-4f01-a7cb-ef8094bfa429"
      unitRef="U_USD">52871000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812"
      decimals="-3"
      id="F_ea68ad94-8618-40c7-beb7-fc4110a05ee7"
      unitRef="U_USD">46071000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      decimals="-3"
      id="F_d41ff43e-4bf8-4726-8140-67a419b27857"
      unitRef="U_USD">247979000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c"
      decimals="-3"
      id="F_3493b3c6-a61c-42a5-93ae-799a79404b8c"
      unitRef="U_USD">245004000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812"
      decimals="-3"
      id="F_efd799b2-0520-49a3-92a1-f23d52b1666a"
      unitRef="U_USD">193822000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      decimals="-3"
      id="F_170b19d5-c44f-448c-87f5-fc3141001f9c"
      unitRef="U_USD">-95669000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c"
      decimals="-3"
      id="F_268d8201-478b-4e5e-afa5-b62a81f6628d"
      unitRef="U_USD">-78205000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812"
      decimals="-3"
      id="F_ece59b9d-d9c0-4701-a8eb-6ef3c2eb865f"
      unitRef="U_USD">12177000</us-gaap:OperatingIncomeLoss>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812"
      decimals="-3"
      id="F_b30a26d0-b10e-4fd3-b7af-3987fc2435f0"
      unitRef="U_USD">-515000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      decimals="-3"
      id="F_ede3e677-cc3b-4ffe-8b06-2226c4d98326"
      unitRef="U_USD">-471000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c"
      decimals="-3"
      id="F_4c50c61d-b48e-414e-be63-43c928977efb"
      unitRef="U_USD">-229000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812"
      decimals="-3"
      id="F_692117be-773c-4771-8409-0ae9a07886b0"
      unitRef="U_USD">-598000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      decimals="-3"
      id="F_295b0b12-03d0-4625-85e4-439236770b6e"
      unitRef="U_USD">15195000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c"
      decimals="-3"
      id="F_c61d9697-5a33-4ad9-a4bf-c7fc8e77db51"
      unitRef="U_USD">16591000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812"
      decimals="-3"
      id="F_cb5f8f94-8cb6-4133-aaf6-76a3e6f2658a"
      unitRef="U_USD">-420000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c"
      decimals="-3"
      id="F_f5955b00-0c8c-48af-b4fd-1a33ee39a13d"
      unitRef="U_USD">33953000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      decimals="-3"
      id="F_d32e70e5-ca35-46ef-9990-9df9a43eb53a"
      unitRef="U_USD">-80945000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c"
      decimals="-3"
      id="F_b3c19a5b-73d1-4ed1-90de-e5cddfa9d5c3"
      unitRef="U_USD">-27890000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812"
      decimals="-3"
      id="F_1bd74819-9ffd-44a9-bea4-26d404061894"
      unitRef="U_USD">10644000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      decimals="-3"
      id="F_e0387b91-776e-4d7a-a38e-c0fc5c90661b"
      unitRef="U_USD">-4000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c"
      decimals="-3"
      id="F_a36554c7-ca6c-4615-adfa-354f8470e158"
      unitRef="U_USD">1835000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812"
      decimals="-3"
      id="F_88802aa8-6bbf-40d2-b6d0-a56f80502f97"
      unitRef="U_USD">1295000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      decimals="-3"
      id="F_19f7700e-5f72-4426-bab9-93828dbd4b12"
      unitRef="U_USD">-80941000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c"
      decimals="-3"
      id="F_9d7b2706-37e1-4c36-bbe1-886b73281b4f"
      unitRef="U_USD">-29725000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812"
      decimals="-3"
      id="F_7ab76c1c-c81b-44e9-89ec-959f1699c22a"
      unitRef="U_USD">9349000</us-gaap:NetIncomeLoss>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      decimals="-3"
      id="F_a5475d06-9a92-4bdc-8f99-915362e67ad9"
      unitRef="U_USD">-80941000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c"
      decimals="-3"
      id="F_b11829d0-3a5c-45f7-adfb-85977fe23de2"
      unitRef="U_USD">-29725000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812"
      decimals="-3"
      id="F_1fccbd61-2bc0-4417-835c-1efb7b95ff3c"
      unitRef="U_USD">9349000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      decimals="2"
      id="F_69b4f5fb-c113-4c9f-a9bf-74f4b5d0a1f6"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-3.00</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c"
      decimals="2"
      id="F_79f8db12-2f48-4515-80b9-3bc3647f388c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.12</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812"
      decimals="2"
      id="F_099d2c2a-64d8-4ee4-b975-8b7dfeae5cf9"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.35</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      decimals="2"
      id="F_def89b71-8cfc-4384-b0f3-c19bc32147e8"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-3.00</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c"
      decimals="2"
      id="F_745f340a-3fa5-407f-9f56-1030af2bfea3"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.12</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812"
      decimals="2"
      id="F_5daca0ed-93d0-40e0-aca6-41f0fad82d56"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.35</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      decimals="-3"
      id="F_f0ca73b3-96d1-4a4a-9468-3308a4826440"
      unitRef="U_shares">27000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c"
      decimals="-3"
      id="F_7feae395-df34-4bb8-bc50-b3c2ac56fc09"
      unitRef="U_shares">26628000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812"
      decimals="-3"
      id="F_6de4baa0-2271-4d52-95b9-c95928f524b9"
      unitRef="U_shares">26445000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      decimals="-3"
      id="F_82924e05-76bf-4c13-87f1-3ba4efb79607"
      unitRef="U_shares">27000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c"
      decimals="-3"
      id="F_a9ea23e3-aad9-4544-b260-cd2c75589e99"
      unitRef="U_shares">26628000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812"
      decimals="-3"
      id="F_c593ae48-445f-49c2-92e5-ee3f68a002b8"
      unitRef="U_shares">27093000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="C_8d83dff5-ceee-4639-a422-5542c54a34d5"
      decimals="-3"
      id="F_2585dcf4-2e12-4bbf-a361-6092a71178cc"
      unitRef="U_shares">26372000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_8d83dff5-ceee-4639-a422-5542c54a34d5"
      decimals="-3"
      id="F_38d37368-bfb4-4a29-8cd8-6b1ad0571244"
      unitRef="U_USD">26000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_59320853-4bcf-4a90-99e2-d4b7e72b628d"
      decimals="-3"
      id="F_64d6e0e8-7ec0-4f33-9e89-0302b9227722"
      unitRef="U_USD">575675000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_9f520c76-36f9-4e10-88ee-34a1bddaa46e"
      decimals="-3"
      id="F_c0b4ebad-b0a9-44c7-8492-853560734ec4"
      unitRef="U_USD">-347490000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_12470630-daf9-4fdf-a875-a3affca4b6e8"
      decimals="-3"
      id="F_dc8428ba-0d82-48c4-8193-aae552c757f1"
      unitRef="U_USD">228211000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_b5b1f0d6-262c-46b3-85ce-a3305beaaa39"
      decimals="-3"
      id="F_4e3d72b7-36c5-4369-a895-60ada7ceee6b"
      unitRef="U_USD">30611000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812"
      decimals="-3"
      id="F_8d4ce848-e488-401c-b38a-55d3455274af"
      unitRef="U_USD">30611000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_6ba7dcb1-88d1-40cc-9caa-9904c066fd42"
      decimals="-3"
      id="F_e7c483bb-34c3-4e12-ad09-9a57e553ee83"
      unitRef="U_shares">161000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_6ba7dcb1-88d1-40cc-9caa-9904c066fd42"
      decimals="-3"
      id="F_98409805-e474-4de2-9989-48bc4720df14"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_b5b1f0d6-262c-46b3-85ce-a3305beaaa39"
      decimals="-3"
      id="F_679c9c0f-70d2-41b7-8897-9cb542e1c3e6"
      unitRef="U_USD">1729000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812"
      decimals="-3"
      id="F_b7ad6988-1a05-4561-9f7d-f6914926c582"
      unitRef="U_USD">1730000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <arct:StockIssuedDuringPeriodSharesUnderEquityPlan
      contextRef="C_6ba7dcb1-88d1-40cc-9caa-9904c066fd42"
      decimals="-3"
      id="F_42d56774-76e3-482b-b54a-79423b4eced8"
      unitRef="U_shares">22000</arct:StockIssuedDuringPeriodSharesUnderEquityPlan>
    <arct:StockIssuedDuringPeriodValueUnderEquityPlan
      contextRef="C_b5b1f0d6-262c-46b3-85ce-a3305beaaa39"
      decimals="-3"
      id="F_d7fb308d-cf8e-43e1-9701-7d655d79747b"
      unitRef="U_USD">411000</arct:StockIssuedDuringPeriodValueUnderEquityPlan>
    <arct:StockIssuedDuringPeriodValueUnderEquityPlan
      contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812"
      decimals="-3"
      id="F_d3c2c498-ff45-4f1a-832e-c1ca0a6fdcba"
      unitRef="U_USD">411000</arct:StockIssuedDuringPeriodValueUnderEquityPlan>
    <us-gaap:NetIncomeLoss
      contextRef="C_dd47aa1c-68e9-4b16-9e78-294207b60f30"
      decimals="-3"
      id="F_c3c75f4f-2144-457c-9a21-b090066ec4e6"
      unitRef="U_USD">9349000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812"
      decimals="-3"
      id="F_b458da51-5e04-4a5b-90f0-042b009bec13"
      unitRef="U_USD">9349000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_382d54f3-b7c1-44dc-b7ac-45940950e7db"
      decimals="-3"
      id="F_5ccdc5ab-3104-4a8c-aa15-2c12f3979be0"
      unitRef="U_shares">26555000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_382d54f3-b7c1-44dc-b7ac-45940950e7db"
      decimals="-3"
      id="F_370d0016-1615-4858-9016-f7702191fa5a"
      unitRef="U_USD">27000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_554b9050-1f94-4300-aff9-82c1bde3198b"
      decimals="-3"
      id="F_1f0e4e30-7641-4e4c-aa46-8158b31c8907"
      unitRef="U_USD">608426000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_1e0106b2-7efd-48ca-85e2-4b61ddf65637"
      decimals="-3"
      id="F_81b517df-bc9c-4c54-b8af-45eb7369a295"
      unitRef="U_USD">-338141000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_9b6438ac-a4af-4cb1-a7e8-04fc1dc8917f"
      decimals="-3"
      id="F_a0846df3-7d74-4cb1-8636-e07a35e31700"
      unitRef="U_USD">270312000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_2177e6fb-ec81-4ef2-b37d-c5ed17225037"
      decimals="-3"
      id="F_d3250862-69d0-46e7-8a46-cd2e7a43eacc"
      unitRef="U_USD">34649000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c"
      decimals="-3"
      id="F_06d4d032-762e-4f02-b0f5-b0bc1b3c9f28"
      unitRef="U_USD">34649000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_deb1657c-7399-402c-8536-0419c46c6233"
      decimals="-3"
      id="F_88663f76-43f6-4044-8687-5c2d903559f3"
      unitRef="U_shares">238000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_2177e6fb-ec81-4ef2-b37d-c5ed17225037"
      decimals="-3"
      id="F_6663b01c-eef1-4afd-a086-ee6b4358d4b6"
      unitRef="U_USD">2668000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c"
      decimals="-3"
      id="F_c29d6c5f-cb7c-4b7b-a41f-827500743b11"
      unitRef="U_USD">2668000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <arct:StockIssuedDuringPeriodSharesUnderEquityPlan
      contextRef="C_deb1657c-7399-402c-8536-0419c46c6233"
      decimals="-3"
      id="F_b090b58c-e214-4cea-9878-683d3c668540"
      unitRef="U_shares">35000</arct:StockIssuedDuringPeriodSharesUnderEquityPlan>
    <arct:StockIssuedDuringPeriodValueUnderEquityPlan
      contextRef="C_2177e6fb-ec81-4ef2-b37d-c5ed17225037"
      decimals="-3"
      id="F_393e2080-8239-4045-b810-70b2755f2e06"
      unitRef="U_USD">609000</arct:StockIssuedDuringPeriodValueUnderEquityPlan>
    <arct:StockIssuedDuringPeriodValueUnderEquityPlan
      contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c"
      decimals="-3"
      id="F_031a31e5-eeea-4491-9fa1-bb05a2394ba2"
      unitRef="U_USD">609000</arct:StockIssuedDuringPeriodValueUnderEquityPlan>
    <us-gaap:NetIncomeLoss
      contextRef="C_94fdde70-e99e-4e78-9fbc-8f8f22d0ba4d"
      decimals="-3"
      id="F_390b3f44-9d56-4dc4-95e8-7ce6381e8c24"
      unitRef="U_USD">-29725000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c"
      decimals="-3"
      id="F_9e29d760-8d9f-49cf-86ad-0f522ad4470f"
      unitRef="U_USD">-29725000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_4fc38bda-72e0-4e2e-bcde-f14d64558664"
      decimals="-3"
      id="F_a01c97ea-c069-422d-ae07-b994851e429b"
      unitRef="U_shares">26828000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_4fc38bda-72e0-4e2e-bcde-f14d64558664"
      decimals="-3"
      id="F_7db6d82a-09f4-417e-bb27-f8d518d9901f"
      unitRef="U_USD">27000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_d2b6f456-3e1e-41e4-bd44-0e037c42e4ca"
      decimals="-3"
      id="F_13210c8d-617e-408a-b5a3-c28c715ad9a2"
      unitRef="U_USD">646352000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_d82ff122-590c-489b-87d2-a9001b2499a6"
      decimals="-3"
      id="F_1c15ec0d-8481-4012-9799-b754e345da2f"
      unitRef="U_USD">-367866000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc"
      decimals="-3"
      id="F_2ca9a7ee-0606-4164-8e3a-5fbcb4625783"
      unitRef="U_USD">278513000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_d6e35e55-99c4-447c-93d6-7979a6be6791"
      decimals="-3"
      id="F_d8e4c51d-489e-4ec5-9254-e78c62999320"
      unitRef="U_USD">37988000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      decimals="-3"
      id="F_b211af64-4976-47f8-a8ec-b633721802c5"
      unitRef="U_USD">37988000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_b6a637cc-890d-47eb-bf8f-c3b46e805e7d"
      decimals="-3"
      id="F_ccd0dffe-ef9b-4063-a5fd-0b0849df1d52"
      unitRef="U_shares">228000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_d6e35e55-99c4-447c-93d6-7979a6be6791"
      decimals="-3"
      id="F_af69755e-11b6-4cb1-a294-32118fd65328"
      unitRef="U_USD">4736000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      decimals="-3"
      id="F_ba24c6ca-d3cc-47bd-a51e-826db64b7b23"
      unitRef="U_USD">4736000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <arct:StockIssuedDuringPeriodSharesUnderEquityPlan
      contextRef="C_b6a637cc-890d-47eb-bf8f-c3b46e805e7d"
      decimals="-3"
      id="F_6590dd78-ea58-45b1-8727-cc05b8fa00bc"
      unitRef="U_shares">40000</arct:StockIssuedDuringPeriodSharesUnderEquityPlan>
    <arct:StockIssuedDuringPeriodValueUnderEquityPlan
      contextRef="C_d6e35e55-99c4-447c-93d6-7979a6be6791"
      decimals="-3"
      id="F_11f41e48-c774-4176-95ae-2e43263edc63"
      unitRef="U_USD">682000</arct:StockIssuedDuringPeriodValueUnderEquityPlan>
    <arct:StockIssuedDuringPeriodValueUnderEquityPlan
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      decimals="-3"
      id="F_e9eaf6e9-73dd-45a9-bf34-f77e3038e475"
      unitRef="U_USD">682000</arct:StockIssuedDuringPeriodValueUnderEquityPlan>
    <us-gaap:NetIncomeLoss
      contextRef="C_08b6efae-4fda-4db6-b9c0-371c0ef137a3"
      decimals="-3"
      id="F_16bc58cb-682c-46c6-b052-ef964f06fa7c"
      unitRef="U_USD">-80941000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      decimals="-3"
      id="F_dda347e6-7e21-4308-bd4e-82ce7f4a9034"
      unitRef="U_USD">-80941000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_e0eeb777-c5ee-445e-89d3-2c8ed430397e"
      decimals="-3"
      id="F_1745df12-f686-40b0-9700-f5ae785f0806"
      unitRef="U_shares">27096000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_e0eeb777-c5ee-445e-89d3-2c8ed430397e"
      decimals="-3"
      id="F_b80dd2f6-c9dc-4ab5-9b29-ec9c20354ccc"
      unitRef="U_USD">27000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_c12666e5-df97-469d-b1e4-3c9a57cc9650"
      decimals="-3"
      id="F_54ff5477-63b6-4172-a453-e57792816223"
      unitRef="U_USD">689758000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_ff6d8148-36b1-4ba9-847e-b95829a0383f"
      decimals="-3"
      id="F_bee4456b-150d-4928-a3b6-13fe4b710c0d"
      unitRef="U_USD">-448807000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212"
      decimals="-3"
      id="F_5319abec-3e2a-4c43-9640-a1842d01a34a"
      unitRef="U_USD">240978000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      decimals="-3"
      id="F_241421a1-1c37-4ca4-bd54-6491534c893b"
      unitRef="U_USD">-80941000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c"
      decimals="-3"
      id="F_0824b906-9376-4869-b517-af7c58599c36"
      unitRef="U_USD">-29725000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812"
      decimals="-3"
      id="F_7834c771-43e0-41f7-9ccb-d96208f9842b"
      unitRef="U_USD">9349000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      decimals="-3"
      id="F_12b00260-549b-479b-b26e-ac5467f725bb"
      unitRef="U_USD">3544000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c"
      decimals="-3"
      id="F_522a4bb3-c8bb-42ff-93c8-4a0c44fc56cd"
      unitRef="U_USD">2957000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812"
      decimals="-3"
      id="F_c44e27eb-1e51-421f-88d2-fb94c2b48af3"
      unitRef="U_USD">1527000</us-gaap:DepreciationAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      decimals="-3"
      id="F_8d74ed85-b42a-46e9-a014-7a91dd6e29a8"
      unitRef="U_USD">37988000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c"
      decimals="-3"
      id="F_dc63f865-2369-4bdc-8e95-a250a084505b"
      unitRef="U_USD">34649000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812"
      decimals="-3"
      id="F_71b08048-18a3-4927-9a87-0a0f7af119fa"
      unitRef="U_USD">30611000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812"
      decimals="-3"
      id="F_52edc4d1-873c-4172-90ec-1d62a3160e70"
      unitRef="U_USD">-515000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c"
      decimals="-3"
      id="F_cb586f44-5b02-453e-9ed0-4a331e3e38be"
      unitRef="U_USD">33953000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ForeignCurrencyTransactionGainLossRealized
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      decimals="-3"
      id="F_6a5a17c3-f377-4cc2-b895-00279872ea19"
      unitRef="U_USD">-471000</us-gaap:ForeignCurrencyTransactionGainLossRealized>
    <us-gaap:ForeignCurrencyTransactionGainLossRealized
      contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c"
      decimals="-3"
      id="F_77cabcc0-d89f-4920-83f4-b5d07d3c8553"
      unitRef="U_USD">-90000</us-gaap:ForeignCurrencyTransactionGainLossRealized>
    <us-gaap:ForeignCurrencyTransactionGainLossRealized
      contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812"
      decimals="-3"
      id="F_ace2002c-dc47-4340-8e9e-53bb70559724"
      unitRef="U_USD">-375000</us-gaap:ForeignCurrencyTransactionGainLossRealized>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c"
      decimals="-3"
      id="F_c803f222-c4a1-460b-a2fd-4bab8dd1670c"
      unitRef="U_USD">-502000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812"
      decimals="-3"
      id="F_5b697845-df41-4030-a250-c65ea66ceedb"
      unitRef="U_USD">-2173000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      decimals="-3"
      id="F_e34315f0-4bc4-4376-9bd5-36296c25152c"
      unitRef="U_USD">-28090000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c"
      decimals="-3"
      id="F_d9581d62-dff2-4c43-9e26-9a94c0978704"
      unitRef="U_USD">29300000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812"
      decimals="-3"
      id="F_b69df02f-2522-40f8-a34d-59e9a6f105a9"
      unitRef="U_USD">-603000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      decimals="-3"
      id="F_aa7f62db-112e-482d-85f8-b3ae82681779"
      unitRef="U_USD">2456000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c"
      decimals="-3"
      id="F_7d51b7ad-bb05-4cdb-82c6-b6bed45281db"
      unitRef="U_USD">-1165000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812"
      decimals="-3"
      id="F_72cff4e8-91dc-47cf-8496-83fd970b2b50"
      unitRef="U_USD">3584000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <arct:IncreaseDecreaseOperatingLeaseRightOfUseAsset
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      decimals="-3"
      id="F_d653fd1c-b475-4a6c-8afd-ccb192799c55"
      unitRef="U_USD">-4562000</arct:IncreaseDecreaseOperatingLeaseRightOfUseAsset>
    <arct:IncreaseDecreaseOperatingLeaseRightOfUseAsset
      contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c"
      decimals="-3"
      id="F_42535b7b-2d35-44e1-b5dd-4b14b1ce96a4"
      unitRef="U_USD">-4045000</arct:IncreaseDecreaseOperatingLeaseRightOfUseAsset>
    <arct:IncreaseDecreaseOperatingLeaseRightOfUseAsset
      contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812"
      decimals="-3"
      id="F_ee0ad45d-ece3-4d9a-a700-ecac9c5ad009"
      unitRef="U_USD">-3264000</arct:IncreaseDecreaseOperatingLeaseRightOfUseAsset>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      decimals="-3"
      id="F_bbb7f197-a3d5-4b2a-b6ba-e0d4a5bdc46f"
      unitRef="U_USD">1915000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c"
      decimals="-3"
      id="F_c29627cd-d25d-4a29-a9f3-32c119aa85f2"
      unitRef="U_USD">-2238000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812"
      decimals="-3"
      id="F_82b46d9b-827a-43be-b18a-65d963e19711"
      unitRef="U_USD">-3112000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      decimals="-3"
      id="F_039739d5-33f8-4f1f-b75a-d4745d1729db"
      unitRef="U_USD">5932000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c"
      decimals="-3"
      id="F_c19a5d7d-24e4-4916-8dfd-416d02253dc9"
      unitRef="U_USD">-588000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812"
      decimals="-3"
      id="F_19e31acd-a835-4066-a36c-81c206429cee"
      unitRef="U_USD">9443000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      decimals="-3"
      id="F_a8820c9b-d343-4217-8c63-7ea82f287c6b"
      unitRef="U_USD">-55207000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c"
      decimals="-3"
      id="F_89be997f-cacd-46d9-a49b-0de58deabfe8"
      unitRef="U_USD">38606000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812"
      decimals="-3"
      id="F_19842f41-eb02-4197-a805-b2ded0bff008"
      unitRef="U_USD">-14694000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      decimals="-3"
      id="F_d6d871c9-dc8a-4585-bc7d-ec7fe70a4990"
      unitRef="U_USD">-3645000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c"
      decimals="-3"
      id="F_d24c7ec5-091d-40e1-a34c-70ee501ed031"
      unitRef="U_USD">-4309000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812"
      decimals="-3"
      id="F_0b459e2d-1509-463f-8ffa-fd97bab08cd6"
      unitRef="U_USD">-4477000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      decimals="-3"
      id="F_fd2d46d0-2aa4-492f-bccc-27a33e2170f4"
      unitRef="U_USD">-59747000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c"
      decimals="-3"
      id="F_e3de5dac-3e9c-4c65-a751-499230aae787"
      unitRef="U_USD">-18099000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812"
      decimals="-3"
      id="F_7087c6ef-d5cf-4287-a3ea-635a174772cb"
      unitRef="U_USD">31993000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      decimals="-3"
      id="F_5d76594a-b774-48b3-8ea4-7e02682ca904"
      unitRef="U_USD">648000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c"
      decimals="-3"
      id="F_d0bedcaa-4324-4d60-95e1-d2d61f5b731d"
      unitRef="U_USD">2901000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812"
      decimals="-3"
      id="F_993ae14e-b72f-4825-b6b0-4fe757752f11"
      unitRef="U_USD">7726000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      decimals="-3"
      id="F_1189a8d1-a39b-4b3f-92d2-feab274e04c3"
      unitRef="U_USD">-648000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c"
      decimals="-3"
      id="F_d169ee1f-7910-4a0e-9123-5a4803d83e23"
      unitRef="U_USD">-2901000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812"
      decimals="-3"
      id="F_32a273d3-5dc3-41f9-acb5-441ea6ae11f0"
      unitRef="U_USD">-7726000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c"
      decimals="-3"
      id="F_8da78c42-2c92-4c71-8bc4-4e84654a3a5e"
      unitRef="U_USD">20000000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      decimals="-3"
      id="F_e5553b4e-bd64-440b-a850-21a77b957383"
      unitRef="U_USD">4736000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c"
      decimals="-3"
      id="F_c57a78b1-4cb6-4b82-8103-0e7082dbbb04"
      unitRef="U_USD">2668000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812"
      decimals="-3"
      id="F_cde62ae7-f0cc-4989-9356-585ab976fff6"
      unitRef="U_USD">1730000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockPlans
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      decimals="-3"
      id="F_25f51d09-eaec-4690-84e0-c1cef7a16bc3"
      unitRef="U_USD">682000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c"
      decimals="-3"
      id="F_d11942da-9563-4495-bb79-41b6e917233d"
      unitRef="U_USD">609000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812"
      decimals="-3"
      id="F_8db0f404-5928-4163-a301-e12b3d6c1fe4"
      unitRef="U_USD">411000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:RepaymentsOfDebt
      contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c"
      decimals="-3"
      id="F_ff3ff2fd-1731-4b24-9d42-297b1159b951"
      unitRef="U_USD">47364000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812"
      decimals="-3"
      id="F_66dddf77-c22a-4e2a-b2c8-01cf0db5533c"
      unitRef="U_USD">5000000</us-gaap:RepaymentsOfDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      decimals="-3"
      id="F_63161f28-d21b-4886-a09d-0fa72dfeaa8d"
      unitRef="U_USD">5418000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c"
      decimals="-3"
      id="F_617c95a4-19e5-474c-8af4-b1f25a9ce80f"
      unitRef="U_USD">-24087000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812"
      decimals="-3"
      id="F_876c2bdd-204e-4f08-aa36-5adc0821f361"
      unitRef="U_USD">-2859000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      decimals="-3"
      id="F_7b025730-2cf2-4d34-86ee-4c95bde3e12f"
      unitRef="U_USD">-54977000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c"
      decimals="-3"
      id="F_904a841d-26cd-43f9-ac85-6600ab64d2e7"
      unitRef="U_USD">-45087000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812"
      decimals="-3"
      id="F_6201a377-a30a-44e6-b444-4543ebad1207"
      unitRef="U_USD">21408000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc"
      decimals="-3"
      id="F_f8695c6a-93d7-45ce-b964-5a9d9cb9fb6a"
      unitRef="U_USD">348890000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_9b6438ac-a4af-4cb1-a7e8-04fc1dc8917f"
      decimals="-3"
      id="F_afcf3578-21d4-4af7-a892-7ee8759c6d1d"
      unitRef="U_USD">393977000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_12470630-daf9-4fdf-a875-a3affca4b6e8"
      decimals="-3"
      id="F_e25c928b-907c-46cc-a9d5-83ba40ea239b"
      unitRef="U_USD">372569000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212"
      decimals="-3"
      id="F_d2ea77af-b226-4faa-b9a1-69d498dfe6c3"
      unitRef="U_USD">293913000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc"
      decimals="-3"
      id="F_60fcc6bf-b1fc-4e7b-81e0-b2b90c59a7f0"
      unitRef="U_USD">348890000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_9b6438ac-a4af-4cb1-a7e8-04fc1dc8917f"
      decimals="-3"
      id="F_ef180a3e-c465-4c2d-8093-16c24b9b027e"
      unitRef="U_USD">393977000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c"
      decimals="-3"
      id="F_d2f7fd42-14e8-48f7-9504-c5be16a14205"
      unitRef="U_USD">2127000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812"
      decimals="-3"
      id="F_886b92af-eb6e-4a27-875e-9a1cc2ce7e68"
      unitRef="U_USD">813000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      decimals="-3"
      id="F_7af2591b-fe82-4f93-bc01-557ee1f970a5"
      unitRef="U_USD">1407000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      decimals="-3"
      id="F_1e40869f-748e-4fea-b913-2a6337c0ddb9"
      unitRef="U_USD">2736000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812"
      decimals="-3"
      id="F_d6a8fa2e-09ae-47ea-9069-c63b15da9f3e"
      unitRef="U_USD">30191000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <arct:NonCashAssetDisposal
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      decimals="-3"
      id="F_8fd9f51a-2659-45a1-ad12-650042249423"
      unitRef="U_USD">473000</arct:NonCashAssetDisposal>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c"
      decimals="-3"
      id="F_49341366-78b6-4ebf-9754-5233fd4b2361"
      unitRef="U_USD">68000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812"
      decimals="-3"
      id="F_0cdd2a88-3774-4742-8f04-c5c273bff9b8"
      unitRef="U_USD">573000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_8ddeb960-3b04-4a08-ade5-d447a0032a31">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Note 1.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Organization&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Description of Business&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Arcturus Therapeutics Holdings Inc. (the &#x201c;Company&#x201d; or "Arcturus") is a messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. Arcturus developed the world&#x2019;s first approved self-amplifying messenger RNA (sa-mRNA) vaccine, KOSTAIVE&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (&#x201c;KOSTAIVE&#x201d;). KOSTAIVE achieved approval in Japan in 2023 as a vaccine against COVID-19. Sales of KOSTAIVE began in Japan in October 2024, marking the transition to a commercial stage company.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Recent Developments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;See &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;&#x201c;Note 3 Revenue &#x2013; CSL Seqirus&#x201d;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for further information on the agreement with Seqirus, Inc. ("CSL Seqirus"), whereby CSL Seqirus and the Company continue to collaborate on research and development, manufacturing and global commercialization of vaccines.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Liquidity&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has incurred significant operating losses since its inception. As of December 31, 2024 and 2023, the Company had an accumulated deficit of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;448.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;367.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s activities since inception have consisted principally of research and development activities, general and administrative activities, and raising capital. The Company&#x2019;s activities are subject to significant risks and uncertainties, including failing to secure additional funding before the Company achieves sustainable revenues and profit from operations. From the Company&#x2019;s inception through the year ended December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company has funded its operations principally with the proceeds from revenues earned through collaboration agreements, including the $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;200.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million upfront payment received from CSL Seqirus during 2022, the sale of capital stock and proceeds from long-term debt. During fiscal year 2024, the Company received milestone payments totalin&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;g $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;96.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million f&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;rom CSL Seqirus. At December 31, 2024, the Company&#x2019;s balance of cash and cash equivalents, including restricted cash, was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;293.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Management believes that it has sufficient working capital on hand to fund operations through at least the next twelve months from the date these consolidated financial statements were available to be issued. There can be no assurance that the Company will be successful in acquiring additional funding, that the Company&#x2019;s projections of its future working capital needs will prove accurate, or that any additional funding would be sufficient to continue operations in future years.&lt;/span&gt;&lt;/p&gt;</us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212"
      decimals="-5"
      id="F_7a5e272a-fdc5-4db4-b44e-b6a3d3fdb9e2"
      unitRef="U_USD">-448800000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc"
      decimals="-5"
      id="F_ed6feb65-8c8b-43e0-bd0c-05d7e56352db"
      unitRef="U_USD">-367900000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <arct:UpfrontPaymentReceived
      contextRef="C_74cdb34c-62d2-473d-9ee0-84ce4b40931f"
      decimals="-5"
      id="F_089f0bcc-8c38-498b-ab65-442b084905ff"
      unitRef="U_USD">200000000</arct:UpfrontPaymentReceived>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_74cdb34c-62d2-473d-9ee0-84ce4b40931f"
      decimals="-5"
      id="F_5e0c48b4-444f-486b-ac5f-e154b87b15ce"
      unitRef="U_USD">96000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212"
      decimals="-5"
      id="F_42dfbf61-27fb-4bbd-ad64-f5c8f73bd2fa"
      unitRef="U_USD">293900000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_1f88e937-24f9-4cfa-a2ca-7335c10f6bcd">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Note 2. Summary of Significant Accounting Policies&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Basis of Presentation and Principles of Consolidation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The accompanying consolidated financial statements include the accounts of Arcturus Therapeutics Holdings Inc. and its subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. These consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States (&#x201c;U.S. GAAP&#x201d;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;), which requires management to make estimates and assumptions regarding the valuation of certain debt and equity instruments, the equity method investment, share-based compensation, accruals for liabilities, income taxes, revenue and deferred revenue, leases, expense accruals, and other matters that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Although these estimates are based on management&#x2019;s knowledge of current events and actions the Company may undertake in the future, actual results could materially differ from those estimates.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Segment Information&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company and its chief operating decision-maker view the Company&#x2019;s operations and manage its business in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; operating segment, which includes all activities related to the discovery, development and commercialization of messenger RNA medicines.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents are short-term highly liquid investments that are readily convertible to cash with original maturities of three months or less at the date of purchase.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Restricted cash&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Restricted cash includes collateral pledged and held at the Company&#x2019;s securities accounts pursuant to a security agreement with Wells Fargo Bank, National Association (&#x201c;Wells Fargo&#x201d;) (&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Note 7, Debt&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;). At December 31, 2024, such collateral amounted to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;55.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Restricted cash also includes cash required to be set aside as security for lease payments and to maintain a letter of credit for the benefit of the landlord for the Company&#x2019;s offices.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;At December 31, 2024 and 2023, the Company had restricted cash of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in conjunction with property leases in San Diego, California, and such restriction is expected to be removed at the end of the lease term.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Fair Value Measurements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. A hierarchy has been established for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Observable inputs are inputs that market participants would use in valuing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the factors market participants would use in valuing the asset or liability developed based upon the best information available under the circumstances. The hierarchy consists of three levels. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, and inputs (other than quoted prices) that are observable for the asset or liability, either directly or indirectly. Level 3 inputs are unobservable inputs for the asset or liability. Categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Accounts Receivable&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accounts receivable are recorded at the net invoice value and are non-interest bearing. The Company considers receivables past due based on the contractual payment terms. The Company reserves for specific receivables if collectability is no longer reasonably assured. Estimates for allowances for doubtful accounts are determined based on existing contractual obligations, historical payment patterns, and individual customer circumstances. The Company reevaluates such reserves on a regular basis and adjusts its reserves as needed. Once a receivable is deemed to be uncollectible, such balance is charged against the reserve. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; reserves have been recorded as of December 31, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2024 or 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Concentration of Credit Risk and Significant Customers&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is exposed to concentrations of credit risk primarily related to cash, cash equivalents, and accounts receivable.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company mitigates credit risk exposure by maintaining cash and cash equivalents only with high-credit-quality financial institutions and investing in instruments with short maturities. The Company continuously monitors counterparty risk to minimize potential financial exposure.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Accounts Receivable Concentration&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024 and 2023, the Company had significant concentrations of credit risk related to accounts receivable from a limited number of customers. The following customers accounted for 10% or more of total accounts receivable in each respective period:&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024:&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;BARDA &#x2013; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;60&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of total accounts receivable&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;CSL &#x2013; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of total accounts receivable&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2023:&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;CSL &#x2013; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;74&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of total accounts receivable&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;BARDA &#x2013; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of total accounts receivable&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company monitors its credit exposure through regular assessments of counterparty risk and maintains ongoing collection efforts to mitigate potential credit losses.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Revenue Concentration&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company generates a substantial portion of its revenue from a limited number of key customers. The following customers accounted for 10% or more of total revenue for each period:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For the year ended December 31, 2024:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;CSL &#x2013; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;91&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of total revenue &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For the year ended December 31, 2023:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;CSL &#x2013; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;92&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of total revenue &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For the year ended December 31, 2022:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;CSL &#x2013; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;75&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of total revenue &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Vinbiocare &#x2013; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of total revenue&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Given this concentration, the Company&#x2019;s financial performance and cash flows may be materially impacted if there are changes in demand, contract renewals, or the financial condition of these key customers. The Company continues to evaluate opportunities to expand its customer base and mitigate concentration risk over time.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Joint Ventures, Equity Method Investments and Variable Interest Entities&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Investments for which the Company exercises significant influence, but does not have control are accounted for under the equity method. Equity method investment activity is related to the Company's joint venture in ARCALIS, Inc. with Axcelead, Inc. The Company&#x2019;s share of the investees&#x2019; results is presented as either income or loss from equity method investees in the accompanying consolidated statements of operations and comprehensive income (loss). As of December 31, 2024, the carrying value of the equity method investment in ARCALIS remained at zero as ARCALIS' cumulative losses exceeded any gains from dilution.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Property and Equipment, net&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property and equipment are stated at cost, net of accumulated depreciation and amortization. The cost of property and equipment is depreciated or amortized using the straight-line method over the respective useful lives of the assets, ranging from &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_a09c2b80-d521-40d4-b228-c34c98f0be33;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Leasehold improvements are amortized using the straight-line method over the shorter of the estimated useful life of the asset or the lease term. Long-lived assets, including property and equipment are reviewed for impairment whenever events or circumstances indicate that the carrying amount of these assets may not be recoverable. The determinants used for this evaluation include management&#x2019;s estimate of an asset&#x2019;s ability to generate positive income from operations and positive cash flow in future periods, as well as the strategic significance of the assets to the Company&#x2019;s business objectives. The Company did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t recognize any impairment losses for the years ended December 31, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2024, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; or 2022.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Comprehensive Income/Loss&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Comprehensive income/loss is defined as the change in stockholders&#x2019; equity during a period from transactions and other events and circumstances from non-owner sources. There was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; other comprehensive loss or income tax effect related to unrealized losses in the years ended December 31, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2024, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; or 2022.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Revenue Recognition&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;At contract inception, the Company analyzes its collaboration arrangements to assess whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities and therefore within the scope of ASC Topic 808, Collaborative Arrangements (ASC 808). For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Company first determines which elements of the collaboration reflect a vendor-customer relationship and are therefore within the scope of ASC 606.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company determines revenue recognition for arrangements within the scope of Topic 606 by performing the following five steps: (i) identify the contract; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when, or as, the company satisfies a performance obligation.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The terms of the Company&#x2019;s revenue agreements include license fees, upfront payments, milestone payments, reimbursement for research and development activities, option exercise fees, consulting and related technology transfer fees and royalties on sales of commercialized products. The event-based milestone payments represent variable consideration, and the Company uses the most likely amount method to estimate this variable consideration because the Company will either receive the milestone payment or will not, which makes the potential milestone payment a binary event. The most likely amount method requires the Company to determine the likelihood of earning the milestone payment. Given the high degree of uncertainty around achievement of these milestones, the Company determines the milestone amounts to be fully constrained and does not recognize revenue until the uncertainty associated with these payments is resolved. The Company will recognize revenue from sales-based royalty payments when or as the sales occur. The Company will re-evaluate the transaction price in each reporting period as uncertain events are resolved and other changes in circumstances occur.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A performance obligation is a promise in a contract to transfer a distinct good or service to the collaborative partner and is the unit of account in Topic 606. A contract&#x2019;s transaction price is allocated to each distinct performance obligation based on relative standalone selling price and recognized as revenue when, or as, the performance obligation is satisfied.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For performance obligations that are recognized over time, the Company measures the progress using an input method. The input methods used are based on the effort expended or costs incurred toward the satisfaction of the performance obligation. The Company estimates the amount of effort expended, including the time estimated it will take to complete the activities, or costs incurred in a given period, relative to the estimated total effort or costs to satisfy the performance obligation. This approach requires the Company to make numerous estimates and use significant judgment. If estimates or judgments change over the course of the collaboration, a cumulative catch up of revenue is recognized in the period such changes are identified.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;See &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;&#x201c;Note 3, Revenue&#x201d;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for specific details surrounding the Company&#x2019;s arrangements.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Grant revenue&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Grant revenue&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;consists of funding under cost reimbursement programs primarily from federal and non-profit foundation sources for qualified research and development activities performed by the Company. Such amounts are invoiced and recorded as revenue as grant-funded activities are performed, with any advance funding recorded as deferred revenue until the activities are performed.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company determines if an arrangement is a lease at inception. Lease right-of-use assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. For operating leases with an initial term greater than 12 months, the Company recognizes operating lease right-of-use assets and operating lease liabilities based on the present value of lease payments over the lease term at the commencement date. Operating lease right-of-use assets are comprised of the lease liability plus any lease payments made and excludes lease incentives. Lease terms include options to renew or terminate the lease when the Company is reasonably certain that the renewal option will be exercised or when it is reasonably certain that the termination option will not be exercised. For the Company's operating leases, if the interest rate used to determine the present value of future lease payments is not readily determinable, the Company estimates its incremental borrowing rate as the discount rate for the lease. The Company's incremental borrowing rate is estimated to approximate the interest rate on a collateralized basis with similar terms and payments, and in&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;similar economic environments. Lease expense for lease payments is recognized on a straight-line basis over the lease term. The Company has elected the practical expedient to not separate lease and non-lease components.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;See &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;&#x201c;Note 11, Commitments and Contingencies&#x201d;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for specific details surrounding the Company&#x2019;s leases.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Research and Development Costs, net&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;All research and development costs are expensed as incurred. Research and development costs consist primarily of salaries, employee benefits, costs associated with preclinical studies and clinical trials (including amounts paid to clinical research organizations and other professional services), pre-launch inventory, in-process research and development expenses and license agreement expenses. Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods are received or the services are performed. The Company recognizes grants that fall within the scope of ASC 808 as contra research and development expense in the consolidated statement of operations on a systematic basis over the periods in which the entity recognizes as expenses the related costs for which the grants are intended to compensate.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company records accruals for estimated research and development costs, comprising payments for work performed by third party contractors, laboratories, participating clinical trial sites, and others. Some of these contractors bill monthly based on actual services performed, while others bill periodically based upon achieving certain contractual milestones. For the latter, the Company accrues the expenses as goods or services are used or rendered.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Clinical trial activities performed by third parties are accrued and expensed based upon estimates of the proportion of work completed over the life of the individual clinical trial and patient enrollment rates in accordance with agreements established with Clinical Research Organizations (&#x201c;CROs&#x201d;) and clinical trial sites. Estimates are determined by reviewing contracts, vendor agreements and purchase orders, and through discussions with internal clinical personnel and external service providers as to the progress or stage of completion of trials or services and the agreed-upon fee to be paid for such services.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;General and Administrative Costs&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;General and administrative expenses consist primarily of personnel-related costs, including share-based compensation, for executives, finance, legal, human resources, business development, and other administrative and operational functions, professional fees, accounting and legal services, information technology and facility-related costs, and expenses associated with obtaining and maintaining intellectual property (&#x201c;IP&#x201d;). These costs relate to the operation of the business, unrelated to the research and development function, or any individual program.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Pre-Launch Inventory&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Prior to obtaining initial regulatory approval for an investigational product candidate, the Company expenses costs relating to production of inventory as research and development expense in its consolidated statements of operations and comprehensive income (loss), in the period incurred. When the Company believes regulatory approval and subsequent commercialization of an investigational product candidate is probable, and the Company also expects future economic benefit from the sales of the investigational product candidate to be realized, it will then capitalize the costs of production as inventory.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Share-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company records share-based compensation for equity awards granted to employees, consultants, officers and directors within general and administrative and research and development expenses on the statements of operations and comprehensive income (loss). &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Share-based compensation is recognized over the requisite service period of the individual awards using the straight-line attribution method, which generally equals the vesting period. Employees and officers&#x2019; stock options have a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ten-year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; life and generally vest &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% on the first anniversary of the grant and in 1/36&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;th&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; equal installments on each monthly anniversary thereafter, such that options are fully vested on the &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;four-year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; anniversary of the date of grant. The exercisability and vesting periods of equity awards granted to consultants and directors vary.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The fair value of stock options is estimated using a Black-Scholes valuation model on the date of grant. This method requires certain assumptions be used as inputs, such as the fair value of the underlying common stock, expected term of the option before exercise, expected volatility of the Company&#x2019;s common stock, expected dividend yield, and a risk-free interest rate. The Company has limited historical stock option activity and therefore estimates the expected term of stock options granted using the simplified method, which represents the average of the contractual term of the stock option and its weighted-average vesting period. For the nine months ended September 30, 2024, the expected volatility of stock options was based on the historical volatility of a peer group of publicly traded companies. For the three months ended December 31, 2024, the Company used its own historical volatility to estimate expected volatility, as it had accumulated sufficient historical stock price data. The Company has not declared or paid any dividends and does not currently expect to do so in the foreseeable future. The risk-free interest rates used are based on the implied yield currently available in United States Treasury securities at maturity with a term equivalent to the expected term of the stock options. The effect of forfeited or cancelled awards is recorded when the forfeiture or cancellation occurs&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Statement of Cash Flows&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets to the total of such amounts shown in the consolidated statement of cash flows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:56.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:10.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.34%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:10.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;237,028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;292,005&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;391,883&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Restricted cash - current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;55,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;55,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Non-current Restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,885&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,885&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,094&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total cash, cash equivalents and restricted cash &lt;br/&gt;&#160;&#160;&#160;&#160;&#160;shown in the statement of cash flows&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;293,913&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;348,890&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;393,977&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Tax Expense&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Income taxes are accounted for using an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial reporting basis and the tax basis of the Company&#x2019;s assets and liabilities at the applicable tax rates, along with net operating loss and tax credit carryovers. The Company records a valuation allowance against its deferred tax assets to reduce the net carrying value to an amount that it believes is more likely than not to be realized. Management has considered estimated taxable income and ongoing prudent and feasible tax planning strategies in assessing the amount of the valuation allowance. Based upon the weight of available evidence, which includes the Company&#x2019;s historical operating performance and limited potential to utilize tax credit carryforwards, the Company has determined that total deferred tax assets should be fully offset by a valuation allowance. When the Company establishes or reduces the valuation allowance against its deferred tax assets, its provision for income taxes will increase or decrease, respectively, in the period such determination is made.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is required to file federal and state income tax returns in the United States and various other state jurisdictions. The Company also files income tax returns in the foreign countries in which it operates. The preparation of these income tax returns requires the Company to interpret the applicable tax laws and regulations in effect in such jurisdictions, which could affect the amount of tax paid by the Company.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Additionally, the Company follows an accounting standard addressing the accounting for uncertainty in income taxes that prescribes rules for recognition, measurement, and classification in the consolidated financial statements of tax positions taken or expected to be taken in a tax return.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Net (Loss) Income per Share&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basic net (loss) income per share is calculated by dividing the net (loss) income by the weighted-average number of shares of common stock outstanding for the period, without consideration for common stock equivalents. Diluted net (loss) income per share is calculated by dividing the net (loss) income by the weighted-average number of shares of common stock and dilutive common stock equivalents outstanding for the period determined using the treasury-stock method. Dilutive shares of common stock for the years ended December 31, 2024 and 2023 were comprised of stock options and restricted stock units. Dilutive shares of stock for the years ended December 31, 2022 were comprised of stock options.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; dividends were declared or paid during the reporting periods.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires public entities to disclose information about their reportable segments&#x2019; significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in ASC 280 on an interim and annual basis. ASU 2023-07 is effective for annual reporting periods beginning after December 15, 2023, and for interim reporting periods beginning January 1, 2025. The Company &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;adopted&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; ASU 2023-07 for the annual reporting period beginning on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;January 1, 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. See &#x201c;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Note 12, Segment Information&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x201d; for further information.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Recently Issued Accounting Standards Not Yet Adopted&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. The Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on the consolidated financial statements and disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2024, the FASB issued ASU 2024-03, Income Statement&#x2013;Reporting Comprehensive Income&#x2013;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, which requires public entities to disclose specified information about certain costs and expenses on an interim and annual basis. ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the impact that adoption of ASU 2024-03 will have on the financial statement disclosures.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_28183089-635e-445d-bd9f-d36117fb649d">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Basis of Presentation and Principles of Consolidation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The accompanying consolidated financial statements include the accounts of Arcturus Therapeutics Holdings Inc. and its subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. These consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States (&#x201c;U.S. GAAP&#x201d;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;), which requires management to make estimates and assumptions regarding the valuation of certain debt and equity instruments, the equity method investment, share-based compensation, accruals for liabilities, income taxes, revenue and deferred revenue, leases, expense accruals, and other matters that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Although these estimates are based on management&#x2019;s knowledge of current events and actions the Company may undertake in the future, actual results could materially differ from those estimates.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_4498fe3a-4cdc-4b22-851a-e4a9fbb2f0d2">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Segment Information&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company and its chief operating decision-maker view the Company&#x2019;s operations and manage its business in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; operating segment, which includes all activities related to the discovery, development and commercialization of messenger RNA medicines.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      decimals="INF"
      id="F_31bac339-9359-4510-9269-e61bee741835"
      unitRef="U_Segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_47bbdf77-2763-4b97-b851-4f7ed5a1c5bd">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents are short-term highly liquid investments that are readily convertible to cash with original maturities of three months or less at the date of purchase.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_9c734a99-9dd9-408b-b5fd-675684d89930">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Restricted cash&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Restricted cash includes collateral pledged and held at the Company&#x2019;s securities accounts pursuant to a security agreement with Wells Fargo Bank, National Association (&#x201c;Wells Fargo&#x201d;) (&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Note 7, Debt&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;). At December 31, 2024, such collateral amounted to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;55.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Restricted cash also includes cash required to be set aside as security for lease payments and to maintain a letter of credit for the benefit of the landlord for the Company&#x2019;s offices.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;At December 31, 2024 and 2023, the Company had restricted cash of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in conjunction with property leases in San Diego, California, and such restriction is expected to be removed at the end of the lease term.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:DebtInstrumentCollateralAmount
      contextRef="C_3e3c5d0e-9c24-4b1b-b7e1-d57a6036bc5a"
      decimals="-5"
      id="F_02c34040-41aa-4bed-8cd0-9f0ca02097de"
      unitRef="U_USD">55000000</us-gaap:DebtInstrumentCollateralAmount>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_dd07c4b0-0b2b-46df-8180-9141d3a4695f"
      decimals="-5"
      id="F_379d2b38-eefd-4aa0-860e-f28b35f1c403"
      unitRef="U_USD">1900000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_860c0a20-b573-41e1-a9a0-9d26576ca073"
      decimals="-5"
      id="F_14a09c70-d47a-44a6-9e7e-f432a0468338"
      unitRef="U_USD">1900000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_bf879196-fae7-4831-b851-d4733b61a668">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Fair Value Measurements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. A hierarchy has been established for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Observable inputs are inputs that market participants would use in valuing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the factors market participants would use in valuing the asset or liability developed based upon the best information available under the circumstances. The hierarchy consists of three levels. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, and inputs (other than quoted prices) that are observable for the asset or liability, either directly or indirectly. Level 3 inputs are unobservable inputs for the asset or liability. Categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ReceivablesPolicyTextBlock
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_edeb76db-f752-4409-8956-362b540e1329">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Accounts Receivable&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accounts receivable are recorded at the net invoice value and are non-interest bearing. The Company considers receivables past due based on the contractual payment terms. The Company reserves for specific receivables if collectability is no longer reasonably assured. Estimates for allowances for doubtful accounts are determined based on existing contractual obligations, historical payment patterns, and individual customer circumstances. The Company reevaluates such reserves on a regular basis and adjusts its reserves as needed. Once a receivable is deemed to be uncollectible, such balance is charged against the reserve. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; reserves have been recorded as of December 31, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2024 or 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:ReceivablesPolicyTextBlock>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212"
      decimals="INF"
      id="F_1efca346-6832-4115-b71b-14470cd24d8a"
      unitRef="U_USD">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc"
      decimals="INF"
      id="F_411ff2eb-39f4-4ffa-85b0-a83dc6790c93"
      unitRef="U_USD">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_9b715545-8b8c-452d-9974-19dbd9eb6990">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Concentration of Credit Risk and Significant Customers&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is exposed to concentrations of credit risk primarily related to cash, cash equivalents, and accounts receivable.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company mitigates credit risk exposure by maintaining cash and cash equivalents only with high-credit-quality financial institutions and investing in instruments with short maturities. The Company continuously monitors counterparty risk to minimize potential financial exposure.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Accounts Receivable Concentration&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024 and 2023, the Company had significant concentrations of credit risk related to accounts receivable from a limited number of customers. The following customers accounted for 10% or more of total accounts receivable in each respective period:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024:&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;BARDA &#x2013; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;60&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of total accounts receivable&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;CSL &#x2013; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of total accounts receivable&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2023:&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;CSL &#x2013; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;74&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of total accounts receivable&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;BARDA &#x2013; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of total accounts receivable&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company monitors its credit exposure through regular assessments of counterparty risk and maintains ongoing collection efforts to mitigate potential credit losses.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Revenue Concentration&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company generates a substantial portion of its revenue from a limited number of key customers. The following customers accounted for 10% or more of total revenue for each period:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For the year ended December 31, 2024:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;CSL &#x2013; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;91&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of total revenue &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For the year ended December 31, 2023:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;CSL &#x2013; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;92&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of total revenue &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For the year ended December 31, 2022:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;CSL &#x2013; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;75&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of total revenue &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Vinbiocare &#x2013; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of total revenue&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Given this concentration, the Company&#x2019;s financial performance and cash flows may be materially impacted if there are changes in demand, contract renewals, or the financial condition of these key customers. The Company continues to evaluate opportunities to expand its customer base and mitigate concentration risk over time.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_ef9e3212-0c72-453d-8e04-d4b0bc08213a"
      decimals="2"
      id="F_105989d7-c79d-4a41-a8a0-5405f5ddb84c"
      unitRef="U_pure">0.60</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_988a9efb-2454-43a7-a157-c666550071c2"
      decimals="2"
      id="F_ee4d6e36-dc2b-44bf-a6c5-3057b3e78663"
      unitRef="U_pure">0.20</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_42551c33-9281-450d-a0e8-7a28c2252c4a"
      decimals="2"
      id="F_162ca301-fa2e-4443-9f2c-aded9d39af5a"
      unitRef="U_pure">0.74</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_2b79e174-202f-44db-a40f-0080c01394ba"
      decimals="2"
      id="F_92ae8b3a-0f38-4bfe-ae81-7e99f2251dcf"
      unitRef="U_pure">0.23</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_c8889a7c-69b1-4f25-be7c-2c7d95316544"
      decimals="2"
      id="F_aaf8be4d-672b-4c1b-bb66-3fb0adaf1174"
      unitRef="U_pure">0.91</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_29eee7a6-fd75-4779-badf-175826fe2dfd"
      decimals="2"
      id="F_97cc0bd4-b572-4b5f-8beb-1c99ad1fe54f"
      unitRef="U_pure">0.92</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_e7cfc84d-4c9d-4d01-afc8-236747b0ea78"
      decimals="2"
      id="F_6414a8ec-14b1-40e5-8efc-7dd06dca957a"
      unitRef="U_pure">0.75</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_5f293e8e-a39e-4833-9e79-510818455bc1"
      decimals="2"
      id="F_f75c436c-8040-4b6e-ac3f-34eb24e59481"
      unitRef="U_pure">0.12</us-gaap:ConcentrationRiskPercentage1>
    <arct:JointVenturesEquityMethodInvestmentsAndVariableInterestEntitiesPolicyTextBlock
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_e942e7b2-a0b3-4f00-9ccd-261adf67d993">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Joint Ventures, Equity Method Investments and Variable Interest Entities&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Investments for which the Company exercises significant influence, but does not have control are accounted for under the equity method. Equity method investment activity is related to the Company's joint venture in ARCALIS, Inc. with Axcelead, Inc. The Company&#x2019;s share of the investees&#x2019; results is presented as either income or loss from equity method investees in the accompanying consolidated statements of operations and comprehensive income (loss). As of December 31, 2024, the carrying value of the equity method investment in ARCALIS remained at zero as ARCALIS' cumulative losses exceeded any gains from dilution.&lt;/span&gt;&lt;/p&gt;</arct:JointVenturesEquityMethodInvestmentsAndVariableInterestEntitiesPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_1a35d833-b509-4563-8d9b-5928224c2904">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Property and Equipment, net&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property and equipment are stated at cost, net of accumulated depreciation and amortization. The cost of property and equipment is depreciated or amortized using the straight-line method over the respective useful lives of the assets, ranging from &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_a09c2b80-d521-40d4-b228-c34c98f0be33;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Leasehold improvements are amortized using the straight-line method over the shorter of the estimated useful life of the asset or the lease term. Long-lived assets, including property and equipment are reviewed for impairment whenever events or circumstances indicate that the carrying amount of these assets may not be recoverable. The determinants used for this evaluation include management&#x2019;s estimate of an asset&#x2019;s ability to generate positive income from operations and positive cash flow in future periods, as well as the strategic significance of the assets to the Company&#x2019;s business objectives. The Company did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t recognize any impairment losses for the years ended December 31, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2024, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; or 2022.&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_de7f4b0b-b0a5-4403-a0c8-005d40a0ea9f"
      id="F_94a13513-207a-4529-a7da-5e446641f8de">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      decimals="INF"
      id="F_14f48dd5-aa84-4fa9-b2f8-e8cf4d26483e"
      unitRef="U_USD">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c"
      decimals="INF"
      id="F_f4ad6654-1a4a-4b6b-870b-a5e4bc4f27bf"
      unitRef="U_USD">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812"
      decimals="INF"
      id="F_450c39d8-cb37-43cf-befd-584ff3cb6293"
      unitRef="U_USD">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_8ccd984a-f116-43c8-82bf-7c3148082ae2">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Comprehensive Income/Loss&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Comprehensive income/loss is defined as the change in stockholders&#x2019; equity during a period from transactions and other events and circumstances from non-owner sources. There was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; other comprehensive loss or income tax effect related to unrealized losses in the years ended December 31, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2024, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; or 2022.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      decimals="INF"
      id="F_4eb99afc-dc53-4c81-9c81-fb77ea351d0b"
      unitRef="U_USD">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c"
      decimals="INF"
      id="F_3932011f-1b02-47d6-982d-0de21299e889"
      unitRef="U_USD">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812"
      decimals="INF"
      id="F_d51d6eea-57df-4ee1-bc47-3ac3aaedd117"
      unitRef="U_USD">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      decimals="INF"
      id="F_1276c662-e5ea-4e1b-8d35-c81b70593c98"
      unitRef="U_USD">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax
      contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c"
      decimals="INF"
      id="F_3d4146ce-63ef-4a2f-adf0-aa2463149497"
      unitRef="U_USD">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax
      contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812"
      decimals="INF"
      id="F_3a6a2670-49db-480a-a9c8-f7e2bbe9d861"
      unitRef="U_USD">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_afb3ea20-6b7a-41da-963b-7f93449bb106">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Revenue Recognition&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;At contract inception, the Company analyzes its collaboration arrangements to assess whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities and therefore within the scope of ASC Topic 808, Collaborative Arrangements (ASC 808). For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Company first determines which elements of the collaboration reflect a vendor-customer relationship and are therefore within the scope of ASC 606.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company determines revenue recognition for arrangements within the scope of Topic 606 by performing the following five steps: (i) identify the contract; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when, or as, the company satisfies a performance obligation.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The terms of the Company&#x2019;s revenue agreements include license fees, upfront payments, milestone payments, reimbursement for research and development activities, option exercise fees, consulting and related technology transfer fees and royalties on sales of commercialized products. The event-based milestone payments represent variable consideration, and the Company uses the most likely amount method to estimate this variable consideration because the Company will either receive the milestone payment or will not, which makes the potential milestone payment a binary event. The most likely amount method requires the Company to determine the likelihood of earning the milestone payment. Given the high degree of uncertainty around achievement of these milestones, the Company determines the milestone amounts to be fully constrained and does not recognize revenue until the uncertainty associated with these payments is resolved. The Company will recognize revenue from sales-based royalty payments when or as the sales occur. The Company will re-evaluate the transaction price in each reporting period as uncertain events are resolved and other changes in circumstances occur.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A performance obligation is a promise in a contract to transfer a distinct good or service to the collaborative partner and is the unit of account in Topic 606. A contract&#x2019;s transaction price is allocated to each distinct performance obligation based on relative standalone selling price and recognized as revenue when, or as, the performance obligation is satisfied.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For performance obligations that are recognized over time, the Company measures the progress using an input method. The input methods used are based on the effort expended or costs incurred toward the satisfaction of the performance obligation. The Company estimates the amount of effort expended, including the time estimated it will take to complete the activities, or costs incurred in a given period, relative to the estimated total effort or costs to satisfy the performance obligation. This approach requires the Company to make numerous estimates and use significant judgment. If estimates or judgments change over the course of the collaboration, a cumulative catch up of revenue is recognized in the period such changes are identified.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;See &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;&#x201c;Note 3, Revenue&#x201d;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for specific details surrounding the Company&#x2019;s arrangements.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Grant revenue&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Grant revenue&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;consists of funding under cost reimbursement programs primarily from federal and non-profit foundation sources for qualified research and development activities performed by the Company. Such amounts are invoiced and recorded as revenue as grant-funded activities are performed, with any advance funding recorded as deferred revenue until the activities are performed.&lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_b2ef6537-2a4b-4dcc-97d9-58665322d78e">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company determines if an arrangement is a lease at inception. Lease right-of-use assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. For operating leases with an initial term greater than 12 months, the Company recognizes operating lease right-of-use assets and operating lease liabilities based on the present value of lease payments over the lease term at the commencement date. Operating lease right-of-use assets are comprised of the lease liability plus any lease payments made and excludes lease incentives. Lease terms include options to renew or terminate the lease when the Company is reasonably certain that the renewal option will be exercised or when it is reasonably certain that the termination option will not be exercised. For the Company's operating leases, if the interest rate used to determine the present value of future lease payments is not readily determinable, the Company estimates its incremental borrowing rate as the discount rate for the lease. The Company's incremental borrowing rate is estimated to approximate the interest rate on a collateralized basis with similar terms and payments, and in&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;similar economic environments. Lease expense for lease payments is recognized on a straight-line basis over the lease term. The Company has elected the practical expedient to not separate lease and non-lease components.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;See &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;&#x201c;Note 11, Commitments and Contingencies&#x201d;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for specific details surrounding the Company&#x2019;s leases.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_fcb4af55-14f7-414c-b75f-022e829ac9a4">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Research and Development Costs, net&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;All research and development costs are expensed as incurred. Research and development costs consist primarily of salaries, employee benefits, costs associated with preclinical studies and clinical trials (including amounts paid to clinical research organizations and other professional services), pre-launch inventory, in-process research and development expenses and license agreement expenses. Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods are received or the services are performed. The Company recognizes grants that fall within the scope of ASC 808 as contra research and development expense in the consolidated statement of operations on a systematic basis over the periods in which the entity recognizes as expenses the related costs for which the grants are intended to compensate.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company records accruals for estimated research and development costs, comprising payments for work performed by third party contractors, laboratories, participating clinical trial sites, and others. Some of these contractors bill monthly based on actual services performed, while others bill periodically based upon achieving certain contractual milestones. For the latter, the Company accrues the expenses as goods or services are used or rendered.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Clinical trial activities performed by third parties are accrued and expensed based upon estimates of the proportion of work completed over the life of the individual clinical trial and patient enrollment rates in accordance with agreements established with Clinical Research Organizations (&#x201c;CROs&#x201d;) and clinical trial sites. Estimates are determined by reviewing contracts, vendor agreements and purchase orders, and through discussions with internal clinical personnel and external service providers as to the progress or stage of completion of trials or services and the agreed-upon fee to be paid for such services.&lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <arct:GeneralAndAdministrativeCostsPolicyPolicyTextBlock
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_f94a6bad-5138-4123-8d3e-b719b6c81bc6">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;General and Administrative Costs&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;General and administrative expenses consist primarily of personnel-related costs, including share-based compensation, for executives, finance, legal, human resources, business development, and other administrative and operational functions, professional fees, accounting and legal services, information technology and facility-related costs, and expenses associated with obtaining and maintaining intellectual property (&#x201c;IP&#x201d;). These costs relate to the operation of the business, unrelated to the research and development function, or any individual program.&lt;/span&gt;&lt;/p&gt;</arct:GeneralAndAdministrativeCostsPolicyPolicyTextBlock>
    <arct:PreLaunchInventoryPolicyPolicyTextBlock
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_1ba86401-794f-4faf-8753-ee71b7a1fdcc">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Pre-Launch Inventory&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Prior to obtaining initial regulatory approval for an investigational product candidate, the Company expenses costs relating to production of inventory as research and development expense in its consolidated statements of operations and comprehensive income (loss), in the period incurred. When the Company believes regulatory approval and subsequent commercialization of an investigational product candidate is probable, and the Company also expects future economic benefit from the sales of the investigational product candidate to be realized, it will then capitalize the costs of production as inventory.&lt;/span&gt;&lt;/p&gt;</arct:PreLaunchInventoryPolicyPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_8f172e73-190d-4273-9840-4ab75378b712">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Share-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company records share-based compensation for equity awards granted to employees, consultants, officers and directors within general and administrative and research and development expenses on the statements of operations and comprehensive income (loss). &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Share-based compensation is recognized over the requisite service period of the individual awards using the straight-line attribution method, which generally equals the vesting period. Employees and officers&#x2019; stock options have a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ten-year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; life and generally vest &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% on the first anniversary of the grant and in 1/36&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;th&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; equal installments on each monthly anniversary thereafter, such that options are fully vested on the &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;four-year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; anniversary of the date of grant. The exercisability and vesting periods of equity awards granted to consultants and directors vary.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The fair value of stock options is estimated using a Black-Scholes valuation model on the date of grant. This method requires certain assumptions be used as inputs, such as the fair value of the underlying common stock, expected term of the option before exercise, expected volatility of the Company&#x2019;s common stock, expected dividend yield, and a risk-free interest rate. The Company has limited historical stock option activity and therefore estimates the expected term of stock options granted using the simplified method, which represents the average of the contractual term of the stock option and its weighted-average vesting period. For the nine months ended September 30, 2024, the expected volatility of stock options was based on the historical volatility of a peer group of publicly traded companies. For the three months ended December 31, 2024, the Company used its own historical volatility to estimate expected volatility, as it had accumulated sufficient historical stock price data. The Company has not declared or paid any dividends and does not currently expect to do so in the foreseeable future. The risk-free interest rates used are based on the implied yield currently available in United States Treasury securities at maturity with a term equivalent to the expected term of the stock options. The effect of forfeited or cancelled awards is recorded when the forfeiture or cancellation occurs&lt;/span&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights
      contextRef="C_f0e7f0b2-1598-4953-9f90-cc64a32fbc98"
      id="F_4fd36679-2a66-4ed9-8418-655ce35cf244">Share-based compensation is recognized over the requisite service period of the individual awards using the straight-line attribution method, which generally equals the vesting period. Employees and officers&#x2019; stock options have a ten-year life and generally vest 25% on the first anniversary of the grant and in 1/36th equal installments on each monthly anniversary thereafter, such that options are fully vested on the four-year anniversary of the date of grant. The exercisability and vesting periods of equity awards granted to consultants and directors vary.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_f0e7f0b2-1598-4953-9f90-cc64a32fbc98"
      id="F_4227c422-ca7d-49ac-afcf-ad571923af6e">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="C_55f99ccf-69c7-4793-a958-d0a9d4e65d04"
      decimals="2"
      id="F_6fd662dd-2b92-4d01-aad5-d3407aa958fb"
      unitRef="U_pure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_f0e7f0b2-1598-4953-9f90-cc64a32fbc98"
      id="F_050c8337-061d-4080-8c29-d210d5c21400">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:InventoryCashFlowPolicy
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_8e1a9b35-86ec-4ab8-8bda-cbc6c6d4d89f">&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Statement of Cash Flows&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets to the total of such amounts shown in the consolidated statement of cash flows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:56.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:10.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.34%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:10.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;237,028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;292,005&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;391,883&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Restricted cash - current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;55,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;55,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Non-current Restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,885&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,885&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,094&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total cash, cash equivalents and restricted cash &lt;br/&gt;&#160;&#160;&#160;&#160;&#160;shown in the statement of cash flows&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;293,913&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;348,890&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;393,977&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;</us-gaap:InventoryCashFlowPolicy>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_e169f369-eee1-4bd1-b202-ea3a7f087e25">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets to the total of such amounts shown in the consolidated statement of cash flows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:56.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:10.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.34%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:10.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;237,028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;292,005&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;391,883&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Restricted cash - current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;55,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;55,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Non-current Restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,885&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,885&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,094&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total cash, cash equivalents and restricted cash &lt;br/&gt;&#160;&#160;&#160;&#160;&#160;shown in the statement of cash flows&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;293,913&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;348,890&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;393,977&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212"
      decimals="-3"
      id="F_fd79bdba-7549-4324-b562-919c0b67777c"
      unitRef="U_USD">237028000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc"
      decimals="-3"
      id="F_08194fab-fc38-4444-abf3-cab1346d0b5f"
      unitRef="U_USD">292005000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_9b6438ac-a4af-4cb1-a7e8-04fc1dc8917f"
      decimals="-3"
      id="F_1d5cdecc-6ea0-48cc-a2a1-9152c97c378f"
      unitRef="U_USD">391883000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212"
      decimals="-3"
      id="F_df1981fc-5752-4189-9f5d-6b430057c5a1"
      unitRef="U_USD">55000000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc"
      decimals="-3"
      id="F_c50429ce-8e21-40f1-9e34-33c1323877a2"
      unitRef="U_USD">55000000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212"
      decimals="-3"
      id="F_3e08fa6f-01a6-49bf-b565-d01cb9019775"
      unitRef="U_USD">1885000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc"
      decimals="-3"
      id="F_c12b18ee-8355-42a6-89ec-09b9f671c21e"
      unitRef="U_USD">1885000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_9b6438ac-a4af-4cb1-a7e8-04fc1dc8917f"
      decimals="-3"
      id="F_860cfdbd-8f34-4c25-8fcb-0f2b263c8364"
      unitRef="U_USD">2094000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212"
      decimals="-3"
      id="F_8ad4b348-ca84-4826-bf6e-6e49feffef0e"
      unitRef="U_USD">293913000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc"
      decimals="-3"
      id="F_063c54eb-7767-41f5-aa97-887b2e2c6ed6"
      unitRef="U_USD">348890000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_9b6438ac-a4af-4cb1-a7e8-04fc1dc8917f"
      decimals="-3"
      id="F_b17f432f-02bf-4256-81fc-dd55ab765421"
      unitRef="U_USD">393977000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_ad20d937-66d0-4ebc-85f6-0424613fa328">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Tax Expense&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Income taxes are accounted for using an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial reporting basis and the tax basis of the Company&#x2019;s assets and liabilities at the applicable tax rates, along with net operating loss and tax credit carryovers. The Company records a valuation allowance against its deferred tax assets to reduce the net carrying value to an amount that it believes is more likely than not to be realized. Management has considered estimated taxable income and ongoing prudent and feasible tax planning strategies in assessing the amount of the valuation allowance. Based upon the weight of available evidence, which includes the Company&#x2019;s historical operating performance and limited potential to utilize tax credit carryforwards, the Company has determined that total deferred tax assets should be fully offset by a valuation allowance. When the Company establishes or reduces the valuation allowance against its deferred tax assets, its provision for income taxes will increase or decrease, respectively, in the period such determination is made.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is required to file federal and state income tax returns in the United States and various other state jurisdictions. The Company also files income tax returns in the foreign countries in which it operates. The preparation of these income tax returns requires the Company to interpret the applicable tax laws and regulations in effect in such jurisdictions, which could affect the amount of tax paid by the Company.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Additionally, the Company follows an accounting standard addressing the accounting for uncertainty in income taxes that prescribes rules for recognition, measurement, and classification in the consolidated financial statements of tax positions taken or expected to be taken in a tax return.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_302fb017-d2c6-4115-9e15-176bdebd091e">&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Net (Loss) Income per Share&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basic net (loss) income per share is calculated by dividing the net (loss) income by the weighted-average number of shares of common stock outstanding for the period, without consideration for common stock equivalents. Diluted net (loss) income per share is calculated by dividing the net (loss) income by the weighted-average number of shares of common stock and dilutive common stock equivalents outstanding for the period determined using the treasury-stock method. Dilutive shares of common stock for the years ended December 31, 2024 and 2023 were comprised of stock options and restricted stock units. Dilutive shares of stock for the years ended December 31, 2022 were comprised of stock options.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; dividends were declared or paid during the reporting periods.&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:Dividends
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      decimals="INF"
      id="F_cdbbad2b-fdfc-40be-9c8d-3bd6349bb91c"
      unitRef="U_USD">0</us-gaap:Dividends>
    <us-gaap:Dividends
      contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c"
      decimals="INF"
      id="F_cd0e25c5-48ff-41ac-a49e-d6a18d54431f"
      unitRef="U_USD">0</us-gaap:Dividends>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_302ef2a4-1871-44f4-a3cc-774fd0212a8f">&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires public entities to disclose information about their reportable segments&#x2019; significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in ASC 280 on an interim and annual basis. ASU 2023-07 is effective for annual reporting periods beginning after December 15, 2023, and for interim reporting periods beginning January 1, 2025. The Company &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;adopted&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; ASU 2023-07 for the annual reporting period beginning on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;January 1, 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. See &#x201c;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Note 12, Segment Information&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x201d; for further information.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Recently Issued Accounting Standards Not Yet Adopted&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. The Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on the consolidated financial statements and disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2024, the FASB issued ASU 2024-03, Income Statement&#x2013;Reporting Comprehensive Income&#x2013;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, which requires public entities to disclose specified information about certain costs and expenses on an interim and annual basis. ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the impact that adoption of ASU 2024-03 will have on the financial statement disclosures.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
      contextRef="C_7b5e8cb5-a2d5-4fd1-a235-2bb6e7524e95"
      id="F_cc8aca20-67a8-490f-b009-60642815fe32">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate
      contextRef="C_7b5e8cb5-a2d5-4fd1-a235-2bb6e7524e95"
      id="F_4a1054ed-2ee9-4340-994d-1da364216cec">2024-01-01</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_37efa941-31a9-43d7-80ce-b47bd991615e">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;NOTE 3. Revenue&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has entered into license agreements and collaborative research and development arrangements with pharmaceutical and biotechnology companies, as well as consulting, related technology transfer and product revenue agreements. Under these arrangements, the Company is entitled to receive license fees, consulting fees, product fees, technological transfer fees, upfront payments, milestone payments if and when certain research and development milestones, technology transfer milestones or success-based milestones are achieved, royalties on approved product sales and reimbursement for research and development activities. The Company&#x2019;s costs of performing these services are included within research and development expenses. The Company&#x2019;s milestone payments are typically defined by achievement of certain preclinical, clinical, and commercial success criteria. Preclinical milestones may include &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;in vivo&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; proof of concept in disease animal models, lead candidate identification, and completion of IND-enabling toxicology studies. Clinical milestones may, for example, include successful enrollment of the first patient in or completion of Phase 1, 2 and 3 clinical trials, and commercial milestones are often tiered based on net or aggregate sale amounts. The Company cannot guarantee the achievement of these milestones due to risks associated with preclinical and clinical activities required for development of nucleic acid medicine-based therapeutics and vaccines.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;
&lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table presents changes in the balances of receivables and contract liabilities related to revenue generating agreements during the year ended December 31, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2024: &lt;/span&gt;&lt;/span&gt;&lt;span style=""&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11pt;font-family:'Calibri',sans-serif;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:44.329%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.2%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.902000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.2%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.902000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.682%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.582%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Additions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Deductions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Contract Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accounts receivable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32,064&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;98,430&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;126,520&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,974&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Contract Liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;87,325&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;97,599&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;152,806&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32,118&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During the year ended December 31, 2024, the Company recognized $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;62.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in revenue from the deferred revenue balance as of December 31, 2023.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the Company&#x2019;s revenue for the periods indicated. Approximately&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;138.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;154.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;192.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of total revenue represents revenue derived from foreign countries for the years ended December 31, 2024, 2023 and 2022, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.33%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.957%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.957%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.697000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Collaboration revenue:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;CSL Seqirus&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;138,389&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;154,264&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;154,425&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Vinbiocare&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,571&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Janssen&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;660&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,201&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Ultragenyx&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,837&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,739&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Israel Ministry of Health&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;987&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,319&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total collaboration revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;138,389&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;157,748&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;205,755&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Grant revenue:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;BARDA&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,921&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,051&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;244&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total grant revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,921&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,051&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;244&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following paragraphs provide information regarding the nature and purpose of the Company&#x2019;s most significant revenue arrangements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;CSL Seqirus&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On November 1, 2022, the Company entered into a Collaboration and License Agreement (as amended, the &#x201c;CSL Collaboration Agreement&#x201d;) with Seqirus, Inc., a part of CSL Limited (&#x201c;CSL Seqirus&#x201d;), for the global exclusive rights to research, develop, manufacture, and commercialize vaccines. Under the terms of the CSL Collaboration Agreement, the Company provides CSL Seqirus with an exclusive global license to its mRNA technology (including STARR&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;) and LUNAR&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; lipid-mediated delivery, along with mRNA drug substance and drug product manufacturing process. CSL Seqirus will lead development and commercialization of vaccines under the collaboration. The collaboration plans to advance vaccines against SARS-CoV-2 (COVID-19), influenza, pandemic preparedness as well as three other infectious diseases.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company received a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;200.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million upfront payment and is eligible to receive over $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; billion in development milestones if all products are registered in the licensed fields and entitled to potentially receive up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; billion in commercial milestones based on &#x201c;net sales&#x201d; of vaccines in the various fields. In addition, the Company is eligible to receive a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% net profit share for COVID-19 vaccine products and up to low double-digit royalties for vaccines against flu, pandemic preparedness and three other pathogens. During 2024, the Company achieve&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;d $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;72.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million o&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;f development and regulatory milestones related to the CSL Collaboration Agreement, of which &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;none&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; was included in accounts receivable as of December 31, 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In evaluating the CSL Collaboration Agreement in accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 606, the Company concluded that CSL Seqirus is a customer. The Company identified all promised goods/services within the CSL Collaboration Agreement, and when combining certain promised goods/services, the Company concluded that there are five distinct performance obligations. The nature of the performance obligations consists of delivery of the vaccine license, research and development services for COVID and non-COVID vaccines&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;and regulatory activities for COVID vaccines. For each performance obligation, the Company estimated the standalone selling price based on 1) in the case of the license, the fair value using costs to recreate plus margin method and 2) in the case of research and development services and regulatory activities, cost plus margin for estimated full-time equivalent (&#x201c;FTE&#x201d;) costs, direct costs including laboratory supplies, contractors, and other out-of-pocket expenses for research and development services and regulatory activities.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024, the transaction price primarily consisted of upfront consideration received and milestones achieved as of December 31, 2024. Additional variable consideration was not included in the transaction price at December 31, 2024 because the Company could not conclude that it is probable that including the variable consideration will not result in a significant revenue reversal.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company allocated the transaction price to the performance obligations in proportion to their standalone selling price. The portion of the upfront payment that was allocated to the vaccine license was recognized at the point in time it was transferred in 2022. The research and development and regulatory activities performance obligations are recognized over a period of time based on the percentage of services rendered using the input method, meaning actual costs incurred divided by total costs budgeted to satisfy the performance obligation. Any consideration related to sales-based royalties will be recognized when the amounts are probable of non-reversal, provided that the reported sales are reliably measurable and the Company has no remaining promised goods/services, as they are constrained and therefore have also been excluded from the transaction price. The revenue recognized in 2024 reflects variable consideration added to the transaction price upon the achievement of milestones, attributable to the license granted in 2022 and research and development services provided through December 31, 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;T&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;otal deferred revenue as of December 31, 2024 and 2023 for the CSL Collaboration Agreement was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;87.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During 2023, the Company also received an advance payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for the manufacturing and supply of ARCT-154 drug product. The advance payment was for specified manufacturing runs of ARCT-154 which include the drug substance utilized, as well as the reservation fees and related manufacturing requirements. The Company concluded that the promise to manufacture and supply ARCT-154 drug product is a customer option as part of the CSL Collaboration Agreement and is accounted for as a separate contract. The Company recognized $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in revenue related to this customer option during the second quarter of 2024. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; amount related to this customer option remained in deferred revenue as of December 31, 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During 2023, the Company entered into an amendment to the CSL Collaboration Agreement, pursuant to which the Company agreed to sponsor and conduct a Phase 1 clinical study in the influenza field. As part of the amendment, the Company received $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million from CSL Seqirus. The amendment also provides for up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in additional payments which are achievable upon meeting certain clinical milestones relating to the Phase 1 clinical study in the influenza field. The Company previously concluded that the expansion of research and development support services under the CSL Collaboration Agreement represented an option that was not a material right. Therefore the Company concluded the promise to sponsor and conduct the Phase 1 clinical study is a separate contract and the sole performance obligation under the new arrangement. During the year ended December 31, 2024, the Company recognized revenue of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million related to the performance obligation compared to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million during the year ended December 31, 2023. The remaining amount of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million is included in deferred revenue.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During the fourth quarter of 2023, the Company received an advance payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million from CSL Seqirus for manufacturing activities related to COVID-19 vaccine product. During the first quarter of 2024, the Company received an additional advance payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million from CSL Seqirus for manufacturing activities related to COVID-19 vaccine product. The Company concluded that the promise to perform manufacturing activities is a customer option as part of the CSL Collaboration Agreement and is accounted for as a separate contract. The Company recognized $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in revenue related to this customer option during the third quarter of 2024 upon the transfer of vaccine product to CSL Seqirus. The remaining $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million is included in deferred revenue as of December 31, 2024 and will be recognized as revenue when the remaining vaccine product is transferred to CSL Seqirus.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In March 2024, the Company entered into an amendment to the CSL Collaboration Agreement, pursuant to which the parties agreed to, among other things, adjust (i) the development plans for certain product candidates, (ii) various development milestones related to such product candidates, (iii) provisions of the CSL Collaboration&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Agreement related to specific royalty payments, (iii) provisions of the CSL Collaboration Agreement related to distributors, and (iv) proprietary payment calculations related to the foregoing.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Vinbiocare&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During 2021 the Company entered into certain agreements with Vinbiocare, a member of Vingroup Joint Stock Company, whereby the Company would provide technical expertise and support services to Vinbiocare to assist in the build out of a mRNA drug product manufacturing facility in Vietnam. The Company received an upfront payment in aggregate of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million as part of the Vinbiocare Agreement. In October 2022, the Company and Vinbiocare executed a letter agreement terminating the Technology License and Technical Support Agreement and the Framework Drug Substance Supply Agreement (collectively, the &#x201c;License &amp;amp; Supply Agreements&#x201d;). The Company incurred no financial penalties in connection with the termination of the License &amp;amp; Supply Agreements and has no further financial obligations to Vinbiocare under these terminated agreements.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In October 2022, in association with the termination of the License &amp;amp; Supply Agreements, the Company signed the Study Support Agreement with Vinbiocare which provides that Vinbiocare shall continue to serve as the regulatory and financial sponsor of clinical studies conducted in Vietnam of ARCT-154 pursuant to the Company&#x2019;s arrangements with Vinbiocare (the &#x201c;Study Support Agreement&#x201d;). To support the continuing activities of these studies, the Study Support Agreement further provides for the Company to conduct certain services and to compensate Vinbiocare to help achieve the objectives of these studies. In February 2023, the Company agreed to provide additional financial support in the amount of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million to allow Vinbiocare to provide additional study support duties related to the ARCT-154 clinical study. As a result, the Company reserved $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of the original upfront payment to be paid to Vinbiocare over the future periods pursuant to the Study Support Agreement by reclassifying a portion of the upfront payment received from Vinbiocare pursuant to the License &amp;amp; Supply Agreements, from deferred revenue to short-term and long-term liabilities, based on the anticipated timing of the payments to Vinbiocare, and removed that portion of the upfront payment from the transaction price of the modified arrangement. The transaction price was not adjusted for payments that are contingent upon the occurrence of future regulatory or sales-related events based on the information currently available to the Company.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has concluded that it has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; remaining performance obligations under its prior arrangements with Vinbiocare as summarized above as of December 31, 2024. As of December 31, 2024, the Company has accrued liabilities related to this arrangement of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in current liabilities that will be paid upon the occurrence of specified events through the end of 2025. Vinbiocare is also eligible to receive a single digit percentage of amounts from net sales, if any, of ARCT-154 (or next-generation COVID vaccine) up to a capped amount of low single digit millions. The Company had &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; remaining deferred revenue as of December 31, 2024 or 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;BARDA Grant&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In August 2022, the Company entered into a cost reimbursement contract with the Biomedical Advanced Research and Development Authority ("BARDA"), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS) for an award of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;63.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for the development of a pandemic influenza vaccine using the Company's STARR&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:8.040000000000001pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; self-amplifying mRNA vaccine platform technology. The Company earns grant revenue for performing tasks under the agreement.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company determined that the agreement with BARDA is not in the scope of ASC 808 or ASC 606. Applying International Accounting Standards No. 20 ("IAS 20"), Accounting for Government Grants and Disclosure of Government Assistance, by analogy, the Company recognizes grant revenue from the reimbursement of direct out-of-pocket expenses, overhead allocations and fringe benefits for research costs associated with the grant. The costs associated with these reimbursements are reflected as a component of research and development expense in the Company&#x2019;s consolidated statements of operations and comprehensive income (loss).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company recognized $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of grant revenue during the years ended December 31, 2024 and 2023, respectively, which is included in revenue on the Company's consolidated statements of operations. As of December 31, 2024, the remaining available funding net of revenue earned was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_a08cf772-7ca7-42a9-b3e0-7a929c4e9fa5">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table presents changes in the balances of receivables and contract liabilities related to revenue generating agreements during the year ended December 31, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2024: &lt;/span&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:44.329%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.2%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.902000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.2%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.902000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.682%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.582%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Additions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Deductions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Contract Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accounts receivable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32,064&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;98,430&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;126,520&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,974&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Contract Liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;87,325&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;97,599&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;152,806&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32,118&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc"
      decimals="-3"
      id="F_f975419d-51e1-48c2-a35f-ecb93c70d8a5"
      unitRef="U_USD">32064000</us-gaap:ContractWithCustomerAssetNet>
    <arct:ContractWithCustomerAssetAdditions
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      decimals="-3"
      id="F_24807bc9-5895-4a59-a2e3-e7bbccefb881"
      unitRef="U_USD">98430000</arct:ContractWithCustomerAssetAdditions>
    <arct:ContractWithCustomerAssetDeductions
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      decimals="-3"
      id="F_8f90a801-1092-485a-b90a-3a696ca1fe1f"
      unitRef="U_USD">-126520000</arct:ContractWithCustomerAssetDeductions>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212"
      decimals="-3"
      id="F_aefc4732-503e-4921-8a6e-52f74fbffcfb"
      unitRef="U_USD">3974000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc"
      decimals="-3"
      id="F_044c4727-54b5-4ec7-950f-341b3b52fe0b"
      unitRef="U_USD">87325000</us-gaap:ContractWithCustomerLiability>
    <arct:ContractWithCustomerLiabilityAdditions
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      decimals="-3"
      id="F_54925808-c444-4ceb-b4e8-f268a3166d40"
      unitRef="U_USD">97599000</arct:ContractWithCustomerLiabilityAdditions>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      decimals="-3"
      id="F_3ccd6b22-05b8-49d1-b79c-0ee37ba3643d"
      unitRef="U_USD">-152806000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212"
      decimals="-3"
      id="F_6ec4ba90-1f38-4280-8bb3-081ef10abd4b"
      unitRef="U_USD">32118000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c"
      decimals="-5"
      id="F_f8d970ee-917b-46e6-9b64-b3c29cb7e1ac"
      unitRef="U_USD">62600000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_e849ddd0-6b1a-4b88-9411-c63df1a5d270">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the Company&#x2019;s revenue for the periods indicated. Approximately&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;138.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;154.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;192.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of total revenue represents revenue derived from foreign countries for the years ended December 31, 2024, 2023 and 2022, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.33%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.957%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.957%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.697000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Collaboration revenue:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;CSL Seqirus&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;138,389&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;154,264&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;154,425&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Vinbiocare&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,571&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Janssen&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;660&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,201&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Ultragenyx&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,837&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,739&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Israel Ministry of Health&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;987&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,319&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total collaboration revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;138,389&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;157,748&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;205,755&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Grant revenue:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;BARDA&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,921&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,051&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;244&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total grant revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,921&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,051&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;244&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_e6a54d12-2d06-43c8-a611-842ff0eff99d"
      decimals="-5"
      id="F_2d88030c-cf39-48a0-8883-492ef3710b93"
      unitRef="U_USD">138400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_e3934ce5-c321-4a31-b7d0-60e3e1ef8264"
      decimals="-5"
      id="F_d4c134de-8a45-45b6-a363-62b35fd9446e"
      unitRef="U_USD">154900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_d88f1ae2-2110-4172-a005-770d3804d551"
      decimals="-5"
      id="F_6de99a51-f9a9-4ffa-b0a9-2e212d0a3097"
      unitRef="U_USD">192700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_cb30b8bf-d65b-4a7e-8e21-e4aa8d48e2f3"
      decimals="-3"
      id="F_b0de60f5-b114-4cf1-acde-64d281c163c5"
      unitRef="U_USD">138389000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_cbbb84bd-f6c0-4979-a42e-6dd1dc94cd5c"
      decimals="-3"
      id="F_1a4f60cf-9db5-4879-9cf8-32a8580b88e0"
      unitRef="U_USD">154264000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_596cb559-9f30-4570-b72b-2e4bf88511d2"
      decimals="-3"
      id="F_854c6e64-1fa0-45e6-9894-0917b37a5f31"
      unitRef="U_USD">154425000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_2d657502-e913-475b-9a66-3a5a4dec9710"
      decimals="-3"
      id="F_67c1196a-08b2-4c39-bab0-58dc95fce8a2"
      unitRef="U_USD">24571000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0a0009ee-75b0-4d6c-8c54-a3de804d67ed"
      decimals="-3"
      id="F_eb3cd49a-1ad3-4200-9b89-974a797c0144"
      unitRef="U_USD">660000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_c25d021b-7bf8-40de-b1c3-f954fd411acc"
      decimals="-3"
      id="F_24b07af1-c2b2-4b74-9702-844f97a2bc4a"
      unitRef="U_USD">9201000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_6aef7a2d-0065-4f49-a030-b4de642f444a"
      decimals="-3"
      id="F_b28d4f24-1fa0-4b8c-95d1-2e400f11c95c"
      unitRef="U_USD">1837000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_48e6c1d3-4d22-4c10-8a2a-1bdd49245c23"
      decimals="-3"
      id="F_dee65b02-c4d0-462d-a185-8c8d5b8bd0de"
      unitRef="U_USD">3739000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_eeccc958-3920-483a-bc18-4d732d1e801f"
      decimals="-3"
      id="F_b68385c4-d6a2-447e-9594-5cbd38660eb1"
      unitRef="U_USD">12500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_cdc3b296-383c-4f2b-8a23-fed8e5efc389"
      decimals="-3"
      id="F_f2dc037c-91a6-4ed0-8a10-c998a9a71f8e"
      unitRef="U_USD">987000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_a35204b8-793a-4f51-b6a2-2dad74d8547e"
      decimals="-3"
      id="F_ef19ead7-9756-4529-a28a-e4fbefe78e51"
      unitRef="U_USD">1319000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_200946b9-b524-4e78-9424-4e601b6b9f68"
      decimals="-3"
      id="F_ace94492-29b8-4c68-82ba-38010b3db31b"
      unitRef="U_USD">138389000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_e22ed845-7d56-4d58-bbda-cdb707f0cae4"
      decimals="-3"
      id="F_0ac418e1-be8f-4766-a51d-9b5e0a19f28d"
      unitRef="U_USD">157748000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_e340decb-8e23-4aec-a50a-9afef8ee8eaf"
      decimals="-3"
      id="F_edbb12fa-eabe-4710-8e13-703d72396c62"
      unitRef="U_USD">205755000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_8a8ee8e1-d0f5-45c7-a284-959089bf94e1"
      decimals="-3"
      id="F_6a6be758-07cb-43d5-b91b-7c3be0e47159"
      unitRef="U_USD">13921000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_db600b02-dfe3-4388-80ba-2f5ad5b53df0"
      decimals="-3"
      id="F_f71f3d96-fc98-4dfa-a4f2-1f92d7273519"
      unitRef="U_USD">9051000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_f92977ac-e76b-4cb7-8d5a-5b699cbdb902"
      decimals="-3"
      id="F_64672112-0791-48d1-9bfb-63d4944d756c"
      unitRef="U_USD">244000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_517ad6a3-e9ae-471c-a53f-67c77e50ab6f"
      decimals="-3"
      id="F_c2487c50-2e22-4d12-b641-939e7d94fff0"
      unitRef="U_USD">13921000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_3dcdc036-b6bb-44cc-9e78-55386dfe3195"
      decimals="-3"
      id="F_1aab2e7e-b488-48f5-992c-7f7e0fafada4"
      unitRef="U_USD">9051000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_45eb8bb7-286d-4047-9f32-b23ce157716c"
      decimals="-3"
      id="F_27d2e00a-5177-4de8-9d86-999df14864fd"
      unitRef="U_USD">244000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <arct:UpfrontPaymentReceived
      contextRef="C_7882f9eb-6eb4-4f9e-bdb7-9be9e4dde643"
      decimals="-5"
      id="F_8a243742-6bfe-41e3-849a-2d69e53f5d34"
      unitRef="U_USD">200000000</arct:UpfrontPaymentReceived>
    <arct:EligibleToReceiveDevelopmentMilestonePayment
      contextRef="C_07fceadb-01ec-4fd6-aff8-7976cff4540e"
      decimals="-8"
      id="F_4617177e-14d8-476f-b294-7d683285f752"
      unitRef="U_USD">1300000000</arct:EligibleToReceiveDevelopmentMilestonePayment>
    <arct:EligibleToReceiveCommercialMilestonePayment
      contextRef="C_07fceadb-01ec-4fd6-aff8-7976cff4540e"
      decimals="-8"
      id="F_89d6d3e9-29d8-404b-883a-fcf636c4a61e"
      unitRef="U_USD">3000000000</arct:EligibleToReceiveCommercialMilestonePayment>
    <arct:PercentageOfNetProfits
      contextRef="C_46790da3-ab07-41f8-bb66-6d90294211d5"
      decimals="2"
      id="F_0acfe189-c7ca-467b-a250-3ff730931557"
      unitRef="U_pure">0.40</arct:PercentageOfNetProfits>
    <arct:DevelopmentAndRegulatoryMilestonesAchieved
      contextRef="C_f0949914-ab4f-42d5-bcb0-e24ecd07e8cf"
      decimals="-5"
      id="F_3311c16c-b1b3-459e-9d3b-22e3c39d810f"
      unitRef="U_USD">72200000</arct:DevelopmentAndRegulatoryMilestonesAchieved>
    <arct:AchievedDevelopmentAndRegulatoryMilestoneIncludedAccountsReceivable
      contextRef="C_7bb37bf1-61a9-4d5a-8bd6-2abfca1a4ec5"
      decimals="INF"
      id="F_fb111700-0bad-447d-a7ab-716877395016"
      unitRef="U_USD">0</arct:AchievedDevelopmentAndRegulatoryMilestoneIncludedAccountsReceivable>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_7bb37bf1-61a9-4d5a-8bd6-2abfca1a4ec5"
      decimals="-5"
      id="F_2316e8b0-4040-4802-b3b1-853ccae4d0eb"
      unitRef="U_USD">30700000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_d4667b25-9ebe-441c-8ace-a7cddce91af6"
      decimals="-5"
      id="F_919df71b-8f59-4706-aeaf-cae6922d5211"
      unitRef="U_USD">87100000</us-gaap:ContractWithCustomerLiability>
    <arct:DevelopmentMilestonesReceivedAdvancePayment
      contextRef="C_de7040c9-0664-4d4f-9974-fddd45db823c"
      decimals="-5"
      id="F_7a21b84f-437a-4647-94ef-6926bc394225"
      unitRef="U_USD">23600000</arct:DevelopmentMilestonesReceivedAdvancePayment>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_6853a270-d4df-4f01-ae68-1bd1f016abe4"
      decimals="-5"
      id="F_3a703692-525b-4a95-9667-769d442f7b15"
      unitRef="U_USD">18000000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_8fd663c7-d616-4fa1-9c31-9db23c56c689"
      decimals="INF"
      id="F_392b69be-f82a-402a-b92f-cd95a1c1d5c2"
      unitRef="U_USD">0</us-gaap:ContractWithCustomerLiability>
    <arct:MilestonePayments
      contextRef="C_6f2bd238-0b95-4b22-8c5a-121d7509ed58"
      decimals="-5"
      id="F_4d41564e-4f27-4568-8dc5-550bbc900700"
      unitRef="U_USD">17500000</arct:MilestonePayments>
    <arct:AdditionalPaymentsUponMeetingCertainClinicalMilestones
      contextRef="C_4a52e6bd-de03-4707-910b-3abb83ab2003"
      decimals="-5"
      id="F_3aa2bff8-5ce0-448e-82d4-d9327f8d1a95"
      unitRef="U_USD">1500000</arct:AdditionalPaymentsUponMeetingCertainClinicalMilestones>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_3ca1293d-fd04-40b8-a46a-57af6a5ac7d7"
      decimals="-5"
      id="F_d3ae46a3-0112-42ce-8168-2c8008e95bc3"
      unitRef="U_USD">12000000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_6f2bd238-0b95-4b22-8c5a-121d7509ed58"
      decimals="-5"
      id="F_86d987a2-60a2-4fe1-89b7-cfb5d2319165"
      unitRef="U_USD">2400000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_ac8997ea-dc9f-4fed-83e0-b13eb0d07432"
      decimals="-5"
      id="F_dd0cb973-7438-4094-822f-a38a89e15c4e"
      unitRef="U_USD">3100000</us-gaap:ContractWithCustomerLiability>
    <arct:DevelopmentMilestonesReceivedAdvancePayment
      contextRef="C_86d66d5d-4c97-45bb-a084-bf8bbda66671"
      decimals="-5"
      id="F_35e5181f-101e-4a82-9ea9-8291b141efca"
      unitRef="U_USD">5300000</arct:DevelopmentMilestonesReceivedAdvancePayment>
    <arct:DevelopmentMilestonesReceivedAdvancePayment
      contextRef="C_22f5e6fe-f31d-416e-a210-33674b90d66e"
      decimals="-5"
      id="F_f701ebf4-3c3a-4eac-9905-337348204a7b"
      unitRef="U_USD">5100000</arct:DevelopmentMilestonesReceivedAdvancePayment>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_c6809d71-13e7-4b1a-924f-d8abae76045c"
      decimals="-5"
      id="F_c6b50ee2-6046-4c72-9a38-eb82036f70f9"
      unitRef="U_USD">5300000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0fe3841a-f105-4a0f-a913-03e14cbebbf8"
      decimals="-5"
      id="F_16fe7da1-ea7f-4564-94ea-c33aec6ae20f"
      unitRef="U_USD">5100000</us-gaap:ContractWithCustomerLiability>
    <arct:UpfrontPaymentReceived
      contextRef="C_8da6d6ac-b3ff-404b-afdf-8fd51a86a7c7"
      decimals="-5"
      id="F_23fcb57d-d49c-4147-8359-b723c50ebdef"
      unitRef="U_USD">40000000</arct:UpfrontPaymentReceived>
    <arct:AdditionalFinancialSupport
      contextRef="C_a8f29617-6dbc-47c2-bf34-7e091c3128a3"
      decimals="-5"
      id="F_44196fb8-a8bf-4ee0-86de-fb54c35f5a08"
      unitRef="U_USD">2100000</arct:AdditionalFinancialSupport>
    <arct:ReservedUpfrontPayment
      contextRef="C_967a80b1-1866-4f20-95dd-a83f22149812"
      decimals="-5"
      id="F_210cc31a-3016-4da0-8497-de3cea5e3e9f"
      unitRef="U_USD">11800000</arct:ReservedUpfrontPayment>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="C_2b4a205f-e9c7-4a9b-9f7d-e2d74d8a8790"
      decimals="INF"
      id="F_4d66d8d8-afa6-4cf3-87a3-daf30c7f41cd"
      unitRef="U_USD">0</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
      contextRef="C_eefa9a8b-a137-4b9b-a9bd-84d6397dcbae"
      decimals="-5"
      id="F_ecdd51da-b9aa-42cb-938a-ca516f083694"
      unitRef="U_USD">2400000</us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_2b4a205f-e9c7-4a9b-9f7d-e2d74d8a8790"
      decimals="INF"
      id="F_f5a230e2-8d65-4489-8ef8-8c81c5dfa911"
      unitRef="U_USD">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_4e71c9fa-246b-4174-807f-580b538d6c44"
      decimals="INF"
      id="F_0375b621-48c9-4dc0-a5c3-4676efec17dc"
      unitRef="U_USD">0</us-gaap:ContractWithCustomerLiability>
    <arct:GrantRevenue
      contextRef="C_bf73fc87-a7ef-43a8-bf1b-0ee33d958d5f"
      decimals="-5"
      id="F_b4cadf41-1a7d-42e1-93ec-b28af3aecad5"
      unitRef="U_USD">63200000</arct:GrantRevenue>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_2bb094b7-f6bc-4639-b097-78aa4e69c032"
      decimals="-5"
      id="F_509e5353-0fa0-4baf-9186-f01b17bb3f32"
      unitRef="U_USD">13900000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_2b4e1b2e-3490-4f8f-9601-99e9e60ed774"
      decimals="-5"
      id="F_895d45c1-942b-4686-a978-c48807126263"
      unitRef="U_USD">9100000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <arct:GrantRevenueOutstanding
      contextRef="C_2bb094b7-f6bc-4639-b097-78aa4e69c032"
      decimals="-5"
      id="F_a4889f3d-9f64-4f4a-b26b-02ecfdb4e00b"
      unitRef="U_USD">40000000</arct:GrantRevenueOutstanding>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_63a6eee6-4d26-4078-b772-180587352a36">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;NOTE 4. Fair Value Measurements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company establishes the fair value of its assets and liabilities using the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company established a fair value hierarchy based on the inputs used to measure fair value.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The three levels of the fair value hierarchy are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 1:  Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 2:  Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 3:  Unobservable inputs in which little or no market data exists and are therefore determined using estimates and assumptions developed by the Company, which reflect those that a market participant would use.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The carrying value of cash, restricted cash, accounts receivable, accounts payable, accrued liabilities and the Singapore loan approximate their respective fair values due to their relative short maturities. The carrying amounts of long-term debt for the amount drawn on the Company&#x2019;s debt facility approximates fair value as the interest rate is variable and reflects current market rates.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company's assets measured at fair value on a recurring basis consisted of money market funds. As of December 31, 2024, the Company's had money market funds with a fair value of&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;230.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, which &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;were classified within Level 1 of the fair value hierarchy. The fair value of these financial instruments was measured based on quoted prices.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_44b8ebcf-fb2f-4241-9026-e24a66edc6b0"
      decimals="-5"
      id="F_aad846b8-4210-4eb2-87d9-4e5b82b486ce"
      unitRef="U_USD">230200000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_0aedb48e-7e95-481b-a362-aa879ca63a9e">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;NOTE 5. Accrued Liabilities Detail&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accrued liabilities consisted of the following:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;   &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:61.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.8%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.8%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,305&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,918&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cystic Fibrosis Foundation liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,443&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,633&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Income tax payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;641&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Current portion of &lt;/span&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_7bcaf8a7-146c-4002-845d-af462601018d;"&gt;&lt;span style="-sec-ix-hidden:F_9747f896-2497-4837-848b-f002a89071bd;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;operating lease liability&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,552&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,309&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Clinical trial accruals&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,828&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,333&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Vinbiocare contractual liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,421&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,514&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Legal accrual&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;130&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;177&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other accrued research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,102&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,356&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;38,781&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31,881&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_143dd367-34c8-4fc3-962d-8d8370981e68">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accrued liabilities consisted of the following:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;   &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:61.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.8%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.8%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,305&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,918&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cystic Fibrosis Foundation liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,443&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,633&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Income tax payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;641&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Current portion of &lt;/span&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_7bcaf8a7-146c-4002-845d-af462601018d;"&gt;&lt;span style="-sec-ix-hidden:F_9747f896-2497-4837-848b-f002a89071bd;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;operating lease liability&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,552&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,309&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Clinical trial accruals&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,828&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,333&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Vinbiocare contractual liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,421&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,514&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Legal accrual&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;130&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;177&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other accrued research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,102&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,356&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;38,781&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31,881&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212"
      decimals="-3"
      id="F_fb40f7e9-82aa-4301-ac8a-07d60a0ffe19"
      unitRef="U_USD">13305000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc"
      decimals="-3"
      id="F_fc4eeb67-33b2-4243-9eaf-a115fb9cdfff"
      unitRef="U_USD">5918000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <arct:AccruedCysticFibrosisFoundationLiability
      contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212"
      decimals="-3"
      id="F_51287b2f-13bb-4d86-9ab7-7068dc1d72ff"
      unitRef="U_USD">7443000</arct:AccruedCysticFibrosisFoundationLiability>
    <arct:AccruedCysticFibrosisFoundationLiability
      contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc"
      decimals="-3"
      id="F_f3d1ec53-c0bd-48e4-bf0d-a979ea0a6d28"
      unitRef="U_USD">7633000</arct:AccruedCysticFibrosisFoundationLiability>
    <us-gaap:TaxesPayableCurrent
      contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc"
      decimals="-3"
      id="F_80f41f4e-07d2-41cb-95d8-555affd5f314"
      unitRef="U_USD">641000</us-gaap:TaxesPayableCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212"
      decimals="-3"
      id="F_c0609769-7a7a-45a3-adda-2719fc34ba18"
      unitRef="U_USD">3552000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc"
      decimals="-3"
      id="F_68569941-51b7-44fb-8246-e7d3a99e1106"
      unitRef="U_USD">4309000</us-gaap:OperatingLeaseLiabilityCurrent>
    <arct:ClinicalTrialAccrualsCurrent
      contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212"
      decimals="-3"
      id="F_782deb28-0311-4422-b7de-f80af56646d1"
      unitRef="U_USD">2828000</arct:ClinicalTrialAccrualsCurrent>
    <arct:ClinicalTrialAccrualsCurrent
      contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc"
      decimals="-3"
      id="F_62cc314f-1389-4fe3-89cb-3283c3b25782"
      unitRef="U_USD">2333000</arct:ClinicalTrialAccrualsCurrent>
    <arct:VinbiocareContractualLiabilities
      contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212"
      decimals="-3"
      id="F_850d604c-67b5-42a7-95ad-9e79c17d4757"
      unitRef="U_USD">2421000</arct:VinbiocareContractualLiabilities>
    <arct:VinbiocareContractualLiabilities
      contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc"
      decimals="-3"
      id="F_ed66031d-a206-4453-b7af-e2cf34660152"
      unitRef="U_USD">2514000</arct:VinbiocareContractualLiabilities>
    <arct:LegalAccrualCurrent
      contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212"
      decimals="-3"
      id="F_626ded6a-88f7-4488-8fc1-90219121941c"
      unitRef="U_USD">130000</arct:LegalAccrualCurrent>
    <arct:LegalAccrualCurrent
      contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc"
      decimals="-3"
      id="F_5b265660-1482-4c55-ae91-567d080d4209"
      unitRef="U_USD">177000</arct:LegalAccrualCurrent>
    <arct:OtherAccruedResearchAndDevelopmentExpenses
      contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212"
      decimals="-3"
      id="F_441ecbba-3c8f-4325-a18f-ab0a7128b413"
      unitRef="U_USD">9102000</arct:OtherAccruedResearchAndDevelopmentExpenses>
    <arct:OtherAccruedResearchAndDevelopmentExpenses
      contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc"
      decimals="-3"
      id="F_385b59e0-0884-47ed-a4d9-953bd26c2465"
      unitRef="U_USD">8356000</arct:OtherAccruedResearchAndDevelopmentExpenses>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212"
      decimals="-3"
      id="F_2742b262-84d4-4324-a77b-1f3acdb74178"
      unitRef="U_USD">38781000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc"
      decimals="-3"
      id="F_027af7d5-31ee-49dd-ba0b-05bdaba669e3"
      unitRef="U_USD">31881000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_29cd3eeb-5d0f-4832-9221-f4a5c59a3d61">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;NOTE 6. Property and Equipment, Net&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property and equipment, net consisted of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:61.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.8%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.8%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,864&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,046&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Computers and software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,131&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,275&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Office equipment and furniture&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;703&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;958&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,644&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,655&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Construction in progress&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;233&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,342&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,167&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,811&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,740&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,531&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,427&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Depreciation and amortization expense was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for the years ended December 31, 2024, 2023 and 2022, respectively. Construction in progress is primarily comprised of&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; research equipment not yet placed in service.&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_5047e589-b5e7-4bc7-a86d-a762fc0ec72a">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property and equipment, net consisted of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:61.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.8%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.8%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,864&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,046&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Computers and software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,131&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,275&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Office equipment and furniture&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;703&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;958&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,644&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,655&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Construction in progress&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;233&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,342&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,167&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,811&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,740&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,531&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,427&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_5a02c86b-64a7-48c8-9d61-fbfa2c4dde8a"
      decimals="-3"
      id="F_23d26532-9110-4204-b4c5-626c1caf8dd4"
      unitRef="U_USD">16864000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_7265865c-204c-46d5-a156-36e79a71f210"
      decimals="-3"
      id="F_4c23db5c-6d51-4cde-b5ee-e2cb0676ceea"
      unitRef="U_USD">16046000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_9f995e84-394b-4f80-b22b-985e9d097bfd"
      decimals="-3"
      id="F_5088a209-1389-4eba-87b0-1a39cf3f5f87"
      unitRef="U_USD">1131000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0c651e95-fd64-4c52-a5f0-0d5b8015a505"
      decimals="-3"
      id="F_9ee38741-229b-4578-9760-c6e9f8887541"
      unitRef="U_USD">1275000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_6e573c31-64c3-4efd-b469-ce13ad81a767"
      decimals="-3"
      id="F_b5a70934-fc7e-4c24-aee6-8e6624c96f63"
      unitRef="U_USD">703000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_ac4a66d0-a617-4eb3-97a5-5efc86181fd2"
      decimals="-3"
      id="F_9f8637dd-6bcd-4006-be03-b5b2717a6431"
      unitRef="U_USD">958000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_c9c5c093-9b6a-4d10-823e-777266370955"
      decimals="-3"
      id="F_7debdcab-b4e5-4ab8-910a-91aa4fc4c71a"
      unitRef="U_USD">2644000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_486087ba-60a6-4677-9a46-887bc39af237"
      decimals="-3"
      id="F_53137bf9-e4cd-44a8-af09-ab2648450c64"
      unitRef="U_USD">2655000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_8a585c58-b141-436d-8855-b3bbdf1ff8a2"
      decimals="-3"
      id="F_4f70ac1c-a249-4150-a556-0caf11890cd2"
      unitRef="U_USD">233000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212"
      decimals="-3"
      id="F_dd52df36-19f3-434c-9aaf-5bec9b67a932"
      unitRef="U_USD">21342000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc"
      decimals="-3"
      id="F_4caccdcf-66b4-4108-a59a-b375d58c53b1"
      unitRef="U_USD">21167000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212"
      decimals="-3"
      id="F_34b54f7e-d307-43b3-b217-9dc13dbc4a07"
      unitRef="U_USD">11811000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc"
      decimals="-3"
      id="F_7fc29068-855b-49ca-938c-d217c914864b"
      unitRef="U_USD">8740000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212"
      decimals="-3"
      id="F_3e25fa3c-6f34-455a-94f5-1449a94339da"
      unitRef="U_USD">9531000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc"
      decimals="-3"
      id="F_ca9c69c4-5258-4128-88e9-0a4bde6b1986"
      unitRef="U_USD">12427000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      decimals="-5"
      id="F_b31b7a4c-a51b-4eae-8712-f92237508f72"
      unitRef="U_USD">3500000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c"
      decimals="-5"
      id="F_f5d1a1e5-bb57-43e7-b397-fe58d59e6723"
      unitRef="U_USD">3000000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812"
      decimals="-5"
      id="F_a4084ef2-5deb-4b82-becc-15e5e4d6dff0"
      unitRef="U_USD">1500000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_f0f753ec-66d4-4825-9185-3d86ae344ee4">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;NOTE 7. Debt&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Wells Fargo Credit Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On April 21, 2023, the Company&#x2019;s wholly-owned subsidiary, Arcturus Therapeutics, Inc. entered into a credit agreement with Wells Fargo (the &#x201c;Credit Agreement&#x201d;) whereby Wells Fargo will make a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million revolving credit line available to the Company (the &#x201c;Loan&#x201d;) and each Loan evidenced by a revolving line of credit note (the &#x201c;Note&#x201d;). On &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;June 26, 2024, the parties entered into Amendment No. 1 to the Credit Agreement, whereby the term was extended by &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;one year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; to April 2026.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Borrowings under the agreement will bear interest at a rate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% above either the Daily Simple SOFR or Term SOFR (as such terms are defined in the Note), with &#x201c;SOFR&#x201d; being the rate per annum equal to the secured overnight financing rate as administered by the Federal Reserve Bank of New York. If an Event of Default (as defined in the agreement) occurs, then all Loans shall bear interest at a rate equal to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% above the interest rate applicable immediately prior to the occurrence of the Event of Default.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The original term of the agreement is &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;two years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, with an option for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;one-year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; renewals subject to Wells Fargo approval and the Company furnishing to Wells Fargo a non-refundable commitment fee equal to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.25&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the Loan amount for each such renewal. There is no penalty for terminating the facility prior to the maturity date of the Note. As collateral, the Company has agreed to pledge $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;55.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in cash to be held at the Company&#x2019;s securities accounts with Wells Fargo Securities, LLC, an affiliate of Wells Fargo, pursuant to a security agreement. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; amounts were outstanding as of December 31, 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Manufacturing Supply Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On November 7, 2020, the Company&#x2019;s wholly-owned subsidiary, Arcturus Therapeutics, Inc., entered into a Manufacturing Support Agreement (the &#x201c;Support Agreement&#x201d;) with the Economic Development Board of the Republic of Singapore (the &#x201c;EDB&#x201d;). Pursuant to the Support Agreement, the EDB agreed to make a term loan (the &#x201c;Singapore Loan&#x201d;) of S$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;62.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million to the Company, subject to the satisfaction of customary deliveries, to support the manufacture of the LUNAR-COV19 vaccine candidate (ARCT-021). The Singapore Loan accrues interest at a rate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% per annum calculated on a daily basis. The Company elected to borrow the full amount available under the Support Agreement of S$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;62.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million ($&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;46.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million) on January 29, 2021.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During the first quarter of 2023, the EDB agreed to an extension of the reconciliation period to March 22, 2023, with unused funds not utilized for the manufacture of ARCT-021 as of such date returned to the EDB. As of December 31, 2022, the outstanding balance of the Singapore Loan, which includes accrued interest, was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of which the Company paid S$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million ($&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million) in March 2023. During the first quarter of 2023, the remaining principal portion of the Singapore Loan plus accrued interest, totaling $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;34.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, was forgiven and recorded as a gain on debt extinguishment in the consolidated statement of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; interest expense was incurred on the Singapore Loan for the year ended December 31, 2024, and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of interest expense was incurred for the years ended December 31, 2023 and 2022, respectively. As of December 31, 2023, the Company no longer had debt or interest related to this agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Termination of Agreement with Western Alliance Bank&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On March 14, 2023, the Loan and Security Agreement, dated as of October 12, 2018 (as amended and supplemented, the &#x201c;Western Alliance Agreement&#x201d;) with Western Alliance Bank, an Arizona corporation (&#x201c;Western Alliance&#x201d;), was terminated (the &#x201c;Termination&#x201d;) upon the receipt by Western Alliance of a payoff amount of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million from the Company. The Western Alliance Agreement provided for a collateralized term loan in the aggregate principal amount of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, with interest at a floating rate ranging from &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.25&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.75&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% above the prime rate and a maturity date of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;October 30, 2023&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The payoff amount was made by the Company to Western Alliance from available cash on hand, pursuant to a payoff letter, and included payment of (i) approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in principal and interest, (ii) $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million fee payable upon prepayment as a result of prior FDA approval of an IND and (iii) de minimis amounts in prepayment charges and various operational fees. The Company was released from all liens under the Western Alliance Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company recorded &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; interest expense for the year ended December 31, 2024, and for the years ended December 31, 2023 and 2022, the Company recorded interest expense of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity
      contextRef="C_86445ba3-f6f4-4676-90ed-50251dd3995d"
      decimals="-5"
      id="F_72b08344-51f6-48a5-b41a-16b7789579e3"
      unitRef="U_USD">50000000</us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity>
    <arct:DebtInstrumentExtendedTermPeriod
      contextRef="C_4c016b15-4aaa-4d51-bf03-ece9dddf38ac"
      id="F_c06b57fe-9649-4be3-bd9f-be61101d4481">P1Y</arct:DebtInstrumentExtendedTermPeriod>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="C_86445ba3-f6f4-4676-90ed-50251dd3995d"
      decimals="4"
      id="F_f93a91f3-2e1a-4bf6-aa6f-6f418c170413"
      unitRef="U_pure">0.01</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LineOfCreditFacilityInterestRateDuringPeriod
      contextRef="C_41912f33-1403-4518-9ac5-80cc445c3148"
      decimals="4"
      id="F_93ee3807-1378-46b7-8471-4fd6b12dae16"
      unitRef="U_pure">0.02</us-gaap:LineOfCreditFacilityInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentTerm
      contextRef="C_41912f33-1403-4518-9ac5-80cc445c3148"
      id="F_7a530f90-b214-4976-b36d-cd36710fd43f">P2Y</us-gaap:DebtInstrumentTerm>
    <arct:DebtInstrumentOptionForRenewalTerm
      contextRef="C_41912f33-1403-4518-9ac5-80cc445c3148"
      id="F_88f18bf2-2dcd-4129-8e45-d99777bb2b97">P1Y</arct:DebtInstrumentOptionForRenewalTerm>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="C_41912f33-1403-4518-9ac5-80cc445c3148"
      decimals="4"
      id="F_6ecda0f3-1a23-485c-8984-b51a9c5920bc"
      unitRef="U_pure">0.0025</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <us-gaap:DebtInstrumentCollateralAmount
      contextRef="C_86445ba3-f6f4-4676-90ed-50251dd3995d"
      decimals="-5"
      id="F_1d342396-0939-4aed-b0fa-be2b03fb7f91"
      unitRef="U_USD">55000000</us-gaap:DebtInstrumentCollateralAmount>
    <us-gaap:LongTermDebt
      contextRef="C_3e3c5d0e-9c24-4b1b-b7e1-d57a6036bc5a"
      decimals="INF"
      id="F_39de122d-aaba-4cf3-9e51-68fabf0d193f"
      unitRef="U_USD">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_eacfa335-f40d-41a3-a10a-eb5d58e4252c"
      decimals="INF"
      id="F_9625418b-d73a-4037-8285-4d7c4d123300"
      unitRef="U_SGD">62100000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="C_eacfa335-f40d-41a3-a10a-eb5d58e4252c"
      decimals="3"
      id="F_2293efcf-f90b-4287-910f-9e5f2602463d"
      unitRef="U_pure">0.045</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:BorrowingsUnderGuaranteedInvestmentAgreements
      contextRef="C_fdc06d4c-b98b-4078-96e6-528aa846af54"
      decimals="-5"
      id="F_e9c6473f-2be2-4741-8e3b-b85796863699"
      unitRef="U_SGD">62100000</us-gaap:BorrowingsUnderGuaranteedInvestmentAgreements>
    <us-gaap:BorrowingsUnderGuaranteedInvestmentAgreements
      contextRef="C_fdc06d4c-b98b-4078-96e6-528aa846af54"
      decimals="-5"
      id="F_ad32c25b-9d44-41da-95a8-fd37f23c7bd4"
      unitRef="U_USD">46600000</us-gaap:BorrowingsUnderGuaranteedInvestmentAgreements>
    <us-gaap:LongTermDebt
      contextRef="C_67ddf72c-3213-4f12-be1f-701d0566198c"
      decimals="-5"
      id="F_f1da9629-e808-4b09-bc94-9096dd31713b"
      unitRef="U_USD">50400000</us-gaap:LongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="C_a3464474-dfd3-43d9-b123-3d9c2d59b71e"
      decimals="-5"
      id="F_a934203a-bca5-40c5-8f3f-d8b074ecc23b"
      unitRef="U_SGD">22800000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="C_a3464474-dfd3-43d9-b123-3d9c2d59b71e"
      decimals="-5"
      id="F_a60aec26-4913-413a-9e1d-1fb83227ef1c"
      unitRef="U_USD">17100000</us-gaap:RepaymentsOfLongTermDebt>
    <arct:RemainingLoanIncludingAccruedInterestForgiveable
      contextRef="C_bc749b60-01c7-407d-a66f-0ad31c3e3223"
      decimals="-5"
      id="F_7ba16ea8-47e8-424e-bb36-620900082881"
      unitRef="U_USD">34000000</arct:RemainingLoanIncludingAccruedInterestForgiveable>
    <us-gaap:InterestExpenseLongTermDebt
      contextRef="C_18e8b3d8-b758-4fc5-9f07-48c66ed98d2a"
      decimals="INF"
      id="F_0aae200b-f4fc-4570-a6c8-1b19d0802842"
      unitRef="U_USD">0</us-gaap:InterestExpenseLongTermDebt>
    <us-gaap:InterestExpenseLongTermDebt
      contextRef="C_2d41c197-8a7f-4abe-8802-3f3779ba2106"
      decimals="-5"
      id="F_d3ccf185-b53d-4721-8c71-0c3f61039264"
      unitRef="U_USD">500000</us-gaap:InterestExpenseLongTermDebt>
    <us-gaap:InterestExpenseLongTermDebt
      contextRef="C_dbe29eec-3da1-447f-afbd-bdbab15adc3a"
      decimals="-5"
      id="F_a4a5ef8e-a7bc-4a26-92fb-3f017a2d0842"
      unitRef="U_USD">2100000</us-gaap:InterestExpenseLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="C_21bee724-74a7-4507-ac63-b66c0326eeb4"
      decimals="-5"
      id="F_aac8962d-8ec2-479e-a516-acfab568a8ba"
      unitRef="U_USD">7400000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_4e721db5-40e6-4075-95cb-a09086f8814b"
      decimals="-5"
      id="F_e7b25916-e27b-4f08-998e-0e4a53f5d6bd"
      unitRef="U_USD">15000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="C_98a6fdf5-4340-4e1b-9ce6-86901cc3549e"
      decimals="4"
      id="F_09b7df03-db62-42e8-9734-04c708fc2c75"
      unitRef="U_pure">0.0125</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="C_69de4a86-a3b0-473a-bcf9-e08244abbdd7"
      decimals="4"
      id="F_6d2fc73c-7c21-4a8a-a070-5722c63afd1a"
      unitRef="U_pure">0.0275</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="C_21bee724-74a7-4507-ac63-b66c0326eeb4"
      id="F_e9346541-1f48-4448-a883-022c23d7a05b">2023-10-30</us-gaap:DebtInstrumentMaturityDate>
    <arct:RepyamentOfPrincipalAndInterestOnCollateralizedTermLoan
      contextRef="C_21bee724-74a7-4507-ac63-b66c0326eeb4"
      decimals="-5"
      id="F_42c8cc12-d2d0-4fff-81ce-4ab086ac85e7"
      unitRef="U_USD">7000000</arct:RepyamentOfPrincipalAndInterestOnCollateralizedTermLoan>
    <us-gaap:DebtInstrumentFeeAmount
      contextRef="C_4e721db5-40e6-4075-95cb-a09086f8814b"
      decimals="-5"
      id="F_1b209132-3645-4a55-8811-f50112fda940"
      unitRef="U_USD">300000</us-gaap:DebtInstrumentFeeAmount>
    <us-gaap:InterestExpenseLongTermDebt
      contextRef="C_e555c3b5-c6bf-47e7-838e-8773ebae68d0"
      decimals="INF"
      id="F_709c78d2-a6c3-44c8-978f-e565d8ddbfdf"
      unitRef="U_USD">0</us-gaap:InterestExpenseLongTermDebt>
    <us-gaap:InterestExpenseLongTermDebt
      contextRef="C_a64be24b-e012-4869-ab48-edbde5729fa1"
      decimals="-5"
      id="F_3094b3a8-39fb-4e81-b0da-14b9acaa59bf"
      unitRef="U_USD">300000</us-gaap:InterestExpenseLongTermDebt>
    <us-gaap:InterestExpenseLongTermDebt
      contextRef="C_dfad2efd-655c-4712-ad55-9208245cce2b"
      decimals="-5"
      id="F_2f4c8f75-aa53-40bc-9ad7-090f6b416762"
      unitRef="U_USD">900000</us-gaap:InterestExpenseLongTermDebt>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_9fc053f7-5bf5-4416-9672-2f20c9226d40">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;NOTE 8. Stockholders&#x2019; Equity&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Net (Loss) Income Per Share&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Potentially dilutive securities that were not included in the calculation of diluted net loss per share for the year ended December 31, 2024 and 2023 as they were anti-dilutive totaled &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively. Potentially dilutive securities that were not included in the calculation of diluted earnings per share for the year ended December 31, 2022 as they were anti-dilutive totaled &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      decimals="-5"
      id="F_e7b22a03-c041-42b7-9e05-56b54feeb5e4"
      unitRef="U_shares">1400000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c"
      decimals="-5"
      id="F_a1b69ee6-185d-4720-a0cd-0225f085e3bd"
      unitRef="U_shares">800000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812"
      decimals="-5"
      id="F_25b17d12-01db-426f-9a4d-bbc47788d2eb"
      unitRef="U_shares">3700000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_ff20b1bb-44d1-463d-ae01-f6f2da6b71d2">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;NOTE 9. Share-Based Compensation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In June 2024 at the Company&#x2019;s 2024 Annual Meeting of Stockholders (the "2024 Annual Meeting"), the stockholders of the Company approved an amendment to the Company&#x2019;s 2019 Omnibus Equity Incentive Plan (as amended, the &#x201c;2019 Plan&#x201d;) which, among other things, increased the aggregate number of shares authorized for use in making awards to eligible persons under the 2019 Plan by &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares, for a total of up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,750,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares available for issuance. As of December 31, 2024, a total of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,834,158&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares remain available for future issuance under the 2019 Plan, subject to the terms of the 2019 Plan.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;   &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In October 2021, the Company adopted the 2021 Inducement Equity Incentive Plan which covers the award of up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock (the &#x201c;2021 Plan&#x201d;) effective as of October 15, 2021. Approval of the Company&#x2019;s stockholders is not required as a condition to the effectiveness of the 2021 Plan for so long as the plan is in compliance with applicable Nasdaq inducement plan rules. In April 2022, the compensation committee of the Company&#x2019;s board of directors approved a proposal to reduce the total number of shares available for future issuance under the 2021 Plan to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;130,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. As of December 31, 2024, a total of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;124,697&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares remain available for future issuance under the 2021 Plan, subject to the terms of the 2021 Plan.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Share Options&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table presents the weighted-average assumptions used in the Black-Scholes valuation model by the Company in calculating the fair value of stock options granted:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.334%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.501%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.867999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.501%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.867999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.648%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected life (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.88&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.04&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.05&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;91.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;76.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;82.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.91&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.93&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Grant date weighted average fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22.62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18.87&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.56&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the Company&#x2019;s stock option activity for the year ended December 31, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2024:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:46%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term (Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic Value&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding &#x2013; December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,971,127&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33.55&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.9&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;53,295&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;740,594&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22.62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;228,328&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20.74&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeited/cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;404,641&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;42.43&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding &#x2013; December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,078,752&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32.38&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.2&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,247&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercisable &#x2013; December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,983,108&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;37.27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.4&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,796&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercisable and expected to vest &#x2013;&lt;br/&gt;&#160;&#160;&#160;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,078,752&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32.38&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.2&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,247&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;At December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the total unrecognized compensation cost of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;48.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million will be recognized over the weighted-average remaining service period of approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2.6&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years. The fair value of the options vested during the years ended December 31, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2024 , 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and 2022 was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively. The total intrinsic value of options exercised during the years ended December 31, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2024, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and 2022 was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Restricted Stock Units&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In August 2023, the Company granted &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,786&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; restricted stock units (&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x201c;RSUs&#x201d;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;) to its board of directors, when the market value of the Company's common stock was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;34.92&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share. These RSUs fully vested at the Company's 2024 annual stockholders' meeting. However, the release of the units remains subject to specific conditions and will occur only in the event of a board separation or a change in control.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the Company&#x2019;s RSU activity for the year ended December 31, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2024:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.58%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.28%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.76%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.96%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant&lt;br/&gt;Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding &#x2013; December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,786&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;34.92&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Awarded&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Released&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding &#x2013; December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,786&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;34.92&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Share-based compensation expenses included in the Company&#x2019;s statements of operations and comprehensive income (loss) for the years ended December 31, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2024,  2023 and 2022 were:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.58%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.82%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.82%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.28%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.700000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,456&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,950&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,081&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,532&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,699&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,530&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;37,988&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;34,649&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,611&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_79b86a89-0a00-45b1-8004-7d4dc0cdea25"
      decimals="INF"
      id="F_8695cd62-7547-4b2a-ad3a-63877d362edf"
      unitRef="U_shares">2000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_f82651ae-69da-4140-af2f-5b915dc1aca7"
      decimals="INF"
      id="F_7376f0c2-a0ea-484b-a964-1cce0a012980"
      unitRef="U_shares">10750000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_1a91ccd4-4bd8-43c2-8051-45a814608dfc"
      decimals="INF"
      id="F_63c7a750-9210-4478-acb6-4fa0a3a0ba1c"
      unitRef="U_shares">1834158</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_2cc45ff1-3360-475a-b5da-15ae2c8d66aa"
      decimals="INF"
      id="F_8aa8ed9c-70a6-4fb5-a60f-451ef4aaca39"
      unitRef="U_shares">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <arct:ReductionInNumberOfCommonStockCapitalSharesAvailableForFutureIssuance
      contextRef="C_e3cf53cd-b1a1-435f-8cee-4794f5764eb6"
      decimals="INF"
      id="F_d82feab8-4cce-4e05-a805-40deb99959f5"
      unitRef="U_shares">130000</arct:ReductionInNumberOfCommonStockCapitalSharesAvailableForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_d22dc742-0007-4f3e-97ad-b0aa9112af8c"
      decimals="INF"
      id="F_400dc19c-0a5d-4576-9306-9fcac87ef6c3"
      unitRef="U_shares">124697</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_5e73e3c9-85b2-46e5-9049-ccaa080fda7b">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table presents the weighted-average assumptions used in the Black-Scholes valuation model by the Company in calculating the fair value of stock options granted:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.334%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.501%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.867999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.501%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.867999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.648%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected life (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.88&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.04&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.05&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;91.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;76.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;82.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.91&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.93&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Grant date weighted average fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22.62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18.87&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.56&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_f94c3743-e85f-4283-b541-3b2a49e36750"
      id="F_78dee1eb-5be8-4df2-ba90-29a0b1f5db8c">P5Y10M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_e343b8cf-c999-46dc-82b2-5e281a84df00"
      id="F_a650983c-060c-41d5-b884-876a6a5ce3ce">P6Y14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_d50d4b6b-e748-48a2-99dc-da00925623e4"
      id="F_6877d5f1-8330-4448-84bd-a96868b11661">P6Y18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_f94c3743-e85f-4283-b541-3b2a49e36750"
      decimals="3"
      id="F_ff238f92-6474-4053-9af1-a54586c46366"
      unitRef="U_pure">0.914</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_e343b8cf-c999-46dc-82b2-5e281a84df00"
      decimals="3"
      id="F_11f0b526-3968-45b3-9d1c-d73a2d0948d7"
      unitRef="U_pure">0.761</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_d50d4b6b-e748-48a2-99dc-da00925623e4"
      decimals="3"
      id="F_0e1d5abc-05c6-4170-aafb-4d2685ce5aa9"
      unitRef="U_pure">0.821</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_f94c3743-e85f-4283-b541-3b2a49e36750"
      decimals="4"
      id="F_b41274f2-c6a0-49cc-9c8d-a22e4ce162ce"
      unitRef="U_pure">0.0424</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_e343b8cf-c999-46dc-82b2-5e281a84df00"
      decimals="4"
      id="F_84f74c9a-0dcd-470b-b7a7-53de8d5c2f29"
      unitRef="U_pure">0.0391</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_d50d4b6b-e748-48a2-99dc-da00925623e4"
      decimals="4"
      id="F_0234816e-49d1-478c-8d06-87f0c3678658"
      unitRef="U_pure">0.0293</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_f94c3743-e85f-4283-b541-3b2a49e36750"
      decimals="2"
      id="F_07021d8d-fe50-4349-ae8f-c5266def208f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">22.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_e343b8cf-c999-46dc-82b2-5e281a84df00"
      decimals="2"
      id="F_623dd13c-197c-419e-be77-8c052334c7ee"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">18.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_d50d4b6b-e748-48a2-99dc-da00925623e4"
      decimals="2"
      id="F_d2a977ac-6504-47bb-91f0-bcb71dd44152"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">15.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_55593d5a-daba-44b3-895d-d4c968956a0d">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the Company&#x2019;s stock option activity for the year ended December 31, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2024:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:46%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term (Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic Value&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding &#x2013; December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,971,127&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33.55&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.9&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;53,295&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;740,594&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22.62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;228,328&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20.74&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeited/cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;404,641&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;42.43&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding &#x2013; December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,078,752&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32.38&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.2&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,247&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercisable &#x2013; December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,983,108&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;37.27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.4&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,796&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercisable and expected to vest &#x2013;&lt;br/&gt;&#160;&#160;&#160;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,078,752&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32.38&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.2&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,247&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc"
      decimals="INF"
      id="F_d3ef3dab-f9d5-46cf-abd2-f5baca76d42c"
      unitRef="U_shares">7971127</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc"
      decimals="2"
      id="F_01fff371-fc97-43ef-b11d-263e0211dbb3"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">33.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c"
      id="F_3440d15c-520d-4670-92a6-e78682bfdd77">P7Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc"
      decimals="-3"
      id="F_334fbabe-48d5-4892-8662-8e998c6a9df5"
      unitRef="U_USD">53295000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      decimals="INF"
      id="F_9015bc2b-cc5d-49c4-bf9b-40cd8e248efa"
      unitRef="U_shares">740594</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      decimals="2"
      id="F_545f3d36-9bfc-48c2-80e0-7e8929a4949a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">22.62</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      decimals="INF"
      id="F_9e7cf2b6-b9ee-4464-954a-98744e34b2ed"
      unitRef="U_shares">228328</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      decimals="2"
      id="F_3a417277-a439-4da2-8570-4fc901888b32"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">20.74</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      decimals="INF"
      id="F_2fd310a9-5bbe-4f15-ad31-0c5d30732529"
      unitRef="U_shares">404641</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      decimals="2"
      id="F_4282339a-d14b-4cb7-8c48-62772dd87003"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">42.43</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212"
      decimals="INF"
      id="F_38061d77-f17b-40b7-85d6-7cebc21c3d27"
      unitRef="U_shares">8078752</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212"
      decimals="2"
      id="F_2956c632-c90d-461e-bce1-852b0d27d89e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">32.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_3f3379d4-ba43-4e94-bf08-b112324eb020">P7Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212"
      decimals="-3"
      id="F_718ea3a9-36a7-4222-8936-d142fbcd7856"
      unitRef="U_USD">9247000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212"
      decimals="INF"
      id="F_de855dc4-a400-433b-a3a2-234213bfc975"
      unitRef="U_shares">4983108</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212"
      decimals="2"
      id="F_1c46efbc-a37f-4bd7-b415-7ea9948eddfd"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">37.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_29c15b9a-4029-40ae-8e33-98c127e7b6c8">P6Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212"
      decimals="-3"
      id="F_4e2ccd24-5fd4-4a30-9ed8-d9b616037099"
      unitRef="U_USD">8796000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212"
      decimals="INF"
      id="F_36ca5c19-6b69-4d84-b108-cb60a2a8dfbc"
      unitRef="U_shares">8078752</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212"
      decimals="2"
      id="F_07eb711a-689b-4f45-b232-bd48722a3e41"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">32.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_1aed82ee-6822-4257-ac02-f89123648363">P7Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212"
      decimals="-3"
      id="F_c35a3afb-a5a0-42e7-ab87-50813d95591c"
      unitRef="U_USD">9247000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212"
      decimals="-5"
      id="F_c7d898b2-c92b-4318-a78d-553d0872127a"
      unitRef="U_USD">48500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_1a3d7126-04d4-4205-a020-8f102c8725ea">P2Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      decimals="-5"
      id="F_eaae903d-0fd8-41b9-95f7-d298e70eb9c3"
      unitRef="U_USD">40500000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c"
      decimals="-5"
      id="F_72c834ed-ad53-4770-a5b2-9eef7e4a3a66"
      unitRef="U_USD">35300000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812"
      decimals="-5"
      id="F_577e8d49-abc7-486d-8ffa-2a59ecafdc46"
      unitRef="U_USD">39200000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      decimals="-5"
      id="F_aa3f5211-e195-40be-b81c-b6cc58a56c45"
      unitRef="U_USD">3300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c"
      decimals="-5"
      id="F_693f53d9-be69-427f-9d38-411845f06e33"
      unitRef="U_USD">4300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812"
      decimals="-5"
      id="F_2fef3ee4-bbeb-4903-b15e-c090929c3737"
      unitRef="U_USD">1600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_7c8f1ee8-0d0f-434d-9eb4-6868c4d8c3c9"
      decimals="INF"
      id="F_59e4531e-d153-44e4-affa-a007f3934c40"
      unitRef="U_shares">18786</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:SharePrice
      contextRef="C_415079ce-5509-40be-96cd-1470dad8f0d8"
      decimals="2"
      id="F_635e853b-9508-49c0-a6fa-04d532753ace"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">34.92</us-gaap:SharePrice>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_bf45e103-dc1d-4363-a04d-8b03b36616cc">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the Company&#x2019;s RSU activity for the year ended December 31, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2024:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.58%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.28%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.76%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.96%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant&lt;br/&gt;Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding &#x2013; December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,786&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;34.92&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Awarded&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Released&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding &#x2013; December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,786&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;34.92&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc"
      decimals="INF"
      id="F_65771d8f-783e-471a-9648-1e22d7e06a41"
      unitRef="U_shares">18786</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc"
      decimals="2"
      id="F_79b4bb72-bdd4-4704-8326-0848d13d169a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">34.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212"
      decimals="INF"
      id="F_5378d9b5-0418-400e-91d1-a710108e0b16"
      unitRef="U_shares">18786</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212"
      decimals="2"
      id="F_3a879217-c72e-44f0-b4f4-04c12ca6aee2"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">34.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_7b4898db-1b61-491c-982f-4a52e5969537">&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Share-based compensation expenses included in the Company&#x2019;s statements of operations and comprehensive income (loss) for the years ended December 31, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2024,  2023 and 2022 were:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.58%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.82%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.82%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.28%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.700000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,456&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,950&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,081&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,532&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,699&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,530&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;37,988&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;34,649&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,611&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_8dcffe65-b98b-4723-af16-5b3daa5d33c2"
      decimals="-3"
      id="F_87b9756d-ec96-45b3-b870-b9724c9c6252"
      unitRef="U_USD">18456000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_152910ca-c407-48c4-8614-914f708479a3"
      decimals="-3"
      id="F_67c79033-310a-4515-8458-0e414f0affc6"
      unitRef="U_USD">14950000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_10ba438f-86e7-4bea-afe6-6381fb76f525"
      decimals="-3"
      id="F_b71aac03-cdf8-4f3f-ad33-53ef73d6bfa1"
      unitRef="U_USD">14081000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_654bde4e-918b-4b9c-901a-10010de70313"
      decimals="-3"
      id="F_64cc021a-0278-4e07-9acc-1bc020030afa"
      unitRef="U_USD">19532000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_ff7ed278-8619-4daa-85d7-a6142360937e"
      decimals="-3"
      id="F_9697d042-ada2-4cc0-9a9b-0c9d154262fe"
      unitRef="U_USD">19699000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_28c7b4d4-46b4-403b-a81e-106c6eae4759"
      decimals="-3"
      id="F_f72be14a-5728-4b00-9084-8dbdcca2e100"
      unitRef="U_USD">16530000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      decimals="-3"
      id="F_8e11889f-46ab-4ad1-94ad-f8f32e4e46d8"
      unitRef="U_USD">37988000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c"
      decimals="-3"
      id="F_4f5a41f6-4030-4fc4-ae96-f090b331e281"
      unitRef="U_USD">34649000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812"
      decimals="-3"
      id="F_6dbeb9dc-67e6-429a-8644-9b507b38f1d0"
      unitRef="U_USD">30611000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_65b20b99-0a80-4494-94f9-18c0c40771d2">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;NOTE 10. Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A reconciliation of (loss) income before income taxes for domestic and foreign locations is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.791%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.642000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.262%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.522%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;United States&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;81,050&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27,890&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,644&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total (loss) income before income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;81,050&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27,890&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,644&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A reconciliation of income tax (benefit) expense for the years ended December 31, 2024, 2023 and 2022 is as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.34%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Current:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,246&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,121&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;589&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;174&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total current income tax (benefit) expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,835&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,295&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total deferred income tax expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total income tax (benefit) expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,835&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,295&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A reconciliation of the federal statutory income tax rate to the Company&#x2019;s effective income tax rate is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.451%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.982%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.581999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.982000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Federal statutory income tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;State income taxes, net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Share-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Officers compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Uncertain tax positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Permanent differences&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Provision for income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&#160;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The significant components of deferred income taxes are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.7%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.46%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.76%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.46%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.620000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net operating loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,413&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,147&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27,472&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,723&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,966&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;943&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,515&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,014&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Inventory&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,961&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Basis difference in equity investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,127&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,202&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Capitalized R&amp;amp;D&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;60,104&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;41,971&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Right-of-use lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,601&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,233&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Share-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,872&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,618&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total gross deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;145,070&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;116,812&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;858&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,184&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Right-of-use asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,168&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,822&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total gross deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,006&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;138,044&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;108,806&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net deferred tax asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In assessing the realization of the deferred tax assets, the Company considers whether it is more likely than not that some portion of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which temporary differences representing net future deductible amounts become deductible. Due to lack of available sources of taxable income, the Company recorded a full valuation allowance against its net deferred tax assets as sufficient uncertainty exists regarding the future realization of these assets. As of December 31, 2024 and 2023, the Co&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;mpany recorded a valuation allowance of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;138.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;108.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively. The valuation allowance changed by $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for the years ended December 31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;At December 31, 2024, the Company has federal and state net operating losses, or NOL, carryforwards of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;47.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;223.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively. The federal net operating loss carryforward includes losses generated in 2018 and after which can be carried forward indefinitely. The state net operating loss carryforward includes $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of losses that can be carried forward indefinitely.  The remaining state net operating losses begin to expire in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2039&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;At December 31, 2024, the Company has federal and state research and development credit carryforwards of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively. The federal credit carryforwards begin to expire in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2037&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, and the state credits carry forward indefinitely. $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of the state credit begin to expire in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2037 &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;and the remainder carryforward indefinitely. Additionally, the Company has an Orphan Drug Credit of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million as of December 31, 2024 which will begin to expire in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2042&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; unless previously utilized.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Pursuant to Internal Revenue Code (IRC) Sections 382 and 383, annual use of the Company&#x2019;s federal and California net operating loss and research and&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;development credit carryforwards may be limited in the event a cumulative change in ownership of more than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% occurs within a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three-year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; period. The Company has completed an IRC Section 382 analysis through December 31, 2024 regarding the limitation of net operating loss carryforwards and other tax attributes. The Company experienced ownership changes in 2018 and 2020; however, the Company estimates that all tax attributes can be utilized. There is a risk that additional ownership changes may occur in the future. If a change in ownership occurs, the NOL carryforwards and other tax attributes could be limited or restricted.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The company accounts for income taxes in accordance with ASC 740-10, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Accounting for Uncertainty in Income Taxes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more likely than not to be sustained upon audit by the relevant taxing authority. An uncertain tax position will not be recognized if it has less than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% likelihood of being sustained.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A reconciliation of unrecognized tax benefits is as follows (in millions):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.7%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.46%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.76%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.46%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.620000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Beginning balance of unrecognized tax benefits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Decrease for prior period tax positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Increase for current period tax positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Ending balance of unrecognized tax benefits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Amounts in the summary rollforward would &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t impact the effective tax rate as the Company maintains a full valuation on its net deferred tax assets. The Company is subject to taxation and files income tax returns in the United States, various U.S. states and foreign jurisdictions. The Company&#x2019;s tax years from 2014 to date are subject to examination by the U.S., and state taxing authorities due to the carryforward of unutilized net operating losses and research and development credits. The Company&#x2019;s policy is to recognize interest expense and penalties related to income tax matters as income tax expense. There was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; tax related interest or penalties recognized for the years ended December 31, 2024, 2023 and 2022.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company does not anticipate any material changes to its unrecognized tax benefits within the next twelve months.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_22f66645-416a-46f6-970e-0d88d1c0c2c9">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A reconciliation of (loss) income before income taxes for domestic and foreign locations is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.791%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.642000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.262%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.522%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;United States&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;81,050&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27,890&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,644&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total (loss) income before income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;81,050&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27,890&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,644&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      decimals="-3"
      id="F_f072b85f-0528-4851-b2ec-e79471351881"
      unitRef="U_USD">81050000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c"
      decimals="-3"
      id="F_9a3a14df-6288-4886-894b-fe624860fff5"
      unitRef="U_USD">-27890000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812"
      decimals="-3"
      id="F_2f88fc81-680a-459d-a8f3-6c1dfe9c5f80"
      unitRef="U_USD">10644000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      decimals="-3"
      id="F_01b3af29-d75d-4fb6-a549-a8d6badbebaf"
      unitRef="U_USD">81050000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c"
      decimals="-3"
      id="F_ba5d3ddf-fd1e-4887-85c0-c1a00cd11077"
      unitRef="U_USD">-27890000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812"
      decimals="-3"
      id="F_eae7e8cb-f13c-4b68-acaa-3bcbc4dae9f4"
      unitRef="U_USD">10644000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_c419aa25-d0ac-4696-819d-5c8adc7fad33">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A reconciliation of income tax (benefit) expense for the years ended December 31, 2024, 2023 and 2022 is as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.34%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Current:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,246&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,121&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;589&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;174&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total current income tax (benefit) expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,835&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,295&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total deferred income tax expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total income tax (benefit) expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,835&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,295&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      decimals="-3"
      id="F_8ea14788-136c-4241-be39-c5d83187547f"
      unitRef="U_USD">-11000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c"
      decimals="-3"
      id="F_ca816c84-4542-4aee-b166-2e8aee24a09f"
      unitRef="U_USD">1246000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812"
      decimals="-3"
      id="F_04943f6e-8e1b-43df-9b4e-3418260be842"
      unitRef="U_USD">1121000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      decimals="-3"
      id="F_6fe11ea1-00c5-44e5-b15d-ed6dfbea9e06"
      unitRef="U_USD">7000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c"
      decimals="-3"
      id="F_f3b73f8e-f857-4784-bcfd-6b9133e599d6"
      unitRef="U_USD">589000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812"
      decimals="-3"
      id="F_39f0b5a0-23ec-4b64-9102-51add4853d71"
      unitRef="U_USD">174000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      decimals="-3"
      id="F_ca4e21e4-7fdf-4180-9f15-634615fdffca"
      unitRef="U_USD">-4000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c"
      decimals="-3"
      id="F_cf8c303f-5d28-4283-961d-51b9f0075b80"
      unitRef="U_USD">1835000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812"
      decimals="-3"
      id="F_8ddd3111-ebb2-4556-a0ec-952dd31a55f6"
      unitRef="U_USD">1295000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      decimals="-3"
      id="F_76ef2162-6da2-4e6d-a482-50db8300a0bb"
      unitRef="U_USD">-4000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c"
      decimals="-3"
      id="F_887981e9-1c80-49b0-9934-708b0afa10fd"
      unitRef="U_USD">1835000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812"
      decimals="-3"
      id="F_6f6d74a5-ff9d-49cf-be73-239c64a07ac6"
      unitRef="U_USD">1295000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_f72c119b-661a-4483-8d85-bd0e074f8cc3">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A reconciliation of the federal statutory income tax rate to the Company&#x2019;s effective income tax rate is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.451%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.982%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.581999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.982000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Federal statutory income tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;State income taxes, net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Share-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Officers compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Uncertain tax positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Permanent differences&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Provision for income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      decimals="3"
      id="F_fd47558d-9d43-4040-95c3-c61dc2f1c23e"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c"
      decimals="3"
      id="F_0541d8c7-dd6f-41d4-b50d-f4660f034f2a"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812"
      decimals="3"
      id="F_ace850ab-9d2b-4fac-8891-bda66aac8882"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      decimals="3"
      id="F_5185c5d4-fac6-42e9-9a5e-2e2a54fd3220"
      unitRef="U_pure">0.019</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c"
      decimals="3"
      id="F_baee6e90-f69b-4b5a-9711-659cc3674abc"
      unitRef="U_pure">0.019</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812"
      decimals="3"
      id="F_7474e7cd-752b-40cc-a86b-fcc49d5a25ca"
      unitRef="U_pure">0.072</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      decimals="3"
      id="F_eaa7350f-e1db-4ee4-83d7-42d6f2e74ab2"
      unitRef="U_pure">-0.019</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c"
      decimals="3"
      id="F_a33634b6-0e43-4a2b-9727-8a143ec11382"
      unitRef="U_pure">-0.025</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812"
      decimals="3"
      id="F_54377556-1d34-4029-a5e6-0f5bef9eb23b"
      unitRef="U_pure">0.161</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <arct:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensation
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      decimals="3"
      id="F_930927d9-4a88-446a-9594-a176cc62be33"
      unitRef="U_pure">-0.034</arct:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensation>
    <arct:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensation
      contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c"
      decimals="3"
      id="F_44d79312-a34f-4594-929c-304d6248d77e"
      unitRef="U_pure">-0.074</arct:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensation>
    <arct:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensation
      contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812"
      decimals="3"
      id="F_4388ec9f-fab7-434d-9c81-d91b340bbc7c"
      unitRef="U_pure">0.218</arct:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensation>
    <arct:EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentCredits
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      decimals="3"
      id="F_a4b3cced-0baf-40c9-af2b-c1e7c40e3d2d"
      unitRef="U_pure">0.24</arct:EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentCredits>
    <arct:EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentCredits
      contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c"
      decimals="3"
      id="F_2eaa181f-603e-4ce5-830c-5d50573e66e1"
      unitRef="U_pure">0.20</arct:EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentCredits>
    <arct:EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentCredits
      contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812"
      decimals="3"
      id="F_e672bdc4-762e-4aca-9d0f-d5f249178304"
      unitRef="U_pure">-0.403</arct:EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentCredits>
    <arct:EffectiveIncomeTaxRateReconciliationUncertainTaxPosition
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      decimals="3"
      id="F_89574350-b313-4f27-b573-beb05eef0105"
      unitRef="U_pure">-0.037</arct:EffectiveIncomeTaxRateReconciliationUncertainTaxPosition>
    <arct:EffectiveIncomeTaxRateReconciliationUncertainTaxPosition
      contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c"
      decimals="3"
      id="F_c69be6c0-9706-4f9e-8069-1b6cd4244104"
      unitRef="U_pure">-0.024</arct:EffectiveIncomeTaxRateReconciliationUncertainTaxPosition>
    <arct:EffectiveIncomeTaxRateReconciliationUncertainTaxPosition
      contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812"
      decimals="3"
      id="F_f76340a3-0ebc-48b4-9af4-0126ca8c07fb"
      unitRef="U_pure">0.09</arct:EffectiveIncomeTaxRateReconciliationUncertainTaxPosition>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      decimals="3"
      id="F_e3b51f55-1bbf-4d48-9074-888f62169914"
      unitRef="U_pure">-0.014</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c"
      decimals="3"
      id="F_7f30c88f-383f-469d-a689-bc7d047c4e95"
      unitRef="U_pure">0.002</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812"
      decimals="3"
      id="F_1a60cd84-7747-480d-ae00-7606da469873"
      unitRef="U_pure">-0.126</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      decimals="3"
      id="F_deebb7b7-8f4b-46b9-9d62-5f562a20e0e8"
      unitRef="U_pure">-0.361</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c"
      decimals="3"
      id="F_11e8d4c1-4c76-41d8-bfff-a43b5a8e2b88"
      unitRef="U_pure">-0.365</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812"
      decimals="3"
      id="F_1a24b0b0-1f30-480f-ad8e-0168c1194c7d"
      unitRef="U_pure">-0.094</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      decimals="3"
      id="F_fc9601eb-4897-4f96-ac0e-d03a4a6d6c38"
      unitRef="U_pure">-0.002</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c"
      decimals="3"
      id="F_5881f5a6-ba7a-4917-ad92-e3dc8f0e5582"
      unitRef="U_pure">-0.003</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812"
      decimals="3"
      id="F_dbac3b76-6844-4f43-915a-5a30267b0cf1"
      unitRef="U_pure">-0.01</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <arct:EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      decimals="3"
      id="F_79efe3b0-9667-4980-8819-062b92577ae6"
      unitRef="U_pure">-0.002</arct:EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences>
    <arct:EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences
      contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c"
      decimals="3"
      id="F_bd12eb28-a1ba-4537-8440-c43f8177c65d"
      unitRef="U_pure">-0.007</arct:EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences>
    <arct:EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences
      contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812"
      decimals="3"
      id="F_8a175b34-3b97-450c-8c4a-0a3ef4788549"
      unitRef="U_pure">0.004</arct:EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      decimals="3"
      id="F_420d053f-d3e2-4371-b2b0-003bdec493ac"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c"
      decimals="3"
      id="F_855bb6c4-0bae-44e6-9cbe-2049760e4170"
      unitRef="U_pure">-0.067</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812"
      decimals="3"
      id="F_6fac4338-dc42-4d29-8499-252645b33652"
      unitRef="U_pure">0.122</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_46ca3fc5-c15b-45b3-b62a-2cd538050325">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The significant components of deferred income taxes are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.7%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.46%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.76%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.46%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.620000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net operating loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,413&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,147&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27,472&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,723&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,966&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;943&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,515&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,014&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Inventory&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,961&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Basis difference in equity investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,127&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,202&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Capitalized R&amp;amp;D&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;60,104&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;41,971&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Right-of-use lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,601&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,233&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Share-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,872&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,618&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total gross deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;145,070&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;116,812&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;858&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,184&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Right-of-use asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,168&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,822&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total gross deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,006&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;138,044&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;108,806&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net deferred tax asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212"
      decimals="-3"
      id="F_7aa65770-dc4c-473e-94ec-f9aed7b21930"
      unitRef="U_USD">25413000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc"
      decimals="-3"
      id="F_b97f7d73-eec2-40ff-a665-38674bcd86e3"
      unitRef="U_USD">19147000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212"
      decimals="-3"
      id="F_3d777a07-f311-4067-af7f-e6a91bc5adf7"
      unitRef="U_USD">27472000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc"
      decimals="-3"
      id="F_018ce71c-aee7-4177-824b-48ff6b3a7b8b"
      unitRef="U_USD">10723000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212"
      decimals="-3"
      id="F_57aa8270-9ca7-4b5c-a735-747677c091c8"
      unitRef="U_USD">2966000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc"
      decimals="-3"
      id="F_a44c06f3-51f0-4c46-ad2b-fdef2eefe787"
      unitRef="U_USD">943000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212"
      decimals="-3"
      id="F_87eaf2c9-3de1-4a9e-b607-72bb0da63981"
      unitRef="U_USD">5515000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc"
      decimals="-3"
      id="F_4a0e13f3-0f3a-4513-8644-79498cab4276"
      unitRef="U_USD">7014000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsInventory
      contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc"
      decimals="-3"
      id="F_f11c81e4-7586-4e8b-851b-7d413ea60051"
      unitRef="U_USD">15961000</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxAssetsEquityMethodInvestments
      contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212"
      decimals="-3"
      id="F_bcf9f880-5d7f-4f9b-b6d2-f8539c4200d0"
      unitRef="U_USD">2127000</us-gaap:DeferredTaxAssetsEquityMethodInvestments>
    <us-gaap:DeferredTaxAssetsEquityMethodInvestments
      contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc"
      decimals="-3"
      id="F_793338fc-c0f4-4efd-b866-78f7dadba5c4"
      unitRef="U_USD">2202000</us-gaap:DeferredTaxAssetsEquityMethodInvestments>
    <arct:DeferredTaxAssetsCapitalizedResearchAndDevelopment
      contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212"
      decimals="-3"
      id="F_e39a3c69-0411-4d4e-bda9-31e8cfb25f03"
      unitRef="U_USD">60104000</arct:DeferredTaxAssetsCapitalizedResearchAndDevelopment>
    <arct:DeferredTaxAssetsCapitalizedResearchAndDevelopment
      contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc"
      decimals="-3"
      id="F_3065df95-cc81-4377-9ed3-e20144abca2b"
      unitRef="U_USD">41971000</arct:DeferredTaxAssetsCapitalizedResearchAndDevelopment>
    <arct:DeferredTaxAssetsRightOfUseLeaseLiability
      contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212"
      decimals="-3"
      id="F_2dbbd9ba-c4f7-4919-90ae-8553416508d5"
      unitRef="U_USD">6601000</arct:DeferredTaxAssetsRightOfUseLeaseLiability>
    <arct:DeferredTaxAssetsRightOfUseLeaseLiability
      contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc"
      decimals="-3"
      id="F_194e296f-d97c-42b9-8aa4-bf1f4ba15ebe"
      unitRef="U_USD">7233000</arct:DeferredTaxAssetsRightOfUseLeaseLiability>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212"
      decimals="-3"
      id="F_7451cdf9-2aac-4a46-b894-9e5773126773"
      unitRef="U_USD">14872000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc"
      decimals="-3"
      id="F_a52412b6-71e9-4d7e-9083-0794cd1de357"
      unitRef="U_USD">11618000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212"
      decimals="-3"
      id="F_26f76e2f-9e22-4cfa-895d-fb614f4bcb75"
      unitRef="U_USD">145070000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc"
      decimals="-3"
      id="F_ed99ad59-ad58-473c-942f-e5a683a73b2b"
      unitRef="U_USD">116812000</us-gaap:DeferredTaxAssetsGross>
    <arct:DeferredTaxLiabilitiesPropertyPlantAndEquipmentAndIntangibleAssets
      contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212"
      decimals="-3"
      id="F_80d92e92-2782-4b69-84bf-07ace4685e83"
      unitRef="U_USD">858000</arct:DeferredTaxLiabilitiesPropertyPlantAndEquipmentAndIntangibleAssets>
    <arct:DeferredTaxLiabilitiesPropertyPlantAndEquipmentAndIntangibleAssets
      contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc"
      decimals="-3"
      id="F_d5c871d7-e071-4a8f-a701-1fcaed2fb4d9"
      unitRef="U_USD">1184000</arct:DeferredTaxLiabilitiesPropertyPlantAndEquipmentAndIntangibleAssets>
    <arct:DeferredTaxLiabilitiesRightOfUseAsset
      contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212"
      decimals="-3"
      id="F_c018343a-1c86-4003-8e0a-02537b1b415e"
      unitRef="U_USD">6168000</arct:DeferredTaxLiabilitiesRightOfUseAsset>
    <arct:DeferredTaxLiabilitiesRightOfUseAsset
      contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc"
      decimals="-3"
      id="F_73d30771-23c3-4c88-b02e-57d1297efe95"
      unitRef="U_USD">6822000</arct:DeferredTaxLiabilitiesRightOfUseAsset>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212"
      decimals="-3"
      id="F_18936f25-c260-47d1-83cc-6b4096f70224"
      unitRef="U_USD">7026000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc"
      decimals="-3"
      id="F_7d52450b-b4b6-475b-a3e1-e198a5981e92"
      unitRef="U_USD">8006000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212"
      decimals="-3"
      id="F_3a571c2a-0b23-4ce9-acff-f41f765d6a8a"
      unitRef="U_USD">138044000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc"
      decimals="-3"
      id="F_91439176-8647-46ee-9cae-398db92b61cc"
      unitRef="U_USD">108806000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212"
      decimals="-5"
      id="F_a9f4247f-d304-4b6c-b8e8-d813fe99fdfc"
      unitRef="U_USD">138000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc"
      decimals="-5"
      id="F_b94e2a70-fa67-4d1d-bd5a-3abe81a91cbc"
      unitRef="U_USD">108800000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      decimals="-5"
      id="F_1c154c2d-1ec3-45db-bf6f-719229ad6abd"
      unitRef="U_USD">29200000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c"
      decimals="-5"
      id="F_cb1ab376-7dee-42b8-8b2c-211055967438"
      unitRef="U_USD">10200000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_42b09082-30d1-4349-88f2-ae97e705f43e"
      decimals="-5"
      id="F_60bd3b5e-2b7c-4339-9b24-8e17cdb33a90"
      unitRef="U_USD">47500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_602adcc3-a068-4d86-ad11-fd96cb49a486"
      decimals="-5"
      id="F_9c2cfa0c-9560-4c03-aac9-7ba67a02c6a1"
      unitRef="U_USD">223500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_e570fa19-3556-454e-8682-69a04831b6bc"
      decimals="-5"
      id="F_63f085b8-571e-45a1-b95c-e4a2cd06dd21"
      unitRef="U_USD">400000</us-gaap:OperatingLossCarryforwards>
    <arct:OperatingLossCarryforwardsExpirationYear
      contextRef="C_26a8b21d-1c26-4459-a1ee-d89f9f331468"
      id="F_ef81da39-1caa-4ccd-9fa5-685fb53f9697">2039</arct:OperatingLossCarryforwardsExpirationYear>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_37d3f9a9-91a0-4432-bb97-b21a720960db"
      decimals="-5"
      id="F_80b014c8-4c54-460e-b547-d9f8267fd1aa"
      unitRef="U_USD">19800000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_a80d4900-cff3-43ef-a5a2-5effe03ec8b3"
      decimals="-5"
      id="F_c93a75b6-482f-413f-a2b3-4121a9a5efaf"
      unitRef="U_USD">11500000</us-gaap:TaxCreditCarryforwardAmount>
    <arct:TaxCreditCarryforwardExpirationYear
      contextRef="C_21d1b797-41f5-49d8-a548-8998a1e9873d"
      id="F_15b12fad-f843-4d51-8dcd-5daa53c4f5b8">2037</arct:TaxCreditCarryforwardExpirationYear>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_602adcc3-a068-4d86-ad11-fd96cb49a486"
      decimals="-5"
      id="F_57dae61d-725d-4eee-823d-aee8ad178779"
      unitRef="U_USD">800000</us-gaap:TaxCreditCarryforwardAmount>
    <arct:TaxCreditCarryforwardExpirationYear
      contextRef="C_26a8b21d-1c26-4459-a1ee-d89f9f331468"
      id="F_1b4c264b-c7fd-49a0-8b78-9a0ff55b32f3">2037</arct:TaxCreditCarryforwardExpirationYear>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_cab06b3d-053b-4c81-b42c-b2445cd0c158"
      decimals="-5"
      id="F_6c0135f9-42f3-40fc-94db-2225ca92cefe"
      unitRef="U_USD">4700000</us-gaap:TaxCreditCarryforwardAmount>
    <arct:TaxCreditCarryforwardExpirationYear
      contextRef="C_a772c31f-b8d4-430f-b45d-52b674305e78"
      id="F_13759c16-01d3-4c49-8bce-294e73821084">2042</arct:TaxCreditCarryforwardExpirationYear>
    <arct:NetOperatingLossAndResearchAndDevelopmentCreditCarryforwardsLimitationsOnCumulativeChangeInOwnershipMinimumPercentage
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      decimals="2"
      id="F_fec4c5dc-8c99-4d04-9294-32137f2748a6"
      unitRef="U_pure">0.50</arct:NetOperatingLossAndResearchAndDevelopmentCreditCarryforwardsLimitationsOnCumulativeChangeInOwnershipMinimumPercentage>
    <arct:NetOperatingLossAndResearchAndDevelopmentCreditCarryforwardsLimitationsOnCumulativeChangeInOwnershipPeriod
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_08c6ab61-0157-48d0-89b0-4a556825f926">P3Y</arct:NetOperatingLossAndResearchAndDevelopmentCreditCarryforwardsLimitationsOnCumulativeChangeInOwnershipPeriod>
    <arct:MaximumPercentageOfLikelihoodOfUncertainTaxPositionRecognizedToBeSustained
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      decimals="2"
      id="F_7694803f-0ab3-480f-be4a-a631f1ae1ce6"
      unitRef="U_pure">0.50</arct:MaximumPercentageOfLikelihoodOfUncertainTaxPositionRecognizedToBeSustained>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_d94273b5-57ba-4857-8960-ec009453e3d2">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A reconciliation of unrecognized tax benefits is as follows (in millions):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.7%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.46%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.76%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.46%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.620000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Beginning balance of unrecognized tax benefits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Decrease for prior period tax positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Increase for current period tax positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Ending balance of unrecognized tax benefits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc"
      decimals="-5"
      id="F_6c7576ff-09fa-48b1-b41a-7a3ece3c066e"
      unitRef="U_USD">3600000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_9b6438ac-a4af-4cb1-a7e8-04fc1dc8917f"
      decimals="-5"
      id="F_afcbb37e-3d65-461e-b2b7-f6429c20ca43"
      unitRef="U_USD">2900000</us-gaap:UnrecognizedTaxBenefits>
    <arct:UnrecognizedTaxBenefitsDecreasesIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      decimals="-5"
      id="F_ecdb6ce2-599c-4cfd-99e8-84891a6bae31"
      unitRef="U_USD">1200000</arct:UnrecognizedTaxBenefitsDecreasesIncreasesResultingFromPriorPeriodTaxPositions>
    <arct:UnrecognizedTaxBenefitsDecreasesIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c"
      decimals="-5"
      id="F_1fb93638-9361-4edc-b29e-bf3e8930adaa"
      unitRef="U_USD">100000</arct:UnrecognizedTaxBenefitsDecreasesIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      decimals="-5"
      id="F_13805539-e798-49e5-b62c-2e3a8ec8c973"
      unitRef="U_USD">2000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c"
      decimals="-5"
      id="F_51d065d3-cc80-4e93-ac5c-06b50d98ba25"
      unitRef="U_USD">600000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212"
      decimals="-5"
      id="F_a14fdf94-289d-481b-8f20-66da1c7e70c3"
      unitRef="U_USD">6800000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_5a840f32-bab4-41fb-a46f-2e08b5d7a8bc"
      decimals="-5"
      id="F_aef91a7f-5843-4cab-b89d-18e30522f09e"
      unitRef="U_USD">3600000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212"
      decimals="INF"
      id="F_f9b890ec-d54e-4a0d-8bd0-b9c78a000e1e"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      decimals="INF"
      id="F_7b85003d-735f-4cf3-9d52-a58759dec4e7"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c"
      decimals="INF"
      id="F_12338fa3-9c08-4e10-9de1-af567dca9ce1"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812"
      decimals="INF"
      id="F_41d848b9-8375-40fb-a654-2ca985514095"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_ad965992-d0fe-4bc1-b68b-25134f938172">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;NOTE 11. Commitments and Contingencies&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Cystic Fibrosis Foundation Therapeutics Funding agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On September 25, 2023, the Company amended its Development Program Letter Agreement, dated May 16, 2017 and as amended July 13, 2018 and August 1, 2019, with the Cystic Fibrosis Foundation (&#x201c;CFF&#x201d;). Pursuant to the amendment, (i) CFF increased the amount it will award to advance LUNAR-CF to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million from approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, (ii) the Company agreed to incur at least $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million toward activities under the research plan. During the fourth quarter of 2023, the Company received the full payment from CFF related to the amendment. For the years ended December 31, 2024, 2023 and 2022, the Company recognized contra expense of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively. As of December 31, 2024, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;million remained in accrued liabilities.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In October 2017, the Company entered into a non-cancellable operating lease agreement for office space adjacent to its previously occupied headquarters. The commencement of the lease began in March 2018 and the lease extends for approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;84&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; months from the commencement date with a remaining lease term through March 2025. Monthly rental payments are due under the lease and there are escalating rent payments during the term of the lease. The Company is also responsible for its proportional share of operating expenses of the building and common areas. In conjunction with the new lease, the Company received free rent for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;four months&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and received a tenant improvement allowance of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. In March 2024, the Company negotiated with the lessor to extend the lease through March 2027.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company entered into an irrevocable standby letter of credit with the landlord for a security deposit of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million upon executing the lease which is included (along with additional funds required to secure the letter of credit) in the balance of non-current restricted cash.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In February 2020, the Company entered into a second non-cancellable operating lease agreement for office space near its current headquarters. The lease extended for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;13&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; months from the commencement date and included a right to extend&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; the lease for one twelve-month period. In February 2021, the Company opted to extend the lease through March 2025 to coincide with the lease term of the Company&#x2019;s headquarters.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; In January 2024, the Company vacated this office space with no intention of operating out of the location in the future. The Company was still engaged in the lease for the property and obligated to make the remaining lease payments through March 31, 2025, and therefore recorded an impairment loss in the amount of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million during the three months ended March 31, 2024, as there was no future economic benefit from the lease. In July 2024, the Company terminated the existing lease agreement, in accordance with its terms, thereby ending their contractual obligation to pay for the premises. As a result, no lease liability remains as of December 31, 2024.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In September 2021, the Company entered into a third non-cancellable lease agreement for office, research and development, engineering and laboratory space near its current headquarters, and such lease term commenced during the second quarter of 2022. The initial term of this lease extends &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ten years and eight months&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; from the date of possession, and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;the Company has the right to extend the term of the lease for an additional five-year period.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; When the lease term was determined for the operating lease right-of-use assets and lease liabilities, the extension option for the lease was not included. The lease has a monthly base rent ranging from $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million which escalates over the lease term. The Company received a free rent period of four months and also pays for various operating costs, including utilities and real property taxes. The Company entered into an irrevocable standby letter of credit with the landlord for a security deposit of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million upon executing the lease which is included (along with additional funds required to secure the letter of credit) in the balance of non-current restricted cash.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Operating lease right-of-use asset and liability on the consolidated balance sheets represent the present value of remaining lease payments over the remaining lease terms. The Company does not allocate lease payments to non-lease components; therefore, payments for common-area-maintenance and administrative services are not included in the operating lease right-of-use asset and liability. The Company uses its incremental borrowing rate to calculate the present value of the lease payments, as the implicit rate in the lease is not readily determinable.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2024, the remaining payments of the operating lease liability were as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:75.855%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.06%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:20.084%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Remaining Lease&lt;br/&gt;Payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,811&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,274&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,132&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,822&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,937&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,813&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total remaining lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33,789&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,239&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;28,550&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average remaining lease term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.2&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Operating lease costs consist of the fixed lease payments included in operating lease liability and are recorded on a straight-line basis over the lease terms. Operating lease costs were $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for the years ended December 31, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2024, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and 2023, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:PaymentsForAdvanceToAffiliate
      contextRef="C_801e363e-339f-4807-9e7b-89e95be99722"
      decimals="-5"
      id="F_fb752ae3-50d4-4eb4-ae2f-15fd5186eda4"
      unitRef="U_USD">24600000</us-gaap:PaymentsForAdvanceToAffiliate>
    <us-gaap:PaymentsForAdvanceToAffiliate
      contextRef="C_35939c21-6356-4b16-b155-5ff282b4b400"
      decimals="-5"
      id="F_8486db38-1f37-4e10-9005-24d5a40580c8"
      unitRef="U_USD">15600000</us-gaap:PaymentsForAdvanceToAffiliate>
    <arct:MinimumAmountAgreedToIncurUnderResearchPlan
      contextRef="C_d0748bb0-90f5-4425-beb5-86fdc83461e7"
      decimals="-5"
      id="F_0921c9db-7cff-4967-8be6-04f36ebe7990"
      unitRef="U_USD">15000000</arct:MinimumAmountAgreedToIncurUnderResearchPlan>
    <arct:ContraExpenseIncludedInResearchAndDevelopmentExpense
      contextRef="C_794d8e75-547e-4d8c-b200-6302eefbd65b"
      decimals="-5"
      id="F_0003f33a-535c-4272-82b1-cabf8774d259"
      unitRef="U_USD">200000</arct:ContraExpenseIncludedInResearchAndDevelopmentExpense>
    <arct:ContraExpenseIncludedInResearchAndDevelopmentExpense
      contextRef="C_6dcaeb74-849b-4892-8d45-1cf1c0c414a7"
      decimals="-5"
      id="F_d6a6b136-2085-49b2-a6b6-aa391008b101"
      unitRef="U_USD">1400000</arct:ContraExpenseIncludedInResearchAndDevelopmentExpense>
    <arct:ContraExpenseIncludedInResearchAndDevelopmentExpense
      contextRef="C_1b0157b0-3108-4ff6-bf3d-93b8178679dc"
      decimals="-5"
      id="F_093e6ef1-6048-49dc-bceb-8b4e4483f8a1"
      unitRef="U_USD">5200000</arct:ContraExpenseIncludedInResearchAndDevelopmentExpense>
    <arct:ContraExpenseRemainingAmountIncludedInAccruedExpenses
      contextRef="C_794d8e75-547e-4d8c-b200-6302eefbd65b"
      decimals="-5"
      id="F_d52b39d9-628a-4a56-b3ca-2ec43792f631"
      unitRef="U_USD">7400000</arct:ContraExpenseRemainingAmountIncludedInAccruedExpenses>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_958a90b7-6a27-4c61-95d4-5f89fe769df8"
      id="F_d93ab2be-5f8c-4e87-9f88-112777f5dbef">P84M</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_958a90b7-6a27-4c61-95d4-5f89fe769df8"
      id="F_d52e2e73-bf66-42e9-8d98-05c5a6263614">P4M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:PaymentsForProceedsFromTenantAllowance
      contextRef="C_b82657d6-82b1-4bfc-88e6-4814252b20d1"
      decimals="-5"
      id="F_fdc4c78b-d7a3-4828-a0f6-e16e3eca0f6d"
      unitRef="U_USD">100000</us-gaap:PaymentsForProceedsFromTenantAllowance>
    <us-gaap:SecurityDeposit
      contextRef="C_958a90b7-6a27-4c61-95d4-5f89fe769df8"
      decimals="-5"
      id="F_b8df3870-be04-4ef5-8b73-355a5e24f750"
      unitRef="U_USD">100000</us-gaap:SecurityDeposit>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_6e132eb5-a5af-499f-bd75-b24d62c5092f"
      id="F_044167a0-03e1-453a-a1df-c40482aaa4f0">P13M</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="C_820e29f3-5ff7-4037-b94b-5b58fd071bfb"
      id="F_c1965a2e-e87b-4571-915a-44a49c166cff"> the lease for one twelve-month period. In February 2021, the Company opted to extend the lease through March 2025 to coincide with the lease term of the Company&#x2019;s headquarters.</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="C_adf77a8d-9580-41d9-9c8e-9064454e7c28"
      decimals="-5"
      id="F_b6b5d9c5-7283-490d-b0c6-b15a604dc461"
      unitRef="U_USD">1300000</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_59dc916f-940a-4c84-98d4-897fc187a986"
      id="F_5a1e1ead-bf44-44a9-a76f-2047fe0c00a1">P10Y8M</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="C_d4c6eb14-ee87-46e1-8ff9-0f1eee8139e1"
      id="F_7c77feae-f0af-4438-aa35-5e1a15e2058c">the Company has the right to extend the term of the lease for an additional five-year period.</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <arct:MonthlyBaseRent
      contextRef="C_e0b98ca8-b4bb-4d0b-9631-02538172e7f5"
      decimals="-5"
      id="F_60da7fc6-34e2-4065-aa0a-7ca58538073e"
      unitRef="U_USD">300000</arct:MonthlyBaseRent>
    <arct:MonthlyBaseRent
      contextRef="C_e1270539-8c54-4b3f-a7ca-d75b1c8c8913"
      decimals="-5"
      id="F_6d3ca4c9-7079-4ca2-b773-36783a96c214"
      unitRef="U_USD">400000</arct:MonthlyBaseRent>
    <us-gaap:SecurityDeposit
      contextRef="C_59dc916f-940a-4c84-98d4-897fc187a986"
      decimals="-5"
      id="F_17210316-926c-4750-9aea-6ec3e43ff086"
      unitRef="U_USD">2000000</us-gaap:SecurityDeposit>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_4e8eab2d-e148-4cf3-a3fa-7e35f5bec3b8">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2024, the remaining payments of the operating lease liability were as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:75.855%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.06%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:20.084%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Remaining Lease&lt;br/&gt;Payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,811&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,274&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,132&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,822&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,937&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,813&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total remaining lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33,789&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,239&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;28,550&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average remaining lease term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.2&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212"
      decimals="-3"
      id="F_74e1daca-7f42-4357-89e9-b5c1fc506c72"
      unitRef="U_USD">4811000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212"
      decimals="-3"
      id="F_8392df9c-5e79-473a-be65-e952b3a303ad"
      unitRef="U_USD">5274000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212"
      decimals="-3"
      id="F_d016176b-c05e-4dec-9228-a2435092e29c"
      unitRef="U_USD">4132000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212"
      decimals="-3"
      id="F_182cdb44-393f-43f1-864f-674b4e22061f"
      unitRef="U_USD">3822000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212"
      decimals="-3"
      id="F_477be685-b9ce-4038-9f6f-10e0e450aa42"
      unitRef="U_USD">3937000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212"
      decimals="-3"
      id="F_7d9273aa-e834-4c14-b53f-e11e48a18a99"
      unitRef="U_USD">11813000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212"
      decimals="-3"
      id="F_84bd3a62-e906-4e27-b811-a061410e1f70"
      unitRef="U_USD">33789000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212"
      decimals="-3"
      id="F_46b5fe15-f0a3-4ca2-83ed-0e0ec77548b9"
      unitRef="U_USD">5239000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212"
      decimals="-3"
      id="F_2e5350a2-4754-46ee-b6ac-df712dbb2c5c"
      unitRef="U_USD">28550000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212"
      id="F_55ee4c3d-ed34-471f-bc6e-3399c7fd64fb">P7Y2M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_4903df66-6bad-45f9-8151-6f6455ee1212"
      decimals="3"
      id="F_a94c2173-4cd3-40ee-a044-dda2448ca7ac"
      unitRef="U_pure">0.047</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseCost
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      decimals="-5"
      id="F_d05196fa-4819-48fb-b998-5b63f6238b23"
      unitRef="U_USD">4500000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c"
      decimals="-5"
      id="F_9dae6d5c-4cbd-4fad-bf4b-468ce016bb6f"
      unitRef="U_USD">5600000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812"
      decimals="-5"
      id="F_9449723a-7241-44a6-ba50-a2307d447e9f"
      unitRef="U_USD">4700000</us-gaap:OperatingLeaseCost>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_c606f05f-81ea-4646-83f1-70973d5dcc91">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;NOTE 12. Segment Information&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company operates in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; business segment, which includes all activities related to the discovery, development and commercialization of messenger RNA medicines. The determination of a single business segment is consistent with the consolidated financial information regularly provided to the Company&#x2019;s chief operating decision maker (&#x201c;CODM&#x201d;). &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s CODM is its &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_806a8df4-c83d-4622-a6aa-7b9d8f050c33;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Chief Executive Officer&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, who reviews and evaluates consolidated net (loss) income for purposes of assessing performance, making operating decisions, allocating resources, and planning and forecasting for future periods.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The CODM does not evaluate the operating segment using asset or liability information.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table presents information about reported segment revenues, segment loss and income, and significant segment expenses:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:63.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.46%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.56%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:7.9399999999999995%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Revenues&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;152,310&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;166,799&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;205,999&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;LUNAR-COVID&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;70,464&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;81,262&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;65,136&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;LUNAR-OTC&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,509&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,315&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,898&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;BARDA&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,807&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,465&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;95&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;LUNAR-CF, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,227&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,666&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,931&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Early-stage programs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,096&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,460&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,681&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Discovery technologies&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,278&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,405&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,082&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Payroll and benefits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;57,474&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50,924&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;42,466&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Facilities and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,301&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,636&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,462&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;195,156&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;192,133&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;147,751&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;52,823&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;52,871&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;46,071&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other &lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,728&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;48,480&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,828&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net (loss) income&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;80,941&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,725&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,349&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Primarily includes interest income and expense, foreign currency gains and losses, and income taxes. The year ended December 31, 2023 includes a $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;34.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million gain on debt extinguishment related to forgiveness of the Singapore Loan.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <arct:NumberOfBusinessSegment
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      decimals="INF"
      id="F_a0342b5c-c5cb-4873-8f02-a6d2e1a34353"
      unitRef="U_Segment">1</arct:NumberOfBusinessSegment>
    <us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_725d864b-c0d1-4a7b-b892-51a7e42e5e4b">The Company&#x2019;s CODM is its Chief Executive Officer, who reviews and evaluates consolidated net (loss) income for purposes of assessing performance, making operating decisions, allocating resources, and planning and forecasting for future periods.</us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_8c41b399-e622-4627-95d6-0e2d58ed4023">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table presents information about reported segment revenues, segment loss and income, and significant segment expenses:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:63.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.46%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.56%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:7.9399999999999995%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Revenues&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;152,310&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;166,799&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;205,999&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;LUNAR-COVID&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;70,464&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;81,262&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;65,136&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;LUNAR-OTC&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,509&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,315&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,898&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;BARDA&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,807&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,465&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;95&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;LUNAR-CF, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,227&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,666&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,931&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Early-stage programs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,096&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,460&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,681&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Discovery technologies&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,278&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,405&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,082&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Payroll and benefits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;57,474&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50,924&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;42,466&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Facilities and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,301&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,636&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,462&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;195,156&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;192,133&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;147,751&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;52,823&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;52,871&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;46,071&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other &lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,728&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;48,480&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,828&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net (loss) income&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;80,941&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,725&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,349&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Primarily includes interest income and expense, foreign currency gains and losses, and income taxes. The year ended December 31, 2023 includes a $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;34.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million gain on debt extinguishment related to forgiveness of the Singapore Loan.&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      decimals="-3"
      id="F_e3908165-651d-479f-8412-f79e05ea254a"
      unitRef="U_USD">152310000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c"
      decimals="-3"
      id="F_d50eeedf-4891-48be-8817-be1135ef2a3a"
      unitRef="U_USD">166799000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812"
      decimals="-3"
      id="F_58c6b6b7-1070-443a-8889-ccfeaf33b4ef"
      unitRef="U_USD">205999000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_06d432cd-fe67-4805-a95e-d98b0424bbc3"
      decimals="-3"
      id="F_7b60f786-2a72-4098-b5fd-a1a28f8051b5"
      unitRef="U_USD">70464000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_79990b5c-27fd-44ab-a481-a933f3b6649e"
      decimals="-3"
      id="F_7308ad7d-0270-47e0-81ab-13c90c298ee3"
      unitRef="U_USD">81262000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_a45712ae-2c2b-44d4-ae48-9d59250b85b6"
      decimals="-3"
      id="F_aa3a73a4-b405-47be-b9ec-102eb2b5ed4a"
      unitRef="U_USD">65136000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0c35a6e2-43f6-4708-bba5-5173dbc3de2f"
      decimals="-3"
      id="F_d88655ea-512e-4db2-9749-d859aeee4332"
      unitRef="U_USD">9509000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_8dd3cd07-367a-4d33-a06e-49f7bc62341e"
      decimals="-3"
      id="F_b940988d-f490-4293-ae43-93f808a4e75f"
      unitRef="U_USD">9315000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_11fe4360-7e34-49ee-baa1-bb4e286f6f12"
      decimals="-3"
      id="F_a02d7dd5-1634-4680-8d9c-745a76315f69"
      unitRef="U_USD">8898000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_1a296724-396e-481f-8c86-b3b311ff76f9"
      decimals="-3"
      id="F_8e9bacc0-e426-4bcd-9948-58cc7ba846ec"
      unitRef="U_USD">7807000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_57101dc7-2fbf-4d4c-8577-c3989e4bc34a"
      decimals="-3"
      id="F_d8a042dd-c270-4058-95f7-2b5e11c18303"
      unitRef="U_USD">5465000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_92f6052b-f423-4970-890f-aaeea914fcef"
      decimals="-3"
      id="F_744dc1cc-9ab1-49bc-a4f0-41112178e4bd"
      unitRef="U_USD">95000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_e2d495bd-d213-4380-9448-1294459b3c51"
      decimals="-3"
      id="F_df3a45bb-5a03-4194-9f0a-8c417b07e073"
      unitRef="U_USD">17227000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_f6556892-c686-4b0f-ad35-b323cfa6c9df"
      decimals="-3"
      id="F_6781d333-81c9-44a8-b622-4470131fe77c"
      unitRef="U_USD">14666000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_08938b4b-8f37-4a42-96af-9374a057c857"
      decimals="-3"
      id="F_29c86b9e-41a4-4dce-b5da-769d1ff340c3"
      unitRef="U_USD">6931000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_8e8fb1ef-45cd-4aa8-9a33-0ec3e20793f1"
      decimals="-3"
      id="F_4c319d7b-398a-45ed-9e8c-90e429f7bb79"
      unitRef="U_USD">16096000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_85b74df8-3891-4246-9852-23bd86a40945"
      decimals="-3"
      id="F_09bd14a4-325b-4c6b-b156-ebfe2f39bbf7"
      unitRef="U_USD">12460000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_e809b54d-dd94-4594-8f54-a7a9ebc5e794"
      decimals="-3"
      id="F_c6b1f33a-64da-4255-a4d9-0c43ce0aa725"
      unitRef="U_USD">9681000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_88537db2-a4c2-4868-aaa9-8f88cee3858f"
      decimals="-3"
      id="F_3989b73f-0c7a-4eae-9668-01f363780b77"
      unitRef="U_USD">6278000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_c0934e56-cff8-4842-acec-a05ccd4099a4"
      decimals="-3"
      id="F_010e9063-0831-4e7b-a29c-8ebcd8de3f05"
      unitRef="U_USD">6405000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_e6b834ef-7cbd-42d2-9ba5-f1ffd18aff0f"
      decimals="-3"
      id="F_db7c3b50-0ea2-4c64-820b-1a750a703758"
      unitRef="U_USD">6082000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_07a158d3-db39-46b0-b8a8-d157b269ad9e"
      decimals="-3"
      id="F_318b5d2d-2ff9-423c-a0b3-dc36d875d231"
      unitRef="U_USD">57474000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_384780c2-a461-484e-90b6-4ba525f2b0cb"
      decimals="-3"
      id="F_46b8daec-0a94-4cc4-9dc9-dbe6ddd8c807"
      unitRef="U_USD">50924000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_b73afaae-41c1-46b6-8616-4cdb808c1c4a"
      decimals="-3"
      id="F_fa34d77c-8d96-43f4-aae3-25e1431c6802"
      unitRef="U_USD">42466000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_fe6dc61d-d3ca-490d-9689-8dcf10e0d322"
      decimals="-3"
      id="F_fd908af1-eb59-4a3c-80ca-40730b85f8fc"
      unitRef="U_USD">10301000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_7f5b7d69-0f16-49c9-8312-5fabb8348a71"
      decimals="-3"
      id="F_55113225-b542-4956-96a0-e0318dbcaba0"
      unitRef="U_USD">11636000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_ed799f3d-249f-4d51-ae92-deaa84f57abd"
      decimals="-3"
      id="F_fc877128-3f5e-46f7-bf38-43e453ff15c6"
      unitRef="U_USD">8462000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      decimals="-3"
      id="F_b1ec607f-e4e6-4626-a29d-7185c8e88c9b"
      unitRef="U_USD">195156000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c"
      decimals="-3"
      id="F_2eceedd5-5351-4127-8c72-560ee479722e"
      unitRef="U_USD">192133000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812"
      decimals="-3"
      id="F_9f8047eb-e713-4efe-981c-f0ab11e6b1a0"
      unitRef="U_USD">147751000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      decimals="-3"
      id="F_7328cc40-d95c-4c7f-bf4e-ef3f0e3b9234"
      unitRef="U_USD">52823000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c"
      decimals="-3"
      id="F_95c549fa-6e0c-44ff-9c68-981f7e9619ea"
      unitRef="U_USD">52871000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812"
      decimals="-3"
      id="F_d1b8a1b5-e706-4c63-8026-dc932561b541"
      unitRef="U_USD">46071000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      decimals="-3"
      id="F_30349b9e-a90b-4868-8b5f-f9f68e52ad16"
      unitRef="U_USD">-14728000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c"
      decimals="-3"
      id="F_9edd83ab-be78-4163-82d9-62024f18eaed"
      unitRef="U_USD">-48480000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812"
      decimals="-3"
      id="F_41de01e3-de04-4166-aef7-c6b8d1aed994"
      unitRef="U_USD">2828000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:NetIncomeLoss
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      decimals="-3"
      id="F_82958dca-b56e-47cb-ab97-735d7a5c1638"
      unitRef="U_USD">-80941000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_652488b3-7499-4d63-b634-9c1ddc35880c"
      decimals="-3"
      id="F_3d868e48-db5f-4903-adb9-06503844479d"
      unitRef="U_USD">-29725000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_9316938d-e4f7-4709-b45f-2d7d8cc44812"
      decimals="-3"
      id="F_4f28203b-b17f-4df3-8e06-49b566382622"
      unitRef="U_USD">9349000</us-gaap:NetIncomeLoss>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="C_2d41c197-8a7f-4abe-8802-3f3779ba2106"
      decimals="-5"
      id="F_6d599068-705c-45a7-8ac9-82ac53f579de"
      unitRef="U_USD">34000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_1c8519ed-75a1-4d67-aa32-34ff6a5fdce3">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;NOTE 13. Related Party Transactions&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;See &#x201c;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Note 2, Joint Ventures, Equity Method Investments and Variable Interest Entities&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x201d; for specific details surrounding the Company&#x2019;s agreement with Axcelead to form the joint venture entity, ARCALIS, Inc.&lt;/span&gt;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="C_c45ae1f6-f871-404f-8826-2b495a729716"
      id="F_a1114de0-75a8-43a2-8c3f-3d20795fef96">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;NOTE 14. Subsequent Events&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;None.&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#F_30349b9e-a90b-4868-8b5f-f9f68e52ad16"
          xlink:label="F_30349b9e-a90b-4868-8b5f-f9f68e52ad16"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_9edd83ab-be78-4163-82d9-62024f18eaed"
          xlink:label="F_9edd83ab-be78-4163-82d9-62024f18eaed"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_41de01e3-de04-4166-aef7-c6b8d1aed994"
          xlink:label="F_41de01e3-de04-4166-aef7-c6b8d1aed994"
          xlink:type="locator"/>
        <link:footnote id="FNT_e7673c3f-e0a4-4c88-8556-e697212050ab" xlink:label="FNT_e7673c3f-e0a4-4c88-8556-e697212050ab" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Primarily includes interest income and expense, foreign currency gains and losses, and income taxes. The year ended December 31, 2023 includes a $</xhtml:span><xhtml:span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34.0</xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million gain on debt extinguishment related to forgiveness of the Singapore Loan.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_30349b9e-a90b-4868-8b5f-f9f68e52ad16"
          xlink:to="FNT_e7673c3f-e0a4-4c88-8556-e697212050ab"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_9edd83ab-be78-4163-82d9-62024f18eaed"
          xlink:to="FNT_e7673c3f-e0a4-4c88-8556-e697212050ab"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_41de01e3-de04-4166-aef7-c6b8d1aed994"
          xlink:to="FNT_e7673c3f-e0a4-4c88-8556-e697212050ab"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
